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Background: Recent advances in the molecular 
classiÀcation of lung adenocarcinoma have led to 
the development of novel cancer therapeutics which 
are more effective and less toxic than chemotherapy 
for patients who harbor speciÀc genetic alterations 
in their tumors such as EGFR mutations and ALK 
fusions. However, progress in squamous cell 
lung cancer (lung SCC) has lagged behind lung 
adenocarcinoma. Reports by our group and others in 
the past year have identiÀed the DDR2 and FGFR1 
tyrosine kinases as potential therapeutic targets in 
lung SCC and we sought to extend these Àndings 
with a more detailed genomic characterization of 
lung SCCs.
Methods: We performed a detailed genomic analysis 
of 118 lung SCCs and matched normal controls 
as part of The Cancer Genome Atlas project. This 
included copy number proÀling using SNP 6.0 
arrays, next-generation whole exome sequencing of 
all samples and whole genome sequencing of Àve 
tumor/normal pairs.
Results: Using the GISTIC 2.0 algorithm we 
identiÀed signiÀcant focal copy number gains in 25 
regions of the genome, including several genes likely 
to be important in the pathogenesis of lung SCC 
including CMYC, SOX2, FGFR1, CCND1, TP63 
and NFE2L2. 14 focal deletion peaks were identiÀed 
and include LRP1B, EPHA3, PTEN, RB1, CDKN2A 
and CSMD1 (Fig 1). Mutational analysis of exome 
sequencing from 64 samples with excellent coverage 
and lack of hypermutation identiÀed an average of 
377 coding mutations per sample and 180 overall 
signiÀcantly mutated genes including TP53, BID, 
SI, NFE2L2, LRB1B, NOTCH1, PTEN, PIK3CA, 
CDKN2A, RB1, KEAP1, KDM6A, FGFR2 and 
CTNNA2. Whole genome sequencing revealed 
multiple in-frame fusions involving RB1, NOTCH1, 
PIK3CB, TP63, VHL and ETV6 (Fig 2).
Conclusion: Together, these results provide an initial 
insight into the genomic abnormalities in lung SCCs 
and suggest that therapeutic targets are likely to 
exist in this disease and include PIK3CA and FGFR 
family members among others.
Keywords: targeted therapies, squamous cell lung 
cancer, cancer genomics
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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5p15.33, 6p21.33 or 15q15.2 inÁuence smoking 
behavior. That smoking causes lung cancer is 
perhaps the most widely known result in the Àeld of 
medical epidemiology(14-15). Smokers are ten times 
more likely to get lung cancer than lifetime non-
smokers, and the geographical and temporal patterns 
in lung cancer incidence can largely be modeled 
based on overall tobacco consumption(2). The 
smoking induced risk of lung cancer is dose 
dependent , increasing with higher numbers of 
cigarettes smoked per day and with the duration of 
smoking as well(16-17), although other aspects of 
smoking such as the type of tobacco used, age at 
onset of smoking, depth and duration of inhalation, 
also come into play(2). Several smoking phenotypes 
are quite heritable, including smoking persistence 
and nicotine dependence (18-19). The main variant 
at 15q25 does not appear to inÁuence the tendency to 
take up smoking, but associates with the amount 
smoked per day and with nicotine dependence(3). 
Since the discovery of this locus additional studies 
have been conducted, providing further evidence 
relating to the matter of how to explain the effect of 
this locus on lung cancer. While reviewing these 
studies it is important to keep in mind that there are 
three main possibilities when it comes to explaining 
why this variant has a stronger effect on the 
consequences of smoking than on CPD. First, the 
variant may associate with other aspects of smoking 
behavior – not adequately measured by CPD – that 
inÁuence risk of lung cancer and some other 
smoking-related diseases. Second, the variant may 
increase the vulnerability to the harmful effects of 
tobacco smoke. Third, the variant may confer risk of 
a smoking-related diseases in a manner that is 
independent of smoking. In light of the key impact 
that smoking has on lung cancer risk it is reasonable 
to expect at least some association with lung cancer 
for variants inÁuencing smoking behavior. Ideed, in 
addition to the chrs 15q25 variants, recent meta-
analyses of smoking behavior have identiÀed loci at 
8p11 and 19q13 containing sequence variants 
exhibiting genome-wide signiÀcant association with 
smoking quantity and nominally signiÀcant 
associations with lung cancer(20). Further studies are 
required to verify the effects on lung cancer at these 
loci. Variants at 15q25 have been the most signiÀcant 
Àndings in three large meta analyses of smoking 
behavior(20-22), and there is no doubt that the 
association with smoking behavior is real.The 
original variant has been shown to confer risk of 
additional smoking-related diseases, including 
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PL01.2 LUNG CANCER SUSCEPTIBILITY 
GENES
Thorgeir E. Thorgeirsson 
University Of California Santa Cruz/United States 
Of America
Abstract: Rapid progress in cancer genetics is 
expected to greatly impact clinical practice in the 
next decade, as the characterization of germline and 
tumor DNA at increasingly high resolution will 
provide valuable insights into cancer, hopefully 
opening new avenues for cancer prevention, early 
detection, and treatment. The mapping of cancer risk 
regions represents an important step toward 
understanding of the pathogenesis of cancer, and in 
the last few years genome-wide association studies 
have yielded over 90 regions associating with 
various cancers(1) including lung cancer(2). 
Genome-wide association studies have identiÀed 
sequence variants associating with risk of lung 
cancer at four loci in populations of European 
descent. Variants at chrs 15q25.1 in a region 
containing genes encoding for three nicotinic 
acetylcholine receptor (nAChR) subunits (CHRNA5, 
CHRNA3, CHRNB4) were discovered Àrst , and 
shown to associate with the number of cigarettes 
smoked per day (CPD) (3-4), nicotine addiction(3, 
5), peripheral arterial disease(3) and lung cancer(3, 
6-7). Three independent Àndings on lung cancer 
were remarkably consistent with regard to the 
estimate of the effect on lung cancer risk at the 
15q25 locus (odds ratios between 1.30-1.32)(3, 6-7), 
but the studies differed with regard to the 
interpretation of the results on smoking behavior(8). 
By expanding various studies and building on meta 
analysis efforts(9) three additional loci have been 
discovered, at 5p15.33 in a region encompassing the 
TERT and CLPTM1L genes(10-12), 6p21.33 within 
the major histocompatabillity region (MHC)(7, 11), 
and 15q15.2 near the TP53BP1 gene(13). There is 
currently no evidence indicating that the loci at 
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Àndings into account and considering that there are 
at least three independent at-risk variants within the 
region, there is certainly need for further studies 
before Àrm conclusions can be reached. The key 
variant at chrs 15q25 clearly inÁuences nicotine 
addiction and smoking behavior, and through these 
effects it also confers risk of lung cancer and other 
smoking related diseases. This variant provides a 
fascinating example of gene-environment 
interactions involved in many disorders, and can be 
studied from that point of view alone for years to 
come. At the present time it appears unnecessary to 
invoke more complicated scenarios to explain the 
effect the main variant has on risk of lung cancer and 
other smoking-related diseases. However, it is clear 
that such effects cannot by any means be ruled out 
based on association studies alone, particularly when 
it comes to other variants within the region that have 
not been as thoroughly studied. Large collaborative 
efforts will be required to reÀne the association 
signals already discovered in lung cancer, and to this 
end current whole genome sequencing efforts, such 
as the 1000 genomes project(39-40), will prove 
invaluable as they are discovering a large number of 
variants from various populations that can be 
imputed into these large datasets for further study, or 
when necessary studied by direct genotyping or 
sequencing. References 1. Hosking FJ, Dobbins SE, 
Houlston RS. Genome-wide association studies for 
detecting cancer susceptibility. Br Med Bull. 
2011;97:27-46. 2. Brennan P, Hainaut P, Boffetta P. 
Genetics of lung-cancer susceptibility. Lancet Oncol. 
2011 Apr;12(4):399-408. 3. Thorgeirsson TE, Geller 
F, Sulem P, Rafnar T, Wiste A, Magnusson KP, et al. 
A variant associated with nicotine dependence, lung 
cancer and peripheral arterial disease. Nature. 2008 
Apr 3;452(7187):638-42. 4. Berrettini W, Yuan X, 
Tozzi F, Song K, Francks C, Chilcoat H, et al. 
Alpha-5/alpha-3 nicotinic receptor subunit alleles 
increase risk for heavy smoking. Mol Psychiatry. 
2008 Apr;13(4):368-73. 5. Saccone SF, Hinrichs AL, 
Saccone NL, Chase GA, Konvicka K, Madden PA, et 
al. Cholinergic nicotinic receptor genes implicated in 
a nicotine dependence association study targeting 
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Broderick P, Gorlov IP, Gu J, Eisen T, et al. Genome-
wide association scan of tag SNPs identiÀes a 
susceptibility locus for lung cancer at 15q25.1. Nat 
Genet. 2008 May;40(5):616-22. 7. Hung RJ, McKay 
JD, Gaborieau V, Boffetta P, Hashibe M, Zaridze D, 
et al. A susceptibility locus for lung cancer maps to 
chronic obstructive pulmonary disease(23) and 
cancers in the upper aerodigestive tract(24). Carriers 
of the variant not only smoke more, but also extract 
more nicotine and more carcinogens from each 
cigarette than non-carriers(25). Furthermore, the 
variant has been shown to associate with continued 
smoking during pregnancy in two studies(26-27), 
and progression to regular smoking and nicotine 
dependence in young smokers may be inÁuenced by 
the variant(28). The last two Àndings suggest that the 
variant may inÁuence smoking duration through an 
effect on cessation, and potentially through 
facilitating early onset of regular smoking, but even 
a relatively small effect on smoking duration could 
be expected to explain the observed odds ratio for 
lung cancer(16-17). Work on rodents has also 
delineated potential mechanisms within the brain, 
including action of the alpha-5 subunit protein within 
the habenula to inÁuence the brain’s reaction to 
aversive stimuli inÁuencing the motivational drive 
for nicotine intake(29), but the lateral habenula has 
been implicated in negative reward 
mechanisms(30-31). Brain imaging studies have 
been conducted in humans revealing that the variant 
modulates an cingulated circuit previously shown to 
be involved in nicotine addiction(32) and to be 
altered in psychiatric patients(33), but involvement 
of the dorsal anterior cingulate cortex in reward-
based decision making has been suggested 
before(34) . It had been argued that the results on the 
risk conferred of lung cancer in never smokers have 
been inconsistent with some studies Ànding 
association(7), and other not(6), but a recent large 
meta analysis with much larger sample size found no 
association with lung cancer in never smokers of 
European descent (35). However, several studies of 
Asian and African American populations have 
reported association of SNPs within the region in 
never smokers including a well powered study 
reporting four common 15q25 variants associating 
with lung cancer in two Chinese case-control studies 
with similar effects among ever and never 
smokers(36). However, the relevance of these 
Àndings remains unclear as some of the key markers 
have low frequencies in these populations(See (2, 
37) and references therein). Additional arguments for 
a more direct effect on lung cancer come from 
studies of the effects of nicotine and various tobacco-
speciÀc carcinogens on nAChR signaling and cell 
proliferation in bronchial mucosal cells(2), and a 
potential involvement of altered nAChR signaling in 
lung cancer has been suggested(38). Taking these 
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men at a ratio of 17:1 yet 20 years later ADC 
surpassed SCC as the most common lung cancer 
in many males populations. Currently ADC is up 
to 1.5 times more common in cigarette-smoking 
men and anywhere from 2 to 7 times more common 
in women than SCC. Outdated assertions from 
the mid 20th century cloud our impressions. Doll 
and Kreyberg described the relationship between 
tobacco smoking and ADC of the lung as “slight, 
if any,” in the late 1950s and early 1960s. At that 
time their conclusion might have been correct since 
women had not yet begun to abuse cigarettes to 
the same extent as men, and cigarettes were simply 
made from tobacco leaves and smoked without 
Àlters. The 10-fold increase in lung ADC incidence 
in men from 1959 through at least the early 1990s 
in the United States, Japan, and parts of Europe is 
directly attributable to changes in cigarettes. The 
market share of Àltertip cigarettes rose from less than 
1% in 1950 to 80% in 1970. Filters remove large 
particles from cigarette smoke, and thus reduce the 
deposition of these particles in central airways where 
SCCs usually develop. The resultant decline in SCC 
incidence has not been subtle. Filters also allow 
smokers to inhale more deeply than with unÀltered 
cigarettes. Deep inhalation carries tobacco-speciÀc 
carcinogens beyond the main airways into peripheral 
lung and into contact with bronchiolar and alveolar 
epithelium, the site of adenocarcinogenesis. Low 
tar and low nicotine cigarettes have also altered the 
smoking habits of abusers. While smokers in the 
1930s and 1940s took approximately one 35 ml puff 
per minute, current users take up to three puffs per 
minute with recorded volumes as high as 65 ml. 
Blended reconstituted tobacco, also introduced in the 
1950s, releases measurably higher concentrations of 
nitrosamines, a potent inducer of ADC in rodents, 
than tobacco leaf products. In women, ADC has 
been the most frequent subtype of lung cancer since 
reliable statistics were collected starting in the 1960s. 
Squamous histology might have been more prevalent 
before the introduction of Àltered cigarettes, but 
given the relatively small number of women smokers 
in the Àrst decades of the past century and our 
current understanding of lung cancer risk factors 
in women, it is difÀcult to imagine a time when 
squamous histology was more common than ADC. 
Thus, when one speaks of a large-scale increase 
in numbers of women with lung ADC, one should 
recognize that these incidence rates simply mirror the 
rapidly growing number of women smokers over the 
past Àfty years rather than a peculiar shift in female 
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PL01.4 CHANGING 
HISTOPATHOLOGICAL PICTURE OF 
LUNG CANCER?
Douglas Flieder 
Pathology, Fox Chase Cancer Center/United States 
Of America
Abstract: Although one might be tempted to suggest 
that we are experiencing an explosive 21st century 
rise in the incidence of lung adenocarcinoma (ADC), 
such is not the case. The slow and inexorable 
displacement of squamous cell carcinoma (SCC) 
by ADC as the most common lung cancer subtype 
began more than 50 years ago. Population- and 
hospital-based studies in the North America, Asia 
and Europe support this contention. In the 1950s 
SCC predominated over ADC in cigarette-smoking 
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of adenocarcinoma subtypes appear stable since 
WHO deÀnitional changes in 1999. Lung cancer 
has risen from obscurity at the start of the 20th 
century to occupy the throne of deadly cancers one 
century later. Equality among the sexes to partake 
in unhealthy behaviors and the evolution of the 
cigarette into a Ànely developed killing machine are 
responsible for the ascendancy of ADC over SCC as 
the most common histologic subtype of lung cancer. 
Purported biases did not play a large role.
Keywords: Adenocarcinoma, lung
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NEVER-SMOKERS
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Abstract: Environmental Factors Contributing to 
Lung Cancer in Never-Smokers Michael J Thun 
American Cancer Society Although active tobacco 
smoking is by far the leading cause of lung cancer 
worldwide, the number of cases caused by other 
factors is still substantial. For example, in the United 
States (U.S.) and Europe, exposure to factors other 
than active cigarette smoking are estimated to 
account for about 10% of all lung cancer deaths in 
men and 15-20% in women. This corresponds to 
approximately 19,000 to 23,000 of the more than 
157,300 lung cancer deaths projected to occur in 
the U.S. in 2010. If these deaths were considered 
as a separate category, they would rank eighth 
among most common fatal cancers in America. 
Environmental factors other than active smoking 
that are known to cause lung cancer include 
occupational or residential exposure to secondhand 
smoke, radon gas, asbestos (particularly among 
smokers), certain metals (chromium, cadmium. 
arsenic), some organic chemicals, ionizing radiation, 
air pollution (particularly from burning coal), and a 
history of tuberculosis or other chronic inÁammatory 
conditions. Besides these established risk factors, 
lung cancer histology. Our heightened awareness of 
lung cancer in non-smokers likely contributes to the 
impression that we are experiencing a surge in ADC 
cases. However, it is not certain whether lung cancer 
incidence rates in non-smokers changed. ADC is 
almost 3.5 times more frequent than squamous cell 
histology in non-smokers and globally this subset 
is more frequent in women, particularly Asian 
women. Increased smoking cessation, at least in 
parts of the Western world, may also contribute to 
a relative rise of adenocarcinoma cases since the 
risk of developing a pulmonary SCC drops faster 
than the risk of developing an adenocarcinoma in 
ex-smokers. While diagnostic advances, including 
changes in tissue procurement techniques and 
tumor classiÀcations cannot be ignored, they are 
not primarily responsible for the changing trend 
in lung cancer histology epidemiology. Historical 
confounders such as a 1970s European belief that 
many ADCs in the lung were metastases rather 
than primary malignancies, or the practice in many 
nations not to subtype non-small cell carcinomas are 
not responsible for the increase in adenocarcinoma 
cases. Furthermore, newer technologies introduced in 
the late 1960s through the 1980s, including Áexible 
bronchoscopy and transthoracic needle aspirates, 
allowed for relatively non-invasive sampling of 
peripheral lesions but did not cause a rise in lung 
cancer cases. With regard to histologic classiÀcation, 
pathologists until recently were encouraged to label 
these cancers simply non-small cell carcinomas and 
there is no evidence that peripheral lesions were 
misdiagnosed as ADCs. Only over the past few 
years have pathologists used immunohistochemical 
stains to subtype morphologically challenging 
non-small cell carcinomas and studies suggest that 
proposed diagnostic algorithms lead to accurate 
diagnoses of localized and advanced lung cancer 
on most small biopsies and cytologic specimens. 
ModiÀcations and personal interpretations of lung 
cancer classiÀcation schemes hardly impact today’s 
epidemiologic perspective on lung cancer histology. 
ClassiÀcation changes in the 1970s and 1980s shifted 
signiÀcant numbers of SCCs into the large cell 
carcinoma category, and cases previously considered 
large cell carcinomas were diagnosed as solid 
ADCs when mucin stain were positive. However, 
several contemporary cohort reviews found that 
such changes did not signiÀcantly alter overall 
results. More recent World Health Organization 
classiÀcation modiÀcations did not alter fundamental 
diagnostic groupings. Furthermore, incidence rates 
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than men who have never smoked. It merely reÁects 
the reality that there are many more older women 
than men who have never smoked regularly. Given 
the substantial disease burden from lung cancer 
among never-smokers, more research is needed 
to understand the important causal factors and to 
strengthen prevention efforts, especially in high risk 
populations. 
Keyword: lung cancer, never-smokers, second-hand 
smoke, radon
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PL02.2 MOLECULAR PATHOGENESIS 
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Abstract: Although tobacco smoking is responsible 
for the majority of lung cancers, up to 25% of lung 
cancers worldwide arise from individuals who never 
smoked. These tumors more commonly arise from 
the distal airways, among younger individuals and 
more commonly women. Familial genetic risk , 
hormonal, environmental and viral factors are being 
discovered. The molecular pathology of these tumors 
is clearly different and much light has been shed on 
these tumors in the last 5 years. Lung tumors from 
non-smokers use biological pathways differently 
including differences in chromosomal segregation 
and chromatin alterations to reach a malignant 
phenotype. Typically a lower number of differently 
expressed genes, lower mutation rate are found 
among them and with different pattern of mutations, 
particularly for EGFR, Kras p53 and EML4–ALK. 
These differences raise the hypothesis that the Àeld 
of cancerization is quite different in non-smokers. 
This presentation will review the major discoveries 
in the Àeld and discuss some unanswered questions 
and strategies to try to address them. What are the 
mechanisms controlling overall genome instability 
in non-smokers? Is the airway epithelium a surrogate 
of lung cancer in non-smokers? What is the mutation 
rate in the epithelium of smokers vs non-smokers? 
Is the response to inÁammation different among 
nonsmokers with familial predisposition? What are 
the characteristics of cancer stem cells in never-
smokers? Recent discoveries already suggest that 
some key molecular drivers have been identiÀed. 
These are the focus of targeted therapies with 
several other exposures have been proposed to 
increase risk. These include infection with certain 
stains of human papillomavirus and chronic 
inhalation of cooking fumes and/or incense. Two 
other characteristics that are consistently associated 
with increased lung cancer risk are leanness and 
physical inactivity. However, these associations 
have been observed predominantly among smokers. 
Because cigarette smoking is strongly associated 
with leanness and physical inactivity as well as 
lung cancer, these observations may represent 
residual confounding by smoking rather than 
causal relationships. The incidence of lung cancer 
among women in certain areas of Northern China is 
higher than that among female smokers in Europe 
and North America for reasons that are currently 
unrelated to smoking. Less than Àve percent of 
all Chinese women smoke, and the prevalence 
of female smoking is generally under seven or 
eight percent, even in the highest risk areas. The 
remarkably high regional risk of lung cancer has 
been attributed to indoor air pollution from cooking 
and heating with low quality coal, in conjunction 
with indoor exposure to second hand smoke from 
male smoking. While female smoking is actually 
decreasing among Chinese women at the national 
level, the lung cancer burden among Chinese women 
is already large because of the high background 
risk and massive population. WHO estimates that 
never-smokers currently account for 30% of lung 
cancers in China. Never smoking women in China 
will confront an even greater risk if and when the 
cultural taboos that deter female smoking begin to 
erode in urban centers, as may already be happening 
in among young middle class women. Publications 
about lung cancer risk in relation to smoking status 
and gender often confuse proportions with rates 
(per 100,000 people per year) and draw erroneous 
claims about risk. For example, while it is true that 
adenocarcinoma comprises a larger proportion of 
all lung cancers in women than men, this does not 
mean that the risk (or incidence rate) of developing 
pulmonary adenocarcinoma is higher in women 
than men irrespective of smoking. In reality, the 
incidence rate is lower in women than men, but 
the proportion is higher because an even greater 
gender difference in incidence of other histological 
subtypes (particularly squamous and small cell 
carcinomas) Similarly, while the proportion of lung 
cancer patients who have never smoked regularly 
is higher in women than men, this does not indicate 
that women who have never smoked have higher risk 
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risk factors for Chinese housewives to develop lung 
cancer(8-11). Cumulative exposure to cooking oil 
fumes from frying was associated with increased 
risk of lung cancer in never-smoking women. 
Additionally, meta-analysis studies conducted in 
China consistently suggested that risk of lung cancer 
increased as a consequence of the exposure to 
domestic coal used for heating and cooking, indoor 
exposure to coal dust, chronic exposure to cooking 
oil vapor, and ETS(12). In Japan, a high risk of 
lung adenocarcinoma in females was observed for 
exposure to smoke in the workplace combined with 
exposure to husbands who smoke. Both endogenous 
and extraneous estrogen might be involved in the 
etiology of lung cancer in Japanese never-smoking 
women (13).
Single nucleotide polymorphisms (SNPS) of 
many genes including IL 1ơ-31 T/T, IL -1RN, 
CYP 1B1, CYP 1A1, MPO, GSTP1, and XRCC1 
have been studied to determine their relationship 
with risk of lung cancer in Asian female patients 
(14,15). ERCC2 751 variant genotypes (AC/CC) 
were found to be associated with increased risk of 
lung adenocarcinoma, especially in those without 
exposure to cooking oil fumes or to fuel smoke (16). 
Odds ratios of lung cancer across increasing levels 
of cooking dish-year were 1, 1.17, 1.92, 2.26 and 
6.15, respectively(17). A genome-wide association 
study of lung cancer in never-smoking women 
revealed that 5p15.33 locus was associated with risk 
of lung adenocarcinoma(18). The most signiÀcant 
association was for rs2736100 on chromosome 
5p15.33. This Ànding was independently replicated 
in 7 studies from East Asia(19,20). We compared 
frequencies of SNPs of 10 genes including 8 DNA 
repair genes among female and male NSCLC 
patients with or without smoking history. SNPs of 
these genes were comparable between both genders 
and not different by smoking status.
Lung cancer in never-smoking Asian women 
may have different molecular biology (21). It is 
well known that smoking is associated with more 
frequent methylation of some genes such as p16 
and MGMT(22) or their different mutation proÀles 
such as epidermal growth factor receptor (EGFR), 
KRAS, EML4-ALK and cMET, etc(18-27). Lung 
cancer, especially adenocarcinoma, in never-smokers 
is associated with more frequent mutations of 
EGFR and EML4-ALK and less frequent mutations 
of KRAS and c-MET. Studies from Hong Kong, 
mainland China, and Taiwan showed incidence 
of KRAS mutation was 13-19% in men with 
impact on patients outcome. These results have 
important implications in urging the community to 
offer genetic testing, to develop new personalized 
therapeutic strategies and to answer the need for 
improving our understanding of the molecular 
pathogenesis of this deadly disease. 
Keywords: molecular pathogenesis, never smoker, 
personalized
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Oncology, Shanghai Pulmonary Hospital, Cancer 
Institute, School Of Medicine, Tongji University/China
Abstract: Lung cancer is a major health burden 
worldwide, accounting for 12% of all new cancer 
cases (1). Most of lung cancer cases are associated 
with a personal history of direct tobacco smoking 
(DTS). But, the proportion of never-smoking patients 
with lung cancer has been signiÀcantly increasing 
over the past 30 years, from 15.9% in the 1970s to 
32.8% in the 2000s(1,2). Most studies on lung cancer 
in never-smokers have emerged from Asia, as the 
smoking prevalence rate in Asia is lower than that 
in west. More and more evidence suggests that lung 
cancer in never-smokers is a distinct disease in terms 
of carcinogenesis, clinical characteristics, molecular 
biology, etc (3-5). This review summarizes some 
data on lung cancer in non-smoking Asian women.
The majority of Asian women with non-small cell 
lung cancer (NSCLC) were never-smokers (76.3% 
in women vs. 9.9% in men)(3). Never-smokers with 
NSCLC were found to be disproportionately Asian 
women with adenocarcinoma. Data from 6 different 
cohorts showed that the truncated age-adjusted 
incidence rates of lung cancer in never smokers 
ranged from 14.4 to 20.8% per 100,000 person-years 
in women and 4.8 to 13.7% per 100,000 person-
years in men, supporting earlier observations that 
women were more likely than men to have never-
smoking-related lung cancer (5,6).
Many factors including air pollution, cooking oil 
fumes, exposure to environmental tobacco smoke 
(ETS), and family history of lung cancer may 
be related with increased risk of lung cancer in 
never-smoking Asian women(1,5,7). Studies from 
Shanghai, Shenyang, Gansu, and Taiwan have 
demonstrated that cooking oil fumes were one of 
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EGFR tyrosine kinase inhibitor (TKI) proves to 
be more effective in Asian never-smoking women 
with NSCLC (35,36). Overall response rate to 
EGFR TKI was 52% in never-smoking women, 
33% in never-smoking men, 0% in smoking women 
and 12% in smoking men. According to the Asian 
subgroup analysis of TRUST study, progression 
free survival (PFS) and overall survival were 9.2 
months and 20.3 months in never-smoking women 
with nonsquamous tumors, respectively. Disease 
control rate and response rate were higher in never-
smoking women. In the IPASS study, geÀtinib was 
associated with signiÀcant improvement in response 
rate, PFS, toxicity proÀle, and quality of life (QOL) 
when used as the 1st line treatment for never- or mild 
ever-smokers with adenocarcinoma compared with 
doublet chemotherapy. Female patients accounted 
for over 80% of the study population. Nevertheless, 
overall survival was not different between the 2 
arms because of high post-study cross-over to EGFR 
TKI in chemotherapy arm (29). In the OPTIMAL 
study, both female and male patients harboring 
EGFR mutations obtained much more clinical 
beneÀt from erlotinib therapy compared with 
chemotherapy (37). PFS was slightly better in the 
women than men (HR: 0.13 vs. 0.27). The response 
rate to chemotherapy was not different between 
never-smoking women and men (20.2% vs. 23.8%), 
but signiÀcantly different between ever-smoking 
women and ever-smoking men (31% vs. 23.6%). 
Women demonstrated modestly longer PFS than men 
when treated with chemotherapy, with no difference 
observed in response rate, serious adverse events, or 
QOL.
Never-smoking and Asian ethnicity have been 
found to be favorable factors for overall survival 
in NSCLC (2,38). Japanese and Korea ethnicities 
had longer overall survival in NSCLC compared 
with Caucasians. Never-smoking Asian female 
patients survived longer than never-smoking Asian 
men regardless of treatment (2,34). But some 
study showed the prognosis of never-smoking men 
with adenocarcinoma was similar to that of never-
smoking women (39).
In conclusion, lung cancer in never-smoking Asian 
women is a distinct disease. NSCLC is associated 
with high proportion of adenocarcinoma and higher 
incidence of EGFR mutation and the EML4-ALK 
fusion gene, but less K-ras mutation and cMET 
mutation. Some SNPs may be associated with 
increased risk of lung cancer in never-smoking Asian 
women. Cooking oil vapor, ETS, etc., are believed to 
lung adenocarcinoma but 0% in women. This is 
not surprising, as it was now known that KRAS 
mutation is due to the mutagenic effect of tobacco 
smoking and the majority of Chinese female patients 
are never-smokers. EGFR mutation is reported to 
be over 60% in never-smoking female patients, 
signiÀcantly higher than that in male patients. But 
EGFR mutation is comparable in its incidence (over 
60%) between never-smoking men and women in 
China and Japan (25,28-29). EGFR mutation was 
also found to be highly associated with high copy 
numbers or over-expression of EGFR. Some studies 
found that ETS exposure was inversely related to 
incidence of EGFR mutation (38.5% vs. 61.4%). 
Patients with ETS exposure also showed a lower 
response rate to EGFR TKI than patients without 
ETS exposure (24.6% vs. 44.8%)(30). Moreover, 
EML4-ALK fusion is more often detected in 
the never-smoking adenocarcinoma of the lung. 
EML-4 ALK fusion was found in 16.13% of lung 
adenocarcinoma and 19.23% in never-smokers and 
42.28% in adenocarcinoma lacking mutation of 
EGFR or KRAS (31). In another study, the incidence 
of EML4 ALK was 15.8% in never-smoking men, 
6.5% in never-smoking women, 1.5% in ever-
smoking men, and 0% in ever-smoking women 
(25). EGFR mutations were mutually exclusive with 
KRAS mutations or the EML4-ALK fusion gene. 
The frequency of HER2 mutations was found to be 
4.3% in the Oriental never-smoking women with 
lung adenocarcinoma and 11% in those lacking 
EGFR mutations (32). MET mutation was also often 
found in Asian patients with NSCLC. But it was 
less often observed in never-smokers than smokers 
and less often in women than men, especially 
for MET N375S mutation, which was thought to 
be responsible for resistance to MET inhibitors 
(33). In China, about 90% of never-smokers with 
adenocarcinoma harbored targetable oncogenic 
kinase mutations, including 78.8% with EGFR 
mutation, 5.8% with EML4-ALK fusion, 3.8% with 
HER2 mutation, and 1.9% with KRAS mutation 
(28). In another study, EGFR mutation was prevalent 
in never- smokers of both genders with lung 
adenocarcinoma (78.9 % vs. 74.1%) while KRAS 
mutation was quite rare (0% vs. 3.7%) (25).
Lung cancer in never-smoking Asian women has 
different clinical features. There were more cases of 
adenocarcinoma (>80%), stage IA disease, and fewer 
co-morbidities (2). Never-smoking women with lung 
cancer were comparatively younger at the time of 
diagnosis compared with smoking women (34).
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be particular risk factors for these patients Because 
of the distinctive nature of their disease, never-
smoking Asian women have a favorable prognosis. 
Those harboring positive EGFR mutation should 
receive EGFR TKI in the 1st line setting.
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Abstract: Never smokers in the context of lung 
cancer have been commonly deÀned as people 
who have smoked less than 100 cigarettes in their 
lifetime.1 Physicians and scientists have long 
recognized that lung cancer in never smokers 
(LCINS) is a very different disease than lung cancer 
in smokers.1-5 Much attention has been drawn to 
LCINS, credited to the rapidly gained knowledge 
from genomic changes to treatment responses.6 
Following will be an overview of Àve key points: 
Lung cancer mortality and survival in never smokers. 
Mortality of primary lung cancer in never smokers 
has been rare, especially in western countries and 
regions without other environmental carcinogens. 
For powerful illustrations of pre-mature mortality 
attributable to current cigarette smoking, never 
smokers have much reduced mortality for major 
diseases, such as lung cancer by over 95%.7 Among 
people who have developed lung cancer, those 
unfortunate never smokers fortunately experience 
better prognosis from treatment responses to 
survival proximities,8,9 which was more pronounced 
in Far East Asian populations than in U.S. White 
populations.9,10 In Japanese never smokers with 
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integrated multi-level genomic approaches become 
crucial in concert with established prognostic and 
predictive markers. Another ongoing Mayo Clinic 
study utilizes a systems biology approach to identify 
overall survival (OS) related networks and gene 
signatures. This study has six steps and results will 
be presented: (1) to analyze whole genome gene 
expression proÀles in lung adenocarcinoma tumor 
tissues from never smokers and Ànd a signiÀcant 
correlation of a top candidate expression module; 
(2) to compare to the conventional model consisting 
of clinical variables for assessing OS prediction 
accuracy; (3) to use Gene Ontology enrichment 
analysis to locate potential biological process of the 
top candidate expression module; (4) to investigate 
the effect of the top candidate network module at 
the germline level; (5) to identify the top 30 genes in 
the OS-related module that overlapped between the 
discovery and validation data sets, namely the “hub” 
genes that were highly connected to other genes; 
and (6) to test these 30 genes, being up- or down-
regulated in adenocarcinoma tumor compared to 
adjacent normal lung tissues, and the added value of 
the hub genes in predicting OS.18 
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advanced stage non-small cell lung cancer (NSCLC), 
being female, having a better performance 
score, and a diagnosis of adenocarcinoma were 
signiÀcant favorable survival predictors.11 Never 
smokers and targeted therapy – EGFR-TKI drugs 
– a few unanswered questions. The essence of the 
breakthrough in lung cancer targeted therapy was 
the remarkably better response to epidermal growth 
factor receptor tyrosine kinase inhibitors (EGFR-
TKI) by never smoking female adenocarcinoma 
patients.12 Unanswered questions include, but not 
limited to, seemingly inconsistent results between 
disease-free and overall survival, true magnitude 
(effect size) of EGFR mutation (and other 
alterations) on NSCLC prognosis with all necessary 
confounding factors under control, and impact of 
both EGFR alterations and various speciÀc-target 
drugs on subgroups of progression and recurrence. 
LCINS and treatment toxicities. Although EGFR-
TKI drugs were generally well-tolerated, unusual 
toxicities have been sporadically reported from 
LCINS.13,14Whether these were speciÀc to never 
smokers and possible mechanisms warrants further 
investigation. Anaplastic lymphoma kinase (ALK) 
alterations in never smoker adenocarcinoma patients. 
The echinoderm microtubule-associated protein-
like 4 (EML4)–ALK translocation was discovered 
in NSCLC in 2007 and results in constitutively 
active ALK kinase activity.15 Several studies have 
reported ALK gene rearrangement being correlated 
with never or light/former smoking status, younger 
age, adenocarcinoma histology, and very rarely 
coincide with EGFR mutations, while mutually 
exclusive of KRAS mutation, as summarized by 
Yi and colleagues.16 An ongoing Mayo Clinic 
study is accomplishing four speciÀc objectives 
and results will be presented: (1) to assess whether 
IHC can be a practical tool for ALK screening in 
adenocarcinoma with a conÀrmatory FISH test; (2) 
to estimate the prevalence of ALK-positivity in an 
enriched study cohort by either or both IHC and 
FISH tests; (3) to describe clinical characteristics 
of cases by IHC, FISH, and combined IHC and 
FISH results; and (4) to evaluate clinical outcomes 
of ALK+ vs. ALK- cases, while controlling for 
clinically important prognostic factors, in a naturally 
followed observational patient cohort, i.e., 303 
never smokers with adenocarcinoma.17 Searching for 
new markers for prognosis and therapy: integrated 
genomic networks approach. Moving forward to new 
discovery and validation of biomarkers with high 
value in outcome prediction and targeted treatment, 
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of sublobar resections in terms of survival and 
recurrence of lesser resections. Therefore, the present 
gold standard for the parenchymal pulmonary 
resection for lung cancer still remains “lobectomy 
with (systematic) lymph node sampling/dissection”. 
[Radical resection for lung cancer: prognostic 
impact of LND] Very recently, the results of large, 
randomized trial to see the difference in survival 
between systematic LNS and LND (ACOSOG 
Z0030) was published [4]. As conclusions, it has 
been demonstrated that only 4% of patients had a 
negative LNS and found to have a positive lymph 
node at mediastinal LND and that mediastinal 
LOND did not improve the survival or disease-free 
survival in early stage lung cancer if preresection 
surgical staging of mediastinal and hilar nodes is 
negative [4]. However, as cautious notes, it needs 
to be mentioned that the results of this study is not 
generalized for resectable lung cancers of any stage, 
and that LND is still recommended for accurate 
staging to determine if postoperative therapy is 
indicated. [Extended indication of the adjuvant 
treatment] Owing to the accumulation of the results 
of many important clinical trials, it is becoming 
clearer that the postoperative adjuvant chemotherapy 
does improve the survival for the patients who 
undergo pulmonary resections for early stage lung 
cancer. Recent meta-analyses have shown that the 
postoperative chemotherapy is able to improve the 
survival by 4-5%. With the use of modern regimens 
of platinum doublet, the improvement is as high as 
9% [5,6,]. The clear deÀnition of the patients who 
might beneÀt from toxic postoperative chemotherapy 
and the sophistication of the regime are the future 
challenge of this topic. [Challenges for the less 
invasive surgery] As a technical challenge, the 
minimally invasive surgical approach is becoming 
more and more common in the surgical community. 
In the past decade, video-assisted thoracoscopic 
lobectomy has been performed for early stage 
lung cancer with increasing frequency. Although 
little direct comparison to see the superiority/
equivalence of survival and perioperative parameters 
between open and video-assisted procedures has 
been made, the fact is being generally accepted 
that thoracoscopic lobectomy is feasible and could 
be performed in safe [8]. However, it is necessary 
to clearly answer the questions such as whether it 
is possible to use the thoracoscopic approach for 
more technically demanding surgery, what is the 
advantage of thoracoscopic lobectomy with regard 
to not only medical but also the cost aspects, what 
15. Soda M, Choi YL, Enomota M, et al: Nature 
2007 
16. Yi ES, Boland JM, Maleszewski JJ, et al: Journal 
of Thoracic Oncology 2011 
17. Yang P, Kulig K, Oliviera AM, et al: European 
Multidisciplinary Conference in Thoracic Oncology 
(EMCTO) Conference 2011 
18. Li Y, Tang H, Sun Z, et al: American Association 
for Cancer Research (AACR) 2011 
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PL03.1 STATE OF THE ART SURGERY IN 
2011
Hisao Asamura 
Division Of Thoracicsurgery, National Cancer 
Center Hospital/Japan
Abstract: The evolution of lung cancer surgery has 
been well described, featuring several epoch–making 
surgical successes and important clinical trials. 
These included the Àrst successful pneumonectomy 
by Dr. Graham at the Barnes Hospital in St. 
Louis, the concept of “radical pneumonectomy” 
[1] and “radical lobectomy” [2] by Dr. Cahan 
at the Memorial Hospital in New York, and the 
randomized, phase III study comparing the surgical 
outcome of lobectomy and sublobar resections by 
North American Lung Cancer Study Group [3]. 
Through these studies and experiences, the standard 
mode of parenchymal pulmonary resection for lung 
cancer has been evolved from “pneumonectomy” to 
“lobectomy with (systematic) lymph node sampling/
dissection (LNS/LND)”. In the last randomized 
study, the comparison was made between lobectomy 
and sublobar resections for patients with T1N0M0 
lung cancer less than 3 cm in diameter, and it was 
shown that the prognosis of patients undergoing 
sublobar resection was signiÀcantly worse, and the 
local recurrence rate for sublobar resection was three 
times higher. Although the following retrospective 
studies have suggested at least the equivalent 
outcome after sublobar resection, there has been 
no deÀnitive demonstration of non-inferiority 
S52 Copyright © 2011 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
References: [1] Cahan WG, Watson WL, Pool 
JL. Radical pneumonectomy. J Thorac Surg 
1951;22:449-73.
[2] Cahan WG. Radical lobectomy. J Thorac 
Cardiovasc Surg 1960;5:555-72. 
[3] Lung Cancer Study Group, Ginsberg RJ, 
Rubinstein LV. Randomized trial of lobectomy 
versus limited resection for T1N0 non-small cell 
lung cancer. Ann Thorac Surg 1995;60:615-23. 
[4] Randomized trial of mediastinal lymph node 
sampling versus complete lymphadenectomy during 
pulmonary resection in the patient with N0 or N1 
(less than hilar) non-small cell carcinoma: results of 
the American College of Surgery Oncology Group 
Z0030 Trial. 
[5] Douillard JY, Tribodet H, Aubert D, et al.; 
LACE Collaborative Group. Adjuvant cisplatin and 
vinorelbine for completely resected non-small cell 
lung cancer: subgroup analysis of the Lung Adjuvant 
Cisplatin Evaluation. J Thorac Oncol. 2010;5:220-8. 
[6], et al. Adjuvant chemotherapy, with or without 
postoperative radiotherapy, in operable non-small-
cell lung cancer: two meta-analyses of individual 
patient data. Lancet. 2010;375:1230-1. 
[7] International Early Lung Cancer Action Program 
Investigators, et al. Survival of patients with stage I 
lung cancer detected on CT screening. N Engl J Med. 
2006;355:1763-71 
Keywords: Lung cancer, Minially invasive surgery, 
lymph node dissection, Surgery
State of the Art Thursday, 7 July 2011 08:30-10:00
PL03.2 STATE OF THE ART 
RADIOTHERAPY IN 2011
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Abstract: SigniÀcant improvements have been 
realised in radiotherapy techniques and results for 
lung cancer. Stereotactic body radiotherapy (SBRT) 
has become a routine treatment for patients with 
inoperable stage I-II NSCLC with local tumour 
control rates of 90 % with few side effects. SBRT 
has therefore the potential to compete with surgery 
in operable patients with early stage disease. 
From a meta-analysis based on individual patient 
data, it is clear that the concurrent administration 
of chemotherapy and radiotherapy resulted in a 
is the future advance of endoscopic surgery with 
the use of robotic technology. [Challenges for the 
lesser resection] Owing to the advent of reÀned 
chest CT images with higher resolution and CT 
screening programs, smaller lung cancers are being 
encountered in our practice more frequently [7]. 
Furthermore, the preoperative work-up for the 
surgical candidates has been sophisticated together 
with new technologies such as PET scan. In these 
situations, we have become able to deal with 
patients with the “true” early stage lung cancers, and 
therefore, the clinical signiÀcance and importance 
of sublobar resection need to be revised by 
deÀnitive clinical trials. The prognostic equivalence 
of segmentectomy against lobectomy could be 
demonstrated only through the scientiÀc, non-biased 
comparison despite the recent accumulation of 
retrospective studies in favor of segmentectomy. For 
these reasons, two large scaled studies are underway 
(Table). Both studies are targeting peripheral 
lung cancers less than 2 cm in diameter without 
nodal involvement, and the accrual of more than 
1,000 patients is planned. The future international/
regional collaboration must be encouraged to 
draw meaningful conclusions from these studies. 
Otherwise, the indication of segmentectomy 
for peripheral lung cancers will continue to be 
undetermined. Randomized, phase III Trials 
comparing lobectomy and sublobar resections. 
CALGB140503 JCOG0802/WJOG 
Patients 
Peripheral small 
(2cm or less) 
NSCLC without 
pure GGO lesion 
Peripheral small (2cm or 
less) NSCLC without non-
invasive lung cancer on 
Chest CT-scan 
Trial design 
Randomized phase 
III / non-inferiority 
trial 
Randomized phase III / 
non-inferiority trial 
Target number. 
/ Entry period / 
follow-up 
1297 cases 
(908 cases after 
randomization) / 5 
years / 3.25 years 
1100 cases / 3 years / 5 
years 
Standard arm Lobectomy Lobectomy 
Investigational arm 
Wedge resection or 
Segmentectomy 
Segmentectomy 
Primary endpoint Overall survival Overall survival 
Secondary endpoints 
DFS, Local 
recurrence rate, 
Distant recurrence 
rate, Postope. 
pulmonary 
function at 6 
months (FEV1.0, 
FVC) 
Postope. pulmonary 
functions at 3 months and 1 
year, DFS, Local recurrence 
rate, Adverse events, 
hospitalization, chest 
drainage term, Operative 
time, bleeding amount, 
number of auto-staplers 
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This is most convincingly demonstrated in patients 
with brain metastases, but is explored in other parts 
of the body as well. PCI was shown to increase 
survival in patients with stage IV SCLC and is now 
considered to be standard care. SBRT has also a role 
to play in the treatment of metastases from other 
tumours than lung cancer. Most studied is SBRT 
to treat lung- or liver metastases from colo-rectal 
cancer. The results are comparable with surgical 
resection with the same low incidence of side effects 
as with SBRT for early stage NSCLC. Standard 
radiotherapy still provides palliative beneÀt for the 
majority of individuals suffering from incurable 
disease with e.g. bleeding, obstruction, pain, 
neurological symptoms … These achievements 
could only be made by a truly multi-disciplinary 
approach involving clinicians from different 
specialities, physicists, biologists, technicians and 
colleagues from imaging and computer sciences. 
Examples include the incorporation of imaging 
such as 4D-CT and Positron Emission Tomography 
(PET) in radiotherapy treatment planning, the 
development of more accurate dose calculation 
algorithms, and use of more sophisticated imaging 
and dose treatment veriÀcation techniques on the 
treatment machine. These developments allow 
treatment adaptation for individual patients during a 
course of radiotherapy based on changes in tumour 
anatomy. These technical and biological reÀnements 
parallel increased standardisation, quality assurance 
and patient safety at all levels of radiotherapy. As 
most patients still die of their cancer, due to both 
distant and local relapses, there is much room 
for improvement at all sites. This includes better 
treatment options for the old and/ or frail patient, 
characterisation of the tumour by Àne needle 
biopsies, circulating tumour cells and imaging, 
tailoring systemic treatment and radiotherapy 
according to these characteristics, taking into account 
intra-tumour heterogeneity, including stem cells, for 
e.g. selective boosting of these areas, heterogeneity 
within organs at risk and the role of prophylactic 
cranial irradiation (PCI) to decrease the incidence of 
brain metastases. In all these and other areas, the role 
of radiotherapy is likely to increase. Finally, even 
with these developments radiotherapy is still the 
cheapest anti-cancer treatment. 
Keywords: Radiotherapy, state of the art
signiÀcant improvement of the 5-year survival of 
patients with locally advanced, stage III NSCLC. 
Most of these patients had multi-level N2 or N3 
disease and had bulky nodes that most would 
consider to be irresectable. The role of radiotherapy 
in patients with resectable N2 disease still fuels hot 
debates. These patients were randomized between 
surgery and deÀnitive chemo-radiation after 
induction concurrent chemo-radiation in the Lung 
Intergroup Trial 0139. 75 % of the patients had 
single nodal station NSCLC. There was no difference 
in survival between the two arms. Although the study 
has often been criticised because of the high rate of 
pneumonectomies and toxic deaths in the surgery 
arm, the overall median survival as well as the 5-year 
survival, about 24 months and 25 %, respectively, is 
at least as good as single-institutional surgical series 
that reported on an intention to treat basis. Indeed, 
a major caveat in surgical series is beside patient 
selection that often only patients that indeed went on 
to surgery are reported, which is mostly only 70-80 
% of the initial population that initiated therapy. In 
the same trial, a hypothesis-generating non-planned 
subgroup analysis was performed of patients that 
were treated with concurrent chemo-radiation (45 
Gy) followed by lobectomy. As expected, the median 
survival increased to 34 months and the 5-year 
survival to 36 %, but this is analogous as what 
has been achieved with concurrent chemotherapy 
and radiotherapy without surgery in patients with 
single nodal station N2 disease. Patients with small 
volume disease (< 50 ml) may even have better 
survival rates with systemic treatment concurrently 
with radiotherapy. In conclusion, radiotherapy is an 
integral part in the management of stage III NSCLC. 
The most signiÀcant advances that were achieved 
for small cell lung cancer came from radiotherapy. 
Meta-analyses done with individual patient data 
showed that the addition of chest radiotherapy and 
prophylactic cranial radiotherapy (PCI) improved 
5-year survival in patients with stage I-III disease. 
Further more, phase III trials and meta-analyses 
demonstrated that the 5-year survival increased 
from 15 % to 26 % by delivering early, accelerated 
chest radiotherapy concurrently with chemotherapy. 
Historically, in patients with distant metastases, 
radiotherapy was considered not to inÁuence 
survival. This is not longer the case. In selected cases 
with 1-4 distant metastases (“oligometastases”), 
high-dose stereotactic radiotherapy results in local 
tumour control rates of 90 % and more and a small, 
but signiÀcant proportion of long-term survivors. 
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TKIs in 1st. line therapy for advanced NSCLC. A 
remaining question is what the most optimal assay 
method for EGFR mutation testing is and what will 
be the most cost-effective screening test in the future. 
Direct sequencing is considered the “gold standard”, 
but more sensitive PCR-based methods for detection 
of the most frequent mutations in exon 19 and 21 are 
developed. (i. e DxS Scorpion). Another remaining 
question is the clinical relevance of the less frequent 
minor mutations found in exons 18-21. EGFR 
Resistant Mutations are reported mainly in exon 
20; T790 M mutations are the most important ones. 
This mutation accounts for about 50% of acquired 
resistance to EGFR TKIs, but occurs also more rarely 
in pretreatment specimens. The exact frequency 
of this mutation in pretreatment specimens is not 
clear. Other EGFR Resistant Mechanisms: Several 
other mechanisms for either intrinsic resistance or 
acquired resistance to EGFR TKIs are suggested. 
MET-ampliÀcation, particularly in EGFR mutation 
positive tumors and IGFR has been hypothesized 
as intrinsic-and/or acquired resistant mechanisms. 
EGFR Protein expression: has been studied in many 
trials by IHC, and no clear association to sensitivity 
to EGFRTKis has been established. However, the 
role of EGFR IHC for cetuximab therapy is still 
under investigation, and most recent data from the 
FLEX study indicate a predictive role for EGFR 
IHC at least in prediction of response to therapy. 
EGFR gene copy number: While EGFR gene 
copy number detected by FISH has demonstrated 
some predictive association to EGFR TKIs, its 
role for clinical practice in not clear. More studies, 
particularly in EGFR wt patients are necessary. 
Preliminary studies indicate a potential predictive 
role for cetuximab, and ongoing prospective phase 
III study (SWOG 0819) is validating this Àndings. 
Proteomics: several prospective studies are currently 
ongoing for validation of the proteomic classiÀer, 
Veristrat® (Biodesix, Colorado, USA). ALK-
Gene Rearrangement: This gene abnormality (or 
abnormalities) occurs in 3-5 % of unselected patients 
with NSCLC and occurs mostly in younger females, 
never smokers with adenocarcinoma histology. 
Although, a few cases are reported where both 
ALK-gene rearrangement and EGFR-mutations 
occur, those are practically mutual exclusive. 
Treatment with the ALK-inhibitor, crizotinib® 
(PÀzer), demonstrated in patients with tumors 
harboring this abnormality had a response rate of 
60% and DCR around 80% with a median PFS> 9 
months, despite progression on previous therapy. 
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Abstract: Personalized medicine has Ànally come 
to lung cancer and is based on molecular pathology. 
This development requires a multidisciplinary 
approach to diagnosis and management of lung 
cancer patients. Many individual prognostic markers 
often based on protein expression (IHC) have been 
published, particularly in early stage NSCLC. 
Similarly, many multigene classiÀers based on 
gene expression array sets or multiple PCR gene 
expression classiÀers have shown prognostic value 
in test sets, but none of them have yet been sufÀcient 
validated for clinical use. Some predictive molecular 
markers have been established and changed 
practice. Many candidate markers are in prospective 
validation studies. New “drugable” molecular 
abnormalities are continuously detected and multiple 
speciÀc targeted agents are rapidly being developed. 
This development is demanding standards for tissue 
acquisition, assay developments and implementation 
into clinical practice. For tissue acquisition it is 
mandatory to secure sufÀcient tissue for exact 
histopathological diagnosis and subtyping as some 
‘standard” chemotherapeutic agents are histological 
restricted in use. While the IASLC/WHO 
international histopathological classiÀcation still is 
based on conventional morphological assessment, 
IHC markers are widely used for supporting the 
histopathological subtyping and to reduce the 
NSCLC NOS diagnosis. Molecular testing of the 
tumor tissue, particularly for EGFR mutations and 
ALK-gene-rearrangement, is today mandatory for 
choice of 1. line therapy for advanced NSCLC, and 
sufÀcient tissue (preferentially core biopsy) should 
be secured. In many institutions this will be done 
by having a pathologist’s assessment in conjunction 
with the diagnostic procedure. While cytology are 
today frequent diagnostic specimens, it is rarely 
sufÀcient for both primary diagnosis and molecular 
testing, unless ‘tissue” blocs are made thereof. 
Predictive biomarkers: Epidermal Growth Factor 
Receptor Mutations: Several prospective clinical 
trials demonstrated the crucial role of activating 
EGFR mutation testing for selection of EGFR 
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relatively static over the same period and will not 
be addressed in this presentation. 1) Regarding 
tumor histology, molecular proÀling studies conÀrm 
that NSCLC represents a heterogeneous group of 
malignancies, linked primarily by site of origin, 
rather than one disease. From the standpoint of 
pathologic subtyping, NSCLC can be differentiated 
into adenocarcinoma (which can be further sub-
classiÀed) squamous cell carcinoma, large cell 
carcinoma (neuroendocrine and non-neuroendocrine) 
and a variable group classiÀed by pathologists 
as non-otherwise speciÀed (NOS). While 
adenocarcinoma histology is known to correlate with 
a higher likelihood of response to EGFR TKIs, this 
association does not directly translate into superior 
survival, absent other factors such as predictive 
biomarkers. For example, in the BR.21 trial testing 
the EGFR TKI erlotinib, the hazard ratios for 
survival were virtually identical for adenocarcinomas 
versus squamous cell histology. For the Àrst time 
in recent history, randomized clinical trials in 
NSCLC now suggest that histologic subtyping can 
also be used as a chemotherapy selection factor. 
However, even these data are primarily restricted 
to a single chemotherapeutic agent: pemetrexed. 
In the randomized trial of Scagliotti, Gandara et al, 
comparing pemetrexed-cisplatin versus gemcitabine-
cisplatin, survival was superior in those patients with 
non-squamous histology receiving the pemetrexed-
based regimen. Conversely, gemcitabine-cisplatin 
resulted in superior survival in patients with 
squamous histology tumors. These data, combined 
with retrospective analyses of other pemetrexed trials 
in NSCLC, suggest that histologic subtype can now 
be used to select individual patients who may beneÀt 
more or less from different chemotherapy regimens. 
From a regulatory standpoint, these Àndings have 
led the FDA in the USA to limit pemetrexed therapy 
to NSCLC patients with non-squamous histology. 
Of note, analysis of the large SWOG data base, 
among others, supports the conclusion that the 
activity of chemotherapeutic drug classes such as 
the microtubule-targeted agents taxanes and vincas 
is not histology-speciÀc, and that these drugs are 
equally effective regardless of histologic subtype of 
NSCLC. In contrast, emerging evidence suggests 
that platinum compounds are generally more active 
adenocarcinomas than squamous cell cancers, based 
on differences in DNA repair capacity as discussed 
below, but that there is high variability between 
individual patient cancers. 2) Predictive Biomarkers: 
It is quite likely that underlying molecular factors 
The “break-apart” FISH (Abbot Diagnostics) has 
been standard diagnostic assay for the crizotinib® 
studies, but more and more data are reported on 
other diagnostic platforms (e. g PCR and IHC). 
Encouraging data are reported for IHC compared to 
FISH, and 100% correlations are reported for FISH 
negative and IHC negative ones and for IHC 3+ and 
FISH, while some discrepant results are reported 
for IHC 1+/2+. However, by standardizing the IHC 
and optimization of antibodies and IHC techniques, 
this assay might be more clinical useful for routine 
pathology screening of the ALK-gene rearrangement. 
Other Predictive Biomarkers: Prospective clinical 
trials are currently ongoing or planned to validate 
c-MET IHC and FISH (e.g MetMab, Genentech/
Roche) and E-cadherin IHC (Entinostat, Syndax). 
Many other biomarkers are currently under clinical 
investigations. Multigene Analyses: For future 
individualized therapy of patients with NSCLC 
multigene analyses seems to be the “way to go”, 
and several mass mutation assays are already in use 
(i. e SnapShot®, Sequenom®), which in the future 
work-up might be combined with other assays, i. 
e gene copy number or protein expression. Large 
prospective studies are currently ongoing among 
multiple institutions in the US (e.g. the Lung 
Cancer Mutation Consortium) performing mass 
mutation analyses of patients with advanced NSCLC 
with speciÀc clinical trials linked to the different 
mutations found. 
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TREATMENT IN 2011
David R. Gandara 
Oncology, UC Davis Cancer Center/United States Of 
America
Abstract: Systemic treatment of non-small cell 
lung cancer (NSCLC) has rapidly evolved over 
the last 10 years. While platinum-based doublet 
chemotherapy continues to be generally accepted as 
a standard of care in advanced stage NSCLC patients 
with a good performance status, with one notable 
exception described below, interlinking themes of 
1) histology-based therapy, 2) predictive biomarkers 
and 3) maintenance therapy have emerged as 
dominant factors in therapeutic decision-making 
for individual patients. In stark contrast, therapy of 
extensive stage small cell lung cancer has remained 
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cetuximab-containing therapy in colorectal cancer, 
this does not appear to be the case in NSCLC. One 
of the most important advances of the last few years 
is development of crizotinib, a selective inhibitor 
of ALK-fusion gene-positive NSCLC. It is likely 
that in the future, this paradigm of selective therapy 
for a molecularly-deÀned population will become 
more the rule rather than the exception. Lastly, one 
of the largest unmet needs in lung cancer therapy is 
identiÀcation of molecular selection factors for anti-
angiogenic therapies, where bevacizumab represents 
a prime example of “untargeted use of targeted 
therapy”. 3) Maintenance therapy: It is a tribute 
to recent advances by lung cancer investigators 
that a discussion of maintenance therapy (deÀned 
as what we do after a patient has derived clinical 
beneÀt from Àrst-line therapy) in advanced NSCLC 
is even possible. Here, there are data in support of 
“switch maintenance” chemotherapy (pemetrexed 
after Àrst-line therapy with a platinum plus non-
pemetrexed regimen) and also for an EGFR TKI. 
How strong the evidence is for these approaches 
remains “in the eye of the beholder”, as well as 
the particulars of exactly which patients derive the 
greatest beneÀt. Clearly, “watch and wait” of therapy 
with close monitoring remains a viable option in 
many patients who have responded and are then 
asymptomatic from their disease. An important 
research question to be addressed in future trials 
is whether “switch maintenance” is truly superior 
to “early second line therapy” at the time of Àrst 
evidence of progressive disease. In Summary, much 
progress has been made in the management of 
advanced NSCLC patients in the last few years. At 
present, integrated decision-making, supplementing 
clinical factors with, histology and molecular factors 
is now feasible. Further, it is desirable that patients 
themselves engage their physicians in this decision-
making process, empowered by as much knowledge 
as possible about their own cancer and their own 
clinical situation. The next few years will determine 
the pace of this transition from empiricism to 
integrated and personalized medicine. 
are responsible for histology-based differences in 
chemotherapy efÀcacy in NSCLC, and that testing 
at the individual patient level will be required 
in the future to optimize therapeutic outcomes: 
hence personalized medicine. In fact, recent data 
suggest that histology is at best a crude method 
of molecular selection, and that tumor molecular 
proÀling will supplant histology in the near future 
for selecting chemotherapy in individual NSCLC 
patients. For example, for pemetrexed a number 
of possible predictive molecular biomarkers have 
been described. The largest body of evidence 
relates to thymidylate synthase (TS), an enzyme 
important in DNA biosynthesis and a molecular 
target of Áuropyrimidine- and pemetrexed-based 
therapies. Lower TS expression levels have been 
associated with a greater likelihood of response 
to Áuoruracil (5FU)-containing therapies in 
gastrointestinal cancers, and to pemetrexed in 
NSCLC, mesothelioma and breast cancer. Although 
TS mRNA expression is statistically lower in groups 
of patients with NSCLC of adenocarcionoma 
or large cell subtypes, compared with those of 
squamous histology, there is tremendous overlap 
of expression ranges in individual patient tumors. 
Conversely, it should be also noted that pemetrexed 
shows limited activity in small cell lung cancer, a 
histiology associated with characteristically high 
levels of TS expression. As noted above, even more 
data are emerging regarding ERCC1 and RRM1 as 
molecular selection factors for platinum compounds 
and/or gemcitabine, respectively. Although a variety 
of different methodologies have been employed to 
measure protein or mRNA expression of these genes, 
cross-study results are consistent in demonstrating 
both prognostic and predictive value. A number of 
clinical trials are in progress worldwide attempting 
to validate these biomarkers. While the issue of how 
to integrate these data into clinical decision-making 
outside of a clinical trial remains “in Áux”, the 
presence of commercially available assays demands 
that Oncologists be up-to-date on relevant literature 
and ready to answer patient questions about use in 
day-to-day practice. Even more relevant in 2011 is 
mutation status for EGFR as a molecular predictor 
of increased efÀcacy of EGFR TKIs. Activating 
EGFR mutations are typically associated with a 
never-smoking history in NSCLC. Of interest, EGFR 
mutation status does appear to predict for activity of 
the EGFR-directed monoclonal antibody cetuximab 
in NSCLC. Further, while KRAS mutations are 
established as a negative predictor for beneÀt of 
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growth factor 2 (c-erbB-2)), regulation of cell 
cycle (cyclins, p16, p21, retinoblastome (Rb)), 
apoptosis (p53, Bax, B cell leukemia 2 (Bcl2), 
(fragile histidin triad (FHIT), survivin, mouse 
double minute 2 (MDM2), p14arf, semaphorins), 
inÁammation (cyclo-oxygenase 2 (COX-2), nuclear 
factor kappa-light-chain-enhancer of activated B 
cells (NF-KB)), invasion (metallopeptidases, tissue 
inhibitors of metallopeptidases), angiogenesis 
(vascular endothelial growth factor (VEGF) and 
VEGF recepteur e.i. neuropilins), cell adhesion 
(E-cadherin, E catenin), DNA repair (checkpoint 
2 (CHK2), Ataxia telangiectasia mutated (ATM), 
p53, histone H2A gene (H2AX)). We performed 
gene expression analyses accross all stages of lung 
squamous carcinogenesis. Canonical pathways 
described in invasive lung carcinomas were 
already activated in pre-invasive lesions, eg hepatic 
Àbrosis/hepatic stellate cell activation, leukocyte 
extravasation signaling, complement system, acute 
phase responding, coagulation system, PXR/RXR 
and LXR/RXR activation, NFB signaling, cell cycle 
G2/M DNA damage checkpoint regulation and role 
of BRCA1 in DNA damage response. In canonical 
pathways analyses, the activation of immune 
response at step 2 was also an important pattern, 
i.e. antigen presentation pathway, IL-4, IL-8 and 
IL-10 signaling, T-cell receptor signaling, natural 
killer cell signaling, TREM-1 signaling, Interferon 
signaling and complement system. We found by 
gene expression analyses that the most signiÀcant 
pathway involved in the transition between the 
lesion at low risk to progress (metaplasia, mild and 
moderate dysplasia) versus the lesion at high risk 
(severe dysplasia) was immune response including 
tumor growth factor B (TGFB) family, tumor 
necrosis factor (TNF) family, immune receptors 
(toll-like receptors, interleukine receptors, integrin 
receptors) chemokine ligands, interleukines, 
complement components, supressor of cytokine 
signaling (SOCS) family, Sry-related HMG box 
(SOX) family. The signiÀcant and early involvment 
of immune response in SCC development indicates 
the importance of microenvironment and the 
potential interest of discovery interesting targets in 
this pathway for chemoprevention and/or therapy. 
Pathways pathogenesis of ADC. AHH are considered 
to be the precursors of ADC. These lesions are very 
rare to diagnose through CT guided transthoracic 
biopsies and they are mainly found on resected 
specimens next to the tumors. Because AHH is 
more difÀcult to sample than SCC precursors, less 
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Abstract: The three major histological subtypes 
of lung cancer are lung squamous cell carcinoma 
(SCC), lung adenocarcinoma (ADC) and small-cell 
lung carcinoma (SCLC). Precursors lesions have 
been identiÀed for these three lesions: dyplasia 
and carcinoma in situ (CIS), atypical adenomatous 
hyperplasia (AAH) and diffuse idiopathic pulmonary 
neuroendocrine cell hyperplasia (DIPNECH) 
are the supposed precursors of SCC, ADC and 
SCLC, respectivelly. Little is know about the 
molecular biology of the precursors of SCLC, 
DIPNECH. This presentation will focus on the 
molecular pathology and pathways of SCC and 
ADC pathogenesis. Pathways pathogenesis of 
SCC. Morphological changes in the bronchial 
epithelium preceeding the development of SCC 
include basal cell hyperplasia, squamous metaplasia, 
dysplasia at three degrees (mild, moderate and 
severe) and carcinoma in situ (CIS). As detected 
with a good sensitivity by using autoÁuorescence 
bronchoscopy, the molecular biology of these 
lesions have been studied. Various mechanism of 
molecular abnormalities are involved at the earliest 
steps of SCC pathogenesis: chromosomes (loss of 
heterozygocity, aneuploidy), genes (mutations), 
epigenic (methylations), transcriptomic changes 
(changes in expression level expression for mRNA 
and miRNA), proteic changes (expression level). 
The molecular functions and pathways that are 
altered in SCC pathogenesis include differenciation 
(cytokeratines), cell immortalization (telomerase, 
RNA component telomerase reverse transcriptase 
(hTERT)), cellular proliferation (Ki-67, PCNA, 
epidermal growth factor (EGFR) and epidermal 
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structure. Remodelers work with other chromatin 
factors to control packaging and unpackaging 
as the DNA elements that control chromosomal 
processes (enhancers, promoters, replication 
origins) must be exposed in a regulated manner 
to properly execute various processes, such as 
gene transcription,DNA replication, DNA repair, 
and DNA recombination. Therefore, chromatin 
structure not only provides a packaging solution, 
but also an opportunityfor regulation. There are 
four different families of chromatin remodeling 
complexes. All four utilize ATP hydrolysis to alter 
histone-DNA contacts and, in addition to the ATPase 
domain, are able to bind to DNA and histones, and 
to modify and alter histones. The Àrst isolated and 
best studied of the remodeler families is the SWI/
SNF complex. Of the 20 odd family members, 10-
12 form large (~2 kDa) complexes. The proteins 
have a different nomenclature from the genes. Each 
complex contains one of the two ATPase proteins 
(SMARCA2 gene or BRM protein, or SMARCA4 
or BRG1 protein), three core proteins essential for 
basic remodeling activity, and several accessory 
proteins that determine cell and gene speciÀcity (). 
Because of its crucial role in controlling chromatin 
remodeling and histone modiÀcation which in turn 
regulate cell cycle, development, differentiation 
and transcription, the complex components may 
function as tumor suppressor genes (TSGs) () and 
mutations of SMARCA4 (mainly homozygous 
deletions) are present in lung cancer cell lines 
and tumors while SMARCA2 may be silenced 
by epigenetic effects (). Some members may be 
mutated in other cancers including ovarian, renal 
cell and malignant rhabdoid tumors (), including the 
accessory protein BAF250A (ARID1A). Because 
preliminary data indicated that the SWI/SNF 
complex was deregulated by multiple mechanisms 
we undertook a comprehensive analysis of the 
entire complex in NSCLC cell lines and tumors, 
using multiple platforms. Such a comprehensive 
examination has never been applied to any tumor 
type. Our preliminary data indicates that multiple 
members of the complex are deregulated in a variety 
of individual samples, often in concordance. Our 
preliminary data are: · About half of the members 
of the 20 gene complex display a wide variety of 
homozygous or heterozygous mutations or are 
inactivated by epigenetic phenomena in about 75% 
of the cell lines. Cell lines frequently have multiple 
mutations, up to 5, in individual cases. More detailed 
analysis of three genes, the ATPases SMARCA2 
markers have been studied in the former than in 
the later. However it is easier to study them on 
mouse models than precursors of SCC. Many of the 
molecular abnormalities have been found in those 
lesions as in SCC precursors: chromosomes (loss 
of heterozygocity, aneuploidy), genes (mutations), 
epigenic (methylations), proteic changes (expression 
level). At the early stages, in AHH, through 
studies in human samples or in mouse models, 
early molecular abnormalities have been identiÀed 
including cell cycle regulation (cyclines, Rb, p21), 
cell proliferation (Ki-67, EGFR, c-erbB-2, K-Ras), 
apoptosis (p53, survivin), inÁammation (COX-2) 
and cell immortalization (telomerase). Conclusions. 
More is know about pathways of early pathogenesis 
in SCC than in ADC because the Àrst one is 
accessible in vivo. But more therapeutic applications 
of signaling pathways have practical impact on 
patients with invasive ADC so far and further 
development of ongoing research in biomarkers are 
expected to provide more therapeutic targets and 
more predictive markers for response or resistance 
to speciÀc therapies for both SCC and ADC. 
Targeting immune pathways could be interesting for 
chemoprevention and/or therapy in SCC. 
Keywords: Carcinogenesis, pathways
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Abstract: There exists a dynamic balance between 
genome packaging and genome access. The 
linear length of chromosomal DNA presents a 
signiï¬cant topological challenge, as nearly two 
meters of DNA must be packaged into a nucleus 
that is about 200,000 fold smaller. The solution 
involves chromatin,the collaboration among 
specialized DNA packaging proteins (primarily 
histones), factors for histone deposition and 
removal, histone modiï¬cation enzymes, and a set 
of chromatin remodeling complexes (remodelers) 
().Remodelers use the energy of ATP hydrolysis 
to change the packaging state of chromatin by 
moving, ejecting, or restructuringthe nucleosome, 
which is the primary repeating unit of chromatin 
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Abstract: K-ras mutations alone do not signiÀcantly 
predict response to chemotherapy or mTOR 
inhibitors. Earlier studies demonstrated a relationship 
with chemotherapy response or prognosis by K-ras 
mutation type. Recently, different K-ras mutations in 
lung cancer cell lines exhibit varying sensitivity to 
chemotherapy drugs such as cisplatin, pemetrexed, 
taxol and sorafenib . We recently observed that 
elevated levels of AEG-1 and NFKBIA correlate 
with the presence of K-ras mutations (unpublished 
data). We have also examined other genes that 
modulate the activity of K-ras mutations, such as 
galectin-3 and nucleophosphamin-1 (NPM1) (See 
Figure). NPM1 speciÀcally interacts with K-ras on 
the plasma membrane and stabilises K-ras plasma 
membrane levels. Recruitment of Gal-3 drives 
K-rasGDP nanoclustering, leading to increased 
ERK activation . Mutations in exon 12 of NPM1 
have been found in AML and predict response to 
chemotherapy (See Figure). We have also examined 
SIAH2 expression which can drive K-ras activation. 
We observed that EZH2, an oncogene which 
activates NFÐšB and RAS, closely correlated with 
BRCA1 expression in a series of 60 metastatic 
NSCLC patients (Santarpia et al. submitted to BJC). 
However, in this small series of patients correlation 
between levels of EZH2 and K-ras mutations was 
not found. Due to the relevance of EZH2 in K-ras 
signalling, further research on this gene should be 
conducted as part of the K-ras mutations project. 
EZH2 mutations (Try641) have been reported in 
follicular and diffuse large B-cell lymphomas. 
BRAF mutations have been identiÀed in NSCLC, 
more frequently in women (9%), and only V600E 
had prognostic signiÀcance in a series of 1000 
lung cancers screened (Marchetti et al. conÀdential 
(protein = BRM), SMARCA4 (protein = BRG1) and 
the accessory protein ARID1A (protein = BAF250A) 
indicates high levels of protein inactivation by 
multiple mechanisms &ndash histone deacetylation 
(SMARCA2), homozygous deletions (SMARCA4), 
mutations (ARID1A) or DNA methylation (PHF10). 
However, protein loss (Western blot analysis of 
nuclear fractions) indicates that these mechanisms 
explain only part of loss, and that other mechanisms 
probably operate at the transcriptional/translational 
level. · Allelic loss of the entire complex occurs more 
frequently than by chance in tumors (p = 0.002) and 
cell lines (p = 0.01), compared to the same number 
of randomly selected genes (1000 permutations 
tested). Pair by pair comparisons indicate that 
several gene pairs demonstrate concordant loss 
at highly signiÀcant rates. Thus our preliminary 
data indicates widespread, frequently concordant 
inactivation or allelic loss of multiple members of 
the SWI/SNF complex in most if not all tumors. 
Inactivation patterns show major differences with 
our previous concepts regarding tumor suppressor 
genes: 1) inactivation may be uni- or biallelic and 
2) multiple members of the same large functioning 
unit are inactivated concordantly. Of interest, 
haploinsufÀciency of the ARID1A gene results in 
peri-implantation embryonic lethality and prevents 
ES cell differentiation (). These Àndings are of 
considerable biological and possibly of clinical 
interest. 
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unpublished data) (See Figure). In addition, MEK1 
mutations have been described at low frequencies 
, which could be susceptible to treatment with 
selective inhibitors. MAP3K8 (the gene encoding 
COT) is a MAPK pathway agonist driving resistance 
to RAF inhibition in BRAF (V600E) cell lines 
(See Figure). Other downstream components that 
can inÁuence clinical behaviour of tumors with 
K-ras mutations is the recently described model for 
PKCƣ regulation of apoptosis and survival in K-ras 
dependent NSCLC (See Figure). Overexpression 
of PKCƣ promotes tumor progression in pancreatic 
cancer . Therefore, in tumors with K-ras mutations 
many genetic modiÀers can be relevant in delivering 
prognostic information and for predicting response 
to selective inhibitors, including MEK inhibitors , 
or mTOR inhibitors. Interestingly, overexpression 
of the atypical PKCƨ confers poor prognosis in 
early NSCLC and is ampliÀed in squamous cell 
lung cancer . LKB1/STK11 is also one of the most 
frequently mutated tumor suppressor genes in 
NSCLC . LKB1 mutations can occur concomitantly 
with the presence of K-ras mutations and tumors 
with double mutations are reported to be more 
sensitive to mTOR and MEK inhibitors . LKB1 
mutations are widespread but three hotspot regions 
were described . LKB1 forms complexes with 
STE20-related adaptor (STRAD) and mouse protein 
25 (MO25), phosphorylates and activates 13 kinases, 
including AMPK. Activated AMPK phosphorylates 
TSC2, activating TSC1-2 complex, which inhibits 
RAS homologue enriched in brain (RHEB), 
preventing activation of mTOR . 
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worse outcome (HR 1.09, p=0.39; adenocarcinoma 
HR 1.03, p=0.93). KRAS as a Predictive Marker 
The role of KRAS in activating the AKT pathway 
suggests a potential role as a predictive marker for 
resistance. JBR.104 that compared adjuvant cisplatin/
vinorelbine to observation in resected stage IB-
II NSCLC included prospective evaluation and 
stratiÀcation by RAS status. The 333 patients with 
WT-RAS enjoyed signiÀcant survival beneÀt from 
chemotherapy (HR=0.69, p=0.03). In contrast among 
117 patients with mutated RAS, there was no beneÀt 
(HR 0.95, p=0.87). However, the interaction test of 
chemotherapy effect in WT versus mutant RAS was 
non-signiÀcant (interaction p=0.29). Similar results 
were found in the LACE-Bio analysis. Patients 
with WT-KRAS derived modest beneÀt from 
adjuvant chemotherapy (HR 0.89, p=0.20); those 
with mutations did not beneÀt (HR 1.02, p=0.91)5. 
However, once again the interaction p-value was 
not signiÀcant (interaction p=0.50). This poses 
an important clinical dilemma. In the absence of 
signiÀcant interaction (in the statistical sense), 
do the results justify making adjuvant treatment 
decisions based on KRAS status? The answer likely 
is “No” at this time. The oncology community 
must be held to a very high level of evidence in 
order to withhold a treatment, and in the absence 
of prospectively validated studies, this remains a 
question of research interest. In advanced NSCLC, 
data on the impact of KRAS on chemotherapy are 
limited. Trials have been retrospective, frequently 
with imbalance in other prognostic factors between 
patients with WT and mutated KRAS. Because 
the studies were underpowered and not performed 
in randomized patient populations controlled for 
potential confounding factors, the results remain 
insufÀcient for use in clinical practice. Small 
molecule EGFR tyrosine kinase inhibitors (EGFR-
TKIs) now have demonstrated clinical activity in 
Àrst to third-line treatment of NSCLC6. Eberhard 
et al7, in their retrospective analysis of KRAS from 
TRIBUTE, were the Àrst to suggest that KRAS 
mutation might predict outcome in patients treated 
with EGFR TKIs. Decreased survival was seen 
in patients who received erlotinib/chemotherapy 
compared to patients with mutations who received 
chemotherapy alone and patients with WT-KRAS 
who received chemotherapy +/- erlotinib (p=0.02). 
Among the patients with mutant KRAS, the hazard 
ratio for survival of erlotinib/chemotherapy versus 
chemotherapy was 2.1 (CI 1.1-3.8). In chemotherapy 
alone patients, KRAS mutation status did not affect 
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Abstract: NSCLCs with Ras mutation present 
a major therapeutic challenge. Agents targeting 
Ras farnesyl transferase or Ras effectors such 
as MEK have only met with limited success. To 
better understand the mechanism of Ras-driven 
oncogenesis and identify additional therapeutic 
targets, we and others recently carried out RNAi 
synthetic lethal screens to evaluate the genetic 
dependencies of cancer cells with Ras mutation. 
These studies have identiÀed a number of genes 
operating in diverse cellular pathways that are more 
critical for the viability of Ras mutant cells compared 
to Ras wild type cells. This reÁects the cancer cell’s 
enhanced need for stress-relief and survival genes – a 
phenomenon we call “non-oncogene addiction” that 
can be exploited for cancer therapeutics. 
Keywords: ras, synthetic lethality, RNAi, genetic 
screen
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Abstract: Clinical Approach to KRAS Mutant 
Non-Small Cell Lung Cancer KRAS as a 
Prognostic Marker Slebos et al1 were the Àrst to 
report that KRAS mutations occurred in ~30% of 
adenocarcinoma and were associated with poorer 
prognosis. Since then, >50 retrospective studies 
have been reported, but with contradicting results. 
A meta-analysis of 23 studies (n=2632) and 11 
restricted to 1170 adenocarcinoma reported worse 
outcome with RAS mutation: hazard ratio (HR) 1.39 
(p=0.03) and 1.50 (p=0.1), respectively2. A meta-
analysis involving 1721 patients from studies of 
platinum-based adjuvant chemotherapy (LACE-Bio)3 
reported KRAS mutation in 19.7%, and a modestly 
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cancer resection. New Engl J Med 352:2589-
97,2005. 5. Tsao MS, Hainaut P, Bourredjem A, et 
al. LACE-Bio pooled analysis of the prognostic and 
predictive value of KRAS mutation in completely 
resected non-small cell lung cancer. Proc ESMO, 
2010 6. Wheatley-Price P, shepherd FA. Epidermal 
growth factor inhibitors in the treatment of lung 
cancer: reality and hopes. Curr Opin Oncol 20:162-
75,2008. 7. Eberhard DA, Johnson BE, Amler LC, 
et al. Mutations in the epidermal growth factor 
receptor and in KRAS are predictive and prognostic 
indicators in patients with non-small-cell lung cancer 
treated with chemotherapy alone and in combination 
with erlotinib. J Clin Oncol 23:5900-9,2005. 8. 
Zhu CQ, da Cunha Santos G, Ding K, et al. Role 
of KRAS and EGFR as biomarkers of response to 
erlotinib in National Cancer Institute of Canada 
Clinical Trials Group Study BR.21. J Clin Oncol 
26:4268-75,2008. 
Keywords: Kras, Non-small cell lung cancer, 
Molecular markers
Session M03: Carcinogenesis and 
Metastasis
Monday, 4 July 2011
Carcinogenesis and Metastasis Monday, 4 July 2011 10:30-12:00
M03.1 MOLECULAR PATHOGENESIS OF 
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Abstract: Since the 1960’s, it has been recognized 
that in smokers at risk for lung cancer, normal 
mucociliary mucosa of the central airways may 
replaced by squamous epithelium. This squamous 
transformation is accompanied by variable 
cytological atypia (dysplasia) and is associated with 
profound increases in epithelial proliferative rate 
and EGFR and HER2 expression1. In some cases, 
evidence of angiogenesis is detected2. SpeciÀc 
proteomic proÀles can be used to distinguish 
dysplastic mucosa from epithelium3. It is postulated 
that these lesions represent precursors of invasive 
squamous carcinoma. Molecular changes that 
outcome. These data must be interpreted with caution 
because of the small patient numbers (25 erlotinib/
chemotherapy; 30 chemotherapy). In BR.21, that 
compared erlotinib to placebo, patients with WT-
KRAS derived signiÀcant beneÀt from erlotinib 
(HR 0.69, p=0.03) whereas those with mutated 
KRAS derived no beneÀt (HR 1.67, p=0.30)8. 
However, the interaction was not signiÀcant 
(interaction p=0.09). Subsequent studies in the 
maintenance and second-line settings have failed to 
demonstrate a signiÀcant predictive role for KRAS. 
Surprisingly, unlike colon cancer, this also is true 
for the monoclonal antibody cetuximab. Whether 
this is due to the types of KRAS mutations seen in 
smoking-related NSCLC (different from those of 
colorectal cancer) remains to be explored. Therefore, 
at this time, KRAS mutational status should not be 
used to select patients for EGFR inhibitor therapy. 
Targeting KRAS To date, attempts to target KRAS 
directly or indirectly, for the most part, have been, 
unsuccessful. A decade ago, numerous farnesyl 
transferase inhibitors were evaluated in combination 
with chemotherapy. Addition of these agents led 
only to increased toxicity with no improvement 
in important activity or efÀcacy endpoints. More 
recent attempts have focused on trying to block the 
effects of KRAS activation by interfering with the 
pathway at various points downstream of RAS itself. 
Targets under investigation include RAF, MEK, 
MET, AKT and PI3K. Although some pre-clinical 
studies have produced “promising” results, the 
clinical trials are too early to draw Àrm conclusions. 
Summary Despite two decades of research, the true 
prognostic and predictive roles of KRAS mutation 
status remain somewhat unclear. Furthermore, only 
with pooling of large well-powered studies, will it 
be possible to determine whether individual RAS 
mutations exert different effects. At this time, there 
is insufÀcient evidence to select or exclude patients 
from speciÀc treatment based on KRAS mutation 
status. References 1. Slebos RJC, Kibbelaar RE, 
Dalesio O, et al. K-RAS oncogene activation as a 
prognostic marker in adenocarcinoma of the lung. 
New Engl J Med 323:561-5,1990. 2. Mascaux 
C, Iannino N, Martin B, et al. The role of RAS 
oncogenes in survival of patients with lung cancer: 
a systematic review of the literature with meta-
analysis. Br J Cancer 92:131-9,2005. 3. Pignon 
JP, Tribodet H, Scagliotti GV et al. Lung Adjuvant 
cisplatin evaluation: a pooled analysis by the lACE 
collaborative group. J Clin Oncol 26:3552-9,2008. 4. 
Winton T, Livingston R, Johnson D, et al. Adjuvant 
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status and predictive power of candidate biomarkers. 
Cytology: Sputum squamous atypia detected by 
conventional cytological examination increases the 
risk for incident cancer in smokers with a hazard 
ratio (HR) of 2.4 overall and 10.3 for those subjects 
tested 5 months before the appearance of carcinoma6. 
Sputum cytology alone is therefore a standard 
against which other markers should be measured. 
Gene methylation: Nested case control studies have 
indicated that methylation of tumor suppressor genes 
may be predictive of lung carcinoma with 6.5 fold 
increased risk for carcinoma7 in a high risk cohort. 
FISH: Aneuploidy indicated by FISH is the most 
strongly predictive biomarker for lung cancer risk 
evaluated to date. In initially cancer-free subjects 
who subsequently develop lung cancer, aneuploidy is 
highly correlated with clinical detection lung cancer 
(HR 29.9) within 18 months. FISH aneuploidy is 
currently being validated as a clinical early detection 
tool8. 
High Throughput Approaches to Squamous 
Carcinogenesis 
Increasingly studies of carcinogenesis and 
premalignancy are driven by data-dense high 
throughput techniques and several of these are 
described below. GWAS: GWAS studies involving 
40,000 to 60,000 individuals have identiÀed loci 
in three chromosomal regions (8p11, 15q25 and 
19q13) harboring nicotine associated genes that 
may affect smoking behavior9 and a locus at 
chromosome 15q15.2 that is associated lung cancer 
risk10. This latter variant is distinct from coding 
variants of TP53BP that are also located at 15q15.2. 
To date GWAS studies have not emphasized risk 
associations for speciÀc histological subtypes of 
carcinoma or premalignant lesions. Gene expression 
(mRNA):Similarly, microarray technology has 
been used to discover predictive gene expression 
changes in bronchial epithelial brushings of patients . 
These studies have provided an 80 gene indicator of 
lung cancer distinguishes smokers with from those 
without prevalent lung cancer. These mRNA changes 
are have not yet been used to predict lung cancer 
prospectively nor predict speciÀc lung tumor types 
in subjects who do not yet have cancer. Microarray 
gene expression signatures have also been derived 
for dysplastic lesions and have been correlated 
with dysplasia grade in squamous lesions11. We 
have found that gene expression changes may be 
divided into those that are related to epidermalization 
underlie squamous dysplasia in the in the airways 
of smokers are increasingly better deÀned. It is now 
possible to construct a multistep molecular model 
for the central airway carcinogenesis that we discuss 
below. 
A model for molecular progression to squamous 
carcinoma 
The initial phase of carcinogenesis is purely 
chemical with direct damage to DNA occurring as a 
result of exposure to the highly reactive compounds 
mainly in tobacco smoke that give rise to DNA 
bulky adducts and DNA methylation. Adducts and 
methylation may interfere with DNA repair and 
resulting double stranded breaks may results in 
chromosomal recombination or partial loss. These 
changes are recognized as loss of heterozygosity 
(LOH) and can now be detected at high density 
throughout the genome using SNP arrays. Losses 
may be small or extensive, involving a major part of 
individual chromosomal arms. This phenomenon has 
been referred to as somatic recombination, mitotic 
recombination, or most recently as uniparental 
disomy (UPD). Recombination may occur 
continuously through the life of the premalignant 
cell. Mutation may also occur in premalignant cells 
and some of these mutations may have an important 
impact on the fate of the affected cells. In particular, 
TP53 may result in increased resistance to apoptosis 
and to a proliferative advantage that results in a 
spreading of tumor cells over the airways. Ongoing 
mitotic recombination may result in further LOH 
in genes that are important in lung carcinogenesis. 
Loss of the normal copy of TP53 in a cell with 
one mutant copy may result in complete loss of a 
mitotic checkpoint and may lead to the complicated 
karyotypes that are characteristic of invasive 
squamous. The extent of genomic damage in fully 
formed squamous carcinoma is being revealed 
by the ongoing sequencing studies. These studies 
have identiÀed not only molecular changes that are 
important in squamous carcinogenesis but also new 
therapeutic targets including FGF1 ampliÀcation4 
and DDR25. 
Biomarkers of Squamous Carcinogenesis in 
Sputum 
A readily available surrogate for biopsy tissue is 
sputum and data regarding cellular and molecular 
changes in sputum have been used to assess the 
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cells with mild to moderate atypia lining the 
involved alveoli and respiratory bronchioles, and is 
considered to be a precursor lesion of peripheral-type 
adenocarcinoma. At this point, abnormality of the 
EGFR gene occurs in about 50% of cases of AAH. 
AAH develops to AIS (adenocarcinoma in situ, pure 
bronchioloalveolar carcinoma, and Noguchi type A 
and B) over a long period, and meanwhile apoptotic 
function, such as that mediated by the p16 gene, 
becomes perturbed and expression of Bax inhibitor 1 
appears. The tumor cells also acquire several allelic 
inbalances such as 13q13. At this stage, the main 
genetic alterations are EGFR gene mutation and anti-
apoptotic abnormality. Therefore, the tumor cells can 
survive, but their growth rate is still very low. AIS 
then progress to early but invasive adenocarcinoma 
(EIA, Noguchi Type C), during which time the tumor 
acquires a malignant stroma (active Àbroblastic 
proliferation) showing a characteristic phenotype. At 
this stage, the tumor cells acquire various additional 
genetic abnormalities, such as p53 mutation and 
allelic imbalances at 17p12-p13, 18p11, and 
11p11-p12. In particular, allelic imbalance at 8p21 
is closely associated with prognosis. Recently we 
compared the expression proÀles of AIS with those 
of EIA showing lymph node metastasis or a fatal 
outcome, and screened the differentially expressed 
genes by cDNA microarray to identify those related 
to tumor progression. This revealed abnormal 
demethylation of stratiÀn (SFN) in the course of 
malignant progression from AIS to EIA. SFN was 
originally identiÀed as a p53-inducible gene that 
causes G2 arrest and allows the repair of damaged 
DNA. Real-time methylation-speciÀc PCR (MSP) 
showed that while normal lung tissue and AIS 
bore a completely methylated SFN promoter, the 
promoter regions of most EIAs (more than 95%) 
were at least partially methylated. Demethylation-
induced overexpression of SFN occurs during the 
course of progression of early lung adenocarcinoma, 
and aberrantly overexpressed SFN is thought to be 
one of the accelerators of malignant progression by 
conferring proliferative ability on the tumor cells. 
of the epithelium and other changes that may be 
related to increased proliferative potential. miR 
signatures: Recent studies have evaluated miR levels 
in dysplastic squamous lesions and identiÀed miR 
signatures associated with progression of dysplastic 
changes to invasive carcinoma12. These promising 
results suggests that it may be possible to use miR 
signatures to support histological interpretations and 
perhaps ultimately as a surrogate for histology. The 
biological signiÀcance of these changes is currently 
being evaluated. 
Conclusions 
Despite the availability of impressive new 
technologies to assess molecular changes in 
premalignant bronchial epithelium, clinical 
applications remain distant. New software tools for 
mapping and recording of cellular and molecular 
changes and assembly of large, properly followed 
cohorts may help to better deÀne the natural history 
of central airway premalignancy. 
References
1. Clin Cancer Res 12: 2281-8, 2006 2. Clinical 
Cancer Research 6:1616-1625, 2000. 3. Am J Respir 
Crit Care Med, 172: 1556-62, 2005 4. Sci Translat 
Med 2: 62 62ra93, 2010 5. Cancer Discovery 
doi:10.1158/2159-8274.CD-11-0005, 2011 6. Cancer 
Epidemiol Biomarkers Prev 17:158-62, 2008 7. 
Cancer Res 66: 3338-44, 2006 8. Cancer Prev Res 
3:447-53, 2010 9. Nature genetics 42: 448-453, 
2010 10. Cancer Research 71:1356-1361, 2011 11. 
Nature Medicine 13:362-366, 2007 12. Eur Respir J 
33:352&ndash359, 2009 
Carcinogenesis and Metastasis Monday, 4 July 2011 10:30-12:00
M03.2 MOLECULAR PATHOGENESIS 
OF ADENOCARCINOMA AND ITS 
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Abstract: Studies of the histology, cytology 
and molecular biology of pulmonary 
adenocarcinogenesis have suggested that it is a 
multistep process. Multi-potential epithelial cells 
located in the terminal respiratory unit (TRU) 
acquire atypical adenomatous hyperplasia (AAH) 
as a result of exposure to various carcinogens. 
AAH is characterized by local proliferation of 
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among metastases. The presentation will also review 
the frequency and the signiÀcance of pathologic 
variables between primary tumor and metastases. 
Keywords: lung cancer, metastases, biology
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M04.1 THE STATISTICIAN 
PERSPECTIVE
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Abstract: Overall Survival (OS), deÀned as the time 
to death from any cause, remains the gold standard 
endpoint that unequivocally assesses the beneÀt 
of a new treatment relative to the current standard 
of care. OS sometimes requires more follow-up 
making it a “long” endpoint to assess, especially 
in a phase II setting where time is of the essence. 
Progression-free survival (PFS), deÀned as the time 
to the earlier of disease progression or death from 
any case, is thus a desirable outcome measure in 
this setting. In a disease with poor prognosis such 
as advanced lung cancer, the true endpoint of OS 
is also mostly determined by the progression status 
of the disease (Mandrekar et al., 2010). PFS is a 
direct measure of the effect of the treatment on the 
tumor burden process, unaffected by subsequent 
treatments the patient may receive (Mandrekar 
et al., 2010; Buyse et al., 2008; Lara et al., 2008; 
Foster et al., 2011; Fleming et al., 2009). PFS has 
become an accepted alternate endpoint in assessing 
treatment efÀcacy in lung cancer especially in a 
Phase II setting, as it includes a patient who achieves 
stable disease for an extended period of time as a 
success, in addition to those who achieve complete 
or partial response (Lara et al., 2008; Mandrekar et 
al., 2010). PFS-based endpoints are controversial and 
challenging for several reasons. PFS considers all 
patients “similarly” although progressive disease is 
inherently different from one patient to the next, i.e., 
all patients, regardless of the size of their baseline 
tumor burden, are considered to have progressive 
Keywords: AIS, EIA, AAH
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M03.4 BIOLOGY OF METASTASIZING 
LUNG CANCER
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Abstract: Non-small cell lung carcinoma (NSCLC) 
remains the leading cause of death from cancer 
in both men and women. Distant relapse remains 
the major cause of morbidity and mortality in the 
patients with lung cancer. The term metastasis is 
deÀned as the transfer of disease from one organ 
to part or to another not directly connected to it. 
Metastasis is the primary clinical challenge as it is 
unpredictable in onset and it exponentially increases 
the clinical impact to the host. Tumor metastasis 
is a multistage process in which malignant cells 
spread from primary tumor to discontiguous organs. 
It involves a rest and growth in different micro-
environments, which are treated clinically with 
different strategies depending on the tumor histotope 
and metastatic location. Some isolated metastases 
may be resected, whereas metastases to other organs 
may be treated with radioisotopes and are virtually 
unresectable. Because of the cellular heterogeneity 
therapies have varying degrees of efÀcacy that are 
challenging not only for the oncologist but also 
for our understanding of the metastatic process. 
This presentation will focus on differences 
regarding morphology and biomarker expression 
between the primary tumor and metastases of lung 
adenocarcinoma. The mutation status of metastases 
can differ from that of the primary tumor and also 
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PFS estimates in lung cancer, an analysis utilizing 
individual patient data from 14 NCCTG and 7 
SWOG trials was performed (Mandrekar et al., 
2011). Reported progression date (RPD) was deÀned 
as either the scan date or the clinical deterioration 
date. Disease progression date was determined 
using one of the 4 approaches: RPD (M1), one day 
after last progression-free scan (M2), midpoint 
between last progression-free scan and RPD (M3), 
or interval censoring (M4). PFS was estimated using 
the method of Kaplan-Meier (M1-3) or maximum 
likelihood (M4). As expected, PFS estimates using 
the reported progression date was the highest, with 
method 2 being the most conservative. Methods 3 
and 4 were similar since majority of DP occurred 
during treatment (frequent disease assessments). All 
4 methods resulted in the same overall conclusion 
for randomized trials. PFS estimates were thus 
signiÀcantly impacted by the approach used for 
declaring DP date with the magnitude of difference 
large enough to alter trial conclusions (Table 1). In 
summary, to obtain reliable evidence about the effect 
of a treatment on PFS and OS, randomized trials 
where all patients are followed to progression and 
death are essential. The magnitude of the treatment 
effect on PFS in addition the statistical reliability 
of this evidence are both important to understand 
the clinical beneÀt. Clear standards for declaring 
progression date and sensitivity analysis are critical 
when reporting efÀcacy or comparing trial results. 
based on PFS. 
Table 1: Median PFS estimates by the disease 
progression date determination method. 
Disease Progression 
Date Method 
Median PFS (months) 
NSCLC SCLC 
NCCTG 
(n =660 ) 
SWOG  
(n =297 ) 
NCCTG (n =116 ) SWOG (n=131 ) 
1 4.3 3.1 2.7 1.3 
2 1.8 1.5 0.03 0.03 
3 3.3 2.2 1.8 0.7 
4 (lower, upper) 3.52, 3.55 2.86, 2.89 1.45, 1.48 0.03, 0.16 
% Difference 
Method 1 vs. 2 
Method 1 vs. 3 
58% 23% 52% 29% 99% 33% 98% 46% 
Keywords: PFS, endpoint, disease assessments
disease if there is a 20% increase in the sum of the 
largest diameters of target lesions from baseline 
(Fleming et al., 2009). The accuracy and validity 
of PFS as an endpoint is also impacted by the 
imbalance in assessment schedules across different 
arms, treatment holidays, missing assessments, and 
occurrence of progression in the middle of a long 
disease evaluation interval. In an open label trial, 
investigator evaluation of progression can cause 
substantial ascertainment bias. While a blinded 
independent review can address this issue, they have 
to occur in real time so that scans oare obtained on 
the patient until progression decision is conÀrmed 
by the independent committee. If not, it leads to 
informative censoring, which is often ignored 
when analyzing these data. Panageas et al. (2007) 
discussed the issues related to assessment times and 
progression date determination. Tumor assessment 
is normally repeated every few cycles while patients 
are on study. Clearly, patients may have progressed 
anytime between a non-progression scan and the 
following scan indicating disease progression, 
referred to as interval censoring. Typically, the Àrst 
documented progression date is used as a surrogate 
for the true progression date, which, to a large 
extent, overestimates the median PFS. In Panageas 
et al.’s (2007) study, a close relationship between 
cycle length and progression date declaration was 
also observed. In extreme cases, if the assessment 
interval is wide, the overestimation could result in 
a positive trial outcome, while in fact the observed 
efÀcacy is just a false positive conclusion arising 
from the length of the assessment interval. This is 
particularly concerning in single-arm phase II trials 
without a concurrent control arm. In a randomized 
trial, due to treatment delays from adverse events, 
progression date may be reported later in the 
more toxic treatment arm, even if the true PFS is 
identical between the treatment arms. In addition, 
when evaluations are performed between scheduled 
assessments out of concern for lack of efÀcacy, or 
signs of clinical progression, patients on the arm 
with inferior efÀcacy may have more frequent 
measurement compared to those with treatment 
of superior efÀcacy, the so-called evaluation-bias. 
Consequently, the efÀcacy of the superior arm is 
overestimated to some extent (Bhattacharya, 2009). 
Simulation studies have also shown that variations 
in the timing of tumor assessment can signiÀcantly 
bias trial conclusions based on PFS analyses 
(Panageas 2007; Friedlin, 2007). To understand the 
impact of disease progression date determination on 
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could subsequently be carried out (3). Another 
strategy proposes an unbiased estimate of BICR PFS 
based on LE and a sample of BICR PFS data(4). 
Importantly, whereas the main purpose of BICR is 
to address the bias associated with the assessment of 
progression by investigators, BICR may introduce 
an equally intractable problem of informative 
censoring when BICR is carried out retrospectively. 
The optimal solution to this may require even more 
complex real-time BICR to be implemented(5). 
Another issue with PFS is bias due to unscheduled 
evaluations. There is a risk, for example, that toxicity 
may prompt for more screening detected progression 
in one of the treatment arms, introducing a bias, 
often in favour of the experimental treatment group. 
Furthermore, skipped or otherwise unavailable 
evaluations generate a missing data problem that 
has no easy solution. Currently these issues are 
addressed through various imputation methods in 
sensitivity analyses. Another proposal is to analyse 
PFS data as interval-censored survival data as this 
may be more robust to bias due to unscheduled 
evaluations(6). Although there are a number of open 
methodological questions about interval-censored 
data(7), more efÀcient statistical approaches of 
handling this problem may soon become part of 
the standard set of supportive analyses of PFS. To 
what extent PFS can be considered as a convincing 
measure of clinical beneÀt in pivotal registration 
trials, is still the subject of debate. In particular, 
the clinical interpretation of this endpoint, which 
is based on radiological deÀnitions intended for 
phase II trials, is often problematic in the context of 
the beneÀt-risk assessment at the time of approval. 
Also, regardless of bias and efÀciency of BICR, 
regulators face a dilemma of interpretation when the 
results of BICR and LE differ signiÀcantly. Whilst 
BICR may estimate PFS in a less biased and more 
precise way, the LE reÁects clinical practice and 
may be equally relevant under real conditions of 
use. Wide differences between BICR and LE due 
to measurement error would necessarily question 
the correctness of the local adjudication and the 
relevance of PFS as an endpoint to change clinical 
practice. In conclusion, there is an opportunity to 
develop more efÀcient risk-based approaches for 
measuring PFS whilst ensuring reliable estimation 
of treatment effect. However, more experience needs 
to be gained before considering the applicability of 
some of these methods. Further work is also needed 
in order to deÀne more objectively the clinical 
relevance of progression in different settings also 
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Abstract: While overall survival (OS) remains the 
most objective and clinically convincing endpoint 
in registration trials in the advanced or metastatic 
cancer setting, other efÀcacy endpoints have been 
explored in the hope of gaining earlier insight about 
the beneÀt of new drugs. Regulators have recently 
shown wider acceptance of progression-free survival 
(PFS) as the primary endpoint in registration 
trials. In a recent EMA series (2006-2010), PFS 
was the primary endpoint for registration in 39% 
of applications, up from 10.5% in the previous 5 
years. The wider acceptance did not come without 
extensive debate, and was often tied with conditions 
obliging companies to submit further data to conÀrm 
the effect on OS with data from longer follow-up or 
from trials in related indications. The use of PFS is 
complicated by several non-trivial methodological 
issues associated with measuring progression in an 
unbiased way. The EMA has issued methodological 
guidance on using PFS as primary endpoint in 
conÀrmatory trials, which is currently under 
review(1-2). An important issue from a regulatory 
perspective is that the local evaluation (LE) of 
PFS attributed by may be subject to measurement 
error and more importantly bias. Regulators have 
traditionally been requesting systematic complete 
blinded independent radiological evaluation (BICR) 
as a more reliable evaluation in the context of 
registration trials. The requirement for BICR has 
been relaxed somewhat for double-blinded trials 
although the real effectiveness of the blinding for 
cancer drugs can always be questioned. BICR, 
however, comes with its own set of problems. From 
the perspective of developers and investigators it 
adds signiÀcant complexity and cost to the trial. 
Several proposals have been made to improve the 
efÀciency of BICR when the primary concern is 
investigator bias in the adjudication of progression 
due to knowledge of the assigned treatment group. 
For instance, the risk of bias could be measured 
based on a sample of patients (“audit”). If bias 
became apparent from the audit, a complete BICR 
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Abstract: Trachea can be affected by malignant and 
benign tumors. Malignant tracheal involvement of 
the trachea can be divided into primary, secondary 
and regional involvement from mediastinal 
structures.. Among primary tracheal tumors, 
squamous cell carcinomas account for 45%, 
adenoid cystic carcinoma for 31%, carcinoïds for 
4.3%, muco-epidermoïd carcinomas for 2.4%, 
adenocarcinoma for 2% and rare tumors (small 
and large cell carcinomas, Kaposi, Àbrosarcoma, 
etc,…) for less than 1%. Secondary lesions can 
be originated from colonic, renal, melanoma, or 
breast malignancies. Involvement of the trachea can 
occur during the course of cancers from regional 
structures (oesophagus, thyroid, lung, thymus) and 
from Hodgkin and non Hodgkin lymphomas of the 
mediastinum. Benign tumors can also affect the 
trachea: lipoma, neuroÀbroma, Àbroma, hamartoma, 
chondroma, schwannoma, plasmocytoma, 
leiomyoma or glomic tumor. Bronchoscopy plays 
an important diagnostic role in obtaining tissues 
for pathologic examination and also in order to 
thoroughly precise the localization and the extension 
of the disease, this is important in case of surgical 
management. Moreover, bronchoscopy has an 
important therapeutic impact either as a neoadjuvant 
treatment before surgery or alone in cases of 
non operable patients and of benign conditions. 
Bronchoscopic management depends on the type 
of tumoral involvement (extrinsic compression, 
endoluminal obstruction or both). Symptomatic 
external compression can be relieved by the use 
of stents. Endoluminal obstruction is generally 
treated by mechanical debulking assisted by laser, 
electrocauthery, cryotherapy, argon plasma,or 
microdebrider. In case of respiratory distress, rapid 
techniques have to be used: laser, electrocauthery, 
argon plasma,or microdebrider. Cryotherapy has 
a delayed action and is not indicated in this case. 
taking into account the perspectives of different 
stakeholders. The EMA Oncology Working Party 
is currently discussing these approaches in view 
of a revision of its methodological guideline on 
PFS. Publication disclaimer The views presented 
here are personal and should not be understood 
or quoted as those of the European Medicines 
Agency. References 1. European Medicines Agency. 
Guideline On The Evaluation Of Anticancer 
Medicinal Products In Man (CPMP/EWP/205/95/
Rev.3). [Internet] London: European Medicines 
Agency; 2006; Available from: http://www.ema.
europa.eu/ema/pages/includes/document/open_
document.jsp?webContentId=WC500017748. 2. 
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guideline on the evaluation of anticancer medicinal 
products in man - methodological considerations for 
using progression-free survival (PFS) as primary 
endpoints in conÀrmatory trials for registration. 
[Internet] London: European Medicines Agency; 
2008; Available from: http://www.ema.europa.eu/
ema/pages/includes/document/open_document.
jsp?webContentId=WC500017749. 3. Amit O, 
Mannino F, Stone AM, Bushnell W, Denne J, 
Helterbrand J, Burger HU. Blinded independent 
central review of progression in cancer clinical trials: 
Results from a meta-analysis. Eur J Cancer2011 
Mar 21. 4. Dodd LE, Korn EL, Freidlin B, Gray R, 
Bhattacharya S. An Audit Strategy for Progression-
Free Survival. Biometrics2011 Jan 6. 5. Dodd 
LE, Korn EL, Freidlin B, Jaffe CC, Rubinstein 
LV, Dancey J, Mooney MM. Blinded independent 
central review of progression-free survival in 
phase III clinical trials: important design element 
or unnecessary expense? J Clin Oncol2008 Aug 
1;26(22):3791-6. 6. Stone AM, Bushnell W, Denne 
J, Sargent DJ, Amit O, Chen C, Bailey-Iacona R, 
Helterbrand J, Williams G. Research outcomes and 
recommendations for the assessment of progression 
in cancer clinical trials from a PhRMA working 
group. Eur J Cancer2011 Mar 22. 7. Zhang Z, Sun 
J. Interval censoring. Stat Methods Med Res2010 
Feb;19(1):53-70.
Keywords: PFS, EMA
Copyright © 2011 by the International Association for the Study of Lung Cancer S69
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
lymph nodes are involved, bilateral paratracheal 
and subcarinal lymphatic regions are included. 
For distal tracheal lesions, the carina, bilateral 
paratracheal soft tissue and the medial half of the 
main bronchi are included. For proximal tracheal 
lesion, a generous margin of bilateral supraclavicular 
regions is included as clinical target volume. Of 108 
consecutive patients with adenoid cystic carcinoma, 
89 (82%) received radiation 2. Extramural tumor 
extension and microscopically positive airway 
margins were common. The disease-free survival 
of 92 patients with extramural tumor was 47% at 
10 and 29% at 15 years, compared to 93 and 85% 
in 16 patients without transmural disease. In 59 
patients with microscopically positive margins, 
disease-free survival was 48% and 24% at 10 and 
15 years, compared to 63 and 56% in 40 patients 
with negative tracheal margins. In a study of 50 
consecutive squamous cell carcinomas, tumor 
characteristics were identiÀed to predict survival 3. 
Prior radiotherapy occurred in 24% of patients, either 
for the same disease or separate, prior lung cancer. 
Only 42% received post-resection radiation. Overall 
survival was 46% at 5 and 27% at 10 years. Tumor 
extension into thyroid and lymphatic invasion were 
associated with worse survival, while keratinization, 
dyskeratosis, acantholysis, necrosis, and tumor 
thickness had no association with survival. An 
earlier study had shown poor long-term survival 
when tracheal resection margins were involved with 
tumor 1. Postoperative radiotherapy for tracheal 
tumors follows treatment principles established 
in other thoracic malignancies, with particular 
attention to successful healing of the anastomosis. 
Long-term survival observed after resection with 
microscopically positive tracheal margins is in part 
attributed to adjuvant radiotherapy, even though 
its precise contribution to overall survival remains 
unknown. Given the low incidence of these tumors, 
alternatives to postoperative radiation have not been 
evaluated. References 1. Gaissert HA, Grillo HC, 
Shadmehr MB, Wright CD, Gokhale M, Wain JC, 
Mathisen DJ. Long-term survival after resection 
of primary adenoid cystic and squamous cell 
carcinoma of the trachea and carina. Ann Thorac 
Surg. 2004;78:1889-96. 2. Honings J, Gaissert 
HA, Weinberg AC, Mark EJ, Wright CD, Wain 
JC, Mathisen DJ. Prognostic value of pathologic 
characteristics and resection margins in tracheal 
adenoid cystic carcinoma. Eur J Cardiothorac 
Surg. 2010;37:1438-44. 3. Honings J, Gaissert HA, 
Ruangchira-Urai R, Wain JC, Wright CD, Mathisen 
The rigid bronchoscope is the technique of choice 
because it allows rapid mechanical debulking 
by coring large pieces of tumors. A stent can be 
inserted in order to prevent recurrences after optimal 
desobstruction in some cases. Tracheal tumors 
management requires a multidisciplinary approach 
involving thoracic surgeons, pulmonologists, 
endoscopists, oncologists and radiologists. 
Keywords: tumors, Endoscopy, bronchoscopy, 
trachea
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M05.3 ROLE OF ADJUVANT 
RADIOTHERAPY IN THE SURGICAL 
TREATMENT OF TRACHEAL 
CARCINOMA
Henning A. Gaissert 
Surgery, Massachusetts General Hospital/United 
States Of America
Abstract: The two most common primary 
malignancies of the trachea are squamous and 
adenoid cystic carcinoma, while other bronchogenic 
carcinomas or sarcomas are rare. Surgical resection 
is the preferred treatment for localized tracheal 
tumors. However, transmural tumors and lymphatic 
invasion are common, while radical resection is 
limited by the narrow conÀnes of the mediastinum 
1. Margins are often close and additional resection 
of microscopic tumor-bearing tracheal margins may 
exceed safe levels of tension at the anastomosis. 
Preoperative radiation is avoided because the 
radiated trachea tolerates poorly anastomotic tension 
following reconstruction. For these reasons, adjuvant 
postoperative radiotherapy is administered to most 
patients. Treatment is begun 6 to 8 weeks after 
resection, following bronchoscopic conÀrmation 
of anastomotic healing, at a dose of 54 to 63 Gray 
(Gy). A majority of patients were treated with 2 D 
conformal therapy. Currently, a typical treatment 
protocol consists of 3D conformal, intensity-
modulated radiation therapy to maximize sparing 
of lungs and esophagus with weekly preportal 
imaging for veriÀcation of set-up and isocenter. 
Daily fractions of 1.8 Gy are administered for a total 
of 35 treatments and a total dose of 63 Gy. A typical 
target volume includes the tracheal anastomotic site 
with a margin of 3-4 cm of remaining proximal and 
distal treachea for potential microscopic disease 
and peritracheal soft tissues at the tumor bed. If 
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M06.1 GLOBAL ATTITUDES TO LUNG 
CANCER
Robert Worcester 
Ipsos Mori/United Kingdom
Abstract: Ipsos MORI were commissioned by the 
Global Lung Cancer Coalition to explore perceptions 
of which cancers kill the greatest number of people 
within countries; and sympathy towards people with 
lung cancer. Two questions were asked: » Which of 
the following cancers do you think kills the most 
people in your country? You may choose up to two 
(Bowel or Colon cancer/Breast cancer/Lung cancer/
Prostate cancer/Skin cancer); and » Lung cancer 
is mainly caused by smoking cigarettes and other 
tobacco products. Bearing this in mind, to what 
extent do you agree or disagree with the following 
statement…I have less sympathy for people with 
lung cancer than people with other types of cancer. A 
quantitative survey was conducted across: Argentina, 
Australia, Brazil, Bulgaria, Canada, Denmark, 
Great Britain, Italy, Japan, Norway, Slovenia, Spain, 
Sweden, Switzerland, the Netherlands, and the 
USA. This compares the Àndings across countries, 
highlighting common sub-group differences.  
Methodology: A nationally representative quota 
sample for each country of c. 1,000 adults was 
interviewed from 25 January – 16 May 2010, using 
the Ipsos Omnibus (although exact ages varied 
slightly between countries). Face-to-face in-home 
interviewing was used where possible (in Brazil, 
Bulgaria, Great Britain, Italy, Japan, Spain and 
Slovenia), and telephone (CATI) interviewing 
elsewhere (in Argentina, Australia, Canada, Norway, 
Denmark, Switzerland, Sweden, The Netherlands, 
and the USA). Data have been weighted to the 
known adult population proÀle of each country.
Discussion of Findings: Which cancer is perceived 
to be the biggest killer? In 13 of the 16 countries 
DJ, Mark EJ. Pathologic characteristics of resected 
squamous cell carcinoma of the trachea: prognostic 
factors based on an analysis of 59 cases. Virchows 
Arch. 2009;455:423-9. 
Keywords: squamous cell carcinoma, Trachea, 
Trachel tumor, Adenoid cystic carcinoma
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M05.4 TRACHEAL TRANSPLANTS
Emmanuel Martinod 
Chirurgie Thoracique, Chu Avicenne. AP-HP, Paris/
France
Abstract: After more than Àfty years of research, 
airway transplantation remains a major surgical and 
biological challenge in the Àeld of thoracic surgery. 
Five principal types of tracheobronchial substitutes 
including synthetic prostheses, bioprostheses, 
allografts, autografts and bio-engineering conduits 
have been experimentally evaluated in numerous 
studies. More recently, few clinical attempts have 
provided encouraging results with bio-engineered 
airways, tracheal allografts implanted after 
heterotopic revascularization, and aortic allografts. 
In-vivo or ex-vivo regeneration of epithelium 
and cartilage has been demonstrated with these 
substitutes. Cryopreserved aortic allografts present 
major advantages because they are available in tissue 
banks and do not require immunosuppressive therapy 
which is contraindicated in cancer lesions. These 
favorable results have to be conÀrmed in larger 
series of patients with extensive tracheobronchial 
diseases. 
Keywords: airway transplantation, tracheobronchial 
diseases, Surgery, tissue regeneration
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However, in all the countries surveyed, the majority 
reject the idea that they are less sympathetic for 
people with lung cancer, despite its link to smoking 
– for example, 52% of Australians disagree that they 
are less sympathetic. Demographic differences in 
opinion In most countries there is no difference in 
sympathy towards people with lung cancer by age, 
but in others there are some notable differences. 
Older people have less sympathy than average in 
Argentina though in the Netherlands and Norway 
younger people have less sympathy than average. 
Sympathy levels are lower among men than women 
in six of the countries surveyed (Australia, Canada, 
Denmark, Great Britain, Norway and Slovenia). 
Furthermore people with lower educational 
attainment are less likely to feel sympathy for people 
with lung cancer than those educated to higher levels 
in Bulgaria, Slovenia Switzerland, and the USA. 
1Smoking is responsible for 90% of all lung cancer 
according to the World Health Organisation. 
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M06.3 LUNG CANCER AND THE NEW 
MEDIA
Tracy Fischer 
Communications, National Lung Cancer 
Partnership/United States Of America
Abstract: This presentation will focus on how 
lung cancer advocacy groups can use new media, 
particularly social media, to advance awareness of 
and commitment to the cause. To drive awareness 
of lung cancer, and to raise funds for research, 
education, legislative and awareness programs, 
advocacy groups have the opportunity to reach out 
to their constituents and connect using technology 
now commonplace in personal interaction. 
surveyed, lung cancer is thought to be the cancer 
responsible for the greatest number of deaths in their 
country. The exceptions are: Japan, where a broadly 
equal proportion cite lung cancer and bowel cancer; 
Australia where a greater proportion cite breast and 
skin cancer; and Bulgaria where a greater proportion 
cite breast cancer. Of all the countries surveyed, 
people in Japan and Norway are most likely to 
believe that lung cancer is the biggest killer in their 
country, although, as mentioned, in Japan there is 
also a perception that bowel/colon cancer is on a par 
with lung cancer (67% and 65% respectively).
Demographic differences in perceptions In seven 
countries surveyed (Australia, Canada, Japan, 
Norway, Spain, Sweden, and the USA) younger 
people (under 34 years old) are more likely than 
older people (aged 55+) to perceive lung cancer as 
the cancer type responsible for the most deaths in 
their country. ReÁecting the higher incidence rates 
of lung cancer among men than women, in a number 
of countries (Argentina, Brazil, Denmark, Japan, 
Norway, Slovenia and Switzerland) men are more 
likely than women to believe lung cancer kills the 
greatest number. Attitudes towards lung cancer In 
line with prevailing medical opinion1, respondents 
were told: “Lung cancer is mainly caused by 
smoking cigarettes and other tobacco products.” 
They were then asked whether or not, bearing this in 
mind, they have less sympathy for people with lung 
cancer than other types of cancer. There is signiÀcant 
variation between countries in the proportion of 
adults who admit that they have less sympathy for 
people with lung cancer – from one in ten (10%) 
Argentineans to around three in ten Australians and 
Brazilians (29% and 28% respectively).
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the state of the relevant technology and for scaling 
technological infrastructure to support the successful 
implementation of this new service. Using US 
Census data, there are about 72 million adults 
over age Àfty-Àve. Between 32-40% were either 
current or former smokers, so about 30 million 
may be candidates for CT-based lung cancer 
screening. Using prior cancer screening experience 
only a fraction of those individuals would avail 
themselves to this new service. If initially 25% of 
the target population availed themselves to lung 
cancer screening, then that would entail following 
about 7.5 million at-risk adults. Since the risk of 
developing lung cancer in a smoker is continuous, 
optimal care would involve serial follow-up of the 
at-risk cohort for the balance of their lives. The 
challenge for lung cancer screening is to develop an 
informatics backbone that can organize the capture, 
analysis and distribution of this vast amount of new 
data. Fortunately, the emergence of economical, 
distributed biomedical informatics resources is 
happening at an opportune time to enable the 
establishment of a web-based system that could 
tie all screening institutions together. A system 
developed by Anthony Reeves currently has the data 
for 55,000 screening subjects including DICOM 
Àles of all screening CT images as well as digitized 
version of all the diagnostic pathology of the lung 
cancer cases and becomes a valuable resource for 
enabling screening research. This systematic capture 
of lung cancer screening data and images allows for 
real time analysis which could enable continuous 
process improvement to optimize all aspects of the 
screening process as proposed in recent publications 
by the Institute of Medicine on the rapid learning 
healthcare system. The remarkable improvement in 
CT image resolution witnessed over the last decade 
is expected to continue for the foreseeable future. 
This provides a number of research options to 
improve lung cancer detection and also to integrate 
image processing tools that could assist the speed, 
accuracy while reducing the cost of lung cancer 
screening. With existing manpower shortage for 
clinical radiologists, measures to improve the 
productivity of lung cancer screening are essential. 
The Quantitative Imaging Biomarker Alliance 
of RSNA has assembled a large community of 
researchers that are already committed to address 
this challenge. A major task is the downstream 
clinical management challenge of segregating the 
potentially benign lung nodules from the potentially 
clinically aggressive lung nodules. This was the 
Utilization of the new bottom-up information 
stream the internet propagates can assist advocacy 
groups in effecting change for lung cancer patients. 
This presentation will provide examples of social 
media: media designed to be disseminated through 
social interaction, created using highly accessible 
and scalable publishing techniques. As online 
fundraising and communication has showed steady 
growth in recent years despite numerable economic 
challenges, this type of communication channel is 
increasing in importance. Recommended strategies 
for advocacy groups will be presented, including 
steps to take when implementing a social media 
initiative: research, plan, post, integrate and evaluate. 
Examples of methods for speciÀc social networks 
will be discussed, as well as common measurement 
and evaluation tools. 
Keywords: advocacy, new media, internet, social 
media
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M06.4 NEW TECHNOLOGY TO 
EFFECT CHANGE IN LUNG CANCER 
OUTCOMES
James L. Mulshine 
Internal Medicine, Rush University/United States Of 
America
Abstract: The Director of the NCI recently 
announced the completion of the National Lung 
Screening Trial in light of Ànding a 20% lung cancer 
mortality reduction beneÀt in that randomized 
screening trial comparing CT to chest X-ray in a 
high risk for lung cancer cohort (). Additionally, 
recent reports have documented mortality reduction 
beneÀt over the range of 37-60% based on a 
comparative analysis of lung cancer mortality 
outcomes with a New York state I-ELCAP cohort or 
with CISNET models of I-ELCAP outcomes. Such 
remarkable results have re-deÀned the dialogue 
about improving lung cancer outcomes. Other 
results suggest improvements in clinical screening 
management such as with better diagnostic work-
up approach reported with the NELSON trial; so 
that a time may come when national public health 
agencies conclude that CT-based lung cancer 
screening is an effective and essential population-
based cancer service. This presentation reviews 
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the essential public health research is required to 
responsibly support these directions. Finally, the 
evolution of imaging technology is providing an 
opportunity for broader collaboration of the disparate 
communities of health care providers involved in 
different tobacco-related diseases. Integration of 
efforts may accelerate improvement of the early 
detection of all major tobacco-related diseases of 
the thorax so that we can rapidly and economically 
provide these new preventive services as they are 
demonstrated to be effective. 
Keywords: Lung cancer, CT screening, Image 
Processing, screening management
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M06.5 LUNG CANCER SPECIALIST 
NURSES - SHOWING THEIR WORTH
Beth Ivimey 
Dept. Medical Oncology, Prince Of Wales Hospital/
Australia
Abstract: Introduction. The Lung Cancer Nurse 
is viewed as an integral member of the Lung 
Cancer Multi Disciplinary Team, being responsible 
for coordinating the care of patients who have 
been diagnosed with a thoracic malignancy. The 
deÀnition of the nursing role varies across the globe, 
whether it be as a Lung Cancer Nurse Specialist, 
Practitioner or Consultant in the U.K, Lung Cancer 
Nurse Navigator in the U.S or Lung Cancer Nurse 
Coordinator in Australia. All embrace the intricacies 
of managing and supporting the care of people 
diagnosed with a thoracic malignancy, steering the 
patient through the diagnostic and investigative 
phase, assisting with informed decision making, 
treatment and follow up, survivorship or end of life 
care. The lung cancer nurse will be supportive to the 
patient and their carer(s) assessing their physical, 
psychosocial, emotional and geographical situation 
and needs. The lung cancer nurse becomes a primary 
contact and link for the patient and members of the 
lung multi disciplinary team and facilitates timely 
referral and appointments. The worth or value that 
this highly experienced nurse brings to the team 
has traditionally been difÀcult to deÀne. Patient 
satisfaction and outcomes for people diagnosed with 
lung cancer were poor prior to the lung cancer nurse 
position commencing. Lead Clinicians with the lung 
subject of a recent report in the NEJM, where the 
NELSON investigators followed a carefully deÀned 
imaging protocol for suspicious nodules based on 
the growth rate of those nodules on repeat high 
resolution CT imaging after a wait of three months. 
The software tool used for this study resulted 
in an over 90% accuracy of identifying clinical 
signiÀcant lung cancers and there was a low number 
of cases picked up outside of scheduling imaging 
on long term follow up. A low rate of incorrect 
lung cancer diagnoses is a critical determinant of 
the overall screening success. Having objective 
software tools to evaluate the aggressiveness of 
cancer cases is a critical measure to address the 
potential for over-diagnosis that plagues other 
cancer screening. The rapid evolution of minimally 
invasive surgical techniques for curative resection 
of early lung cancers is profoundly re-sculpting 
outcome expectations with the surgical management 
of lung cancer. Video-assisted minimally invasive 
lobectomy approaches are being reported in large 
multi-center studies to have lower operative 
mortality rates (2% vs. 0.1%), shorter hospital stays 
and lower complication rates. This development 
greatly enhances the potential therapeutic beneÀt 
of lung cancer screening and research to deÀne the 
optimal approaches to the surgical care of screen-
detected lung cancers is an important priority. Based 
on success with lung cancer screening, we may 
Ànally be making this transition from late to early 
stage care. Systemic side-effects limited the use 
of corticosteroids in the treatment of asthma. With 
both intravenous and oral lung cancer drugs, the 
occurrence of systemic side-effects is a barrier for 
success with existing lung cancer therapies especially 
in the adjuvant setting. Aerosolized drug delivery 
was used to deliver corticosteroids to the lung 
epithelium while reducing side effects for asthma. 
Aerosol drug delivery strategy may be a key step for 
allowing safe delivery of new molecularly-deÀned 
therapeutics to enhance the cure of early lung cancer. 
In closing, the success of CT screening to routinely 
Ànd early curable cancer in conjunction with rapidly 
improving imaging, image processing, diagnostic 
work-up algorithms and surgical management 
approaches brings great hope to the entire lung 
cancer community. Cooperation across institutions 
like IASLC and the GLC along with many other 
potential collaborators is essential to ensure the 
maximum dissemination of the information about 
the potential for improving lung cancer outcomes. In 
addition, coordination of strategic efforts to advance 
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M07.1 EPITHELIAL-MESENCHYMAL 
TRANSITION: FROM DIAGNOSIS TO 
THERAPY
Giuseppe Pelosi 
Department Of Pathology And Laboratory Medicine, 
National Cancer Institute And University Of Milan, 
School Of Medicine/Italy
Abstract: The term epithelial-mesenchymal 
transition (EMT) refers to the loss of epithelial 
cell traits and the acquisition of a mesenchymal 
phenotype by cells with motile properties. This 
phenomenon is deemed to be pivotal in a variety 
of normal and pathological conditions, including 
ontogenesis, Àbrosis, wound healing, inÁammation, 
and tumorigenesis 1, 2. In lung cancer pathology, 
carcinomas containing variable amounts of sarcoma/
sarcoma-like elements in the form of spindle and/
or giant cells or entirely made up of these tissues are 
rare but well-recognized entities 3, although many 
conventional lung tumors may undergo EMT during 
progression. As a whole, carcinomas with sarcoma/
sarcoma-like elements are collectively classiÀed as 
sarcomatoid carcinomas and include Àve histologic 
patterns, namely pleomorphic carcinoma, spindle 
cell carcinoma, giant cell carcinoma, carcinosarcoma 
and pulmonary blastoma, which show quite similar 
clinical presentation and behavior 3. They are 
deemed to have a monoclonal origin from a common 
ancestor lesion undergoing sarcomatoid metaplasia 
of full-blown carcinoma cells during tumor 
progression (conversion paradigm) 4. Recent genetic 
studies have also raised the possibility of separating 
the various members of this tumor family on the 
basis of their chromosome proÀle, supporting once 
again the notion that these tumors are more akin to 
each other than to conventional NSCLC 5. Although 
the pathogenetic bases of pulmonary sarcomatoid 
carcinomas are still largely unknown, the activation 
of an EMT program is felt to play a pivotal role in 
the process of epithelial trans-differentiation into 
sarcoma/sarcoma-like cells 1, 2, 6. In particular, EMT 
program in these tumors could be initiated by an 
upregulation of c-Jun, a nuclear transcription factor 5 
and a consecutive overexpression of vimentin, fascin 
cancer multi disciplinary teams now state that their 
team is incomplete without a lung cancer nurse and 
that the Lung Cancer Nurse is highly valued by all 
members of the team. Lung Cancer patient access to 
best practice, satisfaction and outcomes have been 
enhanced by the implementation of the lung cancer 
nurse role. Enrollment for patients into lung cancer 
clinical trials has increased since the development 
of the Lung Cancer Nurse position and there has 
been greater interest in evaluating the quality of life 
for patients with lung cancer and for their carers. 
Lung Cancer Nurse Specialist follow up clinics have 
shown to be safe, acceptable, and cost effective. 
Lung Cancer Nurses undertake other hidden work 
in addition to their complex clinical work. DeÀning 
the value of time organizing care via telephone, 
assessment, face to face consultation, referral, 
crisis interventions and education has been difÀcult 
because capturing the data referring to every instance 
of service is time consuming. The evidence that 
has come forth describes the complexities well and 
suggests that more research is necessary to further 
enhance and validate our role. The development 
of national and international Lung Cancer Nurse 
Forums is the cornerstone to Lung Cancer Nurses 
working collaboratively across the globe with these 
issues in mind. Moore S,Corner J, Haviland J, Wells 
M, Salmon E, Normand C, Brada M, O’Briend M, 
SmithI. BMJ;2002;1145-1147. Nurse Led Follow up 
and conventional medical follow up in management 
of patients with lung cancer; randomized trial. 
Excellence in Care: The Contribution of the Clinical 
Nurse Specialist Optimising Cancer Care in Australia 
(2003) Clinical Oncology Society of Australia. 
The Cancer Council Australia Leary A et al (008) 
Dimensions of clinical work in the UK. Treating 
Lung Cancer in NSW. NSW Cancer Institute. 
December 2010. The National Lung Cancer Forum 
for Nurses. 2009 Good Practice Guide. Evaluation 
of the Western Australian Cancer Nurse Coordinator 
Role. Yates P, (2004) Cancer Care Coordinators: 
Realising the Potential for Improving the Patient 
Journey, Cancer Forum 28 (3);128-132 
Keywords: Lung Cancer Nurse, Forum, value
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C. Tumours of the lung, pleura, thymus and heart. 
Lyon: IARC Press; 2004. 4. Pelosi G, Sonzogni A, De 
Pas T, et al. Review article: pulmonary sarcomatoid 
carcinomas: a practical overview. Int J Surg Pathol 
2010;18:103-20. 5. Blaukovitsch M, Halbwedl I, 
Kothmaier H, Gogg-Kammerer M, Popper HH. 
Sarcomatoid carcinomas of the lung--are these 
histogenetically heterogeneous tumors? Virchows 
Arch 2006;449:455-61. 6. Gotzmann J, Mikula M, 
Eger A, et al. Molecular aspects of epithelial cell 
plasticity: implications for local tumor invasion and 
metastasis. Mutat Res 2004;566:9-20. 7. Pelosi G, 
Fraggetta F, Nappi O, et al. Pleomorphic carcinomas 
of the lung show a selective distribution of gene 
products involved in cell differentiation, cell cycle 
control, tumor growth and tumor cell motility: a 
clinicopathological and immunohistochemical study 
of 31 cases. Am J Surg Pathol 2003;9:1203-15. 8. 
Siddiq F, Sarkar FH, Wali A, Pass HI, Lonardo F. 
Increased osteonectin expression is associated with 
malignant transformation and tumor associated 
Àbrosis in the lung. Lung Cancer 2004;45:197-205. 
9. Ilyas M. Wnt signalling and the mechanistic basis 
of tumour development. J Pathol 2005;205:130-
44. 10. Nakatani Y, Miyagi Y, Takemura T, et al. 
Aberrant nuclear/cytoplasmic localization and 
gene mutation of beta-catenin in classic pulmonary 
blastoma: beta-catenin immunostaining is useful for 
distinguishing between classic pulmonary blastoma 
and a blastomatoid variant of carcinosarcoma. Am J 
Surg Pathol 2004;28:921-7. 11. Sekine S, Shibata T, 
Matsuno Y, et al. Beta-catenin mutations in pulmonary 
blastomas: association with morule formation. J Pathol 
2003;200:214-21. 12. Koss M, Holzer L, Frommelt 
R. Carcinosarcomas of the lung. A clinicopathologic 
study of 66 patients. Am J Surg Pathol 1999;23:1514-
26. 13. Humphrey P, Scroggs M, Roggli V, Shelburne 
J. Pulmonary carcinomas with a sarcomatoid 
element: an immunocytochemical and ultrastructural 
analysis. Hum Pathol 1988;19:155-65. 14. Barsky 
S, Xiao Y, Ye Y, Ostler J, Leone G. Carcinosarcoma 
exhibit EMT - A phenomenon of tumor progression 
unrelated to metastsis (abstract #1485). Mod Pathol 
2008;21:325A. 15. Nakajima M, Kasai T, Hashimoto 
H, Iwata Y, Manabe H. Sarcomatoid carcinoma 
of the lung. A clinicopathologic study of 37 cases. 
Cancer 1999;86:608-16. 16. Huber A, Weis W. The 
structure of the b-cetenin/E-cadherin complex and 
the molecular basis of diverse ligand recognition by 
b-catenin. Cell 2001;105:391-402. 17. Takeichi M. 
Cadherin cell adhesion receptors as a morphogenetic 
regulator. Science 1991;251:1451-5. 
7 and osteonectin 8. Another well-known activator 
of EMT, the Wnt pathway 9, has been consistently 
demonstrated in pulmonary blastoma, inasmuch as 
b-catenin gene mutation and consequent aberrant 
nuclear/cytoplasmic localization of the protein 
occur in this tumor type 10, 11 but not in other types of 
sarcomatoid carcinoma 5. Depending on the extent 
and timing of EMT, the proportion of epithelial 
vis a vie mesenchymal cells may vary widely from 
tumor to tumor 10. The composition of the metastases 
of pulmonary sarcomatoid carcinomas has been 
assessed in cases of carcinosarcoma 12, 13 and 
pleomorphic carcinoma 4, 13, revealing an exclusive 
or partial epithelial composition in most cases. This 
may implicate that epithelial cells could contribute 
more effectively than sarcomatous elements to 
metastasis formation, as suggested experimentally 
in murine models 14 and clinically by the lack 
of prognostic implications of the percentage of 
sarcomatoid component in the primary tumors 4, 15. 
The activity and efÀcacy of systemic chemotherapy 
in patients with pulmonary sarcomatoid carcinoma 
has not been well deÀned thus far but probably 
is poor with conventional drugs. No prospective 
clinical trial has been published on the subject, and 
the results obtained from conventional NSCLC 
enrolling clinical trials cannot be extrapolated for 
sarcomatoid carcinoma, inasmuch as the latter were 
not analyzed separately. The few available data 
for these tumors are derived from retrospective 
studies, which showed a substantial failure of the 
standard chemotherapy regimens commonly used 
for NSCLC, although single sarcomatoid carcinoma 
patients had beneÀted by postoperative combination 
chemotherapy of carboplatin and paclitaxel. 
In this scenario of ineffective or disappointing 
therapy options, targeting EMT could become a 
useful therapeutic strategy by interfering with the 
development of these tumors. It could include the 
E-cadherin expression restoration or the c-Jun 
or RAS pathway inactivation that are frequently 
engaged in sarcomatoid carcinoma 1, 2. E-cadherin, 
a transmembrane glycoprotein involved in Ca2+-
dependent epithelial cell–cell homophylic adhesion 
at the adherens junctions 16, 17 is downregulated in 
most sarcomatoid carcinoma. 
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M07.3 HARNESSING THE IMMUNE 
SYSTEM TO TREAT CANCER
Lee M. Krug 
Thoracic Oncology, Memorial Sloan-Kettering 
Cancer Center/United States Of America
Abstract: Dendritic cell-derived exosomes (Dex) 
are nanovesicles originating from late endosomes. 
These vesicles are secreted by living dendritic 
cells (DCs) in the extracellular milieu and have 
demonstrated the capacity to activate innate and 
adaptive immunity. These immuno-stimulatory 
properties have stimulated researchers to use Dex as 
a cell free vaccine. The development of a production 
process following good laboratory practices has 
allowed the use of Dex in vaccination protocols in 
patients in the early 2000s. However, no modulation 
of adaptive immune responses was observed in 
these clinical trials. Thus the scientiÀc community 
attempted to decipher mechanisms of action involved 
in the establishment of an effective immune response 
after Dex vaccination. The results stressed that 
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M07.2 CIRCULATING TUMOR CELLS 
AND THE METASTATIC PROCESS
Klaus Pantel 
Department Of Tumor Biology, University Medical 
Center Hamburg-Eppendorf/Germany
Abstract: Early spread of tumor cells is usually 
undetected by current imaging technologies. 
Therefore, in patients with cancer and no signs 
of overt metastases, sensitive methods have been 
developed to detect circulating tumor cells (CTC) in 
the peripheral blood and disseminated tumor cells 
(DTC) in the bone marrow. These technologies can 
be classiÀed into cytometric and/or immunological 
and molecular approaches. Interestingly, the bone 
marrow seems to be a common homing organ 
for cells derived from various epithelial tumors 
including non-small cell lung cancer (NSCLC). 
Sequential peripheral blood analyses, however, are 
more convenient for patients than BM analyses in 
patients with solid tumors and many research groups 
are currently assessing the clinical utility of CTC for 
assessment of prognosis and monitoring of systemic 
therapy. In view of the plethora of prognostic 
indicators—especially in breast cancer—monitoring 
of CTC during and after systemic adjuvant therapy 
might provide unique information for the clinical 
management of the individual cancer patient and 
allow an early change in therapy years before the 
appearance of overt metastases signals incurability. 
There is an urgent need for biomarkers for real-time 
monitoring of the efÀcacy of systemic adjuvant 
therapy in individual patients. At present, the success 
or failure of anti-cancer therapies is only assessed 
retrospectively by the absence or presence of overt 
metastases during the post-operative follow-up 
period. However, overt metastases are, in general, 
incurable by most current therapies. The monitoring 
of CTC as “liquid biopsy” will provide new insights 
into the selection of tumor cells under biological 
therapies. Molecular characterization of DTC 
and CTC opens a new avenue for understanding 
metastatic spread of tumor cells with important 
implications for future therapies. The use of CTC 
analyses in clinical trials testing new anti-cancer 
agents as companion diagnostics has the potential 
to speed up the cumbersome and expensive drug 
validation process in oncology.
References Pantel K, Izbicki JR, Angstwurm M, 
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shown to inhibit Treg cell activity. Therefore, we 
investigated the combined effects of CTX and 
iDex to elicit antitumor immunity leading to tumor 
rejection in the poorly immunogenic B16F10 
melanoma model in mice. iDex-mediated anti-tumor 
effects were improved in CTX treated animals. CTX 
administrated 6 days before iDex vaccination was 
able to boost peptide speciÀc secondary responses 
as assessed by immunomonitoring using speciÀc 
Áuorescent tetramers and IFNƢ secretion by T 
cells after in vitro stimulation. Modulation of Dex 
bioactivity through modulation of DCs maturation 
stage was Àrst described in 2005. This Àrst study 
shows that Dex derived from DC treated with IL-
10 are tolerogenic, resulting in the suppression 
of inÁammation and collagen-induced arthritis in 
mice. Conversely, it appears that exosomes secreted 
by mature DCs are immunogenic (mDex). Indeed, 
Dex produced from LPS-matured DC showed 
enrichment with and CD86 leading to activation 
of CD4+ and CD8+ T cells. Although the full 
understanding of the signiÀcance of Dex requires 
additional studies, these vesicles proved to be a 
naturally occurring minimal antigen presenting unit 
that could orchestrate immune responses according 
to various signals received by producing DCs. 
Exosomes are secreted in large quantities by DCs 
in the absence of any stimulation (steady state), in 
this context exosomes might play a role mainly in 
tissue homeostasis in promoting apoptotic body 
clearance and avoiding harmful inÁammation that 
could lead to autoimmune diseases development. 
By cons, in an anti-inÁammatory or a pro-
inÁammatory context, the molecular composition 
of Dex could play a fundamental role in shaping 
immune responses. Indeed, in vivo the targeting 
to one or the other exosomes presenting cell, the 
expression of molecules that can regulate immunity, 
the presence of inÁammation mediators in Dex but 
also mRNAs or microRNAs content could dictate 
in vivo bioactivity of Dex. The role of Rab27a and 
Rab27b in regulating the secretion of exosomes 
has recently been identiÀed; this should enable us 
to build tools for the understanding of exosomes’ 
role in different pathophysiological contexts. Our 
growing knowledge of the effects of Dex on immune 
responses and their potential use as therapeutic 
agents led us to develop second generation mDex in 
order to propose a maintenance immunotherapy in 
patients with advanced cancer. During this phase II 
clinical trial, we will have a unique opportunity to 
analyze the immunostimulatory capacity of mDex 
the immunogenicity of Dex reÁects the state of 
maturation of DCs. Taking into account these new 
knowledge, our team developed a new generation of 
Dex capable of inducing immune cellular responses 
against tumor antigens. We have engineered human 
mDex, respecting good laboratory processes (GLP), 
harboring a phenotype with increased expression 
of MHC complexes and co-stimulatory molecules 
suggesting potent adaptive immunity. These second 
generation mDex are currently tested in a phase II 
clinical trial in non small cell lung cancer (NSCLC) 
bearing patients. The interest for Dex began in 1998 
when it was shown that these vesicles secreted into 
the culture supernatant of immature dendritic cells 
(immature Dex or “iDex”) could induce stabilization 
and regression of tumors in mice. These antitumor 
effects induced by iDex pulsed with tumor antigens 
were dependant on CD8+ T cells in mice. These 
results provide a rational for the use of iDex as a 
therapeutic vaccine in patients bearing advanced 
cancer.
Two phase I clinical trials using autologous iDex 
pulsed with MAGE-3 peptides in patients with 
stage III/IV (French trial) and (US trial) allowed us 
to monitor immunological responses. These trials 
aimed at evaluating the feasibility of Dex production 
by autologous monocyte-derived DCs and the safety 
of Dex inoculation. Secondary endpoints were 
the immunomonitoring of peptide speciÀc CD4+ 
and CD8+ T cell responses restricted by exosomal 
MHC class II and I molecules. Fifteen patients 
were included in the french trial and thirteen in 
the US trial. Feasibility and tolerance were good; 
however, no T cell responses were pointed out after 
iDex vaccinations. The discrepancy between some 
clinical responses and the lack of any detectable 
T cell responses prompted the search for alternate 
effector mechanisms accounting for the tumoricidal 
activity. We studied NK activity in patients enrolled 
in these clinical trials and we could show that iDex 
were able to restore NK cell activity in half of 
treated patients. All of these preclinical and clinical 
studies have led to improve this vaccine approach in 
order to obtain Dex that could activate an effective 
adaptive immune response in vivo. Three strategies 
were explored to improve the antitumor efÀcacy of 
Dex: - concomitant injection of an immunological 
adjuvant - inhibition of regulatory T cells (Treg) - the 
use of mature DC to produce Dex (mDex). The role 
of Treg in restricting T cell based-immune responses 
has gained renewed recognition. Cyclophosphamide 
(CTX) at immuno-potentiating doses has been 
S78 Copyright © 2011 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
of the symptom of breathlessness in people who 
are not severely hypoxaemic is more controversial 
a systematic review that brings together all of the 
relevant papers in people with cancer and dyspnoea 
who do not qualify for long term home oxygen 
does not demonstrate a symptomatic beneÀt. By 
contrast, in chronic obstructive pulmonary disease 
there appears to be appreciable symptom beneÀt in 
people who do not have hypoxaemia but are severely 
breathless. The most promising intervention is the 
use of heliox (28% O
2
/He 72%). This markedly 
reduces the work of breathing therefore helping to 
reduce breathlessness. Its expense however precludes 
it in use in clinical practice. A recently published 
multi-site international study did not demonstrate 
symptomatic beneÀt for people who do not 
qualify for long term home oxygen with refractory 
breathlessness over a one week period. Both 
medical air and oxygen delivered a similar level of 
symptomatic beneÀt. The science around the use of 
opioids has continued to improve. In a double-blind 
randomised cross-over study of people with mild to 
moderate chronic obstructive pulmonary disease, 
the use of a centrally acting opioid antagonist 
demonstrated increased breathlessness when opioid 
receptors were blocked without changing the 
exercise tolerance. Functional magnetic resonance 
imaging (fMII). This conÀrms the widespread 
activation of opioid receptors with the initiation 
of stimuli that caused breathlessness in healthy 
volunteers and in people with underlying lung 
disease. Adequately powered studies demonstrate an 
adequately powered study and a systematic review 
conÀrmed clinical efÀcacy of opioids for the relief 
of breathlessness. A long term effectiveness study 
conÀrms the safety (no episodes of respiratory 
depression in a patient population predominately 
made up of people with COPD) and no tachyphylaxis 
demonstrated (follow-up up to 22 months). Other 
interventions investigated include the use of selective 
serotonin reuptake inhibitors, promethazine, 
nebulised frusemide (not for its diuretic properties) 
and a number of other medications. All of these 
studies are still investigational. Future questions 
also need to be answered about whether all opioid 
agonists are the same in their ability to inÁuence 
breathlessness. Non-pharmacological interventions 
do have a strongly emerging evidence base with 
a number of therapies that have been shown to 
reduce breathlessness and improve people’s quality 
of function. These allow self management for a 
number of people whose symptoms are ameliorated 
in a dynamic study in patients, to investigate their 
protein and nucleic acid content and to correlate 
those parameters with a potential and expected 
clinical efÀcacy in patients. Together, these studies 
should allow us to identify molecules essential for 
the bioactivity of mDex in vivo in cancer patients 
and to pave the way for the production of synthetic 
exosomes that would have a tailor-made content for 
the induction of a speciÀc immune response. 
Keywords: immunotherapy, exosomes
Session M08: Symptom Control - 
Translating Basic Research to Bedside
Monday, 4 July 2011
Symptom Control - Translating Basic Research to Bedside Monday, 4 
July 2011 16:30-18:00
M08.1 SCIENTIFIC BASIS FOR THE 
MANAGEMENT OF DYSPNEA
David Currow 
Palliative And Supportive Services, Flinders 
University/Australia
Abstract: Dyspnoea is a subjective sensation. It is 
fundamentally a mismatch between afferent drive 
to breath and the body’s efferent response to this. 
At a population level, at least one in 100 people in 
the population are chronically breathless despite 
optimised treatment of the underlying causes of 
breathlessness. This group of people with refractory 
or intractable breathlessness require symptomatic 
treatment. The other important distinction to make 
is between breathlessness at rest and breathlessness 
on exertion. There are a group of people breathless 
at rest or on absolutely minimal exertion (dressing, 
preparing a cup of coffee). Clinically, although 
there are different descriptors that help delineate 
breathlessness, these are not pathognomonic. 
There are two clear components of breathlessness 
however. The Àrst is the intensity of breathlessness. 
The second is an affective component measured as 
how unpleasant the sensation is. The symptomatic 
treatment of breathlessness includes the use of 
oxygen, pharmacological interventions (focussed 
around the use of chronic low dose opioids) and non-
pharmacological interventions. Although oxygen 
has been shown to prolong survival in people with 
severe hypoxaemia, its use in people for the relief 
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consequences include negative nitrogen balance, 
hypo-albuminaemia and weight loss. In addition, 
because of the systemic inÁammation patients 
have an increased cortisol, hyperlipidemia and 
hyperinsulinemia. These nutritional consequences 
result in metabolic alterations in cachexia affecting 
protein, lipid and carbohydrate metabolism. This 
results in changes in body composition in cachexia 
and speciÀcally there is reduced fat free mass 
(skeletal muscle) as well as reduced fat. However, 
extra cellular water is maintained. There are a 
range of clinical sequelae associated with cancer 
cachexia. These include anorexia and weight loss as 
well as wasting of muscle mass and loss of fat. In 
addition, anaemia and fatigue are common features. 
Consequently patients with cancer cachexia have 
reduced function and reduced quality of life and 
they have also been shown to have reduced survival. 
Up to 35% of skeletal muscle may be lost and 
patients with lung cancer particularly are prone to 
respiratory muscle weakness and immobility which 
can result in DVT and PTE. Moreover, the chronic 
systemic inÁammation seen in cancer cachexia down 
regulates the cytochrome P450 enzyme system. The 
systemic inÁammatory response has been reviewed 
in inoperable non small cell lung cancer by the 
Glasgow group and a Glasgow prognostic score has 
been described by this group. In addition a Montreal 
Score has been described by McDonald et al in 
Canada. Therapeutic interventions in lung cancer 
cachexia remain a signiÀcant challenge to clinicians, 
and various treatment modalities will be reviewed. 
Regrettably research into cancer cachexia in lung 
cancer and other cancers remains limited. End 
points for future research in cancer inÁammation 
and cachexia should include not only survival 
but symptoms, quality of life and performance 
status as well as function and anthropometrics. In 
summary, cachexia is common in lung cancer. It is 
often associated with fatigue. It is commoner with 
increasing stage and disease progression. Systemic 
inÁammation mediated by cytokines has major 
metabolic consequences which results in loss of 
skeletal muscle and fat, reduced function and poorer 
survival. 
Keyword: cachexia, systemic inÁammation
somewhat the education and support that is offered 
through these programs. 
Keywords: dyspnoea, oxygen therapy, opioids, Non-
pharmacological
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M08.3 CACHEXIA AND LUNG CANCER
Robert Milroy 
Respiratory Medicine, Glasgow Royal InÀrmary/
United Kingdom
Abstract: Lung Cancer remains one of the 
commonest malignancies worldwide with a 
rising incidence in developing countries. Despite 
advances in treatment it continues to have an 
overall poor prognosis. Lung Cancer is a cancer 
where the symptom burden is particularly high 
and these include both local symptoms such as 
breathlessness, cough, haemoptysis and pain, 
symptoms of metastatic disease and also systemic 
symptoms – speciÀcally fatigue and cachexia. 
This lecture will focus on lung cancer cachexia. 
Cachexia is deÀned as involuntary weight loss and 
loss of skeletal muscle and derives from the Greek 
for poor condition Cachexia is a common symptom 
at presentation and may in fact be the presenting 
symptom. It is increasingly common with increasing 
stage and is increasingly common as the disease 
progresses. Cachexia is often associated with fatigue. 
The patho-physiology of lung cancer cachexia is not 
fully understood. It is not simply related to anorexia 
and reduced intake. There are major metabolic 
changes with signiÀcant clinical consequences. 
The metabolic changes relate to a chronic systemic 
inÁammatory response with increased synthesis of 
proteins involved in the response to tissue injury 
(acute phase proteins). This inÁammatory response 
appears to be mediated by Cytokines. This results in 
redistribution of body protein, depletion of skeletal 
muscle and elevated resting energy expenditure. 
The consequences of this chronic systemic 
inÁammation fall into four categories: behavioural, 
physiological, nutritional and metabolic. Behavioural 
consequences include anorexia, fatigue, malaise 
and altered sleep. Physiological consequences 
comprise increased resting energy expenditure and 
skeletal muscle wasting but also include increased 
body temperature, bone marrow suppression 
and trace mineral sequestration. The nutritional 
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1931 (9), NK
1
-receptors described in 1981 (10) 
and the Àrst clinical trial published in 1997 (11). 
The development of these agents included use 
of a new imaging technique, positron emission 
tomography (PET). This enabled an estimation of 
the percentage of receptor binding necessary to 
obtain optimal antiemetic effect and to correlate 
this to relevant plasma trough concentrations (12). 
Nausea and vomiting were decades ago inevitable 
side effects of chemotherapy, but today effective 
antiemetic prophylaxis has been developed and 
vomiting is successfully prevented in most patients, 
meaning that nausea has overtaken vomiting as the 
most feared side effect of chemotherapy (13). The 
Multinational Association of Supportive Care in 
Cancer (MASCC) has developed evidence-based 
antiemetic guidelines. Chemotherapeutic agents 
are grouped according to emetic risk potential as 
having minimal (< 10% risk of vomiting), low (10-
30%), moderate (30-90%) or high (> 90%) risk. The 
corresponding recommended antiemetic prophylaxis 
(14) is; minimal risk, no routine prophylaxis; low 
risk, a single dose of dexamethasone; moderate 
risk including the combination of an anthracycline 
plus cyclophosphamide (AC), a combination of 
a 5-HT
3
-receptor antagonist plus dexamethasone 
plus the NK
1
-receptor antagonist, aprepitant (or 
fosaprepitant); moderate risk (no AC included), 
a combination of the 5-HT
3
-receptor antagonist, 
palonosetron, plus dexamethasone; high risk, a 
combination of a 5-HT
3
-receptor antagonist plus 
dexamethasone plus the NK
1
-receptor antagonist, 
aprepitant (or fosaprepitant). Both 5-HT
3
-receptor 
antagonists and the NK
1
-receptor antagonist, 
fosaprepitant (15) can be administered as single 
doses together with a single dose of dexamethasone 
before initiation of chemotherapy. The single 
dose regimen optimizes compliance, because 
only dexamethasone has to be administered for an 
additional 2-3 days after chemotherapy. Tolerability 
of combination antiemetic prophylaxis is very 
good with headache and constipation being drug 
class adverse effects of 5-HT
3
-receptor antagonists 
(16) and no speciÀc drug class adverse effects 
allocated to aprepitant (17). This presentation will 
brieÁy summarize the development of antiemetics 
from basic research to clinical use go through 
recommendations from evidence-based guidelines, 
focusing on antiemetic prophylaxis in lung 
cancer patients. References 1. Thumas LJ. Über 
das Brechcentrum und über die Wirkung einiger 
pharmakologischer Mittel auf dasselbe. Archieves 
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M08.4 CHEMOTHERAPY-INDUCED 
NAUSEA AND VOMITING: FROM 
TRANSMITTERS AND RECEPTORS 
TO EVIDENCE-BASED CLINICAL 
GUIDELINES
Jørn Herrstedt 
Oncology, Odense University Hospital And 
University Of Southern Denmark/Denmark
Abstract: The physiology of nausea and vomiting 
has been of scientiÀc interest for more than 100 
years. Using the dog brain Thumas in 1891 proposed 
the existence of an anatomical area, called the 
vomiting center (VC) (1). This was further explored 
by Hatcher in 1923 (2), who demonstrated that 
apomorphine-induced vomiting could be abolished 
by ablation of the nucleus of the tractus solitarius. 
Borison and Wang (3) made a series of studies 
in the 1950s and demonstrated two regions. The 
VC was located in the lateral reticular formation 
and the chemoreceptor trigger zone (CTZ) at the 
area postrema, outside the blood-brain barrier, 
and therefore capable of sensing both blood- and 
cerebrospinal Áuid-borne emetic stimuli. Miller 
and Wilson in 1983 questioned the existence of the 
VC (4) and today we consider the VC as a system 
connecting neural networks penetrating into the 
nucleus of the tractus solitarius. Autoradiography 
technique was soon used to demonstrate dopamine, 
muscarine cholinergic and histamine receptors in 
the gastrointestinal tract, the VC and the CTZ, and 
radioligand-binding studies linked receptors to the 
emetic reÁex arch (5). Today we know that most 
antiemetics act as antagonists at receptors, thereby 
abolishing the emetic effect of neurotransmitters 
such as dopamine and histamine. Two groups of 
drugs, the serotonin (5-HT)
3
 receptor antagonists 
and the neurokinin (NK)
1
 receptor antagonists, 
were speciÀcally developed as antiemetics. These 
developments disclosed the long timeframe from 
isolation of a substance (serotonin and substance 
P), the Ànding of the corresponding receptors (5-
HT
3
 and NK
1
), the hypothesis of a clinical relevant 
application (using speciÀc receptor antagonists 
as antiemetics) and clinical drug development. 
Thus, serotonin was isolated in 1948 (6), 5-HT
3
-
receptors described in 1957 (7) and the Àrst clinical 
trial with a 5-HT
3
-receptor antagonist published 
in 1987 (8), whereas substance P was isolated in 
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vomiting. Expert Opin Drug Safety (published online 
March 2011). 
Keyword: antiemetics, nausea, vomiting, supportive 
care
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M09.1 HEAVY ION RADIOTHERAPY IN 
LUNG CANCER
Hirohiko Tsujii, Naoyoshi Yamamoto, Masayuki 
Baba 
Research Center For Charged Particle Therapy, 
National Institute Of Radiological Sciences/Japan
Abstract: (Introduction) In radiotherapy of non-
small cell lung cancer (NSCLC), carbon ion beams 
offer improved dose distributions as compared 
to photon beams and thus enable dose escalation 
within a target while sparing the surrounding normal 
tissues. Furthermore, carbon ions being heavier than 
protons provide a higher biological effectiveness, 
which increases with depth, reaching the maximum 
at the end of the range. At the National Institute of 
Radiological Sciences (NIRS), clinical research on 
carbon ion radiotherapy (C-ion RT) was started in 
1994 using carbon-ions generated by Heavy Ion 
Medical Accelerator in Chiba (HIMAC). So far, 
almost 6,000 patients have been treated, where the 
beneÀt of C-ion RT over other modalities has been 
demonstrated in terms of high local control rates and 
a signiÀcant reduction in overall treatment time with 
acceptable toxicities in most cases. In this paper, 
the results of treatment for Stage I NSCLC using 9 
and 4 fractions are reviewed, as well as preliminary 
results of single fraction treatment is described. 
Also, results of other RT reported in the literatures 
are compared. (Methods and materials) Stage I 
lung cancer is divided into two types depending on 
tumor location: peripheral-type and central-type. 
This classiÀcation is made on the assumption that 
the two types may tolerate radiation differently. 
Therefore, different fractionation regimens were 
investigated for each type. The patients eligible for 
either treatment are those for whom surgery was 
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fractions over 3 weeks, 4 fractions over one week, 
and eventually to a single fraction treatment. The 
preliminary data suggested favorable local control 
and very few toxic reactions with a median follow up 
time of about 16 months. Compared with pulmonary 
damage reported for stereotactic radiotherapy in 
stage I lung cancer, the incidence and severity in 
our patients seemed to be remarkably low. The 
decreased adverse effects on the lung are likely 
achieved due to the small volume irradiated. When 
comparing proton vs C-ion RT, local control results 
are comparable for T1 tumors, but for T2 tumors 
2-5 year local control rates are higher in C-ion RT. 
It is of note that in most reported data for proton 
therapy, follow-up periods are short relative to 
the time required for full evaluation of TCP, late 
NTCP and survival. Considering that the average 
age of the patients receiving C-ion RT was about 
75 years, about 10 years older than that of 65 years 
in the operated patients, the results of C-ion RT for 
stage-I lung cancer may be comparable to surgical 
results. Thus, the single-fraction irradiation method 
may be described as the ultimate type of treatment 
using carbon ion, and would be a valid alternative 
to surgery, especially for elderly and inoperable 
patients.
Keywords: Particle, Carbon ion, Radiotherapy, 
Hypo-fraction, Lung, NSCLC
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M09.2 ARC-THERAPIES AND OTHER 
APPROACHES FOR IMRT
Wilko F.A.R. Verbakel 
Radiation Oncology, Vu University Medical Center/
Netherlands
Abstract: RapidArc (Varian Medical Systems) is a 
form of volumetric modulated arc therapy which has 
been clinically used at VUmc since its Àrst release 
in May 2008 for over 1400 patients, 500 treated 
with SBRT. In comparison with Àxed beam IMRT, 
RapidArc reduces treatment time for all treatment 
sites. For SBRT for stage I lung tumours, RapidArc 
can achieve better dose conformity than conventional 
10 static Àeld plans. Use of 2 sequentially optimized 
arcs allows overcoming the problem of the different 
dose engines in the optimizer and Ànal dose 
calculation. Radiation delivery time for a fraction 
of 18 Gy takes less than 6 minutes and a fraction of 
not indicated due to medical reasons or refusal. 
From 1999 to 2003, a total of 131 tumors in129 
patients received C-ion RT with 9 fractions and 4 
fractions, including 94 males and 37 females with 
an average age of 74.5 years. Out of the 131 foci, 
there were 72 T1 tumors and 59 T2 tumors. There 
were 85 adenocarcinomas, 43 epidermoid cancers 
and 3 other types. Regarding dose fractionations, 
51 cases were treated with 72.0GyE/9 fractions, and 
80 cases were treated with 52.8GyE/4fr for stage IA 
and 60.0GyE/4fr for stage IB. Since 2003, a dose-
escalation study using single fraction treatment has 
been conducted for peripheral-type NSCLC. The 
initial dose was 28.0 GyE, which was then escalated 
at increments of 5%. At each dose level, about 10 to 
30 patients were registered for evaluation of toxicity 
and local control with carbon ions. C-ion RT has 
also been applied to locally advanced lung cancers 
and hilar-type cancers, and case studies are being 
accumulated. The locally advanced lung cancers 
included Pancoast tumors and mediastinal-type 
tumors in stages II-IIIA. (Results) All of the patients 
treated with 9 fractions/3 weeks (50 patients) and 4 
fractions/1 week (79 patients) developed no evidence 
of severe toxicities. The 5-year local control rates 
were 98.6% for stage-IA cases and 89.7% for stage-
IB cases, and the 5-year survival rates were 63.1% 
for stage-IA cases and 50.0% for stage-IB cases. In 
single fraction treatment, a total of 218 patients have 
been registered, in which the total dose has been 
escalated from 28.0 to 48.0 GyE. So far, no serious 
adverse events have been observed, and local control 
appears to be improving with increasing total dose. 
For skin reactions, six grade 2 toxicity (3.3%) but 
no grade 3 or higher was observed. For radiation 
pneumonitis, only one grade 1 was reported, and 
no toxicities greater than grade 2 occurred. The 
overall local control rate was 91.8%, and the cause-
speciÀc survival rate at 5-years was 71.8%. The 
superÀcial lesions arising at the hilar region have 
been successfully treated with acceptable toxicities. 
Similarly, in the preoperative radiotherapy for 
patients with chest wall invasion, high anti-tumor 
effect was conÀrmed in the pathological Àndings 
after the lung was surgically removed. (Discussion) 
Only at NIRS, Japan, NSCLC has been treated 
with carbon ions. For peripheral tumor, we have 
been conducting clinical studies to establish a 
short-course, hypo-fractionated radiotherapy. We 
Àrst performed a dose-escalation study using 18 
fractions/6 weeks. The number of fractions and 
treatment times were subsequently reduced to 9 
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advantages, but also important limitations: they are 
often resource-intensive and expensive, with a long 
lag-time from study initiation until results, and can 
have limited generalizability. Many questions are 
not amenable to RCTs, due to concerns about ethics, 
practicality, and important barriers to accrual. In 
many cases, a pressing scientiÀc question cannot 
be answered in the context of a randomized trial, 
and physicians must look to other sources in order 
to practice EBM. In the absence of controlled 
trials, population-based studies provide the highest 
level of evidence for medical decision making. By 
deÀnition, such studies include all patients from a 
well-deÀned population, most commonly deÀned 
by a geographic boundaries (province, state, or 
country), but occasionally deÀned differently 
(e.g. by occupation or membership in a health-
maintenance organization). Although population 
studies are not able to control for confounders 
as well as randomization, they have several 
important advantages: they are inherently the 
most generalizable of studies, they reÁect real-
world outcomes, and reduce or eliminate selection 
bias. Population-based studies have advanced the 
understanding and treatment of non-small cell lung 
cancer. Overall, progress in lung cancer has been 
slow, with 5-year survival improving marginally 
from 13% in 1975-1977 to 16% in 1999-2005, 
based on U.S. population data, a gain of only 3%. 
In contrast, breast cancer patients achieved a 15% 
improvement and prostate-cancer patients a 30% 
improvement over the same time period. Population 
studies have also revealed important international 
disparities among developed countries: the age-
standardized 5-year survival in Sweden is nearly 
double the survival in England for both men and 
women, and this difference in mortality is evident 
within the Àrst 3 months after treatment, suggesting 
that early detection and treatment effects play a 
major role in survival. Geographic variation also 
occurs within individual countries, with major 
regional differences in resection rates and operative 
mortality demonstrated in several population studies. 
Stage I NSCLC in the elderly is a particularly 
challenging clinical scenario: although the disease is 
theoretically curable, often treatment is hampered by 
patient co-morbidity, frailty, or physician perception 
of lack of efÀcacy. High-level evidence is limited, 
since RCTs tend to restrict enrollment by elderly 
patients. Canadian population-based data have 
demonstrated that in elderly patients with stage 
I NSCLC treated with radical intent, survival is 
7.5 Gy is delivered in less than 3 minutes. The fast 
treatment reduces the risk of intrafraction motion 
of the patient. The high dose conformity allowed 
us to treat also large PTVs. Early toxicity results 
were collected from 14 patients with large St I 
tumors (PTV range 87-286 cc) treated with risk 
adapted fractionation schemes of 5x11 Gy or 8x7.5 
Gy, prescribed to the 80% isodose. All patients 
with a contralateral lung V5>26% developed CP 
and contralateral V5 was the best predictor for CP 
(p<0.001). Total lung V10 had a weaker correlation 
to CP (p=0.02) and total lung V15 and V20 showed 
no signiÀcant correlation with CP. Our early clinical 
data showed that CL V5 is the best predictor for CP 
and should be kept lower than 26%. This can be 
achieved applying partial arcs or avoidance sectors. 
Use of moving leaves in combination with moving 
(lung) tumours can raise the fear of dosimetric 
interplay effects. This has been studied for different 
levels of plan complexity and tumour amplitudes 
using Gafchromic Àlm measurements in a moving 
phantom, showing that the dosimetric effect in 
the tumour itself is limited to 3%. 3D conformal 
planning can be time consuming, especially for large 
PTVs overlapping with organs at risk. Full IMRT 
provides better opportunities to spare OAR with 
a lower dose and achieve a more conformal dose 
distribution, but it prolongs delivery time. A Hybrid 
solution of a combination of 3D conformal plan with 
a small IMRT component allows for fast planning 
and more conformal dose distributions. 
Keywords: SBRT, treatment planning, Radiotherapy
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M09.3 LUNG SBRT AND POPULATION-
BASED COMPARATIVE-
EFFECTIVENESS RESEARCH
David Palma 
Radiation Oncology, London Regional Cancer 
Program/Canada
Abstract: The goal of Evidence-Based Medicine 
(EBM) is to apply the best-available evidence from 
scientiÀc discovery to clinical decision making. 
EBM was deÀned by Sackett as “the conscientious, 
explicit and judicious use of current best evidence 
in making decisions about the care of individual 
patients.” The randomized control trial (RCT) 
is the gold-standard of EBM. RCTs have many 
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allow treatment with this fractionation scheme 
to lesions within 2 cm of the central pulmonary 
structures. Central tumors are currently the subject 
of a cooperative group investigation utilizing a 
lower dose per fraction (9 to 11.5 Gy) for Àve 
fractions. Dose constraints for speciÀc organs vary 
by institution. For the lungs, some institutions use a 
dose constraints to the V20 of approximately 10 – 
12% for the lung as a paired organ. Other institutions 
try to keep the dose to 1000 cc of lung less than 12.4 
Gy and the 1500 cc less than 11.6 Gy. Other organs 
such as the proximal bronchial tree, esophagus, 
spinal cord, heart, great vessles and brachial plexus 
are subject to a maximum dose constraint, usually 
in the range of 20 – 35 Gy. The chest wall has 
recently been identify as an organ at risk for fracture 
and persistent chest wall pain. Most institutions try 
to limit the volume of chest wall receiving 30 Gy 
regardless of fraction size. 
Keywords: stereotactic body radiation therapy, 
SBRT, toxicity, dose constraints
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M10.1 EARLY DETECTION AND 
SCREENING OF LUNG CANCER VIA 
VOLATILE BIOMARKERS
Hossam Haick1, Nir Peled2, Meggie Hakim1, Orna 
Barash1, Jane Mettei2, Ulrike Tisch1, Paul Bunn2, 
Fred R. Hirsch2 
1Department Of Chemical Engineering, Technion - 
Israel Institute Of Technology/Israel, 2Cancer Center, 
University Of Colorado/United States Of America
Abstract: An emerging approach for diagnosing 
cancer relies on volatile biomarkers that are emitted 
from cells membranes. These volatile biomarkers can 
be detected either directly from the headspace of the 
cancer cells or via the exhaled breath. The principle 
of the latter is that cancer related changes in blood 
chemistry are reÁected in measurable changes in the 
breath through exchange via the lung. 
Methods: Based on these principles, we have 
developed and tested a highly-sensitive, inexpensive, 
and fast-response, non-invasive tool for early 
detection of volatile biomarkers. This tool is based 
predicted by tumor and treatment factors (such as 
stage, sex, and radiotherapy dose), and physiological 
factors (ECOG status), but is not predicted by age, 
suggesting that elderly patients should not be denied 
radical treatment based on age alone. The impact 
of implementing stereotactic ablative radiotherapy 
(SABR) for elderly patients with stage I NSCLC 
has now been measured at the population level. 
Emerging evidence suggests that the implementation 
of SABR is associated with a signiÀcant increase in 
radiotherapy utilization, and a signiÀcant decline in 
the number of patients going untreated. As a result, 
potentially curative therapy is now being offered 
to patients who previously went untreated, and this 
is reÁected in improved overall survival in patients 
treated with radiotherapy at the population level. 
The development of several national administrative 
cancer databases has facilitated increased population-
based oncology research over the past decade. Future 
research should continue to focus on comparative 
effectiveness issues, including survival outcomes, 
resource utilization and cost effectiveness. Although 
randomized studies remain the gold standard of 
EBM, population-based studies provide important 
evidence, especially for questions that cannot be 
answered by randomized trials. 
Keywords: Non-small cell lung cancer, 
Epidemiology, Comparative effectiveness
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M09.4 NORMAL TISSUE CONSTRAINTS 
FOR SBRT
Kenneth Rosenzweig 
Department Of Radiation Oncology, Mount Sinai 
School Of Medicine/United States Of America
Abstract: Stereotactic body radiation therapy 
(SBRT) is increasingly used in the treatment of 
early-stage non-small cell lung cancer (NSCLC), 
particularly in patients with medical conditions 
precluding surgical management. Although many 
of the side effects of SBRT are similar to those 
seem for conventionally fractionated lung cancer 
treatment, there are other toxicities unique to SBRT 
that reÁect its use of high dose per fraction treatment. 
In one study, patients treated with doses of 20 Gy 
per fraction to central lesions had a greater risk of 
treatment related mortality than peripheral lesions. 
As a result of this, newer SBRT protocols do not 
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A series of complementary in-vitro studies3 have 
shown the feasibility of the NA-NOSE concept for 
distinguishing the LC sub-histologies. The NA-
NOSE clearly distinguished NSCLC from the control 
medium, with relatively high accuracy. Furthermore, 
the NA-NOSE could clearly distinguish patterns 
of volatile biomarkers emitted from cell lines that 
exhibited EGFR mutation (mut) from cell lines that 
exhibited EGFR wild type (wt), as shown in Fig. 
2 (p < 0.0001). The accuracy of the method was 
determined as 85-89% through cross-validation. 
Auxiliary chemical analysis of the headspace 
samples was performed using gas chromatography in 
combination with mass spectrometry (GC-MS) and 
solid phase micro extraction (SPME). The results 
showed statistically signiÀcant differences in the 
average abundance of several biomarkers in each cell 
category.
Conclusions: The NA-NOSE concept has the 
potential to reduce cancer mortality, by enabling 
widespread, trustworthy screening, especially for 
high-risk populations, through non-invasive point-
of-care breath testing. It would be suitable for use 
outside of specialist settings and would signiÀcantly 
reduce costs in health budgets. The same tool 
could be used after biopsy in laboratory settings to 
assist treatment decisions. It would allow the easy, 
inexpensive and fast detection of the cancer subtype 
and/or cancer related genetic mutations that can 
beneÀt from oral targeted therapy (e.g. EGFR tyrosin 
kinase inhibitors). The easy-to-use NA-NOSE 
technology detects cancer and identiÀes cancer-
related EGFR mutilations based on a change in the 
blood chemistry and/or metabolic activity rather 
than by tumor imaging, thus permitting earliest 
cancer detection i.e. before a tumor of detectable 
size has formed, and/or assists the swift choice of the 
therapeutic approach. 
References: 1. Peng G, Tisch U, Adams O, et al. 
on an artiÀcial (electronic) nose, which makes use 
of cross-selective and chemical nanosensor arrays 
that are trained in their ensemble to detect cancer 
biomarkers. The signals from all the sensors in 
the array are analyzed using standard principal 
component analysis (PCA) or discriminant factor 
analysis (DFA). We term this new concept as NA-
NOSE. The NA-NOSE concept was applied to 
(i) breath testing, using collected breath samples 
from lung cancer (LC) patients and various control 
groups, and to (ii) headspace sampling from LC cell 
lines. RESULTS Clinical studies on breath samples 
collected from 177 volunteers demonstrated the 
discriminative power of the NA-NOSE breath test 
to distinguish LC patients from healthy controls1 
and from patients having colon cancer (CC), breast 
cancer (CC) or prostate cancer (PC) with >95% of 
diagnosis accuracy (see Fig. 1).2 The NA-NOSE 
distinguished between the breath of cancer patients 
and that of healthy individuals with high accuracy 
and in the presence of confounding factors (e.g., 
age, gender, ethnic origin, family cancer history, 
intake of food additives, drug treatment, exposure 
to environmental toxins and smoking habits, etc.). 
The unambiguous detection of LC within a mixed 
population of healthy persons and persons suffering 
from the four most widespread cancers in a single 
breath test could form the basis of a future cancer 
screening test for the general population.
 
In a complementary study we showed that the NA-
NOSE could identify and distinguish speciÀcally 
between LC and head-and-neck cancer (HNC) 
that are both closely related to tobacco smoking, 
and, therefore occur in the same population. The 
results showed excellent separation between 
LC patients, HNC patients and healthy controls. 
The differential diagnosis of LC and HNC could 
lead to the development of a routine breath test 
for the at-risk population of tobacco smokers. 
S86 Copyright © 2011 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
of seropositivity to ANXA1, YWHAQ, and LAMR1 
for the early detection of lung cancer based on 
blinded validation using pre-diagnostic sera. The 
goal of our current studies has been to identify 
additional antigens that augment the performance of 
our previously established panel. One such antigen 
is ANGPTL3 a protein not previously associated 
with lung cancer. Our studies have demonstrated 
signiÀcant autoantibody reactivity against ANGPTL3 
in the sera of newly diagnosed NSCLC patients 
compared to control sera (p=0.0013). Importantly, 
addition of ANGPTL3 to our previously published 
panel of ANXA1, YWHAQ, and LAMR1 improved 
the predictive performance of the panel to 
discriminate cases from controls in sera collected 
prior to the onset of symptoms and diagnosis of 
lung cancer providing further support for the utility 
of harnessing the immune response against tumor 
antigens for the early detection of lung cancer. 
Keywords: Early Detection, immune response
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M10.3 ANALYSIS METHYLATED DNA IN 
SPUTUM
Steven Belinsky 
Lovelace Respiratory Research Insititute/United 
States Of America
Abstract: Gene promoter hypermethylation is a 
major mechanism in the etiology of lung cancer with 
hundreds of genes epigenetically silenced during 
initiation and progression of this disease. The fact 
that gene methylation can be detected in sputum 
(as Àrst shown by our group) and that methylation 
is reversible by pharmacological intervention led 
us to initiate translational studies to assess whether 
methylation in sputum could be used as a biomarker 
for early lung cancer detection. A second goal of 
these studies was to identify genetic determinants 
that inÁuence the propensity for methylation in the 
aerodigestive tract or are associated with lung cancer 
and to integrate these key variants with methylation 
biomarkers for establishing the most sensitive 
and speciÀc risk proÀle for early lung cancer 
detection. A nested, case-control study was initially 
conducted in the Colorado cohort to determine the 
sensitivity and speciÀcity of 16 genes interrogated 
for methylation in sputum collected 3–18 months 
prior to diagnosis of clinical disease. A panel of six 
genes whose concomitant methylation in sputum 
Diagnosing lung cancer in exhaled breath using gold 
nanoparticles. Nature Nanotechnol 2009;4:669-673.
2. Peng G, Hakim M, Broza YY, et al. Detection of 
lung, breast, colorectal, and prostate cancers from 
exhaled breath using a single array of nanosensors. 
Br J Cancer 2010;103:542 – 551.
3. Barash O, Peled N, Hirsch FR, et al. SnifÀng the 
unique “odor print” of non-small-cell lung cancer 
with gold nanoparticles. Small 2009;5:2618-2624. 
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M10.2 AUTOANTIBODY DETECTION IN 
SERUM
Sam M. Hanash 
Molecular Diagnostics, Fred Hutchinson Cancer 
Center/United States Of America
Abstract: The development of lung cancer is a 
multi-step process. IdentiÀcation of antigens that 
are expressed at early stages of tumor development 
and that induce a humoral response would lead to 
the development of simple non-invasive detection 
strategies. A humoral response to tumor antigens 
results in an ampliÀed signal detected as a 
seropositive response based on antigen-autoantibody 
reactivity. While progress has been made in 
identifying an immune response to deÀned antigens 
in lung cancer using a multitude of technologies 
and some tests based on an immune response are 
becoming available, there are several challenges 
that need to be overcome for this strategy to be 
widely accepted as a means for early detection of 
lung cancer. Antigens need to be identiÀed that are 
expressed at early stages. Most work done to date 
is based on identiÀcation of seropositivity to tumor 
antigens at the time of diagnosis. Given that different 
antigens may be expressed at different stages and the 
balance between amount of antigen vs antibody may 
also be substantially altered with tumor progression, 
the search for antigens and the development of 
related biomarker tests would beneÀt substantially 
from a study design in which the intended clinical 
application drives discovery and validation studies. 
Given that a robust test would have to include 
multiple antigens, there is a need for validation 
studies that allow comparison of performance of 
individual antigens on aliquots from the same study 
samples as appropriate for the intended application. 
We have previously reported the utility of assessment 
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cohort. We are assessing several different models 
that incorporate this genetic index and clinical risk 
factors with the methylation index to determine 
their effect on sensitivity and speciÀcity for lung 
cancer detection. (Supported by P50 CA58184, P50 
CA58187, and R01 CA097356)
Keywords: Early Detection, Sputum, genetic 
polymorphisms, Promoter methylation
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M10.4 MICRO RNA DETECTION IN 
SPUTUM
Feng Jiang, Nevins Todd 
Thoracic Surgery, Cancer Hospital Of Jiangsu 
Province/China
Abstract: Non-small cell lung cancer (NSCLC) 
is the most common type of lung cancer and the 
number-one cancer killer in the United States and 
worldwide. NSCLC mainly consists of two major 
histological types: adenocarcinoma (AC) and 
squamous cell carcinoma (SCC). The disease is 
frequently diagnosed at advanced stages, resulting 
in an overall 5-year survival rate of about 14%. 
Conversely, the 5-year survival rate in stage I 
NSCLC patients who have received effective 
treatments can be as high as 83%. Therefore, 
Ànding NSCLC earlier may reduce the mortality. 
The sensitivity of chest X -ray and sputum 
cytology for early detection of NSCLC is low. 
Bronchoscopy excels at detecting centrally occurring 
lung tumors. However, it is invasive. Although 
CT provides excellent anatomic information and 
can noninvasively detect NSCLC earlier at small 
size, the improved sensitivity is associated with 
over-diagnosis. Therefore, developing minimally 
invasive techniques by taking advantage of recent 
developments in molecular genetics for diagnosis of 
early stage NSCLC is clinically important. Because 
morphological changes of exfoliated bronchial 
epithelium from sputum are associated with incident 
of NSCLC, cytological analysis of sputum has been 
used clinically for its diagnosis. However, it was 
no more effective than chest radiographs in early 
diagnosis of lung cancer in several large prospective 
randomized trials. The molecular genetic alterations 
detected in sputum may correlate with those exist in 
lung tumors, and even occur before morphological 
changes that can be found by a cytological test. 
Therefore, molecular study of sputum could be 
was associated with a 6.5-fold increased risk for 
lung cancer and a sensitivity and speciÀcity of 65% 
for classiÀcation of incident cases was identiÀed. 
Those studies were extended to evaluate 60 genes in 
sputum from incident lung cancer cases and controls 
from the Colorado SPORE and identiÀed a 17-gene 
panel. Five genes (DAL1, PCDH20, KIF1A, P16, 
and DAPK) showed signiÀcantly increased odds 
for methylation in cases compared to controls and 
in total 14 genes were associated with a 2-fold or 
more increased lung cancer risk. A diagnostic test 
for lung cancer should have high speciÀcity and 
sensitivity for identifying early stage disease where 
curative resection and possibly adjuvant therapy 
could reduce mortality. Thus, sputum obtained from 
patients with Stage I lung cancer that are generally 
asymptomatic for disease should be an appropriate 
specimen for reÀning our gene panel for prospective 
studies. Stage I lung cancer patients identiÀed from 
our New Mexico (NM) cancer registry cohorts 
(n = 45) were matched 1:2 with controls by age 
(± 5 yr), gender, smoking status, and enrollment 
site and evaluated for methylation of the same 17-
gene panel. Twelve genes were validated in this 
study. Concomitant methylation of 4 or 5 genes 
from panels of 7 or 8 genes was associated with 
sensitivity and speciÀcities of approximately 70 
and 75%, respectively. In addition, several exciting 
new genes recently discovered by our group that 
are methylated in lung cancer that function as 
chemokines, CXCL12 and CXCL14 were evaluated 
in the NM cases and controls. Odds ratios of 1.6 
(CI, 0.7, 3.3) and 2.9 (CI, 1.7, 7.3) were seen for 
CXCL12 and CXCL14, respectively suggesting 
these genes could also be promising biomarkers 
for early lung cancer detection. A gene panel is 
being Ànalized for validation in a nested, case-
control study of participants from the National Lung 
Screening Trial. An additional goal is to develop and 
then integrate a genetic index of sequence variants 
associated with lung cancer or methylation with the 
panel of methylation biomarkers. As a Àrst step we 
genotyped the six single nucleotide polymorphisms 
(SNPs) identiÀed and validated through genome-
wide association studies in the cases and controls 
from New Mexico and Colorado. These include two 
SNPs on chromosome 15 (nAChR gene cluster), 
one within 6p21.31 (HLA-DQA1 gene), one within 
6p21.33 (BAT3-MSH5) and two within 5p15.33 
(CLPTM1L-TERT locus). An odds ratio of 2.2 
(CI: 0.85, 5.64; p = 0.11) was seen for subjects 
carrying more than 3 risk alleles in the New Mexico 
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in diagnosis of lung SCC patients. However, the 
sensitivities of the gene panel were 72.0% and 92.0% 
in diagnosis of lung AC patients. Additionally, there 
was an association of the changes of the genes with 
smoking packer-year of cancer patients (All p<0.05). 
However, the changes were not related to the age, 
gender, and ethnic of the participants (All p > 
0.05). Taken together, the validation data conÀrmed 
that the identiÀed sputum-based miRNAs had the 
potential to be used as biomarkers for NSCLC, 
particularly lung SCCs in the airways of the lungs. 
We further compared the panel of the miRNA genes 
with cytology in distinguishing early stage NSCLC 
patients from healthy individuals. 36.7% of early 
stage NSCLC patients were diagnosed to be positive 
by cytological examination. All cytologically 
positive specimens also exhibited aberrations of 
the genes, thus were positive for the genetic test. 
Interestingly, of the cytologically negative sputum 
samples from the NSCLC patients, 19 were positive 
for the miRNAs. Therefore, the composite of use of 
the miRNA genes had higher diagnostic sensitivity 
as compared with sputum cytology for early stage 
NSCLC (P< 0.01). Conclusion The sputum miRNA 
biomarkers demonstrated the potential to improve 
the early detection of NSCLC, particularly lung 
SCC. However, future identifying more informative 
miRNAs that can be added to the current panel 
will improve accuracy for the early detection 
of NSCLC. Furthermore, the future use of the 
miRNA biomarkers with CT scan will complete 
CT to improve efÀcacy to screen NSCLC in a high 
risk population. Finally, evaluating whether the 
biomarkers can distinguish lung cancer patients 
from chronic respiratory disease and heavy smokers 
remains to be investigated. 
Keywords: miRNA, Sputum, NSCLC, diagnosis
more sensitive than cytology in diagnosis of lung 
cancer. MicroRNA (miRNSs) are emerging as 
potential biomarkers in cancer diagnosis. The 
objective of this study was to develop a panel of 
miRNAs that can be used as a sputum-based test 
for early stage NSCLC. Patients and Methods We 
Àrst used a microarray platform to analyze primary 
lung tumor tissues from 32 stage I NSCLC patents 
to deÀne miRNAs signatures whose expressions 
are associated with stage I lung cancer. We then 
determined if miRNAs are stably present in sputum 
by quantitative real-time reverse transcriptase PCR 
(qRT-PCR) assay and deÀned a panel of miRNAs 
that can provide potential biomarkers for lung 
cancer in a training set of 36 stage I NSCLC patents 
and 36 healthy controls. We Ànally validated the 
deÀed miRNAs in a testing set of 49 case and 49 
healthy individuals. Results Identifying miRNA 
signatures whose aberrant expression levels were 
associated with lung adenocarcinoma. When P 
value <0.01 was used as a cutoff, of the 377 miRNA 
targets, 26 miRNAs were either underexpression 
or overexpression showed high expression in lung 
tumor compared with matched lung tissues with 
 1.5 fold-change. Using a predeÀned criterion of 
a fold-change 2, we identiÀed seven miRNAs 
that statistically differently expressed between the 
paired lung tumors and normal lung tissues. These 
included seven miRNAs . The miRNAs can be 
reliably measured in sputum samples and a set of 
miRNA are identiÀed in the training set of case 
and control. In the sputum samples, all the seven 
miRNAs can be reliably measured. In the training 
set of cohort, four genes (miR-21, miR-485, and 
miR-205) were selected, which in combination 
produced the best prediction in distinguishing 
lung cancer patients from normal subjects with 
overall sensitivity and speciÀcity at 80.6% and 
94.4% respectively. Furthermore, the panel of 
biomarkers has higher sensitivity in detection SCC 
compared with AC (P<0.05) at similar speciÀcity. 
Validation of the marker panel in the independent 
populations The genes displayed higher abnormal 
levels in the lung cancer patients compared with 
all non-cancer individuals (All p<0.05). We used 
the optimal thresholds established in the training 
set to determine diagnostic value of the genes for 
lung cancer in the testing set. Overall, the panel of 
the genes produced 81.6% and 93.9% sensitivities 
in differentiating NSCLC patients from healthy 
individuals. Furthermore, the genes used together 
generated 87.5% sensitivity and 95.8% speciÀcity 
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multiple endpoints and Bayesian approaches have 
been proposed. Typically the single-arm studies 
enroll 30-70 patients in total. The shift in oncology 
drug development from the evaluation of traditional 
cytotoxic agents to new approaches directed at the 
processes of angiogenesis, invasion, metastases 
and other host-tumor interactions have challenged 
the traditional phase II with objective. For these 
innovative cancer therapies, the optimal dose may 
not be the most toxic, the traditional parameters of 
tumor regression that are used to assess response 
may not apply and reliable surrogates of true 
clinical beneÀt may simply be not available. With 
an excess of options to explore and restrictions on 
the availability of patients and study budgets, the 
issue of prioritizing approaches and selecting ‘the 
winner’ for further testing on large scale, stimulated 
the development of randomized selection designs. 
In principle, the design is usually is equivalent 
to running two-stage single-arm studies for each 
regimen (or schedule), with the beneÀt of obtaining 
a greater degree of comparability between the 
treatments. Given some constraints, the regimen 
that results in the highest response rate is selected 
for further study. The selection design has also 
been adapted for use with progression-free survival 
or overall survival. Where the phase II selection 
design is appropriate, it can often be conducted 
with modest sample size. For example, 30-40 
patients per arm may yield 90% power to detect a 
regimen that has response rate superior by 15% (or 
corresponding hazard ratio of 1.5) in a two-armed 
study. Studies without a simultaneously randomized 
standard-treatment control arm (either single-arm 
or randomized) rely on an implicit comparison 
to historical controls in terms of level of activity. 
However, rapidly changing standards in many 
diseases in therapy, imaging and supportive care 
imply that historical data may not be reÁective of 
the results observed in current clinical practice. 
Due to that reason, some investigators feel more 
comfortable with a randomized phase II study with 
a prospective control. This is the standard approach 
to drug development in other therapeutic areas. 
Within this setting, the control arm is sometimes 
used informally as to check on the similarity 
to historical controls. However, in general the 
reference arm is too small to assure comparability 
and it may be difÀcult to interpret differences if 
they may occur. Alternatively, the control arm can 
be analyzed with the explicit intent of comparing 
treatment arms. Such design, sometimes referred 
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M11.1 RANDOMIZED DESIGN
Harm Van Tinteren 
Department Of Biostatistics, The Netherlands 
Cancer Institute - Antoni Van Leeuwenhoek Hospital, 
Amsterdam/Netherlands
Abstract: Phase II Clinical Trials Designing optimal 
phase II trials continues to be a major challenge 
with an increasing number of potential (molecular 
targeted) agents, alternative endpoints and an 
increasing number of design options on the one 
hand and a rather poor track record of successfully 
screening out inactive agents on the other hand. 
This session is intended to give an overview of 
options for the design of phase II clinical trials for 
different types of cytotoxic and cytostatic agents 
in oncology. After a phase I trial has determined 
a tolerable dose for a new agent or combination, 
in the cancer drug development process, the main 
goals of phase II trials are to screen out inactive 
agents (sometimes referred to as phase IIA) and to 
select promising therapies for (large-scale) phase 
III trials (phase IIB). Historically, the design of 
phase II oncology trials can be divided into three 
categories: single-arm trials, randomized trials with 
multiple experimental regimens but no prospective 
control arm and randomized trials with a concurrent 
standard-treatment arm. The single-arm trial has 
been the most frequently applied approach to the 
efÀcacy evaluation at the phase II level in oncology 
(phase IIA). The single-arm methodology includes 
single-stage designs, in which a predetermined 
number of patients are recruited, and two-stage 
designs, in which patients are recruited in two stages, 
with stage 2 being sequential on the results observed 
in stage 1. The main objective of multi-stage designs 
is to minimize the number of patients treated with 
ineffective regimens. Amongst these latter designs, 
Gehan’s-, Simon’s- and Fleming’s two-stage designs 
are the most commonly used. Multiple variations, 
including optimal selection of interim analysis time 
points, additional stages of accrual, consideration of 
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resource and time following unreliable leads. Even 
when trials were positive for new single agents, it 
has taken many additional years (sometimes 10 or 
more) to complete combination therapy trials that 
may deÀne optimal standard regimens for clinical 
use. In the end, the inefÀciency of this paradigm is 
unsatisfactory to patients and health systems and 
also contributes to the burdensome cost of oncology 
drugs by leaving few remaining years of patent life 
for companies to recoup their costs and realise a 
proÀt. In this presentation I shall introduce a move 
towards improving both the speed and reliability of 
oncology trials through the multi-arm, multi-stage 
(MAMS) designs. This design randomises patients 
to many new treatments, in a seamless phase II/
III setting and adaptively focuses recruitment 
resources onto arms selected according to emerging 
intermediate data from the trial, supplemented by 
any available external data. The implementation 
of this design will be illustrated through the 
STAMPEDE trial, a 6-arm, 5-stage trial for men 
with prostate cancer. This trial has now ceased 
recruitment two of its arms, continuing with the 
remaining 4. We are also in the process of adding a 
new and 5th arm to these remaining 4. The beneÀts 
and difÀculties with designing and running this sort 
of trial will be discussed. 
Keyword: Multi-arm Multi-stage randomised phase 
II/III
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M11.3 BIOMARKER-BASED BAYESIAN 
ADAPTIVE DESIGNS FOR TARGETED 
AGENT DEVELOPMENT
J. J. Lee 
Biostatistics, UT M.D. Anderson Cancer Center/
United States Of America
Abstract: Advances in biomedicine have fueled the 
development of targeted agents in cancer therapy. 
With better understanding of the disease’s etiology 
and mechanism, many targeted agents are being 
developed to tackle the root cause of problems 
with the hope to offer more effective and less toxic 
therapies. Targeted agents, however, do not work for 
everyone. Hence, the development of target agents 
requires the evaluation of prognostic and predictive 
markers. In addition, upon the identiÀcation of 
each patient’s marker proÀle, it is desirable to 
to as phase II screening trials, allow for selecting 
promising regimens for further studying by adjusting 
especially the signiÀcance (false-positive rate) while 
keeping the trial fully powered. The design will have 
low probability of failing to identify active agents 
and allows the sample size to remain restricted. 
Randomized phase II studies, and especially when 
including a standard-treatment control arm, should 
however be designed and interpreted with caution 
because of the unavoidable issues such as high 
false-negative and positive rate, unstable p-values 
and the risk that these studies, whether negative of 
positive, may (incorrectly) preclude later deÀnitive 
studies. In conclusion, phase II studies are important 
screening tools in drug development, but require a 
thoughtful design appropriate for each individual 
agent. Some situations may favor single-arm studies, 
especially in rare tumors and for single agents with 
tumor response endpoints, while randomized designs 
may be preferable for combination therapy, time-
to-event endpoints and when the number of patients 
is of lesser concern. Nevertheless, more innovative 
designs are needed to cope with issues such as the 
selection and validation of the most appropriate 
target-based endpoints, dynamic and adaptive 
randomization and stopping rules, Áexible study 
accrual and population enrichment. 
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M11.2 MULTI-ARM MULTI-STAGE 
RANDOMISED TRIALS
Mahesh Parmar 
Clinical Trials Unit London, Medical Research 
Council/United Kingdom
Abstract: Oncology has made tremendous strides 
in improving clinical outcomes - but often very 
slowly. Until quite recently, potential new therapies 
have been empirically identiÀed (based on general 
antineoplastic effects rather than mechanisms 
relevant to speciÀc cancers) and developed and 
tested via an inefÀcient and protracted process. 
Nearly every candidate drug has been through 
sequential phase I, II and III testing over many 
years and in cohorts of patients typically unselected 
for anything but their disease, despite the plethora 
of designs, phase II trials as currently designed 
and run have proved poor predictors of clinical 
beneÀt in randomised phase III trials, wasting both 
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with use of historical controls. The complexity of 
implementing a phase II study relative to a single 
arm study is greater. In addition, randomized phase 
II studies are often two to four times larger than 
single arm phase II studies, and therefore simply 
take longer to complete. Given these considerations 
it has been suggested that a more efÀcient approach 
would be to combine the randomized phase II and 
phase III study into one study; a so-called phase II/
III study. The objective of the phase II component 
of a phase II/II study is essentially to make a go/no-
go decision as to whether the trial should continue 
on to the phase III as is done with separate phase II 
and phase III studies. The difference in this setting 
is that there is a seamless transition. Goldman, 
LeBlanc, and Crowley (2008) proposed including 
an early interim analysis for futility using an 
intermediate endpoint to increase the probability of 
a trial stopping early when there is no beneÀt. Their 
suggested implementation was based on amount 
of information and used relatively conservative 
likelihood of stopping for futility. Hunsberger, Zhao, 
and Simon (2009) further developed the early look 
to be more akin to a randomized phase II design. As 
in Hunsberger et. al, here we deÀne a phase II/III 
trial to be a trial design which implements an early 
interim analysis that has the operating characteristics 
of a randomized phase II. SpeciÀcally, the “phase 
II” interim analysis is performed on an intermediate 
outcome that is measured earlier than the primary 
outcome and the stopping time is deÀned based 
on the phase II design. As such, the likelihood of 
stopping at this analysis both under no true treatment 
effect and under a true treatment effect is greater 
than the usual interim analysis. In this talk we 
discuss the properties of combining randomized 
phase II and phase III clinical trials. In particular, 
we will highlight the importance of the randomized 
phase II design properties on the overall study and 
the importance intermediate outcome used in the 
phase II component as representing a true surrogate 
for the primary outcome of the phase III study. We 
then apply the phase II interim analysis to completed 
phase III trials in the Southwest Oncology group 
and discuss how well the more aggressive phase II 
analysis would have predictived the success (or lack 
thereof) of these trials. 
Keywords: trial design, futility monitoring, 
surrogate endpoints
treat patients with best available treatments in 
the clinical trial accordingly. We have developed 
biomarker-based Bayesian adaptive designs to 
(1) identify prognostic and predictive markers 
for targeted agents, (2) test the treatment efÀcacy, 
and (3) provide better treatments for patients 
enrolled in the trial. In contrast to the frequentist 
equal randomization designs, Bayesian adaptive 
randomization designs can treat more patients 
with more effective treatments via outcome-based 
adaptive randomization based on the available 
data at the time. They allow more frequent interim 
monitoring so ineffective treatments can be stopped 
early for futility and effective treatments can 
graduate early due to efÀcacy. Through simulations, 
the operating characteristics of different Bayesian 
and frequentist designs are compared and contrasted. 
By carefully choosing the design parameters, types I 
and II errors can be controlled for Bayesian designs. 
By incorporating adaptive randomization and early 
stopping rules, the proposed designs incorporate 
rational learning from the interim data to make 
informed decisions. Bayesian design also provides a 
formal way to incorporate relevant prior information. 
Compared with previously published designs, the 
proposed design can be more efÀcient, more ethical, 
and is also more Áexible in the study conduct. 
However, outcome-based adaptive randomization 
requires the efÀcacy outcome to be assessed in a 
relatively short time period. Additional infrastructure 
must be set up to allow timely and more frequent 
monitoring of interim results. Bayesian adaptive 
randomization designs are distinctively suitable for 
the development of multiple targeted agents and 
the identiÀcation of multiple biomarkers in phase II 
settings. Examples and lessons learned from recent 
trials will be given. 
Keywords: Bayesian adaptive designs, Biomarkers, 
outcome-based adaptive randomization, interim 
analysis
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M11.4 PHASE II INTO PHASE III
Mary W. Redman, Bryan Goldman, Michael Leblanc 
Public Health Sciences, Fred Hutchinson Cancer 
Research Center/United States Of America
Abstract: Randomized phase II studies have become 
the norm in oncology due to concerns about bias 
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mutations are detected in exon 20 of HER2 and 
NSCLC patients with these mutations are clinically 
resistant to EGFR kinase inhibitors geÀtinib and 
erlotinib. Preclinical in vitro and in vivo studies 
suggest that NSCLC harboring HER2 ampliÀcations 
and mutations could be effectively treated with 
HER2 kinase inhibitors. Agents in clinical 
development include PF299804, HKI-272 (neratinib) 
and BIBW-2992 (afatinib). These are all irreversible 
inhibitors of both EGFR and HER2. These agents 
are currently being evaluated speciÀcally in NSCLC 
patients harboring genomic alterations in HER2 
and the clinical trials and available data will be 
presented. Although most genomic alterations to date 
have been limited to adenocarcinomas, recent studies 
suggest that there may be therapeutically targetable 
genetic alterations also in squamous cell lung cancer. 
AmpliÀcations in FGFR and somatic mutations in 
DDR2 have been identiÀed and clinical trials are 
underway to determine whether kinase inhibitors, 
effective in pre-clinical studies, are clinically 
effective in squamous cell lung cancer patients 
whose tumors harbor these somatic changes. The 
evolving incorporation of patient’s tumor speciÀc 
genomic alterations into their therapeutic algorithm 
requires a systematic approach to identifying these 
different patient subsets. The systematic genomics 
approaches currently being used in routine clinical 
practice at Dana Farber Cancer Institute will be 
discussed. 
Keywords: Somatic Mutation, Non-small cell lung 
cancer, kinase inhibitor, HER2
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M12.2 NOVEL THERAPIES
Tony Mok 
Department Of Clinical Oncology, The Chinese 
University Of Hong Kong/China
Abstract: EGFR mutation at exon 19 and 21 in 
patients with pulmonary adenocarcinoma was the 
novel Ànding in 2004, and only Àve years later the 
role of geÀtinib in Àrst-line therapy for patients 
with known EGFR mutations was conÀrmed in the 
randomized phase 3 Iressa Pan-Asia Study (IPASS). 
Other Japanese studies also conÀrmed a higher 
tumor response rate and longer PFS when patients 
with EGFR mutation are treated with EGFR TKI. In 
view of this success, numerous potential molecular 
targets are under investigation. A molecular target 
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M12.1 NOVEL TARGETS AND 
THERAPIES IN NON-SMALL CELL 
LUNG CANCER
Pasi A. Janne 
Lowe Center For Thoracic Oncology, Dana Farber 
Cancer Institute/United States Of America
Abstract: The treatment of non-small cell lung 
cancer (NSCLC) is rapidly shifting away from a 
“one-size Àts all” treatment approach to a disease 
where therapy is based on genomic characteristics of 
the individual patient’s cancer. At the current time, 
for adenocarcinoma patients, there are effective 
molecular targeted therapies for approximately 
20% patients. These therapeutic successes are 
currently limited to cancers harboring epidermal 
growth factor receptor (EGFR) activating mutations 
or chromosomal rearrangements in the anaplastic 
lymphoma kinase (ALK). There is an increasing 
interest in identifying other genomic alterations in 
NSCLC for which there may be effective targeted 
therapies analogous to what has been observed for 
EGFR and ALK. Two other subsets, NSCLCs with 
BRAF mutations and those with HER2 mutations 
and/or ampliÀcations, are actively being actively 
investigated. BRAF mutations have been detected in 
~3% of NSCLC patients and have been exclusively 
detected in adenocarcinomas. Unlike melanoma, 
about 50% of BRAF mutations in NSCLC are 
V600E while the remainder are exon 11 mutations. 
Preclinical studies, both in vitro and in vivo, suggest 
that for V600E BRAF mutations, MEK inhibitors 
may be effective therapies. The clinical development 
and success of BRAF and MEK inhibitors in 
melanoma provides the opportunity to study these 
agents in BRAF mutant NSCLC. A clinical trial 
of the BRAF inhibitor GSK2118436 is currently 
underway for V600E BRAF mutant NSCLC. A 
second trial of MEK inhibitor, GSK1120212, is also 
underway and will include NSCLC patients with 
both exon 11 and 15 BRAF mutations. Genomic 
alterations in HER2 in NSCLC involve both 
ampliÀcations in HER2 and somatic mutations in 
HER2. Both occur at a frequency of 2-5% and are 
exclusive to adenocarcinomas. HER2 kinase domain 
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comparing Stimuvax with placebo after standard 
Àrst line chemotherapy. Two phase III studies are 
ongoing. One is a global registration phase III study 
(START) comparing Stimuvax with placebo after 
standard chemo-radiotherapy for patient with stage 
IIIa and IIIb NSCLC. Second is a study of similar 
design (INSPIRE) in Asian population with the 
assumption of higher incidence of EGFR mutation. 
MAGE-A3 is an antigen related to melanoma that 
may over-express in about 30 to 40% of NSCLC. 
Phase II study on this vaccine as an adjuvant 
therapy to respectable lung cancer patients has 
shown promising result. MARGRIT is the world 
largest adjuvant study with intended accrual of 2270 
patients with MAGE-A3 expression. To date, about 
1700 patients have been accrued. Belagenpumatucel 
(Lucanix) is a tumor cell vaccine intended to block 
the TGF-ơ2 secretion. The current phase III study 
targeted patients who attain tumor response or stable 
disease after Àrst line chemotherapy and randomized 
to either the Belagenpumatucel or supportive care. 
In summary, multiple targeted therapies are under 
investigation and many have entered phase III. 
Biomarker is the key to the success of these studies. 
Keyword: Targeted therapy, C-MET, ELM-4 ALK, 
Cancer vaccine
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M12.3 PREDICTIVE FACTORS
Jean-Charles Soria 
Val De Marne, Institut Gustave Roussy/France
Abstract: Lung cancer is the leading cause of 
cancer-related deaths worldwide. NSCLC is 
currently being revisited on the basis of modern 
molecular portraits that allow the identiÀcation 
of new molecular subtypes. To date, the 
&ldquoquest&rdquo for the perfect predictive 
molecular marker has been mainly based on 2 
technological approaches. (1) High throughput 
technology Despite huge efforts and millions 
of Euros spent worldwide each year to identify 
predictive biological signatures, there has been 
limited progress and the only signature (Metagene) 
being evaluated prospectively has recently been 
challenged in terms of scientiÀc validity (2) single 
biomarker approach we may distinguish such a 
biomarker in 3 categories of therapeutic agents: 
cytotoxic agents, tyrosine kinase inhibitors and 
antiangiogenic agents In the &lsquocytotoxic 
should drive cancer growth. An ideal molecular 
target should be speciÀc to the cancer cell and drive 
cell proliferation such that inhibition of the mutated 
pathway would result in cessation of cancer growth. 
Preclinical studies should be able to demonstrate 
differential growth rates in tumor cells with and 
without the target mutation. In this symposium we 
shall discuss the promising targets and its respective 
therapies that may become available to clinicians 
in near future. EML4-ALK is a fusion gene that 
juxtaposes the echinoderm microtubule-associated 
protein-like 4 (EML-4) gene to the tyrosine kinase 
domain of anaplastic lymphoma kinase gene (ALK). 
This fusion gene occurs in about 2% to 7% of 
lung cancer patients and almost solely in patients 
without EGFR mutation. Crizotinib is an ALK-MET 
kinase inhibitor that was found to induce dramatic 
tumor response in patients harboring the EML4-
ALK fusion gene in a phase I study. An extended 
phase I/II study reported a tumor response rate of 
57% and disease control rate of 77% in patients 
selected by Áuorescence in-situ hybridization 
(FISH) using a break-apart probe to ALK. The 
encouraging Ànding will be conÀrmed in a global 
phase III study comparing crizotinib with single 
agent chemotherapy as second line therapy, and a 
phase III Àrst line study is being planned. C-MET is 
the receptor for Hepatocyte Growth Factor (HGF) 
and plays an important role in oncogenesis. A long 
list of drugs are under intensive investigation. 
Among which the most promising ones include the 
AVEO 299, ARQ 197 and MetMab. AVEO 299 is 
a mono-clonal antibody against the ligand of HGF. 
An ongoing randomized phase II compares the 
combination of AVEO plus geÀtinib with geÀtinib 
alone in an Asian population with high incidence 
of EGFR mutation. ARQ 197 is a tyrosine kinase 
inhibitor for C-MET. A recent randomized phase II 
study reported promising improvement in PFS and 
efÀcacy appeared to be most signiÀcant in patients 
with KRAS mutation. MetMab is a mono-clonal 
antibody against C-MET. Spiegel et al reported 
that the combination of MetMab and erlointib was 
superior to erlotinib alone as second line therapy for 
patients with high C-MET expression. This Ànding 
needs to be validated in a phase III study. Cancer 
vaccine is also being actively pursued. Among 
which, the most promising agents include anti-
MUC-1, anti-MAGE A3 and Belagenpumatucel. 
The anti-MUC-1 vaccine (Stimuvax) was shown to 
have a trend in OS beneÀt in the subgroup analysis 
of stage IIIb patients in a randomized phase II study 
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M13.2 HANDLING OF DIFFERENT 
SAMPLES: CYTOLOGY, BIOPSIES, 
RESECTION SPECIMEN
Koji Tsuta 
Pathology, National Cancer Center/Japan
Abstract: The development of new molecular 
targeted therapies and less invasive diagnostic 
approaches—producing small biopsy and cytology 
specimens for diagnosis—for lung tumors require 
precise molecular analysis and/or immunostaining of 
such small samples to achieve personalized therapy.
In general, surgically resected and biopsy specimens 
are Àxed with formalin, whereas cytologic specimens 
are Àxed with alcohol. Formalin Àxes tissue by 
cross-linking the proteins, primarily the residues of 
the basic amino acid lysine. Formalin Àxation is the 
best method for assessing cell morphology, and most 
commercially available antibodies are optimized 
for formalin-Àxed tissues. However, formalin-Àxed 
tissues more frequently exhibit nonreproducible 
sequence alterations in nucleic acids than frozen 
tissues. This is because formalin can cross-link 
cytosine nucleotides on either strand of the DNA. 
On the other hand, alcohol Àxation reduces the 
solubility of protein molecules and disrupts the 
hydrophobic interactions that confer a tertiary 
structure to many proteins. The precipitation and 
aggregation of proteins that occur during alcohol 
Àxation are very different processes from the cross-
linking that occurs with the use of formalin Àxatives. 
Most commercially available antibodies are not 
used for alcohol-Àxed materials without changes 
in staining protocols. However, ethanol causes 
very little chemical change and therefore preserves 
nucleic acids better than formalin. Frozen materials 
are most suitable for nucleic acid isolation. However, 
cell morphology is better preserved in formalin-Àxed 
tissues than in frozen tissues. In addition, storing 
frozen materials for a long time is both expensive 
and space consuming. Furthermore, degradation 
of nucleic acids may occur during long-term 
preservation.
setting&rsquo, DNA repair pathways have provided 
the most promising biomarkers for cisplatin 
resistance, such as the expression of ERCC1 & 
MSH2 or the level of BRCA1. Others candidate 
biomarkers such as the cell cycle regulator p27, 
class III &beta-tubulin or thymidylate synthase 
had been linked to a beneÀt of chemotherapy. With 
regard to targeted therapies, speciÀc activating 
mutations located in the tyrosine kinase domain of 
the epidermal growth factor receptor (EGFR) are 
associated with an improved response to EGFR-
directed tyrosine kinase inhibitors (TKIs) in NSCLC 
patients. The majority of EGFR mutations occurred 
in exon 19 (small deletion) or in exon 21 (single 
point mutation, L858R). These activating mutations 
are associated to responsiveness to tyrosine kinase 
inhibitors. On the other hand, several mutations 
in exon 20 (T790M or small insertion) seem to 
confer resistance to such treatments. Epidemiologic 
characterization of EML4-ALK translocations is 
ongoing but it seems to be a rare aberration, most 
common in non-smokers or light-smokers with the 
adenocarcinoma subtype of NSCLC (and signet ring 
features) , forming a distinct subgroup from patients 
harbouring EGFR, KRAS, mutations. The frequency 
of EML4-ALK fusion transcripts is around 5% 
or less in Caucasians patients. Crizotinib (PF-
02341066) is an ALK and MET inhibitor that has 
demonstrated outstanding activity in monotherapy 
in patients with EML4-ALK translocations: 57% 
objective response in 82 patients with a median 
duration of treatment of 5,7 months and a predicted 
67% PFS rate at 6 months. Many other abnormalities 
linked to tyrosine kinase receptors could be used for 
selection of speciÀc therapy such as ampliÀcation or 
activation mutation of HER2, HER3, HER4, FGFR 
1, FGFR2, KDR&hellipHowever correlation of 
presence of such abnormalities and clinical response 
are still not Àrmly documented, although some 
interesting case reports have been documented.. 
Table 1 provides a summary of speciÀc alterations 
and their potential corresponding drug. 
Table 1 
Molecular alteration Potential Drugs 
EGFR mutation Erlotinib, geÀtinib New pan-HER inhibitors 
(afatinib, PF 299804 ) 
EML4-ALK translocation Crizotinib 
HER2 mutation or 
ampliÀcation 
Trastuzumab Lapatinib, PF 299804 
PI3K mutation or 
ampliÀcation 
GDC-0941
XL-147
XL-765 PX-866
BEZ-235
BKM120 
MET ampliÀcation XL184 ARQ917 Metmab 
RAS and RAF mutations Sorafenib AZD6244 GSK1120212 AS703026 
FGFR1 ampliÀcation BJG398, AZD4547, TKI258 
Copyright © 2011 by the International Association for the Study of Lung Cancer S95
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
also archival, formalin-Àxed tissue samples. Highly 
sensitive and speciÀc rabbit monoclonal antibodies 
against the 2 most common mutations were recently 
developed for detecting epidermal growth factor 
receptor mutations. The excellent speciÀcities of 
these antibodies will provide a reliable marker for 
the initial screening for epidermal growth factor 
receptor mutational status, similar with human 
epidermal growth factor receptor 2 status for breast 
carcinoma.
A diagnosis resulting from a combination of the 
above-mentioned techniques will help patients select 
more appropriate treatment options. In addition, an 
exchange of knowledge between pathologists and 
clinicians is of utmost importance.
Keywords: biopsy, cytology, surgically resected 
specimen
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M13.3 DETECTION IN BLOOD/SERUM
Miquel Taron 
Laboratory Of Molecular Biology, Medical 
Oncology Service-Ico; Hospital Germans Trias I 
Pujol/Spain
Abstract: In the last 30 years, different analyses 
have shown that cell-free circulating nucleic acids 
containing tumor-associated genetic alterations can 
be detected in peripheral blood of cancer patients. 
The development of sensitive and speciÀc methods 
together with the new technologies for the detection 
of minimal quantities of DNA or RNA have made it 
possible to isolate and characterize tumor associated 
alterations in blood (point mutations, microsatellite 
alterations, epigenetic alterations, etc)(1). In 
contrast to its huge potential clinical application, the 
characterization of circulating nucleic acids has not 
received much attention. We and others have focused 
on the analysis of gene mutations at blood sample 
level as a potential diagnostic tool in Non-Small 
Cell Lung Cancer (NSCLC). It is well known that in 
NSCLC patients, the screening of sensitizing EGFR 
mutations in tumor samples is becoming mandatory 
to treat patients with EGFR tyrosine kinase inhibitors 
(TKIs). However, one of the most important 
limitations is the lack of available tumor cells in 
tumor tissues (biopsies or cytologies) in around 30% 
of patients, and the difÀculty to perform re-biopsies 
at baseline or during the follow-up of the patient. 
The best way to help patients select more appropriate 
treatment options is collection of formalin- and 
alcohol-Àxed tissues and frozen materials. We collect 
formalin- and alcohol-Àxed parafÀn-embedded 
blocks and ethanol-Àxed imprint cytology smears 
obtained from a fresh-cut surface, as well as frozen 
tissues from surgically resected tumor specimens 
in our hospital. However, biopsy or cytologic 
materials whose tumor amount may be small are 
difÀcult to obtain using the above-mentioned storage 
materials. In addition, frequent recutting from 
small samples such as biopsy specimens should be 
avoided because repeated cutting from the same 
block can result in loss of tumor cells. This problem 
may be resolved by preparing many unstained 
slides immediately after biopsy. However, this 
approach bears the problem of protein and/or gene 
degradation with the passage of time. To prevent 
molecular degradation, thinly spreading parafÀn on 
unstained slides is useful. The number of slides for 
cytologic analysis is usually limited. In such cases, 
the cell block approach and cell transfer technique 
can yield some slides for molecular analysis and 
immunostaining. Another approach to circumvent the 
small number of unstained slides is use of multicolor 
immunohistochemical techniques, which can obtain 
information on multiple protein expression on the 
same slide. In addition, this approach can detect not 
only protein expression but also gene status through 
bright-Àeld in situ hybridization.
To detect gene mutations, direct sequencing is 
performed as the gold standard. However, to obtain 
precise data, high-quality DNA and RNA extracted 
from an adequate amount of pure tumor cells are 
required, which necessitates an expensive and 
time-consuming process. Other indirect methods 
have recently been developed to detect gene 
mutations, including the peptide nucleic acid–locked 
nucleic acid PCR clamp system, mutant-enriched 
PCR, the smart ampliÀcation process, and high-
resolution melting analysis. These methods have 
high sensitivities and can be applied to specimens 
with low cancer cell content. We revealed a high 
concordance rate of epidermal growth factor 
mutations between small biopsy materials and 
matched surgically resected materials by using high-
resolution melting analysis. Another approach for 
detecting gene mutations is developing mutation-
speciÀc antibodies. Compared to molecular 
techniques, immunohistochemistry is a fast and 
cost-effective method that can be performed in 
most pathology laboratories on not only fresh, but 
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related to new strategies of massive sequencing 
(9) and nanotechnology (10). One recent example 
has been the use of next generation sequencing of 
serum circulating nucleic acids from patients with 
invasive ductal breast cancer that reveals clear 
differences between healthy and nonmalignant 
controls providing the basis for the development 
of a serum test for breast cancer screening and 
monitoring (11). In conclusion, the analysis of gene 
mutations at the serum or plasma level is a useful 
diagnostic tool that should be used to genotype and 
treat patients. 1.- Fleischhacker M and Schmidt B. 
Cancer Biomark, 2010; 6(3-4):211 2.- Yung T, et al. 
Cancer Res, 2009; 15:2076 3.- Kuang Y, et al. Clin 
Cancer Res, 2009; 15(8):2630 4.- Kimura H, et al. 
Clin Cancer Res, 2006; 12:3915 5.- He C, et al. Int J 
Cancer, 2009 ; 125 : 2393 6.- Mack PC, et al. Journal 
Thoracic Oncol, 2009; 4(12):1466 7.- Bai H, et al. 
Journal Clin Oncol, 2009; 27(16): 2653 8.- Rosell R, 
et al. NEJM, 2009; 361(10): 958 9.- Lo D and Chiu 
R. Clinical Chemistry, 2009; 55(4):607 10.- Kim B, 
et al. NEJM, 2010; 365(25): 2434 11.- Beck J, et al. 
Mol Cancer Res, 2010; 8:335 
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M13.4 HETEROGENEITY EGFR IN LUNG 
CANCER
Erik Thunnissen 
Pathology, VUMC/Netherlands
Abstract: Heterogeneity of EGFR mutations is 
used in context of variation i) between different 
samples taken within one tumor, ii) between different 
tumors within one patient comparing iia) tumors 
from different sites in the lung, iib) primary tumor 
and metastases or iic) between tumor sample before 
and after treatment. Examples iia) and iic) are 
usualy not considered to be part of heterogeneity, 
but represent the question of clonal relationship and 
changes within the tumor population, respectively. 
For each sample holds that the fraction of EGFR 
mutated allele is determined by fraction of tumor 
cells within the sample and amount of mutated 
alleles within these tumor cells. AmpliÀcation occurs 
in lung cancer a later phase of malignant process, 
and therefore will not be distributed equally over the 
tumor: some areas show ampliÀcation while others 
In this sense, the use of strategies to genotype 
patients using cell-free circulating DNA could be a 
crucial tool. There are different studies in literature 
(2-7) showing that plasma- and serum-based 
EGFR mutation testing is not only feasible but has 
considerable value as well. In our experience, (8) we 
have analyzed paired serum and tissue samples from 
164 EGFR mutated (exon 19 deletions and L858R) 
patients. Starting from isolated serum/plasma 
samples, cell-free circulating DNA was puriÀed and 
analyzed for the presence of the mutations. Deletions 
in exon 19 were determined by length analysis after 
PCR ampliÀcation with the use of FAM labeled 
primer in an ABI Prism 3130 DNA analyzer. Exon 
21 L858R point mutations were analyzed with a 5’ 
nuclease PCR assay (TaqMan assay) using FAM and 
VIC MGB labeled probes for the wild-type and the 
mutant sequences respectively. Both reactions were 
done in the presence of a protein nucleic acid (PNA) 
designed to inhibit the PCR ampliÀcation of the wild 
type allele. Of the 164 EGFR positive patients (in 
tissue) in whom EGFR mutations were assessed in 
serum, 97 carried mutations: exon 19 deletions in 64 
patients and L858R in 33 patients. Importantly, in 
the multivariate analysis of this study, the adjusted 
hazard ratios for the duration of progression-free 
survival were 2.94 for men (P<0.001); 1.92 for the 
presence of the L858R mutation, as compared with 
a deletion in exon 19 (P = 0.02); and 1.68 for the 
presence of the L858R mutation in paired serum 
DNA, as compared with the absence of the mutation 
(P = 0.02). Interestingly, we found that EGFR 
mutation status in the serum or plasma matched that 
in the tumor tissue in 45% of patients with PS 0, in 
57% of patients with PS 1, and in 75% of patients 
with PS 2 (P=0.01), showing the importance of 
tumour burden in this analysis. In addition, in our 
study we found a sensitivity of 60%. In previous 
studies, we also analyzed the speciÀcity of our 
technique and we have shown a speciÀcity higher 
than 98%. Altogether, this data reÁects the need 
to incorporate new and more sensitive diagnostic 
tools in the clinical practice when working with 
cell-free circulating DNA, to increase the sensitivity 
without a detriment effect on the speciÀcity of the 
tests. New techniques and technologies are being 
implemented today to increase the sensitivity of 
this technique to allow genotyping of all patients 
for EGFR, but also for common mutations such as 
BRAF1 or k-Ras among others in serum and plasma 
in order to Ànd the “needle in the haystack”. Among 
these techniques, the most salient ones are those 
Copyright © 2011 by the International Association for the Study of Lung Cancer S97
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
Session M14: Image Guided Tissue 
Characterization
Wednesday, 6 July 2011
Image Guided Tissue Characterization Wednesday, 6 July 2011 10:30-
12:00
M14.1 NAVIGATIONAL TARGETING
Fumihiro Asano 
Pulmonary Medicine, Gifu Prefectural General 
Medical Center/Japan
Abstract: Bronchoscopic diagnosis of peripheral 
pulmonary lesions With the recent increase in 
lung cancer, the percentage of the peripheral type 
in the lung Àeld has been particularly increasing. 
Although various imaging modalities have been 
clinically applied, the pathological diagnosis of cell/
tissue specimens collected from the lesion is still a 
gold standard for lung cancer diagnosis. Methods 
to collect samples for pathological diagnosis 
include transbronchial biopsy under bronchoscopy, 
CT-guided percutaneous biopsy, and biopsy by 
surgery. Percutaneous biopsy relatively frequently 
causes complications such as pneumothorax and 
hemorrhage, and lethal complications including 
dissemination and air embolism have also been 
reported. Although surgery is the most reliable 
method, it is highly invasive. In addition, smaller 
lesions are likely to be benign. In contrast, 
transbronchial biopsy has few complications and 
is less invasive. However, the diagnostic yield of 
bronchoscopy for peripheral pulmonary lesions 
is unsatisfactory. The 2007 Guidelines of the 
American College of Chest Physicians (ACCP) 
showed a diagnostic yield of 34% for lesions < 2 
cm in diameter. A major problem with this method 
is difÀculty in the guidance of the bronchoscope 
and biopsy tools. Presently, many bronchoscopists 
mentally reconstruct the 3D bronchial arrangement 
based on 2D planar axial slices of CT performed 
before bronchoscopy, and select a bronchial 
path. However, since this method is inaccurate, 
the diagnostic yield depends on the operator’s 
experience and skill. For this, navigational 
targeting to the lesion during bronchoscopy has 
been developed. The methods of navigational 
bronchoscopy that can be clinically employed at 
present are electromagnetic navigation (EMN) 
and virtual bronchoscopic navigation (VBN). 
don’t. The EGFR test outcome is determined by a) 
estimation of fraction of tumor cells in the sample 
and b) analytical sensitivity of EGFR mutation test. 
The analytical sensitivity provides a threshold when 
a test will be positive and is related to minimum 
input of DNA (1 ng DNA = ~approximately 200 
tumor cells for many techniques). In selecting 
sample area for DNA extraction, the number of 
tumor cells need to be high and areas of tumor 
necrosis, inÁammatory cells and other stromal 
components are avoided. To this end manual macro 
dissection or microdissection is used. The estimation 
of tumor cells fraction (representativity of the 
sample) is quite variable between pathologists. 
Comparing different areas (i) within a tumor may 
reveal a negative test in one area that does not 
have ampliÀcation (i.e. 1 mutated allele) and a low 
fraction of tumor cells (e.g. 10% tumor cells = 5% 
mutated alleles) in case of analytical sensitivity of 
10%, while in another area with ampliÀcation an 
EGFR mutation may be demonstrated (e.g. mutated 
allele ampliÀed 10x, and 10% tumor cells =~30% 
mutated alleles  threshold of the technique). 
This is a form of pseudoheterogeneity, but not 
true heterogeneity. In some studies intratumor 
heterogeneity has been suggested. In at least one 
of these studies subsequent analysis with EGFR 
mutation speciÀc antibodies were positive in the 
initially negative sample. In hindsight suggestive 
of pseudoheterogeneity. An additional argument 
against heterogeneity within one tumor is the fact 
that EGFR mutation is a driver mutation: i.e. this 
mutation is an early event and present in the primary 
tumor and with a clonal relation also present in all 
daughter cells. In comparing (iia) different tumors 
within the lung and Ànding a different mutation in 
both tumors is more an argument for two different 
primary tumors than for a clonal relationship. 
Many studies reveal discrepancies comparing (iib) 
primary tumor and metastases to a variable extend. 
Here the abovementioned technical issues may 
also play a role. In summary, although some papers 
in the literature reports suggest the existence of 
heterogeneity in EGFR mutations, the evidence for 
this is not strong enough to support this notion. 
Keywords: EGFR mutation, heterogeneity
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Although further improvement in performance is 
necessary, VB images automatically synchronize 
with real images. However, unlike Bf-NAVI, 
LungPoint does not have the function to conÀrm 
areas of which VB images could not be produced 
because of the absence of the automatic extraction 
of bronchi, and to add VB images of these areas by 
manual extraction. Therefore, the range of peripheral 
bronchi of which VB images can be produced 
tends to be smaller using the LungPoint than using 
the Bf-NAVI. VBN has been used concomitantly 
with CT-guided ultrathin bronchoscopy and 
endobronchial ultrasonography with a guide-sheath 
(EBUS-GS), and satisfactory results have been 
reported. The diagnostic yield was 65.4-86% by 
CT-guided ultrathin bronchoscopy, 63.3-84.4% by 
EBUS-GS, 62.5% by Áuoroscopy, and 73.6% by all 
techniques combined. Moreover, randomized studies 
have shown that the use of VBN under EBUS-GS 
improves the diagnostic yield and shortens the 
time until the arrival of the bronchoscope to the 
target, and, thus, the total examination time. No 
complications of VBN itself have been reported. 
The advantage of VBN is simplicity. In VBN, only 
the bronchoscope is advanced according to the VB 
images. Since the procedure is similar to that of 
conventional bronchoscopy, even inexperienced 
operators can guide the bronchoscope to the target 
in a short time. In addition, since VBN requires 
no special apparatus except software, the cost is 
not generally prohibitive. A problem is that arrival 
at the lesion cannot be conÀrmed by VBN itself, 
unlike EMN. Its combination with Áuoroscopy, 
CT, or EBUS is necessary to conÀrm arrival. If a 
thin or ultrathin bronchoscope is used, its guidance 
to a site near the lesion is possible. Therefore, in 
most patients, the guidance of biopsy instruments is 
not necessary. A recent study reported a diagnosis 
rate of 80% using VBN alone without employing 
Áuoroscopy. Conclusions Navigational bronchoscopy 
has increased the rate of diagnosing pulmonary 
peripheral lesions. Considering a low complication 
rate compared with transthoracic needle aspiration, 
navigational targeting is a promising diagnostic 
method for pulmonary peripheral lesions, and is 
expected to be more widely used in the future. 
Keywords: Bronchoscopic diagnosis, Virtual 
bronchoscopic navigation, Electromagnetic 
navigation, Transbronchial biopsy
EMN EMN is a procedure in which a steerable 
probe with an electromagnetic sensor is navigated 
to the lesion based on electromagnetic positional 
data in the EM Àeld generated from a board on 
which the patient is placed. The superimposition 
of positional data on previously acquired CT data 
on the patient allows the display of the site of the 
sensor probe in 3 MPR images. The operator guides 
the probe to the lesion based on these images and 
the probe tip view. For the superimposition of 
electromagnetic and CT data, VB images of the 
proximal bronchus are used. However, EMN differs 
from the below VBN since the bronchoscope is 
not guided based on VB images themselves. As 
EMN systems, iLogicTM (superDimension) is used, 
and SPiN DriveTM (Veran Medical Technologies) 
was clinically introduced recently. Previous EMN 
studies have generated diagnostic yields for various 
sized peripheral pulmonary lesions ranging from 
69-76%. There have been reports using or not 
using X-ray Áuoroscopy, but the diagnostic yield 
appears to be similar. A randomized study showed 
that EMN-assisted bronchoscopy combined with 
EBUS is more sensitive than either EBUS or 
EMN alone (diagnostic yield, 88 vs. 69 and 59%, 
respectively). There are also the following problems. 
It is necessary to learn the steps of the procedure 
differing from conventional bronchoscopy such 
as landmark registration and manipulation of the 
steerable probe based on 3D-MPR images and 
the tip view. The diagnostic yield is signiÀcantly 
affected by CT-to-body divergence. In addition, 
the steerable probe with an electromagnetic sensor 
probe is for single use and expensive. VBN Virtual 
bronchoscopic navigation (VBN) is a method in 
which images from virtual bronchoscopy (VB) 
of the bronchial path to a peripheral lesion are 
produced and used as a guide for the navigation 
of a bronchoscope. Since the bronchial branching 
pattern on VB images is similar to that on real 
bronchoscopic images, the bronchoscope can be 
advanced close to the target lesion according to 
the bronchial path to the lesion displayed on VB 
images. Bf-NAVITM (KGT, Olympus Medical 
Systems) as a VBN system was developed and 
clinically introduced in 2008 in Japan. This system 
is characterized by the automatic production of VB 
images along the bronchial path and the display of 
VB matched with real images for bronchoscopic 
navigation. In 2009, LungPointTM (Broncus) as 
another VBN system was clinically introduced 
in the U.S. LungPoint is straightforward to use. 
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while simultaneously giving excellent anatomical 
resolution. Put simply, PET shows what is happening 
(but only at one process of interest at a time, while 
CT maps out where). However, in aiming for the 
long-term goal of a minimally invasive “virtual 
biopsy” there remains the challenge of being able 
to visualise the action of molecular mechanisms 
and their resulting physiological processes. This 
is where the combination of PET and MRI comes 
in, due to its expected proÀciency in delivering 
both physiological and high-deÀnition anatomical 
information. In part the power of MRI lies in its 
superior soft tissue contrast compared to CT, but it 
can also bring physiological information. Much like 
PET tracers elucidate on function at a molecular 
level by attaching to speciÀc receptors, MRI can 
give detailed information on a wide variety of 
processes, and unlike PET can do so for several 
processes in the same scan. MRI techniques can be 
used to assess blood Áow and vessel permeability 
(but cannot differentiate between the two at this 
stage of development), diffusion (the mobility of 
water within tissues, which, subject to validation 
in a research setting, may be able to tell us whether 
cancer cells are being killed by a drug – apoptosis 
– or whether tumour blood vessels are being 
destroyed), and other areas of interest outside of 
the oncological domain. Although some of these 
capabilities overlap those of PET, such as tumour 
blood Áow and water distribution, the increased 
versatility of imaging choices offered by overlapping 
and complementary capabilities means that these 
innovations are by no means redundant. For human 
applications, the sensitivity of PET is unchallenged, 
and pharmacokinetics at minute tracer doses are 
much more likely to mimic the actual molecule 
pharmacokinetics than will ever be possible with 
MRI. Even though the clinical viability of PET-MR 
is remains to be proven, the research possibilities 
are manifold. These new additions to the functional 
imaging landscape have the potential to yield ever 
more detailed insights into tumour characteristics 
and therapeutic effects by increasing the range of 
processes that can simultaneously be measured. In so 
doing, we can expect to gain a greater understanding 
of fundamental both disease processes, individual 
patients’ speciÀc disease characteristics and 
prognosis, and even insights into the mechanism of 
action of therapy. 
Keyword: PET, PET-CT, MRI, PET-MRI
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Abstract: Biomedical imaging delivers added 
value in the clinical management of cancer, as well 
as in the research underpinning pharmaceutical 
therapies. Continuous innovations in the fundamental 
understanding of the science behind the disease, 
combined with advances in the technology behind 
imaging leads to a constant cycle of improvements 
to the scope and depth of the capabilities of 
imaging techniques. In oncology, three techniques 
stand at the forefront of clinical utility. Magnetic 
resonance imaging (MRI) and X-ray computed 
tomography (CT) are two very different methods in 
the radiological domain. MRI has the added value 
of being able to also elucidate upon physiological 
processes in the body, while CT offers mostly 
anatomical information and poorer tissue type 
discrimination than MRI. The third technique, 
positron emission tomography (PET) uses target-
speciÀc radiopharmaceuticals to visualize and 
measure biochemical processes. Both individually 
and in a combined setting these techniques provide 
essential information for cancer diagnosis, treatment 
and monitoring. However, since the inception of 
combined PET & CT imaging, it has become clear 
that multi-modal imaging truly can offer much more 
clinical value than the sum of their parts. Introduced 
into the clinic in 2001, PET-CT has since become 
essential in pulmonary oncology, and this is borne 
out by the fact that currently all PET scanners sold 
are PET-CT combination machines, and sales of 
the scanners have increased ten-fold since 2001. 
The value of this is due to the complementary 
range of capabilities of the two systems. PET is a 
highly sensitive means of quantitatively measuring 
a speciÀc molecular process. The range of potential 
tracers is enormous, meaning that many different 
processes can be studied highly selectively. By 
combining PET and CT, much more information 
can be extracted regarding the stage of disease 
and its precise location, to the beneÀt of patient 
management. PET and CT combined offer detailed 
insights into metabolic and molecular processes 
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scan (in those who are candidates for surgery) and 
consideration of prompt resection. CalciÀcation 
in a benign pattern is an excellent indicator that 
a nodule is a granuloma and needs no further 
pursuit. Eccentric calciÀcation should maintain 
concern for malignancy. Ground-glass opacities 
(GGO) are nodules of low density (attenuation) 
that are generally only visible by CT scan. They 
deserve special mention as they may represent 
low-grade adenocarcinomas (bronchioloalveolar 
cell carcinoma) which behave differently than 
most malignancies presenting as solid nodules. 
Malignant GGOs typically exhibit slow growth with 
doubling times on average over 400 days and, for 
this reason, the 2-year stability rule for solid nodules 
doesn’t apply and a longer period of follow-up is 
needed. PET scanning is not helpful to distinguish 
malignancy due to the low density of the lesions, 
and needle biopsy is often nondiagnostic. GGOs 
may show growth or stay the same size yet change 
to becoming solid or part solid in the process of 
progression. PET scanning uses the injection of the 
glucose analog 18F-2-Áuorodeoxyglucose (FDG) 
and identiÀes nodules with high metabolic activity. 
Nodule enhancement is an indication that a nodule 
is more likely malignant than benign, and absence 
of enhancement is a strong predictor that a nodule is 
benign. In a multicenter prospective study reported 
that FDG-PET had an overall sensitivity of 92% 
and a speciÀcity of 90% for detecting malignant 
nodules, yet the sensitivity fell to only 80% when 
nodules of 15 mm or smaller were analyzed. A meta-
analysis of pulmonary nodules showed that PET had 
a sensitivity of 94% and a speciÀcity of 86%. The 
lower limit of nodule size for PET applicability using 
current techniques is about 8-10 mm. A growing 
nodule that is shows no enhancement on PET should 
still be considered suspicious for malignancy and 
prompt needle biopsy or resection. If multiple 
nodules are present, then follow-up is dictated by 
the largest nodule. Observation may be appropriate 
for patients with nodules that are larger than 8-10 
mm and have a low likelihood of malignancy. 
Whether or not an indeterminate nodule > 8-10 
should be biopsied is the subject of considerable 
debate and practices vary. The two biopsy techniques 
for assessment of SPNs are bronchoscopy and 
transthoracic needle aspiration (TTNA). A number 
of series have shown that bronchoscopy with 
Áuoroscopy has a yield is a function of nodule 
size and may be as less than 20% in the setting 
of malignant nodules less than 2 centimeters and 
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Abstract: The Ànding of a solitary pulmonary 
nodule (SPN) or multiple nodules on CT presents 
a decision point for the patient and physician. The 
vast majority of such nodules are benign; however 
the detection of a nodule may be the Àrst and only 
point in time of a chance of cure in the patient with 
lung cancer. In the absence of a completely sensitive 
and speciÀc non-invasive test for malignancy, the 
physician and patient must weigh the options for 
management. Guidelines for nodule evaluation by 
the American college of Chest physicians (ACCP) 
and the Fleischner Society can help guide the 
decision making. The single arm, observational 
studies have shown that CT screening leads to a high 
rate of detection of small parenchymal nodules. The 
rate of nodule detection is, in part, a function of the 
CT slice thickness (collimation) used. Screening 
with 10 mm collimation results in detection of 
one or more nodules in approximately 20-25% of 
participants, 5 mm collimation increases this to 
40-50% of participants, and 1.25 mm collimation 
raises detection to as high as 60%. A review of the 
data from 8 CT studies in high risk patients (current 
or former smokers, age 50 or above) reported that 
likelihood of malignancy was 0 to 1% for nodules 
< 5 mm, 6 to 28% for nodules 5 to 10 mm, 33 to 
60% for nodules > 11-20 mm, and 64 to 82% for 
nodules > 20-30 mm. The Ànding of a nodule on 
CT should Àrst prompt review of any available old 
images that might include the nodule for comparison. 
Review of old images may show that the nodule is 
growing or establish that it has been stable for 2 or 
more years. The Ànding of nodule stability in size 
over a two-year period has been established as an 
excellent indicator of benignancy. If old images are 
not available, nodules < 8 mm may be observed with 
follow-up CT at an interval determined by the nodule 
size. Evidence for nodule growth is a hallmark of 
malignancy and should lead to a staging PET-CT 
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in CT screening programs. SpeciÀcally, FDG-PET 
may have a useful diagnostic role in the evaluation 
of screen-detected nodules by reducing the number 
of patients undergoing interventional procedures 
to establish the diagnosis. The potential reduction 
in the biopsy rate due to the incorporation of FDG-
PET imaging into the management algorithm of 
patients with nodules is important because, despite 
rigorous criteria determining biopsy of a lung 
nodule, approximately 10% of biopsied nodules 
detected by a CT screening trial are benign. 
However, FDG-PET has been reported to have poor 
sensitivity in diagnosing lung cancer in nodules 
detected on screening CT and raises questions 
about its usefulness in preoperative management 
i.e. FDG-PET can be negative in approximately a 
third of lung cancers detected by screening CT. This 
poor sensitivity may be because screening detects 
a higher percentage of small tumors and low-grade 
tumors, and thus the inherent limitations of FDG-
PET in diagnosing lung cancer are ampliÀed in a 
screened population. The limitations of diagnosis 
aside, FDG-PET has the potential to reduce the 
risk of unnecessary treatment. In this regard, FDG 
uptake has the potential to indicate biologic behavior 
and prognosis. FDG uptake has been reported to 
be highly correlated with 5-year survival i.e. 100% 
for SUV 2.5 and 20% for SUV 8. In summary, 
there are limitations to FDG-PET imaging in the 
diagnosis of non-small cell lung cancer and in the 
determination of management of patients with lung 
cancer detected by screening CT. However, by 
addressing the issue of potential over diagnosis and 
over treatment, PET has the potential to improve the 
clinical management of patients with lung cancers 
detected by CT screening trials. This talk will review 
the current experience as it pertains to the use of 
FDG-PET in the evaluation and management of 
nodules detected in CT screening programs. 
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in the range of 40-60% when the nodule is 3 cm. 
Yield rises with increasing nodule size, however, 
preoperative diagnosis is generally not needed for 
lesions greater than 3 centimeters due to the high 
likelihood of malignancy in nodules of this size. 
Bronchoscopic yield increases if the CT shows that a 
bronchus is present within the nodule. Studies using 
CT, endobronchial ultrasound, or electromagnetic 
guidance have shown marked improvements in 
diagnostic yield over standard Áuoroscopic guidance. 
Studies using one or more of these techniques in 
combination have shown yields of 60 to 80% of 
peripheral nodules of a mean diameter of 2- to 25 
mm. A meta-analysis of 47 studies evaluating small 
peripheral nodules with TTNA reported yields of 
approximately over 90% for nodules < 2 cm and 
95% for nodules > 2 cm (Àgure 7). Likelihood of 
obtaining a speciÀc diagnosis in the setting of a 
benign lesion is greater than with bronchoscopy 
but is still problematic. Pneumothorax is the most 
frequent complication of TTNA. Resection is the 
ultimate management for many lesions that remain 
indeterminate after imaging evaluation especially 
in a high risk individual. Unfortunately there 
are currently too many benign nodules removed 
surgically. Recent series of video assisted thoracic 
surgery (VATS) have reported benign nodules 
representing 50-86% of nodules resected. Reduction 
in benign nodule resections may be achieved by 
observing smaller nodules, by utilizing PET-CT, and 
by performing biopsy by TTNA or bronchoscopy 
when information is discordant. 
Keywords: Nodule guideline, Pulmonary nodule, 
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M15.3 ROLE OF PET IN SCREEN-
DETECTED NODULES
Jeremy J. Erasmus 
Radiology, The University Of Texas MD Anderson 
Cancer Center/United States Of America
Abstract: Positron emission tomography (PET) 
using the radiopharmaceutical 18F-2-deoxy-D-
glucose (FDG), a d-glucose analog improves the 
accuracy of staging in non-small cell lung cancer 
and may have an important role in the assessment of 
therapeutic response and the prediction of prognosis. 
Additionally, FDG-PET may be valuable in the 
evaluation and management of nodules detected 
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M16.2 BIOMARKERS IN CLINICAL 
TRIAL DESIGN – ROLE OF THE 
MOLECULAR PATHOLOGIST/
BIOLOGIST
Ming S. Tsao 
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Abstract: Most clinical trials in oncology are 
designed largely to test the efÀcacy of new 
treatment modalities, such as drugs, radiation or 
surgery. As patients and tumors are genetically 
heterogeneous, responses are also expected to be 
heterogeneous, with some patients beneÀting while 
other do not. A biomarker has been deÀned as a 
characteristic that can be measured objectively 
and evaluated as an indicator of normal biologic 
processes, pathogenic processes, or pharmacologic 
responses to a therapeutic intervention. Biomarkers 
that predict the outcome (usually survival) of the 
patients independent of treatment administered 
are prognostic marker. In contrast, biomarkers that 
predict the response of patients (e.g. survival) or 
their tumors (e.g. shrinkage in size) to treatment 
administered are predictive markers. Biomarkers 
that can be evaluated and potentially adopted as 
clinical tests include DNA, RNA, microRNA 
and protein. At the DNA level, such markers are 
usually mutations, loss or gain in the copy number 
of speciÀc genes. There are many ways to detect 
mutations; most commonly used and regarded by 
many as the gold standard method is sequencing 
of the DNA of the target gene. Mutations occur by 
single nucleotide substitution or the loss of single 
or several such nucleotides. Copy number of the 
target genes may also be lost or gained. Biologically 
signiÀcant gene losses are those involving tumor 
suppressor genes, e.g. P16, RB, P53 or PTEN, 
while gene copy number gains usually involve 
oncogenes, such as EGFR and MYC. High level 
gains greater than the chromosomal gains on which 
the gene is located are referred as ampliÀcation; 
while copy number gains secondary to chromosomal 
gain is called polysomy. The “gold standard” to 
detect gene copy aberrations is Áuorescence in situ 
hybridization (FISH). Other detection methods 
include chromogenic in situ hybridization (CISH) 
and polymerase chain reaction (PCR) that assess 
the relative abundance of the target gene. As tumor 
tissue includes also normal host cells with normal 
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Abstract: A biomarker is a characteristic 
that is objectively measured and evaluated as 
an indicator of normal biological processes, 
pathogenic processes, or pharmacologic responses 
to a therapeutic intervention. Biomarkers can be 
contrasted with clinical endpoints, which capture 
information on how a patient feels, functions or 
survives. Biomarkers may be imaging-based or 
physiological indicators, but with the advent of the 
targeted therapy era, cellular, molecular and genetic 
biomarkers have been identiÀed that hold far better 
potential for being either prognostic or predictive. 
Prognostic biomarkers can potentially be used to 
better predict the course of disease while predictive 
biomarkers are critical to identify patient subsets 
of patients who beneÀt from, or are harmed by new 
therapies. Both types of biomarker require statistical 
validation, usually in prospective trials, often but 
not always randomized trials. Hence biomarkers are 
becoming an integral part of trial design, and can be 
used to stratify or select patients, to adapt treatment 
allocation, to modify treatment, or to predict clinical 
outcomes. Many designs have been proposed to 
integrate known or putative biomarkers alongside 
standard or experimental treatments in clinical 
trials. The purpose of this session will be to discuss 
clinical trial designs such as clinical utility, cross-
over, Bayesian adaptive, randomize-all, interaction, 
biomarker-based strategy, targeted (selection), 
adaptive parallel, tandem two-stage, enrichment, 
and prospective subset designs. The operating 
characteristics of some of these designs will be 
explored, and their relative merits and limitations 
contrasted.
Keywords: biomarker, statistical validation, trial 
design
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the trial protocols, these are commonly referred to 
as “integral” biomarker studies as they are necessary 
for the trials to proceed. In contrast, biomarkers 
studies (a) are largely exploratory and are usually 
included in the trial protocols as “integrated” studies; 
these could be conducted using less or not yet 
validated assays in research laboratories. Such that 
positive results from exploratory studies could be 
validated in other studies, design of the biomarker 
studies should include pre-speciÀed evidence based 
assay methods and scoring criteria, with assays 
conducted independent and blinded to the clinical 
data. An important aspect of designing clinical 
trials with biomarker studies is the prevalence of 
the biomarkers, as this would greatly inÁuence the 
sample size. Low prevalence markers require greater 
sample size for overcoming statistical requirement, 
thus prior knowledge of such prevalence will be 
very useful in the trial design. One of the most 
crucial and controversial issues in biomarker 
studies is the method to determine cut-points for 
classifying tumors as marker positive or negative. 
While this is relatively straight forward for changes 
that are qualitative and clear cut (e.g. wild type vs 
mutant), for biomarkers that are quantiÀed in some 
kind of continuous variables (e.g. 0 to 100% or 
0,1,2,3), determining cut-points can be challenging. 
Arbitrarily chosen cut-points usually lead to over-
Àtting, thus a difÀculty to reproduce results in other 
sample cohorts. While medians could be the most 
stringent approach, they may not make biological 
sense. SigniÀcant efforts and studies devoted to 
this issue are necessary. Such studies should be 
multi-disciplinary that include biostatisticians and 
biologists and pathologists who can provide the 
biological meaning and interpretation of the data. In 
summary, the molecular pathologists and biologists 
play crucial roles in the design of biomarker and 
correlative science studies in clinical trials, thus 
should be an integral member of each clinical trial 
committee evaluating novel targeted therapies. 
Keywords: prognostic markers, predictive markers, 
tumor markers, validation
gene sequences/copy number, techniques that do not 
identify the aberration at an individual cell level are 
prone to reduced sensitivity. In contrast, FISH or 
CISH are more accurate but labour intensive. Many 
believe that proteins should represent the ultimate 
and most biologically meaningful biomarkers of 
disease. There are many methods to detect proteins, 
the standard methods are based on immunological 
assays requiring the generation and availability 
of speciÀc antibodies. Liquid assays including 
enzyme-linked immunosorbent assay (ELISA) are 
used to measure protein levels in serum, plasma and 
body Áuid, or in tissue homogenate. Bright Àeld 
immunohistochemistry (IHC) or immunoÁuorescent 
microscopy is used to detect proteins at tissue level. 
These are already standard techniques in routine 
laboratory medicine practices. Nevertheless, newer 
assay techniques that lend greater throughputs and/
or sensitivity are continually being investigated, 
including the mass spectrometry methods (MALDI-
TOF). Sample pre-processing are critical elements 
that need careful attention in their implementation in 
studies. These include standardization of protocols 
for sample collection, storage, Àxation, antibody 
speciÀcity, assay reliability, scoring system, etc. 
To date limited efforts have been devoted to these 
critical issues, which may impact greatly on the 
reliability, hence reproducibility of study results. 
There are several ways that biomarkers can be 
studied or incorporated into the design of clinical 
trials. These include: (a) retrospective studies to 
explore the prognostic and/or predictive value 
of markers of interest, (b) prospective studies to 
validate prognostic/predictive value of markers of 
interest, (c) prospective studies using the biomarkers 
to select patients for eligibility of participating in the 
trial or assignment to treatment arms, and (d) clinical 
trials that are conducted to validate prospectively 
the predictive value of the biomarkers (biomarker 
trials). Among these, (c) and (d) have the greatest 
and most direct impacts on patients during the trial, 
as treatments are entirely dependent on the results 
of the biomarker studies, while (b) may have some 
impact by inÁuencing the patient randomization. 
Consequently, (b) (c) and (d) demand the most 
stringent requirement for designing biomarker 
studies in the trial, including standard operating 
protocols for specimen handling and processing, 
assay robustness, validated scoring algorithm and 
turnaround time; these assays should be conducted 
in accredited pathology laboratories as their impacts 
on patient are equivalent to routine clinical care. In 
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incision was performed just above the suprasternal 
notch. Once the pre-tracheal fascia was elevated, 
after digital dissection, the videogastroscope was 
introduced through the cervical incision and a 
total mediastinal exploration was performed. The 
second step was the creation of mediastinal pleural 
windows. On the right side, a digital dissection of the 
right mediastinal pleura posteriorly to the superior 
vena cava was performed, creating a communication 
between the mediastinum and the right pleural 
cavity. On the left side, the pleurotomy was also 
digitally performed between the left commun carotid 
and subclavian artery. Then the videogastroscope 
was introduced into the pleural cavities. Mediastinal 
lymph nodes: 2R, 4R, 7 and 4L were consistently 
identiÀed and biopsies were easy to perform. The 
introduction of the videogastroscope into both 
pleural cavities was easy and allowed a wide 
exploration allowing numerous pleural biopsies. 
At the end, a chest tube was placed through pleural 
window and exteriorised from the cervical incision. 
The use of Áexible endoscope through a natural 
oriÀce (NOTES) into thoracic cavity remains still 
ethically doubtful in their human being application 
as much through transoesophageal approach as 
transgastric or vaginal [12, 13]. CITES seems to be 
more adapted for thoracic speciÀcities (eg. chest tube 
placement). Bilateral pleural access using CITES 
approach associated to the extreme Áexibility of the 
endoscope offer the possibility of a complete pleural 
inspection and could be used for biopsies in several 
thoracic sites and in other potential applications 
(ex. Bilateral diaphragm pacing, lung biopsies, hilar 
lymph nodes dissection, thoracic sympathectomy). 
Nevertheless, the access to the left hemi thorax 
through the mediastinum remains challenging. Few 
series in the literature [14, 15] demonstrated that 
aortic arch makes the advancement of the video-
mediastinoscope into the left hemi thorax difÀcult 
and dangerous. Flexible endoscope used in CITES 
could be more secure in left side approaches. In 
conclusion, we believe that our bilateral approach 
(CITES) through a single cervical incision with 
the use of a Áexible endoscope, as a surgical tool, 
and novel instrumentation designed for NOTES 
could have rapidly wide applications in thoracic 
surgery. References 1. Detterbeck FC, Jantz 
MA, Wallace M, Vansteenkiste J, Silvestri GA. 
Invasive mediastinal staging of lung cancer: ACCP 
evidence-based clinical practice guidelines (2nd 
edition). Chest 2007;132:202S-220S 2. Carlens. 
E. Mediastinoscopy: a method for inspection and 
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Abstract: Despite the development of new 
techniques for mediastinal exploration in lung 
cancer staging, as transbronchial needle aspiration 
(TBNA), endoscopic ultrasound-guided Àne-
needle aspiration (EUS-FNA), and endobronchial 
ultrasound-guided Àne-needle aspiration (EBUS-
FNA), still mediastinoscopy and video-thoracoscopy 
remain the more commonly performed invasive 
techniques for mediastinal and pleural staging [1, 
2]. In some cases both mediastinal and pleural 
explorations are needed and required two separate 
procedures in the same patient. Pleural exploration 
and biopsies are commonly performed by the meand 
of videothoracoscopy. The need of thoracic ports 
and chest tube still remains the major cause of 
postoperative pain [3]. Several minimally invasive 
procedures have been recently described for 
performing thoracic surgical interventions through a 
cervical incision [4-6]. Now there is a trend in favour 
of the use of Áexible endoscopy in general surgery 
[7]. Few series in the literature reported the use of 
a Áexible endoscope in NOTES (Natural OriÀce 
Transluminal Endoscopic Surgery) particularly in 
abdominal surgery [8-10]. Up to now NOTES was 
never applied in thoracic surgery on human patients, 
because the risk of major mediastinal complications, 
and therefore ethical limitations. In 2010, we 
conducted an experimental work on human subject 
in the aim to evaluate the feasibility of using a 
Áexible endoscope as surgical tool for simultaneous 
exploration of mediastinum and both pleura 
[11]. We used the same surgical approach as for 
mediastinoscopy. The scope was a standard double-
channel Áexible videogastroscope (STORZ®) and 
KARL STORZ Cold Light Fontaine Xenon 100W, 
TELE PACK™ endoscopic video and 15”Flat Screen 
Monitor. A conventional cervical mediastinoscopy 
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Mediastinopleuroscopy: a new approach to the 
diagnosis of intrathoracic diseases. Ann Thorac Surg 
1976;22:265-9 
Keywords: minimally invasive surgery, 
thoracoscopy, Mediastinoscopy, Lung Cancer 
Staging
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Abstract: Most of general thoracic surgical 
operations is performed through the traditional 
thoracotomy or sternotomy or with modern 
videos-assisted (VATS) approach. SigniÀcant 
severity of pain is a common disadvantage of all 
these procedures, even in case of VATS. In the 
recent years our team developed the transcervical 
extended approach for various thoracic surgical 
procedures, originally introduced by Cooper et 
al for thymectomy [1]. The aim of these study 
is to summarize our experience regarding the 
use of the extended transcervical approach in 
thoracic surgery. Material and Methods Surgical 
technique of an extended transcervical approach 
Transcervical extended approach utilizes a typical 
a 5-8 centimeters collar incision in the neck. The 
critical technical point enabling a wide access to 
the chest is an elevation of the sternal manubrium 
with a special retractor (modiÀed Rochard frame, 
Asculap-Chifa company). A bilateral visualization of 
the laryngeal recurrent and vagus nerves is usually 
performed to avoid injury of these structures [2]. 
We used the transcervical extended approach for 
several types of procedures, including thymectomy, 
transcervical extended mediastinal lymphadenetomy 
(TEMLA), resection of the mediastinal tumors and 
the mediastinal metastases, pulmonary resection 
of the right and left upper lobes, closure of the 
bronchial Àstula after pneumonectomy and as a part 
of the esophageal resection. In case of thymectomy, 
the trascervical approach is usually combined with 
a subxiphoid incision and bilateral single-port VATS 
to achieve a maximal extensiveness of dissection 
(we call the procedure “transcervical-subxiphoid 
VATS maximal thymectomy”)[3]. In case of small 
tissue biopsy in the superior mediastinum. Dis Chest 
1959;36: 343-352 3. Rusch VW, Bains MS, Burt 
ME, McCormack PM, Ginsberg RJ. Contribution of 
videothoracoscopy to the management of the cancer 
patient. Ann Surg Oncol 1994;1:94-8 4. Zielinski 
M, Pankowski J, Hauer L, Kuzdzal J, Nabialek 
T. The right upper lobe pulmonary resection 
performed though the transcervical approach. Eur 
J Cardiothorac Surg. 2007;32(5):766-9. 5. Fowkes 
L, Lau KK, Shah N, Black E. A Cervical Approach 
to Investigating Pleural Disease. Ann. Thorac. Surg 
2009; 88: 315 – 317. 6. Chamberlain MH, Fareed 
K, Nakas A, Martin-Ucar AE, Waller DA. Video-
assisted cervical thoracoscopy: a novel approach 
for diagnosis, staging and pleurodesis of malignant 
pleural mesothelioma. Eur J Cardiovasc Surg 
2008;34:200-3 7. Swanstrom LL, Dunst Cm, Spaun 
GO. Future applications of Áexible endoscopy in 
esophageal surgery.J Gastrointest Surg. 2009 Sep 
12.[Epud ahead of print]. 8. Sanchez-Margallo FM, 
Asencio JM, Tejonero MC, Perez FJ, Sanchez MA, 
Uson J, Pascual S. Technical feasibility of totally 
natural oriÀce cholecystectomy in a swine model. 
Minim Invasive Ther Allied Technol 2008;17:361-
4 9. Perreta S, Dallemagne B, Coumaros D, 
Marescaux J. Natural oriÀce transluminal endoscopic 
surgery : transgastric cholecystectomy in a survival 
porcine model. Surg Endosc 2008;22:1126-30 10. 
Marescaux J, Dallemagne B, Perreta S, Wattiez 
A, Mutter D, Coumaros D. Surgery without scars: 
report of transluminal cholecystectomy in a human 
being. Arch Surg 2007;142:823-6 11. Assouad J, 
Steltzlen C, Masmoudi H, Vignes S, Gounant V, 
Delmas V, Grunenwald D. Cervical incision thoracic 
endoscopic surgery: a minimally invasive endoscopic 
approach in thoracic surgery. Interact Cardiovasc 
Thorac Surg 2010;10:967-70 12. Fritscher-Ravens 
A, Patel K, Ghanbari A, Kahle E, von Herbay A, 
Fritscher T, Niemann H, Koehler P. Natural oriÀce 
transluminal endoscopic surgery (NOTES) in the 
mediastinum: long-term survival animal experiments 
in transesophageal access, including minor surgical 
procedures. Endoscopy 2007;39:870-5 13. Clark 
J, Sodergren M, Correia-Pinto J, Zacharakis E, 
Teare J, Yang GZ, Darzi A, Athanasiou T. Natural 
oriÀce translumenal thoracoscopic surgery: does 
the slow progress and the associated risks affect 
feasibility and potential clinical applications? Surg 
Innov 2009;16:9-15 14. Ginsberg RJ. Extended 
cervical mediastinoscopy. Chest Surg Clin N 
Am 1996;6:21-30 15. Deslauriers J, Beaulieu M, 
Dufour C, Michaud P, Despres JP, Lemieux M. 
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TEMLA (unrelated causes) and 1 patients died 
after transcervical-VATS left upper lobectomy 
because of pulmonary embolism. Complications 
occurred in 85/1335 patients (morbidity 6.4%). 
Our late institutional results of presented technique 
of thymectomy has been very favourable – 
5-years complete remission rates 53.1% 20.0% 
in comparison the basic trassternal thymectomy 
(p<0.0001) which can be only explained by the 
removal of ectopic foci of the thymic tissue from 
the neck and the mediastinum in these patients [3]. 
In our current study presented to WCLC diagnostic 
yield of TEMLA at our institution was signiÀcantly 
better than combined Endobronchial Ultrasound 
(EBUS)/Endoesophageal Ultrasound. Sensitivity and 
Negative Predictive Value (NPV) for TEMLA and 
EBUS/EUS were88.9% and 84.1% versus 98.6% and 
99.7% respectively (p<0.0001 for both parameters) 
[4]. In our recent study on restaging of NSCLC after 
neoadjuvant treatment TEMLA was found to have 
signiÀcantly better sensitivity and NPV (p<0.05) 
than other series of restaging including PET/CT, 
EBUS, EUS and remediastinoscopy [6]. Conclusions 
Transcervical extended approach with elevation 
of the sternal manubrium enables performance of 
various thoracic surgical procedures with minimal 
invasiveness, low mortality and morbidity and very 
high effectiveness. References 
1. Cooper J, Al-Jalaihawa A, Pearson F, Humphrey 
J, Humphrey H: An improved technique to facilitate 
transcervical thymectomy for myasthenia gravis. 
Ann Thorac Surg 1988;45:242-7 
2. Zielinski M, Ku‚ J, Szlubowski A, Soja J: A 
safe and reliable technique for visualization of the 
laryngeal recurrent nerves in the neck. Am J Surg 
2005;189:200-202 
3. Zielinski M, Hauer L, Hauer J, Pankowski J, 
Nabialek T, Szlubowski A. Comparison of complete 
remission rates after 5 year follow-up of three 
different techniques of thymectomy for myasthenia 
gravis. 2010;37:1137-43. 
4. Zielinski M, Hauer L, Hauer J, Nabiaek T, 
Szlubowski A, Pankowski J. Eur J Cardiothorac 
Surg. 2010;37:776-80 
5. Zielinski M, Pankowski J, Hauer L et al: The right 
upper lobe pulmonary resection performed through 
the transcervical approach. 2007;32:766-769. 
6. Zielinski M, Szlubowski A, Koodziej M, 
Orzechowski S, Laczynka E, Pankowski J, 
Jakubiak M, Obrochta A. Comparison of diagnostic 
yield of endoscopic ultrasound staging of Non-
Small Cell Lung Cancer (NSCLC) performed 
thymomas and thymic cysts the entire procedure is 
performed through the neck without opening of the 
mediastinal pleura. TEMLA is performed entirely 
through the neck approach. Most part of TEMLA 
is an open procedure, with exception of dissection 
of the subcarinal, station 7, periesophageal, station 
8 nodes and the left lower paratracheal, station 4 
nodes which are dissected in the mediastinoscopy-
assisted fashion with aid of the linder-Dahan two-
blade mediastinoscope (Wolf Company, Germany)
[4]. The paraaortic, station 6 and aorta-pulmonary 
window, station 5 nodes are sometimes dissected 
with aid of videothoracoscope introduced to the 
mediastinum through the operative wound. Bilateral 
supraclavicular lymphadenectomy and even deep 
cervical lymph node dissection is possible during 
TEMLA through the same incision. In case of the 
mediastinal tumors and the mediastinal metastases 
the surgical approach is dependent on the location 
of the lesion. In most of the patients an entire 
procedure is performed solely through the neck 
incision but in some patients an additional VATS or 
subxiphoid incision might be necessary. The right 
and left upper pulmonary resctions were performed 
throught the transcervical incion combined with 
1-, or 2-port VATS. The technique and preliminary 
results of this operation were described elsewhere 
[5]. The closure of the main bronchial Àstula and 
the dissection of the esophagus were performed 
solely through the neck. Results Starting from 
1.9.2000 to 30.2.2011 there were 1335 transcervical 
operations including 391 transcervical-subxiphoid 
VATS maximal thymectomies for myasthenia gravis 
(MG), 20 thymectomies for thymoma, 781 TEMLA 
procedures for staging of Non-Small Cell Lung 
Cancer (NSCLC), 52 resections of the mediastinal 
tumors, 65 resections of the mediastinal metastases 
(mostly from the thyroid cancer), 5 right upper 
lobectomies and 3 left upper lobectomies combined 
with TEMLA for NSCLC, 15 esophageal dissections 
(combined with laparotomy in 13 patients and with 
laparoscopy in 2 patients) and 3 attempts of closure 
of the right main bronchus postpneumonectomy 
Àstula. 5/1335 (0.4%) patients had to be converted 
because of technical difÀculties, in no case for 
major bleeding or other severe intraoperative 
complications or deaths. 8/1335 (0.6%) patients 
required revision because of postoperative bleeding 
(through the original incision in all but one patient, 
who necessitated thoracotomy) There were 6 
postoperative deaths with 30-day postoperative 
mortality 0.4% (6/1346) with 5 patients died after 
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in maneuverability, 3-dimensional visibility and 
occasional difÀcult hand-eye coordination which 
may hinder general acceptance. For surgery in the 
chest, this can present severe risks to the patient. 
Computer-assisted surgical systems or surgical 
robotics has its origins in the early 1980s, when the 
Àrst institutions began to investigate the potential 
of simulating a surgeon’s movements. Computer 
Motion (Santa Barbara, CA) developed the Àrst 
FDA-approved surgical robot, the Aesop, initially 
foot controlled and later evolved to voice activated 
video system. Then, in a giant leap forward, two 
California-based robotic companies developed two 
surgical robots, the Zeus by Computer Motion and 
the daVinci by Intuitive Surgical, Inc. (Sunnyvale, 
CA). Both have similar features, high-deÀnition 
visual clarity, 3-dimensional visibility, multiple 
degrees of rotational freedom and tremor control. 
The Àrst robotic general surgical procedure was 
performed by Cadiere in 1998. Chitwood performed 
the Àrst mitral valve repair in 2000. The da Vinci 
was approved by the FDA for the use in general 
thoracic surgical procedures in March 2001. 
Since that time there has been continued growing 
interest. To perform an efÀcient case the surgeon 
must possess a thorough understanding of the 
anatomy, the pathology and the robotic technology. 
Placement of the ports and the machinery, and 
organization of the assistant(s) can determine the 
efÀciency of the planned procedure. As with the 
VATS technique, there are 3 basic approaches using 
the surgical robot. Given the greater visibility and 
precision, one approach is to perform the hilar and 
mediastinal lymph node dissection alone performing 
the remainder of the procedure with VATS. This 
may or may not be performed using a mini-
thoracotomy or “utility incision.” Others perform 
the procedure completely robotically with from 4 to 
6 ports, increasing the skin incision to remove the 
specimen. To date, the published reports demonstrate 
a conversion rate of approximately 2% with an 
operating room time of 3.6 hours and a postoperative 
length of stay of 7 days with an approximately 20 
% morbidity and 1% operative mortality. The role 
of robotics in lung resection is unclear. In general 
robotics in thoracic surgery offers numerous 
opportunities for resection and reconstruction with 
excellent visibility and precision. As the technology 
continues to be reÀned and with greater the surgical 
experience, the efÀciency and the cost of the 
procedures will continue to improve. It is likely 
that many of the video-assisted procedures will be 
with use of Endobronchial Ultrasound (EBUS) 
and/or Endoesophageal Ultrasound (EUS) with 
invasive staging of NSCLC performed with 
use of Transcervical Extended Mediastinal 
Lymphadenectomy (TEMLA). Submitted to WCLC, 
Amsterdam 2011. 
Keyword: Lung cancer, Mediastinal lymph nodes, 
mediastinal tumors
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Abstract: Video-assisted minimal-invasive 
resections for early-stage lung cancer are nowadays 
performed throughout the world. However, overall, 
there are only a few specialized centers in every 
region or country which are performing these 
procedures routinely. In most of the institutions, in 
addition to small incisions for the thoracoscopic 
instruments and utility incisions are used for the 
direct manipulation of the lung hilus and for the 
removal of the specimen. In addition to anatomical 
resections there are also a few reports on video-
assisted sleeve resections of primary lung cancers or 
other malignant tumors of the bronchial system. Due 
to the technical limitations of the minimal-invasive 
approach (no palpation) video-assisted sleeve 
resections are technically possible and oncologically 
acceptable in only a few circumstances. In general, 
these are clearly deÀned tumors without lymphatic 
inÀltration and with clear margins on frozen sections. 
Overall results are promising so far. 
Keywords: Lung cancer, Thoracic surgery
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M17.4 ROBOTIC RESECTIONS
Kemp Kernstine
Valencia/United States of America
Abstract: For lung cancer, minimally invasive 
surgery or video-assisted thoracoscopic surgery 
(VATS) appears to be safe with comparable short- 
and long-term outcomes to the open thoracotomy 
approach. VATS has reduced pain, length of hospital 
stay, improved lung function and quicker return to 
preoperative status. Though there are limitations 
S108 Copyright © 2011 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
treatments directed against cancer stem cells should 
be targeted to subsets of patients grouped according 
to their oncogenotype. We have recently obtained 
global gene expression data from the Sca1-sorted 
populations of murine lung tumor cells, as well as 
their normal wild-type counterparts, to uncover 
the molecular pathways responsible for tumor 
propagation in lung adenocarcinoma. I will also 
discuss new avenues we have taken to understand the 
connections between TPCs and metastasis in mouse 
models as well as translating the importance of our 
Àndings in human lung cancer cells and patient 
samples.
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M18.3 HEDGEHOG SIGNALLING IN 
CANCER STEM CELLS
Neil Watkins 
Monash Institute Of Medical Research, Monash 
University/Australia
Abstract: In development and homeostasis, the 
property of long-term self renewal is restricted to a 
small subset of somatic stem cells. It is now clear 
that maintenance of this property is dependant on a 
small number of developmental pathways that are 
distinct from those that regulate growth, apoptosis 
and senescence. These œstemness pathways are an 
evolutionarily conserved set of genes that regulate 
cell fate and patterning in metazoans, and have the 
capacity to regulate all the functional components 
of self-renewal in development and repair. One of 
the most important of these pathways is Hedgehog 
(Hh) signalling, named after the characteristic 
phenotype of the Drosophila mutant in which 
the cuticle of Hh null embryos develop a marked 
expansion in the number of denticle hairs, hence a 
hedgehog-like appearance. This is caused by a loss 
of segmental polarity in the developing Áy, because 
the Hh protein is a diffusible morphogen secreted in 
the posterior compartment of each segment of the 
embryo, and its concentration gradient is required 
for the normal striped pattern of denticles that is 
lost in the Hh mutant. In mammalian development, 
Hh proteins specify cell fate in the same way, and 
are particularly important for axial patterning of the 
central nervous system, limb buds and foregut. More 
recently, Hh signalling now known to be required for 
the maintenance of somatic stem cell populations in 
the central nervous system, skin, cartilage and other 
replaced with robotic technology. An educational 
process is necessary to optimize early outcomes. 
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M18.2 STEM CELLS IN MURINE 
NORMAL LUNG AND LUNG CANCER
Carla Kim 
Stem Cell Program, Children’s Hospital Boston/
United States Of America
Abstract: Lung cancer is the major cause of death 
from cancer worldwide. The Àve-year survival 
rate for the majority of lung cancer patients is 
only 16% because their tumors are refractory to 
chemotherapeutics or quickly become resistant to 
therapeutic response. Also contributing to morbidity, 
most lung cancer patients already have advanced, 
metastatic disease at the time of diagnosis or develop 
metastases after surgical removal of early stage 
primary lung tumors. The cancer stem cell (CSC) 
hypothesis, is an attractive explanation for tumor 
growth, recurrence after treatment, and metastasis 
in some cancers, yet the precise role of CSCs 
in lung tumors has not been established. Since 
successful cancer therapy requires the elimination 
or incapacitation of all tumor cells capable of 
regenerating a tumor, it is crucial to characterize 
the cells that are able to propagate a tumor in vivo.
We refer to these functionally important cancer cells 
as tumor-propagating cells (TPCs). Importantly, 
understanding the identity and molecular nature 
of TPCs will provide new opportunities for early 
detection, treatment and prevention of metastatic 
disease, whether or not they Àt the CSC model 
in each type of cancer. My laboratory recently 
showed that murine lung adenocarcinomas, the 
most prevalent lung cancer subtype, contain a 
TPC population. In mice bearing tumors initiated 
with oncogenic Kras and deletion of p53, the cell 
surface marker Sca1 identiÀes cancer cells with 
stem cell properties. In contrast, TPCs are Sca1-
negative in lung tumors that express a mutant EGFR. 
Thus, the predominant driving oncogenotype is an 
important determinant in the identiÀcation of TPC 
phenotype in lung cancer. This Ànding suggests that 
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of small molecule Hh pathway inhibitors), tumour 
formation in this model was dramatically reduced. 
By using genetic mouse models, these experiments 
establish that Smo is a validated pharmacologic 
target in SCLC. Although we have been unable to 
associate a distinct stem cell phenotype in small 
cell lung cancer (SCLC), we have shown that 
inhibition of Hh signalling is able to block self-
renewal capacity in this tumour model. Although 
Hh inhibitors have no effect on the growth of 
established SCLC tumours, they are highly effective 
in blocking long term clonal capacity in vitro and in 
vivo. Since SCLC is characteristically sensitive to 
platinum-based chemotherapy, we then reasoned that 
the population of tumour cells that can regenerate 
the tumour following chemotherapy, a surrogate 
marker of self-renewal, would be more dependant on 
Hh signalling than bulk tumour cells. Experiments 
in vitro and in vivo show that the self-renewal 
capacity in innately chemoresistant SCLC cells was 
a thousand fold more efÀcient than chemonaive 
cells, and that this cell population was dramatically 
more sensitive to Hh pathway inhibitors. These 
data support the idea that cancer stem cells 
possess the properties of self-renewal and innate 
chemoresistance, and that targeting pathways that 
regulate self-renewal may be effective in depleting 
populations of tumour cells that evade conventional 
chemotherapy.
Keywords: Small cell lung cancer, Hedgehog, stem 
cells
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M18.4 STEM CELLS 
CHEMORESISTANCE
Luca Roz, Giulia Bertolini, Gabriella Sozzi 
Experimental Oncology, Fondazione IRCCS Istituto 
Nazionale Tumori/Italy
Abstract: The cancer stem cells (CSC) model 
carries fundamental implications for cancer therapy. 
One implication of this model is that, regardless of 
the origin of CSCs (either from transformation of a 
normal stem cells or from acquisition of stem like 
properties during cancer evolution), only a fraction 
of the cells in a given tumor might have tumor 
initiating potential and that those cells should be 
targeted to achieve complete remission. Several lines 
of evidence, Àrst in hematological tumors and more 
recently in solid tumors, demonstrate an intrinsic 
organs. Mutations that lead to aberrant activation 
of the Hh pathway result in medulloblastoma and 
basal cell carcinoma. In these tumours, a naturally 
plant-derived Hh pathway antagonist, cyclopamine, 
is highly effective in blocking growth of these 
tumours. Cyclopamine is a competitive antagonist 
of Smoothened (Smo), a transmembrane protein 
that is required for all Hh signalling in metazoans. 
Pharmacologic targeting of Smo has formed the basis 
for the development of small molecule inhibitors 
of Hh signalling as potential cancer therapeutics. 
Our work is based on the premise that self-renewal 
is a unique property restricted in nature to the germ 
line, embryonic and somatic stem cells, and cancer. 
Furthermore, we believe that the acquisition of 
aberrant self-renewal is functionally distinct from 
the hallmarked of cancer, such as uncontrolled 
growth and the escape from apoptosis. Based on 
the evidence in development and repair, we have 
explored the idea that cells within tumours that 
possess self-renewal properties, so called “cancer 
stem cells”, are dependant on the same embryonic 
signalling pathways that maintain stemness in 
normal tissues. We were Àrst able to characterise 
this phenomenon in small cell lung cancer (SCLC), 
where cyclopamine was able to block clonal growth 
in vitro. Since we were unable to identify a robust 
marker for SCLC stem cells, we turned to other 
tumour stem models to explore this idea. In multiple 
myeloma, in which a distinct tumour stem cell 
population can be isolated, we found that the stem 
cell compartment was extremely sensitive to Hh 
pathway inhibition. These stem cells, which resemble 
normal B cells, undergo terminal differentiation 
along a plasma cell lineage when treated with 
cyclopamine, and in doing so lose their capacity 
to self-renew. By contrast, mature myeloma cells 
are totally resistant to Hh pathway blockade. These 
Àndings have since been conÀrmed in other tumour 
stem cell models, including glioblastoma and chronic 
myeloid leukaemia. DeÀnitive conclusions based 
on experiments using small molecule inhibitors are 
hampered by concerns over off-target effects. One 
way to resolve this issue is the use of genetically 
modiÀed mouse models, in which targeted deletion 
of a therapeutic target using a conditional knockout 
approach can be used to validate a therapeutic 
target in vivo. To address this question, we studied 
a genetic mouse model of SCLC in which deletion 
of the p53 and Rb tumour suppressors is targeted to 
the adult airway epithelium. When crossed with a 
conditional knockout of Smo (the molecular target 
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before cisplatin treatment, the residual cells 
recovered after tumor relapse were depleted in tumor 
initiating capability in a serial transplantation assay. 
Additionally, treatment of tumorgrafts with cisplatin 
resulted in dissemination of CD133+CXCR4+ cells 
to the lungs implicating these cells also in the 
metastatic spread. This process could be inhibited by 
combined treatment with retinoic acid derivatives. 
Finally a tendency towards shorter progression free 
survival was observed in CD133+ NSCLC patients 
treated with platinum-containing regimens indicating 
of possible clinical relevance of these Àndings. Taken 
together these results indicate that chemoresistant 
populations with highly tumorigenic and stem-like 
features are present in lung tumors. The molecular 
features of these cells may provide the rationale for 
more speciÀc therapeutic targeting and for deÀning 
predictive factors in clinical management of this 
lethal disease. 
Keywords: chemoresistance, CD133, tumorgrafts, 
stem cells
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M18.5 EPITHELIAL PROGENITOR 
CELLS AND THEIR REGULATION IN 
THE NORMAL AND REPAIRING LUNG.
Barry Stripp 
Departments Of Medicine And Cell Biology, Division 
Of Pulmonary Allergy And Critical Care Medicine, 
Duke University/United States Of America
Abstract: Epithelial remodeling and dysfunction 
is pathognomonic of chronic lung disease and 
directly contributes to declining lung function 
that accompanies disease progression. This can be 
demonstrated by dramatic declines in the abundance 
of low molecular weight secretory products of 
nonciliated bronchiolar epithelial cells in serum 
and/or airway lining Áuid of patients with asthma, 
chronic obstructive pulmonary disease, early 
transplant rejection, and other chronic inÁammatory 
lung diseases. We have developed both in vivo and 
in vitro models of epithelial cell injury and repair to 
better understand cellular and molecular mechanisms 
of epithelial maintenance and remodeling in 
lung disease. Epithelial tissues are maintained in 
adulthood through the action of tissue-speciÀc 
progenitor cells that can be hierarchically organized 
according to their capacity for proliferation, 
differentiation and resistance to environmental 
resistance of CSC to conventional chemotherapeutic 
agents and ionizing radiation, because of their 
low proliferation rate and of defense mechanisms, 
including the expression of multidrug transporters 
of the ATP-binding cassette (ABC) superfamily. 
In lung cancer evidence for the presence of CSC 
has been obtained in transgenic animal models and 
primary tumors. Their prospective identiÀcation 
and characterization may provide new insights to 
identify novel prognostic markers and targets for 
therapeutic intervention. This could represent an 
innovative strategy to completely eradicate tumors 
and potentially lead to cure, even in advanced-stage 
disease. We previously showed that a subpopulation 
of lung cancer cells expressing the stem cells marker 
CD133 displayed higher tumorigenic potential in 
immunocompromised mice and increased expression 
of genes involved in stemness, adhesion, motility 
and drug efÁux than the CD133- counterpart. 
Cisplatin treatment of lung cancer cells in vitro 
resulted in enrichment of the CD133+ fraction both 
after acute cytotoxic exposure and in cells with a 
stable cisplatin-resistant phenotype. Expression of 
transporters of the ABC family was also upregulated 
in the residual population. For in vivo studies 
we established several models of primary tumor 
xenografts (tumorgrafts), derived from direct 
implant of patient biopsies. Tumorgrafts can be 
serially propagated, have been shown to recapitulate 
closely the phenotype of the original tumor and 
to be useful tools to evaluate response to therapy. 
Complete similarity between parental tumors and 
tumorgrafts was conÀrmed for a panel of lung 
cancer antigens, as well as for the CD133+ESA+ 
fraction that was maintained over time in serial 
transplantations. In tumorgraft models the highly 
tumorigenic lung tumor CD133+ cells, endowed 
with stem-like features, were spared by cisplatin 
treatment and reverted to the original values after 
chemotherapy cessation, indicating that these cells 
might represent a chemoresistant sub-population 
responsible for tumor re-growth after treatment. 
In tumorgrafts with high content of CD133, 
only the subpopulations of CD133+ABCG2+ and 
CD133+CXCR4+cells were strongly enriched after 
the in vivo cisplatin treatment, indicating that highly 
resistant cells could represent only a subset within 
the CSC compartment. Cisplatin-treated tumors 
consistently expressed higher levels of stemness 
genes and ABC transporters compared to untreated 
control. When tumorgrafts were treated with retinoic 
acid derivatives to induce CSC differentiation 
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cell secretory protein-expressing cells of the airway 
neuroepithelial body microenvironment include a 
label-retaining subset and are critical for epithelial 
renewal after progenitor cell depletion. Am J Respir 
Cell Mol Biol 2001; 24:671-681. 5. Giangreco A, 
Reynolds SD, Stripp BR. Terminal bronchioles 
harbor a unique airway stem cell population that 
localizes to the bronchoalveolar duct junction. Am 
J Pathol 2002; 161:173-182. 6. Kim CF, Jackson 
EL, Woolfenden AE, Lawrence S, Babar I, Vogel S, 
Crowley D, Bronson RT, Jacks T. IdentiÀcation of 
bronchioalveolar stem cells in normal lung and lung 
cancer. Cell 2005; 121:823-835. 7. Giangreco A, 
Arwert EN, Rosewell IR, Snyder J, Watt FM, Stripp 
BR. Stem cells are dispensable for lung homeostasis 
but restore airways after injury. Proc Natl Acad Sci 
U S A 2009; 106:9286-9291. 8. Rawlins EL, Okubo 
T, Xue Y, Brass DM, Auten RL, Hasegawa H, Wang 
F, Hogan BL. The role of scgb1a1+ Clara cells in the 
long-term maintenance and repair of lung airway, 
but not alveolar, epithelium. Cell Stem Cell 2009; 
4:525-534. 9. Reynolds SD, Zemke AC, Giangreco 
A, Brockway BL, Teisanu RM, Drake JA, Mariani 
T, Di PY, Taketo MM, Stripp BR. Conditional 
stabilization of beta-catenin expands the pool of 
lung stem cells. Stem Cells 2008; 26:1337-1346. 
10. Teisanu RM, Lagasse E, Whitesides JF, Stripp 
BR. Prospective isolation of bronchiolar stem cells 
based upon immunophenotypic and autoÁuorescence 
characteristics. Stem Cells 2009; 27:254-264. 11. 
Teisanu RM, et al. Functional Analysis of Two 
Distinct Bronchiolar Progenitors during Lung Injury 
and Repair. Am J Respir Cell Mol Biol. 2010 (in 
Press). 
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M19.1 RISK MODELING: APPROACHES 
TO POPULATIONS AT HIGH RISK FOR 
DEVELOPING LUNG CANCER
Margaret R. Spitz, Anthony M. D’Amelio, Carol J. Etzel 
Epidemiology, M.D. Anderson Cancer Center/United 
States Of America
stress. Using a chimeric mouse model and sequential 
labeling of proliferating cells with halogenated 
thymidine analogues we show that normal epithelial 
maintenance is achieved through the random 
participation of abundant Clara cells. However, 
Clara cells are the principal site for detoxiÀcation 
of lipophilic environmental pollutants in the lung, 
a function that renders this abundant progenitor 
pool sensitive to injury by environmental agents. 
Airway injury that depletes the abundant Clara 
cell pool results in activation of a rare population 
of chemically resistant reparative cells. We show 
that the clonal origins of specialized epithelial cell 
types within airways differ dramatically between 
normal maintenance versus repair following injury, 
a concept that is of fundamental importance in 
understanding mechanisms leading to the expansion 
of progenitor cells carrying founding mutations that 
impact cancer susceptibility. We have developed 
fractionation and culture methods allowing clonal 
analysis of airway epithelial progenitor cells to gain 
a more comprehensive understanding of mechanisms 
regulating their renewal and differentiation. Using 
a clonal 3D organotypic culture model we show 
that functionally distinct epithelial progenitor cell 
types can be recovered from intralobar airways, 
these progenitors represent subsets of CCSP-
expressing cells, and that these progenitor cell 
types have a non-uniform distribution throughout 
airways. Conducting airways progenitor cells can 
be functionally subdivided by their requirement for 
stromal cell interactions, their response to growth 
factors, and the morphology of clonally derived 
epithelial colonies. Ongoing studies deÀning 
molecular pathways that regulate renewal and 
differentiation of these progenitor cell types will be 
discussed. These Àndings provide new insights into 
cellular mechanisms of epithelial maintenance and 
remodeling, and provide a basis for development 
of cell-based and either genetic or pharmacologic 
therapies aimed at restoring the regenerative capacity 
of injured airways. Supported by the NHLBI and 
NASA. Selected literature: 1. Stripp BR, Reynolds 
SD. Maintenance and repair of the bronchiolar 
epithelium. Proc Am Thorac Soc 2008; 5:328-333. 
2. Stripp BR. Hierarchical organization of lung 
progenitor cells: Is there an adult lung tissue stem 
cell? Proc Am Thorac Soc 2008; 5:695-698. 3. Evans 
MJ, Cabral-Anderson LJ, Freeman G. Role of the 
Clara cell in renewal of the bronchiolar epithelium. 
Lab Invest 1978; 38:648-653. 4. Hong KU, Reynolds 
SD, Giangreco A, Hurley CM, Stripp BR. Clara 
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models have shown only modest improvements in 
discrimination. We have added the top hits from 
four published genome wide association studies 
(including our own) and showed that addition of 
the genetic information improved the area under the 
curve statistic by 1%, with modest improvement 
in both sensitivity (9%) and speciÀcity (6%). The 
receiver operating characteristics (ROC) curve 
may not be sensitive to differences in probabilities 
between models and, therefore, may be insufÀcient 
to assess the impact of adding new predictors. A very 
large independent association of the new marker is 
required for a meaningful improvement in AUC, 
and a substantial gain in performance may not yield 
a substantial increase in AUC. Research is now 
in progress to determine the calibration (based on 
ten year and Àve year absolute risk calculations), 
discriminatory power, and clinical utility of our 
model using prospective cohort data from the Dutch-
Belgian randomized lung cancer screening trial, 
NELSON. 
Keyword: risk models
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M19.2 MOLECULAR PATHOLOGY OF 
LUNG CANCER & INTERMEDIATE 
MARKERS OF CARCINOGENESIS
Ignacio Wistuba, Humam Kadara, Edward Kim, 
Waun K. Hong 
Thoracic And Head & Neck Medical Oncology, 
University Of Texas, M.D. Anderson Cancer Center/
United States Of America
Abstract: Lung cancer continues to be the leading 
cause of cancer-related deaths worldwide with 
over one million deaths each year. Lung cancer 
mortality is high in part because most cancers are 
diagnosed after regional or distant spread of the 
disease had already occurred and due to the lack 
of reliable biomarkers for early detection and risk 
assessment. The identiÀcation of new effective 
early biomarkers will undoubtedly improve clinical 
management of lung cancer and is tightly linked 
to better understanding of the molecular events 
associated with the development and progression of 
the disease. It has been suggested that histologically 
normal-appearing tissue adjacent to neoplastic 
lesions display molecular abnormalities some of 
which are in common with those in the tumors. 
Abstract: Results from the National Lung Screening 
Trial showing a 20% reduction in lung cancer 
mortality in the screened arm have heightened 
awareness of, and the need for, reliable risk 
prediction tools for estimating the probability of lung 
cancer. Such models have substantial public health 
implications and value in clinical decision making. 
High-risk individuals could undergo a program of 
screening surveillance that might not be appropriate 
for a lower risk population. Further, risk prediction 
tools could be incorporated into the design of 
smaller, more powerful, and “smarter” prevention 
trials. The challenges, however, are substantive. Over 
80% of lung cancer cases occur in ever smokers, 
but only an estimated 11% of female smokers and 
17% of male smokers will be diagnosed with lung 
cancer in their lifetimes. For expensive screening 
programs, it is necessary to identify the highest risk 
subgroups of current and former smokers that use 
more than smoking phenotypes to deÀne high risk. 
We have constructed and internally validated clinical 
tools for lung cancer risk prediction for current, 
former and never smokers, based on epidemiologic 
and clinical data derived from a case control study 
of 1851 non Hispanic white lung cancer patients 
and 2001 matched controls. Variables included were 
environmental tobacco smoke (for never and former 
smokers only), family cancer history, dust exposure, 
physician diagnosed emphysema, and smoking 
history variables (packyears for current smokers 
and age stopped smoking for former smokers). All 
have strong biologically plausible etiologic roles, 
and are relatively easy to ascertain through patient 
interview. The validated concordance statistics for 
the former and current smoker models were modest 
(0.63, and 0.58, respectively), but slightly higher 
compared to other cancer risk prediction models 
that do not include co-morbid conditions. We have 
adopted similar approaches to construct risk models 
for African Americans. Since the precision of these 
models is modest, we have also estimated the degree 
of improvement obtainable by adding functional 
assessment of DNA repair capacity, and have shown 
that addition of biomarker assays signiÀcantly 
improved the sensitivity of the expanded models, 
although these assays are technically not suitable 
for wide scale application. The advent of genome-
wide association studies to identify low-penetrance 
common susceptibility alleles heralds the possibility 
of incorporating panels of gene variants into existing 
risk prediction models and of assessing improvement 
in model performance. However, to date, the updated 
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M19.3 EXPERIMENTAL MODELS AND 
HIGH THROUGHPUT SCREENING
Yuhong Du1, Andrea Kasinski1, Shala Thomas1, 
Aiming Sun2, Andrew Gewirtz3, James Snyder2, 
Dennis Liotta2, Fadlo R. Khuri4, Haian Fu1 
1Pharmacology, Emory University/United States 
Of America, 2Chemistry, Emory University/United 
States Of America, 3Pathology, Emory University/
United States Of America, 4Hematology & Medical 
Oncology, Emory University-Winship Cancer 
Institute/United States Of America
Abstract: Many chemical carcinogens, such as 
cigarette smoke, act as major risk factors for lung 
cancer in part through triggering inÁammation. It 
is well established that the inÁammatory response 
in premalignant lesions is a major enabling 
characteristic that helps incipient neoplasias acquire 
hallmark capabilities for cancer development, such 
as cell proliferation, survival, and angiogenesis. 
One major pathway that mediates the inÁammatory 
response occurs through the action of the inhibitor 
of B kinase (IKK)-nuclear factor-B (NF-B) signaling 
cascade. Thus, agents that attenuate IKK-NF-B 
signaling would be expected to have potential 
anti-inÁammatory effects and could be used for 
chemoprevention and chemotherapeutic studies in 
lung cancer. In this study, we aimed to target the 
NF-B signaling pathway using high throughput 
screening (HTS) and high content screening (HCS) 
technologies. Initially, we speciÀcally examined 
the efÀcacy of newly developed curcumin analogs 
and demonstrated their superior activity over the 
parental agent in a panel of lung cancer cell lines. 
In particular, a synthetic monoketone compound, 
3,5-bis(2-Áurobenzylidene)piperidin-4-one 
(referred to as EF24), exhibited a potency that was 
approximately 10 times higher than that of curcumin. 
In order to investigate the mechanism of action 
of these analogs, we examined the effects of test 
compounds on the localization of NF-B. NF-B is 
maintained in an inactive state in the cytoplasm by 
the inhibitor of B (IB), which negates the nuclear 
localization of NF-B. Phosphorylation of IB by 
IKK, via the canonical NF-B pathway, results in 
subsequent ubiquitination of IB and proteasomal 
degradation. It is this degradation of IB that liberates 
NF-B, allowing its localization to the nucleus and 
the transcriptional activation of its target genes. 
This phenomenon, coined Àeld of cancerization, 
has been shown to be important in lung cancer. We 
have demonstrated than mutations in EGFR occur 
in normal appearing bronchial epithelium adjacent 
to EGFR mutant lung adenocarcinomas in never 
smoker patients, and also occurred at a higher 
frequency at sites more proximal to the tumors 
than at more distant regions. More recently, gene 
methylation patterns, as well as global mRNA and 
microRNA (miRNA) expression proÀles, have 
been described in the normal-appearing bronchial 
epithelium of healthy smokers. Importantly, 
modulation of global gene expression in the normal 
bronchial epithelium in healthy smokers is similar 
in the large and small airways, and the smoking-
induced alterations are mirrored in the epithelia of 
the mainstem bronchus, buccal and nasal cavities. 
Increasing our understanding of early phases in lung 
cancer pathogenesis will aid in the identiÀcation 
of early stage non-small cell lung cancer (NSCLC) 
patients at higher risk for recurrence or second 
primary tumor development. Recently, we have 
performed global gene expression analysis of 
the Àeld of cancerization in smoker patients with 
early stages NSCLC to better understand lung 
cancer pathogenesis and predict recurrence or 
second primary tumor development. Our Àndings 
highlight expression signatures and activation of 
cancer-related pathways in a cancerization Àeld 
that may drive lung cancer pathogenesis and be 
associated with recurrence or second primary tumor 
development in NSCLC patients. We propose that 
the study of Àeld cancerization phenomenon using 
high-throughput molecular proÀling (protein, 
mRNA, miRNA and DNA) methodologies combined 
with coupled with functional pathway analysis and 
studies of in vitro and in vivo models will provide 
promising markers to improve risk assessment, new 
targets for novel targeted chemopreventive agents, 
and selecting NSCLC patients who may beneÀt 
from chemopreventive interventions to prevent 
disease recurrence. Supported by DoD grants 
W81XWH-04-1-0142 and W81XWH-10-1-1007. 
Keywords: Àeld cancerization, Preneoplasia, 
molecular proÀling, smoker
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M19.4 MOLECULAR MECHANISMS OF 
CHEMOPREVENTIVE COMPOUNDS 
AND NOVEL APPROACHES 
(MOLECULAR IMAGING) TO ASSESS 
EFFICACY
Fadlo R. Khuri1, Shi-Yong Sun2, Johann C. Brandes3, 
Haian Fu2 
1Hematology And Medical Oncology, Emory 
University/United States Of America, 2Emory 
University/United States Of America, 3Hematology 
& Medical Oncology, Emory University-Winship 
Cancer Institute/United States Of America
Abstract: Several decades of chemopreventive 
trials for lung cancer have failed to demonstrate 
meaningful beneÀt for patients using compound 
development largely based on epidemiologic data1. 
These trials have included attempts at primary, 
secondary, and tertiary prevention of lung cancer. 
These trials focusing on primary prevention of 
lung cancer have attempted to reduce the impact 
of tobacco consumption in lung cancer patients 
and have included large trials using carotentoids, 
retinoids, vitamin E, and other natural compounds, 
which showed that continued exposure to tobacco 
smoke abrogates the anti-oxidant effects of most 
of these compounds2. Recent randomized trials 
that were initiated in patients at the highest risk for 
development of lung cancer, namely patients who 
had already been treated for a previous primary lung 
or head and neck cancer were also unsuccessful. 
These include trials of vitamin A and E derivatives3, 
as well as most recently a phase III trial that 
failed to show any beneÀt for selenomethionine 
supplementation in patients with prior stage I lung 
cancer4. However, there has been some evidence of 
progress using targeted agents in speciÀc lung cancer 
populations. Following on evidence from J.S. Lee 
that indicated that retinoids could have efÀcacy in 
reversing premalignancy in former smokers5, several 
approaches attempting reversal of pre-malignancy 
in former smokers have shown some efÀcacy. A 
targeted approach using 9-cis-retinoic acid, a pan-
retinoid agonist, proved effective in upregulation of 
RAR-ơ in pre-malignant lesions6. However, as we 
and other have demonstrated, presence of RAR-ơ 
in primary stage I lung cancers is associated with a 
poor outcome, and correlates with over-expression 
of COX-2 7,8. However, several approaches targeting 
Importantly, aberrant localization and activation 
of NF-B contributes to deregulated growth and 
resistance to apoptosis. Based on this mechanism, 
we used high content screening technology with 
an automated imaging system to monitor the effect 
of the curcumin analogs on the activation of NF-
B. We found that EF24 rapidly blocks the nuclear 
translocation of NF-B, with an IC50 value of 1.3 M 
compared to curcumin, which had an IC50 value of 
13 M. Furthermore, EF24 effectively inhibited tumor 
necrosis factor (TNF)±-induced IB phosphorylation 
and degradation, suggesting a role for this 
compound in targeting IKK. Indeed, EF24 directly 
inhibited the catalytic activity of IKK in an in vitro-
reconstituted system. Our study identiÀes IKK as a 
target of effective curcumin analogs and provides 
a molecular explanation for the superior activity 
of EF24 over curcumin. In order to discover new 
compounds that inhibit NF-B signaling pathways, 
we have designed a parallel HCS screening assay 
with two distinct activators, TNF± and Áagella. 
TNFï¡ activates IKK through the TNF receptor-
mediated TRADD/FADD signaling complex while 
Áagella trigger IKK activation through the Toll-like 
receptor 5-mediated pathway. Using this strategy, 
we intend to identify three classes of compounds, 
(i) compounds that act on common pathways for 
TNF± and Áagella, (ii) compounds that are speciÀc 
for blocking the TNF± pathway, and (iii) compounds 
that selectively block the TLR5 pathway. We have 
developed and optimized a HCS assay in a 384-
well plate format with satisfactory performance 
parameters as measured by Z’ factor and S/N ratio. 
With this HCS system, we carried out a parallel 
screening with a small molecule chemical library 
of 100,000 compounds. Progress from these studies 
will be presented. This presentation will focus on 
the use of state-of-the-art high throughput screening 
technologies for the discovery of anti-inÁammatory 
agents and for mechanism of action studies in an 
effort to develop the next generation of highly 
efÀcacious lung cancer chemoprevention agents.
Keywords: drug discovery, InÁammation, NF-kB, 
high throughput screening (HTS)
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COX-2 have started to yield evidence of intriguing 
beneÀt. Kim et al randomized 182 patients to 
celecoxib or placebo for three months with half 
the patients on each arm subsequently undergoing 
crossover. In this study, in which celecoxib was 
originally dosed at 200 mg twice daily, evidence of 
efÀcacy was seen for the COX-2 inhibitor in former 
smokers9. In fact, reduction of Ki-67 expression 
was seen in former smokers that was sustainable 
in those individuals who had six months of high 
dose celecoxib. Mao et al conducted a randomized, 
double blind, placebo controlled study of 400 mg 
b.i.d. of celecoxib or placebo to high risk former 
smokers10. This study showed that of the 137 
patients, 101 completed both baseline and six month 
bronchoscopies and were evaluable for the primary 
end point. A signiÀcant treatment effect was seen 
in that celecoxib signiÀcantly decreased Ki-67 
by an average of 34%, versus placebo. Moreover, 
decreases in Ki-67 are associated with reduction 
and/or resolution of lung nodules. The SPORE 
trial of Iloprost also showed substantial evidence 
of efÀcacy in pre-malignant lesions of former 
smokers, but not current smokers12. In order to 
better hone our development of chemopreventive 
agents, it is important to study not only the success 
of these trials through the appropriate intermediate 
biomarker, but to incorporate molecular imaging into 
our therapeutic armamentarium. We have recently 
conducted a trial of pre-operative everolimus in 
patients with resectable lung cancer that suggests 
that in former smokers, everolimus is highly 
effective in reducing metabolic uptake as assessed by 
FDG-PET in patients who take 10 mg of everolimus 
for three weeks prior to surgical resection of their 
non-small cell lung cancer12. This is consistent with 
data from Dennis et al, which suggests that blockade 
of the Akt/mTOR signaling axis leads to abrogation 
of oncogene addicted signaling pathways13. These 
biopsy driven window of opportunity trials that 
utilize surrogate biological markers and attempt to 
correlate them with changes in metabolic imaging 
will become increasingly important as we develop 
compounds that target speciÀc cell survival 
pathways, but require a more non-invasive approach. 
References: 1. Amin AR, et al. Enhanced anti-tumor 
activity by the combination of natural compounds, 
(-)-epigallocatechin-3-gallate and luteolin: potential 
role of p53. J Biol Chem, 285(45):34557-65, 2010. 2. 
Papadimitrakopoulou VA, et al. Randomized trial of 
13-cis retinoic acid compared with retinyl palmitate 
with or without betacarotene in oral premalignancy. 
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NSCLC patients. PET imaging using [11C]docetaxel 
and [11C]erlotinib provides information on the 
biodistribution of these tracers in normal organs as 
well as in tumor tissue. Tumor uptake of both tracers 
is highly variable between patients and appears to 
be associated with subsequent response to treatment 
with therapeutic doses of the corresponding drugs. 
Importantly, PET microdosing can predict tumor 
uptake of a therapeutic dose, which was shown for 
[11C]docetaxel by performing a second [11C]docetaxel 
scan during a therapeutic infusion of docetaxel. 
These Àndings indicate that PET microdosing may 
be of additional value in identifying NSCLC patients 
most likely to beneÀt from a speciÀc drug. Next to 
quantiÀcation of drug uptake itself, more insight 
into factors that affect this uptake in tumor tissue is 
warranted. [11C]erlotinib uptake is associated with 
the mutational status of the epidermal growth factor 
receptor (EGFR) in tumor tissue, whereas [11C]
docetaxel uptake is highly correlated with tumor 
perfusion. The latter indicates that administration of 
drugs that change tumor perfusion may signiÀcantly 
affect delivery of speciÀc drugs such as docetaxel to 
tumors, possibly affecting their efÀcacy. Indeed, this 
hypothesis was conÀrmed by a rapid and signiÀcant 
decline in tumor perfusion and [11C]docetaxel uptake 
in NSCLC tumors after a single dose of the anti-
angiogenic drug bevacizumab. In summary, these 
Àndings indicate that radiolabeled drugs may be 
useful to predict response to anticancer drugs in 
individual NSCLC patients. Therefore, PET using 
radiolabeled drugs may be an important technique 
for optimizing drug scheduling in NSCLC patients 
and for personalized treatment planning. 
Keywords: Non-small cell lung cancer, radiolabeled 
drugs, Positron Emission tomography
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Abstract: Measurements of tumor size on CT 
currently represent the standard for assessing tumor 
response to therapy in patients with NSCLC. CT 
has become an extremely fast and robust technique 
that provides high resolution images of the primary 
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Abstract: In the treatment of non-small cell lung 
cancer (NSCLC) patients, clinical failure of drugs 
remains a major challenge, as patients are subjected 
to therapy-related toxicity without therapeutic 
beneÀt. It is clear that there is a need for techniques 
that can predict tumor response to speciÀc anticancer 
drugs. Molecular imaging techniques, in particular 
positron emission tomography (PET), hold promise 
for early prediction of tumor response in NSCLC 
patients. In clinical practice, PET is mainly used to 
image glucose metabolism and, more recently, DNA 
synthesis using 2v-[18F]Áuoro-2vdeoxy-D-glucose 
(FDG) and 3vdeoxy-3v-[18F]Áuorothymidine (FLT), 
respectively. PET, however, can also be used to 
monitor pharmacokinetics and pharmacodynamics 
of any drug by radiolabeling with a short-lived 
positron emitting radionuclide such as carbon-11. 
As response to anticancer drugs is, at least in part, 
thought to depend on achieving sufÀcient drug 
levels in tumor tissue, assessment of drug uptake 
in tumors in vivo may be useful for understanding 
treatment failure in patients. PET using microdoses 
of radiolabeled anticancer drugs can quantify drug 
uptake in tumors and may be valuable for predicting 
outcome prior to start of treatment and, as such, may 
be an important tool for individualized treatment 
planning. Although the number of human studies is 
still limited, there is an increasing interest in PET 
studies using radiolabeled anticancer drugs, primary 
because of the potential to predict rather than to 
monitor response to treatment. At our institute, 
we have performed several clinical studies using 
radiolabeled drugs, including radiolabeled docetaxel 
([11C]docetaxel) and erlotinib ([11C]erlotinib), in 
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been published 8 . Clinical results of FDG-PET 
for monitoring tumor response In the neoadjuvant 
setting, several studies have correlated Àndings on 
FDG-PET with histopathologic tumor response 9-14. 
While these studies indicate that focal FDG uptake 
correlates with residual viable tumor tissue on 
histopathology, data on the sensitivity and speciÀcity 
of FDG-PET in this setting vary widely. To a large 
extent this is explained by different deÀnition 
of &ldquoresidual viable tumor tissue&rdquo 
and &ldquohistopathologic response&rdquo. A 
more meaningful comparison can be made for the 
correlation between tumor response assessment 
on PET and survival. Here, almost all studies have 
reported a signiÀcant correlation between changes 
in metabolic activity and patient survival as recently 
reviewed by Hicks 15. FDG-PET for monitoring of 
palliative chemotherapy in advanced NSCLC has 
also been evaluated in three single center studies 
16-18. A signiÀcant correlation between metabolic 
changes after one or two cycles of chemotherapy and 
patient survival has been observed. Furthermore, the 
studies indicate a gradual decrease in tumor FDG 
uptake during chemotherapy 17. As a consequence 
optimal threshold values for differentiation between 
responding and nonresponding tumors increase 
with time after start of chemotherapy. Preclinical 
studies19 and four clinical trials 20-23 indicate that 
tumors responding to EGFR kinase inhibitors 
also show rapid changes in FDG uptake. Early 
identiÀcation of patients with nonresponding tumors 
provides the opportunity to change treatment to 
second line regimens and may reduce the side effects 
and costs of ineffective therapies. Conclusions 
FDG-PET allows signiÀcantly more accurate 
assessment of tumor viability than CT. Furthermore, 
FDG-PET has been found to provide prognostic 
information independent from tumor response on 
CT. Nevertheless, larger conÀrmatory studies in a 
multi-center setting are needed in order to deÀne 
more exactly the prognostic value of FDG-PET in 
speciÀc clinical situations. Following evaluation 
in multicenter trials it is expected that monitoring 
tumor response in non-small cell lung cancer 
will be based on CT and PET as these modalities 
are likely to provide complementary prognostic 
information. Furthermore, in patients with locally 
advanced disease, CT will provide exact anatomical 
localization of lesions on PET, which is required for 
determining tumor respectability after preoperative 
therapy. References 1. Birchard KR, et al: Cancer 
115:581-6, 200 2. Ford R, et al: Eur J Cancer 45:268-
tumor, lymph node and distant metastases. Criteria 
for assessing response on CT have been standardized 
by the response evaluation criteria in solid tumors 
(RECIST). While clinical experience and meta-
analyses of large clinical trials demonstrate that 
tumor response according to RECIST is correlated 
with favorable outcome, the correlation is far from 
perfect and several studies did not Ànd a close 
relationship between tumor shrinkage and patient 
outcome 1. CT cannot differentiate between tumor 
and surrounding atelectasis, which can make 
size measurements inaccurate. The interobserver 
variability of assessment of tumor response in 
NSCLC by CT is signiÀcant 2. Furthermore, it 
is generally not possible to differentiate viable 
tumor tissue from treatment induced Àbrosis. 
Finally, some target therapies appear to improve 
survival without causing a rapid decrease in tumor 
size. Methodological considerations for response 
assessment by FDG-PET A series of studies has 
evaluated the use of PET with the glucose analogue 
Áuorodeoxyglucose (FDG-PET) for monitoring 
chemo- and chemoradiotherapy in NSCLC. For 
staging of malignant tumors FDG-PET scans are 
assessed visually, and focally increased FDG-uptake 
not explained by the normal biodistribution of 
FDG is considered to be suspicious for metastatic 
disease. In a similar way PET scans may also be 
read after completion of chemo- or radiotherapy. 
FDG uptake should have normalized at this time 
and focal FDG-uptake generally indicates residual 
viable tumor tissue. Following radiotherapy, 
however, care must be taken not to confuse radiation 
induced inÁammation with residual tumor tissue. 
This can usually be achieved by evaluating not only 
the intensity, but also the pattern of FDG uptake. 
Radiation induced inÁammation involves not only 
the tumor tissue, but also the normal tissues in the 
radiation treatment Àeld 3. Quantitative assessment 
of tumor metabolism is generally necessary, when 
FDG-PET scans are performed during treatment 
in order to predict subsequent tumor response. At 
this time the metabolic activity of the tumor tissue 
has decreased in responders, but generally there 
will be still considerable residual FDG-uptake. 
A series of studies have now indicated that tumor 
FDG uptake can be measured with high test-retest 
reproducibility 4-7. However, it is important to 
emphasize that quantitative analysis of FDG-PET 
scans is only feasible when images are acquired 
according to a standardized protocol. International 
guidelines for quantitative PET studies have recently 
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for enhancing glucose inÁux into cells. The glucose 
transporters GLUT-1 and GLUT-3, subtypes with 
a relatively high afÀnity for glucose, belong to the 
sugar trans-porter family, which currently includes 
133 individual members. Increased concentrations 
of the glucose phosphorylation enzyme, 
hexokinase, with decreased rates of glucose-6-
phophatase are considered to accelerate glucose 
phosphorylation, which results in enhanced FDG 
intracellular trapping. Upregulation of hexokinase 
and glucose transporters, especially GLUT-1, and 
downregulation of glucose-6-phosphatase are 
frequently associated with malignant transformation. 
Glucose transport activity can be regulated by 
alterations in the expression of GLUT transporters 
and by post-translational mechanisms, including 
transporter translocation to plasma membranes. 
It has been shown that squamous cell carcinomas 
demonstrate higher GLUT-1 expression, relative to 
adenocarcinomas. One of the factors responsible 
for the regulation of GLUT1 in malignant cells 
is hypoxia-inducible-factor-1a (HIF-1a), which 
is upregulated under hypoxic conditions. The 
increased level of lactate and acid produced by 
the enhanced glycolysis will decrease intracellular 
pH, which is potentially cytotoxic. To counteract 
this cytoplasmic acidiÀcation, cells can upregulate 
monocarboxylate transporter 4 (MCT4), which is 
composed of a catalytic unit (MCT) and an accessory 
subunit (CD147) and transports lactate/H+ out of 
the cell. In squamous cell carcinomas, GLUT-1 
and MCT4 expression increase with increasing 
distance from the vasculature, whereas upregulation 
of MCT4 is found at closer distance from vessels 
in adenocarcinomas. Adenocarcinomas rely mainly 
on aerobic glycolysis for ATP production, whereas 
the behavior of squamous cell carcinomas is more 
physiologically, i.e. mitochondrial oxidation with 
anaerobic glycolysis where appropriate. High 
GLUT-1 plus high MCT4 expression determined 
an aggressive tumor behavior in adenocarcinomas. 
Moreover, the rate of FDG uptake in the primary 
site of NSCLC has been correlated with tumor 
doubling time and proliferation rates which, in turn, 
are known to correlate with tumor aggressiveness. 
Furthermore, apoptosis plays a central role in the 
elimination of (the precursors of) tumor cells. 
Therapy resistance can be attributed, at least in 
part, to a disabled apoptotic program. Furthermore, 
it was demonstrated that primary tumors showing 
high FDG uptake have the potential to be resistant 
to therapy and to metastasize. Strong expression 
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Phys 60:412-8, 2004 4. Minn H, et al: Radiology 
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Abstract: The great advantage of 
18F-Áuorodeoxyglucose positron emission 
tomography (FDG-PET) is that this technique 
cannot only visualize but can also quantify 
glucose metabolism and thus is able to distinguish 
metabolically highly active from less active 
tumor tissues. It therefore offers an opportunity 
for noninvasive, in vivo tumor characterization. 
As many factors can inÁuence the extent of FDG 
uptake, the underlying mechanisms for FDG 
accumulation in tumors, are still a matter of debate. 
A variety of mechanisms have been proposed 
for accelerated glucose use in growing tumors 
and in transformed and malignant cells: passive 
diffusion, Na+-dependent glucose transport and via 
facilitative glucose transporters (GLUT). The latter 
is considered to be the most important mechanism 
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agents. These agents poses new demands on 
imaging modalities, for which FDG-PET is ideally 
suited, since metabolic changes precede changes in 
tumor volume. Previous studies have also shown 
that EGFR mutations are predominantly found 
in females, in never-smokers, in patients with 
adenocarcinoma, and in Asians. Altogether a very 
new and interesting topic to be studied. 
Keywords: EGFR, FDG-PET, GLUT1, hexokinase
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Abstract: Morphologic Evaluation Small sized, 
smooth, well-deÀned margins are suggestive of, 
but not diagnostic for, benignity and a lobulated 
contour or an irregular or spiculated margin with 
distortion of adjacent vessels is typically associated 
with malignancy. Diffuse, laminated, central nodular, 
and popcorn-like calciÀcations within nodules 
suggest benignity. On the other hand, eccentric 
or stippled calciÀcations have been described in 
malignant nodules. Fat or calciÀcation may be 
observed in up to 50% of pulmonary hamartoma. 
In a multivariate analysis study, a lobulated 
margin, a spiculated margin, and the absence of a 
satellite nodule are independently associated with a 
diagnosis of a malignant nodule with a higher odds 
ratio. The results of the Early Lung cancer Action 
Project (ELCAP) suggested that nodules with pure 
(nonsolid) or mixed (partially solid) ground-glass 
opacity at thin-section CT are more likely to be 
malignant than are those with solid opacity. Mixed 
ground-glass opacity, a subtype with ground-glass 
opacity in the periphery and a high-attenuation zone 
in the center, was seen much more often in malignant 
lesion (41%) than in benign lesions (7%). 
Growth Rate Assessment 
It is difÀcult to reliably detect growth in small (< 
1 cm) nodules. To overcome this limitation, it has 
been proposed that the growth rate of small nodules 
be assessed using serial volume measurements 
rather than diameter. Volumetry for ground-glass 
opacity or semisolid (solid nodule containing 
of the cysteine protease caspase-3, which is a 
key enzyme in apoptotic cell death, might be a 
signiÀcant factor to predict poor prognosis. Better 
understanding of a possible relationship between 
FDG uptake and apoptosis may provide insights into 
sensitivity or resistance of tumor cells. Furthermore, 
tumors that grow too rapidly or have a deÀcient 
vascular system are characterized by the formation 
of necrosis. Necrosis reÁects cell death caused by 
hypoxia. Hypoxia results in enhanced anaerobic 
glycolysis and hence in increased FDG uptake. 
Finally, the presence of inÁammatory cells, might 
be confounding, since inÁammatory cells may have 
a major impact on FDG uptake. At present it is still 
not fully elucidated which of these factors contribute 
to the variable levels of FDG uptake in NSCLC or 
head- and neck cancers. Results from studies on 
other tumor types cannot be extrapolated to NSCLC 
or head- and neck cancer, as different tumors have 
different glucose-regulating mechanisms and enzyme 
expression patterns in association with various 
oncogenic alterations. FDG uptake also seems to 
be a predictor of the presence of epidermal growth 
factor receptor (EGFR) mutations. The problem of 
detecting in vivo EGFR with a noninvasive approach 
is one of the most challenging in the selection of 
patients to receive EGFR inhibitors. It has been 
reported that EGFR mutation could predict favorable 
outcomes in tyrosine kinase inhibitors (TKI)-treated 
patients. This Ànding might justify the conÀrmation 
of EGFR genotype prior to TKI treatment; however, 
in clinical practice, it is often difÀcult to obtain an 
amount of tumor tissue sufÀcient for the genetic test 
in patients with advanced cancer stages, for which 
FDG-PET could provide a solution. In previous 
studies it is suggested that low standardized uptake 
values (SUVs) in primary tumors harbor a higher 
incidence of EGFR mutations, when compared 
with those with high SUVs. However, there are rare 
molecular data to explain the association between 
SUV and EGFR mutation. Although several studies 
have suggested that glucose uptake is related with 
EGFR expression its association with the EGFR 
pathway in lung cancer is unknown. Studying the 
association between FDG uptake and the presence 
of EGFR mutations can be relevant in light of 
treatment response monitoring. In contrast to 
traditional anticancer agents, the effects of tyrosine 
kinase inhibitors are cytostatic rather than cytotoxic. 
Therefore, determining treatment response based 
on anatomical criteria alone (RECIST) probably 
underestimates the therapeutic effect of these 
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primary pulmonary malignancies, such as carcinoids, 
bronchioloalveolar carcinomas, adenocarcinoma 
with predominantly bronchioloalveolar carcinoma 
component, and malignant SPNs of < 10 mm in 
diameter. FDG PET yields false-negative results 
in about 5% of all T1 lung cancers, but in only 3% 
of T1 lung cancers greater than 5 mm in diameter. 
The long-term survival of patients with a negative 
PET scan for lung cancer suggests that these tumors 
behave indolently. Diffusion-Weighted MR Imaging 
(DWI) Diffusion-weighted MR imaging is based 
on single-shot echo-planar imaging. It allows to 
measure microscopic water mobility (Brownian 
motion). Decreased diffusion is seen in pathologic 
processes including malignant tumor (increased 
cellularity, Àbrosis, shape of intercellular spaces, 
etc). Thus, it provides functional information. 
By applying certain cut-off value of apparent 
diffusion coefÀcient (ADC), benign lesions can be 
differentiated from malignant ones. The ADC values 
are smaller in small cell carcinoma than in non-small 
cell carcinoma. Among non-small cell carcinomas, 
poorly-differentiated adenocarcinoma or squamous 
cell carcinoma has less ADC value than well-
differentiated adenocarcinoma or adenocarcinoma 
in situ. Characterization of Sub-centimeter Nodules 
Since the introduction of helical and multi-
detector row CT, the detection of small pulmonary 
nodules < 10 mm has become routine. However, 
characterization of nodule < 10 mm in diameter is 
a challenge to radiologists. Although nodules < 10 
mm in diameter have low chance of being malignant, 
the reported percentage of malignancy varies from 
the series. Currently, serial volume measurements on 
nodules are regarded as most reliable technique for 
small nodule characterization. Helical dynamic CT is 
another reliable modality for nodule characterization. 
However, thin-section (1.0-mm section thickness 
or less) images with large coverage along z-axis 
are required especially for nodule characterization 
located in the lower lung zone, where respiratory 
excursion of the lungs is great. PET or PET/CT is 
suboptimal for the characterization of sub-centimeter 
nodules, because spatial resolution (currently 7 
mm in maximum) is insufÀcient for detection of 
malignant sub-centimeter nodules. Therefore, it is 
necessary to provide practical guidelines for the 
follow-up and management of indeterminate small 
pulmonary nodules. Very small (3-5 mm) well-
deÀned nodules (sometimes called ‘’ditzels’’) has 
been more encountered with the advent of multi-
detector row CT. Treatment decisions regarding these 
ground-glass opacity component) nodules is more 
difÀcult than that of purely solid nodules, because 
the nodules have lower nodule-to-lung parenchyma 
contrast ratio compared to that of solid nodules. 
Hemodynamic Characteristics by Helical Dynamic 
CT The evaluation of tumor vascularity with HDCT 
has proved to be useful in the differentiation of 
malignant and benign nodules. Various threshold 
attenuation values have been reported to be useful 
for distinguishing malignant nodules from benign 
nodules by HDCT. The threshold attenuation 
values refer to the cut-off HounsÀeld Units 
(HUs) of increased attenuation following contrast 
injection for differentiating malignant nodules from 
benign nodules. Evaluation of SPNs by analyzing 
combined wash-in and wash-out characteristics at 
dynamic CT allows more precise evaluations of 
nodule hemodynamics. In addition, the efÀcacy 
of tissue characterization has improved, and now 
sensitivities and speciÀcities of more than 90% are 
achieved using evaluations of wash-out patterns 
in the delayed dynamic phase. Application of the 
dual energy (DE) technique provides a virtual 
nonenhanced and an iodine-enhanced image from 
a single scanning after iodine contrast material 
injection by material differentiation of iodine. With 
this technique, we are able to detect calciÀcation on 
a virtual nonenhanced image and directly measure 
the iodine component on an iodine-enhanced 
image. Thus, the technique prevents additional 
nonenhanced scanning and the patient’s radiation 
exposure can be reduced. Metabolic Characteristics 
by 18F-Áuorodeoxyglucose (FDG) Positron 
Emission Tomography (PET) Malignant cells have 
upregulated metabolisms and proliferate rapidly. 
Comparable enhancements of glucose and FDG 
uptake in malignant cells have permitted malignancy 
detected by PET, which is considered an accurate, 
noninvasive diagnostic test, with a sensitivity of 
88-96% and a speciÀcity of 70-90% for malignant 
nodules. Integrated PET/CT provides more 
anatomic detail, and improved non-small cell lung 
cancer staging accuracy versus PET alone or CT 
alone. SPNs with increased FDG uptake should be 
considered malignant, although false-positive results 
can be obtained in patients with infectious and 
inÁammatory processes such as active tuberculosis, 
histoplasmosis, and rheumatoid nodules. The high 
speciÀcity of FDG PET for the diagnosis of benign 
lesions has important clinical utility. Lesions 
with low FDG uptake may be considered benign. 
However, false negative results may be seen in 
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and type B3 have common and recurrent copy 
number losses and gains in several areas of the 
genome. Gene expression arrays cluster thymomas 
according to WHO classiÀcation. A major limitation 
in these studies is the necessity to select areas in 
the tumor that have a signiÀcant epithelial tumoral 
component, and this leaves out a large proportion of 
thymomas that have large lymphocytic inÀltration 
(WHO B1 and B2). We have recently started a 
large effort of RNA sequencing, exome sequencing 
and whole genome sequencing, and some of those 
results will be presented at this meeting. Functional 
studies in thymomas are severely hampered by the 
very limited number of cell lines and the absence 
of speciÀc tumor models for the disease. Efforts 
should be made to develop tumor models that allow 
investigation of this tumor in more detail in the 
future. 
Keywords: Thymoma, biology, mediastinum, 
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M21.3 STAGING SYSTEM
Kazuya Kondo 
Department Of Oncological Medical Services, 
Institute Of Health Biosciences, The University Of 
Tokushima Graduate School/Japan
Abstract: The clinical staging system for thymoma 
was Àrst introduced by Bergh and associates in 
1978, later modiÀed by Wilkins and Castleman, 
and conÀrmed by Masaoka and associates in 1981. 
The Masaoka clinical staging classiÀcation is the 
most widely accepted nowadays. A modiÀcation 
of this classiÀcation was suggested by Koga et al 
in 1994. In France, multiple centers have adopted 
the Groupe dEtudes des Tumeurs Thymiques 
(GETT) staging system, as described by the French 
Study Group on Thymic Tumours in 1991. In this 
system, the predominant feature is the extent of 
surgical resection. The clinical staging of patients 
should be determined before treatment to select the 
optimal approach. The TNM system classiÀcation 
and clinical staging system for thymic epithelial 
tumors have not been established yet. Until now, 
four TNM staging systems have been proposed: 
Yamakawa and Masaoka in 1991 (Y-M system), 
Tsuchiya et al. in National Cancer Center Hospital 
of Japan in 1994 (NCCHJ system), the WHO 
Consensus Committee in 2004 (WHO system) and 
nodules vary depending on the patient’s age, risk 
of malignancy, risk of developing granulomatous 
disease. Regarding radiologists’ interpretation of 
and management decision for these nodules, most 
radiologists recommended short-term follow-up, 
with less aggressive recommendations in cases 
with a lower likelihood of malignancy and more 
aggressive recommendations in cases with a higher 
likelihood of malignancy. 
Keywords: Solitary pulmonary nodule, 
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M21.1 BIOLOGY
Giuseppe Giaccone, Iacopo Petrini, Yisong Wang 
Medical Oncology Branch, National Cancer 
Institute/United States Of America
Abstract: The biology of thymic malignancies 
is poorly understood. Studies investigating one 
or a small number of genes, that are involved 
in cancer development of other tumors, are 
available, to date. These studies have established 
EGFR and c-Kit mutations in a small subset of 
tumors. Clinical observations have conÀrmed that 
activating mutations in these genes are rare and 
this is responsible for the lack of activity of EGFR 
TKIs such as geÀtinib and c-Kit inhibitors such as 
imatinib. Mutations in p53 and methylation of p16 
have also been described in a varying percentage 
of tumors, as well as upregulation of anti-apoptotic 
genes. However, all these descriptive studies have 
in common the relatively small number of samples 
that were investigated and the limited insight on the 
biology that they provide. Genome-wide studies have 
also been performed. Genetic alterations involving 
changes of large parts of chromosome 1 (1q copy 
number gains) and deletions of chromosome 6 have 
been established by traditional CGH over a decade 
ago. Use of array CGH has allowed us to narrow 
down areas of the genome that may be important 
for prognosis and potentially be involved in the 
progression of the disease. Overall type A thymomas 
according to the WHO classiÀcation, have very few 
changes in copy number, whereas thymic carcinoma 
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between N factor and clinical staging system is 
different. It is very important to determine how T, N 
or M factors inÁuence prognosis of the patients with 
thymic epithelial tumors to establish a suitable TNM 
system classiÀcation. The International Thymic 
Malignancy Interest Group (ITMIG) is currently 
engaged in the development of a validated formal 
stage classiÀcation system for thymic malignancies, 
together with the IASLC and under the auspices 
of the UICC and AJCC in preparation for the next 
edition of the international tumor staging manuals 
in 2017. In order to collect reliable and large-
scale clinicopathological and prognostic data of 
thymic epithelial tumors, ITMIG has chosen to 
use the Masaoka-Koga stage classiÀcation system, 
consistent with what has been adopted most broadly. 
In the Masaoka-Koga stage system, many nuances 
have never been clearly deÀned and are often 
interpreted differently. The deÀnitions adopted 
by ITMIG deÀned precisely what constituted 
mediastinal pleural or pericardial involvement, and 
required that macroscopic suspicion of involvement 
should be conÀrmed microscopically for pathologic 
stage. ITMIG hopes that this standard will be 
adopted worldwide, as it will enhance collaboration 
and deÀnition of a better classiÀcation system 
in the future. ITMIG DeÀnition of Details of the 
Masaoka-Koga Staging System I : Grossly and 
microscopically completely encapsulated tumor II a: 
Microscopic transcapsular invasion IIb: Macroscopic 
invasion into thymic or surrounding fatty tissue, 
or grossly adherent to but not breaking through 
mediastinal pleura or pericardium III: Macroscopic 
invasion into neighboring organ (i.e. pericardium, 
great vessel or lung) IV a: Pleural or pericardial 
metastases IVb: Lymphogenous or hematogenous 
metastasis
Keywords: Thymoma, clinical staging system, 
prognostic factors, Thymic Carcinoma
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M21.4 CHEMOTHERAPY FOR THYMIC 
MALIGNANCIES
Patrick J. Loehrer Sr. 
Department Of Medicine, Indiana University Melvin 
And Bren Simon Cancer Center/United States Of 
America
Abstract: Thymomas and thymic carcinomas 
are rare epithelial tumors, but represent the most 
Bedini et al. in National Cancer Institute of Italy in 
2005 (NCII system). The Masaoka classiÀcation is 
now the most widely accepted and is an excellent 
predictor of the prognosis of thymoma. However, 
several articles have pointed out problems and have 
suggested that an update of the system is desirable. 
These TNM systems for thymic epithelial tumors 
revised Masaoka staging system. 1) The Masaoka 
clinical staging system does not provide appreciable 
prognostic separation between stage I and II. 
NCCHJ system and NCII system combined stage I 
and stage II in the Masaoka system, reclassiÀed as 
stage I. 2) Some deÀnitions in the Masaoka system 
are not clinically applicable because surgical or 
pathological assessment is required. In particular, the 
deÀnition of stage II is unclear. Some pathologists 
propose that microscopic invasion into the capsule 
in stage II should be replaced by microscopic 
transcapsular invasion. NCCHJ and WHO systems 
deÀned T2 thymoma as tumor invades pericapsular 
connective tissue. 3) As stage III thymoma is 
highly heterogenous in terms of involved organs, 
classiÀcation should divide the subgroups according 
to the prognosis. Some studies reported that 
involvement of the great vessels is an independent 
prognostic factor in patients with stage III thymoma. 
Four TNM systems did not divide stage III in 
Masaoka system into subclassiÀcations. Large-scale 
clinicopathological and prognostic data of thymic 
epithelial tumors in stage III subgroups such as 
invasion to the pericardium, great vessels, lung, 
sternum, phrenic nerve, etc, are essential to classify 
suitable groups. 4) Most of the reports about thymic 
epithelial tumors demonstrated that the completeness 
of tumor resection is the most important predictor 
of survival not only in thymoma but also in thymic 
carcinoma, although a value of so-called debulking 
procedures is controversial. NCII system proposed 
that the residual tumor is classiÀed by use of the R 
category. Although the clinical staging of patients 
should be determined before treatment to select the 
optimal approach, R category may be useful for 
predicting the prognosis after surgery. 5) Although 
the Masaoka clinical stage is an excellent predictor 
of the prognosis of thymoma, it is not well suited 
for staging thymic carcinomas. Although the 
deÀnition of T, N and M factors is similar among 
four TNM systems (N0: no lymph node metastasis 
N1: metastasis to anterior mediastinal lymph nodes, 
N2: metastasis to intrathoracic lymph nodes except 
anterior mediastinal lymph nodes, N3: metastasis 
to extrathoracic lymph nodes), the relationship 
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Finally, another trial conducted by ECOG evaluated 
carboplatin plus paclitaxel in patients with advanced 
thymoma and thymic carcinoma resulted in an 
overall response rate of 34.8% and 28.6% in patients 
with thymoma and thymic carcinoma respectively. 
The median overall survival was 84.1 months for 
patients with advanced thymoma where as it was 
only 15.4 months in thymic carcinoma patients. In 
sum, each of these non-anthracycline containing 
regimens produced response rates which appear 
inferior to previous reports with anthracycline–based 
regimens. Collectively, trials conducted by the 
Eastern Cooperative Oncology Group and others 
have suggested that combinations which contain 
anthracyclines have produced higher objective 
response rates (70-90%). The most active single 
agents in advanced thymic tumors appear to be 
cisplatin, corticosteroids, doxorubicin, and alkylating 
agents. Clinical trials agents remains limited, but 
case reports and small series have suggested activity 
with a broad range of agents, including: ifosfamide, 
octreotide (with or w/o prednisone), pemetrexed, 
gemcitabine, soraÀnib(thymic carcinoma), 
Áuoropyrimidines and most recently, belinostat. 
Trials with more targeted therapies with drugs 
such as geÀtinib, erlotinib, bevacizumab, imatinib 
have not demonstrated major clinical activity. This 
presentation will provide an overview of the past 
clinical trials and discuss issues relevant to future 
clinical and translational research. 
Keywords: Thymic Carcinoma, Chemotherapy, 
Thymoma
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M23.1 NURSING SUPPORT
Liz Darlison 
Mesothelioma UK, University Hospitals Of Leicester 
NHS Trust/United Kingdom
Abstract: This abstract highlights the broad 
range of Cancer Nurse Specialists (CNS’s) 
common tumors of the anterior mediastinum. 
Prospective studies on the treatment of thymic 
epithelial tumors are limited due to the very low 
incidence of these tumors. Up to one third of 
patients with thymoma and the majority of patients 
with thymic carcinoma will have locally advanced 
or metastatic disease at presentation for which 
chemotherapy should be considered a component of 
the therapeutic armamentarium. Most combination 
regimens have been platin-based with cisplatin, 
doxorubicin and cyclophosphamide (PAC) with or 
without other agents, cisplatin plus etoposide (PE), 
or carboplatin plus paclitaxel as commonly used 
regimens. Anthracycline-based regimens are the 
standard of care based on various phase II clinical 
trials. Fornasiero and colleagues reported on 37 
patients with stage III and IV thymoma who were 
treated with cisplatin, doxorubicin, vincristine 
and cyclophosphamide (ADOC) combination 
chemotherapy. The overall response rate was 91.8% 
(with 43% CR) but a median survival time of only 
15 months. An intergroup trial in 29 thymoma and 
one thymic carcinoma patients with metastatic or 
progressive locally advanced disease treated with 
cisplatin, doxorubicin and cyclophosphamide(PAC) 
demonstrated an overall 50% response rate (10% 
CR) and a median survival of 37.7 months (Loehrer 
et al). In another phase II study of multidisciplinary 
approach with induction chemotherapy, followed 
by surgical resection, radiation therapy and 
consolidation chemotherapy for unresectable 
thymomas, Kim and colleagues reported on 22 
patients receiving induction chemotherapy with 
PAC plus prednisone for three cycles. Induction 
chemotherapy produced 14% complete responses 
and 63% partial responses. Because thymic 
cancers often occur in elderly patients, the use of 
anthracyclines may be limited in this population, 
based on cardiac history and a possible need to use 
radiotherapy. Therefore non-anthracycline regimens 
may be preferable for this group of patients. The 
European Organization for Research and Treatment 
of Cancer (EORTC) conducted a trial with 16 
patients with advanced or recurrent thymoma were 
treated with cisplatin and etoposide (PE) with 
an overall RR of 56%. The Eastern Cooperative 
Oncology Group (ECOG), twenty patients with 
advanced thymoma and eight patients with thymic 
carcinoma were treated with etoposide, ifosfamide 
and cisplatin (VIP). A RR of 35% and 25% (all 
partial responses) was reported in patients with 
thymoma and thymic carcinoma respectively. 
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based specialist palliative care and District Nurses 
was one issue raised by the benchmarking exercise 
and following discussion this was developed into 
a project to be addressed by the Lung Cancer CNS 
team. The UHL Lung Cancer CNS’s team went on to 
complete a year long project looking at and reÀning 
referral patterns to Community Palliative Care and 
District Nurses resulting in redesigned services that 
avoid inappropriate referrals and maximise current 
resources. References 
1. National Cancer Action Team 2010 .Quality in 
Nursing. Clinical Nurse Specialists in Cancer Care; 
Provision, Proportion and Performance. A census 
of the cancer specialist nurse workforce in England 
2010. 
2. National Cancer Action Team 2010. Excellence in 
Cancer Care: The Contribution of the Clinical Nurse 
Specialist 
3. Department of Health, 2010. National Cancer 
Patient Experience Survey Programme – 2010 : 
National Survey Report. 
4. Department of Health, 2008. End of Life Care 
Strategy. 
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Abstract: Lung cancer patients have many more 
needs than just treating their disease. They may have 
pain or other physical symptoms such breathlessness. 
They may be anxious or depressed. If they have 
advanced, incurable disease they will need to make 
an advanced care plan. Their families need support. 
To address all of these needs, comprehensive care 
of lung cancer patients requires the pulmonologist, 
surgeon and/or oncologist to develop and co-
ordinate a care plan delivered by interdisciplinary 
group. This may include referral to a palliative care 
(PC) specialist. In 2011 most lung cancer care is 
ambulatory, and early involvement of specialist PC 
in the outpatient setting has been shown to improve 
symptom control, quality of life and other outcomes. 
With a few exceptions, most hospitalizations 
of patients with advanced lung cancer is for 
currently practicing in England. Detail about 
the role and function of CNS’s working in lung 
cancer is explored and the beneÀts of the role are 
demonstrated through an End of Life Care Project 
carried out by the Lung Cancer CNS team working 
at the University Hospitals of Leicester NHS Trust 
(UHL). A census of the English cancer specialist 
nurse workforce carried out in 20101 demonstrated 
there are nearly 2800 tumour speciÀc (breast, lung, 
Urology etc) cancer nurse specialists in England. 
The census describes 284 nurses as working in lung 
cancer which mirrors the National Lung Cancer 
Forum for Nurses2 membership of 280 members. The 
National Cancer Action Team describes the high-
level activities of Cancer CNS’s separating them into 
four main functions3. 
1. Using and applying technical knowledge of cancer 
and treatment to oversee and coordinate services, 
personalise ‘the cancer pathway’ for individual 
patients and to meet the complex information and 
support needs of patients and their families 
2. Acting as the key accessible professional for the 
multidisciplinary team, undertaking proactive case 
management and using clinical acumen to reduce the 
risk to patients from disease or treatments 
3. Using empathy, knowledge and experience to 
assess and alleviate the psychosocial suffering 
of cancer including referring to other agencies or 
disciplines as appropriate 
4. Using technical knowledge and insight from 
patient experience to lead service redesign in order 
to implement improvements and make services 
responsive to patient need Much has been written 
about the beneÀt to patients and carers of having 
access to a clinical nurse specialist, most recently in 
the 2010 Cancer Patient Experience Survey Report4. 
SpeciÀc questions regarding access to a CNS were 
included in the survey for the Àrst time and results 
clearly showed how much patients value access to a 
CNS with responses reporting a better experience in 
numerous areas. In 2008 the Department of Health 
published the End of Life Care Strategy5 and in order 
to embrace the actions and recommendations set out 
in the strategy the UHL carried out a benchmarking 
exercise of current end of life care practice within the 
hospital. The benchmarking exercise which involved 
9 clinical directorates and palliative care services 
highlighted several examples of good practice 
however there were also inconsistencies across UHL 
suggesting uncertainty with some aspects of end of 
life care. Inconsistencies and uncertainty about how 
best to communicate with and refer to primary care 
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education, pain management, psychosocial support, 
request consultation, other symptom management, 
advanced care planning, (clarify code status identify 
health care proxy, arrange family conference) and 
spiritual support. Further clinical investigations 
were occasionally recommended. In approximately 
one-third of consults, the patient’s/family’s PC 
needs were deemed to be “simple”, i.e. manageable 
by the oncologists or hospitalists leading the GI 
inpatient team, with only curbside advice from the 
PC specialist. These oncologists and hospitalists 
develop substantial skills in handling simple PC 
issues in hospitalized patients. There are various 
other short and long term outcomes of this project, 
which are currently being analyzed. Patients 
were also asked to rate their symptoms using 
the condensed Memorial Symptom Assessment 
Schedule at the time of screening and 4 days later, 
and to complete a simple satisfaction survey on 
their care, and the impact of the PPC consult; we 
are looking at the changes in symptoms scores 
between Day 0 and Day 4, and patient satisfaction 
with the PPC consult. We are also evaluating if PC 
consultation impacted on length of stay, code status, 
ICU admissions, hospice enrollment, readmission, 
aggressiveness of treatment in the Ànal month of 
life, or survival. This data is still being collated and 
analyzed. In conclusion, hospitalized lung cancer 
patients have a high prevalence of PC needs. Many 
if not most hospitals now have palliative programs, 
and specialist advice is able to assist with these 
patients’ complex needs. Given that the need is far 
in excess of the available resources of specialist PC 
services, the next challenge is to determine which 
patients should be seen by those services during 
their hospitalization, what the services offer, and 
whether it adds value to the care already being 
given. These issues will be discussed during the 
presentation. References 1. Temel JS, Greer JA, 
Muzikansky A, et al. Early PCfor patients with 
metastatic non-small-cell lung cancer. N Engl J 
Med 2010;363:733-42. 2. Virik K, Glare P. ProÀle 
and evaluation of a palliative medicine consultation 
service within a tertiary teaching hospital in Sydney, 
Australia. J Pain Symptom Manage 2002;23:17-
25. 3. Vernooij-Dassen MJ, Groot MM, van den 
Berg J, et al. Consultation in palliative care: the 
relevance of clariÀcation of problems. Eur J Cancer 
2007;43:316-22. 4. Casarett D, Pickard A, Bailey 
FA, et al. Do palliative consultations improve patient 
outcomes? J Am Geriatr Soc 2008;56:593-9. 6. 
Glare P, Plakovic K, Griffo Y, et al. Fast-tracking 
complications of progressive disease or debilitation, 
or toxicity of palliative chemotherapy. These 
hospitalizations are typically short and focused on 
acute medical management. Most large US hospitals 
(>50 beds) now have a PC program/support team, 
but their role is not as well established as in the 
clinic. These programs may be effective, but the data 
are difÀcult to synthesize because of variations in 
the structure, role, scope and degree of integration. 
Usual “consult etiquette” leaves the decision to 
call a PC consult as the prerogative of the treating 
physician. However, the number of patients with PC 
needs is much higher than the number of consults 
called. A German study of hospital physicians found 
18% lung cancer patients had PC needs. A snapshot 
survey by nurses of PC needs in inpatients at 
Memorial Hospital (MH) revealed 58% patients with 
metastatic lung cancer had poor performance status, 
life threatening complications, symptom control 
problems or end of life issues, but only 11% got PC 
consults. The same applies to GI Oncology patients, 
and a quality improvement project to improve 
access to specialist PC for hospitalized GI Oncology 
patients at MH was undertaken. The results should 
be directly applicable to hospitalized lung cancer 
patients. During this past winter (11/1/10-1/28/11), 
the National Comprehensive Cancer Network’s 
PC Guideline was implemented to screen 254 
consecutive GI Oncology patients admitted to MH. 
Floor nurses did the screening and most rated it 
as simple, easy, quick (<5 minutes/patient) and 
helpful, and not a burden when added to their other 
duties. A subset of 104 patients was also evaluated 
by the Guideline’s referral criteria; 66 (58%) met 
the criteria and a PC consult was requested if the 
oncologist concurred. 38 consults were able be done. 
28 consults were missed for various reasons (e.g. 
patient already seen emergently before screening; 
patient not on Áoor during consult rounds; oncologist 
pushback). More than 1/3 of patients got a consult. 
While there was no exact target, but we did expect 
to do consultations in 50-75% but the number done 
was still much higher than the usual level (10%). 
The actual content of the consults was evaluated. 
The median number of PC problems per case was 
three. They included pain, non-pain symptoms, 
psychosocial or spiritual problems, patient/family 
having trouble accepting options are limited, and 
assisting with dispo planning. Recommendations 
made by the PC physician at consultation were 
(in descending order of frequency): disposition 
planning/facilitate hospice transition, patient 
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was 86%. Median PFS was 13.9 and 10.5 months 
in the Àrst and second line settings respectively. 
Common toxicities included diarrhea, rash and 
nail changes. Following on from these results, two 
phase 3 studies are underway evaluating afatinib 
as Àrst line therapy in patients with stage 3B or 4 
adenocarcinoma and activating EGFR mutations. 
The Àrst is an open label study comparing afatinib 
(40 mg daily) to chemotherapy with cisplatin and 
pemetrexed, with a primary endpoint of progression 
free survival. This study completed accrual in early 
2011, and results are awaited. The other is a study 
of similar design which is still accruing patients, 
using cisplatin and gemcitabine as the chemotherapy 
comparator. Afatinib has been evaluated in a double 
blind, placebo controlled phase 3 study in patients 
with stage 3B or 4 adenocarcinoma of the lung 
who had progressed following treatment with 1 
or 2 lines of chemotherapy (including a platinum) 
and at least 12 weeks of treatment with erlotinib 
or geÀtinib. The primary endpoint of the study 
was OS, with PFS, response, quality of life and 
safety as secondary endpoints. 585 patients were 
randomised to afatinib or placebo (2:1 in favour of 
afatinib) between 5/2008 and 9/2009. Median OS 
was similar in both arms (placebo 11.9 months, 
afatinib 10.7 months, HR 1.07, p=0.74) despite 
a better RR (13% vs. 0.5%), and better PFS (3.3 
vs. 1.1 months) in the afatinib treated patients. 
Unexpectedly, for a population that had received 
2 or 3 lines of treatment prior to study entry, 60 
to 70% of patients had chemotherapy subsequent 
to study treatment, and this may have confounded 
the survival results. In a sub-group analysis, those 
patients whose tumors were likely to have had 
EGFR mutations based on clinical features (CR/
PR and or duration of >48weeks with prior EGFR 
TKI) seemed to derive more beneÀt from afatinib. 
However, the results of EGFR mutation analysis 
will be required to understand these observations. 
Ongoing studies with afatinib are evaluating its role 
in tumors with Her2 overexpression, and the beneÀt 
of continuing afatinib beyond the time of objective 
progression, in combination with chemotherapy, 
in patients who have had prior chemotherapy and 
EGFR TKIs. PF299804 is an irreversible inhibitor of 
EGFR, Her2, and Her4, with clinical data available 
in the 1st line, 2nd / 3rd line, and refractory (post 
EGFR TKI) settings. In a phase 2 study untreated 
patients with advanced adenocarcinoma were 
clinically selected (never or light ex smokers, Asian, 
or non Asian but K-Ras wild type). 74 patients were 
aplliative care consults: pilot implementation of 
National Comprehensive Cancer Network (NCCN) 
PC screening and referral guideline (Abstract for 
Electronic Publication only: ID e19636). In: ASCO 
Annual Meeting. Chicago; 2011. 
Keywords: palliative care, consultations, 
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M24.3 IRREVERSIBLE EGFR 
INHIBITORS: CLINICAL DATA
Michael Boyer 
Medical Oncology, Sydney Cancer Centre/Australia
Abstract: EGFR inhibitors, such as geÀtinib 
and erlotinib, are used widely in the treatment of 
advanced non-small cell lung cancer (NSCLC) 
in both Àrst and subsequent lines of treatment. 
However, de-novo or acquired resistance limits the 
efÀcacy of these agents. Irreversible inhibitors of 
the EGFR have been developed in an attempt to 
limit the impact of resistance, especially that caused 
by the exon 20 T790M mutation. Clinical data are 
available for several irreversible EGFR tyrosine 
kinase inhibitors, including EKB 569, neratinib, 
canertinib, afatinib, and PF299804. However, only 
afatinib and PF299804 are continuing to undergo 
development in NSCLC and further discussion will 
be limited to these drugs. Afatinib (BIBW2992) is 
an irreversible inhibitor of both EGFR and Her2 
tyrosine kinases. In a phase 2 study carried out 
in Taiwan and the USA, afatinib was evaluated 
in patients whose tumors were known to have an 
activating EGFR mutation, and who were either 
chemo-naÃ¯ve or had previously received one line 
of chemotherapy. The primary endpoint of this open 
label, single arm study was response rate (RR), with 
secondary endpoints that included progression free 
survival (PFS), overall survival (OS), safety, and 
clinical beneÀt. Treatment was with afatinib 50 mg 
daily, but a high rate of dose reductions for adverse 
events resulted in this being reduced to 40 mg daily 
for the Ànal 30 patients in the trial. 129 patients 
were accrued, 68 of whom were chemo-naive. The 
CR + PR rate was 61%, and the CR + PR +SD rate 
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M25.2 MI-RNA IN LUNG CANCER
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Department Of Internal Medicine, National Taiwan 
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Abstract: Lung cancer is the leading cause of cancer 
mortality worldwide. Delayed diagnosis and poor 
treatment outcome are the unsolved obstacles for 
most physicians in treating the lung cancer patients. 
More than 75% of lung cancer patients are stage III 
and IV diseases at diagnosis. The overall treatment 
outcome of lung is poor and more than 30% of 
patients with early stage non-small cell lung cancer 
(NSCLC) will develop metastasis within 5 years 
after curative surgery. Recent genetic epidemiology 
and pharmacogenomic studies revealed that lung 
cancer in different ethnic groups, particularly in 
East Asia, is a distinct disease entity and different 
from the Caucasian population. NSCLCs in East 
Asia have higher prevalence of female non-smoker 
lung adenocarcinoma (>50%) and EGFR mutations 
(40-50% in female non-smoker adenocarcinoma).
The rapid increase in non-smoker adenocarcinoma 
both in men and women has become an emergent 
health threat to East Asian population. There is an 
urgent need to develop an effective strategy for 
identiÀcation of the high risk patients and detect 
lung cancer in earlier stage. The current staging 
system for NSCLC is inadequate to predict outcome 
of treatment. To identify biomarker and develop an 
outcome prediction model for personalized therapy 
of lung cancer is the most important goal of cancer 
genomics. The biomarker can be classiÀed into 
three types. The prognostic markers are biomarkers 
that can be used to estimate patients’ outcome 
independent of therapeutic decision. The predictive 
markers are biomarkers that can help to make 
therapeutic decision for the patients. The diagnostic 
biomarkers are biomarkers that can assist disease 
diagnosis, disease subclassiÀcation and monitoring 
of the therapeutic response for the patients. Recent 
advances in lung cancer genomics have revealed 
enrolled between 3/2009 and 5/2010 and treated 
with PF299804 at 45 mg daily (later modiÀed to a 
starting dose of 30 mg daily with dose escalation 
if tolerated). EGFR mutations occurred in 34 of 
42 (81%) patients with available samples. Overall 
RR was 42% in all patients and 55% in those with 
known EGFR mutations. PFS data remain immature. 
Common toxicities included rash, diarrhea, hand 
foot syndrome and stomatitis. PF299804 has also 
been compared to erlotinib in a randomized phase 
2 study in patients who had received 1 or 2 lines 
of prior chemotherapy, but not otherwise selected. 
The primary endpoint was PFS. 188 patients were 
randomized between 10/2008 and 11/2009. Median 
PFS was 12.4 months in the PF299804 arm and 8.3 
months in the erlotinib arm (HR 0.68, p=0.019), 
while response rates were 17% and 4% in these arms 
respectively. EGFR mutations were present in 20% 
in the PF299804 arm and 12% in the erlotinib arm. 
Toxicities were similar to those observed in other 
PF299804 studies, though rash and diarrhea were 
more common than with erlotinib. Patient reported 
outcomes indicate that these toxicities were tolerable 
and improved over time. In the refractory setting, 
data are available from two phase 2 studies, one 
performed in Korea, the other in the USA. Both 
included patients who had previously been treated 
with at least one line of chemotherapy as well as 
erlotinib or geÀtinib, and whose tumours were 
either K-Ras wild type or EGFR mutant. In the 
Korean study, amongst 43 patients a RR of 17% was 
observed, with median PFS of 15 weeks. In the US 
study, amongst 66 patients RR was 5%, with PFS of 
11 and 19 weeks in the absence and presence of an 
EGFR mutation respectively. In both studies, patient 
reported outcomes indicate that adverse effects did 
not have a major impact on patients, and that some 
disease related symptoms may have improved with 
treatment. A double blind phase 3 study (NCIC 
BR26) comparing PF299804 to placebo in patients 
who have progressed following 1 or 2 lines of 
chemotherapy as well as erlotinib or geÀtinib is 
currently accruing.
Keywords: PF299804, Afatinib, Irreversible EGFR 
TKI
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miR-146b has been identiÀed as a predictor of 
overall survival in SCC. High miR-146 expression 
correlated with a poor overall survival in SCC 
patients. In summary, the current understanding of 
miRNAs involved in lung cancer progression has 
highlighted their potential to serve as biomarkers 
for lung cancer risk stratiÀcation and outcome 
prediction. The miRNA biomarkers and signatures 
may need further validations by prospective study to 
conÀrm their clinical applicability for personalized 
therapy of lung cancer patients. 
Keywords: Lung cancer, microRNA, biomarker
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M25.3 PROTEOMICS IN LUNG CANCER
Eric B. Haura 
Thoracic Oncology, MofÀtt Cancer Center/United 
States Of America
Abstract: Advances in mass spectrometry-based 
proteomics now allows molecular snapshots of 
systems and networks formed by cancer genes. 
Similarly, chemical proteomics can enable 
mapping of drugs to targets in cancer cells. These 
approaches can enable unbiased and system wide 
views of cancer signaling networks and potential 
therapeutic insertion points. We have used afÀnity 
puriÀcation coupled with liquid chromatography 
- mass spectrometry (LC-MS/MS) to elucidate 
networks driven by oncogenic forms of the 
epidermal growth factor receptor (EGFR) and 
translocation of echinoderm microtubule associated 
protein like 4 – anaplastic lymphoma kinase 
(EML4-ALK). Mutations in EGFR or EML4-ALK 
rearrangements deÀne two unique subsets of lung 
cancer characterized by hypersensitivity to small 
molecule tyrosine kinase inhibitors (TKI). Despite 
striking results with kinase inhibitors directed 
against these targets, not all patients respond, the 
drugs are non-curative, and resistance remains a 
consistent problem. We characterized signaling 
networks driven by EGFR mutations and EML4-
ALK using tandem afÀnity puriÀcation (TAP) and 
liquid chromatography-mass spectrometry (LC-MS/
MS) to map protein-protein interactions and anti-
phosphotyrosine immunoprecipitation coupled with 
LC-MS/MS to map tyrosine phosphorylation. An 
ongoing functional analysis including siRNA and 
small inhibitor screen will functionally validate 
that more than 50% of driver mutations of lung 
adenocarcinoma may be identiÀed, such as EGFR 
activating mutations, KRAS mutation, c-MET, 
RAF, EML4-ALK and others. Several of these 
mutations can be served as predictive markers to 
predict favorable treatment response to speciÀc 
targeted therapy, such as EGFR mutation for 
EGFR-TKIs (GeÀtnib, Erlotinib and Afatinib) and 
EML4-ALK for Crizotinib. Currently, new strategies 
have been developed for individualized therapy of 
lung cancer patients based on detection of genetic 
alterations to predict the response to targeted therapy 
in different population. Biomarkers regarded as 
diagnostic and prognostic factors for cancer has 
been presented in many studies. However, there 
is no mature biomarker used in clinical practice 
for speciÀc prognostic stratiÀcation. MicroRNAs 
(miRNAs) are a class of small non-protein-coding 
RNAs that are approximately 22 nucleotides in 
size. The miRNAs may function as endogenous 
siRNA and can negatively regulate gene expression 
through post-transcriptional gene silencing. Each 
miRNA may regulate hundreds of target mRNAs 
and about 30% of protein coding genes are regulated 
by miRNA. The miRNAs can target multiple 
genes and signaling pathways and are involved in 
diverse cellular functions, including development, 
differentiation, metabolism, proliferation, apoptosis, 
tumorigenesis and metastasis. Dysfunctions of 
miRNAs are frequently seen in malignancies, 
including lung cancer. The miRNAs can serve as 
tumor suppressors or oncogenes in lung cancer. The 
most typical example is the miRNA let-7 family 
which may function as tumor suppressors. The miR-
let-7 can negatively regulate expression of multiple 
oncogenes, including RAS, MYC, HMGA2, and 
cell-cycle progression regulators, such as CDC25A, 
CDK6, and cyclin D2. Reduced let-7 expression 
in non-small cell lung cancer (NSCLC) patients 
is correlated with poor prognosis. The miR-17-
92 cluster and miR-31 may serve as oncogenes in 
lung cancer and can promote tumor growth and 
neoangiogenesis. The miRNA proÀle is also useful 
for histological classiÀcation, risk stratiÀcation and 
outcome prediction. The miR-205 is a useful marker 
to differentiate squamous cell carcinoma (SCC) 
from non-SCC NSCLCs. High miR-155 and low 
miR-let7a-2 expression correlated with poor overall 
survival in lung adenocarcinoma patients. We also 
identiÀed a Àve-miRNA signature (miR-137, miR-
372, miR-182*, miR-221 and let-7a) that correlated 
with disease-free survival in NSCLC patients. The 
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clinic, where lung function tests were performed, and 
questionnaires concerning health, lifestyle, smoking 
habits and psychosocial consequences of screening 
were completed (1). CT scans were evaluated by 2 
experienced radiologists (1) and volumetric analysis 
of detected nodules validated as in the NELSON 
trial (5). PET scans were used to supplement the 
radiological assesment (6). Results: The DLCST 
showed that smoking habits during screening were 
unaffected by CT screening pr se at 1 year follow-
up (2) and also after 5 annual screening rounds with 
CT (to be published). In addition we have shown 
that current smoking status has a major inÁuence on 
lung density assessed by CT, and that lung density 
decreases after smoking cessation, presumably due 
to a reduced inÁammatory reaction in the lung (3). 
Contamination by off study CT scans in the control 
group was low (0.04 %) (4). The detection of lung 
cancers during the trial was: In the CT screening 
group a total of 68 lung cancers were diagnosed. At 
baseline the detection rate was 0.8% (1) , while the 
incidence rounds had a mean annual detection rate 
of 0.6% (chi-square-test; p=0.492). Three were small 
cell lung cancers (SCLC) and 65 were non-small 
cell lung cancers (NSCLC). Fifty-seven (84%) were 
early stage (I-IIIA NSCLC & limited stage SCLC) 
and thus potentially curable. Eleven (16%) were 
diagnosed in late stage (IIIB-IV NSCLC & extensive 
stage SCLC). One interval cancer was diagnosed 
ten months after the 3rd incidence scan, in a patient 
with In the control group: Twenty-four participants 
were diagnosed with lung cancer. Six had extensive 
stage SCLC and one limited stage. Ten (42%) were 
in early stage, and 14 (58%) in late stage. One of 
these early stage lung cancers was in a participant 
who received a CT scan for screening purposes 
through his general practitioner (contamination). 
A stage IA lung cancer was found and was treated 
by surgery. SigniÀcantly more lung cancers were 
diagnosed in the screening group (chi-square-test: 
68 vs. 24 p<0.001) and more were low stage (chi-
square-test: 57 vs. 10; p<0.001). The number of 
late stage lung cancers was the same in both groups 
(chi-square-test: 11 vs.14; p=0.640). The number 
of new lung cancers remained high during all four 
incidence rounds in the screen group as compared 
to the control group: 11+13+12+15 vs. 4+6+7+6 
(p<0.001). A high proportion of the screen detected 
lung cancers ( > 75 %) were treated by minimally 
invasive surgery (VATS). DLCST is approved by 
the Ethics Committee of Copenhagen County and 
the Danish Data Protection Agency, and registered 
these targets and examine combination effects 
with ALK inhibitors. This network approach has 
potential translational applications to identify novel 
combination approaches to treatment of lung cancers 
addicted to RTK and could be useful in patients with 
acquired resistance to TKI. Updated work will be 
presented. 
Keywords: systems biology, tyrosine kinase 
inhibitors, proteomics, Mass spectrometry
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M26.3 DANISH STUDY UPDATE
Jesper H. Pedersen1, Asger Dirksen2 
1Thoracic Surgery, Righospitalet (2152), University 
Of Copenhagen/Denmark, 2Pulmonary Medicine Y, 
Gentofte University Hospital/Denmark
Abstract: The Danish Lung Cancer Screening Trial 
(DLCST) is a Àve-year prospective randomised 
controlled screening trial evaluating the effect of 
annual CT screening for lung cancer. The overall 
design and baseline results has been published in 
2009 (1). Methods: From October 2004 to March 
2006, 4,104 men and women were enrolled after 
giving written informed consent. Recruitment was 
through advertisements in local and regional free 
of charge newspapers, stating the purpose, study 
design, enrolment criteria and that the trial was 
funded in full by a governmental grant. Recruitment 
criteria: Males (55 %) and females (45 %), aged 50 
to 70 years, who were current or former smokers 
with at least 20 pack years of smoking history. 
Former smokers should have quit for no more 
than 10 years. Lung function was measured by 
spirometry and forced expiratory volume in Àrst 
second (FEV1) had to be at least 30% of predicted. 
Exclusion criteria were body weight over 130 kg, 
history of cancer diagnosis and treatment, lung 
tuberculosis, expected life expectancy less than ten 
years, and chest CT received during the last year for 
any reason. Randomisation was to either a screening 
group (n=2,052) or a control group (n=2,052). The 
screening group received Àve annual low dose chest 
CT scans (one baseline scan and four incidence 
scans). All came for an annual visit to the screening 
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launched to answer the question of the efÀcacy and 
cost-effectiveness of lung cancer screening in high 
risk subjects. One arm studies were not sufÀcient 
mainly because the overdiagnosis related to the 
possible detection of indolent lung cancers detected 
at screening by chest Rx in older randomised trials. 
For this reason lung cancer screening randomised 
trials (RT) have been implemented in USA and in 
Europe. Recently the NLST US study (about 50.000 
subjects) was early stopped after 8 years of follow up 
because an interim analysis showed a 20% mortality 
reduction for the intervention arm. In Europe an 
international collaboration between RTs was set 
up in Liverpool with the aim of pooling data from 
national studies. The whole screening cycle has 
been completed (baseline +3 screening rounds) and 
results for the screened subjects are here reported. 
MATERIALS AND METHODS The study was 
carried out in three screening centres in Florence, 
Pisa and Pistoia of the Tuscany Region (Italy) and 
supported by the Regional Health Public Authority. 
and approved by the Local Ethic Committee of 
each participating institution. The Institute for 
Cancer Prevention and Research (ISPO) of Florence 
was the coordinating centre. Subjects received a 
letter and consented to randomized. Eligible were 
subjects aged between 55 and 69 years at the time 
of enrolment with a smoking history of at least 20 
packs–year since the last 10 years . Subjects who 
attended the baseline test (n=1406) were re-invited 
at subsequent 3 rounds. CT Scan had double reading 
by radiologists and positive screening test for nodule 
at baseline was considered a solid or part-solid non 
calciÀc nodule (NCN) with mean diameter more than 
5 mm. at baseline test (3 mm. at repeated screening 
testThe protocol was basically similar to that of the 
International-ELCAP Study. FDG-PET, FNA or 
3-months follow up were suggested for assessment. 
On case-by-case basis FBS was performed. All the 
surgically removed lesions were evaluated according 
to the World Health Organization Criteria. A parallel 
collection of sputum and blood was obtained by 
the screening participants. RESULTS Results of 
baseline and all the three annual repeat CT scans 
will be reported. From 2004 to 2006, 1593 subjects 
were randomised as controls and 1613 enrolled 
in the intervention arm. 1406 (87.2%) accepted to 
be screened and underwent baseline CT scan. Out 
of the screened at baseline (1,406), 97.8%, 96.7% 
and 97.2% were screened at the Àrst, second and 
third subsequent rounds, respectively for a total 
compliance of 78.3%. 426 participants (30.3%) had 
in Clinical Trials.gov Protocol Registration System 
(identiÀcation no. NCT00496977). The collaboration 
and contributions of the steering commitee of the 
DLCST is gratefully acknowledged. It members 
are : Zaigham Saghir, Asger Dirksen, Haseem 
Ashraf, Philip Tønnesen, Karen Bach, Hanne 
Hansen, Birgit Guldhammer Skov, Jann Mortensen, 
Hanne Thorsen, John Brodersen, Martin Døssing, 
Niels Seersholm, Klaus Fuglsang Kofoed, Paul 
Clementsen, Klaus Richter Larsen and Jesper Holst 
Pedersen References: 1) Pedersen JH et al. The 
Danish Lung Cancer CT Screening Trial – Overall 
design and results of the Prevalence Round. J Thorac 
Oncol 2009; 4; 608-14 2) Ashraf H et al. Smoking 
habits were unaffected by CT screening at 1 year 
follow-up in the Danish Lung Cancer Screening 
Trial (DLCST). Thorax 2009; 64; 388-92 3) Ashraf 
H et al. Short term effect of changes in smoking 
behaviour on emphysema quantiÀcation by CT. 
Thorax (2010). Doi:10.1136/thx.2009.132688 4) 
Saghir Z et al. Contamination during 4 years of 
annual CT screening in the Danish Lung Cancer 
Screening Trial (DLCST). Lung Cancer (2010), 
doi:10.1016/j.lungcan.2010.06.006 5) Ashraf H et 
al Lung nodule volumetry: segmentation algorithms 
within the same software package cannot be used 
interchangeably. Eur. Radiol 2010; 20, 1878-85 6) 
Ashraf H et al. Combined use of positron emission 
tomography and volume doubling time in lung 
cancer screening with low-dose CT scanning. Thorax 
(2010). Doi: 10.1136/thx.2010.136747 
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M26.4 THE ITALUNG RANDOMISED 
TRIAL: RESULTS OF THE SCREENING 
ROUNDS AND PERSPECTIVES
Eugenio Paci1, Laura Carrozzi2, Mario Mascalchi3, 
Fabio Falaschi4, Francesco Giusti1, Giulia Picozzi5, 
Francesca M. Carozzi1, Andrea Lopes Pegna6 
1Epidemiology, Ispo/Italy, 2Dept Pneumology, Aou 
Pisa/Italy, 3Dept Diagnostic Imaging, Aou Careggi/
Italy, 4Dept Diagnostic Imaging, Aou Pisa/Italy, 
5Diagnostic Imaging Unit, Asl Pistoia/Italy, 6Dept 
Pneumology, Aou Careggi/Italy
Abstract: After the publication in 1999 of the 
results of the ELCAP study, one arm studies have 
shown the good performance of low dose CT Scan 
screening for the detection of early lung cancer cases 
and high survival rates. Randomised trials were 
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Statement 2005: priorities for the European Union/
United States Spiral Computed Tomography 
Collaborative Group. Thorac Oncol 2006; 1:497–
498. Lopes Pegna A, Picozzi G, Mascalchi M, et 
al. Design, recruitment and baseline results of the 
ITALUNG trial for lung cancer screening with low-
dose CT. Lung Cancer 2008; 64:34–40). 
Keywords: CT Lung cancer screening, randomised 
trial
Screening by Low Dose CT Thursday, 7 July 2011 10:30-12:00
M26.5 LUNG CANCER SCREENING BY 
LOW DOSE CT (DISCUSSANT)
Stephen Lam1, Martin Tammemagi2, Anthony 
Miller3, John Mayo4, Michael Johnston5, James 
Dickinson6, Huiming Yang7, Verna Mai8, William K. 
Evans9 
1Integrative Oncology, BC Cancer Research Centre/
Canada, 2Department Of Community Health 
Sciences, Brock University/Canada, 3Dalla Lana 
School Of Public Health, University Of Toronto/
Canada, 4Department Of Advanced Cardiac 
Imaging, Vancouver General Hospital/Canada, 
5Department Of Surgery, Queen Elizabeth II Health 
Sciences Ctr./Canada, 6Faculty Of Medicine, 
University Of Calgary/Canada, 7Populationa Dn 
Public Health, Alberta Health Services/Canada, 
8Prevention And Cancer Control, Cancer Care 
Ontario/Canada, 9Juravinski Hospital And Cancer 
Centre, Cancer Care Ontario/Canada
Abstract: Lung cancer is the most common cause 
of cancer death world-wide. Despite advances in 
therapies, the outcome of patients with lung cancer 
remains poor. In the last decade, the 5-year survival 
rate changed from 13.9% to 17.7% with a slightly 
better improvement in the one-year survival from 
36% to 43% (Lancet 2011;377:127-138). Roughly 
85-90% of lung cancers are attributable to smoking. 
Currently more than half the lung cancers diagnosed 
in North America are diagnosed in former-smokers, 
and for this reason lung cancer is expected to 
remain a major public health concern for many 
years to come. The recent Ànding by the National 
Lung Screening Trial (NLST) in the United States 
that screening of high-risk smokers with low dose 
computed tomography (LDCT) reduces lung cancer 
mortality by 20% compared to screening with chest 
x-ray may represent a potential strategy that can 
signiÀcantly improve the outcome of patients with 
a NCN detected at baseline CT, and 619 (15.8%). 40 
primary lung cancers were detected in 38 participants 
(2.7%), 21 at the baseline screening (DR: 1.4%), and 
17 (DR:0.4%)at the subsequent screening rounds. 
The adenocarcinomas were the 48% at baseline, and 
71% at repeated tests. 6 subjects were diagnosed 
after the follow-up CT Scan (29%) at baseline ; 
12 lung cancers were diagnosed after a follow-up 
at repeated tests (71%).6.4% of the subjects with 
NCNs, had a FDG-PET; with a positive result in 
29/90 subjects (32.2%) and the 22.2% of lung 
cancers. In 34 subjects (2.4%) work-up was carried 
with 38 CT guided FNA; 24 FNA (24/34= 70.5%) 
were positive for lung cancer and 2 for metastasis. 
Pneumothorax occurred in 11/38 (30%) of the 
subjects, but only 2 cases needed thoracic drainage 
. The combination of FNA and PET positive result 
lead to a 88.2% of subjects preoperatively classiÀed 
as lung cancer. Surgery was the main therapy for 
28/32 NSCLC and for 3/3 typical carcinoid and 
1/1 for mixed cancer NSCLC + SCLC; 6 cancer 
were treated with adjuvant therapy. DISCUSSION 
Member of the group of RCT on going in Europe, 
ITALUNG is a population-based trial randomising 
to 4 screening rounds versus usual care. The 
randomised subjects of the intervention and 
control group were invited to a smoking cessation 
counselling , if not ex smokers. In a recent meeting 
held in Pisa teh European Trialists, including the 
ITALUNG, conÀrmed the opportunity of continuing 
the RT. Most European trials are considering the 
usual care as the reference group. Furthermore 
most of them were based on the invitation from 
the population lists and not on volunteer subjects. 
Information of major side effects and estimates of 
the possible excess of incidence/overdiagnosis for 
lung cancer related to screening is an important 
result for the evaluation of the cost-effectiveness 
of any future service screening programmes. The 
better identiÀcation of the high risk subjects and 
possible integration of biomarkers in the detection 
and followup of subjects will also be important 
for the future. For this reason the ITALUNG study 
will continue the follow up of the subjects enrolled. 
Essential references (Henschke CI, McCauley DI, 
Yankelevitz DF, et al. Early Lung Cancer Action 
Project: overall design and Àndings from baseline 
screening. Lancet 1999; 354:99–105), Henschke 
CI, Yankelevitz DF, Libby DM, et al. Survival of 
patients with stage I lung cancer detected on CT 
screening. N Engl J Med 2006; 355:1763–1771. 
Field JK, Smith RA, Duffy SW, et al. The Liverpool 
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staging, resection techniques and treatment methods 
and pathologists experienced with interpretation of 
small biopsy specimen need to be made available. 
The development of screening programs will need 
to be accompanied by a parallel process of quality 
assurance including medical technologists, picture 
archiving and communications (PACS) specialists, 
radiologists, external evaluators and medical 
physicists. Further developments in computer 
aided diagnosis (CAD) technology should reduce 
radiologist’s interpretive errors.
Screening can be useful for those who are in the 
deÀned target group, but carry a risk of causing net 
harm if performed on low risk individuals. More 
accurate lung cancer risk prediction tools to identify 
individuals at risk of lung cancer beyond age and 
smoking history alone have been developed using 
data from the Prostate Lung Colon and Ovarian 
Cancer Screening Trial (Tammemagi M. et al. J 
Natl Cancer Inst. Under review). The PLCO lung 
cancer prediction tool was applied to recruit high 
risk current and former smokers between 50 to 74 
years of age in the Pan-Canadian Early Detection of 
Lung Cancer Study. Preliminary results suggest this 
prediction tool performs well allowing identiÀcation 
of subjects harboring a 3-year lung cancer risk of  
2%. The incremental value of biomarkers such as 
lung function to the prediction tool has also been 
evaluated. Data from the British Columbia Lung 
Health Study and the Pan-Canadian Early Detection 
of Lung Cancer Study suggest lung function (FEV1) 
adds signiÀcantly to lung cancer risk prediction and 
that there is a gender difference in lung cancer risk 
and decline in lung function (Tammemagi M, Lam S, 
McWilliams A, et al. Incremental value of pulmonary 
function and sputum DNA image cytometry in lung 
cancer risk prediction. Cancer Prediction Research 
2011;4(4);1-11.).
Further research is required in a number of areas in 
lung cancer screening including: features that best 
deÀne the screened population, discrimination of 
benign versus malignant lung nodules, most efÀcient 
follow-up diagnostic and treatment pathways and 
the optimal frequency and duration of screening. 
Evidence based guidelines for treatment of small 
lung cancers using sub-anatomic resection or 
stereotactic body radiation versus conventional 
anatomic resection need to be established. Wide-
spread lung cancer screening programs might be 
best introduced in stages to ensure that adequate 
infrastructures are available and that quality 
assurance and program performance can be 
lung cancer
NLST, NELSON-Danish and the ITALUNG are the 
Àrst randomized trials using superior study designs 
to evaluate the efÀcacy of CT screening to reduce 
lung cancer mortality. Simple case detection and 
demonstration of improvement of survival in single 
arm studies are not equivalent to efÀcacy as some 
cancers may not be curable, nor have their natural 
history modiÀed by available treatment. Some 
cancers may never have become life-threatening 
in the patient’s lifetime (over-diagnosis bias). The 
randomized controlled trial design with lung cancer 
mortality as the outcome avoids length, lead-time 
and overdiagnosis biases that invalidate study 
designs dependent upon survival. Selection or 
participation bias – i.e., the healthy volunteer effect, 
is still present in randomized controlled trials, so 
they may have better outcomes than can be achieved 
in the general population.
Screening is a process, not a single event. It requires 
the use of tests to detect unrecognized health risks or 
diseases in order to permit timely intervention. For a 
screening program to demonstrate effectiveness at a 
population level, the screening tests must be applied 
systematically on a large scale. They are used to 
distinguish apparently unaffected (undiagnosed) 
people from those who may have a disease. A 
screening test is not intended to be diagnostic. The 
test results require conÀrmation through deÀnitive 
diagnostic tests, followed by treatment of conÀrmed 
cases. Screening can only be effective if effective 
treatment is available for the disease revealed by 
screening. The potential beneÀts of screening must 
be balanced against possible harms of screening 
tests, downstream investigations or therapeutic 
intervention for suspicious lesions that turn out to be 
non-malignant, and these may be several times more 
frequent than the true cancers.
Implementation of lung cancer screening at the 
population level requires coordinated and specialized 
professional expertise to ensure beneÀts of 
screening are maximized while the potential risks 
are minimized. For example, population penetration 
strategies for large scale screening will have to be 
developed; pulmonologists and thoracic surgeons 
experienced in management of lung nodules, 
interventional pulmonologists skilled in diagnosis 
of peripheral lung lesions and staging of lung 
cancer using endoscopic ultrasound; radiologists 
skilled in interpretation of lung cancer screening 
low dose CT scans, biopsy and localization of small 
lung nodules, thoracic surgeons knowledgeable in 
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targets that will allow patients to be enrolled on 
clinical trials that will conÀrm or deny the beneÀt of 
the new predicted therapies. An important example 
of this is the results of the Lung Cancer Mutation 
Consortium in deÀning actionable oncogene 
mutations in 1,000 lung adenocarcinomas. Large 
Panel of Lung Cancer Cell Lines and Xenografts 
with Clinical, Molecular, and Drug Response 
Phenotype Annotations: The development of a large 
panel of non-small cell (over 100) and small cell 
lung cancer (over 50) lines (NSCLC, SCLC) with 
clinical annotation and a large legacy database of 
molecular analyses and drug response phenotypes 
has been pivotal in preclinical development of new 
therapeutic approaches. Currently several centers 
are determining if molecular biomarkers (such as 
mRNA or proteomics proÀles) of the tumor cell 
lines associated with in vitro and in vivo (xenograft) 
drug response phenotypes are also predictive of drug 
responses in patients. The recent addition of matched 
pairs of tumor cell lines and immortalized normal 
lung epithelial cells from the same patients has 
allowed comparisons of selective therapeutic toxicity 
for tumor over normal cells as well as providing 
for genome wide sequence analysis. Development 
of Immortalized Human Lung Bronchial and 
Small Airway Epithelial Cells (HBECs, HSAECs) 
including Isogenic Derivatives with DeÀned 
Oncogenic Changes: Cell biologic advances have 
allowed the development of a large panel (over 
50) of immortalized lung epithelial cell lines from 
both the central (HBECs) and peripheral (HSAECs) 
airways. These lung epithelial cell strains have many 
properties of basal stem cells in the lung and can 
differentiate into lung epithelium under controlled 
conditions. They clone with high frequency, are 
non-tumorigenic, can be genetically manipulated, 
and their isogenic derivates (manipulated to have 
deÀned oncogenic changes in oncogenes and tumor 
suppressor genes) permit detailed molecular and cell 
biologic studies of much simpler oncogenotypes 
than are found in full Áedged lung cancers. These 
studies have shown that over 5 such changes are 
needed to develop full malignancy. IdentiÀcation 
of Lung Cancer Stem Cells: Recent advances have 
allowed the detection and characterization of lung 
cancer stem cells (CSCs) or “cancer initiating 
cells”. These studies have shown that NSCLCs that 
are enriched in lung CSCs have worse prognosis, 
that the molecular characteristics and identifying 
markers of lung CSCs can vary depending on the 
lung cancer oncogenotype, and the Notch pathway as 
evaluated at least at a local level, before national 
implementation of a program is instituted. This will 
allow efÀcient troubleshooting of problems before 
they become widely implemented. The data collected 
can then be used to model the effect of potential 
strategies, to facilitate the development of guidelines 
for the most effective program. A well designed 
screening program can also provide the opportunity 
for research such as on tobacco addiction and 
smoking cessation modiÀers as well as lung cancer 
risk reduction through the use of chemoprevention 
drug therapy or immunotherapy.
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M27.1 MOLECULAR AND FUNCTIONAL 
PORTRAITS OF NON-SMALL CELL 
LUNG CANCER THAT PROVIDE 
ENROLLMENT BIOMARKERS FOR 
THERAPY SELECTION
John D. Minna 
Hamon Center For Therapeutic Oncology Research, 
University Of Texas Southwestern Medical Center/
United States Of America
Abstract: The Opportunity and the Challenge: 
Amazing advances on multiple fronts in molecular 
and cell biologic approaches and clinical trials 
have provided an unprecedented opportunity to 
fundamentally alter our approach to classifying 
and developing personalized treatments for lung 
cancer. Besides the recent striking examples of 
targeted therapy in clinical trials that focus on 
deÀned oncogene mutations, these include genome 
wide DNA sequence analyses, DNA copy number, 
DNA methylation, mRNA expression, miRNA 
expression, proteomics, new cell biologic systems 
and understanding of cancer stem cells, and genome 
wide functional (siRNA, shRNA) analysis of lung 
cancer coupled with appropriate biostatistical and 
bioinformatics approaches. These provide exciting 
new leads for new drug development. However, the 
Ànal output needs to be CLIA certiÀed laboratory 
tests of patient’s tumors that identify “actionable” 
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need for multi-disciplinary and multi-institutional 
require the developing, nurturing, and maintenance 
of effective collaborations. Grant Support: NCI 
SPORE in Lung Cancer (P50CA70907), NCI 
CTD2N (RC2CA148225), DOD “PROSPECT”, 
NASA NSCOR, and State of Texas CPRIT grants. 
Collaborators: I thank my long time colleague in 
this effort Dr. Adi Gazdar and my many current and 
former collaborators. References: Gazdar AF et al. 
Lung cancer cell lines: Useless artifacts or invaluable 
tools for medical science? Lung Cancer 68:309-18, 
2010 Gazdar AF et al. Lung cancer cell lines as tools 
for biomedical discovery and research. J Natl Cancer 
Inst 102:1310-21, 2010 Schreiber SL, et al: Towards 
patient-based cancer therapeutics. Nat Biotechnol 
28:904-6, 2010. 
Keywords: Lung Cancer Lines, Lung Cancer 
Xenografts, Molecular ProÀles, Molecular Biology
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M27.2 PATHOLOGY
Adi F. Gazdar 
Hamon Center For Therapeutic Oncology Research, 
Pathology, University Of Texas Southwestern 
Medical Center/United States Of America
Abstract: The past 40 years have witnessed major 
changes in our beliefs and practice of the pathology 
of lung cancer. The major changes are summarized 
below. · The realization in the 1980s that small 
cell lung cancer (SCLC) had different clinical and 
biological features from non-small cell lung cancer 
(NSCLC) and therapeutic responses to cytotoxic 
therapy. This led to the pathologic distinction of 
lung cancers into SCLC and NSCLC types. · The 
realization that true non-invasive adenocarcinomas 
(formerly called brochioloalveolar carcinomas or 
BACs) had an excellent prognosis if small and 
completely resected highlighted the importance of 
precise identiÀcation of the presence and extent of 
invasion (). · The WHO classiÀcation ()at the turn 
of the century was an important contribution in 
identifying the criteria for the major forms of lung 
cancer and their subtyping. It was limited because 
it was basically a “Pathology ClassiÀcation by 
and for Pathologists”. Subtyping of tumors had 
little or no clinical relevance. Diagnosis depended 
on obtaining large tissue specimens such as 
resections. · We have a much deeper understanding 
an attractive therapeutic target. Molecular Portraits 
(“Clades”) of Lung Cancer: The wealth of new 
genome wide molecular analyses of lung cancers and 
lung cancer cell lines has permitted lung cancer to 
be molecularly classiÀed into different “Portraits” or 
“Clades”. NSCLCs can be divided into 5-10 different 
molecular groups and these have distinct clinical, 
histological, oncogenotype, outcome and drug and 
targeted therapy response phenotypes. The molecular 
deÀnitions allow lung cancer cell lines, xenografts, 
and tumor specimens to be linked together and 
comparisons between different groups made. NCI 
Cancer Target Discovery and Development Network 
(CTD2N): The NCI’s new CTD2N has allowed the 
development of genome wide functional approaches 
(knocking down one gene at a time with siRNAs, 
or shRNA library screening) combined with 
screening of large chemical libraries on the panel 
of characterized lung cancer lines. This approach 
has identiÀed genetic targets (“knockdowns’) and 
chemical compounds that are “monogenic lethals” 
– that kill lung cancer by themselves but do not 
kill normal lung epithelial cells. In addition, these 
lethals only kill certain lung cancers which can 
be mapped to the molecular portraits. Together, 
these genome wide and chemical compound 
reagents are permitting a totally new functional 
classiÀcation of for identifying all of the “acquired 
vulnerabilities” lung cancer The relationship of 
this sensitivity to the molecular portrait allows the 
molecular portrait to be an enrollment biomarker 
for moving these new therapies into the clinic. 
Development of CLIA CertiÀed Tests: If these 
new approaches are going to be moved to the 
clinic, the enrollment biomarkers need to have 
tests developed that can be CLIA certiÀed and 
also performed on small biopsy materials which is 
often Àxed and archival as found in real life clinical 
situations. Appropriate Biostatistical Analysis with 
Documentation of Analytic Methods: Recent events 
have demonstrated that the large molecular, genome 
wide datasets needed for these approaches can be 
subject to many errors in analyses. Thus, it is very 
important to provide for independent veriÀcation of 
Àndings and documentation such as that provided 
by “SWEAVE.” Important Role of Patients and 
Advocates in the Process: An important new 
addition to the scientiÀc team has been the role of 
patients and patient advocates in the process. Need 
for International Collaboration and Consortium 
Efforts: All of these new approaches by their 
large scale, resource requirements, data sets, and 
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academic exercise by pathologists to a dynamic 
multidisciplinary approach that is clinically relevant. 
It will continue to evolve as our knowledge of 
the clinical and molecular basis of lung cancer 
increases. References: 1. Noguchi M. Stepwise 
progression of pulmonary adenocarcinoma--clinical 
and molecular implications. Cancer Metastasis 
Rev. 2010;29:15-21. 2. Brambilla E, Travis WD, 
Colby TV, Corrin B, Shimosato Y. The new World 
Health Organization classiÀcation of lung tumours. 
Eur Respir J. 2001;18:1059-68. 3. Brambilla E, 
Gazdar A. Pathogenesis of lung cancer signalling 
pathways: roadmap for therapies. Eur Respir J. 
2009;33:1485-97. 4. Travis WD, Brambilla E, 
Noguchi M, Nicholson AG, Geisinger KR, Yatabe 
Y, et al. International association for the study of 
lung cancer/american thoracic society/european 
respiratory society international multidisciplinary 
classiÀcation of lung adenocarcinoma. J Thorac 
Oncol. 2011;6:244-85. 
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M27.3 RADIOTHERAPY
Andrew T. Turrisi 
Radiation Oncology, Radiation Oncology Center, 
Sinai Grace Hospital/United States Of America
Abstract: Radiotherapy has been the most 
advantaged modality in making progress over the 
past 40 years, as we use it by itself and as integrated 
into combined modality management. The early 
years separated two key features: (SCLC) separate 
from (NSCLC) and thoracic radiotherapy alone 
superior to surgery in small cell (Fox and Scadding) 
, and the role of thoracic radiotherapy dose in non-
small cell seemed to have been established at 60Gy 
[radiotherapy was quickly pushed off center stage 
by the use of even single agent chemotherapy] 
(Bergsagel). It took 20 years for radiotherapy’s 
integral role in limited disease small cell, as thoracic 
radiotherapy (Pignon), and then 30 years to prove 
beneÀt of prophylactic cranial irradiation (Auperin). 
Linear accelerators became standard, skin was 
spared, but normal tissue tolerance to acute and 
late effects limited the dose of radiotherapy. In the 
chest, 50% of treatment came from anterior beams 
the remainder from posterior beams. Dose was 
prescribed to the mid-plane depth, and that meant 
of the pathologic and molecular preneoplastic 
and preinvasive changes that precede the onset of 
invasive and metastatic carcinomas (). Because 
the peripheral lung cannot be serially biopsied, our 
understanding of the multistage pathogenesis of 
lung cancer has lagged behind that of squamous 
tumors. However the onset of CT based screening 
studies has greatly increased our knowledge of the 
origins or peripheral adenocarcinomas. · During 
the past decade we have learnt that the clinical 
responses and toxic effects to both conventional 
and cytotoxic therapy depend on accurate typing of 
NSCLC. The development of simple immunostains 
and mucin stains that can be used to subtype the 
majority of cases including cytological specimens 
and small biopsies has greatly aided this task. This 
also resulted in many fewer cases being given the 
default terms “large cell carcinoma” or “NSCLC, 
NOS” in the absence of obvious differentiation 
along squamous or adenocarcinoma pathways. 
· The advent of targeted therapy, especially for 
speciÀc subgroups of adenocarcinoma, has stressed 
the importance of NSCLC typing and subtyping. 
The gradual realization that speciÀc molecular 
abnormalities are associated with speciÀc subtypes 
of NSCLC has pointed out the importance of 
accurate subtyping and the importance of reporting 
it, especially in clinical trials. · Pathologists play 
a crucial role in the management of clinical trials 
by providing tissue repositories, performing 
prognostic and predictive tests, performing accurate 
typing and subtping of lung cancers, etc. As the 
amount of tissues available for these diagnostic 
and clinically relevant tasks becomes smaller and 
smaller, pathologists have learnt to do more with 
less. · There has been a gradual realization that 
pathology classiÀcations must be multidisciplinary 
In origin and serve the practice of clinical oncology. 
Thus classiÀcations must be devised in close 
collaboration with oncologists, pulmonologists, 
surgeons, radiotherapists and radiologists. Input 
from basic science studies including molecular 
biology is essential. The recent revised classiÀcation 
of pulmonary adenocarcinoma () is the “poster 
child” for such an approach. · Multidisciplinary 
studies with squamous cell carcinoma and SCLC 
have lagged behind adenocarcinoma. However a 
“Systems Genetics” (i.e. comprehensive molecular) 
study of squamous cell carcinomas may help 
rectify the situation. SCLC largely remains the 
“forgotten disease”. In summary, pathology has 
greatly evolved during the last 40 years from an 
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dose per week. Each may be use a fractional dose 
more than once daily. Hyperfractionation with 
small per fraction dose intends to decrease late 
effects and improve long term toxicity. Accelerated 
treatment intends to defeat rapidly re-populating 
cell populations that might double within 24 hours, 
but at the price of acute toxicity. In lung cancer, 
there is no evidence supporting hyperfractionation, 
but accelerated schemes have proven efÀcacy in 
NSCLC (CHART, Saunders) and SCLC (Intergroup, 
Turrisi). Despite evidence, accelerated schemes 
are orphans: misunderstood and hard to adopt. The 
future is indeed now. The Goldilocks paradigm of 
wanting strategies to be not too big (Àeld size, dose, 
toxicity) or too small (missing tumor because of 
set up variation, motion, incorrect target), but just 
right allows for optimizing of radiotherapy with 
other modalities. Chemotherapy is solidly in place 
for both small cell and non-small cell. However, 
molecular determinants may point to use of certain 
agents (i.e,ERCC-1 +/- for cis-platinum; EGFR 
codon mutations for cetuximab or geÀtinib/erlotinib). 
We are not yet clear about PET scan determinates 
for “adaptive therapy” (more dose to persistently 
PET avid areas) or markers for hypoxia. Physics 
determinants for target expansion (GTV, CTV, PTV) 
and motion, as well as dose calculation methods 
(equivalent path length, Monte Carlo) may be more 
or less important. New Technology and techniques 
to apply very high doses to targets have produced 
exciting results in Europe, Asia, and North America. 
The term Stereotaxy has been applied, and unique 
machines (Cyberknife, Tomotherapy HiArt, ? 
Proton beams) may be used to deliver gargantuan 
single or fractionated doses. Anatomic location may 
mitigate toxicity (Fakiris). Total dose and schedule 
vary widely. If local control and survival at 3 years 
with very minimal toxicity and very high survival 
and local control are adequate evidence, we are 
already there for medically inoperable cases, and 
even sufÀcient background for prospective trials 
of peripheral lesions in otherwise operable cases. 
It may even be possible to do this with ordinary 
linear accelerators and multiple beams, especially 
with intermediate dose/fraction and up to 3 week 
treatment – we are enamored of and swept away 
by the technology, but the biology of these very 
high doses/fraction can be mimicked by multiple 
beams and real-time imaging on widely available 
accelerators. It’s not magic. Minimizing the volume 
of normal tissue receiving these very high doses, 
and tailoring dose per fraction to normal tissue to 
tissue at entry and exit might receive 20% higher 
dose. It was normal tissue tolerance rather than 
tumor control that limited dose. Modeling after 
the successful wide-Àeld treatment of Hodgkin’s 
Disease and reasoning of predictable spread to 
regional nodes, targets often included nodes from 
the supraclavicular fossa and thoracic inlet to the 
diaphragmatic hiatus, and both hilar zones. The 
spinal cord tolerance of 50 Gy, and esophageal 
tolerance limited dose. RTOG 73-01 trial established 
60 Gy over 50 Gy and two schedules of 40 Gy as the 
standard that frankly has endured until today.(Perez) 
The survival at 5 years was 5-10%, and local control 
was said to be about 50%. Biology was fueled 
by knowledge of oxygen effect, and interrupting 
therapy (Split Course for 2-4 weeks) was common 
as in one of the arms of RTOG 73-01. The trial was 
under-powered for survival and the arms overlapped 
each other. Chemotherapy was only used in SCLC 
and never in NSCLC. Concurrent therapy was too 
toxic, and no one used doses higher than 60 Gy in 
NSCLC and 50 Gy in SCLC, and even that was 
eschewed due to esophageal toxicity: stricture. Today 
most agree that elective nodal irradiation adds little 
beneÀt, but does increase toxicity. The Ann Arbor 
dose escalation trial introduced this idea recognizing 
that dose escalation could not be achieved with 
Hodgkin’s-like volumes (Hazuka, Hayman). While 
imperfect, the Yuan study adds substantial evidence 
in support. Radiotherapy technology improved 
since 1970 when there were no computerized axial 
tomograms (CT’s). The CT revolutionized radiation 
oncologists’ ability to select patients, deÀne targets, 
and ultimately formed the foundation of three-
dimensional treatment planning (3D-TP). These 
systems were developed in university departments in 
the 80’s and 90’, and then developed commercially 
in the late 1990’s, and almost instantly standard 
by 2000. As collimator assemblies evolved from 
thick blocks of ballast to thin leaÁets with ever 
decreasing width and individual motors, the tools 
for beam modulation that enables dose variation 
across the Àelds. Intensity modulation and multiple 
beams require much professional physics time 
and pre-treatment assurance that systems work 
as planned. Dose described as energy absorbed, 
needs to be thought about as dose per unit of time. 
A standard scheme delivers 10 Gy/week. Using 
very small doses/fraction multiple times per day 
is called hyperfractionation, but generally does 
not increase the dose per week by less than 20%. 
An accelerated scheme delivers more than 50% 
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resection of lung tissue for the sake of maintenance 
of patient’s QOL. Video Assisted Thoracoscopic 
Surgery (VATS) spread throughout the world during 
the past two decades and, more recently, introduction 
of the robotic surgery is underway. VATS and robotic 
surgery are promising surgical technologies for the 
future, however, there are still many issues to be 
solved and further improvements to be made. The 
desire of the people is to enjoy non-invasive, safer, 
higher quality and, yet, cheaper medicine, which 
obliges us to further our effort in developing more 
adequate medicine including surgical procedures. 
In order to satisfy their demands and to achieve our 
goal of eradication of lung cancer, we will have to 
make efforts to Ànd the adequate medicine by means 
of cytobilogical and cytochemical approaches in 
addition to our 40 years of experience. 
Keywords: history, progresses in diagnosis and 
therapy of lung cancer
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M27.5 MANAGEMENT OF NON-SMALL 
CELL LUNG CANCER: 40 YEARS 
EXPERIENCE
Lawrence H. Einhorn 
Medicine - Oncology, Indiana University/United 
States Of America
Abstract: During the past 40 years, lung cancer 
has been the number one cause of cancer-related 
mortality in the United States and most other 
countries around the world. With vigorous efforts 
from cancer agencies, committed governments, 
and the oncology community, the incidence of 
smoking, fortunately, has shown a downward 
trend. For most patients with stage I, stage II, 
and selected patients with stage IIIA, the optimal 
treatment remains surgery. The use of stereotactic 
radiosurgery is a newer modality that is gaining 
prominence, but thus far, there are no randomized 
trials to prove non-inferiority with surgery. In the 
1970s and 1980s, there was no evidence of beneÀt 
with adjuvant chemotherapy. In the 1990s, it was 
demonstrated that post-op radiation therapy, with the 
possible exception of stage IIIA N2 disease, had no 
beneÀcial role. The IALT study, for the Àrst time, 
demonstrated that there was a possibility to improve 
progression-free survival and overall survival in 
selected patients with adjuvant cisplatin combination 
more ordinary fractional doses accomplishes this 
feat without excess toxicity, technology, or cost. 
Protons produce beams with interesting physical 
characteristics. The prospect of neutron-like biologic 
beams (virtually no repair; very little oxygen 
enhancement ratios) such a neon or carbon beams 
require huge resources and trials to prove beneÀt. 
Keyword: Radiotherapy; 40 year’s Progress; 
Radiotherapy in the future
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M27.4 SURGERY
Harubumi Kato 
Thoracic Surgery, Niizashiki Central General 
Hospital/ Tokyo Medical University/ International 
University Of Health And Welfare/Japan
Abstract: Conceptual preparation to form an 
international organization for the study of lung 
cancer started in as early as 1972 and, Ànally, in 
1974, the International Association for the Study of 
Lung Cancer was formally founded. 40 years have 
passed since then, and during these past four decades 
much progress has been made in many diagnostic 
and therapeutic procedures on lung cancer. In the 
meeting, these progresses including surgery as 
well as future direction of lung cancer medicine 
will be presented. In the early 1970’s, therapeutic 
results were quite poor due to most cases being 
at their advanced stages. Surgery was almost the 
only way for the therapy of lung cancer in those 
days. Since the pathogenesis of lung cancer was 
not well-known at the time, there were no adequate 
diagnostic and therapeutic strategies. In 1960’s, the 
sputum cytology, Àberoptic bronchoscopy, and trans-
thoratic percutaneous needle biopsy were developed 
for the diagnosis of lung cancer. The guideline for 
the pathological classiÀcation, staging, detection, 
diagnosis and therapy of lung cancer had further 
developed since then. Lung surgery of lung cancer 
started from pneumonectomy in 1950’s and shifted 
to lobectomy with systemic dissection of mediastinal 
lymph nodes in 1970’s. During 1970’s and 1980’s 
surgeries were performed extensively. We spent 
tremendous amount of time and exerted much of our 
efforts in the study of diagnostic pathology, staging, 
therapeutic effect and prognosis from the resected 
specimens during those years. In 1990’s, surgical 
procedure was gradually shifted to the limited 
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line therapy only for patients with non-squamous, 
non-small cell lung cancer. Erlotinib was the Àrst 
single agent molecular targeted agent to provide 
survival beneÀt. This is particularly pronounced 
in the never smokers and especially those who 
have the EGFR mutation at Exon-19 or Exon-21. 
With the advances in molecular understanding of 
this complicated disease and the desire to achieve 
personalized medicine, hopefully further improved 
therapies will be forthcoming. One of the most 
dramatic of these is the demonstration of the 4 EML 
ALK mutation. Phase II results with crizotinib 
have been very impressive and phase III studies are 
currently being conducted. This is also primarily in 
non-smokers and only 4% of stage IV lung cancer 
patients harbor this mutation. Nevertheless, we 
are now unlocking the molecular mysteries of this 
fascinating disease and are developing successful 
therapies based not just upon histopathology, but the 
molecular determinants that drive the progression of 
disease. 
Keyword: Non-small cell lung cancer and 
chemotherapy
Based on Long Experience: What Brings the Future? Thursday, 7 July 
2011 10:30-12:00
M27.6 PULMONOLOGY
Stephen Spiro 
Respiratory Medicine, Royal Brompton Hospital/
United Kingdom
Abstract: The place of the chest physician in the 
management of lung cancer remains pivotal. Most 
cases are initially referred to a chest physician who is 
responsible for the diagnosis,staging and explaining 
possible treatment options. They should also be 
expert in breaking bad news, and must remain 
the reference point for the patient throughout the 
illness. Once treated, the patient should be referred 
back to the chst physician for long term review of 
care pathways and to prevent confusion common 
with multiple carers. Also, the complications of 
the disease ( and of treatment) are often respiratory 
and he is best positioned to deal with these. As 
respiratory medicine deals with many other illnesses 
in addition to lung cancer,especially COPD, as well 
as many with no serious organic illness, he is best 
placed to give preventative advice. We are unique 
amongst carers of lung cancer in this respect and 
smoking cessation remains one of the most effective 
chemotherapy. This is now the world standard 
for patients with stage IIA, IIB, and IIIA resected 
non-small cell lung cancer. Unanswered questions 
include the number of courses of chemotherapy 
and whether the use of molecular targeted agents 
such as Bevacizumab could further improve results 
when added to a cisplatin doublet. Studies are 
underway to utilize molecular discriminants rather 
than just histopathologic classiÀcation to optimally 
determine which patients should receive adjuvant 
chemotherapy and whether it should include 
cisplatin. In locally advanced inoperable disease, 
radiotherapy alone had been the standard of care 
for several decades. However, in the 1980s, studies 
were done demonstrating improved survival with 
sequential chemoradiotherapy. The standard today 
is concurrent chemoradiotherapy. Clinical trials 
have looked at various forms of combinations of 
chemotherapy and radiotherapy including a study 
looking at prophylactic cranial irradiation and also 
the question of chemotherapy being given before 
and/or after the concurrent chemoradiotherapy. In 
stage IV disease, cure is not the objective, but instead 
palliation of symptoms and modest prolongation 
of survival. Twenty-Àve years ago, there were 
valid arguments as to whether cisplatin-based 
chemotherapy, despite its minimal prolongation of 
survival, was producing more harm than beneÀt for 
patients because of the severe chemotherapy-induced 
nausea and vomiting. Perhaps one of the more subtle, 
but deÀnite advances in the palliation of stage IV 
lung cancer was the development of more effective 
antiemetics to mitigate the chemotherapy-induced 
nausea and vomiting. Platinum combination therapy 
is the standard Àrst-line therapy. Data from the 
ECOG 4599 study demonstrated a further 2 month 
improvement in median survival time (10.3 vs. 12.3 
months) by adding bevacizumab to carboplatin + 
paclitaxel. However, the AVAIL study of cisplatin 
+ gemcitabine with or without bevacizumab failed 
to conÀrm an improvement in overall survival. 
Further advances during the past decade have 
included second, third, and even fourth-line therapy 
for patients with stage IV disease. Docetaxel was 
compared to vinorelbine or ifosfamide or best 
supportive care and demonstrated improved survival 
as second-line therapy. A non-inferiority study 
compared pemetrexed to docetaxel with similar 
results as far as response rate, progression-free 
survival, and overall survival, but with more ease 
of administration and less toxicity. Pemetrexate is 
currently recommended as Àrst-line or subsequent-
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patients have signiÀcantly better survival than 
those with distant metastases and they are now 
classiÀed as T4 (Stage IIIB) (Rami-Porta, 2007). 
The contralateral lung is a relatively uncommon 
site for metastases, and autopsy studies have found 
their presence in only 20- 22% of patients dying of 
NSCLC. 5-year survival for patients who undergo 
resection for bilateral synchronous lung cancers 
is 38-43% [Voltolini 2010, DeLeyn 2008], and 
is approximately 30% for patients who undergo 
resection for a second nodule in an ipsilateral lobe. 
Adrenal oligometastases Autopsy studies have 
shown that the adrenal glands are a common site 
of metastatic involvement (involved in 18-42% 
of patients dying with lung cancer). However, 
the incidence of solitary adrenal metastases is 
reported to be lower (2-4%) (Porte 2001). A recent 
systematic review evaluated 10 studies with a total 
of 114 patients and concluded that patients with 
synchronous metastases had signiÀcantly shorter 
median survival than patients with metachronous 
lesions (12 months vs. 31 months), however no 
difference in 5-year survival was identiÀed (26% 
and 25%, respectively)(Tanvetyanon 2008). A large 
multi-institution study (42 patients) from France, 
which was not included in the systematic review, 
contradicts these results showing no difference in 
outcome between synchronous and metachronous 
metastases (Porte 2001). In this study adrenalectomy 
for solitary NSCLC metastases was associated 
with a median survival of only 11 months with 
only 3 (7%) patients alive at 5 years. The role of 
neoadjuvant or adjuvant systemic therapy in the 
setting of adrenalectomy for oligometastatic NSLC 
is unknown. A literature review of 18 cases from 
1965 to 1999 suggested a possible survival beneÀt 
for adrenalectomy with systemic therapy, but the 
numbers are really too small to draw any Àrm 
conclusions (Abdel-Raheem 2002). In all of the 
above studies there is a large element of selection 
bias that confounds the results making it difÀcult to 
make at deÀnitive conclusions. Other extrathoracic 
sites Surgical resection of extrathoracic non-cranial, 
non-adrenal oligometastases is rare. Luketich 
reported on 14 patients who had metachronous 
solitary NSCLC metastases to extrathoracic lymph 
nodes (6), skeletal muscle (4), bone (3) and small 
bowel (1) (Luketich 1995). The median disease 
free interval before metastases was 19.5 months 
and 10-year survival was 86% in this highly select 
patient population. Other publications have been 
mainly anecdotal reports of single cases. But what 
means of reducing the prevalence of lung cancer. 
Recent developments in practice enhance the role. 
Examples include the management of pulmonary 
nodules found on CT,reÀning endobronchial lymph 
node mapping and biopsy which will become 
routine.The place of lung function testing around 
surgery and radical radiotherapy, must be optimised 
and it is the responsibility of the chest physician 
to maintain these standards.The interested chest 
physician should have expert knowledge on 
screening as thier population is often a high risk 
one.Also, is predictive markers for diagnosis or 
susceptibility become available, this is an area 
outside the routine oncological practice. In an 
increasingly aging population the challenge to 
assess and maintain Àtness despite increasing co-
morbidities is our remit. In future lung cancer may 
become a chronic disease with multiple treatment 
regimes; then overall care of co-morbidities, quality 
of life and Àtness will be as important as prevention.
Keywords: pulmonologist, overall care
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Abstract: It can be difÀcult or even impossible to 
differentiate an oligometastasis in the lung from a 
second primary tumor. Factors such as radiographic 
appearance may help but even metastastic lesions 
may appear spiculated. Molecular markers and 
tumor grade are frequently different among primary 
tumors and metastatic lesions and so are not yet 
reliable tests to determine origin. Characteristics 
that suggest that a tumor is more likely to be a 
second primary, include contralateral location, 
interval of greater than 2 years from the primary 
tumor and absence of metastatic nodes in the shared 
lymphatics, however none of these is conclusive 
(Martini and Melamad 1975). Though same-
histology nodules in a different ipsilateral lobe 
were traditionally considered metastastic (M1), the 
recent IASLC staging project showed that these 
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adrenal metastases in non-small-cell lung cancer: 
a systematic review and pooled analysis. J Clin 
Oncol. 2008 1;26(7):1142-7. Voltolini L, Rapicetta 
C, Luzzi L, et al. Surgical treatment of synchronous 
multiple lung cancer located in a different lobe or 
lung: high survival in node-negative subgroup. Eur 
J Cardiothorac Surg. 2010;37(5):1198-204. Rami-
Porta R, Ball D, Crowley J, et al. The IASLC Lung 
Cancer Staging Project: proposals for the revision 
of the T descriptors in the forthcoming (seventh) 
edition of the TNM classiÀcation for lung cancer. 
International Staging Committee; Cancer Research 
and Biostatistics; Observers to the Committee; 
Participating Institutions. J Thorac Oncol. 
2007;2(7):593-602. 
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M28.4 PULMONARY METASTASECTOMY 
FOR OLIGOMETASTASES IN NON-LUNG 
CANCER
Tom Treasure 
Mathematics, Clinical Operational Research Unit 
UCL/United Kingdom
Abstract: Hellman and Weichselbaum in 1995 
proposed the existence of a clinical state of 
oligometastases.(JCO 1995;13:8) The word gained 
currency in deÀning patients with sufÀciently 
few metastases to offer a reasonable prospect of 
their eradication. Pulmonary metastasectomy was 
already established as a commonplace practice 
from the 1970s particularly for solitary metastases 
from colorectal cancer.(JRSM 2010;103:60) At the 
end of the 1980s substantial series of pulmonary 
metastasectomy operations for sarcoma were 
reported by Goldstraw(EJCTS 1989;3:105) 
and Pastorino(JSO 1989;40:275). The word 
oligometastasis had not yet been proposed.
The descriptive utility of the term is evident but the 
implication that there is an entity distinguishable by 
the “fewness” of metastases is not. It would require 
demonstration of a bimodal distribution in metastatic 
count. It is more likely that these are patients at one 
end of a continuous distribution of the number of 
metastases. Nevertheless, number matters. Fewer and 
particularly solitary pulmonary metastases have been 
shown to be associated with longer survival after 
pulmonary metastasectomy for all cancer types in the 
is the denominator? Only one study has been 
performed that prospectively evaluated surgical 
resection for patients with synchronous solitary 
metastases of NSCLC (Downey 2002). Though this 
study included patients with oligometastases in a 
variety of organs it is important because it provides 
us with a denominator, something missing in all 
other retrospective series reported to date. Downey 
et al conducted a phase II trial in 23 patients with 
solitary synchronous M1 NSCLC with or without N2 
disease who received three cycles of chemotherapy, 
followed by resection of all disease sites, and then 
two additional cycles of chemotherapy. 14 (63%) 
patients had brain metastases and the other sites 
of disease were adrenal (3), bone (3), spleen (1), 
lung (1) and colon (1). 13 patients underwent R0 
resection, of which only 8 completed the prescribed 
preoperative chemotherapy. Nine patients either had 
disease progression during induction treatment or 
were found to be unresectable at surgery. Median 
survival for the whole group (n=23) was 11 months 
and only 2 patients survived 5 years or more. Less 
than half (10/23) of the patients had resection of both 
the primary tumor and the solitary metastasis, which 
would be similar to the patient populations described 
in most retrospective studies. This ‘favorable’ group 
had a 5-year survival of 20%. Thus caution must 
be used when applying the seemingly good results 
of retrospective studies of oligometastasectomy to 
decision making in patient care. Conclusion Surgical 
resection of oligometastatic NSCLC, though feasible, 
remains controversial and should probably be 
performed only in highly selected patients and after 
discussion in a multidisciplinary forum. References 
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such as having few metastases, then the natural 
survivors will be over represented in surgical follow 
up studies. If the presumption is that less invasive 
means of ablation will replicate the claimed beneÀts 
of surgery, but with less harm, then the therapists 
should be reminded of this lack of proof. The best 
way to resolve this uncertainty is with a randomised 
controlled trial. The PulMiCC trial (Pulmonary 
Metastasectomy in Colorectal Cancer) is in essence 
a trial of surgical effectiveness in patients with 
oligometastatic disease.(JTO 2010:5(S6):S203) The 
number is not mandated by protocol; the design 
allows teams to allocate patients to metastasectomy 
when they believe there is uncertainty concerning 
beneÀt. On current evidence and practice this might 
include patients with 2-4 pulmonary metastases. 
However the number of metastases is only one of 
the factors on which a clinical decision might be 
based so solitary metastases, or 5+, are not excluded 
if, taking other factors into account, the team 
conclude that there is uncertainty about the decision 
to perform metastasectomy or not for this patient. 
It is only by such formal studies that we will bring 
a better understanding to whether the “fewness” of 
metastases has a utility in planning management. 
Keywords: Oligometastasis, Pulmonary 
metastasectomy
International Registry of Lung Metastases.(JTCVS 
1997;113:37) Early in the era of clinical acceptance 
of metastasectomy Aberg asked whether the 
effect of metastasectomy was fact or Àction?(ATS 
1980;30:378) He suggested that long survival might 
be related to the selection of good prognosis patients 
rather than surgical eradication of disease. He argued 
that survival might be erroneously attributed to 
surgery. Aberg’s hypothesis has not yet been refuted; 
citation network analysis shows that his challenge 
has largely been ignored(Fiorentino BJC 2011). The 
commonest primary cancer site for which pulmonary 
metastasectomy is undertaken is colorectal cancer. 
There have been many follow up and observational 
cohort studies with statistical analyses of the 
inÁuence of the number of metastases on survival. 
In the quantitative synthesis of 51 reports(JRSM 
2010;103:60) about 60% of 3504 patients had a 
solitary metastasis and that was more favourable 
than multiple metastases for survival as an outcome. 
In an analysis from MSKCC(ATS 2009;87:1684) the 
favourable effect of having oligometastatic disease 
was lost at four or more metastases. In the context 
of colorectal cancer this might serve as an upper 
bound on the oligometastatic state in the process of 
selecting patients for surgery or ablative therapies 
if we are to spare them unavailing interventions. 
The reminder that interventions to remove or 
ablate metastases might be followed by further 
progression of cancer should prompt practitioners 
to consider exactly what beneÀcial outcome they 
are seeking to achieve in the management of so 
called oligometastatic disease. The surgical literature 
is dominated by studies in which the outcome 
reported is survival, usually expressed as the 
proportion alive at Àve years. Symptoms, before or 
after metastasectomy, are very rarely mentioned. 
It is generally assumed that in the natural history 
of metastatic colorectal cancer survival to Àve 
years is a rare occurrence: survival is attributed to 
surgery in surgical reports. There are no controlled 
studies so attempts have been made to approach the 
question of effectiveness of metastasectomy by use 
of mathematical modelling.(JTO 2010;5(S6):S200) 
The Àrst notable Ànding, which contradicts the 
assumption that all survival is attributable to 
metastasectomy, is that in cancer registry data there 
are 5-10% natural survivors amongst patients deÀned 
as having metastatic disease on entry to the registry. 
If only a minority are selected (and data indicate 
that it is low single Àgure percentages) and that 
they are selected on factors which are prognostic, 
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an anti-mesothelin antibody and pseudomonas 
exotoxin (SS1P) are being conducted. Two Phase I 
studies showed SSP1 was relatively well tolerated 
and resulted in some interesting clinical effects, 
including partial responses and stable disease. 
A Phase II trial combining SS1P with standard 
chemotherapy is ongoing at the NCI in the U.S. 
A trial using a modiÀed listeria bacterial vector 
encoding mesothelin was also conducted, however 
preliminary results did not demonstrate generation 
of impressive cellular immune responses. Our group 
at the University of Pennsylvania conducted a series 
of Phase 1 clinical trials of a replication-incompetent 
adenoviral vector encoding HSVtk (Ad.HSVtk) 
delivered intrapleurally (followed by Ganciclovir) 
into 34 patients with pleural mesothelioma. Dose 
limiting toxicity was not reached, side effects were 
minimal and gene transfer was conÀrmed in a 
dose-related fashion with clearly detectable gene 
transfer (evidenced by immunostaining) at tumor 
surfaces and up to 30-50 cell layers deep. Anti-
tumor antibodies and strong anti-adenoviral immune 
responses, including high titers of neutralizing 
antibody and proliferative T-cell responses were 
generated, however, with no obvious adverse side 
effects. Interestingly, a number of clinical responses 
were seen at the higher dose levels, including two 
patients that remained alive (one without disease) for 
more than 10 years after vector instillation. Based 
on a series of preclinical experiments, our group has 
completed a series of Phase 1 dose escalation studies 
evaluating the safety and feasibility of intrapleural 
interferon-beta gene transfer using an adenoviral 
vector (Ad.IFNb) in patients with malignant pleural 
mesothelioma (MM) and metastatic pleural effusions 
(MPE). Ad.IFNb was administered through an 
indwelling pleural catheter in doses ranging from 9 
x 1011 to 3 x 1012 viral particles (vp). A total of 27 
patients in 3 trials have been dosed since 2005 and 
include 17 with malignant mesotheliomas, 5 with 
advanced lung cancer, 3 with metastatic ovarian 
cancer, and 2 with metastatic breast cancer. In the 
Àrst trial, we used one dose of vector; later trials 
used two doses spaced at 14 or 7 days apart.Subjects 
were evaluated for toxicity, gene transfer, humoral, 
cellular, and cytokine-mediated immune responses, 
and tumor responses via 18-Áuorodeoxyglucose 
(18FDG) positron-emission tomography (PET) scans 
and chest CT scans. Intrapleural Ad.INF-b was 
generally well tolerated with transient lymphopenia 
the most common side effect. The presence of the 
vector did not elicit a marked cellular inÀltrate in 
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Abstract: Malignant Mesothelioma has been a 
target of immunotherapy for decades. Early studies 
used systemic and/or intrapleural cytokines delivery 
to initiate immune response. In the early 1990’s, 
Boutin and colleagues showed signiÀcant clinical 
responses in early-stage mesothelioma to intrapleural 
administration of interferon-gamma. Subcutaneous 
interferon-alpha (a Type 1 interferon) demonstrated 
anti-tumor activity in clinical trials. Immunotherapy 
trials using IL-2 have also been conducted, either 
as single agent intrapleural, or in combination 
with multi-modality therapy. Vaccines have also 
been studied in clinical trials. Approaches include 
autologous tumor cells (with and without adjuvants 
such as GM-CSF) and a vaccine containing peptides 
from the Wilms tumor-1 (WT-1) gene product with 
cellular and humoral immune responses induced, 
and notation of anecdotal clinical responses. More 
recently, a trial conducted in the Netherlands by 
Hegmans et al. using tumor antigen-loaded dendritic 
cells has shown promise. Based on strong preclinical 
data, a clinical using an agonistic CD40 antibody 
to stimulate immune responses in combination 
with Gemcitabine chemotherapy was recently 
initiated at the Sir Charles Gairdiner Hospital in 
Perth, Australia. The protein mesothelin, which 
is highly upregulated on mesothelioma, has been 
indentiÀed as a potentially good tumor antigen and 
thus a target for immunotherapy. Clinical trials 
initiated at the NCI using a high afÀnity antibody 
alone (MORAB-009) or a fusion protein between 
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the standard therapeutic armamentarium. 
Keywords: immunotherapy, mesothelioma, Vaccine, 
Cytokine
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E01.3 MPM GUIDELINES IN THE YEAR 
2011
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Abstract: Malignant pleural mesothelioma (MPM) 
has become a serious issue because of its global 
poor prognosis and its growing incidence. This 
incidence seems to have already reached a peak in 
some countries where asbestos was banned earlier 
than in most countries, taking account of the long 
latency of mesothelioma (about 40 years) after 
asbestos exposure, its main tumorogenic factor. 
However, MPM incidence is expected to increase 
for at least the next ten years in several Western 
countries, linked to a late ban of asbestos (for 
example, only in 2005 in the European Community). 
Moreover asbestos is still widely produced and 
used in many emerging or developping countries, 
suggesting the risk of a future worldwide epidemy 
of malignant mesothelioma in the next decades. 
In 2009, the European Respiratory Society (ERS) 
and the European Society of Thoracic Surgeons 
(ESTS) experts proposed practical and up-to-dated 
guidelines on management of MPM (Eur Respir J. 
2010 35(3): 479-95. [Epub 2009 Aug 28]). Are these 
guidelines still relevant in 2011? To obtain an earlier 
and reliable diagnosis of MPM is a crucial issue. The 
experts recommended, except in case of preoperative 
contraindication or pleural symphysis, to perform 
thoracoscopy with multiple histological biopsies for 
the diagnosis of MPM. To date, the performances 
of other diagnostic procedures, i.e. pleural cytology, 
blind or even guided pleural biopsies, are still too 
low compared to thoracoscopy, the gold standard 
for MPM diagnosis. Standard staining procedures 
in pathology are insufÀcient in 7-15% of cases. 
Therefore it is recommended that a diagnosis of 
MPM always be based on immunohistochemical 
examination. The International Mesothelioma 
Panel also recommended to use two markers 
with positive diagnostic value for mesothelioma 
(anti-calretinin and anti-WT1 or anti-EMA, or 
for epithelioid mesothelioma, anti-CK5/6...) and 
the pleural space. Good gene transfer seen after 
Àrst dose with high IFN beta levels measured in 
the pleural Áuid after vector installation. However, 
only very low gene transfer seen after a second 
dose- with either 14 day and 7 day spacing. We 
attribute this to rapid upregulation of neutralizing 
antibodies against adenovirus. Anti-tumor humoral 
immune responses were seen almost all patients with 
reactions seen against known Meso tumor antigens 
(SV40 large T antigen and mesothelin) and against 
unknown proteins in cell lysates. Given the caveats 
of Phase 1 trials (small numbers, different doses, 
heavily pretreated patients), we still saw clinical 
responses (deÀned as prolonged stable disease, 
prolonged survival, partial or complete responses 
by modiÀed RESIST criteria, decreased metabolic 
tumor activity by PET scanning, or “mixed” 
responses) in about 1/3 of the patients. We are 
currently administering two doses of a similar Type 
I interferon transgene - Intrapleural Ad.INF-alpha-
2b - spaced only three days apart. This appears to 
be well tolerated. Based on strong preclinical data 
supporting the combination of gene therapy and 
chemotherapy, we have started a trial using Ad.INF 
instillation into the Àrst treatment cycle of Àrst line 
(Cisplatin/Pemetrexed) or second line chemotherapy 
(Gemcitabine). We are also utilizing concomitant 
COX-2 inhibition with Celecoxib to modulate 
intratumoral immunosuppression, and to decrease 
suppressor cell activity, as has been demonstrated 
by Hegmans, et al. Our groups is also generating 
“designer chimeric T cells” in which a single chain 
antibody fragment is linked to the transmembrane 
and cytoplasmic regions of the T-cell receptor. This 
artiÀcial T-cell receptor is then transduced into 
T-cells that are then reinfused. The T-cells are then 
activated by cells expressing mesothelin. Preclinical 
data show striking activity against mesothelin-
expressing tumors in mice. Mesotheliomas make 
large amounts of the immunoinhibitory cytokine, 
transforming growth factor-beta (TGF-b). Preclinical 
studies using TGF-b blockers have shown activity 
in mouse models of mesothelioma and a clinical 
trial using an anti- TGF-b antibody is ongoing at the 
University of Pennsylvania and the University of 
Chicago. In summary, immunotherapies are being 
actively studied in mesothelioma and have shown 
some promising results. Future trials are focusing 
on combining these approaches with chemotherapy 
and surgery. Given the relatively mild and non-
overlapping toxicities, we believe these, or other 
immunologic approaches will soon become part of 
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(EORTC 08031...) and studies raise the question 
of the feasibility and the value of EPP. Therefore 
several authors suggested that P/D could be a better 
surgical procedure as part of multimodal treatment. 
Due to the lack of strong evidence, it is not possible 
to recommend radiotherapy after EPP or P/D in 
routine, even using intensity-modulated radiotherapy 
(IMRT). Thus post-operative irradiation should only 
be proposed in clinical trials, in specialized centres 
for MPM. Finally there are new exciting therapeutic 
tools or strategies such as targeted therapies, gene or 
cell therapies but still under investigation in MPM 
patients. Some of these new agents such as pro-
apoptotic drugs (histone deacetylase inhibitors...) or 
anti-angiogenic tools will be detailed during this talk. 
In conclusion, guidelines on MPM management from 
2009 ERS/ESTS taskforce are still relevant in 2011. 
Because of still limited data available on the best 
combination treatment for MPM in 2011, it must be 
emphasized that inclusion of MPM patients in Àrst 
and second-line clinical trials is highly encouraged, 
and that potential candidates for a multimodal 
approach should be included in a prospective trial in 
specialized centres. 
Keywords: mesothelioma, guidelines, diagnosis, 
treatment
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Abstract: FDG-PET/CT imaging is a major 
component in the staging of non-small cell lung 
cancer patients. It is an integral part for the optimal 
deÀnition of target volumes as well.[1] Although 
respiratory movements have been incorporated 
in radiation planning by 4D-CT scans, the role of 
respiratory correlated (or 4D) PET imaging is still 
two markers with negative diagnostic value (anti-
Ber-EP4, anti-TTF1...) to validate the diagnosis. 
The staging of MPM is still a difÀcult issue in the 
absence of a uniform, robust and validated staging 
system. A new staging system for MPM should be 
proposed soon by experts from a joined IASLC-
IMIG project. But to date, the ERS/ESTS experts 
adviced to use of the most recent (1995) TNM 
based classiÀcation, and proposed a three steps pre-
treatment assessment according to the therapeutic 
project of each patient. Performance status of the 
patient and histopathological subtype of the tumor 
(the epithelioid subtype is considered of better 
prognosis than other MPM subtypes) are currently 
the only prognostic factors of clinical importance 
in the management of MPM in the general practice. 
Other potential clinical or biological prognostic 
parameters, suggested by the EORTC and the 
CALGB for instance, should be recorded at baseline 
and reported in clinical trials. Monitoring of patients 
still relies mostly on clinical examination and chest 
CT-scan data, using modiÀed RECIST criteria. 
Based on recent but limited literature, PET-scan 
and potential soluble tumor markers such as blood 
mesothelin (SMRP) seem promising in this goal 
but are not validated in routine. MPM exhibits 
a high resistance to standard chemotherapy and 
only few patients are candidate for radical surgery. 
ERS/ESTS guidelines on MPM treatment are still 
relevant in 2011. When a decision is made to treat 
patients with chemotherapy, subjects in a good 
performance status (PS > 60% on the Karnofsky 
scale or < 3 on the ECOG scale) should be treated 
with Àrst line combination chemotherapy consisting 
of platinum and pemetrexed (or raltitrexed). Patients 
demonstrating prolonged symptomatic and objective 
response with Àrst line chemotherapy may be 
treated again with the same regimen (pemetrexed) 
in the event of recurrence. Alternatively, inclusion 
of the patients in Àrst and second-line clinical 
trials is highly encouraged. Radiotherapy and 
surgery indications are limited and still highly 
discussed in MPM. In 2009, it was also stated that 
(a) radical surgery (extrapleural pneumonectomy 
or EPP) should be performed only in clinical trials, 
in specialized centres, as a part of multimodal 
treatment, and (b) pleurectomy/decortication (P/D) 
should not be proposed in a curative intent but 
can be considered in patients to obtain symptom 
control, especially symptomatic patients with 
entrapped lung syndrome who cannot beneÀt from 
chemical pleurodesis. However recent clinical trials 
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For this phase, the corresponding phase of the CT 
scan can be chosen on which the target and organs-
at-risk delineations are performed. The advantage is 
that the statistical accuracy is again comparable to 
the standard 3D PET but without motion-blurring.
In conclusion, compared to 4D CT imaging the 
counterpart for 4D PET has not been widely used 
in clinical practice. There is a potential for 4D 
PET also in the clinical routine. This may also be 
necessary in future where PET imaging will be more 
frequently used in (automatic) target deÀnition or 
with the current trials focusing on boosting and dose-
painting an accurate (sub-)target volume deÀnition 
is mandatory. Using respiration-correlated PET 
imaging removes one of the uncertainties in this 
tumor characterization procedure.
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not implemented in routine clinical practice.
4D PET imaging typically uses a surrogate 
measurement of the patient’s respiratory cycle, e.g. 
a pressure belt strapped around the thorax of the 
patient or imaging of a reÁective marker positioned 
on the patient’s chest. Afterwards the 4D PET scan 
is reconstructed according to measured breathing 
surrogate. A phase-based or an amplitude based 
reconstruction algorithm might be used for this.
The advantages of 4D PET imaging are numerous. In 
principle a more accurate quantiÀcation of the tumor 
volume is possible because motion-blurring due to 
respiration is removed. Small nodules might become 
detectable and accurate SUV quantiÀcation is more 
robust.[2] Removing respiratory blurring from the 
PET images decreases one of the components that 
adds to the overall uncertainty of entire procedure.
Possible drawbacks that are currently hampering 
further implementation are due to non-optimized 
logistics and technical issues in the commercial 
systems. Attenuation correction of the individual 
phases need a proper matching of the corresponding 
CT phase, this might cause problems if the CT is 
made using an amplitude binning algorithm and 
the PET is binned according to a phase-binning 
type. Handling the large amount of data could be 
problematic and viewing stations might not be able 
to show the 4D phases of a respiratory correlated 
acquisition. Prolonged acquisition times are 
necessary to have enough statistical accuracy to yield 
the same contrast-to-noise ratios as in conventional 
non-gated PET acquisitions.
There are various solutions to incorporate tumor 
motion during the respiratory cycle in the image 
acquisition or reconstruction. A Àrst simple approach 
might be to acquire a 3D PET image using multiple 
breath holds, however given the condition of lung 
cancer patients this might not be a feasible approach 
for the majority of the population. A somewhat 
intermediate approach has been proposed by Liu 
et al.[3] and van Elmpt et al.[4] that make use of 
the longer exhale phase in the breathing cycle to 
reconstruct a static PET image with only information 
acquired in this phase. Motion blurring is minimal 
and hence a non-blurred static 3D PET image is 
acquired. Other techniques that are currently under 
development are the use of non-rigid registration 
models either directly implemented in the list-mode 
PET reconstruction software or afterwards applied 
to the reconstructed 4D PET images [5]. These 
techniques allow the reconstruction of a single 3D 
PET image at a reference phase that can be chosen. 
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motion, reducing the beneÀt of gating/tracking 
or potentially even reducing the overall accuracy. 
Alternatively, intra-fraction imaging can be designed 
to monitor the mean (over the respiratory cycles) 
target position, trailing systematic changes to the 
position of the target. Such tumor trailing techniques 
requires less complex systems with lower response 
time and lower imaging frequencies with lower 
imaging dose. Adaptive radiotherapy (ART) typically 
utilizes a feedback loop that operates at a time scale 
of days to weeks. Over this time period, patient 
speciÀc variations and systematic discrepancies 
between planning and delivery are quantiÀed. 
Subsequently, a new treatment plan is designed 
that takes these patient speciÀc parameters into 
account. Because systematic errors have a factor of 
4 larger impact on the delivered dose than random 
error, such adaptations based on information from 
previous days remains effective. For stereotactic 
body radiotherapy (SBRT), delivering a high 
therapeutic dose in only a small number of fractions, 
the beneÀt of ART is expected to be limited. For 
conventional fractionated RT, ART has the potential 
to account for shape changes, differential baseline 
shifts and even geometric and biological response. 
Currently, necessary tools to implement ART are 
not commercially available, hampering large scale 
clinical implementation. Additionally, it has not been 
proven that adapting the treatment plan to treatment 
response (tumor regression and/or biological 
response) is safe and effective. Such adaptations 
should therefore only be implemented in clinical 
trials. 
Keyword: imaging, adaptive radiotherapy, 
intrafraction motion, respiration
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E02.3 ADVANCES IN ON-BOARD IMAGE-
GUIDANCE
Matthias Guckenberger 
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Abstract: Traditionally, patient set-up in daily 
treatment was based on skin marks and portal 
imaging was performed for veriÀcation of patient 
set-up. However, image quality, especially soft-tissue 
contrast, of these portal images was insufÀcient 
for visualization of the pulmonary target itself: the 
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E02.2 INTRAFRACTIONAL AND 
ADAPTIVE CORRECTION STRATEGIES
Jan Jakob Sonke 
Radiology, NKI-AVL/Netherlands
Abstract: Radiation therapy of lung cancer is 
associated with complex geometrical uncertainties 
such as respiratory induced motion, (differential) 
baseline shifts of primary tumor and involved lymph 
nodes and anatomical changes due to treatment 
response. Consequently, the actually delivered dose 
generally does not equal the planned dose (what 
you see is not what you get). In the absence of 
correction strategies, generous safety margins are 
required to account for these uncertainties which 
limit the potential of dose escalation to improve 
treatment outcome. The current state of the art in 
accurate treatment delivery of radiation therapy is 
IGRT (image guided radiotherapy), which is the 
process of 1) acquiring an image of the patients 
anatomy, generally in the treatment room with 
the patient in treatment position, 2) comparing 
the treatment position with planned position of 
the tumor, organs at risk or some surrogate and 3) 
correcting the treatment position, generally with 
a couch correction. Such correction strategies 
are mostly limited to the management of inter-
fraction setup error and inter-fraction baseline 
shifts. Further improvements are expected from 
so-called imaging feedback-loops, e.g. utilizing 
information obtained from repetitive imaging that 
are fed back to the delivery process. Such feedback 
loops can operate at a short time scale (seconds to 
minutes) to manage intra-fractional variability, or 
at a longer time scale (days to weeks) to manage 
inter-fractional variability’s and progressive changes. 
Intra-fraction monitoring generally aims to quantify 
respiratory induced motion and feeds this signal to 
the delivery system to either gate the beam (only 
switch on the beam when the target is predicted to 
be within a region of interest) or to track the target 
(continuously steer the beam to the target). Due to 
the random nature of respiratory induced motion 
during treatment delivery, the expected gain of 
such gating and tracking techniques are likely to be 
limited. Moreover, currently available techniques are 
often based on an external surrogate of respiratory 
motion. Various groups have demonstrated limited 
correlation between external signals and internal 
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which can be detected with CBCT and can be used 
to initiate an adaptation of radiotherapy (Fig. 1). Not 
only changes of tumor but also of the normal tissue 
(atelectasis, pleural effusion) is regularly observed 
and such changes should trigger replanning if certain 
thresholds are exceeded. Such adaptive replanning 
work-Áows, however, are still an area of active 
research and further technologies like deformable 
image registration are required for broad clinical 
implementation. 
Keywords: NSCLC, Onborad imaging, cone beam 
CT, adaptive radiotherapy
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E02.4 ROLE OF PET SCANS IN 
RADIOTHERAPY - PROGNOSIS AND 
TARGET DEFINITION
Michael P. MacManus 
Radiation Oncology, Peter MacCallum Cancer 
Centre/Australia
Abstract: Introduction The advent of PET imaging, 
and more recently of its technically superior 
cousin PET/CT, has transformed the way radiation 
oncologists approach lung cancer. After biopsy, 
18F-Áuorodeoxyglucose (FDG)-PET/CT is the most 
signiÀcant single investigation for selecting patients 
for deÀnitive radiotherapy or chemoradiotherapy. 
PET/CT often contradicts conventional imaging (CI) 
and has a much higher probability of reÁecting the 
true extent of primary, nodal and metastatic disease 
than CI. Role of FDG-PET in Patient Selection for 
Radiotherapy: PET as a Pre-Treatment Prognostic 
Factor Stage is the most important prognostic factor 
in NSCLC. Numerous individual prospective studies 
and several meta-analyses have proven the superior 
accuracy of PET assisted mediastinal staging 
compared to CT based staging. PET and PET/CT 
are also superior for detecting distant metastasis. 
In a prospective study of radiotherapy candidates, 
about one third of 153 cases were found to be 
unsuitable for potentially curative therapy after PET, 
either because of distant metastasis or extensive 
mediastinal disease 1. PET stage was more predictive 
of survival than CI stage. Similar results were 
reported by a Polish group in that only 75 of 100 
radical radiotherapy patients with NSCLC actually 
went on to receive radical RT after PET/CT imaging 
2. The standardized uptake value or SUV, may have 
bony anatomy then served as a surrogate for the 
target position. However, today it is well known 
that substantial tumor motion independently from 
the bony anatomy is observed in many patients. 
This cannot be detected with portal images; if 
not compensated by appropriate, rather large 
safety-margins, underdosage of the tumor with 
decreased local tumor control is the consequence. 
Since several years, image-guidance technology 
has become available for veriÀcation of the target 
position prior to treatment. The most advanced 
and most frequently used technique is the so-call 
cone-beam CT (CBCT): this technology consists 
of a kilo-voltage x-ray source integrated into the 
linear accelerator with a digital Áatpanel for image 
acquisition. The imaging is installed orthogonal to 
the therapeutic mega-voltage beam and allows for 
acquisition of a volumetric image within a 180° 
gantry rotation. The image quality of this CBCT 
is sufÀcient for visualization of soft tissue tumors, 
despite mediastinal structures cannot be fully 
segmented. The major advantage of this on-board 
design is the fact that imaging can be performed 
in treatment position without needing to move the 
patient or the treatment couch, which could introduce 
secondary errors. Since recently, respiration 
correlated CBCT is available for full integration of 
breathing motion into the image-guidance work-Áow. 
For hypo-fractionated stereotactic body radiotherapy, 
veriÀcation of the target position prior to every 
treatment fraction using CBCT is considered as 
best practice: this compensates for both set-up 
errors of the patient as well as base-line drifts of 
the pulmonary tumor within the lung. It needs to 
be considered that such base-lien drifts could cause 
the tumor to move closer to a critical organ-at-risk 
with the risk of increased toxicity if this image-
guided isocenter correction is performed. Depending 
on immobilization, total treatment time and 
fractionation, repeated imaging during the treatment 
fraction might be reasonable for intra-fractional 
target monitoring. It is essential that breathing 
induced motion of the target is fully integrated into 
the image-guidance work-Áow. In conventionally 
fractionated radiotherapy, image-guidance might me 
more complicated. Motion or drifts of the primary 
tumor independently from the mediastinal / hilar 
nodes has been described. Such complex changes of 
the shape of the target volume cannot be corrected 
via a single couch correction. Additionally, shrinkage 
of the macroscopic tumor is frequently observed in 
conventionally fractionated radio(chemo)therapy, 
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an approach currently being investigated by De 
Ruysscher and colleagues. We are exploring PET 
imaging with both FDG and the proliferation marker 
18F-3-deoxy-3-Áuoro-l-thymidine (FLT) to 
assess tumour response during therapy. Role of PET 
Response assessment as a Prognostic Factor after 
Radiotherapy There is clear evidence that FDG-
PET imaging performed approximately 2 months 
after completion of treatment provides powerful 
prognostic information and is far superior to CT 
5. Metabolic response measured by FDG-PET is 
the most important single prognostic factor after 
chemoradiation. Conclusion Molecular imaging with 
FDG-PET/CT has rapidly become established as the 
key imaging modality for lung cancer. It profoundly 
affects patient selection and radiotherapy planning. 
Staging and restaging with PET also provides the 
most powerful pre- and post-treatment prognostic 
information available. The results of studies 
currently in progress may eventually lead to dynamic 
changes in the delivery of radiotherapy during the 
treatment course. References 1. Mac Manus MP, 
Hicks RJ, Ball DL, et al. F-18 Áuorodeoxyglucose 
positron emission tomography staging in radical 
radiotherapy candidates with nonsmall cell lung 
carcinoma: powerful correlation with survival and 
high impact on treatment. Cancer 2001;92:886-95. 2. 
Kolodziejczyk M, Kepka L, Dziuk M, et al. Impact 
of [(18)F]Fluorodeoxyglucose PET-CT Staging on 
Treatment Planning in Radiotherapy Incorporating 
Elective Nodal Irradiation for Non-Small-Cell Lung 
Cancer: A Prospective Study. Int J Radiat Oncol 
Biol Phys. 3. De Ruysscher D, Wanders S, Minken 
A, et al. Effects of radiotherapy planning with a 
dedicated combined PET-CT-simulator of patients 
with non-small cell lung cancer on dose limiting 
normal tissues and radiation dose-escalation: a 
planning study. Radiother Oncol 2005;77:5-10. 
4. Nestle U, Kremp S, Schaefer-Schuler A, et al. 
Comparison of different methods for delineation 
of 18F-FDG PET-positive tissue for target volume 
deÀnition in radiotherapy of patients with non-
Small cell lung cancer. J Nucl Med 2005;46:1342-8. 
5. Mac Manus MP HR, Matthews JP, McKenzie 
A, Rischin D, Salminen EK, Ball DL. Positron 
Emission Tomography is superior to CT scanning 
for response-assessment after radical radiotherapy/
chemoradiotherapy in patients with non-small cell 
lung cancer. J Clin Oncol 2003;21:1285-92. 
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prognostic signiÀcance. Some reports indicate that 
as the SUV rises the prognosis worsens, but not all 
studies are in agreement and it is unclear to what 
extent SUV is an independent prognostic factor 
because SUV is correlated with stage. Role of FDG-
PET for Radiotherapy Target DeÀnition in NSCLC 
Because FDG-PET based imaging is the most 
accurate we have, it is logical to use this information 
routinely in radiotherapy planning, employing it 
as a “gold standard” in the absence of pathological 
staging. All published studies show a clinically 
signiÀcant impact of PET in radiotherapy planning. 
The magnitude of this effect differs between studies 
reÁecting, varied sample sizes and radiotherapy 
planning practices. In cases with atelactasis it is 
often possible to spare collapsed lung and reduce 
the target volume. In other cases, PET may caused 
an increase in the target volume when small lymph 
nodes are found to be FDG positive. PET may based 
planning may enable safe dose escalation 3. Only a 
recent PET/CT scan should be used for radiotherapy 
planning. In a prospective study we reported a 
very rapid rate of disease progression between 
initial staging PET scans and radiotherapy planning 
images performed a median of 3 weeks later. 
Approximately 39% of scans showed progressive 
disease at locoregional or distant metastatic sites, 
which in 29% of cases caused a change from radical 
to palliative therapy. An enormous advantage of 
PET/CT is the reduced observer variability in tumour 
contouring compared to CT alone. However, even 
using PET/CT images, there can be signiÀcant 
variations between observers. Our centre employs 
a visual contouring protocol to achieve a high level 
of reproducibility. Other centres use automated 
approaches to tumour contouring, in which a 
software programme determines tumour margins. 
A wide range of automated methods is available 
and all have their limitations 4. Automated methods 
cannot entirely replace the human observer, but these 
protocols can provide an excellent starting point for 
subsequent human editing. Potential Role of PET 
Response assessment as a Prognostic Factor during 
Radiotherapy/Chemoradiation Tumor imaging during 
therapy may allow for modiÀcation of the treatment 
course in real time. Serial PET imaging during 
a course of radiotherapy can provide prognostic 
information and may also provide an opportunity 
to target higher radiation doses to regions that 
are more resistant to therapy. Alternatively, the 
baseline PET scan may be used to target regions of 
most intense tumour activity with boosting dose, 
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non-invasive cardiac testing treatments. If they 
need coronary intervention, lung resection should 
be postponed at least for 6 weeks. If the condition 
can be treated medically, treatment should be 
instituted and evaluation should proceed with lung 
function tests (6). 4.- Lung function Once the cardiac 
evaluation is performed and the patient is found to 
have low risk or can be medically treated, next step 
is the evaluation of lung function. The recommended 
Àrst step is forced expiratory volume in 1 second 
(FEV1) and diffusing capacity of the lung for carbon 
monoxide (DLCO). If both are greater than 80%, 
lung resection, including pneumonectomy, can be 
performed with acceptable risk. If either one is 
below 80%, further tests are needed. In the latest 
guidelines (6), the next test is the peak oxygen 
consumption (peak VO2). If it is greater than 75% 
or greater than 20 mL.kg-1.min-1, any type of lung 
resection can be performed with an acceptable 
risk. However, if it is less than 35% or less than 
10 mL.kg-1.min-1, lobectomy and pneumonectomy 
are not recommended and other options should be 
considered. For those patients whose peak VO2 is 
between 35 and 75% or 10-20 mL.kg-1.min-1, split 
function tests to calculate the predicted postoperative 
FEV1 (ppo-FEV1) and DLCO (ppo-DLCO) are 
indicated. If both are greater than 30%, resection 
can be performed. If one is below 30%, further 
decisions are based on the ppo-VO2: if greater than 
35% or greater than 10 mL.kg-1.min-1, resection can 
be performed with acceptable risk; but if below 35% 
or less than 10 mL.kg-1.min-1, then resection is not 
recommended. 5.- The borderline operable patient 
There are patients whose scores do not recommend 
resection, but resection could still be possible if 
the proper alternatives are considered. This is the 
borderline operable patient. Parenchyma-saving 
resections are acceptable alternatives to lobectomy 
and pneumonectomy. Sublobar resection, preferably 
segmentectomy, may be a good alternative to 
lobectomy in patients with borderline pulmonary 
function tests, and sleeve lobectomy may be a good 
alternative to pneumonectomy. Sublobar resections 
are associated with higher local recurrence rates, but 
long term survival is similar to that of lobectomies 
(7). Sleeve lobectomies spare lung parenchyma and 
their oncological value is similar to larger resections 
(8). In selected patients with heterogeneous 
emphysema in upper lobes, an upper lobectomy 
may even improve postoperative lung function 
(9). Minimally invasive techniques, such as video-
assisted thoracoscopic lobectomy, segmentectomy 
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Abstract: Introduction In selecting patients with 
lung cancer for lung resection, two different concepts 
have to be considered: operability and resectability. 
Operability is a patient’s condition that will enable 
the patient to undergo the planned lung resection 
or not. Resectability is a condition of the tumour 
that indicates whether it can be completely resected 
or not, providing the patient with a probability of 
long-term survival (1). The assessment of all lung 
cancer patients is recommended to be performed 
by a multidisciplinary team (MDT) of specialists 
from all the disciplines related to the case: imaging, 
pulmonology, oncology, pathology, nuclear 
medicine, and thoracic surgery. The MDT will assess 
the critical factors in each patient and will make the 
necessary diagnostic and therapeutic indications, 
after consideration of the patient’s performance 
status, comorbidity, and cardiac and lung condition 
(2). 2.- General condition The patient’s general 
condition is commonly assessed by a comorbidity 
index (the Charlson index) and the performance 
status index (Karnofsky or Zubrod). The Charlson 
index considers the presence or absence of diabetes, 
renal failure, lung conditions, cardiovascular 
conditions, previously treated cancers (except 
for squamous cell carcinoma of the skin), and 
alcoholism, among others (3). The Charlson index is 
predictive of survival both in patients with resected 
and non-resected tumours (4, 5). The different 
performance status indexes describe the degree of 
activity of the patients and their general condition. 
3.- Cardiac function The European Society of 
Thoracic Surgeons (ESTS)/European Respiratory 
Society (ERS) guidelines for preoperative evaluation 
recommend that patients with cardiac conditions 
requiring medication, or with any newly suspected 
cardiac condition, or inability to climb two Áights 
of stairs should have a cardiac consultation with 
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WITH POOR PULMONARY FUNCTION
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Abstract: Stereotactic Body Radiotherapy (SBRT) 
is characterized by one or a few fractions with a 
high dose per fraction using high precision delivery 
techniques. Because of the reported excellent local 
control rates in the 90% range of SBRT in early 
stage medically inoperable Non Small Cell Lung 
Cancer (NSCLC) patients, SBRT is increasingly 
used. To make a choice for a non-invasive treatment 
like SBRT over surgery is especially valid in 
elderly and frail patients. The most relevant acute 
and late toxicity of SBRT for patients with poor 
pulmonary function is radiation-induced lung 
toxicity like radiation pneumonitis (RP), lung 
Àbrosis, or perfusion changes all resulting in 
decreased pulmonary function (PF). To decide 
whether SBRT is a good treatment option in 
patients with severe pulmonary co-morbidities it 
is important to: 1) Measure changes in pulmonary 
function tests after SBRT in patients with poor PF 
2) Understand the pulmonary perfusion changes 
after SBRT 3) Test available models to estimate the 
incidence of radiation pneumonitis after SBRT 1) 
Pulmonary function test changes after SBRT: In a 
large international group of patients treated with lung 
SBRT four-hundred eleven patients were treated 
using image guided radiotherapy for T1-T2N0M0 
NSCLC. The inÁuence of SBRT on pulmonary 
outcome was presented by Guckenberger et al. at 
ASTRO 2010. The mostly medically inoperable 
patients with peripheral tumors were irradiated 
within Àve radiotherapy departments from 1998-
2009. Median age was 74 years. T1N0 tumors were 
diagnosed in 68%, T2N0 in 30% and 1% with locally 
recurrent lung cancers after surgery. The median 
maximum tumor dimension was 2.4 cm (range 
0.9-8.5 cm). Patients were treated with a variety 
of prescription doses according to each institute’s 
local protocol (median dose 54 Gy in 3 fractions, 
median overall; treatment time 8 days). Median 
or wedge resection minimize the effect of the 
incisions on the chest wall mechanics, reducing 
the postoperative loss of function. Another aspect 
to consider is the improvement of lung function by 
pulmonary rehabilitation. This improvement may 
shift the patient’s condition from borderline operable 
to operable. References: 
1. Grupo Cooperativo Médico-Quirúrgico del 
Carcinoma Broncogénico del Hospital Universitario 
12de Octubre de Madrid. Carcinoma Broncogénico, 
2010 update: www.mbeneumologia.org/pautaCB. 
2. Ninane V, Le Pechoux C, Curran W et al. Critical 
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patients treated with hypofractionated proton 
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incidence of radiation pneumonitis are clinically 
available and can be used before the start of SBRT 
treatment. It may therefore be concluded that a poor 
pretreatment pulmonary function alone should not 
be used to exclude medically inoperable patients 
with early stage NSCLC, who are candidate for 
SBRT, for this treatment. For patients with severe 
pulmonary co-morbidities the advantage of SBRT 
over surgery is the favorable decrease of pulmonary 
function compared to limited resection (for example 
anatomical segmentectomy). 
Keywords: Poor Pulmonary Function, radiation 
pneumonitis, Non small cell lung cancer, SBRT
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Abstract: Integrated Positron Emission Tomography 
/ Computed Tomography (PET/CT), introduced in 
clinical practice in 1998, is the combination of two 
different examination techniques in one machine: 
Computed Tomography (CT) giving anatomic 
information and Positron Emission Tomography 
(PET) giving metabolic information. PET/CT 
has two major advantages: 1/ CT can be used for 
attenuation correction and 2/ PET/CT improves 
diagnostic accuracy when compared to CT and PET 
alone. A rapidly expanding amount of literature 
demonstrates the additional value of PET/CT in the 
diagnosis, staging, prognosis, treatment planning, 
assessment of treatment response and diagnosis 
of recurrence of different tumor types. In general, 
the additional information provided by PET/CT 
is 1) the detection of lesions initially not seen on 
CT or PET alone, 2) a more precise localization 
of the lesion 3) a better delineation of the lesion 
and its relationship with the surrounding structures 
and 4) a better characterization of the lesion as 
pretreatment FEV1 was 1.4l (range 0.43 to 4.4l) 
median predicted DLCO was 53% (range 10-103%). 
Radiation induced pneumonitis grade II occurred 
in only 7% of all patients and was not increased in 
patients with lower pretreatment pulmonary function. 
In multivariate analysis pretreatment DLCO was 
correlated with decreased overall survival. It was 
concluded that a poor pulmonary function should 
not be a contraindication for SBRT. 2) Post SBRT 
pulmonary perfusion analysis : Forty-two inoperable 
patients with early stage NSCLC in the left or right 
upper lobe (median GTV=7.0cc) were irradiated 
with SBRT and analyzed at the NKI-AVL. The 
prescription dose was 54 Gy in 3 fractions and 
median Mean Lung Dose of 7.9 Gy (range 3.4-16.6 
Gy). Prior to treatment and 4 months post SBRT 
a single photon emission computed tomography 
(SPECT) lung perfusion scan was acquired. The 
scans were registered to the planning CT and the 
corresponding planned dose distribution to obtain the 
effect of the local dose with the relative reduction in 
perfusion. The doses were converted to EQD
2
 with 
an Ơ/ơ ratio of 3 Gy. The well-perfused regions in 
the lung were extracted and the local dose effect 
relation for lung perfusion was found established (by 
Àtting a 3-parameter logistic model, maximal effect 
a = 42.36%±1.0, the dose for which 50% of the 
effect was reached D
50
=46.36±0.5 and the steepness 
parameter k=1.5±0.08). In conclusion: a local dose 
response relation for reduction in lung perfusion four 
months after SBRT treatment was established and 
will be tested in a larger group of patients treated 
at different time points. 3) The Mean Lung Dose a 
commonly used model in conventionally fractionated 
radiotherapy to estimate the incidence of RP was 
analyzed in a group of 187 NSCLC patients treated 
with SBRT (54 Gy in 3 fx) at the NKI-AVL (see 
abstract by Scheenstra et al.). Median FU-time was 
17 months. The crude incidence of RP grade 2 was 
4.25%, no grade 3 RP was observed. All RP were 
reported at 3-4 months after SBRT, except in one 
patient that experienced RP 1 month after SBRT. 
For lung SBRT the incidence of RP grade 2 was 
correlated with the Mean Lung Dose. Conclusions: 
The reported incidence of radiation pneumonitis 
grade 2 or higher was low after SBRT (7%) in 411 
medically inoperable stage I lung cancer patients 
treated with SBRT. A poor pretreatment pulmonary 
function was not associated with increased rates 
of toxicity in these patients . Analysis of perfusion 
reduction in SBRT patients at four months revealed 
local perfusion changes. Models to predict the 
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will be very unlikely to gain useful information 
from PET for a lesion below 5 mm. A positive PET 
in a small, intermediate risk lesion might push one 
toward biopsy or excision, though a negative PET 
in such a lesion must be considered to provide 
no information whatsoever. Highly differentiated 
tumors and certain tumor entities such as mucinous 
carcinomas may exhibit only insigniÀcant FDG-
uptake due to only modest hexokinase activities and 
may thus not be detected with FDG-PET/CT. Tracers 
binding to speciÀc receptors or entering different 
metabolic pathways can act as an alternative for 
imaging. Such tracers are e.g. 68Ga-DOTATOC for 
neuro-endocrine tumors, 18F-Flurorothymidine (FLT) 
for proliferation imaging, 18F-Áuoromisonidazole 
(FMISO) for hypoxia imaging. Thoracic 
radiotherapy with curative intent for NSCLC is 
challenging. One distinct advantage of PET/CT in 
radiotherapy planning is its potential to improve 
tumor delineation, reducing intra-observer and inter-
observer variability and making treatment volumes 
more standard across individuals and institutions. 
The high sensitivity and speciÀcity of PET/CT for 
mediastinal lymph node involvement and superior 
capacity to discriminate between tumor extent and 
atelectasis signiÀcantly alters the target volumes with 
a potential to either reduce dose to organs-at-risk 
or deliver increased doses to the tumor and thereby 
improve outcomes (Gupta, 2010) In conclusion, 
by providing both morphologic and metabolic 
information, integrated PET/CT has achieved better 
efÀcacy in staging lung cancer than CT alone or PET 
alone and integrated PET/CT becomes now a Àrst-
line lung cancer imaging and staging technique. 
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Abstract: Despite the advances in surgical treatment 
and multimodality treatment, lung cancer is still 
the leading cause of death from malignant disease 
worldwide. Accurate staging of the disease is 
important not only to determine the prognosis 
but also to decide the most suitable treatment 
plan. During the staging process of non-small cell 
benign or malignant. CT increases the sensitivity of 
the PET/CT examination, but the most beneÀcial 
effect of having the CT data is the increase of the 
speciÀcity of the PET data. PET data also helps to 
specify CT information. Sensitivity and speciÀcity 
of 18F-Fluorodeoxyglucose PET (18F-FDG PET) 
and 18F-Fluorodeoxyglucose PET/CT (18F-FDG 
PET/CT) for determining malignancy of solitary 
pulmonary nodules are close to 95% and 80% 
respectively. The limits of the PET-technology are 
well known. False negative results are mainly due 
to certain histological types with low metabolic 
activity (such as bronchiolo-alveolar carcinoma 
and typical carcinoid), or small size (nodules less 
than 8 mm). False positives are mainly represented 
by granulomatous and infectious processes. 18FDG 
PET/CT is superior to CT alone, PET alone and 
PET and CT images viewed side by side in tumor 
staging of patients with NSCLC as shown in several 
studies (Lardinois 2003, Antoch 2003, Cerfolio 
2004, De Wever 2007). 18FDG PET/CT has a 
pooled average of 82% for correct T-staging with 
a 6% overstaging and 13% understaging. The most 
important advantage of 18FDG PET/CT is the fact 
that the FDG uptake can be located very accurately 
on the CT images. For T-staging this may be helpful 
in the evaluation of tumor invasion in the chest wall 
or mediastinum. Also delineation of the tumor from 
surrounding or retro-obstructive atelectasis may be 
improved. Because of the metabolic information 
that is provided, PET can also often differentiate 
between a malignant and a benign pleural effusion. 
For N-staging, it is shown that PET is better than 
CT to predict the benign or malignant character of 
the mediastinal and hilar lymph nodes but integrated 
PET/CT further increases the speciÀcity to diagnose 
these malignant lymph nodes because a more exact 
localization of the FDG hotspot becomes possible. 
De Leyn (2006) showed that for mediastinal 
restaging integrated PET/CT is the best imaging 
procedure to predict residual mediastinal lymph 
node metastasis. Integrated PET/CT increases the 
speciÀcity and accuracy in predicting residual 
lymph node metastasis. Integrated PET/CT is also 
the best imaging tool to detect distant metastases 
in expected sites as well as in unexpected sites. 
The evaluation of small lesions, especially sub-
centimeter pulmonary nodules, is still difÀcult. The 
sensitivity for malignancy is lower in these smaller 
lesions, while one would expect the speciÀcity 
to be higher. Given that the resolution of current 
generation PET scanners is only 5 to 6 mm, one 
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(N1) lymph nodes. EUS-FNA has access to the 
inferior mediastinal lymph nodes not accessible 
by mediastinoscopy. EBUS-TBNA and/or EUS-
FNA have in fact replaced mediastinoscopy in 
many patients with diffuse mediastinal adenopathy, 
where a simple tissue diagnosis is required to 
determine treatment. It is still uncertain whether 
EBUS-TBNA and/or EUS/FNA will completely 
replace mediastinoscopy for precise mediastinal 
lymph node staging of lung cancer. Endoscopic 
ultrasound, however, is less invasive, safer and 
more cost effective compared to mediastinoscopy. 
Endoscopic ultrasound offers the advantage of 
obtaining a diagnosis as well as lymph node staging 
simultaneously in an outpatient setting. Initial 
mediastinal lymph node staging by EBUS-TBNA/
EUS-FNA will allow mediastinoscopy to be reserved 
for re-staging after induction treatment. 
Keywords: Lung cancer, Staging, EBUS, EUS
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E04.4 CASE PRESENTATION: T2 
ADENOCARCINOMA OF THE LEFT 
UPPER LOBE WITH IPSILATERAL N1 
LYMPH NODES THAT ARE POSITIVE ON 
FDG PET
Daniela E. Oprea- Lager, Emile F. Comans 
Nuclear Medicine & Pet Research, VU Medical 
Center/Netherlands
Abstract: Appropriate tumor staging is essential for 
establishing the best treatment strategy and deÀning 
prognosis in lung cancer patients. Our case demonstrates 
the role of imaging in the revised location of left hilar 
lymph nodes (station 10 L) according to the newly 
proposed International Association for the Study of Lung 
Cancer (IASLC) lymph node map and emphasizes the 
importance of using clear anatomical deÀnitions for 
delineating lymph node stations. A 58-year-old woman 
presented with a 20-pack-year smoking and a negative 
clinical history. She complained about fatigue, dyspnea 
and left chest discomfort since 5 months. Subsequent 
physical examinations revealed no abnormalities, 
except rhonchi in the left upper portion of the chest 
at pulmonary auscultation. The chest x-ray showed a 
diffuse consolidation in the left upper lobe, adjacent 
to mediastinum. A diagnostic contrast-enhanced 
computed tomography (CT) was performed under the 
assumption of Nonsmall cell lung cancer (NSCLC). 
lung cancer (NSCLC), mediastinal lymph node 
staging is one of the most important factors that 
affect the patient outcome. Non-invasive staging 
such as computed tomography (CT) and positron 
emission tomography (PET) indicate size and 
metabolic activity, respectively. However imaging 
alone is inaccurate and therefore tissue sampling 
is the preferred and most reliable. Surgical staging 
by mediastinoscopy is still the gold standard for 
mediastinal lymph node staging. However for 
some parts of the mediastinum not assessable by 
mediastinoscopy, video-assisted thoracoscopic 
surgery (VATS) is necessary. However, 
surgical staging requires general anesthesia and 
complications cannot be ignored. Endoscopic 
ultrasound techniques provide a minimally invasive 
alternative for surgical staging. The current available 
endoscopic ultrasound techniques for mediastinal 
staging include transesophageal endoscopic 
ultrasound guided Àne needle aspiration (EUS-FNA) 
and endobronchial ultrasound guided transbronchial 
needle aspiration (EBUS-TBNA). Both procedures 
can be performed in an outpatient setting under 
local anesthesia. EUS-FNA is a sensitive and safe 
method of evaluating the inferior mediastinal 
nodes (stations 7, 8, and 9) and some parts of the 
anterior mediastinal nodes if the lymph nodes are 
accessible from the esophagus. However, in spite of 
the strength of EUS-FNA for evaluating the inferior 
mediastinal nodes, its ability to evaluate lesions 
anterior to the trachea is limited. On the other hand, 
EBUS-TBNA is an accurate bronchoscopic method 
for lymph node staging which has reach to the 
paratracheal and subcarinal (stations 2R, 2L, 4R, 
4L, 7), as well as the N1 lymph nodes (stations 10, 
11, 12). In experienced hands, EBUS can be used 
through the esophagus for a EUS-like approach to 
the inferior mediastinal lymph nodes. Thus, EUS-
FNA and EBUS-TBNA are complementary methods 
for lymph node staging in lung cancer and most of 
the mediastinum and the hilum can be evaluated with 
these endoscopic procedures. Aortic nodes (stations 
5 and 6) are exceptions and must be evaluated by 
surgical methods (anterior mediastinotomy, VATS, 
thoracotomy). Based on the current evidence, 
EBUS-TBNA and EUS-FNA presents a minimally 
invasive endoscopic procedure as an alternative to 
mediastinoscopy for mediastinal staging of NSCLC 
with discrete N2 or N3 lymph node enlargement, 
provided negative results are conÀrmed by surgical 
staging. EBUS-TBNA can access all lymph nodes 
accessible by mediastinoscopy as well as hilar 
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E04.6 CASE PRESENTATION: T2 
TUMOUR OF THE RIGHT MIDDLE 
LOBE WITH MEDIASTINAL 
LYMPHADENOPATHY IN A PATIENT 
WITH AN IMPAIRED PULMONARY 
FUNCTION
Idris Bahce1, Katrien Grunberg2 
1Pulmonary Medicine, VU University Medical 
Centre/Netherlands, 2Pathology, VU University 
Medical Center/Netherlands
Abstract: Purpose: This case presentation is 
intended to enable participants and tumor board 
members to discuss pre-treatment diagnostic and 
therapeutic strategies, using arguments based on 
clinical and radiological Àndings. Participants 
prerequisite: During this presentation, participants 
will be asked several questions. These are not 
intended to test their knowledge, but to invite them 
to make clinical decisions on which interventions 
should follow, and to argue these choices. 
Knowledge on the management of lung cancer is 
recommended. Case discussion: In this clinical 
case, a 65-year-old patient who suffered from long 
standing cough was seen for haemoptysis. He 
had a history of alcoholic liver disease, peripheral 
vasculopathy and a moderately severe chronic 
obstructive pulmonary disease (COPD). The chest 
X-ray showed a mass in the right lung. The CT 
scan revealed extensive bullous and centrilobular 
emphysema, particularly in the upper lobes, 
furthermore calciÀcations in the aorta, and enlarged 
lymph nodes at several nodal stations (lymph node 
station 4 right, subcarinal and lymph node station 
10 right). A cavitating, partly necrotic and liquiÀed 
tumor was seen in the middle lobe, with involvement 
of the thoracic pleura and the minor Àssure. The 
accompanying positron emission tomography 
(PET) scan showed a weak Áuorodeoxyglucose 
(FDG) uptake at the site of the enlarged lymph 
nodes, and intense FDG uptake in the tumor wall, 
while the necrotic center showed no uptake. As 
he was diagnosed with COPD, a spiroÁowmetry 
was performed, which showed moderate airway 
obstruction. A Àrst dilemma is posed at this point, 
as a choice must be made as to how to obtain 
tissue samples from the tumor and the enlarged 
lymph nodes. Three options were considered: 
bronchoscopy, endobronchial ultrasonography 
The next imaging step used to establish the Tumor 
Node Metastasis (TNM) staging was a whole body 
integrated positron emission tomography (PET)/ low 
dose CT, according to the Dutch guidelines for NSCLC. 
Both the diagnostic CT and the low dose CT in lung 
setting demonstrated the presence of a relative centrally 
located left upper lobe tumor, with a lobulated aspect, 
measuring 3.3 X 3.1 cm. Two ipsilateral enlarged lymph 
nodes were seen lateral to the left pulmonary artery 
and in the left hilar region. According to the previously 
used Mountain-Dressler map, these lymph nodes were 
localized subaortic, in the aortopulmonary window (N2 
disease). With reference to the new IASLC lymph node 
map, these nodes, having as upper border the lower 
rim of the left pulmonary artery and as lower border 
the left interlobar region, are deÀned as hilar nodes (N1 
disease). No other lesions suspicious for metastases 
were found within the scanned part of the body. The 
PET component also showed diffuse high FDG uptake 
in the left pulmonary mass in the two hilar lymph nodes 
left, this being indicative for a T2a lung process with 
additional N1 lymph nodes metastases and no distant 
metastases. Based on imaging, the presented case aims 
to demonstrate the typical lymph node drainage of 
tumors originating from the left upper lobe and to mark 
the difference between the subaortic nodes and left 
hilar nodes. Aspects related to the lymph node staging 
modalities in such patients and therapy management will 
be discussed in detail. 
Keywords: PET/ CT, Hilar lymph nodes, Subaortic 
lymph nodes, Nonsmall lung cancer
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E04.5 CASE PRESENTATION: SMALL T1 
SUBPLEURAL LUNG LESION IN THE 
RIGHT UPPER LOBE, INCIDENTALLY 
FOUND
Mark W. Onaitis 
Surgery, Duke University/United States Of America
Abstract: Modern imaging identiÀes many 
indeterminate lung nodules. Controversy exists as to 
appropriate radiologic work-up and potential surgical 
treatment of patients with these abnormalities. We 
will present pertinent clinical scenarios to stimulate 
discussion of diagnostic and therapeutic alternatives. 
Thoracoscopic approaches to these patients may 
optimize safe diagnosis and treatment.
Keywords: thoracoscopy, Lung nodule
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differences in their investigation by pathologists, 
and treatment by oncologists has driven renewed 
interest in this differential diagnosis. It is no longer 
acceptable to amalgamate these different diseases in 
the increasingly meaningless category of ‘non-small 
cell carcinoma’. Adenocarcinoma is an epithelial 
malignant tumour characterised by combinations 
of tumour showing glandular differentiation. A 
squamous cell carcinoma is an epithelial malignancy 
showing evidence of keratinisation, indicated 
by the presence of cellular keratinisation and/or 
intercellular bridges. In some cases, the degree or 
extent of diagnostic differentiation may be limited 
and such diagnostic areas may not be sampled during 
small biopsy diagnosis (see below). In the context of 
surgically resected tumours, the distinction between 
squamous cell and adenocarcinomas is generally 
straightforward and has no bearing, currently, on 
the selection of patients for adjuvant therapy. In 
patients with advanced disease, however, given the 
differential efÀcacy or toxicity of several possible 
treatments, an accurate and reliable distinction 
between squamous cell and adenocarcinoma is 
becoming essential, not only for the selection of 
appropriate drugs but also for the most judicious 
use of tissue and other laboratory resources in 
appropriate biomarker testing to assist with drug 
selection. The diagnostic distinction between 
squamous cell and adenocarcinoma in advanced 
disease patients may be a challenge. These patients 
generally do not have a surgically resected tumour 
available for examination. Rather, the diagnosis 
and subtyping of the lung tumour is based on small 
diagnostic samples of cytological or histological 
type. The WHO classiÀcation of lung cancers is 
not fully applicable to such small samples. Several 
deÀning diagnostic criteria cannot be applied to 
small samples. Small samples may contain only 
undifferentiated tumour cells, showing none of the 
diagnostic cytological features or tissue architecture 
of the differentiated tumour components on which 
the tumour subtype is predicated. Thus there is an 
inherent inaccuracy in subtyping non-small cell 
(NSCLC)-type lung cancers in small samples. In a 
proportion of cases, the lack of any differentiated 
cells or architecture necessitates the use of the 
term NSCLC-not otherwise speciÀed (NSCLC-
NOS). The proportion of cases, so diagnosed on 
morphological grounds alone, will vary according 
to the sample type (it tends to be higher in 
cytological versus histological samples) and the 
bias / experience of the pathologist. NSCLC-NOS 
(EBUS) or mediastinoscopy. In the present case, 
bronchoscopy and EBUS were performed. Biopsies 
of the tumor showed non-small cell lung cancer; 
however Àne needle aspiration of lymph node station 
4 and 7 using EBUS only revealed reactive lymphoid 
cells, no malignancy. This latter Ànding does not 
exclude the presence of lymph node metastasis. 
Should an additional mediastinoscopy be performed 
to reach a more sensitive mediastinal staging? Or, 
could a treatment decision be made with the current 
information, without full mediastinal staging? How 
valuable is the PET scan at this point? The decision 
to perform full mediastinal staging poses a second 
dilemma, as a choice has to be made on what should 
be the next step: mediastinoscopy, surgery (video 
assisted thoracic surgery (VATS) or thoracotomy?), 
or something else. At this point the need for 
additional testing will also be discussed. This patient 
underwent a cyclo-ergometry, MRI brain, bone scan, 
and liver ultrasound. Eventually, he was treated with 
primary thoracotomy. An extrapleural bilobectomy 
was performed, which showed a 5.8 cm squamous 
cell carcinoma, resection margins were free of tumor. 
There was pleural invasion (Pl1), no involvement in 
any of the 5 resected lymph nodes in stations nr 10, 
11, 4 right, and 7. pT2bN0Mx. The postoperative 
course will only be discussed brieÁy, as this is not 
within the scope of this presentation. Evaluation: 
Finally, the added value of the multidisciplinary 
tumor board discussion will be evaluated. 
Keywords: Imaging, clinical care
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E05.1 DISTINCTION BETWEEN 
ADENOCARCINOMA AND SQUAMOUS 
CELL CARCINOMA
Keith M. Kerr 
Department Of Pathology, Aberdeen Royal 
InÀrmary/United Kingdom
Abstract: Squamous cell and adenocarcinomas 
of lung show differences in their histological 
appearances, usual clinical presentation, molecular 
abnormalities and pathogenesis. The emerging 
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best balance between sensitivity and speciÀcity 
for each test stain. Some cases will not show a 
predictive immunophenotype. This is entirely to be 
expected and so there will remain a small number 
of cases, typically 5-6% overall, which would 
remain NSCLC-NOS, after appropriate IHC. Still, 
a majority of these are differentiated tumours, just 
poorly sampled. A range of more sophisticated 
molecular proÀling techniques (gene expression 
arrays, microRNA etc) have been proposed for 
distinguishing squamous cell from adenocarcinoma. 
Readily diagnosable tumours of each type have their 
differential molecular proÀles determined, from 
‘signatures’ are derived to discriminate between 
these differentiated tumours. There are differences 
in many aspects of the molecular landscape between 
squamous cell and adenocarcinomas. Even in 
tumours easily classiÀed by standard histopathology, 
none of these signatures is 100% successful and none 
have been used to address the NSCLC-NOS issue. 
There is now a therapeutically-driven clinical need 
for accurate, consistent diagnosis of squamous cell 
and adenocarcinomas in patients with advanced lung 
cancer. Even with the constraints of diagnosis on 
small tissue samples, the appropriate, appropriate use 
of IHC can augment diagnosis of the traditionally 
stained material to provide accurate classiÀcation of 
squamous cell and adenocarcinomas. Only a small 
proportion of such cases should remain with a non-
speciÀc diagnosis. 
Keywords: squamous cell carcinoma, differential 
diagnosis, immunohistochemistry, Adenocarcinoma
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E05.3 DISTINCTION BETWEEN SECOND 
PRIMARY AND METASTASES
Sanja Dacic 
Department Of Pathology, University Of Pittsburgh 
School Of Medicine/United States Of America
Abstract: The reported incidence of synchronous 
tumors of the lung ranges from 0.5 to 2%; however, 
the number of patients presenting with multiple 
lung nodules has been increasing. This is most 
likely a result of the development of higher-
resolution chest imaging techniques, more frequent 
screening of smokers for lung cancer, and closer 
follow up of patients with routine chest scans after 
initial surgical resection. The main issue regarding 
multiple lung tumors is to determine whether they 
rates of 20-25% for tissue biopsy samples are not 
unreasonable. Assuming an unselected case cohort 
representing the usual range of NSCLC types, it 
is essentially impossible to achieve NSCLC-NOS 
rates of under 10% in small sample diagnostis using 
only morphological. Large cell and sarcomatoid 
carcinomas account for around 10% of cases, 
cannot be correctly diagnosed in this context and 
should always receive an NSCLC-NOS diagnosis. 
The majority of NSCLC-NOS small samples are, 
in fact, derived from differentiated tumours but 
are undifferentiated due to sampling error. Most 
NSCLC-NOS cases are actually adenocarcinomas. 
It is possible to reÀne the diagnosis of NSCLC-NOS 
cases using immunohistochemistry (IHC). A number 
of IHC markers are preferentially expressed in either 
squamous cell or adenocarcinomas. Few of these 
markers are unique to one particular tumour type; 
none is a deÀning diagnostic criterion for a diagnosis 
of either tumour type. The relevant literature is 
extensive, often confusing, sometimes contradictory 
and difÀcult to interpret due to different 
methodologies and presentation of results. For 
squamous cell carcinoma the most important markers 
currently used are p63, cytokeratin (CK) 5/6, high 
molecular weight (HMW) CK (34betaE12) and 
desmocollin-3 (DSC3). DSC3 is probably the most 
speciÀc of these, HMWCK the least speciÀc and p63 
and CK5/6 the most often used. For adenocarcinoma 
TTF1, Napsin A and CK7, as well as a mucin stain, 
are the most important. Napsin A and mucin stains 
are most speciÀc but lack sensitivity, CK7 has high 
sensitivity but lacks speciÀcity. TTF1 is the best 
compromise for a single marker. It is very important 
to understand that these markers DO NOT conÀrm 
or deÀne the tumour subtype. Their presence/absence 
only supports one subtype rather than the other, 
on a statistical basis – they help predict the likely 
subtype. Thus, when a subtype is predicted on the 
basis of IHC, the correct diagnosis to be rendered is 
still NSCLC, with the appropriate caveat, ‘probably 
squamous’ or ‘probably adenocarcinoma’. The 
predictive value of these tests tends to be around 
80-85%. If these markers are to be used in this way, 
it is essential that the pathologist and laboratory 
are aware of the detailed methods required for 
reliable staining, have clearly deÀned criteria for 
what is considered a positive or predictive IHC 
test and thus have validated the predictive power 
of each test used. If this is not done, errors will 
result. This approach can achieve very high Àgures 
of positive and negative predictive value, and the 
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more comprehensive approaches analyzing a large 
number of single nucleotide polymorphic loci in 
a single assay or large-scale DNA sequencing of 
tumors were used. A comprehensive aCGH analysis 
followed by the analysis of multiple somatic 
mutations of originally presumed cases of multiple 
primary lung cancers based on Martini and Melamed 
criteria, resulted in discrepant classiÀcation between 
molecular data and clinico-pathologic criteria in 
18% of analyzed cases (Clin Cancer Res 2009; 
15(16):5184). These data provided support evidence 
for implementation of genomic analysis into clinical 
practice which would be challenging due to e.g. 
requirement of a large amount of high quality 
DNA, fresh frozen tissue and lack of standardized 
software for array data analysis. A more practical 
approach would be targeted mutational proÀling 
of DNA extracted from formalin-Àxed, parafÀn 
embedded tissue. It was suggested that the strength 
of the evidence from individual mutational matches 
depends on the rarity of the mutation, e.g. speciÀc 
KRAS or EGFR mutations (Clin Cancer Res 2009; 
15(16):5184; Chest 2010; 137(1);46; J Thorac Oncol 
2007;2(1);12; Cancer 1999;85:1734). A role of 
quantiÀcation of the relative amounts of morphologic 
subtypes in lung adenocarcinomas as proposed 
by the recent IASLC/ERS/ATS classiÀcation of 
lung adenocarcinomas has been suggested as 
potentially useful in determining clonal relationship 
between the two or multiple tumor nodules (Chest 
2010; 137(1);46). However, the reproducibility 
of histologic subtyping remains to be established. 
Unlike mutational proÀling, a reliable histologic 
subtyping cannot be performed on the cytology 
specimens. Conclusions: Molecular approaches to 
classiÀcation of multiple lung tumors have not been 
prospectively validated, and their performance in 
routine clinical practice remain to be established. 
Aggressive surgical resection of multiple intralobar, 
ipsilateral, or even bilateral multifocal nodules is 
a standard treatment in many centers. It is very 
unlikely that tumor tissue from multifocal nodules 
will be available for molecular analyses before 
surgery. Therefore management decisions should be 
made after careful clinicopathological evaluation by 
a multidisciplinary team. 
Keyword: synchronous tumors
represent separate primary tumors or metastases. 
This determination has impact on tumor stage and 
subsequent treatment and prognosis. Criteria to 
deÀne multiple primary lung tumors or metastases 
were initially published by Martini and Melamed 
in 1975, and were recently updated by the AJCC. 
The proposed rather empirical criteria sound 
straight forward, but clinicopathologic distinction 
between the two groups is not always possible and 
it may not be genetically or prognostically valid. 
Furthermore, molecular analysis of synchronous 
tumor nodules that may distinguish a primary tumor 
from metastases was not incorporated into the 
current classiÀcation criteria. Methods: PubMed 
available peer-reviewed original articles and 
experience of the author. Results: The diagnosis of 
multiple primary lung carcinomas is easily made 
when the morphology is different (e.g. squamous cell 
carcinoma and adenocarcinoma). If the morphology 
is the same, the distinction between two primary 
carcinomas or metastases can be very difÀcult. 
Recently, several molecular approaches have 
emerged including DNA microsatellite analysis, 
DNA sequencing for common somatic mutations, 
aCHG , and gene expression analysis. A role of 
detailed histologic subtyping, particularly of lung 
adenocarcinomas, was also suggested. Studies 
using clonality assays used two approaches: a panel 
of variable number of polymorphic microsatellite 
markers and X-chromosome inactivation analysis. 
Tumors with largely concordant results were 
considered clonal in origin (metastases), and 
those with discordant Àndings were considered 
to be independent primary tumors. The data 
from published reports indicate a highly variable 
percentage of multifocal tumors identiÀed as 
clonally related (up to 70%)(Am J Surg Pathol 2005; 
29(7):897;Ann Diagn Pathol 2001;5(6):321; Clin 
Cancer Res 2000; 6(10):3994; J Natl Cancer Inst 
2009;101:560). It is difÀcult to determine the correct 
percentage because of the relatively small number 
of analyzed cases, mixed analysis of synchronous 
and metachronous tumors, and use of different 
methods and interpretation criteria. However, all 
reports agree that multifocal tumors may arise either 
as metastases from a single tumor or as independent 
tumors resulting from Àeld cancerization. The main 
shortcoming of earlier studies is a limited number 
of genes analyzed, and data have to be interpreted 
with caution since similar patterns of allelic losses 
may be present throughout the respiratory epithelium 
of smokers with or without lung cancer. Recently, 
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E06.2 EUROPE CONCENTRATION OF 
CARE
Walter Klepetko 
Division Of Thoracic Surgery, Medical University 
Vienna/Austria
Abstract: Surgical treatment of lung cancer within 
Europe is performed under very variable conditions. In 
some countries thoracic surgery is exclusively provided 
by specialised thoracic surgeons, whereas in others it 
is performed by cardiac or cardiothoracic surgeons, by 
general surgeons, or sometimes by vascular surgeons. 
However, the rapid increase in speciÀc knowledge 
and skills and the increasing complexity of treatment 
algorithms, demands for a higher specialisation and 
level of performance, which undoubtedly can only 
be provided by physicians, concentrating on one core 
speciality. Even further, some very complex surgical 
procedures, that nowadays have become available, 
are rare, and therefore should only be provided in 
centers of higher specialisation and concentration. The 
two relevant scientiÀc societies, the ESTS (European 
Society of Thoracic Surgery) and the EACTS 
(European Association of Cardiothoracic Surgery), 
which represent the Àeld of thoracic surgery within 
europe, have therefore suggested a system of centers 
of standard and of excellence (1) , which allows to 
provide the necessary services ubiquitary and for all 
levels of complexity. In addition, requirements in terms 
of stafÀng, ressources, spezial training etc. have been 
deÀned. To follow such suggestions, in order to offer 
patients the best possible care, should be in the interest 
of every physician. This would imply, that creation of 
such circumstances whereever they are not yet available 
should be fostered, and that referral patterns should 
be adapted to the actual quality needs. In doing so, 
even rare, but however very advanced, complex and 
ressource intensive procedures can be provided with 
optimal quality. Ref: 1) Structure of General Thoracic 
Surgery in Europe; W. Klepetko, A. Lerut, T. Aberg. 
European Journal of Cardiothoracic Surgery 2002.
Keyword: thorax
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E05.4 CYTOLOGICAL DIAGNOSIS OF 
LUNG CANCER: OPPORTUNITIES AND 
LIMITATIONS
Maureen Zakowski 
Pathology, Memorial Sloan-Kettering Cancer 
Center/United States Of America
Abstract: Cytology is often used in the diagnosis 
of primary lung cancer. Conventional preparations 
such as sputum, bronchial brushes and washes as 
well as Àne needle aspiration (FNA) biopsies are 
excellent means of documenting the presence of 
tumors. It has always been considered sufÀcient to 
separate bronchogenic carcinoma into the two major 
categories of small cell carcinoma and non small 
cell carcinoma (NSCLC). In addition, little attention 
has been paid to separating adenocarcinoma into 
any speciÀc subtypes. In the era of targeted therapy 
against lung cancer new, non chemotherapeutic 
agents have emerged that successfully “target” 
speciÀc types of lung cancer. The tyrosine kinase 
inhibitor (TKI) Tarceva appears particularly 
useful against well differentiated adenocarcinoma, 
especially when a bronchioloalveolar component 
is present. The presence of EGFR mutations 
underlies the response of adenocarcinoma to 
TKIs. This agent is ineffective in the treatment of 
squamous cell carcinoma. Another agent, Avastin, 
a monoclonal antibody to VEG F, may be cause 
lethal pulmonary hemorrhage on patients with 
squamous cell carcinoma of the lung. The speciÀc 
features of adenocarcinoma and squamous cell 
carcinoma must be identiÀed in cytologic material 
and morphology suggestive of bronchioloalveolar 
carcinoma (BAC) must be recognized in order to 
help direct appropriate therapy. Since cytologic 
cell blocks can be used for the analysis of EGFR 
mutations, it is becoming increasingly important to 
prepare and correctly diagnose cell block material. In 
addition immunohistochemical stains such as TTF-1, 
CK 7, CK 20, 34bE12, 4A4 and p63 can be applied 
to cytologic material to aid in the correct diagnosis 
of lung cancers. Limitations to the use of cytologic 
material include small sample size, lack of pre 
analytical standardization and inability to perform on 
site assessment for sample adequacy. 
Keyword: cytology
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the study and practice of thoracic surgery and related 
medical subjects. This involves the organization 
of European Board Exams in Thoracic Surgery, 
organizing annual conferences, supporting scientiÀc 
publications in thoracic surgery and facilitating 
exchange of teachers and trainees in thoracic surgery. 
In so doing the Charity will be able to provide advice 
and support for European authorities on matters 
concerning thoracic surgery, and coordinate the 
systematic collection of data on thoracic surgical 
activity and outcome. Ultimately the Charity exists 
for the beneÀt of patients with thoracic surgical 
diseases.” The Society has steadily grown in numbers 
over the years crossing the barrier of 1000 members 
in late 2009 and reaching 1200 members in 2011. 
This makes ESTS now the largest society in Europe, 
and probably also worldwide, dealing with general 
thoracic surgery only. In order to improve the results 
and to diminish suffering for our patients, a society of 
this size is obliged to offer its members a platform to 
share knowledge, to invest in education of its trainees, 
and to collect data for benchmarking and accreditation 
of units across Europe. Over the recent years, several 
initiatives have been deployed to meet the educational 
objectives stated in the constitution. This includes the 
installation of an European Conference on General 
Thoracic Surgery (www.estsmeetings.org)a European 
School of Thoracic Surgery (www.estsschool.org) 
with both theoretical courses, held in Antalya, Turkey 
and practical courses run at the Covidien animal 
facilities in Elancourt, France, a Textbook on Thoracic 
Surgery, and a European Thoracic database (www.
thoracicdata.org). The society has appointed four 
directors, each one responsible for the educational 
activities listed above. To evaluate the level of 
training in Europe, the society is hosting during its 
annual meeting the European Board of Thoracic 
and Cardiovascular Surgeons (www.ebtcs.org) that 
organizes the exams that lead to a European CertiÀcate 
in Thoracic Surgery within the structure of UEMS 
(European Union of Medical Specialists; www.uems.
net ). This certiÀcate will facilitate recognition of 
the speciality in Europe and exchange of thoracic 
surgeons between different European countries. Based 
on data accrued in the thoracic surgery database 
and published in the Annual Report (Silverbook), 
bench marking between European institutions has 
now become possible and outcome indicators have 
already been proposed to measure quality of care 
after major lung resection [3, 4]. This instrument will 
greatly facilitate the creation of a system that allows 
accreditation of thoracic surgical units across Europe. 
Quality Control and Concentration of Care Monday, 4 July 2011 
16:30-18:00
E06.4 THOUGHTS ON TRAINING
Dirk E. Van Raemdonck 
Thoracic Surgery, University Hospitals Leuven/
Belgium
Abstract: Every patient in need of medical 
help deserves the right to be treated according 
to the best practice of care. More speciÀcally, 
patients needing a surgical intervention have to 
be assured that the kind of surgical intervention 
to which they have consented is appropriate and 
results in an outcome acceptable by international 
standards. In order to achieve this, young surgeons 
should receive the best training across different 
institutions, both nationally and internationally 
whenever possible and should be exposed to state 
of the art education. Established surgeons and their 
institutions should be able to provide information 
regarding outcomes after surgical treatment based 
upon validated data and risk-adjusted for case mix. 
It is likewise important that healthcare providers 
are reassured that their Ànancial support of surgical 
interventions is being used effectively, not only in 
terms of outcome, but also in resource utilization. 
General Thoracic Surgery is one of the smaller 
specialty groups in medicine. It also has developed 
differently throughout Europe. In some countries, 
it is considered part of cardiothoracic surgery, in 
other countries it lies within the remit of general 
surgery, and in a few countries it is a recognized 
specialty of its own. This diversity has certainly 
contributed to the fact that Europe has lagged behind 
in societal initiatives to help improving quality of 
care compared to the USA. Also, the development 
of instruments, technology, and infrastructure 
necessary to compare outcome after general thoracic 
surgery was hindered compared to cardiac surgery, 
mainly because of limited resources and manpower 
indispensable to succeed. The European Society of 
Thoracic Surgeons (www.ests.org) was established 
in Heidelberg on 18 November 1993 under the 
visionary leadership of Ingolf Vogt-Moykopf - ESTS 
Àrst president. The history of the society has recently 
been reviewed by Laureano Molins (Barcelona, 
Spain) in his Presidential Address delivered to the 
membership during the 17th European Conference 
on General Thoracic Surgery in 2010 in Krakow, 
Poland [1]. The ESTS in its constitution [2] deÀnes 
its objectives as “the advancement of education by 
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limited uptake of the interventions, we have used 
the MRC Framework for the Development of 
Complex Interventions to develop a novel supportive 
care intervention to manage the symptom cluster 
of breathlessness, cough and fatigue, which we 
called a respiratory distress symptom cluster. We 
initially identiÀed that there is such a cluster both 
with qualitative and quantitative work. Three 
systematic reviews from our group have shown that, 
while some interventions with promise do exist 
in relation to the management of breathlessness, 
the evidence for cough management is minimal 
and based on data often from the 1970s or earlier. 
We have worked with patients, carers and health 
professionals to ‘model’ the intervention and explore 
feasibility issues, acceptability and preference. In 
the Àrst study we explored these issues and usability 
of the interventions identiÀed in the systematic 
reviews conducting interviews with 37 patients 
with lung cancer and 23 of their caregivers. Very 
little symptom management was reported other than 
self-management attempts. Crucial issues identiÀed 
included an intervention delivered at home (or close 
to home), by a health professional, had a variety 
of components, led to immediate relief, with the 
caregiver being involved, not in a group of other 
patients and being able to incorporate it in the 
daily life. 5 focus groups with 34 specialist health 
professionals identiÀed very similar attributes of 
an intervention. Finally, a study of 88 patients with 
lung cancer using a Discrete Choices Experiment 
(best-worst scaling method) also identiÀed that 
location of delivery, and intervention delivered 
by a health professional were crucial aspects to 
consider. We have also developed and validated 
a scale to assess cough in lung cancer with 135 
patients, as there was no validated such scale for 
our population. The novel intervention now offers 
two face-to-face sessions one week apart teaching 
patients diaphragmatic breathing, cough suppression 
exercises and acupressure to chest points, together 
with supplementary reading material on issues 
suggested by the patients and carers (for home 
reading), followed by a phone call follow up two 
weeks later and will be delivered considering the 
above aspects Àrst with a feasibility trial later on in 
the year, followed by a large trial. 
Keyword: lung cancer, breathlessness, cough, 
fatigue, supportive care intervention
The initiatives above will be discussed and illustrated 
during the presentation. I am grateful for the support 
received from numerous ofÀcers, councilors, regents, 
ad hoc committee members, and individual members 
over the years in establishing a professional society 
that cares about education of our trainee members to 
guarantee the quality of care that is needed in treating 
patients across all European thoracic surgery centers. 
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E07.1 A COMPLEX INTERVENTION 
FOR THE MANAGEMENT OF A 
RESPITORY DISTRESS SYMPTOM 
CLUSTER (BREATHLESSNESS, COUGH 
& FATIGUE) IN PATIENTS WITH LUNG 
CANCER
Alex Molassiotis 
School Of Nursing, University Of Manchester/United 
Kingdom
Abstract: As many supportive care trials in lung 
cancer fail to complete due to high attrition, loss 
to follow up, major recruitment problems, and 
Copyright © 2011 by the International Association for the Study of Lung Cancer S161
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
their family members during the palliative phase.
Methods
Qualitative interviews were conducted as we looked 
for the personal views of ‘very ill’ cancer patients 
with a Turkish or Moroccan background, their 
family members and their Dutch care providers. 
Eighty-three people were interviewed, accounting 
for a total of 33 cases. Six patients, Àve male and 25 
female family members and 47 care providers were 
interviewed: 19 nurses, 17 general practitioners, 
Àve medical specialists, four social workers and 
two pastoral workers. The interviews were analysed 
qualitatively.
Results
A main Ànding concerns different views on ‘good 
care’. According to Turkish and Moroccan families 
good care implied: maximum treatment and curative 
care until the end of their lives, never having 
hope taken away, receiving devoted care from the 
families, avoiding shameful situations and dying 
with a clear mind. Their views conÁict with those of 
care professionals who emphasize the importance 
of comfort care, quality of life and advance care 
planning, also including discussing diagnosis and 
prognosis with the patient (De Graaff et al., 2010).
Another important aspect is the language barrier. 
Many elderly Turks or Moroccans don’t master the 
Dutch language. Although the Dutch government 
Ànances interpreters, care professionals seldom use 
formal interpreters, as they consider this a time-
consuming practice that requires planning and, 
moreover, one that most relatives did not appreciate. 
Relatives often fear that the information provided 
by the formal interpreter to their beloved sick one 
would be too direct. But patients often appreciate 
the consultations with a formal interpreter and many 
relatives indicate afterwards that care professionals 
could help their families by freeing them from 
overprotective relationships.
Another problematic aspect of the communication 
between care providers and patients with a Turkish 
or Moroccan background relates to the triadic 
form of consultations. Consultations rarely take 
place on a one-on-one basis, as a great deal of 
communication occurs via relatives. This situation 
is generally regarded as normal by patients and 
family, but as troubling by the care providers, Many 
care professionals dislike the dependence on family 
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E07.2 ASPECTS OF (NURSING) CARE 
OF PATIENTS WITH A DIFFERENT 
ETHNICAL BACKGROUND (FOR 
NETHERLANDS FOR INSTANCE 
TURKEY, MOROCCO)
Fuusje De Graaff 
Mutant/Netherlands
Abstract: This conference aims to support and 
inform physicians, nurses and researchers regarding 
current treatment approaches for individuals 
with lung cancer, as well as on issues related to 
prevention, early detection, imaging, staging and 
palliative care. Palliative cancer care aims to improve 
quality of life and ultimately quality of dying for 
patients with an incurable disease. Prolonging life 
is no longer an objective when death nears. The 
question is, however, whether these perspectives on 
palliative care Àt with the perspectives of immigrant 
families with a Turkish or Moroccan background.
Background
Some years ago we investigated why patients with a 
Turkish or Moroccan background in The Netherlands 
make little use of home care even when the patients 
are terminally ill (De Graaff & Francke, 2003). Our 
qualitative research among relatives of these patients 
identiÀed obstacles on various levels.
1) The patient’s level: Lack of understanding of 
illness and cause of death,
2) The family’s level: Complexity of family 
structure, decision making patterns, values and 
standards about care,
3) The community level: Limited care for the 
patient and family and signiÀcant pressure from the 
community,
4) The organizational level: Limited information and 
little or negative experience with home care.
In a survey we also investigated the perspectives 
and experiences of general practitioners and nurses 
regarding the limited access and use of home care 
of families with a Turkish or Moroccan background 
(De Graaff & Francke, 2009). The study among GPs 
and home care nurses conÀrmed the Àndings derived 
from the interviews with relatives.
Aim of the study
The aim of a subsequent study to be presented at this 
conference was to gain insight into decision-making 
and communication among various health care 
professionals and Turkish or Moroccan patients and 
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qualitative study of cancer patients with a Turkish 
or Moroccan background, their relatives and care 
providers. In: BMC Palliative Care, 9:19.
Keyword: palliative care; communication; 
immigrants;
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E07.3 HOW ARE LUNG CANCER NURSES 
ORGANIZED? (NETHERLANDS)
Albert Olijve 
Lung, MCA/Netherlands
Abstract: Since January Àrst 2007 a Special 
Interest Group (SIG) Pulmonary Oncology was 
established in the Netherlands. This SIG is part of 
the formal organisational structure of the Dutch 
Nursing Association (V & VN). It stimulates and 
supports the network of the nursing staff within the 
Pulmonary Oncology Care. The SIG has a permanent 
function and is accessible trough out the country. 
The motivion to start the SIG Pulmonary Oncology 
is the increasing amount of lung cancer patients in 
the Netherlands. In 2009 the breakup of new cases of 
lung cancer was 6867 men and 4118 woman ( Source 
NKR ) The death rate among patients of lung cancer, 
during a period of one year, is just about as high 
as new cases being discovered. In 2010 6500 men 
and 3600 women died of the disease.(Source CBS) 
Unfortunately the medical treatment is still restricted 
in comparison with other tumour types. The nursing 
staff are getting more involved with these type of 
patients. They combine their recourses in the SIG to 
improve their quality of care to these patients. The 
objectives of the SIG are; Ø Support the mission 
and goals of the V & VN oncology Ø Support and 
promote the network for the nursing staff specialized 
in Pulmonary Oncology Ø Function as a platform 
between the nursing staff with the specialization 
in pulmonary Oncology Ø IdentiÀes and examines 
speciÀc questions raised within Pulmonary 
Oncology, like the development and implementation 
of guidelines. Ø Gathers knowledge and experiences 
and makes sure of distribution by doing professional 
development and education Ø Expresses a point of 
view in connection with new developments within 
this Àeld The SIG has a core of nine representatives. 
All members of the V & VN Oncology, active 
within the Pulmonary Oncology, will be able to join 
the SIG. The members of the V&VN are the most 
important target of the SIG. The SIG communicates 
members acting as interpreters, and feel insecure 
because of the – to them – complex relations in 
the family. They may be insufÀciently trained in 
handling triadic communication.
Finally, communication problems may be reinforced 
because a large number of people are involved in 
the decision-making process. Decisions on treatment 
and care frequently depend on preferences of many 
relatives, whose arguments are often related to social 
and religious considerations. Dutch care providers 
may feel helpless because they do not understand 
the relations within the family, nor the normative 
pressure in the migrant communities. Turkish and 
Moroccan families experience a rather comparable 
vulnerability, not understanding the often 
fragmentised network of Dutch health care services. 
In their despair they often go ‘shopping’ among the 
many services in the Netherlands as well as in their 
home country. This journey often enhances their 
losing of conÀdence in professional care and relying 
on their own community and religious traditions.
Conclusion
Physicians and nurses working with incurable ill 
patients may beneÀt from greater awareness of 
some speciÀc aspects of care of patients with a 
different ethnical background. They have to be 
trained in dealing with conÁicting views on ‘good 
care’, in working with a formal interpreter and in 
handling triadic conversations. Besides this, more 
communication among care providers can result in 
considerable beneÀt for the quality of palliative care 
of patients with a different ethnical background.
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E07.5 HOW ARE LUNG CANCER NURSES 
ORGANIZED? (AUSTRALIA)
Mary Duffy 
Lung Service, Peter MacCallum Cancer Centre/
Australia
Abstract: Lung cancer remains the leading cause 
of cancer deaths world wide and in Australia. There 
were 9,703 new cases and 7,626 deaths from lung 
cancer reported in Australia in 2007, accounting for 
one in Àve (19%) of deaths due to cancer nationally 
(The Australian Institute of Health and Welfare, 
2010). The Australian government introduced the 
National Health and Medical Research Council 
(NHMRC) clinical practice guidelines for the 
prevention, diagnosis and management of lung 
cancer in 2004. The NHMRC guidelines suggest 
optimal care for people with lung cancer is 
achieved through care delivery by multidisciplinary 
teams (MDT). Importantly these guidelines also 
acknowledge the contribution of lung cancer nurses 
in care delivery. Individual lung cancer patients also 
advocated for specialist lung cancer nurse roles. 
Lung cancer nurses are an integral part of effective 
MDT’s as they have more contact with patients, in 
terms of time, than any other team member As such 
they are well positioned to provide continuity of 
care across the lung cancer journey. Specialist Lung 
Cancer nurse roles were Àrst appointed in Australia 
in 2002. The Àrst meeting of lung cancer nurses 
occurred at the inaugural Australian Lung Cancer 
Conference (ALCC) in 2006. At that time it was 
agreed the New Zealand lung cancer nurses would 
join the Australian group. Since then the number 
of lung cancer nurses has increased nationwide. 
In addition these nurses identiÀed the need for a 
national professional lung cancer nurses group. 
Over a period of two years with the assistance of 
the Australian Lung Foundation (ALF) the Australia 
and New Zealand Lung Cancer Nurses Forum 
(ANZ-LCNF) evolved. Terms of Reference for the 
forum were established which include a statement 
of purpose, objectives, general principles and an 
organisational structure in the form of a Steering 
Committee. The ANZ-LCNF consists of a group of 
passionate nurses with a common focus of improving 
patient care, health care delivery and outcomes for 
patients, their families and carers with a particular 
emphasis on the importance of supportive care. The 
forum is a special interest group with professional 
with its members regarding new developments in this 
Àeld and is a source of information for the members 
concerned with Pulmonary Oncology. Another target 
group are the professional society of the nursing and 
medical staff. They can join the group discussions 
and the developing of new guidelines and standards. 
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E07.4 HOW ARE LUNG CANCER NURSES 
ORGANIZED? (UK)
John McPhelim 
Cancer Division, Hairmyres Hospital/United 
Kingdom
Abstract: Lung Cancer Nursing is a relatively new 
sub-specialisation in the management of patients 
with lung cancer. The UK has been at the forefront 
of developing this specialist nursing role. The 
National Lung Cancer Forum for Nurses has been in 
existence for 14 years it has led in the development 
of nursing roles, innovations in clinical practice, 
promoting education and learning, it has undertaken 
many audit and research projects and is regarded 
in the UK as the professional body representing 
lung cancer nurses. The forum has representation 
on nationally recognised organisations, including, 
The British Thoracic Society, BTOG, The National 
Intitute for Clinical Excellence and many other 
strategic organisations. This presentation will 
focus on how the clinical role of the lung cancer 
nurse has developed in the last 14 years, as a key 
individual in the lung cancer multidisciplinary team, 
demonstrating quality improvements in service, 
diversity within the role in terms of service delivery, 
it will examine the quality impact of the role on 
patient outcomes and the signiÀcant impact it has 
had on patient’s experience of care. The presentation 
will in addition look to the future, and examine how 
the lung cancer specialist nurse role may develop in 
the years to come and how the role will continue to 
be a positive contributor to the care of patient with 
lung cancer.
Keyword: nursing, development, support, 
innovation
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for networking among nurse lung cancer specialists. 
This role is rapidly evolving and will be critical to 
lung cancer patient care as treatment for lung cancer 
becomes more individualized and complicated in the 
near future.
Keyword: Oncology Nursing Society, Lung Cancer 
Nurse Navigators
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E07.7 HOW CAN/SHOULD LUNG 
CANCER NURSES PLAY A ROLE WITHIN 
THE IASLC?
Liz Darlison 
Respiratory, University Hospitals Of Leicester/
United Kingdom
Abstract: The concept of developing an 
international network for nurses working in lung 
cancer originated after many discussions and visits 
between nurses and Countries. These conversations 
converted into action and it was decided to hold a 
nurse networking lunch at the 13th World Conference 
on Lung Cancer in San Francisco in 2009. This 
meeting was an opened discussion, with fellow 
nurses, and conÀrmed that there was a need for 
an international nurses group. This meeting was 
supported by IASLC and interest was overwhelming 
with approximately 60 international nurses 
attending from many countries including USA, 
UK, Australia, Europe, Canada and Asia. From 
this meeting the International Thoracic Oncology 
Nurses Forum (ITONF) was established and will 
ofÀcially be launched at the 14th WCLC in July 2011 
in Amsterdam UK. This session will provide an 
opportunity to discuss how the ITONF can establish 
a working relationship with the IASLC. 
Keyword: International Nursing in Lung Cancer
afÀliations and collaborative links with the ALF and 
the Cancer Nurses Society of Australia (CNSA).
These links are reÁected in the logo of the forum. 
The ANZ-LCNF was ofÀcially launched in October 
2011 at the 3rd Australian Lung Cancer Conference. 
The steering committee have established a strategic 
plan and goals for the next 12 months. This paper 
will share the process involved in establishing the 
forum, key relationships which include patient 
advocacy groups. Achievements in increasing the 
awareness of lung cancer nationally will also be 
highlighted.
Keywords: lung cancer nurses, australian context
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E07.6 HOW ARE LUNG CANCER NURSES 
ORGANIZED? (USA)
Patricia Palmer 
Patient Care Services, University Of California 
Davis Health System/United States Of America
Abstract: The Oncology Nursing Society (ONS) 
is the organizing body for oncology nurses in the 
United States. Founded in 1975 it now boosts 
membership of more than 37,000 registered nurses 
and other healthcare professionals dedicated to 
excellence in patient care, research, administration, 
and education in the Àeld of oncology. More than 
220 local chapters provide a network for education 
and peer support at the local level. In addition, 27 
special interest groups (SIGS) facilitate national 
networking of members in subspecialty areas. Nurses 
who care for lung cancer patients belong to ONS 
nationally, locally and are involved in the Thoracic 
Cancer Focus Group and the newly formed Nurse 
Navigator SIG as well as other SIG’s organized 
by ONS. The mission of the ONS is to promote 
excellence in oncology nursing and quality cancer 
care. The core work of ONS includes; publishing 
peer-reviewed literature, publishing guidelines and 
standards, providing accredited nursing education, 
advocating for the oncology nursing profession 
and quality cancer care, serving as a community, 
fostering networking, establishing priorities for 
oncology nursing research and preparing oncology 
nursing leaders. The ONS Foundation has provided 
more than $22 million in funding for research, 
education, leadership, career development and public 
education since 1982. The recent advent of Lung 
Cancer Nurse Navigators has provided a new avenue 
Copyright © 2011 by the International Association for the Study of Lung Cancer S165
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
Biology of Radiotherapy - An Update Monday, 4 July 2011 16:30-
18:00
E08.3 TARGETING GALECTIN-1 IN NON-
SMALL CELL LUNG CANCERS
Quynh Thu Le 
Radiation Oncology, Stanford University/United 
States Of America
Abstract: Non-small cell lung cancer (NSCLC) is 
a highly lethal disease. Despite dose escalation with 
conformal radiotherapy (RT) in combination with 
modern chemotherapy, there is still a signiÀcantly high 
rate of intrathoracic failure and poor overall survival 
in patients with locally advanced disease. A novel 
approach is needed to improve RT and chemotherapy 
effectiveness in these tumors. We have previously 
demonstrated that hypoxia does exist in NSCLC though 
to a lesser extent than head and neck cancer. Using 
proteomic analysis, we identiÀed Galectin-1 (Gal-1) as 
a hypoxia-regulated protein at the level of secretion in 
several cancer cell types, including NSCLC. Galectin-1 
(Gal-1) is a secreted carbohydrate binding lectin that is 
well known for its role in modulating T-cell homeostasis. 
More recently, it has been shown to play a major role 
in cancer progression. It is expressed in many cancers, 
including NSCLC, where increased Gal-1 expression 
is closely associated with larger tumors, more nodal 
metastasis and lower overall survival. In human head 
and neck cancer, expression of Galectin-1 was inversely 
related to intratumoral T-cell level and correlated 
with prognosis. Mechanistically, Gal-1 has been 
implicated in several pathologic processes including 
tumor proliferation, adhesion, migration, angiogenesis 
and enhancing T-cell apoptosis, which can, in turn, 
can confer tumor immunity. In addition to hypoxia, 
Gal-1 secretion was also enhanced by RT, raising the 
hypothesis that it may counteract RT effectiveness in 
cancers. Applying a combination of down-regulating 
Gal-1 in a non-NSCLC cell line and knocking-out the 
gene in host mice, we show that tumor-derived Gal-1 is 
more important than host-derived Gal-1 in promoting 
tumor growth and spontaneous metastasis. Further 
mechanistic studies suggested that Gal-1 mediated its 
tumor promoting function by enhancing intratumoral 
T-cell death while protecting hypoxic tumor cells from 
apoptosis. Clonogenic studies also showed that Gal-1 
down regulation increased radiation sensitivity in these 
cells, especially under hypoxia. Based on these data, it 
is logical to evaluate Gal-1 as a new target in NSCLC in 
combination with radiation and chemotherapy. 
Keyword: radiation, galectin-1, hypoxia
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E08.1 CANCER STEM CELLS AND 
RADIORESISTANCE
Maximilian Diehn 
Radiation Oncology And Institute For Stem Cell 
Biology & Regenerative Medicine, Stanford 
University & Cancer Center/United States Of 
America
Abstract: The cancer stem cell hypothesis posits 
that tumors are maintained by a subpopulation of 
cancer cells called cancer stem cells (CSCs) or 
tumor initiating cells. CSCs can divide to give rise 
to more CSCs and to other cancer cells that are not 
able to form tumors upon in vivo transplantation 
(called non-tumorigenic cancer cells). The 
existence of a subpopulation of putative CSCs 
has been documented in a large variety of human 
tumors, including lung cancers. Furthermore, 
accumulating evidence indicates that CSCs are 
often relatively resistant to standard treatments 
such as chemotherapy or radiotherapy. Multiple 
CSC resistance mechanisms have been identiÀed 
and these appear to be both tumor type and patient 
speciÀc. Targeting of CSCs, either directly or 
through sensitizers to standard therapies is an 
active area of investigation. The development of 
CSC-targeted therapies will likely be complicated 
by the risk of normal stem cell toxicity as well as 
the acquisition of treatment resistance. Successful 
targeting of CSCs in the clinic holds the promise of 
signiÀcantly improving patient outcomes.
Keywords: Tumor inititiating cells, Cancer stem 
cells, Radioresistance
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after large doses per fraction may be greater than 
presently recognized due competing risks of death 
in patients who are frequently elderly or with co-
morbidities (ie a large proportion of patients may not 
live long enough to exhibit potential late toxicity), 
the challenges in assigning attribution (eg sudden 
death – was it unrelated to SBRT or due to a SBRT-
related catastrophic event such as ruptured vessel) 
and the difÀculties in recognizing milder forms of 
toxicity (eg grade 2 toxicity). Further challenges in 
creating the most accurate dose-volume-outcome 
data include knowing how best to evaluate the 
importance of volume in different serial organs 
(eg is Dmax important? Dose to a small volume 
of the entire organ? Dose to the ipsilateral wall of 
that organ?), how best to determine the actual dose 
received (ie to include setup and intrafraction motion 
data and organ deformation, and calculate the dose 
accumulated, rather than simply dose planned) 
and how to account for intra-individual patient 
differences (whether due to comorbidity, eg small 
vessel disease, concomitant medications (steroids, 
antioxidants), dietary factors or unknown genetic 
or humoral modiÀers of normal tissue response to 
injury). Given these challenges, it is not likely that 
any of the models will be sufÀciently validated any 
time soon. Thus, we need to proceed carefully with 
SBRT of centrally located tumors, and monitor and 
report toxicities to provide optimal treatments to our 
patients. The approach taken in different center with 
respect to fractionation and planning of centrally 
located tumors will be reviewed, including the 
planning approach and doses used in the RTOG 0813 
phase I/II seamless study of SBRT for early stage 
centrally located NSCLC in medically inoperable 
patients (www. rtog.org) References: Fowler JF and 
Dale RG. When is a “BED” not a “BED”? – when it 
is an EQD2: in regard to Buyyounouski et al. (Int J 
Radiat Oncol Biol Phys 2010; 76: 1297-1304). Int J 
Radiat Oncol Biol Phys 2010; 78(2): 640-641. Borst 
GR, Sonke JJ, Belderbos JS et al. Normal tissue 
complication probability after hypofractionation 
increased due to the high dose per fraction or the 
high total Biological Equivalent Dose? Radiother 
Oncol 2010; 94(3): 388. Guerrero M and Li XA. 
Extending the linear-quadratic model for large 
fraction doses pertinent to stereotactic radiotherapy. 
Phys Med Biol 2004; 49(20): 4825-4835. Park C, 
Papiez L, Zhang S et al. Universal survival curve 
and single fraction equivalent dose: useful tools in 
understanding potency of ablative radiotherapy. Int 
J Radiat Oncol Biol Phys 2008; 70(3): 847-852. 
Biology of Radiotherapy - An Update Monday, 4 July 2011 16:30-
18:00
E08.4 SBRT FOR CENTRAL LUNG 
TUMORS: RADIOBIOLOGICAL 
MODELING AND EMERGING CLINICAL 
DATA
Andrea Bezjak 
Radiation Oncology, Princess Margaret Hospital - 
University Of Toronto/Canada
Abstract: Advances in image guidance, and the 
ability to treat well identiÀed targets with high 
precision and very tight margins through SBRT 
techniques have led to wide-spread use of very 
large doses per fraction, with curative intent. The 
effect of these high ablative doses on normal tissues 
remains a concern. In the case of peripheral lung 
tumors, technical advances, small volumes treated 
and absence of critical structures results in a low 
rate of signiÀcant normal tissue toxicity. However, 
delivery of highly hypofractionated SBRT schedules 
may lead to potentially very signiÀcant and even 
fatal toxicity when lung tumors are located more 
centrally. Organs at risk (OARs) include trachea, 
central bronchial tree, esophagus, great vessels, 
heart, brachial plexus and less commonly spinal 
cord, phrenic or recurrent laryngeal nerves. Being 
able to accurately estimate the risk of RT damage to 
these OARs would greatly facilitate the achievement 
of optimal therapeutic ration of risk vs beneÀt. 
Radiobiological modeling has long been used to 
predict the risk of normal tissue complications, and 
to compare different fractionation schedules, using 
concepts of BED (Biologically effective dose) and 
EQD2 (eguivalent dose at 2 Gy/fraction) [Fowler 
and Dale]. However, it is far from clear whether 
the existing models apply to these very large doses 
per fraction [Borst]. Proposed improvements to the 
linear-quadratic (LQ) model include the modiÀed 
LQ (MLQ) [Guerrero and Li], the lethal –potentially 
lethal (LPL) model, multitarget model, and the 
universal survival curve [Park]. One of the great 
challenges is the paucity of clinical data to validate 
these models. Although data comparing the different 
radiobiological models exists regarding lung toxicity 
post SBRT [Wennberg, Borst], lung, often the dose-
limiting organ in thoracic RT, is not the main OAR 
of concern in SBRT situations, particularly not in 
cases of centrally located tumors. Animal models 
offer some ability to test these models, but data 
is far from deÀnitive to guide practice. Toxicity 
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E09.3 QUALITY OF PALLIATIVE CARE 
SERVICES
Kris C.P. Vissers1, Yvonne Engels1, Jeroen 
Hasselaar1, Karen Van Beek2, Kathrin Woitha1, 
Ahmed Nisar3, Xavier Gomez-Batiste4, Birgit 
Jaspers5, Leppert Wojciech6, Johan Menten7, Sam 
Ahmedzai3, Jean-Marc Mollard8 
1Anesthesiology, Pain And Palliative Medicine, 
Radboud University Medical Centre/Netherlands, 
2Radiation Oncology And Palliative Care, University 
Hospitals Leuven/Belgium, 3University Of ShefÀeld/
United Kingdom, 4Institut Catala D’oncologia/Spain, 
5University Bonn/Germany, 6Poznan University Of 
Medical Sciences/Poland, 7University Hospitals 
Leuven/Belgium, 8Association Ensemble Soigner Et 
Accompagner à Paris/France
Abstract: The WHO deÀnition of palliative care 
launched in 2002 broadens the target population 
to all patients with an incurable disease. Moreover 
palliative care should be applicable early in the 
course of the illness. For politicians, caregivers 
and policy makers it is important to Ànd tools to 
measure the quality of the organization of palliative 
care. For this purpose consensus was sought on 
quality indicators, which are ‘explicitly deÀned 
and measurable items referring to the outcomes, 
processes or structure of care’ A systematic review 
on quality indicators for palliative care showed that 
clinical indicators are widely overrepresented over 
indicators that assess organizational issues. During 
workshops it was agreed that the organization of 
palliative care can be deÀned as follows: “systems 
(structures and processes) meant to enable the 
delivery of good quality palliative care. The quality 
of the organization of palliative care could be 
assessed in a framework with the domains of: 1 
DeÀnition of palliative care service; 2 Access to 
palliative care (a. access and availability, b. out of 
hours care, c. continuity of care); 3. Infrastructure; 
4. Assessment tools; 5 Personnel (a. staff, b. 
education and training for staff/volunteers, c. 
support systems, d. organization of care, e. sharing 
information); 6. Documentation of clinical data (a. 
clinical record, b. timely documentation); 7. Quality 
and safety ( a. quality policies, b. adverse events, 
c. complaints procedures); 8. Reporting clinical 
activity of palliative care services; 9. Regional, 
national and international aspects of palliative care 
Wennberg BM, Baumann P, Gagliardi G et al. NTCP 
modeling of lung toxicity after SBRT comparing 
the universal survival curve and the linear quadratic 
model for fractionation correction. Acta Oncologica, 
2011 (Epub ahead of print) Borst GR, Ishikawa 
M, Nukamp J et al. Radiation pneumonitis after 
hypofractionated radiotherapy: evaluation of the 
LQ(L) model and different dose parameters. Int J 
Radiat Oncol Biol Phys 2010; 77(5): 1596-1603. 
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E09.2 PSYCHOLOGICAL DISTRESS
Mari Lloyd-Williams 
Blank, Hospital/United Kingdom
Abstract: It is acknowledged that depression is 
present in upwards of 20% of patients with advanced 
cancer, that it is seldom assessed, diagnosed or 
treated. This presentation will overview some of 
the outcome tools currently available together with 
their strengths and weaknesses and present data from 
a very recently completed study of a longitudinal 
study of depression in over 600 palliative care 
patients. This study was carried out to determine 
the natural history and determinants of depression 
in this population and to look at what factors may 
predict or prevent depression in the last months of 
life. The presentation will include a brief overview of 
challenges of conducting a large multicentre study in 
palliative care patients in addition to suggestions for 
possible interventions which may be delivered within 
this population and further research that is required. 
Keywords: Psychological Distress, palliative care, 
depression
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for specialized training for professionals working 
in palliative care were considered important. 
On regional and national level the recognition, 
awareness and support of palliative medicine as 
illustrated by associations, policies networks and 
regulations regarding the availability of palliative 
care improve the quality. These indicators can be 
a Àrst step towards improving the quality of the 
organization of palliative care in Europe and should 
be further implemented. Per researched European 
country, different types of indicators are valued as 
relevant for quality of palliative care. This implies 
that besides the international set of indicators, the 
larger national sets are important to assess and 
improve the quality of palliative care in a speciÀc 
country. These indicators can be used in tools for 
cross-country comparisons, and are a Àrst step 
in improving the quality of the organization of 
palliative care in Europe. 
Keywords: palliative care, quality indicators
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E09.4 PALLIATIVE SEDATION IN THE 
NETHERLANDS IN GUIDELINES AND 
PRACTICE
Bregje Onwuteaka-Philipsen 
VU MC, Emgo Institute For Health & Care, VU MC, 
Emgo Institute For Health & Care/Netherlands
Abstract: In the last phase of life patients frequency 
have burdensome symptoms such as dyspnea, 
agitation, pain and anxiety. Alleviation of these 
symptoms is a central goal of medical care in these 
patients. If symptoms are refractory, sedatives can 
be used to render patients unconscious and thus 
oblivious to their symptoms. This palliative sedation 
can be deÀned as the deliberate lowering of the 
patient’s level of consciousness in the last stages of 
life. It can be temporary or intermittent, but the focus 
of this presentation will be on continuous sedation 
until the moment of death. In 2001 a European 
study on end-of-life decision-making in 6 countries 
revealed that continuous sedation until death 
occurred in all countries studied albeit in somewhat 
different percentages of all deaths: Denmark 2.5%, 
Sweden 3.2%, Switzerland 4.8%, the Netherlands 
5.7%, Belgium 8.2%, and Italy 8.5%. In the 
Netherlands, where euthanasia (ending the patient’s 
life by a physician on explicit request of the patient 
(a. national policy, b. guidelines, c. health/insurance 
program, d. networks); 10. Research (a. local level, 
b. national level) and 11 Education. Transmural 
multidisciplinary teams of caregivers were invited 
to participate in the generation of a consensus on the 
usefulness and clarity of the proposed indicators. 
After two rounds of consultation using a modiÀed 
Rand Delphi method in the top 10 indicators with 
the highest median rating, there are 3 indicators 
relative to education, 2 are personnel related, 
2 deal with the accessibility, 1 is infrastructure 
related and two others are in the domain of national 
indicators. Most retained indicators concerned the 
quality of the organization of settings that provide 
palliative care. On a broader level the following 
indicators were considered important: recognition 
of palliative medicine and palliative care nursing as 
specialty, the existence of a national health policy 
regarding palliative care, a national palliative 
care association, the collaboration in palliative 
care networks and national regulations regarding 
availability of palliative care, stafÀng, beds and 
geographical contribution across the country. 
The availability of national guidelines regarding 
pan and symptom control, palliative sedation and 
advanced care planning are considered important 
in the improvement of the quality of palliative care. 
No single indicator from the domain “Quality and 
safety” was considered essential for the quality 
of the organization of palliative care. It is judged 
important to have a home support team as well as 
hospice beds. Access to palliative care facilities 
and the possibility to consult or be visited by the 
caregiver 24 hours a day, and timely transfer of the 
patient and the clinical information are important 
quality indicators. There was consensus on the need 
for a multidisciplinary team and appropriate training 
for staff and volunteers. Validated instruments to 
assess pain and other symptoms should be in place. 
A structured clinical record adds to the quality. It 
was agreed that the use of a database for recording 
clinical activity is important, but no consensus on 
its content was reached. Also on local level the 
availability of a research program and the structural 
governmental funding are judged important quality 
indicators The infrastructure should allow privacy 
of patients and families, including the possibility to 
die in a single bedroom, facilities for relatives to stay 
overnight, the ability of a private place for saying 
good-bye to the deceased and no restrictions of 
visiting hours. Standardized learning objectives for 
basic and continuing training, as well as a program 
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E10.2 PREDICTORS AND MANAGEMENT 
OF LATE RADIATION INJURY TO THE 
CHEST WALL AND BRONCHUS
Lawrence B. Marks, Eda Yirmibesoglu 
Radiation Oncology, University Of North Carolina 
At Chapel Hill/United States Of America
Abstract: Radiation therapy (RT)-induced injury to 
the chest wall and bronchial structures is relatively 
uncommon with conventional radiation techniques. 
With the more-recent adoption of hypo-fractionated 
approaches, this is becoming a more relevant clinical 
challenge. We herein review the incidence of, and 
associated dosimetric predictors for, these toxicities. 
Chest wall: A variety of studies have related the 
incidence of chest wall pain and/or rib fracture, 
to dosimetric parameters with stereotactic body 
radiation therapy (SBRT). The following metrics 
have been implicated as being reasonable predictors 
of the risk of injury: Dmax for chest wall and rib; 
chest wall volume receiving 15, 20, 30, 40, 50 and 
60Gy; dose for 2cc of rib. In particular, the SBRT 
data from Cleveland concluded that the absolute 
risk is approximately 6%, 9%, 19%, 35%, 55%, 
and 74% when the volume chest call receiving 
30Gy exceeds 10, 20, 40, 60, 80, and 100cm3, 
respectively (1). In two separate analyses, from 
the University of Colorado and Indiana, a median 
effective concentration (EC50) dose response model 
has been used to relate dose/volume parameters 
of the rib and the chest wall to incidence of chest 
wall toxicities (pain and/or fracture) (2, 3). The 
data from both analyses well demonstrate increased 
risk with dose/volume parameters. The Colorado 
analysis suggests that EC50 model for the chest 
wall volume receiving 30Gy correlated best for 
the severe chest wall toxicity. They reported that 
the chest wall volume receiving 30Gy in three to 
Àve fractions should be limited to <30cm3 (2). The 
Indiana analysis suggests that the risk of any grade 
rib fracture or chest wall pain increased at Dmax 
doses of >50Gy. They reported that in order to limit 
using drugs) is allowed under strict conditions, the 
presentation of the incidence of continuous sedation 
gave rise to a discussion on whether palliative 
sedation was normal medical practice or euthanasia 
in disguise. Also the national ofÀce of the public 
prosecution wondered whether some cases of 
palliative sedation should be judged judicially as 
cases of euthanasia. These discussions prompted 
the Royal Dutch Medical Association to develop 
a national guideline for palliative sedation. The 
guideline includes, among others, information on 
indications and preconditions for palliative sedation, 
the decision-making, requirements for good medical 
practice, and the distinction between palliative 
sedation and euthanasia. An important precondition 
for palliative sedation in the Netherlands is that the 
patient’s death is expected within one or two weeks. 
On the basis of available evidence the guideline-
committee assumed that if the life expectancy 
of the patient exceeded this period, stopping the 
administration of Áuids would hasten the time of 
death. Palliative sedation should not shorten life, 
while euthanasia usually does. Regarding decision 
making the general rule is that the decision of 
starting palliative sedation is based on consent of the 
patient or his representative. This involves timely 
and open communication with all persons involved. 
Regarding good practice the drugs used are an 
important topic as in 2001 36% of cases of palliative 
sedation physicians indicated to use morphine as 
drug, while benzodiazepines are considered the 
appropriate drugs. In this presentation, besides 
giving information on the guideline for palliative 
sedation, data will be presented on the incidence 
and characteristics of palliative sedation in the 
Netherlands before and after the implementation of 
the guideline for palliative sedation. Furthermore, 
cases of palliative sedation and euthanasia will 
be compared on patient characteristics, reasons 
for opting for this decision, characteristics of 
the decision-making, drugs used and estimated 
shortening of life. 
Keywords: palliative sedation, palliative care, end of 
life care, end of life decision-making
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(broadly to include a variety of bronchial injuries) 
in 44/226 patients (19.5%) following HDR to total 
dose 24-35Gy in 4-6 fractions. The mean time of 
onset was 10 months. Bronchial stenosis occurred 
in 21/226 (9.5%), bronchial wall necrosis in 7 
patients (3.5%), and hemoptysis in 15 patients 
(6.6%) (9). More recently, there is increasing data 
using hypo-fractionated SBRT. Timmerman et al. 
reported increased risks for pulmonary injury for 
centrally-placed lesions following delivery of 60-
66Gy in three fractions. There, the incidence of 
experiencing severe toxicity was 11 fold increased 
with perihilar/central tumors compared to more 
peripheral locations (10). Management: Chest wall 
pain and rib fracture typcially occur within a median 
time to onset of greater than 6 months after SBRT. 
Conservative measures are typically used to treat 
chest wall pain and rib fractures; e.g. pain medicine, 
non-steroidals (oral anti inÁammatory medication, 
gabapentin, or narcotics), and immobilization. 
The typical course in these patients is for gradual 
improvement in chest wall pain was 4.7 months 
(range, 0.67-10.5) (2). Bronchial injury typically 
occurs with a mean of 16-19 weeks for grade 1-2 
toxicities, 43-55 weeks for grade 3-4 toxicities (6). 
For bronchial injury, there are limited treatments. 
Medical treatment has consisted of systemic 
steroid (dexamethasone, prednisone) and inhalation 
steroid therapy. For grade 3-4 toxicities, multiple 
debridements via bronchoscope, vascular balloon 
dilatation and silicone tracheobronchial stent can 
be considered. There’s limited literature on this. 
References: 1. Stephans KL. IJROBP. 2011 [Epub 
ahead of print] 2. Dunlap NE. IJROBP. 2010; 76 
(3): 796-801 3. Andolino DL. IJROBP. 2011 [Epub 
ahead of print] 4. Pettersson N. RO. 2009; 91 (3): 
360-8 5. Speiser BL. IJROBP. 1993; 25 (4): 579-
87 6. Speiser BL. IJROBP. 1993; 25 (4): 589-97 7. 
Hennequin C. IJROBP. 1998 Aug 1;42(1):21-7. 8. 
Miller KL. IJROBP. 2005; 61 (1): 64-9 9. Guilcher 
MA. IJROBP. 2011; 79 (4): 1112-6 10. Timmerman 
R. JCO. 2006; 24 (30): 4833-9 Supported in part by 
a grant from Turkish Society of Radiation Oncology 
(EY) and NIH grant R01-CA69579 (LBM) 
Keywords: chest wall toxicity, Radition therapy, 
Lung cancer, Bronchial injury
the risk of clinically relevant chest wall toxicity 
to <30%, the EC50 model would limit the volume 
of chest wall receiving 15Gy to 240cc, 20Gy to 
130cc, 30 Gy to 40 cc, and the volume of chest wall 
receiving 40 Gy to 15 cc (3). The total radiation 
dose prescribed in these studies typically was 
approximately 20-60Gy in 2-5 fractions. A Swedish 
study, suggests the strongest association between 
risk of rib fracture and DVH parameters lay in the 
small-volume/high-dose region. They concluded 
that for the volume of 2cm3 of a rib, the doses giving 
rise to 50% and 5% probability of rib fracture were 
found to be 49.8 and 27.2Gy, respectively, for total 
dose 60Gy in 3 fractions (4). Bronchial injury: 
Injury is unusual with conventionally fractionated 
external beam radiation (EBRT) to doses less than 
approximately 75Gy. Bronchial injury, typically 
stenosis, has been reported in a series of patients 
treated with brachytherapy, high dose external high 
beam conventionally fractionated therapy (e.g. 
1.6 BID to 74-86 Gy), and with hypo-fractionated 
SBRT. For implants, the risk appears to be >10% 
following delivery of high dose rate (HDR) 22.5-
30Gy in 3 fractions. Speiser and Spartling described 
a large series of 342 patients for bronchial toxicity. 
They suggest risk of development of bronchitis or 
stenosis is correlated with more prolonged survival 
and is increased in patients receiving concurrent 
EBRT and HDR endobronchial treatment. They 
reported grade 4 stenosis in 12/342 patients (3.5%) 
overall, but 6/68 patients (9%) patients who were 
treated to 60Gy EBRT plus 22.5-30Gy HDR RT 
(5, 6). A French study suggests the risk of radiation 
bronchitis, (broadly deÀned an any symptomatic 
event including swelling, stenosis and ever death 
from Àbrinous debris) is especially high for 
tumors located in the trachea or main stem bronchi 
compared to located in distal bronchi (18.5% vs. 
2%). Among factors, median radiation dose, the 
mean volume of the 100% isodose, treatment 
with two catheters and a higher Karnofsky score 
(due perhaps to increased longevity and this more 
time at risk for injury) seems to inÁuence the 
risk of bronchial injury (7). For approximately-
conventionally fractionated external beam radiation, 
at about 1.6-2Gy per fraction, the incidence of 
bronchial stenosis appears to increase markedly at 
doses beyond 80Gy. In one study with the largest 
number of patients with EBRT, albeit limited, the 
apparent risk of bronchial stenosis was 4%, 5% and 
25% following 74, 80 and 86 Gy, respectively (8). A 
recent French study reported “radiation bronchitis” 
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chemotherapy offers an attractive option to improve 
prognosis of patients with stage IIIa NSCLC. Up 
to now no improvement of prognosis could be 
demonstrated by the combination of neoadjuvant 
chemo- and radiotherapy. For the future the 
identiÀcation of patients who might beneÀt from 
induction treatment and who will be candidates 
for surgery will be of importance. Standardized 
assessment of pathological mediastinal clearing 
might be one of the most important instruments for 
this issue. Literature: - Rosell R et al, N Engl J Med 
1994; 330: 153-8 - Roth JA et al, J Natl Cancer Inst 
1994; 86: 673-80 - Westeel V et al, J Clin Oncol 
2010; 28: Abstract 7003 - Eberhardt W et al, J Clin 
Oncol 1999; 17: 622-34 - Thomas M et al, J Clin 
Oncol 1999; 17: 1185-93 - Thomas M et al, Lancet 
Oncology 2008; 6: 636-648
Keywords: locally advanced NSCLC, Neadjuvant 
chemotherapy, Mediastinal Clearing, Mediastinal 
Downstaging
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E11.2 CHEMOTHERAPY AS 
INDUCTION IS BETTER, OR, TO PUT IT 
APPROPRIATELY, MORE PROMISING
Hideo Kunitoh 
Blank, Mitsui Memorial Hospital/Japan
Abstract: Almost all agree that “N2 disease” of 
NSCLC is a heterogeneous group. There are many 
poorly deÀned subgroups, such as clinical N2, 
bulky N2, minimal N2, resectable and unresectable 
N2, “marginally resectable” or even “technically 
resectable” N2, with signiÀcant overlapping among 
them. Patients with pathological N2 status after 
curative surgery seem to beneÀt most from adjuvant 
chemotherapy (Douillard et al). On the other hand, 
many doubt the role of surgery itself in ANY N2 
diseases conÀrmed preoperatively. What makes the 
matter even more complicated is that there seems to 
be little consensus as to how far to perform nodal 
staging procedure before surgery. CT scans, PET 
scans, mediastinoscope, transbronchial aspiration 
and endobronchial- or transesophageal- ultrasound-
guided needle aspiration. It is very difÀcult but 
critically important, therefore, to make a valid 
clinical question before trying to answer it.
Theoretical advantage of chemoradiotherapy as 
induction
Session E11: Surgery After Induction 
Therapy IIIA
Wednesday, 6 July 2011
Surgery After Induction Therapy IIIA Wednesday, 6 July 2011 10:30-
12:00
E11.1 CHEMOTHERAPY AS INDUCTION 
IS ENOUGH
Martin Reck 
Department Of Thoracic Oncology, Hospital 
Grosshansdorf/Germany
Abstract: In locally advanced non-small cell lung 
cancer (NSCLC) with mediastinal lymph node 
involvement most patients will suffer from local 
or distant relapse shortly after primary resection. 
Induction treatment with neoadjuvant chemo- or 
chemoradiotherapy might improve prognosis by 
treatment of circulating tumor cells and sterilization 
of mediastinal lymph nodes. Early randomized 
trials reported a signiÀcant improvement of survival 
for the combination of chemotherapy and surgery 
in stage IIIa/IIIb patients with NSCLC. However 
based on the small number of patients the validity 
of the results remains questionable. A consistent 
survival and signiÀcant disease free survival 
beneÀt was seen in a randomized French phase III 
trial which investigated the role of neoadjuvant 
chemotherapy in stage I-IIIa patients with NSCLC. 
EfÀcacy data of non randomized phase II trials 
suggest that combination of neoadjuvant chemo- and 
radiotherapy might increase efÀcacy of induction 
treatment with response rates between 59-69% and 
4 year survival rates of more than 25% in selected 
patients. Therefore a randomized phase III trial was 
performed comparing induction chemotherapy with 
induction chemotherapy in 558 patients with stage 
IIIa/b NSCLC. Despite improvement of mediastinal 
downstaging and pathological response in the 
chemoradiotherapy arm no signiÀcant prolongation 
of progression free survival (primary endpoint) 
or overall survival (secondary endpoint) could be 
achieved in all eligible as well as in all operated 
patients by the combination of induction chemo- 
and radiotherapy. Furthermore treatment-related 
mortality was higher in the combination arm in 
patients who were treated with pneumonectomia. 
In addition more side effects were observed in 
the interventional arm. In summary neoadjuvant 
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Better local control might be achieved by 
intensifying induction chemotherapy, instead 
of adding radiotherapy to it. Bevacizumab was 
shown to enhance the response rates and prolong 
the PFS of platinum-based chemotherapy, and 
induction chemotherapy plus bevacizumab is being 
investigated. Preliminary data report feasibility of 
the strategy.
Discussion
According to the EBM principle, the question 
“induction chemotherapy or chemoradiotherapy” 
before surgery makes no sense, because induction 
therapy itself has not shown to be standard 
for N2 NSCLC. Many claim that preoperative 
documentation of N2 contraindicates surgical 
intervention. Patients with minimal N2 disease 
would probably beneÀt from curative resection and 
systemic chemotherapy, given post-operatively 
or pre-operatively. Standardization of procedures 
for N2 diagnosis and sub-classiÀcation of this 
heterogeneous population is necessary.
So far, induction therapy was not yet shown to 
improve the “oncological” resectability of N2 
NSCLC, unlike the case in superior sulcus tumor 
(Rusch et al, Kunitoh et al). The strategy is still 
evolving, and the question should be, “which is more 
promising” for future research.
Induction chemotherapy seems to be as effective 
as adjuvant chemotherapy, and it has several 
advantages, such as better tolerance and wider 
applicability. Technical advance will make it possible 
to analyze molecular markers, currently available 
only after tumor resection, from biopsy or even 
cytology specimens in the near future, paving the 
way to “customized” induction therapy.
Induction chemoradiotherapy has not only 
disadvantage in terms of surgical morbidity/
mortality, but also limitation in applicability from 
anatomical tumor location. This is not the case with 
the superior sulcus tumor, always located at the 
apex, for which induction chemoradiotherapy got a 
success. Improvement of chemotherapy, such as in 
combination with target-based drugs, could avert this 
problem.
Conclusion
Neither pre-operative chemotherapy nor 
chemoradiotherapy was shown to be standard in the 
management of N2 NSCLC. Induction chemotherapy 
seems to be more promising for future research. 
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Adding radiotherapy to chemotherapy before 
surgery could contribute to better local control. 
This strategy has been established in management 
of the “marginally resectable” superior sulcus 
tumor. Intensifying local therapy could, at least 
theoretically, also prevent tumor dissemination at the 
time of surgical manipulation.
Theoretical disadvantage of chemoradiotherapy 
as induction
Surgery itself gets technically more difÀcult, and risk 
of bronchial stump insufÀciency would be increased. 
Tumor location, such as lower lobes, might make the 
radiation Àeld too large.
What currently available data show and suggest
There are many phase II reports of induction 
chemotherapy and chemoradiotherapy followed by 
surgery in patients with N2 or selected N3 NSCLC, 
and comparison of efÀcacy is impossible. Overall, 
surgical morbidity or mortality is increased with 
induction chemoradiotherapy, although some claim 
the risk could be minimized by stump coverage.
Induction chemotherapy and surgical resection 
was compared to sequential chemoradiotherapy 
in patients with “unresectable” N2 disease who 
responded to chemotherapy by an EORTC trial (Van 
Meerbeeck et al), with no beneÀt in the surgical arm. 
It implies unresectable disease remains unresectable 
even after response to chemotherapy. On the other 
hand, both adjuvant and induction chemotherapy 
were shown to beneÀt patients, including those with 
pathological N2 diseases, who underwent curative 
resection, implying chemotherapy and surgery do 
work in “resectable” diseases.
Induction chemoradiotherapy was compared to 
deÀnitive chemoradiotherapy alone and by a US 
intergroup trial (Albain et al), and it was also 
compared to induction chemotherapy and post-
surgical radiation by a German trial (Thomas et al), 
both in patients with “technically resectable” N2 
diseases.
The Intergroup trial showed improvement of PFS but 
not OS by surgical resection. Right pneumonectomy 
was associated with unacceptably high surgical 
mortality. In the German trial, the results were 
similar in both treatment arms; some patients in the 
chemo-surgery arm experienced fatal complication at 
the time of post-surgical irradiation.
Taken together, although chemotherapy does 
seem to beneÀt patients with resectable NSCLC 
patients, chemoradiotherapy and surgery was not 
demonstrated to be better than anything else even in 
selected, potentially resectable N2 diseases.
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criteria. The revised RECIST criteria specify that 
lymph nodes with a short axis<10 mm are considered 
to be non-pathological. However, this cut-off size 
may be problematic, since micrometastases might 
be overlooked, and enlarged lymph nodes can occur 
due to inÁammation. To resolve these problems, 
qualitative evaluation such as pathological diagnosis 
is required. Although the optimal management 
of these patients is unclear, a common practice 
has become to consider preoperative therapy 
and possible surgery. Which patients are most 
appropriate to select for this approach is also 
unclear, but it is clear that a major prognostic factor 
is whether induction therapy achieves clearance of 
N2, 3 node involvements. This observation is based 
on the stage as determined after resection and raises 
the question of how well preoperative restaging 
tests can predict the pathologic stage and thus serve 
to select patients for resection. Many physicians 
have, in fact, adopted the management strategy 
for stage IIIa(N2) NSCLC of induction treatment, 
followed by resection of patients believed to have 
been downstaged. This approach is taken despite the 
fact that most of the questions remain unanswered. 
Whether surgical resection adds further beneÀt 
over chemoradiotherapy is controversial. Should 
patients with a good response to chemoradiotherapy 
undergo surgery because of a good response or not 
undergo surgery because of a good response (or 
should resection be avoided in those with a poor 
response or actually be pursued provided there is no 
disease progression)2? Finally, whether restaging 
tests accurately predict the Ànal pathologic stage and 
which restaging test is best are unclear. The most 
widely used method of selecting patients for surgery 
is the radiographic response by CT to induction 
therapy. This occurs despite the fact that virtually 
every study that has analyzed this has found little, 
if any, correlation between the response by CT and 
pathologic Àndings after resection. This review also 
conÀrms that a normal-appearing mediastinum after 
induction therapy carries a 30% FN rate and an 
abnormal mediastinum a 30% FP rate. Therefore, use 
of CT alone to either select patients for or exclude 
them from surgery is not justiÀed, at least not if 
the goal is to only resect those patients who are 
downstaged. Furthermore, a complete response by 
CT cannot be used to justify avoidance of resection 
because of a 50% FN rate. Although a radiographic 
response makes the patient and the physicians 
feel good, it provides little information about the 
presence of absence of viable tumor. PET imaging 
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E11.3 RESTAGING AFTER INDUCTION: 
IS IT NEEDED?
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Abstract: In the past two decades, a large number 
of trials investigated the impact of postoperative 
(adjuvant) chemotherapy on survival after lung 
resection for non-small cell lung cancer. A smaller 
number of trials have been conducted to evaluate 
the impact of neoadjuvant chemotherapy before 
lung resection, and four metaanalyses reported 
pooled hazard ratios in favor of chemotherapy. As no 
published trial has directly compared the outcome of 
preoperative versus postoperative chemotherapy, the 
current surge of information leaves physicians and 
surgeons alike wondering if there are any differences 
in survival regarding the timing for administration. 
Many physicians have adopted the treatment strategy 
of induction therapy followed by resection of those 
patients thought to be downstaged. However, many 
aspects of this are unclear, including whether the 
strategy itself is beneÀcial, what induction treatment 
should be given, or how patients should be selected 
for this approach. Perhaps most surprising is how 
convinced many are that the criteria for selection 
of patients for subsequent resection are well 
established. It is often forgotten that downstaged 
patients have been identiÀed after resection. Use of 
downstaging to select patients for surgery requires a 
reliable method of identifying them before resection. 
Malignant lymph nodes are common targets for the 
evaluation of cancer therapeutics. CT is used for 
assessment of malignant lymph nodes by RECIST 
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E12.1 GENETIC CONTRIBUTIONS TO 
NICOTINE DEPENDENCE AND LUNG 
CANCER
Laura J. Bierut 
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Medicine/United States Of America
Abstract: Genetic studies in human population 
samples have identiÀed associations between 
smoking behavior and lung cancer to single 
nucleotide polymorphisms (SNPs) in the cholinergic 
nicotinic receptor subunit (CHRN) genes. By far 
the most statistically signiÀcant Àndings are in 
the CHRNA5-CHRNA3-CHRNB4 gene cluster 
on chromosome 15q25. Once an association is 
found, the next step is to understand the underlying 
biology that leads to illness. One proposed 
biologic mechanism involves the CHRNA5 SNP 
rs16969968, which causes an amino acid change 
in the a5 nicotinic receptor protein. In vitro studies 
demonstrate that this variant alters receptor function. 
A second biologic mechanism, tagged by rs588765, 
marks varying levels of mRNA of CHRNA5 in 
human brain and lung tissue. By synthesizing the 
evidence from multiple studies, we demonstrate 
statistically independent associations of rs16969968 
and rs588765 with smoking quantity (mutually 
adjusted p-values: rs16969968 p value <10-35 and 
rs588765 p value <10-8). We also observed similar 
patterns of association with lung cancer. Studies in 
other populations such as African-Americans and 
Asians further reÀne the association evidence in the 
CHRNA5-CHRNA3-CHRNB4 gene cluster. These 
multi-faceted human genetics approaches provide 
new insights about the role of cholinergic nicotinic 
receptor genes in smoking behavior and point to 
potential biological mechanisms.
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is also commonly used to predict downstaging, 
although it is well recognized that RT can cause 
Áuorodeoxyglucose uptake due to inÁammation. 
Although PET performs somewhat better than CT, 
approximately one fourth of patients with a negative 
(“cleared”) mediastinum by PET still have pN2 
involvement and approximately one third of those 
with persistent PET uptake in the mediastinum do 
not. Surprisingly, whether RT was given has no 
impact on these results. Indeed, no patient subsets 
could be identiÀed in whom restaging PET is 
reliable. Finally, a complete response by PET in 
all sites cannot justify omitting resection: one third 
of such patients still have viable tumor. Perhaps 
more sophisticated assessments such as the percent 
change in PET activity can be used. However, it 
must be emphasized that such assessments require 
great attention to detail to ensure consistency in 
the measurements. Remediastinoscopy has been 
shown to be feasible and safe in experienced hands, 
but few institutions are comfortable with this 
technique. Because the results are disappointing, 
it is unlikely this will change. EBUS or EUS and 
needle aspiration are gradually becoming more 
widely available. The results seem to be slightly 
better than for remediastinoscopy, but the number of 
studies is limited, and it remains to be seen whether 
these will hold up as the procedure is practiced more 
widely (outside of the pioneering centers and in less 
well-selected patients). Primary mediastinoscopy 
performs fairly well, consistent with the performance 
of primary mediastinoscopy in general (especially 
the more thorough variations such as videoassisted 
mediastinal lymphadenectomy). However, this 
requires avoidance of mediastinoscopy in the initial 
staging. Often little thought is given to the eventual 
treatment strategy at the time that patients are Àrst 
evaluated and staged. Although these methods of 
restaging are commonly used to select or exclude 
patients from surgery, the data show them to be quite 
unreliable. In particular, mediastinal downstaging by 
CT, PET, or remediastinoscopy carry a FN rate of 20 
to 30%. EUS and EBUS may perform slightly better, 
but data are limited. Primary mediastinoscopy seems 
to be the most reliable method of assessment. Ideally, 
initial invasive staging of the mediastinum should be 
done by a needle-based technique, so that primary 
mediastinoscopy can be used for restaging. 
Keywords: Lung cancer, Stage IIIb, downstaging, 
Restaging
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include reduction in treatment efÀcacy, increased 
side effects and complications, increase in recurrence 
and second primary tumors, poorer overall survival, 
and decreased quality of life. A speciÀc review of 
these Àndings, as they pertain to lung cancer, will be 
presented, as well as recent Àndings about nicotine 
and cancer. Smoking cessation interventions can be 
successfully offered to patients undergoing medical 
treatment for lung cancer or afterwards. Success 
rates appear to be higher when treatments are offered 
closer to diagnosis. The highest quit rates are found 
in patients with smoking-related cancers, but relapse 
can be substantial, even after a year of abstinence. 
There are few randomized controlled trials of 
smoking cessation interventions for cancer patients, 
and there are challenging methodological issues, 
which will be reviewed. The USPHS Guideline 
for the treatment of tobacco use and dependence 
(Fiore et al, USDHHS, 2009) presents the evidence 
base for smoking cessation treatments. Tailoring of 
interventions needs to occur for patients with cancer, 
involving education regarding the link between 
cancer and smoking (and continued smoking), 
physical limitations imposed by disease and 
treatment, medical contraindications to certain types 
of pharmacologic treatment, psychological issues 
such as negative affect (anxiety and depression), 
stress, guilt, and co-morbid alcohol/substance use. 
MD Anderson Cancer Center has created a model 
Tobacco Treatment Program that incorporates all of 
these elements and is available at no cost to every 
MD Anderson patient who smokes, their spouse/
partner, and to all employees. Consistent with the 
mission of cancer prevention and tobacco control, 
the program was developed and initiated in 2006 
and continues through the present (Blalock et al, 
in press; Karam-Hage et al, 2011). This clinical 
service offers in-person and/or telephone behavioral 
counseling, based on motivational interviewing 
and social cognitive problem-solving strategies, 
prescription medication and nicotine replacement, 
an initial comprehensive assessment and treatment 
plan followed by six to eight counseling sessions 
over 12-16 weeks, and long-term assessments at 
six and 12 months. The program is staffed by a 
multidisciplinary team (psychologists, psychiatrist, 
social workers, RN and PA), who maintain contact 
with the oncology care providers. New patient totals 
reach almost 600/year, with a total of almost 24,000 
appointments since the program’s inception. Overall, 
patients smoked an average of 16 cigarettes/day for 
32 years; 13% reported a form of hazardous drinking 
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E12.2 SMOKING CESSATION AS A PART 
OF LUNG CANCER TREATMENT
Ellen R. Gritz 
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Anderson Cancer Center/United States Of America
Abstract: Globally, in 2008, lung cancer was the 
leading site in cancer incidence (1,095,200 cases) 
and mortality (951,000 deaths) in males; in women, 
it was the fourth highest site in incidence (513,600 
cases) and second highest in mortality (427,400 
deaths) (Jemal et al, 2011). In the United States, 
approximately 116,750 men and 105,770 women 
were diagnosed with lung cancer in 2010, and 
approximately 86,220 men and 71,080 women died 
of their disease (American Cancer Society, 2010). 
The vast majority of those diagnosed with lung 
cancer in the U.S. smoked during their lifetimes (85-
90%), although half or less were current smokers at 
the time of diagnosis. An ever-expanding literature 
documents the adverse effects of continuing to 
smoke after cancer diagnosis. Yet, a surprisingly high 
percent of patients with chronic diseases, including 
lung cancer, continue to smoke after diagnosis. The 
National Cancer Institute deÀnes a cancer survivor 
as “….anyone who has been diagnosed with cancer 
from the time of diagnosis through the balance of his 
or her life.” NHIS data show that over 15% of adult 
cancer survivors were smokers in 2008. In two age 
groups, about the same percent of cancer survivors 
smoked compared to the remaining US population: 
for ages 45-64, 23.6% vs 22.3%; for ages 65+, 8.6% 
vs 9.4%. However, among the youngest cancer 
survivors, ages 18-44, smoking rates are double in 
cancer survivors vs the remaining population, 40.4% 
vs 24.6%. This is an appalling statistic that calls 
for dramatic attention, education and intervention. 
According to 2006 NHIS data (MMWR, 2007), 
among chronic disease populations, 36.9% of those 
with any smoking-related chronic disease smoke, 
compared to 19.3% of those without a chronic 
disease. Among all smoking-related cancers (except 
lung cancer), 38.8% of survivors smoke, and 20.9% 
of lung cancer survivors smoke. Astoundingly, 30% 
of CVD survivors smoke and 49.1% of emphysema 
survivors. The adverse effects of smoking after a 
diagnosis of cancer have been well-documented for 
surgery and radiation treatment, with some reports 
for chemotherapy, as well. These adverse effects 
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Early work by Chapple et al. found that whether lung 
cancer patients smoked or not, they felt stigmatized 
because their disease is so strongly associated with 
smoking. Stigma in lung cancer is based on the 
belief that one caused their own cancer. Lung cancer 
is associated with short survival times and patients 
with lung cancer can receive stronger messages of 
doom from family care givers and clinicians. These 
messages of doom contribute to self-attribution, a 
strong predictor of distress. Stigma is correlated 
with higher levels of guilt, shame, anxiety, and 
depression and is linked to delayed diagnosis and 
poor compliance with medical treatments. Evidence 
suggests that increases in psychological morbidity 
have a negative impact on treatment effectiveness 
and quality of life (QOL). Until we developed the 
Lung Cancer Stigma Scale, no valid and reliable 
measure of stigma existed for use with lung cancer 
patients. Therefore, no studies had examined the 
severity of Lung Cancer Stigma (LCS) and its 
relationship with physical and psychosocial symptom 
burden and QOL. In our previous work with lung 
cancer patients, strong associations were found 
between LCS and depression (r= .68, p < .0001) and 
QOL (r=-.65, p < .0001). No signiÀcant differences 
were found in demographic characteristics or 
study variables between ever smokers and never 
smokers. A simultaneous multiple regression with 
5 independent variables revealed an overall model 
that explained 62.5% of the total variance of QOL 
(F5,168 = 56.015, P < .001). Lung cancer patients 
experience greater symptom severity throughout 
their illness trajectory. The most common physical 
symptoms include: dyspnea, fatigue, insomnia, 
and pain. Very little research exist on factors that 
contribute to increased symptom severity. Compared 
to other types of cancer, lung cancer patients 
experience the greatest amount of psychological 
distress and are at higher risk for psychosocial 
problems during and after treatment. Studies have 
shown that one out of four persons with lung 
cancer experience periods of depression or other 
psychosocial problems during their treatment. Higher 
QOL scores are associated with increased survival in 
lung cancer patients. Lung cancer survivors do not 
experience the same level of QOL as other cancer 
survivors. Montazeri found that pre-diagnosis rating 
of QOL was the most signiÀcant predictor of the 
length of survival even after adjusting for known 
prognostic factors. Lung cancer patients experience 
greater symptom severity throughout their illness 
trajectory. The most common physical symptoms 
behavior; and over 48% met criteria for one or more 
co-morbid psychiatric diagnoses. At the one year 
follow-up, 30%-50% were abstinent (7 day point 
prevalence), which compares favorably to highly 
motivated populations of healthy smokers treated 
with pharmacotherapy. Among those who did not 
quit entirely, smoking rates were cut by half (Karam-
Hage et al, 2011). This program sets a standard for 
healthcare settings, in terms of serving a cancer 
patient population during and following treatment. 
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E12.4 LUNG CANCER STIGMA AND 
SYMPTOM BURDEN
Janine K. Cataldo 
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Abstract: Lung cancer is the leading cause of cancer 
deaths in the United States. Compared to patients 
with other types of cancer, lung cancer patients 
experience the greatest amount of psychological 
distress. Perceived stigma is deÀned as a personal 
experience characterized by exclusion, rejection, 
blame or devaluation that result from anticipation 
of an adverse judgment. This judgment is based on 
an enduring feature of identity conferred by a health 
problem, the judgment is medically unwarranted, 
and may adversely affect health status. Stigma has 
been extensively studied in HIV/AIDS, mental 
illness, epilepsy and physical disability, but not lung 
cancer. The effects of perceived stigma, depend on 
whether or not patients themselves or others hold 
them responsible for the disease and whether the 
disease leads to serious disability, disÀgurement, 
lack of control, or disruption of social interactions. 
Perceived stigma is associated with an increase in 
the stress associated with illness and contributes 
to psychological, physical and social morbidity. 
Stigma in people with HIV is associated with 
poor physical and mental health outcomes, limited 
sources of social support, concealment of disease 
after prognosis, poor treatment adherence, increased 
disability, and diminished quality of life (QOL). 
Lung cancer can conjure a similar attribution of 
blame as that found with HIV, because HIV is often 
associated with homosexuality and IV drug use and 
lung cancer is associated with smoking cigarettes. 
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E13.1 ADEQUATE PN STAGING: 
WHAT SHOULD THE SURGEON DO? 
SAMPLING, RADICAL DISSECTION, 
SYSTEMATIC NODAL DISSECTION OR 
LOBE-SPECIFIC NODAL DISSECTION?
Mark S. Allen 
Surgery, Mayo Clinic/United States Of America
Abstract: Since the initial successful pneumonectomy 
by Evarts A. Graham in 1933 and the subsequent 
discovery that lobectomy was an acceptable resection 
to cure lung cancer, it has been unclear what is the best 
method to deal with the lymph nodes that drain the 
area of cancer. Memorial Sloan Kettering described 
that patients who underwent a mediastinal lymph node 
dissection had a prolonged survival. Surprisingly, this 
assertion was not scientiÀcally tested, until 20 years 
later, but only then with several retrospective studies. 
These include studies by Naruke, Izbicki, and Keller. 
In 1999 the late Robert Ginsberg was able to convince 
the American College of Surgeons Oncology Group 
(ACOSOG) to perform a large randomized trial 
comparing mediastinal lymph node sampling (MLNS) 
to a complete mediastinal lymph node dissection 
(MLND) in patients with early stage lung cancer. The 
study took about 12 years to complete and was able 
to analyze 1,111 randomized patients. The Àndings 
showed no difference in long-term survival between 
MLNS and MLND. Only 4% of the patients that 
initially had a MLNS were found to have a positive 
mediastinal lymph node on MLND. The study also 
showed that there was no increase in the complication 
rate with MLND vs. MLNS; therefore, doing a LMND 
seems to have very little downside except extending 
the operation about 15 to 20 minutes. However, since 
the trial only studied patients with early stage cancer, 
it is difÀcult to extrapolate the results to patients with 
stage II or stage IIIA cancers. The question of what 
to do with the mediastinal lymph nodes during a 
pulmonary resection for lung cancer can be answered 
with some scientiÀc evidence using the Z0030 study. 
All patients should have a complete evaluation of the 
mediastinum preoperatively with history and physical 
include: dyspnea, fatigue, insomnia, and pain. Very 
little research exist on factors that contribute to 
increased symptom severity. Compared to other 
types of cancer, lung cancer patients experience 
the greatest amount of psychological distress and 
are at higher risk for psychosocial problems during 
and after treatment. Studies have shown that one 
out of four persons with lung cancer experience 
periods of depression or other psychosocial problems 
during their treatment. Very little research exist 
on factors that contribute to increased symptom 
severity. The purpose of this study was to explore 
the severity of LCS and its relationship with the 
severity of physical symptoms (i.e., appetite, cough, 
dyspnea, hemoptysis, pain. sleep), psycho-social 
symptoms (self-esteem, anxiety, depression), and 
QOL. In a sample of 185 lung cancer patients, the 
speciÀc aims were to: 1. Explore the relationships 
between LCS and the severity of physical symptoms; 
2. Explore the relationships between LCS and 
severity of psycho-social symptoms (i.e., self-
esteem, anxiety, and depression); 3. Explore the 
relationships between LCS and QOL; and 4. Identify 
the contributions of physical and psycho-social 
symptom severity and LCS to QOL. Methods: Lung 
cancer patients were recruited from online lung 
cancer support communities. IRB approved consent 
forms and instruments were available on line. Data 
was collected on RedCap. Results: LCS had mild to 
strong associations with all physical symptoms and 
ranged from .26 to .46 (p< .001); LCS had moderate 
to strong associations with all psycho-social 
symptoms from .41 to .55 (p<.001); A simultaneous 
multiple regression with 4 independent variables 
(gender, age, depression, and LCS) revealed an 
overall model that explained 54.5% of the total 
variance of QOL (F4,144 = 41.91, P < .001), stigma 
uniquely explained 5% of the total variance of QOL 
after controlling for age, education, and depression 
(p<.001). A simultaneous multiple regression with 
4 independent variables revealed an overall model 
that explained 36.4% of the total variance in total 
lung cancer symptoms (F4,144 = 19.46, P < .001); 
stigma uniquely explained 6% of the total variance 
of lung cancer symptoms, after controlling for age, 
education, and depression (p<.001) . Conclusion: 
LCS is a strong predictor of psychosocial and 
physical symptoms and QOL among lung cancer 
patients. 
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and mediastinal lymph nodes are idenitiÀed by 
surgeons. Pathologists are required to identify 
hilar and intrapulmonary lymph nodes which are 
found in the resected lung. On gross dissection 
of the resected lung, they should be careful not to 
fail to make a tissue block to examine these lymph 
nodes. SpeciÀcally, pulmonary hilar lymph nodes 
which are directly invaded by a main tumor should 
be counted as pN1, though they may be easily 
overlooked and scored as pN0 by a careless gross 
examination. A single, well-preserved HE-stained 
tissue section from a maximal cut surface of each 
node can provide adequate and sufÀcient histologic 
evaluation of lymph node involvement. Clinical 
signiÀcance of minute metastasis are still under 
investigation, and detailed modiÀcation of practical 
staging requires more evidence before clinical 
introduction. For that purpose, metastatic tumors 
of 0.2 mm to 2 mm in actual size found in lymph 
nodes are deÀned as micrometastasis. They should 
be described differently from those of ordinary 
size, such like pN1(mi), pN2(mi). Sentinel lymph 
nodes could be identiÀed during surgery, separate 
description such like pN0(sn), pN1(sn), for example, 
is recommended. Evaluation and description of 
isolated tumor cells (ITC), less than 0.2 mm by 
deÀnition, found in regional lymph nodes is another 
issue to be discussed. Immunohistochemistry, as 
well as some molecular tests such as PCR, is now 
in our hands of routine laboratorial work. However, 
it should be mentioned that the results of these tests 
should be interpreted very carefully, and hopefully in 
conjuction with conventional histologic evaluation of 
the same lymph nodes. IdentiÀcation and description 
of minimal, often morphologically invisible tumor 
cells would be interpreted as a separate, and an 
important effort devoted to establish the future 
staging system, but does not necessarily mean a 
precise staging in today’s clinical practice in the Àeld 
of primary lung cancer.
Keywords: lymph node metastasis, micrometastasis, 
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(looking for evidence of hoarseness, cervical lymph 
nodes, decreased breath sounds from a paralyzed 
diaphragm, and enlarged neck veins from an obstructed 
central vein), computed tomography (CT), and 
proton emission tomography (PET). When indicated 
a mediastinoscopy, mediastinotomy or endoscopic 
bronchoscopic ultrasound (EBUS) should be used 
to obtain pathological tissue to examine for further 
deÀnition of the status of the mediastinal lymph nodes. 
Once the chest is open all patients should have at least 
a sampling of the hilar and mediastinal lymph nodes 
and any enlarged or abnormal appearing lymph nodes 
should be removed. During the resection intralobar 
lymph nodes should be taken as part of the resection. 
For stage II cancers there is less scientiÀc information 
on which to base a recommendation. Clearly, anyone 
with a stage II based on a positive intralobar lymph 
node should undergo a complete mediastinal lymph 
node dissection since this would seem logical since the 
cancer has already shown its capability for spread to 
lymph nodes, and to not examine the mediastinal lymph 
nodes would make logical sense since the lymph node 
dissection does not increase the complication rate. For 
stage IIIa cancers patients deÀnitely need a complete 
mediastinal lymph node dissection. For patients that 
are undergoing a resection after adjuvant chemotherapy 
and/or radiation therapy, the mediastinal lymph node 
status is a key prognostic indicator, so removal for 
pathologic examination is indicated. For patients that 
are discovered to have a positive mediastinal lymph 
node at the time of sampling, it would seem wise to 
remove the rest of the lymph nodes to be sure there is 
not residual cancer left behind and to completely stage 
the mediastinum.
Keyword: Lymph nodes
TNM 7th Edition - What Should Doctors Do? Wednesday, 6 July 2011 
16:30-18:00
E13.2 ADEQUATE PN STAGING: 
WHAT SHOULD THE PATHOLOGIST 
DO? NUMBER OF SECTIONS, 
IMMUNOHISTO, MOLECULAR 
MARKERS, PCR?
Yoshihiro Matsuno 
Department Of Surgical Pathology, Hokkaido 
University Hospital/Japan
Abstract: Pathologic staging should be performed 
based on a standard procedure. Exact location 
(ie, numbering) of dissected pulmonary hilar 
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more than 2 nodules or disease in other locations 
despite the TNM 7th edition classiÀcation as M1a 
disease. The Ànal change in the TNM 7th edition with 
surgical implications is the downstaging of T4N0-1 
patients from Stage IIIB (unresectable) to Stage IIIA 
where surgery can play a role. The T4N0-1 subset 
was identiÀed early on as a group within TNM 6th 
edition Stage IIIB locally advanced NSCLC that 
has a favorable prognosis. SWOG 8805 treated 116 
Stage IIIA/B NSCLC with concurrent cis/etop and 
45 gy of RT if patients did not progress they received 
surgery. The T4N0-1 subset was identiÀed early on 
as a favorable subset within TNM 6th edition Stage 
IIIB with a median survival of 32 months versus 
12 months. Additionally, Grillo and colleague have 
demonstrated that T4 tumors involving the carina can 
be resected with good long-term survival provided 
the N2 nodes are not involved. Our institution has 
also found similar results with the resection of 
superior sulcus tumors invading the spine (T4N0-1) 
provided the N2 nodes are not involved. In summary 
then the shift in stage groupings of T4N0-1 tumors 
from Stage IIIB to IIIA in the TNM 7th edition does 
indeed appear to reÁect the good outcome of T4N0/1 
tumors and puts them in a category where surgery 
can often help control local disease and potentially 
improve long-term survival. 
Keywords: TNM 7th edition, NSCLC, Surgery
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E13.4 UPSTAGES GROUPS: EVIDENCE 
FOR ADJUVANT THERAPY
Jean Yves Douillard 
Medical Oncology, ICO R Gauducheau/France
Abstract: The TNM classiÀcation is an important 
tool for clinical practice. It allows to deÀne disease 
extension, to group such extension into stages and 
to provide a prognostic value in term of relapse rate 
risk and overall survival. It is also used to decide on 
therapeutic strategies accordingly. It applies to a vast 
majority of cancers and is internationally deÀned 
and recognized under the auspices of International 
Union Against Cancer (UICC) and the American 
Joint Committee on Cancer (AJCC). In 2007 the 
International Association for the Study of Lung 
Cancer (IASLC) published its proposal for a revision 
of the TNM stage grouping and the edition of the 7th 
version of the TNM classiÀcation. Version 6th was 
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E13.3 WHICH CATEGORIES ARE 
AMENABLE FOR SURGERY AFTER 
DOWNSTAGING?
Stephen G. Swisher 
Thoracic And Cardiovascular Surgery, MD Anderson 
Cancer Center/United States Of America
Abstract: Recently a new staging classiÀcation 
(TNM 7th edition) has been put forward that 
reclassiÀes several groups of patients. The major 
changes in the TNM 7th edition staging system 
include further subdivision of the T category by 
size (T1a (2 cm); T1b (>2-3 cm); T2a (>3-5cm); 
T2b (>5-7 cm), T3 (>7 cm)). From the treating 
physician’s perspective one important change of 
this size subclassiÀcation is that larger tumors are 
now T3 (>7 cm) and T3N1M0 patients are now 
reclassiÀed as IIIA (formerly IIB) in the TNM 7th 
edition. Since stage IIIA patients are often treated by 
oncologists without surgery (chemoradiation alone), 
it is important to recognize that these T3N1 patients 
may need to be separated from other TNM 7th edition 
IIIA patients and treated with surgery instead of 
deÀnitive chemoradiation. Another major change 
in the TNM 7th edition staging system with surgical 
implications is that patients with two separate 
nodules in the same lobe have been downstaged from 
T4 to T3 while those with two separate nodules in 
different lobes have been downstaged from M1 to 
T4. This revision reÁects the good overall survival of 
patients with synchronous lung cancers treated with 
surgical resection and highlights the need of surgeons 
to target these patients for surgical therapy. Patients 
with two separate nodules in different lungs are still 
classiÀed as M1 disease (M1a) but it is important to 
recognize that this may be due to a limitation of the 
databases utilized for the TNM 7th edition staging 
system rather than a true biologic difference. The 
databases used for the TNM 7th edition were not able 
to separate patients two nodules in different lungs 
from patients with multiple (>2) nodules in different 
lungs. The good outcome of 2 synchronous lung 
cancers in separate lungs may therefore have been 
missed because this favorable subset could not be 
separated from patients who had clearly metastatic 
disease (multiple (>2) nodules in different lungs). 
It is therefore important to recognize that patients 
with two nodules in different lungs should still be 
considered for surgical resection if they do not have 
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adjuvant chemotherapy. It would however difÀcult 
to Àt these data into the TNM 7th In the JBR10 
trial, the effect of adjuvant Vinorelbine-Cisplatin 
was evaluated in stages pIB/II and showed overall 
a signiÀcant beneÀt. However, subgroup analysis 
showed that former TNM 6th stage pIB did not 
beneÀt from adjuvant treatment and the overall 
beneÀt was driven by the stage pII. Here again, stage 
pIB were T2N0M0 in TNM 6th and would now be 
staged IB, IIA or IIB. A pooled exploratory analysis 
of JBR10 and CALGB has been presented evaluating 
the effect of adjuvant chemotherapy according to T 
size in N0 cases reclassiÀed according to TNM 7th 
. A total of 461 cases were included in this analysis. 
The Hazard Ratios (HR) of adjuvant chemotherapy 
vs. surgery alone showed an increased reduction 
in the risk of death and relapse with increasing T 
size and a clear cut difference between pT2a and 
pT2b/pT3. This data with the limitation of the 
methodology and rather small sample size conÀrm 
the retrospective analysis of the impact of T size in 
CALGB. In other adjuvant trials including IALT, 
ANITA and BLT tumour size was not reported in 
the study data collection and such analysis cannot 
be done retrospectively. In the ANITA trial, impact 
of adjuvant chemotherapy on survival has been 
reported according to pN stage. The TNM 7th is 
not modiÀed in term of pN stage and these data 
might be used to decide on adjuvant chemotherapy. 
Based on what has been published retrospectively, 
T size matters. According to the present knowledge, 
adjuvant chemotherapy should be offered to all 
patients with pN1/pN2 disease. In patients with 
pN0 disease, according to the JBR10/CALGB 
retrospective pooled analysis, chemotherapy should 
be discussed in patients with TNM 7th pT2b and 
above. Patients with smaller T2 tumours (T2a) and 
N0 disease should be discussed individually and take 
into account other prognostic factors. Should the 7th 
TNM classiÀcation modify treatment algorithms in 
term of adjuvant chemotherapy for resected NSCLC? 
First, the revision of the TNM for lung cancer did 
not aim at providing information on the superiority 
of a given treatment approach; second, change in 
treatment algorithm based on the new TNM staging 
should be evaluated in clinical trials. However, a 
recently published survey in the Thoracic Oncology 
community has shown that for “stage shifters” 
treatment strategy would be modiÀed based on the 
new staging classiÀcation. 
Keyword: TNM VII, Upstages Groups, Adjuvant 
chemotherapy
introduced in 2002 and actually did not suggest any 
changes to the 5th edition from 1997. Since, clinical 
stages have improved with better imaging including 
the routine use of CT scan, In addition the set of 
data used to propose the 7th edition included a total 
of more than 67 000 cases of Non-Small Cell Lung 
Cancer (NSCLC) carefully selected by experts of 
the working group, internationally from a total of 46 
sources in 19 countries and a period ranging from 
1990 to 2000. This was a more exhaustive analysis 
than the database used for the 5th classiÀcation (5319 
cases from a single institution and a period starting 
in 1975). . The major modiÀcations implemented 
in the TNM 7th edition essentially amend the T and 
the M parameters of the TNM. Accordingly, stage 
grouping has been modiÀed: -Small T2 tumours (>3 
and <5cm) T2a. T2a N1 M0 are down staged from 
stage IIB to IIA -Large T2 tumours (>5 and <7cm) 
become T2b, >7cm become T3 and are upstaged : 
T2b N0 M0 are moved from stage IB to IIA, T3 N0 
M0 from IB to IIB, T3 N1 M0 from stage IIB to 
IIIA -Nodules in the same lobe become T3 and are 
down staged from IIIB to IIB if N0 and stage IIIA 
if N1or N2. -Nodules in another ipsilateral lobe are 
now T4 and down stage from former stage IV to 
IIIA if N0 or N1, stage IIIB if N2 or N3 -T4 tumours 
with other features are down staged from IIIB to 
IIIA if N0 or N1. -Tumours associated with pleural/
pericardial nodules/effusion are upstaged from IIIB 
to IV. They also provide a more accurate Àgure in 
term of relapse rate and survival. Comparison of the 
5-year survival rate according to the pTNM stages 
between the TNM 6th and 7th version on the data 
base shows the following outcome (6th/7th): -Stage 
IA: 73/73% -Stage IB: 54/58% -Stage IIA: 48/46% 
-Stage IIB: 38/36% -Stage IIIA: 25/24% -Stage IIIB: 
19/9% -Stage IV: 21/13% Most of these survival data 
on pTNM stages for resectable NSCLC have been 
observed for surgery alone More recently another 
single institution retrospective study reported the 
Local /Regional Recurrence (LLR) rate comparing 
the 6th and 7th TNM used. % LLR % Metastasis 
-Stage IA: 16/16 16/16 -Stage IB: 26/23 36/28 -Stage 
IIA: 43/37 64/56 -Stage IIB: 35/39 49/53 -Stage 
IIIA 40/30 85/65 The impact of the use of TNM 7th 
on the indication of adjuvant chemotherapy is more 
difÀcult to predict. For the former stage IB, in the 
CALGB 9633 trial, tumours classiÀed as IB were 
pT2 N0 M0, T2 in the former TNM 6th . Overall this 
study showed no beneÀt of Paclitaxel-Carboplatin 
in the adjuvant setting. An exploratory analysis of 
the subset of tumours > 4cm showed a beneÀt from 
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E14.3 NURSING ASPECTS OF 
TREATMENT WITH (EGFR) TKI: 
IMMEDIATE TOXICITY
Suzan Ras - Van Spijk 
Daniël Den Hoed Clinic- Outpatient Care, Erasmus 
MC/Netherlands
Abstract: Patients with NSCLC can be treated 
with an EGFR-TKI inhibitor. Erlotinib is indicated 
for the treatment of patients with locally advanced 
or metastatic NSCLC after failure of at least one 
prior chemotherapy regimen. GeÀtinib is indicated 
as the treatment for patients with locally advanced 
or metastatic NSCLC with an active EGFR-TKI 
mutation. Treatment with EGFR-TKI inhibitors may 
cause side effects. Adverse reactions that may occur 
within two months are: 
- Rash
- Diarrhea
- Nail abnormalities 
45-100% of patients will experience a 
papolupustulaire eruption. These side effects have 
a major impact on the quality of life. For the rating 
of this skin disorder the NCI CTCEA list is used 
to score the different stages of disorder. These side 
effects may have an undulating course. It may be 
more or less severe during the treatment. Dutch 
Dermatologists have developed a treatment for every 
stage of the skin disorder and nail abnormalities.
The oncology nurse plays a important role in 
coaching the patient and it’s relatives. She discusses 
the preventive measurements that may affect the 
patient. She is the Àrst point of contact for the patient 
if side effects occur. The sooner the patient reported 
side effects, the faster the treatment can be started. 
Of great importance is that the treatment with an 
EGFR-TKI inhibitor will not be interrupted when 
side effects do show up.
Preventive measures against the skin disorder:
- Avoid direct sunlight
- Use a moisturizing cream
- Protect the skin 
Preventive measures against nail abnormalities:
- Wear gloves when doing housework
- Do not wear tight Àtting footwear
- Cut the nails straight across
- Daily inspect of the nails
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E14.2 NURSING ASPECTS OF 
TREATMENT WITH (EGFR) TKI: 
TOXICITY IN PATIENTS TREATED FOR 
6 MONTHS
Atie W. Van Wijk, Annemarie Becker, Egbert F. 
Smit, Pieter E. Postmus 
Pulmonary Diseases, Vrije Universiteit Medical 
Centre/Netherlands
Abstract: 1. Background: Currently the inhibitor of 
the epidermal growth factor receptor (EGFR) tyrosine 
kinase erlotinib is widely used for the treatment of 
non small cell lung cancer. Especially in patients 
with a mutation or deletion in the epidermal growth 
factor receptor gene. As these patients may beneÀt 
most from the treatment, they may receive the drug 
for a long period of time. 2. Methods: In our hospital 
we have reviewed the side effects of twenty-two 
patients receiving erlotinib for over six months. Male/
female: 3/19, EGFR deletion/mutation/unknown: 
15/5/2. All patients suffered from side effects, such 
as: diarrhea, folliculitis, paronchia, hair loss and 
hair changes, chronic cough and fatigue. Main side 
effects were scored 1 and 2 common toxicity criteria 
(CTC). As we did not have much experience with 
patients using erlotinib for months or even years, 
we had to explore ways to treat side effects in a way 
patients could continue therapy without too much 
distress. 3. Results: in the presentation nursing care of 
these side effects and suggestions to support patients 
handling the side effects will be highlighted. Some 
case histories from patients with prolonged erlotinib 
treatment will be shown. 4. Conclusion: suffering 
the side effects of EGFR inhibitors can be hard for 
patients with non small cell lung cancer. New methods 
of treating the effects have to be investigated and 
described in medical/nursing literature. The use of 
specialist health care professionals is necessary to help 
patients in continuing the therapy, especially where 
they beneÀt from this targeted therapy. The specialist 
nurse can play an important role in this process. 
Keyword: Erlotinib, Long term side effects, nursing care
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in clinical trials were not included for the sake 
of interference. A questionnaire was set up by 
respiratory oncologists, a psychologist, and data 
monitors working in our Respiratory Oncology unit. 
They were submitted to patients by a co-worker not 
involved in any treatment decision. It was explained 
to the patients that we were questioning hypothetical 
scenarios. It had to be completed at the start, after 
two and four cycles of chemotherapy, respectively. 
Ten questions covered the topic of MT. Nine of 
the ten questions could simply be answered by 
“yes”, “no” or “don’t know”. One item addressed 
side-effects and this one used a 4 point Likert scale 
format. A Àrst question asked whether patients would 
like to start with MT immediately after completing 
their 1st line treatment instead of a treatment-free 
period with careful follow-up. If not, a reason was 
asked for and the questionnaire ended. If they would 
consider MT, further questions were asked about the 
expected beneÀt to consider MT, speciÀcally with 
regards to a certain expected mean survival beneÀt 
(1 year, 6, 3 and 1 months); or in the absence of 
expected mean survival beneÀt to symptom relief or 
to radiological tumour stabilization. The next group 
of questions was related to the maintenance drug 
itself: would patients consider MT if administration 
of the drug was oral and daily; or if it was three-
weekly and intravenously. The last question dealt 
with the acceptance of possible side effects. Each 
of those (nausea, fatigue, diarrhoea, skin rash) had 
to be graded on the Likert scale as none, mild, 
moderate, severe. Recruitment was ongoing at the 
time of submission of this abstract, and our Àrst data 
will be presented at the meeting. REFERENCES 
1. Ciuleanu T, Brodowicz T, Zielinski C, et al.: 
Maintenance pemetrexed plus best supportive care 
versus placebo plus best supportive care for non-
small-cell lung cancer: a randomised, double-blind, 
phase 3 study. Lancet 374, 1432-1440 (2009). 2. 
Cappuzzo F, Ciuleanu T, Stelmakh L, et al.: Erlotinib 
as maintenance treatment in advanced non-small-cell 
lung cancer: a multicentre, randomised, placebo-
controlled phase 3 study. Lancet Oncol 11, 521-529 
(2010). 
Besides that, the oncology nurse also supervises 
the intake of medication. An important role of the 
oncology nurse is the psychosocial coaching of the 
patient in respect to the disease and observe if any 
adverse reaction occurs. 
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E14.4 MAINTENANCE THERAPY: HOW 
DOES MY PATIENT FEEL ABOUT IT?
Lies Peeters1, Beatrijs Anrys1, Anne Sibille1, Johan 
Vansteenkiste2 
1Respiratory Oncology, University Hospital Leuven/
Belgium, 2Respiratory Oncology Unit, University 
Hospital Leuven/Belgium
Abstract: Non-small cell lung cancer (NSCLC) 
accounts for 80 to 85% of all types of lung 
malignancies. First line chemotherapy for advanced 
stages of NSCLC is well-established and consists 
of 4 to 6 cycles of a platinum-doublet. Second line 
treatment is classically started at disease progression. 
However, over the last years, a new concept has 
emerged: maintenance therapy (MT). This includes 
continuation of a given drug or consolidation 
with/switch to another drug directly after 1st line 
treatment. Both chemotherapeutic and biological 
agents can be used. Published phase III randomised 
studies have demonstrated progression-free survival 
(PFS) and overall survival (OS) beneÀts for MT 
with pemetrexed [1] or with erlotinib [2] after four 
cycles of a non-pemetrexed containing platinum-
doublet chemotherapy. Yet, pros and cons of this 
strategy remain in place. One major limitation 
in the interpretation of the phase III trials is that 
the majority of the patients in the control arm 
never received appropriate 2nd line therapy at the 
time of progression. Therefore, it remains unclear 
whether MT is really better than appropriate 2nd 
line treatment at the time of disease progression. 
Furthermore, issues with costs, quality of life and 
toxicity can be raised. Therefore, the preference of 
patients well informed about pros and cons of MT 
also has to be taken into account. We present our 
preliminary results of a survey conducted on this 
topic. The objectives were to evaluate the patients’ 
attitude towards MT in advanced NSCLC. Patients 
were included if they were diagnosed with stage IV 
NSCLC (any histology) and were planned to start 
1st line doublet chemotherapy. Patients participating 
Copyright © 2011 by the International Association for the Study of Lung Cancer S183
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
in grade  2 in 96 patients 
t Nausea: EfÀcacy of aprepitant 125 mg once weekly 
and metoclopramide 10 mg twice daily in 20 patients 
versus granisetron 1 mg once daily in 12 patients 
t Cetuximab-induced dermatitis: EfÀcacy of 
prophylactic minocycline 100mg once daily 
and elidel on demand in 16 patients versus no 
prophylaxis in cetuximab induced acneiform rash in 
12 patients 
t Weightloss: feasibility en efÀcacy of initiating tube 
feeding by the nutricionist in weight loss > 1 kg a 
week in 50 patients versus tube feeding according to 
the opinion of the phycisian 
t Pain: efÀcacy of additional gabapantin and 
amitryptiline 75 mg once daily in 15 patients with 
pleural pain or pain due to plexus brachialis ingrowth 
t Nefrotoxicity: efÀcacy and contra indications 
in standard hydration with 1000 ml saline before 
chemotherapy in 30 patients versus no hydration in 
30 patients 
t Literature studies were performed on all topics and 
discussed in a multidisciplinary fashion with clinical 
experts prior to the initiation of the interventional 
trials. 
Statistics: The Statistic Package for Social Sciences 
(SPSS) version 18 was used for data entry. 
Correlation and regression tests were performed for 
the analysis 
Results: Two hundred and thirty-seven patients were 
treated concurrently in 2008, 2009 and 2010 in the NKI-
AVL The prescription of oral magnesiumhydroxide 
aluminum in grade 1 hypomagnesaemia resulted in less 
 grade 2 toxicity. Intravenous suppletion of magnesium 
sulphate doesn’t increase the plasma magnesium 
nor reduces the duration of the hypomagnesaemia. 
Aprepitant and metoclopramide increases  grade 2 
nausea and vomiting and are therefore not superior to 
granisetron in daily chemo radiotherapy Prophylactic 
minocycline reduces severe cetuximab induced skin 
toxicity and is superior to minocycline on demand Tube 
feeding according to guidelines is feasible and reduces 
the incidence of severe weight loss Hydration before 
chemotherapy stabilizes the glomerular Àltration rate 
and reduces forced endings of treatment. No increase in 
cardiac failure was observed Conclusions Small pilot 
studies are shown to be feasible and increase the toxicity 
tolerance in patients leading to therapy compliance 
and fulÀllment of treatment Intervention trials in small 
cohorts of uniformly treated patients are an effective way 
to improve supportive care in a short period of time. 
Keywords: chemo radiotherapy, supportive care
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E14.5 STRUCTURAL MANAGEMENT OF 
PAITIENTS TREATED WITH CHEMO-
RADIOTHERAPY
Wilma Uyterlinde 
Thoracic Oncology, NKI/AVL/Netherlands
Abstract: Many of the currently used supportive 
care protocols are not evidence based but are 
empiral. Often, suboptimal care is the result. 
Adequate supportive care is a necessity for the 
fulÀllment of treatment and reasonable tolerance of 
toxicity. It is of importance to gain knowledge on the 
clinical characteristics and the relations with acute 
toxicity and outcomes in patients with non-small 
cell lung cancer treated with chemo radiotherapy.
Based on short-term interventions in small cohorts 
of patients the standardized supportive care program 
was optimized and improved guidelines were 
developed. Concurrent chemo radiotherapy (CCRT) 
is the treatment of choice for locally advanced 
irresectable or inoperable non-small cell lung cancer. 
Since 1990 daily dose cisplatin (6 mg/m2 for 24 
days), is administered concurrently with accelerated 
high dose radiotherapy. The increase in survival 
(resp. 6% and 11% at 3 years) for concurrent versus 
sequential chemo radiotherapy, or radiotherapy alone 
is due to improved local control of the disease(1-3). 
Side effect, however, are signiÀcant for the patient. 
Patients and methods Patients Patients treated 
concurrently with daily low dose cisplatin and 
radiotherapy in 2008, 2009, 2010 in the Netherlands 
Cancer Institute Antoni van Leeuwenhoek Hospital 
(NKI-AVL). Chemoradiotherapy Daily cisplatin 
6 mg/m2 (maximum 12 mg) followed by 2, 75 
Gy on 24 consecutive working days. Because of 
involvement in a randomized clinical trial, some 
patients received cetuximab 250 mg/m2 weekly, 
aften an oading dose of 400 mg/m2 one week prior 
to the start of CRT Methods From January 2008 to 
2010 several prospective small-cohort intervention 
trials were initiated because of the side-effects/
complications of the CRT exempliÀed by the 
following 
t Hypomagnesemia: EfÀcacy of oral 
magnesiumhydroxide/aluminum400/200 mg 4 times 
daily in grade 1 (0.50-0.60 mmol/l) and 2 grams of 
intravenous magnesiumsulphate in grade  2 (0.20-
0.50 mmol/l) hypomagnesaemia in 124 patients 
versus 1-4 grams of intravenous magnesiumsulphate 
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a mean number of four episodes per day (range 
1-14) [4], whilst Portenoy and Hagen reported 
a median duration of 30 min (range 1-240) [5]. 
Management A task group on breakthrough cancer 
pain of the Science Committee of the Association 
for Palliative Medicine of Great Britain and Ireland 
(APM) recommended that the management of 
breakthrough pain should be individualised, and 
that consideration should be given to treatment of 
the underlying cause of the pain and to avoidance / 
treatment of the precipitating factors of the pain [1]. 
Other treatment strategies that should be considered 
include modiÀcation of the background analgesic 
regimen / “around the clock medication”, use of non-
pharmacological methods, and use of interventional 
techniques [1]. However, the cornerstone of the 
management of breakthrough pain episodes is 
the use of so-called “rescue medication”. Rescue 
medication is taken as required, rather than on a 
regular basis: in the case of spontaneous pain or 
non-volitional incident pain the treatment should be 
taken at the onset of the breakthrough pain; in the 
case of volitional incident pain or procedural pain 
the treatment should be taken before the relevant 
precipitant of the pain [1]. In most cases the most 
appropriate rescue medication will be an opioid 
analgesic, rather than a non-opioid or an adjuvant 
analgesic. Traditionally, the most common form 
of rescue medication has been the oral “normal-
release” (“immediate-release”) formulations of 
morphine and other relevant opioid analgesics. 
However, the pharmacokinetic / pharmacodynamic 
proÀles of oral opioids do not tend to mirror the 
temporal characteristics of most breakthrough pain 
episodes [3]. Thus, the slow onset of action (onset 
of analgesia: 20-30 min; peak analgesia: 60-90 min) 
results in delayed / ineffective analgesia, whilst 
the prolonged duration of effect (3-6 hr) results in 
ongoing adverse effects. In other words, oral opioids 
are not the optimal rescue medication for most 
breakthrough pain episodes. The parenteral routes 
of administration (intravenous, subcutaneous) are 
often used to manage breakthrough pain episodes 
in the secondary care setting. However, their use 
in the primary care setting is somewhat limited by 
practical considerations. The oral transmucosal 
routes of administration (buccal, sublingual) have 
increasingly been utilised in the management of 
breakthrough pain episodes, and there are currently 
three products available commercially (i.e. Actiq®, 
Abstral®, Effentora®) with a number of other 
products in development. Other transmucosal 
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E15.3 FAST-ACTING OPIOIDS FOR 
BREAKTHROUGH PAIN MANAGEMENT
Andrew Davies 
Palliative Care, St. Luke’s Cancer Centre/United 
Kingdom
Abstract: Breakthrough pain has been deÀned as 
“a transient exacerbation of pain that occurs either 
spontaneously, or in relation to a speciÀc predictable 
or unpredictable trigger, despite relatively stable 
and adequately controlled background pain” [1]. 
Unfortunately, there is a lack of consistency in 
the use of the term breakthrough pain in clinical 
practice, and also within the medical literature. 
Indeed, the term is widely (mistakenly) used to 
describe similar exacerbations of pain in patients 
with poorly controlled background pain. Clinical 
features Breakthrough cancer pain is a common 
problem in patients with cancer, with an estimated 
prevalence of 40-80% amongst patients with cancer 
pain [2]. Breakthrough pain is not a single entity, 
but a spectrum of very different entities. Thus, 
breakthrough pain may be related to a number of 
different causes (cancer-related, treatment-related, 
concomitant illness) and different pathophysiologies 
(nociceptive, neuropathic, mixed) [3]. Breakthrough 
pain is usually classiÀed into one of two categories 
[3]: § Spontaneous pain (“idiopathic pain”) – the 
episodes are not related to an identiÀable precipitant, 
and so are unpredictable in nature. § Incident pain 
(“precipitated pain”) – the episodes are related to 
an identiÀable precipitant, and so are somewhat 
predictable in nature. Incident pain is usually sub-
classiÀed into one of three categories: 1.Volitional 
incident pain - is brought on by a voluntary act 
(e.g. walking). 2.Non-volitional incident pain - is 
brought on by an involuntary act (e.g. coughing). 
3.Procedural pain - is related to a therapeutic 
intervention (e.g. wound dressing). The clinical 
features of breakthrough pain vary from individual 
to individual, and may vary within an individual 
over time [3]. Nevertheless, breakthrough pain is 
often reported to be frequent in occurrence, acute in 
onset, short in duration, and moderate-to-severe in 
intensity [3]. For example, Zeppetella et al reported 
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Abstract: Small cell lung cancer (SCLC) comprises 
10-15% of all lung tumors. Haematogenous 
metastases are present at diagnosis in about 
two thirds of patients (ES; extensive stage). 
Chemotherapy is crucial in the treatment of SCLC, 
but improvements in survival for patients with 
SCLC have in the last two decades mainly been 
achieved by the use of radiotherapy. Based on the 
effects of radiotherapy in patients with limited stage 
(LS) SCLC, key developments in radiotherapy 
for patients with ES-SCLC will be presented. In 
addition, the rationale behind ongoing studies on the 
use of radiotherapy in ES-SCLC will be addressed. 
Various studies have established the role of thoracic 
radiotherapy (TRT) and prophylactic cranial 
irradiation (PCI) in patients with LS-SCLC. Both 
TRT and PCI not only improve control of disease 
in the thorax and brain, but also lead to improved 
survival. Because the risk of brain metastases is 
even higher in patients with ES- than in those with 
LS-SCLC, the EORTC performed a study on the 
use of PCI in patients with ES-SCLC [Slotman et 
al., N Engl J Med 2007,357,664-72]. Patients who 
had responded to chemotherapy were randomized 
to PCI or no further therapy. Brain imaging was 
not required on a routine basis, but performed 
when signs and/or symptoms suggestive for brain 
metastases were present. In this study, the use of PCI 
resulted in a reduction of the risk of symptomatic 
brain metastases at 1 year of 40.4% in the control 
arm to 14.6% in the patients who received PCI. 
Moreover, the study showed a signiÀcant beneÀt of 
PCI for failure-free and overall survival. Survival at 
1 year after randomization, which was on average 
4 months after diagnosis, was 27.1% for the PCI 
group, compared to 13.3% for patients in the control 
arm. In this study, most patients received a PCI 
routes of administration (nasal, pulmonary) 
have also been utilised in the management of 
breakthrough pain episodes, and there is currently 
two intranasal products available commercially 
(i.e. Instanyl®, PecFent®) with again a number of 
other products in development. These alternative 
routes of administration offer signiÀcant advantages 
in terms of onset of action over the oral route of 
administration. The decision to use a speciÀc opioid 
preparation should be based on a combination 
of the pain characteristics (onset, duration), 
the product characteristics (pharmacokinetics, 
pharmacodynamics), the patient’s previous response 
to opioids (efÀcacy, tolerability), and particularly the 
patient’s preference for an individual preparation. 
Indeed, it is extremely unlikely that any one opioid 
preparation will be suitable for all patients with 
breakthrough pain. It should be noted that some 
patients experience opioid-insensitive breakthrough 
pain, or ultra short duration breakthrough pain 
(that is not amenable to any rescue medication). 
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E16.2 WHAT IS THE OPTIMAL 
RADIOTHERAPY DOSE AND TARGET 
VOLUME IN LD-SCLC
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Abstract: Several variables regarding the treatment 
of limited stage small cell lung cancer, including 
radiotherapy dose, fractionation , timing, and 
treatment volume, have not been well deÀned even 
though randomized clinical trials assessing these 
variables have been completed. Radiotherapy 
treatment guidelines vary greatly in modern 
prospective studies in part because it is not clear 
whether the results of past trials translate to current 
therapy. The development of advanced radiation 
treatment techniques such as conformal radiotherapy 
and image guided radiotherapy have resulted in 
a natural evolution in the treatment approach for 
small cell cell lung cancer. For example, delivery 
of high doses of conventionally fractionated 
radiotherapy to a restricted target volume has 
become common clinical practice in both community 
and academic centers despite the absence of level 
1 evidence. Ongoing randomized trial in North 
America and Europe are assessing the role of high 
dose fractionated radiotherapy in comparison with 
accelerated hyper-fractionated radiotherapy,though 
results are not likely to be available for several years. 
This review will describe the available prospective 
data that may help guide decisions for choosing a 
radiotherapy regimen in patients with limited stage 
small cell lung cancer who are not able to enroll on 
prospective studies.
Keywords: small cell, accelerated hyperfractionated 
radiotherapy, randomized trial
scheme of 20 Gy in 5 fractions. The treatment was 
well tolerated, with very few patients experiencing 
grade 3 or higher acute and/or late toxicity. Although 
acute side effects negatively inÁuenced some quality 
of life scales immediately after treatment, no overall 
effect of global quality of life up to 9 months was 
detected. Thoracic radiotherapy has traditionally 
been reserved in ES-SCLC patients for palliative 
indications. The apparent lack of interest in TRT 
in these patients is probably related to the systemic 
nature of the disease and the rapid progression in 
many patients. Only one study investigated the use 
of TRT in ES patients in detail [Jeremic et al., J Clin 
Oncol 1999,17,2092-9]. Patients with a complete 
response after three cycles of chemotherapy at 
distant sites and a partial or complete response in 
the thorax, were randomized to either chemotherapy 
alone or radiotherapy (54 Gy in 36 fractions over 
18 days) given concurrently with carboplatin and 
etoposide. The use of TRT in these selected patients 
resulted in a signiÀcant improvement of survival 
(median survival 17 versus 11 months. Survival at 
3 and 5 years was 22% and 9% for the TRT group 
and 13% and 4% for the chemotherapy-only group, 
respectively. This single-center study has not yet 
been reproduced and did not lead to the routine use 
of TRT in ES-SCLC. Two studies on the role of 
thoracic radiotherapy in ES SCLC have recently 
been initiated. The Dutch Lung Cancer Study Group 
has activated an international randomized controlled 
trial of TRT versus observation for patients with 
ED-SCLC who have responded to chemotherapy. 
The trial is open since 2009 [CREST-trial in the 
Netherlands, Belgium, Germany and Norway; REST-
trial in the United Kingdom). Patients with ES-SCLC 
who responded to chemotherapy with a WHO score 
of 0–2 are randomized to PCI plus TRT (30 Gy in 
10 fractions) or PCI only. The primary endpoint of 
this study is overall survival. The RTOG has also 
initiated a phase II trial on the role of consolidation 
extracranial radiotherapy. In the experimental arm 
of this trial, radiotherapy to the thorax and residual 
extracranial metastatic sites is given alongside PCI 
after a response to systemic chemotherapy [RTOG 
0937]. Patients with up to three extrathoracic 
metastatic sites can be included. The total dose of 
45 Gy in 15 fractions. The results of these studies on 
TRT are expected in about three years. 
Keywords: thoracic radiotherapy, PCI, Small cell 
lung cancer, extensive stage
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Recently, targeted agents such as anti-angiogenic 
agents, mTOR inhibitors and Bcl-2 inhibitors 
have been studied either in combination with 
chemotherapy or alone without much success6,7.
Topotecan, a topoisomerase inhibitor is the only 
proven agent in patients that relapsed following 
platinum-based chemotherapy, though its efÀcacy 
is restricted to patients with chemotherapy-
sensitive disease8. In a phase III study, topotecan 
was associated with a higher symptom control rate 
compared to the combination of cyclophosphamide, 
doxorubicin and vincristine. An oral formulation 
of topotecan has been compared to intravenous 
formulation and has demonstrated comparable 
efÀcacy and safety proÀle, making this another 
option for patients with sensitive relapse. Amrubicin, 
an anthracycline derivative, has demonstrated 
promising response rates in phase II studies for 
relapsed/recurrent SCLC. This is now being 
evaluated in a phase III study for second line therapy 
of SCLC 9.
Ongoing studies are evaluating newer classes of 
molecularly targeted agents such as the Hedgehog 
inhibitors and the IGF-1R pathway inhibitors. A 
greater understanding mediators of resistance and 
sensitivity to platinum is also necessary to improve 
the efÀcacy of combination chemotherapy for SCLC.
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Abstract: Small cell lung cancer (SCLC) has 
reduced in incidence over the past three decades and 
now accounts for approximately 15% of all cases of 
lung cancer1. It is characterized by the diagnosis at 
an advanced stage in majority of the patients and the 
presence of symptomatic disease. SCLC is usually 
divided into limited stage disease or extensive stage 
disease for the purposes of treatment and prognosis. 
The new staging system for lung cancer (7th Edition 
of the AJCC) developed by the IASLC Staging 
Project, has recommended the use of the TNM 
method for SCLC2. This system provides for better 
categorization of patients and deÀnition of prognosis.
Systemic chemotherapy is the mainstay of treatment 
for SCLC. For patients with advanced stage 
disease, the combination of a platinum compound 
and etoposide is the recommended regimen in the 
United States. In the Japanese patient population, 
the combination of cisplatin and irinotecan has 
demonstrated superior survival compared to cisplatin 
and etoposide and has therefore become a commonly 
used regimen3. However, the cisplatin-irinotecan 
regimen was not superior to cisplatin-etoposide in 
two large randomized studies conducted outside 
Japan4,5. Pharmacogenomic variations could have 
contributed to the conÁicting results across these 
studies. Present evidence supports the use of 4 
cycles of chemotherapy, which is associated with a 
median survival of approximately 8 to 12 months. 
Approximately two-thirds of the patients beneÀt 
from combination chemotherapy, and are referred to 
as the ‘sensitive’ population. The remainder of the 
patients either develop disease progression either 
or within 90 days of completion of chemotherapy 
(refractory population).
Since the adoption of platinum-based chemotherapy 
as the cornerstone of treatment of small cell lung 
cancer in the 1980s, very little progress has been 
achieved in the realm of systemic therapy. Various 
approaches including dose-intense chemotherapy, 
high-dose chemotherapy and alternating regimens 
have all failed to improve survival in SCLC. 
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1998; Slotman 2007]. No dose-effect relationship 
for PCI was demonstrated in LD SCLC patients 
so that the recommended dose is 25 Gy in 10 
fractions. In NSCLC, it reduces the incidence 
of BM but individual trials could not show any 
impact on survival and trials are still ongoing 
[Gore 2010]. However, some clinicians may be 
reluctant to propose it to patients because of its 
potential neurotoxicity. Retrospective studies have 
reported neurological and intellectual impairment 
or abnormalities on brain computed tomography 
(CT) scan potentially related to PCI. Acute toxicity 
is generally manageable and consists mostly in 
alopecia, headache, fatigue, nausea, and vomiting. 
Long-term sequelae such as severe memory loss, 
intellectual impairment or even dementia and 
ataxia have been reported in retrospective studies 
and attributed to PCI. However, most of these 
studies are small, very heterogeneous and with no 
baseline evaluations. Evaluating PCI neurological 
toxicity is difÀcult because the related symptoms 
can be caused by many different factors. It is well 
known that treatment modalities such as PCI dose 
and fractionation scheme (fraction size 3 Gy), or 
the use of concurrent chemotherapy (ccCT) may 
contribute to neurotoxicity. Some studies have also 
suggested that neuropsychological impairment 
could be attributable to cancer itself or pre-PCI 
treatment, as baseline evaluation was impaired 
before PCI in several studies both retrospective 
and prospective. Age, effects of chronic cigarette 
abuse, paraneoplastic syndromes, and undiagnosed 
micrometastases may also contribute to neurotoxicity 
or partly explain neurological symptoms. 
Furthermore, patients may have symptoms of 
depression or anxiety that may interfere with 
neuropsychological evaluations. Neuropsychological 
assessment of long term toxicity is thus difÀcult 
in lung cancer. The best evaluation of PCI toxicity 
comes from long-term follow-up of randomized 
studies using validated questionnaires for QoL, 
general health status, and neurological functions. 
Two large prospective trials evaluating PCI in SCLC 
did not show any signiÀcant decline in neurological 
functions in the PCI group as compared to the 
control group, with a follow-up not exceeding 
30 months [Arriagada, 1995; Gregor,1997]. A 
third trial comprised a prospective neurocognitive 
evaluation of all patients randomly assigned to 
receive irradiation and concomitant chemotherapy 
with or without warfarin [Ahles 1998]. Even if trial 
did not address directly PCI, the authors concluded 
clinical and pharmacogenomic results from SWOG 
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OF PROPHYLACTIC CRANIAL 
IRRADIATION
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Abstract: Whatever the stage and treatment, brain 
failures have become a major concern in lung 
cancer. As survival is poor after development of 
brain metastases in spite of speciÀc treatment, 
prophylactic cranial irradiation (PCI) has been 
developed. PCI has been evaluated in randomized 
trials in both small cell (SCLC) and non-small cell 
(NSCLC) lung cancers to reduce the incidence of 
brain metastases and possibly increase survival. It 
is well established PCI reduces signiÀcantly the 
BM rate in both limited disease (LD) and extensive 
disease (ED) SCLC and in non-metastatic NSCLC. 
Considering SCLC, PCI signiÀcantly improves 
overall survival in LD (from 15 to 20% at 3 years) 
and ED (from 13% to 27% at one year) in patients 
who respond to Àrst-line treatment; thus it has now 
become part of the standard treatment [Auperin, 
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Abstract: Background and purpose Thymic 
epithelial tumors are categorized into thymomas and 
thymic carcinomas including thymic neuroendocrine 
tumors. The main strategy of treatment for thymic 
epithelial tumors is supposed to be surgery. These 
neoplasms are well-known for variability in the 
histological appearance. Characteristics of thymoma 
in microscopic appearance is the organotypic 
nature suggesting the thymic origin, which is 
absent in thymic carcinomas. Nearly 70% of 
thymomas appear as Masaoka stage I or II diseases 
while thymic carcinomas usually in advanced 
stages at the time of diagnosis. Finally, tumor 
death occurs even after 10 years after resection in 
thymoma patients while all the tumor deaths were 
seen within 5 years after resection according to 
our experiences. Thus, thymomas are generally 
indolent and biologically different from thymic 
carcinomas. These neoplasms are also heterogeneous 
in the biological function. Our previous studies 
have revealed that most of thymomas possess 
CD4+CD8+ double positive T cells, which are 
exclusively present in the thymic cortex, suggesting 
that thymomas have immunological function 
similar to the thymic cortical epithelium, while 
thymic carcinomas do not. Consistently with this 
function, thymomas, but not thymic carcinomas, 
are frequently associated with autoimmune 
diseases represented by myasthenia gravis. Based 
on the above heterogeneity of thymic epithelial 
tumors, thymoma and thymic carcinoma should 
be discussed separately. Masaoka stage reÁects the 
survival of thymoma patients, and patients with 
stage I or II diseases have good prognosis while 
those with stage III or IV diseases have more 
chances of tumor deaths. Here, the implication of 
surgical treatment for advanced thymomas, but 
not thymic carcinomas, was exclusively focused, 
and the implication of surgery for thymomas with 
stage III or IV diseases was examined to gain some 
insight into the treatment strategy for this entity of 
neoplasm. Patients Outcome was reviewed based 
on 121 patients with advanced stage (stage III or 
IV) thymoma who underwent surgical resection at 
Osaka University Hospital and the afÀliated hospitals 
were examined. The number of patients with stage 
III, IVA, and IVB were 87, 21 and 13, respectively. 
Results In Masaoka stage III patients, completeness 
of resection and the involved organ are signiÀcant 
prognostic factors in stage III disease. The disease-
speciÀc 10-year survival rates were 91% and 53% 
in patients undergoing complete resection and 
that the combination of chemotherapy and PCI 
had a negative impact on cognitive functioning, 
conÀrming that chemotherapy and PCI should not 
be administered concomitantly. In a more recent trial 
where all patients had PCI but at 2 different doses, 
very few patients had severe deterioration of neuro-
psychological and cognitive functions and some 
items seemed to worsen with age such as memory 
and brain imaging abnormalities [Le Pechoux, 2009]. 
Concerning PCI in extensive stage SCLC, the results 
showed a negative but limited impact of PCI, with a 
signiÀcantly decreased QoL in terms of functioning 
scales among PCI patients at 6 weeks, which tended 
to be not signiÀcant at 3 months and afterwards. 
Ways to possibly reduce the risk of neurocognitive 
decline after whole brain irradiation are being 
explored and will be developed: combination with 
neuroprotective drugs such, and new approaches 
using intensity modulated radiotherapy to spare 
the hippocampus. They are being evaluated 
in BM treatment and they could eventually be 
explored in the future for PCI. At present based 
on randomized trials, neurocognitive functions 
seem to be equivalent or moderately altered after 
PCI as opposed to no PCI. PCI is now part of the 
standard treatment in SCLC patients and should 
continue to be investigated in NSCLC patients with 
locally advanced disease. PCI, if prescribed, should 
always be performed in absence of concomitant CT. 
PCI should be reconsidered if long-term survival 
increased dramatically or if neurotoxicity appeared 
more frequent and more severe. Such risk has to be 
put into balance with the beneÀt of PCI in terms of 
BM incidence and survival. 
Keywords: prophylactic cranial irradiation, non-
small cellung cancer, Small cell lung cancer, multi-
modality treatment
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more efÀcient treatment strategy for thymomas with 
distant metastasis. 
Keywords: Thymoma, Surgery, Induction 
Chemotherapy
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E17.2 INDUCTION THERAPY FOR 
LOCALLY ADVANCED THYMOMA
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Abstract: Although rare, thymomas are the most 
common tumors of the mediastinum and often 
present with either localized or locally advanced 
disease. Overall outcomes for patients with thymoma 
have been consistently shown to correspond to 
tumor stage and the completeness of surgical 
resection.1-3 With the clear prognostic beneÀt of 
complete surgical resection in patients with locally 
advanced thymoma, a number of investigators 
have explored the role of pre-operative therapy for 
optimal management of locally advanced thymoma. 
At least 4 groups have reported prospective clinical 
trials exploring multimodality therapy for locally 
advanced thymoma.4-7 Berruti et al conducted a 
prospective clinical trial of cisplatin, doxorubicin, 
vincristine, and cyclophosphamide in patients 
with stage III and IVa thymoma. They observed 
that Àve of six patients had a partial response and 
then went on to surgery. Despite this high response 
rate, only one patient achieved a complete surgical 
resection, the goal of such induction therapy. 
Patients treated by Kim et al, were patients with 
locally advanced thymoma who received induction 
cisplatin, doxorubicin, cyclophosphamide, and 
prednisone, followed by surgery, radiation, and 
consolidation chemotherapy. Seventeen of 22 
patients had a response with chemotherapy. Six of 
16 patients had greater than 80% tumor necrosis at 
the time of surgical resection. Kunitoh et al gave 
weekly dose dense chemotherapy followed by 
surgery for patients with locally advanced thymoma, 
leading to a 62% response rate and 14% complete 
pathologic response rate.7 These trials emphasize that 
prospective phase 2 trials for patients with locally 
advanced thymoma are feasible. More recently, 
investigators have attempted to incorporate radiation 
or targeted therapies into induction therapy regimens. 
subtotal resection, respectively. Disease-speciÀc 10-
year survival rates were 72% and 92% in patients 
with and without involvement of the great vessels, 
respectively. Complete resection was not achieved 
in 30% of the patients with involvement of the great 
vessel. In patients without involvement of the great 
vessels, Disease-speciÀc 10-year survival rates were 
93% and 83% in patients with involvement of the 
pericardium alone and the lung, respectively. Tumor 
recurrence after complete resection was observed in 
6%, 21% and 52% in patients with involvement of 
the pericardium alone, the lung but not great vessel, 
and the great vessel, respectively. Tumor recurrence 
was observed mainly in the pleural cavity when 
the lung was involved. On the other hand, distant 
metastasis frequently occurred when great vessel was 
involved. Finally, WHO histological classiÀcation 
also reÁected the outcome of surgical treatment 
for stage III thymoma. Survival was signiÀcantly 
better in the group of type A, AB, and B1 than in 
the group of type B2 and B3. In Masaoka stage 
IVA patients, all the patients had plural metastases, 
and only one patient had additional dissemination 
inside the pericardium. Direct invasion to the 
pericardium, lung, and great vessel were also present 
in 10, 21, and 6 patients, respectively. Extrapleural 
pneumonectomy was not performed, and metastatic 
lesions in the pleural cavity were resected with 
the surrounding pleura. The disease-speciÀc 10-
year survival rate was 67% in patients undergoing 
macroscopically complete resection. On the other 
hand, the disease-speciÀc 10-year survival rate was 
31% when there was a residual tumor. In Masaoka 
stage IVB patients, lymph nodal involvement and 
hemotogenous metastasis were seen in 8 and 5 
patients, respectively. The disease-speciÀc 5-year 
survival rate was 33% in stage IVB disease. There 
were no 5-year survivors in patients with distant 
metastasis while 2 patients with nodal metastasis 
survived over 5 years. Conclusion Long term 
survival of more than 10 years can be obtained by 
surgery even in patients with the advanced stage, 
and therefore, surgical resection seems to be the 
treatment of choice when complete resection is 
achieved. Multimodality treatment in combination 
with surgical resection is highly recommended when 
the great vessel is involved. Surgical resection seems 
to have some impact on survival even when the 
tumor is associated with pleural or nodal metastatic 
lesions. On the other hand, stage IVB thymoma with 
distant metastasis has more chances of tumor death, 
and further experiences are required to develop 
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tumor biology and predict response to the therapies 
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Radiation therapy is a common component of post-
operative therapy for patients with locally advanced 
thymoma. The use of radiation was retrospectively 
reviewed by Wright et al, and was associated with 
a 40% rate of >90% tumor necrosis after combined 
cisplatin, etoposide, and radiation therapy for 
patients with locally advanced thymoma.8 Korst 
and colleagues are prospectively evaluating this 
approach in a phase 2 trial of cisplatin, etoposide, 
and concurrent radiotherapy for patients with locally 
advanced thymoma [NCT00387868]. The primary 
endpoint of this clinical trial is complete pathologic 
response. Expression of epidermal growth factor 
receptor (EGFR) protein in a high percentage of 
thymomas suggests that incorporating anti-EGFR 
therapy may be of some beneÀt.9 Cetuximab is a 
monoclonal antibody directed against EGFR that is 
used for patients with colorectal cancer, squamous 
cell cancer of the head and neck and non-small 
cell lung cancer. The use of cetuximab is further 
strengthened by two separate reports documenting 
clinical responses to cetuximab in patients with 
advanced thymoma support the concept that EGFR 
inhibition is a promising therapeutic avenue.10, 11 
To explore the incorporation of cetuximab into a 
preoperative chemotherapy regimen, there is an 
ongoing phase 2 clinical trial of cetuximab with 
cisplatin, doxorubicin, and cyclophosphamide 
in patients with locally advanced thymoma 
[NCT01025089]. The primary endpoint is pathologic 
complete response rate. To prospectively evaluate 
the role of cetuximab alone in these patients with 
locally advanced thymoma, patients receive an 
initial four weeks of cetuximab prior to beginning 
chemotherapy combined with cetuximab. CT scans 
will assess response to cetuximab by itself as well 
as to cetuximab in combination with chemotherapy. 
All patients will undergo surgical resection with a 
goal of complete resection. Additional exploratory 
endpoints include evaluating the role of PET scan 
for identiÀcation of sites of disease and predicting 
response to therapy and outcomes, pathologic 
predictors of response to chemotherapy as well 
as cetuximab. Given the importance of complete 
resection in the optimal management of thymoma, 
ongoing studies hope to deÀne the most active 
combinations of therapy for further validation in 
clinical trials. Prospective clinical trials are the 
model for how we should proceed for evaluating 
therapy for locally advanced thymomas. Induction 
therapy studies provide a unique opportunity for 
evaluating tissue biomarkers to better understand 
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recurrence wsa 8% in patients who were observed 
vs. 0% in the radiotherapy group (p=0.15). Their 
conclusion was that the rates of recurrence after 
complete resection of stage II thymoma were low 
and no beneÀt was observed to postoperative RT in 
Stage II thymoma as a group; however, a higher-
risk subset of these patients may beneÀt from 
adjuvant therapy. Although some studies showed 
no beneÀt from adjuvant radiation therapy, the 
recurrence rates of completely resected invasive 
thymoma may approach 30%. A SEER study of 901 
patients showed 10% absolute improvement in 5 
year overall survival, but interestingly no statistical 
difference in cause speciÀc survival in patients 
with stage II-III disease. In a study by Monden and 
colleagues, patients with resected stage II thymoma 
had recurrence rates of 8% and 29%, respectively, 
with and without adjuvant radiation therapy. Locally 
Advanced Thymoma and Unresectable Disease 
For patients with stage III/IV disease, the evidence 
supporting the use of postoperative radiation therapy 
is more robust. Urgesi and colleagues reported no 
in-Àeld recurrences in a study of 33 patients with 
completely resected stage III thymoma treated with 
postoperative irradiation. Curran and associates 
reported a 53% 5-year actuarial mediastinal relapse 
rate with stage II and III patients after surgery 
alone, compared with 0% after total resection and 
irradiation and 21% after subtotal resection or biopsy 
and irradiation. Similarly, in a study of 70 patients 
with Masaoka stage III/IV thymoma, the relapse 
rate for patients receiving postoperative radiation 
therapy was reduced from 50% to 20%, and most 
disease (80%) recurred outside of the irradiated Àeld. 
Primary radiation therapy alone as the deÀnitive 
treatment has been advocated in nonsurgical 
candidates or patients with unresectable advanced 
disease. In a study of 31 patients with unresectable 
stage III or IV disease, Àve-year survival rates of 
53% to 87% and 10-year survival rates of 44% 
were reported for patients receiving radiation alone 
after biopsy or incomplete resection. Techniques of 
Irradiation High-energy (>4-MV) x-rays usually are 
preferred for irradiation. A CT scan is indispensable 
for adequate treatment planning. Clips placed at the 
time of surgery denoting the extent of resection in 
completely resected tumors or outlining regions of 
residual disease are useful in guiding postoperative 
irradiation. The planning target volume (PTV) 
should include the gross tumor volume (GTV) 
and the thymus, if any, and tumor bed with a 1.5- 
to 2.0-cm margin. Use of a 4-D breathing scan, 
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Abstract: The overall incidence of thymoma 
in the United States is 0.15 cases per 100,000, 
based on data from the National Cancer Institute 
Surveillance, Epidemiology and End Results 
(SEER) Program. Thymomas are the most common 
anterior mediastinal neoplasm in adults and the 
most common tumor of the thymus gland. There 
are two accepted systems for clinical staging of the 
tumor: the 1994 modiÀed anatomic Masaoka staging 
system and the surgical resection-based GETT 
staging system. The best predictors of recurrence of 
thymoma are the Masaoka stage, the World Health 
Organization (WHO) histologic classiÀcation, and 
the extent of surgical resection. Surgery remains 
the cornerstone of treatment and its completeness 
is related to the patient’s outcome. A complete 
resection is the most important prognostic marker for 
disease free survival. Chemotherapy is only used in 
unresectable or metastatic thymomas. Although the 
role of adjuvant irradiation for invasive thymomas 
has never been tested in a prospective, randomized 
fashion, there is general agreement that radiation 
therapy is an effective adjuvant therapy for invasive 
thymomas, and most retrospective studies have 
reported improvements in local tumor control and 
survival after adjuvant irradiation. However, patients 
with encapsulated, noninvasive stage I thymoma 
do not require postoperative radiation therapy 
after complete resection because the recurrence 
rate is approximately 0%to 2%. For patients with 
Masaoka stage II disease, there is controversy about 
whether postoperative radiation therapy should be 
used for completely resected invasive thymomas. 
A meta-analysis of 22 studies with 592 patients 
with completely resected stage II or III thymoma 
found no reduction in recurrence after adjuvant 
radiotherapy. Berman and colleagues reported a 
single institution retrospective cohort comparison of 
74 stage II thymoma patients after complete surgical 
resection. Patients who were felt to be at high risk 
for local recurrence by the operating surgeon and the 
thoracic oncology team were referred for adjuvant 
radiotherapy. In this series, the rate of locoregional 
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if available, should be used to determine tumor 
motion. Depending on histology and surgical 
Àndings, areas of suspicious subclinical disease 
and regional lymphatics are commonly included. 
However, treatment of the entire mediastinal and 
supraclavicular nodal basin prophylactically is not 
advised because of the low incidence of lymph node 
involvementand a higher normal tissue complication 
rate when large target volumes are used. A SEER 
database analysis of 1334 patients from 1973-2005 
by Fernandes and colleagues found no increase in 
long term cardiac mortality and rate of secondary 
malignancies for patients treated with radiotherapy 
compared with patients treated with surgery alone. 
Conventional port arrangements may include a 
single anterior port, two opposed anteroposterior 
ports (weighted 2:1 or 3:2), wedged-pair techniques, 
and other multiple-Àeld arrangements. Given the 
advanced technical capabilities available, three-
dimensional (3D) conformal therapy or intensity 
modulated radiation therapy (IMRT) should be 
considered to provide dose homogeneity and allow 
better sparing of adjacent normal critical structures. 
Postoperative doses of 45 to 55 Gy given by 
conventional fractionation have been used effectively 
in most cases. The dose to the spinal cord should 
be limited to 45 Gy using oblique mediastinal Àelds 
or IMRT. For patients with gross residual disease 
after resection or unresectable disease, doses of 60 
Gy or more probably are required, but higher doses 
correlate with higher risks of complications. This 
presentation will center on the clinical outcome 
data on adjuvant radiotherapy for thymoma and the 
impact of modern radiotherapeutic techniques on 
treating this disease.
Keywords: Radiotherapy, Thymoma
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occult SCLC. Different antibodies involved in 
SCLC leads to different paraneoplastic syndromes, 
although for most disorders of the central nervous 
system (CNS) the clinical syndrome is not speciÀc 
enough to exclude speciÀc antigens. Lambert-Eaton 
myasthenic syndrome (LEMS) is caused by anti-
VGCC antibodies, that show reactivity with the 
presynaptic neuromuscular junction. LEMS affects 
about 3% of patients with SCLC. Encephalitis may 
be caused by anti-Hu, anti-CV2, anti-amphiphysin, 
anti-Ri, anti-GAD, anti-GABAơ-R or anti-AMPA-R 
antibodies. Patients with cerebellar degeneration 
might have anti-Hu, anti-CV2, anti-GAD antibodies, 
while sensory neuropathy can be caused by anti-
Hu and anti-CV2 antibodies. Antiretinal antibodies 
can be found in patients with cancer related 
retinopathy. As the clinical symptoms can be subtle 
and symptoms can be disguised by other features 
of the cancer and chemotherapy, it is important 
to consider PNS and know their clinical picture. 
Important for diagnostics are the antibodies in the 
serum or cerebrospinal Áuid of SCLC patients 
that react with both the nervous system and the 
underlying cancer. For most PNS of the CNS, 
MRI is not reliable to diagnose the disease. In the 
peripheral nerve system, electrophysiological studies 
in patients with SCLC disclose delayed conduction 
velocities (in neuropathies) or abnormalities with 
repetitive nerve stimulation (in LEMS). The most 
important part of the treatment is chemotherapy to 
treat SCLC. Secondly, immunosuppression might be 
necessary to treat or at least stop progression of the 
neurological symptoms as swift treatment improves 
outcome. The Lambert–Eaton myasthenic syndrome 
recovers once the tumor has responded, because the 
damage to the neuromuscular junction is reversible. 
Disorders involving the central nervous system were 
thought to respond poorly, stabilize to the best or 
respond not at all until recently. Encephalomyelitis 
or paraneoplastic cerebellar degeneration, associated 
with SCLC and for example those with anti-Hu, is 
thought to be mediated by T cells. These syndromes 
are usually associated with neuronal loss, and 
because they evolve slowly and chemotherapy is 
often delayed, the neurons die, making recovery 
impossible. Immunosuppressant drugs such as 
cyclosporin, tacrolimus, sirolimus or mycophenolate 
mofetil may be tried, but no evidence exist. Recently, 
new antibodies against membrane receptors were 
found to cause limbic encephalitis in SCLC patients, 
i.e. GABAơ receptor antibodies and AMPA receptor 
antibodies. Like in LEMS, they disrupt an ion 
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Abstract: About 15% of patients with all cancer 
have one or more symptomatic neurologic 
complications during the course of their disease. 
Neurologic disorders may occur, when small-
cell lung cancer (SCLC) is already widespread. 
Brain metastases are the most prominent cause. 
Paraneoplastic syndromes are a smaller part of 
the neurological spectrum of SCLC. However, in 
these cases neurologic symptoms are often the Àrst 
evidence of SCLC. Paraneoplastic syndromes refer 
to a constellation of signs and symptoms coming 
from damage to organs that are remote from the site 
of the cancer or its metastases. Examples include 
hyponatriemia due to the syndrome of inappropriate 
antidiuretic hormone secretion, cancer cachexia, 
hypercalcemia, usually observed in non-small 
cell lung cancer but also in SCLC, and Cushing’s 
syndrome. Paraneoplastic neurological syndromes 
(PNS) occur because the tumor secretes substances 
that mimic hormones or ion channels or that interfere 
with circulating proteins. Most or all paraneoplastic 
neurologic disorders are immune-mediated. The 
symptoms of the PNS, caused by SCLC, usually 
begin before SCLC itself has become symptomatic. 
PNS is sometimes occult, sometimes disabling 
and occasionally lethal. Patients are usually Àrst 
aware of the neurologic symptoms that brings 
them to the medical specialist. A chest X-ray may 
raise suspicion of lung cancer. A work-up with 
FDG-PET/CT, bronchoscopy, transthoracic lung 
biopsy, EUS-FNA and/or EBUS-FNA may lead 
to the diagnosis of SCLC. Whole-body FDG-PET 
may be the best screening method for locating the 
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events occur, leading to the formation of a tumor. It 
has been postulated that mesothelioma may derive 
from either the surface lining cells or an until now 
undeÀned submesothelial stem cell. The carcinogenic 
activity of asbestos may be mediated via a genotoxic 
initiation process or by an epigenetic mechanism. 
Asbestos Àbres induce mostly DNA breaks linked 
to the presence of Àbre-associated iron and reactive 
oxygen species generation. The consequence, at 
least in vitro, of this overall low but persistent 
DNA damage in non-neoplastic cells is senescence. 
The latter is a state of stable cell cycle arrest with 
active metabolism secreting mitogenic factors. 
Therefore, low level of persistent DNA damage 
in mesothelial cells will lead mostly to epigenetic 
effects mediated via senescent cells that are not 
efÀciently cleared by the immune system. During 
mesothelial regeneration primitive mesenchymal 
cells underlying a wounded area of mesothelium 
proliferate, migrate and transdifferentiate into 
surface mesothelial cells to restore the mesothelial 
surface. Wound healing occurs also through the 
recruitment of distant mesothelial cells, which 
move to the site of the injury. During this process 
the mesothelial cell assume a more mesenchymal 
phenotype. Transdifferentiation of mesothelium 
might be inÁuenced by microenvironment cues 
from for example macrophage which secrete factors 
stimulating mesothelial proliferation such as FGF2. 
Asbestos Àbres can induce transdifferentiation in 
tracheal epithelia but in mesothelium the issue is 
more difÀcult to address since mesothelium is an 
epithelium derived from splanchnic mesoderm, 
which maintains mesenchymal characteristics such 
as vimentin expression. WT1 transcription factor is 
expressed at the time of switch from mesenchymal 
to epithelial cells (MET) in precursors during 
embryogenesis. Continuous WT1 expression is 
conserved in mesothelium through adult life and is 
maintained in mesothelioma. However, it decreases 
during epithelial to mesenchymal transition (EMT) 
occurring in sarcomatoid mesothelioma. Although 
during cancer evolution mesothelium undergoes 
phenotypic changes, no data are yet available 
directly related to asbestos exposure. In MexTag 
mice in which the SV40 T antigen (Tag) is under the 
control of mesothelin promoter and which develop 
MPM tumors upon exposure to asbestos Àbres, Tag 
is not detected in the unexposed mice indicating that 
asbestos Àbres stimulate undifferentiated precursor 
cells not yet expressing mesothelin. Persistent 
stimulation of repair leads to oncogenic events 
channel, thereby disrupting neuronal function, but 
the damage can be reversible. Nevertheless, the 
quicker treatment is started, the better. Besides 
chemotherapy, these might contain steroids, 
intravenous immunoglobulins, plasma exchange or 
even rituximab or cyclophosphamide. Summarizing, 
recognizing PNS is important as SCLC might be 
treated earlier in disease course, improving outcome. 
Early treatment of the PNS ameliorates the outcome 
of the neurological symptoms, improving quality of 
life. 
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Abstract: The mechanism of development of 
malignant pleural mesothelioma after exposure 
to asbestos Àbres is not well understood but few 
hypotheses can be proposed based on experimental 
data and observation of clinical samples. Inhaled 
asbestos Àbres pass the alveolar barrier and reach 
the lung interstitium. During this process they 
transiently activate signalling pathway such as 
Nalp3 inÁammasome in alveolar and/or interstitial 
macrophages by “frustrated phagocytosis”; in 
addition they activate the transcription factor NF-
kB in lung epithelial cells and the overall outcome 
is the release of pro-inÁammatory cytokines. Then 
Àbres accumulate in the pleural space, particularly 
at the site of pleural Áuid drainage. The latter 
occurs through the lymphatic stomata in parietal 
pleura which is in agreement with the concept 
that mesothelioma origins primarily from the 
parietal pleura. Following persistent exposure to 
asbestos Àbres or mesothelium injury tissue repair 
is stimulated. Chronic tissue repair activates stem 
cell signalling pathways to regenerate the tissue but, 
because of persistent system stimulation, oncogenic 
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ubiquitin ligase CRL4 and through that controls a 
subset of Hippo pathway target genes. This recent 
observation is consistent with previous evidence of 
NF2 signaling-dependent activation of the Hippo 
pathway. The latter is an essential regulator of cell 
proliferation during development and tumorigenesis. 
Key components of the Hippo pathway include two 
kinases: Mst and Lats. The sequential activation 
of these kinases leads to phosphorylation of the 
transcription factor YAP. When Hippo signalling is 
attenuated, e.g. when NF2 signaling is disrupted, 
YAP phosphorylation is reduced resulting in its 
nuclear localization and regulation of target genes. 
This “Meet the expert” session will illustrate how 
this knowledge may have clinical utility. 
Keywords: mesothelioma, NF2 signalling, Hippo 
signalling, Pi3kinase signalling
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Abstract: There is a widely divergent clinical, 
radiologic, molecular and pathologic spectrum within 
lung adenocarcinoma. Despite remarkable advances 
in understanding of this tumor in the past decade; 
there remains a need for a universally accepted 
criteria for adenocarcinoma subtypes, in particular 
bronchioloalveolar carcinoma (BAC). The use of the 
term BAC encompasses a broad spectrum of tumors 
ranging from solitary small peripheral lung tumors 
with a 100% 5-year survival to widespread advanced 
disease with a 10% 3-5 year survivals, with widely 
varying use of terminology even after publication of 
the 1999 and 2004 WHO ClassiÀcation. There are 
also clinical, radiologic, immunohistochemical, and 
molecular differences that are distinguishable among 
the subsets of mucinous and non-mucinous types 
of BAC. As a result there is confusion in various 
occurring within the components responsible for 
homeostasis. Activated stem cell signalling has 
already been suggested in MPM by the presence 
of an 11-gene signature, correlated with a stem-
cell-like expression proÀle, which is associated 
with a poor prognosis in patients with MPM. Not 
much is known about stem cell signalling in MPM. 
Wnt signalling is activated and Notch1 has been 
found to control PTEN expression. Methylation of 
promoters of BMP3b and BMP6, which are members 
of the TGF-ß superfamily and critical mediators of 
early embryonic patterning, has been observed. In 
a case of biphasic malignant mesothelioma with 
osseous and cartilaginous differentiation expression 
of BMP2 has been observed. Nothing is known 
about sonic hedgehog signalling, but since stem 
signalling pathways are interconnected it is likely 
that this signalling is also deregulated. Overall, the 
little information already available suggests that 
stem cell signalling has a role in tumor progression. 
Knowledge about common alterations observed in 
MPM, conÀrms that alteration in NF2 signalling, 
which is responsible for homeostasis in tissue repair 
and stem cell signalling, is the ideal target for an 
oncogenic event to occur during the development 
of MPM. Indeed, the two most abundant alterations 
in MPM concern CDKN2A and NF2. Mutations in 
NF2 gene have been found in 40% of mesothelioma. 
In MPM tumors with no detectable genetic 
alterations of NF2, its activity is downregulated 
by phosphorylation, which depending on the 
phosphorylated amino acid, leads to functional 
inactivation or AKT-dependent degradation. 
Expression levels of the CPI-17, which inhibits the 
phosphatase reactivating NF2, were signiÀcantly 
higher in 17% of MPM with no detectable NF2 
mutations. On the other hand PTEN immunostaining 
was absent in over 60% of MPM patients and 
correlated with worst outcome. Experimental animal 
models indicate that disruption of the NF2 signalling 
pathway, together with a deÀciency in CDKN2A, 
is essential for mesothelioma development in a 
“permissive” (CDKN2A deÀcient) background. It 
has been proposed that genes which are inactivated 
in a given tumor type and directly regulate tumor 
growth by either inhibiting growth or promoting 
death are “gatekeeper” genes. NF2 does correspond 
to this deÀnition and should be considered a 
“gatekeeper” in mesothelioma. A role of NF2 in 
tissue repair is supported by the observation that 
the active form of NF2 suppresses tumorigenesis by 
migrating into the nucleus where it inhibits the E3 
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Abstract: Advances in molecular and cellular 
biology have accelerated our knowledge of lung 
cancer biology and new data are constantly being 
generated to understand its hallmarks. During 
the last decade, we have built a comprehensive 
catalogue of lung cancer associated molecular 
alterations, including driver mutations; genomic 
abnormalities; copy number variations; gene, 
protein and microRNA expression proÀles; as well 
as epigenetic changes. In the next future, whole 
genome deep sequencing will provide even more 
thorough and complete views of the detailed genetic 
traits of lung tumors. Moreover, the multistep 
molecular changes involved in the carcinogenic 
process of the different histological types of lung 
cancers are also being unveiled. Some of these 
molecular changes have been proposed as potential 
biomarkers. This presentation will summarize 
information concerning the search for biomarker 
candidates, particularly in the early stages of lung 
cancer. The main non-invasive sources of biomarkers 
for lung cancer are blood, sputum, bronchioalveolar 
lavage, and exhaled breath. Molecular markers 
for lung cancer may be used in the following 
Àve clinically relevant scenarios: a) Lung cancer 
risk associated SNPs may help to improve risk 
stratiÀcation models, currently based on exposure 
and clinical factors. b) Recent data suggest that low 
dose CT-based screening is a promising strategy to 
improve early detection at the population level. The 
potential role of biomarkers for early diagnostics as 
adjuncts to imaging-based techniques is currently 
being explored. Molecular markers, such as DNA 
concentration or microRNA analysis in the plasma 
of high risk individuals have been analyzed. c) If 
programs of lung cancer screening are implemented, 
the relative proportion of early stage tumors that 
terminologies that are used for lung adenocarcinoma 
in literature and studies are difÀcult to compare. A 
new classiÀcation is needed to help use standardized 
terminology which is clinically more relevant with 
better multidisciplinary correlations. That would 
allow more uniform criteria to evaluate patient 
therapy and to help predict outcome in clinical 
trials. The widespread availability of MDCT 
and abundance of new information obtained 
especially from low-dose CT lung cancer screening 
programs, have increased our understanding of the 
management and types of small peripheral lung 
nodules encountered in daily clinical practice, in 
particular, the importance and prevalence of subsolid 
pulmonary nodules. Subsolid nodules include both 
pure ground glass nodules (GGN) and part-solid 
nodules. GGNs are deÀned as focal nodular areas 
of increased lung attenuation through which normal 
parenchymal structures such as airways, vessels, and 
interlobular septa can be deÀned. Subsolid nodules 
are now known to frequently represent the histologic 
spectrum of peripheral adenocarcinomas. In the 
new proposed multidisciplinary classiÀcation, these 
lesions include premalignant atypical adenomatous 
hyperplasia (AAH), carcinoma in-situ or 
bronchiolalveolar carcinoma (AIS/BAC), minimally 
invasive (MIA) and invasive adenocarcinoma. Thin 
section CT has emerged as a new biomarker for 
lung adenocarcinoma subtypes. GGN correlates 
with lepidic growth and better clinical outcome 
than part-solid or solid nodules. Pure GGNs are 
typically FDG-PET negative. Key messages from 
radiology lecture are: 1) The term BAC is confusing 
and it should no longer be used in reference to 
adenocarcinoma manifesting as GGNs or ground 
glass opacities. The new terms proposed for the 
adenocarcinoma subtypes that cause this pattern are 
AIS/MIA and lepidic predominant adenocarcinoma. 
2) Mucinous adenocarcinoma (previously called 
BAC) is usually a solid tumor (not GGO). It may 
also present as multilobar and multifocal areas 
of consolidation. 3) Multiple lesions – careful 
description of each lesions is desirable because 
multiple synchronous/metachronous primaries are 
not uncommon. Change in size and attenuationof 
each lesion assists in management. 
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unforeseen avenues in the Àeld, such as new 
proteomics approaches or the search for biomarkers 
in the exhaled breath. 
Keywords: Early Detection, Prognostic and 
predictive markers, Biomarkers, Molecular 
carcinogenesis
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Abstract: Lung cancer is one of the leading 
causes of cancer death. Non small cell lung cancer 
(NSCLC) accounts for the majority of lung cancer 
cases. Survival prediction and therapeutic options 
rely heavily on meticulous and accurate staging. 
Imaging studies such as CT scan and Positron 
emission tomography (PET) scan have been used 
in mediastinal staging and to identify metastasis. 
Mediastinoscopy has been considered a gold 
standard procedure to obtain pathological sample 
for conÀrmation of mediastinal nodal metastasis. 
With the advanced technology of Endobronchial 
Ultrasound (EBUS) and Endoscopic Ultrasound 
(EUS), mediastinal lymph node and hilar lymph 
node can be sampled in much less invasive fashion 
with safety. Positron emission tomography with 
18F-Áuorodeoxyglucose (FDG) has also been widely 
used in cancer staging, especially in lung cancer. It 
has been shown to increase accuracy in lung cancer 
staging. However, the utility of PET scan has been 
challenged due to its limitation in smaller lymph 
node and speciÀcity. The sensitivity, speciÀcity 
and positive predictive value of PET scan were 
reported ranging from 70% to 88%, 59.8 to 92% and 
37.5% to 90% respectively4,11,12. However, false 
negative PET scan can be found in smaller node 
(less than 7mm), carcinoid, and bronchoalveolar 
may be diagnosed in the future will increase. For 
most early stage tumors, surgical resection is the 
therapeutic option of choice. However, disease 
relapse rates are as high as 30% even among stage 
I patients. This has driven the interest in identifying 
additional molecular prognostic markers that may 
add to the TNM staging system and other risk factors 
such as poor differentiation, vascular invasion, 
wedge resection, etc. A large number of reports 
on prognostic individual or multiplexed molecular 
markers, as well as gene expression signatures with 
prognostic value in lung cancer have been published. 
The lack of translation of most of the reported 
prognostic markers to the clinical setting is mainly 
due to problems related to lack of standardization 
of methodology and thus the proposed REMARK 
criteria for reporting on prognostic markers. d) 
Another important unmet medical need, for which 
molecular markers can play a helpful role, is the 
improvement of the existing decision criteria for 
selecting patients for adjuvant treatment in early 
NSCLC. Predictive molecular markers are currently 
being explored in clinical trials in the adjuvant 
setting. A number of markers have been explored 
to predict sensitivity to chemotherapeutic drugs 
in the adjuvant context. e) Markers for molecular 
targeted treatment selection, such as EGFR gene 
alterations or EML4-ALK fusion gene, are mainly 
being studied for late non-surgical stages of the 
disease. All the aforementioned areas of clinical 
management will beneÀt from the increasing efforts 
in our Àeld to develop sensitive and speciÀc, non-
invasive, robust, reproducible and cost-effective 
biomarkers. An emerging issue in the area of 
NSCLC molecular markers is the pressing need 
for more complete information on the different 
biological proÀles of lung squamous cell carcinoma 
(SCC) and adenocarcinoma (AC). In the past, SCC 
and AC have been considered as a single entity in 
the clinical practice. There is increasing evidence 
that these two histologically distinct tumors are 
notably different in their carcinogenic process, 
biology, genetic alterations, etc. and, thus, may differ 
in their sensitivity to conventional or molecular 
targeted therapies. One of the most important 
bottlenecks in the development of clinically useful 
molecular markers is the challenging need for 
rigorous validation steps. There are some multi-
institutional efforts to expedite the validation process 
of lung cancer biomarkers. Finally, there are new 
technological developments in the search of lung 
cancer biomarkers, which may open previously 
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EBUS and EUS have become more commonly 
performed procedures in many medical centers 
and both procedures can be performed safely in 
one setting14. EBUS/EUS may be superior to PET 
scan in mediastinal staging, however, PET scan 
is less invasive and can identify extra thoracic 
metastasis. To achieve the excellent staging result, 
trained and highly skilled interventionists are 
required in EBUS and EUS. In specialized centers, 
EBUS/EUS can achieve excellent result in thoracic 
lymph node sampling and may eventually replace 
mediastinoscopy in the future. Until this can be 
effectively reproduced in all centers, combined 
multi-modality approach including CT scan, PET 
scan, EBUS/EUS and medistinoscopy are the 
current approaches to achieve improved accuracy 
of mediastinal staging in NSCLC13. Reference 1 
Yasufuku K, Nakajima T, Motoori K, et al. Chest 
2006; 130:710–718 2 Bauwens O, Dusart M, 
Pierard P, et al. Lung Cancer 2008; 61:356–361) 3 
Wallace MB, Pascual JM, Raimondo M, Woodward 
TA, McComb BL, Crook JE, Johnson MM, Al-
Haddad MA, Gross SA, Pungpapong S, Hardee 
JN, Odell JA. JAMA. 2008 Feb 6;299(5):540-6. 
4 Hwangbo B, Kim SK, Lee HS, Lee HS, Kim 
MS, Lee JM, Kim HY, Lee GK, Nam BH, Zo JI. 
Chest. 2009 May;135(5):1280-7 5 De Leyn P, 
Lardinois D, Van Schil PE, et al. Eur J Cardiothorac 
Surg. 2007; 32(1):1-8. 6 Detterbeck FC, Jantz 
MA,Wallace M, Vansteenkiste J, Silvestri GA. Chest. 
2007;132(3)(suppl):202S-220S. 7 Kernstine KH, 
Stanford W, Mullan BF, et al. Ann Thorac Surg. 
1999;68:1022–1028. 8 Kramer. Ann Surg 2003;238: 
180–188 9 Takeshi Arita. Chest 1996;110;1004-
1008 10 Porte H, Roumilhac D, Eraldi L, et al. 
Eur J Cardiothorac Surg. 1998;13:196–199. 11 
Dwamena BA, Sonnad SS, Angobaldo JO, et al. 
Radiology. 1999;213:530–536. 12 Hellwig D, Ukena 
D, Paulsen F, et al. Pneumologie. 2001;55:367–377. 
13 Annema JT, van Meerbeeck JP, Rintoul RC, et 
al. JAMA. 2010;304(20):2245-2252. 14 Herth FJ, 
Krasnik M, Kahn N, Eberhardt R, Ernst A. Chest. 
2010 Oct;138(4):790-4. 15 Pieterman RM, Van 
Putten JWG, Meuzelaar JJ, et al. N Engl J Med. 
2000;343:254–261. 16 Gupta NC, Tamim WJ, 
Graeber GM, et al. Chest. 2001;120:521–527. 
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cell carcinoma16. Moreover, known causes of 
false-positive PET results are inÁammation and 
infection (tuberculosis, histoplasmosis, sarcoidosis). 
Therefore, cytologic or histologic conÀrmation may 
be necessary particularly in the case of positive 
mediastinal node. Other advantage of PET scan is 
that it can detect unexpected distance metastasis 
up to 15%15. Cervical mediastinoscopy has been 
considered as gold standard in mediastinal staging. 
However, it requires general anesthesia and 
hospitalization. In addition, the number of lymph 
nodes that mediastinoscopy can access are limited 
particularly in the hilar regions. The sensitivity 
and speciÀcity of cervical mediastinoscopy have 
been reported ranging from 44% to 92% and 
100%9. The complication rate of Mediastinoscopy 
although is not common but had been reported to be 
approximately 2.5%, which includes paresis of the 
left laryngeal recurrent nerve, hemorrhage, injury to 
the azygos vein, perforation of the esophagus, and 
mediastinitis10. Endobronchial ultrasound guided 
transbronchial needle aspiration (EBUS-TBNA) 
and Endoscopic ultrasound guided needle aspiration 
(EUS) have been used in mediastinal lymph node 
staging in lung cancer. These procedures can be 
performed in an outpatient setting under local 
anesthesia with conscious sedation. Comparing 
to mediastinoscopy which has limited access 
mainly to central lymph node (station 1, 2, 4, and 
7), EBUS enables access to hilar lymph nodes 
(Station 10, 11, and 12) and mediastinal lymph 
node (station 2, 4, and 7). Most of hilar, mediastinal 
lymph nodes and left adrenal gland metastasis can 
be accessed by combined EUS and EBUS. With 
real-time ultrasound guided, adequate lymph node 
sampling can be obtained via 21 or 22 gauge needle 
in lymph node as small as 5mm4. Several studies 
have reported high sensitivity (92.3-95%), high 
positive predictive value (100%) and high negative 
predictive value (93-97%) of EBUS-TBNA and 
EUS1,2,3,4. When compare to PET/ CT-PET scan, 
the sensitivity and negative predictive value of 
EBUS-TBNA are also superior (70% vs 90% and 
85.2% vs 96.7%, respectively)4. As compared to 
surgical staging or mediastinoscopy considered the 
gold standard according to guideline5,6, EBUS and 
EUS have higher sensitivity, accuracy and safety in 
mediastinal staging of non small cell lung cancer. 
Summary Accurate mediastinal staging in NSCLC 
can avoid unnecessary thoracotomy. EBUS has 
higher sensitivity, speciÀcity and negative predictive 
value as compared to CT scan and PET scan4. 
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evolves so fast that it would not be feasible to 
perform an RCT for each new version of, say, MRI 
scanning or software. It is also difÀcult to envision 
RCTs in some speciÀc areas such as the clinical 
impact of Quality Assurance (QA) programs. But 
also in these cases, the question remains whether the 
effort and cost of new technologies or intensiÀed QA 
improves clinical outcomes in reasonable relation to 
increased costs. Another problem is that treatments 
validated in an RCT are seen as “proven forever” 
despite other advances in management or diagnosis 
or new insights into the etiology, for example human 
papillomavirus (HPV) associated oropharyngeal 
cancer. Likewise, improvements in diagnostic 
sensitivity may affect the validity of evidence from 
older RCTs. If treatment A+B that improves survival 
over A alone in patients with enlarged mediastinal 
lymph nodes on a chest X-ray, it may not necessarily 
be superior to A alone in the era of routine CT 
imaging when small but enlarged lymph nodes can 
easily be detected. Nevertheless, in the absence of 
new evidence from a phase III trial, A+B will still be 
seen to be the standard therapy. Recently, the concept 
of personalized therapy has put the RCT under 
more pressure, as large trials with wide inclusion 
and minimal exclusion criteria are increasingly seen 
as not the way to go. Moreover, the Áurry of novel 
molecular targeted therapeutic agents, that are under 
pre-clinical development, is confronting the medical 
research community with the problem of prioritizing 
important research questions that should lead to 
the successful completion of randomized phase III 
studies, with signiÀcant Ànancial consequences. 
Given all theoretical permutations, the consequence 
of a too rigid, though scientiÀcally justiÀable, 
conviction that the comparative effectiveness of 
novel interventions should be demonstrated in an 
RCT before they can be regarded “evidence based” 
would be centuries of phase III trials against a 
background of almost unchanging daily patient 
care. On the other hand, lowering the bar for the 
evidence needed for approval of new treatments 
comes with a risk of accepting expensive but 
potentially ineffective or even harmful therapies. 
This is the challenge: how can we build a reasonable 
level of evidence without the ideal requirement 
of randomized allocation to alternative treatment 
options? We need to develop criteria for when a high 
level of “evidence” without RCTs can be reached, 
also when differences between treatment effects are 
not huge. Clearly, we need to reÀne our strategies for 
minimizing and detecting selection biases and for 
Session MTE06: New Technology in 
Radiotherapy - We Do not Need Phase III 
Trials
Monday, 4 July 2011
New Technology in Radiotherapy - We Do not Need Phase III Trials 
Monday, 4 July 2011 07:00-08:00
MTE06.1 NEW TECHNOLOGY IN 
RADIOTHERAPY - WE DO NOT NEED 
PHASE III TRIALS - PRO
Dirk De Ruysscher 
Department Of Radiation Oncology (MAASTRO), 
Grow, Maastricht University Medical Centre/
Netherlands
Abstract: The case for randomized controls in 
clinical trials Since the 1950s, randomized controlled 
trials (RCTs) have become the gold standard for 
comparative effectiveness research of medical 
interventions. Indeed, treatment guidelines often 
rank evidence of clinical beneÀt using a hierarchy 
with evidence from RCTs at the highest level, 
Level I. Many regulatory authorities require Level 
I evidence from RCTs for registration of a new 
drug in a given indication or for reimbursement 
of the associated costs. As a result, when Level 
I evidence is not available, the treatment is often 
viewed as being “unproven”. Ideally, every new 
diagnostic or interventional procedure should be 
tested in RCTs before becoming standard care 
to avoid ineffective or harmful treatments. The 
reason is that even treatments supported by a clear 
biological rationale and strong pre-clinical data may 
not produce a therapeutic gain; examples include 
the detrimental effect of erythropoietin when used 
together with radiotherapy for head and neck cancer 
or class 1c antiarrhythmic agents in myocardial 
infarction patients. The unexpected result of these 
studies provides a strong argument in favour of 
randomization. The limitations to the randomized 
trial paradigm Despite the wide acceptance of the 
randomized trial as the only method for avoiding 
bias, many advances in medicine have never been 
tested in phase III trials. This is particular so when 
the advances are in technological rather than 
pharmaceutical, such as higher resolution imaging 
techniques, CT-based radiotherapy planning or the 
introduction of mega-voltage radiation in cancer 
therapy. One problem with technology is that it 
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through dose escalation and/or hypofractionation 
made possible by greater treatment precision and 
consequent improvement in the therapeutic ratio. The 
endpoints of interest may be biological (survival, 
local control, toxicity or quality of life) or they may 
be economic (cost beneÀt, cost utility). In the case 
of these endpoints, conÀrmation of the superiority of 
the new over the old requires randomised phase III 
trials, since it cannot be assumed that the outcomes 
will inevitably favour the experimental arm. For 
example, a meta-analysis of 57 randomised trials 
conducted by the RTOG revealed that innovative 
treatments were as likely as standard treatments to 
be successful (odds ratio for survival: 1.01, P=0.5). 
On the other hand, treatment related mortality 
was worse on the experimental arms (OR: 1.76, 
P=0.008).1 It is important to distinguish the “direct 
effect” technologies from the “indirect”. The former 
require direct comparison of the technology for 
example IMRT versus 3D conformal. Although the 
dose distributions achieved with IMRT may appear 
superior, there has been unanticipated normal tissue 
injury in organs receiving low doses. Examples 
are the deaths due to pneumonitis which were 
observed following IMRT for mesothelioma2 and 
helical Tomotherapy for lung cancer.3 Although 
these toxicities were observed in single arm studies, 
had they been less frequent, the impact of these 
iatrogenic deaths on outcome may only have 
been detected otherwise by randomisation. The 
proponents of proton beam therapy have argued that 
the beam’s physical characteristics are by themselves 
sufÀcient to establish therapeutic superiority over 
x-rays, and that randomised trials are unnecessary to 
demonstrate the obvious.4 It is possible that protons 
are more effective for treating lung cancer (but we 
don’t know since they have not been compared), but 
given the cost of protons they would need to be very 
much more effective than x-rays to provide a cost 
beneÀt. There is no other way of demonstrating this 
other than by unbiased randomisation with proper 
costings. The “indirect effect” technologies (such 
as hypofractionated stereotactic body radiotherapy 
- SBRT) can be thought of as applications of new 
technology (or combinations of technologies) to 
deliver unconventional treatment schedules which 
may have greater biological effect than conventional 
treatment. Here the primary comparison should not 
be between the various technologies that can be used 
to deliver SBRT, but between novel and standard 
treatment schedules. Nevertheless there is a risk 
that the high levels of local control observed with 
prospectively assessing the effect on new therapies 
on clinical outcome. This is no simple task and has 
not been accomplished convincingly in the past. We 
hypothesize that in situations where phase III trials 
are not feasible, a level of evidence, level M, can 
be reached in situations where 1) a mathematical 
model is available that can predict outcome with an 
accuracy that is known and sufÀcient for the clinical 
question; 2) the limits of validity for application of 
the model (e.g. the speciÀc characteristics of the 
patient population) are known and 3) the model 
has been externally validated in prospective studies 
indicating a non-signiÀcant statistical difference 
from the predicted outcome. Level M may even 
be placed in the hierarchy of levels evidence and 
if the modelling is sufÀciently well supported by 
observations, level M evidence may build at least 
some conÀdence that an observed improved outcome 
relates to a speciÀc intervention. 
Keywords: Radiotherapy, evidence based medicine, 
trial methodology
New Technology in Radiotherapy - We Do not Need Phase III Trials 
Monday, 4 July 2011 07:00-08:00
MTE06.2 NEW TECHNOLOGY IN 
RADIOTHERAPY - WE DO NOT NEED 
PHASE III TRIALS - CON
David Ball 
Radiation Oncology, Peter MacCallum Cancer 
Centre/Australia
Abstract: The computer revolution has led to 
an avalanche of technological innovation in 
radiotherapy treatment planning and delivery over 
the last decade. Some of these developments, 
such as computerised treatment planning and 
patient management systems, have led to greater 
efÀciencies. Others have resulted in improved 
accuracy of treatment planning and delivery, for 
example 4D CT and in-room image guidance. The 
beneÀts whether in terms of time saved or improved 
ability to detect the gross tumour volume seem 
self evident, and it would be hard to persuade an 
ethics committee that a randomised trial should 
be performed to conÀrm the usefulness of the 
“efÀciency and accuracy” technologies, although it 
is likely that all could be tested using randomised 
trial methodology. New technology may also affect 
patient outcomes either directly through a potentially 
greater cytotoxic effect or superior dose distribution, 
for example hadron therapy or IMRT; or indirectly 
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one to three brain metastases: phase III results of 
the RTOG 9508 randomised trial. Lancet. 2004; 
363:1665-72. 6. Timmerman R et al Stereotactic 
Body Radiation Therapy for Inoperable Early Stage 
Lung Cancer. JAMA. 2010; 303:1070-6. 
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Abstract: Brain metastases (BM) develop in 
30%-50% of patients with non-small cell lung 
cancer (NSCLC), conferring a poor prognosis 
and quality of life. Approximately 30% of these 
patients present with signs and symptoms from 
BM prior to the diagnosis of lung cancer. Although 
a few publications suggest a worse outcome for 
a synchronous presentation of BM and NSCLC, 
most series have failed to show different outcomes 
for patients with a synchronous or metachronous 
presentation of BM. Traditionally, in line with the 
concept of short-term palliation for metastatic lung 
cancer, treatment has been directed toward the BM 
only, generally consisting of a short course of whole 
brain radiotherapy (WBRT). However, randomized 
studies have demonstrated improved survival for 
patients presenting with a limited number of BM 
who are treated with either surgical resection or 
stereotactic radiosurgery (SRS). Growing data that 
suggest that long-term survival can be achieved in 
a subset of patients with aggressively treated BM 
have raised the issue of how to treat the primary site 
in NSCLC. Magilligan et al. reported the Àrst study 
hypofractionated SBRT may be mistakenly attributed 
to the technology rather than the treatment schedule, 
especially within the lay community. Marketing 
claims of the superiority of one technology over 
another in terms of improved local control should 
be viewed with scepticism in the absence of a direct 
randomised comparison. The observation that 
outcomes were the same in patients whose brain 
metastases were treated stereotactically by either 
a linac or a Gamma Knife in a non-randomised 
comparison5 make it unlikely there would be 
any enthusiasm for undertaking a phase III trial. 
Finally a word of caution regarding the high dose 
hypofractionated schedules in popular use for the 
treatment of stage I lung cancer. The rates of local 
control are much higher than observed in historical 
controls treated with conventional fractionation. But 
because there has been no randomised comparison, 
we do not know if the better local control translates 
into an improvement in survival. The local control 
in the phase 2 study RTOG 0236 of SBRT in early 
stage lung cancer was an impressive at 90% at 3 
years but survival was only 56%.6 Further, nine 
of 55 patients (16%) died of unknown causes. Is 
this an excess number of deaths, possibly due to 
undetected treatment related toxicity? Only by 
randomisation can we answer this question. In 
summary, computer driven technological advances 
have improved efÀciency and treatment accuracy 
in lung cancer radiotherapy, and we do not need 
randomised trials to conÀrm these beneÀts. But when 
it is claimed that treatment outcomes are improved 
by some inherent property of the technology, then 
those claims should be tested scientiÀcally by 
randomised studies as is the case for any other new 
therapeutic intervention, especially if the toxicity 
and monetary costs are likely to be high. References: 
1. Soares HP et al Evaluation of new treatments in 
radiation oncology: are they better than standard 
treatments? JAMA. 2005; 293:970-8. 2. Allen AM 
et al. Fatal pneumonitis associated with intensity-
modulated radiation therapy for mesothelioma. 
Int J Radiat Oncol Biol Phys. 2006; 65:640-5. 3. 
Song CH et al, Treatment-related Pneumonitis and 
Acute Esophagitis in Non-small-cell Lung Cancer 
Patients Treated with Chemotherapy and Helical 
Tomotherapy. Int J Radiat Oncol Biol Phys. 2010; 
78:651-8. 4. Goitein M, Cox JD. Should Randomized 
Clinical Trials Be Required for Proton Radiotherapy? 
J Clin Oncol. 2008; 26:175-6. 5. Andrews DW et 
al. Whole brain radiation therapy with or without 
stereotactic radiosurgery boost for patients with 
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for their BMs [Lind 2010]. It would appear that 
aggressive thoracic (or cranial) treatment may not 
be justiÀed in these patients. All of the above data 
concern patients who are able to undergo surgery or 
radiosurgery for their BM, and most of these reports 
involve patients with a single BM. Around 50% of 
NSCLC patients with synchronous BM present with 
multiple BM, or large size lesions not amenable to 
(radio)surgery, and will be ineligible for aggressive 
cranial treatment. The prognosis for these patients, 
for which WBRT remains the only available option 
is very poor with a median survival ranging from 3-6 
months and approximately half of patients dying as 
a result of neurological progression. In conclusion, 
the optimal treatment approach of the primary tumor 
in patients with synchronous brain metastases from 
NSCLC remains to be deÀned. The limited, and 
non-randomized data in the literature support radical 
thoracic treatments in patients younger than 65 years 
with a good performance status, who are eligible to 
undergo SRS or surgical resection of synchronous 
BM from NSCLC, even when stage III thoracic 
disease is present. Patients with other synchronous 
(extracranial) metastases may not beneÀt from 
aggressive treatment of the primary tumor (or BM). 
Whether chemotherapy may be beneÀcial in a select 
group of patients after WBRT for synchronous BM 
needs further investigation. 
Keywords: brain metastases, thoracic treatment, 
synchronous, Radiosurgery
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Abstract: Malignant pleural mesothelioma is not 
one disease entity, and therefore not surprisingly 
there is not only one appropriate management 
modality or treatment regimen for all patients. Those 
clinicians who have been involved in the care of a 
of a substantial number of patients undergoing a 
combined resection of the primary lung tumor and a 
synchronous single BM. Long-term survival of 21% 
at 5 years and 15% at 10 years could be obtained 
with this approach in their cohort of 41 selected 
patients. Other authors have reported similar long-
term survival rates in selected patients treated with 
neurosurgery and lung surgery, with 5-year survivals 
ranging from 7% to 21% [Billing 2001; Bonnette 
2001; Downey 2002; Hu 2006]. More recently, 
other authors have published similar outcomes 
after SRS for the BM and surgery for the lung 
tumor [Yang 2008; Flannery 2008]. The majority 
of these published studies were either restricted 
to, or reported signiÀcantly better outcome in, 
patients with thoracic stage I-II disease, i.e. without 
mediastinal involvement or extracranial metastases 
other than the BM [Billings 2001; Granone 2001, 
Louie 2009]. In the study by Billings et al., the 
5-year overall survival was 35% for patients with 
N0 disease, in contrast to 0% in patients with N1 or 
N2 lymph node disease. Thus, negative lymph nodes 
status appears to be a signiÀcant prognosticator, 
even in the presence of a single aggressively treated 
BM. Based on the above data in several studies, it 
can be concluded that combined cranial and thoracic 
surgery or radiosurgery should be regarded as the 
standard of care for Àt patients with thoracic Stage 
I-II and synchronous BM from NSCLC. The vast 
majority of patients with synchronous BM, however, 
consists of patients with more advanced thoracic 
stages. Patients with stage III NSCLC encompass 
a very heterogeneous group with regard to primary 
tumor volume and extent of nodal involvement. 
However, keeping in mind the small number of 
patients in reported subgroups, some data suggest 
that selected patients with 18FDG-PET conÀrmed 
thoracic stage III NSCLC who have their BM treated 
aggressively may beneÀt from subsequent radical 
thoracic treatment [Lind 2010]. Prospective clinical 
data are required to conÀrm the validity of this 
approach, which has become routine clinical practice 
in several centers. Whether thoracic treatment for 
Stage III patients with synchronous BM should 
involve chemotherapy, high-dose radiotherapy, or 
sequential or concurrent chemo-radiotherapy is 
largely unknown, although it seems intuitive to use 
a similar approach as for Stage III disease without 
BM in Àt and relatively young patients. Patients with 
stage IV thoracic disease (ie, with other synchronous 
extracranial metastases) have a limited overall 
survival, whether treated aggressively or palliatively 
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this procedure back in 1991, in the Medical Journal 
of Australia There was only one post-operative death 
and one patient developed an empyema preventing 
effective pleurodesis . The others all had an effective 
life long pleurodesis. Their survival ranged from 3 
to 54 months with a median survival of 16 months. 
3) Surgery also has a role in selected patients in 
an attempt to achieve maximal cytoreduction and 
therefore hopefully lead to a longer survival and 
most importantly longer symptom free survival. 
There has been a Áurry of activity in the last few 
years comparing and contrasting two quite different 
procedures in this regard, in patients whose 
performance status and extent of disease warrants an 
aggressive surgical approach, with or without neo-
adjuvant chemotherapy and/or adjuvant radiotherapy 
and chemotherapy. Extrapleural pneumonectomy 
involves en bloc resection of the parietal pleura, 
lung, ipsilateral hemi-diaphragm and pericardium. 
It is clearly a major procedure and not surprisingly 
varying surgical outcomes between institutions, 
with 30 day mortality rates ranging from 2.2 to 
11.8% in some published series. There is also a 
signiÀcant difference in median survival between 
different centres but in several large centres a 
median survival now exceeds 20 months and most 
importantly there is a signiÀcant tail in the long term 
survival beyond Àve years The role of neoadjuvant 
chemotherapy prior to extrapleural pneumonectomy 
and adjuvant radiotherapy following extrapleural 
pneumonectomy appears to improve survival, 
albeit in non randomised series. In those patients 
completing all components of such a trimodality 
treatment regimen a 2 year survival of 60%, has 
been reported, a Àgure not achieved in any previous 
signiÀcant series. The use of effective neoadjuvant 
chemotherapy has two other beneÀcial effects: i) 
Firstly it assists in identifying those patients with 
rampant disease who should not proceed to radical 
surgery. ii) It provides a period of accustomisation 
for the patient and family to the implications of the 
diagnosis before any radical surgery is performed. 
I Ànd both these issues of signiÀcant import in 
the appropriate selection of patients for radical 
cytoreductive surgery with its attendant risks. The 
other cytoreductive surgery available, as mentioned 
earlier, is pleurectomy and decortication with 
preservation of the underlying lung, followed in 
some centres by adjuvant radiotherapy. There is little 
doubt that this operation carries a lower mortality 
risk (especially in Centres with a high operative 
mortality for extrapleural pneumonectomy) and 
signiÀcant number of patients with mesothelioma 
over many years have seen the full spectrum of this 
disease. We all remember the occasional patient with 
histologically proven mesothelioma who survived 
beyond ten years without any active anticancer 
treatment but with effective early control of the 
recurrent malignant pleural effusion. At the other end 
of the spectrum are those all too frequent patients 
who have the “bushÀre” form of mesothelioma , 
where no matter what cancer treatment modality is 
instituted, their disease progresses rapidly and death 
soon follows. These patients are often best served 
by minimal intervention other than symptom control 
and effective palliative care. Between these two 
extremes lie the majority of patients who contrary 
to popular myth do not all die within twelve months 
and a median survival of only a few months. This 
large group of patients have the potential to beneÀt 
from conventional oncological interventions – 
chemotherapy, surgery, radiotherapy – in various 
forms and combinations. Surgery is a cornerstone in 
the management of patients with malignant plural 
mesothelioma: 1) In some patients surgery may 
simply provide for a deÀnitive tissue diagnosis 
after often multiple attempts at thoracocentsis and/
or closed pleural biopsy in patients with recurring 
pleural effusions and/or pleural thickening. In this 
day and age such surgery takes the form of a “key 
hole” thoracoscopic procedure with three elements 
to that procedure: i) Identifying appropriate areas 
for biopsy and taking adequately deep specimens 
to establish accurately the diagnosis ii) Assessing 
the extent of malignancy such that should it prove 
to be mesothelioma, it’s suitability or otherwise for 
extensive surgery(discussed below) iii) Effective talc 
pleurodesis provided the underlying lung is capable 
of re- expansion. 2) Surgery is used in many patients 
with malignant pleural mesothelioma for symptom 
control. Effective palliation of symptoms is critical 
in all patients with malignant pleural mesothelioma 
and probably the most important is the control 
of recurring pleural effusions. In many patients 
thoracoscopic pleurodesis leads to effective control 
of the pleural space and is the procedure of Àrst 
choice. However, in some of these patients, the bulk 
of the tumour and the resulting large Áuid volume 
produced and/or the failure of the underlying lung to 
re expand to facilitate pleurodesis and obliteration 
of that pleural space, necessitates thoracotomy, 
pleurectomy and pulmonary decortication for control 
of the pleural Áuid. Prior to the reintroduction of 
thoracoscopy we reported our Àrst 50 patients with 
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completeness of resection with added therapeutic 
beneÀt. 2. Pleurectomy/decortication: parietal and 
visceral pleurectomy to remove all gross Tumor 
WITHOUT diaphragm or pericardial resection. 
3. Partial pleurectomy: partial removal of parietal 
and/or visceral pleura for diagnostic OR palliative 
purposes but leaving gross tumor behind. We prefer 
the term “Lung sparing total pleurectomy” to deÀne 
a procedure which mimics EPP in all but resection 
of the lung parenchyma. Staging Extrapleural nodal 
involvement is associated with reduced survival. 
Preoperative staging is important to allow the patient 
to make a fully informed decision about potentially 
morbid treatment. Both cervical mediastinoscopy 
and EBUS have been used to assess nodal spread 
and whilst some nodes lie outside the scope of these 
methods ( mammary, diaphragmatic ) they can give 
a representative sample. Laparoscopy is suggested 
by some to exclude occult peritoneal disease. There 
are deÀciencies in the current IMIG TNM staging 
system which have been recognised by the IASLC 
who have embarked on a new staging project. We 
have noted that the pathological IMIG stage was 
associated with DFI and overall survival; however, 
preoperative IMIG stage was less useful. Further 
improvements in pathological N stage and clinical 
T stage are expected. Case selection Selection 
criteria for EPP include ppoFEV1>50% predicted 
and no evidence of pulmonary hypertension or right 
ventricular dysfunction. PD can be performed in 
more elderly patients with poorer lung function and 
in general has similar selection criteria to lobectomy 
for NSCLC. Radical surgery is not feasible in T4 
tumours with myocardial or vertebral invasion 
although local aortic resection can be undertaken. 
The choice between EPP and PD is the subject of 
intense debate. Some argue that in stage III disease 
MCR cannot be achieved by PD due to local 
invasion and involvement of the Àssures. Others 
report favourable results for PD in stages I and II. 
In the presence of extrapleural nodal disease there 
appears to be no survival advantage of EPP over 
PD. Indeed in a large retrospective review Flores 
found that a hazard ratio of 1.4 for extrapleural 
pneumonectomy (P < .001) controlling for stage, 
histology, gender, and multimodality therapy. In the 
absence of clear survival beneÀt it seems illogical to 
use the treatment with the highest mortality in cases 
with the poorest prognosis and we advocate the use 
of PD in bulky disease. The use of EPP should be 
conÀned to the early stages of disease where long 
term survival is possible. Video presentations will 
it does lead to effective palliation of symptoms. . 
Recent large series have also conÀrmed our much 
earlier Àndings with respect to median survival in 
the range of 12-20 months. A large multi institutional 
non randomised retrospective study comparing 
extrapleural pneumonectomy and pleurectomy/
decortication reported an operative mortality of 7% 
for pleuropneumonectomy and 4 % for pleurectomy/
decortication with an median survival of 16 months 
for pleurectomy/decortication and 12 months for 
extrapleural pneumonectomy. The authors of that 
paper however acknowledged that the choice of 
procedure for individual patients was multifactorial 
and stress that they were not able to advocate one 
procedure over the other. Conclusion Based on a 
25 years evolving experience of over 650 patients 
our current recommendation for the management 
of patient with suspected malignant pleural 
mesothelioma follows the algorithm that will be 
shown. 
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MTE08.2 SURGERY FOR 
MESOTHELIOMA PLEURECTOMY - EPP
David Waller 
Thoracic Surgery, GlenÀeld Hospital, University 
Hospitals Of Leicester/United Kingdom
Abstract: The Àrst major report of extrapleural 
pneumonectomy (EPP) was produced from the 
North East of England by Butchart in 1976 and was 
promoted by Sugarbaker from the North East of 
America in 1991. Rusch in 1993 described ‘radical 
pleurectomy/decortication’ or PD . The goal of 
cytoreductive surgery should be the removal of 
all visible or palpable tumor, or a macroscopic 
complete resection (MCR). The majority of surgeons 
believe that EPP rather than PD is most capable 
of providing MCR . The IASLC Mesothelioma 
Domain and the IMIG have therefore recommended 
the following terminology to be used in the 
forthcoming Mesothelioma Staging Project: 1. 
Extended (or radical) pleurectomy/decortication: 
parietal and visceral pleurectomy to remove all 
gross tumor WITH resection of the diaphragm 
and / or pericardium. The IASLC Mesothelioma 
Domain prefers use of the term ‘extended’ rather 
than ‘radical’ in this instance as the latter implies a 
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MTE09.1 SLEEVE RESECTIONS
Erino Rendina 
Thoracic Surgery, University Of Rome “La 
Sapienza” – Sant’Andrea Hospital/Italy
Abstract: The indication for a sleeve resection is 
well established: a tumor arising at the origin of a 
lobar bronchus but not inÀltrating as far as to require 
pneumonectomy. In addition, a sleeve resection may 
be indicated when N1 nodes inÀltrate the bronchus 
from the outside, as is often the case in the left upper 
lobe tumors requiring a combined reconstruction of the 
bronchus and the pulmonary artery. From a functional 
point of view, sleeve lobectomy is strictly indicated in 
patients who cannot withstand pneumonectomy, but 
recent experiences have shown that the advantages of 
sparing lung parenchyma are evident also in patients 
without cardio-pulmonary impairment. Oncologically, 
the primary goal is in every case the complete resection 
of the tumor with free resection margins. When 
analyzing survival data reported in literature in the 
last years, most of the studies show similar or better 
results for parenchymal sparing resections (including 
pulmonary artery reconstructions) if compared with 
pneumonectomy. Moreover, in the analysis of 5-year 
survival according to stage and nodal status, sleeve 
lobectomy results in higher survival rates for stages 
I, II and III (Deslauriers ’04, Kim ’05, Ludwig ‘05), 
although the survival advantage in stage III appears 
to be limited and the beneÀt is not always conÀrmed 
for stage III-N2 patients. Therefore the role of 
parenchymal sparing operations in patients with N2 
disease still remains not completely deÀned (Fadel’02, 
address practical tips on how to avoid technical 
complications of patch dehiscence, bronchopleural 
Àstula and mediastinal shift. The median sternotomy 
approach for EPP will be demonstrated together 
with exposure of visceral pleurectomy in order to 
achieve MCR in PD. Results In recent systematic 
reviews operative mortality was found to be 7% for 
EPP and 4% for PD . EPP perioperative morbidity 
was 37% including atrial Àbrillation, empyema and 
supraventricular arrhythmias. PD was complicated 
by prolonged air-leak and postoperative empyema 
in 9.8% and 4% of patients respectively . Important 
prognostic factors include histological cell type and 
extrapleural nodal metastases. Favourable factors 
are epithelioid histology and IMIG stage. Median 
survival ranges from 21 months in stage I to 12 
months in stage IV. IMIG stage I has signiÀcantly 
better prognosis than stages III and IV; N0 disease 
has better prognosis than both N1 and N2.There 
appears to be no signiÀcant survival difference 
between EPP and PD in stages II to IV. Only in 
stage I disease is there any beneÀt for EPP over 
PD ( median survival 40 vs 23 months).Long term 
postoperative survival has been reported with up to 
18% 3 year survival seen in younger females with 
epithelioid MPM and normal blood count . Long 
term survival from radical surgery is improved by 
the use of additional systemic chemotherapy. The 
use of preoperative chemotherapy is feasible and 
does not increase perioperative morbidity. There 
remains debate whether postoperative chemotherapy 
is preferable. Some have used intraoperative, 
intracavitary chemotherapy to improve local 
control and with similar intention intracavitary 
photodynamic therapy and radical postoperative 
hemithorax irradiation have been employed. 
However, compliance with radical trimodality 
therapy is limited. Future directions The feasibility 
of assessing radical surgery in a randomised 
controlled trial has been established by the MARS 
group.Whether it is more practical to assess PD 
rather than EPP in such a trial remains to be studied. 
Certainly with the changing epidemiology in the 
Western World there is an increasing incidence 
in the elderly exposed in construction during 
1960s/70s. Hence the typical patient is less likely 
to be Àt for EPP and more for PD. The epidemic 
of mesothelioma is moving eastwards across 
the globe and lessons learned today will be of 
clinical importance around the World for the rest 
of this century. References Butchart EG, Thorax. 
1976 Feb;31(1):15-24. Sugarbaker DJ, J Thorac 
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late phase clinical trials to establish efÀcacy and 
safety. Phase III randomized placebo controlled 
with cancer incidence endpoints remain the “gold 
standard” in determining if an interventional 
strategy is truly effective. However, the lengthy 
time and intensive resources requried to perform 
phase III trials mandate that ther be a high level 
of evidence indicating potential efÀcacy prior to 
such studies. The history of cancer prevention 
trials includes multiple examples of unintended 
harms from the tested agents (e.g., beta carotene 
increased rather than decreased the risk of lung 
cancer; rofecoxib and celecoxib were associated 
with cardiovascular risks despite reducing colorectal 
polyp recurrence). Therefore, phase II randomized 
placebo controlled trials have a critical role in the 
drug development process to help prioritize agents 
for subsequent phase III testing. A number of agents 
have been tested to date in the phase II setting for 
lung cancer prevention, including inhaled steroids, 
cyclooxygenase inhibitors, lipoxygenase inhibitors, 
retinoids, and a prostacyclin analogue. It has 
become clear from these studies that several major 
challenges exist. As multiple molecular pathways of 
carcinogenesis are being identiÀed, intensive eforts 
are underway to identify the targets for intervention 
that could be expected to cover the majority of the 
high risk population. Risk assessment models to 
identify the highest risk smokers who would be 
expected to beneÀt the most from interventions and 
whose inclusion in clinical trials would allow for 
smaller and shorter trials are under development. 
The need for homogeneous populations in clinical 
trials (for instance, separating current versus former 
smokers) is particularly important. Increasing 
experience with trial endpoints is helping to identify 
preliminary efÀcacy of agents targeting the central 
lung (e.g., bronchial dysplasia) versus the peripheral 
lung (e.g., CT-identiÀed non-solid nodules). The 
new generation of clinical trials is incorporating 
high-throughput analyses that will provide abundant 
information on the impact of the interventions on 
the molecular pathways of carcinogenesis. In this 
session, speciÀc lung chemoprevention trials, the 
lessons learned, and pathways forward will be 
discussed. 
Keywords: chemoprevention, Clinical Trials
Yildizeli ‘07). These results justify the increasing 
use of parenchymal sparing procedures for lung 
cancer also in patients with good cardio-pulmonary 
function, as observed in the last years. Postoperative 
morbidity and mortality data reveal overall better 
results for patients undergoing sleeve lobectomy with 
respect to pneumonectomy. Looking at literature data, 
when morbidity is evaluated according to the type 
of complication, pneumonectomy patients appear to 
experience a higher rate of cardiac complications, while 
sleeve lobectomy patients show increased pulmonary 
and airway complications incidence. The preservation 
of lung parenchyma has been indicated by some 
authors as the possible cause of a theoretical increased 
risk for locoregional recurrence after sleeve lobectomy. 
However, although in some experiences (Fadel’02) 
an higher local recurrence rate is reported for sleeve 
resection with advanced nodal status (N2), the few 
studies (Fadel’02, Terzi’02, Kim’05) analysing risk 
factors for recurrence, show that the tumor stage and 
the nodal status are the only negative predictive factors, 
rather than the type of operation performed. A number 
of studies indicate that lung parenchyma sparing 
improves postoperative quality of life determining 
a greater cardio-pulmonary reserve, less pulmonary 
edema and less right ventricular dysfunction due to a 
lower pulmonary vascular resistance (Terzi’02, Martin-
Ucar’02). 
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MTE10.1 CHEMOPREVENTION: 
RANDOMIZED STUDIES & WHAT HAVE 
WE LEARNED
Waun K. Hong 
Thoracic And Head & Neck Medical Oncology, 
University Of Texas M.D. Anderson Cancer Center/
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Abstract: The development of agents to prevent 
lung cancer requries an iterative process of target 
identiÀcation, preclinical testing, and early and 
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new drugs for lung cancer are typically trialled in 
advanced disease after established therapies have 
failed, the clinical beneÀt is often modest. CEAs 
done in this setting are likely to be unattractive. For 
example, the median survival beneÀt of erlotinib is 
only 1.2 months in metastatic NSCLC. The ICER 
of $Cdn 95,868/LYG led to a protracted delay in 
the drug’s approval in Canada. Similarly, the high 
cost of bevacizumab led Roche not to Àle for a lung 
indication in the UK after its breast cancer indication 
was rejected on the basis of cost-effectiveness. The 
high cost of drugs and the economic recession have 
resulted in some governments, such as Greece and 
Spain mandating drug price reductions of up to 23% 
on brand name drugs. Legislation in Germany will 
allow healthcare plans to negotiate a discounted 
price of up to 16% for products after their Àrst 
year on the market. To avoid price controls, some 
pharmaceutical companies have implemented 
price caps and patient assistance programs. For 
example, Astra Zeneca Àxed the UK price of 
geÀtinib at £12,200, irrespective of the duration of 
treatment and there will be no charge for patients 
treated for less than three months. Risk sharing 
partnerships between the pharmaceutical industry 
and national healthcare systems have occasionally 
been negotiated (multiple myeloma in UK) but this 
is a new area for governments and industry. A key 
to success of such agreements will be a workable 
process for collecting effectiveness data after the 
drug is marketed. Another strategy that ensures 
appropriate treatment while containing costs is the 
use of biomarkers for patient selection. The selection 
of patients for treatment with erlotinib based on 
clinical factors and molecular markers can reduce 
cost while ensuring that those who can beneÀt 
receive the appropriate drug (1). Similarly, tumour 
markers can be used to select patients for geÀtinib 
(EGFR mutated tumours) (2) or for crizotinib (ALK 
gene) (3). These strategies are largely irrelevant in 
those countries with low per capita GDP where new 
drugs for stage IV NSCLC are beyond the Ànancial 
means of the majority of patients. One suggested 
strategy is to use pharmacoeconomic modeling 
techniques along with the value-based threshold 
proposed by the WHO to estimate a value-based 
drug price (4). The threshold proposed by WHO is 
a dollar value less than three times the per capita 
GDP of the country. This strategy would make 
drugs for lung cancer available to those in need 
in developing countries. However, it may not be 
economically viable for the manufacturer as the 
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MTE11.1 CRITICAL PERSPECTIVE ON 
THE TREATMENT OF STAGE IV NON-
SMALL CELL LUNG CANCER: COST 
ANALYSIS OF NEW DRUGS.
William K. Evans 
Administration, Juravinski Cancer Centre/Canada
Abstract: The global economic burden of 
lung cancer is large and increasing. As a result, 
economic analyses (EA) are increasingly expected 
by governments prior to drug approval, as they 
provide an estimate of the drug’s beneÀt against 
the cost to achieve the beneÀt. Cost-effectiveness 
analysis (CEA) is the most common form of EA 
and provides the incremental cost of the new drug 
compared to standard therapy over the incremental 
beneÀt measured in life-years gained (LYG). The 
incremental cost per case (ICER) can then be used 
by decision makers to determine if a new drug 
represents good value for money. An ICER less than 
$50,000 per LYG has been commonly accepted as 
“cost-effective” but there is not a strong rationale for 
this number. A CEA does not take into account the 
morbidity of the disease and its treatment, whereas 
a cost-utility analysis (CUA) does. The quality 
adjusted life year (QALY) incorporates morbidity 
into a single measure (i.e. the quantity of life gained 
by treatment is weighted by the quality of that life). 
The QOL is approximated by a utility which is a 
measure of preference for a given health state on 
a scale from 0 (equivalent to death) to 1 which is 
perfect health. CAUs are the preferred analysis for 
cancer drug approval. Although many of the drugs 
used to treat lung cancer have become generic 
and are relatively inexpensive, newer drug entries 
to the market, such as pemetrexed and molecular 
targeted therapies such as erlotinib, geftinib and 
bevacizumab are expensive; some CEAs will be 
presented. However, it is readily apparent that the 
CE or CU ratio is frequently much higher than 
generally accepted and has led to delayed entry into 
some markets or outright rejection by funders. As 
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Abstract: Several factors have hampered the 
development of effective chemotherapy regimens 
for malignant mesothelioma (MM). Because it is 
uncommon, clinical trials are small and accrual can 
be challenging. MM is heterogeneous, with many 
prognostic factors, and 3 pathologic subtypes that 
yield very different outcomes. MM is also difÀcult 
to accurately measure, and staging is unreliable. 
Despite these challenges, there has been modest, 
but genuine recent progress in systemic treatment 
of this disease. Several drugs have been shown to 
improve survival and quality of life, and many novel 
agents are being evaluated. The most active drugs 
are the antifolates. The pemetrexed/cisplatin regimen 
was FDA and EMEA approved for MM based on a 
single-blind, placebo-controlled, phase III trial which 
randomized 456 patients to cisplatin with or without 
pemetrexed. The combination yielded a superior 
overall survival (12.1 vs. 9.3 months, p=0.020), time 
to progression (5.7 vs. 3.9 months, p=0.001), and 
response rate (41% vs. 17%, p<0.001) than cisplatin 
alone. Pemetrexed treatment also improved global 
quality-of-life and pulmonary function. Similar 
results were achieved in a phase III trial of raltitrexed 
plus cisplatin vs. cisplatin (median OS 11.4 vs. 8.8 
months, p=0.048). Cisplatin can be poorly tolerated 
in older patients; fortunately carboplatin achieves 
similar outcomes. The International Expanded 
Access Program demonstrated comparable activity 
for cis- and carboplatin in terms of response 
(26.3% vs. 21.7%), time to progression (7.0 vs. 6.9 
months) and 1-year survival (63% vs. 64%). Similar 
results were observed in two large phase II trials of 
pemetrexed/carboplatin. The role of maintenance 
pemetrexed in MM is uncertain. In a non-
randomized Dutch trial, maintenance pemetrexed 
was well-tolerated and responses occurred after 6 
cycles. A CALGB study that randomizes patients 
to best supportive care or pemetrexed maintenance 
after 4 cycles of platinum/pemetrexed should 
clarify the role of maintenance in this disease. 
In a retrospective analysis of 60 MM patients 
who received a pemetrexed-containing regimen, 
low TS protein levels by immunohistochemistry 
were predictive of improved survival (HR 2.05). 
Prospective studies are required to conÀrm this 
observation. Gemcitabine has minimal single-
agent activity, but is quite active when given with a 
platinum. Response rates vary widely between trials, 
however. Interestingly, a retrospective Canadian 
series reported no difference in overall survival 
in patients who received a platinum with either 
cost of drug production might exceed the threshold 
in some poorer countries. The manufacturer might 
also be placed at risk as drug supplied to poor 
countries might be exported to wealthier nations by 
an intermediary for the intention of proÀt making. 
In conclusion, the high cost of anticancer drugs 
for lung and other cancers is increasingly limiting 
patient access in many parts of the world. A new 
paradigm needs to be developed in collaboration 
with key stakeholders. It is essential that any new 
system reward drug innovation so that new drugs 
continue to be developed, while enhancing global 
patient access. The use of pharmacoeconomic 
modeling techniques in combination with value 
thresholds based on the wealth of a nation is an 
approach meriting further consideration so that lung 
cancer patients worldwide can beneÀt from modern 
advances. References: 1. Bradbury PA, Seymour L, 
Ng R et al. An economic analysis of the National 
Cancer Institute Canada Clinical Trials Group BR 21 
randomized trial of erlotinib versus best supportive 
care after cisplatin-based chemotherapy for advanced 
non-small cell lung cancer. J Thorac Oncol 2007;2 
(suppl 4): 707. 2. Sordella R, Bell DW, Haber DA, 
Settleman J. GeÀtinib-sensitizing EGFR mutations 
in lung cancer activate anti-apoptotic pathway. 
Science 2004 Aug 30; 305 (5687): 1163-7. 3. Kwak 
E, Bang Y-J, Camidge R et al. Anaplastic lymphoma 
kinase inhibition in non-small cell lung cancer. N 
Engl J Med 2010; 363; 1693-1703. 4. Dranitsaris G, 
Truter I, Lubbe MS, Amir W, Evans W. Advances in 
cancer therapeutics and patient access to new drugs. 
Pharmacoeconomics 2010. 
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treated patients who are randomized to vorinostat or 
placebo. The results of this trial should be reported 
at this meeting. Many other novel agents are being 
evaluated, including drugs which target mesotheliin 
(MORAb-009, SS1P), IGF-1R (IMC-A12, OSI-906), 
tumor vasculature (NGR-hTNF), TGF-B (GC1008), 
G2 checkpoint (CBP-501), mTor (everolimus), and 
proteasomes (bortezomib). In summary, there has 
been modest, but genuine recent progress in systemic 
therapy for MM patients. Active drugs, including 
pemetrexed/cisplatin, certainly improve survival 
and quality of life. Yet many issues still need to 
be clariÀed to optimize treatment. Key questions 
include the role of maintenance, the optimal second-
line treatment, the appropriate chemotherapy for 
elderly and frail patients, the timing of initial 
therapy, and the role of biomarkers in patient 
selection. As we learn more about the biology of 
this complex disease, many novel agents are being 
investigated, offering hope for the future. 
Keywords: mesothelioma, Chemotherapy
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MTE13.1 PATHOLOGY FOR NON 
PATHOLOGISTS
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Abstract: There are several common problems 
which confront the pulmonary pathologist. In this 
session, we will discuss many of the usual problems 
confronted by the pulmonary surgical pathologist. 
Using a case-based approach, the issues covered 
will include: Differentiation of adenocarcinoma 
from squamous cell carcinoma: Histology-directed 
therapies have made the classiÀcation of non-small 
cell carcinoma more prominent. Several methods 
including immunohistochemical panels have been 
proposed with some success in the separation of 
these lesions. Neuroendocrine tumors and the 
approach on small biopsy specimens: Often on 
small biopsies, a neuroendocrine lesion will be 
crushed and difÀcult to interpret. Several recent 
pemetrexed or gemcitabine. The encouraging activity 
of vinorelbine (response rate 24%, median OS 10.6 
months in a phase II trial) led to its inclusion in the 
409 patient phase III MS01 trial, which compared 
active supportive care vs. vinorelbine or mitomycin/
vinblastine/cisplatin (MVP). Due to poor accrual, 
the 2 chemotherapy arms were pooled in the Ànal 
analysis; there was a small, non-signiÀcant survival 
advantage with chemotherapy. A trend towards a 
2-month improvement in survival over supportive 
care was observed for vinorelbine (HR 0.80, 
p=0.08) but not for MVP (HR 0.99, p=0.95). The 
role of second-line chemotherapy in MM is not 
well deÀned. In a 161 patient retrospective analysis, 
second-line treatment yielded a median PFS of 5.7 
months and a response or stable disease in 56% 
of patients. In an observational study in patients 
who had responding or stable disease lasting >3 
months after Àrst-line pemetrexed, re-treatment with 
pemetrexed produced a 19% response rate, though 
only patients with durable disease control for >12 
months had a survival beneÀt. The only completed, 
exclusively second-line randomized phase III trial 
in MM compared pemetrexed to best supportive 
care in 223 pemetrexed-naïve patients. Pemetrexed 
improved PFS (3.6 vs. 1.5 mo, p=0.0148) and time 
to initiation of subsequent chemotherapy (15.7 vs. 
4.3 months, p<0.0001), but not overall survival, 
likely due to crossover. In the absence of randomized 
data, vinorelbine has become a reference second-
line regimen, based on a 63 patient single-arm, 
phase II trial, which reported a 16% response rate 
and a median overall survival of 9.6 months in 
previously-treated patients. Unfortunately, many 
novel drugs that appeared promising in preclinical 
models have demonstrated limited activity in 
MM patients, including several EGFR and PDGF 
inhibitors. VEGF inhibitors such as thalidomide, 
vatalanib, sorafenib, sunitinib, axitinib, and cediranib 
have modest activity in single arm phase II studies. 
A randomized phase II trial of gemcitabine/
cisplatin plus bevacizumab or placebo reported no 
difference in progression-free or overall survival. In 
contrast, the randomized phase II/III MAPS study, 
which evaluates the addition of bevacizumab to 
pemetrexed/cisplatin, has met its phase II endpoint; 
the phase III trial is ongoing. A phase I trial of the 
histone deacetylase inhibitor vorinostat reported 
2 partial responses in 13 MM patients, a median 
TTP of 3 months, and symptom improvement. This 
Ànding led to the largest trial ever performed in this 
disease, a global phase III study in 660 previously-
Copyright © 2011 by the International Association for the Study of Lung Cancer S211
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
Session MTE14: Pre-Neoplastic Disease
Tuesday, 5 July 2011
Pre-Neoplastic Disease Tuesday, 5 July 2011 07:00-08:00
MTE14.1 PRE-NEOPLASTIC DISEASE
Sylvie Lantuejoul 
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Abstract: Lung cancer is a major cause of mortality 
worldwide, more than 70% of NSCLC patients 
presenting unresectable advanced diseases at the 
time of diagnosis. Improving the survival rate of 
patients requires understanding of molecular events 
leading to lung cancer, in order to identify genetic 
markers implicated in tumoral progression, to 
improve earlier detection of lung cancer, particularly 
in high-risk patients, and to develop novel targeted 
therapeutic strategies including chemoprevention. 
Histology of Preinvasive Lesions
 Three pulmonary preneoplastic lesions have been 
recognised in the recent WHO classiÀcation (2004): 
squamous bronchial dysplasia and carcinoma in situ 
(CIS), preceding bronchial squamous cell carcinoma 
and basaloid carcinoma, atypical adenomatous 
hyperplasia (AAH) preceeding adenocarcinoma 
in situ and invasive adenocarcinoma, and diffuse 
idiopathic pulmonary neuroendocrine cell 
hyperplasia (DIPNECH), a proposal precursor of 
carcinoid tumours. Of note, no SCLC precursor has 
been identiÀed to date. Squamous cell preneoplasia 
Morphological changes of the bronchial mucosae 
include hyperplasia, squamous metaplasia, 
dysplasia of various degrees (mild, moderate 
and severe) and in situ carcinoma. Bronchial 
hyperplasia and squamous metaplasia represent 
common reactive changes and are not considered 
as preneoplastic conditions. Conversely, dysplasia 
are true preneoplastic lesions, mild dysplasia being 
considered as a low- grade lesion, whereas moderate 
and severe dysplasia, and in situ carcinoma are 
high- grade preneoplastic conditions, at signiÀcant 
risk for cancer development. Their distinction is 
based on morphological criteria well described in 
the WHO classiÀcation, and despite controversies, 
this grading scheme has reached an acceptable level 
of inter-observers and intra-observers variation. 
AutoÁuorescence bronchoscopy (AFB) is a sensitive 
method for detecting them, and a synchronous CIS 
can be detected in 15% of patients with a known 
reviews show that a panel of stains that include a 
proliferation marker and marker of neuroendocrine 
differentiation may help in these diagnoses. Mucinous 
adenocarcinomas and tumors with lepidic growth: 
The recently published criteria for adenocarcinoma 
give more importance to the diagnosis of tumors 
with surface alveolar growth. Diagnosis of invasion 
versus in situ tumor may be difÀcult. Criteria for 
invasion are not well established, and a variety 
of strategies have been proposed. Staging issues 
in lung cancer: The current AJCC/UICC/IASLC 
lung cancer staging system has been in use for two 
years. Some typical issues of staging include pleural 
invasion, tumor size, and multiple tumor nodules. 
Biomarker analysis: Personalized therapy in patients 
with speciÀc mutations including EGFR and EML4/
ALK have required careful handling and triage of 
biopsy specimens. 1: Travis WD, et al. International 
association for the study of lung cancer/american 
thoracic society/european respiratory society 
international multidisciplinary classiÀcation of lung 
adenocarcinoma. J Thorac Oncol. 2011 Feb;6(2):244-
85. PubMed PMID: 21252716. 2: Yoshizawa A, et al. 
Impact of proposed IASLC/ATS/ERS classiÀcation 
of lung adenocarcinoma: prognostic subgroups and 
implications for further revision of staging based on 
analysis of 514 stage I cases. Mod Pathol. 2011 Jan 
21. [Epub ahead of print] PubMed PMID: 21252858. 
3: Butnor KJ. Avoiding underdiagnosis, overdiagnosis, 
and misdiagnosis of lung carcinoma. Arch Pathol 
Lab Med. 2008 Jul;132(7):1118-32. Review. PubMed 
PMID: 18605766. 4: Pelosi G, et al. Typical and 
atypical pulmonary carcinoid tumor overdiagnosed as 
small-cell carcinoma on biopsy specimens: a major 
pitfall in the management of lung cancer patients. 
Am J Surg Pathol. 2005 Feb;29(2):179-87. PubMed 
PMID: 15644774. 5: Pirker R, et al. Consensus for 
EGFR mutation testing in non-small cell lung cancer: 
results from a European workshop. J Thorac Oncol. 
2010 Oct;5(10):1706-13. PubMed PMID: 20871269. 
6: Loo PS, et al. Subtyping of undifferentiated non-
small cell carcinomas in bronchial biopsy specimens. 
J Thorac Oncol. 2010 Apr;5(4):442-7. PubMed 
PMID: 20195168. 7: Nicholson AG, et al. ReÀning 
the diagnosis and EGFR status of non-small cell lung 
carcinoma in biopsy and cytologic material, using a 
panel of mucin staining, TTF-1, cytokeratin 5/6, and 
P63, and EGFR mutation analysis. J Thorac Oncol. 
2010 Apr; 5(4): 436-41. PubMed PMID: 20068475.
Keywords: pathology, lung, Neuroendocrine, 
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to proto-oncogenes activation, (2) inactivation 
of tumour suppressor pathways (3) resistance 
to apoptosis, (4) DNA repair alteration and 
immortalisation, (5) angiogenesis, and (6) cellular 
migration. The sequence of molecular abnormalities 
during bronchial and bronchioloalveolar 
carcinogenesis will be detailed during the 
presentation, but in summary, the working model 
of bronchial carcinogenesis includes allelic loss at 
multiple tumour suppressor genes loci in normal 
bearing bronchial epithelium of smokers, followed 
by telomere attrition in squamous metaplasia, 
and than by telomerase reactivation, p53 and 
p16 inactivation, and cyclin D1 overexpression 
among others occurring in bronchial dysplasia. In 
contrast, genesis of adenocarcinoma arising from 
the peripheral bronchiolo-alveolar epithelium 
involves separate pathways, depending mainly on 
the smoking status of the patients and the origin of 
the adenocarcinoma. The Àrst one, preferentially 
observed in non- smoker females of Asian origin, 
implies mutations and/or ampliÀcation of EGFR 
gene, this genetic abnormality, which occurs since 
the AAH stage (50%), being sufÀcient for malignant 
transformation and progression, but inactivated by 
tyrosine kinase inhibitors (geÀtinib and erlotinib). 
This pathway is mainly available for TTF1 positive 
adenocarcinoma of terminal respiratory unit origin. 
Another pathway, most frequently observed in 
smokers, requires K-ras mutations; they are mutually 
exclusive with EGFR ones, and occur in TTF1 
negative adenocarcinoma, sometimes of mucinous 
subtype. They are observed in 15 to 40% of AAH. 
p53 and p16 inactivation, mainly via 9p21 loss, can 
be found in both pathways and represent late events. 
In 2007, another pathway has been discovered in 
3-7% of adenocarcinoma, involving EML4-ALK 
fusion gene at 2p; it leads to a permanent ALK 
activation and predominates in younger no or light 
smokers,with TTF1 positive solid or papillary 
adenocarcinoma, often with goblet cells. These 
adenocarcinoma present a high response rate to an 
ALK inhibitor, the crizotinib. 
Conclusion
The incidence and mortality associated with lung 
cancers have not been signiÀcantly modiÀed, despite 
the introduction of new drugs. This highlights the 
importance of the characterisation of the molecular 
determinants of lung cancer and the targeted 
development of chemopreventive agents for the 
treatment of pulmonary preneoplasia. 
lung cancer, and among patients with a previous 
squamous cell carcinoma, one third developed 
a high-grade bronchial dysplasia. Atypical 
Adenomatous Hyperplasia Although the cell of 
origin for most adenocarcinomas, such as mucinous 
adenocarcinoma, remains unknown, peripheral- type 
adenocarcinomas arise from Clara cells or type II 
pneumonocytes can be preceded by adenocarcinoma 
in situ AIS (former bronchioloalvaleoar carcinoma, 
according to the IASLC/ATS/ERS international 
multidisciplinary classiÀcation of adenocarcinoma 
in 2011) and AAH. AAH is single or multiple, 
usually less than 5 mm, located at the periphery of 
respiratory bronchioles, and composed of moderately 
atypical cells lining ialveoli and separated by gaps. 
AIS is characterized by a growth without gaps of 
neoplastic cells along preexisting alveolar structures, 
and with no evidence of stroma, vascular and pleural 
invasion. AAH are observed in up to 40% in patients 
with adenocarcinoma, but in less than 4% in patients 
without cancer. These lesions are pure ground 
glass opacities on CT , but even when multiple, 
do not inÁuence the prognosis of patients with 
adenocarcinoma. Diffuse interstitial neuroendocrine 
cell hyperplasia (DIPNECH) DIPNECH has been 
associated with a higher rate of carcinoid tumours 
of the lung, and represent their putative precursors. 
DIPNECH is a generalised proliferation of scattered 
single cells, small nodules (neuroendocrine bodies), 
or linear proliferation of neuroendocrine cells in 
the bronchial and bronchiolar epithelium. There 
is no molecular or genetic marker to distinguish 
DIPNECH from reactive neuroendocrine 
proliferation, but allelic imbalance at 11q13, where 
the tumour suppressor gene MEN1 is located are 
observed in 0 to 50% of typical carcinoids and 50 
to 70% of atypical carcinoids, and DIPNECH is 
recognised as a rare component of patients with 
MEN type 1 syndrome. 
Genetic and Molecular Pathology of Preneoplasia 
Concomitant to morphological changes from 
normal epithelium to preneoplastic to neoplastic 
lesions, genetic alterations occur at the genomic 
level, leading to initiation, development and 
maintenance of lung cancer; these alterations 
are mutations, deletions, microRNAs, epigenetic 
modiÀcations or polysomy, and affect the entire 
bronchial tree, exposed to carcinogen exposure 
(“Àeld cancerisation”). Genomic instability and 
accumulation of several key step events favour 
cellular growth or survival; these events are (1) 
activation of growth-signaling pathways related 
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Abstract: Stage III non-small-cell lung cancer 
represents a rather heterogeneous group of patients. 
The patient population should at the moment best 
be described by a) the current IASLC staging 
classiÀcation b) by the Robinson classiÀcation 
for IIIA(N2) and c) by the comorbidity proÀle 
where pulmonary function tests are of descisive 
importance. Radiotherapy as a single modality does 
no longer represent the optimum treatment for the 
majority of stage III patients. Several prospective 
randomized trials have conÀrmed that concurrent 
chemoradiation is superior to radiotherapy alone as 
well as sequential application of both modalities. 
Methods: We have analyzed the current literature 
on the choice of chemotherapy, the radiotherapy 
scheme and the observed toxicities based on its 
impact on the combined modality treatment strategy. 
Preferably randomized trials were included into this 
analyses but also signiÀcant phase-II trials were 
added. Results: a) chemotherapy: cisplatinum-based 
concurrent treatment is the treatment of choice. 
Carboplatin as a single agent has no evidence-based 
proven activity as chemoradiation agent. When 
overlooking the whole literature, cisplatin plus 
etoposide or cisplatin plus vinca alkaloid are the 
currently most used combinations for concurrent 
chemoradiotherapy protocols (Albain et al, Lancet 
2009, Curran et al, Proc ASCO 2005). The largest 
populations have been published for cisplatin and 
etoposide. Recently, cisplatin in combination with 
vinorelbin has been established as an easy and 
safe alternative (Vokes et al, J Clin Oncol 2002, 
Zatloukal, Lung Cancer 2004.). Carboplatin-based 
protocols (mainly carboplatin and paclitaxel) - 
typically used in North America - have failed with 
rather negative survival outcomes within a large 
Cooperative trial (Vokes et al, Proc ASCO 2006). 
Innovative approaches include addition of cetuximab 
within ongoing clinical trials as a further radiation 
sensitizer but results have to be awaited prior to 
further evaluation. Strategies to give one or two 
cycles of chemotherapy either as induction treatment 
prior to deÀnitive chemoradiation or as consolidation 
treatment after the concurrent chemotherapy 
protocol are added by several centers to address 
the high systemic risks of patients. The reference 
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MTE16.1 RADIATION PULMONARY 
TOXICITY: PREDICTION AND 
PREVENTION
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Abstract: Radiation or treatment-related 
pulmonary toxicity is an unfortunate relatively-
common consequence of deÀnitive radiation 
or chemoradiation. The learning objectives of 
this session are to: a) Review the patient factors 
associated with pulmonary toxicity b) Describe 
the radiation dosimetric factors associated with 
pulmonary toxicity c) Discuss current strategies to 
predict and limit normal tissue injury in the treatment 
of lung cancer Clinical cases will be utilized to 
increase discussion regarding patient selection and 
radiation dose/technique decisions.
Keywords: pulmonary toxicity, radiation treatment
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cisplatinum-based chemotherapy (Flentje et al, 
personal communication) or investigate new 
cisplatinum combinations in full doses (cisplatin and 
pemetrexed). Age is not per se a treatment limitation. 
However, comorbidity proÀles have to be carefully 
checked when deciding onto an intensive concurrent 
chemoradiotherapy protocol in patients older than 75 
years. Future research will also have to investigate 
measures to reduce the high brain-metastasis rate 
observed within the Àrst two to three years following 
deÀnitive chemoradiotherapy in these stage III 
NSCLC patient populations.
Keywords: Lung cancer, Stage III, 
chemoradiotherapy
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Abstract: Simultaneous radiochemotherapy is 
evidence based standard treatment for clinical stage 
IIIA/ IIIB NSCLC. While platin-based second 
and third generation chemotherapy regimens are 
about equally effective, they differ in their toxicity 
spectrum. To increase effectiveness of concurrent 
radiochemotherapy, interest is in radiation dose 
escalation, altered fractionation and extending 
chemotherapy to more than 2 cycles. Advantages 
of induction chemotherapy over consolidation 
chemotherapy exist in terms of tumor shrinkage 
prior to radiotherapy allowing lung sparing. Dose 
limiting organs for radiation dose escalation are 
lung and esophagus. Toxicity data will be analyzed 
for different radiochemotherapy and fractionation 
regimens. In addition, concepts of adaptive 
radiotherapy, individualized dose escalation and 
elective lymphatic drainage irradiation will be 
reviewed. 
data for consolidation are two cycles of cisplatin 
and etoposide in the Intergroup trial (Albain et al, 
Lancet 2009). The reference data for induction are 
either two cycles of cisplatin and vinorelbine (Vokes 
et al, J Clin Oncol 2002) or three cycles of cisplatin 
and paclitaxel (Fournel et al, Proc ASCO 2007). 
Consolidation with single agent docetaxel cannot 
be recommmended based on major toxicity issues 
with increased infections and pneumonitis rates 
(Hanna et al, J Clin Oncol, 2008). Currently, a large 
prospectively randomized Phase-III trial is looking 
at the combination of cisplatin and pemetrexed given 
in full doses concurrently to 66 Gy radiotherapy 
versus standard concurrent chemoradiation based 
on cisplatin and etoposide. Results are awaited to be 
reported within the upcoming years. b) conventional 
fractionation of radiotherapy in 1,8 to 2.0 Gy single 
fractions up to doses of between 66 and 74 Gy is 
currently the most active approach for concurrent 
chemoradiotherapy protocols. The majority of 
studies has been published with cumulative doses 
of 63 to 66 Gy. Currently, based on improvements 
in treatment planning and PET/CT based guidance 
of treatment Àelds doses up to 74 Gy have become 
a possible treatment intensiÀcation in experienced 
centers (Salama et al, Int J Radiat Oncol Biol Phys 
2011). Hyperfractionated accelerated protocols - 
although proven as effective measures for treatment 
intensiÀcation - have not entered clinical practice 
outside induction protocols prior to surgery or within 
speciÀc clinical trials c) Toxicity remains an issue 
for all chemoradiation protocols with pulmonary 
toxicity being the dose limiting one. Other important 
toxicities are effects to spinal cord, esophagus and 
heart. With more effective supportive measures 
now included early into the treatment, esophageal 
toxicity remains no longer a major issue and dose 
limiting. Pulmonary toxicity has to be critically 
estimated within the treatment planning phase based 
on V20 and guided by FEV1, transfer factor (DLCO) 
and ventilation-perfusion scans. Conclusions: 
Concurrent deÀnitive chemoradiotherapy protocols 
based on cisplatin and vinorelbin and conventionally 
fractionated radiotherapy doses of 66 to 74 Gy 
have become a valuable treatment strategy to 
stage III NSCLC patients. Most centers add either 
one or two cycles of induction chemotherapy or 
preferably consolidation chemotherapy to address 
the high systemic risks of the patients. Current 
research is evaluationg to further intensify radiation 
sensitization with EGF-R antibodies (ongoing 
RTOG trial), look at the effects of consolidation 
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up of 47.5 months they found the disease free and 
overall survival rates were the same in the two groups. 
In another study by Sugi et al studying just patients 
with small (<2cm) T1 non-small cell lung cancers 
they also found no difference in survival between 
patients that had a complete MLND and those that 
had sampling alone. The only positive study has 
been reported by Wu et all where they examined 
532 patients and included stages I, II and III in the 
study population. There was an improvement of 11 
months in the median survival in patients that had a 
MLND compared to those that just had sampling of 
the mediastinal lymph nodes. The recently reported 
Z0030 study from the American College of Surgery 
Oncology group reported on 1,111 patients with T1 
or T2 tumors that were clinically N0 or non-hilar 
N1 non-small cell carcinomas of the lung and were 
randomized to either mediastinal node sampling 
(removal of a single node from stations 2R, 4R,7 
and 10R for right sided tumors and 5,6,7 and 10L for 
left sided tumors) or to MLND. The randomization 
yielded a very similar group of patients in the two 
groups, the only demographic difference was that 
patients in the MLND arm had a median age 1 year 
older than the sampling arm. The patients were 
followed for a median of 6.5 years and there was no 
difference in the survival between the two groups. Of 
note, there were 21 (4%) patients that were discovered 
to have at least one positive mediastinal lymph node 
when they were randomized to MLND after having 
undergone initial mediastinal lymph node sampling. 
These patients were all carefully staged preoperatively 
as well with CT, PET and careful history and physical 
examinations. It is also important to note that the 
performance of a complete MLND did not increase 
the incidence of lymph leaks, bleeding, bronchial 
Àstulae or other complications, but did extend the 
length of the operation by about 15 minutes. The 
conclusion from the Z0030 trial is that MLND does 
not improve long term survival or decrease local 
recurrence in patients with an early stage lung cancer. 
When clinical staging, intraoperative sampling and 
visual inspection do not reveal any mediastinal or hilar 
involvement, a complete MLND is not beneÀcial for 
patients with an early stage lung cancer. This should 
not be extrapolated to patients with more advanced 
T3 or hilar N1 cancers. Since the trial speciÀcally 
excluded these patients, no conclusions can be made 
concerning this group of patients. In this instance, a 
complete MLND would seem prudent until further 
randomized trials clarify the situation. 
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MTE18.1 LYMPHNODE DISSECTION
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Abstract: Since the advent of surgical resection for 
lung cancer by Graham’s successful pneumonectomy 
and the subsequent demonstration that an anatomical 
lobectomy was sufÀcient for a curative lung cancer 
procedure the removal of regional and mediastinal 
lymph nodes has been thought to be an integral part 
of surgical therapy of lung cancer. The initial impetus 
for this was from extrapolation of resections of other 
solid organ tumors, such as a lymphadenectomy 
with a gastrectomy for stomach cancer and a axillary 
lymph node dissection as part of a mastectomy for 
breast cancer. The practice of including routing 
lymphadenectomy as a part of lung cancer resection 
was solidiÀed by two reports from Memorial Sloan 
Kettering Cancer Center stating that mediastinal 
lymph node dissection (MLND) leads to a more 
favorable long-term survival. Unfortunately, a 
routine lymph node dissection is not performed 
in the majority of lung cancer resections. Little 
and colleagues found that only 48.1% of patients 
undergoing a lung cancer resection had even one 
mediastinal lymph node sampled at the time of 
surgery. MLND is the gold standard for staging the 
mediastinum. Other techniques such as computed 
tomography, proton emission tomography, endoscopic 
bronchial ultrasound or even mediastinoscopy all 
have a signiÀcant false negative rate and can not be 
considered as the ‘best “ method to accurately stage 
the mediastinum. Whether or not MLND increases 
survival rate is a separate question. Subgroup analysis 
of Intergroup trial 0115 by Keller et al did show 
improved long-term survival in a group of patients 
with right upper lobe tumors that underwent MLND 
compared to a group that just underwent sampling; 
however, this was not a randomized trial and all the 
patients had positive N1 or N2 lymph nodes. In a 
randomized trial reported by Izbicki and colleagues in 
1998, they were not able to demonstrate a difference 
in survival between lung cancer patients undergoing 
resection that had a MLND and those that just had 
sampling of suspicious lymph nodes. After a follow-
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were published by ESTS (European Society for 
Thoracic Surgeons), and these clearly described 
several procedures used for lymph node assessment 
in patients with non-small cell lung cancer. These are 
deÀned as follows: “Selected lymph node biosy”, one 
or multiple suspicious lymph node(s) are biopsied; 
“Sampling”, the removal of one or more lymph nodes 
guided by preoperative or intraoperative Àndings 
which are thought to be representative; “Systematic 
nodal dissection”, all mediastinal tissue containing 
lymph nodes is systematically dissected and removed 
within anatomical landmarks. It was recommended 
that at least three mediastinal nodal stations (but 
always subcarinal) should be excised as a minimum 
requirement. [RELATIVE ADVANTAGES AND 
DISADVANTAGES OF MLND] The goals of 
hilar/mediastinal LND are accurate intraoperative 
staging and improved survival through better local 
control. A more accurate evaluation of the stage 
could be expected by pathological examination of 
the dissected lymph nodes. Some data clearly show 
that systematic LNS or systematic LND improves 
intraoperative staging in contrast to selected lymph 
node sampling, especially in the detection of multi-
level N2 disease. According to the results of recent 
studies on postoperative chemotherapy, a favorable 
outcome could be achieved for patients with lymph 
node involvement compared to those without lymph 
node involvement. Thus, accurate staging by surgical 
exploration of the lymph nodes enables the selection 
of better candidates for adjuvant postoperative 
chemotherapy. These are deÀnitive beneÀts of 
accurate staging. On the other hand, the impact of 
LND on locoregional control and long-term survival 
after surgery has not been clearly deÀned. However, 
the American College of Surgeons Oncology Group 
(ACOSOG) has just performed a randomized, multi-
institutional, prospective trial that was designed to 
determine whether long-term survival is affected 
by mediastinal LND versus LNS at the time of 
pulmonary resection for lung cancer (ACOSOG 
Z0030 trial). Although the details of this study are to 
be covered by Dr. Allen in this session, it has been 
demonstrated that only 4% of patients had a negative 
LNS and found to have a positive lymph node at 
mediastinal LND and that mediastinal LOND did not 
improve the survival or disease-free survival in early 
stage lung cancer if preresection surgical staging of 
mediastinal and hilar nodes is negative. 
Keywords: Lung cancer, lymph node dissection, 
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Abstract: Surgery for lung cancer began with simple 
pneumonectomy some 80 years ago. In the 1930s, 
pioneer surgeons such as Nissen, Graham, and 
Overholt demonstrated that pneumonectomy could 
be performed for lung cancer , and a complete cure 
could be expected with this procedure. Based on the 
observation that the tumor often involved locoregional 
lymph nodes, hilar/mediastinal LND was proposed 
in combination with pneumonectomy in the 1940s 
by Allison and Brock. Cahan, then published an 
important article on “radical pneumonectomy”, and 
the concept of “radical resection for lung cancer” 
was introduced for the Àrst time [3]. He described an 
operative procedure with resection of the entire lung 
(pneumonectomy) and locoregional lymph nodes 
(MLND) in an en bloc manner. Nine years later, he 
published another article on “radical lobectomy”, 
and showed that lobectomy could be considered as 
an alternative to pneumonectomy in the surgical 
management of lung cancer without worsening 
the prognosis as a radical operation for pulmonary 
malignancies. Importantly, he clearly deÀned the 
lobe-speciÀc extent of LND according to the primary 
site (lobe) of the disease. Since this landmark article, 
hilar/mediastinal LND has been adopted as part 
of the standard technique for malignant disease 
of the lung. The expected beneÀts of MLND in 
lung cancer surgery were accurate staging and an 
improved prognosis, although the latter point has been 
controversial until recently. In the 1990s, the pattern 
of lymphatic spread and its relation to the prognosis 
in patients with metastasis at a speciÀc lymph node 
site were studied in detail. Through such studies, a 
“lobe-speciÀc approach”, aiming at efÀcient MLND, 
has recently been proposed. Furthermore, for early 
tumors, the therapeutic signiÀcance of MLND needs 
to be studied further. A “pathology-speciÀc approach” 
is another important issue in MLND for lung 
cancer. [DEFINITION of MLND and RELEVENT 
PROCEDURES] Lymph node dissection (LND), 
also known as “lymphadenectomy”, needs to be 
clearly deÀned so that it can be distinguished from 
other related procedures for thoracic malignancies. 
Guidelines for intraoperative lymph node staging 
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Abstract: For many years nuclear medicine has 
used planar gamma camera images with low 
spatial resolution for diagnosis and staging of 
malignant tumors. These images provided little 
anatomical detail. Furthermore, most available 
radiopharmaceuticals visualized tumors by indirect and 
unspeciÀc mechanisms: bone scans with radiolabeled 
phosphonates demonstrate the osteoblastic response 
to a bone metastasis, liver scans with radiolabeled 
colloids show the displacement of the phagocytic 
Kupffer cells by liver metastases. Because of these 
limitations nuclear medicine reports frequently had 
to be somewhat vague and described increased tracer 
uptake “in the area of” some anatomic structure. 
Furthermore, the reports often had to include a 
differential diagnosis and recommended further 
imaging tests for clariÀcation (“increased tracer uptake 
in the area of the lower thoracic spine due to metastatic 
disease, degenerative changes or trauma/infection, 
radiographic correlation recommended”). Because of 
such unspeciÀc reports “Nuclear Medicine” has been 
mocked as “uNclear Medicine”. With the advent of 
PET and PET/CT this situation has fortunately changed. 
PET radiopharmaceuticals generally demonstrate a 
higher and more speciÀc uptake in malignant tumors 
than tracers for gamma camera imaging. PET scanners 
provide three-dimensional images of the human 
body with considerable higher spatial resolution and 
sensitivity than gamma cameras. The intensity of tracer 
uptake can be quantiÀed in absolute units (such as Bq/
ml). By normalizing tracer uptake to body mass or body 
surface area tracer uptake can be standardized across 
patients by calculation of standardized uptake values 
(SUVs). This allows a standardized display of PET 
images and reduces inter-observer variability of image 
interpretation. Furthermore, changes in tracer uptake in 
response to therapy can be quantiÀed over time. Hybrid 
imaging with PET/CT allows accurate anatomical 
localization of abnormal Àndings on PET. In addition, 
current PET/CT scanners allow the acquisition of state 
of the art, contrast enhanced CT scans. Therefore, 
PET/CT can provide a comprehensive morphologic 
and functional characterization of malignant tumors 
in a single examination. Reports of PET/CT scans 
should utilize all this information to accurately describe 
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MTE20.1 HOW TO REPORT PET
Emile F. Comans 
Nuclear Medicine & Pet Research, VU Medical 
Center/Netherlands
Abstract: HOW TO REPORT PET FDG-PET-
CT has become an important modality during the 
last decade in the process of staging patients with 
a (suspected) primary lung malignancy. Although 
the diagnostic value of the technique has been 
conÀrmed in many clinical studies, there is still room 
for improvement when it comes to the predictive 
value in NSCLC, especially with respect to T and N 
staging. A few studies have focussed on this subject, 
showing considerable inter observer variability of 
the interpretation of PET studies, partly explained 
by differences in individual experience. In addition, 
existing guidelines with respect to the quality of 
PET reports in staging cancer patients are limited to 
the presence of key elements within the PET report. 
The aim of the present presentation is to address the 
issue of the quality of a PET (-CT) report (descriptive 
part and conclusion part) with respect to effective 
communication of the Àndings to referring physicians. 
The items that will be discussed in the presentation 
include aspects of the (new) T and N denominators. 
With respect to a (possible) primary lung malignancy (T 
denominator) factors like appearance on a (diagnostic 
or low dose) CT scan, the level of FDG uptake (FDG 
avidity), the pattern of uptake (focal, diffuse, central 
photopenic areas), possible pathological diagnosis, size 
and loco-regional extension are important elements 
to include in the report. With respect to hilar and 
mediastinal lymph nodes the size, appearance, contrast 
enhancement, location and intensity of FDG uptake 
taking into account the partial volume effects in small 
nodes should be clearly described (and accurate with 
respect to the new IASLC/ATS/ERS staging map) to 
facilitate the decision making process of the referring 
physicians, especially to facilitate a multidisciplinary 
approach. The presence, location, size, degree 
of suspicion and possible routes for pathological 
conÀrmation should be clearly described in patients 
with (suspicion for) distant metastases. 
Keyword: PET report
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new chemotherapeutic agents were introduced 
into clinics in the 1990s. To circumvent this 
situation, a new class of drugs targeting certain 
molecules that play key roles in pathways leading 
to cancer phenotypes is being actively developed. 
Discovery of EGFR mutations in lung cancer and 
its predictive potential for EGFR tyrosine kinase 
inhibitors (TKI) demonstrated how effective the 
targeted therapy is, when so-called “addicted 
oncogene” is pharmacologically inhibited. ALK 
translocation is another example of such oncogene 
addiction. In 2007, Soda et al. identiÀed the gene 
resulting from the fusion of that for echinoderm 
microtubule-associated protein-like 4 (EML4) 
and the gene for anaplastic lymphoma kinase 
(ALK) as a transforming activity in mouse 3T3 
Àbroblasts from DNA of lung cancer in a Japanese 
man with a smoking history. This EML4-ALK 
fusion gene results from a small inversion within 
chromosome 2p. It is postulated that by fusing 
the coiled-coil domain of EML4 with the kinase 
domain of ALK, the ALK protein dimerizes without 
ligand binding, leading to oncogenic activation. 
Rearrangement of the ALK gene is originally 
identiÀed in anaplastic lymphoma as its name shows 
and later in inÁammatory myoÀbroblastic tumors, 
whereas point mutation of the ALK gene have been 
described in neuroblastoma. However, EML4-
ALK fusion appears to be unique to lung cancer. 
The chromosomal break-points are not always the 
same and multiple EML4-ALK variants have been 
identiÀed. All involve the intracellular tyrosine 
kinase domain of ALK beginning at the portion 
encoded by exon 20, but EML4 is variably truncated. 
At least 11 variants have been reported to date. The 
most common variants are fusion of exon 13 of 
EML4 with exon 20 of ALK, and fusion of exon 6a, 
b of EML4 with exon 20 of ALK, which are also 
referred to as variants 1 and 3a/b, and constitutes 
33% and 29% of EML4-ALK, respectively. In 
addition, EML4 is not a sole fusion partner of ALK. 
Two other partners, TFG and KIF5B, have been 
identiÀed in lung cancer. EML4-ALK translocation 
is present in a distinct subset of lung cancer. It 
tends to occur in patients without a smoking history 
or those of younger age. Histologically, ALK 
fusion is associated with histologic subtypes of 
adenocarcinoma with acinar, cribriform, or signet-
ring cell morphology. In our hand, ALK fusion was 
identiÀed in 30 of 713 adenocarcinoma of the lung 
(4.2%) and 21 of these patients were never smokers. 
Median age of all the patients were 63 while that 
the extension of primary tumors and the location of 
metastatic disease. For example, increased metabolic 
activity of lymph nodes in patients with lung cancer 
should be localized to speciÀc lymph node stations 
and not vaguely described as “increased tracer uptake 
in the hilar area”. All efforts should be made to make 
a speciÀc diagnosis regarding the presence or absence 
of metastatic disease. This requires knowledge of 
the typical patterns of loco-regional and metastatic 
spread of lung cancer. The intensity of tracer uptake is 
important for the differential diagnosis of benign and 
malignant lesions, but the pattern of increased tracer 
uptake (diffuse vs. focal, symmetric or asymmetric) 
should always be considered as well. Furthermore, 
readers need to be aware of the normal distribution 
of the used radiopharmaceutical and its variability. 
Factors inÁuencing the normal distribution, e.g. high 
skeletal muscle uptake of FDG in non-fasted patients, 
intense colonic uptake of FDG in patients receiving 
metformin, need to be considered for the interpretation 
of PET scans. When tracer uptake is quantiÀed by 
standardized uptake values the report should specify 
at what time post injection SUV measurements were 
made and whether the maximum or average SUV of 
a lesion was measured. For quality control the SUV 
of normal organs with a relatively stable and uniform 
FDG uptake, e.g. liver should be measured as well. If 
liver uptake is outside the expected range of 2-3 SUV, 
pitfalls in SUV calculation need to be considered (e.g. 
incorrect decay correction, wrong body weight used for 
SUV calculation, etc).
Keywords: reporting, quantitÀcation, PET
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MTE22.1 ALK TRANSLOCATIONS
Tetsuya Mitsudomi1, Yasushi Yatabe2 
1Department Of Thoracic Surgery, Aichi Cancer 
Center Hospital/Japan, 2Pathology And Molecular 
Diagnostics, Aichi Cancer Center Hospital/Japan
Abstract: Lung cancer is the leading cause of 
cancer-related deaths in many countries including 
Japan. For advanced or recurrent disease, the 
standard platinum doublet therapy seemed to have 
reached a therapeutic plateau, although various 
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primary antibody to ALK and the dextran polymer-
based detection reagents and showed high sensitivity 
and speciÀcity. We also showed that IHC using 
commercially available ALK antibody and high 
sensitive visualization kit (Envision Flex+ system 
(DAKO)) was feasible for archival samples and 
small biopsy specimens with high sensitivity and 
speciÀcity, and thus considered as the best suitable 
method for screening ALK-positive tumors We have 
treated lung cancer as one disease. However it is 
actually an aggregate of many genetically different 
diseases. IdentiÀcation of novel addicted oncogenes 
and development of their inhibitors as well as 
efÀcient patient screening methods will be the keys 
to novel cancer therapeutics in the 21st century.
Keywords: Crizotinib, targeted therapy, Tyrosine 
kinase inhibitor, biomarker
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MTE23.1 RESPIRATORY TRACT 
CYTOPATHOLOGY: FROM BASIC 
MORPHOLOGY TO ADVANCED 
MOLECULAR ANALYSES
Kim R. Geisinger 
Pathology, Wake Forest School Of Medicine/United 
States Of America
Abstract: Exfolatiative and aspiration cytology 
has long provided the diagnosis of primary and 
metastatic neoplasms of the respiratory tract. The 
advent of immunocytochemistry has improved our 
diagnostic abilities. Transbronchial aspirates of 
lymph nodes outside of the lung have added staging 
capabilities. Molecular analyses of cytologic samples 
contribute therapeutic and predictive data. Cytologic 
samples are divided into exfoliative and aspiration 
types. The former include sputum, washings, 
lavages, and brushings. Aspirations may be 
transthoracic (TTFNA) or transbronchial. The levels 
of diagnostic sensitivity for sputum range from 42-
97% with an average of 66%. Sensitivity increases 
with daily numbers of sputum specimens. Sensitivity 
depends on the location of the mass: central lesions 
of patients with ALK fusion was 56. There was a 
strict mutual exclusionary relationship among ALK 
fusion, EGFR mutation and KRAS mutation. PF-
02341066 (crizotinib) is an orally available, potent 
and selective ATP competitive inhibitor of MET 
and ALK kinases. Clinical activity of crizotinib 
is certainly promising. In 82 lung caner patients 
with ALK fusion, response rate was 57% with 
46 conÀrmed partial responses and 1 conÀrmed 
complete response; 27 patients (33%) had stable 
disease and median progression free survival was 
9.2 months. The drug resulted in grade 1 or 2 (mild) 
gastrointestinal side effects. However, like in the 
case of EGFR-TKI, acquired resistance seems an 
obstacle, too. Recently two secondary mutations of 
the ALK gene (C1156Y, L1196M) were shown to 
be responsible for at least some cases of acquired 
resistance. Interestingly, L1196 of ALK corresponds 
to the threonine at position 790 in the EGFR gene, 
which is present about half of the cases with acquired 
resistance to EGFR-TKI. In a phase II study of IPI-
504 is a novel, water-soluble, potent inhibitor of 
heat-shock protein 90 (Hsp90) enrolling 76 patients, 
overall response rate was 7%, however among the 
three patients with an ALK gene rearrangement, two 
had partial responses and the third had prolonged 
stable disease (7.2 months, 24% reduction in tumor 
size). However, only one of 28 EGFR mutated 
showed partial response. Although development 
of sensitive and speciÀc diagnosis of ALK 
rearrangement will be very important given the high 
efÀcacy of ALK-targeted therapy, there is currently 
no standard method. RT-PCR, Áuorescent in situ 
hybridization (FISH), and immunohistochemistry 
(IHC) are being evaluated and each method has 
some beneÀts and drawbacks. Since there are many 
variants of ALK fusion, PCR should be multiplexed 
and some times RNA of good quality is difÀcult to 
obtain from the archival tissues. It is never possible 
to detect ALK fusion to the novel protein by PCR. 
In contrast, FISH can theoretically detect any 
rearrangements including fusion with a novel gene. 
However, proximity of location of EML4 and ALK 
gene within chromosome 2 sometimes obscures the 
signal for rearrangement. IHC is commonly used 
in clinical laboratories and works for formalin-
Àxed, parafÀn-embedded, archival specimens. 
However, ALK expression is generally low even in 
ALK rearranged lung cancer compared with ALK-
rearranged lymphoma. Takeuchi et al developed an 
intercalated antibody-enhanced polymer method that 
incorporates an intercalating antibody between the 
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heterogeneous, although commonly, cytoplasm is 
abundant and delicate. Cells may be arranged in 
rosettes and trabeculae; this appearance is probably 
what is responsible for the fact that these tumors 
may be misinterpreted as adenocarcinoma. It is 
probably impossible to determine whether a tumor is 
a typical or an atypical carcinoid. Another problem is 
distinguishing a pure SCCA from a combined tumor. 
With the major advances in therapy in NCSLC 
and the recognition of the association of speciÀc 
tumor cell types with better or worse outcomes 
and with complications, it is imperative to render 
diagnoses as speciÀc as possible. In most patients, 
differentiation of squamous cell carcinoma (SQCA) 
and adenocarcinoma (ACA) is possible. In addition 
to keratinization and intercellular desmosomes, 
other attributes for SQCA are centrally positioned 
nuclei and polygonal contours. Conversely, 
eccentrically located nuclei, delicate cytoplasm, 
and neoplastic acini support a diagnosis of ACA. A 
small minority of cytologic interpretations remain 
as NSCLC, NOS. In two studies of preoperative 
cytologic diagnoses, concurrence of the cytologic 
and histiologic diagnoses was 88% and 93% with 
a better predictive value for ACA. Application of 
limited immunocytochemistry (ICC) increases 
the accuracy of tumor subtyping. A large number 
of antibodies are unnecessary. A major goal is to 
preserve sufÀcient sample for molecular analyses. In 
distinguishing SQCA and ACA, the two most widely 
used antibodies are p63 and TTF-1. If the latter is 
positive, the cancer is generally considered to be 
an ACA. If p63 is positive with a negative TTF-1, 
then squamous differentiation is present. Another 
antigen which points to glandular differentiation is 
napsin-A. If one needs to conÀrm neuroendocrine 
differentiation, a single antibody eg, CD56 or 
synaptophysin, may be used. This occurs most often 
in the diagnosis of LCNEC. A very new arena is the 
use of microRNAs to determine cell types. With the 
advent of personalized thoracic oncology, after a 
speciÀc diagnostic tumor type is rendered, molecular 
testing for a variety of mutations may be necessary. 
Though a number of mutations are recognized, 
three basic evaluations are important currently for 
therapeutic and predictive purposes: mutations in 
EGFR, k-ras, and EML4-ALK. Testing may be done 
on cell blocks, carcinoma scrapped from smears, and 
tumor cells in an aliquot dedicated for such tests. For 
all three mutations, PCR ampliÀcation of neoplastic 
DNA is probably the most widely used. However, 
for EGFR and ALK mutations, ICC , which is very 
have a higher sensitivity (71%) compared with 
peripheral masses (49%). SpeciÀcity hovers around 
99%. The ability to distinguish small cell carcinoma 
(SCCA) from nonsmall cell carcinoma (NSCCA) 
is at least 95%, as with all other cytologic sample 
types. More direct exfoliative cytology developed 
with usage of the Áexible Àberoptic bronchoscope. 
Specimens include brushings, washings, lavages and 
transbronchial aspirations (TBNA). The Àrst two 
are utilized with visualized lesions of the proximal 
bronchi. Lavages are done for more peripheral 
abnormalities. The newest modality is TBNA which 
may be done under endoscopic ultrasound guidance 
(EBUSNA). For central masses, sensitivity for 
tissue biopsies, brushings, washings, lavages, and 
aspirates averages 74%, 59%, 48%, 40%, and 56%, 
whereas for peripheral masses, sensitivity is 46%, 
52%, 3%, and 37%; bronchoscopic aspirates are 
generally not done through the bronchoscope for 
peripheral nodules. Procurement of multiple different 
specimen types during the same bronchoscopic 
session increases diagnostic sensitivity (88% 
central lesions; 59% peripheral lesions). A different 
approach to a patient with suspected lung cancer is 
TTFNA. This can be preformed for centrally situated 
masses, but it is more often done for more peripheral 
lesions. TTFNA possess an average sensitivity 
and speciÀcity of 89% and 96%. In centers which 
use on-site evaluation, these levels are higher. The 
newest method is EBUSNA. This has the major 
advantage of directly visualizing lesions, both 
within the bronchial wall and in the mediastinum, 
in real time. Diagnostic sensitivity ranges from 88-
95%; speciÀcity usually exceeds 95%. One pitfall 
of aspiration diagnoses of nodes is whether the 
needle samples a node or a mass within or extending 
from a bronchus. The morphologist should report 
the presence of lymphocytes to assure that the 
target was a node. In contrast to histopathology, 
cytomorphologic criteria to distinguish among 
primary lung neoplasms are not as well established. 
With neuroendocrine tumors (NET), the differential 
diagnosis of SCCA from other family members 
is uncomplicated. Features of SCCA include 
small size, uniformity, coarse chromatin, a lack 
of nucleoli, and very high nuclear-to-cytoplasmic 
ratios. Distinguishing large cell neuroendocrine 
carcinoma is often relatively straightforward. Smears 
contain variably dispersed large malignant cells 
which typically have a single nucleus with a distinct 
membrane, granular chromatin, and one or more 
prominent nucleoli. Cytoplasm is volumetrically 
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results of conventionally fractionated radiotherapy 
are poor with only 50% of patients achieving local 
control. In an effort to improve these poor outcomes 
a technique generally known as Stereotactic Body 
Radiotherapy (SBRT) has been developed. This 
involves delivering a dose of up to 60 Gy in no 
more than 8 fractions using highly conformal 
radiotherapy, tight margins and stringent patient 
immobilisation and delivered using image guidance. 
Two prospective studies have conÀrmed that using 
such treatment schedules produces local control in 
excess of 90%. The largest is from VU university 
medical centre in Amsterdam using a risk adapted 
fractionation scheme of total dose 60 Gy given in 
3, 5 or 8 fractions, depending on the proximity of 
the lesion to chest wall, great vessels or other vital 
structure (2). Local control was 97% and median 
survival 34 months. However a major criticicism of 
this study is that pathological proof of cancer was 
only obtained in 31% of cases. The RTOG carried 
out a multicentre prospective study. Pathological 
conÀrmation was mandatory and a dose of 54 Gy in 
3 fractions (without inhomogeneity correction) was 
prescribed (3). Again local control was excellent at 
98%. In both of these studies pulmonary toxicity 
was low with grade 3 toxicity recorded in 3%. 
Thus although no randomised control trial of SBRT 
and conventionally fractionated radiotherapy has 
reported (though such a study is in progress in 
Scandinavia) SBRT is now accepted as a valid option 
for the treatment of medically inoperable early stage 
NSCLC. Indeed a population based study from 
Amsterdam has shown that the introduction of SBRT 
has led to both an increase in the number of elderly 
(>75) patients with NSLC receiving active treatment 
with radiotherapy, and an improvement in survival 
over the time frame that SBRT was introduced (4). 
These results suggest that SBRT is a treatment option 
that should be available for all patients with early 
stage, peripheral, NSCLC who are not Àt for surgical 
resection. SBRT is a well tolerated treatment, even in 
those patients traditionally considered at high risk for 
thoracic radiotherapy, such as patients with advanced 
COPD, as manifested by severely impaired lung 
function, even oxygen dependence. Acute toxicities 
are rare and consist of 7% of patients experiencing 
grade 2 or higher pneumonitis (2% grade 3 or higher)
(5). Predisposing factors for pneumonitis include 
interstitial lung disease and a V20 exceeding 10%. 
An emerging toxicity, not previously encountered 
in the standard fractionated regimens, is damage to 
the tissues of the chest wall, namely the skin, muscle 
antibody-dependent, may be of service too. For 
ALK analyses, FISH probes are directed against 
commonly translocated chromosomal segments. In 
several studies, the results of mutational analyses on 
cytologic material parallels that found in concurrent 
tissue samples. For several decades, no widely 
utilized histiologic grading system existed for the 
NSCLC. Recently “grading” has been performed on 
histiologic material from resected tumors wherein the 
predominate histiologic pattern dictates the patient’s 
course. Histiologic patterns of adenocarcinomas are 
not usually recapitulated in cytologic smears. Several 
groups have developed cytologic grading schemes 
based solely on nuclear features. In one study, three 
nuclear attributes were included: size, chromatin 
pattern, and membrane contours. Each was assessed 
a numerical value which were summed to provide 
a nuclear score. The nuclear scores correlated well 
with prognosis. 
Keywords: Lung, Cancer, Sensitivity, Molecular, 
Cytomorphology
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Abstract: Sterotactic Body Radiotherapy (SBRT) 
for Patients with Early Stage Non Small Cell Lung 
Cancer (NSCLC): Setting up an SBRT Program 
Michael Snee MD, Maria Werner-Wasik MD 
NSCLC is a common problem; in England and 
Wales approximately 27,000 cases were diagnosed 
in 2008, with a median age of 71 (1). Around 14% 
present with early stage (IA-B) yet only about half of 
these patients receive surgery due to signiÀcant co-
morbidity such as Chronic Obstructive Pulmonary 
Disease or Cardiovascular Disease (1). Therefore in 
the UK a potential of 2,000 patients with NSCLC are 
candidates for curative radiotherapy. However the 
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non-small cell lung cancer: updated results of 257 
patients in a Japanese multi-institutional study. J 
Thorac Oncol 2:S94-S100, 2007. 6.Guckenberger 
M, Wulf J, Mueller G, et al. Dose-response 
relationship for image-guided stereotactic body 
radiotherapy of pulmonary tumors: relevance of 
4D dose calculation. Int J Radiat Oncol Biol Phys 
74:47-54, 2009. 7.Kestin LL, Grills I, Guckenberger 
M, Belderbos J, Hope AJ, Werner-Wasik M, Sonke 
JJ, Bissonette JP, Xiao Y and Yan D. Substantial 
Dose-Response Relationship with Clinical Outcome 
for Lung Stereotactic Body Radiotherapy (SBRT) 
Delivered Via Online Image Guidance. ). Int J Radiat 
Oncol Biol Phys 78:S14, 2010 8.Onishi H, Shirato 
H, Nagata Y et al. Stereotactic Body Radiotherapy 
(SBRT) for Operable Stage I Non-Small-Cell Lung 
Cancer: Can SBRT Be Comparable to Surgery? Int 
J Radiat Oncol Biol Phys. 2010 Jul 15. [Epub ahead 
of print]
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MTE26.1 BI- VERSUS TRIMODALITY 
THERAPY FOR LOCALLY ADVANCED 
NSCLC
Caro Koning 
Radiation Oncology, AMC/Netherlands
Abstract: Locally advanced Non-Small Lung 
Cancer (NSCLC) forms a group of cancers with 
heterogeneous characteristics. Stage IIIA includes 
T3N1 to T3N2 and stage IIIB T4N0 to T4N2-3 
tumours according to the staging system of 1997. 
In 2009 changes were agreed, making stage IIIA 
T1a,bN2 and T2a,bN2, T3N1,2 and T4N0,1 and 
stage IIIB T4N2 and any T,N3. There is a large 
variation in tumour extent, making treatment choices 
differentiated processes. Until the early nineties of 
the last century radiotherapy only was the treatment 
of choice for stage IIIA and low-volume stage IIIB 
NSCLC patients. The overall survival rates were 
poor with a standard dose of 60 Gray in 30 fractions. 
There is a dose-effect relationship for NSCLC: the 
and ribs, manifesting as dermatitis, possibly skin 
ulceration, chest wall pain syndrome (myositis) and 
rib fractures, many times asymptomatic and observed 
only as a radiographic Ànding. The incidence of 7-8 
percent of such chest wall symptoms including rib 
fractures or myositis and less than 1% developing 
grade 3 skin reactions was reported (5). The 
constraints suggested in the literature for the SBRT 
chest wall dose are 105 Gy and PTVmean BED10 
> 125 Gy demonstrated signiÀcantly higher local 
control than lower doses. An analysis of the multi 
institutional Japanese experience (10) demonstrated 
a 5 year overall survival rate of 92% and 73%, 
respectively, in operable patients with stages IA 
and IB NSCLC treated with SBRT to the BED 
doses >100 Gy, matching or exceeding historically 
reported survival rates of similar patients treated 
with lobectomy. Therefore, the Radiation Therapy 
Oncology Group (RTOG) and the American 
College of Surgeons Oncology Group (ACOSOG) 
are currently opening a Phase III randomized trial 
(1021/Z4099) of SBRT vs sublobar resection, with 
or without mesh brachytherapy. Eligible patients 
include “borderline resectable” patients, deÀned as 
those able to have wedge or segmental resection 
but not lobectomy. The use of brachytherapy is 
left to the choice of each participating institution. 
The trial is designed as a non-inferiority study. 
1. http://www.nice.org.uk/guidance/index.
jsp?action=download&o=53195 2. Lagerwaard FJ., 
Haasbeek CJA, Smit EF, et al. Outcomes of risk 
adapted fractionated stereotactic radiotherapy for 
stage I non-small cell lung cancer. Int J Radiat Oncol 
Biol Phys 70: 685-692, 2008. 3.Timmerman R, 
Paulus R, Galvin J, et al. Stereotactic body radiation 
therapy for inoperable early stage lung cancer. 
JAMA 303:1070-1076, 2010. 4. Palma D, Visser 
O, . Lagerwaard FJ,et al. Impact of introducing 
stereotactic lung radiotherapy for elderly patients 
with stage I non-small cell lung cancer: a population-
based time trend analyis. J Clin Oncol: 5153-5159, 
2010. 5.Grills IS, Hope AJ, Guckenberger M, Kestin 
LL, Werner-Wasik M, Sonke JJ, Bissonette JP, 
Xiao Y and Belderbos J: A Collaborative Analysis 
of Stereotactic Lung Radiotherapy (Lung SBRT) 
Outcomes for Stage I Non-Small Cell Lung Cancer 
(NSCLC) using Daily Online Cone-beam CT Image-
Guided Radiotherapy (CBCT-IGRT). Int J Radiat 
Oncol Biol Phys 78:S14, 2010 4. http://www.nccn.
org/professionals/physician_gls/pdf/nscl.pdf 5.Onishi 
H, Shirato H, Nagata Y, et al. Hypofractionated 
stereotactic radiotherapy (HypoFXSRT) for stage I 
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and 54 pneumonectomies. In the radiotherapy 
group (194 patients) 155 continued with two cycles 
consolidation chemotherapy of whom 144 (74%) 
Ànished the two planned cycles; in the surgery 
arm 121 began the consolidation therapy and 111 
(55%) patients Ànished it. There were no differences 
in overall survival between the two treatment 
groups. At Àve years the progression-free survival 
was 27% in the surgery group versus 20% in the 
radiotherapy group. Of the pneumonectomy group 
14 patients died within 30 days of thoracotomy; 
of the lobectomy group one patient died. There 
were several grade 3 or 4 toxicities as esophagitis, 
nausea and vomiting, and neutrocytopenia. In an 
unscheduled subgroup analysis the survival of 
the patients, who were treated with a lobectomy 
after mediastinal downstaging, was superior to 
the survival of the patients in the chemo-radiation 
group. In both studies patients were selected for 
operability at forehand. This means that patients with 
a favourable stage III only could enter one these two 
studies. Of the patients participating in the study 
by Albain et al 75 % had one N2 positive lymph 
node station only. There are many reports nowadays 
regarding small numbers of patients, all reporting 
selected subgroups of patients being operated after 
some combination of concurrent radiochemotherapy. 
Some of them are phase II studies. With the new 
diagnostic tools as EUS, EBUS with biopsies 
and PET/CT the general approach is to map the 
status of the limited number of suspect mediastinal 
lymph nodes in case of tumour response after 
radiochemotherapy. When surgery follows there is 
a strong preference for performing a lobectomy, as 
pneumonectomy is associated with a much higher 
mortality and morbidity rate. The value of this highly 
selected combined treatment is not exactly clear. 
In a part of the patients who will be operated on, 
NSCLC will be found to have reached a complete 
remission. Unfortunately markers to assess complete 
response are lacking until now. For the majority 
of the patients with stage IIIA disease concurrent 
radiochemotherapy however will be the preferred 
treatment. Nowadays the radiotherapy techniques 
with IMRT and 4D radiotherapy have improved 
impressively compared to radiotherapy in the era 
between 1990 and 2005 as well as the diagnostic 
tools. New agents as EGFR-blockers, VEGF-
inhibitors, apoptosis modulators, PARP-inhibitors 
have come to the clinic and can be combined with 
modern radiotherapy or/and radiochemotherapy. 
This will lead to better selected patients, who can 
higher the radiation dose the higher the loco-regional 
tumour control probability. At Àrst chemotherapy 
was combined with radiotherapy in a sequential 
way. Usually two courses of chemotherapy preceded 
the radiotherapy. According to a meta-analysis this 
resulted in an improvement of the 2-year and 5- 
year overall survival of 4% and 2%, respectively, 
provided the chemotherapy regimen contained 
cisplatin. For many lung cancer physicians this 
became the standard treatment. A different approach 
was the concomitant use of chemo- and radiotherapy. 
Low-dose cisplatin, applied daily before each 
radiotherapy fraction or high-dose cisplatin doublets 
or triplets on day 1 and day 21 or 28 yielded 
comparable results as those obtained with sequential 
combinations. Several phase III clinical trials 
followed comparing sequential versus concurrent 
radiochemotherapy leading to two meta-analyses 
published in 2010. They both conÀrmed that 
concurrent radiochemotherapy has led to superior 
2- , 3- and 5-year overall survival rates. The gain 
was 5.3%, 5.7% and 4.5%, respectively (P=0.004). 
Therefore concurrent radiochemotherapy is the 
new standard treatment of patients with NSCLC 
with stage IIIA and low-volume stage IIIB disease. 
This improved survival was accomplished because 
of improved loco-regional control. Differences 
in distant metastases rates were not observed. 
The most frequent acute but manageable acute 
toxicity was grade 3 or 4 esophagitis in 18% of the 
patients. Depending on the scheme of chemotherapy 
haematological toxicity was observed (high-dose) or 
hardly any (low-dose). An increase of late toxicity 
was not observed. The EORTC studied if there is 
a role of surgery for patients with limited stage 
IIIA NSCLC. Patients were randomized between 
surgery and radiotherapy provided the tumour 
responded to induction chemotherapy. Of all 582 
patients 332 were randomised between 60 Gray 
radiotherapy and surgery. There were no statistically 
signiÀcant differences in 5-year survival between 
the two arms neither in median survival nor in 
progression-free survival. In the surgery arm Àve 
out of six patients died after they had undergone 
a pneumonectomy. Albain et al reported a phase 
III study on stage III NSCLC (T1, T2, T3 with 
cN2) patients who were randomly treated after 
two cycles concurrent chemotherapy and 45 Gray 
radiotherapy with surgery or with a higher dose 
radiotherapy of 61 Gray provided they were without 
progression. In the surgery group (202 patients) 
there were 155 resections, of which 98 lobectomies 
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sternectomy and in the case of a large lateral chest 
wall resection.The completeness of the resection and 
the histologic grade of the tumor are the strongest 
survival predictors. 
Keywords: Chest wall resection and reconstruction, 
Primary chest wall tumors
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MTE27.2 CHEST WALL TUMORS, NON 
PANCOAST
Cengiz Gebitekin 
Thoracic Surgery, Uludag Universitesi Tip Fakultesi/
Turkey
Abstract: Chest wall tumors, benign or malignant, 
are classiÀed as primary or secondary (metastatic), 
consisting of 5% to 10% of all resected cases. 
Primary tumors originate in the bone or muscle of 
the chest wall whereas secondary tumors originate 
elsewhere in the body and spread (metastasize) to 
the chest wall. Bronchogenic and breast carcinoma 
are the most common tumors that may involve 
the chest wall by direct extension. In addition, 
all primary malignancies can cause metastases 
to the soft tissues or bones of the chest wall. 
Virtually all secondary tumors and tumors of the 
sternum are overwhelmingly malignant. The most 
common benign tumors of cartilage and bone is 
osteochondromas that frequently originates from the 
costochondral junction and malignant transfomation 
to chondrosarcoma may be seen. The most common 
malignant tumors of the ribs or sternum are usually 
caused by secondary tumors and chondrosarcoma is 
the most common primary malignant tumor of the 
chest wall that frequently arises from the anterior 
ribs near the costochondral junction than from the 
sternum, clavicle, or scapula. In addition, primary 
soft tissue tumors of the chest wall are typically 
of mesenchymal origin and may arise from any of 
the structures such as fat, Àbrous, vascular, neural, 
muscular, or dermal tissues. Metastatic involvement 
may also occur by direct invasion, such as from lung 
cancer, breast cancer etc..
Pain is the most common symptom of malignant 
chest wall tumors that may be accompanied by 
swelling whereas protrusion as with a lump is 
the most common symptom of benign tumors. 
Chest x-rays usually show an abnormality without 
indicating whether the tumor is malignant or benign. 
be treated more and more on an individual base 
allowing higher doses in the tumour areas while 
sparing the healthy surroundings. A carefully 
selected subgroup can undergo surgery afterwards. 
Especially complex treatment decisions should be 
made after discussion in multidisciplinary meetings. 
Keyword: NSCLC, concurrent radiochemotherapy, 
surgery
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MTE27.1 CHEST WALL TUMORS
Alain Chapelier 
Thoracic Surgery And Lung Transplantation, Hopital 
Foch/France
Abstract: Chest wall tumors can be secondary 
or primary. Clinical features of secondary tumors 
include internal (lung, mediastinal) and external 
(breast, skin) malignancies invading the chest wall 
and metastatic lesions (kidney, breast). Primary chest 
wall tumors are rare and most of them are malignant, 
arising from the bone or soft tissues. The location 
and the extent of the chest wall tumor and adjacent 
structures involvement are determined by computed 
tomography and magnetic resonance imaging. The 
diagnosis of primary malignant chest wall tumor 
(PMCWT) must be conÀrmed by an incisional 
biopsy which will subsequently identify patients 
with a high-grade tumor whose Àrst treatment should 
be chemotherapy. Preoperative assessment includes 
cardiopulmonary tests and PET CT scan. Radical 
resection can offer a deÀnitive cure of PMCWT 
but the surgical management may be difÀcult 
because of the local aggressiveness of these tumors. 
Extensive chest wall resections in free margins 
can be nowadays safely done in most cases with 
a carefully planned repair giving enough stability 
of the chest wall and adequate airtight closure. 
Improvements in reconstruction techniques with 
PolytetraÁuoroethylene (PTFE) prosthetic patch and 
musculocutaneous Áaps have made coverage of wide 
chest wall defects reliable. Rigid reinforcement of 
anterior or anterolateral defects can now be achieved 
with titanium bars and clips after a total or subtotal 
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MTE28.2 HOW TO RUN A STOP 
SMOKING OUTPATIENT CLINIC
Carolyn Dresler 
Tobacco Prevention And Cessation Program, 
Arkansas Department Of Health/United States Of 
America
Abstract: Depending on the adult smoking 
prevalence in the respective country, many 
patients presenting for treatment for a diagnosis 
of lung cancer will still be smoking. As smoking 
cessation is critical to providing optimal treatment 
outcome and longer term survival, it is critical to 
help patients (and their family) to stop smoking 
as soon as possible to improve their treatment 
outcome. If the patient understands that smoking 
cessation will improve treatment outcome and 
future health improvement, they will be more 
motivated to successfully quit. Reinforcing the guilt 
feelings or stigma the patient may already have 
is counterproductive, and is a signiÀcant concern 
of patient and patient advocacy groups. There are 
evidence-based guidelines regarding smoking 
cessation techniques that have resulted from reviews 
of the world’s literature, have been updated, and 
are very well accepted throughout the medical 
and psychological Àelds. Oncologists often must 
deal with the health consequences resulting from 
persistent smoking and since ongoing smoking 
may signiÀcantly affect the outcome of subsequent 
surgery or therapy and negatively impact long-term 
survival, it is imperative for clinicians treating cancer 
patients to provide smoking cessation treatment or to 
assure a readily available smoking cessation clinic. 
Smoking cessation advice includes ‘5 A’s’: ASK 
ADVISE ASSESS ASSIST ARRANGE An even 
simpler algorithm is ASK, ADVISE and REFER: 
The most important step is the Àrst one – ASK the 
patient about smoking behavior This question can be 
asked in a questionnaire while the patient is waiting 
to be seen by the check-in staff or by the nurse as the 
patient is being initially seen, but it certainly should 
be conÀrmed by the physician. ASK response should 
A CT (computed tomography) or MRI (magnetic 
resonance imaging) provides the location and size 
of the tumor as well as give some information about 
what type it is. PET/CT and/or bone scan may be 
performed in order to exclude distant metastases. 
Although an aspiration or core needle biopsy is 
the Àrst intervention to diagnose, the diagnosis is 
made with either excisional or incisional biopsy. 
Preoperative identiÀcation of chest wall invasion 
may aid surgical planning.
Surgical resection and reconstruction for primary 
tumors of the chest wall is the most common 
intervention that provides long term survival. 
Although chest wall reconstruction is unlikely 
necessary for tumors, such as lung cancer, invading 
the chest wall, reconstruction is the most commonly 
used surgical technique for primary tumors of 
the chest wall. In cases where surgery is called 
for, reconstruction with prosthesis or soft tissue 
replacement can be recommended follow-up 
procedure to help restore normalcy to the chest’s 
structure, appearance, and function.
Radical resection can offer a deÀnitive cure of 
PMCWT but the surgical management may be 
difÀcult because of the local aggressiveness of 
these tumours. Extensive chest wall resections with 
free margins can be nowadays safely done in most 
cases with a carefully planned repair giving enough 
stability of the chest wall and adequate airtight 
closure. Advances in reconstruction techniques with 
PolytetraÁuoroethylene (PTFE) or marlex prosthetic 
patches and musculocutaneous Áaps have made 
coverage of wide chest wall defects reliable. Rigid 
reinforcement of anterior or anterolateral defects can 
now be achieved with titanium bars and clips after 
a total or subtotal sternectomy and in the case of a 
large lateral chest wall resection.The completeness 
of the resection and the histologic grade of the tumor 
are the strongest survival predictors.
Keywords: chest wall, reconstruction, Tumour
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therapies alone approximately doubles the Odds 
Ratios for quitting over placebo quit rates. The 
clinician should ask the patient which they would 
prefer or which they have tried – they probably have 
experience with at least one of them. The clinician 
providing the outpatient clinic counseling must 
be very familiar with the pharmacotherapies to 
assist with tobacco cessation: Behavioural Support 
Motivational interviewing and cognitive behavioural 
support is critical throughout the quitting process. 
Much support should be provided prior to and 
early in the quitting process. Many countries have 
quitlines/telephone support services and this should 
be strongly encouraged. Within the outpatient 
clinic, between 4-8 visits of 10-20 minutes each is 
probably adequate to provide the behavioral support 
(see smoking cessation guidelines for more speciÀc 
recommendations). 
References:
1. Gritz ER, Dresler CM, Sarna L. Smoking: the 
missing drug interaction in oncology clinical trials 
OR ignoring the elephant in the room. Accepted to 
CEBP June 2005. 
2. Zevin S, Jacob P, Benowitz NL. Dose-related 
cardiovascular and endocrine effects of transdermal 
nicotine. Clin Pharmacol Ther. 1998;64(1):87-95. 
3. Zevin S, Benowitz NL. Drug interactions with 
tobacco smoking. An update. Clin Pharmacokinet. 
1999;36(6):425-38. Quick Reading List: - an 
evidence-based site containing information in 11 
languages on tobacco dependence treatment relative 
to: efÀcacy, safety, demographics and health effects, 
health economics, and policy. Re: guidelines: or 
Quick Guide to Pharmacotherapies for Smoking 
Cessation 
be included in the electronic medical record for 
every visit. A comprehensive smoking history would 
be most appropriate for either a questionnaire while 
the patient is waiting to see the oncologist or perhaps 
should be asked by the nurse. As there is such a 
paucity of prospective data on smoking status in 
clinical trials in smoking related diseases, especially 
in oncological studies, such a questionnaire would 
provide valuable data on future outcome measures. 
Questionnaires have been developed from the 
National Health Interview Survey and Behavioral 
Risk Factor Surveillance System Survey and should 
provide uniformity between datasets – see reference 
1 below. The discussion of quitting smoking should 
be part of the clinical discussion of ‘next steps’ at 
the very Àrst visit. The clinician should utilize the 
Àrst visit as the ‘teachable moment’ to emphasize 
or ‘personalize’ the importance and urgency for the 
patient to stop smoking immediately. The patient 
must understand that nicotine addiction is one of 
the most difÀcult addictions to overcome with the 
understanding that they probably have tried many 
times to quit. And, with the current diagnosis, the 
patient is very stressed and would not normally 
choose such a stressful time to quit. However, 
usually the patient will understand that quitting 
smoking is one of the most important contributions 
that THEY can currently bring to their therapy and 
it is required of them at this point. If the clinician 
presents such a strong recommendation, the patient 
will often listen. Thus, the ADVISE step is readily 
incorporated into the treatment plan. Not only 
does the clinician tell the patient to stop smoking, 
but to stop immediately. This is often an effective 
approach because one can explain to the patient 
what the next clinical steps are (surgery, radiation 
therapy, chemotherapy, etc) and that the outcome can 
be affected by continued smoking. The outpatient 
clinic can now work with the patient to ‘implement’ 
this immediate quitting. In the outpatient clinic, an 
ASSESSment of the patient’s ‘readiness’ to quit 
can be ascertained and motivation provided to help 
increase the urgency and desire to quit immediately. 
Supportive methodologies to ASSIST with the 
quitting process must also be discussed with the 
patient. ‘Cold turkey’ – or without any support is 
NOT the most successful way to quit smoking. Most 
smoking cessation guidelines recommend three 
different Àrst-line forms of pharmacotherapy: either 
nicotine replacement therapy (NRT), bupropion 
(Zyban) or varenicline (Chantix-USA or Champix-
rest of world). See table below. Each of these 
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MTE29.2 SECOND LINE TREATMENT AT 
RELAPSE OF SMALL CELL
David S. Ettinger 
Oncology, Sidney Kimmel Cancer Center At Johns 
Hopkins/United States Of America
Abstract: Small cell lung cancer (SCLC) represents 
less than 15% of all lung cancers.1 In SCLC, because 
the malignant cells have a high propensity for early 
metastases, only between 30%-40% of patients 
present with limited-disease (LD) at the time of 
diagnosis. In general for LD-SCLC, the overall 
response rates are 85%-95%, complete response 
rates, 50%-60% median survival ~20 months; and 
2-yr DFS rates ~40%. For extensive disease (ED), 
complete response rates are ~20%; median survival 
8-10 mos. and almost all patients are dead within 
2 years. Relapse disease is divided into sensitive 
disease (relapsed >3 months after completing front-
line therapy).2 In the U.S., for sensitive disease 
treatment consists of re-induction with front-line 
therapy. Other agents used include oral Etoposide, 
Cyclophosphamide, Doxorubicin, Vincristine (CAV), 
Topotecan (37% ORR) or investigational agents. 
In patients with sensitive disease, Irinotecan has 
a response rate > 35%. For refractory disease, the 
ORR for Topotecan and Irinotecan was ~6% and 
4% respectively. Docetaxel and Paclitaxel may 
be active against relapsed SCLC however there is 
insufÀcient clinical evidence to use them routinely. 
Gemcitabine, has limited activity against previously 
treated SCLC. Pemetrexed, a multi-targeted 
antifolate agent, while active against NSCLC is 
inactive against SCLC. Picoplatin, a Cisplatin 
analog, in a phase II study in patients with refractory 
SCLC, demonstrated a 4% PR and 43% SD rate. 
However, a phase III study comparing Picoplatin 
with best supportive care did not meet its endpoint. 
There have been a number of phase II prospective 
studies of combination chemotherapy for relapsed 
SCLC with high response rates but median survival 
times usually less than 7 months. Amrubicin is a 
synthetic-9-amino-anthracycline and topoisomerase 
Name Side Effects Precautions Dose Duration Rx or OTC 
Nicotine 
gum 
Mouth 
soreness; 
hiccups/ 
dyspepsia 
Dentures Heavier 
smoker: 4 
mg Lighter 
smoker: 
2mg 1-2/
hr; Up to 
24/day 
Wean 
off by 6 
months; 
12 months 
at latest 
OTC 
Nicotine 
lozenge 
Hiccups/ 
dyspepsia 
Heavier 
smoker: 4 
mg Lighter 
smoker: 
2mg 1-2/
hr; Up to 
24/day 
Wean 
off by 6 
months;12 
months at 
latest 
OTC 
*2mg 
lozenge 
take 1 
or 2/hr 
depending 
on light 
or heavy 
smoker up 
to 40/day 
Wean 
off by 6 
months;12 
months at 
latest 
OTC (if 
available 
– outside 
US) 
Nicotine Irritation 
of buccal 
mucosa and 
throat 
6-16 
cartridges/
day 
Wean 
off by 6 
months;12 
months at 
latest 
Rx in the 
US; OTC 
elsewhere 
Nicotine 
nasal 
spray 
Nasal 
irritation 
8-40 doses/
day 
Wean 
off by 6 
months;12 
months at 
latest 
Rx 
Nicotine 
patch 
Local skin 
reaction 
Insomnia 
Sensitive 
skin 
21 mg} 6 
wk 14 mg} 
2 wk 7 
mg} 2 wk 
or 15 mg 
8wk 
Duration 
is as some 
OTC 
Insomnia, 
dry mouth 
Hx of 
seizure 
or eating 
disorders 
150 mg q 
AM x 3 
days then 
150 mg 
BID 
7-12 wks; 
or up to 1 
year 
Rx 
Nausea 0.5 mg 
AMx3 
days; 
0.5 mg 
12 weeks; 
can 
extend 
another 12 
weeks 
Rx 
Keyword: tobacco cessation
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in patients with platinum-refractory small-cell lung 
cancer. J Clin Oncol 2010; 28:2598-603. 5. Jotte R, 
Conklin P, Reynolds C, et al. Randomized phase 
II trial of single-agent amrubicin or topotecan as 
second-line treatment in patients with small-cell 
lung cancer sensitive to Àrst-line platinum-based 
chemotherapy. J Clin Oncol 2011; 29:287-93. 6. 
Hirose T, Nakashima M, Shirai T, et al. Phase II 
trial of amrubicin and carboplatin in patients with 
sensitive or refractory relapsed small-cell lung 
cancer. Lung Cancer 2011, In Press. 7. Metro G and 
Cappuzzo F. Emerging drugs for small-cell lung 
cancer. Expert Opinion 2009; 14:591-606. 8. Kim 
YH and Mishima M. Second-line chemotherapy for 
small-cell lung cancer. Cancer Treatment Reviews 
2011; 37:143-150. 
Keywords: limited disease, extensive disease, 
combined modality therapy, novel therapies
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MTE30.2 GENOMICS IN LUNG CANCER
Bauke Ylstra 
Pathology, VU University Medical Center/
Netherlands
Abstract: In this meet-the-expert session we will 
discuss the current value of genomics for the clinic. 
Thereby we will mainly focus on the analysis 
of chromosomal copy number aberrations, since 
DNA is a robust molecule which can be obtained 
from routinely collected archival material (FFPE), 
favourable for clinical implementation. Lung cancer 
genome analysis has been performed in a research 
setting ever since the early development of the 
expression microarray now more than a decade ago. 
In recent years array analysis has made its entrance 
in the diagnostic arena. At VU medical center 
Amsterdam array comparative hybridization (aCGH) 
is routinely used for clonality screening in the case 
of doiuble tumors. Meanwhile we are entering a new 
era in genome research with the implementation of 
Massively Parallel Sequencing (MPS). The Àrst lung 
cancer genomes are being deciphered. MPS will also 
be followed soon by diagnostic implementation. We 
II inhibitor is effective to treat SCLC in Japan. 
Is its effectiveness due to ethnic variation? In a 
phase II study of Amrubicin in Japanese previously 
treated SCLC patients; in sensitive disease patients 
the ORR was 52% with a MST of 11.6 months; 
in refractory disease patients the ORR was 50% 
with a MST of 10.3 months.3 In a phase II US/
EU study of Amrubicin refractory SCLC patients 
in 63 evaluable patients, the ORR was 21% with 
a PFS of 3.3 months and OS of 6.1 months.4 In a 
randomized phase II study comparing Amrubicin 
to Topotecan in sensitive SCLC patients the ORR 
was 44% to 15% respectively with an OS of 9.2 
months to 7.6 months respectively.5 The results 
of ACT-1: Phase 3 study of Amrubicin in second 
line SCLC compared to Topotecan with OS as its 
primary endpoint is completed with the results to 
be presented at ASCO 2011. In a Japanese phase II 
trial of Amrubicin and Carboplatin in patient with 
sensitive or refractory relapsed SCLC, in 25 patients 
treated, the ORR was 36% (58.3% sensitive; 15.4% 
refractory); MST overall was 7 months (10 months 
sensitive; 5 months refractory).6 At the present 
time, unfortunately, targeted therapy has failed to 
demonstrate effectiveness for SCLC. Agents such as 
Marimastat, Imatinib, GeÀtinib, Temsirolimus, BEC-
2 and Thalidomide were studied and were ineffective 
against SCLC. In summary, SCLC is becoming an 
“orphan” disease; LD-SCLC is potentially curable. 
ReÀnement of the combined treatment modalities 
should increase the cure rate. New regimens 
should be evaluated in ED-SCLC patients where 
the survival rate is still poor. Molecular target 
therapy also needs to be studied in the treatment 
of SCLC. Unfortunately, progress has been slow 
especially for second-line therapy for SCLC.8 
References 1. Govindan R, Page N, Morgensztern 
D, et al. Changing epidemiology of small-cell lung 
cancer in the United States over the last 30 years: 
analysis of the surveillance, epidemiologic, and end 
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improvement in ventilator settings ICC removed 
and Extubated 8 days later CXR and CT showed 
effective closure of the cavity (in combination with 
the expected deÁation of the RUL) Reference: 
Travaline JM et al. Treatment of persistent 
pulmonary air leaks using endobronchial valves. 
Chest 2009;136:355-60 
Case 3 65 year old man with underlying COPD and 
bullous lung disease Complicated by pneumonia 
with L parapneumonic collection Pleural ultrasound 
done by experienced radiographer in the Radiology 
department with patient’s body position noted 
Pleural aspiration done 30 minutes later in the 
bronchoscopy suite Despite the patient being in the 
same position the Áuid had moved- only a small 
amount of Áuid was aspirable in posterior axillary 
line/ scapular line and the tube was partially placed 
before it was realised little Áuid was draining 
Repeat pleural ultrasound obtained – no Áuid 
present- Áuid had “shifted” into more anterior 
position Tube successfully placed there in mid- ant 
axillary line Comments: it seems not only is the 
correct position important but pleural Áuid shifts can 
occur as patients are moved from one position to 
another, especially in partially loculated collections 
Reference: Havelock T et al. Pleural procedures and 
thoracic ultrasound: BTS pleural disaease guidelines 
2010. Thorax 2010;65 suppl 2 ii61-ii76 
Keywords: intercostal space, pleural procedures, 
endobronchial valves
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MTE31.2 I WISH... SECONDS TO 
DISASTER CASES TO LEARN FROM
Suveer Singh 
Respiratory And Intensive Care Medicine, Chelsea & 
Westminster Hospital/United Kingdom
Abstract: We will discuss the aetiologies behind, 
and management of acute massive bronchial 
haemorrhage, illustrated by a case study. Knowledge 
of your population is crucial. As such, certain 
lung conditions are more likely to create bleeding 
problems; vascular tumours, esp renal cell 
metastases, Àbrocavitatory disease, bronchiectasis, 
bleeding diatheses, pulmonary hypertension, 
chronic steroid use, cardiac patients on combination 
clopidogrel/asprin. A 75y old Caucasian man with 
known idiopathic bronchiectasis, and haemoptysis 
will discuss examples of both arrays and MPS using 
clinical specimens and possible implications for the 
diagnosis of the NSCLC patient. 
Keyword: genomics, microarrays, aCGH, copy 
number, next generation sequencing, NSCLC
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MTE31.1 I WISH... SECONDS TO 
DISASTER CASES TO LEARN FROM 
PLEURAL CASES
David Fielding 
Thoracic Medicine, The Royal Brisbane And 
Women’s Hospital/Australia
Abstract: Case 1. A 68 year old lady presented 
with a moderate sized unilateral pleural effusion. 
Background history chronic liver disease due to 
alcoholism Mild ascites Prior tap drained 1 litre of 
straw Áuid, transudate Repeat pleural aspiration 
due to recurrence of Áuid and moderate shortness 
of breath INR 1.3 Fluid was “blood stained” 1.7. 
litres drained from “posterior position” Patient 
collapsed 3 hours later, unrecordable blood pressure 
CXR showed presumed left hemothorax ICC placed 
emergently, went to VATS exploration laceration 
of intercostal artery conÀrmed Patient died in ICU 
1 day later due to multi-organ failur Comments 
Discussion of “safe triangle” Anatomy of intercostal 
arteries in relation to interspace Reference: Choi 
S. et al. Radiological review of intercostal artery: 
anatomical considerations when performing 
procedures via intercostal space. J Med Imaging and 
Radiation Oncol 2010;54:302-306 
Case 2. A 27 year old lady with community acquired 
pneumonia, empyema and RUL lung abscess; ICC 
placed uneventfully Intubated due to sepsis and 
respiratory failure 48 hours later rupture of the 
abscess followed by massive bronchopleural Àstula 
Near impossible to ventiltate: High pressure support 
tidal volumes 150ml, 100% oxygen with sats of 
85%, Effective placement of 3 endobronchial valves 
with instant cessation of leak, preceeded by balloon 
inÁation demonstrating loss of air leak marked 
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oxyhaemoglobin saturation by pulse oximetry 
was above 90%. The patient was transferred to 
intensive care unit for close monitoring. The 
patient eventually recovered and the histology of 
the endobronchial biopsy turned out to be arterial 
wall. CT thorax later documented this patient had 
bronchiectasis and the nodular lesion was most 
likely a tortuous artery. These vascular lesions might 
mimic endobronchial tumour and can be pulsative 
or non-pulsative. Endobronchial ultrasound might 
be of use in this clinical setting. References 1. 
Soda H, Oka M, Kohno S, Watanabe M, Takatani 
H and Hara K. Arteriovenous Malformation of the 
Bronchial Artery Showing Endobronchial Protrusion. 
Internal Medicine 1995;34:797-800 2. Katoh O, 
Yamada H, Hiura K, Nakanishi Y and Kishikawa 
T. Bronchoscopic and angiographic comparison of 
bronchial arterial lesions in patients with hemoptysis. 
Chest 1987;91;486-489 
Keywords: bleeding, bronchoscopy
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Abstract: Lung cancer remains the one of the 
largest cause of cancer related death in the World. 
Approximately 80% of lung cancer patients will 
have non-small cell lung cancer and of those 40% 
(32% of the total) will have locally advanced disease 
which is normally not amenable to surgical resection. 
Radiotherapy plays a key role in the treatment 
of these patients whether it be part of a curative 
is presented. He had been investigated years 
previously. He was an ex 30 pack year smoker. 
Bronchiectasis and cavitation of the right lower lobe 
was felt related to early adult pneumonic illness. 
Subsequent management was as per standards of care 
for bronchiectasis. New Haemoptysis, not associated 
with clinical infective exacerbation. A plain chest 
radiograph and ct scan revealed opaciÀcation 
and Áuid within cavitation in the right anterior 
upper lobe (RB3) and right lower lobe (RB7/8) 
segments. No explanation for the haemoptysis. 
Normal bronchoscopic Àndings, except a slightly 
irregular mucosal tag at the junction of the RBI and 
RB3 subcarina. This was biopsied x 2. Continuous 
bleeding ensued. When this did not abate through 
observation and suction, a haemorrhage protocol 
was initiated. We describe the ensuing steps, through 
to conclusion and diagnosis. Reference is made to 
the importance of preparation of staff, equipment, 
patient factors. A reminder of Suction, cold 
saline and adrenaline (1 in 200,000 2ml aliquots) 
and balloon blockers is provided. Furthermore, 
which steps to take when immediate measures for 
haemorrhage control are not successful, and which 
multidisciplinary approaches are to be considered.
Keyword: bronchoscopy, haemorrhage, 
bronchiectasis, balloon blocker, protocol
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Abstract: A 49 year old gentleman presented with 
episodic blood stained sputum. He was an ex-light 
smoker and had no chronic illness. Bronchoscopy 
was performed to rule out endobronchial lesion. 
A small nodular lesion was seen at the oriÀce of 
right middle lobe bronchus and biopsy of the lesion 
resulted in massive bleeding and hypovolaemic 
shock. The patient was immediately turned to 
right lateral passion and bronchoscope placed just 
proximal to the bleeding site. Normal saline was 
infused at full rate and intensive care unit staff was 
paged to prepare for single lung intubation. Bleeding 
continued until the whole right lung was drowned, 
though blood pressure was stabilized and all along 
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Abstract: Concurrent CT-RT is the standard 
treatment of locally-advanced NSCLC. According 
to the results of the Meta-Analysis of Radiotherapy 
from the Lung Cancer Collaborative Group 
(LCCG), concurrent CT-RT leads to a signiÀcant 
survival beneÀt of 6.6% at 3 years when compared 
with sequential CT-RT. In order to reproduce such 
result, patients should be accurately selected in a 
routine practice setting. In addition to the careful 
evaluation of co-morbidities which are frequent in 
patients with NSCLC, pulmonary function tests are 
crucial, as a forced expiratory volume in 1 second 
lower than 1L or 40%, and/or a monoxide diffusing 
capacity lower than 60% of the theoretical values 
usually contra-indicate standard radiotherapy. 
Chemotherapy may be delivered only to medically-
Àt patients with PS<2. The major objectives of 
radiotherapy treatment planning are to deliver a 
total dose ranging from 66 to 70 Gy on the Gross-
Tumor Volume (GTV), using a standard fractionation 
scheme (one 2 Gy-fraction per day), without risking 
acute toxicities on non-tumoral tissues. The lung 
V20 (percentage of pulmonary volume receiving 
at least 20 Gy) has to be lower than 30% and the 
lung V30 lower than 20% (and even less in case of 
chronic obstructive pulmonary disease) to avoid 
acute and late radiation-induced pneumonitis. The 
volume of oesophagial tissue has to be limited 
as much as possible. Concurrent CT-RT leads to 
higher oesophagial toxicity rates compared with 
sequential treatment (18% vs. 3% in the LCCG 
meta-analysis); however, oesophagial toxicity may 
not be considered as dose-limiting, as symptomatic 
treatments usually allow the continuation of radiation 
administration. A more concerning -and potentially 
under-evaluated- toxicity is late cardiac toxicity, 
which may occur in 5-8% of patients. The maximum 
treatment plan or indicated for the palliation and 
prompt relief of symptoms including hemoptysis, 
dyspnea due to bronchial obstruction or persistant 
pain. The involvement of the radiation oncologist 
in the treatment of lung cancer is certainly standard 
practice and requires close consultation with both 
medical oncologists as well as thoracic surgeons to 
determine optimal treatment. There has certainly 
been a progression in the approach to locally 
advanced non-small cell lung cancer over the last 
two decades. Radiotherapy alone was the traditional 
standard therapy for stage III disease however it 
was associated with poor survivals. A progression of 
randomized trials have shown that survivals can be 
improved with the addition of chemotherapy in either 
a sequential or concurrent fashion. While concurrent 
therapies are associated with a improved outcomes 
in patients who have a good performance status they 
are also associated with increased toxicities. The goal 
of all cancer therapies is to increase the therapeutic 
ratio; that is, to increase the probability of cure while 
minimizing the toxicity. Theoretically, all cancers 
can be cured if a sufÀcient dose of radiation can be 
delivered to all clonogens without causing undue 
toxicity to the patient. Obviously, this is not the 
case in most instances. Precise target localization, in 
theory, can improve the therapeutic ratio by allowing 
more conformal radiation delivery, enabling one to 
escalate the tumor dose while sparing surrounding 
normal tissue. In the last decade, conventional 
2-dimensional (2-D) radiotherapy, based on surface 
anatomy and bony landmarks, has given way to the 
computed tomography (CT)-based 3-D radiotherapy, 
which allowed for the use of internal anatomy. Great 
interests are now emerging in the Àeld of radiation 
oncology in tracking the motion of the tumor and 
surrounding normal tissue, either from day to day 
or during each treatment session, and in delivering 
treatments that adapt to the detected motion. 
Commercially available 4-D CT imaging capabilities 
and various strategies to deliver the radiation dose 
to the moving target made the implementation of 
this new paradigm possible. In this session, we will 
discuss the how to intergrate systemic therapy as 
well as advanced technology for stage III NSCLC.
Keyword: locally advanced non small cell lung 
cancer
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real-time re-delineation of volumes and adaptation of 
dosimetric variables. Beyond radiotherapy progress, 
optimization of chemotherapy is also crucial, as 
systemic recurrences are frequent after CT-RT. 
In the US, etoposide and cisplatin combinations 
are the most frequently used following trials 
conducted by the SouthWest Oncology Group. In 
Europe, vinorelbine and cisplatin associations are 
also popular. In order to deliver higher doses of 
chemotherapy and to increase systemic control rates, 
several investigators developed mixed therapeutic 
sequences, associating induction and/or consolidation 
chemotherapy, before and/or after concurrent CT-
RT. Some data suggest that consolidation protocols 
may increase progression-free survival, but further 
studies are needed. Moreover, the routine practice 
favors induction chemotherapy, (1) allowing to 
start the initiation of the treatment sequence while 
preparing the patient for radiotherapy with shorter 
delays, (2) potentially obtaining a tumor response 
and decreasing the targeted volume, and (3) leading 
to select most appropriate patients that do not 
present with early progression. One debated issue 
is whether the pre- or the post-treatment volume 
should be the reference for dose prescription in this 
setting. New cytotoxic agents are currently being 
investigated in combination with radiotherapy. We 
recently reported the initial results of a phase I trial 
evaluating the feasibility of combining full-dose 
pemetrexed to optimized radiotherapy to a total dose 
of 66 Gy. This regimen is currently further evaluated 
in a phase II trial. Associations with cetuximab 
are also promising, producing high response rates 
(62%) and prolonged survival (23 months). The 
French Intergroup has launched a phase II trial 
evaluating cetuximab with cisplatin-pemetrexed 
combined with concurrent radiotherapy to a total 
dose of 66 Gy (protocol IFCT 08-03). Overall, 
concurrent chemoradiation is the standard treatment 
of locally-advanced NSCLC. The recent and future 
optimization of radiation delivery and chemotherapy 
regimens allows signiÀcant improvements in tumor 
response rates and overall survival to occur in the 
majority of patients. These developments make 
radiotherapy one of most effective and promising 
curative option in thoracic oncology. 
Keywords: Radiotherapy, Lung cancer, 
Chemotherapy
dose delivered to the cardiac tissue is 40 Gy, with a 
cardiac V20 lower than 60%. Only limited data are 
available regarding the actual compliance of clinical 
trials with these quality control recommendations. 
Repositioning accuracy along treatment courses 
is crucial. Variations are estimated to be 6 mm on 
average, with errors higher than 10 mm in a third of 
the patients, for an estimated loss of tumor control 
up to 5%. Recently-developed cone-beam CT-scan 
allows highly accurate tridimensional veriÀcation of 
the position of the tumor volume and other organs 
before radiation delivery. Current optimization of 
radiotherapy include the development of Intensity 
modulated radiotherapy (IMRT), consisting of a 
real-time modeling of the contours and the amount 
of photons delivered within the radiation beam, 
using a programmed movement of the blades of 
the collimator. This allows the administration of 
beams of variable shapes during a single sequence, 
possibly proving to be helpful to target tumors that 
are close to critical tissues, including the heart, 
the spinal cord, or the brachial plexus. Our group 
reported the interest of IMRT and non coplanar 
Àelds to reduce lung and heart V20. Standard 
practice of radiotherapy is to deliver radiation under 
shallow breathing, and it is then necessary to add 
sufÀcient margins, so that the prescription dose is 
reached everywhere within the moving tumor. For 
intra-thoracic tumors, cranio-caudal breath-induced 
movements may range from 7 mm in the upper lobes 
to 65-70mm in the lower lobes. “4D techniques” 
are based on dosimetry performed at several times 
during the respiratory cycle, and determination of the 
best phase to deliver radiation. Several techniques 
have been reported: respiratory control, which 
involves assisted or voluntary blocking of respiration 
in a selected phase of the respiratory cycle; “Breathe-
Adapted RadioTherapy” or respiratory gating 
consists of activating the photon-beam only when 
the motion amplitude coincides with a pre-selected 
sector of the respiratory cycle; respiratory tracking 
involves intentionally moving the irradiating beam 
so that it follows the movement of the tumor. The 
typical device for 4D-techniques is a pneumotach 
apparatus with real-time visual monitoring. The 
clinical evaluation of 4D-techniques is currently 
ongoing. Another area of investigation is adaptative 
radiotherapy, a radiation-delivery process where 
the treatment plan is modiÀed repeatedly during the 
treatment course, using a systematic feedback of 
tumor response to re-optimize treatment plan. Such 
process requires cone-beam CT-scan imaging, and 
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of-care.1 Current surgical standard-of-care 
recommends a lobectomy rather than a wedge 
resection; in addition to an en bloc resection of the 
adjacent involved structures.1 Classically, the 
extensive posterior lateral approach has been used, 
but the anterior approach provides an additional 
opportunity using either a full or partial sternotomy 
or manipulations/resection of the clavicle to provide 
exposure to the upper extremity neural and vascular 
structures for various types of resection to be 
performed. Minimally invasive techniques have also 
been utilized to improve postoperative morbidity.7 
Incomplete resection appears to have little to no 
survival improvement compared with no resection.8 
With recent surgical advancements, the current 
contraindications to surgical resection, as they relate 
to Pancoast lesions, include metastatic disease, 
contralateral N3 disease, extensive brachial plexus 
and vertebral involvement and performance status 
greater than 2. Postoperative radiation therapy 
whether by external beam or brachytherapy does not 
appear to improve survival. Two-thirds of patients 
recur and of those two-thirds recur locoregionally. 
The brain is the most common site of recurrence, 40 
to 80% of those patients that recurred systemically, 
especially adenocarcinoma and large cell. The bone 
is the second most common site. In 110 selected 
patients with Pancoast NSCLC studied from 1995 to 
1999, the Àrst multi-institutional prospective 
Pancoast trial was performed by the Southwestern 
Oncology Group group (SWOG), S9416, with 
mediastinoscopy-deÀned absence of metastatic 
disease and were treated with etoposide and 
cisplatin, each 50 mg/m2 in 2 cycles over 6 weeks 
with concurrent 45 Gy radiation.9-10 80% were able to 
undergo thoracotomy and a 94% pathologically-
negative surgical margin (R0) rate. Of those that 
were resected, 36% (32/88) had a pathologic 
complete response (pCR), 56% were found to have 
either pCR or minimal disease. As a result of the 
induction therapy, no chest wall resection was 
necessary in 13 of 88(15%) resected patients. 
Induction-related mortality was 2.7%, 8.2% 
progressed on treatment and the surgical mortality 
was 2.3% with a 52% morbidity. 67% were capable 
of initiating the planned adjuvant two cycles of 
cisplatin and etoposide, but 45% completed it. The 
overall survival (OS) was 55% at 2 yrs and 70%, for 
those that had a pCR. R0 and pCR were risk factors 
for longterm survival. For those that relapsed, 
systemic recurrence signiÀcantly outnumbered local 
recurrence, nearly 6 to 1 and for those that recurred 
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Abstract: Pancoast or superior sulcus non-small cell 
lung cancer (NSCLC) is uncommon and a locally 
advanced form of lung cancer, because of its 
anatomical location, early diagnosis by radiological 
imaging and surgical resection alone is challenging. 
According to the ACCP guidelines, it is deÀned as an 
apical lung tumor that involves at the least the 
parietal pleura and above the level of the second rib.1 
The characteristic constellation of symptoms occurs 
in approximately 40% and is attributed to local 
invasion: radiating arm pain that may eventually 
develops into paresthesias, paresis and paralysis; 
Horner’s syndrome or components of it; and local 
chest wall or shoulder pain.2 The true incidence of 
Pancoast NSCLC is difÀcult to determine as apical 
non-locally advanced upper lung cancers are often 
misclassiÀed as Pancoast; thus, comparison analyses 
of single institution and retrospective trials provide 
only inferences to the true issues for Pancoast 
patients. In the 6th AJCC staging system those factors 
conferring a poor prognosis include: T4 compared 
with T3, advanced nodal involvement, subclavian 
vascular invasion, Horner’s syndrome and longer 
duration of symptoms. Prior to the 1950s, these 
patients were considered inoperable, survival 
estimates were 10-14 months after diagnosis in 
untreated patients.3 Then, 65 Gy of postsurgical 
adjuvant radiation was found to achieve longterm 
survival.4 In the 1960s, chemotherapy combined with 
radiation, 30-35 Gy, noted survival improvement in a 
small group of patients.5 Chemotherapy and radiation 
or radiation alone without surgery, although 
palliative, have not consistently improved survival or 
quality-of-life (QOL), especially in those patients 
with rib destruction, scalene node involvement, poor 
performance status and a weight loss greater than 5% 
of baseline.6 Now, for those undergoing a curative 
attempt, trimodality therapy is considered standard-
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biological and anatomical/physiological features of 
the location of origin. None of the prospective phase 
II trials included PET, EBUS/EUS and none 
speciÀcally reported on the quality of their 
lymphadenectomy. However, with the positive 
results of the large recently reported intergroup trial 
and the European cooperative group trial, patients 
with non-bulky and non-multi-station N2 disease are 
likely to have a beneÀcial effect with induction 
therapy.12-13 Further research is necessary with 
current and more aggressive mediastinal staging. In 
conclusion, the 3 well-performed focused phase II 
Pancoast trials have demonstrated that few patients 
progress or die using concurrent induction 
chemoradiotherapy. Resectability is 70-80%. The R0 
rate is approximately 90% and 10-20% of patients 
will be able to avoid chest wall resection. It is 
unclear whether adjuvant chemotherapy provides 
any survival advantage and also unclear how to treat 
the patients with surgical residual disease. In the 
future, opportunities for research in this patient 
population are signiÀcant. A combination of 
minimally invasive surgical techniques as well as 
more aggressive and consistent surgical methods and 
the type, timing and sequence of chemotherapy, 
especially utilizing the more recently discovered 
biomarker-directed therapy may increase 
respectability and the rate of surgical cure. . Over the 
last 15 years we know much more about the 
prevention and treatment of induction-related side 
effects and providing patients with supportive 
management to improve survival and QOL. 
Intensity-modulated radiation therapy is likely to 
improve the effectiveness, yet reduce the 
complication rate and possibly allow increased 
radiation doses to achieve pCR. PET, EBUS/EUS 
and brain MRI have been more recently introduced 
and consistently used in the evaluation of the 
Pancoast NSCLC patients. Additionally, the use of 
circulating biomarkers and tumor cells may all 
provide prognostic and treatment-related information 
to improve results. Hopefully, bringing all of these 
techniques to bear will provide a superior long-term 
survival. 1. Shen KR, Meyers BF, Larner JM, Jones 
DR. Special treatment issues in lung cancer: ACCP 
evidence-based clinical practice guidelines (2nd 
edition). Chest 2007;132:290S-305S. 2. Arcasoy SM, 
Jett JR. Superior pulmonary sulcus tumors and 
Pancoast’s syndrome. The New England journal of 
medicine 1997;337:1370-6. 3. Paulson DL. The 
survival rate in superior sulcus tumors treated by 
presurgical irradiation. Jama 1966;196:342. 4. Haas 
systemically, nearly 1/3 occurred in the brain only. 
These recurrent tumor results were dramatically 
different from those found in the case-controlled 
observations previously reported. The Japan Clinical 
Oncology Group study (JCOG) 9806 conÀrmed the 
SWOG Àndings in a similar phase II trial with 
clinically negative mediastinums, the Pancoast 
patients were treated with 2 cycles of 
mitomycin,vincristine and cisplatin combined with 
concurrent 45 Gy of radiation over a 6 week time 
period.11 In contrast to S9416, this trial included 
patients that supraclavicular lymph node 
involvement (ipsilateral N3). Resection was 
performed 2-4 weeks after the last radiation dose. 
95% of patients completed induction therapy with a 
1.3% mortality. 76% underwent thoracotomy and 
68% of all eligible patients had an R0 resection with 
16% (12/75) of them having a pCR, 21% of those 
that were resected. The 3- and 5-yr survival was 61% 
and 56%, respectively. Survival with and without 
pCR was 70% and 24%, respectively. 52% relapsed, 
13% locoregionally alone and 27% systemically 
alone and 12% with both local and distant relapse. 
Given some initial positive results from locally 
advanced NSCLC clinical trial, consolidative therapy 
with docetaxel was added to the regimen studied in 
S9416 and in a phase II fashion in S0220. In 44 
evaluable patients, 84% completed therapy. 66% 
underwent thoracotomy and all had an R0 resection 
with a 66% pCR. 45% of the patients enrolled 
underwent consolidative therapy, 69% of those that 
underwent surgical resection. The 3-yr OS was 60%. 
The use of consolidative therapy in this group of tri-
modality treated Pancoast patients appears less 
favorable. The long-term results of this patient 
population are soon to be published. From the 
prospective data to date, induction therapy appears to 
improve Pancoast resectability, increases the pCR 
and thus improves longterm survival likelihood. 
Local recurrence is reduced and quality-of-life 
appears to be improved. It is estimated that in the 
highly selected group of surgical patients with 
Pancoast disease that N2 disease is approximately 
10-20%. However, in the single institution and 
retrospective case control series, there is inconsistent 
deÀnition of Pancoast tumors and unbiased means to 
conÀrm it and inconsistent means of staging the 
mediastinum both clinically and surgically, thus we 
do not know the true rate of N2 disease in Pancoast 
NSCLC. Likely, the rate is greater than in other 
locally advanced disease possibly due to the 
insidious nature of Pancoast NSCLC or to the 
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Abstract: Treatment strategy for Pancoast tumor 
Young Mog Shim, MD, PhD Department of 
Thoracic and Cardiovascular Surgery, Samsung 
Medical Center, Sungkyunkwan University School 
of Medicine, Seoul, Republic of Korea Non-small 
cell lung cancer (NSCLC) of the superior sulcus, 
also known as Pancoast tumor is one of the most 
challenging thoracic malignant diseases because of 
their frequent invasion of adjacent vital structures 
such as the subclavian vessels, brachial plexus, 
and spine. In 1932, a radiologist, Henry Pancoast 
originally described this tumor as a carcinoma 
(of uncertain origin) arising in the extreme apex 
of the chest, associated with shoulder or arm 
pain, atrophy of the hand muscles, and Horner’s 
syndrome.1 The clinical manifestation of the 
Pancoast syndrome consists of a constellation of 
characteristic symptoms, including pain down 
the arm, weakness and numbness along the 
distribution of C8/T1–2, Horner’s syndrome and 
radiographic evidence of destruction of the Àrst 
rib or vertebral body. However, any patients with 
a tumor in the typical location of the apex of the 
lung and inÀltration of the Àrst rib are diagnosed 
with a Pancoast tumor, regardless of whether 
Horner’s syndrome or pain radiating down the arm 
is present. Thorough preoperative assessment is 
mandatory because superior sulcus NSCLC are, 
by deÀnition, cancers of stage IIB or greater and 
surgery can lead to substantial morbidity. CT of 
the chest and upper abdomen, whole-body PET, 
and brain MRI need to be done to investigate the 
primary tumor and mediastinal lymph nodes and to 
rule out the possibility of extrathoracic metastasis. 
Since Pancoast tumors with mediastinal nodal 
metastases (N2 or N3 disease) do not usually beneÀt 
from surgical resection due to a poor prognosis, 
mediastinoscopy is needed to conÀrm the presence 
of mediastinal involvement. In addition, the degree 
of nerve-root involvement should be assessed 
through careful neurological evaluation. Resection 
of the T1 nerve root is generally well tolerated, but 
injury to the C8 root or lower trunk of the brachial 
plexus results in signiÀcant sequelae, including 
loss of hand and arm function. Pain extending 
along the ulnar aspect of the forearm and hand is 
consistent with T1 involvement and intrinsic hand 
muscle weakness implies the C8 root or lower 
trunk is affected. Pulmonary function tests and 
cardiac risk evaluation need to be done to assess 
whether patients can tolerate pulmonary resection. 
Initially, Pancoast tumors were considered to be 
LL, Harvey RA, Langer SS. Radiation Management 
of Otherwise Hopeless Thoracic Neoplasms. Journal 
of the American Medical Association 1954;154:323-
6. 5. Shaw RR, Paulson DL, Kee JL. Treatment of 
Superior Sulcus Tumor by Irradiation Followed by 
Resection. Annals of surgery 1961;154:29-40. 6. 
Millar J, Ball D, Worotniuk V, Smith J, Crennan E, 
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lung carcinoma. Australasian radiology 1996;40:55-
60. 7. Truin W, Siebenga J, Belgers E, Bollen ECM. 
The role of video-assisted thoracic surgery in the 
surgical treatment of superior sulcus tumors. 
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2010;11:512-4. 8. Ginsberg R, Martini N, Zaman M, 
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2007;25:313-8. 11. Kunitoh H, Kato H, Tsuboi M, et 
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disease or tumor regression underwent anatomical 
pulmonary resection followed by two additional 
cycles of chemotherapy. Of the 110 patients enrolled, 
83 (75%) underwent thoracotomy, the induction 
regimen was well tolerated and only Àve patients 
had grade 3 or higher toxic effects. A third of 
patients had a complete pathologic response (n=28) 
and another third (n=26) had minimum residual 
microscopic disease in the resected specimen. 
Based on this trial, concurrent chemoradiation 
followed by surgical resection and chemotherapy is 
currently recommended for patients with resectable 
tumors of the superior sulcus. However, patients 
with marginally resectable superior sulcus tumors 
should undergo concurrent chemoradiation before 
surgical re-evaluation. Furthermore, for patients 
with unresectable tumors in the superior sulcus, 
deÀnitive radiotherapy with chemotherapy is 
recommended. Therefore, when considering the 
appropriate approach for superior sulcus tumors, it 
is important to determine whether patients would 
beneÀt from surgical resection, which can be 
inÁuenced by the chances of complete resection and 
the presence of mediastinal lymph node metastasis. 
During the past 40 years, the development of 
effective combined modality treatments and of new 
surgical approaches has substantially increased 
local control and overall survival for patients with 
these tumors. Future studies are needed to address 
the continuing difÀculties of systemic relapse after 
surgery. References 1. Pancoast HK. Superior 
pulmonary sulcus tumor. JAMA 1932;99:1391-1396. 
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the superior sulcus tumor by irradiation followed 
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inoperable and incurable. However, since Shaw 
and Paulson reported 18 patients who received 
radiotherapy followed by complete en-bloc resection 
with excellent local control and favorable survival 
in 1961,2 induction radiotherapy (30 Gy over 2 
weeks) and en-bloc resection via an extended 
posterolateral thoracotomy became the standard for 
superior sulcus NSCLC and for the next 30 years, 
the basic therapeutic strategy for these tumors 
remained unchanged. Several studies based on this 
strategy showed similar results to those of Shaw 
and Paulson, and they deÀned adverse prognostic 
factors, including presence of mediastinal nodal 
metastases, spine or subclavian vessel involvement, 
and incomplete resection.3-5 In the largest series 
from Memorial Sloan-Kettering Cancer Center,4, 
5 which included 225 patients treated between 
1974 and 1988, although operative mortality was 
low (4%), complete resection was achieved in 
only 64% of T3N0 and 39% of T4N0 tumors and 
locoregional recurrence was common. These results 
underscored the need for new treatment strategies 
to increase both local control and overall survival. 
During the late 1980s and the 1990s, several 
thoracic surgical groups developed new approaches 
for resection of superior sulcus tumors. Dartevelle 
and colleagues developed an anterior transcervical 
method for cancers affecting the subclavian vessels.6 
This led to widespread acceptance of the anterior 
approach and its modiÀcations including the 
transmanubrial osteomuscular sparing approach, 
addition of posterior or anterolateral thoracotomy 
to facilitate exposure to the lung and spine, and 
use of hemiclamshell thoracotomy. However, 
although development of these approaches for 
complete resection of superior sulcus tumors was 
a major advance in surgical management of these 
technically challenging tumors, overall survival at 5 
years remained approximately 30% even in highly 
selected patients. During the 1980s and 1990s, the 
success of combined modality treatment for stage 
IIIa (N2) NSCLC led to the development of a large, 
prospective, multicenter, phase II trial (Southwest 
Oncology Group 9416, INT 0160).7 Induction 
chemoradiation followed by surgery is a logical 
treatment strategy for the superior sulcus tumors, 
because local control is a challenge for these tumors. 
In this trial, 110 eligible patients were enrolled 
with mediastinoscopy negative, clinical T3-4 N0-1 
superior sulcus tumors. Induction therapy included 
two cycles of etoposide and cisplatin with 45 Gy 
of concurrent radiotherapy. Patients showing stable 
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targeted therapies. An example is mutation analysis 
of the EGFR gene, which is routinely used in many 
pathology laboratories to guide treatment with 
an EGFR TKI in speciÀc clinical situations. The 
expectation is that in the near future the number 
of targets to be tested with molecular methods 
will increase. For example, testing for the EML4-
ALK translocation via FISH may be indicated in 
a well deÀned subgroup of tumors. In addition, 
the evolving genome-wide platforms for analysis 
of gene expression signatures, post-translational 
modiÀcations, as well as chromosomal, mutation, 
DNA methylation and protein proÀling will result 
in novel analyses to be applied to tissue samples, 
all having their own requirements in terms of tissue 
quality, quantity and processing. Most molecular 
methods are non-morphology-based, and require 
extraction of target material (DNA, RNA or protein) 
from the tumor sample. For many applications 
Àxation with buffered formalin is far from ideal or 
even disastrous, because it induces cross-linking 
and fragmentation of these bio-molecules. It is well 
known that for reliable mRNA analysis samples 
ideally should be snap-frozen. Many DNA analyses, 
on the other hand can be applied to formalin-Àxed, 
parafÀn-embedded (FFPE) tissue, as long as the 
degree of DNA fragmentation does not interfere 
with the quality of the assay. Mutation analysis of 
the EGFR gene can be done on FFPE tissue since 
this method is applied to short fragments of target 
DNA that are pre-enriched by PCR for the various 
exons or parts thereof. All molecular methods 
have their sensitivity limits and require minimal 
amounts of input material. Since the integrity of 
DNA is affected by formalin, more input from 
FFPE specimens than from frozen specimens is 
required to get equally reliable results. In addition, 
admixture of too many normal cells with tumour 
cells in a tissue specimen can result in a failure 
to detect the tumor-speciÀc alteration since it is 
masked by the wild-type genotype represented by 
the normal cells. In some instances pathologist-
guided macro- or micro-dissection of tumor cell 
areas from tissue sections is necessary to enrich for 
tumor cells. Clinical Evidence Supporting Tumor 
Characterization: The response rates to, and risks 
of, various systemic agents have been shown to be 
linked to histology. Examples include the improved 
response rates to pemetrexed in patients with 
adenocarcinoma, and the improved survival of those 
with non-squamous histologies when bevacizumab 
is added to standard care. In addition, knowledge of 
chemoradiation and surgical resection for non-small 
cell lung carcinomas of the superior sulcus: initial 
results of Southwest Oncology Group trial 9416 
(intergroup trial 0160). J Thorac Cardiovasc Surg 
2001;121:472-483. 
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Abstract: The Promise of Personalized Care: 
There have been many advances in our ability to 
characterize lung cancer, and our understanding of 
the importance of doing so. These advances have 
been fostered by progress in our knowledge of 
the pathophysiologic mechanisms responsible for 
lung cancer development and treatment response, 
the availability of new technologies, and the 
application of this knowledge in clinical trials. To 
meet the promise of personalized care the multiple 
disciplines involved in the evaluation and treatment 
of lung cancer must carefully synchronize the 
steps required to characterize each lung tumor. In 
this session we will discuss the principle of novel 
molecular techniques, the processing requirements 
necessary to apply these methods, the clinical 
evidence supporting tissue characterization, and the 
ability of available lung tissue sampling methods to 
provide tissue for modern analyses. Novel Molecular 
Techniques, Principle and Processing: Classically, 
lung tumor tissue is required to conÀrm a diagnosis 
of lung cancer, via standard light microscopy +/- 
immunohistochemistry (IHC). The introduction of 
novel classes of therapeutic agents, effective in only 
subgroups of patients, has rapidly changed clinical 
practice. Companion diagnostics with molecular 
methods are necessary to select those patients who 
will derive the greatest clinical beneÀt from these 
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advances in tumor characterization have changed 
the way we evaluate and treat lung cancer. The 
application of new molecular tools requires careful 
interaction between personnel from all specialties 
involved in lung cancer management to ensure tissue 
is appropriately sampled, handled, and tested 
Keywords: molecular tools, tissue requirements
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Abstract: The mediastinum is deÀned as the 
anatomical compartment between both lungs. 
Mediastinal tumors rarely occur but are fascinating 
due to their surprising complexicity and variety 
in many different ways. Variety of mediastinal 
compartments and organs Although no universal 
agreement exists, the mediastinum is commonly 
divided into a superior compartment above a 
straight line from the sternal angle of Louis to the 
vertebral column and an inferior part below this 
imaginary line. The latter is composed of an anterior 
compartment in front of the heart, a middle at the 
level of the heart, and a posterior part lying behind 
the heart. Each compartment contains different 
organs and structures, varying from heart and great 
vessels to lymphatic tissue and pluripotent cells. 
Variety of histologic types and tumours As well 
in young as old patients, a lot of different primary 
tumors and cysts are encountered in the mediastinum 
and these are summarized in table 1. Also metastases 
may occur in the mediastinum. Variety of symptoms 
Mediastinal tumors can grow to a large size before 
symptoms appear. Pressure on surrounding structures 
may result in hoarseness, dyspnea, dysphagia and 
superior vena cava syndrome. Various paraneoplastic 
syndromes have been described as myasthenia gravis 
and pure red cell aplasia in case of thymoma. Variety 
of diagnostic means Chest computed tomography 
(CT), magnetic resonance imaging and positron 
emission tomography provide exact anatomical 
tumor histology now allows us to selectively apply 
molecular testing to tumors more likely to show a 
given molecular alteration. EGFR mutations and 
EML4-ALK translocations occur almost solely 
in adenocarcinomas. Those with mutations in the 
EGFR and those who harbor the EML4-ALK 
translocation have been shown to beneÀt from Àrst-
line therapy with agents targeting these pathways. 
Multiple additional biomarker signatures are being 
studied, capable of predicting response to therapy, 
prognosticating outcomes, or identifying targets for 
future targeted therapies. Capability of Lung Tissue 
Sampling Methods to Support Modern Analyses: 
The majority of lung cancers are diagnosed by non-
surgical biopsies, since they are locally advanced or 
metastatic at the time of presentation. Non-surgical 
approaches include bronchoscopy and transthoracic 
needle biopsies. Recent advances in bronchoscopic 
sampling of lung nodules include nodule targeting 
via electromagnetic navigation and peripheral 
ultrasound. These techniques have improved 
the yield of bronchoscopy for smaller, more 
peripheral lung nodules. Endobronchial ultrasound 
and endoscopic ultrasound guided sampling of 
mediastinal and hilar lymph nodes allow real-time 
visualization of biopsies from these sites. EBUS 
and EUS have greatly improved the diagnostic 
yield of endosonographic sampling of intrathoracic 
adenopathy. Rapid on-site evaluation (ROSE) of 
cytology specimens obtained during non-surgical 
biopsies has been shown to improve the yield of 
testing and shorten the length of these procedures. 
In addition to advances in non-surgical approaches, 
video assisted approaches have been able to reduce 
complications and length of stay related to surgical 
biopsy. Several authors have reported the yield from 
small, non-surgical biopsies for the diagnosis of 
lung cancer, histologic classiÀcation, and molecular 
testing. The results have shown promise for the 
ability of these procedures to obtain adequate tissue 
to assist with modern analyses. An approach to tissue 
sampling for lung cancer now needs to consider 
molecular testing when determining how many 
samples to take. A practical approach would be to 
take 2-4 extra samples after a diagnosis is likely to 
have been established, so that material is available 
and can be appropriately processed for additional 
testing. Currently, it is not clear if the molecular 
changes within a lung cancer are heterogeneous 
frequently enough between the primary site, 
mediastinal nodes, and metastatic sites, to warrant 
sampling of more than one area. Summary: Recent 
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international collaboration and deÀne uniform 
standards in diagnosis and treatment of these tumors. 
References 1. Date H. Diagnostic strategies for 
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Superior mediastinum Substernal goiter Ectopic 
thyroid 
Inferior mediastinum Anterior Thymoma Thymic cyst Germ 
cell tumors Pleuropericardial 
cysts 
Middle Lymphoma Bronchogenic cyst 
Posterior Neurogenic tumors 
Enterogenic cysts 
Keywords: mediastinal tumors, Thymoma
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Abstract: Mediastinal tumors encompass a variety 
of histologies and may be primary, metastatic 
or result from direct invasion. Compared with 
intrapulmonary lesions mediastinal tumors are 
rare. Due to the proximity of vital structures 
mediastinal lesions and complexity of anatomy 
it is sometimes challenging to diagnose and treat 
those lesions. On the one hand, size and location 
within the speciÀc mediastinal compartment often 
give a hint on its nature. On the other hand, tumors 
may expand and thus grow beyond compartment 
boundaries which makes evaluation and treatment 
more difÀcult. This overview is directed towards 
rare primary lesions. The anterior mediastinum 
is the most common site of primary mediastinal 
lesions and more than 50% are malignant. The most 
common lesions are thymic tumors, lymphomas, 
germ cell tumors, cysts and parathyroid adenomas. 
Malignant tumors are more likely to cause symptoms 
than benign lesions. Differential diagnosis of 
tumors in the middle mediastinum has to take into 
account lymphomas, granulomas and cysts like 
bronchogenic, pericardial and esophageal cysts. In 
the posterior mediastinum predominantly neurogenic 
tumors exist. All compartments alone or together 
may be the origin of still less common tumors, 
delineation of a tumor and may suggest a speciÀc 
entity. To obtain a precise histological diagnosis, 
CT-guided puncture, endoscopic or endobronchial 
ultrasound, mediastinoscopy, mediastinotomy and 
video-assisted thoracic surgery are utilized (1). In 
case of suspicion of lymphoma, germ cell tumor 
or thymoma, large biopsies are required. Well-
circumscribed tumors in young patients should 
be excised at once not to breach the surrounding 
capsule. Variety of therapeutic strategies Operable 
lesions are treated by surgical excision. Minimally 
invasive and even robotic techniques can be applied 
if a complete resection can be obtained by this 
approach. In case of incomplete resection or capsular 
invasion adjuvant radio- or chemotherapy may be 
indicated. Inoperable lesions and lymphomas are 
treated by a combination of chemo- and radiotherapy. 
In selected cases induction therapy may be a valid 
approach to downstage a locally aggressive tumor. 
Salvage surgery may be attempted in tumors that are 
not responsive anymore to chemo- or radiotherapy. 
Long-term survival depends on histologic type and 
completeness of resection. Thymoma Thymomas 
are rare intrathoracic tumors but they are the most 
common tumors in the anterior mediastinum. 
Commonly used staging systems include the 
Masaoka – Koga and World Health Organisation 
(WHO) classiÀcations, based on peroperative and 
pathological Àndings. Surgery is the cornerstone of 
the management of thymomas, initially being useful 
for precise pathological diagnosis and staging, and 
in most cases ensuring at the same time the Àrst-line 
therapy (2). Complete resection is, after tumor stage, 
the most constant and signiÀcant prognostic factor 
for progression-free and overall survival. Adjuvant 
radiotherapy is recommended in incompletely 
resected thymomas. In primary unresectable 
thymomas, multimodal strategy nowadays include 
induction chemotherapy, extensive surgery, 
adjuvant radiotherapy, and in some cases, adjuvant 
chemotherapy. Most popular chemotherapy regimens 
make use of cisplatin, adriamycin, etoposide, 
cyclophophamide or ifosfamide. The management of 
thymomas requires cooperation between clinicians, 
surgeons, and pathologists from establishing the 
diagnosis to organizing the therapeutic strategy and 
evaluating the prognosis. As a consequence of their 
rarity, no prospective randomized trials are available 
and collaborative studies are warranted in order to 
evaluate and improve current therapeutic standards. 
Recently, the International Thymic Malignancies 
Interest Group (ITMIG) was created to stimulate 
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stage, which needs non-surgical treatment Àrst and 
sometimes salvage surgery when a good response is 
documented. A variety of procedures with speciÀc 
diagnostic yield and inherent risks exist (Àne-needle 
aspiration, core needle biopsy, incisional biopsy 
via mediastinoscopy/parasternal mediastinostomy/
video-assisted thoracoscopy). The choice of biopsy 
technique depends on the localization of the tumor, 
clinical aspects and the condition of the patient and 
the availibility of techniques. Fine-needle aspiration 
may be performed by endo-esophageal ultrasound 
(EUS) or endo-bronchial ultrasound (EBUS), 
however the diagnostic yield is dependent on the 
experience of the investigator and the pathologist 
and does not reliably distinguish between thymoma 
and lymphoma. Incisional biopsies, especially 
during transpleural approach, bear the risk of tumor 
implants and pleural dissemination. Decision 
making for the surgeon: Since the introduction 
of video-assisted thoracoscopy the threshold for 
direct exploration and surgical removal has been 
lowered. Today, for patients with mediastinal cysts 
or solid capsulated tumors with short diameters 
in any compartment extirpation by VATS prior to 
biopsy has become standard, being both diagnostic 
and therapeutic. Thymic carcinomas, thymomas, 
germ cell tumors and lymphomas in their advanced 
stages may have similar radiographic appearance 
but different treatment algorithms. Therefore, clear 
histologic diagnosis is required. 
Keywords: mediastinum, tumor, radiologic 
appearance, role of surgery
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Abstract: Transforming rearrangements of the 
anaplastic lymphoma kinase (ALK) gene have been 
recognized in a subset of human hematological 
and solid malignancies (1). In 2007, an ALK gene 
among these leiomyosarcomas, paragangliomas and 
others. From a practical point of view the following 
questions come up when a mediastinal tumor is 
detected by chest radiograph and conÀrmed by CT 
scan and/or MRI: 1) is any further imaging test (e.g. 
PET, Sestamibi) useful, available and necessary? 
2) Should AFP, beta-HCG or serum calcium 
levels be checked? 3) Is the lesion encapsulated 
or more likely to inÀltrate adjacent structures thus 
indicating technical difÀculties in terms of removal 
or inoperability? 4) If encapsulated, should the 
lesion be removed without prior biopsy? 5) If 
pre-therapeutic pathological typing is regarded 
as mandatory, which mode of biopsy is useful? 
1) Extent, morphology, density and relation to 
surrounding structures will be evaluated by CT scan 
and MRI. PET is helpful for staging in patients with 
(suspected) malignant thymic tumors. Sestamibi is 
recommended for localizing parathyroid tissue. 2) 
Increased AFP- and beta-HCG-levels are present 
in most patients with non-seminomatous germ 
cell tumors, whereas a minority of patients with 
seminomas has increased beta-HCG-, but never 
elevated AFP- levels. Serum calcium might lead to 
detection of parathyroid adenoma. 3) Encapsulated 
solitary tumors with normal AFP- and beta-HCG-
levels most often correspond to thymic tumors 
or mature teratomas if located in the anterior 
mediastinum. Cystic lesions are typically well-
demarcated. Tumors in the posterior mediastinum 
especially when located in the paravertebral 
region qualify for direct surgical exploration. 4) 
Since seminomas are sensitive to chemo- and 
radiotherapy, they should be veriÀed by biopsy 
when beta-HCG-levels are elevated. In patients with 
non-seminomatous germ cell tumors, identiÀed by 
elevated AFP- and beta-HCG-levels, chemotherapy 
may be initiated without prior conÀrmation. 
Residual tumor should undergo complete surgical 
removal. As far as an intraspinal extension of a 
tumor in the paraspinal compartment can be safely 
excluded, it may be assumed that the tumor can be 
completely removed by a transpleural approach, 
otherwise a combined neurosurgical/thoracic surgical 
procedure is necessary. 5) Since primary mediastinal 
lymphomas like Hodgkin disease and B-cell-
lymphoma are Àrst of all „non-surgical“ diseases, a 
tissue diagnosis is mandatory whenever the CT scan 
shows a lesion that extends symmetrically to the 
hilar regions and/or indicates involvement of other 
vital structures. An important differential diagnosis 
is a malignant thymoma/thymic carcinoma of higher 
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evaluation of ALK expression in anaplastic large 
cell lymphoma and inÁammatory myoÀbroblastic 
tumors, was found to be unreliable in NSCLC (17). 
Recently, the mouse monoclonal anti-human antibody 
CD246 (clone 5A4; Novocastra) and the rabbit 
monoclonal anti-human CD246 (clone D5F3; Cell 
Signaling Technology) have been shown to detect 
ALK fusion protein in lung adenocarcinomas with 
very high sensitivity and speciÀcity (16, 17). As ALK 
immunoreactivity shows heterogeneous staining 
pattern, the scoring system including the intensity 
and frequency of staining to assign semiquantitative 
scores (0 to 3+) improves the positive predictive value 
of ALK FISH results (16). Additionally, complex 
strategies to improve the accuracy of ALK protein 
detection in lung cancer including ampliÀcation of the 
signal with a tyramide cascade (13) or intercalation of 
an antibody-enhanced polymer (8) also seems to be 
advantageous.
Detection of ALK rearrangement by FISH using 
commercially available break apart ALK probe 
(Abbott Molecular) has been the method of choice 
for patient selection in current clinical trials. Scoring 
of a minimum of 50 tumor cells is recommended 
and a specimen is considered positive for ALK 
rearrangement when >15% of the cells show split 
signals or single red (3’ ALK) signals (13, 16, 18, 
19). However, because the EML4 and ALK loci are 
mapped relatively close on 2p, the interpretation of 
a positive rearrangement through the introduction of 
a gap between the red and green probes in formalin-
Àxed, parafÀn-embedded tissue sections can be 
challenging. This distance is estimated using the 
signal size as a reference, therefore analyses must 
be performed by experienced laboratory personnel. 
Moreover, it is recommended that a 2-person scoring 
approach be adopted when the percentage of positive 
cells is close to the cut-off due to the subtle nature of 
some positive cases. Customized FISH strategies have 
also been proposed to overcome this limitation (18-
20) but no approach has reached clinical validation.
In this session, Dr. Chung will present results 
indicating that ALK IHC scoring is a robust measure 
of the protein overexpression to predict ALK 
rearrangement and might be useful in selecting 
lung cancers for speciÀc targeted therapy. The ALK 
IHC scoring can be especially helpful in assessing 
diagnosis in a range of settings, for instance, in 
patients with adenocarcinoma histology and never-
smokers to minimize tissue loss by repeated genetic 
analysis in the small biopsy samples. Dr. Varella-
Garcia will discuss technical details, explore the 
rearrangement creating an in-frame fusion protein 
between echinoderm microtubule-associated protein-
like 4 (EML4) and ALK was described in NSCLC 
(2). The novel fusion gene arose from an inversion on 
2p [inv(2)(p21p23)] that joined exons 1–13 of EML4 
to exons 20–29 of ALK. In consequence, the ALK 
tyrosine kinase domain is constitutively activated as 
well as the downstream signaling pathways of MAPK, 
PI3K/AKT, and STAT3 (2-4). Since then, numerous 
transforming in-frame fusion variants involving 
different breakpoints in EML4 and ALK and other 
fusion partners, including TFG, KIF5B, and PPFIBP1 
have been described in NSCLC (2-10).
Detection of ALK gene fusions is currently indicated 
as a predictive marker of treatment response to small 
molecule inhibitors of ALK in NSCLC. A recent 
Phase I study evaluating the role of Crizotinib, a 
potent dual inhibitor of ALK and MET, in NSCLC 
found complete or partial response in the majority 
of ALK-rearranged tumors (11). International 
randomized Phase II and III studies comparing the 
efÀcacy of Crizotinib therapy to standard second-
line chemotherapy in ALK FISH positive advanced 
NSCLC patients are underway. The overall incidence 
of ALK gene rearrangements in NSCLC is low 
(<5%) (12); however, is signiÀcantly higher in 
adenocarcinomas with further notable predilection for 
acinar and solid histologic subtypes with signet-ring 
features (12-14). Higher rates of ALK rearrangement 
are encountered in never/light smokers while 
discordant Àndings are reported in relation to age, 
gender, and stage (15, 16).
In this period of personalized health care, the ability 
to accurately identify patients as truly positive or 
negative for ALK rearrangement is essential for 
appropriate therapy selection and outcome assessment. 
For that purpose, the pathologist’s role is becoming 
more crucial than ever. Since the clinical and 
demographic features of the ALK-enriched patients 
group is overlapped with EGFR-mutated NSCLC, 
the establishment of strategies for identiÀcation of 
ALK-rearranged lung cancer has been of great clinical 
interest and become a critical issue. Studies so far 
have indicated a need to improve stratiÀcation of 
these patients to guide the most appropriate speciÀc 
therapies in small biopsy samples and other routine 
anatomic pathology pulmonary specimens such as 
cytology cell blocks and touch preparations.
Detection of ALK overexpression by 
immunohistochemistry (IHC) has been largely 
explored. Early on, the mouse monoclonal anti-human 
CD246 (clone ALK1; Dako) antibody, utilized for 
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challenging, for it entails many aspects, related to 
both patients’ and physicians’ perceptions, mentality 
and expectations.
Estimation of cardiac risk
Risk assessment for pulmonary resection must 
include a preliminary cardiac evaluation. Patients 
deemed at prohibitive cardiac risk should be 
evaluated and treated as per American Heart 
Association/American Society of Cardiology 
guidelines. Those with low cardiac risk or with 
optimized treatment can proceed with pulmonary 
assessment.
For patients whose exercise capacity is limited, 
those with a RCRI  2 or those with known or newly 
suspected cardiac condition, non-invasive cardiac 
evaluation is designed to identify the relatively 
small proportion of patients needing intensiÀed 
interventions to control heart failure or arrhythmias 
or to treat underlying myocardial ischemia. 
Appropriately aggressive cardiac interventions 
should be instituted prior to surgery in patients who 
would need them irrespective of the planned surgery. 
However, prophylactic coronary revascularization 
prior to surgery in patients who otherwise do not 
need such a procedure does not appear to reduce 
perioperative risk.
Systematic measurement of DLCO
Carbon monoxide lung diffusion capacity (DLCO) 
has Àrstly been shown to be a predictor of adverse 
outcomes after pulmonary resection in the 1980s’.
Predicted postoperative DLCO (ppoDLCO), 
calculated in the same manner as ppoFEV1, has 
been shown to be a reliable predictor of pulmonary 
complications and mortality by several investigators. 
However, until now, DLCO measurement has been 
mainly reserved to patients with abnormal FEV1 
based on the wrong assumption that FEV1 and 
DLCO are correlated parameters. Indeed, recent 
papers have shown that the correlation coefÀcients 
between FEV1 and DLCO in different subsets of 
lung resection candidates are invariably below 0.5, 
indicating poor correlation and that Indeed a more 
than 40% of patients with normal FEV1 (>80%) may 
have DLCO < 80%. More studies have demonstrated 
that a reduced ppoDLCO is a reliable predictor of 
cardiopulmonary morbidity and mortality not only 
in patients with reduced FEV1 but also in those 
with normal respiratory function. Hence there is no 
justiÀcation to reserve this test to selective group of 
patients with compromised FEV1. This parameter 
should be measured in all lung resection candidates.
The role ppoFEV1
advantages and examine strategies to overcome 
limitations of the FISH platform.
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Abstract: Introduction Determining the risk for 
pulmonary resection in patients with lung cancer is 
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continuous monitoring of various cardiologic 
and pulmonary parameters, it is standardized and 
easily reproducible in different settings, and in 
addition to VO2peak, which certainly remains the 
most important parameter associated with exercise 
capacity, it provides several other direct and derived 
measures that permit, in case of a limited aerobic 
reserve, to precisely identify possible deÀcits in 
the oxygen transport system. The use of CPET 
appears therefore of particular importance in those 
patients deemed at high surgical risk. Indeed the 
recently published ERS-ESTS functional guidelines 
recommended its use in patients with cardiac 
co-morbidity or impaired pulmonary function or 
both, and in those patients with a reduced exercise 
tolerance at low-technology exercise tests (such 
as stair climbing test or shuttle walk test). It is 
generally accepted that a VO2peak above 20 ml/
kg/min or greater than 75% of predicted represents 
a safe threshold to undergo any kind of pulmonary 
resection. On the other hand, a value below 10 ml/
kg/min or lower than 35% of predicted usually 
contraindicates a major pulmonary resection. 
Selected reference
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Faivre-Finn C, Huber RM, Clini EM, Win T, De 
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Predicted postoperative FEV1 (ppoFEV1), estimated 
by taking into account the number of unobstructed 
segments to be removed during operation, has 
represented the pivotal parameter in preoperative 
evaluation.
Most recent evidences however have shown its 
limited role in patients with pulmonary obstructive 
disease and airÁow limitation both in terms of 
prediction of surgical risk and in the estimation 
of deÀnitive residual pulmonary function. In this 
regard, several studies have shown the minimal loss 
or even the improvement of FEV1 after pulmonary 
lobectomy in the obstructed patients, questioning 
the traditional operability criteria mostly based on 
pulmonary expiratory measures. Nearly one third of 
COPD patients may actually improve their FEV1 3 
months after pulmonary lobectomy for cancer.
Owing to the scarce ability to predict the surgical 
risk in these patients ppoFEV1 should not be used 
alone for patients selection.
Exercise tests: the global physical assessment
Exercise testing is increasingly used in the 
preoperative evaluation of lung resection candidates, 
since it allows global assessment of the physical 
Àtness.
Low-technology tests such as stair climbing test and 
shuttle walk test can provide only a rough estimation 
of the aerobic capacity of the patients without 
providing much information on the causes that are 
behind the performance.
They are typically ideal as screening tests, but for 
their inherent limited monitoring cannot be used 
alone to exclude patients from operation.
Shuttle walk test: regression analysis showed in one 
study that 25 shuttles on the shuttle walk test indicate 
a VO2peak of 10mL/kg/min and for this reason this 
cut off has been largely used to select patients for 
operation. However, recent evidences have shown 
that this test tends to underestimate the exercise 
capacity at the lower range of VO2max questioning 
its role in patients’ selection for operation.
Stair climb: Several studies have shown the ability 
of stair climbing test to predict surgical risk in 
candidates for lung resection. A recent large study 
conÀrmed in 640 patients submitted to major lung 
resection that those climbing less than 12 m had a 
2-fold and 13-fold higher rates of complications and 
mortality compared to those climbing higher than 22 
m (less than 1% mortality rate).
Cardiopulmonary exercise test: Compared to low-
technology test CPET has several advantages. It 
is performed in a controlled environment with 
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COPD is the most common comorbidity (50-60% of 
patients with lung cancer) and is associated with an 
increased risk of developing lung cancer (RR 2.3-
4.0). These factors limit the amount of additional 
parenchyma that can be surgically resected or 
exposed to radiation. When determining the strategy 
for a patient with a subsequent primary tumor, the 
clinician also has to anticipate additional subsequent 
primary lesions in the future. Detection and 
staging The classic screening method for centrally 
located early lung cancer is sputum cytology. This 
method however, is limited by low sensitivity 
due to sampling error, technical difÀculties in the 
preparation of samples and signiÀcant variations 
in intra- and interobserver agreement. White light 
Áexible bronchoscopy (WLB) has enabled visual 
inspection of the central airways, but its sensitivity 
for detecting early lung cancer remains low. 
AutoÁuorescence bronchoscopy (AFB) utilizes the 
spectral differences in Áuorescence and absorption 
properties of normal and (pre-)malignant epithelium. 
AFB performs better than WLB with a sensitivity of 
44-82%. The drawback of the increased sensitivity 
of AFB is a reduced speciÀcity of 46-75%. Other 
techniques for the detection of central lesions include 
high magniÀcation videobronchoscopy, narrow 
band imaging and optical coherence tomoghraphy. 
Staging of central airway lesions can be performed 
with multidetector CT scan (preferably 1mm 
slice thickness) and FDG-PET scan. Although 
FDG-PET scan has not been studied extensively, 
preliminary data show that FDG uptake in a central 
lesion indicates squamous cell carcinoma of 
considerable size which probably precludes curative 
bronchoscopic treatment. Information about airway 
wall invasion and lymph node involvement can be 
obtained by EBUS. Treatment Up to 30% of the 
patients with early proximal lung cancer require 
bilobectomy or pneumonectomy, and the remaining 
70% require lobectomy.[5] Frequent comorbidities in 
these patients such as COPD often limit the amount 
of lung parenchyma that can be resected. Surgery 
is therefore not necessarily the only and primary 
choice. As a result there is signiÀcant interest in the 
use of various bronchoscopic modalities to treat early 
central lung cancers. Commonly used bronchoscopic 
treatment techniques include electrocautery, argon 
plasma coagulation, cryotherapy, Nd:YAG laser, 
photodynamic therapy and intraluminal irradiation 
therapy or brachytherapy. When bronchoscopic 
treatment fails or if the lesion is locally too 
advanced, surgery can still be performed if the 
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GR01.1 A SUBSEQUENT PRIMARY IN 
A COPD PATIENT WITH PREVIOUS 
LOBECTOMY FOR EARLY STAGE LUNG 
CANCER
Johannes M.A. Daniels, Thomas G. Sutedja 
Pulmonary Diseases, VU University Medical Center/
Netherlands
Abstract: Non-small cell lung cancer (NSCLC) is 
the most common cause of cancer deaths worldwide. 
The reason for the unsatisfactory overall 5-year 
survival rate of approximately 15% mainly lies in 
the often advanced stage of the disease at the time of 
diagnosis and the inability to cure metastatic disease. 
Even for early stage lung cancer (stage I & II), 
which is usually treated with curative intent, 5-year 
survival is only about 50-60%. This is caused by 
both subsequent lung cancer primaries and metastatic 
disease. In contrast, the prognosis of early central 
squamous lung cancer in-situ (stage 0) is excellent at 
90%. The World Health Organization has classiÀed 
(pre-)malignant squamous lesions in nine categories, 
raging from normal to invasive cancer.[1] Both the 
invasive potential of these lesions and the need for 
curative treatment are controversial. The natural 
history of premalignant lesions is difÀcult to study 
because these lesions are often asymptomatic and 
discovered by chance. In addition, most centers treat 
the lesions at the time of detection rather than await 
the development of invasion. Reported progression 
rates of carcinoma in-situ (CIS) to invasive 
cancer vary from 20-67% despite bronchoscopic 
therapy in some instances.[2-5] This underscores 
the need for effective detection and treatment 
strategies, especially in patients with a reasonable 
life expectancy. Subsequent primary central lung 
cancer is challenging for clinicians because these 
patients already underwent parenchymal resection 
or radiotherapy for their Àrst cancer. In addition, 
comorbidities are common in this population. 
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surgical resection for T1N0 lung cancer patients. 
Respiration 2004;71:391-396.
Keywords: Minimal invasive, COPD, Lung cancer, 
bronchoscopy
Boundaries of Bronchoscopy: Central Hilar Lesions Monday, 4 July 
2011 10:30-12:00
GR01.2 DIAGNOSIS AND TREATMENT 
OUTCOMES OF EARLY CENTRAL 
LUNG CANCER -INCLUDING A CASE OF 
SYNCHRONOUS DOUBLE SQUAMOUS 
PRIMARIES-
Hidetoshi Honda, Jitsuo Usuda, Norihiko Ikeda 
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Abstract: Sputum cytology is the only examination 
that can detect early central lung cancer. However, 
even when atypical cells are seen in sputum, it 
can be difÀcult to localize the lesions. So, it is a 
challenge for even experienced bronchoscopist. 
The Ànding rate of carcinoma in situ (CIS) is in 
patients with abnormal sputum cytology Àndings 
was only 29%. One reason for this is that white light 
bronchoscopy (WLB) cannot detect early lesions 
due to a lack of abnormal Àndings. To resolve this 
problem, autoÁuorescence bronchoscopy (AFB) was 
developed in the early 1990s. AFB has been reported 
to be useful in diagnosing early central lung cancer 
and dysplasia. But, based on the Japanese guideline, 
the following can be said about AFB; Many reports 
have claimed it to be useful for diagnosis of early 
stage bronchial lesions. There is no deÀnitive 
conclusion regarding its superiority for diagnosis of 
early central lung cancer. It is not currently covered 
by the Japanese insurance system, and it falls within 
the category of exploratory medical therapy. This is 
a bit disappointing, but we have experienced many 
cases of patients in which this technique proved to 
be extremely useful. We found many synchronous 
and metachronus multiple primary lung cancer 
lesions using AFB. Also our department assesses 
tumor depth by Optical coherence tomography 
(OCT) as a reference when determining indications 
for PDT. OCT is a non-invasive imaging technique 
in which images of living tissue are taken using 
light instead of ultrasound. OCT can obtain high-
resolution, cross-sectional microscopic images of 
tissue, potentially enabling optical biopsy in place 
of conventional excisional biopsy. Diagnosis of 
early central lung cancer enables highly invasive 
patient is operable.[6,7] Up to date no trials have 
compared surgical and bronchoscopic techniques for 
early squamous lung cancer. The reported outcomes 
of bronchoscopic treatment are comparable to 
surgical treatment. The cost of treatment and follow-
up of bronchoscopically treated small stage IA 
cancers in inoperable patients was 30% of the cost of 
standard surgery in matched operable patients in one 
published cost effectiveness analysis, and obviously 
surgical procedures are associated with greater 
morbidity.[8] Treatment success with bronchoscopic 
techniques strongly depends on accurate staging. 
Selected lesions should be limited to mostly Áat type 
squamous cell CIS and microinvasive cancer. It is 
also obvious that lesions with nodal involvement 
cannot be regarded as early stage proximal lung 
cancer. If a patient is not eligible for surgical 
resection or bronchoscopic treatment, radiotherapy 
can be an alternative. During this session we will 
present a COPD patient with a subsequent primary 
proximal lesion. With audience and the experts 
important issues regarding the detection, work-up 
and treatment of such lesions will be discussed. 
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for diagnosis in the bronchial surface, it should be 
used in conjunction with techniques such as OCT 
for diagnosis of invasion depth. Combined use of 
AFB, OCT and PDD can lead to more accurate 
diagnosis and treatment of early central lung cancer. 
The primary treatment option for early central lung 
cancer is surgical resection. However, due to the 
incidence of synchronous lung cancer and decreased 
basic respiratory function in many patients, PDT 
is gaining recognition as it enables preservation of 
respiratory function. It is thus recommended by the 
U.S. National Cancer Institute. At our institution, the 
complete response rate to PDT is 94% and outcomes 
are favorable. 
Keywords: Early central lung cancer, 
synchronous lung cancer, photodynamic therapy, 
AutoÁuorescence bronchoscopy
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DEFINITIVE CHEMORADIATION: IS 
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Abstract: About 30% of non-small cell lung cancer 
(NSCLC) patients initially present with locally and 
regionally advanced cancer (IIIA or IIIB)(1,2). Several 
treatment strategies are commonly used for this 
group of patients including induction chemotherapy 
followed by surgery and postoperative radiation 
therapy, induction chemoradiation followed by 
surgery, and deÀnitive radiation therapy with 
concurrent chemotherapy(chemoradiation). Isolated 
local and regional recurrences occur in about 25% 
of patients who receive deÀnitive chemoradiation(3). 
When this occurs the question of surgical resection 
for residual or recurrent disease is frequently raised. 
Chemoradiation given prior to surgery is most often 
used as an induction therapy. The dose is usually 
50Gy or less and surgery is planned six to eight 
weeks after the completion of chemoradiation. In 
contast, patients undergoing salvage surgery for local 
surgery to be avoided and successful treatment to 
be achieved by PDT. We report herein the diagnosis 
and treatment outcomes of early central lung cancer, 
and cases of multiple primary lung cancer cases 
including early central lung cancer at our institution. 
Patient Selection and Methods In our institute, this 
examination is mainly performed for lung cancer 
patients before treatment as well as high risk cohort; 
patients with abnormal sputum cytology Àndings 
and post-operative follow up patients. Between July 
2004 and July 2008 at Tokyo Medical University 
Hospital, we investigated 440 cases using AFB and 
performed biopsy on all regions even in the case 
of abnormality. OCT was additionally performed 
in patients in whom lung cancer was suspected 
following AFB. For patients diagnosed with early 
central lung cancer on both techniques, PDD using 
AFB was performed, the superÀcial invasion range 
of the focus was more clearly determined, and PDT 
was applied. Results 550 sites were recognized to 
be abnormal by AFB. These lesions were biopsied 
and histologically evaluated. There was no statistical 
difference between WLB and AFB in detecting 
cancerous lesions, however, the extent of invasion 
was objectively evaluated by AFB. 50% of dysplasia 
were diagnosed by both WLB and AFB while 41% of 
such lesions were detected only by AFB, which were 
invisible by WLB. AFB showed statistically better 
performance to diagnose dysplasia than WLB alone. 
So, it is useful for determining the extent of the 
irradiation target for PDT. Reduced autoÁuorescence 
was observed in 91 regions of 75 patients diagnosed 
with lung cancer. Through combined use of OCT, 
69 regions of 64 of these patients were diagnosed as 
early central lung cancer. PDD was positive in 68 
regions. The complete response rate for PDT was 
94% (tumor size 1.0 cm). And multiple lung cancer 
cases were noted 22 patients (34.4%, 22 of 64), 
10 had synchronous multiple lung cancer lesions 
whereas 12 had metachronous multiple lung cancer 
lesions. All subjects were male heavy smokers. 
Among the 22 patients, 10 patients received PDT 
for the second and third cancers after undergoing 
radical surgery for peripheral lung cancer, 1 patient 
received radical surgery for the second cancer 
that appeared in the peripheral lung Àeld after 
PDT, and 11 patients received PDT for all lesions 
after onset of multiple early central lung cancer. 
All patients who received PDT for multiple lung 
cancer lesions achieved CR, and are still alive. 
Conclusion AFB is useful for localization of early 
central lung cancer; however, as it is only indicated 
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by salvage surgical resection from January of 
2001 to July 2010. All patients received deÀnitive 
chemotherapy and radiotherapy, either sequential or 
concurrent, at the discretion of the treating physician. 
The mean radiation dose was 64Gy (range 60-74Gy). 
The mean time from completion of treatment to 
salvage resection was 41.5 weeks (range 8 to 144 
weeks). Sixty three percent (10/16) of patients had 
lobectomy, bilobectomy or sleeve lobectomy. The 
indication for resection was progression in 5 patients, 
persistent disease in 9 patients, and recurrence of 
disease in 2 patients. Four of 16 (25%) patients had a 
pneumonectomy, and two of 16 (12.5%) underwent 
sublobar resections. Eight intercostal muscle Áaps, 
2 pericardial fat pad Áaps, and 1 pectoral Áap 
were used for stump coverage. Sixty three percent 
of patients were downstaged pathologically post 
treatment, while only 1 patient (6%) was upstaged. 
Perioperative mortality was 12.5% at 30 days and 
18.8% at 90 days. Overall median survival was 14 
months. Surgery following chemoradiation carries 
a high operative morbidity and mortality. Survival 
is limited. Thus patient selection is critical. Because 
of the increased risk, conÀrmation of recurrent or 
residual cancer is mandatory. Muscle Áap coverage 
of the bronchial stump is a critical component of 
the operation. Reference List 1. Chansky K, Sculier 
JP, Crowley JJ, et al. The International Association 
for the Study of Lung Cancer Staging Project: 
prognostic factors and pathologic TNM stage in 
surgically managed non-small cell lung cancer. J 
Thorac Oncol 2009;4:792-801. 2. Rami-Porta R, 
Ball D, Crowley J, et al. The IASLC Lung Cancer 
Staging Project: proposals for the revision of the 
T descriptors in the forthcoming (seventh) edition 
of the TNM classiÀcation for lung cancer. J Thorac 
Oncol 2007;2:593-602. 3. Fournel P, Robinet G, 
Thomas P, et al. Randomized phase III trial of 
sequential chemoradiotherapy compared with 
concurrent chemoradiotherapy in locally advanced 
non-small-cell lung cancer: Groupe Lyon-Saint-
Etienne d’Oncologie Thoracique-Groupe Francais 
de Pneumo-Cancerologie NPC 95-01 Study. J 
Clin Oncol 2005;23:5910-5917. 4. Albain KS, 
Swann RS, Rusch VW, et al. Radiotherapy plus 
chemotherapy with or without surgical resection 
for stage III non-small-cell lung cancer: a phase III 
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386. 5. Thomas M, Rube C, Hoffknecht P, et al. 
Effect of preoperative chemoradiation in addition 
to preoperative chemotherapy: a randomised trial in 
stage III non-small-cell lung cancer. Lancet Oncol 
recurrences following deÀnitive chemoradiation have 
received 60Gy or more and the surgery takes place 8 
or more weeks after the patient was initially treated. 
The higher dose of radiation and longer interval 
between radiation and surgery with possible increase 
in Àbrosis could increase the risk of surgery. Thus it 
would be useful to assess the operative risks and long 
term survival for patients undergoing salvage lung 
resection. However, most institutions have a very 
limited experience with this group of patients. Most 
patients receiving deÀnitive chemoradiation were 
treated because either the tumor was so extensive 
that complete resection was considered unlikely 
or the patient had co-morbidities such as poor 
pulmonary or cardiac function that made the risk of 
surgery excessive. In these situations, if surgery was 
not possible initially, it is generally not possible after 
chemoradiation. Thus very few series of salvage lung 
resections have been reported, and those that have 
been reported are very small. The most extensive 
experience with surgery following chemoradiation is 
the experience with induction chemoradiation in the 
setting of tri-modality therapy. Although lower doses 
of radiation therapy are given and surgery occurs 
after a planned time interval, this is an instructive 
experience to review to assess surgical risks 
following chemoradiation. Albain reported 14 of 16 
patients died postoperatively after pneumonectomy 
following chemoradiation to 45Gy(4). Thomas 
reported operative mortality increased from 2.3% 
to 7.5% for lobectomy and 5.5% to 14% for 
pneumonectomy following induction chemoradiation 
to 45Gy compared to induction chemotherapy 
alone in a large randomized clinical trial(5). Sonett 
reported a group of forty patients treated with 59Gy 
induction chemoradiation. No operative mortality 
was seen, but signiÀcant complications occurred 
in seven patients(6). Bauman reported the largest 
series of patients having salvage lung resection(7). 
Over an eight year period, 24 patients who had 
received a median of 63.9 Gy (all >59Gy) had 14 
lobectomies and 10 pneumonectomies with 83% of 
the patients stage IIIA or IIIB at initial diagnosis. 
There was one operative death (pneumonectomy) 
and 14 major complications. Median progression-
free survival was 12 months. Four patients in the 
series did not have residual cancer despite positive 
PET scans. We performed a retrospective review 
of the University of Texas MD Anderson Thoracic 
and Cardiovascular Surgery prospective database 
to identify patients who received curative intent 
chemotherapy and radiotherapy (>59Gy) followed 
S248 Copyright © 2011 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
usually non-small cell lung cancers that typically 
produce unrelenting pain in the arm and shoulder, 
weakness and atrophy of small muscles of the 
hand, and Horner’s syndrome. They occur with an 
incidence of less than 5% of all lung cancers. CT is 
routinely indicated when an apical lesion is detected 
by chest radiography. The extent of invasion of the 
tumor into adjacent structures is better determined 
with MRI. PET, while not well studied in this 
subset of patients, is generally performed as part 
of the routine workup because it may be helpful in 
the evaluation of mediastinal nodal involvement 
and distant metastases. The precise nature of the 
lesion, as elsewhere, cannot be determined without 
pathologic diagnosis. Bronchoscopic biopsy is 
typically low yield due to the peripheral location 
of the tumor. On the other hand, CT or ultrasound 
guided transthoracic needle biopsy is diagnostic in 
up to 95% of cases. Sqamous cell carcinoma used 
to be the most frequent pathology, which is now 
switched to adenocarcinoma. Pancoast tumors are 
the most challenging thoracic malignancies to treat 
because of their frequent direct invasion not only 
to the Àrst rib but also to adjacent vital structures 
such as the brachial plexus, subclavian vessels, and 
the spine. According to the report from Japanese 
Association for Thoracic Surgery, only 139 cases 
(0.5%) were for Pancoast tumors among 27,387 
cases surgically treated for primary lung cancer in 
2008. Contraindications of surgery are the presence 
of distant metastases and mediastinal lymph 
node involvement. A speciÀc problem represents 
supraclavicular lymph nodes, which can be involved 
in these patients more frequently. There is a debate 
whether such supraclavicular lymph nodes should 
be classiÀed as N3 or still should be considered to 
be local node areas in view of the special location of 
the tumor. Invasion to the brachial plexus above T1 
indicate inoperable. However, involvement of the 
subclavian vessels is not contraindication because 
complete resection with vascular reconstruction 
may be performed. Pancoast tumors with vertebral 
invasion were long considered a contraindication 
to surgical resection. However, several reports 
suggest that en bloc resection of these tumors 
with vertebrectomy is technically possible with 
encouraging long-term survival. The choice of 
surgical approach is very important for en bloc 
resection of Pancoast tumors. Basically, there are 
two approaches, anterior approach and posterior 
approach. The posterior approach was developed by 
Paulson and his colleagues and is now often called 
2008;9:636-648. 6. Sonett JR, Suntharalingam 
M, Edelman MJ, et al. Pulmonary resection after 
curative intent radiotherapy (>59 Gy) and concurrent 
chemotherapy in non-small-cell lung cancer. Ann 
Thorac Surg 2004;78:1200-1205. 7. Bauman JE, 
Mulligan MS, Martins RG, et al. Salvage lung 
resection after deÀnitive radiation (>59 Gy) for 
non-small cell lung cancer: surgical and oncologic 
outcomes. Ann Thorac Surg 2008;86:1632-1638. 
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GR02.3 CIRCULATORY 
COMPLICATIONS AFTER 
PNEUMONECTOMY
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Abstract: Pneumonectomy is associated with a 
major amputation of the pulmonary vascular bed, and 
transmigration of the heart and large vessels to the 
side of pneumonectomy. Although pneumonectomy 
is rarely complicated with pulmonary hypertension, 
transmigration of the heart and large vessels might 
cause all sort of circulatotoiry impairments in the 
long run. Diagnosis of these complications can be 
difÀcult due to the altered position of the heart and 
large vessels. This lecture aimed to provide insight 
in the nature of these complications by focussing 
on a sery of cases who experienced circulatory 
complications after pneumonectomy. Emphasis 
will be laid on the diagnostic process and possible 
treatments of those conditions.
Keywords: pneumonectomy, Surgery, right 
ventricle, pulmonary veins
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GR02.4 PANCOAST TUMORS
Hiroshi Date 
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Abstract: Pancoast tumors or superior sulcus 
tumors are neoplasms of pulmonary origin that 
are located in the most apical recess of pulmonary 
sulcus and that arise from the lung apex. Dr. Henry 
Pancoast reported the clinical and radiographic 
features of lung tumors in the superior sulcus, 
which were named after him. Pancoast tumors are 
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GR03.1 MESOTHELIOMA - DILEMMAS 
IN ONCOLOGICAL MANAGEMENT
Jan P. Van Meerbeeck 
Respiratory Medicine, Ghent University Hospital/
Belgium
Abstract: Recent progress has reshaped the 
clinical landscape in the treatment of MPM. We 
have now more effective chemotherapy and from 
current evidence, it is clear that histone deacetylase 
inhibitors represent a potentially new treatment 
modality in MPM. Among current investigational 
drugs, mesothelin targeted therapies, dendritic cell 
based immunotherapy and gene therapy hold promise 
and should be further explored. Despite these, 
actual treatment is still amenable to improvement. 
Several factors have hampered the development 
of more effective regimens for mesothelioma. 
MPM is uncommon, is heterogeneous, staging 
is unreliable, response assessement is difÀcult 
and most drugs do not work. For the staging, the 
International Mesothelioma Interest Group are 
actually collaborating with the IASLC to include 
malignant pleural mesothelioma in its proposals 
for the 8th edition of TNM classiÀcation. The 
ability to measure reproducibly tumour response 
to treatment is vital in the development of new 
drugs and therapeutic combinations, particularly for 
the conducting of phase II studies. Conventional 
response criteria have always been difÀcult to apply 
to malignant mesothelioma due to its unique pattern 
of growth. Because the selection of measurement 
sites in mesothelioma is difÀcult, RECIST criteria 
could be applied differently by different investigators 
and that’s why the ModiÀed RECIST criteria have 
been developed. Based on the complex growth 
pattern of MPM, response evaluation in this cancer 
entity is still challenging. Results on value of 
Áuoro-2-deoxy-D-glucose and positron emission 
tomography imaging ((SUVmean, tumor lesion 
glycolysis (TLG) and tumor volume (PETvol)) in 
response assessment in MPM are promising. Where 
Paulson’s approach. After placing the patient in the 
lateral decubitus position, an incision extending around 
the tip of the scapula up to the level of C7 provides 
excellent exposure of the posterior chest wall including 
the transverse processes, the vertebrae and the roots of 
the thoracic nerves. However, this approach does not 
allow a direct and safe visualization of all anatomical 
structures composing the thoracic inlet. As a result, 
resection of the subclavian vessels is difÀcult with this 
approach. Dartevelle and his colleagues developed an 
anterior transcervial approach. The patient is placed 
in the spine position and the L-shaped incision runs 
along the anterior border of the sternocleidomastoid 
muscle and continues laterally at the level of the second 
intercostals space. The excision of the median portion 
of the clavicle provides excellent exposure of the entire 
thoracic inlet, which allows for a safe resection and 
reconstruction of subclavian vessels. Grunenwald and 
his colleagues modiÀed the Dartevelle approach from 
transclavicular to transmanubrial, through a manubrial 
L-shaped transaction and Àrst costal cartilage resection, 
which allows sparing the clavicle and its muscular 
insertions. Shoulder articulations and stability of the 
scapular girdle are respected, thus avoiding functional 
and cosmetic consequences of clavicle resection. The 
surgical treatment of Pancoast tumors continues to 
evolve but typically involves multimodality therapy. 
The changing paradigms in the treatment of non-small 
cell lung cancer since the late 1990s resulted in the 
introduction of induction chemoradiotherapy followed 
by surgical resection in the treatment plan of Pancoast 
tumors. Recently two similar studies were reported 
on a multi-institutional phase II trial of a trimodality 
approach, one from USA and the other from Japan. 
Southwest Oncology Group tested an induction 
regimen of concurrent chemoradiotherapy (cisplatin, 
etoposide and 45 Gy radiation) followed by surgery for 
110 patients with Pancoast tumors. The authors reported 
that completeness of resection was 76% and treatment 
related death occurred in 1.8%. Five-year survival was 
44% for all patients and 54% after complete resection. 
Japan Clinical Oncology Group used mitomycin, 
vindesine, cisplatin and 45 Gy concurrent radiation 
as induction regimens for 76 patients. Complete 
resection was achieved in 68% and treatment related 
death occurred in 3.5%. Fiver-year survival was 56%. 
Induction chemoradiotherapy followed by surgical 
resection has become the standard treatment for patients 
with Pancoast type non-small cell lung cancer. 
Keywords: Superior sulcus tumor, induction 
chemoradiotherapy, Pancoast tumor
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consider the need for enhanced coordination and 
collaboration. The currently paucity of treatment 
options with good clinical outcome for MPM 
means also that signiÀcant research remains to 
discover biomarkers for the early detection of MPM. 
Suggestions to develop a central mesothelioma 
virtual tissue bank may also contribute to the 
ultimate goal to identify druggable targets and 
to develop personalized treatment for the MPM 
patients. 
Keywords: mesothelioma, therapy
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GR03.3 MESOTHELIOMA - DILEMMAS 
IN ONCOLOGICAL MANAGEMENT
Paul Baas1, J A. Burgers1, Jan P. Van Meerbeeck2 
1Thoracic Oncology, The Netherlands Cancer 
Institute/Netherlands, 2Pulmonology, University 
Hospital Ghent/Belgium
Abstract: In this Grand Round we will discus the 
dilemmas that are usually encountered when patients 
with a diagnosis of malignant pleural mesothelioma 
are referred for therapy. In this Grand Round we 
aim to identify and discuss the pitfalls in this special 
group of patients. In the Àrst case we will discus the 
indications for chemotherapy and will focus of the 
selection of the patient; which subtype of tumour can 
best be treated; what is the optimal chemotherapy 
schedule; is there an indication for th use of a 
targeted agent together with the chemotherapy; how 
can we best evaluate the response to treatment and is 
there a role for maintenance therapy. In the second 
case we will discuss the possible indications for 
surgery: what are the surgical options; what can one 
achieve with it; which patient is the best candidate; 
how radical is the surgery from an oncological point 
of view; should it be combined with other types of 
treatment modalities and what kind of complications 
can one expect. 
Keywords: mesothelioma, Chemotherapy, Surgery
do we go from here with the systemic therapy for 
MPM? We need better drugs, probably by more 
accurate preclinical investigation and we have 
to use better the drugs we have: in maintenance 
therapy, in special populations, in multimodality 
setting. More selectivity regarding the “promising” 
drug we choose to move from the bence to the 
clinic and fewer “me too” trials are warranted. 
Better designed trials that are adequately powered, 
multicenter, preferable with randomized phase II 
design to balance for heterogeneity, with appropriate 
endpoints (PFS, OS, QoL) and with correlative 
studies built in, are mandatory. Methods to assay 
individual tumor characteristics are warranted in 
order to avoid toxicity in patients who may not 
respond to treatment and losing precious time in 
a disease associated with a short survival. Drug 
resistance proÀles have been reported to various 
malignant diseases including NSCLC, SCLC, breast, 
ovarian, colon, esophageal and carcinoid tumours. 
Recently the feasibility of performing off-site in vitro 
drug resistance assays on resected mesothelioma 
specimens is reported. For clinical implementation, 
a chemoresistance test applicable to pemetrexed 
should be useful. The effectiveness of assay-directed 
therapy is promising and need to be addressed in 
prospective trials. Multiple biologicals have been 
studied or are still under investigation, however a lot 
of them seems to fail. It is of great importance that 
the molecular biologic research should focus more 
on mesothelioma-speciÀc pathways and biomarkers, 
instead of copying mechanisms and treatments that 
were successful in other tumour types. Looking 
at the list of new VEGFR-inhibitors being tested 
in MPM, one can question if it is a wise use of 
the limited patient resources to perform so many 
“me too” trials in this uncommon disease? One 
can question whether trials with so-called targeted 
agents in an unselected population of mesothelioma 
patients are appropriate. With the use of array 
technology there will be certainly an implicit gain 
in the identiÀcation of new potential prognostic 
or biomarkers or important pathways in the MPM 
pathogenesis, which can individually be worked up 
for independent validation. The concern for many 
researchers is the lack of concordance between 
studies. Nevertheless, an potential successful 
approach may be to collate all the available data to 
a database to identify networks of MPM pathways 
which might allow for the identiÀcation of novel 
therapeutic approaches for the treatment of MPM. 
Research funders and the research community should 
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GR04.1 PLEURAL LAVAGE CYTOLOGY
Haruhiko Kondo, Tomohiro Maniwa, Mitsuhiro 
Isaka, Takehiro Okumura, Kazuo Nakagawa, 
Yasuhisa Ohde 
Division Of Thoracic Surgery, Shizuoka Cancer 
Center/Japan
Abstract: PLC is a cytological examination of 
the aspirated saline which was instilled into and 
retrieved from the pleural cavity during surgery 
for lung cancer. PLC is done immediately after 
thoracotomy before resection (PLC-Pre) or after 
resection (PLC-Post) or both. The results of PLC-
Post, PLC-Pre, and both have been reported as 
early as 1984 by Eagan 1), in 1989 by Kondo 2), in 
1991 by Okumura 3), respectively. The signiÀcance 
of PLC The positive results for malignant cells 
in the PLC have been reported as an independent 
poor prognostic factor 4)-8). PLC was deemed as 
synonymous with minimal intrapleural dissemination 
(IPD) or malignant pleural effusion (MPE), i.e. T4 
(in TNM6) or M1a (in TNM7) disease in several 
reports. However, as the cases accumulated, we have 
experienced many patients with positive PLC results 
otherwise stage I who survived long time without 
disease, which is unlikely for clinically obvious 
IPD or MPE 6),9). As for the recurrence site in the 
PLC positive cases, the intrapleural recurrences 
are relatively common but distant metastases occur 
more often4), 9). Recently International Pleural 
Lavage Cytology Collaborators 10) have reported the 
results of meta-analysis from the individual data of 
the 8763 patients with PLC study in 11 institutes. 
There are 511 (5.8%) patients with positive PLC 
results. As for the prognostic analysis, they reported 
that it may be appropriate to upstage patients 
by 1 T category. In the IASLC staging manual, 
PLC-Pre are recommended to be performed as a 
simple technique of intra-operative staging and 
future validation studies are expected 11). Issues 
concerning PLC It is not determined which should 
be regarded as more important, PLC-Pre or PLC-
Post. Although some authors report as PLC-Post is 
more strong impact on the postoperative prognosis, 
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GR03.5 DESTRUCTIVE PAIN SURGERY 
FOR INTRACTABLE CHEST PAIN IN 
LUNG CANCER (MESOTHELIOMA)
Yucel Kanpolat 
Professor Of Neurosurgery, President Of The Turkish 
Academy Of Sciences/Turkey
Abstract: Chest pain is an important complication 
of lung cancer, especially mesothelioma. Nearly 
all of the patients with mesothelioma complain of 
chest pain. There is no special efÀcient treatment 
for mesothelioma, but there is an extremely 
useful method for mesothelioma pain, known as 
a destructive procedure and termed cordotomy. 
Cordotomy is a special destructive method based on 
lesioning of the anterolateral part of the upper spinal 
cord (C1-C2).
Methods
Computed tomography (CT)-guided cordotomy has 
been performed in the Department of Neurosurgery, 
Ankara University, School of Medicine for 20 years 
and in the private practice of the author. Over this 
period, CT-guided cordotomy was performed 248 
times in 224 patients. The majority, 211 cases, 
suffered from intractable pain related to malignancy. 
In the malignancy group, pulmonary malignancies 
(68 patients), Pancoast tumors (15 patients) and 
mesotheliomas (26 patients) represented the majority 
of cases, at 48.9%.
Results
Following cordotomy, 92.5% of patients reported 
initial pain relief, grade 1 and 2. In the cancer group, 
selective cordotomy was achieved in 83% of the 
patients.
Conclusion
Cordotomy is an efÀcient reliable option in the 
management of pulmonary carcinoma, especially in 
mesothelioma.
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GR04.2 UNSUSPECTED N2 NODE
Paul Van Schil 
Thoracic And Vascular Surgery, Antwerp University 
Hospital/Belgium
Abstract: N2 disease consists of a very 
heterogenous population ranging from intranodal 
involvement of a single mediastinal lymph node 
station to bulky N2 disease. In general, a distinction 
can be made between 4 subgroups [1]. Subset IIIA1 
includes incidental nodal metastases found on Ànal 
pathologic examination of the resection specimen; 
IIIA2 single station, nodal metastases recognized 
intraoperatively; IIIA3 single or multiple stations, 
nodal metastases detected by prethoracotomy staging 
and IIIA4 bulky or Àxed multistation N2 disease. 
Subsets IIIA1 and IIIA2 are often considered 
it might reÁect the contamination of cancer cells by 
surgical manipulation in the disease with other poor 
prognostic factors, i.e. nodal metastasis, lymphatic 
and vascular invasion and so on. And the method of 
PLC, for example the amount of poured saline, the 
need of immunocytochemistry, etc., is not uniÀed. 
Accuracy of cytological examination is also an 
issue. There may occur in false negative or false 
positive results even with a very low incidence. 
How should we do during lung cancer surgery in 
concerns of PLC? 1. If there is a moderate amount of 
pleural effusion, sample it and send for cytological 
examination. Presence of cancer cells in pleural 
effusion corresponds to M1a. 2. PLC-Pre should 
be performed in all cases with no or little pleural 
effusion at thoracotomy. 3. If PLC-Pre is reported as 
positive for cancer cells, re-explore the pleural cavity 
attentively and any suspicious pleural nodules should 
be sent for frozen section. Video-thoracoscopy is 
advisable for the exploration of pleural cavity before 
thoracotomy. 4. In surgical stage I or II cases, the 
indication for resection should not changed by the 
results of PLC-Pre, because there remains a chance 
for cure by radical resections. 5. In surgical stage 
IIIA or IIIB, or N2, T3 or T4 cases, remind that PLC 
positive correspond to upstaging by 1 T category and 
reconsider the curability and indication for resection. 
6. PLC-Post is suggested to be performed, because 
it is one of the important prognostic factors with 
simple technique. 7. Prospective randomized study 
for adjuvant chemotherapy in the pathological stage 
I or II with positive PLC is expected in near future. 
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factors are clinical N2 on chest CT, multilevel N2 
disease, T3 tumors or subcarinal zone involvement 
[2]. Relatively positive prognostic factors are a 
complete R0 resection, T1 and T2 tumors, single-
level N2 involvement and clinical stage N0,1. 
Factors that are probably less important include 
histology, extent of resection, location of the 
tumor and the presence of involved N1 nodes. 
Tumors of the left upper lobe with involvement of 
the aortopulmonary lymph nodes have a similar 
prognosis as tumors in another location with single 
nodal involvement. In every patient, rigorous 
preoperative staging by imaging, minimally invasive 
or invasive techniques is necessary to decrease 
the incidence of unsuspected N2 disease (Àg.1). 
Patients that are carefully staged preoperatively have 
a higher chance of obtaining a complete resection 
when surprise N2 is encountered. Resection can be 
performed when the surgeon is quite conÀdent that 
a complete resection will be obtained, especially 
when favorable prognostic factors are present as 
listed above. A general algorithm for N2 disease is 
provided in Àg. 1. Currently, a more personalized 
treatment for N2 disease is advocated [8]. According 
to the American College of Chest Physicians 
(ACCP) adjuvant platinum-based chemotherapy is 
indicated in patients with a good performance status 
who are found to have unsuspected N2 disease [1]. 
Sequential postoperative radiotherapy should also 
be considered but for deÀnite recommendations 
results of ongoing trials are awaited for (Lung 
Adjuvant Radiotherapy, Lung ART trial). The 
IASLC prospective database which was created 
in preparation of the 8th TNM classiÀcation will 
hopefully determine whether the concept of nodal 
zones remains valid and provide a more deÀnite 
answer on the prognosis of speciÀc N2 subsets. 
In conclusion, surprise N2 will probably never be 
completely eliminated but with careful preoperative 
staging, it is unlikely to Ànd unresectable N2 
disease. On the condition that a complete resection 
can be obtained, the surgeon may proceed with 
the surgical procedure. Adjuvant chemotherapy is 
indicated followed by radiotherapy in patients with 
a good performance status References 1. Robinson, 
L.A. Chest, 2007. 132(3 Suppl): p. 243S-265S. 
2. Detterbeck, F. J Thorac Oncol, 2008. 3(3): p. 
289-302. 3. Rusch, V.W. J Thorac Oncol, 2009. 
4(5): p. 568-77. 4. Rami-Porta, R. Lung Cancer, 
2005. 49(1): p. 25-33. 5. Paulson, D.L. J Thorac 
Cardiovasc Surg, 1971. 62(4): p. 554-62. 6. Graham, 
A.N. J Thorac Cardiovasc Surg, 1999. 117(2): p. 
together and called “unsuspected or surprise N2” 
[2]. In the 7th TNM classiÀcation of lung cancer the 
concept of nodal zones was introduced grouping 
several lymph node stations into 7 speciÀc zones 
[3]. What is the best intra-operative strategy when 
a surgeon is confronted with surprise N2? The Ànal 
aim of every surgical treatment for non-small cell 
lung cancer (NSCLC) is complete resection, also 
after induction therapy. In this respect, speciÀc 
criteria have been established by a working group 
of the International Association for the Study of 
Lung Cancer (IASLC) [4]. Complete resection 
implies that the primary tumor is completely 
removed, no macroscopic tumor is left behind, 
microscopically the margins are free, a systematic 
or lobe-speciÀc systematic nodal dissection has 
been performed, and the highest mediastinal lymph 
node is negative. In which patients is surgical 
treatment generally indicated? In 1971 Paulson 
deÀned the term “surgical salvage”, consisting 
of % 5 year survival - % operative mortality of 
resection - % operative mortality of exploratory 
thoracotomy [5]. When this Àgure approaches 
zero or becomes negative, surgical therapy is 
not indicated anymore. This concept is still valid 
today. For precise N staging during thoracotomy a 
systematic nodal dissection as advocated by Graham 
and Goldstraw should be performed [6]. With this 
technique, dissection of mediastinal, hilar and lobar 
lymph nodes proceeds in a systematic fashion. 
Graham and Goldstraw reviewed their results in 
240 patients with clinical T1-3 N0-1 NSCLC [6]. 
Preoperative mediastinoscopy was performed when 
lymph nodes larger than 1.5 cm were present on 
computed tomography (CT) of the thorax. The rate 
of exploratory thoracotomy was only 3 %. In 20 
% of patients N2 disease was found. There was no 
subgroup with 0 % incidence of N2 involvement 
and skip metastases were found in 34 % of patients 
with N2 disease. Peripheral tumors less than 2 cm 
had a 24 % incidence of lymph node metastases. So, 
systematic nodal dissection is the gold standard for 
accurate N staging during thoracotomy. Guidelines 
for intraoperative lymph node staging were further 
deÀned by a working group of the European Society 
of Thoracic Surgeons (ESTS) [7]. As a minimum 
criterion at least three hilar and three mediastinal 
lymph node stations should be removed; regarding 
the latter, the subcarinal lymph nodes should always 
be included. Can we identify any intraoperative 
factors that will deÀne prognosis when surprise 
N2 is encountered? Relatively negative prognostic 
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the pathology of these lesions by needle biopsy 
due to low diagnostic yield. Although radiologic 
Àndings are important, some reports showed that 
there were no signiÀcant differences between benign 
and malignancy with respect to shape, margin, and 
attenuation value. However, when GGO lesions were 
larger than 10mm, the chance of malignancy was 
67%. When the lesions are diagnosed as malignancy 
from pathologic or radiologic Àndings, next problem 
is to deÀne whether these lesion are lung to lung 
metastasis or synchronous multiple primary lung 
cancer (MPLC). In reality, it is impossible to 
accurately differentiate between the two when the 
cell types are identical. Although accurate diagnosis 
might be possible with molecular biological Àndings, 
most clinicians have adopted the criteria of Martini. 
Patients with MPLC have a relatively favorable Àve 
year survival rate. Some authors showed that node-
negative T1-2 patients with multifocal NSCLC in 
the same lobe or a different lobe had a favorable 
3-year actuarial survival rate of 66.5% and 63.6%, 
respectively. Okada et al. reported that 3.1% of 
second primary lung cancer was synchronous and 
Àve-year survival rate from initial treatment of 
cancer was 70.3%. They concluded that aggressive 
operative approach for node negative early stage and 
oncologically sound parenchymal sparing procedure 
would be possible. However, other authors showed 
unfavorable results than that of Okada’s report. One 
of the reasons for the inconsistent results is perhaps 
the possibility that some with lung to lung metastasis 
had been included, and not ruled out. In regards 
to lung to lung metastasis, a new revision of the 
TNM classiÀcation of lung cancer was established 
and published in 2009. The results of this study 
showed that T4 tumors classiÀed by the presence of 
additional nodules in the lobe of the primary tumor 
have better prognosis than other T4 tumors, which 
also has a very similar prognosis to T3 tumors. In 
addition, the study illustrated to reclassify M1 of 
additional nodules on the ipsilateral different lobe to 
be classiÀed as T4. Japan Lung Cancer Registration 
Committee, the largest study, enrolled 317 patients 
with intrapulmonary metastasis in primary lobe, 
128 patients with intrapulmonary metastasis in 
non-primary lobe. The Àve-year survival rates were 
26.8% and 22.5%, respectively, with no statistically 
signiÀcant difference between two groups. In 
patients with operable non-small cell lung cancer, 
controversy about nodules detected preoperatively 
or intraoperatively has to be addressed in order 
not to lose the opportunity for a curative resection. 
246-51. 7. Lardinois, D. Eur J Cardiothorac Surg, 
2006. 30(5): p. 787-92. 8. Vansteenkiste, J. Expert 
Opin Pharmacother, 2010. 11(10): p. 1605-9. 
Keywords: N2 disease, combined modality 
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GR04.3 MANAGEMENT OF PATIENTS 
WITH ANOTHER PULMONARY 
NODULES OTHERWISE OPERABLE 
NON-SMALL CELL LUNG CANCER
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Thoracic And Cardiovascular Surgery, Seoul 
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Abstract: With the increasing application of high-
resolution computed tomography (HRCT) scan, 
small pulmonary nodules have been more frequently 
detected. Recently, ground-glass opacity (GGO) 
lesions have been found with greater ease in patient 
with primary lung cancer. Therefore, rather than 
attempting to detect these nodules intraoperatively, 
it is common to detect preoperatively with HRCT. 
For non-small cell lung cancer (NSCLC), it is 
difÀcult to deÀne these satellite nodules, including 
GGO, prior to surgery on the HRCT. First of all, it is 
important to determine the probability whether these 
lesions are benign or malignant. CT-guided needle 
aspiration biopsy is possible unless the nodule size 
is less than 1cm or deeply located. If it is impossible 
to perform tissue conÀrmation, other methods such 
as, imaging features of CT or max SUV of PET/
CT may be helpful to differentiate between benign 
and malignancy. Recently, multiple GGO lesions 
are another concern. It is not feasible to conÀrm 
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makes complete resection unlikely or N2/N3 disease 
neoadjuvant chemoradiotherapy followed by surgery 
when down staging is achieved or deÀnitive chemo 
(-radio) therapy is indicated. Take into consideration 
that lymph node metastasis adjacent to the T4 tumor 
is a „regional“ lymph node metastasis in a N2/
N3 position and may therefore not have the same 
oncological meaning than in non-central tumors. 
Adjuvant treatment should be discussed in all 
cases. Occasionally T4 tumors are not deÀnitively 
diagnosed before surgery and detected or proven 
during the operation. However in most cases it 
can be anticipated from CT scans and a possible 
intraoperative strategy can be discussed in advance. 
In a T4 stage found deÀnitively at surgery we would 
follow the same principles as described above and 
perform resection, when it will be complete but stay 
with an exploratory thoracotomy only when surgery 
will be incomplete. In T4 cases with inÀltration 
of the left atrium usually along the pulmonary 
vein or inÀltration of the central pulmonary artery, 
cardiopulmonary bypass may be needed. Long term 
survivors are observed in all series. T4 due to a 
secondary tumor in another lobe is always known 
before from the CT-scan, but in many cases the 
deÀnitive histology is found intraoperatively. A 
lobectomy in combination with a segmentectomy 
or a pneumonectomy in larger tumors should be 
considered for all cases in absence of N2-disease. 
DeÀnitive T4-stage may be found at surgery but 
can be anticipated in advance in most of the cases 
from the chest CT. It is of importance that a strategy 
is discussed beforehand and careful staging with 
exclusion of mediastinal lymph node involvement 
or distant metastases is mandatory. Furthermore an 
evaluation of the pulmonary status after resection 
must be calculated and the risks known. 
Based on above Àndings, I am presenting the data of 
patients who underwent surgical resection for MPLC 
or for ipsilateral pulmonary metastasis in major 
hospitals in Korea. 
Keyword: satellite nodules, non-small cell lung 
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Abstract: In the 7th edition of the TNM staging 
system T4 Non-small-cell lung cancer (NSCLC) 
is deÀned as tumors inÀltrating the mediastinal 
structures such as the heart, the great vessels, the 
oesophagus, vertebrae or the carina. It includes 
furthermore tumors with satellite nodules in other 
lobes of the same side. The T4 stage is diagnosed 
in general by imaging techniques such as chest-CT, 
PET/PET-CT or MRI. InÀltration into structures 
is radiologically proven when a destruction of 
the organ is seen or the tumor is visible beyond 
the layer of the respected organ. A tumor in close 
contact to structures, even for a wide area, indicates 
a possible inÀltration in approximately 50% 
only. In these cases further diagnostic measures 
should be applied such as mediastinoscopy, VATS, 
transoesophageal ultrasound or others. For carinal 
inÀltration bronchoscopy is essential and diagnostic. 
Satellite nodules are usually detected on CT as 
solitary nodules of unknown origin, and may vary in 
size; they are rarely numerous. There is no uniform 
standard of care applied for known T4 NSCLC 
since treatment depends from various cofounding 
factors such as the extent of inÀltration, the nodal 
status, co-morbidities of the patients overall status 
and its tolerability of treatment, risk of procedures, 
availability of treatment options and surgical 
skills. Recommendations are based on relatively 
small sized single center retrospective case series. 
Patients with a T4-stage need to be discussed in a 
multidisciplinary tumour board with presence of an 
experienced thoracic surgeon. Upfront surgery is 
recommended for T4, N0 or T4, N1 when a radical 
resection is achievable with an acceptable mortality 
and morbidity. 5-year survival varies from 19-57%. 
In presence of either extended inÀltration which 
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eliminates unnecessary passes during the procedure. 
However conventional TBNA is a blind procedure 
preventing target visualization and therefore the yield 
for TBNA varies widely (14-91%). A meta-analysis 
of 12 studies in 910 evaluable patients demonstrated 
a sensitivity of 76%. The speciÀcity was very high 
(96%). Although the sensitivity was moderate, the 
patients included in the TBNA studies had enlarged 
mediastinal lymph nodes. The high false negative 
rate makes TBNA less useful for complete staging 
of the mediastinum. Therefore, TBNA would 
probably be the preferred minimal invasive method 
for patients with radiographic evidence of enlarged 
mediastinal lymph nodes adjacent to the airways, 
since bronchoscopy is usually performed in lung 
cancer patients and assessment for endobronchial 
lesions can be performed during the same procedure. 
On the other hand, endobronchial ultrasound-
guided transbronchial needle aspiration (EBUS-
TBNA) utilizes ultrasound technology built into 
a Áexible bronchoscope for real-time ultrasound 
guided sampling of mediastinal and hilar lymph 
nodes. Similar to conventional TBNA, EBUS-
TBNA has access to all of the mediastinal lymph 
nodes accessible by mediastinoscopy as well as N1 
nodes. Recent studies show that EBUS-TBNA has 
equivalent sensitivity to mediastinoscopy for lung 
cancer staging. Due to the real-time procedure, 
EBUS-TBNA can also correctly stage patients 
with normal mediastinum on imaging. The cost-
effectiveness of EBUS-TBNA has also been shown 
in studies comparing mediastinoscopy, EBUS-
TBNA, conventional TBNA for mediastinal staging 
in NSCLC. Ongoing studies are looking at the 
comparison of EBUS-TBNA to mediastinoscopy, 
but currently there is no evidence to suggest that 
EBUS-TBNA will replace mediastinoscopy. It will 
be important to incorporate new minimally invasive 
endoscopic techniques in the algorithm of lung 
cancer staging. EBUS-TBNA may be considered for 
initial staging of NSCLC in patients with suspicious 
mediastinal lymph nodes on non-invasive staging, 
provided negative results are conÀrmed by surgical 
staging. This will allow mediastinoscopy to be 
reserved for re-staging after induction treatment. 
EBUS-TBNA also has potential for providing 
molecular diagnosis. 
Keywords: Staging, EBUS, TBNA, Lung cancer
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Abstract: During the staging process of non-small 
cell lung cancer (NSCLC), accurate mediastinal 
lymph node staging is a critical factor which 
affects patient outcome. Several different invasive 
and non-invasive modalities exist for mediastinal 
staging. Invasive tests include mediastinoscopy, 
thoracoscopy, transbronchial needle aspiration 
(TBNA), transthoracic needle aspiration (TTNA), 
endoscopic ultrasound-guided Àne needle aspiration 
(EUS-FNA) and endobronchial ultrasound-
guided transbronchial needle aspiration (EBUS-
TBNA). Each of the invasive tests has limitations 
for particular locations, has particular risks and 
requires speciÀc skills. Invasive tests are often 
times used to conÀrm staging of lung cancer, but 
also used for the conÀrmation of the diagnosis. The 
determination of the best approach out of these tests 
depends on the clinician’s assessment of the patient. 
Cervical mediastinoscopy has been considered 
the “Gold Standard” for mediastinal staging in 
NSCLC. However, there is increasing interest in 
minimally invasive endoscopic mediastinal staging 
techniques. Transbronchial needle aspiration 
(TBNA) for mediastinal staging is performed 
through the bronchoscope under local anesthesia. 
It can be performed as an outpatient procedure 
with no signiÀcant morbidity. The needle catheter, 
which comes in various sizes, is passed through 
the working channel of the bronchoscope and 
guided to the area of interest. The needle is then 
advanced through the tracheobronchial wall into 
the lymph node. TBNA can be performed from the 
hilar and mediastinal lymph nodes adjacent to the 
tracheobronchial wall. Aspiration biopsies are then 
obtained. Rapid on-site cytologic evaluation of the 
aspirates improves the yield, is cost-effective and 
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the tracheobronchial wall into the lymph node. The 
expected difÀculty of angulating a bronchoscope 
with more rigid needle inserted is overcome in 
the EBUS scope with an angled side port exit for 
the bronchoscope working channel. This ability to 
effectively use a more rigid needle in TBNA is likely 
one of the most signiÀcant advantages of EBUS 
TBNA, allowing for more effective back and forth 
shearing or coring movement during biopsy. The 
methodology for EBUS TBNA is essentially the 
same as for conventional TBNA with few exceptions. 
In conventional TBNA location of the puncture site 
is identiÀed visually using the endoscopic view of 
the airway and the natural landmarks that correlate 
to the CT image of the mediastinum as described in 
1994 by Wang. This map included endobronchial, 
anatomic, and CT correlation for 11 of the most 
common locations for mediastinal adenopathy that 
can be reliably reached from the airways. While this 
map was created for the bronchoscopist performing 
TBNA to enhance their ability to successfully locate 
and biopsy the target lymph nodes, it correlates 
very closely to the latest IASLC staging system and 
is sufÀcient for staging purposes. Unlike biopsy 
from the esophagus, the airways have distinctive 
landmarks to identify the areas where the lymph 
nodes consistently reside. With experience, these 
landmarks are very reliable and do not require 
ultrasound guidance to locate. In our routine clinical 
practice of TBNA diagnosis or staging of lung 
cancer, TBNA is performed on mediastinal and 
hilar lymph nodes using the conventional method 
Àrst followed by EBUS TBNA. This approach 
is extremely practical and efÀcient when using a 
standard bronchoscope initially and then switching 
to the EBUS scope. In diagnostic cases, the largest 
lymph nodes were selected for biopsy. For staging, 
biopsy site and order were based on the highest level 
of possible staging for the patient (i.e. N3, N2, N1). 
Same number of punctures were performed with 
and without EBUS on each station. In 200 patients 
reviewed, 183 had specimens both with conventional 
TBNA and EBUS. 36 patients had mediastinum 
or hilar lymph nodes positive for lung cancer. 
EBUS TBNA was the exclusive positive diagnostic 
modality in 7 patients. Conventional TBNA was 
the exclusive positive diagnostic modality in 12 
patients. Recommendations for EBUS TBNA to 
become the exclusive modality for staging of lung 
cancer regardless of the size of the lymph node is 
premature. The EBUS bronchoscope and needle 
apparatus is more uncomfortable for the patient 
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Abstract: Transbronchial needle aspiration (TBNA) 
has been used for over three decades to sample the 
mediastinum and hilar lymph nodes for diagnosis 
and staging. First described in Argentina in 1949 by 
Dr. Eduardo Schieppati using a rigid bronchoscope 
and rigid needle. This technique was Àrst adapted 
to the Áexible bronchoscope in 1983 at Johns 
Hopkins Hospital, by Wang et al. In the Àrst report 
for staging of lung cancer, the overall diagnostic 
yield for staging was 85% for lung cancer and 96% 
in right side lesions. Over the past several decades, 
numerous experts have reported their diagnostic 
yield using this technique with a sensitivity and 
speciÀcity of over 90%. Recent development of the 
endobronchial ultrasound (EBUS) for TBNA has 
generated special attention and interest in TBNA 
technique and has been shown to be more reliable 
and sensitive than conventional technique by a few 
experts and is being recommended in guidelines as 
a Àrst line diagnostic procedure for all mediastinal 
and hilar adenopathy. EBUS TBNA is different than 
conventional TBNA in several signiÀcant ways. 
First and most obvious is the ability to visualize and 
locate the target lymph node with ultrasound beyond 
the bronchial wall and perform the needle aspiration 
with real time ultrasound guidance. Visualization of 
the lesion before biopsy and during biopsy may not 
play any important role once the lesion is entered, 
but it does ensure the lesion is reached. Direct 
visualization of the needle in the lesion does not 
guarantee an adequate specimen. The EBUS needle 
design is a continuous hollow metallic shaft with 
a sharp needle tip housed in a plastic catheter. The 
lengths of the outer plastic catheter and the working 
length of the needle can be adjusted at the proximal 
end of the needle apparatus. SigniÀcance of the 
adjustable working lengths of the catheter and needle 
is trivial since the scope length is Àxed and the 
target lesions are usually close to tracheobronchial 
wall. The longer and more rigid design of the EBUS 
needle compared to conventional TBNA needles 
allows for easier and deeper penetration through 
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patient, who survived for 18 years after surgery. 
In 1951, Cahan suggested that pneumonectomy 
with regional lymph node dissection should be a 
routine procedure for lung cancer in 1951. Then 
in 1960, Cahan reported the Àrst 48 cases that 
successfully underwent lobectomy with regional 
lymph node dissection, which was called “radical 
lobectomy.” Since then, this procedure was 
universally accepted and has remained a standard 
surgery for lung cancer. As for sublobar resection, 
segmentectomy was initially used for the resection 
of localized bronchiectasis as reported by Churchill 
and Belsey (1939). In 1973, Jensik reported their 
15-year successful experience of segmentectomy 
for lung cancer patients. However, the use of 
sublobar resection as deÀnitive management of 
NSCLC has been a controversial issue. Lung Cancer 
Study Group (LCSG) (1995) conducted the only 
randomized trial comparing sublobar resection 
with lobectomy for stage IA NSCLC patients. They 
observed a 75% increase in recurrence and a 50% 
increase in cancer death in the patients undergoing 
sublobar resection, compared to those in the patients 
undergoing lobectomy. This is the reason why 
lobectomy has remained a standard lung cancer 
surgery for a half century since Cahn’s successful 
report in 1960. Controversies in sublobar resection 
for patients with small-sized NSCLC Sublobar 
resection is a lung parenchyma-preserving surgery 
with limited nodal dissection. However, even small-
sized lung cancer less than 2 cm in size shows hilar 
and mediastinal nodal disease with an incidence 
of more than 20%. Although positron emission 
tomography (PET) is considered to be the most 
sensitive and accurate investigation for screening 
of lymph node involvement, with a sensitivity 
of 79 to 85% and speciÀcity of 90 to 91% in a 
meta-analysis, the assessment of nodal status by 
PET is not reliable in patients with microscopic 
nodal metastasis. Riquet (1989) reported that lung 
cancer metastasizes so easily to the mediastinum 
that selection of the patients for limited surgery 
should be discussed carefully. Furthermore, lung 
cancer has a phenomenon termed “skip metastasis” 
consisting of N2 disease without N1 involvement 
with the incidence of 20-38% in N2 patients. 
Therefore, lobectomy with hilar and mediastinal 
lymph node dissection is considered to be a basic 
standard procedure for lung cancer. Differences in 
survival between sublobar resection and lobectomy 
However, with the recent development of the CT 
scanner, the number of very early-stage lung cancer 
and more difÀcult to use. The availability and cost 
of the equipment are also signiÀcant barriers to its 
widespread use. Continuous improvement of the 
equipment, instruments and technology is needed. 
In fact, the EBUS bronchoscopes have already 
begun this evolution. Olympus second generation 
EBUS scope has increased its working channel 
diameter from the original 2.0 mm to a larger 2.2 
mm channel that can accommodate a wider array of 
intstruments. The Pentax EBUS scope has further 
reduced the scope outer diameter while preserving 
the superior optics of the videobronchoscope. In the 
end, no matter what the technology, the success of 
TBNA relies on the operator’s skill, understanding 
of the anatomy, and the technique in obtaining the 
biopsy. EBUS is an exciting and useful technological 
advancement that has important applications in 
TBNA as well as in training. Still today, for most 
pulmonologist in the world, conventional TBNA 
is the simplest, safest and most cost effective 
procedure for staging of lung cancer in the vast 
majority of patients. 1 Wang KP, Brower R, Haponik 
EF, Stiegelman S. Flexible transbronchial needle 
aspiration for staging of bronchogenic carcinoma, 
Chest 1983; 84(5): 571-6. 2 Patel NM, Pohlman A, 
Husain A, et al. Conventional transbronchial needle 
aspiration decreases the rate of surgical sampling 
of intrathoracic lymphadenopathy. Chest 2007; 
131:773-8. 3 Wang KP. Staging of bronchogenic 
carcinoma by bronchoscopy. Chest 1994; 106:588-
93. 4 Wang KP, Browning R; Transbronchial needle 
aspiration with or without endobronchial ultrasound. 
Thoracic Cancer, 2010 Jul;1(2):87-93. 
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Abstract: History of standard surgical procedure 
for lung cancer In 1933, Graham reported the 
Àrst successful pneumonectomy for a lung cancer 
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Abstract: Limited resection for early-stage lung 
cancer Young Mog Shim, MD, PhD Department of 
Thoracic and Cardiovascular Surgery, Samsung 
Medical Center, Sungkyunkwan University School 
of Medicine, Seoul, Republic of Korea Lobectomy 
with mediastinal lymph node dissection is the 
treatment of choice for patients with stage IA non-
small cell lung cancer (NSCLC).1 Current 
recommendations for lobectomy as the standard 
treatment for early-stage NSCLC is based on the 
only randomized trial comparing lobectomy and 
sublobar resection for the treatment of T1N0 NSCLC 
reported by the Lung Cancer Study Group (LCSG) in 
1995.2 The main Àndings of this study were a 
threefold increase in local recurrence rate and a 75% 
increased risk of overall recurrence in the sublobar 
group compared with the lobectomy group. A similar 
increase in local recurrence among patients 
undergoing sublobar resection was shown in a 
prospective non-randomized multi-institutional study 
by Landreneau and coworkers in 1997.3 For these 
reasons, lobectomy has remained the gold standard 
for the treatment of early-stage NSCLC, whereas 
sublobar resection is considered to be a compromised 
procedure for high-risk patients with poor 
cardiopulmonary function unable to tolerate an 
anatomic lobectomy. However, with the use of 
recently developed methods of radiographic 
investigation and lung cancer screening programs, 
tumors are being identiÀed at earlier stages and 
smaller sizes than ever before. Moreover, the 
growing use of high-resolution computed 
tomographic scans have increased the detection of 
more indolent tumors with ground-glass opacity 
(GGO) features such as bronchioloalveolar 
carcinoma. Although lobectomy is the standard 
extent of surgical resection for stage I NSCLC, it is 
unclear whether lobectomy is really needed for such 
small lesions (i.e. less than 2 cm in diameter) with 
indolent behavior. Based on these circumstances, 
there has been renewed interest in the use of sublobar 
resection such as anatomic segmentectomy or wedge 
resection.4-7 Patients with smaller tumors are less 
likely to have regional or distant metastases at the 
showing ground-grass opacity (GGO) on CT is rising 
as well, and a new therapeutic strategy for nodal 
dissection has been required. Proposals of sublobar 
resection for small-size lung cancer less than 2 cm 
have been undertaken in some previous reports. 
Many retrospective studies of sublobar resection 
have already been undertaken for stage IA NSCLC 
patients. Regarding surgery for compromised stage 
IA patients, Hoffmann (1980), Landreneau (1997) 
and Campione (2004) showed no signiÀcant survival 
difference between sublobar resection and lobectomy 
group. Okada (2001) and Koike (2003) conducted 
the comparative study between intentional sublobar 
resection and standard lobectomy in patients with 
tumors 20mm or less in diameter. They showed no 
signiÀcant difference in survival between two groups 
and suggested that sublobar resection was acceptable 
operation for small-sized lung cancer. Nakamura 
(2005) reported the results of meta-analysis of 14 
comparative studies showing survival difference 
between lobectomy and sublobar resection. He 
showed survival after lobectomy was slightly better 
at 1, 3, and 5 years, but the differences were not 
signiÀcant. Therefore, lobectomy with mediastinal 
dissection could be an excessive resection for selected 
patients with early lesion. Lobectomy, however, still 
remains to be a standard procedure for most patients 
with lung cancer, simply because there has been 
no universally accepted guidelines for conducting 
sublobar resection in the clinical settings. We should 
wait the Ànal results of clinical trials shown in the 
following chapter. Clinical trials regarding sublobar 
resection vs. lobectomy and future perspective 
Currently, a prospective, randomized, multi-
institutional phase III trial for small-sized (<=2 cm) 
lung cancer patients is being conducted by Cancer and 
Leukemia Group B (CALGB 140503) to determine 
the effectiveness of an intentional sublobar resection 
for small-sized peripheral tumors. Similar study is also 
being conducted by Japan Clinical Oncology Group 
(JCOG 0802). Since the clear evidence regarding 
the survival beneÀt of sublobar resection for lung 
cancer patient is lacking so far, lobectomy should 
be an appropriate therapy for medically operable 
lung cancer patient at the moment. Abovementioned 
randomized trials will clearly deÀne the role of 
sublobar resection in patients with stage I patients. 
As the number of early-stage peripheral lung cancers 
is increasing, the surgical procedure for lung cancer 
should be tailored to each case in the near future. 
Keywords: sublobar resection, Surgery, Lung cancer, 
lobectomy
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undergoing limited resection, Àve had 
adenocarcinoma, one had atypical adenomatous 
hyperplasia, and the remaining patients had benign 
etiology. The authors suggested that some pure 
GGOs would never progress to clinical disease. 
Based on these Àndings, new concepts are introduced 
such as adenocarcinoma in situ (AIS) and minimally 
invasive adenocarcinoma (MIA) for small solitary 
adenocarcinomas with either pure lepidic growth 
(AIS) or predominant lepidic growth with 5 mm 
invasion (MIA) to deÀne patients who will have 
100% or near 100% disease-speciÀc survival, 
respectively.10 Therefore, it is also not known 
whether pulmonary resection is really necessary for 
such small lesions with GGO features. When making 
decisions regarding which type of resection to 
recommend, surgeons must balance the potential 
long-term beneÀts of more extensive resections with 
the risks of perioperative complications, decreased 
postoperative lung function, and potential limited 
ability to resect any future new primary lung cancers 
that may develop. With the use of limited resection 
such as segmentectomy and wedge resection, further 
preservation of lung volume can be achieved, 
perioperative morbidity and mortality can potentially 
be reduced, and opportunities for additional lung 
resection in the future could be maintained for 
second primary lung cancer. Over the past decade, 
many studies have suggested that limited resection 
and lobectomy may lead to similar survival among 
patients with small stage IA tumors. These Àndings 
need to be further conÀrmed in randomized 
controlled trials. References 1. Spira A, Ettinger DS. 
Multidisciplinary management of lung cancer. N 
Engl J Med 2004;350(4):379-392. 2. Ginsberg RJ, 
Rubinstein LV. Randomized trial of lobectomy 
versus limited resection for T1 N0 non-small cell 
lung cancer. Ann Thorac Surg 1995;60:615-623. 3. 
Landreneau RJ, Sugarbaker DJ, Mack MJ, et al. 
Wedge resection versus lobectomy for stage I 
(T1N0M0) non-small cell lung cancer. J Thorac 
Cardiovasc Surg 1997;113:691-700. 4. Okada M, 
Yoshikawa K, Hatta T, et al. Is segmentectomy with 
lymph node assessment an alternative to lobectomy 
for non-small cell lung cancer of 2 cm or smaller? 
Ann Thorac Surg 2001;71:956-961. 5. Koike T, 
Yamato Y, Yoshiya K, et al. Intentional limited 
pulmonary resection for peripheral T1 N0 M0 small-
sized lung cancer. J Thorac Cardiovasc Surg 
2003;125:924-928. 6. Kates M, Swanson S, 
Wisnivesky JP. Survival following lobectomy and 
limited resection for the treatment of stage I non-
time of diagnosis, and have an overall better 
prognosis. Over the last decade, several studies have 
demonstrated improved survival and decreased 
recurrence rates for patients with tumors 2 cm or less 
in diameter.4-7 Okada and colleagues4 reported the 
outcomes of extended segmentectomy or lobectomy 
in patients with T1N0 tumors 2 cm or less and 
showed a 5-year survival rates of 87.1% in the 
segmentectomy group and 87.7% in the lobectomy 
group (p = 0.8008). Koike et al5 reported a 9-year 
experience in which 159 patients were treated with 
lobectomy and 74 were treated with sublobar 
resection for T1N0 peripheral NSCLC 2 cm or less 
in diameter. The 5-year survival was 89.1% for the 
sublobar resection group, compared with 90.1% for 
the lobectomy group. Recently, Kates et al6 evaluated 
2090 stage I NSCLC tumors 1 cm or less from the 
Surveillance Epidemiology and End Results registry. 
Among these, 688 patients underwent sublobar 
resection. There was no difference in overall or lung 
cancer-speciÀc survival between the sublobar 
resection and lobectomy groups. Not surprisingly, 
even in the LCSG report2 and Landreneau’s study3, 
although the locoregional recurrence rate for the 
sublobar resection group was signiÀcantly higher 
than for the lobectomy group, the 5-year survival 
rates were similar between the two groups. 
Furthermore, there are several major criticisms 
against the 1995 LCSG report. First, substantially 
many patients in the sublobar resection group 
(32.8%) underwent a wedge resection. A wedge 
resection is not as effective as anatomic 
segmentectomy because immediate regional lymph 
nodes related to the tumor are not always removed, 
and the margin between the surgical staple line and 
tumor is more likely to be smaller. Second, patients 
with tumors up to 3 cm in diameter were included in 
the LCSG study. Smaller tumors ( 2cm in diameter) 
are more likely to have comparable outcomes with 
sublobar resection when compared with lobectomy. 
For the GGO type of tiny lesions, especially those 
less than 1 cm in diameter, the question has been 
raised whether surgical resection itself is really 
needed. Since patients diagnosed with Noguchi type 
A (pure BAC) have a 100% 5-year survival rate8, 
they may not need surgical resection. Kodama et al 
reviewed the natural history of pure GGO through 
long-term observation in 19 patients.9 The size of 
pure GGO did not change in eight patients, increased 
slightly (up to 5 mm) in six patients, and increased 
by more than 5 mm in Àve patients during a follow-
up of 2 years or more. Among the 10 patients 
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several directions focus on the target while sparing 
the adjacent normal tissues with high accuracy. This 
technique basically derived from that of radiosurgery 
for intracranial lesions allows us to deliver high dose to 
the target leading to high control of the tumor without 
causing signiÀcant cytotoxicities associated with the 
treatment. By SBRT, the biological effect of radiation 
on tumors is increased as the overall treatment time 
is shortened. With many encouraging outcomes in 
retrospective studies, several prospective clinical 
trials have been performed world-wide. Retrospective 
and prospective studies published in the past decade 
have established the feasibility, safety, and efÀcacy 
of SBRT in stage I NSCLC using a variety of dose 
regimens and technologies. To date, lung SBRT results 
demonstrate good local control and suggest improved 
overall survival compared to historical controls of 
fractionated radiotherapy. The overall survival rate for 
subgroup of medically operable patients who rejected 
surgery in a large retrospective study was almost 
comparative to that of surgical series. Concerning 
toxicities, SBRT is an almost safe and confortable 
treatment. But rib fracture is a common adverse 
effect when the tumor locates peripherally and severe 
radiation-related pneumonitis occasionally occur 
mostly in the patients having basic pulmonary Àbrosis. 
As the clear dose-constraint for mediastinal organs has 
not been demonstrated, the safety of SBRT for cases 
with a central lesion has not been assured. When the 
tumor recurred only locally after SBRT in operable 
patients, salvage radical surgery can be operated 
safely. Ongoing prospective trials are exploring proper 
dose and fractionation schedules for central or T2 
tumors, a difference between SBRT and conventional 
radiotherapy mostly in the inoperable population, and 
a role of SBRT for operable patients. Japan Clinical 
Oncology Group (JCOG) protocol-0403 is the Àrst 
phase II trial of stereotactic body radiation therapy 
for medically operable T1N0M0 non-small cell lung 
cancer. In the result of the operable 64 patients, the 
rates of 3-year local control, overall survival, and 
progression-free survival were 86.0%, 76.0%, and 
54.5%, respectively. Grade 3 toxicities were chest 
pain in 1 (1.5%), dyspnea in 2 (3.1%), hypoxia in 1 
(1.5%), and pneumonitis in 2 (3.1%). No grade 4 and 
5 toxicity was observed. According to good results 
of these retrospective or prospective studies, some 
phase III prospective trials comparing SBRT versus 
surgery (lobar resection) have been started, but the 
patient accrual seems to be difÀcult. Recently trials 
exploring the efÀcacy and safety of sublobar resection 
for patients with smaller tumors or who are unÀt for 
small cell lung cancer  1 cm in size: a review of 
SEER data. Chest 2011;139:491-496. 7. Okada M, 
Nishio W, Sakamoto T, et al. Effect of tumor size on 
prognosis in patients with non-small cell lung 
cancer: the role of segmentectomy as a type of lesser 
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PC02.3 WHEN IS SBRT BEST?
Hiroshi Onishi1, Shuya Nagata2, Masahiro Hiraoka3, 
Yutaka Kokubo4, Katsuyuki Karasawa5, Yoshiyuki 
Shioyama6, Rikiya Onimaru7, Etsuo Kunieda8, Taro 
Shibata9 
1Department Of Radiology, Yamanashi University 
School Of Medicine/Japan, 2Radiation Oncology, 
Hiroshima University/Japan, 3Radiation Oncology, 
Kyoto University/Japan, 4Foundation For 
Biomedical Research And Innovation/Japan, 
5Komagome Metropolitan Hospital/Japan, 6Kyushu 
University/Japan, 7Hokkaido University/Japan, 
8Tokai University/Japan, 9JCOG Data Center, 
National Cancer Center/Japan
Abstract: With the recent popularization of computed 
tomography (CT) screening, early stage lung cancers 
are increasingly detected at an early stage. For 
patients with stage I (T1 or 2, N0, M0) non-small 
cell lung cancer (NSCLC), resection of full lobe and 
systemic lymph nodes represents standard treatment 
but can be associated with signiÀcant morbidity 
and even mortality, particularly because patients 
suffering from lung cancer are often elderly with high 
comorbidity rates. Stereotactic body radiotherapy 
(SBRT) has emerged as one of the treatment options 
for stage I non-small cell lung cancer (NSCLC), 
mainly in medically inoperable patients. SBRT is a 
new treatment modality where narrow beams from 
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placed within the tumor to dispersive electrodes 
that are placed on the patient. As the RF energy is 
applied, frictional heating of tissues results with cell 
death occurring at temperatures beyond 60ºC. In 
most cases RFA is performed using a percutaneous 
approach with CT guidance. RFA can be used 
for patients with primary lung cancer and limited 
pulmonary metastases. RFA is most effective for 
smaller tumors (3cm or less), although tumors up 
to 5cm can be effectively ablated. Unlike resection, 
lymph nodes are not removed, and occult nodal 
disease may be missed, leading to local-regional 
failure as well as understaging of disease. When 
comparing results of RFA to surgical resection, and 
other new technologies such as SBRT, it should 
be considered that different deÀnitions are used 
to deÀne patterns of failure. SpeciÀcally local 
recurrence rates for SBRT and RFA are often quoted 
as being superior to those after wedge resection. 
However, in the surgical literature local recurrence 
will usually include hilar, sometimes mediastinal, 
as well as parenchymal recurrence within the same 
lobe, which is not the case with reports of non-
operative therapies such as RFA or SBRT. Another 
concern is that it is not guaranteed that there will be 
100% tumor destruction with an adequate therapeutic 
margin when ablation is used, although ablation is 
more likely to be successful for smaller tumors, and 
may be improved with new ablation technologies 
such as microwave, cryotherapy or irreversible 
electroporation. Patients with stage I lung cancer 
can be considered in 3 groups; namely; 1) standard 
risk operable (usually treated with lobar resection 
2) High-risk operable patients (usually treated with 
sublobar resection) and 3) medically inoperable 
(unable to tolerate any form of lung resection and 
usually treated with external beam radiation). RFA is 
a good option for the medically inoperable patients 
and may potentially be considered for some high-risk 
operable patients. RFA should be avoided for tumors 
closely abutting large vessels such as pulmonary 
vessels at the hilum. This is because there is a 
heat-sink effect that will prevent effective heating 
and cancer destruction, and additionally there is 
the potential risk of bleeding. RFA is effective for 
tumors in the lung periphery, as well as the middle 
3rd of the lung, where lobar resection may be the only 
feasible resection available. In this case RFA will 
avoid the need for lobectomy, for a patient who is in 
the high-risk operable group. 
Keywords: radiofrequency ablation, Lung cancer, 
pulmonary metastases
lobar resection have been made by surgeon. SBRT 
essentially should be compared to such a less invasive 
and less radical surgery. Concerning a comparison 
of SBRT with other non-surgical treatment modality 
for stage I NSCLC, radiofrequency ablation (RFA) is 
worse in local control and more invasive than SBRT. 
A higher procedure-related morbidity and mortality 
rate than SBRT has been reported, mainly caused 
by pneumothorax and hemorrhage. So SBRT is 
recommended rather than RFA for most of cases. But 
RFA may be useful for cases with local recurrence 
after SBRT. Particle beam therapy enables better dose 
distribution than SBRT and better local control may 
be achieved by carbon therapy, but survival rate is 
not different among these modalities. The treatment 
cost is very high in the particle therapy. So SBRT can 
be recommended as a Àrst choice for patients with 
peripherally located tumor. Particle-beam therapy may 
have an advantage in cases with a central tumor or 
pulmonary Àbrosis. In conclusion, though surgery has 
been a standard treatment for operable stage I NSCLC 
and the ultimate efÀcacy of SBRT in operable patients 
is difÀcult question to answer, the best timing of SBRT 
is when the tumor locates peripherally in a medically 
inoperable patients who have no pulmonary Àbrosis, 
and marginally operable patients who hope less 
invasive treatment. The combination of initial SBRT 
followed by salvage surgery when local recurrence 
occurs may become a new strategy for marginally 
operable cases. In patients with central tumor or 
pulmonary Àbrosis, SBRT should be performed very 
cautiously. Life is limited. The 150-year survival rate 
of humans must be 0%. All of the so-called “radical” 
treatments are then “palliation”. Hence, whether SBRT 
is selected Àrst or not in operable patients depends on 
their own philosophy, not on the acquired survival time 
after SBRT or other treatment modalities only.
Keywords: stage I non-small cell lung cnacer, 
Operable, stereotactic body radiotherapy, Inoperable
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PC02.4 WHEN IS RADIOFREQUENCY 
ABLATION BEST?
Hiran C. Fernando 
Cardiothoracic Surgery, Boston Medical Center, 
Boston Uniiversity/United States Of America
Abstract: RFA is being used increasingly to treat 
lung tumors. RF energy consists of an alternating 
current that moves from an active electrode that is 
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or not to pursue a career - and or life - in academic 
medicine? FOR - Desire to carry out research - 
Desire to teach - Intellectual stimulation - InÁuence 
of a mentor or role model AGAINST - Lack of 
autonomy - Low income (that’s relative) - Family 
considerations - Competing pressures to do clinical 
service, teach and do research Once you decide to go 
into academic medicine, you have to make a decision 
about either doing (1) basic or translational laboratory 
investigation such as in: - Cancer genetics - Cancer 
cell biology - Tumor cell invasion and metastases 
- Tumor immunology - Cancer etiology - Cancer 
pharmacology or (2) clinical investigation combined 
with clinical care as in: - Experimental therapeutics 
of cancer - Design and execution of phase I, II, III 
clincal trials - Health services/outcomes research 
It is challenging for any single individual to be an 
active participant in both basic/translational research 
and clinical investigation (bench to bedside) and do 
it all well. The more common alternative is for the 
laboratory and clinical scientist to COLLABORATE. 
In general, to be successful in academic medicine, 
one has to “focus”, have a single area of emphasis. 
In this case, lung cancer. As a clinical investigator 
in lung cancer, the goal is to become an expert in 
the natural history, diagnosis and management of 
the disease while any laboratory research should 
relate to lung cancer. Mentor selection is often the 
most crucial decision you will make in becoming 
an academician. The mentor will often inÁuence 
the speciÀc area of research interest. The mentor 
should have an established reputation in their Àeld 
and have time to mentor. The mentor’s experience 
and interest in mentorship can be assessed by the 
level of satisfaction and academic success of former 
students. - Can you have more than one mentor? 
Yes - Must the mentor be in your institution? No 
Successful candidates for an academic position in 
lung cancer demonstrate the following: - Evidence of 
broad clinical training with focused expertise in lung 
cancer (particularly important for a clinical research 
position). - Strong foundation for an independent 
scientiÀc career as evidenced by authorship of peer-
reviewed publications and presentations at national 
meetings. - Initial grant support (particularly important 
for laboratory research). - Positive professional image 
at the interview, demonstrating good interpersonal 
skills. To understand academic medical centers, 
you should read Joseph V. Simone’s article entitled 
“Understanding Academic Medical Centers: Simone’s 
Maxims (Clin Cancer Res 1999; 5:2281-2285. Two 
important maxims are (1) the institution does not love 
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Y.1 HOW TO PLAN AN ACADEMIC 
CAREER IN LUNG CANCER
David S. Ettinger 
Oncology, Sidney Kimmel Cancer Center At Johns 
Hopkins/United States Of America
Abstract: Before I go any further, let’s reÁect for 
a moment on the title. Can you plan an academic 
career in lung cancer? Does planning work or do 
other factors come into play - like coincidence/happy 
accident/also known as being in the right place at the 
right time, having the ability and the opportunity to 
form lasting and productive relationships, having the 
good fortune to be successful at what you do. Let’s see 
what you think as you reÁect on our discussion today. 
When I was asked to give this talk, I asked myself 
“why”? Was it because I am an older person?, seen 
perhaps as smart?, hardworking, successful; or was it 
just because I’ve been at the same institution for 38 
years? You be the judge. For you to understand a bit 
about me, I will present to you a short autobiographic 
sketch. I have been at Johns Hopkins since 1973. I 
did my fellowship there in medical oncology and 
was given the opportunity to stay on the faculty as 
a clinical investigator, rising from an instructor to 
professor by the age of 50 and then in 1993, I received 
an endowed professorship. I was interested in new 
drug development and combined modality therapies 
especially in lung cancer. My group helped to develop 
Paclitaxel as part of my NCI phase I contract when 
I was the principal investigator. I have authored 
or co-authored over 200 articles in peer-reviewed 
journals, edited 3 books, and am presently Editor-
in-Chief of the journal Current Treatment Options 
in Oncology. I am panel chair of three National 
Comprehensive Cancer Network (NCCN) clinical 
practice guidelines including NSCLC. I am an active 
member in ECOG and RTOG besides both national 
and international professional organizations. Based 
on both my own life experiences and my observation 
of the lives and careers of many others over the 
years, what are some key factors - both for and 
against - that inÁuence your decision as to whether 
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relevant papers to pick up any omissions. There are 
of course reviews published that summarise current 
knowledge or recent publications on speciÀc topics. 
Many are good but treat them cautiously. There 
are two types: the expert review and the systematic 
review. The former, written by acknowledged or 
self-proclaimed experts, may be good but may be 
biased not only in the literature selected but in its 
interpretation and summary. Beware of any review 
that does not how the literature was identiÀed, 
selected and evaluated. Systematic reviews do 
attempt to provide an objective summary with an 
explicit search strategy, a clear method for assessing 
the quality of each paper and a systematic summary 
of the evidence, including a synthesis of key 
outcomes in a meta-analysis. Both have strengths 
and weaknesses: the expert review is likely to be 
biased but can give a useful expert perspective; the 
systematic review is more likely to be objective 
but its conclusions still may be biased. Clinical 
guidelines are another useful source of information 
and a means of keeping up to date. But also need 
to be viewed with some caution. Questions to ask 
include: 1.Who created them? A professional body 
or another agency, (e.g. governmental or insurance). 
Each will have a different perspective and be trying 
to inÁuence practice in different ways. 2. Were they 
developed according to international standards, with 
inclusive group membership, systematic review of 
the literature and an explicit method of developing 
recommendations? So, all published literature 
needs to be approached with healthy scepticism. 
High impact journals may still publish misleading 
or frankly fraudulent articles and any research 
publication is likely to contain methodological Áaws, 
frank omissions or more or less obvious personal 
bias. A core skill for any health professional or 
clinical researcher is critical appraisal. Many guides 
have been written about this but here are a few hints. 
If you are interested in a paper, whether primary 
research or a systematic review, and feel its results 
or conclusions may be relevant to your clinical 
practice or research, don’t just read the Abstract and 
Conclusions. Start by reading the Methods (probably 
the least read but most important part of any paper) 
and understand what they were trying to do and 
how they did it. Look for any omissions, errors or 
lack of clarity. Next scrutinise the results. Did they 
follow the methods they described and were key 
data clearly reported? Did those logically lead to 
the results they claim? Look at the authors’ conÁicts 
of interest and assess what biases they might have. 
you and (2) you are not irreplaceable. If you embark 
on an academic career in lung cancer you should 
do the following: - Enjoy what you do - Strive for 
perfection - Be a professional - Be able to “reinvent 
yourself” if you wish to stay at an institution you like - 
Be a team player So, can you plan an academic career 
in lung cancer? The answer is not a simple one - not 
just “yes” or “no.” I would suggest that, as you look 
at your career options, you must develop and exercise 
your skills in self-knowledge, observation, reÁection, 
planning and Áexibility. 
Keywords: Clinical research, Basic science/
translational research, Academic career, Mentor
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Y.4 USING THE PUBLISHED 
LITERATURE EFFECTIVELY
Fergus Macbeth 
Centre For Clinical Practice, National Institute For 
Health And Clinical Effectiveness/United Kingdom
Abstract: The published clinical literature is huge. 
Medline currently cites over 25,000 papers between 
2007 and 2011 for ‘lung neoplasm’. It would be 
impossible for anybody to read more than 1% a year 
and that would be good going. Why do we need this 
literature? As conscientious health professionals 
we need to keep up to date. Secondly it is the 
inescapable platform for any new research. But it 
can also itself be the subject of research. In this 
presentation I will give some on using this resource 
effectively. Subscribing to a service that provides 
an update is helpful, but it may be important to 
Ànd all past publications. The provision of on line 
information has made things easier and often a 
search engine like Google may be an efÀcient way 
of getting things. But sophisticated enquiries will 
mean using one of the dedicated databases such as 
MedLine. It needs training or a tame information 
specialist to use the search terms most efÀciently 
and to create speciÀc search strategies that avoid 
getting only a few irrelevant, titles or a vast list 
that has to sifted one by one. You need to decide 
whether you want a sensitive search which will 
Ànd all the relevant papers at the expense of a 
signiÀcant dross; or a speciÀc one that includes only 
relevant titles but misses others. It is important to 
remember that the databases themselves may not 
be complete and so if you want to Ànd all relevant 
papers, go through the references lists of most 
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Y.5.1 THE FUTURE ROLE OF 
DIFFERENT SPECIALISTS IN 
MULTIMODALITY MEDICINE (LUNG 
CANCER) - MEDICAL ONCOLOGIST
Enriqueta Felip 
Oncology Department, Vall D’Hebron Hospital/
Spain
Abstract: Suspected lung cancer is often identiÀed 
by the primary care physician and patients are then 
usually referred to a hospital for diagnosis. Lung 
cancer diagnosis and management is complex and 
requires a multidisciplinary approach. State-of-the-
art care of lung cancer patients requires the input 
from many specialists in pneumology, pathology, 
thoracic surgery, radiology, medical oncology, and 
radiation oncology among others. How to achieve 
a multidisciplinary approach in lung cancer? 
Multidisciplinary meetings to discuss lung cancer 
patients provide the ideal forum for exchange of 
professional opinions. Regular tumors committee 
meetings are therefore, recommended at each 
institution, at which there should be representation 
from a number of specialist areas, so that the patient 
receives the best attention and optimal disease 
management. All new lung cancer patients should 
be discussed in depth. Medical oncologists should 
take an active part in the multidisciplinary process of 
which tumor committee meetings are an integral part. 
What should be the skills for a medical oncologist 
working in lung cancer? Medical oncologists 
working with thoracic malignancies require: · A 
deep knowledge of prevention of lung cancer and 
familiarity with the risk factors for the development 
of lung cancer. Medical oncologists should be aware 
of lung cancer screening studies, and smoking 
cessation strategies. · Willingness to participate in 
a multidisciplinary approach. Medical oncologists 
should participate fully in the tumors committee 
meetings. They must have extensive knowledge of 
non-invasive and invasive risk assessment work-
up, the staging system, prognostic factors, criteria 
of inoperability and indications for and value of 
surgery, chemotherapy and radiotherapy, particularly 
in locally advanced disease. · Experience in 
determining key factors for treatment selection as 
well as in the use and indications of chemotherapy, 
biological agents and supportive care strategies. · 
Good communication skills. In lung cancer, effective 
communication with patients is important in order to 
Finally read the conclusions and discussion. Are 
conÀdent in the results are valid and do you agree 
with the conclusions? Look out for any subsequent 
correspondence to see what arguments and defence it 
has generated. The published literature is an essential 
platform for research and must be reviewd in order: 
· Not to repeat the research · Not to repeat the 
mistakes · To identify the real gaps in the knowledge 
· Find the best methods. The literature itself can be 
the subject to of research and carrying out a thorough 
high quality systematic review is an important form 
of research in itself which is not only educational but 
a source of publications needing no labs or patients 
but just good methods, a critical mind, attention to 
detail and plenty of time. Plump up your resumé with 
a systematic review or two! Finally the published 
literature would be nothing without peer review . 
Few apart from editors know how variable it quality 
and usefulness are. Only accept to peer review 
a paper if you believe you have the appropriate 
knowledge and have no clear conÁicts of interest. 
Assess the scientiÀc quality (originality, appropriate 
methods, clearly described and believable results, 
justiÀable conclusions, relevant discussion) and 
the presentation (well written, clear tables, helpful 
Àgures and illustrations). Write an overall summary 
of what the paper is trying to show and a brief 
opinion of its quality, relevance and importance. 
Then, if need be, provide line by line comment on 
any major Áaws, errors and omissions. Ensure that 
you are accurate and fair and that all your criticisms 
can be reasonably substantiated. In conclusion this 
huge creature can be tamed and exploited in a variety 
of ways to promote evidence-based clinical practice 
and highly quality research. But like a wild animal 
it needs to be treated with caution and respect. Use 
all its strengths and recognise all its hazards and 
weaknesses.
Keyword: Lung Cancer. Published literature. 
Systematic reviews
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adenocarcinoma update was the adaptation of lung 
cancer classiÀcation to embrace biopsy and cytology 
material (1,2). WHO classiÀcations are based 
primarily on resections whilst this is reality for only 
a minority of cases of lung cancer. As a result, we 
now have recommendations for terminology that 
will hopefully lead to more uniform classiÀcation for 
all patients undergoing both biopsy and cytological 
examination. It is pathologists especially who must 
embrace this terminology to allow consistency in 
diagnosis, especially when patients are to be entered 
into drug trials. At the same time, the limitations of 
needle aspirations etc., in terms of sample size and 
requirements made of the tissue, need to be balanced. 
One cannot have a patient with all material sent for 
molecular review and no diagnosis, equally all the 
material should not be smeared on a single slide 
for diagnosis. The 7th TNM staging revision (3) has 
brought additional responsibility to the pathologist, 
not just continuing to provide minimum data sets 
for national data collection, but proposing that 
microscopic examination by the pathologist be used 
to distinguish synchronous primaries from satellite 
nodules rather than clinically documenting their 
macroscopic presence as multifocal tumours. Of 
note, morphological review has proved as accurate 
as gene proÀling in distinguishing synchronous 
primaries from satellite nodules (4). There was 
also a call for more investigation into the relevance 
of histopathological criteria to TNM staging, for 
example extent of pleural invasion (5,6), and it is up 
to pathologists with interest in lung cancer to involve 
themselves in groups informing the 8th revision. 
The next decade will see further requirements 
for immunohistochemical and moelcular data 
alongside morphological diagnosis. As well as 
looking for genetic abnormalities such as EGFR 
and other mutations, there is testing for excision 
repair cross-complementation group-1 (ERCC-
1), thymidylate synthase (TS) and (ribonucleotide 
reductase messenger-1) RRM-1, in relation to 
potential activities of platin-based, pemetrexed-based 
and gemcitabine-based therapies (7). However, 
pathologists must not forget the importance of 
routine morphological diagnosis as this still remains 
the cornerstone of global lung cancer classiÀcation. 
Reference List 1. Travis WD, Brambilla E, Noguchi 
M, et al. International Association for the Study of 
Lung Cancer/American Thoracic Society/European 
Respiratory Society international multidisciplinary 
classiÀcation of lung adenocarcinoma. J Thorac 
Oncol 2011;6:244-285. 2. Nicholson AG, Gonzalez 
decrease their anxiety and distress. Furthermore, it is 
crucial to maintain a good level of interaction among 
all professionals involved in the management of the 
lung cancer patient. Clinical research in thoracic 
malignancies Clinical investigation is essential for 
ongoing medical education. For medical oncologists, 
clinical trials are the basis of clinical research. There 
is also a need to work in cooperative groups in 
order to arrive at relevant Àndings in investigation. 
Furthermore, it is important for the physicians 
treating lung cancer to understand the disease at a 
molecular level and for them to be familiar with 
emerging technologies. Medical oncologists should 
collaborate in the development and consolidation of 
thoracic clinical research units. 
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Y.5.2 THE FUTURE ROLE OF 
DIFFERENT SPECIALISTS IN 
MULTIMODALITY MEDICINE (LUNG 
CANCER) - PATHOLOGIST
Andrew G. Nicholson 
Departement Of Histopathology, Royal Brompton 
And HareÀeld NHS Foundation Trust/United 
Kingdom
Abstract: To look at the role of the pathologist 
in a multidisciplinary setting  To understand that 
tissue usage needs to be planned in an increasingly 
molecular era. To become aware of the balance 
required between routine morphological diagnosis 
and ancillary data in relation to optimal patient 
management. The last decade has seen rapid 
advances in the Àeld of lung cancer, with signiÀcant 
impact on the diagnostic pathologist. A key 
aspect is increasing recognition of the need for 
multidisciplinary review, borne out by the recently 
published revision of adenocarcinoma classiÀcation 
(1) where previous iterations were criticised for 
being too “for pathologists by pathologists.” 
The importance of multidisciplinary review is 
emphasized in relation to the increasing requests 
for molecular data, the need for further sampling 
in relation to equivocal or ‘non-speciÀc’ categories 
of diagnosis, and whether clinical features may 
assist in reÀning diagnosis and deciding future 
management. The pathologist must be part of 
these discussions, especially ensuring judicious 
use of tissue, in particular preservation of positive 
cytological specimens. One of the products of the 
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to the therapeutic decision through multidisciplinary 
meetings with the surgeons, radiotherapists, 
radiologists, pathologists. Depending on the country 
of origin they may be also involved in the medical 
treatment of lung cancer (chemotherapy and targeted 
therapies). Regarding this speciÀc role, there is at 
present much more controversy. Across European 
countries, medical oncologists are mainly those 
who conduct chemotherapy treatments for example 
in Spain, Italia, United Kingdom, Germany.... 
whereas in France, for example, pulmonologists 
are on historical grounds, strongly involved in the 
medical treatment of lung cancer patients. In US, 
generally speaking, chemotherapy is delivered by 
medical oncologists. There are some noticeable 
exceptions such as the editor in chief of the Journal 
of Thoracic Oncology, Jim Jett. As a matter of fact, 
thoracic oncology is now considered as a major part 
of the medical organizations dealing with respiratory 
diseases. For example, in the European Respiratory 
Society (ERS), thoracic oncology group which 
was part of the clinical assembly has been replaced 
in 2010 by an assembly indicating that thoracic 
oncology has become a strong pillar of the society 
. Since this decision, European guidelines in the 
Àeld of Thoracic Oncology have been published 
either by the ERS alone or in association with the 
European Society of Thoracic Surgeons regarding 
the preoperative assessment of lung cancer patients 
or the management of malignant mesothelioma. 
Collaboration has also been established with the 
European Society of Medical Oncology and the 
European Society for Therapeutic Radiology and 
Oncology and two meetings have been held by the 
European Multidisciplinary Conference in Thoracic 
Oncology. Also Thoracic Oncology is now part of 
the HERMES (Harmonised Education in Respiratory 
Medicine for European Specialists) besides post-
graduate courses which were organised for many 
years by the ERS during the annual congress. The 
American College of Chest Physicians also edit 
recommendations about treatment of lung cancer 
on a regular basis, recommendations that concern 
not only the pretherapeutic management of lung 
cancer but also medical treatment. this seems to 
indicate that at least North American pulmonologists 
are interested in the therapeutic management of 
lung cancer. The future role of pulmonologists 
in the multimodality management of lung cancer 
will probably be deÀned by the health politics of a 
given country, by the relative number of medical 
oncologists and pulmonologists in this country which 
D, Shah P, et al. ReÀning the Diagnosis and EGFR 
Status of Non-small Cell Carcinoma in Biopsy 
and Cytologic Material, Using a Panel of Mucin 
Staining, TTF-1, Cytokeratin 5/6, and P63, and 
EGFR Mutation Analysis. Journal of Thoracic 
Oncology 2010;5:436-441. 3. International Union 
Against Cancer (UICC). TNM classiÀcation of 
malignant tumours. 7 ed. New York: Wiley-Liss; 
2009. 4. Girard N, Deshpande C, Lau C, et al. 
Comprehensive histologic assessment helps to 
differentiate multiple lung primary nonsmall cell 
carcinomas from metastases. Am J Surg. Pathol. 
2009;33:1752-1764. 5. Shimizu K, Yoshida J, Nagai 
K, et al. Visceral pleural invasion classiÀcation in 
non-small cell lung cancer: a proposal on the basis 
of outcome assessment. J Thorac. Cardiovasc. Surg. 
2004;127:1574-1578. 6. Osaki T, Nagashima A, 
Yoshimatsu T, Yamada S, Yasumoto K. Visceral 
pleural involvement in nonsmall cell lung cancer: 
prognostic signiÀcance. Ann. Thorac. Surg. 
2004;77:1769-1773. 7. Coate LE, John T, Tsao MS, 
Shepherd FA. Molecular predictive and prognostic 
markers in non-small-cell lung cancer. Lancet Oncol. 
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Y.5.3 THE FUTURE ROLE OF 
DIFFERENT SPECIALISTS IN 
MULTIMODALITY MEDICINE (LUNG 
CANCER) - PULMONOLOGIST
Elisabeth Quoix 
Pulmonary Medicine Department, Strasbourg 
University Hospital/France
Abstract: Lung cancer is the Àrst cause of death 
by cancer in the developed and developing world 
. While its incidence is decreasing in males in 
developed world, there is still an important increase 
in females. Looking at the present situation, 
pulmonologists are by deÀnition involved in the 
prevention (especially regarding smoking habits) 
the diagnosis and the pre-treatment evaluation 
(disease extent assessment and medical assessment 
especially for surgical management). Taking into 
account that they are especially trained in chest 
imaging, bronchoscopy and pulmonary function 
testing, there is no controversy about their role in 
the diagnosis and pre-therapeutic evaluation of a 
lung cancer. As such they are entitled to participate 
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Y.5.4 THE FUTURE ROLE OF 
DIFFERENT SPECIALISTS IN 
MULTIMODALITY MEDICINE (LUNG 
CANCER) - RADIOTHERAPIST
Billy W. Loo 
Radiation Oncology, Stanford University & Cancer 
Center/United States Of America
Abstract: The role of the Radiation Oncologist in 
the multimodality treatment of lung cancer continues 
to increase. Numerous technological advances 
in imaging and radiation treatment delivery have 
increased both the indications and therapeutic 
window for radiation therapy. Future improvements 
in early detection of lung cancer as well as more 
efÀcacious individualized and molecularly-targeted 
systemic therapies will only increase the potential for 
localized radiation therapy to improve cure rates and 
prolong survival in both early and advanced stage 
lung cancer. For Radiation Oncologists, the future is 
bright!
Keywords: Radiation Therapy, Stereotactic ablative 
radiotherapy (SABR), Image-guided radiation 
therapy (IGRT)
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Y.5.5 THE FUTURE ROLE OF 
DIFFERENT SPECIALISTS IN 
MULTIMODALITY MEDICINE (LUNG 
CANCER) - SURGEON
Gavin M. Wright 
Thoracic Surgery, St Vincent’s Hospital/Australia
Abstract: Traditional Thoracic Surgeon has up 
to now been a highly skilled technician, with a 
large grounding in cardiovascular and respiratory 
physiology, anatomy and pathology. Traditional 
Thoracic Surgeon has often been non-specialized, 
with a signiÀcant workload of cardiac or general 
surgery to contend with. As such, it has been 
difÀcult for all but a minority of thoracic surgeons 
to be complete surgical oncologists. Before this 
decade, that probably mattered little. Patients with 
lung cancer lived or died according to whether 
they had a complete lung cancer resection. 
It was accepted that some patients would be 
explored and closed up. There was no adjuvant 
chemotherapy, no evidence of beneÀt for doing 
will determine either restriction or encouragement 
for chemotherapy delivery by chest physicians. 
Above all, it will depend on the training received 
and in this respect the organization of this training 
by the ScientiÀc Societies of Respiratory Diseases 
is of paramount importance. The pulmonologist is 
at a crucial place for lung cancer management as 
he is the only one who holds the tools of diagnosis 
making. Whether he wants or not to participate to the 
therapeutic management depends on him for a great 
part. 
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The result of advances in survival is that this 
chronic disease will need more sustainable palliative 
measures. There will be more aggressive surgical 
palliation and the long-term returns will justify this 
intervention.
The increasing need for palliation with minimal 
invasion will see Future Thoracic Surgeon widening 
the surgical armamentarium to include endobronchial 
techniques, implantable catheters and more novel 
methods of obtaining good tissue biopsies.
Tissue will also be needed for research purposes as 
recent collaborations have shown that there are still 
mutations to be found if you have a large enough “n” 
for the particular tumour subtype. Surgeons need to 
be involved with the laboratory researchers and the 
latter need to actively engage the surgeons if they 
are to be successful. The increasing need for tissue 
for clinical and research purposes will probably 
increase the workload for Future Thoracic Surgeon. 
This, along with the increased VATS Wedge 
workload from lung cancer screening will more 
than compensate for the probable reduction in major 
anatomical lung cancer resections.
Leadership in the multidisciplinary meeting is a 
role that should be sought by the dedicated Future 
Thoracic Surgeon. This will mean being educated 
and updated in the fundamentals of all the managing 
disciplines, and also knowing where other surgical 
specialists can assist in palliation and tissue 
acquisition. Future Thoracic Surgeon must now 
truly be the consummate surgical oncologist while 
continuing with the successes of Traditional Thoracic 
Surgeon.
Keywords: histology, palliative care, lymph node 
dissection, neoadjuvant
more complete node dissections, and proving a 
recurrence histologically didn’t really change 
the ongoing palliative management of a patient. 
Palliative surgery extended to spraying in some 
talc for a recurrent pleural effusion. The 20-25% 
of presenting patients that could have a resection 
only expected their surgeon to cure about 50% of 
them and for the rest it was “bad luck” and over to 
the medical and radiation oncologists to deal with. 
The last decade has seen some fairly monumental 
changes that have radically altered this traditional 
surgical paradigm. The changes to the staging 
system places more emphasis on very accurate 
staging, and now it actually matters. Finding just 
a single microscopically positive mediastinal node 
will mean a patient will get adjuvant chemotherapy 
and improve their chances of being alive at 5 years 
by 4-15%. PET scanning, EBUS and improved 
spiral CT technology should result in fewer futile 
operations, and surgeons should now hold their 
complete resection benchmark rate at well over 
90%. It is now more important than ever to get 
an accurate histological diagnosis, even in stage 
IV disease, as choice of chemotherapy agent is 
now dependent on histology. Being able to biopsy 
patients to determine mutational status (e.g. EGFR, 
ALK, FGFR1) is now critical for increasing overall 
survival and quality of life. Adenocarcinoma is no 
longer a single disease, and with comprehensive 
histological subtyping Future Thoracic Surgeon 
can offer better prognostication. It is now possible 
to explain the wide variation in survival with 
adenocarcinoma by the predominant subtype. 
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that oncology should be taught as a separate subject. 
Surveys of medical undergraduates have shown that 
over the last decade students had less contact with 
patients and retain some misconceptions about cancer. 
Only one quarter of Egyptian doctors knew that breast 
cancer was commonest in post-menopausal women. 
A survey of 139 medical students at the University 
of Malaysia showed that 29% had rarely visited 
a radiotherapy department and only 35% had the 
knowledge to prescribe morphine for cancer pain.
In order to deliver appropriate standards of cancer 
teaching an undergraduate program should incorporate 
a national or international standard curriculum and a 
minimum number of essential experiences. Because 
assessment drives education, students’ knowledge, 
skills and attitudes relating to cancer should be 
assessed and the outcomes of such assessment 
should inform the curriculum. An example of a 
cancer curriculum that reÁects the diversity of cancer 
knowledge that is required is the Cancer Council 
Australia’s Ideal Curriculum in Oncology for 
Medical Students (http://www.cancer.org.au//policy/
Publications/IdealOncology.htm).
Access to education about cancer has been improved 
by new internet resources for health professionals. 
Information technology offers new opportunities to 
deliver education resources to larger audiences. The 
Applied Sciences of Oncology Course (ASOC) was 
sponsored by International Atomic Energy Agency 
(IAEA). It is a free course in English aimed at trainee 
oncologists. ASOC comprises 80 one-hour modules of 
interactive teaching on CD ROM. The program arose 
from a long-standing face-to-face teaching course. It 
is available from http://www.iaea.org/Publications/
Training/Aso/register.html . In two years it has been 
downloaded over 2000 times.
The Virtual University for Cancer Control and 
Regional Training Network (VUCCnet) is a new 
initiative of the Program for Action on Cancer 
Treatment (PACT) of IAEA to establish a training 
network for oncologists between four centres in 
sub-Saharan Africa. It aims to increase the number 
of trainees and support them with a range of on-line 
resources and mentoring in radiation medicine.
Cure4Kids (https://www.cure4kids.org/ums/home/) 
from St Jude’s Hospital provides medical education 
on children’s cancer with interactive forums, wikis 
and on-line seminars. By establishing collaborations 
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Y.6 IMPROVING ACCESS TO 
EDUCATION AND CANCER CARE IN 
DEVELOPING COUNTRIES
Michael Barton 
Sw Clinical School, Faculty Of Medicine, Univesity 
Of NSW/Australia
Abstract: Cancer in Low and middle income 
countries. Over half of all cases of cancer in the world 
arise in people in low and middle income (LMI) 
countries. These are countries where the average 
annual income is less than US$9386. By 2020 it is 
estimated that 70% of cases of cancer will occur in 
LMI countries.
The causes and distribution of cancer types in LMI 
differ from high income countries with a greater 
proportion of cancers related to preventable causes 
such as HPV, viral hepatitis and smoking. This and 
the perceived cost of cancer treatment have lead to 
a one-sided emphasis on cancer prevention from 
some international organisations. Despite this cancer 
treatment is delivering signiÀcant services in LMI. 
The multidisciplinary nature of cancer care means 
that cancer requires special attention to develop 
comprehensive cancer control plans with involvement 
of health professionals, administrators, politicians and 
academics.
Health professionals and specialists need relevant and 
ongoing education about cancer that has often been 
missing from teaching programs. Cancer treatment 
can be effective and is within the reach of most low 
and middle income countries.
Education about cancer: SigniÀcant gains in cancer 
outcomes can be made by improving education 
of health professionals about cancer. Medical 
undergraduate education about cancer leaves 
many practitioners ill-prepared to deal with it. All 
practitioners need some knowledge of cancer. Those 
practicing in rural areas may need more knowledge 
because of their isolation from tertiary services. 
Many oncologists feel that they do not have adequate 
access to students because of entrenched attitudes 
within universities aimed at protecting established 
teaching programs and leaving little room to adapt 
teaching to the changing needs of society. 80% of 
Argentinean oncologists felt that oncology teaching 
for undergraduates was inadequate and 73% thought 
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Y.7 AN EXAMPLE OF A 
MULTIDISCIPLINARY PATIENT AND 
TREATMENT DECISION MEETING
Emile F. Comans 
Nuclear Medicine & Pet Research, VU Medical 
Center/Netherlands
Abstract: Accurate staging and tailored therapy 
are key elements with respect to the evaluation of 
(suspected) lung cancer patients. The diagnostic 
workup of patient has become increasingly complex 
during the last years. This can be explained in part by 
the extensive use of various conventional (laboratory 
tests, bronchoscopy, physical examination) and 
new (multislice CT, PET-CT, MRI, and EBUS/
EUS) diagnostic tests. In addition, the therapeutic 
options in NSCLC patient have increased both in 
a quantitative (RFA ablation treatment, combined 
modality treatment) and in a qualitative (VATS 
procedures, stereotactic radiotherapy) manner. 
The aim of this presentation is to give young 
docters(potentially) involved in the decision making 
process of a multidisciplinary lung oncology 
meeting suggestions that may help them in their 
(future) role within such a team. A clinical case will 
be presented to illustrate the need to have access 
to essential information available for effective 
communication between the participants of the 
meeting. Adequate preparation of the meeting and 
case presentation, including complete patient data 
(patient demographics, (smoking) history, Àndings 
from physical examination and laboratory test results 
including pulmonary function tests) and the results 
of additional diagnostic tests (conventional X-ray, 
CT scans, PET-CT and Àndings from bronchoscopy) 
should be available during the meeting. From 
the perspective of an imaging specialist (nuclear 
medicine physician) with extensive experience 
in lung cancer staging and a member of such a 
multidisciplinary team frequently encountered 
dilemmas and elements for discussion will be 
addressed. The presenter will focus on conditions 
that are essential for effective communication 
between the different disciplines (pulmonologists, 
surgeons, oncologists, radiotherapists, pathologists 
and imagers) to facilitate the (further) diagnostic 
evaluation and come to the optimal choice of 
therapy.
Keyword: Multidisciplinary
with centres in LMI countries they have demonstrated 
improvements in survival from childhood cancers.
Access to cancer care: Cancer treatment programs 
must be supported along with prevention programs. 
While many cancers may be preventable this will 
not help the current cases of cancer or those that will 
develop in the next 10 to 20 years.
Cancer treatment in LMI has a different focus because 
of the different types of tumours and because patients 
present with more advanced stage cancers. Between 
50% and 80% of breast cancers in LMI countries 
were advanced at diagnosis compared with 15% in 
High Income countries, and 56% of cervix cancers in 
Bangalore, India were Stage III compared with 15% 
in High Income countries. More advanced cancers are 
less likely to be amenable to surgery and therefore are 
more likely to be treated by radiotherapy.
Radiotherapy has a signiÀcant role because tumours 
present later and surgical expertise is often limited. 
Most surgeons are general surgeons or gynaecologists. 
Radiotherapy is one of the most cost-effective forms 
of cancer treatment. A study of 11 countries showed 
that the average cost of cobalt treatment was $4.87. 
Estimates suggest that radiotherapy is the treatment 
of choice in 47% and 67% of cancer patients. Yet a 
survey of 72 LMI countries found 24 countries with 
populations over 1 million that did not have any 
radiotherapy service. Access to chemotherapy drugs is 
difÀcult although many countries purchase the WHO 
“Essential Drugs list”.
The provision of safe and effective oncology services 
is complex. It requires a substantial capital investment 
in radiotherapy equipment and specially-designed 
buildings as well as ongoing investment in drugs, 
maintenance and replacement of the equipment, expert 
teams of doctors, therapists, physicists, and nurses. 
Even if funds are available, the necessary medical, 
scientiÀc and technical expertise is in short supply in 
many countries. This is the main constraint in many 
LMI countries.
Improvements in access will only come with good 
service planning, investment in equipment, linkages 
between facilities to reduce the risks of isolation, 
access to information, and appropriate educational 
resources.
Keywords: access, cancer care, education
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versus zoledronic acid (ZA) for preventing SREs 
in patients with bone metastasis from solid tumors 
(except breast and prostate) or with multiple 
myeloma.
Methods: Patients were randomized 1:1 to receive 
either monthly subcutaneous denosumab 120 
mg or intravenous ZA 4 mg (dose adjusted for 
renal impairment). Daily calcium and vitamin 
D supplementation was recommended. The 
primary endpoint of time to Àrst on-study SRE has 
previously been presented. An exploratory analysis 
was performed analyzing overall survival among 
patients with lung cancer (non-small cell lung cancer 
[NSCLC] or small cell lung cancer [SCLC]).
Results: In 801 patients with lung cancer (N=1776), 
overall survival was prolonged by 1.2 months 
with denosumab over ZA (median 8.9 months 
denosumab, 7.7 months ZA; HR 0.80 [0.67–0.95]; 
P=0.01). Improved survival was seen among 
those with NSCLC (n=702) receiving denosumab 
(median 9.5 months denosumab, 8.1 months ZA; 
0.78 [0.65–0.94]; P=0.01). Further analysis by 
histological type showed denosumab was associated 
with prolonged survival over ZA in squamous cell 
carcinoma (8.6 months denosumab, 6.4 months ZA; 
0.68 [0.47–0.97]; P=0.035) and adenocarcinoma 
sub types (0.80 [0.62–1.02]; P=0.075). Survival 
in patients with SCLC (n=109) was 7.6 months 
with denosumab versus 5.1 months with ZA (0.81 
[0.52–1.26]; P=0.36). Incidence of overall adverse 
events (AEs) among patients with lung cancer was 
balanced between groups (96.8% denosumab, 95.4% 
ZA), with serious AEs occurring less frequently 
with denosumab (66.0% denosumab, 72.9% ZA). 
Cumulative incidence of osteonecrosis of jaw was 
also balanced (0.7% denosumab, 0.8% ZA; P=1.0). 
Rates of hypocalcemia were 8.6% denosumab versus 
3.8% ZA.
Conclusion: In this exploratory analysis among 
patients with lung cancer, denosumab was associated 
with an improved overall survival compared with 
ZA. This observation warrants further investigation.
Keywords: non-small cell, small cell, Overall 
survival, Clinical trial
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O01.01 OVERALL SURVIVAL 
IMPROVEMENT IN PATIENTS WITH 
LUNG CANCER TREATED WITH 
DENOSUMAB VERSUS ZOLEDRONIC 
ACID: RESULTS FROM A RANDOMIZED 
PHASE 3 STUDY
Giorgio Scagliotti1, Vera Hirsh2, Salvatore Siena3, 
David Henry4, Penella Woll5, Christian Manegold6, 
Philippe Solal-Celigny7, Gladys Rodriguez8, Maciej 
Krzakowski9, Nilesh D. Mehta10, Lara Lipton11, José 
A. García-Sáenz12, Jose Pereira13, Kumar Prabhash14, 
Ciuleanu Tudor-Eliade15, Vladimir Kanarev16, Amy 
Feng17, Ira Jacobs17 
1Clinical And Biological Sciences, University Of 
Turino/Italy, 2Department Of Oncology, McGill 
University Health Centre/Canada, 3Ospedale 
Niguarda Cà Granda/Italy, 4Joan Karnell Cancer 
Center/United States Of America, 5Weston Park 
Hospital, University Of ShefÀeld/United Kingdom, 
6Klinikum Mannheim/Germany, 7Clinique Victor 
Hugo/France, 8South Texas Oncology And 
Hematology/United States Of America, 9Medical 
Oncology, The Maria Sklodowska-curie Institute 
Of Oncology/Poland, 10Oncology Hematology 
Associates Of Northern Illinois/United States Of 
America, 11Western Hospital/Australia, 12Hospital 
Clínico San Carlos/Spain, 13Oncopneumology 
Department, Instituto Do Cancer Arnaldo Vieira De 
Carvalho/Brazil, 14Medical Oncology, Tata Memorial 
Hospital/India, 15Institutul Oncologic I. Chiricuta/
Romania, 16Regional Oncology Dispensary With 
Inpatient Sector/Bulgaria, 17Amgen Inc./United 
States Of America
Background: Denosumab (XGEVA™), a fully 
human anti-RANKL monoclonal antibody, is 
approved in the United States to prevent skeletal-
related events (SREs) in patients with solid tumors 
and bone metastasis including lung cancer. We 
present here survival data for patients with lung 
cancer participating in a phase 3 trial of denosumab 
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O01.03 BRITISH THORACIC ONCOLOGY 
GROUP TRIAL, BTOG2: RANDOMISED 
PHASE III CLINICAL TRIAL OF 
GEMCITABINE COMBINED WITH 
CISPLATIN 50MG/M2 (GC50) VERSUS 
CISPLATIN 80MG/M2 (GC80) VERSUS 
CARBOPLATIN AUC 6 (GCB6) IN 
ADVANCED NSCLC
David Ferry1, Lucinda Billingham2, Hugh Jarrett2, 
David Dunlop3, Joyce Thompson4, Muthu Kumar5, 
Geraldine Skailes6, Marianne Nicolson7, Riyaz 
Shah8, Pauline Leonard9, A Chetiyawardana10, Paula 
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1Oncology, New Cross Hospital/United Kingdom, 
2University Of Birmingham/United Kingdom, 
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Cancer Centre/United Kingdom, 4Birmingham 
Heartlands Hospital/United Kingdom, 5Derby Royal 
Hospital/United Kingdom, 6Royal Preston Hospital/
United Kingdom, 7Aberdeen Royal InÀrmary/United 
Kingdom, 8Kent Oncology Centre/United Kingdom, 
9Whittington Hospital/United Kingdom, 10Manor 
Hospital/United Kingdom, 11Whipps Cross Hospital/
United Kingdom, 12Imperial College Healthcare/
United Kingdom, 13University Of ShefÀeld/United 
Kingdom, 14HuddersÀeld Royal InÀrmary/United 
Kingdom, 15Oncology, St James’s Hospital/Ireland
Background: Platins are considered the key 
drugs in the treatment of stage IIIB/IV NSCLC. 
Carboplatin has been reported as inferior to 
cisplatin in meta-analyses (Ardizzoni et al 2007, 
JNCI , 99, 847) and the optimal dose of cisplatin 
has not been subjected to meta-analysis or large 
RCT and is unclear.
Methods: Patients were eligible if they had 
histologically proven NSCLC, performance 
status (PS) 0-2, stage IIIB/IV disease and had a 
glomerular Àltration rate (GFR) of > 60 mL per 
min calculated using the Wright equation. They 
were randomised to gemcitabine (1250mg/m2) 
combined with cisplatin 50mg/m2 , cisplatin 80mg/
m2 or carboplatin AUC 6, all for up to 4 cycles. The 
dose of carboplatin was calculated using the Calvert 
equation. Quality of life was assessed with standard 
tools. At the time of analysis 1223 deaths had been 
reported, allowing the trial to be analysed according 
to the statistical plan.
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O01.02 RANDOMIZED PHASE 3 TRIAL 
OF AMRUBICIN VERSUS TOPOTECAN 
AS SECOND-LINE TREATMENT FOR 
SMALL CELL LUNG CANCER (SCLC)
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United States Of America, 11University Hospital 
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Hospital NHS Foundation Trust/United Kingdom, 
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Abstract under Embargo - will be presented in a 
press conference during WCLC 2011.
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O01.05 PARAMOUNT: PHASE III 
TRIAL RESULTS OF MAINTENANCE 
PEMETREXED PLUS BEST SUPPORTIVE 
CARE (BSC) VERSUS PLACEBO PLUS 
BSC IMMEDIATELY FOLLOWING 
INDUCTION TREATMENT WITH 
PEMETREXED PLUS CISPLATIN FOR 
ADVANCED NONSQUAMOUS NON-
SMALL CELL LUNG CANCER (NSCLC)
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8Jawaharlal Nehru Cancer Hospital And Research 
Center/India, 9University Hospital Of Hamburg-
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Germany, 11University Hospital - Virgen Del Rocio/
Spain, 12Eli Lilly And Company/United States 
Of America, 13Eli Lilly And Company, Suresnes/
France, 14Eli Lilly And Company, The Netherlands/
Netherlands, 15S. Giuseppe Moscati Hospital/Italy
Abstract under Embargo - will be presented in a 
press conference during WCLC 2011.
Results: This trial randomised 1363 patients, 
between April 2005 and November 2009. The 
arms of the trial were well balanced for PS, stage 
and age. Median age of all patients was 63 years, 
32% were PS0, 60% PS1 and 8% PS2. The median 
delivered dose intensity (planned = 100%) in the 
three arms for platinum were GC50 99%, GC80 
96% and GCb6 87% and for gemcitabine were 
95%, 88% and 80% respectively. During treatment 
the proportion of patients on each treatment arm 
who experienced at least one grade 3 or 4 adverse 
event was GC50 27%, GC80 41% and GCb6 57%. 
At time of analysis there were 140 patients alive 
with a median follow-up of 21 months. Response 
rates were signiÀcantly different between the 
arms; GC50 23%, GC80 33% and GCb6 28% (P 
= 0.01). Median survival in the arms were GC50 
8.3 months, GC80 9.5 months and GCb6 10.0 
months, with the GC50 treatment arm statistically 
selected as the one that differs from the other two. 
For the subsequent primary comparisons of non-
inferiority of GC50 v GC80 (HR=1.11) and GCb6 
v GC80 (HR=0.96), the 95% conÀdence interval 
for the cisplatin dose comparison (0.96, 1.27) did 
not exclude the pre-deÀned inferiority region of 
HR>1.2 whereas the 95% conÀdence interval for 
the GCb6 v GC80 comparison (0.84, 1.10) fell well 
below this inferiority region. 
Conclusion: In advanced NSCLC the dose of 
cisplatin is important with GC50 giving the 
poorest outcome in terms of overall survival and 
response rate. GCb6 is not inferior to GC80, thus 
in combination with gemcitabine and in relation to 
survival time carboplatin is clinically equivalent to 
that of cisplatin but other factors such as quality of 
life may have an inÁuence on choice of treatment.
Keywords: Advanced NSCLC, BTOG2, Cisplatin, 
gemcitabine
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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Background: The objective of the phase 3 
MONET1 study was to assess whether treatment 
with motesanib, a selective oral inhibitor of vascular 
endothelial growth factor (VEGF) receptors 1, 2, 
and 3, the platelet-derived growth factor (PDGF) 
receptor and Kit, in combination with carboplatin/
paclitaxel (C/P) improves overall survival (OS) 
compared with placebo plus C/P among patients with 
advanced NSCLC and among a subset of those with 
adenocarcinoma histology.
Methods: This randomized, placebo-controlled, 
double-blind study enrolled patients with 
histologically conÀrmed, unresectable stage IIIB 
(with pericardial or pleural effusion), stage IV, or 
recurrent nonsquamous NSCLC. Exclusion criteria 
included prior chemotherapy, adjuvant chemotherapy 
within 52 weeks of randomization, and prior 
targeted therapies. Based on recommendations from 
the Independent Data Monitoring Committee, the 
study protocol was amended to exclude patients 
with squamous histology owing to the high rate 
of hemoptysis observed in this population. All 
patients were to receive C (AUC, 6 mg/mL·min) 
and P (200 mg/m2) IV on day 1 of each 3-week 
cycle (for up to 6 cycles). Patients were randomized 
1:1 to also receive motesanib 125 mg once daily 
(QD) continuously orally (Arm A) or placebo 
continuously orally (Arm B). Randomization was 
stratiÀed by weight loss, sex, disease stage, and 
prior adjuvant chemotherapy. Treatment continued 
until disease progession, unacceptable toxicity, or 
death. The primary endpoint is OS time. Secondary 
endpoints include progression-free survival (PFS), 
objective response rate, and prespeciÀed biomarker 
analysis. Per the amended protocol, the study has 
a planned sample size of 1060 and is designed to 
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long follow-up. We studied the incidence and risk 
factors for chest wall pain (CWP) and rib fractures 
in patients who were treated with SABR at a single 
center.
Methods: Between 2003-2009 500 patients with 
530 tumors underwent SABR for stage I NSCLC 
(T1N0=307; T2N0=223) using a risk-adapted 
fractionation scheme consisting of 3 fractions of 
20Gy (T1, not adjacent to chest wall), 5 fractions 
of 12Gy (T1, adjacent to chest wall or T2) or 8 
fractions of 7.5Gy (central lesions). Target volumes 
were derived using a 3mm-margin added to tumor 
positions observed on 4D-CT scans. SABR was 
delivered with 8-12 non-coplanar static beams, and 
planning was dedicated to avoid hotspots in the chest 
wall. Toxicity data were collected in a prospective 
database and scored using CTC-AE v4.03. Follow-
up CT scans were performed at 3, 6 and 12 months 
post-SABR, and yearly thereafter.
Results: Median follow-up was 33 months. Overall 
survival and local control rates were 53.1% and 
90.4% at three years, respectively. Early onset of 
chest wall pain after SABR was reported in 32 
patients (6.4%), and represented Grade 1-2 in 27 
patients (5.4%) and Grade 3 in 5 patients (1.0%). 
Chest wall erythema was observed in 2.8%. Any 
late CWP was reported in 25 patients (5.0%). The 
actuarial rates of severe CWP and rib fractures at 
three years post-SABR were 2.2% (10 patients) 
and 2.7% (8 patients). Only two patients with 
fractures had Grade 3 CWP. The median time to 
developing severe CWP and rib fractures was 4 and 
24 months post-SABR, respectively. The median 
tumor-chest wall distance in patients with Grade 3 
CWP and rib fractures were 0mm (range 0-24mm) 
and 2mm (range 0-5mm), respectively. Patients 
who developed CWP had a signiÀcantly larger 
tumor volume (p=.007) and shorter tumor-chest 
wall distance (p=.007) than patients without CWP. 
Conclusion: Severe chest wall pain and rib fractures 
are uncommon after risk-adapted Àxed-beam SABR, 
particularly in tumors located 5mm or more from the 
chest wall.
Keywords: early stage non-small cell lung cancer, 
chest wall toxicity, stereotactive ablative body 
radiotherapy
have 80% power to detect hazard ratios for OS of 
1.25 among nonsquamous patients and 1.3 for the 
subset of patients with adenocarcinoma histology. 
The comparison of OS between Arms A and B will 
be performed using a 2-sided log-rank test with a 3% 
(Ơ=0.03) signiÀcance level for nonsquamous patients 
and 2% (Ơ=0.02) for adenocarcinoma patients. 
Descriptive data for clinical outcomes (PFS and OS) 
will also be presented for patients with squamous 
cell histology (n=360) who were randomized prior to 
the protocol amendment. Adverse event data will be 
reported for all patients with nonsquamous histology, 
the patient subset with adenocarcinoma, and patients 
with squamous cell histology. All presented data will 
be from the primary analysis, which is anticipated to 
be completed in March 2011.
Results: This is a latebreaking abstract.
Conclusion: This is a latebreaking abstract.
Keywords: motesanib, carboplatin/paclitaxel, 
non-squamous non-small-cell lung cancer, Overall 
survival
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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O02.01 CHEST WALL TOXICITY 
FOLLOWING RISK-ADAPTED 
STEREOTACTIC RADIOTHERAPY FOR 
EARLY STAGE LUNG CANCER
Eva Marrit Bongers, Cornelis J. Haasbeek, Frank J. 
Lagerwaard, Ben Slotman, Suresh Senan 
Radiation Oncology, VU University Medical Center/
Netherlands
Background: Stereotactic ablative body 
radiotherapy (SABR) achieves local control rates 
in stage I non-small cell lung cancer (NSCLC) 
that are comparable to those reported after surgery. 
Chronic chest wall toxicity is observed in up to 
30% of patients undergoing lobectomy (Karmaker, 
2004). The exact incidence of chest wall toxicity 
after SABR is unknown, as few reports are available 
on large numbers of patients with sufÀciently 
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60 Gy, 66 Gy, 70Gy, and 80 Gy in 43, 32, 
20, and 7 patients, respectively. Fourteen patients 
developed clinical symptoms consistent with brachial 
plexopathy: 3 RIBP, 7 TRBP, 1 RIBP and TRBP, 
and 2 trauma-related. All patients who developed 
RIBP or TRBP received chemotherapy. Locoregional 
control was 75% and median follow-up was 31.5 
months (range, 8-44) for RIBP patients and 13% and 
13.0 months (range, 4-44) for TRBP patients. Of the 
29 patients with local failure, 24% developed TRBP.
No. 
(%) 
CTCAE 
v.4.0 
Grade 
Chemo-
therapy 
Mean 
Maximal 
Brachial 
Plexus Dose 
(range) 
Mean 
Prescribed 
Tumor 
Dose 
(range) 
Median  
time to 
symptoms 
(range) 
Radiation-
Induced 
4 
(4%) 
II: 3 III: 1 
Concurrent 2 
Sequential 2
84.6 Gy ± 2.7 
(79.1-90.9) 
79.0 Gy ± 
1.0 (76.0-
80.0) 
4.5 
months 
(4-27) 
Tumor-
Related 
8 
(8%) 
II: 5 III: 3 
Concurrent 6 
Sequential 2 
47.2 Gy ± 12.6 
(53.0-81.5) 
67.0 Gy ± 
1.8 (59.4-
76.0) 
6.0 
months 
(1-42) 
Conclusion: The brachial plexus frequently receives 
radiation doses exceeding historical RTOG dose 
constraints (60-66 Gy) in NSCLC patients with 
apical tumors treated with deÀnitive radiation or 
chemoradiotherapy. No patient who received a 
maximal dose of < 79 Gy to the brachial plexus 
developed radiation-induced plexopathy, while a 
high percentage of patients are at risk for developing 
symptomatic tumor-related brachial plexopathy 
if their primary disease is not controlled. These 
Àndings strongly suggest that primary tumor control 
with adequate doses of radiation outweighs the low 
risk of RIBP in this population of patients.
Keywords: RADIATION, Brachial plexopathy, 
Lung cancer
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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CANCER TREATED WITH DEFINITIVE 
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Background: Radiation dose escalation for apical 
non-small cell lung cancer (NSCLC) may be limited 
by the proximity of tumors to the brachial plexus. The 
radiation tolerance of the brachial plexus and radiation-
induced brachial plexopathy (RIBP) are understudied 
in this group of patients. We report on the incidence of 
RIBP and tumor-related brachial plexopathy (TRBP) 
and associated dosimetric parameters in NSCLC 
patients treated with curative intent.
Methods: We evaluated the records of NSCLC 
patients with primary upper lobe, superior 
mediastinal nodal, or supraclavicular/cervical 
neck disease treated with deÀnitive radiation 
or chemoradiotherapy between 2004 and 2010. 
Dosimetric data were gathered on ipsilateral brachial 
plexuses contoured on radiation treatment plans 
according to published RTOG atlas guidelines. 
Brachial plexopathy was deÀned as the development 
of new neuropathic pain, motor weakness, or 
sensory disturbances in the ipsilateral shoulder/
arm after treatment and was categorized as RIBP 
(no tumor progression), TRBP (presence of local 
tumor progression in proximity to brachial plexus), 
or trauma-related. Locoregional control and survival 
data were collected.
Results: Ninety-two patients were identiÀed (stage 
I 14, II 4, III 65, IV 9) with a median follow-up 
and survival time of 16.5 months (range, 1-70) and 
12.5 months (range, 1-38), respectively. The mean 
prescribed radiation dose was 68.9 Gy ± 0.7 (range, 
57.4-84.0). Seventy-two patients (80%) received 
either concurrent (n=52) or sequential (n=20) 
chemotherapy. The mean maximal brachial plexus 
dose was 59.7 Gy ± 2.8 (range, 0.5-90.9) and was 
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were 9.7% and 14.0% at 5 years, respectively. The 
5-year freedom-from-recurrence rate was 78.7%. 
SABR could be completed in all patients, and 42% 
of patients reported no early side effects. Observed 
early side-effects were fatigue (25%), cough (14%), 
local chest wall pain (11%) and dyspnea (10%), with 
some patients reporting more than one side effect. 
Grade 3 radiation pneumonitis and rib fractures 
were late complications, seen in 2% and 3% of 
patients, respectively. 
Conclusion: Potentially operable patients 
undergoing SABR had a median OS exceeding 5 
years and a local control rate of 93% at 5 years. 
These Àndings are comparable to results found in 
surgical series and support ongoing randomized 
clinical trials that compare surgery and SABR in 
potentially operable stage I NSCLC patients. 
Keywords: Stage I non-small cell lung cancer, 
Operable, Stereotactic ablative radiotherapy
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Background: IG-SBRT has been primarily 
employed in patients who are not operative 
candidates, a generally less healthy population. 
The purpose of this study is to compare outcomes 
following IG-SBRT in medically operable vs. 
medically inoperable patients in an international 
multi-institutional patient cohort.
Methods: Five international institutions contributed 
information on patients treated with IG-SBRT for 
University Medical Center/Netherlands, 3Department 
Of Pulmonary Diseases, VU University Medical 
Center/Netherlands
Background: The local control rates reported after 
stereotactic ablative radiotherapy (SABR) for stage 
I NSCLC are similar to those reported after surgical 
resection. In reaction to the high local control rates 
and low toxicity observed after SABR, Àt patients in 
the Netherlands have increasingly elected to undergo 
SABR instead of surgery in recent years. We studied 
SABR outcomes in a group of potentially operable 
stage I NSCLC treated at a single center. 
Methods: In an institutional prospective database, 
24% (n=177) of lung SABR cases treated between 
2003 and 2010 were classiÀed as potentially 
operable. These patients were retrospectively 
identiÀed by excluding the following patient 
categories: those with double lung tumors or other 
concurrent malignancy; those who had undergone 
prior high-dose radiotherapy or pneumonectomy; 
those with a COPD GOLD 3-4; and those with a 
WHO performance score 3 or with or other (mostly 
cardiovascular) co-morbidity precluding surgery. 
The operable group consisted of 101 males and 76 
females with a median age of 76 years. Total SABR 
dose was 60 Gy, delivered in 3, 5 or 8 fractions in 
1-2 weeks treatment time. Choice of fractionation 
depended on tumor size (T1 tumors 60%; T2 
tumors 40%) and location. Median Charlson co-
morbidity score was 2 (range 0-5). Patients without 
a histological diagnosis, but with a FDG-PET-
positive new or growing lesion with CT features of 
malignancy were accepted, as surgical publications 
report a <4% incidence of benign disease when 
the same Dutch tumor boards identiÀed patients 
for surgery. For patients lost to follow-up, survival 
status was obtained using the national population 
registration system containing information about all 
inhabitants of the Netherlands. 
Results: Median follow-up was 32 months. The 
median overall survival (OS) was 61.5 months with 
1-, 3- and 5-year survivals of 94.7%, 84.7% and 
51.3%, respectively. The 30-day mortality after 
SABR was 0%, while predicted 30-day mortality 
for a lobectomy derived using the Thoracoscore 
predictive model [Falcoz ‘07] would have been 
2.6% in this patient cohort. OS at 3 years in patients 
either with (n=59) or without (n=118) a histological 
diagnosis did not differ signiÀcantly (96% versus 
81%, respectively, p=.39). The local control rate at 5 
years was 93%, and regional and distant failure rates 
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declining a thoracotomy treated with IG-SBRT 
had overall survival and cancer-speciÀc outcomes 
equivalent to historic controls from surgical series. 
Although additional follow-up is required, our data 
support the continued investigation of IG-SBRT as 
an equivalent alternative to surgical treatment in 
operable patients. 
Keywords: stereotactic body radiation therapy 
(SBRT), Non-small cell lung cancer (NSCLC), 
medically operable
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Background: Patients with stage I non-small cell 
lung cancer (NSCLC) who are either ineligible 
for or refuse surgery have two curative intent 
treatment options: conventional radiotherapy 
(CRT) or stereotactic body radiotherapy (SBRT). 
No randomized trials have compared these two 
approaches. The purpose of this study was to conduct 
a cost-effectiveness analysis (CEA) comparing 
SBRT to CRT for stage I NSCLC patients within the 
context of a publicly funded health care system.
Methods: All patients with stage I NSCLC treated 
in a single large cancer center with either CRT or 
SBRT from January 2002 – June 2010 were included 
in the analysis, with SBRT being offered from 2004. 
Direct medical costs from the perspective of the 
Ontario public health care system were calculated, 
including physician billing, labour costs for radiation 
therapists, physicists, nurses, equipment maintenance 
staff, information technology support staff, and 
hospitalization due to acute adverse events. In 
addition, the subset of direct radiation treatment 
early stage (T1-T2N0M0) NSCLC. Multiple patient 
parameters including patient age, gender, tumor 
size and histology, pulmonary function, treatment 
regimen, and patient outcomes were recorded for 
both operable and inoperable patients. Operable 
patients treated with SBRT had been offered surgery 
after consultation with a thoracic surgeon and 
declined. Statistical comparison employed Fisher’s 
exact test or t-test. Multivariate proportional hazards 
regression was employed to determine the effect 
of operability on outcome. Overall survival, (OS), 
disease free survival (DFS), and local/regional/
distant failure (LF/RF/DF) were estimated with 
Kaplan-Meier methods.
Results: With a median follow-up of 1.5y for 
surviving patients, 483 patients were identiÀed 
with median age of 73 (42-93). In these patients, 
505 tumors with median tumor size 2.6cm (0.8-
8.5cm) were most commonly treated with dose/
fractionations of 48Gy/4# (n=128) or 54-60Gy/3# 
(n=231); 448 (87%) were in inoperable patients 
and 57 (13%) in operable patients declining 
surgery. Operable patients had higher mean ECOG 
performance status (PS) (0.8 vs. 1.1, p=0.02), 
%-predicted FEV1 (77% vs. 64%, p<0.01), and 
%-predicted DLCO (62 vs. 53%, p=0.001). 
There were no signiÀcant differences in operable/
inoperable patients with regard to mean age 
(73.1/73.5y), tumor size (2.7/2.8cm), T-stage (T1 
64%/68%), tumor grade (2.3/2.3), pre-treatment 
FDG SUV(7.0/7.9), or time from PET to treatment 
(6.4/6.7 weeks). For all patients, the 2-year OS and 
CSS were 62% and 89% respectively. The 2-year OS 
for operable patients was 78% vs. 58% for medically 
inoperable patients (p=0.006). On univariate 
analysis, operability correlated with OS (HR: 2.37, 
p=0.008) as did ECOG PS (HR: 1.53, p<0.001), 
male gender (HR: 1.70, p=0.001), DLCO (HR: 
0.917, p=0.005), GTV size (HR: 1.204, p=0.001), 
and interval between PET and treatment (HR: 1.035, 
p=0.03). There were no signiÀcant differences 
between operable/inoperable patients at two years 
in LF (2%/7%), RF (10%/12%), DF (10%/21%), or 
CSS (93%/89%). On multivariate analysis including 
operability, tumor size, gender, and performance 
status, operability remained signiÀcantly associated 
with OS (p=0.04). With a pulmonary function 
measure (absolute DLCO) included in the model, 
operability was no longer signiÀcantly associated 
with survival (p=0.09), consistent with a relationship 
between pulmonary function and medical operability.
Conclusion: In this dataset, operable patients 
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O02.07 STEREOTACTIC ABLATIVE 
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WITH STAGE I NON-SMALL CELL LUNG 
CANCER: A COMPARISON OF PATIENTS 
WITH AND WITHOUT PATHOLOGICAL 
PROOF
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J. Haasbeek, Ben Slotman, Suresh Senan 
Radiotherapy, VU Medical Centre/Netherlands
Background: Several small prospective studies have 
reported local control rates exceeding 85% after 
stereotactic ablative radiotherapy (SABR) for stage 
I non-small cell lung cancer (NSCLC). In contrast 
to reports from the USA and Japan, the majority of 
patients accepted for SABR in the Netherlands do not 
have a pathological diagnosis, as the likelihood of a 
benign 18FDG-PET positive pulmonary lesion is low in 
Western European populations. We compared outcomes 
of patients who underwent SABR with (N=209) and 
without (N=393) pathological proof of malignancy at 
our centre. 
Methods: SABR was delivered between 2003 and 
2010 using online patient-setup to a total dose of 60 
Gy in 3, 5 or 8 fractions, depending on tumor size 
and location. Patients were referred from 68 Dutch 
centres. Patients without histological diagnosis but 
with a 18FDG-PET-positive lesion with CT features 
of malignancy were accepted by a multidisciplinary 
tumor board, as the surgical literature reported a <4% 
incidence of benign disease following similar patient 
selection for surgery in the Netherlands. The majority 
(70%) were considered to be medically inoperable or 
were at high risk for surgical mortality; the remainder 
had refused surgery. Patients with multiple tumors were 
excluded from this analysis. The SABR population 
consisted of 361 males (60%) and 141 females (40%) 
with a median age of 75 years. Follow up consisted of 
routine chest CT scans obtained at 3, 6 and 12 months 
and yearly thereafter. Local control was deÀned as the 
absence of local progression and 18FDG-PET scans 
were obtained in case of suspected relapse. Both 
SABR cohorts were compared using the Student T-test 
and Chi-Square test and outcome parameters were 
calculated using Kaplan-Meier analysis.
Results: Median follow-up was 23 months. Both 
patient cohorts were well balanced with respect to age, 
gender, co-morbidity score and performance score. 
Patients with pathology had a signiÀcantly larger tumor 
diameter (p < .001) and a higher predicted FEV1% 
delivery costs excluding physician billings and 
hospitalization was calculated. Direct costs were 
obtained from professional groups, manufacturers 
and funding agencies at 2010 Canadian prices. 
Missing costs were derived from published literature 
or expert opinion. The effectiveness outcome of 
interest for both analyses was life-years gained. 
Time-to-event data was captured using Kaplan-
Meier and log-rank statistical methods. One-way 
and two-way sensitivity analyses were carried out 
to determine which factors most inÁuenced overall 
costs.
Results: From January 2002 – June 2010, 170 
patients (51 CRT; 119 SBRT) were treated, with 
a median follow-up of 24 months. Mean overall 
survival for the CRT group was 2.83 years (95%CI: 
1.8 - 4.1 years), and 3.86 years (95% CI: 3.2 - NR) 
for the SBRT group (p=0.06). The mean estimated 
life-years gained (LYG) with SBRT compared to 
CRT treatment was 1.03 years. Total mean direct 
costs for CRT were $6,885 overall, and $5,989 for 
radiation treatment delivery costs. In the SBRT arm, 
mean costs were $8,042, and $6,962 for treatment 
delivery only. The mean incremental cost per patient 
treated with SBRT was $1,156, $972 speciÀcally 
for treatment delivery. The incremental costs per 
LYG for SBRT over CRT were $1,120 from the 
public payer perspective, and $942 including 
treatment delivery costs only. A one-way sensitivity 
analysis showed that varying survival difference 
and direct labour costs +/-20% led to the largest 
changes in incremental cost for both analyses. When 
simultaneously adjusting both survival difference 
and direct labour costs by +/-5% to +/-30% in a two-
way sensitivity analysis to account for selection bias, 
potential stage migration, and efÀciency of SBRT 
over time, the incremental cost per LYG for SBRT 
versus CRT is still within the threshold for accepting 
a new health technology.
Conclusion: In this Àrst study of the cost-
effectiveness of SBRT over CRT in a publically 
funded health care system, SBRT appears highly cost 
effective.
Keywords: stereotactic body radiotherapy, 
conventional radiotherapy, Cost-effectiveness 
analysis, Stage I NSCLC
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O03.02 MEDIASTINOSCOPY AFTER 
NEGATIVE ENDOSONOGRAPHY 
IN LUNG CANCER STAGING. 
SUBANALYSIS OF ASTER WITH FOCUS 
ON CT.
Kurt G. Tournoy1, Robert C. Rintoul2, Christophe 
Dooms3, Ellen Deschepper4, Jouke Annema5 
1Respiratory Medicine - Thoracic Oncology, Ghent 
University Hospital/Belgium, 2Department Of 
Thoracic Oncology, Papworth Hospital/United 
Kingdom, 3Respiratory Oncology Unit, University 
Hospitals Leuven/Belgium, 4Biostatistics, Ghent 
University Hospital/Belgium, 5Respiratory Medicine 
- Thoracic Oncology, Leiden University Medical 
Centre/Netherlands
Background: Mediastinal staging in non-small 
cell lung cancer with endosonography (EUS-FNA 
plus EBUS-TBNA) followed by mediastinoscopy 
is more sensitive to detect nodal metastasis as 
compared to mediastinoscopy alone (ASTER trial, 
JAMA 2010;304:2245). However 11 patients need to 
undergo a mediastinoscopy to detect one with N2/3 
missed by endosonography. We analysed if lymph 
node size measured on CT scan can identify patients 
in whom the mediastinoscopy can be omitted. 
Methods: In ASTER, 123 patients were randomized 
to endosonography followed by mediastinoscopy 
if the former did not show mediastinal metastasis. 
Sensitivity, negative predictive value (NPV) and 
number of mediastinoscopies needed to detect one 
false negative endosonography were calculated in the 
cases with complete data (n=120; 98%). 
Results: With CT, 74 patients had enlarged 
mediastinal nodes (10mm), the prevalence of 
N2/3 was 65 (54-75)%. Sensitivity and NPV of 
endosonography was 86 (74-93) and 77 (60-88)%. 
Adding mediastinoscopy increased sensitivity and 
NPV to 96 (87-99) and 93 (77-98)%. In the 46 
patients without enlarged mediastinal nodes (N0/1) 
the prevalence of N2/3 was 39 (26-54)%. Sensitivity 
and NPV of endosonography was 89 (67-97) and 93 
(79-98)%. Adding mediastinoscopy did not improve 
this. In patients with enlarged vs normal-sized 
mediastinal nodes, the number of mediastinoscopies 
needed to detect one false negative endosonography 
is 6 vs. inÀnite (p=0.026). 
Conclusion: A negative endosonography should 
be followed by a mediastinoscopy in patients with 
enlarged mediastinal nodes on CT. In the absence 
value (p=.031). No signiÀcant difference could be 
demonstrated between both SABR cohorts in overall 
survival and recurrence patterns at three years (table 1). 
3-year endpoints PA+ PA- 
Overall survival 55.4% 54.4% P = .93 
Local control 90.4% 91.5% P = .92 
Regional control 90.3% 87.9% P = .83 
Distant control 79.6% 79.8% P = .95 
Disease free survival 72.1% 73.2% P = .98 
Conclusion: Both baseline patient characteristics 
and clinical outcomes were similar between 
pathology- proven and unproven patients with stage 
I lung cancer treated using SABR. This indicates 
that it is very improbable that previously reported 
outcomes were biased by inclusion of benign lesions.
Keywords: Stereotactic ablative radiotherapy, 
SABR, Radiotherapy, Stage I NSCLC
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O03.01 COMPARISON OF DIAGNOSTIC 
YIELD OF ENDOSCOPIC ULTRASOUND 
STAGING OF NON-SMALL CELL LUNG 
CANCER (NSCLC) PERFORMED WITH 
USE OF ENDOBRONCHIAL ULTRASOUND 
(EBUS) AND/OR ENDOESOPHAGEAL 
ULTRASOUND (EUS) WITH INVASIVE 
STAGING OF NSCLC PERFORMED WITH 
USE OF TRANSCERVICAL EXTENDED 
MEDIASTINAL LYMPHADENECTOMY 
(TEMLA)
Marcin Zielinski1, Artur Szlubowski2, Marcin 
Kolodziej3, Stanislas Orzechowski3, Ewa 
Laczynska3, Juliusz Pankowski4, Magdalena 
Jakubiak4, Anna Obrochta4 
1Thoracic Surgery, Pulmonary Hospital/Poland, 
2Bronchoscopy Unit, Pulmonary Hospital/Poland, 
3Pulmonology, Pulmonary Hospital/Poland, 
4Pathology, Pulmonary Hospital/Poland
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and low N1 LN counts). We tested interventions 
speciÀc to each site.
Methods: We used a special pre-labeled specimen 
collection kit to facilitate collection of N2 LN 
(special specimen collection) and developed a lung 
re-dissection protocol to retrieve discarded N1 LN 
(special pathology examination). We performed a 
3 arm case-control study: Arm 1, routine surgical 
LN collection + routine pathology examination; 
Arm 2, routine specimen collection + special 
pathology examination; Arm 3, special specimen 
collection + special pathology examination. The 
chi-square, Fisher-Freeman-Halton and Wilcoxon-
Mann-Whitney tests were used as appropriate for 
comparisons.
Results: Patient characteristics were similar across 
the 3 arms (Table). The number of N1 LN examined 
was higher in arms 2 and 3, compared to arm 1 
(p<0.0001); there was no difference between arms 2 
and 3 (p= 0.23). Arm 3 had more N2 LN examined 
than arm 1 (p<0.0001), or arm 2 (p <0.006); there 
was no difference between arms 1 and 2 (p= 0.14). 
The total number of LN examined was signiÀcantly 
higher in arms 2 and 3 than arm 1 (p<0.0001), and 
also in arm 3 compared to arm 2 (p<0.05). There 
were strong trends towards increase in number of 
LN with metastasis, and proportion of patients with 
node-positive disease, in arms 2 and 3, compared to 
arm 1.
 
Conclusion: Introduction of corrective interventions 
to improve LN examination was feasible and 
effective. The combination of intraoperative and 
pathology laboratory interventions are required to 
optimally improve pathologic staging accuracy. 
A randomized phase III study of these corrective 
interventions is indicated.
of enlarged nodes, a mediastinoscopy following a 
negative endosonography can be omitted.
Keywords: Staging, endosonography / EBUS-
TBNA / EUS-FNA, Mediastinoscopy, CT-scan
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O03.03 A COMPARISON OF 
INTERVENTIONS TO IMPROVE 
INTRAOPERATIVE LYMPH NODE (LN) 
COLLECTION AND PATHOLOGIC 
EXAMINATION OF LUNG RESECTION 
SPECIMENS.
Raymond U. Osarogiagbon1, Robert A. Ramirez2, 
Christopher G. Wang3, Laura E. Miller3, Jonathan 
Ellichman4, Glenn P. Schoettle4, Alim Khandekar4, 
Samuel G. Robbins5, Thomas O’Brien6, Jeffrey 
Gibson5 
1Multidisciplinary Thoracic Oncology, University 
Of Tennessee Cancer Institute/United States Of 
America, 2Department Of Hematology/oncology, 
University Of Tennessee Cancer Institute/United 
States Of America, 3Department Of Internal 
Medicine, University Of Tennessee Health Science 
Center/United States Of America, 4Thoracic And 
Cardiovascular Surgery, University Of Tennessee 
Medical Group/United States Of America, 5Thoracic 
And Cardiovascular Surgery, Germantown Methodist 
Hospital/United States Of America, 6Department 
Of Pathology, Duckworth Pathology Group/United 
States Of America
Background: Accurate determination of 
pathologic (p) lymph node (LN) status is vital for 
prognostication, post-operative management and 
cross-comparison of outcomes after resection of lung 
cancer. The location and number of positive LN, 
and (in pN0 patients) the number of examined LN, 
have prognostic value. Patients with unexamined LN 
(pNx) have worse survival than T-category matched 
pN0 patients; those with pN1 but no examined 
mediastinal (N2) LN, have worse survival than 
pN1 patients with at least 1 examined N2 LN. In 
the US, 18% of lung cancer resections are pNx; the 
median number of N1 LN examined is 3; 42% have 
no examined N2 LN; the median number of N2 
LN examined is between 0 and 1. We hypothesized 
that these statistics reÁect problems in both intra-
operative collection of LN (especially stations 2 to 
10) and in the pathology laboratory processing of 
submitted specimens (especially the problem of pNx 
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mediastinal nodal dissection. We found 35% of skip 
nodal metastases in the group of patients using US 
guided mediastinal lymphadenectomy. The incidence 
of N2 metastases seemed to be more frequent in 
adenocarcinoma patients (p<0.005), but skip N2 
metastases were signiÀcantly higher (p<0.001) in 
squamous cell carcinoma patients. Although skip 
metastases involved more often upper mediastinal 
lymph nodes and one station level, the difference 
was not found statistically signiÀcant (p<0.227). 
Complications rate showed no difference between 
analyzed groups of patients. 
Conclusion: Higher number and location of 
analyzed mediastinal nodal stations in patients with 
resected NSCLC using hand held ultrasound probe 
suggested to be of great oncology signiÀcance. 
Procedure showed absolute safety and high accuracy. 
Our results indicated that intraoperative US may 
have important staging implication. Further clinical 
studies should be carried out in order to improve 
intraoperative staging in NSCLC patients. 
Keyword: NSCLC, N2 disease, intraoperative 
ultrasound, skip mediastinal metastases
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O03.06 ESTABLISHING GUIDELINES 
FOR THE USE OF ENDOBRONCHIAL 
ULTRASOUND VERSUS 
MEDIASTINOSCOPY IN INVASIVE 
STAGING OF NON SMALL CELL LUNG 
CANCER
Michael F. Humer, Sana Z. Shahram, Bill Nelems 
Interior Group, BC Thoracic Surgery/Canada
Background: Traditionally, mediastinoscopy has 
been the main method for conducting invasive 
mediastinal lymph node assessment in non-small cell 
lung cancer (NSCLC). Endobronchial ultrasound 
(EBUS-TBNA) is a potential, less invasive method 
for sampling mediastinal lymph nodes. There is 
currently a lack of evidence directly comparing 
EBUS to mediastinoscopy; this evidence is necessary 
to establish guidelines for when each method is 
indicated in the mediastinal staging of NSCLC, 
while acknowledging that both methods have 
limitations.
Methods: From January 15, 2007 to January 14, 
2011, 618 patients had concurrent mediastinal 
lymph node sampling by both EBUS-TBNA and 
mediastinoscopy in a Thoracic surgery practice in 
Keywords: Pathologic staging, Quality 
improvement, Comparative effectiveness, lung 
cancer surgery
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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O03.05 INCREASED NUMBER OF SKIP 
MEDIASTINAL NODAL METASTASES IN 
THE IIIA/N2 NSCLC DETECTED USING 
INTRAOPERATIVE ULTRASOUND FOR 
MEDIASTINAL LYMPHADENECTOMY
Nenad Ilic1, Josko Juricic2, Josko Banovic1, Dragan 
Krnic1, Nives Frleta Ilic1, Z Covic1, Darko Ilic1 
1Thoracic Surgery Department, University Surgical 
Hospital/Croatia, 2University Surgical Hospital/
Croatia
Background: To study the incidence and 
characteristics of mediastinal nodal metastases 
without N1 nodal metastases (wskip-N2 metastasesw) 
in patients with resected pIII/A/N2 non-small 
cell lung cancer (NSCLC) using intraoperative 
ultrasound (US) for mediastinal lymphadenectomy.
Methods: A total of 240 NSCLC patients who 
underwent RO surgical resection followed by 
systemic mediastinal nodal dissection in four years 
time period (2005-2008) were retrospectively 
reviewed. Intraoperative hand held ultrasound probe 
was used for systematic mediastinal nodal dissection 
in a group of 120 patients and compared with the 
group of 120 patients who underwent lung resections 
and standard systematic mediastinal nodal dissection. 
Mapping of the lymph nodes by their number and 
station followed by histopathologic evaluation was 
performed. Median follow-up was 38 (range, 10 - 
52) months. Patients data were statistically analyzed. 
Results: The surgical procedure used depended 
on the extent of the disease, as well as the 
cardiopulmonary reserve of the patients and was 
comparable in both groups of patients. Operating 
time was prolonged for 12 (6 – 20) minutes 
in patients with US guided mediastinal nodal 
dissection, but number and stations of evaluated 
lymph nodes was signiÀcantly higher (p<0.001) in 
the same group of patients. Skip nodal metastases 
were found in 24% of patients without N1 nodal 
involvement in the patients using standard systematic 
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O03.07 EFFECTIVENESS OF EXTENDED 
BILATERAL MEDIASTINAL LYMPH 
NODE DISSECTION THROUGH A 
MEDIAN STERNOTOMY IN PATIENTS 
WITH LYMPH NODE METASTASIS TO 
THE MEDIASTINUM IN NSCLC OF THE 
LEFT LUNG.
Toshiya Yokota, Shingo Ikeda, Enjo Hata 
Surgery Respiratory Center, Mitsui Memorial 
Hospital/Japan
Background: The removal of the whole regional 
lymphatic system together with primary tumor 
is one of the fundamental rules in oncological 
surgery. According to the study of regional 
lymphatic drainage, we considered reasonable 
lymphadenectomy contributes the post-operative 
survival of the patient with non-small lung cancer 
(NSCLC). And we had devised Systemic extended 
bilateral mediastinal dissection and lung resection 
through a median sternotomy (ND3 operation).
Methods: We retrospectively studied 282 patients 
[196 male and 86 female, mean ages 59.8 years 
(range, 38-75)], underwent ND3 operation due to 
NSCLC, from January 1988 till December 2009. The 
patients with NSCLC who are estimated to be able to 
conventional radical operation and aged 75 year-old 
or less becomes the adaptation of ND3 operation. 
Results: Postoperative survival rates calculated with 
Kaplan-Meier method. Clinicalpathological data 
were compared according to the p stage. Overall 
5-year survival rate in the 282 patients of left lung 
primary was 65.6%. Operative mortality in 282 
patients was 2.8%. Lymph node metastasis to the 
mediastinum was conÀrmed in 85 (30.1%) patients 
(pN2 was 51 patients,pN3Ơ was 23 patients, pN3ơ 
was 1 patient, pN3Ƣ was 10 patients). According to 
pathological stages, Àve-year survival rate was was 
90.8% in stage IA ,72.8% in stage IB,63.7% in stage 
IIA, 62.7% in stageIIB,46.5% in stageIIIA,39.1% in 
stageIIIB. Five-year survival rate was 47.4% in pN2 
British Columbia; routine PET-CT scans were not 
performed. EBUS versus mediastinoscopy results 
were compared for all cases in which NSCLC was 
detected. If the results did not agree, a false negative 
(FN) was assigned to the method that had a negative 
result. Accuracy for each method was assessed by 
lymph node station (4R, 4L, 7, 10R), lymph node 
size according to CT assessment, and the presence of 
lymphocytes in the sample (EBUS-TBNA).
Results: Preliminary analysis of the Àrst two years of 
the data resulted in a 9.3% (27/290) mediastinoscopy 
and 6.8% (20/290) EBUS-TBNA false negative rate. 
The majority of mediastinoscopy false negatives 
occurred at the subcarinal lymph node station, 7. 
Of the 20 false negative cases for EBUS-TBNA, 
only two occurred when diagnostic lymphocytes 
were noted in the specimen. Complete analysis 
of the data will allow for a robust comparison of 
each method’s efÀcacy by lymph node station, 
adequacy of sample, and size of node according to 
CT assessment. Figure 1 shows an initial comparison 
of EBUS-TBNA versus mediastinoscopy.
Conclusion: Once the current analysis of all 618 
EBUS/mediastinoscopy cases during the study 
period (Jan ‘07-’11) is complete, it will be possible 
to conclude whether or not the trends observed in 
the preliminary analysis continue, and if they are 
signiÀcant. Complete analysis will consist of a 
comparison of EBUS/mediastinoscopy accuracy by 
lymph node station (4R, 4L, 7, 10R), size of node 
on CT scan and the presence of lymphocytes in the 
sample. These results will inform the goal of this 
project: to establish guidelines for clinical decision-
making in Thoracic surgery practice regarding the 
use of EBUS-TBNA and/or Mediastinoscopy for 
invasive mediastinal lymph node assessment in 
NSCLC.
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new IASLC/ATS/ERS classiÀcation of lung ADC 
based on predominant morphology: adenocarcinoma 
in situ (AIS), minimally invasive adenocarcinoma 
(MIA), non-mucinous lepidic (LPD), acinar (ACI), 
papillary (PAP), micropapillary (MIP), solid (SOL), 
invasive mucinous adenocarcinoma (IMA), and 
colloid adenocarcinoma (COL). Log-rank test and 
Cox proportional hazard model were used to analyze 
the association between histologic subtypes and 
recurrence-free survival (RFS). 
Results: There were 304 (62%) females and 183 
(38%) males with a median age of 69 (23-96). By 
stage, 357 (73%) stage were IA and 130 (27%) 
stage IB. Three overall prognostic groups were 
identiÀed (Figure). Low grade consisting of AIS/
MIA (n=23) had 100% 3-year RFS. Intermediate 
grade consisting of LPD predominant (n=66), 
PAP predominant (n=93), and ACI predominant 
(n=194) experienced 3-year RFS of 93%, 90% and 
84%, respectively. High grade consisting of SOL 
predominant (n=64), MIP predominant (n=26), and 
IMA/COL (n=21) experienced 3-year RFS of 76%, 
43%, and 57%, respectively. SigniÀcant difference 
was observed among the three grades (p<0.001). 
On multivariate analysis, high histologic grade was 
signiÀcantly associated with shorter RFS even after 
adjusting for stage, lymphatic invasion, and vascular 
invasion (HR 2.12, 95% CI 1.13-3.98, p=0.020). 
Conclusion: Our data provide further validation 
that the proposed IASLC/ATS/ERS classiÀcation 
of ADC deÀnes prognostically important histologic 
subsets that show signiÀcant differences in RFS. 
This classiÀcation may be helpful to stratify patients 
for additional intervention/therapy. 
Keywords: lung, Adenocarcinoma, histologic 
classiÀcation, recurrence
cases, and 47.2% in pN3Ơ cases.
Conclusion: Comparing with our historical data and 
reported data in the patients underwent conventional 
bilateral mediastinal nodal dissection, the post-
operative survival rates were improved. The survival 
of patients with N2 and pN3Ơ left lung primary 
would be remarkably improved. 
Keywords: ND3 operation, lymphadenctomy
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
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O04.01 VALIDATION OF THE 
PROPOSED IASLC/ AMERICAN 
THORACIC SOCIETY (ATS)/ EUROPEAN 
RESPIRATORY SOCIETY (ERS) 
INTERNATIONAL MULTIDISCIPLINARY 
CLASSIFICATION OF LUNG 
ADENOCARCINOMA (ADC)
Kyuichi Kadota1, Kei Suzuki2, S. P. D’Angelo2, 
Natasha Rekhtman2, Andre L. Moreira2, Camelia S. 
Sima2, Gregory J. Riely2, Christopher G. Azzoli2, 
Mark G. Kris2, Valerie W. Rusch2, Prasad S. 
Adusumilli2, William D. Travis2 
1Department Of Pathology And Surgery, Memorial 
Sloan-Kettering Cancer Center/United States Of 
America, 2Memorial Sloan-Kettering Cancer Center/
United States Of America
Background: Recently, the IASLC/ATS/ERS 
proposed a new histologic classiÀcation of lung ADC 
with an emphasis on the prognostic signiÀcance of 
morphologic subtypes in resected tumors. The aim 
of this study is to validate this classiÀcation using a 
large cohort of stage I ADC patients. 
Methods: H&E slides of 487 stage I lung ADC 
patients from a single institution (2002 to 2009) were 
evaluated. Comprehensive histological subtyping 
was performed to estimate the percentage of each 
histological subtype and to identify the predominant 
subtype. The tumors were classiÀed according to the 
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64%, moderate in 34%, and severe in 3%. The median 
mitotic count per 10 high power Àelds was 0 in AIS and 
MIA, and 1 in LPD. No recurrences occurred in AIS and 
MIA while 4% of LPD had disease recurrence (5-year 
recurrence free survival: 88%, median time to recurrence: 
2.9 years, range: 1.6-3.8 years). These 4 tumors which 
had recurrence were all stage IA with mean tumor size 
1.8 cm (range 1.1-2.5). Three patients underwent wedge 
resections and 1 lobectomy, and the mean distance 
between surgical margin and tumor was 0.4 (range 
0.2-0.5). In addition, 2 tumors had 20% micropapillary 
component and one of them had lymphatic invasion. 
Conclusion: Patients with AIS and MIA 
demonstrated similar clinical characteristics with 
smaller tumor size, earlier T stage, milder nuclear 
atypia, and no recurrence in contrast to LPD. 
Keywords: adenocarcinoma in situ, minimally 
invasive adenocarcinoma, lung, lepidic
Classical Pathology: Adenocarcinoma Monday, 4 July 2011 14:30-
16:00
O04.03 CORRELATION BETWEEN 
THIN-SECTION CT FINDINGS, 
HISTOPATHOLOGICAL, MOLECULAR 
AND CLINICAL FINDINGS OF MIXED 
GROUND-GLASS OPACITY (PART-
SOLID GGO) OF SMALL PLMONARY 
AENOCARCINOMAS.
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O04.02 CLINICOPATHOLOGIC 
CHARACTERISTICS OF 
ADENOCARCINOMA IN SITU 
(AIS), MINIMALLY INVASIVE 
ADENOCARCINOMA (MIA), AND 
LEPIDIC PREDOMINANT (LPD) 
ADENOCARCINOMA OF THE LUNG 
(LAC): MEMORIAL SLOAN-KETTERING 
CANCER CENTER EXPERIENCE
Kyuichi Kadota1, Kei Suzuki2, Akihiko Yoshizawa3, 
Noriko Motoi4, Camelia S. Sima2, Gregory J. Riely2, 
Valerie W. Rusch2, Prasad S. Adusumilli2, William D. 
Travis2 
1Department Of Pathology And Surgery, Memorial 
Sloan-Kettering Cancer Center/United States Of 
America, 2Memorial Sloan-Kettering Cancer Center/
United States Of America, 3Shinshu University/
Japan, 4Cancer Institute Hospital Of Japanese 
Foundation For Cancer Research/Japan
Background: AIS, MIA, and LPD in the new IASLC/
ATS/ERS LAC classiÀcation are newly deÀned 
subtypes with favorable prognosis. However, because 
these tumors are newly deÀned, there is little known 
about their characteristics. The aim of this study is to 
investigate the clinical and pathologic characteristics 
of AIS, MIA, and LPD in a large series from a single 
institution. 
Methods: H&E slides of 972 stage I LAC that 
underwent surgical resection between 1995 and 2009 at 
Memorial Sloan-Kettering Cancer Center were reviewed. 
AIS, MIA, and LPD cases were identiÀed, and their 
clinical characteristics were compared. 
Results: Patient demographics are outlined in the Table. 
We identiÀed 3 (2%) patients with AIS, 32 (23%) with 
MIA, and 107 (75%) with LPD representing 0.3%, 
3.3%, and 11% of the total series. The median age was 
60 in AIS, 69 in MIA, and 69 years in LPD. Females 
composed 67% of AIS, 72% of MIA, and 65% of LPD. 
Never smokers composed 33% of AIS, 22% of MIA, and 
25% of LPD. Sublobar resections were performed for 
66% in AIS, 50% in MIA, and 27% in LPD. The median 
tumor size was 1.2 cm in AIS, 1.4 cm in MIA, and 
1.7 cm in LPD. T1a tumors were found in 100% AIS, 
88% in MIA, and 63% in LPD. Atypical adenomatous 
hyperplasia (AAH) was present in 0% of AIS, 13% of 
MIA, and 10% of LPD. For nuclear atypia, 100% of AIS 
showed mild nuclear atypia. MIA showed mild atypia 
in 91% and moderate in 9% while LPD showed mild in 
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type; 43 cases). Average percentages of pathological 
component areas were GwS type; BAC; 74%, C/
CwB; 25%, invasive areas; 0.6% (0-3.9%) and 
Heterogeneous type; BAC; 68%, CwB; 31%, 
invasive areas 0.4% (0-5.6%) and SwG type; BAC 
39%, CwB; 33%, invasive areas 25.6% (0-95.6%). 
The average size of invasive areas of the SwG/Solid 
types were larger than the SwG/Air types (5.2mm 
vs 0.5mm). Invasive areas were identiÀed in every 
type of mixed GGO tumor. Invasive areas of more 
than 5mm or percentages greater than 10%, were 
recognized in overlapping type tumors of SwG and 
Solid types. Mutation ratios of EGFR were 60% in 
GwS, 87% in Het and 55% in SwG. In only one case 
involving SwG/Solid type, the patient suffered a 
relapse and died. 
Conclusion: Each type of mixed GGO present 
unique characteristics of histopathological, molecular 
and clinical Àndings. Our results indicate that 
evaluating TS-CT Àndings of mixed GGO, by way 
of lung and mediastinal window setting images, is an 
important consideration in speculating on the size of 
histopathological invasive areas. 
Keywords: mixed GGO, Thin-section CT, 
Adenocarcinoma, Invasion
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O04.05 REPRODUCIBILITY OF INVASION 
IN PULMONARY ADENOCARCINOMA. 
AN INTERNATIONAL INTEROBSERVER 
STUDY
Erik Thunnissen1, Marybeth Beasly2, Alain Borczuk3, 
Elisabeth Brambilla4, Lucian R. Chirieac5, Sanja 
Dacic6, Douglas Flieder7, Adi F. Gazdar8, Kim 
Geisinger9, Yuichi Ishikawa10, K M. Kerr11, Yuko 
Minami12, Sylvie Lantejoul4, Yoshihiro Matsuno13, 
Andre L. Moreira14, Noriko Motoi10, Andrew 
G. Nicholson15, Masayuki Noguchi16, Daisuko 
Nonaka17, Giuseppe Pelosi18, Iver Petersen19, Natasha 
Rekhtman17, Victor L. Roggli20, William D. Travis14, 
Ming S. Tsao21, Ignacio Wistuba22, Haodong Xu2, 
Yasushi Yatabe23, Dirk J. Kuik24 
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U823/France, 5Pathology, Brigham And Women’s 
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Of Pathology, University Of Pittsburgh School Of 
Background: Thin-section CT (TS-CT) provides 
us with more precise images of small pulmonary 
carcinomas. Thin-slice sections with thicknesses of 
0.5 mm-1mm accurately reÁect histopathological 
Àndings. Mixed Ground-glass Opacity (part-solid 
GGO) is one characteristic Ànding of pulmonary 
adenocarciomas. These Àndings are various in 
appearance, for example; some contain mainly GGO 
components, and some contain mainly solid portions. 
CT Àndings of mixed GGO, pathological Àndings 
and a clinical prognosis have been reported. We do 
not fully understand the correlation between TS-CT 
Àndings of mixed GGO, histopathological invasive 
areas, molecular and clinical Àndings. 
Methods: We retrospectively reviewed records and 
TS-CT Àndings of 86 patients with mixed GGO 
tumors. All patients had undergone surgical resection 
between 2002 and 2005. Tumor diameters measured 
20mm or less in size. All TS-CT images were 
acquired by Aquillion CT scanner (Toshiba Medical 
System). TS-CT images of tumors were obtained at 
135kVp at 250mAs with 0.5-1mm section thickness. 
All images were photographed using mediastinal 
(level, 40HU; width, 400HU) and lung (level, 
-600HU); width, 1600HU) window settings. All TS-
CT images on lung window setting were classiÀed 
as: (1) GGO with solid type (GwS; solid portion 
areas less than 50% of tumor), (2) Heterogeneous 
type (heterogenous increased density), (3) Solid 
with GGO type (SwG; Solid portion areas more than 
50% of tumor). TS-CT images were classiÀed by 
evaluating lung and mediastinal window settings; 
(A) air-containing type (maximum diameter of tumor 
opacity on mediastinal window images was less 
than or equal to half of that seen on lung window 
images), (B) Solid-density type (maximum diameter 
of tumor opacity on mediastinal window images 
was more than half of that seen on lung window 
images) (Chest 133; 441, 2008). Histopathological 
Àndings (HE and EVG stained) were evaluated by 
measuring percentages of pathological component 
areas using NIH image software. Component areas 
consisted of (1) Bronchioalveolarcell carcinomas 
(BAC), (2) Collapse and/or Collapse with BAC 
(CwB), (3) Invasive area. We analyzed EGFR/Kras 
mutations, the clinical Àndings, and then we studied 
the correlations between these Àndings. 
Results: In all 86 cases, tumors were well-
differentiated adenocarcinomas. GwS type; 15 
cases (Air-type; 12 cases, Solid-type; 3 cases), 
Heteogenous type; 23 cases (Air-type; 23 cases) 
and SwG type 48 cases (Air-type; 5 cases, Solid-
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no-invasion and deÀnite non-invasive combined; 
undetermined) was 0.39 ± 0.50. In 6/64 cases the 
diagnosis of invasion was unanimous. In 15 the 
same 9/28 pathologists favored invasion while 9/28 
different pathologists consistently favored non-
invasion. 
Conclusion: The reproducibility threshold was fair 
to enable an assessment of invasion in pulmonary 
adenocarcinoma by using a POWERPoint image-
based method. Pathologists applied existing criteria 
of invasion according to two different approaches: 
one more restrictive and conservative, the other 
more lenient in diagnosis of invasion in pulmonary 
adenocarcinoma. Improved deÀnition of invasion 
is necessary and collective effort is underway to 
resolve these discrepancies. 
Keywords: Adenocarcinoma, pathology, Invasion
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O04.06 STROMAL INVASION 
AND MICROPAPILLARY 
PATTERN IN 226 CONSECUTIVE 
SURGICALLY RESECTED STAGE 
I LUNG ADENOCARCINOMAS: 
HISTOPATHOLOGIC CATEGORIES FOR 
PROGNOSIS PREDICTION
Yi-Chen Yeh1, Yu-Chung Wu2, Cheng-Yu Chen1, 
Wen-Hu Hsu2, Teh-Ying Chou1 
1Institute Of Clinical Medicine, Yang-Ming 
University/Taiwan, 2Department Of Surgery, Taipei 
Veterans General Hospital/Taiwan
Background: Adenocarcinoma has become the most 
prevailing malignant tumor of lung worldwide. There are 
substantial differences of patient outcome after surgical 
resection in the early-TNM-stage lung adenocarcinomas.
Methods: We retrospectively examined 226 consecutive 
surgically resected stage I lung adenocarcinomas to 
search for prognosticators supplementing the TNM 
staging. With input from the recent literature, we 
restructured the Sakurai’s 4-tier grading system for lung 
adenocarcinomas into a new categorical classiÀcation 
according to stromal invasion and micropapillary pattern. 
Category A tumors have pure bronchioloalveolar growth 
pattern (i.e., bronchioloalveolar carcinoma). Stromal 
invasion in the form of central Àbrotic focus is absent 
in category B tumors and present in category C tumors. 
Category B is subclassiÀed into Category B1, which 
has areas of bronchioloalveolar growth, and B2, which 
does not. Category C is subclassiÀed into Category C1, 
Medicine/United States Of America, 7Pathology, Fox 
Chase Cancer Center/United States Of America, 
8Pathology, University Of Texas Southwestern 
Medical Center/United States Of America, 
9Pathology, Wake Forest University Baptist Medical 
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Cancer Institute, Japanese Foundation For Cancer 
Research/Japan, 11Aberdeen Royal InÀrmary/
United Kingdom, 12Pathology, Graduate School 
Of Human Comprehensive Sciences, University 
Of Tsukuba/Japan, 13Department Of Surgical 
Pathology, Hokkaido University Hospital/Japan, 
14Pathology, Memorial Sloan-Kettering Cancer 
Center/United States Of America, 15Imperial 
College London/United Kingdom, 16Department 
Of Pathology, Graduate School Of Comprehensive 
Human Sciences, University Of Tsukuba/Japan, 
17Mem Sloan-Kettering Cancer CTR/United 
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Background: Histological subtyping of pulmonary 
adenocarcinoma has been associated with predictive 
and/or prognostic features, but inconsistencies 
may originate from difÀculties in interpretation 
due to subjective application of existing criteria. 
This study aimed to establish the reproducibility of 
judging invasion amongst pulmonary pathologists 
worldwide. 
Methods: In a ring study 28 pathologists involved 
with the IASLC reviewed haematoxilin and 
eosin stained microscopic images of relevant or 
controversial areas of adenocarcinomas, pasted 
into a POWERPoint presentation showing typical 
invasion (n=20), no invasion (n=20) and ‘problem 
cases’ (n=24), submitted by 10 group members. All 
cases were randomized (JK) and for each case the 
reviewer provided a diagnosis on invasion divided 
into 5 categories: invasion, deÀnite or probable; no-
invasion, deÀnite or probable; and undetermined. 
Kappa score was calculated. 
Results: Mean Kappa for invasion for all 5 
categories was 0.40 ± 0.50 (mean and SD), while 
Kappa for invasion is for 3 categories (probable 
invasion and deÀnite invasion combined; probable 
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O04.07 INTEROBSERVER 
AGREEMENT IN THE NUCLEAR 
GRADING OF PRIMARY 
PULMONARY ADENOCARCINOMA: 
A COLLABORATIVE MICROSCOPY 
PROJECT
Yoshimasa Nakazato1, Akiko M. Maeshima2, 
Yuichi Ishikawa3, Yasushi Yatabe4, Junya Fukuoka5, 
Tomoyuki Yokose6, Yasuhiko Tomita7, Yuko 
Minami8, Hisao Asamura9, Keisei Tachibana1, 
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3Pathology, Cancer Institute Hospital/Japan, 
4Pathology And Molecular Diagnostics, Aichi 
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Background: Nuclear grading involves an evaluation of 
the size and shape of tumor cell nuclei and the percentage 
of tumor cells that are in the division phase of the cell 
cycle. This grading can be applied prognostically for 
estimating the malignancy of pulmonary adenocarcinoma 
(Nakazato Y. et al, Cancer, 2010). However, according to 
the World Health Organization ClassiÀcation of Tumors, 
its prognostic value for pulmonary adenocarcinoma has 
not been assessed. In the present study, we assessed the 
degree of interobserver agreement on nuclear grading of 
primary pulmonary adenocarcinoma.
Methods: We selected 122 primary pulmonary 
adenocarcinomas 2 cm or less in diameter. Eight 
pathologists independently evaluated the nuclear factors 
using the nuclear grading system devised by Nakazato 
et al. We divided the cases examined into two groups: 
those positive and those negative in terms of nuclear 
grading. The modiÀed version of the WHO classiÀcation, 
Noguchi’s classiÀcation, and the proportion of the 
bronchioloalveolar carcinoma (BAC) component were 
also examined by the same pathologists. Interobserver 
agreement was evaluated using the kappa statistic. The 
disease-free survival curves were drawn according to the 
which has invasive tumor cells in the periphery of central 
Àbrotic focus, and C2, which has invasive tumor cells in 
the center of central Àbrotic focus. Based on the absence 
or presence of micropapillary pattern, the category 
C2 tumors are further subclassiÀed into C2a and C2b, 
respectively. 
Category Description 
A Adenocarcinoma with pure bronchioloalveolar growth 
pattern / without stromal invasion (i.e., Bronchioloalveolar 
carcinoma) 
B Invasive adenocarcinoma without central Àbrotic focus 
B1 Presence of bronchioloalveolar growth pattern (in periphery) 
B2 Absence of bronchioloalveolar growth pattern 
C Invasive adenocarcinoma with central Àbrotic focus 
C1 Invasive tumor cells in the periphery of central Àbrotic focus 
C2 Invasive tumor cells in the center of central Àbrotic focus 
C2a C2 tumor without micropapillary growth pattern 
C2b C2 tumor with micropapillary growth pattern 
Results: The 5-year disease-free survival rates for 
categories B1 (17 cases), B2 (13 cases), C1 (9 cases) 
and C2 (187 cases) are 100%, 83.9%, 100%, and 
61.2%, respectively (p = 0.003). Category C2a (120 
cases) has better 5-year disease-free survival rate 
compared to that of Category C2b (67 cases) (66.6% 
versus 51.2%, p = 0.017).
Conclusion: The histopathologic categorical 
classiÀcation proposed here provides a concise and 
precise scheme for outcome prediction in early-stage 
lung adenocarcinomas. 
Keyword: Adenocarcinoma, Lung, Stromal 
Invasion, Micropapillary Pattern, Prognosis
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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O05.02 DETECTION OF ALK GENE 
REARRANGEMENT IN NON-SMALL-
CELL LUNG CANCER : A COMPARISON 
OF FLUORESCENCE IN SITU 
HYBRIDIZATION AND CHROMOGENIC 
IN SITU HYBRIDIZATION WITH 
CORRELATION OF ALK PROTEIN 
EXPRESSION
Hyojin Kim1, Seol-Bong Yoo1, Ji-Young Choe2, Jin 
Ho Paik1, Xianhua Xu1, Hiroaki Nitta3, Jin-Haeng 
Chung1 
1Pathology, Seoul National University Bundang 
Hospital/Korea, 2Pathology, Seoul National 
University College Of Medicine/Korea, 3Medical 
Innovation, Ventana Medical Systems, Inc./United 
States Of America
Background: Accurate determination of ALK 
rearrangement is important in lung cancer patients, 
especially in determining their eligibility for 
crizotinib therapy. Fluorescence in situ hybridization 
(FISH) has been regarded as the gold standard 
method for detecting ALK rearrangement. However, 
FISH requires a Áuorescence microscope, the 
signals are labile and rapidly fade over time. This 
study evaluates the concordance between ALK 
gene rearrangement in NSCLC assessed by ALK 
FISH and a newly developed ALK chromogenic 
in situ hybridization (CISH) and correlates the 
results with ALK protein expression assessed by 
immunohistochemistry (IHC).
Methods: A total of 465 formalin-Àxed and parafÀn 
embedded non-small-cell lung cancer (NSCLC) 
samples were analyzed by ALK FISH (PathVysion®, 
Vysis, Abbott) and ALK CISH. For comparison, all 
specimens were stained by immunohistochemistry 
(clone 5A4) and interobserver reproducibility was 
assessed.
Results: We found that agreement between the 
pathologists on the CISH-determined ALK status 
was achieved in 449 patients (96.6%) and ALK 
rearrangement was identiÀed in 18 patients (4.0%) 
in CISH method. Among these cases, 443 cases 
(95.3%) had results matching the corresponding 
FISH Results: 17 rearranged, 425 wild types and 1 
discordant case. There was high concordance in the 
assessment of ALK gene rearrangement between 
FISH and CISH techniques (Kappa coefÀcient = 
0.92) and between observers (Kappa coefÀcient = 
0.97). In addition, there was high concordance in 
Kaplan–Meier method and analyzed with the logrank test.
Results: The mean (±SD) kappa values for the modiÀed 
WHO classiÀcation, Noguchi’s classiÀcation and nuclear 
grading were 0.46+0.09, 0.48+0.09, and 0.58+0.09, 
respectively. The cases judged as negative by nuclear 
grading showed a signiÀcantly better prognosis (5-year 
disease-free survival rate, 91.8+2.7%) than the positive 
cases (68.6+3.1%).
Conclusion: Nuclear grading is useful for prognostic 
evaluation of pulmonary adenocarcinoma. The 
interobserver agreement on nuclear grading is 
signiÀcantly higher than that for the modiÀed WHO 
classiÀcation or Noguchi’s classiÀcation, suggesting that, 
clinicopathologically, nuclear grading is a quite reliable 
prognostic factor for small adenocarcinomas.
Keywords: Nuclear Grading, Pulmonary 
Adenocarcinoma, Interobserver Agreement, modiÀed 
version of the WHO classiÀcation
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Abstract under Embargo - will be presented in a 
press conference during WCLC 2011.
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HE-stained slides of whole tumor specimen were 
reviewed. The statistic correlation between histologic 
factors and chimeric variation were calculated using 
SPSS software. 
Results: Distributions of predominant subtype, 
differentiation or cell type in ALK-chimeric 
variants are summarized in Tables. There was no 
correlation between chimeric variants and histologic 
predominant subtypes (p=0.354, chi-square test), 
differentiation (p=0.255) and cell type (p=0.329). 
The percentage of subtypes and signet ring cells (sig) 
in each tumor was as following (mean and range); 
lepidic 16.4 (0-80), papillary 31.6 (0-80), acinar 
24.8 (0-90), micropapillary 8.9 (0-40), solid 18.4 (0-
100), and sig 10.9 (0-60). Table 1 ALK genotype and 
Predominant subtype of adenocarcinoma 
Genotype lepidic acinar pap micropap solid TOTAL 
EML4-ALK V1 5 1 4 0 5 15 
EML4-ALK V2 0 1 5 0 1 7 
EML4-ALK V3 2 6 4 1 2 15 
EML4-ALK V4 0 0 1 0 0 1 
EML4-ALK V5 0 0 1 0 0 1 
EML4-ALK V6 1 0 0 0 0 1 
EML4-ALK V7 0 0 1 0 0 1 
KIF5-ALK K17 1 0 0 0 0 1 
KIF5-ALK K24 0 0 0 0 2 2 
TOTAL 9 8 16 1 10 44 
Table 2 ALK genotype and Tumor Differentiation/ 
Cell type 
Genotype wel mod por TOTAL mixed mucinous non-mucinous TOTAL 
EML4-ALK V1 3 6 6 15 13 0 2 15 
EML4-ALK V2 0 5 2 7 7 0 0 7 
EML4-ALK V3 4 8 3 15 11 3 1 15 
EML4-ALK V4 0 1 0 1 1 0 0 1 
EML4-ALK V5 0 1 0 1 1 0 0 1 
EML4-ALK V6 1 0 0 1 1 0 0 1 
EML4-ALK V7 0 1 0 1 1 0 0 1 
KIF5-ALK K17 1 0 0 1 0 0 1 1 
KIF5-ALK K24 0 0 2 2 2 0 0 2 
TOTAL 9 22 13 44 37 3 4 44 
Conclusion: This study clearly showed the diversity 
of histologic pattern of ALK-LAC. There was no 
strong correlation between morphologic pattern and 
genotype of ALK chimeric gene. Using surgically 
removed specimens, allowing an examination of 
large area, our data indicated that characteristic 
patterns of ALK-LAC, such as acinar/cribriform 
structure or presence of sig/mucinous cells, could be 
the ALK gene status and ALK protein expression 
between CISH and IHC tests (Kappa coefÀcient = 
0.82).
Conclusion: CISH is a highly reproducible and 
practical method to detect ALK gene rearrangement 
and correlated well with ALK protein expression. 
Because, CISH allows a concurrent analysis 
of histological features of the tumors and gene 
rearrangement, it appears to be useful method in 
determining ALK gene rearrangement. 
Keywords: Lung cancer, ALK, Áuorescence in situ 
hybridization, chromogenic in situ hybridization
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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O05.03 MORPHOLOGIC DIVERSITY 
OF ALK-ALTERED LUNG 
ADENOCARCINOMA; NO STRONG 
CORRELATION WITH CHIMERIC 
VARIANTS
Noriko Motoi1, Kengo Takeuchi1, Seijiro Sato1, 
Yuki Togashi1, Satoko Hatano1, Shin Karita1, Yuichi 
Saito1, Hiroshi Ono1, Kentaro Inamura1, Sakae 
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Background: A subset of lung cancer harbors the 
transforming fusion gene joining the EML4 or 
KIF5 gene and the anaplastic lymphoma kinase 
gene (ALK), which is dramatically response to a 
targeted inhibitor of ALK kinase, such as crizotinib. 
The goal of this study is to clarify the histologic 
characteristics of ALK-altered lung adenocarcinoma 
(ALK-LAC) using the newly proposed IASLC/
ATS/ERS classiÀcation and the correlation between 
morphology and genotype (chimeric variant). 
Methods: Surgically resected 44 ALK-LAC detected 
by combination of immunohistochemistry, FISH 
and multiplex RT-PCR were examined the following 
detailed histopathologic Àndings; the percentage of 
each histologic subtypes (lepidic. acinar, papillary, 
micropapillary and solid), tumor differentiation 
(well, moderate, poor), and tumor cell types 
(mucinous, non-mucinous, or mixture of both) based 
on the new IASLC/ATS/ERS classiÀcation of LAC. 
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EGFR mutations were mutually exclusive. ALK 
rearranged patients tend to be younger than EGFR 
mutated or WT/Negative patients (median age of 53, 
59 and 62 years, respectively). Patients with ALK 
positive tumors were predominantly never smokers 
(67%) and adenocarcinomas (83.4%) with equal 
distribution for sex. ALK positive and EGFR mutant 
patients have a better survival than WT/WT patients 
(p=0.003 and p=0.03). IHC was perfomed in tissue 
samples from surgical resections, biopsies or cell 
blocks. Out of 71 patients analized for FISH, ALK 
IHC was perfomed in 64 and in 7 cases there was no 
tissue enough to perform the analysis. All patients 
with ALK FISH negative tumors were also negative 
for ALK IHC. Out of 6 patients positive for ALK 
FISH, 5 were also analized for ALK IHC: Four were 
positive and 1 negative.
Conclusion: The prevalence of ALK rearrangement 
is 8.5% in a caucasian selected population of 
NSCLC. ALK positive patients have different 
clinical features and a better prognostic than EGFR 
WT and ALK negative patients. IHC with D5F3 
mAb against ALK is a promising method for 
detecting ALK positive NSCLC patients.
Keywords: IHC, ALK, NSCLC, FISH
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O05.06 IMPRECISE REPORTING OF ALK 
FISH RESULTS IN TUMOR SPECIMENS 
FROM PATIENTS WITH NON SMALL 
CELL LUNG CANCER: POTENTIAL 
IMPLICATIONS.
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Background: An inversion within chromosome 
2p resulting in formation of a fusion gene product 
comprising portions of the echinoderm microtubule 
associated protein-like 4 (EML4) and the ALK 
genes was discovered in 2007 in NSCLC cell lines 
and in 3-5% of archived clinical specimens (Soda, 
Nature, 2007). Crizotinib, an ALK-inhibitor, was 
shown to have a 57% response rate in highly pre-
treated NSCLC patients who harbored the EML4-
ALK rearrangement (Kwak, NEJM, 2010). In 
all ongoing studies with crizotinib, eligibility to 
a minor component of the tumor. 
Keywords: ALK lung adenocarcinoma, ALK 
chimeric gene, Adenocarcinoma subtype, 
Adenocarcinoma classiÀcation
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O05.05 DIAGNOSTIC METHODS, 
PREVALENCE AND CLINICAL 
OUTCOMES OF PATIENTS WITH ALK 
POSITIVE NON SMALL CELL LUNG 
CANCER
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Background: ALK rearrangement represents a novel 
molecular target in a subset of non small cell lung 
cancers (NSCLC). Our aim is to explore Áuorescence 
in situ hibridation (FISH) and inmunohistochemistry 
(IHC) as diagnostic methods, prevalence and clinical 
outcomes of ALK positive NSCLC in a selected 
population of patients.
Methods: patients with NSCLC previously screened 
for EGFR mutation at our institution bettween 
June 2006 and January 2010 were selected. ALK 
rearrangement was identiÀed by using FISH and the 
value of IHC (D5F3 monoclonal antibody-mAb) was 
explored. For FISH ALK expression, a positive result 
was deÀne as more than 15% of tumor cells positive 
for split red and green signals or single red signals. 
For IHC ALK protein expression positivity was 
deÀned as tumor-speciÀc staining of any intensity in 
10% of the tumor cells.
Results: Ninety-two patients were identiÀed. Data 
is available for 71 patients: median age was 61 
years (range 36-83), 80% were adenocarcinomas, 
7% squamous and 13% NOS carcinomas. Fifty-
one percent of the patients were female. All were 
caucasian. Thirty-two percent of the patients were 
never smokers and 30% former smokers. Six (8.5%) 
patients were ALK rearranged positive by FISH, 
9 (12.7%) were EGFR mutant, and 56 (78.8%) 
were wild type for EGFR and negative for ALK 
FISH (WT/Negative). ALK rearrangements and 
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unclear. Most patients exhibited hyperdiploidy of 
ALK - an as yet indeterminate anomaly with no 
evidence supporting use of ALK inhibitors in this 
setting. Hyperdiploidy appears to be a non-speciÀc 
event since patients with a kras mutation and with 
an EML4-ALK translocation, both displayed 
hyperdiploidy. Failure to emphasize the lack of 
evidence and merely enumerating abnormalities has 
the potential to spur inappropriate prescription of 
ALK inhibitors. Reporting needs to highlight EML4-
ALK translocations as the only current predictive 
Ànding supporting use of crizotinib. Other reported 
abnormalities should be clearly identiÀed as being of 
unknown signiÀcance at this time.
Keyword: ALK-FISH Test Reporting
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SMALL CELL LUNG CANCER PATIENTS
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Kyung Jeon2, Doo Hyun Chung2, Deo Seog Heo1 
1Department Of Internal Medicine, Seoul National 
University Hospital/Korea, 2Department Of 
Pathology, Seoul National University Hospital/
Korea, 3Molecular Epidemiology Research, PÀzer 
Oncology/United States Of America
Background: Fluorescent in situ hybridization 
(FISH) is currently used to detect non-small cell 
lung cancer (NSCLC) patients with anaplastic 
lymphoma kinase (ALK) gene rearrangement, who 
are candidates for ALK inhibitor therapy. However, 
FISH may not be a practical method for screening for 
ALK-positive patients in a large population due to its 
cost and difÀculty in interpretation. We investigated 
the role of immunohistochemistry (IHC) to screen 
for ALK rearrangement in advanced NSCLC 
Methods: We identiÀed 1,100 stage IIIB or IV 
NSCLC patients without squamous cell histology 
from the Seoul National University Hospital NSCLC 
database. To enrich for ALK-positive cases, we 
selected 262 patients who were either EGFR wild-
type or non-responders to previous EGFR tyrosine 
kinase inhibitors (TKI). ALK IHC using monoclonal 
antibody 5A4 (Novocastra) and ALK FISH using 
dual-color break-apart probes (Abbott) were 
receive the agent is determined by demonstrating 
15% or more of cells have the ALK rearrangement 
by break-apart Áuorescence in-situ hybridization 
(FISH). Other abnormalities, including lesser levels 
of rearrangement, as well as increases in gene copy 
number are demonstrated by the same FISH test. 
However, none of these other abnormalities have 
been correlated with beneÀt from crizotinib, nor are 
they known to confer any prognostic value. These 
additional anomalies are not reported when testing 
is performed by the current research studies. The 
goal of this study was to assess the quality of ALK-
FISH reports issued by a commercial laboratory 
with respect to distinguishing between predictive 
abnormalities (EML4-ALK rearrangement>15%) 
and other incidental Àndings.
Methods: Between June 1, 2010 and January 31, 
2010, 11 patient samples from our institution were 
sent to Genzyme laboratories for ALK FISH testing. 
Reports were classiÀed as normal or abnormal and 
the abnormalities enumerated. Kras and EGFR 
mutation test results from the same specimens were 
collected.
Results: Reports on ALK testing performed by 
Genzyme were available for 11 patients. EGFR (11 
patients) and Kras (10 patients) mutation analyses 
were available. Only one patient harbored an EML4-
ALK translocation in > 15% of cells, but 9 of 11 
reports were noted to be abnormal. The table below 
summarizes our Àndings
Number Percent 
95% ConÀdence 
Intervals 
TOTAL 11 100% - 
ALK abnormal 9 82% 48 - 98% 
>15 % EML4-ALK 
translocation* 
1 9% 0 - 41% 
<15 % EML4-ALK 
translocation* 
1 9% 0 - 41% 
ALK hyperdiploidy* 9 82% 48 - 98% 
EGFR mutation 1 9% 0 - 41% 
KRAS mutation 2 20% 3 - 56% 
*ALK translocation and hyperdiploidy observed in same patients 
Conclusion: The small number of specimens in 
this sample and the high percentage abnormalities 
listed without giving particular focus emphasize 
the potential problems in current ALK-FISH test 
results reporting by this commercial laboratory. 
Such ambiguous reporting may exist with other 
laboratories and for other molecular tests. While the 
majority of specimens were reported as “abnormal”, 
the clinical meaning of most of these abnormalities 
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Background: Lung cancer is the leading cause of 
cancer-related death worldwide. Reduced mortality 
is expected from early detection combined with 
treatment. AutoÁuorescence bronchoscopy (AFB) 
is a valid strategy for detecting premalignant 
endobronchial lesions in the central airways. During 
AFB, sites showing abnormal autoÁuorescence 
can be biopsied for (histo)pathological evaluation. 
However, to data no biomarker is available that 
can reliably predict lung cancer risk in individual 
subjects who present with AFB-visualized 
premalignant lesions. Our present study was set out 
to identify AFB-visualized squamous metaplastic 
(SqM) lesions with malignant potential by DNA 
copy number proÀling.
Methods: As referral center in the Netherlands, we 
prospectively collected since 1998 an extensive, 
clinically and histopathologically annotated 
archive of paired FFPE and frozen AFB-guided 
endobronchial biopsies of subjects at risk of lung 
cancer based on smoking habits, COPD, and/or 
history of cancer, and who underwent regular AFB-
examinations. Within our cohort of 474 subjects, 
6 (1.3%) subjects showed rapid progression from 
squamous metaplasia (SqM) to carcinoma (in situ) 
(further referred to as cases). Immunostaining 
patterns (p53, p63 and Ki-67) and DNA copy number 
proÀles (i.e., chromosomal gains and losses) of this 
unique set of progressive SqM lesions (n=6) were 
compared to a subset of SqM lesions of subjects 
(n=23) that did not progress towards carcinoma (in 
situ) (i.e., controls). DNA copy number alterations 
(CNAs) were determined by array comparative 
genomic hybridization (arrayCGH) analysis (4x44K 
Agilent) on genomic DNA that was isolated on laser-
capture micro-dissected areas of the lesion. SpeciÀc 
copy number alterations linked to endobronchial 
cancer risk were identiÀed and accuracy to predict 
endobronchial cancer in this series was determined.
Results: Clinicopathologic characteristics and 
immunostaining patterns were not related to clinical 
outcome of SqM lesions. On the other hand, the 
mean number of CNAs in SqM biopsies of cases 
(22%, range 0.48-39%) was signiÀcantly higher as 
compared to controls (0.09%, range 0.00-1.32%, 
p<0.01). Chromosomal regions signiÀcantly more 
frequently altered in cases were 3p26.3-p11.1, 
3q26.2-q29, 9p13.3-p13.2, and 17p13.3-p11.2 
(FWER<0.10). In cases, baseline-detected CNAs 
persisted in subsequent biopsies taken from the 
initial site (median 93%, range 68-99%), and levels 
increased towards cancer progression (p=0.028). 
performed on formalin-Àxed, parafÀn-embedded 
tissue. Two hundred six biopsied and 56 surgically 
resected specimens were included in this study. 
Immunoreactivity was scored from 0 to 3. FISH was 
regarded as positive when the break-apart signals were 
seen in more than 15% of 50 or more tumor cells.
Results: ALK protein was expressed in 28 (10.7%) 
tumors in 262 patients. ALK FISH was positive in 25 
(9.5%) cases, consisting of 16 tumors (12.9%) out of 
124 EGFR wild-type patients and 9 tumors (6.5%) 
out of 138 EGFR TKI non-responders. All patients 
with IHC scores of 3 (n=9) were FISH-positive and 
all patients with scores of 0 (n=234) were FISH-
negative. Among patients with IHC scores of 1 and 
2, Àve (80.0%, 5/6) and eleven (84.6%, 11/13) were 
FISH-positive, respectively. The sensitivity and 
speciÀcity of ALK IHC with reactivity score of 1 or 
more were 100% and 98.7%, respectively. 
Conclusion: IHC can be a useful test for screening 
ALK FISH-positive cases in advanced NSCLC. 
Advanced NSCLC patients with tumors showing 
mild to moderate staining for ALK IHC should be 
considered to perform FISH study. 
Keywords: Non-small cell lung cancer, anaplastic 
lymphoma kinase, immunohistochemistry, FISH
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O06.01 DNA COPY NUMBER 
ALTERATIONS IN SQUAMOUS 
METAPLASTIC LESIONS VISUALIZED 
BY AUTOFLUORESCENCE 
BRONCHOSCOPY PREDICT LUNG 
CANCER
Robert A. Van Boerdonk1, Thomas G. Sutedja2, Peter 
J. Snijders1, Emilie Reinen1, Saskia M. Wilting1, 
Mark A. Van De Wiel3, Frederik B. Thunnissen1, 
Sylvia Duin1, Clarissa Kooi1, Bauke Ylstra1, Chris 
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silencing of SATB1 was examined in cell lines by 
5-Aza 2-deoxycytidine and Trichostatin A treatment, 
and chromatin immunoprecipitation. 
Results: SATB1 was expressed in normal bronchial 
tissue, in the pseudostratiÀed columnar epithelium of 
bronchi or terminal bronchioles, but not in peripheral 
lung alveoli. SigniÀcant loss of SATB1 expression 
was found in squamous preinvasive lesions and in 
NSCLCs, including adenocarcinomas, squamous cell 
and large cell carcinomas (P=0.001), compared with 
matched normal bronchial epithelium. We found 
that loss of SATB1 independently predicted poor 
cancer-speciÀc survival in squamous cell carcinoma 
patients (HR 2.06, 95% CI 1.1-3.7, P=0.016). Loss 
of SATB1 was also signiÀcantly associated with 
poor cancer-speciÀc survival in SCLC patients 
(HR 14.48, 95% CI 1.3-164.0, P=0.03), however 
further investigation of a larger sample is warranted. 
Treatment of lung cancer cell lines A549 and H520 
with the histone deacetylase inhibitor Trichostatin 
A resulted in up-regulation of SATB1, suggesting 
that SATB1 is epigenetically silenced in these cell 
lines. SATB1 was associated with a decrease in the 
active chromatin mark, acetylated histone H3K9, 
and an increase in the repressive polycomb mark, 
trimethylated H3K27, in the squamous cancer cell 
line NCI-H520 cells relative to normal bronchial 
epithelial cell line NL20. 
Conclusion: This is the Àrst study showing that 
SATB1 is expressed in the bronchial epithelium 
and that this expression is lost in early preinvasive 
squamous lesions and is associated with poor 
prognosis in squamous cell carcinoma patients. As 
SATB1 can act as a transcriptional activator or a 
repressor, loss of SATB1 in early lung lesions may 
result in the widespread disruption of tissue-speciÀc 
epigenetic modiÀcations. This may cause abnormal 
activation or repression of key cancer genes, which 
leads to promotion of lung tumorigenesis. Thus 
SATB1 is an epigenetic regulator, which may itself 
be epigenetically silenced in lung cancer. 
Keywords: SATB1, squamous cell carcinoma, 
biomarker
CNAs at 3p26.3-p11.1, 3q26.2-29, and 6p25.3-
24.3, predicted endobronchial cancer risk for AFB-
visualized SqM with 97% accuracy.
Conclusion: Our data strongly suggest that DNA 
copy number alterations predict endobronchial 
cancer in individual subjects diagnosed with 
AFB-visualized SqM, and may be used to guide 
intervention to prevent lung cancer.
Keywords: AutoÁuorescence bronchoscopy, 
Early Detection, Lung cancer, DNA copy number 
alteration
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O06.02 LOSS OF EXPRESSION OF THE 
CHROMATIN REMODELLING PROTEIN 
SATB1 IS PROGNOSTIC IN SQUAMOUS 
CELL CARCINOMA.
Christina I. Selinger1, Wendy A. Cooper2, Sam 
Al-Sohaily1, Dessislava N. Mladenova1, Laurent 
Pangon1, Catherine W. Kennedy3, Brian Mccaughan4, 
Maija R.J. Kohonen-Corish1 
1Cancer Research Program, Garvan Institute Of 
Medical Research/Australia, 2Tissue Pathology And 
Diagnostic Oncology, Royal Prince Alfred Hospital/
Australia, 3Department Of Surgery, StrathÀeld 
Private Hospital/Australia, 4Cardiothoracic Surgery, 
Royal Prince Alfred Hospital/Australia
Background: Lung cancer is the leading cause of 
cancer-related mortality and requires more effective 
molecular markers of prognosis and therapeutic 
responsiveness. ‘Special AT-rich binding protein 1’ 
(SATB1) is a global genome organiser that recruits 
chromatin remodelling proteins to epigenetically 
regulate hundreds of genes in a tissue-speciÀc 
manner. SATB1 overexpression has been reported to 
be a powerful predictor of poor prognosis in breast 
cancer, but the signiÀcance of SATB1 expression has 
not been previously evaluated in lung cancer. 
Methods: Lung cancer samples were obtained from 
patients treated at the Royal Prince Alfred Hospital, 
Sydney, between 1996 and 2002, and analysed by 
immunohistochemistry for SATB1 expression. The 
cohort totalled 257 patients, including 14 SCLCs 
and 243 NSCLCs. Association between SATB1 
expression and patient survival was determined with 
the Kaplan-Meier log-rank and Cox proportional 
regression models in univariate and multivariate 
analyses. Only lung cancer-speciÀc deaths were 
included in the survival analysis. Epigenetic 
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multivariate analysis. A model including the three 
miRNAs discriminates three prognostic groups: 
Group 1: patients with the three miRNAs under 
the deÀned cut-off (n=129), Group 2: among the 
remaining patients, patients with miR21 under Q1, 
independently of the status of the two other miRNAs 
(n=82), and Group 3: all remaining patients (n=65). 
In univariate analysis, Group 1 showed the best 
OS (> 83 months), Group 2 intermediate OS (66 
months), and Group 3 the worse OS (36 months, 
p=0.001, log-rank test). Adjusted HRs for OS with 
Group 3 as reference were 0.445, 95%CI [0.290-
0.682], p=0.0002 and 0.632, 95%CI [0.406-0.986], 
p=0.043 for Group 1 and 2, respectively. Harrell’s 
concordance index of 0.83, 95%CI [0.67-0.95] 
showed a good predictive accuracy. A Àrst bootstrap 
with 300 random resampling showed the stability 
of the miR model which signiÀcantly predicted OS 
in 260 samples (86.7%). The reproducibility of the 
model was conÀrmed by a second similar bootstrap 
procedure, the c-indexes of the created models 
ranging from 0.74 to 0.85.
Conclusion: A miRNA model associating miR15a, 
miR21, and miR210, accurately discriminates three 
prognostic groups in early-stage NSCLC patients 
treated by perioperative chemotherapy. Predicted or 
validated targets of those three miRs include Rho 
and Ras regulators, angiogenesis and invasion genes, 
hippo pathway and DNA repair genes.
Keywords: MicroRNAs, Early Stage NSCLC, 
prognostic markers
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O06.05 ASSOCIATION OF SEQUENCE 
VARIATIONS IN MICRORNAS WITH 
PROGNOSIS OF NON-SMALL CELL 
LUNG CANCER IN KOREAN PATIENTS
Kyong-Ah Yoon, Jihye Han, Hyekyoung Yoon, 
Sohee Park, Geon Kook Lee, Hyun-Sung Lee, Jae Ill 
Zo, Jin Soo Lee 
Research Institute And Hospital, National Cancer 
Center/Korea
Background: MicroRNAs (miRNAs) have been 
studied to identify their functional signiÀcance as the 
regulators of target gene expression via translational 
repression. Recently, some polymorphisms in 
miRNAs have been known to modify miRNA 
regulation by inÁuencing the miRNA processing 
and/or miRNA-mRNA interaction. Single nucleotide 
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O06.04 A THREE-MICRORNAS 
SIGNATURE ACCURATELY 
DISCRIMINATES THREE PROGNOSTIC 
GROUPS IN EARLY-STAGE NSCLC 
PATIENTS IN THE IFCT-0002 TRIAL
Céline Mascaux1, Guenaelle Levallet2, Emmanuel 
Bergot3, Laurence Baudrin4, Martine Antoine5, 
Geraldine Anthoine6, Virginie Westeel7, Armelle 
Lavolé8, Elisabeth Quoix9, Didier Debieuvre10, Julien 
Mazières11, Jean-Louis Pujol12, Denis Moro-Sibilot13, 
Franck Morin4, Bernard Milleron8, Gérard Zalcman3 
1Medical Oncology, University Of Colorado/United 
States Of America, 2Pathology, Caen University 
Hospital/France, 3Chest Medicine Department, 
Caen University Hospital/France, 4IFCT/France, 
5Pathology, Tenon University Hospital/France, 
6Intensive Care And Thoracic Oncology, Institut 
Jules Bordet/Belgium, 7Chest Medicine Department, 
Besançon University Hospital/France, 8Pulmonary 
Medicine Department, Tenon University Hospital/
France, 9Pulmonary Medicine Department, 
Strasbourg University Hospital/France, 10Pulmonary 
Medicine Department, Haute Saône Community 
Hospital/France, 11Pulmonary Medicine Department, 
Toulouse University Hospital/France, 12Pulmonary 
Medicine Department, Montpellier University 
Hospital/France, 13Chest Medicine Department, 
Grenoble University Hospital/France
Background: No survival differences was observed 
between any arms in the 528 early stage NSCLC 
randomized patients of the IFCT-0002 phase 3 trial 
comparing two chemotherapy timing, all pre- vs. 
peri-operative, and two regimens, CDDP-Gem 
vs. CBDCA-Pac (V. Westeel, ASCO 2009). We 
hypothesized that microRNA (miRNA) expression 
proÀle could discriminate prognostic groups in these 
patients.
Methods: Total RNA was extracted from 277 
parafÀn-embedded surgical macrodissected 
specimens. Expression of 17 miRNAs was 
successfully analyzed by Taqman qRT-PCR in 276 
(99%) samples. Multivariate analysis with Cox 
model for overall survival (OS) was validated with a 
two-step bootstrap resampling analysis.
Results: Low miR210 (under the median) miR21, 
and miR15a, (under the Àrst quartile) expression 
signiÀcantly predicted a better survival when 
adjusted for stage and number of administered 
cycles, the two clinical variables inÁuencing OS in 
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O06.06 THREE MIRNAS IDENTIFIED 
FOR THE EARLY DETECTION OF 
SQUAMOUS CELL CARCINOMA OF 
THE LUNG IN ONE TESTING COHORT 
AND 2 INTERNATIONAL VALIDATION 
COHORTS
Céline Mascaux1, Geraldine Anthoine2, John 
Eckelberger1, York E. Miller3, Timothy C. Kennedy3, 
Robert L. Keith3, William J. Feser4, Anna E. Barón4, 
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States Of America, 4Biostatistics And Informatics, 
Colorado School Of Public Health/United States 
Of America, 5Pathology, University Of Colorado/
United States Of America, 6Medical Oncology And 
Pathology, University Of Colorado/United States Of 
America
Background: Early diagnosis of lung cancer is 
anticipated to reduce its mortality rate. Recently, the 
results of the NSLT CT screening trial showed a 20% 
reduction in lung cancer mortality. However, there 
is still a need for improved screening methods and 
to identify the most optimal screening population. 
The detection of biomarker(s) in the blood or 
sputum could help to stratify high-risk populations 
for screening studies, to detect central lung cancers 
that are difÀcult to visualize by CT, and to identify 
lesions at higher risk that require further invasive 
investigations. Previously, we identiÀed a microRNA 
proÀle (Mascaux et al, ERJ, 2009) that characterizes 
pre- and early cancerous stages in the bronchi of 
individuals at high-risk for lung cancer. Here we 
validate the best candidate biomarkers for early 
detection of lung cancer. 
Methods: From the Àrst study that we published on 
60 fresh frozen bronchial biopsies from patients at 
high risk for lung cancer, we selected the six best 
candidate microRNAs for the early detection of 
lung cancer. We evaluated the expression level of 
these microRNAs with qRT-PCR Taqman assays 
applied to two different validation sets of fresh 
frozen bronchial biopsies : 72 biopsies from the Jules 
Bordet Institute, Brussels, Belgium and 36 biopsies 
from the University of Colorado Denver, USA. 
polymorphisms (SNPs) in miRNAs could be used as 
the genetic markers to predict cancer susceptibility as 
well as the prognosis of cancer. Here we investigated 
the association of seven SNPs in precursor (pre-
miRNA) and primary miRNAs (pri-miRNA) and 
cancer risk, recurrence and survival of patients with 
non small cell lung cancer (NSCLC).
Methods: Five SNPs in pre-miRNAs (rs11614913/
mir-196a2, rs2910164/mir146a, rs6505162/mir423, 
rs2289030/mir492, rs895819/mir27a) and two SNPs 
in pri-miRNAs (rs7372209/mir26a-1, rs213210/
mir219-1) were genotyped in 803 NSCLC patients 
and 853 controls. Lung cancer risk was analyzed 
with the genotyping results of cases and controls. 
Recurrence and patient survival was examined in 444 
patients who underwent surgical resection and also 
had available clinical information. The association 
of SNPs and survival was analyzed with multivariate 
Cox hazards regression models considering age, 
sex, smoking status, histology, stage, and additional 
treatment after surgical operation as the confounding 
factors.
Results: In case-control study, variant allele 
of rs228930 was associated with reduced lung 
cancer risk (adjusted OR = 0.79, 95% CI = 0.65-
0.95, P = 0.014 in additive model). In stratiÀed 
analyses by histologic type, this effect of rs228930 
was only signiÀcant in adenocarcinoma group, 
not in squamous cell carcinoma group. Among 
444 patients, there were 84 recurrences and 72 
deaths. Patients with homozygous TT genotype 
of rs11614913 showed signiÀcantly decreased 
recurrence-free survival (RFS) compared with CC 
and CT genotype carriers (adjusted HR = 1.52, 
95% CI = 1.03-2.23, P = 0.035). The genotypes 
of rs213210 (AG+GG) were also associated with 
reduced RFS (adjusted HR = 1.63, 95% CI = 1.02-
2.60, P = 0.041). Moreover, RFS was signiÀcantly 
decreased in patients with higher number of risk 
alleles of two SNPs of rs11614913 and rs213210.
Conclusion: Our Àndings suggest that 
polymorphisms of rs11614913 in mir-196a2 and 
rs213210 in mir219-1 are associated with the 
prognosis of Korean patients with NSCLC after 
surgical operation. 
Keyword: miRNA polymorphisms, prognosis, 
NSCLC
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Background: Lung cancer (LC) screening with low 
dose CT (LDCT) has been shown to reduce deaths 
by ~20%. However, the low prevalence of LC, even 
in high risk smokers, makes this inefÀcient and 
contributes to the high false positive rate. Therefore, 
a minimally intrusive test pre-screen for LDCT 
would be of major beneÀt. The buccal cavity is ideal 
in that it is the “molecular mirror” for LC (Sidransky, 
Cancer Prev Res 2008). We have developed a suite 
of optical techniques (Gastroenterology 2011) that 
enables detection of microarchitectural changes of 
Àeld carcinogenesis and have demonstrated that 
buccal interrogation is feasible (Cancer Res 2010). 
In order to improve diagnostic performance, we 
evaluated potential synergism between optical and 
molecular markers using microRNAs which have 
increasingly been recognized as a key epigenetic 
modulator in carcinogenesis. 
Methods: Cases were patients with conÀrmed or 
suspected LC. Controls were current/past smokers 
without cancer. The buccal mucosa was interrogated 
in situ with a novel Àberoptic probe using low 
coherence enhanced backscattering spectroscopy 
(LEBS), which evaluates cellular features that are 
10-20 times smaller than detectable by conventional 
microscopy (Cancer Res 2009). The Àberoptic 
probe was used to take 5 measurements from the 
visually normal buccal mucosa (500 milliseconds/
measurement). The contralateral cheek was gently 
brushed and placed in tri-reagent. For molecular 
markers, we selected microRNAs as a novel 
modulator of gene expressions using Taqman low 
density miRNA array cards (ABI). 
Results: The Buccal mucosa was interrogated in 
40 patients (21 LC/19 controls) who were well 
matched for demographic factors. As seen in the 
Àgure, the composite LEBS marker was signiÀcantly 
elevated in patients harboring lung cancer. With 
regards to the microRNA, we noted 67 markers 
were statistically signiÀcantly altered. For diagnostic 
studies, we focused on three microRNAs that were 
most associated with the presence of neoplasia 
(Mir 21, 106b, 367). The area under the ROC curve 
(AUROC) for LEBS, microRNA, and both markers 
Results: In the Brussels cohort, a signiÀcant 
differential expression between high-grade lesions/
early invasive squamous cell carcinoma (SCC) and 
lower grade lesions was conÀrmed for 4 microRNAs. 
Two of these microRNAs, MirA and MirB, showed 
highly signiÀcant up-regulation in two patient groups 
tested (SCC only or SCC and high-grade lesions) as 
compared to three different control groups (group 1: 
normal mucosa of healthy never-smokers, group 2: 
morphologically normal mucosa of high-risk (ex-)
smokers, or group 3: group 2 + low-grade lesions). 
MirA was highly up-regulated in SCC biopsies as 
compared to group 1 (49 fold change (x), p=0.0009, 
area under the curve (AUC)=0.96 ; 95% CI : 0.86-
1.06), group 2 (26x, p<0.0001, AUC=0.93 ; 0.84-
1.02) and group 3 (30x, p<0.0001, AUC=0.93 ; 
0.85-1.00). MirB was also highly up regulated by 
30x (p=0.001, AUC=1 ; 1.00-1.00), 18x (p=0.0002, 
AUC=0.89 ; 0.78-1.00), and 21x (p<0.0001, 
AUC=0.9 ; 0.81-0.99) in SCC as compared to groups 
1, 2 and 3, respectively. Combining MirB and MirA 
did not add signiÀcantly to the AUC of the MirA. 
The Denver cohort did not include any healthy, 
never-smokers nor any samples with a higher grade 
than carcinoma in situ (CIS). Results were validated 
for 3 microRNAs. MirA was up-regulated in CIS by 
42x and 52x as compared to normal mucosa from 
(ex-)smokers (group 2) and to the later group plus 
low-grade lesions (group 3), respectively, and MirB 
by 11x and 14x, respectively.
Conclusion: The high potential of three microRNAs 
to discriminate between SCC and normal mucosa 
of healthy never-smokers or from high-risk (ex-)
smokers as shown previously in a Àrst set of 
biopsies was conÀrmed in two other international 
validation sets. Thus, these biomarkers are very good 
candidates for the early detection and diagnosis of 
lung cancer. 
Keywords: microRNA, Early Detection, Biomarkers
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O06.07 LUNG CANCER RISK 
STRATIFICATION THROUGH BUCCAL 
FIELD CARCINOGENESIS DETECTION: 
COMPLEMENTARY ROLE FOR MICRO-
ARCHITECTURE AND MICRORNA 
BIOMARKERS
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Background: Traditionally non-small cell lung 
cancer (NSCLC) has been regarded as a single 
disease entity in terms of systemic therapy; however, 
recent evidence suggests that the two major subtypes 
of NSCLC, adenocarcinoma (AC) and squamous 
cell carcinoma (SqCC) respond differently to 
both molecular targeted and newly developed 
chemotherapies. Therefore, we hypothesize that 
identifying the molecular differences between the 
tumor subtypes will have a signiÀcant impact in 
designing novel therapies that can improve the 
treatment outcome.
Methods: DNA was isolated from 261 primary 
NSCLC tumors (169 AC and 92 SqCC). Integrative 
analysis of genome wide DNA copy number, 
methylation and gene expression proÀles was 
performed to identify critical subtype-speciÀc 
molecular alterations. Copy number proÀles 
were generated by array comparative genomic 
hybridization and the Fisher’s exact test was used 
to compare frequencies of alteration for each 
subtype. DNA methylation proÀling was performed 
using the Illumina InÀnium HumanMethylation27 
platform. Expression proÀles were generated using 
the Affymetrix U133 Plus 2 platform, and data 
was normalized using RMA. Survival analysis 
was performed using the statistical toolbox in 
the program Matlab on publicly available gene 
expression microarray datasets with survival data. 
Functional identiÀcation of gene networks and 
canonical signalling pathways was performed using 
the Ingenuity Pathway Analysis program.
Results: The characterization of the genomic and 
epigenomic landscapes of AC and SqCC revealed 
778 genes altered at the DNA level with subsequent 
gene expression changes, that were selected for 
during lung tumor development in a subtype-speciÀc 
manner. Analysis of 200 additional NSCLC tumors 
conÀrmed that these genes are responsible for 
combined was 0.9, 0.89 and 1.00, respectively. 
Conclusion: We demonstrate that buccal 
interrogation with LEBS and microRNA was 
able to discriminate between cases and controls. 
Importantly, the combination of microRNA and 
micro-architecture appeared synergistic. While 
promising, one needs to be circumspect given 
the modest number of patients thus requiring 
independent dataset validation to show robustness 
(lack of overÀtting or confounding). Intriguingly 
this suggests that there are important biological 
interactions between epigenetic (microRNA) and 
micro-architectural (LEBS) factors. Large scale 
clinical studies are ongoing to validate this novel 
paradigm for LC screening. 
Keywords: Screening, Lung cancer, microRNA
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O07.01 DIVERGENT GENOMIC AND 
EPIGENOMIC LANDSCAPES OF LUNG 
CANCER SUBTYPES UNDERSCORE 
THE SELECTION OF DIFFERENT 
ONCOGENIC PATHWAYS
Greg L. Stewart1, Larissa A. Pikor1, Ian M. Wilson1, 
Bradley P. Coe1, Raj Chari1, Kelsie Thu1, John 
Yee2, John C. English3, Nevin Murray4, Ming S. 
Tsao5, John D. Minna6, Adi F. Gazdar6, Calum E. 
Macaulay1, Stephen Lam1, Wan Lam1, William W. 
Lockwood7 
1Integrative Oncology, British Columbia Cancer 
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O07.03 COINCIDENCE OF MUTATIONS 
IN KEY GENES: A COMPARISON OF 
ADENOCARCINOMA AND SQUAMOUS 
CELL CARCINOMA OF THE LUNG.
Simon Dearden1, James Stevens1, Gillian Ellison1, 
Andrew Thomas2, Carolyn Gokhale3, Kamlesh 
Mohan4, John Gosney4, Martin Walshaw4 
1R&D Genetics, Personalized Healthcare & 
Biomarkers, Astrazeneca/United Kingdom, 
2Oncology Imed, Astrazeneca/United Kingdom, 
3Central Manchester University Hospitals NHS 
Foundation Trust/United Kingdom, 4Liverpool 
Heart & Chest Hospital; Royal Liverpool University 
Hospital/United Kingdom
Background: Mutations are common events in 
NSCLC, with mutations in key genes deÀning 
speciÀc molecular subtypes. Patterns of mutation 
coincidence in adenocarcinoma of the lung have 
been widely reported. However, the patterns of 
mutation coincidence in squamous cell carcinoma 
of the lung are less well known. Here we report 
data obtained from mutation screening in a panel of 
genes, EGFR, KRAS, TP53, LKB1, BRAF and the 
EML4-ALK translocation in samples from NSCLC 
patients with adenocarcinoma and squamous cell 
carcinoma histologies. This is the Àrst report of these 
genes being screened together in a panel of NSCLC 
adenocarcinoma and squamous tumour samples.
Methods: A total of 157 samples were screened. 
These comprised 105 tissue samples collected 
from lung resection specimens using standard 
operating procedures, and 52 primary tumour explant 
samples. Within this study group there were 77 
adenocarcinoma, 58 squamous and 22 samples from 
other subtypes. Mutation screening was performed 
using Sanger sequencing (EGFR, LKB1, BRAF and 
TP53), ARMS (BRAF) and pyrosequencing (KRAS) 
methodologies. The EML4-ALK translocation was 
identiÀed using an RT-PCR based method.
Results: Mutations in all genes were detected in 
tumour samples. The most commonly mutated 
genes were KRAS and TP53. Mutations in 
EGFR and BRAF were rare in this sample set. 
Overall, mutations were more commonly seen in 
adenocarcinoma samples. However, mutations 
in TP53 were more often seen in squamous 
samples. Mutations in LKB1 were detected in both 
adenocarcinoma and squamous samples. Mutation 
co-incidences were seen between KRAS, LKB1 
driving the differential development and resulting 
phenotypes of AC and SqCC. Importantly, we 
identiÀed key oncogenic pathways disrupted in each 
subtype that likely serve as the basis for differential 
behaviors in tumor biology and clinical outcomes. 
Downregulation of HNF4a target genes was the 
most common pathway speciÀc to AC, while SqCC 
demonstrated disruption of numerous histone 
modifying enzymes as well as the transcription 
factor E2F1. Lastly, through in silico screening of 
candidate therapeutic compounds using subtype-
speciÀc pathway components, we identify HDAC 
and PI3K inhibitors as potential treatments tailored 
to lung SqCC.
Conclusion: The speciÀc genes and networks 
identiÀed in this study provide essential starting 
points for elucidating mechanisms of tumor 
differentiation and developing tailored therapeutics 
for lung cancer treatment. More generally, our results 
conÀrm at the molecular level that these lung cancer 
subtypes are distinct disease entities and should 
be studied separately when designing treatment 
strategies and testing new drugs in clinical trials.
Keywords: Subtype, Genomics, squamous cell 
carcinoma, Adenocarcinoma
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O07.02 LUNG ADENOCARCINOMA 
GENOMES OF NEVER SMOKERS 
EXHIBIT A GREATER EXTENT OF 
GENOMIC INSTABILITY THAN THOSE 
OF SMOKERS
Kelsie Thu1, Daiana Becker1, Raj Chari2, Wei 
Zhang3, Calum E. Macaulay1, Adi F. Gazdar3, 
Stephen Lam1, Wan Lam4 
1Integrative Oncology, Bc Cancer Research Centre/
Canada, 2Genetics, Harvard Medical School/United 
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Abstract under Embargo - will be presented in a 
press conference during WCLC 2011.
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potential to target hundreds of transcripts and each 
transcript may be targeted by numerous miRNAs. 
Thus, miRNAs represent a broad regulatory 
mechanism of global gene expression. We 
hypothesize that deregulation of miRNA expression 
is an important mechanism in determining 
sensitivity/resistance to therapeutic agents. In 
this study, we demonstrate the application of an 
integrative, multi-dimensional approach to identify 
miRNAs that are associated with chemotherapeutic 
resistance/sensitivity utilizing independent, publicly 
available databases on: miRNA loci copy number 
(CN), miRNA expression, and mRNA expression.
Methods: Drug response IC
50
 data for 23 
chemotherapeutic agents on 73 lung cancer cell 
lines was obtained from the Wellcome Trust Sanger 
Institute (WTSI) ”Genomics of Drug Sensitivity 
in Cancer” database. Matching Affymetrix SNP 
6.0 microarray data were obtained from the WTSI 
Cancer Genome Project Data archive (n=67 cell 
lines). CN alteration status for all 636 annotated 
miRNA genes were correlated with drug response 
by comparing the most resistant and sensitive 
cell line tertiles for each drug. The same method 
was applied to miRNA expression data (n=254 
miRNAs), which were obtained from the Broad 
Institute (n= 64 cell lines). CN and expression data 
was integrated to identify miRNAs signiÀcantly 
deregulated at both the CN and expression levels. 
Putative targeted transcripts of these miRNAs were 
compiled using TargetSpy and TargetScan databases. 
Only those transcripts identiÀed by both programs, 
that were differentially expressed between resistant 
and sensitive cohorts, and whose expression was 
inversely correlated with the expression of the 
associated miRNA were analyzed. Target gene 
function analysis was performed using Ingenuity 
Pathways Analysis using mRNA expression data 
obtained from Broad Institute (n=68 cell lines).
Results: Three hundred and seven miRNAs were 
identiÀed to be signiÀcantly altered at the CN level 
between resistant and sensitive cohorts for at least 
one drug. Similarly, 172 miRNAs were deregulated 
at the expression level for at least 1 drug. Six 
miRNAs - miR-10b, miR-193b, miR-203, miR-
328, miR-589, and miR-628 - were signiÀcantly 
deregulated at both the CN and expression levels 
for at least 1 drug, and correlated with either 
resistance or sensitivity to speciÀc chemotherapeutic 
agents. The functions of the putative mRNA targets 
correlated with genetic instability that could facilitate 
drug resistance, and, in some cases, with speciÀc 
and TP53 and between EGFR and TP53. Within 
the samples screened, mutations in EGFR, KRAS, 
BRAF were exclusive to each other. These mutation 
events deÀne molecular subtypes of NSCLC. Whilst 
activating V600E mutations were rare in BRAF, 
we also detected the presence of kinase dead and 
impaired function mutations in a small number of 
samples. The role of these mutations in NSCLC is 
unclear.
Conclusion: This is the Àrst study to present 
mutation coincidence in EGFR, KRAS, TP53, 
LKB1, BRAF and the EML4-ALK translocation in 
samples from NSCLC patients with adenocarcinoma 
and squamous histologies. Overall, these data 
suggest that mutations in EGFR and KRAS, which 
are commonly reported in adenocarcinoma, are 
rare in squamous cell carcinoma patients, whereas 
mutations in TP53 are more common. Mutation 
coincidences are seen in both adenocarcinoma and 
squamous cell carcinoma samples. However, in this 
dataset, these coincidences occur no more often than 
would be expected by chance given the mutation 
frequencies detected.
Keywords: squamous cell carcinoma, Mutation, 
Adenocarcinoma
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O07.05 DEREGULATION OF SPECIFIC 
MIRNAS CORRELATES WITH 
SYSTEMIC THERAPY RESPONSE IN 
NON-SMALL CELL LUNG CANCER
Katey S.S. EnÀeld1, Greg L. Stewart1, Larissa A. 
Pikor1, Carlos E. Alvarez2, Stephen Lam1, Raj Chari1, 
Wan Lam1 
1Integrative Oncology, British Columbia Cancer 
Research Centre/Canada, 2The Research Institute, 
Nationwide Children’s Hospital/United States Of 
America
Background: Genetic testing is increasingly being 
used to determine optimal therapy of patients with 
non-small cell lung cancer (NSCLC). The majority 
of studies have focused on sequence mutations 
and expression changes in protein-coding genes. 
MicroRNAs (miRNAs) are short non-coding RNA 
molecules that are 17-25 nucleotides in length. They 
regulate gene expression by binding complementary 
RNA transcripts, and prevent their translation by 
initiating RNA degradation or interfering with 
translational machinery. Each miRNA has the 
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and NSCLC, may provide novel biomarkers or 
chemoprevention strategies for high risk subjects 
with COPD.
Methods: We generated DNA methylation and 
copy number proÀles for NSCLC tumour and 
matched non-malignant lung tissues from smokers 
with (n=10) and without (n=15) COPD, using 
the Illumina InÀnium and Affymetrix SNP 6.0 
arrays, respectively. Methylation proÀles were also 
generated for bronchial epithelial cells from small 
airways of smokers with COPD alone (n=24), and 
COPD and NSCLC (n=15). Genes that were 1) 
differentially methylated between non-malignant 
lung tissue from COPD patients with NSCLC 
compared to similar tissue from patients with 
NSCLC alone, 2) additionally altered at the level of 
gene dosage in COPD tumours compared to tumours 
from non COPD patients, and 3) differentially 
methylated in bronchial epithelial cells from COPD 
patients with NSCLC compared to COPD alone, 
were selected for gene function and pathway 
analysis.
Results: We identiÀed 544 genes that were 
hypermethylated in non-malignant lung parenchyma 
tissues and concordantly lost at the DNA level in 
corresponding tumours from COPD patients, but not 
in similar tissues from non COPD patients. Of these 
genes, 174 were also hypermethylated in airway 
cells of patients with COPD and NSCLC compared 
to those with COPD alone. These COPD+NSCLC 
speciÀc genes corresponded to the PI3K/AKT, aryl 
hydrocarbon signalling and retinoic acid mediated 
apoptotic pathways. Our results suggest NSCLC in 
COPD patients may develop through unique tumour 
promoting and metabolic pathways.
Conclusion: Our preliminary results suggests 
NSCLC arising from patients with COPD may 
involve different pathways than those with 
NSCLC without COPD. Many of these speciÀc 
alterations can be detected in airways of patients 
with COPD+NSCLC using methylation analysis. 
Understanding COPD speciÀc NSCLC molecular 
biology may lead to development of targeted 
chemoprevention strategies speciÀc to the NSCLC 
promoting aspects of COPD.
Keywords: chronic obstructive pulmonary disease, 
epigenetics, COPD related lung cancer, InÁammation
pathways involved in the drug’s mechanism of 
action.
Conclusion: A method is presented to identify novel 
predictors of chemotherapeutic agent response for 
NSCLC. Our in silico discovery provides a better 
understanding of drug response mechanisms and 
may lead to better predictors of drug response.
Keywords: miRNA, Non-small cell lung cancer, 
Chemotherapy response, Data integration
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O07.06 CONTRIBUTION OF DNA 
METHYLATION IN THE DEVELOPMENT 
OF LUNG CANCER IN SMOKERS WITH 
CHRONIC OBSTRUCTIVE PULMONARY 
DISEASE
Emily A. Vucic1, Kelsie Thu1, Jennifer Y. Kennett2, 
Raj Chari3, Ian M. Wilson1, Don D. Sin4, Stephen 
Lam5, Wan Lam1 
1Integrative Oncology, British Columbia Cancer 
Research Centre/Canada, 2Integrative Oncology, 
British Columbia Cancer Centre/Canada, 3Genetics, 
Harvard Medical School/United States Of America, 
4Faculty Of Medicine, University Of British 
Columbia/Canada, 5British Columbia Cancer 
Agency/Canada
Background: Patients with chronic obstructive 
pulmonary disease (COPD) have an increased risk 
of developing lung cancer. Together these diseases 
contribute tremendously to mortality and morbidity 
worldwide. Our overall goal is to identify molecular 
pathways associated with the link between COPD 
and lung cancer. DNA methylation is highly altered 
in airways of smokers and at sites of chronic 
inÁammation. It is also one of the most frequent 
and earliest aberrations in lung cancer, associated 
with tumour suppressor gene (TSG) silencing and 
genomic instability. We hypothesize that COPD 
related DNA methylation changes constitute early 
events in TSG inactivation, and in order to inactivate 
both alleles, a second gene dosage alteration in 
tumours may be found at these genes. Furthermore, 
we hypothesize that genes uniquely inactivated in 
tissues from COPD patients with non small cell lung 
cancer (NSCLC), compared to similar tissues from 
patients with NSCLC alone, can be used to identify 
molecular pathways causal to lung tumorigenesis in 
COPD patients. The detection of these alterations 
in small airway epithelium in patients with COPD 
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495 has been shown overexpressed in KRAS mutated 
adenocarcinoma of the lung but so far the mRNA target 
is unknown. miR-410 was found enriched in Erlotinib 
treated cells, miR-368 was enriched in both Erlotinib 
and GeÀtinib treated cells and miR-191 resulted in a 
dramatic growth beneÀt independent of Erlotinib or 
GeÀtinib. miR-191 has been shown overexpressed 
in a number of different types of cancer. We are now 
validating these microRNAs and other, and the next 
step will be to search for the microRNA targets and a 
molecular explanation for the biological effects. 
Conclusion: Lung cancer is the leading cause of cancer 
deaths in the world, reÁecting the need for a better 
understanding of the mechanisms that underlie lung 
carcinogenesis. Although focusing on known genes and 
proteins has already yielded new information, unknown 
markers may also lend insight into the biology of lung 
cancer. miRNAs are a class of small noncoding RNA 
genes found to be abnormally expressed in several 
types of cancer including lung cancer, suggesting that 
miRNAs play a substantial role in the pathogenesis 
of human cancers. The research presented here could 
potentially result in the identiÀcation of miRNAs/
target proteins/pathways determining the response to 
treatment with EGFR-inhibitors. The identiÀcation of 
new biomarkers predicting individual tumors response 
to targeted therapy would be a valuable clinical tool for 
improvement of lung cancer treatment and hopefully 
patient outcome.
Keywords: Functional genomics, EGFR-TKI, 
microRNA, drug resistance
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O08.01 CHANGING PREFERENCES FOR 
INFORMATION AND PARTICIPATION 
IN THE LAST PHASE OF LIFE: A 
LONGITUDINAL STUDY AMONG 
NEWLY DIAGNOSED ADVANCED LUNG 
CANCER PATIENTS
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O07.07 MICRORNAS IN LUNG CANCER - 
A FUNCTIONAL GENOMICS APPROACH 
FOR DISCOVERY AND VALIDATION 
OF NOVEL FACTORS DETERMINING 
RESPONSE TO TREATMENT WITH 
EGFR-INHIBITORS.
Lukas M. Orre1, Carlos Le Sage2, Reuven Agami2, 
Janne Lehtiö3 
1Oncology Pathology, Karolinska Institutet/Sweden, 
2The Netherlands Cancer Institute/Netherlands, 
3Oncology And Pathology, Karolinska Institutet/
Sweden
Background: The development of rational drug 
design and molecularly targeted therapies has resulted 
in an array of new therapy options recently approved 
for treatment of lung cancer (LC) or in clinical trials. 
However, response to treatment with targeted therapies 
is restricted to subsets of the LC patients and initial 
response to treatment is often followed by development 
of acquired resistance during prolonged administration 
resulting in tumor progression. The aim of this project 
is to Ànd novel components of EGFR signalling 
and new molecular predictors of treatment response 
with EGFR-inhibitors in lung cancer. The focus on 
microRNAs is primarily based on recent Àndings of 
microRNA deregulation in lung cancer and Àndings 
that microRNAs can regulate cellular functions such as 
cell proliferation and cell death signalling. 
Methods: Initially functional genomics methods were 
used to screen for microRNAs altering the response 
to the EGFR inhibitors geÀtinb and Erlotinib. BrieÁy, 
a miRNA expression library (miR-Lib) containing 
almost all annotated human miRNAs (Agami, R) was 
transduced into U1810 lung cancer cells. After 30 days 
of treatment with either Erlotinib or GeÀtinib, deep 
sequencing was used to identify miRNAs enriched in 
the treated cells compared to untreated control cells. 
Enrichment of a speciÀc miRNA after treatment with 
a speciÀc inhibitor suggests that expression of that 
miRNA results in resistance. Selected microRNAs will 
be validated using cell viability assays and cytotoxicity 
assays. After validation of microRNAs affecting the 
response to EGFR inhibitors, mass spectrometry based 
proteomics methods will be used to identify speciÀc 
mRNA targets.
Results: We have successfully performed all parts of 
the functional genomics experiment, and sequencing 
data revealed several interesting candidates. miR-495 
was enriched four times in GeÀtinib treated cells. miR-
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change over time in ways they might not expect. 
Keywords: Patient-physician communication, 
palliative care, End-of-life decisions, Advanced 
Lung Cancer
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O08.02 DEPRESSION SHORTENS 
SURVIVAL AND MAY MITIGATE 
BENEFICIAL EFFECTS OF A 
CONCURRENT ONCOLOGY 
PALLIATIVE CARE INTERVENTION IN 
LUNG CANCER PATIENTS
Lisa A. Lambert1, Marie Bakitas2, Zhongze Li2, Tor 
Tosteson2, Kathleen Lyons2, James R. Rigas2, Mark 
Hegel2, Tim A. Ahles2 
1Department Of Psychiatry, Dartmouth Medical 
School/United States Of America, 2Dartmouth 
Medical School/United States Of America
Background: Recent randomized control trials 
(RCT) of concurrent oncology palliative care 
(COPC) compared to usual oncology care alone have 
demonstrated improved mood, quality of life and 
survival for patients with lung cancer (Temel et al, 
2010) and other solid tumors (Bakitas et al, 2009). 
In our RCT, the beneÀcial effects of the COPC 
intervention (Project ENABLE) on depression and 
survival were evident for the whole study sample 
(Bakitas et al, 2009). However, subgroup analyses 
of lung cancer participants did not show the same 
beneÀt on mood or survival. Since depression has 
been associated with shorten survival, we conducted 
analyses on our lung cancer subgroup to investigate 
this relationship. 
Methods: Of the 322 participants with newly 
diagnosed solid tumors (breast, gastrointestinal, 
genitourinary and lung), 117 participants had 
advanced NSCLC or extensive SCLC (58 control, 
59 intervention). We measured depressive symptoms 
(Center for Epidemiological Studies Depression 
Scale [CES-D]) at baseline, 1 month and every 
3 months until death or study completion. Lung 
cancer subjects were divided into 3 groups based on 
baseline CES-D scores: low depressive symptoms 
(below study median [CES-D < 12]), “subclinical” 
depressive symptoms (above study median, below 
clinically predictive cut-off [CES-D >12 and < 16]) 
and clinical depressive symptoms (CES-D > 16). 
We evaluated whether baseline depressive symptom 
strata predicted median survival using Kaplan-Meier 
& Vrije Universiteit Brussel/Belgium, 2Heymans 
Institute For Pharmacology, Ghent University/
Belgium, 3Bioethics Institute, Ghent University/
Belgium, 4Department Of Epidemiology, ScientiÀc 
Institute Of Public Health/Belgium, 5Department Of 
Medical Oncology, University Hospital Of Brussels/
Belgium, 6Department Of Pulmonary Medicine, 
Antwerp University Hospital/Belgium, 7Department 
Of Pulmonary Medicine, ZNA Middelheim Hospital/
Belgium
Background: Objective is to explore changes over 
time in the information and participation preferences 
of newly diagnosed stage IIIb/IV non-small-cell lung 
cancer patients. 
Methods: Patients were recruited by physicians in 
13 hospitals in Flanders, Belgium, and interviewed 
every two months until the fourth and every four 
months until the sixth interview.
Results: 128 patients were interviewed once, 13 
six times. The overall rates of wanting information 
or participation did not change much over time, 
but many individual patients changed their minds. 
Looking at the Àrst three interviews over a period 
of four months (N=67), we observed that: 1) 
the preferences for information about diagnosis, 
prognosis and treatment were stable: practically 
all patients wanted this information shortly after 
diagnosis and kept on wanting it; 2) the preferences 
for information about palliative care and end-of-life 
decisions with a possible or certain life-shortening 
effect (ELDs) were unstable: of the patients who 
did not want this information, a quarter changed 
towards wanting it, and of those who wanted this 
information, 39% (palliative care) and a quarter 
(ELDs) changed towards not wanting it; 3) the 
preferences for participation in medical decision 
making were also unstable: from 50% to 78% of 
patients, depending on the type of decision (in 
general, treatment, transfer, end-of-life), changed 
their preference towards wanting more or less 
participation. Changing preferences were associated 
with patients’ quality of life: patients in a worse 
physical condition were more likely to persist in 
wanting information about palliative care and ELDs, 
and those with more pain were more likely to want 
more involvement in medical decisions in general 
and in transfer decisions as time passed.
Conclusion: Doctors should ask their advanced lung 
cancer patients at the beginning of their illness how 
much information and participation they want, and 
should keep on asking them because preferences do 
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O08.03 EXPRESSED WISHES FOR 
EUTHANASIA AND INCIDENCE 
OF END-OF-LIFE DECISIONS IN 
ADVANCED LUNG CANCER PATIENTS: 
A PROSPECTIVE STUDY IN FLANDERS, 
BELGIUM
Koen Pardon1, Reginald Deschepper1, Robert Vander 
Stichele2, Jan L. Bernheim1, Freddy Mortier3, Denis 
Schallier4, Paul Germonpré5, Daniella Galdermans6, 
Luc Deliens1 
1End-of-life Care Research Group, Ghent University 
& Vrije Universiteit Brussel/Belgium, 2Heymans 
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Belgium, 4Department Of Medical Oncology, 
University Hospital Of Brussels/Belgium, 
5Department Of Pulmonary Medicine, Antwerp 
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Belgium
Background: Objective is to explore expressed 
wishes and requests for euthanasia and the incidence 
of end-of-life decisions with possible or certain 
life-shortening effects (ELDs) in stage IIIb/IV lung 
cancer patients.
Methods: This is a prospective, longitudinal, 
observational study of a consecutive sample of 
advanced lung cancer patients who died within 
18 months of diagnosis. The pulmonologist or 
oncologist and the general practitioner (GP) of 
the patient were asked to Àll in a questionnaire on 
the medical circumstances surrounding the death, 
immediately after the patient died.
Relevant information was available for 105 of 115 
deaths. 
Results: According to the specialist or GP, 20% of 
the patients had expressed a wish for euthanasia, 
three quarters of these (14.3% of all patients) had 
made an explicit and repeated request and half of 
these (7.6% of all patients) received euthanasia. 
Those who had expressed a wish for euthanasia 
but had not made an explicit and repeated request 
(5.7% of all patients) did not receive euthanasia. 
Patients with a palliative treatment goal at diagnosis 
of the advanced cancer, and those who lived longer 
were signiÀcantly more likely to express a wish for 
euthanasia and to receive euthanasia. Death was 
preceded by an ELD in 62.9% of all patients. This 
was a non-treatment decision in 14.3%, intensifying 
curves and log rank tests. We applied a longitudinal 
regression model with random subject effects to 
assess treatment effects on depressive symptoms. 
Finally, we analyzed median CES-D scores at the 
assessment time point closest to death in lung versus 
non-lung intervention group subjects. We used a 
random intercept model with unstructured covariance 
to determine whether participants with lung cancer 
had more depressive symptoms than patients with 
other solid tumors.
Results: Based on the strata, median survival time 
for participants with lung cancer was signiÀcantly 
different among groups. Participants with low 
depressive symptoms survived longest with median 
survival of 13 months. Those with “subclinical” 
depressive symptoms survived 5.9 months and those 
with clinical depressive symptoms survived 8.1 
months (p = .016). Longitudinal analysis of treatment 
effects for lung cancer participants showed no 
signiÀcant difference in CES-D between intervention 
and control groups. However, intervention 
participants with non-lung cancer diagnoses had 
signiÀcantly lower levels of depressive symptoms at 
the assessment point closest to death (Mean CES-D 
= 10.2) compared to the lung cancer subgroup (Mean 
CES-D = 16.7), which was above depression cut-off 
(p = .004). 
Conclusion: Patients with lower baseline depressive 
symptoms had longer median survival than those 
with ‘subclinical’ and clinical levels of depressive 
symptoms. At the assessment point closest to death, 
intervention subjects with lung cancer were more 
depressed than subjects with other solid tumors. 
It appears that our COPC intervention had less 
effect on depressive symptoms for the lung cancer 
group than the whole study sample. The signiÀcant 
association of baseline ‘subclinical’ and clinical 
depressive symptoms with survival, combined 
with the lack of intervention effect for participants 
with lung cancer, suggests the need to develop 
more robust interventions that speciÀcally target 
depressive symptoms in this population. 
Keywords: Lung cancer, palliative care, depression, 
survival
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hormones used by the women in the study cohort. 
Results: The study cohort included 2320 women 
with NSCLC. The median age at diagnosis was 
71 years. Forty-seven percent, 36%, and 14% had 
adenocarcinoma, NSCLC-NOS, squamous cell 
carcinoma respectively. Thirty-four percent of 
patients had stage I & II, 24% had stage III and 38% 
had stage IV disease. Smoking status was explored 
for 1317 patients by chart review. The never smokers 
(n=163) had signiÀcantly better overall survival 
(OS) than smokers (p=0.03). In our cohort, 514 
patients were HRT users. The OS of HRT users was 
signiÀcantly better than non-users (median; 1.35 vs 
0.88 years, p<.001). This difference was present with 
stages I & II combined (p=.002), stage III (p<.001) 
but not in stage IV NSCLC (p=.19). Type of HRT 
used (single estrogen or estrogen progesterone 
combination) did not have a signiÀcant effect on OS. 
Conclusion: These Àndings suggest that similar to 
gender difference women who are HRT users have 
improved survival and this difference is seen only in 
early stage disease indicating that HRT likely alters 
the biology of the disease. 
Keywords: Hormone Replacement Therapy, 
survival, Lung cancer, gender
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O08.06 IMPACT OF HORMONE 
REPLACEMENT THERAPY (HRT) AND 
TOBACCO USE ON OUTCOMES OF 
WOMEN WITH ADVANCED NON SMALL 
CELL LUNG CANCER (NSCLC) AT MAYO 
CLINIC ARIZONA (MCA)
Harshita Paripati1, Amylou C. Dueck2, Julia A. Files3, 
Anita P. Mayer3, Helen J. Ross1 
1Hematology/oncology, Mayo Clinic/United States 
Of America, 2Biostatistics, Mayo Clinic/United 
States Of America, 3Internal Medicine, Mayo Clinic/
United States Of America
Background: The gender differences in 
susceptibility to tobacco induced carcinogenesis and 
risk of non-small cell lung cancer (NSCLC)have 
been described in the recent past, but have not been 
well-deÀned. It has been suggested that women are 
more susceptible to tobacco-induced carcinogenesis. 
Recent studies show that estrogen and estrogen 
receptors, speciÀcally ER-ơ may be involved in 
carcinogenesis. In this study, we analyzed the 
effect of tobacco use, menopausal status and use of 
alleviation of symptoms in 39.1% and administration 
of lethal drugs with the explicit intention to shorten 
life in 9.5% (euthanasia in 7.6%, physician assisted 
suicide in 0.0% and ending the patient’s life without 
request in 1.9%). 
Conclusion: Physicians acted with care and did not 
perform euthanasia on the basis of an expressed wish 
only, without explicit and repeated request; however, 
a proportion of explicit and repeated requests were 
not carried out either because the patient died or 
because the treating physician was not aware they 
had been made. 
Keywords: Euthanasia, End-of-life decisions
Palliative and Supportive Care Monday, 4 July 2011 14:30-16:00
O08.05 HORMONE REPLACEMENT 
THERAPY AND SURVIVAL OF WOMEN 
WITH NON-SMALL-CELL LUNG 
CANCER
Loganathan Kathiravelu1, Grace Musto2, Gary 
Harding3, Gefei Qing4, Ketan Badiani1, Sylvain 
Lother5, Leigh C. Murphy6, Sri Navaratnam3 
1Manitoba Insitutie Of Cell Biology, Cancercare 
Manitoba/Canada, 2Epidemiology & Cancer 
Registry, Cancercare Manitoba/Canada, 3Medical 
Oncology And Haematolgoy, Cancercare Manitoba/
university Of Manitoba/Canada, 4Department 
Of Pathology, University Of Manitoba/Canada, 
5Medical Oncology And Haematolgoy, Cancercare 
Manitoba/Canada, 6Manitoba Institute Of Cell 
Biology, Cancercare Manitoba/Canada
Background: Women have a greater risk of 
developing lung cancer, but once they develop the 
disease their clinical outcome is better than men. The 
gender difference is partially due to estrogen thus 
a similar effect may be expected with exogenous 
hormone use (HRT). The present study was 
undertaken to evaluate the impact of HRT use on 
clinical outcome of lung cancer and the interaction 
with the other prognostic variables. 
Methods: All female patients diagnosed with non-
small cell lung carcinoma (NSCLC) from January 
2000 to December 2007 were identiÀed from the 
Manitoba Cancer Registry (MCR) using ICD codes. 
Information on histology, collaborative staging, 
smoking status and treatment were also obtained. 
Drug Program Information Network (DPIN); an 
administrative data base was used to accurately 
capture HRT use, timing, duration and type of 
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Background: Cancer cachexia causes muscle 
wasting and leads to decline in physical function. 
NSCLC represents greater than 80% of newly 
diagnosed lung cancer with over three quarters 
of patients being diagnosed with Stage III or 
IV disease. At diagnosis, 60% of lung cancer 
patients have substantial weight loss, increasing 
to >80% prior to death from malignancy. Much 
of this weight loss is attributed to muscle wasting 
leading to a decline in physical function and other 
detrimental consequences early in the course of 
a patient’s malignancy. Research has shown that 
NSCLC patients with weight loss at diagnosis are 
less likely to tolerate chemotherapy, have worse 
treatment outcomes and shorter overall survival. 
This wasting and decline in function may have 
detrimental consequences early in the course of a 
patient’s malignancy, underscoring the importance 
of diagnosing and treating this condition at an 
early stage. Published data has shown that a 10% 
improvement in physical function is a substantial 
clinically meaningful beneÀt. We conducted a 
randomized, double-blind, placebo controlled, multi-
center study to evaluate the effect of GTx-024 on 
muscle wasting and physical function in patients 
with cancer cachexia.
Methods: Subjects (n=159) were randomized to oral 
GTx-024 (1 or 3 mg) or placebo daily for 16 weeks. 
Subjects were males >45 years and postmenopausal 
females, with 2% weight loss in the 6 months prior 
to randomization and diagnosed with either NSCLC, 
colorectal cancer, non-Hodgkin’s lymphoma, chronic 
lymphocytic leukemia or breast cancer. The primary 
endpoint was change in lean body mass. Secondary 
endpoints included QOL and physical function 
with clinical beneÀt deÀned as 10% improvement 
in physical function assessed by stair climb power 
(responder analysis).
Results: 103 subjects in the MITT population had 
stair climb power assessed at baseline and week 
16. GTx-024 treated subjects demonstrated clinical 
beneÀt compared to placebo (P=0.03). Among 
NSCLC subjects, 28 were included in the physical 
function analysis. Seventy-eight percent treated with 
GTx-024 responded compared to 30% treated with 
placebo (P=0.02). Physical function was positively 
correlated with QOL as assessed by the FAACT 
questionnaire further substantiating clinical beneÀt 
hormone replacement therapy (HRT) on survival and 
outcomes of women with advanced NSCLC. 
Methods: A retrospective review of data from the Lung 
Cancer Registry at Mayo Clinic Arizona (MCA) was 
conducted. All analytic female patients with stages III 
and IV NSCLC from 1998-2006 were analyzed for age 
at diagnosis, type of therapy, outcomes and survival. 
Chart reviews were conducted to obtain speciÀc 
information such as smoking history, menopausal status 
and use of hormone replacement therapy. 
Results: 381 female patients with advanced (Stages 
III & IV) NSCLC were identiÀed from 1998-2006. 62 
patients were excluded due to either incorrect staging, 
or lack of information regarding treatment and survival. 
Of the remaining 319 patients, 95 (30%) patients had 
Stage III disease and 224 (70%) patients had Stage 
IV disease. 307 women were post-menopausal, 7 
women were pre-menopausal and menopausal status 
was unknown in the remaining 5 women. 242 women 
(76%) were not on any HRT, and 77 women (24%) 
were on .HRT Median survival was 8.0 months in the 
patients not on HRT and 11.0 months in the patients on 
HRT (P=0.38). 268 (84%) patients were smokers and 
51 (16%) patients were non-smokers. Median survival 
was 8.0 months in smokers and 14.0 months in non-
smokers (P=0.07). There was no statistically signiÀcant 
interaction between smoking status and HRT on overall 
survival (interaction P=0.92). 
Conclusion: Our study reveals a trend towards 
poor survival in smokers with NSCLC compared to 
non-smokers. There was no statistically signiÀcant 
difference in overall survival based on use of HRT. 
Further studies are needed to evaluate the effect 
of gender based differences in tumor biology and 
determine optimal treatment of women with lung 
cancer. 
Keywords: hormone replacement therapy (HRT), 
Non small cell lung cancer (NSCLC), smoker
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O08.07 GTX-024, A SELECTIVE 
ANDROGEN RECEPTOR MODULATOR 
(SARM), IMPROVES PHYSICAL 
FUNCTION IN NON-SMALL CELL LUNG 
CANCER (NSCLC) PATIENTS WITH 
CANCER CACHEXIA
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Hancock1, Gary Barnette3, Mary A. Johnston1, 
Mitchell S. Steiner3 
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of cardiomyopathy, LVEF was measured by 
echocardiogram or by multiple gated acquisition 
scan every three cycles and in follow-up until death 
or study discontinuation. Cardiac adverse events 
were graded using the NCI CTCAEv 3.0. 
Results: Baseline characteristics were similar 
in the amrubicin and topotecan groups: median 
age 62 versus 61 years; men 58% versus 60%; 
ECOG PS score of 0 30% versus 34%; mean 
LVEF 62% vs 63%. LVEF (Figure) did not differ 
signiÀcantly between treatment arms and did 
not decline with cumulative doses of amrubicin 
exceeding 1000 mg/m2 (Level 4 in Àgure, N=114). 
Grade 3 cardiac adverse events (Table) occurred 
in 5.1% (AMR) versus 4.6% (Topo), (P=0.84). 
Conclusion: In this randomized phase III trial 
of amrubicin vs topotecan for the second-line 
treatment of SCLC, the cardiac safety of amrubicin 
is comparable to that of topotecan. LVEF remained 
stable even in patients with cumulative amrubicin 
dosing >1000 mg/m2. Amrubicin exhibits a safe 
cardiac proÀle compared with historical results of 
other anthracyclines. 
Keywords: amrubicin, SCLC, Anthracycline, 
Topotecan
(Spearman correlation coefÀcient = 0.60, P=0.001).
Conclusion: GTx-024 was well tolerated and 
showed a statistically signiÀcant and clinically 
relevant improvement in physical function in 
NSCLC subjects. These data provide evidence 
that GTx-024 may play an important role in the 
management of patients with NSCLC. Further 
research is needed to assess the effect of GTx-024 on 
overall survival.
Keywords: muscle wasting, Cachexia, Physical 
function, GTx-024
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O09.01 CARDIAC SAFETY OF 
AMRUBICIN IN A RANDOMIZED 
PHASE 3 TRIAL OF AMRUBICIN 
VS TOPOTECAN AS SECOND-LINE 
TREATMENT FOR SMALL CELL LUNG 
CANCER (SCLC)
David R. Spigel1, Joachim Von Pawel2, Robert Jotte3, 
Mark A. Socinski4, Mary E.R. O’Brien5, Richard 
Mcnally6, Markus Renschler6 
1Thoracic Oncology, Sarah Cannon Research 
Institute/United States Of America, 2Asklepios 
Fachkliniken München-Gauting/Germany, 3Us 
Oncology/United States Of America, 4Lineberger 
Comprehensive Cancer Center/United States Of 
America, 5Royal Marsden NHS Foundation Trust/
United Kingdom, 6Celgene Corporation/United 
States Of America
Background: Amrubicin is a third-generation 
anthracycline and potent topoisomerase II inhibitor. 
Prior data suggests that amrubicin has an improved 
cardiac safety proÀle compared to Àrst and second 
generation anthracyclines. The purpose of this report 
is to evaluate the cardiac safety in the randomized 
phase III trial (ACT-1) of amrubicin versus topotecan 
for the second-line treatment of patients with SCLC. 
Methods: Patients with previously treated SCLC, 
an ECOG PS score 1, and left ventricular ejection 
fraction (LVEF)  50% were eligible. Patients 
received amrubicin 40 mg/m2 IV (n=424) on 
days 1–3 or topotecan 1.5 mg/m2 IV (n=213) 
on days 1–5 of a 21-day cycle. To evaluate risk 
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(such as somnolence [46% all grades] and euphoric 
mood [31% all grades]) occurred during and shortly 
after the Ob infusion. The only Grade 3/4 non-heme 
AE with  5% increase in absolute frequency in the 
Ob arm was somnolence (8 vs 0%). Grade 3/4 febrile 
neutropenia was rare (5% both arms). Grade 3/4 
hematologic lab abnormalities were similar for each 
arm (CEOb vs CE): anemia (8 vs 15%), neutropenia 
(61 vs 58%), and thrombocytopenia (17 vs 10%). 
74% of the pts on the CEOb arm alive without 
progression after 6 cycles started maintenance 
therapy. EfÀcacy data, including death or progression 
during initial 6 cycles of chemotherapy (Refractory 
Rate) are summarized in the table below. Patients 
with PS 2 at screening did poorly with median OS of 
6.0 and 5.8 mos in CEOb and CE arms, respectively. 
Conclusion: The CEOb arm demonstrated a trend 
for improved ORR, Clinical BeneÀt Rate, PFS, 12 
mo and overall survival (OS). Most importantly, 
Ob markedly decreased the rate of refractoriness 
to the initial 6 cycles of chemotherapy by 36.5%, 
suggesting that the observed pre-clinical synergy 
translates clinically into a reversal of primary 
resistance to chemotherapy. OS in PS 0-1 patients 
with ES-SCLC will be evaluated in a Phase III trial 
comparing CE to CEOb. 
Study 
Arm 
ORR Clinical 
BeneÀt 
Rate 
PFS 12 
Month 
Survival 
OS OS  
(PS 0-1) 
Refractory 
Rate (PS 
0-1) 
CEOb 64.9% 83.1% 6.0 mos* 45.5% 10.6 mos* 11.9 mos* 25.4% 
CE 53.8% 69.2% 5.4 mos* 37.2% 9.9 mos* 10.1 mos* 40.0% 
One 
sided p 
value 
0.11 0.03 0.08 0.19 0.0506 0.052 0.05 
Hazard 
Ratio 
- - 0.79 - 0.72 0.71 - 
* Median 
Keyword: small cell carcinoma
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O09.03 IPILIMUMAB IN COMBINATION 
WITH PACLITAXEL AND CARBOPLATIN 
AS FIRST-LINE TREATMENT IN 
EXTENSIVE DISEASE-SMALL CELL 
LUNG CANCER (ED-SCLC): RESULTS 
FROM A PHASE 2 TRIAL
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O09.02 RANDOMIZED PHASE II TRIAL 
OF THE PAN BCL-2 ANTAGONIST 
OBATOCLAX (OB) IN COMBINATION 
WITH CARBOPLATIN AND ETOPOSIDE 
(CE) VS CE CHEMOTHERAPY ALONE 
IN EXTENSIVE STAGE SMALL CELL 
CARCINOMA OF THE LUNG (ES-SCLC)
Corey J. Langer1, Istvan Albert2, Peter Kovacs3, L. 
Johnetta Blakely4, Gabor Pajkos5, Petar Petrov6, 
Attila Somfay7, Aleksandra Szczesna8, Petr 
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Marshall Schreeder12, Judy Schnyder13, Mark 
Berger13 
1Hematology/Oncology, Abramson Cancer Center, 
University Of Pennsylvania/United States Of 
America, 2Mátrai Gyógyintézet, Mátraháza/Hungary, 
3Oncology, University Of Debrecen/Hungary, 4The 
West Clinic/United States Of America, 5Oncology, 
Bacs-Kiskun County Hospital/Hungary, 6District 
Dispensary For Cancer Diseases With Inpatient 
Unit/Bulgaria, 7Univ. Of Szeged/Hungary, 8The 
Regional Lung Diseases Hospital/Poland, 9Charles 
University/Czech Republic, 10Tuberculosis And Lung 
Disease Hospital/Poland, 11Integrated Community 
Oncology Network/United States Of America, 
12Clearview Cancer Institute/United States Of 
America, 13Gemin X Pharmaceuticals/United States 
Of America
Background: Ob, a pan-BCL-2 antagonist, is 
synergistic in vitro with cisplatin and etoposide (E). 
A Phase I study concluded that a 3-hr Ob infusion in 
combination with carboplatin (C) and E was favored 
over a 24-hr infusion (ASCO 2010, Ab e13531)
Methods: Patients (pts) with chemotherapy-naïve 
ES-SCLC, measurable disease, & PS 0-2 were 
randomized to receive six 21-day cycles of CE 
(C AUC 5 D1, and E 100 mg/m2 D1-3) or CEOb 
(CE plus Ob [30 mg as a 3-hr infusion D1-3]). 73 
evaluable pts were planned for each arm. 1° endpoint 
was ORR (conÀrmed CR & PR); 2° endpoints 
included PFS and OS. After completing 6 cycles, 
responders received prophylactic cranial irradiation; 
pts on CEOb continued Ob as maintenance therapy. 
Results: 165 pts were randomized; 155 pts (77 
CEOb; 78 CE) received treatment. Median age was 
62 (range 35-80); 56% were male; 31% were PS 0, 
60% PS 1, and 9% PS 2. 21% in each arm had brain 
mets. The arms were well balanced with respect to 
baseline demographics. CNS Adverse Events (AEs) 
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(concurrent vs phased vs P/C alone, all grades) 
pruritus (24% vs 19% vs 5%), rash (36% vs 24% 
vs 2%), and diarrhea (26% vs 33% vs 16%). 
Corresponding rates of grade 3/4 events were 0% 
vs 2% vs 0% for pruritus, 5% vs 0% vs 0% for rash, 
and 5% vs 10% vs 5% for diarrhea. Hematologic 
abnormalities were similar across 3 arms. Overall 
treatment-related grade 3/4 AEs in concurrent, 
phased, and P/C alone arms were 43%, 50% and 
30%, respectively. One death in concurrent arm was 
reported to be treatment-related. 
Conclusion: Phased ipilimumab+P/C, but not 
concurrent ipilimumab+P/C, appeared to improve 
irPFS, irBORR, and OS, compared to P/C alone. 
Ipilimumab did not appear to exacerbate AEs 
observed with P/C alone. AEs seen more frequently 
in ipilimumab arms were consistent with experience 
from other ipilimumab studies. These data, coupled 
with those previously presented for NSCLC patients, 
support further investigation of ipilimumab in SCLC 
as Àrst-line treatment. Table. PFS, BORR, and OS in 
ED-SCLC patients 
Response 
Concurrent
Ipilimumab+ P/C
N=43
Phased
Ipilimumab+ P/C
n=42
Placebo+ P/C 
n=45 
irPFS, median 
mo (95% CI) 
5.7 (5.2, 6.9) 6.4 (5.3, 7.8) 5.3 (4.7, 5.7) 
P HR 0.11 0.75 (0.48, 1.19) 0.03* 0.64 (0.40, 1.02) 
mWHO-PFS, 
median mo 
(95% CI) 
3.9 (2.9, 5.9) 5.2 (4.1, 6.6) 5.2 (4.4, 5.6) 
P HR (95% 
CI) 
0.38 0.93 (0.59, 1.48) 0.37 0.93 (0.59, 1.45) 
irBORR, % 
(95% CI) 
49 (33, 65) 71 (55, 84) 53 (38, 68) 
mWHO-
BORR, % 
(95% CI) 
33 (19, 49) 57 (41, 72) 49 (34, 64) 
OS, median 
mo (95% CI) 
9.1 (6.7, 13.0) 12.9 (7.9, 16.5) 9.9 (8.6, 11.7) 
P HR (95% 
CI) 
0.41 0.95 (0.59, 1.54) 0.13 0.75 (0.46, 1.23) 
HR (hazard ratio) values are based on a Cox proportional hazards model, 
and P values on a one-sided log-rank test. *Statistically signiÀcant per 
protocol-stipulated Ơ = 0.1. Note that the ED-SCLC cohort was not fully 
powered for formal statistical comparison. 
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Medical College/India, 7Department Of Hematology, 
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8Bristol-Myers Squibb/United States Of America, 
9Department Of Oncology, Yale Cancer Center And 
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Background: Ipilimumab, a human monoclonal 
antibody, augments T-cell activation by inhibiting 
cytotoxic T-lymphocyte antigen-4. Ipilimumab 
signiÀcantly improved overall survival (OS) in a 
phase 3 study of patients with previously treated 
metastatic melanoma; adverse events (AEs) were 
managed by drug-speciÀc treatment guidelines (N 
Eng J Med 2010;363:711). Ipilimumab may show 
activity against other advanced cancers. A blinded 
phase 2 study (CA184-041) assessed ipilimumab 
plus paclitaxel/carboplatin (P/C) as Àrst-line 
treatment for ED-SCLC or non-small cell lung 
cancer (NSCLC). Results for ED-SCLC patients are 
described here.
Methods: One-hundred-thirty patients with 
previously untreated ED-SCLC were randomized 
1:1:1 to receive: concurrent ipilimumab+P/C (4 
doses of ipilimumab+P/C followed by 2 doses 
of placebo+P/C); phased ipilimumab+P/C (2 
doses of placebo+P/C followed by 4 doses of 
ipilimumab+P/C); or P/C alone (placebo+P/C). 
Ipilimumab (10mg/kg), paclitaxel (175mg/m2), 
and carboplatin (AUC=6) were administered 
intravenously every 3 weeks for upto 6 doses. Non-
progressors tolerating treatment received ipilimumab 
(ipilimumab arms), or placebo (P/C alone arm) every 
12 weeks in a maintenance phase. Key endpoints 
included progression-free survival (PFS) and best 
overall response rate (BORR) assessed by an IRRC 
using modiÀed WHO (mWHO) and immune-
related (ir) response criteria (Clin Cancer Res 
2009;15:7412); OS; and safety.
Results: Baseline characteristics of randomized 
patients were generally balanced across arms. Table 
presents data for irPFS, mWHO-PFS, irBORR, 
mWHO-BORR, and OS. Most treatment-related 
AEs generally seen with P/C alone, including 
fatigue, alopecia, nausea, arthralgia and peripheral 
neuropathy, were similar across arms. AEs occurring 
more frequently in ipilimumab arms included 
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Results: Four eligible trials were identiÀed 
and all were available for IPD meta-analysis, 
with a total of 663 patients (329 cisplatin, 334 
carboplatin). Baseline characteristics were well 
balanced between arms. Median age was 67 years 
(27-86) and prevalence of male gender was 78%. 
Performance status (PS) was 0-1 in 72%, 2-3 in 
28%. 68% of patients had extensive stage, and 
most of the remaining had poor prognosis limited 
stage. With 589 deaths recorded (89%), median 
OS was 9.5 months with cisplatin, and 9.5 months 
with carboplatin (hazard ratio [HR] carboplatin 
vs. cisplatin 1.03, 95% conÀdence interval [CI] 
0.88–1.22; p = 0.69). For OS there was no evidence 
of treatment difference between cisplatin and 
carboplatin according to gender, PS, age or stage. 
In males, HR of carboplatin vs. cisplatin was 1.02 
(95% CI 0.85-1.23), while in females HR was 1.06 
(95% CI 0.74-1.51) (treatment by gender interaction 
test p = 0.76). In PS 0-1, HR was 1.02 (95% CI 0.84-
1.24), while in PS 2-3 HR was 0.98 (95% CI 0.72-
1.34) (treatment by PS interaction test p = 0.89). In 
patients younger than 70 years, HR was 0.99 (95% 
CI 0.79-1.23), while in elderly patients HR was 1.12 
(95% CI 0.87-1.44) (treatment by age interaction 
test p = 0.53). In limited stage, HR was 0.89 (95% 
CI 0.65-1.22), while in extensive stage HR was 1.09 
(95% CI 0.90-1.32) (treatment by stage interaction 
test p = 0.25). Response rate was 67.5% and 65.6%, 
with cisplatin and carboplatin, respectively (relative 
risk 0.96, 95% CI 0.82-1.13; p = 0.66). Median 
PFS was 5.3 and 5.5 months, for cisplatin and 
carboplatin, respectively (HR 1.01, 95% CI 0.86–
1.19; p = 0.90). Toxicity proÀle was signiÀcantly 
different: hematological toxicity was higher with 
carboplatin, and non-hematologic toxicity higher 
with cisplatin.
Conclusion: COCIS is the Àrst IPD meta-analysis 
performed to deÀne the optimal treatment of poor 
prognosis and/or extensive stage SCLC. No survival 
difference between cisplatin- and carboplatin-based 
chemotherapy was reported, and subgroup analysis 
did not suggest signiÀcant interaction with gender, 
PS, age or stage. However, the two treatments 
showed a different toxicity proÀle, which should 
drive the choice of regimen in the clinical practice.
Keywords: SCLC, Individual patient data meta-
analysis, Cisplatin, Carboplatin
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INDIVIDUAL PATIENT DATA META-
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Background: Platinum-based chemotherapy is 
the standard Àrst-line therapy of SCLC. Whether 
carboplatin or cisplatin are equally effective in 
the treatment of poor prognosis and/or extensive 
stage SCLC remains controversial. We performed 
an individual patient data (IPD) meta-analysis of 
published randomized trials.
Methods: In June 2009, a systematic review 
was performed to identify randomized phase III 
trials comparing cisplatin- vs. carboplatin-based 
chemotherapy as Àrst-line treatment of SCLC. 
Primary endpoint of the meta-analysis was overall 
survival (OS). IPD (baseline characteristics, treatment, 
toxicity and outcome) were obtained via collaborating 
with all groups identiÀed by the systematic review. 
All statistical analyses were stratiÀed by trial. OS and 
progression-free survival (PFS) curves were compared 
by log-rank test. Response rate was compared using 
the Mantel-Haenszel test. Exploratory subgroup 
analyses were performed to describe possible 
heterogeneity of treatment effect for OS. Interaction 
test was also performed.
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IIIa 11,7%, IIIb 66,4%. Mean total GTV was 136 cc ± 
14 cc (7,49 - 895 cc). The median delivered TTD was 
45.0 Gy (6-45 Gy) given in an overall treatment time 
of 34 ± 6.3 days (17-59 days), with an SER of 39 days 
+/- 17 days (range 7-131), a median MLD of 13,17 Gy 
+ 3.7 Gy (5.5-22 Gy). PCI was delivered in 88% of 
cases. 2 patients (1.4%) did not receive the prescribed 
TTD. Isolated nodal failure occurred in 5 patients 
With a median FU of 44 months, the median overall 
survival was 20 months (95% CI 17.7-22.3 months) 
with a 2 year survival of 39%. In univariate analysis 
the size of the GTV showed a signiÀcant impact on 
overall survival (p=0.009) with a hazard ratio of 1.02 
(95% CI 1-1.04) for death for a 10 cc increase in GTV. 
In multivariate Cox regression analysis using GTV, 
stage (I/II vs III), PCI (yes/no), SER (30 days vs > 
30 days, WHO (0/1 vs 2), sex (male vs female), age 
(> 70 yrs vs 70 yrs and LDH (normal vs elevated), the 
only factors showing a signiÀcant inÁuence on OS 
were GTV (p= 0.028), PCI (p< 0.001) and WHO (p= 
0.01). Median PFS is 14 months (95% CI 12.4-15.6 
months). Nodal recurrences occurred in 38 patients. 
19 patients had nodal recurrences located out of the 
irradiated area, associated with other disease sites in 
17 of these patients. Isolated out-of-Àeld nodal failure 
occurred in 2 patients (1.7%).
Conclusion: In this large, homogeneously treated 
series of stage I-III SCLC patients, size of the GTV 
is shown to be an independent risk factor for stage 
I-III SCLC. Furthermore, omission of elective 
nodal radiotherapy based on PET-CT is conÀrmed 
to result in a low number of isolated nodal failures 
with survival results comparable to other series of 
concurrent chemoradiotherapy using elective nodal 
irradiation. 
Keywords: SCLC, PET, Radiochemotherapy, GTV
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O09.07 IRINOTECAN COMPARED TO 
ETOPOSIDE IN COMBINATION WITH 
PLATINUM ANALOG IN EXTENSIVE 
DISEASE SMALL CELL LUNG CANCER: 
SYSTEMATIC REVIEW AND META-
ANALYSIS WITH GEOGRAPHIC ORIGIN 
SUB-ANALYSIS
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O09.06 LONG-TERM RESULTS OF 
CONCURRENT CHEMORADIATION 
USING PET-CT BASED SELECTIVE 
NODAL IRRADIATION FOR STAGE I-III 
SMALL CELL LUNG CANCER IN 119 
PATIENTS.
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Lambin1, Dirk De Ruysscher1 
1Radiation Oncology, MAASTRO Clinic, Grow 
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Laurentius Ziekenhuis/Netherlands, 5Department 
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Background: Standard therapy for Stage I-III 
small cell lung cancer consists of concurrent 
chemoradiotherapy and accelerated radiotherapy using 
CT- based elective nodal irradiation. First results of 
FDG PET-based selective nodal irradiation (SNI) were 
encouraging. We present the largest series of stage I-III 
SCLC irradiated with SNI reported in literature, also 
investigating the prognostic role of GTV on survival.
Methods: Analysis on intent-to-treat basis of all 
patients in our prospectively collected database 
with stage I-III SCLC referred for concurrent 
chemoradiation (WHO-PS 0-2; FEV1/DLCO >30%). 
All patients were irradiated using an accelerated 
regimen up to 45 Gy in 1.5 Gy fractions twice daily. 
Radiotherapy (RT) was started as soon as possible 
after the start of chemotherapy (carboplatin-etoposide). 
Profylactic cranial irradiation (PCI) was delivered in 
case of non-progression. RT planning was 4D-PETCT 
based, only including PET-positive or pathologically 
proven disease sites. Overall survival (OS) and 
progression free survival (PFS) were calculated from 
diagnosis (Kaplan-Meier method). 
Results: 119 patients (69 male, 50 female), median 
age 66 ± 8.8 years (41-85 years) were included 
from May 23 rd 2004 until June 26th 2009. Stage 
distribution was: IA 0.8%, Ib 2.5%, IIa 4%, IIb 5%, 
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Conclusion: The present meta-analysis 
demonstrated that IP improved OS for both Western 
and Eastern patients. The RR may vary according 
geographical origin of patients. The present Àndings 
corroborate the role of ethnic background in cancer 
therapy and demands further conÀrmation. These 
differences must be explored in a pharmacogenomic 
context. 
Keywords: Small cell lung cancer, randomized trial, 
meta-analysis, irinotecan
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O10.01 THE EURTAC (EUROPEAN 
TARCEVA® VS CHEMOTHERAPY) 
STUDY: INTERIM RESULTS OF A 
PHASE III RANDOMIZED TRIAL OF 
ERLOTINIB VS CHEMOTHERAPY (CT) 
IN ADVANCED NON-SMALL-CELL 
LUNG CANCER (NSCLC) PATIENTS (P) 
WITH EPIDERMAL GROWTH FACTOR 
RECEPTOR (EGFR) ACTIVATING 
MUTATIONS
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Insa16, Filippo De Marinis17, Romain Corre18, Isabel 
Bover19, Alfonso Illiano20, Eric Dansin21, Javier 
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Provencio27, Miguel Angel Moreno28, Josefa 
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Campelo37, Gilles Robinet38, Delvys Rodriguez39, 
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Background: Superiority of irinotecan regimens over 
etoposide - both combined with platinum analogs - in 
extensive disease small cell lung cancer (ED-SCLC) 
has been extensively debated, with contradictory 
results in randomized trials worldwide. Ethnic and 
pharmacogenomical issues were hypothesized as major 
causes of these divergent Àndings. A systematic review 
was sought to elucidate this confounding scenario. 
Methods: Randomized controlled trials comparing 
Àrst-line irinotecan-platinum doublets (IP) versus 
etoposide-platinum doublets (EP) in ED-SCLC 
patients were searched in MEDLINE, EMBASE, and 
CENTRAL databases, ESMO, ASCO, and IASLC 
meeting proceedings. Meta-analyses were performed 
using random-effects model. Subgroup analyses were 
undertaken comparing the geographical area of study 
and interaction test were used to compare subgroups. 
The outcomes of interest were overall survival (OS), 
progression-free survival (PFS) and response rate (RR). 
Results: Seven studies (1967 patients) were included. 
OS meta-analysis demonstrated superiority of IP over 
EP (HR = 0.88; 95% CI 0.81-0.97; P=0.003; I²=0%). 
PFS meta-analysis was not feasible due to impending 
heterogeneity (I²=86%). RR was similar between 
IP and EP groups, absolute rates: IP 52%, EP 50%, 
P-value=0.31. The OS analysis according geographical 
area demonstrated that patients around the world 
experienced similar beneÀt from IP (table 1). PFS 
meta-analysis was not feasible due to heterogeneity, not 
caused by geographic differences. RR meta-analysis 
suggests that Asian patients may be more likely to 
respond to IP than Western patients (interaction Asian 
versus Western patients P=0.03; table 2). 
Table 1: OS Meta-
analysis 
Patients HR 95% CI P-value 
Interaction 
test 
All trials 1967 0.88 [0.81-0.97] 0.003 
European trials 834 0.84 [0.71-1.00] 0.03 Reference 
Asian trial 154 0.80 [0.66-0.98 0.05 P=0.73 
US, Canada & 
Australian trials 
979 0.95 [0.83-1.08] 0.44 P=0.27 
Table 2: RR Meta-
analysis 
Patients OR 95% CI P-value 
Interaction 
test 
All trials 1819 1.19 [0.88-1.62] 0.32 
European trials 625 0.86 [0.60-1.22] 0.30 Reference 
Asian trials 215 2.54 [1.36-4.73] 0.40 P=0.02 
US, Canada & 
Australian trials 
979 1.15 [0.89-1.49] 0.29 P=0.26 
Asian versus 
Western trials 
1819 P=0.03 
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O10.02 UPDATED MEDIAN PFS AND 
ANALYSIS OF QUALITY OF LIFE 
(QOL) IN OPTIMAL, A PHASE III, 
RANDOMIZED, OPEN-LABEL, FIRST 
LINE STUDY OF ERLOTINIB VS 
CARBOPLATIN/GEMCITABINE IN 
PATIENTS WITH ADVANCED NON-
SMALL CELL LUNG CANCER (NSCLC) 
WITH EGFR ACTIVATING MUTATIONS
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Background: OPTIMAL demonstrated superiority 
of erlotinib (E) vs carboplatin/gemcitabine (G/C) in 
terms of progression free survival (PFS), objective 
response rate (ORR) and tolerability in 1st line 
advanced NSCLC patients with EGFR activating 
mutations. We update PFS data and Àrstly report the 
pre-planned analyses of patients’ quality of life (QoL).
Methods: Chemonaïve pts with EGFR Act Mut+ 
advanced NSCLC, ECOG PS 0–2 and measurable 
disease were randomized to E (150mg/d, until 
unacceptable toxicity or progressive disease), or G/C 
(G [1000mg/m2, d1, 8] + C [AUC 5, d1], q 3 wks for 
up to 4 cycles), and stratiÀed by histology, smoking 
status and mutation type (n=165). Primary endpoint 
was PFS. Secondary endpoints including ORR, OS, 
QoL (FACT-L, TOL, LCS) and safety. Median PFS 
is updated, the QoL questionnaire was administered 
at randomization and once every 6 weeks until PD. 
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Abstract under Embargo - will be presented in a 
press conference during WCLC 2011.
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doublet chemotherapy, but head-to-head data for 
these agents are limited. In particular, efÀcacy of these 
agents in EGFR wild type (WT) NSCLC is of interest, 
as patients with EGFR mutation-positive (MUT+) 
NSCLC are increasingly likely to receive erlotinib 
Àrst line. The open-label, phase III TITAN study was 
designed to assess the efÀcacy and tolerability of 
second-line erlotinib versus chemotherapy (docetaxel 
or pemetrexed) in advanced NSCLC.
Methods: A total of 2590 patients with untreated, 
advanced NSCLC received up to 4 cycles of Àrst-
line platinum-based chemotherapy in the run-in 
phase. Those with controlled disease were offered 
entry into SATURN (phase III study of maintenance 
erlotinib), while those with disease progression (PD) 
were offered entry into TITAN. Patients entering 
TITAN (n=424) were randomised (1:1) to receive 
erlotinib 150mg/day or chemotherapy (docetaxel or 
pemetrexed, at investigators’ discretion; standard 
regimens), until unacceptable toxicity or conÀrmed 
PD. Overall survival (OS) was the primary endpoint, 
secondary endpoints included progression-free 
survival (PFS), safety and biomarker analyses. 
Methodology for biomarker sampling and analysis 
was as reported for SATURN (Cappuzzo et al. 2010). 
Results: The full analysis population comprised 203 
patients in the erlotinib arm and 221 for chemotherapy 
(116 for docetaxel and 105 for pemetrexed). The erlotinib 
arm had a greater percentage of males and current 
smokers and a lower incidence of adenocarcinoma 
versus the chemotherapy arm. No signiÀcant difference 
in OS or PFS was seen between arms: HR=0.96 for OS 
(95% CI 0.78–1.19; log-rank p=0.73) and HR=1.19 
for PFS (95% CI 0.97–1.46; log-rank p=0.09). The 
biomarker analyses results for OS and PFS are shown 
in the table. For patients with conÀrmed EGFR WT 
disease (n=149), erlotinib and chemotherapy were 
equally effective as second-line therapy, HR=1.25 (95% 
CI 0.88–1.78, p=0.2030) for PFS and HR=0.85 (95% CI 
0.59–1.22, p=0.3725) for OS. 
Clinically relevant improvement during the study 
was predeÀned as patient with clinically relevant 
improvement one or more times during the study.
Results: 165 were randomized and 154 included in 
the study population (82 E; 72 G/C). In the primary 
analysis, PFS was signiÀcantly prolonged with E 
vs G/C: mPFS of 13.1 vs 4.6, HR 0.16; p<0.0001 
(data reported in ESMO 2010). By the cut-off date 
of Jan 7, 2011, an updated analysis showed median 
PFS of 13.7 vs 4.6 months, respectively, HR 0.164, p 
<0.0001). 128 patients with a baseline and at least one 
post-baseline QoL assessment were included for QoL 
analysis (74 E; 54 G/C).Compared with G/C group, 
E had a clinically relevant improvement in QoL, as 
assessed by scores on the FACT-L ( 73% vs 29.6 %; 
OR 6.9; 95% CI 3.07–15.48; p<0.0001) and by scores 
on LCS (75.7% vs 31.5%; OR 6.77; 95% CI 3.04–
15.05; p<0.0001), and by scored on the TOI ( 71.6% 
vs 24.1%, OR 7.79; 95% CI 3.44–17.66; p<0.0001).
Conclusion: Erlotinib demonstrated improved PFS and 
QoL over G/C, with a more favorable tolerability proÀle.
Keywords: erlotinib, Quality of Life, Non-small cell 
lung cancer, EGFR mutations
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CANCER (NSCLC)
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Background: Erlotinib, docetaxel and pemetrexed 
are approved for patients with advanced NSCLC 
whose disease progresses after Àrst-line platinum 
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for the enrollment. Randomized patients received 
either geÀtinib 250 mg per oral every day or 
pemetrexed 500 mg/m2 iv day 1 with vitamin 
B12 and folic acid supplement every 21 days. The 
primary end point was progress-free survival (PFS).
Results: One hundred thirty-Àve patients were 
randomly assigned with being stratiÀed with 
performance status (0-1 vs. 2) and gender. Overall 
response rates were 30.1% and 14.9% (P < 0.001) for 
geÀtinib and pemetrexed, respectively. The primary 
endpoint of PFS was met with 9.4 months for 
geÀtinib versus 2.9 months for pemetrexed, which 
was signiÀcantly different (P = 0.010). The median 
overall survival has not been reached yet in both 
groups. The 1-year survival rate for geÀtinib and 
pemetrexed arm was 73.6% and 70.5% (P = 0.89), 
respectively. The further analyses of EGFR mutation 
status, post-study treatment and adverse events will 
be presented.
Conclusion: GeÀtinib showed superior efÀcacy 
to pemetrexed as second-line therapy in clinically 
selected NSCLC patients in Korea. Considering 
sequence of salvage therapy, geÀtinib would be 
preferable to pemetrexed in enriched NSCLC 
patients.
Keywords: Salvage therapy, Pemetrexed, geÀtinib, 
phase III
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O10.06 A RANDOMIZED, DOUBLE-
BLIND PHASE III STUDY OF ICOTINIB 
VERSUS GEFITINIB IN PATIENTS 
WITH ADVANCED NON-SMALL CELL 
LUNG CANCER (NSCLC) PREVIOUSLY 
TREATED WITH CHEMOTHERAPY 
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Conclusion: Erlotinib provided similar efÀcacy 
outcomes to chemotherapy in second-line advanced 
NSCLC, and was as effective as chemotherapy in 
patients with conÀrmed EGFR WT disease. 
Keywords: erlotinib, Biomarkers, Second-line, Non-
small cell lung cancer
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CELL LUNG CANCER PREVIOUSLY 
TREATED WITH PLATINUM-BASED 
CHEMOTHERAPY (KCSG-LU08-01)
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Background: We try to compare the efÀcacy of 
geÀtinib versus pemetrexed as second-line therapy 
in never-smokers with advanced pulmonary 
adenocarcinoma previously treated with platinum-
based chemotherapy.
Methods: Eligible patients had a performance status 
0 to 2, previous treatment with one prior platinum-
based regimen, pulmonary adenocarcinoma, and 
never-smoking state. Epidermal growth factor 
receptor (EGFR) mutation status was not considered 
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among which 27 (40.9%) were in Ic and 39 (59.1%) 
were in Ge. The ORR and PFS in both Ic and Ge 
groups demonstrated signiÀcant differences between 
pts with mutations (M) and pts with the wild type 
gene (W). In the Ic group, M vs. W was 59.3% 
(16/27) vs. 5.1% (2/39) for ORR and 198 d vs. 70 d 
for PFS. In the Ge group it was 52.6% (20/39) vs. 
3.7% (1/27) for ORR and 158 d vs. 76 d for PFS. 
Conclusion: This study demonstrated that Icotinib 
provides similar efÀcacy to GeÀnib, but with better 
tolerability, in NSCLC patients previously treated 
with one or two chemotherapy agents.
Keywords: EGFR-TKI, icotinib, NSCLC, phase III 
trial
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O10.07 OVERALL SURVIVAL (OS) 
RESULTS OF A RANDOMIZED PHASE 2 
TRIAL OF PF299804 VERSUS ERLOTINIB 
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SMALL CELL LUNG CANCER (NSCLC) 
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Keunchil Park6, Rafael Rosell7, Denis C. Talbot8, 
Ian C. Taylor9, Jane Liang10, Alicyn K. Campbell11, 
Joseph O’Connell9, Suresh Ramalingam12 
1Medical Oncology, Sydney Cancer Centre/Australia, 
2Medical Oncology, The Christie NHS Foundation 
Trust/United Kingdom, 3Medicine, Pucrs School 
Of Medicine/Brazil, 4Oncology, Norwalk Hospital/
United States Of America, 5Internal Medicine, 
Seoul National University Hospital/Korea, 6Div Of 
Hem/onc, Dept Of Medicine, Samsung Med Ctr, 
Sungkyunkwan University School Of Medicine/
Korea, 7Medical Oncology, Catalan Institute Of 
Oncology/Spain, 8Medical Oncology, Oxford 
Oncology Centre/United Kingdom, 9Oncology, PÀzer 
Oncology/United States Of America, 10Clinical 
Statistics At Oncology Business Unit, PÀzer 
Oncology/United States Of America, 11Clinical 
Development And Medical Affairs, PÀzer Oncology/
United States Of America, 12Hematology And 
Medical Oncology, Winship Cancer Institute Of 
Emory University/United States Of America
Background: PF299804 is a potent, irreversible 
inhibitor of human epidermal growth factor receptors 
(EGFR)/HER-1, -2, and -4, with superior antitumor 
activity over reversible EGFR tyrosine kinase 
Army/China, 7Pulmonary Medicine, Changhai 
Hospital, The Second Military Medical University/
China, 8Oncology, Bejiing Chest Hospital/China, 
9Pla Cancer Centre, Nanjing Bayi Hospital/China, 
10Oncology, 2nd Xiangya Hospital/China, 11Internal 
Medicine, Zhejiang Cancer Hospital/China, 12R & D 
Center, Zhejiang Betapharma/China
Background: Icotinib (ComanaTM) is a potent and 
selective inhibitor targeting the tyrosine kinase 
domain of epidermal growth factor receptor (EGFR). 
Of 88 kinases proÀled, Icotinib (Ic) powerfully 
inhibited EGFR and its 3 mutants, with no 
meaningful inhibition of the rest of kinases tested. 
Ic was found to have signiÀcant clinical activity 
in patients with NSCLC in early phase trials. This 
study was designed to show that Ic is not inferior to 
GeÀtinib (Ge).
Methods: Patients (Pts) with NSCLC progressed 
after one or two lines of chemotherapies were 
randomized to receive Ic (125mg Tid) or Ge (250mg 
Qd). The primary endpoint was progression-free 
survival (PFS). The second endpoints included 
overall survival (OS), overall response rate (ORR), 
time to progression (TTP), quality of life (QOL) 
and tolerability. Exploratory endpoints included 
association of efÀcacy with EGFR gene mutation, 
which was examined by DsX Scorpion ARMS. 
Results: From Feb 2009 to Nov 2010, 399 patients 
were randomized to receive either Ic (200) or Ge 
(199). Baseline characteristics were well balanced 
between the two arms . Ic demonstrated 35 day 
(d) median PFS extension compared to Ge (Ic vs. 
Ge: 137 d vs. 102 d, HR 0.84, 95% CI 0.67-1.05), 
reaching the primary objective of non-inferiority. 
In per-protocol set, median TTP in Ic (154 d) was 
signiÀcantly longer than Ge (109 d) (P=0.04). 
With 49.4% maturity, OS was similar between Ic 
and Ge groups (median OS was 504 d and 531 d, 
respectively). Further follow-up of OS is ongoing. 
Furthermore, ORR (Ic vs. Ge: 27.6% vs. 27.2%), 
DCR (75.4% vs. 74.9%), TTP (156 d vs. 111 d ) and 
QoL (101.4± 9.6 vs. 103.0± 19.1) were comparable 
between Ic and Ge groups. Adverse response rate in 
Ic group was 60.5%, which was signiÀcantly lower 
than that in Ge group (70.4%) (P=0.04). SpeciÀcally, 
39.5% pts in Ic developed rash compared to 49.2% 
in Ge; 18.5% pts in Ic had diarrhea compared to 
27.6% in Ge (P=0.03); 8.0% pts in Ic had elevated 
aminotransferase level compared to 12.6% in Ge. 
EGFR gene mutational analysis was performed for 
132 pts. Mutations were identiÀed in 66 pts (50%), 
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treatment discontinuation was uncommon in both arms. 
A phase 3 study of PF299804 vs erlotinib for second-/
third-line therapy of advanced NSCLC is planned. 
1. Ramalingam SS et al. ESMO 2010; abstr 365PD 
Keywords: PF-00299804, Overall survival, Non-
small cell lung cancer, EGFR TKI
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the Late Breaking Abstract Supplement, available 
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O11.01 QUALITY OF LIFE IN ADVANCED 
NON-SMALL CELL LUNG CANCER, 
EFFECTS OF CISPLATIN DOSE AND 
CARBOPLATIN IN COMBINATION 
WITH GEMCITABINE: RESULTS 
FROM BTOG2, A BRITISH THORACIC 
ONCOLOGY GROUP PHASE III TRIAL IN 
1363 PATIENTS
Lucinda Billingham1, Piers Gaunt2, Hugh Jarrett2, 
David Dunlop3, Joyce Thompson4, Kenneth J. 
O’byrne5, Muthu Kumar6, Geraldine Skailes7, 
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A Chetiyawardana11, Paula Wells12, Conrad 
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St James’s Hospital/Ireland, 6Derby Royal Hospital/
United Kingdom, 7Royal Preston Hospital/
United Kingdom, 8Aberdeen Royal InÀrmary/
United Kingdom, 9Kent Oncology Centre/United 
Kingdom, 10Whittington Hospital/United Kingdom, 
11Manor Hospital/United Kingdom, 12Whipps Cross 
Hospital/United Kingdom, 13Oncology, Imperial 
College Healthcare/United Kingdom, 14University 
Of ShefÀeld/United Kingdom, 15HuddersÀeld 
Royal InÀrmary/United Kingdom, 16University Of 
Birmingham/United Kingdom, 17Oncology, New 
Cross Hospital/United Kingdom
inhibitors (TKIs) in geÀtinib- and erlotinib-sensitive 
and -resistant preclinical models. The current 
randomized trial assessed PF299804 vs erlotinib in 
patients with NSCLC after chemotherapy failure. 
Methods: Eligible patients (any histology, ECOG 
performance status [PS] 0–2, no prior HER-directed 
therapy, 1 or 2 prior chemotherapy regimens, 
available tumor tissue) were randomized 1:1 to oral 
PF299804 45 mg or erlotinib 150 mg once daily 
and treated until progression/toxicity. The primary 
endpoint was progression-free survival (PFS); 
secondary endpoints included OS, objective response 
rate (ORR) per RECIST, safety, and patient-reported 
outcomes (PRO). 
Results: 188 patients were randomized: median 
age 61 years, 88% PS 0/1, 41% female, 65% 
adenocarcinoma, 25% East Asian, 21% non-smoker, 
16% EGFR mutation, 16% KRAS mutation. 
Baseline characteristics were balanced between 
arms except for PS 2 (PF299804, n=20; erlotinib, 
n=3), EGFR mutation (PF299804, n=19; erlotinib, 
n=11), and >1 prior chemotherapy regimen 
(PF299804, n=38; erlotinib, n=27). Tumor genotype 
ascertainment rates were high (KRAS, 78%; EGFR, 
81%). All but 3 patients were followed up until 
disease progression or death. PFS was signiÀcantly 
longer with PF299804 vs erlotinib overall (median 
12.4 vs 8.3 weeks; hazard ratio [HR]=0.70, 
P=0.030), with beneÀts across several subgroups 
including adenocarcinoma, non-adenocarcinoma and 
EGFR wild type. At the time of this submission 65 
deaths had been reported on PF299804 and 73 on 
erlotinib, and the median OS was 9.64 months for 
PF299804 and 7.53 months for erlotinib (HR=0.841; 
P=0.31). Frequent treatment-related adverse events 
(TRAEs) for PF299804 vs erlotinib (overall/grade 
3 or 4) were: diarrhea (73%/12% vs 49%/3%), 
acneiform dermatitis (65%/11% vs 57%/6%), 
stomatitis (29%/1% vs 12%/1%), decreased appetite 
(25%/1% vs 22%/0), paronychia (26%/3% vs 
9%/1%), dry skin (24%/1% vs 15%/1%), fatigue 
(18%/2% vs 20%/1%) and nausea (17%/2% vs 
16%/1%). 10 patients discontinued due to TRAEs: 7 
receiving PF299804 and 3 receiving erlotinib. 
Conclusion: PF299804 was associated with a 
signiÀcant improvement in PFS, a trend towards 
superior OS and improvement in lung cancer 
symptoms1 compared with the selective reversible 
EGFR TKI erlotinib in advanced NSCLC. OS 
for relevant clinical and molecular subsets will be 
presented. Common EGFR TKI AEs were more 
frequent with PF299804 than with erlotinib but 
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quality-adjusted life months were 6.1 on GC80, 5.6 
on GC50 and 6.1 on GCb6. 
Conclusion: Although higher doses of cisplatin (80 
mg/m2) are thought detrimental to QoL compared 
to 50 mg/m2 we found minimal differences but a 
noteworthy problem in delayed neuropathy. Also, 
the belief that carboplatin produces superior QoL 
compared to cisplatin at either dose is not obvious. 
Importantly carboplatin treatment may not palliate 
dysponea as well as cisplatin. Adjusting for QoL does 
not change the conclusions from the primary survival 
analysis. As the largest QoL study in advanced 
NSCLC, these data will provide valuable information 
on immediate and long-term effects of treatments, thus 
aiding clinicians and patients in their decisions. 
Keywords: Quality of Life, Cisplatin, BTOG2, 
Advanced NSCLC
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
Medical Oncology V Monday, 4 July 2011 14:30-16:00
O11.02 CLASS III ȕ-TUBULIN, 
HISTOPATHOLOGY AND QUALITY 
OF LIFE IN ADVANCED NSCLC 
PATIENTS RANDOMIZED IN A LARGE 
MULTICENTER PHASE III TRIAL
Adam Vilmar1, Eric Santoni-Rugiu2, Jens B. 
Sorensen3 
1Oncology, Unversity Hospital Of Copenhagen/
Denmark, 2Department Of Pathology, Copenhagen 
University Hospital/Denmark, 3Department Of 
Oncology, Finsen Centre, National University 
Hospital/Denmark
Background: Platinum based doublets are the 
cornerstone of treatment in advanced non-small cell 
lung cancer (NSCLC) and often include vinorelbine 
or taxanes. A valid, predictive biomarker is greatly 
needed in order to select chemotherapy sensitive 
patients for these microtubule interfering agents. 
Class III b-tubulin (TUBB3) has been demonstrated 
of value in NSCLC but evidence is not uniform. 
Accordingly, we explored the predictive role 
of TUBB3 in patients with advanced NSCLC. 
Furthermore, histopathological variations and quality 
of life (QOL) was correlated to biomarker status. 
Methods: 443 patients with advanced NSCLC 
were enrolled in a phase III trial and randomized to 
Background: The standard of care for advanced non-
small cell lung cancer (NSCLC) is platinum-based 
chemotherapy but the optimal dose of cisplatin and 
comparison with carboplatin is uncertain. Given the 
median survival time of these patients is 8-12 months, 
it is important to understand the impact of such 
treatment choices on patients’ quality of life (QoL). 
The BTOG2 trial is a large phase III randomised 
trial comparing three treatment arms: gemcitabine 
(1250mg/m2 day 1 and day8) with either cisplatin 
80mg/m2 (GC80), cisplatin 50mg/m2 (GC50) or 
carboplatin AUC6 (GCb6). Treatment was given for 
a maximum of four 21-day cycles. Primary outcome 
is survival time but due to stage of disease and nature 
of treatment, QoL was recognised as an important 
outcome. The BTOG2 trial was innovative in aiming 
to collect QoL data on all trial patients and is the 
largest study to date addressing this issue in NSCLC. 
Methods: QoL was measured using standard, 
validated questionnaires. The EORTC QLQ-C30 
and lung cancer speciÀc module LC13 provide a 
descriptive proÀle of patients’ quality of life and 
the EQ-5D provides a valuation of patients’ health 
state. The timing of assessments was at each cycle of 
chemotherapy and each follow-up visit. Descriptive 
analysis was used to compare the treatment groups 
in terms of change over time for the 27 different 
measures. EQ-5D measures are combined with 
survival data using the integrated quality-survival 
product to provide mean quality-adjusted life months 
(QALM) for each treatment arm. 
Results: Of the 1363 randomised patients, 97% 
completed at least one QoL assessment, returning 
a total of 8023 questionnaires with a median 
of 6 forms per patient and maximum of 34. 
Questionnaire completion rates at baseline and 
during treatment were 92% and 89% respectively. 
At pre-randomisation, the mean global heath status 
score and EQ-5D utility score were 62% and 0.66 
and this is reasonably balanced across the treatment 
groups. On initiation of treatment, patients in all 
three treatment arms had improved pain, cough, 
haemoptysis, insomnia, appetite loss and emotional 
functioning with associated improvements in global 
measures of QoL but these beneÀts generally fell 
away after completion of chemotherapy (12+ 
weeks). GC50 performed better in terms of the 
functioning scores and in terms of fatigue, nausea 
and vomiting whilst GCb6 performed worst for 
dyspnoea. All treatments had a deleterious effect 
on peripheral neuropathy with the post-treatment 
toxicity momentum markedly worse for GC80. Mean 
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symptom burden and impact on quality of life in 
advanced non small cell lung cancer (NSCLC) 
patients.
Methods: Patients with advanced (stage IIIB/
IV) NSCLC in France (n= 613) and Germany 
(n=600) were recruited into an observational cross-
sectional study. Of these, 837 patients consented 
to complete questionnaires at a single timepoint. 
The study period extended from Jul-Oct 2010. 
Patient reported symptoms using the Lung Cancer 
Symptom Scale (LCSS), which assesses six lung 
cancer symptoms including fatigue, loss of appetite, 
shortness of breath, cough, pain and blood in 
sputum. Each of these symptoms is scored on a 
0-100 visual analogue scale. An average symptom 
burden index was calculated as a mean of the six 
symptom scores. Quality of life was assessed using 
the Functional Assessment of Cancer Therapy- Lung 
(FACT-L), which is a validated lung cancer speciÀc 
questionnaire. Items on the FACT-L are rated on a 
5-point Likert Scale ranging from 0 (not at all) to 
4 (very much). The total FACT-L score can range 
from 0-136. Higher scores indicate higher severity 
of symptoms on the LCSS and a better quality of 
life on the FACT-L. Correlation between the total 
FACT-L score and LCSS symptom burden index 
was assessed. A multivariate regression analysis was 
performed with FACT-L total score as the dependent 
variable and LCSS individual symptom scores 
as predictors. Age, gender, stage and Karnofsky 
scores for performance status were used as control 
variables. 
Results: Majority of the patients were male (67%), 
Caucasian (93%) with an average age of 63 years 
(median= 64 years). Approximately 45% of the 
patients were current smokers and 40% were ex-
smokers. Fifty two percent of the patients were on 
Àrst line therapy and remaining 48% were on second 
or later line therapies. The proportion of patients 
that reported scores greater than zero for each of 
the lung cancer symptoms was: Fatigue (98%), 
loss of appetite (98%), shortness of breath (94%), 
cough (93%), pain (90%) and blood in sputum 
(70%). The average (SD) symptom burden index 
was 41.2 (22.3). The mean± SD severity scores on 
individual symptoms were: fatigue (53.9±26.5), loss 
of appetite (53.1±27.9), cough (41.4±30.9), shortness 
of breath (42.9± 29.5), pain (37.2± 30.6) and blood 
in sputum (19.4±27.9). The average (SD) FACT-L 
score was 71.4(19). A signiÀcant negative correlation 
was found between LCSS symptom burden 
index and FACT-L scores (Ư= -0.67; p<0.001). 
triplet chemotherapy or standard doublet regimen. 
Immunohistochemical evaluation for TUBB3-status 
was mainly performed on bioptic material and 
correlated to response rates (RR), progression free 
survival (PFS), overall survival (OS), QOL and toxicity.
Results: 261 (58.9%) patients had representative 
tissue samples for TUBB3 evaluation. No signiÀcant 
differences were found in RR, PFS or OS according 
to TUBB3-status. Patients with TUBB3-negative 
(neg) adenocarcinomas had a signiÀcantly prolonged 
PFS and OS when compared to the opposite 
subgroup (7.87 versus (vs) 6.83 months, P = 0.035 
& 14.17 vs 11.17 months, P = 0.018, respectively). 
Multivariate analysis revealed a hazard ratio of 1.55 
(95% CI 1.04-2.31, P = 0.032) for patients with 
TUBB3 adenocarcinoma positivity. Concerning 
QOL, in the adenocarcinoma subgroup, patients with 
TUBB3-neg tumors showed a mean decline from 
baseline of -18.25 points (95% CI - 4.28 - -32.22, p = 
0.013) as compared to -3.86 (95% CI -7.0-15.52, P = 
0.5) for patients with positive tumors. 
Conclusion: TUBB3 was found of predictive 
value in patients with advanced NSCLC and 
adenocarcinomas in the largest randomized 
population published to date. TUBB3 may be 
clinically implementated in conjunction with other 
biomarkers, but QOL information should be recorded 
during validation, as prophylactic intervention may 
be needed in speciÀc subgroups at risk of toxicity.
Keyword: NSCLC, predictive markers, Class III 
beta-tubulin, microtubule interfering agents
A revised/updated abstract may be included in 
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O11.03 ADVANCED LUNG CANCER 
SYMPTOM BURDEN AND IMPACT ON 
PATIENT QUALITY OF LIFE
Shrividya Iyer1, Gavin Taylor-Stokes2, Adam 
Roughley2 
1Global Outcomes Research, PÀzer Oncology/United 
States Of America, 2Adelphi Real World/United 
Kingdom
Background: Patients with advanced lung cancer 
experience disease symptoms that could have 
signiÀcant impact on their quality of life. The main 
objective of our study was to assess patient reported 
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topics on a 5-point Likert scale which evaluated 
the importance of each item. Demographic 
characteristics, clinical factors, and support group 
content preferences were assessed.
Results: There were 4402 respondents to the 
invitation to participate, and 3728 patients 
and caregivers elected to participate (85%). 
Characteristics included for all 3728 patients: 70% 
women, mean age 58 (range 20-89). For the 233 
patients with lung cancer, 66.5% were women and 
the mean age was 62; 35.5% had advanced disease. 
For the whole group, the four most common cancers 
were breast 45%, prostate 15%, lung 6%, and 
colorectal 5%. 90% of participants were patients and 
10% were caregivers. 80% of participants rated all 
26 topics. The table below shows rankings by the 
top 2 categories (the percent ranking each topic as 
“Very Important” or “Important”) of the 10 highest 
rated topics for patients with lung cancer and for all 
patients. 
TOPICS (Top 10 
rated of 26) 
LUNG CANCER 
PATIENTS 
(n=233): Very 
Important+Important / 
(Ranking) 
ALL PATIENTS 
(N=3728): Very 
Important+Important / 
(Ranking) 
Side effects and 
their prevention 
95.4% (1) 93.5% (2) 
Cancer treatment 
choices 
94.5.% (2) 95.0% (1) 
Making decisions 
about care 
92.2% (3) 90.1% (4) 
Living with a 
cancer diagnosis 
91.7% (4) 91.4% (3) 
Pain and its 
control 
91.6% (5) 79.9% (13) 
Cancer-related 
fatigue 
91.3% (6) 84.4% (11) 
Dealing with 
anxiety / 
depression 
91.2% (7) 85.8% (6) 
Uncertainty of 
cancer 
89.3% (8) 84.9% (8) 
Stress and stress 
management 
88.0% (9) 85.1% (7) 
Talking with 
medical 
professionals 
87.7% (10) 88.5% (5) 
Conclusion: 1) This is the largest survey of patients 
and caregivers concerning support groups for both 
patients with lung cancer and for a more general 
cancer population. 2) Patients with lung cancer 
ranked most topics in a similar manner to the general 
cancer population; however, topics dealing with pain 
Fatigue (ơ =-0.123; p<0.001), loss of appetite (ơ=-
0.173;p<0.001), pain (ơ=-0.148; p<0.001) , shortness 
of breath (ơ = -0.118; p<0.001), stage IV (ơ= -3.70; 
p<0.05) and performance status (ơ = 0.117;p<0.05) 
were found to be signiÀcant predictors of lung cancer 
speciÀc quality of life.
Conclusion: Fatigue, loss of appetite, shortness of 
breath and pain have a signiÀcant negative impact 
on patient reported disease speciÀc quality of life 
in advanced NSCLC patients. Future treatments 
which alleviate these symptoms may lead to positive 
beneÀts in quality of life in advanced NSCLC 
patients. 
Keywords: Quality of Life, lung cancer symptoms, 
Patient Reported Outcomes
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O11.05 AN EVIDENCE BASED 
ASSESSMENT OF 3728 PATIENTS 
CONCERNING TOPICS FOR 
SUPPORT GROUP DISCUSSION AND 
PRESENTATION AMONG PATIENTS 
WITH LUNG CANCER. DO PATIENTS 
WITH LUNG CANCER DIFFER FROM 
THOSE WITH OTHER CANCERS?
Richard J. Gralla1, Kathleen D. Morse1, Cynthia 
N. Rittenberg1, Judith A. Petersen2, Kenda Burg2, 
Beverly J. Davis2, C Sison3, L M. Rosen3, Martin 
Lesser3 
1Medical Oncology, Hofstra North Shore - LIJ 
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America
Background: Cancer support groups are now 
available at most cancer centers, although this can 
differ depending on the location of the treatment 
center. Even though there is increasing demand 
among patients and families for support groups, little 
data exist outlining which topics patients and their 
caregivers consider as most important for support 
group discussion and presentation. We conducted 
a large web-based anonymous survey to determine 
preferences of patients and caregivers for cancer 
support groups. 
Methods: The established patient base of 
NexCura®, a web-based information resource, was 
used to survey registered patients and caregivers 
in this on-line assessment. Participants ranked 26 
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improved progression-free survival (PFS) and 
the Àrst maintenance study with a pemetrexed-
containing induction regimen. 
Methods: Following four 21-day cycles of 
pemetrexed-cisplatin (N=939), patients with disease 
control of advanced nonsquamous NSCLC were 
randomized 2:1 to pemetrexed 500 mg/m2 plus BSC 
or placebo plus BSC every 21 days until disease 
progression or unacceptable toxicity (N=539). 
Patients in both groups were fully supplemented with 
folic acid and Vitamin B12. Toxicity was assessed 
using CTCAE. Resource use was summarized for 
all patients enrolled in the induction phase and for 
all randomized patients by treatment group. Both 
toxicity and resource use were compared using 
Fisher’s exact test. Patients completed the EuroQol 
5-dimensional scale (EQ-5D), a standardized 
instrument to measure health outcome, at each visit. 
Mean UK population-based index and Visual Analog 
Scale (VAS) scores were calculated and changes 
from baseline during induction and maintenance 
were analyzed using a paired t-test; additionally, 
treatment group differences during maintenance were 
analyzed using a mixed-effects analysis of variance 
model. 
Results: The induction safety results are presented 
elsewhere. Safety of single-agent maintenance 
pemetrexed in PARAMOUNT was similar to the 
Àrst maintenance phase III study (Ciuleanu et al. 
Lancet. 2009;374:1432–1440). Overall, 23.4% of 
pemetrexed-treated patients completed >10 cycles 
(4 induction plus 6 maintenance cycles) compared 
with 13.9% of placebo-treated patients (p=0.009). 
No difference in drug-related Grade 3/4/5 toxicities 
was observed with long-term pemetrexed exposures, 
except neutropenia (>10 cycles, 8.3% versus 10 
cycles, 2.2%; p=0.015), which did not translate into 
increased infections (1.2% and 2.9%, respectively; 
p=0.691). Resource use was similar between 
induction and maintenance, although anti-emetic use 
was higher in induction (66.7%) than maintenance 
(34.7%). During maintenance, transfusions 
(13.4% versus 5.0%; p=0.003) and concomitant 
use of granulocyte colony-stimulating factor or 
granulocyte-macrophage colony-stimulating factor 
(5.3% versus 0.0%; p<0.001) and anti-infectives 
(25.3% versus 16.7%; p=0.028) were greater in 
pemetrexed-treated versus placebo-treated patients. 
The overall rate of hospitalizations was similar 
between treatment groups. During induction, 
overall EQ-5D compliance was 79.4%. Statistically 
signiÀcant but not clinically relevant differences in 
and fatigue were more highly ranked by those with 
lung cancer. 3) Physical and psychological issues 
are the most highly ranked issues by lung cancer 
patients and families. 4) These results should guide 
the content of support groups to meet the needs of 
patients and caregivers. 
Keywords: Support Groups, Quality of Life, PROs
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O11.06 SAFETY, RESOURCE USE, 
AND QUALITY OF LIFE (QOL) 
RESULTS FROM PARAMOUNT: A 
PHASE III STUDY OF MAINTENANCE 
PEMETREXED PLUS BEST SUPPORTIVE 
CARE (BSC) VERSUS PLACEBO PLUS 
BSC IMMEDIATELY FOLLOWING 
INDUCTION TREATMENT WITH 
PEMETREXED-CISPLATIN FOR 
ADVANCED NONSQUAMOUS NON-
SMALL CELL LUNG CANCER (NSCLC)
Cesare Gridelli1, Filippo De Marinis2, Jean-Louis 
Pujol3, Martin Reck4, Rodryg Ramlau5, Barbara 
Parente6, Thierry Pieters7, Gary Middleton8, 
Katherine Winfree9, Symantha Melemed10, 
Annamaria H. Zimmermann10, William John10, Julie 
Beyrer9, Nadia Chouaki11, Carla Visseren-Grul12, 
Luis Paz Ares13 
1Division Of Medical Oncology, S. Giuseppe Moscati 
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Italy, 3Hopital Arnaud De Villeneuve, Montpellier 
Academic Hospital/France, 4Krankenhaus 
Grosshansdorf/Germany, 5Oncology, Wielkopolskie 
Centrum Pulmonologii I Torakochirurgii, 
Poznan University Of Medical Sciences/Poland, 
6Pulmonology, Centro Hospitalar De Vila Nova De 
Gaia/espinho Epe/Portugal, 7Oncology, Cliniques 
Universitaires Saint-luc/Belgium, 8Royal Surrey 
County Hospital Nhs Trust, St. Luke’s Cancer 
Centre/United Kingdom, 9Oncology, Eli Lilly And 
Company/United States Of America, 10Eli Lilly 
And Company/United States Of America, 11Eli Lilly 
And Company, Suresnes/France, 12Eli Lilly And 
Company, The Netherlands/Netherlands, 13University 
Hospital - Virgen Del Rocio/Spain
Background: PARAMOUNT is the second phase 
III, randomized, double-blind, placebo-controlled 
study of single-agent maintenance pemetrexed 
in which maintenance pemetrexed signiÀcantly 
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Background: Afatinib is a novel, irreversible, 
ErbB-family blocker and has activity against the 
EGFR T790M mutation, the frequent mechanism of 
acquired resistance to erlotinib or geÀtinib in non-
small cell lung cancer (NSCLC). A randomized, 
placebo-controlled Phase III trial of afatinib was 
undertaken in NSCLC patients who had previously 
progressed on erlotinib or geÀtinib. Progression-free 
survival (PFS) and overall survival (OS) from this 
trial have been previously reported (Miller VA, et 
al., 2010). There was a three-fold increase in median 
PFS (1.1–3.3 months, P<0.0001). However, no effect 
on OS was noted (hazard ratio [HR]=1.001; through 
January, 2011). Reported here are the patient-
reported symptom and Health-related Quality of Life 
(HRQoL) results from this trial.
Methods: 585 patients with lung adenocarcinoma 
(stage IIIb/IV), who had progressed after 
chemotherapy (one to two lines) and 12 weeks of 
erlotinib or geÀtinib, were randomized (2:1) to receive 
either afatinib or placebo plus best supportive care 
(BSC). Symptom and HRQoL beneÀt were measured 
using the European Organisation for Research 
and Treatment of Cancer (EORTC) questionnaires 
(QLQ-C30/ LC13) at baseline, Weeks 2, 4, 6 and 
8, and then every 4 weeks, at treatment end, and 
Àrst follow up. NSCLC-related symptoms (cough, 
dyspnoea and pain) using the EORTC instrument were 
pre-speciÀed using three pre-planned analyses. First, 
the percentages of patients improved by 10 points 
(EORTC transformed score), at any time during the 
study, who had worsened (by 10 points at any time 
without any improvement), and who were stable (not 
improved or worsened), were determined. Second, 
the change in EORTC scores over time was estimated 
using a mixed-effects growth curve model with the 
average proÀle over time for each endpoint described 
by a piecewise linear model adjusted for baseline 
performance status and gender. Third, the time to 
deterioration (Àrst 10-point worsening in EORTC 
scores) was analyzed using a stratiÀed log-rank test.
Results: Compared to placebo, a signiÀcantly higher 
proportion of afatinib-treated patients showed a 
10-point improvement in the three pre-speciÀed 
symptoms of cough (46% vs. 25%; P<0.0001), 
dyspnoea (51% vs. 36%; P=0.0006) and pain (50% 
vs. 32%; P<0.0001). Compared to placebo, afatinib 
also signiÀcantly improved mean scores over time for 
cough (Mean difference –6.99; P<0.0001), dyspnoea 
(Mean difference –2.68; P=0.0161) and pain (Mean 
difference –4.02; P=0.0056), signiÀcantly delayed the 
time to deterioration for cough (HR=0.60; P<0.001); 
change from baseline were observed in index scores 
at Cycles 3 and 4 during induction. No signiÀcant 
VAS changes were observed. During maintenance, 
most EQ-5D assessments were completed: 
pemetrexed, 84.3%; placebo, 80.9%. At the 
postdiscontinuation visit, where the most worsening 
could be anticipated, 43.9% of pemetrexed-treated 
patients and 44.3% of placebo-treated patients 
completed the EQ-5D. The most common reason 
for missing assessments was failure to administer 
questionnaire. No clinically relevant within-group or 
treatment differences in index or VAS scores were 
observed. 
Conclusion: Long-term use of pemetrexed 
continuation maintenance until disease progression 
was well-tolerated with a safety proÀle similar to 
that in previous single-agent pemetrexed studies. 
Resource use corresponded to toxicities typically 
observed with pemetrexed, and overall resource use 
was low. Increased anti-emetic use in induction was 
likely due to cisplatin. The EQ-5D results suggest 
that patients can tolerate long-term maintenance 
pemetrexed treatment without signiÀcant decreases 
in Qol. 
Keywords: Paramount, Pemetrexed, maintenance, 
Quality of Life
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O11.07 SYMPTOM AND HEALTH-
RELATED QUALITY OF LIFE BENEFIT 
OF AFATINIB (BIBW 2992) IN ADVANCED 
NSCLC PATIENTS PREVIOUSLY 
TREATED WITH ERLOTINIB 
OR GEFITINIB: RESULTS OF A 
RANDOMIZED PHASE III TRIAL (LUX-
LUNG 1)
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Background: Adenocarcinoma of the lung in 
never-smokers is a distinct clinical entity. However, 
whether any such difference exists between 
squamous cell carcinoma (SqCC) patients by 
smoking status is unknown. 
Methods: Retrospective analysis of SqCC patients 
according to smoking status from three cancer 
registries (US, Japan, Korea). Kaplan-Meier survival 
analysis was used to compare survival differences. 
Cox proportional hazards regression was used to 
identify independent prognostic factors. 
Results: 10,196 SqCC patients including 818 (8.0%) 
who were never-smokers were analyzed. 10.1% of 
Asian SqCC patients compared to 4.5% of US SqCC 
patients were never-smokers. Never-smokers with 
SqCC were signiÀcant older than ever-smokers with 
SqCC (71 years vs. 69 years; p < 0.0001) and is 
independent of region: Asia (p < 0.0001) and US (p 
= 0.0383). Overall survival (OS) of never-smokers 
with SqCC was signiÀcant worse than ever-smokers 
with SqCC (11 months vs. 13 months; p = 0.0059). 
Asian SqCC never-smokers had signiÀcant worse 
OS than Asian SqCC ever-smokers (10 months vs. 
14 months; HR = 1.172; p = 0.0008). Furthermore, 
male SqCC never-smokers had signiÀcant worse OS 
than male SqCC ever-smokers (10 months vs. 13 
months; HR = 1.165; p = 0.0040) and is independent 
of country of origin. Cox proportional hazards 
analysis among Asian male SqCC patients revealed 
never-smoking status was found to be a signiÀcant 
unfavorable prognostic factor versus ever-smoker 
(HR = 1.126; p = 0.0498). 
Conclusion: Epidemiologic study revealed 
differences in the age of diagnosis of survival 
outcome between Asian male SqCC lung patients 
according to smoking status indicating potential 
difference in etiologies of SqCC among Asian male 
patients by smoking status.
Keywords: squamous cell carcinoma in never-
smokers, ethnicity
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O12.02 GENOTYPING NON-SMALL CELL 
LUNG CANCER (NSCLC) IN LATIN 
AMERICAN (LATAM) PATIENTS
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Silvia J. Serrano5, Marcelo Castro6, Elena Aréchaga1, 
Edgar Amorin7, Ricardo Kirchuk8, Mauricio Cuello9, 
José R. Borbolla10, Rafael Rosell11 
and showed trends in delaying dyspnoea (HR=0.84; 
P=0.170) and pain (HR=0.88; P=0.287). Afatinib’s 
beneÀt on dyspnoea and pain symptoms appeared 
greater in patients with worse baseline performance 
status (1–2 compared to 0). Consistent with afatinib’s 
tolerability proÀle, a higher proportion of afatinib-
treated patients compared to placebo-treated patients 
showed a signiÀcant (P<0.05) worsening of EORTC 
scores for diarrhoea, sore mouth, dysphagia and 
appetite. However, compared to placebo, afatinib 
signiÀcantly (P<0.05) improved global HRQoL, 
physical functioning and fatigue.
Conclusion: In the LUX-Lung 1 trial, the addition of 
afatinib to BSC signiÀcantly improved not only PFS, 
but also NSCLC-related symptoms, global HRQoL 
and physical functioning.
Keywords: Afatinib, QOL, Non-small cell lung 
cancer, Phase IIb/III
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O12.01 NEVER-SMOKERS WITH 
SQUAMOUS CELL CARCINOMA OF THE 
LUNG: A DISTINCT CLINICAL ENTITY 
AMONG MALE ASIAN PATIENTS? A 
COMBINATION ANALYSIS OF THREE 
CANCER REGISTRIES FROM ASIA AND 
THE UNITED STATES OF AMERICA
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Conclusion: Our Àndings add to a growing body of 
evidence which points to the genetic heterogeneity of 
the EGFR pathway in NSCLC among different ethnic 
groups; LATAM NSCLC patients were signiÀcantly 
more likely to harbor activating EGFR mutations as 
compared with Caucasian population. K-Ras mutations 
appears be less frequent. This data highlights the need 
for these differences to be taken into account in the 
design of future trials. This work was partially funded 
by Astrazeneca and Boehringer Ingelheim Oncology 
Investigator Initiated Study 1200.142. 
Keyword: Epidermal Growth Factor Receptor 
(EGFR), Non Small Cell Lung Cancer (NSCLC), 
K-Ras, Latin American
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O12.03 IMPACT OF HIV INFECTION ON 
SURVIVAL IN LUNG CANCER
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Background: It has been previously reported 
that lung cancer patients with HIV have a poorer 
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Background: Epidermal Growth Factor Receptor 
(EGFR) and K-Ras are key pathways in NSCLC; 
mutations in these genes determine a subgroup of 
patients with different prognosis and therapeutic 
approach. It has been shown that the frequency of 
mutations varies between different ethnic groups. 
Our group previously reported a high response rate 
in non-selected Mexican patients with refractory 
advanced NSCLC treated with erlotinib. Up to now 
EGFR and K-Ras mutation frequencies have not 
been described in the LATAM population. 
Methods: EGFR and K-Ras mutation analyses 
were performed in archived tissues from 933 
LATAM patients from 4 different countries, using 
DNA sequencing or Therascreen (Qiagen, United 
Kingdom) Real Time-PCR-kit. 
Results: EGFR mutations were evaluable in 933 
patients (México 295; Colombia 254; Argentina 
183 and Perú 201), including 530 women (56.8%) 
with a mean age of 60.6 years (SD ± 12.1); 42.7% 
were current smokers, and 50.2% were former or 
non-smokers; smoking history was not available in 
6.9%. 35.2% patients had activating mutations in the 
EGFR, 49.5% with Ex19 deletion; 47.4% with the 
in-frame L858R mutation, 0.009% with Ex18, and 
2.1% had complex mutations; 20.7% patients had 
K-Ras mutation of 318 tissues evaluated (Table 1). 
The sensitivity mutations showed association with: 
female gender (p =0.024), non-smoker status (p 
=0.01), adenocarcinoma histology (p <0.001), and 
lack of K-Ras mutation (p =0.006). Among these 
patients, 55 received treatment with either erlotinib 
or geÀtinib; response rates were as follows: 3/55 
(5.5%) complete response, 25/55 (45.5%) partial 
response, 25/55 (45.5) stable disease, 2/55 (3.6) 
progression. 
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study is limited by small patient numbers, potential 
imbalance between groups in unmeasured covariates 
and that the SEER-Medicare database only captures 
patients who are over 65. Although these results 
are hypothesis generating, these data represent the 
largest comparative analysis of survival with lung 
cancer in HIV infected individuals that the authors 
are aware of and would suggest that HIV status 
should not impact treatment decisions in lung cancer 
patients. 
Keywords: Lung cancer, HIV, AIDS
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O12.05 NEIGHBORHOOD–
LEVEL SOCIOECONOMIC (SES) 
DETERMINANTS NEGATIVELY IMPACT 
TREATMENT DECISIONS AMONG NON-
SMALL CELL LUNG CANCER PATIENTS 
IN THE SOUTHEASTERN UNITED 
STATES
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Background: Lung cancer is increasing throughout 
the world. The Southeastern United States is a 
fair representation of the developing world with 
signiÀcant health and SES disparities and 42% of 
the nation’s extreme poor. While there has been a 
reduction in lung cancer through tobacco control 
measures in most of North America, the Southeastern 
United States is burdened by an increasing incidence 
in smoking, lung cancer and disease mortality rates. 
Technological advances in the treatment of lung 
cancer have been made, but these advances are often 
cost prohibitive and may in fact exacerbate existing 
disparities. 
Methods: A consecutive, prospective cohort of 
NSCLC patients treated within a single health 
system from 1995-2007 had SES determinants 
(median household income; poverty; high school; 
college education) abstracted from corresponding 
2000 census tract (neighborhood) data. Variables 
were divided into quintiles and statistical 
comparisons were performed using the highest 
and lowest 20th percentiles. Categorical data are 
presented as percentages and compared by Pearson’s 
X2. Continuous data are presented as medians and 
prognosis than those that are non-HIV infected. The 
purpose of this project was to examine the SEER-
Medicare registry to determine the impact of HIV 
infection on overall survival in lung cancer.
Methods: Patients with a diagnosis of lung cancer 
with or without HIV infection were analyzed for 
overall survival by querying the SEER-Medicare 
lung database from 2000-2005. HIV infected 
individuals were identiÀed by having either of the 
two ICD 9 codes V08 or 042 (HIV group). The 
control group was identiÀed as any individual in the 
database without either of the HIV codes. A stage by 
stage and overall Kaplan-Meier survival analysis was 
performed comparing the HIV infected group with 
the control group. Cox models with propensity score 
adjustment were used to account for any imbalances 
betweent groups in measured covariates such as 
stage, race, median income, sex, and comorbidities. 
Results: A total of 372 patients were identiÀed in 
the HIV group and 85259 patients were identiÀed 
for the control group; stage I/II: 110 patients in the 
HIV group and 20862 patients in the control group; 
stage IIIA/IIIB: 118 patients in the HIV group and 
26960 patients in the control group; stage IV 144 
patients in the HIV group and 37437 in the control 
group. The median survival of the overall population 
was 6 months for the control group and 7 months 
for HIV group (p=0.17). For stage I/II patients, the 
median survival for the control group was 36 months 
for the control group and 42 months for the HIV 
group (p=0.37). For stage IIIA/IIIB, the median 
survival was 7 months for the control group and 
4.5 months for the HIV group (p=0.03). For stage 
IV patients, the median survival was 3 months for 
both the control group and the HIV group (p=0.98). 
After using propensity scores to adjust for potential 
confounders, there was no difference in survival 
between the two groups (hazard ratio 1.035, 95% CI 
0.92-1.16). 
Conclusion: In contrast to previous reports, we 
found no signiÀcant survival difference between 
HIV infected individuals and controls with lung 
cancer. On a stage for stage basis, only HIV infected 
individuals with stage IIIA/IIIB disease had a poorer 
survival. Although this may be a reÁection of greater 
tumor virulence in HIV patients, this is unlikely 
as there was no signiÀcant difference identiÀed in 
any other stage grouping. Stage III disease requires 
an aggressive regimen of combination therapy 
with chemotherapy, radiation, and surgery, and the 
poorer outcome may be a reÁection of HIV patients 
being treated with a less aggressive approach. This 
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A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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O12.06 COMMON VARIATION IN NF-
ɤB PATHWAY GENES AND RISK OF 
SMOKING-ASSOCIATED LUNG CANCER
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Background: Cigarette smoking elicits airway 
inÁammation in all of those who smoke and is the 
major cause of lung cancer. However, 4 out of 5 
smokers never develop lung cancer and lung cancer 
occurs in never smokers as well. The reasons for 
this are currently unclear but genetic factors likely 
play an important role. Nuclear factor-kappa B 
(NF-kB) signaling plays a key role in inÁammation 
and has been shown to underlie smoking-associated 
pulmonary inÁammation and lung carcinogenesis. 
Functionally relevant polymorphisms in genes 
that encode key components of the NF-kB 
signaling pathway may well inÁuence risk of 
smoking-associated lung cancer by modifying the 
inÁammatory response. 
Methods: We examined associations between 
24 single nucleotide polymorphisms (SNPs) in 
NFKB1, NFKB2, RELA, RELB and REL (all these 
genes encode NF-kB transcription factor subunits) 
and risk of lung cancer in a large case-control 
study. The study population consisted of 639 lung 
cancer cases and 936 controls; all participants were 
Caucasian and current or former cigarette smokers 
who had smoked at least 10 pack-years. Genotyping 
was conducted using Sequenom iPLEX Gold assay. 
Deviation from Hardy-Weinberg equilibrium was 
evaluated with the exact method. Associations 
between alleles and genotypes and lung cancer 
risk were examined using Pearson Chi-square test 
and Cochran-Armitage trend test, respectively. Per 
(minor) allele odds ratios (OR) and corresponding 
95% conÀdence intervals (95% CI) were also 
calculated for each SNP.
Results: Four SNPs in NFKB1 were statistically 
compared by the Wilcoxon test. Survival was deÀned 
as time between initial diagnosis and date of cancer-
speciÀc death or last follow-up and was determined 
utilizing the Kaplan-Meier method. Any difference 
in survival between groups was assessed using 
the log-rank test; signiÀcant univariate associates 
were assessed for independence using Cox logistic 
regression modeling. 
Results: There were 4712 NSCLC patients (median 
follow-up of 32.1 mos.; Clinical Stage 1-2, n=1723; 
Stage 3-4, n=2989). Early stage patients realized 
similar resection and survival rates irrespective of 
median household income, poverty or education. In 
contrast, living in areas of lower education, income 
and higher poverty negatively impacts survival 
and chemotherapy delivery in those with advanced 
disease (Table 1). Moreover, this difference persisted 
even when corrected for Medicare eligibility 
(p<0.0001). Table 1. SES Variables in Advanced-
stage Subjects 
Variable Survival Chemotherapy Delivery 
High School 
Education 
p<0.0001 Median Survival 
Low (68.1%) 7.97 mo. 
High (89.7%) 11.17 mo. 
p<0.0001 
College 
Education 
p=0.046 Median Survival 
Low (10.2%) 8.2 mo. 
High (39.5%) 10.43 mo. 
p=0.0075 
Median 
Household 
Income 
p<0.0001 Median Survival 
Low ($30,757%) 8.07 
mo. High ($52,614%) 
11.23 mo. 
p<0.0001 
Poverty 
p=0.0002 Median Survival 
Low (5.3%) 11.07 mo. 
High (17.5%) 7.67 mo. 
p<0.0001 
Conclusion: Although these patients received initial 
care within a comprehensive cancer center with 
a multi-disciplinary thoracic oncology program, 
data indicate that neighborhood SES signiÀcantly 
impacts treatment decisions among patients with 
advanced lung cancer. This appears independent of 
insurance accessibility and a result of access to care 
due to travel, treatment time, and cost restrictions. 
In contrast, resection requires a limited and Ànite 
treatment course and we observed no difference 
in resection rates or survival among early stage 
subjects residing in high poverty or less educated 
neighborhoods. Currently, we are investigating the 
role of comorbid status and access to care within this 
dataset to further understand disparities in treatment 
decisions. 
Keywords: Non-small cell lung cancer, 
socioeconomic factors, health care disparities
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Background: The presence of certain mutations 
in the Epidermal Growth Factor Receptor (EGFR) 
predicts that a patient with advanced non-small 
cell lung cancer (NSCLC) will respond better 
to Tyrosine Kinase Inhibitors (TKIs) than to 
platinum-based chemotherapy. Previous studies 
with Caucasian patients have shown the prevalence 
of EGFR mutation to be around 10-15%. The 
aim of the REASON study is to determine the 
epidemiology of EGFR mutation in advanced 
NSCLC patients (p) in Spain (all histologies), 
and to better understand the clinical factors 
(gender, smoking habits, tumour histology) that 
may be associated with EGFR mutations, in a 
representative sample of advanced NSCLC p. 
Methods: All newly diagnosed advanced NSCLC 
p in 39 Spanish centers nationwide were included 
prospectively for a 6-month period. Patient’s 
characteristics were recorded from clinical records 
(gender, smoking status, tumour histology, sample 
type –tumour biopsy, cytology, etc-). Mutation 
testing was performed on available tumour samples, 
mainly through two central laboratories (using RT-
PCR-based methodologies), or on-site where EGFR 
mutation testing was customary. 
Results: 1050 p have been included by February 
2011. As of data cutoff in December 2010, data 
from 714 p have been analyzed. 711 were of 
Caucasian ethnicity. 76.2% p were men, 39.2% 
were smokers, 45.9% ex-smokers, and 14.9% 
never-smokers. Median age was 66 years (range 
25-90). 22.7% p had squamous-cell carcinoma, 
69.2% had non-squamous histology (57.6% 
adenocarcinoma, 2.2% bronchoalveolar, 9.4% 
large-cell carcinoma, 1.7% adenosquamous 
carcinoma, and 4.4% non-speciÀed). Mutation 
analysis was not feasible in 61 p (8.5%) due either 
to sample unavailability (6.0%) or inadequacy 
(2.5%) for mutation testing.
Exon 19 deletion and exon 21 L858R point 
mutation were analyzed in 653 samples. Mutation 
rate was 10.7% (82.7% exon 19 del and 17.1% 
exon 21 L858R).
Mutation rates according to clinical features are 
summarized in table 1. 
signiÀcantly associated with lung cancer risk in 
our study population. The minor alleles of these 
SNPs were associated with a decreased risk of lung 
cancer (rs3821958, OR: 0.82, 95%CI: 0.71-0.95, 
P
trend
= 0.01; rs1609798, OR: 0.84, 95%CI: 0.72-
0.99, P
trend
=0.04; rs3755867, OR: 0.83, 95%CI: 
0.71-0.97, P
trend
= 0.02; and rs1801, OR: 0.82, 
95%CI: 0.70-0.96, P
trend
=0.01). No statistically 
signiÀcant associations were observed for the other 
examined SNPs.
Conclusion: NFKB1 encodes the precursor protein 
p105, which contains an inhibitor of NF-kB (IkB)-
like C-terminal portion and functions as NF-kB 
inhibitor. Proteasome-mediated processing of p105 
produces the NF-kB transcription factor subunit 
p50. This is the Àrst study to report associations 
between polymorphisms in NF-kB pathway genes 
and lung cancer risk. Our results suggest that 
common variation in NFKB1 may modify smoking-
associated risk of lung cancer. (Funded by the 
University of Pittsburgh Cancer Institute SPORE in 
Lung Cancer, NCI P50 CA90440) 
Keywords: nuclear factor-kappa B signaling, 
Polymorphisms, lung cancer risk
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O13.01 LUNG CANCER COMPLICATING 
LUNG TRANSPLANTATION: INCIDENCE 
AND OUTCOME – A SINGLE CENTER 
EXPERIENCE
Mir Alireza Hoda, Victoria Augustin, Bahil Ghanim, 
Peter Jaksch, Mai-Britt Ernst, Clemens Aigner, 
Gyoergi Lang, Shahrokh Taghavi, Walter Klepetko 
Division Of Thoracic Surgery, Medical University 
Vienna/Austria
Background: Long-term immunosuppression, 
longer survival times and underlying end-stage 
pulmonary disease might be important contributing 
factors for the development of lung cancer in 
lung transplant patients. Aim of the study was to 
determine the incidence and outcome of lung cancer 
in a single center cohort of lung transplant recipients.
Methods: We retrospectively reviewed the records 
of 962 consecutive patients who underwent lung 
transplantation between 1989 and 2009 at our 
institution to identify patients diagnosed with 
bronchogenic carcinoma. Records were reviewed for 
demographics, lung transplant characteristics and 
outcome.
Results: 10 patients were identiÀed with an 
unexpected lung cancer in the explanted lungs and 
10 patients with lung cancer developing after lung 
transplantation. 6 women and 14 men with mean 
age 55 ± 14 years (range 19-69 years) received 8 
single lung transplants (70 %) and 12 bilateral lung 
transplant (30%). Mean follow up was 2405 ± 1052 
(range 672-4346) days. The underlying diagnoses 
for transplantation were pulmonary Àbrosis (4 
cases), COPD (11 cases), cystic Àbrosis (2 cases), 
alpha1-antitrypsin-deÀciency, Histiocytosis X 
and hypersensitivity pneumonitis. 18 cases were 
identiÀed as non-small cell lung cancer of which 
12 had been adenocarcinoma, 6 squamous cell 
carcinoma while 1 patient was diagnosed with a 
low differentiated neuroendocrine carcinoma and 
another patient with a carcinoid of the lung. In 
patients developing lung cancer after transplantation 
6 cancers occurred in the native lung and 4 in the 
Patients 
with 
available 
tumor 
sample 
(N=653) 
Patients 
with EGFR 
Mut (Exon 
19 del, 
L858R) 
(N=70) 
% of 
mutations 
and 95% 
CI 
% of clinical 
factor within 
mutated 
patients and 
95% CI 
Gender Men 503 29 
5.8  
(3.9-8.2) 
41.4 (29.8-
53.9) 
Women 150 41 
27.3  
(20.4-35.2) 
58.6 (46.2-
70.2) 
Smoking 
Status 
Current Smoker 242 10 
4.1 (2.0-
7.5) 
15.1 (7.5-26.1) 
Ex-smoker 301 21 
7.0  
(4.4-10.5) 
31.9 (20.9-
44.4) 
Never-smoker 93 35 
37.6  
(27.8-48.3)
53.0 (40.3-
65.4) 
Missing 17 4 
Tumor 
Type 
Adenocarcinoma 383 57 
14.9  
(11.5-18.8) 
81.4 (70.3-
89.7) 
Bronchioloalveolar 
adenocarcinoma 
16 3 
18.7  
(4.1-45.6) 
4.3 (0.9-12.0) 
Large-Cell 
carcinoma 
59 3 
5.1  
(1.1-14.1) 
4.3 (0.9-12.0) 
Adenosquamous 
carcinoma 
11 0 
Squamous-Cell 
carcinoma 
145 4 
2.8  
(0.8-6.9) 
5.7 (1.6-14.0) 
NOS 25 3 
12.0  
(2.5-31.2) 
4.3 (0.9-12.0) 
Missing 14 0 
Exons 18 through 21 were analyzed in 401 samples. 
Mutation rate was 16.5% (62.1% exon 19 del, 18.2% 
exon 21, 10.6% exon 18, and 9.1% exon 20).
Updated full results will be provided at the 
Conference.
Conclusion: The estimated prevalence of sensitizing 
EGFR mutations (Exon 19 del, exon 21 L858R) in a 
representative sample of newly diagnosed advanced 
NSCLC patients in Spain (all histologies) agrees 
with previous data obtained in caucasian patients. 
Whenever a sample is available, EGFR mutation 
testing is feasible in over 95% of cases, and may 
therefore become routine clinical practice. Around 
3% of squamous-cell carcinomas show EGFR 
mutations, which is about the same rate as other 
clinically relevant mutations. 
Keywords: Spain, Epidemiology, EGFR mutations, 
NSCLC
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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and deemed necessary to receive immediate cancer 
chemotherapy were included. As advanced lung 
adenocarcinoma was diagnosed, pemetrexed 
(500 mg/m2) combined carboplatin (AUC 5) was 
administered after one week folic acid supplement. 
Patients’ characteristics, ECOG performance 
status (PS) prior to hospitalization, reasons of ICU 
admission, APACHE II score on ICU admission, 
length of ICU and hospital stay, chemotherapy 
response, drug adverse effects, and ICU mortality 
were examined. 
Results: Nine patients were admitted to the ICU with 
newly diagnosed advanced lung adenocarcinoma . 
Two of them did not receive any chemotherapy and 
7 patients received chemotherapy with pemetrexed 
combined carboplatin. One with septic shock, 1 with 
pulmonary tumor embolism, 2 with brain metastasis, 
and 3 with respiratory failure admitted for ICU 
care. These patients did not receive intubation with 
mechanical ventilator support but Àve of them 
needed non-invasive positive pressure ventilator to 
treat. The PS statuses prior to hospitalization were 
0 to 1. The mean of APACHE II scores at the time 
of chemotherapy were 22. The average of ICU stay 
was 12.4 days and hospital stay was 24.2 days. Five 
of them (71.4%) had partial response after Àrst dose 
of chemotherapy. One patient (14.3%) developed 
fatigue, one patient (14.3%) has grade 2 mucositis 
and one (14.3%) has grade 4 neutropenia. Overall, 
one patients (14.3%) died in the ICU due to febrile 
neutropenia and pneumonia with septic shock. 
Conclusion: Chemotherapy in the ICU for lung 
cancer patients can be considered if the critical 
illness related to malignancy. Chemotherapy 
with pemetrexed combined carboplatin for lung 
adenocarcinoma may be a choice as higher response 
rate and less hematologic effect than other cytotoxic 
agents. 
Keywords: lung adenocarcinoma, Pemetrexed, 
Carboplatin, Critical care
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
transplanted lung. Mean time from transplantation to 
diagnosis of lung cancer was 1859 ± 809 (range 264-
2797) days. Late stage lung cancer (IIIB-IV) was 
diagnosed in 7 patients, 3 patients were diagnosed in 
early stage disease (Ia-IIb). Median overall survival 
after detection of lung cancer was 198 days (SE 
144, range 0-2800 days). One-year and three-years 
survival after lung cancer diagnosis were 34% and 
11%, respectively. In patients with unexpected 
lung cancer in the explanted lungs all neoplasms 
were detected in early stages (stage I, T1A and 
T1B). Recurrence of tumor was not found in any 
of these patients. One patient died 6 months after 
transplantation, all other 9 patients are still alive. 
Conclusion: Unexpected lung cancer in explanted 
lungs, with an incidence of 1,03 % in all our patients 
, is found in an early stage and does not affect 
survival. In the case of diagnosis of lung cancer after 
lung transplantation, rapid progression to locally 
advanced disease or metastatic disease is common, 
limiting therapeutic options.
Keywords: Lung cancer, lung transplantation, 
immunosuppression
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O13.02 OUTCOME IN CRITICALLY ILL 
LUNG ADENOCARCINOMA PATIENTS 
RECEIVING CHEMOTHERAPY 
WITH PEMETREXED COMBINED 
CARBOPLATIN IN THE INTENSIVE 
CARE UNIT
Chung-Yu Chen1, Kuan-Yu Chen2, Chong-Jen Yu2, 
Pan Chyr Yang3 
1Internal Medicine, National Taiwan University 
Hospital Yun-lin Branch/Taiwan, 2Pulmonary And 
Critical Care Medicine, National Taiwan University 
Hospital/Taiwan, 3National Taiwan University 
College Of Medicine/Taiwan
Background: The decision to start chemotherapy 
in critically ill cancer patients is extremely complex 
in the intensive care unit (ICU). Therefore, 
this study evaluated the outcomes and the 
complications in critically ill cancer patients with 
lung adenocarcinoma receiving chemotherapy with 
pemetrexed combined carboplatin in the ICU. 
Methods: From January 2010 to February 2011, all 
patients admitted to the ICU for organ failures due 
to newly diagnosed, untreated lung adenocarcinoma 
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15% of febrile neutropenia, 15% esophagitis and 
9% pneumonitis). There were no treatment related 
deaths. Median weight loss during treatment was 
5% (0-17%). At a median follow up of 24 months 
(1.5-82), median progression free survival was 25 
months, median survival was not reached. Time 
to subsequent progression was not associated with 
patient baseline or treatment characteristics. 
Conclusion: The standard treatment for regional 
recurrence of NSCLC is palliative chemotherapy. 
However, selected patients with locally advanced 
recurrent NSCLC might beneÀt from concomitant 
chemoradiotherapy, with a long-term survival 
comparable to patients who present initially with 
Stage III disease. 
Keywords: NSCLC, recurrence, chemo-radiotherapy
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O13.05 VERTEBRAL COLLAPSE 
AFTER COMBINED MODALITY FOR 
LOCALLY ADVANCED LUNG CANCER. 
METASTASES, OSTEOPOROSIS OR 
COMPLICATION OF THERAPY? A 
REPORT OF 4 CASES.
Laurence M.M. Crombag1, Ellen Van Reij2, Erik C. 
Phernambucq2, Suresh Senan2, Pieter E. Postmus1 
1Pulmonary Diseases, Vrije Universiteit Medical 
Centre/Netherlands, 2Radiation Oncology, Vrije 
Universiteit Medical Centre/Netherlands
Background: The standard treatment for patients 
presenting with unresectable lung cancer stage 
III and a good performance score is combined 
chemotherapy with thoracic radiation therapy. This 
approach results in 5-year survival rates for both 
small-cell (SCLC) and non-small-cell lung cancer 
(NSCLC) patients of 10-20%. One reason for the 
poor outcome is disseminated disease becoming 
symptomatic during follow-up. A common mode 
of disease relapse are skeletal metastases which 
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O13.03 CHEMORADIOTHERAPY FOR 
RECURRENT NSCLC; RETROSPECTIVE 
DATABASE ANALYSIS OF TWO LARGE 
CANCER CENTERS.
Dawn Ng1, Patricia Moretto2, Glenwood D. Goss2, 
Garth Nicholas2, Scott Laurie2, Alex Sun3, Natasha 
Leighl1, Robert Macrae4, Jair Bar2 
1Medical Oncology, University Health Network/
Princess Margaret Hospital/Canada, 2Medical 
Oncology, The Ottawa Hospital Cancer Center/
Canada, 3Radiation Oncology, University Health 
Network/Princess Margaret Hospital/Canada, 
4Radiation Oncology, The Ottawa Hospital Cancer 
Center/Canada
Background: Recurrence of NSCLC is commonly 
considered incurable, and is approached similarly 
to metastatic disease. However, local or regional 
recurrence can potentially be treated with curative 
intent. We set out to study the outcomes of 
recurrent NSCLC patients that were treated by 
chemoradiotherapy with a curative intent. 
Methods: Computerized databases of NSCLC 
patients of The Ottawa Hospital Cancer Center 
(TOHCC; 2000-2009) and Princess Margaret 
Hospital (PMH; 1999-2007) Cancer Center were 
systematically screened for patients with recurrent 
NSCLC that were treated with curative intent 
combined chemoradiotherapy. Patients were 
included if they underwent initial curative surgery 
and no more than three years later, had subsequent 
radiologic diagnosis of regional recurrence and were 
treated with chemoradiotherapy with curative intent 
(N=30 patients, 28 and 2, of 5791 and 2225 screened 
from TOHCC and PMH respectively).
Results: Median age was 65 (range 49-79), 38% 
were males. Median interval from primary surgery 
to recurrence was 16 months (range 6-34), and was 
conÀrmed by biopsy in 62%. Stage was IIIA in 23 
patients, IIIB in 6 and IIB (T3, N0) in one patient. 
Median number of involved sites (N stations and/
or lung lobes) was 3 (1-5). A median of 66 Gy 
was given (26-66 Gy) in 33 fractions (10-35). 
Most common chemotherapy regimens delivered 
were cisplatin-vinorelbine q3weekly (41%), 
weekly carboplatin-paclitaxel (21%) and cisplatin-
etoposide (SWOG regimen, 12%). A median of 6 
weeks of treatments were concurrent (0-10). 44% 
of patients suffered grade 3-4 toxicities (including 
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O13.06 PERIPHERAL SKIN EDEMA 
AS UNUSUAL TOXICITY IN THREE 
PATIENTS (PTS) TREATED WITH 
PEMETREXED ALONE OR IN 
COMBINATION WITH CISPLATIN 
(CDDP) IN ADVANCED NON SMALL 
CELL LUNG CARCINOMA (NSCLC).
Domenico Galetta, Nicola Silvestris, Annamaria 
Catino, Giuseppe Colucci 
Medical Oncology, Giovanni Paolo Ii Oncology 
Institute/Italy
Background: To date, pemetrexed is one of 
the most widely used drugs in the treatment of 
pts with NSCLC and non squamous histology. 
This administration is usually associated with a 
favourable toxicity proÀle. Recently, a series of 
14 pts with peripheral skin edema related to the 
administration of pemetrexed has been reported 
(D’Angelo S.P. et al J. Thor Oncol 2011,6:624-626). 
Main relevant aspects of this clinical picture were 
similar to Áuid retention, mainly localized to the end 
of the lower limbs ranging from ankle swelling to 
pitting edema with overlying skin erythema. 
Methods: In our Institution within the last Àve 
years, 3 of 120 consecutive NSCLC pts, observed 
and treated with pemetrexed, showed a peripheral 
skin edema. Two pts (A and B) received pemetrexed 
as Àrst-line treatment, at the dosage of 500 mg/m2 
in combination with cisplatin 75 mg/m2 , and in the 
third case (C) the drug was administered as single 
agent as second line treatment at the same dose. All 
subjects were Caucasian with an ECOG performance 
status of 0-1 in the absence of relevant comorbidities. 
Results: Pts A (59 years old) - He developed skin 
edema to bilateral lower extremities after the 4th 
cycle of therapy without hematological toxicity. 
Edema was initially treated with topical steroids 
with a signiÀcant worsening of the condition after 
the 5th cycle. Dermatological advice interpreted 
this picture as erysipelas and started antibiotic 
therapy with macrolides in combination with 
systemic steroids obtaining a slight improvement 
of clinical picture. Sixth cycle, administered on a 
reduced dose to 75%, was associated with a Áare 
of edema. Discontinuation of pemetrexed was 
decided. A clinical complete regression occurred 
within one month. Pts B (65 years old) - He showed 
dermatologic toxicity after 2nd cycle although with a 
result in pain and pathological fractures. However, 
treatment-induced bone toxicity can also manifest as 
bone fractures. 
Methods: Extensive analysis was performed in 4 
patients initially treated with combined radio- and 
chemotherapy for locally advanced lung cancer who 
developed back pain due to fracture(s) of vertebra(e) 
17 months after completing therapy (median, 
range 0,5-48 months). Plain X-ray, computed 
tomography, dual-energy X-ray absorptiometry, 
magnetic resonance imaging, FDG-positron emission 
tomography and/or radionuclide scintigraphy 
were performed to detect the underlying cause. In 
one patient histology of the vertebral column was 
obtained. Mean and maximal radiation dose to the 
affected vertebral bodies in the radiation Àeld were 
calculated. 
Results: We studied the features of 4 patients (4 
female, median age 64,5 y (59-68 y), 3 NSCLC, 
1 SCLC) who presented with back pain after 
completing chemo-radiotherapy for lung cancer 
(concurrent in 3, sequential in 1) to a total dose 
of 50, 60, 62 en 66 Gy, respectively. Radiologic 
imaging revealed vertebral collapse. None of the 
patients had signs of metastatic disease at FDG-PET 
scan or radionuclide scintigraphy. In 3 patients DXA 
scan revealed osteopenia. One patient underwent 
vertebroplasty and histology obtained revealed no 
malignancy. In all patients affected vertebrae were 
near the treated planning target volume (PTV) and in 
one patient, the PTV incorporated multiple vertebrae. 
One patient had besides one vertebrae near PTV 
also several fractured lumbar vertebrae outside the 
radiation Àelds. The median mean and maximal 
radiation dose to the affected vertebral bodies were 
48,1 Gy (29,7 - 53,3 Gy) and 59,3 Gy (47,3 – 68,3 
Gy) respectively. The median follow-up since the 
onset of the back pain complaints was 14 months 
(10.5-27 months). All patients are still without signs 
of disease progression
Conclusion: Although metastatic disease is an 
important cause for collapsed vertebral bodies in 
lung cancer patients, other benign or treatment-
related aetiologies must be considered as well. All 
our patients were postmenopausal females and it is 
unclear if these collapses could be prevented by the 
use of bisphosphonates. 
Keywords: vertebral collapse, Lung cancer, 
combined modality treatment
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therapy. Nine years earlier, at the age of 73, she had 
been treated with cyclophosphamide, doxorubicin, 
etoposide and PCI, for a SCLC in the left upper lobe, 
resulting in CR. Second primary lung tumor (SPLT) 
in long-term survivors of SCLC is a well-known 
entity and it has been stated that especially these 
patients are at very high risk of developing a SPLT. 
In SCLC patients the SPLT is most frequent NSCLC. 
SCLC after SCLC has been found but will often be 
considered as a late recurrence of the primary SCLC. 
In this patient the “recurrence” was very late and the 
radiological picture much more that of a primary lung 
cancer with spiculae and its pattern of nodal spread. 
Therefore it is unlikely on clinical grounds that this 
second primary is a late metastasis that remained 
dormant for almost nine years. For these reasons we 
decided to compare DNA of both tumors by CGH. 
Methods: Tissue from both episodes was analysed 
by array CGH. DNA was isolated from formalin 
Àxed parafÀn (FFPE) embedded samples. 
Results: The chromosomal alterations were 
essentially different between the two samples.
Conclusion: The results of array CGH make it very 
unlikely that the second tumour is a metastases of the 
Àrst. Sofar we know this is the Àrst reported patient 
with deÀnitive proof of being in long-term remission 
after chemotherapy and developing very late during 
follow-up a 2nd primary SCLC. 
Keyword: Small cell, array CGH, second primary
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O14.01 IS LARGE CELL CARCINOMA 
OF THE LUNG A REAL ENTITY? 
AN IMMUNOHISTOCHEMICAL 
PERSPECTIVE
Giulio Rossi1, Mattia Barbareschi2, Mauro Papotti3, 
Paolo Graziano4, Giuseppe Pelosi5, Maria Cecilia 
Mengoli1, Alberto Cavazza6 
1Azienda Policlinico, Section Of Pathologic 
Anatomy/Italy, 2Unit Of Surgical Pathology & 
Laboratory Of Molecular Pathology, S. Chiara 
Hospital/Italy, 3University Of Turin At San Luigi 
Hospital/Italy, 4Division Of Pathology Of The 
lower intensity. Systemic steroid therapy improved 
clinical picture even if the patient progressed after 
the 4th cycle and crossed to a second line therapy 
with complete resolution of clinical symptoms 
after twenty days. Pts C (66 years old) - In this pts, 
we observed the onset of edema to the limbs after 
the 3rd cycle with bilateral signs of erythema. The 
vascular echodoppler analysis did not show phlebitis 
episodes. Treatment with diuretics was ineffective 
and, after the 4th cycle, a 75% dose reduction of 
pemetrexed was decided without any improvement. 
Subsequently, steroid systemic therapy was started 
with a further dose reduction up to 50% with clinical 
improvement and disappearance of the skin picture. 
Conclusion: Our expertise and the literature data 
suggest that skin edema could be considered a new 
side effect of pemetrexed. The treatment of choice 
appears the reduction of dosage of pemetrexed 
combined with systemic steroids. Treatment 
discontinuation should be considered only in non 
responsive pts. 
Keywords: Advanced NSCLC, Peripheral skin 
edema, Pemetrexed
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O13.07 AN 82-YEAR OLD WOMAN 
WITH SMALL CELL LUNG CANCER: 
LATE RELAPSE AT 9 YEARS OR A NEW 
PRIMARY?
Martijn R. Groenendijk1, Erik Thunnissen2, Bauke 
Ylstra3, Mark A. Van De Wiel4, Paul P. Eijk1, M. A. 
Paul5, Egbert F. Smit6, Pieter E. Postmus7 
1Pulm Diseases, VUMC/Netherlands, 2Pathology, 
VUMC/Netherlands, 3Pathology, VU University 
Medical Center/Netherlands, 4VUMC/Netherlands, 
5Department Of Thoracic Surgery, VU University 
Medical Center/Netherlands, 6Pulmonary Diseases, 
Vrije Universiteit Medical Centre/Netherlands, 
7Department Of Pulmonary Diseases, VU University 
Medical Center/Netherlands
Background: A 82 years old lady was diagnosed 
with a mass in the right upper lobe with lymph nodes 
in mediastinum and supraclavicular. FDG-PET 
was positive with a small mass adjacent to the R 
adrenal. Biopsy revealed SCLC. She was treated with 
carboplatin-etoposide resulting in PR. Shortly after 
chemotherapy was stopped, multiple brain metastases 
became symptomatic for which she refused further 
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Results: Overall, there were 104 males and 17 
females, with a mean age of 66 years. Tumor size 
ranged from 1 to 13 cm (mean, 4 cm). Tumors 
were generally in stage I (55%) and II (36%), 
lymphnode involvement was noted in 29% and 67% 
were peripherally-located. Forty-seven cases were 
classiÀed as large cell neuroendocrine carcinoma 
(LCNEC) (39%), 24 as basaloid carcinoma (BC) 
(20%), 22 as clear cell carcinoma (CCC) (18%), 
6 as LCC with rhabdoid features (RC) (5%), 2 
as lymphoepithelioma-like carcinoma (LELC) 
(2%) and 22 were entirely undifferentiated (16%). 
ImmunoproÀle of the different types of LCC are 
summarized in Figure 1. 
Conclusion: When applying a selective panel 
of immunohistochemical stains, LCC appears as 
a waste-basket of tumors with different lineage. 
Undifferentiated type, CCC, RC are most commonly 
variants of poorly-differentiated adenocarcinomas. 
LELC and BC should be considered as poorly-
differentiated variants of squamous cell 
carcinomas. LCNEC is a true poorly-differentiated 
neuroendocrine carcinoma. Immunostains in 
LCC is a diagnostic tool highlighting tumor 
differentiation and is essential for proper patients 
management. In a future lung cancer classiÀcation, 
it should be considered the relevant diagnostic role 
of immunohistochemistry and the possibility to 
eliminate the LCC category.
Keywords: large cell carcinoma, 
immunohistochemistry, TTF-1
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O14.02 A TWO-HIT MINIMALIST 
DIAGNOSTIC ALGORITHM BASED 
ON P40 (DELTANP63) AND TTF-1 
IMMUNOSTAINING UPON SMALL 
BIOPSY/CELLBLOCK SAMPLES FOR 
DIFFERENTIATING MAIN SUBTYPES OF 
NON-SMALL CELL LUNG CANCER AND 
SPARING MATERIAL
Giuseppe Pelosi1, Alessandra Fabbri1, Giulio Rossi2, 
Patrick Maisonneuve3, Angelica Sonzogni4, Enrica 
Bresaola4, Ugo Pastorino5, Mauro Papotti6 
1Department Of Pathology And Laboratory 
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Of Milan School Of Medicine/Italy, 2Azienda 
Policlinico, Section Of Pathologic Anatomy/Italy, 
3Division Of Epidemiology And Biostatistics, 
Forlanini Hospital/Italy, 5National Cancer Institute 
And University Of Milan/Italy, 6Unit Of Pathologic 
Anatomy, Hospital St. Maria Nuova/Italy
Background: Large cell carcinoma (LCC) is an 
“undifferentiated non-small-cell carcinoma that 
lacks the cytologic and architectural features of 
small cell carcinoma and glandular or squamous 
differentiation”, then not signiÀcantly differing from 
the deÀnition of poorly-differentiated non-small-cell 
lung cancer (NSCLC). The advent of histology-based 
therapies have considerably changed the pathologists’ 
perspectives, requiring immunostains aimed at 
NSCLC subtyping in routine practice. The concept of 
LCC is thus challenged by immunomarkers, basically 
evidencing squamous cell, adenocarcinoma or 
neuroendocrine differentiation. 
Methods: One-hundred-twenty-one surgically-
resected LCC were collected. Cases were reviewed 
according to the 2004-WHO classiÀcation and tested 
for immunoexpression with markers of glandular 
(TTF-1 [clone, 8G7G3/1], cytokeratin 7 [CK7] 
[OV-TL12/30]), squamous (p63 [A4A], CK5/6 
[D5/16B4]) and neuroendocrine (chromogranin 
[DAK-A3], synaptophysin [polyclonal], CD56 
[123C3]) differentiation. When tumor cells presented 
an heterogeneous expression of markers of different 
lineages, TTF-1 and p63 were considered ab initio 
the master markers and some basic rules were 
established, as follows: 1- any TTF-1 positivity 
excluded squamous cell differentiation even in 
presence of staining for p63 and CK5/6; 2- strong 
and diffuse immunostaining for squamous markers 
excluded NE differentiation; 3- a minimal expression 
for NE markers in single tumor cells did not 
excluded squamous or glandular differentiation; 4- 
neuroendocrine LCC can be positive for TTF-1. 
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phenotype TTF1-/p40+ if the latter was 50% or less. 
SC with the proÀle TTF1-/p40- was consistent with 
the presence of glandular differentiation.
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O14.03 ACCURACY OF HISTOLOGICAL 
NON-SMALL CELL LUNG CARCINOMA 
SUBTYPING IN DIAGNOSTIC LUNG 
BIOPSIES: THERE IS NEED FOR 
UNIFORM GUIDELINES
Spasenija Savic1, Katharina Glatz2, Keith M. Kerr3, 
Andrew G. Nicholson4, Masayuki Noguchi5, Helmut 
H. Popper6, Yasushi Yatabe7, William D. Travis8, 
Lukas Bubendorf9 
1Pathology, University Hospital Basel/Switzerland, 
2Institute For Pathology, University Hospital Basel/
Switzerland, 3Pathology, Aberdeen University 
Medical School/United Kingdom, 4Department Of 
Histopathology, Royal Brompton Hospital, National 
Heart And Lung Institute Division Of Imperial 
College School Of Medicine/United Kingdom, 
5Pathology, Institute Of Basic Medical Sciences, 
University Of Tsukuba/Japan, 6Pathology, Medical 
University/Austria, 7Aichi Cancer Center Hospital/
Japan, 8Memorial Sloan-kettering Cancer Center/
United States Of America, 9Departement Of 
Pathology, University Hospital Basel/Switzerland
Background: The accurate stratiÀcation of non-
small cell lung carcinoma (NSCLC) in lung 
biopsies has become crucially important for therapy 
decisions. Treatment has signiÀcantly changed 
especially for squamous cell carcinoma (SCC) and 
adenocarcinoma (AC). The WHO classiÀcation of 
lung cancers and the data supporting the clinical 
importance of this distinction are based on light 
microscopy alone. However, immunohistochemistry 
(IHC) can further reÀne the diagnosis where 
morphological criteria for a deÀnitive diagnosis 
of SCC or AC are not met. The aim of this study 
was to test the level of agreement for histological 
subtyping of NSCLC in diagnostic lung biopsies 
among internationally known experts in pulmonary 
pathology (IEPP), pathologists with special interest 
in pulmonary pathology (SIPP) and all-round 
pathologists (AP).
Methods: We selected 15 diagnostic lung biopsies 
including four AC, one SCC, one combined small 
cell carcinoma (SCLC) with component of SCC, 
European Institute Of Oncology/Italy, 4European 
Institute Of Oncology/Italy, 5National Cancer 
Institute/Italy, 6Department Of Clinical And 
Biological Science, University Of Turin/Italy
Background: The diagnostic assessment of non-
small cell lung cancer (NSCLC) on biopsy or 
cellblock samples may be demanding by morphology 
alone. As precise typing and sparing material 
for further testing are compulsory, a minimalist 
algorithm approach by immunohistochemistry (IHC) 
is warranted as diagnostic adjunct to morphology.
Methods: Forty-six consecutive small biopsies 
and cellblocks and paired surgical specimens (as 
gold standard) from 30 adenocarcinomas (AD), 10 
squamous carcinomas (SQC), 5 adenosquamous 
carcinomas (ADSQ) and one sarcomatoid 
carcinoma (SC) were IHC-evaluated for TTF-
1 (clones 8G7G3/1 and SPT24) and p63 [clone 
4A4 recognizing all known isotypes of p63 and a 
rabbit anti-human polyclonal anti-p40 recognizing 
non-transactivating (non-TA), truncated or deltaN 
isoforms only]. Hierarchic clustering approach and 
the area under the curve (AUC)-receiver operating 
characteristic (ROC) analysis were used in the study.
Results: Unsupervised clustering of surgical 
specimens and biopsies showed a nonrandom and 
overlapping distribution of the relevant markers, 
which closely correlated with each other and the 
diverse tumor categories, as also conÀrmed by 
mosaic plot analysis. There were no differences in 
AUC-ROC curves for each marker between any two 
samples. Diagnostic combinations were TTF1+/
p40- or TTF1-/p40- for AD; TTF1-/p40+ (p40 more 
than 50%) for SQC; and TTF1+/p40+ or TTF1-/
p40+ (p40 less than 50%) for ADSQ. The only case 
of SC lacked TTF1 and p40, this indicating glandular 
cell lineage and absence of squamous differentiation. 
Forty-three out of 46 (93%) lesions were correctly 
classiÀed by IHC on biopsy/cellblock by using these 
two markers compared to 40/46 (87%) by revised 
morphology and to 36/46 (78%) by original site 
pathologists, with a diagnostic accuracy being 98% 
for SQC and sarcomatoid carcinoma, and 96% for 
AD and ADSQ.
Conclusion: This two-hit, IHC-based model of 
TTF1 and p40 on biopsy/cellblock was effective 
to correctly forecast most cases of lung cancer. 
Negativity for p40 excluded all SQC and paved 
the way to AD diagnosis also in event of TTF1 
negativity. Dual adenosquamous differentiation was 
highlighted by coexisting p40 and TTF-1 or the 
S336 Copyright © 2011 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
Molecular Pathology: NSCLC Subtyping Tuesday, 5 July 2011 10:30-
12:00
O14.05 OPTIMAL COMBINATION OF 
MARKERS FOR SUBCLASSIFICATION 
OF POORLY DIFFERENTIATED NON-
SMALL CELL LUNG CARCINOMA
Hyo Sup Shim 
Pathology, Ewha Womans University/Korea
Background: Recently, some studies have been 
reported on the optimal immunohistochemical 
markers for subclassiÀcation of non-small 
cell lung carcinoma (NSCLC). Main pitfall in 
subclassiÀcation of NSCLC is small specimen with 
poorly differentiated (PD) area. In this study, we 
added newly proposed markers (e.g. SOX2, napsin 
A) to conventional markers (p63, TTF-1, CK5/6, 
and CK7) and evaluated optimal combination for 
subtyping of NSCLC, primarily focusing on the PD 
area.
Methods: Two hundred eleven resected NSCLCs 
were classiÀed based on histologic Àndings. After 
histologic review, only PD areas were taken and 
tissue microarrays were constructed to simulate 
small biopsy conditions. The tissue microarrays 
included 36 adenocarcinomas, 38 squamous cell 
carcinomas, and 8 large cell carcinomas. All 
specimens were stained with TTF-1, napsin A, CK7, 
p63, CK5/6, and SOX-2.
Results: p63 was both sensitive and speciÀc for 
PD squamous cell carcinoma (sensitivity 92%, 
speciÀcity 93%, positive predictive value 92%, and 
negative predictive value 93%). A combination of 
p63 and CK5/6 slightly increased the sensitivity 
(95%), however decreased the speciÀcity (91%) 
for PD squamous cell carcinoma. TTF-1 was a 
speciÀc marker (100%) for PD adenocarcinoma as 
well known, but showed lower sensitivity (53%). 
TTF-1 combined with with napsin A increased the 
sensitivity (75%). CK7 was sensitive (92%) but 
not speciÀc marker (76%) for PD adenocarcinoma. 
SOX2 was speciÀc (100%) but not sensitive 
marker (53%) for PD squamous cell carcinoma. 
Combinations of theses markers did not greatly 
increase the diagnostic performance.
Conclusion: A simple combination of p63, TTF-1, 
and naspin A can be enough for the subclassiÀcation 
of poorly differentiaed NSCLC.
Keywords: Non-small Cell Lung Carcinoma, 
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four NSCLC, not otherwise speciÀed (NOS), three 
NSCLC, favor AC, one carcinoid and one NSCLC 
with neuroendocrine features. Histological subtyping 
was performed according to the WHO 2004 criteria. 
When the morphological criteria for a speciÀc 
subtype were not met, we considered IHC results and 
made a diagnosis according to the recently published 
recommendations of the international association for 
the study of lung cancer/American thoracic society/
European respiratory society (J. Thorac Oncol. 2011 
Feb;6(2):244-85). Study participants could view a 
virtual slide of the HE staining and representative 
images of alcian blue PAS and immunohistochemical 
stainings (TTF-1, CK 7, CK 5/6, p63 in all cases; 
neuroendocrine markers in selected cases) Five 
IEPP, 27 SIPP and 56 AP examined the cases and 
completed the online questionnaire ().
Results: IEPP reached full agreement in the 
diagnosis of SCC, combined SCLC with component 
of SCC and the carcinoid. SIPP and AP reached an 
agreement of 96% and 91%, 70% and 34% and 78% 
and 41%, respectively for these cancers. Agreement 
was lowest in the AC biopsies with no signiÀcant 
difference between the IEPP, SIPP and AP (60%, 
69% and 59%, respectively). In the remaining 
NSCLC (NSCLC, NOS; NSCLC, favor AC and 
NSCLC with neuroendocrine features) 33% of IEPP 
agreed with the diagnosis, which was signiÀcantly 
higher compared to 20% and 15% in SIPP and AP, 
respectively. None of the IEPP required IHC in the 
SCC biopsy compared to 56% and 77% of SIPP 
and AP, respectively. In AC most of the pathologist 
would have ordered IHC (IEPP: 75%; SIPP: 87%; 
AP: 96%). 
Conclusion: With the exception of AC expert 
pathologists are more accurate in histological 
subtyping of NSCLC. There is substantial 
disagreement on how to classify NSCLC depending 
on IHC results. Although according to the WHO AC 
and SCC are diagnosed by morphological criteria 
most pathologists rely their diagnosis on additional 
IHC stains. This study demonstrates the need for 
uniform guidelines and education in histological 
NSCLC subtyping in order to be able to make 
appropriate treatment decisions.
Keywords: Histological subtyping, 
immunohistochemistry, Non-small Cell Lung 
Carcinoma
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carcinoma, non-small-cell lung cancer (NSCLC), 
SmartAmp2
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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O14.07 DISTINCTION BETWEEN 
PULMONARY ADENOCARCINOMA 
AND SQUAMOUS CELL CARCINOMA 
ON BIOPSIES. A MOLECULAR 
PATHOLOGIC ANALYSIS
Erik Thunnissen1, Evan Boers2, Katrien Grunberg1, 
Danielle Heideman1, Dirk J. Kuik3, Arnold 
Noorduijn4, Matthijs Oosterhout Van5, Divera Pronk1, 
Cornelis A. Seldenrijk5, Hannie Sietsma6, Egbert F. 
Smit7, Robertjan Suylen Van8, Jan Thusen Von Der9, 
Anne Wiersma10, Bart Vrugt11 
1Pathology, VUMC/Netherlands, 2Zwolle/
Netherlands, 3Epidemiology And Biotatistics, VUMC/
Netherlands, 4Pathologie/Netherlands, 5Pathology, 
Antonius ZHS/Netherlands, 6Pathology, UMCG/
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Medical Centre/Netherlands, 8AZM/Netherlands, 
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Background: For treatment purposes distinction 
between squamous cell carcinomas (SqCC) and 
adenocarcinomas (AdC), is important. In the past 
EGFR and KRAS mutations are occasionally 
detected in squamous cell carcinomas. In these 
studies immunohistochemistry has not been used 
for diagnosis. The aim of this study is to examine 
the diagnostic accuracy on lung cancer biopsies for 
the distinction between AdC and SqCC and relate 
these to immunohistochemical and KRAS and EGFR 
mutation analysis. 
Methods: An interobserver study was performed 
on prospectively collected biopsies obtained by 
bronchoscopy or transthoracic needle biopsy. The 
diagnosis was correlated with immunohistochemical 
(IHC) analysis for markers of adeno (TTF1 and/or mucin 
positivity) and squamous cell differentiation (P63 , 
CK5/6) as well as KRAS and EGFR mutation analysis. 
Results: 11 observers independently read H&E 
stained slides of 110 prospectively collected cases, 
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O14.06 SIGNIFICANCE OF EPIDERMAL 
GROWTH FACTOR RECEPTOR GENE 
MUTATIONAL ANALYSIS IN SQUAMOUS 
CELL LUNG CARCINOMA
Kimihiro Shimizu1, Yohei Miyamae1, Junko Hirato2, 
Seiichi Kakegawa1, Tetsuhiro Nakano1, Masayuki 
Sugano1, Jun Atsumi1, Izumi Takeyoshi1 
1Department Of Thoracic And Visceral Organ 
Surgery, Gunma Univerity Graduate School Pf 
Medicine/Japan, 2Department Of Pathology, Gunma 
Univerity Graduate School PF Medicine/Japan
Background: Epidermal growth factor receptor 
(EGFR) gene mutations have been reported to 
be clinically signiÀcant in non small cell lung 
cancer (NSCLC). However, because most previous 
studies focused only on adenocarcinomas, EGFR 
mutations in other histotypes are poorly investigated. 
Here, we evaluated the frequency of EGFR gene 
mutations in squamous cell carcinoma (SCC) and its 
clinicopathological features.
Methods: In total, 89 frozen tumor specimens that 
had been Àrst diagnosed as SCC, were examined 
for EGFR mutations in exons 19 and 21 using 
direct sequencing, PNA-enriched sequencing, 
and SmartAmp2. Additionally, pathological 
investigation, including immunostaining for p63 and 
TTF-1, alcian blue staining and EGFR mutation-
speciÀc immunohistochemistry in mutation-positive 
samples was also performed.
Results: The frequency of EGFR mutations was 
5.6% (5/89); all mutations were deletions in EGFR 
exon 19. Immunohistological investigation of these 
samples revealed that two of Àve were positive for 
p63 and TTF-1 staining, and showed production 
of mucin, as evidenced by alcian blue staining. 
Consequently, three of the samples were considered 
to be true SCC at the Ànal pathological diagnosis, 
while the remaining two samples were revised to 
adenosquamous carcinoma and adenocarcinoma. The 
Ànal frequency of the EGFR mutations in true SCC 
was 3.4% (3/87).
Conclusion: In conclusion, EGFR mutations were 
found in a small, but signiÀcant, number of SCC 
tumor samples and thus EGFR mutational analysis 
was useful in the accurate diagnosis of SCC. Our data 
demonstrate that EGFR mutational analysis should 
be performed not only in adenocarcinoma, but also in 
SCC to allow an accurate diagnosis and treatment.
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that NSCLC cells expressing certain markers (CD44, 
CD 133 and ALDH 1) have stem cell properties. We 
aimed to investigate the expression of three cancer 
stem cell markers (CD44, CD133, ALDH 1) in 
NSCLC and evaluated their prognostic values for 
postoperative relapse and correlation with histological 
subtypes. 
Methods: Tumours were obtained from 102 patients 
with stage 1 NSCLC (both Adenocarcinoma and 
SCC) who underwent surgical resection (1999-2008). 
Sequentially sampled parafÀn sections were immuno-
probed with antibodies for CD44
standard
, CD133 and 
ALDH 1 followed by reaction with DAB-conjugated 
secondary antibodies. All slides were scored by 
an independent pathologist in a blinded manner. 
Statistical analysis was conducted where correlations 
between CSC biomarker expression, histological 
subtypes and cancer recurrence rates was performed. 
Cumulative risks for developing recurrence of lung 
cancer after curative treatment of primary tumours 
was calculated using the Kaplan-Meier method and 
was compared between the groups using the log-rank 
test. 
Results: 102 pts with age range of 42-84 (median 68) 
underwent radical surgery and were pathologically 
staged as WHO stage1A (64) or 1B (38). Median 
follow up was 60 months (10-108) where follow up 
data was unavailable for 2 patients. Within the patient 
population 39% had relapsed; 31% had distant and 8% 
locoregional relapses where within these relaspses, 
17/63 (23%) were Stage 1A and 22/37(59%) stage 
1B. Analysis demonstrated a higher expression of 
CD44 in Squamous Cell Carcinoma (SCC) than 
Adenocarcinoma (ACA). Within the 102 stained 
sections, 53% in SCC vs. 24% in ACA were positive 
for CD44 (p=0.005) with 61% of positive SCC 
demonstrating high expression (>20% positive cells/
section) versus 21% of ACA tumours. Slightly higher 
expression of ALDH 1 was noted in SCC compared 
to ACA, but the difference did not reach statistical 
signiÀcance. None of the markers individually 
predicted risk of relapse. A majority of relapsed 
cases (69%; 27/39) were associated with positive 
ALDH1 expression but this did not reach statistical 
signiÀcance. However, in stage 1B subpopulation, 
ALDH1 positivity was associated with signiÀcantly 
higher relapse rate (72% vs 40% p=0.02). Concurrent 
dual immuno-localisation of stem cell markers is 
currently on-going. 
Conclusion: The predictive role of stem cell markers 
in early NSCLC treated with potentially curative 
surgery was investigated. The difference in CD44 
resulting in a kappa score of 0.55 ± 0.10. H&E based 
consensus diagnosis ( 8/11 readings concordant), 
showed high concordancy between H&E and 
IHC markers. In All cases with EGFR and KRAS 
mutations immunohistochemical adenocarcinoma 
differentiation was shown. In 2 of 26 cases with a 
consensus diagnosis of SqCC a KRAS mutation was 
present. In poorly differentiated NSCLC a squamoid 
appearance is present in some biopsies leading to the 
erroneous impression of squamous differentiation 
on H&E and subsequent diagnosis of squamous cell 
carcinoma, while additional stains indicate adeno-
differentiation (TTF1+ and/or mucin+; p63-) . 
Conclusion: In the diagnostic workup of 
non-small cell lung carcinoma on biopsies 
immunohistochemical analysis is a useful adjunct 
for reliable molecular pathologic classiÀcation. With 
this diagnostic approach the search for EGFR and 
KRAS mutation analysis may be limited to the non-
squamous NSCLC group. 
Keywords: Adenocarcinoma, squamous cell 
carcinoma, mutation analysis, immunohistochemistry
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O15.01 EVALUATION OF RELATIONSHIP 
OF CANCER STEM CELL MARKERS 
AND RISK OF RECURRENCE IN EARLY 
STAGE NON SMALL CELL LUNG 
CANCER
Muhammad Alamgeer1, Tracy Brown2, Beena 
Kumar3, Gavin M. Wright4, Matthew Conron4, 
Prudence Russell4, Zoe Wainer4, Elizabeth Blake3, 
Vinod Ganju3 
1Medical Oncology, Monash Medical Centre/
Australia, 2Monash University/Australia, 3Monash 
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Background: Current cancer treatment failure is 
due to a small population of slow-growing and drug 
resistant cells known as cancer stem cells (CSCs). 
Unlimited self-renewal and exclusive tumerogenicity 
are hypothesized to be the properties of stem cells 
responsible for relapse. In Vitro studies have proved 
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and malignant adult stem cell populations. In this 
study we set out to determine if ALDH+ cells from 
different lung cancers all had properties of CSCs, 
whether the ALDH+ CSCs from different tumors 
exhibited molecular differences, and whether CSCs 
used different ALDH isozymes for the ALDH+ 
phenotype. 
Methods: We isolated ALDH+ cell populations 
from 12 non-small cell lung cancer (NSCLC) lines 
representing the spectrum of NSCLC oncogenotypes 
using the Áow cytometry based AldeÁuor kit and 
compared their mRNA transcript expression to bulk 
ALDH- cell populations by Illumina microarray 
analysis and their clonogenic phenotypes. Common 
gene differences across cell line ALDH+ and ALDH- 
cell fractions were conÀrmed by qPCR and Western 
blot analysis. Lentiviral shRNA gene knockdown 
and over expression constructs were employed 
to assay for gene function on cancer “stemness” 
including the measure of cell clonogenicity, 
proliferation, expression of stem cell markers, 
and tumorigenicity. Illumina genome wide mRNA 
expression data on 182 clinically annotated resected 
lung adenocarcinomas were analyzed for ALDH 
isozyme expression levels and survival. 
Results: ALDH+ compared to ALDH- tumor cells 
from the same NSCLC demonstrated signiÀcant 
differences in clonogenicity conÀrming the biologic 
importance of the ALDH+ subset within each tumor. 
Genome wide analysis of ALDH+ and ALDH- cells 
revealed that the ALDH+ subpopulations varied 
dramatically in mRNA expression patterns between 
different NSCLCs, however ALDH1A1, ALDH1A3 
or both were observed to be commonly upregulated 
in ALDH+ cells from different NSCLCs. qRT-PCR 
and immunoblotting studies conÀrmed ALDH1A3 
to be more commonly upregulated in ALDH+ 
cells. shRNA mediated knockdown of ALDH1A3 
or ALDH1A1 in NSCLCs was associated with a 
signiÀcant reduction in ALDH activity, proliferation, 
and clonogenicity indicating speciÀc ALDH 
isozymes are required for NSCLC cell survival 
and growth. Finally, elevated ALDH1A3 transcript 
expression in resected lung adenocarcinomas was 
associated with impaired cancer free patient survival. 
Conclusion: We have found that ALDH+ 
subpopulations isolated from NSCLCs exhibit 
dramatically different mRNA expression proÀles. 
We also found that ALDH1A3 and ALDH1A1 
are the predominant ALDH isozymes responsible 
for ALDH+ activity. shRNA knockdown studies 
showed that continued expression of ALDH1A3 
expression between ACA and SCC suggests that the 
positive cells identiÀed were not homogeneous stem 
cells but instead were differentiated. If a relationship 
between stem cell biomarker expression and patient 
prognosis can be derived it is necessary to identify 
additional epitopes other than CD44 and CD133, 
although ALDH1 appears to be a potential indicator 
of stem cell sub-populations. 
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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O15.02 ALDEHYDE DEHYDROGENASE 
1A3 IS A FUNCTIONAL BIOMARKER 
AND THERAPEUTIC TARGET FOR 
LUNG CANCER STEM CELLS.
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Wistuba3, John D. Minna4 
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Background: Many lung cancers are believed to 
be driven by a subpopulation of stem-like tumor 
cells (termed cancer stem cells or CSCs) that 
are deÀned by their capacity for self-renewal, 
high tumorigenicity and clonogenicity (Sullivan, 
Cancer Metastasis Rev. 2010;29:61-72). Because 
of these attributes, a cure will likely depend on 
the total eradication of lung CSCs, which are 
also hypothesized to be resistant to conventional 
chemotherapy. Our group has recently identiÀed 
and characterized a population of lung CSCs in both 
lung cancer cell lines and patient tumor samples 
by their elevated aldehyde dehydrogenase activity 
(Sullivan, Cancer Res. 2010;70:9937-48.). Aldehyde 
dehydrogenases (ALDH) are a family of intracellular 
enzymes that participate in the detoxiÀcation, 
differentiation and drug resistance of many normal 
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restricted Adeno-Cre viruses: Ad5-CC10-Cre, Ad5-
SPC-Cre and Ad5-CGRP-Cre. By restricting Trp53 
and Rb1 deletion to deÀned lung epithelial cells, 
we show that both cells expressing NE and AT2 
cell markers are capable of initiating SCLC in vivo, 
although NE cells do so at a much higher frequency. 
Conversely, loss of Trp53 and Rb1 in Clara cells did 
not cause efÀcient lung tumor formation.
Conclusion: These results highlight the effects of 
inactivation of Trp53 and Rb1 in distinct subsets of 
lung epithelium in the adult mouse and demonstrate 
for the Àrst time, that NE cells are by far the most 
efÀcient to serve as the cell of origin of SCLC. 
Moreover, the technology reported here, will prove 
useful in identifying the cell of origin of different 
lung cancer types.
Keywords: Cell of origin, Small cell lung cancer
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O15.05 AN ARF/EGFR CROSS-TALK 
CONTROLS THE GROWTH OF LUNG 
ADENOCARCINOMA CELLS
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Céline Barrial1, Elisabeth Brambilla1, Beatrice 
Eymin1, Sylvie Gazzeri2 
1Institut Albert Bonniot, Inserm U823/France, 
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Background: The Epidermal Growth Factor 
Receptor (EGFR) is a tyrosine kinase (TK) that 
mainly mediates proliferative and survival signals. 
Somatic mutations in the EGFR TK domain plays a 
critical role in the development and treatment of lung 
adenocarcinoma. These kinase domain mutations 
in EGFR are generally referred to as activating 
mutations as they seem to result in the increased 
activity of the receptor, leading to hyperactivation of 
downstream pro-survival pathways. The ARF tumor 
suppressor is at the crossroad of oncogenic and 
genotoxic pathways and plays a strong protective 
role against lung cancer development. Based on 
recent data showing that ARF expression is strongly 
reduced in almost all lung tumors with EGFR 
activating mutations, we postulated that ARF is part 
of a failsafe mechanism protecting cells against 
untimely or excessive mitotic signals induced by 
EGFR signaling.
Methods: Expression of human ARF was induced 
or ALDH1A1 is required for NSCLC ALDH+ 
activity and tumor cell growth. Finally, ALDH1A3 
NSCLC activity may be a prognostic biomarker. 
Thus, ALDH1A1 and ALDH1A3 are important new 
biomarkers and potential therapeutic targets for 
eliminating lung CSCs.
(Supported by IASLC Fellowship, NCI U24 
CA126608, and SPORE P50CA70907)
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O15.03 CELL OF ORIGIN OF SMALL 
CELL LUNG CANCER: INACTIVATION 
OF TRP53 AND RB1 IN DISTINCT CELL 
TYPES OF ADULT MOUSE LUNG
Kate Sutherland1, Natalie Proost1, Inge Brouns2, Dirk 
Adriaensen2, Ji-Ying Song3, Anton Berns1 
1Division Of Molecular Genetics, Netherlands 
Cancer Institute/Netherlands, 2Department Of 
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Netherlands Cancer Institute/Netherlands
Background: Lung cancer is the most common 
cause of cancer related mortality worldwide. 
Uncovering the identity of the cell type(s) that give 
rise to both lung cancer subtypes and elucidating 
the genetic and molecular changes associated with 
their transformation is of critical importance. This 
knowledge will help focus intervention strategies on 
eliminating the cancer propagating cells that most 
likely retain many of the characteristics of its cell of 
origin.
Methods: To determine whether a speciÀc cellular 
compartment in the lung exhibits cancer-initiating 
properties, we have established a new strategy of 
inducing mouse lung cancer by directly inactivating 
tumor suppressor genes in a small, well-deÀned 
population of cells. We have constructed a series of 
Adeno-Cre vectors that permit cell-type-restricted 
switching of oncogenes and tumor suppressor genes 
in Clara cells, Alveolar type 2 (AT2) cells and 
neuroendocrine (NE) cells, respectively.
Results: Using Rosa26R-LacZ and mT/mG reporter 
animals we show that the cell-type-restricted Adeno-
Cre viruses exhibit high speciÀcity to the distinct 
target cell populations. To gain insight into the target 
cell for transformation in SCLC, we infected Trp53F/
F;Rb1F/F conditional animals with our cell-type-
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Background: NF-ƩB signaling is essential for lung 
cancer development and is activated in over 60% 
of lung cancers. However, the genetic mechanisms 
responsible for its activation remain largely 
unknown. IKBKB (also known as IKK-ơ/IKK-2) 
activates NF-ƩB which enables the transcription of a 
myriad of genes involved in tumorigenesis, making 
IKBKB critical in NF-ƩB signaling. IKBKB is a 
substrate of the KEAP1-CUL3-RBX1 E3 ubiquitin 
ligase complex, thus implicating this complex in 
the regulation of NF-ƩB signaling. We investigated 
complex component gene disruption as a novel 
genetic mechanism of NF-ƩB activation in lung 
cancer. We hypothesize that genetic disruption of 
KEAP1, CUL3 and RBX1 occurs frequently in 
lung tumors and may be ultimately responsible for 
IKBKB accumulation and stimulation of NF-ƩB 
activity. Furthermore, disruption of any one E3 
ubiquitin ligase complex is likely to be sufÀcient to 
result in tumorigenic NF-ƩB activation through the 
loss of complex function. 
Methods: Genomes of 644 NSCLC tumors and 
90 NSCLC cell lines were analyzed for gene 
dosage status of the individual E3 ligase complex 
components and IKBKB. Gene expression levels 
of the complex components, IKBKB and NF-ƩB 
target genes were assessed in 35 adenocarcinomas 
(AC) and 13 squamous cell carcinomas (SCC), 
each with matched non-malignant tissues. Genes 
were classiÀed as over or under expressed if the 
fold change between tumor and matched non-
malignant tissues was greater or less than 2 fold. 
IKBKB protein expression levels were assessed 
in tumors and cell lines with and without complex 
or IKBKB genetic disruption. The importance of 
IKBKB expression to the lung cancer phenotype was 
measured by pharmacological inhibition in NSCLC 
cell lines. 
Results: We observed strikingly high frequencies of 
genetic disruption (42%) of the E3 ligase complex 
and IKBKB in non-small cell lung carcinomas 
(NSCLC) and aberrant expression in 63% of samples 
examined. While both ACs and SCCs showed 
complex disruption, the patterns of gene disruption 
(expression vectors) or abolished (siRNA) in 
H3255 and H1975 cell lines derived from lung 
adenocarcinoma and expressing the L858R missence 
activating mutation of EGFR. Cell growth and 
apoptosis were studied after methylen blue and 
active caspase 3 staining respectively. SpeciÀc 
siRNAs and pharmacological inhibitors were used 
to characterize the signaling pathway controlled 
by ARF. EGFR L858R encoding vector or siRNA 
against EGFR L858R were used to study the role of 
EGFR L858R on ARF expression.
Results: We demonstrate that ARF inhibits the 
growth of lung tumor cells expressing the EGFR 
L858R activating mutation by inducing apoptosis. 
In these cells, expression of ARF promotes the 
nuclear accumulation of phospho-Stat3Tyr705 as 
well as the downregulation of the anti-apoptotic 
bcl-2 protein. Pharmacological inhibition of Stat3 
prevents both bcl-2 repression and apoptosis induced 
by ARF, indicating that ARF triggers apoptosis of 
EGFR L858R mutant cells by a Stat3-dependent 
inhibition of bcl-2 expression. In turn we show 
that the EGFR-L858R mutant downregulates the 
expression of the ARF protein, thereby counteracting 
the antiproliferative effect of ARF.
Conclusion: These results identify for the Àrst time 
an original link between ARF and the EGFR L858R 
activating mutant and suggest that loss of ARF and 
activation of EGFR cooperate to induce lung tumor 
formation.
Keywords: EGFR, INK4/ARF, apoptosis, Lung 
cancer
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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O15.06 KEAP1/CULLIN-3/RING BOX 
PROTEIN-1 E3 UBIQUITIN LIGASE 
COMPLEX DISRUPTION IS A NOVEL 
GENETIC MECHANISM OF NF-țB 
ACTIVATION IN LUNG CANCER
Larissa A. Pikor1, Kelsie Thu1, Raj Chari2, Ian M. 
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188) have been linked to different subtypes of lung 
cancer (LC). In other cancers, such as glioblastoma, 
breast, and prostate was demonstrated that altered 
miRNA expression may be a key modiÀer of their 
sensitivity to chemo/radiotherapy (CT and RT). 
Recently, several miRNAs were linked to cisplatin 
responsiveness of Non-small cell lung carcinoma 
(NSCLC) but role of miRNAs in regulating RT 
sensitivity in NSCLC and small cell lung carcinoma 
(SCLC) is yet unclear. However such analyses 
are warranted as it may indicate miRNAs with RT 
response prediction capacity. Here we report that 
low miR-214 expression may act as such predictor in 
NSCLC but not in SCLC.
Methods: miRNAs expression level in 6NSCLC 
(H23, H1299, A549, H157, H661, U1810) and 
6SCSLC (H69, H82, U1285, U1690, U1906, 
U2020) cell lines was performed using miRNA 
Genechips Array (Affymetrix). The cell lines were 
divided into RT resistant and sensitive groups based 
on their SF2 values (Resistant 3 Sensitive) in 
clonogenic survival. Microarray data was validated 
by qPCR using TaqMan® MicroRNA Assays 
(Applied Biosystems).NSCLC radiosensitive 
(RS) H23 cell line was transfected with miR-214 
mimics (Dharmacon) to overexpress miR-214. To 
irradiate cells with 8 Gy a Co60 source was used. 
The apoptotic cells were measured by assessing 
the percentage of cells with fragmented, condensed 
nuclei after DAPI staining and active caspase3 
analyzed by FACS. The Akt-p and MAPKp38 
expression was analyzed by western blot. 
Results: miRNAs microarray analysis revealed 
certain candidate miRNAs with RT sensitivity 
predicting capacity in NSCLC and SCLC subtypes, 
respectively, namely, miR-214, miR-1827 in 
NSCLC and miR-324-5p in SCLC. Data suggested 
that low expression of miR-214 may confer RT 
sensitivity of NSCLC as miR-214 was signiÀcantly 
less expressed in RT sensitive cell lines, H23 and 
H1299, compared to RT-resistant NSCLCs, U1810, 
H661, H157 and A549. MiR-214 expression was 
conÀrmed by qPCR. Subsequently, role of miR-214 
was analyzed in radiosensitivity of RS H23 cells, 
transfected with miR214 mimics. When miR-214 
transfectedH23 cells were analyzed for their RT 
response, a signiÀcant increase in cell survival was 
observed. Given that proper activation of apoptotic 
signaling may confer radiosensitivity, H23 cells 
became protected from RT induced apoptosis 
with miR-214 expression. Control and scramble-
expressed cell showed 3times more condensed nuclei 
differed between subtypes; KEAP1 loss was more 
prevalent in AC whereas CUL3 loss and IKBKB 
gain occurred more frequently in SCC, suggesting 
that complex disruption in these NSCLC subtypes 
is achieved through different mechanisms. NSCLC 
samples with complex component disruption 
showed elevated protein expression levels of 
IKBKB and overexpression of NF-ƩB target genes, 
demonstrating the effect of complex disruption 
on NF-ƩB activity. Pharmacological inhibition 
of IKBKB proved detrimental to cell viability, 
highlighting the functional signiÀcance of complex 
disruption. 
Conclusion: Our analysis revealed gene dosage 
alteration is a prominent mechanism that disrupts 
each component of the KEAP1-CUL3-RBX1 E3 
ubiquitin ligase complex and its NF-ƩB stimulating 
substrate, IKBKB in a subtype speciÀc pattern. 
Multiple component disruption of this complex 
sensitizes cells to IKBKB inhibition and represents 
a novel mechanism driving aberrant NF-ƩB pathway 
activation in NSCLC.
Keywords: NFkB signaling, IKBKB, KEAP1/
CUL3/RBX1 E3 Ubiquitin ligase, genetic disruption
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O15.07 MIR-214 OVEREXPRESSION 
PROTECTS NSCLC AGAINST 
RADIOTHERAPY-INDUCED CELL 
DEATH BY CAUSING IMPAIRED 
APOPTOTIC SIGNALLING
Nadeem Shahzad Akbar1, Hogir Salim2, Dali 
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Lewensohn3, Boris Zhivotovsky4 
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Background: MicroRNAs (miRNAs) are recognized 
to regulate initiation, promotion and progression of 
carcinogenesis. More recently altered microRNA 
signatures (e.g., miR-15, miR-21, let-7, and miR-
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Background: The ability to detect driver mutations 
including EGFR and EML4-ALK in tumor 
specimens from patients with ACL and administer 
agents targeting the molecular alterations is 
revolutionizing the management of patients with 
ACL. Multiplexed assays are available to detect 
these different driver mutations in adenocarcinoma 
specimens at diagnosis and are enlarging the 
numbers of candidates who can be effectively treated 
with targeted agents. Therefore, we created the 
LCMC to determine the frequency of 10 different 
genetic alterations from 1000 advanced stage ACL 
patients, to compare the presence of the alterations 
with clinical features, with other alterations, and 
with clinical outcome, and to give the information to 
clinicians for their ongoing care and future research. 
Methods: The 14 member LCMC have recruited 
patients with ACL and tested the DNA from their 
ACL in CLIA laboratories for KRAS, EGFR, 
HER2, BRAF, PIK3CA, AKT1, and NRAS using 
standard multiplexed assays and Áuorescence in situ 
hybridization (FISH) for ALK rearrangements and 
MET ampliÀcations (genetic alterations). All had 
advanced stage (IIIB/IV) and performance status 
and 4times higher caspase3 activity as compared 
with H23 overexpressing mir-214. Further analysis 
was focused on survival signaling kinases, namely 
Akt and MAPKp38, aiming to reveal if increased 
signaling through these kinases contributes to 
miR-214 protective character against RT-induced 
cell death. MAPKp38 expression was signiÀcantly 
enhanced in cell lines overexpressing mir-214 but we 
were not able to detect any notable difference in Akt 
level with or without mir-214 suggesting that may be 
Akt expression is not being inÁuenced by mir-214 
particularly in H23 NSCLC cell line. 
Conclusion: we demonstrated that high level of 
miR-214 protects NSCLC cells against RT-induced 
cell death by blocking caspase-3-mediated apoptosis, 
implicating a role for low miR-214 expression as a 
marker of RT sensitive NSCLC phenotype. 
Keyword: miRNA, lung cancer, small cell lung 
cancer, non-small cell lung cancer, radiotherapy.
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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O16.01 CLINICAL CHARACTERISTICS 
OF PLANNED 1000 PATIENTS WITH 
ADENOCARCINOMA OF LUNG 
(ACL) UNDERGOING GENOMIC 
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O16.02 PROTEIN BIOMARKER PANEL 
ACCURATELY RESOLVES NON-
MALIGNANT NODULES IDENTIFIED 
THROUGH LOW-DOSE HELICAL CT 
SCANNING
Charles Birse1, Robet J. Lagier2, Robert N. Bruce1, 
Jennifer L. Tomic1, Steve M. Ruben2, Thomas J. 
Lenk1, Aaron O. Bungum3, Eric S. Edell3, James R. 
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Background: Concerns remain regarding the low 
speciÀcity of CT scanning and the resulting cost 
and morbidity associated with biopsy or resection 
of benign pulmonary nodules. In the CT arm of the 
National Lung Screening Trial (NLST), solitary 
nodules that turned out not to be cancerous were 
detected in about 25% of the subjects. Lung cancer 
biomarkers may serve as a useful complement to 
imaging, serving as a simple, cost-effective means 
of further clarifying the diagnosis in patients 
with suspicious pulmonary nodules identiÀed by 
radiologic imaging. 
Methods: 6 biomarkers were assayed in serum 
collected from subjects with non-small cell lung 
cancer (NSCLC) and appropriately matched controls. 
548 specimens collected from 3 independent sites 
were employed in the study. Samples were randomly 
divided into a training set (NSCLC n=108, controls 
n= 157) and a testing set (NSCLC n=122, controls 
n=161) and used to develop a split-point algorithm 
for lung cancer detection. Subsequently, performance 
of the algorithm was evaluated in an independent 
plasma-based validation study undertaken in a 
cohort of lung cancer subjects (n=50) and controls 
(n=50) matched for age, gender and smoking history. 
Controls included subjects with non-malignant 
pulmonary nodules (n=21). 
Results: The 6-marker split point model identiÀed 
cancer cases with good accuracy in training 
(AUC=0.86) and testing (AUC=0.89) datasets. 
All stages of cancer were well resolved: stage 
I 69% (n=98), stage II = 82% (n=45), stage III 
= 79% (n=48) stage IV = 77% (n=39); at 88% 
speciÀcity. Application of the model to data from the 
independent cohort revealed that the algorithm again 
0-2 with available tissue. This abstract focuses on 
genetic alterations detected by multiplexed assay, 
with FISH results reported in a separate abstract.
Results: To date, 911 patients have been registered 
with about 80 enrolling per month. Each of the 
institutions has enrolled a median of 65 patients 
(range 3 to 238) from 02/10 to 02/11. Multiplexed 
assays have been completed and reported for 420 
patients; among these patients, a genetic alteration 
has been detected in more than 50%. The median 
age of the full evaluable patient population (n=808) 
is 61 (IQR 52 - 68), with 479 (59.3%) women. Two 
patients (0.2%) had no systemic therapy at the time 
of enrollment, 195 (24.1%) had a single course of 
chemotherapy, and 302 (37.4%) had two or more 
treatment regimens (the information on the rest of 
the patients is not yet reported). 237 patients (29.3%) 
are never smokers, 438 (54.2%) are former smokers, 
and 66 (8.2%) are current smokers (8.3% of patients 
have yet to report the data). The 216 patients with 
genetic alterations by multiplexed assay had a 
median age of 62 (IQR 53 – 68.5), compared to a 
median age of 59 (IQR 48.5 – 67) among patients 
without genetic alterations (p=0.0328). Gender and 
smoking history did not show signiÀcant association 
with mutation status; with the complete dataset, 
signiÀcant associations may emerge. The relationship 
of each clinical feature to genetic alteration will be 
further presented.
Conclusion: We detected a driver mutation in more 
than 50% of the DNA from ACL. The results of 
EGFR mutation testing are now used by treating 
physicians to select erlotinib as initial treatment 
according to NCCN, ASCO, and ESMO guidelines. 
Patients with other driver mutations are being 
offered participation in LCMC-linked clinical trials 
testing agents targeting the mutation identiÀed, e.g. 
crizotinib with EML4-ALK. At half of LCMC sites, 
multiplexed testing for all mutations is now routine 
practice of pathology departments for patients with 
ACL.
Keywords: lung neoplasm, genomic changes, 
Epidermal growth factor receptor, EML4-ALK
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were found on rebiopsy of patients with prior EGFR-
mutant ADC who developed acquired resistance to 
erlotinib. 
Results: Of 82 SCLC, 2 (2.4%) harbored EGFR, 
1 (1.2%) KRAS, and 1 (1.2%) PIK3CA mutations. 
Both EGFR-mutations occurred in SCLC that 
were preceded by ADC harboring the same EGFR 
mutation (exon 19 deletion, L858R), and the lone 
KRAS mutation (G12V) occurred in combined 
SCLC. Overall, all EGFR/KRAS mutations were 
restricted to SCLC associated with either prior or 
combined ADC (3/10; 30%) whereas none occurred 
in pure SCLC (0/71) (p=0.0014). In contrast to 
SCLC, pure LCNEC harbored KRAS mutations in 
7 of 51 (14%; 95% CI 4%-23%) cases (p=0.0017). 
Similar to ADC in smokers, KRAS mutations in 
LCNEC were predominantly smoking-related G-T or 
G-C transversions (5/7; 71%). 
Conclusion: EGFR and KRAS mutations are 
extremely rare in SCLC and are restricted to SCLC 
associated with ADC either as unusual form of 
ADC progression or as de-novo combined SCLC/
ADC. In particular, two of our cases reÁect the rare, 
recently described phenomenon of clonal evolution 
of ADC to SCLC in the setting of erlotinib therapy. 
SigniÀcant rate of KRAS mutations in LCNEC is 
a novel Ànding which suggests a histogenetic link 
between a subset of LCNEC and ADC. 
Keyword: EGFR KRAS SCLC LCNEC
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MAP: AN INSTITUTIONAL PROGRAM 
TO ROUTINELY PROFILE TUMOR 
SPECIMENS FOR THE PRESENCE 
OF MUTATIONS IN TARGETABLE 
PATHWAYS IN ALL PATIENTS WITH 
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identiÀed the malignant cases accurately AUC=0.83 
(sensitivity= 70% at speciÀcity=94%). 19/21 non-
malignant nodules within the control population 
were correctly classiÀed. The panel of 6 biomarkers 
described in these studies accurately identiÀes lung 
cancer cases in both serum and plasma.
Conclusion: This panel of 6 biomarkers shows 
promise in differentiating benign from malignant 
pulmonary nodules. While additional studies are 
clearly required, these preliminary results suggest 
that this test may serve as a valuable adjunctive tool 
to imaging, providing a rapid, cost-effective means 
of prioritizing cases for more invasive biopsy.
Keywords: biomarker, NSCLC, nodule
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O16.03 ANALYSIS OF EGFR AND 
KRAS MUTATIONS IN SMALL CELL 
CARCINOMA AND LARGE CELL 
NEUROENDOCRINE CARCINOMA OF 
LUNG.
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Background: EGFR and KRAS mutations occur 
in ~20% and ~30% of lung adenocarcinoma (ADC) 
in North America, respectively. The prevalence and 
signiÀcance of mutations in these and other key 
signaling molecules in high-grade neuroendocrine 
carcinomas of lung is not well established.
Methods: A total of 132 high-grade neuroendocrine 
carcinomas were analyzed for hot-spot point 
mutations EGFR, KRAS, AKT1, BRAF, HER2, 
MEK1, and PIK3CA by Sequenom mass 
spectrometry genotyping and EGFR Exon 19 
deletions by standard methods. Included were small 
cell lung carcinomas (SCLC) (n=81) and large cell 
neuroendocrine carcinomas (LCNEC) (n=51). SCLC 
specimens included resections (n=40), Àne needle 
aspirates (n=36) and small biopsies (n=5), and all 
LCNEC specimens were resections. Eight SCLC 
were combined with non-SCLC, and two SCLC 
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individuals with EGFR and HER2 mutations and 
to identify patients appropriate for clinical trials of 
investigational targeted therapies. Supported by P01 
CA129243 and the Chandler Fund.
Keywords: Driver Mutation, EGFR, 
Adenocarcinoma, Mutation ProÀling
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O16.06 PROGNOSTIC IMPLICATIONS 
OF DRIVER MUTATIONS IN SMOKERS 
AND NEVER SMOKERS WITH LUNG 
ADENOCARCINOMA
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Background: We previously demonstrated a dose-
dependent relationship between smoking history and 
survival in patients with stage IIIB/IV non-small 
cell lung cancer (NSCLC), with never-smokers 
living 50% longer than smokers (Janjigian et. al., 
Cancer 2010). This relationship was independent of 
age, performance status, and gender on multivariate 
analysis. We hypothesized that smoking-dependent 
differences in the distribution of driver mutations 
determined differences in prognosis between these 
two subgroups. 
Methods: We reviewed 301 consecutive never 
smokers and 373 consecutive smokers with lung 
adenocarcinoma who underwent testing for EGFR 
and KRAS mutations and rearrangements in ALK 
between May 2009 and May 2010. KRAS mutations, 
EGFR exon 19 deletions, and exon 21 L858R 
mutations were identiÀed by standard methods. ALK 
rearrangements were identiÀed through FISH and 
conÀrmed by PCR. Clinical outcomes and patient 
characteristics were collected. Survival probabilities 
were estimated using the Kaplan-Meier method. 
Group comparison was performed with log-rank tests 
and Cox proportional hazards methods.
Results: EGFR mutations were present in 111 (37%) 
never smokers vs. 54 (14%) smokers (p<.0001); 
KRAS mutations were present in 12 (4%) never 
smokers vs. 158 (43%) smokers (p<.0001); and 
ALK rearrangements were present in 35 (12%) never 
smokers vs. 9 (2%) smokers (p<.0001). Median 
Background: Mutated oncogenes underlie the 
behavior of lung cancers and can serve as targets 
for therapy. Determining the presence of these 
molecular abnormalities can direct the care of 
individual patients and aid research. To acquire and 
use this information in as many patients as feasible, 
in January 2009 our multidisciplinary Disease 
Management Team began a program within the 
Department of Pathology to prospectively detect 
the presence of mutations in EGFR, KRAS, BRAF, 
HER2, PIK3CA, MEK1, and AKT1 and EML4-
ALK re-arrangements in all patients diagnosed with 
non-small cell lung cancer with sufÀcient tissue 
for testing. We named this effort the Lung Cancer 
Mutation Analysis Project (LC-MAP). 
Methods: Patients sign an institutional consent to 
permit the use of previously obtained (“leftover”) 
tissue for mutation proÀling after standard diagnostic 
studies are completed. In the Department of 
Pathology, we use PCR-based testing for EGFR exon 
19 deletions and HER2 insertions. An additional 91 
mutations in 7 genes were assayed in a multiplexed 
mass-spectrometry-based system (Sequenom™). 
EML4-ALK re-arrangements are determined by 
ALK FISH. 
Results: 1231 patients have entered. For those 
genotyped with adenocarcinoma (n=896) and 
histologies other than squamous cell (n=49), a driver 
mutation was found in 56% of the tumor specimens 
(95% CI 52 to 59%). Mutations detected include 
282 KRAS (30%), 186 EGFR (20%), 23 EML4-
ALK (7%), 12 HER2 (5%), 11 PIK3CA (1%), 10 
BRAF (1%), 2 MEK1 (0.2%), and 1 AKT1 (0.1%). 
For persons with squamous tumors, mutations 
were detected in 3% of specimens (95% CI 0.3 to 
10%). This information lead to the use of the EGFR 
tyrosine kinase inhibitor erlotinib in 78 patients with 
EGFR sensitizing mutations. 46 others were entered 
on clinical trials testing agents targeting the speciÀc 
molecular abnormality detected. 
Conclusion: 1) Determining the presence of 
actionable mutations in patients with lung cancer 
can be made part of the routine evaluation of tumor 
specimens within a department of clinical pathology. 
2) We detected a “known” driver mutation in 
one of the 8 genes assessed in tumors from 56% 
of patients with adenocarcinoma and histologies 
other than squamous cell. 3) We identiÀed a driver 
mutation in any the 8 genes assayed in only 3% of 
specimens from patients with squamous tumors. 4) 
The mutational data obtained can be used to select 
available drugs (erlotinib, geÀtinib, trastuzumab) for 
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Background: When assigning therapy, clinicians 
have historically classiÀed lung cancer as either 
small cell or non-small cell lung cancer (NSCLC) 
despite the detailed observations recorded by 
pathologists. With the increasing evidence that 
histology is predictive of therapeutic outcomes, 
better characterization of lung cancer that is not 
clearly deÀned small cell lung cancer (SCLC), 
adenocarcinoma (ADC), or squamous cell carcinoma 
(SQCC) is needed. The role of genotyping these 
“other lung cancers” has not been systematically 
evaluated. 
Methods: Evaluation of an institutional database 
created as part of the Lung Cancer Molecular 
Analysis Project (LC-MAP) with routine assessment 
of histology and assessment of driver mutations 
in EGFR, KRAS, BRAF, HER2, PIK3CA, AKT1, 
NRAS, MEK1, MAP2K1, and EML4-ALK (Kris, 
Proc ASCO, 2010).
Results: Between 1/1/2009 – 12/31/2010, 1210 
patients with lung cancer signed informed consent 
and had sufÀcient tissue for analysis. 49 of 1210 
(4%, CI 3-5%) were other lung cancers. Of these 49, 
12 were large cell carcinomas (LCC), 9 were large 
cell neuroendocrine carcinomas (LCNEC), 14 were 
pleomorphic/sarcomatoid carcinomas (pleo), 4 were 
NSCLC, not otherwise speciÀed (NOS) and 10 had 
combined histologies. To date molecular results are 
available on 42 patients and driver mutations were 
found in 17/42 (40%, 95% CI 27-56%). There was 
1 EGFR mutation in a patient with adenosquamous 
survival for advanced stage (IIIB/IV) never smokers 
vs. smokers was 53.4 months (95% CI: 43.8-NR) vs. 
24.8 months (95% CI: 18.6-49.9 months) (p<.001). 
Among never smokers with advanced disease, 
median OS was as follows: EGFR 36.6 months 
(95% CI 18.8-NR), KRAS 10.4 months (95% CI: 
5.4-NR), and ALK rearrangements 62.9 months 
(95% CI: 43.8-NR). Multivariate analysis (stage, 
performance status, mutation, age) found signiÀcant 
survival differences between never smokers with 
EGFR mutations vs. KRAS mutations (HR for death 
4.2 95% CI: 1.11-15.63, favoring EGFR) and EGFR 
mutations vs. ALK rearrangements (HR for death 
0.31, 95% CI: 0.1-0.94, favoring ALK). Conversely, 
within a given genotype, no signiÀcant survival 
differences were present when categorized by 
smoking history, as below: 
Overall Survival in Advanced Stage Patients by Smoking 
History and Genotype 
Genotype 
Median OS 
(months) 95% CI (months) p 
EGFR mutation 
Smoker NR 29.9-NR 0.21 
Never-smoker 36.6 18.8-NR 
KRAS mutation 
Smoker 17.8 12.7-34 0.95 
Never-smoker 10.4 5.4-NR 
ALK rearrangement 
Smoker 35.4 35.4-NR 0.86 
Never-smoker 62.9 43.8-NR 
NR, not reached 
Conclusion: The prognostic impact of smoking 
history is genotype-driven. Never smokers and 
smokers with lung adenocarcinomas are not 
homogeneous subgroups. Each is made up of a 
unique distribution of driver mutations. These driver 
mutations, including EGFR and KRAS mutations 
and rearrangements in ALK, are associated with 
different prognoses that do not vary by smoking 
history. Integration of these two factors determines 
the overall prognosis of never smokers and smokers 
with lung adenocarcinomas.
Keywords: never smoker, EGFR, Kras, 
Adenocarcinoma
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Background: Accurate lung cancer risk prediction 
models are useful for individuals, clinicians, 
public health ofÀcials and health administrators. 
The relationship between pulmonary function 
and lung cancer is unclear, and past studies of sex 
differences have been inconsistent. The current study 
investigates the relationship between spirometric 
data and lung cancer, assessing differences by sex.
Methods: The current study analyzes baseline 
data from the Pan-Canadian Early Detection 
of Lung Cancer Study, which has the objective 
to evaluate a new multi-modal early detection 
strategy that integrates risk modeling, spirometry, 
autoÁuorescence bronchoscopy and blood 
biomarkers with computed tomography for early 
detection of lung cancer. Multivariable logistic 
regression models were used to evaluate the 
independent relationship between lung cancer and 
percent predicted forced expiratory volume in 1 
second (FEV1%), percent predicted forced vital 
capacity (FVC%), and FEV1/FVC ratio, and their 
interactions with sex. Likelihood ratio tests (LRT) 
were used to evaluate the contribution of spirometric 
data and interaction terms to models. The receiver 
operator characteristic area under the curve (ROC 
AUC) assessed predictive discrimination. The 
Hosmer-Lemeshow goodness-of-Àt statistic and 
calibration plots were used to assess calibration.
Results: At baseline screening 61 lung cancers 
were detected in 2532 screenees. A full model was 
prepared including lung cancer risk factors: age, 
education, family history of lung cancer, body mass 
index, current smoking status, age at starting regular 
smoking, computed tomography examination of 
the chest in the last three years, sex, FEV1% and 
sex*FEV1% interaction. The LRT p-value for the 
interaction term was 0.076, and for FEV1% and 
the interaction term was 0.002. The relationship 
between FEV1% and lung cancer risk by sex is 
depicted in Figure 1. Compared to women, the risk 
for men climbs much more rapidly as the FEV1% 
decreases below 80. The ROC AUCs for the full 
model and the reduced model excluding FEV1% 
and the interaction term were 0.726 and 0.675. 
The difference, 0.0515 (p = 0.094), is sizeable, 
carcinoma (AS). 14 patients had KRAS mutations, 
3 with NOS, 6 pleo, 2 AS, 1 LCC, 1 LCNEC and 1 
mixed with LCNEC and ADC components. There 
was 1 PIK3CA mutation in a patient with a LCNEC 
and 1 BRAF mutation in a patient with LCC. 25 
patients had no mutations identiÀed and 7 have 
results pending.
Conclusion: We have shown that mutations occur 
in ~40% of the “other lung cancers” with rare 
histologies. While the frequency and epidemiology 
of mutations in adenocarcinoma of the lung has 
been well deÀned with >50% of cases harboring an 
identiÀable driver mutation, the less common lung 
cancer histologies are under studied. These Àndings 
support the molecular testing of “other lung cancers” 
which is now routine at our institution. Support: NIH 
T32 CA009207, P01 CA129243, RC2 CA148394. 
Keywords: Non-small cell lung cancer, molecular 
mutations
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a conclusive or in-conclusive non-surgical workup 
will reduce the resection rate for benign disease in test 
positive participants of a lung cancer screening program. 
Methods: (18)F-Fluorodeoxyglucose-positron 
emission tomography (PET) scans were made 
in 220 test positives. Nodules were classiÀed as 
positive, indeterminate or negative based on visual 
comparison with background activity. Gold standard 
for a positive PET was the presence of cancer in the 
resection specimen, or the detection of cancer during 
> 2 years follow-up. Sensitivity, speciÀcity, positive 
predictive value (PPV) and negative predictive 
value (NPV) were calculated and 95% ConÀdence 
Intervals (CI) constructed. 
Results: The sensitivity of PET to detect cancer was 
84.2% (95%CI: 77.6-90.7%), the speciÀcity 75.2% 
(95%CI: 67.1-83.3), the PPV 78.9% (95%CI: 71.8-
86.0) and the NPV 81.2% (95%CI: 73.6-88.8). The 
resection rate for benign disease was 23%, but 55% of 
them had clinical consequences. A pre-operative PET 
after an in-conclusive non-surgical work-up reduced 
the resection rate for benign disease by 11%, at the 
expense of missing 12% lung cancer cases. A pre-
operative PET after a conclusive non-surgical work-up 
reduced the resection rate for benign disease by 78% 
at the expense of missing 3% lung cancer cases. 
Conclusion: A pre-operative PET scan after 
an inconclusive non-surgical work-up is not 
recommended because of the very low NPV, but after 
a conclusive non-surgical work-up the resection of 
benign disease can be decreased by 72%. 
Keywords: Positron-emission Tomography, 
Pulmonary nodule, Thoracic surgery, Lung cancer
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O17.03 CT SCREENING OF LUNG 
CANCER BRINGS FORWARD EARLY 
DISEASE. THE DANISH LUNG CANCER 
SCREENING TRIAL (DLCST): STATUS 
AFTER FIVE YEARS OF CT SCREENING.
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representing 10.3% of the distance between 
random and perfect classiÀcation. The Hosmer-
Lemeshow goodness-of-Àt test p-values for the 
full and reduced models were 0.781 and 0.965, 
suggesting that both models were well calibrated. 
Conclusion: These Àndings indicate that low 
FEV1% is strongly associated with increased risk 
of lung cancer and that the effect is greater in males 
than in females. Inclusion of FEV1% and FEV1%-
sex interaction in the model substantially improved 
predictive discrimination.
Keyword: spirometry, pulmonary function, FEV1, 
lung cancer risk
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O17.02 THE ROLE OF THE FDG-PET 
SCAN IN THE NELSON LUNG CANCER 
SCREENING TRIAL
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Background: In computer tomography (CT) lung 
cancer screening up to 30% of all resections are 
performed for benign disease. The purpose of this 
study is to to investigate if a pre-operative PET after 
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Background: It is hoped that screening for lung 
cancer with spiral CT may decrease lung cancer 
mortality, but encouraging results have only 
been obtained in uncontrolled studies. Recently, 
the National Lung Screening Trial investigators 
announced that screening by LDCT signiÀcantly 
reduced lung cancer mortality as compared with 
screening by chest X-rays. The purpose of our study 
was to explore the effect of screening with low-
dose spiral CT (LDCT) on lung cancer mortality 
in comparison with no screening in a high-risk 
population. Secondary endpoints were incidence, 
stage and resectability. 
Methods: Male subjects, aged 60-75, smokers 
of 20+ pack-years were randomized to screening 
with low-dose spiral CT or control. All participants 
underwent a baseline, once-only chest X-ray (CXR) 
and sputum cytology examination in order to 
increase accrual. Screening-arm subjects also had a 
LDCT upon accrual, which was to be repeated every 
year for four additional years, while controls had a 
yearly interview and basic medical examination, with 
further testing only in case of suspicious symptoms. 
Results: Starting March 2001 through to February 
2006, 2811 subjects were randomized and 2472 were 
actually enrolled (LDCT 1276, control 1196). As of 
Norway, 4Bispebjerg University Hospital/Denmark, 
5Rigshospitalet/Denmark, 6Nordsjællands University 
Hospital/Denmark, 7University Of Copenhagen/
Denmark
Background: The effects of low dose CT 
screening on true disease stage-shift, mortality and 
overdiagnosis are unclear. We present lung cancer 
Àndings and mortality at end of screening in the 
randomised Danish Lung Cancer Screening Trial 
(DLCST).
Methods: 4,104 men and women, healthy heavy 
smokers/former smokers were randomised to annual 
low dose CT screening or no screening for Àve 
years (baseline and four incidence rounds). Two 
experienced chest radiologists read all CT scans 
and registered the location, size and morphology of 
nodules. Nodules with a diameter between 5 and 15 
mm without benign characteristics were rescanned 
after three months. Volume-doubling-time (VDT) 
was used to measure growth rate. Growing nodules 
(>25% increase in volume) and nodules larger than 
15 mm were referred for diagnostic workup. In the 
control group, lung cancers were diagnosed and 
treated outside the study by usual clinical practice.
Results: The participation rates were high in both 
groups (screen: 95.5%; control 93.0%; p<0.001). 
2.5% of screening tests were positive, and after 
diagnostic workup 1.8% were classiÀed as false 
positive Àndings (non-malignant). Lung cancer 
detection rate was 0.8% at baseline and mean 
annual detection rate was 0.6% at incidence rounds 
(p=0.492). SigniÀcantly more lung cancers were 
diagnosed in the screening group as compared to 
the control group (68 vs.24, p<0.001), and more 
were low stage (57 vs.10 stage I-IIIA NSCLC and 
limited stage SCLC, p<0.001), whereas frequencies 
of high stage were the same (11 vs.14 stage IIIB-IV 
NSCLC and extensive stage SCLC, p=0.640). This 
indicates no absolute stage-shift and some degree 
of overdiagnosis. At end of screening, 60 were 
deceased in the screening group and 42 in the control 
group (p=0.072). 15 and 10 died of lung cancer, 
respectively (p=0.923). 
Conclusion: CT screening of lung cancer brings 
forward early disease, and at this point no absolute 
stage-shift or reduction in mortality was observed. 
SigniÀcantly more lung cancers were diagnosed 
in the screening group indicating some degree of 
overdiagnosis. 
Keywords: mortality, Stage-shift, Lung cancer, CT 
screening
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size, nodule location, gender, age, distance from the 
pleura, and smoking history. Statistical analyses were 
performed by the Kaplan-Meier method.
Results: The results showed that 1267 newly 
developed nodules had been identiÀed in 825 
screenees (825/9754, 8.5%) (356 females, and 469 
males; mean age 64 years, range, 44-84 years). As 
of February 24, 2011, the outcome of 1153 of the 
1267 newly developed nodules had been determined: 
9 nodules had been diagnosed as cancer (2 as 
adenocarcinoma, 3 as squamous cell carcinoma, 2 
as small cell carcinoma, 2 as a pulmonary metastasis 
by prostate cancer and by esophageal cancer, 
respectively), 3 nodules as inÁammation, 1 nodule 
as bronchiolitis obliterans organizing pneumonia, 
453 nodules (453/1153, 39%) had disappeared, 256 
nodules (256/1153, 22%) had shrunk, and 431 nodules 
(431/1153, 37%) were stable. The median follow-up 
period of the screenees whose nodules were stable or 
had shrunk was 29 months (range, 3-67). The results 
according to whether the screenees were smokers 
showed that 87 nodules (87/1153, 8%) had developed 
in female smokers and 458 nodules (458/1153, 40%) 
had developed in female non-smokers, while 454 
nodules (454/1153, 39%) had developed in male 
smokers and 154 nodules (154/1153, 13%) had 
developed in male non-smokers. There were 240 
pure ground-glass nodules (GGNs), and their mean 
size was 6 mm (range, 1.5-27). There were 77 mixed 
GGNs (GGNs with a solid component), and their 
mean size was 6.4 mm (range, 2.5-24.5). There were 
836 solid nodules, and their mean size was 4.8 mm 
(range, 1.5-35). A multivariate analysis is in progress.
Conclusion: As of February 24, 2011, 99.2% 
(1144/1153) of the newly developed nodules in our 
cohort during follow-up after baseline CT lung cancer 
screening or during repeat CT screening were false-
positive. Risk-based follow-up criteria should be 
established.
Keyword: CT, screening, early detection, newly 
developed nodule
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O17.07 CT SCREENING FOR LUNG 
CANCER: THE IMPLICATION OF LUNG 
BIOPSY RECOMMENDATIONS
Ute Wagnetz1, Ravi Menezes2, Scott Boerner2, 
Narinder Paul2, Dirk Wagnetz3, Shaf Keshavjee2, 
Heidi Roberts4 
December 2010, active follow-up was 13541 person-
years (LDCT 7097, Ctrl 6444). LDCT subjects had 
a signiÀcantly higher probability of undergoing an 
invasive 2nd line investigation following a screening 
CT than control arm subjects following medical 
interview and testing on demand. Lung cancer 
was detected in 92 (7.2%) LDCT patients and 58 
(4.8%) controls (p<0.005), with signiÀcantly more 
patients with Stage I disease and signiÀcantly less 
cases detected due to intercurrent symptoms in the 
screening arm (p<0.005). The absolute number 
of lung cancer cases with stage II-IV disease was 
virtually the same as in the control arm (42 vs. 45, 
p=1.0). Resectability rates were similar in both 
groups. Focused effect size measures on lung cancer 
mortality (i.e. mortality rates) are under evaluation. 
Conclusion: Five-year results of the DANTE trial 
still suggest that the beneÀt of lung cancer screening 
by spiral CT is small in patients over 60 as compared 
with clinical surveillance only. Screening for lung 
cancer should continue to remain investigational. 
Collateral studies are needed to improve patient 
selection and outcomes. 
Keywords: Lung cancer, Early Detection, Spiral CT, 
Randomized controlled trial
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O17.06 NEWLY DEVELOPED NODULES 
DURING FOLLOW-UP AFTER BASELINE 
CT LUNG CANCER SCREENING OR 
DURING REPEAT CT SCREENING
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1Screening Technology And Development Division, 
National Cancer Center, Research Center For 
Cancer Prevention And Screening/Japan, 2National 
Cancer Center Hospital/Japan
Background: To evaluate newly developed nodules 
detected during follow-up after baseline CT lung cancer 
screening or during repeat CT screening.
Methods: Between February 2004 and March 2010, 
9754 people were enrolled in our observational CT 
lung cancer screening study. Screenees in whom newly 
developed nodules had been detected during that 
period were identiÀed from the nodule database. The 
following information was retrieved from the database: 
types of change in size, nodule consistency, nodule 
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Background: Several groups have demonstrated that 
the change in the primary tumor FDG uptake by PET 
after a single cycle of platinum-based chemotherapy 
predicted which advanced stage NSCLC patients had 
longer progression-free and overall survival (PFS 
and OS) after administration of the entire multi-cycle 
chemotherapy regimen. Non-responders by early 
PET were highly unlikely to respond by CT RECIST 
and had statistically signiÀcantly lower median PFS 
and OS. 
Methods: We are conducting a prospective clinical 
trial to test the hypothesis that FDG-PET could be 
used to select optimal chemotherapy. Chemotherapy 
naïve patients with metastatic NSCLC and a 
baseline FDG PET receive carboplatin (AUC=6) 
and paclitaxel (175mg/m2) (CP) chemotherapy 
on day 1 and repeat FDG-PET on day 18. Using a 
previously validated measure of response, namely 
a decrease in the SUVmax of > 20% in the primary 
lesion, PET-responding patients are continued on CP 
chemotherapy for a total of 4 cycles. Patients who 
do not respond by PET are switched to alternate 
docetaxel (75mg/m2 d8) and gemcitabine (1000mg/
m2 d1,8) (DG) for three additional cycles. The 
primary outcome is the CT RECIST response rate to 
1Nuklearmedizinische Praxis Am Schwabentor/
Germany, 2University Health Network/Canada, 
3Thoracic Surgery, Universitaetsklinik/Germany, 
4Joint Department Of Medical Imaging, Women’s 
College Hospital/Canada
Background: The purpose of our study was to 
address the implication of invasive diagnostic 
procedures recommended from a lung cancer 
screening protocol; in particular to assess how many 
invasive procedures were recommended for benign 
nodules. 
Methods: Between 2003 and 2009, 4782 high-risk 
smokers were enrolled in a lung cancer screening 
study. A helical low-dose computed tomography 
(LDCT) of the chest was performed using 120 kVp, 
40-60 mA and a collimation of 1 mm or 1.25 mm. The 
morphological features targeted were parenchymal 
nodules; indication for biopsy was made based on the 
diagnostic algorithm provided by the International 
Early Lung Cancer Action Program (I-ELCAP). We 
recorded the time point of biopsy recommendation 
(baseline, follow-up), the morphology and size, 
growth, the types of diagnostic procedures including 
complication rate, and the Ànal pathology. 
Results: A total of 128 diagnostic biopsies were 
recommended for suspicious nodules, 127 were 
performed: 110 percutaneous CT-guided Àne-needle-
aspiration biopsies (FNAB), 9 diagnostic resections 
by video-assisted thoracoscopic surgery (VATS), 7 
bronchoscopies and 1 ultrasound guided biopsy of a 
supraclavicular lymph node. Of the 110 FNABs, 24 
had unsatisfactory results; 13 underwent secondary 
diagnostic VATS resection. The indication for biopsy 
was made based on morphology in 48% (62/128), 
growth on follow-up in 40% (51/128) and in 12% 
(15/128) for new nodules; 61 nodules were smooth 
or lobulated solid, 17 spiculated, 7 cavitary, 27 part-
solid and 12 non-solid. In total 104/124 (84%) were 
true positive for malignancy, 20/124 (16%) were 
false positive; in 4 cases Ànal result is pending. The 
overall false positive rate was 0.42% (20/4782); 
11.6% (16/128) FNAB and 3.6% (5/128) VATS were 
recommended for benign nodules. 
Conclusion: Recommended biopsy procedures 
for screen-detected suspicious pulmonary nodules 
resulted in a low intervention rate for benign 
nodules. The rate of false positive invasive 
procedures is minimal when adhering to a follow up 
protocol that relies on morphology and growth. 
Keywords: computed tomography, lung nodules, 
Screening, false positives
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ANGIOGENIC DRUG BEVACIZUMAB 
ON TUMOR PERFUSION AND 
DRUG DELIVERY OF 11C-LABELED 
DOCETAXEL IN NON-SMALL CELL 
LUNG CANCER (NSCLC) PATIENTS: 
IMPLICATIONS FOR SCHEDULING OF 
ANTI-ANGIOGENIC AGENTS
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Background: Current strategies combining anti-
angiogenic drugs with chemotherapy provide clinical 
beneÀt in patients with advanced-stage NSCLC 
cancer. It has been hypothesized that pre-treatment 
with anti-angiogenic drugs may transiently normalize 
abnormal tumor vasculature and contribute to 
improved delivery of subsequent chemotherapy 
(Nat Med 2001;7:987-9). The purpose of this study 
was to investigate this concept in NSCLC patients 
using a perfusion tracer ([15O]H
2
O), radiolabeled 
chemotherapy ([11C]docetaxel) and positron emission 
tomography (PET) before and after a single infusion 
of bevacizumab. 
Methods: Ten NSCLC patients were included. 
Patients underwent dynamic PET scans with [15O]
H
2
O and [11C]docetaxel before, and at 5 hours 
and 4 days after IV bevacizumab administration 
(15 mg·kg-1). An additional [15O]H
2
O scan 
was performed at 2 hours. Systemic effects of 
bevacizumab were investigated by assessing: 
(1) plasma levels of vascular endothelial growth 
factor (VEGF) using ELISA kits, (2) blood 
pressure, (3) cardiac output using [15O]H
2
O, and (4) 
microcirculation in the skin using capillaroscopy. 
Results: Two hours after bevacizumab 
administration, tumor perfusion did not change 
(Wilcoxon Signed Ranks test, P=0.89). At 5 hours, 
the alternate DG chemotherapy. Secondary endpoints 
include PFS and OS.
Results: The study planned for a total of 45 
evaluable patients. To date, 40 patients have 
sufÀcient data for analysis. Of these, 16 (40%) met 
the FDG-PET criteria for response after a single 
cycle of CP. The primary endpoint was the response 
rate in PET non-responders switched to alternate DG 
chemotherapy. To date, only one non-responding 
patient had a RECIST response, and the study goal 
of 3 or more responding patients has not been met. 
Overall, 28 (70%) patients have died, 27 with disease 
progression. Another 7 (18%) patients had disease 
progression but remained alive at last contact. 
The rates of OS and PFS showed no signiÀcant 
variability according to early PET response (p=0.94 
and p=0.60, respectively).
Conclusion: This is the Àrst trial in solid tumor 
oncology that utilizes early FDG- PET response 
data to select subsequent chemotherapy. Previous 
work suggested that non-responders by early PET 
are unlikely to beneÀt from the continuation of the 
same chemotherapy and have inferior PFS and OS. 
This work demonstrates that although changing 
chemotherapy in the event of non-response by PET 
did not lead to CT RECIST responses, patients 
who switched chemotherapy had similar PFS and 
OS to those who initially responded by PET. It is 
possible that the change in chemotherapy directed 
by PET was responsible for these results. This 
trial demonstrates the feasibility of this FDG-PET 
response based adaptive approach that could be 
tested in a randomized clinical trial.
Keywords: FDG-PET, NSCLC, adaptive therapy, 
personalized therapy
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Methods: 1. Diagnosing malignant pulmonary 
nodules PET and DWI were carried out 
prospectively in 192 patients with 232 pulmonary 
nodules/masses before surgery. FDG uptake of each 
lesion was quantitatively measured by a contrast 
ratio of standard uptake value (SUV-CR) between 
the lesions and contralateral lung. Diffusion of water 
molecule in each lesion was quantitatively measured 
by a minimum ADC (ADC-min). The diagnostic 
results were compared between the two modalities. 
2. N staging of NSCLC Both FDG-PET CT and 
DWI were prospectively used in 169 patients before 
surgical intervention for NSCLC to examine 1558 
lymph node stations. The diagnostic results were 
compared between the two modalities. 
Results: 1. Diagnosing malignant pulmonary 
nodules The receiver operating characteristics curve 
showed cutoff values of the ADC-min and the SUV-
CR for benign/malignant discrimination to be 1.1 
x 10-3 mm2/s and 0.37, respectively. DWI and PET 
showed sensitivities of 0.7 and 0.72 and speciÀcities 
of 0.95 and 0.73, respectively. While there was no 
signiÀcant difference in sensitivity between the 
two methods, DWI showed a signiÀcantly higher 
speciÀcity than PET due to fewer false-positives 
for active inÁammatory lesions (p=0.004). The 
ADC-min and SUV-CR values showed a signiÀcant 
reverse correlation (r=-0.445, p<0.001). 2. N staging 
of NSCLC The accuracy of N staging in the 169 
patients was 0.89 with DWI, which was signiÀcantly 
higher than the value of 0.80 obtained with PET-CT 
(P=0.003), because of less overstaging in the former. 
Among the 1558 lymph node stations examined 
pathologically, 56 had metastases, and the other 1309 
did not. Although there was no signiÀcant difference 
in the diagnosis of the 56 metastatic lymph node 
however, both tumor perfusion and the net inÁux rate 
constant of [11C]docetaxel decreased signiÀcantly 
(P<0.05 for both). These changes persisted until day 
4 (P<0.01 for both). Changes in tumor parameters 
were accompanied by a rapid decrease in circulating 
VEGF at 3 hours (P<0.05) and a decline in cardiac 
output at 4 days (P=0.05). The other systemic 
parameters remained unchanged. 
Conclusion: A single dose of bevacizumab induces a 
rapid and signiÀcant decline in tumor perfusion and 
[11C]docetaxel delivery in NSCLC tumors. These 
rapid changes in tumor parameters are not due to 
changes in cardiovascular parameters. The Àndings 
of the present study highlight the importance of drug 
scheduling for enhancing drug delivery to tumors 
and advocate further studies to optimize scheduling 
of anti-angiogenic drugs. 
Keywords: bevacizumab, Tumor angiogenesis, 
Non-small cell lung cancer, Positron Emission 
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O18.03 DIFFUSION-WEIGHTED 
MAGNETIC RESONANCE IMAGING 
FOR DIAGNOSING MALIGNANT 
PULMONARY NODULES AND NODAL 
STAGING OF NON-SMALL CELL 
LUNG CANCER. COMPARISON WITH 
POSITRON EMISSION TOMOGRAPHY
Takeshi Mori1, Hiroaki Nomori2, Yasuomi Ohba1, 
Kentaro Yoshimoto1, Koei Ikeda1, Makoto Suzuki1 
1Thoracic Surgery, Kumamoto University/Japan, 
2General Thoracic Surgery, Keio University School 
Of Medicine/Japan
Background: Recent developments of diffusion-
weighted magnetic resonance imaging (DWI) 
make it possible to image malignant tumors due to 
provide tissue contrast based on difference in the 
diffusion of water molecules among tissues, which 
can be measured by apparent diffusion coefÀcient 
(ADC) value. The aim of this study is to examine 
the usefulness of 1) diffusion-weighted magnetic 
resonance imaging (DWI) for benign/malignant 
discrimination of pulmonary nodules/masses and 
2) nodal (N) staging of non-small cell lung cancer 
(NSCLC) compared with 18F-Áuorodeoxyglucose 
(FDG) positron emission tomography (PET). 
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LN metastasis in patients with a solid proportion 
50%. Sensitivity, speciÀcity, accuracy, positive and 
negative predictive values of FDG-PET/CT for nodal 
staging on per-patient basis were 14.3%, 87.1%, 
82.4%, 7.1%, and 93.6%. Those of CT were 14.3%, 
95.1%, 89.8%, 16.7%, and 94.1%. There were no 
signiÀcant differences in diagnostic accuracy between 
FDG-PET/CT and CT for nodal staging (P>0.05). On 
per-nodal-station basis, sensitivity, speciÀcity, and 
accuracy of FDG-PET/CT were 16.7%, 95.6%, and 
93.8%. Those of CT were 16.7%, 99.0%, and 97.2%. 
CT showed signiÀcantly higher accuracy than FDG-
PET/CT (P<0.001). Between cases with and without 
LN metastasis, there was a signiÀcant difference in 
solid proportion (P<0.05) and marginal difference in 
central location (P=0.065). 
Conclusion: FDG-PET/CT shows very low 
sensitivity and has little additional value compared 
to CT in nodal staging of T1 NSCLCs manifesting as 
subsolid nodules. The solid proportion was the only 
signiÀcant different feature between patients with or 
without LN metastasis. 
Keywords: T1 NSCLC manifesting as subsolid 
nodule, PET/CT, CT, LN staging
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
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O18.06 PET SUVMAX IN STAGE I 
LUNG ADENOCARCINOMA (LAC) IS 
A PREDICTOR OF RECURRENCE, 
CORRELATES WITH THE NEW 
IASLC/ATS/ERS HISTOLOGICAL 
CLASSIFICATION, AND FURTHER 
STRATIFIES PROGNOSIS IN 
INTERMEDIATE-GRADE ACINAR / 
PAPILLARY SUBTYPE
Kyuichi Kadota1, Christos Colovos2, Kei Suzuki2, E 
C. Zabor2, Camelia S. Sima2, Nabil P. Rizk2, Valerie 
W. Rusch2, William D. Travis2, Prasad S. Adusumilli2 
1Department Of Pathology And Surgery, Memorial 
Sloan-kettering Cancer Center/United States Of 
America, 2Memorial Sloan-Kettering Cancer Center/
United States Of America
Background: Our aims were to investigate whether 
preoperative PET SUVmax in stage I LAC can: 
stations between the 2 methods, DWI was more 
accurate for diagnosing the 1309 non-metastatic 
stations than PET-CT because of fewer false-positive 
results (P=0.001). 
Conclusion: DWI may be able to be used in place 
of FDG-PET for diagnosing malignant pulmonary 
nodules and N staging of NSCLC with fewer false-
positive results compared with FDG-PET.
Keywords: N stage of NSCLC, Lung cancer, 
benign/malignant discrimination, diffusion weighted 
magnetic resonance imaging
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O18.05 IS FDG-PET/CT NECESSARY IN 
DIAGNOSING NODAL METASTASIS 
OF T1 NON-SMALL CELL LUNG 
CANCER MANIFESTING AS SUBSOLID 
NODULES?
Chang Min Park1, Sang Min Lee1, Jin Mo Goo1, 
Kwang Gi Kim2 
1Department Of Radiology, Seoul National 
University Hospital/Korea, 2Department Of 
Biomedical Engineering, National Cancer Center/
Korea
Background: The diagnostic value of FDG-PET/
CT for LN staging in nonsmall cell lung cancer 
manifesting as subsolid nodule has not been evaluated 
yet. The purpose of our study was to retrospectively 
evaluate and compare the diagnostic accuracy of 
FDG-PET/CT and chest CT for LN staging in T1 
NSCLCs manifesting as subsolid nodules. We also 
investigated the predictive factors for LN metastasis 
in T1 subsolid NSCLCs among FDG-PET/CT and CT 
features. 
Methods: From January 2005 to March 2010, 5912 
patients were diagnosed with NSCLC in our hospital. 
Among them, 108 patients with pathologically-
proven T1 NSCLCs manifesting as subsolid nodules 
with lymph node (LN) staging were included in this 
study. Diagnostic accuracies of FDG-PET/CT and 
CT for nodal staging were evaluated on per-patient 
and per-nodal-station basis and compared. SUVmax 
and CT features of primary tumors were evaluated to 
investigate predictive factors for nodal metastasis. 
Results: Of the 108 patients, all tumors were 
adenocarcinoma pathologically, and nodal metastases 
were found in only 7 patients (6.5%). There was no 
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O19.01 APRICOT-L: A BIOMARKER 
BASED PHASE II RANDOMIZED 
PLACEBO- CONTROLLED STUDY OF 
APRICOXIB IN COMBINATION WITH 
ERLOTINIB IN NON-SMALL CELL LUNG 
CANCER (NSCLC) PATIENTS
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Keogh3, Edgardo S. Santos4, Gregory Otterson5, 
Ginger Milne6, Mary C. Syto7, S.L. Zaknoen7 
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Background: Apricoxib is a once-daily, oral, 
potent and selective inhibitor of COX-2. The 
COX-2 pathway plays a key role in tumor growth, 
angiogenesis and resistance to therapy. Combinations 
of a COX-2 inhibitor and EGFR inhibitors are 
of interest in NSCLC because COX-2 signaling 
activates the Erk/MAPK pathway. In a Phase I study 
apricoxib and erlotinib were found to be safe and 
demonstrated a disease control rate of 60%. The 
recommended Phase II dose was based on decreases 
in PGE-M; a urinary marker for tumoral COX-2 
activity. Thus, this Phase II trial used decreases in 
PGE-M to select patients for randomization.
Methods: Pts with IIIB or IV NSCLC that had a 
50% decrease from baseline PGE-M after a 5-day 
open-label run in of apricoxib were randomized. 
Pts were treated with erlotinib 150 mg PO daily 
and apricoxib/placebo 400mg PO daily. Pts must 
have failed a prior platinum-based regimen for IIIB 
or IV disease and have measureable disease. The 
primary objective was a 40% improvement in time to 
progression over the placebo arm.
Results: 176 patients entered run-in and 120/176 
(a) predict recurrence, (b) correlate with the new 
IASLC/ATS/ERS histological classiÀcation, and (c) 
help further stratify the intermediate grade acinar / 
papillary predominant morphology patients, the most 
prevalent subgroup.
Methods: Stage I LAC patients who had SUV values 
available (n=222, 1999 to 2005) were classiÀed 
according to the IASLC/ATS/ERS classiÀcation: low-
grade: lepidic (LPD), intermediate-grade: acinar (ACI), 
and papillary (PAP), and high-grade: micropapillary 
(MIP) and solid (SOL). Median SUVmax (3.0) was 
used to categorize the cohort into high and low. Log-
rank tests and Cox proportional hazards models were 
used to analyze the association between PET SUVmax, 
morphology, and time to recurrence (TTR). 
Results: The IASLC/ATS/ERS histological 
classiÀcation identiÀed: low-grade, 89% 5-year 
recurrence free probability (RFP) (LPD, n=16); 
intermediate-grade, 86% 5-year RFP (PAP, n=63 
and ACI, n=118); and high-grade, 71% 5-year RFP 
(SOL, n=22 and MIP, n=3) (p=0.039). Patients 
with high SUVmax showed signiÀcantly shorter 
TTR compared to patients with low SUVmax 
(78% vs. 92% 5-year RFP, p=0.012). SUVmax 
was signiÀcantly associated with histologic 
grade (p<0.001, Figure 1A). Furthermore, in the 
intermediate-grade, the most common group, patients 
with high SUVmax had signiÀcantly shorter TTR 
compared to patients with low SUVmax (79% vs. 
93% 5-year RFP, p=0.031, Figure 1B). The ability 
of SUVmax to predict recurrence is signiÀcant 
even after adjusting for histologic grade (p=0.033). 
Conclusion: In stage I LAC, pre-operative PET 
SUVmax predicts recurrence, correlates with 
the IASLC/ATS/ERS classiÀcation, and, most 
importantly, helps further stratify prognosis among 
most prevalent acinar and papillary morphology. 
Keywords: lung, Adenocarcinoma, Histological 
classiÀcation, PET
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Background: The insulin-like growth factor 
receptor 1 (IGF-1R) is a receptor tyrosine kinase that 
promotes cell proliferation and is over expressed in 
non-small cell lung cancer (NSCLC). Dalotuzumab 
(MK-0646) is a humanized IgG1 monoclonal 
antibody that binds to and inhibits the function of 
IGF-1R, inhibits tumor growth, and enhances the 
anti-tumor activity of erlotinib in murine xenograft 
models of NSCLC. This phase IIa study was 
designed to evaluate the effect of dalotuzumab 
combined with erlotinib on progression-free survival 
(PFS) in patients with recurrent NSCLC.
Methods: Patients with stage IIIb/IV NSCLC who 
previously failed at least 1, but no more than 2, 
prior chemotherapy regimens were randomized 1:1 
to an intravenous dalotuzumab 10 mg/kg/wk + oral 
erlotinib 150 mg/day arm or an erlotinib-only control 
arm. Patients in the erlotinib control arm were 
eligible for crossover to the dalotuzumab + erlotinib 
arm upon disease progression. The primary study 
endpoint was PFS. Secondary endpoints included 
overall survival (OS), response rate (complete 
response + partial response), safety, and tolerability. 
IGF-1R expression in peripheral blood mononuclear 
cells was assessed before and after therapy.
Results: Between December, 2007 and September, 
2010, 75 patients were enrolled and randomized 
to the dalotuzumab arm (37 patients, median age 
62 yrs, 73% male) or the control arm (38 patients, 
median age 59 yrs, 74% male). All patients were 
included in efÀcacy and safety analyses. Baseline 
patient characteristics were well balanced between 
the dalotuzumab and control arms. One objective 
response was observed in each of the two study 
arms. Median PFS was increased slightly in the 
dalotuzumab arm, but OS decreased. Patients in 
the dalotuzumab arm experienced more Grade 
3-5 adverse events and study-drug related serious 
adverse events (primarily hyperglycemia). Higher 
tumor IGF-1R expression at baseline was not 
associated with improved clinical outcome.
Conclusion: Dalotuzumab 10 mg/kg weekly + 
(73%) were randomized in a 2:1 (active: placebo) 
fashion (82% of patients had at least a 50% drop). 
Characteristics: Sex: M/F: 67/53; age range 36-
87 yrs.; 95% ECOG PS 0 or 1 and 5%, PS2. Most 
common adverse events of any grade included; 
diarrhea (55%), rash (54%), fatigue (38%) and nausea 
(33%). More patients on the active combination arm 
discontinued due to adverse events (7% vs 21%). 
In an analysis based on a pre speciÀed subgroup, 
patients in the 65 age group demonstrated statistically 
signiÀcant clinical beneÀt in all efÀcacy measures. 
ITT N=114 P value  65 N=65 P value HR 
DCR 46% vs 51% NS 35% vs 60% 0.018 
Median TTP 
(months) 
2.1 vs 1.8 0.97 1.4 vs 2.7 0.018 HR 0.5 
(NA, 0.9) 
Median OS 
(months) 
5.6 vs 5.9 0.83 3.8 vs 8.5 0.025 HR 0.4 
(NA,0.9) 
Conclusion: This study is the Àrst randomized 
placebo controlled trial to demonstrate a clinical 
beneÀt in a biomarker selected population of 
NSCLC patients using urinary PGE-M. Safety of this 
combination is acceptable in this patient population 
with patients > 65 years on active drug experiencing 
more study discontinuations due to adverse events. 
Although the overall ITT showed no beneÀt, in 
patients aged 65 or younger DCR, TTP and OS was 
signiÀcantly improved with the active combination. 
A Phase III deÀnitive trial is planned
Keywords: biomarker, COX2
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O19.02 AN OPEN LABEL, RANDOMIZED 
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ERLOTINIB IN PATIENTS WITH 
NON-SMALL CELL LUNG CANCER 
FOLLOWING FAILURE OF PRIOR 
CHEMOTHERAPY
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Background: Met is associated with a poor outcome 
in many cancers, including NSCLC. Met activation 
is a mechanism of resistance to EGFR inhibition, 
supporting dual inhibition of Met/EGFR. MetMAb is 
a monovalent monoclonal antibody that speciÀcally 
binds the Met receptor. 
Methods: MetMAb plus erlotinib (ME) was 
compared with placebo plus erlotinib (PE) in patients 
with 2nd/3rd line NSCLC in a global, randomized, 
double-blind Phase II study (OAM4558g). Tissue 
collection was mandatory to assess c-Met IHC 
expression levels (Met Dx). The co-primary 
endpoints were PFS in the Met Dx+ population and 
ITT population. Additional endpoints included safety 
and OS. Met Dx- patients were removed from the 
ME group after the initial unblinding. 
Results: Patients with NSCLC (n=128) were 
randomized in a 1:1 ratio to receive ME or PE. 
Baseline characteristics were well balanced between 
groups. 95% of tissue was evaluable for c-Met IHC, 
88% for EGFR and KRAS mutations, and 75% 
for MET FISH. Met Dx+ NSCLC, associated with 
a worse outcome (OS HR 2.52, PE cohort), was 
present in 54% of patients. After a median follow up 
of 9.9 months, a total of 99 PFS and 70 OS events 
have occurred. ME resulted in a statistically and 
clinically signiÀcant improvement in both PFS and 
OS in the Met Dx+ group. An OS beneÀt from ME 
was observed in MET FISH+ NSCLC as well as 
in FISH-/IHC+; removing data from patients with 
EGFR mutation did not alter the results. Selective 
beneÀt of ME was not observed in other subgroups. 
Erlotinib-related toxicities were comparable between 
treatment groups. 
Population n PFS HR OS HR 
Median 
(months) 
95% CI p PE ME 
c-Met IHC+ 65 0.47 
1.5 3.0 0.26-0.85 0.01 
0.37 4.6 12.6 0.20-0.71 0.002 
MET FISH+  
(³5 copies) 19 0.47 2.4 12.6 
0.15-1.49 0.19 
FISH-/IHC+ 37 0.44 3.6 7.1 0.17-1.15 0.09 
FISH-/IHC+/
EGFR wt 32 0.59 3.6 7.1 
0.22-1.59 0.29 
*c-Met IHC- 56 3.02 9.2 5.5 1.13-8.11 0.021 
*ITT 128 1.09 8.2 7.1 0.62, 1.91 0.76 
*Initial data cut.
Conclusion: Greater than half the patient population 
had Met Dx+ NSCLC, which was associated with 
a worse outcome. Addition of MetMAb to erlotinib 
signiÀcantly improved PFS and OS in these patients, 
erlotinib 150 mg daily is well-tolerated in patients 
with advanced NSCLC but did not increase 
PFS, OS or response rate. Further development 
of this combination therapy for NSCLC is not 
recommended.
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O19.03 FINAL EFFICACY RESULTS 
FROM A RANDOMIZED PHASE II STUDY 
(OAM4558G) EVALUATING METMAB 
OR PLACEBO IN COMBINATION WITH 
ERLOTINIB IN ADVANCED NSCLC
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3-21). All were hospitalized and 3 died. Flare was 
associated with a preceding shorter initial time to 
progression on TKI (Figure 1), median 9 vs. 15 
months, p=0.002 (Wilcoxon) and the presence of 
pleural or CNS disease (p=0.03, 0.01). There was no 
association between disease Áare and presence of an 
acquired T790M mutation.
Conclusion: In patients with EGFR-mutant lung 
cancer with acquired resistance to EGFR TKI, 
discontinuation of erlotinib or geÀtinib prior to 
initiation of an alternative treatment is associated 
with a clinically signiÀcant risk of accelerated 
disease progression. This risk is correlated with a 
shorter period of initial disease control on TKI and 
with pleural or CNS involvement. Further work is 
merited to discover other clinical and molecular 
characteristics that predict this phenomenon. Future 
clinical trials targeting this patient population should 
eliminate or minimize protocol-mandated washout 
periods. Funded by NIH T32 CA009207, P01 
CA129243
Keywords: EGFR mutatant, acquired resistance, 
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O19.06 LUX-LUNG 4: A PHASE II TRIAL 
OF AFATINIB (BIBW 2992) IN ADVANCED 
NSCLC PATIENTS PREVIOUSLY 
TREATED WITH ERLOTINIB OR 
GEFITINIB
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resulting in a near 3-fold reduction in the risk of 
death. This beneÀt was not exclusive to EGFR 
mutation or MET FISH+ and was observed in FISH-/
IHC+ patients, suggesting that c-MET IHC is a more 
sensitive predictor of beneÀt from MetMAb. 
Keywords: c-Met IHC, NSCLC, cMet, MetMAb
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O19.05 DISEASE FLARE AFTER 
TYROSINE KINASE INHIBITOR 
DISCONTINUATION IN PATIENTS WITH 
EGFR-MUTANT LUNG CANCER AND 
ACQUIRED RESISTANCE
Jamie E. Chaft1, Geoffrey R. Oxnard1, Vincent A. 
Miller1, Mark G. Kris1, Camelia S. Sima2, Gregory J. 
Riely1 
1Medicine, Memorial Sloan-Kettering Cancer 
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Background: Treatment of oncogene-addicted 
malignant neoplasms with targeted kinase inhibitors 
is biologically and clinically different than treatment 
with cytotoxic chemotherapy. We have observed 
that some patients with acquired resistance to 
EGFR tyrosine kinase inhibitors (TKI) (initial 
response followed by RECIST disease progression) 
have accelerated progression of disease after 
discontinuation of EGFR TKI. The risk of a serious 
disease Áare after discontinuing erlotinib or geÀtinib 
in EGFR-mutant lung cancer despite acquired 
resistance has not been systematically evaluated.
Methods: We identiÀed patients with EGFR-
mutant lung adenocarcinoma enrolled in 6 trials 
for treatment of acquired resistance in which TKI 
discontinuation for at least 7 days was mandated 
prior to treatment on trial. Disease Áare was deÀned 
as symptomatic progression of disease leading to 
hospitalization or death during the washout period. 
All patients met consensus criteria for acquired 
resistance (Jackman, JCO, 2010). 
Results: 61 patients were eligible. Baseline EGFR 
mutations were exon 19 deletions (41), L858R (19) 
and 1 patient with E709A & G791A. The median 
time on TKI before discontinuation was 19 months 
(range 7-78). 14 patients (23%; 95% CI 14-35%) 
experienced a disease Áare after discontinuation of 
geÀtinib or erlotinib. The median time to disease 
Áare from discontinuation of TKI was 8 days (range 
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assessment. The median duration of response to 
afatinib was 12 and 16 months, by independent 
review and investigator assessment, respectively. 
Median progression-free survival (PFS) was 4.6 
months. Two patients had primary tumour T790M 
mutations; one, harbouring L858R+T790M, had a 
long stable disease (308 days). At data cut-off, the 
25th percentile of overall survival was 10.6 months. 
Common adverse events included diarrhoea, rash/
acne, stomatitis, nail effects and decreased appetite. 
Trough plasma concentrations of afatinib were rather 
stable throughout courses 1–2, indicating that the 
pharmacokinetics of afatinib did not change during 
multiple administrations. 
Conclusion: This LUX-Lung 4 trial demonstrated 
that afatinib had clinically meaningful efÀcacy 
(including 8.2% overall response rate, 67% DCR 
>8 weeks and 4.6-month median PFS) in spite of 
investigating a patient population expected to have 
acquired resistance to Àrst-generation EGFR TKIs. 
Keywords: NSCLC, BIBW 2992, Phase II, LUX-
Lung 4
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O19.07 ACTIVITY AND TOLERABILITY 
OF COMBINED EGFR TARGETING 
WITH AFATINIB (BIBW 2992) AND 
CETUXIMAB IN T790M+ NSCLC 
PATIENTS
Leora Horn1, Harry J.M. Groen2, Egbert F. Smit3, 
Yelena Y. Janjigian4, Yali Fu5, Fei Wang5, Mehdi 
Shahidi6, Louis Denis7, William Pao8 
1Department Of Medicine, Vanderbilt University 
Medical Center/United States Of America, 
2University Medical Center Groningen/Netherlands, 
3Vrije University Medical Center Groningen/
Netherlands, 4Memorial Sloan-Kettering Cancer 
Center/United States Of America, 5Boehringer 
Ingelheim Pharmaceuticals Inc/United States Of 
America, 6Boehringer Ingelheim/United Kingdom, 
7Boehringer Ingelheim/Germany, 8Vanderbilt 
University/United States Of America
Background: Acquired resistance (AR) after initial 
beneÀt to erlotinib or geÀtinib is associated with a 
second site exon 20 EGFR T790M mutation (M) 
in >50% of cases. To date, there are no effective 
targeted therapies for NSCLC patients who develop 
T790M-mediated AR. Preclinical data suggest that 
afatinib, a potent ErbB family blocker, is active 
Chest Medical Center/Japan, 2Kobe City Medical 
Center General Hospital/Japan, 3Aichi Cancer 
Center Hospital/Japan, 4Cancer Center Hospital 
East/Japan, 5Cancer Institute Hospital/Japan, 
6Tohoku University/Japan, 7Nippon Boehringer 
Ingelheim/Japan, 8Boehringer Ingelheim 
Pharmaceuticals/United States Of America, 
9Boehringer Ingelheim/United Kingdom, 10Shizuoka 
Cancer Center/Japan
Background: There is an unmet medical need in 
non-small cell lung cancer (NSCLC) patients after 
failure of erlotinib or geÀtinib [Àrst-generation, 
reversible EGFR tyrosine kinase inhibitor (TKIs)], 
particularly in patients with T790M EGFR 
mutations, the most common mechanism of acquired 
resistance. Afatinib, an irreversible erbB family 
blocker, has a spectrum of preclinical activity that 
includes activity against T790M. Afatinib was tested 
in this Phase II study (LUX-Lung 4) in patients 
enriched for acquired resistance to Àrst-generation 
EGFR TKIs.
Methods: Patients in Japan with Stage IIIB/IV 
NSCLC (ECOG performance status of 0–1) who 
had radiographic conÀrmed progression after 1–2 
lines of chemotherapy and 12 weeks of erlotinib 
or geÀtinib received 50 mg afatinib orally once 
daily. The primary endpoint was objective tumour 
response. Primary tumour tissue and/or serum were 
tested for EGFR mutations just before administration 
of afatinib. Three trough plasma concentrations were 
investigated from each patient in treatment courses 
1 and 2. 
Results: Of 62 patients, 77% were female, 69% had 
never smoked, 47% had a performance status of 0, 
and the median age was 65 years. Ninety percent 
of patients had their primary tumour and/or serum, 
just before administration of afatinib, tested for 
EGFR mutations by local or central laboratories. Of 
these patients, 73% were EGFR mutation positive. 
11%, 79% and 10% had received prior erlotinib, 
geÀtinib or both, respectively. 65% had achieved 
prior response to erlotinib or geÀtinib. The median 
duration of prior erlotinib or geÀtinib was 58 weeks. 
There was typically a short interval (median 3 
weeks) between stopping prior erlotinib or geÀtinib 
and starting afatinib. For assessment of efÀcacy to 
afatinib, independent review revealed conÀrmed 
partial responses (PRs) in 8.2% of patients and a 
67% disease control rate (DCR) for at least 8 weeks. 
Similar rates of PR (13%) and disease control 
(72% for >8 weeks) were noted by investigator 
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Republic Of Korea/Korea, 2Cancer Biostatistics 
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Background: Sleeve lobectomy has been introduced 
as an alternative procedure for the patients whose 
pulmonary reserves are inadequate to tolerate 
pneumonectomy for lung cancer. However, 
sleeve lobectomy could lead severe anastomotic 
complications such as Àstulas and stenosis.
Wedge bronchoplastic lobectomy has been 
proposed as an alternative procedure to reduce these 
complications. The objective of this study was to 
evaluate the feasibility, safety and oncologic results 
of wedge bronchoplastic lobectomy.
Methods: We retrospectively reviewed the medical 
records of 191 patients who underwent wedge 
bronchoplastic lobectomy and mediastinal lymph 
node dissection from 2001 to 2009. Bronchoscopic 
follow-up was performed in 95 patients.
Results: There were 174 male patients with a mean 
age of 61.8 ± 8.2 years. The median follow-up 
duration was 28 months. Nine patients showed severe 
postoperative complications such as bronchopleural 
Àstula (n=3), necrosis at bronchoplasty site (n=1) or 
total obstruction (n=5). Operative mortality was 7 
(3.7%). Local recurrence was reported in 17 (8.9%) 
patients and regional recurrence was reported in 12 
patients. The 5-year overall survival was 62.8%. The 
5-year overall survival was 68.6% in N0, 64.4% in 
N1 and 52.6% in N2 (p=0.09). The 5-year overall 
freedom from local recurrence and locoregioanl 
recurrence were 85.3% and 78.9%, respectively and 
these were not different according to nodal status. 
Multivariate analysis showed that positive N1 and 
N2 node (p=0.036 and p=0.042, respectively) were 
the risk factors for overall survival after wedge 
bronchoplastic lobectomy.
Risk factors for overall survival after wedge 
bronchoplastic lobectomy using Cox proportional 
hazard model 
in T790M M cell lines such as H1975. Combined 
EGFR targeting with afatinib and cetuximab 
has induced near complete responses in T790M 
transgenic murine models. This is the Àrst clinical 
study to assess safety and preliminary efÀcacy of this 
combination in NSCLC patients. 
Methods: Eligible NSCLC patients with clinically 
deÀned AR (Jackman D. J Clin Oncol 2010; 28:357) 
received oral afatinib (A) 40 mg daily with escalating 
dose cohorts of biweekly cetuximab (C) and at 250 and 
500 mg/m2. Patients receiving the recommended Phase 
II dose (RP2D) were evaluated for objective response. 
Acquisition of tumour tissue for detection of T790M at 
or after emergence of AR was mandated. 
Results: 28 patients were treated, 24 received the 
predeÀned maximum dose = RP2D: A 40 mg + C 
500 mg/m2. No dose-limiting toxicity was observed. 
The common adverse events were grade 1/2 rash 
(29%/46%) and diarrhoea (46%/21%), respectively 
and three (12.5%) patients had grade 3 rash. Disease 
control was observed in all patients enrolled at RP2D 
(tumour size reduction up to 76%, treatment duration up 
to 6+ months so far). ConÀrmed partial responses (PRs) 
were seen in 8/22 (36%, 95% CI: 0.17–0.59) evaluable 
patients, including 4/13 (29%) conÀrmed PRs in 
T790M+ NSCLC. Enrollment continues in an 80-patient 
expansion cohort meeting strict criteria for AR. 
Conclusion: Combined EGFR targeting with 
afatinib and cetuximab is tolerable at RP2D and 
shows encouraging clinical activity following AR 
to prior erlotinib or geÀtinib, including T790M+ 
NSCLC. Updated safety and efÀcacy including data 
from the expansion cohort will be presented. 
Keywords: EGFR targeting, Afatinib, BIBW 2992, 
Non-small cell lung cancer
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O20.01 WEDGE BRONCHOPLASTIC 
LOBECTOMY FOR NON-SMALL CELL 
LUNG CANCER AS AN ALTERNATIVE 
TO SLEEVE LOBECTOMY
Seong Yong Park1, Hyun-Sung Lee1, Hee-Jin Jang1, 
Jungnam Joo2, Bin Hwangbo1, Hee Seok Lee1, Geon 
Kook Lee1, Moon Soo Kim1, Jong Mog Lee1, Jay il 
Zo1 
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75 robotic lobectomy cases by a single surgeon 
are reviewed. Each step, from port placement 
to exctraction of the specimen is analyzed with 
discussion of potential pitfalls at each step.
Results: The Àrst 75 robotic lobectomies by a single 
surgeon are reviewed. The procedure is broken 
down into 7 steps: 1. Patient positioning and port 
placement. 2. Early dissection. 3. Identifying and 
dividing lobar veins and arteries. 4. Completion of 
Àssure. 5. Dividing the bronchus and extraction of 
the specimen. 6. Lymph node dissection. 7. Pain 
management and control of air leaks. Each step has 
its own set of problems which will vary depending 
on the target lobe. Having a plan for each lobe and 
understanding the potential problems at each step 
signiÀcantly reduces the conversion rate and the 
operating room time. 
Conclusion: Robotic approach to lobectomy offers a 
number of advantages over the VATS approach. The 
robotic procedure is however a signiÀcant departure 
from standard surgical techniques and requires 
the development of new set of skills. The robotic 
approach has a unique set of potential problems 
that must be understood and anticipated in order to 
minimize conversion and reduce operating room 
time.
Keywords: lobectomy, Davinci, Robotic
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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O20.03 USEFULNESS OF ECG-GATED 
MULTI DETECTION COMPUTED 
TOMOGRAPHY (MDCT) FOR 
EVALUATION OF CARDIOVASCULAR 
INVASION IN THORACIC MASS
Masanori Tsuchida1, Takehisa Hashimoto1, Hirohiko 
Shinohara1, Hiroyuki Ishikawa2 
1Thoracic And Cardiovascular Surgery, Niigata 
University Graduate School Of Medical And Dental 
Sciences/Japan, 2Radiology, Niigata University 
Graduate School Of Medical And Dental Sciences/
Japan
Background: One of the newest CT application 
technologies is cardiac synchronized image 
reconstruction. ECG synchronized technique on 
multi-slice CT provide the thinner and faster scan 
Univariate analysis 
Multivariate 
analysis 
HR (95% CI) p value HR (95% CI) p value 
Age 1.039 (0.998~1.082) 0.062 … … 
Gender  
(male vs female) 
2.112 (0.511~8.727) 0.302 … … 
Preoperative 
chemotherapy 
1.628 (0.723~3.662) 0.239 … … 
T stage 
T2 (vs T1) 1.802 (0.777~4.176) 0.170 … … 
T3 (vs T1) 1.630 (0.602~4.417) 0.337 … … 
T4 (vs T1) 2.256 (0.658~7.732) 0.196 … … 
Nodal status (N stage) 
N1 (vs N0) 2.203 (1.019~4.763) 0.045 … … 
N2 (vs N0) 2.241 (0.958~5.244) 0.063 … … 
Resection margin 
(above the dysplasia) 
0.509 (0.123~2.105) 0.351 
2.311 
(1.057~5.051) 
0.036 
Concomitant 
pulmonary angioplasty 
1.710 (0.724~4.042) 0.221 
2.426 
(1.032~5.701) 
0.042 
Severe bronchial 
complications 
0.622 (0.085~4.531) 0.639 … … 
Postoperative 
chemotherapy 
1.600 (0.884~2.897) 0.120 
1.778 
(0.978~3.233) 
0.059 
Postoperative 
radiotherapy 
0.606 (0.226~2.377) 0.734 … … 
Conclusion: Wedge bronchoplastic lobectomy 
for lung cancer is a feasible procedure without 
compromising the oncological principles. It could 
be chosen as the Àrst choice as an appropriate 
alternative to sleeve lobectomy and pneumonectomy 
regardless of nodal status. 
Keywords: Survival analysis, bronchoplastic 
procedure
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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O20.02 HOW TO DO A ROBOTIC 
LOBECTOMY
Arthur T. Martella, Jane Upson 
Surgery, University Of Pennsylvania/United States 
Of America
Background: Robotic lobectomy is an alternative 
approach to minimally invasive lobectomy that 
offers some advantages over the traditional VATS 
approach. It is, however, new technology with its 
own set of limitations and technical difÀculties.
Methods: We examine the evolution of the steps 
involved in performing a Totally Endoscopic 
Lobectomy with the DaVinci Robot. The Àrst 
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adjacent cardiovascular structures. ECG-gated 
MDCT can provide additional information and 
improve the accuracy of preoperative staging for 
predicting cardiovascular invasion of a thoracic mass 
by evaluating 
Keywords: ECG-gated MDCT, Cardiovascular 
invasion, Thoracic mass
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O20.05 PHOTODYNAMIC THERAPY 
FOR NSCLC: A SINGLE INSTITUTION 12 
YEAR REVIEW
Patrick Ross, Susan Moffat-Bruce, Megan 
Hendershot, Edmund Kassis, Krista Maxey, John 
Wilson 
Thoracic Surgery, Ohio State University/United 
States Of America
Background: Photodynamic therapy (PDT) is an 
endoluminal treatment which can be utilized for 
bronchogenic carcinoma. A unique combination 
of a photosensitizing drug and an activating non 
thermal laser light (630nm), PDT can treat malignant 
lesions throughout the tracheo bronchial tree. PDT 
was initially conceived as therapy for palliation 
of symptoms in advanced NSCLC. Control of 
hemoptysis and relief of airway obstruction are 
common indications. This series evaluates the 
outcomes at a comprehensive cancer center where 
PDT has been incorporated into curative and 
palliative therapy for early and advanced NSCLC. 
Methods: A retrospective review of medical records 
and the cancer registry database was performed 
for all cancer patients treated with PDT at our 
institution between 1998 and 2010. The cohort of 
NSCLC patients comprising this study were selected 
from this population. All patients received 2mg/kg 
intravenously of Photofrin as the photosensitizing 
drug. Dosimetry was 200 joules/cm for Àrst light 
application. Initial light application occurred 48 
hours after drug injection. Bronchoscopy for tumor 
debridement was performed 48 hours after each light 
application. Subsequent photosensitizing injections 
were separated by at least 4 weeks. 
Results: We treated 681 patients with PDT during 
the study interval. There were 411 patients with 
bronchogenic carcinoma; 381 patients had NSCLC 
and formed the cohort for analysis. There were 
255 males (67%) and 126 females (33%).The 
average age was 61.8 years. The histology was 
than that of the single detector CT within one breath-
hold. To determine the feasibility and usefulness of 
ECG-gated Multi Detection Computed Tomography 
(MDCT) for evaluating cardiovascular invasion of a 
thoracic mass, the sliding motion between the mass 
and adjacent structures were determined by this 
technology. 
Methods: Twenty-Àve patients with regular sinus 
rhythm (20 males and 5 females, mean age 57 years) 
were included in this study. They all had thoracic 
masses with equivocal cardiovascular invasion on 
regular chest CT scan that was surgically conÀrmed. 
The pathologic diagnoses were thymoma in 12, 
thymic cancer in 2, lung cancer in 6, and other 
thoracic tumor in 5. The evaluated cardiovascular 
structures on the ECG-gated MDCT were as follows: 
aorta in 19, main pulmonary artery (MPA) in 10, 
pericardium in 6, atrium in 4, superior vena cava 
(SVC) and brochiocephalic vein (BCV) in 8. Two 
radiologists independently reviewed the ECG-gated 
MDCT to evaluate invasion based on the presence 
or absence of sliding motion between the mass and 
adjacent structures. The results were compared to the 
surgical results. 
Results: The ECG-gated MDCT images showed 
the presence of sliding motion in 39 structures in 
25 patients, which were surgically conÀrmed as 
not being invaded except one case of BCV. The 
ECG-gated MDCT revealed the absence of sliding 
motion in 8 structures (two aortic arch, three MPA, 
one pericardium, one atrium, and three SVC and 
BCA in 8 patients). These structures were surgically 
conÀrmed as tumor invasion, except for one distal 
aortic arch in one patient, which were falsely 
diagnosed as being invaded. The pericardium, 
cardiac chambers, and MPA usually showed 
excellent sliding motion between the thoracic mass 
when there was no adhesion. Absent or minimal 
motion of the distal aortic arch caused the absence 
of sliding motion on the ECG-gated MDCT. 
Conclusion: The presence of sliding motion may 
indicate that thoracic mass does not invade into 
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Background: Accurate prediction of functional loss 
after lung resection (PPO FEV1 and PPO DLCO), 
by regional lung perfusion together with spirometry, 
is well established. A non-invasive, non-radiation 
Vibration Response Imaging (VRIxp) device has 
been developed that analyzes lung sounds and 
calculates quantitative regional acoustic energy. 
A multi-center study is underway to corroborate 
preliminary single-center results that quantitative 
lung sound measurements are comparable to 
quantitative lung perfusion for estimating PPO and 
predicting perioperative risk.
Methods: Currently, 120 patients have been enrolled 
in the study at 6 USA sites; 95 patients met eligibility 
for inclusion in this preliminary analysis. All subjects 
underwent pulmonary function tests, quantitative 
perfusion scans and VRIxp testing before resection 
(84 lobectomies, 12 pneumonectomies) for non-
small cell lung cancer or other intra-thoracic 
malignancies. PPO values were calculated by 
subtracting the percent functional uptake (perfusion) 
or percent acoustic energy (VRI) of the lung 
segments to be resected from the total number of 
segments in that lung; calculations were compared 
for both methods at baseline.
Results: High correlation was found between the 
predictions based on VRI values and those based 
on perfusion (r=0.98 for PPO FEV1% and 0.99 for 
PPO DLCO%). Agreement rate between the two 
methods was 92% for PPO FEV1% and 87% for 
PPO DLCO%; 96% (91/95) of the estimations were 
within 10%. For PPO FEV1% estimations (Table) 
there was 100% agreement for the 16 estimations of 
high surgical risk (PPO FEV1 <=40%). There was 
good agreement between the two methods by the 
Bland-Altman plot (-6.1% to 8.3% for PPO FEV1%; 
mean difference 1.1%±7.2% and -4.9% to 6.8% 
for PPO DLCO%; mean difference 0.96%±5.9%). 
Actual FEV1% of 62%±13% (4.6±2 months post-
op) was compared to PPO predictions in 20 patients: 
54%±13% and 55±16% based on perfusion and 
VRI, respectively. VRI predictions correlated better 
than perfusion with actual values (r=0.7 and 0.6). 
Actual post-op DLCO% was 58%±20% compared 
to 50%±18% and 49±16% for VRI and perfusion, 
respectively. VRI had higher correlation than 
perfusion (r=0.8 and 0.7).
Conclusion: Predictions based on lung function 
testing and quantitative breath sound measurements 
demonstrated high correlations with quantitative 
perfusion estimations and corroborate previously 
published results. Given its simplicity of operation, 
squamous cell in 53%, adenocarcinoma in 10% and 
undifferentiated NSCLC in 37%. The stages were 
Stage I 18%, Stage II 10%, Stage III 43%, Stage 
IV 23%. The indications for PDT were as follows: 
Curative 7%, Induction 29%, Symptom Control 
44%, Palliation 20%. All patients received 200 J/
cm for the Àrst light application; 345 (90%) received 
a second application and 27% received 3 or more 
light applications following a single photosensitizing 
drug injection. The majority (331) of patients had a 
single course of therapy; 10 patients had 3 or more 
courses of injection and light application. There 
were 4 severe photosensitivity reactions. There were 
no perforations of the airway. Tracheobronchial 
strictures occurred in 2 patients; both patients 
required dilation. The 30 day mortality was 16% and 
90 day mortality was 18% reÁecting the advanced 
stage of the cohort. Aggregate survival analysis 
showed 60% 1 year, 30% 2 years, 20% 3 years , 16% 
4 years, and 12% 5years. 
Conclusion: PDT has been incorporated into the 
management of all stages of NSCLC as deÀnitive 
therapy and for control of symptoms. PDT for 
NSCLC of the central airways is associated with low 
morbidity and mortality. Photosensitivity reactions 
are infrequent with proper patient education. 
Multiple courses of PDT can be performed without 
additional risk. Importantly, PDT can be used 
successfully in combination with other therapeutic 
modalities including, external beam radiation, 
brachytherapy, chemotherapy and surgical resection. 
Keyword: photodynamic therapy
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O20.06 ESTIMATING POSTOPERATIVE 
LUNG FUNCTION AND SURGICAL 
RISK OF LUNG RESECTION BY 
QUANTITATIVE BREATH SOUND 
MEASUREMENTS
Frank C. Detterbeck1, Merav Gat2, Daniel Miller3, 
Seth Force3, Cynthia Chin4, Hiran C. Fernando5, 
Joshua R. Sonett6, Rodolfo C. Morice7 
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patients had p-N3. We will report the investigation 
of the prognoses of left non small cell lung cancer 
(NSCLC) patients who underwent initially our 
extended bilateral mediastinal dissection, focused on 
the patients with N2 and N3 disease. According to 
the macroscopic dissection procedure, dissection of 
the lymphatics from the lungs to the supraclavicular 
lymph nodes was performed by sequential 
removal of the related organs. We systematically 
compared and reviewed the route of lymphatic 
communications to the contra lateral side with the 
anatomical signiÀcance of left-to-right lymphatic 
communications in the bilateral mediastinal lymph 
nodes.
Results: The overall 5-year survival rate Kaplan-
Meier method, including operative deaths and deaths 
due to unrelated diseases, was 48.4% in p-N2 left 
lung cancer patients. With respect to the p-N3 factor, 
the 5-year survival rate was 49.9% in p-N3±26.7%in 
N3 (neck lymph node metastases case) .
Conclusion: We found various lymphatic 
communications such as between the left and right 
mediastinal lymph nodes and around the trachea in 
terms of clinical and anatomical status. The overall 
5-year survival rate was 48.4% in p-N2, 49.9% in 
p-N3±, and 26.7% in N3³ left lung cancer patients. 
Our results suggest the importance of the dissection 
of the bilateral mediastinal lymph nodes by median 
sternotomy.
Keywords: Median Sternotomy, ND3, bilateral 
mediastinal lymph nodes
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
lack of radiation and the non-invasive nature of 
VRIxp testing, it could be a good alternative to 
quantitative perfusion scans in preoperative lung 
resection assessment.
Table 1. Distribution of PPO FEV1% Estimations 
Calculated by Perfusion and by VRI Quantitative 
Lung Sound Measurements
VRI PPO 
Perfusion PPO 
<40% 40-60% 60-80% >80% Total 
<40% 16 2 0 0 18 
40-60% 0 34 3 0 37 
60-80% 0 2 30 0 32 
>80% 0 0 1 7 8 
Total 16 38 34 7 95 
% agreement 100% 89% 88% 100% 
% agreement for all distribution ranges = 92% 
(87/95) 
Keyword: Pulmonary function
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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O20.07 SYSTEMATIC BILATERAL 
MEDIASTINAL NODAL DISSECTION 
FOR N2,N3 LEFT LUNG CANCER 
THROUGH MEDIAN STERNOTOMY
Shingo Ikeda, Toshiya Yokota, Tatsuhiro Hoshino, 
Masashi Mikubo, Masahito Naitoh, Enjo Hata 
Surgical Department Of Respiratory, Mitsui 
Memorial Hospital/Japan
Background: Patients with p-N2, N3 cases have a 
poor prognosis, and lung operation is not normally 
indicated. We have performed bilateral mediastinal 
lymph node dissection by median sternotomy 
to resect lung cancer and dissect the bilateral 
mediastinal lymph nodes. However, some studies 
have examined the communication between the left 
and right tracts in lung cancer cases, we anatomically 
analyzed this technique, and conÀrmed its clinical 
result.
Methods: We have performed this operation in 265 
patients with primary left lung cancer excluding 
small cell carcinoma and stageIV since 1987. 43out 
of 265 patients had p-N2 lymph node metastases, 33 
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month assessment. Factors signiÀcantly associated 
with successful quitting were baseline readiness to 
quit and a need for hospitalization during cancer 
treatment. Those who quit had signiÀcantly lower 
distress scores and higher SCQoL self-control 
domain scores at 12 months than non-quitters. 
Conclusion: Patients still smoking when diagnosed 
with a curable cancer are highly-addicted smokers 
who require intensive support to quit. Those who do 
quit report less distress and a greater sense of self-
control. Population measures to stop people starting 
smoking are essential. 
Keywords: Smoking, quitting, supportive care
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
Nursing I Tuesday, 5 July 2011 10:30-12:00
O21.02 BREATHE EASY: A 
PILOT PROJECT FOR DYSPNEA 
MANAGEMENT IN LUNG CANCER 
PATIENTS
Lida Ahmadi1, Tracey Das Gupta2, Tammy Lilien3, 
Magdalene Winterhoff2, Leslie Gibson3, Anita 
Chakraborty2, Giovanna Sirianni2, Jeff Myers2, Yee 
C. Ung4 
1Radiation Oncology, Odette Cancer Centre/Canada, 
2Odette Cancer Centre/Canada, 3Sunnybrook Health 
Sciences Centre/Canada, 4Dept Radiation Oncology, 
Odette Cancer Centre/Canada
Background: Dyspnea is the subjective experience 
of breathing discomfort and is present in 60-70% 
of lung cancer patients. It is a distressing symptom 
which is often inadequately evaluated and managed 
in lung cancer patients. A nursing led initiative 
was piloted to screen, evaluate and educate lung 
cancer patients at a regional cancer centre involving 
a multidisciplinary and interprofessional team 
consisting of nurses, occupational therapist, social 
worker, palliative care physicians and lung cancer 
oncologists. This pilot project used the Edmonton 
Symptom Assessment System (ESAS) to screen 
patients for dyspnea and then depending on the 
severity, the patients were offered educational 
materials, enrollment in a breathing exercise class or 
opiod narcotics for symptom control. 
Methods: Lung cancer patients seen in the outpatient 
department of a regional cancer centre are screened 
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O21.01 A PROSPECTIVE COHORT 
STUDY OF CURRENT AND RECENT EX-
SMOKERS OFFERED ENROLMENT IN 
A SMOKING CESSATION PROGRAM 
FOLLOWING DIAGNOSIS OF A 
POTENTIALLY CURABLE CANCER
Linda Mileshkin1, Ingrid Plueckhahn2, Deborah 
Cruickshank2, Leonid Churilov3 
1Division Of Cancer Medicine, Peter MacCallum 
Cancer Centre/Australia, 2Peter MacCallum Cancer 
Centre/Australia, 3Florey Neuroscience Institutes/
Australia
Background: There is good evidence that people 
treated for curable cancers have better survival rates 
if they quit smoking. A cancer diagnosis provides a 
“teachable moment” when healthcare providers can 
offer smoking-cessation treatment. This prospective 
single-arm study aimed to assess the impact of a 
tailored smoking-cessation intervention for cancer 
patients. 
Methods: Eligible patients had recently diagnosed 
curable cancer, were planned for or were 
receiving treatment with curative intent and were 
current smokers or recent quitters (<30days). 
The intervention involved an initial face-to-face 
motivational interview and regular follow-up by 
a trained quit counsellor nurse. Free nicotine-
replacement therapy and/or access to other 
appropriate pharmacotherapy was provided. Quit 
rate was measured by self-report with biochemical 
conÀrmation, and patient distress and quality of 
life using the distress thermometer and smoking-
cessation quality of life questionnaire (SCQoL) 
respectively. The primary end-point was the 
prolonged abstinence rate at 12 months. 
Results: A pragmatic sample of 71 patients (61% 
male) with a mean age of 54 (range 27-71) was 
accrued. Forty-one pts (58%) had a smoking-related 
cancer with 27 (38%) employed and 24 (34%) living 
with another smoker. Most patients were heavily 
addicted and had started smoking at a mean 16 
years (range 7-25). The prolonged abstinence rate 
at 12 months was 24% (95%CI 14-36%) with 37% 
having not smoked in the 7 days prior to the 12 
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O21.03 AN INTER-PROFESSIONAL 
MODEL OF CARE TO IMPROVE 
SURGICAL OUTCOMES IN 
THORACIC ONCOLOGY OR “BETTER 
PREPARATION EQUALS IMPROVED 
PATIENT OUTCOME”
Chantal Bornais1, Christine Blais1, L. Murphy2, P. 
Chamberland3 
1Integrated Cancer Program, The Ottawa Hospital/
Canada, 2Social Work, The Ottawa Hospital/Canada, 
3Physiotherapy, The Ottawa Hospital/Canada
Background: In January 2007, the Thoracic Cancer 
Assessment Clinic (CAC) in Ottawa, Canada, 
opened with a mandate to provide rapid assessment, 
diagnostic services and initiation of treatment to 
patients with suspected or newly diagnosed lung 
cancer. Since its inception, the CAC has developed 
many new methods of caring for lung cancer patients 
with the intention to provide as much information 
as is available to patients regarding the cancer care 
system; including diagnostic processes, treatment 
and support. The previous model of care involved 
eligible surgical patients having all the pre-operative 
preparation in a pre-admission unit (PAU) that 
services all surgical areas within a large urban 
teaching hospital. With this model, lung cancer 
patients were reporting feeling unprepared for 
surgery and recovery. Indeed, feedback from the in-
patient staff substantiated this viewpoint as patients 
were not participating fully in their recovery with 
discharge delays occurring in some cases. 
Methods: To address this issue, the CAC staff has 
developed a teaching session that replaces the PAU 
teaching. The newly developed session provides an 
inter-professional focus involving nursing, social work, 
physiotherapy, anaesthesia and thoracic surgeons to 
maximize patient comprehension and involvement in 
the preparatory and recovery phases of surgical care. 
Results: The initial goal of increasing patient 
knowledge and thereby reducing anxiety levels 
regarding upcoming surgery was achieved. More 
importantly, many other unplanned beneÀts also 
became apparent. Feedback received from patients 
and their support systems including family and 
friends both pre-operatively and post operatively 
indicates the value of this session beyond the needs 
of the patient. Assessment of potential discharge 
planning issues at time of teaching has evolved as an 
important added beneÀt from this session. 
using ESAS evaluating symptoms of pain, fatigue, 
nausea, depression, anxiety, drowsiness, appetite, 
overall well being and dyspnea. The ESAS is a 10 
point score that rates the severity of each symptom 
from 0 to 10. The severity can be divided into low 
(scores of 1-3), moderate (scores of 4-6) and severe 
(scores of 7-10). Any patient who rates a dyspnea 
score of 4 or higher is immediately identiÀed and 
then evaluated by an oncology nurse to verify 
the severity of the dyspnea. The patient is then 
evaluated by the oncologist and the ESAS scores 
reviewed. Any reversible or medically treatable 
causes of dyspnea are evaluated by the oncologist 
and appropriate care given according to the 
etiology of the dyspnea. In addition the oncologist 
evaluates the need for any intervention with opiods 
for symptom control. If patients are started on 
opiods the oncology nurse contacts the patient 
by telephone within 48-72 hours to evaluate the 
effectiveness of the intervention. The oncology nurse 
further evaluates the patients using a qualitative 
questionnaire and then discusses with the patient any 
educational material on dyspnea management and 
also offers enrollment to the Breathe Easy dyspnea 
class. Patients are asked to complete the EORTC 
QLQ QC30 questionnaire prior to the class. At the 
Breathe Easy class, participants are taught breathing 
exercises as well as other techniques to manage 
their dyspnea. About 4-6 weeks after the class, 
participants are contacted again to repeat the ESAS, 
EORTC QLQ QC30, Canadian Problem Checklist 
and a satisfaction survey. 
Results: This is an ongoing pilot study. Qualitative 
data on patient acceptance of the Breathe Easy class 
is encouraging. ESAS and EORTC QLQ QC30 data 
have been collected on the Àrst 12 patients enrolled 
on the Breath Easy class. Followup reevaluation 
scores will be updated. 
Conclusion: This nursing led initiative on dyspnea 
management has enhanced interprofessional 
collaboration among health care professionals caring 
for lung cancer patients. The Breathe Easy class is 
feasible and has had good patient satisfaction. It 
is hoped the active screening and intervention for 
symptoms of dyspnea will enhance the care of our 
lung cancer patients and decrease the need for these 
patients to be seen in emergency care. 
Keywords: dyspnea, Lung cancer, breathing 
exercises
S368 Copyright © 2011 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
Results: A total of 44 evaluable patients were 
enrolled in the study. Twenty patients were women 
and 24 were men. Forty patients had lung cancer, 37 
non small cell lung cancer and four small cell lung 
cancer histology. Two patients had a diagnosis of 
esophageal cancer and two had pancreatic cancer. 
Eighteen patients had locally advanced cancers 
and 26 had advanced cancers. All but one patient 
received chemotherapy. The median score for the 
baseline KPS was 80 with a range of 50-90, the 
median baseline score for the LCSS item was 47 
with a range of 0-100 and the SF-36 baseline score 
median was 35 with a range of 0-90. When the 
KPS and SF-36 scores were analyzed, there was a 
positive correlation of 0.50 with a signiÀcant Wald 
test p-value < 0.0001. The KPS and LCSS Normal 
Activity scores correlated negatively with a score of 
-0.39 with a signiÀcant Wald test p-value of 0.01. 
Conclusion: Patient reported performance status 
on the SF-36 Health Survey via web-based tools 
correlated positively with KPS as rated by a health 
care provider during clinic visits. However, the KPS 
and normal activity score on the LCCS correlated 
negatively. The disparity between patient responses 
to the question, “How much has your illness 
affected your ability to carry out normal activities?” 
and observer rating of the KPS raises questions 
about routine use of the KPS to determine patient 
functioning. A web based patient completed rating 
tool such as the SF-36 or LCSS may provide more 
accurate measurements of a patient’s performance 
status than subjective rating by a healthcare provider. 
Keywords: Karnofsky Performance Scale (KPS), 
SF-36, Lung Cancer Symptom Scale (LCSS), 
performance status
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O21.06 CHEMOTHERAPY REVIEW BY 
SPECIALIST LUNG CANCER NURSES
Rachel Thomas, Sarah Compton 
Medical Oncology, Guy’s And St Thomas’ NHS 
Foundation Trust/United Kingdom
Background: With appropriate training and 
competencies nurses can review patients receiving 
chemotherapy. This utilises nurse and doctor skills 
more efÀciently and provides opportunities to 
improve the quality of patient care. A patient survey 
identiÀed dissatisfaction with the oncology service 
at Guy’s hospital. SpeciÀcally, it highlighted a lack 
Conclusion: Although initially designed based on 
health care team expectations for patient recovery 
and observed patient struggles during preparation 
for, and recovery from surgery, the pre-operative 
teaching session continues to evolve. The session is 
now reÁective of the needs of patients as dictated by 
the patient population and their support systems. 
Keywords: pre-operative teaching, Interprofessional 
care
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O21.05 COMPARISON OF PERFORMANCE 
STATUS AS RATED BY PATIENTS USING 
WEB-BASED QUALITY OF LIFE TOOLS 
AND KARNOFSKY PERFORMANCE 
STATUS RATINGS AS DETERMINED BY A 
HEALTHCARE PROVIDER
Paula A. Caron, Ellen Parker, Jiang Gui, Mark Carey, 
Ian Williams, Konstantin H. Dragnev, James R. Rigas 
Thoracic Oncology, Dartmouth Hitchcock Medical 
Center/United States Of America
Background: Performance status is a crucial 
variable considered when patients are enrolled 
in clinical trials. Multiple patient administered 
validated tools exist to measure quality of life and 
functional status. The Karnofsky Performance Status 
(KPS) scale is a clinician driven tool to measure 
performance status. Patient performance status is 
usually based on the KPS rather than a patient’s self 
rating using a validated tool. 
Methods: Patients enrolled in a pilot web-based 
study of cancer patients with anemia receiving 
growth factor support completed four web-based 
assessment tools using a PC tablet. The study tools 
were completed at time of enrollment for a baseline 
score and every three to four weeks while the patient 
was on study. For the purpose of this analysis, the 
physical functioning health domain score from each 
entry date of the SF-36 Health Survey, and the score 
for each entry of the normal activity question of the 
Lung Cancer Symptom Scale (LCSS) was compared 
to the KPS score . Each completion date of the SF-
36 and the LCSS was considered a data point for 
comparison with the corresponding KPS score for 
that date. Medical records were reviewed to obtain 
KPS scores corresponding to dates the LCSS and 
SF-36 were completed on-line by patients. A linear 
mixed effect model was employed to account for 
variation introduced by patients’ multiple visits. 
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potential of facilitating communication, maintaining 
continuity of care and improving overall outcomes as 
patients travel through their experiences enrolled in 
clinical trials. 
Methods: This presentation will describe the 
importance of optimal patient management in a 
clinical trial in order to improve outcomes for lung 
cancer patients. Obtaining unique data related to how 
a patient’s personal experience in conducting a trial 
affects his outcome, is very useful. The important 
roles/responsibilities of the clinical research team 
members will be described.
Results: The invaluable collaborative relationship 
between the research team and the IPO in ensuring 
continuity for a complex treatment plan will be 
outlined. 
Conclusion: In conclusion, the potential beneÀts of 
the involvement of the research team and IPO in the 
conduct of clinical trials for lung cancer patients will 
be presented. Future directions will be proposed.
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O22.01 BLOOD-BORNE CANCER CELLS 
IN PULMONARY VEINS IN SURGICAL 
NON-SMALL CELL LUNG CANCER 
(NSCLC)
Samer Alchab1, Stephane Vignes2, Elisabeth 
Memba1, Bernard Bazelly2, Jalal Assouad2, Valerie 
Gounant2, Jean-François Bernaudin1, Dominique H. 
Grunenwald3 
1Histology And Tumor Biology, Er2upmc Hôpital 
Tenon Paris France/France, 2Thoracic Surgery, 
Hopital Tenon./France, 3Thoracic Surgery, Hopital 
Tenon. University Of Paris Vi/France
Background: Patients with NSCLC have a high risk 
of relapse even after complete surgical resection. 
The presence of cancer cells in the pulmonary 
venous blood draining the tumour may be a potential 
primary source of haematogenous dissemination 
even at the time of surgery.
Methods: A consecutive series of 16 patients with 
completely resected primary NSCLC, was studied. 
Blood samples were collected on EDTA from the 
pulmonary vein draining the tumor after vessel ligation. 
of pro-active support, assessment and monitoring 
of patients following the Àrst cycle of treatment. In 
addition patients were waiting between 60 and 90 
minutes to see the oncologist. 
Methods: Following a service review and discussion 
with medical staff and senior management, a 
CNS-led clinic was proposed to address the issues 
identiÀed by the survey. Nurses will have completed 
a chemotherapy course and have competencies in 
running a nurse-led clinic. Initially the clinic will 
include patients receiving the oral and intravenous 
agents, erlotinib, vinorelbine and cisplatin. The CNS 
carries out consent, a pre-treatment consultation 
talk and all treatment reviews. The oncologist sees 
the patient following scans and also if they meet the 
toxicity speciÀc indications for doctor review. 
Results: Patients undergo a comprehensive holistic 
assessment in the new clinic. Waiting time have been 
reduced. The clinic runs in parallel to the oncologist 
clinic who are available for support. The weekly 
clinic is run by one of two nurses, providing cover 
for leave and sickness. 
Conclusion: The new clinic provides a high quality 
nurse-led service with continuity of care and less 
waiting for patients. Nurses are more likely to 
perform a comprehensive protocol-led and holistic 
review. Doctor time is released to see challenging 
and clinical trial patients. Future plans include 
an audit of the new service, expansion into other 
treatment areas with additional clinics and nurse 
prescribing. 
Keyword: Nurse Led On Treat Patient Clinic
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O21.07 CLINICAL RESEARCH TEAM 
AND “ADVANCED PRACTICE NURSE” 
COLLABORATION: IMPROVING 
OUTCOMES THROUGH OPTIMAL 
MANAGEMENT.
Penny Chipman, Carol Burnett 
Department Oncology, Clinical Research Program, 
Mcgill University/Canada
Background: Lung cancer care teams face 
signiÀcant challenges in supporting patients and their 
families throughout the rapid and often short illness 
trajectory of lung cancer patients. The important 
collaborative role between the clinical research 
team and the advanced practice nurse, known as 
”InÀrmier(e)Pivot (IPO)” in Quebec, Canada, has the 
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Background: Mitosis is a highly complex series 
of events that requires careful coordination to 
navigate successfully. Protein phosphorylation 
by a small number of kinases, in particular by the 
Aurora, CDK1-cyclinB and Polo-like kinase 1 (Plk1) 
enzymes, orchestrates almost every step of mitosis, 
from entry to cytokinesis. However, these enzymes 
are also frequently dysregulated in many human 
cancers, including cancers of the lung. To discover 
more about the respective functions of Aurora A, 
Aurora B and Plk kinases, we mapped mitotic 
phosphorylation sites to these kinases through the 
combined use of quantitative phosphoproteomics 
and selective targeting of kinase activities by 
small molecule inhibitors. This work uncovers 
new functional roles and establishes new substrate 
recognition motifs for these kinases, and provides 
an analytical template for further use in dissecting 
kinase signaling events in other areas of systems 
biology and translational biomedical research.
Methods: To scan mitotic cells for substrates 
of the Aurora A, Aurora B, and Plk enzymes, 
we quantitatively determined differences in the 
phosphorylation status of proteins from mitotically 
arrested HeLa cells treated with respective kinase 
inhibitors by SILAC, in which control (light) 
cells were treated with Taxol and MG132, while 
kinase-inhibited (heavy) cells were treated with 
Taxol, MG132 and either MLN8054, AZD1152, 
or BI2536 (selective small molecules that target 
Aurora A, Aurora B, and Plk enzyme activities). 
Heavy and light cells were mixed, lysed, digested, 
and processed for phosphorylation by strong cation 
exchange (SCX) chromatography, followed by TiO2 
treatment to enrich for phosphorylation and analysis 
by LC-Orbitrap MS/MS.
Results: Over the course of eight separate SILAC 
experiments we sequenced a total of almost 900,000 
redundant phosphopeptides on 6061 mitotic proteins. 
Using clustering methods we were able to connect 
127 sites on 101 proteins to Aurora kinase A activity, 
165 sites on 127 proteins to Aurora kinase B activity, 
and 486 sites on 334 proteins to Plk activity. Each 
of these datasets was interrogated separately for 
motifs, revealing both previously described but also 
undescribed linear substrate sequence elements that 
were sufÀcient for enzyme targeting in cells. In 
addition, we were able to observe cross-regulation 
of Aurora kinase A and Plk kinase activities on 
substrates of the cognate kinases, conÀrming 
previous reports of these relationships and 
expanding our view of the biological role that this 
Within 2 hours, blood mononuclear cells were collected 
after Ficoll gradient centrifugation and cancer cells 
were selected after incubation with anti-CD326EpCAM 
microBeads and magnetic isolation [MACS Cell 
isolation Technology (Milteny Biotec France)]. 
Cytospins of the cells obtained either without ( n:10) 
or after (n:6) magnetic isolation were immunolabelled 
with anti CK antibody [Pan-Cytokeratin Mouse 
Monoclonal Antibody NovocastraTM] for epithelial 
characterization. Preliminary experiments have 
been done using A549 cell line and peripheral blood 
mononuclear cells from donors.
Results: Pulmonary venous blood sampling then 
isolation by Ficoll-Hypaque allowed to collect (20 
± 10) ml of blood and (37 ±10) x106 mononuclear 
cells or (1.8 x106) cells/ml. Using the magnetic 
isolation technique, it was possible to recover an 
average of 10 cytokeratinplus cancer cells per 20 
x106 mononuclear cells or per 15 ml of blood. 
Cytokeratinplus cells were detected in respectively 
7/10 and 6/6 patients without or after magnetic 
isolation. Detection of cancer cells without magnetic 
isolation which was a laborious and tedious method 
was obtained in 70% of the patients, while after 
isolation 100% of the samples contained cancer cells. 
This last method provided the necessary sensitivity 
for the detection and isolation of very small numbers 
of circulating tumor cells.
Conclusion: This work has enabled us to develop a 
method for collecting tumor cells in the pulmonary 
venous blood draining NSCLC at time of surgery. 
The results show that it is an important phenomenon 
found in 81.25% of patients. This method allows 
to study more thoroughly the characteristics of 
circulating cancer cells in NSCLC.
Keywords: NSCLC, cancer cells
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O22.02 QUANTITATIVE PROTEOMICS 
IDENTIFIES NOVEL SUBSTRATES 
OF THE AURORA AND POLO-LIKE 
KINASES
Arminja N. Kettenbach1, Devin K. Schweppe2, 
Konstantin H. Dragnev3, James R. Rigas3, Scott A. 
Gerber1 
1Norris Cotton Cancer Center, Dartmouth Medical 
School/United States Of America, 2Genetics, 
Dartmouth Medical School/United States Of 
America, 3Thoracic Oncology, Dartmouth Hitchcock 
Medical Center/United States Of America
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assay data was combined. By this combination, 30 
hypermethylated and down-regulated genes, and 22 
hypomethylated and up-regulated genes were selected. 
The gene expression level and DNA methylation 
pattern were conÀrmed by semi-quantitative RT-PCR 
and pyrosequencing, respectively.
Results: By these validations, we selected 5 hyper-
methylated and down-regulated genes, and 1 
hypo-methylated and up-regulated gene. We could 
identify speciÀc CpG sites of the promoter of those 
6 genes that showed apparent differences of DNA 
methylation between normal lung and SCC. In 
addition, with the aid of pyrosequencing, we could 
obtain the data reÁecting the quantitative differences 
of DNA methylation of speciÀc promoter regions 
between normal lung and SCC. These 6 genes were 
proven to be actually regulated by DNA methylation 
by conÀrming the recovery of their DNA 
methylation pattern and gene expression level using 
a demethylating agent. The DNA methylation pattern 
of the CYTL1 promoter region was signiÀcantly 
different between early and advanced stages of SCC. 
Conclusion: we combined the whole genome DNA 
methylation pattern and the gene expression proÀle 
speciÀc to SCC of the lung. Through this study, 
we proved this method is very effective in Ànding 
genes regulated by DNA methylation and we found 
6 genes (CCDC37, CYTL1, CDO1, SLIT2, LMO3 
and SERPINB5) in SCC of the lung which is highly 
related to smoking. Hypermethylation process occurs 
in the early period of carcinogenesis and is reversible 
by demethylating agent. So cancer related genes 
overexpressed by hypermethylation are supposed to 
be reversible or controllable. We hope that this result 
can contribute to the development of a new method 
for the early detection and prevention of lung cancer.
Keywords: DNA methylation, whole genome 
analysis, Microarray
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O22.05 NEUROENDOCRINE 
TRANSCRIPTION FACTOR ASCL1 
DEFINES MULTIPLE PROGENITORS 
IN THE LUNG DURING THE 
DEVELOPMENT AND REPAIR
Ilona Linnoila1, Yan Li2 
1Exp. Pathology Section, Ccbb, Nci, Nih/United 
States Of America, 2Nci, Nih/United States Of 
America
cross-regulation effects in mitosis. We were able to 
demonstrate that several of these candidate substrates 
were efÀciently phosphorylated by puriÀed kinase 
in vitro, supporting the likelihood of our candidate 
kinase assignment as correct. Using bioinformatic 
tools, we discover a highly interconnected network 
of centrosomal, spindle-associated and kinetochore-
associated proteins that are targets of these kinases. 
Finally, we found that a single, speciÀc Aurora kinase 
A phosphorylation site on the mitotic protein NuMA1 
appears essential for proper spindle localization of the 
protein and for the spindle bipolarity of HeLa cells. 
Collectively, these data advance our understanding of 
the essential role these kinase families in mitosis, and 
reveal candidate mechanisms by which these enzymes 
regulate cell division.
Conclusion: Our technology-driven approach has 
allowed us to connect oncogenic kinase activities 
with phosphorylation sites in lung cancer cells.
Keywords: plk1, aurora, proteomics, kinase
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O22.04 GENOME-WIDE ANALYSIS OF 
DNA METHYLATION AND THE GENE 
EXPRESSION CHANGE IN LUNG 
CANCER
Hae Won Lee, Yong Jae Kwon, Moon-Chul Kang, 
Heejong Baek, Jong Ho Park 
Department Of Thoracic Surgery, Korea Cancer 
Center Hospital/Korea
Background: The recent DNA methylation studies 
on cancers have revealed the necessity of proÀling an 
entire human genome, and not to restrict the proÀling 
to speciÀc regions of the human genome. It has been 
suggested that genome-wide DNA methylation analysis 
enables us to identify the genes that are regulated by 
DNA methylation in carcinogenesis of lung cancer. 
Methods: We used a total of 50 tissue samples from 
50 lung cancer patients who underwent surgery at 
Korea Cancer Center Hospital without preoperative 
treatment. The histology of all the specimens was 
squamous cell carcinoma. The mean age of patients 
was 62.6 years (42-82) and 48 persons (96%) had 
the history of smoking. We used another 21 samples 
for the microarray, 3 samples for the whole genome 
DNA methylation assay and 30 samples for semi-
quantitative RT-PCR and pyrosequencing. The clinical 
information was obtained from the medical records. 
Microarray data and whole genome DNA methylation 
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given naphthalene (300mg/kg of body weight) 
intraperitoneally and examined after 1-5 days. In 
this model naphthalene kills Clara cells, which is 
followed by their rapid regeneration and a transient 
PNEC hyperplasia by day 5.The experiment 
revealed increased contribution of Ascl1 lineage 
cells to PNECs, while a portion of regenarating 
airway epithelial cells was also derived from Ascl-
expressing progenitor cells.
Conclusion: The proneural transcription factor 
Ascl1-deÀned cellular lineage contributes to the 
formation of PNECs as well as to the various known 
progenitor populations of epithelial (non-NE) cells 
which include Clara, Type II and potentially ciliated 
cells during embryonic lung development and injury 
repair. Further studies are needed to determine the 
role of Ascl1 lineage descendants in carcinogenesis.
Keywords: Ascl1, progenitor, lung, Neuroendocrine
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O22.06 SAMPLE HANDLING AND 
PROCESSING ARE CRITICAL FACTORS 
INFLUENCING THE RESULTS OF 
WHOLE GENOME GENE EXPRESSION 
PROFILING IN LUNG CANCER TISSUES
Maxim B. Freidin1, Neesa Bhudia1, Eric Lim2, 
Andrew G. Nicholson2, Sanjay Popat3, William O. 
Cookson1, Miriam F. Moffatt1 
1National Heat And Lung Institute, Imperial College 
London/United Kingdom, 2Academic Department Of 
Thoracic Surgery, Royal Brompton Hospital/United 
Kingdom, 3Royal Marsden Hospital/United Kingdom
Background: Lung cancer is the leading cause 
of cancer death worldwide. Gene expression 
proÀling can allow the identiÀcation of subgroups 
of cancer allowing early prediction of disease 
progression and survival. The quality of biological 
samples and their handling may strongly inÁuence 
global gene expression, but these factors have not 
been controlled for in many reported studies. We 
therefore set out to investigate systematic changes 
in gene expression that may occur between surgical 
resection, routine processing in the histopathology 
department, frozen storage, and long term archiving 
in FFPE blocks. 
Methods: Lung carcinoma tissue samples were 
obtained from six patients undergoing resection of 
primary tumours. Genome-wide gene expression was 
established at 5 time points (T1= at thoracotomy, 
Background: Pulmonary neuroendocrine cells 
(PNECs) are a minor subpopulation in the airway 
epithelium. However, up to one third of lung cancers 
display neuroendocrine (NE) features, ranging from 
less aggressive carcinoids to the highly virulent 
small cell lung cancers. While PNECs possess a self-
renewal function, their role in lung development or 
carcinogenesis remains unclear. We have previously 
shown that Ascl1, a proneural basic helix-loop-helix 
transcription factor, is critical for the development 
of PNECs. The expression of Ascl1 is also tightly 
linked to the NE phenotype in lung cancer. On the 
other hand, little is known about the differentiation 
potential of Ascl1 lineage in the lung. Aim We 
investigated the descendants of Ascl1-deÀned 
cellular lineage during lung development and injury 
repair. 
Methods: We used immunohistochemistry and 
genetically engineered mice.
Results: During mouse embryogenesis pulmonary 
Ascl1 positive cells became Àrst evident on 
embryonic day (E)12.5, while the markers CGRP, 
CC10, ơ-tubulin and SPC for mature PNECs, 
epithelial airway (Clara and ciliated) and alveolar 
Type II cells, respectively, were all detected later 
(E17.5). Ascl1-GIC (Development 2007:135:285-
293) mice were crossed with R26R-stop-lacZ 
reporter mice, to reveal Ascl1-deÀned cells and 
their descendants that expressed Cre recombinase 
and stained blue with X-Gal. The number of blue 
cells increased dramatically with age both along 
the airways and in the alveolar compartment, far 
exceeding the number of any PNEC populations. 
Using in vivo lineage tracing with inducible Cre 
recombinase (Ascl1-CreERTM;R26R-stop-lacZ), 
we followed the cell fate of Ascl1-expressing 
precursors after administering tamoxifen at 
different developmental points. Ascl1 lineage cells 
contributed, in time dependent manner, to several 
diverse phenotypes identiÀed by histology and 
immunohistochemistry. The cells expressing Ascl1 at 
E9.5 gave rise to PNECs, Clara, ciliated and alveolar 
Type II cells during lung maturation. Interestingly, 
Ascl1-expressing progenitor cells also gave rise to 
neural ganglion cells adjacent to embryonic airways. 
In contrast, the lineage of the cells expressing Ascl1 
on E11.5 was only traced to airway lining cells, 
but not alveolar Type II pneumocytes. In order to 
study the fate of Ascl1 lineage descendants during 
injury repair, adult Ascl1-GIC;R26R-stop-lac-Z or 
Ascl1-CreERTM;R26R-stop-lacZ mice that received 
four doses of tamoxifen prior to treatment, were 
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O23.01 PRE-OPERATIVE 
CHEMOTHERAPY IMPROVES SURVIVAL 
AND REDUCES RECURRENCE IN 
OPERABLE NON-SMALL CELL LUNG 
CANCER: PRELIMINARY RESULTS OF 
A SYSTEMATIC REVIEW AND META-
ANALYSIS OF INDIVIDUAL PATIENT 
DATA FROM 13 RANDOMISED TRIALS
Sarah Burdett1, Larysa H. Rydzewska1, Jayne F. 
Tierney1, Jean-Pierre Pignon On Behalf Of The 
Nsclc Meta-Analyses Collaborative Group2 
1Meta-analysis Group, MRC Clinical Trials Unit/
United Kingdom, 2Gustave-Roussy Institute/France
Background: Results from two previous individual 
patient data (IPD) meta-analyses found that giving 
chemotherapy (CT) after either surgery or surgery 
plus radiotherapy (RT) improves survival in patients 
with non-small cell lung cancer (NSCLC). However, 
giving CT prior to surgery may increase resectability 
and eradicate micro-metastases. Pre-operative CT 
may also be given to a broader range of patients and 
be better tolerated.
Methods: We conducted a systematic search for 
randomised controlled trials (RCTs) followed by the 
central collection, checking and analysis of updated 
individual patient data (IPD). For each outcome, 
results from individual RCTs were combined using 
the Àxed-effect model. We pre-speciÀed analyses to 
explore any variation in effect by trial and patient 
characteristics.
Results: We identiÀed 18 RCTs, but data are 
unavailable for two and are awaited for a further 
three of these. Therefore, we currently have IPD 
from 13 trials and 2094 patients; 81% of all patients 
randomised. Nine trials gave all chemotherapy pre-
operatively and four trials used pre and some post-
operative CT. Seven trials also used post-operative 
RT in both arms. Platinum-based chemotherapy 
was used in all but one trial (of docetaxel). 80% 
of patients were male, 57% were aged 65 years or 
younger and 86% had a performance status of 0 or 
1. 6% of the patients had clinical stage Ia disease, 
44% had stage Ib, 26% had stage II and 24%, stage 
III. 52% had squamous tumours and 28% had 
preserved in RNAlater; T2 = immediately after 
tumour resection, preserved in RNAlater; T3 = 
~30 minutes interval between removal of specimen 
and its transition to histopathology department, 
preserved in RNAlater; T4 = ~30 minutes interval 
between removal of specimen and its transition to 
histopathology department, snap-frozen; T5 = 1 
week storage at -80C (after snap freezing) using 
Illumina HumanWG-6 v2.0 Expression Bead-Chip. 
In addition, genome-wide gene expression was also 
examined for samples from standard formalin-Àxed 
and parafÀn embedded blocks (FFPE) for each 
patient. 
Results: Sampling immediately after resection 
closely represented the tissue obtained in situ, with 
only 193 (1%) of genes differing more than two-
fold between T1 and T2. Delaying tissue harvest 
for an average transition time of 30 minutes from 
the operating theatre had a signiÀcant impact on 
gene expression proÀles with approximately 25% to 
33% of genes differing between T1 and T3-T5 time 
points. We found many genes previously identiÀed 
as lung cancer biomarkers that were altered in this 
period. Examination of FFPE specimens showed 
minimal correlation with fresh samples. Two big 
clusters of differentially expressed genes were 
identiÀed which distinguish T1/T2 time points from 
later ones. Top genes in these clusters are those 
recognised to be important for the inÁammatory 
response (TNF, IL18, NFKB), cellular growth and 
proliferation (MAPK, PDGF), cell death and tissue 
development (FOS, OSM, IL6, Cyclin A). Pathway 
analysis revealed “InÁammatory Response” and 
“Cell-to-Cell Interaction and Signalling” among 
the top biological processes appearing in transition 
between T1/T2 and dated samples. 
Conclusion: Sample handling and processing are 
critical factors when conducting and interpreting 
results for Lung Cancer gene expression proÀling. 
Genes affected by sample handling are of functional 
importance of lung cancer development Tissue 
collection for gene expression analysis immediately 
after lung resection with conservation in RNAlater is 
an optimal strategy for gene expression proÀling. 
Keywords: gene expression, FFPE, specimen 
handling, Lung cancer
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Background: Multimodality therapy has curative 
potential in patients presenting with stage III non 
small cell lung cancer. Mediastinal clearance after 
induction chemoradiation has been associated with 
superior outcomes and may serve as an important 
intermediate marker for efÀcacy. RTOG 0229 is 
a phase II trimodality trial designed to evaluate 
mediastinal clearance rates following induction 
concurrent chemotherapy with full dose RT. 
Methods: Patients with stage III NSCLC 
(pathologically proven N2 or N3) were eligible. 
All patients were deemed to be candidates for 
trimodality therapy prior to the initiation of 
therapy. Participating surgeons were required to 
demonstrate expertise in surgery after chemoXRT 
and adhere to speciÀc guidelines regarding surgical 
procedure and postoperative management. Induction 
chemotherapy consisted of weekly CBDCA 
(AUC =2.0) and paclitaxel 50 mg/m2. Concurrent 
radiation was prescribed with 50.4 Gy delivered 
to the mediastinum and primary tumor and boost 
of 10.8 Gy to all gross disease (total dose of 61.2 
Gy to known disease). The mediastinum was 
pathologically reassessed prior to or at the time of 
resection. Consolidation chemotherapy was delivered 
to patients who had not progressed (CBDCA AUC 
=6, paclitaxel 200 mg/m2 q 21d x 2 cycles). The 
primary endpoint of the study was mediastinal nodal 
sterilization (MNS), with secondary endpoints that 
included 2 year overall survival, and post operative 
morbidity/mortality. 
Results: 60 patients were accrued, 57 were eligible. 
Median age for the entire cohort was 59. Sixty-one 
percent of patients were male, 77% had ECOG 
performance status of 0. Ninety-eight percent of 
patients had N2 disease documented by pathologic 
assessment of their mediastinum (N3: 2%). The 
histology included 51% adenocarcinoma, 19% 
squamous cell carcinoma, and 28% NSCLC-NOS. 
Ninety-Àve percent of patients received radiation 
per protocol; 91% received chemotherapy as 
per protocol, (49% with protocol mandated dose 
adenocarcinomas. The results show a signiÀcant 
beneÀt of pre-operative CT on survival (HR=0.88, 
95% CI 0.79-0.98, p=0.025), representing an 
absolute improvement of 5% at 5 years (from 35% 
to 40%). There was no clear evidence of a difference 
in this effect by the CT regimen or scheduling, the 
number of drugs, the platinum agent used or whether 
post-operative RT was given. Also, there was no 
good evidence that any patient subgroup deÀned by 
age, sex, performance status or histology beneÀted 
more or less from pre-operative CT. Similarly, 
neither the relative nor absolute beneÀts differed 
by clinical stage. Recurrence data were available 
from 12 trials (2035 patients) and were analysed at 
a landmark time of 6 months from randomisation to 
the Àrst event. The results show a signiÀcant beneÀt 
of pre-operative CT on time to local recurrence 
(HR=0.83, 95% CI 0.70-1.00, p=0.048), time 
to distant recurrence (HR=0.67, 95% CI 0.57-
0.80, p<0.000003), and recurrence-free survival 
(HR=0.86, 95% CI 0.77-0.96, p=0.007). Based on 
8 trials, there was no clear evidence of increased or 
decreased complete resection rate with pre-operative 
CT. IPD from the remaining trials will be included 
and results updated. 
Conclusion: These preliminary results demonstrate 
that pre-operative CT signiÀcantly reduces local 
and distant recurrence and improves recurrence-free 
survival and overall survival in NSCLC. Absolute 
and relative effects are similar to those seen for 
post-operative CT, necessitating a formal indirect 
comparison of the IPD meta-analyses of pre and 
post-operative CT.
Keywords: Non-small cell lung cancer, 
Chemotherapy, Surgery, meta-analysis
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O23.02 RTOG 0229:A PHASE II TRIAL 
OF CONCURRENT CHEMOTHERAPY 
AND FULL DOSE RADIOTHERAPY 
FOLLOWED BY SURGICAL RESECTION 
AND CONSOLIDATIVE THERAPY FOR 
LOCALLY ADVANCED NON SMALL 
CELL CARCINOMA OF THE LUNG
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Background: TM approaches including induction 
(IND) chemotherapy (CTx), radiotherapy (RTx) 
and surgery (S) for selected pts with LAD stage III 
NSCLC are a valid strategy in the management to 
achieve LTS (Eberhardt et al, JCO 1998, Albain 
et al, Lancet 2009). Here we have performed 
exploratory analysis of our sequential trimodality 
trials performed between 1991 and 2002 to identify 
subgroups either with increased or reduced LTS to 
generate hypotheses to prospectively stratify our pt 
population in future clinical trials with TM.
Methods: From 1/91 till 2/2002 four seqential 
clinical trials were performed at the West German 
Tumor Centre plus selective thoracic/academic 
centers in Germany/Europe: 1) JCO1 was based on 
IND CTx (cisplatin/etoposide=PE) plus concurrent 
(cc) CTx/RTx followed by S (Eberhardt, JCO 
1998) 2) CISTAXOL was based on cisplatinum/
paclitaxel=PT IND plus cc CTx/RTx plus surgery or 
deÀnitive CTx/RTx-boost to 65 Gy (Gauler, (WCLC 
Seoul) JTO 2009) 3) CISTAXOL/EPO was based 
on the same protocol prophylactically supported 
by epoetin alpha 4) KREBSHILFE1/JCO2 was a 
randomized trial based on cisplatin/etoposide=PE 
IND plus cc CTx/RTc plus S supplemented by PCI 
and compared to local treatment alone (S + RTx) - 
only pts from the TM arm are included here in this 
investigation (Poettgen, JCO 2007). All patients 
signed informed consent and trials were submitted to 
the ethics committee of each participating institution.
Results: From 2/91 till 2/02 243 pts were accrued 
to the four sequential trials: 94 pts JCO1, 64 pts 
CISTAXOL, 30 pts CISTAXOL/EPO and 55 pts 
KREBSHILFE1/JCO2. LTS follow-up (F-UP) was 
performed 2/11 to collect information on pts survival 
and disease/comorbidity status. Pts characteristics: 
m 187 f 56; age median 56 range 28-71 ; stages IIB 
6 (UICC5; IIIA UICC6) IIIA 139 IIIB 98; induction 
PE 149 induction PT 94. Complete/R0-res: 122 (50,2 
%); no R0: 121; med S of pts still alive at last FUP 
112 months (m). med OS (m), 5y-OS, 10y-OS, 15y-
OS (%): all pts: 23 m 24.7 19.5 9.9 IIB/IIIA: 25 m 
modiÀcations). The Grade 3/4 toxicities included: 
hematologic 35%, gastrointestinal 14%, and 
pulmonary 23%. Thirty-six patients underwent 
resection. There was a 14% (5/37) incidence of grade 
3 postoperative pulmonary complications. There 
was one 30 day, post-operative grade 5 toxicity 
(3%). Forty-three patients (75%) were evaluable 
for the primary endpoint. Twenty-seven out of 43 
evaluable patients (63%) achieved the primary 
endpoint of MNS (p=0.05). With a median follow-
up of 24 months for all patients, the 2 year overall 
survival was 54% (median OS 27 months), and 2 
year progression free survival was 33% (median PFS 
13 months). The 2 year OS was 67% for those who 
achieved mediastinal nodal clearance, and 54% for 
those with residual nodal disease. 
Conclusion: This multi-institutional trial conÀrms 
the safety of neoadjuvant concurrent chemoradiation 
with full dose radiotherapy and the ability of this 
approach to sterilize mediastinal nodal disease. The 
low surgical morbidity and mortality is likely a result 
of the requirement for proven surgical expertise 
and adherence to speciÀc management protocols. 
These results support the contention that tri-modality 
therapy remains a viable option for selected stage III 
NSCLC pts. This project was supported by RTOG 
grant U10 CA21661, and CCOP grant U10 CA37422 
from the National Cancer Institute (NCI). 
Keywords: mediastinal sterilization, Stage III, 
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O23.03 COMPETING RISKS ANALYSIS 
AND LONG-TERM SURVIVAL (LTS) 
OF PATIENTS (PTS) WITH LOCALLY 
ADVANCED (LAD) STAGE III NON-
SMALL-CELL LUNG CANCER 
(NSCLC) TREATED ON SEQUENTIAL 
TRIMODALITY (TM) TRIALS
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Background: ACRIN 6668/RTOG 0235 is a 
prospective trial rigorously assessing the utility of 
pre- and post-chemoradiotherapy FDG-PET scan 
for Stage III NSCLC. This trial allowed a variety 
of chemoradiotherapy regimens (physicians’ 
preference). We analyzed the effect of the choice of 
chemotherapy regimen and other potential prognostic 
factors for outcomes. 
Methods: A total of 251 patients were accrued to 
this study, of whom 235 were eligible. A subset of 
128 of these patients received a ‘standard’ concurrent 
chemoradiotherapy regimen; either Carboplatin/
paclitaxel/RT (Group A) or Etoposide/cisplatin/
RT (Group B), and were evaluable for follow-up. 
213 patients received XRT (mean dose: 63.9 Gy; 
SD: 10.5 Gy). Analysis was performed for overall 
survival, with emphasis on the effects of choice of 
chemotherapy and radiotherapy dose. 
Results: For all 128 patients analyzed for the 
chemotherapy question, the 2-year overall survival 
was 44.5% (95% CI: 36.0%, 53.4%). Survival rates 
were 42.2% and 51.8% for Group A and Group B, 
respectively. The log-rank test showed that overall 
survival was not different between two groups (p=0.99). 
Within this population, radiotherapy dose was marginally 
signiÀcant as a factor associated with survival (p=0.066). 
When analyzed for the entire evaluable population of 
patients with radiotherapy data (N=213), radiotherapy 
dose became highly signiÀcant (p<.0001). The results 
suggest that the hazard rate for death decrease by 1.9% 
for each 1 Gy increase in radiotherapy dose. 
Conclusion: Carboplatin/paclitaxel or etoposide/
cisplatin as concurrent chemotherapy during 
deÀnitive radiotherapy has similar outcomes. 
Radiotherapy dose appears to be a more important 
factor than choice of doublet concurrent 
chemotherapy regimen. ACRIN receives funding 
from the National Cancer Institute through the 
grant U01 CA079778, and RTOG receives funding 
through grant CA21661. 
Keywords: chemoradiotherapy, Non-small Cell 
Lung Carcinoma, Stage III
27.5 19.8 10.8; IIIB: 22 m 20.5 19.1 8.6 log-rank 
p = NS. ADC: IND PE 38 m 32.0 15.2 11.4 ; IND 
PT 24 m 11.1 11.1 log-rank 0.04. SCC: IND PE 21 
m 20.0 15.7 4.6; IND PT 43 m 45.5 41.7 log-rank 
0.0075. IND PE: ADC 26 m 32.0 15.2 11.4 ; SCC 21 
m 19.9 15.7 4.6 log-rank p = NS; induction PT: SCC 
23 m 45.5 41.7 ; ADC 24 m 11.1 11.1 log-rank p = 
0,0021. Age: less 50 yrs 26 m 27.9 27.9 23.2 greater/
equal 50 yrs 23 m 23.6 16.7 3.1 log-rank p = 0.057. 
Stage, N-status, T-status and gender did not reveal 
signiÀcant impact on LTS. Treatment-dependant 
subgoups: R0-res: 38 m 40.5 32.5 17.0 ; no R0 18 
m, 8.5 6.2 log-rank p = 0.01. Competing risks: all 
events post 5-yrs were either 1) comorbidity-related 
(vascular, pulmonary) 2) second cancers 3) second-
primaries ; not any late relapse could be conÀrmed. 
Brain relapse was observed predominantly before 5 
yrs post diagnosis.
Conclusion: Mature 10-y F-UP of stage III pts put 
on TM conÀrms excellent LTS/cure rate of selected 
subgroups of pts with IIIA and IIIB. Interestingly, 
our exploratory analysis reveals signiÀcant 
interaction between induction therapy (PE vs PT) 
and histopathology: on PT induction SCC have 
excellent whereas ADC reveal poor prognosis. 
This effect was not observed with PE induction. 
Furthermore, age less than 50 yrs at diagnosis 
seems to implicate better LTS. 1) as a consequence 
this Ànding will have to be prospectively analysed/
validated in the ongoing randomized ESPATUE 
trial (KREBSHILFE2) 2) Further improvement 
of LTS has to address and aggressively manage 
comorbidities and second primary/second cancer 
risk. Brain metastases remain an issue in the time 
period prior to 5 years post diagnosis.
Keywords: Surgery, Stage III, combined modality, 
lung cancer, non-small-cell
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REGIMEN FOR STAGE III NSCLC? -- 
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Conclusion: High-dose cisplatin containing 
chemotherapy concurrently combined with 
radiotherapy did not result in better overall survival 
compared to low dose cisplatin RCT regimens for 
locally advanced NSCLC. The series with the best 
overall survival rates and a favorable toxicity proÀle 
was combining high-dose radiotherapy and low-dose 
monochemotherapy consisting of daily cisplatin. 
Keyword: locally advanced NSCLC
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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O23.07 RESULTS OF A PHASE II TRIAL 
ON INDIVIDUALIZED RADIATION 
DOSE-ESCALATION BASED ON 
NORMAL TISSUE CONSTRAINTS IN 
CONCURRENT CHEMO-RADIATION 
FOR STAGE III NON-SMALL CELL LUNG 
CANCER (NSCLC) (NCT00572325 TRIAL)
Angela Van Baardwijk1, Bart Reymen1, Rinus 
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Background: Concurrent chemo-radiation 
and radiation dose-escalation are strategies to 
improve overall survival (OS) in locally advanced 
NSCLC. Previously, we have shown the efÀcacy 
of individualized radical radiotherapy/sequential 
chemo-radiation by individualized dose-escalation 
to the limits of normal tissues (van Baardwijk et al, 
J Clin Oncol 2010). Here, we report the results of a 
phase II trial investigating individualized radiation 
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RADIOCHEMOTHERAPY SCHEMES IN 
LOCALLY ADVANCED NSCLC
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Background: After two meta-analyses reporting 
the superiority of concurrent above sequential 
Radiochemotherapy (RCT) for locally advanced 
NSCLC in 2010, the question which concurrent RCT 
combination to prefer, is still unanswered. 
Methods: A systematic review was performed to 
determine which concurrent RCT regimen (mono- 
versus polychemotherapy, high-dose versus low-
dose schemes) yields superior results. The databases 
of Pubmed, Ovid-Medline, Ovid-Embase and 
the Cochrane library were searched for full text 
publications between January 1992 and December 
2009 on the use of concurrent RCT only, in phase II 
and phase III studies including at least 50 patients 
per treated group. Data on treatment results in terms 
of overall survival and toxicity were collected. 
Results: Seventeen articles were included in this 
analysis. In 11 manuscripts cisplatin containing 
chemotherapy was applied, in eight patient 
series as monochemotherapy and in four as 
polychemotherapy. In six studies high-dose and in 
six series low-dose cisplatin was used as part of the 
RCT. In six reports carboplatin was the treatment of 
choice. Total radiotherapy (RT) doses varied from 
45 Gy to 70.2 Gy, fraction doses from 1.8 Gy to 2.75 
Gy. Concurrent carboplatin did not yield improved 
overall survival compared to RT only. One of the 
series using daily low-dose cisplatin combined with 
high-dose RT resulted in the highest 2- and 3- year 
overall survival of 56 % and 29%, respectively. 
Acute toxicity of this daily cisplatin regimen 
consisted mainly of grade > 3 esophagitis (17%), and 
nausea and vomiting (6%). High-dose concurrent 
cisplatin resulted in considerably higher incidences 
of haematological toxicities and caused higher 
incidences of and more severe nausea and vomiting 
complaints. 
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prescription in concurrent chemo-radiation based on 
normal tissue constraints is feasible, even in patients 
with large tumor volumes and multi-level N2/3 
disease, with acceptable severe late toxicity (<7%) 
and promising results with a 2yr OS of 51.5%. 
Keyword: NSCLC, chemoradiation, dose-escalation, 
individualized
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O24.01 ADENOSQUAMOUS CARCINOMA 
OF THE LUNG: SURGICAL RESULTS 
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Background: Adenosquamous carcinoma of the 
lung (ASC) is a relatively rare tumor. Some studies 
have suggested that ASC is more aggressive than 
adenocarcinoma (AC) or squamous cell carcinoma 
(SC). The purpose of the present study was to test 
the hypothesis that ASC exhibits distinct clinical 
behavior from AC and SC of the lung in the setting 
of a multi-institutional cohort study.
Methods: This retrospective cohort study used a 
prospective database produced by the Japan National 
Hospital Organization Study Group for Lung Cancer 
over a 19-year period (operations from 1975 to 2003, 
follow-up data until March 2010). There were 17,129 
cases that underwent operation during that period 
for various kinds of primary malignant lung tumors. 
When a sample from a tumor comprises at least 20% 
dose-escalation in concurrent chemo-radiation.
Methods: Patients with stage III NSCLC Àt for 
concurrent chemo-radiation (WHO-PS 0-2; FEV
1
 
and DLCO >30%) were included. All patients were 
irradiated using an individualized prescribed total 
tumor dose (TTD) based on normal tissue dose 
constraints: maximal mean lung dose (MLD) 19 Gy, 
maximal spinal cord dose 54 Gy and maximal dose 
to the brachial plexus 66 Gy. A TTD between 51 and 
69 Gy was delivered in 1.5 Gy fractions twice daily 
up to 45 Gy, followed by once daily fractions of 2 
Gy. Radiotherapy (RT) was started at the 2nd course 
of chemotherapy (cisplatin-vinorelbine or cisplatin-
etoposide). RT planning was 4D-PET-CT based. OS 
and Progression Free Survival (PFS) were calculated 
from date of diagnosis (Kaplan-Meier method). 
Toxicity was scored according to CTCAEv3.0. The 
trial (NCT00572325) was approved by the required 
authorities. 
Results: 150 patients (97 males and 53 females, 
median age 63.2 years) were included from April 1st 
2006 till December 31st 2009. Stage distribution: IIB 
0.7%, IIIA 34.7%, IIIB 64.6%, including 7 patients 
(9.7%) with recurrent disease after surgery. Median 
total GTV (±SD, range) was rather large: 73.9 ± 91.3 
cc (3.7-518.9 cc). Median TTD was 65.0 ± 5.9 Gy 
(51-69.0 Gy) given in an overall treatment time of 
35 days (equals a classical scheme of 74 Gy in 37 
fractions QD in 7.4 weeks). The median MLD was 
16.3 ± 3.7 Gy (4.4-21.0 Gy). Six patients (4.0%) 
did not complete radiotherapy (3 due to toxicity, 
3 patient’s wish). Severe acute toxicity (grade 3, 
n=51, 34.0%) consisted mainly of grade 3 dysphagia 
during RT (n=36; 24.0%) and 1 month after RT (n=9, 
6.0%). Pulmonary complaints were less frequent: 
grade 3 and 4 dyspnea resp. 4 and 1 patient (2.7% 
and 0.7%) and grade 3 cough in 13 patients (8.7%). 
With regard to late toxicity 6 patients (4%) had grade 
3 dysphagia (eg. stenosis/ulcus), 3 patients (2%) 
a thoracic empyema/Àstula and 1 patient died of a 
radiationpneumonitis (0.7%). Five patients (3.3%) 
died within 3 months after start of RT (pulmonary 
causes, n=2; sepsis, n=1; cardiomyopathy, n=1; 
unknown cause, n=1). With a median FU of 29.4 
months (95%CI 26.1-32.6 months), the median OS 
was 24.2 months (95%CI 18.9-29.6 months, 2yr OS 
51.5%) and the median PFS 16.5 months (95%CI 
11.9-21.1 months). Eighty-six patients (57.6%) 
showed recurrent disease: 20 (13.4%) local and/or 
regional recurrence, 40 (26.7%) distant metastasis 
and 26 (17.3%) a combination of both as Àrst event. 
Conclusion: Applying an individualized dose 
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O24.02 TIME TRENDS OF SURGICAL 
OUTCOME AND DISTRIBUTION OF 
CLINICOPATHOLOGIC FACTORS IN 
PATIENTS WITH PATHOLOGICAL 
STAGE I NON-SMALL CELL LUNG 
CANCER OVER THE LAST THREE 
DECADES
Jung-Jyh Hung, Wen-Hu Hsu, Yu-Chung Wu 
Department Of Surgery, Taipei Veterans General 
Hospital/Taiwan
Background: The seventh edition of the TNM 
classiÀcation for lung cancer has been published in 
2009. The aim of this study is to evaluate time trends 
of surgical outcome and clinicopathologic factors in 
patients with pathological stage I non-small cell lung 
cancer (NSCLC) according to the seventh edition of 
the TNM classiÀcation. 
Methods: We retrospectively reviewed the 
clinicopathologic characteristics of 1,424 patients 
with resected stage I NSCLC from Taipei Veterans 
General Hospital between January 1980 and 
December 2008, during the three periods of 1980-
1990, 1991-2000, and 2001-2008. The overall 
survival and distribution of clinicopathologic 
characteristics were analyzed. 
Results: The number of patients during the 3 periods 
was 267 (18.8%), 540 (37.9%) and 617 (43.3%), 
respectively. The 5-year overall survival rates during 
the three periods improved signiÀcantly: 52.3, 58.3, 
and 68.2%, respectively (P < 0.001) (Figure 1). 
Surgical mortality (within 30 days after surgery) 
rate during each period was 2.6, 2.6, and 1.1%, 
signiÀcantly decreased in the last period (P = 0.021). 
The percentage of female patients increased during 
each period: 15.4, 24.4, and 35.7%, respectively (P 
< 0.001). The percentage of adenocarcinoma also 
increased during each period: 50.6, 54.6 and 76.5%, 
respectively (P < 0.001). Tumor size during each 
period was 3.2, 3.2 and 2.7 cm, tending to be smaller 
when diagnosed in the last period (P < 0.001). 
The number of mediastinal lymph nodes dissected 
increased during each period: 11.4, 16.6 and 20.6, 
respectively (P < 0.001). The number of mediastinal 
lymph node stations dissected also increased during 
each period: 3.0, 4.2 and 5.3, respectively (P < 
0.001). The overall survival in subgroups of patients 
with squamous cell carcinoma and those undergoing 
pneumonectomy did not improve over time. 
each of SC and AC, the condition is classiÀed as 
ASC. Pathologic staging was done according to the 
6th edition of the International Union Against Cancer 
(UICC) TNM classiÀcation of malignant tumours.
Results: We identiÀed 351 patients with ASC 
(2.0%), 9,469 with AC (55.3%), and 6,183 with 
SC (36.6%). SigniÀcantly more patients with ASC 
presented with T2 or T3 compared with patients 
with AC (49.9% vs 37.7% and 16.5% vs 7.9% 
respectively, p<0.0001). SigniÀcantly more patients 
with ASC presented with N2 (27.6%) compared 
with patients with AC (21.9%, p=0.0004) and SC 
(19.0%, p=0.0002). Consequently, in pathologic 
stage distribution signiÀcantly more patients with 
ASC presented with stage IIIA (29.9%) compared 
with patients with AC (21.5%, p<0.0001) and SC 
(21.6%, p=0.0061). Kaplan-Meier survival curves 
for p-stage IA tumors indicated that ASC has the 
least favorable survival. The 5-year survival rates 
were 75.2% for AC, 67.8% for SC, and 50.0% for 
ASC. There were statistical differences between 
the three groups (p<0.0001). The survival curves 
for p-stage IB tumors also indicated that ASC has 
the least favorable survival. The 5-year survival 
rates were 54.1% for AC, 50.2% for SC, and 
38.5% for ASC. There were statistical differences 
between AC and SC (p=0.0030) and between 
AC and ASC (p=0.0154). The survival curves for 
p-stage IIB tumors also indicated that ASC has the 
least favorable survival. The 5-year survival rates 
were 34.3% for AC, 39.8% for SC, and 27.4% for 
ASC. There were statistical differences between 
SC and ASC (p=0.0278) and between AC and 
ASC (p=0.0444). The survival curves for p-stage 
IIIA tumors also indicated that ASC has the least 
favorable survival. The 5-year survival rates were 
18.1% for AC, 21.3% for SC, and 10.9% for ASC. 
There was statistical difference between AC and 
ASC (p=0.0169).
Conclusion: Adenosquamous carcinoma (ASC) of 
the lung is more aggressive than adenocarcinoma 
(AC) or squamous cell carcinoma (SC). The 
decreased survival of patients with early-stage ASC 
compared with single histology AC and SC suggests 
a role of clinical trial for adjuvant chemotherapy.
Keywords: adenosquamous carcinoma, Surgery, 
Prognosis
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score for choice of approach (VATS versus open) was 
constructed from clinical and tumor characteristics 
(age, gender, histology, performance status, tumor 
location, and T1 versus T2). Overall survival, disease-
free survival and second primary cancers were 
compared using Cox proportional hazards regression 
with 5 strata based on propensity scores
Results: 752 patients (66 VATS and 686 open) were 
analyzed. Results are shown in Table 1. The median 
survival for the open lobectomy group was 8.4 years 
while the median survival for the VATS lobectomy 
groups was not achieved at the time of the analysis, 
p=0.36.
Table 1. Long-term Outcomes 
VATS 
Lobectomy 
(n=66) 
Open Lobectomy 
(n=686) 
5-year survival 
(95% CI) 
5-year survival (95% 
CI) 
HR P 
Overall 
Survival 
71.6%  
(61.3%-83.6%) 
65.9% (63.3%-69.7%) 1.22 0.36 
Disease-
Free 
Survival 
75.2%  
(63.5%-89.1%) 
69.2% (65.4%-73.3%) 1.19 0.55 
Local 
Disease-
free 
Survival 
89.4%  
(81.0%-98.7%) 
92.6% (90.3%-95.0%) 0.65 0.38 
New 
Primary 
87.8%  
(79.6%-96.8%) 
81.7% (78.3%-85.3%) 1.71 0.17 
Conclusion: These data support the assertion that 
VATS lobectomy provides comparable oncologic 
outcomes to those achieved with open lobectomy. 
Keyword: non-small cell lung cancer, VATS, 
lobectomy, randomized trial
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O24.05 JAPANESE LUNG CANCER 
REGISTRY STUDY OF 11663 SURGICAL 
CASES IN 2004: DEMOGRAPHIC AND 
PROGNOSIS CHANGES OVER DECADE
Noriyoshi Sawabata1, Etsuo Miyaoka1, Hisao 
Asamura2, Yoichi Nakanishi2, Kenji Eguchi2, Masaki 
Mori2, Hiroaki Nomori2, Yoshitaka Fujii2, Meinoshin 
Okumura2, Kohei Yokoi2 
1Genetral Thoracic Surgery Osaka University 
Graduate School Of Medicine, Japanese Joint 
Committee For Lung Cancer Registration/Japan, 
2Japanese Joint Committee For Lung Cancer 
Registration/Japan
Conclusion: The surgical outcome in patients of 
stage I NSCLC improved signiÀcantly during the last 
three decades. The prevalence of female gender and 
adenocarcinoma signiÀcantly increased over time, 
while tumor size at diagnosis tended to be smaller. 
However, no survival improvement was identiÀed 
in patients with squamous cell carcinoma and those 
undergoing pneumonectomy. 
Keywords: Non-small cell lung cancer, time trend, 
surgical outcome, survival
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O24.03 SURVIVAL, RECURRENCE 
AND SECOND PRIMARIES AFTER 
VIDEO-ASSISTED (VATS) LOBECTOMY 
COMPARED TO OPEN LOBECTOMY 
FOR THE TREATMENT OF NON-SMALL 
CELL LUNG CANCER
Walter J. Scott1, Mark S. Allen2, Gail Darling3, Bryan 
Meyers4, Paul Decker2, Joe Putnam5 
1Thoracic Surgery, Fox Chase Cancer Center/United 
States Of America, 2Mayo Clinic/United States Of 
America, 3University Of Toronto/Canada, 4Washington 
Univeristy Of St Louis/United States Of America, 
5Vanderbilt Univeristy/United States Of America
Background: Many reports describe a lower 
morbidity, mortality and length of stay after VATS 
lobectomy, but skeptics have challenged the 
oncologic effectiveness of the minimally invasive 
approach. This secondary analysis of a multicenter, 
randomized trial compares long term oncologic 
endpoints between patients receiving either an open 
or VATS lobectomy
Methods: Prospectively collected and audited data 
were analyzed from 964 patients who underwent 
lobectomy, segmentectomy or bilobectomy as part 
of a randomized, multicenter clinical trial. While the 
surgical intervention was not the primary focus of 
the trial, the surgical approach was captured and this 
allows an analysis of the impact of approach on the 
oncologic effectiveness of the surgery. A propensity 
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Conclusion: In Japanese cases of lung cancer 
surgery, demographics, surgical results, and stage-
speciÀc prognoses changed over the 10-year study 
period, while 5-year survival rate for surgical cases 
improved to 69.6% in 2004.
Keywords: Lung cancer, Surgery, Registry, Japan
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O24.06 A RANDOMIZED CLINICAL 
TRIAL OF PREOPERATIVE 
NEOADJUVANT CHEMOTHERAPY 
FOLLOWED BY SURGERY IN THE 
TREATMENT OF STAGE III NON-SMALL 
CELL LUNG CANCER BASED ON 
MOLECULAR STAGING
Qinghua Zhou 
Tianjin Lung Cancer Institute, Tianjin Medical 
University General Hospital/China
Background: To explore the feasibility and 
toxicity of pre-operative neoadjuvant chemotherapy 
followed by surgery in the treatment of stage 
III NSCLC and to evaluate its effects on tumor 
response, resection rate, tumor downstaging, and 
survival rate based on detection of Muc-1 mRNA 
expression.
Methods: From Jan. 1990 to Jan. 2006, 624 
patients were randomly devided into group A 
(preoperative neoadjuvant chemo-therapy group) 
and group B (control group, without neoadjuvant 
chemotherapy). Group A had 314 patients and 
group B had 310 cases. Expression of Muc-1 
mRNA was detected in all the 624 patients before 
and after neoadjuvant chemo-therapy in Group 
A and before operation in Group B by RT-PCR. 
The patients in group A were give 2 cycles of 
neoadjuvant chemotherapy, and operations were 
performed in 4 weeks after Ànishing the last 
chemotherapy. The regimens included Gem‹DDP 
in 214 cases and NVB‹DDP in 100 cases . 
The patients in group B were Àrstly operated. 
All the 624 patients were given postoperative 
chemotherapy with GP or NP regimen for 3-4 
cycles after operation.Thoracic radiation therapy of 
45-50Gy was given in the patients with N2 disease 
both in group A and group B. 
Results: The tumor response to induction 
chemotherapy was 75.16…(236-314) in group A. 
The tumor down- staging was 41.08…(129-314). 
The histological complete response was 14.65…
Background: The Japan Lung Cancer Society, the 
Japanese Association for Chest Surgery, and the 
Japanese Respiratory Society jointly established 
the Japanese Joint Committee for Lung Cancer 
Registration (JJCLCR), which has regularly 
conducted lung cancer registries for surgical cases in 
5-year periods. We analyzed data obtained in these 
registries to reveal the most recent surgical outcomes 
and trends related to lung cancer surgery in Japan.
Methods: Using data from the registry conducted 
in 2010 for cases of surgery performed in 2004, 
demographics, surgical results, and stage-speciÀc 
prognoses were analyzed. In addition, in order to 
comprehend alterations of those parameters over a 
decade, data from the Japanese nationwide registries 
in 1994 and 1999 are also presented.
Results: In cases of lung cancer that underwent 
surgery in Japan, demographics and stage-speciÀc 
prognoses changed in the decade studied. In that 
time period, the percentages for female patients, 
adenocarcinoma, small-sized tumors (<2 cm), stage 
I or II diseases, and aged patients increased, whereas 
the rate of surgery-related deaths decreased to only 
0.8%. With those changes, the 5-YSR in 2004 of 
all lung cancer patients who underwent surgery 
was (n=11663, 7369 males, mean age 66.7 years) 
69.6%. The 5-year survival rates by c-stage and 
p-stage were as follow: IA (n=6295,4978), 82.0% 
and 86.8%; IB (n=2339, 2552), 66.8% and 73.9%; 
IIA (n=819, 941), 54.5% and 61.6%; IIB (n=648, 
848), 46.4% and 49.8%; IIIA (n=1216, 1804), 42.8% 
and 40.9%; IIIB (n=90, 106), 40.3% and 27.8%; and 
IV (n=256, 434), 31.4% and 27.9%, respectively. 
Furthermore, the prognoses of all cases and cases 
in each stage improved over the decade (Table). 
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lobectomy for patients with non-small cell lung 
cancer (NSCLC) in an attempt to stratify potential 
differences in long-term survival outcomes.
Methods: We established a multi-institutional 
registry for 4138 patients with NSCLC who 
underwent lobectomy between January 2000 
and December 2007 from eight institutions in 
the People’s Republic of China. Age, gender, 
histological type and tumor staging based on the 
latest TNM classiÀcation were entered into a non-
parsimonious multivariable logistic regression 
model. The predicted probability derived from the 
logistic equation was used as the propensity score 
for each individual. Based on similar propensity 
scores, we matched 1356 of the 1584 patients 
who underwent VATS lobectomy with 1356 of the 
2554 patients who underwent open lobectomy and 
compared their long-term survival outcomes. 
Results: The mean age of the 2712 matched 
patients was 59 (S.D. = 11) years. After 
propensity-matching, VATS and open lobectomy 
patients were similar in regards to important 
prognostic variables. Four prognostic factors 
were independently associated with improved 
survival in the multivariate analysis: gender (p = 
0.001), histological type (p < 0.001), pathological 
staging (p < 0.001) and operation type (lobectomy/
sleeve resection versus pneumonectomy (p = 
0.044). Patients who underwent VATS versus open 
lobectomy had similar long-term survival (p = 
0.101). 
Conclusion: The current propensity score 
analysis suggests that well-matched patients with 
NSCLC who underwent VATS lobectomy did not 
have inferior long-term survival outcomes when 
compared to those who underwent open lobectomy. 
Keywords: propensity score analysis, video-
assisted thoracic surgery, lobectomy, Non-small cell 
lung cancer
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
(46-314). The resection rate was 94.90… in group 
A, and 90.65… in group B.The positive rate of 
Muc-1 mRNA expression was 28.98% and 5.73% 
in peripheral blood samples in Group A beforeand 
after induction chemotherapy, respectively..The 
positive rate of Muc-1 mRNA expression was 
24.84% in Group B. No signiÀcant differences of 
blood loss, operative complications and mortality 
were observed between the group A and group 
B (P>0.05). The 1-, 3-, 5- and 10-year survival 
rates were 78.30%, 51.46 %, 27.31 % and 20.35 
% in group A, and 64.53%,40.54%, 14.19 % and 
12.64 % in group B respectively. The 1-, 3-, 5- 
and 10-year survival rates of the patients without 
micrometastasis were 89.62 %, 67.46 %, 39.61 
%and 31.75 % in group A, and 77.23%, 54.34 %, 
24.89 % and 20.87 % in group B respectively. The 
long-term survival rates in group A both with and 
without micrometastasis were remarkably higher 
than that in group B (P<0.01). 
Conclusion: The results demonstrate that the pre-
operative neo-adjuvant chemo- therapy is safe 
and effective. It is helpful to decrease the tumor 
staging, to eradicate micrometastasis in peripheral 
blood , to increase the resection rate of the tumor, 
and to improve the long-term survival rate and life 
qualities of patients with stage NSCLC. 
Keywords: Lung cancer, neoadjuvant 
chemotherapy, micrometastasis, Randomized 
clinical trial
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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O24.07 VIDEO-ASSISTED THORACIC 
SURGERY LOBECTOMY FOR NON-
SMALL CELL LUNG CANCER – A 
PROPENSITY SCORE ANALYSIS 
BASED ON A MULTI-INSTITUTIONAL 
REGISTRY
Jianxing He 
Department Of Cardiothoracic Surgery, The First 
AfÀliated Hospital Of Guangzhou Medical College/
China
Background: We conducted a multi-institutional 
propensity-matched study comparing video-assisted 
thoracic surgery (VATS) with conventional open 
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overall and quality adjusted survival outcomes 
stratiÀed by age, sex, smoking history, COPD, 
and T-stage. Sensitivity analyses on the quality 
of life utility (QoL) of SBRT, treatment-related 
death, and proportion of patients with recurrent 
disease receiving radical treatments were performed 
to determine thresholds for treatment modality 
preference.
Results: For surgical patients, overall survival (OS), 
cancer speciÀc survival, and other causes of death 
outcomes as predicted by our model correlated closely 
with Adjuvant! Online, with OS differences ranging 
from 0.0% to 3.8% at 5 years. OS differences at 5 
years between surgery and SBRT ranged from 2.2% 
to 3.0% and 0.07 to 0.09 in quality adjusted life years, 
both in favor of surgery. SBRT was preferred over 
surgery if the QoL of SBRT was  0.90. Outcomes 
were sensitive to the QoL SBRT, the proportion of 
local and regional recurrences treated with radical 
versus palliative treatments, and the surgical and 
SBRT treatment-related mortalities. For high risk 
patients, our model predicted for a beneÀt in 5-year 
OS of 4.0% to 38.2% and 8.8 to 17.4 quality-adjusted 
life months in favor of SBRT over BSC for the 4 
classes. The relative beneÀt of SBRT appeared to be 
the least for T2, GOLD III-IV patients. Outcomes 
were not sensitive to the disutility associated with 
SBRT or disease progression.
Conclusion: Markov modeling suggests that 
withholding SBRT from patients based upon their 
age and/or COPD severity appears to be unjustiÀed. 
In addition, SBRT may offer comparable overall 
survival and quality adjusted life expectancy in 
operable cases, as compared to surgical resection. 
Keywords: Stereotactic radiotherapy, markov 
model, lobectomy, best supportive care
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O25.02 CURATIVE TREATMENT 
OF STAGE I NON-SMALL CELL 
LUNG CANCER IN PATIENTS WITH 
SEVERE COPD: STEREOTACTIC 
RADIOTHERAPY OUTCOMES AND 
SYSTEMATIC REVIEW
David Palma1, Frank J. Lagerwaard2, George 
Rodrigues1, Cornelis J. Haasbeek3, Suresh Senan3 
1Radiation Oncology, London Regional Cancer 
Program/Canada, 2Radiation Oncology, 
VU University Medical Center/Netherlands, 
3Radiotherapy, VU Medical Centre/Netherlands
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O25.01 SBRT FOR MEDICALLY 
OPERABLE AND INOPERABLE EARLY 
NSCLC: MARKOV INSIGHT FOR 
OPTIMAL PATIENT SELECTION
Alexander V. Louie1, George Rodrigues1, Malek 
Hannouf2, David Palma1, Gregory S. Zaric2, Suresh 
Senan3 
1Radiation Oncology, London Regional Cancer 
Program/Canada, 2Clinical Epidemiology And 
Biostatistics, University Of Western Ontario/Canada, 
3Radiation Oncology, VU University Medical Center/
Netherlands
Background: Randomized clinical trials evaluating 
the role of SBRT in stage I NSCLC are now ongoing 
but will require several years before mature results 
are available. We therefore developed Markov 
models, which are tools for statistical modeling, 
to simulate both short- and long-term outcomes in 
different sub-groups of patients presenting with this 
disease. 
Methods: We constructed a Markov model to 
simulate the clinical history of (i) medically operable 
stage I NSCLC patients treated with either SBRT 
or lobectomy, and (ii) patients aged 75 years with 
COPD (i.e. high risk) who undergo SBRT or best 
supportive care (BSC), both for a 5-year timeframe. 
Clinical parameters for recurrence rates and Markov 
state utilities for appropriate AJCC stages of NSCLC 
were extracted and adapted to monthly time intervals 
using population based data from the California 
Cancer Registry, a prospective database of high-risk 
SBRT patients treated at the VUMC Amsterdam, 
and the available literature. For medically operable 
patients, age- and sex-speciÀc rates of death from 
all other causes were extracted from the Centre for 
Disease Control and Prevention standard life tables 
and varied according to smoking habit. To validate 
the model, surgical outcomes were compared to 
Adjuvant! Online. Elderly COPD patients were 
stratiÀed into 4 classes according to T stage (1 vs. 
2) and COPD GOLD score (I-II vs. III-IV). The 
4 patient classes were: I (T1, GOLD I-II), II (T2, 
GOLD I-II), III (T1, GOLD III-IV), and IV (T2, 
GOLD III-IV). We report various treatment strategy 
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1Radiation Oncology, VU University Medical Center/
Netherlands, 2Epidemiology And Biostatistics, VU 
University Medical Center/Netherlands, 3Pulmonary 
Diseases, VU University Medical Center/
Netherlands
Background: Stereotactic ablative radiotherapy 
(SABR) is now a standard treatment option for 
patients with stage I NSCLC who are at high-
risk for surgical mortality and morbidity, or those 
refusing surgery. A high proportion of patients are 
treated with SABR because of poor pulmonary 
function (PF) precluding a lobectomy. As long-term 
data on post-SABR PF are scarce, we investigated 
serial pulmonary function tests (PFT) in patients 
undergoing SABR at a single center. 
Methods: Baseline and serial PFT data after SABR, 
including forced expiratory volume in 1 second 
(FEV1) and vital capacity (VC) were available in 
201 stage I NSCLC patients. In a subset, baseline 
(n=134) and serial (n=86) measurements of diffusion 
capacity for carbon monoxide (DLCO) were also 
available. One hundred and seventy-one patients 
(85%) had a diagnosis of COPD, classiÀed as 
GOLD I/II (104 patients) and GOLD III/IV (67 
patients). Mixed linear models were used to estimate 
post-SABR changes in PFT parameters. Several 
patient and treatment factors were investigated for 
prognostic relevance on PF changes. 
Results: Median baseline FEV1, VC and DLCO 
were 1500 ml (59% predicted), 2940 ml (92% 
predicted) and 54% of predicted, respectively. 
SigniÀcant decreases in all three PFT parameters 
were seen following SABR (all p<.0001). The mean 
observed annual declines were 97 ml or 3.2% of the 
predicted value for FEV1, 111 ml (2.5% predicted) 
for VC and 3.5% of predicted for DLCO. The extent 
of PF-decline correlated with baseline PF. The mean 
decline in FEV1 in patients without COPD was 
5.3% versus 3.8% in COPD GOLD I/II and 1.5% 
in COPD GOLD III/IV (p=.003). Similarly, DLCO-
decline was 5.2% of predicted in the highest tertile 
(baseline DLCO>70%) versus 3.1% in the middle 
tertile (DLCO 50-70%) and 1.5% in the lowest 
tertile (DLCO<50%) (p=.032). The DLCO-decline 
was signiÀcantly greater with increasing PTV size 
(p=.0490) and age 75 years (p=.0346). Age, PTV 
size, smoking history, tumor stage and location failed 
to show a signiÀcant correlation with extent of PF-
change in FEV1 or VC. 
Conclusion: SigniÀcant decreases in commonly 
used PFT parameters were observed following 
Background: Patients with severe chronic 
obstructive pulmonary disease (COPD) have a 
high risk of lung cancer, and a high risk of post-
surgical complications. We studied outcomes after 
stereotactic ablative radiotherapy (SABR) in patients 
with severe COPD (as deÀned by Global Initiative 
for Chronic Obstructive Lung Disease [GOLD] 
criteria), and performed a systematic review of the 
literature on outcomes after SABR or surgery in 
these patients.
Methods: A single-institution cohort of 173 patients 
with COPD GOLD III-IV and stage I NSCLC treated 
with SABR was evaluated. A systematic review 
identiÀed studies reporting outcomes after SABR or 
surgery for stage I NSCLC in patients with GOLD 
III-IV or a predicted post-operative FEV1 of 40%. 
Results: In the single-institution cohort, median 
follow-up was 21 months and median overall survival 
(OS) was 32 months. Actuarial 3-year local control 
was 89%, and 1- and 3-year OS were 79% and 47%, 
respectively (Figure 1A-B). COPD severity correlated 
with OS (p=0.01, Figure 1C). The systematic review 
identiÀed four other studies (two surgical, two SABR, 
n=196 patients). SABR studies were published more 
recently and included older patients than surgical 
studies. Mean thirty-day mortality was 0% post-SABR 
and 10% after surgery. Local or loco-regional control 
was high (89%) after both treatments. Post-SABR, 
actuarial OS was 79-94% at 1 year and 43-70% at 
3 years. Post-surgical actuarial OS was 45-86% at 1 
year and 31-66% at 3 years.
Conclusion: SABR and surgery differ in risk of 30-
day mortality in patients with severe COPD. Despite 
the negative selection of SBRT patients, survival 
at 1- and 3-years is comparable between the two 
treatments.
Keywords: Non-small cell lung cancer, chronic 
obstructive pulmonary disease, Surgery, Stereotactic 
radiotherapy
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O25.03 QUANTIFYING PULMONARY 
FUNCTION CHANGES AFTER 
STEREOTACTIC ABLATIVE 
RADIOTHERAPY (SABR) FOR STAGE I 
NON-SMALL-CELL LUNG CANCER
Erik C. Phernambucq1, Frank J. Lagerwaard1, Peter 
M. Van De Ven2, Herman Groepenhoff3, Pieter E. 
Postmus3, Ben Slotman1, Egbert F. Smit3, Suresh 
Senan1 
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of 811 patients enrolled from 31 institutions, 545 
adenocarcinoma patients who underwent lobectomy 
and lymph node dissection were included in this 
analysis. Based on contrast-enhanced thin-section 
computed tomography (TSCT) scans, we determined 
consolidation/tumor (C/T) ratio as the proportion of 
the maximum consolidation diameter to the maximum 
tumor diameter. Radiological non-invasive lung 
adenocarcinoma was deÀned as a tumor with a C/T 
ratio  0.5. We also examined exploratory deÀnition 
with a C/T ratio  0.25 in the cT1a population. 
Pathological non-invasive cancer was deÀned as a 
cancer without nodal involvement, vascular invasion, 
and lymphatic permeation. The primary endpoint was 
the speciÀcity for the radiological diagnoses of non-
invasive lung adenocarcinoma based on C/T ratios. 
We set the expected speciÀcity to be greater than 97%. 
Overall survival (OS) was calculated by the Kaplan-
Meier method. 
Results: There were 233 men and 312 women. 
Median age was 62 years (range, 35 to 75). Median 
follow-up period was 6.1 years (range, 0 to 7.5). 
Radiological non-invasive lung adenocarcinomas 
were observed in 121 (22.2%) patients among the 
entire population and 35 (12.1%) in cT1a population 
(n = 289), respectively. Among radiological non-
invasive lung adenocarcinomas, pathological non-
invasive cancers were diagnosed in 115 (95.0%) 
patients in the entire population and 34 (97.1%) in 
cT1a patients, respectively. The speciÀcities for the 
radiological correct diagnosis of pathological non-
invasive lung adenocarcinomas were 96.4% (95% 
CI: 92.3-98.7%) for all population and 98.7% (95% 
CI: 93.2-100.0%) for patients with cT1a tumor. 
Our radiological deÀnition of non-invasive lung 
adenocarcinoma on TSCT did not statistically meet 
our pre-determined criterion for speciÀcity. However, 
the exploratory deÀnition of C/T ratio  0.25 for 
cT1a tumor demonstrated acceptable speciÀcity. The 
5-year OS rates of the entire population and cT1a 
population were 90.5% and 93.0%, respectively. For 
radiological non-invasive cancers, the 5-year OS 
rates were 96.7% and 97.0% in the cT1 (n = 121) 
and cT1a (n = 35) patients, respectively. One patient 
with radiological non-invasive lung adenocarcinoma 
in the entire cT1 cohort died of cancer recurrence, 
but none of the cT1a patients died of cancer. 
Conclusion: Our pre-deÀned criterion failed 
to predict pathological non-invasive lung 
adenocarcinoma, but exploratory deÀnition of a C/T 
ratio  0.25 in T1a tumor demonstrated promising 
speciÀcity and good survival. This exploratory 
SABR. The largest decreases were observed in 
patients who had normal baseline PFTs, implying 
that the changes are SABR-related rather than due to 
the natural course of underlying pulmonary disease. 
Limited PF decline in patients with severe/very 
severe COPD may explain the tolerability of SABR 
in these patients. 
Keywords: Stage I NSCLC, Stereotactic ablative 
radiotherapy, Pulmonary function changes
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O25.05 FIVE YEAR-SURVIVAL 
DATA OF RADIOLOGICAL NON-
INVASIVE PERIPHERAL LUNG 
ADENOCARCINOMA; PROSPECTIVE 
COHORT STUDY FOR STAGE IA LUNG 
ADENOCARCINOMA (JCOG0201)
Tomoyuki Hishida1, Kenji Suzuki2, Teruaki Koike3, 
Masahiko Kusumoto4, Hisao Asamura4, Kanji 
Nagai1, Tada Hirohito5, Motohiro Yamashita6, 
Tetsuya Mitsudomi7, Norihiko Ikeda8, Taro Shibata9, 
Hisashi Saji8, Masahiro Tsuboi10, Japan Lung Cancer 
Surgical Study Group (JCOG-LCSSG)4 
1Thoracic Surgery, National Cancer Center Hospital 
East/Japan, 2General Thoracic Surgery, Juntendo 
University School Of Medicine/Japan, 3Chest 
Surgery, Niigata Cancer Center Hospital/Japan, 
4National Cancer Center Hospital/Japan, 5Osaka 
City General Hospital/Japan, 6Shikoku Cancer 
Center Hospital/Japan, 7Aichi Cancer Center 
Hospital/Japan, 8Tokyo Medical University/Japan, 
9Jcog Data Center, National Cancer Center/Japan, 
10Kanagawa Cancer Center Hospital/Japan
Background: Patients with peripheral small 
lung adenocarcinomas are increasing in number. 
Pathological non-invasive lung adenocarcinomas 
might be cured by limited lung resection with an 
adequate surgical margin. However, pathological 
non-invasiveness needs to be correctly predicted in 
preoperative radiological examinations to indicate 
limited surgery. The aim of this study is to validate 
our radiological deÀnition of non-invasive lung 
adenocarcinoma by pathological Àndings and to 
evaluate long-term prognosis.
Methods: Patients with a tumor suspected or 
diagnosed as clinical T1N0M0 peripheral lung 
adenocarcinoma were prospectively recruited by 
a multi-institutional study (JCOG0201) between 
December 2002 and May 2004. Among a total 
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nodule size was 17.4 mm (6-30), including, 66 
(57,3%) patients with nodules up to 20 mm (T1a) 
and 49 (42.7%) greater than 20 mm (T1b). 18 patiens 
of the T1a group presented subcentimeter nodules. 
Men: 54.7%. Mean age 61 years (44-85). Histology: 
adenocarcinoma (82.6%), squamous (6.1%), 
bronchioloalveolar (5.2%), large cell undifferentiated 
(3.5%), adenosquamous (1.7%) and large cell 
neuroendocrine (0.9%). Lobectomy was performed 
in 101 patients (87.8%) and sublobar resection in 14 
(12.2%). 55.2% were smokers, 21% former smokers 
and 23.8% never smoked. 97.9% were asymptomatic. 
Unsuspeted N2 compromise was present in 9 (7.8%) 
patients. When divided into subgroups, 3 (4.5%) 
were T1a and 6 (12.2%) were T1b (p=0,14). All the 
unsuspected N2 was observed un tumors located 
un upper or middle lobes (9/80,11,2%), and none in 
lower lobes (0/35,0%) (p= 0,03). No nodules less 
than 10 mm showed N2 disease. The side, age, sex, 
tumor type and histology does not correlates with 
unsuspected N2 (P=NS). The Àve years survival was 
91% in T1a, and 84% in T1b patients (p=0,12). 8 
patients (12,1%) have a recurrence in T1a group and 
11 (22,4%) in T1b (p=0,01). The Àve years survival 
was 83% in N2 patients.
Conclusion: In patients with clinical stage IA with 
nodules up to 2 cm (T1a) the incidence of unsuspected 
N2 disease is very low (4,5%). The surgical resection, 
without invasive staging, achieves a satisfactory 
5 years survival (91%) in this group of patients. 
Subcentimeter and lower lobes nodules nodules 
showed no unsuspected N2 nodal metastastasis.
Keywords: Lung cancer, Early Stage NSCLC, 
Lymph nodes, Metastasis
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O25.07 TUMOR RESPONSE AND 
TOXICITY IN NEO-ADJUVANT 
ERLOTINIB IN EARLY STAGE NSCLC 
PATIENTS
Eva E. Schaake1, Houke M. Klomp2, J A. Burgers3 
1Thoracic Oncology, NKI-AVL/Netherlands, 
2Surgical Oncology, NKI-AVL/Netherlands, 
3Thoracic Oncology, The Netherlands Cancer 
Institute/Netherlands
Background: Despite radical surgery in patients with 
early-stage non-small cell lung cancer (NSCLC), disease 
recurs in 40% of the patients. The development of 
“targeted therapy” has created new options to improve 
deÀnition can be used to select candidates for 
wide wedge resection or segmentectomy without 
lymph node dissection. The result of our ongoing 
prospective limited resection trial based on this 
deÀnition (JCOG0804/WJOG4507L) is awaited. 
Keywords: small lung adenocarcinoma, non-
invasive lung adenocarcinoma, Limited Resection
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O25.06 UNSUSPECTED N2 IN PATIENTS 
WITH CLINICAL STAGE IA NON-
SMALL CELL LUNG CANCER: IMPACT 
OF CURRENT STAGING AND TUMOR 
LOCATION.
Gustavo A. Lyons1, Leonardo Pankl1, Silvia 
Quadrelli2, Carlos Silva3, Domingo J. Chimondeguy1 
1Thoracic Surgery, Buenos Aires British Hospital/
Argentina, 2Respiratory Medicine, Buenos Aires 
British Hospital/Argentina, 3Oncology, Buenos Aires 
British Hospital/Argentina
Background: Accurate staging in non small cell lung 
cancer (NSCLC) is essential to deÀne the appropriate 
treatment, primary being the affection of mediastinal 
lymph node groups (N2). For this, many imaging and 
invasive mediastinal staging tests are available. The 
data are confusing because patients with particular 
characteristics (ie, node size or location) are selected 
for different staging procedures. The purpose of this 
study was to determine the incidence of unexpected N2 
compromise in patients with clinical stage I NSCLC.
Methods: This study was designed as a retrospective 
cohort. An analysis of consecutive patients operated 
on with curative intent in a single thoracic surgery 
department, presenting as a pulmonary nodule up 
to 3 cm in diameter, with no hilar or mediastinal 
lymphadenopathy on computed tomography or 
clinical examination in supraclavicular region, with 
Ànal histological diagnosis of NSCLC between 2000 
and 2010 was carried out. When present, site-speciÀc 
symptoms were evaluated with the most appropiate 
study (eg, bone scans, magnetic resonance imagery 
or CT of the brain). Incidence of unsuspected N2 
disease was analyzed according the tumor size (2 
cm, >2 to 3 cm), side, lobe location (upper and 
midde, versus lower lobes), sex, age, tumor type 
and smoking history. Survival rates were calculated 
by the Kaplan-Meier method, while survival curves 
were compared using a log-rank test.
Results: There were 115 patients. The average 
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Table patient characteristics 
Characteristics 
Total 
population 
Enriched 
population 
Unselected 
population 
N=60 % N=29 % N=31 % 
Sex M/F 26/34 43-57 3/26 11/99 22/09 72/28 
Mean Age at 
diagnose 64 
range 
37-38 59,4 36-73 64 50-76 
Histology 
Large cell 4 7 1 3 3 11 
Squamouscell 12 20 0 0 12 39 
Adenoca 38 63 26 90 12 39 
Other 6 10 2 7 4 13 
Mutation status 
EGFR mutation 7 12 5 17 2 7 
K-ras mutation 12 20 6 21 6 19 
Median change 
SUV max -10% 
-78% 
to 
76% -20% 
-78% 
to 
43% 0,70% 
-56% 
to 76% 
Median change 
mm T -0,3 
-39 to 
68 -1,3 
-39 to 
17 -0,7 
-35 to 
68 
Median % 
necrosis 29% 
0 to 
97% 40% 
0 to 
97% 18% 
0 to 
60% 
Conclusion: We conclude that only 3-weeks of daily 
erlotinib has sufÀcient activity to deserve further 
testing in future studies in an enriched population 
(response 34%). Metabolic evaluation of response 
by [18F]-FDG-PET may reÁect clinical activity of 
erlotinib more accurately than CT. 
Keywords: toxicity, erlotinib, Neo adjuvant 
treatment, Treatment response
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O26.01 GENOMIC HETEROGENEITY 
BETWEEN PRIMARY NON-SMALL CELL 
LUNG CANCER AND ITS METASTASES
Wen-Zhao Zhong1, Zhi-Yong Chen2, Xu-Chao 
Zhang1, Jian Su1, Xue-Ning Yang1, Zhi-Hong Chen1, 
Jin-Ji Yang1, Qing Zhou1, Hua-Jun Chen1, Tony 
Mok3, Yi-Long Wu1 
1Guangdong Lung Cancer Institute, Guangdong 
General Hospital And Guangdong Academy Of 
Medical Sciences/China, 2Guangdong Lung Cancer 
outcome in selected patients. This report presents the 
results regarding toxicity and response to neoadjuvant 
erlotinib in NSCLC. 
Methods: This study was designed as an open-label 
phase II trial, performed in four hospitals in the 
Netherlands, according to a Simon’s minimax 2-stage 
procedure. Initially, operable patients with early-
stage NSCLC (minimum of n=15) entered from an 
“enriched” population (two or more of the following 
features: never-smoker, female, non-squamous 
histology and/or Asian ethnicity), thereafter inclusion 
was open for all operable patients to a total of 60 
patients. Patients received preoperative erlotinib 150 
mg once daily for 3 weeks. Response to treatment was 
evaluated with [18F]-FDG-PET, CT and pathological 
examination of the resection specimen. Primary 
endpoints were toxicity and pathologic response. 
Results: Between December 2006 and November 
2010, 60 patients were included. In total 29 patients 
met the enrichment criteria and 31 patients without 
enriched features were entered. Seven patients stopped 
erlotinib prematurely (12%). No unexpected toxicity or 
postoperative complications were seen. Skin toxicity, 
any grade, was present in 37 patients (62%), diarrhea in 
21 patients (35%). PET evaluation revealed a metabolic 
response (>25% SUV decrease) in 14 patients (26%), 
CT evaluation by RECIST showed response in 3 
(5%), whereas pathologic response was seen in 14 
patients (23%), with 3 (5%) near-complete pathologic 
responses. The enriched population showed metabolic 
response in 10 patients versus 6 in the unselected 
population. Both EGFR and k-RAS mutation status 
were found in both populations, with 5 EGFR 
mutations and 6 k-RAS mutations in the enriched 
population and respectively 2 and 6 mutations in the 
unselected population. In eight cases not enough tumor 
material was available to assess the tumor mutation 
status. Characteristics and response data of both groups 
are shown in the Table. 
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O26.02 KRAS AND EGFR MUTATIONAL 
RATE, DISCORDANCE AND OUTCOME 
ANALYSIS IN METASTATIC 
LUNG ADENOCARCINOMAS 
IN COMPARISON TO PRIMARY 
LUNG ADENOCARCINOMA. A 
RETROSPECTIVE STUDY OF 344 CASES.
Delicia Munfus-Mccray1, Shuko Harada2, Rex C. 
Yung3, Christina Adams1, Frederic Askin4, Edward 
Gabrielson5, Qing Kay Li6 
1Pathology, Johns Hopkins Medical Institutes/United 
States Of America, 2Molecular Genetic Pathology, 
Johns Hopkins Medical Institutes/United States Of 
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States Of America, 4Pathology, Johns Hopkins 
Medical Institutes At Bayview/United States Of 
America, 5Molecular Pathology, Johns Hopkins 
Medical Institutes/United States Of America, 
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Background: In primary lung adenocarcinoma, 
EGFR and KRAS mutations have been reported in 
approximately 10-20% and 20-30%, respectively. 
Although EGFR mutation is associated with a 70-
80% response rate to tyrosine-kinase inhibitors 
(TKIs) therapy and a longer progression free 
survival rate, an association between the KRAS 
mutation and lack of response to TKIs has also been 
observed. However, the utility of determining KRAS 
mutational status in both primary and metastatic 
tumors remains unclear. In this study, we have 
investigated EGFR and KRAS mutational status in 
both primary and metastatic lung adenocarcinoma, 
with an emphasis on metastatic tumors. 
Methods: Using department of pathology 
archives at the Johns Hopkins Hospital, 2,657 
lung adenocarcinomas were found from January 
2007 to December 2010. EGFR and KRAS studies 
were performed in 375 cases. Among them, 221 
primary and 123 metastatic adenocarcinomas were 
analyzed, which included thirteen pairs of primary 
and matched metastases. DNA was isolated from 
the samples, quantiÀed and ampliÀed by polymerase 
chain reaction (PCR) using primers to exons 18-21 
of the EGFR gene and exon 2 of the KRAS gene 
(in codons 12 and 13). PCR products were analyzed 
by Genzyme for EGFR mutations and by Sanger 
sequencing for KRAS mutations. 
Institute, Guangdong Academy Of Medical Sciences 
& Guangdong General Hospital/China, 3Department 
Of Clinical Oncology, The Chinese University Of 
Hong Kong/Hong Kong
Background: Patients with epidermal growth factor 
receptor (EGFR) activated mutation are known to 
have mixed response to tyrosine kinase inhibitor 
(TKI). Intertumoral heterogeneity in EGFR and/
or KRAS mutation heterogeneity is a potential 
explanation and this study aims to investigate the 
discordance of these mutations in patients with non-
small cell lung cancer(NSCLC).
Methods: We performed direct sequencing for EGFR 
and KRAS mutation in 219 pairs of tumor samples 
(from a database of 2873 samples). The matching 
samples were divided into four groups: Group T are 
primary tumors detected at different time points (n = 
72), Group N are primary lung tumor with matched 
metastatic lymph nodes (n = 58), Group M1a are 
multiple pulmonary nodule (n = 53), and Group 
M1b are primary lung tumor with matched distant 
metastases (n = 36). Multivariate analysis and kappa 
values were used to explore the role of heterogeneity.
Results: EGFR, KRAS, and EGFR/KRAS 
heterogeneity discordance of the studied population 
(185 paired samples without exposure to TKI) is 
14% (kappa = 0.67), 8.8% (kappa = 0.59), and 21.2% 
(kappa = 0.51), respectively. Group M1a has the 
highest EGFR/KRAS mutation discordance of 37.6% 
(18/48; kappa = 0.38, p < 0.001), followed by Group 
N at17.3% (9/52; kappa = 0.64),Group T at 17.2% 
(10/58; kappa = 0.63), and Group M1b at 7.4% (2/27; 
kappa = 0.84). The EGFR/KRAS heterogeneity 
was 19.6% in the remaining 107 cases without 
systematic therapy. In the total 219 paired samples(34 
pairs samples with TKI therapy, 78 pairs samples 
with chemotherapy, 107 pairs samples without any 
systematic therapy), the potential mutagenic effects 
of TKI therapy (p = 0.001) were not reÁected in 
chemotherapy (p = 0.43) in multivariate analysis.
Conclusion: Heterogeneity in EGFR/KRAS mutation 
status is signiÀcant and particularly in patients with 
multiple pulmonary nodule. Our results provide a 
potential explanation for the mixed tumor response to 
EGFR TKI.
Keywords: Lung neoplasms, Epidermal growth factor 
receptor, Kras, heterogeneity
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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Background: EGFR mutation status is the best 
predictor of response to tyrosine kinase inhibitors 
in adenocarcinoma of lung. Approximately 70% 
of lung cancers are diagnosed in advanced stages 
where small biopsies and cytological specimens 
are the only source of material for both diagnosis 
and mutation testing. Recently antibodies that can 
detect mutant EGFR protein have been introduced. 
We evaluated the detection of EGFR mutation 
by immunohistochemistry (IHC) in small biopsy 
specimens of lung adenocarcinoma and correlated 
with EGFR mutation status. 
Methods: 38 cases of adenocarcinoma were 
analyzed (8 core biopsies and 30 cytology cell 
blocks). Antibodies against the L858R mutation and 
the exon 19 deletion (15bp deletion) were used under 
optimized condition (C ell Signaling Technology). 
Stains were scored as negative , 1+ (weak and 
focal positivity), 2+ (moderate intensity and focal 
positivity), 3+ (strong and diffuse positivity). All 
biopsies and cell blocks were analyzed by standard 
molecular methods to detect EGFR mutations. The 
results of these two techniques were correlated. 
Results: Deletions in exon 19 were detected in 36 
%, (8 cores and 6 cell blocks) and L858R mutation 
in 16% (6 cell blocks) of all cases by standard 
molecular methods. Using a cutoff of 2+ or 3+ as 
positive by IHC, the positive predictive value (PPV) 
for L858R mutation and exon 19 deletion was 100% 
each (no false positive cases were detected at this 
cut-off point). The negative predictive values (NPP) 
were 88% and 78 % respectively which reÁect the 
rate of false negative results (4 cases for L858R and 
6 cases for exon 19 deletion). When staining scores 
of 1+ are considered positive, the PPV for L858R 
mutation is of 100%, and 88% for exon 19 deletion. 
The drop in PPV is a result of 2 false positive cases 
detected at this cut-off point using L858R speciÀc 
antibody. The negative predictive value is of 100% 
for both antibodies since no false negative cases are 
indentiÀed. 
Conclusion: Immunostain for speciÀc mutant EGFR 
show a good correlation with mutation analysis 
and can be used as a screening method to identify 
patients for tyrosine kinase inhibition therapy. Cases 
with weak positivity (1+) should be considered 
equivocal due to risk of false positive results. Only 
cases with positivity of 2-3+ should be considered as 
true positive which increases the PPV of the test. All 
equivocal (1+) and negative results by IHC should 
prompt standard molecular methods for detection of 
EGFR mutation. The IHC methodology is potentially 
Results: Patient ages ranged from 29 to 90 years old 
with a median of 62 years old. In metastatic cases, 
59.3% were Caucasian, the male:female ratio was 
1:0.92 and 67.5% (83/123) were current or former 
smokers. EGFR and KRAS mutations in both 
primary and metastatic tumors were summarized in 
Table 1. In metastasis, KRAS mutations occurred 
exclusively in smokers and revealed higher 
mutational rates in all sites than that of primary 
tumors, except in the pleura. 36 of the 41 (87.8%) 
KRAS mutational cases presented as stage III or IV 
cancers and were associated with a shorter survival. 
Furthermore, of the 13 paired cases, EGFR and 
KRAS mutations were concordant in 84.6%; one 
pair displayed acquisition of KRAS mutation, while 
one pair showed loss of EGFR mutation in the 
corresponding metastasis. 
EGFR and KRAS Analysis in Lung Adenocarcinoma 
Categories 
Number 
of cases 
EGFR mutation 
Number  
(ratio, percentage) 
KRAS Mutation 
Number (ratio, 
percentage) 
Primary 
Carcinoma 
221 44 (44/221, 19.9%) 52 (52/221, 23.5%) 
Metastatic 
Carcinoma 
123 19 (19/123, 15.4%) 41 (41/123, 33.3%) 
Lymph node 62 6 (6/62, 9.7%) 25 (25/62, 40.3%) 
Brain 17 5 (5/17, 29.4%) 5 (5/17, 29.4%) 
Pleural 19 5 (5/19, 26.3%) 1 (1/19, 5.3%) 
Bone 5 0 3 (3/5, 60%) 
Other 20 3 (3/20, 15%) 7 (7/20, 35%) 
Conclusion: Our data suggested that EGFR and 
KRAS status might not be stable in metastases, thus, 
they should be tested in metastasis regardless of 
known mutations of the primary tumor.Additional 
studies are needed to further investigate mechanisms 
of higher KRAS mutations and discordances in 
metastatic tumors. 
Keywords: Adenocarcinoma, Metastatic, EGFR, 
Kras
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O26.03 USE OF MUTATION SPECIFIC 
ANTIBODIES TO DETECT EGFR 
STATUS IN SMALL BIOPSY AND 
CYTOLOGY SPECIMENS OF LUNG 
ADENOCARCINOMA.
Andre L. Moreira, Adnan Hasanovic 
Pathology, Memorial Sloan-Kettering Cancer 
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Table 1 Total 
Cases 
Resection Biopsy FNA Fluid P value 
N 601 230 290 55 26 - 
N % N % N % N % N % - 
Mutation (+) 219 36.4 83 36.1 104 35.9 23 41.8 9 34.6 0.85** 
EGFR m(+) 
Ex19del
L858R
Other* 
106 
55 
27 
33 
17.6 
9.2 
4.4 
5.5 
36
20
8
10 
16.0 
8.9 
3.6 
4.4 
54 
27 
12 
20 
18.6 
9.3 
4.1 
6.9 
12 
7 
4 
3 
21.8 
12.7 
7.3 
5.5 
4 
1 
3 
0 
15.4 
3.8 
11.5 
0 
0.67** 
0.62** 
0.16*** 
0.44*** 
KRAS m(+) 
Codon 12 
Codon 13 
114 
104 
10 
19.0 
17.3 
1.7 
47 
43 
4 
20.4 
18.7 
1.7 
51 
47 
4 
17.6 
16.2 
1.4 
11 
9 
2 
20.0 
16.4 
3.6 
5 
5 
0 
19.2 
19.2 
0 
0.87** 
0.88** 
0.58*** 
InsufÀcient 17 2.8 0 0 14 4.8 2 3.6 1 3.8 0.001*** 
* Values of mutation sub-type do not add up to total mutation count as 
some specimens have dual mutations (most notably T790M in conjunction 
with other mutations) ** Chi-square test for differences across groups (not 
including Total Cases group) *** Fisher exact test for differences across 
groups (not including Total Cases group) Abbreviations: m: mutation; (+): 
positive result; Ex19del: Exon 19 deletion 
Conclusion: These data indicate that all specimen 
types evaluated are potentially adequate substrates 
for mutation testing in NSCLC, and that mutation 
testing can be successfully performed on small 
specimens such as biopsies, FNAs or Áuids. These 
Àndings further suggest that small specimens are 
potentially adequate substrates for molecular testing 
in the setting of post-treatment re-biopsy for the 
purpose of ‘molecular restaging’, although treatment 
related changes may impact the number and viability 
of tumor cells . These data also conÀrm that non-
resection cases have a higher rate of insufÀcient 
material for testing compared to resection cases. 
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O26.06 MOLECULAR CORRELATION 
WITH HISTOLOGIC PATTERNS OF 
MUCIN IN LUNG ADENOCARCINOMA 
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1Department Of Pathology And Surgery, Memorial 
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Background: The new IASLC/ATS/ERS 
classiÀcation of lung ADC identiÀes invasive 
mucinous adenocarcinoma (IMA) and colloid 
adenocarcinoma (COL) as variant subtypes. While 
signet-ring cell (SRC) and extracellular mucinous 
(ECM) features are additional patterns, they are not 
useful as a screnning test for the detection of mutated 
EGFR specially in areas where molecular analysis 
is not available and for use in small biopsies when 
material is too scant for molecular analysis.
Keywords: EGFR mutation, small biopsy, 
immunohistology
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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O26.05 MUTATIONS ARE DETECTED 
AT COMPARABLE FREQUENCIES IN A 
VARIETY OF SPECIMEN TYPES IN NON-
SMALL CELL LUNG CARCINOMA
Kevin L. Tyler1, Kathleen Torkko1, David R. 
Camidge2, Robert C. Doebele2, Wilbur Franklin1, 
Dara L. Aisner1 
1Pathology, University Of Colorado Denver/United 
States Of America, 2Medical Oncology, University Of 
Colorado/United States Of America
Background: Molecular characterization of non-
small cell lung carcinoma (NSCLC) is increasingly 
critical for selection of optimal therapy in advanced 
stage disease. In most patients with advanced-
stage disease, diagnosis is based upon small biopsy 
or cytopathology specimens, which can present 
challenges for molecular testing. To determine the 
feasibility of testing on various specimen types, we 
evaluated the outcome of mutation testing for EGFR 
and KRAS with regard to specimen type. 
Methods: We retrospectively evaluated all NSCLC 
cases tested for EGFR and KRAS mutation status, as 
determined by direct sequencing, from October, 2008 
to January, 2011 by review of the in-house laboratory 
database. Specimens were classiÀed according to 
specimen type as surgical resection (R), biopsy (Bx), 
Àne needle aspiration (FNA) and Áuids (F). Overall 
mutation detection rate for any mutation in both 
EGFR and KRAS was determined, as was detection 
rate for individual mutations. 
Results: 601 cases of NSCLC were evaluated for 
EGFR and KRAS mutation in the study period. 
Similar overall mutation detection rate, EGFR 
mutation detection rate and KRAS mutation 
detection rate was found in all specimen types (Table 
1). InsufÀcient specimen rates were higher in non-
resection cases compared to resection cases.
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well recognized. It can occur with multiple ADC 
histologic subtypes (mostly acinar) and it shows a 
strong association with KRAS mutation. Patients 
with >10% ECM had a favorable 3 yr RFS (82%). 
KRAS mutation was also associated with IMA, but 
was present in only 25% of COL. 
Keywords: histologic pattern, lung, 
Adenocarcinoma, Kras
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O26.07 FEASIBILITY OF MUTATIONAL 
ANALYSIS OF EGFR AND K-RAS IN 
CYTOLOGICAL SAMPLES OF NSCLC 
PATIENTS: CORRELATION WITH 
CLINICAL OUTCOMES.
Maria D. Lozano1, Tania Labiano1, Jose I. 
Echeveste1, Alfonso Gurpide2, Luis M. Seijo3, Javier 
J. Zulueta3, Anabel Del Barrio2, Salvador Martin-
Algarra2, Ruben Pio4, Jose Luis Perez-Gracia2 
1Pathology, University Of Navarra/Spain, 2Oncology, 
University Of Navarra/Spain, 3Respiratory Medicine, 
University Of Navarra/Spain, 4Center For Applied 
Medical Research. Division Of Oncology, University 
Of Navarra/Spain
Background: Determination of molecular predictive 
factors should be considered and performed 
if deemed necessary in every NSCLC patient. 
Epidermal growth-factor receptor (EGFR) and K-ras 
mutations guide treatment selection in non-small cell 
lung cancer (NSCLC) patients. Although mutation 
status is routinely assessed in biopsies, cytological 
specimens are frequently the only samples available. 
These samples are commonly regarded as inadequate 
for comprehensive molecular analysis. Then, patients 
diagnosed by cytology are frequently considered 
ineligible for molecular analysis and individualized 
treatment selection, leaving the options of either 
obtaining a new tumor sample or not performing 
molecular analysis. We determined EGFR and K-ras 
mutations in a series of 254 cytological samples. 
Methods: DNA was extracted from 254 consecutive 
samples, including: 204 Papanicolau smears 
(80.3%), 21 cell blocks (8.3%), 9 fresh samples 
(3.5%), 13 ThinPrep (5.1%), and 6 body cavity 
Áuids (2.4%). Papanicolau smears were analyzed 
when they had >50% of malignant cells. PCR and 
direct sequencing of exons 18-21 of the EGFR gene 
and of exon 2 of the K-ras gene were performed. 
EGFR mutations were simultaneously determined in 
regarded as histologic subtypes as they can occur 
in multiple subtypes. The aim of this study was to 
investigate the association between the spectrum of 
mucinous patterns in ADC with EGFR and KRAS 
mutation status. 
Methods: H&E slides of 784 resected ADC (603 
stage I, 94 stage II, 87 stage IIIA) with EGFR and 
KRAS mutation data from 2002 to 2009 were 
reviewed with an emphasis on mucinous patterns. 
Comprehensive histologic subtyping was used to 
estimate the percentage of each histological subtype, 
and tumors were classiÀed according to the new 
IASLC/ATS/ERS classiÀcation. Signet-ring cell 
(SRC) features and ECM were estimated in 10% 
increments. 
Results: There were 1 mucinous minimally invasive 
adenocarcinoma (MIA), 29 IMA, 4 COL, 38 cases 
with 10% SRC features, and 83 cases with 10% 
ECM (Table). The patient with mucinous MIA had 
KRAS mutation. Among the IMA patients, 66% had 
KRAS mutation. Of the 4 COL patients, one had 
KRAS mutation with the other 3 being wild type. 
IMA/COL subtype correlated with KRAS mutation 
compared to EGFR mutation and wild type (p<0.001 
and p<0.001, respectively). Among the patients with 
SRC features, 26% had KRAS mutation, 8% EGFR 
mutation, and 66% wild type. Among the patients 
with ECM, 42% had KRAS mutation, 7% EGFR 
mutation, and 51% wild type. Presence of ECM 
correlated with KRAS mutation compared to EGFR 
and wild type (p<0.001, each). The mucinous MIA 
patient has no evidence of disease at the time of this 
study while three-year recurrence free survival (RFS) 
was 46% in IMA, 50% in COL, 75% in ADC with 
SRC, and 82% in ADC with ECM. 
Conclusion: ECM is a histologic feature occurring 
in approximately 10% of lung ADC that is not 
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Background: The EGFR acquired mutation 
resistance T790M causes resistance to the reversible 
ATP-competitive EGFR kinase inhibitors geÀtinib 
or erlotinib, and to the irreversible EGFR inhibitors 
BIBW2992 and HKI-272 in non-small cell lung 
cancer. PF00299804 (PF) is an irreversible EGFR 
inhibitor effective in NSCLC models harboring 
EGFR T790M and WZ4002 (WZ) is a mutant-
selective EGFR inhibitor with high potency against 
the EGFR T790M. The mechanisms of resistance to 
PF and WZ in EGFR mutated models are not well 
deÀned.
Methods: Resistant clones were obtained by 
prolonged exposure of PC9 cells (EGFR del E746_
A750) to increasing doses (up to 1 M) of PF (PFR 
clones) and high doses (1 M) of WZ (WZR clones). 
IC50 was > 1 M (>100 fold higher than that of 
parental PC9 cells) for the PFR clones and > 100 nM 
(>10 fold higher than that of parental PC9 cells) for 
the WZR clones.
Results: We found that both PFR and WZR clones 
maintained Akt but neither EGFR nor ERK 1/2 
activity upon PF or WZ treatment. No T790M 
or C797S mutation was detected. However, 
the resistant cells contained activated IGF1R 
signaling. Concomitant treatment with the IGF1R 
kinase inhibitor BMS 536924 led to phospho-
Akt downregulation and inhibition of growth 
proliferation in PFR and WZR clones upon EGFR 
inhibition. IGFBP3 was down-regulated in the 
resistant clones, both at the mRNA and protein 
levels, and treatment with recombinant IGFBP3 
re-sensitized these cells to EGFR inhibition. 
Knockdown of IGFBP3 through RNA interference 
in parental PC9 cells conferred partial resistance to 
PF treatment. Sustained exposure of the resistant 
clones to PF or WZ (1 M) led to the emergence 
of clones with a different phenotype characterized 
by maintained Akt and ERK 1/2 but not EGFR 
activity upon PF or WZ treatment, and loss of 
DUSP6 expression. These cells (named “PFR+” 
and “WZR+”) were resistant to EGFR and IGF1R 
inhibitors combination but sensitivity was partly 
restored with the addition of the MEK inhibitor 
CI-1040 or overexpression of DUSP6. PFR+ cells 
had a proliferative advantage over PFR cells in the 
presence of PF.
Conclusion: Resistance to EGFR inhibitors that 
are effective against EGFR T790M in PC9 cells 
can occur through a multistep process that involves 
sequential activation of IGF1R and MAP kinase 
signaling. Our Àndings reveal both mechanistic 
biopsies and cytological samples from 50 patients. 
Activity of EGFR tyrosine-kinase inhibitors (TKI) 
was assessed. 
Results: Cytological diagnosis was adenocarcinoma 
in 187 samples (73.6%), Sqcc in 48 (18.9%), and 
NSCLC-NOS in 19 (7.4%). EGFR mutations 
were identiÀed in 32 samples (12.6%) and K-ras 
mutations in 28 (11%). EGFR and K-ras mutations 
were mutually exclusive. In EGFR mutated cases, 
DNA was obtained from stained smears in 204 cases 
(80.3%), fresh samples in 17 (6.7%), ThinPrep in 13 
(5.1%), and cell block in 21 (8.3%). Response rate to 
EGFR TKI in patients harboring mutations was 75%. 
Mutation status was identical in patients who had 
both biopsies and cytological samples analyzed. 
Conclusion: Cytological samples, including 
stained smears, are adequate for determination 
of EGFR and K-ras mutation status in NSCLC 
patients. The quality of the sample, rather than the 
method to obtain it, is a critical factor to obtain 
adequate results. Joint mutation assessment in both 
cytological samples and biopsies, was concordant, 
suggesting mutation analysis from cytological 
samples is comparable to that derived from biopsy 
samples. This technique might allow to perform 
individualized treatment selection in NSCLC patients 
diagnosed by cytological samples, precluding the 
need for additional biopsies. 
Keyword: NSCLC, Cytology, Papanicolau stained 
smears, EGFR, K-ras, TKI
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O27.01 RESISTANCE TO EGFR T790M 
KINASE INHIBITORS THROUGH A 
MULTISTEP PROCESS INVOLVING THE 
IGF1R PATHWAY
Alexis B. Cortot1, Claire E. Repellin1, Takeshi 
Shimamura1, Marzia Capelletti1, Kreshnik 
Zejnullahu1, James Christensen2, Kwok-Kin Wong1, 
Natanael Gray1, Pasi A. Janne1 
1Medical Oncology, Dana Farber Cancer Institute/
United States Of America, 2Department Of Research 
Pharmacology, PÀzer Global Research And 
Development/United States Of America
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the antibody. The puriÀed antiserum was 
used to examine brain extracts from wildtype 
and PIMT deÀcient mice, and it was used for 
immunohistochemistry of human and murine SCLC 
tumors.
Results: HuD is highly prone to isoaspartyl 
conversion in vitro. Examination of brain extracts 
from wildtype and PIMT deÀcient mice by Western 
blot using our anti-isoaspartyl-HuD antiserum shows 
a strong band in the PIMT deÀcient mice, but very 
little signal in wildtype brain extracts. The antiserum 
also reacts with murine and human SCLC tissue. 
We show that PIMT levels in the lung are much 
lower than in the brain. Thus, we hypothesize that 
PIMT may not be sufÀciently available to repair 
isoaspartylated HuD in the SCLC tumors, potentially 
leading to an immune reaction against HuD in the 
tumor. Spreading of the immune response to Hu 
protein present in the nervous system could then lead 
to autoimmunity.
Conclusion: HuD is highly prone to isoaspartyl 
conversion in vitro. Isoaspartylated HuD is also 
seen in vivo, in the brains of genetically engineered 
mice deÀcient for PIMT, the enzyme that normally 
repairs this highly immunogenic post-translational 
modiÀcation. Immunohistochemical analyses of 
SCLC tumors indicate that isoaspartylation of 
Hu proteins occurs in human and murine SCLC 
tumors. Our data suggests a possible mechanism 
for the development of immuno-responsiveness in 
SCLC. Elucidation of the mechanism of immuno-
responsiveness in SCLC could lead to new tools for 
early detection, diagnosis and treatment.
Keywords: SCLC, Small cell lung cancer, 
paraneoplastic disease, HuD
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O27.04 ROUTINE 
IMMUNOHISTOCHEMICAL STAINING 
FOR ALK IS SPECIFIC FOR THE 
DETECTION OF ALK-REARRANGED 
LUNG ADENOCARCINOMAS
Joanna H. Tong1, Ching Y. So1, Wei Kang1, Chit 
Chow1, Peggy P. Law1, Shuk L. Chau1, Raymond W. 
Lung1, Tony Mok2, Ka F. To1 
1Anatomical And Cellular Pathology, The Chinese 
University Of Hong Kong/Hong Kong, 2Department 
Of Clinical Oncology, The Chinese University Of 
Hong Kong/Hong Kong
insights and the challenges to developing therapeutic 
strategies against EGFR inhibitor resistant cancers.
Keywords: irreversible inhibitors, EGFR, T790M, 
Resistance
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O27.02 SMALL-CELL LUNG CANCER 
AUTOANTIGEN HU IS PRONE TO THE 
ANTIGENIC ISOASPARTYL POST-
TRANSLATIONAL MODIFICATION
Ite A. Laird-Offringa1, Meleeneh Kazarian1, Mario 
Pulido1, Jeffrey A. Tsou1, Trang Luc2, Dana Aswad2 
1Norris Cancer Center, University Of Southern 
California/United States Of America, 2Molecular 
Biology And Biochemistry, University Of California, 
Irvine/United States Of America
Background: Small-cell lung cancer (SCLC) is the 
most aggressive lung cancer subtype. It spreads very 
quickly and is usually diagnosed when the cancer has 
disseminated. A number of rare autoimmune diseases 
are associated with SCLC and are characterized 
by high titers of auto-antibodies against normally 
neuronally expressed proteins. A substantial fraction 
of SCLC patients without autoimmune symptoms 
also carries these antibodies, but at low titer. One 
antigen family against which autoantibodies are 
seen in SCLC are the Hu family of a neuronal RNA-
binding proteins. These proteins are misexpressed 
in all SCLC tumors. The mechanism causing 
immuno-responsiveness of SCLC patients against 
these proteins is currently unknown. Based on 
the N-terminal amino acid sequence of HuD, the 
neuronal Hu protein most commonly expressed in 
SCLC, we hypothesized that a post-translational 
modiÀcation, known as isoaspartylation, might 
trigger the autoimmune response. Isoaspartyl 
conversion is a spontaneous process that can occur 
at asparagines and aspartate residues as proteins age. 
When not properly repaired by protein-L-isoaspartyl 
(D-aspartate) O-methyltransferase (PIMT), 
isoaspartyl residues have been shown to be highly 
immunogenic.
Methods: Using an assay in which isoaspartylated 
substrates are radioactively labeled by the PIMT 
enzyme, we examined whether HuD is prone to 
isoaspartylation when incubated in vitro under 
physiological conditions. We raised a rabbit 
polyclonal antiserum against an isoaspartylated 
HuD peptide, and afÀnity puriÀed and absorbed 
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Conclusion: All the ALK IHC positive 
adenocarcinomas were conÀrmed to have ALK-
rearrangement. Routine immunohistochemistry 
can speciÀcally detect ALK-rearrangement in lung 
adenocarcinomas. It may provide a reliable tool 
for the identiÀcation of candidates that may be 
responsive to ALK inhibitors. 
Keywords: ALK, immunohistochemistry, lung 
adenocarcinoma
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O27.05 MESOTHELIN IS A COMMONLY 
EXPRESSED TUMOR MARKER IN 
LUNG ADENOCARCINOMA (LAC) THAT 
IMPARTS AN AGGRESSIVE PHENOTYPE 
– A CANDIDATE MOLECULAR TARGET
Stefan S. Kachala1, Kei Suzuki1, Eva Vertes1, Luis 
Rodriguez1, Kyuichi Kadota1, Camelia S. Sima2, 
Valerie W. Rusch1, William D. Travis3, Michel 
Sadelain4, Prasad S. Adusumilli1 
1Department Of Surgery, Thoracic Service, Memorial 
Sloan-Kettering Cancer Center/United States Of 
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Sloan-Kettering Cancer Center/United States Of 
America, 3Pathology, Memorial Sloan-Kettering 
Cancer Center/United States Of America, 4Center 
For Cell Engineering, Memorial Sloan-Kettering 
Cancer Center/United States Of America
Background: Mesothelin is a cell surface tumor-
associated antigen. It is commonly expressed in 
mesothelioma, pancreatic, and ovarian cancers, 
imparting an aggressive tumor phenotype and 
chemotherapy resistance. We seek to evaluate the 
expression of mesothelin in LAC and investigate 
the clinical and preclinical correlations for its 
consideration as a molecular target.
Methods: Mesothelin expression was assessed by 
Background: The echinoderm microtubule-
associated protein-like 4-anaplastic lymphoma 
kinase (EML4-ALK) fusion gene has been 
identiÀed as a potent driver mutation in non-small 
cell lung cancers (NSCLC). It deÀnes a unique 
subgroup of lung adenocarcinoma that may be 
responsive to speciÀc targeted therapy. Detection of 
ALK-rearrangement in lung cancers by molecular 
methods, like FISH or RT-PCR is not routinely 
available in most laboratories. We report a reliable 
immunohistochemical staining for the routine 
detection of ALK fusion in lung cancers. 
Methods: A total of 326 resectable lung 
adenocarcinoma samples were retrieved from 
department of Anatomical and Cellular Pathology, 
Prince of Wales Hospital, Hong Kong. Three 
representative tumor parafÀn block samples 
were taken from each case for tissue microarray 
construction. Immunohistochemistry was performed 
on tissue array sections using anti-ALK antibody 
(Abcam 5E4) and Envision FLEX+ visualization 
system. Fluorescence in situ hybridization (FISH) 
for ALK-rearrangement was performed using 
Abbott break-apart probe to conÀrm the presence of 
ALK gene rearrangement. When suitable materials 
were available, fusion gene transcripts were also 
studied by RT-PCR. 
Results: Nineteen out of 326 (5.8%) lung 
adenocarcinomas in this cohort were positive 
for ALK immunohistochemical (IHC) stain. The 
tumor cells demonstrated granular staining in the 
cytoplasm of various intensities. No expression 
was observed in normal bronchial epithelium, 
alveolar pneumocytes and stromal cells. All the 
ALK IHC positive cases were conÀrmed by 
FISH using ALK break-apart probe. EML4-ALK 
variants 1, 2 and 3b were the most common fusion 
products detected by RT-PCR. Histologically, the 
ALK positive adenocarcinomas displayed mixed 
growth patterns including solid with mucin, 
papillary, acinar and bronchioalveolar patterns. 
Figure 1 shows the representative photos of ALK 
immunohistochemistry, FISH and the sequence 
electropherogram from an lung adenocarcinoma 
harboring EML4-ALK variant 2. 
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Conclusion: Mesothelin is a commonly expressed 
antigen in LAC associated with poor outcomes and 
KRAS mutant/EGFR wild-type tumors. Preclinical 
data reveals a phenotype characterized by in vitro 
therapy resistance. Mesothelin’s association with 
clinically aggressive tumors provides rationale for its 
targeting in LAC. 
Keywords: lung adenocarcinoma, mesothelin, Kras, 
biomarker
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O27.06 MIF AND IL-17 PROMOTE 
CHEMOKINE DEPENDENT ADAPTIVE 
TUMOR ANGIOGENESIS IN THE 
CONTEXT OF VEGF INHIBITION.
Douglas Arenberg, Shannon Carskadon, Liujian 
Zhao 
Internal Medicine, University Of Michigan/United 
States Of America
Background: Angiogenesis in lung cancer is 
driven by multiple mechanisms. We have shown 
that many lung cancer tumors (both experimental 
and human tumors) express angiogenic CXC 
chemokines in greater levels than traditional 
angiogenic factors (VEGF), suggesting diversity 
and perhaps adaptability in the mechanism by which 
tumor angiogenesis can occur. We hypothesized 
that inhibition of tumor angiogenesis would trigger 
activation of adaptive responses to maintain tumor 
angiogenesis, and we sought to characterize the 
adaptive mechanism.
Methods: We established heterotopic tumors in mice 
with LLC cells and used two different methods to 
inhibit angiogenic pathways in tumors. We targeted 
VEGF mediated angiogenesis with a mononclonal 
antibody against murine VEGFR2 (DC101. 250 
ƫg three times weekly). To target CXC chemokine 
mediated angiogenesis, we used CXCR2 knockout 
and control (C57Bl6) mice.
Results: In both models, initial tumor growth (up 
to 14 days) was inhibited in the experimental group 
compared with controls. By day 28, tumor growth 
in both anti-angiogenic groups caught up to control 
groups. Tumors were removed and analyzed at 
both early and late time points. Early time points 
demonstrated reduced tumor vascularity in the 
smaller tumors of treated mice. At later time points 
vascularity was equivalent in both groups, but the 
anti-VEGFR group demonstrated higher levels 
immunohistochemical staining in a stage I LAC 
(n=474, 1995-2005) tissue microarray, and correlated 
with survival. InÁuence of mesothelin expression 
in LAC was examined through: clinical correlatives 
(n=98, LAC stage I-III; NIH Director’s Challenge 
dataset – mRNA microarray proÀles and EGFR/
KRAS mutation status) and preclinical correlatives 
utilizing mesothelin-expressing (H1299M) and 
control (H1299) LAC cells. Preclinical investigation 
conducted in vitro by migration and invasion 
[Boyden chamber assay], chemo- and radio-
resistance [cell proliferation and colony formation 
on soft agar] after exposure to cisplatin (IC
50
 31uM) 
or radiation (0-16Gy); in vivo assessment employed 
Kaplan-Meier analysis of median survival in SCID/
bg mice, bearing orthotopically implanted H1299 
and H1299M LAC.
Results: Mesothelin is expressed in 52% of LAC 
and highly expressed (intense staining in >50% 
of the tumor core) in 19% of LAC tumors (Figure 
1A). High mesothelin expression in stage I LAC 
(n=88) demonstrated decreased overall survival as 
compared to low mesothelin (n=386) expressing 
LAC (Figure 1B; median survival 71 vs 92 months, 
p=0.02). High expression of mesothelin in LAC 
was associated with a history of smoking (p=0.005), 
number of pack years (p=0.005), EGFR wild-
type (p=0.02), and KRAS mutant (p=0.02), and 
upregulation of genes promoting tumor invasiveness 
(FDR=0.0062). In vitro, H1299M cells demonstrated 
increased migration and invasion (p<0.0001 
and p=0.0005 respectively), increased viability 
(Figure 1C; p=0.002) and colony formation on 
soft agar (p=0.027) following cisplatin treatment 
or radiation (Figure 1D, p<0.0001). In vivo, mice 
with orthotopic H1299M lung tumors had decreased 
median survival as compared to H1299 lung tumors 
(Figure 1E; n=30, 44 vs 56 days, p=0.0012). 
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Background: Laboratory analyses of selected 
biomarkers are complete for the all of the 974 
patients that were enrolled in RADIANT, a phase 
III trial comparing erlotinib 150 mg daily vs. 
placebo (2:1) in stage IB-IIIA NSCLC patients with 
surgically resected EGFR-positive tumors (IHC and/
or FISH).
Methods: Biomarker analyses completed include: 
protein expression by IHC of EGFR (EGFR 
PharmDx Kit, with +  1% positive tumor cells, 
Dako) and e-cadherin/vimentin (E-cad/vim prototype 
comp Dx kit, Dako); FISH for EGFR gene copy 
number (Vysis, Abbott), and mutations in EGFR 
(Exon 19 Del + Exon 21 L858R) and Kras (Wave 
HS-DHPLC, Transgenomic Inc.)
Results: Preliminary data analyses of results from 
the tumors demonstrated that: 96 % (937/973) were 
EGFR IHC+ and 73 % (699/955) EGFR FISH+, 17 
% (161/938) had an activating EGFR mutation, 16 
% (139/873) had a Kras mut, 80 % (725/905) were 
E-cad+ and 48 % (436/911) were vim+ based on 
a preset cut-point derived from previous studies. 
EGFR mut occurred in 27 % (105/388; 59 Del-46 
L858R) of females, 10 % (56/542; 30 Ex 19 Del-
26 Ex 21 L858R) of males; it occurred in 46 % 
(76/164; 37 Ex 19 Del- 39 Ex 21 L858R) of Asians, 
4 % (1/25; Ex 19 Del) of Blacks, 11 % (84/739 
; 51 Ex 19 Del-33 Ex 21 L858R) of Caucasians; 
and it occurred in 53 % (101/191) never smokers, 
4 % (4/106) current smoker, 9% 56/631 former 
smokers > 100 cig/lifetime. Kras mut occurred in: 
6% (10/175) of never smokers, 14 % (15/105) of 
current smokers, 20% (115/592) of former smokers > 
100 cig/lifetime.. Twenty eight percent (155/560) of 
adenocarcinomas had an EGFR activating mutation 
and 23 % (121/528) had a Kras mut whereas 4% 
(8/286) of squamous cell carcinomas had an EGFR 
mut and 2 % (6/264) had a Kras mut. There were 
7/936 Exon 18 G719A mutations, 15/928 dup/
insertions in Exon 20 and 4/924 L861Q mutations 
of MIF, CXCL1, CXCL2, and CXCL5. We also 
discovered that IL-17A was expressed in tumors after 
anti-VEGFR treatment, but not in other groups. In 
contrast, levels of VEGF in CXCR2 knockout mice 
were signiÀcantly elevated compared to wild type 
control mice, in which CXC chemokine levels were 
increased. Next, anti-VEGFR and control antibodies 
were used to treat CXCR2 knockout mice and 
controls. The duration of tumor-growth inhibition 
in CXCR2 mice by anti-VEGFR2 was signiÀcantly 
longer than in control mice, suggesting that the 
compensatory response to anti-angiogenic therapy 
was dependent upon angiogenic CXC chemokine 
signaling.
Conclusion: Tumors display adaptability in th 
econtext of anti-angiogenic strategies. Our data 
demonstrate that the compensatory response of 
tumors to VEGF inhibition requires angiogenic CXC 
chemokine signaling via CXCR2. We hypothesize 
that VEGF targeted therapy results in tumor 
hypoxia that increases expression of inÁammatory 
cytokines MIF, and/or IL-17A, both of which 
are known to potently up-regulate expression of 
angiogenic CXC chemokine. Our Àndings would 
sugest that angiogenic targeting, much like other 
cancer treatment strategies, would be improved by 
simultaneous targeting of multiple pro-angiogenic 
pathways.
Keywords: angiogenesis, VEGF, microenvironment, 
chemokines
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O28.01 SELECT BIOMARKER ANALYSES 
OF COMPLETELY RESECTED NSCLC 
TUMORS FROM ENROLLED PATIENTS 
IN AN ADJUVANT ERLOTINIB 
(TARCEVA®) CLINICAL TRIAL 
(RADIANT)
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platinum-regimens . 
Methods: CDA polymorphisms were analyzed on 
blood and parafÀn-embedded samples by PCR, 
whereas CDA activity was evaluated by HPLC. 
Univariate and multivariate analyses compared 
biological and clinical parameters with response, 
clinical beneÀt, toxicity, time-to-progression (TTP) 
and overall survival (OS).
Results: Patients with CDA A79A/A79C genotypes 
had a statistically signiÀcant longer TTP (6.0 vs 
3.0 months; P=0.001) and OS (11.0 vs 5.0 months; 
P=0.001) than patients with CDA C79C genotype. 
Patients harbouring CDA C435C/C435T genotypes 
also had a longer OS (P=0.025), resulting in a 
combined genotype (CDA C79C+T435T) effect 
on OS, but no correlations were observed between 
SNPs and objective responses, clinical beneÀt, or 
toxicity. Conversely patients with low CDA activity 
had a signiÀcantly higher response rate (37.7% 
vs 13.8%; P= 0.006), clinical beneÀt (91.8% vs. 
51.7%; P<0.001), as well as longer TTP (8.0 vs 
3.0 months; P<0.001) and OS (19.0 vs 6.0 months; 
P<0.001). Furthermore, enzymatic activity emerged 
as independent predictor for death/progression risk at 
multivariate analysis. 
Conclusion: CDA enzymatic activity appears to 
be the strongest candidate biomarker of activity 
and efÀcacy of platinum-gemcitabine based 
chemotherapy and should be validated in a 
prospective study. 
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O28.04 THE VALUE OF CLINICAL TRIAL 
RESEARCH FOR ERCC1 TESTING IN 
STAGE I NON-SMALL CELL LUNG 
CANCER (NSCLC)
Joshua A. Roth1, Josh J. Carlson1, Lotte Steuten2, 
Scott D. Ramsey3, David L. Veenstra1 
1Pharmacy, University Of Washington/United States 
Of America, 2Health Technology And Services 
Research, University Of Twente/Netherlands, 
3Population Health Sciences, Fred Hutchinson 
Cancer Research Center/United States Of America
Background: Value of research analysis can be used 
to assess the value of proposed clinical trials and 
prioritize research funding decisions. We applied this 
method to assess the value of additional clinical trials 
to investigate ERCC1 expression testing to guide 
adjuvant chemotherapy decisions in fully resected 
Stage I NSCLC in the United States.
in Exon 21. There was one T790M mutation, 
no simultaneous Exon 19 Del/Exon 21 L858R 
mutations, and only one possible simultaneous 
Exon 21 L858R/Kras mutation observed in this 
enrolled population. Currently 93 % (901/974) and 
69 % (670/974; 210 did not consent) patients have 
provided serum and blood samples respectively. 
Additional data on these biomarkers, including 
mutation types/frequencies, scoring frequencies, and 
Ànal biomarker demographics, will be presented. 
Conclusion: Laboratory analyses of selected 
biomarkers in the RADIANT population are 
complete. The results already comprise one of the 
largest datasets in NSCLC with multiple biomarker 
data for each patient; and more analyses in serum, 
blood, as well as tissue are yet to be conducted. 
These data will provide a large scale characterization 
of a multitude of biomarkers in the early-stage 
NSCLC population.
Keywords: Biomarkers, RADIANT, NSCLC 
Adjuvant, EGFR
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O28.02 CORRELATION OF CYTIDINE 
DEAMINASE POLYMORPHISMS AND 
ACTIVITY WITH CLINICAL OUTCOME 
IN GEMCITABINE/PLATINUM-TREATED 
ADVANCED NON-SMALL-CELL LUNG 
CANCER PATIENTS
Carmelo Tibaldi1, Elisa Giovannetti2, Marcello 
Tiseo3, Leticia G. Leon4, Armida D’incecco1, Nienke 
Loosekoot4, Marco Bartolotti3, Richard Honeywell2, 
Federico Cappuzzo1, Andrea Ardizzoni3, Godefridus 
J. Peters4 
1Department Of Oncology, Division Of Oncology, 
Azienda Usl-6/Italy, 2Medical Oncology, VU 
University Medical Center/Netherlands, 3Medical 
Oncology Unit, University Hospital Of Parma/Italy, 
4Department Of Medical Oncology, VU University 
Medical Center/Netherlands
Background: Cytidine deaminase (CDA) is the 
main enzyme in gemcitabine catabolism and the 
common single nucleotide polymorphisms (SNPs) 
79 A>C and 435 C>T might alter its activity as 
well as clinical outcome after gemcitabine-based 
treatment. The aim of this study was to evaluate 
whether CDA SNPs and/or CDA enzymatic activity 
inÁuenced clinical outcome in a cohort of advanced 
NSCLC patients (N=126) treated with gemcitabine-
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A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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O28.05 WNT/BETA-CATENIN 
PHARMACOGENETICS IN PLATINUM-
TREATED PATIENTS WITH ADVANCED 
NON-SMALL CELL LUNG CANCER 
(NSCLC)
David J. Stewart1, David W. Chang2, Yuanqing Ye2, 
Margaret R. Spitz2, Charles Lu1, Xifeng Wu2 
1Thoracic And Head And Neck Medical Oncology, 
M.D. Anderson Cancer Center/United States Of 
America, 2Epidemiology, M.D. Anderson Cancer 
Center/United States Of America
Background: In NSCLC, Wnt/beta-catenin 
signaling is important in tumor development and 
progression. Expression of Wnt/beta-catenin 
pathway components is common and is associated 
with poor prognosis clinically in NSCLC, and is 
associated with cell growth rate and resistance in 
cell lines. Since tumors inherit genes from the host, 
host genotype may inÁuence patient outcome. We 
assessed associations between overall survival and 
Wnt/beta-catenin pathway pharmacogenetics in 
NSCLC patients receiving cisplatin- or carboplatin-
based regimens for advanced NSCLC. 
Methods: In 598 patients with inoperable stage 
III-IV NSCLC, we extracted DNA from peripheral 
blood mononuclear cells, then used Illumina’s 
InÀnium iSelect HD Custom Genotyping BeadChips 
(Illumina, San Diego, CA) and BeadStudio software 
to assess 441 host SNPs in 50 Wnt/beta-catenin 
pathway genes. Hazard Ratios (HRs) were estimated 
using Cox’s proportional hazards model, using the 
Methods: We developed a decision-analytic model 
and used value of information methodology to 
assess the value of research (VOR) comparing two 
treatment strategies: 1) ERCC1 testing to guide 
adjuvant chemotherapy decisions, with ERCC1-
positive patients receiving no chemotherapy 
and ERCC1-negative patients receiving 
cisplatin+vinorelbine chemotherapy; 2) standard 
care, with all patients receiving no chemotherapy. 
Model parameters and uncertainty ranges for test 
characteristics and treatment effects were based 
on the International Adjuvant Lung Cancer Trial, 
which demonstrated signiÀcant overall survival 
gains in ERCC1-negative patients treated with 
cisplatin+vinorelbine (HR: 0.65, 95% CI: 0.5 to 
0.86), but non-signiÀcant overall survival differences 
in ERCC1-positive patients (HR: 1.14, 95% CI: 
0.84 to 1.55). Cost and health-related quality of life 
parameters were derived from published literature 
and government sources. The potential affected 
population was examined over a 10-year time 
horizon (Table 1). To estimate the economic beneÀts 
of treatment outcomes, we used a willingness to 
pay of $150,000 per quality-adjusted life year, in 
accordance with implied thresholds in the United 
States.
Results: There was a high degree of uncertainty 
about ERCC1-guided care vs. standard care, with 
the ERCC1 strategy producing greater net-beneÀt in 
63% of simulations. The consequence of selecting 
the wrong strategy was $14,000 in lost value, a 
combination of lost health beneÀts and unnecessary 
costs. The 10-year affected population was 309,470. 
For this affected population, the VOR for an ideal 
trial large enough to reduce all uncertainty in the 
modeled parameters was $1.5 billion, of which $858 
million was attributable to the value of reducing 
uncertainty about the overall survival hazard ratio 
for ERCC1-negative patients (Table 1). Preliminary 
estimates suggest a VOR of $3 to $672 million for 
a randomized trial with samples of 100 to 1,000 per 
arm, respectively (Table 1).
Conclusion: Clinical trial research of ERCC1 testing 
in NSCLC likely represents a good investment of 
research funds. Forthcoming results will compare 
the VOR of various trial designs and sample sizes to 
the estimated cost of such trials to determine which 
trials are expected to produce the greatest net beneÀt. 
These Àndings can assist research organizations and 
funding agencies in prioritizing funding in cancer 
genomics.
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the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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O28.06 CORRELATION BETWEEN 
TISSUE PLATINUM CONCENTRATION 
AND TUMOR RESPONSE IN NON-SMALL 
CELL LUNG CANCER
Eric Sung-Yung Kim1, Guangan He2, Chi-Wan 
Chow3, Junya Fujimoto3, Neda Kalhor4, Stephen G. 
Swisher5, Ignacio Wistuba6, David J. Stewart7, Zahid 
H. Siddik2 
1Division Of Cancer Medicine, M.D. Anderson 
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Oncology, Ut M.D. Anderson Cancer Center/United 
States Of America, 7Thoracic And Head And Neck 
Medical Oncology, M.D. Anderson Cancer Center/
United States Of America
Background: Platinum-based chemotherapy 
is the mainstay of treatment for advanced non-
small cell lung cancer (NSCLC). Despite initial 
sensitivity, most tumors develop resistance. Reduced 
intracellular drug accumulation is one of the most 
consistently identiÀed features of platinum-resistant 
cell lines, but clinical data are limited. We assessed 
correlations between tissue platinum concentrations 
and response in NSCLC.
Methods: We measured total platinum 
concentrations in 17 archived fresh frozen NSCLC 
specimens from patients who received neoadjuvant 
platinum-based chemotherapy. Approximately 30 
mg of tumor was homogenized in benzethonium 
hydroxide. After acidiÀcation, samples were 
analyzed by Áameless atomic absorption 
spectrophotometry (FAAS) to assess absorbance 
reading associated with platinum content. Two 
specimens from patients who underwent surgery 
only were analyzed as negative controls. Absorbance 
value per mg of tissue was correlated with 
percent change in tumor diameter on post- vs pre-
most common genotype as the reference group and 
with adjustment for age, stage, gender, smoking, 
performance status, ethnicity and therapy modality. 
P values <0.05 were considered signiÀcant. We 
then calculated q values (a false discovery rate 
adjusted P-value) to correct for effects of multiple 
comparisons. The combined effects of unfavorable 
genotypes and survival tree analysis of higher-order 
gene-gene interactions were then assessed using 
SNPs with q<0.10, 
Results: Per BeadStudio software assessments, all 
441 SNPs had call rates of > 95% and were included 
in the analysis. Survival correlated (p<0.05) with 57 
SNPs from 21 Wnt pathway genes, including SNPs 
in AXIN2 (9 SNPs), LRP5 (7 SNPs), Wnt-5A (4 
SNPs), AXIN1, LRP6, WIF1, Wnt-2, Wnt-4, Wnt-
3 and Wnt-5B (3 SNPs each), CXXC4, Wnt-3A, 
Wnt-7A, Wnt-9A and TLE2 (2 SNPs each), and 
DVL3, FRZB, FZD4, Wnt-6, Wnt-9B and Wnt-11 
(1 SNP each). Survival did not correlate with any 
SNPs assessed for the following genes: APC, APC2, 
CTN1, CTNNB1 (beta-catenin), DIXDC1, DKK1, 
DKK4, DVL2, FSHB, FZD1, FZD2, FZD3, FZD7, 
FZD10, LEF1, PPP2CA, PPP2CB, PYGO1, SFRP1, 
SFRP2, SFRP5, TCF7,TLE3, TLE4, TLE6, Wnt-2B, 
Wnt-8A, Wnt-8B, Wnt-10A, Wnt-10B, and Wnt-
16. Five SNPs remained signiÀcant in multivariate 
analysis after correcting for multiple comparisons: 
AXIN2 SNP rs11868547 (HR for variant vs. 
reference SNP=0.77 [95% CI, 0.66-0.89], p=0.0006), 
AXIN2 SNP rs4541111 (HR=0.77 [0.68-0.91], 
p=0.0015), Wnt-5B SNP rs12819505 (HR=1.58 
[1.19-2.09], p=0.0015), CXXC4 SNP rs4413407 
(HR=1.28 [1.10-1.50], p=0.0017), and WIF1 SNP 
rs10878232 (HR=1.36 [1.12-1.66], p=0.0022). For 
these 5 SNPs, median survival was 19.7, 15.6 and 
10.7 months for patients with 1, 2 or 3-5 unfavorable 
genotypes, respectively (p=3.8 x 10-9). Higher order 
gene-gene interactions were suggested by survival 
tree analysis using 4 of these SNPs which classiÀed 
patients into 2 low- vs high-death-risk groups, with 
median survival 17.3 and 11.3 months, respectively 
(p=4.7 x 10-8).
Conclusion: In keeping with the important role 
of the Wnt/beta-catenin pathway in NSCLC 
biology, survival with platinum-based regimens 
correlated with host Wnt/beta-catenin pathway 
SNPs in inoperable stage III-IV NSCLC. It remains 
uncertain whether these SNPs alter tumor growth vs 
chemotherapy sensitivity.
Keywords: Wnt, NSCLC
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O29.01 A LETTER FROM A DYING 
WOMAN – A MESSAGE FROM THE 
OTHER SIDE OF THE “WALL OF 
SILENCE”
Vito D’Alessandro, Mario Freda, Ruggiero Boragine, 
Piergiorgio Cela, Angela P. Piscitelli, Anna Giannolo, 
Gianluigi Vendemiale 
Respiratory Oncology Section - Internal Medicine 
Department, ScientiÀc Institute “Casa Sollievo Della 
Sofferenza” Hospital/Italy
Background: To communicate the diagnosis of 
tumor is not easy, especially if the diagnosis is lung 
cancer. In Italy, perhaps particularly in southern Italy, 
the patient’s family very often ask the physician to 
not communicate the true diagnosis to the tumor 
patient, especially if elderly, for fear of a consequent 
strong psychological distress, including anxiety and 
depression. Communication between the patients and 
their relatives therefore becomes difÀcult, both in 
respect of the illness and of general communication, 
determining the so-called “conspiracy of silence”. 
Methods: We used a letter that appeared in 1998 
in an Italian magazine, Famiglia Cristiana, as a tool 
to try to improve communication between the sick 
and their family. In this letter a female tumor patient 
afÀrms that the debate whether or not tell the patient 
the truth is a false problem, since the tumor patients 
often already know the truth, even if they pretend 
nothing has happened, and that are the patients 
themselves, for the most part, who have to protect 
their relatives, lost and fragile, from the news of 
the illness. The letter was given to the family when 
they themselves were not at ease when faced with 
the same problem. We developed a 12-item ad hoc 
questionnaire to assess family-perceived barriers 
to diagnosis communication with the patient. The 
family was also asked to Àll this questionnaire 
to enable us to understand their difÀculties in 
communication and to see whether the letter had in 
any way improved such difÀculties. The physicians 
gave their availability to discuss any such problems 
with the relatives in presence of patient, if possible. 
Results: Between 2005 and 2010 we gave 104 
letters and questionnaires to families of hospitalized 
chemotherapy CT scans. 
Results: Platinum absorbance values ranged from 
0.00077 to 0.00470 per mg of tissue while two 
negative controls demonstrated absorbance readings 
similar to 0.1N HCL (Table 1). Platinum absorbance 
correlated negatively with percent change in tumor 
size (R2=0.45, P=0.003) (Figure 1).
Conclusion: This is the Àrst tissue-based study to 
demonstrate a correlation between total platinum 
concentrations and response in NSCLC. Reduced 
intracellular platinum accumulation may constitute 
a signiÀcant mechanism of platinum resistance even 
in clinical specimens. Further studies investigating 
factors that modulate intracellular platinum 
concentration are warranted. 
Keywords: platinum, Cisplatin, Resistance, NSCLC
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according to criteria deÀned in literature and with 
help of the software SPSS 15.0.
Results: We veriÀed that most patients (68.4%) 
showed a considerable high level of distress at 
the beginning of the treatment. There was a fall of 
patients with high level of distress at the middle 
(21%) and at the last day of treatment (18.2%). 
The frequencies of items checked in the PL were 
examined using multiple response analyses. The 
frequencies of practical problems progressively 
decreased (beginning to last day of treatment), 
in descending order were insurance/Ànancial 
(36.7% - 23.8%), housing (27.3% - 6.1%), work 
(18.2% - 7.3%) and transportation (18.2% - 3.2%). 
In the family category, items dealing with children 
(54.5% - 23%) and with partner (27.3% - 6.3%) 
were endorsed. In the emotional category, the most 
frequently checked items were worry (54.5% - 
23.8%), sadness (45.5% - 13.7%), nervousness 
(45.5% - 13.7%), loss of interest in usual activies 
(42.4% - 11.5%), depression (36.4% - 11.5%), and 
fears (18.2% - 4.9%). Any patients checked the 
spiritual/religious concern item. With regard to 
physical problems, the Àve most frequently endorsed 
items were sleep (54.5% - 43.4%), pain (36.4% - 
12.6%), appearance (36.4% - 25.6%), eating (36.4% 
- 23.4%), and fatigue (36.4% - 22.4%).
Conclusion: The high incidence of distress in the 
beginning of therapy demonstrates the importance 
of screening and effective management of the 
emotional disturbs related to the diagnosis and 
cancer treatment. Establishing a routine assessment 
of distress and the multidisciplinary discussion opens 
up the opportunity to work before the symptoms 
appear and to choose the best intervention tailored 
to each case. Treating emotional distress must 
be viewed as integral part of quality patient care, 
improving adherence to treatment, quality of life and 
coping with diagnosis and treatment. The distress 
management could be an indicator of the quality 
service offered.
Keywords: distress, quality of care, psycho-
oncology
patients in our department. We analyzed 97 
questionnaires. The mean (SD) age of the patients 
was 66.4 (5.8) years; more than 80% were male, 
and 81% suffered from advanced stage lung cancer. 
Before receiving the letter, in only 9% of the cases 
the family had openly talked about the diagnosis of 
tumor to their own relative. 76% of relatives declared 
the reading of this letter very useful. 69% of family 
members believed that the general communication 
with their relative improved and in 57% of the cases 
they succeeded in speaking more openly of the 
illness. 
Conclusion: Devoting time and giving the family 
a simple letter can be an effective strategy for 
improving the communication between the lung 
cancer patients and their relatives. 
Keywords: Communication, Information, Lung 
cancer, palliative care
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O29.02 PSYCHOLOGICAL DISTRESS 
AMONG LUNG CANCER PATIENTS: A 
PILOT STUDY
Cristiane D. Bergerot1, Marco M. Buso2 
1Psycho-Oncology, Cettro - Centro De Câncer De 
Brasília/Brazil, 2Oncology, Cettro - Centro De 
Câncer De Brasília/Brazil
Background: Lung is among the most common 
cancer site and is the most common cause of cancer-
related death in the world. In a study examining 
psychological distress and its relation to the site of 
cancer, primary lung cancer was strongly associated 
with psychological distress in oncology patients. In 
addition, several previous studies have demonstrated 
that the highest prevalence of psychological distress 
was observed among patient with lung cancer.
Methods: The present pilot study evaluated 
the incidence of distress during three stages of 
chemotherapy (beginning, middle and last day), 
among 19 patients of booth genders (52.6% male 
and 47.4% female), with age between 48 and 81 
years (mean = 64), with advanced lung cancer, from 
a private cancer center in Brazil. This research was 
authorized by the ethics committee. The procedures 
of gathering data included the acceptance of the 
patients, application of the Distress Thermometer 
(DT) and the Problem List (PL), followed by a 
multidisciplinary discussion to deÀne the best 
intervention for each case. The data were analyzed 
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Results: Nine lung cancer patients and seven 
partners participated in the program. About 5% 
of the patients and 3% of the partners missed a 
training-session and 1 couple dropped out. Sixty-
seven percent received chemotherapy during MBSR. 
MBSR resulted in a 22% decrease of anxiety and 
depression according to The Hospital Depression 
and Anxiety Scale. Patients reported a greater 
appreciation of life, a more open attitude towards 
negative emotions, a better communication between 
partners, and more self-reliance. Partners also 
reported less perceived stress and better coping.
Conclusion: MBSR in (locally) advanced lung 
cancer patients and their partners is feasible despite 
an often short life acceptancy and oncological 
treatment. MBSR resulted in a decrease of anxiety 
and depression and improvement in adjustment of 
the disease and symptoms.
Keywords: Lung cancer, mindfulness, psychosocial 
treatment
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O29.05 FAMILY CAREGIVER QOL 
AND SELF CARE CONCERNS IN LUNG 
CANCER
Mihaela C. Cristea1, Betty Ferrell2, Marcia Grant2, 
Marianna Koczywas1, Arti Hurria1, Matthew 
Loscalzo3, Gloria Juarez2, Shirley Otis-Green2, Gwen 
Uman4, Tami Borneman2 
1Medical Oncology And Therapeutic Research, 
City Of Hope/United States Of America, 2Nursing 
Resreach & Education, Dept. Of Population 
Sciences, City Of Hope/United States Of America, 
3Population Sciences, City Of Hope/United States Of 
America, 4Vital Research/United States Of America
Background: Family caregivers play a key role 
in cancer care and are of signiÀcant support in 
advanced diseases such as lung cancer. This National 
Cancer Institute funded Program Project (P01) 
addresses palliative care, quality of life (QOL), and 
self care for family caregivers in lung cancer. The 
purpose of this study is to test usual care versus 
a family caregiver interdisciplinary intervention 
encompassing a QOL education intervention.
Methods: Project 3 of this Program focuses on 
family caregivers in lung cancer, a group with 
signiÀcant QOL concerns. The study uses a two 
group, prospective tandem enrollment comparing 
usual care to a structured palliative care intervention. 
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O29.03 LIVING IN THE MOMENT: 
MINDFULNESS BASED STRESS 
REDUCTION FOR LUNG CANCER 
PATIENTS AND THEIR PARTNERS
Miep A. Van Der Drift1, Desiree G.M. Van Den 
Hurk2, Johan Molema2, Judith B. Prins2, Anne E.M. 
Speckens2 
1Pulmonology, Radboud University Nijmegen 
Medical Centre/Netherlands, 2Radboud University 
Nijmegen Medical Centre/Netherlands
Background: The generally poor prognosis of 
lung cancer patients is often accompanied by 
emotional distress resulting in reduced quality of 
life and increased use of medical care. Emotional 
distress in the oncology setting is most frequently 
characterized by anxiety, depression, fatigue and 
sleep disorders, and can be deÀned as an adjustment 
disorder. Compared to patients with other cancer 
diagnoses, patients with lung cancer report higher 
clinically signiÀcant levels of distress (33% and 43-
62%, respectively). Although many studies describe 
the impaired quality of life and amount of distress 
in lung cancer patients, not much is known about 
psychosocial treatment. Mindfulness is deÀned 
as moment to moment present awareness with an 
attitude of non-judgement, acceptance and openness. 
Recent cancer studies suggest that mindfulness 
based stress reduction (MBSR) may improve cancer 
patients’ psychosocial adjustment to their disease, 
reduce stress and anxiety, and enhance their coping 
and well-being. The number of lung cancer patients 
in these studies was low and even less is known 
about participation of their partners. It is not clear 
if MBSR is feasible in lung cancer patients who 
often have a short life expectancy. The current study 
is a preliminary exploration of the feasibility and 
effectiveness of MBSR in lung cancer patients and 
their partners.
Methods: An 8-week MBSR program of weekly 
two and a half-hour sessions with one full retreat 
day and daily home practice was offered to (locally) 
advanced lung cancer patients and their partners. 
MBSR consisted of formal and informal mindfulness 
practices, including practices of the body scan, 
meditation and mindful movement. Questionnaires 
about symptoms of stress, anxiety, depression, 
mindfulness and coping were taken at baseline, post-
treatment and at 3 months follow-up in patients and 
partners.
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Background: Quality of life (QOL) and palliative 
care in the treatment of cancer have been areas 
of increased focus in recent literature. Lung 
cancer has been well established as a disease 
with consistently high rates of morbidity and 
mortality. The speciÀc aims of the present analysis 
were to document changes in quality of life 
(QOL) and spirituality in lung cancer patients 
(pts) using validated instruments before and after 
radiotherapy (RT) and also to describe differences 
from pts undergoing RT for different diagnoses. 
Methods: A retrospective, IRB-approved chart 
review was performed of 406 pts, 50 with lung 
cancer (LC) and 356 with non-lung cancer (non-
LC) diagnoses, receiving RT between 1/1/2006 
and 12/31/2008 at an NCI-Designated Cancer 
Center. Subjects completed the Functional 
Assessment of Cancer Therapy General (FACT-G) 
and Spirituality (Sp-12) PRO questionnaire 
tools. Pre- and immediately post-RT course 
scores were compared using student t-tests with 
Bonferroni correction for multiple comparisons 
(8 comparisons, alpha =.00625). Distributions of 
responses as reported by LC and non-LC pts were 
compared utilizing chi-square analysis.
Results: Prior to treatment, LC pts reported 
signiÀcantly poorer scores in physical well-
being (PWB) (p<0.001), emotional well-being 
(EWB) (p<0.001), functional well-being (FWB) 
(p<0.001), meaning-peace (p<0.001) and Sp12 
(p<0.001) measures, compared to non-LC pts. 
Following RT, the LC cohort continued to have 
poorer scores in EWB (p<0.001) and FWB 
(p=0.001). FACT-G scores in LC pts improved 
nonsigniÀcantly (p=0.631) over the course 
of RT and a signiÀcant difference in FACT-G 
scores (p=0.002) was noted between the two pt 
cohorts following RT. Differences between the 
two cohorts in PWB (p=0.338), meaning-peace 
(p=0.018), and Sp12 (p=0.168) scores became 
nonsigniÀcant following RT. Pts receiving RT 
for non-LC diagnoses demonstrated clinically 
and statistically signiÀcant worsening of PWB 
(p<0.001), statistically signiÀcant improvement 
in EWB (p>0.001) and worsening in overall well-
being (p<0.001) over the course of treatment while 
LC pts reported no signiÀcant changes in any 
category. 
Family caregivers are followed for 6 months in 
late stage disease and 12 months in early stage 
lung cancer. Outcome measures include the Family 
Caregiver QOL tool, Caregiver Burden tool, 
Self Care Assessment, Psychological Distress 
and Caregiver Preparation measures. A Geriatric 
Core supports this Project to advise on caregiver 
concerns for the geriatric patient such as burden and 
caregiving skill acquisition as well as to evaluate the 
needs of the caregiver.
Results: Family caregivers (N=96) were mean age 
of 57 years, 60% female, 70% spouses/partners, and 
40% minority subjects. Sixty percent had chronic 
illnesses of their own. Key caregiver QOL concerns 
(0= worst to 10 = best outcomes) included distress of 
the initial diagnosis (x=1.3), family distress (x=2.89) 
fear of metastasis (x =3.03) or recurrence (x =3.16) 
for the patient, living with uncertainty (x =3.68) and 
distress from the patient’s treatment. Key areas of 
caregiver burden and stress included time demands, 
overall stress, needing help navigating health 
services, and accessing community resources and 
health information.
Conclusion: Findings demonstrate gaps in 
supporting family caregivers in lung cancer. The next 
phase of this Program Project tests a comprehensive 
education intervention for family caregivers and a 
self care plan for each caregiver. Elements include 
preparing caregivers in managing symptoms in lung 
cancer, supporting patients physical, psychological 
and social concerns and addressing spiritual and end 
of life care. 
Keywords: Lung cancer, Quality of Life
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O29.06 QUALITY OF LIFE AND 
SPIRITUALITY BEFORE AND AFTER 
RADIOTHERAPY IN PATIENTS WITH 
LUNG CANCER: PRELIMINARY 
RESULTS FROM THE KNIGHT CANCER 
INSTITUTE
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Background: The website of the Dutch Lung 
Cancer Information Center (DLIC) was established 
in 2003. Beside providing information, it is also 
possible to pose questions on the interactive page 
“Ask the Physician”. The website is currently visited 
by 20.000 visitors per month, mostly lung cancer 
(LC) patients and caregivers. Objectives: To explore 
the reasons why LC patients and caregivers search 
the internet for information and ask the online lung 
specialists of the DLIC additional questions about 
lung cancer beside face-to-face consultations with 
their own treating specialists. 
Methods: Qualitative study with semi-structured 
telephone interviews about medical information 
seeking behavior (e.g. information needs, reasons 
asking questions to online specialists) Population: 5 
LC patients and 20 caregivers who posed a question 
on the interactive page of the DLIC website. 
Results: Patients and caregivers use the internet 
and the DLIC website for a better understanding of 
the information given by their own specialist. They 
want to be prepared for the treatment trajectory 
and course of disease. Respondents are positive 
about this mode of information supply because not 
only it is supportive for coping, but also it fosters 
hope. The use of the interactive webpage serves as 
second opinion as well (e.g. conÀrmation about the 
administered treatment). The absence of face-to-face 
contact makes respondents feel more free to ask for 
any kind of information. By being able to pose a 
question instantly, it gives relief of anxiety and the 
(relatively quick) reply from the online specialist 
gives an answer to urgent questions within a short 
space of time, without having to wait until the next 
consultation with their treating specialist. 
Conclusion: The DLIC website with its interactive 
page is a valuable complementary mode of 
information supply for LC patients and caregivers. 
Because the online specialist is not able to answer 
patient-speciÀc questions, the use of e-mail contact 
between treating specialists and patients /caregivers 
might be considered as a useful tool. 
Keywords: online lung specialists, patients, 
caregivers, internet
Chi-Square Analysis Comparing LC to non-LC Patient Quality of 
Life at Pre- and Post-Treatment Timepoints 
MID* Pre-Treatment Scores Post-Treatment Scores 
LC Non-LC P-Value LC Non-LC P-Value 
Physical 
Well-Being 2-3 18.19 22.67 0.000 17.32 19.67 0.338 
Social 
Well-Being 2-3 21.86 22.80 0.102 21.68 22.69 0.242 
Emotional 
Well-Being 2-3 15.88 18.76 0.000 17.26 19.57 0.000 
Functional 
Well-Being 2-3 12.81 18.81 0.000 13.38 18.21 0.001 
FACT-G 3-7 68.83 83.02 0.053 69.91 80.11 0.002 
Meaning-
Peace 
subscale N/A 22.32 25.27 0.000 23.28 25.44 0.018 
Faith 
subscale N/A 10.67 10.86 0.079 10.97 11.32 0.276 
Sp-12 N/A 32.99 36.13 0.000 34.25 36.76 0.168 
*MID: previously calculated minimally important 
difference 
Conclusion: At the time of presentation for 
radiotherapy LC pts reported worse physical, 
emotional, functional and spiritual well-being than pts 
undergoing therapy for other diagnoses. Some of these 
differences equalized over the course of treatment, 
with LC pts reporting no signiÀcant changes in any of 
these measures over the course of RT. 
Keywords: Quality of Life, Lung cancer, Radiation 
Therapy, Spirituality
Nursing II Wednesday, 6 July 2011 14:30-16:00
O29.07 WHY DO PATIENTS AND 
CAREGIVERS SEARCH THE 
INTERNET FOR INFORMATION AND 
ASK QUESTIONS TO ONLINE LUNG 
SPECIALISTS? A QUALITATIVE STUDY
Romane M. Schook1, Cilia Linssen2, Marjan J. 
Westerman3, Franz M.N.H. Schramel4, Jan Festen2, 
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Of Pulmonary Diseases, Gelre Ziekenhuizen/
Netherlands, 6Department Of Pulmonary Diseases, 
VU University Medical Center/Netherlands
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P/D 12.9%). Comparing cTNM to pTNM, 80.8% 
of stage I, 65.5% of stage II and 22.8% of stage III 
patients were upstaged. Median survivals by cTNM 
and pTNM were similar: stage I, 21 months, stage II, 
19 months, stage III 16 months, stage IV, 12 months. 
Median survival by histology was epithelioid 
19 months, biphasic 13 months, sarcomatoid 8 
months. Median survivals by stage and surgical 
procedure were better for EPP vs. P/D in stage I 
(40 vs.23 months) but not in higher stage tumors. 
By multivariable analyses, signiÀcant differences 
in overall survival were seen for: stages III and IV 
vs. I (p<.0001) but not II vs. I, epithelioid histology 
vs. other (p<.0001); female vs. male (p=.0001), 
age (p=.007); palliative vs. curative intent surgery 
(p<.0001); T4 vs T3 and T3 vs T2 (p=.003 and 
p=.03) but not T2 vs. T1 (p=.09); N0 vs. N1 and N2 
(p=.007 and <.0001) but not N1 vs. N2 (p=.275).
Conclusion: This is currently the largest 
international multicenter database examining 
outcomes in surgically managed MPM patients. 
Survival differences by tumor stage, histology and 
surgical treatment previously reported from smaller 
databases are conÀrmed. Initial analyses suggest 
the need to revise T and N staging. These should be 
addressed through prospective data collection which 
has just been initiated by the ISC.
Keywords: mesothelioma, international database, 
Staging
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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O30.02 DISEASE CONTROL RATE 
AT 9 AND 18 WEEKS AS PRIMARY 
ENDPOINTS FOR PHASE II 
CLINICAL TRIALS IN PATIENTS 
WITH MALIGNANT PLEURAL 
MESOTHELIOMA: AN INDIVIDUAL 
PATIENT DATA COMBINED ANALYSIS 
OF 10 EUROPEAN ORGANISATION 
FOR RESEARCH AND TREATMENT 
OF CANCER (EORTC) LUNG CANCER 
GROUP STUDIES.
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O30.01 INITIAL ANALYSIS OF IASLC 
MESOTHELIOMA DATABASE
Valerie Rusch1, Dori Giroux2, Catherine Kennedy3, 
David Rice4, Enrico RufÀni5, Harvey I. Pass6, David 
Waller7, John Edwards7, Ayten K. Cangir8, Hisao 
Asamura9 
1Surgery, Memorial Sloan-Kettering Cancer CTR/
United States Of America, 2Cancer Research And 
Biostatistics/United States Of America, 3University 
Of Sydney/Australia, 4M.D. Anderson Cancer 
Center/United States Of America, 5Chirurgia 
Toracica, Ospedale San Giovanni Battista/Italy, 
6Cardiothoracic Surgery, Nyu School Of Medicine/
United States Of America, 7GlenÀeld Hospital/United 
Kingdom, 8Department Of Thoracic Surgery, Ankara 
University Faculty Of Medicine/Turkey, 9National 
Cancer Center Hospital/Japan
Background: The validity of the current UICC 
staging system for malignant pleural mesothelioma 
(MPM) is controversial. To assess whether changes 
should be made to this system, the Mesothelioma 
Domain of the IASLC Staging Committee (ISC) 
developed an international database of MPM 
patients. These initial analyses focus on retrospective 
data from patients managed surgically.
Methods: Participation was solicited from all centers 
known internationally to have MPM registries. 
Common data elements were established and data 
were analyzed by the ISC Statistical Center at 
Cancer Research and Biostatistics (CRAB,Seattle, 
Wa, USA). Survival was analyzed by Kaplan Meier, 
the signiÀcance of prognostic factors assessed 
by logrank and Cox regression model. p<.05 was 
considered signiÀcant.
Results: Data were submitted on 3101 patients 
from 15 centers on 4 continents. cTNM staging 
was available on 1398 patients, pTNM on1976 
and best TNM(bTNM) on 2316 patients. Median 
patient age was 63 years, 79% male patients. 
bTNM stages were: stage I, 11%; stage II, 21%; 
stage III, 48%; stage IV, 20%. Tumor histology was 
62.3% epithelioid. Surgery with curative intent was 
performed in 1494 (64.5%) patients (EPP 51.4%, 
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smaller. Therefore, DCR at 9 weeks should be 
taken into consideration as primary endpoint when 
designing future phase II clinical trials in MPM.
Keywords: Disease Control Rate, mesothelioma, 
Clinical trial, Primary endpoint
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O30.03 DETECTION OF 
MESOTHELIOMA IN ASBESTOS 
EXPOSED INDIVIDUALS WITH 
SOMAMER PROTEOMIC TECHNOLOGY
Rachel Ostroff1, Michael R. Mehan1, Alex Stewart1, 
Stephen Williams1, Stephen Levin2, Brad Black3, 
Michael Harbut4, Harvey I. Pass5 
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Background: Malignant pleural mesothelioma is 
an aggressive, asbestos-related pulmonary cancer 
which is increasing in incidence. This disease causes 
an estimated 15,000 to 20,000 deaths per year 
worldwide. Between 1940 and 1979, approximately 
27.5 million people were occupationally exposed 
to asbestos in the United States. The incidence 
of pleural mesothelioma in the US is 3,000 new 
cases/year and will not peak for another 20 years. 
Mesothelioma has a latency period of 20-40 years 
from asbestos exposure, but once diagnosed this 
aggressive disease is often fatal within 14 months. 
Because diagnosis is difÀcult, most patients present 
at a clinically advanced stage where possibility of 
cure is minimal. Therefore, we have conducted a 
broad search for new serum biomarkers with our 
aptamer-based proteomic platform and deÀned 
a classiÀer for the detection of mesothelioma in 
asbestos exposed individuals.
Secreted proteins and those released during 
apoptosis from tumor cells and surrounding tissues 
undoubtedly contain important biologic information 
that would theoretically enable early diagnosis and 
prognostic and therapeutic decisions in oncology. 
However, there is great difÀculty in Ànding and 
quantifying such signals for large numbers of low 
abundance proteins. We therefore created a highly 
1Service D’Oncologie Multidisciplinaire Et 
Innovations Thérapeutiques, Assistance Publique-
Hôpitaux De Marseille, Université De La 
Méditerranée/France, 2Headquarters, European 
Organisation For Research And Treatment Of 
Cancer/Belgium, 3Thoracic Oncology, NKI AVL/
Netherlands, 4Respiratory Medicine, Ghent 
University Hospital/Belgium, 5Medical Oncology, 
National Cancer Institute/Egypt, 6Royal Marsden 
Hospital/United Kingdom
Background: The development of new drugs is 
urgently needed in malignant pleural mesothelioma 
(MPM) to improve the efÀcacy of Àrst-line treatment 
and identify effective second-line therapies. In phase 
II trials, the response rate (RR) is generally used as 
the primary endpoint to assess the biological activity 
of drugs. However, response criteria have always 
been difÀcult to apply to MPM, due to its unique 
pattern of growth. We hypothesized that the disease 
control rate (DCR) could be a relevant primary 
endpoint for phase II trials in MPM patients.
Methods: Individual patient data from 10 EORTC 
Lung Cancer Group studies (9 phase II and 1 phase 
III trials) of Àrst-line chemotherapy in MPM were 
pooled. WHO criteria were used to assess response 
to therapy in all trials except the 2 most recent trials, 
which used RECIST. Landmark analyses (LA) were 
performed to assess the association of the DCR at 
a Àxed time point with overall survival (OS). Two 
different time points, namely 9 weeks and 18 weeks 
after registration or randomization, were considered. 
Patients who died or were lost to follow up before 
the speciÀed landmark time were excluded from 
LA. Disease control status at the speciÀed time 
points was determined provided that the progression 
date and best overall response were recorded in the 
database.
Results: 523 eligible patients were entered in the 10 
studies. Based on 435 patients (370 deaths) in the LA 
at 9 weeks, disease control (versus progression) was 
associated with longer survival times, with a hazard 
ratio (HR) of 0.37 (95%CI, 0.30-0.47). For the 377 
patients (315 deaths) in the LA at 18 weeks, disease 
control was also conÀrmed as a predictor of OS with 
a corresponding Àgure for HR = 0.50 (95%CI, 0.38-
0.65).
Conclusion: Both DCR at 9 weeks and DCR at 
18 weeks were predictors of OS in MPM patients. 
DCR at 9 weeks shows some further advantage as it 
can be observed as early as the time of Àrst disease 
assessment. In addition, the HR was numerically 
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O30.05 A MULTICENTER, RANDOMIZED 
PHASE III MAINTENANCE STUDY 
OF THALIDOMIDE (ARM A) VS. 
OBSERVATION (ARM B) IN PATIENTS 
WITH MALIGNANT PLEURAL 
MESOTHELIOMA (MPM) AFTER 
INDUCTION CHEMOTHERAPY.
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Background: Since standard chemotherapy does not 
lead to long-term survival in MPM, new treatment 
approaches are required. MPM is known for a high 
vessel count and high levels of vascular growth 
factors. Both are known to be poor prognostic 
factors. Suppression of the neo-vasculature by adding 
thalidomide in the maintenance setting may lead to 
improved time to progression (TTP). We here report the 
Ànal results of TTP, overall survival (OS) and toxicity. 
Methods: Patients who had been treated with 
pemetrexed (500 mg/m2) and cisplatin (75mg/m2) or 
carboplatin (AUC 5) q3wks for > 4 courses and did 
not show signs of progression were eligible. After 
obtaining informed consent patients were randomized 
to receive either thalidomide 200 mg/day orally (A) 
or no treatment (B). CT of the thorax and physical 
examination was performed every 2 months or earlier 
when indicated in both groups. TTP and OS were 
calculated from start of randomization. A number of 
190 events were required to show an improvement of 
50% in TTP. 
Results: From 05/2004 until 12/2009 222 patients 
from 8 Dutch and 4 Australian centers were included 
in this study (111 in each arm). One patient withdrew 
informed consent. Median age: 64 yrs (range 41-82); 
86% epithelial type; 215 WHO 0-1 and 6 WHO 2. 
Based on the physician reported outcome there were 
207 tumor progressions observed, with median TTP in 
multiplexed proteomic assay that currently measures 
>1000 proteins simultaneously from 10ul blood, 
with throughput of 300 samples/day. The average 
dynamic range of each protein in the assay is >3 
logs and the median lower limit of quantiÀcation is 
below 1 pM. The median coefÀcient of variation for 
each protein is <5%. This assay performance arises 
from the selection of high afÀnity SOMAmers (Slow 
Offrate ModiÀed Aptamers) that bind selectively to 
their target proteins with slow off-rates.
Methods: The objective of this study was to 
discover proteins which are involved in malignant 
mesothelioma and to develop algorithms and 
classiÀers for detection of the disease. To this 
end, blood samples from three study centers were 
analyzed with the SOMAmer proteomics platform 
in a prospectively designed case:control study. We 
compared 170 serum samples from 90 patients 
diagnosed with malignant mesothelioma to 80 
asbestos exposed controls. These samples were 
divided into 75% for training and 25% set aside 
as a blinded test set for classiÀer development and 
veriÀcation.
Results: The initial results are promising. Nineteen 
signiÀcant biomarkers were discovered by applying 
a backwards selection strategy. ClassiÀers were built 
with subsets of these biomarkers resulting in an AUC 
of 0.95 or better with an overall accuracy of 93%. 
Applying a 13-plex Random Forest classiÀer to the 
blinded test set resulted in a speciÀcity of 100% and 
sensitivity of 80% for distinction of asbestos exposed 
controls from mesothelioma, including detection of 
15/19 Stage I/II cases.
Conclusion: ReÀnement and conÀrmation of 
classiÀer performance will be established through 
ongoing validation studies. Implementation of 
such a test for screening high risk asbestos exposed 
individuals could lead to earlier detection of 
mesothelioma, when effective treatment options are 
available. 
Keywords: proteomics, mesothelioma, Early 
Detection, Aptamer
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Methods: The Mesothelioma and Radical Surgery 
(MARS) feasibility study was a multi-centre 
randomised controlled trial. In a pre-randomisation 
registration phase all patients underwent induction 
platinum based chemotherapy followed by clinical 
review and further consent for randomisation to EPP 
followed by postoperative hemithorax irradiation or to 
No EPP. The primary aim was to assess the feasibility 
of a larger randomised trial. Secondary study 
endpoints included QL and peri-operative mortality. 
Results: Between October 2005 and November 
2008 112 patients were registered through 12 
UK hospitals and 50 (44.6%) were subsequently 
randomised (24 EPP, 26 No EPP). The main reasons 
for not proceeding to randomisation were disease 
progression/inoperability (38 patients) and patient 
choice (19 patients). EPP was completed satisfactorily 
in 16/24 (66.7%) patients randomised to EPP, in 5 
patients EPP was not started and in 3 patients EPP 
was abandoned. Three EPP patients died in the 
perioperative period and one patient in the No EPP 
group died after received EPP off-trial. There were no 
statistically signiÀcant differences in median QL and 
survival, although both were lower in the EPP group. 
Conclusion: Many patients accepted randomisation 
between these radically different treatment options, 
and inability to encourage more clinicians to refer 
patients was the main obstacle to recruitment. In view 
of the high morbidity associated with EPP in this trial 
and in other non-randomised studies, a larger trial 
of EPP is unlikely to attract enough support to be 
feasible. 
Keyword: mesothelioma surgery radiotherapy 
chemotherapy
Session O31: Medical Oncology III
Wednesday, 6 July 2011
Medical Oncology III Wednesday, 6 July 2011 14:30-16:00
O31.01 SIMILAR EFFICACY OF EGFR 
TYROSINE KINASE INHIBITORS 
REGARDLESS OF TREATMENT 
SEQUENCE FOR THE PATIENTS 
WITH EGFR MUTATION-POSITIVE 
PULMONARY ADENOCARCINOMA
Dong Hoe Koo1, Kyu-Pyo Kim1, Chang-Min Choi1, 
Dae-Ho Lee1, Jae Cheol Lee1, Jung-Shin Lee1, Se Jin 
Jang2, Sang-We Kim1 
arm A of 16 weeks compared to 15 weeks in the control 
arm; p=0.83; HR 0.96 (0.7-1.3). Median OS was 11 
and 13 months respectively; p=0.09; HR 1.3 (0.94-1.8). 
There was no difference in grade 3+ toxicity in both 
groups observed.
Conclusion: This is the largest maintenance study in 
patients with MPM. Minimal toxicity was associated 
with the use of thalidomide, however there is no 
evidence of beneÀt in TTP nor in survival. 
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MESOTHELIOMA AND RADICAL 
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CONTROLLED TRIAL COMPARING 
EXTRA-PLEURAL PNEUMONECTOMY 
(EPP) WITH NO EPP IN PATIENTS WITH 
MALIGNANT PLEURAL MESOTHELIOMA.
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Medicine, London, UK/United Kingdom
Background: The effectiveness of extra-pleural 
pneumonectomy (EPP) for malignant pleural 
mesothelioma on survival and quality of life (QL) has 
never been evaluated in a randomised trial. 
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STUDY
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Background: The phase II FASTACT study 
demonstrated that sequential administration of 
erlotinib following Àrst-line platinum-based 
chemotherapy signiÀcantly prolonged progression-
free survival (PFS) versus chemotherapy alone (Mok 
et al., J Clin Oncol 2009). FASTACT-II is a phase III, 
randomised, placebo-controlled, double-blind study 
designed to further assess the efÀcacy of this treatment 
approach in a larger patient population. The principle 
of pharmacodynamic separation involves avoiding 
potential negative interactions between agents by 
alternating treatments in an optimal sequence. This 
concept has important implications for the use of 
erlotinib in combination with chemotherapeutic agents 
(including pemetrexed, as investigated by Li et al., 
Curr Drug Targets 2010), particularly in EGFR wild-
type NSCLC populations. 
Methods: Eligible patients with untreated stage 
IIIB/IV NSCLC were randomised (1:1) to receive 
gemcitabine (1,250mg/m2 on days 1 and 8 of a 4-week 
cycle) plus platinum (either carboplatin 5×AUC or 
cisplatin 75mg/m2 on day 1 of a 4-week cycle) with 
either sequential erlotinib (150mg/day) or placebo 
1Oncology, Asan Medical Center/Korea, 2Pathology, 
Asan Medical Center/Korea
Background: Although epidermal growth factor 
receptor (EGFR) tyrosine-kinase inhibitors (TKIs) 
are known to be highly effective approach in non-
small-cell lung cancer (NSCLC) patients with EGFR 
mutation, little is known about the efÀcacy according 
to sequence of EGFR-TKIs.
Methods: Between March 2006 and May 2010, a 
total of 1250 patients with recurrent or metastatic 
NSCLC were evaluated EGFR mutational sequence 
at a single institution. And we analyzed response 
rate, progression free survival (PFS) and overall 
survival (OS) of EGFR mutation-positive patients 
who had been treated with EGFR-TKIs from the date 
of initiating EGFR-TKIs, retrospectively.
Results: Two-hundred thirty-seven patients 
were revealed to receive EGFR-TKIs and have 
EGFR mutation-positive NSCLC. Among them, 
222 patients who had EGFR mutation-positive 
adenocarcinoma were evaluated. EGFR-TKIs were 
given to 97, 109 and 16 patients as Àrst, second 
and third-line therapy with a median follow-up 
duration of 27.5 months (range, 8.3-69.2). The 3 
groups showed similar response rates to EGFR-TKIs 
(71.1%, 72.5%, 75.0%; p = 0.802). No signiÀcant 
difference was seen according to Àrst, second and 
third-line EGFR-TKIs in terms of median PFS 
(10.6, 13.0, 10.4 months; p = 0.670) and median OS 
(20.5, 26.2, 17.1 months; p = 0.142). On univariate 
analysis, good performance, recurrent disease (vs. 
metastatic disease), bronchioloalveolar carcinoma 
(vs. other forms of adenocarcinoma), mutation 
in exon 19 or 21 (vs. others, which consisted of 
mutation in exon 18, 20 or 2 exons), geÀtinib (vs. 
erlotinib) were associated with better PFS and 
OS. On multivariate analysis, good performance, 
recurrent disease and mutation in exon 19 or 21 were 
independently associated with better PFS and OS.
Conclusion: When EGFR-TKIs were given to 
patients with EGFR mutation-positive pulmonary 
adenocarcinoma, it may show similar efÀcacy 
regardless of sequence. Good performance status, 
recurrent disease and mutation in exon 19 or 21 
showed better PFS and OS for EGFR-TKIs in our 
analysis.
Keywords: Treatment sequence, Adenocarcinoma, 
EGFR mutation, Tyrosine kinase inhibitor
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(both administered on days 15–28 of each cycle). 
Patients were stratiÀed by disease stage, histology, 
smoking status and chemotherapy regimen. The 
primary endpoint is PFS; secondary endpoints include 
overall survival (OS), response rate, safety, quality of 
life and subgroup/biomarker analyses. 
Results: From 29 April 2009 to 9 September 2010, 
a total of 451 patients were recruited across 28 sites 
in seven countries: China (n=151), Thailand (n=88), 
the Philippines (n=67), Taiwan (n=46), Hong Kong 
(n=40), South Korea (n=30) and Indonesia (n=29). 
Baseline patient demographics for the overall study 
population are: median age 57 years (range 18–81 
years); male/female: 60%/40%; ECOG performance 
status 0/1: 26%/74%; stage IIIB/IV: 10%/90%; 
current/former/never smoker: 29%/23%/49%; 
adenocarcinoma/squamous-cell/other: 76%/16%/8%. 
All patients are of Asian ethnicity; 92% are receiving 
gemcitabine/carboplatin and 8% are receiving 
gemcitabine/cisplatin. Of the 451 enrolled patients, 
397 (88.0%) gave consent for tumour sample 
collection and 301 samples were provided for 
analysis, giving a tissue acquisition rate of 66.7%. 
An interim safety review by the Data and Safety 
Monitoring Board occurred after 100 patients were 
enrolled into the study. No concerning safety signal 
was observed. 
Conclusion: The FASTACT-II study will provide 
important clinical insights into the use of intercalated 
erlotinib and platinum-based chemotherapy in Àrst-
line NSCLC. The high tissue acquisition rate for this 
study will allow for analysis of efÀcacy relative to 
biomarker and histological status. 
Keywords: Non-Small-Cell Lung Cancer, Àrst-line, 
FASTACT II, erlotinib
Medical Oncology III Wednesday, 6 July 2011 14:30-16:00
O31.03 ASSOCIATION OF EPIDERMAL 
GROWTH FACTOR RECEPTOR 
(EGFR) EXPRESSION WITH CLINICAL 
OUTCOME IN FLEX STUDY PATIENTS 
WITH ADVANCED NON-SMALL 
CELL LUNG CANCER (NSCLC) 
RECEIVING CHEMOTHERAPY PLUS 
CETUXIMAB AS FIRST-LINE THERAPY: 
SAFETY ANALYSIS OF EXPRESSION 
SUBGROUPS
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PATIENTS WITH ADVANCED NSCLC 
COMPARED WITH HISTORICAL 
CONTROLS
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Background: Anaplastic lymphoma kinase (ALK) 
represents a new molecular target in lung cancer. The 
ALK tyrosine kinase inhibitor crizotinib is highly active 
in patients with advanced, ALK+ NSCLC. To determine 
whether crizotinib impacts the overall survival (OS) 
of ALK+ patients, we compared the OS of crizotinib-
treated patients with that of matched historical controls.
Methods: We determined overall survival of 82 ALK+ 
patients who enrolled in the international clinical 
trial of crizotinib (Kwak et al., NEJM, 2010). For 
comparators, we identiÀed 37 ALK+ patients from 
clinical sites who were not treated with crizotinib 
(ALK+ controls), as well as 253 ALK-negative/EGFR-
negative patients from one site (ALK- controls). All 
ALK+ and ALK- controls had advanced NSCLC.
Results: Among the 82 ALK+ patients treated with 
crizotinib, the median OS from the date of Àrst dose 
has not been reached (NR); 1-yr OS was 77% and 
2-yr OS was 64%. OS did not differ based on sex 
(p=0.35), ethnicity (Asian vs non-Asian, p=0.46), 
smoking history (never vs any smoking, p=0.82) or 
Background: Crizotinib is a selective, ATP-
competitive, small molecule anaplastic lymphoma 
kinase (ALK) inhibitor. The ALK fusion gene is a 
key oncogenic driver in a subset of patients with 
NSCLC, and crizotinib demonstrated clinical activity 
with a high response rate in an expanded cohort 
study in such patients. Here we present data from an 
ongoing Phase 2 study of crizotinib in patients with 
ALK-positive NSCLC. 
Methods: This study included patients with ALK-
rearranged NSCLC (conÀrmed by centralized 
FISH test) from 57 sites in 12 countries, who had 
progressed after 1 chemotherapy regimens for 
recurrent/advanced/metastatic disease (including 
treated brain metastases). Patients received oral 
crizotinib 250 mg BID continuously in 3-week 
cycles. Disease response was evaluated by RECIST 
(version 1.1) every 6 weeks and safety/tolerability 
was evaluated every 3 weeks. 
Results: Currently, 136 patients are evaluable for 
safety and 76 are evaluable for tumor response. 
Median age was 52 years, 94% of patients had 
adenocarcinoma, 68% had never smoked, and 53% 
were female. The majority of patients had received 
2 prior systemic therapy regimens (93%; range 
1–11). At the time of this analysis, patients had 
received a median of 9 weeks of crizotinib treatment 
(range 0.1–36 weeks’ treatment) and 88% remained 
on therapy. A waterfall plot of tumor measurements 
in evaluable patients showed target lesion shrinkage 
in approximately 90% of patients (41 pts had 30% 
shrinkage). Seven patients experienced objective 
progression by RECIST. The most frequent 
treatment-related adverse events (AEs) were nausea 
(46%), vision disorder (45%), vomiting (39%), 
and diarrhea (29%), and AEs were mostly Grade 
1/2 in severity. Treatment-related Grade 3/4 AEs 
were reported in 15% of patients (mostly increased 
ALT [4%], dyspnea [3%], and neutropenia [2%]). 
Six patients discontinued study treatment due to 
treatment-related events (pneumonitis [two patients], 
nausea, dyspnea, increased ALT and death of 
unknown cause). Updated efÀcacy and safety data 
will be presented. 
Conclusion: Preliminary data from this Phase 2 
global clinical study suggest crizotinib was safe and 
well tolerated with preliminary evidence of clinically 
meaningful antitumor activity in patients with pre-
treated ALK-rearranged NSCLC. 
Keywords: Crizotinib, PF-02341066, Non-small cell 
lung cancer
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Background: Current broad chemotherapy options 
for NSCLC provide limited survival and quality of 
life (QoL) beneÀts. The ALK fusion gene is a key 
oncogenic driver recently identiÀed in a subset of 
patients with NSCLC. In an early clinical study, a 
high response rate (61%) was observed to crizotinib, 
a potent and selective, adenosine triphosphate 
(ATP)-competitive, small-molecule ALK inhibitor, 
in patients with ALK-positive advanced NSCLC. 
PROs were incorporated into the subsequent single 
arm Phase 2 study in second- and third-line ALK-
positive NSCLC patients since understanding the 
improvements patients may experience on crizotinib 
therapy is a key goal in this patient population. 
Clinically signiÀcant changes from baseline disease/
treatment-related symptoms and QoL scores were 
evaluated in this preliminary analysis of PROs. 
Methods: Patients with ALK-positive advanced 
NSCLC (conÀrmed by centralized FISH test) 
from 57 sites in 12 countries, whose disease had 
progressed after 1 chemotherapy regimens for 
recurrent/locally advanced/metastatic disease 
(including treated brain metastases) were treated in 
this study. Patients received oral crizotinib 250 mg 
BID continuously in 3-week cycles. Study endpoints 
included best tumour response, safety/tolerability, 
overall and progression-free survival, and the 
assessment of PROs by the EORTC QLQ-C30/LC13. 
Mean score and clinically signiÀcant change from 
baseline scores (deÀned as a 10 point change from 
baseline; Osoba et al. J Clin Oncol 1998;16:139-44) 
were assessed at each cycle. 
Results: On 29 October 2010, 109 patients were 
age ( or >60 yrs, p=0.93). Among the 37 ALK+ 
controls, median OS from the date of metastatic 
diagnosis was 20 mos; 1- and 2-yr OS was 73% and 
33%, respectively. As ALK+ controls were identiÀed 
at sites outside of Korea, we compared controls with 
the non-Korean cohort of crizotinib-treated patients 
(n=56). Both groups were similar in age (median 51 
vs 51, p=0.97), sex (57% vs 46% F, p=0.40), smoking 
history (68% vs 79% never smokers, p=0.33), presence 
of brain metastases at any time (49% vs 48%, p=1.00), 
number of prior therapies (mean 2.05 vs 2.09, p=0.17), 
and types of prior chemotherapy. From the time of 2nd 
line therapy, the survival of 32 patients treated with 2nd 
/3rd line crizotinib was signiÀcantly longer than that 
of 24 ALK+ controls treated with any 2nd line therapy 
(p=0.004): median OS was NR vs 11 mos, 1-yr OS 
was 71% vs 46%, and 2-yr OS was 61% vs 9% for 
the subset of crizotinib-treated patients vs the subset 
of ALK+ controls, respectively. Among 123 ALK- 
controls who received any 2nd line therapy, median OS 
from the time of 2nd line therapy was 11 mos, and the 
1- and 2-yr OS was 49% and 33%, respectively.
Conclusion: In patients with advanced ALK+ 
NSCLC, treatment with crizotinib is associated with 
a longer OS than that seen with historical, crizotinib-
naive controls.
Keywords: ALK, Crizotinib, Tyrosine kinase inhibitor
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STUDY OF CRIZOTINIB (PF-02341066) 
IN ANAPLASTIC LYMPHOMA KINASE 
(ALK)-POSITIVE ADVANCED NON-
SMALL CELL LUNG CANCER (NSCLC)
Fiona H. Blackhall1, Jennifer A. Petersen2, Keith 
Wilner3, Vera Hirsh4, Alice T. Shaw5, Dong-Wan 
Kim6, Ben Solomon7, Pasi A. Janne8, Arlene L. 
Reisman9, Anna Polli10, Rajiv Mundayat11, Andrew 
Bottomley12 
Copyright © 2011 by the International Association for the Study of Lung Cancer S413
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
Department, Nanjing University/China, 3Department 
Of Respiratory Medicine, Southern Medical 
University/China, 4Department Of Respiratory 
Medicine, Nanjing Chest Hospital/China, 
5Department Of Oncology, The First Hospital 
Of Nanjing/China, 6Department Of Respiratory 
Medicine, Nanjing University, Jinling Hosipital/
China
Background: Can single-agent maintenance therapy 
be considered an ideal strategy for non-small cell 
lung cancer (NSCLC) treatment to achieve prolonged 
survival and tolerated toxicity? Researchers differ on 
this question. A systematic review and meta-analysis 
was performed to elucidate this issue.
Methods: The PubMed and Embase online 
databases and American Society of Clinical 
Oncology (ASCO) annual proceedings (2001-2010) 
were searched for randomized controlled trials 
(RCTs) comparing single-agent maintenance therapy 
versus placebo, best support care or observation. 
The overall response rate (ORR) in patients with or 
without maintenance therapy was extracted from 
each study as an estimation of the curative effect 
of the therapy. The required data for estimation of 
individual hazard ratios (HRs) for survival were 
extracted from the publications and a combined HR 
was calculated. The incidences of Grade 3/4 toxicity 
in the two treatment regimens were also extracted 
to estimate the safety of single-agent maintenance 
therapy.
Results: Ten RCTs to date, involving a total of 3513 
patients and with trial sizes ranging from 130 to 889, 
were identiÀed. We found a statistically signiÀcant 
higher probability of tumor response for patients 
with maintenance therapy versus controlled patients 
(odds ratio (OR): 2.80, 95% CI: 2.15-3.64, P < 
0.001). Patients receiving single-agent maintenance 
therapy had signiÀcantly longer progression-free 
survival (HR: 0.67, 95% CI: 0.62-0.71, P < 0.001) 
and overall survival (HR: 0.84, 95% CI: 0.78-0.90, 
P < 0.001). However, maintenance therapy was 
associated with more severe toxicities.
Conclusion: In patients with advanced NSCLC, the 
use of single-agent maintenance therapy is associated 
with higher response rate and signiÀcantly prolongs 
PFS and OS despite of the risk of additional toxicity.
Keywords: Non-small cell lung cancer, maintenance 
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evaluable for the PRO change from baseline analysis 
and 76 patients for tumour response. Patients 
received a median of 9 weeks of crizotinib and 
88% were still on treatment at the time of analysis. 
Questionnaire compliance rate was exceptionally 
high (>90%) for all cycles and most patients had 
completed four PRO assessments at the time of 
analysis. Patients reported clinically signiÀcant 
reductions of 10 points in key symptoms of 
NSCLC, including pain (29.5 baseline mean score), 
dyspnea (35.9 baseline mean score on the QLQ C30 
scale), and cough (40.0 baseline mean score) as early 
as Cycle 2. Clinically signiÀcant reductions in pain 
(pain, pain in arm or shoulder, pain in other parts, 
and pain in chest), dyspnea (QLQ-C30 scale), cough, 
fatigue, insomnia, and alopecia symptom scales were 
maintained with therapy. Post-baseline increases in 
constipation, diarrhea, and nausea/vomiting were 
also reported; however, only increase in constipation 
was clinically signiÀcant over the course of therapy. 
Improvement in mean QoL was also reported but 
changes were not clinically signiÀcant, indicating 
that QoL was maintained with treatment. Additional 
and updated PRO information will be presented. 
Conclusion: This phase 2 study provides 
preliminary evidence that patients with ALK-positive 
advanced NSCLC treated with crizotinib appeared to 
experience clinically signiÀcant improvements in key 
symptoms of NSCLC while QoL was maintained. 
PROs will continue to be monitored in this study and 
work is ongoing within randomized phase III trials to 
further assess the impact of treatment and hopefully 
conÀrm these initial Àndings. 
Keywords: Crizotinib, PF-02341066, Non-small cell 
lung cancer, Symptons
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THERAPY IN NON-SMALL CELL LUNG 
CANCER: A SYSTEMATIC REVIEW AND 
META-ANALYSIS
Dongmei Yuan1, Shuzhen Wei2, Yanling Lv3, Xiaohui 
Miao2, Like Yu4, Jinfei Chen5, Yi Shi6, Yong Song1 
1Department Of Respiratory Medicine, Nanjing 
University, Jinling Hospital/China, 2Medical 
S414 Copyright © 2011 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
gender 68%, median age 62 (range 36-84), PS 0/1 
45/49%, squamous cell histology 19%, stage IV 79%, 
interval from last 1st-line chemotherapy course and 
randomization  3 months in 71% of patients (42% 
 6 months), prior response to 1st-line chemotherapy 
50%. Despite identical eligibility criteria in the two 
studies, there was heterogeneity for some clinical 
characteristics (more squamous tumors, more advanced 
PS, longer treatment-free interval in the Dutch study). 
In the overall population, survival was not improved 
by the addition of carboplatin to pemetrexed; the HR 
for death was 0.88 (95%CI: 0.71-1.07; p = 0.202; p 
for heterogeneity = 0.693). Objective response rate 
was increased in the carboplatin-containing arm with 
an OR of 1.78 (95%CI: 1.01-3.12; p = 0.046; p for 
heterogeneity = 0.060). A non-statistically signiÀcant 
increase in PFS favouring combined chemotherapy 
was observed with a HR of 0.85 (95%CI: 0.71-1.02; p 
= 0.082; p for heterogeneity = 0.019). In the subgroup 
analyses, there was a statistically signiÀcant interaction 
between histological subtype and treatment: in fact, 
the addition of carboplatin to pemetrexed in patients 
with squamous tumours led to a statistically signiÀcant 
improvement of PFS from 2 to 3.2 months (adjusted 
HR: 0.42; 95%CI 0.27-0.65; p of interaction test = 
0.001) and of OS from 5.4 to 9 months (adjusted HR: 
0.57; 95%CI 0.36-0.90; p of interaction test = 0.05). 
Conclusion: Single agent pemetrexed remains 
the standard of care 2nd-line chemotherapy in 
patients with relapsed non-squamous lung tumors. 
Although pemetrexed has presently no indication 
in the treatment of squamous subtype NSCLC, the 
results of this pooled analysis can support further 
investigation of the carboplatin-pemetrexed regimen 
in the 2nd-line treatment of this histological subtype. 
Keywords: NSCLC, second-line chemotherapy, 
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Background: To evaluate the beneÀt of adding 
carboplatin to single-agent pemetrexed chemotherapy 
in 2nd-line treatment of advanced NSCLC, by pooling 
the results of two identical phase II randomized trials 
(GOIRC 02.2006 and NVALT-7 trials) carried out in 
Italy and The Netherlands, respectively. 
Methods: Main eligibility criteria in both trials were: 
diagnosis of advanced NSCLC, disease progression 
after 1st-platinum-based chemotherapy, normal organ 
function and ECOG performance status 0-2. Patients 
were randomized to receive pemetrexed 500 mg/m2 
alone or combined with carboplatin (AUC5). Cycles 
were repeated every 3 weeks for a maximum of 4 
courses. Both studies were designed to detect a 33% 
decrease in the hazard of disease progression in the 
combination arm. The pooled analysis was pre-planned 
and designed to assess the impact of adding carboplatin 
to pemetrexed in terms of overall survival (OS) in the 
overall population and in certain subgroups. 
Results: A total of 479 patients were randomized in 
the two trials. Main patients characteristics were: male 
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Background: SigniÀcant advances in the systemic 
management of metastatic non-small cell lung 
cancer (NSCLC) have occurred over the past 
decade, with options now including multiple lines of 
chemotherapy, EGFR inhibitors, and anti-angiogenic 
agents. Improvements in overall survival have been 
demonstrated in randomized controlled trials comparing 
these newer agents to best supportive care (BSC) or 
standard therapy. This study examined uptake of these 
therapies in general practice and their impact on survival.
Methods: This retrospective cohort study compared 
demographic, treatment and survival data among 
987 patients diagnosed with stage IV NSCLC at two 
institutions in 1998, 2003, and 2008. Cohorts were 
selected based on intervals when doublet chemotherapy, 
second line chemotherapy, and targeted agents were 
incorporated into the standard treatment regimen.
Results: The proportion of patients receiving 
systemic therapy increased over time (20% in 1998, 
42% in 2008). Treated patients diagnosed in 2008 
were more likely to receive 2 lines of systemic 
therapy (60% vs. 7% in 1998). Overall survival 
improved signiÀcantly across cohorts (P <0.001), 
with 2 year survival rates of 0.3% in 1998, 4% in 
2003, and 15% in 2008. After controlling for other 
variables, risk of death was diminished by 55% in 
patients receiving 1 line of systemic therapy and 
72% in those receiving 2 lines, compared with BSC 
alone. Elderly patients (age 70 years) were also 
more likely to receive systemic therapy over time, 
with improved overall survival (P <0.001).
Conclusion: Over the past decade, there has been 
increased use of systemic therapy in stage IV NSCLC 
patients, including the elderly. This has been associated 
with signiÀcantly improved overall survival.
Keywords: stage IV, NSCLC, systemic therapy, 
survival
Background: In a Àrst-line study of advanced 
NSCLC, pemetrexed plus cisplatin (PC) was more 
effective among patients (pts) with nonsquamous 
histology compared with gemcitabine-cisplatin (GC, 
OS=11.8 v 10.4 m, P=.005) while survival with 
PC was shorter than with GC in pts with squamous 
cell carcinoma. The comparability of PC to other 
commonly used regimens within histology subgroups 
needs to be explored. 
Methods: This retrospective analysis combined the 
pt-level data from 3467 pts enrolled in one of three 
similar phase 3 trials (N=607, 1725, and 1135) with 
mature survival data comparing the efÀcacy of Àrst-
line doublets (6 cycles) in advanced NSCLC. Cox 
covariate-adjusted treatment hazard ratios (HRs) 
with 95% CI were obtained for OS. Overall and 
histology subgroup analyses were reported without 
adjustment for multiplicity.
Results: In the overall analysis, adjusted HRs 
favored PC (HR <1.0) to each of the other 5 
regimens. Among pts with nonsquamous histology, 
PC produced favorable HRs to each of the other 
regimens, achieving statistical signiÀcance when 
compared with vinorelbine-cisplatin and GC. Among 
pts with squamous histology, 4 of the 5 comparison 
regimens were favored to PC (HR >1.0), with 
only the comparison to GC achieving statistical 
signiÀcance. HR (95% CI) for contrast with 
pemetrexed-cisplatin 
Comparitors Overall 
Non-squamous 
subgroup 
Squamous 
subgroup 
Gemcitabine-
carboplatin 
0.88 (0.65, 1.18) 0.80 (0.57, 1.14) 0.96 (0.53, 1.73) 
Gemcitabine-
cisplatin 
0.94 (0.84, 1.05) 0.85 (0.75, 0.97) 1.23 (1.01, 1.51) 
Gemcitabine-
paclitaxel 
0.91 (0.68, 1.22) 0.79 (0.56, 1.02) 1.26 (0.70, 2.27) 
Paclitaxel-
carboplatin 
0.91 (0.71, 1.17) 0.78 (0.58, 1.05) 1.34 (0.84, 2.11) 
Vinorelbine-
cisplatin 
0.80 (0.62, 1.03) 0.67 (0.50, 0.91) 1.25 (0.78, 2.02) 
Conclusion: In the absence of randomized trial 
data comparing PC to commonly used doublets 
in advanced NSCLC other than GC, this analysis 
provides estimates for such comparisons.
Keywords: NSCLC, Pemetrexed
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well balanced between arms. nab-PC produced higher 
ORR compared with PC (33 vs 25%, P = 0.005). A 
signiÀcant improvement of ORR was observed for 
nab-PC (n = 229) vs PC (n = 221) in squamous cell 
carcinoma patients (41 vs 24%, P<.001), while nab-PC 
was as effective as PC in nonsquamous cell carcinoma 
patients. Age (75 vs <75 years old), smoking status, 
and geographic location did not effect primary efÀcacy 
outcome. Differences were observed in the average 
number of cycles administered per regions: 11 cycles 
in Australia/New Zealand, 7 in Eastern Europe, 4 
in Japan, and 5 in North America. nab-PC was well 
tolerated, with signiÀcantly improved safety proÀle 
vs PC despite 30% higher mean total paclitaxel dose 
delivered (1528 vs 1170 mg/m2). Of the statistically 
signiÀcant grade 3 adverse events, neutropenia, 
neuropathy, myalgia, and arthralgia were lower in 
the nab-PC arm, and thrombocytopenia and anemia 
were lower in the PC arm. No bleeding was associated 
with thrombocytopenia. No hypersensitivity reaction 
occurred in the nab-PC arm without prophylactic 
premedication, while 3 occurred in the PC arm with 
premedication (grade 1, 2, and 3, respectively). PFS 
analysis with 47% events revealed no signiÀcant 
differences between the 2 arms. 
Conclusion: The primary endpoint was met, with 
signiÀcantly improved ORR (31% improvement), 
and nab-PC was highly active in the squamous 
cell carcinoma subset. Interim PFS did not show a 
difference between the arms; Ànal survival results 
with 70% patients with an event will be presented. 
nab-PC is efÀcacious and safe as Àrst-line therapy 
for advanced NSCLC. 
Keywords: nab-paclitaxel, Abraxane, taxane, 
Advanced NSCLC
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O32.07 PEMETREXED AND 
CARBOPLATIN VERSUS DOCETAXEL 
AND CARBOPLATIN AS FIRST-LINE 
TREATMENT FOR PATIENTS WITH 
ADVANCED, NON-SQUAMOUS, NON-
SMALL CELL LUNG CANCER (NSCLC)
Vinod Ganju1, Jose Pereira2, Joo-Hang Kim3, 
Manuel Magallanes4, Dae-Ho Lee5, Jie Wang6, Luis 
Martinez7, Helen Barraclough8, Maximiliano Van 
Kooten9, Mauro Orlando10 
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O32.06 NAB-PACLITAXEL AND 
CARBOPLATIN COMPARED WITH 
CREMOPHOR-BASED PACLITAXEL 
AND CARBOPLATIN IS EFFECTIVE 
AND SAFE AS FIRST-LINE THERAPY IN 
ADVANCED NON-SMALL CELL LUNG 
CANCER: FINAL RESULTS OF A PHASE 
3 STUDY
Mark A. Socinski1, Igor Bondarenko2, Nina 
Karaseva3, Anatoly Makhson4, Ihor Vynnychenko5, 
Isamu Okamoto6, Jeremy Hon7, Vera Hirsh8, Paul 
Bhar9, Gregory Berk9, Jose Iglesias10 
1University Of North Carolina, University Of North 
Carolina/United States Of America, 2City Clinical 
Hospital/Ukraine, 3City Oncology Center/Russian 
Federation, 4Moscow Oncology Hospital #62/
Russian Federation, 5Sumy Regional Oncology 
Centre/Ukraine, 6Kinki Univercity Faculty Of 
Medicine/Japan, 7Clearview Cancer Inst/United 
States Of America, 8Department Of Oncology, Mcgill 
University Health Centre/Canada, 9Celgene/United 
States Of America, 10Celgene/Canada
Background: Platinum-based doublet therapy in 
non-small cell lung cancer (NSCLC) has reached 
a therapeutic plateau, regardless of combinations. 
The nanoparticle albumin-bound formulation 
of paclitaxel, nab-paclitaxel, reaches the tumor 
microenvironment efÀciently via caveolae-mediated 
transcytosis, is approved for the treatment of 
metastatic breast cancer, and has shown promising 
antitumor activity in various advanced solid tumors, 
including NSCLC. This phase 3 trial compared 
the efÀcacy and safety of nab-paclitaxel plus 
carboplatin (nab-PC) vs a standard platinum-taxane 
combination treatment, paclitaxel plus carboplatin 
(PC), in patients with advanced NSCLC. Previously 
we reported that overall response rate (ORR), the 
primary endpoint, was signiÀcantly higher in the 
nab-PC arm compared with the PC arm. Here we 
report the Ànal analysis of the survival results.
Methods: First-line stage IIIB or IV NSCLC patients 
(ECOG 0/1) were randomized to receive carboplatin 
AUC6 q3w and either nab-paclitaxel 100 mg/m2 qw 
without premedication (n = 521) or paclitaxel 200 
mg/m2 q3w with premedication (n = 531). Primary 
endpoint was ORR by independent radiologic review. 
The main secondary endpoints included progression-
free survival (PFS), overall survival, and safety. 
Results: Baseline and histologic characteristics were 
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longer with PC than DC (median 3.2 months vs. 
0.7 months, log-rank p<0.001; HR = 0.45 [95% CI: 
0.35 to 0.58]). This signiÀcant difference remained 
when SWT was adjusted for prognostic baseline 
characteristics (adjusted HR = 0.45 [95% CI: 
0.34 to 0.61], p<0.001). There were no signiÀcant 
differences between PC and DC in progression-free 
survival, duration of response, or overall survival 
(OS). Median OS was 14.9 months for PC and 
14.7 months for DC (adjusted HR = 0.93 [95% CI: 
0.72 to 1.42], p=0.698). The tumor response rate 
was 34.0% for PC and 22.9% for DC (p=0.074). 
More patients in the DC arm than the PC arm had 
1 Grade 3 or 4 AE (81.9% vs. 63.2%) or 1 study 
drug-related TEAE (90.5% vs. 80.2%). Grade 3 or 4 
treatment-emergent neutropenia, febrile neutropenia, 
leukopenia, or dyspnoea occurred in more patients 
in the DC arm than the PC arm, whereas grade 3 
or 4 anemia or thrombocytopenia occurred more 
frequently in the PC arm.
Conclusion: The favorable beneÀt-to-risk proÀle of 
PC observed in this study suggests that PC may be 
an appropriate Àrst-line treatment option for patients 
with advanced, non-squamous NSCLC, given the 
palliative nature of therapy in this setting. 
Keywords: Pemetrexed, Docetaxel, Non-squamous 
nsmall cell lung cancer, Carboplatin
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O33.01 ENHANCING EGFR-DIRECTED 
THERAPIES THROUGH A NOVEL 
RESEARCH PLATFORM INTEGRATING 
DATA FROM GENETICALLY 
ENGINEERED MICE, PATIENT DERIVED 
XENOGRAFTS AND CLINICAL TRIALS 
(IGXT)
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Background: In a previous randomized, phase 
3 study, second-line treatment with pemetrexed 
resulted in clinically equivalent efÀcacy outcomes 
compared to docetaxel in patients with advanced 
NSCLC, but had a more favorable toxicity proÀle.
Platinum-based cytotoxic doublets are recommended 
as Àrst-line treatment for patients with advanced 
NSCLC and good performance status (PS). In a 
recent phase 3 study, pemetrexed and cisplatin 
resulted in superior outcomes and less toxicity 
compared to gemcitabine and cisplatin in non-
squamous NSCLC. Relatively few studies have 
assessed treatment outcomes with pemetrexed/
carboplatin (PC), although docetaxel/carboplatin 
(DC) is a well-accepted Àrst-line option. The primary 
objective of this multicenter, randomized, phase 3 
trial was to compare survival without grade 3 or 4 
toxicity (SWT) following Àrst-line treatment with PC 
versus DC in patients with advanced non-squamous 
NSCLC. 
Methods: Chemotherapy-naïve patients with stage 
IIIB/IV, non-squamous NSCLC, aged 18 years, 
with an Eastern Cooperative Oncology Group PS 0 
to 2 were randomized to receive carboplatin (AUC 5) 
with pemetrexed (500 mg/m2) and standard vitamin 
supplementation or docetaxel (75 mg/m2) every 21 
days for a maximum of 6 cycles. Patients in both 
arms received dexamethasone supplementation. 
SWT was deÀned as the time from the date of 
randomization to the Àrst date of any Grade 3 or 4 
treatment-emergent adverse event (TEAE) or death 
due to any cause. 
Results: Between October 2007 and April 2009, 226 
patients with non-squamous histology were enrolled 
at 23 investigative sites in 6 countries, of whom 211 
(93.4%) were evaluable. The median age was 59.5 
years, 41.7% were East Asian, 46.0% were females, 
and 35.5% were never-smokers. There were more 
females and never-smokers in the DC arm than in 
the PC arm. The median number of cycles delivered 
was 5 for DC and 6 for PC.SWT was signiÀcantly 
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pts, histopatholgic features, molecular proÀles and 
initial treatment results in PDXs and patients will be 
presented. 
Conclusion: This EGFR-direct pilot project supports 
the feasibility of systematically integrating data 
derived from iGXT models in order to optimize drug 
development and treatment strategies to address drug 
resistance mechanisms. Findings from this platform 
are likely to advance understanding of differences in 
inter- and intra-patient tumor biology and hasten the 
transition to personalized cancer therapy. 
Keyword: research platform
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O33.02 MURINE TRANSGENIC LUNG 
CANCER MODELS GUIDE A WINDOW 
OF OPPORTUNITY VORINOSTAT TRIAL 
IN LUNG CANCER PATIENTS
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Background: Lung cancer is the most common 
cause of cancer mortality. New treatments for 
lung cancer are needed. We previously engineered 
murine transgenic cyclin E models that recapitulated 
frequent features of lung cancers in patients. These 
included chromosome instability, hedgehog pathway 
and cyclin D1 activation as well as single or multiple 
pre-malignant and malignant (adenocarcinoma) lung 
lesions. Metastases were observed. Cell lines (ED-
1 and ED-2) were derived from these murine lung 
cancers. After tail vein injections of ED-1 or ED-2 
cells into syngeneic FVB mice, lung cancers began 
to form within 2 weeks. These models are useful 
tools to identify promising anti-neoplastic agents. 
This study used these murine lung cancer models to 
guide a window of opportunity trial of the histone 
deacetylase inhibitor vorinostat in lung cancer 
patients.
Methods: For in vitro studies, murine lung cancer 
cell lines ED-1 and ED-2 and human lung cancer cell 
lines HOP62, H522 and H23 were each treated with 
Laboratory Medicine, UC Davis/United States 
Of America, 4Response Genetics/United States Of 
America, 5The Jackson Laboratory/United States Of 
America
Background: Previously described preclinical 
models have proven suboptimal for directing clinical 
application of new anti-cancer therapies. Here we 
describe an integrated research platform (iGXT) 
engaging core resources at The Jackson Laboratory 
(JAX-WEST), the NCI Center for Advanced 
Preclinical Research (CAPR) and a clinical trials 
consortium based at the UC Davis Cancer Center. 
Pilot studies using this strategy are focusing on non-
small cell lung cancer (NSCLC) due to molecular 
targets of interest, such as epidermal growth factor 
receptor (EGFR), heterogeneity in NSCLC tumor 
biology and the complexity of cancer signaling 
pathways. 
Methods: In this pilot project, EGFR-directed drugs 
of interest (example: erlotinib +/-AKT inhibitor 
MK2206 or pan-HER inhibitor BIBW2992) 
are being studied at NCI CAPR in genetically 
engineered mice (GEMs) bearing tumors with 
deÀned EGFR-related characteristics, together 
with in vitro models at UC Davis, while NSCLC 
patients (pts) and JAX Nod Scid Gamma (NSG) 
mice with patient-derived xenografts (PDXs) from 
those pts are concurrently treated in a co-clinical 
trial paradigm, taking advantage of the NSG mouse 
for propagating PDXs. Results in NSG models and 
pt trials are assessed by genome-wide technologies, 
integrated with data from CAPR, and extrapolated 
back to individual pt outcomes to gain insight into 
mechanisms of drug resistance and how to overcome 
them. 
Results: Over 200 cancer pt tumors have 
been xenotransplanted into NSG mice (~60 
from NSCLC). NSCLC PDXs show excellent 
histopathologic and molecular correlation to parent 
patient tumors, including mutation status for KRAS, 
EGFR and gene expression levels. Pilot studies 
at CAPR in GEMs with EGFR mutant (Tet-op-
EGFR L858R +/- T790M) tumors demonstrate 
efÀcacy of MK2206 +/- erlotinib and BIBW2992. 
Complementary in vitro studies at UCD with the 
c-MET inhibitor PHA-665752 or MK2206 conÀrm 
the ability of MK2206 to overcome c-MET-related 
resistance to erlotinib. Simultaneously, an ongoing 
erlotinib-MK2206 clinical trial with associated PDXs 
is designed to evaluate mechanisms of resistance to 
erlotinib and overcome them. Demographics of host 
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O33.03 PEP02 (LIPOSOME IRINOTECAN) 
EFFECTIVELY INHIBITS HUMAN 
LUNG SQUAMOUS CELL CARCINOMA 
AND SMALL CELL LUNG CANCERS IN 
SUBCUTANEOUS AND ORTHOTOPIC 
XENOGRAFT TUMOR MODELS
Daniel C. Chan1, Zhiyong Zhang1, Paul A. Bunn1, 
Grace Yeh2 
1Medical Oncology, University Of Colorado Denver/
United States Of America, 2Pharmaengine, INC/
Taiwan
Background: PEP02 is a nanoparticle liposome 
formulation of irinotecan (CPT-11), a topoisomerase 
I inhibitor, used for the treatment of various tumor 
types including lung cancers. In preclinical and clinical 
studies, PEP02 has been shown to greatly modify the 
pharmacokinetics and biodistribution of CPT-11 and 
its active metabolite, SN-38, thereby improving its 
therapeutic efÀcacy. In this report, we evaluated the in 
vivo efÀcacy of PEP02 in three xenograft models of 
human lung tumors.
Methods: Xenograft models of subcutaneous H157 
squamous cell carcinoma (SCC), known to be resistant 
to various EGFR inhibitors, and H841 small cell 
lung cancer (SCLC), known to be resistant to several 
conventional therapeutic agents, were established in 
mice and rats. Animals (10-12 per group) were treated 
by weekly iv injections after the tumor reached 200 
cubic mm in size with placebo liposome, CPT-11 at 50 
(mouse ) or 25 (rat) mg/kg/wk, docetaxel at 8 (mouse) 
or 12 (rat) mg/kg/wk, or PEP02 at 15, 30 and 50 mg/
kg/wk for three or four weeks. Tumor volumes were 
measured with digital calipers. For the orthotopic 
model, Kaplan-Meier survival curves were generated.
Results: (1) PEP02 effectively suppressed H157 
subcutaneous SCC tumor growth in a dose dependent 
manner, much more efÀcient than CPT-11 or docetaxel. 
PEP02 at 15, 30 and 50 mg/kg/wk inhibited tumor 
growth by 86.7%, 92.9% and 97.6%, respectively 
when compared with that of placebo liposome, and 
the suppressions persisted for 12 to 15 days after the 
last treatment. In contrast, CPT-11 and docetaxel 
only inhibited tumor growth by 29.8% and 71.4%, 
respectively. Retreatment of the regrowth was achieved 
with PEP02 at 50 mg/kg/wk which extended the tumor 
suppression until 130 days. (2) For the SCLC H841 
xenograft, PEP02 at 15, 30 and 50 mg/kg/wk also 
impressively inhibited tumor growth by 81.7%, 96.3% 
and 98.3% respectively, much better than CPT-11 by 
vorinostat (1-5ƫM) for 2 or 4 days to investigate 
growth inhibitory and apoptotic effects. Expression 
of the cell cycle proteins cyclin D1, cyclin E and p27 
were examined after vorinostat treatments. For in 
vivo studies, cyclin E transgenic mice were treated 
with vorinostat to investigate effects on cyclin D1, 
cyclin E and ki-67 expression in lung cancers. FVB 
mice harboring transplanted syngeneic murine lung 
cancer cells were treated with vorinostat to evaluate 
effects on lung cancer formation. For the window 
of opportunity clinical trial, patients with resectable 
non-small cell lung cancer (NSCLC) were treated 
with vorinostat (400mg) orally once daily for 7 
days before surgical resection. Paired pre-treatment 
and post-treatment tumor biopsies were scored for 
immunohistochemical changes in cyclin D1, cyclin E 
and Ki-67.
Results: Among a panel of drugs that caused growth 
inhibition of lung cancer cells and repression of 
cyclin D1 protein, vorinostat was found as most 
potent. Vorinostat treatment caused dose-dependent 
and time-dependent growth inhibition and apoptosis 
induction in murine and human lung cancer cells. 
Effects were reversed by washouts of vorinostat. 
Vorinostat treatments repressed cyclin D1 and cyclin 
E proteins, but increased p27 expression in ED-1 
cells. Notably, vorinostat treatments of cyclin E 
transgenic mice substantially repressed cyclin D1 
expression in pre-malignant and malignant lung 
tissues. Vorinostat treatment signiÀcantly reduced 
lung tumor formation (P = 0.047) in the murine 
transplantation lung cancer model. To translate these 
studies into the clinic, 10 patients were recruited for 
the vorinostat window of opportunity clinical trial. 
Among 7 of the paired tumor specimens examined, 
3 had decreased Ki-67 and cyclin E levels, 2 had 
decreased cyclin D1 expression, and 4 showed 
necrosis in post-treatment biopsies.
Conclusion: Substantial anti-neoplastic effects of 
vorinostat occurred in cultured lung cancer cells and 
in vivo in murine transgenic and transplantable lung 
cancer models. Findings were validated in the clinic 
through a vorinostat window of opportunity trial. 
These studies underscore the value of clinically-
relevant murine lung cancer models for guiding 
clinical trials in lung cancer patients.
Keywords: window of opportunity trial, NSCLC, 
Vorinostat, murine lung cancer model
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Background: Lung cancers harboring anaplastic 
lymphoma kinase (ALK) rearrangements represent a 
unique subpopulation of patients. Crizotinib, an ALK 
tyrosine kinase inhibitor (TKI) is clinically effective 
in this genomically deÀned patient subset. However, 
the clinical success of treatment with ALK-TKIs is 
often limited by the development of acquired drug 
resistance. In this study, we examined resistance 
mechanisms to ALK-TKIs. The understanding 
of resistance mechanism(s) is critical to the 
development of effective subsequent treatments. 
Methods: We examined tumor biopsies from 
patients treated with crizotinib that had developed 
acquired resistance to crizotinib. We also generated 
an ALK-TKI resistant H3122 cell (H3122TR3) by 
exposing the increasing dose of TAE684. Finally 
we generated a cell line (DFCI076) from a pleural 
effusion of a NSCLC patient that developed acquired 
resistance to crizotinib. We examined whether 
genomic changes (mutations or copy number 
changes) were present in the ALK TKI resistant 
tumors and cells. In addition, we evaluated for the 
presence of co-activated signaling pathways. 
Results: We identiÀed a secondary mutation in 
ALK, F1174L (also detected in neuroblastoma), in a 
patient with an inÁammatory myoÀbroblastic tumor 
(IMT) harboring a RANBP2-ALK translocation 
who progressed while on crizotinib therapy. When 
present in cis with an ALK translocation, the F1174L 
mutation causes an increase in ALK phosphorylation, 
cell growth and downstream signaling. This mutation 
likely promotes the active conformation of ALK 
which disfavors crizotinib binding as it binds the 
inactive conformation of ALK. Treatment with a 
structurally distinct ALK inhibitor, TAE684, or with 
3-fold above the current efÀcacious concentrations of 
crizotinib was sufÀcient to inhibit the growth of Ba/
F3 cells harboring the F1174L mutation. In contrast 
the DFCI076 cells (EML4-ALK), were resistant to 
both crizotinib and TAE684. These cells contained 
a novel L1152R ALK secondary mutation. Ba/F3 
cells with EML4-ALK L1152R were also resistant 
to crizotinib and the L1152R mutation diminished 
crizotinib mediated inhibition of downstream 
phosphorylation. In addition, we determined that the 
DFCI076 cells had evidence of signiÀcant Epidermal 
Growth Factor Receptor (EGFR) phosphorylation. 
Infection of an ALK shRNA inhibited the growth 
of DFCI076 cells to 40% of control; however the 
combination of ALK knockdown and PF00299804, 
an irreversible pan-ERBB inhibitor, led to further 
growth inhibition (19% of control). The H3122TR3 
51.6%, when compared with that of placebo liposome. 
Inhibition of tumor growth persisted more than 20 days 
after the last treatment with PEP02 at 15 and 30 mg/
kg/wk before tumor grew again. In contrast, complete 
tumor regression was achieved at 50 mg/kg/wk. (3) 
When implanted orthotopically in the left lung of 
athymic nude rats, H157 SCC tumor grew aggressively 
and metastasized contra-laterally to right lungs, and 
eventually rats died from tumor burden with a median 
survival of 24 days in the placebo liposome group. At 
the maximum tolerated dose, CPT-11 at 25 mg/kg/wk 
or docetaxel at 12 mg/kg/wk did not extend rat survival 
at all. However, PEP02 at 15, 30 and 50 mg/kg/wk 
prolonged median survivals by 4, 12 and 26 days, 
respectively. In all three models, no obvious side effects 
or weight loss were noted in the PEP02 treated groups.
Conclusion: PEP02 effectively inhibited tumor 
growth, regrowth, and prolonged survival in 
subcutaneous and orthotopic lung tumor xenograft 
models. PEP02 has great clinical potential for the 
treatment of human lung SCC and SCLC in which 
there are high unmet medical needs.
Keywords: Liposomal irinotecan, subcutaneous and 
orthotopic models, Squamous carcinoma and SCLC
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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INHIBITORS IN EML4-ALK NON-SMALL 
CELL LUNG CANCER
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the current study, we evaluated the therapeutic and 
radiosensitizing effects of cediranib and paclitaxel, 
alone and in combination, in an orthotopic model 
of human lung adenocarcinoma that mimics clinical 
patterns of malignant progression. 
Methods: PC14PE6 human lung adenocarcinoma 
cells (1 x 106) were injected into the left lungs of 
nude mice. After 2 weeks, mice were randomized (8/
group) to treatment with vehicle control, cediranib 
(3 mg/kg/day po), paclitaxel (200 g/week ip), 
radiation to the lung and mediastinum (20 Gy in 5 
fractions over 2 weeks), or radiation with cediranib 
and/or paclitaxel. When control mice became 
moribund, all mice were sacriÀced and assessed for 
lung tumor burden and regional metastasis. Tumor 
tissues were subjected to immunohistochemical 
analyses. 
Results: 
Inhibition of tumor growth and metastasis by cediranib, radiation, 
and paclitaxel treatment in an orthotopic human lung adenocarcinoma 
(PC14PE6) model in mice 
Treatment 
Tumor 
incidence 
Left lung 
weight 
(mg) 
Left lung 
Tumor 
volume 
(mm3) 
Plueral 
effusion 
(l) 
Mediastinal 
lynph node 
metastasis 
Vehicle 8/8 
710 (490-
1210) 
753 (254-
1089) 
360 (0-850) 7/8 
Paclitaxel 
200ug/week 
8/8 
545 (150-
860) 
506 (37-
817) 
150 (0-400) 6/8 
Radiation 
20Gy/5fraction 
8/8 
220** (50-
360) 
154* (34-
270) 
0 (0-200) 4/8 
Cediranib 3mg/
kg/day 
8/8 
215* (70-
540) 
137* (13-
316) 
0 (0-150) 4/8 
Radiation + 
Paclitaxel 
8/8 
185** (60-
260) 
87** (21-
268) 
0 (0-100) 2/8 
Cediranib + 
Paclitaxel 
7/8 
125** (60-
260) 
41** (0-
150) 
0 (0-150) 1/8+ 
Radiation + 
Cediranib 
3/8 
50** (40-
260) 
0** (0-
28) 
0* (0) 0/8+ 
Radiation + 
Cediranib + 
Paclitacel 
3/8 
40** (40-
60) 
0** (0-1) 0* (0) 0/8+ 
Data are presented as median and range or as incidence. +p<0.05 vs vehicle 
(Lymph nodes), *p<0.01, p<0.001 vs vehicle (others) 
All treatments were well tolerated. Cediranib, 
radiation, or paclitaxel monotherapy inhibited 
primary lung tumor growth by 83.1, 80.4, and 33.7% 
compared to control, respectively, and only partially 
inhibited mediastinal metastasis. Radiation and 
cediranib, cediranib and paclitaxel, and radiation 
with paclitaxel reduced primary tumor volume 
by 99.3, 92.7, and 87.0% compared with control, 
respectively. In the cediranib plus radiation group, 
metastasis and pleural effusion were completely 
cells were resistant in vitro to both TAE684 and 
crizotinib but did not contain a secondary ALK 
mutation. However, the H3122TR3 cells contained 
activation of EGFR signaling mediated by autocrine 
EGF production. The combination of crizotinib and 
PF00299804 effectively inhibited the growth of 
H3122TR3 cells. 
Conclusion: Multiple mechanisms of resistance, 
including secondary mutations in ALK and co-
activation of parallel signaling pathways, can 
develop in response to ALK TKIs and can develop 
simultaneously. Our Àndings suggest the need to 
develop alternative strategies to inhibit ALK and/or 
to develop effective combination therapies that target 
both ALK and EGFR. A phase I clinical trial of 
crizotinib and PF00299804 is currently underway. 
Keywords: Non-small cell lung cancer, gene 
translocation, kinase inhibitor, anaplastic large cell 
kinase
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O33.06 VEGF SIGNALING INHIBITION 
BY CEDIRANIB ENHANCES THE 
ANTITUMOR AND ANTI-METASTATIC 
EFFECTS OF RADIATION THERAPY 
MORE SUBSTANTIALLY THAN 
PACLITAXEL IN A MURINE 
ORTHOTOPIC MODEL OF LUNG 
CANCER
Osamu Takahashi1, Ritsuko Komaki1, Juliane M. 
Jürgensmeier2, Anderson J. Ryan3, Paul D. Smith2, 
Ignacio I. Wistuba4, Benjamin N. Bekele5, Ramesh 
C. Tailor1, Jörg J. Jacoby6, Maria V. Korshunova1, 
Anna Biernacka1, Keiko Hosho1, Baruch Erez6, Roy 
S. Herbst6, Michael S. O’Reilly1 
1Radiation Oncology, The University Of Texas M.D. 
Anderson Cancer Center/United States Of America, 
2Astrazeneca/United Kingdom, 3Astrazeneca (current 
Address, Department Of Oncology, University Of 
Oxford)/United Kingdom, 4Pathology, The University 
Of Texas MD Anderson Cancer Center/United 
States Of America, 5Biostatistics, The University Of 
Texas M.D. Anderson Cancer Center/United States 
Of America, 6Thoracic/head And Neck Medical 
Oncology, The University Of Texas MD Anderson 
Cancer Center/United States Of America
Background: Cediranib (AZD2171, RECENTIN™) 
is an orally available and highly potent inhibitor of 
VEGFR1–3 currently in phase III clinical trials. In 
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Background: Synthetic lethality represents a 
novel therapeutic strategy in the treatment of 
cancer, as exempliÀed by the recent advent of poly 
(ADP-ribose) polymerase (PARP) inhibition in 
BRCA1/2 mutated tumours. Inhibition of PARP, a 
single strand (ssDNA) break repair protein, leads 
to an accumulation of DNA double strand breaks, 
speciÀcally in S-phase cells. Normally these breaks 
are repaired via homologous recombination (HR), 
a process requiring functional BRCA1/2 However, 
the dual loss of both PARP-mediated ssDNA 
repair upon PARP inhibition and defective HR, in 
BRCA-deÀcient cells, results in the accumulation of 
DNA damage and ultimately cell death. Currently, 
it is unknown whether synthetic lethality due to 
inhibition of PARP-mediated DNA repair in HR-
defective tumours requires mitochondrial apoptosis. 
The underlying mechanisms involved in cell killing, 
involving the accumulation of catastrophic DNA 
damage, would be predicted to induce cell death 
independently of the canonical mitochondrial death 
pathway. However, this hypothesis has not yet been 
fully investigated. 
Methods: The effect of BRCA1-depletion and 
in-vitro response to PARP inhibitor treatment 
was performed using clonogenic assays in a 
panel of NSCLC cell line models. In addition, 
BAX/BAK-deÀcient and cisplatin resistant 
NSCLC cell line models were employed. BRCA1 
immunohistochemistry was performed on 302 
primary NSCLC tumours from two independent 
cohorts to determine the frequency of BRCA1-
immunodeÀciency
Results: We demonstrate that BRCA1-depletion 
enhances sensitivity to PARP inhibitor therapy 
in a panel of NSCLC cell lines and that this 
effect is independent of mitochondrial apoptosis. 
Furthermore, we demonstrate that BRCA1 
inhibition cannot override platinum resistance 
but can induce sensitisation to PARP inhibition in 
the platinum resistant setting. We also report the 
existence of a subgroup of NSCLC with BRCA1-
immunodeÀciency representing 11% and 19% 
respectively, in two independent NSCLC patient 
cohorts.
Conclusion: Targeting BRCA1-depleted NSCLC 
with PARP inhibitors induces synthetic lethality, 
results in bypass of mitochondrial apoptosis 
block and can override platinum resistance. 
BRCA1-immunodeÀcient NSCLC represents 
a molecular subgroup that could be effectively 
targeted by PARP inhibitors in the clinic. BRCA1 
inhibited, whilst paclitaxel only marginally improved 
the effects of radiation. Trimodality therapy resulted 
in the near complete suppression of tumor growth 
and metastasis with microscopic tumors detected 
in only 3 of 8 treated mice. Immunohistochemical 
analyses of lung tumors revealed that radiation or 
cediranib reduced microvessel density and tumor 
proliferation and increased tumor and endothelial 
apoptosis. VEGFR2 expression was not impacted 
by any treatments but its activation was blocked 
by cediranib. The most profound antiangiogenic 
and apoptotic effects were observed after treatment 
with cediranib and radiation or trimodality therapy 
but the inhibition of tumor cell proliferation was 
not substantially enhanced with combined modality 
therapy.
Conclusion: Trimodality therapy with cediranib, 
paclitaxel, and radiation resulted in the near 
complete suppression of lung tumor growth and 
metastasis with markedly enhanced antiangiogenic 
and apoptotic effects. The radiosensitizing effects 
of cediranib upon lung tumors and their vasculature 
was superior to those of paclitaxel with markedly 
enhanced apoptosis. The combination of cediranib 
with radiotherapy or chemoradiotherapy is a 
potentially promising therapy for cancer and our 
data provides a strong basis for the design of clinical 
trials in lung cancer patients. 
Keywords: orthotopic lung cancer model, Non-small 
cell lung cancer, cediranib (AZD2171), Radiation 
Therapy
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O33.07 PARP INHIBITION INDUCES 
BAX/BAK INDEPENDENT SYNTHETIC 
LETHALITY OF BRCA1-DEFICIENT 
NON-SMALL CELL LUNG CANCER
Ian Paul1, Kienan I. Savage1, Jaine Blainey1, 
Elisabeth Lamers1, Kathy Gately2, Keith M. Kerr3, 
Michael Sheaff4, Derek J. Richard5, Peter Hamilton1, 
Jackie James1, Kenneth J. O’Byrne2, Paul Harkin1, 
Jennifer E. Quinn1, Dean A. Fennell1 
1Centre For Cancer Research And Cell Biology, 
Queen’s University Belfast/United Kingdom, 
2Department Of Clinical Medicine, St. James’s 
Hospital/Ireland, 3Department Of Pathology, 
Aberdeen Royal InÀrmary/United Kingdom, 
4Department Of Pathology, Barts And The London 
Nhs Trust/United Kingdom, 5Queensland University 
Of Technology/Australia
Copyright © 2011 by the International Association for the Study of Lung Cancer S423
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
and two experts in assessment. 
Three trainees who had performed less than 50 
EUS procedures and three consultants who had 
performed more than 100 procedures were included 
in the study. Each physician performed 5 EUS 
procedures on patients scheduled for mediastinal 
staging. All procedures were observed by an expert 
who Àlled out the assessment form. Furthermore all 
procedures were recorded and assessed blindly and 
independently by two EUS experts.
Results: The assessment tool could sufÀciently 
discriminate between trainees and consultants, 
p=0.001. The intra-rater reliability was high, 
Cronbach’s Alpha 0.80, and the inter-rater 
reliability was very high, Cronbach’s Alpha 0.87. 
Conclusion: The novel assessment tool for 
measuring competence in performance of EUS and 
EUS-FNA for lung cancer staging is reliable and 
valid. It can be used for direct observation or blinded 
using video-recordings. The assessment tool can 
provide valuable feed-back to trainees and help to 
decide when basic competency is established. 
Keywords: Assessment, EUS, Training, Staging of 
NSCLC
immunohistochemistry (IHC) presents a robust, 
relatively simple and cost effective approach for 
identifying a subgroup of BRCA1-immunodeÀcient 
NSCLC, who may derive beneÀt from treatment with 
PARP inhibitors. This biomarker assay now merits 
testing in the clinical trial setting. 
Keywords: apoptosis, BRCA1, Non small cell lung 
cancer, PARP inhibitor
Session O34: Nodal Staging by 
Ultrasound Endoscopy and Alternative 
Image Guided Diagnosis
Wednesday, 6 July 2011
Nodal Staging by Ultrasound Endoscopy and Alternative Image 
Guided Diagnosis Wednesday, 6 July 2011 14:30-16:00
O34.01 RELIABLE AND VALID 
ASSESSMENT OF EUS AND EUS-FNA 
COMPETENCE IN PULMONOLOGY
Lars Konge1, Jouke Annema2, Peter Vilmann3, Paul 
Clementsen4, Charlotte Ringsted1 
1Centre For Clinical Education, Rigshospitalet, 
University Of Copenhagen/Denmark, 2Department 
Of Pulmonology, Leiden Medical Centre/
Netherlands, 3Department Of Surgery, Endoscopic 
Unit, Copenhagen University Hospital Gentofte/
Denmark, 4Pulmonology, Gentofte University 
Hospital/Denmark
Background: Accurate staging is essential for 
choosing treatment for non-small-cell lung cancer. 
Sampling of tissue from the mediastinum has been 
revolutionized by ultrasound guidance, and it seems 
that the combination of EUS-FNA and EBUS-TBNA 
will replace more invasive methods for diagnosis 
and staging of lung cancers in the near future. This 
will create a huge need for doctors who master the 
new techniques. EUS training and implementation 
requirements are under discussion. A reliable 
and valid assessment tool is necessary to provide 
structured feed-back to trainees, measure the effect 
of training methods, and help certify physicians. 
The aim of this study was to explore the reliability 
and validity of a new assessment tool designed to 
measure competence in EUS-FNA for mediastinal 
staging. 
Methods: The tool was created by a group of four 
physicians: Two experts in endoscopic ultrasound 
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stations, our study shows that very little, if anything, 
is gained by an additional mediastinoscopy and can 
be avoided
Keywords: Lung cancer, EBUS-TBNA, 
Mediastinoscopy
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O34.03 COST-EFFECTIVENESS AND 
QUALITY OF LIFE RESULTS FROM THE 
ASTER STUDY: ENDOBRONCHIAL AND 
ENDOSCOPIC ULTRASOUND VERSUS 
SURGICAL STAGING IN POTENTIALLY 
RESECTABLE LUNG CANCER
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Abstract under Embargo - will be presented in a 
press conference during WCLC 2011.
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O34.05 IN VIVO MICROSCOPIC 
IMAGING OF THE BRONCHIAL 
MUCOSA USING AN ENDO-CYTOSCOPY 
SYSTEM
Kiyoshi Shibuya1, Nao Okada1, Hiromasa Kohno1, 
Naomichi Iwai1, Masahiro Noro2, Bunshiro Akikusa2, 
Hidehisa Hoshino3, Ichiro Yoshino3 
1Chest Surgery, Matsudo City Hospital/Japan, 
2Pathology, Matsudo City Hospital/Japan, 3General 
Thoracic Surgery, Chiba University/Japan
Background: We investigated the capabilities of 
an Endo-Cytoscopy system (ECS) that enables 
microscopic imaging of the tracheobronchial tree 
Nodal Staging by Ultrasound Endoscopy and Alternative Image 
Guided Diagnosis Wednesday, 6 July 2011 14:30-16:00
O34.02 IS MEDIASTINOSCOPY 
NECESSARY IN PATIENTS WITH 
NEGATIVE EBUS-TBNA- A CHALLENGE 
TO THE ESTS GUIDELINES FOR 
STAGING OF LUNG CANCER?
Mark Krasnik1, Birgit G. Skov2, Anders 
Mellemgaard2, Peter Vilmann3, Felix J. Herth4 
1Thoracic And Cardiovasc.surg, Rigshospitalet 
Copenhagen University/Denmark, 2Pathology, 
Bispebjerg University Hospital/Denmark, 
3Department Of Surgery, Endoscopic Unit, 
Copenhagen University Hospital Gentofte/Denmark, 
4Dept. Of Pneumology And Respiratory Critical Care 
Medicine, Thoraxklinik, University Of Heidelberg/
Germany
Background: Mediastinoscopy is the golden 
standard for mediastinal staging of lung cancer.The 
aim of the present study was to examine whether 
mediastinoscopy may be avoided if a standardized 
EBUS-TBNA procedure using the same criterias as 
required during mediastinoscopy with representative 
biopsies without malignant cells from lymph nodes 
in station 4R, 7 and 4L, is performed.
Methods: Patients with known or suspected lung 
cancer underwent a standardized EBUS-TBNA 
procedure. . All patients with EBUS-TBNA from 
station 4 R, 4L and 7 without cancer cells og a 
speciÀc diagnose were further referred for a VATS/
thoracotomy
Results: A total of 76 out of 95 consecutive patients, 
48 males, 28 females were enrolled. Mean age 65 
years (range 40-85). The mean sizes of the lymph 
nodes in all 3 stations were 9mm (range 2 - 35mm). 
The Ànal primary diagnosis was cancer in 67 patients 
and benign diagnoses in 8 patients . In 4 patients 
mediastinal metastases were found by surgery (5%). 
One patient had a metastasis in station 4 R and 2 
patients in station 5 and one patient in station 6. The 
NPV was 0.95 and with a speciÀcity of 1
In total the false negative rate of EBUS-TBNA in 
mediastinal staging of lung cancer was 4 out of 76 
(5%).
Conclusion: The results of the present study seem 
to challenge mediastinoscopy as the gold standard. 
When EBUS-TBNA is performed under the same 
standardised conditions as described by the ESTS 
guidelines for mediastinoscopy with demonstration 
of lymphatic tissue from relevant lymph node 
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O34.06 REAL-TIME IMAGE GUIDANCE 
OF BRONCHOSCOPIC PROCEDURES 
USING X-RAY FLUOROSCOPY AND 
EBUS FOR PERIPHERAL PULMONARY 
LESIONS
Ye Xu1, Mingying Zeng2, Di Xu3, Sheng Xu4, Rex C. 
Yung2 
1Clinical Informatics, Interventional, And 
Translational Solutions, Philips Research North 
America/United States Of America, 2Pulmonary 
And Critical Care Medicine, Johns Hopkins 
University School Of Medicine/United States Of 
America, 3Department Of Biomedical Engineering, 
Johns Hopkins University School Of Engineering/
United States Of America, 4Clinical Informatics, 
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Research North America/United States Of America
Background: In bronchoscopic procedures, it is 
difÀcult to navigate the bronchoscope to peripheral 
lesions due to the limited local view of the 
bronchoscope. In addition, the airways to peripheral 
targets are often too small for the bronchoscope to 
reach. X-ray Áuoroscopy can provide intra-operative 
image feedback of the biopsy instruments even for 
the regions beyond the reach of the bronchoscope, 
facilitating global navigation to peripheral targets. 
Radial Endobronchial Ultrasound (EBUS) can 
characterize the tissue beyond the airway walls 
and is often used as a local conÀrmation before 
biopsy samples are obtained. This paper reports the 
effectiveness of using real-time image guidance 
of X-ray Áuoroscopy and EBUS in bronchoscopy 
procedures to peripheral targets. 
Methods: 323 brochoscopic procedures were 
performed by one bronchoscopist (RY) at the Johns 
Hopkins Hospital from Jan 2009 to Dec 2010. 
97 of the 323 procedures involved at least one 
peripheral pulmonary lesion (PPL) and these were 
selected for further analysis under the approval of 
the Johns Hopkins University Institutional Review 
Board. Radial EBUS and/or X-ray were selected 
for real-time image guidance based on the need of 
the procedures, and rapid on-site cytopathologic 
examination (ROSE) was used in all procedures. 
The tissue samples underwent pathologic 
examination and the results were compared with the 
Ànal diagnosis according to additional follow up 
examination. 
during bronchoscopy, including normal bronchial 
epithelium, dysplastic mucosa and hilar lung cancer.
Methods: The newly developed integrated-type 
ECS for the bronchoscope has a built-in two 
imaging system with a conventional mode and a 
high-power endocytoscopic mode. ECS has a high 
magniÀcation of 570 X. Forty-two patients with 11 
hilar lung cancer, 7 abnormal sputum cytology,21 
follow up squamous dysplasia, and 3 after 
photodynamic therapy were entered into the study 
and underwent white light, narrow band imaging and 
autoÁuorescence imaging bronchoscopy. Both the 
abnormal area of interest and surrounding normal 
bronchial mucosa were stained with 0.5% methylene 
blue and examined with ECS. Histological 
examinations with haematoxylin and eosin stain 
were performed using the biopsied specimens. The 
ECS imaging was analyzed and correlated with the 
corresponding histological examination.
Results: ECS imaging could distinguish between 
different types of bronchial epithelium including 
normal bronchial mucosa, squamous dysplasia, and 
hilar lung cancer. Of 16 pathological diagnosed 
dysplastic lesions, superÀcial cells with rounded 
nuclei and abundant cytoplasm were visible in 
13 lesions. Of 13 pathological diagnosed hilar 
lung cancers, polygonal or ovoid malignant tumor 
cells were observed in 11 lesions. Squamous 
dysplasia and hilar lung cancer were predictive with 
sensitivity of 81.3% (13/16) and 84.6% (11/13) 
and speciÀcity of 100 %( 13/13), respectively. 
Conclusion: This novel technology has an excellent 
potential to provide in vivo diagnosis during 
bronchoscopic examinations. 
S426 Copyright © 2011 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
approaches to biopsy of peripheral pulmonary 
lesions (PPL). SpeciÀc clinicoradiologic features 
may guide choice of initial investigation, though 
in many patients therefore the optimal method of 
investigation is not clear.
Methods: We performed a prospective randomized 
pragmatic trial to determine the comparative 
effectiveness of endobronchial ultrasound-guided 
transbronchial lung biopsy (EBUS-TBLB) and 
CT-guided percutaneous needle biopsy (CT-PNB) 
for the investigation of PPL in patients in whom 
clinicoradiologic features could not determine the 
optimal investigation. Consecutive patients referred 
for evaluation of PPL were randomized to undergo 
either procedure. Primary outcomes examined were 
diagnostic accuracy and complication rates.
Results: 358 patients were referred to our service 
for initial evaluation of PPL during the study period. 
71 were eligible for inclusion and 51 (72%) of these 
were randomized. No signiÀcant difference between 
EBUS-TBLB and CT-PNB in diagnostic accuracy 
was seen (87.5% (95%CI 71–96) v. 93.3% (95%CI 
68–99) respectively, p=1.0). Overall complication 
rates were higher in those undergoing CT-PNB 
(27% v 3%, p=0.03). Diagnostic yield in patients 
undergoing EBUS-TBLB was higher in patients with 
lung cancer (p=0.025). 
Conclusion: Diagnostic accuracy of EBUS-TBLB 
in evaluation of PPL is non-inferior to CT-PNB. 
Complication rates following EBUS-TBLB are 
signiÀcantly lower than following CT-PNB. SpeciÀc 
complex clinicoradiologic factors will inÁuence 
the cost-beneÀt analysis between EBUS-TBLB and 
CT-PNB for individual patients. Further studies are 
required to examine the effect of these factors on 
clinical decision-making. 
Keywords: Non-inferiority, Pneumothorax, 
Diagnostic accuracy
Results: In the 97 cases with peripheral targets, a total 
of 158 PPLs were sampled. Lesion size distribution 
was <10 mm (n=32), 10–20 mm (n=51), 21–30 mm 
(n=36), and >30 mm (n=39). X-ray and EBUS usage 
was as follows: 62 procedures involved both X-ray 
and EBUS; 7 procedures involved X-ray only; 18 
procedures involved only EBUS; and 10 cases involved 
neither. Final diagnosis of the 97 procedures resulted 
in 56 cases of cancer, 35 of speciÀc benign pathology, 
and 6 of non-diagnostic pathology. Overall diagnostic 
yield was 94%, and the diagnostic yield was 84%, 91%, 
95% and 100% for PPL<10mm, 10-20mm, 21-30mm, 
and >30mm respectively. All cancer and speciÀc 
benign cases were correctly diagnosed, with the only 
bronchoscopic non-diagnostic Àndings being the same 
6 cases that were non-diagnostic on follow up as well. 
Of the 6 cases nondiagnosed by bronchoscopy, 5 used 
X-ray and EBUS, and 1 used EBUS-only. 
Conclusion: In this cohort of 97 patients with 
peripheral lesions, the bronchoscopist chose to use 
real-time imaging from X-ray or EBUS in 90% of 
cases, resulting in a diagnostic yield of 94%. Other 
authors have reported diagnostic yields of 35%, 61.4%, 
and 94.7% for PPLs <=10, 10-20, and >20 mm, 
respectively, using X-ray guidance alone; and 29.7% 
and 75.6% for PPLs <=20 and >20 mm, respectively, 
using EBUS guidance alone. Although this is a pilot 
study conducted at a single institution, the high 
diagnostic yield, especially in comparison to historical 
data, suggests a navigational beneÀt of using both 
real-time imaging modalities when targeting peripheral 
lesions that are not directly visible in the bronchoscope. 
Keywords: Bronchoscopic procedure, X-ray 
Áuoroscopic guidance, EBUS, peripheral pulmonary 
lesions
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O34.07 COMPARATIVE EFFECTIVENESS 
OF RADIAL PROBE ENDOBRONCHIAL 
ULTRASOUND VERSUS CT-GUIDED 
NEEDLE BIOPSY FOR EVALUATION OF 
PERIPHERAL PULMONARY LESIONS: A 
RANDOMIZED PRAGMATIC TRIAL
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Background: No studies have previously compared 
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tumor was too extensive for radical RT. Overall 
survival (OS) and alteration of RT treatment planning 
volume were secondary outcomes. The radiation 
target volumes were deÀned in the treatment protocol 
and included the primary tumor, ipsilateral hilar and 
mediastinal nodes according to the location of the 
primary. Any biopsy proven mediastinal node, nodes 
 1 cm and any Áuorodeoxyglucose (FDG) avid 
nodes were included in the target volume. 
Results: Overall 310 patients were randomized, 152 
to the PET/CT and 158 to standard CT planning. 118 
(78%) of the 152 patients randomized to the PET/CT 
arm received radical RT compared with 146 (92%) 
of the 158 CT patients. The median follow-up was 
17 months. With regards to the primary outcome, 26 
patients were unsuitable for CMT: 22 in the PET/CT 
arm and 4 in the CT arm. Thus, 22 of 152 (14.5%) 
in the PET/CT arm achieved the primary outcome 
compared with 4 of 158 (2.5%) patients in the CT 
arm, P= 0.00014. The 2-year OS of the PET/CT 
group was 47% compared with 39% for the CT arm 
(hazard ratio [HR] = 0.8; 95% conÀdence interval 
[CI]: 0.6 - 1.0). The overall recurrence rate was 
59/118 (50%) in the PET/CT arm compared with 
92/146 (63%) in the CT arm. InÀeld recurrences 
were similar in the PET/CT (16/59 or 27.1%) and 
CT (22/92 or 23.9%) arm. Outside of radiation Àeld 
recurrences were also similar in the PET/CT (37/59 
or 62.7%) and CT (61/92 or 66.3%) arm. The RT 
parameters evaluated included the planning target 
volume (PTV), maximum spinal cord dose, volume 
of heart receiving  40 Gy and the total volume of 
lung minus the PTV receiving  20 Gy. There were 
no signiÀcant differences in any of these parameters 
in the PET/CT or CT arm. 
Conclusion: The PET START trial is the Àrst 
randomized trial comparing PET/CT planning with 
standard CT planning in patients with NSCLC. 
As expected, the use of PET/CT resulted in fewer 
patients receiving radical RT. The OS trend favoring 
PET/CT may be primarily due to more accurate 
staging. There were no differences in the two arms in 
the radiation treatment parameters but this trial did 
not compare targeting only FDG avid areas on PET/
CT versus CT abnormalities only. 
Keywords: PET CT, Radiation Planning, Lung 
cancer
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Background: Patients with stage 3 non-small 
cell lung cancer (NSCLC) are potentially curable 
using combined modality therapy (CMT) with 
chemotherapy and radical radiation therapy (RT). 
PET/CT imaging is commonly used to stage patients 
with NSCLC. In addition, PET/CT for planning 
of RT may improve the deÀnition of RT treatment 
volumes compared with conventional CT planning 
and thus improve outcomes. 
Methods: Patients with stage 3 NSCLC, who were 
considered candidates for CMT, were randomized 
to either PET/CT or CT alone for RT treatment 
planning. The primary outcome was the proportion 
of patients who did not receive CMT because their 
tumor was upstaged to stage 4 or their intrathoracic 
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for survival, as did tumor size < 3 cm. Survival 
according to tumor size is shown in the table: 
Univariate 
Multivariate  
(adjusting for other factors) 
Size (cm) 
Median 
(yrs) 
5 yr 
(%) 
P-value 
(vs 
previous 
level) 
Hazard 
ratio 
P-value  
(vs previous level) 
<= 3 1.8 16.9 
> 3 & <= 5 1.3 12.9 0.008 1.249 0.0223 
> 5 & <= 7 1.4 16.3 0.625 0.973 0.9333 
> 7 1.1 10.2 0.105 1.178 0.1681 
Conclusion: In patients treated with radiotherapy 
with or without chemotherapy, tumor size < 3 cm 
was associated with better survival than larger 
tumors. Evidence for an effect of size on prognosis 
above this was weak. Five year survival >10% was 
observed in all four size categories.
Keywords: Non-small cell lung cancer, Staging, 
Radiotherapy
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O35.03 BOOSTING A SUB-VOLUME 
WITHIN THE PRIMARY TUMOR ON 
THE BASIS OF FDG UPTAKE: RESULTS 
OF TREATMENT PLANNING IN AN 
ONGOING RANDOMIZED PHASE II 
TRIAL (PET BOOST TRIAL)
Anke Van Der Salm1, Wouter Van Elmpt1, Eugène 
Damen2, Annemarie Lakeman2, Judith Van Der 
Stoep1, Daisy Emans1, Michel Öllers1, Jan Jakob 
Sonke2, José Belderbos2, Dirk De Ruysscher1 
1Department Of Radiation Oncology (MAASTRO), 
Grow, Maastricht University Medical Centre/
Netherlands, 2Department Of Radiation Oncology, 
The Netherlands Cancer Institute - Antoni Van 
Leeuwenhoek Hospital/Netherlands
Background: Improving local control increases 
survival in stage II/III NSCLC patients. We and 
others have shown that the site of relapse is mostly 
located in the high FDG-uptake region within the 
primary tumor prior to treatment. We recently 
embarked on a randomized phase II trial where 
patients are randomized between receiving a dose-
escalation of the entire primary tumour (Arm A) or 
to the high FDG-uptake region (50% maximum SUV 
volume) inside the primary tumour (Arm B). Both 
arms are escalated up to predeÀned normal tissue 
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O35.02 THE EFFECT OF TUMOR SIZE 
ON PROGNOSIS IN PATIENTS TREATED 
WITH RADICAL RADIOTHERAPY 
OR CHEMORADIOTHERAPY FOR 
NON-SMALL CELL LUNG CANCER IN 
THE IASLC LUNG CANCER STAGING 
PROJECT DATABASE.
David Ball1, Alan Mitchell2, Dori Giroux2, Ramon 
Rami-Porta3 
1Radiation Oncology, Peter MacCallum Cancer 
Centre/Australia, 2Cancer Research And 
Biostatistics/United States Of America, 3Matua 
Terrassa University Hospital/Spain
Background: Analysis of the IASLC database 
revealed that for patients with completely resected 
node negative NSCLC, increasing tumor size was 
associated with worsening survival (Rami-Porta 
et al, J Thor Oncol 2007; 2:593). This analysis 
was performed to determine the effect of size 
on prognosis in patients in the same database 
but who were treated with radiotherapy or 
chemoradiotherapy. 
Methods: Patients were eligible if they had 
pathologically conÀrmed NSCLC; no evidence 
of distant metastases; intended treatment radical 
radiotherapy (minimum 50 Gy) or combined 
chemotherapy and radiotherapy; no surgery; and 
tumour diameter was available. Survival was 
estimated using the Kaplan-Meier method and 
comparisons using the logrank test. Univariate and 
multivariate Cox regression was used to model the 
effect of primary tumor size and other prognostic 
factors on survival.
Results: 868 patients were available for analysis. 
Patient characteristics: male sex 65.3%; median age 
64 years (range 32-88); ECOG performance status 
0 - 55%, 1 – 33%, >2 – 5%; chemotherapy 74%, no 
chemotherapy 18%; weight loss < 5 % -70%, >5% 
- 25%; clinical N stage N0 – 18%, N1 – 5%, N2 – 
63%, N3 – 14%. Primary tumor size (based on TNM 
7th edition): <3 cm – 27%, >3 and < 5 cm – 34%, > 
5 and < 7cm – 20%, > 7 cm – 19%. On univariate 
analysis, the following factors were prognostic for 
survival: age (continuous) (P=0.0035), performance 
status > 1 (P=0.0021), weight loss <5% (P<0.0001), 
chemotherapy (P=0.0189) and primary tumor size 
(continuous) (P=0.0002). Sex and clinical nodal 
stage were not signiÀcant. On multivariate analysis, 
age and weight loss remained signiÀcant factors 
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risk was the large vessels in the mediastinum. 
Keywords: FDG-PET imaging, treatment planning, 
sub volume boosting, dose-escalation
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O35.04 DETAILED ANALYSIS OF TUMOR 
REGRESSION DURING RADICAL 
RADIOTHERAPY IN LUNG CANCER 
PATIENTS
Eva E. Schaake1, José Belderbos2, Simon Rit2, Simon 
Van Kranen2, Suzanne Van Beek2, H J. Teerstra3, Jan 
Jakob Sonke2 
1Thoracic Oncology, NKI-AVL/Netherlands, 
2Radiotherapy, NKI-AVL /Netherlands, 3Radiology, 
NKI-AVL /Netherlands
Background: In patients with inoperable, locally 
advanced lung cancer high dose radiotherapy is 
the treatment of choice. Despite new techniques 
local control could be improved in these patients. 
Tumor regression during the 5-6 weeks course of 
irradiation is frequently observed. This raises the 
clinical question whether the treatment plan should 
be adapted to the regressing tumor during the course 
of irradiation. Using cone-beam CT (CBCT) images, 
tumor regression patterns were studied to assess 
if treatment volumes could be adapted during the 
planned treatment course
Methods: Tumor volume change was analyzed in 
114 consecutive lung cancer patients during the 
course of high dose radiotherapy (mainly 17x3 
or 24x2,75 gray). Patient characteristics, volume 
change and pathological characteristics were 
compared. The process of tumor regression during 
the 5-6 weeks course of radiotherapy was analyzed 
on the basis of visual tumor regression on CBCT. 
The CBCT scans were made three times during 
the Àrst week en weekly thereafter. In patients 
with >30% tumor regression, two types of tumor 
regression were distinguished: 1) Elastic, in which 
surrounding tissue moves along with the shrinking 
tumor. 2) Non-elastic tumor regression in which 
the surrounding tissue remains at the same location 
while the tumor shrinks. 
Results: Of the 114 patients that were analyzed, 
65 were male. Eighty-nine patients with a NSCLC 
tumor, 13 with a SCLC tumor and 12 patients 
without a histologically conÀrmed diagnose 
were included, 75% of the patients were treated 
with either induction chemotherapy followed by 
constraints using IMRT. Here we present detailed 
results of the treatment planning strategy of the Àrst 
15 patients. 
Methods: The PET Boost Trial (NCT01024829) 
registered 15 patients on February 1, 2011. During 
treatment planning, Arm A and Arm B are planned. 
Radiotherapy dose to the primary tumour and the 
involved hilar and mediastinal lymph nodes is 66 Gy 
in 24 daily fractions of 2.75 Gy with an integrated 
boost to the whole primary tumour (arm A) or the 
region within the primary tumor with an uptake 
>50% of the maximum SUV inside the primary 
tumour (arm B). In case of overlap between target 
and organs-at-risk (OAR), 15% of the primary 
tumour PTV may be underdosed to the dose-
constraint value of the appropriate organ-at-risk. The 
lung toxicity parameter Mean Lung Dose (MLD) is 
forced equal in both arms by downscaling the arm 
with the highest MLD to the other arm, thus ensuring 
the same chance to develop lung toxicity in both 
arms (iso-toxic trial design). The biological corrected 
dose-constraint to lung is: MLD20 Gy. Other dose-
constraints: esophagus (V35<80%), spinal cord 
(max. 52 Gy), brachial plexus (max. 66 Gy), heart 
(mean dose<46 Gy) and the mediastinal structures 
(max. 94 Gy) All constraints are in biologically 
equivalent dose (EQD2). Patients are randomized 
between arm A and B if the dose-escalation of the 
primary tumour in arm A is at least 72 Gy.
Results: Twelve out of 15 patients could be 
randomized (i.e. receive a dose of at least 72 Gy in 
24 fractions). The average ratio between the volume 
of the entire primary tumour (GTV) and the 50% 
maximum SUV volume was: 35±14%. Average 
prescribed dose-values were 77.8 Gy (3.24 Gy/
fraction) [range: 72.2 – 102.7 Gy; 3.01 – 4.28 Gy/
fraction] and 88.1 Gy (3.67 Gy/fraction) [range: 
76.8 – 129.6 Gy; 3.20 – 5.40 Gy/fraction] for arm A 
and B, resp. Average mean dose inside the primary 
tumour was comparable: 76.7 vs. 76.5 Gy for arm A 
vs. B, resp. The MLD was comparable (as forced by 
iso-toxic design): A vs. B: 15.7 Gy vs. 15.5 Gy. Most 
frequent observed dose-limiting constraints were 
the mediastinal structures (11/12) and the brachial 
plexus (3/12). 
Conclusion: Selective dose-escalation using IMRT 
planning with an integrated boost could be achieved 
while keeping the dose-constraints to the organs 
at risk at safe levels. This integrated boost to the 
primary tumour or the high FDG-uptake region 
was feasible up to 77.8 and 88.1 Gy (24 fractions), 
respectively. The most frequently limiting organ-at-
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Oncology, University Of North Carolina/United 
States Of America, 3Division Of Hematology/
oncology, University Of North Carolina/United 
States Of America
Background: For patients with advanced stage 
IIIB/IV NSCLC and good performance status, 
palliative thoracic radiotherapy is typically reserved 
for patients with symptomatic disease or for those 
with obstructing central disease leading to collapsed 
lung. The aim of this study is to identify clinical and 
radiographic factors found early in a patient’s course 
that predict for the subsequent need for palliative 
radiotherapy or collapsed lobes.
Methods: We conducted a pooled analysis of 11 
prospective phase II and III clinical trials involving 
Àrst line, platinum-based chemotherapy. Baseline 
clinical and radiographic characteristics identiÀed 
before trial enrollment were analyzed as possible 
factors for subsequent pulmonary events (deÀned as 
either a course of palliative thoracic radiotherapy or 
a new subsequent collapased lobe).
Results: 318 consecutive patients who enrolled at 
a single institution were studied; 2 were excluded 
with no follow-up information available. 48 
patients received a palliative course of thoracic 
radiation and 50 exhibited evidence a new lobar 
collapse on follow-up chest imaging. On univariate 
analysis by log-rank test, pulmonary symptoms 
at presentation (p=0.032), pre-chemotherapy 
diagnosis of pneumonia (p<0.001), increasing 
size of hilar disease (p<0.001), and evidence of 
obstruction of major bronchi or vessels on pre-
chemotherapy CT (p=0.001) were associated with 
subsequent pulmonary events. On multivariate 
analysis by Cox proportional hazards regression, 
hilar disease >3cm in size (HR 1.6, p=0.007) and 
pre-chemotherapy pneumonia (HR 2.1, p<0.001) 
were associated with pulmonary events. Those with 
both risk factors or hilar disease >5cm exhibitied 
>50% risk of pulmonary events. These high risk 
groups for pulmonary events were also associated 
with diminshed overall survival (p<0.001). 
radiotherapy (34%) or concurrent chemoradiotherapy 
(41%). Tumor regression during treatment was found 
in 52 patients (46%), while 4 patients had tumor 
progression. The average volume decrease was 33% 
observed in these patients. Tumor regression analysis 
in 27 patients showed four patients (15%) with 
elastic tumor regression, nine (33%) with non-elastic 
tumor regression, and 14 (52%) with a combination 
of both types of regression. The different tumor 
regression types are illustrated in the Figure. 
Conclusion: Detailed analysis of tumor regression 
was performed using repeat CBCT scans acquired 
over the course of irradiation. Tumor regression 
occurs during the 5-6 weeks of curative radiotherapy 
in about half of the patients occurred relatively 
late. Partial response was seen right at the end 
of treatment in 24% of the patients. With elastic 
regression it is potentially safe to adapt the treatment 
plan as healthy tissue moves into the high dose 
region. True elastic regression, however, was rarely 
observed.
Keywords: Tumor regression, adaptive treatment, 
cone beam CT scan
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O35.06 PREDICTING THE NEED 
FOR PALLIATIVE THORACIC 
RADIOTHERAPY FOR ADVANCED NON-
SMALL CELL CARCINOMA
Daniel S. Higginson1, Ronald C. Chen1, Jan Halle2, 
David E. Morris1, Mark A. Socinski3, Lawrence B. 
Marks1 
1Radiation Oncology, University Of North Carolina/
United States Of America, 2Department Of Radiation 
Copyright © 2011 by the International Association for the Study of Lung Cancer S431
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
(MAR-LC) was preformed.
Methods: This updated individual patient data 
meta-analysis was restricted to patients with non 
metastatic lung cancer and included randomized 
trials comparing modiÀed radiotherapy (accelerated, 
hyperfractionated or both) to conventional 
radiotherapy (one 1.8- to 2-Gy fraction per day, 5 
days a week and a minimum total dose of 40 Gy for 
small cell lung cancer -SCLC- and 60 Gy for non-
small cell lung cancer –NSCLC). Data were centrally 
collected and checked. Trials were combined using 
the stratiÀed (by trial) log rank test to calculate 
pooled hazard ratio (HR). Overall survival (OS), 
deÀned as the time from randomization to death from 
any cause, was the main endpoint. 
Results: Among the twelve trials identiÀed, 
two were excluded due to lost data. Two trials 
with concurrent chemotherapy were split into 
two separate trials each (with and without 
chemotherapy), allowed by the factorial design (for 
concomitant chemotherapy) and the stratiÀcation 
design (adjuvant chemotherapy) used. Finally, 
twelve trials were analyzed including 2685 patients. 
In NSCLC (10 trials, 2000 patients, 1849 deaths 
with a median follow-up of 6.9 years), modiÀed 
fractionation improved OS as compared to 
conventional radiotherapy (hazards ratio HR=0.88, 
95% conÀdence interval [0.80-0.97], p=0.009), 
resulting in an absolute beneÀt of 3% at 5 years 
(from 8% to 11%). No heterogeneity between trials 
was found and no subgroup of patients beneÀted 
more or less from modiÀed RT. Similar beneÀt was 
found on lung cancer deaths (HR=0.89 [0.81-0.98], 
p=0.02) and on non-lung cancer deaths even if 
not signiÀcant (HR=0.87 [0.66-1.15], p=0.33). No 
signiÀcant effect of modiÀed fractionation was found 
on the progression-free survival (PFS, HR=0.94 
[0.86-1.03], p=0.19). In SCLC (2 trials, 685 patients, 
622 deaths with a median follow-up of 12.1 years), 
equivalent results were found but non signiÀcant 
(OS: HR=0.87 [0.74-1.02], p=0.08; PFS: HR=0.88 
[0.75-1.03], p=0.11). In both histological types, the 
use of modiÀed radiotherapy was associated with 
an increased risk of acute esophageal toxicity (304 
events, OR=2.4 [1.9-3.1] in NSCLC and 123 events, 
OR=2.4 [1.6-3.6] in SCLC; p<0.001) and in SCLC, 
an increased acute cardiac toxicity (17 events, 
OR=3.0 [1.1-7.7], p=0.03). No association was found 
with acute hematological or pulmonary toxicity.
Conclusion: Accelerated or hyperfractionated 
radiotherapy is beneÀcial to patients with non-
metastatic lung cancer, in NSCLC as well as in 
Conclusion: Patients with bulky hilar diseaes and 
a history of pneumonia at presentation exhibit 
a high risk for subsequent lung collapse and 
palliative thoracic radiation after Àrst line platinum 
chemotherapy. We propose that these patients may 
be studied to determine if early thoracic radiation, 
administered before severe pulmonary symptoms 
arise, could be beneÀcial to preserve quality of life 
and performance status.
Keywords: RADIATION, palliative thoracic 
radiation, stage IV non-small cell lung cancer
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O35.07 EVALUATION OF MODIFIED 
FRACTIONATION RADIOTHERAPY 
EFFECT IN NON METASTATIC LUNG 
CANCER: AN UPDATED INDIVIDUAL 
PATIENTS DATA META-ANALYSIS ON 
10 RANDOMIZED TRIALS AND 2685 
PATIENTS
Cécile Le Péchoux1, Audrey Mauguen2, Michael 
Baumann3, Steven E. Schild4, Mahesh Parmar5, 
Andrew T. Turrisi6, William Sause7, David 
Ball8, Chandra P. Belani9, Katarzyna Behrendt10, 
Jean-Pierre Pignon On Behalf On The Mar-lc 
Collaborative Group2 
1Radiotherapy Unit, Institut Gustave Roussy/France, 
2Service De Biostatistique, Institut Gustave Roussy/
France, 3University Hospital And Medical Faculty 
Carl Gustav Carus Dresden/Germany, 4Radiation 
Oncology, Mayo Clinic/United States Of America, 
5Clinical Trial Unit London, Medical Research 
Council/United Kingdom, 6Radiation Oncology 
Center, Sinai Grace Hospital/United States Of 
America, 7Intermountain Medical Center/United 
States Of America, 8Radiation Oncology, Peter 
MacCallum Cancer Centre/Australia, 9Medicine, 
Penn State Hershey Cancer Institute/United States 
Of America, 10Maria Skãadowska-curie Memorial 
Cancer Center And Institute Of Oncology, Gliwice 
Branch/Poland
Background: There have been numerous debates 
regarding altered fractionation in radiotherapy 
for lung cancer. Randomized trials assessing 
hyperfractionated or accelerated radiotherapy 
yielded conÁicting results for both progression-free 
survival and overall survival. To distinguish between 
inefÀciency of treatment and moderate effect, the 
Meta-Analysis of Radiotherapy in Lung Cancer 
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carcinomas, and three atypical adenomatous 
hyperplasias. A total of 373 patients (93%) were 
pN0, 15 (4%) pN1, 8 (2%) pN2, and 3 (1%) pN3. 
No nodal involvement was observed in any of 
the 136 patients with G100 or G75, in 4 out of 
103 patients (4%) with G25, and in 22 out of 160 
patients (14%) with G0. No vessel invasion was 
observed in any of the 49 patients with G100, in 
2 out of 87 patients (2%) with G75, in 11 out of 
103 patients (11%) with G25, and in 85 out of 160 
patients (53%) with G0. Pulmonary metastasis to 
the same lobe is detected in 4 patients (3%) with 
G0. No visceral pleural involvement (PL0) was 
observed in G100 and G75, however, that was 
observed (PL1<) in 7 (5%) with G25 and in 34 
(21%) with G0. SUV was over 1.62 in 26 patients 
with lymph node metastasis, vessel invasion, 
or pulmonary metastasis. It was suggested that 
limited operation should be indicated by individual 
tumor character due to percentage of GGO area 
and SUV by PET. G100 is good indication for 
partial resection or segmental resection depending 
on tumor location. Although there is no node 
metastasis in G75, possibility of vessel invasion 
recommends segmentectomy with pathological 
certiÀcation of no nodal metastasis. Limited 
resection for G0 and G25 should be avoided; 
however, a few tumors with SUV 1.5 or less 
will be an indication for segmentectomy. Sixty-
seven (G100:34, G75:30, G25 and G0:3) patients 
underwent limited pulmonary resection due to this 
indication. No recurrence is observed and 5-year 
survival is 100%.
Conclusion: Since GGO ratio on HRCT and 
SUV by PET well reÁect malignant potential of 
cT1aN0M0 NSCLC, limited surgery based on 
HRCT and PET promise functional preservation 
and good prognosis.
Keywords: GGO, SUV, limited surgery, T1aN0M0
SCLC. This beneÀt was mainly associated to an 
increased, but expected, risk of acute esophageal 
toxicity. Supported by PHRC, LNCC, SanoÀ-
Aventis.
Keywords: meta-analysis, modiÀed fractionation 
radiotherapy, randomized trials
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O36.01 GGO RATIO ON HRCT AND SUV 
BY PET INDICATE LIMITED SURGERY 
FOR CT1AN0M0 NON-SMALL-CELL 
LUNG CANCER
Hiroshi Niwa, Masayuki Tanahashi, Haruhiro 
Yukiue, Eriko Suzuki, Hiroshi Haneda, Naoko Yoshii 
Thoracic Surgery, Seirei Mikatahara General 
Hospital/Japan
Background: Many patients with cT1aN0M0 
non-small-cell lung cancer (NSCLC) are expected 
good prognosis after surgery. Especially presence 
of GGO on HRCT and low FDG uptake of the 
tumor measured by standardized uptake value 
(SUV) by positron emission tomography (PET) 
are good prognostic factors. Standard lobectomy 
with lymphadenectomy is not always required 
for those patients predicted good prognosis. If we 
select those patients before surgery, both pulmonary 
functional preservation and good prognosis are 
obtained by limited resection. 
Methods: We retrospectively analyzed 399 patients 
with cT1aN0M0 NSCLC. All patients were staged 
as cT1aN0M0 by HRCT and/or PET and underwent 
pulmonary resection. Our data were collected 
based on preoperative GGO ratio (percentage of 
GGO area in the lesion) on the basis of HRCT 
and FDG uptake of the tumor measured by SUV 
and pathological nodal status, vessel invasion, 
pulmonary metastasis in the same lobe, and visceral 
pleural involvement. Patients were separated in 4 
groups by the GGO ratio (G); G=100% (pure GGO, 
G100), 50%<G<100% (G75), 0%<G<=50% (G25), 
G=0% (solid, G0).
Results: There were 353 adenocarcinomas, 39 
squamous cell carcinomas, four adenosquamou 
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operative complications and the operative mortality 
was 0.97%. CK19 mRNA positive expression in 
peripheral blood was found in 141 patients. The 
positive rate of CK19 mRNA positive expression 
was 27.3% in peripheral blood samples in the 
516 cases. The positive rates of micrometastasis 
in peripheral blood was signiÀcantly related to 
histological classiÀcation, P-TNM staging and N 
staging of the cancer (P<0.05), but not to age, sex, 
smoking status of the patients, and size of primary 
tumor, and locations of the tumor (P>0.05). The 
median survival time was 43.74 months. The 1, 3, 
5 and 10 year survival rates of the 516 cases was 
89.1%, 39.3%, 19.8% and 10.4%, respectively. The 
1,3,5 and 10 year survival rates in patents without 
and with micrometastasis was 94.8%,56.6%,38.9% 
and 14.5%, and 84.6%, 9.7%, 0.5% and 0% 
respectively. The postoperative survival rate was 
remarkably correlated with micrometastasis, 
histological classiÀ- cation and size of primary 
cancer and LN metastasis (P<0.05). Multivariable 
Cox model analysis showed that “personalized 
molecular P-TNM staging”, micrometastasis in 
peripheral blood, pathological types of the tumor 
and mediastinal lymph node metastasis of the cancer 
were the most signiÀcant factors for predicting 
prognosis in the patients with LANSCLC.
Conclusion: Detecting of CK19 mRNA expression 
in peripheral blood will be helpful for selection of 
surgical treatment indication, the beneÀciary of 
neoadjuvant chemotherapy and postopertive adjuvant 
therapy in LANSCLC patients. Personalized surgical 
treatment can signiÀcantly improve prognosis and 
increase curative rate and long-term survival rate of 
LANSCLC based on personalized molecular staging. 
Keywords: LANSCLC, molecular staging, 
personalized surgical treatment, micrometastasis
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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O36.02 LONG-TERM SURVIVAL 
OF PERSONALIZED SURGICAL 
TREATMENT FOR LOCALLY 
ADVANCED NON-SMALL CELL LUNG 
CANCER BASED ON MOLECULAR 
STAGING
Qinghua Zhou1, Jun Chen2, Daxing Zhu2 
1Tianjin Lung Cancer Institute, Tianjin Medical 
University General Hospital/China, 2Tianjin Medical 
University General Hospital/China
Background: Approximately 35%-40% of 
patients with newly diagnosed non-small cell 
Lung cancer have locally advanced disease. The 
average survival time of these patients only have 
6-8 months with chemotherapy.The aim of this 
study is to explore and summarize the probability 
of detection of micrometastasis in peripheral 
blood for molecular staging, and for selection of 
indication of surgical treatment, and beneÀciary 
of neoadjuvant chemotherapy and postoperative 
adjuvant therapy in locally advanced non-small cell 
lung cancer(LANSCLC); to summarize the long-
time survival result of personalized surgicaltreatment 
of 516 patients with LANSCLC based on molecular 
staging methods. 
Methods: CK19 mRNA expression of peripheral 
blood samples was detected in 516 LANSCLC 
patients by RT-PCR before operation for molecular 
diagnosis of micrometastasis, personalized 
molecular staging, and for selection of indication of 
personalized surgical treatment and the beneÀciary 
of neoadjuvant chemotherapy and postoperative 
adjuvant therapy in patients with LANSCLC 
invaded heart, great vessels or both. The long-term 
survival result of personalized surgical treatment was 
retrospectively analyzed in the 516 patients based on 
molecular staging methods. 
Results: There were 322 squamous cell carcinoma 
and 194 adenocarcinoma. 112 patients had IIIA 
disease and 404 had IIIB disease according to 
P-TNM staging. 97 patients had M-IIIA disease, 
278 had M-IIIB disease and 141 had M-IV disease 
according to molecular staging. Of the 516 patients, 
bronchoplastic procedures and pulmonary artery 
reconstruction was carried out in 256 cases; double 
sleeve lobectomy combined with resection and 
reconstruction of partial left atrium, superior vena 
cava, carina, aorta and postcava was performed 
in 260 cases in this series. Five patients died of 
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Lobectomy Limited Resection p-value 
155 32 
Mean Age (SD) 67 (11) 70 (11) 0.257 
Male Female 77 (50%) 77 (50%) 13(41%) 19 (59%) 0.437 
FEV 0.8 (0.2) 0.7 (0.2) 0.078 
Smoking Hx 
Median packs 
(min, max) 
40 (1,122 ) 46 (7,100 ) 0.495 
LOS (days) 
Median (min, 
max) 
7 (3,71 ) 6 (4,55 ) 0.12 
Follow-up 
(months) Median 
(min, max) 
50 (0,93) 43 (1,73 ) 0.109 
Stage IA 70 (45%) 19 (59%) 0.175 
Stage IB 85 (55%) 13 (41%) 
Central 72 (54%) 14 (44%) 0.329 
Peripheral 61 (46%) 18 (56%) 
<2cm 122 (79%) 20 (62.5%) 0.068 
>2cm 33 (21%) 12 (37.5%) 
Mean (SD) 3.2 (1.7) 2.4 (1.3) 0.010 
Adenocarcinoma 66 (43%) 14 (45%) 
Squamous cell 17 (11%) 1 (3%) 
Non-small cell 
carcinoma 
45 (29%) 11 (36%) 
Carcinoid 7 (5%) 3(10%) 
BAC 13 (9%) 0 
Large Cell 3 (2%) 0 
Small Cell 3 (2%) 2 (7%) 
Local Recurrence 3 (1.9%) 2 (6.3%) 
Distant 
Recurrence 
41 (27%) 9 (28%) 
With LNs 
sampled 
33 (26%) 7 (37%) 0.651 
Without LNs 
sampled 
3 (45%) 4 (31%) 0.406 
Recurrence age 
>71 yrs 
22 (31%) 8 (45%) 0.677 
Age < 71 yrs 21 (25%) 3 (20%) 0.256 
Recurrence 
tumour >2 cm 
39 (32%) 6 (30%) 0.861 
2 cm and under 4 (12%) 5 (42%) 0.043 
Survival 3 years 
Survival 5 years 
84.5% (78-90) 
72% (62-81) 
73% (57-89) 58% 
(35-81) 
0.146 
Disease free 
survival 3years 
years 5 years 
79% (72-86) 70% 
(62-78) 
68% (51-85) 56% 
(47-70%) 
0.271 
Figure Survival rate Figure Disease-free survival rate
 
Conclusion: These results show a trend toward 
increased survival in the lobectomy treated group. 
Although safer, as more early deaths occured in the 
lobectomy group, segmental resection did not confer 
any long term survival beneÀt over lobectomy even 
Surgery - Treatment Proposals Thursday, 7 July 2011 12:30-14:00
O36.03 LIMITED RESECTION OF 
EARLY STAGED LUNG CANCER: A 
RETROSPECTIVE REVIEW OF OUR 
DATABASE COMPARING LOBAR 
RESECTION AND SEGMENTAL AND 
WEDGE RESECTION. PILOT.
John D. Miller, Yaron Shargall, Christian Finley, M 
Alabdulmohsin, C Ostrander 
Thoracic Surgwery, Mcmaster University/Canada
Background: The Canadian Lung Cancer Study 
Group (LCSG) published their Àndings comparing 
lobectomy and segmental resection of early stage 
lung cancer in 1997. Despite the fact that little or no 
clear survival advantage was demonstrated by the 
larger resection (lobectomy) the thoracic community 
has not embraced limited resection. Lobectomy 
remains the basic standard operation for patients with 
resectable lung cancer. NCIC-BR5 in association 
with international intergroup study has begun a new 
randomized controlled trial to evaluate segmental 
and lobar resections for lung tumours 2cms or less 
in diameter. This report is a retrospective review of 
our experience with limited resection over the past 
several years.
Methods: a:Objective: This pilot assessment of 
long term outcomes will help develop our role and 
understanding as we prepare to evaluate limited 
resection in a multinational RCT (NCIC-BR5). 
Disease recurrence and disease free and overall 
survival are our primary outcomes. 
Methods: b:Source and Statistics:Using the 
Division of Thoracic Surgery Data base and ofÀce 
and hospital charts, consecutive patients who have 
undergone either a lobectomy or lesser resection 
for early staged lung cancer is shown in Table 1. 
Survival appears equivalent between groups but 
lesser resections are associated with more local 
recurrences. A Kaplan-Meier survival analysis 
was performed comparing the time survived since 
surgery between the two treatment groups. 
Results: The overall survival appeared better in the 
lobectomy group, sample size limits statistically 
signiÀcant. 
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p<0.001; DSS not reached vs.136 months, Log 
rank p<0.001). Multivariate analysis controlling for 
covariates also showed patients with lobectomy had 
better survival {hazard ratio (CI): OS = 0.8(0.72-
0.88); DSS = 0.79 (0.68-0.91)}. Multivariate Cox 
regression performed on propensity-matched 
groups conÀrmed superior survival of patients with 
lobectomy vs. sub-lobar resection {hazard ratio (CI): 
OS = 0.75(0.65-0.85); DSS = 0.71 (0.59-0.85)}. 
Conclusion: Lobectomy confers a survival beneÀt 
for patients with small (< 2 cm) non-small cell lung 
cancers when compared to sublobar resection not 
explained by selection bias alone. These observations 
should be veriÀed in a prospective trial. 
Keywords: Lung cancer, SEER, sub-lobar resection
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O36.06 COMBINED INTERVENTION TO 
IMPROVE PATHOLOGIC STAGING OF 
NON-SMALL CELL LUNG CANCER
Mathew Ninan 
Thoracic Surgery, Sarah Cannon Cancer Center/
United States Of America
Background: Quality of pathologic staging during 
lung cancer resection remains poor, as evidenced 
by multiple studies and quality improvement efforts 
have rarely been documented in the literature. We 
aimed to improve pathologic staging of non-small 
cell lung cancer at one tertiary level community 
hospital and to study the effects on specialist and 
non-specialist thoracic surgeons. 
Methods: Surgeons and pathologists were trained 
to conform to National Cancer Center Network 
(NCCN) criteria and to College of American 
Pathologists (CAP) reporting criteria for curative 
lung cancer resection, respectively. All operating 
room nursing personnel on multiple teams were 
trained on AJCC lymph nodal map and provided 
with a specimen list and a pre-labeled, sterile 
in the smaller tumours (<2cms). Lessor resections 
must be saved only for those severely disabled 
patients who cannot tolerate a bigger operation. The 
results of this study encourage us to more fully study 
the possible advantage of a sub-lobar resection and 
the long term outcomes.
Keywords: segmental resection, Lung cancer, 
survival
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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O36.05 LOBECTOMY IS SUPERIOR 
TO SUBLOBAR RESECTION OF NON-
SMALL CELL LUNG CANCERS LESS 
THAN 2 CM.
Rohit Sharma1, Michael Demmy2, Adrienne 
Groman3, Mark Hennon4, Elisabeth U. Dexter4, 
Chukwumere Nwogu4, Todd L. Demmy4, Austin 
Miller3, Sai Yendamuri4 
1Surgical Oncology, Roswell Park Cancer Institute/
United States Of America, 2Thoracic Surgery, 
Roswell Park Cancer Institute/United States 
Of America, 3Division Of Biostatistics, Roswell 
Park Cancer Institute/United States Of America, 
4Department Of Thoracic Surgery, Roswell Park 
Cancer Institute/United States Of America
Background: Extent of resection for stage IA 
(< 2 cm) non-small cell lung cancers (NSCLCs) is 
controversial. This question was addressed using 
the Surveillance Epidemiology End Results (SEER) 
database. 
Methods: Patients with a history of one resected 
stage I NSCLC < 2 cm after 1987 were selected. 
Overall survival (OS) and disease speciÀc survival 
(DSS) associated with lobectomy and sublobar 
resection were compared using multivariate 
proportional hazards methods controlling for age, 
gender, race, grade and number of lymph nodes 
examined (LNE). P values <0.01 were deemed 
statistically signiÀcant. Analyses were repeated using 
propensity-matched samples. 
Results: Of 7006 patients that Àt the selection 
criteria, 1701 (24.3%) had sublobar resection. 
Univariate analysis showed that patients with a 
lobectomy had better OS and DSS when compared 
to sublobar resection (OS 120 m vs. 69 m, Log rank 
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O36.07 COMPARISON OF SHORT-
TERM OUTCOMES BETWEEN ROBOT-
ASSISTED AND VATS LOBECTOMY FOR 
EARLY STAGE LUNG CANCER
Hyun-Sung Lee, Hee-Jin Jang, Seong Yong Park, Jae 
Ill Zo 
Center For Lung Cancer, National Cancer Center, 
Republic Of Korea/Korea
Background: Robotic surgery has proven to be one 
of the most effective cutting-edge technologies for 
successful minimally invasive surgery. The approach 
addresses many drawbacks of thoracoscopic surgery, 
yet few reports have studied robotic surgery in lung 
cancer. This study aimed to compare the feasibility 
and safety of robotic approach for the treatment of 
early stage lung cancer with VATS lobectomy and 
mediastinal lymph node dissection. 
Methods: From February 2009 to February 2011, 
one hundred patients underwent robot-assisted 
lobectomy for clinical stage I or II non-small cell 
lung cancer. The dissection and anatomical isolation 
of the hilar structures were performed using two 
arms or three arms of the Da Vinci S system®. 
The consecutive 100 patients were compared with 
100 patients who underwent VATS lobectomy and 
MLND during the same period. Clinicopathologic 
characteristics and surgical outcomes were analyzed. 
Results: Adenocarcinoma was more prominent in 
VATS group than robotic lobectomy group (p=0.04). 
Tumor size was larger in robot group with 3.2cm in 
mean size of tumor. The mean number of harvested 
lymph nodes was similar in two groups. Robot-
assisted lobectomy needed longer operation time 
than VATS group. However, the console time during 
operation was similar with operation time in VATS 
lobectomy. The median length of postoperative stay 
was signiÀcantly shorter after robotic surgery than 
VATS. Also, robotic surgery showed signiÀcantly 
lower rate of postoperative complications. 
specimen collection tray. The test group consisted of 
all curative NSCLC resections from 1 January 2010 
to 30 June 2010 and the same resections performed 
from 1 January 2008 to 30 June 2008 formed the 
control group. Quality training was commenced in 
July 2008 and operations were performed by the 
same surgeons in both periods. Data was further 
analyzed by whether resection was performed by a 
specialist thoracic surgeon (GTS) or a cardiothoracic 
surgeon (CTS). 
Results: There were 72 resections in the 6 month 
period of 2008 (27 GTS and 45 CTS) and 68 
resections in the six month period of 2010 (30 
GTS and 38 CTS). No signiÀcant differences 
existed between groups with respect to age, sex, 
histology, resection by surgeon specialty, stage or 
extent of resection. Operations were performed by 
1 GTS and 5 CTS. Overall, resections conforming 
to NCCN criteria increased from 31 (43%) to 
51(75%) (p=0.001), mean number of nodal stations 
evaluated increased from 3.29 to 4.54 (p<0.0001) 
and pathology reports conforming to CAP guidelines 
increased from 41(57%) to 63(93%, p<0.0001), 
in 2008 and 2010 respectively. On subgroup 
analysis, in 2008, NCCN criteria were fulÀlled in 
22(81%) of GTS resections versus 9(20%) of CTS 
resections (p<0.0001). This improved to 28(93%) 
of GTS resections (p=0.1734) and 23(61%) of 
CTS resections in 2010. Statistically signiÀcant 
improvement was seen between 2008 and 2010 in 
the CTS group for NCCN criteria (20% vs. 61%, 
p=0.0002) and for number of lymph nodal stations 
(2.31 vs. 3.39, p= 0.001). 
Conclusion: 1. An intervention inclusive of 
surgeons, pathologists and nurses with use of a pre-
labeled specimen tray improves pathologic staging 
of non-small cell lung cancer. 2. There are signiÀcant 
differences in resections fulÀlling NCCN criteria 
and number of nodal stations evaluated between 
specialist and non-specialist thoracic surgeons. 3. 
Pathologic staging of non-small cell lung cancer 
can be signiÀcantly improved by targeted quality 
interventions especially when resections are 
performed by non-specialist surgeons. 
Keywords: Lung Cancer Staging, lobectomy, lung 
cancer surgery
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utility, several trials are already prospectively 
randomizing NSCLC patients by ERCC1 status. 
ERCC1 tumour assessment is also commercially 
available. We aimed to characterize the prognostic 
and predictive effect of ERCC1 by systematic review 
and meta-analysis. 
Methods: Eligible studies assessed survival and/
or chemotherapy response in NSCLC by ERCC1 
status. Effect measures of interest were the hazard 
ratio (HR) for survival or relative risk (RR) for 
chemotherapy response. Random-effects meta-
analyses were used to account for between-study 
heterogeneity, with unadjusted/adjusted effect 
estimates considered separately. Direct evidence 
on ERCC1 predictive utility for platinum-based 
chemotherapy, was assessed from the interaction 
between platinum-based versus non-platinum-based 
chemotherapy and ERCC1 status within studies. 
Indirect predictive inÁuence was assessed by 
collating evidence on ERCC1 prognostic effect in 
platinum-treated and non-platinum-treated groups 
available separately from studies, and relationship 
between ERCC1 and response to platinum-based 
chemotherapy. In addition, we used clinicaltrials.
gov to review the portfolio for lung cancer trials that 
explicitly involve ERCC1 in the design.
Results: 20 eligible studies provided survival results 
in 2,434 patients. Marked variability in thresholds 
deÀning ‘low’ and ‘high’ ERCC1 was observed. 
This partly contributed to substantial heterogeneity 
observed in all meta-analyses (I2 always >30%). 
Only 1 study reported a direct predictive utility 
for ERCC1, and this was statistically signiÀcant 
(p=0.009). For indirect assessment of ERCC1 utility, 
meta-analysis of unadjusted estimates showed high 
ERCC1 was associated with signiÀcantly worse 
overall survival in platinum-treated NSCLC (average 
unadjusted HR=1.61, 95%CI:1.23-2.1, p=0.014), 
but not in NSCLC untreated with chemotherapy 
(average unadjusted HR=0.82, 95%CI:0.51-1.31). 
Meta-analysis of adjusted estimates was limited by 
variable choice of adjustment factors and potential 
publication bias (Egger’s p<0.0001). Relationship 
between ERCC1 expression and platinum-based 
chemotherapy response was reported in 10 
datasets, comprising 656 patients. High ERCC1 
was signiÀcantly associated with reduced response 
(average RR=0.80; 95%CI:0.64-0.99) with moderate 
heterogeneity (I2=25.3%) and no evidence of small 
study effects (Egger’s test: p=0.36). 15 NSCLC trials 
being run in Europe, United States and Asia that 
involve ERCC1 within the design were identiÀed 
Conclusion: Robot-assisted lobectomy with lymph 
node dissection for early stage lung cancer is safe 
as well as feasible, and it results in a satisfying 
postoperative outcomes compared with those after 
VATS lobectomy. Robot-assisted surgery may 
provide a good alternative to thoracoscopic surgery 
for lung cancer, provided that the cost effectiveness 
and long-term prognosis are conÀrmed. 
Keywords: Robotic surgery, minimally invasive 
surgery, video-assisted thoracic surgery, Lung cancer
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O37.01 EXCISION REPAIR CROSS-
COMPLEMENTATION GROUP 1 (ERCC1) 
STATUS AND NON-SMALL CELL LUNG 
CANCER (NSCLC) OUTCOMES: A META-
ANALYSIS OF PUBLISHED STUDIES 
AND RECOMMENDATIONS
Sanjay Popat1, Richard D. Riley2, Lucinda J. 
Billingham3, Richard A. Hubner4 
1Department Of Medicine, Royal Marsden Hospital/
United Kingdom, 2Department Of Public Health, 
Epidemiology And Biostatistics, University Of 
Birmingham/United Kingdom, 3Cancer Research 
Uk Clinical Trials Unit And Mrc Midland Hub 
For Trials Methodology Research, University Of 
Birmingham/United Kingdom, 4Department Of 
Medical Oncology, Christie NHS Foundation Trust/
United Kingdom
Background: Despite discrepant results on clinical 
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and metastasis. In contrast to other cancers, the 
STK11 gene is frequently inactivated by somatic 
mutations in NSCLC.
Methods: Fourteen high resolution melting (HRM) 
assays were developed to cover the entire coding 
sequences of STK11. STK11 mutations were 
screened by HRM in a panel of 195 fresh frozen 
NSCLC samples. All HRM positive samples were 
then characterised by Sanger sequencing.
Results: A total of 30 STK11 mutations, comprising 
27 non-synonymous mutations and 3 synonymous 
changes were detected, giving a mutation frequency 
of 15%. The non-synonymous mutations consisted 
of 9 nonsense, 5 frameshift, 6 missense, and 7 
splice site variants. STK11 muations were detected 
in all coding exons except for exon 7 and were not 
recurrent except with exceptions of a nonsense 
mutation (K191X) and a splice site variant (c.291-
1G>T), which were each found in two tumours. 
Single base substitutions (25/30, 83%) were more 
common than small insertions/deletions (5/30, 17%) 
and the size of insertions/deletions were less than 
20 base pairs. The majority of mutations (28/30, 
93%) were present in the kinase domain and the two 
remaining changes were located in the C-terminal 
regulatory domain. 
Conclusion: These results conÀrm that a signiÀcant 
proportion of NSCLC patients have STK11 
mutations and demonstrate the utility of HRM 
analysis for the cost efÀcient screening of somatic 
STK11 mutations in clinical NSCLC samples.
Keywords: mutation detection, high resolution 
melting, LKB1, STK11
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O37.03 DNA REPAIR PROTEINS MSH2, 
XRCC5, ERCC1, O6MGMT, AND BRCA1 
IN EARLY LUNG CANCER PATIENTS 
TREATED BY PERIOPERATIVE 
CHEMOTHERAPY IN THE IFCT-0002 
PHASE III TRIAL
Gérard Zalcman1, Emmanuel Bergot1, Guenaelle 
Levallet2, Martine Antoine3, Pierre Fouret4, Elisabeth 
Brambilla5, Françoise Galateau-Sallé6, Laurence 
Baudrin7, Christian Creveuil8, Michele Beau-Faller9, 
Florence Defraipont10, Mounia Mounawar11, Virginie 
Westeel12, Jacques Cadranel13, Elisabeth Quoix14, 
Didier Debieuvre15, Julien Mazières16, Jean-Louis 
Pujol17, Denis Moro-Sibilot18, Franck Morin19, 
Bernard Milleron13 
from clinicaltrials.gov. The majority involve patients 
with stage IIIB/IV disease. Four are phase III trials, 
the remainder are single arm or randomised phase II 
or observational. Trial designs at both phases involve 
ERCC1 either in marker-directed therapy or as a 
stratiÀcation factor and some studies are designed to 
provide purely a correlative analysis with outcome. 
No trial is powered to test for biomarker-treatment 
interaction. Ongoing studies are inconsistent in the 
methods that they use to measure ERCC1.
Conclusion: Current evidence suggests high ERCC1 
may be prognostic of poorer survival and response 
in platinum-treated NSCLC patients, but not in 
non-platinum treated, although deÀnitive evidence 
of a predictive inÁuence is lacking. Interpretation 
of results from ongoing studies will continue to be 
problematic due to their variable designs. A properly 
validated predictive tool involving ERCC1 needs 
to be developed and evaluated in a clinical trial to 
enable platinum-based treatment to be stratiÀed 
according to ERCC1 in future clinical practice. Until 
then ERCC1 assessment should not be used for 
routine treatment decision-making.
Keywords: ERCC1, meta-analysis, systematic 
review, Chemotherapy
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O37.02 DETECTION OF LKB1/STK11 
MUTATIONS IN NSCLC PATIENTS 
USING HIGH RESOLUTION MELTING 
ANALYSIS.
Hongdo Do1, Guenaelle Levallet2, Emmanuel 
Bergot3, Martine Antoine4, Franck Morin5, Bernard 
Milleron6, Gérard Zalcman3, Alexander Dobrovic1 
1Pathology, Peter MacCallum Cancer Centre/
Australia, 2Pathology, Caen University Hospital/
France, 3Chest Medicine Department, Caen 
University Hospital/France, 4Pathology, Tenon 
University Hospital/France, 5Intergroupe 
Francophone De Cancérologie Thoracique (IFCT)/
France, 6Pulmonary Medicine Department, Tenon 
University Hospital/France
Background: Germline mutations in the tumour 
suppressor gene STK11 (also known as LKB1) cause 
Peutz–Jeghers syndrome which is characterised by 
mucocutaneous pigmentation, intestinal hamartomas 
and increased risk of developing cancers. In lung 
cancer, STK11 plays a crucial role in pulmonary 
tumorigenesis, controlling initiation, differentiation, 
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specimens were also collected for DNA methylation 
(O6MGMT) and mutations (TP53) studies, 
respectively using methylation-speciÀc PCR and 
DHPLC followed by genomic sequencing of TP53 
exons 4-9. Prognosis values for Progression-free 
Survival (PFS) and Overall Survival (OS), were 
assessed using Cox models. Kaplan-Meier survival 
curves were calculated and Cox models used to 
adjust for patients characteristics associated with the 
corresponding outcome (PFS or OS) with p-value 
under 0.2 in univariate analysis.
Results: Median follow-up was 55 months. TP53 
mutations were found in 27.6% of the 208 specimens 
analyzed. O6MGMT promoter methylation was 
found in 14.9% of the specimens. ERCC1, MSH2, 
XRCC5 and BRCA1 immunostainings were 
successful in respectively 420, 356, 397 and 221 
specimens. Neither TP53 mutations, O6MGMT 
methylation, XRCC5 nor ERCC1 expression 
showed any inÁuence on survival. Conversely, high 
expression of MSH2 protein (over median value), 
and BRCA1 expression signiÀcantly impacted 
survival in univariate as multivariate analyses. In 
multivariate Cox Overall Survival model, including 
stage and number of administered chemotherapy 
cycles (2 or less vs. 3-4, according to response after 
2 cycles), MSH2 expression higher than the median 
H-score value, signiÀcantly predicted a worse OS: 
HR=1.47, 95%CI[1.057-2.036], p=0.02. Conversely, 
as previously reported in other studies, BRCA1 low 
H-Score, under median value predicted worse PFS 
as worse OS, HR for OS=1.940 95%CI[1.27-2.97], 
p=0.0022. A prognostic score was then constructed 
and validated by a bootstrap re-sampling strategy, 
that accurately deÀnes three groups of early-lung 
cancer patients from low to high risk of recurrence 
and death despite perioperative cisplatin-based 
chemotherapy.
Conclusion: A systematic survey of DNA repair 
proteins in a phase 3 controlled trial, led us to 
identify MSH2 and BRCA1 immunostainings as 
independent prognostic biomarkers in patients 
with early lung cancer that received preoperative 
platinum-based doublets. Conversely neither ERCC1 
nor XRCC5/Ku80 had any inÁuence on survival 
contrasting with previous reports. A DNA-repair 
gene expression-based prognostic score will be 
presented which accurately discriminates in early-
stage lung cancer patients, three groups of high, 
intermediate, and low risk of death, according to 
their respective tumour expression of MSH2 and 
BRCA1.
1Chest Medicine Department, Caen University 
Hospital/France, 2Pathology Department, Caen 
University Hospital/France, 3Department Of 
Pathology. Hopital Tenon/France, 4Pathology 
Department, La Pitié University Hospital/France, 
5Institut Albert Bonniot, Inserm U823/France, 
6Pathology, Caen University Hospital/France, 
7Intergroupe Francophone De Cancérologie 
Thoracique/France, 8Biostatistics And Clinical 
Research Unit, Caen University Hospital/France, 
9Chu De Strasbourg, Molecular Laboratory, 
Ea 4438/France, 10Cancer Biochemistry & 
Biotherapy Unit, Grenoble University Hospital/
France, 11Biomarker Group, I.A.R.C/France, 
12Chest Medicine Department, Besançon 
University Hospital/France, 13Pulmonary Medicine 
Department, Tenon University Hospital/France, 
14Pulmonary Medicine Department, Strasbourg 
University Hospital/France, 15Pulmonary Medicine 
Department, Haute Saône Community Hospital/
France, 16Pulmonary Medicine Department, 
Toulouse University Hospital/France, 17Pulmonary 
Medicine Department, Montpellier University 
Hospital/France, 18Chest Medicine Department, 
Grenoble University Hospital/France, 19Intergroupe 
Francophone De Cancérologie Thoracique (IFCT)/
France
Background: DNA-repair proteins ERCC1, 
MSH2 and BRCA1 have been previously reported 
to play a central role in cisplatin resistance, and 
immunohistochemical expression of those proteins 
were shown to alter survival of early NSCLC 
patients, either in retrospective series, or in IALT 
phase 3 trial of adjuvant therapy (for ERCC1 
and MSH2). We therefore aimed to study a panel 
of DNA repair proteins involved in Nucleotide 
Excision Repair (NER), Base Excision Repair 
(BER), Mismatch Repair (MR), Non Homologous 
EndJoining (NHEJ) repair, in stage I-II lung cancer 
patients included in the IFCT-0002 randomized 
phase 3 trial of peri-operative chemotherapy
Methods: The IFCT-0002 phase III trial compared 
two chemotherapy timings, all pre- vs. peri-
operative, and two regimens, CDDP-Gem vs. 
CBDCA-Pac (V. Westeel, ASCO 2009). ParafÀn-
embedded surgical post-chemotherapy specimens 
were prospectively collected and processed for 
IHC studies with speciÀc primary antibodies 
previously described. Semi-quantitative classical 
H-scores were applied to evaluate immunostainings 
by expert thoracic pathologists. 208 snap-frozen 
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(49.4%) belonged to HDGF high expression group, 
the 5-year survival rate was sharply decreased to 
38.2%, the difference was statistically signiÀcant 
(P=0.009). Linear correlation analysis discovered 
that the HDGF expression showed a signiÀcantly 
negative correlation with the survival of the 158 
cases of resected non-small cell lung cancers (R=-
0.183, P=0.022). Patients who received postoperative 
chemo-radiation therapy (47 cases) had a higher 
5-year survival rate of 67.2% when compared 
with those who received surgery only but without 
adjuvant chemo-radiation (111 cases) whose 5-year 
survival was 44.7% (P=0.010). When stratiÀed, in 
the 78 HDGF highly expressed cases, the 5-year 
survival rate for those who received postoperative 
chemo-radiation therapy (19 cases) was 57.0%, 
higher than those who did not receive adjuvant 
chemo-radiation whose 5-year survival was 32.1% 
(59 cases) (P=0.029); however, in the HDGF lowly 
expressed cases, postoperative chemo-radiation did 
not improve the 5-year survival rate with a statistic 
signiÀcance (P=0.232). Cox proportion hazard 
model analysis revealed that pathological stages, 
postoperative chemo-radiation therapy and HDGF 
expression were the independent factors inÁuencing 
the prognosis of this group of 158 cases of resected 
non-small cell lung cancer.
Conclusion: HDGF is highly expressed in human 
non-small cell lung cancer tissues, and highly 
expressed HDGF predicts worse prognosis in 
resected non-small cell lung cancers, suggesting 
that HDGF is a useful novel molecular biomarker 
for predicting the prognosis of resected non-small 
cell lung cancer. Importantly, HDGF could be a 
novel useful predictive biomarker helping decide 
if postoperative chemo-radiation therapy should 
be selected or not for surgically resected non-small 
cell lung cancer patients; adjuvant chemo-radiation 
therapy might beneÀt NSCLC patients with highly 
expressed HDGF much more, instead of NSCLC 
patients with lowly expressed HDGF.
Keywords: Lung neoplasms, Survival analysis, 
Prognostic and Predictive Biomarker, HDGF
Keywords: early lung cancer, DNA repair proteins, 
prognostic biomarker
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O37.05 HDGF AS A NOVEL PROGNOSTIC 
AND PREDICTIVE BIOMARKER 
PREDICTING A WORSE PROGNOSIS 
FOR PATIENTS WITH SURGICALLY 
RESECTED NON-SMALL CELL LUNG 
CANCER
Jun Zhang1, Juan Qi2, Anguang He3 
1Department Of Molecular Targeted Therapeutics 
Of The First Hospital Of China Medical University, 
China Medical University Lung Cancer Center The 
First Hospital Of China Medical University/China, 
2Department Of Molecular Targeted Therapeutics 
Of The First Hospital Of China Medical University/
China, 3China Medical University Lung Cancer 
Center/China
Background: Our recent studies revealed that 
hepatoma-derived growth factor (HDGF) was 
highly expressed in non-small cell lung cancer cells, 
and using siRNA silencing HDGF could inhibit 
signiÀcantly the growth and invasion of non-small 
cell lung cancer cells, including adenocarcinoma 
cells A549, and squamous carcinoma cells H226. 
Here we detect the expression of HDGF in 158 cases 
of surgically resected non-small cell lung cancer, to 
further evaluate the signiÀcance of HDGF expression 
in predicting the prognosis of resected non-small cell 
lung cancer.
Methods: Immunohistochemical SP method was 
used to detect the expression of HDGF in 158 cases 
of resected non-small cell lung cancer tissues and 
12 normal control lung tissues. Survival analysis 
and multivariate analysis were further conducted 
to evaluate the signiÀcance of HDGF expression in 
predicting the postoperative prognosis.
Results: The expression of HDGF in 158 cases of 
non-small cell lung cancer tissues was higher with 
a average HDGF expression level of 170.08±77.97, 
when compared with the average HDGF expression 
level of 113.33±42.07 in the 12 cases of normal 
control lung tissues, the difference was statistically 
signiÀcant (P=0.000). When the 158 cases of non-
small cell lung cancer was divided into two groups 
by the average level of HDGF expression, 80 
cases (50.6%) belonged to HDGF low expression 
group, the 5-year survival rate was 63.1%; 78 cases 
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43% of the exon 9 mutations occurred in ampliÀed 
tumours while none of the exon 20 mutations 
occurred concomitantly with the gene ampliÀcation.
Conclusion: These results indicate a complementary 
relationship between PIK3CA ampliÀcation and 
PIK3CA mutations in lung SCCs. 
Keywords: PIK3CA, Mutation, gene ampliÀcation, 
squamous lung carcinoma
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O37.07 STAGE I NON-SMALL CELL 
LUNG CANCER EXPRESSING SOX2 
SHOW MORE RECURRENCE IN 
ELDERLY MALE PATIENTS WITH NON-
ADENOCARCINOMA HISTOLOGY
Spasenija Savic1, Coya Tapia1, Inti Zlobec2, 
Mariacarla Andreozzi1, Sandra Schneider1, Mathias 
Gugger2, Lukas Bubendorf1, Didier Lardinois3 
1Institute For Pathology, Institute For Pathology, 
University Hospital Basel/Switzerland, 2Institute For 
Pathology, University Berne/Switzerland, 3Surgery, 
Division Of Thoracic Surgery University Hospital 
Basel/Switzerland
Background: Around 30% of patients with 
early-stage non-small cell lung cancer (NSCLC) 
relapse after surgery. Therefore, new prognostic 
and predictive molecular markers are needed to 
identify patients who could beneÀt from adjuvant 
treatment. SOX2 (sex determining region Y-box 
2) at the gene locus 3q26.33 is regarded as an 
oncogene involved in carcinogenesis of squamous 
cell lung carcinoma. Nevertheless, comprehensive 
data on SOX2 gene status and expression as well 
as its prognostic relevance in early-stage NSCLC 
are not yet available. The aim of the present study 
was to investigate the prevalence and the prognostic 
signiÀcance of SOX2 gene status and expression in a 
large series of stage I NSCLC patients. 
Methods: A tissue micro array with 568 parafÀn-
embedded stage I NSCLC with comprehensive 
histopathological and clinical data, including 
follow-up on overall and tumor-speciÀc survival 
was analyzed. SOX2 gene status was determined 
by Áuorescent in situ hybridization (FISH) using 
direct-labeled BAC clones (SOX2: RP11-938O9; 
reference probe (RP): RP11-286G5). SOX2 gene 
status was recorded as follows: AmpliÀcation (ratio 
SOX2/RP 2.2), polysomy (more than 4 signals in 
the CEP or the gene probe) and normal (ratio: 0.8-
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O37.06 PI3KCA ALTERATIONS IN LUNG 
SQUAMOUS CELL CARCINOMAS: ROLE 
FOR MUTATIONS AND AMPLIFICATION
Barbara Angulo1, Esther Conde1, Ana Suarez-
Gauthier1, Ricardo Garcia-Lujan2, Montserrat 
Sanchez-Cespedes3, Angel Lopez-Encuentra2, Luis 
Paz Ares4, Fernando Lopez-Rios1 
1Laboratorio De Dianas Terapéuticas, Hospital 
Universitario Madrid Sanchinarro/Spain, 2Hospital 
Universitario 12 De Octubre/Spain, 3Institut 
D’Investigacions Biomediques Bellvitge (IDIBELL)/
Spain, 4Hospital Universitario Virgen Del Rocio/Spain
Background: PIK3CA is a well-established oncogene 
that is commonly activated by point mutations. In lung 
cancer, PIK3CA mutations are found infrequently. 
However gene ampliÀcation at 3q26, close to where 
the PIK3CA gene resides, is among the most common 
gene ampliÀcation events. In a previous microarray 
study (Angulo et al., J Pathol 2008), we identiÀed an 
increased PIK3CA expression due to gene ampliÀcation 
in lung squamous cell carcinomas (SCC). This 
observation conÀrms the potential oncogenic nature 
of this alteration and suggests a candidate marker of 
sensitivity to therapy with PI3K inhibitors. Our aim 
was to further conÀrm our previous Àndings in another, 
larger, independent series. 
Methods: PIK3CA gene mutations were analyzed 
using a previously described protocol in 178 NSCLC, 
including 123 SCC, 51 adenocarcinomas (AC), and 
four large cell carcinomas (LCC). Based on our 
previous experience, the analysis of the PIK3CA 
gene ampliÀcation by FISH was limited to SCCs. 
We used a commercial probe (Kreatech, Amsterdam, 
Netherlands). The cut-off value to deÀne the PIK3CA 
gene ampliÀcation was established in ratio > 2 
(relationship between the number of gene signals and 
the number of centromeric signals).
Results: We identiÀed 12 PIK3CA mutations 
(6.89%), most of them in well-known hot-spot 
codons (four E545K, three E542K, four H1047R, 
and one less frequent M1043I). Only one AC carried 
PIK3CA mutations, compared with 11 SCCs. We 
identiÀed PIK3CA gene ampliÀcation in 44 SCCs 
(38%). Interestingly, 61% of the ampliÀed tumours 
carried >7 PIK3CA copies per cell, conÀrming our 
previous microarray results. We also identiÀed the 
presence of polysomy in 14 tumours (12%). When 
comparing the presence of PIK3CA mutations with 
the gene ampliÀcation, it is important to note that 
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1Pulmonary Diseases, Vrije Universiteit Medical 
Centre/Netherlands, 2Pathology, Vumc/Netherlands, 
3Department Of Pulmonary Diseases, Vu University 
Medical Center/Netherlands, 4Pathology, 
Vu University Medical Center/Netherlands, 
5Epidemiology And Biotatistics, Vumc/Netherlands
Background: Lung cancer is one of the most 
common types of cancer world-wide, both in men 
and women. Since a few years, EGFR-TKI’s are 
available for treatment of a subset of lung cancer 
patients, i.e., those with a tumor-speciÀc, activating 
EGFR mutation. Mutation analysis requires extra 
time and costs in the diagnostic evaluation of lung 
cancer patients. Ideally, a pre-screening test to select 
specimens eligible for molecular testing would be 
available to avoid unnecessary molecular testing. 
Immunohistochemical analysis may serve as such 
a rapid and less expensive method. Yatabe et al¹ 
suggested that the presence of EGFR-mutations is 
speciÀc for Terminal Respiratory Unit (TRU)-type 
adenocarcinoma, which express TTF-1 as determined 
by immunohistochemistry. The aim of the current 
study is to further investigate the possibility of TTF-
1 immunohistochemistry as a pre-screening test to 
select patients for EGFR mutation analysis.
Methods: A database was constructed of 824 
non-small cell lung cancer patients referred for 
EGFR mutation testing from 2006 until December 
2010. Initially mutation analysis was performed 
with PCR- sequencing and since 2008 with high 
resolution melting conÀrmed by sequencing. 
Immunohistochemistry for TTF-1 was performed 
with clone 8G7G3/1 (Dako). A negative and an 
external positive control was used with every 
immunohistochemical staining procedure. 
Results: A series of 824 lung cancers were evaluated 
for EGFR mutation status. EGFR-mutations were 
detected in 175 cases (21%). Of 743 /824 cases 
(90.2%) TTF-1 expression was available: 238 
cases were TTF-1-negative (32%), 23 case were 
1+-positive (3.1%), 29 cases 2+ (3.9%) and 453 
cases 3+ (61%). In the cases with EGFR mutation 
23 cases were TTF-1-negative (15.2%), 1 case was 
1+-positive (0.7%), 2 cases 2+ (1.3%) and 125 cases 
3+ (82.8%). Strong TTF1 immunohistochemical 
staining was signiÀcantly associated with the 
presence of EGFR mutations (p = 2.4x10-8). If 
in the histological sections of EGFR mutated 
cases with negative TFF1 in the tumor cells, an 
internal control was present, this showed strong 
positivity for TTF1, supporting the quality of TTF1 
1.8). Semi-quantitative expression of SOX2 protein 
was determined by immunohistochemistry (IHC). 
Any nuclear reaction of tumor cells was regarded as 
a positive result. FISH and IHC data were correlated 
with clinicopathological features and overall survival. 
Results: An increased SOX2 gene number 
(ampliÀcation or polysomy) was observed in 4% 
of NSCLC (17/429). 94% of NSCLC (16/17) with 
an increased SOX2 gene number were observed 
in squamous- and large cell carcinomas (non-
adenocarcionomas). Using logistic regression analysis 
an increased SOX2 gene number was signiÀcantly 
(p<0.001) associated with SOX2 protein expression.
SOX2 protein expression was detected in 48% of 
NSCLC and was signiÀcantly associated with a non-
adenocarcinoma histology (p<0.001): it was expressed 
in 78% of squamous cell carcinomas (178/227), 
in 35% of large cell carcinomas (12/34) and only 
in 15% of adeno-carcinomas (29/191). SigniÀcant 
associations with SOX2 protein expression were 
observed with high grade tumors (p<0.001), elderly 
(>50years; p=0.001) and male (p>0.001) patients. 
Elderly male patients with non-adenocarcionoma 
histology and a smoking history expressing SOX2 had 
a tendency toward more recurrence (p=0.06). 
Conclusion: An increased SOX2 gene number is 
rare in stage I NSCLC and it is mostly detected in 
squamous and large cell carcinomas. SOX2 protein 
expression stratiÀes a subgroup of NSCLC from 
elderly patients with a smoking history and non-
adenocarcinoma histology. SOX2 two could become a 
potential therapeutic target molecule in a subgroup of 
patients with early stage NSCLC. 
Keywords: SOX2, non-small cell lung cancer, 
SOX2, immunohistochemistry, FISH
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O38.01 CAN TTF1 STAINING BE USED 
AS SELECTION FOR EGFR-MUTATION 
ANALYSIS IN PATIENTS WITH LUNG 
CANCER?
Julien Vincenten1, Egbert F. Smit1, Wim Vos2, 
Katrien Grunberg2, Pieter E. Postmus3, Danielle 
Heideman4, Peter J. Snijders4, Gerrit A. Meijer4, Dirk 
J. Kuik5, Erik Thunnissen2 
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a joint model based on sensitivity, speciÀcity and an 
assumed prevalence using Beta(1,1) priors on both 
sensitivity and speciÀcity. WinBugs was used for 
Àtting the model for NPV and the mean and 95% 
conÀdence interval (CI) for NPV per prevalence 
were plotted.
Results: Out of the 693 ACs, TTF-1 status was 
known in 301, and EGFR mutations were present 
in 224 specimens (74%). Only 2 of the 224 
EGFR mutation positive specimens were TTF-1 
negative. See table below for association between 
EGFR mutation status, and TTF-1, sensitivity and 
speciÀcity calculations. For true EGFR mutation 
rates of 13% and 15%, the estimated NPVs (95% 
CIs) are 99.5% (98.6%-99.9%) and 99.4% (98.4%-
99.9%), respectively. The estimated NPV with 
the 95% CI for a range of prevalences of EGFR 
mutations are shown in Àgure1.
Conclusion: ACs of the lung that are TTF-1 
negative have a 99% probability of being negative 
for EGFR mutations and therefore could be initiated 
on chemotherapy while their EGFR mutation result 
is awaited, allowing for earlier initiation of treatment 
in 30% of patients. 
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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O38.03 IMMUNOHISTOCHEMICAL 
STAINING FOR THYROID 
TRANSCRIPTION FACTOR-1 (TTF-1) IN 
ADENOCARCINOMAS OF THE LUNG: 
THE SPT24 CLONE IS MORE SENSITIVE 
THAN 8G7G3/1, REGARDLESS OF 
TISSUE PRETREATMENT AND 
DETECTION SYSTEM
Alexander J.J. Smits1, Aryan Vink2, D Castigliego3, 
Wim Vos3, P Van Der Valk3, I. Stuij4, Katrien 
Grunberg3 
immunohistochemical procedure. 
Conclusion: The presence of EGFR mutation is 
strongly related to TTF-1 positive lung cancer, 
supporting the TRU hypothesis. Nonetheless, in 
15% of the lung cancer patients with an EGFR 
mutation the tumor cells are negative for TTF1, 
indicating that this marker cannot be used to exclude 
cases from EGFR mutation analysis. ¹ Yatabe et al, 
AmJSurgPathol 2005;29:633-639 
Keywords: lung carcinoma, TTF1, EGFR mutation, 
TRU
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O38.02 NEGATIVE THYROID 
TRANSCRIPTION FACTOR (TTF-1) 
STATUS PREDICTS FOR NEGATIVE 
EPIDERMAL GROWTH FACTOR 
RECEPTOR (EGFR) MUTATIONS 
STATUS WITH A HIGH NEGATIVE 
PREDICTIVE VALUE (NPV) IN PATIENTS 
WITH ADENOCARCINOMAS (ACS) OF 
THE LUNG.
Neeta Somaiah1, Elizabeth Garrett-Mayer2, Xu 
Huang3, Amy Wahlquist2, Kathleen Danenberg3, 
George Simon1 
1Hematology/oncology, Medical University Of South 
Carolina/United States Of America, 2Biostatistics 
And Epidemiology, Medical University Of South 
Carolina/United States Of America, 3Response 
Genetics/United States Of America
Background: TTF-1 is expressed in about 72% of 
ACs. EGFR mutations are present in 13-15% of 
unselected patients with AC. High TTF1 expression 
and EGFR mutations are associated with female 
sex, never-smoking status and longer survival. 
TTF-1 immunohistochemistry is available in most 
pathology laboratories. However, most clinics 
depend on commercial laboratories for EGFR 
mutation testing, which takes 2 - 4 weeks for results. 
We hypothesized that ACs negative for TTF-1 will 
also be negative for EGFR mutations. 
Methods: Microdissected formalin-Àxed parafÀn-
embedded tumors from 693 patients with NSCLC 
were analyzed for EGFR mutations by allele-
speciÀc PCR. TTF-1 status was determined by the 
pathology report and was documented as positive, 
negative or not reported. Patients’ whose TTF-1 
status was not reported were excluded. NPV for a 
range of prevalences (1%-50%) was estimated using 
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predictive value for selection for mutation analysis, 
while speciÀcity of TTF-1 for lung primary 
carcinoma in metastases might decrease. 
Keywords: thyroid transcription factor-1, TTF-1, 
immunohistochemistry, lung adenocarcinoma
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O38.05 PERIPHERAL VERSUS CENTRAL 
RESECTED PRIMARY SQUAMOUS 
CELL CARCINOMAS OF THE LUNG - A 
REVIEW OF 526 CASES.
Holly Pattenden1, Manjiri Deshmukh2, Michael 
Dusmet1, Peter Goldstraw1, Eric Lim1, Simon 
Jordan1, George Ladas1, Sanjay Popat3, Alexandra 
Rice4, Jan Von Der Thusen2, Andrew G. Nicholson4 
1Thoracic Surgery, Royal Brompton Hospital/United 
Kingdom, 2Department Of Histopathology, Royal 
Brompton Hospital/United Kingdom, 3Department 
Of Oncology, The Royal Marsden Hospital/United 
Kingdom, 4Histopathology, Royal Brompton 
Hospital/United Kingdom
Background: Although the frequency of squamous 
cell carcinoma (SQCC) of the lung is said to be 
decreasing in relation to adenocarcinoma, little is 
known about how this relates to tumour location 
within the lung. The aim of the study was to assess 
resected squamous cell carcinomas, speciÀcally in 
relation to central versus peripheral location.
Methods: From resected non-small cell 
carcinoma (NSCLC) specimens received from 
January 1993-December 2010, 526 SQCCs were 
retrospectively analysed in relation to tumour 
location. Central tumours were deÀned as those 
centered on main stem or lobar bronchi, or showing 
predominant growth within segmental airways. 
Results: There was a reversal in the ratio of central 
to peripheral location from 1.7:1 in 1993-2001 to 
0.8:1 from 2002-2010. The percentage of resected 
SQCCs, in relation to NSCLCs overall, remained 
steady (32-36%) throughout this period. There was 
a lower male: female ratio in peripheral versus 
central tumours (2.8:1 versus 4.4:1). Synchronous 
pre-neoplastic disease and nodal involvement 
were commoner in central tumours. Nearly all 
patients in both groups were current or ex-smokers 
(n=140/143).
Conclusion: Resected peripheral SQCCs became 
more commonly seen than central SQCCs from 
around the year 2001. This may be the result of a 
1Pathology, St. Antonius Hospital/Netherlands, 
2Pathology, University Medical Center Utrecht/
Netherlands, 3Pathology, Free University 
Medical Center, Amsterdam/Netherlands, 
4Stichting Kwaliteitsbewaking Medische 
Laboratoriumdiagnostiek/Netherlands
Background: Thyroid Transcription Factor-1 (TTF-
1) is a highly speciÀc immunohistochemical marker 
for primary adenocarcinomas of the lung, and for 
those that may harbour EGFR or KRAS mutations 
in particular. We assessed TTF-1 sensitivity as part 
of a national immunohistochemistry lab feedback 
program (Stichting Kwaliteitsbewaking Medische 
Laboratoriumdiagnostiek).
Methods: Standard tissue array slides were prepared 
(Elizabeth Hospital, Tilburg, The Netherlands) and 
distributed to participating labs. The array contained 
normal lung and 2 adenocarcinomas with moderate 
and strong TTF-1 expression, respectively. Each 
lab performed TTF-1 staining according to its own 
routine protocol, and Àlled in a questionnaire on 
technical aspects. All slides were read and scored for 
technical quality (0-3 scale, 0: no staining, 3: intense 
staining of correct structures) and for diagnostic 
adequacy (0-3 scale, 0: inadequate, 3: highly 
adequate); a total score of at least 4 was considered 
sufÀcient. Scoring was done by 2 couples, in each 
a pathologist and a technician, blinded to lab and to 
technical details of the staining protocol. As TTF-1 
positivity was observed to vary considerably in the 
moderately staining adenocarcinoma, less than 50% 
positivity was arbitrarily considered diagnostically 
inadequate (score 0-1). 
Results: 50 labs participated, of which 48 also 
submitted the questionnaire. 20/50 had insufÀcient 
total scores (0-3). 16/18 of these used 8G7G3/1 
clone, 2/18 used SPT24 (Chi square p = 0.0001). 
2/23 SPT24 stained slides scored insufÀcient. 3 
used other clones, all scoring sufÀcient. Score was 
not signiÀcantly affected by pretreatment, type of 
immunostainer and detection system. InsufÀcient 
scores were mainly due to low sensitivity in the 
moderately staining adenocarcinoma. Normal lung 
and the strongly staining adenocarcinoma were 
generally diagnostically adequately stained. 
Conclusion: In conclusion, SPT24 is a 
more sensitive clone than G7G3/1 for 
immunohistochemical detection of TTF-1 in 
lung adenocarcinomas, particularly for those 
with moderate and/or variable expression. Use of 
SPT24 is likely to increase sensitivity and positive 
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resistance to therapy (EGFR). In particular, the role 
of PI3Kơ in NSCLC has not been studied.
Methods: Eight tissue microarrays (TMAs) comprising 
211 surgically resected formalin-Àxed parafÀn-
embedded NSCLC specimens (99 squamous cell 
carcinomas; 112 adenocarcinomas) were examined by 
IHC using validated antibodies directed against PI3Kơ 
and PTEN. Cores were scored (0+, 1+, 2+, 3+) in a 
blinded fashion by a clinical pathologist (without prior 
knowledge of the purpose of the study) and the level of 
PI3Kơ expression correlated with PTEN expression for 
squamous and adenocarcinoma specimens. In addition, 
an independent investigation was conducted at the 
MDACC using the same validated antibody methods 
across 32 TMAs comprising 290 squamous and 530 
adenocarcinoma samples
Results: Tumour expression of PI3Kơ was largely 
cytoplasmic, while PTEN was localized to both 
cytoplasmic and nuclear compartments. Results 
from the AZ dataset reveal signiÀcantly (p<0.001) 
elevated expression of cytoplasmic PI3Kơ expression 
in squamous cell carcinomas (88.9% positive; 
57.6% 2+ and 3+) compared with adenocarcinomas 
(51.8% positive; 14.3% 2+ and 3+). Conversely, 
adenocarcinoma samples displayed signiÀcantly higher 
levels of cytoplasmic (p<0.001) and nuclear (p<0.001) 
PTEN (88.3% and 74.8% positive, respectively) 
compared with squamous samples (60.6% and 45.5% 
positive, respectively). Interestingly, over-expression 
of cytoplasmic PI3Kơ in squamous samples correlated 
signiÀcantly (66.3% of squamous samples; p<0.001) 
with negative or low cytoplasmic and nuclear PTEN 
expression, with only 11.5% of adenocarcinoma 
samples showing this pattern of expression and 50% 
exhibiting a converse relationship. Adjacent normal 
lung tissues (n=20) were either weak positive (1+; 
53.8%) or negative for cytoplasmic PI3Kơ and all 
adjacent normal lung samples were positive (1+ or 
2+) for cytoplasmic and nuclear PTEN. Preliminary 
analyses of data derived from the MDACC indicate a 
similar proÀle of expression conÀrming identiÀcation 
of a subset of squamous NSCLC samples with over-
expression of PI3Kơ and low or negative PTEN.
Conclusion: These data identify a pattern of over-
expression of PI3Kơ in squamous NSCLC that, 
accompanied by loss/reduced PTEN, could represent 
a subset for therapeutic intervention.
Keywords: NSCLC, Squamous, PI3Kb, PTEN
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
change in the type and intake of cigarette smoke 
and/or divergent carcinogenetic pathways. The 
percentage of SQCCs per resected NSCLCs 
remained constant during the study period.
Keywords: Central Tumours, Peripheral Tumours, 
squamous cell carcinoma
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O38.06 IDENTIFICATION OF 
A LOW PHOSPHATASE AND 
TENSIN HOMOLOG (PTEN) HIGH 
PHOSPHATIDYLINOSITOL-3 KINASE 
(PI3K) ȕ EXPRESSING SUBSET OF 
SQUAMOUS NON-SMALL-CELL LUNG 
CANCER (NSCLC)
Marie Cumberbatch1, Xi ming Tang2, Garry Beran1, 
S Luke1, P Singh1, A Kvist1, Sabina Cosulich1, Paul 
D. Smith1, Carmen Behrens2, Edward Kim2, Madhuri 
Warren3, Chris Womack1, Neil Gray1, Ignacio 
Wistuba2, David P. Blowers1 
1Oncology Innovative Medicines, Astrazeneca/United 
Kingdom, 2M.D. Anderson Cancer Center/United 
States Of America, 3Pathology Diagnostics Ltd/
United Kingdom
Background: The PI3K/AKT/mTOR signalling 
network is a critical regulator of many cellular 
processes including proliferation, survival and 
transformation. The lipid kinase PI3Kơ is a 
member of the class I PI3K family of enzymes 
which comprise p110Ơ, p110ơ, p110ƣ (class IA) 
and p110Ƣ (class IB); proteins that are activated to 
varying extents by receptor tyrosine kinases and 
G-protein coupled receptors. PI3KƠ and PI3Kơ are 
positioned on chromosome 3q (3q25-27), a region 
often ampliÀed in NSCLC. The activity of the PI3K 
enzymes is counteracted by the tumor suppressor 
PTEN, a nonredundant phosphatase. Clinically, 
PTEN mutations and deÀciencies are prevalent in 
many types of human cancers and severe PTEN 
deÀciency is also associated with advanced tumor 
stage and therapeutic resistance. In lung cancer, loss 
of PTEN protein occurs via a number of mechanisms 
including promoter methylation and LOH, however, 
neither epigenetic silencing nor deletion appear to 
predict for protein loss by immunohistochemistry 
(IHC). The molecular characterization of the PI3K/
AKT/mTOR signalling network in lung cancer is 
not as well deÀned as in other tumour types, yet 
de-regulation of this pathway has been linked to 
S446 Copyright © 2011 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
signal pathways, rather than the quantity of genomic 
aberrations. 
Conclusion: We established a prognostic genomic 
proÀle including 41 DNA regions in lung SCC. The 
characteristic chromosome aberrations identiÀed 
in this study indicated a further study of the critical 
genetic landmarks or key genes involved in lung 
SCC progression.
Keywords: Lung cancer, Metastasis, Prognosis, 
DNA copy number
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O39.01 OUTCOME OF ADVANCED 
NSCLC PATIENTS WITH EGFR EXON 
19 AND 21 MUTATIONS TREATED 
WITH ERLOTINIB (E) ALONE OR IN 
COMBINATION WITH CARBOPLATIN/
PACLITAXEL (CP) IN CALGB 30406.
Pasi A. Janne1, Xiaofei Wang2, Mark A. Socinski3, 
Jeffrey Crawford4, Lin Gu2, Marzia Capelletti1, 
Martin J. Edelman5, Miguel A. Villalona-Calero6, 
Robert A. Kratzke7, Everett Vokes8, Vincent A. 
Miller9 
1Lowe Center For Thoracic Oncology, Dana Farber 
Cancer Institute/United States Of America, 2Duke 
University/United States Of America, 3University Of 
North Carolina/United States Of America, 4Medical 
Oncology, Duke University Medical Center/United 
States Of America, 5Cancer Center, University 
Of Maryland/United States Of America, 6Medical 
Oncology, The Ohio State University/United States 
Of America, 7Department Of Medicine, University 
Of Minnesota/United States Of America, 8University 
Of Chicago/United States Of America, 9Medicine, 
Memorial Sloan-Kettering Cancer Center/United 
States Of America
Background: EGFR kinase inhibitors are 
effective therapies in NSCLC patients harboring 
somatic EGFR mutations. CALGB 30406 
prospectivelyevaluated E and ECP in never or 
light former smokers with chemotherapy naïve 
advanced lung adenocarcinoma and determined the 
impact of EGFR mutations on outcome. Patients 
with EGFR mutations had similar outcomes in both 
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O38.07 DNA COPY NUMBER 
ALTERATIONS PREDICT SURVIVAL 
OF PATIENTS WITH LUNG SQUAMOUS 
CELL CARCINOMA
Yan Cao1, Dongmei Lin1, Yu Liu2, Yanjing Gao2, 
Kaitai Zhang2, Ting Xiao2, Shujun Cheng2 
1Pathology, Cancer Institute (oHspital), Peking 
Union Medical College & Chinese Academy Of 
Medical Sciences/China, 2State Key Laboratory Of 
Molecular Oncology, Department Of Etiology And 
Carcinogenesis, Cancer Institute (Hospital), Peking 
Union Medical College & Chinese Academy Of 
Medical Sciences/China
Background: Tumor metastasis is strongly 
associated with overall survival of patients with lung 
cancer. Although lymph node status at surgery is one 
of the important prognosis factors, some patients 
without lymph node metastasis had very poor 
survival, inferring that lymph node status alone can 
not be an accurate indicator for patients’ outcome 
in lung cancer. In this study, we aimed to establish 
a prognostic genomic proÀle in lung squamous cell 
carcinoma (SCC).
Methods: One hundred lung SCC patients were 
included in this study. Fifty of the patients survived 
for more than Àve years after surgery were 
categorized as a group at low death risk, whereas 
50 patients died in two years were at high death 
risk. DNA copy number alterations in all the cancer 
patients were investigated using high resolution 
array-CGH analysis.
Results: After Àltering potential false positive 
and negative DNA regions, we found a series of 
genomic variants that were associated with patients’ 
survival. A collection of 41 aberrant DNA regions 
was established for prognosis evaluation. Among 
these regions, loss of 3p21.31 and 4q35.1 and 
gains of 5p13.2, 14q32.33 and 19p13.11 were more 
closely related with patients’ survival. Thirteen genes 
were identiÀed to locate in these regions, including 
DAG1, BSN, SLC25A4, SLC1A3, PLD4, GPR132, 
PBX4 EDG4, N1CN1, SNX25, LRP2BP, C14orf79 
and CDCA4. In addition, our results showed that 
the complexity of genome variations was not 
directly related with progression of lung SCC. For 
example, copy number alterations in the high death 
risk group were not more complex than those in the 
low-risk group. Biological behaviors of lung SCC 
might depend on the alterations of key genes or cell 
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Conclusion: E and ECP are effective Àrst line 
therapies in EGFR mutant NSCLC. Patients with 
exon 19 deletions have a trend towards improved 
outcome (RR and PFS) treated with either E or ECP 
compared to L858R patients.
Keywords: EGFR mutation, erlotinib, Randomized 
Phase II clinical trial
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O39.02 INITIAL DETECTION OF THE 
DOUBLE EPIDERMAL GROWTH 
FACTOR RECEPTOR (EGFR) MUTATION 
(L858R OR DELETION IN EXON 19 [DEL 
19] PLUS T790M) IN NON-SMALL-CELL 
LUNG CANCER (NSCLC) PATIENTS (P) 
WITH BRAIN METASTASES (METS) 
AND THE INFLUENCE OF FIRST-LINE 
CHEMOTHERAPY ON OUTCOME TO 
ERLOTINIB
Jia Wei1, Christian Rolfo2, Teresa Moran3, Jose 
Javier Sanchez4, Miguel Angel Molina5, Jordi 
Bertran-Alamillo6, Ana Jimenez-Capitan6, Susana 
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Background: Progression-free survival (PFS) in 
EGFR-mutant NSCLC p treated with erlotinib is 
unpredictable at the individual level. The initial 
presence of double mutations (EGFR L858R or 
del 19 plus T790M) is associated with shorter PFS. 
We hypothesized that the site of mets and/or prior 
chemotherapy could also inÁuence outcome in these 
p with double EGFR mutations. 
arms. Updated data from the study and based on the 
speciÀc EGFR mutation is reported.
Methods: Chemotherapy naïve, never or light 
former (< 10 pack years, > 1year since cessation) 
smokers, with advanced lung adenocarcinoma (do 
you need to save these characters) were randomized 
to E alone (150 mg/day) or ECP (E 150 mg/day 
given continuously; C (AUC = 6) & P (200 mg/m2) 
both q21 days) for 6 cycles followed by E. Primary 
endpoint was progression free survival (PFS) in 
both arms. Collection of pre-treatment tumor for 
assessment of EGFR mutations was mandatory. 
Results: Between 8/05 and 4/09 188 pts were 
accrued; 181 pts randomized (E = 81; ECP = 100) 
and treated. Baseline clinical characteristics (E/ECP) 
were well balanced: Female: 60%/58%; Caucasian: 
75%/84%; never smokers: 79%/78%; ECOG PS0: 
62%/48%; adenoca: 87%/84%. Median number of 
cycles: E:6; ECP:8.Toxicity: Grade 3/4 hematologic 
toxicity: E: 2/0 (2%) ; ECP: 29/20 (49%). Grade 
3/4 non-hematologic toxicity: E: 18/2 (24%); ECP: 
39/13 (52%). EGFR genotyping possible in 164 
pts (91%). EGFR mutant/wild type: 66 (40%)/98 
(60%). Exon 19 del: 39; L858R: 27. Outcomes are 
shown in the Table. Median follow up is 36 mos. 
67% of pts have died. Primary endpoints were met 
in both arms. EGFR mut pts had a signiÀcantly 
better RR (p < 0.0001 both arms), PFS (p < 0.0001 
both arms) and OS (p = 0.0198 E; p = 0.011 ECP) 
than EGFR WT pts. OS for EGFR mut pts is longer 
with ECP vs. E (38 vs. 31 mos) but not signiÀcant 
(p=0.9227). The RR (79% vs. 59%; p = 0.0743) and 
PFS (17.7 vs. 12.1 mos; p = 0.1777) are better for 
exon 19 vs. L858R pts. (both arms combined). PFS 
is longer for exon 19 deletion pts. receiving ECP vs. 
E (27.5 vs. 15.7 mos) but not signiÀcant (p=0.2153) 
E (n=81) RR PFS months 
(95%CI) 
OS months (95%CI) 
All patients 35% 5.0 (2.9-7.0) 24.6 (18.4-33.8) 
EGFR mut (n=33) 70% 14.1 (7.0-19.6) 31.3 (23.8-NA) 
Exon 19 (n= 23) 83% 15.7 (6.9-20.4) 31.3 (22.7-NA) 
Exon 21 (n=10 ) 40% 12.6 (1.6-23.8) 29.8 (3.7-NA) 
EGFR WT (n=44) 9% 2.6 (1.4-3.9) 18.1 (9.5 – 27.8) 
ECP (n =100 ) 
All patients 46% 6.6 (5.4-8.2) 19.8 (14.4-27.8) 
EGFR mut (n=33) 73% 17.2 (8.2-27.8) 38.1 (19.6 -NA) 
Exon 19 (n= 16) 75% 27.5 (7.4-NA) 37.5 (18.7- NA) 
Exon 21 ( n = 17) 71% 11.2 (6.8-23.4) 40.0 (10.4- NA) 
EGFR WT (n=54) 30% 4.8 (2.8 – 5.6) 14.4 (8.7 – 20.2) 
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Background: Established biomarkers to predict the 
beneÀt from EGFR TKI therapy in Non-small cell 
lung cancer (NSCLC) are mutations of Epidermal 
Growth Factor Receptor (EGFR), however, only 
70-80% will respond. Ultimately, all patients 
(pts) develop drug resistance and the insulin-like 
growth factor-1 (IGF-1) pathway may have a role in 
EGFR TKI resistance. We assessed IGF-1R protein 
expression and its association to progressive disease 
(PD) and outcome in EGFR TKI treated NSCLC pts 
using immunohistochemistry (IHC) and automated 
quantitative Áuorescence analysis technology 
(AQUA). 
Methods: IGF-1R protein expression was analyzed 
in 98 geÀtinib-treated Japanese NSCLC pts with 
IHC (Ventana Medical Systems, Inc, Tucson, AZ) 
and in 70/98 of them with AQUA (HistoRx Inc, 
New Haven, CT). IHC scoring was performed by 
evaluating membrane and cytoplasm with the Hybrid 
(H) scoring method (0 to 400).
Results: IGF-1R expression was signiÀcantly higher 
in pts with PD vs disease control (DC = CR + PR + 
SD) using any method of assessment for IHC. Using 
ROC curve analyses, the best discrimination of PD 
vs DC was obtained with IHC scoring of membrane 
+ cytoplasm and a cutoff of 165, with an accuracy 
of 72%, sensitivity and speciÀcity of 68% and 73% 
with an area under the curve of 0.75 (p = 0.0006). 
Overall survival (OS) from geÀtinib was worse in pts 
with high IGF-1R using the 165 cutoff (median 13.2 
vs 22.6 months (ms), p = 0.0199). Progression free 
survival (PFS) was shorter in high IGF-1R pts in the 
whole cohort (median 3.5 vs 12.0 ms, p = 0.0020), as 
well as in the adenocarcinomas (n = 78) where high 
IGF-1R showed worse OS and PFS relative to low 
IGF-1R (median 15.6 vs 26.3 ms, p = 0.0642 and 4.4 
vs 12.1 ms, p = 0.0169). Even in the subgroups of 
patients with EGFR mutated tumors (n = 55), high 
IGF-1R showed worse PFS (9.5 vs 17.9, p = 0.0435). 
Evaluation of over expression (H score >300) versus 
no/very low-expression (H score 100) showed that 
the overexpression had a shorter OS (3.7 vs 29.1 ms, 
p = 0.0220) and PFS (2.5 vs 29.1 ms, p <0.0001). 
In overexpression pts the response rate was 0% 
(0/8; 3 PD, 4 SD and NE). IGF-1R expression as 
assessed by AQUA was also signiÀcantly higher in 
pts with PD vs DC. Using ROC curve analyses, the 
best discrimination of PD vs DC was obtained with 
an AQUA cutoff of 7.656, High IGF-1R expression 
evaluated by AQUA was also predictive of PD (p = 
Methods: The T790M mutation was assessed in 
129 advanced NSCLC p by TaqMan assay in the 
presence of a peptide-nucleic acid designed to inhibit 
the ampliÀcation of the wild-type allele. 
Results: De novo T790M mutations were identiÀed 
in 35% (45 of 129) of EGFR-mutant p before 
receiving erlotinib. PFS was 12 months (m) for 
p with double mutations and 18 for p with only 
L858R or del 19 (P=0.02). The T790M mutation was 
detected more frequently in p with bone mets (35.6% 
vs 16.7%; P=0.03). No effect on PFS or MS was 
observed in p with the T790M mutation according 
to bone, lung, liver or pleura mets. However, when p 
with T790M were divided according to the presence 
of brain mets, PFS was 1 m for 4 p with brain mets 
vs 13 m for 41 p without brain mets (P=0.002), 
and MS was 6 m for p with brain mets vs 36 m for 
those without (P=0.009). Overall, in the multivariate 
analysis, the presence of the double mutation did 
not affect the risk of shorter MS (HR, 1.3; P=0.49), 
but p who had received prior chemotherapy had 
signiÀcantly longer MS (HR, 0.48; P=0.02). 
Conclusion: The initial double EGFR mutation 
(EGFR L858R or del 19 plus T790M) is a marker 
for poor prognosis in p with brain mets. In 
addition, initial chemotherapy can play a role in the 
management of NSCLC p with the double EGFR 
mutation. 
Keywords: erlotinib, T790M, EGFR mutation, Non-
Small-Cell Lung Cancer
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O39.03 IGF-1R IS A PREDICTIVE 
BIOMARKER FOR EGFR TKI 
(GEFITINIB) RESISTANCE IN NON-
SMALL CELL LUNG CANCER USING 
IHC AND AQUA TECHNOLOGY
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Methods: 80 adenocarcinomas of the lung were 
included in the study, 40 samples with proven 
mutation status evaluated by different methods 
and 40 predominantly acinar or papillary 
adenocarcinomas with undetermined EGFR mutation 
status. EGFR-mutation analysis in the Àrst group 
was previously done by either classical sequence 
analysis, pyrosequencing, LightCycler® assay, 
BioFilmChip® microarray hybridisation, IHC 
with mutant speciÀc antibodies, or the use of a 
commercial kit (DxS). DNA was isolated from all 
80 samples and EGFR mutations in exon 18 to 21 
were tested with the GenomeFlex 454 sequencing 
system (Roche). This method has proven to be 
extremely sensitive, having the power to detect 
single cell mutations enabling a clonal analysis on 
cellular level. Different patients were encrypted by 
a genetic ‘barcode’ (4 to 6bp nucleotidadapter) by 
PCR to facilitate a simultaneous sequencing of many 
patient samples. Cut-off was set according to Wang 
(Genome Res. 2007).
Results: 1829 mutations were found in 79 patient 
samples (silent mutations were not included). 77 
different previously evaluated mutations could be 
conÀrmed. Additional 158 different new mutations 
were detected in the tumor cells. When compared 
to the other tested methods our results show a better 
speciÀcity and better sensitivity. Cases analyzed by 
Light Cycler® assay and pyrosequencing showed 
100% correspondence to 454 sequencing, whereas 
the results of IHC with mutant speciÀc antibodies 
showed 1 false positive and 2 false negative results 
(n=28). The comparison of Sanger sequencing 
analysis showed a high discrepancy between the 
different Institutes. All other applied methods 
showed deviations as well, nevertheless with 
acceptable boundaries. Several mutations present in 
small tumor cell clones were not detected by any of 
the other methods. Furthermore, T790M resistance 
mutation combined with an activating mutation 
could be found in two untreated patient samples.
Conclusion: The discrepancy between different 
conventional methods used for routine diagnostics 
result in several samples incorrectly diagnosed. This 
implicates the importance of using either a second 
method for conÀrmation, or using a more sensitive 
method to minimize the risk of a false diagnosis. 
The results underline the need for standardization 
of mutation analysis. However, the application of 
such a sensitive method requires an even closer 
collaboration between pathologists and oncologists, 
since the impact of small tumor cell clones (1% and 
0.033) and shorter PFS (3 vs 9.2 ms, p = 0.0406) in a 
70 pts subset. 
Conclusion: High IGF-1R protein expression, 
evaluated both by IHC and AQUA, predicted 
primary resistance to geÀtinib therapy in NSCLC 
and was associated with worse OS and shorter PFS. 
This observation was also true in the subgroups of 
adenocarcinoma and more interestingly in patients 
wiht EGFR mutated tumors. Thus, IGF-1R protein 
expression appears to be a clinically relevant 
biomarker to identify NSCLC pts with intrinsic 
EGFR TKI resistance, even in pts having EGFR 
mutations.
Keywords: AQUA, immunohistochemistry, IGF-1R, 
Predictive marker
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O39.05 VERY EARLY DETECTION 
OF SMALL CLONES HARBORING 
EGFR MUTATIONS IN NSCLC BY 2ND 
GENERATION SEQUENCING
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Kollmeier6, Thomas Mairinger6, Helmut H. Popper4 
1Biotechnology, 1lausitz University Of Applied 
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Background: Activating mutations of the EGFR 
gene are present in non-small-cell-lung-cancer 
(NSCLC) and respond to EGFR tyrosine kinase 
inhibitor (TKI) therapy. Despite the therapeutic 
success of EGFR-TKIs, about 50% of these 
patients will ultimately show disease progression 
during the course of treatment, possibly due to 
resistant tumor cell clones either primarily present 
as small clones within the carcinoma, or due to 
secondary mutations during TKI treatment. These 
clones may gain a selection advantage, resulting 
in tumor growth unaffected by TKI-treatment. We 
tested adenocarcinomas of the lung for known and 
unknown EGFR mutations comparing different 
methods for mutation analysis, and also tried to 
correlate the new adenocarcinoma classiÀcation with 
EGFR mutation status.
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promoter. Whole blood cells were then stained using 
a LIVE/DEAD® Fixable Red Dead Cell Stain Kit. 
Immunohistochemistry was performed on slides 
using a tyramide signal ampliÀcation kits with 
Alexa 350-labeled tyramide as the substrate for 
horseradish peroxidase (HRP). Anti-CEA and anti-
HRP-goat anti-mouse were applied as primary and 
secondary antibodies, respectively. Two slides for 
each patient were also processed for Áuorescence 
microscopy. Software Image-Pro Plus Ver. 6.0 
(Media Cybernetics) was used to count the number 
of GFP expressing cells and measure GFP intensity. 
GFP positive cells were assumed to have at least a 
200,000 mean equivalent Áuorochrome labeling, 
which is the cut-off level of GFP intensity previously 
obtained using lung, breast, and gastric cell lines, 
and more. Dead cells were assumed to be 20 ƫ m 
diameter or more. The GFP-positive cells were 
regarded as viable CTCs, and the clinicopathologic 
factors were compared with the results of CTC 
analysis. 
Results: Seventy-three (92%) patients had positive 
GFP results (33 women, 40 men), in contrast to none 
of the 72 healthy controls. The mean GFP-positive 
cell count per 7.5 ml PVB was 9.2 (range, 0 -  86). 
As for clinical stages, GFP-positive cells were 
detected in 92% for Stage IA, 100% each for Stages 
IB, IIB, IIIA, and IIIB, and 78% for IV (p=0.29). 
There was no signiÀcant correlation with the stages 
or between GFP-positive cell count or any other 
patient characteristic including age (p=0.68), gender, 
smoking habit (p=0.36), tumor size (p=0.13), and 
histologic type (p=0.20). Among the total 49 patients 
underwent surgical resection, and 46 (94%) had 
positive GFP results. With reference to postoperative 
stages, CTCs were detected in 90% for Stage IA, 
100% each for Stages IB, IIA, IIB, and IIIA, and 
50% for IIIB (p=0.85). 
Conclusion: CTCs were frequently detected in 
clinical and postoperative Stage IA diseases. These 
results indicate that detection of viable CTCs with 
our GFP-expression virus-based method provides 
supersensitive information for NSCLC patients. The 
long-term outcome should be analyzed to assess the 
prognostic impact. 
Keywords: Circulating tumor cell, Non-small cell 
lung cancer, green Áuorescent protein, telomerase
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
less) harboring an activating mutation with respect to 
treatment is not entirely clear. The T790M mutations 
found in untreated patients support the hypothesis 
that NSCLC can harbor TKI resistant clones already 
before treatment besides the more common advent of 
a secondary somatic resistance mutation. This is of 
importance, because TKI treatment will result in an 
earlier resistance in these patients because of clone 
selection.
Keywords: EGFR mutation analysis, deep 
sequencing, primary resistance clone, NSCLC
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Background: Circulating tumor cells (CTCs) in 
peripheral venous blood (PVB) are considered as 
potential surrogates for distant metastases, a critical 
factor inÁuencing decision making and therapy 
of primary non-small cell lung cancer (NSCLC) 
patients. We here evaluated viable CTCs in NSCLC 
patients using a new assay with telomerase-speciÀc 
replication-selective adenovirus expressing green 
Áuorescent protein (GFP). 
Methods: From May 2009 to April 2010, a total of 
79 consecutive NSCLC patients (43 men, 36 women) 
who underwent treatment were included. CTCs in 
PVB were quantitatively examined before treatment. 
For this 7.5 ml aliquots of PVB were collected 
using CPD-anticoagulant agent and incubated at 
37ºC with OBP-401® (Oncolys BioPharma, Japan) 
viruses for 24 hours. Adenovirus OBP-401® features 
a human telomerase reverse transcriptase gene 
promoter inserted upstream of the E1 genes, along 
with a GFP gene driven by a Cytomegalovirus 
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based chemotherapy. The predictive role of TS or 
TTF1 expression is required to be validated in a 
prospective randomized study. 
Keywords: Pemetrexed, Thyroid transcription factor 
1, Thymidylate synthase, predictive factor
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O40.01 COMPLETE GENOME 
SEQUENCING OF A HUMAN B3 
THYMOMA
Iacopo Petrini, Yisong Wang, Marbin Pineda, Sean 
Davis, Giuseppe Giaccone 
National Cancer Institute, National Institute Of 
Health/United States Of America
Background: Molecular biology of thymomas is 
poorly understood. We sequenced the whole genome 
of one B3 thymoma and the matched normal DNA 
from blood sample of the same patient.
Methods: Frozen primary tumor and blood were 
collected from a Caucasian 53 female with B3/
stage IVA thymoma after surgery. DNA and RNA 
were extracted using All Prep kit (Qiagen). Array 
Comparative genomic hybridization (CGH) was 
performed on 180K array (Agilent) and Agilent 
platform. Transcriptome sequencing was performed 
using 72bp paired-end sequencing and 2 Áow cell 
lanes of genome analyzer II (Illumina). Whole 
genome sequencing (WGS) was performed on tumor 
and normal DNA using Complete Genomic Inc 
platform.
Results: In the WGS analysis, a total of 222.02 
gigabases (Gb) of sequence were mapped (95.3% of 
genome called) for the tumor sample and 234.53 Gb 
(96.4% of genome called) for the matched normal 
control. Sequence reads were aligned to a human 
reference genome (NCBI Build 37) and a local de 
novo assembly was used to call and score variants. 
Both array CGH and copy number (CN) aberrations 
estimated from WGS showed CN imbalance patterns 
comparable with those previously described for 
B3 thymomas with CN gain of chromosomes 1q, 
5, 7 and X and CN loss of 3p, 6, 11q42.2-qter and 
q13. We observed 3,096,049 single nucleotide 
variations (SNVs) in the tumor and 3,314,611 in 
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O39.07 SIGNIFICANCE OF 
THYMIDYLATE SYNTHASE AND 
THYROID TRANSCRIPTION FACTOR 
1 EXPRESSION IN PATIENTS WITH 
NONSQUAMOUS NON-SMALL 
CELL LUNG CANCER TREATED 
WITH PEMETREXED-BASED 
CHEMOTHERAPY
Jong-Mu Sun, Myung Ja Kim, So Young Cheon, Se 
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Park 
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Background: We try to evaluate whether 
thymidylate synthase (TS) or thyroid transcription 
factor 1 (TTF1) protein expression can predict 
clinical outcomes for pemetrexed-based 
chemotherapy in patients with nonsquamous non-
small cell lung cancer (NSCLC). 
Methods: A total of 285 consecutive patients with 
nonsquamous NSCLC treated with pemetrexed-
based chemotherapy were reviewed for the 
expression of TS and TTF1 by Immunohistochemical 
stain. 
Results: TS and TTF1 expression were successfully 
analyzed in 193 and 284 cases, respectively. 
Tumors with TS-negativity or TTF1-positivity was 
more frequent in group of female, younger age, 
adenocarcinoma, or never-smoker. Higher response 
rates for pemetrexed-based chemotherapy were 
associated with TS-negativity (33.7% vs. 14.1%, 
P = 0.002) and TTF1-positivity (28.1% vs. 9.8%, 
P < 0.001), respectively. In univariate analysis, 
progression-free survival (PFS) for pemetrexed-
based chemotherapy was signiÀcantly longer in 
groups of adenocarcinoma (2.9 vs. 1.4 months, P = 
0.001), TS-negativity (4.1 vs 2.0 months, P = 0.001), 
and TTF1-positivity (3.9 vs. 1.3 months, P < 0.001). 
In multivariate analysis, TS-negativity (HR = 0.69; 
95% CI, 0.50 – 0.96) and TTF1-positivity (HR = 
0.51; 95% CI, 0.36 – 0.73) were independently 
associated with longer PFS, respectively. Patients 
with TTF1-positive tumors had also signiÀcantly 
longer overall survival time than patients with TTF1-
negative tumors (25.4 vs. 14.2 months, HR = 0.55; 
95% CI, 0.39 – 0.77). 
Conclusion: Low TS or high TTF1 protein 
expression was signiÀcantly associated with 
better clinical outcomes in nonsquamous NSCLC 
patients who were treated with pemetrexed-
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tumor. The Áuorescence-in situ hybridization (FISH) 
probe for CSNK2A1P (chromosome 11p15.3) was 
purchased from BACPAC Resources (Oakland, 
CA). The chromosome 11 centromere was labeled 
by Vysis CEP 11 SpectrumGreen™ probe (Abbott 
Molecular, Abbott Park, IL). The allele-speciÀc 
ampliÀcation was measured using the ABI PRISM 
7700 sequence detection system. For determination 
of the kinase activity of the expressed CSNK2A1 
and CSNK2A1P proteins, Casein Kinase 2 Assay 
Kit (Millipore, Bedford, MA) was used according 
to manufacture’s protocol. The data are shown as 
mean values ± standard deviation (SD). Student’s 
t-test was used to compare results between control 
and experimental groups in the colony formation 
assay. Chi-square test was used to compare the 
frequency of the CSNK2A1P polymorphisms 
between lung cancer tissues and normal controls. 
Pearson correlation coefÀcient was used to access 
the correlation between mRNA expression and 
copy numbers of the CSNK2A1P gene in cancer 
cell lines. Statistical analysis was carried out using 
SPSS (version 10.0, Chicago, IL). A P value of less 
than 0.05 was considered statistically signiÀcant. All 
statistical tests were two-sided. 
Results: We found evidence of ampliÀcation and 
over-expression of the CSNK2A1P gene in non- 
small cell lung cancer and leukemia cell lines and 
25% of the lung cancer tissues studied. The mRNA 
expression levels correlated with the copy numbers 
of the CSNK2A1P gene. We also identiÀed a 
novel polymorphic variant (398T/C, I133T) of the 
CSNK2A1P gene and showed that the 398T allele 
is selectively ampliÀed over the 398C allele in 101 
non-small cell lung cancer tissue samples compared 
to those in 48 normal controls (p = 0.013<0.05). 
We show for the Àrst time CSNK2A1P protein 
expression in transfected human embryonic kidney 
293T and mouse embryonic Àbroblast NIH-3T3 
cell lines. Both alleles are transforming in these 
cell lines, and the 398T allele appears to be more 
transforming than the 398C allele. Moreover, the 
398T allele degrades PML tumor suppressor protein 
more efÀciently than the 398C allele and shows a 
relatively stronger binding to PML. Knockdown of 
the CSNK2A1P gene expression with speciÀc siRNA 
increased the PML protein level in lung cancer cells. 
Conclusion: We report, for the Àrst time, that the 
CSNK2A1P gene is a functional proto-oncogene 
in human cancers and its functional polymorphism 
appears to degrade PML differentially in cancer 
cells. These results are consistent with an important 
the normal DNA. The transition/transversion ratio 
was 2.14 and 1.83 for germ line and somatic SNVs, 
respectively. Somatic SNVs were deÀned as those 
variations present in tumor but not normal matched 
DNA. We observed 5946 diploid somatic indels 
and 6530 SNVs, of which 43 and 83 were within 
exonic regions, respectively. 29 indels and 25 SNVs 
were not previously described as SNPs, nor in 
segmental duplication, or synonymous mutations. 
By comparison with the transcriptome sequencing 
data of the same tumor sample, we conÀrmed the 
expression of 6 mutated genes, while for 45 mutated 
genes there were not enough reads to conÀrm the 
calls.
Conclusion: WGS and accompanying transcriptome 
sequencing offer an unprecedented view of the 
genome of a thymoma cancer patient sample. We 
are actively engaged in determining the potential 
functional signiÀcance of the genomic variants in 
the context of transcriptome sequencing and copy 
number variation to gather clues as to the underlying 
biology driving this relatively rare tumor type.
Keywords: Thymoma, Next generation sequening, 
Whole genome sequencing, CGH
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O40.02 CK2 INTRONLESS GENE 
AMPLIFICATION IN NON-SMALL CELL 
LUNG CANCER
Ming-Szu Hung1, Yu-Ching Lin1, Zhidong Xu2, 
David M. Jablons2, Liang You2 
1Chang Gung Memorial Hospital/Taiwan, 2Surgery, 
University Of California/United States Of America
Background: Protein kinase CK2 is frequently up-
regulated in human cancers, although the mechanism 
of CK2 activation in cancer remains unknown. In 
this study, we investigated the role of the CK2Ơ 
intronless gene (CSNK2A1P, a presumed CK2Ơ 
pseudogene) in the pathogenesis of human lung 
cancer. 
Methods: The human cancer (Jakurt, H1299, 
A549, A427, H441, H1703, H322, H460, HCT116, 
H1975, H322, H358, H838, H28, H2052, Hela and 
H1650) and normal lung (WI-38 and CCL-211) cell 
lines were obtained from American Type Culture 
Collections (Manassas, VA). Fresh tumor tissues and 
adjacent normal tissues were obtained from patients 
with non-small cell lung cancer (NSCLC) who 
were undergoing surgical resection of the primary 
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within. 
Methods: Gene dosage in lung cancer specimens 
was assessed by whole-genome array CGH. DNA 
methylation was assessed using the Illumina 
HumanMethylation27 platform, with additional 
data obtained by MS-PCR for cancer specimens 
and matched normal lung tissues where available 
and appropriate. Gene expression was assessed 
using various microarray platforms, qTR-PCR, 
and western blot techniques. Genotyping studies 
were performed using Affymetrix SNP arrays. 
EYA4 knock-down and knock-in experiments were 
performed by stable viral transfection of appropriate 
constructs.
Results: Using integrated genomic and epigenomic 
analysis of sporadic lung cancers, we have identiÀed 
frequent two-hit inactivation of the gene EYA4 
which is located within the locus at 6q23.2. It is 
inactivated by either deletion or hypermethylation in 
over 75% of tumours examined and is inactivated by 
both at the same time (two-hit) in 20% of those same 
lung tumours. In addition to frequent inactivation 
by these two mechanisms, DNA sequencing in a 
panel of lung cancer cell lines and tumour tissues 
identiÀed a missense mutation which is predicted 
to be pathogenic. Interestingly, this mutation occurs 
in lung cancer cells demonstrating deletion but 
not hypermethylation. Other somatic and germline 
unclassiÀed DNA sequence variants were also 
discovered in the UTR and intronic regions of the 
gene, which may impact gene regulation or splicing. 
We have conÀrmed the role of DNA methylation in 
silencing the gene by pharmacologic restoration of 
EYA4 expression in hypermethyalted cells and by 
demonstrating a robust correlation between DNA 
methylation levels and mRNA expression levels 
in lung cancer cells. We have identiÀed deletion of 
EYA4 at the earliest stages of disease (in carcinoma 
in situ) as well as hypermethylation of the gene 
in histologically normal epithelia of people with 
cancer. Our functional studies in vitro have shown 
that cells depleted of EYA4 exhibit delayed DNA 
repair and avoidance of apoptosis - consistent with 
its proposed role as a tumour suppressor gene and 
a susceptibility gene. Taken together, these data 
indicate that disruption of EYA4 is likely a causal 
event in tumorigenesis. Additionally, examination of 
a familial lung cancer cohort has identiÀed 5 SNPs 
in EYA4 which are associated with lung cancer risk. 
The clinical relevance of EYA4 is further highlighted 
by the association of low EYA4 expression with poor 
prognosis in a number of survival datasets. Finally, 
role for the 398T allele of the CSNK2A1P in human 
lung cancer susceptibility. 
Keywords: ampliÀcation, NSCLC, oncogene, CK2
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O40.03 EYA4 IS A FREQUENTLY 
INACTIVATED TUMOUR SUPPRESSOR 
GENE WITHIN THE 6Q LUNG CANCER 
SUSCEPTIBILITY LOCUS
Ian Wilson1, Emily A. Vucic1, Katey S.S. EnÀeld1, 
Raj Chari2, Yu-An Zhang3, Niki Radulovich4, Daniel 
Starczynowski5, Judit Banath6, May Zhang6, Andrea 
Pusic6, Megan Fuller7, Kim Lonergan6, Timon 
Buys6, John Yee8, Ite A. Laird-offringa9, Pengyuan 
Liu10, Ming S. Tsao11, Marshall Anderson12, Ming 
You13, Kevin Bennewith1, Aly Karsan7, Calum E. 
Macaulay14, Stephen Lam7, Adi F. Gazdar15, Wan 
Lam1, Suhaida Selmat16 
1Integrative Oncology, British Columbia Cancer 
Research Centre/Canada, 2Genetics, Harvard 
Medical School/United States Of America, 
3Pathology, Ut Southwestern/United States Of 
America, 4University Health Network/Canada, 
5Cincinnatti Children’s Hospital/United States Of 
America, 6Integrated Oncology, British Columbia 
Cancer Research Centre/Canada, 7Medical 
Biophysics, British Columbia Cancer Research 
Centre/Canada, 8Thoracic Surgery, British Columbia 
Cancer Agency/Canada, 9Biochemistry & Molecular 
Biology, University Of Southern California/
United States Of America, 10Surgery, Washington 
University/United States Of America, 11Princess 
Margaret Hospital/Canada, 12Cancer And Cell 
Biology, University Of Cincinnati Medical Center/
United States Of America, 13Medical College Of 
Wisconsin Cancer Center/United States Of America, 
14Integrative Oncology, Bc Cancer Research 
Centre/Canada, 15Ut Southwestern Medical Center/
United States Of America, 16Norris Cancer Center, 
University Of Southern California/United States Of 
America
Background: While the environmental factors 
predisposing to lung cancer are well known, 
the genetics underlying lung cancer risk have 
only recently begun to be unravelled. The recent 
discovery of the familial lung cancer susceptibility 
locus at chromosome 6q23-25 has been a pivotal 
discovery in this regard and has spurred further work 
to identify the important gene, or genes, located 
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them, 1265 were over-expressed in tumour tissues 
and 1725 were under-expressed suggesting that 
different LC types have more similarity in depression 
of some processes than in activation. The numbers 
of speciÀc genes were 687, 1049, and 5104 for 
ADC, SCC, and carcinoid tumour, respectively. GO 
analyses showed that the biological processes and 
molecular functions common to different types of 
LC included an increase of proliferative potential, an 
increase of the cell independence, and a decrease in 
mediators of normal morphology and tissue integrity, 
while biological processes for different cancer 
types reÁect the pathophysiologic features, cell-of-
origin, and localization of the tumours. Although 
there was an overlap of biofunctions between the 
different cancer types, we found the direction and 
speciÀcity of some biofunctions was different in 
different cancer types, reÁecting pathophysiologic 
features of the tumours. WGCNA analysis for genes 
differentially expressed between tumours and normal 
tissues identiÀed Àve modules of tightly correlated 
genes. GO analysis of the module members revealed 
an increase of cell independence, a decrease of 
normal lung morphology and function, an increase of 
proliferation, and an increase in keratinisation. One 
of the modules showed a signiÀcant correlation with 
NSCLC subtypes (R = 0.7616; P= 5.5e-08) and was 
mainly represented by the genes encoding keratins, 
serpins, and desmosome component proteins. Six 
genes from this module were tested for their ability 
to discriminate between SCC and ADC. Three of 
them were well-known markers (KRT17, DSG3, 
TP63), and three of them were chosen based on their 
module membership score (novel gene (NG)1, NG2, 
and NG3). The best discrimination model included 
DSG3 and NG1, and was strongly veriÀed in an 
independent publicly available dataset. It was also 
possible to identify genes speciÀc for other tumour 
types, which we are currently verifying.
Conclusion: Lung cancer subtypes share common 
molecular processes, but also evidence the 
expression of speciÀc genes relevant to cell-of-
origin and localization of tumours. GO and WGCNA 
analyses revealed clusters of genes characterising 
different aspects of disease manifestation. Based on 
the WGCNA results, new effective biomarkers for 
SCC/ADC were discovered.
Keywords: Lung cancer, gene expression proÀles, 
genetic networks, Biomarkers
preliminary results in both in vitro soft agar colony 
formation assays as well as in vivo subcutaneous 
tumour growth assays suggest that EYA4 suppresses 
lung tumour growth.
Conclusion: Our results indicate that EYA4 is 
a frequently inactivated tumour suppressor gene 
located in the previously described lung cancer 
susceptibility locus, inactivation of which is 
associated with both poor prognosis and lung cancer 
risk. 
Keywords: susceptibility, hypermethylation, tumour 
suppressor gene
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O40.05 GLOBAL GENE EXPRESSION 
PROFILING TO IDENTIFY COMMON 
NETWORKS UNDERLYING LUNG 
CANCER AND SPECIFIC MARKERS 
OF DIFFERENT LUNG CANCER 
HISTOLOGICAL TYPES
Maxim B. Freidin1, Andrew G. Nicholson2, Eric 
Lim3, Miriam F. Moffatt1, William O. Cookson1 
1National Heat And Lung Institute, Imperial College 
London/United Kingdom, 2Academic Department Of 
Histopathology, Royal Brompton Hospital/United 
Kingdom, 3Academic Department Of Thoracic 
Surgery, Royal Brompton Hospital/United Kingdom
Background: Gene expression proÀles have the 
potential to discover molecular mechanisms of 
underlying lung cancer. They may also identify new 
and better biomarkers of disease progression and 
treatment efÀciency.
Methods: Gene expression proÀling was performed 
in tumour and matched normal tissues of 104 lung 
cancer (LC) patients using Affymetrix HumanGene 
1.1ST microarrays. We identiÀed genes that were 
differentially expressed between tumour and 
normal tissues as well as between different lung 
cancer subtypes. Common LC genes were deÀned 
as the genes which are differentially expressed 
between normal and tumour tissues in carcinoid 
tumour, squamous cell carcinoma (SCC), and 
adenocarcinoma (ADC). SpeciÀc LC genes were 
deÀned as genes differentially expressed between 
one cancer type versus the others. Weighted gene 
correlation network analysis (WGCNA) was 
applied to reveal modules of tightly correlated genes 
characterising different tumour types.
Results: We found 2990 common LC genes; among 
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by histology. We identiÀed 171 CpG loci highly 
methylated in tumours which exhibited substantially 
higher methylation levels compared to commonly 
methylated markers such as CDKN2A, MGMT and 
DAPK1. The most frequently methylated genes 
belonged to 3 major groups, the HOX family, 
Polycomb repressor complex associated genes or 
both. Five high priority candidate genes (HOXB4, 
HOXA9, PTGDR, PRDM14 and HOXD9) were 
selected for further analyses on the basis of high 
methylation differences between normal and 
tumour lung. Methylation levels of two candidates 
PTGDR and PRDM14 were then validated using 
an independent method, Sequenom’s Epityper. 
Moderate correlations were observed between copy 
number and methylation for PRDM14 (Spearmann 
Rho = 0.238, P=0.008). Next we demonstrate 
samples frequently methylated across multiple genes 
demonstrate a survival advantage (Log-rank=0.031). 
Finally, we report methylation signatures capable 
of distinguishing adenocarcinoma and squamous 
cell carcinoma histology (sensitivity = 0.896, 
speciÀcity=0.861, Positive Predictive Value=0.857, 
Negative Predictive Value=0.898). 
Conclusion: DNA methylation proÀles differ 
between normal and tumour lung and are predictive 
for adenocarcinoma and squamous cell carcinoma 
histology. Further validation studies are required 
to conÀrm involvement of candidate genes in lung 
carcinogenesis. Supported by: The Prince Charles 
Hospital Foundation, Queensland Clinical Research 
Fellowship, NHMRC Biomedical Scholarship, 
NHMRC Project Grants 198401 and APP1006695. 
Keywords: Epityper, Methylation proÀling, Non-
small cell lung cancer
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O40.07 NOTCH ACTIVATION DRIVES 
MICRORNA-200-DEPENDENT EMT & 
METASTASIS IN A MURINE MODEL OF 
NSCLC
Don L. Gibbons1, Yanan Yang2, Young-Ho Ahn2, 
Chad J. Creighton3, Alexander Pertsemlidis4, Philip 
A. Gregory5, Jennifer Saik6, B. J. Gill6, Zain H. 
Rizvi2, Jennifer West6, Jonathan M. Kurie2 
1Thoracic, Head/neck Medical Oncology & 
Molecular And Cellular Oncology, University Of 
Texas, MD Anderson Cancer Center/United States 
Of America, 2University Of Texas, MD Anderson 
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O40.06 DISTINCT METHYLATION 
PROFILES IN LUNG CANCER AND ITS 
MAJOR SUBTYPES
Casey M. Wright1, Santiyagu M.F. Savarimuthu2, 
Krishna B. Sriram2, Mitchell Stark3, Nick K. 
Hayward3, Ian A. Yang4, Rayleen Bowman4, Kwun 
M. Fong4 
1School Of Medicine, University Of Queensland/
Australia, 2University Of Queensland/Australia, 
3Oncogenomics Laboratory, Queensland Institute 
Of Medical Research/Australia, 4Department Of 
Thoracic Medicine, The Prince Charles Hospital/
Australia
Background: Epigenetic gene inactivation of 
tumour suppressor genes underlies several human 
cancers. The potential to develop targeted therapies 
is being driven by the recent development of high-
throughput genome-wide approaches including 
methylation-based microarray technology. The 
attractiveness of selecting methylation biomakers 
lies in their ability to be easily reactivated or 
deactivated. The aim of the current study is to 
characterize the lung cancer methylome, to identify 
novel methylated genes and a methylation proÀle 
to distinguish adenocarcinoma and squamous cell 
carcinoma subtypes. 
Methods: Methylation proÀling by Illumina 
InÀnium Methylation27 arrays was performed on 
226 primary lung tumours and 80 normal lung 
samples from the TPCH lung tumour bank. Data 
was feature extracted using proprietary software 
(GenomeStudio, Illumina, Hayward, CA). We used 
two separate approaches in gene identiÀcation: 
1) we utilised stringent criteria employed by the 
The Cancer Genome Atlas (TCGA) project on 
Glioblastoma performing separate analyses for 
training and test sets and 2) we used in-house 
(TPCH) criteria (vis. (1) false discovery rate (FDR) 
Q<1x10E-7, (2) P-value < 1x10E-7, (3) frequency 
of methylation across samples and (4) magnitude 
of difference between normal/tumour pairs (at least 
2-fold)). High priority candidate gene methylation 
levels were validated using Sequenom’s Epityper 
methodology. Prediction proÀling was performed 
using BRB Array Tools. 
Results: Unsupervised cluster analyses demonstrated 
distinct clusters for normal and tumour lung 
and in primary tumours identiÀed six distinct 
clades of tumours which could not be explained 
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the Notch receptors and multiple ligands. Metastasis 
was dependent upon activation of Notch by the 
ligand jagged2, which suppressed microRNA-200 
(miR-200) family expression and thereby triggered 
EMT. Jagged2 activated the Notch transcriptional 
mediator GATA3, which directly bound to the miR-
200 promoter and suppressed its activity. Either 
jagged 2 or GATA3 knockdown increased miR-
200 levels, reversed EMT, abrogated tumor cell 
responsiveness to TGFB and suppressed metastasis. 
We conclude that jagged2/Notch initiates metastasis 
by activating GATA3-mediated suppression of miR-
200 expression. 
Conclusion: New therapeutics to target metastatic 
NSCLC will emerge from a better understanding 
of the tumor biology. This experimental model 
recapitulates many features of human NSCLC and 
has revealed a role for EMT in metastasis, the miR-
200 family as regulators of the cellular switch, and 
a mechanism whereby microenvironmental changes 
inÁuence levels of jagged2 and GATA3, altering 
miRNA expression in the tumor cells and their 
ability to metastasize. We are currently working to 
understand the other factors in microenvironment-
dependent regulation of miR-200 members and the 
downstream targets of miR-200.
Keywords: notch, epithelial-mesenchymal 
transition, microRNA-200, Metastasis
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O41.01 ANALYSIS OF PHASE III 
STUDIES FOR PALONOSETRON, 
ONDANSETRON, DOLASETRON, AND 
GRANISETRON IN THE PREVENTION 
OF CHEMOTHERAPY-INDUCED 
NAUSEA AND VOMITING IN PATIENTS 
WITH LUNG CANCER
Lee Schwartzberg1, Gary R. Morrow2, Sally Y. 
Barbour3, Raza Ahmed4, Gianluca Ballinari5, 
Michael D. Thorn6, David Cox4 
1Senior Partner & Medical Director, Acorn And 
West Clinic/United States Of America, 2University 
Of Rochester/United States Of America, 3Duke 
University Medical Center/United States Of 
America, 4Eisai, Inc./United States Of America, 
College Of Medicine, Duncan Cancer Center/
United States Of America, 4University Of Texas, 
Southwestern, Hammon Cancer Center/United States 
Of America, 5University Of Adelaide/Australia, 6Rice 
University/United States Of America
Background: Non-small cell lung cancer (NSCLC) 
is the leading cause of cancer death worldwide, 
primarily due to metastatic disease. We lack a clear 
understanding of the molecular and cellular basis for 
lung cancer metastasis, partly because of the lack of 
experimental models.
Methods: We have developed an experimental 
syngeneic model of metastatic NSCLC using cell 
lines derived from a genetic mouse model with 
K-rasG12D & p53R172H, which develops spontaneous 
primary lung adenocarcinoma with metastases 
similar to the human disease.
Results: Combined mRNA/microRNA proÀling 
of highly metastatic versus non-metastatic 
syngeneic tumors revealed a signature of EMT 
and associated loss of the miR-200 family (miR-
141, 200a, 200b, 200c & 429) expression. Forced 
miR-200 expression abrogated their capacity 
to undergo EMT, invade, and metastasize and 
conferred transcriptional features of metastasis-
incompetent cells, while forced Zeb expression 
in epithelial cells induced EMT and a metastatic 
phenotype, supporting the idea that miR-200 
repression is necessary and sufÀcient for tumor 
metastasis. Despite signiÀcant genetic alterations, 
the metastasis-prone tumor cells displayed a marked 
plasticity in response to contextual cues, with 
the ability to form growth-limited well-polarized 
epithelial spheres with high miR-200 family 
expression in 3D culture on Matrigel, which were 
tumorigenic & metastatic upon in vivo injection. 
Experiments in a 3D synthetic hydrogel system 
have further demonstrated the regulation of miR-
200/Zeb1 levels and cell phenotype by cell-ECM 
interactions. Analysis of a panel of 40 human 
NSCLC cell lines revealed 2 groups, based upon 
a tight negative correlation between miR-200 and 
Zeb1: those with high miR-200/low Zeb1 levels or 
low/absent miR-200 and high Zeb1 levels. These 
data strongly suggest that the changes found in the 
experimental model are relevant to human NSCLC. 
A metastatic subpopulation of the murine tumors 
demonstrated upregulation of the CD133 marker in 
cells interacting with adjacent stroma. Expression 
proÀling of the metastatic CD133high & non-
metastatic CD133low cells revealed high expression of 
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(5.3%; 3.5%; 1.9%, respectively), and increased ALT 
(1.8%; 5.7%; 8.6%, respectively). 
Conclusion: In this analysis, palonosetron 
demonstrated improved CINV prevention and a 
comparable safety proÀle relative to 1st generation 
5HT
3
-RAs in patients with lung cancer. 
Keywords: Lung cancer, palliative care, 
Chemotherapy-induced nausea
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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O41.02 A 3-DAY ORAL APREPITANT 
REGIMEN PROVIDES SUPERIOR 
PREVENTION OF CINV OVER 
STANDARD THERAPY IN CHINESE 
PATIENTS RECEIVING HIGH-DOSE 
CISPLATIN.
Li Zhang1, Ying Cheng2, Hong-Yu Zhang3, Caicun 
Zhou4, Baohui Han5, Yiping Zhang6, Cheng Huang7, 
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Background: Aprepitant (APR) is a Neurokinin-1 
receptor antagonist that has been shown in clinical 
studies to be efÀcacious in preventing CINV and 
5Helsinn Healthcare Sa/Switzerland, 6Statistical 
Resources, Inc./United States Of America
Background: Lung cancer is the leading cause 
of cancer-related death for both men and women 
worldwide, with chemotherapy-induced nausea 
and vomiting (CINV) a common side effect of 
chemotherapeutic treatment. Patients consistently 
report that CINV is amongst the most distressing 
aspects of chemotherapy, <<1>> with one or 
two emetic episodes associated with a signiÀcant 
deterioration in the quality of life – often 
resulting in dose delay or refusal of therapeutic 
treatment.<<2,3>> Palonosetron is a potent second-
generation 5-HT
3
 receptor antagonist (5HT
3
-RA) 
with a unique pharmacologic proÀle. Palonosetron 
has been shown to trigger receptor internalization, 
inhibit in vivo NK1 agonist responses, as well as 
have a higher binding afÀnity for the 5-HT
3
 receptor 
and longer half-life when compared to 1st generation 
5HT
3
-RAs. 
Methods: We conducted a pooled analysis of 4 
phase III studies to assess the comparative safety 
and efÀcacy proÀles of palonosetron, ondansetron, 
dolasetron, and granisetron in the prevention of 
CINV in patients with lung cancer. EfÀcacy data 
for patients with lung cancer was entered into a 
logistic regression model, with the primary outcome 
variables being complete response (CR) during the 
0-24hr (acute) period, the 24-120hr (delayed) period, 
and the 0-120hr (overall) period. A comparative 
descriptive safety assessment was also conducted. 
Results: This pooled analysis included 783 patients 
with lung cancer. The patients were administered 
either palonosetron 0.25mg, n=57; palonosetron 
0.75mg, n=367; or 1st generation 5HT
3
-RA, n=360. 
In the acute phase, observed CR rates were 78.3% 
for palonosetron and 76.3% for 1st generation 5HT
3
-
RAs (OR=0.88; p=NS from model). SigniÀcantly 
higher CR rates were observed for palonosetron 
when compared to 1st generation 5HT
3
-RAs in both 
the delayed phase (53.5% vs. 41.8%; OR=0.78, 
p=0.0014) and the overall phase (51.2% vs. 39.8%; 
OR=0.79, p=0.0021). The adverse event (AE) 
proÀle of palonosetron (all doses) was similar to 
1st generation 5HT
3
-RA across all trials for CINV 
in patients with lung cancer. The incidence of 
treatment-related AEs was also similar across trials; 
palonosetron 0.25mg, 17.5%; palonosetron 0.75mg, 
30.0%; and 1st generation 5HT
3
-RAs, 31.1%, with 
notable treatment-related AEs including constipation 
(7.0%; 13.6%; 11.9%; respectively), headache 
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O41.03 PALONOSETRON, APREPITANT 
AND DEXAMETHASONE TO PREVENT 
NAUSEA AND VOMITING DURING 
MULTIPLE CYCLES OF CISPLATIN-
BASED CHEMOTHERAPY FOR LUNG 
CANCER PATIENTS
Flavia Longo1, Giovanni Mansueto2, V. Lapadula1, 
G. Del Ben1, L. De Filippis1, E. Del Signore1, B. 
Gori1, L. Stumbo1, R. De Sanctis1, S. Quadrini1, M. 
Di Seri1 
1Medical Oncology A, Policlinico Umberto Primo/
Italy, 2Medical Oncology/Italy
Background: With repeated courses of 
chemotherapy, chemotherapy-induced nausea and 
vomiting (CINV) is progressively more difÀcult to 
be controlled. The aim of our study was to evaluate, 
for the Àrst time, whether the antiemetic efÀcacy 
of the triple combination palonosetron, aprepitant, 
and dexamethasone could be sustained for up to six 
cycles of highly emetogenic chemotherapy (HEC) in 
lung cancer patients. 
Methods: Chemotherapy-naïve patients receiving 
cisplatin-based HEC, were treated with palonosetron 
0.25 mg/i.v., dexamethasone 20 mg/i.v. and 
aprepitant 125 mg/p.o., 1-hour before chemotherapy. 
Aprepitant 80 mg/p.o. and dexamethasone 4 mg 
p.o. were administered on days 2-3. The primary 
endpoint was complete response (CR- no vomiting 
and no use of rescue medication), over Àve days 
following HEC in up to six cycles. Secondary 
endpoints were emesis-free and nausea-free rates 
during the Àve days following HEC in up to six 
cycles. Safety was also evaluated
Results: 158 patients with lung cancer were included 
in the study. Median age was 64 years, 76.6% were 
male, 74.7% with stage IV disease. All patients 
received cisplatin dose 75mg/sqm. EfÀcacy results 
are reported in table: 
Variable Cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycle 5 Cycle 6 
CR % 74 77.2 80 79.2 81.8 83.2 
No emesis % 92.4 93 91.6 90.3 91.7 94.1 
No nausea % 58.9 67.1 65.2 63.6 66.1 69.7 
The most commonly reported side effects were mild 
constipation, headache and hickup.
Conclusion: This study shows that, in lung 
cancer patients, the antiemetic efÀcacy of the 
triple combination palonosetron, aprepitant and 
to be well tolerated. The efÀcacy, safety, and 
tolerability of APR in Chinese patients has not been 
studied. This phase III, multicenter, double-blind, 
placebo-controlled, randomized study assessed the 
efÀcacy, safety, and tolerability of a 3-day oral APR 
regimen compared with that provided by a standard 
therapy regimen (ST), in Chinese patients. 
Methods: Four hundred twenty-one patients, 70% 
of whom were NSCLC, receiving chemotherapy that 
included cisplatin 70 mg/m2 were randomized (1:1) 
to receive the APR regimen (APR 125 mg po d1 and 
80 mg d2-3, granisetron 3 mg iv d1, DEX 6 mg po 
d1, and 3.75 mg d2-4) (n=209) or the ST (placebo 
d1-3, granisetron 3 mg iv d1, and DEX 10.5 mg d1 
and 7.5 mg d2-4) (n=212). The primary endpoint was 
the percentage of patients with complete response 
(CR; no emesis and no use of rescue therapy) in the 
overall phase (0 – 120 hours after chemotherapy); 
secondary endpoints were no vomiting (NV), time to 
Àrst vomiting episode, and patient-reported impact of 
CINV on daily life. 
Results: Overall baseline characteristics were 
balanced between two arms. All 421 patients 
received at least one dose of treatment drug and 
had at least one post-treatment assessment. The 
proportions of patients with CR in the overall 
phase were 69.6% in the APR regimen and 57.0% 
in the ST regimen (p=0.007). The proportions of 
patients with NV in the overall phase were 70.6% 
and 57.0%, respectively (p=0.003) Results from the 
Quality of Life questionnaire showed signiÀcant 
differences between the APR and ST in two of the 
vomiting domains: ‘ability to enjoy a meal’ (76.0% 
vs 66.3%, respectively; p<0.05) and ‘hardship on 
others’ (78.0% vs 67.3%, respectively; p<0.05). The 
incidence of adverse events was generally similar in 
both treatment groups. In addition, the distribution 
of toxicity grades was also generally similar between 
groups. 
Conclusion: In our study, the addition of APR to the 
standard antiemetic treatment regimen was superior 
in preventing CINV and was well tolerated compared 
to the ST alone in Chinese patients undergoing 
cisplatin therapy. 
Keywords: high-dose cisplatin, Aprepitant, CINV
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Methods: NSCLC patients with radiographic 
veriÀcation of BM were treated with at least one 
kind of BPs in this prospective observational study. 
NTX, SRE incidence and adverse event (AE) data 
were collected at baseline and every 3 months after 
treatment. Treatment continued at least until death. 
NTX levels were characterized as normal (N; <50 
nmol/mmol) or elevated (E;  50 nmol/mmol).
Results: 576 patients were enrolled with a median 
follow-up of 3.3 months, of whom 574 were eligible 
for analysis. 14.0% of patients had BM diagnosed 
using only one method (X-ray or CT or ECT). Most 
patients had a combination of methods; the most 
common combination was CT+ECT, accounting 
for 21.1%, and the combination of four (X-ray 
+CT+MRI+ECT) accounted for 9.7%. The E 
baseline NTX patients were 374 (66.6%). Patients 
with multiple BM (465 pts, 81.0%) had signiÀcantly 
higher NTX baseline level than those with single 
BM (108.9 VS 67.3 nmol/mmol, p=0.0003). In 
the overall population, progression free survival 
(PFS) and overall survival (OS) were 5.8 and 14.7 
months respectively. There were no differences 
between patients with baseline E vs N NTX in both 
PFS (6.1 VS 5.4 months, p=0.26) and OS (16.9 VS 
13.3 months, p=0.45), however, normalized NTX 
correlated with improved OS versus persistently 
elevated NTX (>19 VS 15.6 months, p=0.04). The 
median time to Àrst SRE was 2.86 months. The 
overall SRE incidence was 21.7%. There was no 
difference in SRE incidence between patients with 
E and N baseline NTX (21.1 VS 21.8%, p=0.85), 
but zoledronic acid (ZOL) treated patients had a 
signiÀcantly lower SRE incidence than those with 
non-ZOL BPs (22.0 VS 38.6%, p=0.01). All BPs 
were generally well-tolerated, and fever was the 
most common AE (4.51%).
Conclusion: The most common diagnosis method 
of BM is combination of CT and ECT in Chinese 
NSCLC patients. The baseline NTX characteristics 
were nearly consistent with prior retrospective 
studies. Elevated baseline NTX indicated high SRE 
incidence; normalized NTX after BP treatment could 
be a prognostic biomarker for a better PFS and OS. 
ZOL could signiÀcantly reduce the SRE incidence 
more than other BPs.
Keywords: NSCLC, bone metastases, 
bisphosphonate, N-telopeptide
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
dexamethasone could be sustained for up to 
six cycles of cisplatin-based HEC. These data 
conÀrm that adequate control in the Àrst cycle of 
chemotherapy is more likely to be associated with 
control of CINV in subsequent cycles.
Keywords: Highly Emetogenic Chemotherapy, 
Palonosetron, Aprepitant
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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O41.05 A MULTI-CENTER, 
PROSPECTIVE STUDY ON THE 
EFFICACY AND SAFETY OF 
BISPHOSPHONATE (BP) IN NON-
SMALL CELL LUNG CANCER (NSCLC) 
PATIENTS WITH BONE METASTASES 
(BM) AT DIAGNOSIS (C-TONG-0801)
Yi-Long Wu1, Li Zhang2, Caicun Zhou3, Shun Lu4, 
Yiping Zhang5, Mei Hou6, Wenchao Liu7, Jie Wang8, 
Gongyan Chen9, Yun Zhou10, Jun Liang11, Shiying 
Yu12, Chong-Rui Xu13 
1Guangdong Lung Cancer Institute, Guangdong 
Academy Of Medical Sciences & Guangdong 
General Hospital/China, 2Medical Oncology, Sun 
Yat-sen University Cancer Center/China, 3Shanghai 
Pulmonary Hospital, Tongji University/China, 
4Shanghai Chest Hospital, Jiaotong University/
China, 5Zhejiang Cancer Hospital/China, 6West 
China Hospital Of Sichuan University/China, 7The 
4th Military Medical University Xijing Hospital/
China, 8Department Of Thoracic Oncology, Beijing 
Cancer Hospital And Institute/China, 9The Cancer 
Hospital Of Harbin Medical University, Harbin 
Medical University/China, 10Henan Provincial 
Hospital/China, 11The AfÀliated Hospital Of Qingdao 
University/China, 12Tongji Hospital/China, 13Cancer 
Center, Guangdong General Hospital/China
Background: A retrospective study showed 
that bone metastatic NSCLC patients with high 
N-telopeptide (NTX) at diagnosis demonstrated a 
higher risk of skeletal related event (SRE) and death 
than that with lower NTX (Lipton et al. Cancer, 
2008). The present study was to observe the efÀcacy 
and safety of BPs in Chinese NSCLC patients with 
BM, to investigate NTX changes after treatment and 
longitudinal evaluation of BM diagnostic methods. 
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In this pooled analysis of European data, 87 of 
214 SREs (40.7%) were associated with inpatient 
stays with a mean duration of 17.7 (SD=14.9) days 
per inpatient stay for the 92 stays (a SRE could 
contribute multiple hospitalisations). The length 
of inpatient stays varied by facility (i.e., oncology, 
radiation, surgical) and SRE type. The most common 
SRE requiring hospitalisation was spinal cord 
compression (12 of 15 events [80%]) with 14 in-
patient stays requiring an average length of stay 
of 18.7 (SD=12.3) days. The least common SRE 
requiring hospitalisation, radiation to bone (43 of 
140 events [30.7%]), was still associated with 44 in-
patient stays with an average of 19.7 (SD=17.2) days 
per in-patient stay. Of the 214 SREs, 146 (68.2%) 
required an outpatient visit and 29.5% required >5 
visits. As expected, radiation to bone was associated 
with the highest number of outpatient visits (of the 
140 SREs, 80.0% were associated with an outpatient 
visit). Surgery to bone and spinal cord compression 
were associated with the least number of outpatient 
visits with 38.1% of 21 SREs and 40% of 15 SREs 
requiring a visit, respectively. Only 3.3% of 214 
SREs were associated with an emergency room visit. 
Conclusion: SREs in patients with advanced lung 
cancer and bone metastases are associated with 
lengthy hospitalisations and numerous outpatient 
visits. The need for pain control may also have led 
to hospitalisation, although these data were not 
speciÀcally collected. Thus, HRU estimated in this 
study might underestimate the overall HRU among 
lung cancer patients with SREs. The majority 
of SREs (96.7%) in lung cancer patients are not 
associated with an emergency room visit, likely as a 
result of emergency care provided by the specialist 
oncology unit. This may also be impacted by the 
short residual life expectancy of a lung cancer 
patient. Preventing SREs may substantially reduce 
the burden of costly HRU in different European 
healthcare systems.
Keywords: Skeletal-related events, Health resource 
utilisation, bone metastases
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O41.06 HEALTH RESOURCE 
UTILISATION ASSOCIATED WITH 
SKELETAL-RELATED EVENTS IN 
LUNG CANCER PATIENTS WITH 
BONE METASTASES: A PROSPECTIVE 
MULTINATIONAL OBSERVATIONAL 
STUDY
Vito Lorusso1, Ignacio Duran2, Guy Hechmati3, 
Cristina Garzon-rodriguez4, Diana Lüftner5, John 
Ashcroft6, Amit Bahl7, Prayashi Ghelani8, Rachel 
Wei9, Emma Thomas10, Herbert Hoefeler11 
1Medical Oncology Unit, Oncology Institute Asl/
Italy, 2Centro Integral Oncologico Clara Campal 
(ciocc)/Spain, 3Amgen (Europe) Gmbh/Switzerland, 
4Instituto Catalán Oncología ICO-IDIBELLl/Spain, 
5Universitätsmedizin Berlin/Germany, 6PinderÀelds 
General Hospital/United Kingdom, 7University 
Hospitals Bristol/United Kingdom, 8Ovatech 
Solutions/United Kingdom, 9Amgen Inc/United 
States Of America, 10ScientiÀc Publications, Amgen 
(Europe) Gmbh/Switzerland, 11Forschungszentrum 
Ruhr/Germany
Background: Skeletal-related events (SREs) 
are common in patients with bone metastases 
secondary to lung cancer and may be associated 
with increased patient morbidity. However, limited 
data on the related economic burden are available in 
the literature. This information may assist in future 
resource planning and in estimating the value of 
treatment options.
Methods: Patients with bone metastases secondary 
to breast, lung or prostate cancer or multiple 
myeloma; at least one SRE within 90 days prior to 
enrollment; life expectancy >6 months; ECOG2, 
were enrolled. Health-resource utilisation (HRU) 
associated with SREs (spinal cord compression, 
surgery to bone, pathologic fracture or radiation 
to bone) was collected retrospectively for 90 days 
prior to enrollment and prospectively for up to 18-
21 months. HRU type included number and length 
of inpatient hospitalisations, outpatient visits, 
emergency room visits, nursing home/long-term care 
facility stays, home health visits, procedures and 
medications. Attribution of HRU was determined by 
the investigators. This European analysis includes 
data for lung cancer patients from centres in 
Germany, Italy, Spain and UK.
Results: A total of 135 eligible patients with lung 
cancer from the four countries entered the study. 
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Background: Retrospective subset analyses of 
JBR.10 and CALGB-9633 suggest survival beneÀt 
from ACT in stage IB NSCLC patients with tumors 
4cm. However, patients with KRAS mutant tumors 
did not appear to beneÀt from ACT. The 7th edition 
TNM (TNM-7) classiÀcation incorporates new 
T-size descriptors and upstages N0 patients with 
tumors >5cm. We previously showed (Chicago 
Multidisciplinary Symposium in Thoracic Oncology, 
2010) that increasing tumor size, according to 
TNM-7 T-size descriptors, was associated with 
poor prognosis, and may be predictive of greater 
ACT beneÀt. Here, the LACE-bio group study the 
interaction between the prognostic values of T-size 
and KRAS mutations, and the interaction between 
T-size and KRAS mutations in predicting overall 
(OS) and disease-free survival (DFS) beneÀt from 
ACT. We pool data from JBR.10 and CALGB-9633 
as both recorded accurate tumor size. 
Methods: Pre-treatment tumor specimens were 
evaluated for KRAS mutations (codons 12, 13, 
61). JBR.10 and CALGB-9633 N0 patients were 
reclassiÀed as T2a (>3-5cm), T2b (>5-7cm), 
T3 (>7cm) or T3cm (T3cm with other T2 
characteristics). T3cm patients (68 with KRAS 
data) were excluded from analyses to avoid 
confounding bias. The T2b and T3 subgroups 
were pooled due to limited number of events. Cox 
models stratiÀed by trial and adjusted for age, sex, 
PS, histology and surgical procedure were used for 
survival analyses. 
Results: Of 218 JBR.10 and 320 CALGB-9633 
N0 patients with T-size data, 288 (54%) were T2a, 
111 (20%) T2b, 62 (12%) T3 and 77 (14%) T3cm. 
KRAS was evaluable for 207/218 (95%) JBR.10 
and 252/320 (79%) CALGB-9633 patients. KRAS 
mutations were detected in tumors of 107/391(27%) 
patients included in the Ànal study population. 
Increasing T-size was not associated with an 
increased rate of KRAS mutations (p=0.58). Overall, 
a signiÀcant interaction between the prognostic 
value of KRAS mutations and that of tumor size was 
observed for OS (p=0.009), but not DFS (p=0.09). 
The presence of KRAS mutations signiÀcantly 
increased the risk of death only in T2b-T3 (HR 2.20 
[1.27-3.81] p=0.005), but not T2a patients (HR 
0.87 [0.53-1.41], p=0.56). BeneÀt from ACT was 
suggested in T2a patients with wild-type tumors 
(HR 0.82 [0.52-1.29], p=0.39), but not in those 
with KRAS mutant tumors (HR 1.81 [0.79-4.16], 
p=0.51); however, signiÀcant differences were not 
seen in either subset, and the test for interaction was 
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O42.01 A POOLED EXPLORATORY 
ANALYSIS OF THE IMPACT OF TUMOR 
SIZE AND KRAS MUTATIONS ON 
SURVIVAL BENEFIT FROM ADJUVANT 
PLATINUM-BASED CHEMOTHERAPY 
(ACT) IN NODE NEGATIVE (N0) NON-
SMALL CELL LUNG CANCER (NSCLC)
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resected in Ontario between 2001 and 2006. We 
linked this data to electronic records of treatment. 
We compared the uptake of ACT across the age 
groups: <70, 70-74, 75-79 and >80 years. As a 
surrogate of ACT beneÀt, we compared survival 
of patients undergoing surgical resection in 2004-
2006 to those treated in 2001-2003. This reÁected 
reporting of pivotal ACT studies in 2004. As a proxy 
of treatment related toxicities, we evaluated records 
of hospitalization within 6 months of surgery.
Results: Between 2001-2006, 2763/6304 (44%) 
NSCLC patients surgically resected in Ontario 
were elderly (70 years). Older patients were 
more often male, had increased co-morbidities and 
longer postoperative hospitalizations. They were 
signiÀcantly less likely to have adenocarcinoma, 
receive treatment at a regional cancer center, 
or undergo pneumonectomy than their younger 
counterparts. Among the elderly population, 
uptake of ACT signiÀcantly increased from 3.3% 
in 2001-2003 to 16.2% in 2004-2006 (p<0.001). 
Age, geographical region, and pathological stage 
were independently associated with receipt of ACT 
in the elderly. Uptake of ACT declined with age: 
43% in <70yrs, 23% in 70-74yrs, 13% in 75-79yrs 
and 5% in 80+yrs during 2004-2006 (p<0.001). 
Among evaluable cases, 70% of the elderly 
received cisplatin, 28% carboplatin compared to 
85% and 14%, respectively, of younger patients 
(p=0.005). Cisplatin/vinorelbine was the regimen 
of choice in 66% of elderly patients. Rates of drug 
substitutions, dose reductions or dose omissions 
during chemotherapy did not differ signiÀcantly 
between the age groups. Over the study period, 4 
year survival of the elderly increased from 47.1% 
in 2001-2003 to 49.9% in 2004-2006, suggesting 
a signiÀcant survival beneÀt from ACT (p=0.01). 
Furthermore, rates of hospitalization within 6 months 
of surgery in the elderly declined from 40% in 2001-
2003 to 38.3% in 2004-2006, suggesting adoption of 
ACT was well tolerated in this population. Finally, 
there were no signiÀcant differences between the age 
groups with respect to rates of hospitalization with 
6-24 weeks of surgery (p=0.54).
Conclusion: Uptake of ACT for NSCLC has 
increased in the elderly, but continues to lag behind 
that of younger patients. Adoption of ACT in the 
elderly was associated with a signiÀcant survival 
beneÀt, with similar tolerability and toxicity to that 
seen in the younger population. Our Àndings conÀrm 
that the beneÀts of ACT in the elderly, suggested 
by the relevant clinical trials, are being realized in 
non-signiÀcant (p=0.10). Similarly, among T2b-T3 
patients, there was a non-signiÀcant suggestion of 
beneÀt from ACT in those with wild-type (HR 0.82 
[0.45-1.51], p=0.53), but not in those with KRAS 
mutant tumors (HR 1.22 [0.52-2.88), p=0.64) 
(interaction p=0.46). Finally, a three-way interaction 
between KRAS, treatment and tumor size was not 
signiÀcant (OS p=0.58, DFS p=0.93). 
Conclusion: KRAS mutations may identify a subset 
of N0 patients with tumors >5cm who have a worse 
prognosis. In all N0 patients, trends for survival 
beneÀt from ACT were seen only in KRAS WT 
patients, but this relatively small study could not 
demonstrate signiÀcant interaction for ACT beneÀt 
based on T-size and/or KRAS. Supported by: French 
Cancer League, National Cancer Institute, Canadian 
Cancer Society. 
Keywords: KRAS mutation, Tumor size, Non-small 
cell lung cancer, Adjuvant chemotherapy
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O42.02 UPTAKE OF ADJUVANT 
CHEMOTHERAPY, ITS TOLERABILITY 
AND IMPACT ON SURVIVAL AMONG 
ELDERLY NON-SMALL CELL LUNG 
CANCER PATIENTS IN ONTARIO: A 
POPULATION-BASED OUTCOMES 
STUDY
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Background: Non-small cell lung cancer (NSCLC) 
is predominantly a disease of the elderly, with a 
median age at diagnosis of 70 years. Retrospective 
subgroup analyses of JBR.10 and the LACE meta-
analysis suggest that elderly NSCLC patients beneÀt 
from adjuvant chemotherapy (ACT) with acceptable 
toxicity. However, it is known that many elderly 
NSCLC patients are never referred for consideration 
of ACT. Here, we evaluate the uptake of ACT, its 
tolerability and impact on outcome, by age group, in 
the general population of Ontario.
Methods: Using the Ontario Cancer Registry, we 
retrospectively identiÀed all NSCLC cases surgically 
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for this interim toxicity analysis included randomization 
at least one year prior to the data pull (February 
23, 2011). Fisher’s exact test was used to test for 
differences in categorical data; Wilcoxon rank sum test 
was used to test for differences in continuous variables. 
Toxicities were graded using CTCAE v 3.0.
Results: Included here are 591 patients (enrolled 
Aug 2007-Feb 22, 2010) (299 chemotherapy/292 
chemotherapy plus bevacizumab) median age 61 (range 
35-86 year old), 360 (61%) ECOG PS 0, 307 (52%) 
women, 521 (88%) white, 318 (54%) adenocarcinoma, 
180 (31%) squamous histology. Stages enrolled were: 
137 (23%) IB, 259 (44%) II, 167 (28%) IIIA-N2, 
23 (4%) IIIA-T3N1 and only a minority had had a 
pneumonectomy 75 (13%). All demographic features 
were well balanced. Adjuvant chemotherapy regimen 
was CV- 160 (27%), CD- 196 (33%), CG- 155 (26%), 
CP- 82 (14% - limited to non-squamous histology), 
balanced by arm. There is a signiÀcant increase in 
risk of grades 3/4 hypertension (2.0 vs. 19.6%, p less 
than 0.001), proteinuria (0.7 vs. 3.2%, p equal 0.03), 
abdomen pain (0.3 vs. 4.6%, p equal 0.001), and overall 
grade 3/4 toxicity (68.0% vs. 84.0%, p less than 0.001) 
associated with bevacizumab. Grade 5 toxicity rates 
were not signiÀcantly different at 2.4% vs 3.6% without 
or with bevacizumab, p equal 0.46. Only 1 case each of 
fatal hemoptysis and non-fatal bronchopleural Àstula 
have been seen in patients receiving bevacizumab.
Conclusion: This report provides interim 
demographic safety data for E1505, revealing no 
unexpected toxicities. Enrollment challenges include 
lack of adequate lymph node sampling in otherwise 
eligible patients. The study remains open to accrual 
with projected enrollment completion in 2013.
Keywords: Adjuvant chemotherapy, bevacizumab
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O42.05 EVALUATION OF PROGRESSION-
FREE SURVIVAL AS A SURROGATE 
ENDPOINT FOR OVERALL 
SURVIVAL WHEN EVALUATING 
THE EFFECT OF CHEMOTHERAPY 
AND RADIOTHERAPY IN LOCALLY 
ADVANCED LUNG CANCER USING 
DATA FROM FOUR INDIVIDUAL 
PATIENT DATA META-ANALYSES
Audrey Mauguen1, Stefan Michiels2, Sarah Burdett3, 
Jayne F. Tierney3, William Sause4, Sumithra J. 
Mandrekar5, Suzanne E. Dahlberg6, Frances A. 
Shepherd7, Mahesh Parmar8, Michael C. Perry9, 
the general population. Efforts to understand and 
improve the underutilization of ACT among elderly 
NSCLC patients should be prioritized in health care 
planning.
Keywords: Adjuvant chemotherapy, Elderly, Non-
small cell lung cancer
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O42.03 INTERIM REPORT OF ON-STUDY 
DEMOGRAPHICS AND TOXICITY FROM 
EASTERN COOPERATIVE ONCOLOGY 
GROUP (ECOG) E1505, A PHASE III 
RANDOMIZED TRIAL OF ADJUVANT 
CHEMOTHERAPY WITH OR WITHOUT 
BEVACIZUMAB FOR COMPLETELY 
RESECTED EARLY STAGE NON-SMALL 
CELL LUNG CANCER (NSCLC)
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Background: Adjuvant chemotherapy has been shown 
to improve absolute survival after resection of early 
stage NSCLC by 5-15%. Encouraging results with 
bevacizumab on E4599 in advanced stage NSCLC led 
to trial development of bevacizumab with adjuvant 
chemotherapy.
Methods: E1505 aims to enroll 1500 patients with 
resected stage IB (at least 4 cm in size) - IIIA (by 
AJCC 6) NSCLC. All patients receive 4 x 3 week 
cycles of doublet chemotherapy with cisplatin (C) 
plus vinorelbine (V), docetaxel (D), gemcitabine (G) 
or pemetrexed (P). The pemetrexed option was added 
in 2009. Patients are randomized 1:1 to chemotherapy 
alone or chemotherapy plus bevacizumab 
(bevacizumab continued up to 1 year). Inclusion criteria 
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0.88 and 0.92) and trial level (R correlations between 
0.94 and 0.99). Considering PFS events occurring 
in the Àrst two years and OS events in the Àrst Àve 
years, trial-level correlations were lower but still 
strong (R between 0.87 and 0.97). 
Studied 
treatment 
Number of 
trial (patients) 
Number 
of PFS 
events, 
deaths 
% of 
events 
occurring 
in the Àrst 
2 years 
Individual 
level (Ư) 
[95% 
conÀdence 
interval] 
Trial level 
(R) [95% 
conÀdence 
interval] 
Trial level 
(R) [95% 
conÀdence 
interval] 
For PFS 
at 2 years 
and OS at 
5 years 
Sequential 
chemotherapy 
8 trials(1458) 
1375 
events 
1333 
deaths 
90% 
0.88 [0.88-
0.88] 
0.98 [0.95-
1.01] 
0.88 
[0.86-
0.89] 
Concomitant 
chemotherapy 
15 trials(2552) 
2391 
events 
2305 
deaths 
90% 
0.92 [0.92-
0.92] 
0.99 [0.97-
1.00] 
0.97 
[0.94-
1.00] 
Sequential vs. 
concomitant 
chemotherapy 
6 trials(1201) 
1094 
events 
1065 
deaths 
88% 
0.91 [0.91-
0.91] 
0.94 [0.86-
1.03] 
0.87 
[0.67-
1.07] 
ModiÀed 
radiotherapy 
10 trials(2279) 
2166 
events 
2120 
deaths 
84% 
0.91 [0.91-
0.91] 
0.98 [0.96-
1.01] 
0.93 
[0.85-
1.01] 
Conclusion: Our large database provides good 
evidence that progression-free survival is a valid 
surrogate endpoint for overall survival in locally 
advanced lung cancer, when studying both 
chemotherapy and radiotherapy effects. Supported 
by French Cancer League, PHRC and British 
Medical Research Council.
Keywords: surrogate endpoint, Non-small cell lung 
cancer, meta-analysis, survival
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O42.06 FINAL RESULTS AND 
PHARMACOECONOMIC ANALYSIS 
OF A TRIAL COMPARING TWO 
NEOADJUVANT CHEMOTHERAPY (CT) 
REGIMENS FOLLOWED BY SURGERY 
IN PATIENTS WITH RESECTABLE NON-
SMALL CELL LUNG CANCER (NSCLC): 
A PHASE II RANDOMISED STUDY 
BY THE EUROPEAN LUNG CANCER 
WORKING PARTY.
Thierry Berghmans1, Jean-Jacques LaÀtte2, 
Vicente Giner3, Marie-Claude Berchier4, Arnaud 
Scherpereel2, Daniel Lewin1, Marianne Paesmans5, 
Anne-Pascale Meert1, Thierry Bosschaerts6, Nathalie 
Leclercq1, Jean-Paul Sculier1 
Mary O’Brien10, Cécile Le Péchoux11, Jean-Pierre 
Pignon On Behalf Of The Surrogate Lung Project 
Collaborative Group1 
1Service De Biostatistique, Institut Gustave Roussy/
France, 2Institut Jules Bordet/Belgium, 3Meta-
analysis Group, Mrc Clinical Trials Unit/United 
Kingdom, 4Intermountain Medical Center/United 
States Of America, 5Mayo Clinic/United States Of 
America, 6Dana-Farber Cancer Institute & Harvard 
School Of Public Health/United States Of America, 
7Medical Oncology, Princess Margaret Hospital/
Canada, 8Clinical Trial Unit London, Medical 
Research Council/United Kingdom, 9Cancer And 
Leukemia Group B Statistical Center/United States 
Of America, 10Lung Unit, Royal Marsden Hospital/
United Kingdom, 11Institut Gustave Roussy/France
Background: In randomized trials studying the 
effect of chemotherapy or radiotherapy in locally 
advanced lung cancer, the gold standard endpoint 
is overall survival, which is simple to measure 
and reliable. However, a long follow-up period is 
required to reach this endpoint. The objective of this 
study is to evaluate if progression-free survival could 
be used as a surrogate endpoint for overall survival 
in these settings, in order to shorten trial duration.
Methods: Individual patient data from three 
meta-analyses (29 trials) studying the effect of 
chemotherapy in patients with locally advanced non-
small cell lung cancer and one meta-analysis (10 
trials) studying the effect of modiÀed radiotherapy in 
patients with both small cell and non-small cell lung 
cancer were used. Progression-free survival (PFS) 
was deÀned as the time from randomization to the 
Àrst event (local or distant recurrence or death from 
any cause). Overall survival (OS) was deÀned as the 
time from randomization to death from any cause. 
Surrogacy ability was validated through a correlation 
approach: at individual level, the coefÀcient Ư 
estimated the association between distributions of 
the two endpoints; at trial level, the coefÀcient R 
estimated the association between treatment effect on 
PFS and OS. Values of Ư and R closer to 1.0 would 
indicate strong surrogacy.
Results: Sequential chemotherapy analysis included 
8 trials (1458 patients), concomitant chemotherapy 
analysis included 15 trials (2552 patients) and 
sequential versus concomitant chemotherapy 6 trials 
(1201 patients); modiÀed radiotherapy analysis 
included 10 trials (2279 patients). As shown in 
table below, correlations between PFS and OS were 
strong, both at the individual (Ư correlations between 
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Conclusion: While both neoadjuvant chemotherapy 
regimens shared similar efÀcacy in patients with 
resectable NSCLC, costs were signiÀcantly higher 
for second-generation drugs.
Keywords: Non small cell lung carcinoma, Surgery, 
neoadjuvant chemotherapy, Cost-effectiveness
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O42.07 MAGE-A3 VACCINATION IN THE 
ADJUVANT SETTING FOLLOWING 
RESECTION FOR EARLY STAGE LUNG 
CANCER: TOLERABILITY AND LONG-
TERM SURVIVAL.
Nasser Altorki1, Jeff Port1, Sacha Gnjatic2, Achim 
Jungbluth2, Yao Chen3, Djordje Atanackovic2, Gerd 
Ritter2, Farooq Mirza1, Lloyd Old2 
1Cardiothoracic Surgery, Weill Cornell Medical 
Center/United States Of America, 2Ludwig Institute 
For Cancer Research New York/United States Of 
America, 3Weill Cornell Medical Center/United 
States Of America
Background: MAGE- A3, a member of the 
cancer testis (CT) antigen super-family, is the most 
commonly expressed CT antigen in non-small-cell 
lung cancer (NSCLC). Given its highly restricted 
pattern of expression in normal tissue, it is a prime 
candidate for cancer vaccines. We have previously 
reported that MAGE- A3 expression is negatively 
correlated with survival in patients with resected 
NSCLC. Here we report the long- term results of 
a phase 2 trial of MAGE- A3 vaccination in the 
adjuvant setting after resection of MAGE- A3 positive 
NSCLC. 
Methods: We conducted an open label Àxed- dose 
phase 2 trial of MAGE- A3 vaccination in early 
stage NSCLC. Eligible patients included completely 
resected stage I/II NSCLC patients whose tumors 
were MAGE- A3 positive by RT- PCR. MAGE- A3 
(300 g) with (n=12) or without ASO2B (n=7) was 
given by alternating IM injection every 3 weeks 
for a total of 4 doses. Immunological response, the 
primary endpoint of the trial, was previously reported. 
In this report, we present clinical outcome measures 
including adverse events (AE’s) and long-term 
survival. Survival was determined by the KM method 
and was calculated from the date of surgery to the date 
of last follow-up or death. For comparative purposes, 
we matched the study group to 38 patients (2:1) from 
an institutional lung cancer database based on age, 
1Intensive Care And Thoracic Oncology, Institut 
Jules Bordet/Belgium, 2Pneumology, Chru Lille/
France, 3Oncology, Hospital De Sagunto/Spain, 
4Pneumologie, Centre Hospitalier Alpha Santé/
France, 5Data Centre, Institut Jules Bordet/Belgium, 
6Thoracic Surgery, Hôpital Saint-Pierre/Belgium
Background: (Neo)adjuvant cisplatin-based CT 
improving survival in resectable NSCLC, we aimed to 
determine the respective activity of second-generation 
drugs regimen (« GNP ») in comparison with Àrst-
generation drugs based CT (« MIP ») as well as the cost-
effectiveness.
Methods: Patients with previously untreated 
pathologically proven stage I-IIIA resectable NSCLC, 
Karnofsky performance status  60, adequate 
haematological, hepatic, renal, lung and cardiac 
functions were eligible. After central randomisation, 
patients received three courses of MIP (ifosfamide 3g/
m², mitomycin 6 mg/m², cisplatin 50 mg/m²) or GNP 
(gemcitabine 1g/m² D1-8, vinorelbine 25 mg/m² D1-
8, cisplatin 50 mg/m²). The conclusion for feasibility 
of each regimen will be drawn if, at least, 50 patients 
per arm within a sample size of 67 can be completely 
resected (a 5%, b 20%). A cost minimisation analysis, 
considering the direct medical costs, was performed 
separately in the Belgian (Bordet Institute) and French 
(CHU Lille) social security systems.
Results: From 2001 to 2007, 140 eligible patients 
were randomised (MIP 69, GNP 71), without any 
signiÀcant imbalance between both arms. The main 
characteristics were: stage I/II/III in 52, 37 and 51 pts, 
squamous histology in 82 pts, male 114 pts, median 
PS 90. Objective response rates to induction CT were 
60% (MIP) and 65% (GNP) (p = 0.55). 119 patients 
underwent surgery. Complete resection rates were 77% 
(MIP) and 80% (GNP) (p = 0.62). No difference in 
postoperative complications was noted (p = 0.18). At the 
time of analysis (January 2011), 39 (MIP) and 46 (GNP) 
deaths were documented. Median survival times were 
47.2 months (MIP) and 36.6 months (GNP) (p = 0.41). 
In the absence of difference between both arms, we 
performed a cost analysis in a subgroup of 58 patients: 
Belgium France 
MIP GNP p MIP GNP p 
Overall assessment (n=58) 
Mean overall cost (€) 9119 11663 0.009 19618 18998 >0.05 
Cost assessment for patients receiving full treatment (CT plus surgery) 
(n=44) 
Mean overall cost (€) 9471 12815 0.0006 16434 21010 0.047 
D8 chemotherapy (€) 0 1677 0 2944 
Chemotherapy drugs (€) 592 1200 0 1677 
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1Multidisciplinary Thoracic Oncology Program, 
Lineberger Comprehensive Cancer Center/United 
States Of America, 2City Of Hope/United States 
Of America, 3Premiere Oncology/United States 
Of America, 4Piedmont Hematology Oncology 
Associates/United States Of America, 5Vanderbilt 
Ingram Cancer Center/United States Of America, 
6Synta Pharmaceuticals/United States Of America, 
7Dana-Farber Cancer Institute/United States Of 
America
Background: Ganetespib, a potent, non-
geldanamycin small molecule Hsp90 inhibitor has 
shown superior preclinical activity and improved 
safety proÀle compared to ansamycins (17-AAG). 
Ganetespib is broadly active in multiple highly-
resistant cancer models. Preclinical data support 
evaluation of Hsp90 inhibitors in NSCLC driven by 
a variety of mutant oncogenic proteins.
Methods: Patients (pts) with progressing advanced 
NSCLC who failed standard of care treatments 
received 200 mg/m2 ganetespib as a 1-hr infusion 
once weekly for 3 of a 4-wk cycle in a Simon two-
stage study design assessing primary endpoint of 
PFS rate at 16 wks. Patient cohorts were deÀned by 
mutation status: A) mEGFR B) mKRAS, C) EGFR 
and KRAS wild type (WT). If 2/14 pts in A, B 
or C were progression-free at 16 wks, enrollment 
increased to 23 pts for that cohort. Tumor response 
was assessed every 8 wks. Cohort D was later 
added to include 35 additional EGFR and KRAS 
WT pts with adenocarcinoma histology. Additional 
mutational analysis of BRAF, PIK3CA, ERBB2 
and MET, as well as FISH analysis for ALK 
translocation, were performed in a subset of patients.
Results: 73 pts (31 M, 42 F; median age 62 yrs, 
range 28-82; ECOG 0-1; prior therapies range 
1-10) received a median of 2 cycles (range 1-12) 
of ganetespib in cohorts A (14), B (17), and C+D 
(42). AEs reported in 20% of pts included diarrhea, 
fatigue, nausea, anorexia, constipation, and dyspnea 
and were generally grade 1-2. Cohort expansion 
criteria were met for cohort C, including a durable 
partial response (PR) and seven pts with stable 
disease 16 wks. Cohort D continues recruitment 
with preliminary results of two conÀrmed PRs. 
Genetic proÀling data will be presented.
Conclusion: Ganetespib administered as a single 
agent is well tolerated in pts with NSCLC at 200 
mg/m2 once weekly with absence of serious liver 
or common ocular toxicities seen with other hsp90 
inhibitors. Clinical activity has been observed in 
gender, and pathologic stage (table 1). 
Results: 19 patients were vaccinated between 11/2000 
and 4/2003. Median age was 64 and the majority 
were women (n=12). Clinical, demographic, and 
pathologic variables are shown in table 1. Median 
follow- up was 108 months for surviving patients. 
For study patients, Àve- year disease free survival 
(DFS) was 79% and lung cancer- speciÀc survival was 
89%. Corresponding Àve- year DFS and lung cancer- 
speciÀc survival in the matched control group were 
55% and 75% (p= 0.16 and 0.05, respectively). The 
majority of AEs were CTC grades 0-2. Only 6 AEs 
were CTC grade 3 and none were grade 4. 
CASE CONTROL p-value 
N 19 38 
age median/range 64 / 49-85 64.5/ 47-83 0.912 
gender 
male 7 (36.8%) 14 (36.8%) 
1 
female 12 (63.2%) 24 (53.2%) 
pathologic stage 
IA 7 (36.8%) 15 (39.5%) 
0.996 
IB 5 (26.3%) 9 (23/7%) 
IIA 2 (10.5%) 4 (10.5%) 
IIB 5 (26.3%) 10 (26.3%) 
cell type 
squamous 6 (31.6%) 6 (15.8%) 
0.168 
non- squamous 13 (68.4%) 32 (84.2%) 
pack year median/range 50/ 30-110 40/ 0-150 0.185 
Conclusion: In this phase 2 trial, MAGE-A3 
vaccination in the adjuvant setting was well-tolerated 
and was associated with encouraging DFS and lung 
cancer- speciÀc survival at 5 years. The results of the 
ongoing international randomized trial (MAGRIT) 
are eagerly anticipated. 
Keywords: MAGE-A3, Vaccine, NSCLC
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O43.01 AN OPEN-LABEL PHASE II 
STUDY OF THE HSP90 INHIBITOR 
GANETESPIB (STA-9090) IN PATIENTS 
WITH ADVANCED NON-SMALL CELL 
LUNG CANCER (NSCLC)
Mark A. Socinski1, Marianna Koczywas2, Jonathan 
Goldman3, Eugene Paschold4, Leora Horn5, 
Joelle Lufkin6, Ronald K. Blackman6, Florentina 
TeoÀlovici6, Geoffrey Shapiro7 
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consisted in 5 doses, 1 every 14 days (induction period), 
followed by a maintenance period (1 dose every 28 
days) until patient refusal or worsening of ECOG status. 
Results: Safety: The most common adverse events 
were mild and moderate reactions at the injection site 
(pain, erythema, induration) and “Áu-like” symptoms, 
none unexpected. No differences were observed 
between both groups. Overall Survival: Intent to Treat 
Analysis (ITT): Data presented corresponds to 132/176 
patients (75% of the sample), who had been followed 
for  8 months. Median OS is 8.23 months in Arm B 
and 6.17 months in Arm A (log rank test, p= 0.036). 
Long- term OS rate (%) at 24 months: 19.4% in Arm B 
and 7.7% in Arm A. Per Protocol Population Analysis 
(PPP): Shown data only include patients who have 
received  5 doses of vaccine (92/132 patients, 70% 
of the patients in the database). Median OS was 10.97 
months in Arm B and 6.27 months in Arm A (log rank 
test, p= 0.0115). Long- term OS rate (%) at 24 months: 
24% in Arm B and 6.2 % Arm A. 
Conclusion: 
t Immunization with Racotumomab is safe. 
t There is an OS beneÀt for Arm B, both in ITT and 
PPP analyses. 
t Additional data about this trial will be presented at 
the IASLC meeting. 
Keywords: Cancer vaccines, NSCLC, 
immunotherapy, racotumomab
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O43.03 RANDOMIZED MULTICENTER 
PHASE II CLINICAL TRIAL OF A TOLL 
LIKE RECEPTOR-2 (TLR-2) AGONIST 
MYCOBACTERIUM W (CADI-05) IN 
COMBINATION WITH PACLITAXEL 
PLUS CISPLATIN VERSUS PACLITAXEL 
PLUS CISPLATIN IN ADVANCED NON-
SMALL CELL LUNG CANCER (NSCLC)
Chandra P. Belani1, Bhaswat Chakraborty2, Darshini 
Desai2, Bakulesh M. Khamar2 
1Medicine, Penn State Hershey Cancer Institute/
United States Of America, 2Cadila Pharmaceuticals, 
Ltd/India
Background: TLR2 agonist, Mycobacterium w 
(Cadi-05), an active non-speciÀc immunomodulator 
and pure Th 1 response enhancer has demonstrated 
synergistic effects with a number of chemotherapeutic 
agents. It does not target speciÀc tumor associated 
antigens. A phase II randomized study was conducted 
patients with advanced NSCLC tumors harboring 
wild-type EGFR and KRAS.
Keywords: Non-small Cell Lung Carcinoma, STA-
9090, Hsp90 inhibitor, Ganetespib
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O43.02 ACTIVE SPECIFIC 
IMMUNOTHERAPY WITH 
RACOTUMOMAB IN THE TREATMENT 
OF ADVANCED NON SMALL CELL LUNG 
CANCER (NSCLC).
Amparo Macías1, Saily Alfonso2, Eduardo 
Santiesteban3, Darien Toledo4, Carmen Viada4, Ivis 
Mendoza5, Pedro P. Guerra5, Maria L. Ardigo6, 
Roberto E. Gómez6, Ana M. Vazquez4, Tania 
Crombet4, Rolando Pérez4, Agustín Lage4 
1Clnical Research Unit, Center Of Molecular 
Immunology/Cuba, 2Oncology Unit, University 
Hospital Celestino Hernández Robau/Cuba, 
3Oncology Unit, Hospital José Ramón Tabranes/
Cuba, 4Center Of Molecular Immunology/Cuba, 
5National Clinical Trial Coordinator Center/Cuba, 
6Elea Laboratories/Argentina
Background: Gangliosides are an attractive target for 
immunotherapy in cancer since they are not expressed in 
normal human tissue, are overexpressed in several solid 
tumors, including NSCLC, and have been implicated 
in tumor development and progression. Racotumomab 
is an antiidiotype murine monoclonal antibody 
speciÀc to P3 Ab1 MAb, an antibody that reacts with 
NeuGc-containing gangliosides, sulfatides and other 
antigens expressed in tumors. Phase I trials conducted 
in advanced melanoma, breast and lung cancer have 
demonstrated the low toxicity and high immunogenicity 
of Racotumomab. 
Methods: A phase II multicenter, controlled, 
randomized, double blind trial is ongoing to evaluate 
the effect of Racotumomab in Overall Survival (OS) 
in patients with advanced (IIIB and IV) NSCLC 
who have completed onco-speciÀc treatment as 
per the Oncology Therapeutic Guidelines (surgery, 
chemotherapy, radiotherapy according to initial staging) 
and have achieved partial, complete response or disease 
stabilization. ECOG status was < 2 and life expectancy 
 4 months. Vaccination began 4-8 weeks after the end 
of the onco-speciÀc treatment. Prior chemotherapy 
in most cases was cisplatin/ vinblastin (4 - 6 cycles). 
Patients were randomized (1:1) to control group 
(placebo) or vaccine (Racotumomab). Vaccination 
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Wilfried Eberhardt12, Andrew Hughes13, Sebastien 
Lavialle14, Dominique Mery-mignard14, Silvia 
Novello15 
1Department De Medicine Oncologique, Institut 
Gustave-Roussy,/France, 2Hospital Vall D’hebron, 
Barcelona/Spain, 3Hôpital Sainte Marguerite, 
Marseille/France, 4Hôpital Larrey, Toulouse/
France, 5Chu, Côte De Nacre/France, 6Asklepios 
Fachkliniken München-gauting, Gauting/Germany, 
7Krankenhaus Großhansdorf Gmbh, Großhansdorf/
Germany, 8Oncologia Medica, Livorno/Italy, 9New 
Cross Hospital, Wolverhampton/United Kingdom, 
10Hospital Germans Trias I Pujol, Badalona/
Spain, 11Istituto Clinico Humanitas, Milan/Italy, 
12Universitätsklinikum Essen, Essen/Germany, 
13Northern Centre For Cancer Care, Newcastle/
United Kingdom, 14SanoÀ-aventis, Vitry Sur Seine/
France, 15University Of Turin, Turin/Italy
Background: Iniparib (BSI-201) is a novel 
agent whose mechanism of action is still under 
investigation. It binds to poly (ADP-ribose) 
polymerase-1 (PARP1) in high micromolar 
concentrations. Additional targets are being 
investigated. Iniparib has shown activity in some 
cases of triple-negative breast cancer in combination 
with gemcitabine and carboplatin with an adequate 
safety proÀle. This is the Àrst completed efÀcacy trial 
with iniparib in lung cancer. 
Methods: Eligible subjects had measurable disease 
and received no prior chemotherapy for stage IV 
NSCLC (all histologies). Patients were randomized 
(2:1) to GCI vs GC. Gemcitabine (1250 mg/m2, IV) 
was administered on days 1 and 8, cisplatin (75 mg/
m2, IV) on day 1, and iniparib (5.6 mg/kg, IV) on 
days 1, 4, 8 and 11, every 21 days for a maximum of 
6 cycles. The primary objective is overall response 
rate (ORR, per RECIST 1.1) as assessed by the 
investigator. Secondary objectives included OS, 
PFS, safety and biomarker analysis. Patients were 
stratiÀed by squamous/non-squamous cell carcinoma 
and smoker/never smoker. Baseline biopsy for 
translational research was obtained in 66% of 
patients, and 17% were re-biopsied at the end of the 
Àrst cycle. 
Results: A total of 119 patients were randomized 
between May and November 2010: 80 to GCI (77 
treated) and 39 to GC (all treated). Median age 
was 59 years (29 –73) and 76% were male. 12% 
of patients had squamous cell carcinoma and 70% 
adenocarcinoma histologies; 13 pts (11%) were 
never-smokers. PS 0/1 was 49/51% in the GC arm 
to test the efÀcacy of the combination of paclitaxel 
plus cisplatin with or without Cadi-05 as Àrst line 
treatment of advanced NSCLC. 
Methods: Two hundred and twenty-one treatment 
naïve patients (pts) with stage IIIB and IV NSCLC 
were randomized to receive paclitaxel 175mg/m2 
IV 3-hour infusion and cisplatin 100mg/m2 IV with 
or without Cadi-05 administered intradermally, 0.1 
ml on each deltoid on the Àrst visit at least 1 week 
prior to 1st cycle and then on day 8 and 15 of each 
cycle of chemotherapy. The cycles were repeated 
every 3 weeks for a total of 4 cycles. Cadi-05 was 
administered once a month thereafter until progression 
or for a maximum of 12 months from the start of 
treatment in the investigational arm. The primary 
endpoint of the study was overall survival (OS) and 
the secondary outcome measures were response rate 
(RR) and progression free survival (PFS). 
Results: One hundred twelve pts were randomized 
to the control arm and 109 pts to the Cadi-05 arm. 
Pt demographics were balanced in both the arms. 
The RR was 36% in the control arm and 47 Cadi-05 
arm. There were three complete responses all in the 
Cadi-05 arm. Median PFS was 157 days in control 
arm and was improved by 96 days to 253 days in 
the Cadi-05 arm [p=0.0446; HR 0.43 (95% CI 0.25-
0.73)]. Median OS was 236 days in control arm and 
was improved by 59 days to 295 days in the Cadi-05 
arm [p=0.0034;HR 0.55(95% CI 0.37-0.82)]. There 
were no signiÀcant differences in the adverse events 
in the control arm vs. the Cadi-05 arm. 
Conclusion: Addition of Cadi-05 to Paclitaxel plus 
Cisplatin in patients with advanced NSCLC is safe 
and results in both improvement in PFS and OS. 
(The study is supported by Cadila Pharmaceuticals 
Ltd and is being presented on behalf of the Cadi-05 
investigators study group). 
Keywords: Non-small cell lung cancer, 
Mycobacterium w, Carbotaxol
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O43.04 RESULTS OF A RANDOMIZED 
PHASE 2 TRIAL OF GEMCITABINE/
CISPLATIN/INIPARIB (GCI) VS 
GEMCITABINE/CISPLATIN (GC) IN 
PATIENTS WITH STAGE IV NSCLC
Benjamin Besse1, Enriqueta Felip2, Fabrice Barlesi3, 
Julien Mazieres4, Gérard Zalcman5, Joachim Von 
Pawel6, Martin Reck7, Federico Cappuzzo8, David 
Ferry9, Enric Carcereny10, Armando Santoro11, 
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Oncology Unit, University Of Turin/Italy
Background: AÁibercept (A), a novel recombinant 
human fusion protein, binds to VEGF-A, VEGF-B, 
and PlGF and prevents interaction with their 
receptors, thereby acting as a “decoy receptor”. 
Preclinical and clinical evidence supports the 
evaluation of the combination of A with docetaxel 
(D), an effective agent for the treatment of patients 
with recurrent NSCLC.
Methods: Patients with advanced non-squamous 
NSCLC, PS 0-2, adequate organ function and failure 
of one platinum-based therapy were randomized 
(450 planned per arm) to receive D (75 mg/m²) and 
either A (6 mg/kg) or placebo (Pl) administered 
every 3 weeks. The primary endpoint was overall 
survival (OS). The study had 90% power to detect 
a 22% lower hazard rate for death in the AD group 
after 687 events (log-rank test, overall 2-sided Ơ= 
0.05).
Results: Results of the Ànal analysis of OS 
comparing the two treatment arms will be presented 
as well as the analysis of secondary endpoints, 
including progression-free survival, response rate, 
and safety. Between September 2007 and February 
2010, 913 patients have been randomized, with a 
median follow-up duration of approximately 21 
months. Final results are expected mid-March 2011. 
As the database is not locked, only preliminary 
patient and disease characteristics are available: 
median age 60 yr, male 66%, Caucasians 89%, 
adenocarcinoma 83%, metastatic 90%, measurable 
disease 97%, and PS 0-1 94%.
Conclusion: Late Breaking Abstract : The 
conclusion will be provided with the results. 
Keywords: Angiogenesis inhibitors, Vascular 
endothelial growth factor (VEGF), Phase III clinical 
trials
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
and 61/39% in the GCI arm. More than 60% of 
patients are still receiving treatment as of December 
2010. The full report of efÀcacy data will be 
available for the late-breaking abstract presentation. 
The 2 arms performed similarly in terms of dose 
reduction, dose intensity and percentage of patients 
who discontinued due to tumor progression or 
adverse events. The median number of cycles is 3 in 
both arms. Patients with neutropenia leading to dose 
reduction were more frequently found with GC than 
with GCI: 23.1% vs 10.4% with 2 events of febrile 
neutropenia in the GC arm. Asthenia was also more 
common with GC than GCI (All grades: 66.7% vs 
46.8%; Grade 3/4, 15.4% vs 4.9%). 37% of patients 
missed at least one dose of iniparib. Apart from this, 
the safety proÀle was similar in both arms. 
Conclusion: In metastatic NSCLC, the combination 
of iniparib with standard doses of gemcitabine and 
cisplatin had a safety proÀle similar to that of GC 
alone, and no unexpected toxicities were observed 
with the combination. The efÀcacy of GCI vs GC 
will be available for the late-breaking abstract 
presentation in July 2011. (Clinicaltrials.gov number, 
NCT01086254) 
Keywords: iniparib, BSI-201, NSCLC, PARP
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O43.06 AFLIBERCEPT IN COMBINATION 
WITH DOCETAXEL FOR SECOND-
LINE TREATMENT OF LOCALLY 
ADVANCED OR METASTATIC NON-
SMALL-CELL LUNG CANCER (NSCLC): 
FINAL RESULTS OF A MULTINATIONAL 
PLACEBO-CONTROLLED PHASE III 
TRIAL (EFC10261-VITAL).
Silvia Novello1, Rodryg Ramlau2, Vera A. 
Gorbunova3, Tudor E. Ciuleanu4, Mustafa 
Ozguroglu5, Tuncay Goksel6, Clarissa Baldotto7, 
Jaafar Bennouna8, Frances A. Shepherd9, Giorgio 
Scagliotti10 
1U.O. Oncologia Polmonare, Azienda Sanitaria 
Ospedaliera San Luigi/Italy, 2Wielkopolskie Centrum 
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size was based on a hazard ratio (HR) of 0.80, 
corresponding to a median OS of 9 versus 11.24 
months respectively in the placebo and ASA404 
arms, with type I error of 0.025 & 90% power using 
a 1-sided log rank test. Patient reported outcomes 
(PRO) were assessed using the EORTC QLQ-C30 
questionnaire. 
Results: 1,299 patients were randomized. Baseline 
demographics and disease characteristics were well 
balanced. The trial was stopped for futility at interim 
analysis by the DSMC. EfÀcacy results are shown 
below. 
Endpoint CP + ASA404 
(n=649) 
CP + Placebo 
(n=650) 
Hazard Ratio 
(HR) 
Response Rate 
(CR+PR) 
25% (21.4, 28.2) 25% (21.3, 28.1) N/A 
Median PFS, months 
(95% CI) 
5.5 (5.2, 5.6) 5.5 (5.4, 5.6) 1.04 (0.91, 
1.19), 
Median OS, months 
(95% CI) 
13.4 (11.4, 16.6) 12.7 (11.3, 14.4) 1.01 (0.85, 
1.19) 
Median OS, months, 
non-squamous  
(95% CI) 
15.0 (13.4, 20.8) 13.5 (11.7, 15.3) 0.98 
(0.8,1.19) 
Median OS, months, 
squamous (95% CI) 
8.9 (8.3, 11.9) 10.7 (9, 14.2) 1.1 (0.7,1.5) 
Rate of adverse events (AEs) was comparable 
(ASA404 -98.9%; placebo - 98.2%). The most 
common AEs were neutropenia, alopecia, nausea, 
and fatigue. Grade 4 neutropenia (27% vs. 19%) 
and infusion site pain (10% vs. 0.5%) were more 
frequent with ASA404. Number of on-treatment 
deaths was also similar (ASA404-28; placebo-24). 
PRO analysis showed a signiÀcant decrease in the 
physical functioning domain across both arms at the 
end of treatment. However, global health status/QoL 
domain had no change between arms over time. 
Conclusion: The addition of ASA404 to frontline 
CP, although well tolerated, failed to improve 
efÀcacy or QoL in patients with advanced NSCLC. 
Keywords: Vascular Disrupting Agent, Metastatic 
lung cancer, Phase III Clinical Trial
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O43.07 ATTRACT 1 - PHASE III TRIAL 
OF CARBOPLATIN/PACLITAXEL (CP) 
WITH OR WITHOUT THE VASCULAR 
DISRUPTING AGENT ASA404 IN 
ADVANCED NON-SMALL CELL LUNG 
CANCER (NSCLC): FINAL EFFICACY 
AND QUALITY OF LIFE (QOL) RESULTS
Primo N. Lara1, Jean yves Douillard2, Kazuhiko 
Nakagawa3, Joachim Von Pawel4, Mark J. Mckeage5, 
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Background: Vascular disruption of established 
tumor blood vessels is a novel anti-neoplastic 
strategy. In a randomized phase II trial (McKeage et 
al, Br J Cancer 2008), the vascular disrupting agent 
ASA404 in combination with CP was found to be 
feasible and to improve several efÀcacy parameters 
including overall survival (OS) in patients with 
advanced NSCLC. A global, randomized, double-
blind, placebo-controlled phase III trial of frontline 
CP +/- ASA404 in advanced NSCLC was therefore 
conducted to validate these results. 
Methods: Advanced stage IIIB or IV NSCLC 
patients, stratiÀed by gender and histology, who 
had not previously received systemic therapy for 
metastatic disease, were randomly assigned 1:1 
to receive paclitaxel (200 mg/m2) and carboplatin 
(AUC 6) +/- ASA404 (1,800 mg m2), given IV 
q3 weeks for 6 cycles. Primary endpoint was OS; 
secondary endpoints included response rate (RR), 
progression-free survival (PFS), and safety. Sample 
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Conclusion: A signiÀcant shift has occurred over 
the past 3 decades in the design and interpretation 
of phase III trials in advanced NSCLC. The use of 
median survival as the primary measure of beneÀt is 
declining alongside the magnitude of beneÀt deemed 
clinically relevant. This suggests a shift in the oncology 
community towards an increasing willingness to accept 
lesser beneÀt from new treatments.
Keywords: NSCLC, systemic therapy, Phase III 
Trials
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O44.01 EVOLVING PATTERNS IN THE 
INTERPRETATION OF PHASE III TRIAL 
OUTCOMES IN THE TREATMENT OF 
ADVANCED NSCLC
Adrian Sacher, Natasha Leighl 
Medical Oncology, Princess Margaret Hospital/
Canada
Background: The prognosis associated with advanced 
non-small cell lung cancer (NSCLC) remains grim 
despite decades of trials involving novel systemic 
therapies. Over time, there appears to be an increasing 
willingness to study and adopt treatments with very 
modest clinical beneÀt. Here we examine if the primary 
endpoint, outcome and interpretation of large scale 
clinical trials in advanced NSCLC are changing over 
time.
Methods: A literature search for all phase III randomized 
controlled trials of systemic therapy for advanced 
NSCLC was performed using Pubmed. Publication 
date, primary endpoint, clinical outcomes, statistical 
signiÀcance and conclusions of eligible trials were 
recorded. Aggregate data were compiled by 10-year 
intervals. SigniÀcant differences were determined using 
an unpaired t-test and chi-squared test as appropriate. 
Results: A total of 238 trials were reviewed and 207 
were eligible for inclusion in this study. The primary 
endpoint of these trials shifted signiÀcantly from median 
survival in 1980-1990 (97% of trials) and 1991-2000 
(96%) towards progression free survival in 2001-
2010 (15% progression-free survival, 80% median 
survival; p=0.04 for 1980s vs. 2000s). A similar shift 
was noted in trial outcomes (positive vs. negative) from 
uncommonly positive in 1980-1990 (21% of trials) 
to frequently positive in 1991-2000 (65%) and 2001-
2010 (78%; p=0.009 for 1980s vs. 2000s). A decrease 
in the magnitude of median survival gains in positive 
studies between 1980-1990 (4.3 months), 1991-2000 
(2.6 months) and 2001-2010 (2.4 months) was observed 
(p=0.016 for 1980s vs. 2000s). Lastly, only the pre-1990 
cohort of trials was noted to include studies reported as 
negative due to insufÀcient magnitude of clinical beneÀt 
despite statistical signiÀcance.
S472 Copyright © 2011 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
showed statistically signiÀcant higher percentages 
of discrepancies in stage (p<0.05) compared with 
patients initiated second opinions. Discrepancies in 
diagnosis and therapy were also more frequent when 
specialists initiated the second opinions, however 
this trend was not signiÀcant. 
Conclusion: Lung cancer second opinion referrals 
to an expert center resulted in more than 2/3 of the 
patients in a different therapeutic advice, partially 
based on change in stage and/or pathological 
diagnosis. 
Keywords: second opinion referrals, 
histopathological diagnosis, therapy advice, expert 
center
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O44.05 DO RESULTS DIFFER BY META-
ANALYSIS METHOD: COMPARISON 
OF INDIVIDUAL PATIENT DATA-
BASED (IPD) WITH LITERATURE-
BASED ABSTRACTED DATA (AD) IN 10 
CLINICAL SETTINGS INCLUDING OVER 
35,000 PATIENTS
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Background: Meta-analyses are considered to be 
a high level of evidence, especially when based on 
multiple large randomized clinical trials. Several 
key treatment areas in lung cancer have been studied 
by different meta-analysis methods. Controversy 
exists whether the two most frequently used methods 
(IPD or AD) provide equally reliable results. In this 
analysis we examined the conclusions achieved by 
each method using the same panel of studies for each 
method. We weighed agreement/discrepancy and 
evaluated predictivity of AD results with respect to 
IPD using multiple methods.
Methods: 10 different settings (including 3 issues 
in lung cancer, see the table below) which were 
subjected to IPD meta-analysis were selected, and 
were then evaluated by the AD method, including 
the same trials on which the initial IPD was based. 
Hazard and Risk Ratios (Rs) with 95% conÀdence 
Background: Lung cancer is the most important 
cause of cancer death in both men and women 
in the western world. Facing a poor survival, 
patients increasingly ask for a second opinion for 
information, hope and reassurance. Beside this, 
lung specialists also consult expert colleagues for 
diagnostics and therapy. The VU University Medical 
Center, Amsterdam, The Netherlands receives a lot 
of second opinions. Study objectives: To determine 
the characteristics of patients, the outcomes and 
supplemental medical information resulting from 
second opinions of patients visiting the pulmonary 
oncology outpatient clinic of VU University Medical 
Center. 
Methods: In the period of January 2005 to 
December 2009, 525 patients from outside the 
district of the VU University Medical Center 
were referred as second opinions to its pulmonary 
oncology outpatient clinic. Demographics, second 
opinion initiator and oncology data of second 
opinions were collected. Design: Cross sectional, 
retrospective and descriptive study 
Results: Preliminary Results: Of the referred 
patients(n=525), 394 patient Àles have been studied 
until date. Forty-Àve of the referred patients were 
excluded since they did not Àt our second opinions 
criteria. Of the included patients (n=349), 57% 
were male, 78% were diagnosed with NSCLC and 
8% SCLC, 39% had stage IV, and mean age at 
presentation was 58±11.5 years old. Thirty percent 
of the second opinions was initiated by patient, 66% 
by a lung specialist and 4% by both patient and 
specialist. At time of referral, the histopathological 
diagnosis was unknown in 36 patients (10%). In 43 
(14%) patients having a histopathological diagnosis 
(n=313), the stage was unknown. Forty-four percent 
of the patients previously had received therapy for 
lung cancer. In 228 (65%) patients, supplementary 
diagnostics were needed. Revision of pathologic 
material and/or images took place in 241(69%) 
patients. There was a discrepancy between the 
initial and the second pathological diagnosis in 4% 
(n=13) of the patients in whom the histopathological 
diagnosis (n=313) was already determined. In 
288 patients, lung cancer had been staged prior to 
referral, a discrepancy was found in 14% (n=40). 
In 8 out of 13 patients, changes in histopathological 
diagnosis had implications for the prognosis, as well 
as all changes in stages. In 237 cases a therapy had 
been suggested, this advice was changed in 164 cases 
(69%). Eighty-eight patients (25%) received therapy 
in clinical trials. Specialists initiated second opinions 
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O44.07 RANDOMIZED TRIALS IN 
UNSELECTED PATIENTS: MISLEADING 
AND IRRATIONAL?
David J. Stewart 
Thoracic And Head And Neck Medical Oncology, 
M.D. Anderson Cancer Center/United States Of 
America
Background: Randomized phase II trials are 
used to screen new agents, but if a drug hitting 
target present in 40% of patients is compared to 
one hitting target present in 10%, it is erroneously 
concluded that the drug hitting the more common 
target is the better drug. The correct conclusion 
is that each agent is best for subpopulations with 
the relevant target. Similarly, there are published 
examples of drugs that are beneÀcial in one 
subpopulation but harmful in another where 
randomized trials in unselected patients erroneously 
concluded the drug had no effect. 
Methods: Using actual survival of 334 NSCLC 
patients as “controls”, we performed limited 
simulations to assess performance of randomization 
in various clinical scenarios.
Results: For an agent hitting target present in 
10% of patients in a simulated treatment arm, 
and quintupling survival in patients with target 
(eg, from 2 to 10 months), this simulated study 
concluded the drug was ineffective (p=0.16), and an 
agent with marked value in a distinct subpopulation 
would be discarded. If the trial was increased to 
2,000 patients, then p was <0.03 and the drug 
would be approved for use, including in the 90% 
of patients deriving no beneÀt. If the target is Àrst 
intervals (CI) were derived. Methods agreement 
was analyzed (Blant-Altman method) as difference 
or ratio and compared using Variance-Ratio (F-test) 
and Concordance Correlation CoefÀcient (CCC). 
Correlations between AD Risk Ratios and IPD 
Risk Ratios were estimated with linear regression 
[Pearson (r), R2 coefÀcients, Spearman-Rho/
Kendall-Tau coefÀcients] to derive a predictive 
estimation of AD on IPD.
Results: 14 outcomes in 10 meta-analyses (37,002 
patients in total) were analyzed. 
Setting Pts [AD/IPD] Rs [AD/IPD] 
Bladder 458/491 0.76/0.75 
Breast 3672/4006 0.71/0.71 
Breast 2805/3034 0.94/0.92 0.99/0.95 
Breast 11163/9856 0.77/0.77 0.98/0.94 
Breast 8794/9015 0.73/0.71 0.80/0.79 
Breast 2695/2447 0.68/0.64 0.95/0.97 
Lung 4658/4584 0.90/0.89 
Lung 778/778 0.71/0.73 
Lung 857/865 1.06/1.09 
Emesis 1926/1926 0.998/1.00 
Graphical comparison with the B-A method did not 
show meaningful differences between AD and IPD 
(mean difference 0.0075, 95% CI -0.0052, 0.02), 
without signiÀcant discrepancy, with no signiÀcant 
differences in variance (F-test 1.06, p=0.91), and 
high CCC (0.98, 95% CI 0.59, 0.99). A highly 
signiÀcant correlation by both parametric and non-
parametric tests, allowed derivation of a linear 
regression equation able to predict IPD results from 
AD data (YAD=[0.04315] + XIPD[0.958]; R2 0.97). 
Conclusion: This study evaluated two meta-analysis 
methods (AD or IPD). We found 1) no signiÀcant 
differences between the two meta-analysis methods, 
with very similar risk ratios derived from either 
method. Additionally, 2) AD results predict IPD 
results, without signiÀcant risk of overestimation. 
While there may be particular advantages to each 
method (AD can be rapidly and inexpensively 
conducted; IPD may allow greater ability to evaluate 
issues not originally contemplated in the individual 
studies), both give similar and useful results relating 
to the key question analyzed.
Keywords: meta-analysis, comparison, methodology
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O45.01 THE FEASIBILITY OF MEDICAL 
THORACOSCOPY FOR DETECTION 
OF MALIGNANT EFFUSION IN THE 
DIAGNOSIS OF UNDETERMINED 
PLEURAL EFFUSION
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National University Yangsan Hospital/Korea, 
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Background: Thoracoscopic pleural biopsy is 
necessary for the conÀrmative diagnosis of malignant 
pleural effusion. However, the conventional technique 
is inappropriate as a routine diagnostic tool because it 
requires general anesthesia. Medical thoracoscopy is 
thought to be the alternative conventional technique. It 
is more feasible as a routine diagnostic tool because it is 
performed only under local anesthesia. 
Methods: Initially 248 patients were referred to further 
evaluate undetermined pleural effusions. Excluding the 
32 patients who refused the medical thoracscopy, the 
remaining 216 patients underwent cytology, chest CT, 
and medical thoracoscopy. We analyzed the safety of 
medical thoracoscopy and the sensitivity, speciÀcity, 
and accuracy of the three diagnostic tools respectively
Results: There was no mortality, nor any morbidity. 
The Ànal diagnoses were malignant effusion 
30.1% (n=65), tuberculosis pleurisy 28.3% (n=61), 
parapneumonic effusion 40.7% (n=88), and others 
0.9% (n=2). The sensitivity of cytology, chest CT and 
medical thoracoscopy were 22.6%, 78.5%, 93.8%, 
respectively, and the speciÀcity were 99.3%, 91.4%, 
100% respectively, and the accuracy were 75.9%, 87.5 
%, 98.4%respectively. The sensitivity and accuracy 
of medical thoracoscopy are signiÀcantly higher than 
cytology and radiologic evaluation (p<0.05).
Conclusion: Medical thoracoscopy is a safe and feasible 
diagnostic tool for undetermined pleural effusion. The 
routine use of medical thoracoscopy is necessary to 
prevent misdiagnosis of malignant pleural effusion.
Keywords: Medical thoracoscopy, VATS, malignant 
effusion
identiÀed in phase I-II trials by correlating tumor 
shrinkage with target presence, then a trial with just 
16 patients selected for target would demonstrate 
beneÀt (p<0.02), yielding the correct conclusion 
that the drug is effective in patients with target. In 
the 668-patient trial, if drug hit common targets and 
increased survival of all patients by 33% (just 21 
days) from 2 to 2.7 months, the drug was judged 
effective (p=0.03). Hence, agents with miniscule 
beneÀt in a high proportion of patients may do 
better in randomized trials than agents with marked 
impact in subpopulations. In some simulations, 
varying the proportion of patients with target by 
just 2% resulted in drug being declared effective 
rather than ineffective. If one drug quintupled 
survival in 10% of patients, and another quintupled 
survival in a different subpopulation, the 2 drugs 
were declared “equivalent” (p=0.89) despite 
working in completely different subpopulations. 
Randomized phase II nonparametric comparisons 
with respect to % tumor shrinkage would often 
discard agents despite marked beneÀt in a 
subpopulation, even using a “relaxed” 1-sided 
p=0.10. If control patients ranged from tumor 
shrinkage of 15% to growth of 100% and if 
the new agent shrank tumors by 80% in a 10% 
subpopulation of patients carrying a target, 35 
patients would be required for p<0.10 if control 
patients with target had 90-100% tumor growth, but 
300 patients would be required if control patients 
with target had neither shrinkage nor growth, and 
10,000 patients would be needed if control patients 
with target had 10-15% tumor shrinkage. 
Conclusion: Since important new agents often hit 
targets present in small subpopulations, it may be 
misleading and irrational to conduct randomized 
trials in unselected patients.
Keywords: NSCLC, Clinical Trials
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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rigid thoracoscopy was performed 4.2 (4.8) days 
after initiation of work-up. In 122 patients pleural 
abnormalities were seen. In 118 patients (87%) a 
deÀnite diagnosis was established in 10.1 (5.4) days 
after initiation of work-up. In 104 patients the semi-
rigid thoracoscopy was practice changing compared 
to thoracocentesis alone (77%). 85 malignancies 
were found; in 76 of these (89%) the origin of the 
malignancy could be determined (deÀnite diagnosis). 
Other diagnosis revealed Àbrosis, ‘reactive’ and 
inÁammation. Five procedures were converted 
to rigid thoracoscopy, due to insufÀcient biopsy 
material, all in the Àrst two years of the study. 13 
patients received an additional surgical biopsy, 7 
revealed malignancy after all (6 mesotheliomas 
and 1 sarcoma). There was 1 haematothorax as a 
complication of the semi-rigid thoracoscopy itself, 
furthermore 2 patients developed infection of the 
pleural space after pleural drainage. 
Conclusion: Semi-rigid thoracoscopy performed 
immediately after initial thoracocentesis is an easy 
and safe procedure with a high (87%) diagnostic 
rate in a limited diagnostic time period. Compared 
to thoracocentesis alone, it changes the treatment-
plan in 77% of patients. Furthermore thoracoscopic 
assessment yields far more a deÀnite diagnosis of 
cancer (89% vs 10%). 
Keywords: thoracoscopy, malignant pleural 
effusion, diagnostic rate
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O45.03 EFFECTIVE, EFFICIENT 
MANAGEMENT OF MALIGNANT 
PLEURAL EFFUSIONS: 
A COLLABORATION OF 
INTERVENTIONAL RESPIROLOGY, 
PALLIATIVE CARE AND HOME CARE
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2Respirology:interventional Pulmonology, The 
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Background: Malignant pleural effusions are 
common complications for patients diagnosed with 
several advanced cancers, but are most commonly 
associated with bronchogenic carcinoma, found in as 
many as one third of patients. The development of a 
malignant effusion portends a poor prognosis with 
an estimated survival of 3 to 6 months. Patients with 
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O45.02 ASSESSMENT OF SEMI-RIGID 
THORACOSCOPY IN THE DIAGNOSIS 
OF MALIGNANT PLEURAL EFFUSION.
Nicole Scheppers, Gerben Bootsma, Michiel 
Gronenschild, Erik V. Haren 
Pulmonary Diseases, Atrium Mc Parkstad/
Netherlands
Background: Almost all malignancies are able to 
seed to the pleura. In exsudative pleura effusion, 
malignancy is the cause in 42-77%. The diagnosis 
of malignant pleural effusion is of major importance 
for staging and therapy. Guidelines recommend 
up to 3 consecutive diagnostic thoracocenteses to 
diagnose malignant pleural effusion, but even then 
sensitivity is limited to 70%. Furthermore only 
a cytological diagnosis is yielded and it is a time 
consuming procedure. In our hospital it is practise to 
perform semi-rigid thoracoscopy immediately after 
initial thoracocentesis showing an exsudative non-
infectious pleural effusion. We hypothesize that this 
procedure offers a quicker diagnosis and a higher 
diagnostic yield (by addition of (immuno-)histology) 
compared with thoracocentesis, without additional 
complications.
Methods: In a retrospective descriptive study, 
conducted in our large Dutch teaching hospital, all 
patients who underwent semi-rigid thoracoscopy 
for the diagnosis of pleural effusion were included 
between 2006 and 2010. Semi-rigid thoracoscopy 
(Olympus® LTF-160) was performed under local 
anaesthesia according to standard protocol, a pleural 
catheter was left for pleurodesis when necessary. 
Biopsies of the parietal pleura were taken for 
histology. In a standardized protocol, demography, 
(PET-)CT Àndings, aspect of pleural Áuid, results 
of pleural cytology, time between initiation of 
analysis untill deÀnite diagnosis, thoracoscopic 
results including need for conversion (rigid or 
surgical), and complications were recorded. Primary 
endpoint is diagnostic rate. Secondary endpoints are 
time to diagnosis, number of decision changes and 
complication rate.
Results: In 5 years 135 semi-rigid thoracoscopies 
were performed in 135 patients, mean (SD) age 68.4 
(9.7) years, 92 males, 43 females. Initial pleural 
cytology showed a malignancy in 56 patients 
(41%). In only 6 out of these 56 patients (10%) 
a deÀnite diagnosis could be established. Semi-
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Background: Photodynamic therapy (PDT) is 
recommended as a treatment option for centrally 
located early lung cancers (CLELCs). Although 
PDT using Photofrin has not been recommended for 
large tumors or deeply invasive tumors , in the past, 
if their mass is reduced by electrocautery, PDT with 
the NPe6 second-generation photosensitizer has been 
found to be capable of destroying the residual cancer 
lesion. NPe6 is a second-generation photosensitizer, 
and since it has a longer absorption band (664 nm) 
than Photofrin (630 nm), we hypothesized that 
NPe6-PDT would exert a strong antitumor effect 
against cancer lesions greater than > 1.0 cm in 
diameter. 
Methods: Between June 2004 and December 2009, 
90 patients (109 lesions) with CLELC underwent 
NPe6-PDT after the extent of their tumors had 
been assessed by Áuorescence bronchoscopy for 
photodynamic diagnosis and tumor depth had been 
assessed by EBUS 
Results: Eighty six cancer lesions 1.0 cm in diameter 
and 31 lesions >1.0 cm in diameter were identiÀed, 
and the CR rate was 94.1% (81/86) and 90.3% 
(28/31), respectively. After the mass of large tumors 
and deeply invasive tumors, had been reduced by 
electrocautery, NPe6-PDT was capable of destroying 
the residual cancer lesions. Among 90 patients with 
CLELC, multiple lung cancer lesions (MPLC) were 
observed in 31 patients (34.4%). Among the patients 
with MPLC, 13 patients underwent surgery for 
primary lung cancer and then underwent NPe6-PDT 
for the treatment of secondary primary CLELC. In 
17 of the 31 patients, all 37 lesions were CLELC 
were performed PDT alone. Among 31 patients with 
MPLC including peripheral type lung cancers which 
were resected by surgery, all 51CLELC lesions 
exhibited a complete response after NPe6-PDT. 
Conclusion: NPe6-PDT has a strong antitumor 
effect against CLELCs >1.0 cm in diameter, 
thereby enabling the destruction of residual cancer 
lesions after mass reduction of large nodular or 
malignant pleural effusions experience distressing 
symptoms and reduced quality of life in addition to a 
shortened life expectancy. Management of malignant 
pleural effusions varies from inpatient management, 
to repeated outpatient or emergency room visits and 
to formalized outpatient and homecare programs. 
In our community, a collaboration of Interventional 
Pulmonology, Palliative Care, Oncology and Home 
Care, facilitated the establishment of a Malignant 
Effusion Outpatient Clinic linked to the home 
Palliative Care program. The management of 
these patients was accomplished via the insertion 
of a tunneled catheter (PleurX®). The Malignant 
Effusion Clinic provides the expert hub of care for 
insertion, follow up, troubleshooting and community 
education while the home care program provides 
the nursing expertise to conduct ongoing drainages, 
assessment, symptom management and palliative 
care. 
Methods: A retrospective review of all patients 
treated in the Malignant Effusion Clinic from May 
2006 to April 2010 was conducted to assess the 
effectiveness and efÀciency of the program. 
Results: Although the audit included 558 patients 
with all diagnoses who had a total of 643 catheters 
inserted, this presentation will focus only on those 
patients with a diagnosis of lung cancer (n = 200). 
Data reported will include patient parameters such as 
demographics (age, sex, diagnosis, side of effusion), 
functional status (ECOG), and clinical outcomes 
(success of insertion, relief of dyspnea, spontaneous 
pleurodesis, time to pleurodesis, complications, 
length of time catheter in situ and length of survival). 
We will also discuss process outcomes including 
numbers of clinic visits, numbers of home care visits 
and program costs. 
Conclusion: There continues to be much variation 
in the literature regarding appropriate clinical 
management of malignant pleural effusions. The 
outcomes achieved in a comprehensive outpatient 
program for this group of palliative lung cancer 
patients will be presented which may promote further 
discussion of the role of outpatient management for 
malignant pleural effusions. 
Keyword: malignant pleural effusion management
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drain insertion. 3 patients had haemoptysis, 2 
patients developed infection which was treated 
with antibiotics. The mean survival was 189 days 
following stent placement,[primary lung cancer 
mean 150 days, secondary cancer mean 406 days] 
Conclusion: This technique is useful in palliating 
life threatening airway obstruction, particularly for 
secondary cancer, and can be used in any centre 
undertaking Àbreoptic bronchoscopy. 
Keywords: Airway-stenting, Airway-obstruction
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O45.07 BACTERIAL COLONIZATION IN 
PATIENTS WITH TRACHEOBRONCHIAL 
STENTS
Antoni Rosell, Raquel Pascual Cascon, Rosa Lopez-
Lisbona, Noelia Cubero, Susana Padrones, Pablo 
Diaz-Jimenez, Jordi Dorca 
Pulmonology, Hospital Universitari De Bellvitge/
Spain
Background: Interventional bronchoscopic 
procedures are good palliative treatments for 
locally advanced cancer affecting main airways. 
Stent colonization by potentially pathogenic 
microorganisms can be a problem in patients 
undergoing chemotherapy. The aim of the study 
is to describe the prevalence, incidence and 
proÀle of potentially pathogenic microorganisms 
(PPM) colonizating the airways of patients with 
tracheobronchial stents. 
Methods: We included consecutive clinically 
stable patients attended for palliative treatment of 
cancer in which silicone or metal expandible stents 
were implanted. Previous to endoscopic treatment, 
bronchial washings (BW) were obtained by Áexible 
bronchoscope after the patient was intubated with 
rigid bronchoscope under general anesthesia. 
Microbiological results were expressed qualitatively.
Results: We retrospectively studied 30 patients with 
a mean follow up of 119 d( 27-300); 73.3% men, 
age 62.7 (SD 7), former smokers 56%, smokers 
26%,never smokers 17%; FEV1% 57.5% (SD 
17.7%); mean survival time 122 days (95%CI 95-
149), Stents implanted: 60% silicon (Dumon), 26.6% 
metallic (UltraÁex), combines 3.4%. 1 stent 77%, 2 
stents 23%. 
polypoid type-lung cancers by electrocautery. The 
PDT guidelines for lung cancers should therefore 
be revised, because use of NPe6-PDT will enable 
expansion of the clinical indications for PDT, and 
PDT can play an important role for the treatment 
strategy for MPLC. 
Keywords: early lung cancer, photodynamic 
therapy, multiple primary lung cancers
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O45.06 FIBREOPTIC BRONCHOSCOPIC 
INSERTION OF THE GIANTURCO 
STENT FOR TRACHEOBRONCHIAL 
OBSTRUCTION IN PATIENTS WITH 
CANCER AT A LUNG CANCER 
TERTIARY REFERRAL CENTRE: 20 
YEAR EXPERIENCE
Martin J. Ledson, Andrea Mciver, Jean Hughes, Jo 
Dunbar, Andrea Collins, Colin Smyth 
Liverpool Heart And Chest Hospital, Liverpool Lung 
Cancer Unit/United Kingdom
Background: Large airway obstruction is a 
distressing and life threatening complication of 
malignant disease, which may not be amenable to 
urgent radiotherapy treatment. Palliative protection 
of the airway by stenting is a difÀcult procedure, 
traditionally carried out under general anaesthesia 
and Áuoroscopy. Our group has previously shown 
that it is possible to place self expanding Gianturco 
metal stents under local anaesthesia using the 
Àbreoptic bronchoscope and direct vision for the 
treatment of malignant airway tumours. We have 
used this technique routinely for suitable patients 
referred to our regional unit over the last 20 years, 
and we now report our experience. 
Methods: A retrospective review of all stenting 
procedures carried out in our unit between 1990 and 
2010 was performed, looking for histological type, 
number and site of stents, any complications of the 
procedure, other interventions, and survival. 
Results: 238 patients (average age 64 years, [range 
21 to 89]) had 416 stents inserted during 244 
procedures (average 1.72 stents/procedure, [range 
1 to 4]). 186 patients had malignant primary lung 
tumours and 33 secondary malignancy (15 missing 
data, 4 patients stented for benign conditions). There 
were no operative deaths, but 4 patients developed 
a pneumothorax, of which 1 required intercostal 
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Mean time 
(days) 
from 
previous 
control 
n PPM (%) PA (%) SA (%) HI (%) MRSA (%) Other 
(%) 
0 (basal) 30 23.3 10 6.7 6.7 - - 
21 30 66.7 20 26.7 10 3.3 6.7 
33 22 77.3 33 28.6 4.8 4.8 4.8 
51 19 84.2 26.3 26.3 5.3 - 21.1 
29 7 71.4 42.9 14.3 - - 14.3 
33 5 80 60 20 - - - 
30 3 100 66.7 - - - 33.3 
19 2 100 50 50 - - - 
PPM: potential pathogenic microorganisms. PA= 
Pseudomonas aeruginosa. SA= Staphiloccocus 
aureus HI=Haemphilus inÁuenza MRSA= 
multiresistent SA 
Conclusion: Tracheabronchial stents are associated 
with a progressive increase in PPM colonization. 
Pseudomonas aeruginosa and Staphiloccocus aureus 
are the most common bacteria. Microbiological 
sampling during routine bronchosocpy is 
recommended. Funded by CIBERES.
Keywords: tracheobronchial stent, bronchoscopy, 
bacterial colonization
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survival beneÀt. There were practice variations in 
management of patients with advanced stage disease 
(n=71). A multimodality approach that included 
surgery, radiation and chemotherapy correlated with 
better outcomes. Tri-modality treatment for thymoma 
achieved a 5 year OS of 85%; however patients with 
advanced thymic carcinoma had poor outcomes 
despite aggressive treatment. In multivariate analyses 
histology (thymoma vs. thymic carcinoma) and 
surgery were signiÀcant predictors of OS. 5 year 
progression free survival and overall survival 
Stage 5 yr PFS 5 yr OS 
I (n= 13) 91% 91% 
II (n=84) 83% 86% 
III (n=42) 49% 70% 
IV (n=32) 13% 46% 
Conclusion: This study is the Àrst population-based 
series to detail treatment and outcomes for thymoma. 
Outcomes compare favourably to series from single 
institutions. Patients with locally advanced disease 
for whom initial surgical resectability is uncertain 
should be triaged to a multidisciplinary team for 
consideration of multimodality treatment. 
Keywords: Thymoma, Thymic carinoma, 
population-based, locally advanced
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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MO01.02 CLINICAL PROGNOSTIC 
FACTORS IN THYMIC TUMOURS-8 
YEARS FOLLOW UP
Sheng P. Shen1, Shun Lu2 
1Shanghai Lung Tumor Clinical Medical Center, 
Shanghai Chest Hospital,Jiaotong Univercity/China, 
2Department Of Shanghai Lung Cancer Center, 
Shanghai Chest Hospital, Jiaotong University, 
Shanghai/China
Background: To explore the prognostic factor 
by analyzing clinical and pathologic features of 
thymoma and thymic carcinoma.
Methods: 115 cases of thymoma and thymic 
carcinoma were analyzed based on WHO schema 
for thymic tumors classiÀcation(2004), and Masaoka 
stage. The clinical factors include histological 
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MO01.01 MANAGEMENT AND 
OUTCOMES FOR THYMOMA IN 
BRITISH COLUMBIA: A POPULATION-
BASED ANALYSIS.
Caroline J. Mariano1, Diana Ionescu2, Winson 
Y. Cheung1, Rola Ali2, Janessa Laskin1, Hannah 
Carolan3, Kenneth Evans4, Nevin Murray1 
1Medical Oncology, British Columbia Cancer 
Agency/Canada, 2Pathology, British Columbia 
Cancer Agency/Canada, 3Radiation Oncology, 
British Columbia Cancer Agency/Canada, 
4Thorassic Surgery, University Of British Columbia/
Canada
Background: The optimal approach to the 
management of thymoma and thymic carcinomas 
is unclear, particularly for advanced stage disease. 
Our primary study aim was to analyze treatment 
practices and outcomes in a population-based cohort 
of thymoma patients. 
Methods: All patients with a pathological diagnosis 
of thymoma or thymic carcinoma and referred 
to the British Columbia Cancer Agency (BCCA) 
between 1994 and 2009 were reviewed. Kaplan-
Meier curves and Cox proportional hazard models 
were used to correlate histology, stage and treatment 
with outcomes. Pathology review using WHO 
classiÀcation is currently underway. 
Results: 190 patients were identiÀed of which 
171 (90%) were referred to BCCA and eligible 
for analyses. Median was 60 years; 50% of pts 
were male. 26% had paraneoplastic phenomena; 
including 21% with myasthenia gravis. Patients with 
thymic carcinoma (n= 23) and thymoma (n=148) 
had 5 year overall survival (OS) rates of 38% and 
81%, respectively. Survival by stage is detailed in 
table 1. Patients with stage I disease were treated 
primarily with surgery. Selected stage II patients 
received adjuvant radiation therapy, which conferred 
a signiÀcant improvement in progression free 
survival (98 vs. 62 months, p<0.01), but no overall 
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MO01.03 DIFFERENT 
CHARACTERISTICS OF THYMOMAS 
WITH AND WITHOUT MYASTHENIA 
GRAVIS
Lei Yu, Yun-Feng Zhang, Fei Li, Shan Ma 
Department Of Thoracic Surgery, Beijing Tongren 
Hospital, Capital Medical University/China
Background: The objective of this study was to 
evaluate the different pathological and clinical 
characteristics of thymomas with and without 
myasthenia gravis (MG) and determine whether 
the presence of MG inÁuences the prognosis in 
thymoma patients. 
Methods: We retrospectively studied data from 228 
consecutive patients operated on from1992 to 2007 
in the department of Thoracic Surgery of Beijing 
Tongren Hospital. These thymoma patients have 
been subdivided into two groups: Group A with MG 
(n=125) and Group B without MG (n=103). These 
patients underwent extended thymectomy using a 
transsternal approach (n=153) or VATS (n=75). All 
thymic epithelial tumors were classiÀed according to 
the WHO histologic classiÀcation and the Masaoka 
clinical staging system. 
Results: There were no peri-operative deaths. 
19 cases were inoperable. (6 in the group with 
MG, 13 without MG, P=0.035). The proportions 
of type A, AB, B1, B2, B3, and C thymoma in 
this data were 0%, 22.4%, 26.4%, 30.4%, 20.8%, 
and 0% respectively in the group with MG, and 
10.5%, 13.4%, 23.6%, 24.5%, 16.4%, and 11.6% 
respectively in the group without MG. According 
to the modiÀed Masaoka’s clinical staging, in the 
group MG, 24.8 % patients were stage III and IV; in 
the group without MG, 33 % patients were stage III 
and IV. There was a signiÀcant difference between 
hyperplastic paraneoplastic thymus coexisting in 
28.8% patients with MG and only 5.8% in patients 
without MG. Microthymoma was identiÀed in 
the paraneoplastic thymus of 3 patients with MG. 
There were 198 patients followed up. There was 
no recurrence in patients with type A and a few 
patients with type AB, B1, B2, B3 and C recurred. 
The actuarial 5- and 10-year survival rates were 
89.3% and 81.2% for patients with MG respectively, 
and 90% and 78.9% for patients without MG 
respectively. Within 5 years postoperatively, 6 of 9 
patients with MG died of myasthenia crisis, while 
6 out of 7 deaths in patients without MG were 
classiÀcation, Masaoka stage, multimodality 
treatment, and myasthenia gravis (MG). Univariate 
survival analysis were done by Kaplan-Meier and 
Log-Rank methods. Multi-analysis was carried out 
by COX regression.
Results: Histology by WHO was 1 A (0.9%), 
15 AB (13%), 7 B1 (6.1%), 22 B2 (19.1%), 27 
B3 (23.5%), and 43 thymic carcinoma (37.4%), 
respectively. Masaoka staging was stage I, 23 
cases (20%), stage II, 35 (30.4%), stage III, 
43(37.4%), and stage IV 14(12.2%), respectively. 
These patients, the median survival time was 84.4 
months, the 8-year survival rate was 78%. WHO 
histologic subtype closely correlated with Masaoka 
stage (correlation coefÀcient=0.596,P<0.01). The 
8-year survival rate of type A+AB were 91%, type 
B1+B2+B3 were 94%, thymic carcinoma were 60%, 
respectively(P=0.001). The 8-year survival rate 
of stage I, II, III and IV were 95%, 97%, 72% and 
34%, respectively(P<0.001). MG was present in 96 
cases (83.5%). The 8-year survival rate of patients 
with MG was 84%, 77% without MG (p=0.634). 83 
patients received complete resection, and 33(39%) 
were undergone adjuvant radiotherapy, the other 
49(59%) were not. The 8-year survival rate of these 
83 patients was 87%, and 88% for the patients 
treated with adjuvant radiotherapy, 85% for the 
patients without adjuvant radiotherapy, respectively 
(p=0.651). Masaoka stage is a signiÀcant 
independent prognostic factor in patients with thymic 
tumors(p=0.019).
Conclusion: Myasthenia gravis maybe was not 
the favourable prognosis factor of thymic tumors. 
Adjuvant radiotherapy after complete resection 
didn’t prolong the survival time. Only Masaoka 
stage is a signiÀcant independent prognostic factor in 
patients with thymic tumors. 
Keywords: Thymoma, Thymic Carcinoma, 
prognostic factor
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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with Maysthenia Gravis (MG). The median time 
between onset of MG and the procedure was 15 
months (range 3-72 months). 24 patients were 
suspected for a thymoma based on the CT-scan. No 
surgical mortality was reported and there were no 
complications during the procedure. One procedure 
was performed eventually by sternotomy because of 
obesity of the patient. Median hospitalization was 
3.8 days (range 3-25 days). The mean procedure 
time was 139 minutes (range 44-260 minutes). Major 
postoperative complications occurred in 4 patients 
(5.4%) 2 patients experienced a myasthenic crisis 
and 2 patients experienced respiratoiry insufÀciency. 
Histologic analysis of the resected tissue revealed 18 
thymomas (3 type AB, 7 type B2, 5 type B1, 1 type 
A) and 1 thymus carcinoma. Follow-up evaluation 
of 32 patients with MG (mean 22 months) showed 
that 2 (6.25%) patients had complete remission 
and 23 (71,9%) patients had clinical improvement, 
they were asymptomatic or decreased symptoms 
and decreased medication. The follow-up of the 18 
patients with a thymoom showed no tumour relaps 
and no tumour related deaths
Conclusion: A three-dimensional robotic assisted 
videothoracoscopic approach is a safe way to 
remove the thymus. It has a big advantage in tiny 
difÀcult areas, the complication rate is low and, most 
important, it is less invasive for the patient.
Keyword: Robotic surgery
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MO01.06 MALIGNANT 
PLEURAL MESOTHELIOMA 
IMMUNOHISTOCHEMISTRY IN 
SEARCH OF THE MOST SUITABLE AND 
COST-EFFECTIVE ANTIBODY PANEL.
Pier-Giacomo Betta1, Thea Bensi1, Nicol F. 
Trincheri1, Roberta Libener1, Sara Orecchia1, 
Corrado Magnani2 
1Pathology, Azienda Ospedaliera Nazionale/Italy, 
2University Of Eastern Piedmont/Italy
Background: Malignant mesothelioma (MM) 
exhibits phenotypic versatility with frequent overlap 
with reactive mesothelial proliferations or pleural 
metastases. Immunohistochemistry is currently an 
indispensable tool in the histologic diagnosis of 
MM. No single marker entirely conclusive for MM 
has yet been established and most commercially 
available antibodies are used in panels, although 
attributable to inoperable tumors (stage) and type C 
thymoma. 
Conclusion: MG seldom occurs in type A and C 
thymoma. In addition to resection of thymoma, all 
thymic tissue and mediastinal fat should also be 
completely removed to lower possibility of thymoma 
recurrence and achieving complete stable remission 
of MG. The prognosis of thymomas with MG is 
similar to that without MG. The main cause of death 
is myasthenia crisis for thymoma patients with MG 
and stage IV and /or type C for thymoma patients 
without MG.
Keywords: characteristics, Prognosis, Thymoma, 
Myasthenia Gravis
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MO01.04 THORACOSCOPIC 
THYMECTOMY BY A ROBOTIC 
ASSISTED APPROACH
Marlies Keijzers1, Anne-Marie C. Dingemans1, Hans 
Blaauwgeers2, Robertjan Suylen Van3, Monique 
Hochstenbag1, Leen Van Garsse4, Mark De Baets5, 
Jos Maessen4 
1Department Of Pulmonology, Maastricht University 
Medical Center/Netherlands, 2Department Of 
Pathology, Onze Lieve Vrouwengasthuis, Amsterdam/
Netherlands, 3Department Of Pathology, Maastricht 
University Medical Center/Netherlands, 4Department 
Of Thoracic Surgery, Maastricht University Medical 
Center/Netherlands, 5Department Of Neurology, 
Maastricht University Medical Center/Netherlands
Background: Recently, the use of three-dimensional 
robotic assisted videothoracoscopy was suggested 
to improve the accuracy in radical surgical thymus 
resection and to reduce operating time. It offers an 
excellent view and surgical control of the thymus 
gland and its surroundings. Here we report our 5 
year experiences with the Davinci Intuitive Robotic 
system in thymectomies
Methods: We retrospectively analyzed the patients 
who underwent a thymectomy from December 2004 
to January 2009 using the Davinci surgical robotic 
system (by a 3 port, right-sides approach). All the 
procedures were performed by two thoracic surgeons 
who were trained for robotic surgery
Results: 74 patients (54 females, 20 males), mean 
age 39.1 years (range 14-82 years) underwent a 
thymectomy using the Davinci surgical robotic 
system. 60 (81.1%) patients were diagnosed 
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al Am J Clin Pathol 2000 114: 203) with the resulting 
probability of 0,8183 and 0,00002, respectively. 
Conclusion: This study based on a very large set 
of MMs provides support for a cost-effective panel 
of only three antibodies, without compromising 
sensitivity or speciÀcity. 
Keywords: mesothelioma, immunohistochemistry, 
logistic regression
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MO01.07 INTEGRATED ANALYSIS 
OF MICRO-RNAS AND GENES IN 
MALIGNANT MESOTHELIOMA
Chuong D. Hoang1, Andrew Gentles2, Yue Xu2, 
Sylvia Plevritis2, Robert E. Merritt2, Richard I. 
Whyte2, Joseph B. Shrager2, Robert A. Kratzke3 
1Cardiothoracic Surgery, Stanford University/United 
States Of America, 2Stanford University/United 
States Of America, 3University Of Minnesota/United 
States Of America
Background: We hypothesize that certain 
microRNA (miRNA)-mRNA interactions are 
associated with malignant transformation and 
progression of malignant mesothelioma (MM). To 
date, no integrated analysis has been performed to 
identify critical interactions between miRNA-mRNA 
that may drive the MM malignant phenotype.
Methods: Total RNA was extracted from 24 
specimens of biopsy proven human MM and 
6 specimens of normal pleura. Paired global 
transcriptional proÀles of miRNA and genes 
(mRNA) expression were generated using Illumina 
microarrays. To optimize detection of causal 
associations, Spearman correlations between miRNA 
and mRNA expression were calculated among MM 
samples. Correlation p-values were converted to 
false discovery rates (FDR q-values) to account for 
multiple comparisons; associations with q<=0.05 
were considered signiÀcant. To better determine 
relevant genes for a given process, sets of genes 
whose expression levels negatively correlated 
with speciÀc miRNAs were identiÀed as likely 
direct targets of that miRNA. Gene Set Enrichment 
Analysis (GSEA) was used to Ànd target gene sets 
that were signiÀcantly repressed or overexpressed 
in MM vs normal in the opposite direction to 
expression of the miRNA itself. Additionally, 
external data sets (n=2) were interrogated with 
GSEA to reÀne target gene sets whose behavior 
no consensus exists about which and how many 
antibodies should be used. To help optimize 
a combination of antibodies for the histologic 
evaluation of pleural tumor tissue specimens, the 
use of immunohistochemistry was retrospectively 
reviewed in 258 consecutive epithelioid or mixed 
MMs from 2003 to 2009 as well as in 67 carcinoma 
metastases in the pleura. 
Methods: MMs were immunostained with 3 positive 
mesothelioma (calretinin, keratin 5, and WT-1) 
and 5 positive carcinoma markers [polyclonal 
carcinoembryonic antigen (pCEA), CD15 (LeuM1), 
Ber-EP4, MOC-31, and thyroid transcription factor-1 
(TTF-1)], selected following both evaluation of the 
literature and experience in the authors’ laboratory. 
The same antibodies were also applied to the 
67 pleural metastatic carcinomas. The relevant 
sensitivities and speciÀcities were calculated for each 
antibody and logistic regression (LR) was applied 
to determine the optimal combination of antibodies 
for distinguishing MM from pleural metastatic 
carcinoma. 
Results: The sensitivities and speciÀcities were as 
follows: 
Sensitivity (%) SpeciÀcity (%) 
Mesothelioma markers - 
calretinin - keratin 5 - WT-1 
98 99 98 89 81 72 
Carcinoma markers - pCEA 
- CD15 (LeuM1) - Ber-EP4 - 
MOC 31 - TTF-1 
100 92 94 100 100 95 74 94 76 65 
The combined usefulness of the individual 
reactivities of the 3 diagnostically best performing 
antibodies, i.e. calretinin, pCEA and BerEP4, was 
tested by LR analysis, using an exact logistic model 
with estimate of the intercept (SAS v. 8, Proc 
logistic, exact conditional analysis). OR values 
from multivariate LR were as follows: calretinin 
[1 (= positive) vs 0 (= negative)] 66,93; CEA (1 vs 
0) 0,006; and BerEP4 (1 vs 0) 0,0509. This model 
showed no evidence of lack of Àt based on the 
Hosmer-Lemeshow statistic (chi-square = 0.027). 
The likelihood of being an MM for a calretinin-
positive and CEA- and BerEP4-negative case was 
very high (pr = 0,9953), whereas a calretinin-
negative and CEA- and BerEP4-positive case 
had very low probabilities of being an MM (pr = 
0,00097). However, metastatic carcinomas were 
greatly underrepresented in the present material with 
respect to the expected 1:9 proportion in the general 
population. Therefore, the likelihood estimates were 
adjusted according this proportion (Brockstedt U et 
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MO01.08 FREQUENT ACTIVATION OF 
PI3K PATHWAY AND DOWNSTREAM 
SIGNALING ANALYSIS IN MALIGNANT 
PLEURAL MESOTHELIOMA (MPM)
Susana Cedrés1, M. A. Montero2, Davis Torrejon2, 
Pablo Martinez2, Victor Freixinos1, Nuria Mulet-
Margalef1, Isaac Nuñez1, Guillem Argiles1, Maite 
Salcedo2, Santiago Ramón Y. Cajal2, Enriqueta Felip1 
1Medical Oncology, Vall D´hebron University 
Hospital/Spain, 2Vall D´hebron University Hospital/
Spain
Background: MPM is an aggressive and 
heterogeneous neoplasm with strong variability 
in patient survival that may be due to biological 
variability. The AKT/mTOR pathway is frequently 
activated in mesothelioma cell lines. The aim 
of this study is to explore the expression and 
phosphorylation status of PTEN, PI3K/AKT and 
downstream signaling in MPM and its relationship 
with the patient´s (pts) prognosis. 
Methods: Thirty-three consecutive MPM pts 
were retrospectively collected from our institution 
between 2002 and 2009. Clinical data analyzed 
included sex, age, histology, performance status (PS), 
white blood count, and response to chemotherapy 
(CT). ParafÀn-embedded biopsies were used for 
immunohistochemical proÀle quantiÀed through 
the H-score method. Total and phosphorylated (p) 
proteins analyzed: PTEN, mTOR, MAPK, AKT, 
4EBP-1, eiF4E, S6 and FOXO3a. Staining results of 
each protein were compared with clinical features 
and the results were calculated according to the 
median H-score. 
Results: The total cohort of 33 pts included 25 
male/8 female; median age 68 (range 52-83); 
histology epithelial/no-epithelial (22:11); neutrophil/
lymphocyte ratio (NLR) >/5 (14:18); stage III/
IV (17:13); PS 0/1(3:24). Patients received either 
platinum-pemetrexed (70%) or platinum-gemcitabine 
(25%) and 21.7% of pts had partial response and 
43.5% stable disease. Median OS was 16.4months. 
Expression of PTEN, pMAPK, mTOR, 4EBP-1, 
p4EBP-1, eif4E, peif4E, pAKT, p-S6 and FOXO3a 
in MPM was found in 90%, 100%, 93.3%, 100%, 
43.3%, 96.7%, 100%, 80%, 63.3% and 100% of 
tumors respectively. No correlations were found 
between proteins and age, performance status, stage 
and response to chemotherapy. Epithelial subtype 
histology and NLR less than 5 were associated with 
was consistent across the data and identify which 
were associated with patient survival. Associations 
of mRNA expression levels and disease-speciÀc 
survival were evaluated by univariate Cox 
proportional hazard regression. To improve the 
accuracy of predicted miRNA-mRNA pairs, de novo 
DNA motif analysis was performed on the putative 
targets of a subset of important miRNAs.
Results: We found multiple miRNA (total = 
12) showing negative correlation in expression 
to multiple genes, and having the opposite 
expression pattern in MM vs normal compared 
to their putative targets. We arrived at this total 
by retaining only miRNA whose targets were 
consistent across multiple datasets, showed 
signiÀcantly over-represented DNA motifs in their 
3’ untranslated regions, and were signiÀcantly 
differentially expressed in tumors (q<0.05). An 
example: expression of miR-1 negatively correlated 
with expression of 52 mRNA (FDR<0.05). This 
miRNA was underexpressed in MM by 3-fold 
more (FDR<0.01), while its gene targets showed 
an opposite pattern being overexpressed in MM. 
Motif analysis of target genes identiÀed a subset of 
biologically plausible miRNA-mRNA interactions. 
Ingenuity pathway analysis of these subset genes 
showed enrichment in oncogenic genes (e.g. p21, 
TRAF2, SAA1, and NADSYN1) positively affecting 
cell growth, survival, anti-apoptosis, immune cell 
trafÀcking and inÁammation-related signaling. 
Suppressed expression of these genes that are 
negatively-correlated with miR-1, associated with 
better overall survival in an independent dataset, 
indicating that loss of expression of this miRNA 
affects poorer patient outcomes (FDR<0.01).
Conclusion: Integrated analysis of miRNA and 
mRNA expression proÀles in MM revealed novel 
miRNA associated with MM and identiÀed putative 
interactions that may underlie the malignant 
phenotype. These miRNA-mRNA are candidates 
for functional validation. miR-1 is a putative tumor 
suppressor miRNA in MM.
Keywords: microRNA, mesothelioma
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CG, Hendriks RW, et al. Consolidative dendritic 
cell-based immunotherapy elicits cytotoxicity 
against malignant mesothelioma. Am J Respir 
Crit Care Med. [Clinical Trial Research Support, 
Non-U.S. Gov’t]. 2010 Jun 15;181(12):1383-90). 
However, it is known that tumor cells create an 
immunosuppressive environment that can lead to a 
down-regulation of the anti-tumor immunity. Several 
types of suppressive cells (regulatory T cells, M2 
macrophages and myeloid-derived suppressor cells) 
seems instrumental in allowing a growing cancer 
to evade immunological attack and contribute to 
the impaired T cell function frequently observed 
in cancer patients. The goal of this study is to 
investigate the presence and function of regulatory 
T cells (Treg) in tumor bearing animals and cancer 
patients. Here we show measures to overcome these 
suppressive mechanisms in combination with DC-
based immunotherapy with the goal to increase the 
success rate of tumor eradication. New Àndings in 
preclinical models have already led to the initiation 
of a follow-up clinical study in mesothelioma 
patients where DC-based immunotherapy is 
combined with low-dose cyclophosphamide to 
prevent the induction of Treg. 
Methods: Tumor bearing mice were treated with 
DC-immunotherapy combined with low dose 
cyclophosphamide and mean and overall survival 
was measured. Treg in blood, lymph nodes and 
spleens were analyzed by Áowcytometry. Patients 
with MM are treated with three vaccinations of 
clinical-grade ex-vivo generated autologous DC 
at two-week intervals alternating with low-dose 
cyclophosphamide after chemotherapy treatment. 
Each vaccine was composed of mature DC pulsed 
with autologous tumor lysate and keyhole limpet 
hemocyanin (KLH) as a surrogate marker. Delayed-
type hypersensitivity activity to tumor antigens 
and KLH was assessed, both in vivo and in vitro. 
Peripheral blood was analyzed for anti-tumor 
responses and Treg reductions. 
Results: The survival of mice increased when 
simultaneously metronomic cyclophosphamide 
was given due to the reduction of Treg in blood 
and lymphoid organs. Until today, eight of the ten 
included patients with MM completed the protocol. 
Administration of DC pulsed with autologous tumor 
lysate in combination with cyclophosphamice 
was safe with moderate fever as the only side 
effect. There was no evidence of autoimmunity. 
The vaccinations induced distinct immunological 
responses to KLH. Additional results will be 
better survival (OS: 23.4 v 2.3 months, p<0.001, 
for epithelial versus no epithelial and 29.11 v 5.55 
months, p=0.001, for pts with NLR less than 5). 
We found a signiÀcant correlation between low 
pS6 protein expression and longer progression free 
survival (PFS: 7.88 v 5.55 months; p=0.044) and 
overall survival (OS: 23.36 v 5.59 months; p=0.05). 
Among other phosphorylated proteins analyzed no 
differences in survival were detected according to 
median H-score, however, a trend to better results 
in pts with low levels of p4EBP-1 (PFS 7.69 v 5.55 
months, OS 23.36 v 5.55months; p>0.05) was found. 
In multivariate analysis histology and NLR were 
independent prognostic factors for OS (HR 5.42; 
95%CI, 0.44-3.15, p=0.007 and HR 3.43; 95%CI 
1.22-10.79, p=0.018 respectively), but pS6 only 
showed a trend (HR 1.22; 95%CI 0.35-4.07; p=0.7) 
Conclusion: Our results support the prognostic value 
of histologic subtype and NLR in MPM. The PI3K 
pathway and downstream proteins are frequently 
activated. The role of pS6 assessment and its 
prognostic value is worth of prospective validation in 
future studies on MPM. 
Keywords: pS6, prognostic factor, malignant pleural 
mesothelioma, PI3K
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MO01.09 IMPROVING DENDRITIC 
CELL-BASED IMMUNOTHERAPY BY 
MODULATING IMMUNE SUPPRESSIVE 
REGULATORY T CELLS IN 
MESOTHELIOMA
Robin Cornelissen1, Joost Hegmans2, Joris Veltman2, 
Marlies Heuvers2, Margaretha Lambers2, Femke 
Muskens2, Bart Lambrecht3, Rudi Hendriks2, Henk 
Hoogsteden1, Joachim G. Aerts2 
1Pulmonary Medicine, Erasmus MC/Netherlands, 
2Erasmus MC/Netherlands, 3University Of Ghent/
Belgium
Background: Malignant pleural mesothelioma is a 
highly aggressive neoplasm. Median survival from 
the Àrst signs of illness is 9 - 11 months. Because 
of the limited success of current treatments, novel 
therapeutic regimens are urgently needed. We have 
previously demonstrated that vaccination with 
antigen-pulsed dendritic cells (DC) in mesothelioma 
patients was safe, feasible, and capable of inducing 
distinct immune and antitumor responses (Hegmans 
JP, Veltman JD, Lambers ME, de Vries IJ, Figdor 
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patients with high and low SUV and epithelioid and 
non-epithelioid histotype showed a better prognosis 
in both low SUV and epithelioid tumor. The median 
follow-up for all surviving patients was 36 months. 
Disease free survival were 11 and 21 months for 
the high and low SUV groups, respectively. Median 
survivals were 16 and 29 months for the high and 
low SUV groups, respectively. In a multivariable 
analysis, high SUV tumors were associated with a 
4.1 times greater risk of death than low SUV tumors 
(p = 0.04). 
Conclusion: PET/CT appears to give a good support 
in staging and prognosis in MPM. A systematic use 
of PET scan could be anticipate the recurrence of 
MPM in follow-up period in EPP submitted patients. 
Keywords: malignant pleural mesothelioma, 
diagnosis, Prognosis
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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MO01.12 STAGE-INDEPENDENT PRE-
OPERATIVE PROGNOSTIC GROUPING 
OF SURGICALLY-TREATED PATIENTS 
WITH EPITHELIAL MALIGNANT 
PLEURAL MESOTHELIOMA
Ritu R. Gill1, Beow Yeap2, Shin Matsuoka1, Andrea 
S. Wolf3, Raphael Bueno3, Hiroto Hatabu1, David J. 
Sugarbaker3, William G. Richards3 
1Radiology, Brigham And Women’s Hospital/United 
States Of America, 2Cancer Center, Massaschusetts 
General Hospital/United States Of America, 
3Surgery, Brigham And Women’s Hospital/United 
States Of America
Background: We sought to derive and validate 
a practical risk model to predict survival 
following cytoreductive surgery for patients with 
biopsy diagnosis of epithelial malignant pleural 
mesothelioma (MPM). 
Methods: We reviewed 216 (47F:169M) 
MPM patients who underwent extrapleural 
pneumonectomy (EPP;162) or pleurectomy/
decortication (PD;54) during 2001-2008 and had 
available preoperative DICOM CT data, from 
which tumor volume was calculated. Gender, age, 
clinical TNM stage and preoperative laboratory 
factors (platelet count, hemoglobin, and white blood 
presented at the congress. 
Conclusion: For the Àrst time, we showed 
that immunotherapy combined with low-
dose cyclophosphamide is feasible and safe in 
mesothelioma patients. At the time of the congress 
results on the presence and function of Treg in the 
blood of patients are available. 
Keywords: mesothelioma, immunotherapy, dendritic 
cell, regulatory T cell
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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MO01.11 THE ROLE OF PET/CT IN 
STAGING AND SURGICAL APPROACH 
FOR MALIGNANT PLEURAL 
MESOTHELIOMA
Cosimo Lequaglie1, Gabriella Giudice1, Christian 
Rolfo2, Daniela R. Marasco1, Aniello Della Morte1 
1Thoracic Surgery, Irccs-crob/Italy, 2Clínica Rotger/
Spain
Background: To show the PET/CT role in reducing 
the exploratory procedures with an early diagnosis, 
in a better staging of disease and in a postoperative 
follow-up in MPM. 
Methods: Sixty-seven potentially extrapleural 
pneumonectomy (EPP) submitted patients (range 
age of 31-79 years) were observed between 1999 
and 2009. All patients underwent PET/TC scan: 
median preoperative SUV was 6.8 (range 3-20). 
The same surgeon team operated 45 patients (29 
male - 16 female), 23 right-sided lesions and 22 
left-sided. Forty patients underwent EPP, 1 pleural 
decortications, 3 exploratory thoracotomies for 
chest wall or inferior vena cava invasion, and 1 
laparoscopy for peritoneal metastases. One patient 
were no surgical proposed for macroscopically 
evidence of extended diseases and received 
chemotherapy. Thirty-seven patients had epithelioid 
subtype, 3 sarcomatous and 6 biphasics. Eighteen 
tumors were pStage I-II, 24 pStage III and 4 pStage 
IV according IMIG staging system. 
Results: All T4 or M1 cases were detected by PET/
CT preoperative scan. The follow-up study reported 
a PET/TC sensibility of 95% with a diagnostic 
accuracy of 92% regarding the local recurrences 
or distant metastases. The analysis correlation in 
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MO01.13 LUNG SPARING MAXIMAL 
CYTOREDUCTION FOR PLEURAL 
MESOTHELIOMA COMPARES 
FAVORABLY WITH EXTRAPLEURAL 
PNEUMONECTOMY
Harvey I. Pass1, S Gadgeel2, Antoinette Wozniak2, 
Abraham Chachoua3 
1Cardiothoracic Surgery, Nyu School Of Medicine/
United States Of America, 2Karmanos Cancer 
Institute/United States Of America, 3Thoracic 
Oncology, New York University School Of Medicine/
United States Of America
Background: Debate continues regarding the role of 
operations other than extrapleural pneumonectomy 
(EPP) for pleural mesothelioma (MPM). There has 
been recent interest in pleurectomy (P) to achieve 
comparable maximal cytoreduction as an EPP, but 
the number of cases reported is small,the magnitude/
deÀnition of the operation varies, and overall/
progression free survivals (TTP) are difÀcult to 
interpret. Large case series which use consistent 
criteria for lung sparing in MPM may add insight for 
future management. 
Methods: From 1990 to 2010, 318 MPM 
(64F,254M) had either EPP (142), P(102), or Biopsy 
only (B, 74) performed by one surgeon, and 30 
day mortality was 12 (8%), 2(2%), and 1(1%), 
respectively. Our approach has been maximal lung 
sparing hemithoracic cytoreduction whenever 
possible, especially in low tumor volume MPM. 
MPM histology was 182 epithelial, 74 biphasic, 26 
sarcomatoid, 36 NOS. All patients had CT scans q 
3 months until progression/death, and after 1994 
received postoperative or induction chemotherapy. 
Recurrence was documented histologically 
or cytologically when feasible. To achieve 
cytoreduction, the pericardium, diaphragm, and 
portions of lung were frequently combined with P. 
Results: The MS for B was 5 and 6 months 
without/with adjuvant therapy. The results of 
maximal cytoreductive surgery by EPP or P with 
and without chemotherapy are seen below, and 
reveal comparable MS of P to EPP in Stage I (and 
III) when compared to the literature, a 6 month 
increase in MS and TTP with chemotherapy, and 
a role for EPP in patients with Stage II disease. 
cell count) were also assessed. A Cox model was 
derived based on 102 patients with epithelial Ànal 
pathology who underwent EPP 2001-2007 using 
factors signiÀcantly related to survival in univariate 
analyses. A preoperative risk assessment algorithm 
based on the model was then applied to all 2001-
2007 EPP patients with epithelial biopsy including 
the patients used to train the model plus 31 who 
had biphasic histology at Ànal pathology. Algorithm 
performance was assessed using a separate cohort of 
54 patients with epithelial biopsy (PD 2001-2008). 
Results: Multivariate analysis identiÀed tumor 
volume larger than 500 cm3 and preoperative anemia 
as independently associated with shorter survival 
duration following EPP for epithelial MPM. A 
risk assessment algorithm based on these factors 
separated biopsy-determined epithelial patients 
(including some with biphasic MPM on Ànal 
pathology) into three distinct prognostic groups. 
Risk groups 1, 2 and 3 (R1, R2, R3; Ns= 62, 51, 
19) had 35.3, 10.4 and 3.7 month median survival, 
respectively. Similarly, in a separate cohort of 
contemporary MPM patients who had epithelial 
MPM based on preoperative biopsy (including 14 
pathologic biphasic) and subsequently underwent 
PD (Ns= 28, 21, 5) survival was 33.0, 13.9 and 5.0 
months. Pooled results are depicted in the Àgure. 
Conclusion: Radiographic tumor volume and 
hemoglobin level are measurable preoperatively and 
provide robust, stage-independent prognostication 
for patients with apparent epithelial MPM based 
on pleural biopsy treated with EPP or PD. Most R1 
patients experience extended survival following 
surgery-based multimodality therapy. Surgery for 
R2 patients and those with biphasic histology on 
biopsy should be in the context of clinical trials 
investigating novel therapeutic approaches or 
strategies to further delineate risk. R3 patients do not 
demonstrate beneÀt and should be considered for 
non-operative treatment or supportive care. 
Keywords: Prognosis, mesothelioma, Surgery
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in lung function and lung perfusion scans in patients 
with MPM before and after RP.
Methods: All patients with histologically proven 
MPM were evaluated for trimodality therapy 
including RP as surgical procedure in a prospective, 
observational study from January to December 2010. 
Pulmonary function tests and lung perfusion scans 
were obtained before and 2 months after RP. Primary 
end-points were pulmonary function by means 
of forced vital capacity (FVC), forced expiratory 
volume in 1 second (FEV1) and ipsilateral lung 
perfusion, respectively.
Results: Sixteen patients (age 68.8 ± 8.9 years) 
out of 25 consecutively evaluated patients were 
included in the present study. Exclusion were due 
to metastatic disease (n=1), complete remission 
after induction chemotherapy (n=1), rapid 
progressive disease (n=1), chest wall inÀltration 
(n=2) and impaired cardio-pulmonary reserve (n=3), 
respectively. Multimodality treatment was applied 
in all patients including RP followed by adjuvant 
chemotherapy and radiation of the chest wall. 
Macroscopic complete resection could be achieved 
in 81.3% (13/16). Diaphragm resection was indicated 
due to inÀltration in 5 patients (31.3%). Statistically 
signiÀcant improvement of pulmonary function was 
observed after surgery for FVC (L), FVC (%) and 
FEV1 (%) as well as ipsilateral lung perfusion after 
Bonferroni adjustment (P < 0.05/5). The avoidance 
of diaphragm resection resulted in greater increase 
of FVC (=Post-pre FVC (%) +34.6±17.0% vs. 
+13.5±5.4%; p=0.002) and FEV1 (=Post-pre FEV1 
(%) +29.2±18.1% vs. +12.1±6.4%; p=0.015), 
respectively. 
 Pre-operative 
Value 
Post-operative 
Value 
p- value Cohen’s 
d 
Effect 
size 
FVC (Liter) 2.18± 0.49 2.73± 0.55 0.0060 1.06 large 
FVC (%) 54.7 ± 9.9 68.9 ± 9.1 0.0002 1.49 large
FEV1 
(Liter) 
1.79 ± 0.45 2.18 ± 0.50 0.0292 0.81 large 
FEV1 (%) 60.2 ± 10.3 73.6 ± 11.4 0.0015 1.23 large 
Ipsilateral 
Perfusion 
(%) 
29.2 ± 6.5 38.5 ± 3.5 0.0001 1.78 large 
Conclusion: SigniÀcant improvement of pulmonary 
function and lung perfusion can be observed after 
lung-sparing RP and recovery time of two months. 
Preservation of the diaphragm is associated with 
better functional results. Lung-sparing RP might 
preserve physiological reserve and allow patients 
Patients who recurred after EPP survived a median 
of 3 months from the time of recurrence, while those 
who recurred after P survived a median of 9 months 
from the time of the recurrence (p<0.001). 
Conclusion: This is one of the largest single-surgeon 
series documenting that (1) maximal lung sparing 
cytoreductive surgery by multivariate analysis is not 
inferior to EPP (2) and may be preferable in patients 
with Stage I and Stage III disease. EPP appears to 
be associated with a trend towards greater survival 
and signiÀcantly longer TTP in Stage II disease. 
The dramatic differences in survival between EPP 
and P need to be explored to determine whether 
this is due to loss of functional capacity with EPP 
which prevents further therapy. Maximal lung 
sparing cytoreductive surgery should be compared 
prospectively to EPP after standardization of 
techniques and deÀnitions, at least in the form of an 
ongoing IASLC registry. 
Keywords: pleurectomy, Extrapleural 
pneumonectomy, adjuvant therapy
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MO01.14 PROSPECTIVE EVALUATION 
OF THE FUNCTIONAL RESULTS 
AFTER LUNG-SPARING RADICAL 
PLEURECTOMY FOR MALIGNANT 
PLEURAL MESOTHELIOMA
Servet Bölükbas1, Michael Eberlein2, Joachim 
Schirren1 
1Thoracic Surgery, Dr. Horst Schmidt Klinik/
Germany, 2Division Of Pulmonary And Critical 
Care Medicine, Johns Hopkins University School Of 
Medicine/United States Of America
Background: Lung function can be reduced by 
entrapped lung parenchyma via a rind of tumor of 
malignant pleural mesothelioma (MPM) with or 
without concurrent effusion. Expansion of trapped 
lung can be achieved by radical pleurectomy (RP). 
The aim of this investigation was to study changes 
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Tuesday-Friday each week of concurrent therapy. 
After completion of concurrent therapy pts received 
consolidation therapy (CT) with B+ E for 6 cycles. 
All histologies were eligible; an early stopping rule 
for pulmonary hemorrhage (PH) was included for 
the squamous (SQ) pts. The primary end-point was 
1-year progression free survival (PFS).
Results: 45 patients eligible patients were accrued; 
median age 61 yrs (range 34 to 74), 33 non-SQ 
& 12 SQ; 29 stage IIIA & 16 stage IIIB; 33 pts 
PS 0 & 12 PS of 1. Cohort 2 was expanded to the 
phase II trial. CT was determined to not be feasible 
and SQ cohort was closed due to PH. Grade  3 
toxicity observed with IND therapy was neutropenia 
(42%) and grade 3 hypertension (2%). Grade  3 
toxicities observed with CON were esophagitis 
(29%), pneumonitis (2%); neutropenia (13%), hgb 
(7%), thrombocytopenia (7%); one trachoesphogeal 
Àstula was observed. In SQ cohort 3 of 12 patients 
experienced PH; 1 grade 3, 2 grade 5. 33 pts have 
experienced disease progression or death; the 1-year 
PFS rate observed was 44% (95% CI, 29-58%), 
median PFS was 10 months (95% CI, 8-22). 27 pts 
have died, and the median follow-up for survivors is 
37 months (range 5-54); median OS was 19 months 
(95% CI, 13 to 33). The median OS observed in 
the non-SQ and SQ cohorts was 19 and 17 months, 
respectively.
Conclusion: The PFS and OS with the addition of 
B+E to CbP with 74 Gy TCRT appears similar to 
previous experience with CbP alone with 74 Gy 
TCRT.
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MO02.02 DETERMINATION OF 
STANDARD DOSE CETUXIMAB 
TOGETHER WITH CONCURRENT 
INDIVIDUALISED, ISOTOXIC 
ACCELERATED RADIOTHERAPY 
AND CISPLATIN-VINORELBINE FOR 
PATIENTS WITH STAGE III NON-SMALL 
CELL LUNG CANCER (NSCLC): A PHASE 
I STUDY (NCT00522886)
Anne-Marie Dingemans1, Gerben Bootsma2, Angela 
Van Baardwijk3, Bart Reymen3, Rinus Wanders3, 
Monique Hochstenbag1, Arne Van Belle1, Ruud 
Houben3, Jacques Borger3, Philippe Lambin4, Dirk 
De Ruysscher4 
with MPM to be eligible for further therapeutic 
options in the long term.
Keywords: malignant pleural mesothelioma, radical 
pleurectomy, Pulmonary function, Lung Perfusion 
Scan
Session MO02: Concurrent 
Chemoradiotherapy Combined With 
New Drugs And New Radiotherapy 
Schemes and Techniques
Monday, 4 July 2011
Concurrent Chemoradiotherapy Combined With New Drugs And New 
Radiotherapy Schemes and Techniques Monday, 4 July 2011 14:30-
16:00
MO02.01 PHASE I/II TRIAL OF 
BEVACIZUMAB (B) AND ERLOTINIB 
(E) WITH INDUCTION (IND) AND 
CONCURRENT (CON) CARBOPLATIN 
(CB)/PACLITAXEL (P) AND 74 GY 
OF THORACIC CONFORMAL 
RADIOTHERAPY (TCRT) IN STAGE 
III NON-SMALL CELL LUNG CANCER 
(NSCLC).
Mark A. Socinski1, Thomas Stinchcombe2, Dominic 
T. Moore2, Scott N. Gettinger3, Roy H. Decker3, 
William J. Petty4, Aw Blackstock4, Gary Schwartz5, 
Scott Lankford5, David Morris2 
1Hematology/oncology, University Of North 
Carolina/United States Of America, 2University Of 
North Carolina/United States Of America, 3Yale 
University/United States Of America, 4Wake Forest/
United States Of America, 5Northeast Oncology 
Associates/United States Of America
Background: Agents which target the epidermal 
growth factor receptor (EGFR) and inhibit 
angiogenesis have been shown to improve overall 
survival (OS) in advanced NSCLC and have 
radiosensitizing properties. 
Methods: Patients (pts) received Cb (AUC=6), P 
(225 mg/m2) and B (15 mg/kg) on days 1 and 22. 
On day 43 patients received Cb (AUC=2) and P (45 
mg/m2) weekly x 7 weeks (wks) with TCRT to 74 
Gy; cohort 1 (n=5) received B 10 mg/kg q 2 wks, 
cohort 2 (n=5) and cohort 3 (n=5) both received B 
10 mg/kg q 2 wks as well E at 100 mg and 150 mg 
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not reached. The trial was approved by the required 
authorities, all patients gave informed consent. 
Results: Between 09/2007 and 10/2010 24 patients 
(12 males and 12 females, mean age 62.2 years) 
were included. The dose could be escalated to the 
third dose level. Full data are available from the 
Àrst 18 patients. ³ Grade 3 toxicity was observed in 
8/18 patients. Grade 3 toxicities were fatigue 2/18, 
oesophagitis 1/18, skin toxicity 1/18, diarrhoea 1/18, 
cough 1/18, dyspnea 1/18, vomiting 1/18, pulmonary 
embolism 1/18. DLT was not reached. One patient 
with a complete metabolic response in dose level 3 
developed a fatal hemoptoe 4 months after treatment. 
Although not in MTD period it was decided to 
include 6 extra patients in the third dose level. 
Metabolic PET responses in the Àrst 18 patients: 8 
complete response, 8 partial response, 1 progressive 
disease, 1 missing. 
Conclusion: Concurrent isotoxic, accelerated 
chemo-radiotherapy with cetuximab, cisplatin-
vinorelbine seems feasible with acceptable toxicity 
and promising metabolic response rates. Final results 
will be presented. 
Keywords: cetuximab, stage III NSCLC, fase I
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MO02.03 RANDOMIZED PHASE II TRIAL 
OF URACIL/TEGAFUR (UFT) AND 
CISPLATIN VERSUS VINORELBINE 
AND CISPLATIN WITH CONCURRENT 
THORACIC RADIOTHERAPY FOR 
LOCALLY ADVANCED UNRESECTABLE 
STAGE III NON-SMALL-CELL LUNG 
CANCER: NJLCG 0601
Hiroshi Watanabe1, Shunichi Sugawara1, Makoto 
Maemondo2, Motoko Tachihara3, Tomohiro 
Sakakibara4, Takashi Ishida3, Akira Inoue4, Kazuhiro 
Usui5, Osamu Ishimoto1, Nobumichi Matsubara2, 
Yasuo Saijo6, Toshihiro Nukiwa4 
1Pulmonary Medicine, Sendai Kousei Hospital/
Japan, 2Miyagi Cancer Center/Japan, 3Fukushima 
Medical University/Japan, 4Tohoku University 
Hospital/Japan, 5Kanto Medical Center Ntt-ec/
Japan, 6Hirosaki University Graduate School Of 
Medicine/Japan
Background: A treatment with uracil/tegafur(UFT) 
and Cisplatin (UP) in combination with concurrent 
1Pulmonology, Maastricht University Medical 
Center/Netherlands, 2Pulmonology, Atrium Mc 
Parkstad/Netherlands, 3Radiation Oncology, 
MAASTRO Clinic, Grow - School For Oncology 
And Developmental Biology, Maastricht University 
Medical Centre/Netherlands, 4Department Of 
Radiation Oncology (MAASTRO), Grow, Maastricht 
University Medical Centre/Netherlands
Background: Concurrent chemo-radiotherapy 
is the treatment of choice for patients with stage 
III NSCLC. Survival is far from satisfactory and 
strategies to improve outcome are needed. As 
cetuximab, a monoclonal antibody against EGFR, 
improves survival in head and neck cancer when 
added to radiotherapy and has activity against 
NSCLC, we investigated the maximum tolerated 
dose (MTD) of cetuximab with concurrent chemo-
radiation in stage III NSCLC. Individualised, 
isotoxic accelerated radiotherapy was chosen to 
allow the maximal tolerable radiation dose for each 
individual patient based on normal tissue constraints. 
Methods: In this open label phase I study patients 
with stage III NSCLC were included. Main inclusion 
criteria: WHO-PS 0-1, FEV1>50%, DLCO>50%, 
weight loss<10%, no severe cardiac disease, normal 
renal function. Patients without progression after 
2 cycles of gemcitabine 1250 mg/m2 day 1-8 and 
carboplatin AUC 5 on day 1 every 3 weeks were 
included and treated with cetuximab: 400 mg/kg day 
-7 and 250 mg/kg weekly together with concurrent 
radiotherapy and cisplatin (50 mg/m2 day 1-8 and 40 
mg/m2 day 22)-vinorelbine for 5 weeks. The dose of 
vinorelbine was escalated in 3 steps: step 1 10 mg/
m2 day 1-8 and 8 mg/m2 day 22-29; step 2 20 mg/
m2 day 1-8 and 8 mg/m2 day 22-29; step 3 20 mg/
m2 day 1-8; 15 mg/m2 day 22-29. Radiotherapy: 3 
weeks 1.5 Gy BID (45 Gy) followed by 2Gy QD to 
a mean lung dose of 19 Gy. Maximum dose 69 Gy in 
5.5 weeks. 
Toxicity (CTCAEv3.0) was scored till 3 months 
after radiotherapy. An FDG-PET-CT was performed 
3 months after radiotherapy. The primary endpoint 
of the study was MTD 3 months after concurrent 
chemo-radiotherapy. MTD was deÀned as: ³2/6 
patients had ³grade 3 pneumonitis, diarrhoea, liver 
or renal toxicity or ³ 3/6 patients had ³ grade 3 
oesophagitis. When 1/6 patients developed grade 
4 skin or neurological or grade 5 haematological 
toxicity the dose level was extended with 6 patients. 
Patients were included in a next dose level when all 
patients were followed for 3 months and MTD was 
S490 Copyright © 2011 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
Concurrent Chemoradiotherapy Combined With New Drugs And New 
Radiotherapy Schemes and Techniques Monday, 4 July 2011 14:30-
16:00
MO02.04 MULTIMODALITY 
TREATMENT WITH RADIO-
CHEMOTHERAPY AND ERLOTINIB IN 
ADVANCED NSCLC (MARTE TRIAL)
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Background: Chemoradiation is the standard of care in 
locally advanced NSCLC even if the optimal regimen 
of association is still a matter of discussion. Preclinical 
data suggest that Erlotinib have radiosensitizing activity. 
Moreover, the correlation between histology and drugs 
activity was largely demonstrated in metastatic NSCLC. 
We report the results of a phase II trial exploring 
feasibility and the activity of the Tyrosine Kinase 
Inhibitor, Erlotinib, with concurrent Pemetrexed- or 
Gemcitabine-based chemoradiation.
Methods: Previous chemotherapy treated patients with 
histo-citologically conÀrmed NSCLC, stage IIB-IV and 
local recurrences were treated according to a combined 
chemo-radiation protocol with oral Erlotinib, 150 mg/
die (E-) and weekly Gemcitabine (GEM) 300 mg/
m2 (E-GEM group) or Pemetrexed (PEM) 500mg/m2 
every 3 weeks (E-PEM group). IF radiotherapy was 
delivered up to 50,4-59.4 Gy, with standard fractionation. 
Toxicities were assessed according to the NCI CTC 
3.0 scale. Clinical response was evaluate with RECIST 
criteria at 4-5 weeks after the end of radiochemotherapy 
by CT scan with or without PET/TC 18 FDG.
Results: From July 2007 to October 2010, 60 patients, 
20 squamous-cell carcinoma (SCC) and 40 Non-SCC 
were enrolled. Stages were recorded as follows: 63% 
Stage II-III, 10% local relapses after surgery, and 
27% oligometastatic stage IV. The median age was 65 
years (range 39-83). All but 5 patients (92%) received 
previous chemotherapy (median 4 cycles). 23 patients 
was treated in E-GEM group while 37 with in E-PEM 
one. Two groups did not differ in gender (p=0.093) 
and stage (p=0.587). E-PEM group population was 
younger and received more cycles of chemotherapy 
(p=0.017 and p=0.02, respectively). Chemoradiation 
was well tolerated. 4 patients developed a G3 skin 
thorachic radiotherapy (c-TRT) could have favorable 
efÀcacy with less toxicity for locally advanced non-
small-cell lung cancer (NSCLC). We conducted this 
randomized phase II study to compare this regimen 
to a treatment with vinorelbine and cisplatin (NP), 
which is a commonly used regimen with c-TRT for 
locally advaced NSCLC in Japan.
Methods: Patients with locally advanced NSCLC 
were randomized to receive UP (UFT400 mg/m2 on 
days 1-14 and 29-42 and cisplatin 80 mg/m2 on days 
8 and 36) or NP (vinorelbine 20 mg/m2 on days 1, 
8, 29, and 36 and cisplatin 80 mg/m2 on days 1 and 
29), stratiÀed by age, gender, histology, and stage. 
In both arms, c-TRT began on day 1 (total 60Gy 
in 30 fractions). The primary endpoint was overall 
response rate (ORR), and secondary endpoints were 
progression-free survival (PFS), overall survival, 
and toxicity proÀle. Assuming that ORR of 80% in 
eligible patients would indicate potential usefulness 
while ORR of 60% would be the lower limit of 
interest, the estimated accrual was 33 patients in 
each arm. 
Results: From February 2006 to May 2009, 70 
patients were enrolled from 5 institutions. Finally 
66 patients were evaluable for efÀcacy and safety. 
Patient characteristics were: Male/Female 54/12; 
median age 62 (range 40-75); Performance status 0/1 
31/35; IIIA/IIIB 24/42. ORRs were 80% (95%CI: 
67-93) and 71% (95%CI: 55-87) for the UP arm and 
the NP arm, respectively. With a median follow-up 
of 20.2 months, median PFS and median survival 
in the UP arm were 8.2 and 26.9 months, in the 
NP arm were 6.8 and 21.8 months. The 2-/3- year 
survival rates were 51.0/34.3% and 46.9/33.4% for 
the UP arm and the NP arm, respectively. Grade 3/4 
neutropenia occurred in 20% and 58% of patients 
in the arms UP and NP. There was no remarkable 
difference in other toxicities between both arms. Two 
patients in the NP arm died of radiation pneumonitis. 
Conclusion: Combined with c-TRT, UP achieved 
more preferable efÀcacy and safety compared with 
NP, suggesting a promising candidate as a standard 
regimen with c-TRT for locally advanced NSCLC. 
Further evaluation of UP with c-TRT is warranted in 
a phase III setting in comparison with cisplatin-based 
third generation chemotherapy with c-TRT. 
Keywords: concurrent thorachic radiotherapy, 
locally advanced NSCLC, Vinorelbine, uracil/tegafur
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Background: CTx/RTx followed by S 
(TRIMODALITY = TM) had already been 
successfully piloted as possible treatment strategy 
(Tx) for patients (pts) with stage IIIA(N2) NSCLC 
and selected IIIB (Albain, JCO 1995). Here we 
report 15-y VLTS from a large prospective single 
center phase-II with TM Tx (Eberhardt, JCO 1998) 
that served as predescessor/baseline dataset for our 
Àrst multicenter randomized trial (KREBSHILFE1; 
Poettgen, JCO 2007). The long-term F-UP 
information let us perform a detailed CR analysis.
Methods: Pts with histopathologically 
(mediastinoscopy) proven IIIA(N2) and selected 
IIIB NSCLC received three CTx cycles IND P (60 
mg/m2 d 1+8) and E (150 mg/m2 d 1) qd 22. This 
was followed by cc CTx/RTx including P 50 mg/m2 
d 2 + 9 and E 100 mg/m2 d 4-6 cc with 45 Gy (1.5 
Gy bid). Three to Àve weeks after end of RTx pts 
received S if possible. In pts determined inoperable 
NO deÀnitive RTx-boost was added in this trial. We 
have investigated long-term F-UP for this cohort 
(2/11) and have looked for exploratory subgroups.
Results: Pts accrual from 3/1991 to 12/1994. Pts 
characteristics: 94 (IIIA(UICC5) 52; IIIB 42); gender 
m 75; f 19; PS 0-1; age median 55 range 31-71; 
histo: adeno (ADC) 29; squamous cell (SCC) 51; 
large cell (LCC) 14; 62 pts taken to S: R0 50 (53%); 
pCR 24 (26%). Exploratory VLTS analysis (med 
SURV months (m) , 5-y-OS %, 10-y-OS %, 15-y-OS 
%): med SURV of all pts still alive on F-UP: 98 m; 
all pts 20 m 25.0 18.5 9.3; IIIA(N2) 20 m 32.2 22.3 
11.3 ; IIIB 19 m 13.8 13.8 6.9 (ns log rank); groups 
deÀned by Tx-dependant factors: R0-res 32 m 40.9 
31.8 16.0 no-R0 14 m 5.0 0.0 0.0 log rank p = less 
than 0.0001. R0-res: pCR 25 m 37.5 37.5 10.7 vital 
residual TU: 42 m 43.5 24.2 19.3 log-rank ns. No 
signiÀcant impact of age, histopathology, T-status, 
N-status or gender on LTS observed. 25/94 pts 
throughout study and F-UP period died of CR (TOX, 
CARDVASC, PULMONARY, CO-MORBIDITIES, 
rash one and required dose reduction of Erlotinib to 
100 mg daily. G3/4 liver enzyme toxicity occurred in 
16.6%, trombocytopoenia in 11.6%, leucopoenia in 
30% and anaemia in 5%. In E-PEM group more G3/4 
leucopoenia was reported (43.2% vs 8.6%; p=0.004). 
G3/4 esophagitis and lung toxicity occurred in 2% and 
5% of patients, respectively. 1 patients died for ARDS 
and 1 patients had sepsis with positive hemoculture for 
Staphylococcus Epidermidis . All but 1 patients were 
evaluable for clinical response. Objective response 
was 64% and 68% in E-GEM and E-PEM group, 
respectively (p=0.412). Skin rash was not associated with 
clinical response (p=0.762). Median survival was 14.4 
months. E-PEM group reported a statistically signiÀcant 
advantage in survival respect E-GEM one (p=0.036). In 
particular, E-PEM Non-SCC patients reported higher 
median survival (14.4 vs 4.9 months; p=0.01) and higher 
progression free survival (7.5 vs 4.6 months; p=0.06) 
versus E-GEM Non-SCC group. Analysis of EGFR 
mutational status are actually ongoing.
Conclusion: In the era of the right drug for the right 
patients the choice of the concurrent agent to radiation 
is a particular interesting topic. Our data conÀrm the 
role of histology in the selection of drugs in this setting. 
Addition of Erlotinib to chemo-radiotherapy with 
Gemcitabine or Pemetrexed is effective and feasible. 
Further investigations are necessary to identify patients 
subsets that could beneÀt from addition of target therapy 
to chemoradiation and could be target in future studies.
Keywords: erlotinib, chemoradiation, target therapy, 
histology-based chemotherapy
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MO02.06 15-YEAR (VERY) LONG-TERM 
SURVIVAL (VLTS) AND COMPETING 
RISKS (CR) ANALYSIS OF INDUCTION 
(IND) CHEMOTHERAPY (CTX) WITH 
THREE CYCLES CISPLATIN(P)/
ETOPOSIDE(E) FOLLOWED BY 
CONCURRENT (CC) CHEMORADIATION 
(CTX/RTX) PE/45 GY (1.5 GY BID) PLUS 
SURGERY (S) = TRIMODALITY - PHASE-
II WEST GERMAN CANCER CENTRE 
(WGCC) TRIAL (JCO98).
Rodrigo Hepp1, Thomas C. Gauler2, Christoph 
Poettgen1, Soenke Korfee2, Stephan Bildat3, Georgios 
Stamatis4, Siegfried Seeber5, Hansjochen Wilke5, 
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Background: Pneumonectomy after induction 
chemoradiation for lung cancer remains controversial 
because of previously reported high postoperative 
mortality. We reviewed our 16-year experience to 
determine if induction chemoradiation remains a risk 
factor for 90-day mortality post-pneumonectomy. 
Methods: Data were reviewed for patients who 
underwent pneumonectomy for NSCLC from 
February 1993 through January 2010 at Fox Chase 
Cancer Center. Univariate analysis was done via 
Fisher’s exact test to compare patients undergoing 
pneumonectomy from 1993-2003 and after 2003, 
and to identify risk factors for 90-day mortality. A 
multiple logistic regression model predicting 90-day 
survival was Àt using those variables
Results: 171 patients underwent pneumonectomy, 
54/171 (32%) received concurrent induction 
chemoradiation. 53/54 (98%) received platinum-
based regimens. The most frequent radiation dose 
was 50.4Gy (range, 40Gy-66Gy; one patient did 
not complete RT). Induction patients undergoing 
pneumonectomy after 2003 were similar to those 
undergoing induction and pneumonectomy during 
1993-2003 in terms of median age (65.2 vs. 61.5 
years; P=0.6) gender (61% male vs. 58% male, 
P=1.0), overall clinical stage (cStage) distribution 
(P=0.65), Charlson Co-morbidity Index (median 3.0, 
range 2.0-7.0 vs. median 3.0, range 2.0-6.0; P=0.1), 
preop FEV1 % predicted (median 82, range 47-108; 
vs. median 80.5, range 42-111; P=0.6) and preop 
DLCO % predicted (median 68.5, range 38-99 vs. 
median 71.5, range 50-96; P=0.7). From 1993-2003, 
26/125 (21%) of pneumonectomy patients received 
induction chemoradiation compared to 28/46 (61%) 
pneumonectomy patients after 2003 (P<0.001). 
For 1993-2003, 90-day mortality for induction 
chemoradiation and pneumonectomy was higher than 
for pneumonectomy alone (23% vs. 8%, P=0.07). 
90-day mortality for all pneumonectomy patients 
was lower after 2003 compared to 1993-2003 (2.2% 
vs. 11.2%, P=0.07) despite a higher percentage 
of patients undergoing induction chemoradiation. 
90-day mortality for induction chemoradiation and 
pneumonectomy after 2003 was 1/28 (3.6%). Causes 
of 90-day mortality post-pneumonectomy in all 
patients who underwent induction chemoradiation 
included ARDS (3), CHF, PE, BPF and unknown 
(1 each). Chemoradiation prior to pneumonectomy 
was not a predictor of 90-day mortality by logistic 
regression, whereas operation before 2004 and 
postoperative pneumonia were (Table 1). 
SECOND PRIMARIES, SECOND CANCERS): 6 pts 
pre/postop TOX (between 1-8 m) ; 2 pts (pneumonia, 
cerebral infarction) between 12 and 48 m ; 17 pts 
(cardvasc, pulmon, cerebral infarction, co-morbidities, 
second cancer, second primary) post 50 and up to 213 
m. All events post 60 m (5-yrs) were due to CR. With 
VLTS F-UP brain relapse revealed as a signiÀcant 
number of the observed progression sites (21). No 
brain relapse was noted post 60 m (5-yrs).
Conclusion: VLTS of the WGCC-trial JCO98 
deÀned the rationale for our Àrst randomized 
multicenter trial with S after induction (TM) 
in selected pts with operable IIIA NSCLC. 
Interestingly, no pre-treatment factor turned out 
important on 15-y-VLTS in exploratory analysis, 
not even disease stage, T-, N-status, histopathology, 
age or gender. Partly based on selection effects R0-
res for IIIA and IIIB following induction Tx has 
excellent VLTS prognosis. CR analysis revealed 
deaths due to CR (cardvasc, pulmon, cerebrovasc, 
2nd primary, 2nd cancer) as the only events observed 
post 60 m (5-yrs). Further aiming to improve VLTS 
in stage III NSCLC pts treated with TM Tx has 
to consider aggressive prevention, treatment and 
management of CR typical in this population.
Keywords: Stage III, NSCLC, combined modality, 
Surgery
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MO02.07 IS NEOADJUVANT 
CHEMORADIATION A RISK FACTOR 
FOR 90-DAY MORTALITY AFTER 
PNEUMONECTOMY FOR LUNG 
CANCER IN THE CURRENT ERA?
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Background: IND CTx/RTx followed by S remains 
possible treatment (Tx) for pts with stage IIIA(N2) 
NSCLC (Albain, Lancet 2009) and selected IIIB 
(Eberhardt, JCO 1998; Stupp, Lancet Oncol 2009). 
Here we report LTS from a prospective multicenter 
phase-II trial with trimodality (TM) Tx (CISTAXOL) 
that served as predescessor/baseline dataset for 
our ongoing randomized phase-III (ESPATUE) 
(Poettgen, Int J Radiat Oncol Biol Phys 2010).
Methods: Pts with histopathologically 
(mediastinoscopy) proven IIIA(N2) and selected IIIB 
NSCLC received three IND CTx cycles P (50 mg/
m2 d 1+8) and T (175 mg/m2 d 1) qd 22. This was 
followed by cc CTx/RTx including cis 50 mg/m2 d 
2 + 9 and eto 100 mg/m2 d 4-6 cc with 45 Gy (1.5 
Gy bid). Three to Àve weeks after end of RTx pts 
received S if possible. In pts determined inoperable 
at end of RTx, a deÀnitive CTx/RTx-boost (+20 
Gy; 2 Gy qd) was added. Here we report ten-year 
(overall) LTS for this cohort and look for exploratory 
subgroups.
Results: Pts accrual from 3/99 to 2/02. Pts 
characteristics: 64 (IIIA(N2) 24; IIIB 40); gender m 
48; f 16; PS 0-1; histo: adeno (ADC) 17; squamous 
cell (SCC) 28; large cell (LCC) 17; NOS 2; age: 
median 52.5 (range 28-69). 36 pts taken to S: R0 32 
(50%); R1/R2 3; exploratory 1; pCR 16. Exploratory 
LTS analysis (5y-OS %, 10y-OS %): med SURV of 
all pts still alive on F-UP: 8 yrs 10 mo; all pts 30.1 
27.8; IIIA(N2) 34.3 34.3; IIIB 27.7 23.8 (log-rank 
ns); groups deÀned by pre-Tx factors: histo SCC 
46.2 41.0 ; LCC 23.5 23.5 ; ADC 11.8 11.8 log-rank 
p = 0.0075 ; age less 50 45.9 45.9 age greater/equal 
50 23.1 20.3 log-rank p = 0.035; groups deÀned by 
Tx-dependant factors: R0-res 46.4 46.4 ; no R0 14.6 
9.7 log-rank p = 0.0013 ; R0/pCR 66.0 66.0 R0/vital 
TU 27.0 27.0 log-rank p = 0.03.
Conclusion: LTS of CISTAXOL deÀnes the 
rationale for our ongoing randomized trial with 
S after induction (TM) in selected pts with stage 
IIIA/IIIB. Interestingly, histo and age turn out to 
be important factors in exploratory analysis. ADC 
and older pts demonstrate poor prognosis even with 
aggressive TM. We will prospectively validate these 
Àndings in ESPATUE and perform competing risk 
analysis.
Keywords: NSCLC, Stage III, combined modality, 
Surgery
Table.1. Logistic Regression for 90-Day Survival 
after Pneumonectomy 
Variable OR 95% CI P Value 
Induction Therapy 0.380 0.112-1.292 0.1214 
Pneumonectomy after 2003 9.944 1.126-87.804 0.0387 
Pneumonia, None Postop 4.445 1.208-16.348 0.0248 
Conclusion: Based on our data, neoadjuvant 
chemoradiation is not a risk factor for 90-day 
mortality after pneumonectomy in the current era. 
Since baseline patient demographics seemed similar, 
we hypothesize that changes in radiation treatment 
protocols and surgical management may account for 
these Àndings.
Concurrent Chemoradiotherapy Combined With New Drugs And New 
Radiotherapy Schemes and Techniques Monday, 4 July 2011 14:30-
16:00
MO02.08 10-YEAR LONG-TERM 
SURVIVAL (LTS) OF INDUCTION (IND) 
CHEMOTHERAPY (CTX) WITH THREE 
CYCLES CISPLATIN(P)/PACLITAXEL(T) 
FOLLOWED BY CONCURRENT (CC) 
CHEMORADIATION (CTX/RTX) P/
ETOPOSIDE (ETO)/45 GY (1.5 GY BID) 
PLUS SURGERY (S) - A MULTICENTER 
PHASE-II TRIAL (CISTAXOL).
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This was followed by cc CTx/RTx including P 50 mg/
m2 d 2 + 9 and E 100 mg/m2 d 4-6 cc with 45 Gy (1.5 
Gy bid). 3-5 weeks after end of RTx S was performed 
if possible and supplemented by PCI given thereafter. 
In case of non-operability no RTx boost was planned/
scheduled in this trial. Arm A had local treatment 
alone (S + RTx) and no PCI.
Results: Pts accrual 1/95 to 10/01; eligible 106/112 
randomized; Pts characteristics: gender m 90; f 16; 
age median 57 (37-71); PS 0-1; histo: adeno (ADC) 
35; squamous cell (SCC) 55; large cell (LCC) 16; 
ADSCC 5 TN-groups: T3N0-1 6 (IIIA UICC5 IIB 
UICC6/7) T1-2N2 83 T3N2 17. Med SURV of pts 
still alive on F-UP: 130 mo. LTS exploratory analysis 
(2-y-OS %; 5-y-OS %, 10-y-OS %); B: 54.6 20.0 
12.5; A: 44.2 23.5 10.0 (ns log rank, Wilcoxon); PFS: 
B: 36.4 14.6 12.7 A: 29.4 17.3 10.4 (p = 0.30/0.14 
log rank/Wilcoxon) Disease-speciÀc survival: B; 40.5 
25.0 25.0 A: 32.5 23.1 18.5 (p = 0.16/0.059 log rank/
Wilcoxon), Cumulative 10-y prob %: non-disease-
related events (tox, comorbidity, second cancer): B: 
56.3 A: 67.7 (ns); brain relapse as Àrst site of failure: 
B: 16.6 A: 30.4 (p = 0.059/0.020 log rank/Wilcoxon).
Conclusion: LTS after Tx in operable stage IIIA is 
signiÀcantly hampered by cumulative competing risks 
(toxicities, comorbidities, second cancers) regardless 
of Tx intensity. Even if LT-disease-speciÀc SURV 
may be optimized by aggressive multimodality Tx 
these effects may be ultimately dilluted (in LTS) by 
the competing risks/events in later F-UP. Initial pts 
selection based on comorbidity proÀles and aggressive 
handling of comorbidities (smoking stop, pulmonary, 
cardiac, long-term cancer F-UP) may be most 
important in improving LTS with aggressive protocols 
based on TRIMODALITY (+/- PCI) in the future.
Keywords: NSCLC, combined modality, Surgery, 
prophylactic cranial irradiation
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MO02.11 SOCCAR TRIAL: COMPARING 
TOXICITY AND EFFICACY OF 
HYPOFRACTIONATED CONCURRENT 
CHEMORADIATION TO PUBLISHED 
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MO02.09 LONG-TERM SURVIVAL (LTS) 
AND COMPETING RISKS WITHIN 
A PROSPECTIVE MULTICENTER 
GERMAN RANDOMIZED TRIAL 
COMPARING INDUCTION (IND) 
CHEMOTHERAPY (CTX) FOLLOWED BY 
CONCURRENT (CC) CHEMORADIATION 
(CTX/RTX) PLUS SURGERY (S) (= 
TRIMODALITY) SUPPLEMENTED BY 
PCI VERSUS LOCAL TREATMENT 
ALONE (S + RTX) IN OPERABLE IIIA 
NSCLC.
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Volker Budach8, Siegfried Seeber9, Hansjochen 
Wilke9, Martin Stuschke2, Wilfried Eberhardt1 
1Department Of Medicine (Cancer Research), West 
German Tumor Center, University Hospital Essen/
Germany, 2Department Of Radiotherapy, West 
German Cancer Center, University Hospital Essen/
Germany, 3Dept. Of Medicine (Cancer Research), 
West German Cancer Center, University Hospital 
Essen/Germany, 4Pneumological Oncology, 
Asklepios Clinics Gauting/Germany, 5Thoracic 
Surgery, Ruhrlanclinic/Germany, 6Department Of 
Medicine, Division Of Medical Oncology, University 
Of Colorado Denver/United States Of America, 
7Thoracic Surgery, University Of Freiburg/Germany, 
8Radiation Oncology, Charite/Germany, 9Medical 
Oncology, Huyssen Stiftung/Germany
Background: We have already reported cumulative 
probability (prob) of brain relapse as Àrst site of 
failure within our multicenter German randomized 
trial that investigated TRIMODALITY + prophylactic 
cranial irradiation (PCI) versus S + RTx alone in 
operable IIIA NSCLC (Poettgen, JCO 2007). Here 
we report LTS for these arms, look for exploratory 
subgroups and investigate competing risks observed 
on long F-UP..
Methods: Pts with histopathologically 
(mediastinoscopy) proven operable IIIA (1-2 LN 
involved, no clinical N2, no bulky/extranodal disease, 
central T3N0-1, WHO 0,1) NSCLC were stratiÀed 
(TN-group, center) and randomized. Arm B received 
three CTx cycles induction (IND) cis (P) (60 mg/m2 
d 1+7 or 8) and eto (E) (150 mg/m2 d 3,4,5) qd 22. 
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30 fractions over six weeks ranged from 18-37%. 
Complete table of all trials will be presented.
Conclusion: Toxicity of 55Gy in 20 fractions over 
four weeks with concurrent cisplatin and vinorelbine 
is similar to other published regimens but is 
associated with substantially improved survival. 
This is the Àrst randomised trial of a concurrent 
chemoradiation regimen to achieve two year survival 
above 50%. We believe future research should 
pursue the rationale of hypofractionated radiotherapy 
in combination with chemotherapy. 
Keywords: hypofractionated radiotherapy, 
concurrent chemoradiation, favourable toxicity
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MO02.12 PROTON BEAM THERAPY 
VS. INTENSITY-MODULATED (X-RAY) 
RADIATION THERAPY FOR LOCALLY 
ADVANCED NON-SMALL CELL LUNG 
CANCER
James D. Cox1, Xiong Wei1, Pamela K. Allen1, 
Richard Amos2, Radhe Mohan2, Joe Y. Chang1, 
Zhongxing Liao1, Lei Dong2, Ritsuko Komaki1 
1Radiation Oncology, UT MD Anderson Cancer 
Center/United States Of America, 2Radiation 
Physics, UT MD Anderson Cancer Center/United 
States Of America
Background: The current standard of care for 
locally advanced non-small cell lung cancer 
(NSCLC) in patients with good performance status 
is concurrent chemotherapy and radiation therapy 
(RT). We previously found that using 3D conformal 
(X-ray) RT (CRT) cut the risk of severe esophagitis 
in half relative to 2D RT and that using intensity-
modulated (X-ray) RT (X-IMRT) further reduced 
the risk of pneumonitis, but not that of esophagitis, 
relative to 3D CRT. Hypothesizing that the physical 
dose characteristics of proton particles would 
allow proton beam therapy (PBT) to spare critical 
structures such as esophagus, lung, and bone marrow 
from incidental irradiation to a greater extent than 
X-ray-based therapy, we evaluated the rates of 
severe esophagitis, pneumonitis, and bone marrow 
suppression in patients with locally advanced 
NSCLC treated with concurrent chemotherapy and 
either PBT or X-IMRT.
Methods: Patients with locally advanced NSCLC 
Centre/United Kingdom, 3Newcastle Cancer Centre/
United Kingdom, 4Oncology, St James Institute Of 
Oncology/United Kingdom
Background: The optimal management of locally 
advanced NSCLC remains uncertain. Although 
concurrent chemoradiation is now widely used, it 
is not clear what radiation dose and fractionation 
are most effective and with which chemotherapy 
these should be combined. The introduction of 
concurrent regimens has resulted in higher levels 
of acute oesophagitis and increased treatment 
related mortality (TRM) but although survival 
is increased, the rates of local control remain 
disappointing. Accelerated repopulation during 
radiotherapy diminishes efÀcacy of treatment as 
treatment duration increases. Hypofractionated 
therapy offers the potential to improve local control 
and survival by completing treatment in a shorter 
time but there have been concerns this may increase 
toxicity. The recently completed SOCCAR trial 
used hypofractionated radiotherapy (55Gy/20f/4w) 
concurrent with cisplatin and vinorelbine at systemic 
therapy doses. We report here the toxicity data from 
this study comparing the toxicity of the concurrent 
treatment arm with the concurrent treatment 
schedules used in previously published trials. 
Methods: Literature search was conducted for 
randomised trials using concurrent chemoradiation 
for stage III NSCLC in one arm of the trial. Trials 
were included if a minimum of 50 patients in the 
concurrent treatment arm and toxicity data available. 
We recorded radiotherapy dose and fractionation for 
each study with details of chemotherapy schedule. 
We compared rates of grade 3 and 4 toxicity and 
TRM from these trials with the SOCCAR data and 
we recorded 2 year survival for all studies.
Results: 16 randomised trials were identiÀed for 
comparison with SOCCAR. These included 1733 
patients treated with concurrent chemoradiation. 
10 trials used 60-66 Gy in 2Gy fractions. TRM in 
SOCCAR was 4% and in the other trials ranged 
from 0-10%. G3 oesophagitis in SOCCAR was 
17%, with no G4. In other trials G3/G4 oesophagitis 
ranged from 3-66% (median 17%). G3/G4 acute lung 
toxicity in SOCCAR was 4% compared to range 
of 1-16% (median 5%) in other trials. Leucopenia 
rate was 4% in SOCCAR and ranged from 2-99% 
in other trials, depending when assessed. Two year 
survival for concurrent SOCCAR group was 54% 
with 2ys across the other 16 trials ranging from 13-
43%. Two year survival for the trials using 60Gy in 
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MO02.13 EVALUATION OF 
SEQUENTIAL CHEMORADIATION 
WITH HYPERFRACTIONATED 
RADIOTHERAPY FOR UNRESECTABLE 
NON SMALL CELL LUNG CANCER: AN 
INDIAN EXPERIENCE.
Subrata Saha1, Prasenjit Chatterjee2 
1Radiotherapy, Medical College Hospital, Kolkata/
India, 2Radiotherapy, Amri Hospitals/India
Background: It is now well established that 
concomitant chemoradiation for unresectable non 
small cell lung cancer (NSCLC) offer superior 
outcome to sequential chemoradiotherapy, but at the 
cost of signiÀcantly increased grade 3-4 esophagitis. 
To Ànd an edge over sequential chemoradiation 
result without added toxicity as often observed 
with concomitant treatment, this prospective 
randomized trial aims to explore the beneÀt and 
toxicity of hyperfractionated radiotherapy preceeded 
by neoadjuvant chemotherapy and to compare 
with conventionally fractionated concomitant 
chemoradiation. Study end pints are local control, 
progression free survival, systemic failure, acute and 
late toxicity.
Methods: This is a multicentric 2-arm prospective 
randomized trial initiated in April 2008. A total 
of 112 patients with unresectable IIIB NSCLC 
with measurable disease with KPS > 60 have been 
enrolled (after informed consent) to either 60 Gy 
in 30 Fractions over 6 weeks radiotherapy with 
concomitant weekly paclitaxel (45 mg/ m2) and 
carboplatin (AUC 2) (Arm 1, Control arm : n = 57) 
or induction chemotherapy with Paclitaxel 180 mg/ 
m2 plus carboplatin AUC 6, 3-weekly for 2 cycles 
followed by hyperfractionated thoracic radiation for 
a dose of 72Gy/ 6 weeks, 5 days a week, using twice 
daily fractions of 120 cGy each at 6 hours interval 
(Arm 2, Study Arm: n=55).
Meticulous CT scan guided radiotherapy planning 
was done for each patient in 3D- Treatment Planning 
System. V20 varied between 24-28%, mean total 
lung dose was between 6.6 – 13.4 Gy and mean 
esophageal dose was 26.5-33.8 Gy as recorded from 
DVH analysis, During treatment all patients were 
reviewed weekly for assessment of acute reactions 
and nutritional status. After completion, patients 
are on monthly follow up to detect tumor response, 
were treated with chemotherapy+PBT (62 patients) 
or chemotherapy+X-IMRT (66 patients) from 
January 2003 through June 2008; all had concurrent 
chemotherapy, none had had prior thoracic RT, and 
all were treated to at least 60 Gy (X-IMRT) or 60 
CGE (cobalt-60Gy-equivalent) (PBT). Patients who 
had both IMRT and 3D CRT or PBT were excluded. 
Toxicity was graded according to the Common 
Terminology Criteria for Adverse Events version 3.0.
Results: Median follow-up times were similar for 
the two groups (PBT 15.2 months [range, 3.1–25.7 
months] and X-IMRT 17.4 months [range, 1.4–37.6 
months]). Patients in the PBT group were older than 
those in the X-IMRT group (median 67 years vs. 
62 years, P<0.04). Median Karnofsky performance 
scores for both groups were 80. The incidence 
of nodal involvement was similar in both groups 
(X-IMRT 91% vs. PBT 81%, P>0.05). Median dose 
was 74 CGE (range, 63-80.5 CGE) for the PBT 
group vs. 63 Gy (range, 60-76 Gy) for the X-IMRT 
group (P<0.001). Severe (grade 3+) esophagitis 
occurred in 44% of patients treated with X-IMRT vs. 
5% with PBT. Severe (grade 3+) treatment-related 
pneumonitis was observed in 9% of the X-IMRT 
group vs. 2% of the PBT group. Patients treated with 
PBT experienced signiÀcantly smaller reductions in 
hemoglobin levels (P<0.001), neutrophils (P<0.008), 
lymphocytes (P<0.001), and leukocytes (P <0.001) 
than those treated with X-IMRT. Reductions in 
platelet counts were the same for both groups.
Conclusion: This preliminary analysis suggests that 
concurrent chemotherapy and PBT was less toxic 
to normal esophagus, lung, and bone marrow than 
concurrent chemotherapy and X-IMRT; this lesser 
toxicity could allow use of more aggressive systemic 
regimens. These treatments are being compared 
directly in a prospective randomized trial, funded 
by the U.S. National Cancer Institute and conducted 
jointly by MD Anderson and Massachusetts General 
Hospital, to compare high-dose radiation (66-74 
Gy) given by PBT or X-IMRT in conjunction with 
carboplatin and paclitaxel chemotherapy for NSCLC. 
Tumor motion is being accounted for with 4D CT 
simulation. Endpoints are local tumor control and 
pneumonitis.
Keywords: proton therapy, radiation modality 
comparison, pneumonitis, esophagitis
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used during treatment planning at the NKI is V35 
(volume receiving at least 35Gy) <65%, predicting 
a 47% chance to develop AET  grade 2 [1]. The 
purpose of this study was to investigate the dose-
effect relation between AET and dose-volume 
parameters of the esophagus after IMRT and 
concurrent chemotherapy for lung cancer patients. 
Methods: 185 inoperable stage II and III Non-
Small Cell Lung Cancer patients treated with IMRT 
and concurrent chemotherapy were prospectively 
analyzed. The fractionation scheme was 24 x 2.75 
Gy. All pts received concurrent daily dose Cisplatin 
(6 mg/m²). Maximum AET was scored according 
to CTC 3.0. Dose-volume parameters V5 to V70, 
Dmean and Dmax of the esophagus were calculated 
taking biological fractionation effects into account 
for acute reacting tissue (Ơ/ơ of 10 Gy). A logistic 
regression analysis was performed to analyze the 
dose-effect relation between these parameters and 
AET  grade2 and  grade3. The outcome was 
compared to the clinically used esophagus constraint: 
V35 [1]. 
Results: The Dmax ranged from 20 and 84 Gy, 
while Dmean ranged from 4 and 68 Gy. 7.6% of 
these patients did not develop AET, 33.5% developed 
grade1, 36.2% grade 2 and 22.7% grade 3. At 
univariate analysis, the V40 and V50 turned out 
to be the most signiÀcant dosimetric predictor for 
grade 2 AET (p= 0.001) and grade 3 (p= 0.006) 
respectively, although Dmean and V35~V55 were 
all statistically signiÀcant predictors. Comparing our 
new V35 model to the old V35 model [1] derived for 
the current clinical use, the current clinical constraint 
(V35<65%) underestimated the risk to develop AET 
 grade 2 by 27% (74% instead of 47%). For the 
new parameter, when the V40 is 30% there is an 
estimated risk of 50% developing  grade 2 AET. 
Accepting a risk of 25% grade 3, V50 should be 
40%. 
Conclusion: For NSCLC patients treated with IMRT 
and concurrent chemotherapy, the V40 was identiÀed 
as most accurate predictor for AET grade 2 and the 
V50 for AET grade 3. A signÀcant higher incidence 
was observed, especially of grade 3 toxicity, in these 
patients treated with concurrent chemo radiation 
and IMRT, compared to previous series of patients 
treated with radiotherapy alone and 3D conformal 
radiotherapy. This increased risk is probably due to 
the concurrent use of chemotherapy as well as due 
to more modulated dose distributions typically given 
with IMRT. 1: J Belderbos et al. Acute esophageal 
toxicity in non-small cell lung cancer patients after 
recurrence (local or distant), acute and late reactions 
(recorded as per RTOG criteria). Minimum duration 
of follow up is 30 months.
Results: Overall response rate was 52/57 patients 
in Arm 1 and 53/55 of Arm 2. But median time to 
progression was 275 days in Arm 1 and 306 days 
in Arm 2. Systemic failure was recorded in 18/57 
(31.5%) in Arm 1 and 11/55 (20%) in Arm 2. 
Median duration of survival was 14 months in Arm 
1 and 15.5 months in Arm 2. One year survival was 
41/57 (72%) for Arm 1 vs. 40/55 (73%) in Arm 2. 
Corresponding data for 2-year OS were 14/57 (24%) 
and 16/55 (29%) for Arm 1 and 2 respectively. 
Grade 3-4 esophagitis was in 16/57 (28%) of Arm 
1, whereas only 4/55 (7.22%) in sequential chemo-
hyperfraction arm (P = 0.005).Corresponding data 
for grade 3-4 neutropenia was 29/57 (51%) for Arm 
1 and 14/55 (25%) of Arm 2 (P=0.006). Radiation 
pneumonitis was recorded in 12% of Arm 1 and 15% 
of Arm 2.
Conclusion: Sequential chemo radiotherapy using 
twice daily fractionation resulted comparable 
treatment outcome with concomitant chemoradiation 
with conventional fractionation in terms of both 
progression free survival as well as over all survival, 
but treatment toxicity was signiÀcantly less with 
sequential chemo-hyperfractionated radiotherapy.
Keywords: chemoradiation, Hyperfractionation, 
sequential, concomitant
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MO02.14 ACUTE ESOPHAGUS TOXICITY 
IN LUNG CANCER PATIENTS TREATED 
WITH INTENSITY MODULATED 
RADIOTHERAPY (IMRT) AND 
CONCURRENT CHEMOTHERAPY
Margriet Kwint1, Wilma Uyterlinde2, Wilma 
Heemsbergen1, Josien De Bois1, Chun Chen1, 
Michelle M. Van Den Heuvel2, Jan Jakob Sonke1, 
Joost Knegjens1, Marcel Van Herk1, José Belderbos1 
1Radiotherapy, NKI-AVL/Netherlands, 2Thoracic 
Oncology, NKI-AVL/Netherlands
Background: Currently used models to predict acute 
esophageal toxicity (AET) in lung cancer after IMRT 
and concurrent chemotherapy were derived from 
patients treated with 3D conformal radiotherapy 
techniques [1]. The esophagus constraint clinically 
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size, histopathological type, grade, pleural, perineural 
and vascular invasion) were extracted. Forty-three 
tissue micro-arrays (TMAs) were constructed using 
four 1mm in diameter donor cores of tumour and two 
donor cores of non-neoplastic matching lung from 
formalin-Àxed parafÀn-embedded tissue blocks. TMAs 
were processed for immunohistochemical staining for 
phosphorylated-Akt (P-Akt). Two pathologists, blinded 
to patient outcomes, independently reviewed the 
immunohistochemical staining and scored according to 
intensity. Kaplan-Meier and Cox Proportional Hazards 
analyses were used to analyse the relationship between 
cliniocpathologic factors, immunohistochemical 
intensity of phosphorylated-Akt and survival outcome 
in patients with stage IB disease. 
Results: We identiÀed 527 patients (median age 69) 
with stage IB NSCLC. Our overall Àve year survival 
rate was 55%. 378 (72%) were male. 392 (74%) had 
lobectomy, 70 (13%) underwent pneumonectomy and 
the remainder had lesser resections. The tumour size 
ranges from 0.6 to 18cm. The proportion of squamous 
cell carcinoma (41%) and adenocarcinoma (40%) were 
similar. Pleural invasion was consistently reported (477; 
91%) but vessel (214; 41%) and perineural invasion 
(161; 31%) were not. Univariate analysis demonstrated 
Àve signiÀcant prognostic factors: age (p<0.001); 
gender (p=0.008); histopathological grade (p=0.02); 
vessel invasion (p=0.01); pleural invasion (p=0.02). 
Multivariate analysis demonstrated that age (p <0.001) 
and pleural invasion (p=0.003) are independent 
prognostic factors. The immunohistochemical result of 
phosphorylated-Akt is ongoing. 
Conclusion: Pleural invasion is a potential prognostic 
histopathologic marker for overall survival in patients 
with stage IB disease. Its presence may deÀne a 
group of high risk patients with stage IB disease who 
could be assessed for possiible beneÀt from adjuvant 
chemotherapy. 
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MO03.02 FEATURES AND PROGNOSTIC 
FACTORS OF THE “NEW” STAGE II 
NON-SMALL CELL LUNG CANCER 
POPULATION
Francesca Toffalorio1, Davide Radice2, Lorenzo 
Spaggiari2, Valentina Sinno2, Massimo Barberis2, 
Gianluca Spitaleri2, Giovannini Monica2, Angelo 
Delmonte2, Chiara Catania2, Crisitina Noberasco2, 
Daniela Brambilla2, Filippo De Braud2, Tommaso De 
Pas2 
high dose conformal radiotherapy. Radiother Oncol 
2005;75:157-164 
Keywords: esophagitis, imrt, concurrent 
chemoradiation, Radiotherapy
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MO03.01 MARKERS OF PROGNOSIS 
IN RESECTED STAGE IB NON-SMALL 
CELL LUNG CANCER (NSCLC)
Po Yee Yip1, Wendy Cooper2, Annabelle Mahar2, 
James Kench2, Maija R.J. Kohonen-Corish3, Mark 
ChatÀeld4, Alice Boulghourjian3, Catherine W. 
Kennedy5, Brian Mccaughan5, Michael Boyer1, Lisa 
Horvath1 
1Medical Oncology, Sydney Cancer Centre, 
Royal Prince Alfred Hospital/Australia, 2Tissue 
Pathology And Diagnostic Oncology, Royal Prince 
Alfred Hospital/Australia, 3Cancer Research 
Program, Garvan Institute Of Medical Research/
Australia, 4Nhmrc Clinical Trial Centre/Australia, 
5Cardiothoracic Surgery, Royal Prince Alfred 
Hospital/Australia
Background: Adjuvant cisplatin-based chemotherapy 
has been shown to improve survival in resected 
NSCLC. However, much of this beneÀt seems to 
be due to an effect on stage II and IIIA disease, 
although retrospective analyses of randomized 
trials suggest that a subgroup of patients with stage 
IB disease (those with tumours >4cm diameter) 
may also beneÀt. Because of the uncertainty of the 
degree of beneÀt for patients with stage IB disease, 
current guidelines advise against providing adjuvant 
chemotherapy to these patients. Therefore, there is 
a need to identify prognostic markers that deÀne 
high risk stage IB patients who may beneÀt from 
adjuvant chemotherapy. We aimed to identify clinico-
pathologic and molecular markers of prognosis in 
resected stage IB non-small cell lung cancer. 
Methods: Using our patient database, we identiÀed 
patients diagnosed between January 1990 and May 
2008 with pathological stage IB disease and who 
had undergone surgical resection. Pathology reports 
were reviewed and clinicopathologic details (tumour 
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MO03.03 RECURRENCE RISK 
FACTORS FOCUSED ON CLINICAL, 
RADIOLOGICAL AND PATHOLOGICAL 
FEATURES IN RESECTED STAGE IA 
ADENOCARCINOMA OF THE LUNG
Hee Chul Yang1, Eoksung Park1, Jung-Moon Lee1, 
Eunee Sim1, S.-W. Sung2, Sanghoon Jheon1 
1Thoracic And Cardiovascular Surgery, Seoul 
National University Bundang Hospital/Korea, 
2Thoracic Surgery, The Catholic University Of 
Korea/Korea
Background: Prediction of recurrence of early 
stage lung cancer is very important issue. The aim 
of this study was to retrospectively evaluate clinical, 
radiological and pathological factors on recurrence in 
resected stage IA adenocarcinoma. 
Methods: From June 2003 to December 2010, 271 
patients were diagnosed with pathologic stage IA 
adenocarcinoma after complete pulmonary resection. 
Among them, 52 patients were diagnosed with 
adenocarcinoma in situ. T1a and Tlb was 70.5% and 
29.5%. In these patients the impact of the following 
factors on recurrence was evaluated: clinical factors 
(gender, age, and smoking history), computed 
tomography (CT) and positron emission tomography 
(PET) Àndings (diameter of tumor including 
or excluding ground glass opacity (GGO) and 
maximal standardized uptake value (SUVmax)) and 
pathologic Àndings (presence or absence of tumor 
necrosis, vascular invasion, lymphatic invasion, and 
histologic subtype).
Results: Mean age was 64 years (R: 31-85) and 140 
(51.7%) patients were female. The follow-up period 
was median 26 months and 3 year survival was 
97.8%. During the period, recurrence occurred in 16 
patients (6.3%) who were 5 patients with T1a and 
11 with T1b. There was no recurrence in the group 
of pure GGO. Univariate analyses demonstrated 
recurrence risk factors in male (p=0.03), smoking 
history (p=0.03), 2cm diameter of tumor including 
GGO in CT (p=0.002),  15mm of CT solid portion 
(p<0.001), SUV max 2 (p<0.001), presence of tumor 
necrosis (p<0.001), acinar subtype (p=0.006), invasion 
of lymphatics (p<0.001) and vessel (p<0.001), and 
moderate to poorly cell differentiation (p<0.001). 
Male,  15mm of CT solid portion, lymphatic 
invasion, moderate to poorly cell differentiation, 
acinar subtype were signiÀcant (p<0.05) recurrence 
risk factors in multivariate analyses.
1Medical Oncology Unit Of Respiratory Tract 
And Sarcomas, New Drug Development Division, 
European Institute Of Oncology/Italy, 2European 
Institute Of Oncology/Italy
Background: The 7th TNM edition has raised new 
clinical issues, as the role of adjuvant therapy for 
tumours larger then 5 cm without lymph node invasion. 
In the 6th TNM, these tumours were classiÀed as stage 
Ib and international guidelines provided no need for 
adjuvant treatment. In the 7th TNM these tumours 
have shifted to stage II, opening the perspective of 
post-surgery chemotherapy. To challenge this issue, 
we evaluated the rate of tumours shifting from stage 
Ib (6th TNM) to stage IIa/b (7th TNM) and analyzed 
the relationship between their biological characteristic 
and the clinical outcome, in order to identify putative 
prognostic factors of this subset of patients.
Methods: We retrospectively collected tumor related 
and demographics data (histological type, grading, 
vascular invasion, gender, age smoking status and type 
of surgery) from 467 patients who underwent radical 
surgery with total linfoadenectomy for primary 6th 
TNM-T2N0 NSCLC in our Institute from 1998 to 
2009. Categorical variables were cross-tabulated by 
tumor staging according to the 7th TNM edition and 
tested both for association (Fisher’s exact test) with 
stage and survival (Kaplan-Meier method). 
Results: According to the 7th TNM, 87 (19 %) cases 
shifted from stage Ib to stage IIa and 31 (7%) to stage 
IIb. No patients received induction/adjuvant chemo 
and/or radiation therapy. Patients who shifted to 
stage IIb were signiÀcantly older (69.9 ± 8.9) and the 
grading of the tumor was higher compared to the total 
population (p = 0.039) and the stage IIa (p = 0.013). 
Median overall survival times were signiÀcantly worse 
for patient shifted to stage II (4.6 years) than patients 
not shifted (9.3 years, p = 0.018). Among the factors 
investigated, our data suggest a relationship between 
smoking habitus and grading with a worse prognosis, 
even if not statistically signiÀcative. 
Conclusion: A high rate (26%) of patients with 
T2N0 NSCLC shift from stage I (6th TNM) to stage 
II (7th TNM), raising a major need for information 
on the effects of adjuvant chemotherapy in this 
population. Smoking status and grading, but not 
histological type, vascular invasion, gender, age 
and type of surgery, could be explored as possible 
prognostic factors in the adjuvant chemotherapy 
decision-making process.
Keywords: 7th TNM, prognostic factors, adjuvant 
treatment
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The median value of plCEA was 65.2 ng/g protein 
(range, 0-7331.7). plCEA signiÀcantly correlated 
with pleural invasion and serum CEA, but did 
not correlated with PLC. Analysis of ROC curve 
identiÀed an optimal plCEA cut-off value to predict 
recurrence of 38 ng/g protein (area under the curve, 
0.663; sensitivity, 92.3%; speciÀcity, 43.7%; 95%CI: 
0.538-0.788, p = 0.021). Five-year DFS rates were 
91.1% in patients with plCEA < 38 ng/g protein and 
47.8% with plCEA > 38 ng/g protein (p = 0.0005). 
Even in 51 patients with stage I lung cancer, 5-y DFS 
signiÀcantly differed between patients with plCEA 
< 38 and > 38 ng/g protein (94.1% vs. 59.3%, p = 
0.0068). Based on the multivariate Cox analyses, 
plCEA was a signiÀcant independent factor for DFS. 
Conclusion: Intraoperative plCEA was a powerful 
prognostic determinant for patients with NSCLC. 
Keywords: Non-small cell lung cancer, CEA, 
pleural lavage Áuid, prognostic factor
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MO03.06 PREOPERATIVE 
SERUM CARCINOEMBRYONIC 
ANTIGEN LEVEL AND COMPUTED 
TOMOGRAPHIC FINDINGS ARE 
PREDICTORS OF PATHOLOGICAL 
N0 IN CLINICAL STAGE IB LUNG 
ADENOCARCINOMA
Shinya Neri1, Junji Yoshida1, Genichiro Ishii2, Yoichi 
Ohtaki1, Keiju Aokage1, Tomoyuki Hishida1, Mitsuyo 
Nishimura1, Kanji Nagai1 
1Department Of Thoracic Surgery, National Cancer 
Center Hospital East/Japan, 2Pathology Division, 
Research Center For Innovative Oncology, National 
Cancer Center Hospital East/Japan
Background: The standard intervention for 
resectable non-small cell lung cancer (NSCLC) 
has been lobectomy and systematic lymph node 
dissection. Recently, limited surgery with/without 
lymphadenectomy has been repeatedly evaluated 
in clinical stage IA NSCLC, and a clinical trial of 
wedge resection without lymph node dissection is 
now ongoing in Japan for clinical T1aN0M0 sub-solid 
tumors, organized by the Japan Clinical Oncology 
Group. However, few reports have analyzed the 
validity of limited surgery in clinical stage IB (cIB) 
NSCLC. We reviewed cIB pulmonary adenocarcinoma 
patients in an attempt to identify clinical and radiologic 
predictors of pathological N0 (pN0) disease. 
Conclusion: Invasiveness of early stage 
adenocarcinoma might be strongly associated with 
solid portion of the tumor, cutoff value of which 
was 15mm. Male, lymphatic invasion, moderate to 
poorly cell differentiation, and acinar subtype are 
also at high risk for recurrence. These subgroup may 
be considered as risk group for recurrence and may 
need adjuvant therapy or closed follow up. 
Prognostic Factors and Stage Monday, 4 July 2011 14:30-16:00
MO03.04 PROGNOSTIC VALUE OF 
CARCINOEMBRYONIC ANTIGEN FROM 
PLEURAL LAVAGE FLUID IN NON-
SMALL CELL LUNG CANCER
Yasuhiro Tsutani, Yoshinori Yamashita, Keizo 
Misumi, Takuhiro Ikeda, Yoshihiro Miyata, Morihito 
Okada 
Surgical Oncology, Hiroshima University/Japan
Background: Little is known about the signiÀcance 
of carcinoembryonic antigen (CEA) from pleural 
lavage Áuid (plCEA) in patients with operable 
non-small cell lung cancer (NSCLC). This study 
evaluates the prognostic signiÀcance of plCEA in 
patients with completely resected NSCLC. 
Methods: We examined 74 curatively resected 
patients whose pleural lavage Áuid were collected 
at thoracotomy, and pleural lavage cytology (PLC) 
and plCEA were determined. The relationships 
between plCEA and clinicopathological factors were 
analyzed. Frequencies were compared using the Ƶ2 
test for categorical variables and Fischer’s exact 
test was applied to small samples. Mann-Whitney U 
tests were performed when comparing continuous 
variables. Receiver operating characteristic (ROC) 
curves of the plCEA for the prediction of recurrence 
were generated to determine the cut-off value that 
yielded optimal sensitivity and speciÀcity. The 
patient population was subdivided based upon the 
cut-off value of plCEA derived from ROC curves, 
and the duration of disease-free survival (DFS) 
was analyzed using the Kaplan-Meier method. 
Differences in DFS were assessed using the log-rank 
test. To assess the potential independent effects of 
plCEA on DFS, we performed multivariate analyses 
using the Cox proportional hazards model with 
variables with a p value of < 0.05 in the univariate 
analyses, and p < 0.05 was considered to be 
statistically signiÀcant. 
Results: Ten patients (13.5%) had positive PLCs. 
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Background: To evaluate if a more extensive 
lymphadenectomy provides a better staging and 
improves survival depending on the number of 
lymph nodes (LN) obtained.
Methods: Retrospective study of 784 lung cancer 
patients operated between 1995 and 2008. Groups 
based on factor T are divided according to the 
number of LN resected (0-6, 7-12, 13) .
Results: We analyzed a total of 5.237 lymph nodes 
resected, with an average of 6.68 (0-48). (0-48). 688 
were men and 96 women with and average age of 
62.48. Almost the 50% were diagnosed of squamous 
cell carcinoma.
We present the results of the 163 T1 and 621 T2 
patients.The analysis shows that the probability 
to detect positive LN increases when more lymph 
nodes are obtained during the lymphadenectomy 
(Table 1) and these Àndings are also seen when 
considering T stages separately (25%, 18,75% 
and 56,25% vs 78,91%, 14,97% and 6,12%, 
p<0.3897 in T1 and 13,64%, 36,36%, and 50% 
vs 65,44%, 16,16% and 18,40% p<0.0001 in T2). 
We also found that median survival with more lymph 
nodes resected were better in T1 and T2 (Table 3) 
patients (statistically signiÀcant differences). 
Methods: From 2002 through 2009, 224 consecutive 
patients with cIB adenocarcinoma who underwent 
complete resection with systematic lymph node 
dissection were enrolled. We reviewed their 
preoperative clinical data and computed tomographic 
scans, and evaluated the correlations between 
nodal involvement and the following factors: 
age, gender, smoking history, preoperative serum 
carcinoembryonic antigen (CEA) level (normal 
range:  5.0 ng/mL), and tumor disappearance 
ratio (TDR: 1- DM/DL; DM: maximum tumor 
diameter on mediastinal settings, DL: maximum 
tumor diameter on lung settings). Univariate and 
multivariate analyses were performed using logistic 
regression models. 
Results: There were 115 men and 109 women. The 
median age was 67 years (range: 37 – 85). There 
were 164 pN0 patients and 60 pN1-2 patients. In 
univariate analysis, a lower preoperative CEA level 
and a higher TDR were signiÀcant predictors of pN0 
disease. In multivariate analysis, preoperative CEA 
level (OR: 0.032, 95%CI: 0.002 – 0.340) and TDR 
(49.32, 10.94 – 285.5) were signiÀcant independent 
predictors of pN0 disease. All of the 18 patients with 
a  0.9 had pN0 disease. Among 45 patients with 
a TDR  0.7 (pN0/pN1: 44/1), 33 patients with a 
normal preoperative CEA level had pN0 disease. 
Conclusion: Lymph node metastasis was not 
observed in cIB patients with a TDR  0.9 or in 
those with a normal preoperative serum CEA level 
and TDR  0.7. These patients may be successfully 
managed without systematic lymph node dissection.
Keywords: clinical stage IB, Adenocarcinoma, 
lymph node dissection, carcinoembryonic antigen
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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MO03.07 LYMPH NODE DISSECTION IN 
EARLY STAGE NON SMALL CELL LUNG 
CANCER
Laura Romero Vielva1, Amaia Ojanguren Arranz1, 
Maria Deu Martin1, M. A. Montero2, Javier 
Perez Velez1, Joan Sole Montserrat1, Joel Rosado 
Rodriguez1, Iker Lopez Sanz1, Enriqueta Felip3, 
Mercedes Canela1 
1Thoracic Surgery, Hospital Universitario Vall 
D’Hebron/Spain, 2Pathology Department, Vall 
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preoperative high-resolution computed tomography 
(HRCT) imaging in adenocarcinoma cases. First, 
we measured the longest diameter of the tumor in 
lung window and deÀned it as “lung diameter (L).” 
Second, we measured the length of the consolidation 
of “lung diameter” in mediastinal window and 
deÀned it as “mediastinal diameter (M).” Then 
we calculated the ratio (M/L) and analyzed the 
correlation between M/L and the existence of 
pathological vessel invasion.
Results: Mean follow-up period was 40.5 months. 
During this period, 76 patients relapsed. Univariate 
analyses revealed sex, high level of CEA, 
histological type other than bronchioloalveolar 
carcinoma, smoking, interstitial pneumonia, COPD, 
history of other cancer, pathological stage IB or 
higher, and vessel invasion as statistically signiÀcant 
prognostic factors. On multivariate analysis, vessel 
invasion, high level of CEA and history of other 
cancer had signiÀcant impact on disease-free 
survival and their hazard ratios were 3.14, 2.51 and 
1.94, respectively. In HRCT imaging analysis of 198 
adenocarcinoma cases, when we set the cutoff value 
of M/L at 0.64, the sensitivity and speciÀcity of 
detecting pathological vessel invasion existence were 
about 0.8 and 0.7, respectively.
Conclusion: The existence of pathological vessel 
invasion had the most signiÀcant impact on 
relapse of primary non-small cell lung cancer. It 
may be possible to predict the existence of the 
most important prognostic factor associated with 
relapse preoperatively by using this quite simple 
measurement of HRCT imaging.
Keywords: pathology, computed tomography, 
Survival analysis, Non-small cell lung cancer
Conclusion: The probability of Ànding positive 
mediastinal LN increases with a more extensive 
lymphadenectomy. A complete lymphadenectomy 
provides a better staging and improves survival, and 
therefore it should be performed in all lung cancer 
patients even in those with an early stage.
Keywords: Lymphadenectomy, Lung cancer, 
survival
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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MO03.08 CORRELATION BETWEEN 
RADIOLOGICAL COMPUTED 
TOMOGRAPHY FINDINGS AND 
PATHOLOGICAL VESSEL INVASION: 
ANALYSIS OF PROGNOSTIC FACTORS 
FOR RELAPSE IN CLINICAL STAGE IA 
NON-SMALL CELL LUNG CANCER
Takuya Ito1, Tomohiro Murakawa1, Hajime Sato2, 
Aska Tanabe2, Masaki Maekawa2, Akiteru Goto3, 
Shigeki Morita3, Takehiro Tsuchiya1, Yukihiro 
Yoshida1, Atsushi Sano1, Masashi Fukayama3, Jun 
Nakajima1 
1Department Of Cardiothoracic Surgery, University 
Of Tokyo/Japan, 2University Of Tokyo/Japan, 
3Department Of Pathology, University Of Tokyo/
Japan
Background: There have been reports stressing 
the importance of pathological vessel invasion 
as a prognostic factor for relapse in primary lung 
cancer. In this study, we analyzed prognostic impact 
of vessel invasion on relapse in clinical stage 
IA non-small cell lung (NSCLC), and examined 
possible correlation between preoperative computed 
tomography (CT) Àndings and pathological vessel 
invasion.
Methods: For examining prognostic factors, we 
retrospectively analyzed 421 patients with primary 
non-small cell lung cancer who were diagnosed 
as clinical stage IA and underwent surgery from 
1999 to 2009 at our department. The prognostic 
factors affecting disease-free survival were assessed 
by Kaplan-Meier survival analysis, Log rank and 
Wilcoxon test as univariate analyses and Cox’s 
proportional hazards analysis as multivariate 
analysis. Additionally, as a sub-analysis, we analyzed 
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less than 90% in clinical N
0
 patients, suggesting that 
improvement of accurate N staging is warranted 
by incorporating PET with other minimal invasive 
approaches, including EBUS and EUS
Keywords: 18F-FDG PET/CT, Non-small cell lung 
cancer, Mediastinal lymph nodes stage
Prognostic Factors and Stage Monday, 4 July 2011 14:30-16:00
MO03.11 PROTON BEAM THERAPY 
FOR STAGE I NON-SMALL-CELL LUNG 
CANCER
Chiyoko Makita, Tatsuya Nakamura, Haruo 
Inokuchi, Takuya Tomoda, Akinori Takada, Kanako 
Takayama, Miho Shiomi, Takahiro Kato, Nobuyuki 
Fuwa 
Radiation Oncology, Southern Tohoku Proton 
Therapy Center/Japan
Background: Proton beam has an excellent dose 
distribution called Bragg-peak that enables us to 
deliver higher doses to the tumor without increasing 
doses to the surrounding normal tissues. We 
retrospectively evaluated the safety and efÀcacy of 
proton beam therapy (PBT) for Stage I non-small-
cell lung cancer (NSCLC). 
Methods: Between 2009 and 2010, 128 NSCLC 
patients were treated in Southern TOHOKU proton 
therapy center. There were 39 patients in clinical 
Stage I ( IA: 30, IB: 9). A total dose of 66-84 GyE 
was delivered in 10-33 fractions(2.4, 3.2 and 6.6 
GyE per fraction, respectively) over 2-7 weeks with 
2 or 3 portals of 150 or 210 MeV proton beam. The 
relative biological effectiveness (RBE) of our proton 
beam was deÀned as 1.1. Local control and disease 
free were measured by serial chest CT and/or FDG-
PET/CT scans after PBT treatment. CTC version 4.0 
was used to assess toxicity. 
Results: Patient characteristics are as follows: 
median age 75 (range, 48 to 89 years), male/
female: 25/14, Performance status 0/1/2: 27/7/5, 
adenocarcinoma/squamous/unknown: 22/11/6, T1a/
T1b/T2a: 15/15/9, medically in operable/refusal 
of surgery: 27/12, total dose 66/80/72-84GyE: 
18/15/6. With median follow-up period of 12 months 
(range, 3 to 24 months), the local progression-free 
and disease-free rates were 100% and 82% ( IA: 
80%, IB: 89%), respectively. 7 patients showed 
recurrences in regional lymph node and/or distant 
metastases or pleuritis carcinomatosa between 3 and 
22 months after treatment. No serious acute toxicity 
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MO03.09 MEDIASTINAL LYMPH NODES 
STAGING BY 18F-FDG PET/CT FOR 
EARLY STAGE NON-SMALL CELL LUNG 
CANCER: A MULTICENTER STUDY
Xiaolin Li1, Huaqi Zhang2, Ligang Xing2, Lin 
Zhang3, Wengui Xu4, Guoren Yang5, Jinming Yu2 
1Department Of Radiation Oncology, Shandong 
Tumor Hospital And Institute/China, 2Department Of 
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Shandong Province Hospital/China, 4Department 
Of Nuclear Medicine, Tianjin Tumor Hospital And 
Institute/China, 5Department Of Nuclear Medicine, 
Shandong Tumor Hospital And Institute/China
Background: Accurate staging of mediastinal lymph 
nodes is a critical factor determining operability 
and stereotactic body radiation therapy (SBRT) in 
patients with non-small cell lung cancer (NSCLC). 
This multicenter study is to evaluate the accuracy of 
18F-FDG PET/CT to detect mediastinal lymph nodes 
(MLN) metastases for T
1-2
 NSCLC
Methods: The data of patients with T
1-2
 NSCLC 
who received preoperative CT staging, FDG PET/
CT staging and radical surgery were retrospectively 
reviewed in three centers between Oct. 2004 and 
Jan. 2009. The MLN metastatic was conÀrmed 
histopathologically after thoracotomy and lymph 
node dissection. The sensitivity, speciÀcity, accuracy, 
PPV and NPV were calculated and compared for 
PET and CT. Clinical and pathological factors were 
analyzed for the correlation with MLN metastases.
Results: Eighty-six patients were enrolled. The 
sensitivity, speciÀcity, accuracy, PPV and NPV for 
MLN metastasis on CT were 49%, 93%, 89%, 59% 
and 92% respectively, with 80%, 90%, 90%, 62% 
and 93% on PET. (P=0.023, 0.07, 0.87, 0.89, 0.17). 
There were 50 patients with clinical T
1-2
N
0
 NSCLC. 
In these patients, the NPV for MLN metastasis with 
FDG PET were 82% (41 of 50). It was showed that 
FDG uptake of primary tumor (P=0.006) and T 
stage (P=0.007) were correlated with lymph node 
involvement. Only 1 patients were found MLN 
metastasis in 26 patients with primary tumor FDG 
PET SUV<6.67, whereras 8 patients had MLN 
metastases in 24 patients with SUV>6.67, P<0.01. 
There were 6 and 3 patients found MLN metastasis 
in T1 (n=44) and T2 (n=6) NSCLC, respectively
Conclusion: FDG PET/CT improves the sensitivity 
of N staging in T
1-2
 NSCLC. However, the NPV was 
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Conclusion: Brain MRI should be considered 
as initial screening procedure in neurologically 
asymptomatic node-negative patients with >3cm 
sized non-small cell lung cancer. 
Keywords: NSCLC, brain MRI, Brain Metastasis
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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MO04.01 P95HER2 TRUNCATED FORM 
AND HER2 GENE COPY NUMBER IN 
NON-SMALL-CELL LUNG CANCER 
(NSCLC)
Federico Cappuzzo1, Yong Gon Cho2, Greta 
Alì3, Matteo Incarbone4, Annarita Destro5, Luigi 
Terracciano6, Gabriella Fontanini3, Antonio 
Marchetti7, Massimo Roncalli5, Marileila Varella-
Garcia8 
1Oncology, Istituto Toscano Tumori-ospedale Civile/
Italy, 2Medicine/medical Oncology And Pathology, 
University Of Colorado/United States Of America, 
3Pisa University/Italy, 4Multimedica/Italy, 5Istituto 
Clinico Humanitas-milan University/Italy, 6Basel 
University/Switzerland, 7Chieti University/Italy, 
8Medical Oncology, University Of Colorado/United 
States Of America
Background: Anti-HER2 therapies demonstrated to 
signiÀcantly improve the outcome of patients with 
breast and gastric cancer. In metastatic NSCLC, 
anti-HER2 monoclonal antibodies (HER2-mab) 
failed to demonstrate any beneÀt. Recent studies in 
breast cancer suggested that p95HER2, the NH2-
terminally truncated form of HER2, could confer 
resistance to HER2-mab. HER2 gene ampliÀcation 
is considered a negative prognostic factor in many 
human malignancies. In NSCLC a recent meta-
analysis suggested that HER2 overexpression but not 
ampliÀcation is a poor prognostic factor, especially 
in adenocarcinomas. Aim of the present study was 
to investigate the role of p95HER2 and HER2 gene 
copy number (GCN) in NSCLC.
Methods: The present study included 447 surgically 
was observed. Late pulmonary toxicities were 
observed in 5 patients with Grade 2 and 1 patient 
with Grade 3. 
Conclusion: Though further investigation of PBT 
for Stage I NSCLC is warranted, PBT is a promising 
treatment modality for Stage I NSCLC, producing 
favorable results and low toxicity. 
Keywords: Stage I, Proton beam therapy, Non-
small-cell lung cancer
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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MO03.12 PREVALENCE OF 
ASYMPTOMATIC BRAIN METASTASIS 
IN PATIENTS WITH NODE-NEGATIVE 
EARLY STAGE NSCLC
Eun Young Heo1, Sang-Min Lee2, Jae-Joon Yim2, 
Seok-Chul Yang2, Chul-Gyu Yoo2, Sung-Koo Han2, 
Young-Whan Kim2 
1Internal Medicine, Boramae Medical Center/Korea, 
2Seoul National University Hospital/Korea
Background: Routine screening for brain metastases 
in asymptomatic patients has not yet reached a 
consensus in practice guidelines. .In this study, we 
evaluated the prevalence of asymptomatic brain 
metastasis in patients of T1 or T2, node negative 
non-small cell lung cancer at the time of initial 
staging and the efÀcacy of brain MRI as screening in 
patients with node-negative early stage NSCLC. 
Methods: We retrospectively reviewed medical 
records of 132 patients who were diagnosed of 
clinical T1 or T2 node-negative NSCLC and 
underwent brain MRI at initial staging work-up 
between January 2005 to April 2010 at Seoul 
National University Hospital. 
Results: Ninety two out of 132 patients (69.7%) 
were diagnosed as adenocarcinoma. Seventy seven 
(58.3%) were clinical T1N0(T1a : 39, T1b: 38) and 
55 (41.7%) were clinical T2N0(T2a: 41, T2b : 14). 
Of 132 patients, brain MRI detected asymptomatic 
brain metastasis in 13 (9.8%) at initial diagnosis. 
Patients of clinical T2 stage had signiÀcantly 
higher prevalence of brain metastasis than patients 
of clinical T1 stage (18.2% vs. 3.9%, P=0.013). 
Histologic subtypes of tumor didn’t affect the 
prevalence of brain metastasis signiÀcantly.
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Background: ALK rearrangement is a transforming 
event in NSCLC carcinogenesis, particularly observed 
in the rare signet-ring sub-type of adenocarcinoma. 
We aimed to characterize the predictive utility of 
tumour morphology and ALK immunoreactivity 
to identify ALK rearrangements in a cohort of 
adenocarcinomas with signet-ring morphology, 
compared with primary lung adenocarcinoma of other 
morphology.
Methods: Adenocarcinomas from the Royal 
Brompton and HareÀeld Hospitals diagnostic archives 
reported with signet-ring morphology were identiÀed 
and assessed for pattern extent. Adenocarcinomas 
without signet-ring features over the same time 
period were chosen for comparison. Tumours were 
reviewed by 2 thoracic pathologists independently 
for percentage of signet-ring and other growth 
patterns, and then classiÀed into signet-ring, and non-
signet-ring groups. ALK expression was assessed by 
immunohistochemistry using the ALK1 clone (Dako, 
UK; 1 in 20 dilution) and a semi-quantitative scoring 
system. ALK rearrangements were assessed in all 
tumours by FISH using a commercially available 
break-apart probe set. Associations were calculated 
using Fisher’s exact test.
Results: Eighteen adenocarcinomas were assessed. 
All but three were surgical resections. Median age 
did not differ between signet-ring vs non-signet-
ring groups (67 vs 57 years, p=0.32). Seven patients 
had a signet-ring cell component, ranging from 20-
100%; six (86%) were TTF-1 positive. Two cases 
demonstrated diffuse moderate cytoplasmic ALK 
immunoreactivity (2+), and were excision biopsies. 
Both showed pure (100%) signet ring morphology, 
and both harboured ALK rearrangements (29% 
translocation prevalence, 95%CI: 4-71%). The other 
5 mixed-signet-ring and 9 of 11 non-signet-ring 
adenocarcinomas showed no immunoreactivity with 
one each of the non-signet-ring tumours showing 
weak nuclear ALK positivity in 5% of cells and 
very weak cytoplasmic ALK immunoreactivity 
respectively. All 16 showed no ALK rearrangements. 
ALK expression was not associated with ALK copy 
number. Pure signet ring morphology was strongly 
associated with ALK rearrangements (break-apart, 
resected NSCLC patients with known MET GCN 
status and 8 additional parafÀn-embedded tumor 
specimens from NSCLC patients harbouring exon 
20 HER2 mutations. P95HER2 status was evaluated 
by immunoÁuorescence in tissue microarray sections 
and data were correlated with HER2 GCN evaluated 
by Áuorescence in situ hybridization (FISH) and 
HER2 mutations. Tumors were scored as positive for 
p95HER2 expression if any cytoplasmic staining was 
detected.
Results: HER2 GCN was evaluable in 439 patients 
and increased GCN (at least 4 copies in at least 
40% cells) was found in 60 cases, of which 22 
(5.0%) displayed true gene ampliÀcation (GA). 
No difference in survival was observed between 
patients with or without HER2 GA (median 38 
versus 41 months, p=0.46). Interestingly, HER2 
GA was signiÀcantly associated with MET GA (p 
value inferior to 0.001), with no effect on patient 
survival (median survival: 36 versus 21 months in 
MET GA/HER2 GA and MET GA/ HER2 negative, 
respectively, p=0.3). P95HER2 was successfully 
evaluated in 431 patients and the result was positive 
(p95HER2+) in 33 (7.6%) cases. No association 
was detected between P95HER2+ and increased 
HER2 GCN. Among the 22 patients with HER2 
ampliÀcation and among the 8 patients with HER2 
mutation, only one resulted P95HER2+. In the whole 
population, p95HER2- patients had numerically 
higher risk of death than p95HER2+ (HR=1.4, 
IC95%:1.08-1.82) even if the difference was not 
statistically signiÀcant (p=0.2).
Conclusion: HER2 is not prognostic in NSCLC 
even in a context of MET co-ampliÀcation. 
P95HER2 plays a limited prognostic role in resected 
NSCLC. Although p95HER2 is present in a fraction 
of NSCLC, it is unlikely that this event is responsible 
for the lack of efÀcacy of HER2-mab therapies 
observed in clinical trials.
Keywords: HER2, p95HER2, NSCLC
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MO04.02 ALK TRANSLOCATION 
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Background: ALK copy number aberrations have 
been previously described by our group and others 
in Non-Small Cell Lung Cancer (NSCLC). We have 
expanded the series of cases evaluated for ALK 
copy number and analyzed the correlation with 
other relevant biomarkers and clinico-pathological 
characteristics. 
Methods: A series of non-small cell lung carcinomas 
was evaluated for ALK gene status by Áuorescence 
in situ hybridisation (FISH) and all non-squamous 
cases had EGFR and KRAS mutational analysis by 
sequencing and RT-PCR. Clinico-pathological data 
and follow-up was available for these patients. 
Results: Two hundred and twenty seven patients 
were included in this study. Patients’ characteristics 
are presented in Table 1. Of these, 152 tumors 
were evaluable for ALK by FISH. We found 6 
cases of ALK translocation (4%). None of these 
cases had KRAS or EGFR mutations. ALK copy 
number status and its association with EGFR and 
KRAS are detailed in Table 2. Interestingly, we 
found a 15% of cases with ALK ampliÀcation or 
presence of ALK clusters in <10% of cells. In non-
squamous specimens we observed 17% and 19% 
of EGFR and KRAS mutations, respectively. ALK 
ampliÀcation (and clusters) was associated with 
early stage (p=0.048), better performance status (0-
1vs2-3) (p=0.016) and a trend to improved survival 
(p=0.1). This last association was lost in multivariate 
analysis. Table 1. Patients’ characteristics 
Patients characteristics (N:227) Number (%)
Median age (range) 65 (36-88)
Gender Male 172 (76)
Female 75 (24)
Smoking habit Current 99 (44) 
Former 81 (36)
Never 44 (20)
Stage I 54 (24)
II 23 (10)
III 44 (20) 
IV 103 (46)
PS 0-1 158 (70)
2-3 35 (30)
Histology Adenocarcinoma 153 (67)
Squamous cell carcinoma 38 (17)
LCC + LCNEC + BAC 15 (7)
NOS 21 (9)
p=0.007) and ALK immunoreactivity (p=0.007), 
unlike mixed signet-ring (p=1.0) or non-signet ring 
adenocarcinoma (p=0.135).
Conclusion: Adenocarcinomas with signet ring 
morphology are strongly associated with ALK 
rearrangements, showing good correlation with 
cytoplasmic ALK immunoreactivity, in this small 
series. TTF-1 positivity was 86% in primary 
lung signet-ring adenocarcinomas, and can aid in 
distinction from tumours spreading from other more 
common sites of origin. 
ID Age Sex 
Sample 
type 
Signet 
ring/solid 
inÀltrate 
(%) 
ALK 
immunoreactivity 
ALK FISH 
ALK 
Copy 
number 
1 68 F Resection 20 Negative Negative up to 7 
2 46 F Resection 30 Negative Negative 3-4 
3 45 M 
Excision 
biopsy 
100 
Moderate
cytoplasmic 
immunoreactivity 
translocation 
abnormal
+split 
4 67 F 
Excision 
biopsy 
80 Negative Negative 3-4 
5 54 M 
Excision 
biopsy 
100 
Moderate 
cytoplasmic 
immunoreactivity 
translocation 
abnormal
+split
6 78 M Resection 60 Negative Negative 3-4 
7 71 F Resection 30 Negative Negative 3-5 
8 53 F Resection 0 Negative Negative 3-4 
9 57 F Resection 0 
<5% nuclear 
immunoreactivity
Negative 3-5 
10 73 M Resection 0 Negative Negative 3-6 
11 53 M Resection 0 Negative Negative 
5 or 
more 
12 43 F Resection 0 Negative Negative 3-5 
13 71 M Resection 0 
Very weak 
cytoplasmic 
immunoreactivity 
Negative 
3-4 or 
more 
14 66 M Resection 0 Negative Negative 3-4 
15 46 F Resection 0 Negative Negative up to 7 
16 82 M Resection 0 Negative Negative 
3-4 
17 45 M Resection 0 Negative Negative 3-4 
18 76 F Resection 0 Negative Negative 
5 or 
more 
Keywords: ALK, FISH, immunohistochemistry, 
Signet-ring
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MO04.03 ALK COPY NUMBER CHANGES 
IN NON-SMALL CELL LUNG CANCER
Edurne Arriola1, Álvaro Taus1, Marta Salido2, Ana 
B. Galván2, Luz Martínez-Avilés2, Javier Gimeno2, 
Sergio Serrano2, Beatriz Bellosillo2, Francesc Solé2, 
Joan Albanell1 
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outcomes per RECIST. Linear associations between 
the percentage of ALK positive cells and signal copy 
number or response to therapy were summarized by 
Spearman correlations (two-sided p-values). 
Results: Mean percentage cells positive was 56% 
(n = 90, range: 18-100%). Isolated red signal copy 
number (contributing to both single red (n = 33, 
mean cell positivity = 74%) and split positive 
patterns (n = 49, mean cell positivity = 48%) 
strongly correlated with a higher percentage of 
positive cells (r = 0.743, p <0.0001). Isolated green 
signal copy number (contributing to the split positive 
pattern and the single green negative pattern) was 
weakly associated with a lower percentage of 
positive cells (r = -0.264, p = 0.012). However, when 
only those tumors with a split pattern of positivity 
were assessed this correlation strongly reversed (r = 
0.909, p < 0.0001). Fused signal copy number was 
moderately negatively associated with the percentage 
of positive cells (r = -0.466, p <0.0001), but was also 
negatively associated with isolated red signal copy 
number (r = -0.409, p <0.0001). Neither percentage 
cells positive (r = 0.192, p = 0.3), nor isolated red 
(r = 0.274, p = 0.195), isolated green (split pattern) 
(r = 0.438, p = 0.117) or fused signal (r = -0.247, p 
= 0.187) copy number correlated with the maximal 
percentage tumor shrinkage on crizotinib. 
Conclusion: FISH analyses are conducted on 
sectioned cells. The positive association between 
increases in rearranged signal copy number and 
percentage of ALK FISH positive cells supports 
the hypothesis that some signals are missed due to 
nuclear truncation. The higher percentage of positive 
cells with single red, compared to split patterns, 
suggests that difÀculties in detecting the narrow 
probe separation in the dominant EML4-ALK 
paracentric inversion may also contribute towards 
‘missed’ true positive cells. These data suggest that 
ALK FISH negative cells in otherwise ALK positive 
tumors may not represent true biological negatives. 
The lack of correlation between either percentage 
cells positive, or fused/rearranged signal copy 
number and crizotinib response in tumors bearing 
>15% ALK FISH positive cells suggests that these 
are not relevant biological variables with respect to 
beneÀt from ALK inhibition. 
Keywords: ALK, FISH
Table 2. ALK, EGFR and KRAS status 
EGFR KRAS
ALK n (%) Mutant WT Mutant WT
Disomic 28 (18) 1 19 3 18
Gain 96 (63) 11 68 17 59
AmpliÀcation 12 (8) 0 6 2 4
Clusters < 10% 10 (7) 1 8 0 9
Translocation 6 (6) 0 6 0 6
152 (100) 13 107 22 96
Conclusion: ALK copy number gain and 
ampliÀcation are relatively frequent in NSCLC, 
although its biological role remains to be deÀned. 
Keywords: ALK, Kras, EGFR, NSCLC
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MO04.04 THE PERCENTAGE OF 
TUMOR CELLS SHOWING AN ALK 
GENE REARRANGEMENT IN ALK 
FISH POSITIVE LUNG CANCER 
CORRELATES WITH SIGNAL COPY 
NUMBER, BUT NOT WITH RESPONSE 
TO CRIZOTINIB THERAPY.
David R. Camidge1, Mariana Theodoro1, Delee A. 
Maxson1, Margaret Skokan1, Tara O’Brien1, Xian 
Lu2, Robert C. Doebele1, Anna E. Baron2, Marileila 
Varella-Garcia1 
1Medical Oncology, University Of Colorado/United 
States Of America, 2Biostatistics And Informatics, 
University Of Colorado/United States Of America
Background: ALK gene rearrangements occur 
in 3-5% of NSCLC. Increased copy numbers of 
native (fused) and rearranged signals have also been 
reported. FISH using break-apart probes consistently 
shows ALK rearrangements in < 100% of tumor 
cells. ALK positivity is usually deÀned as >15% of 
tumor cells showing split red (3’) and green (5’) and/
or single red patterns. Fused or single green patterns 
are reported as negative. We explored correlations 
between the percentage of ALK positive cells and 
signal copy number and whether either variable is 
associated with response to ALK inhibition. 
Methods: 90 consecutive ALK FISH positive 
NSCLC patient samples were identiÀed. 
The percentage of tumor cells positive for a 
rearrangement, pattern of positivity (split, single red 
or both) and copy number of the fused, isolated red 
and isolated green signals were recorded. 30 of the 
90 patients had received crizotinib with available 
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8.9%, never versus former versus current] did 
not indicate any signiÀcant differences based on 
ethnicity. With respect to treatment with TKI mono-
therapy (irrespective of line or stage) stratiÀed by 
mutation indicated signiÀcant differences according 
to response measures [mutant versus wild type, 
CR+PR: 69.9% versus 11.6%, SD: 14.6% versus 
20.4%, and PD: 15.6% versus 68.0%]. The database 
also details all reported mutations and supports links 
to all published datasets.
Conclusion: Inclusion of over 500 reported datasets 
allows investigation of several trends associated with 
this particular somatic mutation. The cumulative 
nature of the data is a singular limitation; however, 
information extractable per Àeld is paramount to 
patient stratiÀcation. Although the spectrum of 
EGFR mutations is slowly increasing (n>300), 
several distinct mutational hotspots (n=9) account for 
82% of all mutational carriers. Screening practices 
will be formulated on such data. We are currently 
assessing correlative Àelds and incidence using 
Baysian statistics to generate predictive algorithms. 
We implore authors to support this data-source 
primarily through submission of independent patient 
data that will allow more robust analyses to be 
conducted.
Keywords: incidence, EGFR mutation, Smoking, 
Predictive
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MO04.07 COMPREHENSIVE ANALYSIS 
OF MECHANISMS ON ACQUIRED 
RESISTANCE OF LUNG CANCER 
AGAINST EGFR-TKI WITH SPECIAL 
REFERENCE TO ROLE OF PTEN 
EXPRESSION LOSS
Kosei Yasumoto1, Hidetaka Uramoto2, Takashi 
Yoshimatsu1, Tetsuya So1, Naohiro Nose1, Takamitsu 
Onitsuka2, Fumihiro Tanaka2, Mayumi Ono3 
1Respiratory Disease Center, Tiyuukai Hospital 
Groop/Japan, 2Second Dept Surg, Univ Occupat 
Environment Health/Japan, 3Dept Pharmaceutical 
Oncol, Kyushu Univ/Japan
Background: Acquired resistance against EGFR-
TKI may be ascribed to T790M secondary 
mutation(50%) and to MET ampliÀcation(20%). 
However, the mechanisms of remaining 30% of 
acquired resistance of EGFR-TKI has remained 
to be elucidated. Recently, we have reported that 
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MO04.06 UPDATE OF THE SOMATIC 
MUTATIONS EGFR DATABASE (WWW.
SOMATICMUTATIONS-EGFR.NET)
Samuel Murray1, Helena Linardou2, Issa Dahabreh3, 
Christos Papadimitriou4, Dimitrios Bafaloukos2, 
Paris Kosmidis5 
1Oncology, Genekor/Greece, 21st Department Of 
Oncology, Metropolitan Hospital/Greece, 3University 
School Of Medicine, Boston/United States Of 
America, 4Alexandras Hospital/Greece, 5Hygeia 
Hospital/Greece
Background: Somatic mutations particularly in 
exons 18-21 of the epidermal growth factor receptor 
(EGFR) have been correlated with improved 
response outcomes in NSCLC patients treated with 
tyrosine kinase inhibitors (TKIs). The frequency 
and spectrum of these mutations differs depending 
on ethnicity, wherein the incidence in Asians is 
approximately 30% compared to 15% in Whites. In 
addition several clinicopathological factors (gender, 
smoking status and histological type) demonstrate 
correlation with their presence. Aim: To update our 
existing comprehensive database through collation 
of all published data reporting on somatic EGFR 
mutational analysis. Using this resource it should be 
possible to investigate several trends associated with 
several of the correlative factors and also address 
aspects associated with screening issues. 
Methods: Using a broad search string including 
“EGFR”, “geÀtinib”, “NSCLC”, “erlotinib” and 
associated synonyms we identiÀed 9895 abstracts 
from inception through to 01/01/2011 in MEDLINE 
(PubMed). One additional Àeld was added into our 
existing database, former smoker, thus splitting 
smoking status into current-former-never. Data 
extraction was conducted by two investigators 
and all manuscript reference lists were scoured 
for potentially eligible manuscripts. A total of 545 
manuscripts (data sets) have been identiÀed and 
included into the compendium (increasing the 
number from 202).
Results: With a total of 31,749 screened patients 
9,032 have been identiÀed to harbor a mutation 
(28.4%) [33.9% versus 17.3%; asians and whites 
respectively]. Cumulative data split by correlating 
factors of histology [34.6% versus 8.2%; 
adenocarcinoma versus other histologies], gender 
[17.8% versus 41.9%, males versus females], 
and smoking status [50.0% versus 16.9% versus 
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unresponsiveness to EGFR-TKI. In conclusion, 4 
out of 11 resistant tumors remain to be elucidated the 
mechanism of acquired resistant to EGFR-TKI. 
Keywords: EGFR-TKI, PTEN expression, Acquired 
resistance to EGFR-TKI
Biomarkers VI Monday, 4 July 2011 14:30-16:00
MO04.08 HIGH PREVALENCE OF 
GERMLINE EGFR T790M MUTATIONS 
IN LUNG CANCER PATIENTS WHOSE 
TUMORS HARBOR BASELINE T790M
Geoffrey R. Oxnard1, Maria E. Arcila2, Mark G. 
Kris1, Marc Ladanyi2, Vincent A. Miller1 
1Medicine, Memorial Sloan-Kettering Cancer 
Center/United States Of America, 2Pathology, 
Memorial Sloan-kettering Cancer Center/United 
States Of America
Background: EGFR T790M mutations are found in 
up to 68% of lung cancers with acquired resistance to 
EGFR tyrosine kinase inhibitors (TKIs; Arcila, CCR, 
2011), and can also be detected prior to TKI (1% of 
adenocarcinomas; Kris, ASCO, 2010). Additionally, 
lung cancer patients with germline T790M and a 
family history of lung cancer have been described. 
A study screening for germline T790M in blood 
samples of never-smokers with lung cancer (Girard, 
CCR, 2010) found a prevalence of only 0.5%. We 
hypothesized that one way of identifying patients 
with germline T790M mutations would be to study 
those whose lung cancers were found to harbor 
baseline T790M. 
Methods: All patients at our institution with lung 
cancer harboring baseline EGFR T790M, prior 
to TKI exposure, were included in this analysis. 
Mutations had been identiÀed in tumor tissue 
through direct sequencing, mass spectroscopy, or 
a locked-nucleic-acid (LNA) assay. Sequencing 
tracings were reviewed to exclude patients with 
false positive T790M results. With IRB approval, 
patient charts were reviewed and benign tissue was 
collected, which was then anonymously tested for 
T790M by direct sequencing.
Results: 11 patients with baseline T790M were 
identiÀed; all harbored a concurrent sensitizing 
mutation (5 exon 19, 6 exon 21). Median survival 
was 39 months for the 9 patients with advanced 
disease, though 0 of 5 patients treated with single-
agent TKI had a radiographic response. 9 patients 
had benign tissue tested for germline T790M, which 
loss of PTEN expression is a crucial mechanism 
of experimental acquired resistance induced by 
exposing PC9 cells(EGFR-mutated lung cancer 
cell line harboring activating mutation of EGFR( 
delE746-A750)) in vitro to stepwise increasing 
concentrations of EGFR-TKI(geÀtinib)(from 
005 ƫmol/L to 15 ƫmol/L) over 7months which 
does not exhibit T790M ( Cancer Res 70(21), 
8715-8725,2010). Therefore, we evaluated 
PTEN expression in 11 cases showing acquired 
resistance to EGFR-TKI. Also, overexpression of 
MET ligand:HGF is thought to be one of crucial 
mechanisms of acquired resistance of lung cancer 
against EGFR-TKI.
Methods: We have evaluated comprehensively such 
mechanisms as T790M acquired mutation, MET 
ampliÀcation, HGF overexpression and loss of PTEN 
expression in 11 Japanese patients with acquired 
resistance to EGFR-TKI whose pretreatment tumors 
harbor sensitive mutation for EGFR-TKI. Mutations 
of EGFR-TKI and MET ampliÀcation were 
evaluated based on PCR methods. PTEN and HGF 
expressions were evaluated by immunohistochemical 
staining.
Results: Seven had T790M in resistant tumors, no 
MET ampliÀcation was detected, and 6 exhibited 
strong expression of HGF. All of these 6 tumors had 
T790M. PTEN was down-regulated in 3 resistant-
tumors in which all had T790M and responses to 
EGFR-TKI of pretreatment tumors were PR in 2 
with TTP of 5.8 and 11.7m,and SD in one with TTP 
of 7.4m. Moreover, loss of PTEN expression was 
observed in 3 pretreatment tumors having activating 
EGFR mutation. These 3 tumors exhibited CR in 
one, PR in one and SD in one during the treatment 
with EGFR-TKI( geÀtinib) with TTP of 7.0, 7.8 and 
7.4m, respectively.
Conclusion: 
Thus, the loss of PTEN expression seems not to be 
an independent mechanism of acquired resistance 
to EGFR-TKI in clinical setting in contrast to the 
experimental resistance. Furthermore, Loss of PTEN 
expression in pretreatment tumors does not predict 
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at diagnosis ranging from 26 to 89 years (median 65 
years). Seventy-nine patients had stage I disease, 11 
had stage II, 22 had stage III, and 3 had stage IV. In 
65 of 115, environmental tobacco smoke (ETS) data 
were available. 
Results: 
EGFR mutations (72 patients), KRAS mutations 
(6 patients), HER2 mutations (4 patients), and 
ALK translocations (6 patients) were identiÀed in 
77% of all 115 patients and these were mutually 
exclusive each other. Strikingly, all but one (18/19) 
of male never-smoking patients harbored one of 
these alterations, in contrast, 27% (26/96) of female 
never-smoking patients did not have any of these 
alterations, and this difference was statistically 
signiÀcant (Fig.1, left; p=0.042). When we combined 
our data with those of Sun, et al. (JCO. 28: 4616-
4620, 2010), the similar results were obtained; 
i.e., 97% (29/30) of male never-smoking patients 
harbored one of these alterations, while 23% 
(31/137) of female never-smoking patients did 
not have these alterations (p=0.019). To explain 
this difference, we explored the inÁuence of ETS, 
because of suspected higher rate of household 
ETS exposure in elderly Japanese female never-
smokers. Interestingly, 32% (6/19) of patients with 
ETS exposure did not have either of the alterations, 
in contrast, 85% (39/46) of patients without ETS 
exposure had any of these four alterations (Fig.1, 
right).
Conclusion: In lung adenocarcinoma from never-
smoking patients in East Asia, virtually all male 
patients and about 80% of female patients can be 
explained by oncogenic activation of one of EGFR, 
KRAS, HER2, or ALK genes. ETS may be one of the 
reasons for this gender difference. 
Keywords: driver mutations, lung adenocarcinoma, 
never-smoking patients, EGFR mutations
was present in 4 (44%); analysis of benign tissue 
from 2 additional cases is pending. Median age at 
diagnosis for the 4 germline T790M patients was 51; 
2 had a family history of lung cancer.
Conclusion: Germline T790M mutations are 
common in lung cancer patients with tumors 
harboring baseline EGFR T790M, and can occur 
with or without a family history of lung cancer. 
These patients are ideal candidates for germline 
testing; affected probands and their family members 
could then be studied prospectively. A study of CT 
screening in family members with germline T790M 
is under development. Study supported by the NIH 
(P01-CA129243).
Keywords: EGFR, genetics
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MO04.09 ANALYSES OF MUTUALLY 
EXCLUSIVE DRIVER MUTATIONS IN 
LUNG ADENOCARCINOMAS FROM 
NEVER-SMOKING PATIENTS
Kenichi Suda1, Kenji Tomizawa1, Keitaro Matsuo2, 
Yasushi Yatabe3, Tetsuya Mitsudomi1 
1Department Of Thoracic Surgery, Aichi Cancer 
Center Hospital/Japan, 2Division Of Epidemiology 
And Prevention, Aichi Cancer Center Research 
Institute/Japan, 3Pathology And Molecular 
Diagnostics, Aichi Cancer Center Hospital/Japan
Background: It is known that EGFR, KRAS, 
HER2, or ALK oncogenic alterations occur in 
lung adenocarcinomas in mutually exclusionary 
fashion. Therefore, lung adenocarcinomas can be 
subdivided based on these alterations, and this sub-
classiÀcation would be important in understanding 
lung carcinogenesis and in developing treatment 
strategies. The prevalence of these alterations, 
except for KRAS, is higher in never-smokers, and 
a very recent paper that analyzed 52 never-smoking 
Chinese patients (Sun, et al. JCO. 28: 4616-4620, 
2010) showed that about 90% harbor one of these 
alterations. In the present study, we performed 
similar and further analyses using much larger cohort 
of never-smoking Japanese lung adenocarcinoma 
patients. 
Methods: One hundred Àfteen never-smoking 
patients with lung adenocarcinoma had enough 
tumor samples for analyses of all four genes 
described above, and were included in this study. 
Nineteen were men and 96 were women, with ages 
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were analyzed for response and progression-free 
survival (PFS). A subpopulation of 18 evaluable 
KRAS-mutant NSCLC patients who had failed prior 
docetaxel therapy were evaluated for the time on 
treatment for docetaxel and the subsequent time on 
treatment for GSK212 therapy.
Results: GSK212 monotherapy had a response rate 
(RR) of 24% (6/25) in the NSCLC cell line panel, 
deÀned by both cell growth inhibition and apoptosis 
induction assays. In contrast, everolimus or erlotinib 
alone showed little or no activity. Interestingly, 
docetaxel had a RR of 40% (10/25) alone and 84% 
(21/25) in combination with GSK212. Furthermore, 
cell lines that were sensitive to GSK212 alone 
were less responsive to both docetaxel and 
paclitaxel alone. In vitro response to GSK212 
was associated with a distinct proÀle of molecular 
markers including: lower levels of AKT/FOXO3a-
phosphorylation, higher expression levels of genes 
involved in EGFR signaling, adhesion or endocytosis 
such as TGFA, EREG, EPCAM, CTNND1, STN2, 
and lower expression levels of genes involved in 
transcription regulation or cell cycle such as TWIST, 
TYMS, CDKN2C compared with GSK212-resistant 
NSCLC cell lines. Of the 18 evaluable KRAS-
mutant NSCLC patients treated with GSK212 
monotherapy on the ongoing MEK111054 Phase 
I study, two experienced a partial response for a 
preliminary RR of 11% and yielded a preliminary 
PFS for 3.8 months (95% CI: 1.9-5.5). Interestingly, 
there was an inverse correlation (Pearson correlation 
coefÀcient = -0.3, p value >0.3) between GSK212 
treatment duration and prior docetaxel treatment. 
Conclusion: Similar to the preclinical observations, 
the sensitivity to GSK212 monotherapy may be 
restricted to a distinct subpopulation of KRAS-mutant 
NSCLC patients, although these results were not 
statistically signiÀcant. The speciÀc molecular and 
genetic proÀle established in vitro in the 25 NSCLC 
cell line panel will be analyzed in KRAS-mutant 
NSCLC tumor samples obtained from the clinic to 
explore possible predictive markers that may guide 
future GSK212 treatment strategies as monotherapy 
or in combination with other standard or novel 
therapies.
Keywords: Kras, NSCLC, MEK, Biomarkers
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MO04.11 PRECLINICAL MODELING OF 
SUSCEPTIBILITY OF NSCLC CELLS 
WITH RAS MUTATIONS TO GSK1120212, 
A POTENT AND SELECTIVE MEK1/
MEK2 INHIBITOR: IMPLICATION FOR 
CLINICAL DEVELOPMENT
Li Liu1, Tona M. Gilmer1, Hong Shi1, Vivian 
Zhang1, Jennifer Park2, Leslie A. Fecher3, Wells 
A. Messersmith4, Jeffrey R. Infante5, Gerald S. 
Falchook6, Vijay Peddareddigari7 
1Oncology Translational Research, Glaxosmithkline/
United States Of America,
2Oncology,Glaxosmithkline/United States Of 
America, 3Medicine, University Of Pennsylvania, 
Abramson Cancer Center/United States Of America, 
4Medicine/division Of Medical Oncology, University 
Of Colorado Cancer Center/United States Of 
America, 5Drug Development Unit, Sarah Cannon 
Research Institute/United States Of America, 
6Investigational Cancer Therapeutics, University 
Of Texas MD Anderson Cancer Center/United 
States Of America, 7Research And Development, 
Glaxosmithkline/United States Of America
Background: Activating mutations of the KRAS 
oncogene are the most frequent mutations in non-
small cell lung cancer (NSCLC) and may correlate 
with a poorer prognosis, in part due to limited 
beneÀt from systemic treatments. Targeting the 
activated RAS/RAF/MEK pathway in NSCLC with 
the potent, selective MEK1/MEK2 small molecule 
inhibitor GSK1120212 (GSK212) is an innovative 
approach to potentially improve the clinical outcome 
for patients with KRAS-mutant tumors. In this 
study, we assessed the in vitro susceptibility of 
RAS-mutant NSCLC cell lines to GSK212 alone 
or in combination with other therapeutic agents, to 
identify predictive markers of response and provide 
a scientiÀc rationale for the clinical development of 
GSK212.
Methods: A panel of 25 RAS-mutant NSCLC cell 
lines was subjected to genomic alterations, gene 
expression and cell signaling proÀling. Susceptibility 
to GSK212, docetaxel, erlotinib and everolimus 
alone or in combinations was determined by cell 
growth inhibition (CellTiter-Glo® assay, Promega) 
and apoptosis induction (caspase 3/7 activation) 
assays. Additionally, data from 22 KRAS-mutant 
NSCLC patients on the ongoing MEK111054 
Phase I study who were treated with GSK212 alone 
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MO04.13 DETECTING LUNG CANCER 
FROM VOLATILE ORGANIC 
COMPOUNDS WITH AN ELECTRONIC-
NOSE (E-NOSE)
Calum E. Macaulay1, Stephen Lam2, Annette M. 
Mcwilliams2 
1Integrative Oncology, BC Cancer Research Centre/
Canada, 2British Columbia Cancer Agency/Canada
Background: This ongoing study is investigating 
the ability of an array of 32 nanosensors (Cyranose 
E-nose) to discriminate between breath volatile 
organic compounds (VOC) that characterise 
subjects at risk of developing lung cancer from 
subjects harbouring an early lung cancer. The 
operating hypothesis is that the altered metabolic 
and physiologic characteristics of lung cancer 
tissue result in the release of VOC in amounts or 
composition different than normal tissues. The goal 
is that the reliable detection of these changes could 
be used as part of a lung cancer screening program.
Methods: To date VOC data in 139 exhaled breath 
samples from control subjects who are high risk 
smokers and 18 exhaled breath samples from Stage 
I/II lung cancer patients has been collected using the 
E-nose system. These subjects are between 50-79 
years of age and have a smoking history of at least 
20 pack years. Control subjects are from a local lung 
cancer screening study, and cancer patients from 
local referrals
Exhaled breath samples are collected from each 
subject while breathing medical air to control for 
local ambient VOC. The breath collection is then 
sampled by the E-nose device. This is a relatively 
inexpensive organic polymer sensor that changes 
resistance in the presence of certain VOCs. These 
systems measure a differential signal between a 
reference gas (medical air) and the sample being 
tested. In addition to examining the system’s 
response to subject samples we have assessed the 
variability of its response to differing supplies of 
medical gas as well as compared the inter system 
variability between two systems.
Results: The E-nose system is very sensitive to 
changes in temperature and humidity. We developed 
algorithms which remove baseline data drift and 
have Àt individual sensor response to a 5th order 
polynomial and a double exponential to maximize 
sensor sensitivity while minimizing the effects of 
noise. Individual sensor data was found to have very 
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MO04.12 ELECTRONIC NOSE 
DISTINGUISHES LUNG CANCER FROM 
HEALTHY EVER SMOKERS.
Annette G. Dent, Rayleen Bowman, Paul 
Zimmerman, Ian A. Yang, Kwun M. Fong 
Department Of Thoracic Medicine, The Prince 
Charles Hospital And The University Of Queensland/
Australia
Background: The measurement of volatile organic 
compounds (VOCs) in exhaled breath using an 
electronic nose may prove to be a novel, effective and 
simple technique for screening and diagnosing lung 
cancer.
Methods: Aims: To determine whether VOC proÀle in 
individuals with lung cancer can be differentiated from 
that of healthy ever smokers with at least a 30 pack year 
smoking history. 2. To determine whether the VOC 
proÀle differs between lung cancer histologies. Method: 
Subjects performed two exhaled vital capacities (10 
min apart) into a Tedlar sample bag after breathing 
tidally through an inspiratory port Àlter for 5 minutes. 
Samples were analysed using a Cyranose 320. Means 
of the two tests for each of the 32 sensors were reduced 
to principal components and canonical discrimination 
analyses were performed to determine signiÀcance of 
difference between subject groups and cross validated 
accuracy (CVV) of the groups using the leave one out 
classiÀcation method (SPSS V17.0). Spirometry and 
gas transfer measurements were also performed.
Results: The VOC proÀles of lung cancer subjects 
(n=26) were correctly differentiated from healthy 
subjects with a smoking history (n=61) with CVV 
accuracy of 82% (p<0.0001). The VOC proÀles did not 
differ with the type of cancer.
Conclusion: SigniÀcant differences in exhaled breath 
VOC proÀles between subjects with lung cancer and 
healthy ever smokers indicate that the eNose (Cyranose 
320) does have the potential to be a clinically useful 
diagnostic and screening tool for lung cancer however 
may not be able to discriminate between cancer types. 
Supported by The Prince Charles Hospital Foundation, 
The Prince Charles Hospital Private Practice Trust 
Fund, NHMRC Career Development Award (IY), 
NHMRC Practitioner Fellowship (KF). ConÁict of 
Interest: None 
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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for about 80% of cases of which adenocarcinoma 
represents the majority. The appearance of distant 
metastasis is one of the main reasons for failing to 
cure patients with this disease. Thus, understanding 
the biological processes underlying lung cancer cell 
motility, invasion and metastasis should highlight 
novel therapeutic biomarkers to improve the poor 
clinical outcome.
Methods: We performed an automated kinome-
based RNA interference screen for cell migration 
using the A549 non-small cell lung cancer (NSCLC) 
cell line. We studied changes in cell migration 
patterns in response to RNAi treatment using time-
lapse microscopy and automated tracking.
We then tested the capacity of our motility hits 
to regulate cell invasiveness in a 96-well plate 
3-dimensional invasion assay where cells invaded 
upward from the bottom of the well through a 
collagen matrix. Using a human protein-protein 
interactome database we identiÀed novel interactor 
of RSK and conÀrmed that RSK1 interact with 
vasodilator-stimulated phosphoprotein (VASP) by 
co-immunoprecipitation. IdentiÀcation of the VASP 
residues phosphorylated by RSK1 was performed 
using mass spectrometry analysis and phospho-
speciÀc antibody. We further extended our Àndings 
in vivo using A549 xenograft model in zebraÀsh. 
Finally, RSK1 expression was tested in a tissue 
microarrays containing matched primary non-small 
cell lung cancers (adenocarcinomas) and adjacent 
normal lung.
Results: Our cell motility screen identiÀed 48 
previously unknown to regulate cell motility. 
Among our candidates, were several members 
of the ribosomal S6 kinase (RSK) family. In 
particular, RSK1 silencing increased, while RSK2 
and 4 downregulation decreased, cell motility. In 
a secondary screen, more than 50% of our hits 
similarly modulated A549 cell invasion in vitro. 
Amongst these, RSK1 downregulation, in keeping 
with its effect on cell migration, strongly increased 
cell invasiveness. In silico analysis and biochemical 
experimentation revealed that RSK1 interacted with 
the actin regulators VASP and Mena. This correlated 
with the ability of RSK1 to phosphorylate VASP 
on Thr-278, a site regulating VASP-mediated actin 
dynamics. Moreover, RSK1 silencing enhanced 
the metastatic behaviour of A549 cells in vivo 
using a zebraÀsh xenograft model. Importantly, 
immunohistochemical staining showed decreased 
RSK1 expression in metastatic lung cancer lesions 
as compared to their isogenically matched primary 
little classiÀcation ability. However combinations 
of pairs of sensors data were found to be quite 
discriminating. For the 157 samples aquired, using 
data from only 2 of the 32 sensors optimized for a 
speciÀcity of 90%, the observed sensitivity was 50% 
and similarly for a speciÀcity of 50% we observed 
a sensitivity of 94%. Through the measurement of 
many samples in parallel by the two systems, we 
observed that they are substantially equivalent with a 
sensor by sensor average linear correlation R2 value 
of 0.994 with a range of 0.999 to 0.972 across the 
32 sensors. The E-nose system could detect subtle 
differences between medical air supply batches, 
however these differences were signiÀcantly smaller 
than subject to subject differences. The E-nose 
systems performance is encouraging and active 
recruitment is ongoing.
Conclusion: Our results suggest that measurement 
of VOC in exhaled breath is a promising method to 
identify subjects with early lung cancer in a high risk 
population.
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MO04.14 IDENTIFICATION OF RSK1 AS 
A KEY MODULATOR OF LUNG CANCER 
METASTASIS
Romain Lara1, Francesco Mauri2, Harriet Taylor3, 
Rita Derua4, Alice Shia3, Colin Gray5, Alastair 
Nicols5, Robert J. Shiner2, Edward Edward 
SchoÀeld6, Paul Bates6, Etienne Waelkens4, Maggie 
Dallman3, Jonathan Lamb3, Daniel Zicha5, Julian 
Downward7, Michael Seckl1, Olivier Pardo1 
1Oncology, Imperial College London/United 
Kingdom, 2Histopathology, Imperial College 
London/United Kingdom, 3Imperial College London, 
Division Of Cell And Molecular Biology, Department 
Of Life Sciences, Faculty Of Natural Sciences/
United Kingdom, 4Labo Proteïne Fosforylatie 
En Proteomics, Katholieke Universiteit Leuven/
Belgium, 5Cancer Research Uk - London Research 
Institute, Light Microscopy Department/United 
Kingdom, 6Cancer Research Uk - London Research 
Institute, Biomolecular Modelling Laboratory/United 
Kingdom, 7Cancer Research Uk - London Research 
Institute, Signal Transduction Laboratory/United 
Kingdom
Background: Lung cancer is the commonest cancer 
killer worldwide with a 5-year survival rate <5%. 
Non-small cell lung cancer (NSCLC) accounts 
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comorbidity. Volunteers received one prevalence 
scan and two annual incidence scans using a Phillips 
Brilliance 64-slice multidetector scanner at 0.9mm slice 
thickness. Two radiologists independently reported 
scans with the Ànal report agreed by consensus. Any 
non-calciÀed nodule 4mm diameter was deÀned as a 
positive scan. Generally, nodules 4-8mm diameter were 
followed with interval scans whereas larger nodules 
underwent further investigation. Health status follow-up 
will continue for Àve years from study entry.
Results: From December 2007 to December 2010, 
958 persons enquired about enrolment. In total, 
256 volunteers were screened (Table 1). The mean 
estimated Effective Dose was 1.5mSv/scan. 305 
nodules 4mm were detected (35% were in the right 
upper lobe, 72.5% had a smooth margin and 87.9% 
were of soft tissue density). 607 micronodules (<4mm) 
were detected. 53% of participants had positive 
scans; 15% of participants had neither nodules nor 
micronodules; 32% had micronodules only and were 
followed up at a 12 month interval. 8 participants 
(5.8% of those with positive scans) underwent one 
or more invasive diagnostic procedures (CT-guided 
biopsy and/or bronchoscopy). Three out of eight did 
not have malignant disease diagnosed and two of these 
suffered signiÀcant pneumothorax requiring intercostal 
chest drainage. No participants underwent a surgical 
procedure for benign disease. Five cancers were 
diagnosed. The cancer prevalence was 1.95% [95%CI 
0.26 - 3.64] or 3.68% of positive scans. All cancers 
were stage I or II. Four participants had surgery, one 
had radical chemoradiotherapy. Table 1. 
Male Female All participants 
n (%) 171 (66.8) 85 (33.2) 256 
Age, years Median (range) 64.5 (59-75) 64.6 (60-74) 64.5 (59-75) 
Age groups 60-64, n (%) 93 (54.4) 47 (55.3) 140 (54.7) 
65-69, n (%) 59 (34.5) 30 (35.3) 89 (34.8) 
70-74, n (%) 19 (11.1) 8 (9.4) 27 (10.5) 
Spirometry 
FEV1 % 
predicted, 
median (range) 
95.7 (52.1-155.5) 94.2 (46.6-129.4) 95.0 (46.6-155.5) 
Obstructive 
ventilatory 
defect 
Mild 45 (26.3) 21 (24.7) 66 (25.8) 
Moderate 9 (5.3) 4 (4.7) 13 (5.1) 
Moderately 
severe 10 (5.8) 3 (3.5) 13 (5.1) 
Severe 0 1 (1.2) 1 (0.4) 
Smoking Current, n (%) 74 (43.3) 42 (49.4) 116 (45.3) 
Pack-year 
history, median 
(range) 
58 (24 -235) 46 (22 -220) 54 (22-235) 
Nodules per 
participant Median (range) 1 (0-13) 1 (0-9) 1 (0-13) 
Micronodules 
per participant Median (range) 1 (0-18) 2 (0-15) 2 (0-18) 
tumours. Furthermore, loss of RSK1 expression in 
lung primary tumours correlated with an increased 
number of metastatic lesions.
Conclusion: Our screen revealed 48 previously 
unpublished regulators of lung cancer cell migration. 
In particular, we identiÀed RSK1 as a key regulator 
of lung cancer cell metastasis. Importantly, 
immunohistochemical staining demonstrated that 
RSK1 was downregulated in metastatic compared to 
primary tumours establishing RSK1 as a determinant 
of lung cancer cell metastasis and a potential 
predictive marker for disease progression.
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MO05.01 LUNG CANCER SCREENING: 
BASELINE RESULTS FROM 
AUSTRALIAN LOW DOSE COMPUTED 
TOMOGRAPHY STUDY
Henry M. Marshall1, Rayleen Bowman2, Jane 
Crossin3, Melanie Fuentes3, Richard Slaughter3, 
Linda Passmore1, Elizabeth Mccaul1, Deborah 
Courtney1, Morgan Windsor4, Ian A. Yang2, Terry 
Hayes3, Paul Zimmerman1, Stanley Redmond3, Ian 
Smith5, B J. Keir6, Kwun M. Fong2 
1Thoracic Medicine, The Prince Charles Hospital/
Australia, 2Department Of Thoracic Medicine, The 
Prince Charles Hospital/Australia, 3Department Of 
Medical Imaging, The Prince Charles Hospital,/
Australia, 4Thoracic Surgery, The Prince Charles 
Hospital/Australia, 5St Andrew’s Medical Institute, 
St Andrew’s War Memorial Hospital/Australia, 
6Biomedical Technology Services, Royal Brisbane 
And Women’s Hospital/Australia
Background: The National Lung Screening Trial 
reports that LDCT screening can reduce lung cancer 
mortality. The Queensland Lung Cancer Screening 
Study (QLCSS) is an observational study based on the 
NLST protocol. We report our interim baseline Àndings. 
Methods: Using advertisement and press release, we 
recruited healthy volunteers aged 60-74 years with 
a smoking history  30 pack years (current or quit 
within 15 years), FEV1>50%predicted and no major 
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Àfth year. One hundred seventy-Àve primary lung 
tumors were detected. One hundred thirty six cases 
(78%) were initial stage (N0M0). Interval cancers 
occurred in 6 patients. Resectability rate was 88% 
with 0.5% postoperative mortality. Five-year overall 
and cancer speciÀc survival were 76% and 81% 
respectively. Recall rate was 10.2% at baseline and 
ranged from 4.2% to 6.4% at subsequent screening 
rounds. Delayed diagnosis occurred in 16 patients 
(16/186) (Table 1). Causes of misdiagnosis can be 
resumed as follow: protocol failure (nodule < 5 mm 
one year before) in 7 cases; LD-CT failure (central 
position) in 6; human failure (misinterpretation) in 
3. Metachronous second primaries were diagnosed 
at follow-up CT in 11 cancer patients. Sensibility 
of protocol was 168/193 (87.0%); speciÀcity was 
4976/5001 (99.5%); and PPV was 168/202 (83.2%). 
Benign diseases diagnosed with surgical biopsy were 
34 (34/220=15.5%).
Conclusion: The diagnostic performance of our 
CT protocol was high with acceptable number of 
benign disease requiring surgical biopsy, limited 
recall rate and high long term survival. Number of 
interval cancers, advanced stage at diagnosis and 
misdiagnosis will probably be further reduced by 
future application of risk modeling and lung cancer 
serum markers. 
Keyword: lung cancer, screening, early stage
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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MO05.03 PREDICTORS OF EARLY 
CT-DETECTED LUNG CANCERS IN 
DUTCH-BELGIAN RANDOMIZED LUNG 
CANCER SCREENING TRIAL (NELSON)
Eleonora Baecke1, Rob J. Van Klaveren2, C.W.N. 
Looman2, J.W.J. Lammers3, Harry J.M. Groen4, C. 
Weenink5, K. Nackaerts6, Matthijs Oudkerk4, H.J. De 
Koning2 
1Public Health, Erasmus MC/Netherlands, 2Erasmus 
MC/Netherlands, 3Umc Utrecht/Netherlands, 4Umc 
Groningen/Netherlands, 5Kennemer Gasthuis/
Netherlands, 6Umc Leuven/Belgium
Background: Although smoking and age are well-
known risk factors for lung cancer, less evidence 
Conclusion: The prevalence of lung cancer in our 
cohort is similar to other studies. High rates of 
false positive scans and the subsequent potential 
for adverse events following biopsy need to be the 
focus of future studies in order to improve screening 
efÀcacy. Supported by a Queensland Smart State 
Grant, NCARD and NHMRC. 
Keywords: lung cancer screening, low dose 
computed tomography
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MO05.02 DIAGNOSTIC PERFORMANCE 
OF ANNUAL LD-CT SCREENIGN FOR 
LUNG CANCER AFTER FIVE YEARS
Giulia Veronesi1, Lorenzo Spaggiari1, Ptrik 
Maisonneuve1, Cristiano Rampinelli2, Alessandro 
Pardolesi1, Raffaella Bertolotti2, Alessandro Borri1, 
Francesco Petrella1, Stefania Rizzo2, Massimo 
Bellomi2 
1Division Of Thoracic Surgery, European Institute Of 
Oncology/Italy, 2Division Of Radiology, Europena 
Institute Of Oncology/Italy
Background: CT screening is an effective tool to 
reduce lung cancer mortality however to increase 
diffusion and acceptance of screening programmes 
it is essential to identify standardised diagnostic 
protocols and make evidence-based decisions on 
nodule management. We report the long term results 
of a single center low-dose CT screening trial and 
analyze the performance, invasiveness and side 
effects of the diagnostic protocol.
Methods: Between October 2004 and October 
2005, 5203 asymptomatic high-risk individuals 
(20 pack-years, age >50 years) were enrolled in a 
single centre trial and followed annually for 5 years. 
Nodules 5 mm were scheduled for repeat CT a year 
later. Nodules between 5.1 and 8 mm were checked 
with LD-CT 3-6 months later. Nodules >8.1 mm or 
growing lesions were scheduled for CT-PET. True 
positives were deÀned as any stage prevalent lung 
cancer, nodules in progression diagnosed as stage 
I lung cancers or new nodules diagnosed as lung 
cancers; false negatives, as nodules in progression 
diagnosed as lung cancer in stage >1; false positives 
as benign nodules resected surgically; and true 
negatives as patients with no evolving nodules at 
baseline and subsequent LD-CTs.
Results: Compliance was 82% at the end of the 
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initial, low-dose CT scan and their implications on 
the delays in diagnosis of lung cancer. 
Methods: We determined all instances of non-
calciÀed nodule(s) in the initial, low-dose CT scans 
performed in 2006-2009 in the International Early 
Lung Cancer Action Program (I-ELCAP), Using 
the current deÀnitions of positive result for baseline 
and annual repeat and more restrictive ones, we 
determined the frequencies of positive results and 
how often the diagnosis of lung cancer would have 
been delayed using the more restrictive deÀnition.
The current deÀnitions of a positive result of the 
initial, low-dose CT in the lung parenchyma are as 
follows. In baseline screening, a positive result is 
the identiÀcation of at least 1 of: solid or part-solid, 
non-calciÀed nodule 5.0 mm or more in diameter, 
or nonsolid non-calciÀed nodule 8.0 mm or more in 
diameter; or a solid endobronchial lesion 5.0 mm or 
more in diameter (14). In annual repeat screenings, 
a positive result is the identiÀcation of at least 1 
previously unidentiÀed, non-calciÀed parenchymal 
nodule, larger than before, regardless of consistency 
and size, or a solid endobronchial nodule, regardless 
of size. A nodule is classiÀed as solid, part-solid, or 
nonsolid, and as calciÀed or non-calciÀed according 
to speciÀed criteria, and its ‘diameter’ is taken to 
be the average of its ‘length’ and ‘width’. The more 
restrictive alternatives are: In baseline screening, 
a positive result is the identiÀcation in the lung 
parenchyma of at least 1 of: solid non-calciÀed 
pulmonary nodule 7.0 mm or more in diameter, 
or part-solid non-calciÀed nodule 7.0 mm or more 
in diameter; or at least 1 nonsolid, non-calciÀed 
pulmonary nodule 15.0 mm or more in diameter, 
or solid endobronchial lesion 7.0 mm or more in 
diameter. In annual repeat screenings, a positive 
result is the identiÀcation of least 1 previously 
unidentiÀed solid non-calciÀed nodule 3.0 mm 
or more in diameter that was larger than before, 
part-solid non-calciÀed nodule 5.0 mm or more in 
diameter, or nonsolid non-calciÀed nodule 15.0 mm 
or more in diameter, or solid endobronchial lesion 
5.0 or more in diameter. 
Results: For baseline screening using the current 
deÀnition, the frequency of positive result was 18% 
(3,180/17,858), while using the more restrictive 
deÀnition it would have been 8% (1,347/17,858), a 
58% reduction. Using the more restrictive deÀnition, 
the number of lung cancers diagnosed within 1 year 
of the initial CT scan would have been 111 instead 
of 118, 6% fewer. For annual repeat screening, the 
corresponding frequencies were 8% (1,587/20,347) 
is available about other predictors and the role of 
gender, particularly not for early CT-detected lung 
cancers. We investigated predictors of CT-screen-
detected lung cancers among participants of the 
Dutch-Belgian randomized lung cancer screening 
trial (NELSON), who are high-risk current and 
former smokers. 
Methods: We evaluated data, obtained from 
questionnaires sent before randomization, of 6294 
male and 1247 female screen arm participants, aged 
50-75, who underwent at least the baseline CT scan. 
Cox proportional Hazard regression was performed, 
in which screen-detected lung cancer was the 
dependent variable. The mean follow-up was 35.8 
months. 
Results: Till 2010, lung cancer had been detected 
in 159 male and 29 female participants. Age, level 
of education, smoking history, prior diagnosis of 
cancer < 5 years ago and perceived health were all 
signiÀcantly associated with lung cancer detection. 
After correcting for these predictors, the Hazard ratio 
comparing women with men was 1.39 (95% CI: 0.93 
to 2.08). The estimated discriminative value of the 
NELSON model was 0.72 (95% CI: 0.68 to 0.75). 
Conclusion: The NELSON model is the Àrst lung 
cancer risk model based on early CT- detected 
lung cancers and includes age, level of education, 
smoking, prior diagnosis of cancer < 5 years ago, 
perceived health and gender. The calculated Hazard 
ratio suggests a possibly higher risk for women. 
After validation, the model is likely to be useful for 
risk stratiÀcation, especially in the context of a lung 
cancer screening program. 
Keywords: NELSON, lung cancer risk, lung cancer 
screening, risk model
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MO05.04 CT SCREENING FOR LUNG 
CANCER: UPDATE OF THE DEFINITION 
OF POSITIVE RESULT
Claudia I. Henschke1, Rowena Yip1, James P. Smith2, 
Olli S. Miettinen2 
1Radiology, Mount Sinai School Of Medicine/United 
States Of America, 2Pulmonary Medicine, Weill 
Cornell Medical College/United States Of America
Background: Given concerns about ‘false positives’ 
of CT screening for lung cancer, we considered 
alternative deÀnitions of positive results of the 
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biennial (CT2, 1182) LDCT, within the MILD trial. 
Follow-up was obtained on December 2010 from 
the Lombardy Cancer Registry, and the analysis was 
performed by the Istituto Mario Negri, in Milan.
Results: The two arms were superimposable in terms 
of known risk factors: median age was 57 years in 
both arms, males were 68% in CT1 vs. 69% in CT2, 
pack/years 40 vs. 38, former smokers 33% vs. 36%. 
Follow-up was 5,020 vs. 5,011 person years, median 
4.25 years in both arms. The total number of lung 
cancers was 33 in CT1 vs. 17 in CT2 (p=0.06), lung 
cancer deaths were 10 vs. 5 respectively (p=0.20), 
and the total number of deaths was 28 vs. 17 
(p=0.10). 
Conclusion: A less intensive screening modality 
such as LDCT every two years was associated with 
a substantially lower lung cancer detection rate, but 
no difference was observed in terms of lung cancer 
or total mortality between the two arms. A longer 
follow-up is needed to assess the relative beneÀt of 
the two screening modalities in comparison to the 
observational control arm. 
Keyword: lung cancer screening
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MO05.07 LONG-TERM OUTCOMES OF 
A PILOT CT SCREENING FOR LUNG 
CANCER: 10-YEARS RESULTS
Giulia Veronesi1, Rui Kuenzer Silva1, Ptrik 
Maisonneuve1, Cristiano Rampinelli2, Alessandro 
Pardolesi1, Raffaella Bertolotti2, Francesco Petrella1, 
Lorenzo Spaggiari1, Massimo Bellomi2 
1Division Of Thoracic Surgery, European Institute Of 
Oncology/Italy, 2Division Of Radiology, Europena 
Institute Of Oncology/Italy
Background: Low-dose computed tomography (CT) 
screening seems effective to reduce mortality of lung 
cancer in high risk populations however no data on 
long term results of continuous annual screening is 
available in literature. We assessed the long term 
overall survival, the lung cancer detection rate and 
stage distribution according to year of screening over 
a 10 years period. 
Methods: We analysed outcomes in high-risk 
asymptomatic volunteers (smokers and former 
smokers, >50 years) enrolled in a pilot study over 
one year from 2000, who received annual low-dose 
CT for 10 years. Nodules 5mm underwent repeat 
and 5% (992/20,347), a 37% reduction and the 
number of lung cancers diagnosed within 1 year of 
the initial CT scan would have been 40 instead of 41, 
2% fewer. 
Conclusion: Continuing technologic advances 
in imaging and image interpretation increase the 
frequency of positive results that can be identiÀed 
on CT scans. The frequency of positive results, 
however, can be markedly reduced using a more 
restrictive deÀnition without undue delay in the 
diagnosis of lung cancer.
Keywords: Screening, positive result of screening, 
CT, Lung cancer
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MO05.06 A LESS INTENSIVE SCREENING 
MODALITY, SUCH AS CT EVERY 2 
YEARS INSTEAD OF ANNUAL CT, IS 
NOT HARMFUL FOR HEAVY SMOKERS
Ugo Pastorino1, Alfonso Marchianò2, Nicola 
Sverzellati3, Francesco Leo1, Alessandra Fabbri4, 
Carlo Morosi2, Elisa Calabrò1, Carlotta Galeone5, 
Eva Negri5, Giuseppe Pelosi4, Carlo La Vecchia5 
1Thoracic Surgery Dept, National Cancer Institute/
Italy, 2Radiology Dept, National Cancer Institute/
Italy, 3Clinical Sciences Dept, Section Of Radiology, 
University Of Parma/Italy, 4Department Of 
Pathology And Laboratory Medicine, National 
Cancer Institute And University Of Milan School Of 
Medicine/Italy, 5Epidemiology Dept, Mario Negri 
Institute/Italy
Background: The National Lung Screening 
Trial (NLST), that randomised 53,456 former or 
current smokers to annual low-dose computerized 
tomography (LDCT) or chest x-ray (CXR) screening 
for three years, has been prematurely stopped 
on October 2010 due to a signiÀcant mortality 
reduction (-20% for lung cancer, -6.9% overall) in 
the LDCT arm. In order to assess the potential harm 
related to different screening modalities in high risk 
individuals, we analysed the outcome of the two 
interventional arms of the Multicentric Italian Lung 
Detection (MILD) trial. 
Methods: From January 2005, 2367 current or 
former smokers of  20 pack/years and aged 49 years 
or older, have been randomly assigned to active 
screening at the Istituto Nazionale Tumori of Milan, 
and further randomized to annual (CT1, 1185) or 
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Background: The technological development of 
multidetector row CT scanners has reduced slice width 
and improved spatial resolution providing excellent 
image quality with reduced radiation dose. Their use in 
clinical practice and lung cancer screening trials has led 
to the detection of large numbers of small pulmonary 
nodules of uncertain signiÀcance. Published guidelines 
exist to assist in the management of these lesions, but 
there is no available published evidence based longterm 
clinical data and, therefore, the optimum management 
remains controversial. Therefore we aim to assess 
the longitudinal behaviour and malignant risk of all 
screening detected noncalciÀed pulmonary nodules of 
any size in a high risk smoking cohort. 
Methods: Volunteer current or former smokers in an 
early lung cancer detection program received a baseline 
thoracic CT scan and those with nodules were followed 
with serial CT. We systematically recorded and 
analysed the longitudinal behaviour of all pulmonary 
nodules of any size found using the endpoints of: 
diagnosis of lung cancer, stability over 24 months, 
resolution or calciÀcation. 
Results: A total of 1123 subjects had reached the 
endpoints and were included in the analysis. A total 
of 9110 nodules were detected and 76% (6958/9110) 
were <5 mm. The majority were solid in appearance 
(80%) and overall 0.9% were malignant. Of note, 
7.5% of malignant nodules were <5mm when Àrst 
visible, and 34% of observed malignant nodules did 
not exhibit growth for at least 24 months followup. 
The combination of nodule appearance and size were 
important predictors of malignancy and signiÀcant 
differences were seen when lesions were evaluated 
according to these factors (p< 0.0001). Malignancy 
risk in lesions  8mm was 12% if solid and increased 
to 70% if semisolid in appearance. Growth of a solid 
lesion on two sequential scans or increase in the solid 
component of a nonsolid/semisolid lesion were also 
associated with an increase in malignancy risk (70%). 
Conclusion: This longitudinal nodule evaluation 
is useful to predict malignant risk of CT detected 
pulmonary nodules in a high risk smoking cohort. 
It challenges existing guidelines regarding the 
management of very small < 5mm nodules and the 
duration of longitudinal observation. This data conÀrms 
that immediate evaluation of semisolid lesions  
8mm is required due to a very high malignancy risk. 
Evidence of persistent growth or increase in a solid 
component also requires prompt investigation. 
Keyword: Pulmonary Nodule, Lung cancer 
screening, Computed tomography, early lung cancer
LD-CT at 1 year; nodules 5.1—8mm underwent LD-
CT 3 months later; lesions >8mm received combined 
CT-positron emission tomography (CT-PET). 
Cumulative lung cancer survival were represented by 
Kaplan-Meier curves. 
Results: Compliance was 65% at the end of the tenth 
year in 1035 recruited volunteers (71% men, mean 
age 58 years). Ten years after baseline CT, seventy-
two lung cancers were diagnosed (0.83% year), 12 
at baseline (prevalent) and 60 at subsequent rounds 
(incident) . Cell types were as follows: squamous 
cell tumor, 14 (19.4%); adenocarcinoma, 44 (61.1%); 
large cell tumor, 1 (1.4%); non–small cell tumor, 1 
(1.4%); small cell tumor, 7 (9.7%); carcinoid tumor, 
5 (6.94%). The mean size of NSCLC was 12.5 mm. 
The stages were as follows: I, 54 (75%); II, 7; III, 6; 
IV, 5; limited SCLC, 3. Among the operated patients, 
10 (12.1%) were benign lesions. Complete resection 
was achieved in 58 (80.5%) lung cancers. The 5 and 
10-year survival were respectively: 64% and 57% 
overall, 84% and 65% for stage I cases. 
Conclusion: Cancer detection rate and rate of stage I 
disease did not decrease over the all observed period. 
This study conÀrmed that most screen-detected 
cancers were in early stage and survival of screen-
detected cancer patients was high. The number of 
invasive procedure for benign disease was limited.
Keyword: Lung Cancer, Screening, Computed 
Tomography, Surgery
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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MO05.08 PREDICTING THE TRUE 
NATURE OF PULMONARY NODULES 
IN HIGH RISK SMOKERS: THE 
SCREENING DILEMMA
Annette M. Mcwilliams1, Stephen Lam2, John C. 
English3, Richard J. Finley4, John Mayo5 
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Moreover, 1 type E adenocarcinoma showed 
lymphatic invasion.
Pure GGO lesions showing pleural indentation 
on HRCT or those mildly positive on positron 
emission tomography/CT tended to be invasive 
adenocarcinomas and not BAC or AAH (odds ratio 
2.8 and 3.7, respectively). 
Conclusion: Pure GGO lesions do not always 
represent noninvasive BAC. One in four pure GGO 
lesions represent invasive adenocarcinomas. Pure 
GGO lesions should be monitored carefully by 
periodic chest CT and resected at an appropriate 
time. 
Keywords: ground-glass opacity, bronchioloalveolar 
carcinoma, high-resolution computed tomography
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MO05.11 GENOME-WIDE ASSOCIATION 
ANALYSIS OF LUNG CANCER IN 
KOREAN NEVER-SMOKERS
Myung-Ju Ahn1, Jong-Mu Sun1, Hong-Hee Won2, 
Seung-Tae Lee2, Jin Seok Ahn2, Jong-Won Kim2, 
Keunchil Park2 
1Internal Medicine, Samsung Medical Center/Korea, 
2Samsung Medical Center/Korea
Background: Although several studies were 
conducted to Ànd susceptibility loci for lung cancer 
in never-smokers, no regions were replicated except 
for 5p15.33, suggesting locus heterogeneity and 
different environmental toxic effects. To identify 
genetic loci associated with susceptibility of lung 
cancer in never-smokers, we performed genome-wise 
association (GWA) analyses using the Affymetrix 6.0 
SNP array (Affymetrix, Inc., Santa Clara, CA).
Methods: For discovery GWA set, we recruited 
446 never-smoking Korean patients with lung 
cancer and 497 normal subjects. Genomic DNA 
was extracted from peripheral whole blood and 
normalized to 50 ng/ul. After calling genotypes 
using the Birdseed algorithm of the Affymetrix 
Genotyping Console 3.0.2 software, we excluded 
two case samples with missing genotypes >5%. The 
SNPs with missing genotypes >1% or minor allele 
frequency <5% were removed. We also excluded 
SNPs showing deviations from Hardy-Weinberg 
equilibrium in control samples (P<0.001). Finally, 
we tested association of 474,503 autosomal SNPs 
with lung cancer susceptibility in 444 patients and 
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MO05.09 DOES A PURE GROUND-
GLASS OPACITY LESION ALWAYS 
REPRESENT NONINVASIVE 
BRONCHIOLOALVEOLAR 
CARCINOMA?
Junji Ichinose1, Tadasu Kohno1, Sakashi Fujimori1, 
Rie Tagaya1, Takeshi Fujii2 
1Department Of Thoracic Surgery, Toranomon 
Hospital/Japan, 2Department Of Pathology, 
Toranomon Hospital/Japan
Background: Although it is well known that 
localized ground-glass opacity (GGO) lesions on 
high-resolution computed tomography (HRCT) are 
one of the characteristic Àndings of noninvasive 
bronchioloalveolar carcinoma (BAC), the 
relation between malignancy of tumors and their 
radiological Àndings on HRCT has not yet been fully 
investigated. 
Methods: From January 2008 to December 2010, 
1065 patients underwent pulmonary resection at 
Toranomon Hospital. Out of these, 160 patients who 
underwent resection of 20-mm GGO lesions were 
included in this study.
GGO is deÀned as a hazy increase in lung 
attenuation without obscuring underlying vascular 
markings on the lung window of HRCT. Tumor 
disappearance rate (TDR) is deÀned as the ratio of 
tumor area of the mediastinal window to that of the 
lung window on HRCT. GGO lesions that measured 
20 mm in diameter as measured by HRCT and 
those with a GGO ratio of 50% were included in 
this study. They were divided into two groups: pure 
GGO lesions, deÀned as tumors in which both the 
GGO ratio and TDR are 100%, as well as mixed 
GGO lesions.
Results: Out of 191 resected GGO lesions, 114 
were pure GGO lesions and 77 were mixed GGO 
lesions. Histological diagnosis of pure GGO lesions 
revealed BAC in 69, adenocarcinoma in 31, atypical 
adenomatous hyperplasia (AAH) in 6, and benign 
tumors in 8. Histological diagnosis of the mixed 
GGO lesions revealed BAC in 7, adenocarcinoma in 
58, lymphoma in 5, and benign tumors in 7.
Among the 31 invasive adenocarcinomas that 
manifested as pure GGO lesions, 27 were type C 
BAC and papillary mixed-type adenocarcinomas 
as per Noguchi’s classiÀcation, and 4 were type E 
adenocarcinomas containing an acinar component. 
S520 Copyright © 2011 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
characteristics such as tumor histology (Bev and 
Pem), anticoagulant use (Bev), hypertension 
(Bev) and presence of CNS metastases (Bev). 
2) To describe the clinical and demographic 
characteristics of patient who receive Àrst-line 
NSCLC treatment containing Bev and Pem as well 
as those demographics associated with receipt of 
subsequent maintenance treatment. Records of 
advanced NSCLC pts receiving active care at US 
Oncology practices were assessed utilizing the 
iKnowMed electronic medical record system with 
documentation of 1st line chemotherapy regimen 
(and any subsequent maintenance therapy) initiated 
from January 1, 2007 – February 28, 2010. 
Results: Based on the clinical proÀle of the cohort 
of 5,313 pts receiving Àrst-line systemic treatment, 
the distribution of Bev eligibility was: 31% 
eligible, 51% ineligible, and 17% unknown. The 
distribution of Pem eligibility was: 52% eligible, 
22% ineligible, and 26% unknown. Of all pts 
receiving treatment, the percentage of pts receiving 
the observed initial regimens were: 49% Paclitaxel 
+ Carboplatin (Carbo-Pac), 15% Paclitaxel+Carbop
latin+Bevacizumab, 2% Cisplatin+Pemetrexed , 2% 
Carboplatin+Pemetrexed, 8% Erlotinib, 13% other 
mono therapy and 10% other combination therapy. 
Receipt of Carbo-Pac as an initial regimen varied 
by histology (squamous (SQ)=62%, non-squamous 
(NS)=38%, not otherwise speciÀed (NOS)=44%; 
p<0.0001). Characteristics with a statistically 
signiÀcant association with Bev-containing regimen 
were: histology (SQ=2%, NS=21%, NOS=14%; 
p<0.0001), younger age (<65), ECOG performance, 
and payer status. Surprisingly, use of anti-coagulants 
or hypertension were not statistically signiÀcant 
predictors of Bev use in the regimen. Of the 999 
pts receiving a Bev-containing initial regimen, 48% 
were eligible, 34% ineligible and 18% unknown. 
A Pem-containing regimen had a statistically 
signiÀcant association with: tumor histology 
(SQ=1%, NS=6%, NOS=4%; p<0.0001), younger 
age (< 65), male gender, ECOG performance, and 
payer status. Of the 656 pts treated with a Pem-
containing initial regimen, the distribution of 
eligibility was: 66% eligible, 8% ineligible and 25% 
unknown. 59% of pts receiving Carbo-Pac did not 
receive maintenance, while 50% or more of the pts 
with the other initial regimens received maintenance. 
Patient characteristics with a statistically signiÀcant 
association with maintenance therapy were: younger 
age (<65), prior early stage NSCLC, high ECOG 
performance status, and payer status.
497 controls using the Cochran-Armitage trend test. 
For validation, 39 SNPs were selected from the top 
50 SNPs and Àve additional SNPs were selected in 
the DAB1 gene region which showed signiÀcant 
associations in the GWA analysis. The validation 
SNPs were genotyped in an independent validation 
sample including 434 patients and 1000 controls 
using the MassARRAY® system (Sequenom, Inc., 
San Diago, CA). 
Results: Among the 44 validation SNPs, two SNPs 
(rs11080466 and rs11663246) in the 18p11.22 
region harboring the APCDD1, NAPG and FAM38B 
genes were replicated. P value of rs11080466 was 
1.08×10–6 in the combined sets (2.68×10–5 in the 
discovery set and 2.60×10–3 in the validation set) and 
odds ratio was 0.68 (0.58–0.79). We observed similar 
association for rs11663246.
Conclusion: Our result suggests the 18p11.22 region 
as a novel lung cancer susceptibility locus in never-
smokers. 
Keywords: Lung cancer, never smoker, SNPs
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MO05.12 TREATMENT PATTERNS IN A 
COHORT OF ADVANCED NON-SMALL 
CELL LUNG CANCER PATIENTS 
(PTS) TREATED IN THE COMMUNITY 
SETTING
Mitra Corral1, Eric S. Nadler2, Clara Chen2, Michael 
Forsyth2, John R. Penrod1, Mark E. Salvati3 
1Bristol-myers Squibb/United States Of America, 
2Us Oncology/United States Of America, 3Medical 
Services, Bristol-myers Squibb/United States Of 
America
Background: According to NCCN guidelines, 
platinum-containing chemotherapy doublets form the 
backbone treatment for eligible pts with advanced or 
metastatic Non-Small Cell Lung Cancer (NSCLC). 
Recently, newer agents such as bevacizumab (Bev) 
and pemetrexed (Pem) have been demonstrated to 
be effective in combination with platinum based 
regimens for the treatment of NSCLC in eligible 
patient subgroups. Maintenance regimens beyond 
the initial treatment have also been shown to offer 
clinical beneÀt. 
Methods: 1) To describe the % of pts eligible/
ineligible for Bev and Pem regimens, as deÀned 
by NCCN guidelines, based on baseline clinical 
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seen before being referred, when Àrst seen and when 
referred. 
Results: 2 patients declined, so 257 were 
evaluable. 145 patients (56%) were initially mono-
symptomatic, with cough (25%), dyspnoea (25%), 
haemoptysis (10%), chest pain (10%), sputum (7%) 
or other symptom (24%). 105 (41%) initially poly-
symptomatic patients had symptoms of cough (36%), 
dyspnoea (39%), haemoptysis (12%), chest pain 
(9%), sputum (21%), and other (19%). By the time 
patients were seen at the oncology department, the 
frequency of chest symptoms had risen to 78%, 76%, 
60%, 30% and 42% respectively. The remaining 
7 patients (3%) were asymptomatic. Mean time 
from start of Àrst symptom to seeing the GP was 
81 days, with a median of 24, range 0-710 days. 
Mean delay from Àrst seeing GP to MDT decision 
to refer to oncology was 115 days, median 70, range 
2-945 days. Mean delay from that time to starting 
treatment was 25 days, median 15, range 0-37 
days. Within-patient delay is considerably longer 
than within oncology delay (p<0.0001). 98 patients 
(38%) admitted delaying going to see the doctor. 
Of these, 38% said they were worried, 18% did not 
wish to know, 14% were too busy and 10% said 
delay was for family reasons. Patients went to their 
GP 1 to 8 times before being referred for chest X 
ray or to secondary care, (one 49%, 2-3 42%, 4-8 
9%). Staging was IA, IB,IIA, IIB,IIIA, IIIB and IV 
in 5,10,15,6,55,46,and 118 patients respectively. 
Analysis of variance showed no relation between 
stage and time to presentation. 
Conclusion: Within-patient delay is signiÀcantly 
longer than within-oncology delay. The causes of 
within-patient delay are complex. The frequency 
of chest symptoms increases considerably during 
the pathway to oncological treatment. Over 50% of 
patients visited their GP more than once in order to 
be referred for investigation or to secondary care. 
Increased patient and GP awareness could lead to 
earlier treatment with reduced symptoms and thus 
beneÀt quality of life. 
Keywords: Symptoms, Lung cancer, Delay, Patient 
pathway
Conclusion: This examination of a recent cohort of 
pts receiving 1st L treatment for advanced NSCLC 
shows that a substantial number are eligible for 
recently-introduced initial regimens and maintenance 
therapy, however, there still exists a signiÀcant need 
for new agents for ineligible pts. Choice of initial 
therapy and maintenance treatment were related to 
patients’ clinical proÀle and payer status. 
Keyword: NSCLC, Treatment, Bev, Pem, regimen, 
maintenance, therapy
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MO05.13 A STUDY OF SYMPTOMS AND 
DURATION OF PATHWAYS IN LUNG 
CANCER PATIENTS
Zacharias Tasigiannopoulos1, Andrew Wilson2, Allan 
Clark3, Rachel Banham1, Tom Roques1, Thankamma 
Ajithkumar1, Craig Martin1 
1Oncology, Norfolk And Norwich University 
Hospital/United Kingdom, 2Medicine, University Of 
East Anglia/United Kingdom, 3Medical Statistics, 
University Of East Anglia/United Kingdom
Background: Lung cancer is the commonest cause 
of cancer death worldwide. National UK targets 
actively promote shorter times from secondary 
care to starting treatment, but earlier delays in the 
patient’s pathway are signiÀcant. Most previous 
studies of symptomatology or the length of patient 
pathways from primary care to treatment have 
used hospital notes methodology rather than asking 
patients themselves to describe their symptoms and 
identify delays. 
Methods: 259 patients diagnosed with lung cancer 
after a multidisciplinary team (MDT) meeting and 
presenting to the oncology department were asked 
to complete a questionnaire modiÀed from the 
EORTC QLQ C-30 and LC-13, including NICE-
guidance urgent symptoms. The patient was asked 
especially about the symptom or symptoms which 
represented the start of the illness, and subsequent 
symptoms, and to date these to the nearest week, to a 
total of 27 questions. The questionnaire asked about 
common chest symptoms, MRC dyspnoea score, 
pain, analgesia, systemic symptoms, hoarseness, 
neck lumps, Ànger discomfort, xerostomia and 
abnormal taste, when they Àrst saw their GP, whether 
they delayed and if so the reason. The GP was 
independently asked how many times the patient was 
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1-year relative survival has slightly increased from 
14% to 19% for males and from 18% to 24% for 
females. However, survival for the total group of 
SCLC remained stable.
Conclusion: The diverging trends in incidence 
of SCLC between Dutch males and females have 
followed the trends in smoking behaviour in the past. 
Improved staging has resulted in better selection 
for treatment and improved survival in both stage 
groups. However, survival of the total group of 
unselected patients with SCLC has not further 
improved since the 1990s (stage migration, Will 
Rogers phenomenon). This means that prevention 
remains important, especially primary prevention 
of youth smoking, smoking cessation of current 
smokers, and early detection programs for former 
smokers.
Keywords: Small cell lung cancer, trends, incidence, 
survival
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MO06.01 THE UK TWO WEEK RULE 
INITIATIVE IN LUNG CANCER - FIRST 
REPORT OF IMPACT ON DISEASE 
STAGE AND 5-YEAR SURVIVAL
Tom S. Waddell1, James Myerson1, Alison Reid1, 
Sue Ashley2, Naureen Starling1, Ju-Ee Seet3, KoÀ 
Nimako1, Sanjay Popat4, Mary E.R. O’Brien1 
1Lung Unit, Royal Marsden Hospital/United 
Kingdom, 2Dept Of Clinical Research And 
Development, Royal Marsden Hospital/United 
Kingdom, 3Pathology Department, St George’s 
Hospital/United Kingdom, 4National Heart And Lung 
Institute, Imperial College/United Kingdom
Background: UK survival rates from cancer remain 
worse than in other westernised countries. In 2000, 
the UK government introduced the ‘Two Week 
Rule (TWR)’ for suspected cancer to streamline 
pathways and reduce delays. This initiative advised 
that patients with suspected malignancy should be 
seen by a specialist within two weeks of GP referral, 
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MO05.14 DESPITE NEW TREATMENT 
MODALITIES, SURVIVAL OF 
UNSELECTED SMALL CELL LUNG 
CANCER PATIENTS HAS NOT 
IMPROVED SINCE THE EARLY 1990S
Maryska Janssen-Heijnen1, Henrike Karim-Kos2, 
Miep Van Der Drift3, Harry J.M. Groen4, Vincent 
Ho5, Caro Koning6, Esther De Vries2 
1Research, Eindhoven Cancer Registry/Netherlands, 
2Public Health, Erasmus MC University Medical 
Center/Netherlands, 3Pulmonary Diseases, Radboud 
University Nijmegen Medical Centre/Netherlands, 
4Pulmonary Diseases, University Medical Center 
Groningen/Netherlands, 5Registration And Research, 
Comprehensive Cancer Centre The Netherlands 
(iknl)/Netherlands, 6Radiation Oncology, Amc/
Netherlands
Background: Lung cancer was one of the major 
epidemics observed in the last decennia of the 
former century. There is a strong relationship with 
smoking habits. Fifteen to twenty percent of lung 
cancer consists of small cell lung cancer (SCLC). 
Several changes in the diagnostic and treatment 
procedures took place during the last 20 years. This 
paper focuses on trends in incidence, treatment and 
survival of SCLC.
Methods: All cases with primary SCLC diagnosed 
in 1989-2009 in the Netherlands were included 
(N=34,100). Follow-up was complete until February 
1st 2010.
Results: The age-standardised incidence rate (ESR) 
of SCLC among men has decreased from 19 per 
100,000 in 1989 to 10 in 2009. Among women the 
ESR has increased from 4.3 per 100,000 to 7.0. The 
proportion of patients with extensive disease (ED) 
has increased to 65%. The proportion of patients 
with limited disease (LD) receiving chemoradiation 
has increased from 20-30% in 1989-2003 to 65-70% 
in 2004-09 among those younger than 60, from 15% 
to 58% among those aged 60-74, and from 7% to 
27% among those aged 75 or older. Among patients 
with ED the proportion receiving chemotherapy 
remained stable over time (85-90%, 75% and almost 
50% for those younger than 60, 60-74 and 75 or 
older, respectively). One-year relative survival for 
patients with LD was better in 2004-09 as compared 
to earlier periods (54% versus 44% for males and 
61% versus 50% for females). For those with ED, 
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the 2 groups. Amongst patients with NSCLC, TWR 
patients were of lower average stage than non-TWR 
patients (p=0.04). There was no difference in overall 
survival rates (adjusted for age, sex, stage and PS) 
between the 2 groups. 
Conclusion: TWR was associated with a stage 
shift at diagnosis in NSCLC patients. These small 
improvements could lead to more patients having 
radical treatment, but will take many years and large 
numbers of patients to show population changes. 
Nevertheless it is possible to audit and monitor this 
in individual centres as above. However, this audit 
suggests that additional measures are necessary in 
the UK to increase resection rates and signiÀcantly 
improve lung cancer outcomes. 
Keywords: Two week rule, Lung cancer, TWR
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MO06.02 INVESTIGATION OF 
SENTINEL LYMPH NODES USING 
SPECT/CT AND PERIOPERATIVE 
GAMMA ASSAY COMBINED WITH 
IMMUNOHISTOCHEMISTRY IN NSCLC 
PATIENTS UNDERGOING LUNG 
RESECTION
Pinar Cagan Varer1, Okan Falay2, Tugba Coskun1, 
Ferda Aksoy3, Guven Olgac4, Cemal Asim Kutlu4 
1Department Of Thoracic Surgery, Dr. LutÀ 
Kirdar Kartal Teaching And Research Hospital/
Turkey, 2Department Of Nuclear Medicine, 
Medica Diagnostic Center/Turkey, 3Department 
Of Pathology, Sureyyapasa Chest Diseases And 
Thoracic Surgery Teaching And Research Hospital/
Turkey, 4Department Of Thoracic Surgery, 
Sureyyapasa Chest Diseases And Thoracic Surgery 
Teaching And Research Hospital/Turkey
Background: Skip metastasis in NSCLC is more 
common than other organ malignancies. To date, 
the actual usefulness of sentinel lymph node (SLN) 
has not been clearly deÀned for NSCLC. This study 
addresses the clinical beneÀt of a SLN that was 
detected by SPECT/CT combined with perioperative 
gamma probe assays in node negative NSCLC 
patients undergoing lung resection.
Methods: Twenty consecutive NSCLC patients 
with proven cN0 disease on PET-CT and undergoing 
lung resection were included. All patients scanned 
with SPECT/CT following peritumoral injection of 
with maximum 62 days between GP referral and Àrst 
treatment. This audit aimed to retrospectively assess 
the impact of the TWR in lung cancer on disease 
stage, time to treatment and 5-year survival rates.
Methods: All new lung cancer patients referred 
in 2005 were identiÀed from the Royal Marsden 
Hospital (RMH) Electronic Patient Records (EPR). 
The date and type of referral (TWR versus other) as 
well as relevant demographics, treatment and follow-
up data were collected from EPR.
Results: 349 new lung cancer referrals were made 
in the study period, including 106 patients referred 
via the TWR pathway and 243 patients referred via 
alternative routes (61 routine GP referrals, 182 others 
e.g. from another hospital specialist) Table 1 - Patient 
Demographics and Treatment Information (n=349) 
TWR - n(%) Non-TWR - n(%) 
Patients 106 (30) 243 (70) 
Gender Male 61 152 
Female 45 91 
Age (yrs) Median 70 70 
Range 35-88 37-94 
Diagnosis SCLC 14 (13) 38 (16) 
NSCLC 79 (75) 166 (68) 
Histo subtype 
unknown 10 (9) 18 (7) 
Mesothelioma 2 (2) 19 (8) 
Other 1 (1) 2 (1) 
PS 0 / 1 / 2 3(3) / 36(34) / 17(16) 7(3) / 82(34) / 37(15) 
3 / 4 8(8) / 0 35(14) / 1(1) 
Not documented at 
referral 42 (40) 81 (33) 
Median Time to 
Treatment (days) 50 40 
First Treatment Surgery 14 (13) 28 (12) 
Radiotherapy 36 (34) 83 (34) 
Chemotherapy 40 (38) 88 (36) 
Active Monitoring 3 (3) 10 (4) 
Palliative Care 11 (10) 30 (12) 
Other 2 (2) 4 (2) 
There were no signiÀcant differences in age, gender, 
diagnosis, PS, or Àrst treatment received between 
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with perioperative gamma assays can be more 
advantageous in identifying intraparenchymal 
SLNs by guiding both the surgeon and the 
histopathologist as to which lymph nodes should 
be further investigated with immunohistochemistry. 
The interim results of our study are promising and 
warrant further studies containing larger number of 
patients in order to validate actual clinical beneÀt of 
these diagnostic tools.
Keywords: NSCLC, Sentinel lymph node, SPECT/
CT, skip metastasis
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MO06.03 OCCULT NODAL 
METASTASIS IN POSITRON EMISSION 
TOMOGRAPHY AND COMPUTED 
TOMOGRAPHY DIAGNOSED STAGE I 
NON-SMALL CELL LUNG CANCER: A 
POOLED ANALYSIS OF MULTICENTER 
STUDIES
Jingbo Wang1, Luhua Wang2, Feng-Ming (Spring) 
Kong1 
1Radiation Oncology, University Of Michigan/United 
States Of America, 2Radiation Oncology, Cancer 
Hospital, Chinese Academy Medical Sciences & 
Peking Union Medical College/China
Background: Nodal staging of non-small cell lung 
cancer (NSCLC) is crucial in prognosis evaluation 
and therapeutic strategy determination. Combined 
PET and CT (PET-CT) has remarkably improved 
the accuracy of nodal staging in NSCLC. This 
pooled analysis aimed to evaluate the occult nodal 
metastasis in patients with stage I (T1-2N0) NSCLC 
determined by positron emission tomography and 
computed tomography (PET-CT) and study the 
possible risk factors for occult nodal disease. 
Methods: Studies investigating the diagnostic 
performance of PET incorporated with CT, either 
integrated or visually correlated, for stage I 
NSCLC were identiÀed in the MEDLINE database. 
Computerized search was performed according to 
the following key words: . Pathological assessments 
through mediastinoscopy or thoracotomy were 
required as the gold standard for assessment of 
PET-CT accuracy. The standard for reporting of 
diagnostic accuracy (STARD) was used to ensure 
quality of studies included in this analysis. Negative 
predictive value (NPV) and incidence of occult nodal 
99mTc colloidal human albumin via transthoracic 
or transbronchial route a day before the operation. 
Sentinel nodes were also sought using a gamma 
probe perioperatively. All dissected lymph 
nodes were histopathologically analyzed using 
Hematoxylin-Eosin stain. Of them without tumor 
invasion on Hematoxylin-Eosin and all SLNs 
regardless of their involvement were also examined 
with immunohistochemistry.
Results: SPECT/CT Àndings combined with 
perioperative gamma probe assays yielded a SLN in 
all patients. SLN was located within the boundaries 
of pulmonary parenchyma in majority (n=18; 
90%) of patients. Half of the upper lobe tumors 
(n=8) drained into the #11s as a SLN. Second 
most common SLN for upper lobe tumors (n=7) 
was located at #12 station that appeared in 5 and 2 
patients for the left and right sides, respectively. Two 
patients with right lower lobe and one patient with 
left lower lobe tumors Àrst drained into #7, #11i and 
#12 SLN stations, respectively. Eight (40%) patients 
presented with nodal metastasis. Two (25%) patients 
presented with metastasis in only their corresponding 
SLN stations. However, tumor cells skipped 
SLNs and invaded more proximal pulmonary 
and/or mediastinal nodes in 6 (75%) of them. A 
metastatic SLN at #11s location was discovered 
with immunohistochemistry that was missed on 
Hematoxylin-Eosin examination in one patient. Two 
patients demonstrated an unusual skip metastasis.
Clinical and Pathological Characteristics of Node 
Positive Patients
HE=Hemotoxylin-Eosin; 
IHC=Immunohistochemistry; LUL=Left upper lobe; 
RUL=Right upper lobe; AC=Adenocarcinoma; 
SqC=Squamous cell carcinoma; PleoC=Pleomorphic 
carcinoma
Tm. Location Cell Type cTNM-Stage #SLN HE IHC Skip Met. 
LUL-Central AC T2bN0M0-IIA 11s 11s 11s None 
LUL-Central SqC T3N0M0-IIB 11s 11s 11s None 
LUL-Central SqC T3N0M0-IIB 12 11s (-) N1 
LUL-Peripheral AC T3N0M0-IIB 12 6 (-) N2 
LUL-Peripheral PleoC T3N0M0-IIB 12 11s, 5 (-) N1+N2 
RUL-Central AC T2aN0M0-IB 11s 11i 11s N1 
RUL-Central SqC T2aN0M0-IB 12 11i (-) N1 
RUL-Central SqC T3N0M0-IIB 11s 7 (-) N2 
Conclusion: Contrary to other similar studies, 
most of our patients had an intrapulmonary SLN 
that are not easily assessable with other imaging 
techniques. In this respect, SPECT/CT combined 
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in patients with NSCLC treated with chemotherapy. 
Only scarce data are available for radiotherapy alone 
or concurrent chemo-radiation (e.g. van Baardwijk 
et al; Eur J Cancer 2007). In the present study, we 
investigated the correlation between FDG changes 
early during treatment and survival.
Methods: Prospectively, FDG-PET/CT imaging 
was performed at two time-points for 39 consecutive 
lung cancer patients (4 SCLC, 35 NSCLC) treated 
with radical concurrent chemo-radiotherapy 
(N=18), sequential chemo-radiotherapy (N=19) or 
no chemotherapy prior to radiotherapy (N=2). One 
imaging time-point was prior to treatment and the 
second during week 2 of radiotherapy. The FDG 
uptake in the gross tumour volume (GTV) of the 
primary tumour was analysed. The maximum SUV, 
mean SUV and the area-under-the-curve (AUC) for 
a cumulative SUV histogram (SUV
AUC
; calculated 
using SUVmean normalized to the SUVmax of the 
Àrst scan) was tested for correlation with 2-year 
overall survival. The SUV
AUC
 is a measure of 
intra-tumour heterogeneity. Multiple testing was 
accounted for using a Bonferroni correction.
Results: Minimum follow-up was 2.2 years; overall 
survival at 2 years was 52%. One patient had no 
visible tumour at the repeated PET/CT scan and 
was excluded from further analysis. A decrease 
in mean SUV was signiÀcantly correlated with 
higher survival rates: mean±SD (range) decrease 
in SUVmean of 20.7±16.6% (-2.5 to +48%) for the 
patient group alive after 2 years was signiÀcantly 
different (p=0.03) compared to the patients not 
surviving 2 years: 2.9±15.8% (-25 to +45%). For the 
changes in maximum SUV or SUV
AUC
, no signiÀcant 
correlations were found (p>0.2) The maximum, 
mean SUV or SUV
AUC
 on either of the time points 
prior and during treatment was also not correlated 
with 2-year overall survival. We deÀned a cut-off 
point for a reduction in SUVmean of more than 10%, 
the survival curves were then signiÀcantly different 
(p=0.01) between both groups, see Figure. No 
correlations were found between the extracted SUV 
parameters and the use of chemotherapy, volume of 
the primary tumour or prescribed radiotherapy dose. 
metastasis were calculated on a per-patient basis. 
Results: Nine studies with a total of 1025 stage I 
(T1-2N0) NSCLC patients were eligible for analysis. 
STARD quality scores of the included series ranged 
from 10 to 16 (maximum score). The NPV of 
combined PET and CT across studies varied from 
82% to 97% for hilar metastasis (N1 alone) and 86% 
to 100% for N2 mediastinal metastasis. All studies 
were eligible for N2 analysis, yielding a 7.6% (95% 
CI: 6.1%, 9.5%) incidence of occult N2 mediastinal 
metastasis. On the basis of corresponding studies 
with available sub-stage (T1 vs. T2) data, PET-CT 
based false negative N2 nodal disease occurred 
in 7.6% (95% CI: 5.7%, 9.9%) of T1 patients and 
12.3% (95% CI: 7.4%, 19.5%) of T2 patients (P = 
0.068). Six studies (527 patients) also eligible for N1 
analysis revealed that 16.0% of patients had overall 
occult nodal metastases, consisting of 10.1% (95% 
CI: 7.7%, 13.0%) stage N1 disease alone and 5.9% 
(95% CI: 4.1%, 8.3%) stage N2 disease. There was 
signiÀcant difference between the prevalence of 
occult N1 and N2 metastases (P = 0.02). T2 stage, 
central location, adenocarcinoma histology and high 
FDG uptake in primary lesion were associated with 
greater risk of occult nodal metastasis (P<0.05). 
Conclusion: Incidence of N2 mediastinal metastasis 
in PET-CT staged T1N0 patients is relatively low, 
though overall occult nodal metastasis in unselected 
staged I NSCLC is not infrequent. This data may 
help our daily practice of additional invasive staging 
for this group of patients. 
Keywords: 18-FDG PET, Non-small cell lung 
cancer, Stage I, Occult nodal metastasis
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MO06.04 EARLY TREATMENT 
RESPONSE ASSESSMENT IN LUNG 
CANCER: REPEATED FDG-PET 
IMAGING OF THE PRIMARY TUMOUR 
DURING TREATMENT IS CORRELATED 
TO 2-YEAR OVERALL SURVIVAL
Wouter Van Elmpt, Dirk De Ruysscher, Hugo Aerts, 
Philippe Lambin 
Department Of Radiation Oncology (MAASTRO), 
Grow, Maastricht University Medical Centre/
Netherlands
Background: It is known that early changes of the 
FDG uptake in the tumour correlates with survival 
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Methods: Retrospective, single institution study of 
413 consecutive patients with non-small cell lung 
cancer who underwent potentially curative surgical 
resection after PET/CT had been obtained in the 
same PET center between August 2004 and January 
2010. The SUV
max
 was calculated drawing region of 
interest (ROI) around the primitive tumour, the liver 
and the aortic arch in PET images (i.e. the plane with 
the hottest tumour voxel was found and SUV
max
 for 
that plane was measured), using the formula: SUV 
= activity (MBq/mL) x body weight (kg) / injected 
dose (MBq). The same procedure was performed 
for two adjacent planes and the average of these 
measures was considered in the statistical analysis. 
Kaplan-Meier method, log-rank test, and Cox model 
were used in the statistical analysis. 
Results: Nine patients were considered 30-day 
postoperative deaths and were excluded from the 
analysis. At the end of the study in December 2010, 
312 (77.2%) out of the 404 remaining patients were 
living (median follow-up, 24.7 months; range, 
1.4 - 71.9) and 92 had died (median survival, 
15.7 months; range, 1.2 – 64.6). Median (range) 
SUV
max
 of primary tumor, median (range) SUV
max
 
primary tumor/SUV
max
 blood pool ratio, and median 
(range) SUV
max
 primary tumor/SUV
max
 liver ratio 
were 8.6 (1.1-54), 5 (0.6-30), and 3.7 (0.5-16.9), 
respectively. Using univariate analysis, sex (p=0.03), 
T stage (p=0.00004), N stage (p<0.000001), TNM 
stage (p<0.000001), primary tumor characteristics 
including presence of necrosis (p=0.004), presence 
of vascular invasion (p=0.0012) and grading 
(p=0.001), primary tumor SUV
max
 (p=0.00016), 
primary tumor SUV
max
/SUV
max
 blood pool ratio 
(p=0.0005), and primary tumor SUV
max
/SUV
max
 
liver ratio (p=0.00017) were found to be signiÀcant 
prognostic factors. At multivariate analysis, T stage, 
N stage, TNM stage, primary tumor grading and 
SUV
max
 were the parameters that retained signiÀcant 
independent prognostic impact. All the remaining 
variables did not enter the model. 
Conclusion: Maximum standardized uptake value 
of primary tumor is an independent predictor for 
survival in non-small cell lung cancer patients 
undergoing surgery and might be helpful in 
identifying patients at increased risk of death so as 
to guide adjuvant treatment strategies. Maximum 
standardized uptake value of primary tumor 
normalized by SUV blood pool or SUV liver does 
not provide additional prognostic information. 
Keywords: Maximum Standardized Uptake Value, 
prognostic value, Non small cell lung cancer, PET/CT
Conclusion: Early treatment response assessment 
in lung cancer is possible using repeated FDG-PET/
CT imaging. These results should be conÀrmed in an 
external dataset.
Keywords: FDG-PET, response assessment, survival 
prediction, imaging biomarkers
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MO06.06 THE PROGNOSTIC 
SIGNIFICANCE OF MAXIMUM 
STANDARDIZED UPTAKE VALUE OF 
PRIMARY TUMOR IN NON-SMALL CELL 
LUNG CANCER PATIENTS SURGICALLY 
TREATED: ANALYSIS OF 413 CASES.
Andrea Billè1, Andrea Skanjeti2, Luca Errico1, 
Vincenzo Arena3, Mara Gisabella1, Elena Lisi1, 
Ettore Pelosi3, Francesco Ardissone1 
1Department Of Thoracic Surgery, University Of 
Turin, San Luigi Hospital/Italy, 2Nuclear Medicine Ii 
Unit, University Of Turin, Molinette Hospital/Italy, 
3Pet Center Irmet/Italy
Background: Integrated positron emission 
tomography and computed tomography (PET/
TC) is widely used in the preoperative staging 
and prognostic assessment of non-small cell 
lung cancer patients. Aims of this study were to 
evaluate the prognostic signiÀcance of maximum 
standardized uptake (SUV
max
) of primary tumor 
in patients undergoing surgical treatment and, in 
order to minimize technical interferences, to verify 
whether SUV
max
 normalized by SUV
max
 liver and 
SUV
max
 blood pool provided additional prognostic 
information. 
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between the levels of residual MRglc after RT and 
the TCP at 12 m. From this inverse relationship, 
residual MRglc values 0.031, 0.041, and 0.093 
mmol/min/gm by SKM at S2 were associated with 
TCP 95%, 90%, and 50% respectively. Among SUV 
values, SUVmax(bsa.g) showed strongest correlation 
with the SKM (R2>0.90). SUV with no correction 
showed lowest correlation (R2<0.80). 
Conclusion: The nadir values of MRglc at S2 
measured with SKM and SUVmax(bsa.g) are robust 
bioimaging biomarkers capable for predicting 
TCP and survival. Therefore, residual MRglc at S2 
corresponding to TCP ³95%, £90%, £75% and £50% 
are surrogate biomarkers useful for developing a 
new model of personalized RT. SUVmax (bsa.g) 
performed as well as SKM in measuring metabolic 
response and predicting therapy outcome. 
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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MO06.08 CT-BASED AUTO-
SEGMENTATION OF LUNG TUMORS 
SHOWS HIGH OVERLAP WITH 
ONCOLOGIST DELINEATIONS AND 
PATHOLOGY
Emmanuel Rios Velazquez, Hugo Aerts, Dirk De 
Ruysscher, Philippe Lambin 
Radiation Oncology (MAASTRO), Maastricht 
University Medical Center/Netherlands
Background: In radiotherapy, CT data is acquired 
immediately before dose delivery. It is known that 
tumor delineation has a high inter-observer variability. 
An automated delineation method would enable a 
more reproducible tumor deÀnition, to optimize the 
daily workÁow and would facilitate multi-centric trials. 
Here we present and compare an automatic CT-based 
segmentation method, based on region growing and 
context, with pathology and with CT/PET manual 
delineations by Àve independent oncologists in non-small 
cell lung cancer (NSCLC).
Methods: For nineteen NSCLC patients the gross tumor 
volume was delineated manually on CT/PET scans by 
Àve independent oncologists and segmented using a 
CT based automatic tool. Tumor volume and overlap 
fractions between the intersection and union of the 
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MO06.07 METABOLIC RESPONSES 
MEASURED WITH SIMPLIFIED 
KINETIC METHOD AND STANDARD 
UPTAKE VALUE OF 18F-FDG PET 
SHORTLY AFTER RADIOTHERAPY 
OR RADIOTHERAPY OF 
CHEMORADIOTHERAPY: ROBUST 
BIOMARKERS FOR PREDICTING 
THERAPY OUTCOME IN LUNG CANCER
Noah C. Choi1, Tristen Chun1, Andrzej Niemierko1, 
Marek Ancukiewicz1, Alan Fischman2 
1Radiation Oncology, Massachusetts General 
Hospital, Harvard Medical School/United States 
Of America, 2Radiology, Shriners Burns Institute, 
Harvard Medical School/United States Of America
Background: To evaluate early metabolic responses 
measured with SimpliÀed kinetic method (SKM) 
and standard Uptake value (SUV) of 18F-FDG 
PET shortly after radiotherapy (RT) or RT of 
chemoradiotherapy (CRT) for their robustness in 
predicting local tumor control and survival for 
patients with lung cancer. 
Methods: Patients with inoperable stages I - III 
lung cancer were enrolled into a prospective study 
in which 18F-FDG PET was obtained before, 10-
12 days (S2), 3 months (S3), 6 months (S4) and 12 
months (S5) after RT or RT of CRT. To meet the 
study endpoints, patients were to have survived 
12 months (m) without local recurrence or to have 
developed local failure within 12 m. The association 
between residual glucose metabolic rates (MRglc) 
measured with SKM and SUV at S2 and tumor-
control probability (TCP) at 12 m was modeled 
using logistic regression and evaluated with Mann-
Whitney test. 
Results: We accrued 112 patients and 64 of these 
met study endpoints. The baseline values of 
maximum MRglc were 0.23 mmol/min/gm by SKM 
and 0.19 by SUVmax(bsa.g) [SUVmax corrected for 
body surface area and plasma glucose] respectively. 
The nadir of MRglc was realized at S2. Residual 
MRglc (median) representing metabolic response 
for patients with local control vs. local failure were 
0.06, 0.06, 0.07 and 0.07 vs. 0.12, 0.14, 0.18 and 
0.33 mmol/min/gm by SKM and 0.03, 0.03, 0.03 and 
0.03 vs. 0.07, 0.07, 0.09 and 0.16 by SUVmax(bsa.g) 
at S2, S3, S4 and S5 respectively (p<0.0001 for 
each time-point). An inverse relationship was noted 
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Background: The discovery of a non-invasive 
and early marker of response to targeted therapy 
could avoid unnecessary toxicity and ineffective 
treatment. Results from the phase II study testing 
erlotinib plus MetMAb or placebo in advanced 
NSCLC (OAM4558g) revealed that the addition of 
MetMAb to erlotinib resulted in an overall survival 
(OS) beneÀt in Met Diagnostic (Dx)+ patients (OS 
HR 0.37); but an OS detriment in Met Dx- patients 
(OS HR 3.02). This study prospectively evaluated 
whether early modulation of 18F-FDG correlated with 
the observed clinical outcomes. 
Methods: A standardized imaging protocol was 
implemented at 24 global sites; scan quality metrics 
were compiled to monitor adherence during the 
study. FDG-PET scans were acquired at baseline 
(within 14 days of randomization) and between days 
10 and14 following Cycle 1. Changes in 18F-FDG 
uptake were assessed prospectively by a single 
reference radiologist. PET partial metabolic response 
(PMR) was deÀned as a mean decrease in SUV
max
 
20% and no new lesions. Progressive metabolic 
disease (PMD) was deÀned as either a mean increase 
in SUV
max
 >20%, or the presence of new lesions. 
PET responses were compared to PFS, OS, and CT 
responses observed in the Phase II trial. 
Results: Of the 121 FDG-PET patient datasets 
acquired, 84% were considered evaluable. Technical 
imaging protocol adherence was comparable to 
that described in our previous benchmark study 
(OSI3926g). 30 PMRs were observed; 9 were in 
patients with an EGFR mutation. No correlation was 
observed between PMRs and OS, or CT RECIST 
responses in the two treatment arms; no correlation 
was observed between PMRs and clinical outcomes 
in the two diagnostic subgroups, Met Dx+ and Met 
Dx-. However, more Met Dx+ patients on placebo 
had PMD on PET compared to Met Dx+ patients 
treated with MetMAb: 45% (9/20) vs. 18% (3/17); 
this was mostly driven by the presence of new PET 
lesions.
Conclusion: Quantitative FDG-PET was 
successfully and consistently implemented in a 
randomized, global Phase II study. Metabolic 
responses, as measured by changes in SUV
max
, did 
not reÁect the survival beneÀt observed in Met 
Dx+ patients on MetMAb+erlotinib therapy; nor 
did they explain the detriment observed in Met 
Dx- patients on MetMAb+erlotinib. The lower 
manual delineations and the auto-segmentation tool were 
compared. All measurements were correlated with the 
maximal diameter on macroscopic examination of the 
surgical specimen.
Results: High overlap fractions were observed between 
the auto-segmentation tool and the intersection (94.52 ± 
6.38) and union (91.75±9.16) of the manual delineations. 
Differences in tumor volume were not observed between 
the automatic segmentation (median, 30.83 cm3) and 
manual delineations (35.89 cm3; p = 0.98). The maximal 
tumor diameter of the auto-segmented tumor mask 
correlated strongly with the macroscopic diameter of the 
primary tumor (correlation coefÀcient = 0.93).
Conclusion: Tumor volume measurement and 3D 
deÀnition using a CT-based auto-segmentation algorithm 
demonstrated high agreement with CT/PET manual 
delineations and showed a high correlation with the 
macroscopically dimensions on pathology considered 
the “gold standard”. This method may be used routinely 
in clinical practice and could be employed as a validated 
segmentation method for multi-centric clinical trials or 
high-throughput data mining research. 
Keywords: NSCLC, CT Imaging, Tumor 
segmentation
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MO06.09 RESULTS FROM FDG-
PET IMAGING IN OAM4558G, 
A RANDOMIZED, PLACEBO-
CONTROLLED, MULTI-CENTRE PHASE 
II TRIAL OF ERLOTINIB ± METMAB IN 
SECOND- AND THIRD-LINE NSCLC.
Premal Patel1, John Bothos2, Jill Fredrickson2, 
Thomas Bengtsson2, Amy Peterson2, Alex De 
Crespigny2 
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A and arm B, respectively) and OS (18.2 vs. 14.2 
months) were not signiÀcantly different (p=0.354 
and p=0.282, respectively). Incidence of grade 3 or 
4 hematologic and non-hematologic toxicities were 
12.8% and 18.8% (p=0.575) and 26.5% and 20.4% 
(p=0.631) in arm A and B, respectively. Sensitivity 
and speciÀcity for prediction of best response was 
81.8% (95% conÀdence interval [CI], 52.3 – 94.9%) 
and 47.1% (95% CI, 26.2 – 69.0%), respectively. 
Conclusion: In present study, changing 
chemotherapy according to response of PET after 
Àrst cycle of chemotherapy numerically improved 
ORR without statistical signiÀcance but PFS and 
OS were not improved. High sensitivity with 81.8% 
of PET for prediction of best response suggests that 
reduction of metabolic activity observed in PET is 
closely correlated with Ànal outcome of therapy, but 
the speciÀcity was poor. 
Keywords: Non small cell lung cancer, FDG-PET, 
Response
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MO06.12 PET/CT FOR EARLY 
DETECTION OF RECURRENCE AFTER 
LUNG RESECTION IN PATIENTS WITH 
NSCLC
Didier Lardinois1, Mark Wiese1, Flavio Forrer2, 
Daiana Stolz3, Michael Tamm3 
1Surgery, Division Of Thoracic Surgery University 
Hospital Basel/Switzerland, 2Division Of Nuclear 
Medicine University Hospital Basel/Switzerland, 
3Division Of Pneumology University Hospital Basel/
Switzerland
Background: Despite a curative approach and 
complete removal of the tumour the recurrence rate 
of NSCLC is very high following lung resection for 
NSCLC especially in the Àrst two to three years. 
Over the last years the percentage of pneumectomy 
has steadily decreased because experienced thoracic 
surgeons perform parenchyma sparing procedures 
such as sleeve resections whenever possible. 
Follow up of operated patients with NSCLC is 
not standardized and there are no conclusive 
recommendations in guidelines. Therefore follow-up 
investigations vary considerably from centre to centre 
and might include only clinical control or radiological 
examinations such as conventional chest x-rays 
or computed tomography. Integrated whole-body 
PMD rate observed in MetMAb+erlotinib treated 
Met Dx+ patients is intriguing and warrants further 
investigation (see Bengtsson, et al abstract). 
Keywords: cMet, MetMAb, erlotinib, NSCLC
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MO06.11 CHANGING CHEMOTHERAPY 
STRATEGY AS TO FDG-PET RESPONSE 
AFTER 1ST CYCLE OF STANDARD 
CHEMOTHERAPY FOR ADVANCED 
NSCLC
Jeong Eun Kim1, Kyu-Pyo Kim1, Chang-Min Choi1, 
Dae-Ho Lee2, Dae-Hyuk Moon3, Jin-Sook Ryu3, 
Seung Jun Oh3, Jung-Shin Lee1, Sang-We Kim1 
1Oncology, Asan Medical Center/Korea, 2Asan 
Medical Center, University Of Ulsan College Of 
Medicine/Korea, 3Nuclear Medicine, Asan Medial 
Center/Korea
Background: The aim of this study was to evaluate 
whether changing chemotherapy according to 
response of positron emission tomography (PET) 
after 1st cycle of chemotherapy improve overall 
response rate (ORR) of chemotherapy in non-small 
cell lung cancer (NSCLC) patients. 
Methods: This is an open-label, randomized, 
prospective study. Between December 2008 and 
July 2010, 100 patients were randomly assigned 
two groups; 4 cycles of GPMP (GenexolPM 230 
mg/m2 and Cisplatin 60 mg/m2 on Day 1, every 
3 weeks) in arm A; without metabolic response 
(reduction of tumor FDG uptake more than 20% in 
PET) after 1st cycle of GPMP, change to 4 cycles 
of GemOx (Gemcitabine 1000 mg/m2 on Day 1 
and 8 and Oxaliplatin 130 mg/m2 Day 8, every 3 
weeks) in arm B. ORR, progression free survival 
(PFS), and overall survival (OS) were compared. 
Sensitivity and speciÀcity of PET to predict response 
to chemotherapy could be evaluated in 36 patients in 
group A, who performed baseline and follow up PET 
after 1st cycle of chemotherapy. 
Results: Out of 100 patients, 49 patients were 
included in arm A and 51 patients in arm B. Age, 
gender, performance status and smoking history were 
not different between groups. ORR was 26.8% in 
arm A and 47.1% in arm B (p=0.090). In arm B, 11 
patients received GemOx without metabolic response 
after 1st cycle and 3 partial response, 5 stable disease 
were achieved. PFS (4.6 versus 4.9 months in arm 
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Background: As an exploratory biomarker and 
potential predictor of clinical outcome, tumor 
changes as measured by FDG-PET were evaluated as 
predictors of OS in two global, multi-center, Phase II 
studies of second- and third-line NSCLC. 
Methods: Combined data from two NSCLC trials 
were used to evaluate the use of new lesion (NL) 
status as determined by FDG-PET at 2 weeks 
following treatment initiation. 125 second- and 
third-line NSCLC patients were examined by 
FDG-PET at baseline and following 2 weeks of 
daily erlotinib (OSI3926g and OAM4558g). An 
additional 61 patients treated with MetMAb + 
erlotinib (OAM4558g) were similarly assessed. 
The predictive value of NL status by FDG-PET at 2 
weeks with respect to OS was evaluated by survival 
analysis. (For details on OSI3926g, see Mileshkin, et 
al JCO 28:15s, 2010 and for the imaging protocol in 
OAM4558g, see Patel et al., submitted.) 
Results: Positive NL status by FDG-PET at 2 weeks 
was found to be associated with a large reduction 
in survival. In the combined data, the median OS 
for patients with no NL by FDG-PET at 2 weeks 
was 8.0 mo vs. 2.4 mo for patients with NL, with a 
corresponding hazard ratio (HR)=0.40 (p <1.4e-4). 
The analysis of the OAM4558g trial demonstrated 
the median OS was 12.2 mo for patients with no NL 
vs. 2.2 mo for patients with NL (HR=0.24, p <1.4e-
07). Separate Cox regression analysis conÀrmed 
that the result holds even when ECOG is accounted 
for, discounting the confounding effect of baseline 
performance status. The overall rate of new lesions 
in this sample was found to be 18.8% (95% CI: 
13.1–24.6%), while the rate of new lesions among 
patients with longest expected survival was observed 
to be lower. In particular, in OAM4558g, the new 
lesion rate for treated, Met-positive patients was 
<10%, compared with 30% in the control group. 
Conclusion: NL status by FDG-PET is found to be 
a strong predictor of OS in second- and third-line 
NSCLC patients treated with erlotinib and MetMAb. 
A suppressed NL rate among patients with long OS 
(relative to the overall median) suggests that NL 
rates could potentially be used to detect an early 
therapeutic effect in this patient population. 
Keywords: MetMAb, erlotinib, FDG-PET, NSCLC
Positron Emission Tomography (PET/CT) has become 
a routine investigation for the staging of NSCLC. 
Because of the high sensitivity of PET/CT to detect 
mediastinal and distant metastases we perform PET/
CT 6 and 12 months after curative lung resection.
Methods: In this study we analysed the diagnostic 
yield of PET/CT for detection of early recurrence in 
patients with stage I to IIIA disease, who underwent 
anatomical lung resection and mediastinal lymph 
node dissection. Data of 60 patients, with a mean age 
of 62 years (39-77y) were analysed.
Results: Pathological stage of NSCLC was IA, 
IB, IIA, IIB, IIIA in 15, 13, 5, 7, and 20 patients 
respectively. Histology revealed adenocarcinoma 
(31), squamous cell carcinoma (21) and large 
cell carcinoma (8). Follow up PET/CT showed a 
solitary FDG uptake in a total of 29 patients (48%), 
19 at 6 months and 10 at 12 months after surgery. 
Recurrence of the disease was cytologically and/
or histologically proven in 16/60 asymptomatic 
patients (27%), consisting of mediastinal lymph node 
metastases (4), local recurrence in the remnant lung 
(4) and distant metastases (8). A second carcinoma 
of the esophagus was found in one patient, the other 
12 PET/CT positive lesions were of benign origin 
(9 inÁammatory; 3 colon adenoma). Recurrence of 
the disease was diagnosed in 4, 3, and 9 patients 
with stage I, II, and IIIA NSCLC respectively. 
Therapy of the recurrences included reoperation (6), 
radiotherapy (5) and chemotherapy (5). 
Conclusion: PET/CT at 6 and 12 months 
postoperatively allowed to early diagnose recurrence 
of NSCLC in a considerable number of patients, who 
underwent curative resection for NSCLC. If early 
diagnosis of recurrence improves patient survival has 
to be addressed in a prospective randomised trial. 
Keywords: Non small cell lung cancer, early 
recurrence, lung resection, PET/CT
PET, SPECT and CT In The Initial Staging and Response Assessment in 
NSCLC Monday, 4 July 2011 14:30-16:00
MO06.13 NEW LESION (NL) STATUS BY 
FDG-PET IS A STRONG PREDICTOR OF 
SURVIVAL DURATION (OS) IN SECOND- 
AND THIRD-LINE NON-SMALL-CELL 
LUNG CANCER (NSCLC) PATIENTS 
TREATED WITH ERLOTINIB AND 
METMAB + ERLOTINIB.
T. Bengtsson1, J. Fredrickson2, P. Patel2, R. Port2, B. 
M. Fine2, Alex De Crespigny2, Amy Peterson2 
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radiographer/radiologist should explain the risk”. 
49% (n=74) of respondents correctly estimated the 
approximate dose associated with each investigation, 
62% (n=94) signiÀcantly underestimated the dose 
and 14% (n=21) overestimated the dose signiÀcantly. 
Over 60% (n=91) of respondents requested further 
educational activities regarding risks of radiation.
Conclusion: Ionising radiation dose from medical 
imaging potentially poses a small but discernable 
risk of cancer. Experts state that “informed consent 
must include statements alluding to the high 
background risk of cancer, some risk of cancer 
with low-dose radiation, and the beneÀt of having 
the imaging test performed” (9). This study has 
observed that general practitioners do value the risk 
of cancer but that this is not reÁected in their practice 
of informed consent. It is also seen that while 
most general practitioners correctly approximate 
radiation dose, there is a signiÀcant minority 
that underestimate the risk. Numerous barriers 
to obtaining consent are described and general 
practitioners are open to further education. Future 
studies measuring the effectiveness of educational 
interventions would be of beneÀt.
Keywords: Cancer, Consent, RADIATION, Imaging
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MO07.01 THE COMBINATION 
OF MESOTHELIN AND CEA 
SIGNIFICANTLY IMPROVES THE 
DIFFERENTIATION BETWEEN 
MALIGNANT PLEURAL 
MESOTHELIOMA, BENIGN ASBESTOSIS 
AND LUNG CANCER
Thomas R. Muley1, Hans Hoffmann1, Hendrik 
Dienemann1, Felix J. Herth1, Michael Meister1, 
Joachim Schneider2 
1Translational Research Unit, Thoraxklinik, 
University Of Heidelberg/Germany, 2Institute And 
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MO06.14 RADIATION DOSE: 
PERCEPTIONS OF INFORMED 
CONSENT AND CANCER RISK FROM 
MEDICAL IMAGING.
James D. Runciman, Tom Brett, Diane Arnold-Reed 
School Of Medicine, University Of Notre Dame 
Australia - Fremantle Campus/Australia
Background: A growing body of literature supports 
the association of exposure to ionizing radiation from 
medical imaging with a small but statistically signiÀcant 
incidence of cancer (3, 4, 5, 15, 16). Generally the risks 
associated with clinical decisions are managed by the 
practice of informed consent. A recent study of specialists 
across three tertiary hospitals in the United States found 
most believed informed consent should be obtained prior 
to medical imaging however few knew if this practice 
occurred at their institution (9). Further studies have 
found that radiation dose and risks from imaging are 
generally underestimated, especially in regards to CT, 
but that doctor insight is improved by further education 
(12, 21). This study explores the perceptions of general 
practitioners in regards to patient consent and the risks 
from ionising radiation associated with medical imaging.
Methods: An anonymous questionnaire was distributed 
to 485 general practitioners in Western Australia. 
Participants were asked to comment on the practice 
of informed consent, barriers to gaining consent and 
their perception on the radiation dose associated 
with commonly requested imaging investigations. 
International Commission for Radiological Protection 
standards for radiation dose were used for reference 
(14). Data was analysed utilizing SPSS (13). The study 
was approved by the University of Notre Dame Human 
Research Ethics Committee.
Results: A response rate of 31.13% (n=151) of the 
total population 485 was achieved. An overwhelming 
96% (n=144) of respondents agreed that radiation 
risks from medical imaging were important. In 
contrast only 53% (n=80) actually informed all 
their patients of the risks prior to undergoing a CT. 
There is a large correlation between the belief that 
patients should be informed of the risks of CT and 
the reported practice of actually doing so (Pearson 
correlation coefÀcient of 1.0 to +/- 0.5 and p < 0.05). 
51% (n=77) of participants commented on barriers to 
obtaining consent. These included “time constraints”, 
that “I don’t understand the risks”, that “the 
patient is too unwell to comprehend” and that “the 
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Conclusion: The diagnostic yield of the Mesomark-
test can be improved when combined with a CEA 
test in regard to the differential diagnosis between 
MPM and lung cancer and between MPM and benign 
asbestosis. For diagnosis/differential diagnosis the 
use of both tests should be recommended. 
Keywords: MPM, mesothelin, CEA, differential 
diagnosis
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MO07.02 SOLUBLE MESOTHELIN, 
MEGAKARYOCYTE POTENTIATING 
FACTOR AND OSTEOPONTIN AS 
MARKERS OF PATIENT RESPONSE AND 
OUTCOME IN MESOTHELIOMA
Kevin Hollevoet1, Kristiaan Nackaerts2, Robert 
Gosselin3, Walter De Wever4, Lionel Bosquée5, 
Paul De Vuyst6, Paul Germonpré7, Eliane Kellen4, 
Catherine Legrand8, Yoshiro Kishi9, Joris R. 
Delanghe3, Jan P. Van Meerbeeck1 
1Respiratory Medicine, Ghent University Hospital/
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Belgium, 5Chu Sart Tilman/Belgium, 6Erasme 
Hospital Ulb/Belgium, 7Antwerp University Hospital/
Belgium, 8Université Catholique De Louvain/
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Background: Radiological response evaluation 
is notoriously difÀcult in patients with 
malignant pleural mesothelioma, an asbestos-
related malignancy. Soluble mesothelin (SM), 
megakaryocyte potentiating factor (MPF), and 
osteopontin (OPN) are blood biomarkers of 
mesothelioma. This study evaluates their use as 
markers of response to therapy and outcome. 
Methods: 62 patients with malignant pleural 
mesothelioma were surveilled in a Belgian 
observational multicenter study. Blood samples and 
CTs were collected at diagnosis and, when possible, 
during and after therapy, until disease progression 
or death. SM and MPF levels were measured in 
serum with the MesomarkTM ELISA and the non-
commercial Human MPF ELISA, respectively. OPN 
levels were measured in plasma with the Human 
Osteopontin ELISATM. For each patient, the best 
overall radiological response was compared with 
Background: Soluble mesothelin related proteins 
(SMRP) have been reported as potential markers 
for the diagnosis of malignant pleural mesothelioma 
(MPM). We wondered, whether a combination 
with a CEA-test might improve the relatively low 
diagnostic yield of the SMRP-test. 
Methods: 93 newly diagnosed histologically proven 
MPM patients were compared to 75 patients with 
benign asbestosis and 139 patients with lung cancer. 
SMRP serum concentrations were measured with 
MesomarkTM-Kit (Fujirebio Diagnostics, Malvern, 
USA). CEA was measured with Advia Centaur 
immunoassay (Siemens, USA). Statistical analyses 
were done with SPSS 18.0 (Chicago, Illinois, USA). 
Results: The results of the SMRP-test alone have 
been recently published (Schneider et al., 2008). The 
combination of Mesothelin and CEA increased the 
power to differentiate between MPM, lung cancer, 
and benign asbestosis. Whereas CEA was found to 
be low expressed in MPM (median: 0.3 ng/ml) and 
therefore nonspeciÀc for the detection of MPM, most 
lung cancer patients had elevated CEA serum levels 
(median: 3.9 ng/ml). The area under curve (AUC) 
of the receiver operator characteristics (ROC) curve 
for Mesothelin alone was found to be only 0.71 
comparing MPM and lung cancer (Àg. left). When 
Mesothelin was combined with CEA (Mesothelin/
CEA) the AUC of the resulting ROC- curve 
increased to 0.987. The sensitivity rate was 93.5% 
at 95% speciÀcity (68.8% at 100% speciÀcity) for 
the differentiation between MPM and lung cancer. 
The AUC of the ROC-curve for the differentiation 
between MPM and benign asbestosis (Àg. right) 
was 0.887 for the quotient of Mesothelin/CEA. The 
sensitivity rate was 55.9% at 95% speciÀcity (47.3% 
at 100%). In contrast, the AUC for the Mesothelin-
test alone was only 0.715, and for the CEA-test alone 
0.15. 
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Background: MPM patients show widely variable 
survival following EPP and there are no validated 
prognostic/predictive factors that could be used 
preoperatively. We investigated the expression 
of calretinin and D2-40 as well as the neutrophil-
to-lymphocyte ratio (NLR), an index of systemic 
inÁammation as potential preoperative prognostic 
factors in patients undergoing EPP.
Methods: All MPM patients who underwent EPP 
from 1994 to 2008 at participating institutes were 
included in this retrospective study. Potential 
prognostic factors such as age, gender, histological 
subtype, baseline laboratory parameters including 
NLR, and immunohistochemical staining of 
calretinin and D2-40 (scored based on percentage 
of cells labelled) were examined. Overall survival 
(OS) from the date of surgery was determined by the 
Kaplan Meier method. The prognostic value of the 
variables was examined using the Cox regression 
and signiÀcant factors (p<0.05) were entered into 
a multivariate model all together to determine their 
independent effect.
Results: A total of 85 patients were included in 
this retrospective evaluation: median age 58 years 
(range: 22-74); 80% male; 77% epithelial and 23% 
biphasic MPM. The median OS was 19.7 months. 
The following variables were predictive of longer 
OS: female gender (p=0.02), epithelial histological 
subtype (p=0.04), low NLR (p<0.01), and high 
calretinin score (p<0.001). After multivariate 
analysis, NLR 3 (HR 1.79; 95% CI, 1.04-3.07; 
p=0.04), and calretinin score 33% vs. >67% 
(HR 4.72; 95% CI, 1.97-11.32; p<0.01) remained 
independent predictors. The addition of calretinin 
score increased the explained variation by 10.1%.
Conclusion: Both low calretinin expression and 
high NLR were independently associated with poor 
prognosis in MPM patients undergoing EPP and the 
calretinin score appeared to inÁuence the accuracy 
of the prognostic model. Given that calretinin is 
routinely used in daily practice, our Àndings can be 
easily validated in a prospective manner.
Keywords: malignant pleural mesothelioma, 
calretinin, neutrophil-to-lymphocyte ratio, prognostic 
factor
the change in serum SM, MPF and plasma OPN 
levels across the corresponding time points. Survival 
analysis was performed with Cox proportional 
hazard regression and log-rank statistics. 
Results: In Àve patients who underwent extrapleural 
pneumonectomy, SM and MPF markedly 
decreased after surgery, whereas OPN showed a 
median increase. Of the 57 patients who received 
chemotherapy, 27 (47%) had radiological stable 
disease (SD), 14 (25%) partial response (PR), and 
16 (28%) progressive disease (PD). In patients with 
SD, biomarker levels did not change signiÀcantly 
(SM and MPF), or decreased (OPN). For PR and PD, 
biomarker levels typically decreased and increased, 
respectively. A change 15% in all three biomarkers 
was signiÀcantly associated with patient response, 
whereas SM and MPF were more accurate than 
OPN. Low baseline OPN levels were independently 
associated with favorable overall and progression 
free survival. Neither SM nor MPF were informative 
for patient outcome. 
Conclusion: SM and MPF levels were more 
closely associated with disease course than OPN, 
and might prove useful in monitoring patients 
with mesothelioma. Baseline OPN levels were an 
independent negative predictor of survival. Furhter 
valdiation of these promising results remains 
necessary. 
Keywords: mesothelin, mesothelioma, biomarker, 
monitoring
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MO07.03 CALRETININ EXPRESSION 
IMPROVES THE PREDICTIVE 
ACCURACY IN SURVIVAL IN PATIENTS 
WITH MALIGNANT PLEURAL 
MESOTHELIOMA (MPM) UNDERGOING 
EXTRAPLEURAL PNEUMONECTOMY 
(EPP)
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had persisting stable disease (SD) (+270 d), and 8 pts 
PD. DCR was 27.7%. As of January 2011, 4 of the 
alive 6 pts remain on treatment. At a median follow-
up of 8 months, median OS was 8 months (95% CI, 
6.11-9.89). Grade 1-2 AE occurred in 90% of pts; 
one pt had hepatic and pancreatic grade 4 AE that 
resolved with steroid therapy. Among investigated 
markers, a signiÀcant increase in the absolute 
number of CD4+HLA-DR+, CD4+CD45RO+, 
CD4+ICOS+, CD8+HLA-DR+, and CD8+ICOS+ 
T cells was detected at d 14, 30 and 60 after the Àrst 
dose of tremelimumab, it slowly declined thereafter, 
and resumed upon re-dosing. 
Conclusion: CTLA-4 blockade in MM pts is safe 
and shows promising clinical activity. A sizeable 
proportion of pts experienced clinical beneÀt and 
prolonged disease stabilization. Treatment associates 
with major changes in activated and memory T cell 
subpopulations. As of February 2011, 16 pts have 
been enrolled in the study. 
Keywords: Malignant mesothelioma, 
Immunotherapy, Anti-CTLA-4 mAb
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MO07.06 MALIGNANT (DIFFUSE) 
MESOTHELIOMA IN WOMEN: A STUDY 
OF 355 CASES
Elizabeth N. Pavlisko, Thomas A. Sporn, Victor L. 
Roggli 
Department Of Pathology, Duke University Medical 
Center/United States Of America
Background: Malignant mesothelioma has 
long been accepted as a consequence of 
asbestos exposure. The Àrst literature regarding 
mesothelioma in women, especially asbestos 
exposure as a household contact, was in 1965 
(Newhouse and Thompson). Since then others 
have reported signiÀcant exposure to asbestos from 
nonoccupational sources. This is supported by the 
1995 NIOSH Home Contamination Study Report 
and the 1997 Helsinki Criteria. Few have correlated 
nonoccupational exposure with Àber analysis data 
or presence or absence of pleural plaques and 
asbestosis. 
Methods: Our database included cases obtained 
from the consultation Àles of one of the authors 
(VLR) between 1983 and 2010. There were 2858 
cases of histologically conÀrmed malignant (diffuse) 
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MO07.04 A PHASE II STUDY WITH THE 
ANTI-CTLA-4 MAB TREMELIMUMAB 
IN CHEMOTHERAPY-RESISTANT 
ADVANCED MALIGNANT 
MESOTHELIOMA: SAFETY, 
TOLERABILITY, CLINICAL AND 
IMMUNOLOGIC ACTIVITY
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Morra3, Ornella Cutaia2, Ester Fonsatti1, Riccardo 
Danielli1, Maresa Altomonte1, Luciano Mutti4, 
Michele Maio1 
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Background: Anti-CTLA-4 monoclonal antibodies 
(mAb) are showing signiÀcant activity in different 
tumor types; however, no data are available in 
malignant mesothelioma (MM) patients (pts). We 
report preliminary results of a phase II, single 
Institution, study investigating safety, clinical 
and immunologic efÀcacy of the fully-human 
anti-CTLA-4 mAb tremelimumab as second-line 
treatment for MM pts who failed a platinum-based 
regimen. 
Methods: Of the 29 foreseen pts, 6 stage III and 5 
stage IV MM pts (7 males, 4 females), median age 
66 (51-76) years, ECOG performance status 0-2, 
received tremelimumab at 15 mg/Kg i.v on day (d) 1 
and 90 for 4 cycles or until progressive disease (PD). 
Primary endpoint was objective response (OR); 
safety, disease control rate (DCR) (PR+SD), overall 
survival (OS), and immunologic activity were 
secondary. As per Simon’s design at least 1 OR was 
required in the Àrst 11 pts, to continue enrolment. 
Tumor assessment at baseline, and at each cycle 
utilized modiÀed RECIST Criteria. Adverse events 
(AE) were collected according to the Common 
Terminology Criteria v3.0. Peripheral blood 
mononuclear cells collected at baseline, d 14, 30, and 
60 of the 1st and 2nd cycle, were analyzed by Áow 
cytometry for an extensive panel of phenotypic and 
activation markers. 
Results: All pts received at least 1 dose of 
tremelimumab (median 3; range 1-4). One patient 
(pt) achieved partial response (PR) (+180 d); 2 pts 
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had elevated chrysotile above background range, 
all of which also had elevated amphiboles. Of 287 
cases without Àber analysis, only 38 had evidence 
of asbestos exposure as indicated by plaques or 
asbestosis. 
Keywords: Àber analysis, mesothelioma, asbestos
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MO07.07 ASSESSING SURVIVAL 
AND TIME TO TREATMENT (TT) 
FOR PATIENTS DIAGNOSED 
WITH MALIGNANT PLEURAL 
MESOTHELIOMA (MPM) IN ONTARIO, 
CANADA.
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Background: Systemic therapy (ST) is the only 
treatment modality with proven survival beneÀt 
for advanced MPM. There is no proven survival 
advantage to commencing ST earlier rather than later 
for patients diagnosed with MPM. We hypothesised 
that delay in administration of ST would result in 
shorter overall survival from diagnosis.
Methods: Information for patients diagnosed with 
MPM between 2005-2010 were obtained from 
administrative databases at University Health 
Network, Cancer Care Ontario and WSIB. Date of 
diagnosis was deÀned as the date of the procedure 
from which a deÀnitive diagnosis of MPM was 
able to be made pathologically. Overall survival 
(OS) was calculated from date of diagnosis by the 
Kaplan-Meier method, differences between the 
survival curves were analyzed by the log-rank test. 
Analysed cases for TT analysis were restricted to 
those receiving chemotherapy who did not undergo 
extrapleural pneumonectomy (EPP).
Results: 557 patients were diagnosed with MPM 
in Ontario between 2005 and 2010. Of these, most 
were male (82.4%), had right sided tumors (61.7%), 
and epithelioid histology (77.8%). The average 
age was 70.5 years (range 29.3-94.7). Treatment 
consisted of extrapleural pneumonectomy (EPP) in 
mesothelioma, and 355 of those (12.4%) occurred 
in women. Cases of well-differentiated papillary 
mesothelioma were excluded. Data collected 
included tumor location, morphology, exposure 
history, presence of asbestosis and/or pleural plaques 
and survival. Exposure information was categorized 
using 23 previously established exposure groups. 
Fiber analysis was performed in 68 cases according 
to previously described methodology followed by 
light and scanning electron microscopy. Energy 
dispersive x-ray analysis was used to determine Àber 
type. 
Results: Of the 355 cases, 275 (77%) were located 
in the pleura and 80 (23%) within the peritoneum. 
The ratio of epithelial, biphasic and sarcomatoid 
variants for pleural mesothelioma was 8:2:1, and for 
peritoneal was 17:3:1. The median age of women 
with pleural mesothelioma was 65 years (range 
19-93 years) and for peritoneal was 52 years (20-
84 years). There were 326 cases with informative 
data regarding exposure. The largest category 
was nonoccupational with household contacts 
accounting for 60% of cases with single exposure 
and an additional 9% of cases with more than one 
documented exposure. The relationship between 
case and contact(s) was wife (46%), daughter (27%) 
and both (8%). The largest industry/occupation 
for the contact was insulation (16%) followed by 
shipyard (13%), construction (12%) and oil/chemical 
(9%). Fiber analysis data showed elevated asbestos 
bodies by light microscopy in 29/67 cases. Twenty 
had elevated commercial amphibole Àbers, 23 had 
elevated noncommercial amphiboles, and 4 had 
elevated chrysotile. Thirty-three had levels which 
were within our background range. Of 287 cases 
without Àber analysis, 35 had pleural plaques, one 
asbestosis and two both. Survival data was available 
on 276 cases. Median survival was 12 months (range 
0.25 – 268). For pleural tumors by morphologic 
variant, survival was 15 (0.25-268), 9 (0.25-170) 
and 4 (0.25-65) months and for peritoneal tumors, 
survival was 16 (0.75-120), 5 (0.75-25), and 4 (1-
12) months for epithelial, biphasic and sarcomatoid, 
respectively. 
Conclusion: Peritoneal tumors occurred in a 
somewhat younger age group. Nonoccupational 
exposures to asbestos predominated with household 
contact exposure accounting for over half, most 
often as wives of men who worked with insulation, 
in shipyards or in construction. Fiber analysis 
demonstrated elevated asbestos bodies in 43%, with 
amphiboles the dominant Àber type. Only 4 cases 
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C, an oral tyrosine kinase inhibitor of VEGFR 1, 2, 3 
and PDGFR-a, in MM pts.
Methods: Eligible pts had unresectable, 
histologically-conÀrmed MM, measurable disease, 
and performance status 0-1. No more than 1 prior 
chemotherapy regimen was permitted. The initial 
dose of C was 45 mg orally daily. Because of toxicity 
observed in other studies of C, an amendment in 
June 2007 decreased the starting dose to 30 mg daily. 
CT scans were obtained every two 28-day cycles. 
The primary endpoint was objective response rate 
per modiÀed RECIST. Using an alpha level of 0.10 
and 90% power, the Simon, optimal, 2-stage design 
required 3 responses in the Àrst 21 pts to proceed to a 
2nd stage, and 8 responses in 50 MM pts for further 
investigation. 
Results: 50 pts enrolled from March 2006 to 
September 2010 at 9 centers. Pt characteristics: male 
84%; median age 64 (range 44-81); PS 0 30%, PS 
1 70%; disease site: pleural 94%, peritoneal 6%; 
pathologic subtype: epithelial 72%, sarcomatoid 4%, 
biphasic 12%, unknown 12%; prior chemotherapy 
88%; thrombocytosis 26%. The initial dose was 45 
mg in 15 pts and 30 mg in 35 pts. A median of 2 
cycles was delivered (range 1-14). Dose reductions 
were required in 48% of all pts, and in 60% of pts 
at the 45 mg dose. C was discontinued for toxicity 
in 26% of all pts, and in 47% of pts at the 45 mg 
dose. Partial responses (PR): 10% (3/15 pts at 45 
mg, 2/35 pts at 30 mg). The median duration of 
response was 8.3 months (range 7.3-12.9 months). 
All PR occurred in pts with epithelial histology. 
Stable disease (SD): 34% (7/15 pts at 45 mg, 10/35 
pts at 30 mg). The disease control rate (PR + SD) 
was 44% (67% at 45 mg, 34% at 30 mg). Median 
progression-free survival was 1.9 months (95% CI: 
0.1, 14.2). Median overall survival was 4.4 months 
(95% CI: 0.9, 41.7). One-year survival was 15%. 
One patient with a partial response continues on 
study in cycle 10. Grade 3/4 toxicity: fatigue 24%, 
hypertension 22%, diarrhea 8%, hyponatremia 6%, 
thrombosis 6%, acute renal failure 4%, mucositis 
4%, angioedema 2%, arrhythmia 2%, headache 2%, 
posterior leukoencephalopathy 2%, seizure 2%.
Conclusion: Although some prolonged partial 
responses were observed, the trial did not meet its 
pre-speciÀed response endpoint. The 45 mg dose 
of C was poorly tolerated. Supported by NCI grant 
N01-CM-62201 
Keywords: mesothelioma, cediranib, VEGF
57 (10.2%); and Àrst line ST was conÀrmed in 232 
(41.7%) patients. Median OS for those treated with 
ST compared with those not treated with ST was 
13.3 and 5.5 months respectively (p<0.001). Data for 
TT was available for 186 patients, and the median 
TT was 2.4 months (range 0.3-35.3). Patients in the 
lower, middle and upper tertiles for TT had a median 
OS from diagnosis of 8.2, 11.4, and 15.5 months 
respectively (p=0.0011).
Conclusion: Most patients with MPM did not 
receive ST. Of those treated with ST without 
EPP, prolonged TT correlated with increased OS, 
possibly as a result of lead time bias and delayed ST 
administration in patients with indolent disease.
Keywords: mesothelioma, Chemotherapy
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Background: Vascular endothelial growth factor 
(VEGF) signaling is thought to play an important 
role in MM biology. In preclinical models, MM 
growth is inhibited by agents that target VEGF. In 
MM patients, high serum VEGF levels correlate 
inversely with survival. Phase II trials of several 
VEGF inhibitors have demonstrated modest activity 
in MM. We performed a multi-center phase II trial of 
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thrombocytopenic bleeding during radiotherapy 
1.5%, making total treatment induced mortality 14%. 
Median survival rates for cohorts 1 and 2 were 24.3 
and 33.6 months, respectively (p=0.22), while cohort 
2 had 1-, 2-, 3-, and 4-years survival rates of 84%, 
62%, 42%, and 20%, respectively. 
Conclusion: EPP is a safe procedure when 
performed in high-volume institutions but especially 
postoperative radiotherapy is high-risk procedure. 
The survival for cohort 2 is among the best results 
published with 4-year survival rate of 20% but fatal 
radiation pneumonitis remains a serious problem 
which should be further explored. 
Keywords: Extrapleural pneumonectomy, Intensity 
Modulated Radiotherapy, mesothelioma, trimodality 
treatment
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AND CARBOPLATIN AS FIRST-
LINE THERAPY IN PATIENTS 
WITH MALIGNANT PLEURAL 
MESOTHELIOMA (MPM)
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Background: The carboplatin/pemetrexed combination 
showed activity in MPM patients (pts). Vascular 
endothelial growth factor (VEGF) is highly expressed 
in MPM; in pre-clinical models, anti-VEGF antibodies 
were shown to decrease MPM cells growth. The aim 
of this multicenter, open label phase II study was to 
assess the activity of bevacizumab in combination with 
carboplatin/pemetrexed (BPC regimen) as Àrst-line 
therapy in MPM pts. 
Methods: Chemotherapy-naive pts, not candidates 
for curative surgery, received pemetrexed 500 mg/
m2, carboplatin AUC5 and bevacizumab 15 mg/kg, 
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POSTOPERATIVE INTENSITY-
MODULATED RADIOTHERAPY 
(IMRT) IN MALIGNANT PLEURAL 
MESOTHELIOMA (MPM).
Jens B. Sorensen1, Jesper Ravn2, Claus A. 
Kristensen1, Annika Loft3, Anne K. Berthelsen3, 
Gunnar Hillerdal4, Mikael Johansson5, Paal 
Brunsvig6, Stein Sundstrøm7, Ulf Aasebø8 
1Oncology, Finsen Centre/National University 
Hospital/Denmark, 2Thoracic Surgery, National 
University Hospital/Denmark, 3National University 
Hospital/Denmark, 4Karolinska Hospital/Sweden, 
5Umeå Hospital/Sweden, 6Radiumhospital Oslo/
Norway, 7Sct. Olav Hospital Trondheim/Norway, 
8University Hospital Tromsø/Norway
Background: Trimodality treatment combining 
chemotherapy, surgery, and radiotherapy has 
yielded 5-year survival in some MPM patients 
though prognosis is generally poor. Results from a 
PanScandinavian trimodality study in MPM patients 
from Denmark, Norway, and Sweden is presented. 
Methods: IC was 3-6 courses of platinum-based 
doublet chemotherapy. Subsequent restaging 
using F18-FDG-PET/-CT scan fused imaging and 
mediastinoscopy was subsequently performed at 
Rigshospital, Copenhagen, Denmark, followed by 
EPP in epithelial MPM patients having T1-3N0-1M0, 
performance status 0-1, age 70 years, and no major 
comorbidities. Postoperative radiotherapy was 56-
60 Gy in 30 fractions, 5F/W. Patients were divided 
into cohort 1 (2003-2006, 26 patients) and cohort 2 
(2006-2010, 38 patients). Radiotherapy constraints for 
contralateral lung in cohort 1 was V20<20% and mean 
lung dose (MLD) <15 Gy, while in cohort 2 it was 
V20<15%, V10<50%, and MLD<12 Gy. 
Results: Characteristics among all 64 patients 
were: Males 88%, right hemithorax disease 61%, 
median age 61 years (range 45-69 years), and IMIG 
preoperative stages I, II, III, and IV (port metastases) 
in 16%, 66%, 16%, and 3%, respectively. 
Frequencies of fatal radiation pneumonitis were 
15% and 8% in cohorts 1 and 2, respectively. 
Overall, 30-days postoperative mortality was 
1.5%, fatal radiation pneumonitis 10.9%, and fatal 
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a standardized multimodality treatment concept 
and to investigate the effectiveness of this approach 
using lung-sparing Radical Pleurectomy (RP) for 
the treatment of malignant pleural mesothelioma 
(MPM).
Methods: In a prospective, observational study, 
all patients with histologically proven MPM were 
evaluated for trimodality therapy: lung-sparing 
RP (visceral and parietal pleurectomy, as well as 
resection of pericardium and diaphragm as indicated) 
followed by 4 cycles of Cisplatin/Pemetrexed 
and tangential radiation of the chest wall at the 
incision sites (21 Gy in 3 fractions) from November 
2002 to December 2008. Patients with prior 
treatment for MPM were excluded. The primary 
and secondary end-points were overall survival, as 
well as progression-free survival (PFS), patterns of 
recurrence, morbidity and mortality.
Results: Fifty-two out of 135 consecutive patients with 
a median age of 65.3 years were enrolled in the study. 
Forty-nine patients (94.2%, 42 males) completed the 
trimodality therapy. Surgical morbidity and mortality 
were 23.1% (12/52) and 1.9% (1/52), respectively. 
Epithelial histology was detected in 42 study subjects 
(80.8%). Macroscopic complete resection (MCR) 
could be achieved in 34 patients (65.4%). Thirty 
patients (57.7%) had advanced stages III/IV applying 
the International Mesothelioma Interest Group (IMIG) 
staging system. Median follow-up was 24.2 months. 
Cumulative survival, 1- and 5-year-survival were 34.8 
months (95% ConÀdence Interval [CI] 24.6-44.9), 69% 
and 29%, respectively. Mean PFS was 21.5 months 
(95%CI 16.1-26.8). Recurrence were locoregional (27/51, 
52.9%), distant (10/51, 19.1%) and both (2/51, 3.9%), 
respectively. Comparisons of MCR vs. incomplete 
resections (P < 0.001), IMIG stages I/II vs. III/ IV (P 
= 0.013) and nodal disease N0 vs. N1-2 (P = 0.005) 
resulted signiÀcant survival differences. On contrary, 
no signiÀcant impact on survival were seen analyzing 
histology (P = 0.8), gender (P = 0.4) and age (P = 0.4), 
respectively. MCR was the single signiÀcant prognostic 
factor (hazard ratio 0.14, 95% CI 0.058-0.335; P < 0.001) 
when the Cox proportional hazards model was applied.
Conclusion: Trimodality therapy concept including 
lung-sparing RP as surgical modality is associated 
with promising long-term survival, morbidity and 
mortality. MCR is the only prognostiÀcator within this 
multimodality treatment. Further investigation for the 
locoregional control of the disease is warranted because 
of the high rate of locoregional failure.
Keywords: Chemotherapy, RADIATION, malignant 
pleural mesothelioma, radical pleurectomy
administered intravenously every 21 days for 6 cycles, 
followed by maintenance bevacizumab. Main endpoint 
of the study was progression free survival (PFS). It 
was planned to achieve a median PFS of 9 months in 
comparison to a null hypothesis of 6 months.
Results: Seventy-seven pts were enrolled. Their 
characteristics were: M/F 50/27, median age 67 
(range 27–78), EORTC prognostic score good/
poor 66/11. Histology was epithelial in 61 pts, 
sarcomatoid or biphasic in 11, and not speciÀed 
in 5. A partial response was achieved in 31/77 pts 
(40%). Thirty-seven pts (48%) had stable disease, 
for an overall disease control rate of 88%. Median 
PFS and overall survival (OS) were 7.9 and 14.3 
months, respectively. Disease control rate, PFS and 
OS were not correlated to baseline serum VEGF 
levels. Haematological toxicity was low, with 
grade 3/4 adverse events observed in 7 pts (9%). 
Non-haematological toxicity was generally mild; 
however, 2 toxic deaths (one bowel perforation, one 
pneumonitis) were reported. 
Conclusion: First-line treatment with BPC regimen 
in MPM pts was feasible, with acceptable toxicity. 
Bevacizumab-related adverse effects should be 
strictly monitored. Although the survival outcomes 
compared favorably with historical controls of 
platinum/pemetrexed regimens, the primary endpoint 
of the trial was not reached. 
Keywords: mesothelioma, Chemotherapy, 
bevacizumab
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MO07.12 MULTIMODALITY 
TREATMENT OF MALIGNANT PLEURAL 
MESOTHELIOMA: LUNG-SPARING 
RADICAL PLEURECTOMY FOLLOWED 
BY ADJUVANT CHEMOTHERAPY 
(CISPLATIN/PEMETREXED) AND 
TANGENTIAL RADIATION OF THE 
CHEST WALL
Servet Bölükbas1, Michael Eberlein2, Thomas 
Bergmann1, Annette Fisseler-Eckhoff3, Joachim 
Schirren1 
1Thoracic Surgery, Dr. Horst Schmidt Klinik/
Germany, 2Division Of Pulmonary And Critical 
Care Medicine, Johns Hopkins University School Of 
Medicine/United States Of America, 3Pathology And 
Cytology, Dr. Horst Schmidt Klinik/Germany
Background: The aim of the study was to present 
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Methods: Patients with untreated, stage I-III MPM 
receive up to 4 cycles of pemetrexed and platinum 
chemotherapy. If feasible, P/D is performed. IMRT is 
then administered in 28 fractions for a total planned 
dose of 50.4 Gy. There is a two-stage design: if <3 
cases of severe pneumonitis occur among the Àrst 9 
patients, the cohort will expand to 28. The primary 
endpoint is the incidence of severe pneumonitis. 
Secondary endpoints include response rate, 
progression free survival, and overall survival. 
Results: 13 patients have enrolled. Patient 
characteristics include: median age 65 (range 48-79); 
15% women, 85% men; median Karnofsky PS 90% 
(range 70-90%). Four patients came off-study prior to 
receiving IMRT (2 experienced progression of disease, 
1 died from progressive disease, and 1 experienced 
grade 4 toxicity with the Àrst cycle of chemotherapy). 
7 patients have completed IMRT; 2 patients are 
completing their other treatment modalities. There has 
been 1 case of grade 3 pneumonitis and the patient 
was weaned from oxygen after a course of steroids. 
Conclusion: At our institution, we have compiled 
an extensive experience using IMRT to the pleura 
in patients with two intact lungs and shown it to be 
safe, with an incidence of severe pneumonitis 20%, 
and promising with high survival rates. We are 
currently studying induction chemotherapy, P/D when 
feasible, and IMRT to the pleura in a prospective 
study. Given the waning enthusiasm for performing 
EPPs, this approach has the potential to establish a 
new multi-modality paradigm for the treatment of 
locally advanced MPM. Supported, in part, by Lilly 
Oncology. 
Keywords: imrt, multi-modality, mesothelioma
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MO07.14 CONTROVERSIES IN THE 
MANAGEMENT OF MALIGNANT 
PLEURAL MESOTHELIOMA: THE 
CASE FOR CONSERVATIVE SURGERY 
AND HIGH-DOSE HEMITHORACIC 
RADIOTHERAPY
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Gavin M. Wright4, Sze Ting Lee5, Chris Hamilton1 
1Radiation Oncology Centre, Austin Health/
Australia, 2Thoracic Surgery Dept, Austin Health/
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MO07.13 CREATING A NEW MULTI-
MODALITY TREATMENT PARADIGM 
FOR MALIGNANT PLEURAL 
MESOTHELIOMA (MPM) USING 
INTENSITY MODULATED RADIATION 
THERAPY (IMRT) TO THE PLEURA
Marjorie G. Zauderer1, Andreas Rimner2, Kenneth 
Rosenzweig3, Valerie Rusch4, Prasad Adusumilli4, 
Samantha Kass5, Lee M. Krug6 
1Thoracic Oncology Service, Memorial Sloan-
Kettering Cancer Center/United States Of America, 
2Radiation Oncology, Memorial Sloan-Kettering 
Cancer Center/United States Of America, 3Radiation 
Oncology, Mount Sinai Medical Center/United 
States Of America, 4Thoracic Surgery, Memorial 
Sloan-Kettering Cancer Center/United States Of 
America, 5Medicine, Memorial Sloan-Kettering 
Cancer Center/United States Of America, 6Thoracic 
Oncology, Memorial Sloan-Kettering Cancer Center/
United States Of America
Background: Local disease progression is the 
primary cause of morbidity and mortality in MPM, 
and radiation has been added to surgery and 
chemotherapy to improve outcomes. Hemithoracic 
radiation has become widely used as adjuvant 
therapy after extrapleural pneumonectomy (EPP). 
IMRT can also be used in this setting although, if 
not performed within strict parameters, it can be 
associated with fatal pneumonitis. Also, the survival 
beneÀt of EPP over pleurectomy/decortication 
(P/D) has been questioned by a large retrospective 
review (Flores, J Thorac Cardiovasc Surg 2007) 
and many fewer EPPs are now being performed. 
Retrospective reports of IMRT to the pleura without 
surgery or after P/D have demonstrated much less 
severe toxicity. We identiÀed 36 patients with MPM 
who received IMRT to the pleura after P/D (20) or 
without any surgery (16) treated at Memorial Sloan-
Kettering Cancer Center between 2005 and 2010 
(Zauderer, IMIG 2010). There was a 20% incidence 
of severe pneumonitis among these patients and 
almost all patients improved with steroids. Overall 
survival was encouraging at 26 months in the 
P/D patients, and 17 months in those who did not 
undergo surgery. Based on these Àndings, we have 
launched a phase II trial to prospectively characterize 
the safety of IMRT to the pleura in the multi-
modality treatment paradigm for MPM patients. 
S540 Copyright © 2011 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
local control can be achieved with radiation doses 
above 50 Gy. The introduction of advanced radiation 
technologies, including intensity-modulated and 
image-guided radiotherapy, allows adequate sparing 
of adjacent normal tissues. Complete macroscopic 
resection is no longer mandatory and radical 
diaphragmatic and pericardial reconstructions, 
together with mediastinal lymphadenectomy, can 
be avoided since we have shown that high radiation 
doses can sterilize gross residual disease without 
producing signiÀcant pulmonary, hepatic or cardiac 
toxicity, even in patients who retain the affected 
lung. These techniques can be safely delivered to 
selected patients following suboptimal surgery and 
chemotherapy and are recommended to provide 
palliation and locoregional control to patients with 
advanced mesothelioma. Further studies with high 
dose radiotherapy are warranted. 
Keywords: mesothelioma, intensity-modulated 
radiotherapy, conservative surgery, PET scanning
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MO08.01 THE RELATION BETWEEN 
RADIATION PNEUMONITIS AND MEAN 
LUNG DOSE IN PATIENTS TREATED 
WITH LUNG SBRT
Alize Scheenstra, Maddalena M.G. Rossi, Eugène 
Damen, José Belderbos, Heike Peulen, Jan Jakob 
Sonke 
Radiation Oncology, The Netherlands Cancer 
Institute - Antoni Van Leeuwenhoek Hospital/
Netherlands
Background: Both the mean lung dose (MLD) and 
the percentage of lung volume receiving doses more 
than a certain threshold dose (Vx) are known to be 
related to the incidence of radiation pneumonitis 
(RP) in conventionally fractionated radiotherapy 
(RT). This work investigates the relation of RP to the 
MLD and the Vx for stereotactic body radiotherapy 
(SBRT) in NSCLC patients. 
Methods: A total of 187 patients with peripheral 
lung tumors <5cm were treated with SBRT between 
June 2006 and March 2010: 174 patients received 
3x18Gy, 4 patients had other fractionation schemes 
Background: In the absence of deÀnitive medical 
trials, patients diagnosed with mesothelioma face 
difÀcult decisions with limited treatment options and 
many unresolved questions. This disease is almost 
always fatal, has a median survival of only nine 
months and there is no proven beneÀt from standard 
therapies. Hemithoracic radiotherapy is regarded 
by most institutions as unsafe unless the lung has 
been resected. There is an increasing reluctance to 
recommend extrapleural pneumonectomy (EPP), 
supported by the MARS trial results. Multimodality 
treatment programs must balance the potential risk of 
major toxicity with palliative beneÀts. It is imperative 
that clinical research should focus on reducing the 
high rate of locoregional progression that is the 
overwhelming cause of morbidity and death.
Methods: We have delivered high dose intensity-
modulated radiotherapy (IMRT) to the whole 
hemithorax in mesothelioma patients with good 
performance status and incompletely resected 
localized disease. All patients had PET/CT scans 
performed to exclude distant metastases, deÀne 
residual gross tumour volume (GTV), quantify 
metabolic responses by serial total glycolytic volume 
(TGV) analysis, and assess locoregional control. A 
daily online cone beam CT imaging protocol was 
implemented. Strict radiation dose constraints were 
observed and all toxicities were recorded and graded 
according to CTCAE 4.0.
Results: From July 2007 to February 2011, twenty 
patients with incompletely-resected mesotheliomas 
received IMRT to the whole hemithorax. All patients 
received radiotherapy at a single institution to doses 
of 55 - 60 Gy as outpatients over six weeks. Based on 
planning PET scans, 80% had advanced clinical stage 
disease (stage II 4, III 9, IV 7). Only one patient had 
an EPP and all the others had conservative procedures 
including 1 radical pleurectomy, 4 pleurectomy/ 
decortications, 10 pleurodeses or, in 3 cases, biopsy 
only. Chemotherapy was given to 18 patients, all 
of whom had progressed prior to commencing 
radiotherapy. IMRT was well tolerated and we 
found no acute or late grade 4-5 radiation toxicities. 
Assessable TGVs were reduced to 40% of the pre-
irradiation values. Median followup was 8 months 
(range 2 to 44 months) and 13 patients remain alive, 
8 disease-free. Relapses have occurred outside the 
GTV in 11, including only 3 with concurrent in-Àeld 
relapse, a locoregional control rate of 85%. There 
were no cases of relapse conÀned only within the 
irradiated volume. 
Conclusion: Mesothelioma is radiosensitive and 
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MO08.02 LATE OUTCOMES OF 
STEREOTACTIC ABLATIVE 
RADIOTHERAPY (SABR) FOR 
CENTRALLY LOCATED STAGE I LUNG 
CANCER
Cornelis J. Haasbeek, Frank J. Lagerwaard, Ben 
Slotman, Suresh Senan 
Radiation Oncology, VU University Medical Center/
Netherlands
Background: In centrally located lung tumors, the 
use of stereotactic ablative radiotherapy (SABR) has 
been associated with increased toxicity. We studied 
outcomes after delivery of risk-adapted SABR to 
central tumors in patients who were followed-up for 
at least 1 year.
Methods: Between 2003 and 2009, SABR was 
delivered in 8 fractions of 7.5Gy in 63 patients, 
using a median of 10 non-coplanar radiation beams 
on a Novalis linear accelerator. Target volumes 
were based on 4D-CT scans incorporating tumor 
movement. Thirty-seven patients had a stage 
I lung tumor at a central hilar location (RTOG 
criteria), while 26 patients had a tumor abutting the 
pericardium or mediastinal structures. Follow-up 
CT scans were performed at 3, 6 and 12 months 
following SABR, and yearly thereafter. Toxicity was 
scored according to CTC-AEv4 guidelines. Survival 
outcomes were compared to patients with peripheral 
stage I SABR patients treated during the same 
time period with identical treatment techniques. 
Peripheral tumors were treated to 3 fractions of 20Gy 
for T1 tumors, and to 5 fractions of 12 Gy for T2 
tumors and T1 tumors directly adjacent to the chest 
wall.
Results: Acute grade III chest wall pain was 
observed in 1 patient. Late grade III toxicity was 
limited to chest wall pain (n=2) and increased 
dyspnoea (n=2). No grade 4/5 toxicity was observed, 
but grade V toxicity could not be excluded in 9 
patients with a cardiopulmonary cause of death. 
Distant failure was the predominant cause of death, 
and cardiovascular death was not associated with 
a tumor location near the heart. No signiÀcant 
differences were observed in survival outcomes 
between the 63 patients with central and the 445 
patients with peripheral tumors. The 3-year overall 
survival rates were 64.5% and 51.1%, with median 
survival rates of 47 and 36 months, respectively 
(p=0.09). The median follow-up was 34 months for 
and 9 patients were treated with SBRT for 2 lung 
tumors. During follow up (FU) RP grade2 was 
scored according to the CTCAE 3.0. Dose volume 
histograms (DVH) of the biologically equivalent 
dose given in fractions of 2 Gy (EQD2) were 
generated using the LQ model with Ơ/ơ=3Gy. From 
the DVHs the MLD and the Vx with threshold 
doses of 5Gy-15Gy, 20Gy, 30Gy, 40Gy, and 50Gy 
were calculated. A sigmoid dose-effect model with 
parameters d50 or V50 (the dose or volume with 
a 50% probability on RP) and m (steepness of the 
curve) was Àtted to estimate the probability on RP 
as function of the MLD and each Vx separately. The 
optimal Àt for each model was determined by the 
maximum likelihood (ML). 
Results: Median FU-time was 17 months 
(range:2-54 months). The crude incidence of RP 
grade 2 was 4.25%, no grade 3 was observed. All 
RP were reported at 3-4 months after SBRT, except 
in one patient that experienced RP 1 month after 
SBRT. Statistics and optimized parameters for the 
MLD, the V
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 are given 
in Figure 1a. Figure 1b plots the dose-effect models 
MLD and the V
10
. As the MLD is highly correlated 
to the Vx, there were insufÀcient patients to assess 
which model best predicts RP. The Àtted model 
for the MLD is similar to the reported function for 
conventionally fractionated RT (d50=30.8, m=0.37) 
which was assessed on 382 patients [1].
Conclusion: For lung SBRT the incidence of RP 
grade2 is correlated to the MLD. Whether the V
x
 is 
a more sensitive predictor for RP is subject to further 
study in a larger patient cohort. [1] Seppenwoolde et 
al. IJROBP 55(3):724-35(2003) 
Keywords: stereotactic body radiotherapy, NTCP 
function, radiation pneumonitis, mean lung dose
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(56%) patients had COPD GOLD III/IV. Scans were 
reviewed by 3 radiation oncologists experienced 
in lung SABR; toxicity scores and attributes were 
assigned by consensus. 
Results: Within 6 months post-SABR, 54% of 
patients exhibited acute radiological abnormalities, 
mainly patchy or diffuse consolidation. The 
incidence of CT changes at 6, 12, 24 and 36 months 
was 56%, 73%, 87% and 99%, respectively, most 
often categorized as modiÀed conventional pattern. 
Approximately 25% of changes Àrst appeared 1 
year post-SABR and the morphology and/or severity 
continued to evolve after >2 years in 47% of lesions. 
Nearly all changes observed were considered mild 
(50%) or moderate (47%). 55% of patients with 
moderate/severe acute changes had moderate/severe 
late changes compared with 39% of patients with no/
mild acute changes (p=0.002). Treatment volume, 
GOLD score and number of fractions were not 
correlated with maximum severity of lung changes. 
ClassiÀcation of late radiological changes (modiÀed 
from Koenig) 
Term Description 
ModiÀed 
conventional 
pattern 
Consolidation, volume loss, and bronchiectasis similar 
to, but usually less extensive than, conventional 
radiation Àbrosis. Larger than the original tumor size. 
Occasionally with associated GGO 
Mass-like Àbrosis Well-circumscribed focal consolidation limited to area 
surrounding the tumor. The abnormality must be larger 
than the original tumor 
Scar-like Àbrosis Linear opacity in the region of the tumor associated 
with volume loss 
No evidence of 
increased density 
No new abnormalities. Includes patients with tumors 
that are stable, regressing or resolved, or Àbrosis in the 
position of the original tumor that is not larger than the 
original tumor 
Conclusion: Post lung SABR radiological 
changes are observed in nearly all patients. Their 
morphology, severity and size continues to evolve 
long after treatment. Careful and continued follow 
up using standardized descriptions is therefore 
necessary to monitor local tumor control. When 
there is concern over local progression the decision 
between interval imaging and invasive investigations 
will be inÁuenced by salvage options. 
Keywords: Lung changes, computed tomography, 
Stereotactic ablative radiotherapy
both groups (range 13-86 months). Three-year local 
control rates were 92.6% and 90.2% (p=0.9), and 
also no signiÀcant differences were seen for regional 
control, distant control and disease free survival 
rates.
Conclusion: Risk-adapted stereotactic radiotherapy 
in 8 fractions of 7.5Gy did not lead to an increase 
in toxicity for centrally located stage I lung tumors. 
Clinical outcomes were comparable to patients with 
peripheral lesions after SABR.
Keywords: Stereotactic radiotherapy, outcomes, 
toxicity, early stage lung cancer
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MO08.03 LATE RADIOLOGICAL 
CHANGES AFTER STEREOTACTIC 
ABLATIVE RADIOTHERAPY OF 
PRIMARY LUNG TUMORS
Max Dahele, David Palma, Frank J. Lagerwaard, 
Ben Slotman, Suresh Senan 
Radiation Oncology, VU University Medical Center/
Netherlands
Background: Stereotactic ablative radiotherapy 
(SABR) for early-stage peripheral non-small cell 
lung cancer has achieved local control rates above 
90%. Post-treatment, radiological changes on 
computed tomography (CT) are common, and can 
sometimes be difÀcult to distinguish from tumor 
progression. With limited follow up in many reports, 
and varying terminology used to describe post-
SABR changes, we report the incidence, radiological 
severity and long-term morphology of CT changes 
in patients followed for at least 2 years after SABR, 
and considered free of local tumor progression at the 
time of the analysis. 
Methods: CT-scans were evaluated from patients 
treated at VUmc between 2003 and June 2008 
provided that (1) radiological follow-up had been 
performed at our center for at least two years post-
SABR and (2) there was no deÀnite evidence of local 
progression. Patients had been treated with 8-12 non-
coplanar beams. Follow-up CT was obtained 3, 6 and 
12-months post-SABR and then every 6-12 months 
or more frequently depending on CT Àndings and 
clinical status. We standardized the description of 
lung changes (Table), and evaluated severity, timing, 
incidence, and morphology. 325 CT scans (median 5/
patient) were evaluated from 61 patients (68 lesions) 
with median follow-up 2.5 years (2-6.7 years). 34/61 
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doses at the edge of the PTV in SBRT series were 
about 73 Gy, which was sufÀcient to achieve 
about 90% local tumour control in stage I. More 
fractionated and accelerated schedules with equal 
biological doses achieve the same tumour control 
rates as SBRT. Lower, but more homogeneous 
doses to the whole PTV may be sufÀcient to achieve 
similar control rates, with the possibility to deliver 
SBRT in adapted schedules, beneÀcial to centrally 
located tumors in the vicinity of critical stuctures like 
oesophagus and great vessels.
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MO08.05 FDG-PET SUV UPTAKE AS 
A PREDICTOR OF OUTCOME IN 
STEREOTACTIC BODY RADIOTHERAPY 
(SBRT) FOR NON – SMALL CELL LUNG 
CANCER(NSCLC)
Katy Clarke1, Mojgan Taremi2, Marc Freeman2, 
Sharon Fung3, Max Dahele2, Andrea Bezjak2, 
Anthony Brade2, John Cho2, Andrew Hope2, 
Alexander Sun2 
1Radiation Oncology, Princess Margaret Hospital/
Canada, 2Department Of Radiation Oncology, 
Princess Margaret Hospital/Canada, 3Department 
Of Biostatistics, Princess Margaret Hospital/Canada
Background: To identify FDG-PET imaging metrics 
that may predict for outcomes following SBRT for 
early stage NSCLC. 
Methods: Inoperable patients with early stage 
NSCLC undergoing SBRT who had a pre treatment 
FDG-PET scan between Aug 2004-Jan 2009 were 
included. Information on histology, stage, dose, 
GTV volume, performance status, SUV
max
 pre-and 
3 months post-treatment, maximum response to 
treatment, and patterns of failure were prospectively 
collected and analyzed. SUV
max
 was analyzed as a 
continuous and dichotomized variable. 
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MO08.04 WHAT IS THE RADIATION 
DOSE NEEDED TO ERADICATE STAGE 
I NSCLC WITH STEREOTACTIC BODY 
RADIOTHERAPY (SBRT)?
Angela Van Baardwijk1, Wolfgang Tomé2, Wouter 
Van Elmpt1, Søren M Bentzen2, Bart Reymen1, Rinus 
Wanders1, Michel Öllers1, Philippe Lambin1, Dirk De 
Ruysscher1 
1Radiation Oncology, MAASTRO Clinic, Grow - 
School For Oncology And Developmental Biology, 
Maastricht University Medical Centre/Netherlands, 
2Department Of Human Oncology, University Of 
Wisconsin/United States Of America
Background: For SBRT, usually a scheme of 60 Gy 
in 3 to 5 fractions is applied, with local control rates 
around 90%. However, this dose speciÀcation is in 
one point only, and ignores possible underdosages 
at the edge of the Planning Target Volume (PTV). 
Indeed, in many series older techniques and 
calculation algorithms have been used, leading to 
real doses at the edge of the PTV of only 36 Gy in 
3 fractions. We therefore investigated the doses at 
the edge of the PTV and correlated this with local 
tumour control with the aim to shed light on the 
radiation dose needed to eradicate stage I NSCLC.
Methods: Freedom from local progression (FFLP) 
data from SBRT series for stage I NSCLC with a 
follow up of at least 30 months were obtained from 
literature and compared to accelerated high-dose 
conventional radiotherapy series from CALGB 39904 
(Bogart, J Clin Oncol 2010) and MAASTRO Clinic 
(van Baardwijk, J Clin Oncol 2010). The biological 
equivalent dose corrected for time (EQD2,T), 
assuming an Ơ/ơ of 10 Gy and Tk of 21 days, was 
calculated from the dose at the edge of the PTV. 
Results: Nineteen studies for SBRT were identiÀed; 
15 studies (901 patients) provided FFLPs for various 
prescription schemes. For each scheme the dose at the 
edge of the PTV was calculated. The two fractionated 
trials delivered a mean dose of 70 Gy/24 fractions 
(CALGB) and 75.6 Gy/42 fractions (MAASTRO). 
The mean ± SD (range) FFLP for SBRT was 83.6 ± 
13.4% (49.0-100%), with a mean EQD2,T of 73.0 ± 
13.2 Gy (50.4-99.6 Gy). The FFLP was 92.3% in the 
CALGB trial and 83.8% in the MAASTRO study, 
with an EQD2,T of 64.7 Gy and 61.9 Gy, respectively. 
No signiÀcant correlation was found between FFLP 
and the EQD2,T (p=0.16; Fig 1). 
Conclusion: The biological equivalent radiation 
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the high rates of relapse in this group may have 
implications for adjuvant treatment. 
Keywords: SBRT, NSCLC, [18F] FDG PET, 
SUVmax
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MO08.07 THE INCIDENCE OF 
HIPPOCAMPAL METASTASES IN NON-
SMALL CELL LUNG CANCER (NSCLC): 
A CONSECUTIVE POPULATION-BASED 
SERIES OF PATIENTS PRESENTING TO 
THE BRITISH COLUMBIA (BC) CANCER 
AGENCY
Chad R. Lund1, Monty Martin2, Christopher W. Lee3, 
Devin Schellenberg1 
1Radiation Oncology, British Columbia Cancer 
Agency/Canada, 2British Columbia Cancer Agency/
Canada, 3Medical Oncology, British Columbia 
Cancer Agency/Canada
Background: Brain metastases from NSCLC are 
common, but randomised trials of prophylactic 
cranial irradiation (PCI) have failed to accrue due to 
concerns about the effect of radiation on cognitive 
function. Recent radiotherapy advances permit 
hippocampal sparing (HS), which may reduce 
memory impairment. However, the incidence of 
hippocampal metastasis will dictate interest in HS-
PCI. Previous research suggests the incidence of 
failure to be 0% within the hippocampus proper 
and 8.6% within a larger hippocampus + 5mm 
(perihippocampal) volume in patients with a variety 
of primary tumours. The rate of hippocampal failure 
in NSCLC is unknown.
Methods: All patients diagnosed with NSCLC 
in 2005 who underwent brain irradiation were 
identiÀed in the BC Cancer Registry. A single 
radiation oncologist reviewed all reports and images 
of initial diagnostic brain scans, while a single 
neuroradiologist evaluated scans of all temporal lobe 
metastases. Metastases were categorised as being 
within the hippocampus, perihippocampal volume or 
elsewhere. 
Results: Of 119 patients identiÀed, 19 were excluded 
for either receiving PCI or absence of veriÀable 
reports and/or images. There were 100 patients with 
localizable brain metastases. Twenty-one patients 
had a CT scan and MRI, 1 had only MRI and 78 
patients underwent a CT scan only. In almost all 
cases the indication for imaging was to investigate 
Results: 82 pts (40 male, 42 female, median age 
71.5 median follow up 2.0 yr (range 0.74-4.64)) 
with 58 T1 lesions and 24 T2 lesions were analyzed. 
Local, regional, distant and overall relapse-free 
rates at 2 years were 90%, 92%, 83% and 72% 
respectively. Disease free survival (DFS), overall 
survival (OS) and cause speciÀc survival (CSS) at 
2 yrs was 51%, 67% and 91% respectively. Median 
SUV
max
 at baseline was 4.75 (range 0.5-23.3). In 
those patients with diagnostic pathology (n=61/82, 
74.4%), median SUV
max
 was 4.8 (range 0.5-23.3), 
in 21 pts without diagnostic pathology (15 biopsy 
contraindicated, 6 biopsy non-diagnostic) median 
SUV
max
 was 4.5 (range 0.5-16). Post treatment PET 
was obtained in 62 pts with a median SUV
max
 of 2 
(range 0.3-5.2). Median change between the pre/
post SUV
max
 was -2.55 (range-13.1 to +1.73). On 
univariate analysis pre-SBRT FDG-PET SUV
max
 
predicted for local relapse (p=0.04), distant relapse 
(p=0.001) and relapse free survival (RFS) (p=0.04). 
We dichotomized our sample around the median 
and found baseline SUV
max
 4.75 (median) was 
correlated with a higher risk of distant relapse 
(p=0.01) and poorer RFS (p=0.04). Multivariate 
analysis was carried out for RFS and only stage 
(HR 3.4, p<0.01) and only pre-treatment SUV
max
 
(HR1.09, p=0.03) remained statistically signiÀcant. 
Patients who developed any relapse (n=22) had a 
median SUV
max
 on pre treatment scan of 7.7 vs. 
4.2 months for patients without relapse. When 
analyzed as a dicotomized variable patients with 
a post-SBRT SUV
max
  median (2) had a higher 
rate of distant relapse (p=0.005). As a continuous 
variable the SUV
max
 on post treatment PET scan 
did not predict for local or distant failure but was 
predictive for regional relapse (HR 1.75, p=0.03). 
Change in SUV
max
 showed a trend for predicting 
for RFS (p=0.06) when analyzed as a continuous 
variable; patients with a larger reduction in SUV
max
 
had lower rates of distant relapse (HR 0.76, p=0.03). 
We also evaluated change in SUV
max
 (from pre- to 
post-SBRT FDG-PET-CT scan) as a dichotomized 
variable, employing the median change of -2.55 as a 
cut off. There was statistically signiÀcant association 
between greater decrease in SUV
max
 and lower rates 
of distant metastatic relapse (p= 0.03). 
Conclusion: This study showed that FDG-PET 
SUV
max
 may have a role in predicting risk of 
relapse, particularly distant metastases following 
SBRT in NSCLC. How inoperable early stage 
NSCLC patients with high SUV values should best 
be managed remains an area of investigation, but 
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in regional lung perfusion at 6 months post-RT, 
and related the degree of change to regional dose 
to generate a dose response curve (DRC). Each 
patient’s DRC was Àt to a linear model and thus 
described by its slope (% reduction in regional lung 
perfusion / Gy). Data from multiple patents were 
combined via volume-weighted average to generate 
a population DRC. The slope of the population 
DRC was compared for the population of 4 patients 
treated with a single suite of beams throughout (e.g. 
variable fraction size) vs. 51 historical patients with 
sequential Àelds, using a two-sided student’s t-test. 
Results: The slope of the population DRCs for 
reductions in regional lung perfusion for the study 
group (variable fraction daily size) was 0.39, vs. 1.08 
in the historical patients (p=0.0004). 
Conclusion: Patients treated with techniques that 
expose the lung to lower daily fractions (e.g. the use 
of a single suite of beams throughout therapy) appear 
to have lesser degrees of dose-dependent radiation-
induced reductions in regional perfusion. 
Supported in part by NIH grant RO1-CA69579. 
Keywords: RADIATION, Perfusion
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MO08.09 INDIVIDUALISED 
ACCELERATED RADIOTHERAPY 
(INDAR) IMPROVES SURVIVAL OF 
PATIENTS WITH STAGE III NSCLC: A 
PROSPECTIVE POPULATION-BASED 
STUDY
Dirk De Ruysscher1, Jessie Steevens2, Anita 
Botterweck3, Bart Reymen4, Angela Van Baardwijk4, 
Rinus Wanders3, Jacques Borger3, Anne-Marie 
Dingemans5, Gerben Bootsma6, Cordula Pitz7, R 
Lunde7, Wiel Geraedts8, Philippe Lambin1 
1Department Of Radiation Oncology (MAASTRO), 
Grow, Maastricht University Medical Centre/
Netherlands, 2Comprehensive Cancer Center The 
Netherlands, Location Maastricht/Netherlands, 
3MAASTRO Clinic/Netherlands, 4Radiation 
Oncology, MAASTRO Clinic/Netherlands, 
5Pulmonology, Maastricht University Medical 
Center/Netherlands, 6Pulmonology, Atrium Mc 
Parkstad/Netherlands, 7Pulmonology, Laurentius 
Ziekenhuis/Netherlands, 8Pulmonology, Orbis Mc/
Netherlands
Background: Sequential chemotherapy and INDAR 
resulting in promising survival with low toxicity 
neurological symptoms. The mean and median 
number of metastases per patient was 2.8 and 2, 
respectively. Six percent of patients had metastases 
within the hippocampus proper and 12% within the 
perihippocampal volume. 
Conclusion: The high rate of hippocampal and 
perihippocampal metastases in patients with NSCLC 
may preclude clinical studies of HS-PCI.
Keywords: Non-small cell lung cancer, 
Hippocampus, prophylactic cranial irradiation
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MO08.08 THE IMPACT OF FRACTION 
SIZE ON RADIATION-INDUCED 
REDUCTIONS IN REGIONAL LUNG 
PERFUSION
Michael V. Lawrence1, David Fried1, Dorothy 
Riguera1, Terence Wong2, Ronald Jaszczak2, Shiva 
Das2, Sumin Zhou3, Lawrence B. Marks1 
1Radiation Oncology, University Of North Carolina 
At Chapel Hill/United States Of America, 2Duke 
University/United States Of America, 3University Of 
Nebraska Medical Center/United States Of America
Background: Radiation (RT)-induced lung injury 
is common in patients with thoracic tumors. Our 
previous studies have shown that radiation causes a 
reduction in regional lung perfusion at 6 months post-
radiotherapy. The vast majority of patients in prior 
studies were treated conventionally with sequential 
“shrinking Àeld boosts”; e.g. 44 Gy via large AP/PA 
Àelds followed by reduced off-cord oblique boosts to 
60-70Gy. Thus, most of the affected lung was exposed 
to daily fractions of ~ 2 Gy. With the movement away 
from elective nodal irradiation, patients are often 
treated with a single suite of beams (conformal or 
IMRT) throughout the course of RT. This results in the 
lung exposed to a more variable daily dose (e.g. 0.2-
2 Gy). We herein quantify the degree of RT-induced 
reductions in regional lung perfusion in patients 
treated with these newer approaches, and compare the 
results to that of our prior experience. 
Methods: Patients receiving thoracic RT were 
enrolled onto an IRB-approved clinical study (all 
provided informed consent) that included pre- and 
6 months post-RT thoracic single photon emission 
computed tomography (SPECT) scans to assess 
pulmonary perfusion. Pre-RT computed tomography 
(CT) scans were used to calculate radiation dose. 
Using image registration, we quantiÀed changes 
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Conclusion: A clear increase in survival occurred 
with sequential INDAR alone and concurrent chemo-
INDAR.
Keywords: Non-small cell lung cancer, 
Individualised treatment, Radiotherapy, Stage III
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MO08.11 COMPARISON OF ELECTIVE 
NODAL IRRADIATION (ENI) VS. 
INVOLVED-FIELD RADIOTHERAPY 
(IFRT) FOR STAGE III NON-SMALL-
CELL LUNG CANCER: CLINICAL 
OUTCOMES AND TOXICITIES
Su Ssan Kim1, Geumju Park1, Si Yeol Song1, 
Jungshin J. Lee2, Eun Kyung Choi1 
1Radiation Oncology, Asan Medical Center/Korea, 
2Medical Oncology, Asan Medical Center/Korea
Background: To investigate the clinical outcomes 
and toxicities of involved-Àeld radiotherapy (IFRT) 
compared with elective nodal irradiation (ENI) in 
patients with stage III non-small-cell lung cancer 
(NSCLC).
Methods: A total of consecutive 263 patients (133 
ENI vs. 130 IFRT) of stage
III NSCLC who received deÀnitive RT with or 
without chemotherapy from 1999 to 2007 were 
reviewed. 3D-CRT was delivered 1.8 Gy per fraction 
to 64 to 70 Gy for ENI, and 2.2 Gy per fraction to 
66 Gy for IFRT. Only the primary gross tumor and 
lymph nodes involved with tumor either by biopsy or 
radiologic criteria were included in the clinical target 
volume for IFRT. Isolated elective nodal failure 
(ENF) was deÀned as recurrence in an initially 
uninvolved lymph node in the absence of in-Àeld 
progression or distant failure.
Results: The 2-year overall survival, progression-
free survival, and local control rates were 35.3%, 
35.2%, 48.7% for ENI and 32.3%, 36.5%, 58.2% 
for IFRT, respectively. This differences were not 
statistically signiÀcant. No isolated ENF was 
identiÀed in IFRT. The grade 3 radiation esophagitis 
in patients with IFRT was lower than in patients with 
ENI (8% ENI vs. 1% IFRT, p=0.005).
Results: The 2-year overall survival, progression-
free survival, and local control rates were 35.3%, 
35.2%, 48.7% for ENI and 32.3%, 36.5%, 58.2% 
for IFRT, respectively. This differences were not 
statistically signiÀcant. No isolated ENF was 
identiÀed in IFRT. The grade 3 radiation esophagitis 
(van Baardwijk, J Clin Oncol 2010), was introduced 
in clinical routine from 2006. The same concept in 
concurrent chemo-radiotherapy schedules became 
standard in 2008. We hypothesised that these more 
intensive treatment schedules should lead to improved 
overall survival (OS) rates and that this should be 
reÁected in the population of South- and Middle 
Limburg (Maastricht Cancer Registry, MCR), The 
Netherlands.
Methods: All patients with a pathological diagnosis 
of NSCLC in the MCR and with a stage III (UICC 
6th Edition) from 2002 to 2008 were included. MCR 
covers > 98 % of all lung cancer cases. Staging: whole 
body FDG-PET scan and brain CT or MRI. Treatment: 
Period 1: 2002-2005: sequential 3 cycles cisplatin/
carboplatin-gemcitabine and chest radiotherapy (60 Gy/ 
30 fractions/ 6 weeks); Period 2: 2006-2007 3 cycles 
cis(carbo)platin-gemcitabine followed by IDAR (mean 
dose of 64.8 Gy/ 36 fractions/ 3.6 weeks = biological 
equivalent of 82 Gy/ 41 fractions/ 8.2 weeks); Period 3: 
2008 concurrent cisplatin-vinorelbine and IDAR (mean 
dose of 65 Gy/ 40 fractions/ 5.5 weeks = biological 
equivalent of 74 Gy/ 36 fractions / 7.4 weeks). Minimal 
follow-up of all patients is 2 years.
Results: 1002 patients with stage III were diagnosed, 
24.3 IIIA and 47.3 % IIIB. Mean age: 68 ± 10.3 years 
(SD) (r34-90); 71.1 % men, 28.9 % females. The 
number of patients per year diagnosed with stage III 
NSCLC remained constant over de years : 2002 : 
146, 2003 : 144, 2004 : 144, 2005 : 147, 2006 : 137, 
2007 : 140, 2008 : 144. Age, histology and Charlson 
co-morbidity distribution remained constant over the 
time periods. The proportion of patients referred for 
treatment with curative intent increased over time: 
2002 47.3 %, 2003 48.6 %, 2004 50.7 %, 2005 51.7 
%, 2006 54.7 %, 2007 51.4 %, 2008 56.3 %. Taken all 
three periods together, the median OS of all patients 
was 11.6 months (10.5-12.7), for curative intent therapy 
17.3 months (15.6-19.0) and for palliative treatment 6.8 
months (5.6-7.7), p<0.001. Median and two-year OS 
increased over the different time-periods: Period 1: 16.4 
months (14.3-18.5), 2-year 24 %; Period 2: 18.1 months 
(13.9-22.6), 2-year 40.8 %; Period 3: not reached 
median OS, 2-year 51.9 %; p<0.001 (Figure 1). 
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have malignant pleurisy. A predictive model was 
developed using backwards Cox regression analysis 
(excluding variables with p >.20) with R 2.12.0 and 
the Design library. The Ànal model was internally 
validated using a 100 times bootstrap procedure, to 
check whether variables were consistently selected. 
Potential predictors for survival were sex, age, T 
and N-stage, intake WHO-PS, number of positive 
lymph nodes on PET, smoking status, lung function, 
chemotherapy, gross tumor volume, radiotherapy 
dose and overall treatment time. Missing values were 
generally less than 10% and patients with missing 
values had mostly 1 or 2 values missing. These 
values were replaced with regression based multiple 
imputation.
Results: Of all patients, 374 had died at the time 
of the analysis. Median survival time was 16 
months, survival at 2 years was 33%. Backwards 
Cox regression of possible predictors resulted in 
the elimination of age, smoking status, N-stage and 
lung function from the model. GTV could only be 
modeled non-linearly. Concordance statistic for the 
Ànal model was 0.63. A nomogram was constructed 
based on the model in order to predict an individual 
patient’s probability for 2, 3 and 5-year survival 
(Àgure 1).
Conclusion: The predictive model for overall 
survival of stage III lung cancer patients highlights 
the importance of patient, clinical and treatment 
variables. A nomogram for prediction of overall 
survival has been developed. This tool could be 
useful for treatment individualization and design 
of clinical trials. References: Dehing-Oberije 
C, De Ruysscher D, Petit S, Van Meerbeeck J, 
Vandecasteele K, De Neve W, Dingemans AM, 
El Naqa I, Deasy J, Bradley J, Huang E, Lambin 
P. Development, external validation and clinical 
usefulness of a practical prediction model for 
radiation-induced dysphagia in lung cancer patients. 
Radiother Oncol. 2010 Dec;97(3):455-61. 
in patients with IFRT was lower than in patients with 
ENI (8% ENI vs. 1% IFRT, p=0.005).
Conclusion: IFRT did not result in a signiÀcant 
amount of elective nodal failure. IFRT also did 
not compromise survival and local control while 
signiÀcantly decreasing esophageal toxicity when 
compared to ENI. Therefore, IFRT may help 
improve local control and survival by allowing 
higher dose to the primary tumor and involved nodal 
regions while minimizing the toxicity and increasing 
patients’ compliance to concurrent chemotherapy.
Keywords: Non-small cell lung cancer, 
Radiotherapy, elective nodal irradiation
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MO08.12 A PRACTICAL PREDICTION 
MODEL FOR OVERALL SURVIVAL 
FROM STAGE III LUNG CANCER: 
A FIRST STEP TOWARDS DOSE 
INDIVIDUALIZATION
Cary Oberije1, Ruud Houben1, Dirk De Ruysscher1, 
Anne-Marie C. Dingemans2, Gerben Bootsma3, 
Wiel Geraedts4, R. Lunde5, Cordula Pitz5, Philippe 
Lambin1 
1Department Of Radiotherapy, Maastricht 
Radiation Oncology (MAASTRO), Grow - School 
For Oncology And Developmental Biology, 
Maastricht University Medical Centre/Netherlands, 
2Department Of Pulmonology, Grow - School 
For Oncology And Developmental Biology, 
Maastricht University Medical Centre/Netherlands, 
3Department Of Pulmonology, Atrium Mc Parkstad/
Netherlands, 4Department Of Pulmonology, Orbis 
Mc/Netherlands, 5Department Of Pulmonology, 
Laurentius Ziekenhuis/Netherlands
Background: Most models regarding outcome of 
treatment for lung cancer are prognostic in nature. 
Recently, a practical and validated prediction 
model for radiation-induced dysphagia has been 
published (Dehing-Oberije, 2010). We aim to design 
a predictive model for overall survival for patients 
with stage III lung cancer.
Methods: Patient, clinical, treatment and survival 
data for 492 stage III (according to UICC version 
6) lung cancer patients were available for analysis. 
Patients were included in the analysis if they 
(1) were treated with radiotherapy with curative 
intent, (2) had not received surgery, (3) had no 
other tumours in the past 5 years and (4) did not 
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Results: 
ROC area ClassiÀer Training 
dataset 
Cross-
Validation 
procedure 
Prospective 
Validation 
Set 
Naïve Bayes .815 .777 .69 
Bagging .997 .79 .727 
Bayesian Networks .813 .764 .756 
Boosting .824 .614 .756 
Penalized Logistic 
regression 
.82 .772 .752 
Radial Basis Function 
(RBF) network 
.83 .739 .722 
Random Forest .997 .653 .721 
Linear Support Vector 
Machines (SVM) 
.771 .783 .722 
LASSO .82 .76 .732 
Equal-voting of all .77 
Physicians’ predictions .53 
The ten predictive models (classiÀers) performed 
relatively similar on the prospective dataset (see 
Table 1 and Figure 1). However, the combined model 
performed better than any individual model and 
achieved an area under the curve of .77. Physicians’ 
predictions resulted in area-under-the-curve of .53. 
Conclusion: Combining different prediction models 
into one Ànal model worked well and produced 
superior performance than any individual model. The 
approach was successfully validated and predicted 
acute dysphagia better than physicians. Therefore, 
this approach could be used to identify patients at 
high/low risk for developing dysphagia and provide 
assistance in treatment decision making in daily 
clinical practice. 
Keywords: Treatment individualization, nomogram, 
Overall survival, Prediction model
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MO08.13 COMBINING THE 
PREDICTIONS FOR RADIATION-
INDUCED DYSPHAGIA IN LUNG-
CANCER PATIENTS FROM MULTIPLE 
MODELS IMPROVES THE PROGNOSTIC 
ACCURACY OF EACH INDIVIDUAL 
MODEL
Georgi Nalbantov, Cary Oberije, Philippe Lambin, 
Dirk De Ruysscher, André L.A.J. Dekker 
Dept. Of Radiation Oncology (MAASTRO), Grow - 
School For Oncology And Developmental Biology/
Netherlands
Background: Acute dysphagia is a distressing 
dose-limiting toxicity occurring frequently 
during concurrent chemo-radiation or high-dose 
radiotherapy for lung cancer. It can lead to treatment 
interruptions and thus jeopardize survival. A number 
of predictive factors have been identiÀed. It has been 
suggested in the statistical literature that combining 
the predictions of multiple prediction models into 
one Ànal model could improve the accuracy of each 
individual model. We have therefore developed and 
validated such a combined model to predict severe 
acute dysphagia. 
Methods: Clinical data from 469 inoperable lung 
cancer patients, treated with curative intent, were 
collected prospectively. Input variables included 
age, gender, World Health Organization performance 
status, mean and maximum esophagus dose, 
overall treatment time and concurrent/sequential 
chemotherapy. The endpoint for analysis was acute 
dysphagia (grade >= 3 according to CTCAEv3.0). 
We have developed and validated ten prediction 
models for severe acute radiation-induced dysphagia, 
which are based on ten popular data-analysis 
methods. We subsequently combined the predictions 
of these models into one Ànal model using the equal-
voting rule. Model evaluation was based on the area 
under the receiver-operator-characteristic (ROC) 
curve, which was estimated via a cross-validation 
procedure. Model performance was validated on a 
prospective dataset of 138 patients and compared to 
physicians’ predictions. 
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average PD of 75.1Gy. The table shows the impact of 
treatment technique and PD on mean doses to PTV
inc
 
and PTV
tot
, on corresponding TCPs and p-values 
comparing (MLD-escalated ) IMRT to baseline 
3D-CRT. 
Baseline MLD-escalated 
3D-CRT IMRT p-values IMRT p-values 
PTV
inc
 
D
mean
 45.5 Gy 40.2 Gy 0.003 45.6 Gy 0.96 
D
95
 17.7 Gy 11.3 Gy 0.053 12.6 Gy 0.12 
TCP 31% 21% 0.008 25% 0.06 
PTV
tot
 
D
mean
 62.4 Gy 62.3 Gy 0.76 71.0 Gy <0.0001 
D
95
 38.3 Gy 34.8 Gy 0.041 39.0 Gy 0.740 
TCP 57% 55% 0.044 61% 0.055 
The 10% higher risk of isolated nodal failure after 
IMRT is highly statistically signiÀcant, but the 
decrease in local control becomes of borderline 
signiÀcance when considering the TCPs for PTV
tot
. 
MLD-escalated IMRT results in signiÀcantly higher 
D
mean
 and potentially superior chance of local control. 
Conclusion: In one out of three LA-NSCLC 
patients, PET underestimates the actual nodal disease 
extension. Due to reduced INI, using IMRT for IF-
RT entails a statistically signiÀcantly higher risk of 
isolated local recurrence. Our data however suggest 
that this negative impact may be counteracted by the 
potential of isotoxic dose escalation, which in turn 
may positively inÁuence loco-regional control rates. 
Further prospective evaluation of IF-RT using IMRT 
is warranted. 
Keywords: intensity-modulated radiotherapy, 
locally-advanced non-small cell lung cancer, 
involved-Àeld radiotherapy, 18F-deoxyglucose 
positron emission tomography
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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MO08.14 PET-BASED PLANNING IN LA-
NSCLC: SHOULD WE RE-CONSIDER 
ELECTIVE NODAL IRRADIATION IN 
THE IMRT ERA?
An Nulens1, Amr G. Mousa2, Gilles Defraene1, Sigrid 
Stroobants3, Walter De Wever4, Frank Van Den 
Heuvel1, Yolande Lievens1, L. Leuven Lung Cancer 
Group1 
1Radiation Oncology, University Hospitals Leuven/
Belgium, 2Radiation Oncology, KFSH&RC/
Saudi Arabia, 3Radiation Oncology, Universitair 
Ziekenhuis Antwerpen/Belgium, 4Radiology, 
University Hospitals Leuven/Belgium
Background: To compare involved-Àeld 
radiotherapy (IF-RT) in locally-advanced non-small 
cell lung cancer (LA-NSCLC), delivered with 3D 
conformal (3D-CRT) and intensity-modulated 
(IMRT) radiotherapy. The risk of loco-regional 
relapse was analysed using incidental nodal 
irradiation (INI) parameters and tumour-control 
probability (TCP) models. 
Methods: Thirty-one LA-NSCLC patients with 
pathology-proven mediastinal involvement were 
retrospectively retrieved from the Leuven Lung 
Cancer Group database. Involved nodes were 
compared on mediastinoscopy and 18F-deoxyglucose 
positron emission tomography (PET) scans. Patients 
with one or more nodes positive on pathology 
but (falsely) negative on PET were selected for 
further analysis. False-negative nodes on PET were 
deÀned ‘incidental nodes’ and used to delineate 
the incidental clinical and planning target volumes 
(CTV
inc
, PTV
inc
). The sum of PET-based PTV and 
PTV
inc
 formed the total PTV (PTV
tot
). Prescribed 
dose (PD) in baseline 3D-CRT and IMRT plans was 
66Gy/2Gy, isotoxic escalated IMRT plans delivered 
the same mean lung dose (MLD) as the baseline 
3D-CRT plan. Mean dose (D
mean
), dose to 95% of 
the volume (D
95
) and TCPs were analysed for PTV
inc
 
and PTV
tot
. All plans were calculated using Eclipse 
(Varian) software with a pencil beam (PB) algorithm 
and recalculated using a collapsed cone algorithm 
(AAA). TCP models being available for PB only, 
these data are presented. A two-parameter (D
50
 and 
Ƣ
50
) TCP model based on Poisson statistics was used. 
Results: In 11 patients (35%), false negative 
nodes were detected, resulting in a sensitivity and 
speciÀcity for PET at the nodal level of 69% and 
89% res. MLD-escalated IMRT-plans resulted in an 
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PFS was 9m (95% CI:3.5-11), and the median OS 
has not been reached. No grade  2 neuropathy 
or hematologic/gastrointestinal toxicities were 
observed. One pt experienced transitory cerebral 
ischemia, and one had a colon perforation. High, but 
reversible, BP ( 150/100 or 20 mmHg increase in 
diastolic BP from baseline) was observed in 70% of 
the evaluable pts. SigniÀcant proteinuria (3+ or 4+) 
was observed in 2 pts.
Conclusion: Adding bevacizumab to metronomic 
chemotherapy is well tolerated in adv NSCLC pts. 
Preliminary efÀcacy data is encouraging. Updated safety 
and efÀcacy data of this ongoing trial will be presented.
Keywords: Advanced NSCLC, Metronomic 
chemotherapy with bevacizumab, Phase II clinical trial
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MO09.02 SUNITINIB PLUS ERLOTINIB 
FOR THE TREATMENT OF ADVANCED 
NSCLC: SUBSET ANALYSIS OF EAST 
ASIAN PATIENTS PARTICIPATING IN A 
PHASE III TRIAL
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MO09.01 PRELIMINARY RESULTS OF 
A PHASE II STUDY OF METRONOMIC 
CHEMOTHERAPY (MC) WITH 
BEVACIZUMAB (B) IN ADVANCED (ADV) 
NON-SMALL CELL LUNG CANCER 
(NSCLC)
Francisco Robert, Mark Womack, Mollie Deshazo, 
Alan Cantor, Mary Jerome, Debi Miley 
Comprehensive Cancer Center, University Of 
Alabama At Birmingham/United States Of America
Background: Preclinical studies have demonstrated 
dramatic control of tumor growth using protracted 
low dose chemotherapy (MC), also resulting in 
signiÀcant apoptosis of endothelial and tumor 
cells. In order to enhance the antiangiogenic effect 
of MC, we initiated a phase II study using MC 
doses of gemcitabine (G) and paclitaxel (P) in 
combination with B, with the primary objective 
of having a progression-free survival (PFS) of 
30% over historical data (ECOG 4599-6.4m). 
Secondary objectives include: safety, objective 
response rate (ORR) and overall survival (OS). 
Exploratory correlations of the kinetics of several 
angiogenic biomarkers and clinical parameters 
(tumor cavitation, blood pressure [BP], proteinuria) 
are evaluated. 
Methods: Chemo-naive, stage IIIb/IV, non-
squamous NSCLC patients (pts) with performance 
status 0-1, and without active brain metastases 
(mets) were treated with MC doses (weekly x 3, 
4-week cycle) of P (80 mg/m2/wk) and G (200-
300 mg/m2/wk) and B (10 mg/kg q 2 wks). After 6 
cycles, pts were placed on B maintenance. Response 
was determined by CT scans after every 2 cycles 
(RECIST), and toxicity was assessed with CTCAE.
Results: Four of the 26 pts enrolled are not evaluable 
(1- transferred care; 1- ineligible, and 2- too early 
for evaluation), and one pt was not evaluable for 
response because of early death due to a fatal colonic 
perforation. Baseline characteristics include: median 
age, 57 years; female, 64% never smokers, 16%; loss 
of weight, 40%; and brain mets, 16%. Sixteen pts 
had an objective response (CR-1; PR-15), and 3 pts 
each had stable and progressive disease. The median 
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[grade 3/4: 2.0%]) and rash (61.5% [grade 3/4: 
9.6%] vs. 54.9% [grade 3/4: 3.9%], in the sunitinib 
plus erlotinib vs. erlotinib alone arms, respectively). 
Hematologic serious AEs were uncommon (1 case 
of anemia in each study arm). Post-study treatments 
were balanced between study arms. Updated data 
will be presented.
Conclusion: Sunitinib plus erlotinib vs. erlotinib 
alone was associated with signiÀcantly longer OS, 
greater ORR, and a trend toward longer PFS in the 
subgroup of East Asian patients participating in 
this trial. AEs were more frequent and severe in the 
sunitinib arm and reÁect the known toxicity proÀles 
of erlotinib and sunitinib. These data indicate that 
additional studies of sunitinib plus erlotinib in 
patients with advanced NSCLC may be warranted. 
Keywords: erlotinib, Non-small cell lung cancer, 
phase III, sunitinib
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MO09.03 THE COMBINATION OF 
ERLOTINIB/BEVACIZUMAB IN NEVER-
SMOKERS WITH ADVANCED LUNG 
ADENOCARCINOMA: SOUTHWEST 
ONCOLOGY GROUP (SWOG) TRIAL 0636
Howard West1, James Moon2, Fred R. Hirsch3, 
Phillip Mack4, Antoinette Wozniak5, Mary W. 
Redman2, David R. Gandara4 
1Medical Oncology, Swedish Cancer Institute/
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University Of Colorado/United States Of America, 
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Background: Never-smokers with advanced lung 
adenocarcinoma have emerged as a potentially 
relevant clinical subpopulation enriched for a higher 
probability of clinical beneÀt from epidermal growth 
factor receptor (EGFR) tyrosine kinase inhibitors 
(TKIs). Such patients have a high proportion 
of activating mutations and/or copy number 
abnormalities in the EGFR gene associated with 
favorable clinical outcomes with EGFR TKI-based 
therapy. Based on these results and the potential for 
increased clinical activity conferred by addition of 
bevacizumab to erlotinib, SWOG initiated a phase 
II trial (S0126) to test this combination in never-
smokers with advanced lung adenocarcinoma.
Background: Sunitinib is an oral multitargeted 
tyrosine kinase inhibitor of VEGFRs, PDGFRs, KIT 
and other receptors. A recent phase III double-blind 
trial (SUN 1087) investigated sunitinib plus erlotinib 
vs. placebo plus erlotinib in NSCLC patients after 
failure of chemotherapy. A signiÀcant increase 
in overall survival (OS) was not demonstrated. 
However, a signiÀcant improvement in progression-
free survival (PFS) and a greater objective response 
rate (ORR) were observed in the sunitinib plus 
erlotinib arm vs. erlotinib alone. Since subset 
analyses in several trials indicate tumors in Asian 
patients may be more responsive to antiangiogenic 
agents, we investigated the outcome for the subset of 
patients of East Asian descent participating in SUN 
1087.
Methods: Patients (18 years; ECOG PS 0 or 
1, previously treated with 1 or 2 chemotherapy 
regimens, including 1 platinum-based) had 
recurrent NSCLC and were eligible for erlotinib 
treatment. Patients were randomized (1:1) to 
sunitinib 37.5 mg/day plus erlotinib 150 mg/day, 
or placebo plus erlotinib 150 mg/day, stratiÀed by 
prior bevacizumab use, smoking history, and EGFR 
expression. The primary endpoint was OS. Key 
secondary endpoints included PFS, ORR, safety, and 
patient-reported outcomes.
Results: Of the 960 patients randomized, 103 
(10.7%) were of East Asian descent: 52 in the 
sunitinib plus erlotinib arm and 51 in the placebo 
plus erlotinib arm (n=92 [9.6%] randomized in East 
Asia, n=7 [0.7%] in North America and n=4 [0.4%] 
in EU/South America); 67.0% were male, 40.8% 
were never smokers, 69.9% had non-squamous 
histology, and 90.3% had stage IV disease. Mean 
number of cycles started (range) was 6.0 (1–26) for 
sunitinib plus erlotinib and 4.0 (1–30) for erlotinib 
alone. Interim median OS was signiÀcantly longer 
with sunitinib plus erlotinib vs. erlotinib alone: NR 
months (95% CI 13.4, NR) vs. 9.4 months (95% CI 
7.2, 15.4), P=0.0042. The data did not indicate that 
the difference in never smokers between study arms 
(sunitinib plus erlotinib n=23, erlotinib alone n=19) 
confounded the treatment effect on OS (Cox model). 
ORR was markedly greater in the sunitinib arm 
(38.5% vs. 13.7%, P=0.0083), and one conÀrmed 
complete response was observed with sunitinib. 
Median PFS also favored the sunitinib plus erlotinib: 
31.2 weeks vs. 15.2 weeks (HR [95%CI]: 0.723 
[0.451, 1.161], P=0.0889). The most frequent all-
causality non-hematologic adverse events (AEs) 
were diarrhea (94.2% [grade 3: 15.4%] vs. 52.9% 
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MO09.04 CEDIRANIB, A VEGF 
RECEPTOR 1, 2 AND 3 INHIBITOR, AND 
PEMETREXED IN PATIENTS (PTS) WITH 
RECURRENT NON-SMALL CELL LUNG 
CANCER (NSCLC)
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Wozniak3, Deborah Hackstock3, Wei Chen3, Cathy 
Galasso3, Angelika Burger3, Patricia Lorusso3, Percy 
Ivy4, Martin J. Edelman5 
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Background: The role of anti-VEGF therapy in 
recurrent NSCLC is unclear. We are currently 
conducting a phase II trial evaluating cediranib, an 
oral inhibitor of VEGFR 1,2 and 3, and pemetrexed 
in recurrent NSCLC pts who may or may not have 
previously received bevacizumab. 
Methods: Pts with progressive NSCLC following 
1 or 2 prior regimens and with any histologic 
sub-type were eligible. Pts on anti-coagulants and 
with treated brain mets were allowed. Pts received 
cediranib 30mg daily. 1 week after starting cediranib, 
pts received pemetrexed 500 mg/m2 every 21 days. 
The study consists of two cohorts- A (no prior 
bevacizumab) and B (prior bevacizumab). Planned 
accrual is 37 pts each cohort. Accrual to cohort A is 
completed. Consenting pts underwent blood draw 
for circulating tumor cells (CTCs) and circulating 
endothelial cells (CECs) before therapy, 1 week after 
cediranib was commenced, and after 1 cycle of the 
combination. 
Results: 38 pts were enrolled in cohort A. Median 
age- 62, males- 50%, ever smokers- 92%, squamous- 
18% (7 patients), brain mets- 34%, 2 prior regimens- 
42%. Median cycles- 4 (range- 0-26). Grade 3/4 
toxicities- neutropenia- 14%, febrile neutropenia- 
5%, fatigue-22%, diarrhea- 14%, infection- 8%. 
One patient each developed pulmonary hemorrhage, 
cardiac ischemia and cerebrovascular event. Three 
deaths were deemed related to drug related toxicities. 
Response rate is 29% (95% CI- 17%-45%) and 
disease control rate (response+stable disease) is 74% 
(95% CI- 58%-85%). Median PFS is 5.6 (95% CI- 
4.4- 6.8) months and median survival is 11 (95% CI- 
Methods: A total of 85 eligible patients were 
enrolled and received protocol-based treatment. 
Patients received erlotinib 150 mg PO daily 
and bevacizumab 15 mg/kg IV q21 days until 
progression or prohibitive toxicity. Tumor tissue 
submission for assessment of molecular markers 
was mandated. EGFR mutations were assessed by 
microdissection and sequencing; EGFR copy number 
abnormalities were assessed using the Colorado 
FISH scoring system.
Results: The median age was 61.3 (range 31.2- 
84.1); 87% treatment-naive; 66% are female; 97% 
had a performance status of 0/1; 66% of patients 
were Caucasian, and 25% were Asian. The RECIST 
response rate among 53 patients with measurable 
disease was 47%. With a median follow-up in 
patients still alive of 12 months (mo) (range 0-35 
mo), the estimated progression-free survival (PFS) is 
8 mo. Toxicity consisted primarily of rash, diarrhea, 
and hypertension; there have been no treatment-
related deaths and a single case of grade 3 pulmonary 
hemorrhage. In preliminary biomarker analysis, 49% 
of patients were EGFR FISH-positive (17 of 35). 
EGFR mutations were observed in 30% (10 of 33). 
EGFR FISH-positivity correlated with improved 
PFS (p=0.01, HR 0.35 [90% CI: 0.16-0.75]. EGFR-
mutation-positive patients had a signiÀcantly better 
RECIST response rate (47% vs 26%; p = 0.03). 
Patients with a favorable marker (FISH-positivity 
and/or EGFR mutation) had a median PFS of 20 
months compared 6 months for those with no 
favorable marker (p=0.02)
Conclusion: The combination of erlotinib 
with bevacizumab in never-smokers with lung 
adenocarcinoma is associated with a very 
encouraging clinical efÀcacy and modest toxicity in 
a population that was not molecularly selected. The 
addition of bevacizumab did not appear to adversely 
affect erlotinib activity in patients subsets (EGFR 
mutant; EGFR FISH+) expected to beneÀt from an 
EGFR-TKI.
Keywords: Adenocarcinoma, Never-smoker, 
bevacizumab, erlotinib
Copyright © 2011 by the International Association for the Study of Lung Cancer S553
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
And Innovation Hospital/Japan, 12Osaka Medical 
College Hospital/Japan, 13Jcog Data Center, 
National Cancer Center/Japan, 14Data Center, 
West Japan Oncology Group (wjog)/Japan, 
15Kyoto University School Of Public Health/Japan, 
16Department Of Medical Oncology, Kinki University 
Faculty Of Medicine/Japan, 17National Cancer 
Center Hospital/Japan
Background: Tri-weekly DTX is considered one 
of the standard treatment regimens for elderly 
patients with advanced NSCLC, previously reported 
in WJTOG9904 trial. To investigate whether the 
addition of a modiÀed administration schedule of 
CDDP might improve the survival in these patients, 
we previously conducted a phase III trial comparing 
weekly DP with weekly DTX (JCOG0207). 
Concerning ethically, the trial was terminated early 
due to the strong interaction that weekly DP might 
be beneÀcial for subgroup of age between 70-74 
years. Therefore, we brushed up on a phase III trial 
comparing weekly DP with tri-weekly DTX in 
elderly patients with advanced NSCLC. 
Methods: Eligibility criteria in this trial were as 
followed: chemotherapy-naive; unÀt for bolus P 
administration; stage III/IV or relapsed NSCLC 
after completely surgical resection; age70 years 
old; PS (ECOG) 0-1. Patients were randomized to 
receive either weekly DP or tri-weekly DTX by the 
minimization method, balancing for study site, age 
(<75/75), and stage (III/IV). Weekly DP comprised 
administration of DTX (20 mg/m2) and CDDP (25 
mg/m2) intravenously on days 1, 8, and 15 every 4 
weeks. In tri-weekly DTX alone, DTX (60 mg/m2) 
was administered intravenously on day 1 every 3 
weeks. The primary endpoint was overall survival 
(OS). The planned sample size was 190 pts in each 
arm, to provide an 80% power to detect a 0.752 
hazard ratio for weekly DP to tri-weekly DTX in 
regard to the OS, and a 5% one-sided alpha.
Results: Between October 2008 and September 
2010, 276 patients were randomized (DTX/DP: 
137/139). The Àrst planned interim analysis was 
performed on 221 assessable patients (DTX/DP: 
108/113, <75/75: 22/78%, male/female: 70/30%, 
PS 0/1: 35/65%, III/IV or relapse: 32/68%). 
Information time, deÀned as the proportion of 
interim events to planned events, was 24% (73/304). 
The median survival times (MST) of the weekly 
DP and tri-weekly DTX groups were 13.3 and 17.3 
months, respectively (hazard ratio [95% C.I.]: 1.557 
[0.976-2.485]). The predictive probability that 
5.8- 16.6) months. EfÀcacy parameters for squamous 
versus non-squamous patients were- Response rate- 
0% vs. 35%, PFS- 3.7 vs. 5.7 months, survival 5.2 
vs. 11.5 months. Among 18 pts with available data, 
60% had decrease in CTCs and 31% of the patients 
had declines in CECs. There was no signiÀcant 
association between declines in CTCs or CECs and 
PFS. 
Conclusion: 1.The combination of cediranib and 
pemetrexed is tolerable. 2. The response rate of 29% 
(35% in non-squamous patients) and the median PFS 
of 5.6 (5.7 in non-squamous patients) months are 
very promising. 3. Though the numbers are small, 
the addition of a VEGF inhibitor cediranib does not 
reverse the resistance of squamous cell NSCLCs to 
pemetrexed 4. Enrollment to cohort B is ongoing. 
Keywords: cediranib, Pemetrexed, recurrent 
NSCLC
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MO09.06 RANDOMIZED PHASE 
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SMALL CELL LUNG CANCER (NSCLC): 
RESULTS OF AN INTERGROUP TRIAL 
OF JCOG0803/WJOG4307L
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Background: The 2004 ASCO guidelines 
recommended a platinum-based doublet 
chemotherapy for the treatment of Àt patients with 
advanced non-small cell lung cancer (NSCLC) and a 
monotherapy for elderly patients. Subgroup analyses 
of elderly patients within randomized controlled 
trials suggested that a platinum-based doublet might 
increase survival in elderly. Therefore, we conducted 
a phase III trial comparing the carboplatin -weekly 
paclitaxel doublet to monotherapy in elderly patients 
with advanced NSCLC.
Methods: Patients aged 70 to 89 years, PS 0-2, 
with locally advanced or metastatic NSCLC were 
randomized between carboplatin-weekly paclitaxel 
(4 cycles, total duration 16 weeks) and vinorelbine 
or gemcitabine monotherapy (5 cycles, total duration 
15 weeks). Primary endpoint was overall survival. 
Secondary endpoints included progression-free 
survival, response, toxicity and quality of life. 
QOL was assessed during treatment by European 
Organisation for Research and Treatment of Cancer 
QLQ-C30 (inclusion, week 6, week 18)
Results: From April 2006 to December 2009, 451 
patients were included (median age: 77). Median 
overall survival was 10.3 months for the doublet and 
6.2 months for monotherapy (hazard ratio 0.64; 95% 
conÀdence interval, 0.52 to 0.78, p < 0.0001). One-
year survival was 44.5% versus 25.4%, respectively.
Compliance with QOL was 94% at baseline, 62% 
at week 6 and 49% at week 18. Both regimens had 
similar baseline QOL. At week 6, the global QOL is 
comparable between the two regimens (mean score 
54.7 vs 56.9), but there was more pain (30.2 vs 18.7, 
p=0.003) and dyspnea (47.4 vs 36.8, p=0.014) in 
the monotherapy, and more diarrhea in the doublet 
(8.8 vs 18.4, p=0.003). At week 18, the global QOL 
is similar between the two regimens (58.2 vs 61.8). 
Regarding evolution between inclusion and week 
18, the global QOL was similar in the two regimens, 
but there was an improvement in Role Functioning 
(-1.9 versus -15.3, p=0.026) and an increasing of the 
fatigue (-0.6 vs 12.4, p=0.039) in the doublet.
Conclusion: Despite increased toxicity, the 
quality of life analysis of carboplatin-weekly 
paclitaxel doublet was preserved over vinorelbine 
weekly DP would be superior to tri-weekly DTX 
at the time of the Ànal analysis was 0.996%, which 
led to early termination of the trial. In subgroup 
of 75 years, the MST of the weekly DP and tri-
weekly DTX groups were 13.3 and 17.3 months, 
respectively. In this trial, there was no interaction 
like to the results of JCOG0207. The major grade 3-4 
toxicities were (%DTX/DP): neutropenia 88/11%, 
anemia 3/16%, anorexia 1/10%, febrile neutropenia 
17/0%, pneumonitis 3/2%. Treatment-related death 
occurred in 3 patients of the weekly DP arm. The 
proportion of patients with an improved symptom 
score (FACT-L lung symptom subscale) after 3 
courses of treatment was higher in the tri-weekly 
DTX arm.
Conclusion: This trial failed to demonstrate any 
advantage of the addition of CDDP to single-agent 
DTX in Àrst-line chemotherapy for elderly patients 
with advanced NSCLC.
Keywords: Elderly, NSCLC, Cisplatin, Docetaxel
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geriatric assesment as a decision tool. 
Methods: French multicentric randomized phase 
III study in patients aged 70, PS 0-2 with stage 
IV NSCLC comparing a treatment algorithm based 
on standard criteria (PS and age) in arm A with 
an experimental, optimized algorithm based on 
an abbreviated geriatric assessment (aGA) plus 
or more a CGA in arm B. In arm B, if the aGA 
results are normal, the patient is treated with 4 
cycles of dual-agent therapy based on platinum 
(carboplatin AUC 5 D1 + pemetrexed 500 mg/
m2 D1 q21D if the histology is non epidermoid, 
carboplatin AUC5 D1 + gemcitabin 1000 mg/m2 
D1-D8 q21D if the histology is epidermoid), with no 
further geriatric assessment. When the aGA reveals 
abnormalities, a comprehensive geriatric assesment 
(CGA) is used to deÀne two subpopulations on 
Balducci’s fragility scale, who will receive either 
monotherapy (docetaxel 38 mg/m2, D1-D8 q21D) 
or best supportive care. In arm A, the same dual 
agent therapy or monotherapy will be allocated but 
according only to PS and age. The primary endpoint 
is Time to treatment failure.The total number of 
subjects to enroll is 490 patients
Results: From Jan 2010 to feb 2011 data-cut, 156 
patients were randomized. Baseline characteristics 
(%): male 78, adenocarcinoma 61, PS 0/1/2 
:27/56/16, median age 77yr (range 70-87), score 
ADL 0/1/2: 83/8/9, IADL 0/1/2:62/21/17, charlson 
number of co-morbidities 0/1/2:40/32/28. 49% of 
the patients received docetaxel, 15% carboplatine-
gemcitabine, 26% carboplatine-pemetrexed, 14% 
the best supportive care. 83 patients (53%) had an 
adverse event (AE) of any grade. % grade 1/2/3/4/5 
AEs were 40/32/23/1.5/3.5 most commonly anemia 
(24%), asthenia (19%), nausea (8%). 53 patients 
(33%) had 69 serious AEs.
Conclusion: 
This is the Àrst phase III trial that tries to validate 
the use of a CGA as a screening tool in treatment of 
patients70 years old with stage IV NSCLC. The 
use of the CGA is feasible in practise. The different 
chemotherapies used (carboplatin-gemcitabine, 
carboplatine-pemetrexed, or docetaxel) are generally 
well tolerated, most AEs are of mild-moderate 
intensity. The study is ongoing 
Keywords: geriatric assesment, NSCLC, Elderly, 
treatment
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
or gemcitabine monotherapy in elderly patients 
with NSCLC. According to the signiÀcant survival 
beneÀt, this Ànding should modify the paradigm of 
treatment in performance status 0-2 elderly patients 
with advanced NSCLC.
Keywords: Quality of Life, Elderly, Non-small cell 
lung cancer, doublet
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MO09.08 STUDY ESOGIA-GFPC 
08-02 - PHASE III, RANDOMIZED, 
MULTICENTER TRIAL INVOLVING 
SUBJECTS OVER 70 YEARS OF 
AGE WITH NON SMALL-CELL 
LUNG CANCER OF STAGE IV AND 
COMPARING A “CLASSICAL” 
STRATEGY OF TREATMENT 
ALLOCATION (DUAL-AGENT THERAPY 
BASED ON CARBOPLATIN OR 
MONOTHERAPY WITH DOCETAXEL 
ALONE), BASED ON PERFORMANCE 
STATUS AND AGE, WITH AN 
“OPTIMIZED” STRATEGY ALLOCATING 
THE SAME TREATMENTS ACCORDING 
TO A SIMPLIFIED GERIATRIC 
SCREENING SCALE, PLUS A MORE 
THOROUGH GERIATRIC EVALUATION 
IF NECESSARY.
Romain Corre1, Clarisse Audigier-Valette2, Henri 
Bérard3, Lionel Falchero4, Christophe Demattei5, 
Herve Le Caer6 
1Pneumology, Hôpital Pontchaillou/France, 2Service 
De Pathologie Respiratoire, Chi/France, 3Service De 
Pathologie Respiratoire, Hôpital D’Instruction Des 
Armées Sainte Anne/France, 4Pneumologie, Centre 
Hospitalier/France, 5Biostatistics, Ghu Carémeau/
France, 6Oncology, Centre Hospitalier Dracenie/
France
Background: Incidence of advanced NSCLC in the 
elderly is increasing. Current recommendations are 
monotherapies. Study IFCT 05-01 communicated 
in 2010 has demonstrated the superiority of weekly 
paclitaxel plus carboplatin to monotherapies but with 
a high rate of toxic deaths. The use of comprehensive 
geriatric assessment (CGA) is recommended to 
detect the patient’s vulnerability and to predict the 
treatment tolerance but its integration in treatment 
decision making does not remain clearly deÀned. 
The aim of this study is to validate the use of a 
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PFS with V (p=0.03) but no difference in DCR 
nor OS. There was no difference between the age 
groups in grade 3-4 heme AE. However, women > 
65 yrs had a higher rate of grade 3-4 non-heme AE 
(p=0.05) that was primarily seen with S (p=0.04). 
Older pts were more likely to report diarrhea and GI 
symptoms. Women age > 65 and age > 70 were more 
likely to require dose reductions but this was not 
treatment speciÀc. Additional biomarker information 
and differences between age groups and gender will 
be evaluated. 
Conclusion: Fit elderly NSCLC patients should be 
considered for salvage targeted therapy as there is 
no adverse impact on survival; in fact, older men > 
65 yrs derive signiÀcant clinical beneÀt to certain 
agents. Gender differences in tolerance were seen in 
older women. 
Keywords: Elderly, vandetanib, erlotinib, sorafenib
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MO09.11 ETHNIC DIFFERENCES IN 
SURVIVAL OUTCOME IN PATIENTS 
WITH ADVANCED STAGE NON-SMALL 
CELL LUNG CANCER- RESULTS OF 
A META-ANALYSIS OF RANDOMISED 
CONTROLLED TRIALS
Marie Loh1, Tony Mok2, Sai-Hong I. Ou3, Byoung-
Chu Cho4, Wee-Lee Yeo5, Dan G. Tenen1, Richie 
Soong1, Ross A. Soo5 
1Cancer Science Institute Of Singapore, National 
University Of Singapore/Singapore, 2Department 
Of Clinical Oncology, The Chinese University Of 
Hong Kong/Hong Kong, 3Department Of Internal 
Medicine, Chao Family, Comprehensive Cancer 
Center/United States Of America, 4Division Of 
Medical Oncology, Yonsei Cancer Center/Korea, 
5Department Of Haematology-oncology, National 
University Cancer Institute/Singapore
Background: Although inter-ethnic differences 
in survival to cytotoxic chemotherapy in patients 
with NSCLC exist, an analysis of survival 
outcomes based on ethnicity has not yet been fully 
evaluated systematically using large patient cohorts. 
Furthermore, recent trial results may be confounded 
by the use of the epidermal growth factor receptor 
(EGFR) tyrosine kinase inhibitor (EGFR TKI).
Methods: A meta-analysis was performed using 
trials identiÀed through MEDLINE. Summary data 
on median overall survival (OS), time to progression, 
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MO09.09 ELDERLY CHEMO-
REFRACTORY NSCLC PATIENTS 
DERIVE BENEFIT FROM SALVAGE 
TARGETED THERAPY - SUBGROUP 
ANALYSIS OF CLINICAL OUTCOME 
AND TOXICITY FROM THE BATTLE 
TRIAL
Anne Tsao1, Suyu Liu2, J.J. Lee2, Christine Alden1, 
Edward Kim1, George Blumenschein1, Roy Herbst1, 
Scott Lippman1, Ignacio Wistuba3, Waun K. Hong1 
1Thoracic And Head & Neck Medical Oncology, 
University Of Texas M.D. Anderson Cancer Center/
United States Of America, 2Biostatistics, University 
Of Texas M.D. Anderson Cancer Center/United 
States Of America, 3Pathology-research, University 
Of Texas M.D. Anderson Cancer Center/United 
States Of America
Background: BATTLE was a phase II trial that 
randomized 255 patients (pts) into 4 separate trials: 
erlotinib (E), erlotinib-bexarotene (E-B), vandetanib 
(V), and sorafenib (S). Treating elderly chemo-
refractory NSCLC pts is often challenging; we 
sought to determine if older pts on the BATTLE trial 
had worse outcomes or more adverse events (AE). 
Methods: Chemorefractory NSCLC pts with PS 
0-2 and any line of prior therapy were enrolled. 
Following tumor biomarker evaluation, pts were 
randomized to oral therapy with E (150 mg daily), 
E + B (400 mg/m2 daily), V (300 mg daily), or 
S (400 mg twice daily) with Q8 wk radiographic 
assessment. AE were assessed by NCI-CTC v. 3.0. 
Subgroup analysis was conducted via Fisher’s exact 
test for age groups (> 65 v > 65 years; > 70 v 70 
years; > 75 v > 75 years), treatments, and gender. 
Kaplan-Meier method, log-rank tests, and Cox 
proportional hazards models were also used.
Results: In the ITT population, median age 62 
(range 26-84); 16% age < 50, 29% age 51-60, 
34% age 61-70, 22% > 70 yrs; 46% F, 9% PS 0, 
77% PS 1, 14% PS 2. No differences in RR or OS 
were seen between any age groups. However DCR 
at 8 wks was better in older women > age 70 yrs 
(p=0.06) and men > 65 yrs (p=0.008); also, men > 
65 yrs (p=0.0068) and men > 70 yrs (p=0.09) had 
better PFS. Treatment-speciÀc analyses showed 
that older men > 65 yrs treated with V had a better 
PFS (p=0.03). Male pts > 70 yrs had an improved 
DCR with E (p=0.05) and an improved OS with S 
(p=0.04). However, women age > 70 yrs had a worse 
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MO09.12 EFFICACY, TOLERABILITY 
AND BIOMARKER ANALYSES 
FROM A PHASE III, RANDOMIZED, 
PLACEBO CONTROLLED, PARALLEL 
GROUP STUDY OF GEFITINIB AS 
MAINTENANCE THERAPY IN PATIENTS 
WITH LOCALLY ADVANCED OR 
METASTATIC NON-SMALL-CELL LUNG 
CANCER (NSCLC) IN CHINA (INFORM) 
(C-TONG 0804)
Li Zhang1, Shen L. Ma2, Xiang Q. Song3, Bao H. 
Han4, Ying Cheng5, Cheng Huang6, Shu J. Yang7, 
Xiaoqing Liu8, Yun P. Liu9, Meng Z. Wang10, X. 
Zhang11 
1Medical Oncology, Sun Yat-sen University Cancer 
Center/China, 2Zhejiang Cancer Hospital/China, 
3Medical Oncology, AfÀliated Tumor Hospital 
Of Guangxi Medical University/China, 4Internal 
Medicine, Shanghai Jiaotong University AfÀliated 
Shanghai Chest Hospital/China, 5Jilin Cancer 
Hospital, Jilin Cancer Hospital/China, 6Medical 
Department, The Cancer Hospital Of Fujian/China, 
7Henan Cancer Hospital/China, 8Tumor Medical, 
307 Hospital Of The Academy Of Military Medical 
Sciences/China, 9First Hospital Of China Medical 
Univ,/China, 10Peking Union Medical Hospital/
China, 11Astrazeneca, Shang Hai, China/China
Background: The phase III, randomized, 
multicenter, parallel group INFORM study 
investigated the efÀcacy, safety and tolerability 
of geÀtinib v placebo as maintenance therapy 
in patients with locally advanced or metastatic 
NSCLC following standard 1st line platinum based 
chemotherapy.
Methods: Patients (>18years, recruited at 27 centers 
from 26 September 2008-10 August 2009) had 
stage IIIB/IV NSCLC, performance status (PS) 0-2, 
and had completed 4 cycles of 1st line platinum 
based doublet chemotherapy without progression or 
unacceptable toxicity. Patients were randomized 1:1 
to geÀtinib 250mg/day or placebo on discontinuation 
of 1st line therapy. The primary endpoint was 
progression-free survival (PFS). Secondary 
endpoints include overall survival (OS), objective 
response rate (ORR), disease control rate (DCR), 
symptom improvement (Lung Cancer Subscale 
[LCS]) and tolerability. Assuming a geÀtinib:placebo 
hazard ratio of 0.7, 265 PFS events are required to 
demonstrate superiority of geÀtinib (2-sided 5% 
progression free survival and overall response rate 
(ORR) were collected from randomized controlled 
trials. Outcomes were compared between Asian and 
Caucasian studies.
Results: Of the 1182 citations identiÀed, 391 
treatment arms (Asian 90, Caucasian 301) were 
analysed. The median OS and ORR in Asian and 
Caucasian studies for all chemotherapy regimens was 
10.1 months and 8.0 months (p<0.001), and 32.2% 
and 25.9% (p<0.001), respectively. The median OS 
in Asian and Caucasian studies for monotherapy, two 
drugs, and three drug or more combination was 9.9 
and 6.8 months, 10.3 and 8.6 months, and 9.4 and 
8.0 months, respectively (all p<0.001). In studies 
published pre-EGFR TKI, the median OS and ORR 
in Asian and Caucasian studies for all chemotherapy 
regimens was 9.1 months vs 7.3 months (p<0.001), 
respectively and 29.0% and 23.0% (p<0.006), 
respectively. The median OS in Asian and Caucasian 
studies for monotherapy, two drugs, and three drug 
or more combination pre EGFR TKI was 8.9 and 6.5 
months (p<0.005), 9.1 and 7.3 months (p<0.001), 
and 9.3 and 7.6 months (p<0.003), respectively. In 
3rd generation platinum doublets, the median OS in 
Asian and Caucasian studies was 11.3 months and 
9.5 months (p<0.001), respectively and ORR was 
35.0% and 29.8% (p<0.001), respectively.
Conclusion: Ethnic differences in survival and 
response rate to chemotherapy exist and
should be considered in clinical trial designs 
especially in the global context.
Keywords: Chemotherapy, ethnicity, meta-analysis, 
Non-small cell lung cancer
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free survival (PFS) beneÀts compared to placebo, 
irrespective of EGFR status (SATURN,Capuzzo 
2010).In patients with mNSCLC and stable 
disease (SD) after 1L standard platinum-based 
chemotherapy,the overall survival beneÀts observed 
were largest and it is for this group that Erlotinib is 
indicated as a maintenance treatment in the European 
Union (EMA 2010).1LM Erlotinib in SD mNSCLC 
has been demonstrated to be cost-effective in a recent 
analysis (Vergnenègre 2010); the cost-effectiveness 
of 1LM Erlotinib speciÀcally in EGFR wildtype 
(WT) mNSCLC has not yet been assessed.
Methods: The incremental cost per life year gained 
of 1LM Erlotinib in patients with EGFR WT 
mNSCLC and SD after 1L chemotherapy compared 
to BSC was assessed in a cost-effectiveness analysis 
for 5 European countries (the UK, Germany, France, 
Spain, Italy). An Area-under-the-Curve model 
consisting of three health states (PFS, progressive 
disease (PD) and death) was used, where patients 
enter the model in PFS and after each month, can 
stay in PFS or move to PD or death. The model is 
based on OS and PFS data from the SATURN SD 
EGFR wildtype mNSCLC subgroup, which were 
Àtted with log-logistic survival functions to model 
the proportion of patients in PFS and death over 
patients’ lifetime. The proportion of patients in PD 
was modeled as PD=OS-PFS. Country-speciÀc 
costs considered were the 1LM Erlotinib therapy 
cost (modelled as the time to complete treatment 
cessation,using ex-factory prices) and Erlotinib 
adverse event costs (most common Grade 3/4 
events), and 2L treatment cost (90 days of Docetaxel 
assumed for both treatment groups, for proportion 
of patients). Costs and effects were discounted at a 
rate of 3% per annum; deterministic and probabilistic 
sensitivity analyses (PSA) using Monte Carlo 
Simulation (1’000 iterations) were undertaken to 
assess uncertainty in the base case assumptions.
Results: 1LM Erlotinib compared to BSC in SD 
EGFR WT mNSCLC resulted in 4.57 months of 
life gained (Erlotinib:17.82 vs BSC:13.24); and 
1.14 months of life without progression gained 
(Erlotinib:4.29 vs BSC:3.15). The analyses showed 
total costs of Tarceva ranging from 10’542€ (Italy) 
to 13’203€ (Germany) and total costs of BSC from 
2’393€ (Italy) to 3’623€ (Germany), resulting in 
incremental total costs ranging from 7’897€ (the 
UK) to 9’580€ (Germany). The mean incremental 
costs per life year gained of Erlotinib 1LM compared 
to BSC in SD EGFR WT mNSCLC were between 
20’711€ (the UK) and 25’124€ (Germany), and 
signiÀcance level, 80% power). Assessing efÀcacy 
according to tumor biomarker status (EGFR and 
K-Ras mutations) were pre-planned exploratory 
objectives.
Results: By 20 January 2011, 265 PFS events 
had occurred. PFS and OS in the intent-to-treat 
population (n=296) and in clinical and biomarker 
subgroups will be analyzed (Cox proportional 
hazards model adjusted for WHO PS [0,1 v 2], 
histology [adenocarcinoma v non-adenocarcima], 
smoking status [never-smoker v smoker], and best 
response to Àrst-line chemotherapy [complete 
response/partial response v stable disease]). ORR, 
DCR and LCS improvement rates will be analyzed 
using logistic regression adjusted for the same 
covariates as PFS. Tolerability will be assessed. 
Exploratory biomarker analyses will be performed 
according to tumor biomarker status (positive, 
negative, unknown), where appropriate.
Conclusion: Final, event driven PFS data will be 
available in April 2011. We will submit the Ànal 
abstract in 13 May, 2011, which will include PFS, 
OS,ORR , safety and biomarker analysis.
Keywords: maintenance therapy, NSCLC, geÀtinib
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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MO09.13 MAINTENANCE ERLOTINIB 
IN STABLE DISEASE EGFR WILDTYPE 
ADVANCED NON-SMALL-CELL LUNG 
CANCER: A COST-EFFECTIVENESS 
ANALYSIS FOR 5 EUROPEAN 
COUNTRIES
Silke Walleser1, Joshua A. Ray2, Helge Bischoff3, 
Alain Vergnenegre4, Hubertus Rosery5, Stefan 
Walzer2 
1 Independent Consultant/Switzerland, 2F. Hoffmann-
la Roche Pharmaceuticals Ag/Switzerland, 3Thoracic 
Oncology, Thoraxklinik/university Of Heidelberg/
Germany, 4Hôpital Du Cluzeau/France, 5Aim Gmbh 
- Assessment In Medicine Research And Consulting/
Germany
Background: Erlotinib maintenance therapy in 
patients with locally advanced or metastatic non-
small cell lung cancer (mNSCLC) has demonstrated 
signiÀcant overall survival (OS) and progression-
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demonstrated noninferiority in terms of overall 
survival (OS) compared to carboplatin/paclitaxel. 
Here, we present the Ànal analysis of survival data. 
Methods: A total of 564 Patients (pts) with stage 
IIIB or IV NSCLC were randomly assigned to 
receive either carboplatin/S-1, carboplatin AUC 5 
mg/ml/min on day 1 plus oral S-1 80 mg/m2/day 
(40 mg/m2 b.i.d.) on days 1 to 14, or carboplatin/
paclitaxel, carboplatin AUC 6 mg/ml/min plus 
paclitaxel (200 mg/m2) on day 1, every 21 days. The 
study included patients with ECOG PS of 0-1, aged 
20-74, and preserved organ functions. The analysis 
was updated using 2 year follow-up data. The 
planned subgroup (stage, PS, histology, gender and 
smoking status) analysis was assessed using the Cox 
regression model. This study expected 442 events. 
Results: At the Ànal analysis, total of 446 death 
events were observed. The overall median OS 
was 15.2 months (95%CI, 12.3–17.8) for the 
carboplatin/S-1 arm and 13.1 months (95%CI, 
11.7–14.9) for carboplatin/paclitaxel arm. The 
adjusted 95% CI of the hazard ratio (HR) for the OS 
of 0.956 was 0.793–1.151. In subgroup analysis, 
the HRs (95% CI) in each subgroup were 1.004 
(0.689–1.463) / 0.973 (0.786–1.205) for stage IIIB/
IV, 1.132 (0.805–1.594) / 0.920 (0.737–1.149) for 
PS 0/1, 0.713 (0.476-1.068)/ 1.060 (0.859–1.308) 
for squamous (sq)/non-squamous (non-sq), 0.953 
(0.774–1.174) /0.971 (0.640–1.473) for male/female 
and 0.961 (0.785–1.176) / 1.055 (0.654–1.700) for 
smoker /non-smoker. The 95% CI for the HR in each 
subgroup included 1.00. The median PFS was 4.1 
months in the carboplatin/S-1 arm and 4.8 months in 
the carboplatin/paclitaxel arm in the ITT population, 
with a corresponding HR of 1.035 and 95% CI of 
0.875 to 1.224. 
Conclusion: Consistent with the results of interim 
analysis, this updated analysis demonstrated 
improved noninferiority for OS by carboplatin/S-1. 
Subgroup analysis of OS according to stage, PS, 
gender and smoking status were consistent with the 
primary analysis. Conversely, these Àndings suggest 
that carboplatin/S-1 may be more beneÀcial for sq 
carcinoma pts. 
Keywords: S-1, Carboplatin, phase III, Subgroup 
analysis
thus well within a range usually considered as 
cost-effective. Results were not largely variable 
to changes in variables tested in deterministic 
sensitivity analyses. The most sensitive variable was 
the discount rate for effects, which at 6% resulted in 
the highest ICER observed (26’429 €, Germany). 
PSA conÀrmed Àndings from deterministic analyses.
Conclusion: Erlotinib 1L maintenance treatment 
is value for money compared to BSC in SD EGFR 
wildtype mNSCLC independent of country setting.
Keywords: EGFR wildtype, erlotinib, NSCLC 
Advanced Stage, Maintenance treatment
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MO09.14 PHASE III TRIAL COMPARING 
CARBOPLATIN/S-1 TO CARBOPLATIN/
PACLITAXEL IN TREATMENT-NAïVE 
PATIENTS WITH ADVANCED NON-
SMALL CELL LUNG CANCER (NSCLC): 
SUBGROUP ANALYSIS AND UPDATED 
RESULTS OF THE LETS STUDY 
(WJTOG3605).
Miyako Satouchi1, Isamu Okamoto2, Satoshi Morita3, 
Hiroshige Yoshioka4, Koji Takeda5, Takashi Seto6, 
Nobuyuki Yamamoto7, Masahiro Fukuoka8, Toyoaki 
Hida9, Nobuyuki Katakami10, Hiroshi Saito11, Hiroshi 
Senba12, Kenji Tamura8, Soichiro Yokota13, Takashi 
Nakano14, Yoshiro Tanio15, Kazuhiko Nakagawa2 
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2Kinki Univercity Faculty Of Medicine/Japan, 
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City General Hospital/Japan, 6National Kyusyu 
Cancer Center/Japan, 7Division Of Thoracic 
Oncology, Shizuoka Cancer Center/Japan, 8Kinki 
University School Of Medicine, Nara Hospital/
Japan, 9Aichi Cancer Center/Japan, 10Institute Of 
Biomedical Research And Innovation Hospital/
Japan, 11Department Of Respiratory Medicine, Aichi 
Cancer Center Aichi Hospital/Japan, 12Kumamoto 
Regional General Hospital/Japan, 13Toneyama 
National Hospital/Japan, 14Division Of Respiratory 
Medicine, Department Of Internal Medicine, Hyogo 
College Of Medicine/Japan, 15Osaka General 
Medical Center/Japan
Background: We have previously reported the 
results of interim analysis of the LETS study 
[Okamoto et al. JCO 2010] in which carboplatin/S-1 
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for pT2a/p2 (n=67). As a result of model A, VPI 
(P=0.006) were identiÀed as independent predictors 
of a poor prognosis. But As a result of model B, VPI 
(P=0.091) were not identiÀed. 
Conclusion: From the viewpoint of prognosis 
in tumors with a diameter of 3 cm or less, elastic 
layer invasion is a border of VPI, and p1 and p2 
pleural involvement should be combined as a single 
category. So the 7th TNM classiÀcation of UICC and 
JLCS is appropriate. 
Keywords: Lung cancer, Visceral Pleural Invasion, 
Elastic layer invasion, TNM classiÀcation
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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MO10.02 SIGNIFICANCE OF EXTENT OF 
VASCULAR INVASION AND LYMPHATIC 
PERMEATION: PROGNOSTIC 
IMPLICATION IN COMPLETELY 
RESECTED NON-SMALL CELL LUNG 
CANCER
Yoshihisa Shimada1, Genichiro Ishii2, Junji Yoshida1, 
Keiju Aokage1, Tomoyuki Hishida1, Mitsuyo 
Nishimura1, Norihiko Ikeda3, Kanji Nagai1 
1Division Of Thoracic Surgery, National Cancer 
Center Hospital East/Japan, 2Pathology Division, 
Research Center For Innovative Oncology, National 
Cancer Center Hospital East/Japan, 3Department Of 
Surgery, Tokyo Medical University/Japan
Background: The presence of vascular invasion 
(V) and lymphatic permeation (Ly) has been 
reported to be a strong predictor of prognosis, but 
the signiÀcance of the extent of V and Ly has yet to 
be clearly demonstrated. The aim of this study was 
to classify V and Ly according to their extent and to 
assess their prognostic signiÀcance in patients with 
non-small cell lung cancer (NSCLC).
Methods: We reviewed 1155 consecutive patients 
with NSCLC underwent complete resection for their 
clinicopathological characteristics and prognoses.
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MO10.01 ELASTIC LAYER INVASION 
INFLUENCED OVERALL SURVIVAL IN 
RESECTED NON–SMALL CELL LUNG 
CANCER WITH A DIAMETER OF 3 CM 
OR LESS.
Hirofuimi Uehara1, Yukinori Sakao1, Mingyon Mun1, 
Ken Nakagawa1, Yuichi Ishikawa2, Makoto Nishio3, 
Sakae Okumura1 
1Thoracic Surgical Oncology, Cancer Institute 
Hospital/Japan, 2Pathology, Cancer Institute 
Hospital/Japan, 3Thoracic Oncology Center, Cancer 
Institute Hospital, Japanese Foundation For Cancer 
Research/Japan
Background: Visceral Pleural Invasion (VPI) by 
lung tumor was recognized to be a factor of poor 
prognosis in lung cancer. In 2009, the deÀnition of 
VPI was changed from P2 (visceral pleural surface 
invasion) to P1 (elastic layer invasion) in 7th UICC 
TNM classiÀcation. And in 2010, The Japan Lung 
Cancer Society (JLCS) adopted that deÀnition in 
the new version. Thus, if a tumor invades the elastic 
layer and it is 3 cm or less in size, it will be classiÀed 
as T2a. 
Methods: We reviewed the records of 669 patients 
with non–small cell lung cancer with a diameter of 
3 cm or less. Histologically, VPI was evaluated by 
elastic Àber staining and subdivided into four pleural 
invasion grades according to the JLCS criteria, as 
follows: p0, tumor with no pleural involvement 
beyond its elastic layer; p1, tumor extension beyond 
the elastic layer of the visceral pleura but with no 
exposure on the pleural surface; p2, tumor exposure 
on the pleural surface but no involvement of adjacent 
anatomic structures; and p3, tumor that involves 
adjacent anatomic structures. We distributed P factor 
in a model of A (P1-2 vs P0) and B (P2 vs P0-1) and 
performed analysis. 
Results: It was only model A that has correlation 
with lymph node involvement. The 5-year survival 
rates and the number of patients in each p factor 
were 83% for P0 (n=525), 61% for P1 (n=70), 57% 
for P2 (n=61), and 61% for P3 (n=13). In each 
pT factor were 89% for pT1a (n=247), 81% for 
pT1b (n=231), 69% for pT2a/p1 (n=54), and 67% 
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prognostic factors. (a) Patients with T2 tumors of Ly2 
and those with T3 tumors, and (b) patients with T1 
tumors of V+ (V1-2) and those with T2 tumors showed 
essentially identical survival curves (Figure 2).
Conclusion: According to the extent of vessel 
invasion, OS rates were signiÀcantly different 
between each extent group for both V and Ly. Ly2 
and V+ (V1-2) were independently signiÀcant 
prognostic predictors. T2 tumors of Ly2 should be 
upgraded to T3, and T1 tumors of V+ (V1-2) should 
be upgraded to T2 in the future TNM ClassiÀcation.
Keywords: NSCLC, vascular invasion, lymphatic 
permeation
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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MO10.03 PROGNOSTIC SIGNIFICANCE 
OF INTRATUMORAL VASUCULAR 
INVASION IN NON-SMALL CELL 
LUNG CANCER – A CANDIDATE 
OF PATHOLOGICAL PROGNOSTIC 
FACTORS IN THE NEXT TNM 
CLASSIFICATION
Hisashi Saji1, Tatsuya Inoue1, Gaku Yamaguchi1, 
Yujin Kudo1, Masaharu Nomura2, Jun Matsubayashi2, 
Masatoshi Kakihana1, Jitsuo Usuda1, Naohiro 
Kajiwara1, Tatsuo Ohira1, Norihiko Ikeda1 
1Thoracic Surgery, Tokyo Medical University/Japan, 
2Pathology, Tokyo Medical University/Japan
Background: Intratumoral vascular invasion (ITVI) 
in patients with non-small cell lung cancer (NSCLC) 
has been reported to be a strong prognostic predictor 
of recurrence. However, it has not been incorporated 
in the latest 7th TNM classiÀcation. The objective 
of this study is to evaluate its signiÀcance as a risk 
factor for recurrence and survival.
Methods: A total of 1924 consecutive patients with 
pathological T1-4N0-2 non-small cell lung cancer 
underwent complete resection at least lobectomy 
with lymphadenectomy from January 1990 to 
December 2007 at the Tokyo Medical University 
Hospital. Complete resection was deÀned as 
cancer-free surgical margins both macroscopically 
and microscopically. Among these patients, were 
excluded because of preoperative chemotherapy or 
radiotherapy or both (n=94) or because of low-grade 
Results: The numbers of the patients according to 
vessel invasion status and its extent were as follows; 
no V (V0): 608 (52.6%), intratumoral V (V1): 512 
(44.3%), extratumoral V (V2): 35 (3.0%), no Ly (Ly0): 
901 (78.0%), intratumoral Ly (Ly1): 155 (13.4%), and 
extratumoral Ly (Ly2): 99 (8.6%). The overall survival 
(OS) curves stratiÀed by the extent of (a) V or (b) Ly 
were signiÀcantly different from each other (Figure 1). 
Multivariate analysis showed that Ly2 status, presence 
of V (V1-2), older age, larger tumor size, preoperative 
serum CEA (carcinoembryonic antigen) level, lymph 
node metastasis, and pleural invasion were signiÀcant 
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poor prognostic factor. In the 7th edition of the TNM 
ClassiÀcation for Lung and Pleural Tumours, VPI 
is deÀned as comprising both PL1 and PL2. Tumors 
3 cm or less (T1a and T1b) with VPI are upstaged 
as T2a, while tumors greater than 3 cm and 7cm or 
less (T2a and T2b) with VPI remain T2. However, 
it is still controversial whether PL1 and PL2 are 
equivalent and whether they can be combined to 
deÀne VPI, or how tumors with VPI should be 
classiÀed, especially T2 tumors.
Methods: We reviewed 2946 consecutive surgically 
resected NSCLC patients with T1a, T1b, T2a, T2b or 
T3 tumors for their clinicopathologic characteristics 
and prognoses. Visceral pleural invasion was 
classiÀed using the criteria of the 7th edition of the 
TNM ClassiÀcation for Lung and Pleural Tumours.
Results: There were no signiÀcant differences in 
survival between PL1 and PL2 patients (Àg 1A). 
We therefore decided to combine the PL1 and PL2 
patient groups into a single VPI+ group and to 
compare survival with a PL0 (VPI-) group to analyze 
the impact of VPI on T classiÀcation. The best 
survival was observed in patients with a T1a/VPI- 
tumor, followed by those with a T1b/VPI- tumor. 
In comparison, survival was similarly worse among 
patients with a T1a/VPI+, T1b/VPI+, T2a/VPI-, T2b/
VPI-, or T2a/VPI+ tumor. The worst survival was 
observed in patients with a T2b/VPI+ or T3 tumor 
(Àg 1B).
Conclusion: Otherwise T2a tumors with VPI may be 
classiÀed as T2b tumors, and T2b tumors with VPI 
may be classiÀed as T3 tumors in the next edition 
of the TNM ClassiÀcation for Lung and Pleural 
Tumours.
Keywords: Visceral Pleural Invasion, Non-small cell 
lung cancer, TNM classiÀcation
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
malignant histologies (n=31) including carcinoids, 
mucoepidermoid carcinomas and adenoid cystic 
carcinomas. The remaining 1799 patients were 
enrolled in this study. The recurrence-free survival 
(RFS) and overall survival (OS) was estimated using 
the Kaplan-Meier method and differences were 
determined by the log rank test. Cox proportional 
hazard ratios were used to identify independent risk 
factors for RFS and OS.
Results: Patients characteristics as follows: 
Men 1158 (64.4%), Age 64.2 (17-87), 
Adenocarcinoma 1242 (69.0%), Squamous 
cell carcinoma 432 (23.5%), T1a/b/T2a/b/T3/
T4=501/405/555/112/153/73, N0/1/2=1306/253/260, 
Well differentiated 588 (32.7%), ITVI 980 (54.5%), 
Lymphatic permeation 970 (53.9%), Visceral 
pleural invasion 1274 (70.8%). The proportion of 
recurrence-free patients at 5 years was 68.4% for 
patients with ITVI and 86.9% for those without ITVI 
(p<0.0001). The 5 year survival rate was 58.7% 
for patients with ITVI and 81.2% for those without 
ITVI (p<0.0001). On the multivariate analyses, ITVI 
proved to be an independently statistically signiÀcant 
risk factor for RFS (HR=1.347, p=0.0357) and OS 
(HR=1.422, p=0.0017) (Table 1).
Conclusion: In the Patients with resected T1-4N0-2 
NSCLC, ITVI was an independently signiÀcant 
risk factor for RFS and OS. Our data suggested 
that ITVI may provide additional information 
for the next TNM classiÀcation. Further large-
scale cohort studies, including global prospective 
validation analyses and multi-institutional studies are 
warranted.
Keywords: prognostic factor, intratumoral vascular 
invasion
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MO10.04 VISCERAL PLEURAL INVASION 
CLASSIFICATION IN NON–SMALL CELL 
LUNG CANCER.
Akikazu Kawase1, Junji Yoshida1, Genichiro Ishii2, 
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Tomoyuki Hishida1, Mitsuyo Nishimura1, Kanji Nagai1 
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Center Hospital East/Japan, 2Pathology Division, 
Research Center For Innovative Oncology, National 
Cancer Center Hospital East/Japan
Background: Visceral pleural invasion (VPI) by 
non–small cell lung cancer (NSCLC) is known as a 
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A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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MO10.07 MICROPAPILLARY 
MORPHOLOGY IS AN INDEPENDENT 
PREDICTOR OF RECURRENCE 
IN PATIENTS UNDERGOING 
LIMITED RESECTION FOR LUNG 
ADENOCARCINOMA (LAC) 2CM
Junichi Nitadori1, Adam J. Bograd1, Kyuichi 
Kadota1, Camelia S. Sima2, Eduardo Morales1, Kei 
Suzuki1, Nabil P. Rizk1, Valerie W. Rusch1, William 
D. Travis3, Prasad S. Adusumilli1 
1Department Of Surgery, Thoracic Service, Memorial 
Sloan-kettering Cancer Center/United States Of 
America, 2Epidemiology And Biostatistics, Memorial 
Sloan-kettering Cancer Center/United States Of 
America, 3Pathology, Memorial Sloan-kettering 
Cancer Center/United States Of America
Background: Among patients who undergo limited 
resections for stage I lung cancer, prognostic factors 
to stratify patients at increased risk of recurrence 
have not been identiÀed. Comprehensive histological 
subtyping (IASLC/ATS/ERS) has been proposed to 
predict prognosis in stage I LAC. Micropapillary 
(MIP) morphology is associated with high risk of 
recurrence. The aim of this study is to investigate the 
prognostic role of MIP morphology in LAC 2cm 
following limited resections.
Methods: Retrospective review of patients who 
underwent limited resection for lung cancer (n=489, 
01/2004-12/2007) was performed. Inclusion 
criteria: LAC 2cm with available H&E slides for 
pathological review; exclusion criteria: clinical 
/ pathologic stage II and above, multicentric 
disease, lung cancer surgery within preceding 
2 years, and patients who received induction 
therapy. Comprehensive histological subtyping was 
performed as per the newly proposed IASLC/ATS/
ERS LAC classiÀcation (MIP component percentage 
recorded in 5% increments). Recurrence free 
probability (RFP) was assessed via Kaplan-Meier 
survival analysis.
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MO10.06 THE 3-TIER HISTOLOGY 
GRADING SYSTEM OF LUNG 
ADENOCARCINOMA FOR SMALL 
BIOPSY SPECIMENS PREDICTS 
DISEASE RECURRENCE AND OVERALL 
SURVIVAL
Hua-Ling Kao1, Yi-Chen Yeh1, Fu-Pang Chang1, Yu-
Chung Wu2, Chun-Ming Tsai3, Teh-Ying Chou4 
1Department Of Pathology And Laboratory 
Medicine, Taipei Veterans General Hospital/
Taiwan, 2Department Of Surgery, Taipei Veterans 
General Hospital/Taiwan, 3Division Of Thoracic 
Oncology/department Of Chest Medicine, Taipei 
Veterans General Hospital/Taiwan, 4Pathology 
And Laboratory Medicine, Taipei Veterans General 
Hospital/Taiwan
Background: Recently several studies have 
established different objective grading systems 
which provide prognostic information for lung 
adenocarcinoma in surgical specimen. The 
prognostic information provided by small lung 
biopsy specimen has not been studied.
Methods: In our study, the prognostic utility of three 
scoring systems including total scores, worst score 
and predominant score based on a 3-tier grading 
system was applied in 93 lung biopsy specimen. The 
grade 1 tumor has bronchioloalveolar pattern, grade 
2 has acinar and/or papillary patterns, and grade 3 
has micropapillary and/or solid patterns.
Results: The total scoring system ( P = 0.016 ) 
counted by the sum of 2 most predominant grades 
and worst scoring system ( P = 0.01 ) counted by 
highest grade present in specimen both provide 
prediction for patient’s risk of disease recurrence. 
Furthermore, we subdivided patients into low (total 
scores = 2, 3, or 4 or worst score = 1 or 2) and high 
(total scores = 5 or 6 or worst score = 3) risk groups 
based on the scoring systems. In high risk group 
patients, the 5-year disease-free survival rate was 
0.36 and overall survival rate was 0.47, compared to 
0.71 and 0.65 in the low risk group. Patients in high 
risk group had higher stage (II, III and IV) and more 
lymph nodes metastasis compared to the low risk 
group (P=0.007).
Conclusion: These two scoring systems based on 
simpliÀed, objective 3-tier grading system could 
provide valuable outcome prediction information 
for lung adenocarcinoma patients with small biopsy 
specimens.
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MO10.08 PROGNOSTIC SIGNIFICANCE 
OF SOLID COMPONENT IN 
PULMONARY ADENOCARCINOMA
Yoichi Ohtaki1, Junji Yoshida1, Genichiro Ishii2, 
Keiju Aokage1, Tomoyuki Hishida1, Mitsuyo 
Nishimura1, Kanji Nagai1 
1Division Of Thoracic Surgery, National Cancer 
Center Hospital East/Japan, 2Pathology Division, 
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Background: Histologically, solid adenocarcinoma 
is the lesser differentiated adenocarcinoma 
subtype, but only a few studies have evaluated its 
invasiveness and prognostic impact independently 
of the other subtypes. We retrospectively analyzed 
pulmonary adenocarcinoma patient survival in our 
single institution database to evaluate the impact of 
the amount of solid adenocarcinoma components 
(SAC) on survival, and to propose a method of 
incorporating SAC into the T classiÀcation in future 
staging systems.
Methods: We reviewed 504 consecutive patients 
with surgically resected pulmonary adenocarcinoma 
for their clinicopathologic characteristics and 
prognoses, stratifying patients according to 
predominant adenocarcinoma subtype. In the tumors 
containing SAC, we categorized the ratio of SAC 
into the following 3 groups; pure, moderate (1/10 
or more, but not pure), and slight (less than 1/10). 
We deÀned solid adenocarcinoma components 
(SAC) as cancer nests without any other subtype 
of structures (lepidic, acinar, or papillary growth), 
regardless of mucin production. In pure SAC 
tumors, we conÀrmed mucin production by the 
alcian blue-periodic acid Schiff method. To evaluate 
the invasiveness and the prognostic signiÀcance 
of SAC, we examined the correlations between 
presence or absence of SAC and the following 
clinicopathological features by univariate and 
multivariate analyses: age, gender, smoking history, 
preoperative serum carcinoembryonic antigen level, 
T status, nodal involvement, lymphatic permeation, 
vascular invasion, and pleural invasion.
Results: Although patients with SAC (SAC+) 
had signiÀcantly poorer prognoses than patients 
without any SAC (SAC-), there were no statistically 
signiÀcant differences in survival among the 3 
SAC ratio groups (5-year overall survival rate; 
SAC-: 87.5%, SAC+: 60.3%). SAC signiÀcantly 
Results: 121 patients met inclusion criteria 
(64% women, median age 70yr (47-88 yrs), 14% 
never-smokers; 107 Stage IA, 14 stage IB; 86 
and 35 patients underwent wedge resection and 
segmentectomy, respectively). Micropapillary 
component 5% was associated with increased risk 
of recurrence (n=42, 56% 3-year RFP) as compared 
to <5% (n=79, 93% 3-year RFP) micropapillary 
component (p<0.001). Following adjustment 
for both vascular and lymphatic invasion, which 
were signiÀcant on univariate analysis (p<0.001), 
micropapillary component 5% remained an 
independent predictor of recurrence. Tumor to 
surgical margin is not a predictor of recurrence in our 
cohort.
Conclusion: The presence of 5% micropapillary 
component is a strong predictor of recurrence in 
patients undergoing limited resection for LAC 
2cm. With the potential increase in the number of 
small LAC patients detected by screening CT scans 
who may subsequently undergo limited resection, 
predictors of recurrence are needed. As one in two 
patients with 5% micropapillary morphology may 
recur within 3 years, either aggressive surveillance 
or further intervention may be indicated for these 
patients. 
Keywords: NSCLC - Early stage, Limited 
Resection, IASLC/ATS/ERS classiÀcation, 
micropapillary
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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Background: The number of small-sized lung 
cancer is increasing in number. Small sized tumors 
can include adenocarcinoma (AD) with 100%-
5 year survival which should be synonymous of 
histologically adenocarcinoma, in situ (AIS) or 
minimally invasive adenocarcinoma (MIA) of a 
proposed new IASLC/ATS/ERS classiÀcation in 
2011. Intra-operative frozen diagnosis (IOFD) 
could help surgeons to decide the area of resection, 
especially for limited operation of small sized AD. 
The purpose of this study is to clarify the utility 
and limitation of IOFD of pulmonary lesions and 
to evaluate whether IOFD can predict the Ànal 
pathologic diagnosis and invasion degree or not. 
Methods: Surgically resected 124 lung specimens 
were reviewed on pathologic factors of IOFD and 
Ànal diagnosis (FD), and calculated concordance 
rate between them. IOFD was performed on HE 
stained slides of a small part of tumor. FD was done 
based on the HE and elastic stained slides of FFPE 
specimen of whole tumor. The examined pathologic 
factors were as following; pathologic diagnosis 
(PDx), presence or absence of invasion/minimally 
invasion area, histologic predominant subtype 
of proposed IASLC-ATS-ERS revision of AD 
classiÀcation and tumor differentiation. In discordant 
cases, the reasons were examined in detail. 
Results: Among 124 specimens, 88 were primary 
lung cancers (75 AD, 12 Squamous cell carcinoma 
(SQ), 1 large cell carcinoma), 17 metastatic tumors, 
and 19 were benign or mesenchymal tumors. 
Concordance rate for each factor of all specimens was 
as following; 82.3% for overall PDx factors, 98.4 % 
for judgment of benign or malignant, 92.8% for tumor 
type, 99.0% for tumor differentiation, 98.6% for 
predominant subtype of AD, respectively. Among 124 
specimens, Àfty lesions were small sized lung cancer 
(2cm or less in diameter), including 36 primary lung 
cancer (34 AD, 2 SQ), 9 metastatic tumor and 5 other 
lesions. Concordance rate for each factor of small 
sized lesions is as following; 78.0% for overall PDx 
factors, 96.0% for judgment of benign or malignant, 
94.0% for tumor type, 98.0% for tumor differentiation, 
100% for predominant subtype of AD, respectively. 
Concordance rate for invasiveness of small sized AD 
was 82.4%. The reasons of discrepancy were based 
on tumor heterogeneity, sampling error, frozen section 
artifact, or some difÀcult rare cases.
correlated with the following pathological invasive 
features: T classiÀcation, nodal involvement, 
lymphatic permeation, vascular invasion, and 
pleural invasion. Multivariate analysis showed 
SAC was an independent prognostic factor both in 
the entire cohort (p=0.020) and in stage I patients 
(p=0.024). Patient groups stratiÀed by pathological 
T classiÀcation up to T2b, could be divided into 4 
categories according to SAC status in decreasing 
order of survival: I) T1a/SAC-; II) T1b/SAC-; III) 
T1a/SAC+, T1b/SAC+, and T2a/SAC-; and IV) T2a/
SAC+ and T2b/SAC-.
Conclusion: Pulmonary adenocarcinoma patients 
with any amount of SAC had worse prognoses 
than those without any SAC. The presence of 
SAC signiÀcantly correlated with the pathological 
invasive features, and it was an independent 
unfavorable prognostic factor. SAC was an upstaging 
factor in T classiÀcation for T1 and T2a pulmonary 
adenocarcinomas. If SAC is present, we propose T1 
and T2a tumors should be classiÀed as T2a and T2b, 
respectively.
Keywords: mixed subtype, Adenocarcinoma, 
Surgery, solid adenocarcinoma
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EGFR and compared it to an ED-speciÀc EGFR 
antibody. Compared to a presentation at the Chicago 
Multidisciplinary Thoracic Oncology Meeting 2010, 
the patient numbers increased by 40% and the clinical 
data are updated.
Methods: Ninety-eight surgically-treated NSCLC 
Japanese patients who received geÀtinib upon 
recurrence were evaluated using IHC, scoring either 
membrane (MEM) alone or in combination with the 
cytoplasm (MEMC), on a 0-400 H-score scale, with 
either an EGFR ID- (5B7, Ventana Medical Systems, 
Inc, Tucson, AZ) or ED-speciÀc antibody (3C6, VMSI). 
GeÀtinib monotherapy was received in 1st-, 2nd, or 3rd-
line in 10%, 44%, and 46% of the patients, respectively.
Results: EGFR protein expression scores were 
universally higher when using the ID-speciÀc 
antibody with a mean of 170 and 183 for MEM and 
MEMC, respectively, compared to 37 and 50 for the 
ED antibody. EGFR protein expression, as determined 
by the ID speciÀc antibody, was signiÀcantly higher 
in responders (n=21) vs non-responders (n=73) 
with mean values of 213 vs 156 (p=0.021) and 
231 vs 168 (p=0.001), when considering MEM or 
MEMC. EGFR protein expression wasn’t different 
between responders and non-responders using the ID 
antibody. ROC curve analysis using the ID antibody 
and MEMC scores showed 217.5 as the best cutoff 
(AUC=0.73, p=0.002) to predict response with a 
sensitivity, speciÀcity, accuracy, and likelihood ratio 
of 66.6%, 74.0%, 72.3% and 2.56. Evaluation with 
MEM alone was marginally signiÀcant at predicting 
response, while ED antibody evaluation of MEM or 
MEMC was not predictive. Activating EGFR exon 19 
or 21 mutations (n=43) predicted response (p=0.005) 
with sensitivity, speciÀcity, accuracy and likelihood 
ratio of 76.2%, 60.3%, 64.0% and 1.92. Increased 
EGFR expression determined with the ID antibody 
and MEMC evaluation associated with increased 
median PFS (11.7 months vs 5.0, Log-rank p=0.034) 
and OS (38.6 vs 14.9, p=0.040), both from geÀtinib.
Conclusion: We conÀrmed in an expanded cohort 
that EGFR protein expression, evaluated by IHC 
using an internal domain-speciÀc antibody and by 
scoring membrane and cytoplasmic expression, 
better predicts response and outcome to geÀtinib in 
NSCLC patients than the more often used external 
domain-speciÀc antibody. These data emphasize the 
importance of method choice (e.g. antibody speciÀcity 
and compartment assessed) to assess the expression of 
EGFR.
Keywords: immunohistochemistry, EGFR, 
biomarker, Prediction of response
Conclusion: IOFD can predict the Ànal diagnosis 
of lung cancer in most cases (82.3%), even in 
small-sized tumors (78.0%) and invasion degree of 
AD (82.4%). To prevent disagreement about PDx, 
pathologist should pay attention to tumor processing 
(sampling, sectioning and staining). A careful 
macroscopic observation is strongly recommended, 
especially for small sized tumors. 
Keywords: Invasion, adenocarcinoma, in situ (AIS), 
minimally invasive adenocarcinoma (MIA), lung 
adenocarcinoma
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RESPONSE AND OUTCOME TO AN 
EGFR TYROSINE KINASE INHIBITOR.
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Background: Assessment of speciÀc predictive 
biomarkers for response and outcome to targeted 
therapies is today a part of standard management for 
patients with advanced non-small cell lung cancer 
(NSCLC). Several biomarkers are being evaluated 
for response or resistance to epidermal growth factor 
receptor (EGFR) tyrosine kinase inhibitors (TKIs). 
Mutations in the TK domain of EGFR are the best 
predictor of response to EGFR TKIs to date. However, 
~30% of patients with mutations don’t initially 
respond and all relapse. Results from clinical studies 
with EGFR TKIs using EGFR protein expression by 
immunohistochemistry (IHC) with external domain 
(ED) speciÀc detection antibodies are conÁicting. 
In this study we determined the predictive value of 
EGFR protein expression using an antibody that 
speciÀcally detects the internal domain (ID) of 
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metastasises samples (p=0.009) and with samples 
from centres other than university hospital (p=0.018). 
By contrast, frozen and cytological samples were not 
a signiÀcant cause of incomplete results. A binary 
logistic regression model was used to evaluate 
predictive factors for incomplete results. Odds Ratio 
for bone samples is 2.343 (1.005-5.460; p = 0.049). 
EGFR mutations were more common in female than 
male (63% vs 37%, p < 0.0001) and more common 
in adenocarcinomas than in other histologic subtypes 
(p<0.0001). No signiÀcant difference was observed 
according to age, sample type or health centre. Using 
adjusted model, Odds Ratio for mutation in case of 
adenocarcinoma is 0.5552 [0.431-0.708] for male 
and 1.868 [1.538-2.270] for female (p<0.001). 133 
EGFR mutations were found in 121 patients (11 
patients had at least 2 mutations): 51.9% in exon 
19 (89.9% are activating deletions), 27.1% in exon 
21 (86.1% L858R activating mutation), 13.5% in 
exon 20 (38.9% of resistance mutations and many 
unknown mutations) and 7.5% of detected mutations 
were in exon 18 (70% of sensitizing mutation). 
Finally, 20 new mutations are described, mainly in 
exon 18 and 20. 
Conclusion: This retrospective study shows that 
EGFR mutations detection is feasible in routine 
practice. The rate of mutations in this study is 15.7%. 
As expected, mutations mainly occur in female with 
adenocarcinoma. Moreover, bone metastasis samples 
are associated with an incomplete result whereas 
frozen or cytological samples don’t seem to be a risk 
factor of failure. 
Keywords: molecular genetic plaform, EGFR 
mutations, Non small cell lung cancer
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MO10.13 WHICH TYPES OF 
DIAGNOSTIC TISSUE SAMPLES ARE 
ADEQUATE FOR EGFR TESTING OF 
NON-SMALL CELL LUNG CANCER?
Paul Cane, Sioban Fraser, Khalid Tobal, George 
Santis 
Histopathology, Guy’s And St Thomas’ Hospital/
United Kingdom
Background: It is becoming increasingly necessary 
to perform molecular testing of diagnostic samples 
of non-small cell lung cancers (NSCLC) in order 
to determine suitability for targeted therapies. 
There has been concern whether the tissue samples 
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Background: The French National Institute of 
Cancer developed several platforms for routine 
molecular diagnosis of cancer. Platforms perform 
detection of epidermal growth factor receptor 
(EGFR) mutations in stage IV non-squamous 
lung cancer because their presence is correlated to 
response to tyrosine kinase inhibitors. The aim of 
this retrospective study was to describe results of 
routine EGFR mutations diagnosis, to determine risk 
factors for failure or incomplete results, and to assess 
main clinical and molecular features of mutated 
patients. 
Methods: This study was performed on samples 
sent to the Rhône platform between 09/09 and 09/10. 
Genomic DNA was extracted from tissue after 
microdissection. Exons 18 to 21 were PCR ampliÀed 
and sequenced. Data were collected from application 
forms sent to the lab. Results were categorized in 
mutation, wild type, “indeterminate” (failure on 
more than 2 exons) or “partial” (failure on exon 18 
or 20). The latter two categories were considered as 
“incomplete results”. 
Results: 792 tumor samples were analysed. The 
mean patient age was 65 years (42-88), 62% patients 
were male and 79.8% had an adenocarcinoma. 
Samples were sent by university hospital (30.4%), 
secondary hospitals (36.4%) or private clinics 
(33.2%; p=0.131). Samples concerned primitive 
tumor in 70% of cases. EGFR mutations (all kinds) 
were found in 15.7% samples, EGFR wild type in 
65.2%, “partial wild type” results in 10.4% and 
indeterminate results in 8.8%. Main reasons of 
indeterminate results were: poor DNA quality (n=40) 
and not enough tumour cells in analysed sample 
(n=30). The rate of incomplete results was 19.2%. 
Incomplete results were more frequent with bone 
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showed no obvious trend. Unguided FNA, EBUS-
TBNA, bronchoscopic biopsy and core biopsies 
all provided sufÀcient cells for mutation analysis 
in the vast majority of cases using cold PCR and 
direct sequencing. There is no signiÀcant difference 
in sample size between EBUS-TBNA samples and 
bronchoscopic or core biopsy samples. 
Keywords: Non-small cell lung cancer, EGFR, 
Adequacy, Sample size
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MO10.14 SAMPLE QUALITY CRITERIA 
FOR ROUTINE EGFR MUTATION 
SCREENING – PATHOLOGICAL 
FEATURES MAY BE MORE USEFUL 
THAN CLINICAL PHENOTYPE IN A UK 
POPULATION
Alexandra Leary1, David Gonzalez2, Andrew 
G. Nicholson3, Andrew Wotherspoon1, Franklin 
Olansunkanmi4, Mary O’Brien1, Sanjay Popat1 
1Department Of Medicine, Royal Marsden Hospital/
United Kingdom, 2Department Of Molecular 
Diagnostics, Institute Of Cancer Research/United 
Kingdom, 3Histopathology, Royal Brompton 
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Background: There is now a clinical need for 
routine EGFR mutation testing in NSCLC. EGFR 
screening requires good quality tissue, high 
sensitivity, and acceptable turn-around time (TAT). 
The Royal Marsden Hospital started routine EGFR 
screening in January 2009. Here, we report our 
prospective experience, describing sample type/
source, histological subtype, TAT, specimen quality, 
and screening outcome. 
Methods: NSCLC sections received over 24 months 
were screened for EGFR mutations in exons 18 to 21 
using ARMS alone or in combination with fragment 
analysis and sequencing. A total of 907 samples were 
screened from January 2009. We focused this study 
on Year 1 samples, collecting data on cellularity, 
TAT, demographics and clinical outcome. A subset 
of samples (N=96) from a single institution also 
underwent detailed histological subtyping. 
Results: Overall, EGFR mutation(M+) prevalence 
was 12.7%. Numbers tested increased markedly from 
33 in the Àrst 6 months to 473 in the last 6 months to 
January 2011 (Fig1). In Year 1, most samples were 
diagnostic specimens (72% core, 4% FNA, 14% 
currently used for routine diagnosis of NSCLC are 
of sufÀcient size and quality to enable molecular 
testing. 
Methods: We retrieved 126 consecutive NSCLC 
samples from the pathology archives at our 
institution from 2008-10 that had been tested for 
epidermal growth factor receptor (EGFR) and 
kRAS gene mutations by “cold” polymerase chain 
reaction (cold-PCR) sequencing. Cold-PCR uses 
a lower denaturation temperature resulting in 
preferential ampliÀcation of mutant DNA, increasing 
the sensitivity of mutation detection. The series 
included a range of routine specimen types including 
unguided Àne-needle aspirate (FNA), endobronchial 
ultrasound-guided transbronchial needle aspiration 
(EBUS-TBNA), bronchoscopic biopsy, core biopsy, 
surgical biopsy and surgical resection. Cell block 
preparations were used to assess cytological samples. 
For each sample, the total number of viable tumour 
cells present in a single histological section and 
the proportion of the section that was tumour was 
calculated by two authors (PC and SF) using light 
microscopy. 
Results: 
Sample type Number 
of cases 
Median 
tumour % 
(range) 
Median tumour cell 
count (range) 
Number 
Failed DNA 
extraction 
(%) 
Number 
with EGFR 
or kRAS 
mutation (%) 
Unguided FNA 9 45 (10-100) 450 (46-550) 1 (11%) 4 (44%) 
EBUS-TBNA 44 70 (10-95) 2525 (65-39800) 1 (2.3%) 14 (31.8%) 
Bronchial 
biopsy 
12 45 (10-90) 3000 (295-40000) 1 (8.3%) 9 (75%) 
Core biopsy 
(lung or pleura) 
13 55 (5-75) 3000 (260-15000) 0 (0%) 8 (61.5%) 
Surgical biopsy 16 35 (5-95) 35100 (45-600000) 0 (0%) 5 (31.2%) 
Surgical 
resection 
30 70 (30-95) 268000 (4160-
600000) 
0 (0%) 10 (33.3%) 
Only three of the 126 samples could not be tested 
for mutations because they did not provide sufÀcient 
quality DNA for analysis. Two of these were very 
small, containing only 100 and 105 tumour cells 
each per section. The third contained 5900 tumour 
cells and was 50% tumour but still failed, possibly 
due to degraded DNA. The smallest sample in which 
we were able to detect a mutation was also the 
smallest sample in the series, composed of 45 cells, 
5% tumour. The overall detection rate of mutations 
was 14.6% (18/123) for EGFR and 26.0% (32/123) 
for kRAS. There was no signiÀcant difference in 
tumour cell count between the EBUS-TBNA group 
and combined bronchoscopic and core biopsy groups 
using a t-test (p=0.45). 
Conclusion: The number of cells available for 
mutation analysis increases with the size of the 
sample. The percentage of tumour in the samples 
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MO11.01 SMAC MIMETIC (JP1201) 
SENSITIZES WILD TYPE EGFR NON 
SMALL CELL LUNG CANCERS (NSCLCS) 
TO MULTIPLE CHEMOTHERAPY 
AGENTS AND ERLOTINIB IN AN IAP 
DEPENDENT FASHION
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Yang Xie3, Lai Wang4, Adi F. Gazdar1, Patrick 
Harran5, Rolf A. Brekken2, Xiaodong Wang6, John D. 
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Background: The inhibitors of apoptosis proteins 
(IAPs) are key regulators of apoptosis, and are in turn 
inhibited by the second mitochondrial activator of 
caspases (SMAC). In many cancers various IAPs are 
up regulated and are believed to be factors leading to 
increased drug resistance, to combat this many small 
molecule mimetics of SMAC have been created, 
such as JP1201. Cytotoxicity due to SMAC mimetic 
treatment in a subset of cancer cells (including 18% 
of 50 non-small cell lung cancer, NSCLC lines) has 
been well documented, and is dependent on de novo 
synthesis of TNFƠ, and RIPK1 dependent TNFR1 
signaling. Clinical testing of NSCLC with SMAC 
mimetics as a single agent should thus focus on TNFƠ 
producing lung cancers. However, we were interested 
in whether SMAC mimetics sensitize non TNFƠ 
producing NSCLCs to available chemotherapies and 
targeted therapies for lung cancer.
surgical, 10% not speciÀed). TAT was 4.9 working 
days (95%CI=4.5-5.5). EGFR mutations included 
50% ex19del, 38% L858R, and 12% ex20ins. 
Mutation rate was higher (20%) among non-smoking 
women with adenocarcinomas, but 30% of mutations 
were identiÀed among current or ex-smoking 
men. Median survival in EGFR-M+ patients was 
482d compared to 407d for EGFR-M- patients. Of 
the 96 samples with detailed pathological review 
all EGFR-M+ tumours (20/96, 21%) were non-
mucinous adenocarcinomas (ADCs) and 100% were 
TTF1+ (versus 73% in EGFR-M-). No mutations 
were detected in more poorly differentiated NSCLC-
NOS or NSCLC-favouring ADC. Mutation testing 
failure improved markedly from 18% (29/152) in 
Year 1 to 5.4% (41/755) in Year 2. Factors associated 
with successful testing were better sample cellularity 
and higher DNA concentrations. However 75% of 
samples with poor cellularity but representative of 
tumor were informative, and mutation prevalence 
was 9%. Although samples with low DNA 
concentration (<2ng/ƫL) had a higher test failure rate 
(30% vs. 3.9% for [DNA]>2ng/ƫL), the mutation 
detection rate was 9.2%. 
Conclusion: Routine EGFR mutation screening 
using diagnostic samples is feasible, fast and 
informative in over 93% of cases. Although 
pathological review is critical, even small samples 
with low cellularity and DNA content may be 
successfully tested. Mutations tend to occur 
in better-differentiated non-mucinous TTF1+ 
adenocarcinomas. Whether these histological criteria 
may be more useful to select patients for EGFR 
testing in a UK population than smoking status and 
gender merits further investigation. 
Keywords: EGFR, mutation testing
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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Background: Standard clinical doses of chest 
radiotherapy of 60 – 63 Gy cause signiÀcant normal 
lung tissue damage but fail to offer adequate local 
control for NSCLC, despite concurrent use of 
chemotherapy. For that, there is an urgent need to 
develop effective and well tolerated radiosensitizers 
in NSCLC. Recently, we have shown that ionizing 
radiation (IR) activates the energy sensor and tumour 
suppressor AMP-activated kinase (AMPK) which 
leads to expression of cell cycle inhibitors such as 
p53 and p21cip1. Further we observed that metformin 
(MET) also activates AMPK, enhances the activation 
of this kinase by IR and the ionizing radiation 
(IR)-induced cytotoxicity in human NSCLC cells 
in culture. In the present study we investigated, in 
human NSCLC xenografts, the radio-sensitizing 
properties of MET. We also examined, in the same 
tumours, the effects of IR and MET on the activity 
of AMPK, of the radioresistance mediator Akt as 
well as their putative downstream effectors, tumour 
suppressor p53 and mRNA translation repressor 
4EBP1. 
Methods: A549 cells (2x106) were grafted in the 
franks of Balb/c immunodeÀcient athymic nude mice 
and tumours were left to grow to 100 mm³. MET 
supplementation was delivered in drinking water 
at a dose of 250 mg/kg daily, and IR of 10 Gy was 
delivered as a single fraction 7 days after initiation of 
metformin administration. Eight weeks later animals 
were euthanized and tumours where isolated. Half 
of each tumour was snap frozen for preparation of 
whole tumor lysates and immunoblotting analysis 
and the other half was Àxed and embedded for 
immunohistochemistry analysis. Tumour growth 
kinetics and levels of total AMPK, phosphor- (P)-
AMPK and P-Acetyl-CoA Carboxylase (ACC), 
P-Akt, p53 and P-4EBP1 were evaluated.
Results: MET and IR alone inhibited signiÀcantly 
A549 LC xenograft tumour growth. However, 
the combined treatment of MET and IR produced 
an additive effect and inhibited tumour growth 
signiÀcantly more than each treatment alone. IR and 
MET enhanced AMPK phosphorylation and activity, 
detected by ACC phosphorylation. Similar to tumour 
growth kinetics, the combined treatment of MET+IR 
enhanced AMPK activity and phosphorylation 
Methods: Using multiple in vitro assays; 
proliferation assays, colony formation assays, 
annexin V staining, western blotting, we explored 
the ability of JP1201 to sensitize NSCLCs to 
conventional chemotherapies across a panel of 20 
NSCLC lines. We then tested JP1201 alone and with 
chemotherapy in tumor xenografts to conÀrm in vitro 
sensitization. Finally we explore the mechanism of 
sensitization using siRNA knockdowns of individual 
IAPs in a drug response assay, and transiently 
transfected reporter constructs for 10 signaling 
pathways that are involved in stress and cytotoxicity.
Results: We Ànd that JP1201 sensitize (10 t0 1000 
fold) NSCLCs that do not respond to JP1201 alone 
to doxorubicin, erlotinib, gemcitabine, paclitaxel, 
vinorelbine, gemcitabine + cisplatin, paclitaxel + 
carboplatin and that this sensitization does not depend 
on TNFa secretion. Importantly JP1201 sensitized 
NSCLCs with wild type EGFR to erlotinib (10-100 
fold) Furthermore, combinations of JP1201 with 
gemcitabine or vinorelbine can robustly induce 
apoptosis and control in vivo tumor growth which 
translates to extended survival in NSCLC xenograft 
models. The siRNA knockdown mechanistic studies 
show that sensitization to chemotherapy is dependent 
on inhibition of IAPs; however, of great importance 
we Ànd that TNFR1, TNFƠ, and RIPK1 are not 
required for sensitization to chemotherapy. Finally, 
we Ànd that activation of ER stress as measured by 
CBF/NF-Y promoter activity and the JNK pathway as 
measured by AP1 promoter activity are both involved 
in the sensitization of vinorelbine by JP1201.
Conclusion: We conclude that IAP targeted therapy 
using a SMAC mimetic provides a new therapeutic 
strategy for sensitizing NSCLCs to standard 
chemotherapy agents, and that this occurs best when 
multiple pro-apoptotic pathways are activated.
Keywords: synergy, combination chemotherapy, IAP
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MO11.02 THE ANTI-DIABETIC DRUG 
METFORMIN SENSITIZES HUMAN 
NON-SMALL CELL LUNG CANCER 
(NSCLC) XENOGRAFTS TO IONIZING 
RADIATION.
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assays for TNF-Ơ.
Results: HCC193 was found to be more sensitive 
than H460 to BV6-induced apoptosis in a 
concentration-dependent and time-dependent 
manner. BV6 signiÀcantly sensitized both cell lines 
to radiation (HCC193—DER=1.38, p<0.05 at 1mM 
BV6; H460—DER=1.42, p<0.05 at 5mM BV6), 
but a higher concentration of and longer incubation 
timewith BV6 was necessary for H460 cells. The 
BV6-induced radiosensitization of HCC193 favored 
the extrinsic pathway of apoptosis, while that of 
H460 favored the intrinsic pathway.
Conclusion: BV6, an IAP antagonist, signiÀcantly 
enhanced the radiosensitization of HCC193 and 
H460 cells in vitro. More research is warranted to 
test the mechanism of action of BV6,and to assess its 
potential in vivo and in the clinical setting.
Keyword: BV6
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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MO11.04 Y-BOX-BINDING PROTEIN 
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THERAPEUTIC TARGET IN 
MALIGNANT MESOTHELIOMA
Michaela B. Kirschner1, Lyn J. Schedlich1, Yuen 
Yee Cheng1, James J. Edelman2, Rayleen Bowman3, 
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Background: The identiÀcation of novel therapeutic 
targets for malignant mesothelioma (MM), an 
asbestos-related malignancy with intrinsic drug 
resistance, is an important unmet need. The Y-Box-
binding protein 1 (YBX-1), a DNA- and RNA-
binding protein involved in transcriptional and 
translational regulation of many oncogenes and 
tumour suppressor genes, could be one of those 
novel targets. Being overexpressed in various 
cancers (e.g. NSCLC, breast) its nuclear expression 
has been shown to be associated with late stages of 
above the levels of each treatment alone. However, 
we also detected that MET and IR treatments 
increased signiÀcantly the total AMPK Ơ subunit 
levels in tumour tissues and caused a consistent 
potentiation of this effect when the two treatments 
were combined. On the other hand, MET inhibited 
basal and radiation-induced Akt phosphorylation in 
xenografts. IR and MET increased p53 expression 
and reduced phosphorylation of 4EBP1 while the 
combined MET+IR treatment potentiated those 
effects. Our immunoblotting results were veriÀed 
with immunohistochemistry experiments.
Conclusion: The present studies suggest that oral 
therapy with MET inhibits growth and enhances 
IR-induce cytotoxicity in human NSCLC xenograft 
tumours. IR and MET enhance the activity of the 
signalling pathway of the tumour suppressor AMPK 
and inhibit that of the radioresistance mediator Akt. 
These results demonstrate the potential of MET 
to function as a useful adjunct to IR in-vivo and 
support evaluation of this drug in clinical trials in 
combination with radiotherapy.
Keywords: AMP-activated kinase, radiosensitizer, 
metformin, Lung cancer
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MO11.03 BV6, AN IAP ANTAGONIST, 
ACTIVATES APOPTOSIS AND 
ENHANCES RADIOSENSITIZATION OF 
NON-SMALL CELL LUNG CARCINOMA 
IN VITRO
Bo Lu 
Rad Onc, Thomas Jefferson Univ/United States Of 
America
Background: Defects in the apoptosis pathway 
limit the effectiveness of radiation in non-small cell 
lung cancer (NSCLC) therapy. BV6 is an antagonist 
of cIAP1 and XIAP, members of the inhibitors of 
apoptosis (IAP) family. We investigated the potential 
of BV6 to sensitize NSCLC cell lines to radiation.
Methods: HCC193 and H460 lung cancer cell lines 
were treated with BV6 to investigate the effects of 
drug administration on cell proliferation, apoptosis, 
inhibition of XIAP and cIAP1, and radiosensitivity. 
Subsequent immunoblotting and Hoescht staining 
were utilized to determine the role of apoptosis in 
radiosensitization. Finally, the pathway of apoptosis 
was characterized by western blot analysis for 
cleaved caspase-8 and cleaved caspase-9, and ELISA 
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MO11.06 RNA APTAMER BLOCKADE OF 
OSTEOPONTIN DECREASES INVASION 
AND EMT IN NON-SMALL CELL LUNG 
CANCER
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Background: Osteopontin (OPN) is a secreted 
protein with a central role in the malignant 
phenotype of non-small cell lung cancer (NSCLC). 
Epithelial-mesenchymal transition (EMT) is essential 
for tumor invasion and metastatic spread. OPN 
expression in NSCLC is associated with activation 
of EMT. We hypothesize that OPN blockade by RNA 
aptamer technology could decrease tumor invasion 
by down regulation of EMT pathways.
Methods: OPN RNA aptamer (OPN-R3) is a 
single stranded RNA that speciÀcally binds to OPN 
by means of a complimentary three-dimensional 
structure. We exposed three NSCLC cell lines, H358 
(low endogenous OPN), A549 and H460 (both with 
high endogenous OPN) to OPN-R3 and a control 
aptamer at concentration of 100nM/ml. We evaluated 
matrigel invasion at 48H and extracted RNA for RT-
PCR evaluation of downstream targets associated 
with EMT.
Results: OPN blockade by OPN-R3 resulted in 
signiÀcant decreases in the number of invaded 
cells in the A549 (p=0.003) and H460 cell lines 
(p=0.039), but without effect in the H358 cell line. 
(Figure 1) RT PCR analysis demonstrated a decrease 
in expression of Snail-2, TGFb-1R, vimentin 
and N-cadherin with an associated increase in 
the expression of e-cadherin, cytokeratin-20, and 
desmoplakin, all consistent with a decrease in EMT 
pathway activation. (Figure 2)
disease and a poor prognosis. Furthermore, YBX-1 is 
associated with the RNA-induced silencing complex 
(RISC) which is important for the biogenesis of 
microRNAs (miRNAs). 
Methods: We used RNA interference to investigate 
the effects of gene silencing in established ATCC and 
primary MM cell lines as well as the immortalized 
normal mesothelial line Met-5A or primary 
mesothelial cells from pericardial Áuid. Growth 
inhibition was measured by SYBR Green staining of 
DNA, mRNA expression was quantiÀed by SYBR 
Green RT-qPCR and protein expression was assessed 
by western immunoblot. MiRNA expression after 
YBX-1 knockdown was proÀled using NCode 
miRNA Microarrays and validation of array data was 
performed using miRNA speciÀc TaqMan RT-qPCR. 
Results: Preliminary RNAi-based screening 
identiÀed knockdown of a number of genes, 
including YBX-1, to be growth inhibitory in MM 
cells. Further investigations revealed that silencing 
of YBX-1 is followed by profound subtype-speciÀc 
growth inhibition in MM cell lines. Although in all 
cell lines transfection with YBX-1 siRNA led to a 
reduction of YBX-1 mRNA and protein expression 
of 80-90 %, the effect on cell growth was variable. 
Four days after transfection the growth of the 
biphasic cell lines MSTO-211H and MM05 was 
reduced by 50-80 %, but only one of the epithelioid 
cell lines used, H2452, showed similar effects, 
while there was no growth inhibition in H28 and 
H2052 (both epithelioid). Furthermore, silencing 
of YBX-1 does not affect the growth of either Met-
5A or primary mesothelial cells from pericardial 
Áuid. Further experiments identiÀed a subset of 26 
miRNAs, including let-7f and miR-923, which are 
differentially expressed only in those cells that show 
inhibition of cell growth after YBX-1 knockdown. 
In addition, these arrays showed that silencing of 
YBX-1 alters the expression of miRNAs such as 
miR-16 and miR-21, two miRNAs well known to be 
involved in oncogenesis of various solid tumours. 
Conclusion: We have shown that siRNA-
mediated silencing of YBX-1 leads to signiÀcant 
growth inhibition predominantly in biphasic cells, 
suggesting subtype-speciÀcity. YBX-1-silencing 
induced dysregulation of a subset of miRNAs might 
be involved in this effect. A peptide inhibiting YBX-
1 function as used in breast cancer models could be 
developed as a potential treatment for biphasic MM. 
Keywords: YBX-1, Malignant mesothelioma
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PKC isozyme, is an oncogene overexpressed in 
NSCLC tumors and cell lines, particularly those 
with squamous histology (SCC). The PRKCI gene is 
ampliÀed in most SCC and drives PKCƨ expression. 
Aurothiomalate (ATM) disrupts the interaction 
between PKCƨ and Par6 and exhibits potent anti-
tumor activity in NSCLC with elevated PKCƨ. A 
phase I trial established a safe dose of ATM for 
patients with advanced NSCLC. We now report 
synergistic activity against SCC when both PKCƨ and 
mTOR are inhibited. These data form the foundation 
of a clinical trial for patients with advanced SCC. 
Methods: ATM sensitive and insensitive cells were 
grown in soft agar and treated with ATM, rapamycin, 
targeted and/or cytotoxic agents and assessed for 
anchorage independent growth. Representative ACA 
and SCC cells were grown in nude mice treated with 
ATM, rapamycin, both, or diluent. PKCƨ expression 
was assessed by QPCR in primary NSCLC and in 
cell lines. ATM dependent changes in NSCLC and 
peripheral blood leukocyte (PBL) gene expression 
were assessed by genome-wide gene expression 
analysis using Affymetrix chips to identify potential 
biomarkers of ATM-mediated PKCƨ inhibition. 
Results: ATM induced inhibition of anchorage 
independent growth in all NSCLC cell lines tested. 
SCC cells tended to be more sensitive to ATM than 
ACA. PRKCI ampliÀcation was present in the two 
most sensitive cell lines tested, H1703 and A427, 
both SCC cells. PKCƨ mRNA abundance correlated 
highly with ATM sensitivity. In 96 primary NSCLC 
tumors, 23/36 SCC and 18/60 non-SCC tumors 
were high PKCƨ expressers. ATM sensitivity did 
not correlate to chemosensitivity in general but 
correlated well with PKCƨ expression. ATM was 
relatively non-toxic in nude mice bearing A427 
and H460 cells and inhibited growth of established 
tumors at clinically relevant concentrations 
consistent with the in vitro IC
50
 for the cell lines 
tested. Comparison of gene expression proÀles of 
H1703 cells with and without PKCƨ-RNAi treatment 
revealed genes whose expression was signiÀcantly 
altered by knock down of PKCƨ. Comparison with 
genes expressed in H1703 and PBLs treated with 
ATM or diluent revealed 22 genes commonly 
regulated > 2-fold by both ATM and PKCƨ RNAi 
in H1703 and by ATM in PBLs. These are potential 
biomarkers for ATM response. Rapalogs have 
been tested in NSCLC patients with at best modest 
success. One method of resistance to mTOR 
inhibitors is phosphorylation and reactivation of Akt 
signaling. ATM inhibited rapamycin-induced Akt 
Conclusion: RNA aptamers are emerging as a 
viable alternative to small molecules and antibody-
based therapy in oncology because of high stability, 
low immunogenicity and very high afÀnity for 
protein targets. The OPN-R3 aptamer signiÀcantly 
decreased in vitro invasion in NSCLC cell lines 
with high native OPN expression and resulted in 
decreased expression of targets associated with EMT. 
Validation of these effects in vivo is underway.
Keywords: Non-small cell lung cancer (NSCLC), 
osteopontin, Epithelial-mesenchymal transition 
(EMT), Invasion
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
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MO11.07 COMBINED PROTEIN KINASE 
C IOTA AND MTOR INHIBITION FOR 
TREATMENT OF SQUAMOUS LUNG 
CANCER.
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Background: Targeted and maintenance therapies 
for NSCLC are directed largely at adenocarcinomas 
(ACA). However, for the approximately 40% of 
NSCLC patients with squamous histology, targeted 
and maintenance therapies have not been well 
deÀned. Protein kinase C iota (PKCƨ), an atypical 
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bone scan and X-rays in 28 days after inoculating 
and nuclei bone scan examination again before the 
mouse death, bone lesions for pathologic evaluation, 
weight loss and survival time until 6 weeks. 
Results: This study indicated the combination group 
signiÀcantly increased the apoptosis of the three 
lung cancer cells in different time(P=0.00), and 
the G1/G0 phase proportion was higher than other 
treatment group. Western blot conÀrmed that the 
role of p-p70S6K was inhibited apparently in the 
combination group. The zoledronic acid combined 
with everolimus was effective in delay NSCLC 
bone metastatic in animal model. Bone nuclei 
scan results revealed that there were more bone 
metastatic lesions in the control group than that in 
the combination group for the Àrst bone metastasis 
examination. In the treatment groups, bone nuclei 
scan and radiographic imagine indicated that the 
combination therapy signiÀcantly reduced bone 
metastasis (9 versus 2 in the control group and 
combination group, p=0.017). The median survival 
days were 29, 35, 41, 42 in control group, zoledronic 
acid group , everolimus group and combination 
group respectively(P=0.00). 
Conclusion: The results indicated that zoledronic 
acid combined with everolimus had synergistic 
interaction to delay NSCLC bone metastasis and 
prolonged survival time in vivo.
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MO11.09 PI3K INHIBITORS, PI-103, GDC-
0941, AND BEZ235, OVERCOME HGF-
MEDIATED RESISTANCE TO EGFR-TKIS 
IN EGFR MUTANT LUNG CANCER
Seiji Yano1, Ivan S. Donev1, Tadaaki Yamada1, Shinji 
Takeuchi1, Kunio Matsumoto2 
1Medical Oncology, Kanazawa University Cancer 
Research Institute/Japan, 2Tumor Dynamics And 
Regulation, Kanazawa University Cancer Research 
Institute/Japan
Background: The acquired resistance to epidermal 
growth factor receptor (EGFR) tyrosine kinase 
inhibitors (TKIs) is one of the most serious problems 
on the management of EGFR mutant lung cancer. 
We recently reported the novel mechanism that 
hepatocyte growth factor (HGF) induces EGFR-
TKI resistance by activating Met which restores 
phosphorylation of downstream MAPK-ERK1/2 and 
PI3K-Akt pathways.
phosphorylation, suggesting a possible mechanism 
for overcoming resistance. ATM and rapamycin 
were highly synergistic against SCC cell lines and in 
mouse tumor models. 
Conclusion: Taken together, these data suggest that 
combined inhibition of PKCƨ and mTOR with ATM 
and rapamycin may be effective against SCC. We 
are beginning a clinical trial of the combination as 
maintenance therapy for patients with advanced SCC 
after initial chemotherapy with correlative studies to 
assess mechanisms of response and resistance. 
Keywords: PKCiota, mTOR, Squamous lung cancer
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MO11.08 EVEROLIMUS COMBINED 
WITH ZOLEDRONIC ACID TREATING 
LUNG ADENOCARCINOMA BONE 
METASTASIS IN VITRO AND VIVO
Yongfeng Yu, Zhengbo Song, S. Yang, Shun Lu 
Department Of Shanghai Lung Cancer Center, 
Shanghai Chest Hospital, Jiaotong University, 
Shanghai/China
Background: Bone metastases contribute to burden 
of disease in patients with non-small cell lung 
cancer (NSCLC). Zoledronic acid is now proposed 
to have the cytostatic effects on anti-tumour 
effects. Everolimus, an serine-threonine kinase 
mammalian target of rapamycin (mTOR) inhibitor, 
has been proven effective as an anti-cancer agent 
in a broad range. The purpose of this study is to 
detect the effect of different treatment in vitro and 
vivo and to evaluate the efÀcacy of zoledronate 
alone and combined with everolimus treating lung 
adenocarcinoma bone metastasis.
Methods: MTT assay was applied to analyze 
these different treatments (zoledronic acid group, 
everolimus group, zoledronic acid combined with 
everolimus group , control group) on proliferation 
of lung cancer cells(A549, H460, SPC-A1). Flow 
cytometry analysis was performed to assess the cell 
cycle phase distribution and apoptosis. The human 
lung adenocarcinoma cancer high bone metastasis 
cells SPC-A-1BM were inoculated into the cardiac 
ventricle of 40 BALB/c mice. They were randomized 
into 4 groups(zoledronic acid group, everolimus 
group, two drugs combination group, and control 
group), and received treatments for 3 weeks after 
4 days of tumor implantation. Bone metastases 
was assessed by measurement of total-body nuclei 
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Background: NOD-scid IL2Rgammanull (NSG) 
mice lack functional B and T cells and natural killer 
cell activity and are the most immunodeÀcient, yet 
physiologically durable, murine models available for 
consistent xenoengraftment of human primary tumors 
and for in vivo drug testing. The overarching goal of 
this project is to use NSG mice to propagate non-small 
cell lung cancer (NSCLC) tumor cells from individual 
patients and validate a novel “co-clinical trial” strategy 
(i.e., concurrent evaluations of patients and patient-
derived xenografts [PDXs] in immunodeÀcient NSG 
mice) as a platform to directly address and overcome 
bottle-necks in the clinical application of state-of-the-art 
cancer genomics and personalized therapy. 
Methods: Utilizing a transdisciplinary research 
collaboration between the University of California 
at Davis Cancer Center and The Jackson Laboratory, 
fresh tumor specimens are engrafted subcutaneously 
into the Áanks of NSG mice. First human-to-mouse 
(P0) tumors and serially-passaged PDX tumors have 
been subjected to 1) histomorphological assessment by 
H&E and immunohistochemical (IHC) stains, 2) RT-
PCR-based molecular analyses of EGFR and K-Ras 
mutations, EML4-ALK fusion transcripts, 3) RNA 
expression levels of ERCC1, RRM1 and TS genes, 
and 4) comprehensive genomic analyses by Affymetrix 
Human SNP 6.0 and Human Gene 1.0 ST Arrays. 
Passages of Àrst (P1) and second (P2) mouse-to-mouse 
tumors are being evaluated for response to in vivo drug 
testing. 
Results: Of more than 200 cancers engrafted in 
our consortium over the past year, 42 of these were 
NSCLC tumors; of these, 8 were discontinued due to 
non-progressive growth and 1 due to non-matching 
histology. To date, 25 tumors (60%) remain within the 
9-month incubation period. Patients demographics 
and clinicopathologic characteristics corresponding 
to the Àrst 7 NSCLC PDX models are as follows: 
male:female, 6:1; active smokers:prior smokers, 
2:5, cigarette use, median 58.6 pack/year; and 
adenocarcinoma;squamous cell carcinoma, 2:5. The 
median time from engraftment to P0 passage was 70.0 
days (range: 59–106 days). Histomorphological and 
IHC correlation between PDX tumors and original 
Methods: We determined whether inhibition of 
PI3K, a downstream molecule of both EGFR and 
Met, could overcome HGF-mediated EGFR-TKI 
resistance in EGFR mutant lung cancer cells, PC-9 
and HCC827. Here, we explored therapeutic effect of 
inhibitor PI-103, GDC-0941 (a derivative of PI-103 
with better pharmacokinesis), and BEZ235, on HGF-
induced EGFR-TKI resistance in vitro and in vivo.
Results: Unlike geÀtinib or erlotinib, continuous 
exposure with PI-103, GDC-0941, and BEZ235 
inhibited proliferation of PC-9 and HCC827 cells, 
even in the presence of HGF. Moreover, transient 
exposure of PI-103 combined with geÀtinib caused 
sustained inhibition of Akt phosphorylation, but not 
ERK1/2 phosphorylation, resulting in induction of 
tumor cell apoptosis even in the presence of HGF. In 
geÀtinib-resistant xenograft model using PC-9 cells 
mixed with HGF high producing Àbroblasts, PI-103 
or GDC-0941 monotherapy did not inhibit tumor 
growth. However, PI-103 or GDC-0941 combined 
with geÀtinib successfully regressed geÀtinib-
resistant tumor.
Conclusion: These results indicate that transient 
blockade of PI3K-Akt pathway by PI3K inhibitors 
and geÀtinib could overcome HGF-mediated 
resistance to EGFR-TKIs by inducing apoptosis in 
EGFR mutant lung cancer. 
Keywords: drug resistance, PI3K inhibitors, EGFR 
mutant lung cancer, HGF
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MO11.11 CHARACTERIZATION OF 
PATIENT-DERIVED NSCLC NSG 
MOUSE MODELS FOR PERSONALIZED 
THERAPY
Tianhong Li1, Sonal Desai1, Royce F. Calhoun2, 
David T. Cooke2, Valerie Kuderer2, Clifford G. 
Tepper3, Ryan R. Davis4, Laurel A. Beckett5, Phillip 
Mack1, Primo N. Lara1, Regina Gandour-Edwards6, 
Kathleen Danenberg7, Ralph Devere White8, Neal 
Goodwin9, David R. Gandara1 
1Internal Medicine, Div. Hematology/oncology, 
University Of California At Davis/United States 
Of America, 2Division Of Cardiothoracic Surgery, 
University Of California At Davis/United States 
Of America, 3Department Of Biochemistry And 
Molecular Medicine, University Of California At 
Davis/United States Of America, 4Mind Institute, 
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America, 5University Of California At Davis/United 
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susceptible to mutation-based resistance creating 
a medical need for second-generation agents. For 
EGFR inhibitors, the T790M gatekeeper mutation 
accounts for ~50% of resistance. Potent irreversible 
T790M inhibitors are in development but can exhibit 
toxicity due to co-inhibition of native (endogenous) 
EGFR, suggesting that T790M-selective agents will 
be required. For the ALK inhibitor crizotinib, clinical 
resistance has been linked to the L1196M gatekeeper 
mutation. Previously, we have identiÀed AP26113 
as a potent ALK inhibitor that overcomes this and 
other mutations. A broad kinase screen revealed that 
AP26113 also reversibly inhibits EGFR harboring 
activating and T790M mutations. 
Methods: The activity of AP26113 against native, 
activated (L858R or delE746_A750 [DEL]), and 
T790M mutant (L858R/T790M or DEL/T790M) 
forms of EGFR was examined in NSCLC as well 
as engineered Ba/F3 and 3T3 cell lines. EGFR 
signaling was assessed by measuring levels of 
phosphorylated EGFR (Y1068), in vitro proliferation 
measured by MTS assay, and in vivo tumor growth 
measured in mouse xenografts following daily oral 
dosing. 
Results: AP26113 was essentially inactive against 
native EGFR, inhibiting signaling with IC50s >1000 
nM in a NSCLC cell line (H358) and native EGFR-
transduced Ba/F3 and 3T3 cells. In contrast, potent 
activity was demonstrated against activated forms 
of EGFR. EGFR signaling was inhibited with IC50s 
of 10-50 nM in HCC827 (DEL), DEL Ba/F3 and 
L858R 3T3 cells. In HCC827 cells, proliferation 
was inhibited with an IC50 of 105 nM. In an 
HCC827 xenograft model, doses of 25 mg/kg or 
greater induced tumor regression (>33%) and >90% 
and >60% inhibition of EGFR signaling 10 and 
24 hours after dosing. SigniÀcantly, AP26113 also 
demonstrated potent activity against T790M mutant 
forms of EGFR. EGFR signaling was inhibited with 
IC50s of 10-63 nM in H1975 (L858R/T790M), 
and DEL/T790M and L858R/T790M Ba/F3 and 
3T3 cells. In H1975 and DEL/T790M Ba/F3 cells 
proliferation was inhibited with IC50s of 85-350 
nM. In an H1975 xenograft model, doses of 50 and 
75 mg/kg led to signiÀcant tumor growth inhibition 
(45%). In a DEL/T790M Ba/F3 xenograft model, 
doses of 50 and 75 mg/kg led to tumor stasis and 
50% tumor regression. In both models, substantial 
prolonged inhibition of EGFR signaling was 
observed. 
Conclusion: AP26113 is a novel reversible inhibitor 
of activated and resistant mutants of EGFR, and 
patient NSCLC tumors is excellent. Most engrafted 
NSCLC tumors have poor prognostic features: poorly 
differentiated tumors (n=6), K-Ras mutation (n=3), 
and low median expression levels of chemotherapy 
predictive biomarkers ERCC1, RRMI and TS RNA 
(1.00, 0.85, and 1.81, respectively). There was no 
statistically signiÀcant difference between the original 
patient and P0 tumors with respect to RNA expression 
levels of ERCC1 (p=0.52) and TS (p=0.83). Among 
these biomarkers, the best correlation between PDX 
and P0 tumors is seen for ERCC1 expression. Ongoing 
experiments are testing these NSCLC PDX models 
for correlation with patient response to platinum-based 
therapy. Further molecular and genomic analyses are 
ongoing and will be presented. 
Conclusion: To our knowledge, this is the largest 
cohort of NSCLC PDX models yet established. Our 
initial experience demonstrates close similarity between 
PDX and original patient tumors with regards to 
histomorphological features and molecular biomarker 
expression. Further characterization is needed to deÀne 
the role of these models as clinically relevant research 
platforms for selecting and validating personalized 
cancer therapy based on molecular biomarker proÀling 
and in vivo drug testing. 
Keywords: patient-derived xenografts, personalized 
therapy, in vivo drug testing, NSCLC, NSG mice
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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MO11.12 AP26113, A POTENT ALK 
INHIBITOR, IS ALSO ACTIVE AGAINST 
EGFR T790M IN MOUSE MODELS OF 
NSCLC
Juan J. Miret, Frank Wang, Rana Anjum, Sen Zhang, 
Jeffrey Keats, Michelle Cookson, Yaoyu Ning, 
Scott Wardwell, Lauren Moran, Qurish Mohemmad, 
Yihan Wang, Jiwei Qi, Rachel Squillace, Narayana 
Narasimhan, David Dalgarno, Tim Clackson, 
William Shakespeare, Victor Rivera 
Biology, Ariad Pharmaceuticals/United States Of 
America
Background: Activating mutations in EGFR and 
anaplastic lymphoma kinase (ALK) are drivers in 
~20% of all NSCLCs. First generation EGFR and 
ALK inhibitors are clinically efÀcacious, but are 
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cancer are independent of KRAS status. To test 
this hypothesis we evaluated antitumor activity of 
linifanib, as monotherapy or in combination with 
carboplatin/paclitaxel (CP), in NSCLC xenograft 
models utilizing cell lines harboring either wild type 
or mutated KRAS.
Methods: Tumor growth inhibition (TGI) was 
assessed in H1299 (KRAS wt) and Calu-6FP (KRAS 
mut) Áank xenograft models using tumor volumes 
measured when the control groups were terminated 
(day 43 and 32 respectively). Linifanib was 
evaluated as monotheray (6.25 – 25 mg/kg/day BID, 
PO) and in combination with CP.
Results: As monotherapy linifanib was active 
(TGI > 50%) in both NSCL tumor models at all 
doses tested. When dosed in combination with 
CP the response was generally greater than either 
therapy alone. The highest level of inhibition with 
combination therapy was in the KRAS-mutant 
model where maximal TGI (85%) was achieved 
with a dose (6.25 mg/kg/day) 4-fold lower than the 
optimal efÀcacious dose (25 mg/kg/day). Drug-
related toxicity was not observed in any dose group.
 
Conclusion: Linifanib is active in RAS-wild 
type and in RAS-mutant models of NSCLC as 
monotherapy and in combination with carboplatin/
paclitaxel. These results support the potential 
therapeutic utility for linifanib in KRAS-mutant 
NSCLC. The mechanism for the enhanced activity 
with chemotherapy in the KRAS-mutant model is 
being investigated.
Keywords: angiogenesis, VEGFR2 inhibitor, Kras, 
combination therapy
does not inhibit the native enzyme. Importantly, oral 
doses that are efÀcacious in mice against activated 
and T790M mutant EGFR are similar to those 
active against native- and crizotinib-resistant ALK 
variants, suggesting that AP26113 is a dual ALK/
mutant EGFR inhibitor. These data support clinical 
evaluation of AP26113 in patients with resistant 
EGFR-driven tumors.
Keywords: EGFR T790M, reversible kinase 
inhibitor, AP26113, ALK
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MO11.13 EFFICACY OF LINIFANIB IN 
PRECLINICAL MODELS OF NSCLC 
WITH WILD-TYPE AND MUTATED KRAS
Daniel H. Albert1, David Reuter1, Paul A. Ellis1, Gail 
Bukofzer1, Cherrie K. Donawho1, Mark D. Mckee2, 
Justin L. Ricker2, Dawn M. Carlson2, Steve K. 
Davidsen3 
1Dept R4n2, Abbott Laboratories/United States Of 
America, 2R48k, Abbott Laboratories/United States 
Of America, 3R460, Abbott Laboratories/United 
States Of America
Background: KRAS is an oncogene encoding a 
GTP-binding protein that regulates cell growth, 
differentiation and apoptosis via multiple interactions 
including MAPK, STAT and PI3K. KRAS mutations 
have been reported in 22% of lung adenocarcinomas 
and are associated with poor overall outcome in 
cancer. Patients with NSCLC undergoing therapy 
with erlotinib have poorer disease control if a KRAS 
mutation is present (14% vs. 37% for wild-type, 
Kim et al. AACR 2010;#1981). A similar trend 
linking KRAS mutations to resistance to EGFR 
inhibitors has been observed in colorectal carcinoma 
(Dempke WC, Heinemann V. Anticancer Res. 2010 
Nov;30(11):4673-7). EGFR-related resistance is 
not fully understood, but these clinical outcomes 
suggest the need for additional therapy to overcome 
resistance linked to KRAS mutations. Linifanib 
(ABT-869) is a potent VEGF/PDGF RTK inhibitor 
that is active in lung cancer models and has exhibited 
clinical signals of activity in a phase 2 NSCLC 
trial (ESMO 2010, abstract 41). The primary mode 
of action of linifanib is thought to be on tumor 
vasculature through inhibition of the VEGF and 
PDGF signaling pathways with limited direct effects 
on tumor proliferation. Therefore we hypothesized 
that antitumor effects of linifanib observed in lung 
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growth inhibition. Similar results were obtained 
in the HCC827TR3 xenograft model. However, in 
the H1975 xenograft model, combination therapy 
of erlotinib (75 mg/kg) with docetaxel (5 mg/kg) 
showed no synergistic antitumor effect compared 
with docetaxel (5 mg/kg) monotherapy. In in 
vitro tests, EGFR phosphorylation was inhibited 
by erlotinib in EBC-1 and HCC827TR3, but not 
in H1975 cells. In the HPAC xenograft model, 
combination therapy of erlotinib (75 mg/kg) with 
docetaxel (30 mg/kg) showed signiÀcantly superior 
antitumor effect compared with docetaxel (30 mg/
kg) monotherapy (TGI: 89% and 60%; p<0.01). In 
this model, EGFR phosphorylation of HPAC cells 
was inhibited by erlotinib in vivo. 
Conclusion: The combination therapy of erlotinib 
with docetaxel was considered to be a superior 
treatment modality compared to docetaxel 
monotherapy after disease progression on erlotinib 
monotherapy in NSCLC.
Keywords: EGFR, erlotinib, resistant, 
Chemotherapy
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MO12.01 AN INTER-PROFESSIONAL 
DYSPNEA MANAGEMENT CLINIC: 
COLLABORATING TO MANAGE 
SHORTNESS OF BREATH
Lynn Kachuik1, Kayvan Amjadi2 
1Palliative Care, The Ottawa Hospital/Canada, 
2Respirology: Interventional Pulmonology, The 
Ottawa Hospital / University Of Ottawa/Canada
Background: Our cancer centre provides lung 
cancer care for 1.2 million residents. The centre 
has seen 728 new lung cancer patients per calendar 
year from 2007- 2009 and has treated 1103 cases 
with either systemic or radiation therapy. In addition 
lung cancer patients accounted for an average of 
8338 patient visits per calendar year or 695 visits 
per month. Dyspnea is one of the most distressing 
symptoms experienced by lung cancer patients 
at any point in the disease trajectory. A three day 
prevalence study conducted at our centre in 2007 
using the Edmonton Symptom Assessment System 
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MO11.14 CONTINUOUS INHIBITION 
OF THE EPIDERMAL GROWTH 
FACTOR RECEPTOR (EGFR) WITH 
ERLOTINIB ENHANCED ANTITUMOR 
ACTIVITY OF CHEMOTHERAPY 
AGAINST ERLOTINIB-RESISTANT NON 
SMALL CELL LUNG CANCER (NSCLC) 
XENOGRAFTS.
Toshiki Iwai, Masatoshi Shirane, Yoichiro Moriya, 
Kaori Fujimoto-Ouchi 
Product Research, Chugai Pharmaceutical/Japan
Background: Erlotinib, an effective EGFR 
tyrosine kinase inhibitor, has been shown to 
provide signiÀcant clinical beneÀt for patients 
with metastatic NSCLC (BR.21, SATURN) and 
pancreatic cancer. But signiÀcant numbers of patients 
proceed to progressive disease (PD) during erlotinib 
monotherapy due to the occurrence of erlotinib 
resistance caused by a secondary mutation (T790M) 
in EGFR or by MET ampliÀcation though tumor 
maintains the expression of EGFR. Standard therapy 
for the patients with PD has not been established. In 
the present study, we investigated the combination 
therapy of erlotinib with docetaxel in erlotinib-
resistant xenograft models. 
Methods: Three erlotinib-resistant NSCLC cell-lines 
(EBC-1, H1975, HCC827TR3) were subcutaneously 
inoculated into BALB/c nude mice. Drug 
administration started when tumor volume reached 
100-300 mm3. Erlotinib was orally administered once 
a day and docetaxel was intravenously administered 
once every 3 weeks. Antitumor effect was evaluated 
by tumor growth inhibition (TGI) on day 22. As 
an in vivo erlotinib-resistant tumor model, HPAC 
pancreatic cancer cells were subcutaneously 
inoculated and erlotinib administration started when 
tumor volume reached approximately 100-300 mm3, 
and was continued until tumor growth inhibition 
was not observed. The mice were rerandomized and 
treated with erlotinib in combination with docetaxel. 
Antitumor effect was evaluated on day 22. EGFR 
and downstream signal transduction molecules were 
analyzed by western blotting. 
Results: In the EBC-1 xenograft model, combination 
therapy of erlotinib (75 mg/kg) with docetaxel (5 
mg/kg) showed signiÀcantly superior antitumor 
effect compared with docetaxel (5 mg/kg) 
monotherapy (TGI: 84% and 55%; p<0.01), whereas 
erlotinib (75 mg/kg) monotherapy showed no tumor 
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MO12.02 ASSESSMENT OF PALLIATIVES 
CARE (PC) IN ADVANCED NON SMALL 
CELL LUNG CANCER PATIENTS 
(NSCLC): AN OBSERVATIONAL STUDY 
FROM GFPC. BASELINE DATA AT 
INCLUSION
Alain Vergnenegre1, Stéphane Hominal2, Isabelle 
Monnet3, Gérard Oliviero4, Nathalie Baize5, 
Clarisse Audigier-Valette3, Henri Bérard6, Gislaine 
Fraboulet7, Herve Le Caer8, Christos Chouaid9 
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France, 2Ch, Service De Pathologie Respiratoire/
France, 3Service De Pathologie Respiratoire, Chi/
France, 4Service De Pathologie Respiratoire, Chr/
France, 5Département De Pneumologie, Centre 
Hospitalaire Universitaire Angers/France, 6Service 
De Pathologie Respiratoire, Hôpital D’instruction 
Des Armées Sainte Anne/France, 7Service De 
Pathologie Respiratoire, Ch/France, 8Oncology, 
Centre Hospitalier Dracenie/France, 9Service De 
Pathologie Respiratoire, Chu Saint Antoine/France
Background: Palliatives cares (PC) appears as 
an important modality of advanced non small cell 
lung cancer patients (NSCLC) management (1). 
Little is known in France about the time of their 
initiation, their contents, the quality of life (QoL) and 
economical impact.
Methods: ETOBSUP was an observational study, 
performed in 39 centres of the GFPC, a national 
network of lung cancer management specialized 
centres. All the consecutives patients, with PC 
initiated, were included between July 1st 2009 and 
June 30th 2010. Information about management, 
type of PC and QoL assessment (EQ5-D) were 
prospectively collected every 3 months, with one 
year follow-up. Uni and multivariate analyses 
researched factors associated to PC. 
Results: The study included 444 patients, median 
age was 63 y [37-90], 72.5% males, 59.9% PS 0-1, 
19.2% PS2, 8.3% PS>2; median weight loss was 
5.1% [0-38.9]. Histology was: adenocarcinoma in 
61.2% of patients, squamous cell 18.9%, others 
19.9%. Metastases were preferentially in bones 
(25%), lung (21%), brain 15%, adrenal glands 
(12.7%). An organized announcement of cancer 
was performed in 71% of cases, with the help of a 
psychologist in 17.6%. The mean delay between 
diagnosis and announcement was 9 days ± 15. 
Before PC, NSCLC management was surgery 
(ESAS) indicated that shortness of breath of > 4/10 
was an issue in 51% of 54 lung patients included 
in the study. Since dyspnea was such an issue for 
our patients, we piloted a ½ day inter-professional 
clinic for patients experiencing distressing dyspnea 
(ESAS score > 4/10). It included assessment of the 
patient by various clinicians (physician, nurse, social 
worker, occupational therapist, respiratory therapist) 
with oncology and palliative care expertise. The goal 
of the clinic was to identify any underlying clinical 
causes of the dyspnea and apply best evidence 
in individualizing interventions, education and 
counseling to help patients manage their shortness 
of breath. Validated tools were used in the initial and 
follow up assessments to measure the effectiveness 
of interventions as well as patient outcomes. 
Methods: The patients were assessed at initial and 
follow up visits using a series of validated tools 
relevant to dyspnea. These included: the Edmonton 
Symptom Assessement System, the Baseline 
Dyspnea Index, the Transitional Dyspnea Index, 
the six minute walk test, incentive spirometry, 
oxygen saturation levels, respiratory rate, pulse, 
blood pressure, the Palliative Performance Scale, the 
Eastern Cooperative Oncology Group scale and the 
European Organization for Research and Treatment 
of Cancer Quality of Life Questionnaire 30. In 
addition, patients were asked about their satisfaction 
with the care received. All results were entered into a 
protected data base. 
Results: In analyzing our data we wanted to know 
if patients attending the Dyspnea Management 
Clinic beneÀted from the inter-professional team’s 
involvement and collective knowledge related to 
managing shortness of breath. We will report on the 
results of our data analysis including parameters 
such as dyspnea scores, clinical outcomes, functional 
status, and quality of life. 
Conclusion: Dyspnea is a very distressing 
symptom for lung cancer patients. Data related 
to targeted management via a focused clinic with 
a knowledgeable inter-professional team, use of 
appropriate tools and individualized strategies will 
be presented. 
Keyword: interprofessional dyspnea management
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chemotherapy. Toxicity was manageable and 36 pts 
(37%) presented G3+ toxicities (NCI-CTC v.3.0). 
Partial tumor response was seen in 17 pts (18%), 
complete response in 1 pt (1%) and stable disease 
in 35 pts (36%). In a mean follow-up of 13 mo, 47 
deaths were observed. The median OS was 15.4 mo. 
No difference in 1-year OS was observed between 
pts with CCI < 7 vs.  7 (56% vs. 71%, HR 1.51, 
p=0.174). Estimated 1-year OS was signiÀcantly 
better for pts with ECOG-PS 0-1 vs. 2+ (65% vs. 
55%, HR 0.46, p=0,017), BMI > 21 vs.  21 kg/m2 
(70% vs. 48%, HR 0.58, p=0.059), HB  12 vs. < 12 
g/dL (70% vs. 46%, HR 0.43, p=0.003), low CRP (< 
66 mg/L, ROC analysis) vs. elevated CRP (75% vs. 
53%, HR 0.39, p=0.045). ECOG-PS 0-1 and BMI > 
21 kg/m2 before chemotherapy remained signiÀcant 
as favorable prognostic factors in terms of OS in a 
multivariate analysis.
Conclusion: Our results suggest that chemotherapy 
can be delivered safely and good outcomes can be 
observed in selected NSCLC patients aged  65 y. 
Those pts with ECOG-PS 0-1 and BMI >21 kg/m2 
presented better OS rates and, if conÀrmed in other 
studies, these prognostic factors must be taken into 
account in treatment selection.
Keywords: elderly patients, Chemotherapy, 
prognostic factors, Non-small cell lung cancer
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MO12.04 INCIDENCE OF PAIN IN 
CA.LUNG PATIENTS REFERRED TO 
PALLIATIVE CARE
Lingegowda K. Boregowda 
Palliative Medicine, Kidwai Memorial Institute Of 
Oncology/India
Background: Lung cancer being the major cancer 
in men in the world, in developing country like India 
Ca.Lung constitutes 7.1% in men and 2%in women. 
Still majority of our patients present to hospital in an 
advanced stage. More than 80% will be having pain 
in this stage and they need only palliative care as 
there is no role for curative treatment.
Methods: 446 patients were screened who were 
rererred to palliative care department over a perios 
of 3 months from all the departments. Total 38 
patients with diagnsis of Ca.Lung were rererred from 
Surgical and Medical oncology.
Results: 90% of patients had pain at the time of 
reporting to palliative care centre.
(10.3%), chemotherapy (36%), radiotherapy 
(14.9%), symptomatic treatments (43.4%). 
Conclusion: ETOBSUP was an observational study, 
which could provide characteristics and follow-up 
of NSCLC patients with palliative cares. Complete 
data’s, including type of PC and factors signiÀcantly 
associated with PC will be presented at the meeting. 
Keywords: palliative care, Lung cancer, 
observational study
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MO12.03 CHEMOTHERAPY IN ELDERLY 
PATIENTS WITH ADVANCED NSCLC: 
A RETROSPECTIVE ANALYSIS OF THE 
IMPACT OF PERFORMANCE STATUS, 
CHARLSON COMORBIDITY INDEX, 
BODY MASS INDEX AND HEMOGLOBIN 
AND C-REACTIVE PROTEIN LEVELS 
ON OVERALL SURVIVAL
Tiago K. Takahashi, Caroline C.L. Barbosa, Paulo 
M. Hoff, Gilberto Castro Jr 
Clinical Oncology, Instituto Do Cancer Do Estado 
De Sao Paulo/Brazil
Background: Elderly patients (pts) diagnosed 
with advanced NSCLC can be safely treated with 
platinum-based chemotherapy, but pt selection is 
a critical issue. We aimed to study the outcomes 
of pts aged  65 y and diagnosed with advanced 
NSCLC treated with chemotherapy, and the impact 
of performance status (PS), Charlson comorbidity 
index (CCI), body mass index (BMI), hemoglobin 
(HB) and C-reactive protein (CRP) levels on overall 
survival (OS).
Methods: It is a retrospective study on pts aged 
 65 y diagnosed with advanced NSCLC and 
consecutively treated with chemotherapy from 
Jul/2007 to Jun/2010. Pre-treatment ECOG-PS, 
CCI, BMI, HB and CRP levels were analyzed as 
prognostic factors. OS was estimated by the Kaplan-
Meier method and curves were compared with 
log-rank. A multivariable Cox proportional hazards 
model was used to control for prognostic factors.
Results: 97 pts were identiÀed: median age 70 y (65-
89 y), 68% male, 75% ECOG-PS 0-1, 72% smokers; 
61% adenocarcinoma; median of 1 metastatic site. 
Chemotherapy regimens included carboplatin-
paclitaxel (47%), cisplatin-gemcitabine (33%) and 
gemcitabine alone (9%), delivered in a median 
of 4 cycles. 37 pts were treated with second line 
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the 6 months, with the highest uncertainty in the 6 
month of diagnosis (T4) (M= 64.7, SD= 9.4). 
Conclusion: The relatively low scores in role 
and social functions and high uncertainty in these 
patients have suggested the major impact of lung 
cancer on patients’ daily life. Future intervention 
studies to integrate these concerns and disease related 
psychological/ physical care would be strongly 
suggested to improve lung cancer patients’ QOL. 
Keywords: Quality of Life, uncertainty, social function, 
role function
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MO12.07 HEALTH-RELATED QUALITY 
OF LIFE IN PATIENTS WITH LUNG 
CANCER: VALIDATION OF THE 
MEXICAN-SPANISH VERSION OF THE 
EORTC QLQ-LC13 QUESTIONNAIRE
Carolina Nuñez-Valencia1, Luis Fernando Oñate 
Ocaña2, Leonardo Reynoso-Erazo3, Pablo Espinoza-
Mireles-de-Villafranca2, Patricia Angulo Camarena4, 
Diana Flores Estrada4, Oscar Arrieta4 
1Unidad De Postgrado, Facultad De Psicología, 
Universidad Nacional Autónoma De México/Mexico, 
2División De Investigación, Instituto Nacional De 
Cancerología/Mexico, 3Unidad De Postgrado, 
Universidad Nacional Autónoma De México/Mexico, 
4Clínica De Cáncer De Pulmón, Instituto Nacional 
De Cancerología/Mexico
Background: Lung cancer (LC) is the main cause 
of cancer-related mortality worldwide and health-
related quality of life (HRQL) is fundamental 
to evaluate treatment results. Our objective is 
to validate the Mexican-Spanish versions of the 
European Organization for Research and Treatment 
of Cancer (EORTC) Quality-of-Life Questionnaire 
QLQ-C30 and QLQ-LC13 disease-speciÀc 
questionnaire module in Mexican patients with LC. 
Methods: Translation procedures followed EORTC 
guidelines. Both instruments were completed by 
patients with LC, before, during and after treatments. 
Tests for reliability and validity were performed. 
Test-retest was performed on a subset of patients. 
Results: One hundred and Àfty-three patients 
completed both questionnaires. Compliance rates 
were high, and questionnaires were well accepted.
Patients with better Karnofsky or ECOG 
performance status reported better functional HRQL 
scores. Different scales in the QLQ-C30 and QLQ-
Conclusion: Routine referral to palliative care centre 
from the day of diagnosis solve many problems 
in Ca.Lung patients. Early referral will improve 
patients comfort from pain.
Keywords: palliative care, Ca.Lung, pain
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MO12.06 CHANGES OF QUALITY OF 
LIFE AND UNCERTAINTY IN NEWLY 
DIAGNOSED ADVANCED LUNG 
CANCER PATIENTS – A 6 MONTHS 
LONGITUDINAL STUDY
Yeur-Hur Lai1, Yu-Chio Liao2, Yun-Hsing Lee1, 
Chong-Jen Yu3, Pan Chyr Yang4 
1School Of Nursing, National Taiwan University/
Taiwan, 2Yuanpei University/Taiwan, 3Pulmonary 
And Critical Care Medicine, National Taiwan 
University Hospital/Taiwan, 4National Taiwan 
University College Of Medicine/Taiwan
Background: Lung cancer is one of the most 
threatening diseases due to its limited survival time. 
However, limited information has reported about 
patients’ quality of life and uncertainty during the 
Àrst 6 months of being diagnosed as lung cancer. The 
purposes of this study were to (1) examine the changes 
of quality of life (QOL; global & multi-dimensions); 
and (2) examine the changes of uncertainty in advanced 
lung cancer patients during the Àrst 6 months of 
diagnosis. 
Methods: A prospective longitudinal study was 
conducted to recruit 83 newly diagnosed non-operable 
non-small cell lung cancer (NSCLC) patients from 
a medical center in Northern Taiwan. Patients 
were assessed of their QOL changes (measured by 
EORTC-QLQ) and uncertainty (measured by Mishel’s 
’Uncertainty of Illness Scale; MUIS) at four time 
points (pretreatment and 1, 3, 6 months from receiving 
treatments, T1- T4, respectively). 
Results: The results showed that patients had a 
moderate level of global QOL across the Àrst 6 
months of diagnosis. Among the Àve QOL related 
dimensions, patients reported to have relatively lower 
scores in social function and role function related QOL 
dimensions. Patients reported to have lowest social 
function (SF) related QOL before treatment (T1) and 
relatively highest SF in the 6 months of diagnosis. 
Patients had relatively better physical and emotion 
functions related QOL across the 6 months. However, 
patients also reported to have high uncertainty across 
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Conclusion: The Mexican-Spanish versions of 
EORTC QLQ-C30 and QLQ-LC13 questionnaires 
are reliable and valid for HRQL measurement 
in Mexican patients with LC and therefore are 
recommended to be used in clinical trials. 
Keyword: cancer, quality of life, EORTC, validation 
studies, questionnaires, Mexico.
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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MO12.08 RELIABILITY AND VALIDITY 
OF THE THAI TRANSLATED VERSION 
(THAI PPS ADULT SUANDOK) OF THE 
PALLIATIVE PERFORMANCE SCALE 
(PPSV2)
Busyamas Chewaskulyong1, Ladarat Sapinun2, 
Michael Downing3 
1Department Of Medicine, Chiangmai University/
Thailand, 2Maharajnakornchiangmai Hospital, 
Chgiangmai University/Thailand, 3Of Palliative 
Care, Victoria Hospice/Canada
Background: The Palliative Performance Scale 
(PPS) was Àrst introduced by Anderson and 
Downing in 1996 as a new tool for measurement of 
performance status in palliative care and has been 
used for communication, analysis of home nursing 
care workload, proÀling admissions and discharges 
to the hospice unit and prognostication. PPS has been 
translated into other languages including French, 
Japanese, German, Portuguese, Spanish, Arabic and 
Thai. The Thai version is known as Thai PPS Adult 
Suandok where the word Suandok is representative 
of a university hospital in Chiang Mai, Thailand 
and meaning ‘Àeld of Áowers’ The Thai PPS Adult 
Suandok tool was translated from the Palliative 
Performance Scale (PPSv2) and tested for reliability 
and validity.
Methods: A set of 22 simulated palliative care 
patients’ cases were based on real patient scenarios 
but modiÀed for anonymity and contain brief 
descriptions of each case’s demographics, primary 
diagnosis, medical, social and family history, signs 
and symptoms, medications and care plan. The set 
was used by 70 nurses and physicians to determine 
a PPS score on time-1, and then repeated two weeks 
later as time-2. A survey questionnaire was also 
LC13 were accurately related to the of patients 
clinical characteristics. The scale of global health 
status and the Àve functional scales correlated with 
KPS and ECOG. Some of the symptom scales from 
both QLQ-C30 and the QLQ-LC13 questionnaires 
correlated with some indicators; e.g. the fatigue scale 
correlated with KPS, ECOG, lymphocyte levels and 
body mass index (BMI); both the scales of dyspnea 
and cough correlated with smoking history. Nine 
out of ten multi-item scales of both questionnaires 
presented Cronbach’s alpha coefÀcients >0.7. 
Multitrait scaling analysis demonstrated good 
convergent and discriminant validity. The test-
retest differences were expected; functional scales 
improved after chemotherapy as well as disease 
symptom scales. Treatment side-effects scales 
worsened. Additionally, patients with better scores 
on the (>66) had a median survival of 16.6 months, 
compared to 8.3 months for those with lower scores 
(P=0.009).
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MO12.09 INTERNATIONAL 
PRACTICE SURVEY ON PALLIATIVE 
LUNG RADIOTHERAPY: THIRD 
INTERNATIONAL CONSENSUS 
WORKSHOP ON PALLIATIVE 
RADIOTHERAPY AND SYMPTOM 
CONTROL
George Rodrigues1, Fergus Macbeth2, Bryan 
Burmeister3, Karie-Lynn Kelly4, Andrea Bezjak5, 
Corey J. Langer6, Carol Hahn7, Anushree Vichare8, 
Benjamin Movsas9 
1Radiation Oncology, London Regional Cancer 
Program/Canada, 2National Institute For Health 
And Clinical Excellence/United Kingdom, 3Princess 
Alexandra Hospital/Australia, 4Kootenai Cancer 
Center/United States Of America, 5Princess 
Margaret Hospital/Canada, 6University Of 
Pennsylvania/United States Of America, 7Duke 
Radiation Oncology/United States Of America, 
8American Society For Radiation Oncology (astro)/
United States Of America, 9Henry Ford Hospital/
United States Of America
Background: The purpose of this work is to 
disseminate international practice survey results 
and consensus statement on palliative therapy 
of lung cancer created in conjunction with the 
Third International Lung Cancer (LC) Consensus 
Workshop. 
Methods: In conjunction with an ASTRO practice 
guideline, an online international practice survey and 
international consensus statements was conducted 
during the summer of 2010. The palliative lung 
RT workshop committee agreed on Àve questions 
relating to (1) patient selection, (2) thoracic external 
beam (XRT) fractionation, (3) endobronchial 
brachytherapy (EBB), (4) concurrent chemotherapy 
(CC), and (5) palliative endpoint deÀnitions. A 
PubMed search for primary/cross-referenced practice 
guidelines, consensus statements, meta-analyses, 
and/or systematic reviews was conducted. Final 
consensus statements were created after review 
and discussion of the available evidence. The 
practice survey consisted of 3 sections focusing 
on respondent demographics, factors for use and 
dose fractionation of radiotherapy, and 5 cases 
exploring the role of external beam radiotherapy, 
endobronchial brachytherapy, and concurrent 
chemoradiation in the setting of metastatic lung 
cancer. 
completed for qualitative analysis. Sample size 
calculations are based on the Ho study with a 
minimum required of 44 raters. Data was analyzed 
for inter- and intra-rater reliability using the single 
rating intraclass correlation coefÀcient (ICC) for 
absolute agreement and for consistency using 
two-way random-effects models. Participant 
reliability was evaluated using Cohen’s kappa, 
which is a chance-corrected measure of agreement 
between two participants. Rater reliability was 
also evaluated using a randomized block ANOVA 
incorporating rater as a random effect. This 
analysis accommodates the dependent nature 
of the data, where the same rater is providing 
observations for both time points. It allows 
evaluation of the effects over time and possible 
interactions of time with the cases. . The study was 
reviewed and received ethics approvals by both the 
Chiang Mai University and University of Victoria 
Research Ethics Boards. 
Results: 70 raters consisting of 51 nurses and 
19 physicians completed both time periods. The 
Time-1 ICC for absolute agreement is 0.911 (95% 
CI 0.86-0.96) and for consistency is 0.92 (95% 
CI 0.87-0.96). The Time-2 ICC for agreement is 
0.905 (95% CI 0.85-0.95) and for consistency 
is 0.912 (95% CI 0.86-0.96). These Àndings 
indicate good agreement among participants and 
also were somewhat higher in the Time-2 re-test 
phase. Cohen’s kappa score is 0.55 demonstrated 
a moderate agreement. Thematic analysis from the 
surveys showed that 91% felt PPS to be a valuable 
clinical tool overall, with it being “very useful” or 
“useful” in several areas including care planning of 
78% and 20%, disease monitoring 69% and 27% 
and prognostication 61% and 31% respectively. 
Some respondents noted difÀculty in determining 
appropriate scores in paraplegic patient or those 
with feeding tubes, while others found the 
instructions long or difÀcult.
Conclusion: The Thai PPS Adult Suandok 
translated tool has good inter- and intra-rater 
reliability and can be used regularly for clinical 
care. 
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MO12.11 PROSPECTIVE STUDY ON THE 
IMPACT OF ANXIETY AND DEPRESSION 
IN SURVIVAL AND QUALITY OF LIFE OF 
CANCER PATIENTS WITH NON-SMALL 
CELL LUNG CANCER WITH ADVANCED 
DISEASE AND GOOD PERFORMANCE 
STATUS
Laura P. Angulo Camarena1, Yuzmiren Dorantes 
Gallareta2, Carolina Nuñez-Valencia1, Oscar Arrieta2 
1Clinica De Cancer De Pulmon, Instituto Nacional 
De Cancerologia/Mexico, 2Subunidad De 
Investigación, Instituto Nacional De Cancerologia/
Mexico
Background: Lung cancer is a very often disease, with 
a high mortality rate, often accompanied with anxiety 
and depression, and are not recognized as capable of 
been corrected, and can affect the quality of life and 
survival in this patients
Methods: In a prospective manner, we studied 82 
patients with NSCLC in IIIB-IV stage Immediately 
after the diagnosis, before to receive treatment. We 
measure depression and anxiety with 2 scales HADS 
and MINI, and quality of life with (EORTC QoL 30 
LC11) in three times. 
Results: We found depression in 32.9%, anxiety 
in 34.1% in the Àrst evaluation, with a signiÀcant 
difference in women (RR 3.23; CI 95%, 1.1-9.4; p= 
0.035) and people with poor performance status (RR 
2.7; CI95%, 1.01-7.6; p= 0.045). Depression and 
anxiety patients showed signiÀcant differences in 
quality of life in all the functional subscales of the QoL. 
GHS, RF, FF, FE, FS, FC (p= 0.05). Survival rates 
were markedly different in depressed patients (6.8±2.2 
months), comparing with non depressed (14±1.8 
months) on anxiety patients (11.6±2.3) (p=0.05). 
Results: A total of 279 individuals responded to the 
survey over a 3 month period. Most respondents were 
hospital-based academic or government radiation 
oncologists. A wide distribution of practice location 
and experience was observed. Factors consistently 
related to use and choice of external beam dose 
fractionation included: expected treatment effect to 
patient, symptom severity, patient choice, performance 
status, and previous radiation to site. Factors 
consistently not related to use and dose fractionation 
included: requirement for future radiation therapy, 
department policy, and wait lists. A signiÀcant range 
of dose fractionation schedules existed for external 
beam (n=35) and endobronchial brachytherapy 
treatment (n=10). The integration of concurrent 
chemotherapy was recorded by a signiÀcant minority 
of respondents despite lack of level I evidence 
to support its use. Geographical differences in 
usage of external beam dose fractionation, and of 
concurrent chemotherapy were seen in the survey. The 
following summary statements reÁect the consensus 
of the international working group. 1. Key factors 
involved in the decision to deliver palliative RT 
include performance status, tumor stage, pulmonary 
function, XRT volume, symptomatology, weight 
loss, and patient preference. 2. Palliative thoracic 
XRT is generally indicated for stage IV patients with 
current/impending symptoms and stage III patients 
treated for palliative intent. 3. There is no evidence 
to routinely recommend EBB alone or in conjunction 
with other palliative maneuvers in the initial palliative 
management of endobronchial obstruction due to 
LC 4. There is currently a no evidence to routinely 
recommend CC with palliative-intent RT. 5. Standard 
assessment of symptoms and health-related quality-of-
life using validated questionnaires should be utilized 
in palliative RT LC trials. 
Conclusion: Various patient, tumor, treatment, and 
logistical factors are associated with the variable use 
and external beam dose fractionation of palliative lung 
treatments. Despite an expanding literature, continued 
prospective randomized investigations to better 
deÀne the role of external-beam RT, endobronchial 
brachytherapy, and concurrent chemotherapy in the 
context of thoracic palliation of LC patients is needed.
Keywords: Lung cancer, External-beam Radiation 
Therapy, Consensus Statement, Practice Survey
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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of end of life options, CPR, ICU care, palliative 
chemotherapy and site of death. Details of discussion 
were analyzed in terms of feasibility and effect on 
understanding of end of life care option and patients 
–health care agents relationship. 
Results: Early intervention of end-of life care 
discussions were feasible in 21 of 23 patients with 
newly diagnosed advanced stage non-small cell lung 
cancer. Only 2 patients were refused to discuss further 
regarding end-of- life care options due to emotional 
disturbance. Two months follow-up discussion 
revealed that all 21 patients who completed the Àrst 
end-of life care discussions were still maintainng their 
hope of getting well and satisÀed with their choices 
as well. Although the patients choices on various 
end-of-life options were varied, they also reported 
better understanding of end-of-life care options and 
increased conÀdence in their health care agents.
Conclusion: Early intervention of this sensitive and 
difÀcult end of life care discussion between patients 
and health care agent might be feasible without 
losing the hope of getting well in most of the patients 
with newly diagnosed non-small cell lung cancer. 
Furthermore, early end-of-life discussion might have 
some beneÀcial effect on improving patients-health 
care agent relationship. 
Keywords: end of life discussion, palliative care, 
hospice care
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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MO12.13 PALLIATIVE CARE FOR 
PATIENTS WITH ADVANCED LUNG 
CANCER
Marianna Koczywas1, Betty R. Ferrell2, Karen L. 
Reckamp1, Mihaela C. Cristea3, Brian Tiep4, Dana 
Tarcatu5, Jay Thomas5, Fred Grannis6, Gwen Uman7 
1Medical Oncology And Therapeutic Research, 
City Of Hope/United States Of America, 2Nursing 
Resreach & Education, Dept. Of Population 
Sciences, City Of Hope/United States Of America, 
3Dept Of Medical Oncology, City Of Hope/United 
States Of America, 4Pulmonary, City Of Hope/
United States Of America, 5Palliative Care, City Of 
Hope/United States Of America, 6Thoracic Surgical 
Oncology, City Of Hope/United States Of America, 
7Vital Research/United States Of America
Conclusion: Depression strongly inÁuences the 
evolution of the lung cancer patient, resulting in a 
lower quality of life, and survival. Depression is an 
independent prognostic factor, so can receive attention. 
Keywords: depression, Anxiety
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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MO12.12 EARLY INTERVENTION OF 
END-OF-LIFE CARE DISCUSSION IN 
PATIENTS WITH ADVANCED NON-
SMALL CELL LUNG CANCER: A PILOT 
STUDY
Sang Won Shin, Sun Goo Kim, Yeul Hong Kim 
Oncology Hematology Dept, Korea University/Korea
Background: Frank and early discussion of end-of-
life options with patients diagnosed with incurable 
cancer should be an essential part of medical 
practice. However, these conversations occur most 
often during a patient’s Ànal days or weeks of life. A 
recent study suggests health care agents may put off 
holding end-of -life discussion that involve subjects 
like advance directives, hospice or site of death.
Methods: We conducted a pilot study to assess the 
feasibility of early end-of- life discussion, less than 
1 month of diagnosis, in patients with advanced 
non-small cell lung cancer. Early intervention with 
facilitated and detailed questionnaire followed by 
frank discussions between the physician/nurse and 
the patients/family members regarding the beneÀt 
and burdens of life sustaining treatment, choices 
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MO12.14 EVALUATION OF NON-
SMALL CELL LUNG CANCER (NSCLC) 
PATIENT’S QUALITY OF LIFE 
DURING 2ND LINE CHEMOTHERAPY 
TREATMENT
Bárbara Parente1, Encarnação Teixeira2, Henrique 
Queiroga3, João Cunha4, Ana Fernandes5, António 
Meleiro6, Ulisses Brito7, Maria P. Ferreira8, Maria 
J. Melo9, António Araújo10, Cristina Matos11, Teresa 
Cardoso12, Ana C. Duarte13, Maria L.S. Valente14, 
Marco Liebermann15, José Duarte16, Fernando 
Barata17 
1Pneumology, Centro Hospitalar De Vila Nova De 
Gaia/Portugal, 2Hospital De Santa Maria/Portugal, 
3Hospital De São João/Portugal, 4Hospital De São 
Marcos/Portugal, 5Centro Hospitalar De Trás-os-
montes E Alto Douro/Portugal, 6Centro Hospitalar 
De Setúbal/Portugal, 7Hospital Central De Faro/
Portugal, 8Instituto Português De Oncologia, 
Lisboa/Portugal, 9Hospital Pulido Valente/Portugal, 
10Instituto Português De Oncologia, Porto/Portugal, 
11Hospital Egas Moniz/Portugal, 12Hospital Espírito 
Santo/Portugal, 13Hospital Distrital De Beja/
Portugal, 14Centro Hospitalar Cova Da Beira/
Portugal, 15Hospital Distrital De Santarém/Portugal, 
16Hospital Garcia De Orta/Portugal, 17Centro 
Hospitalar De Coimbra/Portugal
Background: With recent evolutions on 1st line 
treatment better response rates and lower toxicities, 
2nd line therapy had a major. For most advanced non-
small cell lung cancer (NSCLC) patients therapeutic 
goals for this stage includes not only to live longer 
but also to have better Quality of Life. For these 
patients, 2nd line chemotherapy provides an important 
impact in improving symptoms and Quality of 
Life. To evaluate the impact of 2nd line treatment on 
NSCLC patients’ Quality of Life measured by the 
scales EORTC-C30 and EORTC-LC13. 
Methods: Prospective, observational and multicenter 
study. Data from NSCLC patients who have initiated 
2nd line chemotherapy were collected. Quality of life 
assessments were performed at 5 different moments: 
at baseline, and 6, 12, 18 weeks and one year after 
entering the study or in case of disease progression 
or death. 
Results: A total of 219 patients with a median age 
of 62 years were included. Included patients were 
mostly men (74.4%) and had a history of smoking 
habits (former smokers 41.6%; smokers 31.5%). Most 
Background: This National Cancer Institute 
funded Program Project (P01) is an interdisciplinary 
research project focused on palliative care, quality 
of life (QOL), and symptom control in lung cancer 
which is diagnosed in 213,000 Americans each year. 
The purpose of this study is to test usual care versus 
integration of palliative care encompassing four 
dimensions of QOL. 
Methods: Our two previous pilot projects in a NCI 
Comprehensive Cancer Center demonstrated the 
unmet needs in lung cancer across QOL domains 
and the limited use of supportive care services by 
those with lung cancer. Project 2 of this Program 
focuses on late stage lung cancer, and uses a two 
group, prospective, tandem enrollment comparing 
usual care to a structured palliative care intervention. 
Patients are followed for 6 months and measures 
include the FACT-L, FACIT- Spiritual, MSAS, 
Social Support tool and a Chart Audit capturing 
medical care and health system resources used. A 
Geriatric Oncology Core also supports this project 
addressing concerns in elderly patients with lung 
cancer, including function, social support and 
comorbidities. 
Results: This usual care phase sample of Stage IV 
lung cancer (N=80) included 70% female, 43% 
minority patients. Seventy one percent had at least 
1 other chronic illness and 20% had a prior cancer 
diagnosis. MSAS scores revealed key symptoms 
to include lack of energy, difÀculty sleeping, 
worrying, dyspnea and pain and MSAS distress of 
x=3.3 on scale of 0-4. FACT-L data indicated key 
QOL concerns related to sexuality (x=2.83), fear 
of worsening disease (x=3.18), sleep disruption 
(x=3.2), overall poor QOL (x=3.24) and lack of 
energy (x=3.3). Greatest spiritual concerns from the 
FACIT-Spiritual tool included lack of meaning, lack 
of purpose and trouble feeling at peace. Chart audit 
data documented limited use of advanced directives 
or palliative care consultation. 
Conclusion: Findings identify signiÀcant gaps in 
supportive care in lung cancer and provide direction 
for the intervention phase of a comprehensive 
educational intervention and enhanced resources for 
lung cancer patients. These Àndings lead to creation 
of a four part, QOL education program speciÀc to 
lung cancer and a interdisciplinary care planning 
process involving multiple disciplines. 
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1School Of Medicine, University Of Queensland/
Australia, 2Department Of Thoracic Medicine, The 
Prince Charles Hospital/Australia, 3Oncogenomics 
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Background: MicroRNAs (miRNAs) are a family 
of small, non-coding RNA species that negatively 
regulate expression of numerous target genes, 
including oncogenes and TSGs. Aberrant miRNA 
expression has been documented in multiple 
tumour types and has been linked to development 
and progression of cancer. The aim of this study 
was to identify miRNAs that may be important 
in the pathogenesis of non-small cell lung cancer 
(NSCLC).
Methods: Global miRNA expression was measured 
in 175 fresh-frozen primary NSCLCs and 90 normal 
lung samples selected from TPCH Lung Tumour 
Bank using the Agilent miRNA array (G4470A). 
Differentially expressed miRNAs were identiÀed 
using class comparison analysis (univariate t-test and 
random permutation) in BRB-ArrayTools (Version 
6.3.0-Beta_3) and considered statistically signiÀcant 
if p <0.05. Differentially expressed (DE) miRNAs 
were identiÀed within the following cohorts: i) 
Primary NSCLCs and paired normal lung (n=126); 
ii) Non-recurrent (clinically disease-free for 36 
months post-resection) compared to recurrent 
cases (recurrence within 3-18 months) (n=93); iii) 
Adenocarcinomas with EGFR mutation (Exon 19/21) 
and/or ampliÀcation compared to EGFR negative 
controls (n=59); iv) Never smokers compared to ever 
smokers adenocarcinomas (n=77); and v) Asbestos 
exposed (>20 asbestos bodies per gram wet weight) 
compared to non-exposed (0 AB/gww; n= 60) 
NSCLCs (n=120).
Results: Class comparison analysis identiÀed DE 
miRNAs unique to each lung cancer phenotype and 
these results are summarised in Table 1. Biological 
validation of candidate miRNA expression will be 
performed using TaqMan qRT-PCR and this data will 
be presented at the meeting.
Conclusion: Genome-wide proÀling of miRNA 
expression has yielded putative candidate miRNAs 
that may contribute to the biology of important lung 
cancer phenotypes including recurrence, EGFR 
mutations and asbestos-related lung malignancies. 
Further validation of these candidate miRNAs 
commonly used 2nd line treatment was pemetrexed 
(58.4%), followed by erlotinib (21.2%), docetaxel 
(17.8%) and other (2.7%). Quality of life assessed by 
EORTC-C30 scale presented signiÀcant differences 
for global health status and functional evaluation 
scores between baseline and Ànal evaluation (p=0.001; 
p<0.001, respectively). The various functioning scales 
presented signiÀcant differences: physical (p<0.001), 
role (p<0.001), emotional (p=0.049), cognitive 
(p=0.002) and social (p<0.001). Concerning symptoms’ 
scores, signiÀcant differences were found only for 
symptoms such as fatigue (p<0.001), pain (p<0.001), 
and dyspnea (p=0.012). No signiÀcant differences were 
found for these three global scores between the patients 
treated with different drugs (pemetrexed, erlotinib and 
docetaxel). Using the EORTC-LC13 scale, signiÀcant 
differences were found only for symptoms such as 
dyspnea (p=0.047), cough (p=0.042) and chest pain 
(p=0.024).Between patients treated with different drugs 
only alopecia was increasedfor patients treated with 
docetaxel (Mean: pemetrexed -1.0 vs. erlotinib -1.4 vs. 
docetaxel 2.9; p=0.003). 
Conclusion: Patients’ Quality of Life improved 
signiÀcantly between baseline and the last visit in 
all evaluated global scores (global health status and 
overall functioning). However, between patients treated 
with different drugs only docetaxel seemed to have a 
negative impact on alopecia. Despite, in general, no 
signiÀcant differences were registered for patients’ 
symptoms or for the EORTC-LC13 scale, it is worth 
noting that all functional scales, such as physical, role, 
emotional, cognitive and social functioning presented 
signiÀcant differences between baseline and the Ànal 
evaluation.
Keywords: non-small cel lung cancer, Quality of 
Life, Chemotherapy
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MO13.01 IDENTIFICATION OF 
ABERRANT MICRORNAS IN LUNG 
CANCER
Morgan R. Davidson1, Santiyagu M.F. Savarimuthu1, 
Ian A. Yang2, Casey M. Wright1, Krishna B. Sriram1, 
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sequencing was performed to characterise the 
mutation spectrum in non-small cell lung cancer 
(NSCLC) samples and to assess the contribution of 
genomic variants to disease outcome.
Methods: 16 NSCLC samples were selected for 
sequencing on the SOLiD platform. The tumour 
samples were partitioned based on post-surgery 
disease outcome (Progressive disease – PD; 
Disease Free - DF) and were pairwise matched 
on epidemiological and cytological parameters. 
Microarray analysis was used to select speciÀc genes 
for targeted exon sequencing using the SureSelect 
system. Bioinformatics pipelines were developed for 
variant detection and characterisation. Nucleotide 
variants were scored using SNVMix and compared 
with known variant/polymorphism datasets 
(dbSNP/1000 genomes).
Results: Within the targeted areas of the genome, high 
sequence coverage was achieved (~40x). A number 
of single nucleotide variants (SNVs) were identiÀed 
within the targeted genes in lung tumour samples from 
both PD and DF categories. In the initial analysis, the 
SNVs contained some novel variants, some previously 
known polymorphisms and some variants previously 
shown to associate with cancer. For example, in the 
latter category we were able to identify KRAS codon 
12/13 mutations within a subset of the PD samples, 
but not within the DF samples.
Conclusion: Second-generation sequencing has 
been used to identify coding mutations in 361 genes 
within lung cancer samples. The methods developed 
may have future prognostic utility in determining 
disease outcome amongst lung cancer patients.
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MO13.03 CLINICAL RELEVANCE OF 
GENOMIC COPY NUMBER VARIATIONS 
IN SPIRAL-COMPUTED TOMOGRAPHY 
(CT) DETECTED LUNG TUMORS
Carla Verri1, Patrizia Gasparini1, Mattia Boeri1, 
Federica Facchinetti1, Giovanna Chiorino2, Paola 
Ostano2, Maurizia Mello Grand2, Ugo Pastorino3, 
Gabriella Sozzi1 
1Dep.of Experimental Oncology And Molecular 
Medicine, Fondazione Irccs Istituto Nazionale Dei 
Tumori/Italy, 2Cancer Genomics Lab, Fondazione 
Edo Ed Elvo Tempia/Italy, 3Unit Of Thoracic 
Surgery, Fondazione Irccs Istituto Nazionale Dei 
Tumori/Italy
is required to explore potential role in lung 
tumourigenesis. Once conÀrmed, these miRNAs 
represent a basis from which to design novel 
diagnostic, prognostic and therapeutic tools and 
focus individualised treatments. Supported by: 
National Health and Medical Research Council, 
Cancer Council Queensland, Australian Lung 
Foundation, The Prince Charles Hospital Research 
Foundation Table 1. Summary of candidate miRNAs 
identiÀed in each clinical phenotype from global 
miRNA expression proÀling. Abbreviations: AC – 
Adenocarcinoma; SCC – Squamous Cell Carcinoma 
Analysis Group miRNA Fold Change 
Lung Cancer (p=0.00001) AC (n=72) 3 B 2.0 – 3.4 
8 ? 2.4 – 8.0 
SCC (n=54) 2 B 2.9 – 27.0 
11 ? 2.3 – 4.9 
Recurrence (p=0.05) AC (n=50) 8 ? 1.6 - 2.2 
1 B 1.3 
SCC (n=43) 1 ? 2.0 
EGFR (p=0.05) AC (n=59) 3 B 2.1 - 2.6 
Never Smoking (p=0.05) AC (n=77) 3 B 2.1 - 2.8 
Asbestos Exposure (p<0.05) NSCLC (n=120) 2 ? 1.3-1.4 
AC (n=60) 1 ? 1.5 
Keywords: NSCLC, MicroRNAs
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MO13.02 SECOND-GENERATION 
SEQUENCING OF NON-SMALL CELL 
LUNG CANCER: IDENTIFICATION 
OF MUTATIONS ASSOCIATED WITH 
PROGRESSIVE DISEASE
Russell Hyde1, Olaide Y. Raji1, Lisa Olohan2, Olga 
Vasieva2, Kevin Ashelford2, Andy Brass3, Richard D. 
Page4, Neil Hall2, John K. Field1 
1Molecular And Clinical Cancer Medicine, 
University Of Liverpool/United Kingdom, 2Institute 
Of Integrative Biology, University Of Liverpool/
United Kingdom, 3School Of Computer Science, 
University Of Manchester/United Kingdom, 
4Liverpool Heart And Chest Hopital/United Kingdom
Background: Genetic mutations are a hallmark 
of lung cancer progression. Recent advances in 
sequencing technology provide a window into the 
genomic variability within individual tumours, and 
may ultimately have prognostic and/or predictive 
value. A study involving second-generation 
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relevance in spiral-CT detected tumors. The common 
deÀned regions could identify a class of tumors 
with elevate grade of malignancy. Gene expression 
analysis and microRNA expression proÀling, 
both obtained with microarray platforms, will be 
correlated with CNV data to identify target genes 
involved in tumorigenesis. 
Keywords: spiral CT-detected lung cancer, Genomic 
unbalances, clinico-pathological association, Array-
CGH
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
Novel Cancer Genes and Pathways Wednesday, 6 July 2011 14:30-
16:00
MO13.04 PROGNOSTIC VALUE OF 
HSA-MIR-210 OVEREXPRESSION IN 
NON-SMALL CELL LUNG CANCER BY 
QUANTITATIVE REAL-TIME RT-PCR
Jun Ohsugi, Yuka Kimura, Yuzuru Watanabe, Takumi 
Yamaura, Naoyuki Okabe, Hiroshi Yaginuma, Takeo 
Hasegawa, Yoko Mera, Athushi Yonechi, Mika 
Hoshino, Mithunori Higuchi, Yutaka Shio, Hiroyuki 
Suzuki, Akio Ohishi, Mitukazu Goto, Thoracic 
Surgery, Fukushima Medical University/Japan
Background: Hypoxic conditions in solid 
malignances are thought to be involved to the 
resistance to cytotoxic chemotheraphy and also be 
associated with a poorer prognosis. Recently, several 
studies have been reported that hsa-miR-210 is 
one of the highly up-regulated miRNAs in hypoxic 
cells. In this study, we examined the expression of 
hsa-miR-210 to identify a prognostic signiÀcance in 
patients with non-small cell lung cancer (NSCLC).
Methods: The subjects of this study consistes of 
80 patients with NASLC who underwent complete 
resection since 2004 to 2007. No patients had 
received any prior anticancer treatment. They 
included 61 adenocarcinomas and 19 squamous cell 
carcinomas, and 54 stage1, 11 stage2, 13 stage3, 1 
stage4 cases. Hsa-miR-210 expression, determined 
by real time RT-PCR, was deÀned by ƋƋ Ct 
method. The level of hsa-miR-210 expressions in 
cancer tissues were assessed after comparison with 
corresponding noncancerous tissues and with respect 
to RNU6B expression. The relationship between 
the hsa-miR-210 expression and clinic pathological 
Background: Lung cancer is the leading cause of 
cancer deaths worldwide. Early detection studies 
using spiral-CT in heavy smokers have reported a 
major increase in lung cancer diagnosis and reduction 
of mortality. These observations indicate the need 
for biomarkers of indolent or aggressive disease. 
Chromosomal alterations play a critical role in tumor 
initiation and progression and particularly in lung 
cancer where multiple chromosome alterations were 
commonly reported in cytogenetic analysis, indicative 
of a marked genomic instability. The purpose of 
the study is to characterize genomic unbalances in 
lung tumor cases identiÀed in a completed spiral-CT 
screening trial with an extensive follow-up and to 
identify the clinical relevance of recurrent chromosome 
changes investigating the association with clinico-
pathological characteristics of patients. 
Methods: Array-CGH proÀling (Agilent platform) was 
performed in a selected series of 20 CT-detected lung 
tumor samples (17 NSCLC, 1 SCLC, 2 carcinoids) 
and the regions with signiÀcant copy number variation 
(CNV) were identiÀed using ADM-2 algorithm. 
Results: A different level of genomic complexity 
(number and size of unbalances) was observed: 6 cases 
with high level changes, 7 cases with an intermediate 
level and 7 cases with limited unbalances. In NSCLC 
extensive regions with CNV were observed in 1q, 
2q, 3q, 5p, 7p, 8q (gains) and 3p, 7q, 8p, 10q, 13q, 
16, 17p, 19p, 22q (losses), in SCLC cases CN gains 
in 2q, 5p and CN losses in 1p, 2p, 3p, 5q, 6q, 16q, 
17p, 21p and in carcinoid tumors ampliÀcation of the 
entire chromosome 5 and CN losses in 1p, 6q, 10, 11, 
18q were observed. Smaller regions were delimited 
and were observed to be recurrently altered in several 
samples as reported in Table 1. Preliminary statistical 
analysis demonstrated that CNV of speciÀc genomic 
regions was signiÀcantly correlated with high tumor 
stage (2q37.3 ; 8p11.23), histotype (14q13.1-13.2 
gain in ADC and loss in other histotype), FEV1% 
<90% (19p13.3-12), tumor growth rate (6p21.32). 
Interestingly, CNV of 4q13.2 was associated with 
patients’ outcome. Table 1. Recurrent regions of copy 
number alterations in 20 CT-detected tumors. 
Gains Losses Gains or Losses 
1q21.1-21.3 5p15.33 
7q11.21-q11 1q11.23 
17p25.3 22q 
2p21 2q37.3 3p25.3 
3p26.3-26.1 5q13.1-
13.2 7p11.2-p11.1 
8p23.1 15q11.2 
17p13.1 19p13.3-12 
3q26.1 3q26.32 4q13.2 
6p21.32 8p11.23 
12p13.31 14q13.1-13.2 
16q21-q23.1 
Conclusion: We demonstrated that chromosome 
unbalances could be of clinical and pathological 
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MO13.06 AN EFFECTIVE DNA DAMAGE/
REPAIR SIGNALING PATHWAY-
TARGETED THERAPY FOR LUNG 
CANCER COMBINING A NOVEL DUAL-
FUNCTIONAL DNA-ALKYLATING/HDAC 
INHIBITOR WITH TUMOR SUPPRESSOR 
GENE NANOPARTICLES
Lin Ji1, Jing Lin1, Kai Xu1, Shaoyu Yan1, Yi Chen2, 
Jack A. Roth1 
1Thoracic & Cardiovascular Surgery, The University 
Of Texas M.D. Anderson Cancer Center/United 
States Of America, 2Northlake Biosciences/United 
States Of America
Background: DNA alkylating agents such as 
platinum and nitrogen mustard are effective cancer 
chemotherapeutics. They kill proliferating tumor 
cells by inducing high levels of DNA damage 
leading to cell-cycle arrest and cell death. However, 
their highly toxic side effects and the common drug 
resistance exhibited in tumors limit their anticancer 
efÀcacy and clinical beneÀts. Here we describe 
a novel strategy using a new class of rationally 
designed DNA alkylating agents combined with gene 
therapy targeting the DNA damage/repair pathway.
Methods: We evaluated the therapeutic effects of 
a novel alkylating agent NL101, a bendamustine 
derivative that has a dual function of DNA alkylation 
and pan-HDAC inhibition, in a panel of more than 
50 human NSCLC and SCLC cell lines. We also 
explored treatment strategies of combining NL101 
with novel tumor suppressor genes NPRL2, a 
regulator of the DNA damage checkpoint pathway, 
and p53, a regulator of apoptosis and drug resistance 
in the DNA damage/repair pathway, in lung cancer.
Results: We detected a high potency of tumor cell 
proliferation inhibition by NL101 treatment across 
lung cancer cell lines, with IC
50
 doses ranging from 
nanomolar to lower micromolar levels. A 20 to 
100-fold higher level of cytotoxicity was observed 
across these lung cancer cell lines, particularly in 
SCLC cell lines, treated by NL101 than in cell lines 
treated by bendamustine, a nitrogen mustard agent 
that is currently in Phase II and III clinical trials in 
SCLC patients. We analyzed the NL101-induced 
DNA damage in NSCLC H1299 cells by Comet 
assay and found that NL101 induced a signiÀcantly 
higher degree of DNA damage than that induced 
by either bendamustine or cisplatin at the same IC
20
 
factors was statistically analyzed.
Results: To analyze impacts of the expression 
of hsa-miR-210 on clinic pathological variables 
and survaival, the patients were divided into two 
subgroups by median value (high expression 
group and low expression group). Then, we 
examined for correlations between the hsa-miR-210 
expression and clinic pathological variables.The 
high expression group had an association with 
recurrent disease (p=0.04), whereas hsa-miR-210 
expression was not correlated with age, gender, 
tumor size, histology, lymph metastasis, pathological 
stage, ly factor and v factor. In terms of survival 
analysis, there was the weak correlation between 
the expression of hsa-miR-210 and overall survival 
(p=0.090, 5y-survaval rate of high epression group 
and low expression group are 66.6% and 77.4% 
respectively). Futhermore, high expression group 
showed signiÀcant short disease free survival as 
compared with low expression group (5y-desase 
free survaival in high expression group and low 
expression group were 35% and 59.1% respectively, 
p=0.001). More importantly, hsa-miR-210 
expression was an independent prognostic factor in 
disease free survaival analyzed by Cox multivariate 
analysis(HR: 1.24, 95%Cl 1.046-12.173, p=0.042).
Conclusion: According to our resluts, the expresson 
of hsa-miR 210, one of the major miRNA associates 
hypoxic state of cancer tissues, could be an important 
prognostic factor in patients with NSCLS.
Keyword: hsa-miR-210 lung cancer RT-PCR
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proÀles of AIS with those of eIA showing lymph 
node metastasis or a fatal outcome, and used cDNA 
microarray to screen for differentially expressed 
genes that were related to tumor progression. (Aya 
Shiba-Ishii, Int J Cancer. 2011)
Methods: Among genes showing signiÀcantly 
higher expression in eIA than in AIS, we 
Ànally focused on stratiÀn (SFN, 14-3-3 
sigma), and performed real-time RT-PCR 
and immunohistochemistry (IHC) using lung 
adenocarcinoma specimens. For functional analysis, 
we carried out siRNA transfection and subsequent 
cell proliferation assay with a lung adenocarcinoma 
cell line (A549). Furthermore, the methylation status 
in the promoter region of SFN was examined by 
real-time MSP.
Results: IHC revealed that more than 95% of eIAs 
were immunopositive for SFN, in comparison to 
only 13% of AISs (P <0.05). Functionally, after 
suppression of SFN expression by siRNA, A549 
showed lower cell proliferation than untreated 
controls. Real-time MSP showed that normal lung 
tissue and AIS bore a completely methylated SFN 
promoter, and that the promoter regions of most 
invasive adenocarcinomas were at least partially 
methylated (Figure). The expression of SFN was 
strongly correlated with its methylation level. 
Furthermore, statistical analysis revealed that the 
methylation level became lower with increased 
pathological stage, but no clear relationship with p53 
abnormality was found.
SFN was originally identiÀed as a p53-inducible gene 
causing G2 arrest and allowing the repair of damaged 
DNA. Functional inactivation of SFN, mostly by 
epigenetic hypermethylation, has been observed in 
various human malignancies. On the other hand, 
many reports have indicated up-regulation of SFN in 
various types of Here we also demonstrated that the 
expression of SFN was signiÀcantly higher in eIA 
than in AIS, and enhanced the proliferative capacity 
of lung adenocarcinoma cells. Therefore, SFN might 
be a context-dependent gene that acts as an oncogene 
in lung adenocarcinoma. Methylation analysis 
suggests that methylation-related silencing of SFN 
dose level for each individual agent. A combination 
of NL101 with either DOTAP:Cholesterol (DC)-
complexed NPRL2 or p53 expressing plasmid DNA 
nanoparticles showed no signiÀcant effect on drug-
induced DNA damage. We analyzed DNA-damage-
induced apoptosis using an anti-ssDNA antibody-
based apoptosis assay by FACS and detected a 
signiÀcantly enhanced induction of apoptosis in 
both combination treatments with NL101+DC-
NPRL2 and NL101+DC-p53. We also found that 
combination treatment with NL101 and DC-NPRL2 
nanoparticles promoted a synergistic inhibitory 
effect on growth of SCLC H69 and GLC16 cells at 
effective dose levels of NL101 from IC
10
 to IC
75
. 
Conclusion: Our results suggest that a combination 
treatment using a novel dual targeting DNA 
alkylating agent/HDAC inhibitor with pro-apoptotic 
tumor suppressor genes in the DNA damage/repair 
signaling pathway will enhance chemotherapeutic 
sensitivity, promote anti-cancer therapeutic 
synergism, and overcome drug resistance. This 
implies a translational application of this novel 
combination therapy for a more effective lung cancer 
treatment strategy. (Supported by NIH/NCI SPORE 
P50CA70907 and RO1CA116322). 
Keywords: DNA damge and repair pathway, DNA 
Alkylating Agents, Tumor Suppressor Genes, 
combination therapy for lung cancer
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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MO13.07 DEMETHYLATION-INDUCED 
OVEREXPRESSION OF STRATIFIN 
IS A UNIVERSAL ABNORMALITY 
DURING THE PROGRESSION OF LUNG 
ADENOCARCINOMA
Aya Shiba-Ishii, Junko Kano, Masayuki Noguchi 
Department Of Pathology, Graduate School Of 
Comprehensive Human Sciences, University Of 
Tsukuba/Japan
Background: Adenocarcinoma in situ (AIS) of 
the lung has a very favorable prognosis, with a 
5-year survival rate of 100%. However, early but 
invasive adenocarcinoma (eIA) sometimes has a 
fatal outcome. Here we compared the expression 
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months). Array CGH log 2 data was analyzed using the 
Genomic IdentiÀcation of SigniÀcant Targets in Cancer 
(GISTIC) algorithm. Thresholds for ampliÀcation and 
deletions were set at log2 values of 0.848 and -0.737. 
Validation of the DNA copy number of candidate genes 
was performed using quantitative PCR (q-PCR), using 
QuantiTect primers (Qiagen, Hilden, Germany). 
Results: In the 62 SCC samples, GISTIC identiÀed 
frequent and high amplitude ampliÀcations in six regions 
and deletions in 14 regions. Loss of 18q22.3 occurred 
signiÀcantly more frequently in recurrent versus non-
recurrent SCCs (54% vs. 24%, p=0.033) and contained 
7 genes, SOCS6, DOK6, RTTN, CYB5A, C18orf55, 
NETO1 and CCDC102B with signÀcantly lower DNA 
copy number in the recurrent tumors (p<0.05 for all 
7 genes). Technical validation using an independent 
method, q-PCR, conÀrmed lower DNA copy number 
in recurrent versus non-recurrent SCCs for SOCS6 
(p=0.003). Biological validation using q-PCR in an 
independent cohort of 85 SCCs provided further 
conÀrmation that SOCS6 deletion was more common in 
recurrent vs. non-recurrent tumors (p=0.006). 
Conclusion In this study, we have used array CGH to 
identify genomic regions associated with recurrence in 
primary lung SCC. Loss of 18q22.3 occurs at greater 
frequency in recurrent SCCs and contains SOCS6. The 
biological role of SOCS6 in promoting recurrence in 
SCC requires further investigation using in-vitro and in-
vivo models. 
Keywords: recurrence after surgical resection, 
squamous cell carcinoma, Array comparative genomic 
hybridization
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MO13.09 ACTIVATION OF PI3K/AKT/
MTOR/S6RP AND MEK/ERK SIGNALING 
PATHWAYS IN NSCLC DEPENDING ON 
EGFR AND KRAS MUTATIONS STATUS.
Nathalie Prim1, Michele Legrain2, Anne-Claire 
Voegeli2, Eric Guerin2, Agnès Neuville3, Gilbert 
Massard4, Mircea Vasilescu4, Nicola Santelmo4, 
Jean-Marie Wihlm4, Marie Pierre Gaub2, Bertrand 
Mennecier1, Elisabeth Quoix1, Marie Pierre 
Chenard3, Michele Beau-Faller2 
1Service De Pneumologie, Chu De Strasbourg/
France, 2Chu De Strasbourg, Molecular Laboratory/
France, 3Service De Pathologie, Chu De Strasbourg/
France, 4Service De Chirurgie Thoracique, Chu De 
Strasbourg/France
usually occurs in normal lung tissue and AIS, and 
that promoter demethylation triggers aberrant SFN 
overexpression in invasive adenocarcinoma in p53-
independent manner. 
Conclusion: Demethylation-induced SFN 
overexpression occurs during progression of early 
lung adenocarcinoma, and this accelerates malignant 
progression by enhancing the proliferation capacity 
of tumor cells.
Keywords: stratiÀn, demethylation-induced 
overexpression, lung adenocarcinoma
Novel Cancer Genes and Pathways Wednesday, 6 July 2011 14:30-
16:00
MO13.08 SOCS6 DELETION IS 
ASSOCIATED WITH RECURRENCE 
IN SURGICALLY RESECTED LUNG 
SQUAMOUS CELL CARCINOMA
Krishna B. Sriram1, Jill E. Larsen2, Santiyagu M.F. 
Savarimuthu1, Casey M. Wright1, Belinda E. Clarke3, 
Edwina E. Duhig3, Nick K. Hayward4, Rayleen 
Bowman1, Ian A. Yang1, Kwun M. Fong1 
1Department Of Thoracic Medicine, The Prince 
Charles Hospital/Australia, 2Hamon Center For 
Therapeutic Oncology Research, University Of 
Texas Southwestern Medical Center/United States Of 
America, 3Department Of Anatomical Pathology, The 
Prince Charles Hospital/Australia, 4Oncogenomics 
Laboratory, Queensland Institute Of Medical 
Research/Australia
Background: Despite undergoing surgical resection, 
recurrence of the primary lung squamous cell 
carcinoma (SCC) occurs in 50% of subjects within 
5 years. DNA copy number aberrations may be an 
important mechanism of regulation for putative 
oncogenes and tumor suppressor genes involved in 
promoting recurrence of lung SCC. Array comparative 
genomic hybridization (array CGH) is a high-
resolution platform that can identify DNA copy number 
aberrations of genes and has recently been used for the 
identiÀcation of novel cancer genes in several solid 
organ malignancies. To date, it has not been used to 
study the genes involved in recurrence of lung SCC. 
Methods: Array CGH was performed using 
Agilent G4410B aCGH 4 (Agilent Technologies 
Inc) microarrays on DNA from fresh frozen 
tumour tissue obtained from 62 SCCs; 28 recurrent 
(recurrence of disease within 18 months) and 34 
non-recurrent subjects (no disease recurrence at 36 
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among mutational status. These results of weak 
expression of phospho-ERK could be explained 
by negative feedback of phosphatase MKP-3/
DUPS6 which is expressed in 59/61 (97%) of all 
the tumors. In the wild-type tumors, expression of 
phospho-mTOR is correlated with expression of 
both phospho-S6RP Ser235/236 (p = 0.009) and 
phospho-S6RP Ser240/244 (p = 0.02), but only 
with expression of phospho-S6RP Ser235/236 (p 
= 0.04) in EGFR mutated tumors and not expected 
with KRAS mutated tumors. Median progression 
free survival was 30 months, and no signiÀcant 
prognostic value was found for phospho-mTOR, 
phospho-S6RP Ser235/236 and phospho-S6RP 
Ser240/244 in all the group as well as in the EGFR 
or KRAS mutated sub-groups.
Conclusion: Different types of phosphorylation of 
S6RP, phospho-S6RP Ser235/236 and phospho-S6RP 
Ser240/244 could be differently activated depending on 
EGFR and KRAS mutation status, suggesting interest 
of inhibiting the both pathways in wild-type tumors.
Keywords: MEK/ERK, PI3K/AKT/mTOR, EGFR, 
Kras
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MO13.11 MOLECULAR MECHANISMS 
AND MODULATION OF KEY KINASE 
PATHWAYS UNDERLYING THE 
SYNERGISTIC INTERACTION OF 
SORAFENIB WITH ERLOTINIB IN NON-
SMALL-LUNG CANCER (NSCLC) CELLS
Elisa Giovannetti1, Henk Dekker1, Rocco Sciarrillo1, 
Joline S. Lind2, Richard Honeywell1, Egbert F. Smit2, 
Henk M. Verheul1, Godefridus J. Peters1 
1Medical Oncology, VU University Medical Center/
Netherlands, 2Department Of Pulmonary Diseases, 
VU University Medical Center/Netherlands
Background: Combination of drugs with different 
targets is a logical approach in order to overcome 
multilevel cross-stimulation among key pathways 
in NSCLC progression such as EGFR, K-Ras and 
VEGFR. Sorafenib-erlotinib combination showed 
clinical activity and an acceptable safety proÀle 
in two phase-II studies in chemo-naive stage IIIB/
IV NSCLC patients (Lind et al., 2010; Gridelli 
et al., 2011), suggesting its role as potential 
salvage therapy in EGFR mutation-negative or 
elderly patients. Therefore, this study was aimed 
Background: Among the different signaling pathways 
controlled by epidermal growth factor receptor 
(EGFR) and involved in progression of non small 
cell lung carcinomas (NSCLC), phosphatidylinositol 
3-kinase (PI3K)/Akt/ mTOR and the RAS/RAF/
MAPK pathways seems to play a critical role in the 
cell survival or metabolism and in the cell growth 
respectively. The activated status of these two 
pathways, according to the presence/absence of 
EGFR or KRAS mutations could be of interest in the 
perspective of multi-targeted therapies. Therefore, we 
searched for the activation of several proteins of these 
two signalling pathways and analyzed their relationship 
with clinicopathologic features.
Methods: 74 primary lung tumors and matched 
non-malignant lung tissues provided by the tumor 
bank of the HÃ´pitaux Universitaires of Strasbourg, 
were obtained from NSCLC patients who underwent 
resection with curative intend,. All tumors contained 
more than 50% of tumor cells and have been 
selected according to the EGFR/KRAS mutation 
status previously determined by direct sequencing: 
19 mutated EGFR (16 adenocarcinomas, 11 
females, 10 never-smokers), 22 mutated KRAS (17 
adenocarcinoma, 8 females, 2 never-smokers) and 33 
wild-type tumors (11 adenocarcinoma, 23 females, 4 
never-smokers). Tissue microarray containing three 
samples of each tumor and matched normal tissue 
was constructed. Immunohistochemistry analysis 
was realized for ERK (phospho-ERK Thr202/
Tyr204), mTOR (phospho-mTOR Ser2448), two 
phosphorylated forms of S6RP (phospho-S6RP 
Ser235/236 , phospho-S6RP Ser240/244) targeted by 
RAS pathway or PI3K pathway respectively, PTEN 
and MKP-3/DUSP6.
Results: Phospho-mTOR is expressed in 46 (70%) 
tumors among them by 32 (72%) adenocarcinoma 
and 13 (45%) squamous cell carcinomas, and highly 
expressed in the mutated EGFR/KRAS (29, 78%) 
tumors rather wild-type cases (17, 58%, p= 0.05). 
Phospho-S6RP Ser235/236 is expressed in 28 (63%) 
adenocarcinoma and 12 (41%) of squamous cell 
carcinoma, and associated to KRAS mutated tumors 
(16, 84%, p = 0.02). Phospho-S6RP Ser240/244 
is expressed in 21 (48%) adenocarcinoma and 17 
(58%) squamous cell carcinoma, and half of the 
EGFR/KRAS mutated cases and in 18 (54%) of 
wild-type cases, with no statistically difference was 
observed among mutational status. Phospho-ERK is 
expressed in only 14 (20.9%) tumors mostly in by 11 
(25%) adenocarcinoma and 4 (14%) squamous cell 
carcinoma with no statistically signiÀcant difference 
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that can be studied to identify NSCLC patients who 
are likely to respond to this treatment.
Conclusion: Erlotinib-sorafenib combination is 
an attractive approach to block different signalling 
pathways as well as the same pathways at different 
levels, overcoming erlotinib-resistance. Several 
mechanisms including apoptosis-induction, 
modulation of expression/phosphorylation of RKIP 
and crucial kinases contribute to this synergistic 
interaction and should be evaluated in future trials 
for the rational development of erlotinib-sorafenib 
combination in NSCLC.
Keywords: synergistic interaction, sorafenib, 
erlotinib, Kinase modulation
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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MO13.12 AN RNAI SCREEN IDENTIFIES 
NEW MOLECULAR TARGETS IN 
MALIGNANT MESOTHELIOMA
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Michaela B. Kirschner1, Rayleen Bowman2, Kwun 
M. Fong2, Nico Van Zandwijk1 
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Background: Treatment options in malignant 
mesothelioma (MM) are limited. Despite some 
improvement in chemotherapy and combined 
modality approaches of MM, new therapeutic targets 
are urgently needed. RNAi screening provides a 
means of identifying potential new targets for further 
pre-clinical assessment.
Methods: Data from previous gene expression 
proÀling studies in MM were used to select targets 
for a rational RNAi screen. Two siRNAs per target 
gene were used to screen established and primary 
mesothelioma cell lines using optimised transfection 
conditions. Proliferation was used as the primary 
readout for effects of gene knockdown. Hits from 
the primary screen were followed up by analysing 
time and dose dependency of growth inhibition and 
knockdown at the mRNA level. Effects of silencing 
were further assessed using small molecule drugs 
speciÀc for targets.
at evaluating mechanisms underlying sorafenib-
erlotinib interaction and novel possible determinants 
to predict outcome to this therapy.
Methods: Eight NSCLC cell lines were selected 
on the basis of their heterogeneous pattern of 
EGFR and Raf-kinase-inhibitor protein (RKIP) 
expression, as well as by differential EGFR and 
K-Ras mutations. Pharmacologic interaction 
was studied using the MTT/SRB assays and data 
were evaluated with the combination index (CI) 
method, while effects on EGFR, Erk1/2 and Akt 
phosphorylation, cell cycle and apoptosis were 
studied with western blot, ELISA, Áow cytometry 
and Áuorescence microscopy, respectively. Finally, 
drug measurements in medium and cells were 
performed using a previously validated LC-MS/
MS method (Honeywell et al., 2010), while kinase 
activity proÀles of cell lysates in the presence and 
absence of erlotinib, sorafenib and their combination 
were generated on PamChip arrays comprising 144 
tyrosine containing peptides derived from known 
human protein phosphorylation sites.
Results: MTT demonstrated the key role of EGFR 
and K-Ras mutations for erlotinib activity, with 
IC50s ranging from 0.05 uM in H3255 (carrying 
EGFR-L858R activating mutation) to 2.88 uM in 
A549 (G12S-K-Ras mutated) and 20.2 uM in H1975 
(carrying EGFR-T790M resistant mutation) cells, 
while a reverse relationship was found between 
sorafenib cytotoxicity and RKIP expression. 
Synergism was detected in all cell lines, with CI 
mean values ranging from 0.4, in H460 (G61H-
K-Ras mutated), to 0.9, in H292 (K-Ras/EGFR 
wild-type cells), in the simultaneous 72h exposure. 
Erlotinib produced a slight G1 blockade, while 
sorafenib slowed cell cycle progression and induced 
apoptosis, which was signiÀcantly increased in the 
combination, i.e. 20.0 and 19.3% in H1975 and 
A549 cells, respectively. Sorafenib alone and in 
combination reduced Akt and ERK phosphorylation 
in both erlotinib-sensitive and resistant cells, e.g. in 
A549 cells the pERK/totalERK ratio decreased by 
-75%, associated with signiÀcant RKIP modulation. 
No direct drug interaction in medium from exposed 
cells was detected by LC-MS/MS measurement. 
Finally, studies in lysates from A549 and H1975 cells 
exposed to erlotinib+sorafenib, after appropriate 
statistical analysis with multiple corrections, showed 
a signiÀcant inhibition of the phosphorylation of 13 
overlapping peptides in both cell lines, including 
sites from VEGFR, RAF and PDGF-beta, but also 
CDK2 and SRC, suggesting possible new pathways 
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involved in malignant growth in several tumor types 
including NSCLC and esophageal cancer. The aim of 
the present study was to investigate activin signals in 
MPM cell models and their contribution to malignant 
growth and spreading. 
Methods: The expression of the activin ơA, ơB, ơC 
and ơE subunits (INHBA, INHBB, INHBC, INHBE), 
activin receptors (ACVR2, ACVR2B, ALK4 and 
7) and activin antagonizing factors was analyzed in 
a panel of 10 MPM cell lines by RT- and qRT-PCR 
and activin ơA expression was also analyzed by 
immunohistochemistry in parafÀn embedded tissue. 
For functional analysis of activin signals, MPM cell 
lines were treated with exogenous activin A, activin 
receptor inhibitors or activin A-targeting siRNA. Cell 
growth was assessed by MTT and clonogenic growth 
assays and cell migration by scratch and transwell 
assays. Phosphorylation of Smad2 was analyzed 
by Western blotting as readout for activation of the 
canonical activin/TGFbeta signaling pathway. 
Results: Expression data in mesothelioma cell 
models obtained by real-time PCR revealed high 
expression of activin ơA and activin receptors in most 
cell lines compared to non-malignant mesothelial 
cells. Likewise, immunohistochemistry in parafÀn 
embedded tissue sections of MPM patients showed 
intense cytoplasmic staining for activin A in the tumor 
cells of a subset of the cases analyzed. Treatment with 
exogenous activin A induced Smad2 phosphorylation 
in all cell lines tested, thus demonstrating functionality 
of the activin signaling axis in mesothelioma cells 
models. In contrast to the human hepatoma cell line 
HepG2, which in agreement with previous reports 
was inhibited, proliferation of mesothelioma cell 
models was stimulated by activin A as observed by 
MTT assays and clonogenic assays. Treatment with 
two different kinase inhibitors of activin receptors 
(SB43154, A8301) in contrast, inhibited mesothelioma 
cell proliferation and clonogenicity as well as 
migration. As kinase inhibitors are not absolutely 
speciÀc for activin receptors and also co-target 
TGFbeta receptors, we also silenced activin ơA with 
siRNA oligonucleotides. As expected, transfection 
with activin ơA siRNA but not scrambled control 
siRNA decreased activin ơA expression level and 
impaired cell proliferation. 
Conclusion: The data generated during this 
investigation clearly suggest that deregulated activin 
A signaling contributes to the malignant phenotype 
of mesothelioma cells and might therefore represent a 
valuable candidate for therapeutic interference.
Keywords: pleural mesothelioma, activin signaling
Results: The gene expression data from previous 
studies was used to select 40 gene targets that were 
upregulated in MM. The knockdown of a number of 
these genes was growth inhibitory in MM cell lines. 
These included genes involved in DNA synthesis 
(RRM1 and RRM2), control of cell cycle and cell 
division (PLK1, NDC80, CHK1 and CDK1), and 
apoptosis (BIRC5). The extent of growth inhibition 
was greatest with RRM1, RRM2 and PLK1, with 
less growth inhibition seen with CDK1 and NDC80, 
and the least inhibition seen following knockdown 
of CHK1 and BIRC5. All targets were signiÀcantly 
silenced (>90 % reduction in mRNA). Small 
molecule drugs were also growth inhibitory in the 
cell lines tested. The PLK1 inhibitor BI2536 was 
very potent, with IC50 values in the range of 5-10 
nM. AZD, a CHK1/2 inhibitor was slightly less 
potent, with ranges of 30-60 nM. Roscovitine, a 
pan-CDK inhibitor, and the NDC80 inhibitor INH1 
were least effective, with IC50 values in the high 
nanomolar range.
Conclusion: RNAi screening identiÀed a number of 
genes involved in the proliferation of MM cells, a 
number of which have not been previously linked to 
MM biology. Small molecules speciÀc or selective 
for these targets were also growth inhibitory and 
further testing in pre-clinical models is warranted. 
An expanded RNAi-based screen may increase the 
number of candidate therapeutic targets.
Keywords: Malignant mesothelioma, RNAi
Novel Cancer Genes and Pathways Wednesday, 6 July 2011 14:30-
16:00
MO13.13 DEREGULATION OF 
ACTIVIN SIGNALS CONTRIBUTES TO 
AGGRESSIVENESS OF MALIGNANT 
PLEURAL MESOTHELIOMA CELLS
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Background:  Malignant pleural mesothelioma 
(MPM) is an asbestos-related malignancy 
characterized by frequent resistance to chemo- and 
radiotherapy. Growth factors of the activin family are 
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MO14.01 AN ACADEMIC CENTER CAN 
MOVE FROM OPEN LOBECTOMY 
TO VATS LOBECTOMY AS UP FRONT 
THERAPY FOR EARLY STAGE LUNG 
CANCER AND MAINTAIN A QUALITY 
RESIDENT OPERATIVE EDUCATION
David T. Cooke, Minghui Liu, Walid O. Mari, A P. 
Mahfoozi, Valerie Kuderer, J. N. Young, Royce F. 
Calhoun 
Division Of Cardiothoracic Surgery, University Of 
California, Davis Medical Center/United States Of 
America
Background: Video-assisted thoracic surgery 
lobectomy (VATSL) for early stage non-small cell 
lung cancer (NSCLC) has been shown to improve 
peri- and postoperative outcomes and patient quality 
of life compared to open lobectomy (OL). VATSL 
has also proved to be an oncologic equivalent 
operation to OL for early stage NSCLC. VATSL 
requires a high level thoracoscopic skill set with a 
steep learning curve. Completion of an attending 
level VATSL learning curve might diminish the 
operative experience of cardiothoracic (CT) surgery 
residents. Through this study we sought to compare 
VATSL vs. OL, during the period of moving from 
OL to VATSL with respect to patient outcomes, as 
well as measure the evolution of the CT surgery 
resident operative experience. 
Methods: This is a single institution retrospective 
review of a prospective thoracic surgery database. 
The period of transition from OL to VATSL for early 
stage NSCLC was 2006-2007. The initial 65 VATSL 
were compared to 70 OL during this time period, 
matched by clinical variables. The CT resident Ànal 
American Board of Thoracic Surgery (ABTS) case 
logs for the categories Pneumonectomy, Lobectomy, 
Segmentectomy (PLS) and VATS were examined. 
Four chief residents from 2002-2005 (before 
initiation of the VATSL program) were compared 
to four chief residents from 2006-2009 (after 
initiation of the VATSL program). Case numbers are 
presented as percentages of the ABTS CT Pathway 
requirements for categories PLS (30 required cases) 
and VATS (15). Thoracic surgery residents after 
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MO13.14 MOLECULAR 
CLASSIFICATION OF LUNG 
ADENOCARCINOMA
Jun Yokota1, Reika Iwakawa1, Hirokazu Okayama1, 
Kouya Shiraishi1, Takashi Kohno2 
1Division Of Multistage Carcinogenesis, National 
Cancer Center Research Institute/Japan, 2Division 
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Background: Lung Adenocarcinoma has a 
heterogeneous feature in molecular pathways for its 
development. Up to present, three distinct pathways 
with alterations of EGFR, KRAS or ALK have been 
elucidated. However, a considerable fraction of lung 
ADC cases do not carry these alterations. Therefore, 
we attempted to elucidate the clinicopathological and 
molecular characteristics of ADCs without mutations of 
the EGFR/KRAS/ALK genes (Triple-negative ADCs).
Methods: Two hundred and twenty six cases of 
primary lung ADCs were subjected to mutation analysis 
of the EGFR/KRAS/ALK genes and genome-wide 
expression proÀling.
Results: EGFR, KRAS and ALK were mutually 
exclusively mutated in 127 (56%), 20 (9%) and 11 
(4.9%) cases. Therefore, the remaining 68 cases 
(30%) were deÀned as triple-negative ADCs. These 68 
cases were divided into two subclasses, groups A (36 
cases) and B (32 cases), by an unsupervised clustering 
analysis according to the expression of 174 genes. 
Relapse free survival as well as overall survival of 
group A patients were signiÀcantly worse than those of 
group B patients and EGFR (+) patients. Although the 
number of KRAS (+) and ALK (+) patients were small, 
similar trends were also observed.
Conclusion: A subclass of triple-negative ADCs with 
unfavorable outcome was identiÀed by combination 
of mutation and expression proÀling analyses. Further 
characterization of this subclass will be useful for 
selection of patients who will beneÀt from adjuvant 
chemotherapy after surgery.
Keywords: biomarker, pathway, Adenocarcinoma, 
Prognosis
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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following lobectomy on a national scale. 
Furthermore, inaccurate procedure codes may have 
been used in the identiÀcation of patient cohorts in 
recent analyses comparing perioperative outcomes 
following VATS vs. open lobectomy (OPEN). 
Methods: The 2008 Healthcare Utilization Project-
Nationwide Inpatient Sample (HCUP-NIS) database 
was culled using the ICD-9-CM procedure codes 
distinguishing VATS vs. OPEN lobectomies (32.41 
and 32.49, respectively) that were only available 
after October 2007. Prior to that date, only a non-
speciÀc procedure code for lobectomy existed 
(32.4). Patient and provider demographic and 
clinical characteristics, including hospital VATS 
volume (deÀned as  95th percentile, or  21 VATS/
year), were recorded. Bivariate and multivariate 
analyses were used to identify independent 
predictors of outcome measures (30-day in-hospital 
total complications, length-of-hospital-stay [LOS], 
inpatient hospital costs, and in-hospital mortality).
Results: In the 2008 HCUP-NIS database, there 
were 6,292 lobectomies identiÀed for patients with 
primary lung cancer, including 1,523 with VATS 
(24%). Compared with OPEN, patients undergoing 
VATS had fewer total complications (38% vs. 44%, 
p<0.001) and shorter median LOS (5 vs. 7 days, 
p<0.001). There were no signiÀcant differences in 
median costs or mortality. Adjusting for patient/
provider characteristics in multivariate analysis, 
VATS was an independent predictor of fewer total 
complications (OR=0.83, p=0.004) and shorter LOS 
(2.3±0.3 day difference, p<0.001) compared with 
OPEN. Patients undergoing VATS at high-volume 
VATS hospitals had shorter median LOS (4 vs. 6 
days, p=0.001) than those at low-volume VATS 
hospitals. There were no signiÀcant differences 
in total complications, median costs, or mortality. 
Adjusting for patient/provider characteristics in 
multivariate analysis, high hospital VATS volume 
was an independent predictor of shorter LOS 
(1.2±0.4 day difference, p=0.001) compared to low 
hospital VATS volume.
Conclusion: On a national scale, VATS lobectomy 
is independently associated with fewer total 
complications and shorter LOS for patients with 
primary lung cancer, compared with OPEN 
lobectomy. For patients undergoing VATS 
lobectomy, high hospital volume is also associated 
with shorter LOS. The Àndings of this study may 
warrant further investigation as the national VATS 
experience and the collection of VATS lobectomy-
speciÀc data continue to increase.
2005 are provided with VATSL operative technique 
literature and instructional videos. Residents were 
taken through stepwise milestone sequences of 
operative VATSL techniques before supervised 
completion of an entire VATSL. Results were 
considered signiÀcant if p0.05. 
Results: There were no operative deaths in either 
the VATSL or OL groups. Two patients in the 
VATSL group were converted to open secondary 
to intraoperative bleeding. Compared to OL the 
VATSL group had reduced mean days on mechanical 
ventilation (0.00 vs. 0.30, p = 0.03), ICU length of 
stay (0.20 vs. 3.70, p=0.004) and hospital length of 
stay (4.30 vs. 8.80, p=0.001). Examining resident 
education, both the 2002-2005 and 2006-2009 
cohorts had similar mean case numbers for PLS 
(44.8 vs. 51.3, p=0.63; % of requirement 149% vs. 
171%) and the 2006-2009 group performed a greater 
number of VATS cases (71.8 vs. 16.3, p=0.13; 478% 
vs. 108%). 
Conclusion: These results illustrate that a 
teaching institution can effectively move 
from an OL approach to VATSL and, through 
carefully planned and structured instruction of 
the residents, maintain patient safety and reduce 
postoperative complications. At the same time, the 
resident operative experience is enriched. Further 
enhancement of resident VATSL education in the 
future may involve surgical simulation. 
Keywords: VATS lobectomy, Lung cancer, Medical 
Education, Early Stage
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MO14.02 IMPACT OF HOSPITAL 
OPERATIVE VOLUME OF VIDEO-
ASSISTED THORACOSCOPIC 
LOBECTOMY ON PERIOPERATIVE 
OUTCOMES FOR PRIMARY LUNG 
CANCER
Henry S. Park, Frank C. Detterbeck, Daniel J. Boffa, 
Anthony W. Kim 
Department Of Surgery (thoracic), Yale University 
School Of Medicine/United States Of America
Background: Video-assisted thoracoscopic surgery 
(VATS) is an increasingly utilized approach for 
pulmonary lobectomy throughout the United States. 
Hospital operative volume of VATS lobectomy 
in primary lung cancer has not previously been 
evaluated as a predictor of short-term outcomes 
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Results: There are no signiÀcant differences in sex, 
age, or histopathological Àndings among three groups. 
There are no operative death but one hospital death in 
C-Gp., of interstitial pneumonia. There are no signiÀcant 
differences in operating time, blood loss and transfusion 
rate among the groups. The mean observation period 
after the operation was 38.7 months ( range, 0.6 to 
122 ms ). The overall 5-year survivals was 95.3 % for 
C-Gr., 75 % for S- Gr., respectively. Major postoperative 
complication in C-Gr. was signiÀcantly less than other 
Grps. CPK ratio (CPKmax / preCPK) as a marker 
indicating surgical damage to the muscles In C-Gr.is 
signiÀcantly less than S-Gr. And mean maximum CRP 
degree postoperatively in C-Gr. is signiÀcantly less than 
the two other Grps. We used analogue pain scale and 
record the self-estimation of the patients on the day 1, 
2, and 3 after operation.Post surgical pain which patient 
felt is tended to reduce in C-Gr.
Conclusion: The results of major pulmonary 
resection for C-IA lung cancer by c-VATS with 
subxiphoid route is feasible and acceptable by a 
patients’ view of point over operative phase.
Keywords: Complete VATS Lobectomy, Subxiphoid 
route, Minimally invasive
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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MO14.05 EXPERIENCE WITH 
CT-GUIDED HOOK WIRE FOR 
LOCALIZATION OF SMALL 
PULMONARY NODULES PRIOR TO 
VIDEOTHORACOSCOPIC RESECTION.
Laureano Molins1, Eduard Mauri2, Marcelo 
Sanchez3, Juan J. Fibla4, Jose M. Gimferrer5, Pedro 
Arguis3, Jose M. Mier4, Abel Gomez-Caro5, Miguel 
Catalan5, Jose M. Sancho6, Jose Ramirez7 
1Thoracic Surgery, Hospital Clinic/Spain, 
2Diagnostic Imaging (CRC Sagrat Cor), Hospital 
Universitari Sagrat Cor/Spain, 3Radiology, Hospital 
Clínic, Barcelona, Spain/Spain, 4Thoracic Surgery, 
Hospital Universitari Sagrat Cor/Spain, 5Thoracic 
Surgery, Hospital Clínic/Spain, 6Pathology, Hospital 
Universitari Sagrat Cor/Spain, 7Pathology, Hospital 
Clínic/Spain
Background: Resection of peripheral pulmonary 
nodules by videothoracoscopy offers a speciÀcity 
Keywords: hospital volume, VATS lobectomy, 
perioperative outcomes
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MO14.03 MINIMUM INVASIVE 
COMPLETE VATS LOBECTOMY FOR 
C-IA LUNG CANCER WITH SUBXIPHOID 
ROUTE
Yoshinori Doki1, Kazutaka Senda1, Takahiro 
Homma1, Masayoshi Tohge1, Naoki Yoshimura1, 
Tatsuhiko Kashii2, Shigeki Sugiyama3 
1Thoracic And Cardiovascular Surgery, Toyama 
University Hospital/Japan, 2Division Of Clinical 
Oncology, Toyama Uniersity Hospital/Japan, 
3Pulmonology, Tohmei-Atsugi Hospital/Japan
Background: Pulmonary lobectomy by Complete 
Video-assisted thoracic surgery (c-VATS) for early-
staged lung cancer patients has gained wide spread 
acceptance in recent years. Its advantages are less 
invasiveness, better cosmesis and that contributes to 
patients’ quality of life after the operation. So as to 
prevent all neuromuscle damages of the chest wall 
structures from rib spreading or cutting by electric 
devices as possible, we have performed c-VATS 
lobectomy with subxiphoid route when the resected 
specimen is extracted from chest cavity.In this 
congress, we introduce our technical procedures, 
perioerative data and survival.
Methods: From January 2003 to December 
2010, there are 39 patients we have treated major 
lung resection followed by ipsilateral hilum and 
mediastinal radical dissection for c-IA lung cancer 
patients by c-VATS with subxiphoid route. Our ordinal 
procedure is performed by 3 or 4 ports, and resected 
specimen is over-wrapped in a pouch and extracted 
through subxiphoid route. We studied and investigated 
clinical data of the patients by this procedure(C-
groupe) and compared to that by mini-thoracotmy 
VATS(M-groupe) or by standard thoracotomy(S-
groupe) performed on the same period.
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Conclusion: The perioperative identiÀcation of the 
small-sized pulmonary nodules enables a resection 
through videothoracoscopic surgery without the need 
of having to extend the incision or the practice of a 
mini thoracotomy for palpation of the nodule. The 
introduction of a CT-guided hook wire is, in expert 
hands, a very safe and effective procedure that can 
be carried out in an outpatient surgery programme. 
Keywords: Videothoracoscopy, CT-guided Hook 
wire, Resection of Pulmonary nodule, Localization 
of Pulmonary Nodule
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MO14.06 IMAGE-GUIDED VIDEO-
ASSISTED THORACOSCOPIC (VATS) 
RESECTION FOR DIAGNOSIS OF SMALL 
PERIPHERAL PULMONARY NODULES 
(SPN)
Richard J. Finley1, John Mayo2, Joanne C. Clifton3, 
John Yee1, Annette Mcwilliams4, Stephen Lam5, 
Kenneth Evans1, John C. English6 
1Surgery/thoracic Surgery, Vancouver General 
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Hospital/Canada, 3Surgery/thoracic, University Of 
British Columbia/Canada, 4Medicine/respiratory, 
University Of British Columbia/Canada, 5Integrative 
Oncology, Bc Cancer Research Centre/Canada, 
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Background: Poor diagnostic accuracy of 
bronchoscopy, needle biopsy or PET scan of growing 
SPN in patients at high risk for either primary or 
metastatic lung cancer leads to requests for VATS 
resection for pathologic diagnosis .Failure to visualize 
or palpate SPN at VATS results in thoracotomy for 
resection in over 50% of cases .The purpose of this study 
is to determine if preoperative CT-guided microcoil 
localization of SPN followed by Áuoroscopically guided 
VATS resection decreases the need for thoracotomy for 
diagnosis of SPN. 
Methods: Between April 2003 – January 2011, 113 
undiagnosed SPN (£15 mm) in 110 consecutive patients 
were preoperatively localized using percutaneously 
placed CT-guided platinum microcoils. Coils were placed 
with the distal end deep to nodule and the superÀcial end 
coiled on the pleural surface. Nodule and microcoil were 
removed using endostaplers by Áuoroscopically guided 
VATS wedge excision. Intraoperative frozen section 
histopathologic diagnosis was performed.
of 100% with low morbidity. It sometimes requires 
extension of one of the incisions or the practice of 
a mini thoracotomy and digital palpation in order 
to locate them, when they are not totally subpleural 
and/or because of their small size. The objective is to 
assess the results of the introduction of a CT-guided 
hook wire prior to the videothoracoscopic resection 
as a perioperative localization method. 
Methods: From November 2004 to January 2011 
Àfty two patients were programmed for localization of 
pulmonary nodules smaller than 20mm by introduction 
of a CT-guided harpoon. The patient was later taken to 
the surgical theatre for a videothoracoscopic resection 
using endostaplers with a protected extraction of the 
specimen for anatomo-pathological examination, and 
proceed in consequence. 
Results: Fifty two patients – 31 men and 21 women 
– from 28 to 84 years old (mean of 62,2 years) with 
nodules of a diameter maximum of 20mm (mean 
of 9,57 mm and 37 nodules <10 mm). Six patients 
had the nodule(s) detected during the staging of 
a recently-diagnosed neoplasm; 29 patients with 
nodules detected during the follow-up of a previous 
neoplasm, and 17 patients without previous oncologic 
history. Nine nodules were deÀned as GGO. Fifty 
Àve harpoons were placed – three patients had 
two simultaneous harpoons placed. During the 
videothoracoscopic exploration, 52 harpoons were 
found in place and three of them had detached 
themselves –2 were a different type of hook wire from 
the original ones. A videothoracoscopic resection 
was carried out in all but two cases without need of 
extending the incisions of ports. No complications 
like hemorrage or pneumothorax were observed. 
Among the 35 patients with a previous oncologic 
history, the nodules were neoplasic in 26 cases (13 
lung carcinoma, 4 colon, 3 melanoma, 2 breast and 
1 of each: tipical carcinoid, parotid, endometrium 
and urothelial) and 9 turned out to be benign (2 
hamartomas, 1 adenomatous hyperplasia, 1 chronic 
pneumonia, 1 sarcoidosis, 3 inÁammatory inÀltrates 
and 1 intraparenchymal lymph node). Among the 
17 patients without previous oncologic history, the 
nodules were as follows: 12 bronchogenic carcinomas 
(3 doubles) and 5 benign (3 hamartomas, 1 
tuberculous nodule and 1 Àbrous nodule). The average 
stay ranged between 4 and 72h, with 19 patients 
included in an Outpatient surgical program (36,5%); 
15 patients were discharged after 24 hours (28.8%), 
1 after 72h due to air leak (1.9%) and 17 after 5 days 
because an additional resection was performed after 
the pathologic intraoperative diagnosis. 
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is poppyseed oil used as a radio-opaque contrast 
agent such as lymphangiography. We herein show 
the preoperative multi-marking with lipiodol using 
real-time CT Áuoroscopy for several lung resections. 
Methods: One hundred and twenty-eight pulmonary 
nodules in 47 patients (32 male and 15 female) 
were enrolled in this study. A number of the marked 
nodules were ranged from 2 to 5 in unilateral lung of 
each patient. Of these, 14 were nodules with ground-
glass opacity, 12 were cystic nodules, and 102 were 
solid nodules on CT images. Our indication for 
lipiodol making was as follows: the nodules were 1) 
in the ipsilateral lung, 2) less than 10mm, 3) located 
far from the surface of visceral pleura, or 4) they 
showed non-solid (ground-glass opacity or cystic) 
images on CT. All nodules were marked with 0.1 
to 0.5 ml lipiodol under a real-time CT Áuoroscopy 
just before the surgery. At surgery, we grasped the 
marked nodules with ring-shaped forceps under a 
C-arm Áuoroscope and then performed thoracoscopic 
lung resection. 
Results: All 128 nodules were successfully in multi-
marking with lipiodol, and completely resected 
under the intraoperative Áuoroscopy. The mean 
time required to marking for a nodule was 18.5 
minutes. Complications of the multi-marking were 
pneumothorax required thoracic drainage in 19 
(40%) patients, pulmonary hemorrhage in 4 (9%), 
bloody sputum in 2 (4%), and hematoma in the chest 
wall in 1 (2%). The high incidence of pneumothorax 
was caused by the frequency of needle puncture 
to the lung. No other complications such as aero-
embolism were observed. The mean size of the 
nodules was 6.8 mm (in range from 2 to 23 mm), 
and their mean depth from the visceral pleural 
surface was 8.2 mm (in range from 0 to 39 mm). 
The pathologic diagnosis was primary lung cancer 
in 6 lesions (including 3 of bronchioloalveolar 
carcinoma), metastatic lung tumor in 73, atypical 
adenomatous hyperplasia in 4, and other benign 
lesion in 45. The use of lipiodol did not affect the 
pathological Àndings. 
Conclusion: Preoperative multi-marking with 
lipiodol is a useful and precise procedure for 
thoracoscopic resection of several small pulmonary 
nodules. This method can be also recommended for 
impalpable lung lesion such as ground-glass opacity 
or cystic lesions. 
Keywords: Lipiodol marking, CT Áuoroscopy, 
thoracoscopic resection, VATS
Results: On average, nodules were 10.8± 
3mm in diameter and 14.3±11 mm deep to the 
visceral pleural surface. Using CT guidance the 
microcoil was placed within 5mm of the nodule 
in 106/109 with 2/107 requiring a chest tube for 
pneumothoraces. Complete resection was successful 
in all patients (111/113 by VATS and 2/113 by 
thoracotomy). Mean microcoil insertion, Áuoroscopy 
and wedge resection operative minutes were: 
31.4±10; 1.4±1; 32.0±24. Backward linear regression 
for operating time was dependent on nodule depth 
(p<0.001), Áuoroscopy minutes (p=0.007), and 
location segment of nodule (p=0.017). Pathologic 
diagnosis was: 27 benign, 21 metastatic, 65 primary 
(Adenocarcinoma 45, BAC 9, Squamous cell 8, 
Large cell 1, Small cell 2) cancers. Completion 
lobectomy occurred in 32 patients. Median follow-up 
is 13.8 months (min 0.2, max 86.5). There were no 
local tumor recurrences. In the 52 Stage I patients, 
there have been four new primaries and one death 
(48 months). In the 72% (81/113) of patients with 
bronchoscopy, needle biopsy or PET investigations, 
preoperative treatment plan was changed by 
microcoil guided VATS excision biopsy in 44% 
(36/81). 
Conclusion: Pre-operative localization of small 
peripheral pulmonary nodules (<15mm) using 
percutaneous CT guided platinum microcoils 
followed by Áuoroscopic guided VATS excision 
provided pathologic diagnosis in 98% and changed 
management in 44% of cases. 
Keyword: microcoil
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MO14.07 PREOPERATIVE MULTI-
MARKING WITH LIPIODOL FOR 
THORACOSCOPIC RESECTION OF 
SEVERAL SMALL PULMONARY 
NODULES
Kunihiko Terauchi, Junichi Shimada, Daishiro Kato, 
Masanori Shimomura, Hiroaki Tsunezuka, Kaori 
Ichise 
Department Of General Thoracic Surgery, Kyoto 
Prefectural University Of Medicine/Japan
Background: As the development of the 
computed tomography (CT) screening, several 
small pulmonary nodules are often detected on CT 
scanning. Several techniques have been reported for 
their localization in thoracoscopic resection. Lipiodol 
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Conclusion: In this pilot study CT-guided 
transbronchial metallic coil marking with an ultrathin 
bronchoscope with a coin on a patient’s chest wall 
after CT-assisted stimulation was found to be feasible 
and safe. In our previous report, CT had been needed 
at least three times, but this method needed only twice 
CT scan. It might be a useful method not only for 
making a diagnosis but also for therapeutic wedge 
resection in selected early lung cancers.
Keywords: coil marking, VATS, CT assisted 
bronchoscopy
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MO14.10 MEDIASTINAL LYMPH 
NODE DISSECTION IN EARLY STAGE 
NON-SMALL CELL LUNG CANCER: 
TOTALLY THORACOSCOPIC VERSUS 
THORACOTOMY
Dominique Gossot1, Ricard Ramos1, Philippe 
Girard1, Pierre Validire2 
1Thoracic, Imm/France, 2Pathology, Imm/France
Background: Although major pulmonary resections 
for early stage non-small cell lung cancer (NSCLC) 
are more and more frequently performed through 
thoracoscopy, the adequacy of lymphadenectomy 
achieved via this approach is still questioned. The 
aim of this study was to evaluate the results of lymph 
node dissection during totally thoracoscopic major 
pulmonary resections. 
Methods: Clinical and pathologic data of 
consecutive patients who underwent lobectomy or 
segmentectomy for clinical-N0 NSCLC between 
January 1st, 2007 and December 31st , 2009 were 
reviewed .The main evaluation criterion was the 
number of mediastinal lymph nodes and mediastinal 
stations dissected through a totally thoracoscopic 
(TT) approach as compared with the classical 
posterolateral thoracotomy (PLT) approach. 
Results: : A total of 296 major pulmonary resections 
(278 lobectomies and 18 anatomic segmentectomies) 
for clinical stage I-II NSCLC were performed, 96 
via a TT approach and 200 through PLT. Patients’ 
clinical characteristics were similar in both groups. 
The overall numbers of dissected mediastinal lymph 
nodes and of dissected mediastinal stations were 
similar in both groups (TT: mean±SD=17.7±8.2; 
PLT: 18.2±9.3, p: 0.937, and 3.2±0.9 vs 3.4±0.9, 
respectively). The overall numbers of stations (TT: 
mean ±SD 5.1±1.1; PLT: 4.5±1.2) and lymph nodes 
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MO14.08 FLUOROSCOPY-ASSISTED 
THORACOSCOPIC RESECTION OF 
PULMONARY NODULES AFTER 
COMPUTED TOMOGRAPHY–ASSISTED 
BRONCHOSCOPIC METALLIC COIL 
MARKING
Takanori Miyoshi, Hisashi Matsuoka, Masami 
Morimoto, Naoki Hino, Masaru Tsuyuguchi 
Surgery, Tokushima Municipal Hospital/Japan
Background: With advances in computed 
tomography (CT), small pulmonary lesions 
previously unseen on chest radiographs are being 
increasingly detected. Among lesions less than 10 
mm in size, a considerable number of malignancies 
have been reported. To localize small and deeply 
situated pulmonary nodules during thoracoscopy 
with roentgenographic Áuoroscopy, we developed a 
marking procedure that uses a metallic coil and a coin.
Methods: Eleven patients underwent video-assisted 
thoracoscopic surgery for removal of 11 pulmonary 
lesions. Fluoroscopy-assisted thoracoscopic 
surgery after CT-assisted bronchoscopic metallic 
coil marking was performed using an ultrathin 
bronchoscope under Áuoroscopy viewing a coin 
on a patient’s chest wall. The coin was simulated a 
pulmonary lesion by the CT Àndings, and it was put 
on the patient’s chest wall. During thoracoscopy, a 
C-arm-shaped roentgenographic Áuoroscope was 
used to detect the radiopaque nodules. The nodule 
with coil markings was grasped with forceps and 
resected with endostaplers under Áuoroscopic and 
thoracoscopic guidance.
Results: The marking procedure took 10 to 30 minutes 
from insertion to removal of the bronchoscope. 
There were no complications from the marking, and 
all 11 nodules were easily localized by means of 
thoracoscopy. The metallic coil showed the nodules 
on the Áuoroscopic monitor, which aided in nodule 
manipulation. Nodules were completely resected under 
thoracoscopic guidance, in partial resection in 10 cases 
and in segmentectomy in one case. The pathologic 
diagnosis was primary adenocarcinoma in 6 patients, 
primary lung cancer except adenocarcinoma in 2 
patients, a pulmonary metastasis from colon cancer 
in 1 patient, an atypical adenomatous hyperplasia 
in 1 patient and a nontuberculous mycobacteriosis 
in 1 patient. One case of a bronchiolo-alveolar 
adenocarcinoma with an extensive two segments was 
performed a curative segmentectomy.
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operating time was 215 min (range, 190–280 min). 
Ten lobectomies and two wedge resections were 
performed with en bloc chest-wall resection and 
mediastinal lymphadenectomy. In one patient, a 
combined transmanubrial and posterior thoracotomy 
was required to remove the tumor. In another, a 
liquoral Àstula was treated intra-operatively. R0 
resection was achieved in all 12 patients. The 
average blood loss was 415 mL (range, 250–1200 
mL). There was no postoperative mortality; four 
patients developed postoperative pneumonia. The 
median length of hospitalization was 9,5 days 
(range, 8–30 d). The mean operative follow-up to 
date is 25,4 months (range, 6-46 months). No repeat 
surgical procedure has been required. Seven patients 
remain well with no clinical or radiological evidence 
of recurrence. One patient developed a controlateral 
lung nodule and is under chemiotherapic treatment. 
Four patients died; two developed metastatic disease, 
one developed acute myeloid leukemia and the last 
died of a cardiopulmonary insufÀciency.
Conclusion: This technique is technically 
demanding. A high-quality video system and the 
ability to combine the use of thoracoscopic and 
standard instruments are essential for success, but no 
new instruments are required other than those used in 
standard procedures. Additionally, all team members 
can follow the surgical steps in detail, which is a 
useful teaching tool. The short-term results have 
been encouraging, but it would be interesting to 
conduct this technique in a randomized study with 
a larger series against the use of thoracotomy alone. 
This is an effective and safe approach to assess 
resectability and minimize postoperative trauma in 
complex surgery for superior sulcus tumors, and it is 
now in routine use in our department.
Keywords: Lung cancer, video-assisted thoracic 
surgery, superior sulcus tumors
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MO14.12 POSITIVE PLEURAL LAVAGE 
CYTOLOGY IS A PREDICTOR OF POOR 
PROGNOSIS IN RESECTED NSCLC
Federico Mazza1, Paola Maineri2, Enrico Ferrari3, 
Antonella Alloisio3, Maria Teresa Piras3, Giovanni 
Battista Ratto3 
1Thoracic Surgery, Istituto Nazionale Per La Ricerca 
Sul Cancro/Italy, 2Ospedale Santa Corona - Asl2 
Savona/Italy, 3Istituto Nazionale Per La Ricerca Sul 
Cancro/Italy
(TT: 22.6±9.4, PLT: 25.4±10.8) were slightly but 
signiÀcantly different between the 2 groups (p<0.001 
and p=0.033, respectively); There was no difference 
in terms of postoperative complications, although 
patients from the TT group had signiÀcantly fewer 
chest tube days (mean±SD=4.0±1.8 vs 5.7±3.9, p< 
0.001) and shorter hospital length of stay (7.0±2.5 
days vs 10.3±7.4, p< 0.001). 
Conclusion: For patients undergoing thoracoscopic 
lobectomy or segmentectomy for clinical early 
stage NSCLC, the quality of mediastinal lymph 
node dissection is equivalent to that performed by 
thoracotomy.
Keywords: lymph node dissection, Surgery, VATS
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MO14.11 THE VIDEO-ASSISTED 
MODIFIED SHAW-PAULSON APPROACH 
FOR PANCOAST TUMORS
Francesco P. Caronia1, Enrico RufÀni2, Attilio 
Ignazio Lo Monte3 
1Thoracic Surgery, Policlinico Morgagni/Italy, 
2Chirurgia Toracica, Ospedale San Giovanni 
Battista/Italy, 3Surgery, University Of Palermo/Italy
Background: We describe the initial use of video 
assisted thoracic surgery (VATS) with the Shaw-
Paulson approach in 12 patients with Pancoast tumors, 
in order to minimize chest wall trauma.
Methods: Between March 2004 and September 
2010, 12 patients with Pancoast tumors underwent a 
modiÀed VATS Shaw-Paulson approach, lung resection 
with an en bloc chest-wall resection and mediastinal 
lymphadenectomy. All patients underwent neoadjuvant 
chemoradiotherapy. The procedure began with the 
exploration of the pleural cavity using a 30-degree 
videothoracoscopic camera. Surgery was performed 
using standard techniques and combining the use of 
a high posterior thoracotomy parallel to the vertebral 
border of the scapula, and thoracoscopic ports. After the 
involved chest wall attached to the lung was resected 
through the posterior thoracotomy, either lobectomy or 
wedge-resection could be performed with VATS.
This posterior thoracotomy preserves the latissimus 
dorsi, and avoids extension of the thoracotomy through 
the fourth or Àfth intercostal space. No prosthesis was 
necessary to cover the Ànal chest wall defect.
Results: There were 9 men and 3 women with 
a mean age of 61 yrs (range, 39-73 yr). Patients 
were either IIB (n=5) or IIIA (n=7). The average 
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MO14.13 PARATRACHEAL 
LYMPHADENECTOMY DURING A LEFT 
SIDED THORACOTOMY FOR LUNG 
CANCER RESECTION. WHAT CHANGES 
WHEN COMBINED WITH SYSTEMATIC 
DISSECTION ?
Alper Toker1, Serhan Tanju1, Erkan Kaba1, Serkan 
Kaya1, Dilek Yilmazbayhan2 
1Thoracic Surgery, Istanbul University Istanbul 
Medical School/Turkey, 2Pathology, Istanbul 
University Istanbul Medical School/Turkey
Background: Theoretical reasons which are often 
cited to support systematic nodal sampling or 
complete mediastinal lymphadenectomy during 
lung cancer resection, are skip metastasis and occult 
lymph node metastasis. The goal of this study was to 
determine effects of paratracheal lymphadenectomy.
Methods: Sixty-six patients who had left sided hilar 
primary lung cancer with a negative mediastinal 
uptake in PET-CT and negative mediastinoscopy, 
underwent left thoracotomy. Dissection of the nodes 
(2R, 4R, 2L, 4L) were accomplished without ductus 
arteriosus division and arcus aorta mobilization. 
Patients’ demographics, histology, total number 
of lymph nodes dissected, number of nodes from 
each station, number of metastatic lymph nodes, 
morbidity and mortality were recorded. The 
number of dissected paratracheal lymph nodes were 
compared to the number of standart systematic 
lymph nodes dissected from the left lung.
Results: The mean number of resected nodes in the 
superior mediastinum was 8.7 (range 2 – 20 nodes), 
3.4 from 4R, 2.5 from 4L, 0.5 from 2L and 2.1 from 
2R. Six patients (9.0 %) were diagnosed with occult 
N2 disease, and two (3.0%) of these patients also had 
concomitant N3 disease. Complications related to 
the operation and this technique were observed in 18 
patients (27.2%) patients. A total of 567 nodes were 
dissected from paratracheal area with a total of 10 
nodes positivity in six patients. Systematic dissection 
of the stations 5 to 9 nodes recruted 509 nodes with 
10 nodes positivity in 10 patients. There were 3 
common patients in both positive groups.
Conclusion: Paratracheal lymp node dissection 
through left thoracotomy increases the number 
of nodes dissected twice as much. In this study, 
this technique provided 3 more N2 patients when 
combined with standard systematic dissection. This 
technique could be considered prior to a decision 
Background: TNM is the best prognostic descriptor 
about Lung Cancer. Nevertheless there are some 
clinicopathological characteristics not included in 
TNM, but potentially related to NSCLC prognosis: 
one of them is Pleural Lavage Cytology (PLC). 
Methods: From January 2003 to December 2008, 
PLC has been performed in 397 consecutive NSCLC 
patients who underwent surgical resection. Follow-up 
was available in 376 patients. PLC was obtained from 
100ml of saline solution instilled in the pleural cavity 
soon after thoracotomy, before any lung manipulation 
and in absence of pleural effusion. 
Results: There were 280 male and 96 female, with 
a median age of 69 (ranging from 36 to 86). PLC 
was positive in 13 patient (3,5%). Positive cytologic 
Àndings were observed only in adenocarcinoma 
patients (13 of 193 resected adenocarcinomas: 6,7%). 
Positive PLC was signiÀcantly related to pT category 
(1,6% in pT1; 2,4% in pT2; 12,2% in pT3-4; p = 
0,001) and pN2 with more than one mediastinal 
lymph node station involved (38,5% versus 2,3% of 
single-pN2, p = 0,003); no correlations were found 
between PLC and age, extent of surgery, R0 resection, 
p-stage, presence of lymph node skip metastasis or 
extranodal inÀltration. The overall 5-year survival 
rates were 27,7%% in PLC positive cases and 54,9% 
in PLC negative cases (p = 0,001) (Àgure 1); this 
difference was also signiÀcant when the analysis 
was limited to p-stage I NSCLC (50% vs 68%; p 
= 0,005). Despite the longer median follow-up for 
PLC negative patients (2,87 years versus 2,1 years), 
recurrences were observed more frequently in PLC 
positive patients: 69,2% versus 34,5% (p = 0,034). 
Among PLC positive cases there was no difference in 
the patterns of recurrence (55,6% local versus 44,4% 
distant metastasis, p = 0,729). Multivariate analysis 
showed Àve independent prognostic factors (age, R0 
resection, pT, pN, bulky-pN2), not including PLC. 
Conclusion: This study showed that PLC positive 
NSCLC patients have a worse overall survival and 
an higher recurrence rate, even in early stage disease. 
We suggest to consider PLC positive patients as 
an high risk category, eligible for adjuvant therapy 
regardless of the p-stage. 
Keywords: Prognosis, NSCLC, pleural lavage, cytology
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Methods: Advanced NSCLC patients who 
experienced disease progression following 1 or 2 
prior chemotherapy regimens, ECOG PS 0-2, and 
measurable disease were included. Study treatment 
was randomly assigned to include erlotinib (150 
mg PO QD) in combination with either placebo, 
R1507 at 9mg/kg/week or R1507 at 16 mg/kg/Q 3 
weeks, i.v. Treatment cycles were repeated every 
3 weeks. The primary endpoint was comparison of 
the 12-weeks PFS rate and the secondary endpoints 
included response rate, PFS, OS, safety assessment 
and exploratory correlative studies. 
Results: 171 patients were enrolled, with the 
following characteristics: median age 61 years, 33 % 
female, 12% never-smokers, 86% stage IV, 88% PS 
0/1, 25% squamous histology, 51% adenocarcinoma, 
and 74% with 1 prior regimen. The median number 
of doses of R1507 was 6 and 3.5 for the weekly 
and Q3 weeks arms respectively. Grade 3/4 adverse 
events were noted in 37%, 44%, and 48% of patients 
with placebo, weekly, and Q 3 weeks R1507 therapy 
respectively. 
Parameter E + Placebo E + R1507
(weekly) 
E+R1507
(Q 3 wks) 
N 57 pts 57 pts 57 pts 
Response rate 8.8% 8.8% 7% 
12-weeks PFS rate 39% 37% 44% (NS) 
Median PFS 1.5 m 1.6 m 2.7 m (P= NS) 
Median OS 8.1 m 8.1 m 12.1 m (P=0.04) 
Gr 3/4 skin rash 8% 7% 10% 
Gr 3/4 fatigue 6% 10% 7% 
Hyperglycemia (any) 0 3% 9% 
Candidate biomarkers including IGF-1R, free IGF1, 
total IGF, IGFBP-3, pAKT, PTEN, EGFR and Kras 
were evaluated in tissue specimens (n=165). The 
12-weeks PFS rate was higher with R1507 Q3 weeks 
in patients with high free IGF-1 levels, compared to 
placebo (46% vs. 18%). The 12-weeks PFS rate in 
patients with K-ras mutation was 22% with R1507 
compared to 0 with placebo. 
Conclusion: The addition of R1507 to erlotinib did 
not result in a signiÀcant improvement in PFS for 
an unselected group of advanced NSCLC patients in 
the 2nd/ 3rd line therapy setting. K-ras status and free 
IGF-1 bioactivity in serum demonstrated predictive 
potential in an exploratory analysis. 
Keywords: NSCLC, IGF-1R, R1507, erlotinib
for a major resection if intraoperative N1 and N2 
positivity was diagnosed. Also, when an exploratory 
thoracotomy for an undiagnosed mass turns out to 
be a NSCLC, dissection of the mediastinum may be 
considered prior to resection. 
Keywords: Lung cancer, Mediastinal staging, 
Mediastinal lymph node dissection, Left 
thoracotomy
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MO15.01 R1507, A MONOCLONAL 
ANTIBODY TO INSULIN-LIKE GROWTH 
FACTOR RECEPTOR-1 (IGF-1R), IN 
COMBINATION WITH ERLOTINIB FOR 
ADVANCED STAGE NON-SMALL CELL 
LUNG CANCER (NSCLC): A PLACEBO-
CONTROLLED, RANDOMIZED PHASE II 
STUDY.
Suresh Ramalingam1, David Spigel2, Martin Steins3, 
Jeffrey Engelman4, Silvia Novello5, Wilfried 
Eberhardt6, Claus Schneider7, Lucio Crino8, 
Pasi A. Janne9, Lian Liu10, David Chen11, Carrie 
Brownstein11, Martin Reck12 
1Hematology And Medical Oncology, Winship 
Cancer Institute Of Emory University/United 
States Of America, 2Sarah Cannon Research 
Institute/United States Of America, 3Thorax Klinik/
Germany, 4Massachusetts General Hospital/
United States Of America, 5Clinical And Biological 
Sciences, University Of Turin, Aou San Luigi/Italy, 
6Internal Medicine [Cancer Research], University 
Duisburg-Essen/Germany, 7Zentral Klinik/Germany, 
8University Of Perugia/Italy, 9Lowe Center For 
Thoracic Oncology, Dana Farber Cancer Institute/
United States Of America, 10Roche Pharmaceuticals/
China, 11Roche Pharmaceuticals/United States Of 
America, 12Krankenhaus Großhansdorf, Zentrum Für 
Pneumologie Und Thoraxchirurgie/Germany
Background: R1507 (Hoffman LaRoche) is a 
selective, fully human, recombinant monoclonal 
antibody (IgG1 subclass) against IGF-1R. Activation of 
IGF-1R pathway contributes to resistance to geÀtinib 
and erlotinib therapy. Therefore, we conducted a 
randomized study of R1507 with erlotinib (E). 
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dose intensity of IMC-A12 88%, erlotinib 78%. 2 
patients at 15 mg/kg q21 experienced DLTs (1 x grade 
3 fatigue, 1 x grade 3 rash and mucositis requiring 
dose reduction), 2 required dose modiÀcation or 
cessation in cycle 1, and mean dose intensity of 
IMC-A12 95%, and erlotinib 75%. 14 patients were 
evaluable for response. 3 patients had stable disease as 
best response and 11 patients had progressive disease. 
13/18 patients had EGFR mutation testing performed. 
3 patients had EGFR mutant tumors (1 x 6mg/kg, 2 
x 5mg/kg), with median Progression Free Survival 
(PFS) 217 days (range 91 - 245). 10 patients had 
EGFR wild type tumors: median PFS was 31 days. 
Tissue and serum have been collected from patients 
and will be analyzed for other biomarkers of toxicity 
and response.
Conclusion: The combination of IMC-A12 at 6mg/
kg q7 and 15mg/kg q21 and full dose erlotinib is not 
tolerable in unselected NSCLC patients as measured 
by both DLTs and achievable dose intensity. IMC-A12 
at 5mg/kg q7 was tolerable per DLT but also required 
dose reductions in a signiÀcant proportion of patients. 
Progression to the planned randomized phase II 
study in unselected patients has been cancelled. The 
combination may be beneÀcial to EGFR mutant 
patients but randomized data in a mutant speciÀc 
population would be required to conÀrm this.
Keywords: EGFR, IGFR, NSCLC
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MO15.03 EXPLORATORY BIOMARKER 
ANALYSES FROM A PLACEBO-
CONTROLLED PHASE II STUDY 
(OAM4558G) OF METMAB IN 
COMBINATION WITH ERLOTINIB IN 
PATIENTS WITH ADVANCED NON-
SMALL-CELL LUNG CANCER (NSCLC)
Wei Yu1, Ajay Pandita1, Elicia Penuel1, Rajiv Raja1, 
Jiping Zha1, Sankar Mohan1, Rupal Desai1, Rajesh 
D. Patel1, Ling Fu1, An Do1, Jason Mango1, Vaishali 
Parab1, Marina Lipkind1, Jenny Huang1, Mirella 
Lazarov1, Vanitha Ramakrishnan1, Lukas Amler2, 
Premal Patel1, Amy Peterson1, Robert Yauch3 
1Genentech/United States Of America, 2Genentech, 
Genentech/United States Of America, 3Oncology, 
Genentech/United States Of America
Background: Met is associated with a poor outcome 
in many cancers, including NSCLC. MetMAb is a 
monovalent anti-cMet receptor antibody that inhibits 
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MO15.02 A PHASE I/II STUDY OF 
ERLOTINIB IN COMBINATION WITH 
THE ANTI-INSULIN-LIKE GROWTH 
FACTOR-1 RECEPTOR (IGF-1R) 
MONOCLONAL ANTIBODY IMC-A12 
(CIXUTUMUMAB) IN PATIENTS WITH 
ADVANCED NON-SMALL CELL LUNG 
CANCER (NSCLC).
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B. Oton1, Grace Dy2, Jannice Lettieri1, Delee A. 
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Background: Crosstalk between the IGF-1R and 
the Epidermal Growth Factor Receptor (EGFR) is a 
potential mechanism of resistance to EGFR Tyrosine 
Kinase Inhibitors (TKIs). This study evaluated 
the combination of erlotinib with an anti-IGF-1R 
recombinant fully humanized IgG1 monoclonal 
antibody (IMC-A12) to assess safety and efÀcacy.
Methods: Eligibility included: PS 0-2, metastatic 
NSCLC, age >18, adequate organ function. Initial 
safety-lead and drop-down cohorts used erlotinib 
150mg QD with IMC-A12 6 or 5mg/kg days 1, 
8, 15, 22 in q28 day cycles (Cohorts 1 and 2). 
Tolerability required completion of 1 cycle in 8 of 
10 patients without dose limiting toxicity (DLT). 
Emerging PK data led to a third cohort (3+3 design) 
at IMC-A12 at 15mg/kg day 1 in q21 day cycles. 
Dose limiting toxicity (DLT; CTC v. 3.0) was any 
non-hematological toxicity => grade 3 within cycle 
1, excluding rash, diarrhea, nausea or hyperglycemia 
if controllable within 7 days of holding drug and no 
dose reductions occurred, or treatment delay of => 7 
days due to drug-related toxicity.
Results: 18 patients entered the study (6 at 6mg/
kg, 8 at 5mg/kg, 4 at 15mg/kg at 6mg/kg), with 
median age 65. PS 0/1 = 5/13. 4 patients at 6mg/kg 
q7 experienced DLTs (3 x grade 3 fatigue, 1 x grade 
3 rash not resolving within 7 days), 5 requiring dose 
modiÀcation or cessation in cycle 1, with mean dose 
intensity across all cycles of IMC-A12 60%, erlotinib 
58%. At 5mg/kg, 1 patient experienced DLT (1 x 
grade 3 rash not resolving within 7 days), 3 requiring 
dose modiÀcation or cessation in cycle 1, with mean 
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MO15.04 BIOMARKER ANALYSIS OF 
A RANDOMIZED, DOUBLE-BLIND, 
PLACEBO-CONTROLLED PHASE 2 
STUDY OF ERLOTINIB WITH AND 
WITHOUT ENTINOSTAT, A CLASS 
1 ISOFORM SELECTIVE HISTONE 
DEACETYLASE INHIBITOR (HDAC) 
IN PATIENTS WITH ADVANCED NON-
SMALL CELL LUNG CANCER (NSCLC; 
ENCORE-401)
Robert Jotte1, Samir Witta2, Marcus Neubauer3, 
Alexander Spira4, Robert Ruxer5, Kartik Konduri6, 
Fred R. Hirsch7 
1Lung Cancer, Lung Cancer Clinic Of The Rockies/
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Cancer Center/United States Of America, 4Fairfax 
Northern Va/United States Of America, 5Texas 
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Background: Epigenetic processes have been shown 
to contribute to de novo and reversible acquired 
drug resistance to EGFR-TKI. We have previously 
presented that exploratory biomarker analysis of 
patient samples from ENCORE-401, a randomized, 
placebo controlled phase 2 clinical trial with the 
class 1 selective HDACi, entinostat in combination 
with the EGFR-TKI erlotinib (ENCORE-401) 
identiÀed a subset of patients expressing high 
e-cadherin levels who derived greater clinical beneÀt 
with the entinostat combination vs erlotinib alone; 
PFS (3.7 mos vs 1.9 mos; HR 0.55 (95% CI 0.22-
1.37 p=0.19))and OS (9.4 mos vs 5.4 mos; HR 0.36 
(95% CI 0.14-0.94 p=0.03))1. Completed biomarker 
characterization of this study will be presented.
Methods: 132 patients with previously treated 
stage IIIB/IV NSCLC, no-prior erlotinib, PS < 2, 
and tissue available for biomarker assessment, were 
randomized (1:1) to erlotinib 150 mg PO QD days 
1-28 plus entinostat 10mg PO or placebo days 1 and 
15 Q 28 days [ = 1 cycle] for a maximum of 6 cycles. 
Biomarker analysis completed to date includes 
E-cadherin IHC, EGFR FISH, EGFR sequencing, 
KRAS sequencing, and Veristrat serum proteomic 
proÀling.
Results: Updated biomarker results are as follows:
HGF-mediated activation of c-Met. In a Phase II 
study of MetMAb in combination with erlotinib 
in patients with advanced NSCLC (n=128), an OS 
beneÀt was demonstrated in Met Dx + patients 
(n=65, deÀned as ³50% of tumor cells staining 2+ or 
3+ intensity for c-Met by IHC), HR=0.37, p=0.002. 
Methods: Archival tumor tissue specimens were 
analyzed using FISH, qRT-PCR or various mutation 
detection techniques to explore tumor biomarkers 
related to c-Met and/or EGFR signalling. Analyses 
with outcome were carried out independently of Met 
Dx status. 
Results: In general, baseline characteristics were 
comparable for patients with evaluable tumor or 
plasma specimens. MET median mean copy number 
was 3.44 copies/cell (range 1.6–25.0 [96 evaluable 
specimens]; true gene ampliÀcation was detected 
in 8%. There was a non-signiÀcant trend toward 
improved OS when MET FISH-positivity was 
deÀned as 5 copies/cell (HR=0.47, p=0.19), but 
not at lower thresholds (ie. 4 copies; HR=0.89, 
p=0.82). An OS HR of 1.37 (95% CI: 0.43–4.36) 
was observed in 23 patients with both MET and 
EGFR FISH copy number gains (high polysomy or 
ampliÀcation). EGFR mutations were detected in 
13 of 112 evaluable specimens (12%); mutations 
were detected in 6 of 7 patients with objective 
responses. KRAS mutations were detected in 26 
of 112 evaluable specimens (23%); status did not 
affect OS on MetMAb. High expression levels 
(median) of MET, HGF, EGFR, AREG or EREG 
mRNA were not an independent predictor of OS 
beneÀt. However, the OS beneÀt in Met Dx+ patients 
(n=32) was not as robust (HR=0.69, p=0.48) in the 
patient population for whom qRT-PCR data was 
available (n=67). In addition, a non-signiÀcant 
trend for improved OS with MetMAb was observed 
in patients with low baseline plasma HGF levels 
(HR=0.46, p=0.11). 
Conclusion: This study provides further support 
for c-Met IHC as the most robust, sensitive and 
independent predictor of OS beneÀt from MetMAb. 
Analysis of biomarkers is warranted in future clinical 
studies. 
Keywords: NSCLC, cMet, MetMAb, erlotinib
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Background: Mutations in KRAS are present in 
~25% of patients with advanced NSCLC. Preclinical 
data support the role of mammalian target of 
rapamycin (mTOR) in KRAS mediated oncogenesis. 
Ridaforolimus is an inhibitor of mTOR which has 
been shown to have efÀcacy in advanced endometrial 
cancer and soft tissue sarcoma. Everolimus, another 
mTOR inhibitor was previously evaluated in 
unselected patients with advanced NSCLC and found 
to have a response rate <5%. We hypothesized that 
by enrichment for patients with NSCLC and KRAS 
mutations, treatment with ridaforolimus would be 
associated with higher response rates and prolonged 
stable disease relative to available standard 
treatments for NSCLC.
Methods: Patients with stage IIIB/IV non-small cell 
lung cancer who had received prior chemotherapy 
for NSCLC were eligible. All patients initiated 
treatment with oral ridaforolimus 40 mg once 
daily on a 5 day per week schedule. After 8 weeks, 
patients had response assessment. Patients with 
>30% tumor shrinkage remained on ridaforolimus, 
patients with >20% tumor growth came off study. 
Patients with stable disease were randomized 1:1 to 
placebo or ridaforolimus. The primary endpoint of 
the study was progression-free survival (PFS) during 
the randomization. Here, we report the results of a 
planned interim analysis of 8 week progression-free 
survival and radiographic response after initial 8 
weeks of treatment.
Results: 72 patients were enrolled at the time of 
the interim analysis (36 women, median age 58 
[range 28-85]). All patients had KRAS mutations. 
Data from 61 patients was available for efÀcacy 
analysis. 29/61 (44%, 95% CI 36-60%) patients were 
progression-free at 8 weeks. The overall response 
rate (CR+PR) at 8 weeks was 1/61 (2%, 95% CI 
0-10%). 14/61 patients discontinued study treatment 
prior to 8 weeks. Median progression-free survival 
was < 2 months. The most common grade 3 adverse 
For e-cadherin, previously stained slides were re-
scored using a semi-quantitative hybrid scoring 
algorithm with a strong association between scoring 
methods (p<0.0001). Patients classiÀed as e-cadherinHI 
by either scoring system derived greater clinical 
beneÀt from entinostat plus erlotinib vs erlotinib 
alone. A full characterization of the e-cadherin high 
and low subsets by EGFR mutation, EGFR copy 
number, KRAS status, and Veristrat will be presented. 
Conclusion: E-cadherin may deÀne a subset of 
patients for whom epigenetic modulation with an 
HDACi can provide clinical beneÀt with EGFR-
TKI. Follow-up studies should be carried out 
to conÀrm these promising Àndings in selected 
patient populations deÀned by sensitivity to 
EGFRi. In addition, recently completed biomarker 
characterization of samples from these patients 
indicates that EGFR copy number and EGFR 
mutation status be evaluated in follow on studies 
along with e-cadherin levels to conÀrm the role of 
epithelial mesenchymal tumor phenotype as the 
determinant of clinical beneÀt to the entinostat – 
erlotinib combination. 
Keywords: EGFR-TKI, histone deacetylase, 
Biomarkers, epigenetics
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MO15.06 A RANDOMIZED 
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RIDAFOROLIMUS IN NON-SMALL CELL 
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(11.1%). The majority of histological diagnoses 
were adenocarcinomas (14 cases; 77.8%) and 
squamous cell carcinomas were followed (3 cases; 
16.7%). However, there was no signiÀcant difference 
according to KRAS mutation status because of small 
population of mutation group. The median PFS time 
of total 10 patients with KRAS mutation treated 
with EGFR-TKIs were 2.1 months. Interestingly, 
3 patients had both mutations of EGFR and KRAS 
unlike previous studies, 2 patients who treated with 
EGFR-TKIs showed favorable response.
Conclusion: The data indicate that KRAS mutation 
is less frequent in Asian than Caucasian patients. 
Although it is suggested that EGFR and KRAS 
mutations occur in mutually exclusive, very few of 
the patients with KRAS mutation showed also EGFR 
mutation and relatively favorable response to EGFR-
TKIs. Additional large scale prospective studies are 
needed in order to validate the clinical signiÀcance 
of KRAS mutation.
Keywords: KRAS mutation, Non small cell lung 
cancer
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MO15.08 PHASE II STUDY OF 
REOVIRUS WITH PACLITAXEL (P) AND 
CARBOPLATIN (C) IN PATIENTS WITH 
METASTATIC NON-SMALL CELL LUNG 
CANCER (NSCLC) WHO HAVE KRAS OR 
EGFR-ACTIVATED TUMORS.
Miguel A. Villalona-Calero1, Elaine Lam1, Gregory 
Otterson1, Weiqiang Zhao2, Kavitha Donthireddy1, 
Jennifer Thurmond1, Erin Hade3, Justin Pennington1, 
Karl Mettinger4, Matt Coffey4 
1Medical Oncology, The Ohio State University/
United States Of America, 2Pathology, The Ohio 
State University/United States Of America, 3Center 
For Statistics, The Ohio State University/United 
States Of America, 4Oncolytics/Canada
Background: Reovirus is a naturally occurring virus 
which preferentially infects and causes oncolysis in 
tumor cells with a Ras-activated pathway. Cells that 
express high levels of EGFR are also susceptible to 
reovirus infection. In preclinical studies, reovirus 
induces host immunity and cell cycle arrest, acting 
synergistically with standard cytotoxic agents. 
Its adverse effects are mild to moderate Áu-like 
symptoms. We have hypothesized those patients with 
EGFR-mutated, EGFR-ampliÀed, or Kras-mutated 
events were fatigue (10%), diarrhea (5%), and 
mucositis (8%).
Conclusion: Due to lack of efÀcacy meeting pre-
deÀned thresholds, this study was discontinued. 
Ridaforolimus at this dose and schedule does not 
have sufÀcient activity in KRAS mutant NSCLC to 
warrant further study. Multicenter studies enrolling 
only patients with KRAS mutant NSCLC are 
feasible.
Keywords: Kras, ras, mammalian target of 
rapamycin, Non-small cell lung cancer
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MO15.07 CLINICAL FEATURES OF 
PATIENTS WITH NON SMALL CELL 
LUNG CANCER WHO HARBOR KRAS 
MUTATION: A SINGLE CENTER 
EXPERIENCE IN KOREA
Hee Joung Kim1, Sun Jong Kim1, Gwang Ha Yoo1, 
Won Dong Kim1, Seo Young Oh2, Wan Seop Kim2, 
Kye Young Lee1 
1Internal Medicine, Konkuk University Hospital/
Korea, Democratic People’s Republic Of, 
2Pathology, Konkuk University School Of Medicine/
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Background: It is currently known that KRAS 
mutation is a poor predictive biomarker to 
chemotherapy and epidermal growth factor receptor 
(EGFR) kinase inhibitors (geÀtinib and erlotinib) in 
patients with non–small cell lung cancer (NSCLC). 
This study aims to deÀne the incidence of KRAS 
mutations and evaluate clinical features and 
outcome of patients with NSCLC who harbor KRAS 
mutation.
Methods: Two hundred and twenty-seven patients 
with NSCLC who performed KRAS mutation 
analysis by pyrosequencing were included in this 
retrospective study and their clinical characteristics 
were analyzed according to KRAS mutation status of 
their tumors.
Results: KRAS mutation was found in 18 (7.9%) 
of 227 patients and which was less prevalent than 
in western countries. Ten mutations (55.6%) were 
point mutation at codon 12 (GGT), 6 mutations 
(33.3%) were point mutation at codon 61 (CAA), 
and 2 mutations (11.1%) were found at codon 13 
(GGC) in exon 2. Median age of 18 patients with 
KRAS mutation was 66.5 years (range 43-85 years). 
There were 15 males (88.3%) and 2 never-smokers 
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Background: In the era of PET scan, the incidence 
of oligometastatic non-small cell lung cancer 
(NSCLC) has increased. Even though, chemotherapy 
remains the mainstay of therapy for metastatic 
NSCLC, the pattern-of-failure after Àrst-line 
chemotherapy needs to be deÀned to determine if 
local ablative therapy can be pursued to a limited 
number of metastatic sites.
Methods: We performed a retrospective review on 
consecutive patients with advanced NCSLC treated 
at the Medical College of Wisconsin, Milwaukee 
between 2007 and 2010. All sites of disease at 
presentation and at subsequent follow-ups after Àrst-
line chemotherapy were abstracted, including the 
number of organs involved and individual metastatic 
sites. Patients were classiÀed as oligometastatic 
if they had  3 metastatic sites (not including the 
primary lung tumor).
Results: A total of 116 patients were analyzed: 
median age 61.9 years (28-88 years) and males 66 
(57%). Tumor histology: 63% adenocarcinoma, 18% 
squamous cell carcinoma, 14% poorly differentiated 
carcinoma, 3% bronchoalveolar carcinoma and 2% 
adenosquamous carcinoma. First-line chemotherapy: 
68% platinum-doublet, 28% platinum-doublet 
with bevacizumab, 2% single-agent non-platinum 
chemotherapy and 2% erlotinib. At presentation, 
48 patients (41%) had oligometastatic NSCLC. At 
last follow-up, 87 (75%) had tumor progression 
after Àrst-line chemotherapy, of which 84 had 
well documented sites of progression. Tumor 
progression occurred only in existing disease sites 
(primary tumor and existing metastatic sites) without 
development of new metastatic lesions in 46%.
NSCLC should all have a common downstream 
activated Ras pathway and should be susceptible to 
treatment with reovirus
Methods: We designed a Fleming, single-arm, phase 
II study to evaluate the objective response rate and 
6-month progression-free survival of reovirus in 
combination with P and C as Àrst-line therapy in patients 
with metastatic NSCLC. Eligible patients had ECOG 
PS 0-2, adequate organ function, no prior systemic 
chemotherapy for metastatic disease, and tumors with 
the speciÀed genotype, as per CLIA certiÀed testing. 
Adjuvant chemotherapy, or erlotinib/geÀtinib for pts 
with EGFR mutant tumors was permitted.
Results: 17 patients have received Reovirus (3 x 
1010 TCID
50
) intravenously daily on days 1-5, in 
combination with C and P. Initial doses used were 
C AUC 6 on day 1, and P 200 mg/m2,on day 1 of 
each 21-day cycle. Due to exacerbation of prior 
gastrointestinal conditions and febrile neutropenia 
(1 each) in Àrst two pts, doses were reduced to P 175 
mg/m m2 and C AUC 5. Overall, 73 cycles (per pt 
median 4, range 1-8) have been administered. Grade 
3-4 adverse events included grade 4 neutropenia 
(4 pts), anemia,fatigue, electrolyte abnormalites, 
diarrhea, (2 pts), and single cases of nausea, 
vomiting, and sepsis. Molecular tumor demographics 
included: 8 Kras mutant, 2 EGFR mutant, 7 EGFR 
ampliÀed. Response evaluation to date in 16 pts 
showed 5 PR, 9 SD, 2 PD. 
Conclusion: Reovirus can be administered safely 
in combination with C/P and patient selection is 
feasible in the clinical setting. Clinical efÀcacy and 
best setting for subsequent randomized evaluation 
will be assessed at the completion of the trial. 
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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MO15.10 PREVALENCE OF 
OLIGOMETASTATIC NON-SMALL CELL 
LUNG CANCER AND PATTERN-OF-
FAILURE ANALYSIS AFTER FIRST-LINE 
CHEMOTHERAPY: A POTENTIAL ROLE 
FOR CONSOLIDATIVE RADIOTHERAPY.
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Secondary endpoints: Progression-Free survival 
(PFS), dyspnoea (CTCAE3.0), dysphagia, patterns 
of recurrence. The trial was approved by the required 
authorities and all patients gave informed consent. 
The study is listed in clinicaltrials.gov number 
NCT01282450.
Results: 39 patients (23 males and 16 females, 
mean age 62.9 ± 9.7 years, range 44-82) were 
included from 27-07-2006 till 14-11-2010. 
Performance status: 0: 3 patients, 1: 33, 2: 3. 
Histologies: Squamous cell carcinoma: 10 patients, 
adenocarcinoma: 13, large cell: 10, NSCLC not 
speciÀed: 6. T-stage: T0: 1 patient, T1: 7, T2:11, 
T3: 8, T4:12. N-stage: N0: 12 patients, N1: 2, N2: 
17, N3: 8. “Local stage”: I: 1 patient, II: 9, IIIA: 10, 
IIIB: 19. 33 patients had a single distant metastasis, 
2 patients 2, 3 patients 3 and 1 patient 4 metastases. 
Location metastases: Brain: 15, bone: 10, pleura: 
3, adrenal gland: 4, extra-thoracic lymph nodes: 
3, ovary: 1, muscle: 2, contra-lateral lung: 1. 35 
patients received chemotherapy; 11 sequential 
chemo-radiation (cisplatin-gemcitabine), 24 
concurrent chemo-radiation (cisplatin-etoposide or 
cisplatin-vinorelbine). All patients received 3 cycles 
of chemotherapy. Mean radiation dose to the primary 
tumour and hilar or mediastinal lymph nodes: 65.6 
± 6.5 Gy/ 33 ± 12.3 days; radiation dose to brain 
metastases: 20 Gy/ 1 fraction (stereotactic), mean 
dose to other than brain metastases: 63.7 ± 6.9 Gy. 
Surgery: adrenal metastasis: 3/3 patients, ovary 1/1, 
contralateral lung: 1/1. Median OS: 13 months (95 
% CI: 5.7-20.3), 1-year OS: 53 %, 2-year OS: 17 
%. Median PFS: 10 months (95 % CI: 6.8-13.4), 
1-year PFS: 45 %, 2-year PFS: 10 %. Location of 
Àrst tumour progression: in radiation or surgical 
Àeld: none; brain: 52 %, bone: 33 %, skin: 5 %, 
mediastinal lymph nodes: 5 %, liver: 5 %, Toxicity: 
Oesophagus: G3: 15 %, no G4-5; dyspnoea: G2: 5 
%, no G3 or more. 
Conclusion: In this prospective series, exclusively 
consisting of NSCLC patients with oligometastatic 
disease at presentation and with 75 % of them having 
“local stage III” disease, radical treatment may 
improve PFS but long-term survival remains very 
low, mostly due to brain (52 %) and bone (33 %) 
metastases. Improved systemic control is needed and 
PCI may be worth investigating. 
Keywords: Non-small cell lung cancer, 
Oligometastases, combined modality treatment, 
advanced disease
Conclusion: In metastatic NSCLC, we identiÀed 
that progression after Àrst-line chemotherapy 
occurred commonly in the primary tumor or existing 
metastatic sites. This supports the concept that there 
is a subset of patients with limited metastatic disease 
that may beneÀt from local ablative therapy. 
Keywords: Non-small cell lung cancer, Metastasis, 
Sites of disease
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MO15.11 RADICAL TREATMENT 
OF NON-SMALL CELL LUNG 
CANCER (NSCLC) PATIENTS WITH 
SYNCHRONOUS OLIGOMETASTASES: 
RESULTS OF A PROSPECTIVE PHASE II 
TRIAL (NCT01282450)
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Background: Mainly retrospective series suggest 
that a subgroup of patients with NSCLC with less 
than 5 metastatic lesions may experience long-term 
survival when all macroscopic tumour sites are 
treated radically. We therefore started a prospective 
single-arm phase II trial to investigate the outcome 
of patients with synchronous oligometastatic disease 
when treated radically. 
Methods: Main inclusion criteria: Pathological 
proven NSCLC; UICC 6th edition stage IV; 
oligometastases (< 5) at primary diagnosis, which 
are amendable for radical local treatment (i.e. 
surgery or radiotherapy to a biological equivalent 
of at least 60 Gy/ 30 fractions), performance status 
0-2. Main exclusion criteria: stage I-III, except 
for T4 because of pleural metastases without 
effusion. Primary endpoint: Overall survival (OS). 
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radiotherapy (CT then CTRT) to residual thoracic 
disease; 13 underwent concurrent chemoradiation 
(CTRT) followed by systemic chemotherapy; and 11 
had multiple chemotherapeutic regimens followed by 
radiotherapy (CT then RT) at time of progression of 
intrathoracic disease. The table summarizes median 
survival from diagnosis in these patients both by site 
of metastases at diagnosis and treatment approach. 
Univariate analyses identiÀed no signiÀcant 
predictors of survival across race, sex, N-stage at 
diagnosis, site of metastatic disease at diagnosis, 
tumor histology, treatment dose and treatment type. 
Survival from Diagnosis by Metastases Survival from Diagnosis by Treatment 
Metastases N Median 
Survival 
95% CI Treatment N Median 
Survival 
95% CI 
M1 nodes only 4 38 m >10 m CT then CTRT 4 44 m >17 m 
Contralateral 
lung only 
2 Last seen at 
28 & 32 m 
CTRT 13 19 m 12 – 40 m 
Brain only 8 17 m >11 m CT then RT 11 13 m >10 m 
Bone only 10 14 m 5 – 44 m 
Multi-organ 4 12 m >6 m 
Conclusion: Median survival of these select patients 
with metastatic NSCLC at diagnosis treated with 
deÀnitive thoracic radiation compares favorably 
to those with more advanced stage IV disease at 
diagnosis. Prospective trials are needed to determine 
if these outcomes are result of an aggressive 
treatment approach or selection bias. 
Keywords: oligometastatic, deÀnitive dose 
radiotherapy, stage IV, Non-small cell lung cancer
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MO15.13 OLIGOMETASTASES IN NSCLC 
PATIENTS: IS SURGERY JUSTIFIED?
Oleg Pikin, Konstantin Kolbanov, Vladimir Glushko, 
Ali Amiraliev, Dmitriy Vursol, Artem Kartoveshenko 
Thoracic Surgery, P.a.hertsen Moscow Research 
Institute Of Oncology/Russian Federation
Background: The prognosis in patients with distant 
metastases of NSCLC is generally poor. Surgical 
resection of isolated distant metastases in NSCLC 
patients is not widely accepted and chemotherapy 
is usually administered. The study was aimed to 
evaluate the long-term results and prognosis after 
surgical resection of oligometastases in NSCLC 
patients.
Methods: 63 patients with isolated distant 
metastases of NSCLC were operated on in our 
clinic from 1998 to 2009. Solitary brain metastasis 
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Hahn1, Ramesh Rengan1 
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Background: Stage IV NSCLC patients have less 
than a one year median survival from diagnosis, 
usually due to distant progression. Currently, the 
role of deÀnitive thoracic radiotherapy in these 
patients is controversial. This study reports treatment 
parameters and associated survival outcomes 
in patients receiving deÀnitive dose thoracic 
radiotherapy for stage IV disease.
Methods: An institutional database was reviewed 
to identify patients that (1) presented with Stage 
IV NSCLC at initial tumor diagnosis, who were 
(2) subsequently prescribed at least 50 Gy for their 
thoracic disease. The Kaplan-Meier method was 
used to estimate survival outcomes. The relationship 
between parameters and survival were assessed using 
log rank tests and Cox models.
Results: Between January 2003 and July 2010, the 
University of Pennsylvania treated 28 oligometastic 
stage 4 NSCLC patients with thoracic radiotherapy 
to 50+ Gy. 11 patients were male and 13 non-
caucasian. They had a median age of 57.5 y and 
treatment dose of 66 Gy. Of 25 with known nodal 
status, 3 had N1, 9 N2 and 9 N3 disease. All patients 
had a Karnofsky Performance Status of 80+ at 
diagnosis. And they each had fewer than Àve sites 
of extrathoracic or contralateral lung metastases. 
Across all patients, the median survival time was 19 
months (95% CI 13 – 40 months) from diagnosis 
and 15 months (95% CI 7 – 37 months) from start 
of deÀnitive dose radiotherapy. The median lag 
between diagnosis and start of radiotherapy was 5 
months. Patients were treated as follows: 4 received 
systemic chemotherapy followed by consolidative 
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MO16.01 EVALUATION OF NSCLC 
DIAGNOSTIC EFFICIENCY OF DNA 
METHYLATION BIOMARKERS IN 
BRONCHIAL WASHINGS
Georgios Nikolaidis1, Olaide Y. Raji1, Julie Bryan1, 
Jennie Goggin1, Stephanie Unsworth1, Tom Giles2, 
John K. Field1, TriantaÀllos Liloglou1 
1Molecular & Clinical Cancer Medicine, University 
Of Liverpool/United Kingdom, 2Royal Liverpool 
Broadgreen University Hospital Trust/United 
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Background: Lung cancer is the most lethal 
malignancy worldwide and late diagnosis is a 
signiÀcant reason for this. The Liverpool Lung 
Project (LLP) encompasses retrospective and 
prospective studies aiming to the reduction of lung 
cancer mortality through the development of a 
molecular-epidemiological risk assessment model 
which will facilitate early detection of lung cancer 
and thus early intervention. DNA methylation is 
an epigenetic modiÀcation with key role in gene 
transcriptional control, embryonic development, 
imprinting and cancer. A large number of studies 
in lung cancer have revealed abnormal DNA 
methylation patterns involving a variety of genes. 
The aim of this study is to evaluate a number of 
DNA-methylation biomarkers in bronchial washings 
for their efÀciency in assisting diagnosis of new lung 
cancer cases. 
Methods: Targets from previous high throughput 
approaches were validated in an independent set of 
48 non-small cell lung cancer samples and paired 
normal tissues using Pyrosequencing. Quantitative 
methylation-speciÀc PCR (qMSP) assays were 
subsequently for the successful 11 candidates. These 
were evaluated in a training set of 408 bronchial 
washing (BW) samples (194 Cases and 214 Controls). 
Multifactor Dimensionality Reduction (MDR) was 
used to select the best subset of the markers with 
good discrimination. The diagnostic efÀciency of this 
panel was evaluated in an independent validation set 
of 248 BW samples (139 cases and 109 controls). A 
logit method was used to obtain the sensitivity and 
speciÀcity of the six markers 
was diagnosed in 32, pleural metastases – in 15, 
adrenal metastases – in 11, renal metastases – in 
2, chest wall – in 2 and mesentery sigmoid colon 
metastasis – in one patient. Synchronous metastases 
were detected in 42 (66,7%) (brain – 18, pleura 
- 15, adrenal – 7, others – 2), metachronous – in 
21 (33,3%) patients. The primary lung cancer was 
completely resected in all cases. Surgery included 
pneumonectomy – in 12 (19,0%), lobectomy – in 48 
(76,2%) and wedge resection – in 3 (4,8%) patients. 
Simultaneous lung resection and metastatic lesion 
removal was performed in 24 (38,1%) patients 
(brain – 1, pleura – 15, adrenal – 7, chest wall – 
2). In patients with pleural spread lung resection 
and pleuroectomy was followed by intraoperative 
photodynamic therapy.
Results: Postoperative complications were 
registered in 10 (15,9%) patients, mortality rate was 
4,7%. Median survival after pulmonary resection 
and removal of brain metastasis was 16,8 months, 
after lung resection with pleuroectomy – 14,2 
months, adrenalectomy – 10,6 months. Patients 
after nephrectomy (2), chest wall resection (2) 
and sigmoid colon resection survived 14, 18, 6, 
14 and 36 months respectively. One and 3-year 
survival after removal of brain, pleural and adrenal 
metastases was 58,0%, 52,0%, 32,6% and 21,8%, 
20,0%, 0% respectively. Two patients (6,2%) with 
solitary brain metastasis and T1N0 primary lung 
cancer survived more than 5 years without evidence 
of recurrence. One patient after pleuroectomy 
and PDT is alive 62 months with recurrence. 
Synchronous or metachronous detection of distant 
lung cancer metastases does not inÁuence the 
survival.
Conclusion: Aggressive surgery in patients with 
oligometastatic NSCLC is justiÀed in selected 
patients especially with solitary brain metastasis 
and limited pleural dissemination. Surgical 
resection permits to improve long-term results and 
quality of life in patients with isolated distant lung 
cancer metastases.
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was thought to make little difference in terms of 
patient response to therapy. However, increasing 
efforts toward developing new molecularly targeted 
agents, which tend to have signiÀcant activity in 
certain groups of patients but not others, has driven 
a need to identify biomarkers that can distinguish 
clinically relevant biological subsets of NSCLC. We 
have shown that NSCLC can be differentiated into 
epithelial-like (EL) and mesenchmyal-like (ML) 
tumors based on gene expression and biomarkers 
of this epithelial vs. mesenchymal state have been 
associated with erlotinib activity in vitro and in the 
clinic. Increasing evidence suggests that changes in 
DNA methylation may accompany the phenotypic 
transition from an epithelial to a mesenchymal 
state in lung cancer cells. It follows that speciÀc 
methylation patterns may reÁect the underlying 
biology and pathogenesis of a given tumor. Thus 
knowledge of the methylation proÀle of tumors 
may enable clinical decision-making. To further 
explore the question of whether phenotypic subsets 
of NSCLC can be deÀned by their DNA methylation 
patterns, we developed an integrated genomics 
approach combining gene expression proÀling and 
methylated DNA immunoprecipitation (meDIP). 
Methods: Microarray expression proÀling, treatment 
with 5-aza-2’-deoxycytidine, microtiter assays for 
in vitro response to erlotinib, meDIP-chip, QPCR, 
QMSP, bisulÀte sequencing, pyrosequencing.
Results: Using a supervised analysis strategy based 
on in vitro drug response to erlotinib and EL/ML 
status for both gene expression and meDIP-chip, 
we identiÀed >200 candidate markers that show 
potential phenotypic speciÀcity – i.e. induced or 
enriched. 62 of these markers were further analyzed 
by sodium bisulÀte sequencing with 25-75% 
showing phenotype speciÀc methylation patterns, 
depending on the discovery strategy. We developed 
quantitative methylation speciÀc PCR (QMSP) 
assays on 14 markers and pyrosequencing assays for 
another Àve. All of these markers were tested in a 
panel of NSCLC lines (N=90) with deÀned response 
phenotypes to erlotinib. Both classes of methylation 
biomarkers (methylated in either sensitive or 
resistant subsets, but not both) showed a good 
correlation with erlotinib activity or EL/ML status. 
We further examined these markers in matched 
NSCLC tumors, and all showed signiÀcant tumor 
speciÀcity. We are in the process of retrospectively 
testing these novel methylation biomarkers in 
clinical samples to determine their prognostic or 
predictive signiÀcance.
Results: Pyrosequencing methylation analysis 
conÀrmed signiÀcant hypermethylation in the 
NSCLC tissue for the following promoters: RASSF1, 
p16, WT1, CYGB, RARơ, CDH13, DAPK, p73, 
TMEFF2, TERT and MGMT. Analysis in the 
training BW set demonstrated signiÀcant differences 
in the detected hypermethylation frequency in cases 
over controls for RASSF1, p16, WT1, CYGB, 
RARơ and TERT. This panel of six markers was 
used to screen independent BW samples in a 
validation set. The overall performance analysis of 
the six biomarkers in addition to cytology revealed 
that there was no detection bias in different groups 
of gender, age or smoking status. LogicF analysis 
demonstrated that the top Àve predictors were WT1, 
cytology, RASSF1, TERT and p16. While cytology 
alone provides a 49.5% sensitivity, 99.5% speciÀcity, 
the use of Àve classiÀers provided 76.2% sensitivity, 
92.3% speciÀcity (AUC=0.89). 
Conclusion: DNA methylation can be detected 
in bronchial washings with high speciÀcity. It is 
estimated that a panel of 10-12 markers would be 
sufÀcient to increase diagnostic sensitivity to >90% 
at >95% speciÀcity.
Keywords: molecular diagnostics, epigenetic 
biomarkers, bronchial washings
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MO16.02 DNA METHYLATION 
PROFILING DEFINES CLINICALLY 
RELEVANT BIOLOGICAL SUBSETS OF 
NSCLC
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Inc/United States Of America
Background: Non-small cell lung cancer (NSCLC) 
has multiple histological subtypes including 
adenocarcinoma, squamous cell carcinoma, large 
cell carcinoma, and others. Until recently, histology 
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represented samples collected at diagnosis, mid-way 
through treatment, and at six months follow-up. 
NMR data was analyzed using the Chenomx NMR 
Suite to ascertain metabolite identiÀcation and 
concentrations. The Wiley-NIST database (2005) 
was used be used for metabolite identiÀcation of 
GC-MS data. Multivariate statistical analysis was 
conducted using either in-house tools developed in R 
or Umetrics software for analysis using unsupervised 
principal component analysis (PCA) or orthogonal 
partial least squares discriminant analysis (OPLS-
DA). Model signiÀcance was assessed using a cross-
validated ANOVA. 
Results: Median patient age=64 years (range 42-77), 
60% were male, 29% were current smokers, 7 had 
limited SCLC and 18 had NSCLC (stage I=1, II=3, 
III=18). The median disease free survival=17 months 
(range 8-25) and 2 year overall survival=53%. 
The metabolite proÀles were highly reÁective of 
the binary survival (p<0.001 by NMR & GCMS), 
disease progression (NMR, p<0.001; GCMS, 
p=0.007) and stage (NMR, p=0.001). The NMR 
data was also reÁective of disease pathophysiology 
(NSCLC vs SCLC) across all time points (p=0.003), 
and survival from the baseline samples alone 
(p=0.004). The NMR metabolomics data was weakly 
reÁective of the difference between the various 
time points (p=0.103), however a signiÀcant model 
could be built distinguishing baseline from post-
treatment samples (p=0.0005), suggesting that the 
samples during treatment represent an intermediate 
state. Multivariate regression of cotinine levels to 
metabolite proÀles indicate that smoking status can 
be predicted in baseline samples, during treatment 
and post-treatment.
Conclusion: This exploratory study suggests that 
there may be differences in the metabolomic proÀle 
between NSCLC vs. SCLC, smokers vs. non-
smokers and pre- and post-treatment. Intriguingly, it 
appears as though there remains a metabolic imprint 
in the serum from baseline, through treatment and 
post-treatment which can predict survival, disease 
progression, and pathophysiology. Larger cohorts 
will be needed to corroborate these Àndings and 
determine whether metabolomic patterns could be 
useful as predictive or prognostic markers. 
Keyword: metabolomics
Conclusion: These results validate our integrated 
genomics approach to identifying methylation 
biomarkers that reÁect an underlying clinically 
relevant biology in lung cancer cells. This work 
provides proof-of-principle that DNA methylation 
proÀles could be used to inform clinical decision-
making in the context of early-phase targeted therapy 
trials.
Keywords: erlotinib, Predictive biomarkers, DNA 
methylation, EMT
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MO16.03 A PILOT STUDY 
CHARACTERIZING PRE- AND POST-
TREATMENT METABOLOMIC 
PROFILES OF LUNG CANCER PATIENTS
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Camelia Lee4, Cynthia M. Card3, Marilyn David5, 
Anthony M. Magliocco6, Aalim Weljie2 
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Background: The metabolic proÀle of various 
cancerous /non-cancerous tissues can be correlated 
with cell growth and death, tumour type and stage. 
Changes in the serum metabolome not only reÁect 
the changes that are caused directly by the disease, 
but may also register host response to treatment. 
Analysis of the metabolome in bioÁuids by nuclear 
magnetic resonance (NMR) spectroscopy or gas 
chromatograph mass spectrometry (GC-MS) can 
simultaneously quantify hundreds of metabolites 
resulting in patterns that may deÀne tumour types, 
stage, differences in physiologic state (smokers vs 
non-smokers) and in turn, may correlate with clinical 
outcomes. In this pilot study, we sought to evaluate 
the pre- and post-treatment metabolomic proÀles of 
25 non-metastatic lung cancer patients undergoing 
chemotherapy ± radiation.
Methods: Serum specimens were prospectively 
collected prior to treatment, 5 times during treatment, 
and in follow-up at 30 days, 3, 6 and 12 months post-
treatment. A subset of samples were characterized 
using NMR spectroscopy and GC-MS. These 
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early stages and homogeneous treatments. We 
realize during this side-biological project BIO-
IFCT-00-02 II, high resolution micro-arrays with 
Agilent Technologies (44K) on 100 snap-frozen 
tumors. An univariate analysis (Fisher exact test) 
following by a multivariate analysis of biological 
markers and clinical data (age, gender, performans 
status, histological type, TNM classiÀcation, and 
modalities of surgery) could be helpful to deÀne 
different prognosis/predictive sub-groups of 
NSCLC patients. 
Results: The population of the 100 selected frozen 
tumors appeared comparable to the whole group 
of patients (n= 528), excepted for histological 
criteria with more adenocarcinomas in the CGH 
array group (p = 0.002) and for response rate with 
an objective response rate at 38% in the CGH array 
group versus 56% in the other patients (p<0.001). 
Survival analysis is comparable between patients 
included in the CGH array analysis and the others 
(Log Rank test at 0.6 for overall survival and at 
0.8 for progression-free survival). Most frequent 
ampliÀcations are observed for chromosome arms 
5p, 1q, 8q, 7p, 3q, 14q and 20q and most frequent 
deletions for chromosome arms 9p, 8p, 3p, 13q, 
17p, 18q. No signiÀcantly different CGH array 
features were found when considering sex, tumor 
stage or chemotherapy treatment group. Squamous 
cell carcinoma displays a higher penetrance of 
gains of 3p arm (SOX2, FXR1, PI3KCA) and losses 
of 6p, with the strongest difference at the end of 
the chromosome 3q. Comparison of responders and 
non-responders points at the end of chromosome 
10q (MGMT, GLRX3, FGFR2) being deleted 
more frequently in responders. AmpliÀcation 
of chromosome 1q (RRM2B) and 7p (EGFR) is 
associated with a lower PFS (14.7 vs 48.6 months, 
p< 0.005 and 15 vs 49 months respectively). When 
combining 7p and 11q alterations, the altered group 
diplays a mean OS of25.5 months versus 56 months 
for patients not displaying these alterations. 
Conclusion: CGH array could be useful to select 
candidates genes to be study at a genomic level in 
order to select NSCLC for adjuvant chemotherapy. 
Keywords: NSCLC, prognostic marker, Predictive 
marker, CGH array
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MO16.04 PROGNOSTIC AND 
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00-02 TRIAL (PHASE III STUDY 
COMPARING A PREOPERATIVE AND 
A PERIOPERATIVE CHEMOTHERAPY 
WITH TWO DIFFERENT 
CHEMOTHERAPY REGIMENS IN 
RESECTABLE NSCLC).
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Background: Early stages of non small-cell 
lung cancer (NSCLC) could beneÀt of complete 
resection, but Àve-years survival appeared less 
than 50%. Completely resected NSCLC patients 
frequently experience local or systemic relapse 
of their disease. In order to decrease the risk of 
relapse, combination of surgery and chemotherapy 
could be proposed. The aim of the clinical trial 
IFCT-00-02 is to determine optimal treatment 
schedules of stage I and II NSCLC patients. It is 
a an open-labeled randomized phase III national 
multicentric trail in which two doublets of 
chemotherapy are administrated, one with cisplatin-
gemcitabine and the other one with carboplatin-
paclitaxel. At present, apart from clinical stage, 
there are no established cancer - speciÀc clinical 
variables or biomarkers that reliably identify 
individuals at increased risk of death after surgical 
resection – individuals who could be candidates 
for adjuvant therapy or alternative management 
strategies. It is also no predictive molecular DNA of 
chemosensitivity. 
Methods: This national clinical trial had included 
528 consecutive patients, and lung tumor 
tissues were systematically collected to realize a 
unique tumor bank of NSCLC patients all with 
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There was no signiÀcant prognostic value of EGFR 
mutation: HR=1.26 [0.81-1.96] p=0.31 for OS and 
HR=1.25 [0.84-1.85] p=0.26 for DFS. There was no 
statistically signiÀcant heterogeneity between trials 
(p=0.77 and 0.56 for OS and DFS). Patients with 
both WT and mutated EGFR derived OS beneÀt 
from ACT (HR WT: 0.60 [0.39-0.92] p=0.02; HR 
mutated: 0.67 [0.30-1.50] p=0.33). There was no 
signiÀcant interaction between EGFR status and 
treatment arm for OS (p=0.80). No heterogeneity 
was observed between trials (p=0.59). Similar results 
were observed for DFS (WT HR: 0.67 [0.46-0.97] 
p=0.03; mutated HR: 0.66 [0.33-1.33] p=0.24; 
interaction p=0.97). No heterogeneity was observed 
between trials (p=0.62). Among the patients with 
ADC and KRAS mutation, the rates of EGFR 
mutation were 0% (0/27), 4% (3/78) and 2% (1/58) 
in IALT, JBR.10 and CALGB, respectively. 
Conclusion: In this pooled analysis, EGFR 
mutations status was neither signiÀcantly prognosis 
nor predictive for OS and DFS in patients with KRAS 
wild-type lung adenocarcinoma in three adjuvant 
chemotherapy trials. This work was supported by 
LNCC, SanoÀ-Aventis. 
Keyword: EGFR mutation, meta-analysis, predictive 
value, lung adenocarcinoma
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MO16.07 INSULIN-LIKE GROWTH 
FACTOR-1 RECEPTOR INHIBITION 
OVERCOMES GEFITINIB 
RESISTANCE IN MUCINOUS LUNG 
ADENOCARCINOMA
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Background: An appropriate selection of patients is 
a major challenge for the treatment of non-small cell 
lung cancer (NSCLC) with epidermal growth factor 
receptor-tyrosine kinase inhibitors (EGFR-TKI). In 
individuals with tumors harboring EGFR mutation, 
EGFR-TKI is an option as initial therapy and have 
demonstrated signiÀcant clinical efÀcacy against the 
disease. However, de novo or acquired resistance to 
EGFR-TKI invariably develops. Prospective trials 
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Background: EGFR mutation occurs in 10-15% in 
lung cancer, mainly in tumors of adenocarcinoma 
(ADC) histology. This mutation is rare in patients 
with KRAS mutation. Because the prognostic and 
adjuvant chemotherapy (ACT) predictive roles of 
EGFR mutation status remain unclear, the LACE-
Bio group undertook this pooled analysis of EGFR 
mutation status in 295 patients with ADC and KRAS 
wild-type (WT) who participated in 3 randomized 
trials of platinum-based ACT or observation. 
Methods: Pooled analysis included IALT, JBR10 
and CALGB-9633 trials. EGFR exon 19 and 21 
mutations were assessed by polymerase chain 
reaction / bidirectional sequencing in cases with 
DNA quality allowing KRAS mutation search. Main 
endpoint was overall survival (OS). The hazard ratio 
(HR) and its 95% conÀdence interval were estimated 
using the multivariable Cox model stratiÀed by trial 
and adjusted for clinical and pathological variables. 
Results: Among 295 lung ADC KRAS WT patients 
with a 5.6-years median follow-up, 55 (19%) had an 
EGFR mutation: 21% (n=19), 20% (n=24) and 15% 
(n=12) in IALT (n=91), JBR10 (n=123) and CALGB 
(n=81), respectively (p=0.56). More females 
had EGFR mutations than males (26% vs. 14%, 
p=0.01). There were 128 and 159 events for OS 
and disease-free survival (DFS), respectively from 
290 analysed patients due to missing covariates. 
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Background: Non-small-cell lung cancer (NSCLC) 
patients bearing epidermal growth factor receptor 
(EGFR) mutations treated with erlotinib attain 
a median progression-free survival (PFS) of 14 
months. However, the duration of PFS is variable 
and there is a need to identify genetic cofactors that 
allow predictive accuracy to be improved. We had 
previously determined that low BRCA1 mRNA 
expression correlates with a signiÀcantly prolonged 
PFS of 27 months. We hypothesize that the detection 
of aberrant expression of other components in 
multiple parallel signalling pathways involved in 
DNA repair could further deÀne the predictive model 
based only on BRCA1 expression and the pre-
treatment T790M EGFR mutation. 
Methods: We used the NanoString nCounter gene 
expression system, which captures and counts 
in lung adenocarcinoma with bronchioloalveolar 
carcinoma (BAC) features demonstrated that the 
mucinous subtype presents a poorer outcome 
under EGFR-TKI treatment than the non-mucinous 
subtype. Our aim was to determine the molecular 
characteristics associated with resistance to 
EGFR-TKI in mucinous and non-mucinous 
adenocarcinoma.
Methods: Eighty adenocarcinoma-BAC samples, 
including 34 tumors from patients treated with 
geÀtinib in a phase II clinical trial from Intergroupe 
Francophone de Cancérologie Thoracique 
(IFCT0401), were classiÀed as mucinous (n=32) 
or non-mucinous (n=48) adenocarcinoma. 
EGFR, insulin-like growth factor-type 1 receptor 
(IGF1R), amphiregulin and thyroid-transcription 
factor-1 (TTF-1) expressions were studied by 
immunohistochemistry and EGFR and KRAS 
mutations status were evaluated in these samples. 
EGFR and IGF1R pathways and treatments were 
further analyzed on relevant cell lines.
Results: We demonstrated that four biological 
markers were differentially expressed between the 
two subtypes: mucinous tumors that overexpressed 
IGF1R (p <0.0001) and amphiregulin (p=0.004) with 
a tendency for more frequent KRAS mutations, in 
contrast to non-mucinous tumors that overexpressed 
EGFR (p <0.0001) and TTF-1 (p <0.0001) with more 
frequent EGFR mutations (p=0.037). Higher IGF1R 
(p=0.02) and lower TTF-1 (p=0.02) expression was 
associated with disease progression under geÀtinib 
treatment. We observed in vitro cross talk between 
EGFR and IGF1R signaling pathways in geÀtinib-
resistant H358 mucinous cells. Anti-amphiregulin 
siRNAs and anti-IGF1R treatments sensitized the 
H358 cells to geÀtinib-induced apoptosis with 
additive effects.
Conclusion: Anti-amphiregulin and anti-IGF1R 
treatments could overcome the resistance of 
mucinous tumors to EGFR-TKI, including those with 
KRAS mutation. Our results highlight that mucinous 
and non-mucinous adenocarcinoma subtypes are 
different entities with different therapeutic responses 
to EGFR-TKI. Characterizing adenocarcinoma 
subtype and status of IGF1R and amphiregulin 
might allow identifying patients that could beneÀt 
new combinational therapy with EGFR-TKI and 
anti-IGF1R molecules, especially for mucinous 
subtype. These data will foster the development of 
therapeutic strategies for treating adenocarcinoma 
with mucinous component.
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Background: NSCLC p with EGFR mutations respond 
to the oral EGFR tyrosine kinase inhibitors erlotinib 
and geÀtinib, although the duration of response in 
individual p is unpredictable. In our previous study, 
we found that erlotinib-treated p with low BRCA1 
mRNA levels had a progression-free survival (PFS) of 
27 months (m) vs 10 m for p with high levels (P=0.02). 
AEG-1 is a multifunctional oncogene that plays a role 
in several carcinogenic processes. Through PI3K/Akt, 
AEG-1 activates IKK, leading to phosphorylation and 
destabilization of the NF-kB inhibitor NFKBIA, which 
is a gatekeeper for EGFR signaling. 
Methods: Tumor mRNA expression levels of BRCA1 
and AEG-1 were assessed by quantitative PCR in 77 
erlotinib-treated p with EGFR mutations. Expression 
levels were dichotomized at the median. 
Results: PFS was longer in p with low AEG-1 
expression (27 vs 12 m; P=0.003). Median survival 
(MS) was not reached for p with low AEG-1 levels 
and was 24 m for p with high levels (P=0.08). Based 
on these results, we generated an AEG-1/BRCA1 
risk model: p with high levels of both genes were 
considered high-risk, p with low levels of both genes 
were low-risk, and p with high levels of one and low 
levels of the other gene were intermediate-risk. PFS 
was not reached in the low-risk group, while it was 
18 m for the intermediate-risk group and 8 m for the 
high-risk group (P=0.00006) (HR for high- vs low-risk 
groups, 6.6; 95%CI, 2-4-18; P<0.00001). MS was not 
reached in the low-risk group, while it was 31 m for 
the intermediate-risk group and 18 m for the high-risk 
group (P=0.05). In the multivariate analysis for PFS, 
the only independent prognostic variables were bone 
metastases (HR, 2.7; 95%CI, 1.1-6.5; P=0.03) and the 
AEG-1/BRCA1 risk groups (HR for high-risk group, 
7.7 (95%CI, 2.8-21.3; P<0.00001).
Conclusion: The two-gene risk model based on 
AEG-1 and BRCA1 mRNA expression was strongly 
associated with clinical outcome, with signiÀcantly 
shorter PFS and MS in the high-risk group. This 
model can be useful for the proper individualized 
management of p with EGFR mutations. 
Keywords: AEG-1, EGFR mutations, Non-Small-
Cell Lung Cancer
individual mRNA transcripts, to analyze the expression 
of 48 selected genes, most of which are involved in 
homologous recombination repair. CodeSets (Reporter 
and Capture probe sets) were custom designed by 
NanoString Technologies. Gene expression levels were 
correlated with clinical outcomes. 
Results: Fifty-Àve erlotinib-treated NSCLC patients 
were examined. PFS for patients with low BRCA1 
and low-intermediate astrocyte elevated gene-1 
(AEG-1) was not reached, while it was 4 months 
for those with intermediate-high BRCA1 and high 
AEG-1 levels and 18 months for those with other 
combinations (P=0.004). Median survival for 
patients with low BRCA1 and intermediate AEG-
1 levels was not reached, while it was 21 months 
for those with intermediate-high BRCA1 and high 
AEG-1 levels and 29 months for those with other 
combinations. Based on these Àndings we generated 
a BRCA1/AEG-1 combined risk group model, 
classifying patients into low-, intermediate-, and 
high-risk groups. Complete response was attained in 
42.9% of patients in the low-risk group, compared 
to 3% in the intermediate-risk group and 0% in the 
high-risk group (P=0.02). The hazard ratio for the 
high-risk group was 7.29 (P=0.007). 
Conclusion: The BRCA1/AEG-1 gene expression 
model could be an essential tool for therapeutic 
decision making and could provide robust predictive 
information for physicians, patients and families.The 
early identiÀcation of a high-risk group can be useful 
in the development of new therapeutic strategies. 
Keywords: Non-Small-Cell Lung Cancer, BRCA1, 
AEG-1, NanoString
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MO16.09 ASTROCYTE ELEVATED GENE 
1 (AEG-1) MRNA EXPRESSION IN NON-
SMALL-CELL LUNG CANCER (NSCLC) 
PATIENTS (P) WITH EPIDERMAL 
GROWTH FACTOR RECEPTOR (EGFR) 
MUTATIONS
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MO16.12 ONCOGENE STATUS PREDICTS 
PATTERNS OF METASTATIC SPREAD IN 
TREATMENT-NAïVE LUNG CANCER
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Paul A. Bunn1, Marileila Varella-Garcia1, Dara L. 
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Background: The discovery of distinct subsets 
of non-small cell lung cancer characterized by 
molecular oncogenes has greatly impacted oncogene-
directed therapy. We hypothesized that the unique 
signaling pathways engaged by different dominant 
oncogenes in lung cancer would be associated with 
distinct patterns of metastatic spread.
Methods: 229 consecutive patients with stage 
IV non-small cell lung cancer (NSCLC) at the 
University of Colorado (all non-squamous histology) 
who were positive for EGFR mutation (N=46), 
KRAS mutation (N=45), ALK gene rearrangement 
(N=39), or wild-type for all three (triple negative, 
N=99) were included. SpeciÀc organ sites of 
metastatic disease (intra- and extrathoracic lymph 
nodes, intrapulmonary nodules, pleura, pericardium, 
brain, liver, bone, adrenal) at the time of diagnosis 
were collected from initial staging using PET/
CT or CT body imaging, MR or CT brain imaging 
and clinical notes. The percentage of patients with 
metastatic disease at a given site was compared 
between each molecular cohort (EGFR, KRAS, or 
ALK) and the triple negative cohort.
Results: ALK gene rearrangement was signiÀcantly 
associated with pleural effusion (OR=4.03, 95% CI 
1.85, 8.80, p<0.001.), pericardial effusion (OR=5.82, 
95% CI 1.38, 24.59, p=0.0155) and intrapulmonary 
nodules (OR=2.97, 95% CI 1.36, 6.46, p=0.008) 
compared to triple negative patients. ALK gene 
rearrangement was also signiÀcantly associated 
with metastatic spread to intrathoracic lymph nodes 
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MO16.11 CLONALITY STATUS 
OF MULTIFOCAL LUNG 
ADENOCARCINOMAS BASED ON THE 
MUTATION PATTERNS OF EGFR AND 
K-RAS
Kazuya Takamochi, Shiaki Oh, Kenji Suzuki 
Division Of Thoracic Surgery, Juntendo University 
School Of Medicine/Japan
Background: The purpose of this study is to clarify 
the clonality status of multifocal lung adenocarcinomas 
based on the mutation patterns of the epidermal growth 
factor receptor (EGFR) and K-ras. 
Methods: We analyzed 82 multifocal lung 
adenocarcinomas from 36 patients who underwent 
surgical resection. Genomic DNA was extracted from 
formalin-Àxed, parafÀn-embedded tissue and analyzed 
for EGFR and K-ras mutations. We determined the 
clonality status of multifocal lung adenocarcinomas 
based on the mutation patterns of the EGFR and K-ras. 
Actuarial survival time was estimated and risk factors 
inÁuencing survival were evaluated for 31 patients with 
synchronous multifocal lung adenocarcinomas. 
Results: EGFR and K-ras mutations were detected in 
36 (44%) and 19 (23%) of the 82 tumors, respectively. 
EGFR mutations had occurred randomly in 19 (92%) 
of the 22 patients with at least one EGFR mutated 
tumors. K-ras mutations had occurred randomly in 
14 (93%) of the 15 patients with at least one K-ras 
mutated tumors. Combing the results for the EGFR and 
K-ras mutation patterns, the clonality status could be 
determined in 30 (83%) of 36 patients with multifocal 
lung adenocarcinomas. The 5-year survival was 100% 
for patients with multifocal lung adenocarcinomas 
harboring the same clonality and 76% for patients 
with those harboring different clonality (p = 0.21). The 
Cox regression identiÀed the pathological diagnosis 
based on Martini and Melamed’s criteria as the only 
signiÀcant prognostic factor. 
Conclusion: Both EGFR and K-ras mutations 
frequently occur randomly in multifocal lung 
adenocarcinomas. Patients with multifocal lung 
adenocarcinomas are expected to beneÀt from 
surgery regardless of the tumor clonarity status 
because there was no signiÀcant difference between 
patients with tumors harboring the same clonality 
and patients with those harboring different clonality. 
Keywords: Clonality, EGFR, K-ras, Multifocal 
Lung Adenocarcinomas
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Background: Primary tumor xenografts (XG) 
demonstrate greater representation of the spectrum 
of tumor histology and heterogeneity found in 
clinical tumors than established cell lines. We have 
systematically attempted to establish XG from 
surgically resected non-small cell lung cancer 
(NSCLC) by implanting the tumors into NOD-SCID 
mice. However, not all tumors engrafted to form 
xenograft lines (Clin Cancer Res 2011;17:134-141). 
As the ability to form XG is correlated with poorer 
disease-free survival of the patients, identiÀcation of 
molecular markers that are correlated with xenograft 
establishment could indicate aberrations that are 
drivers of aggressive biology in the primary tumor 
and impact on clinical outcomes. 
Methods: Tissue microarrays (TMAs) were 
constructed from the archival parafÀn blocks of the 
primary patient tumors that formed XG or did not 
formed XG (no-XG). DNA was isolated from tumor 
cores obtained from the same blocks. The gene copy 
number of MYC and KRAS were evaluated by the 
silver in situ hybridization (SISH) assay (Ventana 
Medical Systems, Tucson, AZ) using gene speciÀc 
probes (Ventana). For each tumor, 90 tumor cells 
were scored. The tumor was considered to have 
MYC or KRAS ampliÀcation if there was clear 
formation of probe clusters. For p53 and PTEN, 
immunohistochemisty (IHC) was performed. Cases 
were considered aberrant for p53 (P53+) if more 
than 15% tumor cells were stained, and negative for 
PTEN expression (PTEN-) if there was a complete 
absence of tumor cell staining. In addition, the 
DNA of patient primary tumors was analysed for 
19 oncogenes and 238 somatic mutations using the 
OncoCarta MassARRAY Chip (Sequenom®, San 
Diego, CA). All mutations were validated by direct 
sequencing. 
Results: Primary tumor samples from 153 patients 
(94 adenocarcinomas, 44 squamous cell carcinomas 
and 15 other types) were implanted. XG was 
established in 64 (41.8%) cases. Of 153 total 
cases, MYC ampliÀcation was seen in 49 (32.0%), 
KRAS ampliÀcation in 52 (34.0%), p53+ staining 
in 68 (44.4%) and PTEN- staining in 63 (41.2%) 
of the primary tumors. Tumors of XG patients 
showed signiÀcantly greater proportion of MYC 
ampliÀcation (43.8% vs 23.6%, p=0.014), p53+ 
(OR=3.81, 95% CI 1.54-9.45, p=0.003), compared 
to the triple negative cohort, and had a similar but 
non-signiÀcant association with extrathoracic lymph 
nodes (OR=2.94, 95% CI 1.02, 8.48, p=0.07). 
Patients with ALK gene rearrangements (OR=5.2, 
95% CI 1.43, 18.91, p= 0.012) and patients with 
EGFR mutations (OR=5.0, 95% CI 1.42, 17.59, 
p= 0.019) were predisposed to liver metastasis 
compared to the triple negative cohort. KRAS 
mutation was not associated with increased risk of 
any metastatic site compared to the triple negative 
cohort. No molecular cohort had a predisposition 
to adrenal, bone, or brain metastasis compared to 
the triple negative cohort. The mean number of 
metastatic disease sites in patients within the triple 
negative cohort (mean=1.7 sites) was signiÀcantly 
smaller than that of the ALK gene rearranged cohort 
(mean=3.0 sites, p<0.0001), but not within the EGFR 
(mean=1.8 sites, p=0.5624) or KRAS mutation 
cohorts (mean=1.6 sites, p=0.7031). 
Conclusion: Untreated patients with ALK gene 
rearrangements displayed an increased likelihood 
of metastatic spread to several organ sites including 
pleura, pericardium, lung parenchyma, lymph 
nodes and liver at the time of diagnosis compared 
to patients without a known molecular driver (triple 
negative control group). EGFR mutation positive 
patients showed an increased likelihood of liver 
metastases. The results support the hypothesis that 
the dominant molecular oncogenes in NSCLC are 
associated with distinct patterns of metastatic spread.
Keywords: NSCLC, ALK, EGFR, Kras
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MO16.13 AMPLIFICATION OF MYC AND 
ABERRANT EXPRESSION OF P53 AND 
PTEN ARE PREDICTIVE OF ABILITY TO 
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mutations are of emerging clinical signiÀcance. 
Unfortunately, resources for understanding this 
complex genetic information are limited. 
Methods: We performed a literature review 
regarding the prevalence and clinical signiÀcance 
of various treatments for ~40 mutations in 10 genes 
(EGFR, KRAS, BRAF, NRAS, PIK3CA, MEK1, 
AKT1, HER2, PTEN, and ALK) for NSCLC. Data 
from prospective and retrospective trials as well as 
preclinical studies were collected. We also conducted 
a retrospective review of the literature and identiÀed 
reports on over 1300 patients with EGFR mutations. 
We collected data including gender, age, smoking 
status, therapy and mutation status. 
Results: Greater than 150 articles and abstracts were 
reviewed and synthesized. Data was incorporated 
into a website [www.mycancergenome.org] which 
health care providers and patients will be able to 
use within the clinic to improve their understanding 
of common and rare mutations and to aid in 
their prioritization of therapies for patients with 
lung cancer. We provide direct links to available 
local and international clinical trials targeting 
speciÀc mutations. In our individual patient data 
review of EGFR mutations, we evaluated over 
2000 publications and identiÀed 115 papers 
containing data on 1152 individual patients: 91% 
adenocarcinoma, 62% never smokers, and 92% stage 
IV. 154 different mutations identiÀed: 48% exon 19 
deletion, 27% L858R, 3% G719X, 1% L861Q and 
21% other. We are now developing a searchable 
database – DNA mutation Inventory to ReÀne 
and Enhance Cancer Treatment [DIRECT] – for 
providers to access at the point of care.
Conclusion: Mycancergenome.org has been 
launched and is being evaluated for functionality, 
ease of use and satisfaction. The DIRECT database 
has started with patients with known EGFR 
mutations, and will be expanded to incorporate all 
known mutations with potential clinical signiÀcance. 
We encourage other clinicians, investigators, and 
interested pharma/diagnostic companies to contribute 
data as they emerge. 
Keywords: Non-small cell lung cancer, Mutations, 
Metastatic Disease
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
staining (57.8% vs 34.8%, p=0.005), and PTEN- 
staining (56.3% vs 30.3%, p=0.002) than no-XG 
patients. KRAS ampliÀcation was slightly, but not 
signiÀcantly increased in XG tumors (42.2% vs 
28.4%, p=0.08). In multivariate analysis, MYC 
ampliÀcation, p53+ and PTEN- were signiÀcantly 
associated with the ability to XG [Odds ratio and 
95% conÀdential interval (CI)]: MYC, 2.48 (1.02-
5.19, p=0.016); p53, 2.73 (1.35-5.53, p=0.005); 
PTEN, 3.17 (1.56-6.44, p=0.002), but not KRAS 
ampliÀcation (1.59, 0.77-3.26, p=0.21). KRAS 
mutations were seen in 34 (22.2%), and EGFR 
mutations in 23 (15.0%) primary tumor specimens, 
mostly adenocarcinomas (AC). In AC, MYC 
ampliÀcation was frequently seen in cases with wild-
type KRAS (p=0.061), but was not associated with 
EGFR mutation status (p=0.80). KRAS ampliÀcation 
was not associated with the presence of KRAS 
mutation (p=0.18), EGFR mutation (p=0.79) or 
MYC ampliÀcation (p=0.80).
Conclusion: MYC ampliÀcation by SISH, p53+ and 
PTEN- are predictive of the ability for early stage 
NSCLC to form XG, and potentially are associated 
with poorer survival.
Keywords: Non-small cell lung cancer, MYC, 
PTEN, primary tumor xenograft
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MO16.14 MYCANCERGENOME.ORG: 
DEVELOPING A WEB-BASED TOOL TO 
ENABLE A GENETICALLY INFORMED 
APPROACH TO LUNG CANCER 
TREATMENT
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Background: The treatment of patients with non-
small cell lung cancer (NSCLC) in the twenty 
Àrst century has evolved into a complicated 
algorithm, requiring knowledge of an individual 
patient’s mutation status prior to initiating therapy. 
Some mutations are associated with primary drug 
sensitivity, some with primary drug resistance, 
and some with secondary resistance. Other rarer 
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MO17.02 SUICIDE IN PATIENTS WITH 
THE CARCINOMA OF LUNG AND 
BRONCHUS IN CALIFORNIA, 2000-2005
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Background: Compared to general population, 
patients with carcinoma of the lung and bronchus are 
at higher risk of suicide, which is clustered in White 
men diagnosed with cancers with poor prognosis. 
The objectives of this study were to determine the 
relative risk of suicide in lung cancer patients by 
detailed race/ethnicity and stage at diagnosis.
Methods: . Age adjusted suicide rates were 
calculated for patients with cancers of the lung 
and bronchus, based on cases registered with the 
California Cancer Registry for the years 2000-2005. 
Suicide rates in general population were based on the 
California Death CertiÀcate Master Àles for the same 
period and same race/ethnicity. Relative risks (RR) 
for stage at diagnosis, marital and socioeconomic 
status were also calculated.
Results: . Of the 929,369 registered cases, 105,916 
were identiÀed as carcinoma of the lung and 
bronchus and accounted for 134 of the 716 suicides 
in this population. Although 0.2 percent of all death 
among cancer patients was suicide, its RR in the 
non-Hispanic White men and women, and Hispanic 
men were 5.87, 4.99, and 8.05, respectively. Suicide 
in patients with lung cancer was only signiÀcantly 
higher only in non-Hispanic White men with a 
relative risk of 5.85. It was also signiÀcantly higher 
in metastatic cases with a relative risk of 1.75.
Conclusion: s. Considering the multifactorial nature 
of suicide and its association with severity of the 
disease, and some of the patients demographics, 
it is concluded that diagnosis of cancer, and the 
advanced stage of diagnosis that reduces the hope 
for successful treatment, acts as precipitating factor 
for suicide in patients who are already suicidal. 
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MO17.01 NATURAL COURSE OF 
GROUND-GLASS OPACITY LUNG 
NODULE DETECTED BY LOW-DOSE 
COMPUTED TOMOGRAPHY IN 
SUBJECTS WITHOUT HISTORY OF 
PREVIOUS MALIGNANCY
Boksoon Chang1, Jung Hye Hwang2, Hojoong Kim1, 
Sang-Won Um1 
1Medicine, Samsung Medical Center/Korea, 2Center 
For Health Promotion, Samsung Medical Center/
Korea
Background: Although focal ground-glass opacity 
(GGO) nodule is generally reported to grow slowly, 
its natural course is still unclear. The purpose of this 
study was to elucidate the natural course of screening-
detected focal GGO nodules without history of 
malignancy.
Methods: We retrospectively reviewed the records 
of patients who underwent screening low dose chest 
computed tomography (CT) at the Samsung Medical 
Center between June 1997 and September 2006. The 
patients who underwent CT follow-up of more than 
2 years and had persistent focal GGO nodule(s) were 
included in the study. The patients with a history of 
previous malignancy or transient focal GGO nodule(s) 
were excluded from the study. 
Results: Ninety-four patients and 129 GGO nodules 
were included in the analysis. The median CT follow-
up period was 59 (24–140) months. The median size 
of nodule at the time of discovery was 6 (3-20) mm 
in largest dimension. During follow-up, the size of 
nodules were not changed in 81 patients (86.2%) and 
increased in 13 patients (13.8%). Increase in nodule 
size was associated with initial size (p<0.001) and 
existence of solid part (p=0.003). Median volume 
doubling time of nodules with increase in size was 
614 (330-4338) days. Twelve patients with increase 
in nodule size underwent surgical resection and 12 
nodules were diagnosed as primary lung cancer.
Conclusion: Screening detected focal GGO nodules 
grows less than 20 percent in subjects without 
history of malignancy. However, long-term follow-
up of more than 5 years are required for focal GGO 
nodules due to slow growth rates. 
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Methods: This analysis utilised genotyped data 
on 2385 (Case=728, controls=1657) individuals 
included in a candidate gene replication study. 
Potential epistasis among 20 replicated SNPs 
was explored using Multifactor Dimensionality 
Reduction (MDR) analysis to Àt all possible 
n-loci SNPs combination models. The overall 
best combination was selected based on cross 
validation consistency (CVC) and model accuracy 
in testing data (TA). Model coefÀcient for each 
allelic combination of the best SNPs combination 
was estimated from the model-based MDR(MB-
MDR) and incorporated into the LLP risk model. 
Predictive performance of extended model was 
examined using measures of discrimination, risk 
reclassiÀcation and clinical utility. 
Results: A 3-locus combination assuming additive 
genetic model provide the best discrimination 
of subject’s status (CVC= 100%, TA=65%). The 
MB-MDR also shows strongest associations for 
all 2- & 3-way interactions among SNPs is the 
‘best’ combination. However, entropy analysis 
suggests redundancy for their pairwise interactions 
(information loss range between -0.01 and -1.50%). 
Five allelic combinations were estimated to be of 
low risk, 11 each as uninformative and high risk 
with corresponding subject percentage of 5.4, 62.4 
and 32.2% respectively.
A statistically signiÀcant 8% increase in ROC-AUC 
was obtained with the addition of the SNP epistasis 
allelic effects into the prediction model with a net 
reclassiÀcation of 17.5% subjects. The decision 
curve analysis revealed superior ‘net’ beneÀts for 
the extended model across a reasonable range of 
threshold probabilities (10-40%) at which patients 
may be indifferent to an intervention.
Conclusion: The LLP risk model shows 
improvement with addition of a 3-locus epistasis 
effect. The expanded model provides improved 
stratiÀcation for a net 18% cases with no net 
loss in controls. This expansion of the model 
allows reÁection on disease pathway mechanism 
unmeasured in non-genetic factors. 
Keywords: risk prediction, Lung cancer, SNPs 
Epistasis
Oncologists who diagnose and manage patients with 
cancers of the lung and bronchus should include 
psychological evaluation in their routine to identify 
patients with suicidal tendencies and prevent it from 
happening.
Keywords: Lung cancer, Suicide, Epidemiology
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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MO17.03 ADDED PREDICTIVE VALUE 
OF SNPS EPISTASIS IN THE LLP LUNG 
CANCER RISK PREDICTION MODEL
Olaide Y. Raji1, Stephen W. Duffy2, T. Liloglou1, 
Robert P. Young3, John K. Field1 
1Molecular And Clinical Cancer Medicine, 
University Of Liverpool/United Kingdom, 2Queens 
Mary University Of London/United Kingdom, 
3University Of Auckland/New Zealand
Background: Lung cancer risk models estimate 
individual‘s absolute risk of the disease within 
a speciÀed period. Such models are useful in 
identifying and targeting high risk individuals 
for early detection interventions. Smoking is a 
known causal factor for lung cancer, the majority 
of long term smokers would not develop the 
disease whilst approximately 10-15% cases occur 
in non-smokers. This implies that lung cancer 
risk models should include other important risk 
factors including genetic and molecular variants for 
accurate risk. Relatively few genetic SNP variants 
have been identiÀed for lung cancer through genetic 
association studies using Genome-Wide Association 
Study (GWAS) or Candidate gene approach. As 
seen in other diseases, these markers only confer a 
small effect leading to scepticism regarding their 
usefulness in risk prediction. Recent research trend 
has suggested a role for gene-gene interactions 
in disease aetiology. Addition of such interactive 
effects may improved risk model predictions since 
many variants may exhibit strong interactions even 
with weak or insigniÀcant marginal effect. We 
explore potential epistasis (non-linear interactions) 
amongst a panel of lung cancer susceptible SNPs 
and assess their contributions to the predictive 
ability of the Liverpool Lung Project (LLP) risk 
model. 
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106 (5%), other NSCLC variant in 129 (6%) and 
not otherwise speciÀed in 668 (31%). 250 patients 
(12%) received surgery, 1681 received radiotherapy 
(78%) and 669 (31%) received chemotherapy. The 
optimal predicted radiotherapy utilisation in this 
population was 77-87% and chemotherapy 78%. 
613 (29%) received curative treatment, 1314 (61%) 
palliative treatment and 226 (10%) received best 
supportive care alone. The use of curative treatment 
increased from 21% in 2000 to 35% in 2007. The 
use of curative radiotherapy increased from 10.9% 
to 19.6% and chemoradiotherapy from 8% to 18.6%. 
The use of surgery and best supportive care remained 
similar over time. The median survival was 13 
months for Stage IIIA and 8 months for Stage IIIB 
NSCLC. Patients who had curative surgery had a 
median survival of 30 months, curative radiotherapy 
21 months, palliative treatment 8 months and best 
supportive care 5 months (p<0.001). There was no 
change in survival over time. 
Conclusion: A signiÀcant proportion of patients 
lacked pathological subtyping of their cancer which 
has become increasingly important in the era of 
targeted therapies. The utilisation of radiotherapy 
was similar to that predicted by models whereas 
the utilisation of chemotherapy was signiÀcantly 
less. There was an increase in the use of curative 
radiotherapy and chemoradiotherapy over time 
suggesting translation of evidence into practice. 
Keywords: Non-small cell lung cancer, 
Radiotherapy, Chemotherapy, patterns of care
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MO17.06 IMPROVED PROGNOSTIC 
STRATIFICATION OF STAGE I LUNG 
ADENOCARCINOMA (LAC) PATIENTS: 
CLASSIFICATION AND REGRESSION 
TREE (CART) ANALYSIS BASED ON 
HISTOLOGICAL SUBTYPING
Camelia S. Sima1, Kyuichi Kadota2, Akihiko 
Yoshizawa3, Emily C. Zabor1, Mithat Gonen1, Valerie 
Rusch4, William D. Travis5, Prasad S. Adusumili2 
1Epidemiology And Biostatistics, Memorial Sloan-
Kettering Cancer Center/United States Of America, 
2Memorial Sloan-Kettering Cancer Center/United 
States Of America, 3Pathology, Kyoto University/
Japan, 4Thoracic Surgery, Memorial Sloan-
Kettering Cancer Center/United States Of America, 
5Pathology, Memorial Sloan-Kettering Cancer 
Center/United States Of America
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MO17.04 STAGE III NON-SMALL CELL 
LUNG CANCER (NSCLC): PATTERNS OF 
TREATMENT IN BRITISH COLUMBIA, 
CANADA
Shalini K. Vinod1, Elaine Wai2, Cheryl Alexander2, 
Jennifer Christie2 
1Collaboration For Cancer Outcomes, Research 
& Evaluation, Liverpool Hospital/Australia, 
2Vancouver Island Centre, British Columbia Cancer 
Agency/Canada
Background: Stage III NSCLC comprises a 
heterogeneous group of patients. Management 
options range from any combination of surgery, 
radiotherapy and chemotherapy to no treatment. Based 
on guidelines, estimates of optimal radiotherapy 
utilization at diagnosis range from 84%- 92% and 
for chemotherapy 88%. However guideline-based 
treatment is not applicable in many patients due to 
age and comorbidities. The aims of this study were 
to describe the patterns of treatment in a population-
based cohort of patients with Stage III NSCLC 
and compare the utilization of chemotherapy and 
radiotherapy to that predicted by models. 
Methods: All patients diagnosed with clinical or 
pathologic Stage III NSCLC between January 1st 
2000-December 31st 2007 were identiÀed from 
the prospective database of the British Columbia 
Cancer Agency (BCCA). Those who were cNX 
or cMX were excluded as were patients with 
concomitant malignancies, a prior history of 
malignancy and multifocal lung cancers. Details on 
patient demographics, tumour characteristics, and 
Àrst course of treatment were extracted. Survival 
data was derived from the British Columbia Vital 
Statistics Death Listings. All records were censored 
on 31st December 2008. Initial treatment was deÀned 
as that commenced within six months of diagnosis. 
Curative radiotherapy was deÀned as a minimum 
dose of 50Gy. 
Results: 3429 patients with newly diagnosed 
lung cancer were referred to BCCA. 1275 patients 
were excluded leaving 2153 patients in the study 
population. The median age was 69 years and 55% 
were male. ECOG performance status was 0-2 
in 1369 (64%), 3-4 in 392 (18%) and unknown 
in 392 (18%). Stage of disease was pIIIA in 160 
(7%), cIIIA in 904 (42%), pIIIB in 54 (3%) and 
cIIIB in 1035 (48%). Pathology was SCC in 661 
(31%), adenocarcinoma 589 (27%), large cell in 
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Conclusion: A simple classiÀcation system based 
on the mix percentage of histological subtypes 
efÀciently stratiÀes patients with stage I LAC 
with respect to their risk of recurrence and, in 
combination with clinic-pathological factors, can 
provide clinicians with an accurate instrument 
for individual recurrence prediction in this very 
homogeneous population.
Keywords: Stage I lung adenocarcinoma, Individual 
risk prediction, Histological subtyping
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MO17.07 POLYMORPHISMS IN X-RAY 
REPAIR CROSS-COMPLEMENTING 
GROUP 1 (XRCC1) BASE EXCISION 
REPAIR GENE AND LUNG CANCER 
RISK IN INDUSTRIAL WORKERS WITH 
CHROMATE EXPOSURE.
Yui Fujita1, Kazuya Kondo1, Abdellah H.K. Ali2, 
Toshiaki Namura1, Yoshitaka Senba1, Yukari Oiwa1, 
Chikako Takai1, Hiromitsu Takizawa3, Yasushi 
Nakagawa3, Hiroaki Toba3, Koichiro Kenzaki3, Shoji 
Sakiyama3, Akira Tangoku3 
1Department Of Oncological Medical Services, 
Institute Of Health Biosciences, The University Of 
Tokushima Graduate School/Japan, 2Respiratory 
Medicine, Sohag University, Faculty Of Medicine/
Egypt, 3Department Of Thoracic, Endocrine 
And Oncological Surgery, Institute Of Health 
Biosciences, The University Of Tokushima Graduate 
School/Japan
Background: Polymorphisms in DNA repair genes 
have been associated to repair DNA lesions, and 
might contribute to the individual susceptibility 
to develop different types of cancer. The main 
DNA repair pathways include nucleotide excision 
repair (NER), base excision repair (BER), and 
Background: In patients with resected stage I 
LAC, we hypothesized that a classiÀcation system 
incorporating the distribution percentages of 
multiple histological subtypes within the tumor 
would efÀciently stratify patients and better predict 
recurrence than the IASLC/ERS/ATS classiÀcation 
system based on the most predominant histological 
subtype (PredHist).
Methods: In 485 stage I LAC resected tumors 
(training set, median follow-up=4 years), each 
histological subtype (lepidic=LIP, acinar=ACI, 
papillary=PAP, solid=SOL, micropapillary=MIP) 
was quantiÀed in 5% increments. CART 
methodology was applied to generate a decision 
algorithm that clustered patients with respect to 
their time to recurrence, based on the mix % of 
histological subtypes. The resulting classiÀcation 
system (%Mix) stratiÀed patients into groups whose 
risk of recurrence was calculated using Kaplan-
Meier estimates. Results were compared to those of 
PredHist. A multivariate Cox proportional hazards 
model was built, and its ability to predict recurrence 
was validated on an independent set of 487 stage I 
LAC.
Results: CART decision algorithm (Figure) stratiÀed 
patients into three groups with signiÀcantly different 
risk of recurrence (p<0.001). Compared to PredHist, 
%Mix reclassiÀed 29% (n=141) of patients, reducing 
the proportion in the intermediate-risk category 
from 76% to 59% (Table). Eighteen percent of all 
patients had their risk classiÀcation improved (to 
higher risk if recurred by 5 years, or to lower risk 
otherwise). In a multivariate model adjusting for 
gender, stage (IA vs. IB), necrosis and lymphatic 
invasion, %Mix was independently associated with 
recurrence (p=0.028). The multivariate model had 
a concordance probability of 0.72 (training dataset) 
and 0.71 (independent validation dataset), indicating 
very promising prediction ability.
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MO17.08 THE EFFECT OF SEX AND 
HISTOLOGY ON OUTCOME IN 
A POPULATION OF NON-SMALL 
CELL LUNG CANCER PATIENTS IN 
MANITOBA, CANADA
Marshall Pitz, Srisala Navaratnam 
Internal Medicine - Section Of Medical Oncology 
And Hematology, University Of Manitoba/Canada
Background: Non-small cell lung cancer (NSCLC) 
is the leading cause of cancer-related mortality. 
There is mounting evidence that cancer outcomes 
are worse for males than for females. The effect of 
sex as an independent prognostic factor has not been 
completely described at the population level. We 
sought to evaluate the effect of sex on mortality in a 
population of patients with NSCLC.
Methods: All patients with a diagnosis of NSCLC 
in Manitoba, Canada, from January 1, 1985, to 
December 31, 2004, were identiÀed from the 
Manitoba Cancer Registry. Treatment data for 
these patients were extracted from the Manitoba 
Health Physician Claims Database. The primary 
outcome was survival of males compared to females, 
calculated from date of diagnosis to date of death or 
administrative censoring. Quantile regression with 
generalized estimating equations and robust variance 
estimation, along with stratiÀed Cox proportional 
hazards regression were used to determine the 
independent effect of sex on survival and the 
interaction with histology, controlling for age, year 
of diagnosis, and treatment group.
Results: A total of 10 908 patients with NSCLC 
were identiÀed from the Manitoba Cancer Registry. 
Of these, 6665 were male and 4243 were female. 
Females had an overall median survival of 9.4 
months compared to 6.8 months for males (p 
<0.001). Females treated with surgery had a 
median survival of 53.3 months (95%CI 52.8-
53.9) compared to 33.4 months (95%CI 32.9-33.9) 
for males. Females treated with chemotherapy, 
radiotherapy, and supportive care had median 
survivals of 10.1 months (95%CI 9.2-11.0), 6.6 
months (95%CI 6.0-7.1), and 2.2 months (95%CI 
1.6-2.8), respectively. For males, median survivals 
were 8.5 months (95%CI 7.6-9.4), 6.0 months 
(95%CI 5.5-6.5), and 1.9 months (95%CI 1.3-2.4), 
respectively. The adjusted hazard ratio (HR) for 
death for males compared to females was 1.12 
(95%CI 1.03-1.21, p = 0.01). Sex modiÀed the effect 
double-strand break repair (DSBR). It is known 
that chromium is an important inhaled carcinogen 
for lung cancer, and causes a variety of genetic 
and related effects such as Cr-DNA adducts DNA 
single-strand breaks, DNAdouble-strand breaks, 
DNA base damage and mutations. We investigated 
the relationship between 3 polymorphism sites 
(Arg194Trp, Arg280His, Arg399Gln) in the BER 
gene x-ray repair cross-complementing group 1 
(XRCC1) and the risk of developing lung cancer in 
industrial workers with chromate exposure.
Methods: We divided 75 workers with chromate 
exposure into 2 groups: workers with lung cancer 
(LC+ group) and workers without lung cancer 
(LC- group). Time of chromate exposure (years): 
23.1 vs 19.4, smoker rate: 85% vs 73%, Brinkman 
index: 510 vs 338. DNAs were extracted from 
specimens of sputum cytology or biopsy of 
bronchscopic examination for screening. Genotypes 
were determined by nested PCR-RFLP using each 
speciÀc primer of 3 polymorphism sites (Arg194Trp, 
Arg280His, Arg399Gln).
Results: Variant genotypes of 399Gln (Arg/Gln and 
Gln/Gln) presented a statistically signiÀcant risk of 
developing lung cancer in workers with chromate 
exposure (OR = 3.76; 95%CI = 1.38-10.25). On 
the other hand, variant genotypes of 194 Trp (Arg/
Trp and Trp/Trp) presented a statistically signiÀcant 
reverse risk of developing lung cancer in workers 
with chromate exposure (OR = 0.22; 95%CI = 0.08-
0.61). Variant genotypes of 280 His (Arg/His and 
His/His) presented a not statistically signiÀcant risk 
of developing lung cancer (OR = 1.89; 95%CI = 
0.30-12.01). The frequency of Trp variant genotypes 
in Arg194Trp, His in Arg280His, Gln in Arg399Gln 
in this study is similar to that in Asian-populations 
studies (62.6% vs 39.3-63.2%, 6.7% vs 15.3-24.1%, 
60% vs 37.6-58.7%, respectively) .
Conclusion: In conclusion, we found that XRCC1 
399Gln variant genotypes were associated with 
increased risk of lung cancer, and 194 Trp variant 
genotypes showed a protective effect for lung cancer 
in workers with chromate exposure. These results are 
compatible with the results of in vitro studies, which 
demonstrated that the 399 Gln allele is associated 
with higher mutagen sensitivity and higher levels of 
DNA adducts, and that 194Trp allele is associated 
with lower mutagen sensitivity.
Keywords: Lung cancer, chromium, polymorphism, 
base excision repair XRCC1
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patients and >75nmol/L in 2 patients. There was no 
correlation between vitamin D levels, deprivation 
score, stage of disease, timing or type of treatment 
or seasonal time of vitamin D measurement. 
Incidentally, 10 of the 38 patients with low vitamin 
D levels had been diagnosed with bone metastases 
on the basis of symptoms and bone scans. 
Conclusion: In this study, 83% of patients had 
vitamin D deÀciency. This problem may be more 
widespread. Correction of vitamin D deÀciency may 
reduce symptoms and improve quality of life. If 
the sole site of progression is bone metastases, then 
replenishing vitamin D Àrst (unless there is evidence 
of bone destruction) before switching systemic 
therapies may be appropriate. Bone metastases could 
potentially be misdiagnosed2. 
Keywords: Vitamin D DeÀciency, Lung cancer
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MO17.11 IMPACT OF DIETARY HABITS 
ON EPIDERMAL GROWTH FACTOR 
RECEPTOR (EGFR) MUTATION STATUS 
OF JAPANESE PATIENTS WITH LUNG 
ADENOCARCINOMAS
Yuki Yamane1, Motoki Iwasaki2, Akikazu Kawase1, 
Katsuya Tsuchihara3, Sachiyo Mimaki3, Genichiro 
Ishii4, Horonobu Ohmatsu1, Seiji Niho1, Kiyotaka 
Yoh1, Kanji Nagai1, Yuichiro Ohe1, Shoichiro 
Tsugane2, Atsushi Ochiai4, Hiroyasu Esumi3, Koichi 
Goto1 
1Division Of Thoracic Oncology, National Cancer 
Center Hospital East/Japan, 2Epidemiology And 
Prevention Division, Research Center For Cancer 
Prevention And Screening, National Cancer Center/
Japan, 3Cancer Physiology Project, Research Center 
For Innovative Oncology, National Cancer Center 
Hospital East/Japan, 4Pathology Division, Research 
Center For Innovative Oncology, National Cancer 
Center Hospital East/Japan
Background: Epidermal growth factor receptor 
(EGFR) mutation plays a key role in the 
carcinogenesis of lung adenocarcinoma. However 
little is known about the environmental and life 
style factors, in particular dietary habits, inÁuencing 
EGFR mutations.
Methods: Between July 1999 and July 2004, 
1995 consecutive patients with lung cancer were 
prospectively assessed on dietary habits using the 
semiquantitative Food Frequency Questionnaire 
of surgical treatment on survival with a HR of 1.26 
(1.13-1.40, p<0.001). Adenocarcinoma histology 
signiÀcantly modiÀed the effect of sex on mortality 
such that in those with adenocarcinoma, males had a 
HR for death of 1.37 (1.24-1.51, p<0.001) compared 
to females. This effect was consistent across all 
treatment groups.
Conclusion: In this large population-based cohort, 
females with NSCLC had a signiÀcantly better 
survival than males with the same disease. For 
patients with adenocarcinoma, this difference was 
signiÀcantly stronger, and was seen in each treatment 
group. Sex and adenocarcinoma are independent 
prognostic factors for patients with NSCLC.
Keywords: Non-small cell lung cancer, sex, 
Adenocarcinoma, population-based
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MO17.09 VITAMIN D LEVELS IN 
PATIENTS WITH LUNG CANCER: A 
POTENTIAL CAUSE OF CONFUSION?
Janabel Said, Elaine M. Rankin, Colin S. Barrie 
Oncology Department, Ninewells Hospital/United 
Kingdom
Background: Bone metastases are common in lung 
cancer, affecting 40% of patients with non-small cell 
and 70% with small-cell lung cancer1. Sievenpiper 
et al2 noted that breast cancer patients with vitamin 
D deÀciency may have similar symptoms to those 
with bone metastases including bone pain and ‘hot 
spots’ on bone scans, indistinguishable from bone 
metastases. Thus, if bone pain and scan Àndings are 
attributed incorrectly to metastatic disease rather 
than vitamin D deÀciency, anti-cancer therapy may 
be changed inappropriately. We were interested in 
the incidence of vitamin D deÀciency in our lung 
cancer population and report the results of our 
survey. 
Methods: Forty-six consecutive patients were 
studied: age range 40–81, 31 female. Their diagnosis, 
stage of disease, treatment, month of vitamin D 
measurement and Carstairs deprivation score3 were 
noted. In Scotland, the lower limit of normal for 
the active metabolite, 1,25-dihydroxyvitamin D3, is 
50nmol/L4. 
Results: Only 8 of 46 patients had normal vitamin 
D levels; none were taking vitamin D supplements. 
Vitamin D levels were <25nmol/L in 16 patients, 
26-49nmol/L in 12 patients, 50-74nmol/L in 6 
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been 35 case series describing the occurrence of 
LELC of the lung with Caucasians accounting 
for only 20 cases of 155 cases. We present here a 
review of LELC of the lung in patients seen at the 
Mayo Clinic, Minnesota from January 1, 1979 - 
December 31, 2010.
Methods: We searched Mayo Clinic Tumor 
Registry by using the words “lymphoepithelioma” 
and “lymphoepithelioma-like carcinoma”. In 
addition, we searched the pathology SnoMed 
coding system using the codes ICD-8, and ICD-9. 
Search was limited to the period of 1979 - 2010.
Results: There were 14 patients with a diagnosis 
of LELC of the lung (4 females, mean age=50.3 
years and 10 males, mean age=64.9 years). Most 
patients were either current or former smokers 
except one for never-smoker of Asian ethnicity. 
Angiolymphatic or visceral pleura invasion 
was seen in 3 patients. Nine patients (64%) 
presented with early stage disease (I, II), and 5 
patients (35%) presented with advanced stage 
disease (III, IV). Two patients (stage II and IV) 
were Asian and positive for EBV by in-situ 
hybridization. From the remaining 12 Caucasian 
patients, 2 (stage II and IV) were positive for 
EBV by in-situ hybridization; 3 were negative; 
and 1 had EBV Viral Capsid Antigen (VCA) 
IgG positive. Results were not available in the 
remaining 6 patients. Surgery was done in all 
patients except for 2 stage IV patients. Only 2 
patients received adjuvant chemotherapy, 5-FU/
platinum in one patient and cisplatin/etoposide 
concurrent with radiation in another one. This 
patient developed brain metastasis 5 months 
after Ànishing chemoradiation. Locally recurrent 
disease occurred in one patient. Three patients had 
distant metastatic disease on follow-up which with 
one of them being positive for EBV. One stage IV 
patient had complete remission after 2 cycles of 
5-FU/platinum then it progressed during period of 
consolidate chemoradiation with weekly low dose 
carboplatin, but responded after re-initiation of 
5-FU-based therapy. Patients Summary 
(FFQ) which contains questions regarding 138 
foods in National Cancer Center Hospital East. 
EGFR mutations (exon 19 deletion and exon 21 
L858R) were examined in 298 adenocarcinomas 
of whom by direct sequence method. The intake 
of nutrients was calculated with standard tables of 
food composition in Japan, 5th revised and enlarged 
edition. The differences of consumption of 22 food 
groups and 45 nutrients (energy-adjusted values 
using the residual method) between EGFR mutations 
positive (156 patients) and negative (142 patients) 
were investigated by multivariate logistic regression 
model adjusted for gender, age, smoking status and 
body mass index, regarding patients without EGFR 
mutations as control cases. 
Results: The grain and carbohydrate consumption 
of patients with EGFR mutations was signiÀcantly 
lower than patients without EGFR mutations. 
The multivariate-adjusted odds ratios and 95% 
conÀdence intervals for the third tertile of grain and 
carbohydrate consumption of patients with EGFR 
mutations in comparison with the Àrst tertile were 
0.46 (0.24-0.87) (p for trend =0.021) and 0.44 (0.23-
0.85) (p for trend =0.016), respectively. 
Conclusion: In the present study, it was 
suggested that the lower consumption of grain and 
carbohydrate correlated with EGFR mutations. 
Further research to investigate the inÁuence of these 
dietary components and habits on carcinogenesis 
of lung adenocarcinoma with EGFR mutations is 
warranted. 
Keywords: Epidermal growth factor receptor 
(EGFR), EGFR mutation, lung adenocarcinoma, 
Dietary habits
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MO17.12 LYMPHOEPITHELIOMA-
LIKE CARCINOMA OF THE LUNG: 31 
YEARS EXPERIENCE AT MAYO CLINIC, 
ROCHESTER, MINNESOTA
Thanyanan Reungwetwattana, Julian R. Molina 
Medical Oncology, Mayo Clinic/United States Of 
America
Background: Lymphoepithelioma-like carcinoma 
(LELC) of the lung, an Epstein-Barr virus 
associated undifferentiated carcinoma, is the 
very rare subtype of non-small cell lung cancer 
(NSCLC). It has high incidence in young, non-
smoking, Asian patients. Currently, there have 
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estimated that less than 5% of adult cancer patients 
enroll to clinical trials. As a university hospital with 
a dedicated thoracic oncology department, we aim to 
identify barriers to patients enrollment in lung cancer 
clinical trials.
Methods: We prospectively tracked factors that 
potentially affected patient accrual into lung cancer 
clinical trials at the Toulouse University Hospital. 
Physicians were asked to complete questionnaires 
in the weekly oncology multidisciplinary staff from 
1rst January 2010 to 28th June 2010. We collected 
data regarding patient characteristics, therapeutic 
decision, protocol availability, clinical trial inclusion 
proposition and reasons of non participation.
Results: We recruited three hundred and twenty one 
patients. Patients were mostly men (69%) with an 
average age of 62.7 years within a range of 40 to 
89. Patients were proposed chemotherapy for 71%, 
radiotherapy for 17% and surgery for 12%. Two 
hundred Àfty seven were ineligible (80%); there was 
no available clinical trial for 136 patients (42.3%) 
and one hundred twenty one didn’t met eligibility 
criteria (37.7%). The main reasons for ineligibility 
were : presence of co-morbidities (6.5%), history of 
a previous malignancy (6.9%), poor performance 
status (10.6%, advanced age (5.6%), residence far 
from the hospital (10%) and tumor characteristics 
(10.3%). Of the remaining sixty four patients, 
only twenty one (32%) agreed to enroll onto a 
clinical trial. Eligible patients were younger with 
a median age of 60.5 years. 43 patients have been 
excluded due to patient-related criteria (poor PS, 
abnormal blood tests results) and protocol-related 
criteria (histology subtype, stage, therapeutics drugs 
proscribed, prior treatment).
Conclusion: Our results highlight the difÀculty 
in accrual onto lung cancer clinical trials. Only 
a small proportion of patients were eligible for a 
clinical trial in our study due to a lack of clinical 
trials availability. IdentiÀcation of barriers to the 
participation to clinical trials may help us to enhance 
accrual and to develop tailored trials, particularly in 
orphan disease (small cell lung cancer, squamous 
cell lung cancer, thymoma), and underrepresented 
patients.
Keywords: participation, Lung cancer, Clinical trial, 
eligibility criteria
Table 
ID Age Sex 
Smoking 
(Packyears) 
Race Staging EBV Surgery 
Chemo- 
therapy 
RT Recurrence 
Overall 
Survival 
(months) 
1 64 Male 
Ex-smoker 
(45) 
White I T1N0M0 
NA not 
available 
Wedge RUL No No Bone 44 
2 40 Female 
Ex-smoker 
(23) 
White I T2N0M0 NA LUL lobectomy 
Palliative 
Taxol+ 
Carboplatin 
Yes 
Local Left 
hilar mass 
47 
3 72 Male 
Current- 
smoker (70) 
White I T1N0M0 NA RUL lobectomy No No No 145 
4 67 Male 
Ex-smoker 
(30) 
White I T1N0M0 NA Wedge LLL No No No 113 
5 69 Male 
Ex-smoker 
(60) 
White I T1N0M0 
negative 
EBV in situ 
hybridization 
Wedge LUL No No No 7 
6 57 Female 
Ex-smoker 
(30) 
White I T1N0M0 
EBV VCA 
IgG postive 
wedge RUL No No No 30 
7 75 Male 
Current- 
smoker (45) 
White II T1N1M0 NA RUL lobectomy No No No 16 
8 52 Female 
Never 
smoker 
Asian II T1N1M0 
positive 
EBV in situ 
hybridization 
LLL lobectomy 
Adjvant 
5-FU+ 
Platinum 
No NA NA 
9 52 Male 
Ex-smoker 
(37) 
White II T2N1M0 
negative 
EBV in situ 
hybridization 
Right 
pneumonectomy 
No No NA 12 
10 68 Male 
Ex-smoker 
(50) 
White IIIA T2N2M0 NA Wedge LUL No Yes Right lung 89 
11 52 Female 
Ex-smoker 
(NA) 
White IIIB T4N0M0 
positive 
EBV in situ 
hybridization 
RML, RLL 
bilobectomy 
Adjuvant 
CCRT 
Cisplatin + 
Etoposide 
Yes Brain 12 
12 68 Male 
Ex-smoker 
(45) 
White IIIA T2N2M0 
negative 
EBV in situ 
hybridization 
Right 
pneumonectomy 
No No No Alive 
13 61 Male 
Ex-smoker 
(45) 
White IV (colon) 
positive 
EBV in situ 
hybridization 
No 
Palliative 
5-FU + 
Cisplatin 
No NA NA 
14 53 Male NA Asian 
IV (cervical 
lymph node) 
positive 
EBV in situ 
hybridization 
No 
Palliative 
5-FU + 
Platinum 
Yes 
Cervical 
lymph 
node 
Alive 
Conclusion: The natural history of disease of LELC 
of the lung in Caucasian might be different from 
Asian patients in term of patient’s age, smoking and 
EBV infection status. LELC of the lung is a very 
uncommon form of lung cancer in Western countries 
that needs collaborative studies for achieving the 
most beneÀt therapies.
Keyword: lymphoepithelioma of the lung
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MO17.13 PATIENT PARTICIPATION 
IN THORACIC CANCER CLINICAL 
TRIAL : PROSPECTIVE ANALYSIS IN A 
UNIVERSITARY HOSPITAL
Stephanie Lozano1, Ludivine Leseux1, Elsa Peyrat-
Detis1, Laurence Bigay-Gamé1, Laurent Brouchet2, 
Alain Didier3, Julien Mazieres1 
1Thoracic Oncology, Toulouse University Hospital/
France, 2Thoracic Surgery, Toulouse University 
Hospital/France, 3Pneumologie, Toulouse University 
Hospital/France
Background: Lung cancer is a worldwide concern, 
with a low survival rate. Clinical trials are essential 
for improving patient outcomes. Unfortunately, it is 
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MO18.01 RECURRENT AND/OR 
BILATERAL PNEUMOTHORAX 
INDUCED BY BEVACIZUMAB
Pascal Dô1, Adrien Dixmier2, Radj Gervais3 
1Calvados, Centre Francois Baclesse/France, 
2Centre Hospitalier Régional/France, 3Centre 
Francois Baclesse/France
Background: Bevacizumab, a monoclonal antibody 
directed to vascular endothelial growth factor 
(Avastin; Genentech, Inc, South San Francisco, 
CA), increases the efÀcacy of chemotherapy in 
many cancers. Bevacizumab’s principle side effects 
are hypertension and proteinuria. Haemoptysis and 
gastro-intestinal perforation are other rare, yet life-
threatening side effects.
Methods: We report three cases of recurrent and/
or bilateral life-threatening pneumothorax in three 
patients receiving bevacizumab.
Results: Patient 1 was a non-smoking 42-year-old 
man with a colorectal cancer and cavitary pulmonary 
metastases. Bevacizumab and capecitabine achieved 
stabilisation. Five weeks later, left pneumothorax 
required chest tube insertion. At thoracoscopy, 
multiple necrotic metastases were observed on 
the visceral pleura. Air leaks persisted despite 
surgical suture. The patient died eight weeks 
after the occurrence of the pneumothorax. Patient 
2 was a non-smoking 55-year-old woman with 
pulmonary metastases of bronchial adenocarcinoma, 
presenting with right partial pneumothorax six 
weeks after starting carboplatine, paclitaxel and 
bevacizumab. Chemotherapy was pursued without 
bevacizumab. Three weeks later, chest CT revealed 
partial response but bilateral pneumothorax. Right 
thoracoscopy achieved pneumothorax resolution. 
Left pneumothorax was stable until death one 
year later. Patient 3 was a non-smoking 33-year-
old woman with breast cancer and lymphangitic 
spread to the left lung. Bevacizumab and paclitaxel 
achieved a partial response. Two months later, the 
patient presented with bilateral pneumothorax. 
Despite chest tubes insertion and talc slurry, bilateral 
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MO17.14 LUNG CANCER RISK AT 
LOW ASBESTOS EXPOSURE: META-
REGRESSION OF THE EXPOSURE-
RESPONSE RELATIONSHIP
Sjoukje Van Der Bij1, Hendrik KofÀjberg1, Virissa 
Lenters2, Lutzen Portengen2, Karel G.M. Moons1, 
Dick Heederik2, Roel C.H. Vermeulen2 
1Julius Center For Health Sciences And Primary 
Care, University Medical Center Utrecht/
Netherlands, 2Division Of Environmental 
Epidemiology, Institute For Risk Assessment 
Sciences/Netherlands
Background: Most previous lung cancer studies 
focused on individuals heavily exposed to asbestos. 
Therefore, the existing estimated lung cancer risks 
per unit of exposure are mainly based on, and 
applicable to, high exposures. However, increasing 
interest lies in estimating risk at low exposures. 
Methods: We Àtted linear and non-linear meta-
regression models to 104 aggregated risk estimates 
extracted from 19 asbestos lung cancer studies. 
Associated relative risks (RRs) were calculated for 
several low cumulative asbestos exposure levels. The 
sensitivity of these RRs to the inclusion or exclusion 
of speciÀc studies was assessed. 
Results: A natural spline model Àtted our data best. 
With this model the relative lung cancer risk for 
cumulative exposures levels of 0.1 f-y/ml, 4 f-y/ml, 
and 40 f-y/ml was estimated to lie between 1.000-
1.001, 1.013-1.027, and 1.13-1.30, respectively. 
After stratiÀcation by Àber type, a 3 to 4-fold 
difference in RRs between chrysotile and amphibole 
Àbers was found for exposures below 40 f-y/ml. 
Fiber type-speciÀc risk estimates were strongly 
inÁuenced by a few studies
Conclusion: The natural spline regression model 
indicated that at lower asbestos exposure levels, 
the increase in RR of lung cancer due to asbestos 
exposure may be larger than expected from previous 
meta-analyses. Heterogeneity in the results, however, 
limited accurate assessment of potency differences 
between different Àber types. Low exposed industry 
or population-based cohorts with quantitative 
estimates of asbestos exposure are required to 
substantiate the risk estimates at low exposure levels 
from our new, Áexible meta-regression. 
Keywords: Amphiboles, asbestos, Chrysotile, meta-
analysis
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with NSCLC and spontaneous pneumothoraces 
treated with Bevacizumab.
Results: 1st case: A 41-year old never smoking asian 
female was diagnosed with stage IV adenocarcinoma 
of the lung with extensive intrapulmonary metastases 
in March 2006. She received Àfth line therapy 
with Bevacizumab, Gemcitabine and Vinorelbin 
from January 2008 until November 2008, when 
she presented with a pneumothorax on the right 
side. Besides, chest CT showed a regression 
of the pulmonary nodules and the mediastinal 
lymph nodes. Bevacizumab was continued while 
cytotoxic chemotherapy was stopped to decrease 
the risk for empyema. A few weeks later the 
patient presented with bilateral pneumothoraces. 
A chest tube was placed on the left side when a 
tension pneumothorax developed. While the right 
pneumothorax had resolved completely, the left 
pneumothorax persisted partially after the chest 
tube was accidentally removed. The patient was 
discharged, and three weeks later she was admitted 
to hospital again with a pneumothorax on the 
right side. Bevacizumab was stopped because of 
the poor performance status; best supportive care 
was started. At discharge, X-ray showed bilateral 
pneumothoraces again. The patient died three weeks 
later. 2nd case: A 61-year old former smoking male 
with adenocarcinoma of the right upper lobe, stage 
IV, with lymphangiosis carcinomatosa was treated 
with Bevacizumab and Docetaxel as third-line 
therapy. He received two cycles of therapy and then 
presented with worsening dyspnoea. Chest-X-ray 
revealed a small pneumothorax on the right side. 
A chest tube was placed, but the patient died a few 
days later due to respiratory failure. 3rd case: A 73-
year old male had a left upper lobe resection due 
to pulmonary adenocarcinoma in February 2010. 
He rejected adjuvant chemotherapy. Five months 
later, malignant pleural effusion on the left side, 
diagnosed by cytology, developed. Chemotherapy 
with Carboplatin, Vinorelbine and Bevacizumab 
was initiated. Pleural effusion regressed. After 
six cycles of therapy, the patient presented with 
an asymptomatic Áuidopneumothorax on the left. 
Clinically, there was no evidence for an insufÀciency 
of the bronchus stump, so bronchoscopy was not 
performed. Bevacizumab was continued and six 
weeks later, X-ray revealed only pleural effusion. 
Bevacizumab is still given as a maintenance therapy, 
and the patient is still in a good state.
Conclusion: Bevacizumab is active in lung cancer 
and other solid tumours. To our knowledge, these 
pneumothoraces recurred. She declined thoracoscopy 
and died a further two months later. 
Conclusion: Pneumothorax in cancer patients 
is a rare event. Smoking, chronic obstructive 
pulmonary disease, proximal bronchial obstruction, 
chemotherapy- or radiation-induced pulmonary 
Àbrosis, rapid tumour lysis and necrosis of large 
metastatic pulmonary lesions, enlargement of a 
rapidly necrotising tumour, are possible causes. None 
of these mechanisms was present in our patients. As 
antiangiogenesis agents are responsible for tumour 
cavitation when administered for patients with lung 
cancer, it is reasonable to assume that bevacizumab 
may have favoured the disruption of pleural-based 
metastases into the pleural space. Recurrence may be 
due to healing defect secondary to antiangiogenetic 
effect. We conclude that pneumothorax in these 
patients was related to bevacizumab on the grounds 
that: 1.The pneumothorax occurred only a few 
weeks after initiating bevacizumab 2. Bilateral 
involvement and/or recurrence despite chest tube 
insertion are unusual features 3. Usual causes were 
absent. Physicians using bevacizumab should be 
aware of this rare, yet potentially life-threatening 
complication consisting in bilateral and/or recurrent 
pneumothorax. 
Keywords: bevacizumab, Pneumothorax
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MO18.02 SPONTANEOUS 
PNEUMOTHORAX IN NSCLC PATIENTS 
TREATED WITH BEVACIZUMAB
Lorena Koch, Ali Sensoy, Tamara Hernler, Friederike 
Lins, Thomas Jenny, Simona Müller, Peter Cerkl 
Pulmonology, Department For Pulmonology, 
Landeskrankenhaus Hohenems/Austria
Background: Spontaneous pneumothorax in 
neoplasm of the lung is rare. There have been few 
reports on pneumothoraces in pulmonary metastases 
from different malignancies treated with effective 
cytotoxic chemotherapy. There is one recent report 
of a pneumothorax in a patient with lung metastases 
from colorectal cancer treated with Bevacizumab, 
and one report of a bilateral pneumothorax in a 
patient with renal cell carcinoma treated with another 
anti-VEGF drug, suggesting tumour shrinking from 
effective therapy as the cause for the pneumothorax.
Methods: Here, we report three cases of patients 
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Figure 1 illustrates 6 patients with tumor cavitation. 
The histological diagnosis in cavitated tumors 
was squamous cell carcinoma (SCC, n=14), 
adenocarcinoma (n=1) or undifferentiated large 
cell carcinoma (n=1). In total, 8 patients with 
a tumor cavitation (7 SCC) developed severe 
pulmonary complications; tumor abscess (n=5), fatal 
hemorrhage (n=2) and fatal embolism (n=1). Despite 
intravenous antibiotics, 2 patients with a tumor 
abscess required open-window thoracostomy post-
CCRT. Overall survival for patients with or without 
tumor cavitation was median 9.9 and 18.2 months, 
respectively (log-rank p=.208, ns). 
Conclusion: During the course of CCRT, grade III 
acute pulmonary complications developed in 50% 
of patients with stage III NSCLC who presented 
with radiological features of a tumor cavitation. 
The majority of patients had a SCC and the most 
common complication was a tumor abscess. 
Keywords: concurrent chemoradiotherapy, tumor 
cavitation, stage III NSCLC
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MO18.04 RISK OF RIB FRACTURE 
AFTER STEREOTACTIC BODY 
RADIATION THERAPY FOR PATIENTS 
WITH PERIPHERAL LUNG TUMORS
Su Ssan Kim1, Eun Kyung Choi1, Si Yeol Song1, 
Jungshin J. Lee2 
1Radiation Oncology, Asan Medical Center/Korea, 
2Medical Oncology, Asan Medical Center/Korea
Background: The aim of this study is to evaluate the 
risk of rib fracture after stereotactic body radiation 
therapy (SBRT) for patients with primary or metastatic 
peripheral lung tumors . An analysis for risk factors 
correlated with the rib fracture was also performed.
are the Àrst reports of Bevacizumab-associated 
pneumothoraces in NSCLC. Physicians using 
this agent should be aware of the occurence of 
spontaneous pneumothorax, recognizing its toxicity 
may be closely related to its efÀcacy.
Keywords: case report, Pneumothorax, 
bevacizumab, NSCLC
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MO18.03 TUMOR CAVITATION IN 
PATIENTS WITH STAGE III NON-
SMALL-CELL LUNG CANCER 
UNDERGOING CONCURRENT 
CHEMORADIOTHERAPY: INCIDENCE 
AND OUTCOMES
Erik C. Phernambucq1, Koen J. Hartemink2, Egbert 
F. Smit3, M. A. Paul2, Pieter E. Postmus3, Suresh 
Senan1 
1Radiation Oncology, VU University Medical Center/
Netherlands, 2Department Of Thoracic Surgery, VU 
University Medical Center/Netherlands, 3Pulmonary 
Diseases, VU University Medical Center/
Netherlands
Background: Commonly reported complications 
following concurrent chemoradiotherapy (CCRT) 
in patients with stage III non-small-cell lung cancer 
(NSCLC) include febrile neutropenia, radiation 
esophagitis and pneumonitis. After observing cases 
of infected tumor cavitation or ‘tumor abscess’ 
shortly after CCRT, we studied the incidence and 
outcomes of tumor cavitation in a single institutional 
cohort. 
Methods: Between 2003-2010, 87 patients with 
a stage III non-small-cell lung cancer (NSCLC) 
underwent platinum-based CCRT without subsequent 
surgical resection. Diagnostic and radiotherapy 
planning computed tomography (CT) scans were 
reviewed for tumor cavitation, which was deÀned as 
a non-bronchial air-containing cavity located within 
the primary tumor. Pulmonary toxicities scored as 
Common Toxicity Criteria v3.0 grade III occurring 
less than 90 days after end of radiotherapy, as well as 
all follow-up data were obtained from a prospective 
database. 
Results: In the entire cohort, tumor cavitation 
was observed on CT scans of 16 patients (18.4%), 
and 20 patients (23%) experienced any grade III 
pulmonary toxicity other than radiation pneumonitis. 
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up. However, early regional or stump recurrence 
is easily missed on serial MDCT or FDG PET 
due to anatomic distortion, chronic granulation 
tissue, combined complication, or surgical 
artifacts on image modalities even on dedicated 
chest radiologists. Learning objectives are 1) the 
understanding of characteristics and spectrums 
of early regional or stump recurrence, and 2) the 
improvement early diagnosis of recurrence of 
NSCLC, using MDCT or FDG PET. 
Methods: We retrospectively reviewed the serial 
MDCT images of 30 patients with regional or stump 
recurrence without distant or obvious lung to lung 
metastases. Among them, 25 patients had correlated 
FDG PET. Clinical symptoms were hemoptysis, 
cough or dyspnea. No signiÀcant clinical symptoms 
were also frequent. 
Results: We will illustrate growing endobronchial 
mass, daughter nodule, bulging out mass/ contour 
change/voluminous at central portion, localized 
lymphangitic tumor spread, new enhancing foci 
within granulation tissue, localized chest wall 
invasion, adjacent radiotherapy or suture materials, 
as regional or stump recurrence on MDCT. We will 
also demonstrate ipsilaterally located, localized 
nodal mass with or without extra-nodal extension. 
Conclusion: Familiarity with early regional or 
stump recurrence on follow-up MDCT and FDG 
PET may help the clinicians to establish adequate 
treatment plan such as reoperation, chemotherapy, 
or radiotherapy. MDCT and FDG PET may augment 
diagnostic accuracy. 
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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MO18.07 RETROSPECTIVE STUDY 
OF SIX PATIENTS WITH PRIMARY 
TRACHEAL CARCINOMA
Yoshiro Nakahara1, Yukio Hosomi1, Yusuke Okuma2, 
Yusuke Takagi3, Mari Iguchi1, Tatsuru Okamura3, 
Masahiko Shibuya1, Hirotoshi Horio4 
1Department Of Respiratory Medicine, Tokyo 
Metropolitan Cancer And Infectious Disease Center 
Komagome Hospital/Japan, 2Respiratory Medicine, 
Tokyo Metropolitan Cancer And Infectious Disease 
Center Komagome Hospital/Japan, 3Department Of 
Methods: From January 2006 to December 2009, 375 
lung tumors (296 patients) were treated with body-
frame-based hypofractionated radiation therapy at 
Asan Medical Center. This study included 133 lesions 
(125 patients) which were adjacent to chestwall (less 
than 1cm) and followed up with chest CT for more 
than 6 months. Fractional dose of 10-20 Gy was 
delivered to 85-90% of the planning target volume 
for consecutive for 4 days or twice a week. Total dose 
ranged from 36-60 Gy. The rib fracture was deÀned as 
the appearance of the fracture line or the dislocation of 
the ribs on follow-up CT scans. Kaplan-Meier method 
and Log-rank test were used to get survival rate and 
analyze the risk factors respectively.
Results: Patients’ age ranged from 19-90 years 
(median 70) and male gender was predominant 
(70.4%). Primary or recurrent lung cancer lesions 
were 60% (80 lesions). With the median follow-up 
period of 18 months (range: 7-54), total 47 cases of 
the rib fracture were veriÀed. Median time to the rib 
fracture was 16 months (range: 4-40). The 18-month 
actuarial risk of the rib fracture was 31.7%. Female 
gender and the higher prescribed dose were revealed 
to be statistically signiÀcant risk factors.
Conclusion: The risk of the rib fracture was 
considerable especially for the peripheral lung tumors 
after stereotactic body radiation therapy, so clinical 
attention should be given to the high-risk patients. The 
effort to decrease the dose to the chestwall should be 
made to reduce the risk of the rib fracture.
Keywords: rib fracture, Lung tumor, stereotactic 
body radiation therapy
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MO18.06 ILLUSTRATIVE REVIEW OF 
VARIOUS EARLY DETECTION OF THE 
REGIONAL OR STUMP RECURRENCE 
AFTER SURGERY AND/OR CCRT OF 
THE NON SMALL CELL LUNG CANCER 
USING MDCT AND FDG PET
Mi Young Kim 
Department Of Radiology And Research Institute Of 
Radiology, Asan Medical Center/Korea
Background: Early detection of intra-thoracic 
regional or stump recurrence after open thoracotomy 
and/or concomitant (pre- or post operative) 
chemo-radiotherapy is very important for proper 
management for NSCLC patients during follow-
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Background: Obesity is a risk factor for increased 
peri-operative morbidity and mortality in surgical 
patients. However, there have been limited studies 
to correlate morbidity of lung cancer resection with 
obesity. 
Methods: We performed a retrospective study 
of patients who underwent surgical resection for 
Lung cancer at the Medical College of Wisconsin 
from 2008 to 2010. Data on patient demographics, 
weight, pathology Àndings and hospital course were 
abstracted after appropriate IRB approval.Peri-
operative morbidity was deÀned as atrial Àbrillation, 
heart failure, respiratory failure, pulmonary 
embolism or any medical complications arising 
within 30 days after surgery. 
Results: Between 2008 and 2010,144 lung resections 
were performed for lung cancer. Median age were 
68(25-89) and 86(59.7%) were females. The body 
mass index (BMI) distribution were 32(22.2%) 
in BMI 30, 60(41.6%) in BMI 25-29.9 group, 
46(31.9%) in 18.5-24.9 and 6(4.1%) were <18.5. 
In patients with BMI < 25, surgical procedures 
consisted 31(59.6%) open lobectomy, 4(7.7%) 
VATS lobectomy, 16(30.8%) wedge resection and 
1(1.9%) pneumonectomy. In patients with BMI  
25, surgical procedures consisted: 54(58.7%) open 
lobectomy, 7(7.6%) VATS lobectomy, 27(29.3%) 
wedge resection and 4(4.3%) pneumonectomy. 
Tumor histology were: adenocarcinoma 64(44%), 
squamous cell cancer 48(33%), bronchoalveolar 
8(5%), large cell 5(3%) and mixed 19(13%). The 
30 day mortality rate was 3.4% (5 patients), all of 
whom underwent open lobectomy and only 1 had 
BMI  25. Peri-operative morbidity occurred in 
7(13.5%) of normal BMI patients and 18(19.6%) of 
BMI  25 patients (p=0.3455). SpeciÀc morbidities 
encountered by patients with normal vs. BMI  25 
were: atrial Àbrillation 5(9.6%) vs. 9(9.7%) (p=0.97), 
Pulmonary embolism 0(0%) vs. 2(2.1%) (p=0.18), 
congestive heart failure 0(0%) vs. 3(3.2%) (p=0.09), 
acute respiratory failure 0(0%) vs. 3(3.2%) (p=0.09) 
and ARDS 2(3.8%) vs. 1(1.08%) (p=0.69).Median 
hospital stay in both groups were 4.3 days. 
Conclusion: Although there may be a slight trend 
towards increased peri-operative congestive heart 
failure and respiratory failure in overweight patients, 
overweight and normal weight patients do not differ 
signiÀcantly in rates of peri-operative morbidities. 
Thus potentially curative resection of lung cancers 
can be offered to even signiÀcantly overweight 
patients, even if pneumonectomy might be required. 
Keywords: Lung cancer, Surgery, Morbidity
Respiratory Medicine, Tokyo Metropolitan Cancer 
And Infectious Diseases Center Komagome Hospital/
Japan, 4Department Of Thoracic Surgery, Tokyo 
Metropolitan Cancer And Infectious Diseases Center 
Komagome Hospital/Japan
Background: Primary tracheal carcinomas are rare and 
little is known about the prognoses for such patients. 
Methods: We retrospectively analyzed data from six 
patients (male, n = 3; female, n = 3; median age, 59.5 
y; range, 34 - 75 y) with primary tracheal carcinoma 
treated at our hospital between 1980 and 2010. 
Results: Four of the patients had adenoid cystic 
carcinoma and one each had squamous cell 
carcinoma and adenocarcinoma. Five patients had 
been treated by surgical resection of the tumor and 
one with advanced disease was treated only by 
tracheal dilation using a stent. This patient died of 
disease progression 50 months after diagnosis. Four 
of the Àve patients who had undergone resection 
received postoperative adjuvant radiotherapy 
because of positive surgical margins. Brain 
metastasis that developed 27 months after resection 
of the primary tracheal tumor in one patient was 
resected and intraoperative radiotherapy was 
delivered, but he died 2 months thereafter. Multiple 
lung metastases that developed 43 months after 
resection of the primary tracheal tumor in one 
patient were resected and she remained alive at 76 
months thereafter. One patient died of hepatocellular 
carcinoma without tracheal carcinoma recurrence. 
Two patients remained alive without recurrence 
for 53 and 78 months after resection. The median 
survival was 51.5 months (range, 30 - 119 months). 
Conclusion: Although the prognosis of primary 
tracheal carcinomas was relatively good, distant 
metastases tend to arise late after resection. 
Keyword: tracheal carcinoma
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MO18.08 SURGERY FOR LUNG CANCER 
IN OBESE PATIENTS, RISKIER OR NOT?
Binod Dhakal1, Sunitha Sukumaran2, George Hassler3, 
William Tisol3, Mario Gasparri3, Nicholas Choong2 
1Internal Medicine, Medical College Of Wisconsin/
United States Of America, 2Hematology/oncology, 
Medical College Of Wisconsin/United States Of 
America, 3Cardiothoracic Surgery, Medical College 
Of Wisconsin/United States Of America
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Conclusion: Pulmonary resection for patients with 
severe coronary disease were feasible. Strategy 
for preoperative anti-coagulant or platelet were 
successful. Further investigation is warranted 
especially for patients with recent coronary stent 
treatment, such as drug-eluting stent.
Keywords: pulmonary resection, Anti-coagulant 
Agent, Anti-platelet Agent, Coronary Disease
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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MO18.11 A CASE OF PRIMARY 
SYNOVIAL SARCOMA OF THE LUNG 
DIAGNOSED BY GENE ANALYSIS 
AFTER THE SURGICAL RESECTION OF 
CHONDROSARCOMA ARISING FROM 
SCAPULA
Yasuaki Kubouchi, Yuji Taniguchi, Yohei Yurugi, 
Yuzo Takagi, Tomohiro Haruki, Shinji Fujioka, Ken 
Miwa, Hiroshige Nakamura 
Thoracic Surgery, Tottori University Hospital/Japan
Background: Most synovial sarcomas arise around 
joints, and primary synovial sarcoma of the lung is 
rare. We report a patient who was diagnosed with 
primary pulmonary synovial sarcoma based on gene 
expression analysis.
Methods: The following is the case.
Results: Case: A 63-year-old male has received 
regularly check up by orthopedic surgen in our 
hospital for 12 years after curative resection of right 
scapula chondrosarcoma. He was introduced to 
our department because of an abnormal chest x-ray 
shadow in the right upper lung without respiratory 
symptoms. A chest CT revealed a 12×9mm tumor in 
size that has relatively clear margin in the right upper 
lobe. The patient was suspected of metastasis of 
chondrosarcoma to lung since tumor size increased 
to 13×11mm for 3 months, so we performed a wedge 
resection of the right lung by VATS (video assisted 
thoracic surgery). Intraoperative histopathology 
showed that the proliferation of fusiform cell 
was observed and denied lung cancer. Final 
histology revealed that the tumor was composed 
of densely proliferating uniform spindle-shaped 
or oval cells in fascicles. The tumor cells were 
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MO18.09 PULMONARY RESECTION FOR 
PATIENTS WITH SEVERE CORONARY 
DISEASE: HOW TO MANAGE 
PREOPERATIVE ANTI-COAGULANT OR 
ANTI-PLATELET AGENT
Yoshitaka Kitamura, Nobumasa Takahashi, 
Yoshikazu Miyasaka, Takamitsu Banno, Kohta 
Imashimizu, Kazuya Takamochi, Shiaki Oh, Kenji 
Suzuki 
General Thoracic Surgery, Juntendo University/
Japan
Background: The number of lung cancer patients 
with severe coronary disease is increasing. 
According to the developed coronary intervention, 
preoperative anti-coagulant or anti-platelet is 
frequently necessary for those. However, feasibility 
of pulmonary resection for such patients remains 
controversial and there are no guidelines at all. 
Methods: Retrospective study was conducted on 
754 patients who underwent pulmonary resection 
at our institute between February 2008 and May 
2010. Among them, 51 patients were complicated 
with severe coronary disease. The reason for anti-
coagulant or platelet medication was as follows; 
percutaneous coronary intervention in 28 patients 
(54.9%), atrial Àbrillation in 21 (41.2%), coronary 
artery bypass graft in 2 (3.9%). All those patients 
were systemically heparinized and discontinued to be 
medicated with anti-coagulant or anti-platelet agents 
for one week prior to surgery. Forty one patients 
(80.4%) had primary lung cancer, 7 (13.7%) had 
metastatic lung tumor, 2 (3.9%) had benign tumor 
and pneumothorax was one (2.0%). Thirty four 
patients (66.7%) underwent lobectomy, 5 (9.8%) 
segmentectomy and 12 (23.5%) wedge resection. 
Surgical outcome and feasibility of pulmonary 
resection of this strategy was investigated.
Results: There was no mortality, and surgical 
resections were completed for all patients without 
any lethal complications. There were no signiÀcantly 
differences between hepariniaed patients and the 
other non-heparinized 703 patients in operation time, 
intraoperative blood loss and the duration of chest 
drain placement ( 146 vs 150 min; p=0.657, 49 vs 72 
ml ; p=0.332, 3.3 vs 3.7 days; p=0.643, respectively). 
No perioperative cardiovascular events were found 
at all. One patient developed hemosputum on the 
operation day, resulting in conservative cure.
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appears to arise a wide range at presentation and the 
most common anatomic setting for myopericytoma 
is the skin and superÀcial soft tissues of distal 
extremities.2 In the past few years, a wider 
distribution is described, including the oral or nasal 
region, the trunk, the intravascular location and even 
the intracalvarium.2,3 This unusual tumor had hitherto 
not been reported in the lung. 
Methods: Here, we introduce an unusual case of 
pulmonary myopericytoma presented as multiple 
nodules in a 26-year-old man. Clinical presentation, 
radiological features and histopathologic Àndings of 
the patient are reported.
Results: A 25-year-old man presented with dry 
cough for Àve months. CT and MRI of the chest 
was notable for the bilateral, heterogeneously, 
multiple nodules(Figure 1). Open lung biopsy was 
performed. The microscopic examination of the 
mass showed that the lesions were composed of 
oval to spinal-shaped cells with a striking concentric 
arrangement of cells around numerous variably 
sized lesional blood vessels. Tumor cells were ill-
deÀned cytoplasmic membranes with eosinophilic 
cytoplasm. Immunostaining demonstrated an 
accentuated vascular proliferative pattern with 
CD31 and CD34 antibody which stained endothelial 
cells. The cells surrounding vascular lumina 
are strongly positive for vimentin and smooth 
muscle actin, but negative for desmin or S-100. 
Correlating the histopathological features with 
the immunohistochemical Àndings, a diagnosis of 
myopericytoma was established (Figure2).
immunohistochemically positive for vimentin, bcl-2 
protein and CD99 and partially for cytokeratin, AE1/
AE3 and EMA. From these examinations, although it 
was indicated synovial sarcoma or malignant solitary 
Àbrous tumor, we could not reach a deÀnitive 
diagnosis. Reverse transcription polymerase chain 
reaction (RT-PCR) performed on frozen sections 
demonstrated fusion gene transcripts of SYT-SSX 
(synaptotagmin- synovial sarcoma X). A deÀnitive 
diagnosis of synovial sarcoma of the lung was made. 
Reoperation was not performed, for the following 
reasons: (1) small tumor, (2) pleural lavage cytology 
during thoracotomy is negative (3) the metastases to 
hilar or mediastinal lymph node was not detected by 
preoperative diagnostic imaging. At present 5 months 
after surgery, there are no signs of recurrence.
Conclusion: Few cases of pulmonary 
carcinosarcoma after chondrosarcoma operation 
have been reported. In patients with past history of 
malignant disease, it is important to be distinguished 
from metastatic lung cancer preoperatively. Since 
diagnosis of spindle cell tumors by cytological 
examination alone is difÀcult, immunohistochemistry 
and genetic studies are necessary. Primary synovial 
sarcoma easily develops local recurrence and distant 
metastasis, so the prognosis has been reported to 
be poor. We must be very careful with follow-up in 
these cases.
Keyword: synovial sarcoma
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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MO18.12 MYOPERICYTOMAS 
PRESENTING AS MULTIPLE 
PULMONARY NODULES
Xiaolian Song1, Changhui Wang1, Yongwei Yu2 
1Department Of Respiratory Medicine, Shanghai 
Tenth People’s Hospital/China, 2Pathology 
Department, Changhai Hospital, Second Military 
Medical University/China
Background: Myopericytoma is a rare soft tissue 
tumors with a hemangiopericytoma-like vascular 
pattern. Histologically, it is characterized by a 
concentric proliferation of oval to spindle-shaped 
cells around vascular channels. Myopericytoma 
Copyright © 2011 by the International Association for the Study of Lung Cancer S637
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
was present in a conventional chest x-ray. CT 
scan showed the mass (95x88x98mm) in anterior 
mediastinum with invasion of the parietal pleura. No 
distant metastases were found.
Results: The diagnosis was performed by 
thoracoscopy. The pathology was mesenchymal 
sarcoma. The case was inoperable, therefore 
chemotheraphy was planned for the patient.
Conclusion: Radiation–induced sarcoma is a 
very rare complication of radiotherapy. It shows 
aggressive proliferation with a median survival of 
about 12 months. Early diagnosis can be possible 
because of tumor calciÀcation might be detectable 
even on the chest x-ray. Therefore calciÀcation seen 
on chest x-ray after RT should be a reason for further 
examination. In general, if the early diagnosis is 
done, surgical removal is often the only curative 
treatment.
Keyword: mesenchymoma, radiotherapy, thorax
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MO18.14 PRIMARY MEDIASTINAL 
SARCOMAS: AN ANALYSIS OF 
TREATMENT AND OUTCOMES
Matthew J. Bott1, Nicole Moraco2, Manjit Bains3, 
Robert Downey3, Valerie W. Rusch3, Samuel Singer2, 
James Huang3 
1Thoracic Surgery, Memorial Sloan-Kettering 
Cancer Center/United States Of America, 2Surgery, 
Memorial Sloan-Kettering Cancer Center/United 
States Of America, 3Thoracic Service, Department Of 
Surgery, Memorial Sloan-Kettering Cancer Center/
United States Of America
Conclusion: To the best of our knowledge, this is 
the Àrst report of myopericytoma that involves the 
pulmonary. The diagnosis of myopericytoma was 
made on the basis of the prominent morphological 
and immunoreactive Ànding. The differential 
diagnosis includes a series lobus intermedius tumors 
and other lung nodules, such as inÁammatory 
pseudotumor, tuberculosis, sarcoidosis, lymphoma, 
primarily lung cancer and metastatic tumor. 
Keywords: Pulmonary, Histopathology, 
Myopericytoma
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MO18.13 MALIGNANT 
MESENCHYMOMA OF THE CHEST 
WALL FOLLOWING RADIOTHERAPY 
FOR BREAST CANCER
Tugce K. Hurkal1, Ozkan Demirhan2, Zuleyha 
Bingol1, Ferah Ece1 
1Chest Diseases, Istanbul Bilim University Medical 
School/Turkey, 2Thoracic Surgery, Istanbul Bilim 
University Medical School/Turkey
Background: The carcinogenic effect of ionizing 
irradiation has been well known. A long interval 
(usually 10-20 years) between irradiation and 
development of cancer is characteristic of radiation – 
induced malignancy.
Methods: Our Case: Fifty three year old woman 
who had radiotherapy for breast cancer 13 years 
ago, developed a malignant mesenchymoma of 
the chest wall. The Àrst clinical symptom for this 
second malignancy was left sided chest pain which 
was progressively increasing and a regular opacity 
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well-differentiated liposarcoma associated with the 
best prognosis. Surgical resection has remained the 
mainstay of treatment and the beneÀt of adjuvant 
therapies is unclear. Further progress in such rare 
diseases will likely require multi-institutional 
collaboration.
Keywords: Sarcoma, mediastinum, survival, 
treatment patterns
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MO19.01 OMIT ELECTIVE NODAL 
IRRADIATION AND IRRADIATE 
POST- VERSUS PRE-INDUCTION 
CHEMOTHERAPY TUMOR EXTENT 
FOR LIMITED-STAGE SMALL CELL 
LUNG CANCER: AN INTERIM ANALYSIS 
OF A PROSPECTIVE RANDOMIZED 
NON-INFERIORITY TRIAL
Ming Chen1, Xiao Hu1, Yong Bao1, Li Zhang2, Yuan 
Y. Chen1, Ying Guo3, Kai X. Li4, Wei H. Wang5, Yuan 
Liu6, Han He7 
1Radiation Oncology, Sun Yat-sen University Cancer 
Center/China, 2Medical Oncology, Sun Yat-sen 
University Cancer Center/China, 3Good Clinical 
Practice, Sun Yat-sen University Cancer Center/
China, 4Radiation Oncology, People’s Liberation 
Army 180 Hospital/China, 5Radiation Oncology, 
Kiang Wu Hospital/China, 6Radiation Oncology, 
AfÀliated Tumor Hospital Of Guangzhou Medical 
College/China, 7Radiation Oncology, The First 
People’s Hospital Of Foshan City/China
Background: Controversies exist with regard 
to thoracic radiotherapy (TRT) target volumes 
for limited-stage small cell lung cancer (SCLC) 
and few prospective studies specially designed 
to solve this issue were available in the past two 
decades. This study compared the clinical outcomes 
between limited-stage SCLC patients who received 
TRT to different target volumes after induction 
chemotherapy.
Methods: Chemotherapy consisted of 6 cycles 
of etoposide and cisplatin (EP) administered 
intravenously at 21-day intervals. After 2 cycles of 
EP, patients were randomly assigned to receive TRT 
Background: Primary sarcomas of the mediastinum 
are rare tumors and limited data regarding their 
natural history have been published. We analyzed 
the treatment and outcomes of these tumors in a 
contemporary cohort of patients.
Methods: Retrospective review of a single 
institution experience to assess presentation, 
treatment, and outcomes in patients with primary 
mediastinal sarcomas. Data included demographics, 
treatment details, pathologic Àndings, recurrence 
patterns, and survival.
Results: During the period 1983 to 2009, 48 patients 
were seen at our institution for initial treatment 
of primary mediastinal sarcomas. The median 
age was 45 years (range 18-79 years) with a male 
predominance (60%). The majority of tumors 
(46/48, 96%) were symptomatic with pain (29%), 
dyspnea (25%), and cough (12.5%) as the most 
frequent chief complaint at presentation. The most 
common histologic subtypes were: liposarcoma 
(12, 25%), malignant Àbrous histiocytoma (7, 
15%), and synovial sarcoma (5, 10%). Surgery was 
the primary treatment modality in 90% of cases 
(n=43) and half of these patients some received 
adjuvant treatment post-operatively (chemotherapy 
12%, radiation 33%, both 5%). R0 resections were 
achieved in 51% of patients. Median follow-up for 
all surviving patients was 50.9 months (range 0.7 to 
244 months). Overall survival for the entire cohort 
was 35 months with 5- and 10- year survivals of 43% 
and 30%, respectively. Patients who were unable to 
undergo surgery or who were otherwise inoperable 
had signiÀcantly worse survival (p=0.0003). Low- 
grade tumors were associated with a signiÀcantly 
better survival than high-grade tumors (p=0.004). 
Survival was signiÀcantly different amongst the 
different histologies (p=0.0006), with liposarcoma, 
desmoid tumors, and synovial sarcoma having the 
longest median survivals (153 months, 85 months, 
and 61 months, respectively). Although liposarcomas 
had the longest median survival of the cohort, well-
differentiated tumors (median survival 153 months) 
were associated with signiÀcantly better survival 
(p=0.006) compared with the de-differentiated 
tumors (median survival 18 months). Tumor size, 
adjuvant treatment, and mediastinal location had no 
signiÀcant impact on outcomes.
Conclusion: Mediastinal sarcomas are a 
heterogenous group of rare tumors with a poor 
prognosis in general. Among the histologies, 
liposarcoma, synovial sarcoma, and desmoid 
tumors have a more favorable prognosis, with 
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MO19.02 PHASE II STUDY OF 
ACCELERATED HIGH-DOSE 
RADIATION THERAPY WITH 
CONCURRENT CHEMOTHERAPY FOR 
PATIENTS WITH LIMITED STAGE 
SMALL-CELL LUNG CANCER: FINAL 
RESULTS OF RTOG 0239
Ritsuko Komaki1, Rebecca Paulua2, David S. 
Ettinger3, Gregory M. Videtic4, Jeffery D. Bardley5, 
Bonnie S. Glisson6, Hak Choy7 
1Radiation Oncology, Unit 97, Ut MD Anderson 
Cancer Center/United States Of America, 2Statistics, 
Rtog/United States Of America, 3Medical Oncology, 
Johns Hopkins Hospital/United States Of America, 
4Cleveland Clinic/United States Of America, 
5Radiation Oncology, Washington University/United 
States Of America, 6Ut MD Anderson Cancer Center/
United States Of America, 7Ut Southwest/United 
States Of America
Background: The purpose of this study was to 
evaluate the effects of accelerated, high-dose 
thoracic radiotherapy (TRT) given concurrently with 
etoposide and cisplatin on overall survival (OS), acute 
esophageal toxicity, and local control for patients with 
limited-stage small cell lung cancer (LSCLC). 
Methods: Patients with LSCLC and good 
performance status received TRT to 61.2 Gy over 5 
weeks in once-daily 1.8-Gy fractions (fx) on days 
1-22 followed by twice-daily 1.8-Gy /fx on days 
23-33. Cisplatin (60 mg/m2 IV) and etoposide (120 
mg/m2 IV) were given on days 1 and 22 of TRT 
and etoposide (120 mg/m2 IV or 240 mg/m2 p.o.) 
on days 2 & 3 and 23 & 24; 2 cycles of adjuvant 
chemotherapy were given on days 43-45 and 64-66. 
Patients achieving complete response were offered 
prophylactic cranial irradiation (PCI). The primary 
endpoint was OS at 2 years; secondary endpoints 
were progression-free survival (PFS) and OS rates 
at 1 year, median survival times, and rates of acute 
esophagitis and treatment-related deaths (CTC v2.0), 
response (RECIST1.0), and local and distant failure. 
Results: Seventy-two patients were accrued between 
June 2003 and May 2006; 71 were eligible for 
analysis (median age 63, 52% female, 58% Zubrod 
0). Median follow-up time was 19.0 months for 
all patients (54.6 months for living patients). The 
2-year OS rate was 36.6% (95% conÀdence interval 
[CI] 25.6%-47.7%); 1-year OS, 77.5% (95% CI 
65.9%-85.5%); 1-year PFS, 42.3% (95% CI 30.7%-
to either the post- or pre-chemotherapy tumor extent 
as study arm or control. Elective nodal irradiation 
(ENI) was omitted for both arms. Forty-Àve 
Gy/30Fx/19d TRT was administered concurrently 
with cycle 3 chemotherapy. Prophylactic cranial 
irradiation was administered to patients achieved 
complete remission. This study was designed as 
a prospective randomized non-inferiority trial. 
An interim analysis was planned when the Àrst 80 
patients had been followed for at least 6 months, for 
consideration of potentially inferiority in the study 
arm.
Results: Forty-two and 43 patients were randomly 
assigned to study arm and control respectively. 
Thirty-one patients remained alive at the time of 
analysis, with a median follow-up of 29.5 months 
(6.4-97.9 months). Four patients of the study arm and 
1 patient of the control developed distant metastasis 
after induction chemotherapy were not included in 
analysis for local control. The local recurrence rates 
were 31.6% (12/38) in the study arm and 28.6% 
(12/42) in control respectively (P = .81). The isolated 
nodal failure (INF) rates were 2.6% (1/38) and 2.4% 
(1/42) respectively (P = 1.00). All INF sites were 
in the ipsilateral supraclavicular fossa. Mediastinal 
N3 was the only factor to predict INF (P = .004, 
OR = 29.33, 95% CI, 2.94-292.38). The median 
survival time was 22.1 months in the study arm (95% 
CI, 16.6-27.6 months) and 25.4 months (95% CI, 
20.4-30.4 months) in control, one to 3-year overall 
survival (OS) rates were 80.6%, 42.2%, 36.2% and 
78.9%, 52.2%, 36.4% respectively (P = .54).
Conclusion: The preliminary results indicated that 
irradiate the post-chemotherapy tumor extent and 
omit ENI did not decrease local-regional control, 
and the OS difference was not statistically signiÀcant 
between the two arms. Further investigation is 
warranted.
Keywords: limited-stage, combined modality 
treatment, Lung cancer, small cell, radiation target 
volume
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Background: Small cell lung cancer (SCLC) 
accounts for about 10-15% of all lung cancer cases, 
with only one third presenting with limited stage 
(LS). Combination of chemotherapy (CT) and 
chest radiotherapy (RT) has improved survival at 
2 and 3 years but the optimal timing and duration 
of RT remains controversial. The objective of this 
individual patient data meta-analysis was to assess 
the timing of RT (early versus late) on the survival of 
patients in SCLC. 
Methods: Trials of combined CT-RT for LS-SCLC, 
with accrual between 1969 and 2006, comparing 
early (before days 49) versus later RT or short versus 
longer duration RT were eligible. Patients with good 
performance status (WHO 0-2) and who received 
Àrst line therapy were included. Primary endpoint 
was overall survival (OS). Progression-free survival 
(PFS), and acute severe toxicities were also studied. 
CT compliance by arm was taken as the percentage 
of the planned number of cycles that the patients 
actually received. Pre-speciÀed trial classiÀcation 
was performed to take into account the differences 
of CT compliance between arms. Compliance was 
considered different if the CT compliance rates 
between the two arms were  10%, otherwise it was 
considered to be similar. Intent-to-treat analysis 
based on Peto-Àxed effect model was used. 
Results: There were nine trials including 2,304 
patients with a 10-years median follow-up. PFS 
data were not available for 2 trials (513 patients). 
No statistically signiÀcant effect on OS and PFS 
was seen between early and late RT (HR=1.00 
[0.91-1.09] for OS (p=0.92); heterogeneity test 
between trials p=0.006; HR=0.93 [0.84-1.02] for 
PFS (p=0.14); heterogeneity test p=0.07). For OS, 
a HR=0.79 [0.69-0.91] and 1.19 [1.05-1.34] were 
estimated in trials with similar and different CT 
compliance rates, as deÀned above (interaction 
test p<0.0001). There was an absolute beneÀt at 3 
and 5-years (5.7% and 7.7%) in favour of early RT 
in trials with similar CT compliance, but in those 
trials were the two arms showed different rates of 
compliance, survival was worse in early RT arm 
(- 3.8% and - 2.2% at 3 and 5 years). Similar results 
were observed for PFS (HR=0.81 vs. 1.12 p=0.0024) 
and after exclusion of patients dying before 6 months 
for both endpoints (test of interaction, OS, p=0.0002, 
53.4%); and median PFS time was 9.9 months 
(95% CI 7.9-12.4 months). Thirteen patients (18%) 
experienced acute severe (grade 3+) esophagitis, 
and three patients (4%) died of treatment-related 
causes( One each : Neutropenic Sepsis, Neutropenic 
Pneumonia & Pericardial Effusion). At 2 months 
after chemoradiation, 41% had a complete response 
and 39% a partial response. Fourteen patients (20%) 
experienced local failure (LF), 31 (44%) distant 
metastasis (DM), and 5 (7%) both LF and DM. 
Nine (12.7%) patients experienced brain metastases. 
Forty-three patients received PCI, 22 of whom 
received 25Gy in 10fx. There was no signiÀcant 
difference in OS between PCI vs. no PCI, although 
the number was small. 
Conclusion: RTOG 0239 showed a 2-year OS of 
36.6% which did not reach to the goal of 47%. 
The treatment was well tolerated with acceptable 
toxicities. Main cause of failure was DM. This 
protocol is now one of three arms of a prospective 
randomized trial of chemoradiation for LSCLC 
(RTOG 0538/CALGB 30610). 
Keyword: LSMCLC, Accelerated TRT with 
Chemotherapy
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MO19.03 A META-ANALYSIS OF 
RANDOMISED TRIALS USING 
INDIVIDUAL PATIENT DATA ON THE 
TIMING OF CHEST RADIOTHERAPY 
IN PATIENTS WITH LIMITED STAGE 
SMALL CELL LUNG CANCER
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in the West Anglian region were retrospectively 
searched for patients with a histological diagnosis 
of SCLC made between 2005 and 2009. Clinical 
information on staging, treatment, incidence and 
timing of brain metastases and date of death was 
gathered. Data was analysed using GraphPad Prism 
4.0 and Instat 3.0 (). 
Results: 425 patients with a histological diagnosis 
of SCLC were identiÀed between 2005-2009. The 
male to female ratio was 60:40 and median age 
was 68. 294 patients (69%) had extensive stage 
(ES) disease and 131 (31%) had limited stage (LS) 
disease. Overall survival was 14.9 months for LS 
versus 3.6 months for ES patients (p<0.0001). 
67% of all patients received chemotherapy, 87% 
(114/131) with LS compared to 58% (170/294) with 
ES disease. Median survival for LS disease receiving 
chemotherapy was 16.7 months versus 7.3 months 
without. For ES disease, survival with chemotherapy 
was 8.4 months versus 0.8 months without. PCI after 
chemotherapy was given to 65% (74/114) patients 
with LS disease and 27% (41/154) ES patients 
without brain metastases at diagnosis. Regional 
practice for delivery of PCI in ES patients changed 
in June 2007 in line with the EORTC 08993-2293 
trial data which showed a improved overall survival 
with PCI; prior to this trial, only 11% (8/72) 
ES patients were given PCI after chemotherapy 
compared to 41% (33/80) subsequently (p<0.0001). 
Overall survival for LS patients receiving PCI was 
19.9 months and 12.0 months without (p=0.009). 
Overall survival was 12.6 months in patients with ES 
disease who received PCI and 7.0 months without 
(p=0.0007). In total 17% (73/425) patients developed 
symptomatic brain metastases with 7% (30/425) 
presenting at diagnosis. The brain was not routinely 
imaged in asymptomatic patients. Brain metastases 
developed after chemotherapy in 11% (13/115) 
patients receiving PCI compared to 18% (28/153) 
patients not receiving PCI (p=0.126). 
Conclusion: The outcome data from this multicentre 
study compares well with published data on survival 
for SCLC and incidence of brain metastases. This 
study supports the use of PCI in extensive as well 
as limited stage patients and shows how a change in 
regional practice can improve outcomes. However, 
for any individual, brain metastases can still occur 
after PCI and conversely, may not develop even 
if PCI is not given. We are now investigating 
whether a subgroup of SCLC patients most at risk 
for developing brain metastases can be identiÀed in 
advance, using novel magnetic resonance imaging 
PFS, p=0.056). Trials giving hyperfractionated 
RT (vs. standard RT), and trials with concomitant 
platinum (vs. those without) showed higher effect 
on survival (test of interaction, p=0.005 and 
p=0.01 respectively). We have observed more 
severe anaemia (337 events), HR=1.38 [1.07-1.79], 
oesophageal (226 events), HR=1.85 [1.39-2.45] and 
cardiac (26 events), HR=2.79 [1.28-6.04] toxicity in 
early RT. 
Conclusion: Differences in CT compliance between 
arms within trials mostly explains the heterogeneity 
of OS between the trials. This meta-analysis shows 
promising results for early RT in improving the 
5-years survival in trials where CT compliance is 
similar in both arms.
Grants from PHRC and LNCC.
Keyword: Meta-analysis, Radiotherapy timing, 
Chemotherapy compliance, SCLC
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MO19.04 MULTICENTRE STUDY OF 
OVERALL SURVIVAL, INCIDENCE 
OF BRAIN METASTASES AND USE 
OF PROPHYLACTIC CRANIAL 
IRRADIATION IN PATIENTS WITH 
SMALL CELL LUNG CANCER FROM 
2005-2009.
Niki Ainsworth1, David Saunders2, Lavinia Magee3, 
Ramesh Bulusu1, Kate Fife1, Yvonne Rimmer1, 
Kathryn Waite1, David Greenberg4, Susan V. Harden1 
1Department Of Oncology, Cambridge University 
Hospitals NHS Foundation Trust/United Kingdom, 
2Cambridge University Medical School/United 
Kingdom, 3Papworth Hospital NHS Foundation 
Trust/United Kingdom, 4Eastern Cancer Registration 
And Information Centre/United Kingdom
Background: Small cell lung cancer (SCLC) 
commonly metastasises to the brain and is associated 
with a poor prognosis. Prophylactic cranial irradiation 
(PCI) after chemotherapy was recently shown to 
improve overall survival in extensive as well as 
limited stage SCLC. This led to a change in practice 
in 2007, to offer PCI to both extensive and limited 
stage SCLC patients who responded to chemotherapy. 
Survival data and the effect of PCI on clinical 
outcomes for patients in the West Anglian region, 
receiving radiotherapy in Cambridge, were assessed. 
Methods: Eastern Cancer Registry and Information 
Centre (ECRIC) data and multiple hospital databases 
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to treatment sequence & was found in pts who 
received concurrent TRT&PCI. Dose-fractionation 
could only be compared for LSCLC pts & 
25Gy/10 was associated with better survival than 
30Gy/15(HR=0.72,p=0.05). 
Conclusion: PCI was associated with a signiÀcant 
survival beneÀt for both ESCLC&LSCLC pts 
who had stable disease or a better response to 
chemotherapy+/-TRT. Dose-fractionation appears 
important. PCI’s use was also associated with an 
increase in overall & speciÀc grade 3+ AE rates.
Keywords: Small cell lung cancer, prophylactic 
cranial irradiation, toxicity, survival
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MO19.07 A PHASE II STUDY OF 
AMRUBICIN AND TOPOTECAN 
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DISEASE SMALL-CELL LUNG CANCER: 
OKAYAMA LUNG CANCER STUDY 
GROUP TRIAL 0401
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Background: Chemotherapy is a mainstay in the 
treatment of extensive-disease small-cell lung cancer 
(ED-SCLC), although the survival beneÀt remains 
modest. We conducted a phase II trial of amrubicin 
(a topoisomerase II inhibitor) and topotecan (a 
topoisomerase I inhibitor) in chemotherapy-naïve 
and relapsed SCLC patients.
Methods: Amrubicin (35mg/m2) and topotecan 
(0.75mg/m2) were administered on days 3–5 and 
1–5, respectively. The objective response rate (ORR) 
was set as the primary endpoint, which was assessed 
separately in chemotherapy-naïve and relapsed cases.
Results: Fifty-nine patients were enrolled 
(chemotherapy-naïve 31, relapsed 28). The ORRs 
were 74% and 43% in the chemotherapy-naïve 
and relapsed cases, respectively. Survival data 
were also promising, with a median progression-
free survival time and median survival time of 5.3 
and 14.9 months and 4.7 and 10.2 months in the 
chemotherapy-naïve and relapsed cases, respectively. 
techniques within the UK National Cancer Research 
Institute (NCRI) Lung Clinical Studies Group 
portfolio-approved CLUB-01 study. 
Keywords: SCLC, PCI, brain metastases
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Background: This meta-analysis was performed to 
evaluate the results of PCI in SCLC patients(pts). 
739 pts with stable disease or better following 
chemotherapy+/-thoracic RT(TRT) were included to 
examine the potential advantage of PCI in a wider 
spectrum of pts than generally participate in PCI trials.
Methods: 318 pts with extensive SCLC(ESCLC) 
& 421 pts with limited SCLC(LSCLC) participated 
in 4 NCCTG phase II trials. 459 pts received 
PCI(30Gy/15 or 25Gy/10)& 280 did not. Survival 
and Acute Events(AEs) were compared.
Results: The 1 & 3-year survival rates were 73% 
& 20% for PCI pts vs 52% & 6% for no-PCI pts(p< 
0.0001). This difference with PCI ((HR=0.61 (95% 
CI: 0.52-0.72), p=0.0007)) was still signiÀcant 
in both ESCLC & LSCLC pts in multivariate 
analyses adjusting for age, performance status, 
gender, stage, & number of metastatic sites. There 
were signiÀcantly more grade 3+AE’s associated 
with PCI(64%) compared to no PCI(50%)
(p=0.0096). AE’s signiÀcantly associated with PCI 
were: alopecia, anemia, esophagitis & lethargy. 
The esophagitis Ànding appeared to be related 
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every 8 weeks and remained on therapy until disease 
progression or unacceptable toxicity. The trial used 
a two-stage design to assess the objective response 
rate (ORR) in both SR (H
1
 30%, Ơ.10, ơ.20) and RR 
cohorts (H
1
 20%, Ơ.05, ơ.20).
Results: 40 pts with SR disease were enrolled over 
11 months. The RR arm is completing enrollment. 
Pt characteristics of the SR pts: median age 62 
years, female 48%, ECOG 0-1 95%. Pts received 
a median of 4 cycles (range 1-10) of NK012. The 
ORR assessed in 37 SR pts was 22% including 
2 complete responses; the disease control rate 
(DCR=ORR+stable disease) was 68%. Fifteen SR 
pts remained on treatment beyond 4 cycles. Survival 
analyses are in progress. NK012 was well-tolerated 
with the following grade 3/4 toxicities (> 5%): 
neutropenia (44%, 1 pt with febrile neutropenia), 
thrombocytopenia (13%), anemia (5%), diarrhea 
(8%), and no treatment-related deaths.
Conclusion: NK012 was active in pts with sensitive 
relapsed SCLC with a 22% ORR and a 68% DCR. 
Treatment was generally well tolerated with low 
rates of serious thrombocytopenia, anemia, and 
diarrhea. Neutropenia was manageable and rarely 
associated with fever. A NK012 and platinum 
combination phase I study is in progress.
Keywords: Lung neoplasms, recurrence, Carcinoma, 
Small Cell, Topoisomerase I inhibitors
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MO19.09 PATIENT OUTCOME AND 
EXPLORATORY ANALYSIS FROM A 
PHASE 2A STUDY OF NAVITOCLAX 
(ABT-263) IN PATIENTS WITH 
ADVANCED/RELAPSED SMALL CELL 
LUNG CANCER (SCLC)
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Even refractory-relapsed cases responded to the 
treatment favorably (27% ORR). The primary 
toxicity was myelosuppression with grades 3 or 
4 neutropenia in 97% of the patients, which led 
to grades 3 or 4 febrile neutropenia in 41% of the 
patients and two toxic deaths.
Conclusion: This phase II study showed the 
favorable efÀcacy and moderate safety proÀles of 
a topotecan and amrubicin two-drug combination 
especially in relapsed patients with ED-SCLC.
Keywords: Small-cell lung cancer, SCLC, 
Topotacan, Amurubicin
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WITH RELAPSED SMALL-CELL LUNG 
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Background: NK012 is a polymeric micelle 
designed to release a slow and sustained 
concentration of SN-38, the active metabolite of 
irinotecan. Safety and antitumor activity have been 
demonstrated in Phase I studies in patients (pts) with 
refractory tumors including small-cell lung cancer 
(SCLC). A phase II trial was performed to evaluate 
NK012 in pts with sensitive relapsed (SR) and 
refractory relapsed (RR) SCLC.
Methods: Pts with relapsed SCLC following one 
systemic regimen for extensive-stage SCLC or 
chemoradiation for limited-stage SCLC were eligible. 
Pts had measurable disease, an ECOG performance 
status (PS) of 0-2, and adequate organ function. Pts 
with untreated brain metastases or prior irinotecan 
were excluded. NK012 was given IV over 30 minutes 
once every 28 days at a dose based on pretreatment 
UGT1A1 genotyping: 28 mg/m2 (wild-type (wt)/wt 
and wt/*28) or 18 mg/m2 (*28/*28). Pts were restaged 
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(R=0.93) was conÀrmed. Exploratory analyses 
using Cox Proportional Hazard Model for overall 
survival demonstrated a positive relationship with 
the hazard of death for neuron-speciÀc enolase 
NSE (p=0.0028), and circulating tumor cell (CTC) 
number (p=0.016) at baseline. NSE, progastrin 
releasing peptide (Pro-GRP) and CTC concentrations 
after 14 days on therapy were lower in responders 
(deÀned as conÀrmed PR or SD > 4 cycles) vs 
non-responders (p=0.029, 0.0014, and 0.016 
respectively), Pro-GRP concentrations after 35 
days were lower in responders vs non-responders 
(p=0.002), and correlated with lack of progression. 
Conclusion: Bcl-2 targeting by navitoclax is well 
tolerated, but demonstrates modest single-agent 
activity against advanced and recurrent SCLC. 
Correlative analyses suggest several putative 
biomarkers of clinical beneÀt. Based on preclinical 
synergy observed in multiple models, and the 
results of this single agent study, a phase 1 trial of 
navitoclax with Àrst-line combination chemotherapy 
for SCLC has been initiated.
Keywords: Navitoclax, Phase 2 Trial, SCLC, 
apoptosis
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MO19.11 BENEFITS AND RISKS 
OF USING ERYTHROPOIESIS-
STIMULATING AGENTS (ESAS) IN NON-
SMALL CELL LUNG CANCER (NSCLC) 
AND SMALL CELL LUNG CANCER 
(SCLC) PATIENTS: RESULTS FROM 
STUDY-LEVEL AND PATIENT-LEVEL 
META-ANALYSES OF CONTROLLED 
ESA TRIALS IN LUNG CANCER
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Background: The safety of ESAs in oncology 
patients is a topic of ongoing debate. We performed 
study-level and patient-level meta-analyses of 
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Background: Small cell lung cancer (SCLC) is an 
aggressive malignancy with few effective treatment 
options after 1st-line therapy. Bcl-2 is a critical 
regulator of apoptosis that is overexpressed in the 
majority of SCLC. Navitoclax is a potent and selective 
oral inhibitor of anti-apoptotic bcl-2 family members. 
We conducted a phase 1/2a study of navitoclax, which 
in the phase I trial demonstrated antitumor activity and 
an acceptable safety proÀle in patients with SCLC and 
other solid tumors. This report summarizes the clinical 
outcome and exploratory molecular correlative 
analyses from the completed phase 2 study. 
Methods: This was an open-label, multicenter phase 
2a trial assessing safety and preliminary efÀcacy of 
navitoclax in patients with advanced/relapsed SCLC. 
Enrolled patients received oral navitoclax at 325 mg 
daily, following an initial lead-in of 150 mg daily for 
7 days, on a 21-day cycle until progressive disease or 
intolerable toxicity. Key eligibility criteria included 
measurable SCLC and ECOG status < 1. Endpoints 
include tumor response by RECIST, progression-
free survival, time to progression, overall survival, 
and ECOG performance status. Tumor assessments 
were performed at the end of every 2 cycles. Adverse 
events (AE) were graded by NCI CTCAE V3.
Results: 39 patients (median age, 64 yr [45-78]; 
54% female; ECOG status  1) were enrolled 
in the phase 2 study; 5 had limited and 34 had 
extensive disease. 54% of patients received  2 prior 
treatments (median 2 [1-8]). The most common 
treatment emergent toxicities at any grade were 
thrombocytopenia (64%), nausea (59%), fatigue 
(56%), diarrhea (54%) and vomiting (41%). 
The most common  grade 3 toxicities included 
thrombocytopenia (44%) and neutropenia (13%). 
Partial response was observed in one (2.7%) patient 
and stable disease in 9 (24%). Median PFS was 
46 days, and median OS was 96 days. A strong 
association between serum pro-gastrin-releasing 
hormone (GRP) and tumor Bcl-2 gene copy number 
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Conclusion: An excess in the odds of mortality 
was not observed for ESA-treated patients in the 
study-level analyses of CIA studies; an increased 
risk of death or progression-related endpoints was 
not observed when patient-level data for DA were 
summarized across studies. ESA use was associated 
with fewer transfusions.
Keywords: meta-analysis, SCLC, NSCLC, mortality
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CIRCULATING TUMOR CELLS (CTCS) 
IN PATIENTS WITH SMALL CELL LUNG 
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Background: The limited availability of tissue 
in SCLC has been a barrier to research and care. 
New approaches are needed for this malignancy to 
aid in monitoring treatment response, assess risk, 
and serially interrogate tumor genotypes in a non-
invasive manner. CTCs represent a source of tissue 
in SCLC that would enable us to accomplish these 
tasks.
Methods: We are conducting a phase II trial of 
temozolomide for patients with relapsed sensitive 
or refractory SCLC. Using the Veridex CellSearch 
SystemTM , CTCs are being enumerated before 
initiating temozolomide and at the time of repeat 
imaging (at four weeks, eight weeks, and every eight 
weeks thereafter). The number of CTCs is correlated 
controlled ESA trials in lung cancer to evaluate the 
impact of ESA use on outcomes in patients with 
NSCLC and SCLC.
Methods: Nine randomized, controlled studies 
in lung cancer were identiÀed by literature search 
for inclusion in the study-level analysis (2319 
patients total; 1179 ESA-treated, 1140 control). 
Eight studies were conducted in patients with 
chemotherapy-induced anemia (CIA) and 1 in 
NSCLC patients with anemia of cancer (AoC). Of 
the 8 CIA trials, 5 had SCLC patients (581 ESA-
treated, 545 control), 2 had NSCLC patients (409 
ESA-treated, 400 control), and 1 trial had both 
SCLC and NSCLC patients (156 ESA-treated, 158 
control). Because of differences in studies, random 
effects models were used to estimate overall effects; 
data from the AoC study were not combined 
with CIA studies but are provided separately. 
For patient-level meta-analysis, data from four 
placebo-controlled darbepoetin alfa (DA) studies 
of SCLC patients (n = 714) and NSCLC patients 
(n = 295) with CIA were analyzed. Mortality, 
progression-related endpoints, and transfusions 
were summarized in both analyses; the patient-level 
meta-analysis also summarized adverse events 
(AEs) and fatigue.
Results: Study-level analysis: odds ratio 
(OR) for death in CIA studies was 0.87 (95% 
conÀdence interval [CI], 0.68 to 1.12). The OR 
for progression-related endpoints in 5 CIA studies 
with progression data was 0.84 (0.65 to 1.09). 
The OR for transfusion incidence in CIA studies 
was 0.34 (0.28 to 0.41). Patient-level analysis: 
median survival was 41 weeks for the DA arms 
and 38 weeks for placebo arms; the hazard ratio 
for death was 0.90 (0.78 to 1.03). Overall, 87% 
of control and 84% of DA patients progressed 
during treatment or follow-up. AEs summarized 
included thromboembolic events (DA 11%, placebo 
7%), cerebrovascular disorders (both groups 
4%), pulmonary edema (both groups  1%), and 
pulmonary embolism (both groups  2%). From 
week 5 to end-of-study, transfusions occurred in 
19% of DA patients and 43% of placebo patients. A 
3-point improvement in FACT-F score occurred in 
54% of DA patients and 50% of placebo patients.
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Background: Although it has been generally 
accepted that the standard treatment for limited 
disease (LD) small cell lung cancer (SCLC) is 
chemoradiation, several small series have reported 
favorable survival outcomes in patients who 
underwent surgical resection. One recent study using 
a large population-based database in the US (SEER) 
demonstrated the use of surgery in selected patients 
with LD-SCLC was associated with improved 
survival outcomes. However, the effective therapies 
for patients with SCLC arising from the peripheral 
lung have yet to be determined. Thus we analyzed 
the date of those patients so as to elucidate the 
clinical features and Ànd promising design for future 
prospective trials. 
Methods: We retrospectively evaluated the clinical 
courses of 25 patients with peripheral SCLC who 
underwent surgery in our institute from August, 1987 
through February, 2010. 
Results: Of the 25 patients, 24 were men and the 
average age was 66 (range, 47-82). Median smoking 
index was 1,000 (500-2,400). Average tumor 
diameter was 2.5 cm (0.7-11.5). Average serum 
level of speciÀc tumor markers such as pro-gastrin-
releasing peptide (ProGRP) and neuron-speciÀc 
enolase (NSE) were 35 pg/ml (17.2-763) and 8.2 
ng/ml (5-12.3), respectively. Sixteen patients (64%) 
were diagnosed using bronchoscopy. Pathological 
study demonstrated that 6 patients were diagnosed 
as having combined SCLC (4 had adenocarcinoma 
component, 1 had large cell carcinoma, and 
another 1 had large and squamous cell carcinoma). 
Twenty one patients underwent lobectomy and 
another 4 underwent pneumonectomy. Clinical 
stage (UICC TNM classiÀcation ver. 7) of IA/
IB/IIA/IIB/IIIA/IIIB was 13/1/4/1/3/3, and 
with clinical variables, including type of relapse 
(sensitive or refractory), line of treatment (second 
or third) and sites of metastases; radiographic 
response; and survival. 
Results: To date, 39 patients have had blood 
evaluated for CTCs before and after temozolomide. 
Prior to starting therapy, the number of CTCs ranged 
from zero (0) to 929: 7 patients had 0 CTCs detected 
(18%); 13 had between 1 and 4 CTCs (33%); and 19 
had  5 CTCs detected (49%). The number of CTCs 
is higher in patients with liver metastases (21% < 
5 CTCs vs 79%  5 CTCs, p<0.001). Patients with 
new sites of metastases have signiÀcantly higher 
numbers of CTCs (60%  5 CTCs), compared to 
those that progress at pre-existing sites of disease 
(100% < 5 CTCs), p=0.008. At the end of cycle 
1, the change in number of CTCs is correlated 
to RECIST response (p=0.041). Increased CTCs 
at the end of cycle 1 are associated with worse 
overall survival, compared to stable or decreased 
CTCs (median: 5 vs 8 months, p=0.008). At 
disease progression with temozolomide, high CTC 
numbers ( 5) are associated with worse overall 
survival (median: 3 months), compared to low CTC 
numbers (median survival, not reached), p=0.003. 
At baseline, the number of CTCs is not predictive 
of response to treatment, nor associated with 
progression-free and overall survival. No signiÀcant 
correlations have been found between patient 
characteristics (gender, age, Karnofsky performance 
status, response to Àrst line therapy, previous lines 
of treatment) and baseline CTCs. For patients with 
brain and bone metastases, numbers of CTCs are 
similar to those without metastases at these sites. 
Conclusion: CTCs can be routinely enumerated 
in patients with SCLC during the course of 
treatment using the Veridex CellSearch System TM. 
A signiÀcantly higher number of CTCs is found 
in patients with liver metastases and those that 
progress at new sites. Increased CTCs at the end of 
cycle 1 and upon disease progression are associated 
with a poorer prognosis.
Keywords: Veridex CellSearch System, circulating 
tumor cells, Small cell lung cancer, Temozolomide
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Methods: As of February 2002, a concurrent CRT 
protocol was launched for patients with conÀrmed 
diagnosis of SCLC-LD. All patients treated in 
accordance with the protocol were reviewed. 
LD staging was documented by using computed 
tomography (CT) scan of the chest, upper abdomen, 
and brain and, in most cases, 18F-deoxyglucose 
positron emission tomography (PET). The CRT 
protocol consisted of thoracic radiotherapy delivered 
up to a dose of 50 Gy in daily fractions of 2 Gy, 
starting concurrently with the second of four cycles 
of platinum-based chemotherapy (cisplatin 60 mg/
m2 d1, Q3w and etoposide 120 mg/m2 d1-3, Q3w). 
Radiotherapy was given using IF-RT, targeted to 
the tumor, PET positive nodes and nodes >1cm in 
smallest diameter on CT-scan. Response after CRT 
was evaluated with CT-scan. Patients with a (near) 
complete response (nCR) received prophylactic 
cranial irradiation (PCI) up to 30Gy/2Gy within 6 
weeks after completion of CRT. 
Results: Between 2/2002 and 2/2009, 53 patients 
were treated according to this CRT protocol: 
female/male 15/38; median age: 58 years (range 
39-72); clinical TNM: cT1-4N0-3M0. Pathology 
was obtained using bronchoscopy/TBNA (72%), 
mediastinoscopy (26%) or thoracotomy (2%). PET-
staging was performed in 41/53 patients (77%): 33 
isolated PET, 8 PET-CT. CRT was given according 
to protocol in 50 patients, 2 received cisplatin-
pemetrexed as Àrst chemotherapy cycle, 1 started 
radiotherapy with the 3rd chemotherapy cycle. 
Median time between start of treatment and end 
of radiotherapy was 59 days (range 53-73). Of the 
32 patients in nCR, 30 received PCI 30Gy/2Gy, 
2 of them 30Gy/3Gy. Ten out of 21 patients in 
partial remission (PR) received PCI (8: 30Gy/2Gy; 
1:30Gy/3Gy; and 1: 20Gy/4Gy). Of the total group, 
20 patients did not relapse/progress. In the remaining 
33 patients, site of Àrst relapse/progression was loco-
regional in 10, distant in 15 and both combined in 8. 
Of the primary loco-regional relapses, 3 were in-Àeld 
(2 were salvaged by surgery) and 3 partially in- and 
out-of-Àeld. Only one patient developed an isolated 
out-of-Àeld relapse. Three PR patients progressed 
loco-regionally before developing metastases. After a 
median (mean) follow-up of 24 (38) months, median 
overall and progression-free survival were 28,3 and 
26 months, respectively. Overall survival at 1, 2 and 
5 years was 81,1%, 58,4% and 40,6%. At the same 
time points, respectively 85,5%, 63,1% and 52,6% 
of patients were free of loco-regional recurrence, 
respectively. 
pathological stage of IA/IB/IIA/IIB/IIIA/IIIB/IV was 
10/1/3/1/6/2/1, respectively. Adjuvant or neoadjuvant 
chemotherapies all of which included platinum 
compound were initiated for 19 patients (76%), 
and the average number of chemotherapies was 
2.7. All but one patient who received neoadjuvant 
chemotherapy showed at least partial remission. 
After neoadjuvant chemotherapy, 1 patient archived 
complete remission and 1 was deÀned as having 
pathological down staging from IIIA to IA. The 
primary lesion, mediastinal lymph node, brain and 
bone were the sites of major recurrence. Progression 
free survival and overall survival were 55.7 and 
73.7 months, respectively. Subgroup analyses 
demonstrated that survival of the patients with 
c-stage IA was statistically longer than that of other 
stages (p=0.023). 
Conclusion: Patients with peripheral SCLC showed 
favorable prognosis, suggesting the potentiation 
of combined modalities including surgery with 
chemotherapy. These Àndings might provide 
valuable information for the management of the 
patients with peripheral SCLC. We are discussing 
our present study by comparing with previous reports 
and proposing several designs of future prospective 
trial.
Keywords: Surgery, Chemotherapy
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Background: To evaluate, in a tertiary referral 
center, the results of CRT using IF-RT in SCLC-LD 
patients in terms of loco-regional tumor control, 
survival and toxicity. 
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Tumor histology was limited to either squamous cell 
carcinoma (SC) or adenocarcinoma (AC). Five tumor 
groups based on the 7th edition TNM lung cancer 
staging system (T1a  2cm, T1b > 2cm but  3cm, 
T2a > 3cm but  5cm, T2b > 5cm but  7cm and T3 
> 7cm ) with clinical, demographic and tumor speciÀc 
variables were analyzed to determine which variables 
inÁuenced survival.
Results: Overall survival was reduced in larger 
sized T3, T2a, and T2b subtypes compared with 
the smaller subtypes of T1a and T1b (P < 0.001). A 
higher proportion of male patients had T3 disease 
(74%, compared to 43.4% in T1a and 53.1% in T2b; 
P< 0.001). All tumor subtypes tended towards right 
sided laterality (58%) and were predominately grade 
II/II (88%). Larger tumors were more likely to be SC 
(T1a=14.5%, T1b= 20.65%, T2a=26.5%, T2b=35.5% 
and T3= 50%; p<0.001), while smaller tumors were 
more likely to be AC (T1a= 85.5%, T1b=79.4%, 
T2a=73.5%, T2b=64.5%, and T3=50%; p <0.001). 
Survival estimates were found to correlate with tumor 
size, with worse survival in T3, followed by T2b, T2a, 
and then T1b and T1a (Figure 1). After adjusting for 
important relevant confounders, T1a (Hazard Ratio 
[HR) 0.53, 95% conÀdence interval [CI] 0.32 to 0.86; 
P=0.011) and T1b (HR 0.54, 95% CI 0.33 to 0.88; P= 
0.014) were both found to have decreased hazard of 
death relative to T3. Negative predictors of survival, 
in addition to increasing tumor size, included age and 
male gender, while positive predictors included tumor 
grade I and upper lobe location.
Conclusion: Our study demonstrates that increased 
size of tumor is an independent negative risk factor 
for survival in patients undergoing lobectomy or 
similar procedure for N2 positive stage IIIA NSCLC. 
These results should help guide the oncology 
clinician on recommendations for post-therapy 
surveillance and enrollment in clinical trials. 
Keywords: Lung cancer, Surgery, lobectomy, Stage 
IIIA
Conclusion: The outcome of concomitant 
chemotherapy with IF-RT (up to 50Gy/2Gy) starting 
with the second chemotherapy cycle, compares 
favorably with results from other series, which 
may in part be due to the dedicated staging strategy 
resulting in truly limited SCLC. The low number of 
isolated local relapses seems to support the use of 
IF-RT, provided that PET is used for diagnosis and 
treatment planning. The observation that a relatively 
high proportion of patients fails to reach nCR, 
suggests that higher radiotherapy doses may be the 
way to further improve the outcome. 
Keywords: Small-cell lung cancer, limited 
disease, involved Àeld radiotherapy, concomitant 
chemoradiotherapy
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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MO20.01 SIZE OF PRIMARY TUMOR 
MATTERS IN THE CLINICAL OUTCOME 
OF N2 POSITIVE STAGE IIIA PRIMARY 
LUNG CANCER AFTER LOBECTOMY
Steven Maximus1, Danh V. Nguyen2, Yi Mu2, Royce 
F. Calhoun1, David T. Cooke1 
1Division Of Cardiothoracic Surgery, University Of 
California, Davis Medical Center/United States Of 
America, 2Department Of Public Health Sciences, 
University Of California, Davis/United States Of 
America
Background: Size of the primary lesion is important 
in the prognosis of patients with early stage lung 
cancer. Using a large United States national database, 
we examined if size of the primary lesion was an 
independent risk factor of survival in patients undergoing 
lobectomy or similar procedure for N2 positive stage 
IIIA non small cell lung cancer (NSCLC). 
Methods: This is a retrospective study querying the 
Surveillance, Epidemiology and End Results database 
to identify 1,971 surgical patients diagnosed with 
N2 positive stage IIIA NSCLC from 1998 to 2007 
who underwent lobectomy or similar procedure. 
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for postoperative complications. All patients were 
staged according to the 6th TNM classiÀcation.
Results: The median age was 82 years (range, 80-
91). Of the total patient number, 166 (27.6%) had 
some form of comorbidity diagnosed preoperatively. 
Seventy-two (12.0%) patients presented with 
postoperative complications and the 30-day 
operative mortality was 8 (1.3%). The 5-year 
survival rates were 64.3% for p-stage IA (N=224), 
53.5% for p-stage IB (N=173), 62.9% for p-stage IIA 
(N=15), 27.2% for p-stage IIB (N=68), and 21.5% 
for p-stage IIIA (N=55). In patients with completely 
resected c-stage I NSCLC, the 5-year survival 
rates were 55.7% for c-stage I, 62.0% for c-stage 
IA, and 47.2% for c-stage IB patients (Figure). 
Multivariate analyses were performed to elucidate 
prognostic factors and risk factors in this population. 
Advanced pathological stage and comorbidity were 
signiÀcant independent predictors of shortened 
survival (P<0.0001 and P=0.032, respectively). 
Comorbidity and mediastinal lymph node dissection 
were identiÀed as factors that increased the risk of 
postoperative complications (P<0.0001 and P=0.036, 
respectively). Survival rates were independent of the 
extent of pulmonary resection (lobectomy or limited 
resection).
Conclusion: Octogenarian patients in this study had 
a satisfactory long-term outcome and low mortality 
rate. In c-stage I patients, comorbidity is a factor 
associated with both prognosis and operative risks. 
Another risk factor for postoperative complication 
is mediastinal lymph node dissection in c-stage I 
patients. Therefore, to avoid unnecessary mediastinal 
lymph node dissection based on an accurate 
preoperative nodal staging can be beneÀcial to 
decrease postoperative complications.
Keywords: Lung cancer, Surgery, Elderly
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MO20.02 PULMONARY RESECTION 
IN PATIENTS AGED 80 YEARS OR 
OVER WITH NON-SMALL CELL LUNG 
CANCER: A RETROSPECTIVE SURVEY 
OF 602 CASES IN A JAPANESE JOINT 
COMMITTEE FOR LUNG CANCER 
REGISTRATION STUDY
Jiro Okami1, Masahiko Higashiyama1, Noriyoshi 
Sawabata2, Etsuo Miyaoka3, Hisao Asamura4, Yoichi 
Nakanishi5, Kenji Eguchi6, Masaki Mori7, Hiroaki 
Nomori8, Yoshitaka Fujii9, Meinoshin Okumura2, 
Kohei Yokoi10 
1General Thoracic Surgery, Osaka Medical Center 
For Cancer And Cardiovascular Diseases/Japan, 
2General Thoracic Surgery, Osaka University, 
Graduate School Of Medicine/Japan, 3Mathematics, 
Science University Of Tokyo/Japan, 4Thoracic 
Surgery, National Cancer Center Hospital/
Japan, 5Clinical Medicine, Research Institute 
For Diseases Of The Chest, Graduate School 
Of Medical Sciences, Kyusyu University/Japan, 
6Respirology Medicine, Teikyo University School Of 
Medicine/Japan, 7Pulmonary Medicine, Sapporo-
kosei General Hospital/Japan, 8General Thoracic 
Surgery, Keio University School Of Medicine/Japan, 
9Surgery, Nagoya City University,graduate School 
Of Medicine/Japan, 10Thoracic Surgery, Nagoya 
University Graduate School Of Medicine/Japan
Background: The number of elderly lung cancer 
patients is increasing rapidly worldwide. Comorbid 
illness and adverse medical conditions due to aging 
is a signiÀcant concern to treat elderly patients with 
lung cancer. Surgeons often hesitate to recommend 
surgery for elderly patients because of the higher 
perioperative risks and uncertainty of long-term 
beneÀt. More information regarding short- and long-
term postoperative outcomes would help surgeons 
to select a subgroup of elderly patients suitable for 
pulmonary resection.
Methods: The Japanese Joint Committee of Lung 
Cancer Registry collated clinicopathological proÀles 
and outcomes for 13,344 patients who underwent 
pulmonary resection for primary lung cancer in 
1999. Data of 602 patients aged 80 or over with 
non-small cell lung cancer (NSCLC) were analyzed 
to assess the morbidity, mortality, and long-term 
survival. Next, 367 patients who underwent complete 
resection for stage I NSCLC were enrolled to the 
study to identify prognostic factors and risk factors 
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conÀrm signiÀcant pleural adhesions in any patient. 
Furthermore, since there was no apparent SBRT-
related change in the pulmonary structure, dissection 
around the vessels and bronchus was performed 
without difÀculties. There were no complications 
during surgery and postoperative course was also 
uncomplicated in all cases. Pathological staging 
was pT1N0M0 in 2 patients, pT2N0M0 in 3, and 
cT1-2N2M0 in 2. No adjuvant chemotherapy was 
performed except for 2 patients with pN2. Despite 
a short follow-up time (5-47 months after salvage 
surgery, median 21 months), all the patients are alive 
without apparent recurrences.
Conclusion: During surgical extirpation, we did not 
Ànd any signiÀcant SBRT-related adhesions in any 
of the patients. We found that surgical resection was 
feasible after SBRT. More cases with longer follow-
up should be mandatory to evaluate the true meaning 
of salvage lung resection for NSCLC after SBRT.
Keywords: salvage resection, Non-small cell lung 
cancer, stereotactic body radiotherapy
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MO20.04 REPEATED PULMONARY 
RESECTION FOR METASTATIC 
OSTEOSARCOMA: IS IT SAFE AND 
EFFECTIVE?
Hae Won Lee, Jinwook Hwang, Heejong Baek, Jong 
Ho Park, Moon-Chul Kang 
Department Of Thoracic Surgery, Korea Cancer 
Center Hospital/Korea
Background: Surgical resection has been considered 
as treatment of choice for pulmonary metastatic 
osteosarcoma. However, studies are insufÀcient to 
establish any consensus on the safety and efÀcacy of 
repeated pulmonary resection. The purpose of this study 
is to evaulate the clinical efÀcacy of repeated resection 
for pulmonary metastatic osteosarcoma.
Methods: We reviewed the medical records of 108 
consecutive patients who underwent operations 
for pulmonary metastatic osteosarcoma from 1992 
to 2008 in single institution. All the patients were 
followed up and mean duration of follow-up was 47 
months. Preoperatively, we evaluated the patients with 
MRI, PET-CT or CT scan for checking resectability 
and extrathoracic metastasis. Selection criteria for 
pulmonary resection were the possibility of complete 
resection, treatable or no longer present extrathoracic 
lesions and acceptable operative risks. Median 
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MO20.03 SALVAGE LUNG RESECTION 
FOR NON-SMALL CELL LUNG 
CANCER AFTER STEREOTACTIC 
BODY RADIOTHERAPY IN INITIALLY 
OPERABLE PATIENTS
Fengshi Chen1, Yukinori Matsuo2, Akihiko 
Yoshizawa3, Toshihiko Sato1, Takuji Fujinaga1, 
Tsuyoshi Shoji1, Makoto Sonobe1, Hiroaki Sakai1, 
Toru Bando1, Cheng-Long Huang1, Hiroshi Date1 
1Thoracic Surgery, Kyoto University Hospital/
Japan, 2Radiation Oncology And Image-applied 
Therapy, Kyoto University/Japan, 3Pathology, Kyoto 
University/Japan
Background: Stereotactic body radiotherapy 
(SBRT) is a recently developed radiotherapeutic 
method for early-stage non-small cell lung cancer 
(NSCLC) and failure of local control is estimated 
to occur in around 10% of the patients treated 
with SBRT. It has been reported that some patients 
develop local recurrence after SBRT and are then 
considered for salvage surgical resection. Herein, we 
retrospectively reviewed 7 such cases treated at our 
institution to further understand the indications for 
salvage lung resection for NSCLC after SBRT.
Methods: Since 1998, three-dimensional conformal 
SBRT has been performed in patients with solitary 
lung tumors at the Kyoto University Hospital. 
The biological effective dose was 105.6 Gy at the 
isocenter. The patients were followed up every 2 to 
3 months after SBRT. When local recurrence was 
suspected from follow-up CT images, an FDG-PET 
scan was performed and radiology peer review 
was undertaken. If local recurrence without distant 
metastasis was considered highly probable on the 
basis of the review, the patient was referred to a 
thoracic surgeon for possible salvage resection. We 
encountered 7 patients who underwent salvage lung 
resection for NSCLC after SBRT.
Results: All the patients were initially operable, 
but they chose SBRT. After SBRT, the tumors 
shrank initially in all patients, but increased in 
size within 16 months of SBRT in the case of 6 
patients. In 1 case, the tumor relapsed more than 8 
years after SBRT. Clinical staging before salvage 
surgery was cT1N0M0 in 3 patients, cT2N0M0 in 
3, and cT2N2M0 in 1. The mean patient’s age at 
surgery was 75 years, ranging 64-86. As salvage 
surgery, lobectomy with lymph node dissection was 
performed in all patients. Surgical extirpation did not 
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metastasectomy
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MO20.06 RESULTS OF SURGICAL 
RESECTION FOR SECOND PRIMARY 
LUNG CANCER
Takehiro Watanabe1, Tatsuhiko Hirono2, Nozomu 
Motono2, Akira Okada2 
1Division Of Chest Surgery, Nishi-Niigata Chuo 
National Hospital/Japan, 2Nishi-Niigata Chuo 
National Hospital/Japan
Background: Recently, there are many patients who 
underwent surgical resection for early non-small cell 
lung cancer in Japan. In the careful follow-up using 
high resolution CT, frequency of determining second 
primary lung cancer is increasing. But there is no 
standard treatment for second primary lung cancer. 
The aim of this study is to detail clinicopathological 
characteristics, surgical procedures, and the outcome 
of surgery for second primary lung cancer.
Methods: A retrospective review of a prospective 
lung cancer database was carried out to identify 
patients with second primary lung cancer. During 
the time period 1996-2010, 900 patients underwent 
surgical resection for primary lung cancer. Of the 900 
patients, 70 (7.8%) had second primary lung cancer. 
Among them, 57 patients underwent surgical resection 
for second primary lung cancer, and these patients are 
subject of this paper. Survival was calculated from 
the time of the second primary lung cancer using the 
Kaplan-Meier method, and differences in survival 
were determined by log-rank analysis.
Results: There were 44 men and 13 women. 
The average age at initial operation was 67. The 
average age at the 2nd operation was 71. The initial 
pulmonary resection was lobectomy in 49 patients, 
segmentectomy in 4 and wedge resection in 4. 
The 2nd pulmonary resection was lobectomy in 10 
patients, segmentectomy in 12 and wedge resection 
in 35. Thirty-eight of 57 second primary lung cancers 
were stage IA, 10 were IB, 1 was IIA, 3 were IIB, 2 
were IIIA and 3 were IIIB. Surgical complications 
occurred in 4, but there were no perioperative deaths. 
The 5 year survival rate for 2nd primary lung cancer 
was 59.9%. The 5 year survival rate for patients 
treated with wedge resection was 71.1%. The 5 year 
survival rate of the patients with stage IA was 72.7%, 
and that for patients with stage IB or more advanced 
sternotomy or bilateral sequential thoracotomy were 
chosen for examination of bilateral lungs. We analyzed 
the prognostic factors after repeated pulmonary 
resection. In the prognostic factors, primary tumor 
factors such as tumor size, resection margin of primary 
tumor and response to chemotherapy are included as 
well as metastatic tumor factors.
Results: From 1992 to 2008, 653 osteosarcoma 
patients were treated at Korea Cancer Center 
Hospital. Among these patients, pulmonary 
metastasis developed in 221 patients. One 
hundred eight patients could receive pulmonary 
metastasectomy and 40 patients underwent the 
second pulmonary resection and 13 of these 40 
patients had the third operation. There was no 
signiÀcant morbidity and no mortality after operation 
in these patients. Five-year survival rates after 
1st, 2nd and 3rd resection were 37.5%, 37.1% and 
44.0%, and 1-year disease-free survival rates after 
each metastasectomy were 55.6%, 40.0%, and 
22.2%, respectively. Frequency of operation was 
not a negative prognostic factor. Primary tumor 
size (p=0.003), primary tumor resection margin 
(p=0.006), the number of resected pulmonary 
nodules (p=0.007) and completeness of resection 
(p=0.045) were signiÀcant prognostic factors.
Conclusion: Primary tumor factors including size 
and resection margin are inÁuencing prognosis. 
Patients with disease free interval less than one 
year had worse prognosis but 5year survival rate 
of this group is as good as 33%. The number of 
metastatic nodules is a signiÀcant prognostic factor, 
but complete resection for a few patients with more 
than hundred metastatic nodules achieved good 
long term survival. And frequency of pulmonary 
metastasectomy was not a signiÀcant prognostic 
factor. These results suggest that repeated pulmonary 
resection can be done without severe morbidity and 
mortality in properly indicated patients and improves 
survival when complete resection is done. 
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activity of all lesions decreased or deactivated. 
Among 202 patients with peripheral lung cancer 
and chest wall invasion who complained chest 
pain pre-cryoablation, 40 patients(19.8%) showed 
complete pain relief after cryoablation and 124 
patients(61.4%) showed partially pain relief, 
respectively. The overall survival rates were 
70.2%% for 1-year and 54.1% for 2-year. The 
1-year survival rate were 100.0%, 93.5%, 84.1%, 
57.6% and 49.0%, and 2-year survival rate were 
100.00%,81.36%,71.27%, 48.19% and 38.48% for 
patients in stage I, stage II, stage III and stage IV 
of primary lung cancer and metastatic lung cancer, 
respectively. Tab. 1 Survival rate of lung cancer 
patient treated by cryoablation 
N 1-year survival rate(%) 2-year survival rate(%) 
Stage I 46 100.0(44/44) 100.0(21/21) 
Stage II 137 92.6(100/108) 83.6(51/61) 
Stage III 296 81.7(/156/191) 70.8(84/104) 
Stage IV 206 57.3(75/174) 48.2(25/52) 
Metastatic 
lung cancer 
131 47.1(56/119) 33.0(13/40) 
Conclusion: CT guided cryoablation showed some 
efÀcacy in controlling the progress of lung cancer 
and may contribute to pain relief and prolong 
survival for lung cancer patients.
Keywords: Lung cancer, CT-guided, EfÀcacy, 
Cryoablation
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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MO20.08 BILOBECTOMY FOR 
LUNG CANCER: INDICATIONS, 
POSTOPERATIVE RESULTS AND LONG-
TERM OUTCOMES
Domenico Galetta, Piergiorgio Solli, Alessandro 
Borri, Roberto Gasparri, Francesco Petrella, Stefano 
Donghi, Alessandro Pardolesi, Lorenzo Spaggiari 
Division Of Thoracic Surgery, European Institute Of 
Oncology/Italy
Background: Bilobectomy for lung cancer is 
considered a high risk procedure for the increased 
postoperative complication rate and for the negative 
impact on survival. The aim of this study is to 
analyze if bilobectomy is a safety operation and the 
diseases was 32.9%(p=0.002).
Conclusion: The outcomes of aggressive surgical 
approach for second primary lung cancers are 
satisfactory. It is important to perform careful and 
long-term follow-up for early detection of second 
primary lung cancer. It is linked with good outcome 
if the tumor is detected stage IA, when the possible 
cure by performing wedge resection is promising.
Keywords: second primary lung cancer, wedge 
resection, Surgery
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MO20.07 THE EFFICACY OF CT GUIDED 
CRYOABLATION IN LUNG CANCER
Li Z. Niu, Li H. He, Hai B. Li, Feng Mu, Bing H. 
Wu, Ke C. Xu 
Oncology, Fuda Cancer Hospital/China
Background: Lung cancer has been the commonest 
cause of cancer death, with a very poor survival 
rate. By the time of diagnosis, most cases are at an 
advanced stage. In recent years, little progress has 
been in improving the quality of life of patients 
with advanced lung cancer. While the possiblity 
of surgery has been limited, the other palliative 
measures must be considered.
Methods: From Jan 2002 to Apr 2006, 816 
patients(568 male and 248 female) at an median age 
of 64±1.2 years old(range from 12 to 95 years old) 
with primary or metastatic lung cancer were treated 
with cryoablation, including 46 patients in I, 137 in 
stage II, 296 in stage III and 206 in stage IV and 131 
patients with metastatic lung cancer.A total of 1139 
cryoablations were done for 1014 lesions, which with 
mean diameter of 6.3±0.4 cm (ranged from 1.0 to 
25.0cm). According to the size, shape and location of 
the lesion, 2-8 cryo-probes were inserted as following: 
1-2 cryo-probes for the tumor smaller than 2 cm in 
diameter, 2-4 cryo-probes for tumor with 2-4 cm 
in diameter, and 5-8 cryo-probes for tumor up to 5 
cm or more. Freeze-thaw cycle was set as 15 min of 
freezing at -140±10 Celsius degree with argon and 5 
min of thawing at 15±5 Celsius degree with helium. 
Three freeze-thaw cycles were performed during each 
cryoablation. Recheck CT or PET/CT and reappraise 
Karnofsky Performance Status(KPS) every 1-3 
monthes, and followed up every 3 months. 
Results: 1006 lesions (68.3%) decreased in size 
with mean size reducing from 4.7±0.3 cm to 
3.5±0.4 cm in diameter, CR+PR was 97.2%. Tumor 
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1Thoracic Surgery, Hospital Clínico San Carlos/
Spain, 2Pathology, Hospital Clínico San Carlos/
Spain, 3Preventive Medicine, Hospital Clínico San 
Carlos/Spain
Background: Controversy persists in relation to the 
indications and results of surgery in the treatment 
of patients with stage pIIIA-N2 non-small cell lung 
cancer (NSCLC). The objective of this study was to 
analyze the overall survival of a multicenter series 
of these patients and the factors that may inÁuence 
survival after complete surgical resection. 
Methods: A retrospective study was made of 287 
patients with stage pIIIA-N2 NSCLC submitted to 
complete resection. Patients were taken from the 
multi-institutional database of the Bronchogenic 
Carcinoma Cooperative Group of the Spanish 
Society of Pneumology and Thoracic Surgery, 
including 2,994 prospectively collected consecutive 
patients who underwent surgery for lung cancer. 
Adjuvant treatment (chemotherapy – CT – and/or 
radiotherapy – RT –) was administered in 238 cases 
(82.9%). We analyzed age, gender, histological type 
and adjuvant treatment (CT and/or RT). 
Results: The 5-year survival was 23.9% with a 
median survival of 22 months. Survival stratiÀed 
by adjuvant treatment was 26.5% with adjuvant 
treatment versus 10.7% without (p = 0.069). No 
signiÀcant difference was found with respect 
to gender. However age modiÀed the effect of 
adjuvant treatment on survival (interaction p = 
0.049). In patients under 70 years of age, adjuvant 
treatment reduced the mortality rate by 37% (HR 
0.63 CI 95% 0.42-0.95; p = 0.036) adjusted for 
histological type and induction treatment. 
Conclusion: Our series shows that complete 
surgical resection in patients with stage pIIIA-N2 
NSCLC leads to a 5-year survival of 23.9%, 
which increases to 26.5% with adjuvant treatment. 
Patients under 70 years of age with epidermoid 
cancer who have received neoadjuvance 
chemotherapy, reach a signiÀcantly greater survival 
when receiving adjuvant treatment after pulmonary 
resection.
Keywords: Stage IIIA, Complete resection, 
NSCLC, N2-disease
oncologic results of this procedure.
Methods: We retrospectively reviewed a prospective 
electronic database of patients who underwent 
bilobectomy for lung cancer between 1998 and 
2009. Age, gender, bilobectomy type and indication, 
complications, pathology, stage, and survival were 
analyzed.
Results: Bilobectomy was performed on 146 patients 
(101 men; mean age, 62 years) with lung cancer. 
There were 77 upper-middle and 69 middle-lower 
bilobectomies. Indications for bilobectomy were tumor 
extending across the Àssure in 27 (18.5%) patients, 
endobronchial tumor in 39 (26.7%), extrinsic tumor or 
nodal invasion of bronchus intermedius in 66 (45.2%), 
and vascular invasion in 14 (9.6%). An extended 
resection was performed in 24 patients (16.4%). 
Induction therapy was performed in 43 patients 
(29.4%). Istology was squamous cell carcinoma in 
45 patients, adenocarcinoma in 51, other pathologies 
in 50. Thirty-day mortality was 1.4% (n=2). Overall 
morbidity was 47.2%. Mean chest tube persistence was 
7 days (range, 6-46 days) and mean hospital stay was 
9 days (range, 5-174 days). The overall 5-year survival 
was 58%. SigniÀcance differences in survival were 
observed among the different stages (stage I, 70%; 
stage II, 55%; stage III, 40%; p=.0003) and the N status 
(N0, 69%; N1, 56%; N2, 40%; p=.0005). An extended 
procedure (p=.0003) and a superior bilobectomy 
(p=.0008) adversely inÁuence 5-year survival. 
Multivariate analisys demonstrated that an extended 
resection (p=.01) and an upper-mild lobectomy (p=.02) 
adversely affected prognosis. 
Conclusion: These date demonstrate that 
bilobectomy is associated with a low mortality and 
with an increased morbidity. Survival relates to 
disease stage and N factor. Optimal prognosis is 
obtained in patients with a lower-middle lobectomy 
without extension of the resection.
Keywords: NSCLC, Bilobectomy, Surgery
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MO20.09 WHAT AFFECTS THE 
SURVIVAL OF PATIENTS WHO 
UNDERGO COMPLETE RESECTION 
FOR STAGE IIIA-N2 NON-SMALL CELL 
LUNG CANCER?
Ana M. Gomez1, Florentino Hernando1, Antonio 
J. Torres1, Jose A. López García-Asenjo2, Cristina 
Fernández3, Joaquín Calatayud1, Jose R. Jarabo1, 
Elena Fernandez1 
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p=0.191), and they were intermediate between pN0 
(n=1113, 5-ys; 83.7%) and pN2 patient survival rates 
(n=243, 5-ys; 32.0%).
Conclusion: Node involvement patterns had 
signiÀcant prognostic impact in pN1 NSCLC 
patients. This impact was different between SCC 
and AD cases. The subclassiÀcation of N1 based on 
node involvement pattern is of signiÀcance for SCC 
patients but not for AD patients.
Keywords: Non-small cell lung cancer, lymph node 
involvement, direct involvement
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MO20.12 ROLE OF POSITRON 
EMISSION TOMOGRAPHY 
(PET), MUTATION STATUS AND 
PREDOMINANT HISTOLOGIC SUBTYPE 
AS PREDICTORS OF SURVIVAL IN 
PATIENTS WITH STAGE IIIA(N2) 
RESECTED NON SMALL CELL LUNG 
CARCINOMA (NSCLC).
Stephen A. Barnett1, Prudence A. Russell2, Marzena 
Walkiewicz3, Zoe Wainer4, Gavin M. Wright1, Simon 
Knight5, Siven Seevanayagam5, Julian Gooi5, Naveed 
Alam1, Matthew Conron6, Richard A. Williams2, 
Rochelle Wynne7, Thomas John3 
1Department Of Thoracic Surgery, St Vincent’s 
Hospital/Australia, 2Department Of Anatomical 
Pathology, St Vincent’s Hospital/Australia, 3Austin 
Health, Ludwig Institute For Cancer Research/
Australia, 4Department Of Surgery, University Of 
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MO20.11 PROGNOSTIC IMPACT OF 
NODE INVOLVEMENT PATTERN IN 
PN1 NON-SMALL CELL LUNG CANCER 
PATIENTS
Masayuki Nakao1, Junji Yoshida1, Genichiro Ishii2, 
Akikazu Kawase1, Ryo Maeda1, Keiju Aokage1, 
Tomoyuki Hishida1, Mitsuyo Nishimura1, Kanji Nagai1 
1Division Of Thoracic Surgery, National Cancer 
Center Hospital East/Japan, 2Pathology Division, 
Research Center For Innovative Oncology, National 
Cancer Center Hospital East/Japan
Background: Although it is possible that the 
prognostic effect of direct node involvement by the 
primary tumor may be different from that of node 
involvement separated from the primary tumor, 
nothing regarding this possibility is suggested in the 
current TNM ClassiÀcation on N1 (peribronchial, 
interlobar, or perihilar) lymph node involvement 
patterns. We evaluated the prognostic impact of 
node involvement patterns in pN1 non-small cell 
lung cancer (NSCLC) patients, with special attention 
given to any differences between squamous cell 
carcinoma (SCC) and adenocarcinoma (AD).
Methods: We reviewed 324 consecutive patients 
who underwent complete resection of pN1 NSCLC 
from July 1992 through December 2005 and 
classiÀed them into 2 groups based on their node 
involvement patterns: directly or separately involved 
N1 groups. To compare survival rates, 1545 pN0 
patients and 330 pN2 patients were also investigated.
Results: The median length of overall follow-up 
period for the censored patients was 8.6 years. 
Univariate and multivariate analyses showed that 
the node involvement pattern was signiÀcantly 
associated with pN1 NSCLC patient outcome. The 
directly involved N1 group (n=130) had a much 
better 5-year overall survival rate (5-ys) of 61.0% 
compared with 43.4% for the separately involved 
N1 group (n=194). In SCC patients, the directly 
involved N1 group (n=80, 5-ys; 68.4%) showed 
an overall survival similar to pN0 patients (n=302, 
5-ys; 63.9%, p=0.561), while overall survival of the 
separately involved N1 group (n=40, 5-ys; 33.5%) 
was identical to that of pN2 patients (n=59, 5-ys; 
25.6%, p=0.870), and their survival rates were 
signiÀcantly different (p<0.001). In AD patients, 
however, the survival rates were marginally different 
between the directly (n=33, 5ys=49.6%) and 
separately involved N1 groups (n=135, 5-ys; 42.9%, 
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Conclusion: In pN2 patients, 18F-FDG avidity of 
mediastinal nodes identiÀes preoperatively patients 
with poor OS and may guide treatment paradigm. 
Post-operatively, in locoregionally advanced 
NSCLC, KRAS mutations correlate with poorer OS 
independent of known prognostic variables. 
Keywords: NSCLC, PET, Kras, Predominant 
histologic subtype
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MO20.13 FACTORS AFFECTING 
VARIATIONS IN INTRA-OPERATIVE 
STAGING FOR LUNG CANCER 
RESECTION
Annabel Sharkey, Justine Downing, David 
Hopkinson, Timothy Locke, Jagan Rao, John 
Edwards 
Cardiothoracic Surgery, Northern General Hospital/
United Kingdom
Background: Systematic lymph node dissection 
(SLND) is recommended by the European Society 
of Thoracic Surgeons as the gold-standard for intra-
operative staging of non-small cell lung cancer 
(NSCLC). The aim of this study was to investigate 
the differences in intra-operative staging between 
four consultant surgeons in a single institution.
Methods: Retrospective analysis of histopathology 
reports from 350 consecutive patients from 11/06/08 
to 30/03/10 who underwent resections for conÀrmed 
Melbourne/Australia, 5Department Of Thoracic 
Surgery, Austin Health/Australia, 6Department 
Of Respiratory Medicine, St Vincent’s Hospital/
Australia, 7School Of Health Sciences, University Of 
Melbourne/Australia
Background: Overall survival (OS) in resected 
NSCLC with metastasis to mediastinal lymph nodes 
(pN2) is poor, with 5-year OS ranging from 13-
42%. Prognostic information known preoperatively 
allows avoidance of a futile thoracotomy or 
stratiÀcation to induction therapy. Addition of 
prognostic information known postoperatively may 
inform adjuvant treatment choices. Predominant 
histologic subtype and mutation status correlate with 
survival in early stage disease. 18F-FDG avidity of 
mediastinal nodes is an emerging prognostic variable 
possibly more strongly associated with survival than 
avidity of the primary tumour. In a cohort of resected 
pN2 patients, we identiÀed factors associated with 
survival, focusing on 18F-FDG avidity of mediastinal 
nodes, histologic subclassiÀcation, genetic 
mutations.
Methods: Patients with pre-operative PET and 
pN2 on Ànal pathology were identiÀed. N2 nodal 
status based on original PET report was recorded 
as avid or not. Tumours were classiÀed according 
to 2004 WHO or IASLC/ATS/ERS ClassiÀcations. 
Predominant subtype was circled on the slide, a core 
punched from the parafÀn block, DNA isolated and 
mutational proÀling performed using Sequenom’s 
MassArray platform. Univariate and multivariate 
models examined predominant subtype, mutation 
status, 18F-FDG avidity of mediastinal nodes and OS.
Results: Between 1993 and 2010, 108 patients were 
identiÀed. On univariate analyses 18F-FDG avidity 
of mediastinal nodes, male sex, pneumonectomy, 
T-stage and mediastinal nodal predominant subtype 
correlated with poorer OS (Table, Fig.). On 
multivariate analysis of factors potentially known 
preoperatively, 18F-FDG avidity of mediastinal 
nodes (HR=2.25[1.28-3.97],p=0.005), KRAS 
mutation (HR=2.13[1.13-4.00],p=0.019), and age 
(HR=1.03[1.01-1.06],p=0.023) correlated with 
OS. On multivariate analysis of factors known 
postoperatively, 18F-FDG avidity of mediastinal nodes 
(HR=2.21[1.24-3.93],p=0.007), KRAS mutation 
(HR=1.94[1.01-3.72],p=0.046), pneumonectomy 
(HR=2.86[1.54-5.26],p=0.001) and age 
(HR=1.03[1.00-1.06],p=0.023) correlated with OS.
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1Oncology, Asan Medical Center/University Of 
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University Of Ulsan/Korea
Background: Epidermal growth factor receptor 
tyrosine kinase inhibitors (EGFR TKI) have not been 
fully evaluated regarding their efÀcacy for brain 
metastasis related to adenocarcinoma of the lung.
Methods: This is a prospective study of patients 
with histologically conÀrmed adenocarcinoma of 
the lung, EGFR mutations of either exon 19 or 21, 
and documented brain metastatic lesions without 
prior therapy including radiotherapy or radiosurgery 
or surgical resections. Either erlotinib 150 mg or 
geÀtinib 250 mg was administered every day. EGFR 
mutations were genotyped by direct sequencing.
Results: A total of 23 patients were enrolled. Median 
age was 57 years (range 37-77). Female accounted 
for 61% (14/23) and ECOG PS 0-1 74% (17/23). 
Fourteen patients (61%) had mutations in exon 19 
and 9 (39%) exon 21. Synchronous brain metastasis 
was documented in 15 patients (65%). Seventeen 
patients used EGFR TKI as second line therapy. Six 
patients (26%) received erlotinib and 17 geÀtinib. 
Response rate was 70.0%. Median PFS and OS were 
6.6 months (95% CI: 0.0-14.7) and 19.8 months 
(14.1-25.6). Drug modiÀcation related to toxicities 
occurred in 4 patients (17.4%). Patients with exon 
19 mutations had longer PFS than those with exon 
21 mutations (14.0 months vs 4.6 months; P=0.031); 
however, no difference in OS was seen (exon 19 15.9 
months, exon 21 19.8 months; P=0.498). Patterns of 
treatment failure included progression of intracranial 
lesions (42%, 5/12), extracranial lesions (25%, 
3/12) and both intra- and extracranial lesions(33%, 
4/12). Following progression, 6 patients underwent 
gamma-knife radiosurgery and 2 patients whole 
brain radiation.
Conclusion: EGFR TKI were effective in NSCLC 
patients with brain metastasis harboring either 
exon 19 or 21 mutations. Exon 19 mutations 
were associated with better disease control when 
compared to exon 21.
Keywords: Brain Metastasis, EGFR mutations, 
EGFR TKI
or suspected NSCLC. Comparisons in the lymph 
node stations reported by the pathologist were made 
between surgeons. 
Results: Twenty-eight patients without NSCLC 
proven at or after surgery were excluded from 
subsequent analysis. Anatomical resection 
was in 290 (90.1%) (87.5% lobectomy/8.3% 
pneumonectomy/4.1% segmentectomy), wedge 
resection performed in 32 (9.9%). Sixty one of 322 
(18.9%) patients did not have separate N2 lymph 
nodes sent for staging (range between surgeons 0% 
to 58.7%, p<0.0001). Only one patient with no N2 
nodes sent was pN1, 46 were pN0 and 14 were pNx. 
The median number of N2 nodal stations reported 
varied from 0 to 3 between surgeons (p<0.0001). 
The percentage of cases with Station 7 nodes sent 
for histopathology varied between 17.4% and 91.0% 
(p<0.0001). The percentages of patients with three or 
more N2 stations reported ranged from 2.2% to 56.2% 
(p<0.0001) and the range for lobe-speciÀc SLND 
was 0% to 25.8% (p<0.0001). The sub-speciality 
of the surgeon (p<0.001) and whether surgery 
was performed by thoracotomy (p=0.001) were 
independent predictors of three or more N2 stations 
dissected in multivariate linear regression analysis, but 
PET nodal positivity and patient age were not.
Conclusion: There were signiÀcant differences 
between the intra-operative staging practices of 
consultant surgeons. Lobe-speciÀc lymph node 
dissection rates were generally low. The sub-speciality 
of the surgeon and route of surgical access were 
factors affecting nodal dissection strategy. 
Keywords: Lymph nodes, Non small cell lung cancer
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MO21.01 EFFICACY OF EPIDERMAL 
GROWTH FACTOR RECEPTOR 
TYROSINE KINASE INHIBITORS FOR 
BRAIN METASTASIS IN NON-SMALL 
CELL LUNG CANCER PATIENTS 
HARBORING EITHER EXON 19 OR 21 
MUTATIONS
Kyu-Pyo Kim1, Dae-Ho Lee1, Jungshin J. Lee1, 
Cheolwon Suh1, Sang-We Kim1, Jae Cheol Lee1, 
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December 2010, 26 pts had intracranial PD; 16 pts 
had non-PD and continued on erlotinib; and 5 pts 
stopped erlotinib due to extracranial PD. Median 
PFS was 10.1 months (95% CI 8.97–13.966) overall; 
for pts with 3 or >3 BM, median PFS was 10.2 
and 8.3 months, respectively (p=0.35); for pts with 
EGFR mutation, wild-type or unknown, median PFS 
was 23.2, 8.2 or 15.1 months respectively (p=0.06). 
ORR considered both intracranial and extracranial 
lesions: 2 pts (4.2%) had a CR and 25 (52.1%) had 
a PR, giving an ORR of 56.3%. Six-month and 
1-year OS rates were 87% and 74%, respectively. 
Adverse events (AEs) occurred in 72.9% (35/48) of 
pts; 7.3% of AEs were grade 3/4 and no SAEs have 
been reported to date. The most common AE was 
rash (64.6%). No unexpected AEs or ILD-like events 
were reported.
Conclusion: Erlotinib as monotherapy after 1st-
line CT for NSCLC pts with asymptomatic BM has 
promising efÀcacy and is well tolerated. The best 
PFS was seen in EGFR mutant patients.
Keywords: NSCLC, Brain Metastasis, erlotinib, 
Clinical trial
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MO21.03 RATES OF CENTRAL NERVOUS 
SYSTEM (CNS) METASTASES IN 
PATIENTS WITH ADVANCED NON-
SMALL CELL LUNG CANCER (NSCLC) 
AND SOMATIC EGFR MUTATIONS 
INITIALLY TREATED WITH 
GEFITINIB OR ERLOTINIB VERSUS 
CHEMOTHERAPY
Stephanie Heon1, Beow Yeap2, Neal I. Lindeman3, 
Michael S. Rabin1, David M. Jackman1, Bruce E. 
Johnson1 
1Medical Oncology, Dana-Farber Cancer Institute/
United States Of America, 2Cancer Center, 
Massachusetts General Hospital/United States 
Of America, 3Pathology, Brigham And Women’s 
Hospital/United States Of America
Background: The impact of tumor genotype and 
treatment with targeted therapies on the control and 
development of CNS metastases from NSCLC has 
not been extensively studied. We recently reported 
a lower than expected rate of CNS progression in 
patients with advanced NSCLC and somatic EGFR 
mutations initially treated with the EGFR tyrosine 
kinase inhibitors (TKIs), geÀtinib or erlotinib. This 
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MO21.02 ERLOTINIB AS 2ND-LINE 
TREATMENT IN ADVANCED NON-
SMALL-CELL LUNG CANCER (NSCLC) 
PATIENTS (PTS) WITH ASYMPTOMATIC 
BRAIN METASTASES (BM) AND ITS 
BIOMARKER ANALYSIS - A PHASE 2 
STUDY (CTOMG0803)
Yi-Long Wu1, Caicun Zhou2, Ying Cheng3, Shun Lu4, 
Gongyan Chen5, Cheng Huang6, Yi-Sheng Huang1, 
Hong-Hong Yan1, Jin-Ji Yang1 
1Guangdong Lung Cancer Institute, Guangdong 
General Hospital & Guangdong Academy Of 
Medical Sciences/China, 2Shanghai Pulmonary 
Hospital, Tongji University/China, 3Jilin Cancer 
Hospital, Jilin Cancer Hospital/China, 4Shanghai 
Chest Hospital, Jiaotong University/China, 5The 
Cancer Hospital Of Harbin Medical University, 
Harbin Medical University/China, 6Medical 
Department, The Cancer Hospital Of Fujian/China
Background: About 20–30% of all pts with 
NSCLC develop BM, leading to a poor prognosis 
and a median survival of <6 months after whole 
brain radiotherapy. The role of systemic CT in the 
management of BM is limited and controversial. The 
CTONG0803 study (NCT00663689) was designed to 
evaluate 2nd-line erlotinib in NSCLC pts with BM.
Methods: Eligible pts had conÀrmed 
adenocarcinoma or activating EGFR mutation-
positive NSCLC and asymptomatic BM (1 lesion 
of 10mm diameter or 3 lesions of <10mm); 
without extracranial progressive disease (PD) after 
2–6 cycles of 1st-line platinum-doublet CT; aged 
18–75y with ECOG PS of 0–2, and life expectancy 
>3 months. Pts received erlotinib 150mg/d until 
radiologically-veriÀed intracranial PD or clinically 
symptomatic BM. The primary endpoint was PFS 
(time from starting erlotinib to occurrence of either 
clinically symptomatic BM or conÀrmed intracranial 
PD). Secondary endpoints included ORR, 6-month 
and 1-year OS rates and safety. EGFR mutation was 
detected by DNA direct sequencing.
Results: From June 2008 to April 2010, 48 pts 
were enrolled in the study; 1 pt withdrew consent 
to receive erlotinib after 7 days, without efÀcacy 
assessment. Demographics were: median age 
56y (range 21–75y); male/female: 19/29; PS 1/2: 
18/30; adeno/BAC/other: 45/1/2; no. of BM: 3/>3 
23/25; non-smoker/smoker/unknown: 38/8/1; 
EGFR mutant/wild-type/unknown: 7/15/26. As of 
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Conclusion: Our data suggest lower rates of CNS 
progression in patients with advanced NSCLC 
and somatic EGFR mutations initially treated 
with geÀtinib or erlotinib compared with upfront 
chemotherapy. Additional patients with advanced 
NSCLC initially treated with chemotherapy are 
undergoing EGFR sequencing to increase the number 
of EGFR mutant patients treated with chemotherapy.
Keywords: Secondary brain neoplasms, Secondary 
meningeal neoplasms, Non-small cell lung cancer, 
Epidermal growth factor receptor tyrosine kinase 
inhibitors
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MO21.04 CEREBROSPINAL FLUID 
CONCENTRATION OF GEFITINIB IN 
PATIENTS WITH CENTRAL NERVOUS 
SYSTEM METASTASES OF NON-SMALL 
CELL LUNG CANCER
Yaping Xu1, Shenglin Ma2, Nengming Lin3, Yang 
Yu3, Luo Fang3, Xiaojiang Sun3, Hao Jiang3 
1Department Of Radiotherapy, Zhejiang Cancer 
Hospital/China, 2Hangzhou Cancer Hospital/China, 
3Zhejiang Cancer Hospital/China
Background: Although there have been several 
reports in which central nervous system (CNS) 
metastases of non-small cell lung cancer (NSCLC) 
were improved by geÀtinib, however, very little is 
known about the CNS penetration and exposure to 
this drug. We measured plasma and cerebrospinal 
Áuid(CSF) concentrations of geÀtinib. The another 
purpose of this study was to demonstrate the 
beneÀcial effect of geÀtinib in the treatment of CNS 
metastasis for a select group of NSCLC patients who 
had a sensitive EGFR mutation or good predictive 
clinical factors for EGFR TKI treatment.
Methods: We administered 250 mg geÀtinib daily 
concurrently with whole brain radiotherapy (in 3Gy 
fraction Àve times weekly to a total dose of 30 Gy) to 
six patients with NSCLC who had CNS metastases, 
and we investigated plasma and CSF concentrations 
of geÀtinib on day 8, when steady-state plasma 
concentrations of geÀtinib were assumed to be 
achieved. Objective response rate according to the 
RECIST criteria was recorded and performence 
status (PS) was evaluated using Zubrod-ECOG-
WHO(ZPS) score.
Results: In all cases, plasma and CSF concentrations 
of geÀtinib data on day 8 were similar to those 
retrospective study was undertaken to investigate the 
impact of geÀtinib or erlotinib versus chemotherapy 
on the outcome of CNS progression in EGFR mutant 
advanced NSCLC patients.
Methods: Patients with stage IV or relapsed 
metastatic NSCLC with somatic EGFR mutations 
seen at the Dana-Farber Cancer Institute between 
08/2000 and 02/2010 who were initially treated 
with geÀtinib or erlotinib or chemotherapy without 
receiving geÀtinib or erlotinib for at least 6 months 
following treatment initiation were identiÀed 
from a prospective trial. The cumulative risk of 
CNS progression was calculated using death as a 
competing risk. CNS progression included both 
newly developed brain or leptomeningeal metastases 
and progression of preexisting brain lesions.
Results: One hundred and twenty-nine patients with 
somatic EGFR mutations were eligible for inclusion 
in this analysis (99 EGFR-TKI, 30 chemotherapy). 
Twenty-one patients (21%) in the EGFR-TKI group 
and 9 patients (30%) in the chemotherapy group had 
brain metastases at the time of diagnosis of advanced 
NSCLC (P=0.331); twenty-eight of the 30 patients 
received CNS therapy before initiating systemic 
treatment. Thirty patients (30%) in the EGFR-TKI 
group and 15 patients (50%) in the chemotherapy 
group developed CNS progression after a median 
potential follow-up of 49 months (P=0.040). The 1- 
and 2-year cumulative risk of CNS progression was 
5% (95% CI, 2–11%) and 21% (95% CI, 13–30%), 
respectively, in the EGFR-TKI group compared with 
corresponding rates of 24% (95% CI, 10–40%) and 
31% (95% CI, 15–48%) in the chemotherapy group. 
Progression-free survival was prolonged in patients 
initially treated with geÀtinib or erlotinib (median 
11.5 v 6.9 months; P<0.001), whereas there was no 
difference in overall survival (median 32.2 v 36.2 
months; P=0.366).
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Background: Ipilimumab, a fully human 
monoclonal antibody, augments T cell activation 
by selectively inhibiting cytotoxic T-lymphocyte 
antigen-4. Ipilimumab signiÀcantly improved overall 
survival (OS) in a phase 3 study of previously treated 
patients with metastatic melanoma; principal adverse 
events (AEs) were immune-mediated and managed 
using drug-speciÀc treatment-guidelines (N Eng J 
Med 2010;363:711). We conducted a phase 2 study 
(CA184-041) of ipilimumab plus paclitaxel and 
carboplatin (P/C) as Àrst-line treatment in non-small 
cell lung cancer (NSCLC) or extensive-disease small 
cell lung cancer. Imunohistochemical evaluation 
indicates that T-cell inÀltration level may correlate 
with NSCLC histology (Br J Cancer 2006;94:275). 
Given this, we report our analysis of NSCLC cohort 
by histology (squamous/non-squamous). 
Methods: Patients were randomized 1:1:1 to 
receive: concurrent ipilimumab+P/C, (4 doses 
of ipilimumab+P/C followed by 2 doses of 
placebo+P/C); phased ipilimumab+P/C, (2 
doses of placebo+P/C followed by 4 doses of 
ipilimumab+P/C); or P/C alone, (placebo+P/C). 
Ipilimumab (10 mg/kg), paclitaxel (175 mg/
m2) and carboplatin (AUC=6) were administered 
intravenously every 3 weeks for a maximum of 6 
doses. Patients without disease progression who 
tolerated treatment received ipilimumab (ipilimumab 
arms) or placebo (P/C alone arm) every 12 weeks in 
maintenance phase.
Results: As reported previously, 204 untreated 
NSCLC (57 squamous; 147 non-squamous) patients 
were randomized. The study met its primary 
endpoint of immune-related PFS (irPFS) with irPFS, 
mWHO-PFS and OS being more favorable for 
phased schedule. Analysis by histology in phased 
ipilimumab+P/C arm suggests greater improvements 
in PFS versus P/C alone among patients with 
squamous NSCLC [HR= 0.40 (95%CI, 0.18-0.87) 
for squamous and HR=0.81 (95%CI, 0.53-1.26) 
previously reported. The CSF penetrations of 
geÀtinib in patients with NSCLC who had CNS 
metastases were approximately 2.4% (Table 1). 
Five of 6 patients showed overt improvement in 
ECOG performance status. The overall response 
rate was 100% (Table 2). Table 1. Plasma and CSF 
concentrations of geÀtinib in six patients 
Case Plasma concentration CSF concentration CSF penetration 
rate (%) ng/mL nmol/L ng/mL nmol/L 
1 31.73 70.99 0.91 2.03 2.86 
2 107.12 239.69 4.81 10.77 4.49 
3 56.90 127.33 0.89 1.98 1.56 
4 28.15 62.98 0.68 1.52 2.41 
5 35.43 79.27 0.53 1.18 1.48 
6 23.27 52.07 0.40 0.89 1.71 
Table 2. Clinical Characteristics of the Patients, 
Tumor Response 
Case Age 
(yr) 
Sex Cigarettes/
year 
Histology EGFR 
Mutation 
Change 
of PS 
Tumor 
Response 
1 43 F Never Ad + 1 to 1 PR 
2 64 M Never Ad + 1 to 0 CR 
3 60 F Never Sq + 2 to 1 PR 
4 35 F Never Ad + 2 to 0 CR 
5 23 M <400 Ad - 1 to 0 PR 
6 37 F Never Ad + 2 to 1 PR 
Conclusion: The CSF penetrations of geÀtinib in 
patients with NSCLC who had CNS metastases were 
approximately 2.4%. GeÀtinib are effective in the 
treatment of CNS metastases from NSCLC when 
patients were selected properly. 
Keywords: Cerebrospinal Áuid, Non-small cell lung 
cancer, geÀtinib, Central nervous system metastases
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MO21.06 IPILIMUMAB IN 
COMBINATION WITH PACLITAXEL 
AND CARBOPLATIN AS FIRST-
LINE TREATMENT IN NON-SMALL 
CELL LUNG CANCER: ANALYSIS BY 
BASELINE HISTOLOGY IN A PHASE 2 
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Background: NGR-hTNF is a highly selective 
vascular targeting agent consisting of human tumor 
necrosis factor (hTNF) fused with the NGR peptide, 
which is able to bind to a CD13 overexpressed on 
tumor blood vessels. By damaging tumor vasculature 
and decreasing tumor interstitial pressure, NGR-
hTNF improves penetration of cytotoxic agents 
within the tumor. 
Methods: Chemo-naive, stage IIIb-IV NSCLC 
patients, including patients with brain metastasis, 
stratiÀed by histology (nonsquamous vs squamous) 
and PS (0 vs 1), were randomly assigned to 
receive and cisplatin 80 mg/m2 day 1 plus either 
gemcitabine 1,250 mg/m2 days 1 and 8 for squamous 
histology or pemetrexed 500 mg/m2 day 1 for 
nonsquamous histology for up to six cycles plus 
NGR-hTNF 0.8 ƫg/m2 day 1 until progression (arm 
A) or chemotherapy alone (arm B). Primary study 
objective was progression-free survival (PFS). 
Assuming a 15% absolute increase in PFS rate 
(ơ=20% and 1-sided Ơ=10%), a sample size of 102 
patients was calculated. 
Results: Of the 86 patients recruited so far, 64 
patients (32 in each arm) were presently assessed 
for safety and preliminary activity. Baseline 
characteristics were (arm A/B): median age: 63/62 
years; PS of 1: 11/9; squamous histology: 8/8. A total 
of 180 cycles (range 1-17) were administered in arm 
A and 133 cycles (range 1-6) in arm B. Treatment-
related grade 3-4 toxicities for arm A vs B were 
23% vs 34% for all adverse events and included: 
neutropenia 13% vs 15%; thrombocytopenia 3% vs 
6%; fatigue 3% vs 12%; renal or respiratory failures 
0% vs 6%; thromboembolism 6% vs 0%. Grade 
1-2 hypertension was 3% in arm A and 11% in arm 
B. No grade 3 or 4 toxicities related to NGR-hTNF 
were observed, while 31% of patients, as espected, 
experienced NGR-hTNF-infusion related grade 1 
transient chills. Neither pulmonary hemorrhage nor 
bleeding were reported in both arms. Median follow-
up time was 8.6 months in arm A and 5.5 months 
in arm B. In patients with nonsquamous histology 
(n=48), PFS rates at eight months were 38% in arm 
A and 18% in arm B. In nonsquamous patients who 
achieved disease control (partial response plus stable 
disease; n=36), PFS rates at eight months were 51% 
in arm A and 21% in arm B. Among patients with 
for non-squamous vs P/C alone]. Similar results 
were noted with OS [HR= 0.48 (95%CI, 0.22-1.03) 
for squamous and HR=1.17 (95%CI, 0.74-1.86) 
for non-squamous vs P/C alone]. In the concurrent 
ipilimumab+P/C arm, however, PFS and OS were 
similar among squamous and non-squamous patients 
when compared to P/C alone [PFS:HR= 0.87 
(95%CI, 0.42-1.81) for squamous and HR=0.88 
(95%CI, 0.57-1.35) for non-squamous vs P/C alone; 
OS: HR= 1.02 (95%CI, 0.50-2.08) for squamous and 
HR= 0.96 (95%CI, 0.60-1.53) for non-squamous vs 
P/C alone]. Overall safety in NSCLC patients was 
previously reported with grade3/4 AEs being 57%, 
54% and 40% in concurrent ipilimumab+P/C, phased 
ipilimumab+P/C, and P/C alone arms, respectively. 
Hematologic abnormalities observed were those 
generally expected with P/C. Two treatment-related 
deaths were reported, one each in concurrent 
ipilimumab+P/C and P/C alone arms. Most common 
(>5% in any arm) treatment-related grade3/4 AEs 
(concurrent vs phased vs P/C alone) were: fatigue 
(10% vs 7% vs 6%) and diarrhea (10% vs 7% vs 4%) 
among non-squamous patients; nausea (0% vs 5% vs 
7%), vomiting (0% vs 5% vs 7%) and dyspnoea (0% 
vs 0% vs 7%) among squamous patients.
Conclusion: In NSCLC patients, a statistically 
signiÀcant improvement (phase 2 criteria) in irPFS 
and PFS was previously reported with phased 
ipilimumab+P/C versus P/C alone. Analysis 
by histology suggests greater improvements in 
squamous NSCLC with phased schedule. AE 
proÀle in ipilimumab arms was generally similar in 
squamous and non-squamous patients. While sample 
size precludes deÀnitive conclusions, these results 
are encouraging and warrant exploration in a larger 
clinical trial.
Keywords: ipilimumab, CTLA-4, NSCLC, Lung 
cancer
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MO21.07 RANDOMIZED PHASE II TRIAL 
OF NGR-HTNF AND CHEMOTHERAPY 
IN CHEMO-NAIVE PATIENTS WITH 
NON-SMALL CELL LUNG CANCER 
(NSCLC): PRELIMINARY RESULTS.
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normal tissue antigens. On this basis, the MAGE-A3 
Antigen-SpeciÀc Cancer Immunotherapeutic 
(ASCI) (recombinant MAGE-A3 protein + an 
immunostimulant AS15) has been developed 
and is currently under evaluation in a double-
blind, randomized, placebo-controlled Phase III 
study, the MAGRIT trial (NCT00480025) as 
adjuvant treatment in patients with MAGE-A3 
positive stage IB-IIIA resected non-small cell lung 
cancer (NSCLC). We present here the tumor and 
patient characteristics associated with MAGE-A3 
expression.
Methods: Univariate logistic regression analysis 
was performed with tumor and patient characteristics 
(including age, race, region, sex, stage, T stage, 
N stage, histopathology and tumor size) to select 
variables that impact signiÀcantly on MAGE-A3 
expression (based on available information for 8470 
of the 9347 screened patients, data from 06 Dec 
2010). This was also done separately for squamous 
and non-squamous tumors. Variables associated with 
MAGE-A3 expression in the univariate analysis 
were then used to build a multivariate model to 
predict MAGE-A3 expression by histopathology. 
Results: The overall rate of MAGE-A3 expression 
was 33.4%. We observed major differences between 
MAGE-A3 expression in squamous (47.5%) and 
non-squamous tumors (25.7%). For squamous 
tumors, none of the tested independent variables 
had a clinically relevant predictive capacity for 
MAGE-A3 expression (MAGE-A3 expression in the 
different subcategories ranged from approximately 
40-50%). For non-squamous tumors, the independent 
variables signiÀcantly associated with MAGE-A3 
expression were race (Asian: 18.3%; others: 28.2%), 
region (East Asia: 18.9%; Europe: 29.5%; North 
America: 24.4%; Other International: 24.6%), sex 
(male: 29.6%; female: 20.6 %); stage (IA: 11.0%; 
IB: 25.5%; IIA: 21.0%; IIB: 28.8%; IIIA: 25.9%; 
IIIB: 29.6%), T category (T1: 20.1%, T2: 25.5%; 
T3: 34.6%; T4: 27.9%), and size of tumor ( < 4 cm: 
21%;  4cm: 31.5%%). In a multivariate model for 
non-squamous tumors (based on 5326 patients for 
whom all required information was available), the 
variables race, sex and tumor size were signiÀcantly 
associated with MAGE-A3 expression. To illustrate 
the variation, among non-squamous histopathologies 
cancers, MAGE-A3 expression was signiÀcantly 
lower in Asian female with a tumor size < 4 cm 
(8.8%), compared to male from “non-Asian” regions 
and with a tumor size 4cm. (36%). 
Conclusion: In patients with stage IB-IIIA 
squamous histology (n=16), 2 partial responses, 
5 stable diseases and 1 progressive disease in arm 
A and 1 partial response, 4 stable diseases and 3 
progressive diseases in arm B were observed. 
Conclusion: NGR-hTNF and chemotherapy can be 
safely combined in NSCLC regardless of histology 
showing promising antitumoral activity. 
Keywords: NSCLC, Chemotherapy, NGR-hTNF
Medical Oncology III Thursday, 7 July 2011 12:30-14:00
MO21.08 PATIENT AND TUMOR 
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MAGE-A3 EXPRESSION: SCREENING 
DATA FROM THE MAGRIT PHASE III 
TRIAL
Joo-Hang Kim1, Jae Ill Zo2, Haruhiko Nakayama3, 
Tommaso De Pas4, Jubrail Dahabreh5, Marcin 
Zielinski6, Nasser Altorki7, Tonu Vanakesa8, 
Keunchil Park9, Herjan Leszek10, Kenji Suzuki11, 
János Strausz12, Emilio Esteban González13, Tetsuya 
Mitsudomi14, Sumitra Thongprasert15, Lecia 
Sequist16, K robert Shen17, Bart Spiessens18, Channa 
Debruyne19, Johan Vansteenkiste20 
1Oncology, Yonsei Cancer Center/Korea, 2Center 
For Lung Cancer, National Cancer Center/Korea, 
3Thoracic Oncology, Kanagawa Cancer Center/
Japan, 4European Institute Of Oncology/Italy, 
5Medical Center/Greece, 6Szpital Chorob Pluc/
Poland, 7Weil Medical College, Cornell University/
United States Of America, 8North Estonia Medical 
Center/Estonia, 9Samsung Medical Center, 
Sungkyunkwan University School Of Medicine/
Korea, 10Wojewodzki Szpital/Poland, 11Juntendo 
University Hospital/Japan, 12Koranyi National 
Institute For Pulmonology/Hungary, 13Hospital 
Central De Asturias/Spain, 14Aichi Cancer Center 
Hospital/Japan, 15Maharaj Nakorn Chiangmai 
Hospital, Chiangmai University/Thailand, 
16Massachusets General Hospital Cancer Center/
United States Of America, 17Mayo Clinic/United 
States Of America, 18Glaxosmithkline Biologicals/
Belgium, 19Gvd, Glaxosmithkline Biologicals/
Belgium, 20Univ. Hospital Gasthuisberg/Belgium
Background: Active immunization against 
MAGE-A3 tumor antigen is currently under 
investigation. MAGE-A3 belongs to the cancer-
germline shared tumor antigens also called cancer-
testis tumor-speciÀc antigens, which are appealing 
because they have little crossover with accessible 
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Solid Tumors. Adverse events were graded according 
to National Cancer Institute Common Toxicity 
Criteria (version 3.0).
Results: Between 1998 and 2010, 43 patients were 
treated with dendritic cell-based vaccines, and 26 
patients (60.5%) with mean age of 61.1 years (range, 
39-77 years) were assessable for response. Among 
these assessable patients, 1 partial response and no 
complete responses were obtained, giving an overall 
response rate of 4.7%. Fifteen patients (57.7%) had 
stable disease, yielding an overall disease control 
rate of 61.5%. Seven patients had progressive disease 
as the best response. Survival of those patients was 
evaluated in 19 patients. Of them, 5 patients were 
still alive for more than 6 months, and 14 were dead, 
with mean survival time of 12.2 months after the 
vaccines. Adverse events related to the vaccines were 
mild, and grade 1-2 of fever/chill was observed in 10 
patients (21.7%).
Conclusion: MUC1-targeting dendritic cell-based 
vaccine immunotherapy is feasible, and has a 
potential to control the diseases in patients with 
treatments-refractory lung cancer. 
Keywords: immunotherapy, MUC1, Advanced Lung 
Cancer, dendritic cell
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MO21.11 TREATMENT WITH TKI 
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TERM RESPONDERS TO ERLOTINIB IN 
ADVANCED NSCLC
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Background: Some patients with advanced 
inoperable NSCLC show prolonged disease 
stabilization on the EGFR-tyrosine kinase inhibitor 
(TKI) erlotinib. It is so far not clear how to treat 
patients who progress after prolonged response to 
erlotinib. From a pathophysiological point of view, 
it might be better, to continue TKI therapy beyond 
progression and add further therapy as appropriate 
rather than to discontinue TKI and use standard 
therapy alone.
Methods: We retrospectively analyzed all NSCLC 
resected NSCLC; we observed major differences 
in MAGE-A3 expression between squamous and 
non-squamous tumors. For squamous tumors, the 
overall expression rate was 47.5% and other clinical 
variables had little impact on predicting MAGE-A3 
expression. However, among non-squamous tumors, 
three factors have been identiÀed as signiÀcant 
predictors for MAGE-A3 expression: non-Asian 
race, male sex, and larger tumor size.
Keywords: MAGE-A3, Antigen-SpeciÀc Cancer 
Immunotherapeutic, Non-small cell lung cancer
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Background: MUC1, a tumor antigen, has been 
considered to a promising target antigen for cancer 
immunotherapy because it possesses a strong 
immunogenicity. It is processed and presented by 
antigen-presenting cells in a MHC-unrestricted 
pattern. Dendritic cell-based vaccine immunotherapy 
can elicit antigen-speciÀc cytotoxic T lymphocytes 
in tumor-bearing hosts, and activated cytotoxic 
T lymphocytes are expected to attack cancer 
cells. In this study, we evaluated the efÀcacy and 
feasibility of MUC1-targeting dendritic cell-based 
vaccine immunotherapy in patients with advanced 
treatments-refractory lung cancer.
Methods: The eligibility criteria of this 
immunotherapy were as follows: histologic or 
cytologic evidence of lung cancer that have been 
proven to express MUC1 abundantly; an Eastern 
Cooperative Oncology Group performance status of 
0-2; advanced stage of diseases refractory for other 
cancer treatments. The dendritic cells were prepared 
from peripheral blood mononuclear cells with 
cytokines interleukin-4 and granulocyte macrophage 
colony stimulating factor, were pulsed with MUC1 
peptides, and subsequently administered to patients 
subcutaneously. The vaccinations were repeated 
bi-weekly, and assessable patients were received at 
least 6 vaccinations. Tumor response was assessed 
according to the Response Evaluation Criteria in 
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ERLOTINIB FOR PATIENTS WITH 
NSCLC WHO BENEFITTED FROM 
PREVIOUS EGFR-TKI TREATMENT.
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Background: Tyrosine kinase inhibitors (TKIs) 
of the epidermal growth factor receptor (EGFR) 
are globally approved as treatment in any line of 
non-small-cell lung cancer (NSCLC). Patients with 
an activating mutation who despite an initially 
impressive response to EGFR TKI’s invariably 
relapse. For these patients few treatment options are 
available after additional progression during or after 
chemotherapy. The aim of this retrospective study 
is to study whether acquired resistance to an EGFR-
TKI is reversible after a drug holiday.
Methods: We retrospectively reviewed the medical 
records of 14 patients with stage IV NSCLC who 
progressed after previously achieved long term 
disease control on treatment with EGFR-TKI’s, were 
subsequently treated with standard chemotherapy 
and at renewed progression retreated with TKI . 
Treatment was continued until radiographic tumor 
progression. All patients were retreated with erlotinib 
(two in combination with cetuximab) at the maximal 
tolerated dose. Tumor response was evaluated by 
radiologic examinations according to the Response 
Evaluation Criteria in Solid Tumors (RECIST). 
Progression-free survival was deÀned as the period 
from the start of treatment until disease progression.
Results: 14 patients (5 male, 9 female, median age 
55 years (39-70 years), ECOG PS 0-1) received 
retreatment with erlotinib. The median interval 
from the discontinuation of EGFR-TKI to the 
2nd episode was 9.5 months (3-36 months). With 
erlotinib retreatment 36% (n=5) received partial 
response, 50% had stable disease (n=7) and 14% 
had progressive disease (n=2) as their best response. 
Median follow up is 9 months (1,5- 16+ months) 
and median PFS is 6,5 months (1- 16+ months). 
7 patients are still on therapy without signs of 
progression. Toxicity of treatment consisted of grade 
patients treated with erlotinib at our institutions since 
February 2004 who progressed after stable disease 
on erlotinib for at least 6 months.
Results: Of 43 patients, those 28 who were treated 
with TKI beyond progression had a signiÀcantly 
longer overall survival (OS)than those 15 who did 
not receive further TKI treatment after progression. 
The two groups did no differ signiÀcantly with 
respect to progression-free survival (PFS) on TKI, 
ECOG or age at progression. Of the 28 patients 
treated beyond progression, 24 received erlotinib, 
whereas 4 were switched to the second generation 
TKI afatinib (LUX-LUNG5 trial). 12 patients on 
erlotinib beyond progression received 1 further 
line of chemotherapy, 6 patients received 2 lines 
(15 pemetrexed, 7 gemcitabine, 1 vinorelbine, 
1 carboplatin). Treatment with erlotinib and 
chemotherapy was well tolerated with no increase in 
grade 3 and 4 toxicities.
TKI beyond 
progression 
No TKI beyond 
progression 
SigniÀcance 
(p) 
n 28 15 - 
OS after progression on 
TKI (months) 
9 2 0.0002 
OS from start of TKI 
therapy (months) 
25.5 14.5 0.019 
PFS from start of TKI 
therapy (months) 
13 11.75 n.s. (0.49) 
Age at progression 65.1 67.8 n.s. (0.37) 
Patients receiving 
Chemotherapy after 
progression 
18 (64.3%) 8 (53.3%) 
Patients receiving 
Radiotherapy after 
progression 
7 (25%) 3 (20%) 
Patients receiving BSC 
after progression 
3 (10.7%) 5 (33.3%) 
Conclusion: In long-term erlotinib responders, 
treatment with TKI beyond progression in addition 
to chemotherapy or radiotherapy is feasible and well 
tolerated. TKI-treatment beyond progression may 
lead to prolonged OS.
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Methods: We analyzed four hundred and seventeen 
NSCLC patients who showed partial response or 
complete response at the Àrst 2 months evaluation and 
stable disease for more than 6 months after the initiation 
of geÀtinib. All clinical data were obtained from 9 centers 
of Korean Molecular Lung Cancer Group (KMLCG). 
The time to progression, overall survival, clinical 
manifestations, and EGFR genotype were analyzed in 
the aspect of acquired resistance development.
Results: The median time to the development 
of acquired resiatance to geÀtinib (time to 
progression) was 10.2 months and overall survival 
was 20.8 months. Survival analysis of the patients 
experienced acquired resistance to geÀtinib showed 
signiÀcant predominance in female, non-smoker, 
and adenocarcinoma histology and these trend was 
more prominent in responder group (CR/PR) than 
in stable disease group. EGFR genotype does not 
affect the developmemt of acquired resistance to 
geÀtinib even though EGFR genotyping data was 
obtained in only 30% of the patients. At the time 
of acquired resistance, 35.3 % of the patients were 
asymptomatic. The incidence of primary tumor 
progression was 53.2% and CNS failure was noted 
in 17.1% of the patients. Median time to death after 
acquisition of resistance was 8.9 months (7.4 – 10.4) 
and multivariate analysis showed signiÀcantly high 
risk in smoker, poor performance status, CNS failure 
and chemotherapy after acquisition of resistance. 
Conclusion: These retrospectively analyzed clinical 
data for the clinical characteristics of acquired 
resistance to geÀtinib will support to set up the 
clinical deÀnition of acquired resistance to EGFR-
TKI and the strategy to overcome the acquired 
resistance
Keywords: Non small cell lung cancer, acquired 
resistance, geÀtinib, EGFR mutations
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MO21.14 HER2 MUTATIONS IN 
NON-SMALL CELL LUNG CANCER: 
PRELIMINARY EFFICACY OF 
TARGETED THERAPY WITH 
NERATINIB + TORISEL ON A PHASE I 
TRIAL.
Leena Gandhi1, Mohit Butaney1, Alice T. Shaw2, 
Rastislav Bahleda3, Kathleen Fiel1, Andrew 
Wolanski1, Kathleen Turnbull4, Anna Berkenblit4, 
Bruce E. Johnson1, Pasi A. Janne1, Jean-Charles 
Soria3, Geoffrey Shapiro1 
1-3 skin rash, grade 2 hair loss, grade 1 diarrhea, 
grade 2 constipation and grade 1 esophagitis 
(CTCAE v 3.0). Dose reduction was often necessary. 
Conclusion: Our Àndings suggest that retreatment with 
erlotinib is an option for patients with NSCLC who 
initially beneÀtted from previous EGFR-TKI treatment 
and recurred after standard cytotoxic chemotherapy. 
Keywords: NSCLC, EGFR-TKI retreatment
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Background: The NSCLC patients who experienced 
good clinical responses to epidermal growth 
factor receptor tyrosine kinase inhibitos (EGFR-
TKIs) such as geÀtinib or erlotinib will inevitably 
develop acquired resistance. Molecular mechanisms 
including T790M secondary mutation and c-Met 
have been suggested,but the clinical deÀnition and 
characteristics of acquired resistance to EGFr-TKIs 
is not clearly established. Herein, we investigated 
the clinical characteristics of acquired resistance to 
geÀtinib in NSCLC retrospectively.
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disease control rate on neratinib + temsirolimus 
despite signiÀcant prior treatment, suggesting HER2-
mutant NSCLC, like other molecular subgroups, 
may be uniquely sensitive to the appropriate targeted 
therapy. An expansion cohort of 12 NSCLC pts has 
been initiated. 
Keywords: HER2, neratinib, torisel, lung
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MO22.01 TUMOR IMMUNE 
MICROENVIRONMENT IN STAGE I 
LUNG ADENOCARCINOMA (LAC): 
STROMAL FOXP3/CD3 RATIO, TUMOR 
IL7R, AND IL12Rȕ2 ARE INDEPENDENT 
PREDICTORS OF RECURRENCE
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Background: The NIH Director’s Challenge multi-
institutional gene proÀling study identiÀed immune-
related genes with prognostic signiÀcance in LAC. 
The aims of this study are to investigate in stage 
I LAC: (a) immune microenvironment (immune 
cell inÀltration, chemokines, interleukins, and their 
receptors) in the tumor nest and the tumor-associated 
stroma and (b) assess the strength of immune 
markers in predicting recurrence in a multivariate 
analysis. 
Methods: Stage I LAC tissue microarrays (n=479, 
1995-2005, median follow-up 4.3 years) were 
constructed, and immunohistochemistry was 
performed for immune cell inÀltration (CD3, 
CD4, CD8, CD20, FoxP3), chemokines/receptors 
(CXCL12, CXCR4, CCR7), and interleukin 
receptors (IL7R and IL12Rơ2). Stains were analyzed 
for tumor and stromal immune cell inÀltration (low 
1Medical Oncology, Dana-Farber Cancer Institute/
United States Of America, 2Cancer Center, 
Massaschusetts General Hospital/United States Of 
America, 3Institut Gustave Roussy/France, 4PÀzer, 
Inc/United States Of America
Background: Distinct populations of patients (pts) 
with non-small cell carcinoma (NSCLC) carry 
somatic activating mutations uniquely sensitive 
to speciÀc targeted therapies. Human Epidermal 
Growth Factor Receptor 2 (HER2) mutations were 
Àrst identiÀed in NSCLC in 2004, but the clinical 
signiÀcance of these mutations is still unclear. 
Preclinical data have demonstrated that mutant 
HER2 activates the Akt/mTOR pathway and is 
oncogenic in vitro and in vivo. In a HER2-driven 
transgenic murine model of lung cancer, synergistic 
anti-tumor activity was seen with the combination 
of a HER family inhibitor and an mTOR inhibitor 
compared to either drug alone. 
Methods: A phase I clinical trial of neratinib (HER2 
inhibitor) + temsirolimus (mTOR inhibitor) was 
designed in part to assess the clinical efÀcacy of 
this combination in selected molecular cohorts of 
NSCLC. Sequencing across HER2 Exon 20 was 
conducted on tumor samples from non-squamous 
cell carcinoma pts under an IRB-approved protocol. 
Eligible pts with identiÀed HER2 mutations 
were enrolled to the phase I trial of neratinib + 
temsirolimus and assessed for best response. 
Results: As part of a comprehensive genotyping 
effort of non-squamous lung cancer at Dana-Farber 
Cancer Institute, Àfteen pts with tumors harboring 
HER2 mutations were identiÀed from 509 tumors 
sequenced from July 2009-December 2010 (3%). 
The majority was women (60%) and had no (60%) 
or limited (33%) smoking history (< 10 pack-years). 
Six pts with HER2-mutated NSCLC (including one 
not of this cohort) with progressive disease after a 
median of 3 prior therapies were treated on the phase 
I study of neratinib + temsirolimus. Pts were treated 
at dose levels of neratinib ranging from 120-240 
mg daily and temsirolimus ranging from 15-75 mg 
weekly. Four of six patients showed some tumor 
regression (2 partial response and 2 stable disease). 
Median progression-free survival among evaluable 
patients was 5 months (1.7, 10.5). 
Conclusion: Systematic genotyping of NSCLC 
pts identiÀed those who were eligible for HER2-
targeted therapy. These pts share similar clinical 
characteristics to epidermal growth factor receptor 
(EGFR) mutation-carriers. We observed a 67% 
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IL12Rơ2. Prognostic ability of two markers even in 
tumors 2cm underscores the signiÀcance of tumor-
immune interactions in the progression of early 
LAC. 
Keywords: early lung adenocarcinoma, tumor 
stroma, tumor immunology, prognostic marker
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LIGAND MRNA LEVELS MAY PREDICT 
SURVIVAL AND RELAPSE IN NON-
SMALL CELL LUNG CANCER
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Background: Programmed death-1 ligand (PD-L) 
involved in PD-1/PD-L1 pathway has been shown 
to associate with tumor progression via suppression 
of T-cell immunity. However, the prognostic value 
of PD-L1 in non-small cell lung cancer (NSCLC) 
remains unclear, especially in human papillomavirus 
(HPV)-infected lung cancer. 
Methods: Two hundred and twenty one lung tumors 
surgically resected from NSCLC patients were 
enrolled to determine PD-L1 mRNA expression by 
real-time RT-PCR. HPV 16/18 E6 expression in lung 
tumors was examined by immunohistochemistry. 
The role of E6 on PD-L1 expression was examined 
by E6-knockdown and E-overexpression in HPV16 
E6-positive lung cancer cells. Kaplain-Meier and 
Multivariate Cox regression analysis were used to 
verify whether PD-L1 mRNA levels may predict 
overall survival (OS) and relapse free survival (RFS) 
in NSCLC, especially in patients with E6-positive 
tumors. 
Results: PD-L1 mRNA levels in E6-positive TL-1 
and TL-2 cells were remarkably higher than E6-
negative A549, H23, H1355, TL-4, TL-5, TL-6 lung 
cancer cells. PD-L1 expression was decreased in 
E6-knockdown TL-1 and TL-2, and increased in E6-
overexpression A549 and TL-4 cells compared with 
their control cells. Patients with low PD-L1 mRNA 
levels had poorer OS and RFS than those with high 
PD-L1 mRNA levels. Among patients with high 
versus high) as well as immune marker expression 
(sum of intensity and distribution). Log-rank tests 
and Cox proportional hazard models were used to 
analyze the association between each marker and 
recurrence-free survival (RFS). 
Results: The 5-year RFS for the entire cohort was 
82%. No prognostic signiÀcance was demonstrated 
for the immune cells independently. However, a 
relative ratio of stromal FoxP3 (regulatory T-cells) 
and CD3 (total T-cells) was a signiÀcant predictor 
of recurrence (Figure 1A). Univariate analysis 
identiÀed tumor expression of IL7R (Figure 1B) 
and IL12Rơ2 (Figure 1C) as signiÀcant predictors 
of recurrence. IL12Rơ2 and stromal FoxP3/CD3 
ratio were prognostic even within tumors 2cm 
(Table 1A). In a multi-variate analysis including 
gender, stage (IA and IB), and lymphatic invasion, 
these three immune markers were independently 
associated with recurrence (Table 1B). 
Conclusion: In this study of the largest dataset-
to-date of stage I LAC tumor and stromal 
immune microenvironment characterization 
by immunohistochemistry, we identiÀed three 
independently associated with recurrence: stromal 
FoxP3/CD3 ratio, tumor expression of IL7R and 
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the percentage of tumor cells that stained at each 
intensity, respectively. The score median value was 
a priori chosen as the cutoff point for classifying 
tumors as CTLA-4-negative (score  20) and 
positive (>20). In addition, IHC expression proÀles 
were correlated with clinicopathological features. 
Results: The median follow-up time was 41 months 
(range 28-54), and 27 deaths were observed. CTLA-
4 expression was positive in 48% of tumors and 
similar in males and females (47 vs 47%), age  
70 and > 70 (46 vs 49%), ex-never smokers and 
current smokers (46 vs 47%), whereas was higher in 
non-squamous than in squamous carcinoma (53 vs 
36%). Cox’s multiple regression analysis identiÀed 
stage and CTLA-4 expression as the only variables 
associated with survival. The hazard ratio (HR) was 
2.76, (95%CI, 0.9-8.3; p= 0.07) and 6.61 (95%CI, 
2.6-16.8; p 0.001 ) for tumor stage II and III 
compared to stage I respectively, and 0.39 (95%CI, 
0.2-0.9; p= 0.03) for CTLA-4 score >20. 
Conclusion: Clinical trials with CTLA-4 inhibitors 
(ipilimumab and tremelimumab) in NSCLC 
combined with chemotherapy or alone in unselected 
population showed promising results encouraging 
further investigations. Our results demonstrate 
an association between CTLA-4 expression and 
increased overall survival in NSCLC pts suggesting 
a prognostic role for CTLA-4 in NSCLC. An 
increased CTLA-4 expression may contribute to 
NSCLC progression by modulating the interaction of 
microscopic disease with CTLA-4 ligand-expressing 
cells leading to NSCLC cell death. 
Keywords: CTLA-4, NSCLC, tissue microarray, 
prognostic factor
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MO22.04 T LYMPHOCYTE SUBSET 
MICROLOCALIZATION IS A STRONG 
PREDICTOR OF CLINICAL OUTCOME 
IN SURGICALLY RESECTED NON-
SMALL CELL LUNG CANCER.
Dermot S. O’Callaghan1, Elton Rexhepaj2, Kathy 
Gately1, Liam Gallagher2, Kenneth J. O’Byrne1 
1Thoracic Oncology Research Group, Trinity College 
Dublin/Ireland, 2University College Dublin/Ireland
Abstract under Embargo - will be presented in a 
press conference during WCLC 2011.
PD-L1 mRNA levels, the hazard ratio (HR) of E6-
positive patients was elevated to 1.89 (95% CI, 1.17-
2.66, P = 0.003) compared with that of E6-negative 
patients (HR, 1.31, 95% CI, 1.07-1.58, P = 0.007). 
Conclusion: PD-L1 mRNA levels may predict 
survival and relapse in NSCLC. We suggest that PD-
L1 may be a potential immunotherapeutic target in 
NSCLC, especially in patients with HPV infection. 
Keywords: Lung cancer, PD-L1, HPV
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MO22.03 EVALUATION OF CTL 
ANTIGEN 4 (CTLA-4) EXPRESSION AS 
PROGNOSTIC FACTOR IN NON-SMALL 
CELL LUNG CANCER (NSCLC)
Francesco Grossi1, Sandra Salvi2, Domenico F. 
Merlo2, Erika Rijavec2, Giulia Barletta2, Maria 
Giovanna Dal Bello2, Carlo Genova2, Edoardo 
Margallo2, Simona Boccardo2, Anna Morabito2, 
Stefania Laurent2, Marco Mora2, Matilde Mannucci2, 
Giovanni Battista Ratto2, Paolo Pronzato2, Mauro 
Truini2, Maria Pia Pistillo2 
1S.S. Tumori Polmonari, Istituto Nazionale Per La 
Ricerca Sul Cancro/Italy, 2Istituto Nazionale Per La 
Ricerca Sul Cancro/Italy
Background: CTLA-4, a close homologue to CD28, 
is a vital negative regulator of T-cell activation 
and proliferation. Preclinical studies and clinical 
trials have demonstrated that the administration 
of antibodies that block CTLA-4 can provoke the 
elimination or reduction of established tumors. 
We previously reported that CTLA-4 is expressed 
by NSCLC cell lines providing evidence of its 
involvement in apoptosis induction upon engagement 
with soluble CTLA-4 ligands (Contardi E, Int J 
Cancer 2005). The present study examined the 
expression of CTLA-4 on tumor tissues of patients 
(pts) with radically resected stage I-IIIA NSCLC. 
Methods: Tumor tissue samples from 82 pts 
who underwent surgery between 7/2005-3/2007 
were analyzed for expression of CTLA-4 using 
immunohistochemistry (IHC). Viable tumor was 
sampled in triplicate for tissue microarray analysis, 
and slides were stained by IHC with 14D3 mAb 
(eBioscence, San Diego, CA, USA). All tissue arrays 
were independently scored by two observers (M.T. 
and S.S.), blinded to the patients. CTLA-4 score 
was calculated using the following formula: (1 + 
I) x PC, where I is the staining intensity and PC 
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DNA; and is sensitive enough to use with small 
samples such as core needle biopsies (CNB), Àne 
needle aspirates (FNA), and CTCs. We developed a 
lung cancer assay panel of 12 genes/135 mutations 
(including AKT1, BRAF, CTNNB1, EGFR, ERBB2, 
KRAS, MEK1, NRAS, PIK3CA, PIK3R1,PTEN, 
and STK11) to test for somatic mutations in genes 
representing multiple pathways known to be 
involved in lung cancer. All assays can detect a 
mutation in < 25% of a sample. 
Results: In the effort to analyze CTCs, we Àrst 
analyzed 57 NSCLC cell lines with known mutations 
and conÀrmed known mutation status. Next, we 
successfully analyzed DNA from 90 frozen and 
matched FFPE NSCLC resected tissues. Analysis 
of unampliÀed and matched WGA cell line DNA 
quantity CNB and FNA equivalents gave the 
same mutational status results. Moving to CTC 
equivalents, we successfully analyzed cell line DNA 
and matched WGA DNA equivalents of 100-1000 
cells with known EGFR L585R and KRAS G34A 
mutations and negative control DNA (negative for 
all assays). Next, WGA methodology for direct 
CTC cell lysate DNA ampliÀcation was developed 
using CTC cell number equivalents (3 – 200 cells) 
obtained from a typical clinical blood sample CTC 
preparation. Then, we directly compared unampliÀed 
and matched ampliÀed CTC cell equivalents (50, 
100, and 200 cells). Analysis of both unampliÀed and 
ampliÀed CTC cell equivalents reported identical 
mutation status results. Thus, we demonstrated that 
we are able to study mutations in multiple genes 
using small amount of DNA from CTC cell numbers 
in a high-throughput manner. 
Conclusion: We developed a robust method for 
accurately determine cancer-associated genetic 
mutations in NSCLC CTC cell number equivalent 
lysates using MALDI-TOF MS SNP analysis which 
can be applied to better understand the molecular 
characteristics of lung cancer during treatment and 
progression. As clinical NSCLC CTC samples are 
collected, we will apply this methodology to assess 
CTC mutation status as potential diagnostic and/or 
prognostic markers.
Keywords: mutation analysis, circulating tumor 
cells, Non-small cell lung cancer, MALDI-TOF MS
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MO22.06 MALDI-TOF MS MUTATION 
ANALYSIS FOR NSCLC CIRCULATING 
TUMOR CELLS
Heidi S. Erickson1, Nana E. Hanson1, Katherine 
Stemke-Hale2, Hector G. Galindo3, Uma Giri1, 
Christina Mcdowell1, Luc Girard4, J.J. Lee5, Roy 
Herbst1, John D. Minna4, Hai Tran1, Gordon B. 
Mills2, Edward Kim1, John V. Heymach1, Ignacio 
Wistuba6 
1Thoracic / Head & Neck Medical Oncology, Ut MD 
Anderson Cancer Center/United States Of America, 
2Systems Biology, Ut MD Anderson Cancer Center/
United States Of America, 3Pathology, Ut MD 
Anderson Cancer Center/United States Of America, 
4Hamon Center For Therapeutic Oncology Research, 
University Of Texas Southwestern Medical Center/
United States Of America, 5Biostatistics, University 
Of Texas M.D. Anderson Cancer Center/United 
States Of America, 6Pathology And Thoracic/head & 
Neck Medical Oncology, UT MD Anderson Cancer 
Center/United States Of America
Background: Circulating tumor cells (CTC) 
associated with solid tumors are being studied for 
their diagnostic and prognostic value. In patients 
with metastatic tumors, CTC presence in the blood 
has been putatively associated with short survival. 
Since blood collection is relatively non-invasive, 
CTC molecular analysis opens up the possibility 
of monitoring genotypic changes during cancer 
treatments. Unfortunately, CTCs are not present 
in large numbers, often at rates as low as one cell 
per 106-107 leukocytes. Thus, to perform genotypic 
biomarker analysis on CTCs, methodologies must 
be developed to using highly speciÀc and sensitive 
technologies and an enrichment step to increase 
analytes to detectable levels.
Methods: We developed a methodology for 
detecting mutations in multiple oncogenes and 
chemotherapy resistance genes in non-small cell 
lung cancer (NSCLC) CTC specimens using 
high-throughput matrix-assisted laser desorption/
ionization time-of-Áight mass spectrometry 
(MALDI-TOF MS) single nucleotide polymorphism 
(SNP) analysis (MASSarray; Sequenom, Inc.) to 
determine cancer-associated genetic mutations in 
lung cancer specimens. This system allows for up 
to 10 different somatic mutations to be assayed per 
well in a 384-well format; requires very little DNA; 
can be used with whole genome ampliÀed (WGA) 
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Cytokeratins) and mesenchymal markers (Vimentin 
and N-Cadherin) were heterogeneously expressed 
in CTCs and CTM within and between lung cancer 
patients. E-Cadherin expression was absent, 
cytoplasmic or nuclear but only rarely expressed 
at the surface of contiguous cells within CTM. 
Vimentin was expressed in a subpopulation of CTCs 
but was observed in the majority of cells within 
CTMs. There were subpopulations of apoptotic and 
of proliferating solitary CTCs but neither cell death 
nor proliferation was observed in cells comprising 
CTM. 
Conclusion: We have for the Àrst time revealed the 
substantial heterogeneity of CTCs and CTM in lung 
cancer patients with respect to EMT markers. The 
different proÀles of apoptosis and proliferation in 
CTCs and CTM are consistent with our hypothesis 
of CTM possess a survival advantage and the lack 
of proliferation may render them relatively resistant 
to conventional cytotoxic drugs that preferentially 
kill proliferating cells. CTCs and CTM have been 
demonstrated as a useful research tool and a potential 
surrogate tissue to further our understanding of 
metastasis biology for lung cancer.
Keywords: Molecular characteristics, Circulating 
tumour cells, Circulating Tumour microemboli, Lung 
cancer
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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MO22.08 MICRORNA BIOMARKERS OF 
LUNG CANCER IN WHOLE BLOOD
Santosh K. Patnaik1, Sai Yendamuri1, Eric Kannisto1, 
Anil Vachani2 
1Department Of Thoracic Surgery, Roswell Park 
Cancer Institute/United States Of America, 
2Division Of Pulmonary Medicine, University Of 
Pennsylvania/United States Of America
Background: Development of simple non-invasive 
assays to diagnose lung cancer is of signiÀcant 
clinical importance. In this study, we explored the 
utility of microRNA expression in whole blood for 
identifying biomarkers of lung cancer. 
Methods: PAXgeneTM blood RNA kit (Qiagen®) 
was used to collect blood and isolate RNA from 
22 cases of non-small cell lung adenocarcinoma at 
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MO22.07 MOLECULAR 
CHARACTERISTICS OF CIRCULATING 
TUMOUR CELLS AND CIRCULATING 
TUMOUR MICROEMBOLI IN PATIENTS 
WITH LUNG CANCER
Jian-Mei Hou1, Matt Krebs1, Tim Ward1, Robert 
Sloane1, Lynsey Priest1, Fiona Blackhall2, Caroline 
Dive3 
1Clinical & Experimental Pharmacology, Paterson 
Institute For Cancer Research/United Kingdom, 
2Department Of Medical Oncology, The Christie 
NHS Foundation Trust/United Kingdom, 3Paterson 
Institute For Cancer Research/United Kingdom
Background: Enhanced cell migration, a key 
change in cellular behaviour during Epithelial to 
Mesenchymal Transition (EMT) involves loss of 
cell-cell contacts, and is widely reported to facilitate 
invasion and metastasis. However, collective 
migration of tumour cells also occurs where the 
cells maintain cell-cell contacts. We have observed 
circulating tumour cells (CTCs) and circulating 
tumour microemboli (CTM, clusters of tumour 
cells) in peripheral blood samples from patients 
with small cell lung cancer (SCLC) and non-small 
cell lung cancer (NSCLC). It is thought that only 
0.1% tumour cells in the circulation survive. We 
hypothesise that maintenance of cell-to-cell survival 
signals may confer a survival advantage on CTM 
over single CTCs. Here, we have characterised the 
expression proÀle of EMT markers in CTCs and in 
CTM of SCLC and NSCLC patients. The apoptosis 
and proliferation status of CTCs and CTM have 
also been explored to address the hypothesis of the 
survival advantage of CTM. 
Methods: A Àlter-based size exclusion approach 
(ISET, RareCell) and an epithelial marker (EpCam 
and cytokeratins) dependent platform (CellSearch, 
Veridex) have been utilised for detection and 
isolation of CTCs and CTM from patients with 
SCLC and NSCLC. Expression of EMT markers 
(cytokeratins, E-Cadherin, Vimentin, N-Cadherin) in 
CTCs and CTM isolated by ISET was assessed by 
single marker immunohistochemistry (IHC) staining. 
Apoptotic cells were identiÀed via fragmented and 
condensed, DAPI stained, nuclear morphology using 
the CellSearch technology. The proliferation marker 
Ki67 was evaluated in ISET isolated CTCs and CTM 
using IHC. 
Results: Epithelial markers (E-Cadherin, 
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blood-based assays for diagnosing lung cancer. 
Studies using larger cohorts are needed to further 
develop and validate such microRNA biomarkers. 
Keywords: Lung cancer, MicroRNAs, Blood
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MO22.09 A PROSPECTIVE STUDY OF 
SERIAL MEASUREMENTS OF CELL-
FREE DNA IN PLASMA, RADIOGRAPHIC 
RESPONSE, AND SURVIVAL IN 
PATIENTS WITH METASTATIC NON-
SMALL CELL LUNG CANCER (NSCLC)
Christopher G. Azzoli1, Christopher Mcginn1, 
Melissa Johnson1, Meier Hsu2, Camelia S. 
Sima2, Janine Cooc3, Kathleen Danenberg4, Peter 
Danenberg3, Valerie W. Rusch5, Mark G. Kris1 
1Medicine, Memorial Sloan-kettering Cancer 
Center/United States Of America, 2Epidemiology 
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Biochemistry, University Of Southern California, 
Keck School Of Medicine/United States Of America, 
4Response Genetics/United States Of America, 
5Department Of Surgery, Thoracic Service, Memorial 
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America
Background: Radiologic response by RECIST 
category (PR, SD, PD) and progression-free 
survival (PFS) are surrogates for overall survival 
(OS) in phase II, and some phase III trials of 
chemotherapy for patients with metastatic NSCLC. 
Most patients have SD at their Àrst follow-up scan, 
and discriminatory biomarkers for this subgroup are 
sorely needed. Levels of cell-free DNA in plasma are 
higher in patients with metastatic NSCLC compared 
to early-stage patients, and healthy controls. 
Published data suggest that high levels of cell-free 
DNA in plasma predict worse survival, and that 
changes in DNA over time may be used to predict 
the efÀcacy of therapy.
Methods: We conducted a prospective study to 
measure cell-free DNA in the plasma of patients 
with metastatic NSCLC. 182 patients had pre-
treatment blood collected in citrated tubes containing 
Ficoll Hypaque density Áuid and a polyester gel 
barrier, kept on ice, and processed within 1 hour 
of collection. Tubes were spun at 1800 RCF for 20 
minutes at room temperature. Plasma was removed 
without disturbing the mononuclear cell layer, and 
pathologic stage IA-IIIB, and 23 clinically-relevant 
controls at a high risk of developing lung cancer 
either because of smoking or because of the presence 
of pulmonary nodules later found to have a benign 
pathology. Two-color microarrays were used to 
quantify microRNAs in each sample. ClassiÀcation 
analyses were done using linear kernel support 
vector machines (SVM) and top-scoring pair (TSP) 
methods, and classiÀers were tested in internal cross-
validations. 
Results: Cases and controls were evenly matched 
for demographic, clinical, and pathologic variables 
(Table 1). After data pre-processing, 387 of the 
1268 (31%) human microRNAs on the platform 
were considered expressed, 89 (23%) of which were 
differentially expressed between the two cohorts 
with Benjamini-Hochberg-adjusted P values <0.05 
based on moderated t-statistics. Forty differentially 
expressed microRNAs had a >1.25 fold-change in 
mean expression level between groups. In leave-one-
out cross-validation, the TSP classiÀcation method 
had a prediction accuracy, sensitivity, speciÀcity, 
positive predictive value (PPV) and negative 
predictive value (NPV) of 95.6%, 90.9%, 100%, 
100%, and 92%, respectively. Values with SVM 
were 91.1%, 90.9%, 91.3%, 90.9%, and 91.3%, 
respectively. Areas under curve of 0.95 and 0.97 
in receiver operating characteristics analysis were 
obtained respectively for the TSP and SVM methods 
(Figure 1). Similar results were obtained in Monte 
Carlo cross-validations. 
Conclusion: This pilot study suggests that whole 
blood microRNA expression proÀles can be used 
for developing biomarkers for use in non-invasive 
Copyright © 2011 by the International Association for the Study of Lung Cancer S671
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
Background: Secreted proteins and those released 
from tumors and surrounding tissues contain 
important information that could enable early cancer 
diagnosis. However, there is great difÀculty in 
quantifying such signals for large numbers of low 
abundance proteins. Immunoassays are sensitive but 
assays are difÀcult to multiplex at the level (100s 
to 1000s of analytes) required to discover novel 
biology. Mass spectrometry measures many proteins, 
but throughput is low and the technology cannot 
easily quantify low abundance proteins.
SomaLogic therefore created a highly multiplexed 
proteomic assay which is continuously expanding 
in breadth. It currently measures >1000 proteins 
simultaneously from 10ul blood, with throughput 
of 300 samples/day. The median lower limit 
of quantiÀcation is below 1 pM with a median 
coefÀcient of variation for each protein below 5%. 
This assay performance arises from the selection 
of high afÀnity SOMAmers that bind selectively to 
their target proteins with slow off-rates.
Methods: We have applied this proteomic 
technology to discover blood and tissue protein 
biomarkers for NSCLC detection. A multi-center 
case-control study was conducted in archived serum 
samples from 1,326 subjects from four independent 
studies of non-small cell lung cancer (NSCLC) in 
long-term tobacco-exposed populations. Samples 
were divided into 75% training and 25% blinded 
veriÀcation prior to analysis. We then calculated 
the Kolmogorov-Smirnov (KS) statistic to quantify 
the difference in the populations for each protein, 
developed Bayesian classiÀers and veriÀed with 10-
fold stratiÀed cross validation prior to analyzing the 
blinded sample set. In addition, to investigate the 
connection between serum and tissue biomarkers, 
we analyzed homogenates prepared from NSCLC 
resected tumor tissue and compared the proteomic 
proÀle with adjacent and distal tissue from the same 
individuals. The Mann-Whitney test for signiÀcance 
was applied to compare adjacent to distant, adjacent 
to tumor and distant to tumor protein proÀles.
Results: We identiÀed 44 candidate serum 
biomarkers and developed a 12-protein panel and 
naive Bayes classiÀer that distinguished NSCLC 
from controls with 91% sensitivity and 84% 
speciÀcity in a training set and 89% sensitivity and 
83% speciÀcity in a blinded, independent veriÀcation 
set. In the tissue homogenate analysis, 36 proteins 
were most signiÀcantly different between the 
NSCLC tumor and adjacent or distant non-tumor 
tissue. Of these, 20 were elevated in the tumor and 
frozen at -80°C. DNA was extracted from a Àxed 
volume of plasma, and measured using quantitative 
PCR of the ơ-Actin gene. Radiologic response 
was recorded by RECIST, including sum longest 
diameter of measurable lesions. Additional blood 
was collected coincident with up to 3 radiologic 
response assessments during chemotherapy (until 
PD). Progression-free and overall survival was 
analyzed by Cox regression.
Results: 128 patients had at least one follow-up 
CT scan and plasma DNA level. Baseline plasma 
DNA levels were highly variable (baseline range 
0.2-5128 ng/mL, median 7.7 ng/mL). Clinical 
characteristics did not correlate with baseline DNA 
level (smoking history, gender, performance status, 
prior chemotherapy, prior XRT, sites of metastases). 
In follow-up, median percent change in DNA was 
-12% for PR (n=21), +6% for SD (n=86), +6% 
for PD (n=21), p=0.06. For Cox regression, a log 
transformation was performed to minimize the effect 
of extreme values of DNA on the estimates of the 
hazard ratios. Neither DNA levels at baseline and 
follow-up, nor % change in DNA, were associated 
with PFS, or OS.
Conclusion: In this large, prospective study, pre-
treatment levels of cell-free plasma DNA were not 
prognostic of outcome in patients with metastatic 
NSCLC. Changes in cell-free plasma DNA over time 
were not predictive of PFS or OS, and did not add 
discriminatory value to radiologic response. Ongoing 
efforts focus on detection of speciÀc oncogene 
mutations (EGFR or KRAS mutation) in the plasma 
as opposed to quantitative assays of total DNA. 
Supported by R01-CA092315.
Keywords: plasma DNA, radiologic response, blood 
biomarker, RECIST
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MO22.11 LARGE SCALE APPLICATION 
OF SOMAMER PROTEOMIC 
TECHNOLOGY FOR EARLY DETECTION 
OF LUNG CANCER: BIOLOGICAL 
INSIGHTS FROM SERUM AND TISSUE
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Nebojsa Janjic1, Thale Jarvis1, Michael R. Mehan1, 
Alex Stewart1, Sheri K. Wilcox1, Wei Xiong2, 
Stephen Williams1 
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SDF1a were analyzed by blinded duplicate ELISA 
(sensitivity ~3-70 pg/ml). Cut-points (VEGF-A:< 
or 1ng/ml, sVEGFR2: < or  11ng/ml, sVEGFR3: 
< or  35.5ng/ml and SDF-1a:  or > 3.5ng/ml) 
were determined using graphical methods based on 
Martingale residuals derived from the prognostic 
model for placebo pts, & the estimated baseline 
cumulative hazard and coefÀcients. Changes in 
biomarker levels from baseline to post-treatment 
were categorized into decreased >10%, stable within 
10%, or increased >10%. Cox regression models 
were used to correlate biomarker data with pt 
characteristics and PFS. 
Results: There were no signiÀcant differences in 
baseline pt characteristics for 149 pts with baseline 
biomarker values compared to those without (147). 
PFS was longer in the marker vs no-marker cohort 
(p=0.03), but hazard ratio (HR) for PFS beneÀt 
from cediranib was similar in both (HR 0.81, 95% 
C.I. 0.54-1.24 with and HR 0.81, 95% C.I. 0.56-
1.17 without marker data, interaction p=0.84). High 
baseline sVEGFR2 levels were prognostic for better 
PFS in the placebo arm (aHR 0.40, 95% C.I. 0.20-
0.70, p=0.0008), while low baseline sVEGFR2 and 
sVEGFR3 were predictive of increased beneÀt from 
cediranib in univariate analysis. However, following 
multivariate analysis, only low baseline sVEGFR3 
remained statistically signiÀcant (interaction 
p=0.05). Correlation between changes in plasma 
biomarker levels from baseline to post-treatment and 
PFS are currently being analyzed and will also be 
presented. 
Biomarker-Level Placebo (n) Cediranib (n) HR (95% C.I.) p-value Interaction 
Baseline Biomarker Level-Progression Free Survival 
VEGF-low 5.6m (59) 6.9m (52) 0.86 (0.53-1.42), p=0.56 
p=0.46 
VEGF-high 5.5m (19) 5.7m (19) 0.69 (0.30-1.60), p=0.38 
sVEGFR2-low 4.3m (33) 6.6m (33) 0.52 (0.28-0.97), p=0.04 
p=0.06 
sVEGFR2-high 6.6m (45) 6.8m (38) 1.07 (0.60-1.92), p=0.82 
sVEGFR3-low 5.6m (60) 6.9m (53) 0.60 (0.36-0.99), p=0.04 
p=0.05 
sVEGFR3-high 6.2m (18) 4.4m (18) 1.79 (0.80-4.01), p=0.15 
SDF-1a-low 5.5m (72) 6.6m (61) 0.71 (0.45-1.12), p=0.13 
p=0.22 
SDF1a-high 6.4m (6) 3.3m (10) 1.69 (0.54-5.21), p=0.36 
Conclusion: While high sVEGFR2 was prognostic 
for better PFS, only low baseline sVEGFR3 was 
signiÀcantly predictive for PFS beneÀt from 
cediranib after adjusting for confounding factors. 
Our results suggest that analysis of soluble receptor 
levels may assist in identifying pt populations 
most likely to respond to cediranib treatment, and 
prospective studies validating these Àndings are 
planned. 
16 were lower. There was considerable overlap 
between proteins elevated in tumor tissue and the 
identiÀed serum biomarkers.
Conclusion: Proteomic analysis of serum and tissue 
taken from NSCLC patients agreed with many of 
the Àndings in the literature and uncovered new 
biomarkers and biological insights. The role of these 
proteins in angiogenesis, growth and metabolism, 
inÁammation and apoptosis, and invasion and 
metastasis provide a comprehensive view of the 
complex proteomic changes associated with the 
development and progression of NSCLC. Based 
on these discoveries, we have initiated clinical 
validation studies for early detection in populations 
at risk for lung cancer. Additional application of the 
multidimensional SOMAmer proteomic technology 
may provide insights into therapeutic target 
identiÀcation and characterization of individual 
therapeutic response.
Keywords: Aptamer, Tissue proteomics, proteomics, 
Early Detection
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MO22.12 CIRCULATING PLASMA 
ANGIOGENIC FACTORS AND SOLUBLE 
RECEPTORS IN NCIC CTG BR.24
Glenwood D. Goss1, Christina L. Addison2, 
Keyue Ding3, Huijun Zhao2, Aurelie Le Maitre3, 
Scott Laurie1, Frances A. Shepherd4, Penelope A. 
Bradbury3, Lesley Seymour5 
1Medical Oncology, The Ottawa Hospital Cancer 
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Research Institute/Canada, 3Lung, NCIC Clinical 
Trials Group/Canada, 4Medical Oncology And 
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University Health Network, Princess Margaret 
Hospital And University Of Toronto/Canada, 5NCIC 
Clinical Trials Group/Canada
Background: BR.24 randomized 296 NSCLC (IIIB/
IV) patients (pts) to placebo or cediranib (30 or 45 
mg/kg) in combination with  6 cycles paclitaxel 
(200mg/m2) and carboplatin (AUC 6) q3 weeks 
followed by placebo/cediranib. Improved response 
and progression free survival (PFS) was observed in 
the cediranib vs placebo arm. We examined potential 
predictive or prognostic biomarkers at baseline or 
post-treatment and their correlation with PFS. 
Methods: Pretreatment baseline or post-treatment 
(4-10 weeks) VEGF-A, sVEGFR2, sVEGFR3 and 
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Note: *Fisher Exact Probability 
Conclusion: Plasma samples can be used as an 
alternative of or supplement to tissue samples 
in EGFR mutation detection. Only 50% patients 
harboring EGFR mutations can be detected both in 
plasma and in tissue samples. We found that one in 
Àve patients with EGFR mutations would be missed 
by tissue sample analysis. The positive consistence 
in female, non-squamous cell lung cancer and late 
stage patients were higher. The results suggest that 
blood test for EGFR mutation analysis could be used 
in female, non-squamous cell lung cancer and late 
stage patients. For squamous cell lung cancer and 
early stage patients, detection of EGFR mutations 
from plasma is not a wise choice..
Keywords: NSCLC, EGFR, Mutation, plasma
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MO22.14 VELOCITY OF RISE IN PLASMA 
OSTEOPONTIN DIFFERENTIATES NON-
SMALL CELL LUNG CANCERS FROM 
CONTROLS IN A CT SCREENING TRIAL
Jessica S. Donington1, Ryan Harrington2, Dawn 
Walter2, Amanda Beck2, Tyler Litton2, Nathalie 
Hirsch2, Judith Goldberg2, Justin D. Blasberg2, 
William Rom2, Harvey I. Pass2 
1Cardiothoracic Surgery, NYU School Of Medicine/
United States Of America, 2NYU School Of 
Medicine/United States Of America
Background: Determining cancers from benign 
nodules on CT scan can be difÀcult. As CT screening 
initiatives are integrated into non-small cell lung 
cancer (NSCLC) care additional variables that 
further guide clinicians are essential to decrease 
frequency of unnecessary biopsies. Osteopontin 
(OPN) is a secreted phosphoprotein and plasma OPN 
levels are known to be elevated in patients with early 
stage NSCLC. We hypothesize that the absolute 
change or velocity of change in plasma OPN levels 
can differentiate NSCLC patients from high risk 
patients without cancer in a CT screening population. 
Methods: A nested case-control trial was performed 
to evaluate plasma OPN as a biomarker within 
a large phase II CT screening trial for the early 
detection of NSCLC. Current or former smokers 
over the age of 50 with at least a 20 pack year 
smoking history and without previous cancer were 
eligible for screening. Incidence cancers with serial 
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MO22.13 EGFR MUTATION STATUS IN 
PAIRED PLASMA AND TISSUE SAMPLES 
OF 93 NSCLC PATIENTS FROM CHINA
Xiao Zhao, Meng Z. Wang 
Respiratory Medicine, Peking Union Medical 
College Hospital/China
Background: EGFR-TKIs are playing an increasingly 
important role in treating patients with active EGFR 
mutations. The golden standard of detection EGFR 
mutations is using tissue samples. However, tissue 
samples are unavailable or limited for mutation 
analysis at some occasions. The aims of this study 
were to compare the mutation status in plasma with 
in tissue, and thus to determine the speciÀc group of 
patients who may be the best candidates for EGFR 
mutation analysis using blood circulating DNA.
Methods: 93 paired formalin-Àxed, parafÀn-embedded 
tissues and blood samples were collected. Tissue 
samples were derived from percutaneous lung biopsy 
(9), bronchial mucosal biopsy (55), operation (27) and 
others (5). Nest PCR was used to amplify exon 19 and 
21 fragments. After the Àrst round, Mse I and Msc I were 
used to digest wild type fragments of exon 19 and 21, 
respectively. Subsequent sequencing results were for 
mutation analysis.
Results: 3 tissue samples (all from bronchial mucosal 
biopsy) and 1 plasma sample failed to give any target 
product after nest PCR. Mutations were found in 37.6% 
patients (35/93). In 90 tissue samples, exon 19 mutation 
rate was 17.8% (16/90), exon 21 mutation rate was 
14.4%(13/90); in 92 plasma samples, exon 19 mutation 
rate was 17.4%(16/92), exon 21 mutation rate was 
10.9%(10/92). The consistence of EGFR mutation status 
in 89 paired plasma and tissue samples was 80.9%, and it 
was analyzed for gender, pathology and disease stage. 
 
Total N 
(pairs) 
Overall 
consistence 
(%) 
Positive 
consistence 
(%) 
Negative 
consistence 
(%) 
Mutation 
rate in 
plasma 
(%) 
Mutation 
rate in 
tissue 
(%) 
P value 
(mutation 
rate) 
Gender male 63 84.1 41.2 82.1 19 19 0.0006 
female 26 73.1 58.8 37.5 46.2 57.7 0.0171* 
 
P (between 
group) 
 0.2278    
Pathology 
Non- 
Squamous 
59 74.6 51.6 65.1 35.6 44.1 0.0002 
 Squamous 30 93.3 33.3 93.1 10 3.3 0.1* 
P (between 
group) 
0.0333 
Disease 
Stage 
I-IIIA 31 77.4 12.5 76.7 9.7 19.4 0.4883* 
IIIB-IV 58 82.8 61.5 76.2 36.2 36.2 <0.0001 
 
P (between 
group) 
 0.5415      
Total  89 80.9 50 76.4 27 30.3 0.5335 
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MO23.01 TARGETING TUMOR-
ASSOCIATED MACROPHAGES AS 
A THERAPEUTIC APPROACH IN 
MALIGNANT MESOTHELIOMA
V. Courtney Broaddus1, Sailaja Battula1, Dario 
Barbone1, Collin Blakely2, Nikita Kolhatkar2, 
Raphael Bueno3, David J. Sugarbaker3, David M. 
Jablons4, Lisa M. Coussens2 
1Medicine, University Of California San Francisco/
United States Of America, 2Pathology, University 
Of California San Francisco/United States Of 
America, 3Surgery, Brigham & Women’s Hospital/
United States Of America, 4Surgery, University Of 
California San Francisco/United States Of America
Background: Mesothelioma is highly resistant 
to chemotherapy. One feasible approach could be 
to harness the immune system to undermine the 
chemoresistance of mesothelioma. We studied 
the chemoresistance of mesothelioma cells in a 
spheroid model wherein mesothelioma cells acquire 
multicellular apoptotic resistance that resembles that 
of the solid tumor.
Methods: Immunohistochemistry and Áow 
cytometry were used to analyze the leukocyte 
compositions of human mesotheliomas. 
Macrophages, either derived from human 
mesothelioma, THP-1-derived or matured from 
peripheral blood monocytes, were polarized to 
a Th1 or Th2 phenotype by exposure for 48 h to 
cytokines (IFN-gamma & LPS or IL-4 respectively). 
Polarized macrophages were then grown with 
mesothelioma cells either together in heterotypic 
3-dimensional spheroids or in a Transwell system 
in which macrophages were grown separately 
from mesothelioma spheroids by a 3 micron Àlter. 
After 24 h, mesothelioma spheroids with and 
without macrophages were treated with TRAIL plus 
gemcitabine or carboplatin plus pemetrexed for 48 
h and studied for apoptosis by analysis of Hoescht-
stained nuclear morphology.
Results: We found that all subtypes of mesothelioma 
harbor a large macrophage population (31±4.6% of 
the inÁammatory cell population [CD45+]). Indeed, 
the percentage of macrophages in mesotheliomas 
banked plasma and 2-4 matched controls for each 
cancer were identiÀed. Controls were matched for 
age, sex, pack years, character of nodules, and time 
interval for surveillance and plasma collection. 
Plasma OPN was measured by ELISA (Arbor 
Assays, Ann Arbor MI). The initial and Ànal OPN 
levels prior to nodule removal, the scanning interval 
and the velocity of rise in plasma OPN over time 
were evaluated.
Results: 10 incidence cancers and 33 matched 
controls with banked serial plasma samples were 
identiÀed. Median number of months of evaluation 
was similar between cancers and controls (22.9 
vs. 25.5, p=0.60). At initiation of surveillance 
the average plasma OPN levels were similar in 
the cancers and controls (46.6 ng/ml vs. 53.6 ng/
ml, p=0.57), but at completion of surveillance the 
average plasma OPN level in the cancer cases was 
slightly higher than controls (80.8 ng/ml vs. 62.9 
ng/ml, p=0.07). The velocity of rise in plasma OPN 
levels over time were signiÀcantly greater in cancers 
than controls (2.92 ng/ml/month vs. 0.34 ng/ml/
month, p=0.03)
Conclusion: Although OPN is a central regulator 
of pathogenesis in NSCLC, OPN plasma elevations 
are not unique to NSCLC and have been reported 
for infectious processes. This case controlled 
trial provides preliminary evidence for the utility 
of monitoring serial changes plasma OPN to 
differentiate cancers from benign etiologies in a 
high-risk screening population. The velocity of rise 
in plasma OPN was greater in NSCLC cancer cases 
than controls. Further evaluation of this biomarker in 
larger CT screening populations is warranted. 
Keywords: biomarker, Non-small cell lung cancer 
(NSCLC), osteopontin, CT screening
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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approaches that may further enhance the anti-tumour 
activity of this platinum drug. This is essential in 
elucidating the mechanisms underlying this drug-
resistant phenotype. Cancer stem cells (CSC’s) 
are rare, drug-resistant, stem-like tumour cells that 
drive tumour progression and metastasis through 
aberrant self-renewal and differentiation. Although 
CSC’s have been described in leukaemia, breast, 
brain and colon cancer, little is currently known 
about the biology of CSC’s in lung cancer. There 
is increasing evidence showing that CSC’s may be 
resistant to the cytotoxic effects of chemotherapy 
due to their low proliferation rate and resistance 
mechanisms. The aim of this study was to generate 
and characterise a clinically relevant, isogenic 
model of cisplatin resistance in a panel of NSCLC 
cell lines. Furthermore, a preliminary study 
examining potential stem-like markers present in 
the chemoresistant cell lines generated, was carried 
out using the lung cancer stem cell markers, CD133 
(Prominin-1) and aldehyde dehydrogenase (ALDH). 
Methods: Dose-response curves were generated to 
determine IC
50
 concentrations of cisplatin (0.1M-
100M) in a panel of NSCLC cell lines (A549, 
SKMES-1, MOR and H460). Cells were treated 
with cisplatin (IC
50
) for 72h and allowed to recover. 
Over a period of twelve months, cisplatin resistant 
(CisR) cell lines were derived from original, age-
matched parent cells (PT) and were maintained 
in the continuous presence of cisplatin (IC
50
) to 
generate a resistant subpopulation. Characterisation 
studies were performed between PT and CisR 
cell lines. Proliferation (MTT) and clonogenic 
survival assays (crystal violet) were carried out on 
PT and CisR cells. Cellular response to cisplatin-
induced apoptosis and cell cycle distribution were 
examined by FACS analysis. Expression of the 
lung cancer stem cell marker CD133 and aldehyde 
dehydrogenase (ALDH) activity were examined by 
FACS. 
Results: A panel of NSCLC cell lines with a 
cisplatin resistant phenotype were generated and 
characterised based on their decreased proliferative 
capacity in response to cisplatin, increased resistance 
to cisplatin-induced cell death, cell accumulation 
in the G0/G1 phase of the cell cycle and enhanced 
clonogenic survival ability. Chemoresistant 
cells displayed characteristic stem-like features, 
demonstrating signiÀcantly increased expression of 
CD133+ cells and increased ALDH activity relative 
to their corresponding parent cells. 
Conclusion: We have developed a clinically 
exceeded that found in other thoracic malignancies 
thus far evaluated (NSCLC cancer, 9%; esophageal, 
4%). We found that Th1-polarized macrophages 
increased the response of mesothelioma spheroids 
to TRAIL plus gemcitabine by 155% and to 
carboplatin plus pemetrexed by 47.6% respectively, 
compared to Th2 polarization. The pro-apoptotic 
effect was similar whether macrophages were grown 
together with or separately from the mesothelioma 
cells, suggesting the mediation of macrophage-
derived cytokines. The pro-apoptotic effect of 
Th1 polarization depended on the presence of 
macrophages: mesothelioma spheroids without 
macrophages exposed to Th1 cytokines showed no 
increase in apoptosis.
Conclusion: Polarization of macrophages within 
mesothelioma tumors to an Th1 phenotype could 
enhance the efÀcacy of standard and novel therapies.
This work was supported by grants from the NCI and 
a DoD Mesothelioma Program grant PR080717 to 
Broaddus and Coussens 
Keywords: heterotypic, trail, gemcitabine, 
Carboplatin
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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MO23.02 GENERATION AND 
CHARACTERISATION OF CISPLATIN-
RESISTANT NON-SMALL CELL LUNG 
CANCER CELL LINES DISPLAYING 
STEM-LIKE FEATURES
Martin P. Barr1, Dean A. Fennell2, Kenneth J. 
O’Byrne1 
1Clinical Medicine, St. James’ Hospital/trinity 
College Dublin/Ireland, 2Centre For Cancer 
Research And Cell Biology, Queen’s University 
Belfast/United Kingdom
Background: Lung cancer is the leading cause 
of cancer-related mortality worldwide and is 
typically characterised by low treatment response 
rates and poor overall prognosis. Unfortunately, 
the outcome of cisplatin therapy in NSCLC has 
reached a plateau, with the development of resistance 
being a major obstacle in the use of this drug. An 
understanding of the mode of action of cisplatin is 
therefore warranted in order to reÀne therapeutic 
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of VPA (0.1mM-1mM) for 72 hrs and assayed 
for global epigenetic changes by western blot. 
Similarly treated cells were measured for gene 
expression changes by qRT-PCR. Chromatin-
immunoprecipitation experiments for H3K9/14-Ac, 
H3K9me3, H3K4me3, HeK27me3, H4K20me3 are 
being conducted. 
Results: Long-term carcinogen exposure of 3kt cells 
leads to anchorage-independent colony formation. 
The methylation status of several genes is affected 
by long-term carcinogen exposure as assayed by 
MSP. Treatment of these carcinogen-exposed cells 
with 0.1mM-0.5mM VPA signiÀcantly decreased 
anchorage-independent colony formation. VPA 
treatment of carcinogen exposed cells increased 
global levels of gene-activation associated histone 
marks H3K9/K14-Ac and H3K4-me2, but had 
little effect on gene-repressive marks H3K9-me3 
and H3K27-me3. Protein levels of DMNT1 and 
H3K9methyltransferase G9a are up-regulated in 
carcinogen exposed cells, but are rescued to normal 
levels by VPA. The effect of HDAC inhibition 
on DNMT1 levels is through a post-translational 
modiÀcation mediated by HDAC1&2. G9A however 
is transcriptionally regulated by VPA. Lastly, VPA 
treatment of established NSCLC lines with known 
hyper-methylation patterns and gene suppression 
causes partial promoter demethylation and re-
expression of suppressed genes. 
Conclusion: We have established a model of 
early-stage carcinogenesis in human bronchial 
epithelial cells. Treatment of these cells with the 
HDAC inhibitor valproate (VPA) ameliorates these 
transformative events. Our evidence points to global 
epigenetic changes mediated by HDAC inhibition, 
which reach far beyond a merely increase in 
acetylated histones. Taken together, VPA is a HDAC 
inhibitor which has potential as a chemopreventive 
agent to reprogram epigenetic changes associated 
with early carcinogenesis. 
Keywords: chemoprevention, Tobacco Carcinogen, 
HDAC inhibitor, epigenetics
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
relevant, isogenic model of cisplatin resistance in a 
panel of NSCLC cell lines and characterised these 
based on a number of functional cellular parameters 
relative to their original parental cell lines. The 
presence and enrichment of speciÀc stem-cell 
markers in cisplatin resistant cells further supports 
the presence of a chemoresistant population with 
stem-like properties and may be useful as a model 
for studying mechanisms of cisplatin resistance in 
NSCLC. 
Keywords: NSCLC, Cisplatin resistance, stem cells
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MO23.03 ROLE OF HDAC INHIBITION 
IN THE REVERSAL OF EPIGENETIC 
GENE SILENCING IN LUNG 
CARCINOGENESIS.
Seth A. Brodie, Adam El-Kommos, Suresh 
Ramalingam, Fadlo R. Khuri, Johann C. Brandes 
Hematology & Medical Oncology, Emory 
University-Winship Cancer Institute/United States Of 
America
Background: We present a model by which 
epigenetic therapy with HDAC inhibitors prevents 
smoke-carcinogen induced bronchial epithelial cell 
transformation. Epigenetic alterations have been 
identiÀed as a key event in the pathogenesis of 
NSCLC. In addition to DNA methylation, aberrantly 
silenced promoter regions are characterized by 
loss of the active histone marks H3K4 di-and 
tri-methylation (me2-3), histone H3 K9/K14-
acetylation and acquisition of the repressive 
histone mark H3K9-trimethylation (me3). Our data 
show a profound induction of H3-acetylation and 
H3K4me2-3 after exposure to the HDAC inhibitor 
valproate (VPA) and downregulation of DNMT1 
and the H3K9 methyltransferase G9A, resulting in 
HDAC inhibition mediated reversal of gene silencing 
in lung carcinogenesis. 
Methods: Human bronchial epithelial cells 
immortalized with hTERT/cdk4 (HBEC-3kt) were 
treated with methylnitrosourea (MNU) and benz-
a-pyrene (BaP) for 24 hours/ week over numerous 
passages. Anchorage-independent colony formation 
was assayed in the presence or absence of VPA by 
soft agar method. Methylation status of several genes 
were assayed by methylation speciÀc PCR (MSP) in 
later-passage cells. Normal and carcinogen-exposed 
3kt cells were treated with clinical concentrations 
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that AXL is the main resistant mechanism in H820.
Conclusion: Axl activation was involved in the 
acquisition of erlotinib-resistance suggesting the 
role of Axl as a bypass signal for survival like MET. 
Axl should be considered as a new therapeutic target 
to overcome the resistance to EGFR-TKIs in lung 
cancer. 
Keywords: Lung cancer, EGFR, AXL, Resistance
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MO23.06 CLINICAL AND 
BIOLOGICAL SIGNIFICANCE OF 
CD157 IN MALIGNANT PLEURAL 
MESOTHELIOMA.
Simona Morone1, Erika Ortolan1, Alice Giacomino1, 
Rossella Parrotta1, Nicola Lo Buono1, Ida Rapa2, 
Luisella Righi2, Marco Volante2, Enrico RufÀni3, 
Sara Demichelis4, Giulia Rovere2, Silvia Novello4, 
Fabio Malavasi1, Ada Funaro1 
1Department Of Genetics, Biology And Biochemistry, 
Lab Of Immunogenetics/Italy, 2Department Of 
Clinical And Biological Science, University Of Turin/
Italy, 3Thoracic Surgery Department, San Giovanni 
Battista Hospital/Italy, 4Thoracic Oncology Unit, 
University Of Turin/Italy
Background: Malignant pleural mesothelioma 
(MM) is an asbestos-related tumor with poor 
prognosis, difÀcult to diagnose and treat effectively. 
Understanding the mechanisms of MM development 
and invasiveness, and identifying potential 
biomarkers are intrinsic to the prevention, screening 
and effective therapies.
Recently, we have demonstrated that CD157, a 
glycosylphosphatidylinositol-anchored NADase/
ADP-ribosyl cyclase-related molecule regulating 
leukocyte diapedesis, plays a pivotal role in the 
control of ovarian cancer cell migration and 
peritoneal invasion and represents a marker of poor 
prognosis in serous ovarian cancer.
Here we investigated the clinical and biological 
signiÀcance of CD157 in MM analyzing i) the 
expression of CD157 in tissue sections from 
surgical samples of MM in correlation to clinical-
pathological features and outcome and ii) its 
biological effects in both native and engineered 
mesothelioma cell lines.
Methods: CD157 expression was examined by 
immunohistochemistry in tissue sections from 
surgically resected MM (n = 81), quantiÀed by 
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MO23.04 THE ROLE OF AXL IN 
ACQUIRED RESISTANCE TO EGFR 
TYROSINE KINASE INHIBITORS
Jae Cheol Lee1, Se Jin Jang2, Chang-Min Choi1, Kyu-
Pyo Kim1, Dae-Ho Lee1, Sang-We Kim1, Jung-Shin 
Lee1, Woo Sung Kim3 
1Oncology, Asan Medical Center/Korea, 2Pathology, 
Asan Medical Center/Korea, 3Pulmonary And 
Critical Medicine, Asan Medical Center/Korea
Background: Axl has been considered as one of 
receptor tyrosine kinases collaterally activating 
signals for cancer cell growth and survival if the 
major oncogenic signal pathway is blocked by 
targeted agent in gastrointestinal stromal tumor and 
breast cancer. We investigated whether the Axl also 
contributes to the resistance to EGFR tyrosine kinase 
inhibitors (EGFR-TKIs) in lung cancer cells with 
EGFR sensitizing mutations.
Methods: Sublines resistant to erlotinib (HCC827/
ER) were established by chronic, repeated 
exposure in HCC827 lung cancer cell line with 
deletion mutation on exon 19. RT-PCR, Western 
blots and immunoprecipitation were used to 
evaluate AXL expression. To modulate AXL, 
siRNA and adenovirus-AXL transfection were 
performed. Response to drugs and combination 
effect were determined by MTT, 3D culture assay 
and combination index by CalcuSyn software, 
respectively.
Results: HCC827/ER cells showed approximately 
1000-fold higher resistance to erlotinib than parental 
cells. The basal phosphorylation of receptor HER 
family was signiÀcantly decreased and erlotinib 
failed to suppress Akt and ERK activation despite 
effective inhibition of EGFR. HCC827/ER cells 
showed the induction of Axl activation and increase 
of migratory and invasive capability. XL880, a 
MET and Axl inhibitor, effectively down-regulated 
Axl phosphorylation, which made HCC827/ER 
cells more susceptible to erlotinib regarding cell 
proliferation and survival. Axl silencing by siRNA 
in combination with erlotinib completely suppressed 
sustained Akt and ERK activation and enhanced 
apoptosis via caspase-3 activation and PARP-1 
cleavage. Further, we found AXL activation in 
H820, another erlotinib-resistant lung cancer cell 
line harboring T790M and MET ampliÀcation. 
The sensitivity to erlotinib was restored through 
inhibition of Axl by XL880 or Axl siRNA suggesting 
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MO23.07 RELATIONSHIP OF BRCA1 
MRNA EXPRESSION PATTERNS WITH 
EGFR/KRAS MUTATION STATUS IN A 
LARGE LUNG CANCER COHORT
Philip C. Mack1, Karen Kelly1, Xu Huang2, Primo N. 
Lara1, Kathleen Danenberg2, David R. Gandara1 
1Internal Medicine, UC Davis Cancer Center/United 
States Of America, 2Response Genetics/United States 
Of America
Background: Differential expression of DNA repair 
proteins plays a role in drug sensitivity, and may 
be inÁuenced by the mutational status of signal 
transduction oncogenes such as EGFR and KRAS 
(Gandara JTO 2010). BRCA1, which participates 
in homologous recombination, has emerged as a 
potential biomarker for chemosensitivity (Rosell 
CCR 2011). To examine the distribution of BRCA1 
expression in NSCLC, relative to other key NSCLC 
factors (EGFR, KRAS, ERCC1, histology and 
patient demographics), we quantiÀed BRCA1 mRNA 
levels in specimens from the extensive Response 
Genetics Inc (RGI) tumor collection.
Methods: RNA from microdissected formalin-Àxed 
parafÀn-embedded lung cancer specimens in the 
RGI database were analyzed for BRCA1 mRNA 
expression by RT-PCR, reported as a ratio of gene 
expression to ơ-actin. The data was correlated to 
patient demographics, ERCC1 mRNA levels and 
mutational status of KRAS and EGFR.
Results: 425 tumor specimens with known ERCC1 
expression levels were analyzed for BRCA1 
expression. Patient demographics: Median age - 66 
(range 34-90 ); Gender - 53% female; Stage- early 
4%, late 96%; Histology-adenocarcinoma (Adeno) 
60%, squamous cell (SCC) 15% and (not otherwise 
speciÀed/other 25%; The median BRCA1 mRNA 
expression level was 0.81 with a range of 0 – 12.05. 
There was no association between age or gender and 
BRCA1 levels but there was a signiÀcant association 
with histology. Median BRCA1 gene expression was 
higher in SCC at 2.39 vs 0.57 for adeno (p.<0.0001). 
histological score (H-score), categorized as at/above 
or below the median value of 60, and compared with 
clinical parameters.
Native and engineered MM cell lines were analyzed 
for CD157 expression using Áow cytometry, Western 
blot and RT-PCR. Cell proliferative activity, tumor 
cell migration and invasion were studied using 
conventional in vitro cell-based assays. Soluble 
CD157 in serum and pleural effusion was detected 
by means of a novel enzyme-linked immunosorbent 
assay.
Results: Immunohistochemical analysis revealed 
that CD157 is expressed in 85% (69/81) of the 
specimens analyzed at varying levels and with 
discrete localization patterns. CD157 H-score did not 
associate with patient age at surgery, sex, histological 
type, IMIG disease stage, or asbestos exposure, 
whereas, it was statistically associated with outcome 
on follow up in patients with biphasic MM (P 
= 0.034, n=43). Univariate analysis of patients 
with biphasic MM demonstrated that patients 
with CD157-H-score 60 and those with CD157 
immunostaining localized at the cell membrane 
had signiÀcantly shorter survival then patients with 
CD157-H-score <60 (log-rank test: P = 0.037) or 
with cytoplasmic staining (log-rank test: P = 0.038), 
respectively. Multivariable Cox regression showed 
that CD157 H-score and membrane localization were 
powerful independent prognostic factors of poor 
prognosis in biphasic MM.
In vitro studies highlighted that CD157 is expressed 
in selected cell lines; moreover, forced expression of 
CD157 in the CD157-negative MSTO-211H biphasic 
MM cell line i) signiÀcantly increased the rate of 
tumor cell proliferation, ii) enhanced cell motility 
and, iii) increased the ability of tumor cells to invade 
the extracellular matrix .
Preliminary results indicated that CD157 is 
released in the serum and in the pleural effusion 
of patients with mesothelioma. The evaluation of 
soluble CD157 potential clinical signiÀcance and/or 
prognostic utility deserves further investigation.
Conclusion: These Àndings indicate that CD157 
could represent a novel biomarker in MM since 
it is expressed by the majority of MM tissues and 
its expression level and localization are associated 
with shorter survival in patients with biphasic MM. 
Moreover, CD157 expression promotes proliferation 
and motility and increases the invasive potential of 
MM cells.
This study was supported by the Regione Piemonte, 
Ricerca Sanitaria Finalizzata (2009) to A. Funaro.
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airway epithelial (Clara) cells leads to progressive 
bronchiolization of alveoli (BOA) in CC10-hASH1 
transgenic (TG) mice, which mimics metaplastic 
and potentially premalignant BOA lesions in human 
lungs. In the TG mice, hASH1 also attenuates 
pulmonary NE cell maturation during injury repair 
following exposure to naphthalene. In small cell lung 
cancer, hASH1 regulates NE features and enhances 
tumor-initiating capacity. Taken together, the results 
suggest that ASH1 is important in maintaining a 
phenotype that promotes renewal of both NE and 
epithelial (non-NE) cells. However, little is known 
about the contribution of ASH1 into the ‘stemness’ 
in the airway epithelium. Aims We investigated 
whether hASH1 regulates stem cell features that 
might contribute to BOA formation and possible 
mechanisms.
Methods: We used CC10-hASH1 TG mice, human 
immortalized bronchial epithelial (BEAS2B) 
cells, immunohistochemistry (IHC), qRT-PCR, 
laser capture microdissection (LCM), Áuorescence 
activated cell sorting (FACS) and cell culture.
Results: Microscopic analysis of TG mice revealed 
that BOA localized at the proposed stem cell niche 
bronchioalveolar junction (BADJ) in the peripheral 
lung. There was a 2-4 fold increase in the expression 
of stem cell marker CD133, CD44, Sca-1, Msi1 
and Nanog mRNAs in the lungs of TG mice. Using 
LCM we were able to demonstrate an increased 
expression of the stem cell marker nestin mRNA 
in BOA lesions. By IHC ALDH1 was also highly 
expressed in the terminal bronchioli (TB). The assay 
to mark the retention of bromodeaoxiuridine (BrdU) 
in DNA, indicating the presence of an ‘immortal’ 
strand of DNA over many divisions revealed label-
retention in only 2.1+0.5% of TB cells in control 
mice, in contrast to 6.9+0.9 and 14.8+1.1 % in 
TBs and BOAs of TG mice, respectively. This is 
consistent with the asymmetric division property 
of stem cells. To further study the role of hASH1 
in Clara cells, we sorted the CC10+ (positive) and 
CC10- (negative) populations from control and TG 
lungs by FACS. Our results showed that the mRNA 
expression of CD133, CD44, Sca1 and nestin was 
dramatically increased in TG CC10+ population 
compared with one derived from control animals. 
To explore molecular mechanisms, we focused on 
the WNT pathway. IHC revealed nuclear relocation 
of ơ-catenin and a decrease in the WNT inhibitor 
DKK1 expression in the airways of TG mice, 
consistent with pathway activation. Furthermore, 
overexpression of hASH1 in human BEAS2B cells 
When dichotomized at the medians, there was a 
small but statistically signiÀcant positive correlation 
between BRCA1 and ERCC1 expression (P<0.001). 
This relationship was retained when using the 
clinically established cutpoint of 1.7 for ERCC1 
(p<0.001). In a subset of samples where EGFR and 
KRAS mutational status were available (n = 386), 
BRCA1 mRNA levels were signiÀcantly higher in 
wild-type tumors compared to either mutant form 
(p=0.0092 ANOVA). EGFR mut-positive tumors 
(n=60) had a median BRCA1 level of 0.55 (range 0 
to 4.73); KRAS mut (n =113) had a median BRCA1 
level of 0.59 (range 0 to 7.22); WT tumors (n = 
213) had a median BRCA1 level of 0.91 (range 0 to 
12.05).
Conclusion: BRCA1 expression levels are 
signiÀcantly higher in SCC compared to adeno and 
modestly correlate with ERCC1 expression levels. 
BCRA1 levels were signiÀcantly higher in WT 
tumor compared to either EGFR or KRAS mutant, 
albeit with signiÀcant variance. To further evaluate 
these associations and their impact on treatment 
outcome, a clinical trial is planned.
Keywords: BRCA1, EGFR mutation, KRAS 
mutation
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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MO23.08 PRONEURAL TRANSCRIPTION 
FACTOR ACHAETE-SCUTE HOMOLOG 
1 REGULATES STEMNESS IN THE 
AIRWAY EPITHELIUM THROUGH 
ACTIVATION OF THE WNT/ȕ-CATENIN 
PATHWAY
Ilona Linnoila1, Xiaoyang Wang2, Kathleen M. 
Keefe2, Sandra M. Jensen-Taubman2, Abeba 
Demelash2 
1Exp. Pathology Section, CCBB, NCI, NIH/United 
States Of America, 2NCI, NIH/United States Of 
America
Background: Achaete-scute complex homolog 1 
(ASH1 or ASCL1) is a critical transcription factor 
that regulates the development of pulmonary 
neuroendocrine (NE) cells. It also promotes 
proliferation and prevents apoptosis. Constitutive 
expression of human ASH1 (hASH1) in the 
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epithelia as well as lung cancer cells. Repression 
of miR-487b in these cells persisted for several 
weeks following cessation of CSC exposure. 
Expression levels of miR-487b were signiÀcantly 
down-regulated in a panel of resected lung cancers 
relative to adjacent normal tissues; the magnitude 
of miR-487b repression was more pronounced in 
tumors from active or former smokers relative to 
non-smokers. Software-guided analysis revealed 
numerous potential targets for miR-487b including 
Wnt5a, encoding a noncanonical Wnt ligand, as well 
as SUZ12 and BMI1, which encode components 
of polycomb repressor complexes implicated in 
aberrant silencing of Wnt signaling antagonists 
such as Dickkopf-1 (Dkk-1), SFRP1, SFRP4, and 
WIF-1 in lung cancer cells. Constitutive over-
expression of miR-487b mediated ~3 - 11 fold 
reductions in Wnt5a, SUZ12 and BMI1 expression 
in SAEC, HBEC, Calu-6 and H841 cells; depletion 
of endogenous miR-487b induced Wnt5a, SUZ12 
and BMI1 expression in these cells. Constitutive 
expression of miR-487b up-regulated Dkk-1, SFRP1, 
SFRP4, and WIF1, and down-regulated Wnt5A, 
Wnt3A, TCF7, LRP6, and LRF1 in SAEC and/or 
Calu-6 cells. CLIP experiments conÀrmed direct 
interference of miR-487b with Wnt5a, SUZ12 and 
BMI1 transcripts. Repression of miR-487b coincided 
with recruitment of SUZ12 and BMI1 to Dkk-1, 
SFRP1, SFRP4, and WIF-1 promoter regions, and 
down-regulation of these genes in normal respiratory 
epithelia and lung cancer cells. CSC enhanced CpG 
methylation, decreased occupancy of TCF-1, and 
reduced H2AZ levels within the miR-487b genomic 
locus in SAEC and Calu-6 cells; deoxyazacytidine 
(DAC) mediated demethylation of the miR-487b 
promoter region, induced miR-487b expression, 
and markedly attenuated CSC-mediated repression 
of miR-487b in SAEC and Calu-6 cells. Over-
expression of miR487b inhibited proliferation and 
tumorigenicity of H841 and Calu-6 lung cancer cells.
Conclusion: CSC-mediated repression of miR-
487b promotes pulmonary carcinogenesis, via 
activation of genes encoding proteins implicated in 
modulation of cancer stem cell signaling. These data 
may account in part for clinical observations linking 
cigarette smoking with aggressive phenotype of lung 
cancers, and poor outcome of patients with these 
malignancies. 
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
activated the T-cell transcription factor which drives 
the WNT pathway, detected by TopFlash® luciferase 
reporter assay.
Conclusion: Proneural ASH1 regulates many airway 
stem cell features, potentially contributing to the 
formation of BOA through activation of the WNT 
pathway.
Keywords: Ascl1, stem cell, Wnt, premalignant
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MO23.09 CIGARETTE SMOKE 
ENHANCES POLYCOMB EXPRESSION 
AND ACTIVATES WNT SIGNALING IN 
NORMAL RESPIRATORY EPITHELIA 
AND LUNG CANCER CELLS VIA 
EPIGENETIC REPRESSION OF MIR-487B
David S. Schrump1, Sichaun Xi1, Hong Xu2, Jigui 
Shan3, Yongguang Tao2, Mary Zhang1, Suzanne 
Inchauste1, Leandro Mercedes1, Julie A. Hong1 
1Thoracic Oncology, National Cancer Institute/
United States Of America, 2Laboratory Of Cancer 
Prevention, National Cancer Institute/United States 
Of America, 3Advanced Biomedical Computing 
Center, National Cancer Institute/United States Of 
America
Background: Limited information is available 
regarding the mechanisms by which miRNA 
alternations contribute to initiation and progression 
of tobacco-induced lung cancers. 
Methods: Array techniques were used to assess 
miRNA expression proÀles in normal small airway 
epithelial cells (SAEC) and immortalized human 
bronchial epithelial cells (HBEC), as well as Calu-6 
and H841 lung cancer cells cultured in normal media 
(NM) with or without cigarette smoke condensate 
(CSC). Quantitative RT-PCR, Super-Array, Western 
blot, and RNA cross-link immunoprecipitation 
(CLIP) techniques were used to evaluate expression 
of miR-487b and target genes. Chromatin 
immunoprecipitation (ChIP) and sodium bisulÀte 
sequencing experiments were used to examine 
chromatin structure within the miR-487b promoter 
region. MTT assays and nude mouse xenograft 
experiments were used to assess proliferation and 
tumorgenicity of lung cancer cells constitutively 
expressing miR-487b or control sequences. 
Results: Under relevant exposure conditions, CSC 
consistently mediated ~2.5-7.5 fold decreases in 
miR-487b expression in cultured normal respiratory 
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compared the allelic frequencies between T790M 
and the activation mutation. As shown in Table 1, 
T790M was found to be present in similar frequency 
to L858R in cases 1. However in cases 2 and 3, 
T790M was present at lower frequencies and 
suggested that in some instances, T790M might be a 
secondary mutation occurred in a sub-clone of TKI-
treatment naïve cancer cells. 
Case No. Mutation 
Wild type 
allele 
Mutant 
allele 
Total 
clones 
Mutant% 
T790M/Activation 
mutation 
1 T790M 61 38 99 38% 1.2 
L858R 51 23 74 31% 
2 T790M 59 8 67 12% 0.5 
L858R 73 25 98 26% 
3 T790M 87 6 93 6% 0.1 
Del2235-2249 44 67 111 60% 
Conclusion: T790M mutation occurs alone or 
coexist with other activation EGFR mutation can be 
detected in a small subset of EGFR-TKI treatment 
naïve adenocarcinomas by direct sequencing. T790M 
mutation often occurs in cis to EGFR activation 
mutation. It can also present as minor clones in some 
instances. Determination of T790M status is essential 
for the clinical management of patients with lung 
adenocarcinoma and may have implications in the 
optimal design and interpretation of clinical trials. 
Keywords: EGFR, Tyrosine kinase inhibitor, lung 
adenocarcinoma
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MO23.12 STAT3 IS ACTIVATED BY JAK2 
INDEPENDENT OF KEY ONCOGENIC 
DRIVER MUTATIONS IN NSCLC
Glen J. Weiss1, Brendan D. Looyenga2, Danielle 
Hutchings2, Irene Cherni3, Chris Kingsley4, Carlos D. 
Lorenzo3, David K. Edwards V3, Shravan Sridhar3, 
Jeffrey P. Mackeigan2 
1Medical Oncology, Virginia G. Piper Cancer Center 
At Scottsdale Healthcare/tgen/United States Of 
America, 2Systems Biology, Van Andel Research 
Institute/United States Of America, 3Lung Cancer 
Unit, The Translational Genomics Research Institute 
(TGEN)/United States Of America, 4Diabetes, 
Cardiovascular & Metabolic Diseases Division, The 
Translational Genomics Research Institute (TGEN)/
United States Of America
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MO23.11 FREQUENCY OF DE NOVO 
T790M GATE-KEEPER MUTATION IN 
EGFR TKI-TREATMENT NAïVE LUNG 
ADENOCARCINOMAS DETECTED BY 
DIRECT SEQUENCING.
Ka F. To1, Joanna H. Tong1, Shuk L. Chau1, Peggy P. 
Law1, Raymond W. Lung1, Wei Kang1, Ching Y. So1, 
Tony Mok2 
1Anatomical And Cellular Pathology, The Chinese 
University Of Hong Kong/Hong Kong, 2Department 
Of Clinical Oncology, The Chinese University Of 
Hong Kong/Hong Kong
Background: Lung adenocarcinomas harboring 
activation mutations in epidermal growth factor 
receptor (EGFR) gene are sensitive to EGFR-
tyrosine kinase inhibitors (TKI). However, almost 
all patients that initially responded would develop 
resistance. The T790M gate-keeper mutation on 
EGFR contributes to ~50% of acquired resistance 
to TKI-therapy. De novo T790M mutation has been 
reported in the absence of TKI therapy. However, 
the prevalence of T790M mutation in EGFR-TKI 
treatment naïve patients varies from 1% to 38% 
which partly related to the detection methods 
employed. Here we report our experience of the 
frequency of de novo T790M mutation in EGFR 
TKI-treatment naïve lung cancers detected by direct 
sequencing. 
Methods: DNA from 689 EGFR-TKI treatment 
naïve adenocarcinoma samples was used for 
detection of both EGFR-activation and T790M 
mutations by PCR-direct sequencing. The allelic 
frequencies for the activation and/or T790M 
mutations were determined by sub-cloning method. 
Results: T790M mutation was detected in 8 
out of 689 (1.2%) EGFR-TKI treatment naïve 
adenocarcinoma samples by PCR-direct sequencing. 
Of 8 cases that harbored T790M mutations, 2 
harbored T790M only and 6 had additional EGFR 
activation mutations (L858R in 5 cases, and in-frame 
deletion Del2235-2249 in 1 case). To determine 
whether the double mutations were in cis or trans 
to each other, we used RT-PCR to amplify cDNA 
fragments spanning the 2 mutations in 2 cases (both 
carried L858R and T790M mutations) where frozen 
tumor tissues were available. Sequencing analysis 
indicated that L858R and T790M mutations occurred 
on the same allele in both cases. In another 3 cases 
where only parafÀn sections were available, we 
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clinically-annotated TMA derived from community-
based early-stage NSCLC may be useful for 
meaningful exploratory research on other key 
signaling pathways in NSCLC.
Keywords: stat3, jak2, Non-small cell lung cancer, 
tyrosine kinase inhibitors
Cancer Biology Thursday, 7 July 2011 12:30-14:00
MO23.13 GENE EXPRESSION 
PROFILING OF ASBESTOS-RELATED 
SQUAMOUS CELL CARCINOMAS
Casey M. Wright1, Santiyagu M.F. Savarimuthu1, 
Maxine Tan2, Maria Martins2, Nick K. Hayward3, Ian 
A. Yang2, Rayleen Bowman2, Kwun M. Fong2 
1School Of Medicine, University Of Queensland/
Australia, 2Department Of Thoracic Medicine, The 
Prince Charles Hospital/Australia, 3Oncogenomics 
Laboratory, Queensland Institute Of Medical 
Research/Australia
Background: Asbestos-related lung cancer 
accounts for 4–12% of all lung cancers worldwide. 
Since putative mechanisms of carcinogenesis 
differ between asbestos and tobacco induced lung 
cancers, tumours induced by the two agents may 
be genetically distinct. We previously reported 
analysis of high dimensional gene expression data 
for asbestos-related lung adenocarcinoma. Since the 
major lung cancer subtypes, adenocarcinoma and 
squamous cell carcinoma, are emerging as distinct 
diseases with markedly different susceptibilities to 
molecularly targeted therapies, the aim of this work 
was to identify expression biomarkers of asbestos-
related squamous cell carcinoma of lung.
Methods: Gene expression proÀling by Illumina’s 
HumanHT-12 v3 arrays was performed on a total of 
56 tumours with squamous cell carcinoma histology; 
26 cases with lung asbestos body counts above 
levels associated with urban dwelling (ARLC-
SCC: asbestos-related lung cancer-squamous cell 
carcinoma) and 30 controls with no lung asbestos 
bodies (NARLC-SCC: non-asbestos related lung 
cancer - squamous cell carcinoma). Data was feature 
extracted using proprietary software (GenomeStudio, 
Illumina, Hayward, CA) and normalised to the 75th 
percentile using GeneSpring (GeneSpring, Agilent 
Technologies, CA, USA). Supervised analysis based 
on lung asbestos body content was used to identify 
differentially expressed genes which were then 
prioritized on p-value (P<0.001) and fold change 
Background: Constitutive activation of STAT3 
is common in cancer. While somatic mutations 
to JAK2 are responsible for STAT3 activation in 
hematologic malignancies, these mutations are rare 
or lacking in non-small cell lung cancer (NSCLC). 
Instead, STAT3 activation can be induced by 
autocrine cytokine signaling or activated growth 
factor receptors. We sought to investigate the 
interaction between well-characterized oncogenic 
“driver” mutations in NSCLC and STAT3 activation.
Methods: STAT3 activation was assessed in seven 
well-characterized NSCLC cell lines with known 
oncogenic “driver” mutations. The effects of a 
JAK1/2 inhibitor, siRNA knockdown of JAK2, and 
gp-130 neutralizing antibody blockade on p-STAT3 
were determined. Drug dose response with EGFR, 
MEK, PDGFR, or ALK/MET tyrosine kinase 
inhibitors (TKI) on MAPK and STAT3 was assessed 
in selected NSCLC cells in 2D culture and 3D assays 
with and without a JAK1/2 inhibitor, ruxolitinib. 
In addition, stage I-II NSCLC clinically-annotated 
tumor samples collected from a community hospital 
were immunohistochemically (IHC) stained and 
scored for STAT3, p-STAT3, and JAK2. EGFR exon 
19 deletion and KRAS mutation analysis was also 
performed on the same samples. The relationship 
between IHC staining intensities, mutational status 
and various patient statistics was analyzed using an 
array of statistical tests.
Results: STAT3 is constitutively activated 
independent of activating KRAS or tyrosine 
kinase mutations in all of the NSCLC cell lines we 
analyzed. We also found that STAT3 was tyrosine 
phosphorylated in 22% of human NSCLC tumor 
samples independent of mutations in the EGFR 
or KRAS oncogenes. As with randomized clinical 
trial patients, in this cohort of early-stage NSCLC 
patients, EGFR and KRAS mutations are not 
signiÀcantly associated with progression-free or 
overall survival. Inhibition or blockage of the gp130/
JAK2 signaling pathway disrupts STAT3 activation 
in vitro. Interestingly, treatment of NSCLC cells with 
the JAK1/2 inhibitor ruxolitinib has no effect on cell 
proliferation and viability in 2D culture, but prevents 
anchorage-independent growth of these cells in 3D 
assays.
Conclusion: JAK2/STAT3 signaling operates 
independent of known driver mutations in NSCLC 
and plays critical roles in tumor cell behavior 
that may not be effectively inhibited by drugs 
that selectively target these mutations, suggesting 
a potential role for combination therapy. Our 
Copyright © 2011 by the International Association for the Study of Lung Cancer S683
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
Biochemistry And Cell Biology/China, 2Institute Of 
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Of Thoracic Surgery, Fudan University Shanghai 
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Background: Over 90% of lung cancer patients 
die from metastasis. We have previously shown 
that somatic mutation of a serine/threonine kinase 
LKB1 frequently occurs in lung cancer and promotes 
the metastasis process for unknown reason (Ji et al 
Nature ’07). Through the integrative bioinformatic 
analysis on microarray datasets from either human 
cell lines or murine lung tumors with LKB1 
deÀciency, we here identify lysyl oxidase (LOX) 
as a downstream target negatively regulated by 
LKB1. LOX is an extracellular copper residues 
in precursors. We plan to investigate the detailed 
mechanism how LKB1 modulates the process 
of lung cancerigenesis through LOX. We aim to 
identify biomarkers for diagnosis or prognosis 
purpose as well as therapeutic targets in lung cancer.
Methods: Over-expression or knockdown of LKB1 
in human lung cancer cell lines was performed to 
conÀrm the regulation of LOX expression by LKB1 
assessed by real-time PCR and western blot. The 
function of LOX in lung cancer progression was 
investigated through a series of in vitro functional 
studies including cell proliferation, soft agar colony 
formation, three-dimensional matrigel invasion 
and wound healing assay. The impact of LOX 
inhibition upon cancer progression in vivo was tested 
using treatment of a pharmacological inhibitor, 
b-aminoproprionitrile, in a previously established 
lung cancer mouse model with Lkb1 deÀciency. 
Immuno-Áuorescence staining on three-dimensional 
cell culture was carried out to study the contribution 
of collagen and b1 integrin signaling to cell polarity 
disruption and cell proliferation promoted by 
increased LOX expression. A published microarray 
dataset of a cohort of 111 lung cancer patients 
with survival information was used for studying 
the correlation of LOX expression with prognosis. 
To test if LOX serves as diagnosis biomarker, its 
serum activity was measured in a cohort of 80 lung 
adenocarcinoma patients and 28 healthy subjects by 
enzyme assay for Áuorescence detection in Hitachi 
(>2-fold). The Expression Analysis Systematic 
Explorer (EASE) Online Interface was used to 
identify important gene ontologies. Technical and 
biological validation was performed on the training 
set and three independent test sets (in-house data 
and two public datasets). Candidate genes of 
interest were sequenced to identify possible somatic 
mutations and single nucleotide polymorphisms. 
Results: Differential expression analysis identiÀed 
six putative candidates of biological and statistical 
signiÀcance (p<0.001) with known function. Expression 
of two of these six candidate genes (MS4A1 and 
CARD18) was replicated by the qRT-PCR method. 
Expression of MS4A1, but not CARD18, was 
consistently up-regulated in independent data of 
phenotypic relevance to asbestos related squamous 
cell carcinoma of lung. Integration of MS4A1 gene 
expression, copy number, and methylation showed 
no evidence that methylation or DNA copy number 
alterations were factors responsible for the differential 
expression observed in a subset of asbestos related SCCs. 
No somatic mutations were observed for MS4A1. 
Conclusion: There are distinct genomic proÀles 
for asbestos and non-asbestos related squamous 
cell carcinoma of the lung. Microarray proÀling has 
identiÀed one candidate gene MS4A1 consistently 
up-regulated across independent datasets. Integration 
of gene expression, methylation and copy number 
data failed to show a signiÀcant relationship with gene 
expression suggesting that these processes are not major 
regulators of expression ARLC-SCC. It is possible that 
other regulatory processes including microRNAs may 
be responsible.Further validation studies are required 
to conÀrm involvement of candidate genes in asbestos-
related lung carcinogenicity.
Keywords: asbestos, squamous cell carcinoma, gene 
expression proÀling
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MO23.14 IDENTIFICATION OF LYSYL 
OXIDASE AS A DIAGNOSIS AND 
PROGNOSIS BIOMARKER AND A 
THERAPEUTIC TARGET IN LUNG 
CANCER
Yijun Gao1, Qian Xiao2, Huimin Ma2, Li Li2, 
Jun Liu2, Yan Feng2, Zhaoyuan Fang2, Jing Wu2, 
Xiangkun Han2, Junhua Zhang3, Yihua Sun3, 
Gongwei Wu2, Robert Padera4, Haiquan Chen3, 
Kwok-Kin Wong5, Gaoxiang Ge2, Hongbin Ji6 
1Laboratory Of Molecular Cell Biology, Institute Of 
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tomography (PET-CT) can detect up to 15% of these; 
nevertheless it has a low sensibility in detecting 
cerebral metastases. Clinical guidelines recommend 
performing MRI only if there are neurological 
symptoms. The aim of this study was to assess the 
role of MRI in detecting silent brain metastasis in the 
initial staging of NSCLC.
Methods: Retrospective analysis of newly diagnosed 
cases of NSCLC without distant metastasis by PET-
TC over a ten month period (January - October 
2010). MRI was performed in all of NSCLC patients 
as initial work up, except those in stage IV, according 
to the protocol of the Institution. A multivariate 
statistical analysis was performed to determine those 
clinical variables associated to the presence of brain 
metastasis with or without neurological symptoms.
Results: Cerebral MRI was performed in 95 patients 
with lung cancer. 85% were men, 93% had a history 
of smoking and a mean age of 65 years. 39% had a 
squamous cell carcinoma, 40% had adenocarcinoma 
(ADK) and 21% had other histology. 20% were 
stage I, 21% were stage II and 59% were stage III. 
Brain metastasis were diagnosed by MRI in 11,6% 
(11/95) of the patients, and six of them (6/95, 
6,35%), did not present neurological symptoms. A 
stratiÀed binary logistic regression analysis showed 
that there were not any clinical variable associated 
with the presence of silent brain metastasis in the 
asymptomatic subgroup, whereas central tumours 
(p=0,005) and ADK (p= 0,01) were more frequently 
associated to brain metastasis in patients with 
neurological symptoms. In both subgroups, staging, 
SUVm, tumour size and mediastinal lymph nodes 
were not statistically indicative of brain metastasis.
Conclusion: Prevalence of silent brain metastasis at 
initial staging is 6,35% in our study. Neither clinical 
nor radiological variables could predict silent brain 
F-2000 Áuorescence spectrophotometer. 
Results: Lysyl oxidase is negatively regulated by 
LKB1 through mTOR-HIF-1Ơ signaling axis and 
mediates lung cancer progression. Inhibition of 
LOX activity dramatically alleviates lung cancer 
malignancy progression. Up-regulated LOX 
expression triggers excess collagen deposition in 
Lkb1-deÀcient lung tumors, and thereafter results in 
enhanced cancer cell proliferation and invasiveness 
through activation of ơ1 integrin signaling. High 
LOX expression and increased serum LOX activity 
correlates with metastatic status and poor prognosis. 
Moreover, in contrast to healthy population, serum 
from lung cancer patients have a signiÀcant increase 
of LOX activity.
Conclusion: We have identiÀed a novel mechanism 
involving extracellular matrix remodeling in lung 
cancer metastasis elicited by LKB1 loss. LOX may 
serves as a target for lung cancer therapy as well as a 
prognosis biomarker. More importantly, serum LOX 
activity serves as a potential diagnosis biomarker for 
lung cancer. 
Keywords: lysyl oxidase, extracellular matrix, 
LKB1, lung cancer metastasis
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MO24.01 PREVALENCE OF SILENT 
BRAIN METASTASIS (BM) IN THE 
INITIAL STAGING OF NON-SMALL 
CELL LUNG CARCINOMA (NSCLC)
Daniel Huertas, Lisbeth Marizell Pari, Susana 
Padrones, Nuria Gonzalez, Samantha Aso, J. Ignacio 
Martínez-Ballarin, Jordi Dorca, Antoni Rosell 
Pulmonology, Hospital Universitari De Bellvitge/
Spain
Background: Distant metastases are a common 
event and a determining factor in the treatment 
strategy for lung cancer. Positron emission 
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retrospectively enrolled. Patients with multiple lung 
tumors and/or who received induction chemotherapy 
were excluded. From three institutions, 199 patients 
(99 men, 100 women) who underwent surgery from 
May 2004 through December 2009 were enrolled. 
Patients had pathological stage IA (n=133) or stage 
IB (n=66) adenocarcinoma. Patient age ranged from 
32 to 84 years old (average, 67 years old). Tumor 
size ranged from 0.6 to 5.0 cm (average, 2.3 cm). 
Surgical procedures included lobectomy (n=177; 
88.9%) and limited resection (segmentecotmy and 
wedge resection; n=22; 11.1%). The corrected SUV 
was deÀned as the SUV index, which was calculated 
as the ratio of tumor SUV
max
 to liver SUV
mean
. 
Associations between disease-free survival (DFS) 
and the following factors were analyzed: gender, 
age, smoking history (+ or -), CEA level ( 5.0 or > 
5.0 ng/ml), SUV index, tumor size, lymphovascular 
invasion (+ or -), pleural invasion (+ or -), and 
surgical procedure (lobectomy vs. segmentectomy 
and wedge resection).
Results: Median follow-up was 46 months. The 
SUV index ranged from 0 to 12.4 (average, 2.0; 
median, 1.4). The overall 5-year survival rate after 
surgery was 92.3%. Twenty-Àve patients (12.6%) 
experienced recurrence after surgery. The 5-year 
DFS rate was 84.7%. Multivariate analysis showed 
that SUV index (P=0.02) was independent predictive 
factors for recurrence. ROC curve analysis identiÀed 
an optimal cut-off value of 2.24 for lung cancer 
recurrence. Even in stage IA patients, SUV index 
was an independent predictive marker for recurrence 
(P=0.01), and an optimal cut-off value was 1.73 for 
lung cancer recurrence. Notably, no patients with an 
SUV index < 1.0 experienced recurrence.
Conclusion: This study revealed that SUV index 
can be used as a predictive factor for recurrence. 
Although this was a small and retrospective study, 
we found that SUV index is a signiÀcantly predictive 
marker for recurrence in pathological stage I 
lung cancers. Many additional cases need to be 
prospectively evaluated to conÀrm the utility of SUV 
index in this setting.
Keywords: SUV, PET, Lung cancer, 
Adenocarcinoma
metastasis. Thus, we concluded that cerebral MRI 
is justiÀed as a routine diagnostic procedure in all 
NSCLC patients without distant metastasis in the 
PET-TC. Partially funded by SOCAP.
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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MO24.02 STANDARDIZED UPTAKE 
VALUE CORRECTED BY MEAN 
LIVER STANDARDIZED UPTAKE 
VALUE (SUV INDEX) IS A MARKER 
FOR PREDICTING RECURRENCE IN 
STAGE I LUNG ADENOCARCINOMA: A 
RETROSPECTIVE STUDY OF PATIENTS 
AT THREE INSTITUTIONS: JAPANESE 
NORTHERN EAST AREA THORACIC 
SURGERY STUDY GROUP (JNETS)
Satoshi Shiono1, Hirotsugu Notsuda2, Hiroyuki 
Suzuki3, Masami Abiko1, Toru Sato1, Chiaki Endo2, 
Motoyasu Sagawa4, Takashi Kondo2 
1Department Of Thoracic Surgery, Yamagata 
Prefectural Central Hospital/Japan, 2Department 
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Kanazawa Medical University/Japan
Background: F-18 Áuorodeoxyglucose (FDG) 
positron emission tomography (PET) has become 
an important staging tool for patients with lung 
cancer, and determination of the standardized uptake 
value (SUV) is the most widely used method for 
evaluating patients. Although SUV is recognized 
as a powerful surrogate marker for lung cancer 
outcomes, SUV standardization and reproducibility 
in clinical practice remain major concerns. This 
study was conducted to evaluate the signiÀcance 
of standardized uptake value corrected by mean 
liver standardized uptake value (SUV index) and 
to investigate the possibilty of using PET results in 
clinical trials.
Methods: This was a retrospective study. 
Pathological stage I lung adenocarcinoma patients 
who underwent curative resection after PET-CT were 
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PET-CT showed signiÀcant uptake in 24 of 25 
cases of carcinoid tumours . 18F FDG/PET-CT 
showed uptake in only 18 of 25 cases of carcinoids 
. 68Ga DOTATOC/PET-CT had 100% sensitivity in 
predicting presence of typical carcinoid and 85.71% 
in predicting atypical carcinoids. 68Ga DOTATOC/
PET-CT could even predict the metastasis into 
mediastinal lymph nodes in one case. Two cases of 
Ectopic ACTH producing tumors were localized 
using 68Ga DOTATOC/PET-CT. Based on the 
results the efÀcacy of 68Ga DOTATOC/PET-CT 
and 18F FDG/PET-CT in evaluation of suspected 
bronchopulmonary carcinoids was assesed and 
compared(Table-1) (Table-1)Comparison of 
efÀcacies of 68Ga DOTATOC/PET-CT & 18F 
FDG/PET-CT in the evaluation of suspected 
bronchopulmonary carcinoids 
68Ga DOTATOC/PET-CT 18F FDG/PET-CT 
Sensitivity 96 72 
SpeciÀcity 83.3 25 
Positive predictive 
value 
92.31 66.67 
Negative predictive 
value 
90.90 20 
Conclusion: 68Ga DOTATOC/PET-CT was found 
to be an effective investigation in evaluation of 
Broncho-Pulmonary carcinoid. It was found to be 
effective, not only in localising the primary tumour, 
but also the metastatic spread. 18F FDG/PET-CT 
had low sensitivity and speciÀcity in differentiating 
carcinoid from other tumours. Absence of uptake on 
68Ga DOTATOC practically rules out the possibility 
of typical carcinoid according to our study. 
Keywords: Bronchopulmonary carcinoid, 68Ga 
DOTATOC/PET-CT
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THE EVALUATION OF SUSPECTED 
BRONCHO-PULMONARY CARCINOIDS
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Background: Broncho-pulmonary neuroendocrine 
tumors are a subset of broncho-pulmonary 
neoplasms that share a distinctive basic microscopic 
appearance, resembling Neuro-endocrine tumours 
found elsewhere in the body. Diagnosis of Broncho-
pulmonary carcinoids by non invasive techniques is 
largely limited due to the lack of deÀnitive diagnostic 
features. Structural imaging like CT/MRI, lack the 
ability to assess the functional activity of carcinoids. 
Functional imaging like 111In-Pentetreotide 
scintigraphy although can assess the activity of 
the tumour, lack spatial resolution. Low metabolic 
activity of carcinoids, limit the use of 18F FDG/
PET-CT(2-[Áuorine-18]-Áuoro-2-deoxy-D-glucose/
PET-CT), as a diagnostic entity. 68Ga DOTATOC/
PET-CT(1, 4, 7, 10 e Tetraazacyclododecane - NI, 
NII, NIII , NIIII, - tetra acetic acid (D) ePhe1-thy3-
octreotide /PET-CT) has the advantage of combining 
spatial resolution with assessment of functional 
status of carcinoids. Use of 69Ga DOTATOC/PET-CT 
as primary investigating modality in gastrointestinal 
carcinoids is well documented. However there are 
no large studies evaluating its efÀcacy in broncho-
pulmonary carcinoids . 
Methods: A prospective evaluation of 37 patients, 
who presented in surgical outpatient department with 
clinically/radiologically suspicious bronchopulmonary 
carcinoid tumours was done using 68GaDOTATOC/
PET-CT and 18 F FDG/PET-CT , between July 2007 
and Jan 2011. The nuclear imaging studies of the 
patients were compared, considering histopathological 
tissue diagnosis as gold standard. 
Results: Of the 37 patients, 25 were positive for 
carcinoid on histopathology. 68Ga DOTATOC/
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Conclusion: In this report, we Àrst observed the 
direct lymphatic Áow from the pulmonary segment 
to the mediastinum without passing hilum pulmonis 
by invisible near-infrared Áuorescence imaging 
system using ICG. These results might be a clue for 
investigating the mechanism of skip metastasis to the 
mediastinal lymph node.
Keywords: skip metastasis, Indocyanine green, 
Lung cancer, pleural lymph Áow
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OF EARLY CT-SCAN EVALUATION 
IN FIRST-LINE TREATMENT OF 
ADVANCED BRONCHIOLOALVEOLAR 
CARCINOMA (BAC), BY ERLOTINIB (E) 
OR CARBOPLATIN/PACLITAXEL (C/P)
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Background: Lymphatic spread of carcinoma of 
the lung to the mediastinum is an essential factor 
determining prognosis. To the knowledge, in 
lymph Áow from the pulmonary segment to the 
mediastinum, there is direct drainage of mediastinal 
lymph node without hilar lymph node. This 
phenomenon has been called skip metastasis. We 
studied the lymphatic Áow from the subpleural area 
to the mediastinum using indocyanine green (ICG) 
by invisible near-infrared Áuorescence imaging 
system (Hamamatsu Photonics, Hamamatsu, Japan) 
(Fig.1). 
Methods: 17 patients with lung cancer suspected 
were enrolled in this study between March 2008 
and December 2008 after obtaining written 
informed consent. 25 mg of ICG (Diagnogreen; 
Daiichi Pharmaceutical, Tokyo, Japan) in a total 
of 5 ml of distilled water was prepared. After 
induction of thoracotomy, 0.3ml of ICG was 
injected at the subpleural site near the primary 
tumor. Direct lymphatic Áow by Áuorescence image 
from the injected site to the mediastinum was 
observed for 5 minutes. Correlations of anatomic 
segment of the primary tumor with the direct 
lymphatic Áow to the mediastinum were examined.
Results: There were no complications or adverse 
effects associated with ICG injection. The 
lymphatic vessels draining from the injected 
site were visualized by bright Áuorescence (Fig 
.2). Lymphatic vessels were detected in 14 of 17 
patients (82.4%). Direct lymphatic Áow drained 
from the injected site to the mediastinum was 
conÀrmed in 3 of 14 patients (21.4%). There were 
3 failure cases in detecting lymph Áow due to 
invasion of the primary tumor to the pleura.
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(p=0.02), respiratory symptoms score (p=0.004) 
and with treatment arms (p=0.03). Although PFS 
improved with P/C compared to E (HR=0.667 
[0.461-0.966], p=0.03), OS did not differ between 
the two arms (21.0 [15-33] and 16.4 [12-29] for 
E and C/P, respectively). Finally, an independent 
interaction (p=0.035) was observed for the PFS, 
between treatment arms and cytological subtypes. 
Increased risk of progression was observed with E 
compared to C/P for M-BAC (HR=2.7 [1.4-5.1], 
p=0.003), but not for NM-BAC (HR=0.90 [0.51-
1.54]). 
Conclusion: IFCT-0504 trial showed that: 1) C/P is 
effective in both M- and NM-BAC; 2) Early tumoral 
evaluation is not pertinent to select the best strategy, 
and 3) E is as effective as P/C in NM-BAC, but 
less in M-BAC. Finally, it suggested that strategy 
including C/P and E contributed to improve survival 
in advanced BAC.
Keywords: Adenocarcinoma, bronchiolo-alveolar, 
EGF-R, paclitaxel
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Background: F-18 FDG PET-CT has been reported 
as a valuable tool in determining surrenal gland 
metastasis in different types of tumors. Increased 
F-18 FDG uptake in surrenal glands has been 
determined as a frequent Ànding in PET-CT scans. 
We aimed to investigate the diagnostic value of 
increased F-18 FDG in surrenal glands and to Ànd a 
cut-off SUVmax value in differentiating malignant 
and benign lesions.
Methods: A total of 119 surrenal glands that have 
been reported to have increased F-18 FDG uptake in 
98 patients were included in the study. The PET scan 
Multidisciplinaire Et Innovations Thérapeutiques, 
Hôpital Nord/France, 11Pneumologie, CH/France, 
12Service De Pathologie Respiratoire, CHI/France, 
13Hôpital Privé De L’estuaire/France, 14Service De 
Pathologie Respiratoire, CHR/France, 15Service 
De Pneumologie Dr Souquet, Hôpital Lyon Sud, 
Hospices Civils De Lyon/France, 16IFCT/France, 
17Chest Medicine Department, Caen University 
Hospital/France
Background: First-line EGFR-TKI in advanced 
BAC yielded a 2.9 to 4-month PFS in Phase II 
trials. We and others have suggested that EGFR-
TKI had a reduced activity in M-BAC but that C/T 
and pemetrexed could have some effect, in both 
cytological BAC subtypes. Furthermore, IFCT-0401 
trial has suggested that patients with M-BAC should 
early progress after EGFR-TKI administration. To 
determine the best therapeutic strategy for advanced 
BAC, we conducted a multicentric randomized phase 
II trial to evaluate in Àrst-line treatment E (150 mg/d) 
or C/P (AUC 6 d1 / 90mg/m² d1,8,15 four-weekly) 
with a cross-over at progression and pemetrexed 
in third-line. A secondary objective was also to 
investigate the impact of an early CT-scan evaluation 
i.e. at week 4, on the DCR at 4 months.
Methods: Inclusion criteria: previously untreated, 
cyto/pathologically proven advanced BAC. Primary 
objective: 4-month disease control rate (DCR) 
>30% and PFS >3.0 months. Secondary objectives: 
impact of 4-weeks CT-Scan evaluation on 4-month 
evalution, tolerance, QOL, OS and subgroups 
analyses by arms, cytological subtypes and 
predeÀned biomarkers.
Results: From 09/06 to 07/09, 130/133 patients were 
eligible: median age (68 yrs), PS <2 (87%), females 
(39%), never smokers (27%), stage IIIB-IV (91%), 
NM (46%), M (41%) and undetermined (13%) 
BAC. DCR was 46% (37-55), PFS=3.5 months (2.6-
5.6) and OS=19.5 months (12.1-28.7). Grade 3 
toxicity (>5%): skin for E and hematological/febrile 
neutropenia and neuropathy for C/T; 1 death-related 
toxicity with E. Early evaluations by investigators 
showed early progression for 14 patients in E 
(31%) and 13 in P/C (28%). Among these 37 early 
progressive patients at 4 weeks, 4-month DCR 
was observed in 25% and 22% in E and P/C arms, 
respectively. Finally, DCR was independently 
associated with smoking (p=0.008 and p=0.02), 
respiratory symptoms score (p=0.01), and age >70 
yrs (p=0.03), but not with early CT-Scan evaluation.
PFS was independently associated with smoking 
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Background: Bone metastasis is common in lung 
cancer and affects approximately 30% of patients 
during the course of the disease. In other tumour 
types a well-known response pattern of bone marrow 
metastasis is osteoblastic bone Áare
Methods: Observations summarized in this report 
are based on a preplanned, independent, blinded, 
centralized, radiological review of a randomized 
study of single agent amrubicin (A), amrubicin 
combined with cisplatin (AP), and etoposide 
combined with cisplatin (PE) as Àrst line treatment 
in extensive disease (ED) small cell lung cancer 
(SCLC). CT scans of the chest and upper abdomen 
of 71/88 patients who had an investigator reported 
CR, PR or SD as best response were reviewed 
by one blinded radiologist using RECIST 1.0. 
In 11/71 patients review was not assessable due 
to missing image data. The radiologic reports 
were retrospectively analysed to assess previous 
knowledge of bone involvement.
Results: In this group of patients, 3 had bone 
was performed after at least 12 hours of fasting state. 
Blood glucose levels of patients were less than 200 
mg/dl during the injection. A low dose-non enhanced 
CT was performed preceding a PET scan which was 
obtained in 7-8 bed positions (1 bed position/1.5 
minute) using PET-CT scanner with time-of-
Áight technology 60 minutes after FDG injection. 
SUVmax values were obtained for all lesions. Final 
decision on surrenal lesions were performed by 
using histopathological evaluation, MRI imaging or 
clinical follow-up. Mann-Whitney U test, Wilcoxon 
Signed Rank test and ROC curve analysis were 
performed for statistical analysis.
Results: A total of 70 lesions were evaluated as 
benign. The mean SUVmax for benign lesions was 
3.03 ± 1.14. Patients without any primary malignancy 
had 16 benign surrenal lesions (SUVmax: 3.37 ± 
1.43). Patients with a primary malignancy had 54 
surrenal benign lesions (SUVmax: 2.93 ± 1.03). There 
was no statistically signiÀcant difference in SUVmax 
values between these groups (p: 0.54) with benign 
surrenal lesions. There were 49 metastatic surrenal 
lesions with a mean SUVmax of 8.77 ± 5.37. Forty-
one of these malignant lesions were in patients with 
diagnosis of nonsmall cell lung cancer (NSCLC) and 
6 lesions were in patients diagnosed to have small 
cell lung cancer (SCLC), 1 with unknown primary 
and the last with submandibular adenocarcinoma. The 
mean SUVmax value of surrenal lesions in patients 
with NSCLC was 9.12 ± 5.60 and for SCLC was 6.62 
± 3.62. The SUVmax values of surrenal metastasis 
in patients with NSCLC were signiÀcantly higher 
than the SUVmax values of surrenal metastasis in 
patients with SCLC (p<0.05). The SUVmax values 
of all malignant surrenal lesions were signiÀcantly 
higher than the SUVmax values of all benign lesions 
(p<0.001). A ROC curve was generated. A sensitivity 
ratio of % 73.5 and a speciÀcity % 94.3 was obtained 
using the SUVmax: 5.45 as a cut-off value for the 
differentiation of a benign from a malignant surrenal 
lesions.
Conclusion: F-18 FDG PET study can diagnose a 
surrenal metastasis with a sensitivity of 75.5% and 
speciÀcity of 94.3% using a SUVmax 5.45 as a cut-
off value. In our study we demonstrated that using 
a SUVmax value smaller than 5.45 can differentiate 
benign surrenal lesions with a speciÀcity of 94.3 %. 
Metastatic surrenal lesions in patients with NSCLC 
demonstrated statistically higher SUVmax values 
than SCLC.
Keywords: SUVmax, surrenal glands, F-18 FDG 
PET-CT
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Background: Tumours invading the mediastinum 
can often be resected en-bloc with neighbouring 
structures, however extensive invasion of the 
superior vena cava (SVC), pulmonary artery (PA) 
trunk, aortic wall, atria or ventricular wall require 
adequate preoperative planning and are often 
considered a limit. As the identiÀcation of a surgical 
resection plane if often doubtful on CT scans, we 
tested if cine-Magnetic Resonance (CMR) would 
allow for a better differentation between contact and 
inÀltration of vital structures.
Methods: Sites of contact between tumour and 
mediastinal structures on CT scans were individually 
assessed by CMR. The CMR study protocol included 
3 orthogonal stacks of Steady State Free Precession 
(SSFP) sequences after administration of contrast 
medium. We deÀned inÀltration as absence of sliding 
motion and/or absence of chemical shift (seen as a 
dark line) between tumour and adjacent structures. 
Surgical Àndings (presence or absence of a resection 
plane) were reported postoperatively for each 
individual site. 
Results: Twelve patients with mediastinal tumours 
(8 males and 4 females, age 23-72), in whom a 
total 59 contact sites were identiÀed by CT scans, 
were preoperatively assessed by CMR. Histology 
was lung cancer in 5, thymoma-thymic carcinoma 
in 5, sarcoma in 1, and theratoma in 1. Surgical 
procedures were: pneumonectomy 5, mediastinal 
mass resection 5, extrapleural pneumonectomy 1, 
and exploratory thoracotomy 1 in one. The negative 
predictive value was 0.94, positive predictive 
value 0.80, sensitivity 0.91, speciÀcity 0.86, and 
accuracy 0.88. CMR imaging always correctly 
anticipated or excluded invasion of SVC (6 cases), 
supra-aortic vessels (2), aortic wall (7), PA trunk 
(2), atrial wall (7), ventricular wall (3), oesophagus 
(2), and pericardium (9) but was less reliable 
for intrapericardial pulmonary vessels and left 
anonymous vein. 
Conclusion: Preoperative CMR imaging allows 
for an accurate selection and surgical planning 
of complex resections in patients with advanced 
tumours in contact with mediastinal structures. 
Keywords: MRI, Preoperative assessment, 
Mediastinal mass, Surgery
metastases as a site of disease at baseline and 2/3 
developed new osteoblastic lesions. In 11 patients 
there were no baseline/pre-existing/documented 
bone lesions, but new osteoblastic lesions developed 
on follow up scans. The 13 patients who developed 
new osteoblastic bone lesions on follow-up CT 
scans were treated with A, AP and PE in 4, 5 and 4 
cases, respectively. All 13 patients were responders 
(had PR as assessed by both independent reviewer 
and local investigators). We cannot comment on 
bone metastasis in the patients who had progressive 
disease to their primary chemotherapy as they were 
excluded from the radiological review.
Conclusion: In this study new developing 
osteoblastic bone lesions were observed in a 
surprisingly large number of responding patients 
indicating a high prevalence of occult bone 
marrow metastasis in SCLC and did not represent 
progressive disease. To our knowledge this is the Àrst 
report of osteoblastic bone ‘Áare’ in SCLC patients 
with previously unknown bone metastasis. Staging 
of SCLC should therefore include imaging tests 
sensitive for bone marrow metastasis (e.g. MRI or 
PET).
Keywords: Imaging, Osteoblastic bone Áare, CT, 
SCLC
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FLT SUVpeak 3.1 had a signiÀcantly better overall 
survival (15.67 months [95% CI 6.4 to 25 months]) 
compared to patients with an SUVpeak >3.1 (3.2 
months [95% CI 0 to 8.2 months]) (p=0.008, log 
rank). For FDG, the OS groups divided by the 
median (6.3) were 9.79 months (0-27.03 months, 
95% CI) vs 4.89 months (1.77-8.03 95% CI)
(p=0.042). Of the clinical parameters, only age was 
signiÀcantly associated with OS (p=0.046). Both 
FLT and and FDG baseline values were signiÀcant 
prognostic factors in multivariate analysis with age 
(p=0.020 and p=0.033, respectively).
Conclusion: The uptake of both tracers of the most 
active tumor manifestation site are strong prognostic 
markers for overall survival among patients with 
advanced NSCLC treated with erlotinib Àrst-line.
Keywords: NSCLC, FLT-PET, FDG-PET, Prognosis
New Imaging Techniques and New Applications of Established 
Imaging Techniques in Thoracic Malignancies Thursday, 7 July 2011 
12:30-14:00
MO24.12 CHARACTERISATION AND 
PROGNOSTIC SIGNIFICANCE OF 
GLOBAL AND REGIONAL HYPOXIA IN 
MESOTHELIOMA USING 18F-MISO PET/
CT IMAGING
Tatiana M.L. Segard1, Anna K. Nowak2, Y.C. 
Gary Lee3, Michael Millward4, Laurence M.J.A. 
Morandeau5, Elaine M. Campbell1, Roslyn J. 
Francis2 
1Nuclear Medicine, Sir Charles Gairdner Hospital/
Australia, 2School Of Medicine And Pharmacology, 
University Western Australia/Australia, 3Pleural 
Disease Unit, Lung Institute Of Western Australia/
Australia, 4School Of Medicine And Pharmacology 
(m503), The University Of Western Australia/
Australia, 5Medical Technology & Physics, Sir 
Charles Gairdner Hospital/Australia
Background: Malignant pleural mesothelioma 
(MPM) is a relatively chemoresistant cancer with a 
poor prognosis. Compelling evidence now suggests 
that the presence of hypoxia induces tumour 
aggressiveness and confers cellular resistance 
to both chemotherapy and radiation treatment. 
The aim of this pilot study was to determine the 
activity of the hypoxia imaging agent (18)F-labeled 
Áuoromisonidazole (FMISO) using positron 
emission tomography/computed tomography 
(PET-CT) in MPM and to compare FMISO 
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TOMOGRAPHY (PET) AND THEIR 
PROGNOSTIC IMPACTS IN PATIENTS 
WITH ADVANCED NON-SMALL CELL 
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Background: Imaging tools gain in importance for 
assessment of pharmacodynamics, prognosis and 
prediction of therapeutic outcome. We evaluated 
the prognostic value of 3’-deoxy-3’-[18F]Áuoro-
L-thymidine (FLT) and 2’-deoxy-2’-[18F]Áuoro-
D-glucose (FDG) uptake measured by positron 
emission tomography (PET) with regards to the 
prognosis in patients with metastatic non-small cell 
lung cancer (NSCLC) prior to systemic therapy with 
erlotinib.
Methods: FLT and FDG uptake were analyzed in 41 
chemonaive patients with advanced NSCLC (stage 
IV) treated with erlotinib Àrst-line prior to systemic 
therapy. The median peak SUV of the lesion with 
the highest SUV (SUVpeak) for both FLT and FDG 
was used for dichotomizing the patients into two 
groups. Both were analyzed in univariate analysis 
using Kaplan-Meier statistics and log rank for 
the association with survival and compared with 
clinical parameters (age, gender,histology, ECOG 
performance state). Multivariate analysis was 
performed using Cox regression.
Results: Median follow-up was 21.9 months. As 
expected, the baseline values of FLT and FDG 
were strongly correlated with each other (p 0.0001, 
Pearson). In univariate analysis, patients with an 
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Background: We reported results which evaluated 
the clinical value of MRI for differentiating among 
the invasiveness of lung adenocarcinoma in patients 
by comparing the MRI Àndings with the pathological 
Àndings in WCLC 2009. In the near future, MRI 
with the several sequences may thus be valuable 
as additional modality for evaluating the grade of 
invasiveness in the lesions. Diffusion-weighted 
magnetic resonance imaging (DWI) represents the 
biological characteristics of tissue. DWI reÁects the 
random thermal motion of molecules (Brownian 
motion). The Brownian motion of protons in 
bulk water are considered to mainly contribute to 
the signal in DWI. We retrospectively evaluated 
the usefulness of DWI for differentiating among 
different types of invasiveness in small-sized lung 
adenocarcinomas by comparing the DWI Àndings 
with the pathologic Àndings.
Methods: MRI was performed on a 1.5T system 
(Magnetom Avanto; Siemens, Erlangen, Germany) 
with high-performance gradients and total imaging 
matrix (Tim). All MRI images were posted on a 
Picture Archiving and Communication System 
(PACS) workstation for review by the radiologists. 
From May 2005 to June 2008, forty-six patients 
with lung adenocarcinoma measuring 2 cm or less 
across the greatest dimension underwent a surgical 
operation including preoperative MRI study in 
Gunma prefectural Cancer Center. Of all the tumors, 
14 were bronchioloalveolar carcinoma (so-called 
Noguchi’s type A and B; type A+B group), 26 were 
adenocarcinomas with mixed subtypes (so-called 
Noguchi’s type C; type C group) and 6 were the 
other histological subtypes of adenocarcinoma 
(Noguchi’s type D, E and F in this study; type 
D+E+F group). The signal intensities of a lesion 
(DWI) and the spinal cord (SC) were severally 
analyzed in the region of interests (ROIs), and the 
activity with glucose metabolism reÁected by (18)
F-Áuorodeoxyglucose (FDG). 
Methods: Consenting patients with histologically 
or cytologically conÀrmed MPM not currently 
receiving systemic or local treatment underwent 
both FMISO and FDG PET-CT scans as part of a 
prospective study from March 2010 to December 
2010. The study had Human Research Ethics 
(HREC) and Radiological Council approval. Patients 
received 300 MBq/m2 of FMISO with an uptake 
phase of 2 hours prior to imaging. FDG PET was 
performed as per standard clinical protocol (6 hour 
fast, 200 MBq/m2 FDG, 60 minute uptake phase). 
FMISO and FDG PET-CT scans were analysed by 
two independent PET physicians. Regions of interest 
were drawn on the FDG and FMISO images at the 
sites of maximal tumour activity. The maximum 
standardized uptake value (SUVmax) was used to 
depict FDG activity, and SUVmax and tumour to 
background (muscle) ratio were used to quantify 
FMISO activity. 
Results: Eleven patients (all male) have completed 
FDG and FMISO PET-CT scans. Visual analysis 
demonstrated that FMISO activity was detected in 10 
of 11 patients. One patient had no evidence of FDG 
or FMISO activity in tumour (previously treated 
mesothelioma in remission). In the 10 patients with 
FDG and FMISO activity in tumour the average 
tumour SUVmax was 5.7 (range 1.9 to 10.0) for 
FDG activity and 2.2 (range 1.4 to 3.3) for FMISO 
activity. FMISO tumour to background ratios in 
the 10 patients visually assessed to have signiÀcant 
FMISO activity was 1.6 (range 1.2-1.9). There was 
a positive correlation between intensity of metabolic 
activity on FDG PET-CT and hypoxia on FMISO 
PET-CT as assessed by SUVmax (r=0.89, p<0.001) 
and between FDG SUVmax and FMISO tumour to 
background activity (r=0.78, p=0.008). 
Conclusion: MPM demonstrates areas of hypoxia 
as assessed by FMISO. Tumours exhibiting a higher 
SUVmax on FDG PET also had more hypoxia. The 
relationship of tumor hypoxia to treatment response 
(chemotherapy and/or radiotherapy) should be 
assessed prospectively.
Keywords: mesothelioma, PET/CT, 
Fluoromisonidazole, Hypoxia
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cases, and radiation alone in 11. The mid-radiation 
scans were performed when patients had received 
30-36 Gy. The gross tumor volume and maximum 
standardized uptake value (SUVmax) at each 
imaging time point were recorded. Age, stage, and 
Karnofsky performance status (KPS) were also 
recorded as potential prognostic factors. Endpoints 
analyzed were local (within the radiation Àeld) 
and distant (out-of-Àeld) progression, and overall 
survival. Progression was deÀned as biopsy-proven 
recurrence or progression by imaging sufÀciently 
suspicious to warrant a change in treatment.
Results: Median follow-up from the time of 
radiotherapy simulation was 16.4 months. The 
median age was 69 years (range 47-90). Stage 
distribution was 7 stage I-II, 33 stage III, 4 stage IV 
(oligometastatic), 10 recurrence after prior treatment. 
Median KPS was 80. Median radiation dose was 
66 Gy. On multivariate Cox proportional hazards 
analysis, lower KPS (p<0.001), higher pre-radiation 
tumor volume (p=0.003), and higher mid-radiation 
SUVmax (p=0.05) were signiÀcantly associated with 
shorter overall survival after controlling for age and 
stage. Higher mid-radiation SUVmax also correlated 
signiÀcantly with shorter time to any progression 
(p<0.001) and distant progression (p=0.01), and 
insigniÀcantly but with a trend with shorter time to 
local progression (p=0.09).
Kaplan-Meier survival plots stratiÀed by tertiles of 
mid-radiation SUVmax demonstrate its impact on 
overall survival (Figure 1) and distant progression 
(Figure 2).
DWI/SC ratio was calculated with the value of DWI 
divided by the value of SC.
Results: The calculated mean DWI/SC ratio for 
the lesions were as follows: 0.448 ± 0.261 (mean 
± standard deviation) for type A+B group, 0.963 ± 
0.465 for type C group, and 0.816 ± 0.291 for type 
D+E+F group. The mean DWI/SC ratio of type A+B 
group was signiÀcantly lower than those type C 
(p=0.0005) and type D+E+F group (p=0.0117).
Conclusion: DWI is therefore considered to be 
a useful diagnostic modality for differentiating 
the subtypes of lung adenocarcinomas. MRI 
Àndings may be used to help characterize lung 
adenocarcinomas, and these Àndings may provide 
useful supplementary information before regular 
medical checkups or decisions of surgical procedures 
such as limited resection.
Keywords: magnetic resonance imaging, 
diffusion weighted imaging, lung adenocarcinoma, 
bronchioloalveolar carcinoma
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MO24.14 MID-RADIATION THERAPY 
PET CORRELATES WITH SURVIVAL IN 
LOCALLY ADVANCED NSCLC
Billy W. Loo1, Christine Chang1, Julian Hong1, 
Heather Wakelee2, Quynh Thu Le1, Wendy Y. 
Hara1, Andrew Quon3, Peter G. Maxim1, Edward E. 
Graves1, Maximilian Diehn1, Michael Olson1 
1Radiation Oncology, Stanford University & Cancer 
Center/United States Of America, 2Oncology, 
Stanford University/United States Of America, 
3Radiology, Stanford University/United States Of 
America
Background: Results of chemoradiotherapy for 
locally advanced non-small cell lung cancer (LA-
NSCLC) are suboptimal. We studied mid-radiation 
PET as a potential early response prediction 
biomarker that would be valuable for individualized 
therapy adaptation at a time point when additional 
intervention is possible.
Methods: We retrospectively studied the outcomes 
of 54 consecutive patients who were treated with 
deÀnitive radiation therapy for LA-NSCLC from 
October 2005 to July 2009 and who also received 
both pre- and mid-radiation PET-CT scans. 
Concurrent chemoradiotherapy was given in 43 
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Conclusion: Mid-radiation PET is a strong 
prognostic factor for progression and survival in LA-
NSCLC treated with deÀnitive chemoradiotherapy. 
It may be useful as a risk-stratiÀcation biomarker 
and perhaps ultimately to guide individual therapy 
adaptation.
Keywords: Radiation Therapy, PET-CT, Early 
response prediction
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P1.001 TARGETING THE EPIGENETIC 
SIGNATURES AS EARLY EVENT 
FOR THE CONTROL OF TUMOR 
DEVELOPMENT
Krishna P. Gupta, Manuraj Pandey 
Carcinogenesis, Indian Institute Of Toxicology 
Research/India
Background: Lung cancer is among the major 
causes of death due to cancer. There is need to 
detect the cancer at an early stage by developing 
the newer targets and its control by newer agents. 
Epigenetic changes are among the earliest changes 
in tumorigenesis. Epigenetics / methylation precede 
neoplasia and if they are responsive to anticancer 
agents that could be used as an early marker for the 
assessment or detection of cancer. The study is to 
assess the early changes for the detection and control 
of tumor development.
Methods: We used mouse model for lung tumor 
development. A studied was done at the time of 
no tumors i.e. three months and another study 
was after the tumors were developed i.e. at eight 
months. 3 ip injections of ethylnitosourea (ENU) 
were administered weekly at the dose of 40 mg/kg. 
2% inositol hexaphosphate (IP6) was used as anti 
tumor agent in drinking water. At the end lungs were 
isolated and were used for the histopathological 
analysis, genes expression and methylation study. 
Results: There were no tumors but hyperplasia and 
lymphocytic inÀltrations were observed at three 
months and tumors were present at eight months 
after the ENU exposure. To pick up the early 
changes, detailed study was carried out in the three 
months exposure samples. Tumor suppressor gene, 
p16, was down regulated by ENU at the level of 
protein and mRNA both. IP6 tried to revert this down 
regulation. At the same time, ENU down regulated 
the global DNA methylation and up regulated the 
p16 gene promoter CpG methylation. Thereafter, we 
observed the up regulation of the critical events of 
epigenetic machinery in terms of the expressions of 
DNMT1, MeCP2, MBD1 and HDAC1 by ENU. IP6 
protected the alterations at three months and also the 
tumor development at eight months. Other changes 
before and after the tumor development will also be 
discussed. 
Conclusion: The alterations in the epigenetic 
machinery were observable before the appearance of 
tumor and were responsive to the anticancer agent 
as well. DNA methylation appeared to be involved 
in the development and progression of tumors and 
methylation of promoter CpG islands is a mechanism 
for inactivation of tumor-suppressor genes, p16. We 
suggest that these epigenetic signatures are involved 
even before the tumor is developed and through 
these changes IP6 modulates the gene expression. 
They can be targeted for the timely management/ 
prevention of the tumor development by anticancer 
agents. 
Keywords: Epigenetic, Lung tumor, Prevention, 
Inositol hexaphosphate
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P1.002 IN VIVO INHIBITION OF 
LUNG CANCER BY PYRROLIDINE 
DERIVATIVES: A NOVEL HUMAN 
CYTOSOLIC PHOSPHOLIPASE A2Į 
INHIBITOR
Soundarapandian Kannan, Shenbagamoorthy 
Sundarraj 
Zoology, Bharathiar University/India
Background: Cytosolic phospholipase A
2
Ơ 
(cPLA
2
Ơ) produces free arachidonic acid and 
lysophospholipds, contributes to the production 
of eicosanoids and platelet activating factors. We 
aim to determine the level of cPLA
2
Ơ expression in 
lung cancer cell lines and the effect of pyrrolidine-1 
targeting cPLA
2
Ơ in vitro and in vivo. 
Methods: The expression of cPLA
2
Ơ was 
determined in selected mammalian cancer 
cell lines by RT-PCR, Western blot, and 
immunocytochemistry. Growth inhibition and 
cPLA
2
Ơ activity were determined after inhibition 
with pyrrolidine-1. Cytosolic PLA
2
Ơ inhibitor 
namely pyrrolidine-1 was also administered to lung 
cancer xenograft mouse models and assessed the 
inhibitory level in both in vitro and in vivo.
Results: cPLA
2
Ơ is expressed in all the selected 
mammalian cancer cell lines. The cPLA
2
Ơ 
expression was increased in A549 cells when 
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compared to other selected cell lines. Pyrrolidine-1 
inhibitory assay revealed a signiÀcant reduction not 
only in cell proliferation rate but also in cPLA
2
Ơ 
activity in the lung cancer cells. The inhibitory 
assay clearly demonstrating that the approximately 
38% of A549 xenograft growth was inhibited when 
compared with the respective control.
Conclusion: In conclusion, Cytosolic PLA
2
Ơ 
is present in cancer cell lines. These levels are 
increased in A549 lung cancer cell lines. Cytosolic 
PLA
2
Ơ may play a role in lung cancer cell 
proliferation and apoptosis, and its inhibition results 
in decreased cell growth. The drug pyrrolidine-1 
seems to act speciÀcally through the cPLA
2
Ơ 
enzyme. These Àndings are replicated in vivo, 
with pyrrolidine-1 treatment. Cytosolic PLA
2
Ơ is a 
potentially effective target for therapy of lung cancer. 
Keywords: Cytosolic phospholipase A2 Alpha 
protein (cPLA2Ơ), Nonsmall cell lung cancer cells, 
Phyllanthus niruri, Pyrrolidine-1
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P1.003 SMOKING HISTORY AFFECTS 
THE PRODUCTION OF TUMOR 
ANTIGEN SPECIFIC ANTIBODIES IN 
PATIENTS WITH LUNG CANCER
Dagmar Myšíková1, Anna Fialová2, Radek Špíšek2, 
Robert Lischke1 
13rd Deptartment Of Surgery, University Hospital 
Motol/Czech Republic, 2Institute Of Immunology, 
University Hospital Motol/Czech Republic
Background: Understanding the characteristics and 
importance of tumor speciÀc immune responses 
is a prerequisite for the development of cancer 
immunotherapy strategies. In order to evaluate 
the clinical relevance of tumor speciÀc immune 
responses, we prospectively analyze the presence 
of cellular and humoral tumor speciÀc immune 
responses in lung cancer patients. In this study, we 
compared the differences in the frequency of tumor 
antigen speciÀc antibodies according to the patients´ 
smoking history. 
Methods: Serum from patients with non-small cell 
lung cancer (n=32) and normal controls (n=19) was 
analyzed for the presence of antibodies against three 
tumor antigens HER2 neu, NY-ESO-1 and MAGE 
A4 by enzyme-linked immunosorbent assay. Cut-
off point of positive seroreactivity was deÀned as 
an optical density value greater than the mean plus 
3SDs of the normal controls. Seropositivity was 
evaluated in three subgroups of lung cancer patients- 
smokers, exsmokers, nonsmokers. Exsmokers were 
deÀned as former smokers with at least one year 
abstinence from smoking. 
Results: There were no signiÀcant sex differences 
in the antibody production. 37,5% (12 lung cancer 
patients) produced at least one of three investigated 
tumor antigen speciÀc antibodies: 31,25% (10 
patients) had antibodies against NY-ESO-1, 
25,00% ( 8 patients patients) had antibodies against 
MAGE A4 and 18,75% ( 6 patients) against HER2 
neu. Production of tumor speciÀc antibodies has 
cumulative character- 50% of patients produce 
both NY-ESO and MAGE A4 antibodies, 40% 
produce NY-ESO together with HER 2 neu speciÀc 
antibodies. There was no correlation between the 
presence of tumor speciÀc antibodies and the stage 
of the disease or tumor histology. Interestingly, 
the presence of tumor antigen speciÀc antibodies 
strongly correlated with the history of smoking 
and with the elevated levels of CRP (a negative 
prognostic factor). There was a signiÀcant difference 
in the frequency of NY-ESO-1, MAGE-A4 and 
HER 2/neu antibodies. The frequency of tumor 
speciÀc antibodies is signiÀcantly higher in smokers 
and sharply declines in the groups of ex- and non-
smokers. 
Smoker 
n=18 
Exsmoker 
n=9 
Nonsmoker 
n=5 
Signi¿cance 
level 
NY-ESO 
positive 
50%, n=9 11,11%, n=1 0%, n=0 p=0,014 
HER 2 neu 
positive 
33,33%, n=6 0%, n=0 0%, n=0 p=0,019 
MAGE A4 
positive 
33,33%, n=6 11,11%, n=1 20%, n=1 p=0,048 
Conclusion: We show that the history of active 
smoking has a profound impact on the frequency 
of tumor antigens speciÀc antibodies in the serum 
of lung cancer patients. The ethiology of this 
phenomenon and its clinical relevance remains 
unknown and requires further studies. Antibody 
production and higher CRP levels in smokers 
might indicate the chronic inÁammatory state that 
potentiates the development of tumor speciÀc 
immune response. 
Keywords: effect of smoking history, tumor antigen 
speciÀc antibodies
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Conclusion: Secretory phospholipase A2 inhibition 
attenuates proliferation and viability in lung cancer 
cells by promoting apoptosis. The effect of sPLA2 
on growth and proliferation is mediated in part by 
ERK 1/2 intracellular signaling. These Àndings 
justify further evaluation of secretory phospholipase 
A2 as a potential therapeutic target in lung cancer.
Keywords: secretory phospholipase A2, Lung 
cancer
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
Poster Session 1 – Cancer Biology Monday, 4 July 2011 12:15-14:15
P1.005 MICRORNA-145 SUPPRESSES 
LUNG ADENOCARCINOMA INITIATING 
CELLS PROLIFERATION BY 
TARGETING OCT4
Rong Yin, Shuai Zhang, Yaqin Wu, Feng Jiang, Lin Xu 
Thoracic Surgery, Cancer Hospital Of Jiangsu 
Province/China
Background: Recent studies demonstrated that 
microRNA-145 was downregulated in human 
cancer cells and may function as a tumor suppressor. 
However, its role in the tumorigenesis of lung 
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P1.004 SECRETORY PHOSPHOLIPASE 
A2 INHIBITION PROMOTES APOPTOSIS 
IN LUNG CANCER CELLS AND 
MODULATES ERK 1/2 ACTIVATION
Jessica A. Yu1, Miral R. Sadaria2, Xianzhong Meng2, 
David A. Fullerton2, Michael J. Weyant2 
1Division Of Cardiothoracic Surgery, University Of 
Colorado Denver School Of Medicine/United States 
Of America, 2University Of Colorado Denver School 
Of Medicine/United States Of America
Background: Lung cancer remains the leading 
cause of cancer death in the world with limited 
options for prevention or treatment. We recently 
identiÀed secretory phospholipase A2 (sPLA2) as 
integral to the invasive potential of lung cancer cells. 
SPLA2 has also been demonstrated to inÁuence 
proliferation and viability in numerous cancer cell 
types though the mechanism of this has not been 
well elucidated. ERK 1/2 has been implicated in 
regulating proliferation and apoptosis in cancer. We 
hypothesize a link between sPLA2 activity, ERK 1/2 
activation, and tumor cell viability and proliferation. 
We propose that inhibition of sPLA2 modulates ERK 
1/2 activation in lung cancer cells and promotes 
apoptosis. 
Methods: A549 and H358 cells were treated 
with a speciÀc inhibitor of group IIa secretory 
phospholipase A2. Apoptosis was evaluated 
by Áow cytometric detection of annexin V and 
propidium iodide. Cell viability and proliferation 
were measured with 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) 
and bromodeoxyuridine (BrdU) incorporation 
assays, respectively. Cell necrosis was evaluated 
by LDH assay. The effect of sPLA2 inhibition on 
phosphorylation of ERK 1/2 was detected by western 
blot. 
Results: Inhibition of group IIa secretory 
phospholipase A2 resulted in a signiÀcant dose-
dependent increase in apoptosis in both A549 and 
H358 cells (p<.001, Figure 1). Proliferation and 
viability also decreased signiÀcantly in both cell 
lines in a dose-dependent manner without causing 
cell necrosis (p<.001). These effects were associated 
with a dose-dependent decrease in phosphorylation 
of ERK 1/2 (p<.001, Figure 2).
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accumulating data indicate that some miRNAs can 
function as tumor suppressors or oncogenes and are 
important in cancer development. Deletion or loss 
of function of a tumor-suppressing miRNA results 
in overexpression of target oncogenes. Conversely, 
activation or overexpression of an oncogenic miRNA 
results in silencing of tumor-suppressing target 
genes. According to miRNA proÀles on microarray, 
miR-99b was down-expressed in Korean lung cancer. 
FGFR-3 is predicted target of miR-99b through two 
public algorithms. FGFR-3 has been demonstrated to 
be involved in the RAS/RAF/MEK/MAPK pathway 
through activation of p90 ribosomal S6 kinase. 
It has been reported that FGFRs are frequently 
overexpressed in NSCLC cell lines, suggesting that 
an FGFR-dependent autocrine signaling pathway 
may operate in a subset of NSCLCs.
Methods: We studied expression of miR-99b and 
FGFR-3 using quantitative reverse transcription 
PCR (qRT-PCR) in lung cancer tissue. To examine 
whether miR-99b could regulate FGFR-3 in lung 
cancer, we performed transient transfection of 
pre-miR-99b into lung cancer cell line, then we 
performed qRT-PCR and western blot in HCC1438, 
HCC95, and H522 cells for analysis of FGFR-
3 expression. Luciferase reporter gene assays 
were performed to identify miR-99b targets. We 
hypothesized the miR-99b has a role of inhibitor cell 
growth in lung cancer. To test this hypothesis, we 
performed cell proliferation assay.
Results: miR-99b was down-regulated and FGFR-3 
was up-regulated in lung cancer. Over-expression 
of miR-99b induced marked reduction of FGFR-3 
mRNA levels and protein level. The signal from a 
luciferase reporter was signiÀcantly decreased at 
one miR-99b target site at the 3’UTR of FGFR3, 
suggesting that miR-99b directly regulates FGFR3. 
The growth rate in miR-99b precursor treated cell 
was lower than in negative control of miR treated 
cell.
Conclusion: Abnormal down-regulation of miR-99b 
could lead to the over-expression of FGFR-3 in lung 
cancer. miR-99b may be a potent tumor suppressor 
and may be a potential candidate of therapeutic tool 
in lung cancer.
Keywords: microRNA, FGFR-3, tumor suppresor 
gene, Lung cancer
cancer remains unclear. Here we demonstrated that 
upregulation of miR-145 suppressed the cancer 
initiating cells proliferation of the human lung 
adenocarcinoma A549 cell line via targeting Oct4 
mRNA.
Methods: A549 cells were transfected by miR-145 
mimics, inhibitors, and their negative controls. Cell 
Counting Kit-8 assay was employed for evaluating 
proliferation capacity. Cell migration capacity 
was evaluated by using the matrigel and millicell 
chambers. Flow cytometry was used for cell cycle 
and CD133 phenotype analysis. Oct4 protein level 
was also analyzed by western blot. Tumorspheres 
were cultured in a serum-free medium with the 
support of providing growth factors. Finally, 
the targeting gene of miR-145 was predicted by 
bioinformatics analysis and validated by a luciferase 
reporter system.
Results: Overexpression of miR-145 by transfecting 
mimics can signiÀcantly suppress A549 cells 
proliferation and migration capacity, decrease 
the percent of S phase cells, the ratio of CD133+ 
initiating cells and the Oct4 protein level, as well as 
inhibiting the capacity of tumorspheres formation. 
Oct4 mRNA is directly targeted by miR-145 which 
was validated by the luciferase reporter system.
Conclusion: It is therefore conÀrmed that miR-
145 can impair the proliferation of human lung 
adenocarcinoma initiating cells via targeting OCT4 
and then lead to lung cancer development inhibition.
Keywords: cancer initiating cells, proliferation, lung 
adenocarcinoma, microRNA
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P1.006 MICRORNA-99B INHIBITS 
LUNG CANCER GROWTH THROUGH 
REGULATION OF FIBROBLAST 
GROWTH FACTOR RECEPTOR 3
Yumi Lee1, Soo Young Lee2, Sun Jung Kwon1, 
Eugene Choi1, Moon Jun Na1, Young Jin Kim3, Hyun 
Min Cho3, Jae Ku Kang4, Ji Woong Son1 
1Internal Medicine, Konyang University Hospital/
Korea, 2Myunggok Research Institute For Medical 
Science, Konyang University/Korea, 3Department 
Of Thoracic Surgery, Konyang University Hospital/
Korea, 4Department Of Pharmacology, College Of 
Medicine, Konyang University/Korea
Background: Dysregulation of miRNA expression 
has been identiÀed in a number of cancers and an 
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bladder and mesothelial cells of tunica vaginalis 
produced intelectin-1 partially. In adrenal cortex and 
renal collecting tubule, intelectin-1 was detected 
weakly. Intelectin-1 in epithelial MPMs was detected 
in cytoplasm. In mucinous type adenocarcinomas, 
intelectin-1 was showed in mucus of the goblet 
cells and in cytoplasm of epithelial cells. Lung 
non-mucinous adenocarcinomas did not produce 
intelectin-1.
Conclusion: In non-neoplastic tissues, only limited 
cells produced intelectin-1. In mucinous type 
adenocarcinoma (stomach, colon, pancreas, lung, 
uterine body), intelectin-1 was partially detected in 
mucus of goblet cells and in cytoplasm of epithelial 
cells. However, in histologically, it is not difÀcult to 
differentiate MPM from these metastatic mucinous 
type adenocarcinoma in pleura. Lung non-mucinous 
adenocarcinomas, which is difÀcult to differentiate 
from MPM, did not produce intelectin-1. Therefore, 
we consider intelectin-1 is useful for diagnosing 
MPM.
Keywords: intelectin-1, immunohistochemistry, 
malignant pleural mesothelioma
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.008 RELATION OF LUNG CANCER 
HISTOLOGY TO PERIPHERAL 
MICROVASCULAR SATURATION 
MEASURED BY OPTICAL 
SPECTROSCOPY
Cor Van Der Leest1, Hendricus Sterenborg2, Paul 
Mulder2, Remco Djamin1, Henk Hoogsteden3, 
Joachim Aerts1 
1Pulmonary Diseases, Amphia Hospital/Netherlands, 
2Erasmusmc/Netherlands, 3Erasmus Medical Center/
Netherlands
Background: Lung cancer is historically divided 
into Non-Small Cell Lung Cancer (NSCLC) and 
Small Cell Lung Cancer (SCLC), due to differences 
in treatment options and prognosis. Hypoxia is a 
well known parameter in many solid tumors and 
has been related to high metastatic rate and poor 
prognosis. Whether hypoxia is different between the 
histological subtypes of lung cancer is unknown. 
The aim of the study was to compare spectroscopic 
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P1.007 IMMUNOHISTOCHEMICAL 
EVALUATION OF INTELECTIN-1 
EXPRESSION, A MESOTHELIOMA 
MARKER, IN NON-NEOPLASTIC AND 
NEOPLASTIC TISSUES.
Kota Washimi1, Shoutaro Tsuji2, Tomoyuki Yokose1, 
Yohei Miyagi3, Mitsuyo Yoshihara3, Rurika 
Hamanaka4, Miki Ohe4, Chikako Hasegawa1, 
Kimitoshi Nawa4, Tetsukan Woo4, Yoichi Kameda1 
1Department Of Pathology, Kanagawa Cancer 
Center/Japan, 2Cancer Therapy Division, Kanagawa 
Cancer Center Research Institute/Japan, 3Molecular 
Pathology And Genetics Division, Kanagawa Cancer 
Center Research Institute/Japan, 4Department Of 
Thoracic Oncology, Kanagawa Cancer Center/
Japan
Background: Recently, malignant pleural 
mesothelioma (MPM) patients have increased. 
Since a pathological diagnosis of MPM is 
difÀcult, improvement of MPM diagnosis has 
been required. We previously reported that human 
intelectin-1, host defense lectin is secreted by 
epithelial MPM cells (S Tsuji et al. Br J Cancer 
2010;103:517-523). Intelectin-1 may become 
an useful immunohistochemical markers for a 
differential diagnosis of epithelial MPM. However, 
intelectin-1 expression in human tissues has not been 
investigated in detail. In this study, we examined 
intelectin-1 expression in non-neoplastic and 
neoplastic tissues by immunohistochemistry.
Methods: Anti-intelectin-1 monoclonal antibody, 
15:3G9, was used for immunohistochemical 
assessment of intelectin-1 expression. Non-
neoplastic tissues were prepared as a tissue 
microarray (TMA). The 264 cores of non-neoplastic 
tissues were made from six cases for which 
pathological autopsies were conducted at Kanagawa 
Cancer Center between 2006 and 2010. Intelectin-1 
expression was also analyzed in epithelial MPM 
(two cases) , lung adenocarcinoma (three cases) and 
mucinous type adenocarcinoma (stomach, colon, 
pancreas, lung, breast, uterine endocervix, uterine 
body; two cases, respectively).
Results: In non-neoplastic tissues, goblet cells 
and their surrounding cells in gastric metaplastic 
epithelium ,duodenal epithelium, and colonic 
mucosal epithelium produced intelectin-1 protein 
largely. Reactive mesothelial cells on the pulmonary 
pleura and peritonea, the umbrella cells of urinary 
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proliferation, oncogenesis and cancer progression. 
Currently, a combination of cisplatin + etoposide is 
the standard Àrst-line therapy for SCLC. Hence, we 
wanted to test whether increased GLI1 expression 
contributes to cisplatin and etoposide resistance in 
SCLC.
Methods: H69 cells (H69-wt) were transduced with 
GLI1 over-expressing vector to create H69-GLI1. 
Proliferation assays and drug dose response to 
combination of cisplatin +/- etoposide was conducted 
on H69-wt and H69-GLI1 cells and on four 
additional SCLC lines: H146, H187, H345, H1688. 
We mined the literature to identify genes previously 
been described as GLI1 targets or shown as 
associated with GLI1. Subsequently, the expression 
of these candidate genes was validated by qRT-PCR.
Results: Proliferation assays showed no signiÀcant 
differences in H69-wt vs. H69-GLI1 cells. Drug 
dose response experiments showed at least 1.5 
fold increase in cisplatin resistance in H69-GLI1 
compared to H69-wt cells and similar trend was 
observed in cisplatin/etoposide combination 
dosing. In other SCLC cell lines a positive trend 
was observed where increased GLI1 expression 
correlated with elevated cisplatin resistance. From 
literature review search, we identiÀed two genes, 
SFRP1 and FOXA2, which have been associated 
with GLI1. We tested their expression in H69-wt and 
H69-GLI1 cells and found that both genes are over-
expressed in H69-GLI1, which is in concordance 
with previously published data. Interestingly, 
microRNA 21 (miR-21) was over-expressed in H69-
GLI1 cells. This is intriguing, as miR-21 expression 
has previously been related to chemoresistance in 
various other cancers. We are currently performing 
GLI1 knockdown experiments using siRNA to 
validate the role of GLI1 in chemoresistance and 
also conÀrm that SFRP1, FOXA2 and miR21 
are its effectors and contribute to GLI1’s role 
in chemoresistance. We are also testing GLI1’s 
expression in tumors from SCLC patients to see if 
there is a correlation between GLI1 expression and 
de novo chemoresistance
Conclusion: GLI1 plays an important role in 
conferring cisplatin + etoposide resistance in H69 
SCLC cells and once validated its expression could 
be used to predict chemotherapy response in SCLC 
patients.
Keywords: microRNA, Small cell lung cancer, 
GLI1, chemoresistance
determined saturation levels of endobronchial 
NSCLC and SCLC tumors and relate this to survival.
Methods: Differential pathlength spectroscopy 
(DPS) was used during bronchoscopy. Hereby 
peripheral microvascular saturation data were 
obtained in vivo in different histological subtypes 
of lung tumors. DPS data were correlated with 
endobronchial tumors histology corrected for stage 
of disease.
Results: In 98 patients DPS data could be correlated 
to histological-conÀrmed endobronchial tumor 
tissue. No differences in microvascular saturation 
between NSCLC and SCLC were established. 
Adenocarcinomas and squamous cell carcinomas 
had a signiÀcant better peripheral oxygenation, 
StO2 65% (sd 20,0) and 58% (sd 28,9) respectively, 
compared to large cell carcinoma and SCLC, StO2 
42% (sd 28,9) and 38% (sd 28,2) respectively. No 
relation between peripheral microvascular tumor 
saturation and survival could be established.
Conclusion: Although differences in peripheral 
microvascular saturation, measured during 
bronchoscopy, between the histological subtypes of 
lung cancer can be observed, no relation was found 
to survival.
Keywords: Lung cancer, Differential pathlength 
spectroscopy, microvascular saturation, histology
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P1.009 CONNECTING GLI1 WITH 
CHEMORESISTANCE IN SMALL CELL 
LUNG CANCER
Glen J. Weiss1, Kristi E. Allen2, David K. Edwards 
V2, Irene Cherni2, Carlos Lorenzo2, Shilpi Arora2 
1Medical Oncology, Virginia G. Piper Cancer 
Center At Scottsdale Healthcare/tgen/United 
States Of America, 2Cancer And Cell Biology, The 
Translational Genomics Research Institute (TGEN)/
United States Of America
Background: Small cell lung cancer (SCLC) 
accounts for ~15% of all lung cancers. Drug 
resistance to chemotherapeutic drugs is particularly 
crippling in SCLC. We examined gene expression 
in cisplatin-resistant SCLC cell line H69, and 
found aberrant expression of a subset of Hedgehog 
Signaling (Hh) Pathway-related genes, among which 
GLI1 was signiÀcantly elevated. GLI1 is a known 
transcription factor that is involved with regulation 
of a number of key genes in cell fate determination, 
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not increased in PC-14/lung, PC-14/kidney, PC-
14/bone, and PC-14/muscle. They appeared to be 
candidate for the genes that inÁuence organotropism 
of lung cancer adrenal metastasis.
Conclusion: Microarray analysis was applied to 
Ànd the gene expression inÁuencing organotropism 
of lung cancer adrenal metastasis. Our study 
results detected 19 genes as the candidates. This 
experimental method seems to be promising. Further 
experiments using additional cell lines will be 
needed to deÀne them precisely.
Keywords: adrenal metastasis, microarray analysis, 
organotropism
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P1.011 MASS SPECTROMETRY 
ANALYSES OF KAPPA AND LAMBDA 
FRACTIONS OF IGG RESULT 
IN INCREASED NUMBER OF 
COMPLEMENTARITY DETERMINING 
REGIONS IDENTIFICATIONS
Ingrid Broodman1, Dominique De Costa2, Christoph 
Stingl3, Lennard J.M. Dekker3, Martijn M. Vanduijn3, 
Jan Lindemans1, Rob J. Van Klaveren2, Theo M. 
Luider3 
1Clinical Chemistry, Erasmus Medical Center/
Netherlands, 2Pulmonology, Erasmus Medical 
Center/Netherlands, 3Neurology, Erasmus Medical 
Center/Netherlands
Background: Antibodies against tumor associated 
antigens in early stage lung cancer have been 
identiÀed before the tumor was detectable by a 
CT scan. SpeciÀc amino acid sequences of the 
complementarity determining regions (CDRs) 
in the antigen-binding fragment (Fab) of these 
antibodies have potential as biomarkers for early 
detection of lung cancer. IdentiÀcation of CDRs 
depends on the sensitivity of the mass spectrometry 
to detect these very low-abundant CDR peptides. 
However, ion suppression in the mass spectrometer 
especially for complex peptide mixtures can reduce 
the sensitivity. Reducing the complexity decreases 
ion suppression and leads to a signiÀcantly higher 
sensitivity to detect CDR peptides. Our aim was 
to molecular dissect IgG into kappa and lambda 
fragments to reduce the complexity and thereby 
identify substantially more CDRs than by just total 
Fab isolation. 
Methods: In this pilot study, we puriÀed Fab, Fab-Ʃ, 
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P1.010 MICROARRAY ANALYSIS 
TO DETECT GENES PREDICTING 
ORGANOTROPISM OF LUNG CANCER 
ADRENAL METASTASIS.
Tatsuya Yoshimasu, Shoji Oura, Fuminori Ohta, 
Yoshimitsu Hirai, Koma Naito, Rie Nakamura, 
Haruka Nishiguchi, Sayoko Hashimoto, Mitsumasa 
Kawago, Yoshitaka Okamura 
Department Of Thoracic And Cardiovascular 
Surgery, Wakayama Medical University/Japan
Background: Lung cancer easily metastasizes to 
multiple organs, such as bone, lung, brain, liver, 
and adrenal gland. The frequency of the distant 
metastasis usually appears to be dependent on the 
volume of each target organ. However, metastasis 
to the adrenal gland is frequently observed in spite 
of its small volume. We hypothesized that some 
organotropic mechanisms exist in lung cancer 
adrenal metastasis. We applied microarray analysis to 
Ànd the gene expression inÁuencing organotropism 
of lung cancer adrenal metastasis.
Methods: Human non-small cell lung cancer cell 
line PC-14 was used. The cell was cultured for 7 
days on the fresh tissue slice of athymic mouse 
(Balb/c-nu/nu) adrenal gland. After that, proliferated 
cancer cells were collected from the surface of 
adrenal gland and cultured in the Áask again. This 
process was repeated 5 times. The cells conditioned 
in this manner, which was named as PC-14/adrenal, 
showed higher organotropism to adrenal gland than 
original PC-14 cells when they were inoculated to 
the athymic mice. The same procedure was also 
applied to the other organs, such as lung, kidney, 
bone, and muscle. Then the conditioned cells PC-
14/lung, PC-14/kidney, PC-14/bone, and PC-14/
muscle were obtained. These 4 subclones were used 
as control cells against PC-14/adrenal. Microarray 
analysis was applied to these 6 cells including 
original PC-14 cells.
Results: Expressions of 28869 genes were evaluated 
in each cell using microarray analysis. Expression 
was signiÀcantly higher in 20, 57, 70, 29, and 23 
genes in PC-14/adrenal, PC-14/lung, PC-14/kidney, 
PC-14/bone, and PC-14/muscle, respectively, when 
they were compared with original PC-14 cells. 
Increase in DUSP1 was commonly observed in all 5 
conditioned cells. This alteration of DUSP1 seemed 
to be derived from this experimental method itself. 
The other 19 genes increased in PC-14/adrenal were 
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P1.012 DYNAMIC MOLECULAR 
CHANGES ASSOCIATED WITH 
EPITHELIAL-MESENCHYMAL 
TRANSITION AND SUBSEQUENT 
MESENCHYMAL-EPITHELIAL 
TRANSITION IN THE EARLY PHASE OF 
METASTATIC TUMOR FORMATION
Keiju Aokage1, Genichiro Ishii2, Tomoyuki Hishida1, 
Junji Yoshida1, Mitsuyo Nishimura1, Kanji Nagai1 
1Division Of Thoracic Oncology, National Cancer 
Center Hospital East/Japan, 2Pathology Division, 
Research Center For Innovative Oncology, National 
Cancer Center Hospital East/Japan
Background: Metastatic tumor formation via vessel 
route begins with cancer cell extravasation from 
vessel lumen, migration into the connective tissue 
surrounding vessels, and invasion into target organ 
parenchyma. Epithelial-mesenchymal transition 
(EMT) and mesenchymal-epithelial transition 
(MET) have been recognized to play an important 
role in these metastatic processes, however, how 
and where these biological changes take place in the 
early phase of metastatic tumor development has 
never been clariÀed. The aim of this study was to 
determine how the biological features of tumor cells 
change dynamically during early metastatic tumor 
development.
Methods: Examination of the surgical specimens 
of the 3161 consecutive patients who underwent 
surgical resection of a primary lung cancer at our 
hospital between July 1992 and October 2008 
revealed intrapulmonary metastasis by the NSCLC 
in 222 of them. We extracted the cases of primary 
adenocarcinoma of the lung alone and evaluated 
the 233 metastatic tumors in the 129 patients 
with a pulmonary metastasis less than 10 mm in 
diameter. An intrapulmonary metastatic tumor 
was judged to have formed by the lymphogenic 
mechanism if all of the following criteria were 
met: both the primary tumor and metastatic tumor 
positive for lymphatic permeation and presence of 
a metastatic focus in the lung parenchyma adjacent 
to a bronchovascular bundle involved by lymphatic 
permeation. So we extracted 34 lymphogenic 
intrapulmonary metastases, immunostained them 
for 13 molecular markers of EMT and MET and 
scored the immunostaining intensity of cancer 
cells Áoating in lymphatic vessels (LV), migrating 
into the connective tissue surrounding vessels 
Fab-ƪ, Ʃ and ƪ light chains of IgG from serum from 
10 stage I lung adenocarcinoma patients and 10 
matched controls from current and former smokers 
of the Dutch Belgian randomized lung cancer 
screening trial (NELSON). After puriÀcation, the 
immunoglobulin fragments were enzymatically 
digested and measured by nanoLC Orbitrap mass 
spectrometry. Label-free quantiÀcation of MS data 
was performed by Progenesis software. Peptide 
sequences were identiÀed by a Mascot search 
against the NCBInr human database and de novo 
sequencing by Peaks software. CDRs were identiÀed 
by using the IMGT/DomainGapAlign tool. Finally, 
we compared the number of CDRs identiÀed in 
these immunoglobulin fragments with the number 
of CDRs identiÀed in the Fab fragments. Statistical 
tests were performed using Microsoft Excel 2007, 
VassarStats and Stata.
Results: Our method provided reproducible 
separations (CV%<5) with high recovery rates 
(>90%). In addition, a normal Ʃ:ƪ ratio was 
measured in both cases and controls. Cases and 
controls revealed 1663 CDR peptides of Fab, 1422 
of Fab-Ʃ, 971 of Fab-ƪ, 859 of Ʃ and 991 of ƪ. The 
non-parametric Kruskal-Wallis test (two-sided) 
showed a signiÀcantly (p<0.001) higher CDR3 ratio 
in the three Fab fractions (Fab, Fab-Ʃ, Fab-ƪ) than in 
the light chain fractions (Ʃ and ƪ). On average, 1.73 
times more CDRs were found in the combination 
of Fab-Ʃ, Fab-ƪ, Ʃ and ƪ than in Fab. Pearson Chi-
square tests with odds ratios revealed no statistically 
signiÀcant difference (p>0.50) between cases and 
controls in the number of CDRs identiÀed in the 
individual and combined IgG fractions compared 
with that of Fab. The mean additional number of 
unique CDRs (mean%) to the Fab fraction was for 
Ʃ 320 CDRs (23.1%), ƪ 501 CDRs (36.0%), Fab-Ʃ 
679 CDRs (48.7%) and Fab-ƪ 315 CDRs (22.7%). 
Combined Ʃ and ƪ fractions resulted in 804 (57.8%), 
and combined Fab-Ʃ and Fab-ƪ fractions in 978 
(70.3%) additional unique CDRs. In addition, these 
four fractions combined showed an additional 1683 
unique CDRs (121.0%) to Fab. In total, twice as 
many CDRs were identiÀed when Fab-Ʃ, Fab-ƪ, Ʃ 
and ƪ (3330) were combined than in the Fab (1663) 
fraction alone. 
Conclusion: Molecular dissection of IgG identiÀes 
signiÀcantly more CDRs, which will increase the 
likelihood of Ànding early lung cancer-related CDR 
proÀles. 
Keywords: CDRs, lambda, Kappa, 
immunoglobulins
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Background: Small cell lung cancer (SCLC) 
is an aggressive neuroendocrine tumour that 
shows early metastasis and eventual resistance 
to chemotherapy. Currently both epithelial and 
neuroendocrine biomarkers can provide information 
on the diagnosis/prognosis of SCLC. However it 
is not clear whether the tumour cells express both 
neuroendocrine and epithelial markers or if there 
are distinct cell sub-populations in the primary 
tumour, in metastases and/or in circulating tumour 
cells (CTCs). The aims of this study were to 
investigate the expression of neuroendocrine (pro-
opiomelanocortin, POMC, the precursor of ACTH) 
and epithelial markers (cytokeratin) in vitro, in vivo 
in primary tumours from SCLC xenografts and their 
metastases and in patient samples. 
Methods: A SCLC cell line (DMS 79) and a 
negative control, non SCLC cell line (A549), were 
grown in culture (1) and prepared as cytospins. 
Cells were stained using immunoÁuorescence with 
antibodies for POMC (2), cytokeratin (pan CK, 
Sigma) and DAPI (nuclear stain, DAKO). For the 
xenograft model (1) nude mice injected with DMS 
79 cells were left until the tumour reached 4 times 
the relative tumour volume (approximately 800mm3). 
The tumours and metastatic sites were excised and 
sections were stained for POMC and cytokeratin 
using a DAB stain. 
Results: SCLC cells (DMS 79) release POMC and 
cytokeratin in culture. ImmunoÁuorescent staining 
of these cells showed some were positive for POMC, 
some for cytokeratin and some positive for both 
markers. The epithelial non-SCLC control cell line 
(A549) was negative for POMC and positive for 
cytokeratin. Xenografts stained positive for both 
CK and POMC. Terminal POMC concentrations in 
the circulation of the xenografted mice were highly 
elevated (mean values 2850pmol/l vs 150pmol/l 
at baseline, p<0.001). Seven mice had evidence 
of liver metastases and 4 had evidence of brain 
metastases. In both the brain and liver, metastases 
stained positive for POMC. In 25 patients with 
SCLC, plasma POMC levels correlated with 
circulating tumour cell (CTC) number and poor 
prognosis. The markers will also be measured to 
assess neuroendocrine and epithelial characteristics 
in clinical CTC samples. 
Conclusion: Our results provide evidence that SCLC 
(bronchovascular bundle; BVB), and growing in 
lung parenchyma (LP). 
Results: The mean staining score ± standard 
deviation (S.D.) for E-cadherin in LV, BVB, and 
LP was 1.03 ± 0.45, 0.6 ± 0.32, and 0.82 ± 0.36, 
respectively. The mean staining score ± S.D. for 
ơ-catenin in LV, BVB, and LP was 1.09 ± 0.67, 0.44 
± 0.33, and 1.07 ± 0.58, respectively. The E-cadherin 
and ơ-catenin expression levels in BVB were 
signiÀcantly lower than in LV (E-cadherin: p<0.001; 
ơ-catenin: p<0.001) and LP (E-cadherin: p=0.011; 
ơ-catenin: p<0.001). The mean staining score ± S.D. 
for Laminin 5Ƣ2 in LV, BVB, and LP was 0.07 ± 
0.11, 0.3 ± 0.4, and 0.05 ± 0.16, respectively, and 
the Laminin 5Ƣ2 expression levels in BVB were 
signiÀcantly higher than in LV (p=0.037) and LP 
(p=0.001). SigniÀcantly more Geminin-positive 
cells per 100 tumor cells were detected in LV (mean 
± S.D.; 15.9 ± 11.8) and LP (10.4 ± 8.0) than in 
BVB (5.9 ± 4.6) (LV vs. BVB: p<0.001; BVB vs. 
LP: p=0.037). The mean staining score ± S.D. of 
MMP7 in LV, BVB, and LP was 0.05 ± 0.12, 0.15 ± 
0.26, and 0.05 ± 0.1, respectively, and The MMP7 
expression level in BVB was signiÀcantly higher 
than in LV (p=0.046) and LP (p=0.038). 
Conclusion: Our results suggested that in the early 
phase of metastatic tumor formation cancer cells 
undergo dynamic phenotypic change associated with 
EMT and subsequent MET. Further understanding 
of tumor cell behavior during the early metastatic 
process will provide insight into therapeutic 
strategies to overcome metastasis. 
Keywords: Metastasis, lymphogenic, epithelial 
mesenchymal transition, mesenchymal epithelial 
transition
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P1.013 NEUROENDOCRINE AND 
EPITHELIAL PHENOTYPES IN SCLC IN 
VITRO AND IN VIVO: IMPLICATIONS 
FOR METASTASIS IN PATIENTS WITH 
SMALL CELL LUNG CANCER
Rachel Stovold1, Suzanne Meredith1, Muhammad 
Babur2, Jessica Booth3, Brian Telfer2, Caroline Dive4, 
Kaye Williams2, Fiona Blackhall5, Anne White2 
1Faculty Of Life Sciences, University Of Manchester/
United Kingdom, 2Faculty Of Medical And 
Human Sciences, University Of Manchester/
United Kingdom, 3Clinical And Experimental 
Pharmacology, Paterson Institute For Cancer 
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the media compared to controls. Overexpression of 
OPNa (p<.002) and exposure to OPNa conditioned 
media (p<.002), each signiÀcantly increased invasion 
compared to controls and the effects were additive. 
Over expression of OPNc and exposure to OPNc 
conditioned media decreased invasion compared to 
controls. (Figure) OPNc conditioned media differed 
from that of OPNa and control most notably by the 
lack of CD44 detection.(Table)
pcmv2 OPNa OPNc 
galactin-3-binding protein osteopontin isoform a precursor osteopontin precursor 
agrin precursor galectin-3-binding protein galectin-3-binding protein 
laminin B2 chain agrin precursor Alpha-enolase 
amyloid-like protein 2 14-3-3 protein zeta/delta syndecan-4 precursor 
syndecan-4 precursor syndecan-4 precursor 14-3-3 protein zeta/delta 
proactivator polypeptide a proactivator polypeptide a unnamed protein product 
golgi membrane protein CD44 
amyloid beta A4 precursor Myosin-9 
calmodulin 
basigin isoform 1 precursor 
CD44 
Conclusion: The divergent impact of OPN splice 
variants on invasion in NSCLC is mediated 
extracellularly. The effects of overexpression can be 
mimicked by isoform speciÀc conditioned media. 
Alterations in cellular attachment related to CD44 
represents possible pathway of effect. These Àndings 
increase the likelihood of being able to target 
isoform-speciÀc differences for therapy of NSCLC.
Keywords: osteopontin, Non-small cell lung cancer, 
Invasion, splice variants
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
cells in vitro comprise a mixture of cell populations 
consisting of those with a neuroendocrine or 
epithelial phenotype and those that express both 
characteristics. It is possible that the contribution 
of each cell type to metastasis and chemoresistance 
varies, and understanding the role of each type may 
help to drive new targeted treatment strategies. 
References: 1 Sommer et al 2010, ERC 17 (1) p203-
13 2 Stevens et al 2011 Eur J Pharmacology in press 
Keywords: SCLC, Neuroendocrine, POMC, 
Cytokeratin
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P1.014 EXTRACELLULAR MEDIATION 
OF DIVERGENT EFFECTS OF 
OSTEOPONTIN SPLICE VARIANTS IN 
NON-SMALL CELL LUNG CANCER
Jessica S. Donington, Chandra M.V. Goparaju, 
Nathalie Hirsch, Ryan Harrington, Justin D. 
Blasberg, Harvey I. Pass 
Cardiothoracic Surgery, NYU School Of Medicine/
United States Of America
Background: Osteopontin (OPN) is a secreted 
phosphoprotein with an important but poorly 
understood role in non-small cell lung cancer 
(NSCLC) pathogenesis. We previously demonstrated 
that OPN splice variants have divergent patterns 
of expression and impact on invasion in NSCLC. 
OPNa, which is selectively up regulated in tumors 
and cell lines, increases invasion, while OPNc is 
not expressed in tumors or cell lines, but decreases 
invasion when overexpressed.We hypothesize 
that these divergent effects on NSCLC invasion 
are mediated extracellularly through associated 
difference in secreted proteins.
Methods: cDNA plasmids speciÀc to OPNa, 
OPNc and pcmv empty vector controls (Origene, 
Rockville, MD) were transfected into NSCLC cell 
lines H358 and H460. At 24H cells were washed and 
placed in serum free media. Conditioned media was 
harvested at 48H. OPN levels in conditioned media 
were measured by ELISA (IBL, Yuma, Japan) and 
proteomics analysis performed using NanoLC-MS/
MS peptide sequencing (Prottech, Fairview Village, 
PA). Invasion assay was performed with pooled 
populations of transfected cells in OPNa, OPNc and 
control conditioned media.
Results: Overexpression of either OPNa or OPNc 
signiÀcantly increased the OPN concentration of 
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EpCAM knockdown dramatically inhibited growth 
of shZEB1-expressing ACC-MESO-1 but only 
modestly inhibited growth of shGFP-expressing 
ACC-MESO-1 cells, supporting our hypothesis.
Conclusion: ZEB1 knockdown may be a promising 
therapeutic strategy for MPM, but the possibility of 
EpCAM up-regulation induced by ZEB1 knockdown 
must be taken account in the development of ZEB1-
targeted therapeutics.
Keywords: mesothelioma, EMT, ZEB1, EpCAM
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P1.016 CLINICAL IMPACT OF THE DNA 
METHYLATION LEVEL IN NON-SMALL 
CELL LUNG CANCER DETERMINED 
USING A PYROSEQUENCING METHOD
Riichiroh Maruyama1, Yasunori Shikada1, Tsukihisa 
Yoshida1, Yosuke Morodomi1, Kensaku Ito1, Akira 
Haro1, Mitsuhiro Takenoyama1, Tokujiro Yano1, 
Hiroyuki Kitao2, Yoshihiko Maehara1 
1Surgery And Science, Kyushu University/Japan, 
2Department Of Molecular Oncology, Graduate 
School Of Medical Sciences, Kyushu University/
Japan
Background: Given the aging of society in Japan, 
the number of elderly patients with lung cancer is 
expected to increase. It is necessary to distinguish 
the epigenetic differences between elderly and young 
patients in order to develop more speciÀc population-
based treatment strategies. Global hypomethylation 
and the hypermethylation of gene promoter regions 
are common events in tumor DNA. Because of their 
high frequency in the genome, Long interspersed 
nuclear element 1 (LINE-1) methylation serves as a 
useful surrogate marker of global methylation. The 
p16 tumor suppressor gene is an important signaling 
molecule involved in cell cycle regulation. Down-
regulation of p16 by promoter hypermethylation 
occurs early in lung carcinogenesis, such as during 
acquisition of abnormal proliferative potential. The 
aim of the present study was to quantitate the LINE-
1 and p16 methylation levels using bisulÀte-PCR 
and a pyrosequencing analysis, and to analyze their 
relationship with the clinicopathological features in 
a large series of unselected NSCLC and matching 
normal lung tissues.
Methods: From May 2008 to May 2009, 57 patients 
underwent surgical resection in our department. 
Genomic DNA was isolated from frozen tissues 
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P1.015 TRANSIENT BUT NOT STABLE 
ZEB1 KNOCKDOWN DRAMATICALLY 
INHIBITS GROWTH OF MALIGNANT 
PLEURAL MESOTHELIOMA CELLS: 
IMPLICATION OF EPCAM UP-
REGULATION INDUCED BY ZEB1 
KNOCKDOWN
Mihoko Horio1, Mitsuo Sato1, Yoshihiro Takeyama1, 
Tetsunari Hase1, Elshazley Momen1, Kenya Yoshida1, 
Yoshitaka Sekido2, Masashi Kondo1, Adi F. Gazdar3, 
John D. Minna3, Yoshinori Hasegawa3 
1Respiratory Medicine, Nagoya University Graduate 
School Of Medicine/Japan, 2Division Of Molecular 
Oncology, Aichi Cancer Center Research Institute/
Japan, 3Hamon Center For Therapeutic Oncology 
Research, University Of Texas/United States Of 
America
Background: ZEB1, a master epithelial-to-
mesenchymal transition (EMT) regulator gene, 
contributes to several important malignant properties 
in a wide variety of epithelial malignancies. 
However, its role in malignancies of mesodermal 
origin including malignant pleural mesothelioma 
(MPM) is unclear.
Methods: Eighteen MPM cell lines and the 
normal immortalized pleural mesothelial cell line 
MeT-5A were used. The expression of ZEB1, 
E-cadherin, vimentin and epithelial cell adhesion 
molecule (EpCAM) was determined by quantitative 
real-time PCR and /or western blotting. RNA 
interference-mediated knockdown of ZEB1 and 
EpCAM was done in two MPM cell lines (ACC-
MESO-1, H2052). Cellular growth was evaluated 
by colorimetric proliferation and liquid and soft agar 
colony formation assays.
Results: Most MPM cell lines expressed ZEB1 at 
higher levels than MeT-5A. Transient knockdown of 
ZEB1 with short interfering RNA in ACC-MESO-1 
and H2052 signiÀcantly suppressed their growth. 
Unexpectedly, stable ZEB1 knockdown with a 
short hairpin (sh) ZEB1-expressing vector had only 
modest or no effects on the growth of these cell lines. 
EpCAM, which functions as a mitogen activator, was 
up-regulated in shZEB1-expressing ACC-MESO-1 
and H2052 and thus we hypothesized thatEpCAM 
up-regulation counteracts the ZEB1 knockdown-
induced growth inhibition. To test this hypothesis 
we examined whether EpCAM knockdown inhibits 
the growth of shZEB1-expressing ACC-MESO-1. 
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P1.017 YAP TRANSCRIPTION 
COACTIVATOR INDUCES 
MALIGNANT MESOTHELIOMA CELL 
PROLIFERATION BY UP-REGULATING 
CELL CYCLE PROGRESSION
Tetsuya Mizuno1, Hideki Murakami1, Makiko Fujii1, 
Futoshi Ishiguro1, Yutaka Kondo1, Shinya Akatsuka2, 
Shinya Toyokuni2, Kohei Yokoi3, Hirotaka Osada1, 
Yoshitaka Sekido1 
1Division Of Molecular Oncology, Aichi Cancer 
Center Research Institute/Japan, 2Department 
Of Pathology And Biological Responses, Nagoya 
University Graduate School Of Medicine/Japan, 
3Division Of Thoracic Surgery, Nagoya University 
Graduate School Of Medicine/Japan
Background: Malignant mesothelioma (MM) is 
highly refractory to conventional therapies including 
cytotoxic chemotherapy, radiotherapy and surgery. 
Although comprehensive understanding of key 
genetic/epigenetic alterations underlining MM 
development/progression is limited, inactivating 
deletion or mutation of p16INK4a/p14ARF and 
neuroÀbromatosis type2 (NF2) genes are frequently 
detected. While recent studies have shown that the 
Hippo signal transduction cascade plays a key role in 
organ size control by regulating cell proliferation and 
apoptosis, Merlin (a product of NF2) has also been 
shown to be one of the upstream regulators of this 
tumor suppressive cascade. Furthermore, the Hippo 
signaling regulates cell proliferation by suppression 
of the activity of YAP, a transcriptional coactivator, 
and we also found YAP gene ampliÀcation in a 
subset of MM specimens. Our Àndings and those of 
others suggest a signiÀcant involvement of the Hippo 
signaling pathway inactivation and subsequent 
activation of YAP for MM cell development/
progression. However, the detailed roles of YAP in 
MM cell growth/survival remain unclear. The aims 
of this study are to delineate the biological effects of 
YAP on MM cell proliferation and progression, to 
reveal key transcriptional target genes of YAP. 
Methods: Two MM cell lines (NCI-H290, 
Y-MESO-27) were knocked-down for YAP with a 
lentivirus-mediated system, and the effects of the 
knockdown on cell proliferation, motility, invasion 
of MM cells were evaluated. Microarray based-
expression proÀling and subsequent gene ontology 
(GO) analyses were performed to identify potential 
transcriptional targets of YAP. Luciferase reporter 
of 57 resected non-small cell lung cancer, and 
DNA methylation was quantitated using bisulÀte-
PCR and pyrosequencing (PyroMark® Q24). The 
clinicopathological characteristics of the patients 
are shown in Table. Corresponding normal lung 
tissues were available for 56 of these patients. 
Methylation of long interspersed nuclear elements 1 
(LINE-1) was used as a surrogate marker for global 
hypomethylation. Hypermethylation of the p16 
promoter region was also evaluated. 
Table Clinicopathological characteristics of the 
patients 
Parameter No. % 
Age (years), median (range) 70 (47-85) 
Gender Female Male 21 36 37 63 
Smoking status Brinkmann Smoking 
Index, median (range) Never Ex-smoker 
Current smoker 
500 (0-2160) 22 15 20 39 26 35 
Histological type Adenocarcinoma 
Squamous cell Carcinoma Others 41 10 6 72 18 10 
Pathological stage IA IB IIA IIB IIIA 
IIIB IV 29 14 3 3 5 2 1 51 24.5 5 5 9 3.5 2 
Results: Tumor tissue showed signiÀcantly lower 
LINE-1 methylation levels compared with normal 
lung tissue, but higher p16 methylation levels. 
The methylation level of LINE-1 has a negative 
correlation with the p16 methylation level (r=-0.269, 
p=0.043) and age (r=-0.233, p=0.08) as determined 
using Pearson’s product moment correlation 
coefÀcient. Of the 57 patients examined, 5 (8.8%) 
had hypermethylation of the p16 gene. All Àve 
cases with hypermethylation were squamous cell 
carcinomas, while there was no association between 
smoking status and the methylation levels of p16.
Conclusion: These results suggest that global 
hypomethylation, as well as hypomethylation 
of LINE-1 in tumor tissues is linked to the 
hypermethylation of p16, one of the tumor 
suppressor genes. A higher age also correlated with 
a lower methylation level of LINE-1. Patients with 
an abnormal methylation status may thus be suitable 
candidates for novel antimethylation therapeutic 
strategies in future studies.
Keywords: LINE-1, p16, Non-small cell lung 
cancer, DNA methylation
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family of proteins. These proteins participate both 
in constitutive and alternative pre-mRNA splicing. 
Owing to their numerous serine residues, the SR 
proteins are phosphorylated and this phosphorylation 
controls their activity. The purpose of this study was 
to analyze the status of the SR proteins SRSF1 and 
SRSF2 as well as of the SR-phosphorylating kinases 
SRPK1 and SRPK2 in a large series of non small cell 
lung carcinoma (NSCLC). 
Methods: One hundred and seventeen NSCLC 
and 25 associated normal lung parenchyma were 
included in this study. Tumors consisted of 58 
adenocarcinoma (ADC) and 59 squamous cell 
carcinoma (SCC). The expression of SRSF1, 
SRSF2 and its phosphorylated form P-SRSF2, 
SRPK1 and SRPK2 proteins was studied by 
immunohistochemistry. Results were conÀrmed 
by western blotting using a small number of 
representative samples.
Results: As compared to normal lung tissues, we 
showed that SRSF1 is overexpressed in 70% of 
NSCLC, with the same frequency in ADC (71%, 
p<0.0001) and SCC (69%, p<0.0001). We observed a 
signiÀcant correlation between SRSF1 upregulation 
and the appearance of distant metastasis (p=0.02). 
Regarding SRSF2 and P-SRSF2 status, we showed 
that SRSF2 and P-SRSF2 proteins are overexpressed 
in 80% (p<0.0001), and 62% (p<0.0001) of NSCLC, 
respectively. High levels of SRSF2 and P-SRSF2 
were more frequent in SCC than in ADC (91% and 
66% versus 69% and 59%, respectively) and were 
clearly associated in both ADC (p=0.0008) and 
SCC (p=0.02). Interestingly, SRSF2 and P-SRSF2 
overexpression was detected in ADC displaying 
low pTNM stage (stages I-II; p=0.01) whereas it 
was associated with SCC of higher pTNM stage 
(III-IV; p=0.01). These results indicated that SRSF2 
and P-SRSF2 proteins could play a distinct role 
depending on the histological sub-type. Finally, and 
consistent with the accumulation of a phosphorylated 
SRSF2 product, we found that SRPK1 and SRPK2 
are upregulated in 89% of ADC (p<0.0001) and 
77% of SCC (p<0.0001) and mainly display a 
nuclear staining pattern. We also noticed a clear 
association between P-SRSF2 accumulation and 
SRPK2 overexpression in ADC (p=0.03). Again, the 
upregulation of SRPK1 and SRPK2 was detected 
in ADC displaying low pTNM stage while it was 
associated with late stage of carcinogenesis in SCC 
(p=0.04).
Conclusion: To conclude, we provide the Àrst 
evidence that the critical splicing factors SRSF1, 
assay and chromatin immunoprecipitation (ChIP) 
assay and were performed for selected target genes 
to determine the transcriptional activities and binding 
of YAP on their promoter regions.
Results: YAP knockdown decreased the motility 
and invasion activities by 60-80% and proliferation 
by ~50% in two MM cells. Expression proÀling 
analyses detected 236 genes whose expression 
levels were decreased less than 0.5-fold by YAP 
knockdown. GO analysis revealed signiÀcant 
expression changes of a subgroup of genes that were 
involved in cell cycle machinery. Among them, 
expressions of cyclin D1 (CCND1) and forkhead box 
M1 (FOXM1) were decreased to 0.1-0.5 and 0.2-0.4-
fold by YAP knockdown, respectively. Luciferase 
reporter assay showed that YAP transduction 
strongly induced their promoter activities. The 
promoter activities of CCND1 and FOXM1 were 
further enhanced by combined transduction of 
TEAD. ChIP assay conÀrmed the binding of YAP to 
their promoter regions. 
Conclusion: YAP plays an oncogenic role in MM 
cells by regulating a subgroup of genes which are 
involved in cell cycle progression. Among them, 
CCND1 and FOXM1 were direct transcriptional 
target genes of YAP. 
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P1.018 THE SPLICING FACTORS SRSF1 
AND SRSF2 AND THEIR REGULATORS, 
THE KINASES SRPK1 AND SRPK2, ARE 
OVEREXPRESSED IN NON SMALL CELL 
LUNG CARCINOMA
Stephanie Gout1, Elisabeth Brambilla1, Christian 
Brambilla1, Sylvie Gazzeri2, Beatrice Eymin2 
1Team 2, Inserm U823/France, 2Institut Albert 
Bonniot, Inserm U823/France
Background: Alternative splicing of pre-mRNA 
plays a dominant role in regulating gene expression 
and affects the expression of about 90% of human 
genes. Through the generation of aberrant transcripts, 
it is a widespread source of human diseases, such 
as cancer. Although mutations in cis-acting splicing 
elements occur in cancer, changes in the expression 
of trans-acting splicing regulators are thought to 
contribute to tumor progression. However, only a 
few studies have veriÀed this hypothesis in human 
tumors. A key role in splice site choice regulation 
is played by members of the SR (Ser/Arg-rich) 
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prediction tools. Quantitative real-time PCR was used 
to assess the expression levels of the miRNAs. The 
reference gene RNU6B was used for normalization. 
An immunohistochemical (IHC) staining with 5 
antibodies (STAT1, pSTAT1(Ser727), STAT3, SOCS1, 
PIAS1) was performed on tissue microarray sections 
to correlate it with the results of the miRNA detection.
Results: MiR-106a (targeting STAT3) expression was 
increased in 63% of cases. MiR-155, miR-19a, and 
miR-30d* (targeting SOCS1, SOCS1 and STAT1, 
respectively) were downregulated in all cases. Due 
to very low expression levels, miR-196a*, miR-608 
and miR-765 (targeting SOCS6, PIAS1, SOCS3 
respectively) were not detected. Positive IHC staining 
was achieved for STAT1, pSTAT1(Ser727), STAT3 
and PIAS1. STAT1 was higher expressed than STAT3; 
SOCS1 was not detected by IHC. This conÀrms 
results of a previous study in mesothelioma cell lines, 
where we could demonstrate STAT1 overexpression 
as well as downregulated PIAS1 and SOCS1 proteins.
Conclusion: Total STAT1 is upregulated in 
mesotheliomas and - to a lesser degree - even pSTAT1 
(Ser727). The inverse correlation between pSTAT1 
(Ser727) and miR-30d* (p = 0,014) indicates a 
regulatory effect of this miRNA. MiR-30d* may 
even have a regulatory effect on nonphosphorylated 
STAT1 (p = 0,062). The semi-quantitative assessment 
done by immunohistochemistry might explain the 
discrepancy between pSTAT1 and STAT1. Therefore 
additional investigations using other techniques will 
be performed to clarify this. STAT3 is downregulated 
but not affected by miR-106a (p = 0,53). However, the 
upregulation in 63% of cases implicates an important 
role of this miRNA in MM like it is reported for 
different solid cancers. Additional targets (JAK1, 
SOS1 and OSM) of miR-106a have been selected 
which are currently under investigation.
Keywords: mesothelioma, STAT signaling, 
microRNA
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P1.020 APOPTOSIS AND GROWTH 
INHIBITION BY SPROUTY2 IN NON-
SMALL CELL LUNG CANCER
Byoung Chul Cho, Joo-Hang Kim 
Medical Oncology, Yonsei Cancer Center/Korea
Background: Sprouty2 proteins function as 
inhibitors of receptor tyrosine kinase signaling 
mainly by interfering with the Ras/Raf/mitogen-
SRSF2 and its phosphorylated form as well as their 
regulators, the kinases SRPK1 and SRPK2, are 
upregulated in a large series of non small cell lung 
carcinoma, thereby indicating that deregulation of 
pre-mRNA splicing patterns is likely to occur during 
lung tumorigenesis.
Keywords: SRSF1, SRSF2, SRPK, splicing factors
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.019 STAT SIGNALING IN MALIGNANT 
MESOTHELIOMA: IS DEREGULATION 
OF STAT1 AND STAT3 CAUSED BY 
MICRORNAS?
Lisa Arzt1, Hannelore Kothmaier1, Franz 
Quehenberger2, Iris Halbwedl1, Helmut H. Popper1 
1Institute Of Pathology, Medical University Graz/
Austria, 2Institute For Medical Informatics, Statistics 
And Documentation, Medical University Graz/
Austria
Background: Human malignant mesothelioma 
(MM) is an aggressive cancer due to former asbestos 
exposure, with little knowledge about predictive 
factors of outcome and resistance to conventional 
chemotherapy. Little is known about the mechanisms 
regulating proliferation and apoptosis in MM, but it 
was reported previously that STAT1 is up- whereas 
STAT3 is downregulated in this particular cancer. In 
a current study we found that the negative feedback 
loop of STAT1 is deregulated: SOCS1, the inhibitor 
of STAT1 activation, was undetectable in MM. 
PIAS1 acts in the nucleus and inhibits DNA binding 
of pSTAT1 and was found to be downregulated 
too. It is known that the developmental timing of 
protein expression is controlled by non-coding 
RNAs; microRNAs (miRNA) are one class. They are 
typically about 22 nucleotides in size and regulate 
the expression of target mRNAs. In addition they are 
expected to act as oncogenes or tumor suppressors. 
Therefore we aimed to quantify selected miRNAs 
in MM which are thought to be involved in the 
regulation of the STAT signaling pathway.
Methods: RNA was obtained from 35 formalin-Àxed 
and parafÀn-embedded tumor tissue samples; only 
tumor areas with more than 85% of tumor cells were 
included. MiRNAs were selected via in silico target 
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capacity, and growth inhibition by enhancing JNK-
mediated mitogen-activated protein kinases pathway. 
Results of this study implicate that sprouty2 
represents a tumor suppressor in NSCLC and suggest 
sprouty2 re-expression as a promising therapeutic 
target against NSCLC. 
Conclusion: Overexpression of sprouty2 promotes 
cellular apoptosis and inhibits tumor cell migration 
and cell cycle progression via activation of c-Jun NH 
(2)-terminal kinase and in NSCLC. Furthermore, 
overexpression of sprouty2 showed synergistic 
antitumor effects in combination with geÀtinib. 
Sprouty2 overexpression suppressed tumor growth 
and VEGF production in H1975 xenograft model. 
Keywords: sprouty2, Epidermal growth factor 
receptor, Non-small cell lung cancer
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P1.021 DELETIONS OF 11Q22.3-Q25 ARE 
ASSOCIATED WITH ATYPICAL LUNG 
CARCINOIDS AND POOR CLINICAL 
OUTCOME
Dorian R.A. Swarts1, Sandra M.H. Claessen1, 
Yvonne M.H. Jonkers1, Robert-Jan Van Suylen2, 
Anne-Marie Dingemans3, Wouter W. De Herder4, 
Ronald R. De Krijger5, Egbert F. Smit6, Frederik B. 
Thunnissen7, Cornelis A. Seldenrijk8, Aryan Vink9, 
Aurel Perren10, Frans C.S. Ramaekers1, Ernst-Jan M. 
Speel1 
1Molecular Cell Biology, Maastricht University/
Netherlands, 2Pathology, Maastricht University 
Medical Center/Netherlands, 3Pulmonology, 
Maastricht University Medical Center/Netherlands, 
4Internal Medicine, Erasmus MC/Netherlands, 
5Pathology, Erasmus MC/Netherlands, 6Pulmonology 
Department, Vrije Universiteit Medical Centre/
Netherlands, 7Pathology, Vumc/Netherlands, 
8Pathology, St. Antonius Hospital/Netherlands, 
9Pathology, University Medical Center Utrecht/
Netherlands, 10Pathology, University Of Bern/
Switzerland
Background: Lung carcinoids are neuroendocrine 
tumors that can be subclassiÀed as typical (TC) or 
atypical (AC) carcinoids. ClassiÀcation is difÀcult and 
its reliability to predict disease outcome is variable.
Methods: To identify genetic alterations which can 
improve prediction of prognosis we investigated 34 
lung carcinoids (18 TCs, 15 ACs, 1 unclassiÀed) 
by array comparative genomic hybridization (array 
activated protein kinase cascade, a pathway 
frequently deregulated in human non-small cell 
lung cancer (NSCLC). The aim of the study 
was to investigate the role of sprouty2 in anti-
proliferation, pro-apoptosis, tumor suppression, 
and antiangiogenesis in NSCLC. Furthermore, 
we examined the role of sprouty2 in modulating 
responses to therapies, such as chemotherapy and 
EGFR inhibitors, in NSCLC.
Methods: NSCLC cell lines and normal embryonic 
lung Àbroblasts were used. Western blot analysis 
was performed to investigate signal transduction 
pathway. Cell viability and cell cycle assays were 
done to see the effects of sprouty2 expression on 
apoptosis and cell cycle. To examine the effects on 
migration, Boyden chamber assay was performed. 
Yeast two hybridization experiments was done for 
identiÀcation of binding partner of sprouty2. The 
effects of sprouty2 overexpression was examined in 
vivo xenograft model.
Results: In this study, it was shown that sprouty2 
protein expression was consistently downregulated 
in NSCLC. Analysis of sprouty2 using ONCOMINE 
data set further indicated that sprouty2 was 
downregulated in NSCLC tissues compared 
with normal lung tissues. Ectopic expression 
of sprouty2 not only induced cell death in an 
apoptotic manner but also resulted in cell cycle 
arrest in various NSCLC cell lines. Furthermore, 
sprouty2 overexpression substantially reduced 
migratory capacity in H1975 cells. Overexpression 
of sprouty2 did not interfere with activation of the 
major downstream targets of epidermal growth 
factor receptor (EGFR) including extracellular 
signal–regulated kinase, Akt, and signal transducer 
and activator of transcription 3/5. Instead, sprouty2 
overexpression promoted apoptosis in H1975 cells 
via activation of c-Jun NH (2)-terminal kinase 
(JNK). The transfection of H358 cells with sprouty2 
siRNA decreased phosphorylation of JNK, which 
further suggested the speciÀcity of sprouty2 on the 
activation of JNK. In addition, sprouty2 expression 
in combination with geÀtinib, a small molecule 
EGFR inhibitor, synergistically induced apoptosis 
via augmented activation of JNK in NSCLC 
cells. Finally, sprouty2 expression resulted in the 
regression of H1975 tumor xenograft in vivo due 
to the combined effects on tumor cell proliferation, 
survival and tumor angiogenesis. In conclusion, 
sprouty2 expression is generally repressed in 
NSCLC, and overexpression of sprouty2 contributes 
to induction of apoptosis, reduced migratory 
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Background: Pulmonary carcinoids are 
neuroendocrine tumors (NETs) that can be 
histopathologically classiÀed as typical (TC) or 
atypical (AC) carcinoids. Despite the fact that ACs 
generally show more often malignant behavior 
and have a lower 5-year survival rate compared to 
TCs, more reliable indicators of poor prognosis are 
required. MEN1 mutations and associated LOH of 
11q13 have been implied in tumorigenesis. Our aim 
was to examine MEN1 promoter hypermethylation 
and gene expression and their correlation with 
clinical outcome. 
Methods: We determined MEN1 mRNA expression 
(exon 2/3 PCR product) relative to the housekeeping 
genes ß-Actin and cyclophilin A for 20 ACs, 31 TCs 
and 10 NE carcinomas by quantitative RT-PCR. In 
addition, normal tissue and 9 neuroendocrine cell 
lines (including the Bon-1, H720 and H727 carcinoid 
cell lines) were included for comparison. Genomic 
DNA from these and 29 additional tumors (15 ACs, 
11 TCs and 3 NE carcinomas) were analyzed for 
MEN1 promoter hypermethylation by Methylation 
SpeciÀc PCR, and the carcinoid cell lines were also 
examined by next-generation sequencing. Deletion 
of the MEN1 gene was determined for a subset of 
cases with Áuorescence in situ hybridization (FISH) 
with a MEN1 gene-speciÀc BAC probe. Results 
were correlated with clinical outcome. 
Results: Quantitative RT-PCR revealed that the 
average MEN1 mRNA expression is lower in (1) 
lung carcinomas than carcinoids (0.25 vs. 0.36; 
p=0.024), (2) ACs than TCs (0.28 vs. 0.36) and (3) 
carcinoids with a poor prognosis (0.17 vs. 0.36, 
p=0.0078). Relative MEN1 expression  0.15 
correlated with (1) distant metastasis, both within 
the group of lung carcinoids (p=0.0017) and within 
ACs (p=0.0077), and (2) a poor prognosis, both 
within the complete group of lung NETs (p=0.00064) 
and within carcinoids (p=0.042). MEN1 promote r 
hypermethylation was not detected in lung NETs. 
This was conÀrmed by next-generation sequencing 
analysis of methylation-bound genomic DNA 
showing MEN1 hypermethylation neither in the 
promoter region of the Bon-1, H720 and H727 
carcinoid cell lines, nor in other tumors and normal 
tissue (> 50 samples). Deletion of the MEN1 locus 
(11q13) was identiÀed in 3/28 cases (2 with a MEN1 
mutation and 1 unknown), of which 2 showed low 
and 1 intermediate gene expression. 
Conclusion: We identiÀed correlations of reduced 
MEN1 gene expression with both metastatic disease 
and lower 10-year survival in lung carcinoid 
CGH) on 3.7 k genomic BAC arrays (resolution 1 
Mb). Results were correlated with clinical patient 
data and long term follow-up.
Results: When comparing ACs with TCs our data 
revealed: 1) a signiÀcant difference in the average 
number of chromosomal alterations (10 Mb) (9.6 
versus 4.2, respectively, p=0.036), with a subgroup of 
Àve ACs with  15 chromosomal alterations; 2) in  
25% of ACs multiple gains (1 Mb) at chromosomes 
8pq, 9q, and 17pq, and losses at 1p, 2q, 10q, and 
11q; and 3) deletions in 8/15 of ACs vs. 1/18 of TCs 
(p=0.004), which was conÀrmed by Áuorescence in 
situ hybridization. The four critical regions of interest 
in 45% of ACs comprised 11q14.1, 11q22.1-q22.3, 
11q22.3-q23.2 and 11q24.2-q25, all telomeric of 
MEN1 at 11q13. There was a strong association of 
11q22.3-q25 loss with a poorer prognosis, alone or in 
the combination with absence of 9q34.11 alterations 
(p=0.0022 and p=0.00026, respectively).
Conclusion: A subgroup of ACs can be identiÀed 
harboring 11q22.3-q25 deletions, with a signiÀcantly 
poorer prognosis as compared to carcinoids without 
these 11q deletions.
Keywords: 11q loss, pulmonary carcinoids, Array 
CGH, MEN1
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P1.022 REDUCED MEN1 GENE 
EXPRESSION IN PULMONARY 
CARCINOIDS IS ASSOCIATED WITH 
METASTATIC DISEASE AND POOR 
PROGNOSIS
Dorian R.A. Swarts1, Mieke E. HenÁing1, Annick 
Haesevoets1, Robert-Jan Van Suylen2, Anne-Marie 
Dingemans3, Marco Volante4, Aurel Perren5, Marie-
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Criekinge8, Kim Wouters2, Jürgen Veeck2, Frans C.S. 
Ramaekers1, Manon Van Engeland2, Ernst-Jan M. 
Speel1 
1Molecular Cell Biology, Maastricht University/
Netherlands, 2Pathology, Maastricht University 
Medical Center/Netherlands, 3Pulmonology, 
Maastricht University Medical Center/Netherlands, 
4Pathology, University Of Turin At San Luigi 
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Am J Pathol 2010), cell lines could be classiÀed into 
two groups: Group I (n=26) was characterized by 
high activation proÀles of EGFR and MET, and high 
expressions of E-Cadherin, MET, lamininC2, and 
COX2, while Group II (n=15) was characterized by 
low expression and activation of EGFR and MET 
and high expressions of vimentin and FGFR1. All 
Group I cells formed round or spheroid colonies, 
while all cell lines forming grape-like or stellate-
shaped aggregates belonged to Group II. Most EGFR 
mutant (n=6) belonged to Group I and formed round 
spheroid. In contrast, KRAS mutant (n=11) were 
heterogeneous: 5 of them belonged to Group I and 
they all formed round spheroid, while 4 of the 6 cell 
lines that belonged Group II formed grape-like or 
stellate-shaped aggregates. All MET-ampliÀed cell 
lines (n=3) belonged to Group I and formed round 
colonies. Strikingly, most of KRAS mutant that 
belonged to Group II showed loss of expression of 
p16 and LKB1. Abnormalities of LKB1 were not 
found in EGFR mutants.
Conclusion: Lung adenocarcinomas show genetic-
morphologic correlations in three dimensional 
culture. The results reinforce the genetic-histologic 
correlations previously documented in primary 
tumors. Inactivation of p16 and LKB1 that occurs 
in KRAS mutant tumor may result in alterations of 
morphology in three dimensional culture.
Keywords: EGFR, MET, Kras, E-cadherin
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P1.024 GENOME-WIDE ASSOCIATION 
STUDY IDENTIFIES SUSCEPTIBILITY 
LOCI FOR LUNG CANCER IN CHINESE 
HAN POPULATION
Shun Lu1, Yun Liu2, Xiaomin Niu1, Zhiwei Chen1, 
Daizhan Zhou3, Yongyong Shi4, Ziming Li1, 
Yongfeng Yu1, Lin He4 
1Department Of Shanghai Lung Cancer Center, 
Shanghai Chest Hospital, Jiaotong University, 
Shanghai/China, 2Institutes Of Biomedical Sciences, 
Fudan University/China, 3Institute For Nutritional 
Sciences, Shanghai Institutes For Biological 
Sciences, Chinese Academy Of Sciences/China, 
4Bio-x Center, Jiaotong University, Shanghai/China
Background: Lung cancer is the most common 
cause of cancer mortality worldwide. Although 
smoking is known to be the most important risk 
factor, there is a signiÀcant genetic predisposition 
patients, independent of promoter hypermethylation. 
Because a considerable number of cases with low 
MEN1 expression also lack deletion of the MEN1 
gene locus (and thus most probably do not have a 
MEN1 mutation), other mechanisms must underlie 
the decreased MEN1 gene expression during tumor 
progression, which remains to be examined.
Keywords: Promoter hypermethylation, Bronchial 
carcinoids, Menin, Multiple Endocrine Neoplasia 
Type I
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P1.023 THREE DIMENSIONAL CULTURE 
REVEALS GENETIC-MORPHOLOGIC 
CORRELATIONS THAT MAY BE 
RELEVANT TO CLASSIFICATION OF 
LUNG ADENOCARCINOMAS
Toshiro Niki1, Daisuke Matsubara1, Shumpei 
Ishikawa2, Masashi Fukayama2 
1Pathology, Jichi Medicaluniversity/Japan, 2Human 
Pathology, The University Of Tokyo/Japan
Background: We have recently reported that 
lung cancer cells can be classiÀed into two groups 
(Group I and Group II) according to (1) genetic 
alterations and activation status of epidermal growth 
factor receptor (EGFR) and MET, and (2) gene 
expression proÀles, and further demonstrated that 
this classiÀcation reÁects sensitivities to geÀtinib, 
MET inhibitor (PHA6657852), and cisplatin 
(Matsubara et al. Am J Pathol 2010; Matsubara et al. 
J Thorac Oncol 2010). In this study we analyzed the 
relationship among (1) gene expression proÀles, (2) 
mutation and copy number alterations of epidermal 
growth factor receptor (EGFR), MET, and KRAS, 
and (3) morphology of colonies formed on Matrigel 
Methods: We analyzed a panel of cell lines 
consisting of 35 adenocarcinomas, 4 large cell 
carcinomas, and one adenosquamous cell carcinoma. 
The cell lines included 6 cell lines with EGFR 
mutation, 11 cell lines with KRAS mutation, and 3 
cell lines with MET ampliÀcation. The cells were 
plated on Matrigel (BD Biosiences) and colony 
shapes at day 3-4 were classiÀed according to Bissell 
et al. with minor modiÀcations (Mol Oncol 2007).
Results: On Matrigel cell lines formed either round 
(n=32), grape-like (n=4) or stellate-shaped (n=5) 
colonies. All cell lines with high thyroid transcription 
factor-1 (TTF-1) and/or E-cadherin formed round 
colonies. As reported previously (Matsubara et al. 
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Background: Small-cell lung cancer (SCLC) is 
the most aggressive subtype of lung cancer with no 
early detection strategy or targeted therapy currently 
available. We hypothesized that the identiÀcation 
of membrane-associated proteins speciÀc to 
SCLC may lead to the discovery of new candidate 
diagnostic or therapeutic biomarkers and advance 
our understanding of SCLC biology.
Methods: Quadruplicate membrane-associated 
protein lysates were independently prepared 
from three SCLC, three non-small cell lung 
cancer (NSCLC) and three immortalized normal 
bronchial epithelial cell lines. The 36 samples 
were co-analyzed by two-dimensional difference 
gel electrophoresis (DIGE) using a mixed-sample 
internal standard on each of the 18 DIGE gels. 
Subsequent protein identiÀcation was performed 
using mass spectrometry (LTQ-Orbitrap) and 
database interrogation. IdentiÀed proteins were 
investigated further using Ingenuity Pathway 
Analysis (IPA).
Results: Principle Component Analysis on the global 
DIGE dataset demonstrated that the four replicates 
derived from each of the nine cell lines clustered 
very closely, as did samples within each histological 
group. A total of 135 distinct protein features were 
differentially expressed (ANOVA p<0.0001) in 
SCLC as compared to NSCLC and normal samples 
combined. They included 137 different proteins 
identiÀed by mass spectrometry. IPA revealed that 
these proteins were overrepresented in the cellular 
assembly, organization, morphology and tissue 
morphology networks. Of the proteins that were 
upregulated in SCLC, membrane-associated and 
part of interesting networks or with relevant cellular 
functions, Àve have been selected to be investigated 
further.
Conclusion: Using DIGE to analyze the membrane-
associated subproteome, we identiÀed 137 proteins 
differentially expressed in SCLC. These proteins 
were overrepresented in the cellular assembly, 
organization, morphology and tissue morphology 
networks. Five proteins have been selected for 
validation as candidate diagnostic or therapeutic 
biomarkers in an independent tumor dataset and for 
investigation of their functional relevance.
to be responsible for lung tumorigenesis. Recently 
the availability of genome-wide association study 
(GWAS) across the whole genome allows for 
efÀcient and comprehensive analysis for lung cancer. 
Methods: To identify genetic loci which are related 
to the risk of lung cancer in Chinese Han population, 
we do a GWAS of lung cancer using Affymetrix SNP 
6.0 chips. Totally, about 1 million single-nucleotide 
polymorphisms (SNPs) in a series of 400 lung 
cancer cases and 1000 controls were genotyped. The 
association with lung cancer risk was estimated by 
the odds ratio and 95% conÀdence interval using 
the multivariate unconditional logistic regression 
by PLINK software. Study matching variables of 
smoking status, age and gender were included in the 
regression as covariates. 
Results: The GWAS identiÀed several genomic 
locations as potentially associated with lung cancer 
risk in Chinese Han population in the discovery 
phase. In particular, three loci were strongly 
identiÀed exceeding the genome-wide signiÀcance 
level of P=10-6, including 3p14.3 (representative 
SNP, P=6.34×10ï6; odds ratio for patients vs. 
controls, 1.71); 6p21.32 (representative SNP, 
P=4.56×10ï6; odds ratio for patients vs. controls, 
2.92); 9q33.1 (representative SNP, P=1.41×10ï7; 
odds ratio for patients vs. controls, 2.14). 
Conclusion: Further replications of these most 
signiÀcant associations with lung cancer risk from 
GWAS are being done in an additional case-control 
database. These Àndings will provide new insight 
into the pathogenesis of lung cancer. Further studies 
to elucidate their function will aid the understanding 
of the etiology of lung cancer. 
Keywords: Lung cancer, risk genetic loci, genome-
wide association study
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P1.025 ANALYSIS OF MEMBRANE-
ASSOCIATED PROTEINS BY DIGE 
REVEALED NEW CANDIDATE 
BIOMARKERS OF SMALL-CELL LUNG 
CANCER
Sebahat Ocak1, David B. Friedman2, Mohamed 
Hassanein3, Jamie A. Ausborn4, Pierre P. Massion3 
1Medicine, Pulmonary Division, Cliniques 
Universitaires Ucl De Mont-godinne/Belgium, 
2Department Of Biochemistry, Mass Spectrometry 
Research Center, Vanderbilt University/United 
States Of America, 3Medicine, Division Of Allergy, 
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P1.027 THE CLINICAL SIGNIFICANCE 
OF PLASMA DNA QUANTIFICATION IN 
NSCLC
Adam Szpechcinski1, Michal Skronski1, Krystyna 
Maszkowska-Kopij2, Wãodzimierz Kupis3, 
Jolanta Zaleska4, Elzbieta Radzikowska4, Elzbieta 
Puscinska5, Pawel Sliwinski6, Tadeusz Orlowski3, 
Kazimierz Roszkowski-Sliz4, Joanna Chorostowska-
Wynimko1 
1Laboratory Of Molecular Diagnostics And 
Immunology, National Institute Of Tuberculosis And 
Lung Diseases/Poland, 2Outpatient Clinic, National 
Institute Of Tuberculosis And Lung Diseases/Poland, 
3Dept. Of Thoracic Surgery, National Institute Of 
Tuberculosis And Lung Diseases/Poland, 4Iii Dept. 
Of Lung Diseases, National Institute Of Tuberculosis 
And Lung Diseases/Poland, 5Ii Dept. Of Lung 
Diseases, National Institute Of Tuberculosis And 
Lung Diseases/Poland, 6Department Of Diagnosis 
And Treatment Of Respiratory Failure, National 
Institute Of Tuberculosis And Lung Diseases/Poland
Background: The increased amount of free-
circulating DNA is present in peripheral blood of 
non-small cell lung cancer (NSCLC) patients, most 
likely due to up-regulated cell death processes. 
We believe that dynamics of plasma DNA changes 
monitored throughout treatment and follow-up 
period might prove useful for assessment of therapy 
effectiveness in NSCLC.
Methods: We analyzed plasma DNA concentrations 
in 50 NSCLC patients prior and following the 
radical treatment (stage I-IIIA) or chemotherapy 
(IIIB), using qPCR method. In order to determine 
a potential contribution of chronic respiratory 
inÁammation to this phenomenon the levels of 
plasma DNA were analyzed in 30 COPD, 30 
sarcoidosis and 30 persistent asthma patients as well. 
Control group consisted of 30 healthy individuals.
Results: Only resectable NSCLC (12.1 ng/ml), but 
not advanced NSCLC (4.4 ng/ml) group, showed 
signiÀcantly higher mean plasma DNA concentration 
with respect to patients with chronic respiratory 
inÁammation (3.9 ng/ml) and healthy controls (2.8 
ng/ml; p<0.001). Furthermore, a drastic increase 
in plasma DNA levels up to mean 68.74 ng/ml was 
observed a week after primary tumor resection or 
24/48 hours after chemotherapy administration 
(16.4 ng/ml). Most resected NSCLC patients with 
no disease recurrence during 6-12 month follow-up 
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P1.026 THE PROTEOME ANALYSIS 
OF HUMAN LUNG LARGE CELL 
NEUROENDOCRINE CARCINOMA
Hiroaki Komtsu, Noritoshi Nishiyama, Koshi 
Nagano, Nobuhiro Izumi, Keiko Tei, Shoji Hanada, 
Hideki Wanibuchi, Shigefumi Suehiro 
Thoracic Surgery, Osaka City University/Japan
Background: In terms of prognosis, large cell 
neuroendocrine carcinoma(LCNEC) differs 
distinctively from other non small cell lung 
carcinoma, with prognosis of LCNEC being poor, 
even for early-stage disease.Improvements in 
survival require a new biomarker for early detection, 
deÀning cancer risk, prognosis, and therapy targets. 
The purpose of this study was to investigate the 
molecular background of lung carcinogenesis and 
to search useful biomarkers for clinical treatment 
including early detection and prognosis prediction 
of lung LCNEC by performing proteome analysis of 
human lung LCNEC. 
Methods: Subjects were cases with primary lung 
LCNEC on which surgical resection was performed. 
Tumor and adjacent non-tumor tissue sample 
were collected and proteome analysis was carried 
out using QSTAR Elite LC-MS/MS with iTRAQ 
technology and validated the expression of target 
proteins by immunohistochemistry in 38 cases 
with lung carcinomas, which included 25 SCLC, 6 
LCNEC, and 7 large cell carcinomas.
Results: All through the examined cases, several 
proteins were found overexpressed in tumor tissue 
compared to adjacent non-tumor tissue, and these 
proteins were thought as novel potential biomarkers 
associated with lung LCNEC. Especially, one of the 
proteins  showed immunohistochemical staining. 
We assessed the statistical signiÀcance of the 
associations between expression level of this protein 
and clinicopathologic variables, and found that 
this protein had possibility to be a novel predictive 
biomarker of prognosis in lung LCNEC.
Conclusion: This study enables the indentiÀcation 
of biomarker candidates for novel tumor markers and 
therapetic targets that will eventually lead to early 
detection, prevention and treatment of cancer.
Keywords: komatty, 818, komatty818, 0818
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examined and four tumor areas were selected; two 
tumor areas representative of the peripheral area of 
the tumor close to the border of normal lung tissue 
and two areas representative of more central areas. 
The location of the core samples on the TMA were 
blinded until immunohistochemical scoring was 
Ànished. The distribution of the staining was scored 
using a 4-category scoring-scheme for p53, p63, 
CK7, TTF1 and Napsin A. The interpretation of the 
scores was as follows: 0 (1%), 1 (>1% and 10%), 
2 (>10% and  50%), and 3 (>50%). For p53, p63, 
CK7, TTF1 and Napsin A, a positive staining were 
regarded to be score 2 and 3.
Results: The data for the central and peripheral 
cores were concordant (weighted Kappa 80%) for 
all markers (Table 1). However, the disconcordance 
(McNemar´s test) was highest between the two 
peripheral cores for CK7, TTF1 and Napsin A 
respectively, compared to the central cores and 
between central versus peripheral cores. For p53 the 
disconcordance were high between the peripheral 
cores (McNemar´s p=0.04) versus the central cores 
(McNemar´s p=1.00). Table 1. Comparison of 
immunohistochemical staining results. Only samples 
with all four readings were used
Conclusion: Immunohistochemical marker 
expressions of TMAs are valid, with a high 
correlation between the TMAs within the same 
tumor. The disconcordance is highest among the 
peripheral cores, which could be an indication 
of a higher degree of intratumoral heterogeneity 
in the peripheral parts of a tumor. In general it is 
recommended to use 2-4 cores per tumor to avoid 
sampling error due to intratumoral heterogeneity. 
This also reduces the number of cases not evaluable 
because of loss of samples during processing, and it 
enhances the conÀdence of the read-out of TMAs.
Keywords: Non-small cell lung cancer, NSCLC, 
Tissue microarrays, intratumoral heterogeneity
demonstrated reduced plasma DNA levels (2.4 ng/
ml) with respect to their presurgical values.
Conclusion: Increased plasma DNA level in 
NSCLC patients is due to the cancer but not chronic 
inÁammatory process. Drastic raise in plasma 
DNA levels observed after radical therapy is most 
likely due to the surgical trauma. Importantly, a 
trend towards reduction of free-circulating DNA 
concentration was observed in relapse-free patients. 
The effect of chemotherapy on plasma DNA in 
NSCLC IIIB patients is currently analyzed.
Keywords: free-circulating DNA, Biomarkers, 
genetics, real-time PCR
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.028 TISSUE MICROARRAYS 
IN NON-SMALL CELL LUNG 
CANCER (NSCLC): A STUDY OF 
INTRATUMORAL HETEROGENEITY OF 
IMMUNOHISTOCHEMICAL MARKER 
EXPRESSION.
Mette Poehl1, Karen E. Olsen2, Henrik J. Ditzel3, 
Olfred Hansen1 
1Department Of Oncology, Odense University 
Hospital/Denmark, 2Department Of Pathology, 
Odense University Hospital/Denmark, 3Department 
Of Cancer And InÁammation Research, Institute 
Of Molecular Medicine, University Of Southern 
Denmark/Denmark
Background: The use of tissue microarray (TMA) 
for biomarker studies has several advantages. 
However, heterogeneous expression of certain 
markers may cause the staining read-out of small 
tissue cores not to be representative of that of larger 
tissue sections. Further, it is not clear whether 
different tumor areas; peripheral versus central, 
exhibit different biomarker expressed. To our 
knowledge this issue has not been examined in 
NSCLC. In this retrospective study we have focused 
on evaluating the staining pattern of antibodies 
directed against p53, p63, CK7, TTF1 and Napsin A 
and the extent of the intratumoral heterogeneity.
Methods: A total of 178 formalin Àxated and 
parafÀn embedded operated NSCLC specimens 
were collected. Routinely-stained slides were 
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LR-IKKơ). It also signiÀcantly reduced the number 
of visible tumors on the lung surface of CC-LR 
mice by >60% (2.6-fold) after inducing COPD-like 
airway inÁammation using weekly NTHi exposure 
for 8 weeks (156 ± 9 in CC-LR NTHi treated vs 
60 ± 8 in CC-LR-IKKơ NTHi treated). We also 
genetically ablated IL-6 in CC-LR mice, which not 
only inhibited intrinsic lung cancer development 
(1.7-fold, 41%), but also inhibited the promoting 
effect of extrinsic COPD-like airway inÁammation 
(2.6-fold, 62%). Then we targeted expression of TNF 
under the control of the mouse Clara cell secretory 
protein (CCSP) promoter in a C57BL/6 background 
(CCSP- TNF overexpressing transgenic mouse) then 
crossed it with a CC-LR mouse. This resulted in 
severe inÁammatory cell inÀltration of the airway 
wall and peribronchovascular lymphoid aggregates, 
increased levels of TNF, IL-6, and total neutrophil 
numbers in BALF. Furthermore, TNF overexpression 
resulted in a 1.8-fold increase in lung surface tumor 
numbers compared to age and sex matched control 
CC-LR mice (50 ± 2 in CC-LR vs 91 ± 9 in CC-LR/
TNF-Tg).
Conclusion: We conclude that there is a clear 
speciÀcity for the nature of inÁammation in lung 
cancer promotion, and the NF-kB pathway has 
an essential role in this phenomenon. Therefore, 
suppression of NF-kB and more selectively its target 
genes could be a tool to protract the premalignant 
phase in patients with COPD and inhibit lung cancer 
progression in patients with early stage lung cancer. 
Keywords: NF-kB, InÁammation, TNF, IL-6
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P1.030 “MECHANISM OF PAI-1 ANTI-
PROLIFERATIVE ACTIVITY TOWARDS 
LUNG AND PROSTATE CANCER CELLS”
Adriana Roŧy1, Marta Kĕdzior1, Joanna 
Chorostowska-Wynimko1, Paulina Jaguŋ1, Michal 
Skronski1, Adam Szpechcinski1, Ewa Skrzypczak-
jankun2, Jerzy Jankun2 
1Laboratory Of Molecular Diagnostics And 
Immunology, National Institute Of Tuberculosis And 
Lung Diseases/Poland, 2Urology Research Center, 
University Of Toledo Health Science Campus/United 
States Of America
Background: Plasminogen activator inhibitor type 
1 (PAI-1) plays an important role in tumor growth 
and metastasis formation, directly via speciÀc 
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P1.029 ROLE OF AIRWAY 
INFLAMMATION IN LUNG 
CARCINOGENESIS: A MECHANISTIC 
DISSECTION
Cesar E. Ochoa1, M. Miguelina De La Garza1, 
Seyedeh Golsar Mirabolfathinejad1, Nelly Torres 
Garza2, Alejandra Garza Flores2, Burton F. Dickey1, 
Seyed Javad Moghaddam1 
1Pulmonary Medicine, Ut MD Anderson Cancer 
Center/United States Of America, 2Tecnologico De 
Monterrey School Of Medicine/Mexico
Background: Worldwide, lung cancer is the leading 
cause of cancer mortality and cigarette smoking is 
the principal cause of it. However, several studies 
have found that smokers with chronic obstructive 
pulmonary disease (COPD), an inÁammatory 
disease of the lung, have an increased risk of lung 
cancer compared to smokers without COPD. This 
suggests a strong link between COPD-related 
airway inÁammation and lung cancer promotion 
independent of smoking, however, the precise 
mechanistic link in not known. Importantly, 
lung inÁammation persists even after cessation 
of cigarette smoking among former smokers 
with COPD. One possible explanation is chronic 
colonization of the lungs by microbial pathogens, 
such as non-typeable Haemophilus inÁuenzae 
(NTHi).
Methods: We have established a mouse model of 
COPD-like airway inÁammation through repeated 
aerosol challenge to a lysate of NTHi, and we have 
shown that this type of airway inÁammation, but 
not asthma-like airway inÁammation, promotes 
lung cancer 3.2 fold in a K-ras mutant mouse model 
(CCSPCre/LSL–K-rasG12D or CC-LR). This was 
associated with NF-kB pathway activation, and up-
regulation of its downstream target genes including 
IL-6, and TNF. Therefore, we further studied the role 
of NF-kB in lung cancer promotion by COPD-like 
airway inÁammation by targeting its expression in 
airway epithelium. CC-LR mice were crossed with 
IKK-ơf/f mice to develop a mouse with lack of NF-
kB in airway secretory cells (CC-LR-IKKơ mice).
Results: NF-kB deÀciency in the airway epithelium 
changed the bronchoalveolar lavage Áuid (BALF) 
cellular component of CC-LR mice, and resulted in 
a ~70% (3.4-fold) reduction in lung surface tumor 
number compared to age and sex matched control 
CC-LR mice (44 ± 6 in CC-LR vs 13 ± 4 in CC-
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Background: Acquisition of ability to uncontrolled 
migration is one of the fundamental properties of 
cancer cells, enabling them to inÀltrate tissues and 
metastasize. PAI-1 is the major physiological inhibitor 
of urokinase (uPA), which plays a key role in migration 
and invasion of tumor cells. The aim of present study 
was to analyze the impact of increasing concentrations 
of PAI-1 mutated forms: VLHL PAI-1 with very long 
half-life time, Vn neg PAI-1 - devoid of afÀnity towards 
vitronectinand wPAI -1 on lung (A549, NCI-H1299) 
and prostate (LNCaP, DU145) cancer cells invasive 
activity. Selected cell lines are characterized by 
different (normal and high) urokinase production. 
Methods: The impact of PAI-1 proteins on 
invasiveness of cancer cells A549, H1299, LNCaP, 
DU145 was examined by using commercial kit 
QCMTM 96-Well Cell Invasion Assay (ECM 
555 - Chemicon, Europe) in accordance with the 
manufacturer’s recommendations. 
Results: No effect of PAI-1 proteins on invasiveness 
of lung cancer cells was observed, while dose-
dependent signiÀcant inhibition was demonstrated 
in both prostate cancer lines (DU145 and LNCaP) 
cultured with VLHL PAI-1 (respectively p<0,05 and 
p<0,01) and Vn PAI-1 neg (p<0,05). Not surprisingly 
wPAI-1 signiÀcantly stimulated prostate cancer cells 
invasiveness in all concentrations.
Conclusion: PAI-1 inhibitory effect on prostate cancer 
invasive activity is associated with anti-proteinase 
activity. Lung cancer cells invasiveness regulation 
seems not to be PAI-1-urokinase regulated.
Keywords: PAI-1, invasiveness, urokinase, Cancer
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.032 PROTEOME ANALYSIS AND 
TISSUE ARRAY FOR PROFILING 
PROTEIN MARKERS ASSOCIATED 
WITH THYMOMA CLASSIFICATION
Sun Qiangling1, Sha Huifang1, Fang Wentao2 
1Basic Research Laboratory, Shanghai Chest Hospital 
AfÀliated To Shanghai Jiaotong University/China, 
2Department Of Surgery, Shanghai Chest Hospital 
AfÀliated To Shanghai Jiaotong University/China
urokinase complexing or indirectly due to its afÀnity 
to vitronectin. The aim of this study was to analyze 
the impact of the mutant forms of PAI-1: very long 
half-life (VLHL PAI-1) or devoid of afÀnity towards 
vitronectin (Vn neg PAI-1) and wild form (wPAI -1) 
on proliferation of lung cancer (A549 and H1299) and 
prostate cancer (LNCaP and DU145) cells characterized 
by different proteinase (urokinase) production.
Methods: Proliferative activity of cancer cells after 
addition of PAI-1 was evaluated after 24, 48 and 
72 hours using a commercial kit EZ4Y cytotoxicity 
assay (Biomedica). The analysis was performed 
according to the manufacturer’s recommendations.
Results: The dose- and time-dependent inhibition of 
cell proliferation in the presence of VLHL PAI-1 was 
evident in A549 and LNCaP cultures. In H1299 cells 
inhibitory effect was only dose-depended (p<0.001), 
while in DU145 only 100 ƫg/ml of VLHL PAI-1 
in 72 hrs cultures suppresed prostate cancer cells 
proliferative activity (p <0.001). No signiÀcant effect 
of Vn neg PAI-1 on the proliferation of A549 and 
H1299 was observed while in prostate cancer lines 
(DU145, LNCaP) only the inhibitory effect of the 
highest Vn neg PAI-1 concentration (100 ƫg/ml) was 
evident (p <0.001) but not time-dependent. wPAI-1 
did’t affect A549 and LNCaP proliferation while in 
highest concentration it had the stimulating effect on 
H1299 and Du145 (24,48 hrs cultures).
Conclusion: PAI-1 is a negative regulator of cancer 
cells proliferation due to its anti-proteinase activity. 
Its biological effect on lung cancer cells is time and 
dosage-dependent. 
Keywords: Cancer, PAI-1, cell proliferation, 
urokinase
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.031 “PAI-1 REGULATES PROSTATE 
CANCER BUT NOT LUNG CANCER 
CELLS INVASIVENESS”
Adriana Roŧy1, Marta Kĕdzior1, Joanna 
Chorostowska-Wynimko1, Paulina Jaguŋ1, Michal 
Skronski1, Adam Szpechcinski1, Ewa Skrzypczak-
Jankun2, Jerzy Jankun2 
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Immunology, National Institute Of Tuberculosis And 
Lung Diseases/Poland, 2Urology Research Center, 
Copyright © 2011 by the International Association for the Study of Lung Cancer S717
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
thymoma tissues. For the Àrst time, differentially 
expressed proteins between type B1 and B2 
thymoma tissues were explored by comparative 
proteomic analysis. Increases in alteration of 
GSTP1 and ezrin were found to be signiÀcantly 
associated with poorly differentiated histology and 
higher clinical stage. The techniques of proteomic 
analysis tissue microarray provide us a dramatic 
tool for screening of key molecules for helping with 
thymoma histological classiÀcation. 
Keywords: GSTP1, Thymoma, proteomics, tissue 
array
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P1.033 A GIANT SOLITARY 
MESOTHELIOMA / FIBROUS TUMOUR 
ARISING FROM VISCERAL PLEURA OF 
THE LUNG.
K. V.V. Kumar 
Surgical Oncology, Kidwai Memorial/India
Background: A Giant solitary mesothelioma / 
Fibrous tumour arising from visceral pleura of 
the lung is rare and sometime produces diagnostic 
difÀculties. Surgical excision is the treatment of 
choice and is curative.
Methods: I am reporting a case of giant 
Àbroadenoma / mesothelioma arising form visceral 
pleura of lung. I present the clinical scenario, 
investigations and our management.
Results:
Background: The histologic classiÀcation of 
thymoma has been attracting more controversy 
on account of morphological variation and tumor 
epithelial heterogenicity for the past several decades. 
Molecular proÀling at protein levels may elucidate 
the biological variance of tumors and contribute to 
the pathological classiÀcation system that correlates 
better with biological, clinical and prognostic 
parameters. The recent application of two-
dimensional electrophoresis (2-DE) coupled with 
mass spectrometry (MS) to the study of thymoma 
allows the characterization of global alterations in 
protein expression in thymoma classiÀcation. 
Methods: In this study, proteins extracted from 12 
thymoma tissue specimens (six type B1 and six type 
B2 thymoma) were analyzed by two-dimensional 
electrophoresis (2-DE) coupled with MALDI-TOF-
MS. Some of the differentially expressed proteins 
identiÀed by proteomics analysis were detected 
by tissue microarray with immunohistochemistry 
staining to access the clinicopathological 
characteristics in different histologic types of 
thymomas. 
Results: Twenty proteins were found to be 
differentially expressed between type B1 and B2 
thymoma tissue. GSTP1 and ezrin were identiÀed 
to be over expressed in type B2 thymoma. The 
statistical analysis demonstrated that type B2, B3 
group had signiÀcantly higher positive expressions 
of GSTP1 than B1 group (type B2 vs B1: Z=-2.582, 
P=0.010; type B3 vs B1: Z=-4.012, P=0.000). 
Moreover, the results showed signiÀcantly 
correlation between GSTP1 and WHO classiÀcation 
from type B1 to type B3 (Spearman’s correlation 
coefÀcients: 0.633, P=0.000). There was existed 
statistically signiÀcant difference in the positive 
rate of ezrin between type B1 thymoma and type B3 
thymoma (Z=-2.963, P= 0.003). However, there is no 
difference between ezrin expression in type B1 and 
B2 thymoma (Z=-1.814, P=0.070) or between type 
B2 and B3 (Z=-1.047, P=0.295). The ezrin showed 
a tendency to be expressed in higher classiÀcation 
tumors from type B1 to B3. There is correlation 
between ezrin and WHO classiÀcation from type 
B1 to type B3 (Spearman’s correlation coefÀcients: 
0.515, P=0.002). Statistical analysis showed 
that there is correlation between GSTP1 or ezrin 
expression and clinical stage (Spearman’s correlation 
coefÀcients, Ezrin: 0.481, P=0.032; GSTP1: 0.484, 
P=0.002). 
Conclusion: To our knowledge, this study is the 
Àrst report on proteomic approach towards human 
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P1.035 CO-TRANSFECTION OF 
MRP AND BCL-2 ANTISENSE 
S-OLIGODEOXYNUCLEOTIDES 
REDUCES DRUG RESISTANCE IN 
CISPLATIN-RESISTANT LUNG CANCER 
CELLS
Shiying Zheng1, Hong Li2, Dong Jiang1 
1Department Of Cardio-thoracic Surgery, The First 
AfÀliated Hospital Of Soochow University/China, 
2Department Of Geriatrics, The First AfÀliated 
Hospital Of Soochow University/China
Background: To detect the inÁuence of antisense 
s-oligodeoxynucleotides](S-ODNs) of bd-2 and 
multidrug resistamce-associated protein (MRP) 
genes multidrug resistance-associated protein gene 
and bcl-2 antisense S-oligodeoxynucleotides on 
cisplatin-resistant lung adenocarcinoma cell line 
A549DDPwhich overexpresses both bcl-2 and MRP.
Methods: A549DDPcells were treated with sense 
and antisense S-ODN mediated by lipofection. 
Expression of MRP and bcl-2 mRNA and protein 
in the treated cells was measured by RT-PCR and 
Áow cytometry (FCM), respectively. Apoptosis was 
identiÀed by DNA electrophoresis and terminal 
deoxynucleotidyl transferase (TdT)-mediated biotin 
dUTP nick end-labeling(TUNEL). The degree of 
drug resistance of the treated cells was detected 
by a cell viability 3’-4,5-dimethylthiazol-2-y-2,5-
diphenyl-tefrazolium bromide thiazolylblue (MTT) 
assay.
Results: Expression of bcl-2 and MRP signiÀcantly 
decreased in the cells treated with bcl-2 or/and MRP 
antisense S-ODN for 48h as compared to the cells 
untreated and sense-treated (P<0.05). Resistance 
to cisplatin in the cells treated with bcl-2 or/and 
MRP antisense S-ODN decreased by 60.6% (6.5 
times), 56.4% (7.2 times) and 71.0% (4.8 times), 
respectively, which paralleled the decrease of bcl-2 
and MRP expression. Similarly, the resistance to 
etoposide and epirubicin in antisense-treated cells 
also reduced in parallel to decreases of the two 
gene expressions. The drug resistance in sense-
treated cells was similar to that in untreated cells. 
Statistically signiÀcant dose-and concentration-
dependent increases of apoptotic cells were observed 
in the groups exposed to 100 ƫmol/L cisplatin for 48 
h after treatment by bcl-2 or/and MRP antisense.
Conclusion: Bcl-2 and MRP were at least additive 
and possibly synergistic in conferring drug resistance 
Final diagnosis was based on histopathology and 
immuno histochemistry.
Conclusion: Lesions arising from the visceral pleura 
of the lung are reviewed. 
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P1.034 CASTLEMAN’S DISEASE OF THE 
PLEURA: A CASE REPORT
K. V.V. Kumar1, Rajaram Burrah2, Vijayalakshmi 
Deshmane2, Sayed Althaf2, Srinivasalu Yapamakula2, 
Sathyanarayana Kurubabala2, Anand Hanumaiah2 
1Surgical Oncology, Kidwai Memorial/India, 
2Surgical Oncology, Kidwai Memorial Institute Of 
Oncology/India
Background: Castleman’s disease is a rare benign 
non-clonal disease of the lymphnodes.It can occur 
in the mediastinum, neck, axilla & abdomen.
Castleman’s disease arising from the pleura is 
very rare.In our case, the lesion was found arising 
from the parietal pleura & was completely excised.
Histopathological & immunohistochemistry (IHC) 
examination revealed it to be a hyaline vascular 
variant of Castleman’s disease.We describe the 
presentation & management of our patient and 
review the litrature.
Methods: Surgical excision when feasible appears to 
provide good results.We encountered a patient who 
had the disease arising from the parietal pleura.
Results: Castleman’s disease of the pleura is a rare 
disorder.Though it is a benign disorder a small risk 
of malignant transformation has been described in 
other sites.
Conclusion: The surgical resection would aapear 
to be the optimal treatment modality when feasible. 
The prognosis following complete surgical resection 
appears to be good.Minimal invasive surgery may be 
attempted in experienced centres.
Copyright © 2011 by the International Association for the Study of Lung Cancer S719
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
as spheres within 20 days (neuroendocrine) and 
3 months (SCC). Injection of spheres derived 
from two adenocarcinomas into the right lung of 
immunodeÀcient mice was also followed by tumor 
growth within 1 month. CICs and differentiated cells 
were further analysed by Áow cytometry. 
Results: The percentage of CD133 positive cells 
was variable with a mean of 5,1% within a range 
of 0,1-40%. In three cultures the expression of 
CD133 showed a tendency to increase (from 3% 
to 18%) after three weeks of CICs culture, and 
the % of CD133+ cells was particularly high in 
the neuroendocrine tumor (40%). The EPCAM 
molecule and ATP-binding cassette transporter 
(ABC), involved in drug resistance, ABCB1 and 
ABCG2 were expressed at higher levels in CICs 
than in the cells from the same tumors maintained in 
differentiating conditions (standard medium + FCS).
Conclusion: These data suggest that a higher level of 
drug resistance is associated with an undifferentiated 
phenotype. Indeed, the cytotoxic activity of cisplatin 
was lower in CICs than in differentiated cultures, 
in agreement with Áow cytometry results. We are 
presently investigating the functional relationship 
between ABC transporters and cisplatin resistance 
in CICs as well as the possible in vivo growth 
advantage of subpopulations selected by EPCAM, 
CD133 and ABC phenotypic markers. 
Keywords: drug resistance, cancer initiating cells, 
Lung cancer
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.037 ESTABLISHMENT OF 
MULTIDRUG RESISTANCE LUNG 
ADENOCARCINOMA CELL LINE A549/
ADM AND INVESTIGATION OF THE 
REVERSAL OF DRUG RESISTANCE BY 
AZITHROMYCIN.
Yin Li1, Shiying Zheng2, Dong Jiang3 
1Department Of Thoracic Surgery, The Tumor 
Hospital Of Henan ,zhengzhou/China, 2The First 
AfÀliated Hospital Of Soochow University, The First 
AfÀliated Hospital Of Soochow University/China, 
3Department Of Cardio-thoracic Surgery, The First 
AfÀliated Hospital Of Soochow University/China
in a cisplatin-resistant lung adenocarcinoma cell line. 
Antisense S-ODN could attenuate drug resistance 
by promoting cells apoptosis, which might lead 
to a new treatment for patients with non-small 
cell lung cancers (NSCLCs) who are refractory to 
conventional chemotherapy.
Keywords: A549 and A549DDP cell lines, 
drug resistance, apoptosis, antisense•S-
oligodeoxynucleotide
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.036 IN VITRO AND IN VIVO 
CHARACTERIZATION OF HUMAN 
LUNG CANCER–INITIATING CELLS
Angela Alama1, Anna Maria Orengo2, Francesco 
Grossi1, Silvano Ferrini2, Rosaria Gangemi2 
1Lung Cancer Unit, National Institute For Cancer 
Research/Italy, 2Immunotherapy Unit, National 
Institute For Cancer Research/Italy
Background: Lung cancer is the most deadly cancer 
worldwide. Non small cell lung cancer (NSCLC) 
accounts for about 85% of all lung cancers. The 
current 5-year survival rate for all stages of NSCLC 
is only 15%. Recent evidence indicates that tumors 
contain a small population of cancer-initiating cells 
(CICs) that are responsible for tumor maintenance, 
resistance to chemotherapy and spreading. The 
purpose of our study is the characterization of 
CICs derived from human lung cell carcinomas 
and the development of a mouse model of human 
lung carcinoma by orthotopic xenotransplants. 
The in vivo model will allow the identiÀcation of 
molecules involved in the control of tumor growth 
and spreading, in the natural immune response and to 
study therapeutic approaches at preclinical level.
Methods: Cell suspensions and tumor spheres, 
were obtained in non-differentiating culture 
conditions (operationally deÀned as CICs), from 
24 samples of NSCLC (17 adenocarcinomas, 6 
squamous carcinomas (SCC) and 1 neuroendocrine 
carcinoma. Xenotransplantation experiments were 
performed with cells derived from 4 tumors (1 
SCC, 2 adenocarcinoma and 1 neuroendocrine 
cancers). Xenografts were obtained after 
subcutaneous injection of all the tumors injected 
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P1.038 CHEMOTHERAPY RESISTANCE 
AND ONCOGENE EXPRESSION IN NON–
SMALL CELL LUNG CANCER
Yin Li1, Shiying Zheng2, Dong Jiang2 
1Department Of Thoracic Surgery, The Tumor 
Hospital Of Henan ,zhengzhou/China, 2Department 
Of Cardio-thoracic Surgery, The First AfÀliated 
Hospital Of Soochow University/China
Background: Empiric chemotherapy for patients 
with non–small cell lung cancer who have 
undergone resection is recommended without 
knowledge of the tumor’s speciÀc biologic 
characteristics, and many patients may not beneÀt. 
In vitro chemotherapy resistance is associated 
with clinical unresponsiveness in some tumors, 
and in lung cancer, chemotherapy resistance is 
prevalent. Multiple-agent chemotherapy resistance 
and association of chemotherapy resistance with 
molecular markers are described.
Methods: Chemotherapy resistance to doublets—
carboplatin and paclitaxel, cisplatin and navelbline, 
cisplatin and docetaxel, and cisplatin and 
gemcitabine—was analyzed in 4571 non–small 
cell lung cancer tumors with the extreme drug 
resistance assay. Chemotherapy resistance is deÀned 
as follows: extreme drug resistance, 1 SD above the 
median chemotherapy resistance; intermediate drug 
resistance, between the median and extreme drug 
resistances; and low drug resistance, 1 SD below 
the median. Chemotherapy resistance was compared 
with DNA ploidy measured by Áow cytometry, and 
markers p53 and epithelial growth factor receptor 
were assayed by immunohistochemistry.
Results: Tumors with extreme or intermediate 
drug resistance were noted in 30% to carboplatin-
paclitaxel, in 24% to cisplatin-navelbline, in 42% 
to cisplatin-gemcitabine, and in 27% to cisplatin-
docetaxel. Extreme or intermediate drug resistance 
to at least one drug occurred in 74% to carboplatin-
paclitaxel, in 68% to cisplatin-navelbline, in 
88% to cisplatin-gemcitabine, and in 68% to 
cisplatin-docetaxel. More intermediate plus extreme 
chemotherapy resistances occurred in aneuploid 
tumors to etoposide (53% vs 36%, P = .0002) and 
topotecan (48% vs 36%, P = .0094), with less 
intermediate or extreme chemotherapy resistance 
to gemcitabine (88% vs 81%, P = .0345). p53-
Positive tumors had more intermediate or extreme 
resistance to etoposide (57% vs 44%, P = .0009) 
Background: To establish a multidrug-resistant cell 
line A549/ADM induced by azithromycin in vitro 
and investigate the reversal effect of azithromycin to 
A549/ADM. Methods A549 cells were treated with 
adriamycin ADM.
Methods: The cells were treated with low 
concentration of ADM Àrstly and then gradually 
increased concentration of ADM intermittently. 
The expressions of P-GP and MRP in A549 and 
A549/ADM were conÀrmed by Áow cytometry 
FCM. The 50% restrain concentration (IC50) of 
four drugs to A549 and A549/ADM were evaluated 
with MTT assay. Same methods were used to A549/
ADM when treated with azithromycin AZM. The 
inhibition rates of different concentration of AZM 
to A549/ADM were also evaluated with MTT assay. 
The Áuorescence intensity of ADM in A549 and 
A549/ADM with or without AZM added were also 
evaluated with FCM.
Results: The expressions of P-GP and MRP in 
A549 were 2.3% and 2.5% respectively, but those of 
A549/ADM were 33% and 46.3% respectively.The 
resistance index of A549/ADM to ADM was 17.80 
times higher than that of A549 and the cells showed 
resistant to DDP, VCR and MTX incoordinately. 
With AZM added 5ƫg/ml, the sensitivities of A549/
ADM to ADM were 2.81 times higher than before 
and sensitivities to DDP,VCR and MTX increased 
by 1.86, 3.78 and 3.86 times respectively. The 
sensitivities of A549/ADM to these drugs were much 
higher when treated with 10ƫg/ml of AZM. With the 
same treatment, the Áuorescence intensities in A549, 
A549/ADM and A549/ADM were 121.4, 51.2 and 
96 respectively.
Conclusion: A549/ADM were multidrug- 
resistantMDR.The high expressions of P-GP and 
MRP might play an important role in MDR. AZM 
could reverse the MDR of A549/ADM through 
increase the accumulation of drugs in cells and the 
effection of reversal correlates with concentration.
Keywords: A549/ADM, multidrug resistance 
(MDR), Azithromycin, Reversal
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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and tumorigenicity were tested for SP and non-
SP (NSP) cells. Tumors were characterized by 
mesothelin, calretinin, N-cadherin, D2-40 and Wilms 
tumor 1 (WT-1) immunohistochemistry. Surface 
expression of mesenchymal stem cell markers CD90, 
CD73 and CD105 was investigated in SP and NSP 
cells. 
Results: We identiÀed SP cells with self-renewal 
properties and increased chemoresistance in MPM 
cell lines and tumor derived primary cell cultures. 
Compared to the non-SP fraction (NSP), the SP 
fraction led to the development of tumors with 
mesothelium precursor phenotype characterised by 
mesenchymal morphology, being WT1 negative 
but podoplanin positive, and having a tendency 
of increased tumorigenicity. The same phenotypic 
shift was observed in patients with relapsing tumors 
after chemotherapy. Furthermore the SP cells were 
enriched in CD105 -/low expressing cells which 
were small sized and had increased tumorigenicity 
compared to CD105 high cells.
Conclusion: Taken together our results support the 
hypothesis that MPM CD105-/low, chemoresistant, 
small sized SP cells may constitute the cellular 
pool out of which recurrence develops. Further 
characterization of mechanisms of chemoresistance 
and self-renewal should lead to targets speciÀc for 
this subpopulation in MPM patients. 
Keywords: mesothelioma, side population, 
chemoresistance, tumor relapse phenotype
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P1.040 HIF1 MODULATES CARCINOGEN 
METABOLISM AND DNA DAMAGE: 
IMPLICATIONS FOR LUNG CANCER
Roland Chiu, Marten Schults, Roger Godschalk, 
Frederik Jan Van Schooten 
Toxicology, Maastricht University/Netherlands
Background: A ten times increased risk for lung 
cancer is observed in smokers with an associated 
chronic obstructive pulmonary disease (COPD). 
We hypothesized that low oxygen concentrations 
in COPD affected lung tissues may be involved 
in the enhanced risk. Benzo[a]pyrene (B[a]P) is 
an important mutagen present in tobacco smoke 
and recently we demonstrated that hypoxia related 
activation of hypoxia-inducible factor 1 (HIF1a) 
ampliÀes the B[a]P induced mutagenic phenotype. It 
appears that HIF1a sequester a critical cofactor for 
and doxorubicin (73% vs. 58%, P = .0324) and less 
intermediate or extreme resistance to cisplatin (44% 
vs 54%, P = .0125), to carboplatin (47% vs 57%, 
P = .0129), to taxol (47% vs 57%, P = .0056), and 
to gemcitabine (78% vs 87%, P = .0108). Fewer 
epithelial growth factor receptor–positive tumors 
were extremely drug resistant to cisplatin (13% vs 
26%, P = .0074) and carboplatin (13% v. 30%, P = 
.0008).
Conclusion: Multi-drug chemotherapy resistance 
in non–small cell lung cancer tumor cultures is 
common, and associations between molecular 
markers and in vitro chemotherapy resistance are 
noted. Clinical validation through integration of such 
testing into clinical trials seems warranted.
Keywords: non–small cell lung cancer, 
chemotherapy resistance;, P53
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.039 PLEURAL MESOTHELIOMA SIDE 
POPULATIONS HAVE A PRECURSOR 
PHENOTYPE AND ARE SIMILAR TO 
PATIENT’S RELAPSES
Emanuela Felley-Bosco1, Claudia Frei2, Isabelle 
Opitz2, Alex Soltermann2, Bruno Fischer2, Ubiratan 
Moura2, Hubert Rehrauer2, Walter Weder3, Ralf 
Stahel1 
1Zurich University Hospital, Laboratory Of 
Molecular Oncology/Switzerland, 2Zurich 
University/Switzerland, 3Thoracic Surgery, 
University Hospital Zurich/Switzerland
Background: Inhaled asbestos Àbres accumulating 
in the pleural cavity confer both chronic tissue repair 
as well as oncogenic damage to the mesothelial 
lining cells, ultimately leading to malignant pleural 
mesothelioma (MPM). We hypothesized that 
such damage may primarily occur in mesothelial 
precursor cells, recruited to repair tissue injury and 
that this subpopulation would be associated with 
chemoresistance and tumor recurrence. 
Methods: DyeCycleViolet was used to set up 
the side population (SP) functional assay aimed 
at identifying subpopulations of tumor cells with 
chemoresistance phenotype associated with ABCG2 
transporter activity. Self-renewal, chemoresistance 
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anti-EGFR monoclonal antibody, and geÀtinib, a 
tyrosine kinase inhibitor, in non-small cell lung cancer 
(NSCLC) in vitro and in vivo.
Methods: Two NSCLC cell lines, A549 and SPC-A-1 
were treated with cetuximab (1 n mol/L,5n mol/L,25n 
mol/L,125n mol/L,625n mol/L), geÀtinib (0.2 
ƫmol/L,1ƫmol/L,5 ƫmol/L,25 ƫmol/L,125ƫmol/L) 
or a combination of both at a range of concentrations. 
PI marked and the cells were observed using Áow 
cytometry apoptosis, CCK8 measured the inhibition 
of cell proliferation in each group; under the power 
to change the status of apoptosis, downstream protein 
expression of EGFR, p-EGFR, and p-Akt were 
evaluated by Western blot. The in vivo effects of 
cetuximab and geÀtinib on tumor cell growth were 
examined using a xenografted nude mouse model and 
tumor growth analyses.
Results: The combined treatment with geÀtinib and 
cetuximab resulted in a synergistic effect on cell 
proliferation and in superior inhibition of EGFR-
dependent signaling and induction of apoptosis (p<0.05). 
In the combination-treated tumors, there was a superior 
inhibition of EGFR, mitogen-activated protein kinase, 
and Akt phosphorylation, as well as greater inhibition of 
cell proliferation and enhanced apoptosis. A combination 
of geÀtinib and cetuximab signiÀcantly inhibited 
tumor growth and caused a substantial growth delay in 
vivo models of both cell lines while each single-agent 
exposure caused no delay of tumor growth.
Conclusion: Our Àndings suggest combined therapy 
with geÀtinib and cetuximab can add the potency of 
EGFR signaling inhibition, however, selective targeting 
of distinct molecular pathways is required for effective 
clinical response. 
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.042 EFFECTS OF ANTIANGIOGENIC 
AGENTS PLUS EP REGIMEN ON SMALL 
CELL LUNG CANCER(SCLC) CELL LINE 
NCI-H446
Zhiwei Chen1, Xiang-Yun Ye1, Ziming Li2, Xiaomin 
Niu1, Yongfeng Yu1, Shun Lu2 
1Department Of Shanghai Lung Cancer Center, 
Shanghai Chest Hospital, Jiaotong University, 
Shanghai/China, 2Shanghai Chest Hospital, Jiaotong 
University/China
carcinogen detoxiÀcation, HIFb/ARNT. Reduced 
availability of this cofactor for coupling with the 
aryl hydrocarbon receptor (AhR) leads to decreased 
expression of carcinogen metabolising enzymes. 
Although we observed a 3 fold increase in mutation 
frequency at the hprt locus in cells after B[a]P 
exposure following HIF1a induction, the changes in 
DNA adduct formation are minimal. This suggests 
that other cellular response pathways are modiÀed 
concurrently with HIF1a activation. 
Methods: We have identiÀed three mechanisms that may 
be involved. These are changes in metabolism of B[a]P; 
the transmembrane transport of B[a]P or its metabolites; 
or the capacity to repair the subsequent DNA damage. 
Results: First, under conditions of low oxygen, 
the B[a]P-9,10-dihydrodiol metabolites decreased 
while the B[a]P-7,8-dihydrodiol and 3-OH-B[a]P 
metabolites are formed in higher quantities compared to 
normoxia. Furthermore, when HIF1a was upregulated 
under hypoxic conditions (0.2% O
2
 or CoCl
2
), the 
extracellular concentrations of the parent B[a]P 
compound were dramatically increased compared 
with cells treated under higher (20% and 5%) oxygen 
concentrations. And Ànally, using a modiÀed comet 
assay to determine the DNA repair capacity, we 
observe that cells in which HIF1a is dysregulated (VHL 
mutants) have an approximately 10 fold decrease in the 
ability to repair B[a]P-DNA adducts. 
Conclusion: These results show that all three 
processes may in part be responsible for the 
enhanced mutagenic phenotype under hypoxia. 
Insight into these pathways may provide further 
understanding of the intrinsic risks for mutagenic 
exposures and provide new targets and tools for 
therapies directed against cancer. 
Keywords: benzo[a]pyrene, Hypoxia, HIF, COPD
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P1.041 ANTICANCER EFFICACY 
OF CETUXIMAB COMBINED WITH 
GEFITINIB IN THE TREATMENT OF 
NON-SMALL CELL LUNG CANCER
Ziming Li, Shun Lu, Zhiwei Chen 
Department Of Shanghai Lung Cancer Center, 
Shanghai Chest Hospital, Jiaotong University, 
Shanghai/China
Background: The purpose of this study was to 
evaluate the anticancer efÀcacy of EGFR pathway 
inhibition achieved by combining cetuximab, an 
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development of promising investigational regimens 
for the treatment of patients with SCLC.
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.043 THE SYNTHETIC EFFECT 
OF AROMATASE INHIBITOR 
ANASTROZOLE IN COMBINATION 
WITH EGFR TYROSINE KINASE 
INHIBITOR GEFITINIB IN NON-SMALL 
CELL LUNG CANCER CELL LINES
Lan Shen1, Shun Lu2, Fei Y. Zhang1, Ziming Li2 
1Shanghai Lung Tumor Clinical Medical Center, 
Shanghai Chest Hospital, Shanghai Jiaotong 
University/China, 2Department Of Shanghai Lung 
Cancer Center, Shanghai Chest Hospital, Jiaotong 
University, Shanghai/China
Background: Several studies implicated that lung 
cancer progression was governed by the interaction 
between estrogen receptor(ER) and epidermal 
growth factor receptor(EGFR) signaling pathways. 
So combined targeting of EGFR and ER may have 
the synthetic effect in lung cancer treatment. The 
aim of this study was to explore the potential utility 
of targeting these two pathways with combination 
of Anastrozole and GeÀtinib in non-small cell lung 
cancer cell lines. 
Methods: The expression levels of ERs(ER-Ơ and 
ER-ơ) in lung cancer cell lines (A549,H460,SPC-
A-1,H1299) and normal bronchus epithelial cell 
BEAS-2B were detected using Real-time PCR and 
Western-blot(WB).Immunohistochemistry(IHC) 
was used to locate ER-Ơ and ER-ơ in cell lines with 
highest ERs expression levels. The cell lines were 
treated with Anastrozole or GeÀtinib alone or in 
combination. The cell proliferation inhibition was 
detected with CCK8 assay, Cell cycle and apoptosis 
effects detected with Áow cytometry, the expression 
of EGFR, p-EGFR, ERK, p-ERK, AKT and p-AKT 
detected with Western-blot.
Results: The expression levels of ERs in A549 
cells were highest among these cell lines. In 
A549 cell line, ER-Ơ was mainly localized in the 
cytoplasma, whereas ER-ơ was mainly localized 
in the cytoplasma and to a lesser degree in the 
nucleoli. The single agent of Anastrozole or GeÀtinib 
Background: Despite the characters of broad-
spectrum effects on different tumors and low-
toxicity, antiangiogenic therapy is also effective on 
neuroendocrine tumors and has a synergistic effect 
when administered with chemotherapy concurrently. 
As small cell lung cancer (SCLC) is a cancer 
of higher growth ability and with higher tumor 
angiogenesis, we hypothesize that antiangiogenic 
agents plus EP regimen would be more effective than 
the currently-used EP regimen, which needs to be 
further investigated by both laboratory and clinical 
studies. Here, we evaluated the effects of three 
different antiangiogenic agents in combination with 
EP regimen on proliferation inhibition and apoptosis 
of SCLC cell line NCI-H446, respectively.
Methods: NCI-H446 cells were treated with 
Bevacizumab (Avastin, Roche), Recombinant 
Human Endostatin Injection (Endostar, Xiansheng), 
a multi-targeted agent(SoraÀnib, Bayer) respectively 
and in combination with EP regimen(VP16+DDP). 
The growth-inhibitory activities and apoptosis of 
single-agent and combinations of EP and individual 
antiangiogenic agents, were evaluated using a PI 
labelled Áow cytometer. Each two-drug combination 
was studied over a range of concentrations at a Àxed 
ratio corresponding to the ratio of the IC5 values of 
the individual agents. Transwell invasion assays were 
performed to detect in vitro invasion and metastasis 
of NCI-H446 cells. ELISA were performed to detect 
the expression of VEGF in different groups. 
Results: Compared with EP group, all three 
antiangiogenic agents(Avastin, Endostar and 
SoraÀnib) in combination with EP can enhance the 
growth activities of NCI-H446 cells to some extent. 
The results of Áow cytometer showed that single 
agent of all three antiangiogenic drugs(Avastin, 
Endostar and SoraÀnib) could signiÀcantly induce 
cell apoptosis respectively( EP: 0.02 Avastin 1.07 
Endostar:0.41 soraÀnib 8.27 P<0.05). Moreover, 
SoraÀnib plus EP induced more apoptosis than EP 
regimen only EP+soraÀnib 17.82 soraÀnib 8.27 P 
0.05 . However, when compared with EP group, 
only the Avastin plus EP could signiÀcantly decrease 
the migration and invasion activity (EP 35.33 
EP+Avastin 31.67 P<0.05). The expression of VEGF 
were signiÀcantly decreased in both single-agent and 
angiogenic agent plus EP groups (P<0.05). 
Conclusion: There is a signiÀcant synergic 
inhibitory effect of antiangiogenic agents plus EP 
regimen on SCLC cell line NCI-H446. Angiogenic 
drugs’ potent single-agent activity and potential 
synergy with standard EP regimen will allow for the 
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circular double-stranded DNA molecule. The 6 early 
open reading frames (ORF) include E1, E2, E4, E5, 
E6, and E7. The high-risk HPV E6 and E7 ORF 
encode the viral oncoproteins that are invariably 
expressed in HPV-positive human cancers. E6 and 
E7 oncoproteins, mainly act oncogenic by decreasing 
tumor suppression pathways, and unpublished data 
have shown similar expression of both on HPV 
related malignancies. Previously, we successfully 
generated E7 fusion proteins of HPV16 and 18. This 
study explores the presence of antibodies (IgG) in 
serum against recombinant E7 for HPV 16,18, in 100 
patients with NSCLC and assesses correlation with 
clinical NSCLC characteristics.
Methods: 100 deidentiÀed serum samples of 
NSCLC patients were randomly obtained from the 
institutional biorepository . Clinical data included 
gender, age, smoking history, histology. E7 genes 
of HPV16 or 18 were cloned into prokaryotic 
expression vectors, pMal C2 (New England 
BioLabs.) or pQE30 vector (Qiagen) by PCR 
cloning technology. The E7 proteins were expressed 
in E.coli, and puriÀed as recommended by the 
manufacturers (NEB and Qiagen, respectively). 
Direct ELISA method was used to measure IgG 
antibodies against E7 of HPV16 and 18. PuriÀed 
MBP proteins were used as control negative. Positive 
control human sera, which have been previously 
tested as positive, for these HPV oncoproteins, was 
employed for each experiment.
Results: Cases were age 42-86 and 53% males. 
23% had a history of another cancer. 88% had a 
history of smoking, 7% have never smoked, and 
5% the history of smoking was unknown. Of the 
100 samples 43% were adenocarcinoma (AC), 39% 
squamous cell carcinoma (SCC), 10% NSCLC not 
otherwise speciÀed (NOS), 4% large cell carcinoma, 
2% neuroendocrine type (NEC). Analyzing the data 
utilizing two standard deviations of the mean as a 
reference. IgG serology for HPV/E7 was positive 
in 13%. HPV 16 in 5, HPV 18 in 7 and positive 
for HPV 16 and 18 in 1 case. Of the 5 positive 
for HPV16, 2 were AC, 2 SCC, 1 NOS. For the 7 
HPV18 positives, 5 were AC, 2 SCC. The only case 
with both types of HPV, was AC.
Conclusion: This is the Àrst study detecting the 
presence of antibodies against E7 for HPV 16/18 
in serum. The 13% is in accordance with previous 
studies detecting HPV in NSCLC in a similar 
proportion. The fact that an immune response to 
HPV’s oncogene E7 is found in NSCLC patients 
raises the question of HPV’s role in NSCLC 
inhibited the proliferation of A549 cells in a time- 
and dose-dependent manner. The proliferation 
inhibition rates of A549 cells treated with 
Anastrozole for 24h,48h,72h were (23.32±0.97)%, 
(31.81±1.30)%, (35.88±0.78)% respectively,while 
the proliferation inhibition rates of A549 cells treated 
with GeÀtinib for 24h,48h,72h were (21.32±1.57)%, 
(34.44±0.47)%, (39.56±0.45)% respectively.The 
combination of two drugs increased the proliferation 
inhibition rates for 24h,48h,72h to (37.66±1.02)%, 
(63.41±2.02)%, (70.50±0.86)%respectively, which 
was closely associated with elevation of the G0/
G1 phase fraction(P<0.05). Apoptosis rates of A549 
cells treated with Anastrozole, GeÀtinib alone or in 
combination were (10.72±1.12)%, (17.40±1.28)%, 
(23.02±2.32)% respectively (P<0.05). The synthetic 
effect of the combination therapy was accompanied 
by reduction of p-EGFR,p-ERK and p-AKT 
expression compared with individual treatment.
Conclusion: The results of this vitro study suggest 
the combination of Anastrozole and GeÀtinib 
compared with either drug alone can maximally 
inhibit cell proliferation, induce apoptosis, and affect 
downstream signaling pathways. Our study supports 
functional interaction between the ER and the EGFR 
pathways in lung cancer and provides a clinically 
exploitable strategy for non-small cell lung cancer 
patients .
Keywords: GeÀtinib, NSCLC, EGFR/ER pathway, 
Anastrozole
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the Late Breaking Abstract Supplement, available 
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P1.044 DETECTION OF IGG AGAINST 
E7 OF HPV 16,18 IN NON-SMALL CELL 
LUNG CANCER
Raul E. Storey, Joh Joongho, Alfred B. Jenson, Shin-
Je Ghim, Goetz Kloecker 
Hematology Oncology, James G. Brown Cancer 
Center, University Of Louisville/United States Of 
America
Background: 10-20 % of non-small cell lung 
cancers (NSCLC) occur in never smokers. Human 
papilloma virus (HPV) has been identiÀed in 20-
25% of NSCLC. HPV’s role in the carcinogenesis 
of NSCLC is unclear. The genome of HPV is a 
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cell survival was reduced and the mean number of 
ƢH2AX foci increased. DNA Topoisomerase IIƠ 
and POLB were co-immunoprecipitated from cells 
treated with Etoposide. 
Conclusion: In a cell line model of in vivo acquired 
Etoposide chemoresistance DNA Polymerase ơ 
prevents Etoposide-induced apoptosis by preventing 
the generation of double strand DNA breaks through 
promotion of the repair of excess single strand DNA 
breaks. 
Keywords: etoposide, chemoresistance, Small cell 
lung cancer, DNA Polymerase beta
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P1.046 OPTIMISING REGULATORY 
T CELL (TREG) DEPLETION IN 
COMBINATION WITH CHEMOTHERAPY 
FOR ENHANCED ANTI-TUMOUR 
IMMUNITY
Alison M. Mcdonnell, Bruce W.S. Robinson, 
Michael Millward, Anna K. Nowak, Richard A. Lake 
School Of Medicine And Pharmacology (m503), The 
University Of Western Australia/Australia
Background: Cytotoxic chemotherapy is widely 
used to palliate malignant pleural mesothelioma 
(MM) and non small cell lung cancer (NSCLC). 
While originally considered detrimental to the 
immune system, there is now abundant preclinical 
data showing that chemotherapy can enhance anti-
cancer immunotherapy. Tregs are immunosuppressive 
CD4+ T cells thought to inhibit anti-tumour immune 
responses; murine data suggests that Treg eradication 
may augment existing anti-tumour immunity. 
Cyclophosphamide (CTX) is immunostimulatory 
and at low doses selectively depletes Tregs in mice 
and humans. The primary objective of this study is to 
identify an optimum dose and schedule of iterative 
low dose oral CTX for Treg depletion in the context 
of pemetrexed-based chemotherapy, and to determine 
how treatment affects the function and phenotype of 
the cellular immune response. 
Methods: This single centre phase 1b study enrolled 
patients with advanced MM or NSCLC planned for 
pemetrexed based chemotherapy. Patients received 
pemetrexed 500 mg/m2 ± cisplatin 75 mg/m2 or 
carboplatin AUC 4-6 on a standard 21 day schedule, 
and from the second cycle received escalating doses 
of oral CTX taken every day for days 1-14 of each 
cycle, with an initial dose of 50 mg daily. CTX 
carcinogenesis.
Keywords: HPV, Lung cancer
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P1.045 DNA POLYMERASE ȕ PROTECTS 
SMALL CELL LUNG CANCER 
CELLS FROM ETOPOSIDE INDUCED 
APOPTOSIS
Malcolm H. Lawson1, Natalie M. Cummings2, Doris 
M. Rassl3, Roslin Russell1, James D. Brenton1, 
Robert C. Rintoul4, Gillian Murphy1 
1Li Ka Shing Centre, Cruk Cambridge Research 
Institute/United Kingdom, 2Thoracic Oncology, 
Papworth Hospital/United Kingdom, 3Pathology, 
Papworth Hospital/United Kingdom, 4Department 
Of Thoracic Oncology, Papworth Hospital/United 
Kingdom
Background: Small Cell Lung Cancer (SCLC) 
typically responds well to Àrst line chemotherapy 
with Etoposide and a Platinum containing agent. 
However survival is poor due to rapid relapse 
with chemoresistant disease. DNA Polymerase 
ơ (POLB) has been implicated in single strand 
DNA break repair caused by Temozolamide and 
in the repair of DNA adducts caused by platinum 
containing chemotherapeutics. POLB was identiÀed 
as a potential Etoposide chemoresistance factor by 
cDNA microarray using a unique series of cell lines 
derived from a single patient during the course of her 
treatment. This work was planned to investigate the 
functional role of POLB in Etoposide resistance in 
SCLC. 
Methods: POLB was cloned and transiently 
expressed in the cell lines which were then treated 
with Etoposide and assayed for cell survival using 
a chemoluminescent method. The speciÀc POLB 
inhibitor Pamoic Acid was used to determine if 
reducing POLB activity altered cell survival after 
Etoposide treatment. Imaging Áow cytometry was 
used to investigate the role of POLB in preventing 
Etoposide-induced DNA double strand breaks. 
Results: Protein expression of POLB was highest 
in the cell line that was most resistant to Etoposide 
compared to the line most sensitive to Etoposide. 
When POLB was transiently expressed in the 
cell line most sensitive to Etoposide cell survival 
after Etoposide treatment was increased. When 
the most Etoposide resistant cells were pre-treated 
with Pamoic Acid prior to Etoposide treatment, 
S726 Copyright © 2011 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
Respiratory And Pulmonary Circulation, Beijing 
Institute Of Respiratory Medicine, Beijing Chao-
yang Hospital/China, 2Beijing Key Laboratory Of 
Respiratory And Pulmonary Circulation, Beijing 
Institute Of Respiratory Medicine, Beijing Chao-
yang Hospital, Department Of Physiology, Capital 
Medical University/China
Background: Lung cancer is one of the leading 
causes of cancer related deaths worldwide, 
representing about 29% of all such cases while fewer 
than 15% of patients are living after 5 years.Non-small 
cell lung cancer (NSCLC) accounts for approximately 
85% of all lung cancer cases. The most promising 
therapy for NSCLC is complete lung resection.
However, the survival rate after complete lung 
resection for NSCLC is far from satisfactory and most 
patients are offered chemotherapy as an alternative, 
in particular cisplatin (cis-diamminedichloroplatinum 
II) based chemotherapy.4 Cisplatin has been used 
clinically for approximately 30 years and is effective 
against a variety of cancers, including testicular, 
ovarian, head and neck, cervical, and NSCLC. It is 
primarily effective through formation of adducts with 
DNA, causing induction of apoptosis.5 However, 
the efÀcacy of chemotherapy is limited due to the 
development of multidrug resistance (MDR). Despite 
a recent increase in the understanding of the signaling 
pathways activated by cisplatin and the mechanisms 
contributing to resistance, cisplatin resistance remains 
a major problem that severely limits the usefulness 
of this chemotherapeutic agent. Thus, elucidation of 
the mechanisms will lead to the development of more 
effective methods to combat resistance of cisplatin for 
lung cancer.
Recently, multiple studies have pointed to the 
involvement of plasma membrane ion channels 
in a cell’s response to chemotherapy. Okada et al. 
reported that pretreatment with cisplatin enhanced the 
activity of volume-sensitive Cl- channels in human 
epidermoid cancer KB cells; cisplatin-resistant KCP-
4 cells derived from KB cells, on the other hand, 
lacked functional expression of these channels.6 
Our previous study also found that activation of 
volume sensitive Cl- channels (VSOR) is involved 
in carboplatin-induced apoptosis in A549 cells and 
that blockage of VSOR Cl- channels can eliminate 
chemotherapeutic agent induced A549 cell apoptosis. 
These results, along with the Ànding that VSOR 
Cl- current activation is essential to the progression 
of apoptosis in various cell lines, suggest that the 
alteration in VSOR Cl- channel functional expression 
dose was increased in subsequent cycles until Tregs 
comprised <4% of the CD4+ T cell population. Weekly 
peripheral blood samples were collected and the 
proportion of CD25+CD127loFoxp3+ Tregs in whole 
blood determined by Áow cytometry in real time. 
Peripheral blood mononuclear cells (PBMC) were 
cryogenically stored for subsequent analysis. Toxicity 
and radiological response were assessed. 
Results: To date, 12 patients with MM (10/12) 
or NSCLC (2/12) have completed treatment. 
Preliminary analyses demonstrate the proportion of 
CD25+CD127loFoxp3+ Tregs is stable during the Àrst 
cycle of standard care chemotherapy, with a mean 
baseline Tregs 7.70% ± 1.60% of all CD4+ T cells. 
Following treatment with CTX, the proportion of 
peripheral blood Tregs decreased, with optimal Treg 
depletion achieved during treatment with alternating 
50/100 mg per day, then increased back to/and above 
baseline during the treatment break. The Treg nadir 
was 5.90% ± 1.51%, and was achieved on cycle 3 
day 15. Increasing doses up to alternating 100/150 
mg daily did not result in improved Treg depletion. 
Analysis of PBMC T cell populations indicates that 
cell proliferation (Ki67) and activation (inducible co-
stimulator; ICOS) peak and trough with each cycle 
of chemotherapy, declining during treatment and 
increasing during the treatment break. Combining CTX 
with routine cytotoxic chemotherapy is feasible with no 
additional haematological or other toxicities. 
Conclusion: The addition of CTX to pemetrexed based 
chemotherapy is safe and feasible, but depletes Tregs 
during CTX administration only. Doses above alternate 
days 50/100 mg do not improve depletion. The next 
patient cohort will receive continuous oral CTX to 
establish if this schedule results in more continuous or 
more profound Treg depletion. Additional work will 
investigate the effect of this chemo-immunotherapy 
protocol on tumour-speciÀc cellular immunity.
Keywords: Chemo-immunotherapy, Regulatory T 
cells, Thoracic malignancy, Tumour Immunology
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P1.047 MALFUNCTION OF VOLUME-
SENSITIVE CL- CHANNELS IS 
INVOLVED IN CISPLATIN RESISTANCE 
IN HUMAN LUNG ADENOCARCINOMA 
CELLS
Xian J. Min1, Hui Li1, Jun Wang2 
1Department Of Thoracic Surgery, Beijing 
Chao-yang Hospital, Beijing Key Laboratory Of 
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P1.048 THE FUNCTIONAL ROLE 
OF EPITHELIAL CELL ADHESION 
MOLECULE (EPCAM) IN THE NON-
SMALL CELL LUNG CANCER CELL 
LINES.
Masashi Kondo1, Tetsunari Hase1, Mitsuo Sato1, 
Yoshida Kenya1, Yoshihiro Takeyama1, Elshazley 
Momen1, Yoshitaka Sekido2, Adi F. Gazdar3, John D. 
Minna4, Yoshinori Hasegawa1 
1Respiratory Medicine, Nagoya University/Japan, 
2Division Of Molecular Oncology, Aichi Cancer 
Center Research Institute/Japan, 3Hamon Center 
For Therapeutic Oncology Research, Pathology, 
University Of Texas Southwestern Medical Center/
United States Of America, 4Hamon Center For 
Therapeutic Oncology Research, University Of 
Texas Southwestern Medical Center/United States Of 
America
Background: A transmembrane glycoprotein, 
epithelial cell adhesion molecule (EpCAM), was the 
Àrst tumor-associated antigen indentiÀed by means 
of monoclonal antibodies. Subsequently, it was found 
to be frequently over-expressed in a great variety of 
human cancers, including lung, esophagus, gastric, 
breast, colorectal, and hepatocellular carcinomas and 
its contribution to increased proliferation through 
up-regulating cell cycle accelerators such as cyclins 
A and E is well demonstrated in breast and gastric 
cancers. Nevertheless, very little is known about its 
role in the survival of cancer cells. In addition, the 
functional role of EpCAM in the pathogenesis of 
lung cancer remains to be explored.
Methods: 18 human non-small cell lung cancer 
cell lines and an immortalized normal human 
bronchial epithelial cell lines (HBEC4) were used. 
The expressions of EpCAM were measured by 
quantitative real-time PCR (qRT-PCR), Western 
blot analysis and FACS. RNA interference (RNAi)-
mediated gene silencing for EpCAM was performed 
in several non-small cell lung cancer cell lines and 
HBEC4. Cell proliferation was measured by WST-1 
and clonogenic growth was measured by liquid and 
soft agar colony formation assays. Apoptosis was 
evaluated by Annexin V/7-AAD staining. FACS 
with PI staining was done to examine apoptosis and 
cell cycle. The expression of p27 was evaluated by 
Western blot analysis. In vitro invasion assay was 
done by using transwell chambers layered with 
matrigel.
might contribute to cisplatin resistance in A549 cells.
Methods: Cisplatin-induced the process of apoptotic 
volume decrease (AVD) was measured using 
an inverted microscope with a high-resolution 
electronic camera and the cell images were captured 
and analyzed with a medical digital image analysis 
system. Whole cell patch clamp technology was 
applied to record Volume-Sensitive Cl- current and 
the data were acquired using an EPC-10 ampliÀer 
and Pulse software, and the sampled data were 
analyzed using an original software application 
called PulseÀt and Origin 6.1. RT-PCR was used to 
evaluate the expression of the molecular candidates 
for VSOR Cl- channel, which include ClC-3, MDR1 
and PIcln. Cell viability was performed by cell 
counting and MTT assay and the apoptosis rate was 
measured by TUNEL Kit. 
Results: 1. A549 cells, which serve as a 
model of sensitive to cisplatin, underwent the 
process of apoptotic volume decrease (AVD) 
when treated with cisplatin. This AVD process 
were blocked by chloride channel blockers, 
4,4’-diisothiocyanostilbene-2,2’- disulfonic acid 
(DIDS). But in A549/CDDP cells, which serve as 
a model of cisplatin-resistance, AVD processes 
were nearly absent. 2. Cisplatin treatment activated 
a Cl- current in A549 cells, which shows similar 
properties to hypotonicity-induced volume-sensitive, 
outward rectifying (VSOR) Cl- current in A549 cells, 
however, VSOR Cl- currents were nearly absent in 
the parallel A549/CDDP cells. 3. The expression of 
MDR1, which is one of the molecular candidates for 
VSOR Cl- channel also obviously decreased in A549/
CDDP cells. 4. Pretreatment A549/CDDP cells with 
trichomycin A (TSA), a drug which inhibits histone 
deacetylases could partially restore VSOR Cl- current 
but not the expression of MDR1. 5. Treatment of 
the cells with both cisplatin and TSA resulted in 
a decrease in cell viability and an increase in cell 
apoptosis rate. 
Conclusion: Malfunction of volume sensitive 
chloride channels contributes to cisplatin resistance 
in human lung adenocarcinoma cells 
Keywords: volume sensitive chloride 
channels(VSOR), apoptotic volume decrease (AVD), 
cisplatin-resistance, lung adenocarcinoma cells
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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Methods: Mice(Female BALB/c mice, 8-10 
weeks of age) were divided into four experimental 
groups. (control;C, tumor;T, tumor injecction with 
essential oil inhalation;T and E, tumor injection 
and then essential oil with 1week interval; T and 
then E) Lewis lung cancer cells were injected at 
back subcutaneously in T, T and E and T and then 
E group, respectively. 1% Chamaecyparis Obtusa 
Essential oil was dissolved in PBS and administered 
by nebulizer (1% or 2.5mg/ml, respectably) Àve 
times to each animal at 24-hour intervals for 5 days 
in T and E group and T and then E group. The extent 
of tumor growth was measured three per week using 
sterile metric calipers. 
Results: Tumor bearing(TB) mice showed 
splenomegaly and essential oil inhalation decreased 
splenomegaly of TB-mice. Relatively CD4/CD8 
ratio was decreased in spleen by essential inhalation. 
Foxp3-positive Treg cells in spleen were highly 
expressed in C and T group comparing with T and 
E, T and then E group but, tumor inÀltrating Foxp3-
positive Treg cells, COX-2, IL-17a and IL-10 in 
tumor were decreased in T and E, T and then E 
group. Tumor growth rate was low in T and E, T and 
then E group. 
Conclusion: Our results indicate that Chamaecyparis 
Obtusa Essential oil has a promising anticancer 
activity and anti-inÁammatory properties as an 
immune modulating agent.
Keywords: Chamaecyparis Obtusa, Lewis Lung 
Carcinoma, immune modulating agent
Poster Session 1 – Cancer Biology Monday, 4 July 2011 12:15-14:15
P1.050 IL-23 EXPRESSION AND 
REGULATION IN NSCLC
Kenneth J. O’Byrne, Jennifer Leonard, Lisa 
Kilmartin, Steven G. Gray 
Clinical Medicine, Trinity College Dublin/st James’ 
Hospital/Ireland
Background: IL-23 is a heterodimeric 
proinÁammatory cytokine consisting of a p40 subunit 
(IL12B), covalently linked to a p19 subunit (IL23A). 
Critically, IL-23 has been shown to promote tumor 
incidence and tumor growth. In addition, IL-23 
stimulates neutrophil and macrophage inÀltration, 
and also promotes angiogenesis and expression 
of inÁammatory mediators within the tumor 
microenvironment. It is thought that IL-23 redirects 
the adaptive cytotoxic effector response away from 
Results: EpCAM was expressed at highly variable 
levels by lung cancer cells lines. EGFR mutant 
cell lines expressed EpCAM at higher levels than 
EGFR wild-type lines. The knockdown of EpCAM 
suppressed proliferation and clonogenic growth 
of two EpCAM-expressing lung cancer cell lines 
(H3255 and H358) in both anchorage-dependent and 
-independent conditions, but did not affect cell cycle 
proÀling in either cell line. EpCAM knockdown 
suppressed the invasiveness of highly invasive 
H358 cells but not poorly invasive H3255 cells. The 
EpCAM knockdown induced massive apoptosis 
in both cell lines as well as in another EpCAM-
expressing lung cancer cell line (HCC2279), but 
to a much lesser extent in HBEC4, suggesting that 
targeting EpCAM in lung cancer may have a high 
therapeutic index. In addition, EpCAM knockdown 
partially restored contact inhibition in a contact 
inhibition-resistant cell line HCC827, accompanying 
p27Kip1 up-regulation.
Conclusion: These results demonstrate that EpCAM 
contributes substantially to the pathogenesis of lung 
cancer, especially cancer cell survival, and that the 
development of an EpCAM-targeted therapy for lung 
cancer may have promise.
Keywords: NSCLC, EpCAM
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P1.049 CHAMAECYPARIS OBTUSA 
ESSENTIAL OILL MODULATES THE 
TREG INTRA-TUMORAL INFILTRATED 
CELL AND INHIBITS LEWIS LUNG 
CARCINOMA GROWTH IN VIVO
Jeong Eun Lee1, Sun Young Kim2, Sun Young Jung2, 
Seung Pyung Lim3, Ju Ock Kim2, Hee Sun Park2 
1Internal Medicine, Chungnam National University 
Hospital/Korea, 2Internal Medicine, Chungnam 
National University/Korea, 3Cardiothoracic Surgery, 
Chungnam National University/Korea
Background: Chamaecyparis Obtusa Essential oil are 
volatile antimicrobial organic compounds that have 
multiple biological properties, such as antifungal, 
insecticidal, and anti-inÁammatory activities. A 
correlation has been shown between survival and the 
frequency of tumor-inÀltrating Foxp3-positive Treg 
cells in cancer patients. The aim of this study was to 
study the anti-tumor activities of the essential oils of 
C. obtuse in vivo via tumor growth and inÀltration of 
Foxp3-positive Treg cells in tumor.
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P1.051 ANTICANCER EFFECT AND 
APOPTOSIS INDUCTION OF GAMBOGIC 
ACID IN HUMAN LUNG CANCER LINE 
A549
Dong Jiang1, Shiying Zheng2, Hong Li3 
1Department Of Cardio-thoracic Surgery, The First 
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2.department Of Cardio-thoracic Surgery, The First 
AfÀliated Hospital Of Soochow University/China, 
3Department Of Geriatrics, The First AfÀliated 
Hospital Of Soochow University/China
Background: To investigate the anticancer effect of 
a traditional Chinese medicine gambogic acid (GA) 
in human lung cancer line A549 and further study the 
mechanism of apoptosis induction of GA.
Methods: Low differential human lung cancer line 
A549 were treated with GA at different doses and 
different times, the inhibitory rates were detected by 
MTT assay. Apoptosis induced by GA in A549 cells 
was observed by Annexin-V/PI doubling staining 
Áow cytometry assay. And T/C (%) was chosen to 
detect the inhibition of GA on human lung cancer 
line A549 nude mice xenografts. Apoptosis on 
nude mice xenografts was observed by Annexin-V/
PI doubling staining Áow cytometry assay and 
DNA fragmentation assay. To further determine the 
molecular mechanism of apoptosis induced by GA, 
the changes on the expression of bcl-2 and bax genes 
were detected by RT-PCR.
Results: After incubation with GA, low differential 
human lung cancer line A549 was dramatically 
inhibited in a dose-dependent manner. After these 
cells were exposed to GA for 24, 48 and 72 h, 
the IC50 value was 1.02±0.05, 1.41±0.20 and 
1.14±0.19 ƫmol/L, respectively. Apoptosis in A549 
cells induced by GA was observed by Annexin-V/
PI doubling staining Áow cytometry assay. The 
apoptotic population of A549 cells was about 
12.96% and 24.58%, respectively, when cells were 
incubated with 1.2 ƫmol/L GA for 48 and 72 h. T/C 
(%) of human lung cancer line A549 nude mice 
xenografts was 44.3, when the nude mice were 
treated with GA (8 mg/kg). Meanwhile, apoptosis 
induced by GA was observed in human lung cancer 
line A549 nude mice xenografts. The increase of 
bax gene and the decrease of bc1-2 gene expressions 
were found by RT-PCR.
Conclusion: The inhibition of GA on human 
lung cancer line A549 was conÀrmed. This effect 
anti-tumor immunity towards proinÁammatory and 
proangiogenic effector pathways that nourish the 
tumor. Consequently, IL-23 enables the persistence 
of the recognized tumor cells, accompanied by 
tumor-associated inÁammation. We hypothesized 
that IL-23 expression is important in the 
pathogenesis of NSCLC and have examined its 
expression and role in NSCLC. 
Methods: IL-23A mRNA expression was examined 
using RT-PCR in a series of resected fresh frozen 
NSCLC tumors and matched normal tissue samples, 
and in a panel of NSCLC cell lines including 
normal bronchial epithelial cells. The effects of 
epigenetic targeting on the regulation of IL-23 
expression was examined in a NSCLC cell line 
using histone deacetylase inhibitors (HDACi) and 
DNA methyltransferase inhibitors (DNMTi) by RT-
PCR and chromatin immunoprecipitation (ChIP). 
IL-23 expression in response to treatment with the 
antimetabolite chemotherapeutic agent gemcitabine 
was also studied. Finally, the effect of recombinant 
IL-23 protein on NSCLC cell line cellular 
proliferation was examined. 
Results: IL-23A was overexpressed in a subset 
of NSCLC tumors, and only very low basal 
levels could be detected in a panel of NSCLC 
cell lines. Treatments of cell lines with the DNA 
methyltransferase inhibitor 5-aza-2-deoxycytidine 
induced IL-23. The HDAC inhibitors (Trichostatin 
A, Phenylbutyrate and SAHA) also induced IL-
23A gene expression. ChIP analysis revealed direct 
chromatin remodeling at the IL23A promoter in 
response to HDACi. Cells treated with gemcitabine 
were found to have elevated IL-23A expression. 
The cellular proliferation of an NSCLC cell line was 
increased in response to treatments with recombinant 
IL-23. 
Conclusion: Based on our results IL-23A is 
expressed in a subset of primary NSCLC tumors. 
Expression of IL-23A in NSCLC is dynamically 
regulated by epigenetic mechanisms. The 
chemotherapy drug gemcitabine enhanced IL23A 
expression, while recombinant IL-23 stimulated 
NSCLC cell line proliferation. These results may 
therefore have important implications for treating 
patients with epigenetic targeting therapies or 
gemcitabine. 
Keywords: pro-inÁammatory, epigenetics, anti-
metabolite, Cytokine
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GOLM1 gene expression and lung adenocarcinoma 
progression.
Methods: We analyzed 174 cases of surgically 
resected lung adenocarcinoma with tumors less than 
2 cm in diameter. The mean age of the patients was 
65.18 years (SD 8.94). Written informed consent 
was obtained from all patients. We performed 
immunohistochemical analysis of GOLM1 and 
the Golgi marker protein Giantin. The staining 
intensity of GOLM1 was judged as high and low, 
relative to that of the normal bronchial epithelium. 
We then carried out a morphometric analysis 
of immunohistochemical staining. A BZ-9000 
microscope system with BZ-II Analyzer software 
(KEYENCE, Japan) was used for the morphometric 
analysis and measurement of GOLM1-positive 
signals in lung cancer cells. Furthermore, we 
examined the lung cancer cells by electron 
microscopy. 
Results: Of the 174 cases, 153 were at 
pathological stage I while 21 were at stage II or III. 
Immunohistochemical tests showed that, in normal 
lung tissues, GOLM1 staining appeared as coarse 
uniform signals around the nuclei of bronchial 
epithelial cells. In lung cancer cells, on the other 
hand, these signals were small but irregularly 
sized. GOLM1-positive signals in cancer cells were 
distributed similarly to the Giantin-positive signals. 
High GOLM1 expression was evident in 135 cases, 
and low GOLM1 expression in 39. The mean size 
of the GOLM1-positive signals in cancer cells was 
2.05 ƫm2 (SD 1.23). The data obtained through 
our morphometric analysis were then compared 
with the groupings of the Noguchi classiÀcation. 
GOLM1-positive signals had a signiÀcantly smaller 
mean size in type A tumors than in type B and C 
tumors. In addition, GOLM1-positive signals had a 
signiÀcantly larger mean size in non-lepidic tumors 
(types D, E, and F) than in lepidic tumors (types A, 
B, and C). Electron microscopy revealed signiÀcant 
development of the ER-Golgi in cases with high 
GOLM1 expression. Cases with low GOLM1 
expression tended to have a better outcome than 
cases with high GOLM1 expression. 
Conclusion: GOLM1 expression pattern may affect 
the prognosis of lung cancer. SigniÀcant variation 
of GOLM1 expression in lung cancer cells may be 
associated with morphological variation in the Golgi 
apparatus. 
Keywords: cDNA microarray, GOLM1, 
Adenocarcinoma, Noguchi clasiÀcation
connects with the inducing apoptosis in A549 cells 
and the molecular mechanism might be related to 
the reduction of expression of apoptosis-regulated 
gene bcl-2, and the improvement of the expression 
of apoptosis-regulated gene bax. The result was also 
conÀrmed in vivo.
Keywords: Gambogic acid, apoptosis, human lung 
cancer line A549, bcl-2/ bax
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.052 ABNORMAL GOLM1 GENE 
EXPRESSION IN ADENOCARCINOMA 
OF THE LUNG
Tsutomu Yoshida1, Yuko Minami1, Aya Shiba-Ishii1, 
Shingo Sakashita1, Keisei Tachibana2, Yoshimasa 
Nakazato3, Tomoyuki Goya2, Masayuki Noguchi1 
1Department Of Pathology, Institute Of 
Basic Medical Sciences, Graduate School Of 
Comprehensive Human Sciences, University Of 
Tsukuba/Japan, 2Department Of Surgery, School Of 
Medicine, Kyorin University/Japan, 3Division Of 
Diagnostic Pathology, Gunma Prefectural Cancer 
Center/Japan
Background: Noguchi type C lung adenocarcinoma 
is an early invasive adenocarcinoma, some cases 
of which show an extremely favorable outcome. 
Such cases are considered to be minimally 
invasive adenocarcinoma. Although various sets 
of histological criteria have been proposed for the 
evaluation of minimally invasive adenocarcinoma, 
none have yet been widely accepted. Previously, we 
compared the gene expression proÀles of Noguchi 
Type A lung adenocarcinoma (adenocarcinoma in 
situ) with those of Type C lung adenocarcinoma 
associated with lymph node metastasis or a fatal 
outcome, and screened the differentially expressed 
genes using a cDNA microarray (Shiba-Ishii et 
al., Int J Cancer 2011). Among the genes showing 
signiÀcantly higher expression in type C than in type 
A, we focused on GOLM1, which encodes a 73-kDa 
human Golgi protein. Up-regulation of GOLM1 
has been observed in certain other cancers such as 
hepatocellular carcinoma, prostate carcinoma, and 
renal cell carcinoma. The purpose of the present 
study was to investigate the relationship between 
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was conÀrmed as cells lacking Ephrin B3 expression 
showed decreased clonogenic survival potential, 
alone and when combined with RT. Inhibition of 
Ephrin B3 expression sensitized NSCLC cells to RT 
by increased senescence and apoptotic signalling. 
We also observed altered activation of EphA2 and 
Ephrin B3 in response to RT and conÀrmed a role 
for Ephrin B3 in EphA2 activation. Knockdown 
of Ephrin B3 in combination with RT altered Eph 
downstream targets such as Akt and p38MAPK. 
Analysis of EphA2 mRNA expression revealed 
its increase in NSCLC compared to SCLC with 
a tendency of higher expression in radioresistant 
compared to radiosensitive cell lines. Moreover, 
inhibiting EphA2 expression resulted in reduced cell 
proliferation and induction of a senescent phenotype, 
similar to downregulation of Ephrin B3 expression in 
NSCLC cells. 
Conclusion: Our data imply that Ephrin B3, 
Ephrin A1 and EphA2 are putative molecules 
which inÁuence NSCLC proliferation and RT 
responsiveness. The RT sensitizing effect of Ephrin 
B3 knockdown and the reported Eph mutations 
in NSCLC suggest Ephrins and Ephs to be novel 
molecules for targeted therapy approach to combat 
RT resistance in LC. 
Keyword: Ephrin, Eph, radiotherapy, senescence, 
PathScan® Antibody Array
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P1.054 EGFR MUTATION ASSESSMENT 
FROM FIXED AND FRESH 
CYTOLOGICAL MATERIAL IN NON-
SMALL CELL LUNG CANCER
Anna Szumera-Cieckiewicz1, Andrzej Tysarowski2, 
Michal Wćgrodzki1, Dariusz M. Kowalski3, Maciej 
Glogowski3, Janusz A. Siedlecki2, Wlodzimierz T. 
Olszewski1 
1Department Of Pathology, Maria Skãodowska-curie 
Memorial Cancer Center And Institute Of Oncology/
Poland, 2Department Of Molecular Biology, Maria 
Skãodowska-curie Memorial Cancer Center And 
Institute Of Oncology/Poland, 3Medical Oncology, 
The Maria Sklodowska-curie Institute Of Oncology/
Poland
Background: Recent progress in lung cancer 
biology has led to the development of small-
molecule inhibitors of target proteins involved 
in proliferation, apoptosis and angiogenesis. The 
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P1.053 ROLE OF AN EPHA2/EPHRIN 
B3 SIGNALLING CIRCUIT IN 
REGULATION OF NSCLC RESPONSE TO 
RADIOTHERAPY.
Ghazal Efazat1, Sara Ståhl1, Vitaliy Kaminskyy2, 
Claudia Selck1, Petra Hååg1, Rolf Lewensohn1, Boris 
Zhivotovsky2, Kristina Viktorsson1 
1Oncology/pathology, Karolinska Institutet/Sweden, 
2Enviromental Medicine, Karolinska Institutet/
Sweden
Background: Lung cancer (LC) is the leading 
cause of cancer deaths in the world. The current 
treatment regimens include a combination of chemo- 
and radiotherapy (CT and RT) and for some cases 
targeted therapies against EGFR/IGFR growth factor 
(GF) receptor signalling circuits. Ephrin ligands 
and their receptors Ephs, are other GF signalling 
molecules reported to inÁuence proliferation and 
migration of tumour cells. Their function is also 
deregulated in various tumors compared to normal 
tissue. Moreover, several mutations are reported 
in different Ephs both in the ligand binding and 
kinase domain placing Ephs among the top ten most 
frequently mutated genes in NSCLC. Using global 
gene array analysis we recently identiÀed Ephrin B3 
as a potential RT sensitizing target in NSCLC cells. 
The aim of these studies was to further explore the 
potential of Ephrins and Ephs as novel molecules 
with RT sensitizing capacity in LC. 
Methods: A panel of SCLC and NSCLC cell lines 
with different RT sensitivities was used. RNA and 
protein expression of Ephrin B3, Ephrin A1 and 
EphA2 were analysed by real-time quantitative 
PCR (RT-Q-PCR) and western blotting (WB). Small 
interfering RNA (siRNA) was used to knock down 
Ephrin B3 and EphA2. RT response was examined 
by clonogenic survival and apoptotic assays. 
PathScan® Antibody Array was used to determine 
activation of Ephs and their downstream targets prior 
and post RT in LC cells with or without Ephrin B3 or 
EphA2 protein expression. 
Results: Ephrin B3, EphA2 and Ephrin A1 
expressions were analyzed in the SCLC and NSCLC 
cell line panel using RT-Q-PCR and WB. We found 
higher expression of Ephrin B3 in radioresistant 
(SF2>0.3) compared to radiosensitive (SF2<0.3) 
NSCLC cell lines with a correlation of 0.6. No 
correlation was observed in SCLC cells. A role for 
Ephrin B3 in NSCLC proliferation and RT response 
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P1.055 CONSISTENT LOW DEGREE 
ANTAGONISM OF COMBINED 
EPIDERMAL GROWTH FACTOR 
RECEPTOR-TYROSINE KINASE 
INHIBITOR (EGFR-TKI) AND 
INDIVIDUAL CHEMOTHERAPEUTIC 
AGENTS IN NON-SMALL CELL LUNG 
CANCER (NSCLC) CELLS HARBORING 
SENSITIZING-EGFR MUTATIONS
Chun-Ming Tsai, K.-T. Chang, Chao-Hua Chiu, 
Shih-Yin Hsiao 
Division Of Thoracic Oncology/department Of Chest 
Medicine, Taipei Veterans General Hospital/Taiwan
Background: NSCLC cells harboring sensitizing-
EGFR mutations are supposed to be more sensitive 
than EGFR wild type cells to the treatment of 
combined EGFR-TKI and chemotherapy. We tested 
this theory in a panel of NSCLC cell lines.
Methods: Using the MTT assay and the classical 
isobole method, we examined the combination 
effects of six geÀtinib (G)-containing doublets, 
namely, G/C (cisplatin), G/Gem (gemcitabine), G/
Pem (pemetrexed), G/P (paclitaxel), G/D (docetaxel) 
and G/V (vinorelbine) in a panel of 15 (three 
harboring sensitizing-EGFR mutations) chemonaive 
NSCLC cell lines, in a concomitant administration 
schedule.
Results: In the whole group of 15 cell lines, overall 
results showed marked antagonism (Ant) of G/C, 
additivism (Add) of G/Gem, marginal synergism of 
G/P, marked synergism (Syn) of G/Pem, G/D and G/V, 
with the mean values of combination index (mCIs) 
were 1.184 (95% conÀdence interval: 1.12-1.24, 
P=0.001), 1.027 (0.948-1.107, P=0.683), 0.911(0.833-
0.989, P=0.078), 0.814 (0.7-0.92, P=0.011), 0.870 
(0.78-0.96, P=0.017), and 0.899 (0.816-0.982, 
P=0.041), respectively. The mCIs of G/C, G/Gem, G/
Pem, G/P, G/D and G/V of the 3 sensitizing mutants 
were 1.116 (Ant), 1.110 (Ant), 0.993 (Add), 1.077 
(Ant), 1.067 (Ant), and 1.082 (Ant), respectively. In 
contrast, the mCIs of the other 12 cell lines were 1.201 
(Ant), 1.007 (Add), 0.769 (Syn), 0.869 (Syn), 0.820 
(Syn), and 0.853 (Syn), respectively. The combination 
effects of geÀtinib and single chemotherapeutic agents 
that act through a variety of anti-cancer mechanisms 
showed consistent low degree antagonism (G/Pem, 
additivism) in the sensitizing-EGFR mutants, while 
the combination effects could be marked antagonism 
(G/C), additivism (G/Gem), or obvious synergism (G/
epidermal growth factor (EGFR) super family 
was identiÀed as a potential therapeutic target 
in non-small-cell lung cancer (NSCLC) and 
several EGFR inhibitors have been synthesized 
including geÀtinib and erlotinib. Concurrently, 
studies on deÀning predictive factors to the anti-
EGFR therapy responsiveness have started. Most 
of the patients with advanced and non-resectable 
NSCLC can be diagnosed only on the examination 
of cytology specimens. Thus, in order to apply 
the EGFR mutation strategy to all patients, a new 
method that requires only a small number of cells 
is necessary. The aim of the study was to evaluate 
the EGFR mutations in two types of material – 
fresh and Àxed cytology specimens – obtained by 
trans-thoracic, computed tomography supported 
biopsy and brush cytology material acquired during 
bronchoÀberoscopy. 
Methods: 89 patients with cytologically conÀrmed 
NSCLC were entered into the study. Each specimen 
contained at least 50% of neoplasmatic cells. The 
Àxed material comprised 78 (87.6%) and fresh - 11 
(12.4%). DNA was extracted from both types of 
material and the EGFR mutation was analyzed in 
exons 18, 19 20 and 21 using the direct sequencing 
method. 
Results: The mean age of patients was 63.3 
years (range 30 – 82) with males predominance 
(50 males vs. 39 females). The histological types 
included: adenocarcinoma 60 (67.4%), non-small 
cell carcinoma non-otherwise speciÀed 17 (19.1%), 
squamous cell carcinoma 9 (10.1%) and large cell 
carcinoma 3 (3.4%). Both types of material were 
equally sufÀcient to evaluate EGFR mutations. The 
ratio of molecularly non-diagnostic material due 
to DNA degradation or too scant DNA probe was 
5.6% (5 cases). In 10 (11.2%) cases EGFR somatic 
mutations was conÀrmed. 
Conclusion: This study demonstrates that EGFR 
mutation status can be analyzed from fresh samples 
as well as regained material from cytological smears. 
The classical cytology may become a useful tool to 
provide molecular biological information, essential 
for the targeted treatment of advanced and recurrent 
lung cancer. 
Keywords: Lung cancer, EGFR mutation, cytology
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Methods: Total RNA was extracted from resected 
lung adenocarcinomas (from Hong Kong, Univ of 
Michigan, and MSKCC, NY) followed by reverse 
transcription and hybridization onto Affymetrix 
GeneChips HG U133A-B and Plus 2. Captured gene 
expression signals were analyzed by SigniÀcance 
Analysis of Microarray (SAM) and class prediction 
analysis with Support Vector Machine (SVM) to 
identify the discriminatory gene expression signature 
with respect to the presence of different types of 
EGFR gene mutations at exons 18 – 21. DNA 
extracted was PCR-ampliÀed and directly sequenced 
to read for EGFR gene mutations at exons 18 – 21.
Results: 96 lung adenocarcinomas were included 
(M:F = 28:68, smokers: non-smokers = 54: 42, 
pTNM Stages I/II/III/IV = 55/19/20/2, Chinese: 
Caucasian = 49: 47). EGFR mutations were present 
in 52 tumors (2 with point mutations at exon 18, 
25 with in-frame deletion and 1 with silent L760L 
mutation at exon 19, 5 with insertion at exon 20, 
18 with L858R and 1 with L861Q mutations at 
exon 21). The most discriminatory gene expression 
differences between tumors with EGFR gene 
mutations at exons 18 and 20 compared to those 
with mutations at exons 19 and 21 were the large 
tumor suppressor homolog 2 (LATS2) and the 
serine/threonine kinase 17b (STK17B), with known 
regulatory function in apoptosis.
Conclusion: We conclude, there are deÀned 
discriminatory gene expression differences between 
tumors with more sensitive EGFR mutations at 
exons 19 and 21 compared to tumors with lesser 
sensitive EGFR mutations at exons 18 and 20. 
Further investigation into the biological roles of 
these discriminatory genes could allow for further 
understanding of the mechanisms of differential 
sensitivity to treatment of different EGFR gene 
mutation in lung adenocarcinomas
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P1.057 DIFFERENTIAL SIGNALING 
CONTROL OF CAP-DEPENDENT 
TRANSLATION: NOVEL TARGETED 
THERAPY FOR SMALL CELL LUNG 
CANCER
Tanawat Jirakulaporn1, Marian G. Kratzke2, Blake A. 
Jacobson3, Manish R. Patel3, Robert A. Kratzke3 
1Department Of Biochemistry, Faculty Of Medicine 
Siriraj Hospital/Thailand, 2Research Service, 
Minneapolis Veterans Affairs Medical Center/
Pem, G/P, G/D and G/V) in cells with no sensitizing 
mutations.
Conclusion: We hypothesized that the geÀtinib 
hypersensitivity and associated oncogenic 
shock might lead to a broad spectrum of chemo-
refractoriness in the sensitizing-EGFR mutants 
when concomitantly treated with EGFR-TKI plus 
individual chemotherapeutics.
Keywords: geÀtinib, drug combination, sensitizing-
EGFR mutations
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P1.056 EXPRESSION OF LATS2 AND 
STK17B DISTINGUISHES EPIDERMAL 
GROWTH FACTOR RECEPTOR (EGFR) 
GENE MUTATIONS IN EXONS 19 AND 
21 FROM THOSE IN 18 AND 20 IN LUNG 
ADENOCARCINOMAS
David C. Lam1, Luc Girard2, David G. Beer3, 
Mark G. Kris4, Marc Ladanyi5, William L. Gerald 
(deceased)4, Alan D. Sihoe6, Lik-Cheung Cheng6, 
Maria P. Wong7, Lap Ping Chung7, Mary Ip1, Wah 
Kit Lam1, Adi F. Gazdar2, Ignacio I. Wistuba8, John 
D. Minna9 
1Medicine, University Of Hong Kong/Hong Kong, 
2Hamon Center For Therapeutic Oncology Research, 
University Of Texas Southwestern Medical Center/
United States Of America, 3Medicine, Univeristy 
Of Michigan/United States Of America, 4Medicine/
thoracic Oncology Service, Memorial Sloan-
kettering Cancer Center/United States Of America, 
5Pathology, Memorial Sloan-kettering Cancer Center/
United States Of America, 6Cardiothoracic Surgery, 
University Of Hong Kong/Hong Kong, 7Pathology, 
University Of Hong Kong/Hong Kong, 8Pathology, 
The University Of Texas MD Anderson Cancer 
Center/United States Of America, 9Hamon Center For 
Therapeutic Oncology Research, Internal Medicine, 
Pharmacology, University Of Texas Southwestern 
Medical Center/United States Of America
Background: Lung adenocarcinomas bearing EGFR 
gene mutations at exons 19 and 21 are associated 
with better clinical response to treatment with 
EGFR-tyrosine kinase inhibitors than tumors with 
EGFR mutations at exons 18 and 20. The aim of 
this study was to explore the discriminatory gene 
expression signatures between tumors bearing 
different types of EGFR gene mutations at exons 
18 – 21.
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translation was conÀrmed by an increased eIF4G/
eIF4E ratio in the cap-afÀnity assays. Inhibition 
of the cap-dependent translation by DA-4EBP1 
overexpression in these four SCLC cell lines 
resulted in a marked decrease in cell proliferation as 
quantitatively measured by CCK-8 assays.
Conclusion: The differential upstream signaling 
activation (c-Met, Akt, MAPK and JNK pathways) 
found in SCLC cell lines may eventually converge 
their signals to upregulate the cap-dependent 
translation process. Inhibition of the cap-mediated 
translation reduced cell proliferation in all tested 
SCLC cell lines; therefore, this cap-dependent 
translation process could be the common link served 
as a novel potential target for SCLC therapy.
Keywords: signaling, cap-dependent translation, 
targeted therapy, Small cell lung cancer
Poster Session 1 – Cancer Biology Monday, 4 July 2011 12:15-14:15
P1.058 ANALYSIS OF KRAS MUTATIONS 
IN NON-SMALL CELL LUNG CANCER 
(NSCLC) BRAZILIAN PATIENTS
Patrícia G.P. Couto1, Luciana Bastos-rodrigues2, 
Cristina Sabato2, Fernanda Guieiro2, Alyne Vilhena3, 
Nilson F. Amaral3, Luiz De Marco2 
1Surgery, Universidade Federal De Minas Gerais 
Ufmg/Brazil, 2Surgery, Universidade Federal De 
Minas Gerais/Brazil, 3Hospital Julia Kubitscheck/
Brazil
Background: Lung cancer is the leading global 
cause of cancer-related mortality. To improve 
the survival rate of lung cancer patients, a better 
understanding of tumor biology is required as well 
as the subsequent development of new therapeutic 
strategies. The RAS family has been implicated 
in the development of human malignancies. The 
KRAS oncogene resides on chromosome 12p12 and 
encodes a protein (p21RAS) involved in the MAP-
kinase signal transduction pathway modulating 
cellular proliferation and differentiation. KRAS 
mutations, mainly codons 12, 13 and 61 (exons two 
and three) are present in roughly 25% of NSCLC 
tumors but the overall impact of these mutations on 
clinical outcome in NSCLC remains unclear. 
Methods: To determine the presence of KRAS 
mutations in a Brazilian population, we studied 50 
patients with NSCLC. The target regions of KRAS 
gene’s exons 2 and 3 were ampliÀed using speciÀc 
primers, puriÀed and sequenced. We also ascertained 
United States Of America, 3Department Of Medicine, 
University Of Minnesota/United States Of America
Background: Molecular targeted therapy, such as 
tyrosine kinase inhibitor and mTOR inhibitor, failed 
to demonstrate any clinical beneÀt in unselected, 
previously treated small cell lung cancer (SCLC) 
patients. The possible explanation is that they 
were tested in unselected fashion and SCLC is a 
heterogenous disease involving different signaling 
pathways in each individual patient. It would be 
necessary to learn more about cell signaling network 
in SCLC in order to identify a common link of these 
various signals that could be a potential target for 
SCLC treatment. Akt/mTOR pathway is well-known 
to positively control cap-dependent translation by 
inducing 4EBP1 phosphorylation. MAPK and c-Met 
signaling can cross-talk and transduce their signals to 
the Akt/mTOR pathway to stimulate cap-dependent 
translation. JNK activation was recently proposed 
by our group to positively regulate cap-dependent 
translation by phosphorylating 4EBP1 (Patel et 
al (2007) J. Thorac. Oncol. 2(9), 789-95). This 
differential upstream signaling activation (c-Met, 
Akt, MAPK and JNK pathways) can converge their 
signals to upregulate the cap-dependent translation 
process that may serve as the common link in the 
SCLC carcinogenesis.
Methods: We conducted a series of immunoblotting 
assays to determine c-Met, Akt, MAPK and JNK 
activation in several SCLC cell lines derived 
from different patients. Phospho-4EBP1 and 
eIF4E expression were also assessed by Western 
blot analysis. Cap-afÀnity assays to assess the 
activation of cap-mediated translation process were 
performed in the SCLC cell lines and in human 
bronchial epithelial cells as a control. To determine 
if cap-dependent translation is essential to SCLC 
proliferation, dominant-active 4EBP1 (DA-4EBP1) 
mutant, which constitutively binds to eIF4E and 
blocks cap-dependent translation, was overexpressed 
in the SCLC cell lines and subsequently cell 
proliferation was measured by Cell Counting Kit-8 
(CCK-8).
Results: Immunoblotting assays demonstrated 
that c-Met, Akt, ERK1 and JNK activation was 
preferentially observed in H69, H1092, H146 and 
N417 SCLC cell line, respectively. Interestingly, 
4EBP1 phosphorylation and eIF4E expression were 
increased in all four cell lines, suggesting that cap-
dependent translation is commonly upregulated in 
SCLC. Indeed, the upregulation of the cap-mediated 
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most common symptom is dyspnea, followed by 
cough and chest pain. The predominant histologic 
Cancer non-small cells (91.6%) in relation to snuff 
most frequent histological type is the undifferentiated 
carcinoma. The predominant stage IIIB / IV, going 
mostly with a ECOG2. As for treatment: surgery 
were only 10 patients. Chemotherapy or radiotherapy 
performed exclusively for 26.7% and 8.3% 
respectively, the combination of both 14%, 27.4% 
refused treatment, received exclusive palliative care 
10.1% and 12.9% died before deciding a treatment. 
Of the 113 patients who received chemotherapy, 
100% used platinum, with more than 50% response 
in only 21.2%. Radiotherapy was performed to 
62 patients where the emergency was 51.2%. 
A signiÀcant number of patients discontinued 
treatment, with no record of its evolution. 
Conclusion:  The consultation late and advanced 
stages, and the lack of adherence to treatment by the 
patient and sometimes their environment, not allow 
us to offer better quality of life to them, being at our 
disposal only palliative measures. 
Keywords: Lung Cancer, Snuff, Chemotherapy.
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.060 INCREASED TUMOR 
EXPRESSION OF ESTROGEN 
RECEPTOR ALPHA (ERĮ) MRNA 
CORRELATES WITH POOR PROGNOSIS 
IN RESECTED NON SMALL CELL LUNG 
CANCER (NSCLC)
Sergio Carrera Revilla1, Unai Aresti Goiriena1, 
BegoÑa Calvo Martinez1, Itziar Rubio Etxebarria1, 
Juan Jose Vilanova Rodriguez2, Aitziber Buque1, 
Rafael Zalacain Jorge3, Alberto MuÑoz Llarena1, 
Juan Manuel Mañé Martínez1, Joaquin Pac Ferrer4, 
Guillermo Lopez Vivanco1 
1Medical Oncology, Cruces Hospital/Spain, 
2Anatomical Pathology, Cruces Hospital/Spain, 
3Neumology, Cruces Hospital/Spain, 4Thoracic 
Surgery, Cruces Hospital/Spain
Background: Although several studies have shown 
the presence of estrogen receptors (ERs) in lung 
tumors, a considerable number of reports have 
published inconsistent conclusions about their 
the ancestry of patients using 40 ancestry informative 
indels.
Results: In our sample, no KRAS mutations were 
found and ancestry analysis showed a higher African 
component among cancer patients than controls.
Conclusion: To our knowledge our study is the 
Àrst to examine the association between KRAS 
mutations and NSCLC in the Brazilian population. 
The lack of mutations can be explained by the fact 
that adenocarcinoma, the cancer subtype mainly 
associated with KRAS mutations, is less prevalent 
in our sample (24%) than other subtypes. These 
Àndings suggest that genes other than KRAS are 
related to NSCLC. Therefore, it is necessary to 
investigate possible molecular alterations in other 
tumor-related genes. 
Keywords: INDELS, NSCLC,, Kras
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.059 PROFILE OF PATIENTS WITH 
LUNG CANCER: REVIEW OF NATIONAL 
CANCER INSTITUTE OF PARAGUAY. 
PERIOD FROM 2004 TO 2008.
Miguel A. Aguero Pino, Cinthia Gauna Colas, Maria 
Rita Pereira 
Medical Oncology, Instituto Nacional Del Cancer/
Paraguay
Background: Objective: To demonstrate the proÀle 
is presented to the consultation and the development 
of a patient with lung cancer in our department, as 
well as diagnostic and therapeutic limitations. 
Methods:  A retrospective analysis of records 
of patients seen at the National Cancer Institute 
between the period January 2004 to December 
2008. Inclusion criteria: Patients with histologically 
conÀrmed attending their Àrst consultation in the 
independent set period of treatment. Data Collection: 
We analyzed the sex, age, origin, occupation, risk 
factors, reason for visit, ECOG, histology, stage and 
treatment performed in 277 patients
Results: Of 277 patients studied are predominantly 
male (86.6%) from mostly rural area. The mean age 
was 59.6 years. Risk factors are smoking 68.5%, 
41.1% alcohol, environmental exposures have 54.8% 
and family history of cancer only 9% have such. The 
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Background: Squamous cell lung cancer (SCC) is 
the second commonest type of non-small cell lung 
cancer, which is the leading cause of cancer death 
in western countries. Because tumor associated 
Àbroblasts (TAFs) have been involved in tumor 
initiation, growth, invasion, angiogenesis and 
metastasis in a variety of solid tumors including 
lung cancer, there is growing interest in developing 
speciÀc therapies against TAFs dependent tumor-
progression effects. While our understanding of the 
mechanisms underlying these tumor-progression 
effects is still scarce, recent studies in breast cancer 
support the hypothesis that loss of caveolin-1 
(cav1) expression is necessary to transform normal 
Àbroblasts into tumor-promoting TAFs. However, 
this hypothesis has not been examined in lung 
cancer so far.
Methods: We examined the expression of cav1 
and alpha-smooth muscle actin (a-sma), a common 
marker for activated Àbroblasts or myoÀbroblasts, 
in primary human lung Àbroblasts isolated from 
either tumor-free regions - non-cancer associated 
Àbroblasts (NTAFs)- or squamous tumor tissue 
(TAFs). Fibroblast proliferation was assessed by 
MTT assay. Cell morphology was examined by 
phase contrast microscopy.
Results: Cultured TAFs from SCC tissue exhibited 
abnormal proliferation and differentiation patterns 
compared to patient’s matched NTAFs. TAFs 
exhibit increased spreading, reduced proliferation 
and increased a-sma expression (all markers 
of Àbroblast activation) compared to NTAFs. 
Downregulation of cav1 in TAFs occurred only in 
a subset of patients, whereas activation of TAFs 
was observed in all patients suggesting the presence 
of cav1-independent mechanisms of Àbroblast 
activation.
Conclusion: Our Àndings reveal that the tumor 
microenvironment of SCC is enriched in activated 
Àbroblasts, and suggest that unlike breast cancer, 
loss of cav1 is common but not essential for SCC 
Àbroblast activation.
Keywords: caveolin-1 (cav1), tumor associated 
Àbroblasts (TAFs), squamous cell lung cancer 
(SCC)
activity and importance. The biological role of ERƠ, 
ERơ and aromatase in the development of NSCLC is 
unclear and there is little consensus on whether their 
expression constitutes a prognostic factor. The aim of 
this study was to investigate the prognostic value of 
ER and aromatase in resected NSCLC. 
Methods: Lung tumor samples and normal lung 
tissue samples were analyzed for the expression of 
ERƠ, ERơ and aromatase. Reverse transcription-
polymerase chain reaction (RT-PCR) analysis was 
performed for the detection of ER and aromatase 
expression using RNA from lung cancer tissues 
immediately submerged in RNA Later (Qiagen) after 
surgery, and then maintained one night at 4ºC, and 
stored at -80ºC until RNA extraction. We included 
96 consecutive patients (81 male/15 female) with 
resected NSCLC; 51% were adenocarcinoma, 
43% squamous and 6% others. The pathological 
stages were as follows: 43% stage I, 33% stage 
II, 22% stage III and 2% stage IV. Neoadjuvant 
chemotherapy was not allowed. 
Results: The mean expression of ERƠ in normal lung 
tissues was signiÀcantly higher than in lung tumor 
samples (0.1554 vs. 0.1182 p < 0.0001). No statistically 
signiÀcant differences in ERơ and aromatase 
expression were found between normal lung samples 
and lung tumor samples. Tumoral expression of ERơ 
inversely correlated with cigarette consumption (pack/
years) in those identiÀed as current smokers(ANOVA, 
p =0.004). Furthermore, patients with highest values of 
tumoral ERƠ mRNA had better overall survival than 
those with lowest values (25th percentile = 83 weeks vs. 
75th percentile = 104 weeks; p= 0.025). 
Conclusion: We report a signiÀcant association 
between quantitative expression of mRNA ERƠ and 
overall survival in tumor tissue samples of resected 
NSCLC. Our results could be useful for selecting 
resected NSCLC with poor prognosis. A better 
understanding of estrogen action in lung cancer 
could provide the basis for future targeted therapies. 
Keywords: aromatase, survival, Lung cancer, 
estrogen receptors
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P1.061 CAVEOLIN-1-INDEPENDENT 
FIBROBLAST ACTIVATION IN 
SQUAMOUS CELL LUNG CANCER (SCC)
Marta Puig1, Alicia Gimenez2, Abel Gomez-Caro3, 
Roberto Lugo2, Roland Galgoczy2, Pere Gascon1, 
Jordi Alcaraz2, Noemi Reguart1 
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measured by BLI (P<0.0001, all groups vs PBS). 
The mean BLI signal in hind limbs of mice treated 
with OPG-Fc or docetaxel (35 mg/kg) alone 
decreased 6.7-fold and 28.9-fold versus controls, 
respectively. Combined treatment with OPG-Fc and 
docetaxel (35 mg/kg) resulted in a 322-fold decrease 
in hind limb BLI, 10-fold greater than with docetaxel 
alone, and signiÀcantly reduced tumor progression 
when compared to treatment with docetaxel alone 
(P=0.0003). Similar results also were observed with 
the 50 mg/kg dose of docetaxel in combination with 
OPG-Fc. Docetaxel alone reduced skeletal tumor 
burden in the hind limb and decreased development 
of osteolytic lesions. However, in all groups treated 
with OPG-Fc osteolytic lesions were completely 
prevented. In the combination treatment groups, 
skeletal tumor burden was reduced below the level of 
detection. 
Conclusion: These results clearly demonstrate that 
RANKL is a required factor for development of 
tumor-induced osteolytic lesions caused by a non-
small cell lung cancer cell line in vivo. RANKL 
inhibition reduced skeletal tumor burden, presumably 
by blocking tumor-induced osteoclastogenesis and 
the resultant production of growth factors from 
the bone microenvironment. RANKL inhibition 
with OPG-Fc also provided an additive beneÀt to 
docetaxel treatment by augmenting the reduction 
of tumor burden. The results support the clinical 
evaluation of these combined treatments for the 
reduction of skeletal tumor burden in lung cancer 
patients. 
Keywords: RANK Ligand, OPG-Fc, Docetaxel, 
bone metastases
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P1.063 NOVEL FACS-BASED 
CHARACTERISATION OF 
INFLAMMATORY LUNG PHENOTYPES 
IN PATIENTS WITH LUNG CANCER
Mubing Duan1, Catherine Li2, Daniel Steinfort3, 
Louis Irving3, Gary Anderson4, Magaret Hibbs1 
1Immunology, Monash University/Australia, 
2Ludwig Institute (parkville)/Australia, 3Respiratory 
Medicine, Royal Melbourne Hospital/Australia, 
4Pharmacology, University Of Melbourne/Australia
Background: In recent years, there has been a 
growing awareness of the link between chronic 
inÁammation and cancer. Chronic inÁammation is 
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P1.062 INHIBITION OF LUNG CANCER-
INDUCED OSTEOLYTIC LESIONS AND 
SKELETAL TUMOR BURDEN WITH 
THE RANKL INHIBITOR OPG-FC AND 
DOCETAXEL IN A MURINE MODEL OF 
METASTATIC NON-SMALL CELL LUNG 
CANCER
Robert Miller, Jon Jones, Mark Tometsko, Michelle 
Blake, William Dougall 
Hematology/oncology Research, Amgen Inc./United 
States Of America
Background: Bone metastases occur in up to 
40% of patients with lung cancer. Tumor cells 
interact with the bone microenvironment to induce 
osteoclastogenesis via RANK ligand (RANKL), the 
essential mediator of osteoclast formation, function, 
and survival. The resulting bone destruction and 
release of growth factors have the potential to 
promote tumor growth and survival within bone. 
In animal models of breast or prostate cancer bone 
metastasis, inhibition of RANKL blocks tumor-
induced osteolysis and prevents increase in skeletal 
tumor burden. Docetaxel, a well-established 
chemotherapy approved for the treatment of 
metastatic lung cancer, arrests the cell cycle and 
induces apoptosis of tumor cells. In this study we 
used the RANKL inhibitor OPG-Fc in combination 
with docetaxel to assess the effects of combining 
an anti-resorptive therapy with a chemotherapeutic 
agent on tumor-induced osteolysis and skeletal tumor 
burden in a murine model of non-small cell lung 
cancer bone metastasis. 
Methods: Human non-small cell lung carcinoma cell 
line NCI-H1299 was engineered to express ÀreÁy 
luciferase to allow for non-invasive assessment of 
tumor burden using bioluminescent imaging (BLI). 
Tumor cells were injected into the left cardiac 
ventricle of mice. BLI and radiography were used to 
conÀrm that the lung cancer cell established tumors 
and progressed to bone. Beginning 5 days after 
tumor challenge, mice were treated therapeutically 
with either OPG-Fc (SC, 3 mg/kg, 3x/week) or 
two cycles of docetaxel (IP, 35 or 50 mg/kg 1x/
week) alone, or in combination. Tumor progression 
was monitored twice weekly by BLI and osteolytic 
changes by radiography. 
Results: Both OPG-Fc and docetaxel, alone or in 
combination, signiÀcantly reduced NCI-H1299 
tumor progression in the hind limbs of mice as 
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1Internal Medicine, Wonkwang University Hospital/
Korea, 2Pathology, Wonkwang University Hospital/
Korea, 3Radiation Oncology,, Wonkwang University 
Hospital/Korea, 4Thoracic Surgery, Wonkwang 
University Hospital/Korea, 5Radiology, Wonkwang 
University Hospital/Korea
Background: Most of lung cancer patients had 
received the systemic chemotherapy because they 
had diagnosed the advanced stage at presentation. 
Cislplatin-based chemotherapy is main regimen for 
advanced lung cancer. But serious adverse reaction 
(SAE) had occurred after chemotherapy. This is main 
reason for chemotherapy withdrawal. If we will use 
the reduced dose of cispaltin, cisplatin-based the 
chemotheray will be continued. To Àgure out whether 
the effect of low dose of cisplatin will be synergistically 
enhance by autophagy inhibiton, even though the 
reduced dose of cisplatin less effect for treatment 
response, We investigated that role of autophagy 
by 3-methyladenine, class III PI3kinase inhibitor in 
cisplatin-treated lung cancer cells. 
Methods: Lung cancer cells were incubated with 
normal media and treated the 5uM (LD20) and 
20uM(LD50) of cislpaltin according to time dependent. 
We examined the sensitivity to low or high doses of 
cisplatin treatment using the MTT cell viability assay 
and compared apoptosis and autophagy by nuclear 
stianing, apoptotic or autophagic related proteins or 
autophagic vacuoles. autophagy is also displayed the 
development of acidic vascular organelles by acridine 
orange and the Áuorescent expression of GFP-LC3 
protein in the GFP-LC3 transfected cells. 
Results: Low dose of cisplatin-treated lung cancer 
cells is relatively less sensitive to cell death rather 
than high dose treated cells in a time-dependent 
manners. We didnot Ànd out the nuclear fragmentation 
in lower dose even though detected its in high dose. 
PARP cleavages also were not detected in low dose 
of cisplatin exception 24H. We observed that massive 
vacuolization in the cytoplasm were seen at lower 
dose treated cells. Acridine orange stain-positive cells 
also were increased according to time dependent. 
We Àgured out that the autophagosome-incorporated 
LC3 II protein expression more increased in low dose 
treated cells (24H to 48H) in spite of no detection 
of LC3 II in high dose treated cells. The expression 
of GFP-LC3 were increased in 5uM treated cells by 
time-dependent manner. When 3-methyladenine, 
class III PI3kinase inhibitor, was pretreated in 5uM 
cisplatin-treated lung cancer cells, cell survival 
signiÀcantly were decreased. 
now postulated to promote tumourigenesis through 
i) the establishment of a stromal microenvironment 
favouring tumour growth and progression by 
tumour associated macrophages (TAMs), and 
ii) circulating myeloid derived suppressor cells 
which suppress anti-tumour immune surveillance 
mediated by cytotoxic T lymphocytes. The role 
of these two features in the development and 
progression of primary lung carcinoma, however, 
remains relatively unknown. This is chieÁy due to a 
difÀculty in studying lung macrophage phenotypes, 
whose highly autoÁuorescent properties hamper 
their characterisation by Áuorescence-activated cell 
sorting (FACS). 
Methods: We have recently developed a novel 
approach of characterising inÁammatory lung 
macrophages in mice using FACS. 
Results: This work has allowed us to proÀle alveolar 
macrophages in animal models of acute and chronic 
lung inÁammation, and identify a pathological Mac-
1+ alveolar macrophage subpopulation associated 
with the development of type II alveolar epithelial 
cell hyperproliferation and lung Àbrosis. We are now 
translating this approach to the characterisation of 
alveolar macrophage phenotypes associated with 
human lung cancer lesions. Here, we report both 
its feasibility and the inÁammatory BAL proÀle 
of patients with lung cancer ± chronic obstructive 
pulmonary disorder (COPD) versus sarcoidosis. 
Conclusion: Using our FACS-based approach to 
characterise patient inÁammatory lung phenotypes 
may help determine whether discreet macrophage 
subpopulations are associated with lung cancer 
(patient prognosis, tumour subtype and staging) and 
if chronic inÁammatory macrophage gene signatures 
discriminate early-stage disease from locally 
advanced disease. 
Keywords: alveolar macrophages, Áow cytometry, 
chronic inÁammation
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.064 AUTOPHAGY INDUCES 
CYTOPROTECTION IN CISPLATIN-
TREATED LUNG CANCER CELLS
Sei-Hoon Yang1, Hyang Jeong Jo2, Sun Rock Moon3, 
Soon Ho Choi4, Sung Hoon Park5 
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contrast, the percentage of a-sma positive Àbroblasts 
rose from 10 to 25% upon treatment with TGF-b1, 
whereas it remained below 1% in NSCLC cell lines. 
Likewise, expression of Àbrillar collagens was more 
than 3 orders of magnitude larger in Àbroblasts than 
in NSCLC cells. Interestingly, TGF-b1 efÀciently 
stiffened all vimentin positive NSCLC cells, whereas 
it only stiffened ~50% of Àbroblasts and non 
vimentin positive NSCLC cells. 
Conclusion: Our data indicate that EMT, as 
induced by treatment with TGF-b1 for 3 days, 
is not sufÀcient to render NSCLC cells with a 
myoÀbroblast-like phenotype. These results suggest 
that either cancer cells undergoing EMT do not 
contribute to the abnormal increase of myoÀbroblasts 
in NSCLC, or that higher doses of TGF-b1 or other 
factors are required to efÀciently transdifferentiate 
carcinoma cells into myoÀbroblasts. Furthermore, 
these Àndings strongly suggest that TGF-b1 is a key 
effector molecule in altering the normal balance of 
forces in NSCLC. 
Keywords: Tumor Microenvironment, Epithelial-to-
mesenchymal transformation, myoÀbroblast
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P1.066 EVALUATION OF INCREASED 
SENSITIVITY TO ETOPOSIDE AND 
HYPERTHERMIA IN CISPLATIN-
RESISTANT HUMAN LUNG CANCER 
CELLS
Ichiro Tsujino, Tetsuo Shimizu, Toshio Sugane, 
Yasushi Ochi, Noriaki Takahashi, Shu Hashimoto 
Department Of Medicine, Division Of Respiratory 
Medicine, Nihon University School Of Medicine/
Japan
Background: In the present study, we sought to 
determine whether or not the sensitivity to etoposide 
and hyperthermia could be changed and also 
evaluated the intracellular alteration in cisplatin-
resistant human lung cancer cells. 
Methods: We examined continuous exposure to 
etoposide and short time exposure to hyperthermia 
in PC14, H69 and the corresponding cisplatin-
resistant mutant subline of PC14, H69 human lung 
cancer cells, respectively. Clonogenic surviving 
assay was employed for the evaluation of cell killing. 
We further analyzed intracellular accumulation of 
etoposide, intracellular pH for thermosensitivity and 
also intracellular glutathione content. 
Conclusion: Autophagy induces cytoprotection in 
lower dose of cisplatin-treated lung cancer cells. 
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P1.065 EPITHELIAL CONTRIBUTION TO 
THE MYOFIBROBLASTIC PHENOTYPE 
IN NON SMALL CELL LUNG CANCER 
VIA EPITHELIAL TO MESENCHYMAL 
TRANSFORMATION
Jordi Galgoczy1, Marta Puig2, Roberto Lugo1, 
Alicia Gimenez1, Marta Gabasa3, Antoni Xaubet3, 
Daniel Navajas1, Noemi Reguart2, Jordi Alcaraz 
Casademunt1 
1Unit Of Biophysics And Bioengineering, University 
Of Barcelona/Spain, 2Medical Oncology, Hospital 
Clinic Barcelona/Spain, 3Idibaps/Spain
Background: A hallmark of most solid tumors in 
the lung and other organs is a reactive stroma rich 
in alpha-smooth muscle actin (a-sma) positive cells 
and Àbrillar collagens. A-sma positive cells are 
indicative of activated Àbroblasts or myoÀbroblasts. 
In normal conditions, myoÀbroblasts appear at the 
Ànal stages of wound healing and are regarded as 
essential contributors to tissue repair. In tumors, 
myoÀbroblasts provide biochemical and mechanical 
cues that support tumor progression. Although it 
is currently thought that most myoÀbroblasts arise 
from the activation of resident Àbroblasts, it has been 
suggested that carcinoma cells undergoing epithelial-
to-mesenchymal transformation (EMT) may also 
acquire a myoÀbroblast-like phenotype. However 
this hypothesis has not been examined yet. 
Methods: Human non-small cell lung cancer 
(NSCLC) carcinoma cell lines or primary lung 
Àbroblasts were cultured for 3 days in serum free 
medium with or without the potent Àbroblast 
activator TGF-b1. Expression of vimentin and 
a-sma, which are standard markers for EMT 
and myoÀbroblasts, respectively, was examined 
by immunoÁuorescence. Expression of Àbrillar 
collagens was performed by qRT-PCR. The elastic 
modulus E (indicative of cell stiffness) of single cells 
was assessed by Atomic Force Microscopy. 
Results: TGF-b1 induced a ~two-fold increase 
in vimentin expression in two of the NSCLC cell 
lines examined (H1975, A549), whereas vimentin 
levels remain unaltered in the other cell lines (H441, 
PC9). Unlike vimentin, TGF-b1 failed to induce a 
marked increase in a-sma in the NSCLC cell lines. In 
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levels of AURKA gene.
Results: AURKA expression was signiÀcantly 
up-modulated in tumor samples compared to 
matched lung tissue (p<0.01, mean log2(FC) 
= 1.5). Moreover, AURKA was principally up-
modulated in moderately and poorly differentiated 
lung cancers (p<0.01), as well as in squamous and 
adenocarcinomas compared to the non-invasive 
bronchioloalveolar histotype (p= 0.029). No 
correlation with survival was observed.
Conclusion: These results indicate for the Àrst time 
that NSCLC histological subtypes showed a different 
degree of AURKA modulation with the highest over-
expression observed in squamous carcinoma whereas 
no signiÀcant modulation in bronchioloalveolar 
carcinoma was reported. We also showed that 
AURKA transcript over-expression was signiÀcantly 
associated to tumor de-differentiation.
Keywords: Non small cell lung carcinoma, 
quantitative PCR, immunohistochemistry
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P1.068 ENDOPLASMIC RETICULUM 
STRESS INDUCERS AND EFFECT OF 
CANCER DRUGS
S. Saveljeva, Juana M. Barceló 
Neumología, Universitat De Les Illes Balears-iunics 
And Hospital Son Espases/Spain
Background: The aim of this research project 
is to exploit the intrinsic and the drug-induced 
stressed status of the endoplasmic reticulum (ER) 
in lung cancer cells to convert this organelle/cell 
compartment into a target of chemotherapeutic 
treatments. In a cell culture based in vitro system 
the exposure of ER stress-inducing drugs combined 
with chemotherapeutic lung cancer treatments will 
be assessed for the possible presence of synergy 
in cell death or cell cycle arrest induction. One of 
the advantages of this approach is the possibility 
of inducing speciÀc lung cancer cell toxicity while 
reducing the nuclear toxicity (mutations) of standard 
drugs as well as part, if not practically all, of their 
genetically acquired resistance problems. 
Methods: Both available established standard cell 
lines and primary cell lines obtained directly from 
the tumours of lung cancer patients will be exposed 
to selected treatments. Those treatments will include 
subsets in which common drugs in lung cancer 
therapy are combined with a panel of available ER 
Results: It was found that cisplatin-resistant lung 
cancer cells showed higher sensitivity to etoposide and 
intracellular etoposide accumulation, furthermore, also 
higher thermosensitivity and lower intracellular pH. 
Intracellular glutathione content was found increased in 
cisplatin-resistant human lung cancer cells. 
Conclusion: Cisplatin-resistance increased sensitivity 
to both etoposide and hyperthermia. It was thought that 
intracellular acidiÀcation and glutathione higher content 
in cisplatin-resistance were related. 
Keywords: Hyperthermia, increased sensitivity, 
cisplatin-resistance, etoposide
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.067 AURORA KINASE A EXPRESSION 
IS ASSOCIATED WITH LUNG CANCER 
HISTOLOGICAL-SUBTYPES AND WITH 
TUMOR DE-DIFFERENTIATION
Marco Lo Iacono, Valentina Monica, Silvia Saviozzi, 
Paolo Ceppi, Enrico Bracco, Mauro Papotti, Giorgio 
Scagliotti 
Department Of Clinical And Biological Sciences, 
University Of Torino/Italy
Background: Aurora kinase A (AURKA) is a 
member of serine/threonine kinase family. It plays 
an important role in completing mitotic events 
such as centrosome separation, bipolar spindle 
assembly, chromosome segregation and cytokinesis. 
Ectopic expression of Aurora A leads to an increase 
in centrosome numbers, causes catastrophic loss 
or gain of chromosomes, and results in either cell 
death or survival through malignant transformation. 
Over-expression of AURKA has been detected in 
many tumor cells and tissues, such as breast, gastric, 
colorectal, bladder, pancreatic, ovarian, prostate and 
lung cancers. The purpose of the present study was 
to investigate the expression of AURKA in non small 
cell lung cancer (NSCLC) specimens and to correlate 
its mRNA or protein expression with patients’ 
clinico-pathological features.
Methods: A quantitative real-time PCR and 
immunohistochemistry analysis on matched cancer 
and corresponding normal tissues from surgically 
resected non-small cell lung cancers (NSCLC) have 
been performed aiming to explore the expression 
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Methods: NSCLC, mesothelioma and prostate 
cancer cell lines were treated with 5-aza-2-
deoxycytidine and gemcitabine. Reactivation of 
epigenetically silenced genes was examined by 
RT-PCR/qPCR. DNA methyltransferase activity 
in nuclear extracts was measured using a DNA 
methyltransferase assay, and alterations to DNA 
methylation status were examined using methylation-
speciÀc PCR (MS-PCR).
Results: Reactivation of several previously 
published epigenetically silenced genes was 
observed for all cell lines tested, including 
GSTP1 (p<0.05) and IGFBP-3 (p<0.05). Using 
a DNA methyltransferase activity assay, DNA 
methyltransferase activity was inhibited in nuclear 
extracts from cells treated with gemcitabine. Finally, 
using MS-PCR, we show a direct loss of DNA CpG 
methylation at the promoter of GSTP-1 in response 
to gemcitabine treatment. 
Conclusion: Gemcitabine is a demethylating 
agent having activity equivalent to decitabine 
at concentrations signiÀcantly lower than those 
achieved in the treatment of patients with solid 
tumours. This property may contribute to the 
anticancer activity of gemcitabine.
Keywords: epigenetics, DNA methyltransferase, 
gemcitabine, inhibitor
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P1.070 SPLICING FACTOR HSLU7 
EXPRESSION IN NON SMALL CELL 
LUNG CANCER AND CORRESPONDING 
MORPHOLOGICAL NORMAL LUNG 
TISSUE
Marco Lo Iacono, Valentina Monica, Silvia Saviozzi, 
Enrico Bracco, Silvia Novello, Mauro Papotti, 
Giorgio Scagliotti 
Clinical & Biological Sciences, University Of Turin/
Italy
Background: Alternative splicing is the biological 
process that could generate different transcripts from 
a single mRNA precursor with a profound effect 
on the functions of the Ànal protein. Recent data 
indicate that the majority of human genes undergo 
alternative splicing and alterations in this process 
could affect essential biologic processes contributing 
to develop several diseases, including cancer. The 
splicing factor hSlu7 plays an important role in 3’ 
splice site selection during the second step of splicing 
stress inducing drugs. Analysis of cell survival will 
involve the use of cellular and molecular biology 
assays. Markers of ER stress and cell death will 
be assessed through RNA and protein levels and 
electronic microscopy imaging.
Results: (To be included upon submission of the 
Late Breaking abstract)
Conclusion: (Dependent on the results of this study)
Keywords: ER, ER stress, endoplasmic reticulum, 
lung cancer chemotherapy, toxicity
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
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P1.069 GEMCITABINE ALTERS DNA 
CPG METHYLATION AND MAY ACT 
AS A DNA METHYLTRANSFERASE 
INHIBITOR
Steven G. Gray1, Anne-Marie Baird1, Fardod 
O’kelly2, Armelle Meunier2, Donal Hollywood2, 
Antoinette Powell2, Kenneth J. O’Byrne3 
1Clinical Medicine, Trinity College Dublin/st James’ 
Hospital/Ireland, 2Prostate Molecular Oncology, 
Trinity College Dublin/Ireland, 3Oncology (hope), St 
James’s Hospital/Ireland
Background: Gemcitabine is indicated in 
combination with cisplatin as a Àrst-line therapy 
for solid tumours including non-small cell lung 
cancer (NSCLC), bladder cancer, and mesothelioma 
(MPM). Gemcitabine is an analogue of the 
pyrimidine cytosine and functions as an anti-
metabolite. Structurally, however, gemcitabine 
has similarities to (Dacogen®), more familiarly 
known as Decitabine or 5-aza-2’-deoxycytidine, a 
DNA methyltransferase inhibitor (DNMTi). Based 
on this structural similarity, we hypothesized that 
gemcitabine may also inhibit DNMTs.
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Background: The modulation of tumor 
characteristics, including their metastatic 
potential, by stromal cells within a tumor is well 
established. We were interested to determine 
whether tumor cell heterogeneity itself might fulÀll 
a similar role. Using a mouse model for small 
cell lung cancer (SCLC), based upon conditional 
deletion of both Trp53 and Rb1 genes in lung 
epithelium, we previously identiÀed two distinct 
cell populations present within the primary lung 
tumors: a neuroendocrine (NE) cell component and 
a non-neuroendocrine (NonNE) cell component. 
Interestingly, in a series of subcutaneous graft 
experiments it was shown that metastasis occurs 
only following co-injection of both cell lines, 
indicating that crosstalk exists between the two cell 
populations.
Methods: In order to investigate the underlying 
molecular events occurring between these two 
tumor cell variants that drive metastasis, we 
performed a series of in vitro assays. Moreover, 
whole genome microarray analysis of NE cells 
following culture with conditioned medium from 
NonNE was performed to identify differentially 
expressed genes.
Results: We examined the invasion activity of 
NE cells and found that conditioned medium from 
NonNE cells enhanced the invasive capacity of NE 
cells in vitro. Moreover, microarray analysis of NE 
cells following culture with conditioned medium 
from NonNE revealed altered expression of Pea3, 
a member of the ETS transcription factor family. 
The invasion activity of NE cells was regulated 
by the overexpression of Pea3 and knockdown 
of the endogeneously expressed Pea3. We further 
identiÀed that Ras-dependent MAPK signaling 
regulated the invasion activity of NE cells via Pea3 
expression.
Conclusion: Our results reveal that tumors can be 
heterogeneous in functional ways and the activation 
of Pea3 is an essential mediator between the cell 
variants for the metastasis of SCLC
Keyword: tumor heterogeneity, metastasis, small 
cell lung cancer, SCLC, Pea3, Etv4
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
in vitro and has been suggested to affect alternative 
splicing in vivo. Recently, it was identiÀed that 
down-modulation of hSLU7 mediated through the 
activation of c-Jun N-terminal kinase 1 (JNK1) 
promote splicing of TP73 gene to production of 
oncogenic isoform Ƌex2p73. The purpose of the 
present study was to investigate the expression of 
hSLU7 mRNA in non small cell cancer (NSCLC) 
and analyze the correlation between hSLU7 mRNA 
expression and clinicopathological features. 
Methods: A real-time PCR analysis on matched 
cancer and corresponding normal tissues from 86 
surgically resected patients has been performed. 
Expression levels of hSLU7, POL2 and ESD 
(two reference genes) were evaluated via SYBR 
technology with ABI PRISM 7900HT Sequence 
Detection System using speciÀc primers. 
Results: The hSLU7 expression in NSCLC 
was signiÀcantly associated with tumor subtype 
(p<<0.001). When all considered specimens were 
evaluated as a whole, no difference in hSLU7 
mRNA expression levels between tumor cells and 
matched normal tissue were detected. By contrast, 
when tumor subtypes were taken into consideration 
we identiÀed that hSLU7 mRNA was signiÀcantly 
up-modulated in adenocarcinoma (p<0.01, mean 
log2(FC)=0.79), while was down-modulated in 
squamous cell carcinoma (p=0.01, mean log2(FC)= 
-0.73). Moreover, low hSLU7 transcript levels in 
tumors were signiÀcantly correlated with adverse 
prognosis in NSCLC patients (p= 0.025). 
Conclusion: These results indicate that the splicing 
gene hSLU7 is deregulated in NSCLC and its 
modulation could contributes to the molecular 
differences existing between lung adenocarcinoma 
and squamous cell carcinoma. Moreover, low hSLU7 
mRNA expression in tumors is a putative marker of 
poor prognosis in NSCLC patients. 
Keywords: Non small cell lung carcinoma, 
quantitative PCR, Splicing Factor
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P1.071 THE ROLE OF TUMOR CELL 
HETEROGENEITY IN THE METASTASIS 
OF SMALL CELL LUNG CANCER
Min Chul Kwon, Joaquim Calbo, Erwin Van 
Montfort, Natalie Proost, Anton Berns 
Molecular Genetics And Centre For Biomedical 
Genetics, Netherlands Cancer Institute/Netherlands
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P1.073 ROLE OF SRC FAMILY KINASES 
IN NSCLC: AUTOPHAGY INHIBITORS 
POTENTIATE KILLING EFFECTS OF 
DASATINIB
Ewa Rupniewska1, Francesco Mauri2, Diane 
Watling1, Olivier Pardo1, Michael Seckl1 
1Surgery And Cancer, Imperial College London/
United Kingdom, 2Histopathology, Imperial College 
London/United Kingdom
Background: Lung cancer is the commonest 
cause of cancer mortality, mostly due to the 
rapid development of drug resistance and early 
metastasis. Src family kinases (SFKs) are frequently 
overexpressed in various cancers and are strongly 
implicated in all hallmarks of tumorigenesis 
including proliferation, survival and invasiveness. 
Therefore, we sought to evaluate the involvement of 
SFKs in lung cancer biology and assess the possible 
therapeutic beneÀts of their inhibition, either alone or 
in combination with other treatments.
Methods: The following NSCLC cell lines were 
used: A549, EKVX, HOP62, HOP92, H226, H23, 
H322M, H460, H522, HCC78, HCC95. Proliferation 
was assessed using crystal violet staining and 
Western Blotting (WB) for cyclin D3 and p27; DNA 
synthesis by EdU proliferation assay; apoptosis by 
caspase 3/7 activity assay, FACS analysis and WB 
for caspases 3/7 and PARP cleavage; autophagy by 
Áuorescent microscopy using LC3-GFP-expressing 
cells and by WB for LC3.
Results: We demonstrate that Src family kinases are 
commonly overexpressed and activated in vitro in a 
panel of lung cancer cell lines as well as in vivo in 
lung cancer tissue microarrays, as compared to normal 
lung tissue. Furthermore, this overexpression seems 
to correlate with poor patient survival. Dasatinib is 
a novel Src/Abl inhibitor which effectively blocks 
SFKs activity at nanomolar concentrations. We show 
that 10 of 11 NSCLC cell lines tested are sensitive 
to dasatinib treatment. Observed reduction in cell 
numbers can be mostly attributed to strong inhibition 
of DNA synthesis and proliferation. Additionally, 
dasatinib treatment induces autophagy and, in some 
cell lines, apoptosis. In this context, autophagy 
seems to be a pro-survival mechanism as autophagy 
inhibitors sensitise NSCLC cells towards dasatinib 
treatment through enhanced apoptosis. These results 
were conÀrmed by siRNA-mediated depletion of 
essential autophagy-related proteins.
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P1.072 THE EFFECT OF TTF-1 PROTEIN 
EXPRESSION ON N2 STATUS IN 
PRIMARY ADENOCARCINOMA OF THE 
LUNG
Ozgur Samancilar1, Kenan C. Ceylan1, Ozan Usluer1, 
Seyda O. Kaya1, Ali G. Yener2 
1Thoracic Surgery, Dr. Suat Seren Chest Diseases 
And Thoracic Surgery Training And Research 
Hospital/Turkey, 2Pathology, Dr. Suat Seren Chest 
Diseases And Thoracic Surgery Training And 
Research Hospital/Turkey
Background: In this study, the effect of thyroid 
transcription factor-1 (TTF-1) protein expression on 
N2 status in primary adenocarcinoma of the lung is 
investigated. 
Methods: The patients operated between January 
2009 and December 2010 with a diagnosis 
of primary adenocarcinoma of the lung are 
retrospectively analyzed and devided into two groups 
according to their TTF-1 protein expression. The 
relationship between TTF-1 protein expression and 
N2 status is evaluated. 
Results: There were 73 patients (58 male, 15 
female) with a mean age of 58,4+10,2 in the study 
group. Sixty-six lobectomies or pneumonectomies 
and mediastinal lymph node dissection, and seven 
mediastinoscopies were performed. The positivity 
of the TTF-1 protein expression detected by the 
immunohistochemical staining of the specimens 
were present in 33 patients (45,2%) and these 
patients are classiÀed as group A and the rest of the 
patients as group B. Eleven patients had N2 disease 
in group A against Àve pateints in group B and the 
difference between the two groups were statistically 
signiÀcant. 
Conclusion: Patients with primary adenocarcinoma 
of the lung having TTF-1 protein expression are 
more tendant to have N2 disease. They might be 
considered as candidates for adjuvant chemotherapy 
even without any N1 or N2 disease. 
Keywords: thyroid transcription factor-1, N2
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Results: miRNA proÀling revealed a number of 
miRNAs to be correlated to RT resistance in NSCLC 
and SCLC, respectively. Among those were miR-
214, miR-1827, miR-625, miR-21, miR-339-5p, 
miR-768-3p, miR-532-3p and miR-1301 which were 
up-regulated in RR NSCLC and miR-324-5p, miR-
1227, miR-1249, miR-423-5p and miR-625 which 
were up-regulated in RR SCLC cells respectively. 
We focused our analysis on miR-214 and conÀrmed 
a higher miR-214 expression in RR NSCLC cells 
using real time PCR. In order to examine if ablation of 
miR-214 expression could sensitize for RT, NSCLC 
cells were transfected with anti-miR-214 antagomir 
and the RT response of these cells was compared to 
mock transfected cells. Clonogenic survival assay 
as well as proliferation assessment conÀrmed a role 
of miR-214 in RT resistance as the cell growth after 
RT was reduced by about 40% after knock down of 
miR-214 and irradiated by a dose of 8-Gy. Following 
these results we examined if down regulation of miR-
214 altered RT-induced apoptotic signalling in these 
NSCLC cells by evaluating caspase-3 activation as well 
as induction of apoptotic morphology. No increase in 
RT-induced apoptosis was observed in NSCLC with 
ablated miR-214 expression. However, we found that 
down regulation of miR-214 increased RT-induced 
senescence. We then looked for the predicted targets 
of the miR-214 in Targetscan, PicTar and Microcosm 
and found about 120 putative target genes which in 
turn regulate several different pathways including 
senescence, ex. P27 and CDK6. 
Conclusion: In conclusion, we demonstrate that 
increased miR-214 expression contributes to RT 
resistant phenotype of NSCLC. Analysis of miR-
214 expression in NSCLC patient derived material 
as well as in depth analysis of miR-214 targets in 
relation to RT resistance is in progress. 
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P1.075 THE ROLE OF EGFR 
TRAFFICKING IN DRUG RESISTANCE 
OF LUNG CANCER CELLS
Chao-Hua Chiu, Yu-Ting Huang, Ting-Chun Huang, 
Chun-Ming Tsai 
Division Of Thoracic Oncology/department Of Chest 
Medicine, Taipei Veterans General Hospital/Taiwan
Background: Epidermal growth factor receptor 
(EGFR) can transduct signaling for cell proliferation 
and survival and plays important roles in 
Conclusion: Our results suggest that inhibition of 
Src family kinases alone or in combination with 
autophagy inhibitors, may be a beneÀcial therapeutic 
strategy in the management of lung cancer patients.
Keywords: Src Family Kinases, NSCLC, Dasatinib, 
autophagy
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P1.074 DOWN REGULATION OF MIR-
214 SENSITIZES NSCLC CELLS TO 
IONIZING RADIATION BY INCREASING 
THE SENESCENCE SIGNALLING
Hogir Salim1, Nadeem Shahzad Akbar2, Dali 
Zong1, Ali Moshfegh1, Kristina Viktorsson1, Rolf 
Lewensohn1, Boris Zhivotovsky2 
1Oncology-pathology, Karolinska Institutet/Sweden, 
2Department Of Environmental Medicine, Karolinska 
Institutet/Sweden
Background: MicroRNAs are small single 
stranded endogenous RNA molecules that act 
as negative regulators of gene expression at the 
posttranscriptional level and thereby greatly 
inÁuence tumour cell behaviour, i.e. causing 
differentiation, increasing proliferation and 
metastatic capacity and impairing apoptotic 
signalling processes. The importance of miRNAs 
in regulating small (SCLC) and non-small cell lung 
cancer (NSCLC), radiotherapy (RT) resistance is, 
however, unknown. Therefore, we aimed to analyze 
this by performing miRNA expression proÀling of a 
panel of SCLC and NSCLC cell lines with different 
degrees of RT resistance. 
Methods: A panel of SCLC and NSCLC cell lines 
were used and subdivided into radioresistant (RR), 
having an SF2 value (surviving fraction after 2-Gy 
irradiation)  0.3 or radiosensitive (RS) with an SF2 
value < 0.3. RNA was extracted from cells by using 
Trizol reagent and microRNA expression proÀling was 
performed using Affymetrix genechip microRNA array. 
For validation of identiÀed microRNA expression, real 
time PCR was used. Antagomir against the miRNAs 
were designed and obtained from Dharmacon. A Co60 
was used for the irradiation which was performed at 
ambient room temperature. Level of apoptosis was 
measured using caspase-3 antibody followed by FACS. 
Colony formation assay was analyzed by Giemsa-
staining. Beta-galactosidase assay was performed for 
analyzing senescence of the cells upon treatment and 
for protein analysis western blot was applied. 
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among the depositions of crystalline silica in 
different lung tissues, nuclear factor NF-ƩB protein 
expression caused by oxidative damage and female 
non-small cell lung cancer (NSCLC ) in Xuanwei. 
Methods: Transmission electron microscopy 
(TEM), selected area electron diffraction(SAED) and 
energy dispersive X-ray analysis (EDS) detect the 
occurrence of quartz in lung tissues of the following 
cases: experimental group , 18 cases of Xuanwei 
female lung cancer patients; control group A, 15 
cases of Xuanwei male lung cancer patients; 16 
cases of Non-xuanwei female lung cancer patients; 
control group B, 16 cases of Xuanwei male benign 
pulmonary diseases patients; 15 cases of Xuanwei 
female benign pulmonary diseases patients; 15 cases 
of Non-xuanwei female benign pulmonary diseases 
patients. Observing average particle size of quartz 
and local pathology in each group, the occurrence 
rates of quartz in different lung tissues as count data, 
using SPSS statistical software (R×C Ƶ2 test, if more 
groups would be a difference, then adjusting the test 
level compared to 2-sided) for statistical analysis.
Results: 1. the smallest particle size of quartz is 
10.0nm × 12.5nm, the maximum size of quartz 
is 1578.94nm × 2500nm, average particle size 
is distributed around 200nm ~ 450nm; quartz 
(<120nm) were often under the nuclear membrane or 
on the border of nuclear membrane and cytoplasmic 
in interstitial lung cells and alveolar type cells, 
with accumulation of sand-like polycrystalline 
compounds; The larger particles (>120nm) presented 
in alveolar, interstitial, or occasionally in the 
cytoplasm, there were a large number of collagen 
Àbers, Àbrosis in local occurrences. 2. For Xuanwei 
NSCLC groups, the occurrence rates of crystalline 
silica in cancer tissues, adjacent tissues and normal 
lung tissues showed no signiÀcant difference 
(P>0.05); 3. The lung tissues of Xuanwei female and 
male NSCLC were no difference in occurrence rate 
for crystalline silica; but both of them were above 
non-xuanwei female NSCLC lung tissures(P <0.01). 
5. In benign lesions, there were the same overall 
distribution for the occurrence rates of crystalline 
silica, but they were signiÀcantly lower than 
Xuanwei female NSCLC (P <0.01).
Conclusion: 1. quartz has different degrees of 
deposition in the lung tissues of each group, the 
deposition in Xuanwei NSCLC was signiÀcantly 
higher than in patients of Non-xuanwei NSCLC 
and lung benign lesions, suggesting that quartz in 
Xuanwei lung cancer, especially Xuanwei female 
NSCLC plays an important role for the incidence of 
tumorigenesis and drug resistance. It is thought that 
EGFR undergoes rapid internalization after ligand 
binding and this trafÀcking is simply a mechanism 
for cell to terminate signaling. However, it is now 
clear that, in fact, internalized EGFR can continue 
signaling. We hypothesize that chemotherapeutic 
agents may inÁuence EGFR trafÀcking and play a 
role in drug resistance.
Methods: Lung cancer cell lines were treated with 
different kinds of platinum and EGFR trafÀcking was 
evaluated by subcellular fractionation and Western 
blotting and confocal microscopy. MTT assay and the 
classical isobole method were used to examine the 
combination effects of platinum and other inhibitors.
Results: In consistent with previous studies, cisplatin 
could result in EGFR internalization and nuclear 
translocation in a p38-dependent manner. Interestingly, 
two other clinically-used platinum, carboplatin and 
oxaliplatin, also activated p38 and induced EGFR 
internalization and nuclear translocation. However, a 
non-toxic platinum, transplatin, could not effectively 
activate p38 and did not induce EGFR internalization. 
We further demonstrated that, in response to cisplatin 
treatment, p38 induced S1046/7 phosphorylation of 
EGFR. Lastly, combination of cisplatin and EGFR-
TKI did not show a synergistic effect; instead, an 
antagonistic effect was noted. These data will be 
updated and further study results will be presented in 
the Conference.
Conclusion: Cytotoxic platinum could induce EGFR 
internalization and nuclear translocation which 
might contribute to chemoresistance. It is possible to 
overcome drug resistance by targeting the aberrant 
EGFR trafÀcking.
Keywords: EGFR trafÀcking, platinum, Non-small 
cell lung cancer
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P1.076 THE RELATIONSHIP BETWEEN 
NUCLEAR FACTOR NF-țB EXPRESSION 
BY QUARTZ PEROXIDATION AND 
XUANWEI FEMALE NON-SMALL CELL 
LUNG CANCER
Yunchao Huang, Mengjiao Quab 
Thoracic And Cardiovascular Surgery, Yunnan 
Tumor Hospital/China
Background: Yunnan Xuanwei county is one of the 
highest cancer incidence of lung cancer in the world. 
To study the relationship and biological signiÀcance 
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with BRCA1 expression level in a panel of 6 
mesothelioma cell lines. We then investigated the 
effect BRCA1 silencing on vinorelbine sensitivity. 
The downregulation blocked caspase-3 activation, 
PARP cleavage and the percentage of subG1 cell 
population. Moreover, when cells were selected 
for resistance to vinorelbine, this was associated 
with a reduction in BRCA1 expression compared 
to parental cells. BRCA1 mRNA expression was 
not altered as shown by gene expression analysis, 
suggesting a post-transcriptional regulation 
mechanism. Data obtained in BAX/BAK double 
negative cells show that vinorelbine mediates 
toxicity irrespective of a functional mitochondrial 
apoptosis pathway, however caspase 8 can be 
activated in these cells; furthermore silencing 
of Caspase8 induced resistance to apoptosis by 
vinorelbine. We are addressing the prevalence of 
BRCA1 negativity in primary mesotheliomas to 
delineate its potential as a predictive biomarker.
Conclusion: Our data highlight the BRCA1 as 
a candidate predictive biomarker for vinorelbine 
induced apoptosis suggesting a potential utility in 
personalising therapy with this agent. 
Keywords: Malignant mesothelioma, BRCA1, 
Vinorelbine, chemoresistance
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P1.078 THE EMT REGULATOR SLUG 
CONTROLS THE DNA REPLICATION 
AND GENOMIC INSTABILITY
Wen-Lung Wang1, Shih-Han Kao2, Shu-Ping Wang3, 
Szu-Hua Pan3, Tse-Ming Hong4, Pan Chyr Yang5 
1Graduate Institute Of Life Sciences, National 
Defense Medical Center/Taiwan, 2Institute Of 
Molecular Medicine, Nation Taiwan University 
College Of Medicine/Taiwan, 3Institute Of 
Biomedical Sciences, Academia Sinica/Taiwan, 
4Graduate Institute Of Clinical Medicine, National 
Cheng Kong University/Taiwan, 5Department Of 
Internal Medicine, National Taiwan University 
College Of Medicine/Taiwan
Background: The well-characterized function 
of the transcription factor, Slug, is to promote 
EMT and tumor invasion/metastasis by down-
regulating E-cadherin expression. In addition, 
Slug also functions in cell cycle but the underlying 
mechanisms are still unclear. We thus infer that the 
EMT regulator, Slug, affects the normal cell cycle 
lung cancer. 2. The high expression of NF-kB protein 
in cancer tissues, the high expression of NF-kB 
protein in adjacent tissues and normal lung tissues 
in Xuanwei female NSCLC that was signiÀcantly 
higher than other group could be further studied 
as a diagnostic marker for lung cancer in Xuanwei 
and a possible target for treatment. 3. The smaller 
the crystal size was, the stronger the cytotoxicity 
of quartz was, leading to NF-kB protein highly 
expressed, which provides an important clue for 
further study of the pathogenesis of Xuanwei 
NSCLC.
Keywords: Non-small cell lung cancer, quartz, NF-
ƩB, Xuan Wei county
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P1.077 BRCA1 REGULATES APOPTOSIS 
INDUCED BY VINORELBINE IN 
MALIGNANT MESOTHELIOMA
Sara Busacca1, Ian Paul1, Niall Mctavish1, Keith M. 
Kerr2, Michael Sheaff3, Jennifer E. Quinn1, Dean A. 
Fennell1 
1Centre For Cancer Research And Cell Biology, 
Queen’s University Of Belfast/United Kingdom, 
2Department Of Pathology, Aberdeen Royal 
InÀrmary/United Kingdom, 3Department Of 
Pathology, Barts And The London Nhs Trust/United 
Kingdom
Background: Malignant mesothelioma is an 
aggressive tumor refractory to current therapies and 
this may be due to intrinsic apoptosis resistance. 
Vinorelbine has been shown to exhibit useful clinical 
activity in phase II trials and showed a trend to 
improved survival as front-line monotherapy in the 
MS01 phase III study. BRCA1 has been reported 
to regulate sensitivity to microtubule poisons; 
however its involvement in regulating apoptosis in 
Mesothelioma has not been investigated. We have 
hypothesised that loss of BRCA1 confers resistance 
to vinorelbine induced apoptosis. 
Methods: Dose-response curves were generated by 
vialight assay and caspase 3/7 activity determined by 
a luminescence assay. Three resistant cell lines were 
generated by increasing exposure to vinorelbine. 
Cells were transfected with 10nM non-targeting 
siRNA or BRCA1 /Caspase8 siRNA. The percentage 
of apoptotic cell population was determined by PI 
staining and measurement of hypodiploidy. 
Results: Vinorelbine induced cytotoxicity correlated 
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demonstrated clinical beneÀt, outcomes remain 
poor with overall Àve-year survival rates of <15%. 
Angiogenesis is critical for the growth, progression 
and metastasis of solid tumours, including NSCLC. 
The biological effects of VEGF are mediated via 
binding to the classical VEGF receptors, VEGFR-1 
and VEGFR-2 that have shown to be important 
for angiogenesis, while VEGFR-3 plays a role in 
lymphangiogenesis. In addition, VEGF also binds 
to the non-tyrosine kinase receptors, the Neuropilins 
(NP1 and NP2), and stimulates cell signalling 
transduction in conjunction with VEGFR-2. 
Downstream signalling, triggered by ligand-receptor 
binding, leads to endothelial cell proliferation and 
migration, increased permeability of blood vessels, 
and changes in the tumour microenvironment. The 
VEGF pathway has therefore become an important 
therapeutic target. In Phase III trials, blocking 
VEGF using the humanised VEGF monoclonal 
antibody, Bevacizumab (Avastin®), has yielded 
improved progression-free and overall survival in 
NSCLC patients when combined with standard 
chemotherapy, demonstrating the use of VEGF as 
a target for therapy. The precise mode of action 
of removing VEGF from the circulation however, 
remains uncertain. In this study, we examined the 
mechanisms of VEGF-mediated survival in non-
small cell lung cancer cells. 
Methods: A panel of NSCLC cells (H460, H647, 
A549 and SKMES-1) were screened for expression 
of VEGF and its receptors, VEGFR-1, VEGFR-2 
and the Neuropilins (NP1 and NP2) at the mRNA 
and protein levels. The survival effects of VEGF 
were examined using a pharmacological (VEGF 
antibodies) and genetic (siRNA) approach. The 
effect of recombinant VEGF (100ng/ml), and its 
blockade using neutralising antibodies (1g/ml) 
on lung tumour cell proliferation was examined 
using the BrdU assay. Cell cycle was assessed by 
propidium iodide staining following neutralisation 
of VEGF and analysed by FACS. Phosphorylation 
of the PI3-K and MAPK signalling proteins, Akt and 
Erk1/2, respectively, was examined by High Content 
Screening (HCS) analysis and confocal microscopy. 
The effects of silencing VEGF (100nM siVEGF) 
on cell proliferation/survival and pAkt expression 
were assessed using BrdU and Western blot analysis, 
respectively. 
Results: VEGF increased proliferation of NSCLC 
cells (H647, A549 and SKMES-1) expressing 
VEGFR-2 and Neuropilin receptors. VEGF blockade 
inhibited VEGF-mediated proliferation and induced 
control. In this study, we investigate how Slug 
proteins are regulated and the signiÀcance of Slug 
during the S phase.
Methods: Cells synchronized with nocodazole 
or double thymidine were released into drug-free 
medium for the indicated time, following by the 
Western blot and FACS analysis. The Slug mRNA 
expression was detected by qRT-PCR. Next, the half-
life of protein was performed by the cycloheximide 
inhibition assay. The phosphorylation of Slug by 
Cdk2/cyclin E was detected by the in vitro kinase 
assay . Further, DNA synthesis on the S phase was 
conÀrmed by the [3H]-thymidine incorporation assay 
and 32P-orthophosphate labeling. Finally, genomic 
instability was analyzed by cytokinesis-block 
micronucleus cytome assay and array cGH.
Results: We found that the endogenous Slug 
protein levels in CL1-5 lung cancer and U2OS 
osteosarcoma cells were Áuctuated during the cell 
cycle progression, which obviously decreased at 
two stages: G1/S transition and from M phase to 
early G1 phase. Downregulation of Slug protein 
at these phases was possibly attributed to protein 
destabilization mediated by the ubiquitin-proteasome 
degradation system. During the G1/S transition, 
Cdk2 interacted with and phosphorylated Slug. 
Furthermore, overexpression of Cdk2 and cyclin E 
facilitated Slug degradation. In contrast, knockdown 
of Cdk2 and cyclin E increased the Slug protein 
accumulation. We then found that overexpression of 
Slug markedly reduced DNA replication, increased 
micronuclei formation and genomic instability. 
Conclusion: This study indicates that Cdk2/cyclin 
E regulates the Slug protein stability to control Slug 
within normal protein levels and it may be critical 
for the regulation of DNA replication.
Keywords: Cell cycle, Slug, DNA replication, Cdk2/
cyclin E
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P1.079 VEGF IS AN AUTOCRINE 
SURVIVAL FACTOR IN NON-SMALL 
CELL LUNG CANCER
Martin P. Barr, Kathy A. Gately, Kenneth J. O’Byrne 
Clinical Medicine, St. James’ Hospital/trinity 
College Dublin/Ireland
Background: Lung cancer is the leading cause 
of cancer mortality worldwide, where NSCLC 
accounts for 85-90% of all lung cancers. Despite 
S748 Copyright © 2011 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
inhibition of these receptors in lung cancer cell lines.
Methods: T-type calcium channel expression and its 
role in cell proliferation were examined in non-small 
cell lung cancer. In vitro studies were conducted 
using H23 adenocarcinoma, H460 carcinoma, H522 
adenocarcinoma and H1299 carcinoma cell lines. 
Initial investigation involved Western blot analysis 
with antibodies for all three isoforms in all lines. To 
determine if the expressed proteins were functional 
voltage clamp studies were conducted to detect the 
unique t-current generated by the channels. The 
effects of the channels in NSCLC proliferation were 
examined using Mibefradil, a putative t-type calcium 
channel antagonist. Mibefradil was introduced in 
vitro and cell proliferation assays were performed 
pre and post treatment. Voltage clamp studies 
were again performed to ensure the channels were 
blocked. Finally, ex-vivo studies are underway 
utilizing immunohistochemistry in conjunction with 
the Glans-Look Lung Cancer Database.
Results: Several of the NSCLC lines expressed 
one or more of the t-type calcium channel isoforms. 
Using densitometry to analyze the Western blot 
results, H460 seems to express Ca(v)3.1 signiÀcantly 
more than the other cell lines, while H522 has a 
greater expression of Ca(v)3.2 when compared to 
H23, H460 and H1299. Preliminary in vitro results 
suggest that t-type calcium channel blockers can 
inÁuence the viability of these cell lines in vitro.
Conclusion: T-type calcium channels are expressed 
with differing levels within the NSCLC cell lines 
studied. Based on the t-type antagonist results, 
t-type calcium channels may have an inÁuence on 
the proliferative abilities of NSCLC and continued 
study is warranted. Further inquiry into the clinical 
signiÀcance of t-type channel expression in NSCLC 
patients is currently underway using the Glans-Look 
Lung Cancer Database, in which expression of the 
channels in resected tumors are correlated with 
patient outcome. Full results will be presented.
Keywords: t-type calcium channel, Non small cell 
lung cancer
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P1.081 CIGARETTE SMOKE ENHANCES 
THE MALIGNANT PHENOTYPE OF 
LUNG CANCER CELLS VIA INDUCTION 
OF THE PUTATIVE STEM CELL 
MARKER ABCG2
David S. Schrump1, Mary Zhang1, Aarti Mathur1, 
growth arrest in the G0/G1 phase of the cell cycle. 
Phosphorylation of Akt and Erk1/2 proteins was 
signiÀcantly upregulated in response to VEGF, while 
antibodies to VEGF inhibited this effect. VEGF 
gene silencing inhibited the survival of A549 and 
SKMES-1 cells and reduced pAkt protein expression 
in both cell lines. 
Conclusion: Tumour angiogenesis is mediated 
by VEGF and its receptors in many tumour types. 
While a number of anti-angiogenic small molecule 
tyrosine kinase inhibitors and monoclonal antibodies 
against VEGF and its receptors have been developed 
and tested in clinical trials, our data support the 
hypothesis that VEGF is a survival factor for 
NSCLC cells, acting primarily via VEGFR-2 and 
the Neuropilin receptors. Targeting the VEGF 
survival pathway in NSCLC may potentially be more 
effective in the development of anti-cancer therapies 
than anti-angiogenics. 
Keywords: VEGF, NSCLC, cell survival
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P1.080 T-TYPE CALCIUM CHANNEL 
EXPRESSION IN NON SMALL CELL 
LUNG CANCER
Allison Childers1, Gerald Zamponi2, Huong Muzik3, 
Shannon Otsuka1, Dafydd G. Bebb3 
1Medicine, University Of Calgary/tom Baker Cancer 
Centre/Canada, 2Physiology And Pharmacology, 
University Of Calgary/Canada, 3Department Of 
Medical Oncology, Tom Baker Cancer Centre/
Canada
Background: Calcium signaling is ubiquitous 
throughout the cell cycle and is known to directly, 
and indirectly, regulate cell proliferation via 
numerous channels and pathways. A newly emerging 
therapeutic target in cancer treatment is the t-type 
calcium channel. These channels are low-voltage 
activated and exist in three isoforms Ca(v)3.1, 
Ca(v)3.2, and Ca(v)3.3, differing by their a1 
subunits, a1G, a1H and a1I respectively. Typically 
these channels are only expressed in epithelia during 
development, and usually only found at other stages 
in abnormal conditions. T-type calcium channels 
have been implicated in breast and prostate cancer 
as a facilitator of cell proliferation, although the 
mechanism is not well understood. Their role in lung 
cancer has not been thoroughly investigated. We 
set out to assess the expression level and effect of 
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response elements as well as SP-1 recognition 
sequences within the ABCG2 promoter. CSC-
mediated induction of ABCG2 coincided with 
recruitment of aryl hydrocarbon receptor (AHR) 
and SP-1, as well as increased levels of RNA pol II 
and H3K9Ac within the ABCG2 promoter. Under 
exposure conditions potentially achievable in clinical 
settings, mithramycin A decreased AHR and SP-1 
levels within the ABCG2 promoter, and markedly 
down-regulated ABCG2 expression in lung cancer 
cells.
Conclusion: Cigarette smoke enhances the 
malignant phenotype of lung cancer cells, in part, 
via induction of ABCG2. These Àndings provide 
a mechanistic link between cigarette smoking and 
adverse outcome of lung cancer patients, and suggest 
that mithramycin infusions may be a novel strategy 
to target lung cancer stem cells. 
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.082 PROANGIOGENESIS FACTORS 
AND CELL PHENOTYPING IN THE 
ETHIOLOGY AND DIAGNOSIS OF 
MALIGNANT PLEURAL EFFUSIONS
Elizabeth Lieser1, Michael Bradshaw2, Gary 
Croghan1, John Mullon2, K robert Shen2, Francis 
Nichols2 
1Oncology, Mayo Clinic/United States Of America, 
2College Of Medicine, Mayo Clinic/United States Of 
America
Background: Malignant pleural effusions (PEs) 
are a signiÀcant source of cancer morbidity and 
mortality, and are associated with a median survival 
of 5 months. Treatments, including pleural catheters, 
pleurodesis, and thoracentesis, which provide some 
degree of symptomatic relief, do not address the 
underlying pathobiology. Our prior data shows that 
many malignant PEs contain high levels of VEGF. 
The purpose of this study was to compare levels of 
VEGF and other markers of angiogenesis in lung 
adenocarcinoma-induced malignant PEs relative to 
non-malignant PEs. 
Methods: PE samples from nine patients were 
collected and evaluated by ELISA for VEGF 
(R&D, Minneapolis, MN). An angiogenesis protein 
Mahadev Rao1, Sichaun Xi1, Yuwei Zhang1, Julie A. 
Hong1, Clinton Kemp1, R taylor Ripley1, Fang Liu1, 
Gordon Weigand2, Itzak Avital2 
1Thoracic Oncology, National Cancer Institute/
United States Of America, 2Gastrointestinal And 
Hepatobiliary, National Cancer Institute/United 
States Of America
Background: Limited information is available 
regarding epigenetic mechanisms by which cigarette 
smoke mediates initiation and progression of lung 
cancers, and how smoking status at diagnosis affects 
outcome of patients with these malignancies.
Methods: Lung cancer cells as well as small airway 
epithelial cells (SAEC) were cultured in normal 
media (NM) with or without cigarette smoke 
condensate (CSC) under clinically relevant exposure 
conditions. Microarray, quantitative RT-PCR 
and immunoblot experiments were performed to 
examine ABCG2 expression levels. Flow cytometry 
techniques were used to assess side population 
(SP) in lung cancer cells exposed to NM or CSC. 
Transfection experiments using shRNA or cDNA 
were used to stably knock-down, or constitutively 
express ABCG2 in lung cancer cells. MTT, scratch, 
soft agar and murine xenograft experiments were 
performed to assess proliferation, migration, 
clonogencity and tumorgenicity of lung cancer cells 
following manipulation of ABCG2 expression. 
Transient transfection assays with promoter-
reporter constructs, pyrosequencing, and chromatin 
immunoprecipitation (ChIP) techniques were used 
to examine ABCG2 expression, chromatin structure, 
and transcription factor occupancy within the 
ABCG2 promoter. 
Results: Five day CSC exposure signiÀcantly 
up-regulated ABCG2 (a xenobiotic pump highly 
expressed in cancer stem cells), in cultured lung 
cancer lines as well as SAEC. CSC increased the 
pluripotent side population (SP) of lung cancer cells; 
interestingly, ABCG2 up-regulation was observed in 
SP as well as non-SP cells following CSC exposure. 
Knock-down of ABCG2 inhibited proliferation, 
migration, and clonogenicity of A549 lung cancer 
cells endogenously expressing high levels of 
ABCG2. In contrast, constitutive over-expression 
of ABCG2 signiÀcantly enhanced proliferation, 
migration, clonogenicity, and tumorigenicity of 
Calu-6 lung cancer cells endogenously expressing 
low levels of ABCG2. CSC-mediated induction 
of ABCG2 was unrelated to ABCG2 promoter 
demethylation, but was attributable to xenobiotic 
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1Biochemistry & Molecular Biology, University Of 
Calgary/Canada, 2Department Of Medical Oncology, 
Tom Baker Cancer Centre/Canada, 3Medicine, 
University Of Calgary/tom Baker Cancer Centre/
Canada
Background: Lung cancer continues to cause 
signiÀcant morbidity and mortality and the need for 
newer, gentler therapeutic interventions remains. 
It is reported that 40-60% of non small cell lung 
cancer (NSCLC) tumors over-express Bcl-2. 
The attenuation of apoptosis by bcl-2 is thought 
to contribute to tumor malignancy and increase 
resistance to some cytotoxic agents. GX15-070 is a 
small molecular inhibitor of the BH3 binding groove 
of Bcl-2 that has shown promise in the treatment of 
several malignancies in Phase I and II clinic trials. 
We have previously shown that anti-sense based anti-
Bcl-2 strategies when combined with vinorelbine 
increase survival in an orthotopic xenograft murine 
model. We set out to assess the utility of this agent 
alone and in combination on a series of NSCLC cell 
lines in-vitro. 
Methods: Five NSCLC cell-lines (A549, H23, 
H226, H522, H460, H1299) previously characterized 
in detail representing three histological subtypes 
(squamouos, adeno and large cell) were used. Bcl-2 
expression was assessed by Western blot techniques. 
Cells were grown in standard media and exposed to 
a range of concentrations of GX15-070. The dose-
response curve was assessed by measuring viability 
at 24 and 48 hours using the MTT assay. When 
used in combination with other cytotoxic agents, 
Calcusyn, a mathematical software was used to 
calculate the optimum range of drug ratio with the 
highest drug synergy. 
Results: Each of the NSCLC cell lines grew well 
in-vitro. Each cell line expresses Bcl-2 protein. At 48 
hours incubation each cell line exhibited resistance 
to GX15-070 at all concentrations tested. Only a 
minor reduction in viability was seen at the highest 
concentration. There was no difference according 
to histological subtype. However, an increased in 
sensitivity was observed when 25uM of GX15-070 
was used in combination with 5M of Vinorelbine, 
as compared to treatments when individual drugs 
were used.
Conclusion: Although our results demonstrate 
GX15-070 to be less effective on NSCLC cell lines 
as a single agent, an increase in sensitivity was 
observed when it was used in combination with 
Vinorelbine. Using this synergistic combination, a 
array was completed in order to perform a semi-
quantitative comparison of peptide expression in 
malignant and non-malignant effusions (R&D, 
Minneapolis, MN). Cells were isolated from PE 
Áuid and phenotyped using Áuorescent cell sorting 
(FACS). 
Results: Five lung adenocarcinoma-derived 
malignant PEs and four non-malignant PEs were 
assayed for levels of VEGF. Malignant PEs were 
found to have 280-fold higher VEGF levels 
compared to non-malignant by ELISA. The semi-
quantitative protein array demonstrated elevated 
levels of Leptin, CXCL4 and FGF-7, and decreased 
levels of IL-8, MCP-1 and IL-1ơ in malignant PEs. 
FACS analysis of malignant cells showed effusions 
express low levels cytotoxic T-cells (CD3.8) and 
high levels of dendritic cells (CD11c), monocytes 
(CD14) and tumor cells (EpCAM) compared to 
benign PEs. No signiÀcant difference was noted 
between natural killer (CD16.56) and helper T-cell 
(CD3.4) populations. Fluid from adenocarcinomas 
demonstrated an 8 fold increase of mesothelial cells 
when compared to non-malignant PEs.
Conclusion: Our research demonstrates that 
malignant effusions possess increased expression 
of VEGF-A and other proangiogenic factors may 
lead to increased vascular permeability, blood 
vessel formation and tumor cell implantation. 
Levels of other VEGF species, chemokines and 
proinÁammatory proteins, did not show signiÀcant 
differences between benign and malignant effusions. 
There is a strong indication that mesothelial cells 
play an important role in malignant effusions, but 
that function remains indeterminate. Treatment 
with an anti-angiogenesis therapy, such as a 
VEGF inhibitor, may improve the quality of life 
and prognosis for patients with malignant pleural 
effusions. 
Keywords: malignant pleural effusions, 
proangiogenesis factors
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P1.083 SUSCEPTIBILITY OF NON SMALL 
CELL LUNG CANCER CELL (NSCLC) 
LINES TO TARGETING BCL-2 USING 
THE SMALL MOLECULAR INHIBITOR, 
GX15-070, ALONE AND IN COMBINATION 
WITH CYTOTOXIC AGENTS.
Poh Soo Lee1, Huong Muzik2, Shannon Otsuka3, 
Dafydd G. Bebb3 
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expression in lung cancer cells were used to verify 
the role of KIF14 in tumor progression in several 
experiments including cell proliferation, anchor-
independent growth, migration, invasion and tumor 
growth. The expression patterns of KIF14 mRNA 
and protein in non-small-cell lung cancer (NSCLC) 
patients were investigated by real-time reverse 
transcription polymerase chain reaction (RT-PCR) 
and immunohistochemistry (IHC), respectively in 
an independent cohort and evaluated the correlation 
with patients’ clinical outcomes. 
Results: Overexpression of KIF14 in non-small-
cell lung carcinoma CL
1-5
 cell lines did not affect 
the proliferation remarkably but decreased colony 
formation in soft agar and the tumor size of 
transplantation in mice. We also observed that the 
expression of KIF14 reduces the abilities of cell 
migration and invasion in vitro. Furthermore, the 
results of real-time RT-PCR and IHC are both shown 
that low level expression of KIF14 signiÀcantly 
decreased overall survival (P=0.0128 and P<0.0001 
respectively, log-rank test). 
Conclusion: KIF14 may consider a tumor 
suppressor and biomarker of lung cancer risk. 
Keyword: KIF14
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P1.085 UNRAVELING SUCCESSIVE 
MOLECULAR EVENTS IN LUNG 
CARCINOGENESIS: A CASE REPORT
Robert A. Van Boerdonk1, Thomas G. Sutedja2, 
Peter J. Snijders1, Frederik B. Thunnissen1, Sylvia 
Duin1, Bauke Ylstra1, Gerrit A. Meijer1, Johannes 
M. Daniels2, Pieter E. Postmus2, Egbert F. Smit2, 
Daniëlle A. Heideman1 
1Pathology, Vu University Medical Center/
Netherlands, 2Pulmonary Diseases, Vu University 
Medical Center/Netherlands
Background: Lung cancer is believed to arise 
via sequential accumulation of genetic changes. 
The current study was set out to evaluate the 
genetic changes present in normal lung tissues and 
preneoplastic lesions adjacent to the tumours in 
subjects with lung squamous cell carcinoma (SqCC) 
to identify the earliest genetic changes that may 
be responsible for tumour development in these 
subjects. 
Methods: Post surgical resection, multiple cross-
sections of the bronchial tree of a subject with SqCC 
lower dose of Vinorelbine could be used to achieve a 
similar reduction in viability to that achieved with a 
much higher vinoerlbine conentraion. This suggests 
GX15-070 to be a plausible candidate that could be 
used to boost the effect of current chemotherapeutic 
drugs. With a lower drug dosage, this will in turn 
reduce the side effects experienced by patients, yet 
improving clinical outcome. Work assessing the 
utility of combining this agent with other cytotoxic 
agents in-vivo is currently ongoing and will be 
presented. 
Keywords: Bcl2, small molecular inhibitor, Non 
small cell lung cancer
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P1.084 MOTOR PROTEIN KIF14 AS 
A TUMOR SUPPRESSOR IN LUNG 
CANCER
Pei-Fang Hung1, Szu-Hua Pan2, Yih-Leong Chang3, 
Chen-Tu Wu3, Tse-Ming Hong4, Pan Chyr Yang5 
1Graduate Institute Of Life Sciences, National 
Defense Medical Center/Taiwan, 2Institute Of 
Biomedical Sciences, Academia Sinica/Taiwan, 
3Department Of Pathology And Graduate Institute 
Of Pathology, College Of Medicine, National 
Taiwan University/Taiwan, 4Institute Of Clinical 
Medicine, National Cheng Kung University/Taiwan, 
5Department Of Internal Medicine, National Taiwan 
University College Of Medicine/Taiwan
Background: Intracellular transport is essential for 
the morphology and function of the cell. The kinesin 
superfamily proteins (KIFs) have been identiÀed 
as motor proteins which can transport organelles, 
proteins and mRNAs in an ATP- and microtubule-
dependent manner. They perform diverse functions 
in cell, including membrane motility, chromosome 
segregation, microtubule dynamics, ciliogenesis 
and intracellular signaling. Recently, several studied 
showed that KIFs also involve in cancer progression 
such as KIF1B in oligodenrogliomas, KIF11 in 
B-cell leukemia, KIF18A in colon cancer and so on. 
KIF14 which belongs to Kinesin-3 family has been 
isolated from human immature myeloid cell and is 
involved in the organization of central spindle. Until 
now, little is known about its’ function. 
Methods: Loss of heterozygosity (LOH) was used 
to analyze the region of chromosome 1q near the 
loci of KIF14 in lung adenocarcinoma patients. 
Overexpressing and knocking down KIF14 
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that this miRNA has target sites in the 3’UTR of 
the Zic1 mRNA. The aim of the current study was 
to investigate the functional signiÀcance of Zic1 
silencing and hsa-miR-23a over-expression in MM.
Methods: We analysed the mRNA expression 
level of Zic1 in MM cell lines (H2052, H452, H28, 
H226 and MSTO), normal mesothelial line Met-
5A, and human mesothelial cells from pericardial 
Áuid (HMCs) using RT-PCR. The DNA methylation 
status of Zic1 in MM cell lines was conÀrmed using 
MSP and the COBRA assay. DNA methylation of 
Zic1 in MM tumours was assessed with MSP. The 
expression level of hsa-miR-23a was measured in 
MM cell lines and primary MM specimens using 
a TaqMan assay. To investigate the functional 
signiÀcance of Zic1 silencing, Zic1 was re-expressed 
in MM cell lines and the effects on cell cycle, 
proliferation, migration and colony formation were 
assessed. The relationship between hsa-miR-23a and 
Zic1 expression was investigated by the use of an 
antagonist of hsa-miR-23a.
Results: RT-PCR analysis indicated high levels of 
mRNA expression of Zic1 in Met-5A and HMCs. 
In contrast, Zic1 was not expressed or was down-
regulated in MM cell lines. Following treatment 
with 5’Aza, expression of Zic1 was signiÀcantly 
up-regulated in all mesothelioma lines but was 
unchanged in Met-5A and HMCs. Zic1 COBRA and 
MSP analysis correlated with mRNA expression, 
suggesting Zic1 is silenced in MM through DNA 
hypermethylation. Enforced Zic1 expression 
inhibited cell migration and colony formation in H28 
cells. Hsa-miR-23a overexpression in MM and is 
closely linked to Zic1gene expression. 
Conclusion: Our results show that Zic1 behaves 
in MM cell culture as a functional tumour 
suppressor that is silenced by a combination of 
hypermethylation and hsa-miR-23a-mediated 
inhibition. hsa-miR-23a is a potential therapeutic 
target deserving further studies.
Keyword: Zic1, microRNA, Mesothelioma
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P1.087 EPIGENETIC INACTIVATION 
OF THE SFRP FAMILY BY DNA 
METHYLATION IN MALIGNANT 
MESOTHELIOMA
Yuen yee Cheng1, Chris Mclaughlin2, Hongchuan 
Jin3, Francis K.L. Chan4, Michaela B. Kirschner1, 
Tony George2, Nico Van Zandwijk1, Glen Reid1 
were dissected. Each cross-section was evaluated by 
histopathology. Genomic DNA was isolated from 
laser-capture micro-dissected normal lung tissue, 
premalignant lesions and SqCC, and subjected 
to array comparative genomic hybridization 
(arrayCGH) analysis (4x44K Agilent).
Results: Preliminary evaluation indicates the 
presence of tumour-adjacent, histomorphologically 
premalignant changes of various grades. At this 
moment, starting with tumour distant normal 
epithelium the DNA copy number proÀles of the 
tumour adjacent cross-sections are being determined 
in order to unravel molecular events associated with 
histomorphological progression.
Conclusion: It is expected that data and statistical 
analyses will be Ànished by May 2011.
Keywords: lung carcinogenesis, molecular events, 
Array comparative genomic hybridization
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
Poster Session 1 – Cancer Biology Monday, 4 July 2011 12:15-14:15
P1.086 FUNCTIONAL SIGNIFICANCE 
OF ZIC1 AND HSA-MIR-23A OVER-
EXPRESSION IN MALIGNANT 
MESOTHELIOMA
Yuen Yee Cheng1, Michaela B. Kirschner1, 
Hongchuan Jin2, Francis K.L. Chan3, Nico Van 
Zandwijk1, Glen Reid1 
1Asbestos Diseases Research Institute, The 
University Of Sydney/Australia, 2Biomedical 
Research Center, Zhejiang University/China, 
3Medicine, The Chinese University Of Hong Kong/
Hong Kong
Background: Epigenetic inactivation of tumour 
suppressor genes through DNA hypermethylation 
plays a crucial role in the progression of malignant 
mesothelioma (MM). Our previous work indicated 
that Zic1 silencing in MM lines is only partially 
explained through DNA hypermethylation. Zic1 
is essential for the regulation of proliferation and 
differentiation of the neural crest and subsequent 
cerebellar development. It is also a tumour 
suppressor gene down-regulated through promoter 
hypermethylation in gastric cancer. Interestingly, 
miRNA microarray analysis revealed that hsa-
miR-23a is over-expressed in MM cell lines, and 
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(16/17) primary clinical MM samples, respectively.
Conclusion: Our results indicate that SFRP2 and 
SFRP5 genes are silenced by DNA methylation 
and reactivated by the DNA demethylating agent 
5’Aza. Methylation of SFRP2 and 5 promoters was 
observed in a majority of MM tumour specimens, 
suggesting that epigenetic inactivation of SFRP gene 
family plays a pivotal role in MM development.
Keyword: SFRP, Tumour suppressor, mesothelioma
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P1.088 GENDER RELATED 
GENOMIC DIFFERENCES IN LUNG 
ADENOCARCINOMA
Greg L. Stewart1, Kelsie Thu1, Emily A. Vucic1, 
Jennifer Y. Kennett1, Larissa A. Pikor1, Raj Chari2, 
Wan Lam1, Stephen Lam1 
1Integrative Oncology, British Columbia Cancer 
Research Centre/Canada, 2Genetics, Harvard 
Medical School/United States Of America
Background: Gender disparities related to 
incidence, clinical presentation, mortality and 
therapeutic response in non small cell lung cancer 
(NSCLC) are becoming increasingly apparent. 
It is unclear whether environmental, behavioral, 
hormonal, genetic, or biological factors, including 
nicotine clearance, can fully explain such disparities. 
For example, women on hormone replacement 
therapy have an increased risk of NSCLC, but 
these changes cannot explain observed clinical 
disparities. Recent Àndings in never smokers with 
adenocarcinoma, have shown females display a 
higher rate of EGFR mutation than males. It is 
possible that other gender based genetic differences 
play a role in susceptibility to lung cancer in 
smokers. We hypothesize that lung tumor genomes 
of males and females smokers harbor differences 
at the molecular level that may underlie the gender 
based disparities observed in adenocarcinoma.
Methods: Global gene dosage proÀles for 48 lung 
adenocarcinoma from 16 males and 32 females 
(all current smokers) were generated by array 
comparative genomic hybridization. A Fisher’s test 
was used to identify genomic regions differentially 
altered between males and females. The identiÀed 
candidate regions from our discovery set were 
validated in an external cohort comprised of male 
(n=29) and female (n=37) current smokers with lung 
adenocarcinoma from the database of Genotypes and 
1Asbestos Diseases Research Institute, The 
University Of Sydney/Australia, 2The University 
Of Technology And Science/Australia, 3Biomedical 
Research Center, Zhejiang University/China, 
4Medicine, The Chinese University Of Hong Kong/
Hong Kong
Background: The etiology of Malignant 
Mesothelioma (MM) is closely linked with asbestos 
exposure. Asbestos is capable of inducing chronic 
inÁammation with the potential to contribute to 
epigenetic silencing of tumour suppressor genes. 
Epigenetic silencing of the Wnt pathway, well 
characterized in the progression of colon cancer, is 
associated with chronic inÁammation. The SFRP 
gene family acts as antagonist to the Wnt pathway 
and expression of SFRPs is silenced in colon, gastric, 
breast, ovarian and lung cancers, with some members 
silenced in mesothelioma. The Wnt pathway has 
been found activated in MM. There is evidence that 
inÁammation can lead to epigenetic silencing of 
members of the SFRP family. In this study, we aimed 
to investigate the relationship between gene silencing 
and DNA methylation of the SFRP gene family in 
MM.
Methods: We investigated SFRP expression in MM 
cell lines, mesothelial cell line Met5A and primary 
human mesothelial cell cultures from pericardial 
Áuid (HMCs). The effect of the demethylating agent 
5’Azacitidine (5 days, 2mM) on SFRP expression 
was also determined. Expression of SFRP mRNA 
was measured by conventional RT-PCR, and DNA 
methylation analysis using methylation-speciÀc PCR 
(MSP) and COBRA. MSP was used to study the 
DNA methylation status of SFRPs in MM tumour 
specimens. 
Results: SFRP2 and SFRP5 expression was absent 
in 3 and 4 out of 5 MM lines, respectively. And 
high levels were detected in Met-5A and HMCs. In 
contrast SFRP1 and SFRP4 were highly expressed 
and unmethylated in all MM lines. As previously 
reported SFRP2 and 5 were down-regulated in the 
lung cancer line A549 and we showed corresponding 
results as others. Following treatment with 5’Aza, 
expression of SFRP2 and SFRP5 was signiÀcantly 
up-regulated in all 5 MM lines but unchanged in 
Met-5A and HMCs. COBRA analysis of SFRP2 
and SFRP5 correlated with presence of mRNA 
expression. MSP analysis of the DNA methylation 
status of SFRP2 and SFRP5 in cell lines revealed 
methylation in non-expressing cell lines. SFRP2 and 
SFRP5 were methylated in 65% (11/17) and 94% 
S754 Copyright © 2011 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
non-small cell lung cancer (NSCLC), and on the 
clinical severity of NSCLC in 52 NSCLC patients 
and 60 control subjects were examined. A hospital-
based case-control study was undertaken in Ankara 
University Hospital. PON 1 L55M 55 and Q192R 
192 genotypes were determined by PCR, RFLP and 
agarose gel electrophoresis techniques.
Results: The analysis showed genotype distributions 
and allele frequencies for PON 1 Q192R 
polymorphism were not signiÀcantly different 
between controls and NSCLC patient group ( 
p>0.05), but in genotype and allele distribution 
of PON 1 L55M polymorphism, there was 
signiÀcantly difference among groups (p<0.05). 
Genotype distributions for both polymorphisms 
were not signiÀcantly different between subgroups 
of squamous cell carcinoma and adenocarcinoma 
type. There was a statistically signiÀcant difference 
of NSCLC risk in mutant genotypes, especially for 
current smokers and heavy smokers. Moreover, 
mutant genotypes present signiÀcantly lower risk of 
developing cancer in stage IV for NSCLC.
Conclusion: Our results suggest that both of PON1 
polymorphisms appear to be common genetic traits 
that are associated with a decreased risk and severity 
for NSCLC. The effect is especially strong for heavy 
smokers.
Keywords: Paraoxonase I gene, SNP, Non small cell 
lung cancer, Heavy smoker
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.090 THE FUNCTION OF STAT3 
SIGNALING PATHWAY DURING 
LEPTIN PROMOTING HUMAN 
LUNG ADENOCARCINOMA CELLS’ 
PROLIFERATION PROCESS
Yanbei Zhang, Bidan Hu 
Department Of Geriatric Pulmonary, The First 
AfÀliated Hospital Of Anhui Medical University/
China
Background: lung cancer is one of the most 
prevalent malignancies in the whole world, and now 
it has been on the top of deaths caused by cancer. 
There are about 600 thousand people died of cancer, 
and the number was increasing every year. The 
Phenotypes (dbGaP).
Results: We found 7 distinct differentially 
altered regions between male and female lung 
adenocarcinoma, that overlapped between our 
discovery and external datasets, which encompassed 
200 genes in these chromosomal regions: chr14 
q12-q21.3, chr17 q21.33-q22, chr8 q11.22-q12.1, 
chr8 q22.1-q22.2, chr8 q22.2-q24.13, chr8 q24.3, 
chr3 q26.1. Using Ingenuity Pathways Analysis we 
identiÀed several pathways and biological functions 
affected by genes located in these regions. Many 
of these genes are known oncogenes previously 
shown to be involved in NSCLC and inÁammatory 
pathways such as PI3/AKT and IL6 while others 
are new. These Àndings imply that these seven 
differentially altered regions and the genes they 
encompass may play a signiÀcant role in gender 
differences observed in NSCLC.
Conclusion: Our study suggests there are gender 
speciÀc genetic disparities in NSCLC at the gene 
dosage level, and provides rationale for further 
investigation in larger cohorts. On-going studies that 
include analyses of different genomic dimensions 
such as gene expression and DNA methylation, may 
lead to additional information on gender differences 
in NSCLC, potentially leading to improvements in 
prevention, diagnosis, and treatment.
Keywords: Current Smokers, gender, Non small cell 
lung cancer, Genomics
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P1.089 A STUDY OF PARAOXONASE I 
GENE POLYMORPHISMS WITH THE 
RISK AND SEVERITY OF NON-SMALL 
CELL LUNG CANCER (NSCLC) IN 
TURKISH PATIENTS
Fadhil Ahsan1, Asuman Sunguroglu2 
1Internal Medicine, University Of Indonesia/
Indonesia, 2Medical Biology, Ankara University/
Turkey
Background: Paraoxonase 1 is a high-density 
lipoprotein (HDL)-associated enzyme that was 
thought to against lung cancer (LC) because it may 
has a role in protecting from oxidative stress in 
the lung and circulation. PON 1 has two genetic 
polymorphisms in coding region; L55M and Q192R.
Methods: In the present study, distribution of 
PON 1 L55M and Q192R polymorphisms and 
the effect of these polymorphisms on the risk of 
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and pathological process of lung. For example, it 
is involved in fetal lung maturity and play a role in 
physiological function in the maintenance of adult 
normal lung epithelial cells. It also found that leptin 
can promote the proliferationof SQ-5 lung squamous 
cell carcinoma cell line. Therefore, leptin is closely 
related to the development of the occurrence of lung 
cancer. Currently, however, it is still unclear the 
concrete mechanism of leptin in the development 
of lung cancer. Another study showed that leptin 
signal transduction pathways have relationships 
with the activity of JAKs / STATs family. Animal 
tests also suggested that the hypothalamus of leptin 
signal transduction mainly involves JAK2/STAT3. 
Ob-R ligand binds to Ob-Rb and phosphorylate 
tyrosine residue in cells, and then activates JAK2 by 
transphosphorylation. A connection site with single 
STAT3 is formed through phosphorylation of Ob-Rb. 
STATs are a group of cytoplasmic proteins. Its role as 
a signal transductor and transcription factor involved 
in the reaction to cytokines and growth factors in 
normal cells. STAT3 is a potential cytoplasmic 
transcription factor in STATs family. Once STAT3 
attachs its receptors, in the No. 705 carboxy-terminal 
tyrosine phosphorylation site (Y705) has been 
phosphorylated by JAK2, and the STAT3 transforms 
into p-STAT3. Through the role of SH2 region 
STAT3 forms the homodimer or heterodimer, and 
transfers into the nucleus. nteracted with a speciÀc 
gene promoter region of the DNA components or 
other transcription factors or ancillary proteins, the 
homodimer or heterodimer regulate the downstream 
target genes, Such as: bcl-2 transcription, which 
can cause growth disorders, promote cell malignant 
transformation and tumorigenesis. 
Methods: The immunohistochemical SP method 
was used to examine the protein expressions of 
leptin, STAT3, p-STAT3, Bcl-2 in 52 cases of non-
small cell lung cancer and 34 cases of paracancerous 
normal lung tissues. Their correlations with 
clinical stage, and lymph node metastasis of lung 
cancer were statistically analyzed. MTT assay was 
used to determine the effect of leptin on the cell 
proliferation. Flow cytometry was used to detect 
the growth rate of A549 cells treated by different 
concentration of leptin. Immunocytochemistry 
staining were used to evaluate the protein expression 
of STAT3, p-STAT3 and Bcl-2 in human lung 
adenocarcinoma A549 cells. 
Results: The positive staining rates of leptin, STAT3, 
p-STAT3 and Bcl-2 protein in NSCLC tissues were 
signiÀcantly higher than Para cancerous normal lung 
incidence rate of female patients especially got an 
increasingly trend. China is also a country which 
has a high incidence of lung cancer. Therefore, the 
reacerch of correlation of lung cancer has been 
taken to attention. According to pathohistology, 
lung cancer is devided into two category. One is 
small cell lung cancer (SCLC), another is non-
small cell lung cancer(NSCLC). Non-small cell 
lung cancer(NSCLC) comprises about 75-80% of 
all lung cancers and represents a heterogeneous 
group of cancers, consisting mainly of squamous 
cell carcinoma, adenocarcinoma, adenosqamous 
carcinoma and large cell carcinoma subtypes. In 
the tumor process, abnormality of the cell signal 
transduction and loss of balance of cell proliferation 
and apoptosis have been proven to be the two 
key elements. These two aspects are inseparable 
with lung cancer occurrence and development of 
mechanisms. Leptin is a N terminal signal peptide 
with 21 amino acid peptide which is coded by 
obese gene (OB) and mainly secreted by adipose 
tissue. Its main function is to regulate the body’s 
energy metabolism and fat synthesis. Serum leptin 
levels were directly correlated with patient’s body 
weight, suggesting that leptin is closely related 
with the feeding. Leptin also has many important 
physiological functions, including ampliÀcation 
of inÁammation and immune function. However, 
further studies have shown that leptin can stimulate 
the proliferation of tumor cells, inhibit tumor cell 
apoptosis and can increase the invasiveness of 
tumor cells and to promote the formation of new 
blood vessels within the tumor, Therefore, in tumor 
occurrence and development of leptin plays a role 
can not be ignored. The current study conÀrmed 
that leptin over expressed in various tumor tissues 
and cells, and was closely linked with tumor 
occurrence and development. Leptin can only 
perform its biological function through combining 
with its receptor (Ob-R) on different target organs. 
The long leptin receptor (Ob-Rb) of its receptors 
is the only complete intracellular domain and has 
intracellular tyrosine residues of the Ob-R forms, 
which have a signal transduction function. Many 
clinical trials conÀrm that functional leptin and 
leptin receptor (OB-Rb) have high expressions in 
endometrial cancer, stomach cancer, breast cancer, 
prostate cancer and a variety of tumor tissue and 
tumor cell lines. Meanwhile, we found expression of 
OB-Rb in human lung tissues, which indicated that 
the lung is the target organ of leptin. As a cytokine, 
leptin have functions both in physiological process 
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Background: Transforming growth factor-alpha 
(TGF-alpha) and transforming growth factor-beta 
(TGF-beta) are two pivotal cytokines regulating 
positive and negative proliferation, respectively, 
of tracheobronchial epithelial cells during normal 
development as well as cancer progression. Though 
Cited2, a novel cytokine inducible modulator, 
regulates mouse fetal lung development and possess 
transforming ability, the role of Cited2 in lung 
tumorigenesis is still elusive. 
Methods: Immunohistochemical analysis was 
performed to analyze the Cited2 expression in 45 
lung adenocarcinoma cases. TGF-alpha and TGF-beta 
mediated Cited2 expressions were also determined in 
lung cancer cells by Q-PCR and immunoblotting. 
Results: We observed that Cited2 correlates with 
tumor staging in human adenocarcinoma, suggesting 
the involvement of Cited2 in lung tumorigenesis. 
We discovered that Cited2 is induced by TGF-alpha 
via c-Myc and further activates TGF-alpha/EGFR 
signaling in a positive feedback manner. Moreover, 
Cited2 acts collaboratively with c-Myc to induce 
E2F3a and G1/S cell cycle transition. Whereas TGF-
beta inhibits growth of lung cancer cells, it decreases 
Cited2 level but induces p21CIP1 expression. Cited2 
inhibits cellular senescence through binding to 
p21CIP1 promoter, potentiating c-Myc-mediated 
suppression of p21CIP1. Overexpression of Cited2 
enhances tumor growth in nude mice; furthermore, 
knockdown of Cited2 causes tumor shrinkage and 
increases overall survival rates of host mice. Clinical 
data analysis showed that Cited2 is highly expressed 
in human lung adenocarcinoma and correlated with 
c-Myc expression. 
Conclusion: These data demonstrate that Cited2 
plays an emerging role in cytokine induced 
proliferation and senescence of lung cancer, 
with potential applications as a novel prognostic 
biomarker and therapeutic target in lung cancer.
Keywords: Cited2, c-Myc, proliferation, senescence
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P1.092 COMPREHENSIVE EVALUATION 
OF THE RESPONDED GENES BY THE 
ADMINISTRATION OF ANTI-TUMOR 
DRUG, S-1 USING LOW DENSITY ARRAY.
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Toba2, Koichiro Kenzaki2, Shoji Sakiyama2, Akira 
Tangoku2 
tissues. The expression of STAT3 and p-STAT3 had 
close relationships with TNM stage of lung cancer and 
Lymph node metastasis (P 0.05). The expression of 
STAT3 was positively correlated with the expression 
of p-STAT3(P 0.05), and the expression of p-STAT3 
was positively correlated with the expression 
of Bcl-2 (P 0.05). The expressions of STAT3, 
p-STAT3 and Bcl-2 were detected in the human lung 
adenocarcinoma A549 cells, which were gradually 
increased accompaning time and concentration 
increasing. And The expressions of STAT3, p-STAT3 
and Bcl-2 were signiÀcantly increased in 100ng/
ml leptin treated group. Leptin can stimulate the 
proliferation of A549 cells, especially when leptin 
was 100 ng/ml after 24-hour treatment. Moreover, the 
ratio of cells in G2/M cell cycle in those treated with 
100 ng/ml leptin was signiÀcant higher than in 0ng/
ml,10ng/ml leptin treated group. 
Conclusion: (1) The high expression of leptin, STAT3, 
p-STAT3 may play an important role in the progression 
and development of human NSCLC which may be 
useful in the assessment of the malignant processing 
and biological behavior of the malignant tumor. (2) 
The activation of STAT3 is possibly mediated by over-
expression of anti-apoptosis gene bcl-2 in the lung 
cancer cells which make continued proliferation of lung 
cancer cells. It plays an important role in malignant 
transformation and evolution of lung cancer cells. (3) 
Leptin may promote the proliferation of A549 cells by 
activating STAT3 signaling pathway and inducing the 
over expression of bcl-2. 
Keywords: Non-small cell lung cancer, leptin, JAK/
STAT3 signal pathway, Bcl-2
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.091 THE EMERGING ROLE OF 
CITED2 IN CYTOKINE MEDIATED 
PROLIFERATION AND SENESCENCE OF 
LUNG CANCER
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1Institute Of Biomedical Sciences, Academia 
Sinica/Taiwan, 2Department Of Oral Diagnosis & 
Pathology,, Tri-service General Hospital/Taiwan, 
3Microbiology And Immunology, National Yang-ming 
University/Taiwan
Copyright © 2011 by the International Association for the Study of Lung Cancer S757
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
have positive correlation with TGI . 
Conclusion: In orthotopically implanted SCID 
mice model of the lung cancer 4 cell lines, the 
expression of PRSS3, ABCC4, TXN, SHMT1 and 
CMPK genes were signiÀcantly prompted by the 
administration of S-1, and the expression of LMO7 
and FOLH1 genes were signiÀcantly suppressed. 
However, the extent of variation of gene expressions 
except FOLH1 was low (1.5-2.0). There were not a 
signiÀcant variation of TS (thymidylate synthase), 
DPD (dihydropyrimidine dehydrogenase), TP 
(thymidine phosphorylase) and OPRT (orotate 
phosphoribosyltransferase) gene expressions which 
were reported to be related to chemosensitivity of 
5-FU by several previous studies. Resistant tumor 
group (A549) and moderately effective group (Lu99, 
Lu130, LC6) were classiÀed by tumor growth 
inhibition rate (TGI) for S-1. The expression of 
ABCC1, 2and TST genes have negative correlation 
with TGI. The expression of TK1 and ERCC2 genes 
have positive correlation with TGI . 
Keywords: S-1, orthotopically implanted SCID 
mice, low density array
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P1.093 ANALYSIS OF INTRA-TUMOR 
HETEROGENEITY OF EGFR 
MUTATIONS IN MIXED-TYPE LUNG 
ADENOCARCINOMA
Nanae Tomonaga1, Yoichi Nakamura1, Hiroyuki 
Yamaguchi1, Takaya Ikeda1, Kosuke Mizoguchi1, 
Kohei Motoshima1, Katsumi Nakatomi1, Tetsuya 
Iida1, Tomayoshi Hayashi2, Takeshi Nagayasu3, 
Kazuhiro Tsukamoto4, Shigeru Kohno1 
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Nagasaki University Hospital/Japan, 2Department 
Of Pathology, Nagasaki University Hospital/
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Pharmacotherapeutics, Nagasaki University 
Graduate School Of Biomedical Science/Japan
Background: Epidermal growth factor receptor 
(EGFR) mutations are predictive of the success of 
EGFR tyrosine kinase inhibitor (TKI) treatment in 
patients with advanced non-small-cell lung cancer 
(NSCLC). As with other solid tumors, lung cancer is 
thought to be the result of an accumulation of genetic 
alterations following exposure to carcinogens. 
Here, we aim to clarify the relationship between the 
1Department Of Oncological Medical Services,, 
Institute Of Health Biosciences, The University Of 
Tokushima Graduate School/Japan, 2Department 
Of Thoracic, Endocrine And Oncological Surgery, 
Institute Of Health Biosciences, The University Of 
Tokushima Graduate School/Japan
Background: There were several studies which have 
comprehensively examined genes which predict 
the response of cancer cells to chemotherapies, 
including 5-FU using in vitro cancer cell lines 
and xenograft subcutaneous implantation models. 
In 1889, Paget proposed the original “seed and 
soil” theory that organ-site-speciÀc implantation 
of tumor cells is essential for optimal growth and 
progression of tumors in vivo. Fidler established 
an orthotopic implantation metastatic model using 
tumor cell suspensions which were inoculated into 
the corresponding organ of nude mice. ATo identify 
genes that might be associated with chemosensitivity 
of the anti-tumor drug S-1, we used a low density 
array representing 93 genes to analyze expression 
proÀles in 4 orthotopically implanted lung cancers 
derived from human lung cancer cell lines. 
Methods: The mice were orthotopically implanted 4 
cell lines( A549,LC6,Lu99,Lu130) . After 6 weeks, 
we administered S-1 (10mg/kg) to SCID mice for 
3 weeks. Then mice were sacriÀced and tumors 
were resected. We extracted RNA from tumors and 
examined the expression of 96 genes related to 5-FU 
using low density array. 
Results: In A549, the tumor weight was 
0.020g±0.011g in control group and 0.019±0.008g 
in S-1 group. TGI (%)[=(1-Average tumor weight 
of S-1 dosed group/ Average tumor weight of 
Control group)*100] was 3.6. The expression of 
TXN, SHMT1 and CMPK genes were signiÀcantly 
prompted by the administration of S-1. In LC6, the 
tumor weight was 0.029g±0.017g in control group 
and 0.020±0.011g in S-1 group. TGI was 32.1. 
The expression of LMO7 and FOLH1 genes were 
signiÀcantly suppressed by the administration of 
S-1. In Lu99, the tumor weight was 0.14g±0.11g 
in control group and 0.092±0.048g in S-1 group. 
TGI was 34.6. The expression of PRSS3 and 
ABCC4 genes were signiÀcantly prompted by 
the administration of S-1. In Lu130, the tumor 
weight was 0.024g±0.016g in control group and 
0.015±0.008g in S-1 group. TGI was 37.5. No 
gene had signiÀcant difference. The expression of 
ABCC1, 2 and TST genes have negative correlation 
with TGI. The expression of TK1 and ERCC2 genes 
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Background: Survivin is a member of Inhibitor of 
Apoptosis (IAP) family and plays signiÀcant role 
of tumorigenesis and proliferation of Non-small 
cell lung cancer (NSCLC). Survivin has at least Àve 
kinds of spliced variants, but the details of their role 
have been unclear. We presented that Survivin-2B 
expression had correlated with good prognosis, and 
Survivin-3B expression had correlated with poor 
prognosis. Thus, we have studied the relationship 
between survivin spliced variants and cell viability 
of non small cell lung cancer.
Methods: To knockdown survivin variants 
expression, small interfering RNAs targeting against 
survivin variants was synthesized. and transfected 
into NSCLC cell lines. The down regulation of 
survivin spliced variants expression at mRNA 
levels were detected by RT-PCR. Cell proliferation 
inhibition rates were determined by MTT assay.
Results: Both non-speciÀc and speciÀc siRNA to 
survivin and its variants could efÀciently suppress 
mRNA levels of survivin and its variants. The 
non-speciÀc siRNA could efÀciently inhibit cell 
proliferation but the speciÀc siRNA could not.
Conclusion: The use of survivin siRNA deserves 
further investigation to cancer therapy but survivin 
variant speciÀc siRNA may be useless.
Keywords: survivin, NSCLC
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P1.095 FOXF1 OVEREXPRESSION 
IN NSCLC CORRELATES WITH 
ACTIVATION OF THE HEDGEHOG (HH) 
SIGNALING PATHWAY
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Mathioudakis2, Ioannis Sarantitis1, Nikolia 
Sotiropoulou1, Vasiliki Bravou1, Helen Papadaki1 
1Anatomy Medicine School, University Of Patras/
Greece, 2General Hospital Of Nikea/Greece
Background: The Hedgehog (Hh) signaling 
pathway is crucial for normal development while 
activation of the pathway in adult tissues is 
associated with the development of different types of 
multistep carcinogenesis and the accumulation of 
EGFR mutations.
Methods: We analyzed intra-tumor heterogeneity 
of EGFR mutations in 38 patients with resected 
mixed type lung adenocarcinoma in accordance 
with the distribution of histological subtypes. Each 
part of each specimen was classiÀed into its lung 
adenocarcinoma subtype, papillary, acinar or BAC, 
by a pathologist. Then, formalin-Àxed, parafÀn-
embedded surgical specimens were microdissected 
in accordance with the pathological subtypes using 
a Leica application solutions laser micro dissection 
(AS LMD) system. We extracted genomic DNA 
from tumor cells obtained from each microdissected 
specimen. The mutations of EGFR, deletions in exon 
19 and point mutation of L858R in exon 21,
were analyzed using mutant-enriched polymerase 
chain reaction (PCR) to increase the sensitivity of 
these mutations. Finally, we evaluated the clinical 
features of the patients harboring intra-tumor 
heterogeneity of EGFR mutations. 
Results: We detected intra-tumor heterogeneity of 
EGFR mutations in 9 of 38 tumors.
EGFR mutations were more common in the BAC 
subtype than the papillary and acinar subtypes, 
although this difference was not statistically 
signiÀcant.
However, we found a statistically signiÀcant 
correlation between intra-tumor heterogeneity of 
EGFR mutations and smoking history (P<0.043).
Conclusion: Intra-tumor heterogeneity of EGFR 
mutations correlates with the distribution of 
histological subtype in mixed-type adenocarcinoma, 
and is associated with smoking history.
Keywords: Non-small cell lung cancer, EGFR, intra-
tumor heterogeneity
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P1.094 SURVIVIN SPLICED VARIANTS 
AND CELL VIABILITY OF NON SMALL 
CELL LUNG CANCER.
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Background: p190-A RhoGAP(Grlf1) is a 172-kDa 
protein that is encorded by GRLF1 gene which locates 
on 19q13.3. In some cancer cell lines, Grlf1 is reported 
to be one of negative regulators of RhoA and inhibit 
cell migration and invasion. This suggests that Grlf1 
protein plays potential tumor suppressor roles. On the 
other hand, EGF – induced Grlf1 phosphorylation has 
been reported to be essential in Ras activation and cell 
proliferation. Recent large scale screening using mass 
spectrometry indicated that Grlf1 is involved in EGFR 
pathways in lung adenocarcinoma cells. To clarify 
the role of Grlf1in lung adenocarcinoma cells is an 
important issue. 
Methods: We used 4 lung adenocarcinoma cell lines, 
A549 (Ras mutation and WT EGFR), 11-18 (L858R 
mutation EGFR), PC-14 (Exon19 deletion EGFR), 
and H1975 (L858R and T790M mutation EGFR) 
respectively. Immunoprecipitation technique was used 
to detect the phosphorylation of p190-A RhoGAP. 
Effects of Grlf1 siRNA knockdown in 4 cell lines were 
analyzed by RT-PCR and MTS assay in Grlf1 mRNA 
expression and cell proliferation. We studied relative 
expression level of Grlf1 mRNA in lung tissue from 67 
human samples (67 tumor and 67 normal) by RT-PCR. 
Results: Phosphorylation of Grlf1 was induced in 
4 cell lines by EGF stimulation. Phosphorylation 
of Grlf1 was inhibited by administration of EGFR-
TKI (geÀtinib) 11-18 and PC-14, but not in A549 
and H1975. The proliferation of A549, 11-18, PC-
14 and H1975 cells was inhibited by Grlf1 siRNA 
knockdown, while no obvious inhibition was 
observed in normal human bronchial epithelial cells. 
mRNA expression level of Grlf1 was conÀrmed by 
RT-PCR in set of 67 human lung tissue samples. 
Conclusion: p190-A RhoGAP is involved in 
epidermal growth factor receptor pathways and 
activates cell proliferation in lung adenocarcinoma. 
Overexpression of Grlf1 mRNA was detected 
from some human lung cancer samples. Further 
conÀrmation for the role of Grlf1 in lung 
adenocarcinoma seems to be important. 
Keywords: p190-A RhoGAP, EGFR, proliferation
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cancer. Recent studies have shown that members of 
Forkhead Box (Fox) family of transcription factors 
are targets of Hh pathway. We have previously 
shown that Hh signaling pathway is activated in 
NSCLC and correlates with histologic subtype, 
prognostic parameters of the tumors as well as 
with the increased expression of FoxM1. The aim 
here was to determine the expression pattern of the 
fox gene FoxF1 in relation to the Hh pathway in 
NSCLC. 
Methods: A total of 80 NSCLC (35 
adenocarcinomas, 22 squamous cell carcinomas, 
17 large cell carcinomas, 3 adenosquamous 
and 3 bronchioloalveolar carcinomas) were 
immunohistochemically analyzed with anti-FoxF1 
antibody on parafÀn tissue sections. Correlations 
with Hh signaling components Shh, Ptch1 and Gli1 
as well as FoxM1 and clinicopathological data were 
evaluated. 
Results: FoxF1 expression was positive in 77.5% 
of tumors while was absent in adjacent non-tumoral 
lung tissue. Cytoplasmic expression of FoxF1 was 
correlated with Hh pathway activation (expression 
of both Ptch1 and Gli1 in the tumor) (p=0.047). 
There was also a statistical signiÀcant correlation 
of lymph node metastasis and FoxF1 nuclear 
expression (p=0.044). Statistical analysis also 
revealed a signiÀcant correlation between nuclear 
FoxF1 expression and histological type of the tumor 
(p=0.005), higher expression in squamous cell 
carcinomas. 
Conclusion: Overexpression of the Fox transcription 
factor FoxF1 is implicated in lung cancer 
pathogenesis and correlates with activation of the Hh 
pathway.FoxF1 seems to play an important role in 
the development of squamous cell carcinomas and 
also controls the potential of lymph node metastasis. 
Keywords: FoxF1, Hedgehog, NSCLC, Shh
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concentrations of 17AAG prior to gamma-irradiation 
(3-5 Gy) sharply enhanced the apoptotic death in 
both the treated lung cancer cell lines and decreased 
their clonogenic ability, whereas without 17AAG 
analogous treatments induced the considerably 
less cytotoxicity and only a slight decrease in the 
clonogenicity. This 17AAG-conferred sensitization 
seemed to be due to down-regulation and/or 
inactivation of pro-survival proteins (e.g. Akt, Bcl-
2, survivin, XIAP) and activation of pro-apoptotic 
proteins (e.g. Bad, GSK-3). In contrast to the 
described responses of the lung cancer cells, 17AAG 
affected neither apoptosis nor clonogenicity in the 
normal lung-derived Àbroblast cultures irradiated 
at the same doses. Besides the enhancement of 
killing of the irradiated lung cancer cells, 50-100 nM 
17AAG considerably reduced their angiogenicity 
that was revealed on down-regulation of the HIF-
1alpha and VEGF expression levels, and on the 
impaired stimulation of EC proliferation by adding 
lung carcinoma cell culture-conditioned medium.
Conclusion: Clinically achievable (nanomolar) 
concentrations of 17AAG allow to selectively 
enhance the cytotoxicity of radiotherapy toward 
the lung carcinoma cells and to suppress the lung 
cancer-associated angiogenesis. So, pharmacological 
inhibition of Hsp90 may become a beneÀcial tool in 
Àght against lung cancer. 
Keywords: radiosensitization, Radiotherapy, lung 
carcinoma, radioprotective response
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P1.098 INVOLVEMENT OF 
CASPASE-3 ACTIVITY AND 
SURVIVIN DOWNREGULATION IN 
CINOBUFOCINI-INDUCED APOPTOSIS 
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Background: Cinobufocini injection is a preparation 
containing water-soluble components of the toad 
skin. The aim of the present study was to investigate 
the apoptosis of human lung adenocarcinoma cell 
line A 549 induced by cinobufocini.
Methods: A 549 or HLF-1(human lung Àbroblast) 
cells were treated with cinobufocini at different 
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P1.097 INHIBITION OF HEAT SHOCK 
PROTEIN 90 ACTIVITY IN HUMAN 
LUNG CANCER CELLS ENABLES TO 
SENSITIZE THEM TO RADIOTHERAPY
Alexander Kabakov, Vladimir Kudryavtsev 
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Background: Human lung carcinomas are often 
resistant to radiotherapy; therefore, development 
of approaches to their radiosensitization is of 
paramount importance. On the other hand, such 
radiosensitization must be selective toward the 
tumor cells without aggravating radiation damage 
to adjacent normal tissues. Here we explored how 
17-N-allilamino-17-demethoxygeldanamycin 
(17AAG), known as a pharmacological inhibitor 
of the heat shock protein 90 (Hsp90) chaperone 
activity, affects responses of human lung cancer 
cells and human normal lung cells to ionizing 
radiation exposure. Our study was mainly aimed at 
comparison of the effects of 17AAG on human lung 
carcinoma cells and normal lung cells subjected 
to radiation exposure modeling the action of 
radiotherapy.
Methods: In vitro cultured human lung carcinoma 
cell lines SQ-5 and A549, and human normal 
lung-derived Àbroblasts were exposed to clinically 
relevant doses (3-5 Gy) of gamma-photon 
irradiation, while some samples were co-treated 
with 10-500 nM 17AAG. Inhibition of the 
intracellular Hsp90 chaperone activity was detected 
on a delay in the Hsp90-dependent reactivation of 
thermally denatured luciferase in the heat-stressed 
transfectants. The cell death/survival was assessed 
in TUNEL, annexin V-staining and clonogenic 
assays. The expression levels of cell death/survival- 
and angiogenesis-related proteins were probed by 
Western blot analyses. The angiogenic potential of 
lung cancer cells was tested in cell-proliferation 
assays with cultured human vascular endothelial 
cells (EC).
Results: In both the lung cancer cell cultures (SQ-5 
and A549), very low (40-150 nM) concentrations 
of 17AAG inhibited the chaperone function of 
Hsp90 and down-regulated the protein levels 
of Bcl-2, survivin, HIF-1alpha and Akt; also, 
the phosphorylation of Akt and its down-stream 
targets such as Bad, XIAP or GSK-3 became 
markedly suppressed. Pretreatments with the same 
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lung adenocarcinoma cells.
Methods: The identiÀcation of methylation-
silenced genes is offering new insights into tumor 
development and may reveal the potential for 
inhibiting DNA methylation as a cancer treatment. 
In this regard, a number of strategies have been 
used to uncover methylation-regulated genes, 
including candidate gene analysis, representational 
difference analysis, restriction landmark genome 
scanning, methylation-sensitive, arbitrarily primed 
PCR, and methylated DNA-binding protein afÀnity 
chromatography. Another strategy, gene expression 
microarrays, is particularly suited for identifying 
candidate, methylation-silenced genes and for 
assessing the downstream, cellular consequences 
of reactivating these genes. Microarray technology 
permits the systematic examination of thousands 
of gene expression changes simultaneously and 
has been used to follow the transcriptional changes 
that accompany disease development and cellular 
responses to environmental stimuli.
Results: we found that 5-Aza-CdR treatment 
sensitized A549 cells to growth inhibition by 
exogenous IFN-Ơ2a, indicating that 5-Aza-CdR 
should be investigated as a potentiator of IFN 
responsiveness in certain IFN-resistant tumors.
DNA cytosine methyltransferase I (DNA MeTase) 
recognizes hemimethylated CpG dinucleotides 
in mammalian DNA and catalyzes the transfer 
of methyl groups to cytosine residues in newly 
synthesized DNA. The methylation of cytosines 
within CpG islands located in core promoter regions 
can negatively regulate the transcription of the 
adjacent genes. The basis for this negative regulation 
may involve recruitment of histone deacetylases to 
methylated CpG islands. Holliday Àrst suggested a 
relationship between abnormal DNA methylation 
and cancer. Subsequently, a number of methylation-
silenced tumor suppressor genes, including 
p16Ink4a, retinoblastoma, estrogen receptor, 
hMLH1, and E-cadherin, have been identiÀed in 
cancer cells in vitro and in vivo. It is becoming clear 
that epigenetic processes constitute a signiÀcant 
factor in the formation of cancer. In this regard, DNA 
methylation abnormalities have been implicated 
in colon cancers in both mouse and human tumor 
model systems. 5-Aza-2v-deoxycytidine (5-Aza-
CdR) inhibits DNA methylation and often is used in 
vitro to induce the reexpression of genes putatively 
silenced by promoter methylation. 5-Aza-CdR is 
substituted for cytosine during replication and is 
recognized by DNA MeTase. Attempted transfer of 
concentrations for 24 and 48 h, respectively. The 
proliferation of cells was detected with the 3-(4, 
5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium 
bromide (MTT) assay. Morphology of cells was 
carried out with scanning electronic microscopy 
(SEM) and Hoechst 33258 staining. The apoptosis 
rate was examined by Áow cytometry. The 
expression of survivin was examined with RT-PCR 
and Western blot assay. The caspase-3 and caspase-7 
activities were detected with caspase colorimetric 
protease assay.
Results: We found that cinobufocini signiÀcantly 
inhibited tumor growth of A 549 cells in a dose- 
and time-dependent manner without damaging 
non-cancerous cells (HLF-1) and induced granular 
apoptotic bodies of A 549 cells. Next, cinobufocini 
increased the percentage of cells in G1 phase and 
decreased the percentage of cells in S phase in A 549 
cells. Furthermore, cinobufocini downregulated the 
expression of survivin mRNA and protein. Finally, 
cinobufocini upregulated caspase-3 activity.
Conclusion: We concluded that cinobufocini induces 
apoptosis of A 549 cells, which is associated with 
the decreasing expression of survivin mRNA and 
protein, increasing caspase-3 activity of A 549 cells.
Keywords: apoptosis, survivin, caspase-3, A 549 cel
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P1.099 INHIBITION OF DNA 
METHYLTRANSFERASE STIMULATES 
THE EXPRESSION OF SIGNAL 
TRANSDUCER AND ACTIVATOR OF 
TRANSCRIPTION 1, 2, AND 3 GENES IN 
LUNG CANCER CELLS
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Background: Inhibitors of DNA methyltransferase, 
typiÀed by 5-aza-2v-deoxycytidine (5-Aza-CdR), 
induce the expression of genes transcriptionally 
down-regulated by de novo methylation in tumor 
cells. We utilized gene expression microarrays to 
examine the effects of 5-Aza-CdR treatment in A549 
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hypomethylation induced the re-activation of tumor 
suppressor genes that were silenced by methylation-
mediated mechanisms, could inhibit proliferation and 
induce differentiation of tumor. Histone deacetylase 
(HDAC) inhibitor, sodium phenylbutyrate (SPB), has 
multiple effects on tumor cells that include inhibition 
of proliferation, induction of differentiation and 
induction or repression of gene expression. The 
aims of this research were as follows:(l)To compare 
the proliferation inhibition and apoptosis effect of 
5-aza-C or SPB used alone or in combination.(2)To 
evaluate the synergistic effect of 5-aza-C and SPB.
(3)To analyze the inÁuence of 5-aza-C and SPB on 
the expression of DNMTl,DNMT3a and HDAC 
when they were used alone or in combination.(4)
To evaluate the effect of 5-aza-C and SPB on re-
activation of genes that are silenced by epigenetics 
mechanisms.
Methods: (1) The antiproliferation and apoptosis 
effect were assayed by ordinary microscopy, 
transmission electron microscopy, Áow cytometry 
and DNA fragment. (2) The synergistic effect 
of 5-aza-C and SPB were observedby 5-aza-C 
combination with SPB or 5-aza-C (or SPB) 
combination with nolatrexed, a thymidylate synthase 
inhibitor, in vivro. (3)The inÁuence of 5-aza-C and 
SPB used alone or in combination on the expression 
of DNMT1, DNMT3a and HDAC was measured by 
RT-PCR. (4) Used microarray to evaluate the effect 
of 5-aza-C and SPB on re-activation of genes that are 
silenced by epigenetics mechanisms.
Results: (1) 5-aza-C used alone or SPB used 
alone or both used in combination all have 
antiproliferation, differentiation and apoptosis 
effect when showed by ordinary microscopy and 
Áow cytometry.Both 5-aza-C used alone and two 
drugs used in combination caused nucleus change 
and DNA fragment when showed by transmission 
electron microscopy and Áow cytometry, but these 
did not show in case of SPB used alone. (2)Results 
showed both 5-aza-C and SPB have markedly 
synergistic effect. (3) DNMT1, DNMT3a and HDAC 
were inhibited 59.3%, 38.6% and 7.4% respectively 
when 5-aza-C used alone; they were inhibited 7.6%, 
4.6% and 60.3% respectively when SPB used alone; 
and they were inhibited 78.9%, 75.0% and 84.4% 
respectively When two drugs used in combination. 
(4) Four genes were down-regulated when 5-aza-C 
used alone, while fourteen genes were activated at 
the same time. Two genes were down-regulated by 
SPB used alone while elevated fourteen genes.When 
two drugs combination, twelve genes were inhibited, 
methyl groups to 5-Aza-CdR, however, covalently 
traps the enzyme to newly synthesized DNA. This 
sequestration ultimately depletes cellular stores of 
DNA MeTase and results in widespread genomic 
hypomethylation. Clinical trials have demonstrated 
promise in the use of 5-Aza-CdR (decitabine) for 
treating leukemia, and current trials are evaluating 
5-Aza-CdR in the treatment of lung and prostate 
cancers. It is plausible that the antitumor activity 
of 5-Aza-CdR results from the induction of 
methylation-regulated tumor-suppressive pathways.
Conclusion: This analysis revealed the induction of 
a set of genes that implicated IFN signaling in the 
A549 cellular response to 5-Aza-CdR. Subsequent 
investigations revealed that the induction of this gene 
set correlates with the induction of signal transducer 
and activator of transcription (STAT) 1, 2, and 3 
genes and their activation by endogenous IFN-Ơ. 
These observations implicate the induction of the 
IFN-response pathway as a major cellular response 
to 5-Aza-CdR and suggests that the expression 
of STATs 1, 2, and 3 can be regulated by DNA 
methylation. Consistent with STAT’s limiting cell 
responsiveness to IFN.
Keywords: DNA methylation, A549 lung 
adenocarcinoma cells, 5-aza-2v-deoxycytidine 
(5-Aza-CdR)
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P1.100 ANTITUMOR EFFECT BASED 
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Background: Both aberrant DNA methylation and 
altered histone acetylation are two key mechanisms 
in epigenetics, which play an important role in 
the development and progression of cancer. DNA 
methyltransferase (DNMT) inhibitor, 5-aza-cytidine 
(5-aza-C), was widely studied because DNA 
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is forming.According to the results of observation 
in normal cells,TGF-ơ1 can regulate Fas/FasL.Fas/
FasL system is a very important apopatosis pathway.
In normal cells,TGF-ơ1 can upregulat Fas,so that 
caspases in Fas/FasL pathway are activated to 
induce cell apoptosis.Moreover,caspases can be 
activated by combination of Fas with FasL.So 
TGF-ơ1 can be regarded as an important factor that 
induces apoptosis and plays the role of abnormal 
cell clearance.But the relationship between TGF-ơ1 
and cancer cell apoptosis is not very clear yet.The 
experimental report on it is very scarce.
Methods: In order to study the relationship of 
TGF-ơ1 and cancer apoptosis,the experiment 
develops according to three steps:step1,siRNA target 
sequences were analysed and synthesized by siRNA 
design software plus Angela siRNA principle.Then 
siRNA vehicle was reformed by the inserting of 
siRNA target sequences to PAVU6+27.Expressing 
Level of TGF-ơ1 was analysed with indirect 
immunoÁuorescence and western blotting after 
siRNA vehicles were transfected into A549 cells.
Step2,the expression level of Fas/FasL and activity 
of caspase-3/caspase-8 was detected in A549 cells 
that had been transfected with pOligo1216 or pOligo 
Control.Then the expression level of Fas/FasL and 
activity of caspase-3/caspase-8 was detected in A549 
cells that had been transfected with TGF-ơ1 protein.
In this way the relationship between TGF-ơ1 and 
Fas/FasL system can be found out.Step3,accoridng 
to the methods of Saitoh and Crowley,HLA-ABDR 
genes in A549 and Calu-6 cells were detected and 
then HLA-A2+A549 cells had been founded.The 
foundation of tumor speciÀc CTL was preliminarily 
studied and explored with MLTC.
Results: 1.SiRNA effects are different.The effects 
of pOligo1858 are the lowest as it meets with 2 
Angela’s principles.While the effects of pOligo1216 
are the highest as it meets with 7 Angela’s principles.
Lung adenocarcinoma strain in which TGF-ơ1 has 
been scilenced is obtained.
2.Expression level of FasL/Fas and activity of 
caspase-3/caspase-8 has no changes after the content 
of TGF-ơ1 is upregulated or downregulated.
3.HLA-ABDR genes in A549 cells are HLA-A30/
HLA-B44/-HLA-DR7/HLA- DR53.While HLA-
ABDR genes in Calu-6 cells are HLA-A01/-HLA-
B08/-HLA-DR17/HLA-DR52.Both A549 cells and 
Calu-6 cells lose their HLA gene but retain HLA-
gene.
4.A549 cell line in which HLA-A2 gene is stably 
expressed is obtained with the transfection of 
and forty-six genes were activated.
Conclusion: (1) Both 5-aza-C and SPB have 
favorable anti antiproliferation and apoptosis 
effect. (2) Both 5-aza-C and SPB have markedly 
synergistic effect, inhibitors of DNMT and HDAC 
may have well foreground in drugs combination 
and overcome muti-drugs resistance. (3)Aberrant 
epigenetics inactivated many genes which suppress 
tumorigenesis, inhibitors of DNMT and HDAC 
can reverse this morbidity. (4) The combination of 
HDAC and DNMT inhibition is very effective (and 
synergistic) in inducing apoptosis, differentiation and 
cell growth arrest, this suggested that methylation 
and deacetylation are coupled with each other.
Keywords: DNA methyltransferase inhibitor, 5-aza-
cytidine, Histone deacetylase inhibitor, sodium 
phenylbutyrate
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P1.101 EXPERIMENTAL STUDY ON THE 
APOPTOSIS REGULATION OF TGF-ȕ1 IN 
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Background: TGF-ơ1 belongs to super family 
of growth factor and its biological effect is very 
common including regulation of cell proliferation 
and differentiation,regulation of embryonic 
development,enhancement of ECM formation and 
suppression of immune-system.TGF-ơ1 is highly 
expressed in many malignant tumor cells including 
lung cancer cells and it can be expressed in matrix 
cells around cancer cells.In current opinion,TGF-ơ 
1 suppresses proto-oncogene such as c-myc to 
inhibit cell growth cycle of G1 stage to S stage.
But in the middle or later stage of cancer when 
the tumor inÀltrating blood vessels has been 
forming,TGF-ơ1 can make tumor cells be of much 
maliganancy by stimulation of tumor inÀltrating 
blood vessls,by enhancement of cell migration and 
by immune suppressing.So the microenvironment 
of growth,inÀltration and metastasis for cancer cells 
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Background: Lack of surface Fas expression 
is a main route for apoptotic resistance which is 
considered an important mechanism of tumorigenesis 
and tumor progression.
Methods: Fas and FasL expressions in 110 non-
small cell lung carcinomas (NSCLCs) were 
investigated to evaluate their roles in pulmonary 
carcinogenesis and to examine the clinico- 
pathologic signiÀcance of Fas expression with its 
relationship with p53 and bcl-2 over- expressions.
Results: Immuno- histochemical analysis using 
tissue microarray demonstrated that a large 
proportion of NSCLC patients (60%) showed lack 
of membranous Fas expression. The Fas- negative 
cases revealed the signiÀcantly lower survival rate 
than Fas-positive ones. Also, the loss of Fas receptor 
expression was found more frequently in advanced 
stage and higher nodal status. FasL protein was 
increased in most NSCLCs (89%) compared to 
normal lungs. p53 and bcl-2 overexpressions showed 
no association with Fas expression.
Conclusion: reduced membranous Fas expression 
as a mechanism of apoptotic resistance is considered 
to play an important part of the pulmonary 
carcinogenesis, which may predict poor survival 
and have a bad prognostic inÁuence. Increased FasL 
expression is thought to be a basis for the immune 
evasion in NSCLCs. The rare bcl-2 overexpression 
suggests that this anti- apoptotic protein is unlikely 
to play a role in the apoptotic resistance of NSCLCs
Keywords: FasL protein, Non-Small- Cell Lung, 
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P1.103 PHARMACOLOGIC INHIBITION 
OF SULF-2 IN LUNG CANCER CELLS 
REVERTS TRANSFORMED PHENOTYPE
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Background: Heparan sulfate proteoglycans 
(HSPGs) bind to multiple growth factors/
pcDNA3.1D/V5.
5.The proliferation trend of PBL from 4 healthy 
donators is obvious and it is consistent with the 
morphology features of tumor speciÀc CTL.
Four groups T lymphocytes are induced with the 
stimulation of tumor cells.The proliferation is 10-
20 times after 5 days MLTC from such above PBL 
that is consistent with proliferation features of 
tumor speciÀc CTL.But there are some disparities 
according to kill test,antibody blocking and the test 
of caspase activity on tumor speciÀc CTL.We make a 
presumption that stimulation times are not enough so 
that the CTL is too little or the activity of CTL is so 
weak that tumor cells can not be killed.
Conclusion: 1.TGF-ơ1 is highly expressed in human 
lung adenocarcinoma that indicates it plays an 
important role in the biological behavior.
2.SiRNA efÀciency can be improved according 
to Angela’s principle when the siRNA targets are 
screening.While the method of none-degeneration 
polypropylene gel can be widely applicated in the 
screening of siRNA recombinant plasmid.
3.In A549 cells TGF-ơ1 losing the function of 
apoptosis inducing and the decreasing of TơR and 
mutation plays an important role possibly.
4.HLA genes are losing and HLA-genes retain.It 
may be another important mechanism of immune 
tolerance and immnue evading for tumor..
5.Some experience and experimental data are 
obtained from the initial study on foudation of tumor 
speciÀc CTL with HLA-A2+adenocarcinma.That is 
very helpful for the optimization of CTL model to 
study immune evading and tolerence in tumor cells
Keywords: Fas/FasL, lung adenocarcinoma, 
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(NSCLC) cell lines and in actual NSCLC tumors from 
patients. Using RNAi knockdown, we demonstrated 
that Sulf-2 promoted the in growth on plastic, growth in 
soft agar and cell migration of several Sulf-2+ NSCLC 
lines. In addition, Sulf-2 knockdown in the same cells 
strongly suppressed xenograft tumor formation in nude 
mice. Previous work (Hossain et al. Glycobiology, 
2010) has shown that PI-88 (a heparin mimetic) inhibits 
the endosulfatase activity of both Sulfs. In the present 
studies, we found that overnight culture of a Sulf-2+ 
NSCLC line (H292 cells) with PI-88 resulted in an 
increase of 6-O-S on the cell surface, as detected by 
phage-display antibody (not shown). In H292 cells with 
Sulf-2 knockdown, PI-88 had a minimal effect on the 
epitope. These results indicate that PI-88 inhibits the 
endogenous sulfatase activity of Sulf-2 and prevents 
the loss of 6-O-S from the cell surface. Furthermore 
PI-88 (3 g/ml) inhibited the growth of H292 cells on 
plastic to the same extent as Sulf-2 knockdown. Similar 
results were obtained with 4 other Sulf-2 positive 
NSCLC cell lines. However, PI-88 did not affect the 
growth of NSCLC cells that lack endogenous Sulf-2. In 
addition, PI-88 inhibited the migration of H292 cells in 
the monolayer scratch assay, recapitulating the effect of 
Sulf-2 knockdown. Finally, PI-88 markedly decreased 
the growth of H292 cells in soft agar but not that of the 
same cells with Sulf-2 knockdown
Conclusion: These Àndings establish the principle 
that the Sulfs can be inhibited pharmacologically in 
lung cancer cells. PI-88 is not a selective inhibitor 
of the Sulfs in that it binds to heparanase and a 
number of growth factors. The experiments above 
control for off-target effects by taking advantage of 
Sulf-2 knockdown cells. More selective inhibitors 
of the Sulfs are potential therapeutic agents for the 
treatment of NSCLC and other cancers in which the 
Sulfs are overexpressed
Keywords: Lung cancer, Sulf-2, Extracellular 
Sulfatase, Pharmacologic Inhibitor
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P1.104 THE MACROPHAGE 
STIMULATING PROTEIN (MSP)-RON/
MST1R AXIS IN MALIGNANT PLEURAL 
MESOTHELIOMA.
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morphogens and regulate their signaling. 
6-O-sulfation (6-O-S) of glucosamine within 
HS-chains is critical for many of these ligand 
interactions. Sulf-1 and Sulf-2, are extracellular 
neutral-pH sulfatases that provide a novel post-
synthetic mechanism for regulation of HSPG 
function by removing 6-O-S from intact HS-chains. 
The Sulfs can thereby modulate several signaling 
pathways, including the promotion of Wnt signaling.
Methods: Cell lines and cell culture: H292, cells 
were from American Type Culture Collection. P-ST, 
which were obtained by exposing primary human 
bronchial epithelial cells to an aqueous extract of 
cigarette smoke (Lemjabbar-Alaoui et al., 2006). All 
cells were grown in RPMI-1640 with 10% FBS and 
penicillin/streptomycin. HSPG sulfation analysis: To 
determine the effects of Sulf-2 inhibition (Knockdown 
or PI-88) on HSPGs, we used a phage-display 
antibody (RB4CD12) (Dennissen et al., 2002) with 
an irrelevant antibody as a control. A Cy3-conjugated 
mouse anti-VSV secondary antibody (Sigma) was 
used and cells were analyzed by Áow cytometry. Cell 
growth, proliferation and survival assays: Cell growth 
was determined by Cell Titer Blue cell viability assay 
(Promega). BrieÁy, 1000 cells were seeded per well 
of a 96 well plate. Cultures were maintained in a 
37°C incubator in a humidiÀed atmosphere of 5% 
CO2. Medium was removed and replaced with fresh 
medium every 2 days. PI-88 was added on day 0 and 
replenished at the time of medium change every 2 
days. After 6 days of incubation at 37ºC, counts of 
viable cells were determined with the Cell Titer Blue 
assay. Monolayer wound healing assays: Cells were 
grown to conÁuency on 6-well plates. Scratches were 
made with a pipette tip. Cell migration was quantiÀed 
by measuring the width of the wounds at 0, 24, 48 
and 72 hours. Colony formation in soft agar: One 
thousand cells were seeded into 60-mm dishes in a 
suspension of 0.5% bacto-agar (Difco) in medium 
supplemented with 10% fetal calf serum on top of a 
bed of 0.5% bacto-agar (Difco) in the same medium. 
Cells were plated on top of 1 ml of 0.5% agarose. 
Plates were incubated at 37ºC in 5% CO2. Medium 
was removed and replaced with fresh medium every 
2 days. PI-88 was added on day 0 and replenished at 
the time of medium change every 2 days. Colonies 
that had formed after 15 to 30 days incubation were 
counted. All cell lines were seeded in triplicate and all 
experiments were repeated a minimum of three times.
Results: In previous work (Lemjabbar-Alaoui et 
al. Oncogene, 2010), we have shown that Sulf-2 is 
overexpressed in a set of non-small cell lung cancer 
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pathway and paracrine activation of macrophages. 
The MSP-RON axis may be a novel therapeutic 
target in mesothelioma.
Keywords: mesothelioma, receptor, Prognosis, 
target
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Background: IL-20 is a pleiotrophic member of the 
IL-10 family and plays a role in skin biology and the 
development of haematopoietic cells. It has potent 
angiogenic, inÁammatory and chemo-attractive 
characteristics with an involvement in rheumatoid 
arthritis and atherosclerosis. It activates STAT3 
through two receptor complexes, IL-20RA/IL-20RB 
and IL-22R1/IL-20RB, which in turn promotes 
proliferation, apoptosis resistance and immune 
tolerance. Recently, IL-20 has been demonstrated to 
have potential anti-angiogenic effects in non-small 
cell lung cancer (NSCLC) by down regulating COX-
2. 
Methods: The expression of IL-20 and its cognate 
receptors (IL-20RA/B and IL-22R1) was examined, 
at both the protein and mRNA level, in a series of 
resected fresh frozen tumour normal matched tissue 
samples from NSCLC patients. In addition, the 
expression of IL-20 family members was examined 
at the mRNA level in a panel of NSCLC and normal 
bronchial epithelial cell lines. To determine if this 
family was epigenetically regulated in our cell 
lines, the effect of a histone deacetylase inhibitor, 
Trichostatin A (TSA-250 ng/mL) and a DNA 
methyltransferase inhibitor, 5-aza-2-deoxycytidine 
(DAC-1 ƫM), was also studied. A ChIP assay was 
performed to investigate the direct effect of TSA on 
the IL-20 promoter region. The effect of recombinant 
IL-20 on cellular proliferation and VEGF expression 
was also determined. 
Results: The expression of IL-20 and its receptors 
were frequently deregulated in NSCLC. The mRNA 
Hospital/Ireland, 2Zurich University/Switzerland, 
3Cardiothoracic Surgery, Nyu School Of Medicine/
United States Of America, 4Centre For Cancer 
Research And Cell Biology, Queen’s University 
Belfast/United Kingdom, 5Dept Of Medicine, 
Laboratory Of Clinical Oncology, Hospital Of 
Vercelli/Italy, 6St James’s Hospital And Trinity 
College Dublin, Ireland/Ireland
Background: Evidence supports a role for 
macrophage activity in mesothelioma genesis. 
Malignant pleural mesothelioma (MPM) is resistant 
to chemotherapy, and receptor tyrosine kinases 
(RTK) represent novel therapeutic targets. We 
previously identiÀed macrophage stimulating 1 
receptor (MST1R/RON) as frequently activated 
in MPM. Immunohistochemistry (IHC) studies 
found high positivity for RON staining was an 
independent predictor of favourable prognosis (J 
Clin Oncol 28:15s, 2010 (suppl; abstr 10583). We 
therefore hypothesized that the MST1R/RON ligand, 
Macrophage stimulating protein (MSP), may also 
play a role in MPM. 
Methods: Expression and function of MSP was 
examined in MPM. IHC was performed for MSP on 
a TMA array of FFPE samples resected from 352 
patients. MSP was also immunoprecipated from 
MPM cell culture medium and detected by Western 
Blot analysis. ELISA was used to study MSP in 
serum derived from n=20 patients with MPM vs 
n=20 normal. Expression of RON was analysed on a 
second set of FFPE samples of MPM.
Results: Immunoprecipitation and western blot 
analysis detected MSP in culture medium from 
MPM cell lines. The presence of MSP message was 
conÀrmed by RT-PCR in MPM cells. Recombinant 
MSP did not promote proliferation but was found 
to reduce migration of MPM cells. By ELISA, sera 
from patients with MPM contained immunoreactive 
MSP, but levels were not signiÀcantly different from 
control patients. IHC was performed on a TMA array 
of FFPE samples. 71% showed MSP expression 
as follows: weak (32%), moderate (38%), intense 
(21%). Most mesotheliomas were double positives 
(RON/MSP), small subpopulations expressed MSP 
or RON alone, and a fraction were double negatives. 
Correlation of the IHC scores with clinico-
pathological and outcomes variables is ongoing.
Conclusion: RON staining is an independent 
predictor of favourable prognosis. MSP is frequently 
expressed in MPM. Co-expression of MSP and RON 
in MPM cells may indicate an autocrine signalling 
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Background: The expression of the co-stimulatory 
molecule CD28 and death receptor CD95 on T cells, 
which change with age, are considered as important 
immunological parameters of immunosenescence. 
It is well established that CD28 and CD95 are 
associated with tumorgenesis and tumor progression, 
but the relationship between the age-related changes 
of these two immunological markers and cancer in 
the elderly is largely unknown.
Methods: The levels of CD28 and CD95 mRNA 
in peripheral blood mononuclear cells (PBMCs) 
from sixty-three elderly patients (aged 60 years) 
with primary non-small cell lung cancer (NSCLC) 
were analyzed by real-time Áuorescence-based 
quantitative polymerase chain reaction (FQ-PCR). 
In addition, twenty young patients (aged <60 years) 
with NSCLC, thirty elderly healthy donors and thirty 
young healthy donors were enrolled as controls.
Results: CD28 mRNA levels were signiÀcantly 
lower and CD95 mRNA levels were signiÀcantly 
higher in elderly patients with NSCLC than in the 
other groups. Similar results were found in elderly 
healthy donors comparing with young healthy 
donors. By Logistic regression analysis an increased 
risk of NSCLC was markedly associated with aging, 
down-regulation of CD28 mRNA and up-regulation 
of CD95 mRNA, and CD28 mRNA had an obvious 
negative correlation with the CD95 mRNA. In 
addition, the mRNA levels of CD28 and CD95 in the 
peripheral blood of the elderly patients was closely 
associated with the tumor node metastasis (TNM) 
stages, grade of cell differentiation and lymph node 
metastasis status, but not related to pathological 
types.
Conclusion: The results suggest a close relationship 
between T cell senescence and NSCLC tumour 
progress in the elderly, and that up-regulation of 
CD28 mRNA or down-regulation of CD95 mRNA 
in peripheral blood T cells may play an important 
role in inhibiting oncogenesis and development of 
primary NSCLC in the elderly.
Keywords: Non-small Cell Lung Carcinoma, 
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level of IL-20RB was signiÀcantly elevated in 
NSCLC tumours compared with normal tissue 
(p<0.01). At the protein level, two receptors, IL-
20RB and IL-22R1, were signiÀcantly increased 
(p<0.01) in the patient tumour samples. IL-20 and its 
receptors were found to be epigenetically regulated 
through histone post-translational modiÀcations 
and DNA CpG residue methylation in NSCLC and 
normal bronchial epithelial cell lines. Treatment 
with DAC reactivated the expression of IL-20RA in 
an adenocarcinoma (A549) cell line (p<0.01). IL-
20 treatment increased the cellular proliferation of 
a squamous cell line (SK-MES-1), however there 
was no effect observed in either A549 or a normal 
cell line (HBEC4). In addition, treatment with 
recombinant IL-20 resulted in decreased expression 
of VEGF (HBEC4, A549 – p<0.05) and its receptors 
(VEGFR1, VEGFR2 and Nrp-1) at the mRNA level. 
Conclusion: While the anti-angiogenic properties 
of IL-20 require further clariÀcation, this study 
demonstrates that the IL-20 family are epigenetically 
regulated by histone post-translational modiÀcations 
and DNA CpG methylation in NSCLC and normal 
cell lines. Our results for IL-20RA at the protein 
and mRNA level in the A549 cell line, conÀrm 
those of a methylation study, which observed a lost 
of IL-20RA expression in approximately 26% of 
samples studied. Although this had no association 
with survival, IL-20RA is found on the lung cancer 
susceptibility locus 6q23-25 and may be associated 
with sporadic lung cancer cases. We have also shown 
that IL-20 possesses anti-angiogenic properties 
within the setting of NSCLC by down regulating 
VEGF expression. IL-20 is signiÀcantly up regulated 
by treatment with TSA and IL-20RA is reactivated 
by DAC. Therefore, our results would suggest that 
targeting this family via epigenetic means may be 
a viable therapeutic option in the treatment of lung 
cancer.
Keywords: Non-small cell lung cancer, IL-20, 
VEGF, epigenetics
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with some clinicopathologic features of patients. 
Therefore, methylation assays offer the promise of 
a noninvasive test for detecting cancer. In addition, 
the identiÀcation of cancer-speciÀc epigenetic 
changes may be useful for molecular classiÀcation 
and disease stratiÀcation. Genomic approaches 
in NSCLC have the potential to advance our 
understanding of underlying disease biology, to 
improve current prognostic and treatment paradigms, 
to identify new targets for treatment, ultimately 
improving survival in patients with NSCLC and 
providing an opportunity for personalized medicine.
Keywords: Quantitative Methylation, NSCLC, 
pyrosequencing
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P53 AND ACTIVATION OF CASPASE 3
Shiying Zheng1, Hong Li2, Dong Jiang1 
1Department Of Cardio-thoracic Surgery, The First 
AfÀliated Hospital Of Soochow University/China, 
2Department Of Geriatrics, The First AfÀliated 
Hospital Of Soochow University/China
Background: Arsenic trioxide (As2O3) can induce 
clinical remission in patients suffering from acute 
promyelocytic leukemia, through induction of 
apoptosis and activation of caspases.Apoptosis is 
regulated by gene products, which are conserved 
from nematodes to mammals. We investigated the 
potential use of As2O3 in human lung cancer and its 
possible mechanisms. 
Methods: Human lung cancer cell lines A549 were 
treated with various concentrations (0.1 to 100 ƫM) 
of As2O3 for 24-72 hours. Apoptosis was determined 
by acridine orange staining, Áow cytometry and 
DNA fragmentation. The protein levels of p53, 
p21waf1/cip1, c-myc, bcl-2 and bax were detected 
by Western blotting. Effects of As2O3 on caspase 
3 protease activity, its protein concentration and 
cleavage of poly-ADP ribose polymerase (PARP) 
were also studied.
Results: Triptolide inhibited cell growth in A549 
cells. We examined the antiproliferative effect of 
As2O3 on human gastric cancer cell lines A549 by 
exposing them to different concentrations of As2O3 
for 24 to 72hrs. Cell viability was determined by 
MTT assay. When A549 cells were exposed to 
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Background: Detection of cancer-speciÀc 
methylation changes heralds an exciting new 
era in the diagnosis of cancer, its prognosis, and 
therapeutic responsiveness, and warrants further 
investigation in NSCLC. Aim of our study was to 
examine quantitative methylation patterns using 
pyrosequencing in multiple genes in tumor, matching 
normal lung tissue and blood of patients with non-
small cell lung cancer. We also tracked possible 
relationships between clinicopathologic features of 
patients and DNA methylation. 
Methods: Primary tumor samples (n=65), 
corresponding nonmalignant lung tissues (n=65) and 
blood samples (n=51) were obtained from NSCLC 
patients, treated with curative resectional surgery. 
Hypermethylation status was quantiÀed at multiple 
CpG sites within each promoter in multiple genes- 
SOX1, RASSF1A, HOXA9, CDH13, MGMT, ESR1 
and DAPK by pyrosequencing.
Results: Our results showed signiÀcant difference 
between tumor methylation, normal tissue and blood 
samples for the most of the genes. Methylation in 
tumors was signiÀcantly higher then in normal lung 
for SOX1, DAPK, RASSF1A, HOXA9 and CDH13. 
Tumor samples had signiÀcantly higher methylation 
than blood samples for all genes except DAPK. 
Tumor hypermethylation was more frequently for 
adenocarcinoma at CDH13 and ESR1. A higher 
proportion of SSC tumors were hypermethylated 
at HOXA9 and SOX1 compared to other types of 
NSCLC. Patients with stage four more likely had 
hypermethylation at MGMT and patients with 
hypermethylation at HOX9 more likely had stage 
two and three tumors. Gender was associated with 
hypermethylation at CDH13 with females being 
more likely to have hypermethylated tumors.
Conclusion: Our results show that elevated 
methylation levels observed in genes SOX1, 
RASSF1A, HOXA9, CDH13, MGMT, ESR1 
and DAPK were cancer-speciÀc and associated 
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Background: Lung cancer is one of the most 
common malignancies, and its overall incidence 
is increasing. Although conventional therapy uses 
modalities such as surgery or chemotherapy, the 
therapeutic effects are poor, with a 5-year survival 
rate of around 14%, due to widespread metastasis to 
various organs. In the murine system, introduction 
of the co-stimulatory molecule B7-1 into a tumour 
can increase anti- tumour immunity and eradicate 
tumour growth.8–10 Few investigations have 
been conducted with human tumours to examine 
the effect of B7-1 transduction on the generation 
of CTL. It has been shown, however, that the 
stimulation of autologous or allogenic lymphocytes 
by B7- transduced melanoma cell lines and cervical 
carcinoma cell lines expressing viral antigens 
induces a proliferative response and cytotoxicity 
against tumours. To evaluate autologous lymphocyte 
responses to B7-1-transduced human lung cancer 
cells, Interaction between the co-stimulatory 
molecule B7-1 (CD80) on antigen-presenting cells 
and its counter-receptor CD28 on T lymphocytes 
plays a key role in the induction of cellmediated 
immune responses. Many tumours, including lung 
cancer, lack expression of B7-1 and this has been 
suggested to contribute to the failure of immune 
recognition of these diseases. Based on this 
knowledge, we hypothesized that the co-stimulatory 
signal delivered through the B7-1 molecule 
expressed on lung cancer cells using replication 
deÀcient adenovirus vector would induce efÀcient 
tumour immunity in T lymphocytes. 
Methods: To evaluate this hypothesis, we 
constructed two adenovirus vectors: AdCMVhB7 
(an E1- deleted-Ad5-based vector containing human 
B7-1 cDNA driven by cytomegalovirus immediate 
early promoter and enhancer) and AdNull (same 
vector as above without expression of exogenous 
gene) as control. Using these adenovirus vectors, 
As2O3 ranging from 0.1ƫM to 100ƫM, the growth 
of both cell lines was inhibited in a dose dependent 
manner.
As2O3 induced apoptosis in A549 cells following 
a concentration- and time-dependent manner. 
Morphological changes typical of apoptosis, 
including chromatin condensation, fragmentation 
of the nuclei, and formation of apoptotic bodies 
were observed in A549 cells after 12 hours with the 
concentration of more than 1 ƫM. The percentage 
of apoptotic cells increased in a time- and dose-
dependent manner. Approximately 25% of the 
A549 cells underwent apoptosis with treatment 
of 10 ƫM As2O3 for 24 hours. Apoptosis was 
further conÀrmed by agarose gel electrophoresis 
of the genomic DNA. A characteristic pattern of 
nucleosomal-sized ladders of DNA fragments, which 
characterized programmed cell death, was detected 
after 24 hours exposure to As2O3 (1ƫM, 10ƫM) in 
A549 cells. FACS analysis showed that As2O3 could 
induce apoptosis in A549 cells, with a typical sub-
diploid peak on the DNA histogram.
Treatment resulted in a marked increase in p53 
protein level as early as 4 hours. Co-incubation with 
p53 antisense oligo-nucleotide suppressed As2O3-
induced intracellular p53 over-expression and 
apoptosis. As2O3 increased the activity of caspase 
3, with appearance of its p17-kD peptide fragment, 
and cleavage of PARP with appearance of the 85-kD 
cleavage product, both in parallel with the induction 
of apoptosis. The tripeptide caspase inhibitor zVAD-
fmk or the speciÀc caspase 3 inhibitor DEVD-fmk 
both partially suppressed As2O3-induced caspase 3 
activation and apoptosis.
Conclusion: Our study and others have shown that 
lung cancer cells were more sensitive to As2O3 
than other tumors. As2O3 inhibits cell growth and 
induces apoptosis in lung cancer cells, involving 
p53 overexpression and activation of caspase 3. The 
potential use of As2O3 in treatment of lung cancer is 
worth further exploration. 
Keywords: Arsenic trioxide (As2O3), Human lung 
cancer cell lines A549, cell growth, apoptosis
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Background: Protein phosphatase 2A (PP2A) is a 
tumor suppressor enzyme, whose activity is inhibited 
by the oncoprotein I2PP2A (inhibitor 2 PP2A) in 
NSCLC cell lines. Our structural, molecular, genetic, 
and pharmacologic studies reveal that PP2A activity 
is regulated by direct and selective binding of C
18
-
ceramide to I2PP2A, which then relieves PP2A, 
allowing it to exert its tumor suppressor function. 
The freed C
18
-ceramide is then released in the serum.
Methods: NSCLC cell line and xenograft studies 
were done by standard procedures. Cell lines and 
A549 xenografts were treated with FTY720, a 
sphingosine derivative that targets I2PP2A, to 
demonstrated reduction in tumor proliferation and 
induction of apoptosis. We also measured C
18
-
ceramide in the serum of the treated mice by liquid 
chromatography/mass spectrometry (LC/MS). 
Additionally, primary human NSCLC and adjacent 
normal lung were examined for I2PP2A expression 
by immunohistochemistry (IHC). 
Results: We found that I2PP2A is highly expressed, 
while C
18
-ceramide levels are down-regulated in 
the majority of primary human NSCLC specimens 
compared to their adjacent normal lung tiussues. 
FTY720 was found to directly bind to I2PP2A through 
a ceramide-binding domain resulting in inhibition of 
growth in the tested human lung cancer cell lines and 
A549-Xenograft-derived tumors. The reduction in 
tumor size in senograft studies were accompanied by 
an increase in serum C
18
-ceramide levels. 
Conclusion: Our studies suggest I2PP2A is a key 
intracellular therapeutic target for NSCLC. I2PP2A 
levels can be routinely estimated by IHC and therefore 
the presence or absence of this target can be estimated 
in diagnostic biopsy specimens. FTY720 targets 
I2PP2A and has been shown to decrease proliferation 
and enhance apoptosis in NSCLC cell lines and 
xenograft studies. Tumor response to FTY720 can be 
measured by LC/MS in serum. Based on these novel 
data a phase II clinical trial with FTY720 for the 
treatment of patients with previously treated advanced 
NSCLC that overexpress the I2PP2A oncoprotein is 
to be initiated soon. Detailed preclinical, xenograft 
studies, and the design of the clinical trial will be 
presented at the meeting. 
Keywords: oncoprotein, Non small cell lung cancer, 
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efÀcient generation of tumour immunity in T 
lymphocytes was studied using primary cultured 
lung cancer cells and peripheral blood lymphocytes 
(PBL) obtained from patients with lung cancer.
Results: Inoculation of lung cancer cells with 10 
multiplicity of infection of AdCMVhB7 resulted 
in rapid and efÀcient cell surface expression of 
B7-1 molecule (> 90% of cells at 24 h). Cytolytic 
activity of PBL in 51Cr-release assay (E/T = 40) 
demonstrated that effector lymphocytes induced 
by hB7-1 (+) lung cancer cells treated with 
AdCMVhB7could lyse parental lung cancer cells 
hB7-1 (–). In contrast, effector lymphocytes induced 
by lung cancer cells treated with AdNull as control 
virus or PBS as control could not lyse parental 
lung cancer cells at all. Furthermore, cytolytic 
activity of the effector lymphocytes induced by B7-
1- transduced lung cancer cells was inhibited by 
addition of anti-CD3 antibody.
Conclusion: These data demonstrate that primary-
cultured lung cancer cells treated with AdCMVhB7 
would efÀciently generate tumour immunity in T 
lymphocytes. Adenovirus- mediatedhB7-1 gene 
transfer may be a useful means for gene therapy of 
lung cancer using adoptive immunotherapy.
Keywords: CTL, gene therapy, B7-1 (CD80), Lung 
cancer
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
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Background: MicroRNAs (miRNAs) are a family 
of small, non-coding RNAs, regulating the activity 
of ~20-30% of human genes, including numerous 
cancer genes. We have recently identiÀed hsa-
miR-218 as a potential tumour suppressor miRNA in 
lung cancer, located within a region of genomic loss 
in lung cancer with concordant reduction in miR-
218 expression (Davidson et al, PLOS One, 2010). 
Therefore the aims of this study were to ascertain the 
functional effect of miR-218 on cancer phenotypes 
in cell lines and identify the genes and pathways 
regulated by miR-218. 
Methods: A549 lung cancer cells were transiently 
transfected with pre-mir-218 (over-express miR-218) 
or a scrambled pre-mir (negative control) for 24hrs-
48hrs. Phenotype assays (proliferation, matrigel 
invasion and anchorage independent growth using 
soft agar) were performed. Post-transfection global 
mRNA expression was measured using Illumina’s 
HumanHT-12 v3 arrays (as per manufacturers 
protocol), analysed using BRB-ArrayTools (Version 
6.3.0-Beta_3; ) and overlayed with predicted miR-
218 targets identiÀed from at least two prediction 
algorithms.
Results: Our preliminary data has demonstrated 
that over-expression of miR-218 in A549s 
was associated with a reduction in cancer cell 
proliferation (28% reduction at Day 3; p<0.05) and 
invasion (51% reduction). However, no effect was 
observed in anchorage independent cell growth. 
A total, of 578 target genes were identiÀed by 
two or more prediction algorithms, including 
numerous oncogenes, such as KIT, RET, BCL9, 
DCUN1D1 and PDGFRA. Data from miR-218 target 
identiÀcation will be presented at the meeting. 
Conclusion: The preliminary data from this 
study supports a role for miR-218 in tumour cell 
proliferation and invasion, and suggests miR-218 
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Background: The functions of large non-coding 
RNAs (ncRNA) have remained elusive in many 
cases. MALAT-1 (Metastasis-Associated-in-Lung-
Adenocarcinoma-Transcript-1) is a ncRNA, that is 
highly expressed in several tumor types.
Methods: Overexpression and RNA interference 
(RNAi) approaches were used for the analysis of 
the biological functions of MALAT-1 RNA. Tumor 
growth was studied in nude mice. For prognostic 
analysis MALAT-1 RNA was detected on parafÀn 
embedded lung cancer tissue probes (n=352) using 
in-situ hybridization.
Results: MALAT-1 was highly expressed in 
several human non-small cell lung cancer cell 
lines. MALAT-1 expression was regulated by 
an endogenous negative feedback loop. In A549 
NSCLC cells, RNAi mediated suppression 
of MALAT-1 RNA suppressed migration and 
clonogenic growth. Forced expression of MALAT-1 
in NIH 3T3 cells signiÀcantly increased migration. 
Upon injection into nude mice, NSCLC xenografts 
with decreased MALAT-1 expression were impaired 
in tumor formation and growth. In-situ hybridization 
on parafÀn embedded lung cancer tissue probes 
revealed that high MALAT-1 RNA expression in 
squamous cell carcinoma of the lung was associated 
with a poor prognosis.
Conclusion: These data indicate that MALAT-1 
expression levels are associated with patient 
survival and identify tumor promoting functions of 
MALAT-1. 
Keywords: Non-small cell lung cancer, tumor 
formation and growth, MALAT-1, RNA interference
S772 Copyright © 2011 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
reaching conÁuence. Hereafter, they were splitted 
and transfection of siRNA was performed in a non-
viral manner with speciÀc siRNA targeting SRF in 
both cell lines .Cells treated with unspeciÀc siRNA 
(SCR siRNA) served as controls. qRT-PCR was 
performed for mRNA expression levels. RNA from 
transfected cells was isolated, reverse transcribed 
and used for qRT-PCR. Normalized gene expression 
was calculated by the _DCt method using GAPDH 
as a reference, furthermore transfection efÀciency 
was evaluated by Áow cytometry with FITC labeled 
SCR siRNA. The analysis of cell proliferation was 
determined with a CASY cell counter 3 days after 
transfection with SRF or SCR siRNA
Results: Transfection of the NSCLC cell lines 
with increasing concentrations of FITC labelled 
SCRsiRNA resulted in an increasing cell 
Áuorescence, determined by Áow cytometry. 
Furthermore, transfection of the NSCLC cell lines 
A549 and NCI-H460 with speciÀc siRNA against 
SRF resulted in a highly signiÀcant reduction of the 
intracellular SRF-mRNA concentration, respectively. 
CASY conÀrmation of cell viability demonstrated 
a highly signiÀcant survival of the cell lines treated 
with unspeciÀc siRNA similareley in contrast to 
application of speciÀc siRNA. 
Conclusion: These results demonstrate a reliable 
transfectability of two different NSCLC subtypes by 
siRNA in a non viral manner offering a multitude of 
therapeutic targets by different siRNA. This might 
be a valuable capacity of NSCLC- cells offering 
different and valuable therapeutic capacities. 
Furthermore the highly signiÀcant knock-down of 
intracellular SRF and the subsequently following 
senescence conÀrmed by qRT-PCR and CASY 
respectively by speciÀc siRNA might offer some new 
therapeutic targets in the therapy of NSCLC. 
Keywords: siRNA, Serum Response Factor, 
NSCLC, liposomal transfection
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OVEREXPRESSION INCREASES 
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may regulate cancer-related target genes. Combined 
with our recent report, this study provides further 
support for miR-218 as a strong candidate tumour 
suppressing miRNA in NSCLC.Supported by: National 
Health and Medical Research Council, Cancer Council 
Queensland, Australian Lung Foundation, The Prince 
Charles Hospital Research Foundation
Keywords: microRNA, NSCLC, miR-218
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Background: Serum response factor (SRF) is a 
well known transcription factor thereby involved 
in a multitude of gene regulation processes. In the 
scope of cancer therapy it might be of particular 
interest because it is hardly involved in replicative 
transactions with a known relation of reduced 
cell division connected with a diminished cellular 
SRF activity. Although its prospective character 
has been known for a long time, no sufÀcient way 
could be found for its potential use in the therapy of 
NSCLC. Short interfering RNA (siRNA) could Àll 
this deÀciency. Determined by its highly speciÀc 
character, it might be of an outstanding interest in 
the Àeld of new concepts in the therapy of unsolved 
therapeutic problems of NSCLC so far. This study 
deals with questions of siRNA transfection efÀciency 
by liposomal and therefore non-viral transfection 
of NSCLC cell lines and the power of siRNA to 
transiently block cell division in NSCLC cell lines 
by SRF-inhibition. 
Methods: NSCLC cell lines A549 (squamous 
epithelial tumour) and NCI-H460 (adeno carcinoma) 
were cultured under standard conditions for 
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Background: Personalising therapy for non-small 
cell lung cancer has been validated as an effective 
treatment paradigm. Somatic gene alterations 
confer sensitivity to inhibition of growth survival 
pathways irrespective of underlying resistance to 
chemotherapeutic agents, and enables efÀcient 
activation of BCL-2 family-dependent pro-apoptotic 
signalling. In platinum resistant cancers this 
signalling is blocked, however the intrinsic pathway 
remains sensitive to exogenous BH3 death signals. 
Methods: Microarray proÀling coupled to focused RNAi 
screening was used to reveal those resistance genes 
involved in derepression of proapoptotic BCL-2 family 
proteins. Analysis of the effect of MYRIP expression on 
survival was generated from studying 6 NSCLC datasets 
from Gene Expression Omnibus which were paired with 
survival time and status information. The toxic effect of 
MYRIP depletion on NSCLC and non-cancerous lung 
cells was determined by cell viability and clonogenic 
assays. Apoptotic induction was examined by caspase 
and PARP cleavage experiments, and fractionation of 
mitochondrial proteins. FACS analysis was used to 
examine effects on cell cycle.
Results: MYRIP/Slac2c, a gene hitherto associated 
with vesicle trafÀcking but not apoptosis, was 
overexpressed in platinum resistant NSCLC cells. 
In particular, cisplatin resistant cells expressed a 
heavier protein isoform of MYRIP which appeared 
to be associated with the mitochondria. Silencing 
of MYRIP induced BIM and BAX/BAK-dependent 
mitochondrial apoptosis which was selective for 
NSCLC, but not non-cancerous lung cells. In 
addition, loss of MYRIP induced S-phase arrest.
Conclusion: Overexpression of MYRIP is an 
independent, poor prognostic factor suggesting that 
targeting these genes may be therapeutically relevant. 
In summary, MYRIP exhibits a previously unknown 
survival function associated with suppression of pro-
apoptotic BCL-2 family proteins and maintenance of 
cancer cell proliferation and survival.
Keywords: Novel Target Discovery, drug resistance, 
apoptosis
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Background: Ơ-Catulin is an 82-kDa Ơ-catenin-related 
protein containing regions of strongly homology with 
Ơ-catenin and vinculin. It has been known to regulate 
NF-ƩB through directly binding IKK-ơ and confer 
resistance to apoptosis, but little is known about the 
functional role of Ơ-catulin in cancer progression. 
Methods: Knockdown and overexpression of Ơ-catulin 
gene were performed in lung cancer cells A549. The 
cell proliferation was determined by MTS assays. 
Cellular senescence was analyzed by a senescence-
associated ơ-galactosidase activity staining. Cell 
invasion and migration assays were done in 24-
well Transwell polycarbonate Àlters coated with or 
without Matrigel. To determine the actin cytoskeleton 
reorganization, cells were stained with rhodamine-
conjugated phalloidin to visualize F-actin distributions. 
Density and length of Àlopodia were analyzed by 
MetaMorgh imaging software. 
Results: In the present study, we found that 
knockdown of Ơ-catulin gene in lung cancer cells A549 
dramatically decreases cell proliferation and contributes 
to cellular senescence. Ơ-Catulin overexpression 
doesn’t inÁuence cell proliferation but signiÀcantly 
enhance cancer cell migration and invasion by 
increasing the Àlopodia density and length in A549 
cells. To dissect the underlying mechanism of Ơ-catulin-
promoted cancer cell migration and invasion, we found 
that Ơ-catulin increases the expression of Àbronectin 
and Àbronectin-associated integrin Ơ5ơ1 and Ơvơ3. 
Contrarily, Ơ-catulin knockdown only decreases the 
expression of Àbronectin and Ơvơ3. We also found that 
NF-ƩB inhibitor, Bay117082, decreases the expression 
of integrin ơ3 and suppresses Ơ-catulin-promoted cell 
migration. Blocking Ơvơ3 signaling pathway by using 
neutralizing antibody effectively inhibits Ơ-catulin-
promoted cell migration.
Conclusion: Taken together, our present study 
revealed that Ơ-catulin might through regulating NF-
ƩB activity to increase the expression of Àbronectin 
and Ơvơ3, and then promote cell migration. 
Keywords: migration, integrin, Àlopodia
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P1.115 THE RAB27A EFFECTOR MYRIP 
IS AN ESSENTIAL REGULATOR OF 
SURVIVAL IN NON-SMALL CELL LUNG 
CANCER CELLS
Alex Chacko1, Puthen Jithesh2, Claire Grills3, Nyree 
Crawford1, Ian Paul1, Martin Barr4, Kenneth J. 
O’Byrne4, Dean A. Fennell1 
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kinases with SP600125, PD098059, and LY294002, 
respectively, showed a 2-fold increase in apoptosis 
when combined with TRAIL. The activation of 
MAPK p38 on the other hand was pro-apoptotic, 
since its inhibition with SB203580 resulted in a 
reduction of TRAIL-induced apoptosis in H460 
cells. In resistant A549 cells, however, Akt, ERK, 
p38 MAPK, and JNK1/2 activation appeared to have 
anti-apoptotic activity. Furthermore, in these cells 
an increase in IƩBƠ phosphorylation was observed 
that was not seen in H460 cells, where levels of 
phosphorylated IƩBƠ decreased after 1 hour that 
correlated with cleavage of RIP.
Conclusion: Thus suppression of NFƩB activation 
could be associated with TRAIL sensitivity. PepChip 
kinase arrays, revealed the activation of kinases that 
are involved in cell migration, such as Rho/Rock in 
A549 cells, and further investigations are ongoing. 
In conclusion, we observed differential TRAIL-
dependent activation of p38 MAPK, JNK1/2, ERK, 
Akt and IƩBƠ in sensitive and resistant NSCLC 
cells as well as in pathways that regulate migration. 
The relationship with TRAIL antitumor activity is 
currently further explored.
Keyword: TRAIL NSCLC kinases
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P1.117 TARGETING THE IGF-1R 
SIGNALLING PATHWAY IN NON-SMALL 
CELL LUNG CANCER (NSCLC)
Lydia Forde1, Steven G. Gray1, Kathy Gately1, 
Kenneth J. O’Byrne2 
1Department Of Clinical Medicine, Trinity College 
Dublin/Ireland, 2Oncology, St James’s Hospital/
Ireland
Background: Non-small cell lung cancer (NSCLC) 
is the commonest cause of cancer related deaths 
worldwide and has a very poor prognosis. Research 
into cell signalling pathways has paved the way 
for the creation of targeted therapies for patients. 
Insulin-like growth factor receptor (IGF-1R) 
overexpression has been identiÀed in several tumour 
types and protects cells from apoptosis-inducing 
agents, including hypoxia and anti-cancer drugs. 
The IGF-1R pathway has emerged as an attractive 
target for anti-cancer drug development. This study 
investigates whether the IGF-1R tyrosine kinase 
domain may contain mutations/deletions that may 
inhibit the effectiveness of targeted therapy. This 
Poster Session 1 – Novel Cancer Monday, 4 July 2011 12:15-14:15
P1.116 TRAIL-INDUCED KINASE 
ACTIVATION IN NON SMALL CELL 
LUNG CANCER CELLS
Kaamar Azijli1, Saravanan Yuvaraaj2, Maikel 
P. Peppelenbosch3, Henk Dekker4, Jos Joore5, 
Godefridus J. Peters4, Steven De Jong2, Frank A. 
Kruyt2 
1Medical Oncology, Vu University Medical Center/
Netherlands, 2Umcg/Netherlands, 3Erasmus MC/
Netherlands, 4Vu University Medical Center/
Netherlands, 5Pepscan/Netherlands
Background: Non-small cell lung cancer (NSCLC) 
is a disease with poor prognosis and novel 
therapeutic approaches are greatly needed. Tumor 
necrosis factor (TNF)-related apoptosis-inducing 
ligand (TRAIL) is an interesting agent that is able 
to trigger apoptosis through interactions with 
TRAIL receptors. An important feature of TRAIL 
is its ability to induce apoptosis in a wide variety 
of tumors without harming normal cells, making it 
an attractive anti-cancer therapeutic compared to 
conventional anti-cancer agents. However, TRAIL 
is also able to activate signaling pathways that are 
involved in survival, proliferation and migration of 
tumor cells. Thus, TRAIL-based therapies combined 
with inhibitors of such pathways are expected to 
enhance therapeutic beneÀt.
Methods: In this study, we aimed to identify 
and characterize kinases that are activated by 
recombinant TRAIL in NSCLC cells. We monitored 
the activation of a number of kinases known to be 
involved in TRAIL signaling by Western blotting, 
including p38 MAPK, JNK, ERK and Akt. In 
addition we employed PepChip kinase arrays. With 
these arrays 1024 peptide kinase substrate can be 
screened in one experiment, whereby a comparison 
of kinase patterns between untreated and treated cells 
can be obtained.
Results: NSCLC, H460 and A549 cell lines, which 
are sensitive and resistant for TRAIL, respectively, 
were exposed to 50 ng/ml TRAIL for different 
periods of time (5 to 240 minutes) to evaluate the 
kinetics of kinase activation. In H460 cells, TRAIL 
induced the phosphorylation of p38 MAPK after 2 
hours and JNK1/2 after 3 hours. As the activation 
of these kinases can be both anti- and pro-apoptotic, 
kinase inhibitors were used to explore this further. 
In H460 cells the activation of JNK, ERK and 
Akt had anti-apoptotic activity. Inhibition of these 
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P1.118 CHEMOTHERAPY INDUCED 
INFLAMMATORY MARKERS AND 
RELEVANCE FOR PROGNOSIS AND 
RESPONSE IN RESECTED STAGE IIIA 
NSCLC
Philipp Huesecken1, Tobias Schulte1, Jan-Hendrik 
Egberts1, Roland Kurdow1, Thomas Becker1, Peter 
Dohrmann1, Holger Kalthoff2, Bodo Schniewind1 
1General And Thoracic Surgery, University Hospital 
Of Schleswig-holstein Campus Kiel/Germany, 
2Molecular Oncology, University Hospital Of 
Schleswig-holstein, Campus Kiel/Germany
Background: In addition to cell death chemotherapy 
can induce various other mechanisms that 
inÁuence biological behaviour of tumour cells. 
In the following analysis, the pro-inÁammatory 
and pro-invasive chemotherapy induced effects 
were analysed for the non-small cell lung cancer 
(NSCLC).
Methods: Cytotoxicity of 5 different cytotoxic drugs 
was measured (cisplatin, etoposide, gemcitabine, 
paclitaxel, 5-FU) in 4 NSCLC cell lines. With 
ED20/50 PI-FACS cell cycle analysis and Àbroblast 
layer invasion analyses were done. In ELISA/
Multiplex-FACS analyses induction of expression 
of 16 proteins (IL1ß, 4,6,8,10,12, TNF, VEGF, 
MIP1a, 1b, angiogenin, bFGF, FAS-L, uPA, MMP2, 
7, 9) were measured. In an orthotopic SCID mouse 
model tumour growth, RNA and protein expression 
of orthotopic growing tumors were analysed by 
RT-PCR and Western Blot in a selection of the 
aforementioned genes. Next to histologic regression 
analyses corresponding analyses were performed 
in 32 patients (23 with / 10 without neo-adjuvant 
chemotherapy) with NSCLC in stage IIIA in resected 
tumour material.
Results: The cell lines showed a different sensitivity 
to the various cytotoxic drugs in PI-FACS and 
viability analyses. For individual cell lines and 
cytostatica combinations an increased invasiveness 
could be shown. The ELISA / FACS analysis 
demonstrated a universal stimulation of IL-8. 
Increased induction IL-8 was associated with an 
increased sensitivity towards chemotherapy. For 
the other proteins a speciÀc expression proÀle was 
shown related to the drug / cell line combination. 
In the orthotopically growing tumours the results 
of could be reproduced on the mRNA and protein 
level. Although histologic regression indices did 
study also examines the regulation of the IGF 
binding proteins (IGFBP 1–6) by hypoxia and may 
help in the design of new therapeutic uses for IGF-I/
IGF-IR inhibitors. 
Methods: A cohort of 100 NSCLC patients who 
had undergone lung tumour resection surgery 
were screened for mutations in the 6 exons of the 
tyrosine kinase (TK) domain of the IGF-1R. Each 
exon was sequenced in both directions using a 
direct sequencing method (AB3130). A SNP at 
codon 3129A>G, in exon 1 of the tyrosine kinase 
domain, was examined using a genotyping SNP 
assay (Applied Biosystems) in 200 NSCLC patients 
and 866 control individuals. IGFBP expression was 
examined in NSCLC cell lines and human bronchial 
epithelial cell (HBEC) lines by RT-PCR and Western 
blot analysis. 
Results: No mutations or deletions were detected in 
exons 2-6 of the IGF-1R TK domain in 100 NSCLC 
patients. A heterozygous SNP at codon 3129A>G 
was identiÀed in exon 1 of the TK domain. A 
further 100 NSCLC patients and 866 control 
individuals were examined for both genotype and 
allelic frequency of this SNP however there was 
no signiÀcant difference between NSCLC patients 
compared to control individuals. The presence of this 
SNP had no inÁuence on either IGF-1R expression 
or patient survival. IGFBP mRNA expression was 
examined in a panel of NSCLC and HBEC cell 
lines. RT-PCR results showed that BP2 and BP3 
were expressed in all NSCLC cell lines and 3 out of 
5 NSCLC cell lines expressed BP1 and BP4. A549 
had the highest expression of BP1-4 compared to 
the other cells lines. No differences in BP2 and BP3 
expression were observed in A549 and H1299 cells 
grown under hypoxia compared to normoxia over 
24 hours. BP3 was over-expressed in all HBEC cell 
lines grown under hypoxia compared to normoxia 
at 24 hours. No difference in BP3 expression was 
observed at the protein level in HBEC cell lines 
under hypoxia compared to normoxia at 24 hours. 
Conclusion: A heterozygous SNP at codon 
3129A>G, identiÀed in exon 1of the tyrosine 
kinase domain, had no inÁuence on either IGF1R 
expression or patient survival. Further investigation 
into the interaction and regulation of the IGFBPs 
in the IGF-1R signaling pathway is warranted to 
elucidate their role in NSCLC. 
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days after reperfusion with intact nuclear and increased 
lamellar bodies in SIM group.
Conclusion: Simvastatin exerts therapeutic effects 
in a rodent model of LIRI, mainly by promoting the 
proliferation of ATII cells.
Keywords: Alveolar, Ischemia, Reperfusion injury
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.120 IMPROVEMENT IN THE 
DETECTION OF GENOMIC 
ABERRATIONS WITH SINGLE 
NUCLEOTIDE POLYMORPHISM 
ARRAYS USING MICRODISSECTED 
SAMPLES
Isabel Zudaire1, Alberto Orta1, María J. Pajares1, 
Angel Rubio2, María Ortiz-Estevez2, José A. 
Martínez-Climent1, Ruben Pio1, Luis M. Montuenga1 
1Biomarkers Lab. Oncology Division., Center Of 
Applied Medical Research. University Of Navarra./
Spain, 2Group Of Bioinformatics, Ceit And Tecnun. 
University Of Navarra./Spain
Background: Microarray technology is a powerful 
tool for cancer research because of its ability to 
simultaneously measure expression, copy number 
and genotype of thousands of genes. The high 
resolution of this technology is conditioned mainly 
by the quality of the sample. Fresh or frozen samples 
with 100% of tumor cells are preferable. However 
tumor tissue represents a mixture of tumor and 
non-tumor cells. An excess of DNA from normal 
cells could signiÀcantly diminish the sensitivity 
of the detection of genomic aberrations such as 
copy number changes and loss of heterozigosity 
(LOH). In order to evaluate the effect of normal cell 
contamination in the analysis of single nucleotide 
polymorphism (SNP) arrays, we performed a study 
comparing microdissected and non-microdissected 
non-small cell lung cancer (NSCLC) tissues.
Methods: Tumors from surgical NSCLC patients 
were used. From each patient, we selected two 
different frozen tissue blocks containing around 70% 
of tumor cells. Tumor cells were microdissected 
from one block and the other was processed without 
microdissection. In order to perform a paired analysis, 
not correlate with oncologic long term outcome, 
increased expression of VEGF and MMP2 in tumor 
samples with neoadjuvant chemotherapy correlated 
with an improved outcome in survival analyses (log 
rank p<0.05).
Conclusion: Chemotherapy is able to stimulate in 
vitro and in vivo a subset inÁammation associated 
genes. Increased induction of inÁammatory 
genes was associated with enhanced sensitivity 
towards chemotherapy in vitro and improved long 
term prognosis in vivo. Enhanced inÁammatory 
responsiveness in NSCLC seems to be associated 
with an increased sensitivity towards chemotherapy.
Keywords: Chemotherapy, InÁammation, NSCLC
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P1.119 SIMVASTATIN ATTENUATES 
LUNG ISCHEMIA-REPERFUSION 
INJURY VIA THE PROMOTION 
OF ALVEOLAR TYPE II CELLS 
PROLIFERATION
Feng Jiang, Dong-Jie Feng, Lin Xu 
Thoracic Surgery, Cancer Hospital Of Jiangsu 
Province/China
Background: We sought to explore the mechanism 
of simvastatin to ameliorate lung ischemia 
reperfusion injury (LIRI).
Methods: A long-term survival model of rat lung 
ischemia reperfusion injury was steady established. 
We randomly divided 72 male Sprague-Dawley 
rats into 3 groups: sham group (n=24); ischemia 
reperfusion (IR) group (n=24); simvastatin (SIM) 
group (n=24). Lung tissues were collected at 
baseline, 1 day, 3 days and 7 days after LIRI. 
Measured variables included surfactant protein-C 
(SP-C) expression determined by reverse 
transcription polymerase chain reaction (RT-PCR), 
the proliferation proÀle of ATII cells evaluated 
by immunoÁuorescence double staining and the 
ultrastructure of ATII cells.
Results: Compared with IR group, the SP-C mRNA 
level were signiÀcantly lower in SIM group at 1 day 
and 3 days after reperfusion (P<0.01 respectively). 
The number of SP-C/PCNA double positive ATII cells 
displayed that compared with IR group, the proliferation 
of ATII cells in SIM group was signiÀcantly increased 
at 3 days after reperfusion. Ultrastructural analysis also 
showed that ATII cells almost returned to normal at 3 
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devices which are included in smart phones, such 
as iPhone ®, and tablet PCs, touch panal controls 
on monitors become rapidly popular in the world. 
In this study, we have developed multi-touch panel 
robotic arm control system for thoracoscopic surgery.
Methods: Our multi-touch panel navigation system 
consists of green laser guide maker, robotic arms with 
four spindles, multi-touch panel monitor, and PCs for 
control regulation. The PCs has the motion control 
program for exclusive use. We can see a green laser spot 
on the surface of organ and touch the spot with right 
foreÀnger. The multi-touch panel monitor recognized 
the Ànger-touch; thereby the tip of the robot arm is 
controlled just on the green maker. When we move 
your Ànger-touched point on the panel, the tip of the 
arm will follow the trace of the movement of the Ànger. 
To appraise the value of our touch panel navigation 
for VATS operation, we performed the operation using 
an animal model in the canonical animal laboratory 
in Kobe, Japan. In the right-sided VATS operation for 
the swine, we made an arterial-bleeding model from 
intercostals’ artery. Then, we tried blood stanching with 
Argon plasma coagulation (VIO300D) controlled with 
our touch panel navigation system.
Results: Touch panel navigation system followed up 
the foreÀnger movement on the monitor closely and 
rapidly. In the right-sided VATS operation of swine, 
we could immediately stop bleeding with Argon 
plasma coagulation controlled with our touch panel 
navigation system.
Conclusion: We demonstrated the ability of this 
touch panel navigation system with green laser guide 
in swine operation. We have developed multi-touch 
panel robotic arm control system for thoracoscopic 
surgery and succeeded in using our intuitive touch 
panel robotic control system for VATS model surgery.
Keywords: lung surgery, touch panel navigation, 
VATS, robotic system
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P1.122 ESTABLISHMENT OF A NOVEL 
ORTHOTOPIC PERIPHERAL LUNG 
TUMOR ANIMAL MODEL SUITABLE 
FOR IMAGING AND THORACIC 
INTERVENTIONAL STUDIES
Takashi Anayama1, Takahiro Nakajima1, Nona 
Zeitlin1, Michael Dunne2, Catherine Coolens3, 
Thomas Waddell1, Shaf Keshavjee1, David Jaffray3, 
Kazuhiro Yasufuku1 
DNA from blood was extracted from each patient. 
Affymetrix GeneChip® Human Mapping 250K Nsp 
arrays were used. Pre-ampliÀcation was not required. 
Array results were analyzed under R using the aroma.
affymetrix package. A copy number paired analysis 
was performed using ACNE algorithm. For each 
sample, we quantiÀed the number of chromosomal 
segments with genomic aberrations (ampliÀcation, 
deletion and LOH), and the copy number variation 
(CNV) estimated in each segment.
Results: We found signiÀcant differences between 
microdissected and paired non-microdissected 
samples. CNV analysis showed that microdissection 
allows a better estimation of the real CNV present in 
the tumor tissue. Differences were also remarkable 
in LOH, where microdissection allowed us to detect 
abnormal regions overlooked in the analysis of non- 
microdissected samples.
Conclusion: Microdissection signiÀcantly improves 
the sensitivity of SNP arrays for the detection of copy 
number aberrations and LOH in frozen NSCLC tissue.
Keywords: Lung cancer, genomic aberrations, SNP 
arrays, microdissection
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.121 INTUITIVE TOUCH PANEL 
NAVIGATION SYSTEM FOR VATS
Junichi Shimada, Kunihiko Terauchi, Daishiro 
Kato, Kazuhiro Ito, Masanori Shimomura, Hiroaki 
Tsuneduka, Kaori Ichise 
Department Of General Thoracic Surgery, Kyoto 
Prefectural University Of Medicine/Japan
Background: Improvement of medical technology 
has resulted in the rapid and widespread use 
of endoscopic surgery over the last 2 decades. 
Development of VATS allows minimally invasive 
surgery to be performed via small, non-rib-spreading 
incisions, and let the patients enable early physical 
recovery and comeback to normal life. However, 
when the lung is severely adhered the chest wall 
during VATS, the thoracic surgeon must do an 
operation with the electrical scalpel, while watching 
the operating Àeld directly or thoracoscopically. 
While a lot of people begin to use multi-touch panel 
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showed chest wall invasion on Day 16 (n=2/2). 
Radial type EBUS visualized the tumor in each 
cases successfully (n=7/7). EBUS measurement was 
signiÀcantly correlated with the CT measurement 
(n=9, CT: 22.0±15.1 vs EBUS: 20.3±12.2 (mm), 
Spearman rank correlation coefÀcient, rs=0.98, 
p<0.01). 
Conclusion: Minimally invasive inoculation of 
tumor cells into lung parenchyma is a reproducible 
technique to make orthotopic peripheral lung VX2 
tumor in rabbits. EBUS is useful to assess the size 
of the lung tumor in this model. This model may 
provide the useful platform for imaging and thoracic 
interventional studies. This study was supported by 
The Ontario Institute for Cancer Research (OICR) 
Keywords: Rabbit VX2 tumor model, Orthotopic 
peripheral lung cancer animal model, Endobronchial 
ultrasonography, Minimally invasive technique
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P1.123 CREATION OF PULMONARY 
CARCINOID TUMOR CELL LINES
Charles F. Thomas1, Sandra C. Tomaszek2, Tobias 
Peikert2, Bharati Sanyal2, Shari Sutor3, Marie 
Christine Aubry2, Dennis A. Wigle2 
1Pulmonary & Critical Care, General Thoraic 
Surgery, Anatomic Pathology, Mayo Clinic/United 
States Of America, 2Pulmonary And Critical Care 
Medicine, Mayo Clinic/United States Of America, 
3General Thoracic Surgery, Mayo Clinic/United 
States Of America
Background: Pulmonary carcinoid tumors account 
for 5% of all lung malignancies in adults. They 
comprise 30% of all carcinoid tumors after those 
found in the GI tract. Histologically they are 
classiÀed as typical or atypical. There are limited 
reagents available to study the biology of these 
rare tumors, and consequently no major advances 
have been made for patient treatment. Complete 
surgical excision remains the only curative treatment 
due to the relative ineffectiveness of chemo- and 
radiotherapy.
Methods: We established human pulmonary 
carcinoid tumor cell lines from surgically resected 
tumors to provide models for testing novel 
chemotherapeutic agents and studying the biology of 
these rare tumors. Tissue was harvested from three 
patients with primary pulmonary typical carcinoid 
1Department Of Thoracic Surgery, Latner Thoracic 
Surgery Laboratory, Division Of Thoracic Surgery, 
Toronto General Hospital, University Health 
Network/Canada, 2Sttarr Innovation Centre, 
Radiation Medicine Program, Princess Margaret 
Hospital, University Health Network/Canada, 
3Department Of Radiation Oncology, University 
Of Toronto, Department Of Radiation Physics, 
Radiation Medicine Program, Princess Margaret 
Hospital, University Health Network/Canada
Background: There is a need to develop an 
orthotopic peripheral lung tumor animal model 
for the development of both new diagnostic and 
therapeutic modalities for lung cancer. Previous 
reported techniques for establishment of Rabbit 
VX2 orthotopic lung tumor model such as 
percutaneous inoculation and inoculation from a 
tracheostomy is invasive and is associated with 
risks of pneumothorax and pleural dissemination. 
The purpose of this study is to establish a minimally 
invasive technique to make an orthotopic peripheral 
lung tumor model which is suitable for both imaging 
and interventional studies. 
Methods: New Zealand rabbits were anesthetised 
and intubated with an endotracheal tube. The guide 
sheath was inserted into the bronchus through 
the endotracheal tube and guided to the point of 
interest under Áuoroscopy. A transbronchial needle 
aspiration needle was passed through the sheath for 
tumor inoculation. The suspension of VX2 tumor 
and collagen gel matrix (Matrigel) was inoculated 
through the needle into the lung parenchyma 
with varying numbers of tumor cell set (group I : 
n=3; 6.0 x 107, Group II : n=4; 1.0 x 107, Group 
III: n=4 ; 2.0 x106, Group IV : n=4; 8.0 x 106). 
Subsequent tumor growth was evaluated with both 
computed tomography (CT) and endobronchial 
ultrasonography (EBUS) following euthanasia and 
necropsy. 
Results: Lung tumor developed in the lung 
parenchyma in 12 out of 15 cases (80.0%). In the 7 
cases in which the tumors were grown in right Lower 
lobe, CT study revealed that the tumor sizes were 
signiÀcantly smaller in group III ( Group III(n=3): 
8.2±4.6 vs Group I,II and IV(n=6) 18.7±3.5 (mm), 
p<0.001), in which the tumors had grown up to 15-
20 mm in size without any pulmonary metastasis 
on day 16 (n=3/4). Only 1 case out of the 10 cases 
of tumor that grew in the right lower lobe showed 
chest wall invasion (n=1/10), whereas both of the 
2 cases with tumor grown in the right middle lobe 
Copyright © 2011 by the International Association for the Study of Lung Cancer S779
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
sacriÀce and longitudinal subgroups. Mice from the 
sacriÀce subgroups were euthanized 8 weeks (CG 
n=6, EG n=6), 23 weeks (CG n=6, EG n=7), and 35 
weeks (CG n=12, EG n=11) after urethane injection. 
Lungs were Àxed with formalin at constant pressure, 
and the number and size of lesions measured on 
H&E stained sections. Mice on the longitudinal 
subgroup (control n=11, emphysema n=10) 
underwent microCT scans with respiratory gating at 
all time points and were sacriÀced after the last scan 
for tissue collection. 
Results: The histological analysis of the sacriÀce 
subgroups revealed that at week 35 the mean area 
(mm2) per lesion was signiÀcantly larger (p<0.01) 
in the EG (1.14±0.74) than in the CG (0.90±0.65). 
Indeed, there is a greater number of large (area > 
3mm2) lesions (CG 14, EG 35). Contrarily, at 23 
weeks, EG lesions (0.21±0.09) were signiÀcantly 
smaller (p<0.01) than CG lesions ( 0.42±0.15). 
No differences in size were found at 8 weeks (CG 
0.06±0.02, EG 0.05±0.02). Large lesions in both 
groups displayed the classical adenocarcinoma 
phenotype, as shown by presence of nuclear atypia, 
papillary morphology and invasive margins. In 
addition, preliminary Àne histological analysis 
suggests that the ratio adenoma/adenocarcinoma 
may be altered between both groups. The average 
number of lesions per animal was signiÀcantly lower 
(p<0.01) in the EG at 23 weeks (CG 14.67±2.01, 
EG 7.43±0.69). No differences were found either 
at 35 (CG 20.33±1.59, EG 18.55±1.78) or 8 weeks 
(CG 4.17±0.70, EG 4.50±0.62). The results obtained 
by microCT analysis of the longitudinal subgroups 
follow the same trend as those obtained by 
histology conÀrming the feasibility of doing in vivo 
longitudinal studies of these models. 
Conclusion: We show that the combined elastase/
urethane treatment causes larger lesions at advanced 
stages, suggesting that tumors grow faster and more 
aggressively in emphysematous environment, where 
the need for tissue repair affects proliferation rates. 
In conclusion, our data suggest that elastase induced 
emphysema promotes lung cancer progression in 
mice. Molecular studies currently being performed 
could possibly determine the potential mechanisms 
involved in this promotion. 
Keywords: Mouse model, Emphsema, MicroCT, 
Lung cancer
tumors undergoing surgical resection. The tumor 
was dissociated and mechanically homogenized into 
a cell suspension and plated onto dishes in culture 
media. The established cell lines were characterized 
by immunohistochemistry, western blotting, and cell 
proliferation assays. Tumorigenicity was conÀrmed 
by soft agar growth and the ability to form tumors in 
a mouse xenograft model.
Results: Three human typical pulmonary carcinoid 
tumor cell lines were created. All grew as adherent 
monolayers in vitro, expressed neuroendocrine 
markers consistent with the primary tumor, and 
formed colonies in agar. A single cell line produced 
lung tumors in nude mice after intravenous injection.
Conclusion: We have created three human 
pulmonary typical carcinoid tumor cell lines as a tool 
for understanding the biology of these rare tumors 
and for testing of novel therapeutic agents.
Keywords: Lung cancer, Neuroendocrine, Xenograft
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Research, University Of Navarra/Spain, 2School Of 
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Background: Recent clinical studies suggest that 
Chronic Obstructive Pulmonary Disease (COPD) 
patients suffering emphysema have higher risk of 
developing lung cancer than the average population. 
We have tested this hypothesis on a mouse model, by 
studying the effect of elastase-induced emphysema 
prior to urethane-mediated lung cancer. 
Methods: Male A/J mice were split into two groups: 
the control group received a single intraperitoneal 
injection of urethane (100mg/100g); the emphysema 
group received an injection of urethane 9 days after 
one oropharyngeal aspiration of porcine pancreatic 
elastase (20U/100g). The latter caused remarkably 
emphysematous lungs, measured by respiratory 
function, micro-Computed Tomography (microCT) 
and histology. Each group was in turn split into 
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mice were imaged by a small animal PET/CT as 
pre-treatment before administration of cetuximab on 
day 1 and secondly imaged with the same procedure 
as post-treatment on day 3. In the PET/CT imaging 
group, tumor cell proliferative activity (Ki-67) was 
also determined and was compared with the non-
treated control group as control value. 
Results: There was no difference in tumor volume 
between the control or cetuximab treatment groups 
on day 3, although the difference became signiÀcant 
after day 8. Considering this result, we performed 
ex vivo study and 18F-FLT-PET/CT on day 3 as early 
therapeutic evaluation. In the ex vivo study, 18F-FLT 
uptake was speciÀcally high in tumor comparing 
with normal tissues and was decreased by cetuximab 
treatment as early as day 3. Radioactivity of 18F-FLT 
in tumor were 0.098 ± 0.005 (%ID/g/kg) in the 
control group and 0.029 ± 0.010 (%ID/g/kg) in the 
cetuximab-treated group, respectively (p < 0.001). 
In the PET/CT imaging group, the decrease of 
tracer uptake in tumor was clearly visualized after 
the treatment with cetuximab on day 3 while the 
high uptake of 18F-FLT in tumor was seen before 
treatment on day 1. Ki-67 positive cells were 12.8 ± 
4.0% in the non-treated control group on day1 and 
5.0 ± 1.5% in the cetuximab treated group on day3 ( 
p = 0.01), respectively. 
Conclusion: These results suggest 18F-FLT-PET/CT 
can be a useful predictor to evaluate a response to 
molecular targeted drug such as cetuximab at a very 
early time-point before a signiÀcant change of tumor 
size. 
Keywords: response predictor, 
18F-Fluorothymidine, cetuximab
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University/Japan, 2Department Of Nuclear 
Medicine, Hokkaido University Graduate School 
Of Medicine/Japan, 3Central Institute Of Isotope 
Science, Hokkaido University/Japan, 4Department Of 
Tracer Kinetics & Bioanalysis, Hokkaido University 
Graduate School Of Medicine/Japan
Background: SpeciÀc inhibition of epidermal 
growth factor receptor (EGFR) is one of the 
most promising treatment in the clinical setting. 
Cetuximab, a chimeric monoclonal antibody 
that binds to the extracellular domain of EGFR, 
has activity in various types of cancer. Because 
cetuximab is very expensive and has unique side 
effects, the development of appropriate evaluation 
for the therapeutic effects is necessary to use this 
drug effectively. Measurement of tumor proliferative 
activity by PET using 18F-Fluorothymidine (18F-FLT) 
may serve to assess early therapeutic effect. The 
purpose of this study is to determine whether 
18F-FLT positron emission tomography/computed 
tomography (18F-FLT-PET/CT) is useful to evaluate 
a response to EGFR antibody cetuximab therapy 
at very early time-points in human lung cancer cell 
xenografts.
Methods: Human tumor xenograft model was 
established in male BALB/c athymic mice with 
human lung cancer cell line NCI-H1975. These 
mice were randomly assigned to four groups; tumor 
growth follow-up, ex vivo study, PET/CT imaging 
and non-treated control. Mice were administered 
saline as control or cetuximab 1.0 mg on day 1. 
In the tumor growth follow-up group, tumor sizes 
were measured by caliper on day 3, 5, 8, and 10 
after the treatment. In the ex vivo study group, 
radioactivity of 18F-FLT in tumor and other tissue 
samples (%Injected Dose/g/kg) was measured using 
liquid scintillation. In the PET/CT imaging group, 
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A MULTIDISCIPLINARY QUALITY 
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Background: ICPs are structured multidisciplinary 
care plans for a speciÀc clinical condition; they 
describe the tasks to be carried out along with their 
timing and sequence and the department involved. 
ICPs have been proposed as quality improvement 
strategies of both clinical and organizational aspects 
of patient-oriented care. Nowadays few data remain 
available to detail existing ICPs for NSCLC pts and 
the methodology for design an optimum care plan.
To reliably assess current practice, quality of care 
indicators are needed, that is measurable elements of 
practice performance for which there is evidence or 
consensus that they can assess the quality of the care 
provided. Aim of this project was to review current 
clinical pathways in the care of NSCLC pts who 
were referred to the University Hospital of Udine, 
Italy. 
Methods: A multidisciplinary focus group was set 
up to:
1. map the existing local care process for NSCLC 
patients from the Àrst hospital visit to the follow-up 
phase;
2. review literature and evidence-based guidelines to 
identify quality of care indicators and corresponding 
benchmarks in this setting. Quality indicators consist 
in intermediate outputs of the care process and 
are able to assess both clinical, organizational and 
economical points of view of the care provided.
3. compare the set of indicators selected with the 
current process of care in order to monitor the 
Cancer Center Research Institute/Japan, 4Pathology 
And Molecular Diagnostics, Aichi Cancer Center 
Hospital/Japan
Background: The EGFR mutation is the key 
information of geÀtinib and erlotinib treatments 
for non-small-cell lung cancer (NSCLC) patients. 
Previously, we or others reported the association 
of EGFR mutations with adenocarcinoma, sex 
and smoking dose. Here we have Ànd the new 
information of interaction between sex and smoking 
dose, and age on EGFR mutation. Based on new 
Àndings, we have established the statistical model to 
predict EGFR mutation probability.
Methods: With IRB approval, we reviewed the 
medical records and EGFR mutation status of all 
1262 patients from two institutes (737 patients of 
Aichi Cancer Center and 525 patients of Okayama 
University). The associations of EGFR mutation with 
histological types, smoking dose, sex, age, stage and 
these combinations were evaluated. Then best model 
for prediction of EGFR mutation probability using 
logistic regression with these factors was evaluated. 
All results were cross-checked by comparison of 
each institution result.
Results: EGFR mutation was found in 33% 
(417/1262), 42.1% (406/964) in adenocarcinoma, 
17.4% (4/23) in adeno-squamouscarcinoma 
and 2.5% (7/275) in other histological types. In 
adenocarcinoma, EGFR mutation was associated 
with sex, smoking dose represented by pack-
year (PY), interaction of sex and smoking 
dose and age. The best model for prediction of 
EGFR mutation was: logit(probability)= -0.1562 
-0.5523*(1=male/2=female) -0.0652*PY(male) 
-0.0308*PY(female) +0.2460*age/10. The EGFR 
mutation rate of male and PY=0 was 75.4% (52/69), 
female and PY=0 was 57.8% ( 234/405). The EGFR 
mutation of male was greater decreased as PY 
increasing (odds ratio OR=0.937) than that of female 
(OR=0.970). Increasing 10 age showed increasing 
the OR=1.279.
Conclusion: EGFR mutations were associated with 
sex, smoking dose, interactions of sex and smoking 
dose, and age. Our model for predicting EGFR 
mutations in adenocarcinoma patients can be a useful 
tool for patient selection for EGFR-TKI treatment 
in patients whose EGFR mutation status is not 
available.
Keywords: NSCLC, EGFR, smoking, sex, age, 
model
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Background: ICPs have been proposed as quality 
improvement strategies and represent a mechanism 
to encourage the use of guidelines into clinical 
practice. They provide a means to improve 
multidisciplinary communication and care planning 
and allow systematic collection and abstraction 
for audits, promoting change in practice and the 
identiÀcation of research and development questions. 
In this study, the quality of the existing care process 
for patients with NSCLC referred to a university 
hospital has been assessed, in order to estimate 
the potential room for improvement and guide the 
redesign of the ICP. Special attention was given to 
making the existing care process more appropriate 
and reducing the avoidable costs. 
Methods: 175 NSCLC cases referred to the 
Oncology Department of the Udine University 
Hospital from 1/1/2008 to 31/12/2008 were 
identiÀed. A multidisciplinary focus group composed 
of all the professionals involved in the management 
of the care pathways of NSCLC patients was set up. 
The focus group identiÀed eleven quality of care 
indicators and corresponding benchmarks. They 
were gained from previously published studies or 
from international professional guidelines. By means 
of the electronic information system of both the 
Hospital and the Oncology Department the quality of 
care indicators were tested on the study population. 
In cooperation with researchers of the Cergas Center, 
Bocconi University, Milan, Italy, the extra costs 
for inappropriate procedures were estimated by 
the charges through which the regional health care 
system funds the hospital. 
Results: The gap between current practice and the 
benchmark objectives has been identiÀed, allowing 
the quantiÀcation of the distance of real pathways 
from the benchmark standards also in terms of 
avoidable costs. The most critical area was early 
disease stage patient management, but even the 
follow up phase seems to be more intensive in 
terms of visits and procedures than that suggested 
by the guidelines. There were 46 unexpected 
biopsies: 30 patients had more than one biopsy 
(2, 3, 4 or 5 biopsies), with a total avoidable cost 
of 7585.40€. There were 31 bronchoscopies: 24 
patients have more than one bronchoscopy with a 
quality of care delivered and assess the effective 
implementation of the guidelines within the 
framework;
4. recognize key areas with room for improvement 
and develop proposals for redesign of the ICPs. 
Results: Eleven quality of care indicators were 
identiÀed. Indicators were used to survey the ICPs of 
175 NSCLC pts referred to the oncology department 
of the Udine University Hospital in 2008. Data for 8 
representative indicators are shown below: 
INDICATOR MEDIAN BENCHMARK 
Days from ¿rst evaluation in a Lung Unit to histological 
diagnosis 15 15-20 
(A) 
Surgical pts undergoing a CT-PET followed by a 
mediastinoscopy (%) 2 80-100 
(A) 
Days from ¿rst Lung Unit to ¿rst Oncology Unit 
evaluation (Stage IA-IIIA) 106 56-84 
(B) 
Days from ¿rst Lung Unit to ¿rst Oncology Unit 
evaluation (Stage IIIB-IV) 31 28-42 
(B) 
Pts multidisciplinary evaluation (%) 50 55 (A) 
Days from histological diagnosis to surgery 49 28-35 (B) 
Poor (>1) ECOG PS pts receiving a two-drug regimen (%) 1 0 (A) 
>3 lines of cytotoxic treatment (%) 0 0 (A) 
According to: (A) evidence-based guidelines or (B) 
expert consensus 
Conclusion: By means of a limited set of quality 
indicators, we were able to verify the adherence 
of routine clinical practice to clinical guidelines 
and to elicit some critical issues in the care of 
NSCLC pts. Results need to be shared and discussed 
with Hospital Managers, with the aim of guiding 
the redesign of ICPs and improving the clinical, 
organizational and economic efÀciency of the care 
process. 
Keywords: Quality of care indicators, Benchmark, 
Integrated care pathways
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phantom organs such as skin, fat, muscle, liver and 
bones. The experiment was repeated Àve times for 
each type of needle. 
Results: The forces varied according to the type 
of organ and the size of the needle. During needle 
insertion phase, the friction force linearly increased 
by the depth in skin and muscle, while liver didn’t 
add up any consistent amount of the reaction force. 
Rather the reaction forces inside liver appeared 
highly sensitive to the type of needle. During the 
extraction phase, a substantial negative force holding 
the needle was initially induced, but the pattern 
showed linear decrease throughout liver, muscle and 
skin soon after omental bursa region. 
Conclusion: The force needed to insert or extract 
a biopsy needle for each organ and for each needle 
can be assessed and modeled with the aid of 3D 
CT images. 3D visualization simulator would be 
a useful tool to Ànd the optimal route for 3D CT 
image-guided biopsy if the properly modeled organ 
property is included in the simulator. Future research 
will include the design of master/slave system with 
force feedback for the precise control of the CT 
image-guided biopsy robot based on the analysis of 
measured forces from this study. 
Keywords: biopsy, phantom, force measurement, 
robot,
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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INDETERMINATE MASSES BY LUNG CT
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Background: The bioelectrical properties of 
cancerous tissue are well characterized and vary 
total avoidable cost of 3270.50€. The repetition of 
these examinations was mainly due to an insufÀcient 
amount of biological sample. There were 53 
unexpected CTs: 36 patients have more than one 
CT before the surgical procedure because the last 
CT was dated more than thirty days in advance with 
a total avoidable cost of 6312.30€. In summary 
the total estimated avoidable cost was 17,168.20€ 
(about 100 € per patient). 
Conclusion: The study shows that analysis of ICP 
in NSCLC is feasible and allows the monitoring of 
the actual application of international guidelines 
in a public and university teaching hospital, both 
in terms of better appropriateness and reduced 
avoidable costs. This is only a Àrst simulation; 
however the extension of this methodology could 
produce interesting results that should be shared and 
discussed with the Hospital Managers in order to 
guide the redesign of ICPs. 
Keywords: Integrated care pathways, Avoidable 
Costs Analysis, Quality Improvement Project
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BIOPSY
Kwang Gi Kim1, Chang Min Park2, Hun Soo Shin1, 
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Background: In computed tomography (CT) image-
guided biopsy, a lesion is observed and the target 
tissue of biopsy is identiÀed using CT images prior 
to the insertion of a biopsy needle. However, major 
nerves and organs along the path of the biopsy 
needle also need to be identiÀed to ensure safe 
and accurate biopsy. In this study, we measured 
the reaction force pattern during insertion and 
extraction of the needle in a general purpose multi-
tissue phantom , for using it in later biopsy route 
optimization using a 3D image based simulator 
Methods: The needle reaction force was measured 
using a biopsy robot built in this lab, equipped with 
a force sensor located at the base of biopsy needle. 
The forces required to insert and extract the needle 
were measured along the route, which was set to pass 
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technology requires no specimen handling, and 
differs from developing “biomarkers” by focusing 
strictly upon the characterization of an indeterminate 
mass. This objective is clinically relevant and 
distinct from blood and sputum-based biomarkers 
wherein a positive result may occur in the absence of 
an identiÀed mass so the appropriate clinical action 
is often complicated. 
Keywords: CB Test - Computerized Bioconductance 
Test, BSP - Bioconductance Scanning Platform, 
Indeterminate Masses
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Background: High sensitivity methods for detecting 
somatic mutations are required in the discipline 
of cancer therapy where key genetic changes are 
associated with EGFR antagonists’ effectiveness, e.g. 
in the genes EGFR, K-RAS, PIK3CA, BRAF, p53 
and NRAS. To enrich for all types of substitutions, 
insertions and deletions in a single assay, we have 
developed EGFR exon-speciÀc Ice COLD-PCR 
assays which preferentially amplify low levels of 
mutant DNA in samples containing a vast excess 
of wild-type DNA. Use of reference sequence 
oligonucleotides (RS-oligos) complementary to 
wild-type strands results in linear ampliÀcation of 
wild-type sequences but exponential ampliÀcation of 
any mutant sequences present. This is not an allele-
speciÀc technique; therefore all mutations, both 
known and unknown, are enriched and identiÀed in a 
single reaction. 
Methods: NSCLC tumors harboring the EGFR 
L858R mutation and exon 19 deletions respond to 
anti-EGFR therapy while those containing the exon 
20 T790M mutation do not. Ice COLD-PCR methods 
have been developed using RS-oligos, containing 
locked nucleic acids (LNAs), complementary to the 
wild-type sequence corresponding to the relevant 
EGFR regions of exons 18-21. 
signiÀcantly from normal and benign tissue. We 
tested a non-invasive Bioconductance Scanning 
Platform (BSP) developed for the rapid acquisition 
of transthoracic bioconductance measurements, or 
the Computerized Bioconductance Test (CB Test). 
The CB Test evaluates speciÀc bioconductance 
properties of indeterminate lung masses. 
Methods: The BSP delivers a safe current of 
<25micro amps to measure bioconductance between 
reference electrodes placed on the patient’s back or 
hands and a computerized bioconductance Probe 
(Probe). The operator is prompted to place the 
Probe at 62 anatomical locations. Measurements 
are sampled 25 times per second and recorded and 
evaluated. Each measurement contains 9 attributes 
of bioconductivity behavior acquired in less than 
12 seconds. Certain locations include diagnostic 
information while others are controls. Stored data 
is analyzed to train a predictive classiÀer algorithm 
that discriminates between masses with either 
benign or malignant characteristics. This situation 
is analogous to genome-wide association studies 
where each marker has its own signiÀcance test. Our 
Probe removes variability associated with moisture, 
skin type, and operator error (Reliability Index 0.989 
and Correlation between Device Replicates 0.980). 
The operator receives 1.5 days training to ensure 
uniformity of measurement and protocol compliance. 
Following the Test, a questionnaire asked: (1) 
Did measurement cause discomfort? (2) Did Test 
duration seem reasonable? (3) Would you undergo 
measurement again? 
Results: The BSP algorithm discriminated between 
the subjects with benign and malignant outcomes 
with an ROC of 91%. No reported Adverse Events, 
Serious Adverse Events or Unanticipated Adverse 
Device Effects were reported. One patient noticed 
a “little pressure”, and all responded that the testing 
time was acceptable. 1 subject responded “maybe” 
to undergoing repeat measurement and 2 subjects 
responded “no”. Of the 2 “no” responses, one 
provided no reason and another cited excessive 
travel from home to clinic. 
Conclusion: The BSP is non-invasive, safe, easy-
to-use and has high patient acceptability. This 
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this study, we examined the anti-cancer and 
radiosensitizing effect of CH-205-O on human 
esophageal cancer cells. 
Methods: Human squamous cell carcinoma (CE81T/
VGH and TE-2) and adenocarcinoma (BE-3 and 
SKGT-4) cell lines were kept in exponential growth 
status. MTT assay was used for cell viability. Cell cycle 
was analyzed by using propidium iodide staining and 
Áow cytometry. Mitochondrial transmembrane potential 
was measured by DiOC
6
 staining and Áow cytometry. 
Colony formation assay was performed for estimation 
of radiation surviving fraction. Xenograft of human 
CE81T/VGH cells was established for evaluation of 
therapeutic activity in vivo. 
Results: CH-205-O inhibited the viability of 
human esophageal cancer cell lines, including 
squamous cell carcinoma (CE81T/VGH and TE-
2) and adenocarcinoma (BE-3 and SKGT-4). The 
estimated IC
50
 for these four cell lines was 3.4 
– 6.9 ƫM. CH-205-O induced a hypoploid cell 
population and morphological alterations typical 
of apoptosis in CE81T/VGH and BE-3 cells. This 
apoptosis induction activity was accompanied by 
reduction of mitochondrial transmembrane potential, 
indicating an intrinsic apoptotic pathway involved. 
Furtherrmore, CH-205-O treatment accumulated 
cell cycle at G2/M phase and enhanced the 
radiosenstivity with a sensitizer enahncement ratio 
up to 1.6 in CE81T/VGH cells. In vivo, CH-205-O 
inhibited the growth of CE81T/VGH xenograft 
without signiÀcant impact on body weight and white 
blood cell counts.
Conclusion: CH-205-O is capable of inhibiting 
growth and enhancing radiosensitivity of huamn 
esophageal cancer cells. Further assessment of 
mechanism is undergoing.
Keywords: radiosensitization, CH-205-O, 
Esophageal cancer, Anti-cancer
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Results: Ice COLD-PCR ampliÀcation of control 
and L858 mutation plasmids followed by Sanger 
sequencing had a limit of detection (LOD) of 0.1–0.5%. 
Ice COLD-PCR was also used for detecting exon 19 
deletions; after Sanger sequencing, an LOD of 0.5% 
mutant DNA was achieved. DNA samples extracted 
from plasma from NSCLC patients were tested by Ice 
COLD-PCR for both the L858R mutation and exon 19 
deletions. All mutations previously identiÀed by Sanger 
sequencing were conÀrmed along with additional, 
previously undetected mutations. These new mutations 
were detected due to Ice COLD-PCR’s ability to enrich 
mutations in a wild-type background making them 
detectable by DNA sequencing. Preliminary results for 
detection of T790M and the G719X mutations will also 
be presented. 
Conclusion: The results demonstrate Ice COLD-
PCR’s utility for highly sensitive detection of 
EGFR mutations in DNA derived from plasma. 
Following Ice COLD-PCR, DNA sequencing can 
be used to verify the somatic mutations in samples 
such as low tumor-load biopsies, formalin-Àxed 
parafÀn-embedded slides, Àne-needle aspirates, 
circulating tumor cells and circulating free tumour 
DNA in plasma and serum. This method can also 
be used to conÀrm low signal Pyrosequencing and 
next-generation deep-sequencing results. Coupled 
with mutation detection methods such as Sanger 
sequencing, Ice COLD-PCR provides a new model 
for highly sensitive, economical testing of EGFR 
mutations to aid patient treatment decisions. 
Keywords: Ice COLD-PCR, Somatic mutations, 
Non-small cell lung cancer, EGFR
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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Background: CH-205-O is an aromatic ester 
compound isolated from Armillaria mellea. In 
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LCRMP-1 cells formed larger orthotopic tumors 
(P=0.003) and more metastatic lung tumor nodules 
(P<0.001) than the vector control cells. Besides, we 
could also observe several tumor nodules formed 
at the other organelles such liver, heart and chest 
wall which could only saw a spread image by IVIS 
observation. 
Conclusion: We developed a reÀnement lung 
orthotopic tumor implantation model without 
surgery, which is suitable to detect the development 
of cancer metastasis in vivo and it may decrease 
the risk of infection caused by surgery. Using this 
animal model, we can evaluate the effects of study 
genes or drugs on cancer metastasis. In the past, 
most scientists use several models involving the 
implantation of tumor cells intravenously, from the 
portal vein, or from the left ventricle to evaluate 
the development of cancer metastasis, but all 
these models only show you the effects on distant 
metastasis. Through lung orthotopic implantation, we 
can detect not only the distant metastasis but also the 
true effects on primary cancer metastasis.
Keywords: Metastasis, Orthotopic Thoracic mouse 
model, Lung cancer
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P1.134 THE PRELIMINARY STUDY ON 
THE RELATIONSHIP BETWEEN TREE 
SHREW LUNG CANCER MODEL AND 
BIOMATERIALS CENTERED
Kaiyun Yang, Guangqiang Zhao 
Thoracic And Cardiovascular Surgery, Yunnan 
Tumor Hospital/China
Background: To explore the inÁuence of biological 
material implantation into the lung cancer mode of 
tree shrew. Provide useful help for the prevention and 
treatment of Biomaterial Centered Infection (BCI).
Methods: Use different methods of immune 
suppression to establish the tumor models of tree shrew. 
Collect 26Adult healthy tree shrews, male and female 
half and half. 20 tree shrews were selected randomly 
into 2 groups the control group and the experimental 
groups. The control group for the negative control 
group were given only saline. The experimental group 
was divided into two groups the irradiaton group 
and cyclophosphamide group. 3 subgroups (R1 R2 
R3) in the irradiation group, were given 6Gy, 8Gy, 
10Gy irradiation by electron accelerator respectively. 
1Institute Of Biomedical Sciences, Academia Sinica/
Taiwan, 211. Institute Of Biomedical Sciences 
And Molecular Biology, National Chung Hsing 
University/Taiwan, 3Graduate Institute Of Life 
Sciences, National Defense Medical Center/
Taiwan, 44. Department Of Pathology And Graduate 
Institute Of Pathology, College Of Medicine, 
National Taiwan University/Taiwan, 5Department 
Of Pathology And Graduate Institute Of Pathology, 
College Of Medicine, National Taiwan University/
Taiwan, 6Institute Of Biomedical Materials And 
Engineering, Taipei Medical University/Taiwan, 
7Institute Of Biomedical Sciences And Molecular 
Biology, National Chung Hsing University/Taiwan, 
8Institute Of Clinical Medicine, National Cheng 
Kung University/Taiwan, 9Department Of Internal 
Medicine, National Taiwan University College Of 
Medicine/Taiwan
Background: Lung cancer is the leading cause of 
cancer-related mortality, especially non-small cell 
lung cancer (NSCLC). Paramount to this problem 
is the fact that approximately 85% of diagnoses are 
made when the tumor can no longer be removed 
surgically, and among patients with early-stage 
NSCLC, the relapse rate approximates 40% within 5 
years after potentially curative treatments. Metastasis 
remains to be the major cause of treatment failure 
in lung cancer patients. Although more and more 
complex molecular mechanisms have been found to 
be involved in cancer metastasis, it is infrequently to 
be evaluated in vivo.
Methods: Tumor cells with different invasive 
abilities were orthotopically introduced into the lung 
parenchyma of 6-week-old SCID mice (supplied 
by the animal center at the College of Medicine, 
National Taiwan University, Taipei, Taiwan; n=10 
per group), and luciferase image were used to make 
sure the successfully inoculated into the pleura 
cavity. 28 days after implantation, mice will be 
sacriÀced by anesthesia with carbon dioxide, and all 
organs will be removed and Àxed in 10% formalin. 
The image of each tissue was taken and the lung 
nodules were counted under gross and microscopic 
examination. The number of mice used for the 
experiments (n=10) was based on the goal of having 
98% power to detect a two-fold between-group 
difference in nodule number at P < 0.05.
Results: Recently, we identiÀed that LCRMP-1 is 
a novel invasion enhancer. When A549/LCRMP-1 
overexpressing cells were orthotopically inoculated 
into the pleural cavities of mice, we found that A549/
Copyright © 2011 by the International Association for the Study of Lung Cancer S787
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like most cancers, it must gain access to the host 
vasculature system in order to grow. The induction 
of angiogenesis is regulated through a balance 
of stimuli from the tumor and the surrounding 
microenvironment including inÀltrating cells of 
hematopoietic origin. Targeting angiogenesis has 
been an active area of research however, tumor 
relapse is common as not all cells undergo apoptosis/
necrosis and some cells may even develop a selective 
growth advantage under hypoxic conditions. 
Traditionally, imaging tumor vasculature relied 
on serial immunohistological sectioning or use of 
CT or MRI imaging with an appropriate contrast 
agent, however, the architectural resolution of the 
vasculature was not ideal. We have developed a 
novel method for 3-dimensional quantiÀcation of 
architectural changes to the tumor vasculature in our 
syngeneic mouse model system. 
Methods: Murine cell lines were developed from the 
p53R172Hrg/+ K-rasLA1/+ mouse strain at varying stages 
of malignancy. Cell lines were stably transfected 
with EGFP-Luc and sorted for the highest expressing 
cells, and were proÀled for their expression level of 
various angiogenic cytokines. Tumors were grown 
subcutaneously in 129/Sv wild-type syngeneic hosts 
by injecting 5x105 cells over both the right and 
left Áank of 6 week old mice. Tumor growth was 
monitored with bioluminescent imaging and after 2 
weeks mice were perfused with a radio-opaque dye. 
Experimental animals were administered a vascular 
disrupting agent, 24 hours prior to euthanization, 
while control animals received vehicle only. Tumors 
were excised, and Àxed, followed by high-resolution 
Micro-CT scanning. Three-dimensional tumor 
analysis was obtained for total vessel volume, vessel 
thickness, vessel separation and tumor/vessel ratio.
Results: Results in progress, will be available by May 
13, 2011 for the late-breaking abstract submission
Conclusion: Using our novel method of imaging 
the microarchitecture of the tumor vasculature we 
are able to evaluate changes to the vasculature of a 
tumor in reponse to different agents. In addition, we 
can quantify the effectiveness of drugs speciÀcally 
aimed at targeting the tumor vasculature by 
visualizing, at high resolution, the changes that 
happen throughout the entire tumor vascular bed. 
Keywords: angiogenesis, syngeneic mouse model, 
micro-CT
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
Cyclophosphamide group were treated with 
cyclophosphamide for immunosuppressive treatment. 
Each group were implanted with tumor cell suspension. 
Observe the survival of tree shrew and tumor situation 
to select the best experimental conditions for Tree 
shrew lung cancer model.
Results: 1. The immune suppressed tree shrews 
which treated by Electron accelerator radiation 
processing were activities reduced, slow, inactive, 
eating less, and even antifeedant. After tree shrews 
inoculated tumor cell suspension 2 days, the tumor 
growth can be seeing. Tumor was growth rapidly 
and tumor nodules became maximum at the 3rd 
week, after which tumor was growth slow and some 
nodules were narrowing. Blood cell analysis and 
thrombocyte counting showed that signiÀcant bone 
marrow suppression appeared in tree shrews after 
irradiation. It recovered after 1 week and white cell 
count near normal at the 3rd week. P value >0.05 
and indicted immune system had recovered. 2. The 
tree shrews which immunosuppressive treated by 
cyclophosphamide were like the tree shrews treated 
by electron accelerator radiation. Those animals 
had high mortality and had no tumor nodule growth 
during the experiment. 3. The best condition to 
establish adult tree shrews tumor model maybe 
8Gy irradiation by electron accelerator. 5×106 
XWLC-05 was used to inoculate in tree shrews. The 
survival rate was 63.89%, and the formed tumor rate 
was.61.11%.
Conclusion: The tree shrew tumor model can 
be established by implanting XWLC-05 into the 
tree shrews whose immunological function was 
suppressed by irradiation with Electron accelerator 
radiation.
Keywords: Tree shrew, Animal lung cancer models
Poster Session 1 – Technology and Models Monday, 4 July 2011 
12:15-14:15
P1.135 IMAGING THE TUMOR 
VASCULATURE IN A SYNGENEIC 
MOUSE MODEL OF NON-SMALL CELL 
LUNG CANCER
Charlene M. Downey, Michelle Villemaire, Frank R. 
Jirik 
Biochemistry And Molecular Biology, University Of 
Calgary/Canada
Background: Lung cancer is one of the leading 
causes of cancer-related death in the world, and 
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installed was the SQL Server 2008; Clear Canvas 
Image Server and Workstation; DCMTK DICOM 
toolkit; RSNA Clinical Trial Processor CTP and 
Matlab Runtime Component. Clear Canvas Image 
Server is a PACS and was installed with a temporary 
partition (TempPACS) holding identiÀable DICOM 
headers and a research partition (ResearchPACS) 
holding only de-identiÀed DICOM objects. SQL 
Server 2008 was used to host the ResearchDB, 
OntologyDB and KeyDB as well as the database of 
the Clear Canvas Image Server. A linked server to 
the clinical database containing medical data was 
setup. A synchronization mechanism for DICOM 
and clinical data was set up and was scheduled to 
run nightly as to minimize interference with clinical 
work. To retrieve data from the ResearchDB and 
ResearchPACS, a VPN connection was established.
Results: The data-sharing infrastructure was 
implemented in two months (July-August 2010) at 
low cost. As of January 2011, the ResearchDB holds 
about 2600 patients and the ResearchPACS holds 
about 5.000 de-identiÀed DICOM objects using a 
total of 1 TB storage. All new patients are added 
automatically to the ResearchDB and PACS through 
the nightly synchronization.
Conclusion: After obtaining institutional approvals 
for the protection and use of the data, a data sharing 
infrastructure was built. This platform permits to pool 
data from institutional databases and combine them 
enhancing the capability to construct predictive models 
that are more widely applicable and better powered 
to accurately identify key predictive factors (whether 
dosimetric, image-based, clinical, or biological). 
Keywords: Technology development, data-sharing, 
predictive models, de-identiÀcation
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P1.137 FACILE AND SENSITIVE 
MUTATION DETECTION IN LUNG 
CANCER FROM NEVER SMOKERS
Jin Jen1, Jin S. Jang1, Adam M. Lee2, Hema 
Liyanage3, Ping Yang4, Robert B. Diasio2 
1Pulmonary And Critical Care Medicine, Mayo 
Clinic/United States Of America, 2Molecular 
Pharmacology And Experimental Therapeutics, 
Mayo Clinic Cancer Center/United States Of 
America, 3Sequenom/United States Of America, 
4Epidemiology, Mayo Clinic/United States Of 
America
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P1.136 RESEARCH PLATFORM FOR 
DATA SHARING IN EUROPEAN 
RADIOTHERAPY COLLABORATION
Pierluigi M. Granone1, Elisa Meldolesi2, Maria 
Letizia Vita1, Giulia Carnassale1, André L.A.J. 
Dekker3, Vincenzo Valentini2, Lorenzo Bonomo4, 
Philippe Lambin3 
1Department Of Thoracic Surgery, Policlinico 
Universitario Agostino Gemelli/Italy, 2Radiotherapy, 
Policlinico Universitario Agostino Gemelli/Italy, 
3Radiation Oncology, MAASTRO Clinic/Netherlands, 
4Department Of Bio-sciences And Radiological 
Imaging, Policlinico Universitario Agostino Gemelli, 
Rome/Italy
Background: To understand how clinical aspects 
and treatment decisions can affect outcomes is crucial 
for current and future research. A key element to 
accelerate progress in radiation oncology is storing 
high-quality data (e.g. clinical, biological, dosimetric, 
imaging) that can help to improve and validate 
predictive models for personalize prognosis and 
treatments. This process is connected to the concept of 
rapid learning based research, in which the routinely 
collected real-time clinical data drives the process of 
scientiÀc discovery as a natural outgrowth of patient 
care. Considering that sharing data from institutional 
databases can increase the quantity of high-quality 
data available, an infrastructure able to join the Sacro 
Cuore University located in Rome (Italy) and the 
MAASTRO Clinic of Maastricht (the Netherlands) 
was built, for speciÀc research projects. 
Methods: Once obtained institutional approvals, 
a research database (ResearchDB) was created 
combining clinical information with diagnostic 
imaging and treatment information (RT and non RT 
data). A patient-centric data model was designed that 
would enable queries for both medical and imaging 
data. A coding scheme was employed in which a 
secure-key database (KeyDB) holds the link between 
the random patient identiÀcation code (ResearchID) 
and all identifying data. This KeyDB is maintained 
by local hospital personnel and only accessible from 
within the hospital. In the ResearchDB, the patient is 
only identiÀed by a ResearchID which is a random, 
non-sequential 9-digit number. To convert Italian to 
English standard terms local terms were mapped, 
in the OntologyDB, to the SNOMED Clinical 
Terms that were used as dictionary. The software 
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EGFR and MET genes; one tumor had an EGFR and 
a PIK3CA gene mutation; and one tumor had triple 
mutations involving EGFR, JAK2, and AKT1 genes. 
Clinically, the status of EGFR gene mutation was 
not signiÀcantly different among sex, age, and tumor 
stage. 
Conclusion: We developed a MassArray based 
mutation detection panel for lung cancers from 
never smokers. This makes it feasible to better direct 
and augment the treatment of lung cancer as well 
as allowing us to rapidly survey a large number of 
tumor samples and to examine the interplay between 
gene mutations and clinical characteristics of lung 
cancer in never smokers. 
Keywords: gene mutation, MassArray, non-smoker, 
Lung cancer
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.138 A PHASE II TRIAL OF 
ACCELERATED HYPOFRACTIONATED 
THREE-DIMENSIONAL CONFORMAL 
RADIATION THERAPY IN LOCALLY 
ADVANCED NON-SMALL CELL LUNG 
CANCER
Zheng-Fei Zhu, Min Fan, Kai-Liang Wu, Kuai-Le 
Zhao, Huan-Jun Yang, Gui-Yuan Chen, Guo-Liang 
Jiang, Li-Juan Wang, Sen Zhao, Xiao-Long Fu 
Department Of Radiation Oncology, Fudan 
University Shanghai Cancer Center/China
Background: Accelerated hypofractionated 
radiotherapy (HypoRT) is a potential way to improve 
local control for non-small cell lung cancer (NSCLC) 
owing to the higher biological effect of larger 
fraction and shorter overall treatment time. However, 
HypoRT has often been avoided in curative treatment 
for a long time during two-dimensional radiotherapy 
era, because large dose per fraction was often 
expected to accompany more side effects. With 
the development of radiation techniques, renewed 
enthusiasm was given to HypoRT. The aim of 
this study was to evaluate the safety and efÀcacy 
of accelerated HypoRT using three-dimensional 
conformal radiation therapy (3D-CRT) in locally 
advanced NSCLC.
Methods: A total of 34 patients with stage III 
Background: Lung cancer is the leading cause of 
cancer death worldwide. A signiÀcant fraction of 
the female lung cancer patients have never smoked. 
Genetic studies showed that lung cancer from 
smoker and non-smokers have different mutation 
spectrum which can contribute to signiÀcantly 
different therapeutic responses in the clinic. For 
example, epidermal growth factor receptor (EGFR) 
gene mutations are more likely found in female 
never smokers and these patients often beneÀt from 
gene targeted therapy by tyrosine kinase inhibitors 
(TKI) such as geÀnitib. In contrast, lung cancers 
from smokers are more likely to carry k-RAS gene 
mutations and these patients do poorly with TKI 
treatment. Therefore, the ability to rapidly assess the 
genetic status of the primary lung tumors can offer a 
signiÀcant advantage in the clinic to improve patient 
prognosis and therapeutic management. MassArray 
technology is a single nucleotide extension and mass 
spectrometry-based detection method (Sequenom, 
San Diego, California). It is capable of identifying 
and quantiÀcation single base mutations based on 
the molecular mass difference of the allele speciÀc 
extension primers. Using this method, MassArray 
panels can simultaneously analyze hundreds of 
oncogene mutations in a single run and offers a 
rapid and sensitive screening tool for mutation 
identiÀcation in clinical samples. 
Methods: We Àrst screened 99 non-smoker (NS) 
lung cancers using the MassArray based technology 
and the commercially available OncoCartaTM 
panel which examines gene mutation status in 19 
oncogenes and 238 mutations. We then developed 
a customized non-smoker lung cancer panel that 
focused on nine oncogenes most frequently affected 
in the tested tumor samples. We evaluated this NS 
speciÀc assay panel for its sensitivity and speciÀcity 
to detect mutations using a variety of clinical 
samples including DNA from lung cancer cell lines, 
fresh frozen lung tumors and formalin-Àxed parafÀn 
embedded tissues. 
Results: In a survey of 99 primary lung cancers of 
mostly adenocarcinoma from never smokers, EGFR 
gene mutation was identiÀed in 48 (48.5%) samples. 
In contrast, the rate of k-RAS gene mutation was less 
than 5% (4 of 99 cases) while mutations in MET1/
MET2 (5), PIK3CA (3), ERBB2 (2), BRAF (2), and 
JAK, KIT, and AKT gene (1 each) accounted for 
15% of all the mutations observed. Consistent with 
previous studies, no tumor had concomitant EGFR 
and k-RAS or EGFR and ERBB2 gene mutations. 
However, four tumors had mutations involving both 
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A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.139 COMPARISON OF PLANNING 
TARGET VOLUMES BASED ON 
THREE-DIMENSIONAL CT AND FOUR-
DIMENSIONAL CT SIMULATION 
IMAGES OF NON-SMALL-CELL LUNG 
CANCER
Feng X. Li1, Jianbin Li2, Ying-Jie Zhang1 
1Department Of Radiation Oncology, Shandong 
Cancer Hospital/China, 2Radiation Oncology 
Department, Shandong Cancer Hospital/China
Background: To compare positional and volumetric 
differences of planning target volumes (PTV) based 
on axial 3D-CT and 4D-CT for the primary tumor of 
non-small cell lung cancer (NLCLC).
Methods: Twenty-eight patients with 16 lesions 
located in the upper lobe and 12 lesions in middle 
and lower lobes initially underwent 3D-CT scans 
followed by 4D-CT scans of the thorax under normal 
free breathing. PTV
vector
 was deÀned the GTV 
contuored on 3D-CT and its motion vector: CTVs 
were created by adding 7 mm to GTVs, then, ITVs 
were produced by enlarging CTVs isotropically 
based on the individually measured amount of 
motion in the 4D-CT, lastly, PTVs were created 
by adding 3 mm setup margin to ITVs; PTV
4D
 was 
deÀned on the fusion of CTVs on all phases of the 
4D data: the CTV was generated by adding 7mm to 
the GTV on each phase, then, PTVs were produced 
by fusing CTVs on 10 phases and adding 3 mm setup 
margin. The position of the target center, the volume 
of target and the degree of inclusion (DI) were 
compared reciprocally between PTV
vector
 and PTV
4D
, 
and the 3D motion vector on the relative parameters 
were compared on the grouping.
Results: The median of the 3D motion vector for 
lesions in the upper lobe and in the middle and 
lower lobe were 0.28cm and 0.70cm respectively. 
A comparison of the target center coordinates only 
demonstrated signiÀcant spatial difference in the 
x axe for lesions in the upper lobe (z = -2.010, p = 
0.044), while in the z axe for lesions in the middle 
and lower lobe (z = -2.136, p = 0.033). The median 
of ratio of PTV
4D
 and PTV
vector
 was 0.75 and 0.52 
respectively. A signiÀcant correlation was found 
NSCLC were enrolled between April 2006 and 
April 2008 at our hospital. All patients received 
accelerated HypoRT using 3D-CRT, omitting 
elective nodal irradiation (ENI), to a total dose of 
65-68Gy. Radiotherapy was given by two phases. 
In the Àrst phase, a total dose of 50Gy was given 
in 20 fractions at 2.5Gy per fraction, once per day. 
In the second phase of irradiation, the dose per 
fraction was changed from 2.5Gy to 3Gy without 
any amendment of target volumes. All patients 
received 2 cycles of induction chemotherapy, and 1-2 
cycles of consolidation chemotherapy were given 
to 31 patients. The primary outcome measure was 
the proÀle of radiation toxicity. Treatment-related 
toxicity was scored according to the Common 
Terminology Criteria for Adverse Events (CTCAE) 
version 3.0. The secondary endpoints included 
overall survival (OS), progression-free survival 
(PFS), locoregional PFS (LR-PFS) and the pattern of 
initial failure.
Results: Radiation-associated toxicities are shown in 
Table 1. No patient experienced grade 4-5 radiation-
associated complications. Median follow-up among 
all patients was 20 months (range: 4-51 months) 
and median follow-up of survivors was 45 months 
(range: 35-51 months). The median survival was 
19.0 months (95% CI: 11.-27.), and 2- and 3-year 
OS was 38.2% and 32.1%, respectively. The median 
time to progression was 10.0 months (95% CI: 7.4-
12.6), with 2- and 3- year PFS of 29.8% and 29.8%, 
respectively. The 1-, 2-, and 3-year LR-PFS were 
69.6%, 60.9% and 60.9%, respectively. No patient 
experienced isolated elective nodal failure as the Àrst 
site of failure. 
Table 1. Rate of radiation-associated toxicities 
Toxicity Grade 
1 (%) 2 (%) 3 (%) 4(%) 5 (%) 
Pneumonitis 9 (26.5) 9 (26.5) 1 (2.9) 0 0 
Pulmonary ¿brosis 22 (64.7) 0 0 0 0 
Pleural effusion 13 (38.2) 2 (5.9) 0 0 0 
Bronchial stenosis 3 (8.8) 1 (2.9) 0 0 0 
Esophagitis 15 (44.1) 5 (14.7) 2 (5.9) 0 0 
Esophageal stenosis 0 2 (5.9) 0 0 0 
Pericardial effusion 4 (11.8) 0 0 0 0 
Skin toxicity 9 (26.5) 2 (5.9) 0 0 0 
Source: National Cancer Institute Common Toxicity Criteria version 3.0 
Conclusion: In summary, this study suggests 
that accelerated HypoRT using 3D-CRT omitting 
ENI can be used in locally advanced NSCLC and 
warrants further investigation.
Keywords: Non-small cell lung cancer, Accelerated 
radiotherapy, Hypofractionation
Copyright © 2011 by the International Association for the Study of Lung Cancer S791
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
phase of 4D-CT were delineated based on 50% phase 
image. The position of the target center, the volume 
of target, the matching index (MI) and the degree 
of inclusion (DI) were compared between different 
volumes.
Results: The difference of the center of GTV 
from different phase of 4D-CT and GTV_3D on 
three dimensional direction induced by respiration 
motion was not statistically signiÀcant (F = 0.037, 
p = 0.990). The ratios of GTV_0, GTV_20%, 
GTV_50%, GTV_70% to GTV_3D were 0.94±0.18, 
0.95±0.18, 0.98±0.15 and 1.00±0.18 respectively. 
While the ratio of IGTV_10 to GTV_3D was 
1.60±0.55, which showed a statistically signiÀcant 
correlation to the motion vector (r = 0.667, p < 
0.001). ID of IGTV_10 to GTV_3D was 0.59±0.16, 
which also showed a statistically signiÀcant 
correlation to the motion vector (r = -0.420, p = 
0.026).
Conclusion: The beginning time of 3D-CT is 
random, which dose not show an intrinsic correlation 
to some a phase of 4D-CT. The volume of GTV_3D 
is larger than that of GTV from single a phase of 4D-
CT, but signiÀcantly less than that of IGTV_10. As 
the amplitude of tumor motion increases, the degree 
of GTV_3D covering IGTV_10 becomes less, 
while the motion information included by IGTV_10 
increases.
Keyword: Non-small-cell lung cancer; Four-
dimensional CT simulation ; Gross tumor volume; 
Respiratory phase
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P1.141 IMAGE-GUIDED 
HYPOFRACTIONATED SMALL VOLUME 
RADIO-THERAPY OF NON-SMALL CELL 
LUNG CANCER –FEASIBILITY AND 
CLINICAL OUTCOME
Stefan Janssen1, Carolin Koenig1, Michael Bremer1, 
Martin Werner1, Johann Karstens1, Nicolas 
Dickgreber2, Tobias Welte2, Andreas Meyer1 
1Radiooncology, Mh Hannover/Germany, 
2Pulmology, Mh Hannover/Germany
Background: Local hypofractionated stereotactic 
radiation treatment of early stage non-small lung 
cancer (NSCLC) represents a highly effective 
treatment alternative in medically inoperable 
patients.
Methods: Between 06/07 – 12/10 65 patients 
for the motion vector and the ratio of PTV
vector
 and 
PTV
4D
 in both groups (r = -0.638, -0.850, p < 0.05). 
For all patients, fhe median of DI of PTV
4D
 in 
PTV
vector
 was 66.39%, showed a signiÀcant inverse 
correlation with the motion vector (r = -0.814, p 
< 0.001); while the median of DI of PTV
vector
 in 
PTV
4D
 was 99.55%, showed a positive signiÀcant 
correlation with the motion vector (r = 0.613, p = 
0.001).
Conclusion: The amplitude of tumor motion in 
the middle and lower lobe is larger than that in the 
upper lobe. The location of PTV
vector
 and PTV
4D
 
demonstrate a signiÀcant difference in some a 
direction. PTV
4D
 is smaller than PTV
vector
, the ratio 
of PTV
4D
 and PTV
vector
 is correlated to motion vector 
of the tumor. As the amplitude of tumor motion 
increases, the DI of PTV
vector
 in PTV
4D
 increases, 
while the DI of PTV
4D
 in PTV
vector
 decreases.
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P1.140 COMPARISON OF PRIMARY 
GROSS TUMOR VOLUMES BASED 
ON THREE-DIMENSIONAL CT AND 
FOUR-DIMENSIONAL CT SIMULATION 
IMAGES OF NON-SMALL-CELL LUNG 
CANCER
Jianbin Li, Feng X. Li, Ying-Jie Zhang 
Radiation Oncology Department, Shandong Cancer 
Hospital/China
Background: To compare positional and volumetric 
differences of the gross tumor volume (GTV) 
delineated based on 3D-CT, single a phase of 4D-CT 
and fused phase of 4D-CT for the primary tumor of 
non-small cell lung cancer (NLCLC).
Methods: Twenty-eight patients with NLCLC 
suitable for three-dimensional conformal 
radiotherapy (3D-CRT) sequentially underwent 3D-
CT and 4D-CT simulation scans of the thorax under 
normal free breathing. During 4D-CT scanning, 
real-time position management (RPM) system 
simultaneously recorded the respiratory signals. 
The CT images with respiratory signal data were 
reconstructed and sorted into 10 phase group in a 
respiratory cycle. Data sets for the 3D-CT and 4D-
CT scans were then transferred to Eclipse treatment 
planning software. GTV_3D from 3D-CT, GTV_0, 
GTV_20%, GTV_50% and GTV_70% from end-
inspiration, mid-expiration, end-expiration and 
mid-inspiration of 4D-CT, and IGTV_10 from fused 
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Background: Despite advances in treatment, 5 
year survival for NSCLC remains poor. Radical 
radiotherapy regimes for NSCLC vary between 
centres in the UK. CHART was demonstrated to 
have a superior survival to standard radiotherapy 
(60 Gray in 30 fractions). More recently hypo-
fractionated radiotherapy (55Gy in 20 fractions) has 
been shown to have similar outcomes to CHART.
Methods: Retrospective audit from single institution 
(Velindre Cancer Centre), using CANISC database. 
Demographic, diagnostic, staging, treatment and 
survival data were collected on all NSCLC patients 
treated with radical radiotherapy between 2004 and 
2009. Survival was analysed using Kaplan-Meier 
methodology.
Results: 252 patients were treated with radical 
radiotherapy. 5 patients did not complete planned 
radiotherapy. Median follow-up was 23 months. 
Median age was 71 years (range 42-87). 52% were 
male. 23% were stage IA; 29% stage IB; 3% stage 
IIA; 13% stage IIB; 17% stage IIIA; 13% stage IIIB 
and 2% stage IV (AJCC TNM Version 6). Stage 
distribution was similar between CHART and non-
CHART patients. Histology: 27% had no histological 
conÀrmation; 33% NSCLC NOS, 27% squamous 
cell; 12% adenocarcinoma. 44% were treated with 
CHART; 53% had hypo-fractionated radiotherapy 
(20 fractions); 3% had standard fractionation. 24% 
were treated additionally with chemotherapy as part 
of their planned radical treatment (neo-adjuvant 
or adjuvant); 28% of those who had CHART, 19% 
of those who had hypo-fractionated radiotherapy. 
Survival was similar across all histological groups 
(including those with no histological conÀrmation), 
CHART conferred no signiÀcant beneÀt for any 
histological subtype. There was no signiÀcant 
survival beneÀt for those treated with CHART in any 
stage group. The median overall survival time for 
CHART was 30 months and hypo-fractionated 35 
months. 
Conclusion: This data supports previously published 
data that hypo-fractionated radiotherapy may be 
equivalent to CHART in routine practice. More 
patients in the CHART cohort had chemotherapy 
as part of their planned radical treatment, either 
neo-adjuvant or adjuvant despite age, stage groups 
and histology being similar between the two groups 
(those having CHART and those having non-
CHART). Despite this there was still no survival 
advantage for the CHART group for the cohort 
as a whole or for any stage group or histological 
subtype. This information is clinically helpful when 
with NSCLC were treated with image-guided 
hypofractionated radiotherapy. UICC stage 
distribution was as follows: IA 19 patients, IB 15 
patients, IIB 5, IIIA 10 patients, IIIB 6 patients, 
and IV 10 patients, respectively. Mean age was 69 
years. Histology revealed squamous cell carcinoma 
in 30 patients, non-squamous cell carcinoma in 25 
patients. Fractionation schedule used was 3 x 12.5 
Gy (n=36) prescribed to the encompassing 67% 
isodose line for peripheral primary tumours and 8 
x 6 Gy (n=26) or 8 x 5 Gy (n=3) prescribed to the 
encompassing 80% isodose line for centrally located 
tumours.
Results: Mean follow-up was 13.8 months (range 
0.87 – 41.33 months). Until now six patients (9.2 
%) developed a local recurrence, two of them in 
combination with mediastinal lymph node failure. 
One year actuarial local control rate was 93 %, 
overall survival was 79 %, respectively. Pneumonitis 
(CTCAE grade I and II) was seen in 14 patients 
(21.5 %) after a median time period of 9.5 months. 
No patient developed a pneumonitis CTCAE grade II 
or higher.
Conclusion: Image-guided hfSRT is effective and 
feasible in patients with non-operable NSCLC even 
in higher stages whenever local control is crucial and 
there are contraindications against systemic therapy. 
With acceptable acute and subacute side effects it 
is a valuable therapeutic option in interdisciplinary 
treatment schedules.
Keywords: stereotactic extracranial radiotherapy, 
Lung cancer, outcome
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P1.142 SINGLE INSTITUTION AUDIT 
OF SURVIVAL AFTER RADICAL 
RADIOTHERAPY FOR NON-SMALL 
CELL LUNG CANCER (NSCLC) AND 
COMPARISON OF OUTCOMES OF 
CONTINUOUS HYPER-FRACTIONATED 
ACCELERATED RADIOTHERAPY 
(CHART) VERSUS ONCE-DAILY 
HYPOFRACTIONATED RADIOTHERAPY
Mick Button1, Hazel Bailey1, Alison Brewster1, 
Rebecca Cox2, Carol Davies3, Louise Hanna1, Jason 
Lester1, Rosie Stevens1, Jake Tanguay1 
1Clinical Oncology, Velindre Cancer Centre/United 
Kingdom, 2Cardiff University/United Kingdom, 
3Nevill Hall Hospital/United Kingdom
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function of patients was relatively favorable. 
Radiation pneumonitis was diagnosed by serial chest 
X-ray or computed tomography after radiotherapy 
and its severity was determined by CTCAE 
(Common Toxicity Criteria of Adverse Events) 
version 4.0. Cut-off points from ROC (Receiver 
Operating Characteristic) curve of MLD (mean lung 
dose) and Vn (volume percentage of lung receiving 
more than n Gy; range V5~V50 with 5 Gy interval) 
were investigated to determine the sensitivity and 
speciÀcity in prediction of radiation pneumonitis. 
Results: Radiation pneumonitis occurred in 37 
patients (82.2%) and the incidence of grade II 
or more radiation pneumonitis II was 26.6% (12 
patients) including three radiation pneumonitis 
of grade III (6.6%). In development of radiation 
pneumonitis regardless of its severity, V30, V35, 
V45 and V50 were signiÀcant predictable parameters 
(p<0.05) and 5.8% cut-off value of V30 was thought 
the most powerful predictor (sensitivity 83.8%, 
speciÀcity 75.0%). On the other side, in grade II or 
more radiation pneumonitis, MLD, V5, V10, V15, 
V25 and V30 were signiÀcant parameters (p<0.05). 
Of these parameters, MLD and V5 were shown as 
the most powerful parameter. Cut-off value of MLD 
was 13.2 Gy (sensitivity 91.7%, speciÀcity 63.6%) 
and cut-off value of V5 was 77.8% (sensitivity 
91.7%, speciÀcity 60.6%). Age, sex, ECOG (Eastern 
Cooperative Organization Group) performance 
status, number of targets, summation of PTVs, 
previous thoracic radiotherapy, chemotherapy, total 
dose and daily dose have no statistically signiÀcant 
correlation with radiation pneumonitis. 
Conclusion: We can conclude that cut-off value 
of MLD (13.2 Gy), V5 (77.8%) and V30 (5.8%) 
showed the powerful sensitivity and speciÀcity on 
prediction of radiation pneumonitis, so we should 
carefully consider them for safe simultaneous 
multitarget hypofractionated radiotherapy using 
helical tomotherapy in lung metastases. However, 
further clinical study should be required to 
supplement or corroborate this outcome. 
Keywords: radiation pneumonitis, pulmonary 
dosimetric parameter, hypofractionated radiotherapy, 
multiple lung metastases
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
planning and counselling patients regarding radical 
radiotherapy treatment options in NSCLC. 
Keywords: NSCLC, CHART, survival
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P1.143 PREDICTION OF RADIATION 
PNEUMONITIS THROUGH PULMONARY 
DOSIMETRIC PARAMETERS IN 
SIMULTANEOUS MULTITARGET 
HYPOFRACTIONATED RADIOTHERAPY 
USING HELICAL TOMOTHERAPY FOR 
MULTIPLE PULMONARY METASTASES
Chul-Seung Kay1, Ji Yoon Kim2, Eun Jung Yoo2, Ki 
Jun Kim2 
1Radiation Oncology, Incheon St Mary Hospital 
Catholic University Of Korea/Korea, 2Catholic 
University Of Korea/Korea
Background: High precision radiotherapy using 
hypofractionation has been commonly used for 
pulmonary metastases because tumorcidal dose 
can be accurately delivered to the target without 
increasing dose to adjacent normal lung. However, 
radiation pneumonitis is still major problem and 
sometimes fatal complication after radiotherapy. To 
determine cut-off points of pulmonary dosimetric 
parameters for safe radiotherapy in pulmonary 
metastases, we retrospectively investigated the data 
from patients treated with simultaneous multitarget 
hypofractionated radiotherapy using helical 
tomotheapy for lung metastases. 
Methods: Total 45 patients were included and 
median age was 53 years old (range, 33~81 
years old). Their original malignancies were 
hepatocellular carcinoma (28.9%), breast cancer 
(15.6%), colorectal cancer (15.6), thymoma (8.9%), 
salivary cancer (6.7%), sarcoma (4.4%), lung cancer 
(2.2%), endometrial cancer (2.2%) and kidney 
cancer (2.2%). The patients treated with previous 
thoracic radiotherapy and with chemotherapy within 
six months before the start of radiotherapy were 
Àve (11.1%) and twenty (44.4%), respectively. 
Average number of pulmonary metastases was 
4.7 (median, 4; range, 1~10) and median value of 
PTVs’ summation from multiple targets was 198.2 
ml (range 17.6~1142.9 ml). Median 50 Gy (range, 
30~60 Gy) was delivered to PTV in 10 fractions 
during 2 weeks. Normal lung volume not involved 
by PTV (planning target volume) was from 1380.3 
ml to 4340.3 ml (median 2446.8 ml). The pulmonary 
S794 Copyright © 2011 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
and full IMRT plans occasionally resulted in 
unacceptable hot spots outside the PTV. Three of 
the patients were Ànally treated to a dose of only 
54-62Gy, due to their performance score or clinician 
choice. Data on early clinical outcomes will be 
presented. Table 1. Dosimetric comparison of four 
planning techniques. 
conventional Full IMRT RapidArc H-IMRT 
PTV V95 (%) 97.2 ± 1.6 97.4 ± 1.1 97.5 ± 0.5 97.8 ± 0.8 
PTV V107 (%) 2.6 ± 4.1 1.6 ± 2.8 0.5 ± 0.5 0.02 ± 0.04 
Total lung V20 (%) 33.4 ± 6.6 33.4 ± 6.2 30.3 ± 5.7 30.3 ± 5.7 
Contralateral lung V5 (%) 54 ± 13 46 ± 12 45 ± 9 36 ± 12 
Total body V107 (cc) 44 ± 97 31 ± 49 15 ± 15 1.4 ± 2.1 
Planning time (h) 2-5 2-4 1.5-2.5 1-2 
Conclusion: This novel H-IMRT approach, which 
uses an IMRT component of 12% on average, 
enabled routine treatment of large volume stage 
III tumours to 66Gy. It enables faster planning and 
is superior to other IMRT techniques in reducing 
ipsilateral (V20) and contralateral (V5) lung doses 
and dose hot spots.
Keywords: imrt, Radiotherapy, stage III NSCLC, 
RapidArc
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P1.145 OPTIMAL 4D-CT BASED IMAGE-
GUIDED RADIOTHERAPY IN LUNG 
CANCER APPLICATIONS
Stewart Gaede1, Emily Peat2, Brian Yaremko3, 
Rashid Dar3, Edward Yu3, David Palma3, George 
Rodrigues3 
1Physics And Engineering, London Regional 
Cancer Program/Canada, 2Department Of Civil 
Engineering, University Of Waterloo/Canada, 
3Radiation Oncology, London Regional Cancer 
Program/Canada
Background: The pitfalls of using a single 
respiratory phase of a four-dimensional computed 
tomography (4D-CT) dataset in image-guided 
radiotherapy (IGRT) of lung cancer include noisy 
images, inaccurate simulation of a free-breathing 
patient, and mis-registration with in-room free-
breathing Cone-Beam CT (CBCT) imaging. 
Phantom studies have shown that a low-pitch helical 
CT scan or untagged average intensity projection 
(untagged-IP) dataset for un-gated radiotherapy 
or a subset average intensity projection (subset-
IP) dataset for respiratory-gated radiotherapy can 
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P1.144 DOSIMETRIC BENEFITS OF 
A NOVEL INTENSITY MODULATED 
RADIOTHERAPY (IMRT) TECHNIQUE 
FOR TREATING LARGE VOLUME 
STAGE III LUNG CANCER
Wilko F.A.R. Verbakel1, Ellen Van Reij1, Lonka 
Ladenius-Lischer1, Ben Slotman2, Suresh Senan2 
1Radiation Oncology, VU University Medical Center/
Netherlands, 2VU University Medical Center/
Netherlands
Background: Delivery of doses >60Gy to large-
volume Stage III lung tumours is often difÀcult 
due to the need to limit low dose regions to lung 
tissue. Non- intensity modulated radiotherapy 
(IMRT) planning is often time consuming, use of 
IMRT often increases low dose irradiation to the 
lungs. We clinically implemented a novel hybrid 
IMRT (h-IMRT) approach for large tumors. In the 
present study, dose distributions in patients treated 
using h-IMRT were compared to plans using 3 other 
planning approaches.
Methods: H-IMRT was used to treat 14 patients who 
had an average PTV of 825cc (range 591-1258cc), 
and who underwent concurrent chemo-radiotherapy 
to 66Gy. H-IMRT plans comprised of AP-PA 
open Àelds of 15 MV, with an additional oblique 
PA Àeld avoiding the spinal cord, and planned to 
an average PTV dose of 58Gy. Each plan had a 
3-Àeld IMRT component which was optimized to 
supplement the conventional plan in order achieve 
a Ànal homogeneous dose of 66Gy. Planning was 
performed using the Eclipse TPS (Varian Medical 
Systems) with objectives being: PTV V95>97%, 
hot spots of >107% limited to <5 cm3, spinal cord 
Dmax<50Gy and total lung V20 and contralateral 
lung V5 as low as possible. Plans of all 14 patients 
were retrospectively replanned using either a full 3D 
conformal technique (3Dconf) applying 5-9 static 
Àelds, a 2-arc RapidArc
(v10.0.11) or an IMRT technique, applying 6 Àelds 
of 6 MV, all of which were chosen such that lung V5 
and V20 was optimally spared. Dosimetric data for 
all plans were compared and early follow-up data 
was analyzed. 
Results: 
Both H-IMRT and RapdiArc plans were rapidly 
generated. H-IMRT consistently achieved the 
combination of lowest V5 and V20 in combination 
with smallest hot spots (Table 1). Both conventional 
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A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.146 FEASABILITY ANALYSIS 
AND PRELIMINARY FINDINGS 
OF A PROSPECTIVE STUDY OF 
VARIATION IN BREATH HOLDING 
TIMES AT VARIOUS PHASES OF 
RESPIRATION DURING THE COURSE 
OF RADIOTHERAPY INCLUDING THE 
EFFECT OF RESPIRATORY TRAINING 
IN LUNG CANCER PATIENTS IN A 
DEVELOPING COUNTRY
Anusheel Munshi1, Jai P. Agarwal1, Sarbani G. 
Lakar1, Anil Tibdewal1, Anuradha Daptardar2, 
Vincent Singh2, C S. Pramesh3, G Karimundackal3, 
Kumar Prabhash4, Vanita Narohna4, Sandeep Tandon5 
1Radiation Oncology, Tata Memorial Hospital/India, 
2Occupational Therapy, Tata Memorial Hospital/
India, 3Thoracic Surgery, Surgical Oncology, Tata 
Memorial Hospital/India, 4Medical Oncology, Tata 
Memorial Hospital/India, 5Pulmonary Medicine, 
Tata Memorial Hospital/India
Background: Radiotherapy in lung cancer has 
evolved from conventional 2 dimensional approaches 
to 3 dimensional conformal radiotherapy(3D CRT), 
Intensity modulated radiotherapy(IMRT) and more 
importantly Image guided radiotherapy (IGRT). 
The aim of the present study is to Ànd the breath 
holding times in the Indian population and to see 
the factors (patient related, disease related, training 
related) that have a correlation with breath holding 
times at various phases of the respiratory cycle. 
These Àndings have implications in IGRT for lung 
cancer and for other thoraco abdominal sites as well. 
This abstract reports the feasibility and preliminary 
Àndings of our study
Methods: All the patients of lung cancer being taken 
for radical RT or chemoradiation were eligible for 
the study. All the patients had IIIA or III B disease. 
Out of the proposed 100 suitable patients of Non 
small cell and small cell lung cancer(for radical 
treatment) over a period of 2 years, 25 patients 
have been accrued so far over a period of 4 months. 
overcome these pitfalls. Therefore, the purpose of 
this work is to report on the clinical implementation 
of respiratory motion management in lung cancer 
applications in the IGRT era highlighting the beneÀts 
of these CT datasets.
Methods: All lung cancer patients who are 
candidates for radical radiotherapy received a 
low-pitch helical 4D-CT using a Philips Big Bore 
multi-slice CT scanner (Philips Medical Systems, 
Cleveland, USA). For tumour motion <= 7mm, 
the untagged-IP was generated retrospectively by 
reconstructing a 3D- helical CT scan by using all the 
projection data acquired during the 4D-CT scan. The 
extreme phases from 4D-CT were then registered 
to the untagged-IP to delineate the internal gross 
tumour volume (IGTV). For tumour motion > 7mm, 
the subset-IP was calculated over the range of phases 
representing the intended respiratory gating window. 
The GTV delineated on this dataset automatically 
incorporates the intended residual motion during 
gated delivery. For setup veriÀcation of un-gated 
radiotherapy, the CBCT was registered to the 
untagged IP. Matching was performed on the tumour. 
For gated radiotherapy, the CBCT was registered 
to the subset-IP. Matching was performed by 
encompassing the tumour by the full 4D-CT deÀned 
IGTV. To verify the gating window, an additional 
gated 2D-kV anterior-posterior (AP) planar image 
was compared to the gated AP digitally reconstructed 
radiograph (DRR).
Results: The untagged-IP dataset and subset-IP have 
been used for treatment planning for 150 non-gated 
lung cancer patients since May, 2009 and 11 gated 
lung cancer patients since March, 2010, respectively. 
A decrease in image noise (see Figure) was observed 
in all patients, making tumour delineation easier, 
especially in low contrast areas. This change in 
practice also initiated the use of CBCT and gated 
kV planar imaging for improved setup and gating 
window veriÀcation.
Conclusion: The implementation of IGRT of lung 
cancer radiotherapy in our centre was facilitated by 
the use of the untagged-IP and the subset-IP. The 
use of such imaging overcame the pitfalls of using a 
single respiratory phase as the planning CT.
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P1.147 SUBMILLIMETRE ACCURACY 
IS ACHIEVED WHEN USING 
STEREOTACTIC RADIOSURGERY 
WITH A DEDICATED IMMOBILIZATION 
SYSTEM FOR PATIENTS WITH LUNG 
OLIGOMETASTASES
Shankar Siva1, Brent Chesson1, Yolanda Aarons1, 
Natalie Clements1, Tomas Kron1, Michael P. 
Macmanus2, David Ball1 
1Radiation Oncology, Peter MacCallum Cancer 
Centre/Australia, 2Department Of Radiation 
Oncology, Peter MacCallum Cancer Centre/
Australia
Background: Stereotactic ‘Radiosurgery’ to 
the lung refers to the delivery of a single dose 
of high-precision radiotherapy. Treatments are 
highly conformal, typically with narrow margins 
from the estimated tumour position to the planned 
target volume. We report a veriÀcation study of 
immobilization using a linear accelerator based 
stereotactic treatment system for metastatic cancer to 
the lung.
Methods: Stereotactic ‘Radiosurgery’ with a single 
dose of 26Gy was performed for 9 patients with 
pulmonary oligometastases. Patients were planned 
using 4-dimensional computed tomography (4DCT) 
to account for tumour motion. All patients were 
rigidly immobilized on a dedicated stereotactic 
Elekta BodyFix® system (Medical Intelligence, 
Schwabmuenchen, Germany). Patients were allowed 
shallow free-breathing. Linear accelerated mounted 
slow acquisition CT (cone-beam CT) was performed 
over one minute immediately prior to treatment. 
Pre-treatment tumour images were matched to 
the planning 4DCT reference image with a zero 
millimetre tolerance for treatment couch shifts. The 
cone-beam CT was then repeated immediately after 
the couch shifts and at the mid-point of treatment 
delivery in order to verify tumour position.
Results: Initial mean shifts for pre-treatment soft-
tissue matching were 1.9mm in the longitudinal, 
1.7mm medio-lateral, and 2.9mm in the ventero-
dorsal axis, correlating to a mean shift of 2.1mm 
± 1.5mm (mean ± standard deviation) in any plane 
(range 0mm - 4mm). After initial shifts, the residual 
error was <1mm in all planes prior to treatment 
(mean 0.03mm ± 0.2mm). A mid-treatment cone-
beam CT was performed at a median time of 21 
minutes. At mid-treatment, the mean displacement 
All suitable patients undergo a routine Pulmonary 
function testing (PFT). Subsequently, recording of 
the breath hold is done at a) radiotherapy simulation 
b) Àrst fraction of radiotherapy c) mid radiotherapy 
d) radiotherapy conclusion. After the recording at 
“ a) ” patients are asked to perform deep breathing 
exercises/ spirometer ball exercise to see the effect 
of training on the breath holding times. Assessment 
is made to see the breath holding times in deep 
inspiration (DIBH), deep expiration (DEBH) 
and mid ventilation (MVBH) to see the effect of 
respiratory training on the breath holding times. This 
shall also enable us to Ànd the number of beam on/
off times required for the particular patient based on 
the breath hold timings.
Results
Results: 25 patients have been accrued in the trial so 
far. There were 12(48%) upper lobe, 3(12%) middle 
lobe and 10(40%) lower lobe tumours. 11 patients 
had left sided and 14 had right sided tumours. 
All patients had stage IIIA or III B disease. In all 
patients, the recording at the four speciÀed times 
could be easily taken by the speciÀed method. The 
mean (SD) values in seconds at RT simulation were 
as follows. DIBH 27.9 (11.43), DEBH 19.9(7.78), 
MVBH 21.8(9.68). The compliance rate of patients 
with the speciÀed respiratory training schedule has 
been 100% so far. The values after 1-2 weeks of 
respiratory training were 31.65(16.14), 21.1(8.13), 
23.2(12.2). The mid radiotherapy recording for 
the same parameters was 29.7(20.8), 19.1(10.4), 
22.1(11.9) respectively. At radiotherapy conclusion 
the respective parameters were 29.9 (25.7), 19.7 
(13.4) and 25.8 (17.9). A formal analysis of the 
factors inÁuencing the breath holding time shall be 
done after 100 patients have been accrued into the 
trial. 
Conclusion: As of now, for each of the time points 
of measurement, DIBH>MVBH>DEBH. In our 
preliminary experience, deep inspiratory breath hold 
is the best phase for breath hold for image guidance 
techniques in developing countries. Also there is a 
suggestion of beneÀcial effect of respiratory training 
on breath holding time. These Àndings need to be 
conÀrmed after the stipulated number of subjects has 
been accrued. 
Keywords: lung cancer patients, Breath holding 
times
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during treatment planning and delivery. The standard 
technique at our institution is to treat patients without 
external immobilization. We report clinical data in 
support of this.
Methods: The target for rapid, image-guided SABR 
treatment was identiÀed with a 4-dimensional (4D) 
CT scan that incorporated tumor motion. Patients 
were imaged and treated in free-breathing, with no 
external body immobilization, while comfortably 
lying supine on a thin mattress with arm and knee 
support. Before treatment delivery, a cone-beam 
CT (CBCT) was performed to correctly position 
the tumor in 4 directions (3 translational and 1 
rotational). After the necessary corrections had been 
carried out, then provided that the spine could be 
visualized, stereoscopic spine x-rays (ExacTrac) 
were acquired for the purpose of intra-fraction 
position monitoring. These were repeated at the end 
of treatment delivery and the difference in the two 
sets of readings represented spine, and therefore 
patient, stability in 6 directions (3 translational and 
3 rotational). SABR was delivered with a minimum 
of 2 volumetric intensity-modulated arcs (RapidArc) 
on a Novalis Tx machine at a dose rate of 1000 
monitor units/minute, and with continuous infra-red 
positional tracking using external body markers.
Results: For 109 treatment sessions from 30 patients 
(23M and 7F, median age 72yrs, range 38-90) 
receiving a range of dose-fractionation schedules 
(3x18Gy n=6, 5x11Gy n=8, 8x7.5Gy n=11, 12x5Gy 
n=5) the mean time from start of CBCT acquisition 
to start of Àrst treatment arc was 6.2 minutes (SD 
2.7, range 3.97-27.6). The mean time to deliver the 
prescribed fraction dose was 4.1 minutes (SD 1.3, 
range 2.95-10.05). Mean absolute intra-fraction spine 
movement during treatment delivery was 0.3mm 
(SD 0.3), 0.4mm (0.4) and 0.5mm (0.5) in vertical, 
longitudinal and lateral directions respectively. 
Maximum motion in any direction was 2.8mm and 
2.3 degrees of roll.
Conclusion: Rapid SABR delivery is now 
routine using volumetric intensity-modulated arc 
therapy and CBCT. A simpliÀed and comfortable 
approach to patient set-up and positioning achieves 
comparable stability to that reported with near-rigid 
immobilization devices, without the associated cost 
and complexity. Positioning can be veriÀed with 
x-rays or CBCT when the infra-red tracking signal 
detects excessive body motion, and between arcs for 
selected patients and longer treatment sessions.
Keywords: Stereotactic ablative radiotherapy, 
Immobilization
discrepancy was <2mm in all planes (mean 0.4mm 
± 0.6mm). Of the 9 pulmonary metastases, 5 
were located in the right lower lobes, 3 in the 
left lower lobes, and 1 in the left upper lobe. No 
pattern emerged correlating tumour location with 
displacement.
 
Conclusion: Patients were accurately immobilized 
throughout the treatment with submillimetre 
variation of tumour position throughout treatment. 
Reproducibility and immobilization are robust using 
a dedicated linear accelerator based stereotactic 
immobilisation system.
Keywords: stereotactic, Radiotherapy, 
Immobilization, metastases
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P1.148 FAST DELIVERY OF 
STEREOTACTIC ABLATIVE 
RADIOTHERAPY FOR LUNG TUMORS: 
IS RIGID PATIENT IMMOBILIZATION 
NECESSARY?
Max Dahele, Ben Slotman, Wilko F.A.R. Verbakel, 
Suresh Senan 
Radiation Oncology, VU University Medical Center/
Netherlands
Background: To date, stereotactic ablative 
radiotherapy (SABR) for early-stage peripheral non-
small cell lung cancer has been associated with local 
control rates exceeding 90% in some studies. SABR 
requires high quality treatment plans that concentrate 
the dose on the tumor whilst sparing normal 
tissues, and accurate tumor targeting, an important 
component of which is patient stability. For this 
reason, some guidelines support the use of near-
rigid Àxation devices to reduce patient movement 
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patients had acute side effects: 10 headache, 2 
nausea, 2 erythema of the irradiated skin. After PCI 
six (13%) patients complained for late persistence 
side effects: 3 for vertigo, 1 for nausea, 2 excessive 
excitements, one for deterioration of hearing and 
olfactory hyperaesthesia, one for weakness of 
lower extremities. All patients developed alopecia 
after PCI, in all patients but one hair re-grow was 
observed between 1,5 and 6 months after PCI. 
There were no hematological toxicity. Not statically 
signiÀcant increase in hemoglobin level and WBC 
count was noted at the end of PCI. A decline in 
testosterone level was observed, the difference 
between testosterone level before and after 1 months 
post treatment in Wilcoxon test was close to be 
statistical signiÀcant (p=0,062). Visual memory 
did not change during examination. Visual – motor 
function deteriorated immediately after treatment 
(p<0,053) and 6 months later returned to basic level. 
Slight but signiÀcant decrease
of performance IQ (p<0,011, 6 points) and increased 
difference between performance IQ and verbal IQ 
(p<0,011) were observed.. In MRI a slight atrophy 
in white matter was observed, involution of pituitary 
gland, and slight increase in CSF. 
Conclusion: Prophylactic cranial irradiation in this 
group of patients had relatively low, acceptable 
toxicity although in 13 % of patients a late side 
effects of treatment were reported. Neurological test 
revealed slight decrease of cognitive functions in 
WAIS examination 6 months after treatment. 
Keywords: prophylactic cranial irradiation, NSCLC
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P1.150 NON-RESECTED NSCLC IN 
STAGES I - III: ACCELERATED (TWICE 
DAILY), DOSE-DIFFERENTIATED HIGH-
DOSE RADIOTHERAPY - MATURE 
RESULTS OF A PROSPECTIVE STUDY
Karl Wurstbauer1, Heinz Deutschmann1, Christoph 
Gaisberger1, Peter Kopp1, Manfred Kranzinger1, 
Florian Merz1, Helmut Schöller1, Michael 
Studnicka2, Felix Sedlmayer1 
1University Clinic Of Radiation Oncology, 
Paracelsus Medizinische Privatuniversität/Austria, 
2University Clinic Of Pneumology, Paracelsus 
Medizinische Privatuniversität/Austria
Background: Can the results of the current ‘state of the 
art’ treatment for patients with non-resected NSCLC 
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P1.149 TOXICITY AND RESULTS 
OF PROPHYLACTIC CRANIAL 
IRRADIATION IN PATIENTS WITH 
NSCLC.
Marzena T. Gawkowska-Suwiĸska1, Alicja Heyda2, 
Aleksander Zajusz2, Elŧbieta Nowicka2, Katarzyna 
Behrendt2, Grzegorz Plewicki2, Beata Smolska-
Ciszewska2, Monika Giglok2, Rafaã Tarnawski2 
1Iii Department Of Radiotherapy/ Department Of 
Brachyteraphy, Maria Skãadowska-curie Memorial 
Cancer Center And Institute Of Oncology, Gliwice 
Branch/Poland, 2Maria Skãadowska-curie Memorial 
Cancer Center And Institute Of Oncology, Gliwice 
Branch/Poland
Background: Prophylactic cranial irradiation is a 
standard treatment for patients with small cell lung 
cancer. In NSCLC there are increasing amount of 
data supporting PCI. The aim of the study is to deÀne 
the toxicity PCI in a group of patients with NSCLC. 
Methods: From 1999 to 2007 47 patients with 
NSCLC treated in MCS Memorial Institute of 
Oncology in Gliwice underwent PCI. The total dose 
was 30 Gy dose per fraction was 2 Gy given once 
daily. The treatment was based on 3D planning. 
Inclusion criteria were: NSCLC treated with curative 
intent. The age of patients ranged from 42 to 73 
years, with median 53, mean follow-up was 2, 8 
years. Survival was estimated by means of Kaplan-
Meyer plots. Distance recurrences were recorded. 
Any complains and side effects were recorded 
during the treatment and follow-up. Full blood 
count was performed before and immediately after 
PCI. Alopecia was recorded, time for hair re-grow 
was recorded. Pituitary function was estimated 
by measuring serum testosterone level before, 
immediately after PCI and during follow-up in 10 
patients. Benton Visual Retention Test - BVRT, 
Bender Visual Motor Gestalt Test in Pascal were 
performed before and immediately after PCI (32 
pts) and 6 months after PCI (10pts). Suttel version 
and Wechsler Adult Intelligence Scale - Revised 
(WAIS-R) WAIS examination was performed before 
(32pts) and 6 month after the treatment (10 pts). MRI 
was performed before, immediately after PCI and 
during follow-up in 10 patients. Friedman Anova and 
Wilcoxon test were applied for statistical analysis. 
Results: Mean survival was 1,7 years. 18 patients 
developed distant metastases, 2 of the them (4, 
2%) had brain metastases. During PCI 14 (30%) 
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compare favorably in all parameters with the results 
of simultaneous chemo-radiotherapies, at present 
considered ‘state of the art’ for non-resected NSCLC.
Keywords: sequential chemo-radiotherapy, high 
dose radiotherapy, conformal radiotherapy, Non-
small cell lung cancer
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P1.151 A PROSPECTIVE PILOT STUDY 
TO INVESTIGATE THE USE OF 4DPET/
CT FOR PATIENTS WITH NON-SMALL 
CELL LUNG CANCER (NSCLC) 
UNDERGOING RADIOTHERAPY (RT).
Danny Duplan1, Yolanda Aarons2, Steven David2, 
Jason Callahan2, Alan Herschtal2, David Binns2, 
Belinda Campbell2, Aldo Rolfo2, Tomas Kron2, 
Michael P. Macmanus2, David Ball2 
1Radiation Oncology, Peter MacCallum Cancer 
Center/Australia, 2Peter MacCallum Cancer Center/
Australia
Background: The standard of care for planning high 
dose radiotherapy (RT) for patients with a diagnosis 
of NSCLC at our institution is volumetric FDG-PET/
CT scan (3DPET/CT) acquired in treatment position; 
if PET/CT is unavailable then it is a 4 dimensional 
CT-scan (4DCT). 3DPET/CT is more sensitive than 
CT for tumour localisation, and may incorporate 
ventilatory tumour motion due to the long acquisition 
time. However, partly because of this motion, the 
tumour edge is more difÀcult to deÀne with 3DPET/
CT than with CT. This study was undertaken to 
determine if 4 dimensional PET/CT scan (4DPET/CT) 
results in superior tumour deÀnition than with 3DPET/
CT, and if there are differences in radiotherapy 
treatment volumes generated using 4D vs 3DPET/CT. 
Methods: Patients were eligible if they had 
pathologically proven NSCLC, were planned for 
high dose palliative (>36Gy) or radical (>60Gy) RT, 
and there was some degree of tumour motion over 
the ventilatory cycle. They underwent sequential 
3DPET/CT and 4DPET/CT scans in treatment 
position using an integrated PET/CT scanner (GE 
discovery STE8 or Siemens Biograph). Reference 
tattoos and landmark measurements were used to aid 
reproducibility. 3DCT was acquired Àrst, followed 
by 3DPET. 4DCT and 4DPET were then acquired 
using the Varian Real Time Position Management 
TM (RPM) system. This allowed us to yield 10 scans 
of respiratory gated CT data as well as 10 scans of 
(simultaneous chemo-radiotherapy) be improved?
Methods: Radiation doses are correlated to primary 
tumor size (mean number of 3 perpendicular 
diameters) within 4 groups: <2,5 cm/ 2,5-4,5 cm/ 
4,5-6,0 cm/ >6,0 cm; ICRU-doses of 73,8 Gy/ 79,2 
Gy/ 84,6 Gy/ 90,0 Gy, respectively are applied. To 
macroscopically involved nodes 59,4 Gy median are 
given (range 54,0-75,6 Gy; adapted to size and grade 
of invasion). Fractional doses 1,8 Gy bid, interval 
>10h. Image guidance, margins GTV to PTV of 7 
mm only are used, mostly with the conformal target 
splitting technique. 2 cycles chemotherapy are given 
before radiotherapy, with an interval preferentially 
<10 days. Primary end points of this prospective 
study are local and regional tumor control, secondary 
endpoints are survival and tolerability. Patients were 
rigorously followed especially regarding locoregional 
tumor control (by systematic periodic CT and/or PET 
scanning) and toxicity. With a median follow-up time 
of 29,9 months for patients alive (range 13,6-81,1 
months) mature results are presented.
Results: Between 2004 and 2009 160 patients with 
164 histologically/ cytologically proven NSCLC 
were enrolled. Stage I: 39 patients; II: 6 pts.; IIIA: 
68 pts.; IIIB: 47 pts. Weight loss >5%/ 3 months: 38 
patients (24%). In 82 patients, mainly in stages II and 
III, 2 cycles of chemotherapy before radiotherapy 
were given. We observed 31 local recurrences, 
distributed within the above described tumor size 
groups as follows: 2/27, 20/94, 6/30 and 3/13. 
Eight patients failed regionally. 92% of all failures 
occured within two years after starting therapy. The 
overall local tumor control rate at 2 years is 77%. 
The median overall survival time and the 2-/ 3-year 
overall survival rate are 26,5 months and 55% / 38%, 
respectively. Excluding stage I patients and patients 
with weight loss >5% during the three months 
before diagnosis (for comparison with the trials 
presently deÀning the ‘state of the art’ treatment), the 
median overall survival time is 27,1 months. Two 
treatment-related deaths occurred 5 and 6 months 
after the end of radiotherapy: pulmonary Àbrosis (in 
the pretherapeutic CT scans both patients showed 
already radiologic signs of pulmonary Àbrosis). The 
further acute toxicity was mild: pneumonitis grade 
3 in 6 patients; esophagitis grade 1/ 2/ 3 in 51/ 16/ 
8 patients, respectively. One patient showed late 
esophageal toxicity grade 3. Furthermore no late 
toxicity scored >grade 1 was observed.
Conclusion: The Àgures for locoregional tumor 
control and survival are encouraging high; and in 
general treatments are well tolerated. The results 
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Background: Stereotactic radiotherapy (SRT) has 
recently been used for the treatment of early stage 
or small lung malignant tumors while standard 
method has not been established.We retrospectively 
evaluated the efÀcacy and safety of SRT for non-
small cell lung cancer (NSCLC) treated in our 
hospital which is popular local community core 
hospital for cancer treatment.
Methods: Between October 2007 and December 
2010, 39 tumors of 37 patients were treated by 
SRT(mean age, 74 years old: stage I,n=22; stage 
III,n=3; recurrence,n=14)
Results: Two patients with stage III NSCLC 
underwent SRT for primary tumors followed 
concurrent chemoradiotherapy for mediastinal lymph 
node metastasis. Risk-adapted SRT schemes were 
used with the two total dose of 48 grays in 26 site 
and 52 grays in 5 site by 4 fractions, depending 
on the patient’s risk for toxicity. All of the patients 
completed the treatment. In one patient who had 
radiation pneumonitis before SRT, progression of 
pulmonary Àbrosis was observed, and treated with 
steroid therapy. In the patients who underwent SRT 
followed concurrent chemoradiotherapy, severe 
adverse effects caused by SRT was not observed. 
In evaluable 37 tumors, the recurrence rates are 
14/37(37.8%). Median progression free survival 
time was 13 months. The recurrence rate and median 
progression free survival time of stage I subgroups 
was 5/22(22.7%) and 17 months respectively.
Conclusion: SRT is thought to be safe and effective 
treatment for stage I NSCLC.For patients stage I 
NSCLC, SRT can be comprehensive therapy for 
surgical resection even in local community hospital. 
And SRT followed concurrent chemoradiotherapy 
for stage III NSCLC was feasible in terms of safety. 
Keyword: Stereotactic radiotherapy
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P1.153 CLINICAL AND DOSIMETRIC 
RISK FACTORS FOR RADIOTHERAPY 
INDUCED BONE INJURY (RIBI) 
FOLLOWING STEREOTACTIC BODY 
RADIOTHERAPY (SBRT)
Mojgan Taremi1, Andrew Hope2, Max Dahele3, 
Patricia E. Lindsay2, Sharon Fung4, Tom Purdie2, 
David A. Jaffray2, Laura A. Dawson2, Andrea 
Bezjak5 
1Radiation Oncology, Southlake Regional Health 
Center/Canada, 2Radiation Oncology, Princess 
respiratory gated PET data each corresponding to 
one of 10 pre-determined phases of each patient’s 
respiratory cycle. These images were co-registered 
to create the 10 individual phases of the 4DPET/CT. 
For each of these phases, a Gross Tumour Volume 
(GTV) was contoured by a radiation oncologist using 
a blend of PET and CT data following a standard 
protocol used in our institution. This amounted to 
a total of 10 GTVs which were summed to create 
a single aggregate volume (V
4D
). We proceeded to 
compare this volume to the GTV contoured by the 
same physician on the 3DPET/CT (V
3D
). To do so, 
we used the difference between V
4D
 and V
3D
 (V
4D
 - 
V
3D
) as well as a Conformity Index (CI=2(V
3D
ƗV
4D
)/
(V
3D
+V
4D
)). A clinically signiÀcant difference was 
deemed to exist between the V
3D
 and V
4D
 if the 
relative difference between these volumes was 
more than 5%. The CI was considered to represent 
a clinically signiÀcant difference between these 
volumes when its value was less than 0.95. 
Results: Five patients were available for analysis. For 
all patients, the difference between the V
4D
 and V
3D
 
was consistently over 5% (15% to 59%). The V
4D
 was 
larger than the V
3D
 in all 5 cases. Conformity Index was 
consistently less than 0.95 (0.40 to 0.82) suggesting a 
clinically signiÀcant difference between the V
3D
 and V
4D
. 
Conclusion: Our preliminary results revealed 
that the use of 4DPET/CT for planning of RT 
in patients with moving tumours may generate 
treatment volumes which are very different to the 
ones contoured on a planning 3DPET/CT. This 
suggests better deÀnition of the tumour volume 
(with incorporation of motion) using 4DPET/CT. 
This difference could be clinically relevant. Further 
patient accrual is necessary to conÀrm these Àndings. 
Keywords: 4DPET/CT, volumetric PET/CT, 
3DPET/CT, planning
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P1.152 STEREOTACTIC RADIOTHERAPY 
(SRT) AS COMPREHENSIVE THERAPY 
FOR NON-SMALL CELL LUNG 
CANCER INCLUDING STAGE III AND 
RECURRENCE CASES
Yohei Futamura1, Toshiyuki Sawa1, Akane Horiba1, 
Takashi Ishiguro1, Tsutomu Yoshida1, Takayoshi 
Iida2, Takaaki Hasegawa1 
1Respiratory Medicine And Oncology, Gifu 
Municipal Hospital/Japan, 2Radiology, Gifu 
Municipal Hospital/Japan
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gender (HR 4.43, 95% CI: 1.68 - 11.68) remained 
statistically signiÀcant risk factors. Based on the 
dose-event curve, a D
0.5
 of 50 Gy is associated with 
an estimated 30% risk of RIBI. A nomogram was 
generated based on the multivariate model including 
age, female gender and D
0.5
.When analyzed via 
receiver operating characteristic (ROC), the Ànal 
RIBI nomogram had an area under the curve (AUC) 
of 0.93. 
Conclusion: Both dosimetric and clinical factors are 
correlated with risk of RIBI and should be included 
when modeling risk of toxicity. A nomogram using 
D
0.5
, age, and female gender may be useful to 
estimate risk of RIBI following SBRT and requires 
validation. 
Keywords: stereotactic body radiotherapy, 
radiotherapy toxicity, rib fracture, nomogram
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P1.154 IS SBRT ALONE APPROPRIATE 
FOR EARLY-STAGE NON-SMALL-
CELL LUNG CANCER WITH PRIMARY 
TUMOURS LARGER THAN 4CM?
Zishan Allibhai1, John Cho1, Soha Atallah1, Andrew 
Hope1, Anthony M. Brade1, Alex Sun1, Mojgan 
Taremi2, Andrea Bezjak1 
1Radiation Medicine Program, Princess Margaret 
Hospital/Canada, 2Radiation Oncology, Southlake 
Regional Health Center/Canada
Background: While stereotactic body radiation 
therapy (SBRT) has proven to be safe and effective 
in the management of early-stage non-small-cell 
lung cancer (NSCLC), there is concern that larger 
tumours have poorer outcomes with higher rates of 
failure as well as potentially greater toxicity. 
Methods: Between October 2004 and October 
2010, we treated 208 medically inoperable patients 
with T1-T2N0M0 NSCLC on a prospective REB-
approved single-institution protocol. Patients were 
planned conformally using 4D-CT with 8-10 non-
coplanar beams. Typical dose regimens used for 
peripheral tumours were 54-60 Gy/3 fractions or 
48/4 for peripheral tumours (only if <3 cm) while 
central tumours were treated with 50/8 or 60/10. 
Cone-beam CT (CBCT) was used for daily tumour 
localization. Follow-up included regular medical 
visits and serial CT scans (q3-6months). Post-SBRT 
radiological changes were carefully reviewed to 
distinguish RT Àbrosis from possible local failure. 
Margaret Hospital/Canada, 3Radiation Oncology, Vu 
University Medical Center/Netherlands, 4Department 
Of Biostatistics, Princess Margaret Hospital/
Canada, 5Department Of Radiation Oncology, 
Princess Margaret Hospital/Canada
Background: Limited data exist to estimate risk of 
RIBI following SBRT. The purpose of this study was 
to identify clinical and dosimetric factors associated 
with RIBI and to develop a nomogram model to 
estimate risk of RIBI following SBRT. 
Methods: Inoperable patients with early stage 
non-small cell lung cancer, treated with SBRT, 
who received 54 or 60 Gy in 3 fractions, and had 
a minimum of 6 months follow up were selected 
for this retrospective institutional study. Archived 
treatment plans were retrieved, ribs were delineated 
individually and treatment plans were re-computed 
using heterogeneity correction. RIBI was identiÀed 
by reviewing the serial CT images. Clinical and 
dosimetric factors were evaluated for their association 
with rib fracture using logistic regression analysis; a 
dose-event curve and nomogram were created. 
Results: 46 patients with median follow-up 25 
months (range 6 – 51m) were included. 41 fractured 
ribs were detected in 17 patients; median time to 
fracture was 21m (range 7 – 40m). Of 41 identiÀed 
fractured ribs the original radiologic report did 
not report fracture in 37% (n=15). Analyses were 
performed per rib and per patient. The mean of 
the maximum point dose to any rib in 46 patients 
was 55.2 Gy + 17.9 Gy (range: 21.6 to 88 Gy). A 
signiÀcant difference was noted between patients 
with no rib fracture (n=29) vs. patients with rib 
fracture (n=17), 50.2 Gy + 17.7 Gy (range: 21.6- 
73.2 Gy), vs. 63.7 Gy + 15.3 Gy (range: 26.6-88 
Gy) p = 0.02. 1095 ribs were available for analysis; 
the mean of maximum point dose to all ribs (1095) 
was 12.7 Gy + 17.5 Gy (range: 0.2 to 88 Gy). In 
non-fractured ribs (n=1049), the mean of maximum 
point dose was 10.5 Gy + 10.2 Gy (range: 0.2-
87 Gy), and in the fractured ribs (n=46) was 
48.5 Gy + 24.3 Gy (range 0.6-88 Gy) which was 
statistically signiÀcant (p < 0.0001). On univariate 
analysis, age, dose to 0.5 cc of the ribs (D
0.5
), and 
the volume of the rib receiving at least 25 Gy 
(V
25
) were signiÀcantly associated with RIBI. As a 
signiÀcant cross-correlation exists between D
0.5
 and 
V
25
 (Spearman coefÀcient 0.57, P < 0.001); only 
D
0.5
 was used for further analysis. In multivariate 
analysis age (HR 1.121, 95% CI: 1.04 –1.21), D
0.5
 
(HR 1.0009, 95%CI: 1.0007 – 1.0011), and female 
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P1.155 THE EFFECT OF SET-UP ERROR 
ON DELIVERED DOSE IN CURATIVE 
RADIOTHERAPY FOR NON-SMALL 
CELL LUNG CANCER
Aitang Xing, Lois Holloway, Shivani Kumar, Cesar 
Ochoa, Shalini K. Vinod 
Liverpool Hospital, Radiation Oncology/Australia
Background: Setup uncertainties in the treatment 
of lung cancer can lead to differences between 
the planned and delivered dose. At our centre, a 
literature-derived margin of 10mm in the transverse 
direction and 15mm in the cranio-caudal direction is 
added to the clinical target volume (CTV) to account 
for setup uncertainty in curative radiotherapy for 
lung cancer. The aim of this study was to model the 
impact of daily set-up variation on the delivered dose 
for lung cancer patients based on measured treatment 
set-up. 
Methods: Daily set-up deviation was measured 
utilising perpendicular planar imaging for 25 patients 
over 20 fractions of radiotherapy treatment and the 
random and systematic set-up deviation determined. 
To model the effect of geometrical uncertainties on 
delivered dose distributions to the CTV over the 
course of treatment a Monte Carlo (MC) and a direct 
method were used to simulate the delivered dose. 
The MC method uses random shifts to replicate 
the clinically measured deviations. In the direct 
method, a treatment plan was created for each patient 
incorporating the measured daily shifts for the Àrst 
20 fractions. To evaluate the clinical coverage the 
resulting CTV covered by 95% of prescribed dose 
was determined. These results were compared to the 
ICRU guidelines and used to assess the adequacy 
of the current PTV margins and protocols for set-up 
veriÀcation. 
Results: The average systematic error for the group 
of 25 patients was 0.3cm(x), 0.54cm(y) and 0.25cm 
(z) and this was used for MC simulation. The 
average random error was 0.24cm(x), 0.46cm(y), 
0.16cm (z) with the greatest set-up error in the Y 
direction. The MC and direct methods for simulating 
delivered dose showed a maximum difference of 
1.1 % (Table 1). The average CTV covered by the 
prescribed dose in the simulations was above 95% 
for all patients except Patient 1. The original plan for 
this patient had suboptimal coverage of the CTV due 
to proximity to spinal cord, which worsened when 
the isocentre shifts were applied. 
Patterns of failure, toxicity proÀle and survival 
outcome (calculated from start of SBRT) for tumour 
size 4 cm and the effect of gross-tumour-volume 
(GTV) and planning-target-volume (PTV) size on 
outcomes was determined. 
Results: There were 28 patients whose primary 
tumour had a maximum dimension 4cm (median 
4.5 cm, range 4.0 - 5.7 cm). Eighteen patients were 
treated using 54-60 Gy in 3 fractions, four 60/8, and 
six 50/10, respectively. The increased use of central 
dose regimens reÁected the tendency for larger 
tumours to approach central structures. Median 
follow-up was 14.1 months (range 2-53 months). 
Of the 28 pts, 2 (treated with 50/10 and 60/8) had 
likely local failure (LF) based on imaging (not 
biopsy proven), 5 had regional failure (RF) and 7 had 
distant failure (3 with lung metastases only). One 
of the patients with LF also had distant metastasis 
(DM) while 4 of 5 patients with RF also had DM. 
The rate of LF, RF and DF-free survival was 92.9%, 
82.1%, and 75.0% respectively, while overall failure-
free-survival was 64.3%. The rate of local control 
is similar to that previously reported for the entire 
patient cohort (median tumour size 2.4 cm, Taremi 
IJROBP 2011). The most common acute toxicity 
was fatigue (19/28 patients), and the most common 
clinically signiÀcant toxicity was symptomatic rib 
fracture (8/28 patients). However, the rate of G2-3 
pneumonitis was 17.6%, substantially higher than 
previously reported (10.2%). The average V20 was 
9.1%. Within this cohort of patients, there was no 
signiÀcant difference in control, toxicity or survival 
outcomes between tumours larger or smaller than the 
median tumour size of 4.5 cm. Similarly, there was 
no difference in outcomes between tumours larger or 
smaller than the median GTV (34.7 cm3). Tumours 
with PTV’s larger than the median size (100.6cm3) 
had similar pneumonitis rates despite having a 
signiÀcantly higher V20 (p=0.01).
Conclusion: For patients with early-stage NSCLC 
treated with SBRT, we did not observe an effect of 
tumour size on local control. However large tumours 
may extend closer to central structures and may 
be at risk of local failure if lower SBRT doses are 
used. However, there may be more toxicity (such as 
radiation pneumonitis) associated with treating larger 
tumours, and this should be monitored carefully.
Keywords: large primary, NSCLC, prospective, 
SBRT
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(Medical Intelligence®). We contoured the ITV 
using the maximum intensity projection in lung 
window. An ITV-PTV margin of 3 mm was taken. 
The planning was performed on the average 
scan using the Tomotherapy Hi-Art convolution 
superposition algoritm. 99% of the PTV received 
100% of the prescribed dose. In the central part of 
the tumor an overdose of 20-25% was given. Dose 
prescription was T1 peripheral tumor: 3 x 18 Gy, 
T2 tumor or adjacent to ribs: 5 x 12 Gy and T1-2 
tumors with central location: 8 x 7.5 Gy, all three 
times a week. Before treatment a control MV-CT 
scan was performed. Table and gantry position 
were corrected based on an automated registration 
on bony structures adapted manually on the visual 
tumor shadow in relation to projected PTV/isodoses. 
The treatment time ranged from 6 to 12 minutes. 
Patients were followed at regular intervals of 3 
months. 
Results: The median follow up period was 14.5 
months. In one patient a symptomatic rib fracture 
occurred that was treated conservatively and 3 
patients (3.4%) had grade 2-3 radiation pneumonitis 
requiring temporary treatment with corticosteroids. 
The median age for lung carcinoma patients treated 
group was 73 years. Tumor staging was 55 T1, 19 
T2 and 3 (limited)T3. Histologic conÀrmation of 
malignancy was derived in 23 patients. In total 13 
patients were previously treated with radiotherapy 
(4 patients, 50-55 Gy) or surgery (wedgeresection 
(1), lobectomy (5), bi-lobectomy (1), pneumectomy 
(2)) for a previous malignancy. In total 21 patients 
deceased of which 7 due to lung cancer. Median 1- 
and 2-year survival are 86% and 58%, which agrees 
with other studies. We observed 2 local recurrences 
with an act. 2-year local progression free survival 
of 95%. Simultaneously these recurrent patients 
showed also a regional or distant metastasis. One 
patient had a solitary regional recurrence, 7 patients 
had distant metastases without local recurrence
Conclusion: SBRT with the tomotherapy Hi-Art 
system is a good solution and leads to a high local 
control and low toxicity
Keywords: SBRT, Stage I NSCLC, Tomotherapy
Patient 
No 
Random Std(cm) CTV coverage 
X Y Z Original plan 
Direct method 
modelled shifts 
MC method 
modelled shifts 
1 0.26 0.42 0.41 89.22% 83% 84.1% 
2 0.089 0.150 0.182 100% 99.99% 99.80% 
3 0.09 0.15 0.182 99.99% 99.65% 99.62% 
4 0.18 0.59 0.21 98.02% 96% 96% 
5 0.37 0.52 0.24 99.91% 99.87% 98.60% 
6 0.31 0.69 0.17 99.61% 99.18% 96.18% 
7 0.28 0.56 0.17 99.95% 99.66% 99.22% 
8 0.23 0.43 0.18 96.78% 96.15% 95.80% 
Table 1: Measured random set-up error and resulting modelled CTV coverage from the 
original plan, the direct method and the Monte Carlo method. 
Conclusion: The current PTV margins and set-up 
veriÀcation protocols have resulted in delivered 
dose meeting ICRU guidelines in all but one patient. 
The direct and Monte Carlo methods were similar 
in terms of modelling, the latter will be used to 
analyse the remaining patients. In the absence 
of daily imaging, measurement of set-up error 
and resultant isocentre deviations is important to 
evaluate adequacy of PTV margins in the curative 
radiotherapy treatment of lung cancer.
Keywords: Lung cancer, Set-up deviation
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P1.156 IMAGE GUIDED SBRT USING 
TOMOTHERAPY FOR STAGE I NSCLC: 
FIRST CLINICAL RESULTS
Ernest J.A. Vonk, Andre Minken, Marloes I. Ten 
Brinke, Margo C. Noordhoek 
Radiotherapy, Riso/Netherlands
Background: For patients with stage I non-small 
cell lung cancer (NSCLC) the common treatment 
is lobectomy or pneumonectomy. However, a large 
group of patients is medically inoperable due to 
cardiac or pulmonary co-morbidity. In recent years 
stereotactic body radiotherapy (SBRT) proves to be 
a good alternative to surgery for these patients with 
a high local control rate and few side effects
Methods: In 2007 we started with SBRT of lung 
tumors using the Tomotherapy Hi-Art system. 
We report the results of 89 patients treated for 
lungcarcinoma (75), local recurrent lung carcinoma 
(2) or metastases (12). We treated patients with 
SBRT with tumors <5 cm, which on CT scan 
examination were suspicious for malignancy 
(new or growing lesion with spiculae). A positive 
PET-CT without evidence of hilar or mediastinal 
lymphadenopathy was mandatory. During treatment 
patients were immobilised with a vacuum bag 
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highest for tumor and heart, with Dice similarity 
coefÀcients ranging between 0.83-0.86 and 0.87-
0.92, respectively. Lower levels of agreement were 
observed for esophagus and proximal bronchial 
tree with similarity coefÀcients between 0.51–0.72 
and 0.58-0.66, respectively. The differences in 
Dice coefÀcients between the different sites were 
statistically signiÀcantly different (P <0.05). 
Conclusion: Despite the use of an atlas, large 
contouring variations in some critical organs were 
observed, even in an institution where SABR is 
routinely used for treating large and central tumors. 
TaCTICS can complement contouring guidelines 
by objectively evaluating clinician contours against 
a reference. Further efforts to develop software-
assisted training tools that also include real-time 
capabilities are justiÀed. Such tools might have a 
role in risk-management, quality assurance, and 
transferring SABR knowledge and techniques to 
other regions. 
Keywords: Stereotactic ablative radiotherapy, 
contouring variation, interactive software tool, 
delineation
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P1.158 DETECTION OF EGFR GENE 
MUTATIONS IN PATIENTS WITH 
ADVANCED NSCLC IN SLOVAK 
REPUBLIC.
Katarina Hlinkova1, Barbora Piackova1, Ivan Majer2, 
Pavel Babal3, Lucia Copakova1 
1Department Of Cancer Genetics, National 
Cancer Institute/Slovak Republic, 2Department Of 
Pneumology And Phtisiology, Faculty Of Medicine 
Comenius University/Slovak Republic, 3Department 
Of Pathology, Faculty Of Medicine, Comenius 
University/Slovak Republic
Background: Somatic mutations of the EGFR gene 
in exons 18 to 21, particularly an in-frame 15 bp 
deletion (delE746_A750) in exon 19 and the L858R 
mutation in exon 21, are associated with enhanced 
clinical responsiveness to EGFR tyrosine kinase 
inhibitors. Recently, the epidermal growth factor 
receptor (EGFR) tyrosine kinase inhibitor geÀtinib 
was approved in Slovak republic for the treatment of 
advanced NSCLC. 
Methods: We established and validated methods 
for mutation screening of the EGFR gene by a 
high resolution melting analysis. HRMA assay 
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P1.157 VARIATION IN CONTOURING 
NORMAL ORGANS FOR STEREOTACTIC 
ABLATIVE RADIOTHERAPY: TRAINING 
ANALYSIS WITH AN INTERACTIVE 
SOFTWARE TOOL (TACTICS)
Eva Marrit Bongers1, Max Dahele1, Jayashree 
Kalpathy-Cramer2, Clifton D. Fuller3, Suresh Senan1 
1Radiation Oncology, Vu University Medical Center/
Netherlands, 2Oregon Health & Science University/
United States Of America, 3Department Of Radiation 
Onoclogy, University Of Texas Health Science 
Center/United States Of America
Background: Stereotactic ablative radiotherapy 
(SABR) has achieved high local control rates with 
minimal toxicity in the treatment of peripheral lung 
tumors. Larger and more central tumors are now 
being treated, but the use of high doses and steep 
dose-gradients near adjacent critical structures can 
increase the risk of toxicity. Inter-observer variation 
in contouring tumors and critical organs is well 
recognized and may contribute to suboptimal SABR 
plans. We evaluated a novel approach to contouring 
training using an interactive tool that is currently 
being developed to provide individual clinicians 
with quality metrics and visual feedback of the 
delineation process. 
Methods: The TaCTICS (Target Contour Testing/
Instructional Computer Software) tool is an open-
access, web-based application (http://skynet.
ohsu.edu/tactics_nl/) being designed to evaluate 
the similarity between submitted and reference 
contours using quantitative metrics and graphical 
displays. The quantitative metrics are derived using 
algorithms from the Insight Toolkit (ITK, http://
www.itk.org/). Three thoracic radiation oncologists 
with expertise in lung SABR delineated a large, 
central lung tumor and critical organs in accordance 
with published guidelines (Kong FM, 2010). The 
STAPLE (Simultaneous Truth and Performance 
Level Estimation) algorithm, which computes a 
probabilistic estimate of the true segmentation 
(WarÀeld SK, 2004) was used to derive a single 
reference contour for each structure from the 3 
expert contours. Subsequently, 3 radiation oncology 
residents independently contoured the same tumor 
and critical organs. Similarity metrics and images 
were generated. 
Results: The level of agreement between each 
resident’s contour and the reference contour was 
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pneumonitis (RP)(RTOG grade 2 or more) in non 
small cell lung cancer patients treated with combined 
modality therapy.
Methods: Between January 2008 to December 
2010, 41 patients of non-small cell lung cancer 
were treated with combined modality therapy. 31 
were treated with concurrent chemoradiotherapy 
and 10 with neoadjuvant chemotherapy followed 
by radiotherapy alone. Cisplatinum 50mg/m2 
d1,8,29,36 and etoposide 50mg/m2 d1-5,d 29-33 was 
administered concurrent to radiotherapy. All patients 
underwent three dimensional treatment planning 
(including dose volume histograms) and were treated 
with curative intent to a dose of 50-66Gy. Patients 
were treated only if the percentage of whole lung 
volume receiving 20 Gy ( V20) was less than 37% 
and mean lung dose (MLD) was less than 20Gy.
Pulmonary function tests (PFT), site of tumour, 
planning target volume and the various dose volume 
parameters like the total (V20, V5 and MLD) and 
ipsilateral (V20 ipsi, V5 ipsi amd MLD ipsi) lung 
dose–volume histogram (DVH) parameters were 
correlated with incidence of signiÀcant pneumonitis.
Results: Out of 41 patients, 31 patients were treated 
with 21 (53.4%) developed grade 2 pneumonitis.
The factors signiÀcantly correlating with radiation 
pneumonitis were V5 (p=0.04), V5 ipsi (p=0.007) , 
V20 ipsi (p=0.012), and MLD ipsi (p=0.03). V20, 
MLD, PTV, PFT, site of tumour were not statistically 
signiÀcant. When the analysis was limited to patients 
receiving concurrent chemoradiation (n=31) factors 
correlating with radiation pneumonitis were V20 
(p=0.02), MLD (p=0.02),V20 ipsi (p=0.03), and 
V5ipsi (p=0.02).PFT (Fev1<2litres/min) correlated 
with MLDipsi. On multivariate analysis V20 ipsi 
was retained as the most signiÀcant factor. 
PTV V20 V5 MLD V20ipsi V5ipsi MLDipsi 
No RP group 564 25.9 38.1 14.5 47.5 57.3 24.4 
RP group 552 32.4 49.1 18.6 61.17 71.2 32.5 
P value 0.86 0.06 0.04 0.08 0.012 0.007 0.031 
Table 1: Dosimetric constraints in RP 
Conclusion: The correlation between pneumonitis 
and dosimetric constraints has been validated. Adding 
ipsilateral V20, V5 and MLD to the classical total 
lung constraints could reduce pulmonary toxicity in 
concurrent chemoradiation. V20ipsi, V5ipsi and MLD 
ipsi are important if the classical total lung constraints 
ie V20, MLD have not exceeded the constraints of 
37% and 20Gy respectively. 
Keywords: ipsilateral lung, dose volume parameters, 
radiation pneumonitis
demonstrated a sensitivity of 1% of mutanted 
DNA in a background of wildtype DNA. The 
positive results of HRMA were conÀrmed by direct 
sequencing. In samples containing less than 25% 
tumor cells, we were able to conÀrm positive HRMA 
results by direct sequencing after the enrichment of 
tumor-associated DNA by mutant-enriched PCR. 
Results: We examined 321 patients with advanced 
NSCLC (193 cases of squamous cell carcinomas, 
120 adenocarcinomas and 8 large cell carcinomas). 
We analyzed 234 cytological specimens, 72 parafÀn 
embedded (FFPE) blocks and 12 tumors. Mutations 
of EGFR gene were detected in 36 cases (11%). 
The in-frame deletions in exon 19 and L858R 
mutation in exon 21 were detected in 15 (44%) 
and 12 (35%) cases, respectively. Two patients 
had double mutations and one patient had L861Q 
mutation in exon 21. We found 2 types of mutations 
in exon 18 of EGFR gene not previously described 
(K712T and K715E). These patients with a novel 
mutations received GeÀtinib. Two patients have 
T790M mutations without prior exposure to EGFR-
TKI. Mutations of EGFR gene were found in 27 
adenocarcinomas, 8 squamous cell carcinomas and 1 
large cell carcinomas. 
Conclusion: Our results indicated that HRMA in 
combination with mutant-enriched PCR with the 
possibility of direct sequencing provides an effective 
method for mutation screening of EGFR gene in 
routine oncologic practice from various clinical 
samples. 
Keywords: EGFR mutations, HRMA, Direct 
sequencing, mutant-enriched PCR
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P1.159 IPSILATERAL LUNG DOSE 
VOLUME PARAMETERS PREDICT 
RADIATION PNEUMONITIS IN 
ADDITION TO CLASSICAL DOSE 
VOLUME CONSTRAINTS IN STAGE 
IIIA-B NSCLC TREATED WITH 
COMBINED MODALITY THERAPY
Sushma Agrawal1, Sunil Kumar2, Shaleen Kumar1 
1Department Of Radiotherapy, Sanjay Gandhi Pgi/
India, 2Department Of Radiotherapy, Snajay Gandhi 
Pgi/India
Background: To determine the correlation 
of clinical and lung dose volume parameters 
(ipsilateral and whole lung) with signiÀcant radiation 
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Results: PSPT resulted in the lowest dose to the 
OAR, while keeping the dose to the target at 70 Gy. 
The mean lung dose (MLD) reduced from 18.9 Gy 
for 3DCRT and 16.4 Gy for IMRT to 13.5 Gy for 
PSPT. The average integral dose was signiÀcantly 
higher for 3DCRT (59%) and IMRT (43%) than for 
PSPT, while the maximum doses to the spinal cord 
were 6% and 11% higher, respectively, although 
this was not signiÀcant. The mean dose to the heart 
was lowered by 50% and 47%, respectively, while 
the V40Gy was reduced by 53% and 37%. The 
V55Gy for the oesophagus was signiÀcantly higher 
for 3DCRT but lower for IMRT compared to PSPT 
(31.0%, 26.4% and 28.3%, respectively).
For 10 patients, the plans could be escalated to an 
MTD of around 87 Gy for all three modalities . 
The average integral dose was about 65% higher 
for photons than for protons. The MLD was 42% 
higher for 3DCRT than for PSPT, while it was 40% 
higher for IMRT. For the spinal cord, the maximum 
dose was 90% higher for IMRT than for PSPT. For 
the oesophagus, the maximum dose was about 72 
Gy for all modalities. The mean dose to the heart 
for photons was double the dose for protons, while 
the V40Gy was 117% higher for 3DCRT and 57% 
higher for IMRT than for PSPT.
Conclusion: These results show a reduction of 
integral dose and the dose to the OAR when treating 
with protons instead of 3DCRT or IMRT photons.
Even with dose-escalation, PSPT is able to use its 
beneÀcial dose distribution to give a high tumour 
dose, while keeping the OAR dose lower than with 
the photon modalities.
Keywords: In silico planning study, Particle therapy, 
NSCLC, Radiotherapy
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P1.161 CHANGES IN TUMOUR VOLUME 
DURING RADIOTHERAPY FOR 
LOCALLY ADVANCED NON SMALL 
CELL LUNG CANCER.
Sushma Agrawal, Sunil Kumar, Anil K. Maurya, 
Shaleen Kumar 
Department Of Radiotherapy, Sanjay Gandhi Pgi/
India
Background: Dose escalation for lung cancer is 
limited by normal tissue toxicity. We evaluated a 
sequential computed tomography scan to assess the 
possibility of adaptively reducing treatment volumes 
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P1.160 COMPARING RADIOTHERAPY 
WITH PHOTONS AND PROTONS FOR 
NON-SMALL CELL LUNG CANCER: 
RESULTS OF A MULTICENTRIC IN 
SILICO CLINICAL TRIAL
Erik Roelofs1, Martijn Engelsman2, Coen Rasch3, 
Lucas Persoon1, Sima Qamhiyeh1, Dirk De 
Ruysscher1, Frank Verhaegen1, Madelon Pijls-
Johannesma1, Philippe Lambin1 
1Department Of Radiation Oncology (MAASTRO), 
Grow – School For Oncology And Developmental 
Biology, Maastricht University Medical Centre/
Netherlands, 2Massachusetts General Hospital 
And Harvard Medical School (MGH)/United States 
Of America, 3Netherlands Cancer Institute (NKI)/
Netherlands
Background: Lung cancer remains the number one 
cause of death among cancer patients in Europe and 
North America, despite the advances in its treatment 
options. Different approaches in combining surgery, 
chemotherapy and radiotherapy to increase tumour 
control and to lower complication rates are the 
subject of intense investigation.
Within the radiotherapy Àeld, proton and also 
carbon ion (C-ion) radiotherapy is gaining interest 
and popularity because its advantage in ballistic 
properties over conventional photon radiotherapy.
To investigate the possible treatment beneÀt we 
compared photon and proton radiotherapy treatment 
planning results for non-small cell lung cancer 
(NSCLC) patients in an international multicentric 
in silico trial: the Radiation Oncology Collaborative 
Comparison (ROCOCO).
Methods: Twenty-Àve consecutive NSCLC patients, 
stage IA-IIIB, were prospectively included. On 4D 
FDG-PET/CT scans, the gross tumour, clinical and 
planning target volumes and organs at risk (OAR) 
were delineated and subsequently uploaded onto 
the central MISTIR data repository (www.mistir.
info). Three-dimensional conformal (3DCRT) 
and intensity-modulated (IMRT) photon as well 
as passive scattered conformal proton therapy 
(PSPT) plans were created according to a strict 
planning protocol, including pre-deÀned patient 
setup accuracy, breathing motion and fractionation 
schedules. The prescribed dose to the tumour was 70 
Gy in 35 fractions. Subsequently, dose (de-)escalation 
was performed by rescaling to the maximum tolerable 
dose (MTD) of one or more of the OAR.
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possibility of using an adaptive approach toward RT 
of non–small-cell lung cancer to minimize the dose 
to normal structures and more safely increase the 
dose directed at the target tissues. 
Keywords: nonsmall cell lung cancer, tumour 
regression, adaptive radiotherapy
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P1.162 IMPROVING INTENSITY 
MODULATED RADIOTHERAPY 
PLANS USED FOR HIGH-DOSE 
CHEMORADIOTHERAPY IN STAGE III 
NSCLC
Ellen J.F. Van Reij, Wilko F.A.R. Verbakel, Ben 
Slotman, Suresh Senan 
Radiation Oncology, VU University Medical Center/
Netherlands
Background: Concurrent chemoradiotherapy 
(CT-RT) is current standard treatment in stage III 
NSCLC, but it is accompanied by an increase in 
pulmonary toxicity. Since 2008, we routinely applied 
intensity modulated radiotherapy (IMRT) to achieve 
a dose of 66 Gy for CT-RT in large and/or complex 
tumor volumes. Previous reports suggested that 
the volume of lung treated to low doses (e.g. V
5
) 
was related to higher risk of radiation pneumonitis. 
EORTC-guidelines recommend that lung toxicity 
should be limited by restricting planning parameters 
such as the V
20
 and mean lung dose to below 35%-
37% and 20-23 Gy, respectively. Prior to 2008, the 
mean tumor dose used for CT-RT at our center was 
59.5 Gy, with corresponding V
20
 values of 26.6% 
and V
5
 of 54.8%. We evaluated IMRT planning 
parameters in all patients undergoing high-dose 
platinum-based CT-RT in order to evaluate the 
compliance of planning constraints.
Methods: We reviewed dosimetry records of all 43 
stage III patients treated between 2008 and 2010 
with CT-RT using 3-weekly concurrent cisplatinum-
etoposide. All plans utilized a hybrid-IMRT 
technique to deliver doses of 66 Gy. The hybrid-
IMRT technique consists of a base dose plan with 3 
conventional open Àelds of 15 MV, optimized using 
IMRT-Àelds in order to achieve a homogeneous 
planning target volume (PTV) dose. Planning dose 
constraints used were V
20
<35%, V
5
<60% and V
5
 
contralateral lung as low as possible. The PTV dose 
criteria required that 95% of PTV should receive 
95% of prescribed dose. Toxicity was analyzed 
by quantifying the tumor volume reduction occurring 
during a course of radiotherapy (RT). 
Methods: A total of 20 patients underwent RT 
for Stage III non–small-cell lung cancer with 
conventional fractionation; 10 received concurrent 
chemotherapy and radiotherapy (CONC) and 10 
received neoadjuvant chemotherapy (NACT) 
followed by external radiotherapy alone. One repeat 
CT scan was performed at a nominal dose of 40 Gy. 
Primary gross tumor volume (GTV_P), gross nodal 
volume (GTV_N) and planning target volume (PTV) 
were evaluated for regression. Both the image sets 
were spatially co-registered by rigid registration 
(planning CT data with the repeat scan) for evaluation. 
Coordinates of centre of mass (COM) of both the 
GTV’s (GTV_P and GTV_N at pretreatment and at 40 
Gy) were recorded to measure the spatial shifts. 
Results: The mean (±SD) volume of GTV_P , 
GTV_N and PTV in CONC arm before start of 
radiotherapy were 112.63(± 64.3), 13.1 (±9.4), 
and 567 (±219) cc and that of NACT arm were 
67.85 (±49.4), 43.2 (±31.2), and 446.2 (±293) cc 
respectively. At 40Gy mean GTV_P, GTV_N, PTV 
in CONC arm were 39.5(±18.7), 11.0(±9.3) and 
319.66 (±166.4)and that of NACT arm were 39.5 
(±47.9), 15.3 (±7.9)and 320.4(±187.2)cc respectively. 
The mean GTV_P, GTV_N and PTV reduction in 
CONC arm were 73.05 cc (64.8%), 2.07 cc (15.7%)
and 248 (43.7%) cc and that of NACT arm was 28.31 
cc (41.7%), 27.9 cc (64.58%), and 125.8cc (28.2%) 
respectively .The difference in GTV_P in concurrent 
arm as compared to NACT arm was signiÀcant 
(p=0.02) resulting in a signiÀcant PTV difference 
between the 2 arms (p=0.04).There was no statistically 
signiÀcant difference (p=0.28)in the regression of 
GTV_N between the two arms. In the CONC arm, 
the mean ±SD COM shifts of GTV_P were 2.9mm 
(±10.5), -4.6mm(±9.4) and 0.3 mm(±9.5) and in the 
NACT arm it were 1.4mm (±2.8), 2.1mm(±3.3) and 
2.1mm (±5.3)in the x , y and z direction respectively. 
In the CONC arm, the mean ±SD COM shifts of 
GTV_N were -1.6 (±4.5)mm, -4.6mm(±4.0) and 
-4.6mm( ±4.0) and in the NACT arm it were 5mm (± 
6.5 mm), 0.2(±4.8) and 0.2(±4.8) mm in the x , y and 
z direction respectively. 
Conclusion: The results of this study have 
demonstrated considerable reduction in the GTV_P 
in both arms though higher in CONC (64.8%) arm 
as compared to NACT (41.7%) arm. Although 
reduction in GTV_N volume was remarkable in 
a number of patients but statistically it was found 
to be non signiÀcant.These observations raise the 
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clinically suggestive of stage I lung cancer at 
Hyogo Ion Beam Medical Center (HIBMC) 
retrospectively 
Methods: Between June 2001 and June 2009, 
a total of 63 patients with HULN, all of that 
were diagnosed as lung cancer on radiologic 
examination, received proton or carbon ion 
radiotherapy at HIBMC. Among these patients, 
15 patients were excluded from this study because 
seven were staged as IIA or IIB (UICC TNM 
2009) and six had other active malignancies. 
Also excluded were two patients who were lost to 
follow-up. The remaining 48 patients (50 lesions) 
with stage I (T1a, 29; T1b, 15; and T2a, 6) were 
identiÀed and retrospectively analyzed. Tumor size 
ranged from 8 to 50 mm in maximum diameter, 
with a median of 19 mm. Twenty-nine lesions 
(58%) were treated with proton therapy of 52.8-
80 GyE/4-20 fractions and 21 lesions with carbon 
ion therapy of 52.8-68.4 GyE/4-10 fractions. 
Survival and local control were evaluated using the 
Kaplan-Meier method. Acute and late morbidities 
were assessed based on the Common Terminology 
Criteria for Adverse Events (CTCAE) v3.0. The 
median follow-up time was 28 months (range, 8-69 
months). For T1 patients, subgroup analyses were 
performed to compare the results of HULN with 
those of histologically proven lung cancer (HPLC), 
which have been previously published from our 
institution. 
Results: The actuarial 3-year rates of overall 
survival (OS), progression-free survival and local 
control were 83%, 80% and 90%, respectively. 
Local (marginal) progression occurred in 3 patients 
(6%). Lymphatic and distant metastases were 
observed in 5 patients (10%) and 7 patients (15%), 
respectively. As for grade 3 or greater morbidities, 
grade 3 dermatitis was observed in 1 patient. 
The tumor size of HULN was signiÀcantly small 
as compared to that of HPLC. Furthermore, T1 
patients with HULN showed better OS rates than 
those with HPLC. 
Conclusion: This study showed that particle 
therapy provided favorable outcome with 
acceptable toxicity, therefore serving as an effective 
treatment option for patients with HULN highly 
suggestive of stage I lung cancer on radiologic 
examination. 
Keyword: hibmc
with Common Toxicity Criteria and Adverse Events 
(CTC-AE v4.0).
Results: The median PTV size was 664 cc (range: 
236-1425); 27.9% (n=12) of patients had a T4-
tumor and 25.6% (n=11) had a N3-nodal status. The 
mean dose to PTV was 66.7 Gy. Mean lung dose 
was 16.6 Gy; median V
20
 was 27.3% (7-35.8%); 
median V
5
 for both lungs was 50.8% (23.7-82.6%) 
while the median V
5
 contralateral lung was 26.1% 
(4-72%). V
20
 planning constraints were exceeded in 
2 patients with T2N3M0 tumors with PTV-sizes of 
422 and 727cc. Both had besides a V
20
>35%, a V
5
 
that exceeded 60%. A V
5
 total lung exceeding 60% 
was observed in 7 patients (median PTV-size 657cc), 
5 of whom had stage IIIB disease (one patient 
with T4 and 4 patients with N3-disease). The V
5
 
contralateral lung was signiÀcantly higher in patients 
with cN3- disease (p=.005), especially in patients 
with contralateral mediastinal nodes (52.3-66.9Gy). 
In contrast, PTV-size for the entire group showed no 
correlation with poorer lung dosimetry. At a median 
follow-up of 9.9 months, only 16.3% (n=7) and 4.7% 
(n=2) of all patients developed respectively grade 2 
and grade 3 radiation pneumonitis. 
Conclusion: The use of hybrid-IMRT planning 
enables improved planning parameters in patients 
treated with CT-RT to 66 Gy. However, further 
improvements in planning techniques are required 
for selected subgroups of stage III NSCLC 
who present with N3 disease, especially in the 
contralateral mediastinum. 
Keywords: imrt, locally advanced
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P1.163 PARTICLE THERAPY FOR 
HISTOLOGICALLY UNPROVEN LUNG 
NODULES HIGHLY SUGGESTIVE 
OF STAGE I LUNG CANCER ON 
RADIOLOGIC EXAMINATION
Osamu Fujii 
Radiology, Hyogo Ion Beam Medical Center/Japan
Background: Although pathologic conÀrmation 
is essential for the treatment of small pulmonary 
lesions, it is difÀcult in some cases due some 
medical problems. Nevertheless, these lesions 
could be candidates for radical treatment including 
particle therapy. The purpose of this study was 
to analyze the results of particle therapy for 
histologically unproven lung nodules (HULN) 
Copyright © 2011 by the International Association for the Study of Lung Cancer S809
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
Methods: The masses were created as above and 
constituted the CTV within the simulated plans on 
10 patients who had previously been scanned and 
treated in the department for thoracic malignancies 
(and were deceased); these patients previous scans 
served as the planning phantoms for this study. 
A 5mm isotropic margin was added to the CTVs 
to create PTVs within the plans. The median 
CTV volume was 4.5 ccs; PTV volume, 17.8 ccs. 
A nine-Àeld equally spaced coplanar static Àeld 
beam arrangement was employed using dMLCs, 
600MU/min dose rate. The PTV was optimized to 
receive 100% of the Rx dose (60 Gy/30 fx). The 
maximum plan inhomogeneity at optimization was 
set to be 62 Gy. A smoothing factor of 20/20 X/Y 
was used for optimization. No other optimization 
parameters were utilized. Eclipse DVO v8.9.08 was 
used for optimization. After initial optimization, 
plans were calculated using Eclipse AAA v8.9.08 
(Plan 1). All plans were normalized such that 
95% of the PTV received 100% of the Rx dose or 
more. PTV minimum, median and maximum doses 
were recorded, and PTV conformity indices (CIs) 
calculated. Next, each Plan 1 was re-optimized and 
re-calculated (again using AAA) to correct for OCEs 
using the method and tools of Zacarias and Mills 
(Plan 2). A smoothing factor of 0/0 X/Y was used for 
OCE-corrected optimization. PTV minimum, median 
and maximum doses, and PTV CIs, were recorded 
for each Plan 2. Plan metrics were compared using 
the Mann-Whitney test.
Results: Plan 1 non-OCE and Plan 2 OCE-corrected 
plans differed signiÀcantly. PTV minimum dose 
differed for Plan 1 vs 2 (median 56.5 Gy vs 58.3 
Gy, p=0.0004). PTV median dose differed for Plan 
1 vs 2 (median 62.6 Gy vs 60.7 Gy, p=0.0002). PTV 
maximum dose differed for Plan 1 vs 2 (67.4 Gy vs 
62.2 Gy, p=0.0002). The CI differed for Plan 1 vs 2 
(median 1.77 vs 1.67, p=0.0002). Plan 1 calculations 
revealed signiÀcantly more target inhomogeneity 
(median 112%) than Plan 2 calculations (median 
104%), normalizing 95% of the PTV volumes to 
receive 60 Gy Rx dose or more.
Conclusion: Correcting for OCEs in this simulated 
group of patients with intraluminal tracheal tumors 
resulted in signiÀcantly more conformal and 
homogenous plans.
Keywords: Trachea, imrt
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P1.164 DOSIMETRIC IMPROVEMENTS 
IN A COHORT OF PATIENTS WITH 
SIMULATED TRACHEAL TUMORS 
RECEIVING INTENSITY MODULATED 
RADIOTHERAPY (IMRT) ACCOUNTING 
FOR OPTIMIZATION CONVERGENCE 
ERRORS (OCES)
Todd J. Scarbrough1, Samuel R. Faught2, Charles R. 
Thomas3 
1Radiation Oncology, Owensboro Medical Health 
System/United States Of America, 2Radiation 
Oncology, Omhs/United States Of America, 3Dept Of 
Radiation Medicine, Ohsu/United States Of America
Background: In many commercially available 
treatment planning systems (TPSs), when planning 
IMRT, the Áuence optimization process uses a 
different algorithm than the actual dose calculation 
workspace. In the Eclipse treatment planning 
system (v8.9.09.18617, Varian Medical Systems, 
Palo Alto, CA, USA), for static Àeld IMRT, the 
Áuence optimization algorithm used is dose volume 
optimizer(DVO) v8.9.08. Of the calculation 
algorithms available in Eclipse, there is evidence that 
the analytical anisotropic algorithm (AAA v8.9.08) 
is signiÀcantly more accurate in predicting delivered 
dose in most clinical situations, especially air/tissue 
interface scenarios as encountered in lung or tracheal 
carcinoma cases. However, the discrepancy in the 
DVO and AAA calculation algorithms induces 
optimization convergence errors (OCEs) which are 
especially noticeable in the TPS in these particular 
clinical situations: doses become signiÀcantly 
inhomogenous within targets such that plans must 
be normalized to very low isodose lines in turn 
inducing unwanted high target inhomogeneities 
and/or hot spots in the plan. Zacarias and Mills (J 
Appl Clin Med Phys, 10:3061, 2009) have devised 
a Áuence summing method to correct for OCEs 
in the Eclipse TPS by forcing the DVO to look at 
calculated AAA results. We selected a non-random 
cohort of 10 patients from our institution for this 
treatment planning study and created, within the 
TPS, simulated tissue masses (using the assign CT 
number function to voxels in the Eclipse TPS) within 
the mid-trachea 3 cm in longitudinal dimension and 
having AP and lateral dimensions equal to half the 
diameter of the trachea. We then performed IMRT 
plans on these simulated masses with or without 
OCE corrections, and recorded the results.
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to the primary tumor in three fractions. A total plan 
will be calculated in NTD using the LQ-model, 
consisting of the simultaneous delivery of 3 SBRT 
fractions to the primary tumor and 3 x 2.75 Gy to 
the lymph nodes, and the conventional plan of 21 x 
2.75 Gy to the lymph nodes. Fraction size of SBRT 
is calculated depending on the MLD risk group that 
is open for accrual, starting at a fraction dose of 18 
Gy and de-escalated to a minimum of 14 Gy (which 
is a conservative estimation of a similar biologically 
equivalent dose to 24 x 2.75 Gy using the LQL-
model Ơ/ơ=10 and d
t
 = 4) until an MLD is reached 
that is predicted to be safe. A planning study in ten 
eligible patients was performed and feasible [1]. 
Conclusion: A phase I/II dose escalation trial was 
initiated, to detect the maximal tolerable MLD using 
a hybrid treatment plan of combined SBRT and 
CRT for stage II and III NSCLC. [1] E. Damen et al, 
Extending the beneÀt of hypofractionated SBRT to 
stage II/III NSCLC: A feasibility study. J. Thorac. 
Oncol. 2010 May;5(5 Suppl 1): S69. 
Keywords: hybrid, SBRT, conventional 
radiotherapy, NSCLC
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P1.166 INTENSITY MODULATED 
RADIOTHERPAY (IMRT) ENABLES 
RADICAL TREATMENT IN LOCALLY 
ADVANCED LUNG CANCER PATIENTS 
WHO WOULD HAVE BEEN TREATED 
WITH PALLIATIVE INTENT WITH 3D 
CONFORMAL RADIOTHERAPY (3D 
CRT)
Raj K. Shrimali1, Gareth J. Webster2, Lip W. Lee1, 
Neil Bayman1, Hamid Sheikh1, Michelle Bewley3, 
Paul A. Burt1, Laura Pemberton1, Maggie A. Harris1, 
Abbas Chittalia1, Helen Lander1, Joanne Coote1, Phil 
Whitehurst2, Carl Rowbottom2, Corinne Faivre-Finn1 
1Clinical Oncology, The Christie NHS Foundation 
Trust/United Kingdom, 2North West Medical 
Physics, The Christie NHS Foundation Trust/United 
Kingdom, 3The Wade Centre For Radiotherapy 
Research, The Christie NHS Foundation Trust/
United Kingdom
Background: IMRT improves the therapeutic ratio 
in lung cancer by decreasing high dose delivery to 
the spinal cord and lung tissue. In locally advanced 
disease, dose constraints to organs at risk can be 
unattainable with 3D CRT planning and high dose 
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P1.165 DESIGN OF A HYBRID STUDY: 
COMBINED STEREOTACTIC BODY 
RADIOTHERAPY AND CONVENTIONAL 
FRACTIONATION IN STAGE II AND 
III NON SMALL CELL LUNG CANCER 
WITH PERIPHERAL TUMORS
Heike Peulen1, Eugène Damen1, Alize Scheenstra1, 
Jan jakob Sonke1, Harm Van Tinteren2, Paul Baas3, 
José Belderbos1 
1Radiation Oncology, NKI-AVL/Netherlands, 
2Netherlands Cancer Institute/Netherlands, 
3Thoracic Oncology, NKI-AVL/Netherlands
Background: Stereotactic body radiotherapy 
(SBRT) results in excellent local control with 
low toxicity in stage I non small cell lung cancer 
(NSCLC). In stage II and III NSCLC the site 
of failure after concurrent chemoradiotherapy 
is predominantly at the primary tumor site. To 
expand SBRT to stage II and III NSCLC patients, 
we designed a phase I/II mean-lung dose (MLD) 
escalation trial of combined SBRT to the peripheral 
tumor and conventional radiotherapy (CRT) to the 
hilar and mediastinal lymph nodes. 
Methods: Eligibility criteria are stage III or 
inoperable stage II NSCLC treated with or without 
concurrent or sequential chemotherapy, WHO 0-2 
and peripheral lung tumors  5 cm. The primary 
endpoint is the maximum tolerated MLD, secondary 
endpoints are locoregional control, overall survival 
and quality of life. Dose limiting toxicity (DLT) will 
be monitored using the Time-to-Event Continuous 
Reassessment Method (TITE-CRM), which allows 
continuous accrual of patients and iteratively updates 
the probability of DLT. Dose limiting toxicity was 
deÀned according to the CTCAE v4; radiation 
pneumonitis  grade 3, esophagitis  grade 3, 
pulmonary bleeding  grade 4 and skin toxicity  
grade 4. Six risk groups will be deÀned, increasing 
the MLD with 2 Gy in each step, starting with 
an MLD  16 Gy. If 60 days post treatment the 
estimated risk on DLT is < 15%, the next risk group 
is open for accrual, while the other (lower) risk 
groups will be continuously reassessed on DLT. 
Results: The design of this phase I/II dose escalation 
trial to detect the maximal tolerable MLD using 
a hybrid treatment plan is as follows. Eligible 
patients will be treated with an IMRT treatment 
plan delivering 24 x 2.75 Gy in 5 weeks to the 
pathological lymph nodes with concurrent SBRT 
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cancer, imrt
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P1.167 EXPERIENCES OF PRE-TRIAL 
QUALITY ASSURANCE (QA) FOR THE 
CONVERT TRIAL. A MULTICENTRE 
RANDOMISED PHASE III TRIAL 
FOR GOOD PERFORMANCE STATUS 
PATIENTS WITH LIMITED STAGE 
SMALL CELL LUNG CANCER
Nicki Groom1, Elena Wilson2, Ethan B. Lyn3, 
Corinne Faivre-Finn4 
1Clinical Oncology, Mount Vernon Hospital/United 
Kingdom, 2Clinical Oncology, The Royal Free 
Hospital/United Kingdom, 3Radiation Oncology, 
Cancercare Manitoba/Canada, 4Clinical Oncology, 
The Christie NHS Foundation Trust/United Kingdom
Background: Patients in CONVERT are randomised 
to either 45Gy in 30 fractions twice-daily or 66Gy 
in 33 fractions once-daily (given concurrently with 
cisplatin/etoposide). A radiotherapy QA programme 
was set up to eliminate inconsistencies across the 
various participating centres. 
Methods: Pre-trial QA involves completion of a 
site speciÀc questionnaire and a treatment planning 
exercise, which tests the complete radiotherapy 
procedure. Each participating clinician was asked 
to select a previously treated patient, who Àtted the 
entry criteria for the trial, and provide disease and 
critical structure outlines, and a treatment plan for 
both arms of the trial. Radiotherapy QA guidelines 
were distributed to each participating centre. We 
reviewed our observations of patient selection, 
tumour and organs at risk outlining and treatment 
planning. We describe common deviations from trial 
protocol and some of the challenges of running such 
a QA programme. 
Results: In January 2011, 59 cancer centres across 
8 countries had entered patients into CONVERT. 
Site speciÀc questionnaires were received between 
April 2008 and January 2011. From the returned 
questionnaires and planning data, it was possible 
to deÀne the type of equipment, techniques, beam 
energies and conÀguration and planning algorithms 
used, and to ensure that centres were adhering to 
CONVERT trial protocol. 65% of centres were using 
type a algorithms, and 35% of centres were using 
type b. The deviations from trial protocol included: 
palliative treatments are delivered instead. 
Methods: Patients who would not have been suitable 
for radical radiotherapy according to our local dose 
constraints were planned with IMRT (V20£35% and 
spinal cord dose 44 Gy, for hypofractionated RT 
regimen or 48 Gy, for conventional RT regimen). 
In some patients a 3D CRT plan was attempted, 
whereas in others IMRT was deemed to be the 
only way to deliver a radical dose from the outset. 
Static IMRT (<30 control points in total) was used 
and 44.8-66 Gy was delivered in 20-33 fractions 
using 5-8 6MV beams. Thirty-four patients, treated 
between January 2009 and January 2011, were 
included in this retrospective analysis. CTCAE v3.0 
was used to grade toxicity. 
Results: 4 patients had two synchronous primaries, 
1 patient had stage IIB NSCLC, 18 patients stage 
IIIA/IIIB NSCLC and 11 patients had LS-SCLC. 
Reasons for treating with IMRT were as follows: 
high V20 (21 patients), high cord dose (1 patient), 
both reasons (12 patients). 13 patients were treated 
with concurrent chemo-radiotherapy (5 SCLC and 8 
NSCLC). 
Parameters Mean Range 
Gross Tumour Volume 77 cc 6.4 to 164. cc 
Planning Target Volume 481.8 cc 177 to 1113 cc 
Cranio-caudal extent of the PTV 12.2 cm 6.5 to 19.0 cm 
Whole Lung Volume 3593 cc 1917 to 6562 cc 
PTV/ Whole lung Volume (%) 14.9 % 3.24 to 48.33 % 
Mean lung dose 16.8 Gy 6.77 to 23.8 Gy 
V-20 (Mean of 4 plans with 3D CRT) 43.4 % 33 to 60.4 % 
V-20 (Mean of all the IMRT plans) 27.6 % 11.6 to 35.3 % 
Improvement in V-20 (For the 14 patients who 
had both 3D CRT & IMRT plans) 
11.6 % 2.7 to 27.7 % 
V- 10 54.9 % 17.7 to 76.67 % 
V-5 68.7 % 22.34 to 92.62 % 
Max dose to Spinal cord (EQD2) (Į/ȕ=.87) 34.5 Gy 24.4 to 41.25 Gy 
25 patients developed oesophagitis, 23 (68%) grade 
2, 1 grade 3 (3%) and 1 grade 4, a stricture (3%). 
No grade 3 (or higher) pneumonitis was reported. 
Median follow-up is relatively short at 8 months 
for the 19 patients still alive. Fourteen patients have 
died due to disease progression and 1 due to other 
causes. Of the 19 surviving patients, 2 have had local 
progression and 17 are progression free. The median 
survival is projected at 13 months and the 1-year 
survival is projected to be 56%. 
Conclusion: Although resource intensive, IMRT 
enables radical radiotherapy, where previously only 
high dose palliative radiotherapy was possible, with 
manageable toxicity. The impact of this technique 
on late toxicity, local control and survival will be 
evaluated in further studies.
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Kingdom, 2Dept Of Clinical Oncology, Weston Park 
Hospital/United Kingdom
Background: 55 Gy in 20 fractions is a widely 
used UK regimen for NSCLC radical radiotherapy 
treatment1. There is little phase 3 evidence for this 
regimen and this study reports the outcome for 
patients treated in routine practice though recent 
phase II studies have explored the addition of 
chemotherapy to this schedule2,3. 
Methods: All case notes and RT records of patients 
with NSCLC treated with radiotherapy to a dose 
of 55 Gy in 20 fractions over a period of 5 years 
between Jan 2005 and Dec 2009 were reviewed. 
Basic patient demographics, tumour characteristics, 
use of prior chemotherapy and survival data were 
collected, anonymised and descriptive statistics 
applied. Kaplan Mier curves were used for survival 
analysis and log rank test for comparison. 
Results: 135 patients were identiÀed the median 
age was 71 (41-87). 56% were male and 84% had 
histological conÀrmation. Tumour stages 1, 2, 3 
and 4 were 34%, 19%, 44%, 3% respectively. The 
WHO performance status was 0/1 and 2/3 in 77%, 
23% respectively. 34% received prior chemotherapy. 
99% received the prescribed treatment and toxicity 
was recorded using the RTOG toxicity scales. 
One grade 3-5 toxicity was identiÀed (broncho-
oesophageal Àstula). Grade 1-2 pneumonitis was 
identiÀed in 26% and 23% of patients reported 
grade 1-2 oesophagitis. Median overall survival 
(OS) from diagnosis was 32 months; 1, 2, 3 and 5 
year overall survivals were 82%, 61%, 40% and 
18% respectively. Variables governing survival were 
analyzed using Log rank test. Statistically signiÀcant 
prognostic features were stage (p=0.019) and prior 
chemotherapy (p=0.02) but not age, performance 
status, histology or PET staging. 
Conclusion: This 4 week fractionated schedule is a 
widely used radical radiotherapy regime in the UK. 
This retrospective analysis reinforces other series4 
in showing the treatment to be well tolerated with a 
low toxicity rates and a promising median survival 
of 32 months. There is a need for phase 3 studies 
to compare chemo-radiotherapy schedules using 
this schedule with those that are conventionally 
fractionated. Ref. 1. Price A. Results of a survey of 
UK clinical oncologists. Presented at the Medical 
Research Council; 2001 2. Price A. et.al J Thoracic 
Oncol2009:4(9) S587 3. Maguire J et.al. J Thoracic 
Oncol 2010;5(12):S558 3. Din O et.al J Thoracic 
Oncol2009:4(9) S960 
1) patient selection: the most common being the 
inclusion of patients with a history of cancer or with 
evidence of metastatic disease. 11.4% of clinicians 
submitted ineligible patients for the QA exercise. 2) 
Disease outlining and expansion: 4.3% of centres 
used incorrect margins and 8.6% incorrectly included 
areas as Gross Tumour Volume 3) Organs at risk 
outlining: this was generally done well according 
to the trial protocol, with the exception of the heart 
and oesophagus outlining. In 64% of cases the heart 
was not outlined superiorly enough. The oesophagus 
was not outlined superiorly to the level of the cricoid 
cartilage in 24.3% of cases and inferiorly to the 
level of the gastro-oesophageal junction in 4.3% of 
cases. The oesophageal contours did not extend out 
to the fatty adventitia in 2.9% of cases. 4) Treatment 
planning: conformity of isodoses to the Planning 
Target Volume (PTV) was suboptimal in 32.9% of 
submitted cases; initial Àndings suggest that some 
centres moving from type a to type b planning 
algorithms, were inclined to increase their Àeld size 
to try to achieve the level of PTV coverage that was 
possible with their original planning system/software 
version. 
Conclusion: Such a pre-trial QA programme helps 
to ensure that centres conform to trial protocol, 
and should therefore reduce inconsistencies in 
radiotherapy planning across the participating 
centres that may confound the results of the study, 
particularly with respect to tumour targeting 
and normal tissue toxicity. The QA programme 
also provides an advice forum for clinicians and 
physicists involved in the trial in each centre. Issuing 
QA guidelines is helpful to centres that may have to 
change their routine procedures to adhere to the trial 
protocol. 
Keywords: Quality Assurance, Radiotherapy, 
CONVERT, Small cell lung cancer
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P1.168 ACCELERATED 
HYPOFRACTIONATED RADIOTHERAPY 
(RT) FOR NON-SMALL CELL LUNG 
CANCER (NSCLC): A SINGLE CENTRE 
AUDIT OF OUTCOME USING 55GY IN 20 
DAILY FRACTIONS.
Satya Garikipati1, Dev Srinivasan1, Nathaniel L. 
Hatton1, Caroline Lee1, Patricia M. Fisher1, Jayaram 
Mohanamurali1, Matthew Hatton2 
1Clinical Oncology, Weston Park Hospital/United 
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Glc/tCr, Glx/tCr, Lac/tCr, Lip/tCr. The absolute 
metabolite concentrations and metabolite ratios were 
paired according to the examinations schedule and 
subjected to the Wilcoxon matched pair test: exam.1 
vs. exam.2, exam.1 vs. exam.3 and exam.2 vs. 
exam.3. The analyses were performed separately for 
frontal and occipital VOIs. 
Results: The Wilcoxon test showed no statistically 
signiÀcant differences in the occipital NAWM 
while in the frontal NAWM statistically signiÀcant 
differences are observed only between exam.1 
vs. exam.2 for both the metabolite absolute 
concentrations and ratios. These differences concern 
the tCr (p = 0.027709), Lac (p = 0.017961) and Glc 
(p = 0.0464) as well as Lac/NAA (p = 0.027993), 
Lac/tCr (p = 0.017961) and Lip/tCr (p = 0.042523). 
The prominent increase of Lac concentration as 
well as Lac/NAA and Lac/tCr ratios observed up till 
30 days after PCI could be explained by radiation 
damage leading to impaired lactate washout due 
to post-irradiation edema, increase of lactate 
concentration caused by radiation-induced cell-kill or 
by disturbed glucose metabolism. Similarly, increase 
in Lip/tCr ratio could be explained by disintegration 
of cell membranes by ionization. Both Lac/tCr and 
Lip/tCr ratios reach the highest level immediately 
after irradiation (less than 30 days) and vary in a 
wide range among individual patients. 
Conclusion: PCI induces alterations in brain 
tissue metabolism visible in period less than 30 
days after irradiation. Both the metabolite absolute 
concentrations and the ratios tend to normalize after 
90 days post treatment. 
Keywords: spectroscopy, prophylactic cranial 
irradiation
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P1.170 18F-FDG PET/CT SIMULATION IN 
AN ALREADY PET/CT STAGED NSCLC 
PATIENTS. THE IMPACT ON INTER-
OBSERVER VARIATION AND NORMAL 
TISSUE DOSE ESTIMATES.
Gerard G. Hanna1, Kathryn J. Carson2, Jonathan 
Mcaleese1, Viv P. Cosgrove3, Ruth L. Eakin1, David 
P. Stewart1, Ashraf Zatari4, Joe M. O’sullivan5, Alan 
R. Hounsell4 
1Clinical Oncology, Cancer Centre, Belfast City 
Hospital/United Kingdom, 2Nuclear Medicine, Royal 
Victoria Hospital, Belfast Health And Social Care 
Trust/United Kingdom, 3Department Of Medical 
Keywords: NSCLC, Acclerated Radiotherapy
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P1.169 COMPARISON OF THE 1H 
MAGNETIC RESONANCE IN VIVO 
SPECTROSCOPY (MRS) BEFORE AND 
AFTER PROPHYLACTIC CRANIAL 
IRRADIATION IN PATIENTS WITH 
NSCLC.
âukasz Boguszewicz1, Marzena T. Gawkowska-
Suwiĸska2, Maria Sokóã1, Anna Cichoĸ1, Blamek 
Sãawomir1, Aleksander Zajusz1 
1Maria Skãadowska-curie Memorial Cancer Center 
And Institute Of Oncology, Gliwice Branch/Poland, 
2Iii Department Of Radiotherapy/ Department Of 
Brachyteraphy, Maria Skãadowska-curie Memorial 
Cancer Center And Institute Of Oncology, Gliwice 
Branch/Poland
Background: The 1H magnetic resonance in vivo 
spectroscopy (MRS) is a versatile and powerful tool 
for noninvasive investigation of tissue metabolism. 
The high usefulness of this technique has been 
proved in many types of central nervous system 
diseases as well as in monitoring treatment effects. 
Methods: The studied group consisted of ten 
patients (aged 42 – 73, median 53) whose underwent 
prophylactic cranial irradiation (PCI) as part of 
radical treatment for non small cell lung (NSCLC) 
cancer (the subgroup of patients from clinical trial 
evaluated toxicity of PCI). The examined patients 
were treated with radical radiotherapy or chemo-
radiotherapy for locally advanced NSCLC. The 
patients received 30 Gy in 15 fractions to the 
whole brain. The patients were scheduled to three 
consecutive spectroscopic examinations: before 
the PCI (exam.1), up till one month after PCI 
(exam.2) and three months after PCI (exam.3). The 
44 1H in vivo NMR spectra were acquired with the 
whole-body MRI/MRS 2T system operating at the 
proton resonance frequency of 81.3 MHz during 
the routine NMR examinations. For each patient 
the VOIs of 1.5x1.5x1.5 cm3 were located in left 
frontal and occipital normal-appearing white matter 
(NAWM). The absolute concentrations of the main 
brain metabolites (NAA, Cho, mI, tCr, Glc, Glx, 
Lac and Lip) were calculated as described in (5). 
The metabolite concentrations were additionally 
presented as the following ratios: NAA/tCr, Cho/
tCr, Cho/NAA, mI/tCr, Lac/NAA, Lip/NAA, 
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subgroup of those with atelectasis the mean PTV
CT
 
was 0.68 and was signiÀcantly improved to 0.78 
when comparing PTV
PET/CT
 (WSRT p=0.005). In all 
patients there was a signiÀcant reduction from the 
median V20 based on the PTV
CT
 (V20=19.3) to the 
V20 using the PTV
PET/CT
 plan (V20=16.2, p<0.001). 
In those with atelectasis a similar improvement 
was seen (PTV
CT
 based V20=22.1, PTV
PET/CT
 based 
V20=19.7, p=0.005).
Conclusion: TV delineation based on PET/CT 
simulation reduces mean lung dose estimates and 
reduces interobserver variation, particularly in those 
patients with atelectasis. The potential reduction in 
lung dose estimates may permit RT dose escalation 
in future clinical investigations. In addition to PET/
CT staging, PET/CT RTP simulation may be of most 
beneÀt in those patients with atelectasis.
Keywords: NSCLC, PET/CT, Target Volume 
Delineation, Radiotherapy
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P1.171 CLINICAL SIGNIFICANCE OF 
PROGNOSTIC SCORES LUNG CANCER 
PATIENTS WITH BRAIN METASTASIS 
WHO TREATED WITH GAMMA-KNIFE 
RADIOSURGERY
Min Ki Lee1, Young Dae Kim2, Hosuk Lee2, Mi 
Hyun Kim2 
1Internal Medicine, Pusan National University 
Hospital/Korea, 2Pusan National University 
Hospital/Korea
Background: Patients with lung cancer have a 
high risk for development of brain metastases. And 
optimal treatment is very important for improving 
survival rate with patients who have brain metastasis.
The purpose of this study was to analyze prognostic 
scores in a population of lung cancer patients who 
undergone gamma-knife radiosurgery.
Methods: We anayzed 147 patients with brain 
metastases from lung cancer who treated with 
gamma knife radiosurgery (GKRS) to compare 
prognostic scores for overall survival. Four available 
scores for brain metastases were evaluated in 
patient with lung cancer group after gamma knife 
radiosurgery.
We carried out a retrospective study through review 
of medical record to determine prognostic factors 
and prognostic scores. Reviewed prognostic factors 
are age, Karnofsky performance status, extracranial 
Physics, St James Institute Of Oncology, St James 
University Hosptial, Leeds./United Kingdom, 
4Medical Physics, Cancer Centre, Belfast City 
Hospital/United Kingdom, 5Clinical Oncology, 
Centre For Cancer Research And Cell Biology, 
Queen’s University Of Belfast/United Kingdom
Background: In the treatment of NSCLC with 
radiotherapy (RT) 18F-FDG PET/CT has been shown 
to reduce target volumes and normal tissue dose 
estimates when used in the radiotherapy treatment 
planning (RTP) process. This is particularly evident 
in those patients with atelectasis. However, this may 
be due to improved baseline tumor staging as distinct 
from the impact that PET/CT may have at RTP 
simulation. The impact of PET/CT simulation on 
PTV volumes and normal lung tissue dose estimates 
in a cohort of patients already PET/CT staged is 
reported.
Methods: RTP PET/CT scans were performed on 
28 already PET/CT staged NSCLC patients (stage 
IA to IIIB; 14 received induction chemotherapy). 
In place of a RTP CT scan, patients were scanned 
on a PET/CT scanner. In a virtual planning study 
4 radiation oncologists independently delineated 
the GTV on the CT (GTV
CT
) alone, and then on 
PET/CT (GTV
PET/CT
). PTV were obtained using 
standardized expansion margins with no respiratory 
compensation. Dosimetry plans were generated 
following standard department procedures. The 
mean percentage volume change (MPVC) from 
the CT PTV (PTV
CT
) to the PET/CT PTV (PTV
PET/
CT
) for each case was calculated for all patients 
and for those with atelectasis alone. Interobserver 
variation was assessed using the concordance index 
(CI) and normal lung tissue dose estimates were 
calculated using the percentage volume of normal 
lung receiving 20 Gy (V20). The Wilcoxin signed 
ranks test (WSRT) was used for paired samples 
comparison and the Mann-Whitney U (WHU) in 
independent samples comparison.
Results: For all patients the median of the MPVC 
from PTV
CT
 to PTV
PET/CT
 was -2.3%. The MPVC 
from PTV
CT
 to PTV
PET/CT
 was -5.0% in those 
with atelectasis (n=10) and was 4.3% with no 
atelectasis (WHU p=0.084). Assessing the impact 
on interobserver variation, for all patients the 
mean GTV
CT
 CI was 0.55 signiÀcantly improved 
to 0.59 for the mean GTV
PET/CT
 (p=0.001). The 
PTV
CT
 CI was 0.74 and this improved to 0.78 
comparing PTV
PET/CT
 but this difference failed to 
reach signiÀcance (WSRT p=0.08). However in the 
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synchronous metastases and 30 patients had 
metachronous metastases. As primary, 27 patients 
had a colorectal tumor and 13 patients a lung 
cancer. The rest was scored as other. Depending 
on tumor size and location, different treatment 
schedules were used. Thirty eight tumors were 
treated with a total dose of 60 Gy (20 Gy/fr), 22 
with a single dose of 30 Gy, 8 with a total dose of 
60 Gy (12 Gy/fr), 6 with a total dose of 50 Gy (10 
Gy/fr), 6 with a total dose of 45 Gy (15 Gy/fr), 6 
with a total dose of 48 Gy (8 Gy/fr), 4 with a total 
dose of 56 Gy (8 Gy/fr) and 3 with a total dose of 
45 Gy (9 Gy/fr). PTV = GTV + 5 mm. The dose to 
the PTV was prescribed to the 70-90% isodose line. 
The median follow up was 18 months (range, 1-53). 
The median age was 67 years old (range: 34-86).
Results: The 3-years overall survival for the whole 
group was 42%. A signiÀcant better survival was 
found for patients with a central tumor compared to 
patients with peripheral tumor(s) (p=0.04, 3-years 
overall survival of 64% vs. 24%). The 3 years 
overall survival for patients with synchronous 
metastases was 45% compared to 42% for patients 
with metachronous metastases. The 3-years overall 
survival for the lung cancer patients was 38%, for 
a colorectal patients 42% and for the remaining 
patients 54%. The 2-years local control for a total 
dose of 50 Gy or  more was 83% compared to 
46% with doses lower than 50 Gy (p=0.0001). 
Thirty eight peripheral tumors treated with a total 
dose of 60 Gy in 3 fractions had a actuarial local 
control at 2 years of 84% compared to 57% from 
22 peripheral tumors treated with a single dose of 
30 Gy (p=0.01). Central tumors had a 2-years local 
control of 63%. Side effects were low, also in the 
group of patients with central tumors.
Conclusion: Patients with a central solitary or 
oligometastases should be treated because a 3-years 
overall survival of 64% was found. Patients with 
synchronous or metachronous lung metastases 
had an almost equal 3-years overall survival of 
45%. Real-time tumor tracking for lung metastases 
treated with a total dose of 50 Gy or more resulted 
in a 2-years local control of 83%. Central tumors 
had a 2-years local control of 69%.
metastases status, systemic disease status, number 
of brain metastases and largest brain lesion 
volume. Calculated prognostic scores are recursive 
partitioning analysis classiÀcation (RPA), score 
index for stereotatic radiosurgery in brain metastases 
(SIR), basic score for brain metastases (BSBM) and 
graded prognostic assessment (GPA) score.
Results: The median age is 64.5 years (28-85years) 
and small cell lung cancer, non-small cell lung 
cancer and patients not performed biopsy are 
respectively 22 patients, 117 patients, 8 patients. 
Using the Cox model analysis of survival, clinical 
signiÀcance was observed for RPA, SIR, BSBM and 
GPA (, p=0.047, p=0.001, p=0.015 and p=0.033, 
respectively).
Conclusion: All fourl scores are achieved statistical 
signiÀcance in prediction of overall survival in brain 
metastases patients from lung cancer underwent 
gamma-knife radiosurgery.The SIR score revealed 
as most superior accuracy and applicability among 
studied scores. 
Keyword: lung cancer, brain metastasis, prognosis
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.172 CENTRAL AND PERIPHERAL 
LUNG METASTASES TREATED 
WITH REAL-TIME TUMOR 
TRACKING DURING STEREOTACTIC 
RADIOTHERAPY: A 5 YEARS 
EXPERIENCE
Joost J. Nuyttens, Noelle Van Der Voort Van Zijp, 
Mischa Hoogeman 
Radiotherapy, Erasmus MC-Daniel Den Hoed 
Cancer Center/Netherlands
Background: To report local recurrence rate and 
survival of 56 patients with 93 solitary metastases 
or oligometases treated with the CyberKnife.
Methods: Fifty six patients had 93 metastases: 69 
peripheral tumors and 24 central tumors. Central 
tumors were deÀned as tumors <2 cm from the 
trachea, main stembronchus, or oesophagus or 
as tumors <6 mm from the heart or if they were 
located in the mediastinum. Of the 93 metastases, 
76 tumors were smaller than 3 cm and 17 larger 
(range 5-52 mm). Twenty four patients had 
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Direction Within Tolerance n (%) Out of Tolerance n (%) 
Right-Left 4 (8.7%) 5 (45.5%) 
Superior-Inferior 5 (15.2%) 14 (58.3%) 
Anterior-Posterior 7 (16.7%) 9 (64.3%) 
Conclusion: CBCT successfully improves tumour 
positioning to within acceptable tolerance. It is noted 
that the post-treatment localisation errors are higher. 
This could be a reÁection of long-treatment duration, 
which could be reduced with arc therapy IMRT. In a 
minority of patients the end of treatment CBCT was 
out of tolerance. Those out of tolerance at the end 
of treatment are more likely to be out of tolerance 
mid-treatment. If localisation errors are observed 
mid-treatment, it may be necessary to increase 
the number of mid-treatment CBCTs to maintain 
positioning accuracy. 
Keywords: SBRT, CBCT, Non-small cell lung 
cancer, Radiotherapy
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P1.174 IMAGE GUIDED RADIOTHERAPY 
(IGRT): ADAPTATION OF INTRA-
THORACIC ANATOMICAL CHANGES 
VISUALIZED ON CONE BEAM CT FOR 
LUNG CANCER PATIENTS DURING THE 
COURSE OF IRRADIATION
Maddalena M.G. Rossi1, José Belderbos2, Sanne 
Conijn1, Eva Schaake1, Joost Knegjens1, Peter 
Remeijer1, Jan Jakob Sonke1 
1Radiation Oncology, The Netherlands Cancer 
Institute - Antoni Van Leeuwenhoek Hospital/
Netherlands, 2Department Of Radiation Oncology, 
The Netherlands Cancer Institute - Antoni Van 
Leeuwenhoek Hospital/Netherlands
Background: Image guided radiotherapy (IGRT) 
using cone-beam CT (CBCT) images of the 
patient is widely applied in setup correction 
protocols for stage III lung cancer. However 
these protocols do not take into account more 
complex geometrical uncertainties which may 
result from multidimensional intra-thoracic 
anatomical changes. Inadequate response to these 
changes could result in geographical misses 
which ultimately inÁuence the efÀcacy of the 
radiotherapy treatment. For example, in large and 
centrally located tumors atelectasis (progression 
or resolvement) may cause displacements of 
mediastinal structures resulting in shifts in tumour 
position. Repetitive imaging of the patient during 
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P1.173 PATIENT POSITIONING DURING 
AND AFTER STEREOTACTIC BODY 
RADIOTHERAPY (SBRT) FOR NON-
SMALL CELL LUNG CANCER (NSCLC) 
USING CONE-BEAM COMPUTED 
TOMOGRAPHY (CBCT)
Asad Qureshi, Simon Hughes, David Landau, Clare 
Hartill, Keely Barnett, Kate Wildermuth, Alison 
Gammie, Shahreen Ahmad 
Clinical Oncology, Guy’s And St Thomas’ NHS 
Foundation Trust/United Kingdom
Background: Many centres performing SBRT use 
CBCT to determine localisation errors and to perform 
on-line corrections. We evaluated our localisation 
errors to investigate emerging patterns relating to 
tumour position or other variables and therefore 
predict the need for further CBCTs/patient. This may 
enable customisation of radiotherapy planning and 
delivery to the individual patient. 
Methods: 14 patients received SBRT (3-5 fractions) 
for NSCLC. Immobilisation and positioning was 
achieved with a custom thoracic board. A vacuum bag 
was used on the majority of patients. Our protocol is 
to perform CBCT scans at set-up and mid-treatment 
with matching performed against the tumour. In 
addition a post-treatment CBCT was performed 
on completion of each fraction to study tumour 
localisation and intrafraction motion. The couch 
position was adjusted when positional discrepancies 
exceeded 2mm in any direction. Any adjustments to 
couch position were veriÀed with a repeat CBCT. All 
localisation errors were collected prospectively. 
Results: A total of 248 CBCT scans were performed 
for 64 fractions of treatment. CBCT data suggests 
that the average magnitude of initial set-up errors 
were reduced from 2.6mm (Right-Left), 3.9mm 
(Superior-Inferior) and 2.3mm (Anterior-Posterior) 
to 1.0mm (R-L), 1.6mm (S-I) and 1.1mm (A-P). At 
the mid-treatment point errors were reduced from 
1.3mm (R-L) and 1.6mm (A-P) to 1.1mm (R-L) 
and 1.3mm (A-P). The error in the S-I direction 
remained 1.8mm. At the end of treatment the average 
positional discrepancy was 1.5mm (R-L), 2.2mm 
(S-I) and 1.7mm (A-P). Table showing the number 
of scans (n) out of tolerance (>2mm) at the mid-
treatment point separated into those who were within 
tolerance and those out of tolerance on the post-
treatment scan. 
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P1.175 FEASIBILITY AND EARLY 
OUTCOMES OF STEREOTACTIC 
BODY RADIOTHERAPY IN EARLY 
LUNG CANCER AT THREE CANCER 
CENTRES; ST. JAMES’S INSTITUTE 
OF ONCOLOGY, CLATTERBRIDGE 
CANCER CENTRE AND JAMES COOK 
UNIVERSITY HOSPITAL (PART OF THE 
UK SBRT CONSORTIUM)
Vicky Sangha1, Robin Prestwich1, John Lilley1, Alan 
Needham1, Michael J. Flatley1, Michael P. Snee2, 
Clive Peedell3, Neil Richmond3, James Green3, 
Angela Baker4, Alison Scott4, Pooja Jain4, Matthew 
Hatton5, Kevin N. Franks1 
1St James’s Institute Of Oncology/United Kingdom, 
2Department Of Clinical Oncology, St James’s 
Institute Of Oncology/United Kingdom, 3James Cook 
University Hospital/United Kingdom, 4Clatterbridge 
Centre Of Oncology/United Kingdom, 5Dept Of 
Clinical Oncology, Weston Park Hospital/United 
Kingdom
Background: There is now good non-randomised 
evidence suggesting that SBRT is superior to 
conventional radiotherapy with local control rates of 
over 80-90% being achieved with minimal toxicity. 
Therefore, the UK SBRT Consortium was created to 
develop SBRT in the UK. The UK SBRT Consortium 
includes > 30 UK centres and with its Àrst guidelines 
issued in April 2009. These guidelines provide 
standard dose/fractionation regimes, radiotherapy 
Q/A requirements and recommendations for data 
collection. The Consortium aims to develop SBRT 
across the UK and promote novel research. 
treatment provides volumetric information on 
intra-thoracic anatomy in addition to measuring the 
position of the tumor necessary for accurate dose 
delivery. This minimizes discrepancies between 
treatment planning and delivery and provides 
unique anatomical information which may result 
in adaptive re-planning to account for the changes 
observed. The purpose of this study was to evaluate 
these changes and the frequency of adaptive 
replanning using IGRT. 
Methods: In this study, 180 consecutive lung 
cancer patients (T1-4N0-3), treated with curative 
intent between January 2010 to November 2010 
were retrospectively analyzed. These patients were 
treated with or without concurrent chemotherapy 
and Intensity Modulated Radiotherapy (IMRT) to 
a dose of 66Gy (24x2.75Gy), or 51Gy (17x3Gy). 
Patients received repetitive 3D/4DCBCT for 
setup veriÀcation using our clinical off-line setup 
correction procedure. The occurrence or resolving 
of atelectasis, pleural effusion and other anatomical 
changes within the thorax were scored qualitatively 
together with the frequency of adaptive re-planning. 
Results: In 83 (45%) of the 180 patients evaluated, 
intra-thoracic anatomical changes were visually 
detected on these CBCTs. Changes affecting the 
position of tumour and/or lymph nodes were 
observed in 12% with 6% requiring a re-scan and 
re-plan as the tumour and/or lymph nodes were no 
longer fully within the treatment beam. In 2% of 
patients adaptation of the registration method due 
to tumour shrinkage was necessary.Minor changes 
such as slight increases/decreases of atectelasis or 
pleural effusion were observed in 27% of patients 
without considerable displacement of the centre of 
mass of the tumour. 
Conclusion: Image guided radiotherapy increased 
the precision of radiotherapy in lung cancer patients 
because of frequently seen intra-thoracic changes 
requiring radiotherapy treatment adaptation or 
even re-planning. Volumetric information is 
provided using IGRT which not only increases the 
geometrical accuracy in patient alignment but also 
facilitates easy monitoring of anatomical changes 
resulting in a reduction of geographical misses 
which ultimately affect treatment outcome. 
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P1.176 PRELIMINARY RESULTS OF A 
PET BOOST TRIAL : A RANDOMIZED 
PHASE II DOSE-ESCALATION TRIAL 
IN ADVANCED NSCLC WITH AN 
INTEGRATED BOOST TO THE PRIMARY 
TUMOR OR TO THE HIGH FDG-UPTAKE 
REGION WITHIN THE TUMOR
José Belderbos1, Wouter Van Elmpt2, Eugène 
Damen1, Wouter Vogel1, Michel Öllers2, Harm Van 
Tinteren3, Jan Jakob Sonke1, J A. Burgers4, Anne-
Marie C. Dingemans5, Dirk De Ruysscher6 
1Department Of Radiation Oncology, The 
Netherlands Cancer Institute - Antoni Van 
Leeuwenhoek Hospital/Netherlands, 2Radiation 
Oncology, MAASTRO Clinic, Grow - School For 
Oncology And Developmental Biology, Maastricht 
University Medical Centre/Netherlands, 3Department 
Of Biostatistics, The Netherlands Cancer Institute 
- Antoni Van Leeuwenhoek Hospital, Amsterdam,/
Netherlands, 4Thoracic Oncology, The Netherlands 
Cancer Institute/Netherlands, 5Department Of 
Pulmonology, Grow - School For Oncology And 
Developmental Biology, Maastricht University 
Medical Centre/Netherlands, 6Radiation Oncology, 
MAASTRO Clinic/Netherlands
Background: Purpose/Objective: In NSCLC patients 
optimizing loco-regional control is a necessity to 
improve treatment outcome. We initiated a multicenter 
randomized phase II PET Boost Trial (NCT01024829) 
trial on dose-escalation for advanced NSCLC patients 
using Intensity Modulated Radiotherapy (IMRT). 
Patients receive accelerated radiotherapy (66 Gy in 
24 fractions of 2.75 Gy) to the primary tumor and 
involved lymph nodes with an integrated boost to the 
whole primary tumour (arm A) or the region within 
the primary tumour with an FDG-uptake >50% of 
the maximum SUV (arm B). Both treatment arms 
A and B are normalized (forced isotoxic mean lung 
dose (MLD)) to each other by performing dual arm 
treatment planning for every patient. 
Methods: The primary objective of this study is to 
select the treatment arm with the most favourable 
local progression-free survival (LPFS) at 1 year. 
Based on an expected increase of local progression-
free survival at 1 year of 15% (from 70 to 85 %) 
a total of 53 patients per treatment arm will be 
randomized. Secondary objectives are toxicity as 
a function of radiotherapy dose and volume of the 
tissues irradiated, overall survival and quality of life. 
Methods: We analysed patients treated with SBRT 
for early stage NSCLC (May 2009 and December 
2010). The eligibility criteria were; peripheral early 
stage NSCLC (<5cm) which were either histologically 
conÀrmed or evidence of PET positivity and serial 
growth, medically inoperable due to comorbidities 
and no cut off for lung function. Radiotherapy 
was planned with 4DCT or multiple helical CTs 
and a typical plan was generated using a 7-9 Àeld 
class solution and then optimised. All patients had 
image-guided RT with cone beam CT. Standard 
dose prescriptions were 54Gy in 3 fractions(#) (for 
peripheral lesions not close to ribs), 55Gy in 5# (when 
the PTV overlapped the chest wall) or 60y in 8# 
(patients previously treated with radiotherapy/or too 
close to pericardium) on alternate days, prescribed to 
the isodose covering the PTV (typically~80%). 
Results: 102 patients, mean age 74±9.2 SD, were 
treated. Median follow-up is 6 months (range 1-20). 
From the available data the T stage was T1(65pts), 
20 had T1 and T2(20pts), T3(3) and T4(3) of which 
68 were deemed medically inoperable and 6 patients 
refused surgery. The mean tumour size was 2.3cm 
(range 0.8-4.7cm). For those with available data 
the patients’ WHO PS was 1(45pts), 2(39pts) and 
3(10pts). Mean FEV1 was 54% and DLCO 44%. 
20pts received 54Gy/3#, 2pts 55Gy/3#, 74 pts 
55Gy/5#, 1pt 52Gy/8#, 1pt 2 treatments of 55Gy/5# 
for bilateral tumours, 3pts 60Gy/8# and 1pt 31Gy/3# 
prior to early treatment cessation due to anxiety. 
Grade 3 breathlessness occurred in 2 patients during 
treatment, 10 patients had Grade 2 pneumonitis at 3 
months and one patient had Grade 4 hypoxia which 
probably contributed to their death (G5). 1 local 
recurrence; 3 patients regional recurrences; 3 regional 
and distant metastases and 5 distant metastases alone. 
12 patients (11.8%) relapsed. 20 (19.6%) patients 
have died - 3 from unrelated causes, 1 from Grade 
5 hypoxia, 2 from probable COPD exacerbations, 6 
unknown and 9 patients from progression (9%). 
Conclusion: The formatiation of the UK SBRT 
Consortium and subsequent guidelines has allowed 
SBRT to be introduced in a controlled and safe 
manner into the UK. At present 5 UK centres now 
offfer SBRT with 10 expected by the end of the 
year. Our results conÀrm that SBRT appears to be 
well tolerated with low rates of acute toxicity and 
high rates of local control. The UK SBRT also aims 
to promote reseach with the proposed Surgery or 
SBRT (SOS) trial in patients considered high risk for 
surgery and expand into other cancer sites. 
Keyword: SBRT, early lung cancer, outcomes
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Methods: From January 2004 to June 2009 17 
patients (15 males 2 female; mean age 73 years) with 
early Stage lung cancer (13 IA and 4 IB according to 
TNM 7th edition) underwent SBRT at our Institution 
at average of 10 years (range 2-28 years) after lung 
surgery (4 pneumonectomy, 13 lobectomy). In 13 
patients a histological diagnosis was not available due 
to the high risk of complications. In this subgroup the 
lung nodules were considered malignant if increased 
in diameter at two CT-scans and positive at PET-
scan (clinical proof of malignancy). All patients had 
peripheral tumors (located more than 2 cm away from 
airways or more than 1 cm away from major blood 
vessels) and median disease volume was 5 cc (GTV). 
All patients underwent 4-dimensional computed 
tomography (4D-CT) scans for SBRT target volume 
deÀnition. Three fractions of 15 Gy were delivered 
during 1 week. Dose-constraints to organs at risk 
damage were as follows: mean lung dose ipsilateral 
lung (MLD) < 15 Gy, spinal cord < 18 Gy, chest 
wall < 30 Gy; radiation doses were prescribed to the 
80%-isodose encompassing PTV (Internal Target 
Volume plus 5 millimeter), with normalization to 
100% at the isocenter. SBRT was delivered with an 
Elekta Precise® Linear Accelerator, using 6-8 static 
non-opposing, non-coplanar shaped Àelds, with 6-10 
MV photons. Follow-up CT scans were obtained at 3 
months after SBRT for the Àrst 2 years, 6 months for 
the other 3 years, and then annually .
Results: Median follow-up was 29 months. The 
SBRT was well tolerated, without any acute clinical 
toxicities; Àve patients developed a RTOG grade 2 
radiological pulmonary late toxicities (over 90 days 
after SBRT), without impaired pulmonary function. 
No local failures were observed. Overall survival rate 
was at 1 years was 94% and at 3 years 65%. The 1 and 
3-years disease-free survival rates were respectively 
82% and 59% with majority of events represented 
by systemic failure (3 patients), one patient died for 
haematological disease and one for cardiovascular 
complication not related to radiation therapy.
Conclusion: SBRT was a safe and well tolerated 
treatment for patients with secondary Stage I lung 
tumors after previous thoracic surgery for NSCLC. 
Survival rates in this subgroup were similar to SBRT 
outcomes in previously untreated patients.
Keywords: Surgery, Radiotherapy, Lung cancer, 
Early Stage
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
Eligibility criteria are stage III or inoperable stage II 
NSCLC patients treated with or without concurrent 
or sequential chemotherapy, WHO 0-2. Patients 
are randomized if an integrated boost of 3 Gy per 
fraction (72 Gy total dose) to the entire primary tumor 
fulÀls the criteria of the organs at risk. The biological 
corrected dose-constraint to lung is: MLD20 Gy. 
Other dose-constraints: esophagus (V35<80%), 
spinal cord (max. 52 Gy), brachial plexus (max. 66 
Gy), heart (mean dose<46 Gy) and the mediastinal 
structures (max. 94 Gy). All constraints are in 
biologically equivalent dose (EQD2). 
Results: On February 1, 2011, 15 eligible patients 
were registered. Twelve patients were randomized 
and completed the 24 fractions. Median prescribed 
fraction dose for arm A 3.14 Gy and arm B 3.49 
Gy. Mean PTV dose delivered in 24 fractions to the 
entire primary tumor were comparable: a median of 
74.3 Gy and 75.0 Gy for arm-A and B, respectively. 
Nine patients received concurrent chemotherapy and 
for six patients no chemotherapy was prescribed. 
Treatment toxicity was according to expectations. 
Dysphagia was the most common side effect; with 
30% grade 3 according to CTCAE v 4.0 and 15% 
dyspnoe grade 3. No unexpected toxicities were 
observed. One patient died shortly after the end of 
treatment due to a gastrointestinal bleeding during 
hospitalization for a myocardial infarction. 
Conclusion: The PET Boost Trial, a randomized phase II 
trial on dose-escalation for advanced NSCLC patients with 
a boost to the primary tumor or a boost to the high FDG-
uptake region within the tumor, is ongoing and accruing 
well. Esophageal toxicity is severe, but manageable. 
Keywords: NSCLC, Radiotherapy, FDG PET, imrt
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P1.177 STEREOTACTIC RADIOTHERAPY 
FOR STAGE I LUNG CANCER AFTER 
PREVIOUS LUNG RESECTION
Niccolò Giaj Levra, Alessia Silvia Guarneri, 
Andrea Riccardo Filippi, Riccardo Ragona, Cristina 
Mantovani, Umberto Ricardi 
Department Of Medical And Surgical Sciences, 
Radiation Oncology Unit/Italy
Background: Lung resection of new primary lung 
cancer after previous thoracic surgery is associated 
with a high risk of complications. We retrospectively 
analyzed efÀcacy and tolerance of stereotactic body 
radiation therapy (SBRT) in this subgroup of patients.
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VOICT VOIPET 
OBS1 0.82 0.87 
OBS2 0.76 0.86 
OBS3 0.82 0.85 
OBS4 0.75 0.82 
OBS5 0.83 0.87 
OVERALL 0.79 0.86 
Table1 Student t-test performed on VOI
CT
 and VOI
PET
 
estimate a p-value of 0.01, which is considered 
signiÀcant. 
Conclusion: Despite the uncertain due to the 
qualitatively contours obtained on CT-PET, that we 
correct with a quite large CTV margin, the precision 
in GTV lung contouring on PET is comparable 
with the precision in CT lung cancer contouring. 
However, the analysis performed on the volume 
overlapping index, VOI
CT
 and VOI
PET
, demonstrate 
that GTV localization is signiÀcantly different 
between the two imaging modalities. We conclude 
that PET imaging improve the accuracy in lung 
cancer deÀnition.
Keywords: CT-PET, Target deÀnition, Interobserver 
Variability
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.179 MEDIASTINAL RECURRENCE 
AS THE SITE OF FIRST FAILURE FOR 
STAGE I NON-SMALL CELL LUNG 
CANCER PATIENTS TREATED WITH 
RADIOTHERAPY
Ryan Hogg1, Tsz Kin Lee2, Robert Macrae2, Scott A. 
Laurie3, Jason R. Pantarotto2 
1Faculty Of Medicine, University Of Ottawa/Canada, 
2Radiation Oncology, The Ottawa Hospital Cancer 
Centre, University Of Ottawa/Canada, 3Medical 
Oncology, The Ottawa Hospital Cancer Centre, 
University Of Ottawa/Canada
Background: A signiÀcant proportion of stage I 
non-small cell lung cancer (NSCLC) patients are 
deemed inoperable and offered radiotherapy (RT) as 
an alternative curative treatment. Mediastinal staging 
for these patients is often less robust compared to 
their surgical counterparts, implying a higher risk 
of inadvertently treating Stage II or III disease 
inappropriately. This study is a single-institution 
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P1.178 PRECISION AND ACCURACY 
IN LUNG CANCER GROSS TUMOR 
VOLUME DEFINITION ON CT OR CT-
PET: AN INTEROBSERVER STUDY
Anna Delana1, Andrea Bolner2, Elena Magri2, Nicola 
Nagliati2, Mariangela La Macchia3, Loris Menegotti1, 
Luigi Tomio2, Valentina Vanoni2 
1Physics, S. Chiara/Italy, 2Radiotherapy, S. Chiara 
Hospital/Italy, 3Radiotherapy, Atrep/Italy
Background: The use of CT-PET imaging in 
deÀnition of target is nowadays routinely used. The 
porpuose of this study is to determine the precision 
and accuracy in lung cancer contouring on CT 
(GTV
CT
) or on CT-PET (GTV
PET
). 
Methods: Five trained physicians determined GTV
CT
 
and GTV
PET
 of 10 patients (pts) with lung tumour. 
Three pts were affected by small cell carcinoma 
limited disease (without lymph nodes involved), 
5 pts by a non small cell carcinoma early stage 
(without lymph nodes involved) and 2 pts by a single 
lung metastasis. Two patients had atelectasys due 
to the tumor. CT-PET was acquired in treatment 
position and fused with CT on Pinnacle TPS; 
GTV
PET
 was determined qualitatively without using 
any Standard Upteke Value (SUV). To measure the 
precision in GTV lung deÀnition on PET and CT, 
the calculation of the coefÀcient of variation (COV
CT
 
and COV
PET
) was performed: COV=s/m where s 
and m are the standard deviation and mean value 
of GTV
CT
 and GTV
PET
 contoured for each patient 
from the 5 observers. COV measure the dispersion 
of GTV
CT
 and GTV
PET
, between observers. To 
evaluate the accuracy in GTV lung contouring, the 
volume overlapping index (VOI
CT
 and VOI
PET
) was 
calculated. VOI consider the positional variability 
of GTV
CT
 and GTV
PET
, between observers: 
VOI=2*(V1ÇV2)/ (V1+V2) where V1 and V1 are 
deÀned by two different observers. All combination 
between the observers where considered. To 
determine statistical signiÀcance of the difference 
between VOI
CT
 and VOI
PET
, Student t-test was 
performed, with a p-value of 0.05 considered to be 
signiÀcant. 
Results: Mean coefÀcient of variation for GTV
CT
 is 
0.15 (SD 0.11) and for GTV
PET
 0.16 (SD 0.10). Mean 
VOI
CT
 and VOI
PET
 for the two imaging modalities 
contoured by all the observers are summarized in the 
table1: 
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P1.180 PRECISE ACCOUNTING 
FOR UNCERTAINTIES OF TUMOR 
LOCATION IN NSCLC ALLOWS 
INCREASING TARGET RADIATION 
DOSE WITHOUT INCREASING DOSE TO 
ORGANS AT RISK
Georgy Shakirin1, Marnix Witte2, Wouter Van 
Elmpt3, Matthieu Bal4, Dirk De Ruysscher3, Marcel 
Van Herk2, Philippe Lambin3 
1Bio-molecular Engineering, Philips Research/
Netherlands, 2Department Of Radiation Oncology, 
The Netherlands Cancer Institute, Antoni Van 
Leeuwenhoek Hospital (NKI-AVL)/Netherlands, 
3Department Of Radiation Oncology (MAASTRO), 
Grow-school For Oncology And Developmental 
Biology, Maastricht University Medical Centre/
Netherlands, 4Philips Healthcare/Netherlands
Background: There is a known dose response 
curve in NSCLC treated by radiation. Target dose 
escalation strategies based only on a maximum 
predeÀned “safe” dose to organs at risk (OAR) are 
becoming standard in radiation therapy of NSCLC. 
The dose inside the target can be distributed 
uniformly (uniform escalation) or increased to 
preselected subvolume(s) of the target (dose 
painting). For both strategies it is crucial to take 
uncertainties of tumor location appearing during 
planning and irradiation into account. A classical 
way to this is a margin approach, i.e., extending the 
clinical tumor volume (CTV) to the planning tumor 
volume (PTV). A probabilistic approach developed 
and implemented at NKI-AVL tests a distribution 
of possible CTV locations based on systematic and 
random uncertainties in target location. The aim of 
this work is to compare margin and probabilistic 
approaches for the two dose escalation strategies 
mentioned above.
Methods: Treatment plans were designed using a 
research version of the Pinnacle treatment planning 
system (Philips) extended with probabilistic tools 
(NKI-AVL). Probabilistic plans accounting for 
patient systematic (ƙ=0.29 cm) and random (Ʊ=0.3 
cm ) set-up errors were generated using constraints 
working for a conÀdence level of 90%. Systematic 
set-up errors were simulated by shifting target 
volumes with respect to the dose. The random errors 
were simulated by dose blurring. Margin based 
treatment plans used a 8 mm CTV to PTV margin 
that is adequate for the above mentioned errors. 
retrospective analysis of the nodal failure rate in 
stage I patients and associated factors.
Methods: All stage I biopsy-proven NSCLC patients 
treated with RT alone to a dose of >50 Gy from 2002 
to 2009 were identiÀed. Patients whose treatment 
Àelds electively included the hilum or any part of the 
mediastinum and those without at least one post-RT 
computed tomography (CT) scan for follow up were 
excluded. With ethics approval, scans identifying 
mediastinal failure were reviewed and when failure 
was not conÀrmed histologically, the date of the 
Àrst CT scan demonstrating growth of a mediastinal 
or hilar lymph node post-RT was recorded as the 
date of nodal failure. Correlation with pre-RT 
staging investigations such as mediastinoscopy, 
endobronchial biopsy (with or without ultrasound), 
or positron emission tomography CT (PET-CT) was 
performed. Details regarding any salvage curative 
therapy were recorded.
Results: Of 744 identiÀed cases, data from the Àrst 
149 eligible patients assessed thus far is presented. 
In addition to diagnostic CT, pre-treatment staging 
investigations included mediastinoscopy (9%), 
endobronchial biopsy (2%) and PET-CT (42%). 
103 tumors were < 3cm in diameter and 59 were 
> 3cm. 35% of tumors were adenocarcinoma, 
19% squamous cell and the remainder not 
otherwise speciÀed. 112 patients were treated with 
conventional RT (dose range 50-66Gy over 13-33 
fractions) and 37 with stereotactic body RT (54-60 
Gy over 3-8 fractions). Nodal failure was observed 
in 12% of patients and as the Àrst site of failure in 
5% (7 of 149). Of these 7 patients: 5 failed within 
6 months of treatment, 7 had tumors in peripheral 
location, 4 were T1a, 2 had pre-treatment PET-CT, 
0 had invasive mediastinal staging. One patient was 
treated with salvage chemoradiotherapy as the other 
6 were deemed to have a poor performance status at 
time of failure.
Conclusion: Despite a low rate of invasive 
mediastinal staging, isolated nodal failure in stage 
I NSCLC patients treated with RT alone is rare. A 
negative PET-CT may be enough to proceed with 
deÀnite treatment to the primary alone. Data from 
the entire cohort will be further analyzed to assess 
any differences in the pre- versus post-PET-CT era.
Keywords: Non-small cell lung cancer, Mediastinal 
recurrence, Radiotherapy, Stage I
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.181 HIGH-DOSE-RATE 
ENDOBRONCHIAL BRACHYTHERAPY 
FOR NON SMALL CELL LUNG 
CARCINOMA: LONG TERM RESULTS 
OF A CURATIVE STRATEGY
SoÀa Rivera, Laurent Quero, Pierre Maroun, 
Stéphanie Wong Hee Kam, Claude Maylin, 
Christophe Hennequin 
Radiotherapy, Hôpital Saint Louis/France
Background: High-dose-rate endobronchial 
brachytherapy (HDR-EBBT) is an effective palliative 
treatment for tumoral endobronchial obstruction with 
no risk of professional radiation exposure and very short 
treatment time. The purpose of this study is to evaluate 
outcomes after HDR-EBBT for limited inoperable 
endobronchial carcinoma treated with curative intent. 
Methods: we retrospectively reviewed 229 patients 
with non small cell carcinoma treated with HDR-EBBT 
between January 1990 and December 2009. Among 
them 126 patients with no extrabronchial spread were 
treated with curative intent. They presented local relapse 
after surgery (40.6%) or external beam radiotherapy 
(25.5%), or early inoperable stage with respiratory 
insufÀciency (33.9%). Treatment consisted of 6 fractions 
of 5 or 7 Gy, prescribed at 1 cm from the source (192Ir). 
Results: With a mean age of 62 years (range, 43-86) and 
a majority of male (90.6%) and squamous cell carcinoma 
(95.3%) mean follow-up was 4 years. Complete 
endoscopic and histologic response rate, 3 months after 
HDR-EBBT was 81.2%. At 3 and 5 years, local control, 
overall survival and disease speciÀc survival rates were 
60.3% and 51.6%, 47.4% and 24%, 67.9% and 48.5%, 
respectively. High tumor volume (length>2cm, bronchial 
obstruction>25%, tumor visibility on CT scan) and 
previous endoscopic treatment were associated with a 
higher risk of local failure. Disease speciÀc survival, but 
not overall survival, was associated with local control. 
Toxicities included 1,6% grade 5 haemoptysis (within 
less than 3 months after HDR-EBBT procedure), 2.4% 
grade 5 bronchial necrosis, 3.8% grade 3 and 8.5% grade 
2 radiation bronchitis. 
Conclusion: This large retrospective study indicates 
HDR-EBBT is an efÀcient potentially curative 
therapeutic strategy with acceptable toxicity proÀle in 
patients with inoperable endobronchial carcinoma. 
Keywords: High-dose-rate endobronchial 
brachytherapy, endobronchial carcinoma, Non small cell 
lung carcinoma
Margin based and probabilistic plans were created 
for these two dose escalation strategies: a) non-
speciÀc uniform dose escalation to the target and 
b) dose boosting to the area of 50 % and more of 
SUV maximum derived from an FDG PET scan. 
All plans were normalized to the same mean lung 
dose to ensure an “isotoxic” approach. The Ànal 
dose distribution was tested using a standalone 
Monte Carlo evaluation tool (NKI-AVL) which 
creates 10000 histories of possible target positions 
according to the given systematic and random 
errors. Endpoints were mean dose (D
mean
), dose to 
98% (D
98%
) and to 2% (D
2%
) of target volume.
Results: 12 plans were evaluated (margin based 
and probabilistic plans for uniform and SUV based 
dose escalation strategies for 3 patients). For two 
plans D
98%
 was slightly less for probabilistic plans. 
In all other cases probabilistic plans outperformed 
corresponding margin based plans. For CTV, on 
average, D
98%
 was 0.81 Gy higher, D
2%
 was 5.36 Gy 
higher, D
mean
 was 5.29 Gy higher for probabilistic 
plans. For volume of high SUV uptake, on average, 
D
98%
 was 3 Gy higer, D
2%
 was 7.18 Gy higher, D
mean
 
was 8.38 Gy higher for probabilistic plans.
Conclusion: Dose escalation techniques beneÀt 
from probabilistic planning. An increase in mean 
target dose is achieved both for uniform dose 
escalation and dose painting techniques without 
increasing toxicity. Probabilistic planning is a 
useful tool for designing treatment plans for dose-
escalation of lung tumors. This “software based” 
dose-escalation could lead to better outcome in 
NSCLC. This research was supported by the Center 
for Translational Molecular Medicine AIRFORCE 
project. M. van Herk and P. Lambin contributed 
equally to this work.
Keywords: probabilistic planning, Radiation 
Therapy, dose escalation, margin
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
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P1.183 CLINICAL TOXICITY AND EARLY 
OUTCOME DATA OF PATIENTS WITH 
EARLY STAGE NSCLC TREATED WITH 
STEREOTACTIC BODY RADIOTHERAPY 
(SBRT) AT GUY’S & ST THOMAS’ 
HOSPITAL NHS FOUNDATION TRUST, 
UK
Asad Qureshi, Simon Hughes, David Landau, Bhakti 
Gajjar, Shahreen Ahmad 
Clinical Oncology, Guy’s And St Thomas’ NHS 
Foundation Trust/United Kingdom
Background: Stereotactic Body Radiation Therapy 
(SBRT) is being increasingly used as an alternative 
treatment to surgery in medically inoperable stage 
I non-small-cell lung cancer (NSCLC). Several 
studies have reported excellent clinical outcomes, 
and the treatment has now been adopted in many 
countries worldwide. SBRT has only recently 
been implemented in UK cancer centres and was 
introduced at Guy’s and St Thomas’ Hospitals NHS 
Foundation Trust, London, UK in November 2009. 
We report early toxicity data on 14 patients treated at 
this Institution from a UK perspective. 
Methods: 14 patients with Stage 1 NSCLC were 
treated with SBRT. 11 were medically inoperable 
and 3 refused surgery. All patients had pathological 
conÀrmation of malignancy. Patients were planned 
using 4DCT scanning technique on a Siemens 
scanner and treated with on-line conebeam CT 
correction using the Elekta Synergy system. 
Fractionation regimes used were 18Gy x 3 and 
11Gy x 5 with a type B algorithm for radiotherapy 
planning. Toxicity was assessed using CTCAE v4.0 
criteria at baseline, prior to each treatment and at 
follow-up. We report our institution’s toxicity data 
at baseline and 6-8 weeks post treatment to assess 
treatment tolerability and early treatment-related 
toxicity. 
Results: Median age was 77years. 4 patients had 
T1aN0M0 tumours and 10 had T1bN0M0. Table 
1 shows the commonest toxicities. Most patients 
had Grade 0, 1 or 2 toxicity. Only 1 patient, who 
had numerous co-morbidities, described Grade 3 
dyspnoea and pain following treatment. One patient 
had a rib fracture, but there were no reports of 
skin toxicity. There are no reported local or distant 
recurrences at a median follow-up of 4 months. One 
patient died 9 months after treatment due to non-
cancer or treatment-related causes. 
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P1.182 ASSESSMENT OF GTV MOTION 
AND THE INFLUENCE FACTORS 
DURING RESPIRATION FOR LUNG 
CANCER USING FOUR-DIMENSIONAL 
COMPUTED TOMOGRAPHY(4DCT)
Zongmei Zhou, Xiao Ju, Minghui Li, Luhua Wang 
Department Of Radiation Oncology, Cancer 
Hospital, Chinese Academy Of Medical Science 
(cams) Beijing/China
Background: This study was to assess the three-
dimensional gross tumour volume(GTV) motion 
of lung cancer caused by respiration using four-
dimensional computed tomography(4DCT),and to 
analyse the inÁuence factors.
Methods: The 4DCT scans of up to 22 lung focus 
in 21 patients with lung cancer were analysed. 
The gross tumour volume was contoured in all 10 
respiration phases of 4DCT scans. The changes 
in volume of GTV, the 3D motion of the centroid, 
boundary of GTV and the 3D spatial motion vector 
were caculated and the inÁuence factors were 
analysed.
Results: The average change in volume of GTV 
was +14.3% 0.2%- 42.5-8.4% (0.4%-38.6%), the 
GTV centroid average movement was (0.18±0.12)
cm,(0.20±0.16)cm and (0.53±0.59)cm for the 
medio-lateral, vertro-dorsal and cranio-caudal(CC) 
direction. The CC movement was larger than other 
directions(P<0.05),and there were no signiÀcant 
differences observed in 3D motion of GTV 
boundary. The CC motion of tumour in lower 
lobe was large than in upper lobe(P<0.05),and no 
signiÀcant differences were found in other directions. 
There was no signiÀcant correlation of the 3D 
movement of GTV to the adjacency, volume of GTV.
Conclusion: GTV motion of patients with lung 
cancer is individual, the CC movement is the most 
obvious, using 4DCT to assess is comparatively 
accurate. The motion of lower lobe focus is larger. 
No signiÀcant correlation of the GTV motion to the 
volume was observed. The inÁuence of adjacency to 
the GTV motion still needs large sample study. 
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
S824 Copyright © 2011 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
Patients underwent 4D-CT simulation with image 
acquisition from 8 phases of the respiratory cycle. 
A gross tumor volume (GTV) was contoured on 
the free breathing CT, and an internal gross tumor 
volume (IGTV) encompassing the motion envelope 
of the GTV was created. Patients were initially 
positioned with orthogonal KV-matching to bony 
anatomy followed by conebeam CT (CBCT), 
wherein the CBCT-visualized tumor was matched to 
the IGTV from the simulation dataset. Intrafraction 
motion was assessed on an immediate post-treatment 
CBCT, which was matched to the IGTV. 807 total 
shift events were analyzed. 
Results: The average CBCT-based shifts after 
initial KV matching to bony anatomy in the vertical, 
longitudinal, and lateral axes were: 2.5 mm (n=145; 
Ʊ=3.5), 2.0 mm (n=145; Ʊ=2.8), and 1.7 mm (n=145; 
Ʊ=1.7), respectively. The mean total shift vector 
was 4.4 mm (n=435; Ʊ=4.0). There were 88 CBCT-
based shifts greater than 3 mm (37 vertical, 31 
longitudinal, and 20 lateral shifts). The population 
systematic error (ȸ) and random error (Ʊ) were 0.33 
and 0.28 vertically, 0.24 and 0.32 longitudinally, 
and 0.16 and 0.18 laterally. Applying the Van Herk 
margin formula, the optimal PTV for KV positioning 
was 10.2 mm vertically, 8.3 mm longitudinally, 
and 5.3 mm laterally. The average post-treatment 
CBCT-based shifts were: 1.4 mm (n=124; Ʊ=1.7) 
vertically; 1.5 mm (n=124; Ʊ=2.0) longitudinally, 
and 0.9 mm (n=124; Ʊ=1.1) laterally. The mean total 
vector shift was 2.8 mm (n=372; Ʊ=2.3). 39 shifts 
were greater than 3mm (17 vertical, 20 longitudinal, 
and 2 lateral shifts). There was no correlation 
between intra-fraction motion and patient age, body 
mass index, pulmonary function, or tumor size. 
Pearson’s correlation analysis demonstrated a weak 
relationship between shift magnitude and treatment 
time (r=0.2). 
Conclusion: This study shows that KV matching of 
the tumor to the IGTV required CBCT-based shifts 
greater than 3 mm in approximately 20% of cases, 
and intrafraction motion was greater than 3mm 
in approximately 10% of cases. Since the typical 
IGTV-PTV expansion employed in RTOG protocols 
is 3-5 mm, these data suggest that (1) orthogonal 
KV matching to bony anatomy is inadequate for 
accurate tumor positioning; (2) intrafraction motion 
can result in tumor motion outside the PTV; and (3) 
further work is required to Ànd determinants of inter- 
and intra-fraction motion that may help guide the 
individualized application of PTV margins. 
Keywords: stereotactic body radiation therapy 
Table showing baseline and early toxicity 
Baseline toxicity 6-8 weeks post treatment 
Grade 1 Grade 2 Grade 3 Grade 1 Grade 2 Grade 3 
Bronchospasm 7 5 0 4 2 0 
Cough 9 2 0 11 2 0 
Dyspnoea 8 5 0 6 4 1 
Fatigue 12 2 0 5 3 1 
Pain 6 0 0 5 1 0 
Conclusion: SBRT is well-tolerated in early stage 
NSCLC patients not suitable for curative surgery. 
These patients have multiple co-morbidities and it 
is therefore important that the treatment does not 
involve excessive toxicity. The toxicity data from our 
UK experience is similar to those of other countries 
and the early outcome data is at least as good as 
conventional radiotherapy. Other centres have also 
reported long-term results comparable to radical 
surgery. For these reasons, this treatment should be 
considered in other UK centres as an alternative to 
conventional radiotherapy in medically inoperable 
patients.
Keywords: Radiotherapy, SBRT, Non small cell 
lung cancer, early toxicity
Poster Session 1 – Radiotherapy Monday, 4 July 2011 12:15-14:15
P1.184 A MOVING TARGET: IMAGE 
GUIDANCE FOR STEREOTACTIC BODY 
RADIATION THERAPY
Michael Corradetti, Kevin Teo, Nathan Anderson, 
Lara Bonnar Millar, Christian Barlow, Ramesh 
Rengan 
Department Of Radiation Oncology, Hospital Of 
The University Of Pennsylvania/United States Of 
America
Background: Stereotactic Body Radiation Therapy 
(SBRT) is a promising treatment for patients with 
early-stage non-small cell lung cancer (NSCLC). 
Due to the large fractional doses and small treatment 
margins employed, precise patient positioning is 
critical. The aims of this study were to determine: (1) 
the accuracy of kilovoltage (KV) X-ray matching to 
bony anatomy for tumor positioning; (2) the optimal 
planning target volume (PTV) margin; (3) the 
magnitude of intrafraction motion; and (4) whether 
treatment time or patient characteristics correlate 
with intrafraction motion. 
Methods: 43 patients with early-stage NSCLC were 
enrolled on an image-guided radiotherapy protocol. 
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Multivariable competing risk regression models was 
used to assess the association between failures and 
radiation therapy groups, adjusted for confounding 
variables.
Results: There were 154 (31.3%) patients in the 
ACRT group, 99 (20.1%) in STRT1 and 239 (48.6%) 
in STRT2. More patients in the ACRT group had 
KPS  60 (p<0.001), more commonly presented with 
weight loss  10% (p<0.001), and had larger tumors 
(p<0.001). After adjusting for clinical variables, there 
were no differences in the radiation groups in terms 
of the patterns of local failure, distant tumor control 
or overall survival. Toxicity proÀles in the ACRT 
were signiÀcantly lower for grade  2 pneumonitis 
(p=0.009), radiation dermatitis (p=0.001), nausea/
vomiting (p=0.005), constipation (p=0.023), and 
weight loss during treatment (p=0.002).
Conclusion: Patients receiving accelerated 
radiotherapy had comparable local and distant 
recurrence rates with no difference in overall 
survival compared to conventionally fractionated 
radiotherapy, even though these patients initially 
presented with worse prognostic factors. Side effects 
were signiÀcantly less in the accelerated treatment 
arm compared to conventional fractionation. 
Overall, accelerated radiation therapy with 45 Gy 
in 15 fractions is an acceptable treatment option 
for patients with inoperable tumors with poor 
performance status and other major comorbidities.
Keywords: Inoperable, Accelerated Radiation 
Therapy, Poor prognostic factors, Non-small cell 
lung cancer
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P1.186 HIGH LINEAR ENERGY 
TRANSFER (LET) RADIOTHERAPY IN 
THE TREATMENT OF RECURRENT 
PREVIOUSLY IRRADIATED NON-SMALL 
CELL LUNG CANCER (NSCLC)
Andre Konski1, George Chen1, Mike Joiner1, Laura 
Kollar1, Shirish Gadgeel2, Antoinette Wozniak2 
1Radiation Oncology, Wayne State University/ 
Barbara Ann Karmanos Cancer Center/United 
States Of America, 2Oncology, Karmanos Cancer 
Institute/wayne State University/United States Of 
America
Background: Few options are available for 
treatment of patients with symptomatic previously 
irradiated non-small cell lung cancer once they 
(SBRT), Image-guided radiation therapy (IGRT), 
conebeam CT (CBCT), kilovoltage (KV) imaging
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P1.185 TREATMENT AND TOXICITY 
OUTCOMES USING ACCELERATED 
RADIATION THERAPY FOR 
INOPERABLE NON-SMALL CELL LUNG 
CANCER
Steven H. Lin1, Arya Amini1, Caimiao Wei2, Daniel 
Gomez1, Kayoko Ohnishi1, Pamela K. Allen1, James 
D. Cox1, Ritsuko Komaki1 
1Radiation Oncology, The University Of Texas MD 
Anderson Cancer Center/United States Of America, 
2Biostatistics, The University Of Texas MD Anderson 
Cancer Center/United States Of America
Background: While conventionally fractionated 
radiation therapy alone is an acceptable option 
for patients presenting with unresectable NSCLC 
due to major comorbid diseases, the optimal dose 
and fractionation scheme has not been established. 
We hypothesize that accelerated hypofractionated 
radiotherapy will have similar efÀcacy without 
increased toxicity when compared to conventionally 
fractionated radiation therapy.
Methods: This is a retrospective analysis of 492 
patients diagnosed with NSCLC treated with 
radiation therapy at MD Anderson Cancer Center 
between 1993 and 2009. Patients included in the 
study were medically or surgically inoperable, were 
free of metastatic disease at initial workup and did 
not receive concurrent chemotherapy. Patients were 
categorized into three groups. Group 1 received 
45 Gy in 15 fractions over 3 weeks (Accelerated 
Radiotherapy (ACRT)) while group 2 received 60-63 
Gy (Standard Radiation Therapy 1, STRT1) and group 
3 received > 63 Gy (Standard Radiation Therapy 
(STRT2). Chi-squared and Fisher’s exact tests were 
used to analyze the associations between categorical 
variables and radiation therapy groups. Kruskal-
Wallis tests were used to assess the association 
between continuous variables and radiation therapy 
groups. Overall survival was calculated using the 
Kaplan and Meier method and comparisons were 
made using the log-rank test. Multivariable Cox 
proportional hazards model was used to account for 
confounding variables. Cumulative incidence of local 
failure and distant failure was estimated using the 
method of subdistribution analysis of competing risks. 
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Background: Three-dimensional (3D) conformal 
beams are conventionally used in lung cancer 
stereotactic body radiotherapy (SBRT). Volumetric 
modulated arc therapy (VMAT) has been introduced 
recently as a new lung SBRT treatment modality. 
As it usually delivers treatment in a shorter time, 
this modality promises the possibility of target 
misalignment due to patient motion during each 
treatment. The dose distributions of VMAT plans 
differ from standard 3D therapy. This study 
quantiÀes dosimetric differences between the VMAT 
plans and the 3D ones. Furthermore, because a 
Áattening-Àlter-free (FFF) linear accelerator is now 
commercially available, we also analyzed VMAT 
plans generated using the FFF beams (FFF-VMAT).
Methods: Fifteen lung cancer patients previously 
treated with 3D or VMAT SBRT were randomly 
selected. For each patient, 3D, and coplanar and 
non-coplanar VMAT plans and FFF-VMAT plans 
were generated to meet the same objectives with 
5000 cGy to cover 95% PTV. Two dynamic arcs 
were utilized in each VMAT plan. The couch was 
set at ± 5 degrees to the straight position for the two 
non-coplanar arcs in normal VMAT and FFF-VMAT. 
Pinnacle version 9.0 (Philips, Fitchburg WI) was 
used to generate plans. SmartArc was used for the 
VMAT planning. The conformity index (CI), which 
is the ratio of the total volume receiving at least the 
prescription dose to the target volume receiving at 
least the prescription dose the conformity number 
(CN) which is the ratio of the target coverage to CI 
and the gradient index (GI) which is the ratio of the 
volume of 50% of the prescription isodose to the 
volume of the prescription isodose were compared. 
Results: The CI for the 3D, coplanar, non-coplanar 
VMAT and non-coplanar FFF-VMAT plans ranged 
from 1.20 to 2.45, 1.07 to 1.89, 1.07 to 1.79 and 1.07 
to 1.72 respectively, with an average and standard 
deviation of 1.52 ± 0.33, 1.29 ± 0.21, 1.28 ± 0.18 
and 1.28 ± 0.19 respectively. The CN values were 
0.65 ± 0.11, 0.75 ± 0.10, 0.76 ± 0.09 and 0.76 ± 0.10 
respectively. The GI values were 8.41 ± 3.78, 7.42 
± 2.98, 7.33 ± 3.00 and 7.87 ± 2.79 respectively, 
indicating sharper dose fall-off in normal tissues 
in VMAT plans. The GI values for the FFF VMAT 
plans were slightly higher than that of other VMAT 
plans. The mean dose to the PTV was 5348 ± 
118, 5294 ± 125, 5291 ± 117 and 5279 ± 97 cGy 
respectively. The total monitor units (MU) used in 
the plans were 1521 ± 159, 1652 ± 205, 1583 ± 209 
and 1744 ± 214 respectively. More MUs were used 
in the VMAT plans than 3D ones. The FFF-VMAT 
failed systemic therapy. The objective of this study 
was to report on our experience in the use of high 
LET radiotherapy in the treatment of patients with 
recurrent previously irradiated non-small cell lung 
cancer (NSCLC).
Methods: Between April 1993 and February 2011 
18 patients, (8 F, 10M) were treated with fast neutron 
therapy for recurrent NSCLC. Equivalent dose 
in 2 Gy fractions (EQD
2
) of photon and neutron 
radiotherapy were calculated with a alpha/beta ratio 
of 3 for normal lung and 10 for tumor for photon 
radiotherapy and  for normal lung and tumor for 
neutrons. The radiobiologically equivalent (RBE) 
factor of 3 was used for neutrons for the EQD
2
 
dose calculation for lung and 4 for tumor. A total 
EQD
2
was calculated for primary and recurrent 
treatment. Survival was calculated from the end of 
neutron radiotherapy.
Results: Median age at recurrence was 60 (range: 
40-92). Median pre neutron photon radiotherapy dose 
was 61.5 (30-90) Gy at a median of 11 months (range: 
3-36) prior to receiving neutron therapy. The median 
EQD2 previous photon dose was 60.6 Gy (range: 36-
90). The median neutron retreatment dose was 8NGy 
(range: 5-15). Total combined EQD
2
 of pre and post-
recurrent radiotherapy was 86 Gy(range: 66-120). 
8/12 patients presenting with symptomatic disease 
were successfully palliated. The treatment was fairly 
well tolerated with 3 patients having acute grade 1 
dermatitis, 8/18 having acute grade 2 esophagitis and 
no patients with radiation pneumonitis. Mean overall 
survival was 5 months (0-28).
Conclusion: Neutron therapy provided excellent 
palliative beneÀt with little acute toxicity in this 
patient population with few therapeutic options. 
Future studies incorporating molecular markers for 
radioresistance are planned to understand the biology 
of these tumors and their response to high LET 
radiotherapy.
Keyword: High LET Radiotherapy lung cancer
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P1.187 DOSIMETRIC STUDY IN LUNG 
STEREOTACTIC BODY RADIOTHERAPY 
USING VMAT TECHNIQUES
Geoffrey Zhang1, Thomas Dilling1, Lichung Ku2, 
Craig Stevens1, Weiqi Li1, Vladimir Feygelman1 
1Radiation Oncology, MofÀtt Cancer Center/United 
States Of America, 2Radiation Oncology, Salem 
Hospital/United States Of America
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Results: 260 analyzed patients comprise 184 from 
China and 76 from US. RILT occurred at a rate of 
25.5%, 14.5% and 22.3% for the Chinese center, 
US center and combined setting, respectively. The 
mean FEV1%pred, FVC%, DLCO% and MLD for 
entire group are 71.7%, 71.9%, 65.0% and 14.5 
Gy, respectively. There is no signiÀcant correlation 
between FEV1%pred and MLD (R2 = 0.024, P = 
0.051). Mean FEV1%pred for RILT and non-RILT 
patients are 81.7% vs. 75.1% (P = 0.054) in Chinese 
population and 64.5% vs. 58.3% for Americans (P 
= 0.348). In the combined population, RILT patients 
have remarkably higher FEV1%pred than non-RILT 
patients (78.4% vs. 69.7%, P = 0.012). Using the 
median of FEV1%pred as a cutoff point, the incidence 
of RILT was 16.0% and 28.7%, respectively (P = 
0.014). No difference is observed in either FVC% or 
DLCO% between patients with and without RILT. 
Under univariate analysis, FEV1%pred, MLD, 
COPD are signiÀcantly correlated with risk of RILT. 
FEV1%pred and MLD remain signiÀcantly associated 
with RILT in multivariate analysis, with odds ratios of 
1.016 and 1.114. A traditional model using predictors 
of MLD and COPD, yields a receiver operating 
characteristic (ROC) curve with the area under the 
curve (AUC) of 0.638 (P = 0.002). The addition of 
FEV1%pred slightly improves the AUC to 0.658 
(95% CI: 0.578, 0.738, P < 0.001), corresponding to a 
sensitivity, speciÀcity and accuracy of 67.9%, 60.7% 
and 62.3%, respectively. 
Conclusion: Pre-RT FEV1%pred and MLD were 
predictive of RILT. Poor baseline pulmonary function 
did not increase the risk of RILT and might even be 
associated with lower RILT probability, which has yet 
to be independently validated in larger patient cohorts. 
Keywords: Non-small cell lung cancer, radiation 
induced lung toxicity, Pulmonary function
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P1.189 CLINICAL AND TECHNICAL 
ASSESSMENT OF RESPIRATORY 
GATED INTENSITY MODULATED 
RADIOTHERAPY FOR LOCALLY 
ADVANCED LUNG CANCER
Alexander V. Louie1, George Rodrigues1, Philip Lee1, 
Brian Yaremko1, Rashid Dar1, Edward Yu1, David 
Palma1, Inge Aivas1, Stewart Gaede2 
1Radiation Oncology, London Regional Cancer 
Program/Canada, 2Physics And Engineering, 
London Regional Cancer Program/Canada
plans tended to use the highest number of MU. 
Conclusion: Besides the advantage of faster delivery 
times, VMAT plans demonstrated better conformity to 
target and sharper dose fall-off in normal tissues than 
the 3D plans for lung SBRT while maintaining mean 
target dose, though at the expense of additional MUs. 
Keywords: radiotherapy dosimetry, lung SBRT, 
VMAT
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P1.188 POOR BASELINE PULMONARY 
FUNCTION MAY BE ASSOCIATED WITH 
LOWER RISK OF RADIATION INDUCED 
LUNG TOXICITY: A POOLED ANALYSIS 
FROM CHINA AND US
Jingbo Wang1, Luhua Wang2, Jianzhong Cao2, 
Shuanghu Yuan1, Wei Ji2, Douglas Arenberg3, 
Randall K. Ten Haken1, Jianrong Dai2, Feng-Ming 
(Spring) Kong1 
1Radiation Oncology, University Of Michigan/United 
States Of America, 2Radiation Oncology, Cancer 
Hospital, Chinese Academy Medical Sciences & 
Peking Union Medical College/China, 3Internal 
Medicine, University Of Michigan/United States Of 
America
Background: Despite limited evidence, poor pulmonary 
function (PF) often leads to a contraindication for 
deÀnitive radiation therapy for lung cancer. This study 
investigates whether baseline pulmonary function 
predicts radiation induced lung toxicity (RILT) in 
patients with non-small cell lung cancer (NSCLC) 
receiving conformal radiation therapy (CRT). 
Methods: This pooled analysis included NSCLC 
patients from two centers (one in China and the other 
one in US) who were treated with CRT between 2001 
and 2009 and had pre-RT pulmonary function test 
(PFTs). Baseline PF parameters recruited percent 
predicted value of forced expiratory volume at 1st 
second (FEV1%pred), forced volume capacity 
(FVC%) and diffusion capacity of lung for carbon 
monoxide (DLCO%). Additional factors evaluated for 
the risk of RILT included age, gender, smoking status, 
KPS, coexisting COPD, concurrent chemotherapy and 
mean lung dose (MLD). Grade  2 RILT according to 
the modiÀed common terminology criteria for adverse 
event version 3.0 served as the primary endpoint, 
subject to pulmonary symptoms worsened by at least 
one grade over pre-RT levels without evidence of 
tumor progression or other speciÀc etiology. 
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Conclusion: The use of concurrent respiratory-
gated IMRT and chemotherapy is safe and shows 
promising clinical outcomes in locally advanced lung 
cancer with signiÀcant tumor motion. The toxicity 
proÀle associated with this treatment is within 
clinical expectation. 
Keywords: pneumonitis, esophagitis, imrt, 4DCT
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P1.190 STEREOTACTIC BODY 
RADIOTHERAPY FOR LUNG CANCER 
USING EXACTRAC X-RAY 6D AND 
FOUR-DIMENSIONAL CONE BEAM CT 
IMAGE GUIDANCE
Fen Wang1, Rajeev Badkul2, John Park1 
1Radiation Oncology, University Of Kansas Medical 
Center/United States Of America, 2University Of 
Kansas Medical Center/United States Of America
Background: To quantify the localization accuracy 
of lung cancer patients treated with ExacTrac x-ray 
6D and four-dimensional (4D) cone beam computed 
tomography (CBCT)-guided Stereotactic Body 
Radiotherapy (SBRT) and to calculate and validate 
planning target volume (PTV) margins to account for 
the residual geometric uncertainties
Methods: 40 patients with small lung tumors 
were treated with SBRT using Brain Lab BodyÀx 
immobilization to 50-60 Gy in three to Àve fractions. 
For each fraction, patient was aligned Àrst with 
infrared-based optical positioning system using skin 
markers. Patient position veriÀcation and adjustment 
were made by fusing the stereoscopic radiographs 
with simulation CT images using 6 degree of 
freedom (6D) fusion algorithms (bone registration). 
CBCT scans were then acquired for Ànal veriÀcation 
and adjustment of patient position by aligning tumor 
position with simulation CT images (soft tissue 
registration). The couch shifts with image guidance 
were collected to determine set up margins 
Results: The alignment to skin markers with no 
image guidance resulted in systemic (ƙ) errors of 
3.95, 5.57, and 6.49 mm and random (ƣ) errors 
of 4.22, 6.60, and 11.01 mm for the left-right, 
craniocaudal, and anteroposterior direction, 
respectively. The margin required to account for this 
setup error was 12.83-23.93 mm. The difference 
in the couch shifts obtained from ExacTrac x-ray 
6D and CBCT resulted in systemic (ƙ) and random 
(ƣ) errors of 0.32-1.02mm and 0.48-0.83 mm, 
Background: Intensity-modulated radiation 
therapy (IMRT) is an advanced radiation treatment 
delivery technique that can improve the therapeutic 
ratio. Thoracic tumors, however, pose a treatment 
challenge in optimizing the therapeutic ratio in part 
due to respiratory motion. Treatment simulation with 
a four-dimensional computed tomography (4DCT) 
scanner allows for assessment of tumor motion. 
In situations where tumor motion is excessive, 
the radiation beam can be gated to synchronize 
delivery of radiotherapy during the optimal point 
of the patient’s respiration cycle. As the clinical 
use of concurrent chemotherapy and respiratory-
gated IMRT in locally advanced lung cancer has 
not been well studied, we report our institution’s 
clinical outcomes and complications with this new 
technology.
Methods: According to our institutional protocol, 
non-small cell lung cancer (NSCLC) patients are 
treated concurrently with cisplatinum and vinblastine 
and 64 Gy in 32 fractions and small cell lung cancer 
(SCLC) patients are treated with cisplatinum and 
etoposide and 60 Gy in 30 fractions. Beginning 
in early 2006, all thoracic cancer patients treated 
radically were planned on a 4D-CT scanner. For 
tumors with motion  7 mm, treatment is performed 
with respiratory-gated IMRT. We identiÀed thirty-
four patients simulated for respiratory-gated IMRT 
between November 2006 and August 2010 from our 
institutional database. From this group, we excluded 
four patients that were lost to follow-up (n = 3), 
or did not receive the prescribed treatment (n = 1). 
Toxicities were graded by the Common Terminology 
Criteria for Adverse events version 3.0. Spearman’s 
rank correlation was used to evaluate potential 
parameters predictive of symptomatic esophagitis or 
pneumonitis. 
Results: There were 24 NSCLC (10 = 
adenocarcinoma, 11 = squamous cell, 3 = large cell) 
and 6 SCLC patients. Median overall survival was 
11.8 months (range 2.9 – 39.6 months), while 2-year 
and 3-year overall survival were 45% and 30% 
respectively. Local, regional, and distant recurrences 
occurred in 2 (7%), 5 (17%), and 15 (50%) 
patients respectively. Ten (33%) patients developed 
symptomatic treatment-related pneumonitis ( grade 
2) while 6 (20%) developed symptomatic acute 
esophagitis ( grade 2). Using Spearman’s rank 
correlation, V
5
, V
10
, V
13
, V
20
, and mean lung dose 
were not predictive of symptomatic pneumonitis. 
Similarly for esophagus, V
50
, V
60
, and D
max
 were not 
predictive of symptomatic esophagitis.
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checked weekly with CBCT unless >0.7 cm 
displacement persisted, for which continued CBCT-
based correction was applied.
Results: 15 patients were enrolled and 11 completed 
the protocol. Across all CBCT, unidirectional shifts 
ranged from 0.1 to 1.8 cm. The mean maximum 
displacement over the Àrst 5 CBCT was 1.05 cm 
and over all subsequent CBCT acquisitions, it was 
0.93 cm. This relative lack of improvement was 
primarily due to 3 patients who had displacements 
>1.2 cm after the initial assessment period. One 
was obese, one had orthotopic heart transplant with 
physical difÀculties, and one had small cell lung 
cancer showing continuous anatomic change in 
response to treatment. Excluding these 3 patients, 
the mean maximum displacement after the Àrst 5 
CBCT was 0.67 cm. Figure 1 shows 3-D shifts as a 
function of day of treatment. Data for the 3 patients 
with persistent displacement are displayed as large 
squares.
Conclusion: Conclusion: Propensity to systematic 
error can be identiÀed during the initial phase of 
radiation therapy. In most patients, eliminating 
systematic error reduces the amplitude of 
displacements over the remaining treatment course 
and conÀrms the validity of planning margins. 
One third of the patients had excessive persistent 
displacement requiring continued correction. 
Additional research is needed to determine if setup 
error reduction can be used to trim planning margins 
on an individualized basis, if the degree of variation 
can be predicted in advance from patient or tumor 
characteristics, and to what degree error reduction 
affects intrafractional motion. 
Keywords: image-guided radiotherapy, cone-beam 
CT
respectively. The margin required to account for 
this setup error introduced using bony anatomy 
(ExacTrac) as a surrogate for the target, instead of 
localizing the target itself, was 1.32-3.13mm. 
Conclusion: The CBCT soft tissue registration to 
localize the tumor in SBRT reduced the required 
setup margin by up to approximately 3.13 mm 
compared with ExacTrac bony registration as 
a surrogate for the target. This setup margin 
reduction by using CBCT may not be necessary 
in conventional fractionated radiotherapy using 
ExacTrac image guidance
Keywords: SBRT, IGRT
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P1.191 INITIAL DETERMINATION OF 
SETUP ERRORS USING DAILY CONE-
BEAM CT REDUCES SUBSEQUENT 
VARIATION OVER A LUNG CANCER 
RADIOTHERAPY TREATMENT COURSE
Sue S. Yom1, Josephine Chen1, Michele Aubin1, 
Olivier Morin1, Pierre Graff2, Martina Descovich1, 
Jean Pouliot1 
1Radiation Oncology, University Of California San 
Francisco/United States Of America, 2Service De 
Radiothérapie, Centre Alexis Vautrin/France
Background: Variations of daily radiotherapy 
setup necessitate larger planning margins around 
clinical target volumes, increasing the toxicity of 
lung radiotherapy. However, daily image guidance 
can be onerous and delivers additional dose to the 
lung and other non-target organs. We implemented a 
procedure to identify initial systematic errors using 
megavoltage Cone-Beam CT (CBCT), to determine 
the feasibility of reducing subsequent variation over 
the course of treatment.
Methods: Lung cancer patients scheduled to 
receive at least 3 weeks of radiotherapy were 
enrolled in a prospective imaging protocol. For 5 
consecutive sessions, a 5MU CBCT was acquired 
after conventional patient setup. CBCT-CT image 
registration was performed based on the position 
of the carina and if speciÀed as clinically relevant, 
target volumes or the spine. Planning margins were 
>=0.7 cm after accounting for motion. Therefore, 
shifts were enacted for any unidirectional error >0.4 
cm. After 5 CBCT were obtained, a permanent shift 
was enacted to minimize the mean 3-dimensional 
vector displacement from ideal. Patients were 
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A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.193 PRELIMINARY RESULTS OF THE 
FIRST 26 PATIENTS TREATED WITH 
STEREOTACTIC BODY RADIOTHERAPY 
(SBRT) FOR STAGE I-II LUNG CANCER
Edith Dieleman, Lon Uitterhoeve, Martijn 
Kamphuis, Pieter Gangel, Rob Van Os, C. 
Koedooder, Niek Van Wieringen, Caro Koning, 
Markus Wendling 
Radiation Oncology, Academic Medical Center 
Amsterdam/Netherlands
Background: To evaluate toxicity, survival, local 
recurrence (LR), regional recurrence (RR), and 
distant metastases (DM) in 26 patients treated with 
SBRT for stage I-II lung cancer. 
Methods: Between 2009 and 2010, 28 tumours in 26 
patients were treated with SBRT at our department. 
Median age of the patients is 75 years (range 51-
87). Fifty percent of the patients are female. In 
two patients two lesions were treated. Pathologic 
diagnosis was conÀrmed in 13 cases (46%). If no 
pathologic diagnosis was conÀrmed, the lesion 
should be FDG positive and progressive in time. 
FDG-positivity of the tumours was found in 25 
cases. Treatment plans were mainly based on PET-
CT in radiation position and Slow CT scans. The 
prescribed dose was 3 x 20 Gy for T1 tumours (n= 
8), 5 x 12 Gy for T1 tumours with broad contact to 
the chest wall (n=11) and T2 tumours (n=5) and 8 x 
7,5 Gy (n=4) for large tumours and tumours nearby 
organs at risk.
Results: Median follow-up was 6 months (range 
0 -15 months). Local recurrence free survival was 
100% at 6 and 12 months. Regional recurrence free 
survival (see Àgure) was 81% at 6 and 12 months. 
Metastases free survival at 6 and 12 months was 
67% and 50% respectively. Overall survival was 
87% and 65% at 6 and 12 months. Neither severe 
toxicity (grade 3) nor late toxicity was observed in 
this patient group. 
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P1.192 CONFIRMATION OF INTERNAL 
TARGET VOLUME AND DOSIOLOGY 
STUDY FOR LUNG CANCER USING 4D-
CT TECHNOLOGY
Bai Tong1, Li Jianbin2, Yin Yong1, Lu Jie1, Zhu Jian1, 
Liu Tonghai1 
1Department Of Radiation Physics, Shandong 
Cancer Hospital And Institute/China, 2Department 
Of Radiation Oncology, Shandong Cancer Hospital 
And Institute/China
Background: For the effect of breathing motion, it 
is difÀcult to conÀrm the tumor accurately in lung 
cancer in the intensity-modulated radiotherapy 
(IMRT). This study is to conÀrm the internal target 
volume (ITV) and compare the volumetric and 
dosiology differences between 3D-CT and 4D-CT, 
using 4D-CT technology.
Methods: Eight patients with primarily lung cancer 
were enrolled and both 3D and 4D-CT were taken. 
For each patient, 3D-CT was taken as reference 
image and clinical target volume (CTV) was deÀned 
on it. Extended CTV with setup margin was deÀned 
as PTV-3D; for each respiratory phase, CTV were 
drawn separately and mixed together as ITV, which 
was extended as PTV-4D. Design different IMRT 
plans on PTV-3D and 4D separately for each patient 
with same prescription doses, Àeld degrees and 
optimization target functions. The differences of 
target volumes, dose distributions on targets and 
organs as risk (OAR) were compared.
Results: The volume is 150.67±86.67 cm3 for 
PTV-3D and 130.17±79.89 cm3 for PTV-4D, which 
is 13.61% 8.51%~23.53% smaller. There is no 
signiÀcant difference of target conformal index (CI) 
and homogeneity index (HI). About the dose on OARs 
(including lung, heart and spinal-cord), 4D plans have 
lower dose to the 3D plans: V5, V10, V20 and V30 
for total-lung is cut separately from 41.25%, 29.75%, 
21.25%, 13.00% to 38.13%, 27.00%, 17.25%, 9.13%; 
mean lung dose (MLD) is cut from 1103.63cGy to 
911.21cGy; mean heart dose is cut from 450.43cGy to 
372.20cGy; maximum dose for spinal-cord is cut from 
3162.83cGy to 2967.63cGy.
Conclusion: 4D-CT technology can be used to 
bridge the gap of missing or extending the target 
volume on 3D radiotherapy. It will bring better 
accuracy an lower dose on OARs as well.
Keywords: Lung cancer, Internal-target volume, 
4D-CT
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cGy, respectively, compared with those in the 
anatomic plans. The median reductions in the 
percentage of volume irradiated with >5 Gy, >10 
Gy, >20Gy , >30Gy and >40Gy for functional 
lung in the functional plans were 6.50%, 10.21%, 
14.02%, 22.30% and 23.46% in 3DCRT planning, 
respectively, and 3.05%, 15.52%, 14.16%, 4.87%, 
and 3.33% in IMRT planning, respectively. No 
greater degree of sparing of the functional lung was 
achieved in functional IMRT than in 3DCRT.
Conclusion: Function-guided 3DCRT and IMRT 
plannings both appear to be effective in preserving 
functional lung in NSCLC patients.
Keywords: lung function, Lung cancer, 
Radiotherapy, lung perfusion
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P1.195 COMPARATIVE STUDY 
OF CONVENTIONAL AND 3D- 
CONFORMAL RADIOTHERAPY 
IN LOCALLY ADVANCED LUNG 
CANCER IN CONCOMITANT CHEMO-
RADIOTHERAPY PROTOCOLS.
Aloke Ghosh Dastidar 
Radiotherapy, Amri Hospital/India
Background: Treatment outcome of locally 
advanced lung cancer is not much encouraging 
even after development of newer molecules of 
chemotherapeutic agents. Advancement in radiation 
techniques claims to improve treatment related 
toxicities and better tolerance to patients. The present 
study was to compare the conventional radiation 
technique (CRT) with the 3-Dimentional Conformal 
Radiotherapy (3D-CRT) in relation to tolerance, 
cardiac exposure, treatment outcome and quality of 
life in stage matched lung cancer patients. An open 
randomized controlled trial. 
Methods: Forty biopsy proved stage 3b squamous 
cell lung cancer (NSCLC) patients who were 
inoperable at presentation were selected for 
concomitant chemo-radiation schedule. Twenty 
patients (Group A) were treated by weekly 
concomitant chemotherapy with inj. Paclitaxol 
30mg/m2and external beam Radiotherapy with AP 
portals in conventional fraction schedule of total 
dose of 54 Gy (40Gy in phase I and 14 Gy in phase 
II). Twenty patients (Group B) were treated by same 
weekly regimen for chemotherapy and external beam 
Radiotherapy was given by 3D-CRT schedule to 
Conclusion: With limited follow-up, SBRT for lung 
cancer showed a good control of LR and RR and was 
well tolerated in the Àrst group of patients treated 
with SBRT in the AMC, University of Amsterdam.
Keywords: SBRT, lungcancer, local control, 
regional recurrence
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
Poster Session 1 – Radiotherapy Monday, 4 July 2011 12:15-14:15
P1.194 THE APPLICATION OF 
SPECT LUNG PERFUSION SCANS IN 
PROTECTION OF LUNG FUNCTION 
OF PATIENTS WITH LUNG CANCER IN 
RADIOTHERAPY
Jinhu Chen 
Radiation Physics, Shandong Cancer 
Hospital&institute/China
Background: The lung functional status could 
be displayed on lung perfusion images. With the 
images, the radiotherapy plans of lung cancer could 
be guided to more optimized. This study aimed to 
assess quantitatively the impact of incorporating 
functional lung imaging into 3-dimensional 
conformal radiotherapy (3DCRT) and intensity-
modulated radiation therapy (IMRT) planning for 
non–small cell lung cancer (NSCLC).
Methods: Ten patients with NSCLC who had 
undergone radiotherapy were included in this study. 
Before radiotherapy, each patients underwent CT 
simulation and lung perfusion imaging with single 
photon emission computed tomography (SPECT). 
The SPECT images were registered with simulation 
planning CT and used to contour functional lung 
(lung-F) and non-functional lung (lung-NF). Two 
3DCRT plans and two IMRT plans were designed 
and compared in each patient: two anatomic plans 
using simulation CT alone and two functional plans 
using SPECT-CT in addition to the simulation CT. 
Dosimetric parameters of the four types of plans 
were compared in terms of tumor coverage and 
avoidance of normal tissues. Total radiation dose was 
set at 66 Gy (2Gy×33 fractions).
Results: In incorporating perfusion information 
in 3DCRT and IMRT planning, the reductions 
on average in the mean doses to the functional 
lung in the functional plan were 168 cGy and 89 
S832 Copyright © 2011 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
Radiation Oncology (MAASTRO), Grow, Maastricht 
University Medical Centre/Netherlands, 3Department 
Of Radiation Oncology, The Netherlands Cancer 
Institute, Antoni Van Leeuwenhoek Hospital (NKI-
AVL), Amsterdam/Netherlands
Background: The brain is one of the major sites 
of failure for stage III non-small cell lung cancer 
(NSCLC), with approximately 22% of the patients 
developing brain metastases. The recent RTOG-0214 
trial showed a highly signiÀcant decrease in the 
incidence of brain metastases, assessed with brain 
MRI scans, from 18 % in the control group to 7.7 
% in the Prophylactic Cranial Irradiation (PCI ) arm 
at 1 year. PCI in itself, however, induces adverse 
effects like neurocognitive deÀcits. These cognitive 
side effects may be reduced by the application of 
hippocampus avoiding PCI (HA-PCI). Within the 
Netherlands the NVALT-11 trial (a randomized 
phase III trial with or without PCI in stage III 
NSCLC patients number NCT01282437) is currently 
performed. The patients with and without (HA)-PCI 
have repeated tests for neurocognitive functioning 
in a side study. We developed a simple technique 
using two lateral beams with a PTV coverage of 
85% to deliver PCI while keeping the dose in the 
hippocampus as low as possible. This technique 
was compared with a complex technique using 
Volumetric Modulated Arc Therapy (VMAT). 
Methods: For 10 patients, the brain and 
hippocampus were delineated on a CT scan matched 
with a 3D T1 weighted MRI-scan. For the PTV, 
classically deÀned as the whole brain volume minus 
the hippocampus volume with a 5 mm margin, 30 Gy 
(12 fractions of 2.5 Gy) dose was prescribed. Two 
techniques were compared: a simple technique (A) 
using two opposing Àelds and a complex technique 
(B) using Volumetric Modulated Arc Therapy 
(VMAT). For technique A the collimator angle was 
chosen such that two 1 cm leafs optimally block 
the hippocampi. For technique B beam modulator 
plans with 2 dual arcs with the couch @ 0° and 90° 
(beam-on time: 4x180 sec = 12 min) were generated. 
The maximum and mean dose to the hippocampus 
was calculated, as well as the volume of the PTV 
receiving 95% of the prescribed dose (V95%).
Results: On average, the V95% of the PTV was 
85.7 ± 0.6 % for the simple technique and 96.4 ± 
0.24 % for technique B. For the simple technique, 
the average mean dose delivered in the hippocampus 
was 6.2 ± 0.3 Gy, the maximum dose was 11.9 ± 1.6 
Gy. The mean biological dose (with Ơ/ơ = 2 Gy) to 
deliver more precise and multiple portals of radiation 
Àelds to deliver total dose of 54 Gy (range 50.4Gy 
– 54 Gy) with off-cord cardiac sparing planning. 
Patients of both groups were studied for acute and 
late toxicity, tolerance, post treatment Quality of Life 
and recurrence free survival on clinical, radiological, 
DVH -dosimertic analysis and Lung function test 
report. 
Results: All twenty patients of both the groups 
could complete successfully the chemo-radiotherapy 
in deÀned time schedule. Tolerance to treatment 
for radiation by conventional arm was poorer than 
the 3D-CRT arm. Cough, weight loss, chest pain, 
anorexia, dizziness, haemoptesis, nausea, vomiting, 
muscle cramp were the criteria for comparison 
between the two groups. Mean integral dose in group 
A patients were higher than Group B patients. After 
individual CT-scan based planning on Organ At Risk 
analysis - healthy lung tissue received more radiation 
due 5-6cm margin for CTV in groupA compared 
to 1cm margin in Group B; Cardiac exposure – in 
group A 40% of healthy heart compared to 15% of in 
group B received radiation. 60 % of group A patients 
had progressive disease at 3month check-up CT-scan 
report and 40% in group B. Recurrence free survival 
at 18 months were 30% and 40% respectively. 
Details of reports will be discussed. 
Conclusion: Concomitant chemoradiation is the 
standard care of therapy in stage 3b lung cancer. 
Radiation and weekly Paclitaxel injection gives 
adequate tumor control. CT scan based treatment 
planning with judicious use of multi leaf collimators 
save normal tissue, prevents OAR, alleviates 
toxicities and improves tolerance. 3D-CRT thus 
helps recurrence free survival and better quality of 
life in locally advanced lung cancer. 
Keyword: Lung Cancer, Concomitant CT-RT
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P1.196 HIPPOCAMPUS AVOIDING 
PROPHYLACTIC CRANIAL 
IRRADIATION FOR NSCLC PATIENTS: 
USING A SIMPLE TECHNIQUE
Zdenko Van Kesteren1, José Belderbos1, Dirk De 
Ruysscher2, Agnieszka Olszewska1, Emmy Lamers1, 
Eugène Damen1, Marcel Van Herk3, Corine Van 
Vliet-Vroegindeweij1 
1Department Of Radiation Oncology, The 
Netherlands Cancer Institute - Antoni Van 
Leeuwenhoek Hospital/Netherlands, 2Department Of 
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centres have treated over 100 patients. SBRT for 
lung lesions is only provided in 4 provinces and 6 
of the 13 centres are located in Ontario. No centre 
in the Maritimes is currently providing SBRT. 48Gy 
in 4 fractions is the most common regimen (64%) 
followed by 54Gy in 3 fractions (28%). Four centres 
are treating lesions within 2 cm of the proximal 
airways (‘central’), although only 1 centre is enrolled 
in a clinical trial for central lesions. Seven centres 
are treating pulmonary metastases. Most centres are 
using a combination of coplanar and non-coplanar 
static beams. One centre is using respiratory gating. 
Treatment times average 50 minutes per fraction 
(range 30 – 90). Peer review of the target volumes 
occurs in only 6 centres and peer review of dose 
distributions in 5. Five centres have no systematic 
tracking of patient outcomes.
Conclusion: The use of SBRT for lung lesions has 
increased dramatically within the previous 3 years, 
however access continues to vary considerably 
by geography. Techniques and doses vary across 
institutions. Quality assurance and systematic 
tracking of outcomes remains sporadic.
Keywords: stereotactic body radiotherapy, Non 
small cell lung cancer, Oligometastases
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P1.198 USING DURING-RT PET TO 
INDIVIDUALIZE ADAPTIVE RT FOR 
PATIENTS WITH STAGE III NSCLC: A 
MULTICENTER PLANNING STUDY
Feng-Ming (Spring) Kong1, Ying Xiao2, Mitchell 
Machtay3, Maria Werner-Wasik4, Gregory M. 
Videtic5, Billy W. Loo6, Henry Wagner7, Elizabeth 
M. Gore8, John Varlotto9, Sergio Faria10, Thomas 
J. Dilling11, Alex Sun12, Todd Swanson13, Luhua 
Wang14, James Galvin2, Randall K. Ten Haken1, 
Jeffrey Bradley15 
1Radiation Oncology, University Of Michigan/
United States Of America, 2Rtqa, Radiation 
Therapy Oncology Group/United States Of 
America, 3Radiation Oncology, Case Western 
Reserve University/hospitals/United States Of 
America, 4Radiation Oncology, Thomas Jefferson 
University/United States Of America, 5Radiation 
Oncology, Cleveland Clinic/United States Of 
America, 6Radiation Oncology, Stanford University 
& Cancer Center/United States Of America, 7M.s. 
Hershey Medical Center/United States Of America, 
8Radiation Oncology, Medical College Of Wisconsin/
the hippocampus for technique A was 3.9 ± 0.2 Gy 
versus 7.4 ± 0.55 Gy for the VMAT technique. 
Conclusion: Opposing Àeld HA-PCI is a 
simple technique with a maximal sparing of the 
hippocampus. By accepting the V95% of the PTV to 
drop to 85%, an excellent sparing the hippocampus 
was achieved. This strategy is currently being tested 
in a randomized phase III trial (with or without PCI 
in stage III NSCLC patients) with an additional 
analysis of the neurocognitive sequels and the impact 
of PCI on neurological symptoms and health-related 
quality of life. 
Keywords: Hippocampus avoidance, profylactic 
cranial irradiation, NSCLC, brain metastases
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P1.197 THE CURRENT USE OF 
STEREOTACTIC BODY RADIOTHERAPY 
FOR LUNG TUMOURS ACROSS CANADA
Chad R. Lund, Mitchell Liu, Jonn Wu, Hannah 
Carolan, Rob Olson, Devin Schellenberg 
Radiation Oncology, British Columbia Cancer 
Agency/Canada
Background: Stereotactic body radiotherapy 
(SBRT) is a novel technique that can be used to 
deliver ablative doses of radiation to T1-T2N0 
primary lung cancers or small lung metastases. 
Though clinical data demonstrates excellent 
local control for lung lesions, the availability and 
utilization of SBRT for lung cancer across Canada is 
unknown.
Methods: In order to assess the use of SBRT 
for the treatment of primary lung malignancies 
and oligometastases to the lung, all Canadian 
radiotherapy (RT) centres were identiÀed from a list 
provided by the Canadian Association of Radiation 
Oncology (CARO). English surveys were emailed 
to all centres and reminder emails were sent to those 
that did not respond. The survey was comprised 
of 1 section each for lung, liver, spine, other (e.g. 
prostate) and for centres not currently using SBRT. 
Each section was to be representative of the practice 
at that centre at the time of survey completion. Lung 
SBRT results are presented here.
Results: Thirty-two of the 41 RT centres (78%) 
in Canada responded. Currently, 45% (14/32) are 
treating patients with SBRT, of which 13 (93%) 
are treating lung tumours. Nine centres began 
lung SBRT within the previous 3 years and only 3 
S834 Copyright © 2011 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
and 69/35, 55-82/30-41 and 13-132/14-49 cc during-
RT, respectively. The mean sensitivity/speciÀcity 
for GTV and MTV from STAPLE analysis were 
86%/99% and 86%/98% pre-RT, 66%/98% and 
51%/99% during-RT, respectively. MTV volumetric 
variations between physicians were not signiÀcant 
compared to GTVs in either pre- or during-RT 
scans (P>0.05). OAR volumes showed the greatest 
variations, with maximum upto 4 fold greater than 
minimum for one structure. For adaptive plans, 11/14 
centers escalated PTV doses >74 Gy, the remaining 
3 decreased OAR doses. Overall, plan A generated a 
mean PTV dose of 73 Gy (95% CI 73-75) with MLD 
of 21 (95% CI 19-21) Gy. Plan Bs PTV dose was 
escalated to a mean of 82 Gy (95% CI 79-84), with a 
MLD of 18 Gy (95% CI 18-19). Plan B reduced the 
means of mean esophageal, heart V40, esophageal 
V60, and maximum cord doses, with a small increase 
(1.1 Gy) increase in maximum esophageal doses. All 
plan Bs had MLD<20 Gy. Figure shows the detailed 
dosimetric differences between plan Bs and As of all 
individual centers. 
Conclusion: Although differences in tumor and 
OAR delineations were seen, variations in CT-GTV 
and PET-MTV either pre- or during-RT were not 
signiÀcant. All centers generated “during-RT PET”-
based adaptive plans with either PTV dose escalation 
or OAR dose reduction.
Keywords: Adaptive radiation therapy, Non-small 
cell lung cancer, PET-CT
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P1.199 ENDOBRONCHIAL 
BRACHYTHERAPY IN THE 
TREATMENT OF LUNG AND PRIMARY 
TRACHEAL CANCER: ELEVEN YEARS’ 
EXPERIENCE WITH IRIDIUM-192 HIGH-
DOSE RADIATION
Rachele Z. Grazziotin1, Márcio L. Reisner2, Edson 
Toscano3, Aureliano Sousa3, Célia M.P. Viégas1, 
Carlos M.M. Araújo1, Mauro Zamboni3 
1Radiation Oncology, National Cancer Institute 
Of Brazil/Brazil, 2Radiation Oncology, Clinicas 
Oncológicas Integradas/Brazil, 3Thoracic Surgery, 
National Cancer Institute Of Brazil/Brazil
Background: Lung cancer is the leading cause 
of cancer mortality in both men and women Most 
of the cases are diagnosed at stage III or with 
metastatic disease. In stage III patients, 50 - 75% 
United States Of America, 9Penn State Hershey 
Cancer Institute/United States Of America, 10Mcgill 
University Health Center - Montreal General 
Hospital/United States Of America, 11H. Lee 
MofÀtt Cancer Center/United States Of America, 
12Radiation Medicine Program, Princess Margaret 
Hospital/Canada, 13University Of Texas Medical 
Branch/United States Of America, 14Radiation 
Oncology, AfÀliate Of University Of Michigan/
United States Of America, 15Department Of 
Radiation Oncology, Washington University/United 
States Of America
Background: This RTOG developing concept is 
to individualize adaptive radiotherapy (RT) based 
on PET response during concurrent chemoRT for 
stage III lung cancer. This study aimed to examine 
the consistency across institutions of: 1) PET-based 
metabolic tumor volume (MTV) contouring versus 
CT-based gross tumor volume (GTV); and 2) the 
dosimetry of dose-adapted plans they produced. 
Methods: Fourteen RTOG Centers/AfÀliates 
planned on pre-RT and “during-RT” PET-CT scans 
of one T4N2M0 NSCLC of the right lower lobe. The 
initial plan (A) based on pre-RT PET-CT was to 74 
Gy. An adaptive plan (B) used “during-RT PET-CT” 
to create an adapted boost, after 50 Gy to the initial 
planning target volume (PTV). The Ànal adaptive 
plan limited total mean lung dose (MLD) to 20 Gy, 
and other organs at risk (OARs) to institutional 
or RTOG0617 criteria. Target/OAR volumes and 
doses and doses to 95% of PTV were compared 
between centers. Agreement between institutions was 
analyzed using simultaneous truth and performance 
level (STAPLE), an expectation-maximization 
algorithm. 
Results: 
The mean, 95% conÀdence interval (CI), and 
minimum-maximum of GTVs/MTVs were 146/128, 
134-158/117-140 and 111-203/69-165 cc pre-RT, 
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basis of the RTOG acute morbidity criteria, RTOG 
grade I toxicities occurred in 11 patients (25%). 
There were no cases of fatal hemoptysis, Àstulae or 
abscesses.
Conclusion: This study showed a high objective 
palliative response of HDREB in most of patients 
with advanced endoluminal lung and tracheal cancer, 
with minor non-fatal complications and a low 
morbidity rate.
Keywords: brachytherapy, tracheal cancer, 
endobronchial lung cancer, Radiotherapy
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.200 A PILOT STUDY USING 4D 
PET/CT TO DEFINE THE ITV FOR 
PATIENTS WITH NON-SMALL CELL 
LUNG CANCER (NSCLC) UNDERGOING 
RADIOTHERAPY (RT)
Yolanda K. Aarons1, Danny Duplan2, Steven David2, 
Tomas Kron3, Jason Callahan4, Aldo Rolfo1, David 
Binns4, Alan Herschtal5, Michael Macmanus2, David 
Ball2 
1Radiotherapy, Peter MacCallum Cancer Centre/
Australia, 2Radiation Oncology, Peter MacCallum 
Cancer Centre/Australia, 3Physical Sciences, Peter 
MacCallum Cancer Centre/Australia, 4Medical 
Imaging, Peter MacCallum Cancer Centre/Australia, 
5Centre For Biostatistics & Clinical Trials, Peter 
MacCallum Cancer Centre/Australia
Background: This study builds upon earlier work 
investigating 4-Dimensional CT (4DCT) compared 
to volumetric Positron Emission Tomography/CT 
(3DPET/CT), to delineate the Internal Target Volume 
(ITV), since both scans account for tumour motion 
in different ways. As compared with PET where a 
halo of reduced SUV (Standardised Uptake Value) 
intensity surrounding the tumour is mostly attributed 
to the tumour moving over a long acquisition time, 
4DCT is thought to be the gold standard. Although 
acceptable agreement between 4DCT and volumetric 
PET/CT ITVs was established, an inherent co-
registration error existed between the scans since 
they were acquired on separate scanners at different 
times. Furthermore, as 4DCT lacks biological 
information inherent to PET, not all the biologically 
have local recurrence and disease progression 
within the irradiated Àeld occurs in 33 to 50% 
within 15 months. The vast majority of patients with 
obstructive lesions are not curable so it is desirable to 
palliate these patients as quickly as possible without 
compromising their quality of life. This study’s aim 
was to assess outcome and toxicity of iridium-192 
high-dose-rate endobronchial brachytherapy 
(HDREB) for palliation of endobronchial and 
tracheal carcinoma.
Methods: Forty two patients with endobronchial 
lung and tracheal cancer underwent HDREB, in a 
total of 110 insertions, between 1998 and 2009, at the 
National Cancer Institute, in Brazil. All patients had 
previously undergone external beam radiotherapy 
with a median dose of 45Gy (ranging from 20 
to 75Gy) and 5 (13%) were also submitted to 
chemotherapy. Six patients presented relapse in the 
bronchial stump, six presented tracheal invasion and 
11 presented bronchial relapse (six in the right and 
Àve in left bronchus). All patients were submitted 
to a Áexible Àberoptic bronchoscopy, under local 
anesthesia, to visualize the tumor location. A hollow 
closed ended catheter was advanced beyond the 
site of the obstruction. The distal and proximal 
tumor limits were measured and the catheter was 
positioned 3- 6 centimeters distal to the tumor area. 
The application was performed with a high dose rate 
Ir-192 afterloading, and the dose was prescribed at 
1 cm from the source. The response was assessed 
by bronchoscopy and chest computed tomography 
at the end of treatment and one month after the last 
HDREB session. Survival time and symptom control 
were calculated from the date of initiation of the 
endobronchial brachytherapy. Overall survival was 
calculated using the Kaplan-Meier method.
Results: There were 34 (81%) men and 8 (19%) 
woman, (median age of 57,5 years, ranging from 
28 to 72 years old). Twenty-nine patients (69%) 
had squamous cell carcinoma, 11 (25%) had 
adenocarcinoma, and 2 had (4%) primary tracheal 
cancer. Thirty-two patients (75%) were submitted 
to three sessions of HDREB 7,5 Gy and 8 (19%) 
received two sessions of HDREB 7,5 Gy each 
with a 2-week interval. Two (6%) received only 
one fraction of 7,5 Gy. Bronchoscopic complete 
regression of tumor occurred in 32 patients (75%) 
and partial response (more than 30%) was assessed 
in 10 ( 25%) patients. Tumor regression was 
correlated with symptomatic relief of dyspneia. The 
overall survival was 56% in 15 months of follow 
up. The treatment-related morbidity was low. On the 
S836 Copyright © 2011 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
tumour were contoured on 4DCT, particularly in 
patients with nodal involvement. Further patient 
accrual is necessary to conÀrm these Àndings. 
Keywords: 4DCT, 4DPET/CT, ITV, Radiotherapy
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P1.201 THE SPECIFIC FEATURES OF 
MANAGEMENT AT PATIENTS WITH 
COMPLICATED LUNG CANCER.
Armen S. Benyan1, Sergey Y. Pushkin2, Nikolay V. 
Lyas3 
1Thoracic Surgery, Samara Regional Clinical 
Hospital/Russian Federation, 2Samara Regional 
Clinical Hospital/Russian Federation, 3Samara 
Regional Oncologic Hospital/Russian Federation
Background: The patients with complicated lung 
cancer by acute suppurative diseases need in phasic 
application of different methods of treatment. At 
Àrst, sanation of suppurative focus in lung or pleura 
and diagnostics have to be done. And if inÁammation 
has regressed and malignant tumor is conÀrmed, it is 
necessary to continue speciÀc treatment of tumor. 
Methods: In the department of thoracic surgery from 
2000 to 2009 years 129 patients with complicated 
lung cancer were treated. The onset of a disease 
has symptoms of acute inÁammation. Acute lung 
abscess was diagnosed at 42 patients, perifocal 
cancer pneumonia – at 42, pleural empyema 
– at 23, pleurisy – at 26 patients. At Àrst we 
perform the management of purulent disease and 
diagnostics of lung cancer. All patients received 
intensive antibacterial therapy. At 60 patients with 
pulmonary destruction we performed draining and 
biopsy by Àberoptic bronchoscopy. At 12 patients 
with pulmonary hemorrhage X-ray endovascular 
occlusion of the bronchial arteries was done. At 
patients with pleural empyema we used draining (14 
patients), surgical thoracoscopy with sanation and 
biopsy (13 patients), and punctures (20 patients). 
Results: The results of Àrst treatment period can be 
evaluated by the possibilities of special treatment in the 
second period. On that period, when diagnosis of lung 
cancer was conÀrmed, we applied different methods 
of special treatment. Surgical treatment, including 
combined operations, was performed at 38 patients. 
There were: 14 pneumonectomies, 15 lobectomies, 4 
bilobectomies, 3 atypical lung resections. 44 patients 
were directed on a chemotherapy and radial therapy. 
Mortality was 9 patients (7%). 
active components of tumours were contoured 
accurately. With the introduction of 4DPET/CT at 
our institution, we aimed to determine if 4DPET/
CT could provide biological information as well as 
accurately model the ITV. Another paper will discuss 
comparisons between 3DPET/CT and 4DPET/CT 
volumes, while this paper will examine the inÁuence 
of 4DPET to deÀne the ITV for patients with lung 
cancer undergoing radiotherapy (RT). 
Methods: Patients with pathologically proven 
NSCLC, due to undergo high dose palliative 
(>36Gy) or radical (>60Gy) RT, and had some 
degree of tumor motion were enrolled. Sequential 
4DCT and 4DPET scans coupled with the Varian 
RPM
TM
 system were acquired on an integrated PET/
CT scanner (GE discovery STE8) with patients in 
the RT treatment position. Ten scans of both gated 
CT and PET data corresponding to a phase of each 
patient’s respiratory cycle were reconstructed and co-
registered in the RT treatment planning system. ITVs 
were contoured individually by a single radiation 
oncologist using blended 4DPET and 4DCT data 
using our institutions protocol. ITVs were then 
summed to create an aggregate volume (V
4DPET/
CT
) and compared an ITV based solely upon 4DCT 
(V
4DCT
). 
Results: Data from Àve patients has been analysed, 
two of which had mediastinal disease. Volume 
analysis showed ITVs generated using 4DPET/
CT were larger than 4DCT ITVs in all cases. The 
% difference between V
4DPET/CT
 and V
4DCT
 as well 
as a Concordance (C=2(V
4DPET/CT
ƗV
4DCT
)/(V
4DPET/
CT
+V
4DCT
)) was calculated. A clinically signiÀcant 
difference was deemed to exist between the V
4DPET/
CT
 and V
4DCT
 if the relative difference between these 
volumes was more than 5%. The concordance 
was considered to represent a clinically signiÀcant 
difference between these volumes when its value 
was less than 0.95. The difference between V
4DPET/
CT
 and V
4DCT
 was consistently over 5% for both 
primary disease (12% to 28%) and nodal disease 
(53%). Conformity Index for V
4DPET/CT
 and V
4DCT
 was 
consistently inferior to 0.95 for both primary (0.59 
to 0.84) and nodal disease (0.13 to 0.45) suggesting 
a clinically signiÀcant difference between volumes 
deÀned using 4DPET/CT compared to 4DCT alone. 
Conclusion: Preliminary results found ITVs 
generated using 4DPET/CT were larger and 
signiÀcantly different to those using 4DCT alone, 
demonstrating a clinical impact when using 4DPET 
to delineate the ITV. However, as 4DCT lacks 
biological information inherent to PET, not all avid 
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pediculated muscle Áap was successfully used.
Conclusion: Fistula between the respiratory 
and gastrointestinal tracts is a potentially fatal 
complication requiring early intervention and 
recurrence or metastatic cancer must be ruled out.
Keywords: Tracheogastric Àstula,, Surgery, 
Mediastinal infection,
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.203 MIDDLE LOBE SYNDROME 
CAUSED BY ENDOBRONCHIAL 
MALIGNANT TUMOR
Krzysztof Kurowski1, Jolanta I. Matuszek2, Carlos 
Francisco M. Nunez2 
1Thoracic Surgery, Hospital De Torrevieja/Spain, 
2Hospital De Torrevieja/Spain
Background: Review of the major literature dealing 
with the right middle lobe syndrome (RMLS) shows 
that benign inÁammatory disease is the most common 
etiological factor (62%). However, 22% of patients 
reviewed had malignant tumors as a cause of the 
syndrome. Bronchial occlusion is the pathophysiological 
abnormality leading to the development of the RMLS 
has been rejected by more recent authors.
Methods: We described a case of a 26-year-old man 
who presented massive hemoptysis. He was found to be 
bleeding from a endobronchial tumor on the right middle 
lobe oriÀce.
Results: The Surgical treatment was undertaken and 
superior bilobectomy was successfully performed. 
Postoperatively the patient was clinically and 
radiologically disease-free.
Conclusion: Diagnosis of right middle lobe syndrome 
(RMLS) is mainly based on the presence of atelectasis 
of the right middle lobe of long duration. Rule out 
acute right middle lobe pneumonia with repeat chest 
radiography within 3-4 weeks of initial onset. Surgical 
treatment should be performed if malignancy is 
suspected or if medical therapy fails.
Keywords: Middle lobe syndrom, Endobronchial 
tumor, Haemoptysis, Surgery
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
Conclusion: At patients with complicated lung 
cancer the phasic application of different methods 
of treatment is necessary. Primary therapy of acute 
purulent disease helps to improving of results of 
special treatment. 
Keyword: ararat
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.202 MANAGEMENT OF A DIFFICULT 
TRACHEOGASTRIC FISTULA
Krzysztof Kurowski1, Jolanta Iwona Matuszek2, 
David Costa Navarro3 
1Thoracic Surgery, Hospital De Torrevieja/Spain, 
2Division Of Anaesthesiology/Spain, 3Division Of 
General Surgery/Spain
Background: Granulomatous infection, foreign 
bodies, and trauma used to be the most common 
causes of benign acquired Tracheoesophageal 
Àstulas.
Methods: Added to these were Àstulas from 
complications of surgical procedures as 
Tracheogastric Àstula after Akiyama procede due 
to esofageal cancer appears as a rare complication. 
Various treatment options have been described and 
the general consensus is to use stents to cover them 
and relieve patient symptoms, that in our case failed.
Results: We describe a case in which a surgical 
treatment - closure of tracheogasrtric Àstula with 
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Conclusion: Thoracoscopic talc pleurodesis with 
hyperthermic intrapleural chemotherapy seems to 
be proÀtable to NSCLC with malignant pleural 
effusions and, along with chemoradiation, have an 
encouraging impact on improving the survival time 
of NSCLC with malignant pleural effusions. 
Keywords: Non-Small-Cell Lung Cancer, malignant 
pleural effusions, thoracoscopic talc pleurodesis, 
hyperthermic intrapleural chemotherapy
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P1.205 SARCOMATOID CARCINOMA OF 
THE LUNG; IS CURRENT SURGICAL 
INDICATION REALLY BENEFICIAL?
Joon Suk Park1, Yong Jik Lee2, Joung Ho Han3, Hong 
Kwan Kim1, Yong Soo Choi1, Jhingook Kim1, Young 
Mog Shim1, Kwhanmien Kim1, Sumin Shin4 
1Department Of Thoracic And Cardiovascular 
Surgery, Samsung Medical Center/Korea, 
2Department Of Thoracic And Cardiovascular 
Surgery, Asan Medical Center/Korea, 3Deparment 
Of Pathology, Samsung Medical Center/Korea, 
4Departement Of Thoracic And Cardiovascular 
Surgery, Samsung Medical Center/Korea
Background: Sarcomatoid carcinoma of the lung 
is a rare and aggressive subtype of non-small cell 
lung cancer (NSCLCa), with distinct differences 
from other NSCLCa. Based on our experience, we 
explored the clinical characteristics, prognostic 
factors, and outcome of this tumor, seeking clues to 
diagnosis and treatment.
Methods: Among 4212 patients who underwent 
curative resection for NSCLCa from September 
1994 to December 2009, the pathologic examination 
identiÀed 99 patients with sarcomatoid carcinoma. 
Medical records of patients were reviewed 
retrospectively.
Poster Session 1 – Surgery Monday, 4 July 2011 12:15-14:15
P1.204 THORACOSCOPIC TALC 
PLEURODESIS WITH HYPERTHERMIC 
INTRAPLEURAL CHEMOTHERAPY 
TO TREAT NSCLC WITH PLEURAL 
DISSEMINATION
Lei Yu, Jian-Ye Li, Fei Li, Yun-Feng Zhang 
Department Of Thoracic Surgery, Beijing Tongren 
Hospital, Capital Medical University/China
Background: The treatment of Non-Small-Cell 
Lung Cancer (NSCLC) with malignant pleural 
effusions remains controversial. Its prognosis is 
poor. The purpose of our study is to discuss about 
thoracoscopic talc pleurodesis with hyperthermic 
intrapleural chemotherapy combined with 
chemoradiation to treat NSCLC with pleural 
dissemination. 
Methods: From 2005 to 2008, there were 45 NSCLC 
patients with malignant pleural effusions undergoing 
thoracoscopic talc pleurodesis with hyperthermic 
intrapleural chemotherapy at our department. 
With the help of video-assisted thoracoscopy, the 
hyperthermic perfusion system was set up for 
hyperthermic intrapleural chemotherapy. Before 
the hyperthermic perfusion system worked, it was 
necessary to heat Sodium Chloride 0.9% Normal 
Saline 4500-5000ml up to 43°C and cisplatin 
(100 mg/m2) was added. The thoracic cavity was 
perfused at a speed of approximately 1.8-2.3 L/
min with 0.9% Normal Saline. The intrathoracic 
temperature remained between 42°C to 43°C. The 
process of perfusion lasted for 2 hours. After that, 
talc pleurodesis was made. 15 to 20 days after 
thoracoscopy, chemotherapy and radiation therapy 
were also involved one after another. 
Results: There were no peri-operative deaths. 
During the hyperthermic perfusion, patient’s core 
temperature varied from 36.2ºC and 39.3ºC and 
pulse from 58/m and 128/m. Intraoperative sinus 
tachycardia occurred in 4 old cases. No hematologic 
toxicity and nephrotoxicity was observed within 
one week after surgery. Postoperative pneumonia 
occurred in 3 old cases. 2 patients died within 3 
months after the therapy. After this therapy, the 
metastasis in the pleural wall dwindled markedly in 
11 patients (Figure 1). Median survival time for all 
patients was 15.5 months (2 months to 51 moths). 
No recurrence of pleural effusion was observed. 
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P1.206 VIDEO-ASSISTED 
THORACOSCOPIC SURGERY 
LOBECTOMY FOR LUNG CANCER: THE 
LEARNING CURVE
Hui Zhao1, Jun Wang2 
1Thoracic Surgery, People’s Hospital, Peking 
University, Beijing/China, 2People’s Hospital, Peking 
University, Beijing/China
Background: Video-assisted thoracoscopic surgery 
(VATS) lobectomy is an acceptable alternative to 
open lobectomy for treating early stage lung cancer. 
As with any video-assisted surgical procedure, there 
is a learning curve to overcome before becoming 
proÀcient. In this study, the outcomes of 90 
consecutive VATS lobectomies for lung cancer were 
evaluated to determine the learning curve for this 
procedure.
Methods: A single group of surgeons performed 
VATS lobectomy with systematic lymph node 
dissection in 90 lung cancer patients between 
September 2006 and January 2009. The patients 
were divided equally and chronologically into three 
groups (group A, B, and C), with group A being 
the earliest group of patients treated. Clinical data 
were collected. The operative time, blood loss, 
number of dissected mediastinal lymph nodes and 
nodal stations, conversion rate to thoracotomy, 
postoperative complications, duration of chest 
drainage, and hospital stay duration were compared 
between the three groups.
Results: There were no differences between the three 
groups with respect to age, gender, size of tumor, 
pathological stage and operative procedure (table 1.). 
The operative time and blood loss were signiÀcantly 
lower in groups B and C than in group A (P<0.01); 
however there were no differences between groups B 
and C. There were no differences among the groups 
in the number lymph nodes harvested, conversion 
rate, postoperative complications, duration of chest 
drainage, or hospital stay duration (table 2.).
Conclusion: A learning curve for VATS lobectomy 
existed in this series. The surgeon became more 
proÀcient after 30 to 60 cases, and was able to 
perform the procedure with decreased blood loss and 
operative time.
Keywords: Lung cancer, Video-assisted 
thoracoscopic surgery, lobectomy, Learning curve
Results:
The mean follow-up period was 16.07 months. 
Thirty-six patients had pathologic stage I disease, 
31 stage II, 28 stage III, and 4 stage IV. Surgery 
included 2 wedge resections, 67 lobectomies, 17 
bilobectomies, and 13 pneumonectomies. There 
were 90 patients with pleomorphic carcinoma, 6 
spindle cell carcinoma, one giant cell carcinoma, 
one carcinosarcoma, and one pulmonary blastoma. 
Overall 5-year survival was 54.3%. Forty-three 
patients (43.4%) experienced recurrence and 42 
of these died of the cancer. Pathologic T stage 
as deÀned by the 7th IASLC staging system 
was signiÀcantly associated with survival and 
recurrence (P = 0.004 and 0.002, respectively). Mean 
Positron Emission Tomography (PET) uptake was 
signiÀcantly higher than other types of lung cancer 
(P < 0.0001).
Conclusion: The prognosis of sarcomatoid 
carcinoma was distinctly unfavorable than for other 
NSCLCa, especially in advanced disease. In the case 
of a large peripheral tumor with high PET uptake, 
intense effort should be made to obtain an accurate 
preoperative histological diagnosis. Indications 
for surgery with sarcomatoid carcinoma should be 
reconsidered.
Keywords: Positron Emission tomography, 
Sarcomatoid carcinoma of the lung, Non-small cell 
lung cancer
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of the affected chest wall) was performed and 
followed by immediate intra-operative pathological 
examination of the tumor. The deÀnitive diagnoses 
in Cases 1, 2, 3 and 4 were moderately differentiated 
squamous cell carcinoma pT2aN2M1b (chest 
wall), pleomorphic carcinoma pT4 (intrapulmonary 
metastasis in the right lower lobe) N1M1b (brain), 
bronchioloalveolar carcinoma pT3N0M0 (including 
the inÀltrative shadow around the tumor), and 
moderately differentiated papillary adenocarcinoma 
pT1bN0M0, respectively.
Conclusion: In certain circumstances, lung tumors 
with a strong suspicion of lung cancer should 
be resected by lobectomy followed by thorough 
pathological examination, without pre-resectional 
diagnosis. One of these conditions is when 
lobectomy is expected to result in a more favorable 
patient status, regardless of deÀnitive diagnosis 
where larger tumor volume is involved. A second 
condition is when the lesion is deeply located near 
the major pulmonary vessels, and is not a candidate 
for wedge resection or segmental resection. The 
following conditions are common to each case: 
curative resection should be performed, detailed 
informed consent is required including risks of 
lobectomy for deÀnitively benign disease, and the 
patient should have good tolerance to surgery.
Keywords: lobectomy, lung cancer surgery, lung 
cancer diagnosis
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P1.208 EXTENDING INDICATIONS OF 
ROBOTIC SURGERY FOR THORACIC 
TUMORS
Naohiro Kajiwara1, Masahiro Taira1, Koichi 
Yoshida1, Masaru Hagiwara1, Masatoshi Kakihana1, 
Hisashi Saji1, Jitsuo Usuda1, Tatsuo Ohira1, Norihiko 
Kawate2, Norihiko Ikeda1 
1Surgery, Tokyo Medical University/Japan, 2Health 
Science And Social Welfare, Waseda University 
School Of Human Sciences/Japan
Background: Recently, we reported the utility of the 
da Vinci® Surgical System and its later version (the 
da Vinci® S) for various types of anterior and middle 
mediastinal tumors in clinical practice. We evaluated 
the feasibility, safety and appropriate settings of this 
system for the surgical treatment of these tumors. 
Methods: In this study, we evaluated extending the 
indications for the surgical treatment of posterior 
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P1.207 LOBECTOMY FOR 
INDETERMINATE LUNG TUMORS 
WITH A STRONG SUSPICION OF LUNG 
CANCER
Noritoshi Nishiyama, Koshi Nagano, Nobuhiro 
Izumi, Keiko Tei, Shoji Hanada, Hiroaki Komatsu 
Thoracic Surgery, Osaka City University Hopspital/
Japan
Background: For tissue diagnosis of an 
indeterminate lung tumor with a strong suspicion of 
lung cancer, wedge resection is sometimes difÀcult 
because of tumor size or location. Intra-operative 
needle aspiration biopsy can be considered when 
tumor biopsy via Áexible bronchoscopy (FB), or 
using transthoracic needle aspiration biopsy (TTNA), 
fails to prove malignancy in tumors with a high 
rate of false negatives. There are numerous lesions 
where an easy wedge resection or TTNA cannot be 
carried out, and lobectomy followed by thorough 
pathological examination is required.
Methods: From April through September in 2010, 
35 patients underwent lobectomy for primary lung 
cancer. Of these, four patients with indeterminate 
lung tumors who underwent lobectomy followed by 
thorough pathological examination were reviewed.
Results: The age and gender of case No.1 to 4 was 
a 75-year-old man, a 70-year-old woman, a 46-year-
old man, and a 75-year-old woman, respectively. 
The size and location of the lesion in each case 
was a 35 mm tumor in the left lower lobe, a 35 mm 
tumor in the right lower lobe, a 7 cm mass in the 
right upper lobe involving the chest wall, and a 20 
mm tumor in the left upper lobe near the pulmonary 
artery across the upper and lingular segments, 
respectively. Positive emission tomography showed 
accumulation of SUVmax 2.9~3.5 in case No.1 and 
SUVmax 4.5 in case No.3 in the tumor and serum 
carcinoembryonic antigen (CEA) was elevated to 
13 ng/ml in case No.1 and 9 ng/ml in No.2 (normal 
range; < 5.0 ng/ml). In all four patients, although 
lung cancer was strongly suspected, transbronchial 
biopsy through FB failed to prove malignancy. 
The patients were recommended surgery without 
TTNA. During surgery, intra-operative incisional 
biopsy or needle biopsy were avoided because of the 
possibility of a false negative result, or due to the 
tumor being in a difÀcult location to successfully 
achieve a deep puncture. In each case, lobectomy 
(in Case 2 lobectomy was combined with resection 
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Methods: 10 patients aged 85 years or older who 
underwent surgery for non-small cell lung cancer at 
our hospital between 2000 and 2010 were studied. 
The patients’ medical records were reviewed with 
type of operation, histological diagnosis, coexisting 
disease, smoking history, postoperative morbidity, 
mortality and survival results.
Results: There were seven men and three women 
with a mean age of 86.1 years (range,85-89). 7 
patients were smoker. Coexisting disease was 5 
patients (one patient had FEV1% less70%, one 
patient had cardiovascular disease, one patient had 
FEV1 less1000ml, one patient had dementia and one 
patient had erythroderma). Adenocarcinoma was 
identiÀed in 8 patients and squamous cell carcinoma 
was identiÀed in 2 patients. Lung resection was 
performed 4 lobectomies, 3 segmentectomies 
and 3 wedge resections. All patients were clinical 
stage1 and pathological stage1. The incidence 
of postoperative complications was 40%(atrial 
Àbrillation 2 patients, heart failure 1 patient, delirium 
1 patient). All patients are still alive(median follow-
up 29.5 months, range 2months-103months) and no 
recurrence.
Conclusion: Surgery in patients aged 85 years or 
older affected by non-small cell lung cancer is safe 
and feasible when careful preoperative respiratory 
and cardiac studies have been carried out. Long term 
survival for patients aged 85 years or older with early 
stage lung cancer treated by pulmonary resection is 
expected.
Keyword: osamucha
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P1.210 CHEST WALL AND STERNAL 
RESECTION FOR PRIMARY OR 
SECONDARY TUMORS, OUR 
EXPERIENCE IN SINGLE UNIT IN 
ALBANIA.
Fadil Gradica1, Agron Menzelxhiu1, Alma Cami2, 
Epaminonda Fype2, Fahri Kokiqi2, Ilir Skenduli1, 
Rezart Oketa1, Ilir Peposhi3, Zef Perduka3, Dhimitraq 
Argjiri4, Fatmir Caushi1 
1Thorax Surgery Service, University Hospital 
Of Lung Disease/Albania, 2Anestesireanimation 
Department, University Hospital Of Lung Disease/
Albania, 3Pneumologie, University Hospital Of 
Lung Disease/Albania, 4Pneumologye Department, 
University Hospital Of Lung Disease/Albania
mediastinal tumors which including those located 
beside upper vertebrae, beside the aorta and the chest 
wall (including the pleura) using the da Vinci® S 
Surgical System. The patients gave written informed 
consent to undergo robotic surgery using the da 
Vinci® S Surgical System. 
Results: All resected tumors were benign tumors 
histologically. Robotic surgery enables treatment 
for various types of tumors which are located in a 
variety of sites, such as the posterior mediastinum, 
and chest wall. In particular, to dissect tumors 
located beside the aorta, or beside upper thoracic 
vertebrae are very difÀcult to reach, making resection 
with the conventional video-assisted thoracoscopic 
surgery technique extremely difÀcult. However, 
all such procedures by robotic surgery using the da 
Vinci® S were performed safely and more easily than 
by conventional thoracoscopic surgery. 
Conclusion: Robotic surgery enables dissection 
of thoracic tumors located in sites that are difÀcult 
to reach, more safely and easily than conventional 
video-assisted thoracoscopic surgery and less 
invasively than by open thoracotomy. Care in 
selecting the appropriate settings, which depend 
on tumor location, is the most important point 
for robotic surgery for such lesions. Crucial to 
the success of these operations were selecting the 
appropriate placement and the angle of the da Vinci® 
special surgical ports in relation to the target and 
patients’ position, which varied according to the 
tumor location.
Keyword: Robotic surgery
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P1.209 SURGERY OF NON-SMALL CELL 
LUNG CANCER IN THE ELDERLY 
ESPECIALLY AGED 85 YEARS OR 
OLDER
Osamu Kawamata 
Surgery, Onomichi Municipal Hospital/Japan
Background: Japan is becoming the aging 
society, and aging goes ahead through Onomichi 
in particular(75years and older 10.4% in Japan 
comparison to 16.3% in Onomichi). Due to the aging 
of the general population, non-small cell lung cancer 
is a typical disease of the elderly, and is becoming 
increasingly. This study investigated the criteria for 
surgery in non-small cell lung cancer patients aged 
85 years or older.
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Keyword: Sternectomy • Sternal tumor • Plastic 
repair • Long-term survival
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P1.211 ANATOMIC MISADVENTURES 
DURING ROBOTIC LOBECTOMY
Jane Upson1, Arthur T. Martella2 
1Surgery, Phoenixville Hospital/United States Of 
America, 2Surgery, University Of Pennsylvania/
United States Of America
Background: The robotic approach for lobectomy 
offers certain advantages over the traditional VATS 
approach. However, the high magniÀcation with the 
DaVinci Robot (10 – 15x), unfamiliar camera angles, 
and the normal tendency for anatomic variations, 
may lead to anatomic problems during robotic 
lobectomy. 
Methods: We review 12 robotic lobectomy cases 
that required conversion to a VATS procedure 
or thoracotomy because of uncertainty about the 
anatomy. Three cases were at the home institution 
and seven were at outside institutions. 
Results: 12 patients (6 female, Mean age 68) had 
attempted totally endoscopic robotic lobectomy 
(RUL – 6, RLL - 3, LUL – 2, LLL – 1). There were 
3 identiÀable anatomic reasons for conversion. 
Four patients were converted because of confusing 
bronchial anatomy that upon direct inspection was 
due to a tendency for the dissection to drift up into 
the lobe. This resulted in a need to divide more 
vessels and segmental bronchi beyond their branch 
points. Two additional RUL patients had uncertain 
takeoff of the bronchus intermedius. Three patients 
were converted during RLL due to confusion of a 
low take-off of the RML bronchus with the RLL 
bronchus. 3 patients required conversion due to 
an incomplete minor and major Àssure making 
identiÀcation of normal structures difÀcult. 
Conclusion: Anatomic problems will occur during 
a totally endoscopic robotic lobectomy, particularly 
early in the learning of the procedure. Early division 
of all pleural attachments helps to isolate the target 
lobe from the rest of the lung. During RUL the minor 
Àssure is frequently incomplete. Partially dividing 
the Àssure with an endoGIA stapler early on can help 
maintain orientation. Use of the 4th arm improves 
exposure and may facilitate moving from one area of 
dissection to another. 
Keywords: Davinci, Robotic, lobectomy
Background: Chest wall resection involves 
resection of the ribs, sternum, costal cartilages and 
the accompanying soft tissues and the reconstruction 
strategy depends on the site and extent of the 
resected chest wall defect . 
Methods: From December 2003, to December 
2008, 18 patients underwent chest wall resection 
and reconstruction with prosthetic material at the 
University Hospital of Lung Disease ,thorax surgery 
division . There were 18 patients (13 male and 5 
female ,rate M/F 13:5). The median age was 53 
years and ranged from 16 to 65 years. The indication 
for resection was primary chest wall and sternal 
malignancy in 10 patients (55.5%) (5 patients 
osteosarcom 3 patients condrosarcom ,2 solitare 
plasmocitoma), recurrent chest wall malignancy in 3 
patient(16.7%), contiguous lung cancer (NSCLC)in 
2 patient (11.1%), breast cancer recidive in 3 patient 
(16.7%).Often both ribs and sternum were included 
in the chest wall resection. The median number 
of ribs resected was 3 (range, 2-8 ribs). A partial 
sternectomy was performed in 12 patients (66.7%), 
and a subtotal sternectomy was performed in 6 
patient (33.3%). Two patients (11.1%) underwent 
pulmonary resection, which included upper 
lobectomy in 1 patient (5.5%), wedge excision in 1 
patient (5.5%),two patients partial pericardectomi.
Results: Skeletal reconstruction was achieved with 
prosthetic material alone in 4 patients (22.2%) 
and with Prosthetic materials covered by Áaps of 
myocutaneous or muscle tissue were used (Prolen 
mesh and methylmethacrylat sandwich plastica)in 
11 patients ( 61.1%), myocutaneous or muscle Áaps 
alone in 2, and other techniques in the remaining 1. 
Soft tissue coverage was achieved with transposed 
muscle in 14 patients, local tissue only in 1 patients. 
Muscles transposed included latissimus dorsi in 2 
patients, pectoralis major in 10 patients, serratus 
anterior in 2 patients. The resection was radical 
in 15 cases and palliative in the other 3 cases . 
No perioperative deaths occurred. After a median 
follow-up of 30 months, the overall 3-year survival 
was 48% and the 5-year survival 36%, with a median 
survival of 40 months. In 10 patients with primary 
tumor the 5-year survival after radical resection 
was 53%, and in 8 patients with secondary invasion 
(direct extension or metastasis) the 5-year survival 
was 28% (median 25 months).
Conclusion: Conclusions: Our experience 
demonstrates that sternal resection is a safe and 
effective treatment, which may improve the patient’s 
quality of life and achieve a long-term survival. 
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Results: For the 27 patients with distant metastasis 
alone, the 2-year progression-free survival rate 
after treatment was 17.7% with an 8 month of 
median progression-free survival time. Of these 
patients, 15 (56%) had oligometastatic disease. 
The oligometastatic sites were the lung in 5 
patients, brain in 3, bone in 3, lung and brain 
in 2, adrenal gland in 1, and soft tissue in 1. 
Thirteen of the 15 patients Àrst received a local 
treatment, including radiotherapy or surgical 
resection. Three patients (lung, adrenal gland, 
soft tissue) received surgical resection, and 10 
other patients received radiotherapy. Two patients 
with pulmonary oligometastases Àrst received a 
systemic chemotherapy. On the other hand, of the 12 
patients with multiple metastases, 10 Àrst received 
systemic chemotherapy (3 platinum-doublets, 4 
geÀtinib, 3 other agents). The remaining two patients 
received best supportive care alone. The median 
progression-free survival time was 15 months in the 
oligometastatic patients who received local treatment 
while it was 4 months in the multiply metastatic 
patients who received systemic chemotherapy 
(p<0.01). 
Conclusion: Local therapy, such as radiotherapy 
and surgery, is therefore suggested to be an effective 
Àrst-line treatment for patients with a postoperative 
oligometastatic recurrence of NSCLC. 
Keywords: Non-small cell lung cancer, 
postoperative recurrence, Oligometastases, local 
therapy
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P1.213 EVALUATION OF 
RESECTABILITY OF LUNG CANCER 
INVADING LEFT MAIN PULMONARY 
ARTERY
Mariko Fukui, Yoshikazu Miyasaka, Kazuya 
Takamochi, Shiaki Oh, Kenji Suzuki 
Division Of Thoracic Surgery, Juntendo University 
School Of Medicine/Japan
Background: Left pnemonectomy is one of the 
most invasive procedures for lung cancer and 
respectability frequently depends on the relationship 
between the left main pulmonary artery and lung 
cancer. The purpose of this retrospective study was 
to evaluate resectability of lung cancer invading left 
pulmonary artery and veins based on the Àndings on 
thoracic computed tomography.
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.212 POSTOPERATIVE 
OLIGOMETASTASES IN PATIENTS 
WITH NON-SMALL CELL LUNG 
CANCER – CLINICAL MANIFESTATIONS 
AND THE PROGNOSIS AFTER LOCAL 
TREATMENT
Tokujiro Yano, Tsukihisa Yoshida, Yosuke 
Morodomi, Kensaku Ito, Akira Haro, Yasunori 
Shikada, Riichiroh Maruyama, Mitsuhiro 
Takenoyama, Yoshihiko Maehara 
Surgery And Science, Kyushu University/Japan
Background: We previously reported a 
retrospective study indicating the prognostic 
impact of local treatment against postoperative 
oligometastases in patients with non-small cell 
lung cancer (NSCLC) (Yano et al. J Surg Oncol 
2010; 102: 852-5). However, the previous study 
was not sufÀcient to determine the therapeutic 
signiÀcance of local treatment against postoperative 
oligometastases since the conclusions were based 
on retrospectively collected data. In the present 
study, we observationally investigated postoperative 
oligometastatic cohorts and clariÀed the effect of 
local treatment on the progression-free survival of 
these patients. 
Methods: At Kyushu University Hospital from 
October 2007 through December 2010, we 
experienced 44 consecutive postoperative recurrent 
patients who had previously undergone complete 
resections for NSCLC, which were performed 
from May 2004 through June 2010. The Àrst 
recurrence site was loco-regional in 15 patients, 
distant in 27 patients, and combined in 2 patients. 
Of the 44 patients with recurrence, we reviewed 
27 patients with distant metastases alone for 
their clinicopathological information, treatment 
modality, and progression-free survival. The 27 
patients with distant metastases alone consisted of 
15 males and 12 females. The histologic types were 
adenocarcinoma in 23, squamous cell carcinoma in 
3 and other in 1. ‘Oligometastases’ was deÀned as 
limited recurrence with the potential to be controlled 
with local treatment. 
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Absence of pulmonary vein Áow indicated tumor 
embolus.
Keywords: resectability, pneumonectomy, left, CT
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P1.214 A RETROSPECTIVE STUDY: 
PROGNOSTIC FACTORS OF STAGE IB 
UPPER LOBE NON-SMALL CELL LUNG 
CANCER
Yang Shentu 
Thoracic Surgery, Shanghai Chest Hospital/China
Background: Even after presumably curative 
resection the 5-year survival rates are only 60–70% 
in stage IB non-small cell lung cancer (NSCLC). 
Existing studies viewed that compared to lower lobe 
or middle lobe lung cancer, upper lobe lung cancer 
was more prone to regional lymph node metastasis. 
The purpose of this study is to explore the factors 
related to the prognosis of stage IB upper lobe 
NSCLC and the best way of lymph node dissection.
Methods: A retrospective study of 147 consecutive 
subjects who had undergone curative resection for 
stage IB upper lobe NSCLC was performed. Patients 
who had received any adjuvant or neo-adjuvant 
chemotherapy were excluded. Survival time curves 
were estimated using the Kaplan–Meier product 
method and statistical differences were assessed 
using the log-rank test. The inÁuence of variables 
on the survival was analyzed by the Cox regression 
model.
Results: 3-year and 5-year overall survival rates 
were 76.2% and 70.7% respectively; for patients 
with lesion in right upper lobe, they were 80.2% 
and 73.5% respectively and for patients with lesion 
in the left upper lobe, they were 71.8% and 67.6% 
respectively. There was no signiÀcant statistical 
difference between the two groups in overall survival 
(P=0.240). Both univariate and multivariate analysis 
showed that age, tumor size and number of removed 
superior mediastinal lymph node stations were the 
important prognostic factors of stage IB upper lobe 
NSCLC.
Conclusion: In surgically treated stage IB upper 
lobe NSCLC patients, age, tumor size and number of 
removed superior mediastinal lymph node stations 
are the important prognostic factors of survival and 
lobe-speciÀc systematic lymph node dissection may 
be a more efÀcient procedure.
Methods: Retrospective study was performed 
on consecutive 11 patients who underwent left 
pneumonectomy for lung cancer at our institute 
between April 2008 and September 2010. The 
radiological Àndings of thoracic computed 
tomography were reviewed and investigated the 
relationship surgical outcome and these factors. The 
distance between the left border of pulmonary artery 
and tumor is reviewed.
Results: 
Left side pneumonectomy was performed on 11 
patients. Ten were men. Five patients required 
combined resection of other organs; left atrium in 
two, carina in one, eshophagus in one, esophagus 
and aorta in one. Among them, eight patients 
underwent complete resection. Bronchial margin 
was microscopically positive for tumor cells in 
two patients, and one patient had residual cancer 
at esophagus. No surgical mortality was observed. 
Postoperative complications occurred in Àve 
patients (45%): atrial Àbrillation in two, leak of 
esophagus in one, thrombocytopenia in one. As to 
pulmonary artery, computed tomography revealed 
tumor invading left main pulmonary artery in three 
cases. The distance between the left border of 
pulmonary artery and tumor (Figure1(d)) ranged 2.6 
to 6.6mm. Among complete resection, 2.6cm is the 
shortest at our institution. As to pulmonary artery, 
CT scan suggested pulmonary invasion. In patients 
with absence of pulmonary vein Áow, 2 cases had 
invasion and 3 cases had tumor embolus. Narrowed 
pulmonary vein was invaded.
Conclusion: Invasion to pulmonary artery and vein 
was predictable by CT Àndings. 2.6cm is limit for 
pneumonectomy without extracorporeal perfusion. 
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SCLC it was signiÀcantly worse – 0% and 18,6% 
respectively. Histological type of pulmonary 
carcinoid was an important prognostic factor. The 
5-year survival of patients with typical carcinoid 
was signiÀcantly better: 100,0% versus 63,8% with 
atypical carcinoid (p<0,05). The type of resection 
did not inÁuence the survival. All patients after 
bronchoscopic resection of typical carcinoid are 
alive without evidence of recurrence from 12 to 
106 months. The prognosis in patients with positive 
lymph nodes (N+) was worth then in patients 
without lymph node metastases: 5-year survival rate 
43,6% and 86,2% respectively. The 5-year survival 
in patients with stage I SCLC was 43,2%, stage II – 
22,0% and stage IIIA – 8,0%.
Conclusion: Neuroendocrine tumors of the lung 
are heterogeneous group of pulmonary neoplasms. 
Surgery with mediastinal lymphadenectomy is the 
treatment of choice for pulmonary carcinoid. The 
most important prognostic factors are histological 
type and lymph node status. LCNLC is a high-
grade neuroendocrine tumor with unfavourable 
outcome. Patients with stage I SCLC could be 
treated in combination of surgery and chemotherapy, 
but its efÀcacy should be analyzed in prospective 
randomized trials. 
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P1.216 RESULTS OF VIDEO-ASSISTED 
THORACOSCOPIC PULMONARY 
METASTASECTOMY
Oleg Pikin, Konstantin Kolbanov, Vladimir Glushko, 
Dmitriy Vursol, Ali Amiraliev, Dmitriy Astakhov 
Thoracic Surgery, P.A.hertsen Moscow Research 
Institute Of Oncology/Russian Federation
Background: Video-assisted thoracic 
metastasectomy is not widely excepted and its 
efÀcacy is controversial in patients with pulmonary 
metastases of different origin. The study was aimed 
to evaluate short and long-term results of video-
assisted pulmonary metastasectomy in comparison 
with standard thoracotomy approach.
Methods: 94 consecutive patients with pulmonary 
metastases operated on in the thoracic surgery 
department of our clinic from 2004 till 2009 
were enrolled in the study. 80 patients undergone 
pulmonary metastasectomy for solitary lesion: video-
assisted lung resection was performed in 42 patients 
(wedge resection – in 37, VATS lobectomy – in 5 
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.215 SURGERY OF NEUROENDOCRINE 
LUNG TUMORS – A SINGLE 
INSTITUTION EXPERIENCE IN 359 
PATIENTS
Oleg Pikin, Alexander Trachtenberg, Georgiy Frank, 
Konstantin Kolbanov, Victor Sokolov, Vladimir 
Glushko, Ali Amiraliev 
Thoracic Surgery, P.A.hertsen Moscow Research 
Institute Of Oncology/Russian Federation
Background: Neuroendocrine neoplasms of the 
lung include pulmonary carcinoids (PC), large-cell 
neuroendocrine (LCNLC) and small-cell lung cancer 
(SCLC). The aim of this retrospecrive study is to 
evaluate how different prognostic factors (histology, 
variant of surgical resection, lymph node status) 
impact on survival.
Methods: 359 patients with pulmonary 
neuroendocrine tumors were operated on in our 
clinic from 1980 till 2009. According to WHO 
criteria (1999), pulmonary carcinoid was diagnosed 
in 235 (64,4%) (typical – in 138, atypical – in 97), 
LCNLC – in 12 (3,3%) and SCLC – in 112 (31,1%) 
patients. Centrally located carcinoid was detected in 
majority of patients – 192 (81,7%). Pneumonectomy 
was performed in 36 (16,1%), lob/bilobectomy in 88 
(37,4%), sleeve lobectomy – in 68 (28,9%), isolated 
sleeve bronchi resection – in 15 (6,4%) and sublobar 
resection in 10 (4,2%) patients with pulmonary 
carcinoid. Bronchoscopic removal of centrally 
located carcinoid was performed in 18 (7,7%) 
patients and was indicated in selective cases of 
typical carcinoid without evidence of peribronchial 
invasion. Mediastinal lymph node dissection was 
routinely performed in all cases. Metastases to the 
regional lymph nodes were diagnosed in 3,0% of 
patients with typical and in 32,9% of cases with 
atypical carcinoid, while in patients with LCNLC 
and SCLC metastases to the regional lymph nodes 
were detected in 66,7% and 61,6% respectively. All 
patients with SCLC received adjuvant chemotherapy. 
Results: Postoperative morbidity was 12,5% with 
mortality rate about 3,1%. The overall 5-year 
survival was 81,0% in patients with pulmonary 
carcinoid, while in patients with LCNLC and 
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Background: The azygos vein lobe is an anatomic 
variant reported in 0.1 to 8% of the population and 
results from an anomalous development of the right 
lung upper lobe. Since the original description of a 
tumor of the azygos vein lobe, in 1969, several cases 
have been reported in the literature. The presence of 
synchronous bilateral lung carcinoma is an other rare 
condition. Optimal treatment of synchronous lung 
carcinomas remains controversial. The authors report 
the Àrst clinical case of a 63 years old smoker man 
after coronary artery bypass surgery, in which a chest 
x-ray revealed a large mass in the left upper lobe and 
small lesion in the azygos vein lobe.
Methods: The Computed Tomography and Positron 
Emission Tomography of the chest revealed a 13mm 
positive speculated nodule in the azygos vein lobe 
and a 60mm solid central mass of left upper lobe, 
without mediastinal lymphadenopathy or distant 
metastasis. Needle Biopsy of the left lung mass 
revealed a squamous cell primary lung carcinoma. 
The patient was planned for video-assisted surgery 
of right lesion to exclude metastatic disease. At 
surgery the mediastinal pleura was open on the 
azygos vein, the azygos lobe was removed beneath 
the vein and resected anatomically. Pathologic 
examination revealed primary lung adenocarcinoma. 
The patient recovered from the Àrst operation and 
left thoracotomy with left upper curative lobectomy 
was done two weeks later.
Results: 
patients), while standard postolateral thoracotomy 
was used in 38 patients (control group). There were 
no any differences in patients age, sex, histology 
of the primary tumor, disease-free interval, type 
of surgery (wedge resection/lobectomy) between 
thoracoscopy and control group. Video-assisted 
pulmonary resections (11 – bilateral, 3 – unilateral) 
using a hand-port for palpation were performed in 14 
patients with multiple lesions.
Results: Morbidity rate was 2,4% in thoracoscopy 
group versus 5,3% in control group (not signiÀcant) 
with no mortality. The mean hospital stay was 5,2 days 
after video-assisted thoracoscopy resection versus 9,6 
days after open procedure. Overall 1, 3 and 5-year 
survival in thoracoscopy group was 87,8%, 54,3%, 
36,8% that was very similar to control group – 82,3%, 
50,8% and 34,2% respectively. There were not any 
statistical differences in overall and disease-free 
survival between two groups (log-rank, 0.078). The 
recurrence in the operated lung was diagnosed in 11,9% 
of patients (local – 4,7%) in the thoracoscopy group and 
in 10,5% of patients (local – 5,2%) in the control group 
(p>0.05). Among 14 patients with multiple metastases 
operated on using a hand-port for palpation 7 additional 
lesions (metastases – 4, benign – 3) were found in 4 
patients. 5-year survival in patients after resection of 
multiple metastases was 21,7%.
Conclusion: Video-assisted thoracoscopy pulmonary 
metastasectomy in patients with solitary subpleural 
lesion is an effective and safe procedure with 
survival very close to the standard thoracotomy 
approach. In patients with multiple metastases 
video-assisted thoracic surgery using a hand-port 
for palpation is minimally-invasive tool that helps to 
Ànd small additional lesions. 
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P1.217 SYNCHRONOUS AZYGOS VEIN 
LOBE ADENOCARCINOMA AND 
LEFT UPPER LOBE SQUAMOUS CELL 
CARCINOMA IN A MAN AFTER OPEN 
HEART SURGERY.
Michael Papiashvilli1, Henri Hayat2, Letizia 
Schreiber3, Lior Sasson1, Israel E. Priel4 
1Cardio-thoracic Surgery Department, Edith Wolfson 
Medical Center/Israel, 2Department Of Oncology, 
Edith Wolfson Medicalcenter/Israel, 3Department 
Of Pathology, Edith Wolfson Medical Center/Israel, 
4Department Of Pulmonary Medicine, Edith Wolfson 
Medical Center/Israel
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200 mL/day and remained serous upon trying fatty 
ice cream. 
Results: Thirty-seven patients (2.3%) had 
postoperative chylothorax develop. There were 33 
men and 4 women with a median age of 69 years 
(range 44 to 84 years). The initial procedures were 
pneumonectomy in 1 patient and lobectomy in 
36 patients. Twenty-three (62%) patients had the 
condition cured with low fat diet only. Ten (27%) 
patients underwent OK-432 pleurodesis, and 8 of 
them were cured with continued low fat diet. These 
31 (84%) conservatively-cured patients resumed 
a normal diet at a median of 10 days after initial 
surgery (range: 5 - 27 days). The remaining 6 (19%) 
patients underwent reoperation and were cured 
and discharged at a median of 18 days after initial 
surgery (range: 14 - 33 days). 
Conclusion: Our management strategy of low fat 
diet and OK-432 pleurodesis cured conservatively 
more than 80% of chylothorax after pulmonary 
resection with systematic mediastinal lymph node 
dissection within 4 weeks after initial surgery. 
Indicating surgical intervention based on chest tube 
drainage of more than 500 mL during the Àrst 24 
hours after low fat diet appeared valid.
Keywords: chylothorax, primary lung cancer, 
surgical resection, management
Our case showed the Àrst report of synchronous 
azygos vein lobe adenocarcinoma (Àg.1) and 
left upper lobe squamous cell carcinoma (Àg.2) 
successfully treated surgically by combined 
thoracoscopic and open approaches.
Conclusion: The selected patients with synchronous 
lung carcinoma may beneÀt from an aggressive 
approach, Àrst distinguishing between contralateral 
metastasis and a second removing bilateral lung 
cancer at early stages, that in our case obtained 
optimal results also by preserving the postoperative 
lung function as much as possible. 
Keyword: Synchronous lung carcinoma, Azygos 
vein lobe carcinoma, Thoracoscopy, Lung Cancer
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P1.218 LOW FAT DIET FOR 
CHYLOTHORAX AFTER PULMONARY 
RESECTION AND LYMPH NODE 
DISSECTION FOR PRIMARY LUNG 
CANCER
Junji Yoshida, Teruhisa Takuwa, Keiju Aokage, 
Tomoyuki Hishida, Mitsuyo Nishimura, Kanji Nagai 
Department Of Thoracic Oncology, National Cancer 
Center Hospital East/Japan
Background: We reviewed our experience with 
iatrogenic chylothorax after pulmonary resection 
for primary lung cancer to evaluate our low fat diet 
management strategy. 
Methods: From October 2003 through March 
2010, a total of 1580 patients underwent lobectomy 
or greater and systematic mediastinal lymph node 
dissection for primary lung cancer at our division. 
Chylothorax was diagnosed on the basis of chylous 
leakage from the chest tube and was conÀrmed 
by an elevated triglyceride level (> 110 mg/dL) in 
the drainage Áuid. We initially treated chylothorax 
patients conservatively with low fat diet (fat intake 
< 10 g/day), prohibiting any other fat-containing 
food or drink. If chest tube drainage was more than 
500 mL during the Àrst 24 hours after low fat diet, 
surgical intervention was indicated. If chest tube 
drainage was more than 300 mL/day after 3 days of 
low fat diet, we performed pleurodesis by injecting a 
preparation of OK-432, penicillin-treated lyophilized 
preparation of a Streptococcus strain, into the 
thoracic cavity through a chest tube. A cure was 
diagnosed when chest tube drainage was less than 
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pulmonary resection for lung cancer, are to make 
operation time shorter and to reduce blood loss. Once 
the ARDS has occurred for the lung cancer resection 
patients, especially for the acute phase cases, the 
immediate use of the high-dose glucocorticoid is 
essential because the outcome of ARDS is very 
lethal. 
Keywords: glucocorticoid therapy, acute respiratory 
distress syndrome
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P1.220 SURGICAL TREATMENT FOR 
OCTOGENARIANS WITH LUNG 
CANCER －RISK ASSESSMENT 
USING “LUNG AGE” AND CHARLSON 
CORMOBIDITY INDEX－
Hiroshige Nakamura, Yuji Taniguchi, Tomohiro 
Haruki, Ken Miwa, Shinji Fujioka, Yuzo Takagi, 
Yohei Yurugi, Yasuaki Kubouchi 
General Thoracic Surgery, Tottori University 
Hospital/Japan
Background: With the increasing life span, elderly 
patients with non-small cell lung cancer (NSCLC) 
are increasing. This retrospective study was designed 
to make a risk assessment of the surgical treatment 
for patients aged 80 years or older using “lung age” 
and Charlson cormobidity index (CCI). 
Methods: Patients aged 80 years or older with 
NSCLC who received surgical treatment in the 
period of January 2000 to May 2010 were reviewed. 
Total number of patients was 68 (gender; 49 men 
and 19 women, mean age; 82.5, range; 80 to 89). 
The surgical procedures comprised 37 lobectomy, 
8 segmentectomy, and 23 wedge resection. “Lung 
age” (the age of the average healthy individual 
who would perform similar to them on spirometry) 
was calculated using the methods advocated by the 
Japanese Respiratory Society. Patients were classiÀed 
in followed three groups by the difference between 
“lung age” and “real age”. There were 14 patients in 
group A (”real age”-“lung age” > 5), 18 patients in 
group B (5>=”real age”-“lung age” > -5), 36 patients 
in group C (”lung age”-“real age” > 5). Patients were 
also divided into two groups by CCI. There were 
52 patients with low CCI (CCI<3) and 16 patients 
with high CCI (CCI>=3). Operative complication 
and overall accumulative survival among groups 
were analyzed and associated factors with operative 
complication were investigated statistically. 
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P1.219 IS HIGH-DOSE 
GLUCOCORTICOID THERAPY 
EFFECTIVE FOR ACUTE RESPIRATORY 
DISTRESS SYNDROME AFTER 
PULMONARY RESECTION FOR LUNG 
CANCER?
Ken Miwa, Yasuaki Kubouchi, Yohei Yurugi, Yuzo 
Takagi, Tomohiro Haruki, Shinji Fujioka, Yuji 
Taniguchi, Hiroshige Nakamura 
General Thoracic Surgery, Tottori University 
Hospital/Japan
Background: Acute respiratory distress syndrome 
(ARDS), a frequent lethal postoperative outcome, 
follows after the pulmonary resection for a lung 
cancer. For patients in the acute phase stage, the 
glucocorticoid infusion has been applied and has 
rescued some cases. The aim is to investigate the risk 
factors of ARDS and analyze the efÀcacy of a high-
dose glucocorticoid therapy in lung cancer patients 
who have received the pulmonary resection.
Methods: Among 526 lung cancer with resection 
cases from January 2005 to December 2010 in 
our institution, 24 cases (4.6%) had preoperative 
interstitial pneumonia, and 8 cases (1.5%) had 
postoperative ARDS.
Results: We analyzed risk factors of ARDS 
(preoperative PaO2, %VC, FEV1.0%, CRP, LDH, 
KL-6, area of interstitial pneumonia, degree of 
emphysema, operative methods, operative time, 
perioperative blood loss, perioperative hypoxemia 
management, histology, histological grade, and 
pathological stage). The operative time and the 
blood loss during the operation were signiÀcant 
risk factors for ARDS. Among the 8 patients who 
had developed ARDS after the cancer resection, 5 
patients had preoperative IP, and 5 cases were in 
acute phase and 3 in delayed phase. The patient 
with the ARDS received preoperative cralisromaisin 
and postoperative syverstat Na respectively for the 
prevention. For acute phase cases, they received 
syverstat Na and glucocorticoid for therapy. The low 
dose of glucocorticoid (the Àrst case 0.5g/day, the 
second case 1g/day for 3 days respectively) could 
not rescue those patients from ARDS, so we applied 
the higher dose of glucocorticoid, 3g/day for 3 days 
which resulted in 2 out of 3 rescued. Delayed phase 
cases received 1g/day for 3 days of glucocorticoi 
which rescued all.
Conclusion: The keys to prevent ARDS after 
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Hystological types were: squamous cell – 10, adeno 
- 4, large cell - 2. At the time of diagnosis all patients 
were considered as unresectable or inoperable, 
reasons were tracheal involvement (7), functional 
intolerance to pneumonectomy (7) and N3 disease 
(2). Preoperative treatment included three cycles 
of chemotherapy and two courses of endobronchial 
PDT. During operation, after lung resection 
(pneumonectomy – 8, carinal pneumonectomy 
– 3, lobectomy - 5) intraoperative PDT of 
resection margins (bronchial and vascular stumps, 
mediastinum) was done. Water-soluble chlorine e6 
complex was used as a photo sensitizer in dose of 
2 mg/kg. The interval between the injection and 
illumination was 2 hours. Red light at 662+1 nm 
wavelength was used to achieve a total illumination 
dose of 250 j/cm2.
Results: After preoperative treatment partial 
response of tumor was achieved in all cases and 
patients underwent surgery with radical intent. 
There was no any post PDT complication. 14 
operations were R0, 2 – R1. No major postoperative 
complications noted except cardiac arrhythmia in 
3 patients (23%). Average period of follow-up was 
16 months (4 to 30 months), all patients are alive 
without any signs of recurrence.
Conclusion: The Àrst experience of the combined 
treatment including intraoperative PDT for 
locally advanced NSCLC has shown safety and 
effectiveness. Additional studies are needed to proof 
the value of intraoperative PDT.
Keywords: Lung cancer, resection margins, 
photodynamic therapy
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P1.222 OUTCOMES OF PATIENTS WITH 
LUNG ADENOCARCINOMA DIAGNOSED 
TO HAVE PLEURAL DISSEMINATION 
DURING SURGERY
Madoka Kimura1, Haruyasu Murakami1, Hiroaki 
Akamatsu1, Akira Ono1, Takehito Shukuya1, 
Hirotsugu Kenmotsu1, Yukiko Nakamura1, Asuka 
Tsuya1, Tateaki Naito1, Toshiaki Takahashi1, 
Masahiro Endo2, Takashi Nakajima3, Haruhiko 
Kondo4, Nobuyuki Yamamoto1 
1Division Of Thoracic Oncology, Shizuoka Cancer 
Center/Japan, 2Diagnostic Radiology, Shizuoka 
Cancer Center/Japan, 3Diagnostic Pathology, 
Shizuoka Cancer Center/Japan, 4Division Of 
Thoracic Surgery, Shizuoka Cancer Center/Japan
Results: “Lung age” showed 69.5 years old in Group 
A, 82.3 in group B and 94.2 in group C. There were 
a lot of men and smokers in group C. The incidence 
rate of respiratory complications and 5-year survival 
rate were 7.1%, 85.1% in group A, 0%, 71.5% in 
group B, 19.4%, 56.5% in group C, respectively. On 
the other hand, regarding CCI, patients with high 
CCI had signiÀcantly higher rate of men, smokers, 
sublobar resection of the surgical procedures. The 
incidence rate of total complications and 5-year 
survival rate were 17.3%, 71.4% in patients with 
low CCI, 50.0%, 53,3% in patients with high CCI. 
Logistic statistical analysis showed that ASA-PS, 
CCI, and “lung age” in respiratory complications 
and only CCI in all complications were signiÀcantly 
associated factors respectively . 
Conclusion: In the risk assessment of the surgical 
treatment for octogenarian patients with lung 
cancer, “lung age” and CCI were very important 
factors and also reÁect prognosis. Especially, for 
patients with higher CCI, even if who underwent 
sublobar resection, having higher incidence rate of 
postoperative complications and poorer prognosis, 
it will be very important to compare the outcome 
with the less invasive treatments like stereotactic 
radiotherapy in the prospective study. 
Keywords: NSCLC, Octogenarian, Surgical 
treatment, Lung age and CCI
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P1.221 INTRAOPERATIVE 
PHOTODYNAMIC THERAPY - NEW 
PROPOSED METHOD OF IMPROVING 
SURGICAL RADICALISM IN STAGE III 
NSCLC
Andrey Akopov, Anatoly Rusanov, Garry Papayan, 
Valentina Molodtcova, Margarita Urtenova, Nikita 
Kazakov, Ivan Chistiakov 
Research Institute Of Pulmonology, Pavlov State 
Medical University/Russian Federation
Background: Incomplete resections for locally 
advanced lung cancer remain an important 
problem that needs to improve surgical techniques 
and options for combine treatment. To increase 
the radicalism we proposed an intraoperative 
photodynamic therapy (PDT) of resection margins. 
Methods: 16 patients with central non small cell 
lung cancer (12 men, 4 women) were prospectively 
included in the study (10 - IIIb, 6 – IIIa). 
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P1.223 BLOOD COAGULATION FACTOR 
XIII IN PULMONARY RESECTION
Koshi Nagano, Notitoshi Nishiyama, Nobuhiro 
Izumi, Takuma Tsukioka, Keiko Tei, Shoji Hanada, 
Hiroaki Komatsu, Hidetoshi Inoue, Shigefumi 
Suehiro 
Thoracic Surgery, Osaka City University/Japan
Background: Alveolar Àstula is a common 
complication after pulmonary resection and its 
management is difÀcult in many cases. Blood 
coagulation factor XIII is known to play a role 
in wound healing. We evaluated the possible 
association of peri-operative changes in blood 
coagulation factor XIII with HbA1c that is a risk 
factor for prolonged alveolar Àstula as well as with 
total protein (TP) and albumin, and the possible 
association of post-operative factor XIII with 
duration of chest tube drainage.
Methods: In 27 patients who underwent pulmonary 
resection at our department and experienced 
air leakage for at least 2 days after-operation. 
Preoperative factor XIII level was compared with 
the value measured at 5 days postoperatively. Pre-
operative HbA1c, TP, and albumin (measured within 
7 days pre-operatively and at 5 days post-operatively) 
were also measured as an indicator of nutritional 
status. We evaluated the relationship between factor 
XIII and HbA1c, between factor XIII and TP, between 
factor XIII and albumin, and between post-operative 
factor XIII and duration of chest tube drainage. For 
statistical analysis, t-test was used.
Results: Six patients experienced a decrease in 
factor XIII to 70% or under normal range that was 
indication for administration of blood coagulation 
factor XIII. Patients were stratiÀed by pre-operative 
HbA1c (within normal vs. higher than normal), 
total protein and albumin measured 5 days post-
operatively (within normal vs. lower than normal) to 
compare pre-operative and post-operative value of 
factor XIII. In this analysis, no signiÀcant difference.
Conclusion: Factor XIII promotes crosslinks of 
Àbrin in the early stages of wound healing. Thus, 
factor XIII is considered to be consumed for lesion 
repair. Patients with diabetes mellitus, who show 
delayed wound healing, were expected to show 
a larger post-operative decrease in factor XIII 
compared to non-diabetic patients. However, no 
signiÀcant difference.
Keywords: Blood coagulation factor XIII, Alveolar Àstula
Background: Pleural dissemination detected 
by computed tomography is considered to be 
unfavorable for patients with lung adenocarcinoma. 
However, the prognosis of patients with lung 
adenocarcinoma diagnosed to have pleural 
dissemination at the time of surgery has not yet been 
fully assessed. 
Methods: To describe the outcomes of platinum-
based chemotherapy in patients with lung 
adenocarcinoma in whom pleural dissemination 
was found at exploratory thoracotomy with or 
without a videoscope, we reviewed the clinical 
records of patients with lung adenocarcinoma who 
were admitted to Shizuoka Cancer Center between 
September 2002 and April 2009. 
Results: A total of 19 patients were included in this 
study. The median age was 65 years (range, 48-80 
years). Seven patients (37%) were females, and 8 
patients (42%) were never-smokers. The EGFR 
mutation data for 10 patients (53%) was available. Of 
the 10 patients, 6 patients (60%) were positive for a 
mutation; 5 had exon 19 deletions and 1 had an exon 
21 point mutation (L858R). The PS, clinical TNM 
stage and platinum-based chemotherapy regimens 
were as follows: 17 patients with PS 0, 2 patients with 
PS 1; 7 patients with stage IA, 8 patients with stage 
IB, 1 patient with stage IIA, 3 patients with stage 
IIB; 13 patients received carboplatin and paclitaxel, 
2 patients received carboplatin and nab-paclitaxel, 1 
patient received carboplatin and gemcitabine, 1 patient 
received carboplatin and paclitaxel plus bevacizumab, 
1 patient received cisplatin and pemetrexed plus 
VEGFR-TKI, 1 patient received cisplatin and 
gemcitabine. Of the 19 patients, 7 patients (37%) 
received additional EGFR-targeted therapy (geÀtinib 
or erlotinib). The median follow-up time was 30.7 
months (range 20.6-54.1 months). The median 
number of treatment cycles of Àrst-line platinum-
based chemotherapy was 4 (range, 1 to 6 cycles), and 
the overall response rate was 21.1% [95% conÀdence 
interval (95% CI), 8.5-43.3]. The median progression-
free survival and overall survival were 10.4 months 
(95% CI, 6.3-18.4) and 50.6 months (95% CI, 27.8-
not reached), respectively. Among the 17 patients who 
had reported sites of Àrst failure, 9 patients (53%) 
developed locoregional tumor progression. 
Conclusion: Patients with lung adenocarcinoma in 
whom pleural dissemination is found at surgery tend 
to have a favorable prognosis for survival. Additional 
local treatment may therefore improve their clinical 
outcomes. 
Keywords: Pleural dissemination, Chemotherapy
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offer favorable postoperative outcomes as well as 
saving pulmonary reserve and morbidities from 
pneumonectomy. It must be considered preferentially 
over sleeve pneumonectomy for tumors invading 
carina.
Keywords: Carina reconstruction, Thoracic 
malignancy
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P1.225 PLACE OF COMBINED LUNG 
RESECTION IN THE COMBINED 
TREATMENT OF RESECTABLE STAGE 
II B AND III NON–SMALL-CELL LUNG 
CANCER
Andrey V. Vazhenin, Marina N. Mironchenco, 
Andrey A. Lukin, Elena U. Lukina, Evgeniy O. 
Manzhirev, Iakov A. Gnatuk 
Thorax Surgery, Chelabinsk Regional Oncology 
Clinic/Russian Federation
Background: To evaluate whether combined lung 
resection and adjuvant radiotherapy could improve 
survival in respectable stage IIb, and III non–small-
cell lung cancer (NSCLC). 
Methods: Retrospective comparison of parallel 
groups is lead. It is included 135 pations with IIb, 
III stage NSCLC. The combined lung resection or 
pneumonectomy was executed to each patient. All 
patients were divided into 4 groups. Group A consist 
of the patients with were made only pneumonectomy 
(n=60), group B consist of the patients, were undergo 
pneumonectomy and adjuvant radiotherapy (n=32). 
The group C included the patients with were made 
only combined lobectomy or combined bilobectomy 
(n=24), and group D included the patients with 
were made combined lobectomy or combined 
bilobectomy and adjuvant radiotherapy (n=19). It 
has been executed 92 pneumonectomy (68,1 %), 
39 combined lobectomy (28,9 %) and 4 combined 
bilobectomy (3 %). Among them was 25,2 % of the 
expanded operations, 34,1% expanded and combined 
operations, 28,1 % - combined resections and 
12,6 % - typical pneumonectomy. The most often 
type of the combined operations was vasculoatrial 
- 51 % (53 resections). The less often type was 
parietalodiaphragm resections - 13 % (13 resections). 
There was executed 36 % of tracheobronhoplastycal 
resections. In total 103 resections of thorax organ 
have been executed. 
Results: Postoperative Morbidity was 4,4 % 
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P1.224 LONG-TERM RESULT OF 
PARENCHYMA-SAVING CARINA 
RECONSTRUCTION IN THORACIC 
MALIGNANCY
Joon Suk Park1, Young Mog Shim1, Jhingook Kim1, 
Hong Kwan Kim1, Sumin Shin2 
1Department Of Thoracic And Cardiovascular 
Surgery, Samsung Medical Center/Korea, 
2Department Of Thoracic And Cardiovascular 
Surgery, Samsung Medical Center/Korea
Background: In selected patients with 
tracheobronchial malignant tumors involving carina, 
surgery can offer a chance of cure. However, due 
to technical and oncological issues, most of carina 
reconstruction has been sleeve pneumonectomy, 
which is still associated with high early and late 
morbidity. Based on our experience, we explored 
the feasibility of parenchyma-saving carina 
reconstruction. 
Methods: Between July 1996 and December 2010, 
24 patients underwent surgery for malignant tumors 
involving carina, and their medical records and 
follow-up data were retrospectively analyzed.
Results: Among the 24 patients, 18 had squamous 
cell carcinoma, 5 had adenoid cystic carcinoma, 
and 1 had mucoepidermoid carcinoma. All patients 
had T3 or T4 tumors. Six parenchyma-saving 
carina reconstructions with (n=5) or without (n=1) 
right upper lobectomy were performed via right 
thoracotomy. The other 18 patients received sleeve 
right pneumonectomy via right thoracotomy (n=16) 
or sleeve left pneumonectomies via sternotomy (n=1) 
and bilateral thoracotomy (n=1). All the anastomoses 
were intact on follow-up bronchoscopic examination. 
No operative mortality occurred. Of patients with 18 
sleeve pneumonectomy, 2 experienced postoperative 
acute respiratory failure, and another 2 had delayed 
postpneumonectomy empyema. One patient with 
carina reconstruction with RULobectomy underwent 
esophagocologastrostomy 8 years later due to 
delayed bronchoesophageal Àstula. During the 
median follow up of 30.0 months, 4 loco-regional 
recurrence and 4 distant metastases were observed 
(7 after sleeve pneumonectomy and 1 after carina 
reconstruction with RULobectomy). Ten late 
deaths occurred and 5-year overall and disease-free 
survivals were 54.3% and 59.9%, respectively.
Conclusion: Parenchyma-saving carina 
reconstruction for thoracic malignancy could 
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recurrent lung carcinoma involving the hilum and 
mediastinum. 
Methods: This study is a retrospective review 
of 70 patients undergoing EBUS-TNBA for 
mediastinal lymphadenopathy from March 2009 - 
December 2010. A total of 30 lymph node stations 
were biopsied in 27 patients who were diagnosed 
with lung carcinoma or suspected of having lung 
carcinoma. The EBUS bronchoscope contains a 
curvilinear ultrasound probe at the distal end of the 
bronchoscope, which provides a linear continuous 
B-mode ultrasound image and color Doppler 
capability to allow identiÀcation of vascular 
structures. EBUS-TBNA was performed under 
general anesthesia. A 21-gauge biopsy needle was 
placed into the lymph node under direct ultrasound 
guidance. Rapid onsite cytology was utilized in the 
operating room to conÀrm adequacy of diagnostic 
material and for preliminary diagnoses. The 
observation of moderate to abundant numbers of 
lymphocytes or pigmented histiocytes served as an 
indicator of adequate sampling of lymph nodes that 
are free of metastatic carcinoma. The prevalence, 
sensitivity, speciÀcity, positive predictive value, and 
negative predictive value were calculated. Procedure 
related complications were also recorded. 
Results: A total of 30 lymph node stations 
were sampled in 24 patients with a diagnosis of 
lung carcinoma and 3 patients with suspicious 
lymphadenopathy that was concerning for lung 
carcinoma. Twelve of the lymph node biopsies 
were to evaluate recurrent lung carcinoma. Seven 
hilar lymph nodes [6 right and 1 left] were biopsied 
with EBUS-TBNA. Nine paratracheal lymph 
node stations [8 right and 1 left] were biopsied. 
A total of 14 subcarinal lymph node stations were 
sampled. Nineteen of the biopsies demonstrated 
Non-small cell lung carcinoma and two cases 
involved small cell carcinoma. There was one 
case involving mesothelioma. Three of the cases 
were non-diagnostic. Five of the biopsies yielded 
moderate lymphocytes with no evidence of lung 
carcinoma. The prevalence, sensitivity, speciÀcity 
were 76.6%, 87%, and 100 % respectively. There 
were no complications or operative mortalities. The 
hemorrhage rate was 0%. All the patients underwent 
Positron Tomography scanning (PET). The mean and 
median SUV max values of the lymph node stations 
were 7.1 + 5.7 and 5.4 respectively. The mean and 
medium size of the lymph node stations was 15.4 
mm + 8.6 mm and 12.5 mm respectively. A total of 
eight of the lymph node station biopsies were tested 
(p <0,05). It has met only in group A, surgical 
treatment, included pneumonectomy. Postoperative 
complications was 18,5 %. There was 14,8 %, after 
the pneumonectomy executing, and 3,7 % after the 
combined lobectomy executing (p <0,05). Survival 
rate in group A: at 1year: 57,2 %, at 3 years - 24 
%, at 5 years - 21,2 %. In group B 1, 3 and 5-years 
survival was 62,5 %, 34,4 % and 25 % accordingly. 
In group C, at 1 year survival was 69,7 %, at 3 
years - 39,2 %, and at 5 years - 26,1 %. Results 
of treatment of patients of group D it is a little bit 
better, than in the previous groups. At 1 year survival 
was 76 %, at 3 year - 40 %, and at 5 years - 26,3 % 
(p> 0,05). 
Conclusion: 1. There were not statistically 
signiÀcant of survival between Methods of the 
local control of lung cancer, such as surgical 
and radiotherapy. 2. The Àrst choice for surgical 
treatment of patients with Resectable Stage II b 
and III Non-Small-Cell Lung Cancer is Combined 
lobectomy. There is statistically signiÀcant the 
decrease Postoperative Morbidity and Postoperative 
complications. 
Keywords: combined treatment, combined lung 
resection, resectable Non–Small-Cell lung cancer
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.226 ENDOBRONCHIAL ULTRASOUND 
IS HIGHLY EFFECTIVE FOR THE 
DIAGNOSIS OF LUNG CARCINOMA AND 
ENABLES EGFR MUTATION ANALYSIS
Robert E. Merritt, Chuong D. Hoang, Richard I. 
Whyte, Joseph B. Shrager 
Cardiothoracic Surgery, Stanford University/United 
States Of America
Background: Mediastinoscopy has been the gold 
standard for biopsying mediastinal lymph nodes 
for staging and diagnosis of lung carcinoma. 
Endobronchial ultrasound with transbronchial 
needle aspiration (EBUS-TBNA) has become a less 
invasive alternative to mediastinoscopy. The role 
of EBUS-TBNA in lung cancer staging remains 
unclear; however, this technique may provide a 
safe and effective mechanism for the diagnosis 
of new cases of lung cancer as well as cases of 
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lung Àeld on CT and candidate for the intentional 
segmentectomy were enrolled in this study. 
Preoperative tumor size and tumor disappearance 
rate (TDR) were measured by high-resolution CT 
(HRCT). We analyzed their lymph node metastatic 
patterns, and identiÀed clinical and radiological 
factors to predict nodal metastases. 
Results: Of all patients, 34 patients (11%) had 
lymph node metastases (pN1: 10, pN2: 24). 
Compared with the pN0 patients (n = 273), mean 
tumor size and TDR on preoperative HRCT of node 
positive patients were signiÀcantly larger and lower, 
respectively. All 34 node positive patients revealed 
TDR less than 0.25. Metastasis to lsNs (#11, 12, 13) 
was observed in 22 patients (7% of all patients, 11% 
of TDR<0.25 patients, pN1: 9, pN2: 13). Among 
them, 4 patients (18%) had metastases in the #13 
station which belonged to the different segmental 
bronchus (ds13) from the primary tumor. Although 
it is technically demanding to dissect ds13 during 
segmentectomy, all 4 patients had other metastases 
in #12 or mediastinal station. No patients had sole 
metastasis in ds13 station. 
Conclusion: Advisable extent of dissection for 
an intentional segmentectomy for small (2cm) 
peripheral NSCLC includes lobar-segmental nodes 
belonging to tumor-located segment as well as hilar 
and mediastinal nodes. Nodes along the adjacent 
segmental bronchi are not required to be inspected. 
On the other hand, systematic lymph node dissection 
might not be necessary for tumors with TDR0.25 
on preoperative HRCT. 
Keywords: segmentectomy, lymph node dissection
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.228 PROSPECTIVE STUDY OF RADIO-
FREQUENCY ABLATION THERAPY 
FOR THORACIC MALIGNANCIES 
EVALUATING BY FDG-PET
Hiroyuki Suzuki1, Yuzuru Watanabe1, Takumi 
Yamaura1, Satoshi Mutoh1, Naoyuki Okabe1, Hiroshi 
Yaginuma1, Takeo Hasegawa1, Yoko Odashima1, 
Atsushi Yonechi1, Jun Ohsugi1, Mika Hoshino1, 
Mitsunori Higuchi1, Yutaka Shio1, Akio Ohishi2, 
Hiroshi Honjo3, Mitsukazu Gotoh4 
1Thoracic Surgery, Fukushima Medical University/
for EGFR mutations and all were successful. 
Conclusion: EBUS-TNBA provides a safe and 
effective alternative to mediastinoscopy for the 
diagnosis of lung carcinoma in patients with PET 
positive lymphadenopathy. Recurrent lung cancer 
involving the mediastinum or hilum can be accessed 
with EBUS-TBNA for diagnosis. EGFR mutation 
analysis can be successfully performed on the cell 
blocks prepared from the aspirates. 
Keyword: lung cancer diagnosis
Poster Session 1 – Surgery Monday, 4 July 2011 12:15-14:15
P1.227 REASONABLE EXTENT OF 
LYMPH NODE DISSECTION AT 
INTENTIONAL SEGMENTECTOMY 
FOR SMALL-SIZED PERIPHERAL 
NON-SMALL CELL LUNG CANCER - 
FROM THE CLINICOPATHOLOGICAL 
RESULTS OF THE CASES WHO 
UNDERTOOK LOBECTOMIES 
WITH SYSTEMATIC LYMPH NODE 
DISSECTIONS -
Yuki Matsumura1, Tomoyuki Hishida1, Junji 
Yoshida1, Mitsuyo Nishimura1, Genichiro Ishii2, 
Keiju Aokage1, Masayuki Nakao3, Akikazu Kawase1, 
Kanji Nagai1 
1Department Of Thoracic Oncology, National 
Cancer Center Hospital East/Japan, 2Pathology 
Division, Research Center For Innovative Oncology, 
National Cancer Center Hospital East/Japan, 
3Division Of Thoracic Surgery, National Cancer 
Center Hospital East/Japan
Background: Currently randomized clinical trials 
are ongoing to evaluate segmentectomy compared 
with lobectomy for peripheral cT1aN0M0 non-
small cell lung cancer (NSCLC). When the 
surgeon encounters a positive lymph node during 
segmentectomy, the operation should be converted 
to a lobectomy. However, the proper extent of 
dissection, in particular, extent of lobar-segmental 
node (lsN) dissection, is unclear. The purpose of this 
study is to clarify the reasonable extent of dissection 
during an intentional segmentectomy for small 
peripheral NSCLC. 
Methods: We reviewed the records of the patients 
who underwent lobectomies and systematic lymph 
node dissections for cT1aN0M0 NSCLC from 1992 
to 2009. Among them, a total of 307 patients whose 
nodule was located in the outer third peripheral 
S854 Copyright © 2011 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
Poster Session 1 – Surgery Monday, 4 July 2011 12:15-14:15
P1.229 SURGICAL RESECTION OF 
CLINICAL T4 NON-SMALL CELL LUNG 
CANCER INVADING GREAT VESSELS 
AND LEFT ATRIUM.
Toru Bando1, Toshi Menjyu1, Toshihiko Sato1, 
Fengshi Chen1, Tsuyoshi Shoji1, Takuji Fujinaga1, 
Makoto Sonobe1, Hiroaki Sakai1, Ryo Miyahara1, 
Cheng-Long Huang1, Kenichi Okubo2, Hiroshi Date1 
1Thoracic Surgery, Kyoto University Hospital/Japan, 
2Tokyo Medical And Dental University/Japan
Background: We retrospectively analyzed the 
results of surgical resection in patients with non-
small cell lung cancer invading the great vessels 
and left atrium in order to determine the appropriate 
treatment of the locally-advanced disease.
Methods: Between January 2001 and December 
2010, 1357 patients underwent surgical resections 
for primary lung cancer at our hospital. Among them, 
we reviewed the records of 27 patients (2.0%) with 
clinical T4 non-small cell lung cancer invading great 
vessels (aorta, superior vena cava, intrapericardial 
pulmonary artery, and bracheocephalic and 
subclavian vessels) and left atrium. Of the 27 
patients, 22 were male and 5 were female. Their 
ages ranged from 44 to 76 years with the average 
of 62.3 years. The histologic type was squamous 
cell carcinoma in 17 patients, adenocarcinoma in 6, 
pleomorphic carcinoma in 2, adenosquamous cell 
carcinoma in 1, and large cell carcinoma in 1.
Results: The overall 5-year survival rate and 
disease-free 5-year survival rate for the 27 patients 
were 35.7%, and 27.8%, respectively. The operative 
mortality was 0%, and hospital mortality was 
3.7% (n = 1). Mean follow up time of 37.1 months 
revealed 11 locoregional recurrences and 8 distant 
recurrences. Eleven patients died of lung cancer, 
and 3 died of other diseases, the remaining 13 are 
alive 10 to 118 months postoperatively. Twenty 
patients received preoperative treatments, chemo-
radiotherapy in 10 patients, and chemotherapy 
in 10. Out of the 20 patients after preoperative 
treatments, postoperative pathological examination 
revealed no invasion of great vessels or left atrium 
in 13 patients. Among the 13 patients, 3 survived 
longer than 5 years, and the other 3 survived longer 
than 3 years. Pneumonectomy was performed in 
9 patients, bilobectomy in 2, and lobectomy in 
12. The left atrium was resected in 6 patients, the 
adventitia of the aorta in 4, the pulmonary artery in 
Japan, 2Thoracic Surgery, Fukushima Red Cross 
Hospital/Japan, 3Radiology, Shirakawa Kosei 
General Hospital/Japan, 4Regenerative Surgery, 
Fukushima Medical University/Japan
Background: Computed tomography (CT)-
guided radio-frequency ablation therapy (RFA) 
is minimally invasive treatment modality for 
patients with several types of solid cancer. It has 
also been applying for the treatment of thoracic 
malignancies as a local treatment. RFA technique 
is thought to be safe and effective for patients 
with thoracic malignancy. However, assessment of 
therapeutic efÀcacy following RFA procedure is not 
well established. Lately, several studies showing 
the beneÀt of 18-Fluoro-deoxyglucose positron 
emission tomography (FDG-PET) in RFA for 
thoracic malignancies have been reported. However, 
optimal follow-up schedule using FDG-PET are 
still controversial. In this report, we are showing the 
long term results on patients treated with RFA and 
efÀcacy of FDG-PET as an evaluation tool for early 
detection of local recurrence.
Methods: Twenty patients have enrolled in this 
study and 24 ablations have been performed. They 
were 15 males and 5 female with a mean age of 72 
years (range of 34-85 years old). Seven lesions were 
primary lung cancer, 17 lesions were metastatic 
or recurrent tumor. Tumor size was 0.4-3.3cm in 
diameters (mean: 1.5cm). CT and FDG-PET analyses 
were scheduled to perform pre and post (7-14days 
after RFA and 3-6 months after RFA) treatment.
Results: No mortality was noted. Seventeen adverse 
events out of 24 ablations (58.3%) including 13 
pneumothorax, 2 pains and 2 fevers were observed. 
With a median follow-up of 40 months (range 1-62 
months), overall 5years-survival rate were 75.8%, 
local recurrences were observed in 4 lesions (2-years 
local control rate were 86.1%) and distant metastases 
followed by RFA were observed in 9 patients. 
Positive FDG-PET results 7-14days after RFA was 
not correlated with recurrence, whereas 3-6 months 
after RFA weakly correlated with local recurrence 
(p=0.07)
Conclusion: RFA for thoracic malignancy has 
conÀrmed to be a safe and feasible technique. FDG-
PET analysis 3-6 months after ablation could be a 
useful evaluation tool for local control.
Keywords: Thoracic malignancy, radiofrequency 
ablation, FDG-PET
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(LWLS), and tumor diameter of 5 mm or less in 
the mediastinal window level setting (MWLS). 
After obtaining informed consent from patients, we 
performed limited lung resection under these criteria 
and conÀrmed the absence of cancer cells on the 
surgical margin in frozen sections.
Results: Between November 2004 and December 
2010, we performed limited lung resection for 52 
lung cancer patients under the aforementioned 
criteria. In all, 8 segmentectomies and 44 wedge 
resections were performed. Tumor sizes ranged from 
5 mm to 26 mm (average, 13.2 mm) in the LWLS 
and from 0 mm to 5 mm (average, 0.6 mm) in the 
MWLS. Histopathological type of all the patients 
was adenocarcinoma; 48 patients had AIS or MIA, 
and another 4 patients invasive adenocarcinoma but 
showed no vascular invasion and refused to undergo 
further treatment. Median follow-up period was 
25 months. None of the cases showed recurrence; 
however, 1 patient died.
Conclusion: It was difÀcult to make a deÀnite 
diagnosis of AIS and MIA on the basis of 
preoperative HRCT Àndings. Although the 
observation period was short, there was no case of 
recurrence. The indication for limited lung resection 
based on HRCT Àndings might be a suitable option.
Keywords: Limited Resection, Lung cancer, 
Ground-glass Appearance
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P1.231 BILATERAL SPONTANEOUS 
PNEUMOTHORAX AS A COMPLICATION 
OF METASTATIC THIN WALLED 
CAVITARY PULMONARY 
ANGIOSARCOMA
Gustavo A. Lyons1, Silvia Quadrelli2, Lorena 
Maldonado2, Carlos Silva3, Domingo J. 
Chimondeguy1, Cesar Delgado2, Felipe Chertcoff2, 
Juan C. Spina4 
1Thoracic Surgery, Buenos Aires British Hospital/
Argentina, 2Respiratory Medicine, Buenos Aires 
British Hospital/Argentina, 3Oncology, Buenos Aires 
British Hospital/Argentina, 4Radiology, Buenos Aires 
British Hospital/Argentina
Background: Angiosarcomas are rare malignant 
tumors of vascular origin, accounting for 2 to 3% of 
all sarcoma, and regardless of their sites of origin, 
are particularly likely to metastasize to the lung.
Methods: We report an unusual case of simultaneous 
4, bracheocephalic or subclavian vessels in 2, and 
the superior vena cava in 1. A total of 20 patients 
underwent complete resection. Postoperative 
surgical site infection (empyema, mediastinitis, 
chest wall abscess, etc.) developed in 5 patients, 
and reoperation for the infection was necessary in 
3. Although the completeness of resection did not 
signiÀcantly inÁuence survival, operative procedure 
of pneumonectomy, and resection of the adventitia of 
the aorta were signiÀcant risk factors for survival.
Conclusion: Surgical resection of the locally-
advanced disease can be an adequate therapeutic 
option for selected patients. Induction chemo-
radiotherapy may improve the outcome of the 
locally-advanced NSCLC. Minimally invasive 
approaches, such as transmanubrial approach, and 
less invasive resection, would be preferable for these 
patients.
Keyword: cT4 NSCLC invading GV and LA
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P1.230 LIMITED RESECTION FOR 
LUNG CANCER THAT SHOWED 
GROUND-GLASS APPEARANCE ON 
PREOPERATIVE HIGH-RESOLUTION 
COMPUTED TOMOGRAPHY
Yuji Asato1, Moriyuki Kiyoshima1, Motohiro Sato2, 
Tatsuo Iijima3, Ryuta Amemiya1 
1Respiratory Surgery, Ibaraki Prefectural Central 
Hospital & Cancer Center/Japan, 2Radiology, 
Ibaraki Prefectural Central Hospital & Cancer 
Center/Japan, 3Pathology, Ibaraki Prefectural 
Central Hospital & Cancer Center/Japan
Background: Lung adenocarcinoma in situ (AIS) 
and minimally invasive adenocarcinoma (MIA) are 
not associated with vascular invasion or lymph node 
metastasis. Hence, limited resection for these tumors 
would be a good therapeutic option. These tumors 
show ground-glass opacity (GGO) on high-resolution 
computed tomography (HRCT). Since November 
2004, we have been deÀning AIS and MIA on the 
basis of the Àndings of preoperative HRCT and have 
been performing limited resection for these lesions. 
We reviewed the appropriateness of our eligibility 
criteria.
Methods: The following were the indications for 
limited resection based on HRCT Àndings: tumor 
diameter of 3 cm or less, appearance is pure or 
mainly GGO in the lung window level setting 
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metastatic squamous cell carcinoma. However, a 
thin-walled cavitary lesion is usually not considered 
to be a malignancy. Although prognosis of 
angiosarcoma is poor, in the presence of persistent 
air leak, videothoracoscopy allows wedge resection 
of the tumor and mechanical pleurodesis to be 
performed safely and it is an option that should be 
considered.
Keywords: Angiosarcoma, Pneumothorax, Cavitary 
pulmonary, Metastatic pulmonary
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P1.232 CLINICAL PREDICTORS 
OF MEDIASTINAL METASTASIS 
IN PATIENTS WITH SURGICALLY 
RESECTABLE NON-SMALL CELL LUNG 
CANCER.
Gustavo A. Lyons1, Silvia Quadrelli2, Carlos Silva3, 
Domingo J. Chimondeguy1, Matías Lescano1 
1Thoracic Surgery, Buenos Aires British Hospital/
Argentina, 2Respiratory Medicine, Buenos Aires 
British Hospital/Argentina, 3Oncology, Buenos Aires 
British Hospital/Argentina
Background: Accurate preoperative staging is 
essential for patients with lung cancer in order to 
identify mediastinal lymph node metastasis. In this 
retrospective study we identiÀed potential clinical 
predictors of N2 metastasis in order to deÀne 
a subset of patients that should receive a more 
extensive evaluation of the mediastinum before 
deÀning surgical treatment.
Methods: Patients with NSCLC were included if 
they underwent pulmonary resection with curative 
intent. Cases were excluded if they had small cell 
lung cancer or if they had received neoadjuvant 
chemotherapy. Clinical and pathology records of 
each patient were analyzed in order to identify 
potential predictive factors for N2 metastases. The 
analyzed variables were size of the tumor, age, 
gender, symptoms, side, location, histology and chest 
CT Àndings. During surgery, bronchopulmonary, 
hilar and mediastinal lymph nodes were 
systematically sampled. Unpaired t tests were used 
to compare differences in continuous variables, and 
chi-square test statistic or Fisher´s exact test for 
categorical variables. Univariate and multivariate 
logistic regression models were used to ascertain 
the association between individual factors and the 
presence of mediastinal metastasis.
bilateral spontaneous pneumothorax, secondary to 
metastases from angiosarcoma of the scalp.
Results: In August 2008, a 65 year old man 
was detected a lesion on his scalp. Histologic 
examination disclosed it to be an angiosarcoma. The 
patient received chemotherapy and radiotherapy 
with adequate local control. Two years later, he 
was noted to have a right lower lobe and left lower 
lobe cystic lesions on a chest CT scan without any 
distinct pulmonary solid nodules or masses. A new 
CT revealed signiÀcant bilateral pneumothoraces. A 
closed thoracostomy was performed with complete 
reexpansion. Fifteen-days later he was admitted 
to our hospital because of severe dyspnea. A CT 
showed large bilateral pneumothoraces (Figure). 
Bilateral closed-tube thoracostomies were put in 
place. Both lungs were only partially expanded. 
As moderate air leak persisted bilaterally, video-
assisted thoracoscopic evaluation of his right 
hemithorax was performed Àrst disclosing two 
ruptured cystic lesions. A wedge resection of these 
lesions was performed followed by talc pleurodesis. 
His postoperative course was uneventful and seven 
days later the procedure was performed on the left 
hemithorax with similar Àndings and results. The 
biopsy specimen of the lung showed metastatic 
angiosarcoma. 
Conclusion: Metastatic pulmonary angiosarcoma 
exhibits in chest radiography bilateral peripheral 
solid nodules that are often accompanied by 
inÀltrates. CT Àndings of metastatic angiosarcoma 
have been described only in case reports or small 
series. In a Japanese series of 24 patients (Tateishi, U 
et al. AJR 2003), the commonest CT manifestations 
were multiple solid nodular lesions and multiple 
thin-walled cysts, often mixed with hemorrhagic 
changes. The most common presenting symptom 
of pulmonary metastasis in angiosarcoma was 
haemoptysis, and only a few cases presented with 
spontaneous pneumothorax, pneumomediastinum 
or pulmonary haemorrhage. Cavitary pulmonary 
metastases are an infrequent but well-known 
phenomenon, most commonly associated with 
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Background: Czech pioneering of pulmonary 
segmentectomy for cancer. 
Methods: Pulmonary opacity suspect of lung 
cancer without enlargement of lymphnodes on CT 
imaging was detected in twenty persons from high 
risk group (n=305) by follow up through 5127 
examinations during the period of 1999-2008 yrs. 
Proven non small cell lung cancer and tumours 
of uncertain histopathology with diameter up to 
20mm were indicated to segmentectomy (Figure 
1) . Borderline diameter for segmentectomy of a 
metastatis was 30 mm. They were implemented 
21 Overholts procedures. The histopathology was 
stated under hematoxylin-and-eosin staining and 
immunohistochemistry examination. Figure 1. 
Scheme of the Surgical Lung Segment 
© Marek Malik Legend to Figure 1 1 – 
intersegmental pulmonary vein 2 – intrasegmental 
pulmonary vein 3 – subpleural pulmonary vein 4 
– pulmonary artery segmental branch 5 – segmental 
lymphnodes 6 – subsegmental lymphatics 7 – 
segmental bronchus 8 – intersegmental space 9 – 
visceral pleura
Results: Nine non - small cell lung cancers, six 
metastases, and six benign lesions were found 
histopathologically. No local recurrence and no 
involvement of regional lymphnodes were recorded 
postoperatively in both cancer series with median 
age of 63 yrs (range 45-79) and median duration 
of follow up 35 months. No perioperative 30-days 
mortality was registered. Six distant recurrences 
appeared, 3 in NSCLC and 3 in extrapulmonary 
cancer patients. Five cancer-patients died, three of 
them through the general progression of the disease, 
two deaths were non-cancer related. Patients with 
Results: Four hundred and fourteen patients were 
included (males, 74.3%, mean age 61.2 ±9.8 years). 
Patients with positive pathological N2 (n=89) nodes 
were no different from node negative patients with 
regard to age and sex distribution. Patients with 
positive N2 disease had statistically signiÀcant larger 
mean tumor size (5.1 ± 1.86 versus 3.9 ± 1.14 cm 
, p < 0.001) but were not different in histological 
distribution. Preoperative CT scan was more likely 
to demonstrate suspected N2 metastasis in the node-
positive patient group (38.2% vs 2.4%, p= <0.0001). 
Univariate analysis identiÀed two signiÀcant 
predictors of N2 disease: a tumor larger than 3 cm 
on CT scan and a clinical suspicion of mediastinal 
metastases (cN2). Using multivariate analyses, both 
of these remained signiÀcant predictors of pN2 
disease. Comparation between patients with positive 
and negative N2 nodes 
Variable pN2 (N=89) Node negative (N=325) p 
Age (mean ± SD) 59,5 ± 9,1 61,6 ± 8,7 0.065 
Gender (Male %) 71,9 75,3 0.590 
Symptoms from primary tumor (%) 51.7 40.0 0.063 
Tumor > 3 m in CT (%) 79.8 60.9 0.000 
Solitary pulmonary nodule (%) 21.3 33.2 0.042 
Right side (%) 59.5 58.4 0.949 
Upper lobes (%) 34.8 38.4 0.615 
Central location (%) 32.6 25.2 0.210 
Squamous (%) 20.2 25.2 0.668 
Adenocarcinoma (%) 64.0 63.1 0.965 
Mediastinal metastasis suspected on 
CT (%) 38.2 2.4 0.000 
Conclusion: Our Àndings suggest the predictive 
value of tumor size, and CT-related suspicions for 
N2 disease, especially for those patients with Stage 
I disease. These results can help to determine which 
patients should undergo invasive mediastinal staging. 
The routine use of mediastinoscopy in cN0 patients 
with tumors smaller than 3 cm (T1) does not appear 
to be justiÀed in view of the low incidence of occult 
N2 disease.
Keywords: Mediastinal staging, Tumor size, Lung 
cancer, Lymph nodes metastasis
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P1.233 PULMONARY SEGMENTECTOMY 
FOR TUMOUR. A MIDDLE EUROPEAN 
VIEW
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Vomela1 
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metastases, including surgical procedures and 
pathologic results, were registered. Univariate and 
multivariate analysis were carried out to identify 
signiÀcant prognostic factors related to overall 
survival.
Results: There were 398 cases included in Ànal 
analysis. Median follow up was 24.4 months. 
Median age was 35 years. Preferred surgical 
approach was posterolateral thoracotomy in 309 
cases (77.6%) Metastases were resected with a 
wedge resection in 297 cases (74.6%), with an 
anatomic segmentectomy in 63 patients (15.8%), 
while lobectomy and pneumonectomy were 
performed in 42 (10.6%) and 10 cases (2.5%) 
respectively. Complete resection was achieved in 
351 patients (88.2%). Median overall survival for 
all patients was 81.9 months. The overall 10-year 
survival was 64.3% for germ-cell tumors, 57.8% 
for cervical cancer, 46% for osteosarcoma, 28.7% 
for breast cancer, 24.3% for soft-tissue sarcoma and 
21.4% for renal cancer. Factors related to overall 
survival in multivariable analysis were complete 
resection (0.7 HR [95% CI 0.48 - 1.0] p= 0.05) and 
the interval free of metastases > 6 months (1.4 [1.001 
- 2.06] p=0.049)
Conclusion: Our results are according with 
previously reported series of lung metastasectomy, 
and really encourage the surgical resection of lung 
metastases for prolonging overall survival in well 
selected patients. This is especially true for those 
patients with an interval free of metastases longer 
than 6 months and those that undergo a complete 
resection.
Keywords: metastases, lung metastasectomy, 
thoracic neoplasms
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P1.235 PREOPERATIVE SERUM VALUE 
OF SIALYL LEWIS X IS ASSOCIATED 
WITH PATHOLOGICAL STAGE 
AND SURVIVAL IN PATIENTS WITH 
SURGICALLY TREATED SMALL CELL 
LUNG CANCER
Takashi Iwata1, Noritoshi Nishiyama1, Koshi 
Nagano1, Nobuhiro Izumi1, Keiko Tei1, Shoji 
Hanada1, Hiroaki Komatsu1, Kiyotoshi Inoue2, 
Masahide Kaji2, Shinzoh Kudoh3, Shigefumi 
Suehiro1 
1Department Of Thoracic Surgery, Osaka City 
University/Japan, 2Department Of Thoracic 
NSCLC represent 1‰ among all operated Czech 
pacients with lung cancer of the period. 
Conclusion: Lung segmentectomy seems to 
accomplish local control of early stage NSCLC and 
pulmonary metastasis of extrapulmonary cancer. 
Broad multidisciplinary collaboration focused on 
early stage disease is needed. 
Keyword: Early Lung Cancer; Segmentectomy; 
Lymphadenectomy.
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.234 SURGICAL RESECTION OF 
LUNG METASTASES. RESULTS FROM 
398 PATIENTS TREATED AT A SINGLE 
INSTITUTION
Jose F. Corona-Cruz1, Luis M. Dominguez-Parra1, 
Miguel Rios-Trejo2, David Saavedra-Perez2, Digna 
Pachuca2, Edgardo Jimenez-Fuentes1, Leon Green-
Schnneweiss1, Enrique Guzman-de Alba3, Alejandro 
Eduardo Padilla-Rosciano1, Oscar Gerardo Arrieta-
Rodriguez4 
1Surgical Oncology, Instituto Nacional De 
Cancerologia/Mexico, 2Laboratory Of Experimental 
Oncology, Instituto Nacional De Cancerologia/
Mexico, 3Thoracic Surgery, Instituto Nacional De 
Enfermedades Respiratorias/Mexico, 4Medical 
Oncology, Instituto Nacional De Cancerologia 
Mexico/Mexico
Background: Pulmonary metastases are a common 
problem in oncologic patients, and although most 
of them are not curable, well selected cases may 
be amenable for surgical treatment. There are not 
randomized trials that compare surgery to any other 
form of treatment, however small series and an 
International Registry has conÀrmed an advantage 
in survival for those patients that undergo complete 
resection. We present a single institution experience 
with pulmonary metastasectomy from several 
primary tumors.
Methods: We retrospectively reviewed all patients 
treated with lung metastasectomy from January 1990 
to December 2008. Preoperative assessment and 
surgical indication was according to international 
recommendations. Clinical variables as well as 
those related to the primary and to the pulmonary 
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P1.236 5-YEAR SURVIVAL OF NON-
SMALL CELL LUNG CANCER 
PATIENTS AFTER RADICAL SURGERY 
SIGNIFICANTLY DEPENDED ON PHASE 
TRANSITION “EARLY-INVASIVE 
CANCER”, LYMPH NODE METASTASES 
AND CELL RATIO FACTORS
Oleg Kshivets 
Surgery, Siauliai Public Hospital/Lithuania
Background: We examined factors associated with 
low/high-risk of generalization of lung cancer (LC) 
(T1-4N0-2M0) after complete (R0) lobectomies/
pneumonectomies.
Methods: We analyzed data of 602 consecutive 
LC patients (LCP) (age=57.5±8.1 years; tumor 
size=4.4±2.3 cm) radically operated and monitored 
in 1985-2010 (m=536, f=66; pneumonectomies=222, 
lobectomies=380, combined procedures with 
resection of pericardium, atrium, aorta, VCS, 
carina, diaphragm, esophagus, liver, chest wall, 
ribs, etc.=155; squamous cell carcinoma=367, 
adenocarcinoma=192, large cell carcinoma=43; 
T1=215, T2=232, T3=114, T4=41; N0=377, 
N1=118, N2=107; G1=150, G2=180, G3=272; early 
LC: LC till 2 cm in diameter with N0=110, invasive 
LC=492) was reviewed. Variables selected for 5-year 
survival (5YS) study were input levels of blood 
cell subpopulations, TNMG, tumor size. Survival 
curves were estimated by Kaplan-Meier method. 
Differences in curves between groups were evaluated 
using a log-rank test. Neural networks computing, 
multivariate Cox regression, clustering, discriminant 
analysis, structural equation modeling, Monte Carlo 
and bootstrap simulation were used to determine any 
signiÀcant regularity.
Results: 
Overall life span (LS) was 1973.4±1466.8 days and 
cumulative 5YS reached 67.9%, 10 years - 59.2%, 
20 years - 29.9%. 371 LCP lived more than 5 years 
without LC. 186 LCP died because of LC. Cox 
modeling displayed (Chi2=171.3, df=6, P=0.000) 
that 5YS of LCP signiÀcantly depended on: phase 
transition (PT) early-invasive LC in terms of 
synergetics, PT N0--N1-2, cell ratio factors (CRF) 
(ratio between cancer cells:CC and blood cells 
subpopulations) (P=0.000-0.011). Neural networks, 
genetic algorithm selection and bootstrap simulation 
revealed relationships between 5YS and PT early-
invasive LC (rank=1), PT N0--N1-2 (rank=2), 
Surgery, Osaka City University Graduate School 
Of Medicine/Japan, 3Department Of Respiratory 
Medicine, Osaka City University Garaduate School 
Of Medcine/Japan
Background: We investigated various tumor 
markers in patients with surgically treated small cell 
lung cancer (SCLC) to identify the markers closely 
correlated to pathological staging and to predict 
survival by retrospective analyses.
Methods: Thirty-six patients with SCLC were 
revealed by reviewing our cancer registry database 
between 1990 and 2007. The patients were grouped 
according to clinical and pathological stages. 
Clinical features and survival curves were calculated 
and compared for each group. Receiver operating 
characteristic (ROC) curves were calculated for 
serum levels of various tumor makers to predict the 
pathological stage. The cut-off value was calculated 
from the ROC curve of the signiÀcant marker. 
Survival in patient groups divided by the new cut-off 
value was calculated.
Results: Serum levels of various tumor makers were 
not signiÀcantly different between the pathological 
stage groups, except for serum sialyl Lewis X (SLX). 
Patients with pathological stage 1 disease had a 
signiÀcantly longer survival than those with stage 2A 
or more (p = 0.0313), whereas differences in survival 
among equivalent clinical stages were not signiÀcant 
(p = 0.6386). ROC curve of SLX was signiÀcantly 
correlated to pathological stages (p = 0.0136). The 
calculated SLX cut-off value was 25.1 U/ml, with 
80% sensitivity and 70% speciÀcity. Five-year 
survival of patients selected by this new cut-off was 
82.5%, whereas that with the standard cut-off (38.0 
U/ml) was 55.9%.
Conclusion: Serum SLX values were associated 
with pathological stage and survival after surgery 
in SCLC patients and may be useful in determining 
the best candidate for surgical treatment even with a 
reduced cut-off value.
Keyword: Lung cancer, Small cell carcinoma, 
Tumor maker, Surgery, Outcome
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little long instruments for usual thoracic surgery. The 
most characteristic point of our method is that the 
operator mainly watched the operative Àeld directly 
through the small main wound, and assistants watch 
it by video monitor. So we do not enlarge wounds 
for lymphnode dissection or other complicated 
manipulations.
Results: Operation time: from 76 to 407 (mean 204) 
minutes. Bleeding: from 0 to 1010 (mean 136) ml. 
Seven cases with bronchoplasty (including 3 cases 
of sleeve lobectomy) and 5 cases with pulmonary 
angioplasty were all performed through the same 
wounds. No case needed to enlarge the wound for 
hemostasis or other reasons except for removal 
of large tumors. Histology: adenocarcinoma 141, 
squamous cell carcinoma 40, large cell carcinoma 7, 
small cell carcinoma 5, and others 19. Pathological 
stage: IA 104, IB 52, IIA 12, IIB 18, IIIA 27, IIIB 3, 
and IV 1. Duration of postoperative drainage: from 
1 to 16 (mean 2.7) days. Post operative hospital 
stay: from 2 to 22 (mean 4.9) days. One hundred 
and thirty cases (60%) were discharged by 4th 
postoperative day. The main reason of delay of 
discharge was at a request of a patient, followed by 
prolonged air leakage. There is no cases of hospital 
death, and there was no major complication. Patients 
in pathological stage IA have no recurrence so far.
Conclusion: Though the wound is small, we 
operate mainly directly, and the thoracoscope 
is used additionally. As we can perform certain 
manipulations, even bronchoplasty or angioplasty 
can be done by same methods. And the 
manipulations are almost the same as that of usual 
operation for lung cancer, for doctors who are not 
used to VATS, our method would be easy to learn 
and would have good results.
Keywords: Lung cancer, operation, VATS
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P1.238 ASSESSMENT FOR LUNG 
RESECTION SURGERY IN LUNG 
CANCER PATIENTS; ALL MAY NOT 
NEED CARDIO PULMONARY EXERCISE 
TESTING(CPET).
Samantha C. Herath, Fiona Horwood 
Respiratory Medicine, Middlemore Hospital/New 
Zealand
Background: Resectable lung cancer requires major 
surgery. Pre-operative evaluation is important to 
erythrocytes/CC, healthy cells/CC, thrombocytes/
CC, segmented neutrophils/CC, monocytes/CC, 
leucocytes/CC, stab neutrophils/CC, lymphocytes/
CC, eosinophils/CC. Correct prediction of 5YS 
was 100% by neural networks computing. Cox 
Regression: Dependent Variable: 5YS (LCP=602); 
Chi2=171.334; df=6; P=0.0000 
Beta t-value Wald P 
PT early-invasive LC -1.26048 -3.1602 9.98697 0.001578 
Leucocytes/CC -0.98620 -4.1127 16.91422 0.000039 
Stab Neutrophils/CC 1.01536 2.51917 6.34619 0.011768 
Segm.Neutrophils/CC 1.05533 4.22974 17.89070 0.000023 
Lymphocytes/CC 0.79332 2.98631 8.91802 0.002826 
PT N0--N1-2 1.07588 7.32680 53.68200 0.000000 
Conclusion: 5YS of LCP after radical procedures 
signiÀcantly depended on: 1) PT early-invasive LC; 
2) PT N0--N1-2; 3) CRF.
Keywords: Prognosis, Lung cancer, Surgery
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P1.237 THE EASIEST AND THE SAFEST 
WAY OF VIDEO ASSISTED THORACIC 
SURGERY FOR LUNG CANCER
Shogo Toda, Tsunehiro Ii 
General Thoracic Surgery, Otsu Municipal Hospital/
Japan
Background: Video assisted thoracic surgery 
(VATS) is now one of the most important methods 
for lung cancer operation. It seems to be less 
invasive and more cosmetic than the operation under 
standard thoracotomy. But it also seems to be more 
difÀcult to operate because of inaccuracy of handling 
instruments under thoracoscopic vision. And it 
sometimes seems to be questionable if sufÀcient 
curability is obtained by VATS. The aim of this study 
is to present the method and advantages of our video 
assisted thoracic surgery.
Methods: Two hundred and seventeen cases 
(male 140, and female 77) of lung cancer were 
operated by VATS from April 2004 to December 
2010. Age: from 25 to 88 years old (mean 66). 
Lobectomies (including bilobectomies) with 
systematic lymphnode dissection were performed. 
The main wound was usually 3.5 to 4cm long on 
the 4th intercostal space of mid-axillar line with 2 
small wounds for insertion of a thoracoscope and 
other instruments. Only a plastic wound retractor for 
traction of soft tissues was attached. We do not use 
special instruments for endoscopic surgery, but use a 
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P1.239 SURGICALLY TREATED 
EPITHELIAL NON SMALL CELL LUNG 
CANCER PATIENTS: PATTERNS OF 
RELAPSE AND OUTCOME
Shoshana Keren-Rosenberg1, Olecia Goldman1, 
Eduard Grikstas1, Michelle Leviov1, Anna Rabkin1, 
Larissa Leizin1, Natalia Sikorsky1, Israel Serapov2, 
Mariana Steiner1 
1Oncology, Lin Medical Center/Israel, 2Thoracic 
Surgery, Carmel Medical Center/Israel
Background: From 2001 to 2008, 146 operated 
NSCLC patients were treated at our oncology center. 
Methods: Their Àles were retrospectively reviewed 
in order to examine the patterns of relapse and the 
general outcome. 
Results: Their median age was 70.6 years (43-91). 
60% were male. 75% had stage I disease, 10% stage 
II and 15% stage III. 88% of patients were referred 
after curative operation while 12% were operated 
after neoadjuvant therapy. Lobectomy was performed 
in 79% of patients, 12% underwent pneumonectomy 
and 9% wedge resection of lesion. 29% of patients 
had squamous cell carcinoma, 40% adenocarcinoma, 
27% bronchoalveolar carcinoma and 4% other 
histologies. 18% of patients had adjuvant therapy 
(13% platinum based chemotherapy and 5% 
radiotherapy). During a median follow up of 46 
months (1.5- 118) 21% of patients relapsed. Median 
time to relapse was 15 months (2.5-85). Relapse 
occurred in 15% of stage I patients, in 29% of stage 
II and in 56% of stage III patients. 27% of patients 
who recurred had loco-regional recurrence, 66% 
had distant metastases and 7% had both. In 43% of 
patients relapse was detected by clinical symptoms 
while 57% of relapses were detected by routine 
tests. Median survival from relapse was 10 months 
(1-60). At present, 58% of patients are alive with no 
evidence of disease, 4% are alive with disease, 22% 
died of lung cancer, 1.5% died in the preoperative 
period (after neoadjuvant chemotherapy) and 14.5% 
died of unrelated causes. 5 year actuarial survival 
rate was 74% for stage I disease, 67% for stage II 
and 40% for stage III disease. Patient’s gender, age 
and histological type did not inÁuence survival. 
Conclusion: We conclude that our data is similar to 
other presented results in operated lung carcinoma. 
Relapse is usually incurable whether detected 
clinically or by routine follow up testing. 
Keywords: lung-cancer, relapse, survival, Surgery
ensure beneÀt. Current practice involves a battery of 
lung function testing (LFT) including CPET for all 
patients considered for surgery.
Methods: This is a retrospective clinical audit. All 
pre-operatives LFT from 2009- 2010 were analysed. 
We compared the predicted risk for lobectomy and 
pneumonectomy; calculated using combination 
FEV1/ DLCO testing alone (According to British 
Thoracic Society(BTS) Guidelines 2002-see below 
for calculation and risk), to that of measured 
Vo2 peak reached during CPET.Patient record 
were followed up and immediate post- operative 
complications were recorded. BTS guidlines 2002- 
on selection of patients with lung cancer for surgery 
published in Thorax2001;56:89-108 Predicted 
FEV1 = (pre operative measured FEV1*(19 - no 
of segments removed)/19, Predicted DLCO=(pre 
operative measured DLCO*(19 -no of segments 
removed)/19, Risk Categorisation: High risk = 
(predicted FEV1 & DLCO < 40%), Indeterminant= 
(any other FEV1/DLCO combination),Low risk = 
(predicted FEV1 & DLCO > 40%). 
Results: 44 patients were considered for lung 
resection. Mean age; 64.9 +/- SD10.7. 66% were 
Male. The predicted high risk group for lobectomy 
on combination FEV1/DLCO was identiÀed to be 
having an oxygen uptake (Vo2 peak) of 14 or less 
consistently. Twenty patients proceeded to surgery 
.No one with predicted high risk had surgery. The 
post-operative complication rate was low. No deaths 
occured.VO2peak for lobectomy patients was mean 
21.1 +/- 6.7 SD with a minimum of 13.4ml/kg/min. 
Conclusion: There is good correlation between 
calculated (using predicted FEV1/DLCO) and 
measured (using VO2 peak) surgical risk. The high 
risk group may be deemed unÀt for surgery with 
DLCO and FEV1 alone without the need for further 
testing. In our unit we found a cautious approach to 
surgery and low complication rates.
Keywords: NSCLC, Surgery, risk, exercise testing
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P1.241 POSTOPERATIVE ACUTE 
EXACERBATION OF PULMONARY 
FIBROSIS IN LUNG CANCER PATIENTS 
AND PREOPERATIVE CT FINDINGS
Motoki Yano1, Hidefumi Sasaki1, Satoru Moriyama1, 
Yu Hikosaka1, Katsuhiro Okuda1, Keisuke Yokota1, 
Masaki Hara2, Yoshitaka Fujii1 
1Oncology, Immunology And Surgery, Nagoya City 
University Graduate School Of Medical Sciences/
Japan, 2Radiology, Nagoya City University/Japan
Background: Acute exacerbation (AE) of pulmonary 
Àbrosis in lung cancer patients with idiopathic pulmonary 
Àbrosis (IPF) often leads to postoperative mortality. 
However, AE may occur in the patients who have not 
been diagnosed with IPF preoperatively, and it is difÀcult 
to predict which patient will develop AE postoperatively.
Methods: We have conducted a retrospective study of 
481 consecutive patients who underwent lung cancer 
surgery since January 2004. Even if the patients had 
not been diagnosed with IPF, they were rerolled if they 
had Àbrous changes in preoperative high resolution 
CT. Sixty-two patients with such Àndings have been 
included. AE was analyzed un reference to radiological 
and laboratory Àndings.
Results: AE was observed in 6 of 62 patients; 1/7 with 
usual interstitial pneumonia (UIP) pattern, 1/16 with 
cellular non-speciÀc interstitial pneumonia (cNSIP) 
pattern, 4/25 with Àbrotic non-speciÀc interstitial 
pneumonia NSIP (fNSIP) pattern, and 0/14 with 
unclassiÀed Àbrous changes (UFC) pattern. High KL-6 
appeared to be a prognostic factor of AE. In patients who 
underwent limited surgery with partial resection, AE was 
not observed.
Conclusion: AE may develop in the patients with not 
only UIP but also with NSIP pattern. In patients with a 
high risk of AE; high KL-6, limited surgery may be an 
option.
Keywords: acute exacerbation, pulmonary Àbrosis, 
Lung cancer
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P1.242 PERCUTANEOUS CT-GUIDED 
RADIOFREQUENCY ABLATION FOR 
NSCLC:PRELIMINARY REPORT
Yi Zhang, Xiuyi Zhi, Liu Baodong, Mu Hu 
Thoracic Surgery Dept., Beijing Lung Cancer 
Center, CMU/China
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P1.240 A PURELY RETICULAR 
PULMONARY CT PICTURE CAN WELL 
REPRESENT A LUNG CANCER (REPORT 
OF THREE CASES)
Hiroki Hayashi 
Surgery, Kanto Central Hospital/Japan
Background: We have recently experienced that 
Reticular pattern on chest CT Ànding is not rarely 
of a lung cancer. We report three cases to warrant 
an early intervention to treat such a patient. 
Methods: We analyzed three patients who resected 
lung cancer following thoracotomy in spite of a 
reticular pattern of the lesion on chest computed 
tomography, in Kanto Central Hospital during 
2010. 
Results: Case1. A 79-year-old man whose chest CT 
Àlm showed a purely reticular pattern shadow in 
the left lower lobe. Adenocarcinoma was diagnosed 
by transbronchial lung biopsy (TBLB). FDG-PET 
conÀrmed abnormal accumulation in the same 
legion. Left lower lobectomy was performed 21 
days after TBLB. Case2. An 80-year-old man 
complained of bloody sputum, whose chest CT 
showed a reticular pattern shadow in the right lower 
lobe. FDG-PET showed an abnormal accumulation 
in the same legion. Right lower lobectomy was 
performed 42 days after TBLB. Case3. A 75-year-
old man, whose chest CT Àlm showed a reticular 
pattern shadow in the segment 6 of the right lobe. 
FDG-PET showed a normal accumulation in 
the region. Adenocarcinoma was diagnosed by 
a wedge ressection. Right lower lobectomy was 
subsequently performed. 
Conclusion: Three cases that we hereby reported 
warrant an exploratory thoracotomy for a possible 
lung cancer in cases. Which present with a localized 
purely reticular shadow in the lung, even when 
Interstitial pneumonitis may well be in the top of its 
differential diagnosis. 
Keyword: Reticular pattern
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P1.243 ROUTINE MEDIASTINOSCOPY 
VERSUS ROUTINE POSITRON 
EMISSION TOMOGRAPHY (PET) AND 
SELECTIVE MEDIASTINOSCOPY. 
MATURE RESULTS OF A CLINICAL 
PROTOCOL FOR STAGING NON-SMALL 
CELL LUNG CANCER
Sergi Call1, Ramon Rami-Porta1, Carme Obiols1, 
Mireia Serra1, Sonia Gonzalez2, Roma Bastus-
Piulats2, Montserrat Domenech3, Jose M. Gonzalez4, 
Montserrat Ysamat4, Lidia Canales5, Jose A. De 
Marcos5, Guadalupe Gonzalez-Pont6, Enric Barbeta7, 
Josep M. Soler8, Josep Belda1 
1Thoracic Surgery Service, Mutua Terrassa 
University Hospital/Spain, 2Oncology/hematology 
Service, Mutua Terrassa University Hospital/
Spain, 3Oncology Department, Althaia (Xarxa 
Assistencial De Manresa)/Spain, 4Centro Tecnologia 
Diagnostica (CTD), Mutua Terrassa University 
Hospital/Spain, 5Diagnostic Imaging Service, Mutua 
Terrassa University Hospital/Spain, 6Department 
Of Pathology, Mutua Terrassa University Hospital/
Spain, 7Respiratory Unit, Hospital General De 
Granollers/Spain, 8Radiation Oncology Department, 
Institut Oncologic Del Valles/Spain
Background: In 2004, routine positron emission 
tomography (PET) was introduced in our staging 
protocol to evaluate the metabolic activity in the 
mediastinum and to rule out extrathoracic disease. 
The objective of this study is to compare the accuracy 
of our current clinical staging protocol with selective 
surgical mediastinal exploration (SME) based on PET 
and the previous protocol with routine SME.
Methods: From 1994 to 2003, routine SME 
(mediastinoscopy, parasternal mediastinotomy or 
extended cervical mediastinoscopy) was performed 
to 655 patients with NSCLC as the last clinical 
staging procedure prior to thoracotomy. Those with 
no mediastinal involvement underwent thoracotomy 
for lung resection (T) and systematic nodal 
dissection (SND). From 2004 to 2010, PET was 
routinely done in 625 patients. SME was reserved 
for those with positive mediastinal or hiliar uptake 
on PET, large lymph nodes on CT scan or central 
tumors. The remaining patients and those with 
negative SME underwent T and SND. SND was 
considered the gold standard to compare the negative 
results of PET and SME. Pathological Àndings were 
reviewed and staging values were calculated using 
Background: Although the most effective treatment 
for lung cancer is surgery at present, 70% of lung 
tumors are not suitable for potentially curative 
resection. There are two main reasons that account 
for the unsuitability of surgery as the prime treatment 
modality: advanced stage due to lack of effective early 
diagnostic method and poor operation tolerance due 
to advanced age or co-morbid medical conditions. 
In recent years, Radio Frequency Ablation (RFA), 
a newly-developed local physiotherapy, has been 
applied as an alternative therapeutic strategy for lung 
cancer, receiving remarkable clinical effect. 
Methods: From March 2007 to Dec 2010, two-
hundred twenty-six patients with two-hundred Àfty 
NSCLC or metastases lesions underwent percutaneous 
CT guidance RFA with RITA electrodes. Contrast–
enhanced CT was performed immediately, 1 month, 
and then every 3 months after RFA to evaluate the 
response and result to therapy. 
Results: Ten (1.6%) lesions showed complete 
necrosis, 176 lesions (70.4%) showed partial response, 
contrast CT revealed cavity formation or scar 
formation. 51 lesions (20.4%) with stable disease, 
19 lesions (7.6%) showed progressive disease and 
received second session of RFA. The density of 242 
lesions was lowered (96.8%). Post-procedure PET 
or SPECT showed loss of virtually all FDG activity 
in the previously positive areas in 205 of 250 lesions 
(82.4%). No procedural mortality occurred. Minor 
complications included small pneumothorax in 26, 4 
requiring drainage, intrapulmonary hemorrhage in 4, 
chest pain in 14, cough in 10.Side effects (moderate-
grade fever <38.5 ƒ, and/or chest pain) were 
commonest complications, however, most of them 
were cured within a couple of days. 
Conclusion: This pilot clinical study demonstrates 
that CT-guided RFA is a relatively safe, effective and 
promising procedure for the treatment of inoperable 
NSCLC. Follow-up CT scan is helpful in assessing the 
effect of RFA, accurate localization of the electrode 
needle and searching possible complications. PET 
or SPECT is also a good and sensitive procedure for 
follow-up, providing good discrimination between 
residual granulation tissue and recurrent tumor. 
Keyword: radiofrequency ablation； lung tumors； 
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atelectasis requiring bronchoscopy and respiratory 
distress necessitating ICU admission. We endeavored 
to develop a standardized post-operative respiratory 
therapy pathway to improve perioperative outcomes. 
Methods: A multidisciplinary team composed of 
thoracic surgeon faculty, physician assistants, nurses 
and respiratory therapists developed an evidence-
based pathway that would provide intensive RT for 
thoracic surgery patients beginning in the recovery 
room and continuing for 72 hours in their stay on a 
thoracic surgery progressive step-down unit (Figure 
1). Once the pathway was approved by the faculty, 
the entire RT and thoracic surgery care teams were 
in-serviced to pathway content and implementation. 
Instructional postings were placed throughout the 
step-down unit. Key team members were chosen 
as “pathway champions” to help coordinate and 
implement the changes. A Progress Scoring Tool was 
developed to determine achievement by the patient 
of recovery benchmarks. 
Results: The pathway identiÀed 4 cohorts of 
patients (Low Risk, Moderate Risk, High Risk 
and Acute Risk). Low risk patients received deep 
breathing and incentive spirometry (IS) exercises 
by the registered nurse (RN) four times /day (QID). 
Moderate risk patients received positive pressure 
therapy twice/day in addition to IS QID. High risk 
patients received a percussion vest or intrapulmonary 
percussive ventilation (IPV) three times /day in 
addition to IS QID. Acute risk patients received 
percussion vest or IPV every 6 hours in addition to 
incentive spirometry QID. Bronchodilators were 
initiated in most patients. Moderate through acute 
risk patients were re-evaluated every 24 hours using 
a Progress Scoring Tool. Continuation, change or 
discontinuation of therapy was determined by the 
Progress Scoring Tool score. Implementation of this 
intensive program resulted in marked decrease in the 
number of thoracic surgery patients needing transfer 
the standard formulas. 
Results: The staging values of each period are 
described in table 1. In the routine PET protocol, 
43 (6.8%) patients with pN2 disease were clinically 
understaged and underwent T. This rate is not 
statisticallly different from the 6.1% pN2 (40 
patients) found in routine SME period. Table1. 
Staging values of each period. 
Staging Protocol with 
Routine SME 
Staging Protocol with Selective 
SME based on PET 
N 655 625 
Sensitivity 0.85 0.81 
Speci¿city 1 1 
PPV 1 1 
NPV 0.90 0.90 
Accuracy 0.94 0.95 
Abbreviations: N: number of patients; PPV: Positive 
Predictive Value; NPV: Negative Predictive Value.
Conclusion: The staging protocol with routine PET 
and selective SME saves up to 25% of SME and 
yields a similar rate of pN2 disease compared to 
routine SME. Therefore, if availble, PET and SME 
should be thoughtfully combined in the clinical 
staging of NSCLC. 
Keywords: Staging, PET, Mediastinoscopy
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P1.244 ESTABLISHMENT OF A FIRST 
72 HOUR CHEST PHYSIOTHERAPY 
PATHWAY IN A THORACIC SURGERY 
ONCOLOGY PROGRAM TO REDUCE 
POSTOPERATIVE PULMONARY 
COMPLICATIONS
Felicia Tanner-Corbett, David T. Cooke, Patrica 
Brown, Royce F. Calhoun 
Division Of Cardiothoracic Surgery, University Of 
California, Davis Medical Center/United States Of 
America
Background: Thoracic surgery, especially pulmonary 
resection for lung cancer, poses a unique set of 
challenges that require intensive respiratory therapy 
(RT) in order ensure successful patient outcomes 
and expedited recovery. Patients require aggressive 
pulmonary hygiene to achieve lung expansion 
after single lung ventilation in the operating room. 
There is a limited window of time to optimize 
patient postoperative pulmonary function and avoid 
complications such as hospital acquired pneumonia, 
Copyright © 2011 by the International Association for the Study of Lung Cancer S865
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
cardiac, hepatic and renal disease were excluded 
from the study. All patients underwent arterial blood 
gases and lung spirometry prior to surgery, and 
they were intubated with a left-sided double-lumen 
endobroncheal tube during general anesthesia. Our 
indication for using NO (20 ppm) is severe hypoxia 
(SpO
2
<90%) occurred at one lung ventiration (OLV) 
with 100% O
2
 during general anesthesia. 
Results: Patients were performed standard 
radical lobectomy with mediastinal lymph node 
dissection. Histological types of lung cancer were: 
adenocarcinoma (n=7), squamous cell carcinoma 
(n=3), large cell carcinoma (n=1), meta from thyroid 
carcinoma (n=1). Pathological stages were: Stage I 
(n=6), Stage II (n=2), Stage III (n=3) and Stage IV or 
metastasis (n=1). OLV was performed for 188±68.7 
(min), and inhaled NO was used for 103.7±56.1 
of the period. PaO
2
 improved from 62.4±6.1 
(mmHg) to 96.5±41.2 (p=0.034) under identical 
ventilating conditions (FiO
2
 1.0) with inhaled NO, 
and PaCO
2
 was not affected: (46.5±4.3 to 45.5±4.0). 
Furthermore systemic blood pressure, heart rate were 
not affected after NO inhalation. Complications due 
to the use of NO did not occur prior to and following 
the surgery. The surgery went well without speciÀc 
problems. 
Conclusion: The maintenance of NO inhalation 
during general anesthesia with respiratory distress 
syndrome would be beneÀcial to surgical treatment 
for lung cancer. In addition, inhaled NO provide 
high-quality perioperative care at lower cost than 
other treatment. This review also highlights the 
application of inhaled NO to surgical treatment for 
lung cancer with respiratory distress syndrome, 
strategies to augment the efÀcacy of inhaled NO, and 
potential applications of the systemic effects of the 
gas. 
Keywords: Surgical treatment, perioperative care, 
nitric oxide inhalation, Lung cancer
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P1.246 ADJUVANT CHEMOTHERAPY 
FOLLOWING RADICAL SURGERY FOR 
NON-SMALL-CELL LUNG CANCER: A 
RANDOMIZED STUDY ON 70 PATIENTS
Shiying Zheng1, Dong Jiang1, Hong Li2 
1Department Of Cardio-thoracic Surgery, The First 
AfÀliated Hospital Of Soochow University/China, 
2Department Of Geriatrics, The First AfÀliated 
Hospital Of Soochow University/China
to the intensive care unit secondary to respiratory 
complications. Hospital length of stay for patients 
undergoing video-assisted thoracic surgery (VATS) 
also decreased.
Conclusion: Multidisciplinary collaboration 
between thoracic surgery faculty, nursing, physician 
assistants and other allied health clinicians can 
lead to successful implementation of a needed 
Àrst 72 hours thoracic surgery respiratory therapy 
postoperative pathway to the beneÀt of the patient. 
Further metrics determining effects on other 
cardiopulmonary complications and a cost savings 
analysis is forthcoming.
Keywords: Surgery, Respiratory Therapy, Clinical 
Pathways, Lung cancer
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P1.245 CLINICAL MAINTENANCE OF 
NITRIC OXIDE INHALATION DURING 
GENERAL ANESTHESIA TO SURGICAL 
TREATMENT FOR LUNG CANCER WITH 
RESPIRATORY DISTRESS SYNDROME
Fumiaki Watanabe1, Toshiya Tokui1, Shuhei Kogure1, 
Naoki Yamamoto1, Uhito Yuasa1, Sekira Shoumura1, 
Sigehito Kondou2, Motoaki Tanigawa2, Yuko Hara3 
1Thoracic Surgery, Yamada Red Cross Hospital/
Japan, 2Respiratory Medicine, Yamada Red Cross 
Hospital/Japan, 3Department Of Anesthesiology, 
Yamada Red Cross Hospital/Japan
Background: Inhaled nitric oxide (NO) is occasionally 
used to treat hypoxemia for adult patients with acute 
respiratory distress syndrome in the intensive care 
unit. Moreover, inhaled NO is currently indicated for 
the treatment of term and near-term neonates with 
hypoxemia and pulmonary artery hypertension. Since 
regulatory approval, several studies have suggested 
that NO inhalation can prevent chronic lung disease. 
However, it is controversial whether or not to maintain 
inhalation of NO during general anesthesia.We studied 
efÀcacy of NO inhalation during general anesthesia 
in surgical treatment for lung cancer with respiratory 
distress syndrome. 
Methods: We retrospectively investigated patients 
with respiratory distress syndrome from the 91 cases 
performed surgical treatment for lung cancer from 
January 2009 to December 2010. Twelve patients 
(6 males and 6 females) were enrolled in this study, 
with a mean age of 75 years (71-80 years). Patients 
with a documented history of uncompensated 
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Keywords: non-small-cell lung cancer (NSCLC), 
Adjuvant chemotherapy, survival rate
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.247 ANALYSIS OF MINIMALLY 
INVASIVE SURGICAL TECHNIQUES IN 
THE TREATMENT OF LUNG CANCER
You B. Cui, Yong X. Wang, Xue Shan, Qi C. Cui, 
Yong Zhao 
Thoracic Surgery, The First AfÀliated Hospital Of 
Jilin University/China
Background: To analyze three minimally invasive 
surgeries for lung cancer comparatively,and to Ànd 
some clues for selection of the three minimally 
invasive surgical technique in the treatment of Lung 
Cancer.
Methods: The cases of 131 hospitalized 
patients with lung cancer in the First AfÀliated 
Hospital of JiLin University were analyzed 
retrospectively,incluing 44 treated by video-
assisted thoracoscopic surgery(VATS), 43 by 
Video-assisted mini-thoracotomy(VAMT) and 44 
by Mini-thoracotomy(MT). The comparison of 
the feasible and safe, the operative duration, the 
number of lymph node resected,the blood loss, the 
pain,the complication and the time returning to full 
preoperative activities were analyzed.
Results: The operative duration of VATS group was 
shorter than those of VAMT and MT groups,but there 
was not signiÀcant difference(P>0.05). The blood 
loss and the pain in MT group were more than those 
of VATS and VAMT groups(P<0.05).There was no 
signiÀcant difference in the complication and the 
time returning to full preoperative activities in three 
groups,however,the complications in MT group were 
more than the other two groups,such as the morbidity 
of shoulder function limitation.
Conclusion: Compared with this three minimally 
invasive surgical technique, VATS is a safe and 
effective technique,howere,which surgical technique 
should be selected Ànally depends on the age,clinical 
stage and pathology of the patient ,and the 
indications should be complied with carefully.
Keyword: lung cancer ;minimally invasive surgery ; 
Background: Surgery is a major treatment approach 
for non-small-cell lung cancer (NSCLC). The 
5-year survival rate following surgical resection is 
60%-80% for patients with stage disease, 25%-50% 
for patients with stage , and 10%-40% for stage a. 
Surgery has rarely been used alone in the treatment 
of patients with stage b disease. We performed this 
prospective randomized study to assess the effect of 
adjuvant chemotherapy in NSCLC patients who had 
undergone radical resections using the regimen of 
cyclophosphamide, vincristine, adriamycin, cisplatin, 
lomustine and ftorafur (FT-207).
Methods: Seventy patients who underwent radical 
surgery for NSCLC in the Department of Cardio-
Thoracic Surgery, The First AfÀliated Hospital 
of Soochow University from January 2003 to 
July 2008 were selected for the study. Seventy 
patients with NSCLC (stages) undergoing radical 
surgery were randomized into two groups. Group 
1 (n=35): combination group, which received 
adjuvant chemotherapy with cyclophosphamide 
300 mg/m2, vincristine 1.4 mg/m2, adriamycin 
50 mg/m2, and lomustine 50 mg/m2on day 1, and 
cisplatin 20 mg/m2on days 1-5. The treatment was 
repeated every 4-6 weeks for 4 cycles, followed by 
oral administration of ftorafur (FT-207) 600-900 
mg/d for 1 year. Group 2 (n=35): surgery group, 
which received surgical treatment only. Follow-up 
was scheduled monthly for 6 months, then every 
3 months for the Àrst year and every 6 months 
thereafter. Routine follow-up consisted of physical 
examination, chest X-ray, ultrasound scan of the 
abdomen, electrocardiogram, routine blood tests, 
liver and renal function tests, and tumor marker tests. 
Further testing was performed as clinically indicated. 
Follow-up examinations were sometimes performed 
in a local hospital, with the results provided by letter 
or telephone.
Results: The overall 5-year survival rate was 48.6% 
in the combination group versus 31.4% in the surgery 
group, and difference between the two groups 
was not statistically signiÀcant (Ƶ2=3.09,P>0.05). 
The 5-year survival rate for patients with stage 
disease was 44% and 20.8% in the combination and 
surgery groups, respectively, showing a statistically 
signiÀcant difference (Ƶ2=5.28,P<0.025). The 5-year 
survival rates of patients in stages in the two groups 
were 60.0% and 54.5%, respectively, and were not 
signiÀcantly different (Ƶ2=0.03,P>0.75).
Conclusion: Postoperative adjuvant chemotherapy 
provides statistically signiÀcant improvement in 
the 5-year survival rate only in patients with stage  
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P1.249 ANALYSIS OF THE EFFECTS OF 
THE SURGICAL THERAPY FOR AGED 
PATIENTS WITH LUNG CANCER
You B. Cui, Shi Y. Feng, Yong X. Wang, Wei F. 
Song, Xue Shan 
Thoracic Surgery, The First AfÀliated Hospital Of 
Jilin University/China
Background: With the aging process an, the old 
age disease incidence was inevitable signiÀcantly 
increased. As for our thoracic surgeon, we have 
more and more elder (> 70 years) or even more elder 
(> 80 years) patients with lung cancer. The aim of 
this study was to evaluate the surgical treatment of 
elderly patients with lung cancer and summarizes the 
clinical experience of surgical treatment, to diminish 
postoperative mortality, improve the surgical effect.
Methods: Retrospective clinical data were analyzed 
for 60 lung cancer sufferers over 70 who received 
operation.
Results: All patients received pneumoectomy 
lobectomy and other surgical treatment under general 
anesthesia. The surgical resection rate was 93.9 %. 
Postoperative mortality was 3.3 % within 30d. The 
post-operative complication was 59.1 %. The follow-
up rate was 94.3%. Survival rates of radical resection 
after 1, 2, and 5 years were 81.6 %, 50.9 % , and34.7 
% respectively.
Conclusion: The age is not an absolute 
contraindication of the surgery , Surgical treatment 
is still an effective treatment for elderly lung 
cancer. The comprehensive evaluation on the 
clinical functions is needed. Tumor stage, and 
cardiopulmonary etc vital organs function status is 
to determine whether surgery basis. Correct surgical 
methods and preoperative period care are the key to 
ensure the surgical treatment effects.
Keyword: aged patients ；Survival rates ；surgical 
therapy；
VATS;VAMT;MT
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P1.248 THE ANALYSIS OF PROGNOSTIC 
FACTORS ON 321 CASES OF PATIENTS 
WITH LUNG CANCER
You B. Cui, Xue Shan, Yong X. Wang, Tian Y. Lu, 
Yong Zhao 
Thoracic Surgery, The First AfÀliated Hospital Of 
Jilin University/China
Background: To analyze prognostic factors of 321 
cases of lung cancer of our hospital over a period 
of recent 2 years, and try to Ànd some clues for 
prevention and treatment of lung cancer in future.
Methods: The data of 321 hospitalized patients with 
primary lung cancer in the First AfÀliated Hospital of 
JiLin University from 2003 to 2005 were reviewed 
retrospectively, and analyzed their survival rate and 
explored the factors which inÁuence prognosis and 
survival rate,such as age,clinical stage,pathology 
and treatment.The survival rate was calculated by 
Product-limit method, its signiÀcance was tested by 
logrank test.
Results: The overall one-,three-andÀve- year 
survival rates were 79.31%,35.43%,15.02%.The 
Àve-year survival rate of 40~50 years old patients 
was higher than the Àve-year survival rate of 
others(P<0.05). The Àve-year survival rate was 
22.02% for patients whose clinical TNM stage is 
stageI,11.21% in stageII,2.87% in stageIIIa, 0 in 
stageIIIb andIV(P<0.05).The Àve-year survival rate 
was 16.34% for patients with squamous carcinoma, 
10.51% for patients with adenocarcinoma,0 for 
SCLC patients(P<0.05). The Àve-year survival 
rate was 18.1% in treatment with operation,0.02%, 
without operation.The 5-year survival rate was 
found to increase as following order: chemotherapy 
combined with radiotherapy,radiotherapy and/or 
chemotherapy post-operation and operation only.
The 5-year survival rate for operation alone(25.13%) 
was higher than those for radiotherapy and/or 
chemotherapy post-operation,but there was not 
signiÀcant difference(P>0.05).The 5-year survival 
rate was 8.23% for chemotherapy combined with 
radiotherapy group (P<0.05).
Conclusion: Age,clinical stage,pathology and 
different therapy were important factors affecting 
prognosis of lung cancer.
Keyword: lung cancer ; prognostic factor ; survival 
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Center/Japan
Background: After lung cancer surgery, we often 
experience cases in which an initial recurrence lesion 
is discovered in the brain. In our institute, brain 
MRI or CT is routinely performed for postoperative 
patients at two or three months postoperatively and 
at Àve or six months postoperatively. In this study, 
we reviewed whether early diagnosis by regular 
brain examination inÁuenced the later course and 
prognosis.
Methods: We retrospectively analyzed the records 
of 389 patients with lung cancer who underwent 
curative surgery from January 2004 to January 2009 
at the Tochigi Cancer Center. For all patients, the 
frequency of metastasis, method of brain metastases 
detection, treatment for brain metastases, clinical 
course after treatment, and prognosis were reviewed. 
Results: Of the 389 cases, 258 underwent regular 
brain examination after surgery. Among these 258 
patients, brain metastases as initial recurrence lesions 
were detected in 10 (regular group). In addition, 
brain metastases were detected due to symptoms in 
8 cases (symptom group). Six of the patients in the 
regular group had solitary metastases and four had 
multiple metastases. Regarding the pathological 
background of the regular group, 7 patients had 
adenocarcinoma, 2 had large cell carcinoma, and 
1 had squamous cell carcinoma. The pathological 
tumor stages were stage 1B in 3, stage 2A in 1, 
stage 2B in 1, stage 3A in 4, and stage 3B in 1. 
All cases in the regular group were treated with 
stereotactic radiosurgery. Of the 10 patients in the 
regular group, 9 had local or distant recurrence 
1 to 5 months after the Àrst treatment for brain 
metastases. Only one patient was recurrence-free 
for 30 months. Of the 9 relapse cases, 7 died and 2 
were alive with the disease. In the symptom group, 
4 patients had solitary brain metastases and 4 had 
multiple metastases. Regarding the pathological 
background of the symptom group, 5 patients had 
adenocarcinoma, 1 had squamous cell carcinoma, 1 
had adenosquamous cell carcinoma, and 1 had small 
cell carcinoma. The pathological tumor stages were 
stage 1B in 3, stage 2B in 1, and stage 3A in 4. Three 
of the 8 patients in the symptom group were treated 
with stereotactic radiosurgery and the remaining 
cases were treated with surgery or whole brain 
radiotherapy. Seven patients in the symptom group 
relapsed after the Àrst treatment for brain metastases, 
of whom 5 died and 2 were alive with the disease. 
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P1.250 ANALYSIS OF 
BRONCHOPLEURAL FISTULA AFTER 
LOBECTOMY FOR THE PATIENT WITH 
LUNG CANCER
You B. Cui, Yong X. Wang, Xue Shan, Wei F. Song, 
Shi Y. Feng 
Thoracic Surgery, The First AfÀliated Hospital Of 
Jilin University/China
Background: This study was to analyze the 
bronchial stump closure by different methods 
to reduce the incidence of the postoperative 
bronchopleural Àstula in pneumonectomy for lung 
cancer and treatment for bronchopleural Àstulae 
(BPF) after pneumonectomy for lung cancer.
Methods: This study was to analyze the bronchial 
stump closure by different methods to reduce the 
incidence of the postoperative bronchopleural Àstula 
in pneumonectomy for lung cancer and treatment for 
bronchopleural Àstulae (BPF) after pneumonectomy 
for lung cancer.
Results: Six BPFs developed postoperatively 
among the 276 cases (overall incidence,2.2%): 1 
after manual suturing (2.2%) and four after stapling 
(1.7%), and this difference was not statistically 
signiÀcant. Of all the BPF cases , One of 2 cases 
of conservative treatment and one of 2 cases of 
operation treatment were dead, the total mortality 
rate were 33%. Tow cases sufferance from bronchial 
Àstula postoperatively regain.
Conclusion: The incidence of the postoperative 
bronchopleural Àstula was acceptable and was 
not directly associated with the methods of 
bronchial stump closure. The key therapy for 
post- pneumonectomy BPF is to close the stoma 
and thoroughly eliminate infection. Malnutrition, 
lower pulmonary lobectomy, total pneumonectomy, 
perioperative chemotherapy and radiontherapy, are 
high risk factors of BPF after pneumonectomy.
Keyword: lobectomy; bronchopleural Àstula; 
mechanical stapling; lung cancer
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P1.251 FOLLOW-UP EXAMINATION 
FOR DETECTING BRAIN METASTASES 
AFTER LUNG CANCER SURGERY
Rie Nakahara, Akiko Ui, Norihisa Oohata, Haruhisa 
Matsuguma 
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octogenarians made up 6.1%; 5.6% and 2.5% of 
lobectomies each year whereas in the Ànal year they 
comprised 14.6% (p=0.004 Fisher’s). Co morbidities 
were commoner in the control group 58% [11 
cardiovascular (CV) and 13 non-CV] compared to 
27% in the octogenarian group [8 CV; 3 non-CV] 
p=0.007. There were no in hospital deaths in either 
group. Lung function was signiÀcantly poorer in the 
control group (table). Twelve (29%) octogenarians 
had post operative complications, six were admitted 
to intensive care (2 unplanned) compared to 16 
(39%) (p=0.4) controls who suffered complications, 
four of which were admitted to intensive care (3 
unplanned). Hospital stay was similar in the two 
groups (table) In the octogenarian group histology 
revealed two typical carcinoid tumours; 14 
adenocarcinomas; 24 squamous cell carcinomas and 
one large cell carcinoma. Pathological staging of the 
NSCLC was IA 12, IB 17, IIA 1, IIB 6, IIIA 2, IIIB 
1. Over a median follow up of 637 days (range 22-
1720) seven octogenarians have died; the controls 
have been followed for a median 1023 days (range 
170 - 1722) with nine deaths. Log rank test, Kaplan 
Meier method shows no signiÀcant difference 
between the two groups (p=0.89).
Conclusion: Lobectomy for primary lung tumour in 
octogenarians is feasible with similar morbidity and 
mortality to younger patients whom undergo surgery 
despite a greater number of co-morbidities. The 
post operative survival of octogenarians justiÀes an 
aggressive surgical approach.
Keyword: lung surrgery in octogenarians
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P1.253 THE EXTENT OF LUNG 
PARENCHYMA RESECTION 
SIGNIFICANTLY IMPACTS LONG-TERM 
QUALITY OF LIFE IN PATIENTS WITH 
NON SMALL CELL LUNG CANCER
Tobias Rose1, Roland Kurdow2, Peter Dohrmann1, 
Thomas Küchler1, Bodo Schniewind1 
1General And Thoracic Surgery, University Hospital 
Of Schleswig-holstein Campus Kiel/Germany, 
2General And Thoracic Surgery, St. Marien Hospital/
Germany
Background: Secondary to clinical outcome, 
health-related quality of life (QOL) after resection 
of NSCLC is of particular interest. However, few 
studies have explored QOL following lung resection.
One of the 8 patients in the symptom group was 
recurrence-free for 8 months. No signiÀcant 
correlation was observed between the clinical course, 
prognosis and method of detection. 
Conclusion: Regular brain examination in the 
early postoperative period identiÀed silent early 
metastasis to the brain, which allowed us to choose a 
minimally aggressive treatment, such as stereotactic 
radiosurgery. However, because of the limited 
number of cases, these results do not suggest that 
regular follow-up radiological examinations of the 
brain should be performed after lung cancer surgery. 
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P1.252 IS LOBECTOMY FOR PRIMARY 
LUNG TUMOUR IN OCTOGENARIANS 
WORTH THE RISK? A CASE CONTROL 
STUDY
Marco A. Scarci, Saina Attaran, Lewis Haywood, 
Loic Lang-Lazdunski, Juliet King, Tom Routledge, 
Karen Harrison-Phipps, John Pilling 
Thoracic Department, Guy’s Hospital/United 
Kingdom
Background: For early stage non small cell lung 
cancer (NSCLC) surgery is the treatment of choice. 
The aging population will lead to increasing requests 
for surgical intervention in octogenarians. There 
are some reservations that this may be excessively 
dangerous for the survival gained.
Methods: We reviewed 41 consecutive 
octogenarians [24 male, median age 82 years (range 
80 - 88)] who underwent lobectomy via thoracotomy 
(36) or VATS (5) for suspected NSCLC over 48 
months. These were compared to 41 younger 
controls [median age 65 years (range 34 -78)] 
matched for incision, lobe resected, histology, TNM 
stage and sex.
Results: Comparison between octogenarians and 
controls 
Octagenarians Controls p value 
Median Range Median Range 
FEV1(L) 1.98 1.14-3.3 1.78 0.9-4.57 0.2 
FEV1%(predicted) 93 51-136 78 37-131 0.02 
FVC(L) 2.7 1.4-4.8 2.8 1.8-6.1 0.08 
TLCO % (predicated) 78 43-119 60 30-96 0.01 
Hospital Stay 8 5-42 6 3-67 0.16 
Octogenarians made up 7.5% of the 545 patients 
who underwent lobectomy for suspected NSCLC 
during the study. In the Àrst three years of the study 
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Background: We observe a great number of cases 
with lung cancer and coronary artery disease as 
their development is caused with common risk 
factors: age, smoking and improper way of living. 
Methods: From December 2002 to December 
2009 we performed 112 operations for combined 
pulmonary, chest, cardiac and esophageal 
pathologies. In 89 cases (79.4%) we carried 
out simultaneous operations for cardiac and 
pulmonary diseases. In others, in 18 cases we 
performed transcutaneous angioplasties before the 
pulmonary resections and in 2 (1.8%) - myocardial 
revascularization on a beating heart via the lateral 
thoracotomy and in 3 – staged cardiac and then 
pulmonary operations. All simultaneous operations 
were carried through the same anesthesia with 
CPB. 
Results: We performed lobectomies – 91% of all 
operations, of those 54% right-sided procedures. 
There were seven bronchoplastic operations – 
lobectomies with circular bronchial resections. 
Six patients (86%) had upper lobectomies and 
only one patient had a lower lobectomy with 
anastomosed upper lobar bronchus and left main 
bronchus. Comparing mortality and morbidity 
rates in groups with staged and simultaneous 
operations we did not observe authentic 
differences: a morbidity rate was 20% (staged 
procedures) versus 14% (simultaneous operations) 
and a mortality rate was 5% (staged procedures) 
versus 5.4% (simultaneous). Overall 5-year 
survival rate among patients with lung cancer was 
35%, median survival was 41 months. 
Conclusion: Thus, we state that simultaneous 
surgery for cardiac and pulmonary pathologies 
performed through the sternotomy with CPB is 
an effective surgical technique as it improves life 
quality in patients with lung cancer and decreases 
mortality rates in patients with severe cardiac 
pathology. 
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
Methods: Between January 1998 and December 2004, 
a total of 159 patients with NSCLC underwent surgical 
resection and were enrolled in this prospective study. 
QOL and clinical data were assessed prior to resection 
and for up to 24 months after surgery by applying the 
EORTC QLQ C-30 questionnaire and the lung-speciÀc 
questionnaire, QLQ-LC13. QOL was calculated and the 
QOL following bi-/lobectomy was compared with QOL 
after pneumonectomy.
Results: Overall, the 5 year survival rate was 
42%. Mean survival of the pneumonectomy group 
was slightly lower than that of the bi-/lobectomy 
group, although the difference was not statistically 
signiÀcant (p=0.058). The rate of complications was 
not signiÀcantly different between the two groups. 
After a postoperative drop, most QOL indicators 
remained near baseline for up to 24 months, with 
the exception of physical function (p<0.001), pain 
(p=0.034), and dyspnoea (p<0.001), which remained 
signiÀcantly impaired. QOL was signiÀcantly better 
(difference >10 points) after bi-/lobectomy than 
after pneumonectomy. However, differences were 
statistically signiÀcant only with regards to physical 
function (at 3 months), social function (at 3 and 6 
months), role function (at 3, 6 and 12 months), global 
health (at 3 and 6 months), and pain (at 6 months).
Conclusion: Patients who underwent lung resection 
for NSCLC failed to make a complete recovery after 
24 months. Patients who underwent pneumonectomy 
had signiÀcantly worse QOL values and a decreased 
tendency to recover, compared with patients who 
underwent bi-/lobectomy. Therefore, major lung 
resection has a much more serious impact on the QOL 
of affected patients than does major visceral surgery.
Keywords: Lung cancer, Quality of Life, EORTC 
QLQ
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.254 SIMULTANEOUS OPERATION 
FOR MALIGNANT PATHOLOGY 
OF HEART AND LUNG THROUGH 
STERNOTOMY
Vladimir Porhanov1, Igor Polyakov2, Kirill Barbukhatti1 
1Cardiothoracic Surgery Center/Russian Federation, 
2Oncological Department, Cardiothoracic Surgery 
Center/Russian Federation
Copyright © 2011 by the International Association for the Study of Lung Cancer S871
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
Keywords: pulmonary resection, metastatic lung 
tumors, colorectal carcinoma
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.256 COMPLICATIONS FOLLOWING 
LUNG SURGERY IN THE NELSON 
LUNG CANCER SCREENING TRIAL: A 
COMPARISON WITH THE LITERATURE
Susan V.’. Westeinde1, Harry J. De Koning2, Paul De 
Leyn3, Nanda Horeweg1, Frederik B. Thunnissen4, 
Matthijs Oudkerk5, Harry J.M. Groen6, Jan-Willem 
J. Lammers7, Carla Weenink8, Rene Vernhout1, 
Kristiaan Nackaerts9, Willem Mali10, Rob J. Van 
Klaveren1 
1Pulmonary Medicine, Erasmus MC/Netherlands, 
2Public Health, Erasmus MC/Netherlands, 
3University Hospital Leuven/Belgium, 4VUMC/
Netherlands, 5Radiology, UMC Groningen/
Netherlands, 6Pulmonary Medicine, UMC 
Groningen/Netherlands, 7Pulmonary Medicine, 
UMC Utrecht/Netherlands, 8Pulmonary Medicine, 
Kennemer Gasthuis/Netherlands, 9Respiratory 
Oncology Unit, University Hospitals Leuven/
Belgium, 10Radiology, UMC Utrecht/Netherlands
Background: Lung cancer screening populations 
usually consist of heavy current and former smokers 
at an advanced age and at high risk for co-morbid 
disease. The objective was to assess the complication 
rate in participants of the screen arm of the NELSON 
lung cancer screening trial who underwent surgical 
resection and to investigate, based on a literature 
review, whether the complication rate, length of 
hospital stay, re-thoracotomy and mortality rates 
after a surgical procedure were different from non-
screening series. 
Methods: Between April 2004 and December 2008 
198 subjects underwent thoracic surgery. Co-morbid 
conditions were retrieved from the medical records 
and scaled according to the Charlson-Co-morbidity 
Index. Post-operative complications were classiÀed 
as minor and major. 
Results: In total, 182 thoracotomies, 5 thoracotomies 
after Video Assisted Thoracoscopic Surgery (VATS) 
and 11 VATS procedures were performed. In these 
patients, 36% had chronic obstructive lung disease, 
16% coronary artery disease, 14% diabetes mellitus 
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P1.255 RADIOLOGICAL PROGNOSTIC 
FACTORS IN PATIENTS WITH 
RESECTED METASTATIC LUNG 
TUMORS IN PATIENTS WITH 
COLORECTAL CARCINOMA
Takeshi Matsunaga1, Yoshikazu Miyasaka2, Kazuya 
Takamochi2, Shiaki Oh2, Kenji Suzuki2 
1Division Of General Thoracic Surgery, Juntendo 
University School Of Medicine/Japan, 2Division Of 
Thoracic Surgery, Juntendo University School Of 
Medicine/Japan
Background: Metastasectomy is performed as 
one of treatment strategy for pulmonary metastasis 
of colorectal carcinoma. However, the indication 
remains controversial.
Methods: A retrospective study was conducted 
on 108 patients (126 resections) with pulmonary 
metastases of colorectal cancer, resected between 
January 2000 and October 2010. We reviewed 
radiological Àndings of computed tomography in 
all cases, and classiÀed as follows; Type 1; solitary 
big tumor (>3cm), type 2; solitary small tumor 
(3cm), type 3; solitary big tumor and other small 
multiple tumors, and type 4; multiple small tumors. 
We analyzed the following preoperative prognostic 
factors: gender, age, CEA, tumor size, numbers 
of tumors, presence of metastases at other sites, 
DFI (disease-free interval) and the classiÀcation of 
type1-4. Survival was estimated with Kaplan-Meyer 
method and multivariate analysis was performed by 
the Cox proportional hazards regression.
Results: There were 62 men and 46 women and 
age ranged 35 to 81 with median of 64. The actual 
5-year survival of over all patients was 49.3%. That 
of type 3 was 28.1% less than type 1 (61.1%), 2 
(51.9%) and 4 (52.9%). In multivariate analysis, the 
signiÀcant prognostic factors were type 3 (risk ratio: 
7.75, 95% CI: 2.31-25.97, p-value: <0.001), DFI(risk 
ratio: 0.23, 95% CI: 0.06-0.87, p-value: 0.031) 
and females(risk ratio: 5.16, 95% CI: 1.64-16.26, 
p-value: 0.005).
Conclusion: Radiological classiÀcation of metastatic 
lung tumors of colorectal carcinoma was one of the 
signiÀcant prognostic predictors. Recently outcome 
of chemotherapy for colorectal carcinoma continues 
to be improving. Thus prognosis of resected 
metastatic lung tumor of colorectal carcinoma 
could be improved and the indication should be re-
considered based of those prognostic factors. 
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CI: 15;35). The median hospitalization was 9 days 
(5-28) and drainage time was 5 days (0-17). In 19 
(36,5%) patients complications occurred. Pulmonary 
complications occurred in 8 (15,4%) patients: 1 with 
bronchialstump-insufÀcieny, 1 with hemothorax, 
1 with prolonged air leak and 5 with pneumonia. 
Reoperation was necessary in 3 patients. In 12 
(23.1%) patients cardiovascular morbidity occurred 
requiring medical and antiarrhytmic treatment, 6 
(11.5%) had other complications (cerebrovascular 
incident, urinary tract infection). 
Conclusion: Lung resections in selected 
octogenarians can be performed safely and without 
a higher risk of perioperative mortality. The 
perioperative morbidity does not differ from other 
patients. Long term survival justiÀes an active 
approach. 
Keyword: lung cancer, surgery, octogenarians
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P1.258 PPOFEV1.0% FOR THE 
PREOPERATIVE RISK ASSESSMENT 
IS BETTER THAN PPOFEV1.0 IN LUNG 
CANCER RESECTION.
Keita Tokuishi, Shinichi Yamashita, Takafumi 
Hashimoto, Toshihiko Moroga, Michiyo Miyawaki, 
Masao Chujo, Satoshi Yamamoto, Katsunobu 
Kawahara 
Surgery ɉ, Oita University Faculty Of Medicine/
Japan
Background: The purpose of this study is to asses 
the outcome of the patients after VATS lung resection 
by preoperative lung function test.
Methods: We retrospectively reviewed the results 
of 324 patients who underwent VATS or open lung 
resection between January 2003 and November 
2009.Predicted postoperative FEV1.0(ppo FEV1.0) 
was calculated by FEV1.0×(1- number of resected 
subsegments /42). Four groups according to ppo 
FEV1.0, such as less than 0.8L, 0.8-1.0L, 1.0-
1.2L, and more than 1.2L were compared. In 
%ppoFEV1.0, three groups were divided to less than 
40%, 40-60%, and more than 60%.
Results: Postoperative pulmonary complication 
were 3 cases in ppoFEV1.0 less than 0.8L (n:10), 
4 in 0.8-1.0L(n:14), 6 in 1.0-1.2L (n:25) and 54 
in more than 1.2L (n:270). These results were not 
statistically signiÀcant (p=0.74). Mortality was only 
2 cases (0.6%). However, postoperative complication 
and 11% peripheral vascular disease. Following 
thoracotomy, 48% (90/187) had  1 minor and 
10% (18/187)  1 major complication; following 
VATS, 38% (6/16) had  1 minor complication, but 
no major complications. Seventeen percent (3/18) 
of major complications and, 21% (20/96) of minor 
complications were seen in subjects operated for 
benign disease. The re-thoracotomy rate was 3% and 
there was no 30-day mortality after thoracotomy or 
VATS. 
Conclusion: Mortality and major complication rates 
after surgical procedures are lower in the screen arm 
of the NELSON lung cancer screening trial than in 
non-screening series. 
Keywords: Early detection of lung cancer, 
Postoperative complications, Thoracotomy, Thoracic 
Surgery, Video-assisted
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P1.257 PERIOPERATIVE MORBIDITY, 
MORTALITY AND SURVIVAL 
AFTER LUNG RESECTIONS IN 
OCTOGENARIANS
Michaela Tutic, Dagmar Paredes, Peter Kestenholz, 
Isabelle Opitz, Didier Schneiter, Walter Weder 
Thoracic Surgery, University Hospital Zurich/
Switzerland
Background: Due to a rapid aging population and 
increased life expectancy in octogenarians, lung 
surgeries are more commonly being performed in 
elderly patients. The purpose of the present study 
was to evaluate our current mortality, morbidity and 
long term survival in this patient population. 
Methods: Retrospective analysis of 52 patients 
(13 females) who were 80 years or older (80-88) 
who underwent surgery for Non-Small-Cell-Lunger 
Cancer (NSCLC) over the past 10 years. 
Results: The histology revealed squamous cell 
carcinoma in 21, adenocarcinoma in 22, large cell 
carcinoma in 5, and 4 patients with other histological 
types. Tumor staging of the 49 patients with NSCLC 
showed 29 patients with stage I, 8 with stage II, 9 
with stage IIIA, 2 with stage IIIB, 1 with stage IV. 
Lobectomy was performed in 32, bilobectomy in 10, 
sleeve-lobectomy in 1, pneumonectomy in 4, and 
segmental-/wedge resections in 5 patients. There 
was no in-hospital or 90-day mortality. Out of the 
52 patients 9 patients died, the Àrst after 16 months. 
The median survival time was 25 months (95% 
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for pulmonary resection. 
Results: It took 18.3 ± 9.4 seconds for patients with 
artiÀcial pneumothorax to be initiated the surgery, 
on the other hand it took about 300 seconds for those 
without artiÀcial pneumothorax. The reduction in the 
blood Áow from the whole body to heart leaded to 
decrease in blood pressure, approximately 20mmHg 
during artiÀcial pneumothorax, which had no effect 
on the initiation of the pulmonary resection. There 
were some patients who had pulmonary adhesion. 
But if it was mild adhesion, it was possible to 
separates the lung from the wall of the chest using 
the way of the artiÀcial pneumothorax . 
Conclusion: When there was only single port hole 
for a thoracoscope in chest wall, a conÀned space 
can be maintained and artiÀcial pneumothorax can 
be created with relative ease. It induces no serious 
side effects and needs little costs. This method 
shortens deÁating time of lung,that solves decrease 
in SpO2 from ventilation-perfusion mismatch during 
the differential lung ventilation. In this way it is 
suggested that artiÀcial pneumothorax is becoming a 
useful option intra VATS. 
Keywords: artiÀcial pneumothorax, VATS
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.260 WHAT IS THE PROGNOSIS 
OF SURGICALLY RESECTED NON 
SMALL CELL LUNG CANCER WITH 
UNEXPECTED PATHOLOGICAL N2 
DISEASE?
Andrea Billie1, Saina Attaran1, Lewis Haywood2, 
Loic Lang-Lazdunski2, Juliet King1, Tom Routledge2, 
Karen Harrison-Phipps1, John Pilling2 
1Thoracic Surgery, Guys Hospital/United Kingdom, 
2Thoracic Department, Guy’s Hospital/United 
Kingdom
Background: The prognosis of non-small cell 
lung cancer (NSCLC) is stage related. Staging 
investigations are used to exclude patients with 
mediastinal nodal disease from surgical resection. 
Due to limitations in these tests a number of N2 
positive patients undergo resection. The aim of this 
study was to investigate the outcome after lung 
resection in patients with N2 involvement.
was signiÀcantly related to ppoFEV1.0%, which the 
complication rates were 50% (9 out of 18 cases) in 
less than 40% group, 27% (38 out of 141) in 40-60% 
group, and 12.5% (20 out of 160). (p <0.01)
Conclusion: These results suggested that 
ppoFEV1.0% should be used for the preoperative 
risk assessment rather than ppoFEV1.0.
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.259 A PILOT STUDY OF THE 
ARTIFICIAL PNEUMOTHORAX 
FOR A VATS LOBECTOMY AND 
SEGMENTECTOMY.
Masami Morimoto, Takanori Miyoshi, Hisashi 
Matsuoka, Naoki Hino, Masaru Tsuyuguchi 
Surgery, Tokushima Municipal Hospital/Japan
Background: Video-assisted thoracoscopic (VATS) 
lobectomy remains controversial. Recently, VATS 
lobectomy and segmentectomy for malignancies 
has spread slowly. It is necessary to deÁate the 
illness side lung under the single-lung ventilation 
for VATS lobectomy, and then the deÁation of 
lung is an important factor to its feasibility and 
safety. As problems, the single-lung ventilation 
causes ventilation perfusion ratio inequality, which 
decreases in SpO2. Thus, the purpose of this study 
was to be given the lung collapse in a short time, 
and to be given enough operative Àelds of vision. 
We have developed the method by the artiÀcial 
pneumothorax.
Methods: Of the 27 patients who underwent 
pulmonary resections with the artiÀcial 
pneumothorax at Tokushima Municipal Hospital 
from May 2010 to February 2011, these patients 
were reviewed retrospectively. At Àrst, under 
single-lung anesthesia, the patient was placed in 
the lateral decubitus position. A 5-mm, 30-degree 
thoracoscope was placed through the seventh 
intercostal space in the midaxillary line. Then 
the artiÀcial pneumothorax was produced at 8-10 
cmH2O using the pneumoperitoneum apparatus. 
And a 2-cm incision was then made in the seventh 
intercostal space in the auscultatory triangle. An 
access thoracotomy was always located in the fourth 
intercostal space in the anterior axillary line (3 cm) 
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P1.261 FEV1 IS NOT A PROGNOSTIC 
MARKER IN OPERATED PATIENTS 
WITH STAGE I OR II NON-SMALL CELL 
LUNG CANCER (NSCLC)
Anouschka Cogen1, Yanina Dockx1, Annelies 
Janssens2, Joost Weyler3, Paul Van Schil1 
1Thoracic And Vascular Surgery, Antwerp University 
Hospital/Belgium, 2Pulmonary Medicine, Antwerp 
University Hospital/Belgium, 3Epidemiology And 
Social Medicine, University Of Antwerp/Belgium
Background: Prognosis of patients with NSCLC 
depends on stage, histology, gender and is also 
determined by other tumor and patient related 
factors. In retrospective studies lung cancer mortality 
was found to be higher in patients with chronic 
obstructive pulmonary disease (COPD) and a forced 
expiratory volume in one second (FEV
1
) < 70% 
(Sekine et all. Association of chronic obstructive 
pulmonary disease and tumor recurrence in patients 
with stage IA lung cancer after complete resection. 
Ann Thorac Surg 2007; 84: 946-51). In the Cher@
Nostrial and the Paccora trials a strong relationship 
was observed between FEV
1
 and overall survival 
(OS) (Germonpré P et al. J Thor Oncol 2007; 2: 
S640. Germonpré P et al. Chicago multisdisciplinary 
symposium in thoracic oncology 2010). These 
studies were based on patients with clinical stage 
III with unresectable disease. In a smaller Japanese 
study FEV
1
 was a prognostic factor for OS in 
operated patients (Nakaljima T, Sekine Y, Yamada 
Y et all. Long-term surgical outcome in patients 
with lung cancer and coexisting severe COPD. 
Thorac Cardiovasc Surg 2009; 57: 339-342). In the 
present study we investigate whether the presence 
of moderate COPD deÀned as a FEV
1
  70% of the 
predictive value, is a prognostic marker in patients 
with resectable stage I and II NSCLC. 
Methods: Study population: 
All relevant clinical information was gathered •  
retrospectively from 77 consecutive patients 
undergoing complete resection between January 
2003 and January 2006. 
All patients were staged according to the 7•  th TNM-
classiÀcation. 
Primary endpoints were OS and progression-free •  
survival (PFS). 
Patients dying within 30 days after the operation •  
were excluded (5 patients). 
None of the patients received systemic •  
Methods: We reviewed all patients (n=663) 
undergoing anatomical lung resection for NSCLC at 
our institution over a 48 month period from January 
2006. Patients underwent staging by CT and PET, 
if indicated, by mediastinoscopy or EBUS. Patients 
without clinical mediastinal nodal disease were 
subjected to anatomical resection.
Results: Of all the patients who had lung resection, 
58 (8.7%) were pN2 [38 male, median age 66 
years (range 43 - 82)]. The majority, 49 underwent 
lobectomy, 9 pneumonectomy and 3 sleeve resection; 
5 patients had concomitant chest wall resection There 
was one death within 30 days of operation (1.7%). 
Postoperative staging showed seven T1, n=38 T2 and 
n=13 T3. All patients were referred to oncologists 
for consideration of adjuvant therapy. Follow up is 
complete for all patients. The median follow up for the 
surviving patients is 818 days. The median survival 
(Kaplan Meier method) was 859 days. Survival at 
one, two and three years being 73%, 51% and 44% , 
respectively. Histology; presence of N1 disease; single 
versus multiple, station or zone N2 disease; resection 
margins and extent of resection were not signiÀcantly 
associated with altered survival. Increasing T stage was 
signiÀcantly associated with poorer survival (p=0.009).
Conclusion: While these data need to mature further 
it seems that surgery can make a contribution to the 
multimodality treatment of low volume mediastinal 
nodal disease. It is time to study the place of surgery 
in the treatment of clinically apparent mediastinal 
nodal disease, especially with an early T stage.
Keyword: surgery in N2 disease
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Methods: 53 lung cancer patients (15 females, 38 
males), without pleural adhesions were enrolled and 
eligible for the study. Three pneumonectomies, 3 
bilobectomies, 47 lobectomies (including 6 VATS 
lobectomies) and 1 anatomical segmentectomy 
were performed. Patients were randomized after 
completion of lung resection and lymphadenectomy. 
In 29 patients from the Tachosil® group 1 to 3 
large pieces of Tachosil (mean 1.8, SD±0.7) were 
applied, while in 24 patients from the control group 
only coagulation was allowed. Clinical data were 
collected, and pleural concentrations of IL-6, IL-
1ra and IL-8 on postoperative days 1, 2 and 3 were 
measured, with ELISA method. 
Results: Both groups were well balanced according 
to sex, age, number of packyears of cigarettes, 
time from smoking cessation, pulmonary function 
test results, concomitant diseases, BMI index and 
perioperative serum concentrations of IL-6, IL-1ra 
and L-8. Postoperative complications occurred in 
8/29 and 12/24 patients from each group (p=0.3), 
respectively, with no mortality. No differences 
in time of surgery, intraoperative blood loss, 
amount of drainage and drainage hemoglobin 
concentration on postoperative days 1, 2 and 3, 
time to drainage removal and number of blood units 
transfused between the groups were observed. The 
total postoperative pleural drainage was lower in 
Tachosil® group (1289.1±641.39, vs. 1987±1462mL, 
p=0.025). There was a positive correlation between 
poor performance status (PS) and the volume of 
postoperative drainage on postoperative days 2 and 
3, as well as total postoperative drainage. Decreased 
IL-6 concentrations in pleural Áuid on the Àrst 
postoperative day correlated with increased drainage 
on the 2nd and the 3rd postoperative days, as well 
as with total postoperative drainage in the whole 
group and in the non-Tachosil® group, but not in 
the Tachosil® group. No signiÀcant differences of 
IL-1ra and IL-8 in pleural Áuid on postoperative 
days 1, 2 and 3 between the groups were observed. 
Concentration of IL-6 in pleural drainage was higher 
in the Tachosil® group on the Àrst (188790 (119135-
290380) vs 104052.5(80286.25-176356.3)pg/mL, 
p=0.01) and the second (117155 (75505-184670) vs 
68205 (43268-113625)pg/mL, p=0.03) postoperative 
days. 
Conclusion: This study did not show any serious 
impact of application of Tachosil® on mediastinum 
after lymphadenectomy on clinical outcome, except 
decreased amount of total postoperative drainage. 
It also showed a signiÀcantly higher concentration 
chemotherapy or radiotherapy before the operation. 
Follow-up information was complete for all •  
patients and ended in July 2010. 
Patients were classiÀed as having a FEV
1
  70% or a 
FEV
1
 > 70%. 
Results: According to the Kaplan Meier analysis 
(log rank test) FEV
1
 was not a signiÀcant prognostic 
factor for OS [p=0.461] (Àg.1) or PFS [p=0.530]. 
In a Cox multiple regression analysis the adjusted 
hazard ratio for FEV
1
 (measured on a continuous 
scale) was 1.632 (p= 0.458) after adjustment for 
stage and age.
Conclusion: In contrast to other studies our data 
show that FEV
1
 is not a prognostic factor in patients 
with resectable stage I and II NSCLC. Precise 
selection criteria regarding cardiopulmonary function 
excluding patients with a very poor cardiopulmonary 
function for surgical therapy, could be responsible 
for this Ànding. 
Keywords: FEV1, prognostic factor, non-small cell 
lung cancer (NSCLC), Overall survival
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P1.262 THE ROLE OF TACHOSIL® IN 
LYMPHOSTASIS AFTER MEDIASTINAL 
LYMPHADENECTOMY IN LUNG 
CANCER PATIENTS.
Tomasz Szczĕsny1, Izabela Kubiszewska2, 
Agnieszka Rybak3, Jacek Michaãkiewicz2, Maria 
Szymankiewicz3, Janusz Kowalewski1 
1Department Of Thoracic Surgery, Oncology Center 
In Bydgoszcz/Poland, 2Department Of Immunology, 
Nicolaus Copernicus University In Torun, Collegium 
Medicum In Bydgoszcz/Poland, 3Oncology Center In 
Bydgoszcz/Poland
Background: Final results of prospective randomized 
study to assess the inÁuence of Tachosil® applied on 
mediastinum after lymphadenectomy are presented.
S876 Copyright © 2011 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology t Volume 6, Number 6, Supplement 2, June 2011 14th World Conference on Lung Cancer
65.4% and 44.6%, respectively.
Conclusion: ASC was found more frequently in older 
patients. Compared with AC patients, ASC patients 
had worse pathological stage and poor prognosis.
Keyword: adenosquamous cell carcinoma
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.264 NEW SURGICAL STRATEGY FOR 
STAGE III THYMOMA COMBINED WITH 
VIDEO-ASSISTED THORACIC SURGERY
Kyoji Hirai 
Division Of Thoracic Surgery, Nippon Medical 
School Chiba Hokusou Hospital/Japan
Background: Whether thoracoscopic surgical 
treatment is acceptable for invasive thymoma 
remains to be still controversial. We performed the 
video-assisted thoracoscopic surgery for Masaoka 
stage III thymoma invaded to adjacent organs 
after acquisition of the patient permission. We 
examined the feasibility of modiÀed video-assissted 
thoracoscopic thymectomy (MVAT-T) with lateral 
thoracotomy for Masaoka stage III thymoma. We 
demonstrate the outcomes of the resected cases and 
introduce our representative operations. 
Methods: We evaluated the short-term outcomes of 
8 cases undergoing surgery for stage III thymomas 
without myasthenia gravis between Jan 2007 and 
Dec 2010. A part of stage III thymomas occurred in 
lower pole of the thymus, which locally invaded the 
lung, the pericardium and the left brachiocephalic 
vein was selected for this technique. Of these, 5 
cases were operated via right thoracic cavity, and 3 
cases were operated via left thoracic cavity. Lateral 
thoracotomy was done at fourth or Àfth intercostal 
space. One or two thoracoscopic ports were inserted 
at sixth or seventh intercostal space on the anterior 
axillary line. We inserted unilateral hand into thoracic 
cavity adequately and touched the tumor directly 
under thoracoscopic vision. As for surgical treatment 
of upper pole of thymus, all cases were carried out 
using chest wall lifting method by the kirchner wires 
inserted under the skin on the sternum. 
Results: Complete follow-up data were available 
in 8 patients (4 females, and ages ranged from 46 to 
74 years with a mean age of 58.5). Mean operative 
of IL-6 in pleural Áuid on postoperative day 1 
and 2, which may be the result of local immune 
response to Tachosil®, without signiÀcant impact on 
postoperative complications. 
Keywords: Lung cancer, Tachosil, mediastinal 
lymphadenectomy
A revised/updated abstract may be included in 
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P1.263 CLINICOPATHOLOGICAL 
FEATURES OF RESECTED 
ADENOSQUAMOUS CELL CARCINOMA 
OF THE LUNG.
Yoshinori Shitara1, Kouhei Tajima2, Masatoshi 
Ishizaki2, Toshiki Yajima3, Shigebumi Tanaka3, 
Hiroyuki Kuwano4 
1Surgery, Fujioka General Hospital/Japan, 2Fujioka 
General Hospital/Japan, 3Isesaki Municipal 
Hospital/Japan, 4General Surgical Science, Gunma 
University/Japan
Background: Primary adenosquamous cell 
carcinoma(ASC) of the lung is a rare disease. The 
purpose of this retrospective study is to investigate 
the clinicopathological features of resected ASC lung 
cancer patients.
Methods: From September 1997 to December 2010, 
20 patients with ASC of the lung underwent pulmonary 
resection. ASC represented 3.1% of the 651 patients. 
We investigated the clinicopathological features of ASC 
patients and compared with 352 adenocarcinoma(AC) 
patients and 227 squamous cell carcinoma(SC) patients 
underwent pulmonary resection.
Results: ASC patients consisted of 14 male and 6 
female with a mean age of 71 years old. The surgical 
procedures comprised 15 lobectomies and 5 sublober 
resections (two segmentectomies, three wedge 
resections). Four patients had pathological stage IA, 
5 patients had stage IB, 2 patients had stage IIA, 5 
patients had stage IIIA, 3 patients had stage IIIB, 
and one patient had stage IV. Median tumor size was 
38.1mm in length. Nine patients had lymphnodes 
metastases. Median follow-up was 30.1 months. 
The overall 5-year survival rate of ASC patients 
was 38.2%. Mean age of both AC patients and 
SC patients were 67 years old. The overall 5-year 
survival rates of AC patients and SC patients were 
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Methods: Retrospective analyses were performed 
of all patients who underwent surgical resection 
after neoadjuvant chemoradiation therapy for stage 
IIIA-N2 non-small cell lung cancer from 1998 to 
2007. The chemotherapy regimens consisted of 
weekly paclitaxel plus cisplatin or weekly paclitaxel 
plus carboplatin for 5 weeks. Concurrent thoracic 
radiotherapy dose was 45 Gy over 5 weeks. Surgical 
resection was planned at around 4 weeks following 
the completion of neoadjuvant therapy. 
Results: Of 186 patients who underwent 
neoadjuvant therapy, 23 bilobectomies, 28 
pneumonectomies, and 135 lobectomies were 
performed. Early postoperative mortality rate (within 
30 days after operation) was 7.1%, 8.7%, and 1.5% 
in pneumonectomy, bilobectomy, and lobectomy, 
respectively. In addition to, late postoperative 
mortality rate (within 90 days) of lobectomy, 
bilobectomy, and pneumonectomy were 5.9%, 
13% and 10.7%, respectively. Overall survival 
was signiÀcantly higher among patients treated by 
lobectomy than among those treated by bilobectomy 
(p=.041) or pneumonectomy (p=.010) (Fig 1). 
Recurrence was signiÀcantly lower among patients 
treated by lobectomy than among those treated by 
pneumonectomy (p=.034) (Fig 2). 
Conclusion: Bilobectomy carries high operative 
mortality and poor longterm survival after 
neoadjuvant concurrent chemoradiotherapy for stage 
IIIA-N2 non-small cell lung cancer. Outcomes of 
bilobectomy were similar as pneumonectomy in 
terms of overall survival, disease-free survival, and 
postoperative mortality 
Keywords: Lung cancer, Surgery, Neoadjuvant 
Treatment
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P1.266 OBSERVATION ON EFFECT OF 
INTERCOSTAL NERVES FREEZING 
FOR ELDERLY PATIENTS UNDERGONE 
CHEST OPERATION
Lei Liu 
Thoracic Surgery, China Capital University 
Hospital/China
Background: To investigate the clinical effect 
of intercostal nerves freezing for elderly patients 
undergone chest operation 
Methods: Collect and analyze the postoperative 
pain situation and complications of more than 200 
duration was 212 minutes (range, 160 to 265 
minutes) . The median postoperative hospital stay 
was 7.5 days. The pathological examinaton showed 
that type AB was in two cases, type B1 in three 
cases, and type B2 in three cases. In all cases tumor 
cells at surgical margin and in postoperative pleural 
effusion could not be found. Postoperative radiation 
therapy was carried out in four cases. At a median 
follow-up of 2.1 ± 0.7 years (range, 0.6-3.8 years) 
, there was no recurrence on enhanced CTor PET/
CT. No patient in this group underwent conversion to 
median sternotomy. No severe surgical complications 
and postoperative complications were detected. 
Conclusion: The operative wound and postoperative 
ADL was very satisfactory to all patients. For 
females, compared with median sternotomy, this 
technique decreases mental stress of operation and 
gives superior cosmesis. These results suggest that 
MVAT-T for a part of stage III thymomas is safe 
and may confer some advantages over conventional 
methods of standard median sternotomy. However, 
this technique requires further investigation in a large 
series with a long-term follow-up data. 
Keywords: video-assisted thoracic surgery, 
Thymoma
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P1.265 RISK OF BILOBECTOMY 
AFTER NEOADJUVANT CONCURRENT 
CHEMORADIOTHERAPY FOR STAGE 
IIIA-N2 NON-SMALL CELL LUNG 
CANCER
Jong Ho Cho1, Hong Kwan Kim2, Jhingook Kim2, 
Yong Soo Choi2, Kwhanmien Kim2, Young Mog 
Shim2, Keunchil Park3, Yong Chan Ahn4 
1Thoracic And Cardiovascular Surgery, Samsung 
Medical Center/Korea, 2Department Of Thoracic 
And Cardiovascular Surgery, Samsung Medical 
Center/Korea, 3Division Of Hematology-oncology, 
Department Of Medicine, Samsung Medical Center/
Korea, 4Department Of Radiation Oncology, 
Samsung Medical Center/Korea
Background: The aim of this study was to evaluate 
the outcomes of surgical resection, especially 
bilobectomy, after chemoradiation therapy. 
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Results: 12 patients were converted to thoracotomy, 
thoracotomy rate was 2.5% (12/475). The operation 
time was 80 to 410mins, the average was 195mins; 
intraoperative bleeding was 50ml to 1600ml, average 
was 356ml, and intraoperative blood transfusion 
were taken in 64 patients. Postoperative drainage 
was 70ml to 2100ml, average was 420ml. Extubation 
time was 1 day to 10 days, average was 4.3 days. 
The number of stapple was 3 to 16, average was 6.5. 
Intraoperative lymph node dissection was 3 groups 
to 7 groups and 3 nodes to 34 nodes, average was 5.4 
groups and 12.8 nodes respectively. Serious air leak 
of bronchial stump was found and sutured during 
operation in 2 cases.Patients started to walk on the 
Àrst day after surgery,and the postoperative hospital 
stay was 3 days to 25 days, 9.7 days on average. 
No patient died during the surgery. Cardiovascular-
related complications occurred within Àrst week 
in 17 cases, Àberoptic bronchoscopy sputum 
suction in 23 cases, pulmonary infection in 12 
cases, chylothorax in 4 cases, 1 patient underwent 
thoracoscopic repair after 8 days of surgery due to 
bronchopleural Àstula,and two cases of right upper 
lobectomy had implemented middle lobectomy 
due to the middle lobe reverse within 2 weeks after 
operation, pumping pleural effusion in 11 cases, 
postoperative complication rate was 15% (70/475). 
One case with bilateral VATS died of respiratory 
failure owing to pulmonary hemorrhage on 21 day 
after surgery, and perioperative mortality was 0.2% 
(1/475); one case underwent radiotherapy because of 
wound tumor recurrence 3 months later and made an 
improvement. Patients with pathological TNM stage 
II and above were treated by conventional adjuvant 
chemotherapy. 
Conclusion: VATS lobectomy for lung cancer with 
less trauma and faster recovery, fewer complications, 
can be applied to patients with stage I, II or part 
of stage III,and even some stage IV patients 
with isolated brain metastases after gamma knife 
treatment. 
Keyword: VATS; Lobectomy; Lymph Node 
Dissection; Lung Cancer
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
cases of elderly patients ,who have received chest 
operation in our hospital since 2006. 
Results: Among all the cases ,the patients who 
received intercostal nerves freezing feel pain relief 
the ratio of total 86% .Received routine methods 
including taking analgesic drugs or muscle and 
intravenous anesthesia class analgesics the patients 
feel pain relief the ratio of total 68%.And the Àrst 
group’s adverse effects and complications have 
signiÀcantly reduced . 
Conclusion: For elderly patients open-chest surgery 
is concerned, intercostal nerves freezing technology 
in alleviate postoperative pain, curative effect really, 
simple operation, post-operative fewer adverse 
effects, the proposal is in thoracic Àeld widely used. 
Keyword: intercostal nerves freezing
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P1.267 CLINICAL ANALYSIS OF 475 
CASES OF VATS LOBECTOMY FOR 
LUNG CANCER
Li Wen-Tao 
Department Of Thoracic Surgery, Shanghai 
Pulmonary Hospital,tongji University/China
Background: To evaluate the feasibility of the 
implementation of complete resection by VATS 
for lung cancer, analysising of issues such as their 
surgical procedure, indications, intraoperative lymph 
node dissection, operative time, blood loss and 
postoperative complications, etc. 
Methods: From July 2007 to February 2010, 475 
cases of VATS complete resection for lung cancer 
were implemented, of which 250 male cases, 225 
female cases, aged from 27 to 89 years old, mean 
59.42 years old. Surgical procedure: right upper lobe 
resection of 143 cases, right lower lung resection of 
103 cases, right middle lobe resection of 32 cases, 
right middle-upper lobe resection of 2 cases, right 
middle-lower of 7 cases, left upper lobe resection of 
101 cases, lingular lobectomy of 2 cases, left lower 
lobe resection of 81 cases, bilateral lobectomy of 4 
cases. All patients were treated with routine systemic 
mediastinal lymph node dissection which including 
level 2,3a,3p,4,7,8 9,10,11 in the right side and level 
4,5,6,7,8,9,10,11 in the left side.
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were no differences in the risk of having a metastasis 
vs a new primary tumor (OR 0,2000, CI 1,8609 to 
0,0215, p = 0,1573). Prevalence of malignant SPN 
according to the antecedent of a previous malignancy 
No previous 
malignancy 
Previous lung 
cancer 
Previous 
extrapulmonary 
malignancy 
Total 
Benign SPN 120 (29%) 6 (50%) 15 (36,3%) 141 (29,2%) 
Malignant SPN 294 (71.0%) 6 (50%) 42 (73,6%) 342 (70,8%) 
Total 414 12 57 483 
Conclusion: The occurrence of an SPN in the setting 
of a patient with a history of extrapulmonary cancer 
cannot be automatically considered a lung metastasis 
as often represents a primary lung tumor rather than 
a metastasis.
Keywords: Solitary pulmonary nodule, Lung cancer, 
LUNG METASTASIS
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P1.269 APPROACH TO METASTASIS-
SUSPECTED NODULE IN OTHERWISE 
OPERABLE NON-SMALL CELL LUNG 
CANCER
Sumin Shin1, Joon Suk Park2, Hong Kwan Kim1, 
Yong Soo Choi1, Kwhanmien Kim1, Young Mog 
Shim1, Jhingook Kim1 
1Departement Of Thoracic And Cardiovascular 
Surgery, Samsung Medical Center/Korea, 
2Department Of Thoracic And Cardiovascular 
Surgery, Samsung Medical Center/Korea
Background: Although the seventh edition of 
the lung cancer staging system draws attention to 
the synchronous additional pulmonary nodules in 
patients with non-small cell lung cancer (NSCLC), 
it doesn’t clarify how to approach to these patients. 
We retrospectively reviewed radiologic features and 
pathologic diagnoses of additional solid pulmonary 
nodule with otherwise operable non-small cell lung 
cancer. 
Methods: From January 2003 to December 2007, 
77 patients who had operable NSCLC, only except 
suspected pulmonary metastasis in non-primary 
lobe, underwent lung resections. We retrospectively 
reviewed radiologic features and pathologic 
diagnoses, clinical results.
Results: In 45 patients, suspected nodules were 
pathologically conÀrmed by lung resection with 
or without curative intent. In 32 patients in whom 
Poster Session 1 – Surgery Monday, 4 July 2011 12:15-14:15
P1.268 SOLITARY PULMONARY 
NODULES IN PATIENTS WITH A 
HISTORY OF PREVIOUS MALIGNANCY
Gustavo A. Lyons1, Silvia Quadrelli2, Domingo J. 
Chimondeguy1, Felipe Chertcoff2, Carlos Silva3, 
Pablo Jordan2, Karina Vera3 
1Thoracic Surgery, Buenos Aires British Hospital/
Argentina, 2Respiratory Medicine, Buenos Aires 
British Hospital/Argentina, 3Oncology, Buenos Aires 
British Hospital/Argentina
Background: The Ànding of nodules in patients 
already diagnosed with cancer poses a clinical 
dilemma. Such nodules may represent scarring, 
metastatic disease, or new previously unknown 
primary tumours. The objectives of this study were 
to determine the probability of malignancy in a 
pulmonary nodule in the setting of a history of 
previous cancer and identify factors that may alter 
such probability.
Methods: All patients undergoing pulmonary 
resection with of a solitary pulmonary nodule (SPN) 
in the British Hospital in Buenos Aires between 
January 1986 and January 2007 were eligible for 
inclusion in this retrospective study. Based on cancer 
history, patients were grouped as having no history 
of malignancy; history of lung cancer; or history of 
extrapulmonary cancer.
Results: Four hundred and eighty three patients 
(483) with SPN were included. Sixty nine (14.2%) 
had a history of a previous malignancy. Among 
all the 483 patients (age 52,2 ± 18,9 years, 37,1% 
female) 70,8% were malignant. Lung was the 
most prevalent malignancy among the malignant 
SPN (n = 305, 89,2%). Patients with a malignant 
SPN were slightly older (55,4 ±19,3 vs 51,4 ± 
17,8 year-old, p = 0,035) and had a larger SPN ( 
2,18 ±1,8 vs 1,39 ± 0,7cm , p =0,001 ) In a logistic 
regression model the antecedent of a previous 
malignancy did not increase the risk of having a 
malignant SPN (OR 0,8638, CI 0,4887 to 1,5269, p 
= 0,6144). However, being older than 60 (OR 1,634 
CI 1,0909 to 2,4485, p = 0,017) and a SPN  2 cm 
(OR 2,4196, CI 1,3920 to 4,2059, p = 0,00171) had 
a signiÀcantly higher risk of Ànding a malignant 
SPN. Forty-two of the 57 patients with a previous 
extrapulmonary malignancy had a malignant SPN, 
21 (50%) of them were new primaries. If patients 
with a previous lung cancer were compared with any 
other previous extrapulmonary malignancy there 
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Results: Histologic analysis revealed lung cancers 
in 65 patients (including adenocarcinoma in 33 
patients, squamous cell carcinoma in 19, carcinoid 
in 5 small cell lung cancer in 3, adeno-squamous 
carcinoma in 3, large cell lung cancer in 2), benign 
lesions in 19 patients ( includeing tuberculoma in 
6 , inÁammatory pseudotumor in 5, harmatoma 
in 5, sclerosing hemangioma in 3). The accuracy, 
sensitivity, speciÀcity of PET/CT for diagnosing 
lung cancer were 83.3% 70/84‰, 86.2% 56/65 
‰and 73.7% 14/19 ‰, respectively; compared with 
75.0%(63/84 ‰, 78.5% 51/65 ‰, 63.1% 12/19 ‰for 
CT (P=0.55, 0.12, 0.63, respectively); No signiÀcant 
difference was seen between PET/CT and CT. The 
sensitivity, speciï¬city, accuracy of PET/CT for 
lymph nodes were 80.3%(57/71), 83.7%(297/355), 
83.1%(354/426), respectively; compared with 
62.0%(297/355), 70.4%(250/355), 69.0%(294/426) 
for CT (P= 0.03, 0.000, 0.005, respectively. 
Preoperative nodal staging was compared with 
postoperative histopathological staging, 81.5% (53 
of 65) of patients correctly staged, 12.3% (8 of 65) 
of patients were overstaged, and 6.2% (4 of 65) 
were understaged by PET/CT, while those values for 
CT were 58.5% (38 of 65), 24.6% (16 of 65), and 
6.2% (11 of 65), respectively. Eight patients being 
overstaged and 10 petients being understaged on 
CT were corrected by PET/CT. One patients being 
overstaged and 2 petients being understaged on 
PET/CT were corrected by CT. Seven patient being 
overstaged and 1 petient being understaged both on 
CT and PET/CT. The SUVmax for the 65 NSCLC 
was 4.12± 2.05 0.52-8.46 ‰, and the Ki67 were 
41.29±15.59% 16%-83%. The 11C-CH uptakes 
showed a signiÀcant correlation with Ki-67 staining 
scores (r=0.505 p=0.002). 
Conclusion: The value of diagnosing pulmonary 
leision by CH PET/CT was not signiÀcant high 
than enhanced CT;however, CH PET/CT improves 
the value in the assessment of locoregional lymph 
nodes, and provides more accurate nodal staging. 
SUV-indexed CH metabolic activity correlated 
signiÀcantly with proliferative activity (Ki67 
expression). 
Keyword: Keywords: 11C-choline PET; CT; lung 
cancer; Lymph node metastasis; Ki67
pathologic diagnosis was unavailable, curative 
resection for primary tumor was performed and 
suspected lesion was carefully monitored by regular 
follow-up CT scan. As a result, 13 patients were 
Ànally diagnosed to have had true metastasis. The 
accuracy of radiologic diagnosis of pulmonary 
metastasis was 16.9%. Tumors were located in 
the ipsilateral different lobe in 10 patients and 
contralateral in 2, and bilateral in 1 patient. The 
overall survival rate in patients with true metastasis 
was 38.5% and mean survival was 32.6 months(1.7 
months ~ 68.4 months). 
Conclusion: The radiologic diagnosis of pulmonary 
metastasis was not always reliable, and can deprive 
patients of the opportunity of curative resection. 
When an additional nodule is detected in otherwise 
operable lung cancer, aggressive approach for 
pathological assessment should be considered. 
Keywords: Non-small cell lung cancer, Radiologic 
features, Pathologic diagnoses, Surgery
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P1.270 VALUE OF 11C-CHOLINE PET/CT 
IN THE EVALUATION OF DIAGNOSIS 
AND STAGING IN LUNG CANCER.
Zhongmin Peng1, Meng Li2, Qi Liu2, Sun Jian2, Qi 
Liu3 
1Thoracic Surgery, Provincial Hospital AfÀliated 
To Shandong University/China, 2Department Of 
Thoracic Surgery, Provincial Hospital AfÀliated 
To Shandong University/China, 3Cancer Center, 
Provincial Hospital AfÀliated To Shandong 
University/China
Background: The aim of this study was to 
evaluate the value of diagnosis and staging of 
11C-choline(CH) PET/CT images in the patients with 
lung cancer, and evaluating its tumor aggressiveness. 
11C -CH-PET and enhanced CT were compared. 
Methods: From June 2007 to Feb 2010, 84 
potentially operable patients with proven or 
suspected non-small cell lung cancer underwent 
integrated PET/CT and CT scans followed by 
surgical nodal staging. The results of reviewing PET/
CT and enhanced CT images for the locoregional 
lymph node metastasis were compared in relation 
to pathologic ï¬ndings. The 11C-CH uptakes were 
examined to determine the relationship with the 
proliferative activity determined by Ki-67 staining 
score. 
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suture line of the bronchus (sutured with tantalum 
staples or synthetic sutures). This prevents infectious 
spreading into peribronchial tissues and pleural 
cavity, improves bronchial stump healing due to 
omentum plastic properties and thus, is an effective 
for prevention of Àstulae development following 
pneumonectomy.
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.272 CLINICAL OUTCOMES IN 
COMPLETION PNEUMONECTOMY 
FOR CANCER: A RETROSPECTIVE 
MULTICENTRIC STUDY ABOUT 46 
CASES.
Mayeul Tabutin1, Sebastien Couraud2, Benoit 
Guibert2, Pierre Mulsant2, Pierre Jean Souquet2, 
François Tronc3 
1Chirurgie Thoracique, Hopital Louis Pradel/
France, 2Hôpital Lyon-sud/France, 3Hôpital Louis 
Pradel/France
Background: Aims of the study are to describe 
postoperative complications and long term results 
of completion pneumonectomy and to highlight 
prognostic factors. 
Methods: We retrospectively reviewed 46 patients 
operated of completion pneumonectomy for cancer 
between 1995 and 2009, in two thoracic surgery 
departments (38 men, 8 women). 89% were current 
or former smokers. Among those, 57% quit smoking 
at least one year before completion surgery. At 
surgery, mean age was 59years (ranged 38 to 79). 
Most of patients did not undergo chemotherapy 
(76%) or radiotherapy (83%) before surgery. Surgery 
was performed mainly on the right lung (61%). 
Bronchial stump was covered for 17 patients, 59% 
underwent an intrapericardic technique, and none 
had parietal or vascular resection. 
Results: Complications after surgery were 
respiratory failure (15%), bronchopleural Àstula 
(13%, with no preference according to the side) and 
empyema (13%). Blood transfusion (preoperative or 
post-operative) was necessary for 45% (average of 
2 blood packs). Day30 death rate was 13% (n = 6). 
Postoperative staging showed mostly limited disease: 
79.5% T2 or less and 87% N1 or less. Twenty eight 
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P1.271 BRONCHIAL STUMP 
INSUFFICIENCY FOLLOWING 
PNEUMONECTOMY FOR LUNG 
CANCER
Vladimir Porhanov1, Igor Polyakov2, Nikolay 
Naryzhny2 
1Cardiothoracic Surgery Center/Russian Federation, 
2Oncological Department, Cardiothoracic Surgery 
Center/Russian Federation
Background: Fistula development following lobar 
resections and pneumonectomies accounts for 
0,5 - 3% and 1-20%, respectively. One of the most 
common and severe complications is bronchial 
stump insufÀciency (8-20%). We analyzed different 
methods of treatment and preventive care for main 
bronchus stump following pneumonectomy.
Methods: We studied history reports of 484 patients, 
treated from 2002 to 2009, all of them were operated 
on for pneumonectomy. Age range was 18 - 75 
years, mean age was 56 years. In 169 cases we 
performed right-sided pneumonectomies (34,9%), 
left pneumonectomies were performed in 314 
(65,1%) patients. Pneumonectomies were performed 
via thoracotomy approach in 454 and in 30 cases 
via sternotomy. All patients underwent systematic 
lymph node dissection. And in patients operated via 
transsternal approach we performed bilateral lymph 
node dissection. In all cases with thoracotomy, right 
main bronchus stump was covered with a pericardial 
Áap with a vascular pedicle. In patients operated 
on via transsternal approach with bilateral lymph 
node dissection and high risk of development of 
main bronchus stump insufÀciency (21 patients) we 
carried out covering of main bronchus with omentum 
(pedicled vascular Áaps). After the main surgical 
stage completion, we performed superior-median 
laparotomy with retrosternal omentum carrying and 
covering of main bronchus stump or anastomosis. 
This technique was applied in 9 cases for BPF with 
transsternal occlusion, left in 7 cases and right in two 
cases.
Results: Main bronchial stump Àstula developed 
in 23 of 484 patients (4,7%), of those 13 had right-
sided Àstulae and 5 were found to have left-sided 
Àstulae. This technique showed deÀnite beneÀt as a 
rate of BPF development was reduced to 3,3%. Total 
mortality rate was 4,3%.
Conclusion: While performing this technique we 
safely cover a line of bronchial transsection and a 
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patients (84.3%), Bilobectomy in 14 (5.6%) and 
pneumonectomy in 25 (10.1%). The most common 
histology was squamous cell carcinoma (117 patients, 
47.2%). Adenocarcinoma was in 96 patients (38.7%) 
and other type of histology was in 35 patients 
(14.1%). Thirty three patients (71.7%) of 46 pN2 
patients had the single zone metastasis, 13 patients 
(28.3%) had multiple zone metastases over two nodal 
zone metastasis. The 5-year disease free survival 
rates were 58% in pN0, 39% in pN1, and 30% in 
pN2. The disease free survival was signiÀcantly 
better in pN0 compared with pN1 or pN2 (p = 0.030 
and p = 0.000). However, there was no statistically 
signiÀcant differences between pN1 and pN2 (p = 
0.326). The 5-year disease free survival rates was 
29% in the single zone metastasis and 30% in the 
multiple zone metastasis group (p = 0.635). There 
were no statistically differences between two groups. 
Recurrences occurred in 91 patients (36.7%). Loco-
regional recurrences were in 46 patients (18.5%), and 
distant recurrences were in 45 patients (18.1%). Loco- 
regional recurrence most commonly occurred in post 
operative pathologic N1 patient’s group (20 (37.0%) 
of 54 patients), and distant recurrence most commonly 
occurred in post operative pathologic N2 patient’s 
group (22 (47.8%) of 46 patients). 
Conclusion: The 5 year disease free survival of 
patients of unsuspected N2 disease who underwent 
complete resection was statistically similar with 
pathological N1 disease in this study. The beneÀt of 
chemotherapy in these patients was still unproven. 
Therefore, a prospective randomized analysis for 
conÀrming the beneÀt of surgery or chemotherapy in 
patients with unsuspected N2 disease is needed
Keywords: Non-small cell lung cancer, unsuspected 
N2 disease
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.274 CLINICAL EXAMINATION 
OF PRIMARY LUNG CANCER IN 
OCTOGENARIAN
Satoshi Yamamoto1, Katsunobu Kawahara2, Shinichi 
Yamashita2, Michiyo Miyawaki2, Keita Tokuishi2 
1Sergery Ii, Oita University Faculty Of Medicine/
Japan, 2Surgery Ii, Oita University Faculty Of 
Medicine/Japan
patients (61%) were operated for a second or primary 
cancer, 16 for local recurrence (35%), including 
4 for microscopically incomplete resection, 2 for 
metastases (4%). After completion, 31% patients 
had adjuvant treatment. Median overall survival 
after completion surgery is 30,4months. Among 15 
patients alive (33%), 11 are free of disease (24%). In 
a Cox regression model, factors inÁuencing overall 
survival are age up to 65 years old (OR = 2,47 [1,1-
5,4], p=.012) and being a current smoker (OR=2,285 
[1,07-4,88], p=.033). There was no signiÀcant 
inÁuence on prognosis of demographical data, co 
morbidities, disease stage, or technical used. 
Conclusion: Despite increased postoperative 
complications and mortality, compared to standard 
pneumonectomy, completion pneumonectomy has 
encouraging long term results. Two main factors 
appear predictive of better overall survival: age less 
than 65 years, having quit smoking since at least one 
year before surgery. 
Keywords: completion pneumonectomy, Cancer, 
Surgery, Morbidity
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P1.273 SURVIVAL OF PATIENTS WITH 
UNSUSPECTED N2 (STAGE IIIA) NON-
SMALL CELL LUNG CANCER
Chang Kwon Park1, Deok Heon Lee2 
1Thoracic Surgery, Dongsan Medical Center, 
Keimyung University/Korea, 2Thoracic Surgery, 
Donsan Medical Center Keimyung University/Korea
Background: The aim of this study was to determine 
the survival of patients (unsuspected N2 disease) 
who were preoperatively diagnosed with negative 
N2 lymph node, but postoperatively conÀrmed as N2 
node positive by pathological evaluation
Methods: Between May 1994 and December 2009, 
we retrospectively reviewed the hospital records of 
248 patients with primary non-small cell lung cancer 
who underwent pulmonary resection and mediastinal 
lymphadenectomy at our hospital. All patients were 
preoperatively diagnosed with negative of N2 lymph 
node. 148 (59.7%) patients were in pathological N0, 
54 (21.8%) were in pathological N1 and 46 (18.5%) 
were in pathological N2 after the surgery. 
Results: There were 175 males (70.6%) and 73 
females (29.4%) and, with mean age of 62.3 ± 
9.4 years. The mean follow-up period was 36.1 ± 
31.5 months. Lobectomy was performed in 209 
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P1.275 INTRAOPERATIVE INJECTION 
OF 99MTC-NEOMANNOSYL HUMAN 
SERUM ALBUMIN (99MTC-MSA) FOR 
SENTINEL NODE IDENTIFICATION IN 
LUNG CANCER: COMPARISON WITH 
99MTC-PHYTATE
Hyun Koo Kim1, Sungeun Kim2, Jae Min Jeong3, 
Young Ho Choi1 
1Thoracic And Cardiovascular Surgery, College Of 
Medicine, Korea University Guro Hospital/Korea, 
2Nuclear Medicine, College Of Medicine, Korea 
University Guro Hospital/Korea, 3Nuclear Medicine, 
College Of Medicine, Seoul National University 
Hospital/Korea
Background: A novel radiotracer (Technetium-99m 
neomannosyl human serum albumin, 99mTc-MSA) 
can pass quickly through lymphatics and stay longer 
in sentinel lymph node due to its small size and 
receptor-binding property. The aim of this study was 
to compare the intraoperative injection of 99mTc-MSA 
between 99mTc-phytate for sentinel node mapping in 
patients with early stage non-small cell lung cancer. 
Methods: One-hundred and six patients (73 men, 
33 women; mean age 63.0±9.3 years) that were 
candidates for lobectomy with mediastinal lymph 
node dissection for clinical stage I non-small cell 
lung cancer were enrolled. 99mTc- MSA or 99mTc-
phytate was administered at the peri-tumor region 
soon after thoracotomy. The radioactive lymph nodes 
were identiÀed with a handheld gamma probe after 
lymph node dissection (ex vivo). 
Results: The patient’s age and the sex ratio of both 
groups were similar. The tumor size, pathology, 
clinical stage, and tumor location did not differ. 
The total number of dissected lymph nodes was not 
different (22.5±10.65 in MSA group, 20.2±12.28 
in phytate group, p=NS). The sentinel nodes were 
detected in 56 of the 57 patients (98.2%) in MSA 
group and 44 of the 49 patients (89.8%) in phytate 
group (p<0.05). The number of sentinel nodes per 
patient did not differ (2.2±1.21 in MSA group, 
2.1±1.41 in phytate group, p=NS). False-negative 
sentinel lymph nodes were not detected (0/13, 0%) 
among the 13 patients with pathologic N1 or N2 
disease in MSA group and two (2/12, 16.7%) of 
the 12 patients with pathologic N1 or N2 disease in 
phytate group (p<0.05).
Conclusion: Intraoperative injection of 99mTc-MSA can 
be a better choice than 99mTc-phytate for identiÀcation 
Background: The high age population has been 
increase in Japan. We have performed lung 
resection for the octogenarian patients. In this 
study, we try to exam of clinical outcome in the 
population.
Methods: In 2004 – 2010, we performed lung 
resection for 466 primary lung cancer patients. 
In those patients, 46(9.9%) were octogenarian 
population. 
Results: The range of age is 80-90 year old, the 
average is 82.5 year old. Performance status of 
all ectogenarian patients is 0-I. The each clinical 
stage of those patients were c-IA: 20 cases (43.4%), 
IIA: 16 cases (34.8%), IIB: 5 cases (10.9%), IIIA: 
5 cases (10.9%). The performed operations were 
lobectomy for 26 cases (56.5%), bi-lobectomy 
for one case (2.2%), segmentectomy for 9 cases 
(19.6%), partial resection for 10 cases (21.7%). 
The eight patients of those 46 patients had any 
preoperative complication. 6 patients had Chronic 
Obstructive Lung Disease (COLD), one patient 
had pneumoconiosis, one patient had heart failure. 
The seven patients had postoperative complication. 
Pulmonary complication occurred for four patients, 
thoracic hematoma, Interstitial pneumonia (IP) 
and prolonged thoracic effusion (8days) were 
occurred each one patient. Four patients were died 
without primary disease on 1504, 1001, 449, 330 
postoperative days. The remaining patients are Àne 
without lung cancer recurrence.
Conclusion: The lung resection for the good 
performance octogenarian primary lung cancer 
patients is safety operation and the oncological 
outcome is feasible. However, the preoperative 
complication rate in the octogenarian is gradually 
high, so there is careful observation after surgical 
treatment in long term.
Keywords: Octogenarian, Complication, lung 
resection
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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Background: Surgical criteria for pulmonary 
metastasectomy of colorectal cancer have been 
extended nowadays by the development of surgical 
and anesthetic technique. We have also expanded 
the surgical criteria, case with bilateral pulmonary 
metastases, multiple metastases(more than 3 lesions), 
with concomitant extra-thoracic metastasis, or 
with local recurrence, which were contraindication 
historically, were all indication if all lesions will be 
resected by planned procedure, or all extra-thoracic 
or local disease will be resected another procedure or 
controlled another modality in our rule. However, the 
signiÀcance of extension of surgical criteria has not 
been well discussed. 
Methods: This study was retrospective analysis 
from our clinical data base and clinical charts. 
From January 2003 to June 2010, a total of 132 
patients underwent pulmonary metastasectomy 
of colorectal cancer in our hospital. We reviewed 
the results of surgical resection, and analyzed the 
results of overall survival, disease free survival 
and the pattern of recurrence. Overall and disease 
free survival were calculated from the date of 
pulmonary metastasectomy. Median follow-up 
period was 32.9 months. We divided patients in 3 
subgroups for comparison of surgical criteria. Group 
A: standard criteria, classical Thomford’s criteria, 
Group B: Extended criteria, more than 3 pulmonary 
metastases, with extra-thoracic lesion or with local 
recurrence which will be controlled by surgery or 
another treatment, Group C: convert case, a case 
of initially in-operable and conversion to surgery 
after chemotherapy. The statistical analysis was 
performed by SPSS software and survival estimates 
were achieved using the Kaplan-Meier method. 
The signiÀcant differences between subgroup were 
calculated using the log-rank test. 
Results: There were 81 men and 51 women, median 
age was 64-year old. There were 105 patients in 
Group A, 11 in Group B, 16 in Group C. In all 
patients, 3, 5-year overall survival and disease 
free survival were 92.0 %, 64.8%, 51.9 %, 43.6 % 
respectively. In subgroups, 5-year overall survival 
of Group A, B, C were 65.8 %, 83.3 %, 47.6 % 
respectively (p=0.2655). 5-year disease free survival 
of Group A, B, C were 46.0 %, 48.0 %, 22.2 % 
respectively (p=0.0016). There was signiÀcant 
difference between Group A / B and C, but not 
between Group A and B. In Group C, recurrence rate 
was relative high, however, overall median survival 
was 54.3 months. This result is not inferior to that of 
conversion surgery of liver metastases. 
of the sentinel node in lung cancer patients.
Keywords: Lung cancer, Mediastinal lymph node 
dissection, Sentinel lymph node
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P1.276 MAJOR LUNG RESECTION FOR 
THE TREATMENT OF LUNG CANCER IN 
OCTOGENARIAN PATIENTS
Donghong Chen 
Thoracic Surgery, Beijing Lung Cancer Center, 
Capital Medical University/China
Background: To explore the clinical characteristics of 
bronchial carcinoma in elder patients and determine 
the operative indication, surgical technique, and 
management in the perioperative period.
Methods: From January 2005 to July 2010, 16 
patients with bronchial carcinoma aged 80 and over 
received major pulmonary resection through muscle 
sparing mini-thoracotomy. The operative procedures 
were lobectomy(8 cases), bilobectomy(3cases), 
sleeve lobectomy(2cases), pneumonectomy(1 
cases),and lobectomy plus wedge resection(2cases). 
Clinical data were analyzed retrospectively.
Results: Of the 16 patients, 6 with stage I disease, 
3 with stage II and 7 with stage III disease. There 
were no perioperative death occurred. The most 
popular postoperative complications were cardiac 
arrhythmia, pulmonary infection and hypoxemia.
Conclusion: Major pulmonary resection is a rational 
choice for part of the octogenarian patients with lung 
cancer.
Keywords: aged, 80 and over, Lung neoplasms, 
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P1.277 OUTCOMES OF EXTENDED 
SURGICAL CRITERIA FOR 
PULMONARY METASTASECTOMY OF 
COLORECTAL CANCER
Yasuhisa Ohde, Shinsuke Saisho, Mitsuhiro Isaka, 
Tomohiro Maniwa, Kazuo Nakagawa, Takehiro 
Okumura, Haruhiko Kondo 
Thoracic Surgery, Shizuoka Cancer Center/Japan
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is at the poorest level and mostly manual. VATS is 
present at one of the units but mostly being used for 
diagnostic purposes due to lack of expertise. Even 
diagnostic pathological services are unreliable except 
in few of private diagnostic laboratories. There is 
no prevention program at both hospital & media 
level except a general warning on packs stressing on 
mouth cancer rather than carcinoma lungs.
Conclusion: It is concluded that Role of surgery in 
carcinoma lung is at very low level. Professional 
medical bodies as well as government should follow 
standard guidelines to improve this service and take 
into consideration the largest killing cancer in the 
world for such a big population.
Keywords: Lahore, Surgery, Lungs
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P1.279 FACTORS INFLUENCING 
SURVIVAL OF PATIENT WITH 
PATHOLOGICAL PROVEN N1 NON-
SMALL CELL LUNG CANCER
Hirohiko Shinohara, Takehisa Hashimoto, Masanori 
Tsuchida 
Thoracic And Cardiovascular Surgery, Niigata 
University Graduate School Of Medical And Dental 
Sciences/Japan
Background: The population of patients with 
pathological (p-) N1 disease is small among non-
small cell lung cancer (NSCLC) and limited data 
regarding prognosis is available in this group. We 
analyzed patients with pN1 disease to identify 
factors inÁuencing survival.
Methods: From January 1983 to November 2010, 
we performed 1446 anatomic resections in patients 
with primary lung cancer in our institution. Of 
these, 110 patients had N1 nodal metastases, and a 
total of 86 consecutive patients with pathological 
N1 NSCLC who underwent lobectomy or 
pneumonectomy with systematic lymph node 
dissection were retrospectively reviewed using the 
seventh edition of the TNM classiÀcation system. 
The pN1 NSCLC patients in this study included 71 
men and 15 women with their mean age 65.0±7.9 
years (range, 33 to 80). A total of 50 patients (58.8%) 
had tumors on the right side, whereas 35 patients 
(41.2%) had tumors on the left side. Histopathologic 
tumor types included squamous cell carcinoma (Sq) 
in 44 cases (51.1%), adenocarcinoma (Ad) in 33 
cases (38.4%), and others in 9 cases (10.5%). Of 
Conclusion: Overall survival in recent extended 
criteria is acceptable, not inferior to that in classical 
criteria. In conversion surgery with initially non-
resectable case, although recurrence rate is high, 
recurrent disease was well controlled by systemic 
therapy, overall survival is similar to that of 
conversion surgery of hepatic metastasis from 
colorectal cancer. 
Keywords: Surgery, pulmonary metastasis, 
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P1.278 ROLE OF SURGERY IN 
MANAGEMENT OF CARCINOMA LUNG 
IN PAKISTAN.
Imran Javed 
Surgery, Private Medical College/Pakistan
Background: Surgical treatment of carcinoma of 
the lung is not an option for the management of 
the disease due to many factors like: - Advanced 
carcinoma of the lung. _ Lack of expertise of the 
surgeons. - Financial reasons. - Non awareness 
of medical community about importance of early 
diagnosis. - Non existence of screening programs 
- Limited scope for thoracic surgery units. - An 
extremely small number of trained Thoracic 
surgeons. _ Non- Availability of Thoracic Surgical 
Oncologists. _ No referral collaboration between 
chest physicians & surgeons. - Ignorance of Public 
health deptt of local & federal governments.
Methods: Standard methods of data collection 
between various units of thoracic surgery in the city 
of Lahore, Pakistan is used. Data is analyzed by 
SPSS.
Results: There are only 3 units of Thoracic surgery 
for a city 12 million people which is also 2nd largest 
city of the 6th largest nation in the world. No unit 
in the city of Lahore is recognized for postgraduate 
training in Thoracic surgery even by local body i.e. 
College of Physicians & Surgeons Pakistan. There is 
no special emphasis on Thoracic surgery oncology. 
Most of the people working there are not even 
formally trained in thoracic surgery but in general 
surgery and then they started practicing specialty. 
Record keeping with reference to Carcinoma lung 
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P1.280 PREDICTING POSTOPERATIVE 
PULMONARY FUNCTION IN PATIENTS 
UNDERGOING LUNG RESECTION
Yohei Yatagai1, Takefumi Saito1, Yasuhiro Umetsu2, 
Shimao Fukai1, Kenji Hayashihara1, Masa Shiina2 
1Respiratory Medicine, Ibarakihigashi National 
Hospital/Japan, 2Clinical Research, Ibarakihigashi 
National Hospital/Japan
Background: The inÁuence of pulmonary resection 
on functional capacity can be assessed in different 
ways. The aim of our study was to determine the 
effect of lung resection on spirometric lung function 
and to evaluate the accuracy of simple calculation 
in predicting postoperative pulmonary function in 
patients undergoing lung resection. 
Methods: We reviewed preoperative and 
postoperative pulmonary function test results on 
patients who underwent lung resection for lung 
cancer between January and December 2008. In 
lobectomies, the predicted postoperative forced 
expiratory volume in one second (ppo FEV1) 
and predicted postoperative forced vital capacity 
(ppo FVC) were calculated based on the number 
of segments resected and were compared with 
the actual postoperative FEV1 and FVC. The ppo 
FEV1 (or FVC) were calculated using the following 
formula: ppo FEV1 (or FVC) = [1-(b-n) / (42-n)] 
x preoperative FEV1 (or FVC), where n and b are 
the number of obstructed subsegments and total 
subsegments respectively, in the resected lobe. In 
wedge resections, we investigated the association of 
pulmonary function (preoperative and postoperative 
FVC, preoperative and postoperative FEV1) with 
smoking index, histological type (adenocarcinoma or 
squamous cell carcinoma), size of tumor, underlying 
lung disease (with or without emphysema) and 
location of cancerous lesions.
Results: Sixty-Àve patients underwent functional 
assessment with pulmonary function test before 
and 6 months after lung resection. In 45 (29 males 
and 16 females; mean age 72 yrs), a lobectomy was 
performed and in 20 (14 males and 6 females; mean 
age 74 yrs), a wedge resection was performed. After 
lobectomy, in 22 patients, the actual postoperative 
FEV1 was greater than 120% of ppo FEV1 (Group 
A). In the other 23 patients, the FEV1 decreased 
under 120% of ppo FEV1 (Group B). In four 
patients of Group A, the FEV1 was improved after 
lobectomy. In Group A, there were more patients 
the 86 patients, 16 had pT1, 47 had pT2, 19 had 
pT3, and 4 had pT4 disease. According to the TNM 
classiÀcation system, 54 were stage IIA, 9 were 
stage IIB, and 23 were stage IIIA.
Results: For completely resected patients, the 
5-year survival rate was 42.0%, respectively. 
The 5-year survival rate for patients with hilar 
N1 (station 10), interlobar (station 11), and 
intrapulmonary N1 (stations 12 to 13) involvement 
were 33.9%, 35.6%, and 49.8%, respectively (Fig.)
.  
Although patients with hilar and interlobar N1 
(stations 10 and 11) involvement tended to show 
poorer survival than patients with intrapulmonary 
N1 (station 12 to 13), no statistically signiÀcant 
difference was observed. The 5-year survival rates 
for patients with Sq and Ad were 55.8% and 30.3%. 
Patients with Sq had a signiÀcantly better prognosis 
than those with Ad (p=0.034). The 5-year survival 
rates for patients with right-sided cancer tended to 
show better prognosis than those with left-sided 
cancer (49.9% and 27.1%, respectively; p=0.088), 
but no statistically signiÀcant differences were 
observed.
Conclusion: Squamous cell carcinoma was 
signiÀcant factors to predict a better prognosis than 
adonocarcinoma, and involvement of the hilar and 
interlobar N1 and left-sided cancer tended to be a 
worse prognosis in resected pN1 NSCLC.
Keywords: pathological N1, Prognosis, Lung 
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or bilateral disease. Complete resection is the goal 
and the most important prognostic factor in survival. 
The minimally invasive approach is the alternative 
of choice in selected patient in lieu of thoracotomy 
and sternotomy. Its application is both diagnostic 
and therapeutic. Despite advances in prevention and 
multi-modality therapy, metastatic disease remains 
the leading cause of cancer mortality and further 
research is warranted.
Methods: We carried out a retrospective review 
of the main characteristics of patients undergoing 
pulmonary metastasectomies during a 3-year period 
(2007-2010) at a single referral center and the type of 
surgical approach used (open vs minimally invasive 
surgery). A description of our three year experience 
is presented.
Results: There were 40 patients that underwent 
lung resection for metastatic disease between 2007 
and 2010. There were 21/40 (53%) female patients 
and 19/40 (47%) were men, with an average age 
of 50.8 years. Primary cancers were: 11/40 (27%) 
had colorectal carcinoma, 10/40 (25%) had renal 
carcinoma, there were 8/40 (20%) patients with 
metastatic germ cell tumors and 11/40 (28%) patients 
with other primary cancers. The treatment for the 
primary cancer was surgery in 19/40 patients (47%), 
14/40 (35%) underwent surgery plus chemotherapy, 
4/40 (10%) had surgery plus radiotherapy, and 3 
patients (8%) had chemotherapy only. The mean 
overall disease-free period was 33.7 months. More 
patients 25/40 (63%) had disease only in the right 
lung, 13/40 (32%) in the left and 2 (5%) had bilateral 
disease. Three quarters of the patients 29/40 (73%) 
underwent resection my minimally invasive surgery 
(thoracoscopy or VATS), 10/40 (25%) had an open 
resection (thoracotomy or mini-thoracotomy), and 
1 patient (2%) had a combined approach. In 31/40 
(78%) of the patients had one or more non-anatomic 
resections (wedge) , anatomic resection in 6/40 
(15%) and 1/40 (2%), lobectomy and segmentectomy 
respectively. Combined, wedge resection and 
segmentectomy in 2/40 (5%) patients. Today 34/40 
(85%) of patients are alive and 6 (15%) have died.
Conclusion: In our experience there is no sex 
difference in the development of lung metastases. 
Colorectal cancer, renal carcinoma and germ cell 
tumors are the main cause of resectable metastases 
at our institution. The lesions were mainly in the 
right hemitorax. The most commonly performed 
procedure at our center was minimally invasive non 
anatomic resection. Today most of our patients are 
still alive, and have not reached median survial. 
with male-sex, upper lobe resection, squamous cell 
carcinoma and heavy smoking, compared to Group 
B. The difference of FVC between before and after 
wedge resection (ƋFVC) was signiÀcantly smaller 
in patients with heavy smoking (smoking index 30 
pack years) (p=0.001), adenocarcinoma (p=0.013), 
larger size of tumor (major axis 11mm) (p=0.030) 
and underlying lung disease (emphysema) (p=0.048). 
There was, however, no factor inÁuencing the 
difference of FEV1 between before and after wedge 
resection (ƋFEV1). 
Conclusion: After lobectomy, the postoperative 
FEV1 and FVC tended to be higher than ppo FEV1 
and ppo FVC in patients with male-sex, heavy 
smoking, squamous cell carcinoma, upper lobe 
resection and with emphysema than with female-sex, 
light smoking, adenocarcinoma, lower lobe resection 
and without emphysema. After wedge resection, 
the postoperative FVC tended to be higher than ppo 
FVC in patients with adenocarcinoma, small size 
of tumor, light smoking and without emphysema. 
There was, however, no apparent factor inÁuencing 
postoperative FEV1.
Keyword: predicting postoperative pulmonary 
function
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P1.281 PULMONARY 
METASTASECTOMIES: A 3-YEAR 
EXPERIENCE AT A QUATERNARY 
REFERRAL CENTER IN MEXICO CITY
Luis M. Argote-Greene1, Patricio Santillan-Doherty2, 
Rocio E. Carrera-Cerón2, Said Urbina-Terán1, Ixchel 
Carranza-Martinez2, Juan C. Jacinto-Tinajero2, Jesús 
Herrera-Zamora2 
1Thoracic Surgery, Instituto Nacional De Ciencias 
Médicas Y Nutrición/Mexico, 2Thoracic Surgery, 
Instituto Nacional De Ciencias Médicas Y Nutrición 
“salvador Zubirán”/Mexico
Background: Pulmonary metastases correspond 
to secondary deposits of tumor cells in the lung 
parenchyma from a known primary neoplasm. 
Pulmonary metastasectomy is a potentially curative 
surgical procedure and has become standard therapy 
in appropriately selected patients. However, the 
role of pulmonary metastasectomy treatment is 
still debated by some oncologic groups. The type 
of approach for resection of metastases depends 
mostly on the patient, and the presence of unilateral 
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patients with unexpected pleuritis carcinomatosis, 
patients with positive N2 lymph nodes and patients 
with unanticipated hilar invasion. Unnecessary 
thoracotomies were avoided in these patients. The 
second category consisted of patients considered 
not VATS suitable during the preoperative workup, 
that could unexpectedly undergo a radical VATS 
resection. The third category included patients with 
chest wall invasion. VATS offered the opportunity to 
dissect the hilum, lymph nodes, and interlobar Àssure 
and offered excellent visibility of the extent of chest 
wall invasion. These patients had a VATS lobectomy 
combined with a minimally invasive chest wall 
resection. 
Conclusion: An “always VATS” strategy offers 
great advantages and reduces morbidity in many 
patients. Unnecessary thoracotomies can be avoided 
in unexpected hilar invasion, positive N2 lymph 
nodes and pleural metastases. Furthermore, several 
patients can undergo VATS lobectomy unexpectedly 
and wide resections can be avoided. Therefore, we 
conclude that every lung surgical procedure for 
malignancy should be started thoracoscopically. 
Keywords: VATS, lobectomy, Lung cancer, Surgery
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P1.283 THE PERIOPERATIVE FACTORS 
ASSOCIATED WITH POSTOPERATIVE 
ACUTE EXACERBATION OF 
INTERSTITIAL PNEUMONIA WITH 
LUNG CANCER.
Tomohiro Maniwa, Mitsuhiro Isaka, Kazuo 
Nakagawa, Yasuhisa Ohde, Takehiro Okumura, 
Haruhiko Kondo 
Thoracic Surgery, Shizuoka Cancer Center/Japan
Background: The relationship between interstitial 
pneumonia (IP) and primary lung cancer has been 
previously reported. The preoperative factors 
associated with acute exacerbation (AE) of IP after 
pulmonary resection have often been reported, the 
postoperative factors rarely. This study investigated 
the perioperative factors associated with AE of IP 
after pulmonary resection. 
Methods: A retrospective chart study was 
undertaken of 1309 patients with lung cancer who 
However, the monitoring of these patients and their 
speciÀc characteristics should be analyzed in further 
studies.
Keywords: metastasectomy, VATS, minimally 
invasive surgery, secondary lung cancer
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P1.282 WHY TO START EVERY 
LUNG SURGICAL PROCEDURE 
FOR MALIGNANCY WITH 
THE INTRODUCTION OF A 
THORACOSCOPE?
Niels Smakman, Jan Siebenga, Karel Hulsewé, 
Ewald Bollen 
Surgery, Atrium Medical Center/Netherlands
Background: Since the introduction of video-
assisted thoracic surgery (VATS), the morbidity of 
pulmonary resections for malignancy has improved 
dramatically. Furthermore, VATS offers excellent 
visibility and gives the opportunity to assess the 
pleura, to dissect and sample the N2 lymph nodes 
and to determine the extent of hilar and chest wall 
invasion in a minimally invasive manner. Therefore, 
an “always VATS” strategy may avoid unnecessary 
thoracotomies, unnessary wide resections and 
may identify patients that can be treated by VATS 
lobectomie unexpectedly. 
Methods: Our institution was the Àrst to introduce 
VATS resections in the Netherlands in 2006. Since 
the introduction in 2006, we started with VATS in 
every patient with resectable lung cancer. Patient 
characteristics, preoperative data, operative details 
and postoperative course were collected in a 
prospective database. The database was analyzed to 
identify different patient categories that experienced 
great beneÀt by the “always VATS” strategy. 
Results: From 2006 to 2011 more than three hundred 
patients were operated for lung cancer in our 
institution. The procedure was started by VATS in all 
cases. By analyzing the data we were able to identify 
three categories that experienced great beneÀt by 
this “always VATS” strategy. The Àrst category 
consisted of patients considered resectable by the 
preoperative workup, that turned out not resectable 
during thoracoscopy. This category included 
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P1.284 SURVIVAL BENEFIT OF THE 
SURGICAL INTERVENTION FOR THE 
TREATMENT OF PATHOLOGICAL N2 
NON SMALL CELL LUNG CANCER.
Masanori Kaneda, Katsutoshi Adachi, Tomohito 
Tarukawa 
Thoracic Surgery, Nho Mie Chuo Medical Center/
Japan
Background: Many surgeons had considered that 
any patient with superior mediastinal lymph node 
metastasis is inoperable. But a selected group of 
patients with N2 disease will beneÀt from complete 
resection. However, its survival beneÀt has not 
been established. We have summarized ten years’ 
experience and analyzed an achieved survival 
beneÀt. 
Methods: Among 519 patients who underwent 
surgical resection from 1998 to 2007, 94 patients 
were conÀrmed to be a pathological N2 disease. 
After excluding the patients with M1 disease and 
insufÀcient data description, total 90 patients were 
selected for analysis. Disease-speciÀc survival curve 
and disease-free survival curve were generated by 
the Kaplan-Meier method and 3- and 5-year survival 
rate were estimated. Independent prognostic factors 
were also retrieved by the multivariate analysis using 
Cox proportional hazard model with the p value of 
under 0.05. 
Results: Disease-speciÀc 3- and 5-year survival 
rate was 59.9% and 51.7% respectively. Median 
survival time was estimated as 68 months. As for 
the disease-free survival, it was estimated as 43.7% 
and 32.4%. The disease-free survival curve reached 
its plateau in 74 months after surgery and survival 
rate at that point was 26.2%. It was considered to be 
the complete cure rate, which is unusual sequence 
in medical treatment without surgery. According 
to the multivariate analysis, pathological T and 
number of mediastinal lymph node stations with 
metastasis were signiÀcant prognostic factors. But 
age, gender, clinical N2, and affected lobe were 
not signiÀcant in our study. 85 patients (83.3%) 
had an adjuvant chemo- and/or radiation therapy. 
But we could not identify the routine regimens 
or methods. Consequently, it was not signiÀcant 
either. Postoperative recurrence was conÀrmed in 52 
patients (57.8%). The recurrence with mediastinal 
lymph node enlargement (including lymphangitis 
carcinomatosa of the lung) was only 9 cases (17.3%). 
underwent pulmonary resection at Shizuoka Cancer 
Center Hospital between September 2002 and 
January 2011. One hundred Àfteen patients were 
diagnosed with IP by chest computed tomography 
or pathological Àndings. Eleven patients (AE 
group) suffered from AE after surgery while the 
remaining 104 patients (non-AE group) did not. We 
investigated the clinicopathological Àndings and 
postoperative management of the two groups. 
Results: The two groups did not differ signiÀcantly 
in age, sex, Brinkman index, tumor site, histology, 
staging, white blood cell count, C-reactive protein 
level, respiratory function, bleeding or operative 
time. However serum lactase dehydrogenase (LDH) 
was signiÀcantly higher in the AE group (p=0.0466). 
Thirty-six patients required chest tube drainage for 
more than 5 days after surgery, 23 of these because 
of pleural effusion. Of these 23 patients, six suffered 
from AE of IP and 17 did not (p=0.0069). Table. 
Patient’s clinico-pathological and postoperative 
details of patients with or without postoperative 
acute exacerbation. 
AE (n=11) non-AE (n=104) P value 
Age 72(63-83) 70(47-83) 0.4080 
Sex (Male/Female) 11/0 89/15 0.0717 
Brinkman index 1000(0-3920) 1060(0-2400) 0.8103 
Site (Left/Right) 2/9 45/59 0.0930 
Histology (Sq/non-Sq) 6/5 59/45 0.8896 
WBC (/mm3) 6500(4080-8310) 6805(3620-20550) 0.2190 
LDH (IU/L) 203(174-314) 192(89-323) 0.0466 
CRP (mg/dL) 0.20(0.005-1.42) 0.305(0.001-9.91) 0.1934 
PaO2 (mmHg) 86.9(69.7-107.0) 83.1(61.8-120.0) 0.5618 
%VC (%) 93.2(77.3-102.4) 102.75(56.0-133.0) 0.0725 
FEV1.0% (%) 77.11(55.3-86.3) 74.45(34.6-100.0) 0.8020 
FEV1.0 (L) 7.08(7.171-2.56) 2.265(1.06-3.34) 0.3527 
Operative ï½”ime (min) 200(165-713) 251(73-507) 0.6030 
Blood ï½Œoss (g) 87(13-373) 94(0-961) 0.9069 
Duration of drainage (day) 5(2-8) 4(1-41) 0.8232 
»More than 5 days 7 29 0.0199 
»»Prolonged air leak 1 8 0.8722 
»»Pleural effusion 6 17 0.0069 
Conclusion: Serum LDH is a predictor of AE of IP. 
In addition, we should pay attention to the volume of 
chest tube drainage after pulmonary resection for IP. 
Keywords: Lung cancer, Surgery, interstitial 
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upper lobectomies and one right lower lobectomy. 
Two patients were adenocarcinomas and one was 
squamous carcinoma. A new and uncommon method 
to the problem of postsurgical chylothorax for lung 
cancer with hypertonic glucose (50%) pleurodesis 
through the chest drainage tube is presented.
Results: All patients were initially treated 
conservatively. These three patients needed more 
intervention of hypertonic glucose pleurodesis 
through the chest drainage tube. Patients received 
conservative treatment from initial operation to 
pleurodesis at a median of 4 days (range 3-5days). 
Chest tubes were taken out after pleurodesis at 
a median of 7 days (range 4-9days).The patients 
underwent initial operation at a median of 12 days 
of chest tube drainage (range 9-14days). All patients 
were discharged without recurrent chylothorax.
Conclusion: It is conÀrmed that to try hypertonic 
glucose pleurodesis through the chest drainage 
tube to a thoracic duct leak before resort to a 
thoracoscopic or thoracotomic ligation. This method 
is simple, cheap, rapid recovery, less pain and 
effective. The treatment with hypertonic glucose 
through the chest tube gives more successful chance 
to conservative management.
Keyword: Chylothorax; Pulmonary Resection; lung 
cancer; Pleurodesis
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P1.286 MODERN MANAGEMENT OF 
EARLY BRONCHOPLEURAL FISTULA 
AFTER PNEUMONECTOMY FOR LUNG 
CANCER
Yang Li1, Chang Y. Li1, You B. Cui1, Jean 
Deslauriers2, Yong X. Wang1 
1Thoracic Surgery, The First AfÀliated Hospital Of 
Jilin University/China, 2Centre De Pneumologie De 
Hospital/Canada
Background: Bronchopleural Àstula remains a 
devastating complication after pneumonectomy with 
a reported mortality between 25.0% and 79.2%. 
Especially postpneumonectomy bronchopleural 
Àstula occurred in the early postoperative period 
following a high mortality. The aim of this paper 
was to review management of early bronchopleural 
Àstula within 30 days after pneumonectomy for lung 
cancer.
Methods: A 20-years period, thirty cases (2.7%) 
developed a bronchopleural Àstula within 30 days 
The cancer had recurred with distant metastasis in 
33 patients (63.5%). These results implied a great 
efÀcacy of the surgical intervention on the local 
control of the N2 disease. All the patients treated 
with ordinary medical treatment after the recurrence 
except one who underwent surgical resection for 
a metastatic pulmonary nodule. Disease-speciÀc 
survival after the recurrence was estimated as 24.2% 
in 3-year survival rate, 12.1% in 5-year survival rate, 
and 14months in median survival time. These values 
were in no way inferior to the medical treatment 
without surgery. Then, it could be concluded that the 
time obtained between the surgery and recurrence, 
which was estimated as long as 17.8 months in 
average, is the survival beneÀt of the surgical 
intervention even in the case with recurrence. 
Conclusion: Complete cure rate was estimated as 
26.2% of the surgical patients. Survival beneÀt of 
17.8 months in average was a beneÀt of surgical 
intervention also in the case with recurrence. 
Keywords: N2 NSCLC, survival beneÀt, Surgical 
Intervention
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P1.285 TREATMENT OF CHYLOTHORAX 
COMPLICATING PULMONARY 
RESECTION FOR LUNG CANCER WITH 
HYPERTONIC GLUCOSE PLEURODESIS
Yang Li1, Chang Y. Li1, You B. Cui1, Jean 
Deslauriers2, Yong X. Wang1 
1Thoracic Surgery, The First AfÀliated Hospital Of 
Jilin University/China, 2Centre De Pneumologie De 
L’hôpital/Canada
Background: Chylothorax following pulmonary 
resection is not a frequent complication, ranging 
from 0.25% to 1.0% in modern reports. However, 
the mortality rate of this complication can approach 
50% in untreated patients. The optimal method 
of treatment remains controversial, as variable 
results have been obtained after conservative and 
operative treatment. It is not very clear that when 
the treatment should be changed from conservative 
to video-assisted thoracoscopic surgery (VATS) or 
thoracotomy.
Methods: From January 2006 to December 2008, 
3 patients developed chylothorax after pulmonary 
resection for lung cancer. There are 2 men and one 
woman with a median age 61 years (range 75 to 
52 years). The initial procedures were two right 
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pus, early recurred cancer, or some small Àstulas. 
Some patients, because of poor prognosis of cancer 
or associated multisystem disorders, are managed 
best without aggressive surgical intervention and 
discharged with open thoracic window.
Keyword: management; bronchopleural Àstula; 
pneumonectomy; lung cancer
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P1.287 NODAL INVOLVEMENT PATTERN 
IN CLINICALLY EARLY LUNG CANCER 
ACCORDING TO TUMOR LOCATION
Somcharoen Saeteng1, Juntima Euathrongchit2, 
Nirush Lertprasertsuke3, Apichat Tantraworasin1, 
Sumitra Thongprasert4, Yutthaphun Wannasopha2 
1Surgery, Faculty Of Medicine, Chiang Mai 
University/Thailand, 2Radiology, Faculty Of 
Medicine, Chiang Mai University/Thailand, 
3Pathology, Faculty Of Medicine, Chiang Mai 
University/Thailand, 4Internal Medicine, Faculty Of 
Medicine, Chiang Mai University/Thailand
Background: A retrospective cohort study was 
performed to deÀne the nodal status of the patients 
with lung cancer, received surgery, grouped by 
location to evaluate the nodal spreading pattern.
Methods: From 2006 -2010, 197 patients underwent 
lobectomy with systemic nodal resection for primary 
lung cancer in Chiang Mai University. There were 
123 male and 74 female with age ranging 16 – 85 
years old, average 61.31 years old. Analysis of tumor 
location, histology type and nodal metastasis were 
done.
Results: The tumor locations were RUL in 63 
(31.98%), RML in 18 (9.14%), RLL in 30 (15.23%), 
LUL in 55 (27.92%), LLL in 16 (8.12%) and mixed 
lobes in 15 (7.61%). The mean size was 4.45 cm in 
diameter (range 1.2 - 16.5 cm). Adenocarcinoma 
was the most common histological type, which were 
132 cases (67.01%), following by squamous cell 
carcinoma in 41 (20.81%), bronchioloalveolar cell 
carcinoma in 9 (4.57%), large cell carcinoma in 7 
(3.55%), respectively. Distribution of node in each 
location was summarized in table 1. Seventeen cases 
(8.63%) had positive mediastinal node without hilar 
node metastasis-also called skip metastasis. 
after 1046 pneumonectomies for lung cancer. 
These patients were treated by reoperation, closed 
drainage with or without open thoracic window, or 
endobronchial glue.
Results: 20 bronchopleural Àstulas developed 
within the Àrst two weeks postoperatively (66.7%), 
especially 15 bronchopleural Àstulas occurred in 3 
to 10 days after pneumonectomy (50%). The most 
common symptoms of early postpneumonectomy 
bronchopleural Àstula are shortness of breath 
(65.0%), increased sputum (65.0%), and increased 
cough (65.0%). A decrease of pleural Áuid-air level 
of more than 1 to 2 cm is the most common sign 
(50%) to suggesting a bronchopleural Àstula in 
chest radiograph. Four (13.3%) of thirty patients 
who had bronchopleural Àstulas died. In Seventeen 
patients that were returned to the operating room for 
reclosure of bronchopleural Àstula, one patient died 
of bronchopleural Àstula and sixteen reoperations 
were successful. All the repairs of stumps were 
all buttressed with vascularized pedicle Áap of 
intercostal muscle (n=11), pectoralis major muscle 
(n=4), or pericardial fat (n=1). 12 cases that 
were treated by closed drainage with or without 
followed open thoracic window. Three cases died 
of bronchopleural Àstula. One patient successfully 
underwent endoscopic glue to close bronchopleural 
Àstula with injection three times. 
Conclusion: The majority of bronchopleural 
Àstulas developed within the Àrst two weeks 
postoperatively, especially occurred in 3 to 10 days 
after pneumonectomy. The most common symptoms 
of early postpneumonectomy bronchopleural Àstula 
are shortness of breath, increased sputum, and 
increased cough. A decrease of pleural Áuid-air 
level of more than 1 to 2 cm is the most common 
sign to suggesting a bronchopleural Àstula in chest 
radiograph. Chest radiograph and bronchoscopy 
are the most effective and simple methods to 
detect and conÀrm an early bronchopleural Àstula. 
Within one month postoperatively, bronchopleural 
Àstula without established empyema with pus 
should be reoperated if the patient had enough 
cardiopulmonary reserve and could therefore tolerate 
reclosed. Contamination of pleural space is not 
the contraindication to reoperation. Reclosure via 
original thoracotomy and repair the Àstula with 
pedicled intercostal muscle Áap are convenient and 
efÀcient. Drainage with or without followed open 
thoracic window is appropriate for the patients 
with limited cardiopulmonary reserve, impaired 
general condition, secondary to empyema with 
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pathological Àndings showed 15 cases of squamous 
cell carcinoma, 34 of adenocarcinoma, 4 of LCNEC 
and 1 of small cell carcinoma, and their pathological 
stages were 36 patients of stage 1, 11 of stage 2 
and 7 of stage 3. Forty-eight patients (89%) had an 
underlying disease, and almost all of those were 
circulatory system diseases (31 patients). Respiratory 
rehabilitation was performed in 42 patients.
Results: 1) Postoperative acute phase progress: All 
patients could get out of bed at an early postoperative 
day; 36 patients could walk within 2 days. As for 
the postoperative complications, 11 patients had a 
cardiac arrhythmia, 5 patient had difÀculty in mucus 
expectoration, and 5 patients had postoperative 
disorientation. All of the patients recovered well 
and were discharged from the hospital, but two 
patient died from pneumonia within 3 months after 
discharge. Postoperative complications occurred in 
80% in patients with over 3 underlying diseases. 
2) Postoperative chronic stage progress: The 
postoperative survival rate by Kaplan-Meyer was 
40% for 3 years and 20% for 5 years. Six patients 
(12%) died of recurrence, and 2 of those 6 patients 
died within one year. Four patients (8%) died with 
other diseases, and 2 patients died with unknown 
causes due to loosing our clinical follow-up.
Conclusion: Postoperative survival of an 
octogenarian with stage 1 or stage 2 lung cancer was 
feasible with the control of the underlying disease 
before surgery. However, surgery had no signiÀcant 
survival beneÀt, comparing to other treatment 
options.
Keyword: lung cancer, pulmonary resection, 
octogenarian
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P1.289 SURGICAL PREVENTION 
OF DEVELOPMENT OF 
BRONCHOPLEURAL FISTULA AFTER 
PNEUMONECTOMY IN PATIENTS WITH 
LUNG CANCER
Otabek Eshonkhodjaev1, Shukhrat Khudaybergenov2, 
Georgiy Pahomov3, Ortikali Irisov2, Rustem 
Hayaliev3 
1Department Of Surgery Of Lungs And Mediastynum, 
Republican Specialized Centre Of Surgery Named 
After Academician V.vakhidov/Uzbekistan, 
2Republican Specialized Centre Of Surgery Named 
After Academician V.vakhidov/Uzbekistan, 3Tashkent 
Medical Academy/Uzbekistan
Conclusion: The tumor location cannot predict the 
pattern of nodal metastasis. Although, there were 
stastistic signiÀcant different between tuor in RUL 
and RLL in lower mediastinal node metastasis. 
Moreover, we found 8.63% of skip metastasis. 
We thus recommend to perform lobectomy with 
systematic nodal dissection rather than sampling 
nodal dissection for accurate lung cancer staging in 
spite of the early stage lung cancer.
Keywords: Lung cancer, Nodal metastasis
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P1.288 PULMONARY RESECTION FOR 
LUNG CANCER IN OCTOGENARIANS
Keigo Takagi, Yoshinobu Hata, Shuichi Sasamoto, 
Shoji Takahashi, Fumitomo Sato, Hidenori Goto, 
Kazuyoshi Tamaki, Hajime Otsuka, Rena Yuasa 
Chest Surgery, Toho University Omori Medical 
Center/Japan
Background: With an extension of the average 
length of life, the number of pulmonary resection for 
lung cancer in octogenarians (patients of older than 
80 years old) has increased. Our objective was to 
analyze their postoperative complications, quality of 
life, survival period, and we discussed the beneÀt of 
pulmonary resection for octogenarians.
Methods: From 1998 to 2010, there were 54 
octogenarians (6.3%) of clinical stage 1 and stage 
2 among 855 patients who were operated on lung 
cancer. There were 39 males and 15 females; 41 
patients were aged from 80 to 82 years old, 9 
patients were from 83 to 84 years old and 4 patients 
were over 85 years old. The operative methods 
were one pneumonectomy, 43 lobectomies, 4 
segmental resections and 6 partial resections. The 
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Conclusion: Introduction of tactics of surgical 
intervention based on the worked out factor 
estimation of risk degree of development of BSF 
after PE permitted to decrease an incidence of 
lethality from 7.1% (34 of 477 patients in control 
group) up to 3.1% (3 of 98 patients in main group). 
Keywords: bronchial stump Àstula, pneumonectomy
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P1.290 MEDIASTINOSCOPY AFTER 
NEGATIVE ENDOSONOGRAPHY 
IN LUNG CANCER STAGING. 
SUBANALYSIS OF ASTER WITH FOCUS 
ON PET.
Kurt G. Tournoy1, Christophe Dooms2, Robert C. 
Rintoul3, Ellen Deschepper4, Jouke Annema5 
1Respiratory Medicine - Thoracic Oncology, Ghent 
University Hospital/Belgium, 2Respiratory Oncology 
Unit, University Hospitals Leuven/Belgium, 
3Department Of Thoracic Oncology, Papworth 
Hospital/United Kingdom, 4Biostatistics, Ghent 
University Hospital/Belgium, 5Respiratory Medicine 
- Thoracic Oncology, Leiden University Medical 
Centre/Netherlands
Background: Mediastinal staging in non-small 
cell lung cancer with endosonography (EUS-FNA 
plus EBUS-TBNA) followed by mediastinoscopy 
Background: Bronchial stump Àstula and 
related to it pleural empyema are general causes 
of efÀcacy decrease of surgical treatment of 
lung cancer and purulent destructive pulmonary 
diseases. Development of bronchial stump Àstula 
after pneumonectomy (PE) was always related to 
bronchial suture failure and unfavorable conditions 
of its healing. It allows to determine heterogenicity 
of patients’ group in relation to the nearest and 
remote prognosis as well as to work out and to 
implement optimal volumes of surgical treatment 
into practice.
Methods: StratiÀcation data of risk factors of 
bronchial stump failure (BSF) development in 575 
patients, who underwent pneumonectomy were 
presented. Control group (CG) consisted of 477 
patients, 390 patients of them had lung cancer and 87 
patients had purulent diseases of the lungs. The main 
group (MG) consisted from 98 patients, 72 patients 
of them had lung cancer and 26 patients had purulent 
pulmonary diseases. In CG BSF developed in 52 
(10.9%) patients, at the same time an incidence of 
this complication in patients of oncologic proÀle was 
10.5% (41 patients), and in patients with purulent 
pulmonary diseases – 12.6% (11 patients). In MG 
BSF was observed in 3 (3.1%) patients, at the same 
time an incidence of this complication in patients of 
oncologic proÀle was 2.8% (2 patients), and with 
purulent pulmonary diseases – 3.8% (1 patient). To 
evaluate adequate a retrospective distribution of 
patients in risk groups in CG and prospective one in 
MG were performed. 
Results: The minimal risk of development of this 
complication reached 67.9% to the left and only 
6.7% to the right, mean risk was 21.8% and 70.3% 
respectively, where as maximal degree of risk was 
revealed in only 10.3% to the left and in 23.1% to 
the right. An incidence of BSF after PE in patients 
of CG accounted for minimal risk 1.3%, at an 
average – 16.0%, and maximal – 32.3%, in its turn, 
an implementation of factor estimation of risk degree 
of development of BSF after PE in MG allowed to 
reduce an incidence of this complication until 0.0%, 
2.6% and 9.1% respectively. 
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Pathology, Osaka Prefectural Medical Center 
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4Department Of Thoracic Malignancy, Osaka 
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Respiratory Diseases/Japan
Background: Effective staging systems for lung 
cancer are required to stratify patient survival and 
assess the treatment results of deÀned the patient 
subgroups. This study evaluated the surgical results of 
non-small cell lung cancer (NSCLC) with interlobar 
pleural invasion (IPI) to investigate whether NSCLC 
with IPI should be classiÀed as either T2 or T3 
according to the seventh TNM staging criteria. 
Methods: Nine-hundred and thirty-Àve patients with 
pathologic T2 and T3 NSCLC (690 males and 245 
females; age range 26-87 years, mean, 65.2years) 
treated between January 1980 and December 2004 
were retrospectively evaluated. All the medical records, 
including surgical records and pathology reports, were 
retrospectively reviewed to conÀrm the presence of 
IPI. The pathological staging was evaluated according 
to the seventh TNM staging criteria. Among these, 
682 patients were pathologically staged as T2 without 
IPI (T2 group), T2 with IPI (IPI group), and 228 as 
T3 (T3 group). The surgical results of these groups 
were analyzed using Kaplan-Meier method and the 
log-rank test. A multivariate analysis for prognostic 
factors including T factors (using IPI as a T factor) 
and N factors was performed by the Cox multivariate 
proportional hazard model. 
Results: The median follow-up interval was 47 
months (range 1–301 months). The 5-year survival 
rate for the T2 group, IPI group, and T3 group 
were 51.9%, 31.1% and 38.8% respectively. There 
were statistically signiÀcant differences in survival 
between the T3 and T2 group (p < 0.001), and 
between the IPI and T2 (p = 0.045) group. The 
difference of survival between the IPI group and 
T3 group was not signiÀcant (p=0.904). In patients 
without nodal involvement, the 5-year survival rate 
for the T2N0 group, IPI N0group, and T3N0 group 
were 61.0%, 40.0% and 45.7% respectively. There 
were statistically signiÀcant differences in survival 
between the T3N0 and T2N0 group (p < 0.001), and 
between the IPIN0 and T2N0 (p = 0.026) group. The 
difference of survival between the IPIN0 group and 
T3N0 group was not signiÀcant (p=0.684). The results 
of the multivariate analysis using T and N factors 
showed that the hazard ratio for death of the IPI group 
tend to be higher than that of T2 group, however, the 
is more sensitive to detect nodal metastasis as 
compared to mediastinoscopy alone (ASTER trial, 
JAMA 2010;304:2245). However 11 patients need to 
undergo a mediastinoscopy to detect one with N2/3 
missed by endosonography. We analysed if FDG-
PET identiÀes patients in whom the mediastinoscopy 
can be omitted. 
Methods: In ASTER, 123 patients were randomized 
to endosonography followed by mediastinoscopy 
when the former did not show mediastinal 
metastasis. Sensitivity, negative predictive value 
(NPV) and number of mediastinoscopies needed 
to detect one false negative endosonography were 
calculated in the cases with complete data (n=120; 
98%). 
Results: With PET, 77 patients had FDG-avid 
mediastinal nodes; the prevalence of N2/3 
was 73(62-81)%. The sensitivity and NPV of 
endosonography was 88 (76-94) and 75 (57-88)%. 
Adding mediastinoscopy increased sensitivity and 
NPV to 96 (88-99) and 91 (73-98)%. 43 patients 
did not have FDG-avid mediastinal nodes, the 
prevalence of N2/3 was 23 (13-38)%. The sensitivity 
and NPV of endosonography was 70 (40-89)% and 
92 (78-97)%. Adding mediastinoscopy increased 
sensitivity and NPV to 80 (49-94)% and 94 (81-
98)%. In patients with FDG-avid vs. FDG-cold 
mediastinal nodes, the number of mediastinoscopies 
needed to detect one false negative endosonography 
is 6 vs 36 (p=0.078). 
Conclusion: A negative endosonography should 
be followed by a mediastinoscopy if PET positive 
mediastinal nodes are present. In the absence of 
PET positive nodes, a mediastinoscopy following a 
negative endosonography can be omitted. 
Keywords: PET-CT scan, Staging, endosonography 
/ EUS-FNA / EBUS-TBNA, Mediastinoscopy
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P1.291 SURGICAL RESULTS AND 
STAGING OF NON-SMALL CELL LUNG 
CANCER WITH INTERLOBAR PLEURAL 
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Results: The remaining work-up was normal 
without any sign of distant relapse. A bronchoscopy 
was performed and the pathological showed Àbro-
collagenic tissue without neoplastic cell. The Ànal 
diagnosis was therefore a pseudo-tumor after using 
sleeves for staple-line reinforcement.
Conclusion: The use of sealant during 
pneumonectomies or lobectomies is frequent and 
efÀcient to avoid suture dehiscence. These cases 
point a potential cause of mistake for clinicians 
as staple-line reinforcement may mimic a tumor 
relapse. A multidisciplinary team discussion 
together with a pathological exam is obviously 
always required to exclude a tumor relapse. 
However, knowing this rare outcome may speed up 
the work up and reinsure patients and physicians 
when following lung cancer patients treated with a 
bronchial reinforcement after thoracic surgery. 
Keywords: tumor relapse, sleeve, staple-line 
reinforcement, Lung cancer
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P1.293 THE UTILITY OF 
ULTRASONICALLY ACTIVATED SHEARS 
IN LYMPH NONE DISSECTION FOR 
NON-SMALL CELL LUNG CANCER
Hirozo Sakaguchi, Hironori Ishida, Hiroyuki 
Nitanda, Nobuhiro Yamazaki, Hiroyoshi Tsubochi, 
Koichi Kaneko 
Department Of General Thoracic Surgery, Saitama 
Medical University International Medical Center/
Japan
Background: Ultrasonically activated coagulated 
shears (UACS) has been reported to be useful for 
lymphadenectomy in patients with gastrointestinal 
malignancy. We evaluated the use of UACS 
in reducing the operative blood loss and the 
postoperative drained Áuid for NSCLC. 
Methods: We designed retrospective study to 
determine the effectiveness of the UACS versus 
monopolar electrosurgery in ND2 dissection. 
Forty patients, who were treated by same surgeon, 
with NSCLC c-Stage I were enrolled. Group 
A: 2008-2009,twenty patients were underwent 
lymphatic dissection with UACS. Group B: 
2004-2006,twenty were underwent lymphatic 
dissection with monopolar cautery. BMI, 
preoperative serum total protein level, operative 
blood loss and postoperative drained Áuid were 
difference was not signiÀcant (hazard ratio, 1.589; 
95% conÀdence interval, 0.936-2.622; p = 0.070). 
Conclusion: Survival of the IPI group was similar 
to that of the T3-group. Therefore, we propose that 
NSCLC with IPI be classiÀed into T3 according to 
the seventh TNM staging system. 
Keywords: Lung cancer, Staging, pathology
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P1.292 TUMOR RELAPSE AFTER 
SURGERY USING A SLEEVE FOR LUNG 
STAPLE-LINE REINFORCEMENT: NOT 
ALWAYS!
Marie-Eve Garcia1, Pascale Tomasini2, Pascal 
Thomas3, Laurent Greillier4, Fabrice Barlesi2 
1Service D’oncologie Multidisciplinaire Et 
Innovations Therapeutiques, Chu Nord/France, 
2Oncologie Multidisciplinaire Et Innovations 
Thérapeutiques, Hôpital Nord/France, 3Thoracic 
Surgery, Hôpital Nord/France, 4Service D’oncologie 
Multidisciplinaire Et Innovations Thérapeutiques, 
Hôpital Nord, Assistance Publique- Hôpitaux De 
Marseille/France
Background: Standard treatment of early stages 
of non small cell lung cancer (NSCLC) is based on 
thoracic surgery and radical lymphadenectomy. Air 
leaks are one of the most common complications and 
may occur in up to 28 to 60% of cases. They may be 
avoided using a sealant. 
Methods: Our institution participated in a clinical 
trial of FOREseal® sleeve reinforcement for lung 
cancer patients treated (n=66) with a lobectomy. 
During the follow-up of these patients, two of them 
(a stage pT2N2M0 adenocarcinoma and a stage 
pT2N1M0 squamous cell carcinoma) presented with 
a CT-scan enlargement and the PET-CT scan showed 
a hyper-metabolic pulmonary lesion at the site of 
the previous bronchial resection. A local relapse was 
obviously suspected.
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NSCLC (94). 10 patients underwent induction 
therapy. Median operative time, complication rate, 
redo-operation rate, 30 days mortality and length 
of stay were 190 minutes, 30,2%, 7,9%, 3,2% and 
9 days. Lymph nodes from median 5 stations were 
sampled which led to a pathological upgrading 
in 3 patients. Conversion to open thoracotomy 
was performed in 9 (8%) patients. Reasons for 
conversion was pulmonary artery bleeding in 4 
patients (emergency thoracotomy in 2 of them), 
clinical mis-staging in 2 patients and technical 
difÀculties in 3 patients, respectively.
Conclusion: A VATS lobectomy program has been 
introduced with promising short term results and 
a reasonable low conversion rate. In this series, 
induction chemotherapy and clinical staging 
higher than IA/B have not been associated with a 
higher conversion rate. When introducing a VATS 
lobectomy program, safety and oncological accuracy 
rather than a low conversion rate are the main 
concerns determining the programs fate. 
Keywords: NSCLC, VATS, Conversion
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P1.295 RELEVANCE OF 
POSTOPERATIVE FOLLOW-UP AFTER 
SURGERY FOR NSCLC AND HIGH-
GRADE NEUROENDOCRINE TUMOR 
(HGNET)
Ryu Nakajima, Makoto Takahama, Ryoji Yamamoto, 
Tada Hirohito 
General Thoracic Surgery, Osaka City General 
Hospital/Japan
Background: Large Cell Neuroendocrine carcinoma 
(LCNEC) was classiÀed in NSCLC, but clinical 
behaviors of LCNEC were similar to Small Cell 
Lung Cancer (SCLC). Several investigators proposed 
LCNEC and SCLC as HGNET. Large numbers 
of post operative lung cancer patients (especially 
HGNET) were relapsed and periodic clinic visits is 
usually recommended after surgery. But there is no 
consensus of ideal visit span, follow up range and 
modality have not deÀned yet. Objectives of this 
retrospective study were to determine the feasibility 
of follow-up program of NSCLC (except LCNEC) 
and HGNET.
Methods: We retrospectively reviewed 265 of 
relapsed patients (NSCLC: 238(40%), HGNET: 
37(35%)) after surgery in our institution (1994-
compared in two groups. Values represent the mean 
± SD, and Mann-Whitney U-test were used. 
Results: Right side disease was performed in 8 
patients of group A and 11 of group B. No statistical 
difference were seen for BMI and preoperative 
serum total protein level. The operative blood loss 
was 21-170ml (mean 82±47) in group A and 60-
243ml (mean 125±51) in group B (p=0.01). The 
total amount of drained Áuid was 270-1830ml 
(mean 959±352) in group A and 540-2650ml 
(mean1438±384) in group B (p=0.036). 
Conclusion: UACS is a useful method of Stage I 
lobectomy followed by lymphatic dissection (ND2) 
to reduce operative blood loss and postoperative 
lymphorrhea. 
Keywords: Lymph None Dissection, Ultrasonically 
Activated Shears, Lymph None Dissection
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P1.294 LESSONS LEARNED FROM 8% 
CONVERSION RATE DURING FIRST 111 
VATS LOBECTOMIES IN AN ACADEMIC 
THORACIC SURGERY CENTER
Johannes Bodner1, Herbert Maier2, Thomas Schmid2, 
Florian Augustin2 
1Division Of Thoracic Surgery, University Hospital 
Giessen/Germany, 2Visceral Transplant Thoracic 
Surgery, Innsbruck University Hospital/Austria
Background: VATS (Video Assisted Thoracic 
Surgery) lobectomy has gained increasing 
acceptance as an alternative treatment option for 
early stage NSCLC (non small cell lung cancer). 
Recently also in Europe, an increasing number 
of (academic) centers have introduced a VATS 
lobectomy program. Main criterias during the initial 
phase of a VATS lobectomy program are patients 
safety and oncologic accuracy.
Methods: From February 2009 to February 2011 
111 patients underwent complete thoracoscopic 
lobectomy through three non rib-spreading 
thoracocenteses with individual control of vascular 
and bronchial structures and oncologic lymph node 
sampling. Retrospective analysis of prospectively 
collected data was performed. Special attention was 
given to those patients in who conversion to open 
thoracotomy was performed.
Results: The median age of 63 men and 48 women 
was 62 years. Indications were benign lesions (3), 
a neuroendocrine tumor (14) and (stage IA to IIIA) 
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Background: In terms of morbidities and 
mortalities, lobectomy is safe modality for non-
small cell lung cancer(NSCLC) patients, if the 
postoperative expected (PPO) FEV1 is over 40%. 
However, effect of moderate pulmonary dysfunction 
on longterm survival is not clearly deÀned, and 
furthermore was not analysed according to stage. 
Because standart treatment strategies are different 
between stages, the effect of pulmonary dysfunction 
on longterm survival might be assessed by stage. 
We intended to study whether the effect of moderate 
pulmonary dysfunction on survival is different 
according to stages.
Methods: NSCLC patients underwent 
lobectomy from Jan, 1992 to Dec, 2009 were 
analysed retrospectively. Demographic data and 
clinicopathologic data including pulmonary function 
tests, pulmonary perfusion scans were obtained from 
institutional prospective database with 2100 cases. 
Criteria for moderate pulmonary dysfunction was 
PPO FEV1 between 40% and 60%. PPO FEV1 was 
calculated with preoperative FEV1 and perfusion 
scan data. Survival differences of patients with 
moderate (M) versus mild or no (G) pulmonary 
dysfunction were analysed according to pathologic 
stages. 
Results: Out of 941 eligible patients, 314 
(33.4%) were female. Mean age was 62.9 years. 
Adenocarcinoma consisted 59.3% of cases and 
squamouscarcinoma consisted 34.9%. Patients in 
M group were 129 (13.7%). Operative mortality 
rate was 2.0% (19). Pathologic stages were I in 592, 
II in 146, and IIIa in 203 patients. Overall 5 year 
survival rate (5yr OS) of whole cohort was 60.8% 
and median survival time (MST) was 107.9months. 
Operative mortality were not different signiÀcantly 
between M and G groups (3.1% vs 1.8%, p=0.36). 
M group showed signiÀcantly worse survival than 
G group (5yr OS: 51.9% vs 62.5%, MST: 64m 
vs 124m, p=0.017). However, subgroup analysis 
based on stage did not reveal signiÀcantly different 
survival but showed worse trend in M groups. In 
stage I, 5yr OS were 63% in M and 73% in G (p= 
0.11). In stage II, 5 yr OS were 40.2% and 49.2% 
(MST 39m vs 54m, p=0.20). In stage II, 5 yr OS 
were 30.5% and 41.7% (MST 23m vs 43m, p=0.27). 
(Fig 1) In multivariate analysis, moderate pulmonary 
dysfunction was not signiÀcant risk factor for 
longterm survival also.
2004). In several group, follow up procedure, 
detected pattern of recurrence (scheduled / 
unscheduled), Àrst relapse site and timing, and 
survival were analyzed. X2-test and log-rank test 
were used for statistically analysis. In follow up 
procedure, scheduled study included physical exam, 
chest X-ray, blood analysis (within tumor makers) 
and thoracic CT scan in all patients. In some patients, 
periodic brain MRI (17%) and born scan (7%) were 
performed.
Results: Seventy-eight of NSCLC patient and 100% 
of HGNET patient were relapsed within 3 years. 
In HGNET, there was no born metastasis after 
1 year, but NSCLC was featureless. Recurrence 
was detected by scheduled study in 190 patients 
(72%). In both groups, born scan could not detect 
recurrence, and 33 % of HGNET patients was 
detected brain metastasis by MRI (no patient in 
NSCLC). The Patient that was detected relapse by 
scheduled study had signiÀcant superior survival 
(NSCLC; 46 mo. vs. 30mo. and HGNET; 26 mo. vs. 
12 mo.).
Conclusion: Recurrence was detected over 5years 
in NSCLC patients but 3years in HGNET. Periodic 
born scan and brain MRI were useless to detect 
recurrence in NSCLC patients, but In HGNET 
patients, Brain MRI was useful in some patients. 
Periodic postoperative follow up may improve 
survival. Large scale prospective study was needed 
to verify the necessity.
Keywords: post operative follow-up, NSCLC, 
HGNET
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P1.296 STAGE STRATIFIED ANALYSIS 
OF THE EFFECT OF MODERTE 
PULMONARY DYSFUNCTION ON 
LONGTERM SURVIVAL AFTER 
LOBECTOMY IN PATIENTS WITH NON-
SMALL CELL LUNG CANCER
In Kyu Park1, Mi Kyung Bae2, Chun Sung Byun2, 
Dae Joon Kim2, Kil Dong Kim3, Kyung Young 
Chung2 
1Thoracic And Cardiovascular Surgery, Seoul 
National University Hospital/Korea, 2Thoracic And 
Cardiovascular Surgery, Yonsei University College 
Of Medicine/Korea, 3Thoracic And Cardiovascular 
Surgery, Eulji University Hospital/Korea
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Results: From 2/09 until 1/11, 94 patients underwent 
VATS lobectomy for early stage NSCLC. Clinical 
staging according to ESTS guidelines were based 
on contrast enhanced high resolution computed 
tomography scan (94, 100%), positron emission 
tomography (n=82, 87%) and invasive mediastinal 
staging (mediastinoscopy and/or endobronchial 
ultrasound Àne needle aspiration, n=14, 15%). In 
18 patients (19%) a pathological upstaging was 
revealed, based on a higher T factor in 4 patients 
and on a higher N factor in 14 (15%) patients, 
respectively.
Shift from N0 to N1 was seen in 7, from N1 to N2 in 
1 and from N0 to N2 in 6 patients.
Conclusion: Best available clinical staging 
techniques are still inaccurate. Detection of positive 
N1 or N2 lymph nodes during surgery strengthens 
the hypothesis that oncologic lymph node dissection 
is feasible by a VATS approach.
Keywords: NSCLC, VATS, Staging
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P1.298 THE PREVENTION AND 
TREATMENT REGARD PLEURAL 
REACTION IN THE CT-GUIDED 
LUNG TUMOR RADIOFREQUENCY 
ABLATION--REPORT OF 10 CASES.
Kun Qian 
Thoracic Surgery, Xuanwu Hospital Of Cmu/China
Background: Investigate the reasons and treatment 
measures of pleural response which is caused by CT-
guided lung tumor radiofrequency ablation. 
Methods: Retrospective analysis about 10 patient 
occurred pleural reaction during CT-guided lung 
tumor radiofrequency ablation treatment.
Results: pleural reactions are related to 
psychological factors, physiological factors, 
temperature factors and the location of the tumor.
Conclusion: effective intervention and treatment 
during preoperative and intraoperative stage can 
reduce the incidence of pleural reactions.
Keywords: radiofrequency ablation, pleural 
reactions, CT
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
Conclusion: Moderate pulmonary dysfunction 
did not signiÀcantly impair longterm survival 
after lobectomy in NSCLC in each stage. Standard 
treatment strategy should not be compromised in the 
patients with moderte pulmonary dysfunction. To 
verify this conclusion, muti-institutional study with 
larger volume cohort is necessary.
Keywords: Pulmonary function, longterm survival, 
Non-small cell lung cancer
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P1.297 UPSTAGING FROM CLINICAL TO 
PATHOLOGICAL TUMOR STAGE AFTER 
MINIMALLY INVASIVE LOBECTOMY 
FOR NON-SMALL CELL LUNG CANCER
Johannes Bodner1, Herbert Maier2, Wilhelm 
Stertmann1, A Vollerthunn1, Thomas Schmid2, 
Florian Augustin2 
1Division Of Thoracic Surgery, University Hospital 
Giessen/Germany, 2Visceral Transplant Thoracic 
Surgery, Innsbruck University Hospital/Austria
Background: Clinical staging is the single most 
important factor determining therapy in patients 
with non-small cell lung cancer (NSCLC). For early 
stage disease (stage I and II, T1,2N0,1) primary 
surgical treatment is the gold standard. If clinical 
staging techniques were state-of-the-art, upstaging 
from clinical to pathological staging may reÁect high 
quality of surgical technique.
Methods: Retrospective analysis comparing pTNM/
UICC stage with preoperative cTNM stage in patients 
who underwent video-assisted thoracoscopic (VATS) 
lobectomy for early stage NSCLC. Initial clinical staging 
was re-evaluated in every case of pathological upstaging.
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P1.300 PROGNOSTIC VALUE AND 
SIGNIFICANCE OF SUBCARINAL 
LYMPH NODE METASTASIS IN STAGE 
IIIA –N2 NON-SMALL CELL LUNG 
CANCER FOLLOWING PULMONARY 
CURATIVE RESECTION
Jalal Assouad1, Mihaela Giol2, Claudia Vlas2, Didier 
Adodo2, Ibrahim Al Koudeimat2, Majdi El Husseini2, 
Dominique H. Grunenwald2, Valerie Gounant2 
1Thoraci Surgery, Department Of Thoracic Surgery. 
Hopital Tenon/France, 2Department Of Thoracic 
Surgery. Hopital Tenon/France
Background: The prognostic value of pN2 subcarinal 
metastasis (station 7) after curative resection in Non 
Small Cell Lung Cancer (NSCLC) is still debated, 
as well as the prognosis of isolated pN2 subcarinal 
metastasis in comparison with multiple station pN2. 
In this retrospective study, we aimed to evaluate the 
survival of pN2 subcarinal metastasis in several groups 
of patient operated on with the intent of complete 
resection in a large single institution study. 
Methods: We retrospectively reviewed the records 
of 408 consecutive patients who underwent complete 
resection for NSCLC associated with pN2 metastases. 
Three groups were individualised: group one with 
single pN2 subcarinal metastasis, group 2 with 
simultaneous pN2 subcarinal and other pN2 location, 
and group 3 with multiple pN2 without subcarinal 
location. The clinico-pathological records were 
examined with regard to age, sex, nodal status, T factor, 
lung resection and histological type. Five- year overall 
survival is calculated using Kaplan Meier method. 
Results: Among the 408 studied patients, there were 
125 patients with pN2 subcarinal location. The follow 
up was complete for 50 patients. We compared the three 
groups (group one n= 23, group two n= 27 and group 
three n= 28). Statistical results will be given by authors 
at the 14th World Conference on Lung Cancer
Conclusion: Subcarinal pN2 location could have 
poorer prognosis, compared with other mediastinal 
lymph node involvements in NSCLC. The comparison 
between these three groups could help us to assess our 
therapeutic strategy in case of cN2 subcarinal location. 
Keywords: NSCLC, Stage IIIA, subcarinal node, 
Surgery
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.299 EARLY RECURRENCE AFTER 
VIDEO-ASSISTED THORACOSCOPIC 
LOBECTOMY FOR NON SMALL CELL 
LUNG CANCER
Johannes Bodner1, Thomas Schmid2, A Vollerthunn1, 
Wilhelm Stertmann1, Florian Augustin2 
1Division Of Thoracic Surgery, University Hospital 
Giessen/Germany, 2Visceral Transplant Thoracic 
Surgery, Innsbruck University Hospital/Austria
Background: VATS (Video Assisted Thoracoscopic 
Surgery) lobectomy has gained increasing 
acceptance as an alternative treatment option for 
early stage NSCLC (non small cell lung cancer). 
Follow-up data of large series from high volume 
centers suggest equal oncologic results when 
compared to open series.
Methods: Retrospective analysis of a prospective 
database. Primary endpoint was disease free survival. 
Secondary endpoints were overall survival, site of 
recurrence and time of recurrence after operation
Results: From 2/09 until 1/11, 96 patients underwent 
VATS lobectomy for NSCLC in a newly introduced 
VATS lobectomy program. Clinical staging was 
performed according to ESTS guidelines and was 
IA in 47 patients (46%), IB in 9 patients (9,4%), 
IIA in 20 patients (20,8%), IIB in 10 patients 
(10,4%), and IIIA in 10 patients (10,4%). Median 
follow up was 12,3 months. Recurrent disease 
was observed in 8 patients (8,3%), locally in 4 and 
distant in 4, respectively. Tumor recurrences were 
observed between 4 and 17 months after the initial 
operation.1-year disease free survival was 92,5%. 
Stage related 1-year disease free survival was 93,3%, 
77,8%, 100%, 100%, 90% for stages IA, IB, IIA, 
IIB, IIIA, respectively. Overall 1-year survival was 
96,9%.
Conclusion: These early oncologic results of a 
learning-curve series of VATS lobectomies for stage 
I-IIIA NSCLC are comparable with large VATS 
as well as with open series. These data justify the 
inclusion of oncologic cases when starting a VATS 
lobectomy program. These favorable early results 
have to be proven by longer follow-up.
Keywords: VATS, NSCLC, outcome
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.302 CLINICOPATHOLOGICAL 
FEATURES IN LUNG CANCER ARISING 
IN THE WALL OF BULLAE
Yukio Watanabe1, Kenji Suzuki2 
1General Thoracic Surgery, Juntendo Univeisity School 
Of Medicine/Japan, 2Division Of Thoracic Surgery, 
Juntendo University School Of Medicine/Japan
Background: Lung cancer arising in the wall 
of bulla is not so rare. Preoperative diagnosis is 
sometimes difÀcult for this tumor, because of the 
presence of the bulla. Preoperative evaluation and 
clinicopathological features were investigated.
Methods: A retrospective study was conducted on 
862 patients with primary lung cancer, which were 
resected between January 2000 and December 2008 
at our institute. We reviewed radiological Àndings of 
computed tomography in all cases. Among them, 36 
patients (4.1%) had lung cancer arising from the wall 
of bulla (WB group). It was deÀned as follows; tumor 
was close to bulla and bulla was emphysematous space 
of more than 1cm in the diameter in the inÀltrated 
lung. We analyzed clinicopathologic features of WB 
group, compared with non-WB group. The relationship 
was evaluated using chi-square test. The Survival was 
estimated with Kaplan-Meyer method. 
Results: There were 32 men and 4 women and age 
ranged 49 to 80 with a madian of 66 in WB group. 
The actuarial 5-year survival of overall patients was 
65.0% in WB group, less than in non-WB group 
(75.5%). There were differences signiÀcantly in 
gender (P=0.004), smoking states (p=0.002), ratio of 
adenocarcinoma (p=0.005), tumor size (p=0.013) and 
poorly differenciated pathological Àndings(p=0.005) 
between groups. 
Conclusion: There are often difÀcult to diagnose 
of cancer associated with wall of bulla because of 
their uncertain appearance and difÀculty of diagnosis 
using cytological or pathological methods before 
surgery. Futhermore, patients in BW group have poor 
prognosis compared with in non-BW group because 
incidence of poor differentiation of tumor was high. 
If we Ànd a lesion close to the wall of bulla , it is 
necessary to observe clinical course and operative 
timing carefully.
Keyword: yag2mxdm
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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P1.301 BLAKE DRAIN IS FEASIBLE 
AFTER PULMONARY RESECTION FOR 
LUNG CANCER
Tomoaki Kinno, Yoshikazu Miyasaka, Kazuya 
Takamochi, Shiaki Oh, Kenji Suzuki 
General Thoracic Surgery, Juntendo University, 
School Of Medicine/Japan
Background: The drainage of the pleural space after 
lung resection is usually performed by conventional 
thoracic drain. But it frequently creates discomfort 
and pain, which results in restricting the early 
recovery. Recently, the use of developed silastic 
Áexible drains (Blake drains, Ethicon, Inc.) is 
acceptable to general thoracic operations. However, 
the indication of Blake drain is still controversial for 
lung cancer patients.
Methods: A retrospective study was conducted on 
224 patients with lung cancer, between February 
2008 and January 2009 at our institute. Blake drains 
were used in 166 cases (74%). The other cases (26%) 
were used conventional thoracic drain. The selection 
of drain was made by the staff surgeons (K.T., S.O., 
K.S.) who have the same strategy for the use of 
Blake drain. . We analyzed the duration of chest 
tube, the ratio of prolonged air leak and the ratio of 
re-inserted chest tube.
Results: There were 96 men and 70 women, with 
a median of 67 years (19-86). The procedures were 
consisted of two pneumonectomies, 122 lobectomies, 
28 segmentectomies and 14 wedge resections. The 
mean duration of chest tube drainage was 2.99 
days. Postoperative prolonged air leak occurred in 7 
(4.2%) patients. Trocar drains were inserted for three 
patients (1.8%) after the removal of Blake drain. 
All of the three patients were male who underwent 
lobectomy, and they were heavy smoker or had low 
pulmonary function. Furthermore two of them were 
advanced stage.
Conclusion: The management of air leaks by Blake 
drain is feasible for the patients after lung resection. 
However we should consider the indication of using 
Blake drain, evaluating the characteristic of patients. 
Drainage of alveolar air-leakage is not effective for 
Blake drain.
Keyword: Blake drain
A revised/updated abstract may be included in 
the Late Breaking Abstract Supplement, available 
at the 14th World Conference on Lung Cancer.
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was initially treated before lung cancer surgery. On 
the other hand, 9 patients died from non-lung cancer 
malignancy which diagnosed and developed after 
lung cancer surgery.
Conclusion: Nearly 20 percent of the patients who 
underwent surgery for primary lung cancer had 
positive history for prior malignancy. Prognosis of 
the patients with primary lung cancer who has well-
controlled prior malignancy seems to be acceptable.
Keywords: Other malignancy, Surgery, Prognosis
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P1.304 SURVIVAL RATES OF R0,R1,R2 
RESECTION IN LUNG CANCER
Mark Krasnik1, Ramon Rami-Porta2, Kary Chansky3 
1Thoracic And Cardiovasc.surg, Rigshospitalet 
Copenhagen University/Denmark, 2Matua Terrassa 
University Hospital/Spain, 3Crab/United States Of 
America
Background: Publications on partial resection are rare 
and usually only present small numbers of patients. 
None of these studies have systematically analyzed 
the survival rates according to the Residual Tumour 
descriptors: R0, no residual tumour; R1, microscopic 
residual tumour; and R2, macroscopic residual tumour; 
in relation to the tumour, node and metastasis (TNM) 
classiÀcation of lung cancer. The aim of the study was 
to validate the three categories of the R descriptor and 
its inÁuence on the survival rates after surgery for lung 
cancer, based on the International Association for Lung 
Cancer (IASLC) database. 
Methods: Survival rates were analysed in a series 
of 12913 patients, 11980 R0 resections, and 933 R1 
and R2 resections. We analyzed the survival rates 
comparing survival of R0, R1 and R2 resection with 
the different TNM
Results: Five-year survival rates for T1N0M0 were 
70% for R0 and). 40% for R1-R2 (p = 0.001); for 
T2N0M0 were 60% for R0 and 38% for R1-R2 (p = 
0.0002 . 
Conclusion: The R descriptor separates tumours 
with signiÀcantly different prognosis according to 
the completeness of resection.Therefore, it should 
be considered along with the pathologic TNM 
classiÀcation. Its effect, however, loses strength in 
patients surviving beyond 5 years whose tumours 
have nodal disease.
Keywords: Lung cancer resection, Survival R0/R1/
R2, TNM
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P1.303 HOW DOES POSITIVE 
HISTORY FOR MALIGNANCY AFFECT 
PROGNOSIS OF PATIENTS WITH 
PRIMARY LUNG CANCER WHO 
UNDERGO SURGERY?
Akira Sakurada, Chiaki Endo, Hirotsugu Notsuda, 
Yoshinori Okada, Takashi Kondo 
Thoracic Surgery, Tohoku University Hospital/Japan
Background: Patients with lung cancer occasionally 
have history of other organ malignancy or develop other 
organ malignancy after lung cancer surgery. Effect of 
other organ malignancy on prognosis of the lung cancer 
patients those who underwent surgery is unclear.
Methods: Four hundred and seventeen patients those 
who received surgery for primary lung cancer in 
Tohoku University Hospital from January 2000 to 
December 2005 were analyzed in this study. History 
of treatment for malignancy except carcinoma in 
situ region at the point of lung cancer surgery was 
screened by reviewing medical records. Surgery for 
lung cancer was indicated when the prior malignancy 
was well controlled. Survival curves were calculated 
according to Kaplan-Meier method and p value less 
than 0.05 was regarded as statistically signiÀcant.
Results: Among 417 patients, 75 patients (17.9%) 
had history of treatment for malignancy. Age of 
the patients distributed from 21 to 82 (mean 64) 
years old, 402 were male and 185 were female. 
Pathological staging of lung cancer was IA in 179 
patients, IB in 90 patients, IIA in 12 patients, IIB in 
42 patients, IIIA in 45 patients, IIIB in 34 patients, 
and IV in 15 patients. Histology was adenocarcinoma 
in 248 patients, squamous cell carcinoma in 140 
patients, large cell carcinoma in 10 patients, small 
cell carcinoma in 9 patients, adenosquamous 
carcinoma in 4 patients, and other types in 6 patients. 
Origin of malignancy prior to lung cancer was 
oral cavity in 2 (1 within 5 years before surgery) 
patients, pharynx /larynx in 4 (1), thyroid in 2 (1), 
esophagus in 2 (1), lung 13 (13), mammary grand 
in 7 (3), thymus in 1 (1), stomach in 11 (5), bile 
duct in 1 (1), kidney in 1 (1), colon/rectum in 9 
(8), prostate in 12 (8), testis 1 (1), and uterus in 5 
(1) patients. Five - year survival was 72.7% in the 
patients with the history of lung (meta-chronous 
lung cancer), 61.6% in those who with non-lung 
malignancy, and 65.5% in those who without history 
of treatment for malignancy, respectively. Three 
patients died from progression of malignancy which 
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